23494106
T15_T27 NONE cannabinoids_5\NNS\1740|of|selected|synthetic|showing (l_acl) showing_6\VBG\2137132|affinities (l_dobj) affinities_9\NNS\11426530|high|binding|cb1 (l_nmod) cb1_15\NN\1740|to|the|cannabinoid|receptor|subtype
T16_T27 NONE cannabinoid_12\NN\1740| (r_compound) cb1_15\NN\1740|to|the|cannabinoid|receptor|subtype
T10_T26 NONE am-694_37\NN\1740|(|) (r_appos) benzoylindole_35\NN\1740|of|one|am-694 (r_conj) compounds_22\NNS\5869584|of|four|naphthoylindole|jwh-018|and|benzoylindole (r_nmod) activities_18\NNS\30358|scarce|,|cytotoxic|compounds (r_nsubjpass) studied_40\VBN\630380|activities|were|lines|;|included (l_parataxis) included_51\VBN\690614|tetrahydrocannabinol|was|ligand|. (l_nmod) ligand_58\NN\20090|as|the|classical|non-endogenous|cannabinoid|receptor (l_compound) receptor_57\NN\5225602|
T11_T26 NONE tetrahydrocannabinol_49\NN\4017137| (r_nsubjpass) included_51\VBN\690614|tetrahydrocannabinol|was|ligand|. (l_nmod) ligand_58\NN\20090|as|the|classical|non-endogenous|cannabinoid|receptor (l_compound) receptor_57\NN\5225602|
T4_T26 NONE naphthoylindole_21\NN\1740| (r_compound) compounds_22\NNS\5869584|of|four|naphthoylindole|jwh-018|and|benzoylindole (r_nmod) activities_18\NNS\30358|scarce|,|cytotoxic|compounds (r_nsubjpass) studied_40\VBN\630380|activities|were|lines|;|included (l_parataxis) included_51\VBN\690614|tetrahydrocannabinol|was|ligand|. (l_nmod) ligand_58\NN\20090|as|the|classical|non-endogenous|cannabinoid|receptor (l_compound) receptor_57\NN\5225602|
T5_T26 NONE jwh-018_24\NN\1740|(|,|jwh-073|,|jwh-122|and|jwh-210|) (r_dep) compounds_22\NNS\5869584|of|four|naphthoylindole|jwh-018|and|benzoylindole (r_nmod) activities_18\NNS\30358|scarce|,|cytotoxic|compounds (r_nsubjpass) studied_40\VBN\630380|activities|were|lines|;|included (l_parataxis) included_51\VBN\690614|tetrahydrocannabinol|was|ligand|. (l_nmod) ligand_58\NN\20090|as|the|classical|non-endogenous|cannabinoid|receptor (l_compound) receptor_57\NN\5225602|
T6_T26 NONE jwh-073_26\NN\1740| (r_conj) jwh-018_24\NN\1740|(|,|jwh-073|,|jwh-122|and|jwh-210|) (r_dep) compounds_22\NNS\5869584|of|four|naphthoylindole|jwh-018|and|benzoylindole (r_nmod) activities_18\NNS\30358|scarce|,|cytotoxic|compounds (r_nsubjpass) studied_40\VBN\630380|activities|were|lines|;|included (l_parataxis) included_51\VBN\690614|tetrahydrocannabinol|was|ligand|. (l_nmod) ligand_58\NN\20090|as|the|classical|non-endogenous|cannabinoid|receptor (l_compound) receptor_57\NN\5225602|
T7_T26 NONE jwh-122_28\NN\1740| (r_conj) jwh-018_24\NN\1740|(|,|jwh-073|,|jwh-122|and|jwh-210|) (r_dep) compounds_22\NNS\5869584|of|four|naphthoylindole|jwh-018|and|benzoylindole (r_nmod) activities_18\NNS\30358|scarce|,|cytotoxic|compounds (r_nsubjpass) studied_40\VBN\630380|activities|were|lines|;|included (l_parataxis) included_51\VBN\690614|tetrahydrocannabinol|was|ligand|. (l_nmod) ligand_58\NN\20090|as|the|classical|non-endogenous|cannabinoid|receptor (l_compound) receptor_57\NN\5225602|
T8_T26 NONE jwh-210_30\NN\1740| (r_conj) jwh-018_24\NN\1740|(|,|jwh-073|,|jwh-122|and|jwh-210|) (r_dep) compounds_22\NNS\5869584|of|four|naphthoylindole|jwh-018|and|benzoylindole (r_nmod) activities_18\NNS\30358|scarce|,|cytotoxic|compounds (r_nsubjpass) studied_40\VBN\630380|activities|were|lines|;|included (l_parataxis) included_51\VBN\690614|tetrahydrocannabinol|was|ligand|. (l_nmod) ligand_58\NN\20090|as|the|classical|non-endogenous|cannabinoid|receptor (l_compound) receptor_57\NN\5225602|
T9_T26 NONE benzoylindole_35\NN\1740|of|one|am-694 (r_conj) compounds_22\NNS\5869584|of|four|naphthoylindole|jwh-018|and|benzoylindole (r_nmod) activities_18\NNS\30358|scarce|,|cytotoxic|compounds (r_nsubjpass) studied_40\VBN\630380|activities|were|lines|;|included (l_parataxis) included_51\VBN\690614|tetrahydrocannabinol|was|ligand|. (l_nmod) ligand_58\NN\20090|as|the|classical|non-endogenous|cannabinoid|receptor (l_compound) receptor_57\NN\5225602|
T1_T17 NONE jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) release_6\NN\3748886|on|cytokine (l_compound) cytokine_5\NN\14728724|
T1_T18 NONE jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα
T1_T19 NONE jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα (l_conj) il-6_13\NN\1740|
T1_T20 NONE jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα (l_conj) il-12/23p40_15\NN\1740|
T1_T21 NONE jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα (l_conj) il-12/23p40_15\NN\1740|
T1_T22 NONE jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα (l_conj) tnfα_17\NN\1740|
T1_T23 CPR:4 jwh-210_29\NN\1740|except|with|and|jwh-122|caused (l_acl:relcl) caused_33\VBD\1617192|which|decrease (l_dobj) decrease_35\NN\7296428|a|tnfα (l_nmod) tnfα_37\NN\1740|of|and|il-12/23p40
T1_T24 CPR:4 jwh-210_29\NN\1740|except|with|and|jwh-122|caused (l_acl:relcl) caused_33\VBD\1617192|which|decrease (l_dobj) decrease_35\NN\7296428|a|tnfα (l_nmod) tnfα_37\NN\1740|of|and|il-12/23p40 (l_conj) il-12/23p40_39\NN\1740|
T1_T25 CPR:4 jwh-210_29\NN\1740|except|with|and|jwh-122|caused (l_acl:relcl) caused_33\VBD\1617192|which|decrease (l_dobj) decrease_35\NN\7296428|a|tnfα (l_nmod) tnfα_37\NN\1740|of|and|il-12/23p40 (l_conj) il-12/23p40_39\NN\1740|
T2_T17 NONE jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) release_6\NN\3748886|on|cytokine (l_compound) cytokine_5\NN\14728724|
T2_T18 NONE jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα
T2_T19 NONE jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα (l_conj) il-6_13\NN\1740|
T2_T20 NONE jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα (l_conj) il-12/23p40_15\NN\1740|
T2_T21 NONE jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα (l_conj) il-12/23p40_15\NN\1740|
T2_T22 NONE jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (r_nmod) seen_21\VBN\2106506|furthermore|,|impact|was|pbmcs|,|jwh-210|. (l_nsubjpass) impact_3\NN\7339329|no|release|levels|) (l_nmod) levels_18\NNS\4916342|(|i.e.|,|on|il-10 (l_compound) il-10_11\NN\1740|,|il-6|,|il-12/23p40|and|tnfα (l_conj) tnfα_17\NN\1740|
T2_T23 CPR:4 jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (l_acl:relcl) caused_33\VBD\1617192|which|decrease (l_dobj) decrease_35\NN\7296428|a|tnfα (l_nmod) tnfα_37\NN\1740|of|and|il-12/23p40
T2_T24 CPR:4 jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (l_acl:relcl) caused_33\VBD\1617192|which|decrease (l_dobj) decrease_35\NN\7296428|a|tnfα (l_nmod) tnfα_37\NN\1740|of|and|il-12/23p40 (l_conj) il-12/23p40_39\NN\1740|
T2_T25 CPR:4 jwh-122_31\NN\1740| (r_conj) jwh-210_29\NN\1740|except|with|and|jwh-122|caused (l_acl:relcl) caused_33\VBD\1617192|which|decrease (l_dobj) decrease_35\NN\7296428|a|tnfα (l_nmod) tnfα_37\NN\1740|of|and|il-12/23p40 (l_conj) il-12/23p40_39\NN\1740|
1280065
T3_T25 NONE lysine_8\NN\14605787| (r_compound) acid_12\NN\14818238|by|the|lysine|analogue|epsilon-amino|caproic|eaca (r_nmod) inhibited_5\VBN\2510337|binding|was|not|significantly|acid|,|indicating|. (l_advcl) indicating_17\VBG\952524|sites|suggested (l_ccomp) sites_27\NNS\8673395|that|binding|was|not|just|through|lysine|binding (l_nsubj) binding_20\NN\4688246|plasminogen (l_compound) plasminogen_19\NN\14983774|
T3_T26 NONE lysine_8\NN\14605787| (r_compound) acid_12\NN\14818238|by|the|lysine|analogue|epsilon-amino|caproic|eaca (r_nmod) inhibited_5\VBN\2510337|binding|was|not|significantly|acid|,|indicating|. (l_advcl) indicating_17\VBG\952524|sites|suggested (l_ccomp) suggested_29\VBN\1010118|as|sites (l_nmod) sites_34\NNS\8673395|for|other|plasminogen|binding (l_compound) plasminogen_32\NN\14983774|
T4_T25 NONE acid_12\NN\14818238|by|the|lysine|analogue|epsilon-amino|caproic|eaca (r_nmod) inhibited_5\VBN\2510337|binding|was|not|significantly|acid|,|indicating|. (l_advcl) indicating_17\VBG\952524|sites|suggested (l_ccomp) sites_27\NNS\8673395|that|binding|was|not|just|through|lysine|binding (l_nsubj) binding_20\NN\4688246|plasminogen (l_compound) plasminogen_19\NN\14983774|
T4_T26 NONE acid_12\NN\14818238|by|the|lysine|analogue|epsilon-amino|caproic|eaca (r_nmod) inhibited_5\VBN\2510337|binding|was|not|significantly|acid|,|indicating|. (l_advcl) indicating_17\VBG\952524|sites|suggested (l_ccomp) suggested_29\VBN\1010118|as|sites (l_nmod) sites_34\NNS\8673395|for|other|plasminogen|binding (l_compound) plasminogen_32\NN\14983774|
T5_T25 NONE eaca_14\NN\1740|(|) (r_appos) acid_12\NN\14818238|by|the|lysine|analogue|epsilon-amino|caproic|eaca (r_nmod) inhibited_5\VBN\2510337|binding|was|not|significantly|acid|,|indicating|. (l_advcl) indicating_17\VBG\952524|sites|suggested (l_ccomp) sites_27\NNS\8673395|that|binding|was|not|just|through|lysine|binding (l_nsubj) binding_20\NN\4688246|plasminogen (l_compound) plasminogen_19\NN\14983774|
T5_T26 NONE eaca_14\NN\1740|(|) (r_appos) acid_12\NN\14818238|by|the|lysine|analogue|epsilon-amino|caproic|eaca (r_nmod) inhibited_5\VBN\2510337|binding|was|not|significantly|acid|,|indicating|. (l_advcl) indicating_17\VBG\952524|sites|suggested (l_ccomp) suggested_29\VBN\1010118|as|sites (l_nmod) sites_34\NNS\8673395|for|other|plasminogen|binding (l_compound) plasminogen_32\NN\14983774|
T6_T25 NONE lysine_25\NN\14605787| (r_compound) sites_27\NNS\8673395|that|binding|was|not|just|through|lysine|binding (l_nsubj) binding_20\NN\4688246|plasminogen (l_compound) plasminogen_19\NN\14983774|
T6_T26 NONE lysine_25\NN\14605787| (r_compound) sites_27\NNS\8673395|that|binding|was|not|just|through|lysine|binding (r_ccomp) indicating_17\VBG\952524|sites|suggested (l_ccomp) suggested_29\VBN\1010118|as|sites (l_nmod) sites_34\NNS\8673395|for|other|plasminogen|binding (l_compound) plasminogen_32\NN\14983774|
T1_T14 CPR:4 benzamidine_11\NN\1740|by (r_nmod) inhibition_0\NN\1068773|binding|benzamidine (l_nmod) binding_2\NN\4688246|of|plasminogen|gp330 (l_nmod) plasminogen_5\NN\14983774|of|both|and|plasmin
T1_T15 CPR:4 benzamidine_11\NN\1740|by (r_nmod) inhibition_0\NN\1068773|binding|benzamidine (l_nmod) binding_2\NN\4688246|of|plasminogen|gp330 (l_nmod) plasminogen_5\NN\14983774|of|both|and|plasmin (l_conj) plasmin_7\NN\14732946|
T1_T16 NONE benzamidine_11\NN\1740|by (r_nmod) inhibition_0\NN\1068773|binding|benzamidine (l_nmod) binding_2\NN\4688246|of|plasminogen|gp330 (l_nmod) gp330_9\NN\1740|to
T1_T17 NONE benzamidine_11\NN\1740|by (r_nmod) inhibition_0\NN\1068773|binding|benzamidine (r_nsubj) similar_13\JJ\1740|inhibition|was|,|inhibited|. (l_advcl) inhibited_17\VBD\2510337|although|eaca|binding|more (l_dobj) binding_19\NN\4688246|the|plasmin|gp330 (l_nmod) plasmin_21\NN\14732946|of
T1_T18 NONE benzamidine_11\NN\1740|by (r_nmod) inhibition_0\NN\1068773|binding|benzamidine (r_nsubj) similar_13\JJ\1740|inhibition|was|,|inhibited|. (l_advcl) inhibited_17\VBD\2510337|although|eaca|binding|more (l_dobj) binding_19\NN\4688246|the|plasmin|gp330 (l_nmod) gp330_23\NN\1740|to
T1_T19 NONE benzamidine_11\NN\1740|by (r_nmod) inhibition_0\NN\1068773|binding|benzamidine (r_nsubj) similar_13\JJ\1740|inhibition|was|,|inhibited|. (l_advcl) inhibited_17\VBD\2510337|although|eaca|binding|more (l_advmod) more_25\RBR\1740|slightly|binding (l_nmod) binding_28\NN\4688246|than|the|plasminogen|gp330 (l_nmod) plasminogen_30\NN\14983774|of
T1_T20 NONE benzamidine_11\NN\1740|by (r_nmod) inhibition_0\NN\1068773|binding|benzamidine (r_nsubj) similar_13\JJ\1740|inhibition|was|,|inhibited|. (l_advcl) inhibited_17\VBD\2510337|although|eaca|binding|more (l_advmod) more_25\RBR\1740|slightly|binding (l_nmod) binding_28\NN\4688246|than|the|plasminogen|gp330 (l_nmod) gp330_32\NN\1740|to
T2_T14 NONE eaca_16\NN\1740| (r_nsubj) inhibited_17\VBD\2510337|although|eaca|binding|more (r_advcl) similar_13\JJ\1740|inhibition|was|,|inhibited|. (l_nsubj) inhibition_0\NN\1068773|binding|benzamidine (l_nmod) binding_2\NN\4688246|of|plasminogen|gp330 (l_nmod) plasminogen_5\NN\14983774|of|both|and|plasmin
T2_T15 NONE eaca_16\NN\1740| (r_nsubj) inhibited_17\VBD\2510337|although|eaca|binding|more (r_advcl) similar_13\JJ\1740|inhibition|was|,|inhibited|. (l_nsubj) inhibition_0\NN\1068773|binding|benzamidine (l_nmod) binding_2\NN\4688246|of|plasminogen|gp330 (l_nmod) plasminogen_5\NN\14983774|of|both|and|plasmin (l_conj) plasmin_7\NN\14732946|
T2_T16 NONE eaca_16\NN\1740| (r_nsubj) inhibited_17\VBD\2510337|although|eaca|binding|more (r_advcl) similar_13\JJ\1740|inhibition|was|,|inhibited|. (l_nsubj) inhibition_0\NN\1068773|binding|benzamidine (l_nmod) binding_2\NN\4688246|of|plasminogen|gp330 (l_nmod) gp330_9\NN\1740|to
T2_T17 CPR:4 eaca_16\NN\1740| (r_nsubj) inhibited_17\VBD\2510337|although|eaca|binding|more (l_dobj) binding_19\NN\4688246|the|plasmin|gp330 (l_nmod) plasmin_21\NN\14732946|of
T2_T18 NONE eaca_16\NN\1740| (r_nsubj) inhibited_17\VBD\2510337|although|eaca|binding|more (l_dobj) binding_19\NN\4688246|the|plasmin|gp330 (l_nmod) gp330_23\NN\1740|to
T2_T19 CPR:4 eaca_16\NN\1740| (r_nsubj) inhibited_17\VBD\2510337|although|eaca|binding|more (l_advmod) more_25\RBR\1740|slightly|binding (l_nmod) binding_28\NN\4688246|than|the|plasminogen|gp330 (l_nmod) plasminogen_30\NN\14983774|of
T2_T20 NONE eaca_16\NN\1740| (r_nsubj) inhibited_17\VBD\2510337|although|eaca|binding|more (l_advmod) more_25\RBR\1740|slightly|binding (l_nmod) binding_28\NN\4688246|than|the|plasminogen|gp330 (l_nmod) gp330_32\NN\1740|to
18466433
T1_T3 NONE mtor_7\NN\1740|
23253441
T3_T6 NONE oxadiazepines_4\NNS\1740|of|fused (r_nmod) discovery_1\NN\30358|the|oxadiazepines|modulators|. (l_nmod) modulators_8\NNS\1740|as|gamma|secretase|treatment (l_compound) secretase_7\NN\14732946|
T1_T4 NONE oxadiazepines_33\NNS\1740|of|fused|7i (r_nmod) identification_30\NN\151497|in|the|oxadiazepines (r_nmod) resulted_27\VBD\2633881|attempt|,|modifications|identification|. (l_nmod) attempt_2\NN\407535|in|an|improve (l_acl) improve_5\VB\126264|to|further|profiles (l_dobj) profiles_7\NNS\6999802|overall|series|,|activity (l_appos) activity_19\NN\30358|particular|the|herg (l_compound) herg_18\NN\1740|
T1_T5 CPR:4 oxadiazepines_33\NNS\1740|of|fused|7i (l_nmod) 7i_36\NN\1740|such|had (l_acl:relcl) had_38\VBD\2108377|which|profile|and|gsm (l_dobj) profile_43\NN\6999802|an|improved|herg|inhibition (l_compound) herg_41\NN\1740|
T2_T4 NONE oxadiazine_10\NN\1740| (r_compound) series_11\NN\8456993|of|the|oxadiazine|gsms (r_nmod) profiles_7\NNS\6999802|overall|series|,|activity (l_appos) activity_19\NN\30358|particular|the|herg (l_compound) herg_18\NN\1740|
T2_T5 NONE oxadiazine_10\NN\1740| (r_compound) series_11\NN\8456993|of|the|oxadiazine|gsms (r_nmod) profiles_7\NNS\6999802|overall|series|,|activity (r_dobj) improve_5\VB\126264|to|further|profiles (r_acl) attempt_2\NN\407535|in|an|improve (r_nmod) resulted_27\VBD\2633881|attempt|,|modifications|identification|. (l_nmod) identification_30\NN\151497|in|the|oxadiazepines (l_nmod) oxadiazepines_33\NNS\1740|of|fused|7i (l_nmod) 7i_36\NN\1740|such|had (l_acl:relcl) had_38\VBD\2108377|which|profile|and|gsm (l_dobj) profile_43\NN\6999802|an|improved|herg|inhibition (l_compound) herg_41\NN\1740|
19023039
T13_T17 NONE acid_17\NN\14818238| (r_dep) structural_12\JJ\1740|,|not|amino|acid|, (r_amod) homology_19\NN\4743605|structural|proteins (r_dobj) shares_11\VBZ\2660631|that|homology (r_acl:relcl) protein_9\NN\14944888|pannexin|is|a|expressed|shares|. (l_nsubj) pannexin_0\NN\1740|panx|1 (l_nummod) 1_4\CD\13741022|
T13_T20 NONE acid_17\NN\14818238| (r_dep) structural_12\JJ\1740|,|not|amino|acid|, (r_amod) homology_19\NN\4743605|structural|proteins (l_nmod) proteins_23\NNS\14944888|with|gap|junction|,|connexins (l_appos) connexins_26\NNS\1740|the
T14_T39 CPR:4 carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T15_T39 CPR:4 4,4'-diisothiocyanatostilbene-2,2'-disulfonate_17\NN\1740|disodium|dids (r_compound) acid_26\NN\14818238|4,4'-diisothiocyanatostilbene-2,2'-disulfonate|4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate|approximately|5-nitro-2-(3-phenylpropylamino)benzoic (r_conj) carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T16_T39 CPR:4 dids_19\NN\1740|(|) (r_appos) 4,4'-diisothiocyanatostilbene-2,2'-disulfonate_17\NN\1740|disodium|dids (r_compound) acid_26\NN\14818238|4,4'-diisothiocyanatostilbene-2,2'-disulfonate|4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate|approximately|5-nitro-2-(3-phenylpropylamino)benzoic (r_conj) carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T1_T39 CPR:4 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate_23\NN\1740|disodium (r_amod) acid_26\NN\14818238|4,4'-diisothiocyanatostilbene-2,2'-disulfonate|4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate|approximately|5-nitro-2-(3-phenylpropylamino)benzoic (r_conj) carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T2_T39 CPR:4 acid_26\NN\14818238|4,4'-diisothiocyanatostilbene-2,2'-disulfonate|4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate|approximately|5-nitro-2-(3-phenylpropylamino)benzoic (r_conj) carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T3_T39 CPR:4 94_30\CD\1740| (r_nummod) acid_29\NN\14818238|>|indanyloxyacetic|94 (r_conj) carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T4_T39 CPR:4 probenecid_33\NN\3740161| (r_appos) carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T5_T39 CPR:4 acid_37\NN\14818238|>|flufenamic|acid (r_conj) carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T6_T39 CPR:4 acid_40\NN\14818238|=|niflumic (r_appos) acid_37\NN\14818238|>|flufenamic|acid (r_conj) carbenoxolone_14\NN\1740|>|acid|acid|>|>|probenecid|>|acid (r_dep) found_1\VBD\2426171|we|compounds|:|carbenoxolone (l_dobj) compounds_2\NNS\5869584|inhibited (l_acl:relcl) inhibited_4\VBD\2510337|that|currents|order (l_dobj) currents_6\NNS\11449002|panx1 (l_compound) panx1_5\NN\1740|
T10_T18 CPR:4 utp_8\NN\1740| (r_conj) atp_3\NN\14964590|(|,|gtp|,|and|utp|) (r_dep) nucleotides_1\NNS\14850483|triphosphate|atp (r_nsubj) inhibited_13\VBD\2510337|nucleotides|and|currents|mechanism(s|. (l_dobj) currents_15\NNS\11449002|panx1 (l_compound) panx1_14\NN\1740|
T10_T19 NONE utp_8\NN\1740| (r_conj) atp_3\NN\14964590|(|,|gtp|,|and|utp|) (r_dep) nucleotides_1\NNS\14850483|triphosphate|atp (r_nsubj) inhibited_13\VBD\2510337|nucleotides|and|currents|mechanism(s|. (l_nmod) mechanism(s_17\NN\1740|via|)|independent (l_amod) independent_19\JJ\1740|receptors (l_nmod) receptors_22\NNS\5225602|of|purine
T7_T18 CPR:4 nucleotides_1\NNS\14850483|triphosphate|atp (r_nsubj) inhibited_13\VBD\2510337|nucleotides|and|currents|mechanism(s|. (l_dobj) currents_15\NNS\11449002|panx1 (l_compound) panx1_14\NN\1740|
T7_T19 NONE nucleotides_1\NNS\14850483|triphosphate|atp (r_nsubj) inhibited_13\VBD\2510337|nucleotides|and|currents|mechanism(s|. (l_nmod) mechanism(s_17\NN\1740|via|)|independent (l_amod) independent_19\JJ\1740|receptors (l_nmod) receptors_22\NNS\5225602|of|purine
T8_T18 CPR:4 atp_3\NN\14964590|(|,|gtp|,|and|utp|) (r_dep) nucleotides_1\NNS\14850483|triphosphate|atp (r_nsubj) inhibited_13\VBD\2510337|nucleotides|and|currents|mechanism(s|. (l_dobj) currents_15\NNS\11449002|panx1 (l_compound) panx1_14\NN\1740|
T8_T19 NONE atp_3\NN\14964590|(|,|gtp|,|and|utp|) (r_dep) nucleotides_1\NNS\14850483|triphosphate|atp (r_nsubj) inhibited_13\VBD\2510337|nucleotides|and|currents|mechanism(s|. (l_nmod) mechanism(s_17\NN\1740|via|)|independent (l_amod) independent_19\JJ\1740|receptors (l_nmod) receptors_22\NNS\5225602|of|purine
T9_T18 CPR:4 gtp_5\NN\1740| (r_conj) atp_3\NN\14964590|(|,|gtp|,|and|utp|) (r_dep) nucleotides_1\NNS\14850483|triphosphate|atp (r_nsubj) inhibited_13\VBD\2510337|nucleotides|and|currents|mechanism(s|. (l_dobj) currents_15\NNS\11449002|panx1 (l_compound) panx1_14\NN\1740|
T9_T19 NONE gtp_5\NN\1740| (r_conj) atp_3\NN\14964590|(|,|gtp|,|and|utp|) (r_dep) nucleotides_1\NNS\14850483|triphosphate|atp (r_nsubj) inhibited_13\VBD\2510337|nucleotides|and|currents|mechanism(s|. (l_nmod) mechanism(s_17\NN\1740|via|)|independent (l_amod) independent_19\JJ\1740|receptors (l_nmod) receptors_22\NNS\5225602|of|purine
T11_T21 NONE dids_13\NN\1740| (r_nsubjpass) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_advcl) coexpressed_3\VBN\1740|when|panx1|was|receptor (l_nsubjpass) panx1_1\NN\1740|
T11_T22 NONE dids_13\NN\1740| (r_nsubjpass) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_advcl) coexpressed_3\VBN\1740|when|panx1|was|receptor (l_nmod) receptor_8\NN\5225602|with|purinergic|p2x(7|)|p2x(7)r
T11_T23 NONE dids_13\NN\1740| (r_nsubjpass) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_advcl) coexpressed_3\VBN\1740|when|panx1|was|receptor (l_nmod) receptor_8\NN\5225602|with|purinergic|p2x(7|)|p2x(7)r (l_appos) p2x(7)r_10\NN\1740|(|)
T11_T24 CPR:6 dids_13\NN\1740| (r_nsubjpass) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_xcomp) act_17\VB\1619354|to|antagonist|inhibit (l_nmod) antagonist_21\NN\7846|as|a|p2x(7)r (l_compound) p2x(7)r_20\NN\1740|
T11_T26 NONE dids_13\NN\1740| (r_nsubjpass) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_conj) inhibited_33\VBD\2510337|none|currents (l_dobj) currents_35\NNS\11449002|p2x(7)r (l_compound) p2x(7)r_34\NN\1740|
T12_T21 NONE atp-evoked_24\JJ\1740| (r_amod) currents_25\NNS\11449002|atp-evoked (r_dobj) inhibit_23\VB\2510337|to|currents (r_xcomp) act_17\VB\1619354|to|antagonist|inhibit (r_xcomp) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_advcl) coexpressed_3\VBN\1740|when|panx1|was|receptor (l_nsubjpass) panx1_1\NN\1740|
T12_T22 NONE atp-evoked_24\JJ\1740| (r_amod) currents_25\NNS\11449002|atp-evoked (r_dobj) inhibit_23\VB\2510337|to|currents (r_xcomp) act_17\VB\1619354|to|antagonist|inhibit (r_xcomp) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_advcl) coexpressed_3\VBN\1740|when|panx1|was|receptor (l_nmod) receptor_8\NN\5225602|with|purinergic|p2x(7|)|p2x(7)r
T12_T23 NONE atp-evoked_24\JJ\1740| (r_amod) currents_25\NNS\11449002|atp-evoked (r_dobj) inhibit_23\VB\2510337|to|currents (r_xcomp) act_17\VB\1619354|to|antagonist|inhibit (r_xcomp) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_advcl) coexpressed_3\VBN\1740|when|panx1|was|receptor (l_nmod) receptor_8\NN\5225602|with|purinergic|p2x(7|)|p2x(7)r (l_appos) p2x(7)r_10\NN\1740|(|)
T12_T24 NONE atp-evoked_24\JJ\1740| (r_amod) currents_25\NNS\11449002|atp-evoked (r_dobj) inhibit_23\VB\2510337|to|currents (r_xcomp) act_17\VB\1619354|to|antagonist|inhibit (l_nmod) antagonist_21\NN\7846|as|a|p2x(7)r (l_compound) p2x(7)r_20\NN\1740|
T12_T26 NONE atp-evoked_24\JJ\1740| (r_amod) currents_25\NNS\11449002|atp-evoked (r_dobj) inhibit_23\VB\2510337|to|currents (r_xcomp) act_17\VB\1619354|to|antagonist|inhibit (r_xcomp) found_15\VBN\2426171|coexpressed|,|dids|was|act|,|but|inhibited|. (l_conj) inhibited_33\VBD\2510337|none|currents (l_dobj) currents_35\NNS\11449002|p2x(7)r (l_compound) p2x(7)r_34\NN\1740|
17704420
T1_T15 NONE histidine_17\NN\14605787| (r_compound) allele_18\NN\5436752|any|histidine (r_appos) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|)
T1_T16 NONE histidine_17\NN\14605787| (r_compound) allele_18\NN\5436752|any|histidine (r_appos) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|) (l_conj) fcgr3a_21\NN\1740|,|allele
T1_T17 NONE histidine_17\NN\14605787| (r_compound) allele_18\NN\5436752|any|histidine (r_appos) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|) (r_dep) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (r_nmod) patients_8\NNS\9898892|genotypes (r_nsubj) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_parataxis) had_58\VBD\2108377|patients|pfs|ci (l_nsubj) patients_46\NNS\9898892|genotypes (l_nmod) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (l_dep) arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (l_compound) fcgr2a_53\NN\1740|
T2_T15 NONE phenylalanine_24\NN\14605787| (r_amod) allele_25\NN\5436752|any|phenylalanine (r_appos) fcgr3a_21\NN\1740|,|allele (r_conj) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|)
T2_T16 NONE phenylalanine_24\NN\14605787| (r_amod) allele_25\NN\5436752|any|phenylalanine (r_appos) fcgr3a_21\NN\1740|,|allele
T2_T17 NONE phenylalanine_24\NN\14605787| (r_amod) allele_25\NN\5436752|any|phenylalanine (r_appos) fcgr3a_21\NN\1740|,|allele (r_conj) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|) (r_dep) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (r_nmod) patients_8\NNS\9898892|genotypes (r_nsubj) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_parataxis) had_58\VBD\2108377|patients|pfs|ci (l_nsubj) patients_46\NNS\9898892|genotypes (l_nmod) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (l_dep) arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (l_compound) fcgr2a_53\NN\1740|
T3_T15 NONE arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (r_dep) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (r_nmod) patients_46\NNS\9898892|genotypes (r_nsubj) had_58\VBD\2108377|patients|pfs|ci (r_parataxis) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_nsubj) patients_8\NNS\9898892|genotypes (l_nmod) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (l_dep) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|)
T3_T16 NONE arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (r_dep) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (r_nmod) patients_46\NNS\9898892|genotypes (r_nsubj) had_58\VBD\2108377|patients|pfs|ci (r_parataxis) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_nsubj) patients_8\NNS\9898892|genotypes (l_nmod) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (l_dep) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|) (l_conj) fcgr3a_21\NN\1740|,|allele
T3_T17 NONE arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (l_compound) fcgr2a_53\NN\1740|
T4_T15 NONE arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (r_dep) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (r_nmod) patients_46\NNS\9898892|genotypes (r_nsubj) had_58\VBD\2108377|patients|pfs|ci (r_parataxis) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_nsubj) patients_8\NNS\9898892|genotypes (l_nmod) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (l_dep) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|)
T4_T16 NONE arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (r_dep) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (r_nmod) patients_46\NNS\9898892|genotypes (r_nsubj) had_58\VBD\2108377|patients|pfs|ci (r_parataxis) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_nsubj) patients_8\NNS\9898892|genotypes (l_nmod) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (l_dep) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|) (l_conj) fcgr3a_21\NN\1740|,|allele
T4_T17 NONE arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (l_compound) fcgr2a_53\NN\1740|
T5_T15 NONE valine/valine_56\NN\1740| (r_conj) arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (r_dep) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (r_nmod) patients_46\NNS\9898892|genotypes (r_nsubj) had_58\VBD\2108377|patients|pfs|ci (r_parataxis) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_nsubj) patients_8\NNS\9898892|genotypes (l_nmod) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (l_dep) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|)
T5_T16 NONE valine/valine_56\NN\1740| (r_conj) arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (r_dep) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (r_nmod) patients_46\NNS\9898892|genotypes (r_nsubj) had_58\VBD\2108377|patients|pfs|ci (r_parataxis) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_nsubj) patients_8\NNS\9898892|genotypes (l_nmod) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (l_dep) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|) (l_conj) fcgr3a_21\NN\1740|,|allele
T5_T17 NONE valine/valine_56\NN\1740| (r_conj) arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (l_compound) fcgr2a_53\NN\1740|
T6_T15 NONE valine/valine_56\NN\1740| (r_conj) arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (r_dep) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (r_nmod) patients_46\NNS\9898892|genotypes (r_nsubj) had_58\VBD\2108377|patients|pfs|ci (r_parataxis) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_nsubj) patients_8\NNS\9898892|genotypes (l_nmod) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (l_dep) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|)
T6_T16 NONE valine/valine_56\NN\1740| (r_conj) arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (r_dep) genotypes_51\NNS\7941170|with|any|two|unfavorable|arginine/arginine (r_nmod) patients_46\NNS\9898892|genotypes (r_nsubj) had_58\VBD\2108377|patients|pfs|ci (r_parataxis) showed_27\VBD\2137132|that|patients|pfs|ci|,|whereas|had (l_nsubj) patients_8\NNS\9898892|genotypes (l_nmod) genotypes_12\NNS\7941170|with|the|favorable|fcgr2a (l_dep) fcgr2a_14\NN\1740|(|,|allele|,|and|fcgr3a|) (l_conj) fcgr3a_21\NN\1740|,|allele
T6_T17 NONE valine/valine_56\NN\1740| (r_conj) arginine/arginine_54\NN\1740|(|fcgr2a|or|valine/valine|) (l_compound) fcgr2a_53\NN\1740|
23324400
23625915
T10_T51 NONE amp-activated_21\JJ\1740| (r_amod) kinase_23\NN\14732946|through|amp-activated|protein|and|kinase
T10_T52 NONE amp-activated_21\JJ\1740| (r_amod) kinase_23\NN\14732946|through|amp-activated|protein|and|kinase (l_conj) kinase_28\NN\14732946|p38beta|mitogen-activated|protein (l_compound) p38beta_25\NN\1740|
T10_T53 NONE amp-activated_21\JJ\1740| (r_amod) kinase_23\NN\14732946|through|amp-activated|protein|and|kinase (l_conj) kinase_28\NN\14732946|p38beta|mitogen-activated|protein
T10_T54 NONE amp-activated_21\JJ\1740| (r_amod) kinase_23\NN\14732946|through|amp-activated|protein|and|kinase (r_nmod) inhibit_15\VB\2510337|to|soce|kinase (r_advcl) mediates_11\VBZ\761713|entry|phosphorylation|inhibit|. (l_nsubj) entry_3\NN\6502378|store-operated|ca2|+|soce|induced (l_acl) induced_7\VBN\1627355|receptor-1 (l_nmod) receptor-1_10\NN\1740|by|protease-activated
T10_T55 NONE amp-activated_21\JJ\1740| (r_amod) kinase_23\NN\14732946|through|amp-activated|protein|and|kinase (r_nmod) inhibit_15\VB\2510337|to|soce|kinase (r_advcl) mediates_11\VBZ\761713|entry|phosphorylation|inhibit|. (l_dobj) phosphorylation_13\NN\1740|stim1 (l_compound) stim1_12\NN\1740|
T11_T51 NONE +_2\NN\1740| (r_compound) entry_3\NN\6502378|store-operated|ca2|+|soce|induced (r_nsubj) mediates_11\VBZ\761713|entry|phosphorylation|inhibit|. (l_advcl) inhibit_15\VB\2510337|to|soce|kinase (l_nmod) kinase_23\NN\14732946|through|amp-activated|protein|and|kinase
T11_T52 NONE +_2\NN\1740| (r_compound) entry_3\NN\6502378|store-operated|ca2|+|soce|induced (r_nsubj) mediates_11\VBZ\761713|entry|phosphorylation|inhibit|. (l_advcl) inhibit_15\VB\2510337|to|soce|kinase (l_nmod) kinase_23\NN\14732946|through|amp-activated|protein|and|kinase (l_conj) kinase_28\NN\14732946|p38beta|mitogen-activated|protein (l_compound) p38beta_25\NN\1740|
T11_T53 NONE +_2\NN\1740| (r_compound) entry_3\NN\6502378|store-operated|ca2|+|soce|induced (r_nsubj) mediates_11\VBZ\761713|entry|phosphorylation|inhibit|. (l_advcl) inhibit_15\VB\2510337|to|soce|kinase (l_nmod) kinase_23\NN\14732946|through|amp-activated|protein|and|kinase (l_conj) kinase_28\NN\14732946|p38beta|mitogen-activated|protein
T11_T54 NONE +_2\NN\1740| (r_compound) entry_3\NN\6502378|store-operated|ca2|+|soce|induced (l_acl) induced_7\VBN\1627355|receptor-1 (l_nmod) receptor-1_10\NN\1740|by|protease-activated
T11_T55 NONE +_2\NN\1740| (r_compound) entry_3\NN\6502378|store-operated|ca2|+|soce|induced (r_nsubj) mediates_11\VBZ\761713|entry|phosphorylation|inhibit|. (l_dobj) phosphorylation_13\NN\1740|stim1 (l_compound) stim1_12\NN\1740|
T3_T12 NONE +_2\NN\1740| (r_compound) sensor_3\NN\3183080|+ (r_compound) stim1_4\NN\1740|the|ca2|sensor (r_nsubj) crucial_6\JJ\1740|stim1|is|activation|. (l_nmod) activation_8\NN\13561719|for|entry (l_nmod) entry_13\NN\6502378|of|store-operated|ca2|+|soce|channels (l_nmod) channels_21\NNS\6251781|through|trpc
T3_T29 NONE +_2\NN\1740| (r_compound) sensor_3\NN\3183080|+ (r_compound) stim1_4\NN\1740|the|ca2|sensor
T3_T47 NONE +_2\NN\1740| (r_compound) sensor_3\NN\3183080|+ (r_compound) stim1_4\NN\1740|the|ca2|sensor (r_nsubj) crucial_6\JJ\1740|stim1|is|activation|. (l_nmod) activation_8\NN\13561719|for|entry (l_nmod) entry_13\NN\6502378|of|store-operated|ca2|+|soce|channels (l_nmod) channels_21\NNS\6251781|through|trpc (l_compound) trpc_18\NN\1740|and|orai
T8_T12 NONE +_12\NN\1740| (r_compound) entry_13\NN\6502378|of|store-operated|ca2|+|soce|channels (l_nmod) channels_21\NNS\6251781|through|trpc
T8_T29 NONE +_12\NN\1740| (r_compound) entry_13\NN\6502378|of|store-operated|ca2|+|soce|channels (r_nmod) activation_8\NN\13561719|for|entry (r_nmod) crucial_6\JJ\1740|stim1|is|activation|. (l_nsubj) stim1_4\NN\1740|the|ca2|sensor
T8_T47 NONE +_12\NN\1740| (r_compound) entry_13\NN\6502378|of|store-operated|ca2|+|soce|channels (l_nmod) channels_21\NNS\6251781|through|trpc (l_compound) trpc_18\NN\1740|and|orai
T2_T31 NONE amp-activated_6\JJ\1740| (r_amod) kinase_8\NN\14732946|amp-activated|protein|ampk
T2_T32 NONE amp-activated_6\JJ\1740| (r_amod) kinase_8\NN\14732946|amp-activated|protein|ampk (l_appos) ampk_10\NN\1740|(|)
T2_T33 NONE amp-activated_6\JJ\1740| (r_amod) kinase_8\NN\14732946|amp-activated|protein|ampk (r_dobj) activates_5\VBZ\1641914|that|soce|kinase|;|phosphorylates (l_parataxis) phosphorylates_23\VBZ\1740|kinase|stim1|,|inhibiting (l_nsubj) kinase_18\NN\14732946|effector|p38β|mitogen-activated|protein|mapk (l_compound) p38β_15\NN\1740|
T2_T34 NONE amp-activated_6\JJ\1740| (r_amod) kinase_8\NN\14732946|amp-activated|protein|ampk (r_dobj) activates_5\VBZ\1641914|that|soce|kinase|;|phosphorylates (l_parataxis) phosphorylates_23\VBZ\1740|kinase|stim1|,|inhibiting (l_nsubj) kinase_18\NN\14732946|effector|p38β|mitogen-activated|protein|mapk
T2_T35 NONE amp-activated_6\JJ\1740| (r_amod) kinase_8\NN\14732946|amp-activated|protein|ampk (r_dobj) activates_5\VBZ\1641914|that|soce|kinase|;|phosphorylates (l_parataxis) phosphorylates_23\VBZ\1740|kinase|stim1|,|inhibiting (l_nsubj) kinase_18\NN\14732946|effector|p38β|mitogen-activated|protein|mapk (l_appos) mapk_21\NN\1740|(|p38β|) (l_compound) p38β_20\NN\1740|
T2_T36 NONE amp-activated_6\JJ\1740| (r_amod) kinase_8\NN\14732946|amp-activated|protein|ampk (r_dobj) activates_5\VBZ\1641914|that|soce|kinase|;|phosphorylates (l_parataxis) phosphorylates_23\VBZ\1740|kinase|stim1|,|inhibiting (l_nsubj) kinase_18\NN\14732946|effector|p38β|mitogen-activated|protein|mapk (l_appos) mapk_21\NN\1740|(|p38β|)
T2_T37 NONE amp-activated_6\JJ\1740| (r_amod) kinase_8\NN\14732946|amp-activated|protein|ampk (r_dobj) activates_5\VBZ\1641914|that|soce|kinase|;|phosphorylates (l_parataxis) phosphorylates_23\VBZ\1740|kinase|stim1|,|inhibiting (l_dobj) stim1_24\NN\1740|
T4_T38 CPR:3 aicar_4\NN\1740| (r_dobj) using_3\VBG\1156834|aicar (r_acl) activation_0\NN\13561719|ampk|using (l_nmod) ampk_2\NN\1740|of
T4_T39 CPR:3 aicar_4\NN\1740| (r_dobj) using_3\VBG\1156834|aicar (r_acl) activation_0\NN\13561719|ampk|using (r_nsubj) resulted_5\VBD\2633881|activation|phosphorylation|and|prevented|. (l_nmod) phosphorylation_8\NN\1740|in|stim1|residues (l_compound) stim1_7\NN\1740|
T4_T40 CPR:4 aicar_4\NN\1740| (r_dobj) using_3\VBG\1156834|aicar (r_acl) activation_0\NN\13561719|ampk|using (r_nsubj) resulted_5\VBD\2633881|activation|phosphorylation|and|prevented|. (l_conj) prevented_13\VBD\1740|entry (l_dobj) entry_17\NN\6502378|par-1-induced|ca2|+ (l_amod) par-1-induced_14\JJ\1740|
T5_T38 NONE serine_10\NN\14601829| (r_compound) residues_11\NNS\20827|on|serine (r_nmod) phosphorylation_8\NN\1740|in|stim1|residues (r_nmod) resulted_5\VBD\2633881|activation|phosphorylation|and|prevented|. (l_nsubj) activation_0\NN\13561719|ampk|using (l_nmod) ampk_2\NN\1740|of
T5_T39 NONE serine_10\NN\14601829| (r_compound) residues_11\NNS\20827|on|serine (r_nmod) phosphorylation_8\NN\1740|in|stim1|residues (l_compound) stim1_7\NN\1740|
T5_T40 NONE serine_10\NN\14601829| (r_compound) residues_11\NNS\20827|on|serine (r_nmod) phosphorylation_8\NN\1740|in|stim1|residues (r_nmod) resulted_5\VBD\2633881|activation|phosphorylation|and|prevented|. (l_conj) prevented_13\VBD\1740|entry (l_dobj) entry_17\NN\6502378|par-1-induced|ca2|+ (l_amod) par-1-induced_14\JJ\1740|
T6_T38 NONE +_16\NN\1740| (r_compound) entry_17\NN\6502378|par-1-induced|ca2|+ (r_dobj) prevented_13\VBD\1740|entry (r_conj) resulted_5\VBD\2633881|activation|phosphorylation|and|prevented|. (l_nsubj) activation_0\NN\13561719|ampk|using (l_nmod) ampk_2\NN\1740|of
T6_T39 NONE +_16\NN\1740| (r_compound) entry_17\NN\6502378|par-1-induced|ca2|+ (r_dobj) prevented_13\VBD\1740|entry (r_conj) resulted_5\VBD\2633881|activation|phosphorylation|and|prevented|. (l_nmod) phosphorylation_8\NN\1740|in|stim1|residues (l_compound) stim1_7\NN\1740|
T6_T40 NONE +_16\NN\1740| (r_compound) entry_17\NN\6502378|par-1-induced|ca2|+ (l_amod) par-1-induced_14\JJ\1740|
T7_T41 CPR:4 aicar_2\NN\1740| (r_compound) pretreatment_3\NN\1740|aicar (r_nsubj) blocked_4\VBD\1476483|further|,|pretreatment|increase|. (l_dobj) increase_6\NN\13576355|par-1-induced|permeability (l_amod) par-1-induced_5\JJ\1740|
T1_T46 NONE +_22\NN\1740| (r_compound) entry_23\NN\6502378|ca2|+ (r_conj) formation_19\NN\7938773|to|sustained|stim1-puncta|and|entry (r_nmod) led_15\VBD\1752884|formation (r_conj) blocked_11\VBD\1476483|interestingly|,|sb203580|phosphorylation|and|led|. (l_nsubj) sb203580_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_6\NN\20090|a|selective|mapk (l_nmod) mapk_9\NN\1740|of|p38 (l_compound) p38_8\NN\1740|
T1_T48 NONE +_22\NN\1740| (r_compound) entry_23\NN\6502378|ca2|+ (r_conj) formation_19\NN\7938773|to|sustained|stim1-puncta|and|entry (r_nmod) led_15\VBD\1752884|formation (r_conj) blocked_11\VBD\1476483|interestingly|,|sb203580|phosphorylation|and|led|. (l_nsubj) sb203580_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_6\NN\20090|a|selective|mapk (l_nmod) mapk_9\NN\1740|of|p38
T1_T49 NONE +_22\NN\1740| (r_compound) entry_23\NN\6502378|ca2|+ (r_conj) formation_19\NN\7938773|to|sustained|stim1-puncta|and|entry (r_nmod) led_15\VBD\1752884|formation (r_conj) blocked_11\VBD\1476483|interestingly|,|sb203580|phosphorylation|and|led|. (l_dobj) phosphorylation_13\NN\1740|stim1 (l_compound) stim1_12\NN\1740|
T1_T50 NONE +_22\NN\1740| (r_compound) entry_23\NN\6502378|ca2|+ (r_conj) formation_19\NN\7938773|to|sustained|stim1-puncta|and|entry (l_compound) stim1-puncta_18\NN\1740|
T9_T46 CPR:4 sb203580_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_6\NN\20090|a|selective|mapk (l_nmod) mapk_9\NN\1740|of|p38 (l_compound) p38_8\NN\1740|
T9_T48 CPR:4 sb203580_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_6\NN\20090|a|selective|mapk (l_nmod) mapk_9\NN\1740|of|p38
T9_T49 CPR:4 sb203580_2\NN\1740|,|inhibitor|, (r_nsubj) blocked_11\VBD\1476483|interestingly|,|sb203580|phosphorylation|and|led|. (l_dobj) phosphorylation_13\NN\1740|stim1 (l_compound) stim1_12\NN\1740|
T9_T50 NONE sb203580_2\NN\1740|,|inhibitor|, (r_nsubj) blocked_11\VBD\1476483|interestingly|,|sb203580|phosphorylation|and|led|. (l_conj) led_15\VBD\1752884|formation (l_nmod) formation_19\NN\7938773|to|sustained|stim1-puncta|and|entry (l_compound) stim1-puncta_18\NN\1740|
2386945
T25_T46 NONE estradiol-induced_6\JJ\1740| (r_amod) growth_7\NN\13526110|estradiol-induced|cells (r_dobj) blocked_5\VBD\1476483|concentrations|growth|,|but|seem (l_conj) seem_21\VB\2604760|interactions|do|not|involved|. (l_nsubj) interactions_18\NNS\37396|receptor (l_compound) receptor_14\NN\5225602|estrogen|er
T25_T47 NONE estradiol-induced_6\JJ\1740| (r_amod) growth_7\NN\13526110|estradiol-induced|cells (r_dobj) blocked_5\VBD\1476483|concentrations|growth|,|but|seem (l_conj) seem_21\VB\2604760|interactions|do|not|involved|. (l_nsubj) interactions_18\NNS\37396|receptor (l_compound) receptor_14\NN\5225602|estrogen|er (l_appos) er_16\NN\14625458|(|)
T26_T46 NONE estrogen_13\NN\14745635| (r_compound) receptor_14\NN\5225602|estrogen|er
T26_T47 NONE estrogen_13\NN\14745635| (r_compound) receptor_14\NN\5225602|estrogen|er (l_appos) er_16\NN\14625458|(|)
T1_T48 NONE estradiol_27\NN\14749794|by (r_nmod) induction_22\NN\7450842|with|the|receptors|estradiol (r_nmod) interfere_19\VB\2451370|nor|did|pimozide|induction|. (r_conj) had_3\VBD\2108377|pimozide|effect|properties|,|interfere (l_nmod) properties_10\NNS\32613|on|the|estradiol|binding|er (l_nmod) er_14\NN\14625458|of|the|mcf-7
T1_T49 NONE estradiol_27\NN\14749794|by (r_nmod) induction_22\NN\7450842|with|the|receptors|estradiol (l_nmod) receptors_25\NNS\5225602|of|progesterone
T27_T48 NONE pimozide_0\NN\3203641|and|thioridazine (r_nsubj) had_3\VBD\2108377|pimozide|effect|properties|,|interfere (l_nmod) properties_10\NNS\32613|on|the|estradiol|binding|er (l_nmod) er_14\NN\14625458|of|the|mcf-7
T27_T49 NONE pimozide_0\NN\3203641|and|thioridazine (r_nsubj) had_3\VBD\2108377|pimozide|effect|properties|,|interfere (l_conj) interfere_19\VB\2451370|nor|did|pimozide|induction|. (l_nmod) induction_22\NN\7450842|with|the|receptors|estradiol (l_nmod) receptors_25\NNS\5225602|of|progesterone
T28_T48 NONE thioridazine_2\NN\3713736| (r_conj) pimozide_0\NN\3203641|and|thioridazine (r_nsubj) had_3\VBD\2108377|pimozide|effect|properties|,|interfere (l_nmod) properties_10\NNS\32613|on|the|estradiol|binding|er (l_nmod) er_14\NN\14625458|of|the|mcf-7
T28_T49 NONE thioridazine_2\NN\3713736| (r_conj) pimozide_0\NN\3203641|and|thioridazine (r_nsubj) had_3\VBD\2108377|pimozide|effect|properties|,|interfere (l_conj) interfere_19\VB\2451370|nor|did|pimozide|induction|. (l_nmod) induction_22\NN\7450842|with|the|receptors|estradiol (l_nmod) receptors_25\NNS\5225602|of|progesterone
T29_T48 NONE estradiol_8\NN\14749794| (r_compound) properties_10\NNS\32613|on|the|estradiol|binding|er (l_nmod) er_14\NN\14625458|of|the|mcf-7
T29_T49 NONE estradiol_8\NN\14749794| (r_compound) properties_10\NNS\32613|on|the|estradiol|binding|er (r_nmod) had_3\VBD\2108377|pimozide|effect|properties|,|interfere (l_conj) interfere_19\VB\2451370|nor|did|pimozide|induction|. (l_nmod) induction_22\NN\7450842|with|the|receptors|estradiol (l_nmod) receptors_25\NNS\5225602|of|progesterone
T30_T48 NONE pimozide_18\NN\3203641| (r_nsubj) interfere_19\VB\2451370|nor|did|pimozide|induction|. (r_conj) had_3\VBD\2108377|pimozide|effect|properties|,|interfere (l_nmod) properties_10\NNS\32613|on|the|estradiol|binding|er (l_nmod) er_14\NN\14625458|of|the|mcf-7
T30_T49 NONE pimozide_18\NN\3203641| (r_nsubj) interfere_19\VB\2451370|nor|did|pimozide|induction|. (l_nmod) induction_22\NN\7450842|with|the|receptors|estradiol (l_nmod) receptors_25\NNS\5225602|of|progesterone
T31_T48 NONE progesterone_24\NN\14747338| (r_compound) receptors_25\NNS\5225602|of|progesterone (r_nmod) induction_22\NN\7450842|with|the|receptors|estradiol (r_nmod) interfere_19\VB\2451370|nor|did|pimozide|induction|. (r_conj) had_3\VBD\2108377|pimozide|effect|properties|,|interfere (l_nmod) properties_10\NNS\32613|on|the|estradiol|binding|er (l_nmod) er_14\NN\14625458|of|the|mcf-7
T31_T49 NONE progesterone_24\NN\14747338| (r_compound) receptors_25\NNS\5225602|of|progesterone
T2_T34 NONE pimozide_2\NN\3203641| (r_nsubj) inhibited_4\VBD\2510337|furthermore|,|pimozide|also|incorporation|. (l_dobj) incorporation_5\NN\1237415|[3h]thymidine|cells (l_nmod) cells_10\NNS\3080309|into|mcf-7|stimulated (l_acl) stimulated_11\VBN\137313|hormones (l_nmod) hormones_14\NNS\5404728|by|polypeptide|medium
T3_T34 NONE [3h]thymidine_7\NN\1740|of (r_nmod) incorporation_5\NN\1237415|[3h]thymidine|cells (l_nmod) cells_10\NNS\3080309|into|mcf-7|stimulated (l_acl) stimulated_11\VBN\137313|hormones (l_nmod) hormones_14\NNS\5404728|by|polypeptide|medium
T4_T35 NONE pimozide_3\NN\3203641|for|medium (r_nmod) ki_1\NN\14050143|the|pimozide|, (r_nsubj) similar_13\JJ\1740|ki|was|that|. (l_nmod) that_15\DT\1740|to|determined (l_acl) determined_16\VBN\1645601|presence (l_nmod) presence_19\NN\13954253|in|the|insulin (l_nmod) insulin_21\NN\5407119|of|microm|,|factor|,|and|factor
T4_T36 NONE pimozide_3\NN\3203641|for|medium (r_nmod) ki_1\NN\14050143|the|pimozide|, (r_nsubj) similar_13\JJ\1740|ki|was|that|. (l_nmod) that_15\DT\1740|to|determined (l_acl) determined_16\VBN\1645601|presence (l_nmod) presence_19\NN\13954253|in|the|insulin (l_nmod) insulin_21\NN\5407119|of|microm|,|factor|,|and|factor (l_conj) factor_29\NN\7326557|insulin-like|growth|i (l_nummod) i_30\CD\14622893|microm
T4_T37 NONE pimozide_3\NN\3203641|for|medium (r_nmod) ki_1\NN\14050143|the|pimozide|, (r_nsubj) similar_13\JJ\1740|ki|was|that|. (l_nmod) that_15\DT\1740|to|determined (l_acl) determined_16\VBN\1645601|presence (l_nmod) presence_19\NN\13954253|in|the|insulin (l_nmod) insulin_21\NN\5407119|of|microm|,|factor|,|and|factor (l_conj) factor_39\NN\7326557|epidermal|growth|microm
T6_T38 NONE pimozide_0\NN\3203641| (r_nsubj) blocked_2\VBD\1476483|pimozide|also|growth|. (l_dobj) growth_4\NN\13526110|cell|and|incorporation|t47d (l_nmod) t47d_11\NN\1740|into|the|er-positive|and|zr75|-|1b|lines|and|line (l_amod) er-positive_10\JJ\1740|
T6_T39 NONE pimozide_0\NN\3203641| (r_nsubj) blocked_2\VBD\1476483|pimozide|also|growth|. (l_dobj) growth_4\NN\13526110|cell|and|incorporation|t47d (l_nmod) t47d_11\NN\1740|into|the|er-positive|and|zr75|-|1b|lines|and|line (l_conj) line_28\NN\8426461|the|er-negative|human|breast|cancer|cell|,|mda-mb-231 (l_amod) er-negative_23\JJ\1740|
T7_T38 NONE [3h]thymidine_6\NN\1740| (r_compound) incorporation_7\NN\1237415|[3h]thymidine (r_conj) growth_4\NN\13526110|cell|and|incorporation|t47d (l_nmod) t47d_11\NN\1740|into|the|er-positive|and|zr75|-|1b|lines|and|line (l_amod) er-positive_10\JJ\1740|
T7_T39 NONE [3h]thymidine_6\NN\1740| (r_compound) incorporation_7\NN\1237415|[3h]thymidine (r_conj) growth_4\NN\13526110|cell|and|incorporation|t47d (l_nmod) t47d_11\NN\1740|into|the|er-positive|and|zr75|-|1b|lines|and|line (l_conj) line_28\NN\8426461|the|er-negative|human|breast|cancer|cell|,|mda-mb-231 (l_amod) er-negative_23\JJ\1740|
T8_T40 CPR:6 pimozide_6\NN\3203641|of|and|thioridazine (r_nmod) action_4\NN\30358|of|pimozide (r_nmod) mechanisms_2\NNS\13446390|numerous|action (r_nsubjpass) identified_11\VBN\699815|although|mechanisms|have|been (r_advcl) antagonists_17\NNS\7846|identified|,|drugs|are|calmodulin|concentrations|. (l_compound) calmodulin_16\NN\1740|
T9_T40 CPR:6 thioridazine_8\NN\3713736| (r_conj) pimozide_6\NN\3203641|of|and|thioridazine (r_nmod) action_4\NN\30358|of|pimozide (r_nmod) mechanisms_2\NNS\13446390|numerous|action (r_nsubjpass) identified_11\VBN\699815|although|mechanisms|have|been (r_advcl) antagonists_17\NNS\7846|identified|,|drugs|are|calmodulin|concentrations|. (l_compound) calmodulin_16\NN\1740|
T12_T41 CPR:6 w-13_10\NN\1740|and|w-12 (r_dep) antagonists_9\NNS\7846|by|the|selective|calmodulin|w-13 (l_compound) calmodulin_8\NN\1740|
T12_T42 NONE w-13_10\NN\1740|and|w-12 (r_dep) antagonists_9\NNS\7846|by|the|selective|calmodulin|w-13 (r_nmod) inhibition_0\NN\1068773|growth|antagonists (r_nsubj) consistent_14\JJ\1740|inhibition|is|role|. (l_nmod) role_17\NN\719494|with|a|antagonism|properties (l_nmod) antagonism_20\NN\24720|for|calmodulin (l_compound) calmodulin_19\NN\1740|
T13_T41 CPR:6 w-12_12\NN\1740| (r_conj) w-13_10\NN\1740|and|w-12 (r_dep) antagonists_9\NNS\7846|by|the|selective|calmodulin|w-13 (l_compound) calmodulin_8\NN\1740|
T13_T42 NONE w-12_12\NN\1740| (r_conj) w-13_10\NN\1740|and|w-12 (r_dep) antagonists_9\NNS\7846|by|the|selective|calmodulin|w-13 (r_nmod) inhibition_0\NN\1068773|growth|antagonists (r_nsubj) consistent_14\JJ\1740|inhibition|is|role|. (l_nmod) role_17\NN\719494|with|a|antagonism|properties (l_nmod) antagonism_20\NN\24720|for|calmodulin (l_compound) calmodulin_19\NN\1740|
T15_T41 NONE pimozide_27\NN\3203641|of (r_nmod) properties_25\NNS\32613|in|the|broad|growth-inhibitory|pimozide (r_nmod) role_17\NN\719494|with|a|antagonism|properties (r_nmod) consistent_14\JJ\1740|inhibition|is|role|. (l_nsubj) inhibition_0\NN\1068773|growth|antagonists (l_nmod) antagonists_9\NNS\7846|by|the|selective|calmodulin|w-13 (l_compound) calmodulin_8\NN\1740|
T15_T42 CPR:4 pimozide_27\NN\3203641|of (r_nmod) properties_25\NNS\32613|in|the|broad|growth-inhibitory|pimozide (r_nmod) role_17\NN\719494|with|a|antagonism|properties (l_nmod) antagonism_20\NN\24720|for|calmodulin (l_compound) calmodulin_19\NN\1740|
T16_T43 NONE pimozide_3\NN\3203641|and|thioridazine (r_nsubj) useful_8\JJ\1740|that|pimozide|may|be|control (l_nmod) control_11\NN\5190804|in|the|growth (l_nmod) growth_17\NN\13526110|of|estradiol-|tumors (l_amod) estradiol-_13\NN\1740|and|hormone-induced (l_conj) hormone-induced_16\JJ\1740|polypeptide
T16_T44 NONE pimozide_3\NN\3203641|and|thioridazine (r_nsubj) useful_8\JJ\1740|that|pimozide|may|be|control (l_nmod) control_11\NN\5190804|in|the|growth (l_nmod) growth_17\NN\13526110|of|estradiol-|tumors (l_nmod) tumors_24\NNS\14234074|of|er-positive|human|breast (l_amod) er-positive_19\JJ\1740|and|er-negative
T16_T45 NONE pimozide_3\NN\3203641|and|thioridazine (r_nsubj) useful_8\JJ\1740|that|pimozide|may|be|control (l_nmod) control_11\NN\5190804|in|the|growth (l_nmod) growth_17\NN\13526110|of|estradiol-|tumors (l_nmod) tumors_24\NNS\14234074|of|er-positive|human|breast (l_amod) er-positive_19\JJ\1740|and|er-negative (l_conj) er-negative_21\JJ\1740|
T17_T43 NONE thioridazine_5\NN\3713736| (r_conj) pimozide_3\NN\3203641|and|thioridazine (r_nsubj) useful_8\JJ\1740|that|pimozide|may|be|control (l_nmod) control_11\NN\5190804|in|the|growth (l_nmod) growth_17\NN\13526110|of|estradiol-|tumors (l_amod) estradiol-_13\NN\1740|and|hormone-induced (l_conj) hormone-induced_16\JJ\1740|polypeptide
T17_T44 NONE thioridazine_5\NN\3713736| (r_conj) pimozide_3\NN\3203641|and|thioridazine (r_nsubj) useful_8\JJ\1740|that|pimozide|may|be|control (l_nmod) control_11\NN\5190804|in|the|growth (l_nmod) growth_17\NN\13526110|of|estradiol-|tumors (l_nmod) tumors_24\NNS\14234074|of|er-positive|human|breast (l_amod) er-positive_19\JJ\1740|and|er-negative
T17_T45 NONE thioridazine_5\NN\3713736| (r_conj) pimozide_3\NN\3203641|and|thioridazine (r_nsubj) useful_8\JJ\1740|that|pimozide|may|be|control (l_nmod) control_11\NN\5190804|in|the|growth (l_nmod) growth_17\NN\13526110|of|estradiol-|tumors (l_nmod) tumors_24\NNS\14234074|of|er-positive|human|breast (l_amod) er-positive_19\JJ\1740|and|er-negative (l_conj) er-negative_21\JJ\1740|
T18_T43 NONE estradiol-_13\NN\1740|and|hormone-induced (l_conj) hormone-induced_16\JJ\1740|polypeptide
T18_T44 NONE estradiol-_13\NN\1740|and|hormone-induced (r_amod) growth_17\NN\13526110|of|estradiol-|tumors (l_nmod) tumors_24\NNS\14234074|of|er-positive|human|breast (l_amod) er-positive_19\JJ\1740|and|er-negative
T18_T45 NONE estradiol-_13\NN\1740|and|hormone-induced (r_amod) growth_17\NN\13526110|of|estradiol-|tumors (l_nmod) tumors_24\NNS\14234074|of|er-positive|human|breast (l_amod) er-positive_19\JJ\1740|and|er-negative (l_conj) er-negative_21\JJ\1740|
18593927
T5_T13 NONE nitrosoureas_24\NNS\1740|of (r_nmod) effects_22\NNS\13245626|the|nitrosoureas|processes (r_dobj) determine_20\VB\1645601|effects (r_conj) establish_4\VB\2426171|to|role|and|determine (l_dobj) role_6\NN\719494|a|stathmin|motility (l_nmod) stathmin_8\NN\1740|for
T1_T14 NONE ccnu_41\NN\1740|) (r_appos) 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea_38\NN\1740|(|[|]|;|ccnu (r_compound) concentrations_43\NNS\4916342|of|nitrosourea|1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (r_nmod) absence_30\NN\14449405|in|the|and|presence|concentrations (r_conj) down-regulation_22\NN\1740|before|the|levels|and|absence (l_nmod) levels_26\NNS\4916342|of|cellular|stathmin (l_compound) stathmin_25\NN\1740|
T6_T14 NONE nitrosourea_35\NN\1740|sublethal (r_compound) concentrations_43\NNS\4916342|of|nitrosourea|1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (r_nmod) absence_30\NN\14449405|in|the|and|presence|concentrations (r_conj) down-regulation_22\NN\1740|before|the|levels|and|absence (l_nmod) levels_26\NNS\4916342|of|cellular|stathmin (l_compound) stathmin_25\NN\1740|
T7_T14 NONE ]_39\-RRB-\1740| (r_punct) 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea_38\NN\1740|(|[|]|;|ccnu (r_compound) concentrations_43\NNS\4916342|of|nitrosourea|1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (r_nmod) absence_30\NN\14449405|in|the|and|presence|concentrations (r_conj) down-regulation_22\NN\1740|before|the|levels|and|absence (l_nmod) levels_26\NNS\4916342|of|cellular|stathmin (l_compound) stathmin_25\NN\1740|
T3_T9 CPR:4 ccnu_6\NNP\1740|by (r_nmod) inhibition_2\NN\1068773|the|direct|stathmin|ccnu (l_nmod) stathmin_4\NN\1740|of
23327794
T8_T11 NONE acetylcholine_11\NN\14807558| (r_compound) receptors_12\NNS\5225602|nicotinic|acetylcholine|nachrs
T8_T12 NONE acetylcholine_11\NN\14807558| (r_compound) receptors_12\NNS\5225602|nicotinic|acetylcholine|nachrs (l_appos) nachrs_14\NNS\1740|(|)
T8_T13 NONE acetylcholine_11\NN\14807558| (r_compound) receptors_12\NNS\5225602|nicotinic|acetylcholine|nachrs (r_dep) α3β4_7\NN\1740|on|human|or|α4β2|receptors (r_nmod) effects_4\NNS\13245626|for|their|α3β4 (r_nmod) evaluated_1\VBN\670261|when|effects (r_advcl) shown_22\VBN\2137132|evaluated|,|several|were|active|. (l_xcomp) active_25\JJ\1740|to|be|antagonists (l_nmod) antagonists_28\NNS\7846|as|nachr (l_compound) nachr_27\NN\1740|
T9_T10 NONE a_8\NN\13649268|microgrewiapine|(|1|) (r_nsubjpass) found_13\VBN\2426171|result|,|a|was|agent|. (l_ccomp) agent_19\NN\7347|to|be|a|selective|cytotoxic|cells|and|exhibit (l_conj) exhibit_30\VB\2632167|to|activity (l_dobj) activity_34\NN\30358|nicotinic|receptor|antagonistic|subtypes (l_nmod) subtypes_42\NNS\1740|for|both|the|hα3β4|receptor (l_compound) receptor_41\NN\5225602|
T9_T14 CPR:6 a_8\NN\13649268|microgrewiapine|(|1|) (r_nsubjpass) found_13\VBN\2426171|result|,|a|was|agent|. (l_ccomp) agent_19\NN\7347|to|be|a|selective|cytotoxic|cells|and|exhibit (l_conj) exhibit_30\VB\2632167|to|activity (l_dobj) activity_34\NN\30358|nicotinic|receptor|antagonistic|subtypes (l_compound) receptor_32\NN\5225602|
19281809
T28_T38 CPR:4 etabonate_1\NN\1740|sergliflozin|,|inhibitor|, (l_appos) inhibitor_6\NN\20090|a|selective|sglt2 (l_compound) sglt2_5\NN\1740|
T29_T38 NONE streptozotocin-induced_12\JJ\1740| (r_amod) rats_14\NNS\2329401|in|streptozotocin-induced|diabetic|and|rats (r_nmod) control_10\NN\5190804|glycemic|rats (r_dobj) improves_8\VBZ\126264|etabonate|control|. (l_nsubj) etabonate_1\NN\1740|sergliflozin|,|inhibitor|, (l_appos) inhibitor_6\NN\20090|a|selective|sglt2 (l_compound) sglt2_5\NN\1740|
T11_T32 NONE sodium_2\NN\14625458| (r_compound) cotransporter_4\NN\1740|the|low-affinity|sodium|glucose|sglt2
T11_T35 NONE sodium_2\NN\14625458| (r_compound) cotransporter_4\NN\1740|the|low-affinity|sodium|glucose|sglt2 (l_appos) sglt2_6\NN\1740|(|)
T13_T32 NONE glucose_3\NN\14710501| (r_compound) cotransporter_4\NN\1740|the|low-affinity|sodium|glucose|sglt2
T13_T35 NONE glucose_3\NN\14710501| (r_compound) cotransporter_4\NN\1740|the|low-affinity|sodium|glucose|sglt2 (l_appos) sglt2_6\NN\1740|(|)
T25_T32 CPR:9 glucose_14\NN\14710501| (r_compound) reabsorption_15\NN\13526110|of|the|glucose|kidney (r_nmod) most_11\JJS\1740|for|reabsorption (r_nmod) responsible_9\JJ\1740|cotransporter|is|most|and|highlighted|. (l_nsubj) cotransporter_4\NN\1740|the|low-affinity|sodium|glucose|sglt2
T25_T35 CPR:9 glucose_14\NN\14710501| (r_compound) reabsorption_15\NN\13526110|of|the|glucose|kidney (r_nmod) most_11\JJS\1740|for|reabsorption (r_nmod) responsible_9\JJ\1740|cotransporter|is|most|and|highlighted|. (l_nsubj) cotransporter_4\NN\1740|the|low-affinity|sodium|glucose|sglt2 (l_appos) sglt2_6\NN\1740|(|)
T12_T33 CPR:4 etabonate_3\NN\1740|sergliflozin|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|novel|selective|sglt2 (l_compound) sglt2_8\NN\1740|
T12_T34 CPR:4 etabonate_3\NN\1740|sergliflozin|,|inhibitor (r_dobj) discovered_1\VBD\2163746|we|etabonate|,|and|found|. (l_conj) found_12\VBD\2426171|increased (l_ccomp) increased_18\VBD\169651|that|inhibition|excretion|and|decreased (l_nsubj) inhibition_15\NN\1068773|selective|sglt2 (l_nmod) sglt2_17\NN\1740|of
T14_T33 NONE glucose_20\NN\14710501| (r_compound) excretion_21\NN\13466586|urinary|glucose (r_dobj) increased_18\VBD\169651|that|inhibition|excretion|and|decreased (r_ccomp) found_12\VBD\2426171|increased (r_conj) discovered_1\VBD\2163746|we|etabonate|,|and|found|. (l_dobj) etabonate_3\NN\1740|sergliflozin|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|novel|selective|sglt2 (l_compound) sglt2_8\NN\1740|
T14_T34 NONE glucose_20\NN\14710501| (r_compound) excretion_21\NN\13466586|urinary|glucose (r_dobj) increased_18\VBD\169651|that|inhibition|excretion|and|decreased (l_nsubj) inhibition_15\NN\1068773|selective|sglt2 (l_nmod) sglt2_17\NN\1740|of
T15_T33 NONE glucose_26\NN\14710501| (r_compound) levels_27\NNS\4916342|plasma|glucose (r_dobj) decreased_24\VBD\169651|consequently|levels (r_conj) increased_18\VBD\169651|that|inhibition|excretion|and|decreased (r_ccomp) found_12\VBD\2426171|increased (r_conj) discovered_1\VBD\2163746|we|etabonate|,|and|found|. (l_dobj) etabonate_3\NN\1740|sergliflozin|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|novel|selective|sglt2 (l_compound) sglt2_8\NN\1740|
T15_T34 NONE glucose_26\NN\14710501| (r_compound) levels_27\NNS\4916342|plasma|glucose (r_dobj) decreased_24\VBD\169651|consequently|levels (r_conj) increased_18\VBD\169651|that|inhibition|excretion|and|decreased (l_nsubj) inhibition_15\NN\1068773|selective|sglt2 (l_nmod) sglt2_17\NN\1740|of
T16_T36 NONE etabonate_11\NN\1740|of|sergliflozin (r_nmod) effects_8\NNS\13245626|the|antihyperglycemic|etabonate|rats (r_dobj) examined_5\VBD\789138|report|,|we|effects|comparison|. (l_nmod) comparison_18\NN\635850|in|those (l_nmod) those_20\DT\1740|with|sulfonylurea (l_nmod) sulfonylurea_23\NN\2719105|of|a|gliclazide|and|inhibitor (l_conj) inhibitor_30\NN\20090|an|alpha-glucosidase|voglibose (l_compound) alpha-glucosidase_29\NN\1740|
T17_T36 NONE sulfonylurea_23\NN\2719105|of|a|gliclazide|and|inhibitor (l_conj) inhibitor_30\NN\20090|an|alpha-glucosidase|voglibose (l_compound) alpha-glucosidase_29\NN\1740|
T18_T36 NONE gliclazide_25\NN\1740|(|) (r_appos) sulfonylurea_23\NN\2719105|of|a|gliclazide|and|inhibitor (l_conj) inhibitor_30\NN\20090|an|alpha-glucosidase|voglibose (l_compound) alpha-glucosidase_29\NN\1740|
T19_T36 CPR:4 voglibose_32\NN\1740|(|) (r_appos) inhibitor_30\NN\20090|an|alpha-glucosidase|voglibose (l_compound) alpha-glucosidase_29\NN\1740|
T20_T37 NONE etabonate_1\NN\1740|sergliflozin (r_nsubj) increased_2\VBD\169651|etabonate|excretion|manner|,|and|inhibited|. (l_conj) inhibited_12\VBD\2510337|increase|independently|secretion (l_nmod) secretion_24\NN\13526110|of|insulin|rats (l_compound) insulin_23\NN\5407119|
T21_T37 NONE glucose_4\NN\14710501| (r_compound) excretion_5\NN\13466586|urinary|glucose (r_dobj) increased_2\VBD\169651|etabonate|excretion|manner|,|and|inhibited|. (l_conj) inhibited_12\VBD\2510337|increase|independently|secretion (l_nmod) secretion_24\NN\13526110|of|insulin|rats (l_compound) insulin_23\NN\5407119|
T22_T37 NONE glucose_17\NN\14710501|in|plasma (r_nmod) increase_14\NN\13576355|the|glucose|loading (r_dobj) inhibited_12\VBD\2510337|increase|independently|secretion (l_nmod) secretion_24\NN\13526110|of|insulin|rats (l_compound) insulin_23\NN\5407119|
T23_T37 NONE sucrose_19\NN\14836642| (r_compound) loading_20\NN\4571088|after|sucrose (r_nmod) increase_14\NN\13576355|the|glucose|loading (r_dobj) inhibited_12\VBD\2510337|increase|independently|secretion (l_nmod) secretion_24\NN\13526110|of|insulin|rats (l_compound) insulin_23\NN\5407119|
T6_T30 CPR:4 etabonate_4\NN\1740|with|sergliflozin (r_nmod) treatment_1\NN\654885|chronic|etabonate (r_nsubj) reduced_5\VBD\441445|treatment|levels|,|and|improved|. (l_dobj) levels_7\NNS\4916342|the|hemoglobin (l_nmod) hemoglobin_10\NN\14888884|of|glycated|and|glucose
T7_T30 NONE glucose_14\NN\14710501|fasting|plasma (r_conj) hemoglobin_10\NN\14888884|of|glycated|and|glucose
T8_T30 NONE glucose_22\NN\14710501| (r_compound) loading_23\NN\4571088|after|glucose (r_nmod) response_20\NN\11410625|the|glycemic|loading (r_dobj) improved_17\VBD\126264|response|rats (r_conj) reduced_5\VBD\441445|treatment|levels|,|and|improved|. (l_dobj) levels_7\NNS\4916342|the|hemoglobin (l_nmod) hemoglobin_10\NN\14888884|of|glycated|and|glucose
T10_T31 NONE etabonate_5\NN\1740|sergliflozin (r_nsubj) improve_7\VB\126264|that|etabonate|could|control|use|,|and|provide (l_nmod) use_12\NN\407535|without|its|resulting (l_acl) resulting_13\VBG\2633881|secretion (l_nmod) secretion_16\NN\13526110|in|insulin|,|hypoglycemia|,|and|gain (l_compound) insulin_15\NN\5407119|
23373704
T4_T10 NONE tetranitrate_9\NN\1740| (r_compound) reductase_10\NN\14732946|in|pentaerythritol|tetranitrate|petnr (l_appos) petnr_12\NN\1740|(|)
T4_T9 NONE tetranitrate_9\NN\1740| (r_compound) reductase_10\NN\14732946|in|pentaerythritol|tetranitrate|petnr
T5_T10 NONE (13)c_29\NN\1740|(|,|(15)n|) (r_appos) isotope_27\NN\14619225|with|the|corresponding|heavy|(13)c (r_nmod) replaced_22\VBN\1631072|where|atoms|were|isotope (r_acl:relcl) substitution_16\NN\7337390|by|isotopic|replaced (r_nmod) perturbed_4\VBN\1770501|here|,|we|have|motions|substitution|. (l_dobj) motions_6\NNS\6873252|vibrational|reductase (l_nmod) reductase_10\NN\14732946|in|pentaerythritol|tetranitrate|petnr (l_appos) petnr_12\NN\1740|(|)
T5_T9 NONE (13)c_29\NN\1740|(|,|(15)n|) (r_appos) isotope_27\NN\14619225|with|the|corresponding|heavy|(13)c (r_nmod) replaced_22\VBN\1631072|where|atoms|were|isotope (r_acl:relcl) substitution_16\NN\7337390|by|isotopic|replaced (r_nmod) perturbed_4\VBN\1770501|here|,|we|have|motions|substitution|. (l_dobj) motions_6\NNS\6873252|vibrational|reductase (l_nmod) reductase_10\NN\14732946|in|pentaerythritol|tetranitrate|petnr
T6_T10 NONE (15)n_31\NN\1740|,|and|(2)h (r_conj) (13)c_29\NN\1740|(|,|(15)n|) (r_appos) isotope_27\NN\14619225|with|the|corresponding|heavy|(13)c (r_nmod) replaced_22\VBN\1631072|where|atoms|were|isotope (r_acl:relcl) substitution_16\NN\7337390|by|isotopic|replaced (r_nmod) perturbed_4\VBN\1770501|here|,|we|have|motions|substitution|. (l_dobj) motions_6\NNS\6873252|vibrational|reductase (l_nmod) reductase_10\NN\14732946|in|pentaerythritol|tetranitrate|petnr (l_appos) petnr_12\NN\1740|(|)
T6_T9 NONE (15)n_31\NN\1740|,|and|(2)h (r_conj) (13)c_29\NN\1740|(|,|(15)n|) (r_appos) isotope_27\NN\14619225|with|the|corresponding|heavy|(13)c (r_nmod) replaced_22\VBN\1631072|where|atoms|were|isotope (r_acl:relcl) substitution_16\NN\7337390|by|isotopic|replaced (r_nmod) perturbed_4\VBN\1770501|here|,|we|have|motions|substitution|. (l_dobj) motions_6\NNS\6873252|vibrational|reductase (l_nmod) reductase_10\NN\14732946|in|pentaerythritol|tetranitrate|petnr
T7_T10 NONE (2)h_34\NN\1740| (r_conj) (15)n_31\NN\1740|,|and|(2)h (r_conj) (13)c_29\NN\1740|(|,|(15)n|) (r_appos) isotope_27\NN\14619225|with|the|corresponding|heavy|(13)c (r_nmod) replaced_22\VBN\1631072|where|atoms|were|isotope (r_acl:relcl) substitution_16\NN\7337390|by|isotopic|replaced (r_nmod) perturbed_4\VBN\1770501|here|,|we|have|motions|substitution|. (l_dobj) motions_6\NNS\6873252|vibrational|reductase (l_nmod) reductase_10\NN\14732946|in|pentaerythritol|tetranitrate|petnr (l_appos) petnr_12\NN\1740|(|)
T7_T9 NONE (2)h_34\NN\1740| (r_conj) (15)n_31\NN\1740|,|and|(2)h (r_conj) (13)c_29\NN\1740|(|,|(15)n|) (r_appos) isotope_27\NN\14619225|with|the|corresponding|heavy|(13)c (r_nmod) replaced_22\VBN\1631072|where|atoms|were|isotope (r_acl:relcl) substitution_16\NN\7337390|by|isotopic|replaced (r_nmod) perturbed_4\VBN\1770501|here|,|we|have|motions|substitution|. (l_dobj) motions_6\NNS\6873252|vibrational|reductase (l_nmod) reductase_10\NN\14732946|in|pentaerythritol|tetranitrate|petnr
23562076
T1_T10 NONE glucose_40\NN\14710501| (r_compound) homeostasis_41\NN\13934900|host|glucose (r_dobj) impacts_38\VBZ\1527271|that|expression|homeostasis (r_ccomp) demonstrating_25\VBG\2137132|impacts (r_advcl) lost_11\VBN\1794668|however|,|phenotype|was|mice|,|demonstrating|. (l_nmod) mice_15\NNS\2329401|in|t-bet(-/-|lacking (l_compound) t-bet(-/-_13\NN\1740|)
T1_T11 NONE glucose_40\NN\14710501| (r_compound) homeostasis_41\NN\13934900|host|glucose (r_dobj) impacts_38\VBZ\1527271|that|expression|homeostasis (r_ccomp) demonstrating_25\VBG\2137132|impacts (r_advcl) lost_11\VBN\1794668|however|,|phenotype|was|mice|,|demonstrating|. (l_nmod) mice_15\NNS\2329401|in|t-bet(-/-|lacking (l_acl) lacking_17\VBG\1740|also|immunity|t-bet(-/-)xrag2(-/- (l_dep) t-bet(-/-)xrag2(-/-_21\JJ\1740|(|)|)
T1_T12 NONE glucose_40\NN\14710501| (r_compound) homeostasis_41\NN\13934900|host|glucose (r_dobj) impacts_38\VBZ\1527271|that|expression|homeostasis (r_ccomp) demonstrating_25\VBG\2137132|impacts (r_advcl) lost_11\VBN\1794668|however|,|phenotype|was|mice|,|demonstrating|. (l_nmod) mice_15\NNS\2329401|in|t-bet(-/-|lacking (l_acl) lacking_17\VBG\1740|also|immunity|t-bet(-/-)xrag2(-/- (l_dep) t-bet(-/-)xrag2(-/-_21\JJ\1740|(|)|)
T1_T13 NONE glucose_40\NN\14710501| (r_compound) homeostasis_41\NN\13934900|host|glucose (r_dobj) impacts_38\VBZ\1527271|that|expression|homeostasis (l_nsubj) expression_28\NN\4679549|t-bet|adaptive (l_compound) t-bet_27\NN\1740|
T1_T9 NONE glucose_40\NN\14710501| (r_compound) homeostasis_41\NN\13934900|host|glucose (r_dobj) impacts_38\VBZ\1527271|that|expression|homeostasis (r_ccomp) demonstrating_25\VBG\2137132|impacts (r_advcl) lost_11\VBN\1794668|however|,|phenotype|was|mice|,|demonstrating|. (l_nsubjpass) phenotype_5\NN\4933544|the|favorable|metabolic|observed (l_acl) observed_6\VBN\2163746|hosts (l_nmod) hosts_9\NNS\9605289|in|t-bet-deficient (l_amod) t-bet-deficient_8\JJ\1740|
23409765
T3_T10 NONE porphobilinogen_4\NN\1740| (r_compound) synthase_5\NN\1740|of|porphobilinogen|pbgs (l_appos) pbgs_7\NN\1740|(|)
T3_T9 NONE porphobilinogen_4\NN\1740| (r_compound) synthase_5\NN\1740|of|porphobilinogen|pbgs
T1_T4 NONE phenylalanine_15\NN\14605787| (r_compound) hydroxylase_16\NN\1740|for|the|morpheeins|phenylalanine|,|integrase|,|kinase|,|and|α
T1_T5 NONE phenylalanine_15\NN\14605787| (r_compound) hydroxylase_16\NN\1740|for|the|morpheeins|phenylalanine|,|integrase|,|kinase|,|and|α (l_conj) integrase_19\NN\1740|hiv
T1_T6 NONE phenylalanine_15\NN\14605787| (r_compound) hydroxylase_16\NN\1740|for|the|morpheeins|phenylalanine|,|integrase|,|kinase|,|and|α (l_conj) kinase_22\NN\14732946|pyruvate
T1_T7 NONE phenylalanine_15\NN\14605787| (r_compound) hydroxylase_16\NN\1740|for|the|morpheeins|phenylalanine|,|integrase|,|kinase|,|and|α (l_conj) α_28\NN\1740|tumor|necrosis|factor
T2_T4 NONE pyruvate_21\NN\1740| (r_compound) kinase_22\NN\14732946|pyruvate (r_conj) hydroxylase_16\NN\1740|for|the|morpheeins|phenylalanine|,|integrase|,|kinase|,|and|α
T2_T5 NONE pyruvate_21\NN\1740| (r_compound) kinase_22\NN\14732946|pyruvate (r_conj) hydroxylase_16\NN\1740|for|the|morpheeins|phenylalanine|,|integrase|,|kinase|,|and|α (l_conj) integrase_19\NN\1740|hiv
T2_T6 NONE pyruvate_21\NN\1740| (r_compound) kinase_22\NN\14732946|pyruvate
T2_T7 NONE pyruvate_21\NN\1740| (r_compound) kinase_22\NN\14732946|pyruvate (r_conj) hydroxylase_16\NN\1740|for|the|morpheeins|phenylalanine|,|integrase|,|kinase|,|and|α (l_conj) α_28\NN\1740|tumor|necrosis|factor
16232421
T15_T33 NONE glucose_8\NN\14710501|% (r_dobj) containing_5\VBG\2632940|glucose (r_acl) medium_4\NN\3575240|in|ypd|containing (r_nmod) cultured_1\VBN\245457|when|medium|conditions (r_advcl) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_nsubj) mutant_21\NN\4475|the|kgd1|gene|disrupted (l_compound) kgd1_14\NN\1740|dehydrogenase
T15_T34 NONE glucose_8\NN\14710501|% (r_dobj) containing_5\VBG\2632940|glucose (r_acl) medium_4\NN\3575240|in|ypd|containing (r_nmod) cultured_1\VBN\245457|when|medium|conditions (r_advcl) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_nsubj) mutant_21\NN\4475|the|kgd1|gene|disrupted (l_compound) kgd1_14\NN\1740|dehydrogenase (l_appos) dehydrogenase_17\NN\1740|(|alpha-ketoglutarate|)
T15_T35 NONE glucose_8\NN\14710501|% (r_dobj) containing_5\VBG\2632940|glucose (r_acl) medium_4\NN\3575240|in|ypd|containing (r_nmod) cultured_1\VBN\245457|when|medium|conditions (r_advcl) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_advcl) produced_42\VBD\1617192|while|mutant|level (l_nsubj) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) sdh1_35\NN\1740|
T15_T36 NONE glucose_8\NN\14710501|% (r_dobj) containing_5\VBG\2632940|glucose (r_acl) medium_4\NN\3575240|in|ypd|containing (r_nmod) cultured_1\VBN\245457|when|medium|conditions (r_advcl) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_advcl) produced_42\VBD\1617192|while|mutant|level (l_nsubj) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) dehydrogenase_38\NN\1740|(|succinate|)
T16_T33 NONE alpha-ketoglutarate_16\NN\1740| (r_compound) dehydrogenase_17\NN\1740|(|alpha-ketoglutarate|) (r_appos) kgd1_14\NN\1740|dehydrogenase
T16_T34 NONE alpha-ketoglutarate_16\NN\1740| (r_compound) dehydrogenase_17\NN\1740|(|alpha-ketoglutarate|)
T16_T35 NONE alpha-ketoglutarate_16\NN\1740| (r_compound) dehydrogenase_17\NN\1740|(|alpha-ketoglutarate|) (r_appos) kgd1_14\NN\1740|dehydrogenase (r_compound) mutant_21\NN\4475|the|kgd1|gene|disrupted (r_nsubj) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_advcl) produced_42\VBD\1617192|while|mutant|level (l_nsubj) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) sdh1_35\NN\1740|
T16_T36 NONE alpha-ketoglutarate_16\NN\1740| (r_compound) dehydrogenase_17\NN\1740|(|alpha-ketoglutarate|) (r_appos) kgd1_14\NN\1740|dehydrogenase (r_compound) mutant_21\NN\4475|the|kgd1|gene|disrupted (r_nsubj) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_advcl) produced_42\VBD\1617192|while|mutant|level (l_nsubj) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) dehydrogenase_38\NN\1740|(|succinate|)
T17_T33 CPR:9 succinate_27\NN\1740|of (r_nmod) level_25\NN\4916342|a|lower|succinate|strain (r_dobj) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_nsubj) mutant_21\NN\4475|the|kgd1|gene|disrupted (l_compound) kgd1_14\NN\1740|dehydrogenase
T17_T34 CPR:9 succinate_27\NN\1740|of (r_nmod) level_25\NN\4916342|a|lower|succinate|strain (r_dobj) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_nsubj) mutant_21\NN\4475|the|kgd1|gene|disrupted (l_compound) kgd1_14\NN\1740|dehydrogenase (l_appos) dehydrogenase_17\NN\1740|(|alpha-ketoglutarate|)
T17_T35 NONE succinate_27\NN\1740|of (r_nmod) level_25\NN\4916342|a|lower|succinate|strain (r_dobj) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_advcl) produced_42\VBD\1617192|while|mutant|level (l_nsubj) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) sdh1_35\NN\1740|
T17_T36 NONE succinate_27\NN\1740|of (r_nmod) level_25\NN\4916342|a|lower|succinate|strain (r_dobj) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_advcl) produced_42\VBD\1617192|while|mutant|level (l_nsubj) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) dehydrogenase_38\NN\1740|(|succinate|)
T18_T33 NONE succinate_37\NN\1740| (r_compound) dehydrogenase_38\NN\1740|(|succinate|) (r_compound) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (r_nsubj) produced_42\VBD\1617192|while|mutant|level (r_advcl) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_nsubj) mutant_21\NN\4475|the|kgd1|gene|disrupted (l_compound) kgd1_14\NN\1740|dehydrogenase
T18_T34 NONE succinate_37\NN\1740| (r_compound) dehydrogenase_38\NN\1740|(|succinate|) (r_compound) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (r_nsubj) produced_42\VBD\1617192|while|mutant|level (r_advcl) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_nsubj) mutant_21\NN\4475|the|kgd1|gene|disrupted (l_compound) kgd1_14\NN\1740|dehydrogenase (l_appos) dehydrogenase_17\NN\1740|(|alpha-ketoglutarate|)
T18_T35 NONE succinate_37\NN\1740| (r_compound) dehydrogenase_38\NN\1740|(|succinate|) (r_compound) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) sdh1_35\NN\1740|
T18_T36 NONE succinate_37\NN\1740| (r_compound) dehydrogenase_38\NN\1740|(|succinate|)
T19_T33 NONE succinate_47\NN\1740|of (r_nmod) level_45\NN\4916342|an|increased|succinate (r_dobj) produced_42\VBD\1617192|while|mutant|level (r_advcl) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_nsubj) mutant_21\NN\4475|the|kgd1|gene|disrupted (l_compound) kgd1_14\NN\1740|dehydrogenase
T19_T34 NONE succinate_47\NN\1740|of (r_nmod) level_45\NN\4916342|an|increased|succinate (r_dobj) produced_42\VBD\1617192|while|mutant|level (r_advcl) produced_22\VBD\1617192|cultured|,|mutant|level|,|produced|. (l_nsubj) mutant_21\NN\4475|the|kgd1|gene|disrupted (l_compound) kgd1_14\NN\1740|dehydrogenase (l_appos) dehydrogenase_17\NN\1740|(|alpha-ketoglutarate|)
T19_T35 CPR:9 succinate_47\NN\1740|of (r_nmod) level_45\NN\4916342|an|increased|succinate (r_dobj) produced_42\VBD\1617192|while|mutant|level (l_nsubj) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) sdh1_35\NN\1740|
T19_T36 CPR:9 succinate_47\NN\1740|of (r_nmod) level_45\NN\4916342|an|increased|succinate (r_dobj) produced_42\VBD\1617192|while|mutant|level (l_nsubj) mutant_41\NN\4475|the|sdh1|dehydrogenase|gene-disrupted (l_compound) dehydrogenase_38\NN\1740|(|succinate|)
T20_T37 CPR:9 fumarate_18\NN\1740|of (r_nmod) levels_16\NNS\4916342|higher|fumarate (r_dobj) produced_13\VBD\1617192|hand|,|mutant|levels|but|form|. (l_nsubj) mutant_12\NN\4475|the|fum1|(|fumarase|)|gene|disrupted (l_compound) fum1_6\NN\1740|
T20_T38 CPR:9 fumarate_18\NN\1740|of (r_nmod) levels_16\NNS\4916342|higher|fumarate (r_dobj) produced_13\VBD\1617192|hand|,|mutant|levels|but|form|. (l_nsubj) mutant_12\NN\4475|the|fum1|(|fumarase|)|gene|disrupted (l_compound) fumarase_8\NN\1740|
T21_T37 NONE malate_23\NN\1740| (r_dobj) form_22\VB\1617192|did|not|malate|all (r_conj) produced_13\VBD\1617192|hand|,|mutant|levels|but|form|. (l_nsubj) mutant_12\NN\4475|the|fum1|(|fumarase|)|gene|disrupted (l_compound) fum1_6\NN\1740|
T21_T38 NONE malate_23\NN\1740| (r_dobj) form_22\VB\1617192|did|not|malate|all (r_conj) produced_13\VBD\1617192|hand|,|mutant|levels|but|form|. (l_nsubj) mutant_12\NN\4475|the|fum1|(|fumarase|)|gene|disrupted (l_compound) fumarase_8\NN\1740|
T3_T28 CPR:9 succinate_15\NN\1740|of (r_nmod) level_13\NN\4916342|the|increased|succinate|disruptants (l_nmod) disruptants_18\NNS\1740|in|sdh1 (l_compound) sdh1_17\NN\1740|
T3_T29 NONE succinate_15\NN\1740|of (r_nmod) level_13\NN\4916342|the|increased|succinate|disruptants (r_nsubjpass) observed_22\VBN\2163746|shifted|,|level|was|longer|,|observed|. (l_parataxis) observed_36\VBN\2163746|whereas|level|was|still (l_nsubjpass) level_27\NN\4916342|the|decreased|succinate|diruptant (l_nmod) diruptant_33\NN\1740|in|the|kgd1 (l_compound) kgd1_32\NN\1740|
T4_T28 NONE succinate_29\NN\1740|of (r_nmod) level_27\NN\4916342|the|decreased|succinate|diruptant (r_nsubjpass) observed_36\VBN\2163746|whereas|level|was|still (r_parataxis) observed_22\VBN\2163746|shifted|,|level|was|longer|,|observed|. (l_nsubjpass) level_13\NN\4916342|the|increased|succinate|disruptants (l_nmod) disruptants_18\NNS\1740|in|sdh1 (l_compound) sdh1_17\NN\1740|
T4_T29 CPR:9 succinate_29\NN\1740|of (r_nmod) level_27\NN\4916342|the|decreased|succinate|diruptant (l_nmod) diruptant_33\NN\1740|in|the|kgd1 (l_compound) kgd1_32\NN\1740|
T5_T30 NONE fumarate_6\NN\1740| (r_compound) genes_9\NNS\8459252|of|the|two|fumarate|reductase|isozyme (l_compound) reductase_7\NN\14732946|
T5_T31 NONE fumarate_6\NN\1740| (r_compound) genes_9\NNS\8459252|of|the|two|fumarate|reductase|isozyme (r_nmod) mutant_2\NN\4475|a|double|genes|osm1 (l_dep) osm1_11\NN\1740|(|and|frds|)
T5_T32 NONE fumarate_6\NN\1740| (r_compound) genes_9\NNS\8459252|of|the|two|fumarate|reductase|isozyme (r_nmod) mutant_2\NN\4475|a|double|genes|osm1 (l_dep) osm1_11\NN\1740|(|and|frds|) (l_conj) frds_13\NNP\1740|
T6_T30 CPR:9 succinate_17\JJ\1740| (r_amod) productivity_18\NN\5147381|a|succinate|% (r_dobj) showed_15\VBD\2137132|mutant|productivity|compared|. (l_nsubj) mutant_2\NN\4475|a|double|genes|osm1 (l_nmod) genes_9\NNS\8459252|of|the|two|fumarate|reductase|isozyme (l_compound) reductase_7\NN\14732946|
T6_T31 CPR:9 succinate_17\JJ\1740| (r_amod) productivity_18\NN\5147381|a|succinate|% (r_dobj) showed_15\VBD\2137132|mutant|productivity|compared|. (l_nsubj) mutant_2\NN\4475|a|double|genes|osm1 (l_dep) osm1_11\NN\1740|(|and|frds|)
T6_T32 CPR:9 succinate_17\JJ\1740| (r_amod) productivity_18\NN\5147381|a|succinate|% (r_dobj) showed_15\VBD\2137132|mutant|productivity|compared|. (l_nsubj) mutant_2\NN\4475|a|double|genes|osm1 (l_dep) osm1_11\NN\1740|(|and|frds|) (l_conj) frds_13\NNP\1740|
T8_T30 NONE glucose-buffered_32\JJ\1740| (r_amod) solution_33\NN\14586258|in|glucose-buffered (r_nmod) incubated_30\VBN\252019|when|cells|were|solution (r_advcl) compared_23\VBN\644583|as|parent|incubated (r_advcl) showed_15\VBD\2137132|mutant|productivity|compared|. (l_nsubj) mutant_2\NN\4475|a|double|genes|osm1 (l_nmod) genes_9\NNS\8459252|of|the|two|fumarate|reductase|isozyme (l_compound) reductase_7\NN\14732946|
T8_T31 NONE glucose-buffered_32\JJ\1740| (r_amod) solution_33\NN\14586258|in|glucose-buffered (r_nmod) incubated_30\VBN\252019|when|cells|were|solution (r_advcl) compared_23\VBN\644583|as|parent|incubated (r_advcl) showed_15\VBD\2137132|mutant|productivity|compared|. (l_nsubj) mutant_2\NN\4475|a|double|genes|osm1 (l_dep) osm1_11\NN\1740|(|and|frds|)
T8_T32 NONE glucose-buffered_32\JJ\1740| (r_amod) solution_33\NN\14586258|in|glucose-buffered (r_nmod) incubated_30\VBN\252019|when|cells|were|solution (r_advcl) compared_23\VBN\644583|as|parent|incubated (r_advcl) showed_15\VBD\2137132|mutant|productivity|compared|. (l_nsubj) mutant_2\NN\4475|a|double|genes|osm1 (l_dep) osm1_11\NN\1740|(|and|frds|) (l_conj) frds_13\NNP\1740|
23526814
T9_T15 CPR:4 tert-butylcarbamate-containing_0\JJ\1740| (r_amod) inhibitors_3\NNS\20090|tert-butylcarbamate-containing|histone|deacetylase|:|induction|. (l_compound) deacetylase_2\NN\1740|
T1_T10 CPR:4 tert-butylcarbamate_22\NN\1740| (r_compound) group_23\NN\2137|the|tert-butylcarbamate (r_dobj) bearing_20\VBG\2630189|group|moiety (r_acl) 2'-aminoanilides_14\NNS\1740|9|bearing (r_conj) hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac
T1_T11 CPR:4 tert-butylcarbamate_22\NN\1740| (r_compound) group_23\NN\2137|the|tert-butylcarbamate (r_dobj) bearing_20\VBG\2630189|group|moiety (r_acl) 2'-aminoanilides_14\NNS\1740|9|bearing (r_conj) hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac (l_appos) hdac_32\NN\1740|(|)
T2_T10 CPR:4 pyrrole-_4\NN\1740|and|benzene-based (r_amod) hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac
T2_T11 CPR:4 pyrrole-_4\NN\1740|and|benzene-based (r_amod) hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac (l_appos) hdac_32\NN\1740|(|)
T4_T10 CPR:4 benzene-based_6\JJ\1740| (r_conj) pyrrole-_4\NN\1740|and|benzene-based (r_amod) hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac
T4_T11 CPR:4 benzene-based_6\JJ\1740| (r_conj) pyrrole-_4\NN\1740|and|benzene-based (r_amod) hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac (l_appos) hdac_32\NN\1740|(|)
T6_T10 CPR:4 hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac
T6_T11 CPR:4 hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac (l_appos) hdac_32\NN\1740|(|)
T8_T10 CPR:4 2'-aminoanilides_14\NNS\1740|9|bearing (r_conj) hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac
T8_T11 CPR:4 2'-aminoanilides_14\NNS\1740|9|bearing (r_conj) hydroxamates_7\NNS\1740|novel|pyrrole-|8|and|2'-aminoanilides (r_dobj) report_2\VBP\831651|herein|we|hydroxamates|inhibitors|. (l_nmod) inhibitors_34\NNS\20090|as|deacetylase (l_compound) deacetylase_30\NN\1740|histone|hdac (l_appos) hdac_32\NN\1740|(|)
T3_T12 NONE hydroxamates_19\NNS\1740|the|other (r_nsubj) effected_20\VBD\1645601|hydroxamates|increase (r_advcl) inhibited_9\VBD\2510337||b|selectively|hdac6|level|,|whereas|effected|. (l_dobj) hdac6_10\NN\1740|
T3_T13 CPR:3 hydroxamates_19\NNS\1740|the|other (r_nsubj) effected_20\VBD\1645601|hydroxamates|increase (l_dobj) increase_22\NN\13576355|an|levels (l_nmod) levels_25\NNS\4916342|in|acetyl-α-tubulin|cells (l_compound) acetyl-α-tubulin_24\NN\1740|
15075397
T2_T13 NONE hydroxyurea_5\NN\1740|to|hu|,|aphidicolin|,|and|light (r_nmod) hypersensitive_3\JJ\1740|mutants|were|hydroxyurea|but|sensitive|. (l_nsubj) mutants_1\NNS\4475|atr (l_compound) atr_0\NN\1740|
T3_T13 NONE hu_7\NN\1740|(|) (r_appos) hydroxyurea_5\NN\1740|to|hu|,|aphidicolin|,|and|light (r_nmod) hypersensitive_3\JJ\1740|mutants|were|hydroxyurea|but|sensitive|. (l_nsubj) mutants_1\NNS\4475|atr (l_compound) atr_0\NN\1740|
T4_T13 NONE aphidicolin_10\NN\1740| (r_conj) hydroxyurea_5\NN\1740|to|hu|,|aphidicolin|,|and|light (r_nmod) hypersensitive_3\JJ\1740|mutants|were|hydroxyurea|but|sensitive|. (l_nsubj) mutants_1\NNS\4475|atr (l_compound) atr_0\NN\1740|
T5_T16 NONE aphidicolin_11\NN\1740|to (r_nmod) response_9\NN\11410625|in|aphidicolin (r_nmod) observed_4\VBN\2163746|arrest|also|was|plants|response|but|defective|. (l_conj) defective_14\JJ\1740|was|mutants|,|resulting (l_nmod) mutants_17\NNS\4475|in|atr (l_compound) atr_16\NN\1740|
15180525
T25_T53 NONE tyrosine_2\NN\14601829| (r_compound) kinase_3\NN\14732946|flt3|receptor|tyrosine|target|.
T22_T40 NONE tyrosine_5\NN\14601829| (r_compound) kinase_6\NN\14732946|class|iii|receptor|tyrosine|rtk (r_compound) flt3_10\NN\1740|the|hematopoietic|kinase|flk2
T22_T46 NONE tyrosine_5\NN\14601829| (r_compound) kinase_6\NN\14732946|class|iii|receptor|tyrosine|rtk (r_compound) flt3_10\NN\1740|the|hematopoietic|kinase|flk2 (l_dep) flk2_12\NN\1740|(|,|stk1|)
T22_T48 NONE tyrosine_5\NN\14601829| (r_compound) kinase_6\NN\14732946|class|iii|receptor|tyrosine|rtk (r_compound) flt3_10\NN\1740|the|hematopoietic|kinase|flk2 (l_dep) flk2_12\NN\1740|(|,|stk1|) (l_appos) stk1_14\NN\1740|
T23_T41 NONE phosphoinositide-3-kinase/akt_16\NN\1740| (r_compound) cascades_18\NNS\9475292|the|phosphoinositide-3-kinase/akt|signaling (r_conj) ras/map-kinase_13\NN\1740|including|the|and|cascades (r_nmod) pathways_9\NNS\5483677|of|several|conserved|,|ras/map-kinase (r_nmod) activation_5\NN\13561719|pathways (r_dobj) involves_4\VBZ\2676054|transduction|activation|. (l_nsubj) transduction_1\NN\13526110|signal|flt3 (l_nmod) flt3_3\NN\1740|of
T23_T42 NONE phosphoinositide-3-kinase/akt_16\NN\1740| (r_compound) cascades_18\NNS\9475292|the|phosphoinositide-3-kinase/akt|signaling (r_conj) ras/map-kinase_13\NN\1740|including|the|and|cascades
T23_T43 NONE phosphoinositide-3-kinase/akt_16\NN\1740| (r_compound) cascades_18\NNS\9475292|the|phosphoinositide-3-kinase/akt|signaling (r_conj) ras/map-kinase_13\NN\1740|including|the|and|cascades
T23_T44 NONE phosphoinositide-3-kinase/akt_16\NN\1740|
T23_T45 NONE phosphoinositide-3-kinase/akt_16\NN\1740|
T24_T50 NONE tyrosine_4\NN\14601829| (r_compound) activity_6\NN\30358|of|flt3|tyrosine|kinase (l_compound) flt3_3\NN\1740|
T24_T51 NONE tyrosine_4\NN\14601829| (r_compound) activity_6\NN\30358|of|flt3|tyrosine|kinase (l_compound) kinase_5\NN\14732946|
T24_T52 NONE tyrosine_4\NN\14601829| (r_compound) activity_6\NN\30358|of|flt3|tyrosine|kinase (r_nmod) inhibitors_1\NNS\20090|selective|activity (r_nsubj) have_7\VBP\2108377|inhibitors|potential|. (l_dobj) potential_9\NN\14481929|the|suppress (l_acl) suppress_11\VB\2510337|to|signaling (l_dobj) signaling_14\NN\33020|aberrant|flt3 (l_compound) flt3_13\NN\1740|
T1_T26 NONE phenylaminopyrimidine_14\NN\1740| (r_compound) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (r_nmod) resistant_11\JJ\1740|homologous|,|flt3|is|sti571|. (l_advcl) homologous_2\JJ\1740|although|highly|rtks (l_nmod) rtks_7\NNS\1740|to|other|class|iii
T1_T27 NONE phenylaminopyrimidine_14\NN\1740| (r_compound) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (r_nmod) resistant_11\JJ\1740|homologous|,|flt3|is|sti571|. (l_nsubj) flt3_9\NN\1740|
T1_T28 CPR:4 phenylaminopyrimidine_14\NN\1740| (r_compound) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (l_dep) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor
T1_T29 CPR:4 phenylaminopyrimidine_14\NN\1740| (r_compound) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (l_dep) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor (l_nmod) pdgfbeta-receptor_35\NN\1740|such|the|or|c-kit
T1_T30 CPR:4 phenylaminopyrimidine_14\NN\1740| (r_compound) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (l_dep) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor (l_nmod) pdgfbeta-receptor_35\NN\1740|such|the|or|c-kit (l_conj) c-kit_37\NN\1740|
T2_T26 NONE sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (r_nmod) resistant_11\JJ\1740|homologous|,|flt3|is|sti571|. (l_advcl) homologous_2\JJ\1740|although|highly|rtks (l_nmod) rtks_7\NNS\1740|to|other|class|iii
T2_T27 NONE sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (r_nmod) resistant_11\JJ\1740|homologous|,|flt3|is|sti571|. (l_nsubj) flt3_9\NN\1740|
T2_T28 CPR:4 sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (l_dep) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor
T2_T29 CPR:4 sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (l_dep) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor (l_nmod) pdgfbeta-receptor_35\NN\1740|such|the|or|c-kit
T2_T30 CPR:4 sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (l_dep) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor (l_nmod) pdgfbeta-receptor_35\NN\1740|such|the|or|c-kit (l_conj) c-kit_37\NN\1740|
T3_T26 NONE gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (r_dep) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (r_nmod) resistant_11\JJ\1740|homologous|,|flt3|is|sti571|. (l_advcl) homologous_2\JJ\1740|although|highly|rtks (l_nmod) rtks_7\NNS\1740|to|other|class|iii
T3_T27 NONE gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (r_dep) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (r_nmod) resistant_11\JJ\1740|homologous|,|flt3|is|sti571|. (l_nsubj) flt3_9\NN\1740|
T3_T28 CPR:4 gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor
T3_T29 CPR:4 gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor (l_nmod) pdgfbeta-receptor_35\NN\1740|such|the|or|c-kit
T3_T30 CPR:4 gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor (l_nmod) pdgfbeta-receptor_35\NN\1740|such|the|or|c-kit (l_conj) c-kit_37\NN\1740|
T4_T26 NONE imatinib_19\NN\1740| (r_appos) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (r_dep) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (r_nmod) resistant_11\JJ\1740|homologous|,|flt3|is|sti571|. (l_advcl) homologous_2\JJ\1740|although|highly|rtks (l_nmod) rtks_7\NNS\1740|to|other|class|iii
T4_T27 NONE imatinib_19\NN\1740| (r_appos) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (r_dep) sti571_15\NN\1740|to|the|phenylaminopyrimidine|gleevec (r_nmod) resistant_11\JJ\1740|homologous|,|flt3|is|sti571|. (l_nsubj) flt3_9\NN\1740|
T4_T28 CPR:4 imatinib_19\NN\1740| (r_appos) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor
T4_T29 CPR:4 imatinib_19\NN\1740| (r_appos) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor (l_nmod) pdgfbeta-receptor_35\NN\1740|such|the|or|c-kit
T4_T30 CPR:4 imatinib_19\NN\1740| (r_appos) gleevec_17\NN\1740|(|,|imatinib|)|,|inhibitor (l_appos) inhibitor_24\NN\20090|a|potent|rtks (l_nmod) rtks_27\NNS\1740|of|other|family|,|pdgfbeta-receptor (l_nmod) pdgfbeta-receptor_35\NN\1740|such|the|or|c-kit (l_conj) c-kit_37\NN\1740|
T5_T31 NONE sti571_0\NN\1740|binding (l_acl) binding_1\NN\4688246|flt3 (l_nmod) flt3_3\NN\1740|to
T5_T32 NONE sti571_0\NN\1740|binding (r_nsubjpass) prevented_5\VBN\1740|sti571|is|side-chain|and|renders (l_conj) renders_22\VBZ\120316|mutating|sensitive|. (l_xcomp) sensitive_27\JJ\1740|mutant|sti571 (l_nsubj) mutant_26\JJ\1740|the|corresponding|flt3 (l_compound) flt3_25\NN\1740|
T6_T31 NONE phenylalanine_8\JJ\1740| (r_amod) side-chain_10\NN\1740|by|the|phenylalanine|691|center (r_nmod) prevented_5\VBN\1740|sti571|is|side-chain|and|renders (l_nsubjpass) sti571_0\NN\1740|binding (l_acl) binding_1\NN\4688246|flt3 (l_nmod) flt3_3\NN\1740|to
T6_T32 NONE phenylalanine_8\JJ\1740| (r_amod) side-chain_10\NN\1740|by|the|phenylalanine|691|center (r_nmod) prevented_5\VBN\1740|sti571|is|side-chain|and|renders (l_conj) renders_22\VBZ\120316|mutating|sensitive|. (l_xcomp) sensitive_27\JJ\1740|mutant|sti571 (l_nsubj) mutant_26\JJ\1740|the|corresponding|flt3 (l_compound) flt3_25\NN\1740|
T7_T31 NONE atp_13\NN\14964590| (r_compound) center_15\NN\8497294|in|the|atp|binding (r_nmod) side-chain_10\NN\1740|by|the|phenylalanine|691|center (r_nmod) prevented_5\VBN\1740|sti571|is|side-chain|and|renders (l_nsubjpass) sti571_0\NN\1740|binding (l_acl) binding_1\NN\4688246|flt3 (l_nmod) flt3_3\NN\1740|to
T7_T32 NONE atp_13\NN\14964590| (r_compound) center_15\NN\8497294|in|the|atp|binding (r_nmod) side-chain_10\NN\1740|by|the|phenylalanine|691|center (r_nmod) prevented_5\VBN\1740|sti571|is|side-chain|and|renders (l_conj) renders_22\VBZ\120316|mutating|sensitive|. (l_xcomp) sensitive_27\JJ\1740|mutant|sti571 (l_nsubj) mutant_26\JJ\1740|the|corresponding|flt3 (l_compound) flt3_25\NN\1740|
T8_T31 NONE threonine_21\NN\14605787|to (r_nmod) mutating_17\VBG\109660|site|threonine (r_csubj) renders_22\VBZ\120316|mutating|sensitive|. (r_conj) prevented_5\VBN\1740|sti571|is|side-chain|and|renders (l_nsubjpass) sti571_0\NN\1740|binding (l_acl) binding_1\NN\4688246|flt3 (l_nmod) flt3_3\NN\1740|to
T8_T32 NONE threonine_21\NN\14605787|to (r_nmod) mutating_17\VBG\109660|site|threonine (r_csubj) renders_22\VBZ\120316|mutating|sensitive|. (l_xcomp) sensitive_27\JJ\1740|mutant|sti571 (l_nsubj) mutant_26\JJ\1740|the|corresponding|flt3 (l_compound) flt3_25\NN\1740|
T9_T31 NONE sti571_29\NN\1740|to (r_nmod) sensitive_27\JJ\1740|mutant|sti571 (r_xcomp) renders_22\VBZ\120316|mutating|sensitive|. (r_conj) prevented_5\VBN\1740|sti571|is|side-chain|and|renders (l_nsubjpass) sti571_0\NN\1740|binding (l_acl) binding_1\NN\4688246|flt3 (l_nmod) flt3_3\NN\1740|to
T9_T32 CPR:4 sti571_29\NN\1740|to (r_nmod) sensitive_27\JJ\1740|mutant|sti571 (l_nsubj) mutant_26\JJ\1740|the|corresponding|flt3 (l_compound) flt3_25\NN\1740|
T10_T34 CPR:4 quinoxaline_9\NN\1740| (r_compound) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T10_T35 CPR:4 quinoxaline_9\NN\1740| (r_compound) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T11_T34 CPR:4 ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T11_T35 CPR:4 ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T12_T34 CPR:4 bis(1h-2-indolyl)-1-methanone_13\NN\1740| (r_compound) d-65476_14\NN\1740|the|bis(1h-2-indolyl)-1-methanone (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T12_T35 CPR:4 bis(1h-2-indolyl)-1-methanone_13\NN\1740| (r_compound) d-65476_14\NN\1740|the|bis(1h-2-indolyl)-1-methanone (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T13_T34 CPR:4 d-65476_14\NN\1740|the|bis(1h-2-indolyl)-1-methanone (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T13_T35 CPR:4 d-65476_14\NN\1740|the|bis(1h-2-indolyl)-1-methanone (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T14_T34 CPR:4 indolinones_17\NNS\1740|the|su5416 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T14_T35 CPR:4 indolinones_17\NNS\1740|the|su5416 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T15_T34 CPR:4 su5416_18\NN\1740|and|su11248 (r_dep) indolinones_17\NNS\1740|the|su5416 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T15_T35 CPR:4 su5416_18\NN\1740|and|su11248 (r_dep) indolinones_17\NNS\1740|the|su5416 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T16_T34 CPR:4 su11248_20\NN\1740| (r_conj) su5416_18\NN\1740|and|su11248 (r_dep) indolinones_17\NNS\1740|the|su5416 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T16_T35 CPR:4 su11248_20\NN\1740| (r_conj) su5416_18\NN\1740|and|su11248 (r_dep) indolinones_17\NNS\1740|the|su5416 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T17_T34 CPR:4 indolocarbazoles_23\NNS\1740|the|pkc412 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T17_T35 CPR:4 indolocarbazoles_23\NNS\1740|the|pkc412 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T18_T34 CPR:4 pkc412_24\NN\1740|and|cep-701 (r_dep) indolocarbazoles_23\NNS\1740|the|pkc412 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T18_T35 CPR:4 pkc412_24\NN\1740|and|cep-701 (r_dep) indolocarbazoles_23\NNS\1740|the|pkc412 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T19_T34 CPR:4 cep-701_26\NN\1740| (r_conj) pkc412_24\NN\1740|and|cep-701 (r_dep) indolocarbazoles_23\NNS\1740|the|pkc412 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T19_T35 CPR:4 cep-701_26\NN\1740| (r_conj) pkc412_24\NN\1740|and|cep-701 (r_dep) indolocarbazoles_23\NNS\1740|the|pkc412 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T20_T34 CPR:4 quinazoline_31\NN\1740|the|piperazonyl|ct53518 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T20_T35 CPR:4 quinazoline_31\NN\1740|the|piperazonyl|ct53518 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
T21_T34 CPR:4 ct53518_32\NN\1740| (r_dep) quinazoline_31\NN\1740|the|piperazonyl|ct53518 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3 (l_compound) flt3_38\NN\1740|
T21_T35 CPR:4 ct53518_32\NN\1740| (r_dep) quinazoline_31\NN\1740|the|piperazonyl|ct53518 (r_conj) ag1296_10\NN\1740|including|the|quinoxaline|,|d-65476|,|indolinones|,|indolocarbazoles|,|and|quinazoline (r_nmod) compounds_0\NNS\5869584|families|,|ag1296|, (r_nsubj) inhibitors_36\NNS\20090|compounds|are|potent|kinase|. (l_nmod) kinase_39\NN\14732946|of|flt3
15665864
T12_T23 NONE minocycline_2\NN\4416530|of (r_nmod) effects_0\NNS\13245626|minocycline|hepatitis|. (l_nmod) hepatitis_6\NN\14127211|on|fas-mediated|fulminant|mice (l_amod) fas-mediated_4\JJ\1740|
T5_T20 NONE minocycline_5\NN\4416530|of (r_nmod) effects_3\NNS\13245626|the|minocycline|hepatitis (l_nmod) hepatitis_8\NN\14127211|on|fulminant|mice (l_nmod) mice_11\NNS\2329401|in|c57bl/6j|induced (l_acl) induced_12\VBN\1627355|challenge (l_nmod) challenge_15\NN\13927383|by|lethal|antibody (l_nmod) antibody_20\NN\14728724|of|the|activating|anti-fas|,|jo2 (l_amod) anti-fas_19\JJ\1740|
T7_T21 NONE alanine/aspartate_23\NN\1740| (r_compound) activities_25\NNS\30358|of|serum|alanine/aspartate|transaminase (l_compound) transaminase_24\NN\15077571|
T8_T21 NONE alanine/aspartate_23\NN\1740| (r_compound) activities_25\NNS\30358|of|serum|alanine/aspartate|transaminase (l_compound) transaminase_24\NN\15077571|
T11_T13 NONE minocycline_12\NN\4416530| (r_compound) pretreatment_13\NN\1740|by|minocycline (r_nmod) inhibited_10\VBN\2510337|activation|was|pretreatment|,|and|failed (l_conj) failed_28\VBD\1798936|yet|addition|block|. (l_xcomp) block_30\VB\1476483|to|activation|vitro (l_dobj) activation_32\NN\13561719|caspase (l_compound) caspase_31\NN\14999106|
T11_T22 NONE minocycline_12\NN\4416530| (r_compound) pretreatment_13\NN\1740|by|minocycline (r_nmod) inhibited_10\VBN\2510337|activation|was|pretreatment|,|and|failed (l_nsubjpass) activation_1\NN\13561719|jo2-induced|caspase-3|tissues (l_nmod) caspase-3_3\NN\1740|of|or|-9 (l_conj) -9_5\CD\1740|
T1_T13 NONE minocycline_21\NN\4416530|of (r_nmod) addition_19\NN\3081021|the|direct|minocycline|extracts (r_nsubj) failed_28\VBD\1798936|yet|addition|block|. (l_xcomp) block_30\VB\1476483|to|activation|vitro (l_dobj) activation_32\NN\13561719|caspase (l_compound) caspase_31\NN\14999106|
T1_T22 NONE minocycline_21\NN\4416530|of (r_nmod) addition_19\NN\3081021|the|direct|minocycline|extracts (r_nsubj) failed_28\VBD\1798936|yet|addition|block|. (r_conj) inhibited_10\VBN\2510337|activation|was|pretreatment|,|and|failed (l_nsubjpass) activation_1\NN\13561719|jo2-induced|caspase-3|tissues (l_nmod) caspase-3_3\NN\1740|of|or|-9 (l_conj) -9_5\CD\1740|
T2_T14 CPR:4 minocycline_2\NN\4416530| (r_nsubj) suppressed_4\VBD\2510337|moreover|,|minocycline|efficiently|release|. (l_dobj) release_6\NN\3748886|the|c|mitochondria (l_nmod) c_9\NN\13714184|of|cytochrome
T3_T15 NONE minocycline_15\NN\4416530| (r_compound) pretreatment_16\NN\1740|by|minocycline|livers (r_nmod) diminished_13\VBN\169651|contrast|,|activation|were|not|pretreatment|. (l_nsubjpass) activation_4\NN\13561719|caspase-8|and|truncation|triggered (l_compound) caspase-8_3\NN\1740|
T3_T16 NONE minocycline_15\NN\4416530| (r_compound) pretreatment_16\NN\1740|by|minocycline|livers (r_nmod) diminished_13\VBN\169651|contrast|,|activation|were|not|pretreatment|. (l_nsubjpass) activation_4\NN\13561719|caspase-8|and|truncation|triggered (l_conj) truncation_7\NN\5137557|bid (l_compound) bid_6\NN\7160883|
T4_T17 NONE minocycline_10\NN\4416530|by (r_nmod) easing_4\NN\7296428|hepatitis|minocycline (l_nmod) hepatitis_8\NN\14127211|of|fas-triggered|fulminant (l_amod) fas-triggered_6\JJ\1740|
T4_T18 CPR:4 minocycline_10\NN\4416530|by (r_nmod) easing_4\NN\7296428|hepatitis|minocycline (r_nsubj) involve_12\VB\2676054|that|easing|may|pathway|,|preventing (l_advcl) preventing_20\VBG\1740|probably|through|release|and|blocking (l_dobj) release_23\NN\3748886|c (l_compound) c_22\NN\13714184|cytochrome
T4_T19 CPR:4 minocycline_10\NN\4416530|by (r_nmod) easing_4\NN\7296428|hepatitis|minocycline (r_nsubj) involve_12\VB\2676054|that|easing|may|pathway|,|preventing (l_advcl) preventing_20\VBG\1740|probably|through|release|and|blocking (l_conj) blocking_26\VBG\1476483|thereby|activation (l_dobj) activation_29\NN\13561719|downstream|caspase (l_compound) caspase_28\NN\14999106|
17581967
T11_T27 CPR:3 na+/cl-_0\JJ\1740| (r_compound) dipole_1\NN\9257563|na+/cl- (r_nsubj) couples_2\VBZ\1295275|dipole|binding|. (l_dobj) binding_4\NN\4688246|agonist|activation (l_nmod) activation_8\NN\13561719|to|receptor (l_compound) receptor_7\NN\5225602|kainate
T12_T27 NONE kainate_6\NN\1740| (r_compound) receptor_7\NN\5225602|kainate
T13_T27 CPR:3 na+/cl-_0\JJ\1740| (r_compound) dipole_1\NN\9257563|na+/cl- (r_nsubj) couples_2\VBZ\1295275|dipole|binding|. (l_dobj) binding_4\NN\4688246|agonist|activation (l_nmod) activation_8\NN\13561719|to|receptor (l_compound) receptor_7\NN\5225602|kainate
T1_T14 NONE kainate-selective_0\JJ\1740| (r_amod) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs
T1_T19 NONE kainate-selective_0\JJ\1740| (r_amod) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs (l_appos) glurs_5\NNS\1740|(|)
T2_T14 CPR:3 l-glutamate_17\NN\1740|the|neurotransmitter (r_conj) na+_9\NN\1740|external|and|cl-|as|l-glutamate (r_dobj) require_7\VBP\754942|receptors|na+|activation|. (l_nsubj) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs
T2_T19 CPR:3 l-glutamate_17\NN\1740|the|neurotransmitter (r_conj) na+_9\NN\1740|external|and|cl-|as|l-glutamate (r_dobj) require_7\VBP\754942|receptors|na+|activation|. (l_nsubj) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs (l_appos) glurs_5\NNS\1740|(|)
T4_T14 NONE glutamate_2\NN\15010703| (r_compound) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs
T4_T19 NONE glutamate_2\NN\15010703| (r_compound) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs (l_appos) glurs_5\NNS\1740|(|)
T6_T14 CPR:3 na+_9\NN\1740|external|and|cl-|as|l-glutamate (r_dobj) require_7\VBP\754942|receptors|na+|activation|. (l_nsubj) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs
T6_T19 CPR:3 na+_9\NN\1740|external|and|cl-|as|l-glutamate (r_dobj) require_7\VBP\754942|receptors|na+|activation|. (l_nsubj) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs (l_appos) glurs_5\NNS\1740|(|)
T7_T14 CPR:3 cl-_11\NN\1740| (r_conj) na+_9\NN\1740|external|and|cl-|as|l-glutamate (r_dobj) require_7\VBP\754942|receptors|na+|activation|. (l_nsubj) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs
T7_T19 CPR:3 cl-_11\NN\1740| (r_conj) na+_9\NN\1740|external|and|cl-|as|l-glutamate (r_dobj) require_7\VBP\754942|receptors|na+|activation|. (l_nsubj) receptors_3\NNS\5225602|kainate-selective|ionotropic|glutamate|glurs (l_appos) glurs_5\NNS\1740|(|)
T3_T16 NONE kainate_8\NN\1740| (r_compound) receptors_9\NNS\5225602|kainate|kars
T3_T17 NONE kainate_8\NN\1740| (r_compound) receptors_9\NNS\5225602|kainate|kars (l_appos) kars_11\NNS\1740|(|)
T5_T20 NONE na+_8\NN\1740|with (r_nmod) compete_6\VB\1740|consequently|,|species|may|na+|regulate|. (l_xcomp) regulate_10\VB\296178|to|time (l_dobj) time_12\NN\7308889|the|remain (l_acl:relcl) remain_14\VBP\2604760|kars|state (l_nsubj) kars_13\NNS\1740|
T8_T25 CPR:3 na+_2\NN\1740|and|cl- (r_amod) ions_5\NNS\9386422|na+ (r_nsubj) coactivate_6\VBP\1740|additionally|,|ions|receptors|establishing|,|accounting|. (l_dobj) receptors_8\NNS\5225602|glur6 (l_compound) glur6_7\NN\1740|
T8_T26 NONE na+_2\NN\1740|and|cl- (r_amod) ions_5\NNS\9386422|na+ (r_nsubj) coactivate_6\VBP\1740|additionally|,|ions|receptors|establishing|,|accounting|. (l_advcl) accounting_14\VBG\2604760|effect (l_nmod) effect_18\NN\34213|for|their|common|kars (l_nmod) kars_20\NNS\1740|on
T9_T25 CPR:3 cl-_4\JJ\1740| (r_conj) na+_2\NN\1740|and|cl- (r_amod) ions_5\NNS\9386422|na+ (r_nsubj) coactivate_6\VBP\1740|additionally|,|ions|receptors|establishing|,|accounting|. (l_dobj) receptors_8\NNS\5225602|glur6 (l_compound) glur6_7\NN\1740|
T9_T26 NONE cl-_4\JJ\1740| (r_conj) na+_2\NN\1740|and|cl- (r_amod) ions_5\NNS\9386422|na+ (r_nsubj) coactivate_6\VBP\1740|additionally|,|ions|receptors|establishing|,|accounting|. (l_advcl) accounting_14\VBG\2604760|effect (l_nmod) effect_18\NN\34213|for|their|common|kars (l_nmod) kars_20\NNS\1740|on
23008503
T10_T21 NONE )_46\-RRB-\1740|pge(2 (r_punct) e(2_45\NN\1740|prostaglandin|) (r_compound) level_51\NN\4916342|isoforms|and|e(2|duodenum (r_nmod) expression_39\NN\4679549|on|the|level (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_nmod) inhibitors_24\NNS\20090|of|cox-1 (l_compound) cox-1_11\NN\14737847|selective|sc-560|and|cox-2
T10_T22 NONE )_46\-RRB-\1740|pge(2 (r_punct) e(2_45\NN\1740|prostaglandin|) (r_compound) level_51\NN\4916342|isoforms|and|e(2|duodenum (r_nmod) expression_39\NN\4679549|on|the|level (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_nmod) inhibitors_24\NNS\20090|of|cox-1 (l_compound) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (l_conj) cox-2_18\NN\14737847|celecoxib
T10_T23 NONE )_46\-RRB-\1740|pge(2 (r_punct) e(2_45\NN\1740|prostaglandin|) (r_compound) level_51\NN\4916342|isoforms|and|e(2|duodenum (l_compound) isoforms_42\NNS\1740|of|cox (l_compound) cox_41\NN\14732946|
T10_T24 NONE )_46\-RRB-\1740|pge(2 (r_punct) e(2_45\NN\1740|prostaglandin|) (r_compound) level_51\NN\4916342|isoforms|and|e(2|duodenum (r_nmod) expression_39\NN\4679549|on|the|level (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) localization_59\NN\151497|3|isoforms (l_nmod) isoforms_62\NNS\1740|of|cox|duodenum (l_compound) cox_61\NN\14732946|
T11_T21 NONE )_49\-RRB-\1740| (r_punct) pge(2_48\NN\1740|(|)|) (r_appos) )_46\-RRB-\1740|pge(2 (r_punct) e(2_45\NN\1740|prostaglandin|) (r_compound) level_51\NN\4916342|isoforms|and|e(2|duodenum (r_nmod) expression_39\NN\4679549|on|the|level (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_nmod) inhibitors_24\NNS\20090|of|cox-1 (l_compound) cox-1_11\NN\14737847|selective|sc-560|and|cox-2
T11_T22 NONE )_49\-RRB-\1740| (r_punct) pge(2_48\NN\1740|(|)|) (r_appos) )_46\-RRB-\1740|pge(2 (r_punct) e(2_45\NN\1740|prostaglandin|) (r_compound) level_51\NN\4916342|isoforms|and|e(2|duodenum (r_nmod) expression_39\NN\4679549|on|the|level (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_nmod) inhibitors_24\NNS\20090|of|cox-1 (l_compound) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (l_conj) cox-2_18\NN\14737847|celecoxib
T11_T23 NONE )_49\-RRB-\1740| (r_punct) pge(2_48\NN\1740|(|)|) (r_appos) )_46\-RRB-\1740|pge(2 (r_punct) e(2_45\NN\1740|prostaglandin|) (r_compound) level_51\NN\4916342|isoforms|and|e(2|duodenum (l_compound) isoforms_42\NNS\1740|of|cox (l_compound) cox_41\NN\14732946|
T11_T24 NONE )_49\-RRB-\1740| (r_punct) pge(2_48\NN\1740|(|)|) (r_appos) )_46\-RRB-\1740|pge(2 (r_punct) e(2_45\NN\1740|prostaglandin|) (r_compound) level_51\NN\4916342|isoforms|and|e(2|duodenum (r_nmod) expression_39\NN\4679549|on|the|level (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) localization_59\NN\151497|3|isoforms (l_nmod) isoforms_62\NNS\1740|of|cox|duodenum (l_compound) cox_61\NN\14732946|
T5_T21 CPR:4 sc-560_13\NN\1740|(|,|ketorolac|) (r_dep) cox-1_11\NN\14737847|selective|sc-560|and|cox-2
T5_T22 NONE sc-560_13\NN\1740|(|,|ketorolac|) (r_dep) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (l_conj) cox-2_18\NN\14737847|celecoxib
T5_T23 NONE sc-560_13\NN\1740|(|,|ketorolac|) (r_dep) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (r_compound) inhibitors_24\NNS\20090|of|cox-1 (r_nmod) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) effect_32\NN\34213|2|feeding|expression (l_nmod) expression_39\NN\4679549|on|the|level (l_nmod) level_51\NN\4916342|isoforms|and|e(2|duodenum (l_compound) isoforms_42\NNS\1740|of|cox (l_compound) cox_41\NN\14732946|
T5_T24 NONE sc-560_13\NN\1740|(|,|ketorolac|) (r_dep) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (r_compound) inhibitors_24\NNS\20090|of|cox-1 (r_nmod) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) localization_59\NN\151497|3|isoforms (l_nmod) isoforms_62\NNS\1740|of|cox|duodenum (l_compound) cox_61\NN\14732946|
T6_T21 CPR:4 ketorolac_15\NN\3828465| (r_appos) sc-560_13\NN\1740|(|,|ketorolac|) (r_dep) cox-1_11\NN\14737847|selective|sc-560|and|cox-2
T6_T22 NONE ketorolac_15\NN\3828465| (r_appos) sc-560_13\NN\1740|(|,|ketorolac|) (r_dep) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (l_conj) cox-2_18\NN\14737847|celecoxib
T6_T23 NONE ketorolac_15\NN\3828465| (r_appos) sc-560_13\NN\1740|(|,|ketorolac|) (r_dep) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (r_compound) inhibitors_24\NNS\20090|of|cox-1 (r_nmod) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) effect_32\NN\34213|2|feeding|expression (l_nmod) expression_39\NN\4679549|on|the|level (l_nmod) level_51\NN\4916342|isoforms|and|e(2|duodenum (l_compound) isoforms_42\NNS\1740|of|cox (l_compound) cox_41\NN\14732946|
T6_T24 NONE ketorolac_15\NN\3828465| (r_appos) sc-560_13\NN\1740|(|,|ketorolac|) (r_dep) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (r_compound) inhibitors_24\NNS\20090|of|cox-1 (r_nmod) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) localization_59\NN\151497|3|isoforms (l_nmod) isoforms_62\NNS\1740|of|cox|duodenum (l_compound) cox_61\NN\14732946|
T7_T21 NONE celecoxib_20\NN\3124700|(|,|meloxicam|) (r_appos) cox-2_18\NN\14737847|celecoxib (r_conj) cox-1_11\NN\14737847|selective|sc-560|and|cox-2
T7_T22 CPR:4 celecoxib_20\NN\3124700|(|,|meloxicam|) (r_appos) cox-2_18\NN\14737847|celecoxib
T7_T23 NONE celecoxib_20\NN\3124700|(|,|meloxicam|) (r_appos) cox-2_18\NN\14737847|celecoxib (r_conj) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (r_compound) inhibitors_24\NNS\20090|of|cox-1 (r_nmod) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) effect_32\NN\34213|2|feeding|expression (l_nmod) expression_39\NN\4679549|on|the|level (l_nmod) level_51\NN\4916342|isoforms|and|e(2|duodenum (l_compound) isoforms_42\NNS\1740|of|cox (l_compound) cox_41\NN\14732946|
T7_T24 NONE celecoxib_20\NN\3124700|(|,|meloxicam|) (r_appos) cox-2_18\NN\14737847|celecoxib (r_conj) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (r_compound) inhibitors_24\NNS\20090|of|cox-1 (r_nmod) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) localization_59\NN\151497|3|isoforms (l_nmod) isoforms_62\NNS\1740|of|cox|duodenum (l_compound) cox_61\NN\14732946|
T8_T21 NONE meloxicam_22\NN\1740| (r_appos) celecoxib_20\NN\3124700|(|,|meloxicam|) (r_appos) cox-2_18\NN\14737847|celecoxib (r_conj) cox-1_11\NN\14737847|selective|sc-560|and|cox-2
T8_T22 CPR:4 meloxicam_22\NN\1740| (r_appos) celecoxib_20\NN\3124700|(|,|meloxicam|) (r_appos) cox-2_18\NN\14737847|celecoxib
T8_T23 NONE meloxicam_22\NN\1740| (r_appos) celecoxib_20\NN\3124700|(|,|meloxicam|) (r_appos) cox-2_18\NN\14737847|celecoxib (r_conj) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (r_compound) inhibitors_24\NNS\20090|of|cox-1 (r_nmod) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) effect_32\NN\34213|2|feeding|expression (l_nmod) expression_39\NN\4679549|on|the|level (l_nmod) level_51\NN\4916342|isoforms|and|e(2|duodenum (l_compound) isoforms_42\NNS\1740|of|cox (l_compound) cox_41\NN\14732946|
T8_T24 NONE meloxicam_22\NN\1740| (r_appos) celecoxib_20\NN\3124700|(|,|meloxicam|) (r_appos) cox-2_18\NN\14737847|celecoxib (r_conj) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (r_compound) inhibitors_24\NNS\20090|of|cox-1 (r_nmod) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) localization_59\NN\151497|3|isoforms (l_nmod) isoforms_62\NNS\1740|of|cox|duodenum (l_compound) cox_61\NN\14732946|
T9_T21 NONE cimetidine_36\NN\14778019| (r_conj) feeding_34\NN\838098|of|and|cimetidine (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_nmod) inhibitors_24\NNS\20090|of|cox-1 (l_compound) cox-1_11\NN\14737847|selective|sc-560|and|cox-2
T9_T22 NONE cimetidine_36\NN\14778019| (r_conj) feeding_34\NN\838098|of|and|cimetidine (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_nmod) inhibitors_24\NNS\20090|of|cox-1 (l_compound) cox-1_11\NN\14737847|selective|sc-560|and|cox-2 (l_conj) cox-2_18\NN\14737847|celecoxib
T9_T23 NONE cimetidine_36\NN\14778019| (r_conj) feeding_34\NN\838098|of|and|cimetidine (r_nmod) effect_32\NN\34213|2|feeding|expression (l_nmod) expression_39\NN\4679549|on|the|level (l_nmod) level_51\NN\4916342|isoforms|and|e(2|duodenum (l_compound) isoforms_42\NNS\1740|of|cox (l_compound) cox_41\NN\14732946|
T9_T24 NONE cimetidine_36\NN\14778019| (r_conj) feeding_34\NN\838098|of|and|cimetidine (r_nmod) effect_32\NN\34213|2|feeding|expression (r_conj) effects_8\NNS\13245626|the|1|ulcerogenic|inhibitors|mucosa|,|effect|,|and|localization (l_conj) localization_59\NN\151497|3|isoforms (l_nmod) isoforms_62\NNS\1740|of|cox|duodenum (l_compound) cox_61\NN\14732946|
T12_T26 NONE )_15\-RRB-\1740| (r_punct) pge(2_14\NN\1740|) (r_compound) level_16\NN\4916342|pge(2|(|immunoassay (r_conj) localization_0\NN\151497|and|expression|isoforms|and|level (l_nmod) isoforms_5\NNS\1740|of|cox|immunohistochemistry (l_compound) cox_4\NN\14732946|
T3_T14 NONE )_12\-RRB-\1740| (r_punct) pge(2_11\NN\1740|) (r_conj) expression_6\NN\4679549|both|the|isoforms|and|pge(2|level|duodenum (l_nmod) isoforms_9\NNS\1740|of|cox (l_compound) cox_8\NN\14732946|
T4_T14 CPR:4 cimetidine_27\NN\14778019|with (r_nmod) pretreatment_25\NN\1740|by|cimetidine (r_nmod) inhibited_23\VBN\2510337|effects|were|markedly|pretreatment|. (r_conj) increased_3\VBD\169651|second|,|feeding|expression|,|and|inhibited (l_dobj) expression_6\NN\4679549|both|the|isoforms|and|pge(2|level|duodenum (l_nmod) isoforms_9\NNS\1740|of|cox (l_compound) cox_8\NN\14732946|
9851542
T23_T37 NONE tacrine_5\NN\1740|of|and|inhibitors|rat (l_conj) inhibitors_9\NNS\20090|other|acetylcholinesterase (l_compound) acetylcholinesterase_8\NN\1740|
T19_T32 CPR:4 physostigmine_9\NN\14712692|,|tacrine|and|rivastigmine|injected (r_dep) effects_2\NNS\13245626|the|cardiovascular|inhibitors|:|physostigmine (l_nmod) inhibitors_7\NNS\20090|of|three|different|acetylcholinesterase (l_compound) acetylcholinesterase_6\NN\1740|
T21_T32 CPR:4 tacrine_11\NN\1740| (r_conj) physostigmine_9\NN\14712692|,|tacrine|and|rivastigmine|injected (r_dep) effects_2\NNS\13245626|the|cardiovascular|inhibitors|:|physostigmine (l_nmod) inhibitors_7\NNS\20090|of|three|different|acetylcholinesterase (l_compound) acetylcholinesterase_6\NN\1740|
T2_T32 CPR:4 rivastigmine_13\NN\1740| (r_conj) physostigmine_9\NN\14712692|,|tacrine|and|rivastigmine|injected (r_dep) effects_2\NNS\13245626|the|cardiovascular|inhibitors|:|physostigmine (l_nmod) inhibitors_7\NNS\20090|of|three|different|acetylcholinesterase (l_compound) acetylcholinesterase_6\NN\1740|
T12_T33 CPR:4 tacrine_0\NN\1740| (r_nsubjpass) chosen_2\VBN\697589|tacrine|was|model|. (l_nmod) model_5\NN\5888929|as|a|study (l_acl) study_7\VB\630380|to|mechanisms (l_dobj) mechanisms_9\NNS\13446390|the|underlying (l_acl) underlying_10\VBG\2604760|effects (l_dobj) effects_13\NNS\13245626|the|cardiovascular|inhibitors (l_nmod) inhibitors_17\NNS\20090|of|i.v.|cholinesterase (l_compound) cholinesterase_16\NN\14732946|
T17_T34 CPR:6 prazosin_3\NN\2698769| (r_dep) antagonist_2\NN\7846|the|alpha1-adrenoceptor|prazosin|or|antagonist (l_amod) alpha1-adrenoceptor_1\NN\1740|
T17_T35 NONE prazosin_3\NN\2698769| (r_dep) antagonist_2\NN\7846|the|alpha1-adrenoceptor|prazosin|or|antagonist (l_conj) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (l_compound) receptor_8\NN\5225602|
T17_T36 NONE prazosin_3\NN\2698769| (r_dep) antagonist_2\NN\7846|the|alpha1-adrenoceptor|prazosin|or|antagonist (l_conj) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (l_appos) vasopressin_20\NN\5407119|o-me-tyr2|]
T18_T34 NONE vasopressin_6\NN\5407119| (r_compound) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (r_conj) antagonist_2\NN\7846|the|alpha1-adrenoceptor|prazosin|or|antagonist (l_amod) alpha1-adrenoceptor_1\NN\1740|
T18_T35 NONE vasopressin_6\NN\5407119| (r_compound) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (l_compound) receptor_8\NN\5225602|
T18_T36 NONE vasopressin_6\NN\5407119| (r_compound) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (l_appos) vasopressin_20\NN\5407119|o-me-tyr2|]
T20_T34 NONE vasopressin_20\NN\5407119|o-me-tyr2|] (r_appos) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (r_conj) antagonist_2\NN\7846|the|alpha1-adrenoceptor|prazosin|or|antagonist (l_amod) alpha1-adrenoceptor_1\NN\1740|
T20_T35 CPR:6 vasopressin_20\NN\5407119|o-me-tyr2|] (r_appos) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (l_compound) receptor_8\NN\5225602|
T20_T36 NONE vasopressin_20\NN\5407119|o-me-tyr2|]
T22_T34 NONE tacrine_25\NN\1740| (r_compound) effect_27\NN\34213|tacrine|pressor (r_dobj) reduced_24\VBD\441445|antagonist|but|effect|and|abolished|. (l_nsubj) antagonist_2\NN\7846|the|alpha1-adrenoceptor|prazosin|or|antagonist (l_amod) alpha1-adrenoceptor_1\NN\1740|
T22_T35 NONE tacrine_25\NN\1740| (r_compound) effect_27\NN\34213|tacrine|pressor (r_dobj) reduced_24\VBD\441445|antagonist|but|effect|and|abolished|. (l_nsubj) antagonist_2\NN\7846|the|alpha1-adrenoceptor|prazosin|or|antagonist (l_conj) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (l_compound) receptor_8\NN\5225602|
T22_T36 NONE tacrine_25\NN\1740| (r_compound) effect_27\NN\34213|tacrine|pressor (r_dobj) reduced_24\VBD\441445|antagonist|but|effect|and|abolished|. (l_nsubj) antagonist_2\NN\7846|the|alpha1-adrenoceptor|prazosin|or|antagonist (l_conj) antagonist_9\NN\7846|the|vasopressin|v1|receptor|,|vasopressin (l_appos) vasopressin_20\NN\5407119|o-me-tyr2|]
T1_T24 NONE tacrine_1\NN\1740| (r_compound) response_3\NN\11410625|the|tacrine|pressor (r_nsubjpass) inhibited_5\VBN\2510337|response|was|manner|administration|. (l_nmod) administration_13\NN\1133281|by|the|i.c.v.|atropine (l_nmod) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_compound) antagonist_19\NN\7846|non-selective|muscarinic|receptor (l_compound) receptor_18\NN\5225602|
T1_T25 NONE tacrine_1\NN\1740| (r_compound) response_3\NN\11410625|the|tacrine|pressor (r_nsubjpass) inhibited_5\VBN\2510337|response|was|manner|administration|. (l_nmod) administration_13\NN\1133281|by|the|i.c.v.|atropine (l_nmod) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) pirenzepine_33\NN\1740|the|muscarinic|m1|receptor|antagonist|= (l_compound) receptor_31\NN\5225602|
T1_T26 NONE tacrine_1\NN\1740| (r_compound) response_3\NN\11410625|the|tacrine|pressor (r_nsubjpass) inhibited_5\VBN\2510337|response|was|manner|administration|. (l_nmod) administration_13\NN\1133281|by|the|i.c.v.|atropine (l_nmod) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) methoctramine_46\NN\1740|the|muscarinic|m2|receptor|antagonist|= (l_compound) receptor_44\NN\5225602|
T1_T27 NONE tacrine_1\NN\1740| (r_compound) response_3\NN\11410625|the|tacrine|pressor (r_nsubjpass) inhibited_5\VBN\2510337|response|was|manner|administration|. (l_nmod) administration_13\NN\1133281|by|the|i.c.v.|atropine (l_nmod) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) para-fluoro-hexahydro-sila-difenidol_59\NN\1740|the|muscarinic|m3|receptor|antagonist|= (l_compound) receptor_57\NN\5225602|
T3_T24 CPR:6 atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_compound) antagonist_19\NN\7846|non-selective|muscarinic|receptor (l_compound) receptor_18\NN\5225602|
T3_T25 NONE atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) pirenzepine_33\NN\1740|the|muscarinic|m1|receptor|antagonist|= (l_compound) receptor_31\NN\5225602|
T3_T26 NONE atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) methoctramine_46\NN\1740|the|muscarinic|m2|receptor|antagonist|= (l_compound) receptor_44\NN\5225602|
T3_T27 NONE atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) para-fluoro-hexahydro-sila-difenidol_59\NN\1740|the|muscarinic|m3|receptor|antagonist|= (l_compound) receptor_57\NN\5225602|
T4_T24 NONE pirenzepine_33\NN\1740|the|muscarinic|m1|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_compound) antagonist_19\NN\7846|non-selective|muscarinic|receptor (l_compound) receptor_18\NN\5225602|
T4_T25 CPR:6 pirenzepine_33\NN\1740|the|muscarinic|m1|receptor|antagonist|= (l_compound) receptor_31\NN\5225602|
T4_T26 NONE pirenzepine_33\NN\1740|the|muscarinic|m1|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) methoctramine_46\NN\1740|the|muscarinic|m2|receptor|antagonist|= (l_compound) receptor_44\NN\5225602|
T4_T27 NONE pirenzepine_33\NN\1740|the|muscarinic|m1|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) para-fluoro-hexahydro-sila-difenidol_59\NN\1740|the|muscarinic|m3|receptor|antagonist|= (l_compound) receptor_57\NN\5225602|
T5_T24 NONE methoctramine_46\NN\1740|the|muscarinic|m2|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_compound) antagonist_19\NN\7846|non-selective|muscarinic|receptor (l_compound) receptor_18\NN\5225602|
T5_T25 NONE methoctramine_46\NN\1740|the|muscarinic|m2|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) pirenzepine_33\NN\1740|the|muscarinic|m1|receptor|antagonist|= (l_compound) receptor_31\NN\5225602|
T5_T26 CPR:6 methoctramine_46\NN\1740|the|muscarinic|m2|receptor|antagonist|= (l_compound) receptor_44\NN\5225602|
T5_T27 NONE methoctramine_46\NN\1740|the|muscarinic|m2|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) para-fluoro-hexahydro-sila-difenidol_59\NN\1740|the|muscarinic|m3|receptor|antagonist|= (l_compound) receptor_57\NN\5225602|
T6_T24 NONE para-fluoro-hexahydro-sila-difenidol_59\NN\1740|the|muscarinic|m3|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_compound) antagonist_19\NN\7846|non-selective|muscarinic|receptor (l_compound) receptor_18\NN\5225602|
T6_T25 NONE para-fluoro-hexahydro-sila-difenidol_59\NN\1740|the|muscarinic|m3|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) pirenzepine_33\NN\1740|the|muscarinic|m1|receptor|antagonist|= (l_compound) receptor_31\NN\5225602|
T6_T26 NONE para-fluoro-hexahydro-sila-difenidol_59\NN\1740|the|muscarinic|m3|receptor|antagonist|= (r_conj) atropine_20\NN\14712692|of|the|antagonist|=|,|pirenzepine|,|methoctramine|and|para-fluoro-hexahydro-sila-difenidol (l_conj) methoctramine_46\NN\1740|the|muscarinic|m2|receptor|antagonist|= (l_compound) receptor_44\NN\5225602|
T6_T27 CPR:6 para-fluoro-hexahydro-sila-difenidol_59\NN\1740|the|muscarinic|m3|receptor|antagonist|= (l_compound) receptor_57\NN\5225602|
T7_T28 NONE tacrine-induced_10\JJ\1740| (r_amod) bradycardia_11\NN\14110674|tacrine-induced (r_dobj) affect_9\VB\126264|injection|did|not|bradycardia|. (l_nsubj) injection_1\NN\320852|central|antagonists (l_nmod) antagonists_6\NNS\7846|of|such|muscarinic|receptor (l_compound) receptor_5\NN\5225602|
T8_T29 NONE vasopressin_32\NN\5407119| (r_compound) release_33\NN\3748886|vasopressin (r_conj) outflow_30\NN\7407777|in|sympathetic|and|release (r_nmod) increase_27\NN\13576355|a|secondary|outflow (r_dobj) inducing_24\VBG\1627355|increase (r_acl) receptors_23\NNS\5225602|of|central|muscarinic|m2|inducing (r_nmod) stimulation_18\NN\242808|mainly|by|the|receptors (r_nmod) mediated_14\VBN\761713|stimulation (r_acl) response_13\NN\11410625|with|a|pressor|mediated (r_nmod) induce_6\VBP\1627355|that|inhibitors|effects|response (l_nsubj) inhibitors_5\NNS\20090|acetylcholinesterase (l_compound) acetylcholinesterase_4\NN\1740|
T8_T30 NONE vasopressin_32\NN\5407119| (r_compound) release_33\NN\3748886|vasopressin (r_conj) outflow_30\NN\7407777|in|sympathetic|and|release (r_nmod) increase_27\NN\13576355|a|secondary|outflow (r_dobj) inducing_24\VBG\1627355|increase (r_acl) receptors_23\NNS\5225602|of|central|muscarinic|m2|inducing
10939639
T12_T20 CPR:3 b_1\NN\1355326|schisandrin (r_nsubj) protects_2\VBZ\1127795|b|hepatotoxicity|enhancing|. (l_advcl) enhancing_7\VBG\227165|by|activity (l_dobj) activity_9\NN\30358|dt-diaphorase (l_compound) dt-diaphorase_8\NN\1740|
T13_T20 NONE menadione-induced_4\JJ\1740| (r_amod) hepatotoxicity_5\NN\1740|against|menadione-induced (r_nmod) protects_2\VBZ\1127795|b|hepatotoxicity|enhancing|. (l_advcl) enhancing_7\VBG\227165|by|activity (l_dobj) activity_9\NN\30358|dt-diaphorase (l_compound) dt-diaphorase_8\NN\1740|
T2_T14 CPR:4 menadione-induced_33\JJ\1740| (r_amod) damage_36\NN\7296428|against|menadione-induced|hepatic|oxidative|mice (r_nmod) protected_31\VBD\1127795|pretreating|damage|,|evidenced|. (l_advcl) evidenced_41\VBN\1015244|as|decreases|compared (l_nmod) decreases_43\NNS\7296428|by|activity|, (l_nmod) activity_48\NN\30358|in|plasma|alanine|aminotransferase|%|and|level (l_compound) aminotransferase_47\NN\15077571|
T3_T14 NONE b_4\NN\1355326|with|schisandrin|b|,|derivative (r_nmod) pretreating_0\VBG\1740|mice|b|,|dose (r_nsubj) protected_31\VBD\1127795|pretreating|damage|,|evidenced|. (l_advcl) evidenced_41\VBN\1015244|as|decreases|compared (l_nmod) decreases_43\NNS\7296428|by|activity|, (l_nmod) activity_48\NN\30358|in|plasma|alanine|aminotransferase|%|and|level (l_compound) aminotransferase_47\NN\15077571|
T4_T14 NONE malondialdehyde_55\NN\1740| (r_compound) level_56\NN\4916342|hepatic|malondialdehyde|% (r_conj) activity_48\NN\30358|in|plasma|alanine|aminotransferase|%|and|level (l_compound) aminotransferase_47\NN\15077571|
T5_T14 NONE b_7\NNP\1355326|(|sch|) (r_appos) b_4\NN\1355326|with|schisandrin|b|,|derivative (r_nmod) pretreating_0\VBG\1740|mice|b|,|dose (r_nsubj) protected_31\VBD\1127795|pretreating|damage|,|evidenced|. (l_advcl) evidenced_41\VBN\1015244|as|decreases|compared (l_nmod) decreases_43\NNS\7296428|by|activity|, (l_nmod) activity_48\NN\30358|in|plasma|alanine|aminotransferase|%|and|level (l_compound) aminotransferase_47\NN\15077571|
T6_T14 NONE menadione_66\NN\15092751| (r_nmod:npmod) intoxicated_67\JJ\1740|menadione (r_amod) control_68\NN\5190804|with|the|intoxicated (r_nmod) compared_63\VBN\644583|when|control (r_advcl) evidenced_41\VBN\1015244|as|decreases|compared (l_nmod) decreases_43\NNS\7296428|by|activity|, (l_nmod) activity_48\NN\30358|in|plasma|alanine|aminotransferase|%|and|level (l_compound) aminotransferase_47\NN\15077571|
T7_T15 NONE b_14\NN\1355326|sch (r_compound) pretreatment_15\NN\1740|by|b (r_nmod) afforded_11\VBN\2267060|pretreatment (r_acl) hepatoprotection_10\NN\1740|in|the|afforded (r_nmod) involved_7\VBN\2676054|hepatoprotection (r_acl) mechanism_6\NN\13446390|the|biochemical|involved (r_dobj) define_3\VB\2604760|in|to|mechanism (r_advcl) examined_18\VBD\789138|define|,|we|activity|. (l_dobj) activity_20\NN\30358|the|dt-diaphorase|hepatocytes (l_nmod) dt-diaphorase_22\NN\1740|of|dtd
T7_T16 NONE b_14\NN\1355326|sch (r_compound) pretreatment_15\NN\1740|by|b (r_nmod) afforded_11\VBN\2267060|pretreatment (r_acl) hepatoprotection_10\NN\1740|in|the|afforded (r_nmod) involved_7\VBN\2676054|hepatoprotection (r_acl) mechanism_6\NN\13446390|the|biochemical|involved (r_dobj) define_3\VB\2604760|in|to|mechanism (r_advcl) examined_18\VBD\789138|define|,|we|activity|. (l_dobj) activity_20\NN\30358|the|dt-diaphorase|hepatocytes (l_nmod) dt-diaphorase_22\NN\1740|of|dtd (l_appos) dtd_24\NN\1740|(|)
T8_T15 NONE b_31\NN\1355326|sch (r_nmod:npmod) pretreated_32\JJ\1740|b (r_amod) rats_33\NNS\2329401|from|pretreated (r_nmod) isolated_28\VBN\2512305|rats (r_acl) hepatocytes_27\NNS\1740|in|isolated (r_nmod) activity_20\NN\30358|the|dt-diaphorase|hepatocytes (l_nmod) dt-diaphorase_22\NN\1740|of|dtd
T8_T16 NONE b_31\NN\1355326|sch (r_nmod:npmod) pretreated_32\JJ\1740|b (r_amod) rats_33\NNS\2329401|from|pretreated (r_nmod) isolated_28\VBN\2512305|rats (r_acl) hepatocytes_27\NNS\1740|in|isolated (r_nmod) activity_20\NN\30358|the|dt-diaphorase|hepatocytes (l_nmod) dt-diaphorase_22\NN\1740|of|dtd (l_appos) dtd_24\NN\1740|(|)
T9_T17 CPR:3 b_4\NN\1355326|sch (r_nmod:npmod) pretreated_5\JJ\1740|b (r_amod) dose_9\NN\3740161|from|pretreated|(|a|daily|mmol/kg|days|)|rats (r_nmod) isolated_1\VBN\2512305|dose (r_acl) hepatocytes_0\NNS\1740|isolated (r_nsubj) showed_18\VBD\2137132|hepatocytes|increase|. (l_dobj) increase_21\NN\13576355|a|significant|%|activity (l_nmod) activity_28\NN\30358|in|dtd (l_compound) dtd_27\NN\1740|
T10_T18 NONE menadione_12\NN\15092751| (r_compound) elimination_13\NN\391599|of|menadione|culture (r_nmod) rate_10\NN\13815152|with|the|enhanced|elimination (r_nmod) associated_6\VBN\628491|increase|was|rate|. (l_nsubjpass) increase_1\NN\13576355|the|activity (l_nmod) activity_4\NN\30358|in|dtd (l_compound) dtd_3\NN\1740|
T11_T19 CPR:3 b_10\NN\1355326|sch (r_compound) pretreatment_11\NN\1740|of|b (r_nmod) ability_7\NN\4723816|the|pretreatment|enhance (l_acl) enhance_13\VB\227165|to|activity (l_dobj) activity_16\NN\30358|hepatocellular|dtd (l_compound) dtd_15\NN\1740|
T1_T19 NONE menadione_28\NN\15092751| (r_compound) hepatotoxicity_29\NN\1740|against|menadione (r_nmod) protection_26\NN\407535|to|the|hepatotoxicity (r_nmod) attributed_23\VBN\670261|that|ability|may|part|be|protection (l_nsubjpass) ability_7\NN\4723816|the|pretreatment|enhance (l_acl) enhance_13\VB\227165|to|activity (l_dobj) activity_16\NN\30358|hepatocellular|dtd (l_compound) dtd_15\NN\1740|
23423942
15292070
T1_T2 CPR:4 acarbose_0\NN\1740| (r_nsubj) served_1\VBD\2669789|acarbose|inhibitor|,|allowed|. (l_nmod) inhibitor_3\NN\20090|as|alpha-glucosidase (l_nmod) alpha-glucosidase_8\NN\1740|of|an|interfering|acid|present
16917142
T20_T33 NONE estrogen_7\NN\14745635| (r_compound) modulators_9\NNS\1740|with|selective|estrogen|receptor|serms (l_compound) receptor_8\NN\5225602|
T10_T22 NONE estrogen_5\NN\14745635| (r_compound) receptor_6\NN\5225602|the|estrogen|er (r_dobj) targets_3\VBZ\1151110|that|receptor (r_acl:relcl) therapy_1\NN\657604|endocrine|targets (r_nsubj) standard_12\NN\13577171|therapy|is|a|care|treatment|. (l_nmod) treatment_17\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|postmenopausal|cancer (l_nmod) cancer_24\NN\14239425|with|er-positive|breast (l_amod) er-positive_22\JJ\1740|
T10_T29 NONE estrogen_5\NN\14745635| (r_compound) receptor_6\NN\5225602|the|estrogen|er
T10_T32 NONE estrogen_5\NN\14745635| (r_compound) receptor_6\NN\5225602|the|estrogen|er (l_appos) er_8\NN\14625458|(|)
T9_T26 NONE tamoxifen_7\NN\2714883|the|modulator (l_compound) modulator_3\NN\1740|selective|er|serm (l_compound) er_2\NN\14625458|
T9_T28 NONE tamoxifen_7\NN\2714883|the|modulator (r_nsubjpass) been_9\VBN\836236|tamoxifen|has|use|and|option|. (l_conj) option_29\NN\6480506|is|currently|a|treatment|stages (l_nmod) stages_32\NNS\15113229|for|all|disease (l_nmod) disease_35\NN\14061805|of|er-positive (l_amod) er-positive_34\JJ\1740|
T11_T30 NONE tamoxifen_0\NN\2714883| (r_nsubj) blocks_1\VBZ\1476483|tamoxifen|action|binding|,|and|possesses|. (l_advcl) binding_7\VBG\1290422|by|er (l_nmod) er_10\NN\14625458|to|the
T11_T31 CPR:5 tamoxifen_0\NN\2714883| (r_nsubj) blocks_1\VBZ\1476483|tamoxifen|action|binding|,|and|possesses|. (l_conj) possesses_13\VBZ\2630189|er-agonist (l_dobj) er-agonist_15\NN\1740|both|and|antagonist|properties
T12_T30 NONE estrogen_5\NN\14745635|of (r_nmod) action_3\NN\30358|the|estrogen (r_dobj) blocks_1\VBZ\1476483|tamoxifen|action|binding|,|and|possesses|. (l_advcl) binding_7\VBG\1290422|by|er (l_nmod) er_10\NN\14625458|to|the
T12_T31 NONE estrogen_5\NN\14745635|of (r_nmod) action_3\NN\30358|the|estrogen (r_dobj) blocks_1\VBZ\1476483|tamoxifen|action|binding|,|and|possesses|. (l_conj) possesses_13\VBZ\2630189|er-agonist (l_dobj) er-agonist_15\NN\1740|both|and|antagonist|properties
T3_T21 NONE estrogen_20\NN\14745635|"|no (r_compound) environment_22\NN\13927383|a|estrogen|" (r_dobj) creating_16\VBG\2367363|by|environment (r_advcl) advance_14\NN\7311115|development|is|an|important|therapeutic|creating|. (l_nsubj) development_2\NN\248977|the|subsequent|inhibitors (l_nmod) inhibitors_6\NNS\20090|of|the|aromatase|ais (l_compound) aromatase_5\NN\1740|
T4_T23 CPR:6 fulvestrant_0\NN\1740| (r_nsubj) antagonist_5\NN\7846|fulvestrant|is|a|novel|er|destroys|. (l_compound) er_4\NN\14625458|
T4_T24 CPR:4 fulvestrant_0\NN\1740| (r_nsubj) antagonist_5\NN\7846|fulvestrant|is|a|novel|er|destroys|. (l_acl:relcl) destroys_7\VBZ\1619231|that|er|and|associated (l_dobj) er_9\NN\14625458|the|and|pathway
T5_T23 NONE tamoxifen-like_19\JJ\1740| (r_amod) effects_21\NNS\13245626|with|tamoxifen-like|agonist (r_nmod) associated_17\VBN\628491|is|not|effects (r_conj) destroys_7\VBZ\1619231|that|er|and|associated (r_acl:relcl) antagonist_5\NN\7846|fulvestrant|is|a|novel|er|destroys|. (l_compound) er_4\NN\14625458|
T5_T24 NONE tamoxifen-like_19\JJ\1740| (r_amod) effects_21\NNS\13245626|with|tamoxifen-like|agonist (r_nmod) associated_17\VBN\628491|is|not|effects (r_conj) destroys_7\VBZ\1619231|that|er|and|associated (l_dobj) er_9\NN\14625458|the|and|pathway
T6_T25 NONE tamoxifen_14\NN\2714883|to|or|inhibitors (l_conj) inhibitors_17\NNS\20090|aromatase (l_compound) aromatase_16\NN\1740|
T7_T25 NONE anastrozole_26\NN\1740|as|the|ai (r_nmod) effective_22\JJ\1740|is|equally|as|anastrozole|treatment (r_conj) cross-resistant_12\JJ\1740|is|not|tamoxifen|and|effective (l_nmod) tamoxifen_14\NN\2714883|to|or|inhibitors (l_conj) inhibitors_17\NNS\20090|aromatase (l_compound) aromatase_16\NN\1740|
T8_T25 NONE tamoxifen_43\NN\2714883| (r_compound) therapy_44\NN\657604|on|prior|adjuvant|tamoxifen (r_nmod) progressed_39\VBN\252019|who|have|therapy (r_acl:relcl) women_32\NNS\9605289|of|postmenopausal|cancer|progressed (r_nmod) treatment_29\NN\654885|in|the|women (r_nmod) effective_22\JJ\1740|is|equally|as|anastrozole|treatment (r_conj) cross-resistant_12\JJ\1740|is|not|tamoxifen|and|effective (l_nmod) tamoxifen_14\NN\2714883|to|or|inhibitors (l_conj) inhibitors_17\NNS\20090|aromatase (l_compound) aromatase_16\NN\1740|
23606243
20053189
T20_T30 NONE abarelix_0\NN\1740|and|antagonists|cancer|. (l_conj) antagonists_5\NNS\7846|other|gonadotrophin-releasing|hormone (l_compound) hormone_4\NN\5404728|
T21_T30 NONE hormone_4\NN\5404728|
T10_T22 NONE gnrh_25\NN\1740| (r_compound) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|) (r_dobj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_nsubj) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh
T10_T23 NONE gnrh_25\NN\1740| (r_compound) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|) (r_dobj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_nsubj) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh (l_appos) lhrh_4\NN\1740|(|)
T10_T24 NONE gnrh_25\NN\1740| (r_compound) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|)
T10_T25 NONE gnrh_25\NN\1740| (r_compound) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|) (r_dobj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_advcl) leading_30\VBG\1752884|ultimately|de-sensitization (l_nmod) de-sensitization_33\NN\1740|to|its|and|reduction (l_conj) reduction_36\NN\351485|subsequent|levels (l_nmod) levels_41\NNS\4916342|of|lh (l_compound) lh_38\NN\5410315|and|testosterone
T11_T22 NONE testosterone_40\NN\14747587| (r_conj) lh_38\NN\5410315|and|testosterone (r_compound) levels_41\NNS\4916342|of|lh (r_nmod) reduction_36\NN\351485|subsequent|levels (r_conj) de-sensitization_33\NN\1740|to|its|and|reduction (r_nmod) leading_30\VBG\1752884|ultimately|de-sensitization (r_advcl) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_nsubj) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh
T11_T23 NONE testosterone_40\NN\14747587| (r_conj) lh_38\NN\5410315|and|testosterone (r_compound) levels_41\NNS\4916342|of|lh (r_nmod) reduction_36\NN\351485|subsequent|levels (r_conj) de-sensitization_33\NN\1740|to|its|and|reduction (r_nmod) leading_30\VBG\1752884|ultimately|de-sensitization (r_advcl) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_nsubj) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh (l_appos) lhrh_4\NN\1740|(|)
T11_T24 NONE testosterone_40\NN\14747587| (r_conj) lh_38\NN\5410315|and|testosterone (r_compound) levels_41\NNS\4916342|of|lh (r_nmod) reduction_36\NN\351485|subsequent|levels (r_conj) de-sensitization_33\NN\1740|to|its|and|reduction (r_nmod) leading_30\VBG\1752884|ultimately|de-sensitization (r_advcl) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_dobj) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|)
T11_T25 NONE testosterone_40\NN\14747587| (r_conj) lh_38\NN\5410315|and|testosterone
T5_T22 CPR:5 buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh
T5_T23 CPR:5 buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh (l_appos) lhrh_4\NN\1740|(|)
T5_T24 CPR:3 buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (r_nsubj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_dobj) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|)
T5_T25 CPR:4 buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (r_nsubj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_advcl) leading_30\VBG\1752884|ultimately|de-sensitization (l_nmod) de-sensitization_33\NN\1740|to|its|and|reduction (l_conj) reduction_36\NN\351485|subsequent|levels (l_nmod) levels_41\NNS\4916342|of|lh (l_compound) lh_38\NN\5410315|and|testosterone
T6_T22 CPR:5 goserelin_12\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh
T6_T23 CPR:5 goserelin_12\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh (l_appos) lhrh_4\NN\1740|(|)
T6_T24 CPR:3 goserelin_12\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (r_nsubj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_dobj) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|)
T6_T25 CPR:4 goserelin_12\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (r_nsubj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_advcl) leading_30\VBG\1752884|ultimately|de-sensitization (l_nmod) de-sensitization_33\NN\1740|to|its|and|reduction (l_conj) reduction_36\NN\351485|subsequent|levels (l_nmod) levels_41\NNS\4916342|of|lh (l_compound) lh_38\NN\5410315|and|testosterone
T7_T22 CPR:5 leuprorelin_14\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh
T7_T23 CPR:5 leuprorelin_14\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh (l_appos) lhrh_4\NN\1740|(|)
T7_T24 CPR:3 leuprorelin_14\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (r_nsubj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_dobj) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|)
T7_T25 CPR:4 leuprorelin_14\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (r_nsubj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_advcl) leading_30\VBG\1752884|ultimately|de-sensitization (l_nmod) de-sensitization_33\NN\1740|to|its|and|reduction (l_conj) reduction_36\NN\351485|subsequent|levels (l_nmod) levels_41\NNS\4916342|of|lh (l_compound) lh_38\NN\5410315|and|testosterone
T8_T22 CPR:5 triptorelin_16\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh
T8_T23 CPR:5 triptorelin_16\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh (l_appos) lhrh_4\NN\1740|(|)
T8_T24 CPR:3 triptorelin_16\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (r_nsubj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_dobj) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|)
T8_T25 CPR:4 triptorelin_16\NN\1740| (r_conj) buserelin_10\NN\1740|such|,|goserelin|,|leuprorelin|and|triptorelin (r_nmod) agonists_6\NNS\9613191|hormone|,|buserelin|, (r_nsubj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_advcl) leading_30\VBG\1752884|ultimately|de-sensitization (l_nmod) de-sensitization_33\NN\1740|to|its|and|reduction (l_conj) reduction_36\NN\351485|subsequent|levels (l_nmod) levels_41\NNS\4916342|of|lh (l_compound) lh_38\NN\5410315|and|testosterone
T9_T22 NONE hormone_23\NN\5404728| (r_compound) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|) (r_dobj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_nsubj) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh
T9_T23 NONE hormone_23\NN\5404728| (r_compound) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|) (r_dobj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_nsubj) agonists_6\NNS\9613191|hormone|,|buserelin|, (l_compound) hormone_2\NN\5404728|luteinizing|hormone-releasing|lhrh (l_appos) lhrh_4\NN\1740|(|)
T9_T24 NONE hormone_23\NN\5404728| (r_compound) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|)
T9_T25 NONE hormone_23\NN\5404728| (r_compound) receptor_27\NN\5225602|pituitary|gonadotrophin-releasing|hormone|(|gnrh|) (r_dobj) stimulate_18\VBP\137313|agonists|receptor|,|leading|. (l_advcl) leading_30\VBG\1752884|ultimately|de-sensitization (l_nmod) de-sensitization_33\NN\1740|to|its|and|reduction (l_conj) reduction_36\NN\351485|subsequent|levels (l_nmod) levels_41\NNS\4916342|of|lh (l_compound) lh_38\NN\5410315|and|testosterone
T12_T26 NONE testosterone_18\NN\14747587| (r_conj) lh_16\NN\5410315|and|testosterone
T13_T27 NONE gnrh_2\NN\1740|
T13_T28 NONE gnrh_2\NN\1740| (r_compound) antagonists_3\NNS\7846|two|pure|gnrh (r_nsubjpass) developed_6\VBN\1753788|antagonists|have|been|,|abarelix|,|devoid|. (l_dep) devoid_14\JJ\1740|that|are|effect|and|result (l_nmod) effect_18\NN\34213|of|any|agonist|receptor (l_nmod) receptor_22\NN\5225602|on|the|gnrh
T14_T27 CPR:6 abarelix_8\NNP\1740|and|degarelix (r_dep) developed_6\VBN\1753788|antagonists|have|been|,|abarelix|,|devoid|. (l_nsubjpass) antagonists_3\NNS\7846|two|pure|gnrh (l_compound) gnrh_2\NN\1740|
T14_T28 NONE abarelix_8\NNP\1740|and|degarelix (r_dep) developed_6\VBN\1753788|antagonists|have|been|,|abarelix|,|devoid|. (l_dep) devoid_14\JJ\1740|that|are|effect|and|result (l_nmod) effect_18\NN\34213|of|any|agonist|receptor (l_nmod) receptor_22\NN\5225602|on|the|gnrh
T15_T27 CPR:6 degarelix_10\NNP\1740| (r_conj) abarelix_8\NNP\1740|and|degarelix (r_dep) developed_6\VBN\1753788|antagonists|have|been|,|abarelix|,|devoid|. (l_nsubjpass) antagonists_3\NNS\7846|two|pure|gnrh (l_compound) gnrh_2\NN\1740|
T15_T28 NONE degarelix_10\NNP\1740| (r_conj) abarelix_8\NNP\1740|and|degarelix (r_dep) developed_6\VBN\1753788|antagonists|have|been|,|abarelix|,|devoid|. (l_dep) devoid_14\JJ\1740|that|are|effect|and|result (l_nmod) effect_18\NN\34213|of|any|agonist|receptor (l_nmod) receptor_22\NN\5225602|on|the|gnrh
T16_T27 NONE gnrh_21\NN\1740| (r_compound) receptor_22\NN\5225602|on|the|gnrh (r_nmod) effect_18\NN\34213|of|any|agonist|receptor (r_nmod) devoid_14\JJ\1740|that|are|effect|and|result (r_dep) developed_6\VBN\1753788|antagonists|have|been|,|abarelix|,|devoid|. (l_nsubjpass) antagonists_3\NNS\7846|two|pure|gnrh (l_compound) gnrh_2\NN\1740|
T16_T28 NONE gnrh_21\NN\1740| (r_compound) receptor_22\NN\5225602|on|the|gnrh
T17_T27 NONE testosterone_29\NN\14747587| (r_compound) flare_30\NN\27807|in|testosterone (r_nmod) result_27\VB\2633881|consequently|do|not|flare (r_conj) devoid_14\JJ\1740|that|are|effect|and|result (r_dep) developed_6\VBN\1753788|antagonists|have|been|,|abarelix|,|devoid|. (l_nsubjpass) antagonists_3\NNS\7846|two|pure|gnrh (l_compound) gnrh_2\NN\1740|
T17_T28 NONE testosterone_29\NN\14747587| (r_compound) flare_30\NN\27807|in|testosterone (r_nmod) result_27\VB\2633881|consequently|do|not|flare (r_conj) devoid_14\JJ\1740|that|are|effect|and|result (l_nmod) effect_18\NN\34213|of|any|agonist|receptor (l_nmod) receptor_22\NN\5225602|on|the|gnrh
T18_T29 CPR:6 abarelix_0\NNP\1740| (r_nsubj) antagonist_5\NN\7846|abarelix|was|the|first|gnrh|developed|and|approved|. (l_compound) gnrh_4\NN\1740|
T19_T29 NONE gnrh_4\NN\1740|
T1_T29 NONE androgen_37\NN\14745635| (r_compound) suppression_38\NN\13489037|rapid|androgen (r_nsubj) necessary_40\JJ\1740|when|suppression|is (r_acl:relcl) carcinoma_33\NN\14239918|in|advanced|hormone-dependent|prostate|,|necessary (r_nmod) castration_26\NN\692506|of|hormonal|carcinoma (r_nmod) initiation_23\NN\7450842|for|the|castration (r_nmod) approved_11\VBN\803325|was|administration|2004|initiation (r_conj) antagonist_5\NN\7846|abarelix|was|the|first|gnrh|developed|and|approved|. (l_compound) gnrh_4\NN\1740|
11304699
T1_T17 CPR:3 aom-treated_38\JJ\1740| (r_amod) rats_39\NNS\2329401|aom-treated (r_conj) mice_36\NNS\2329401|in|both|min|and|rats (r_nmod) bowel_32\NN\5298729|to|the|proximal|mice (r_nmod) relative_28\JJ\1740|bowel (r_amod) excess_24\NN\5119367|a|3-|distal|relative (r_dobj) demonstrated_19\VBD\2137132|excess (r_conj) assessed_8\VBD\670261|evaluate|,|we|expression|and|demonstrated|. (l_dobj) expression_13\NN\4679549|cyclo-oxygenase-2|mucosa (l_compound) cyclo-oxygenase-2_9\NN\1740|cox-2
T1_T18 CPR:3 aom-treated_38\JJ\1740| (r_amod) rats_39\NNS\2329401|aom-treated (r_conj) mice_36\NNS\2329401|in|both|min|and|rats (r_nmod) bowel_32\NN\5298729|to|the|proximal|mice (r_nmod) relative_28\JJ\1740|bowel (r_amod) excess_24\NN\5119367|a|3-|distal|relative (r_dobj) demonstrated_19\VBD\2137132|excess (r_conj) assessed_8\VBD\670261|evaluate|,|we|expression|and|demonstrated|. (l_dobj) expression_13\NN\4679549|cyclo-oxygenase-2|mucosa (l_compound) cyclo-oxygenase-2_9\NN\1740|cox-2 (l_appos) cox-2_11\NN\14737847|(|)
T4_T15 NONE nabumetone_5\NN\3828465|of (r_nmod) predilection_3\NN\6200178|the|striking|distal|nabumetone (r_nsubjpass) explained_13\VBN\831651|predilection|may|be|,|partially|,|over-expression|. (l_nmod) over-expression_17\NN\1740|by|distal|bowel|cox-2 (l_nmod) cox-2_19\NN\14737847|of|and|ppar-delta
T4_T16 NONE nabumetone_5\NN\3828465|of (r_nmod) predilection_3\NN\6200178|the|striking|distal|nabumetone (r_nsubjpass) explained_13\VBN\831651|predilection|may|be|,|partially|,|over-expression|. (l_nmod) over-expression_17\NN\1740|by|distal|bowel|cox-2 (l_nmod) cox-2_19\NN\14737847|of|and|ppar-delta (l_conj) ppar-delta_21\NN\1740|
23123257
T1_T5 NONE polyglutamate_27\NN\1740|by (r_nmod) replacement_23\NN\196485|plasmid|polyglutamate (r_nsubj) reduced_28\VBD\441445|replacement|elevation|. (r_conj) triggered_14\VBD\1641914|injection|production|and|reduced (l_dobj) production_16\NN\30358|a|cytokines|mice (l_nmod) cytokines_19\NNS\14728724|of|several
T1_T6 CPR:4 polyglutamate_27\NN\1740|by (r_nmod) replacement_23\NN\196485|plasmid|polyglutamate (r_nsubj) reduced_28\VBD\441445|replacement|elevation|. (l_dobj) elevation_30\NN\7445480|the|cytokines (l_nmod) cytokines_34\NNS\14728724|of|all|assayed
23639626
T16_T36 CPR:3 tcdd_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|tcdd|expression|:|tale|. (l_dobj) expression_3\NN\4679549|the|protein|cells (l_nmod) protein_9\NN\14944888|of|insulin-like|growth|factor|binding|4 (l_nummod) 4_10\CD\13741022|
T17_T36 NONE dioxin_30\NN\14911057| (r_compound) toxicity_31\NN\13576101|on|dioxin (r_nmod) studies_28\NNS\635850|in|toxicity (r_nmod) use_22\NN\407535|of|the|line|studies (r_nmod) tale_19\NN\6598915|a|cautionary|use (r_dep) induces_1\VBZ\1627355|tcdd|expression|:|tale|. (l_dobj) expression_3\NN\4679549|the|protein|cells (l_nmod) protein_9\NN\14944888|of|insulin-like|growth|factor|binding|4 (l_nummod) 4_10\CD\13741022|
T11_T26 NONE rapamycin_30\NN\1740|of|mtor (r_nmod) target_28\NN\7258332|of|the|mammalian|rapamycin (r_nmod) substrate_24\NN\19613|target (r_conj) regulator_19\NN\3096960|a|initiation|and|substrate (r_appos) protein_15\NN\14944888|of|eukaryotic|translation|initiation|factor|4e-binding|1|,|regulator (l_nummod) 1_16\CD\13741022|
T11_T27 NONE rapamycin_30\NN\1740|of|mtor
T11_T28 NONE rapamycin_30\NN\1740|of|mtor (l_appos) mtor_32\NN\1740|(|)
T9_T26 NONE tcdd_0\NN\1740| (r_compound) treatment_1\NN\654885|tcdd|cells (r_nsubj) prevented_6\VBD\1740|treatment|largely|activation|. (l_dobj) activation_8\NN\13561719|the|protein (l_nmod) protein_15\NN\14944888|of|eukaryotic|translation|initiation|factor|4e-binding|1|,|regulator (l_nummod) 1_16\CD\13741022|
T9_T27 NONE tcdd_0\NN\1740| (r_compound) treatment_1\NN\654885|tcdd|cells (r_nsubj) prevented_6\VBD\1740|treatment|largely|activation|. (l_dobj) activation_8\NN\13561719|the|protein (l_nmod) protein_15\NN\14944888|of|eukaryotic|translation|initiation|factor|4e-binding|1|,|regulator (l_appos) regulator_19\NN\3096960|a|initiation|and|substrate (l_conj) substrate_24\NN\19613|target (l_nmod) target_28\NN\7258332|of|the|mammalian|rapamycin (l_nmod) rapamycin_30\NN\1740|of|mtor
T9_T28 NONE tcdd_0\NN\1740| (r_compound) treatment_1\NN\654885|tcdd|cells (r_nsubj) prevented_6\VBD\1740|treatment|largely|activation|. (l_dobj) activation_8\NN\13561719|the|protein (l_nmod) protein_15\NN\14944888|of|eukaryotic|translation|initiation|factor|4e-binding|1|,|regulator (l_appos) regulator_19\NN\3096960|a|initiation|and|substrate (l_conj) substrate_24\NN\19613|target (l_nmod) target_28\NN\7258332|of|the|mammalian|rapamycin (l_nmod) rapamycin_30\NN\1740|of|mtor (l_appos) mtor_32\NN\1740|(|)
T12_T29 NONE tcdd_11\NN\1740| (r_nsubj) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (r_ccomp) observed_9\VBD\2163746|working|,|we|inhibited|. (l_advcl) working_2\VBG\2524171|by|"|upwards (l_advmod) upwards_3\NNS\1740|"|mtor (l_nmod) mtor_6\NN\1740|from
T12_T30 CPR:4 tcdd_11\NN\1740| (r_nsubj) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (l_dobj) akt_16\NN\1740|endogenous|and|activation (l_amod) endogenous_13\JJ\1740|and|igf-i-induced (l_conj) igf-i-induced_15\JJ\1740|
T12_T31 CPR:4 tcdd_11\NN\1740| (r_nsubj) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (l_dobj) akt_16\NN\1740|endogenous|and|activation
T12_T32 CPR:4 tcdd_11\NN\1740| (r_nsubj) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (l_dobj) akt_16\NN\1740|endogenous|and|activation (l_conj) activation_19\NN\13561719|erk (l_compound) erk_18\NN\1740|
T12_T33 NONE tcdd_11\NN\1740| (r_nsubj) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (l_advcl) interfering_21\VBG\2451370|by|phosphorylation (l_nmod) phosphorylation_24\NN\1740|with|tyrosine|substrate (l_nmod) substrate_28\NN\19613|of|insulin|receptor|1 (l_nummod) 1_29\CD\13741022|
T13_T29 NONE tyrosine_23\NN\14601829| (r_compound) phosphorylation_24\NN\1740|with|tyrosine|substrate (r_nmod) interfering_21\VBG\2451370|by|phosphorylation (r_advcl) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (r_ccomp) observed_9\VBD\2163746|working|,|we|inhibited|. (l_advcl) working_2\VBG\2524171|by|"|upwards (l_advmod) upwards_3\NNS\1740|"|mtor (l_nmod) mtor_6\NN\1740|from
T13_T30 NONE tyrosine_23\NN\14601829| (r_compound) phosphorylation_24\NN\1740|with|tyrosine|substrate (r_nmod) interfering_21\VBG\2451370|by|phosphorylation (r_advcl) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (l_dobj) akt_16\NN\1740|endogenous|and|activation (l_amod) endogenous_13\JJ\1740|and|igf-i-induced (l_conj) igf-i-induced_15\JJ\1740|
T13_T31 NONE tyrosine_23\NN\14601829| (r_compound) phosphorylation_24\NN\1740|with|tyrosine|substrate (r_nmod) interfering_21\VBG\2451370|by|phosphorylation (r_advcl) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (l_dobj) akt_16\NN\1740|endogenous|and|activation
T13_T32 NONE tyrosine_23\NN\14601829| (r_compound) phosphorylation_24\NN\1740|with|tyrosine|substrate (r_nmod) interfering_21\VBG\2451370|by|phosphorylation (r_advcl) inhibited_12\VBD\2510337|that|tcdd|akt|interfering (l_dobj) akt_16\NN\1740|endogenous|and|activation (l_conj) activation_19\NN\13561719|erk (l_compound) erk_18\NN\1740|
T13_T33 NONE tyrosine_23\NN\14601829| (r_compound) phosphorylation_24\NN\1740|with|tyrosine|substrate (l_nmod) substrate_28\NN\19613|of|insulin|receptor|1 (l_nummod) 1_29\CD\13741022|
T14_T34 CPR:3 tcdd-induced_6\JJ\1740| (r_amod) factor_8\NN\7326557|by|a|tcdd-induced|secreted|identified (l_acl:relcl) identified_11\VBN\699815|which|was|protein (l_nmod) protein_17\NN\14944888|as|insulin-like|growth|factor|binding|4|igfbp-4 (l_nummod) 4_18\CD\13741022|
T14_T35 CPR:3 tcdd-induced_6\JJ\1740| (r_amod) factor_8\NN\7326557|by|a|tcdd-induced|secreted|identified (l_acl:relcl) identified_11\VBN\699815|which|was|protein (l_nmod) protein_17\NN\14944888|as|insulin-like|growth|factor|binding|4|igfbp-4 (l_appos) igfbp-4_20\NN\1740|(|)
T1_T18 NONE hydrocarbon_11\NN\14727670| (r_compound) receptor_12\NN\5225602|on|a|functional|aryl|hydrocarbon (r_nmod) dependent_6\JJ\1740|induction|was|receptor|and|preceded|. (l_nsubj) induction_1\NN\7450842|the|protein (l_nmod) protein_4\NN\14944888|of|igfbp-4 (l_compound) igfbp-4_3\NN\1740|
T1_T19 NONE hydrocarbon_11\NN\14727670| (r_compound) receptor_12\NN\5225602|on|a|functional|aryl|hydrocarbon
T1_T20 NONE hydrocarbon_11\NN\14727670| (r_compound) receptor_12\NN\5225602|on|a|functional|aryl|hydrocarbon (r_nmod) dependent_6\JJ\1740|induction|was|receptor|and|preceded|. (l_conj) preceded_15\VBN\2690708|was|increase|indicating (l_nmod) increase_19\NN\13576355|by|a|rapid|level (l_nmod) level_22\NN\4916342|in|the|mrna (l_nmod) mrna_25\NN\14832193|of|igfbp-4 (l_compound) igfbp-4_24\NN\1740|
T1_T21 NONE hydrocarbon_11\NN\14727670| (r_compound) receptor_12\NN\5225602|on|a|functional|aryl|hydrocarbon (r_nmod) dependent_6\JJ\1740|induction|was|receptor|and|preceded|. (l_conj) preceded_15\VBN\2690708|was|increase|indicating (l_xcomp) indicating_26\VBG\952524|target (l_ccomp) target_34\NN\7258332|that|igfbp-4|is|a|unknown|transcriptional|tcdd|cells (l_nsubj) igfbp-4_28\NN\1740|
T2_T18 NONE tcdd_36\NN\1740|of (r_nmod) target_34\NN\7258332|that|igfbp-4|is|a|unknown|transcriptional|tcdd|cells (r_ccomp) indicating_26\VBG\952524|target (r_xcomp) preceded_15\VBN\2690708|was|increase|indicating (r_conj) dependent_6\JJ\1740|induction|was|receptor|and|preceded|. (l_nsubj) induction_1\NN\7450842|the|protein (l_nmod) protein_4\NN\14944888|of|igfbp-4 (l_compound) igfbp-4_3\NN\1740|
T2_T19 NONE tcdd_36\NN\1740|of (r_nmod) target_34\NN\7258332|that|igfbp-4|is|a|unknown|transcriptional|tcdd|cells (r_ccomp) indicating_26\VBG\952524|target (r_xcomp) preceded_15\VBN\2690708|was|increase|indicating (r_conj) dependent_6\JJ\1740|induction|was|receptor|and|preceded|. (l_nmod) receptor_12\NN\5225602|on|a|functional|aryl|hydrocarbon
T2_T20 CPR:4 tcdd_36\NN\1740|of (r_nmod) target_34\NN\7258332|that|igfbp-4|is|a|unknown|transcriptional|tcdd|cells (r_ccomp) indicating_26\VBG\952524|target (r_xcomp) preceded_15\VBN\2690708|was|increase|indicating (l_nmod) increase_19\NN\13576355|by|a|rapid|level (l_nmod) level_22\NN\4916342|in|the|mrna (l_nmod) mrna_25\NN\14832193|of|igfbp-4 (l_compound) igfbp-4_24\NN\1740|
T2_T21 NONE tcdd_36\NN\1740|of (r_nmod) target_34\NN\7258332|that|igfbp-4|is|a|unknown|transcriptional|tcdd|cells (l_nsubj) igfbp-4_28\NN\1740|
T3_T22 NONE tcdd_5\NN\1740|by (r_nmod) induced_3\VBN\1627355|igfbp-4|was|not|tcdd|line|. (l_nsubjpass) igfbp-4_0\NN\1740|
T4_T23 NONE dioxin_20\NN\14911057| (r_compound) element(s_22\NN\1740|dioxin|responsive|)|leading (r_dobj) containing_19\VBG\2632940|element(s (r_acl) promoter_18\NN\9773962|of|a|containing (r_nmod) control_15\NN\5190804|under|the|promoter (r_nmod) got_12\VBN\146138|that|cells|gene|may|have|control (l_nsubj) gene_9\NN\8459252|the|igfbp-4 (l_compound) igfbp-4_8\NN\1740|
T4_T24 NONE dioxin_20\NN\14911057| (r_compound) element(s_22\NN\1740|dioxin|responsive|)|leading (l_punct) )_23\-RRB-\1740|
T4_T25 NONE dioxin_20\NN\14911057| (r_compound) element(s_22\NN\1740|dioxin|responsive|)|leading (l_acl) leading_24\VBG\1752884|induction (l_nmod) induction_27\NN\7450842|to|the|igfbp-4|tcdd (l_nmod) igfbp-4_29\NN\1740|of
T5_T23 NONE tcdd_31\NN\1740|by (r_nmod) induction_27\NN\7450842|to|the|igfbp-4|tcdd (r_nmod) leading_24\VBG\1752884|induction (r_acl) element(s_22\NN\1740|dioxin|responsive|)|leading (r_dobj) containing_19\VBG\2632940|element(s (r_acl) promoter_18\NN\9773962|of|a|containing (r_nmod) control_15\NN\5190804|under|the|promoter (r_nmod) got_12\VBN\146138|that|cells|gene|may|have|control (l_nsubj) gene_9\NN\8459252|the|igfbp-4 (l_compound) igfbp-4_8\NN\1740|
T5_T24 NONE tcdd_31\NN\1740|by (r_nmod) induction_27\NN\7450842|to|the|igfbp-4|tcdd (r_nmod) leading_24\VBG\1752884|induction (r_acl) element(s_22\NN\1740|dioxin|responsive|)|leading (l_punct) )_23\-RRB-\1740|
T5_T25 CPR:3 tcdd_31\NN\1740|by (r_nmod) induction_27\NN\7450842|to|the|igfbp-4|tcdd (l_nmod) igfbp-4_29\NN\1740|of
10887187
T11_T27 NONE k+_6\NN\1740| (r_compound) channel_7\NN\6251781|an|inactivating|2p|domain|k+ (r_appos) twik-2_0\NNP\1740|,|channel|.
T11_T28 NONE k+_6\NN\1740| (r_compound) channel_7\NN\6251781|an|inactivating|2p|domain|k+
T5_T17 NONE )_13\-RRB-\1740| (r_punct) channel_14\NN\6251781|this|novel|2p|domain|k(+|) (r_dobj) expressed_7\VBD\928630|channel|cells (r_conj) cloned_1\VBD\1693881|we|twik-2|and|expressed|. (l_dobj) twik-2_5\NN\1740|human
T5_T21 NONE )_13\-RRB-\1740| (r_punct) channel_14\NN\6251781|this|novel|2p|domain|k(+|)
T3_T16 NONE )_22\-RRB-\1740| (r_punct) gradient_23\NN\13859043|in|a|physiological|k(+|) (r_nmod) rectification_17\NN\13548105|outward|gradient|and|rectification (r_dobj) exhibit_15\VBP\2632167|both|rectification|conditions (r_conj) larger_7\JJR\1740|currents|are|15|currents|,|but|exhibit|. (l_nsubj) currents_2\NNS\11449002|rat|twik-2 (l_compound) twik-2_1\NN\1740|
T3_T18 NONE )_22\-RRB-\1740| (r_punct) gradient_23\NN\13859043|in|a|physiological|k(+|) (r_nmod) rectification_17\NN\13548105|outward|gradient|and|rectification (r_dobj) exhibit_15\VBP\2632167|both|rectification|conditions (r_conj) larger_7\JJR\1740|currents|are|15|currents|,|but|exhibit|. (l_nmod) currents_11\NNS\11449002|than|human|twik-2 (l_compound) twik-2_10\NN\1740|
T4_T16 NONE )_31\-RRB-\1740| (r_punct) k(+_30\NN\1740|) (r_compound) conditions_32\NNS\14512817|in|symmetrical|k(+ (r_nmod) exhibit_15\VBP\2632167|both|rectification|conditions (r_conj) larger_7\JJR\1740|currents|are|15|currents|,|but|exhibit|. (l_nsubj) currents_2\NNS\11449002|rat|twik-2 (l_compound) twik-2_1\NN\1740|
T4_T18 NONE )_31\-RRB-\1740| (r_punct) k(+_30\NN\1740|) (r_compound) conditions_32\NNS\14512817|in|symmetrical|k(+ (r_nmod) exhibit_15\VBP\2632167|both|rectification|conditions (r_conj) larger_7\JJR\1740|currents|are|15|currents|,|but|exhibit|. (l_nmod) currents_11\NNS\11449002|than|human|twik-2 (l_compound) twik-2_10\NN\1740|
T6_T23 NONE )_4\-RRB-\1740| (r_punct) gradient_5\NN\13859043|in|a|physiological|k(+|) (r_nmod) inhibited_10\VBN\2510337|gradient|,|twik-2|is|half|+|,|quinine|,|and|quinidine|. (l_nsubjpass) twik-2_7\NN\1740|
T7_T23 CPR:4 )_16\-RRB-\1740| (r_punct) +_15\NN\1740|by|mm|ba(2|) (r_nmod) inhibited_10\VBN\2510337|gradient|,|twik-2|is|half|+|,|quinine|,|and|quinidine|. (l_nsubjpass) twik-2_7\NN\1740|
T8_T23 CPR:4 quinine_18\NN\2721948| (r_conj) inhibited_10\VBN\2510337|gradient|,|twik-2|is|half|+|,|quinine|,|and|quinidine|. (l_nsubjpass) twik-2_7\NN\1740|
T9_T23 CPR:4 quinidine_21\NN\2715941| (r_conj) inhibited_10\VBN\2510337|gradient|,|twik-2|is|half|+|,|quinine|,|and|quinidine|. (l_nsubjpass) twik-2_7\NN\1740|
T10_T24 NONE cysteine_2\NN\14601829|53|loop (l_nmod) loop_8\NN\3323703|in|the|m1p1|external
T10_T25 NONE cysteine_2\NN\14601829|53|loop (r_nsubjpass) required_10\VBN\754942|finally|,|cysteine|is|expression|but|critical|. (l_nmod) expression_13\NN\4679549|for|functional|twik-2 (l_nmod) twik-2_15\NN\1740|of
T1_T12 NONE )_8\-RRB-\1740| (r_punct) channel_9\NN\6251781|twik-2|is|the|first|reported|2p|domain|k(+|)|inactivates|.
T1_T26 NONE )_8\-RRB-\1740| (r_punct) channel_9\NN\6251781|twik-2|is|the|first|reported|2p|domain|k(+|)|inactivates|. (l_nsubj) twik-2_0\NNP\1740|
T2_T13 NONE )_17\-RRB-\1740| (r_punct) channel_18\NN\6251781|this|novel|2p|domain|k(+|) (r_nsubj) play_20\VB\1072262|that|channel|may|role|electrogenesis (r_ccomp) suggest_10\VBP\1010118|activities|play|. (l_nsubj) activities_7\NNS\30358|the|base-line|twik-2 (l_nmod) twik-2_9\NN\1740|of
T2_T14 NONE )_17\-RRB-\1740| (r_punct) channel_18\NN\6251781|this|novel|2p|domain|k(+|)
23210662
T1_T12 NONE ethynyl-g2.0-pamam_33\NN\1740|of|or|ethynyl-g3.0-pamam (r_compound) dendrons_36\NNS\1740|ethynyl-g2.0-pamam (r_dobj) consisting_31\VBG\2603699|dendrons (r_acl) region_30\NN\27167|a|cationized|shell|consisting (r_conj) reservoir_22\NN\13777344|as|a|molecules|and|region (r_nmod) serves_19\VBZ\2669789|that|reservoir (r_acl:relcl) core_17\NN\7996689|of|a|albumin|serves (l_compound) albumin_13\NN\14736972|human|serum|hsa
T1_T14 NONE ethynyl-g2.0-pamam_33\NN\1740|of|or|ethynyl-g3.0-pamam (r_compound) dendrons_36\NNS\1740|ethynyl-g2.0-pamam (r_dobj) consisting_31\VBG\2603699|dendrons (r_acl) region_30\NN\27167|a|cationized|shell|consisting (r_conj) reservoir_22\NN\13777344|as|a|molecules|and|region (r_nmod) serves_19\VBZ\2669789|that|reservoir (r_acl:relcl) core_17\NN\7996689|of|a|albumin|serves (l_compound) albumin_13\NN\14736972|human|serum|hsa (l_appos) hsa_15\NN\1740|(|)
T2_T12 NONE ethynyl-g2.0-pamam_33\NN\1740|of|or|ethynyl-g3.0-pamam (r_compound) dendrons_36\NNS\1740|ethynyl-g2.0-pamam (r_dobj) consisting_31\VBG\2603699|dendrons (r_acl) region_30\NN\27167|a|cationized|shell|consisting (r_conj) reservoir_22\NN\13777344|as|a|molecules|and|region (r_nmod) serves_19\VBZ\2669789|that|reservoir (r_acl:relcl) core_17\NN\7996689|of|a|albumin|serves (l_compound) albumin_13\NN\14736972|human|serum|hsa
T2_T14 NONE ethynyl-g2.0-pamam_33\NN\1740|of|or|ethynyl-g3.0-pamam (r_compound) dendrons_36\NNS\1740|ethynyl-g2.0-pamam (r_dobj) consisting_31\VBG\2603699|dendrons (r_acl) region_30\NN\27167|a|cationized|shell|consisting (r_conj) reservoir_22\NN\13777344|as|a|molecules|and|region (r_nmod) serves_19\VBZ\2669789|that|reservoir (r_acl:relcl) core_17\NN\7996689|of|a|albumin|serves (l_compound) albumin_13\NN\14736972|human|serum|hsa (l_appos) hsa_15\NN\1740|(|)
T3_T12 NONE ethynyl-g3.0-pamam_35\NN\1740| (r_conj) ethynyl-g2.0-pamam_33\NN\1740|of|or|ethynyl-g3.0-pamam (r_compound) dendrons_36\NNS\1740|ethynyl-g2.0-pamam (r_dobj) consisting_31\VBG\2603699|dendrons (r_acl) region_30\NN\27167|a|cationized|shell|consisting (r_conj) reservoir_22\NN\13777344|as|a|molecules|and|region (r_nmod) serves_19\VBZ\2669789|that|reservoir (r_acl:relcl) core_17\NN\7996689|of|a|albumin|serves (l_compound) albumin_13\NN\14736972|human|serum|hsa
T3_T14 NONE ethynyl-g3.0-pamam_35\NN\1740| (r_conj) ethynyl-g2.0-pamam_33\NN\1740|of|or|ethynyl-g3.0-pamam (r_compound) dendrons_36\NNS\1740|ethynyl-g2.0-pamam (r_dobj) consisting_31\VBG\2603699|dendrons (r_acl) region_30\NN\27167|a|cationized|shell|consisting (r_conj) reservoir_22\NN\13777344|as|a|molecules|and|region (r_nmod) serves_19\VBZ\2669789|that|reservoir (r_acl:relcl) core_17\NN\7996689|of|a|albumin|serves (l_compound) albumin_13\NN\14736972|human|serum|hsa (l_appos) hsa_15\NN\1740|(|)
T4_T12 NONE ethynyl-g3.0-pamam_35\NN\1740| (r_conj) ethynyl-g2.0-pamam_33\NN\1740|of|or|ethynyl-g3.0-pamam (r_compound) dendrons_36\NNS\1740|ethynyl-g2.0-pamam (r_dobj) consisting_31\VBG\2603699|dendrons (r_acl) region_30\NN\27167|a|cationized|shell|consisting (r_conj) reservoir_22\NN\13777344|as|a|molecules|and|region (r_nmod) serves_19\VBZ\2669789|that|reservoir (r_acl:relcl) core_17\NN\7996689|of|a|albumin|serves (l_compound) albumin_13\NN\14736972|human|serum|hsa
T4_T14 NONE ethynyl-g3.0-pamam_35\NN\1740| (r_conj) ethynyl-g2.0-pamam_33\NN\1740|of|or|ethynyl-g3.0-pamam (r_compound) dendrons_36\NNS\1740|ethynyl-g2.0-pamam (r_dobj) consisting_31\VBG\2603699|dendrons (r_acl) region_30\NN\27167|a|cationized|shell|consisting (r_conj) reservoir_22\NN\13777344|as|a|molecules|and|region (r_nmod) serves_19\VBZ\2669789|that|reservoir (r_acl:relcl) core_17\NN\7996689|of|a|albumin|serves (l_compound) albumin_13\NN\14736972|human|serum|hsa (l_appos) hsa_15\NN\1740|(|)
T5_T11 NONE ethynyl-g2.0-pamam_3\NN\1740| (r_compound) dendrons_4\NNS\1740|of|ethynyl-g2.0-pamam (r_nmod) attachment_1\NN\7544647|the|dendrons|hsa (l_nmod) hsa_6\NN\1740|to
T6_T11 NONE ethynyl-g2.0-pamam_3\NN\1740| (r_compound) dendrons_4\NNS\1740|of|ethynyl-g2.0-pamam (r_nmod) attachment_1\NN\7544647|the|dendrons|hsa (l_nmod) hsa_6\NN\1740|to
T7_T11 NONE pamam_28\NN\1740| (r_compound) shell_29\NN\2703275|of|the|dendritic|pamam (r_nmod) presence_24\NN\13954253|due|the|shell (r_nmod) uptaken_15\VBN\1740|that|was|clearly|cells|presence (r_acl:relcl) macromolecule_11\NN\14682133|a|nontoxic|core-shell|uptaken (r_dobj) yielded_7\VBD\2327200|attachment|macromolecule|. (l_nsubj) attachment_1\NN\7544647|the|dendrons|hsa (l_nmod) hsa_6\NN\1740|to
T8_T13 NONE doxorubicin_4\NN\2716866|of (r_nmod) loading_2\NN\4571088|higher|doxorubicin (r_nsubjpass) observed_6\VBN\2163746|loading|was|g2-dhsa|protein|availability|. (l_nmod) availability_18\NN\4718563|due|the|pockets|,|and|interaction (l_nmod) pockets_21\NNS\3993180|of|binding|core (l_nmod) core_25\NN\7996689|of|the|hsa (l_compound) hsa_24\NN\1740|
21207059
T1_T10 NONE n-acetylglutamate_10\NN\1740| (r_compound) synthetase_11\NN\1740|of|n-acetylglutamate
T4_T11 NONE leucine_8\NN\14605787| (r_compound) metabolism_9\NN\13526110|of|leucine (r_nmod) disease_6\NN\14061805|acidemia|is|an|autosomal|recessive|metabolism|deficiency|. (l_nmod) deficiency_12\NN\14449126|due|to|dehydrogenase (l_nmod) dehydrogenase_15\NN\1740|of|isovaleryl-coa
T5_T11 NONE isovaleryl-coa_14\NN\1740| (r_compound) dehydrogenase_15\NN\1740|of|isovaleryl-coa
16298345
T2_T13 CPR:6 maraviroc_25\NNP\1740|such|(|uk-427,857|) (r_nmod) antagonists_21\NNS\7846|of|novel|ccr5|,|maraviroc (l_compound) ccr5_20\NN\1740|
T3_T13 CPR:6 uk-427,857_27\CD\1740| (r_appos) maraviroc_25\NNP\1740|such|(|uk-427,857|) (r_nmod) antagonists_21\NNS\7846|of|novel|ccr5|,|maraviroc (l_compound) ccr5_20\NN\1740|
T4_T16 NONE [125i]-mip-1beta_17\NN\1740|of|and|[3h]-maraviroc (r_nmod) properties_15\NNS\32613|the|binding|[125i]-mip-1beta (r_dobj) compared_12\VBD\644583|properties|ccr5 (r_conj) cloned_4\VBD\1693881|do|we|and|expressed|ccr5|and|compared|. (l_dobj) ccr5_7\NN\1740|macaque
T4_T17 NONE [125i]-mip-1beta_17\NN\1740|of|and|[3h]-maraviroc (r_nmod) properties_15\NNS\32613|the|binding|[125i]-mip-1beta (r_dobj) compared_12\VBD\644583|properties|ccr5 (l_nmod) ccr5_23\NN\1740|with|human|recombinant
T5_T16 NONE [3h]-maraviroc_19\NN\1740| (r_conj) [125i]-mip-1beta_17\NN\1740|of|and|[3h]-maraviroc (r_nmod) properties_15\NNS\32613|the|binding|[125i]-mip-1beta (r_dobj) compared_12\VBD\644583|properties|ccr5 (r_conj) cloned_4\VBD\1693881|do|we|and|expressed|ccr5|and|compared|. (l_dobj) ccr5_7\NN\1740|macaque
T5_T17 NONE [3h]-maraviroc_19\NN\1740| (r_conj) [125i]-mip-1beta_17\NN\1740|of|and|[3h]-maraviroc (r_nmod) properties_15\NNS\32613|the|binding|[125i]-mip-1beta (r_dobj) compared_12\VBD\644583|properties|ccr5 (l_nmod) ccr5_23\NN\1740|with|human|recombinant
T6_T18 NONE [125i]-mip-1beta_0\NN\1740| (r_nsubj) bound_1\VBD\1831531|[125i]-mip-1beta|affinity|and|properties|. (l_nmod) affinity_5\NN\11426530|with|similar|high|ccr5 (l_nmod) ccr5_7\NN\1740|to|macaque
T7_T21 NONE maraviroc_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|maraviroc|binding|=|and|antagonised|. (l_dobj) binding_2\NN\4688246|[125i]-mip-1beta|ccr5|potency (l_nmod) ccr5_6\NN\1740|to|macaque
T7_T22 CPR:6 maraviroc_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|maraviroc|binding|=|and|antagonised|. (l_conj) antagonised_30\VBD\2367363|release|= (l_dobj) release_35\NN\3748886|induced|intracellular|calcium|mediated (l_acl) mediated_36\VBN\761713|ccr5 (l_nmod) ccr5_38\NN\1740|through|macaque
T8_T21 NONE [125i]-mip-1beta_4\NN\1740|of (r_nmod) binding_2\NN\4688246|[125i]-mip-1beta|ccr5|potency (l_nmod) ccr5_6\NN\1740|to|macaque
T8_T22 NONE [125i]-mip-1beta_4\NN\1740|of (r_nmod) binding_2\NN\4688246|[125i]-mip-1beta|ccr5|potency (r_dobj) inhibited_1\VBD\2510337|maraviroc|binding|=|and|antagonised|. (l_conj) antagonised_30\VBD\2367363|release|= (l_dobj) release_35\NN\3748886|induced|intracellular|calcium|mediated (l_acl) mediated_36\VBN\761713|ccr5 (l_nmod) ccr5_38\NN\1740|through|macaque
T9_T21 NONE calcium_34\NN\14625458| (r_compound) release_35\NN\3748886|induced|intracellular|calcium|mediated (r_dobj) antagonised_30\VBD\2367363|release|= (r_conj) inhibited_1\VBD\2510337|maraviroc|binding|=|and|antagonised|. (l_dobj) binding_2\NN\4688246|[125i]-mip-1beta|ccr5|potency (l_nmod) ccr5_6\NN\1740|to|macaque
T9_T22 NONE calcium_34\NN\14625458| (r_compound) release_35\NN\3748886|induced|intracellular|calcium|mediated (l_acl) mediated_36\VBN\761713|ccr5 (l_nmod) ccr5_38\NN\1740|through|macaque
T10_T11 NONE [3h]-maraviroc_0\NN\1740| (r_nsubj) bound_1\VBD\1831531|[3h]-maraviroc|affinity|ccr5|,|but|found|. (l_nmod) ccr5_6\NN\1740|to|macaque
T10_T12 NONE [3h]-maraviroc_0\NN\1740| (r_nsubj) bound_1\VBD\1831531|[3h]-maraviroc|affinity|ccr5|,|but|found|. (l_conj) found_30\VBN\2426171|was|dissociate (l_xcomp) dissociate_32\VB\2431320|to|quickly|ccr5 (l_nmod) ccr5_39\NN\1740|from|macaque
T1_T14 CPR:6 maraviroc_8\NN\1740| (r_nsubjpass) shown_10\VBN\2137132|however|,|receptor|,|maraviroc|was|antagonist|indicating|. (l_xcomp) antagonist_19\NN\7846|to|be|a|affinity|potent|functional|ccr5 (l_nmod) ccr5_22\NN\1740|of|macaque
T1_T15 CPR:6 maraviroc_8\NN\1740| (r_nsubjpass) shown_10\VBN\2137132|however|,|receptor|,|maraviroc|was|antagonist|indicating|. (l_xcomp) indicating_24\VBG\952524|thereby|species (l_ccomp) species_32\NNS\7992450|that|macaque|should|be|a|suitable|evaluate (l_acl:relcl) evaluate_36\VB\670261|which|to|pharmacology (l_dobj) pharmacology_38\NN\6043075|the|,|safety|and|toxicology|antagonists (l_nmod) antagonists_48\NNS\7846|of|novel|ccr5 (l_compound) ccr5_47\NN\1740|
23246481
T14_T25 CPR:4 wogonin_0\NN\1740| (r_nsubj) inhibits_1\VBZ\2510337|wogonin|permeability|suppressing|. (l_advcl) suppressing_6\VBG\2510337|through|phosphorylation (l_dobj) phosphorylation_8\NN\1740|the|caveolin-1 (l_nmod) caveolin-1_10\NN\1740|of
T15_T25 CPR:3 h2o2-induced_2\JJ\1740| (r_amod) permeability_4\NN\4940146|h2o2-induced|vascular (r_dobj) inhibits_1\VBZ\2510337|wogonin|permeability|suppressing|. (l_advcl) suppressing_6\VBG\2510337|through|phosphorylation (l_dobj) phosphorylation_8\NN\1740|the|caveolin-1 (l_nmod) caveolin-1_10\NN\1740|of
T6_T16 CPR:4 wogonin_3\NN\1740| (r_nsubj) suppress_5\VB\2510337|that|wogonin|can|remodeling (l_dobj) remodeling_9\NN\1740|the|h2o2-stimulated|actin|and|uptake|huvecs|,|as|migration (l_compound) actin_8\NN\14736972|
T6_T17 CPR:4 wogonin_3\NN\1740| (r_nsubj) suppress_5\VB\2510337|that|wogonin|can|remodeling (l_dobj) remodeling_9\NN\1740|the|h2o2-stimulated|actin|and|uptake|huvecs|,|as|migration (l_conj) uptake_12\NN\13440063|albumin (l_compound) albumin_11\NN\14736972|
T7_T16 CPR:3 h2o2-stimulated_7\JJ\1740| (r_amod) remodeling_9\NN\1740|the|h2o2-stimulated|actin|and|uptake|huvecs|,|as|migration (l_compound) actin_8\NN\14736972|
T7_T17 CPR:3 h2o2-stimulated_7\JJ\1740| (r_amod) remodeling_9\NN\1740|the|h2o2-stimulated|actin|and|uptake|huvecs|,|as|migration (l_conj) uptake_12\NN\13440063|albumin (l_compound) albumin_11\NN\14736972|
T8_T18 CPR:4 wogonin_4\NN\1740| (r_nsubj) inhibited_5\VBD\2510337|that|wogonin|phosphorylation (l_dobj) phosphorylation_7\NN\1740|h2o2-induced|caveolin-1|associating (l_nmod) caveolin-1_9\NN\1740|of|cav-1
T8_T19 CPR:4 wogonin_4\NN\1740| (r_nsubj) inhibited_5\VBD\2510337|that|wogonin|phosphorylation (l_dobj) phosphorylation_7\NN\1740|h2o2-induced|caveolin-1|associating (l_nmod) caveolin-1_9\NN\1740|of|cav-1 (l_appos) cav-1_11\NN\1740|(|)
T8_T20 CPR:4 wogonin_4\NN\1740| (r_nsubj) inhibited_5\VBD\2510337|that|wogonin|phosphorylation (l_dobj) phosphorylation_7\NN\1740|h2o2-induced|caveolin-1|associating (l_acl) associating_13\VBG\628491|suppression (l_nmod) suppression_16\NN\13489037|with|the|stabilization (l_nmod) stabilization_18\NN\1158690|of|ve-cadherin (l_nmod) ve-cadherin_20\NN\1740|of|and|β-catenin
T8_T21 CPR:4 wogonin_4\NN\1740| (r_nsubj) inhibited_5\VBD\2510337|that|wogonin|phosphorylation (l_dobj) phosphorylation_7\NN\1740|h2o2-induced|caveolin-1|associating (l_acl) associating_13\VBG\628491|suppression (l_nmod) suppression_16\NN\13489037|with|the|stabilization (l_nmod) stabilization_18\NN\1158690|of|ve-cadherin (l_nmod) ve-cadherin_20\NN\1740|of|and|β-catenin (l_conj) β-catenin_22\NN\1740|
T9_T18 CPR:3 h2o2-induced_6\JJ\1740| (r_amod) phosphorylation_7\NN\1740|h2o2-induced|caveolin-1|associating (l_nmod) caveolin-1_9\NN\1740|of|cav-1
T9_T19 CPR:3 h2o2-induced_6\JJ\1740| (r_amod) phosphorylation_7\NN\1740|h2o2-induced|caveolin-1|associating (l_nmod) caveolin-1_9\NN\1740|of|cav-1 (l_appos) cav-1_11\NN\1740|(|)
T9_T20 NONE h2o2-induced_6\JJ\1740| (r_amod) phosphorylation_7\NN\1740|h2o2-induced|caveolin-1|associating (l_acl) associating_13\VBG\628491|suppression (l_nmod) suppression_16\NN\13489037|with|the|stabilization (l_nmod) stabilization_18\NN\1158690|of|ve-cadherin (l_nmod) ve-cadherin_20\NN\1740|of|and|β-catenin
T9_T21 NONE h2o2-induced_6\JJ\1740| (r_amod) phosphorylation_7\NN\1740|h2o2-induced|caveolin-1|associating (l_acl) associating_13\VBG\628491|suppression (l_nmod) suppression_16\NN\13489037|with|the|stabilization (l_nmod) stabilization_18\NN\1158690|of|ve-cadherin (l_nmod) ve-cadherin_20\NN\1740|of|and|β-catenin (l_conj) β-catenin_22\NN\1740|
T10_T22 CPR:4 wogonin_2\NN\1740| (r_nsubj) repressed_3\VBD\2424652|moreover|,|wogonin|phosphorylation|. (l_dobj) phosphorylation_5\NN\1740|anisomycin-induced|p38|,|cav-1|and|permeability (l_nmod) p38_7\NN\1740|of
T10_T23 CPR:4 wogonin_2\NN\1740| (r_nsubj) repressed_3\VBD\2424652|moreover|,|wogonin|phosphorylation|. (l_dobj) phosphorylation_5\NN\1740|anisomycin-induced|p38|,|cav-1|and|permeability (l_conj) cav-1_9\NN\1740|
T11_T22 CPR:3 anisomycin-induced_4\JJ\1740| (r_amod) phosphorylation_5\NN\1740|anisomycin-induced|p38|,|cav-1|and|permeability (l_nmod) p38_7\NN\1740|of
T11_T23 CPR:3 anisomycin-induced_4\JJ\1740| (r_amod) phosphorylation_5\NN\1740|anisomycin-induced|p38|,|cav-1|and|permeability (l_conj) cav-1_9\NN\1740|
T12_T24 CPR:4 wogonin_4\NN\1740| (r_nsubj) inhibit_6\VB\2510337|that|wogonin|could|permeability|downregulating|,|and|have (l_advcl) downregulating_11\VBG\1740|by|phosphorylation (l_dobj) phosphorylation_13\NN\1740|the|cav-1 (l_nmod) cav-1_15\NN\1740|of
T13_T24 CPR:3 h2o2-induced_7\JJ\1740| (r_amod) permeability_9\NN\4940146|h2o2-induced|vascular (r_dobj) inhibit_6\VB\2510337|that|wogonin|could|permeability|downregulating|,|and|have (l_advcl) downregulating_11\VBG\1740|by|phosphorylation (l_dobj) phosphorylation_13\NN\1740|the|cav-1 (l_nmod) cav-1_15\NN\1740|of
23332762
T1_T23 NONE serine-26_4\NN\1740|at|ser26 (r_nmod) phosphorylates_1\VBZ\1740|ikk|bad|serine-26|and|primes|. (l_nsubj) ikk_0\NN\1740|
T1_T24 NONE serine-26_4\NN\1740|at|ser26 (r_nmod) phosphorylates_1\VBZ\1740|ikk|bad|serine-26|and|primes|. (l_dobj) bad_2\NN\4723816|
T2_T23 NONE ser26_6\NN\1740|(|) (r_appos) serine-26_4\NN\1740|at|ser26 (r_nmod) phosphorylates_1\VBZ\1740|ikk|bad|serine-26|and|primes|. (l_nsubj) ikk_0\NN\1740|
T2_T24 NONE ser26_6\NN\1740|(|) (r_appos) serine-26_4\NN\1740|at|ser26 (r_nmod) phosphorylates_1\VBZ\1740|ikk|bad|serine-26|and|primes|. (l_dobj) bad_2\NN\4723816|
T3_T25 NONE ser26_2\NN\1740| (r_compound) phosphorylation_3\NN\1740|of|ser26 (r_nmod) elimination_0\NN\391599|phosphorylation (r_nsubj) promotes_4\VBZ\2556126|elimination|activity|,|accelerating|. (l_dobj) activity_7\NN\30358|bad|proapoptotic (l_compound) bad_5\NN\4723816|
T3_T26 NONE ser26_2\NN\1740| (r_compound) phosphorylation_3\NN\1740|of|ser26 (r_nmod) elimination_0\NN\391599|phosphorylation (r_nsubj) promotes_4\VBZ\2556126|elimination|activity|,|accelerating|. (l_advcl) accelerating_10\VBG\226566|thereby|apoptosis|and|increasing (l_dobj) apoptosis_12\NN\11486178|tnfα-induced|cells (l_amod) tnfα-induced_11\JJ\1740|
23000507
T7_T13 NONE tyrosine_25\NN\14601829| (r_compound) hydroxylase_26\NN\1740|such|tyrosine|th|and|y (r_nmod) neuromarkers_21\NNS\1740|also|sympathetic|,|hydroxylase (r_conj) neuromarkers_7\NNS\1740|for|only|sensory|,|peptide|,|but|neuromarkers (l_nmod) peptide_13\NN\14724264|such|calcitonin|gene-related|cgrp
T7_T14 NONE tyrosine_25\NN\14601829| (r_compound) hydroxylase_26\NN\1740|such|tyrosine|th|and|y (r_nmod) neuromarkers_21\NNS\1740|also|sympathetic|,|hydroxylase (r_conj) neuromarkers_7\NNS\1740|for|only|sensory|,|peptide|,|but|neuromarkers (l_nmod) peptide_13\NN\14724264|such|calcitonin|gene-related|cgrp (l_appos) cgrp_15\NN\1740|(|)
T7_T15 NONE tyrosine_25\NN\14601829| (r_compound) hydroxylase_26\NN\1740|such|tyrosine|th|and|y
T7_T16 NONE tyrosine_25\NN\14601829| (r_compound) hydroxylase_26\NN\1740|such|tyrosine|th|and|y (l_appos) th_28\NN\15163157|(|)
T7_T17 NONE tyrosine_25\NN\14601829| (r_compound) hydroxylase_26\NN\1740|such|tyrosine|th|and|y (l_conj) y_32\NN\14625458|neuropeptide|npy
T7_T18 NONE tyrosine_25\NN\14601829| (r_compound) hydroxylase_26\NN\1740|such|tyrosine|th|and|y (l_conj) y_32\NN\14625458|neuropeptide|npy (l_appos) npy_34\NN\1740|(|)
22893351
T3_T14 NONE hg_5\NN\14625458| (r_nsubj) accumulates_6\VBZ\2281093|because|hg|tubules (r_advcl) expected_30\VBN\670261|that|accumulates|,|(gst)-α|would|be|related (l_nsubjpass) (gst)-α_16\NN\1740|glutathione-s-transferases|(|suggestive
T3_T15 NONE hg_5\NN\14625458| (r_nsubj) accumulates_6\VBZ\2281093|because|hg|tubules (r_advcl) expected_30\VBN\670261|that|accumulates|,|(gst)-α|would|be|related (l_xcomp) related_34\JJ\1740|to|be|more|exposure|gst-π (l_nmod) gst-π_39\NN\1740|than|(|suggestive
T4_T14 NONE glutathione-s-transferases_15\NNS\1740| (r_compound) (gst)-α_16\NN\1740|glutathione-s-transferases|(|suggestive
T4_T15 NONE glutathione-s-transferases_15\NNS\1740| (r_compound) (gst)-α_16\NN\1740|glutathione-s-transferases|(|suggestive (r_nsubjpass) expected_30\VBN\670261|that|accumulates|,|(gst)-α|would|be|related (l_xcomp) related_34\JJ\1740|to|be|more|exposure|gst-π (l_nmod) gst-π_39\NN\1740|than|(|suggestive
T5_T14 NONE glutathione-s-transferases_15\NNS\1740| (r_compound) (gst)-α_16\NN\1740|glutathione-s-transferases|(|suggestive
T5_T15 NONE glutathione-s-transferases_15\NNS\1740| (r_compound) (gst)-α_16\NN\1740|glutathione-s-transferases|(|suggestive (r_nsubjpass) expected_30\VBN\670261|that|accumulates|,|(gst)-α|would|be|related (l_xcomp) related_34\JJ\1740|to|be|more|exposure|gst-π (l_nmod) gst-π_39\NN\1740|than|(|suggestive
T6_T14 NONE hg_36\NN\14625458| (r_compound) exposure_37\NN\5042871|to|hg (r_nmod) related_34\JJ\1740|to|be|more|exposure|gst-π (r_xcomp) expected_30\VBN\670261|that|accumulates|,|(gst)-α|would|be|related (l_nsubjpass) (gst)-α_16\NN\1740|glutathione-s-transferases|(|suggestive
T6_T15 NONE hg_36\NN\14625458| (r_compound) exposure_37\NN\5042871|to|hg (r_nmod) related_34\JJ\1740|to|be|more|exposure|gst-π (l_nmod) gst-π_39\NN\1740|than|(|suggestive
T7_T16 NONE hg_12\NN\14625458| (r_compound) exposure_13\NN\5042871|between|increasing|hg|amalgams|and|gst-α|biomarkers (l_conj) gst-α_18\NN\1740|and|gst-π
T7_T17 NONE hg_12\NN\14625458| (r_compound) exposure_13\NN\5042871|between|increasing|hg|amalgams|and|gst-α|biomarkers (l_conj) gst-α_18\NN\1740|and|gst-π (l_conj) gst-π_20\NN\1740|
T1_T11 NONE hg_29\NN\14625458|to (r_nmod) exposure_27\NN\5042871|between|cumulative|hg|amalgams|and|levels (l_conj) levels_35\NNS\4916342|urinary|gst-α (l_nmod) gst-α_37\NN\1740|of
T1_T12 NONE hg_29\NN\14625458|to (r_nmod) exposure_27\NN\5042871|between|cumulative|hg|amalgams|and|levels (r_nmod) correlation_24\NN\13841213|a|significant|dose-dependent|exposure (r_dobj) revealed_19\VBD\2137132|overall|,|study|,|correlation|,|adjustment|;|observed|. (l_advcl) observed_50\VBN\2163746|where|as|,|relationship|was|levels (l_nmod) levels_53\NNS\4916342|with|urinary|gst-π (l_nmod) gst-π_55\NN\1740|of
23578993
T27_T43 NONE alanine_0\NN\14601829| (r_compound) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin
T27_T44 NONE alanine_0\NN\14601829| (r_compound) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_appos) alt_3\NN\13836371|(|)
T27_T45 NONE alanine_0\NN\14601829| (r_compound) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) aminotransferase_7\NN\15077571|aspartate|ast
T27_T46 NONE alanine_0\NN\14601829| (r_compound) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) aminotransferase_7\NN\15077571|aspartate|ast (l_appos) ast_9\NN\1740|(|)
T27_T47 NONE alanine_0\NN\14601829| (r_compound) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) phosphatase_13\NN\14732946|alkaline|alp
T27_T48 NONE alanine_0\NN\14601829| (r_compound) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) phosphatase_13\NN\14732946|alkaline|alp (l_appos) alp_15\NN\9359803|(|)
T28_T43 NONE aspartate_6\NN\1740| (r_compound) aminotransferase_7\NN\15077571|aspartate|ast (r_conj) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin
T28_T44 NONE aspartate_6\NN\1740| (r_compound) aminotransferase_7\NN\15077571|aspartate|ast (r_conj) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_appos) alt_3\NN\13836371|(|)
T28_T45 NONE aspartate_6\NN\1740| (r_compound) aminotransferase_7\NN\15077571|aspartate|ast
T28_T46 NONE aspartate_6\NN\1740| (r_compound) aminotransferase_7\NN\15077571|aspartate|ast (l_appos) ast_9\NN\1740|(|)
T28_T47 NONE aspartate_6\NN\1740| (r_compound) aminotransferase_7\NN\15077571|aspartate|ast (r_conj) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) phosphatase_13\NN\14732946|alkaline|alp
T28_T48 NONE aspartate_6\NN\1740| (r_compound) aminotransferase_7\NN\15077571|aspartate|ast (r_conj) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) phosphatase_13\NN\14732946|alkaline|alp (l_appos) alp_15\NN\9359803|(|)
T29_T43 NONE bilirubin_18\NN\14756039| (r_appos) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin
T29_T44 NONE bilirubin_18\NN\14756039| (r_appos) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_appos) alt_3\NN\13836371|(|)
T29_T45 NONE bilirubin_18\NN\14756039| (r_appos) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) aminotransferase_7\NN\15077571|aspartate|ast
T29_T46 NONE bilirubin_18\NN\14756039| (r_appos) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) aminotransferase_7\NN\15077571|aspartate|ast (l_appos) ast_9\NN\1740|(|)
T29_T47 NONE bilirubin_18\NN\14756039| (r_appos) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) phosphatase_13\NN\14732946|alkaline|alp
T29_T48 NONE bilirubin_18\NN\14756039| (r_appos) aminotransferase_1\NN\15077571|alanine|alt|,|aminotransferase|,|phosphatase|,|bilirubin (l_conj) phosphatase_13\NN\14732946|alkaline|alp (l_appos) alp_15\NN\9359803|(|)
T30_T49 NONE hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) catalase_11\NN\14732946|cat
T30_T50 NONE hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) catalase_11\NN\14732946|cat (l_appos) cat_13\NN\2120997|(|)
T30_T51 NONE hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) peroxidase_17\NN\14971234|glutathione|gpx
T30_T52 NONE hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) peroxidase_17\NN\14971234|glutathione|gpx (l_appos) gpx_19\NN\1740|(|)
T31_T49 NONE glutathione_16\NN\1740| (r_compound) peroxidase_17\NN\14971234|glutathione|gpx (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) catalase_11\NN\14732946|cat
T31_T50 NONE glutathione_16\NN\1740| (r_compound) peroxidase_17\NN\14971234|glutathione|gpx (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) catalase_11\NN\14732946|cat (l_appos) cat_13\NN\2120997|(|)
T31_T51 NONE glutathione_16\NN\1740| (r_compound) peroxidase_17\NN\14971234|glutathione|gpx
T31_T52 NONE glutathione_16\NN\1740| (r_compound) peroxidase_17\NN\14971234|glutathione|gpx (l_appos) gpx_19\NN\1740|(|)
T32_T49 NONE glutathione_22\NN\1740|gsh (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) catalase_11\NN\14732946|cat
T32_T50 NONE glutathione_22\NN\1740|gsh (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) catalase_11\NN\14732946|cat (l_appos) cat_13\NN\2120997|(|)
T32_T51 NONE glutathione_22\NN\1740|gsh (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) peroxidase_17\NN\14971234|glutathione|gpx
T32_T52 NONE glutathione_22\NN\1740|gsh (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) peroxidase_17\NN\14971234|glutathione|gpx (l_appos) gpx_19\NN\1740|(|)
T33_T49 NONE gsh_24\NN\1740|(|) (r_appos) glutathione_22\NN\1740|gsh (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) catalase_11\NN\14732946|cat
T33_T50 NONE gsh_24\NN\1740|(|) (r_appos) glutathione_22\NN\1740|gsh (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) catalase_11\NN\14732946|cat (l_appos) cat_13\NN\2120997|(|)
T33_T51 NONE gsh_24\NN\1740|(|) (r_appos) glutathione_22\NN\1740|gsh (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) peroxidase_17\NN\14971234|glutathione|gpx
T33_T52 NONE gsh_24\NN\1740|(|) (r_appos) glutathione_22\NN\1740|gsh (r_conj) hydroxyproline_0\NN\14601829|hp|,|peroxidation|,|catalase|,|peroxidase|and|glutathione (l_conj) peroxidase_17\NN\14971234|glutathione|gpx (l_appos) gpx_19\NN\1740|(|)
T34_T53 CPR:9 aniline_15\NN\14739004|of (r_nmod) hydroxylation_13\NN\1740|as|aniline|microsomes (r_nmod) determined_11\VBN\1645601|activity|was|hydroxylation|. (l_nsubjpass) activity_9\NN\30358|p450 (l_compound) p450_1\NN\1740|cytochrome|2e1 (l_nummod) 2e1_2\NN\1740|450
T34_T54 CPR:9 aniline_15\NN\14739004|of (r_nmod) hydroxylation_13\NN\1740|as|aniline|microsomes (r_nmod) determined_11\VBN\1645601|activity|was|hydroxylation|. (l_nsubjpass) activity_9\NN\30358|p450 (l_compound) p450_1\NN\1740|cytochrome|2e1 (l_nummod) 2e1_2\NN\1740|450 (l_appos) 450_5\NN\1740|(|cyp|2e1|, (l_nummod) 2e1_6\CD\1740|)
T1_T38 NONE bilirubin_12\NN\14756039| (r_conj) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|)
T1_T39 NONE bilirubin_12\NN\14756039| (r_conj) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|) (l_conj) alt_8\NN\13836371|
T1_T40 NONE bilirubin_12\NN\14756039| (r_conj) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|) (l_conj) alp_10\NN\9359803|
T3_T38 CPR:3 ccl4_17\NN\1740|and|taa (r_compound) intoxication_20\NN\14034177|by|ccl4 (r_nmod) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|)
T3_T39 CPR:3 ccl4_17\NN\1740|and|taa (r_compound) intoxication_20\NN\14034177|by|ccl4 (r_nmod) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|) (l_conj) alt_8\NN\13836371|
T3_T40 CPR:3 ccl4_17\NN\1740|and|taa (r_compound) intoxication_20\NN\14034177|by|ccl4 (r_nmod) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|) (l_conj) alp_10\NN\9359803|
T4_T38 CPR:3 taa_19\NN\1740| (r_conj) ccl4_17\NN\1740|and|taa (r_compound) intoxication_20\NN\14034177|by|ccl4 (r_nmod) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|)
T4_T39 CPR:3 taa_19\NN\1740| (r_conj) ccl4_17\NN\1740|and|taa (r_compound) intoxication_20\NN\14034177|by|ccl4 (r_nmod) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|) (l_conj) alt_8\NN\13836371|
T4_T40 CPR:3 taa_19\NN\1740| (r_conj) ccl4_17\NN\1740|and|taa (r_compound) intoxication_20\NN\14034177|by|ccl4 (r_nmod) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|) (l_conj) alp_10\NN\9359803|
T5_T38 CPR:4 nac_28\NN\8310949|with (r_nmod) co-treatment_26\NN\1740|nac (r_nsubj) reversed_29\VBD\109660|whereas|co-treatment|changes|p<0.001 (r_advcl) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|)
T5_T39 CPR:4 nac_28\NN\8310949|with (r_nmod) co-treatment_26\NN\1740|nac (r_nsubj) reversed_29\VBD\109660|whereas|co-treatment|changes|p<0.001 (r_advcl) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|) (l_conj) alt_8\NN\13836371|
T5_T40 CPR:4 nac_28\NN\8310949|with (r_nmod) co-treatment_26\NN\1740|nac (r_nsubj) reversed_29\VBD\109660|whereas|co-treatment|changes|p<0.001 (r_advcl) increased_15\VBN\169651|markers|were|intoxication|p<0.001|,|reversed|. (l_nsubjpass) markers_1\NNS\21939|serum|damage|ast (l_dep) ast_6\NNS\1740|(|,|alt|,|alp|and|bilirubin|) (l_conj) alp_10\NN\9359803|
T10_T41 NONE gsh_5\NN\1740| (r_nsubj) decreased_10\VBD\169651|while|as|gsh|,|cat|administration|p<0.001 (l_nsubj) cat_7\NN\2120997|and|gpx
T10_T42 NONE gsh_5\NN\1740| (r_nsubj) decreased_10\VBD\169651|while|as|gsh|,|cat|administration|p<0.001 (l_nsubj) cat_7\NN\2120997|and|gpx (l_conj) gpx_9\NN\1740|
T12_T41 CPR:3 nac_24\NN\8310949|of (r_nmod) co-administration_22\NN\1740|nac (r_nsubj) restored_25\VBD\1631072|co-administration|markers|levels|p<0.001|. (r_parataxis) increased_2\VBN\169651|lpo|was|decreased|;|restored (l_advcl) decreased_10\VBD\169651|while|as|gsh|,|cat|administration|p<0.001 (l_nsubj) cat_7\NN\2120997|and|gpx
T12_T42 CPR:3 nac_24\NN\8310949|of (r_nmod) co-administration_22\NN\1740|nac (r_nsubj) restored_25\VBD\1631072|co-administration|markers|levels|p<0.001|. (r_parataxis) increased_2\VBN\169651|lpo|was|decreased|;|restored (l_advcl) decreased_10\VBD\169651|while|as|gsh|,|cat|administration|p<0.001 (l_nsubj) cat_7\NN\2120997|and|gpx (l_conj) gpx_9\NN\1740|
23292249
12679340
T20_T32 NONE ornithine_13\NN\14601829| (r_compound) carbamoyltransferase_14\NN\1740|of|ornithine|and|arginase|responsible (r_nmod) residues_11\NNS\20827|of|carbamoyltransferase (r_nmod) identification_9\NN\151497|residues (r_dep) regulation_2\NN\6652242|yeast|epiarginase|,|control|:|identification|. (l_compound) epiarginase_1\NN\1740|
T20_T33 NONE ornithine_13\NN\14601829| (r_compound) carbamoyltransferase_14\NN\1740|of|ornithine|and|arginase|responsible (l_conj) arginase_16\NN\1740|
T20_T34 NONE ornithine_13\NN\14601829| (r_compound) carbamoyltransferase_14\NN\1740|of|ornithine|and|arginase|responsible
T3_T23 NONE ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_dobj) complex_19\NN\5869584|a|one-to-one|enzyme|inhibited (l_acl:relcl) inhibited_27\VBN\2510337|which|activity|is|remains (l_nsubjpass) activity_23\NN\30358|the|otcase (l_nmod) otcase_25\NN\1740|of
T3_T24 NONE ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_dobj) complex_19\NN\5869584|a|one-to-one|enzyme|inhibited (l_acl:relcl) inhibited_27\VBN\2510337|which|activity|is|remains (l_advcl) remains_30\VBZ\2604760|whereas|arginase|active (l_nsubj) arginase_29\NN\1740|
T3_T25 NONE ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_nsubj) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase
T3_T29 NONE ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_nsubj) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase (l_appos) otcase_11\NN\1740|(|)
T3_T30 NONE ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_nsubj) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase (l_conj) arginase_14\NN\1740|
T4_T23 NONE arginine_6\NN\14605787| (r_conj) ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_dobj) complex_19\NN\5869584|a|one-to-one|enzyme|inhibited (l_acl:relcl) inhibited_27\VBN\2510337|which|activity|is|remains (l_nsubjpass) activity_23\NN\30358|the|otcase (l_nmod) otcase_25\NN\1740|of
T4_T24 NONE arginine_6\NN\14605787| (r_conj) ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_dobj) complex_19\NN\5869584|a|one-to-one|enzyme|inhibited (l_acl:relcl) inhibited_27\VBN\2510337|which|activity|is|remains (l_advcl) remains_30\VBZ\2604760|whereas|arginase|active (l_nsubj) arginase_29\NN\1740|
T4_T25 NONE arginine_6\NN\14605787| (r_conj) ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_nsubj) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase
T4_T29 NONE arginine_6\NN\14605787| (r_conj) ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_nsubj) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase (l_appos) otcase_11\NN\1740|(|)
T4_T30 NONE arginine_6\NN\14605787| (r_conj) ornithine_4\NN\14601829|of|and|arginine (r_nmod) presence_2\NN\13954253|in|the|ornithine (r_nmod) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_nsubj) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase (l_conj) arginase_14\NN\1740|
T5_T23 NONE ornithine_8\NN\14601829| (r_compound) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase (r_nsubj) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_dobj) complex_19\NN\5869584|a|one-to-one|enzyme|inhibited (l_acl:relcl) inhibited_27\VBN\2510337|which|activity|is|remains (l_nsubjpass) activity_23\NN\30358|the|otcase (l_nmod) otcase_25\NN\1740|of
T5_T24 NONE ornithine_8\NN\14601829| (r_compound) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase (r_nsubj) form_15\VBP\1617192|presence|,|carbamoyltransferase|complex|. (l_dobj) complex_19\NN\5869584|a|one-to-one|enzyme|inhibited (l_acl:relcl) inhibited_27\VBN\2510337|which|activity|is|remains (l_advcl) remains_30\VBZ\2604760|whereas|arginase|active (l_nsubj) arginase_29\NN\1740|
T5_T25 NONE ornithine_8\NN\14601829| (r_compound) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase
T5_T29 NONE ornithine_8\NN\14601829| (r_compound) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase (l_appos) otcase_11\NN\1740|(|)
T5_T30 NONE ornithine_8\NN\14601829| (r_compound) carbamoyltransferase_9\NN\1740|ornithine|otcase|and|arginase (l_conj) arginase_14\NN\1740|
T6_T26 NONE cysteines_4\NNS\14601829|two|terminus (r_nsubj) crucial_13\JJ\1740|arginase|,|cysteines|are|function|. (l_nmod) arginase_1\NN\1740|in
T6_T27 NONE cysteines_4\NNS\14601829|two|terminus (r_nsubj) crucial_13\JJ\1740|arginase|,|cysteines|are|function|. (l_nmod) function_17\NN\13783581|for|its|epiarginase|but|activity (l_compound) epiarginase_16\NN\1740|
T7_T26 NONE c_7\NN\13714184| (r_compound) terminus_8\NN\8566028|at|the|c|protein (r_nmod) cysteines_4\NNS\14601829|two|terminus (r_nsubj) crucial_13\JJ\1740|arginase|,|cysteines|are|function|. (l_nmod) arginase_1\NN\1740|in
T7_T27 NONE c_7\NN\13714184| (r_compound) terminus_8\NN\8566028|at|the|c|protein (r_nmod) cysteines_4\NNS\14601829|two|terminus (r_nsubj) crucial_13\JJ\1740|arginase|,|cysteines|are|function|. (l_nmod) function_17\NN\13783581|for|its|epiarginase|but|activity (l_compound) epiarginase_16\NN\1740|
T10_T28 NONE asn-184_12\NN\1740| (r_conj) asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_nmod) otcase_1\NN\1740|in
T10_T31 NONE asn-184_12\NN\1740| (r_conj) asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_conj) impaired_27\VBD\258857|interaction (l_dobj) interaction_29\NN\37396|the|arginase (l_nmod) arginase_31\NN\1740|with
T11_T28 NONE asn-185_14\NN\1740| (r_conj) asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_nmod) otcase_1\NN\1740|in
T11_T31 NONE asn-185_14\NN\1740| (r_conj) asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_conj) impaired_27\VBD\258857|interaction (l_dobj) interaction_29\NN\37396|the|arginase (l_nmod) arginase_31\NN\1740|with
T12_T28 NONE cys-289_16\NN\1740| (r_conj) asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_nmod) otcase_1\NN\1740|in
T12_T31 NONE cys-289_16\NN\1740| (r_conj) asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_conj) impaired_27\VBD\258857|interaction (l_dobj) interaction_29\NN\37396|the|arginase (l_nmod) arginase_31\NN\1740|with
T13_T28 NONE glu-256_19\NN\1740| (r_conj) asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_nmod) otcase_1\NN\1740|in
T13_T31 NONE glu-256_19\NN\1740| (r_conj) asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_conj) impaired_27\VBD\258857|interaction (l_dobj) interaction_29\NN\37396|the|arginase (l_nmod) arginase_31\NN\1740|with
T14_T28 NONE ornithine_25\NN\14601829|for (r_nmod) affinity_23\NN\11426530|the|ornithine (r_dobj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_nmod) otcase_1\NN\1740|in
T14_T31 NONE ornithine_25\NN\14601829|for (r_nmod) affinity_23\NN\11426530|the|ornithine (r_dobj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_conj) impaired_27\VBD\258857|interaction (l_dobj) interaction_29\NN\37396|the|arginase (l_nmod) arginase_31\NN\1740|with
T8_T28 NONE ornithine_6\NN\14601829| (r_compound) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_nmod) otcase_1\NN\1740|in
T8_T31 NONE ornithine_6\NN\14601829| (r_compound) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_conj) impaired_27\VBD\258857|interaction (l_dobj) interaction_29\NN\37396|the|arginase (l_nmod) arginase_31\NN\1740|with
T9_T28 NONE asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_nmod) otcase_1\NN\1740|in
T9_T31 NONE asp-182_10\NN\1740|,|asn-184|,|asn-185|,|cys-289|,|and|glu-256 (r_appos) residues_8\NNS\20827|of|putative|ornithine|binding|,|asp-182 (r_nmod) mutations_3\NNS\4475|residues (r_nsubj) reduced_21\VBD\441445|otcase|,|mutations|greatly|affinity|and|impaired|. (l_conj) impaired_27\VBD\258857|interaction (l_dobj) interaction_29\NN\37396|the|arginase (l_nmod) arginase_31\NN\1740|with
T15_T21 NONE lysine_2\NN\14605787| (r_compound) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) otcase_29\NN\1740|of
T15_T22 NONE lysine_2\NN\14605787| (r_compound) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) ornithine_31\NN\14601829|to|and|arginase (l_conj) arginase_34\NN\1740|to
T16_T21 NONE lys-260_10\NN\1740|,|lys-263|,|lys-265|,|and|lys-268 (r_appos) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) otcase_29\NN\1740|of
T16_T22 NONE lys-260_10\NN\1740|,|lys-263|,|lys-265|,|and|lys-268 (r_appos) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) ornithine_31\NN\14601829|to|and|arginase (l_conj) arginase_34\NN\1740|to
T17_T21 NONE lys-263_12\NN\1740| (r_conj) lys-260_10\NN\1740|,|lys-263|,|lys-265|,|and|lys-268 (r_appos) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) otcase_29\NN\1740|of
T17_T22 NONE lys-263_12\NN\1740| (r_conj) lys-260_10\NN\1740|,|lys-263|,|lys-265|,|and|lys-268 (r_appos) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) ornithine_31\NN\14601829|to|and|arginase (l_conj) arginase_34\NN\1740|to
T18_T21 NONE lys-265_14\NN\1740| (r_conj) lys-260_10\NN\1740|,|lys-263|,|lys-265|,|and|lys-268 (r_appos) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) otcase_29\NN\1740|of
T18_T22 NONE lys-265_14\NN\1740| (r_conj) lys-260_10\NN\1740|,|lys-263|,|lys-265|,|and|lys-268 (r_appos) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) ornithine_31\NN\14601829|to|and|arginase (l_conj) arginase_34\NN\1740|to
T19_T21 NONE lys-268_17\NN\1740| (r_conj) lys-260_10\NN\1740|,|lys-263|,|lys-265|,|and|lys-268 (r_appos) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) otcase_29\NN\1740|of
T19_T22 NONE lys-268_17\NN\1740| (r_conj) lys-260_10\NN\1740|,|lys-263|,|lys-265|,|and|lys-268 (r_appos) residues_3\NNS\20827|the|four|lysine|located|,|lys-260|, (r_nsubj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) ornithine_31\NN\14601829|to|and|arginase (l_conj) arginase_34\NN\1740|to
T1_T21 CPR:4 ornithine_31\NN\14601829|to|and|arginase (r_nmod) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) otcase_29\NN\1740|of
T1_T22 NONE ornithine_31\NN\14601829|to|and|arginase (l_conj) arginase_34\NN\1740|to
T2_T21 NONE ornithine_48\NN\14601829|by (r_nmod) given_46\VBN\2327200|ornithine|closure (r_acl) signal_45\NN\33020|the|given (r_dobj) transducing_41\VBG\381013|in|and|enhancing|signal (r_advcl) involved_39\VBN\2676054|to|be|transducing (r_xcomp) appear_36\VBP\2604760|involved (r_conj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) otcase_29\NN\1740|of
T2_T22 NONE ornithine_48\NN\14601829|by (r_nmod) given_46\VBN\2327200|ornithine|closure (r_acl) signal_45\NN\33020|the|given (r_dobj) transducing_41\VBG\381013|in|and|enhancing|signal (r_advcl) involved_39\VBN\2676054|to|be|transducing (r_xcomp) appear_36\VBP\2604760|involved (r_conj) play_20\VBP\1072262|residues|also|role|mediating|and|appear|. (l_advcl) mediating_25\VBG\761713|in|sensitivity (l_dobj) sensitivity_27\NN\5651971|the|otcase|ornithine (l_nmod) ornithine_31\NN\14601829|to|and|arginase (l_conj) arginase_34\NN\1740|to
17498496
T3_T42 NONE cysteinyl-aspartate_17\NN\1740| (r_compound) protease_19\NN\14732946|cysteinyl-aspartate|specific
T3_T43 NONE cysteinyl-aspartate_17\NN\1740| (r_compound) protease_19\NN\14732946|cysteinyl-aspartate|specific (r_conj) beta_11\NN\6828818|of|interleukin-1|,|factors|and|protease
T4_T42 NONE saponins_5\NNS\14887801|of|panax|notoginseng (r_nmod) effects_1\NNS\13245626|[|saponins|expressions|]|. (l_nmod) expressions_8\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_11\NN\6828818|of|interleukin-1|,|factors|and|protease (l_conj) protease_19\NN\14732946|cysteinyl-aspartate|specific
T4_T43 NONE saponins_5\NNS\14887801|of|panax|notoginseng (r_nmod) effects_1\NNS\13245626|[|saponins|expressions|]|. (l_nmod) expressions_8\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_11\NN\6828818|of|interleukin-1|,|factors|and|protease
T1_T12 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_appos) beta_21\NN\6828818|(|il-1|)
T1_T16 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) type_26\NN\5839024|interleukin-1|receptor|i|il-1ri (l_nummod) i_27\CD\14622893|
T1_T18 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) type_26\NN\5839024|interleukin-1|receptor|i|il-1ri (l_appos) il-1ri_29\NN\1740|(|)
T1_T19 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) antagonist_34\NN\7846|interleukin-1|receptor|il-1ra
T1_T25 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) antagonist_34\NN\7846|interleukin-1|receptor|il-1ra (l_appos) il-1ra_36\NN\1740|(|)
T1_T28 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) molecule-1_41\NN\1740|intercellular|adhesion|icam-1
T1_T29 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) molecule-1_41\NN\1740|intercellular|adhesion|icam-1 (l_appos) icam-1_43\NN\1740|(|)
T1_T30 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1
T1_T31 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (l_appos) caspase-1_50\NN\1740|(|)
T1_T32 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) caspase-3_53\NN\1740|
T1_T33 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) caspase-8_55\NN\1740|
T1_T41 NONE cysteinyl-aspartate_46\NN\1740| (r_compound) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (r_conj) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8
T2_T12 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_appos) beta_21\NN\6828818|(|il-1|)
T2_T16 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) type_26\NN\5839024|interleukin-1|receptor|i|il-1ri (l_nummod) i_27\CD\14622893|
T2_T18 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) type_26\NN\5839024|interleukin-1|receptor|i|il-1ri (l_appos) il-1ri_29\NN\1740|(|)
T2_T19 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) antagonist_34\NN\7846|interleukin-1|receptor|il-1ra
T2_T25 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) antagonist_34\NN\7846|interleukin-1|receptor|il-1ra (l_appos) il-1ra_36\NN\1740|(|)
T2_T28 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) molecule-1_41\NN\1740|intercellular|adhesion|icam-1
T2_T29 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) molecule-1_41\NN\1740|intercellular|adhesion|icam-1 (l_appos) icam-1_43\NN\1740|(|)
T2_T30 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1
T2_T31 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) protease-1_48\NN\1740|cysteinyl-aspartate|specific|caspase-1 (l_appos) caspase-1_50\NN\1740|(|)
T2_T32 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) caspase-3_53\NN\1740|
T2_T33 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8 (l_conj) caspase-8_55\NN\1740|
T2_T41 NONE saponins_9\NNS\14887801|of|panax|notoginseng|pns (r_nmod) effects_5\NNS\13245626|the|saponins|expressions (l_nmod) expressions_15\NNS\4679549|on|mrna|beta|ischemia-reperfusion (l_nmod) beta_18\NN\6828818|of|interleukin-1|beta|,|type|,|antagonist|,|molecule-1|,|protease-1|,|caspase-3|and|caspase-8
23143891
T14_T24 CPR:9 acetonide_14\NN\1740|triamcinolone|,|flunisolide|,|budesonide|,|and|propionate (r_appos) gcs_11\NNS\15286249|of|four|prescribed|inhaled|,|acetonide|, (r_nmod) metabolism_5\NN\13526110|the|gcs|family (l_nmod) family_27\NN\8189659|by|the|cyp3a|enzymes (l_compound) cyp3a_26\NN\1740|
T15_T24 CPR:9 flunisolide_16\NN\1740| (r_conj) acetonide_14\NN\1740|triamcinolone|,|flunisolide|,|budesonide|,|and|propionate (r_appos) gcs_11\NNS\15286249|of|four|prescribed|inhaled|,|acetonide|, (r_nmod) metabolism_5\NN\13526110|the|gcs|family (l_nmod) family_27\NN\8189659|by|the|cyp3a|enzymes (l_compound) cyp3a_26\NN\1740|
T16_T24 CPR:9 budesonide_18\NN\1740| (r_conj) acetonide_14\NN\1740|triamcinolone|,|flunisolide|,|budesonide|,|and|propionate (r_appos) gcs_11\NNS\15286249|of|four|prescribed|inhaled|,|acetonide|, (r_nmod) metabolism_5\NN\13526110|the|gcs|family (l_nmod) family_27\NN\8189659|by|the|cyp3a|enzymes (l_compound) cyp3a_26\NN\1740|
T17_T24 CPR:9 propionate_22\NN\1740|fluticasone (r_conj) acetonide_14\NN\1740|triamcinolone|,|flunisolide|,|budesonide|,|and|propionate (r_appos) gcs_11\NNS\15286249|of|four|prescribed|inhaled|,|acetonide|, (r_nmod) metabolism_5\NN\13526110|the|gcs|family (l_nmod) family_27\NN\8189659|by|the|cyp3a|enzymes (l_compound) cyp3a_26\NN\1740|
T1_T19 CPR:9 acetonide_20\NN\1740|triamcinolone|,|budesonide|,|and|propionate (r_dobj) metabolize_18\VB\1740|to|efficiently|acetonide (r_xcomp) shown_15\VBN\2137132|cyp3a5|was|also|metabolize|. (l_nsubjpass) cyp3a5_0\NN\1740|,|relevant|,
T2_T19 CPR:9 budesonide_22\NN\1740| (r_conj) acetonide_20\NN\1740|triamcinolone|,|budesonide|,|and|propionate (r_dobj) metabolize_18\VB\1740|to|efficiently|acetonide (r_xcomp) shown_15\VBN\2137132|cyp3a5|was|also|metabolize|. (l_nsubjpass) cyp3a5_0\NN\1740|,|relevant|,
T3_T19 CPR:9 propionate_26\NN\1740|fluticasone (r_conj) acetonide_20\NN\1740|triamcinolone|,|budesonide|,|and|propionate (r_dobj) metabolize_18\VB\1740|to|efficiently|acetonide (r_xcomp) shown_15\VBN\2137132|cyp3a5|was|also|metabolize|. (l_nsubjpass) cyp3a5_0\NN\1740|,|relevant|,
T4_T20 CPR:9 flunisolide_3\NN\1740| (r_nsubjpass) metabolized_6\VBN\1740|contrast|,|flunisolide|was|only|cyp3a4|,|turnover|. (l_nmod) cyp3a4_8\NN\1740|via
T4_T21 NONE flunisolide_3\NN\1740| (r_nsubjpass) metabolized_6\VBN\1740|contrast|,|flunisolide|was|only|cyp3a4|,|turnover|. (l_nmod) turnover_13\NN\13819207|with|no|significant|cyp3a5 (l_nmod) cyp3a5_15\NN\1740|by|or|cyp3a7
T4_T22 NONE flunisolide_3\NN\1740| (r_nsubjpass) metabolized_6\VBN\1740|contrast|,|flunisolide|was|only|cyp3a4|,|turnover|. (l_nmod) turnover_13\NN\13819207|with|no|significant|cyp3a5 (l_nmod) cyp3a5_15\NN\1740|by|or|cyp3a7 (l_conj) cyp3a7_17\NN\1740|
18450949
T5_T19 CPR:5 cevimeline_15\NN\1740|by|,|agonist (l_appos) agonist_21\NN\9613191|an|m3|muscarinic|receptor (l_compound) receptor_20\NN\5225602|
T5_T20 CPR:3 cevimeline_15\NN\1740|by|,|agonist (r_nmod) recovery_13\NN\7357388|its|cevimeline (r_conj) degradation_0\NN\199130|aqp5|denervation|and|recovery|. (l_nmod) aqp5_4\NN\1740|of|submandibular|gland
T1_T10 CPR:5 hydrochloride_3\NN\14817592|of|cevimeline|,|agonist|,|not|pilocarpine|, (l_appos) agonist_9\NN\9613191|an|m3|muscarinic|receptor|mg/kg (l_compound) receptor_8\NN\5225602|
T1_T11 CPR:3 hydrochloride_3\NN\14817592|of|cevimeline|,|agonist|,|not|pilocarpine|, (r_nmod) administration_0\NN\1133281|hydrochloride (r_nsubj) recovered_31\VBD\2210855|administration|level|and|increased|. (l_dobj) level_35\NN\4916342|the|aqp5|protein|reduced (l_compound) aqp5_33\NN\1740|
T1_T12 CPR:3 hydrochloride_3\NN\14817592|of|cevimeline|,|agonist|,|not|pilocarpine|, (r_nmod) administration_0\NN\1133281|hydrochloride (r_nsubj) recovered_31\VBD\2210855|administration|level|and|increased|. (l_conj) increased_40\VBD\169651|level|one (l_dobj) level_44\NN\4916342|the|aqp1|protein (l_compound) aqp1_42\NN\1740|
T2_T10 NONE pilocarpine_21\NN\14712692|mg/kg (r_conj) hydrochloride_3\NN\14817592|of|cevimeline|,|agonist|,|not|pilocarpine|, (l_appos) agonist_9\NN\9613191|an|m3|muscarinic|receptor|mg/kg (l_compound) receptor_8\NN\5225602|
T2_T11 NONE pilocarpine_21\NN\14712692|mg/kg (r_conj) hydrochloride_3\NN\14817592|of|cevimeline|,|agonist|,|not|pilocarpine|, (r_nmod) administration_0\NN\1133281|hydrochloride (r_nsubj) recovered_31\VBD\2210855|administration|level|and|increased|. (l_dobj) level_35\NN\4916342|the|aqp5|protein|reduced (l_compound) aqp5_33\NN\1740|
T2_T12 NONE pilocarpine_21\NN\14712692|mg/kg (r_conj) hydrochloride_3\NN\14817592|of|cevimeline|,|agonist|,|not|pilocarpine|, (r_nmod) administration_0\NN\1133281|hydrochloride (r_nsubj) recovered_31\VBD\2210855|administration|level|and|increased|. (l_conj) increased_40\VBD\169651|level|one (l_dobj) level_44\NN\4916342|the|aqp1|protein (l_compound) aqp1_42\NN\1740|
T3_T14 NONE hydrochloride_12\NN\14817592|cevimeline (r_conj) ctd_9\NN\1740|by|and|hydrochloride (r_compound) administration_13\NN\1133281|ctd (r_nmod) affected_7\VBN\126264|level|was|scarcely|administration|. (l_nsubjpass) level_2\NN\4916342|the|mrna|aqp5 (l_nmod) aqp5_4\NN\1740|of
T4_T16 CPR:3 chloroquine_2\NN\2721948|of|mg/kg (r_nmod) administration_0\NN\1133281|chloroquine (r_nsubj) increased_17\VBD\169651|administration|level|. (l_dobj) level_21\NN\4916342|the|protein|reduced (l_compound) protein_20\NN\14944888|aqp5 (l_compound) aqp5_19\NN\1740|
23521495
T1_T3 NONE cys-ala-leu-asn-asn_5\NN\1740|(|)
10193663
T17_T33 NONE 5-ht_3\NN\1740| (r_compound) profile_6\NN\6999802|of|the|5-ht|receptor|binding|eletriptan (r_nmod) characterisation_0\NN\6724763|profile|and|kinetics|. (l_conj) kinetics_10\NNS\6100236|binding (l_nmod) binding_13\NN\4688246|of|[3h]eletriptan|receptors (l_nmod) receptors_19\NNS\5225602|5-ht1b (l_compound) 5-ht1b_16\NN\1740|at|human|and|5-ht1d
T17_T34 NONE 5-ht_3\NN\1740| (r_compound) profile_6\NN\6999802|of|the|5-ht|receptor|binding|eletriptan (r_nmod) characterisation_0\NN\6724763|profile|and|kinetics|. (l_conj) kinetics_10\NNS\6100236|binding (l_nmod) binding_13\NN\4688246|of|[3h]eletriptan|receptors (l_nmod) receptors_19\NNS\5225602|5-ht1b (l_compound) 5-ht1b_16\NN\1740|at|human|and|5-ht1d (l_conj) 5-ht1d_18\NN\1740|
T17_T35 NONE 5-ht_3\NN\1740| (r_compound) profile_6\NN\6999802|of|the|5-ht|receptor|binding|eletriptan (l_compound) receptor_4\NN\5225602|
T18_T33 NONE eletriptan_8\NN\1740|of (r_nmod) profile_6\NN\6999802|of|the|5-ht|receptor|binding|eletriptan (r_nmod) characterisation_0\NN\6724763|profile|and|kinetics|. (l_conj) kinetics_10\NNS\6100236|binding (l_nmod) binding_13\NN\4688246|of|[3h]eletriptan|receptors (l_nmod) receptors_19\NNS\5225602|5-ht1b (l_compound) 5-ht1b_16\NN\1740|at|human|and|5-ht1d
T18_T34 NONE eletriptan_8\NN\1740|of (r_nmod) profile_6\NN\6999802|of|the|5-ht|receptor|binding|eletriptan (r_nmod) characterisation_0\NN\6724763|profile|and|kinetics|. (l_conj) kinetics_10\NNS\6100236|binding (l_nmod) binding_13\NN\4688246|of|[3h]eletriptan|receptors (l_nmod) receptors_19\NNS\5225602|5-ht1b (l_compound) 5-ht1b_16\NN\1740|at|human|and|5-ht1d (l_conj) 5-ht1d_18\NN\1740|
T18_T35 NONE eletriptan_8\NN\1740|of (r_nmod) profile_6\NN\6999802|of|the|5-ht|receptor|binding|eletriptan (l_compound) receptor_4\NN\5225602|
T19_T33 NONE [3h]eletriptan_12\NN\1740| (r_compound) binding_13\NN\4688246|of|[3h]eletriptan|receptors (l_nmod) receptors_19\NNS\5225602|5-ht1b (l_compound) 5-ht1b_16\NN\1740|at|human|and|5-ht1d
T19_T34 NONE [3h]eletriptan_12\NN\1740| (r_compound) binding_13\NN\4688246|of|[3h]eletriptan|receptors (l_nmod) receptors_19\NNS\5225602|5-ht1b (l_compound) 5-ht1b_16\NN\1740|at|human|and|5-ht1d (l_conj) 5-ht1d_18\NN\1740|
T19_T35 NONE [3h]eletriptan_12\NN\1740| (r_compound) binding_13\NN\4688246|of|[3h]eletriptan|receptors (r_nmod) kinetics_10\NNS\6100236|binding (r_conj) characterisation_0\NN\6724763|profile|and|kinetics|. (l_nmod) profile_6\NN\6999802|of|the|5-ht|receptor|binding|eletriptan (l_compound) receptor_4\NN\5225602|
T3_T21 NONE 5-ht_13\NN\1740| (r_compound) receptors_14\NNS\5225602|of|5-ht
T3_T25 NONE 5-ht_13\NN\1740| (r_compound) receptors_14\NNS\5225602|of|5-ht (r_nmod) range_11\NN\5123416|for|a|receptors (r_nmod) affinity_1\NN\11426530|the|eletriptan|range (r_nsubjpass) compared_16\VBN\644583|affinity|was|values|. (l_nmod) values_18\NNS\5941423|to|obtained (l_acl) obtained_19\VBN\2210855|agonists (l_nmod) agonists_24\NNS\9613191|for|other|5-ht1b/1d|receptor|known (l_compound) 5-ht1b/1d_22\NN\1740|
T5_T21 NONE eletriptan_3\NN\1740|of|ethyl]-1h-indole (r_nmod) affinity_1\NN\11426530|the|eletriptan|range (l_nmod) range_11\NN\5123416|for|a|receptors (l_nmod) receptors_14\NNS\5225602|of|5-ht
T5_T25 NONE eletriptan_3\NN\1740|of|ethyl]-1h-indole (r_nmod) affinity_1\NN\11426530|the|eletriptan|range (r_nsubjpass) compared_16\VBN\644583|affinity|was|values|. (l_nmod) values_18\NNS\5941423|to|obtained (l_acl) obtained_19\VBN\2210855|agonists (l_nmod) agonists_24\NNS\9613191|for|other|5-ht1b/1d|receptor|known (l_compound) 5-ht1b/1d_22\NN\1740|
T8_T21 NONE ethyl]-1h-indole_7\NN\1740|(|(r)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl|)|) (r_appos) eletriptan_3\NN\1740|of|ethyl]-1h-indole (r_nmod) affinity_1\NN\11426530|the|eletriptan|range (l_nmod) range_11\NN\5123416|for|a|receptors (l_nmod) receptors_14\NNS\5225602|of|5-ht
T8_T25 NONE ethyl]-1h-indole_7\NN\1740|(|(r)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl|)|) (r_appos) eletriptan_3\NN\1740|of|ethyl]-1h-indole (r_nmod) affinity_1\NN\11426530|the|eletriptan|range (r_nsubjpass) compared_16\VBN\644583|affinity|was|values|. (l_nmod) values_18\NNS\5941423|to|obtained (l_acl) obtained_19\VBN\2210855|agonists (l_nmod) agonists_24\NNS\9613191|for|other|5-ht1b/1d|receptor|known (l_compound) 5-ht1b/1d_22\NN\1740|
T10_T26 NONE naratriptan_7\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor
T10_T27 NONE naratriptan_7\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) 5-ht1d_18\NN\1740|
T10_T28 NONE naratriptan_7\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) receptor_22\NN\5225602|putative|5-ht1f (l_compound) 5-ht1f_21\NN\1740|
T11_T26 NONE rizatriptan_9\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor
T11_T27 NONE rizatriptan_9\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) 5-ht1d_18\NN\1740|
T11_T28 NONE rizatriptan_9\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) receptor_22\NN\5225602|putative|5-ht1f (l_compound) 5-ht1f_21\NN\1740|
T6_T26 NONE eletriptan_0\NN\1740| (r_nsubj) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor
T6_T27 NONE eletriptan_0\NN\1740| (r_nsubj) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) 5-ht1d_18\NN\1740|
T6_T28 NONE eletriptan_0\NN\1740| (r_nsubj) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) receptor_22\NN\5225602|putative|5-ht1f (l_compound) 5-ht1f_21\NN\1740|
T7_T26 NONE sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor
T7_T27 NONE sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) 5-ht1d_18\NN\1740|
T7_T28 NONE sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) receptor_22\NN\5225602|putative|5-ht1f (l_compound) 5-ht1f_21\NN\1740|
T9_T26 NONE zolmitriptan_5\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor
T9_T27 NONE zolmitriptan_5\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) 5-ht1d_18\NN\1740|
T9_T28 NONE zolmitriptan_5\NN\1740| (r_conj) sumatriptan_3\NN\1740|like|,|zolmitriptan|,|naratriptan|and|rizatriptan (r_nmod) had_10\VBD\2108377|eletriptan|,|sumatriptan|affinity|. (l_dobj) affinity_12\NN\11426530|highest|5-ht1b (l_nmod) 5-ht1b_16\NN\1740|for|the|human|,|5-ht1d|and|receptor (l_conj) receptor_22\NN\5225602|putative|5-ht1f (l_compound) 5-ht1f_21\NN\1740|
T12_T29 NONE [3h]eletriptan_6\NN\1740|of|and|[3h]sumatriptan (r_nmod) binding_4\NN\4688246|the|[3h]eletriptan|5-ht1b (l_nmod) 5-ht1b_13\NN\1740|to|the|human|recombinant|and|5-ht1d|receptors|expressed
T12_T30 NONE [3h]eletriptan_6\NN\1740|of|and|[3h]sumatriptan (r_nmod) binding_4\NN\4688246|the|[3h]eletriptan|5-ht1b (l_nmod) 5-ht1b_13\NN\1740|to|the|human|recombinant|and|5-ht1d|receptors|expressed (l_conj) 5-ht1d_15\NN\1740|
T13_T29 NONE [3h]sumatriptan_8\NN\1740| (r_conj) [3h]eletriptan_6\NN\1740|of|and|[3h]sumatriptan (r_nmod) binding_4\NN\4688246|the|[3h]eletriptan|5-ht1b (l_nmod) 5-ht1b_13\NN\1740|to|the|human|recombinant|and|5-ht1d|receptors|expressed
T13_T30 NONE [3h]sumatriptan_8\NN\1740| (r_conj) [3h]eletriptan_6\NN\1740|of|and|[3h]sumatriptan (r_nmod) binding_4\NN\4688246|the|[3h]eletriptan|5-ht1b (l_nmod) 5-ht1b_13\NN\1740|to|the|human|recombinant|and|5-ht1d|receptors|expressed (l_conj) 5-ht1d_15\NN\1740|
T14_T31 NONE [3h]eletriptan_2\NN\1740| (r_nsubj) had_3\VBD\2108377|however|,|[3h]eletriptan|affinity|k(d|and|affinity|. (l_dobj) affinity_7\NN\11426530|higher|[3h]sumatriptan|receptor (l_nmod) receptor_13\NN\5225602|at|the|5-ht1d (l_compound) 5-ht1d_12\NN\1740|
T14_T32 NONE [3h]eletriptan_2\NN\1740| (r_nsubj) had_3\VBD\2108377|however|,|[3h]eletriptan|affinity|k(d|and|affinity|. (l_conj) affinity_29\NN\11426530|higher|[3h]sumatriptan|nm (l_nmod) [3h]sumatriptan_31\NN\1740|than|receptor (l_nmod) receptor_35\NN\5225602|at|the|5-ht1b (l_compound) 5-ht1b_34\NN\1740|
T15_T31 NONE [3h]sumatriptan_9\NN\1740|than (r_nmod) affinity_7\NN\11426530|higher|[3h]sumatriptan|receptor (l_nmod) receptor_13\NN\5225602|at|the|5-ht1d (l_compound) 5-ht1d_12\NN\1740|
T15_T32 NONE [3h]sumatriptan_9\NN\1740|than (r_nmod) affinity_7\NN\11426530|higher|[3h]sumatriptan|receptor (r_dobj) had_3\VBD\2108377|however|,|[3h]eletriptan|affinity|k(d|and|affinity|. (l_conj) affinity_29\NN\11426530|higher|[3h]sumatriptan|nm (l_nmod) [3h]sumatriptan_31\NN\1740|than|receptor (l_nmod) receptor_35\NN\5225602|at|the|5-ht1b (l_compound) 5-ht1b_34\NN\1740|
T16_T31 NONE [3h]sumatriptan_31\NN\1740|than|receptor (r_nmod) affinity_29\NN\11426530|higher|[3h]sumatriptan|nm (r_conj) had_3\VBD\2108377|however|,|[3h]eletriptan|affinity|k(d|and|affinity|. (l_dobj) affinity_7\NN\11426530|higher|[3h]sumatriptan|receptor (l_nmod) receptor_13\NN\5225602|at|the|5-ht1d (l_compound) 5-ht1d_12\NN\1740|
T16_T32 NONE [3h]sumatriptan_31\NN\1740|than|receptor (l_nmod) receptor_35\NN\5225602|at|the|5-ht1b (l_compound) 5-ht1b_34\NN\1740|
23348754
T15_T24 NONE oxytocin_4\NN\5407119|of
T8_T19 NONE oxytocin_7\NN\5407119|the|polypeptide
T7_T18 NONE oxytocin_0\NN\5407119|
T9_T20 NONE oxytocin_11\NN\5407119|of
T10_T21 NONE oxytocin_16\NN\5407119|of
T11_T22 NONE oxytocin_10\NN\5407119|of
T12_T23 NONE oxytocin_4\NN\5407119|
T13_T23 NONE cocaine_10\NN\3492717|and|methamphetamine (r_nmod:npmod) induced_13\JJ\1740|cocaine (r_amod) behaviors_14\NNS\407535|of|induced (r_nmod) number_8\NN\5107765|a|broad|behaviors|and|activity|rodents (r_dobj) attenuates_5\VBZ\224901|that|oxytocin|number (l_nsubj) oxytocin_4\NN\5407119|
T14_T23 NONE methamphetamine_12\NN\2704153| (r_conj) cocaine_10\NN\3492717|and|methamphetamine (r_nmod:npmod) induced_13\JJ\1740|cocaine (r_amod) behaviors_14\NNS\407535|of|induced (r_nmod) number_8\NN\5107765|a|broad|behaviors|and|activity|rodents (r_dobj) attenuates_5\VBZ\224901|that|oxytocin|number (l_nsubj) oxytocin_4\NN\5407119|
T1_T16 NONE oxytocin_6\NN\5407119|for
T2_T16 NONE 3,4-methylenedioxymethamphetamine_12\NN\1740|of|mdma|rodents (r_nmod) effects_10\NNS\13245626|in|the|prosocial|3,4-methylenedioxymethamphetamine (r_nmod) role_4\NN\719494|a|oxytocin|effects (l_nmod) oxytocin_6\NN\5407119|for
T3_T16 NONE mdma_14\NN\3054098|(|,|ecstasy|) (r_appos) 3,4-methylenedioxymethamphetamine_12\NN\1740|of|mdma|rodents (r_nmod) effects_10\NNS\13245626|in|the|prosocial|3,4-methylenedioxymethamphetamine (r_nmod) role_4\NN\719494|a|oxytocin|effects (l_nmod) oxytocin_6\NN\5407119|for
T4_T16 NONE ecstasy_16\NN\13985818| (r_appos) mdma_14\NN\3054098|(|,|ecstasy|) (r_appos) 3,4-methylenedioxymethamphetamine_12\NN\1740|of|mdma|rodents (r_nmod) effects_10\NNS\13245626|in|the|prosocial|3,4-methylenedioxymethamphetamine (r_nmod) role_4\NN\719494|a|oxytocin|effects (l_nmod) oxytocin_6\NN\5407119|for
T5_T17 NONE oxytocin_8\NN\5407119|of
T6_T17 NONE mdma_29\NN\3054098|of|investigated (r_nmod) properties_27\NNS\32613|in|the|therapeutic|mdma (r_nmod) role_23\NN\719494|its|specific|properties (r_dobj) determine_20\VB\1645601|to|role (r_xcomp) aim_18\VB\1987160|should|determine (r_conj) investigate_4\VB\644583|trials|should|now|effectiveness|and|aim|. (l_dobj) effectiveness_6\NN\5190804|the|oxytocin|intervention (l_nmod) oxytocin_8\NN\5407119|of
22956632
T5_T24 CPR:6 gdc-0152_6\NN\1740|antagonist (l_compound) antagonist_5\NN\7846|of|small-molecule|iap (l_compound) iap_4\NN\1740|
T5_T25 NONE gdc-0152_6\NN\1740|antagonist (r_nmod) profile_1\NN\6999802|toxicity|gdc-0152 (r_nsubjpass) linked_8\VBN\628491|profile|is|pharmacology|. (l_nmod) pharmacology_11\NN\6043075|to|tnf-α (l_compound) tnf-α_10\NN\1740|
T2_T13 CPR:6 gdc-0152_0\NN\1740| (r_nsubj) drug_4\NN\14778436|gdc-0152|is|a|small-molecule|triggers|. (l_acl:relcl) triggers_6\VBZ\1641914|that|apoptosis|antagonizing (l_advcl) antagonizing_12\VBG\1787955|by|selectively|iaps (l_dobj) iaps_13\NNS\1740|
T3_T14 CPR:3 gdc-0152_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|gdc-0152|activity|. (l_dobj) activity_4\NN\30358|nf-κb|transcriptional|leading (l_compound) nf-κb_2\NN\1740|
T3_T15 NONE gdc-0152_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|gdc-0152|activity|. (l_dobj) activity_4\NN\30358|nf-κb|transcriptional|leading (l_acl) leading_5\VBG\1752884|expression (l_nmod) expression_7\NN\4679549|to|chemokines (l_nmod) chemokines_10\NNS\1740|of|several|and|cytokines|,|important
T3_T16 NONE gdc-0152_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|gdc-0152|activity|. (l_dobj) activity_4\NN\30358|nf-κb|transcriptional|leading (l_acl) leading_5\VBG\1752884|expression (l_nmod) expression_7\NN\4679549|to|chemokines (l_nmod) chemokines_10\NNS\1740|of|several|and|cytokines|,|important (l_conj) cytokines_12\NNS\14728724|
T3_T17 NONE gdc-0152_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|gdc-0152|activity|. (l_dobj) activity_4\NN\30358|nf-κb|transcriptional|leading (l_acl) leading_5\VBG\1752884|expression (l_nmod) expression_7\NN\4679549|to|chemokines (l_nmod) chemokines_10\NNS\1740|of|several|and|cytokines|,|important (l_acl:relcl) important_26\JJ\1740|which|alpha|is|the|most|activity (l_nsubj) alpha_19\NN\6828818|tumor|necrosis|factor|tnf-α
T3_T18 NONE gdc-0152_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|gdc-0152|activity|. (l_dobj) activity_4\NN\30358|nf-κb|transcriptional|leading (l_acl) leading_5\VBG\1752884|expression (l_nmod) expression_7\NN\4679549|to|chemokines (l_nmod) chemokines_10\NNS\1740|of|several|and|cytokines|,|important (l_acl:relcl) important_26\JJ\1740|which|alpha|is|the|most|activity (l_nsubj) alpha_19\NN\6828818|tumor|necrosis|factor|tnf-α (l_appos) tnf-α_21\NN\1740|(|)
T1_T11 NONE gdc-0152_20\NNP\1740| (r_compound) exposure_21\NN\5042871|to|gdc-0152|and|toxicity (r_nmod) corresponded_18\VBD\2664769|furthermore|,|elevations|exposure|and|have|. (l_nsubj) elevations_2\NNS\7445480|count (l_nmod) count_6\NN\13582013|in|blood|neutrophil|,|protein-1|,|and|markers (l_conj) protein-1_11\NN\1740|serum|monocyte|chemoattractant
8733007
T10_T13 NONE alpha-fluorocortisol_85\NN\1740|of|9 (r_nmod) administration_82\NN\1133281|by|the|alpha-fluorocortisol (r_nmod) rendered_75\VBN\120316|hypertensive|administration (r_acl) rats_74\NNS\2329401|in|rendered (r_conj) right_67\JJ\1740|in|and|left|ventricles|,|and|rats (r_nmod) seen_65\VBN\2106506|in|that|it|is|equally|right (r_nmod) independent_55\JJ\1740|iii|is|hypertrophy|,|seen|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked
T10_T14 NONE alpha-fluorocortisol_85\NN\1740|of|9 (r_nmod) administration_82\NN\1133281|by|the|alpha-fluorocortisol (r_nmod) rendered_75\VBN\120316|hypertensive|administration (r_acl) rats_74\NNS\2329401|in|rendered (r_conj) right_67\JJ\1740|in|and|left|ventricles|,|and|rats (r_nmod) seen_65\VBN\2106506|in|that|it|is|equally|right (r_nmod) independent_55\JJ\1740|iii|is|hypertrophy|,|seen|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked (l_advcl) blocked_133\VBN\1476483|in|that|it|is|administration (l_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (l_nmod) canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (l_compound) mr_139\NNS\6339416|
T10_T15 NONE alpha-fluorocortisol_85\NN\1740|of|9 (r_nmod) administration_82\NN\1133281|by|the|alpha-fluorocortisol (r_nmod) rendered_75\VBN\120316|hypertensive|administration (r_acl) rats_74\NNS\2329401|in|rendered (r_conj) right_67\JJ\1740|in|and|left|ventricles|,|and|rats (r_nmod) seen_65\VBN\2106506|in|that|it|is|equally|right (r_nmod) independent_55\JJ\1740|iii|is|hypertrophy|,|seen|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) may_148\MD\15209706|vi|or|effect|,|conflicting (l_advcl) conflicting_172\VBG\2666882|inasmuch|as|data|are (l_nsubj) data_160\NNS\7951464|effects (l_nmod) effects_164\NNS\13245626|for|in|formation (l_nmod) formation_167\NN\7938773|on|collagen|fibroblasts (l_compound) collagen_166\NN\15026716|
T10_T18 NONE alpha-fluorocortisol_85\NN\1740|of|9 (r_nmod) administration_82\NN\1133281|by|the|alpha-fluorocortisol (r_nmod) rendered_75\VBN\120316|hypertensive|administration (r_acl) rats_74\NNS\2329401|in|rendered (r_conj) right_67\JJ\1740|in|and|left|ventricles|,|and|rats (r_nmod) seen_65\VBN\2106506|in|that|it|is|equally|right (r_nmod) independent_55\JJ\1740|iii|is|hypertrophy|,|seen|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) appears_27\VBZ\2604760|ii|involve|; (l_xcomp) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T10_T19 NONE alpha-fluorocortisol_85\NN\1740|of|9 (r_nmod) administration_82\NN\1133281|by|the|alpha-fluorocortisol (r_nmod) rendered_75\VBN\120316|hypertensive|administration (r_acl) rats_74\NNS\2329401|in|rendered (r_conj) right_67\JJ\1740|in|and|left|ventricles|,|and|rats (r_nmod) seen_65\VBN\2106506|in|that|it|is|equally|right (r_nmod) independent_55\JJ\1740|iii|is|hypertrophy|,|seen|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) appears_27\VBZ\2604760|ii|involve|; (l_xcomp) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T10_T20 NONE alpha-fluorocortisol_85\NN\1740|of|9 (r_nmod) administration_82\NN\1133281|by|the|alpha-fluorocortisol (r_nmod) rendered_75\VBN\120316|hypertensive|administration (r_acl) rats_74\NNS\2329401|in|rendered (r_conj) right_67\JJ\1740|in|and|left|ventricles|,|and|rats (r_nmod) seen_65\VBN\2106506|in|that|it|is|equally|right (r_nmod) independent_55\JJ\1740|iii|is|hypertrophy|,|seen|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr
T10_T21 NONE alpha-fluorocortisol_85\NN\1740|of|9 (r_nmod) administration_82\NN\1133281|by|the|alpha-fluorocortisol (r_nmod) rendered_75\VBN\120316|hypertensive|administration (r_acl) rats_74\NNS\2329401|in|rendered (r_conj) right_67\JJ\1740|in|and|left|ventricles|,|and|rats (r_nmod) seen_65\VBN\2106506|in|that|it|is|equally|right (r_nmod) independent_55\JJ\1740|iii|is|hypertrophy|,|seen|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr (l_appos) mr_116\NN\6339416|(|)
T11_T13 NONE aldosterone_108\NN\14751863|peripherally|with (r_nmod) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked
T11_T14 NONE aldosterone_108\NN\14751863|peripherally|with (r_nmod) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked (l_advcl) blocked_133\VBN\1476483|in|that|it|is|administration (l_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (l_nmod) canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (l_compound) mr_139\NNS\6339416|
T11_T15 NONE aldosterone_108\NN\14751863|peripherally|with (r_nmod) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) may_148\MD\15209706|vi|or|effect|,|conflicting (l_advcl) conflicting_172\VBG\2666882|inasmuch|as|data|are (l_nsubj) data_160\NNS\7951464|effects (l_nmod) effects_164\NNS\13245626|for|in|formation (l_nmod) formation_167\NN\7938773|on|collagen|fibroblasts (l_compound) collagen_166\NN\15026716|
T11_T18 NONE aldosterone_108\NN\14751863|peripherally|with (r_nmod) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) appears_27\VBZ\2604760|ii|involve|; (l_xcomp) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T11_T19 NONE aldosterone_108\NN\14751863|peripherally|with (r_nmod) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) appears_27\VBZ\2604760|ii|involve|; (l_xcomp) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T11_T20 NONE aldosterone_108\NN\14751863|peripherally|with (r_nmod) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr
T11_T21 NONE aldosterone_108\NN\14751863|peripherally|with (r_nmod) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr (l_appos) mr_116\NN\6339416|(|)
T12_T13 NONE ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (r_conj) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked
T12_T14 NONE ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (r_conj) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked (l_advcl) blocked_133\VBN\1476483|in|that|it|is|administration (l_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (l_nmod) canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (l_compound) mr_139\NNS\6339416|
T12_T15 NONE ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (r_conj) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) may_148\MD\15209706|vi|or|effect|,|conflicting (l_advcl) conflicting_172\VBG\2666882|inasmuch|as|data|are (l_nsubj) data_160\NNS\7951464|effects (l_nmod) effects_164\NNS\13245626|for|in|formation (l_nmod) formation_167\NN\7938773|on|collagen|fibroblasts (l_compound) collagen_166\NN\15026716|
T12_T18 NONE ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (r_conj) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) appears_27\VBZ\2604760|ii|involve|; (l_xcomp) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T12_T19 NONE ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (r_conj) infused_105\VBN\606335|aldosterone|and|ru28318 (r_acl) animals_104\NNS\4475|in|normotensive|infused (r_nmod) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) appears_27\VBZ\2604760|ii|involve|; (l_xcomp) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T12_T20 CPR:6 ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr
T12_T21 CPR:6 ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr (l_appos) mr_116\NN\6339416|(|)
T1_T13 CPR:6 canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (r_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (r_nmod) blocked_133\VBN\1476483|in|that|it|is|administration (r_advcl) mr_127\NN\6339416|v|is|via|classical|,|blocked
T1_T14 CPR:6 canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (l_compound) mr_139\NNS\6339416|
T1_T15 NONE canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (r_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (r_nmod) blocked_133\VBN\1476483|in|that|it|is|administration (r_advcl) mr_127\NN\6339416|v|is|via|classical|,|blocked (r_conj) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) may_148\MD\15209706|vi|or|effect|,|conflicting (l_advcl) conflicting_172\VBG\2666882|inasmuch|as|data|are (l_nsubj) data_160\NNS\7951464|effects (l_nmod) effects_164\NNS\13245626|for|in|formation (l_nmod) formation_167\NN\7938773|on|collagen|fibroblasts (l_compound) collagen_166\NN\15026716|
T1_T18 NONE canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (r_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (r_nmod) blocked_133\VBN\1476483|in|that|it|is|administration (r_advcl) mr_127\NN\6339416|v|is|via|classical|,|blocked (r_conj) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) appears_27\VBZ\2604760|ii|involve|; (l_xcomp) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T1_T19 NONE canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (r_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (r_nmod) blocked_133\VBN\1476483|in|that|it|is|administration (r_advcl) mr_127\NN\6339416|v|is|via|classical|,|blocked (r_conj) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (r_ccomp) independent_91\JJ\1740|iv|is|pressure|,|found (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) appears_27\VBZ\2604760|ii|involve|; (l_xcomp) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T1_T20 NONE canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (r_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (r_nmod) blocked_133\VBN\1476483|in|that|it|is|administration (r_advcl) mr_127\NN\6339416|v|is|via|classical|,|blocked (r_conj) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr
T1_T21 NONE canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (r_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (r_nmod) blocked_133\VBN\1476483|in|that|it|is|administration (r_advcl) mr_127\NN\6339416|v|is|via|classical|,|blocked (r_conj) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr (l_appos) mr_116\NN\6339416|(|)
T6_T13 NONE renin-angiotensin_35\JJ\1740| (r_amod) systems_36\NNS\3575240|the|plasma|renin-angiotensin (r_dobj) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked
T6_T14 NONE renin-angiotensin_35\JJ\1740| (r_amod) systems_36\NNS\3575240|the|plasma|renin-angiotensin (r_dobj) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked (l_advcl) blocked_133\VBN\1476483|in|that|it|is|administration (l_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (l_nmod) canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (l_compound) mr_139\NNS\6339416|
T6_T15 NONE renin-angiotensin_35\JJ\1740| (r_amod) systems_36\NNS\3575240|the|plasma|renin-angiotensin (r_dobj) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) may_148\MD\15209706|vi|or|effect|,|conflicting (l_advcl) conflicting_172\VBG\2666882|inasmuch|as|data|are (l_nsubj) data_160\NNS\7951464|effects (l_nmod) effects_164\NNS\13245626|for|in|formation (l_nmod) formation_167\NN\7938773|on|collagen|fibroblasts (l_compound) collagen_166\NN\15026716|
T6_T18 NONE renin-angiotensin_35\JJ\1740|
T6_T19 NONE renin-angiotensin_35\JJ\1740|
T6_T20 NONE renin-angiotensin_35\JJ\1740| (r_amod) systems_36\NNS\3575240|the|plasma|renin-angiotensin (r_dobj) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr
T6_T21 NONE renin-angiotensin_35\JJ\1740| (r_amod) systems_36\NNS\3575240|the|plasma|renin-angiotensin (r_dobj) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr (l_appos) mr_116\NN\6339416|(|)
T7_T13 NONE losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked
T7_T14 NONE losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked (l_advcl) blocked_133\VBN\1476483|in|that|it|is|administration (l_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (l_nmod) canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (l_compound) mr_139\NNS\6339416|
T7_T15 NONE losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) may_148\MD\15209706|vi|or|effect|,|conflicting (l_advcl) conflicting_172\VBG\2666882|inasmuch|as|data|are (l_nsubj) data_160\NNS\7951464|effects (l_nmod) effects_164\NNS\13245626|for|in|formation (l_nmod) formation_167\NN\7938773|on|collagen|fibroblasts (l_compound) collagen_166\NN\15026716|
T7_T18 NONE losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T7_T19 NONE losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T7_T20 NONE losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr
T7_T21 NONE losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr (l_appos) mr_116\NN\6339416|(|)
T8_T13 NONE perindopril_49\NN\1740| (r_conj) losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked
T8_T14 NONE perindopril_49\NN\1740| (r_conj) losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_conj) mr_127\NN\6339416|v|is|via|classical|,|blocked (l_advcl) blocked_133\VBN\1476483|in|that|it|is|administration (l_nmod) administration_136\NN\1133281|by|concurrent|canrenoate (l_nmod) canrenoate_142\NN\1740|of|the|mr|antagonist|potassium (l_compound) mr_139\NNS\6339416|
T8_T15 NONE perindopril_49\NN\1740| (r_conj) losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) may_148\MD\15209706|vi|or|effect|,|conflicting (l_advcl) conflicting_172\VBG\2666882|inasmuch|as|data|are (l_nsubj) data_160\NNS\7951464|effects (l_nmod) effects_164\NNS\13245626|for|in|formation (l_nmod) formation_167\NN\7938773|on|collagen|fibroblasts (l_compound) collagen_166\NN\15026716|
T8_T18 NONE perindopril_49\NN\1740| (r_conj) losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T8_T19 NONE perindopril_49\NN\1740| (r_conj) losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (l_dobj) systems_36\NNS\3575240|the|plasma|renin-angiotensin (l_amod) renin-angiotensin_35\JJ\1740|
T8_T20 NONE perindopril_49\NN\1740| (r_conj) losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr
T8_T21 NONE perindopril_49\NN\1740| (r_conj) losartan_47\NN\1740|of|or|perindopril (r_nmod) administration_45\NN\1133281|by|concurrent|losartan (r_nmod) unaffected_42\JJ\1740|as|fibrosis|is|largely|administration (r_advcl) involve_30\VB\2676054|not|to|systems|,|unaffected (r_xcomp) appears_27\VBZ\2604760|ii|involve|; (r_conj) reversed_17\VBN\109660|that|fibrosis|i|is|not|correction|;|appears|independent|independent|and|may (l_conj) independent_91\JJ\1740|iv|is|pressure|,|found (l_ccomp) found_101\VBN\2426171|in|that|it|is|animals|;|mr|; (l_nmod) animals_104\NNS\4475|in|normotensive|infused (l_acl) infused_105\VBN\606335|aldosterone|and|ru28318 (l_conj) ru28318_119\NN\1740|intracerebroventricularly|with|antagonist (l_compound) antagonist_118\NN\7846|the|receptor (l_compound) receptor_114\NN\5225602|mineralocorticoid|mr (l_appos) mr_116\NN\6339416|(|)
T2_T16 NONE aldosterone_10\NN\14751863|of (r_nmod) action_8\NN\30358|the|aldosterone|cause (r_nsubj) effect_21\NN\34213|that|action|is|an|mr (l_nmod) mr_24\NN\6339416|via|non-epithelial
T2_T17 NONE aldosterone_10\NN\14751863|of (r_nmod) action_8\NN\30358|the|aldosterone|cause (r_nsubj) effect_21\NN\34213|that|action|is|an|mr (r_ccomp) probability_5\NN\33615|a|high|effect (r_nsubj) is_2\VBZ\836236|although|there|probability (r_advcl) remains_31\VBZ\2604760|is|,|locus|established|,|do|. (l_dep) do_37\VBP\1640855|as|mechanisms (l_nsubj) mechanisms_40\NNS\13446390|the|molecular|linking (l_acl) linking_41\VBG\628491|occupancy (l_dobj) occupancy_43\NN\1053920|mr|aldosterone|and|deposition (l_compound) mr_42\NN\6339416|
T3_T16 NONE aldosterone_29\NN\14751863| (r_compound) action_30\NN\30358|of|aldosterone (r_nmod) locus_27\NN\8645963|the|action (r_nsubj) remains_31\VBZ\2604760|is|,|locus|established|,|do|. (l_advcl) is_2\VBZ\836236|although|there|probability (l_nsubj) probability_5\NN\33615|a|high|effect (l_ccomp) effect_21\NN\34213|that|action|is|an|mr (l_nmod) mr_24\NN\6339416|via|non-epithelial
T3_T17 NONE aldosterone_29\NN\14751863| (r_compound) action_30\NN\30358|of|aldosterone (r_nmod) locus_27\NN\8645963|the|action (r_nsubj) remains_31\VBZ\2604760|is|,|locus|established|,|do|. (l_dep) do_37\VBP\1640855|as|mechanisms (l_nsubj) mechanisms_40\NNS\13446390|the|molecular|linking (l_acl) linking_41\VBG\628491|occupancy (l_dobj) occupancy_43\NN\1053920|mr|aldosterone|and|deposition (l_compound) mr_42\NN\6339416|
T4_T16 NONE aldosterone_45\NN\14751863|by (r_nmod) occupancy_43\NN\1053920|mr|aldosterone|and|deposition (r_dobj) linking_41\VBG\628491|occupancy (r_acl) mechanisms_40\NNS\13446390|the|molecular|linking (r_nsubj) do_37\VBP\1640855|as|mechanisms (r_dep) remains_31\VBZ\2604760|is|,|locus|established|,|do|. (l_advcl) is_2\VBZ\836236|although|there|probability (l_nsubj) probability_5\NN\33615|a|high|effect (l_ccomp) effect_21\NN\34213|that|action|is|an|mr (l_nmod) mr_24\NN\6339416|via|non-epithelial
T4_T17 NONE aldosterone_45\NN\14751863|by (r_nmod) occupancy_43\NN\1053920|mr|aldosterone|and|deposition (l_compound) mr_42\NN\6339416|
23318731
T12_T25 NONE pb_10\NN\14625458|to|or|bap (r_nmod) exposed_8\VBN\2110927|samples|were|pb|,|and|performed (l_conj) performed_18\VBN\2367363|staining|was|evaluate|. (l_xcomp) evaluate_20\VB\670261|to|caspase-3 (l_dobj) caspase-3_22\NN\1740|active|,|alpha|,|and|3-nitrotyrosine
T13_T25 NONE bap_12\NN\7679356| (r_conj) pb_10\NN\14625458|to|or|bap (r_nmod) exposed_8\VBN\2110927|samples|were|pb|,|and|performed (l_conj) performed_18\VBN\2367363|staining|was|evaluate|. (l_xcomp) evaluate_20\VB\670261|to|caspase-3 (l_dobj) caspase-3_22\NN\1740|active|,|alpha|,|and|3-nitrotyrosine
T15_T25 NONE alpha_26\NN\6828818|8-epi-prostaglandin|f2|8-epi-pgf2a (r_conj) caspase-3_22\NN\1740|active|,|alpha|,|and|3-nitrotyrosine
T16_T25 NONE 8-epi-pgf2a_28\NN\1740|(|) (r_appos) alpha_26\NN\6828818|8-epi-prostaglandin|f2|8-epi-pgf2a (r_conj) caspase-3_22\NN\1740|active|,|alpha|,|and|3-nitrotyrosine
T17_T25 NONE 3-nitrotyrosine_32\NN\1740|3-nt (r_conj) caspase-3_22\NN\1740|active|,|alpha|,|and|3-nitrotyrosine
T18_T25 NONE 3-nt_34\NN\1740|(|) (r_appos) 3-nitrotyrosine_32\NN\1740|3-nt (r_conj) caspase-3_22\NN\1740|active|,|alpha|,|and|3-nitrotyrosine
T19_T26 CPR:3 pb_0\NN\14625458|and|bap (r_compound) treatments_3\NNS\654885|pb (r_nsubj) increased_5\VBD\169651|treatments|significantly|levels|manner|. (l_dobj) levels_8\NNS\4916342|active|caspase-3 (l_compound) caspase-3_7\NN\1740|
T20_T26 CPR:3 bap_2\NN\7679356| (r_conj) pb_0\NN\14625458|and|bap (r_compound) treatments_3\NNS\654885|pb (r_nsubj) increased_5\VBD\169651|treatments|significantly|levels|manner|. (l_dobj) levels_8\NNS\4916342|active|caspase-3 (l_compound) caspase-3_7\NN\1740|
12844134
T7_T17 NONE metoprolol_8\NN\2832168|to (r_nmod) response_6\NN\11410625|antihypertensive|metoprolol (r_conj) polymorphisms_3\NNS\11418750|beta|1-adrenergic|receptor|and|response|. (l_compound) receptor_2\NN\5225602|
T3_T14 NONE metoprolol_20\NN\2832168|to (r_nmod) response_18\NN\11410625|with|antihypertensive|metoprolol|patients (r_nmod) associated_15\VBN\628491|that|polymorphisms|are|response (l_nsubjpass) polymorphisms_7\NNS\11418750|2|common|gene (l_nmod) gene_10\NN\8459252|in|the|receptor (l_nmod) receptor_13\NN\5225602|for|beta(1)-adrenergic
T1_T13 NONE metoprolol_16\NN\2832168|to (r_nmod) response_14\NN\11410625|of|antihypertensive|metoprolol (r_nmod) determinants_11\NNS\5686481|that|polymorphisms|are|important|response (l_nsubj) polymorphisms_8\NNS\11418750|beta(1)-adrenergic|receptor (l_compound) receptor_7\NN\5225602|
T2_T15 NONE metoprolol_24\NN\2832168|to (r_nmod) response_22\NN\11410625|the|diastolic|blood|pressure|metoprolol|patients (r_dobj) predict_17\VB\916909|to|response (r_xcomp) used_15\VBN\1156834|future|,|genotypes|might|be|predict|. (l_nsubjpass) genotypes_8\NNS\7941170|codon|49|or|haplotypes (l_conj) haplotypes_12\NNS\7963711|beta(1)-adrenergic|receptor (l_compound) receptor_11\NN\5225602|
23414838
T6_T10 CPR:5 quinolone_6\NN\1740| (r_compound) agonists_11\NNS\9613191|of|quinolone|α7|nicotinic|acetylcholine|receptor (l_compound) receptor_10\NN\5225602|
T7_T10 NONE acetylcholine_9\NN\14807558| (r_compound) agonists_11\NNS\9613191|of|quinolone|α7|nicotinic|acetylcholine|receptor (l_compound) receptor_10\NN\5225602|
T4_T8 CPR:5 quinolone_12\NN\1740| (r_compound) receptor_16\NN\5225602|quinolone|α7|nicotinic|acetylcholine|nachr (l_appos) nachr_18\NN\1740|(|)
T4_T9 CPR:5 quinolone_12\NN\1740| (r_compound) receptor_16\NN\5225602|quinolone|α7|nicotinic|acetylcholine|nachr
T5_T8 NONE acetylcholine_15\NN\14807558| (r_compound) receptor_16\NN\5225602|quinolone|α7|nicotinic|acetylcholine|nachr (l_appos) nachr_18\NN\1740|(|)
T5_T9 NONE acetylcholine_15\NN\14807558| (r_compound) receptor_16\NN\5225602|quinolone|α7|nicotinic|acetylcholine|nachr
19496999
T22_T32 NONE dopamine_0\NN\14807737| (r_compound) receptor_2\NN\5225602|dopamine|d2/3|potential|.
T23_T32 NONE olanzapine_15\NN\1740| (r_conj) haloperidol_13\NN\3713736|by|,|olanzapine|and|clozapine (r_nmod) midbrain_8\NN\5462674|in|and|cortex|haloperidol (r_nmod) potential_4\NN\14481929|binding|and|occupancy|midbrain (r_dep) receptor_2\NN\5225602|dopamine|d2/3|potential|.
T24_T32 NONE clozapine_17\NN\3713736| (r_conj) haloperidol_13\NN\3713736|by|,|olanzapine|and|clozapine (r_nmod) midbrain_8\NN\5462674|in|and|cortex|haloperidol (r_nmod) potential_4\NN\14481929|binding|and|occupancy|midbrain (r_dep) receptor_2\NN\5225602|dopamine|d2/3|potential|.
T25_T32 NONE haloperidol_13\NN\3713736|by|,|olanzapine|and|clozapine (r_nmod) midbrain_8\NN\5462674|in|and|cortex|haloperidol (r_nmod) potential_4\NN\14481929|binding|and|occupancy|midbrain (r_dep) receptor_2\NN\5225602|dopamine|d2/3|potential|.
T9_T28 NONE dopamine_7\NN\14807737| (r_compound) receptor_10\NN\5225602|dopamine|d(2|)
T10_T29 NONE dopamine_10\NN\14807737| (r_compound) receptor_13\NN\5225602|dopamine|d(2/3|)
T11_T29 NONE clozapine-_29\NN\1740|,|olanzapine-|and|haloperidol-treated (r_amod) patients_35\NNS\9898892|among|clozapine-|schizophrenia (r_nmod) midbrain_24\NN\5462674|in|and|cortex|patients (r_nmod) potential_16\NN\14481929|receptor|apparent|binding|bp(app|and|occupancy|midbrain (l_compound) receptor_13\NN\5225602|dopamine|d(2/3|)
T12_T29 NONE olanzapine-_31\NN\1740| (r_conj) clozapine-_29\NN\1740|,|olanzapine-|and|haloperidol-treated (r_amod) patients_35\NNS\9898892|among|clozapine-|schizophrenia (r_nmod) midbrain_24\NN\5462674|in|and|cortex|patients (r_nmod) potential_16\NN\14481929|receptor|apparent|binding|bp(app|and|occupancy|midbrain (l_compound) receptor_13\NN\5225602|dopamine|d(2/3|)
T13_T29 NONE haloperidol-treated_33\JJ\1740| (r_conj) clozapine-_29\NN\1740|,|olanzapine-|and|haloperidol-treated (r_amod) patients_35\NNS\9898892|among|clozapine-|schizophrenia (r_nmod) midbrain_24\NN\5462674|in|and|cortex|patients (r_nmod) potential_16\NN\14481929|receptor|apparent|binding|bp(app|and|occupancy|midbrain (l_compound) receptor_13\NN\5225602|dopamine|d(2/3|)
T14_T30 NONE dopamine_2\NN\14807737| (r_compound) d(2/3_3\CD\1740|dopamine|) (l_punct) )_4\-RRB-\1740|
T15_T30 NONE [(123)i]epidepride_14\NN\1740|on|single-photon|emission|computed|tomography|ligand (r_nmod) studied_7\VBN\630380|binding|was|[(123)i]epidepride|patients|. (l_nsubjpass) binding_5\NN\4688246|d(2/3 (l_compound) d(2/3_3\CD\1740|dopamine|) (l_punct) )_4\-RRB-\1740|
T16_T30 NONE haloperidol_25\NN\3713736|with (r_nmod) two_23\CD\13741022|(|haloperidol|,|four|,|patients|and|controls (r_dep) patients_18\NNS\9898892|in|13|schizophrenia|treated|two (r_nmod) studied_7\VBN\630380|binding|was|[(123)i]epidepride|patients|. (l_nsubjpass) binding_5\NN\4688246|d(2/3 (l_compound) d(2/3_3\CD\1740|dopamine|) (l_punct) )_4\-RRB-\1740|
T17_T30 NONE olanzapine_29\NN\1740|with (r_nmod) four_27\CD\13741022|olanzapine|and|seven (r_conj) two_23\CD\13741022|(|haloperidol|,|four|,|patients|and|controls (r_dep) patients_18\NNS\9898892|in|13|schizophrenia|treated|two (r_nmod) studied_7\VBN\630380|binding|was|[(123)i]epidepride|patients|. (l_nsubjpass) binding_5\NN\4688246|d(2/3 (l_compound) d(2/3_3\CD\1740|dopamine|) (l_punct) )_4\-RRB-\1740|
T18_T30 NONE clozapine_33\NN\3713736|with (r_nmod) seven_31\CD\13741022|clozapine|) (r_conj) four_27\CD\13741022|olanzapine|and|seven (r_conj) two_23\CD\13741022|(|haloperidol|,|four|,|patients|and|controls (r_dep) patients_18\NNS\9898892|in|13|schizophrenia|treated|two (r_nmod) studied_7\VBN\630380|binding|was|[(123)i]epidepride|patients|. (l_nsubjpass) binding_5\NN\4688246|d(2/3 (l_compound) d(2/3_3\CD\1740|dopamine|) (l_punct) )_4\-RRB-\1740|
T19_T31 NONE dopamine_7\NN\14807737| (r_compound) bp(app_11\NN\1740|in|midbrain|dopamine|d(2/3|)|receptor|) (l_compound) receptor_10\NN\5225602|
T1_T31 NONE haloperidol_33\NN\3713736| (r_conj) clozapine_29\NN\3713736|,|olanzapine|and|haloperidol (r_compound) groups_34\NNS\2137|between|the|clozapine (r_nmod) observed_26\VBN\2163746|differences|were|groups|. (l_nsubjpass) differences_4\NNS\4723816|significant|bp(app|=|and|occupancy (l_nmod) bp(app_11\NN\1740|in|midbrain|dopamine|d(2/3|)|receptor|) (l_compound) receptor_10\NN\5225602|
T20_T31 NONE clozapine_29\NN\3713736|,|olanzapine|and|haloperidol (r_compound) groups_34\NNS\2137|between|the|clozapine (r_nmod) observed_26\VBN\2163746|differences|were|groups|. (l_nsubjpass) differences_4\NNS\4723816|significant|bp(app|=|and|occupancy (l_nmod) bp(app_11\NN\1740|in|midbrain|dopamine|d(2/3|)|receptor|) (l_compound) receptor_10\NN\5225602|
T21_T31 NONE olanzapine_31\NN\1740| (r_conj) clozapine_29\NN\3713736|,|olanzapine|and|haloperidol (r_compound) groups_34\NNS\2137|between|the|clozapine (r_nmod) observed_26\VBN\2163746|differences|were|groups|. (l_nsubjpass) differences_4\NNS\4723816|significant|bp(app|=|and|occupancy (l_nmod) bp(app_11\NN\1740|in|midbrain|dopamine|d(2/3|)|receptor|) (l_compound) receptor_10\NN\5225602|
T6_T26 NONE dopamine_9\NN\14807737| (r_compound) receptors_12\NNS\5225602|cortical|dopamine|d(2/3|)
T7_T27 NONE dopamine_4\NN\14807737| (r_compound) d(2/3_5\CD\1740|dopamine|) (l_punct) )_6\-RRB-\1740|
T8_T27 NONE dopamine_22\NN\14807737| (r_compound) neurotransmission_23\NN\1740|altered|nigrostriatal|dopamine (r_dobj) modulating_19\VBG\1724459|by|neurotransmission|phase (r_advcl) have_15\VB\2108377|differences|may|relevance|modulating|. (l_nsubj) differences_1\NNS\4723816|observed|occupancy|antipsychotics (l_nmod) occupancy_7\NN\1053920|in|midbrain|d(2/3 (l_compound) d(2/3_5\CD\1740|dopamine|) (l_punct) )_6\-RRB-\1740|
17603555
T47_T61 NONE amp-activated_3\JJ\1740| (r_amod) kinase_5\NN\14732946|of|amp-activated|protein
T48_T61 NONE na+_10\NN\1740| (r_compound) processes_12\NNS\407535|on|na+|transport|cells (r_nmod) have_6\VBP\2108377|activators|effects|processes|. (l_nsubj) activators_1\NNS\19613|pharmacological|kinase (l_nmod) kinase_5\NN\14732946|of|amp-activated|protein
T27_T55 CPR:3 aicar_24\NN\1740|(|) (r_appos) 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside_22\NN\1740|aicar (r_appos) mimetic_20\NN\1740|the|amp|,|5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (r_conj) metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk
T27_T57 CPR:3 aicar_24\NN\1740|(|) (r_appos) 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside_22\NN\1740|aicar (r_appos) mimetic_20\NN\1740|the|amp|,|5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (r_conj) metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk (l_appos) ampk_8\NN\1740|(|)
T30_T55 NONE amp-activated_4\JJ\1740| (r_amod) kinase_6\NN\14732946|amp-activated|protein|ampk
T30_T57 NONE amp-activated_4\JJ\1740| (r_amod) kinase_6\NN\14732946|amp-activated|protein|ampk (l_appos) ampk_8\NN\1740|(|)
T3_T55 NONE amp_19\NN\13633375| (r_compound) mimetic_20\NN\1740|the|amp|,|5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (r_conj) metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk
T3_T57 NONE amp_19\NN\13633375| (r_compound) mimetic_20\NN\1740|the|amp|,|5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (r_conj) metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk (l_appos) ampk_8\NN\1740|(|)
T40_T55 CPR:3 metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk
T40_T57 CPR:3 metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk (l_appos) ampk_8\NN\1740|(|)
T42_T55 CPR:3 phenformin_15\NN\1740| (r_conj) metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk
T42_T57 CPR:3 phenformin_15\NN\1740| (r_conj) metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk (l_appos) ampk_8\NN\1740|(|)
T8_T55 CPR:3 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside_22\NN\1740|aicar (r_appos) mimetic_20\NN\1740|the|amp|,|5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (r_conj) metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk
T8_T57 CPR:3 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside_22\NN\1740|aicar (r_appos) mimetic_20\NN\1740|the|amp|,|5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (r_conj) metformin_13\NN\2719105|by|,|phenformin|,|and|mimetic (r_nmod) activated_11\VBN\1641914|kinase|is|metformin (l_nsubjpass) kinase_6\NN\14732946|amp-activated|protein|ampk (l_appos) ampk_8\NN\1740|(|)
T31_T56 NONE nucleotide_18\NN\14850483| (r_compound) concentration_19\NN\4916342|adenine|nucleotide (r_conj) activation_15\NN\13561719|on|ampk|,|concentration|,|current (l_compound) ampk_14\NN\1740|
T32_T56 NONE amiloride-sensitive_22\JJ\1740|transepithelial|i(amiloride|and|basolateral (r_amod) current_36\NN\11449002|amiloride-sensitive|circuit|cells (r_conj) activation_15\NN\13561719|on|ampk|,|concentration|,|current (l_compound) ampk_14\NN\1740|
T33_T56 NONE i(amiloride_24\NN\1740|(|)|) (r_appos) amiloride-sensitive_22\JJ\1740|transepithelial|i(amiloride|and|basolateral (r_amod) current_36\NN\11449002|amiloride-sensitive|circuit|cells (r_conj) activation_15\NN\13561719|on|ampk|,|concentration|,|current (l_compound) ampk_14\NN\1740|
T34_T56 NONE ouabain-sensitive_28\JJ\1740| (r_amod) basolateral_29\JJ\1740|ouabain-sensitive|i(ouabain (r_conj) amiloride-sensitive_22\JJ\1740|transepithelial|i(amiloride|and|basolateral (r_amod) current_36\NN\11449002|amiloride-sensitive|circuit|cells (r_conj) activation_15\NN\13561719|on|ampk|,|concentration|,|current (l_compound) ampk_14\NN\1740|
T35_T56 NONE i(ouabain_31\NN\1740|(|)|) (r_dep) basolateral_29\JJ\1740|ouabain-sensitive|i(ouabain (r_conj) amiloride-sensitive_22\JJ\1740|transepithelial|i(amiloride|and|basolateral (r_amod) current_36\NN\11449002|amiloride-sensitive|circuit|cells (r_conj) activation_15\NN\13561719|on|ampk|,|concentration|,|current (l_compound) ampk_14\NN\1740|
T38_T58 NONE phosphate_9\NN\15010703|of|radiolabelled|transferred (r_nmod) amount_6\NN\13329641|as|the|phosphate (r_nmod) measured_3\VBN\697589|activity|was|amount|. (l_nsubjpass) activity_1\NN\30358|ampk (l_compound) ampk_0\NN\1740|
T43_T59 CPR:3 phenformin_3\NN\1740|,|aicar|and|metformin (r_nsubj) increased_8\VBD\169651|results|phenformin|activity|and|decreased|. (l_dobj) activity_13\NN\30358|ampk (l_compound) ampk_9\NN\1740|alpha1 (l_appos) alpha1_11\NN\1740|(|) (l_punct) )_12\-RRB-\1740|
T44_T59 CPR:3 aicar_5\NN\1740| (r_conj) phenformin_3\NN\1740|,|aicar|and|metformin (r_nsubj) increased_8\VBD\169651|results|phenformin|activity|and|decreased|. (l_dobj) activity_13\NN\30358|ampk (l_compound) ampk_9\NN\1740|alpha1 (l_appos) alpha1_11\NN\1740|(|) (l_punct) )_12\-RRB-\1740|
T45_T59 CPR:3 metformin_7\NN\2719105| (r_conj) phenformin_3\NN\1740|,|aicar|and|metformin (r_nsubj) increased_8\VBD\169651|results|phenformin|activity|and|decreased|. (l_dobj) activity_13\NN\30358|ampk (l_compound) ampk_9\NN\1740|alpha1 (l_appos) alpha1_11\NN\1740|(|) (l_punct) )_12\-RRB-\1740|
T46_T59 NONE i(amiloride_16\NN\1740|) (r_dobj) decreased_15\VBD\169651|i(amiloride (r_conj) increased_8\VBD\169651|results|phenformin|activity|and|decreased|. (l_dobj) activity_13\NN\30358|ampk (l_compound) ampk_9\NN\1740|alpha1 (l_appos) alpha1_11\NN\1740|(|) (l_punct) )_12\-RRB-\1740|
T1_T60 NONE metformin_9\NN\2719105|of|and|aicar|not|phenformin (r_nmod) action_7\NN\30358|the|metformin (r_dobj) prevented_5\VBD\1740|c|action|. (l_nsubj) c_4\NN\13714184|the|ampk|inhibitor|compound (l_compound) ampk_1\NN\1740|
T2_T60 NONE aicar_11\NN\1740| (r_conj) metformin_9\NN\2719105|of|and|aicar|not|phenformin (r_nmod) action_7\NN\30358|the|metformin (r_dobj) prevented_5\VBD\1740|c|action|. (l_nsubj) c_4\NN\13714184|the|ampk|inhibitor|compound (l_compound) ampk_1\NN\1740|
T4_T60 CPR:3 phenformin_14\NN\1740| (r_conj) metformin_9\NN\2719105|of|and|aicar|not|phenformin (r_nmod) action_7\NN\30358|the|metformin (r_dobj) prevented_5\VBD\1740|c|action|. (l_nsubj) c_4\NN\13714184|the|ampk|inhibitor|compound (l_compound) ampk_1\NN\1740|
T20_T49 NONE amiloride-sensitive_13\JJ\1740| (r_amod) channels_16\NNS\6251781|of|apical|amiloride-sensitive|na(+|)|enac (r_nmod) inhibition_10\NN\1068773|with|channels (r_nmod) associated_8\VBN\628491|activation|is|inhibition|,|has (l_nsubjpass) activation_4\NN\13561719|alpha1-ampk (l_nmod) alpha1-ampk_6\NN\1740|of
T20_T50 NONE amiloride-sensitive_13\JJ\1740| (r_amod) channels_16\NNS\6251781|of|apical|amiloride-sensitive|na(+|)|enac
T20_T51 NONE amiloride-sensitive_13\JJ\1740| (r_amod) channels_16\NNS\6251781|of|apical|amiloride-sensitive|na(+|)|enac (l_appos) enac_18\NN\1740|(|)
T21_T49 NONE )_15\-RRB-\1740| (r_punct) channels_16\NNS\6251781|of|apical|amiloride-sensitive|na(+|)|enac (r_nmod) inhibition_10\NN\1068773|with|channels (r_nmod) associated_8\VBN\628491|activation|is|inhibition|,|has (l_nsubjpass) activation_4\NN\13561719|alpha1-ampk (l_nmod) alpha1-ampk_6\NN\1740|of
T21_T50 NONE )_15\-RRB-\1740| (r_punct) channels_16\NNS\6251781|of|apical|amiloride-sensitive|na(+|)|enac
T21_T51 NONE )_15\-RRB-\1740| (r_punct) channels_16\NNS\6251781|of|apical|amiloride-sensitive|na(+|)|enac (l_appos) enac_18\NN\1740|(|)
T22_T49 NONE metformin_30\NN\2719105|of (r_nmod) use_28\NN\407535|for|the|clinical|metformin (r_nmod) implications_24\NNS\5774614|important|use (r_dobj) has_22\VBZ\2108377|which|implications (r_advcl) associated_8\VBN\628491|activation|is|inhibition|,|has (l_nsubjpass) activation_4\NN\13561719|alpha1-ampk (l_nmod) alpha1-ampk_6\NN\1740|of
T22_T50 NONE metformin_30\NN\2719105|of (r_nmod) use_28\NN\407535|for|the|clinical|metformin (r_nmod) implications_24\NNS\5774614|important|use (r_dobj) has_22\VBZ\2108377|which|implications (r_advcl) associated_8\VBN\628491|activation|is|inhibition|,|has (l_nmod) inhibition_10\NN\1068773|with|channels (l_nmod) channels_16\NNS\6251781|of|apical|amiloride-sensitive|na(+|)|enac
T22_T51 NONE metformin_30\NN\2719105|of (r_nmod) use_28\NN\407535|for|the|clinical|metformin (r_nmod) implications_24\NNS\5774614|important|use (r_dobj) has_22\VBZ\2108377|which|implications (r_advcl) associated_8\VBN\628491|activation|is|inhibition|,|has (l_nmod) inhibition_10\NN\1068773|with|channels (l_nmod) channels_16\NNS\6251781|of|apical|amiloride-sensitive|na(+|)|enac (l_appos) enac_18\NN\1740|(|)
T23_T52 NONE aicar_5\NN\1740|by|and|phenformin (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (l_nmod) effects_15\NNS\13245626|with|potential|secondary|conductance (l_nmod) conductance_19\NN\11449002|on|apical|na+|,|activity|and|resistance (l_conj) activity_22\NN\30358|enac (l_compound) enac_21\NN\1740|
T23_T53 CPR:3 aicar_5\NN\1740|by|and|phenformin (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (r_nsubj) have_27\VBP\2108377|effects|consequences|. (l_dobj) consequences_29\NNS\34213|important|use (l_nmod) use_32\NN\407535|for|their|activators (l_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) ampk_37\NN\1740|of
T23_T54 NONE aicar_5\NN\1740|by|and|phenformin (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (r_nsubj) have_27\VBP\2108377|effects|consequences|. (l_dobj) consequences_29\NNS\34213|important|use (l_nmod) use_32\NN\407535|for|their|activators (l_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) systems_40\NNS\3575240|in|cell|component (l_acl:relcl) component_46\NN\5867413|where|na+k+atpase|is|an|important (l_nsubj) na+k+atpase_42\NN\1740|
T24_T52 NONE phenformin_7\NN\1740| (r_conj) aicar_5\NN\1740|by|and|phenformin (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (l_nmod) effects_15\NNS\13245626|with|potential|secondary|conductance (l_nmod) conductance_19\NN\11449002|on|apical|na+|,|activity|and|resistance (l_conj) activity_22\NN\30358|enac (l_compound) enac_21\NN\1740|
T24_T53 CPR:3 phenformin_7\NN\1740| (r_conj) aicar_5\NN\1740|by|and|phenformin (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (r_nsubj) have_27\VBP\2108377|effects|consequences|. (l_dobj) consequences_29\NNS\34213|important|use (l_nmod) use_32\NN\407535|for|their|activators (l_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) ampk_37\NN\1740|of
T24_T54 NONE phenformin_7\NN\1740| (r_conj) aicar_5\NN\1740|by|and|phenformin (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (r_nsubj) have_27\VBP\2108377|effects|consequences|. (l_dobj) consequences_29\NNS\34213|important|use (l_nmod) use_32\NN\407535|for|their|activators (l_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) systems_40\NNS\3575240|in|cell|component (l_acl:relcl) component_46\NN\5867413|where|na+k+atpase|is|an|important (l_nsubj) na+k+atpase_42\NN\1740|
T25_T52 NONE i(ouabain_9\NN\1740|on|) (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (l_nmod) effects_15\NNS\13245626|with|potential|secondary|conductance (l_nmod) conductance_19\NN\11449002|on|apical|na+|,|activity|and|resistance (l_conj) activity_22\NN\30358|enac (l_compound) enac_21\NN\1740|
T25_T53 CPR:3 i(ouabain_9\NN\1740|on|) (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (r_nsubj) have_27\VBP\2108377|effects|consequences|. (l_dobj) consequences_29\NNS\34213|important|use (l_nmod) use_32\NN\407535|for|their|activators (l_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) ampk_37\NN\1740|of
T25_T54 NONE i(ouabain_9\NN\1740|on|) (r_nmod) evoked_3\VBN\1617192|aicar|i(ouabain (r_acl) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (r_nsubj) have_27\VBP\2108377|effects|consequences|. (l_dobj) consequences_29\NNS\34213|important|use (l_nmod) use_32\NN\407535|for|their|activators (l_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) systems_40\NNS\3575240|in|cell|component (l_acl:relcl) component_46\NN\5867413|where|na+k+atpase|is|an|important (l_nsubj) na+k+atpase_42\NN\1740|
T26_T52 NONE na+_18\NN\1740| (r_compound) conductance_19\NN\11449002|on|apical|na+|,|activity|and|resistance (l_conj) activity_22\NN\30358|enac (l_compound) enac_21\NN\1740|
T26_T53 NONE na+_18\NN\1740| (r_compound) conductance_19\NN\11449002|on|apical|na+|,|activity|and|resistance (r_nmod) effects_15\NNS\13245626|with|potential|secondary|conductance (r_nmod) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (r_nsubj) have_27\VBP\2108377|effects|consequences|. (l_dobj) consequences_29\NNS\34213|important|use (l_nmod) use_32\NN\407535|for|their|activators (l_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) ampk_37\NN\1740|of
T26_T54 NONE na+_18\NN\1740| (r_compound) conductance_19\NN\11449002|on|apical|na+|,|activity|and|resistance (r_nmod) effects_15\NNS\13245626|with|potential|secondary|conductance (r_nmod) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (r_nsubj) have_27\VBP\2108377|effects|consequences|. (l_dobj) consequences_29\NNS\34213|important|use (l_nmod) use_32\NN\407535|for|their|activators (l_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) systems_40\NNS\3575240|in|cell|component (l_acl:relcl) component_46\NN\5867413|where|na+k+atpase|is|an|important (l_nsubj) na+k+atpase_42\NN\1740|
T28_T52 NONE na+k+atpase_42\NN\1740| (r_nsubj) component_46\NN\5867413|where|na+k+atpase|is|an|important (r_acl:relcl) systems_40\NNS\3575240|in|cell|component (r_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (r_nmod) use_32\NN\407535|for|their|activators (r_nmod) consequences_29\NNS\34213|important|use (r_dobj) have_27\VBP\2108377|effects|consequences|. (l_nsubj) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (l_nmod) effects_15\NNS\13245626|with|potential|secondary|conductance (l_nmod) conductance_19\NN\11449002|on|apical|na+|,|activity|and|resistance (l_conj) activity_22\NN\30358|enac (l_compound) enac_21\NN\1740|
T28_T53 NONE na+k+atpase_42\NN\1740| (r_nsubj) component_46\NN\5867413|where|na+k+atpase|is|an|important (r_acl:relcl) systems_40\NNS\3575240|in|cell|component (r_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) ampk_37\NN\1740|of
T28_T54 NONE na+k+atpase_42\NN\1740|
T29_T52 NONE na+k+atpase_42\NN\1740| (r_nsubj) component_46\NN\5867413|where|na+k+atpase|is|an|important (r_acl:relcl) systems_40\NNS\3575240|in|cell|component (r_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (r_nmod) use_32\NN\407535|for|their|activators (r_nmod) consequences_29\NNS\34213|important|use (r_dobj) have_27\VBP\2108377|effects|consequences|. (l_nsubj) effects_2\NNS\13245626|additional|pharmacological|evoked|,|effects|, (l_nmod) effects_15\NNS\13245626|with|potential|secondary|conductance (l_nmod) conductance_19\NN\11449002|on|apical|na+|,|activity|and|resistance (l_conj) activity_22\NN\30358|enac (l_compound) enac_21\NN\1740|
T29_T53 NONE na+k+atpase_42\NN\1740| (r_nsubj) component_46\NN\5867413|where|na+k+atpase|is|an|important (r_acl:relcl) systems_40\NNS\3575240|in|cell|component (r_nmod) activators_35\NNS\19613|as|pharmacological|ampk|systems (l_nmod) ampk_37\NN\1740|of
T29_T54 NONE na+k+atpase_42\NN\1740|
23538201
T5_T29 NONE iron_3\NN\14625458| (r_compound) restriction_4\NN\5846054|dietary|iron (r_conj) phlebotomy_0\NN\698004|and|restriction (r_nsubj) reduces_5\VBZ\441445|phlebotomy|transaminase|. (l_dobj) transaminase_7\NN\15077571|serum|patients
15700891
T2_T6 NONE glucose_14\NN\14710501| (r_compound) excursion_15\NN\306426|postprandial|plasma|glucose|insulinotropism|,|suppression|,|and|slowing (l_conj) suppression_19\NN\13489037|glucagon (l_nmod) glucagon_22\NN\5407119|of|plasma
7554708
T17_T25 CPR:4 nabumetone_9\NN\3828465| (r_dep) drug_8\NN\14778436|of|the|anti-inflammatory|nabumetone (r_nmod) metabolite_4\NN\20090|the|active|drug (r_nsubjpass) characterized_12\VBN\609683|background|:|metabolite|has|been|inhibitor|. (l_nmod) inhibitor_16\NN\20090|as|a|selective|synthase (l_nmod) synthase_22\NN\1740|of|the|inducible|prostaglandin|h|pghs
T17_T28 CPR:4 nabumetone_9\NN\3828465| (r_dep) drug_8\NN\14778436|of|the|anti-inflammatory|nabumetone (r_nmod) metabolite_4\NN\20090|the|active|drug (r_nsubjpass) characterized_12\VBN\609683|background|:|metabolite|has|been|inhibitor|. (l_nmod) inhibitor_16\NN\20090|as|a|selective|synthase (l_nmod) synthase_22\NN\1740|of|the|inducible|prostaglandin|h|pghs (l_appos) pghs_24\NN\1740|(|)
T6_T25 NONE prostaglandin_20\NN\5414534| (r_compound) synthase_22\NN\1740|of|the|inducible|prostaglandin|h|pghs
T6_T28 NONE prostaglandin_20\NN\5414534| (r_compound) synthase_22\NN\1740|of|the|inducible|prostaglandin|h|pghs (l_appos) pghs_24\NN\1740|(|)
T11_T30 NONE b2_13\NN\1740|(|11-dehydro-thromboxane|txb2|) (r_dep) platelet_10\NN\5432736|of|b2|and|renal (r_amod) metabolism_30\NN\13526110|platelet|arachidonate (r_nmod) products_8\NNS\3076708|of|metabolism (r_nmod) excretion_6\NN\13466586|the|urinary|products (r_dobj) measured_3\VBD\697589|methods|we|excretion|indexes|. (l_nmod) indexes_34\NNS\13850304|as|in|pathway (l_nmod) pathway_39\NN\5483677|of|the|constitutive|pghs-1 (l_compound) pghs-1_38\NN\1740|
T12_T30 NONE txb2_15\NN\1740|[|] (r_appos) b2_13\NN\1740|(|11-dehydro-thromboxane|txb2|) (r_dep) platelet_10\NN\5432736|of|b2|and|renal (r_amod) metabolism_30\NN\13526110|platelet|arachidonate (r_nmod) products_8\NNS\3076708|of|metabolism (r_nmod) excretion_6\NN\13466586|the|urinary|products (r_dobj) measured_3\VBD\697589|methods|we|excretion|indexes|. (l_nmod) indexes_34\NNS\13850304|as|in|pathway (l_nmod) pathway_39\NN\5483677|of|the|constitutive|pghs-1 (l_compound) pghs-1_38\NN\1740|
T13_T30 NONE alpha_23\NN\6828818|(|prostaglandin|if2|alpha|) (r_dep) renal_19\JJ\1740|alpha (r_conj) platelet_10\NN\5432736|of|b2|and|renal (r_amod) metabolism_30\NN\13526110|platelet|arachidonate (r_nmod) products_8\NNS\3076708|of|metabolism (r_nmod) excretion_6\NN\13466586|the|urinary|products (r_dobj) measured_3\VBD\697589|methods|we|excretion|indexes|. (l_nmod) indexes_34\NNS\13850304|as|in|pathway (l_nmod) pathway_39\NN\5483677|of|the|constitutive|pghs-1 (l_compound) pghs-1_38\NN\1740|
T14_T30 NONE alpha_26\NN\6828818|[|pgf2|] (r_appos) alpha_23\NN\6828818|(|prostaglandin|if2|alpha|) (r_dep) renal_19\JJ\1740|alpha (r_conj) platelet_10\NN\5432736|of|b2|and|renal (r_amod) metabolism_30\NN\13526110|platelet|arachidonate (r_nmod) products_8\NNS\3076708|of|metabolism (r_nmod) excretion_6\NN\13466586|the|urinary|products (r_dobj) measured_3\VBD\697589|methods|we|excretion|indexes|. (l_nmod) indexes_34\NNS\13850304|as|in|pathway (l_nmod) pathway_39\NN\5483677|of|the|constitutive|pghs-1 (l_compound) pghs-1_38\NN\1740|
T15_T30 NONE arachidonate_29\NN\1740| (r_compound) metabolism_30\NN\13526110|platelet|arachidonate (r_nmod) products_8\NNS\3076708|of|metabolism (r_nmod) excretion_6\NN\13466586|the|urinary|products (r_dobj) measured_3\VBD\697589|methods|we|excretion|indexes|. (l_nmod) indexes_34\NNS\13850304|as|in|pathway (l_nmod) pathway_39\NN\5483677|of|the|constitutive|pghs-1 (l_compound) pghs-1_38\NN\1740|
T16_T31 CPR:9 txb2_5\NN\1740|of (r_nmod) production_3\NN\30358|the|txb2|clotting (r_nsubjpass) assessed_11\VBN\670261|moreover|,|production|was|index|ex|. (l_nmod) index_14\NN\13850304|as|an|activity (l_nmod) activity_18\NN\30358|of|the|cyclooxygenase|pghs-1 (l_compound) cyclooxygenase_17\NN\14732946|
T16_T32 CPR:9 txb2_5\NN\1740|of (r_nmod) production_3\NN\30358|the|txb2|clotting (r_nsubjpass) assessed_11\VBN\670261|moreover|,|production|was|index|ex|. (l_nmod) index_14\NN\13850304|as|an|activity (l_nmod) activity_18\NN\30358|of|the|cyclooxygenase|pghs-1 (l_nmod) pghs-1_21\NN\1740|of|platelet
T4_T24 CPR:4 aspirin_5\NN\2707683|of|low-dose|mg|,|inhibitor|, (l_appos) inhibitor_13\NN\20090|a|selective|pghs-1 (l_nmod) pghs-1_16\NN\1740|of|platelet
T5_T24 CPR:9 11-dehydro-txb2_24\NN\1740|of|urinary|and|production|recovered (r_nmod) inhibition_21\NN\1068773|a|cumulative|11-dehydro-txb2 (r_dobj) caused_18\VBD\1617192|administration|inhibition|. (l_nsubj) administration_2\NN\1133281|the|daily|aspirin (l_nmod) aspirin_5\NN\2707683|of|low-dose|mg|,|inhibitor|, (l_appos) inhibitor_13\NN\20090|a|selective|pghs-1 (l_nmod) pghs-1_16\NN\1740|of|platelet
T7_T24 CPR:9 txb2_28\NN\1740| (r_compound) production_29\NN\30358|blood|txb2 (r_conj) 11-dehydro-txb2_24\NN\1740|of|urinary|and|production|recovered (r_nmod) inhibition_21\NN\1068773|a|cumulative|11-dehydro-txb2 (r_dobj) caused_18\VBD\1617192|administration|inhibition|. (l_nsubj) administration_2\NN\1133281|the|daily|aspirin (l_nmod) aspirin_5\NN\2707683|of|low-dose|mg|,|inhibitor|, (l_appos) inhibitor_13\NN\20090|a|selective|pghs-1 (l_nmod) pghs-1_16\NN\1740|of|platelet
T8_T26 CPR:4 nabumetone_2\NN\3828465| (r_nsubj) inhibit_5\VB\2510337|nabumetone|does|dose-dependently|activity (l_dobj) activity_8\NN\30358|the|cyclooxygenase|pghs-1|and (l_compound) cyclooxygenase_7\NN\14732946|
T8_T27 CPR:4 nabumetone_2\NN\3828465| (r_nsubj) inhibit_5\VB\2510337|nabumetone|does|dose-dependently|activity (l_dobj) activity_8\NN\30358|the|cyclooxygenase|pghs-1|and (l_nmod) pghs-1_11\NN\1740|of|platelet|subjects
23368996
16829128
T1_T10 CPR:3 menthol_0\NN\14818238|,|known|, (r_nsubj) activates_9\VBZ\1641914|menthol|trpm8|. (l_dobj) trpm8_10\NN\1740|-|channel
T1_T11 CPR:3 menthol_0\NN\14818238|,|known|, (r_nsubj) activates_9\VBZ\1641914|menthol|trpm8|. (l_dobj) trpm8_10\NN\1740|-|channel (l_appos) channel_16\NN\6251781|-a|cold-activated|thermotrp|ion
T2_T12 NONE menthol_10\NN\14818238|of (r_nmod) role_8\NN\719494|a|paradoxical|menthol|modulation (r_dobj) demonstrate_5\VBP\2137132|however|,|studies|role|,|and|show (l_conj) show_21\VBP\2137132|here|,|we|activates|. (l_ccomp) activates_25\VBZ\1641914|that|menthol|also|trpv3 (l_dobj) trpv3_27\NN\1740|heat-activated
T3_T12 CPR:3 menthol_23\NN\14818238| (r_nsubj) activates_25\VBZ\1641914|that|menthol|also|trpv3 (l_dobj) trpv3_27\NN\1740|heat-activated
T4_T13 CPR:4 menthol_4\NN\14818238| (r_nsubj) inhibits_5\VBZ\2510337|that|menthol|trpa1|,|explaining (l_dobj) trpa1_6\NN\1740|
T5_T13 NONE menthol_13\NN\14818238|of (r_nmod) use_11\NN\407535|the|menthol|analgesic (r_dobj) explaining_9\VBG\831651|potentially|use (r_advcl) inhibits_5\VBZ\2510337|that|menthol|trpa1|,|explaining (l_dobj) trpa1_6\NN\1740|
T6_T14 CPR:3 menthol_2\NN\14818238|to (r_nmod) similar_0\JJ\1740|menthol (r_advmod) modulate_23\VBP\1724459|similar|,|camphor|also|thermotrps|. (l_nsubj) camphor_5\NN\14894481|both|and|cinnamaldehyde|(|reported|) (l_acl) reported_10\VBN\831651|initially|activators (l_xcomp) activators_14\NNS\19613|to|be|specific|trpv3|,|respectively (l_nmod) trpv3_16\NN\1740|of|and|trpa1
T6_T15 CPR:3 menthol_2\NN\14818238|to (r_nmod) similar_0\JJ\1740|menthol (r_advmod) modulate_23\VBP\1724459|similar|,|camphor|also|thermotrps|. (l_nsubj) camphor_5\NN\14894481|both|and|cinnamaldehyde|(|reported|) (l_acl) reported_10\VBN\831651|initially|activators (l_xcomp) activators_14\NNS\19613|to|be|specific|trpv3|,|respectively (l_nmod) trpv3_16\NN\1740|of|and|trpa1 (l_conj) trpa1_18\NN\1740|
T6_T16 NONE menthol_2\NN\14818238|to (r_nmod) similar_0\JJ\1740|menthol (r_advmod) modulate_23\VBP\1724459|similar|,|camphor|also|thermotrps|. (l_dobj) thermotrps_25\NNS\1740|other
T7_T14 CPR:3 camphor_5\NN\14894481|both|and|cinnamaldehyde|(|reported|) (l_acl) reported_10\VBN\831651|initially|activators (l_xcomp) activators_14\NNS\19613|to|be|specific|trpv3|,|respectively (l_nmod) trpv3_16\NN\1740|of|and|trpa1
T7_T15 CPR:3 camphor_5\NN\14894481|both|and|cinnamaldehyde|(|reported|) (l_acl) reported_10\VBN\831651|initially|activators (l_xcomp) activators_14\NNS\19613|to|be|specific|trpv3|,|respectively (l_nmod) trpv3_16\NN\1740|of|and|trpa1 (l_conj) trpa1_18\NN\1740|
T7_T16 NONE camphor_5\NN\14894481|both|and|cinnamaldehyde|(|reported|) (r_nsubj) modulate_23\VBP\1724459|similar|,|camphor|also|thermotrps|. (l_dobj) thermotrps_25\NNS\1740|other
T8_T14 CPR:3 cinnamaldehyde_7\NN\1740| (r_conj) camphor_5\NN\14894481|both|and|cinnamaldehyde|(|reported|) (l_acl) reported_10\VBN\831651|initially|activators (l_xcomp) activators_14\NNS\19613|to|be|specific|trpv3|,|respectively (l_nmod) trpv3_16\NN\1740|of|and|trpa1
T8_T15 CPR:3 cinnamaldehyde_7\NN\1740| (r_conj) camphor_5\NN\14894481|both|and|cinnamaldehyde|(|reported|) (l_acl) reported_10\VBN\831651|initially|activators (l_xcomp) activators_14\NNS\19613|to|be|specific|trpv3|,|respectively (l_nmod) trpv3_16\NN\1740|of|and|trpa1 (l_conj) trpa1_18\NN\1740|
T8_T16 NONE cinnamaldehyde_7\NN\1740| (r_conj) camphor_5\NN\14894481|both|and|cinnamaldehyde|(|reported|) (r_nsubj) modulate_23\VBP\1724459|similar|,|camphor|also|thermotrps|. (l_dobj) thermotrps_25\NNS\1740|other
22677475
23470280
T11_T26 NONE catecholamines_4\NNS\5407119| (r_conj) factor_2\NN\7326557|corticotropin|releasing|and|catecholamines
T5_T18 NONE catecholamine_14\NN\5407119| (r_compound) signaling_15\NN\33020|catecholamine (r_conj) factor_9\NN\7326557|by|corticotropin|releasing|crf|and|signaling
T5_T19 NONE catecholamine_14\NN\5407119| (r_compound) signaling_15\NN\33020|catecholamine (r_conj) factor_9\NN\7326557|by|corticotropin|releasing|crf|and|signaling (l_appos) crf_11\NN\1740|(|)
T6_T20 NONE dopamine_23\NN\14807737|da (r_conj) crf_21\NN\1740|,|dopamine|and|isoproterenol|all
T6_T21 NONE dopamine_23\NN\14807737|da (r_conj) crf_21\NN\1740|,|dopamine|and|isoproterenol|all (l_conj) isoproterenol_32\NN\3740161|the|β-adrenergic|receptor|agonist|iso (l_compound) receptor_30\NN\5225602|
T7_T20 NONE isoproterenol_32\NN\3740161|the|β-adrenergic|receptor|agonist|iso (r_conj) crf_21\NN\1740|,|dopamine|and|isoproterenol|all
T7_T21 NONE isoproterenol_32\NN\3740161|the|β-adrenergic|receptor|agonist|iso (l_compound) receptor_30\NN\5225602|
T8_T20 NONE iso_34\NN\1740|(|) (r_appos) isoproterenol_32\NN\3740161|the|β-adrenergic|receptor|agonist|iso (r_conj) crf_21\NN\1740|,|dopamine|and|isoproterenol|all
T8_T21 NONE iso_34\NN\1740|(|) (r_appos) isoproterenol_32\NN\3740161|the|β-adrenergic|receptor|agonist|iso (l_compound) receptor_30\NN\5225602|
T9_T20 NONE glutamate_57\NN\15010703| (r_compound) release_58\NN\3748886|presynaptic|glutamate (r_dobj) increase_55\VBP\169651|they|release (r_ccomp) suggesting_53\VBG\1010118|increase (r_advcl) enhance_37\VBP\227165|that|crf|frequency|altering|,|suggesting (l_nsubj) crf_21\NN\1740|,|dopamine|and|isoproterenol|all
T9_T21 NONE glutamate_57\NN\15010703| (r_compound) release_58\NN\3748886|presynaptic|glutamate (r_dobj) increase_55\VBP\169651|they|release (r_ccomp) suggesting_53\VBG\1010118|increase (r_advcl) enhance_37\VBP\227165|that|crf|frequency|altering|,|suggesting (l_nsubj) crf_21\NN\1740|,|dopamine|and|isoproterenol|all (l_conj) isoproterenol_32\NN\3740161|the|β-adrenergic|receptor|agonist|iso (l_compound) receptor_30\NN\5225602|
T10_T12 NONE catecholamines_13\NNS\5407119|of (r_nmod) effect_11\NN\34213|the|catecholamines|transmission (r_dobj) mediate_9\VBP\761713|that|crfrs|effect (r_ccomp) suggests_6\VBZ\1010118|while|work|mediate (r_advcl) failed_31\VBD\1798936|suggests|,|blockade|alter|. (l_nsubj) blockade_25\NN\952963|crfrs|ceal (l_nmod) crfrs_27\NNS\1740|of
T10_T25 NONE catecholamines_13\NNS\5407119|of (r_nmod) effect_11\NN\34213|the|catecholamines|transmission (r_dobj) mediate_9\VBP\761713|that|crfrs|effect (l_nsubj) crfrs_8\NNS\1740|
T1_T12 NONE iso_39\NN\1740| (r_conj) da_37\NN\10484858|of|and|iso (r_nmod) effects_35\NNS\13245626|da|transmission (r_dobj) alter_34\VB\126264|to|significantly|effects (r_xcomp) failed_31\VBD\1798936|suggests|,|blockade|alter|. (l_nsubj) blockade_25\NN\952963|crfrs|ceal (l_nmod) crfrs_27\NNS\1740|of
T1_T25 NONE iso_39\NN\1740| (r_conj) da_37\NN\10484858|of|and|iso (r_nmod) effects_35\NNS\13245626|da|transmission (r_dobj) alter_34\VB\126264|to|significantly|effects (r_xcomp) failed_31\VBD\1798936|suggests|,|blockade|alter|. (l_advcl) suggests_6\VBZ\1010118|while|work|mediate (l_ccomp) mediate_9\VBP\761713|that|crfrs|effect (l_nsubj) crfrs_8\NNS\1740|
T2_T13 NONE catecholamine_4\NN\5407119|and|crf (l_conj) crf_6\NN\1740|
T3_T14 NONE glutamate_4\NN\15010703| (r_compound) release_5\NN\3748886|spontaneous|glutamate|ceal (r_dobj) increased_2\VBD\169651|while|crf|release (l_nsubj) crf_1\NN\1740|
T3_T15 NONE glutamate_4\NN\15010703| (r_compound) release_5\NN\3748886|spontaneous|glutamate|ceal (r_dobj) increased_2\VBD\169651|while|crf|release (r_advcl) caused_11\VBD\1617192|increased|,|crf|changes|release|. (l_nsubj) crf_10\NN\1740|
T4_T14 NONE glutamate_18\NN\15010703| (r_compound) release_19\NN\3748886|to|evoked|glutamate|region (r_nmod) caused_11\VBD\1617192|increased|,|crf|changes|release|. (l_advcl) increased_2\VBD\169651|while|crf|release (l_nsubj) crf_1\NN\1740|
T4_T15 NONE glutamate_18\NN\15010703| (r_compound) release_19\NN\3748886|to|evoked|glutamate|region (r_nmod) caused_11\VBD\1617192|increased|,|crf|changes|release|. (l_nsubj) crf_10\NN\1740|
23103563
T11_T25 CPR:3 ibandronate_0\NN\1740| (r_nsubj) increases_1\VBZ\169651|ibandronate|expression|mechanisms|cells|. (l_dobj) expression_3\NN\4679549|the|fas (l_nmod) fas_8\NN\14304060|of|the|gene
T8_T23 NONE geranylgeranyl-pyrophosphate_28\NN\1740|by|both|and|farnesylpyrophosphate (r_nmod) re-isoprenylation_25\NN\1740|by|geranylgeranyl-pyrophosphate (r_nmod) rescued_23\VBN\2551832|which|was|re-isoprenylation (r_acl:relcl) down-regulation_17\NN\1740|to|dnmt1|,|rescued (r_nmod) due_15\JJ\1740|that|was|down-regulation (r_acl:relcl) demethylation_12\NN\1740|of|epigenetic|dna|due (r_nmod) result_8\NN\34213|as|a|demethylation (r_nmod) found_2\VBD\2426171|further|we|stimulation|result|. (l_dobj) stimulation_3\NN\242808|fas-expression (l_nmod) fas-expression_5\NN\1740|of
T8_T24 CPR:3 geranylgeranyl-pyrophosphate_28\NN\1740|by|both|and|farnesylpyrophosphate (r_nmod) re-isoprenylation_25\NN\1740|by|geranylgeranyl-pyrophosphate (r_nmod) rescued_23\VBN\2551832|which|was|re-isoprenylation (r_acl:relcl) down-regulation_17\NN\1740|to|dnmt1|,|rescued (l_nmod) dnmt1_19\NN\1740|of
T9_T23 NONE farnesylpyrophosphate_30\NN\1740| (r_conj) geranylgeranyl-pyrophosphate_28\NN\1740|by|both|and|farnesylpyrophosphate (r_nmod) re-isoprenylation_25\NN\1740|by|geranylgeranyl-pyrophosphate (r_nmod) rescued_23\VBN\2551832|which|was|re-isoprenylation (r_acl:relcl) down-regulation_17\NN\1740|to|dnmt1|,|rescued (r_nmod) due_15\JJ\1740|that|was|down-regulation (r_acl:relcl) demethylation_12\NN\1740|of|epigenetic|dna|due (r_nmod) result_8\NN\34213|as|a|demethylation (r_nmod) found_2\VBD\2426171|further|we|stimulation|result|. (l_dobj) stimulation_3\NN\242808|fas-expression (l_nmod) fas-expression_5\NN\1740|of
T9_T24 CPR:3 farnesylpyrophosphate_30\NN\1740| (r_conj) geranylgeranyl-pyrophosphate_28\NN\1740|by|both|and|farnesylpyrophosphate (r_nmod) re-isoprenylation_25\NN\1740|by|geranylgeranyl-pyrophosphate (r_nmod) rescued_23\VBN\2551832|which|was|re-isoprenylation (r_acl:relcl) down-regulation_17\NN\1740|to|dnmt1|,|rescued (l_nmod) dnmt1_19\NN\1740|of
T10_T12 NONE ibandronate_3\NN\1740| (r_nsubj) affect_6\VB\126264|contrast|,|ibandronate|did|not|fas|. (l_dobj) fas_7\NN\14304060|and|expression|cells
T10_T13 NONE ibandronate_3\NN\1740| (r_nsubj) affect_6\VB\126264|contrast|,|ibandronate|did|not|fas|. (l_dobj) fas_7\NN\14304060|and|expression|cells (l_conj) expression_10\NN\4679549|dnmt1 (l_compound) dnmt1_9\NN\1740|
T1_T14 NONE bisphosphonates_3\NNS\1740| (r_nsubj) induce_11\VBP\1627355|that|bisphosphonates|modulation|apoptosis|dna-cpg-demethylation (l_nmod) modulation_5\NN\7044917|via|activity (l_nmod) activity_8\NN\30358|of|the|small-gtpases (l_nmod) small-gtpases_10\NNS\1740|of
T1_T15 NONE bisphosphonates_3\NNS\1740| (r_nsubj) induce_11\VBP\1627355|that|bisphosphonates|modulation|apoptosis|dna-cpg-demethylation (l_nmod) dna-cpg-demethylation_17\NN\1740|by|and|stimulation
T1_T16 CPR:3 bisphosphonates_3\NNS\1740| (r_nsubj) induce_11\VBP\1627355|that|bisphosphonates|modulation|apoptosis|dna-cpg-demethylation (l_nmod) dna-cpg-demethylation_17\NN\1740|by|and|stimulation (l_conj) stimulation_19\NN\242808|fas-expression (l_nmod) fas-expression_21\NN\1740|of
T2_T14 NONE dna-cpg-demethylation_17\NN\1740|by|and|stimulation (r_nmod) induce_11\VBP\1627355|that|bisphosphonates|modulation|apoptosis|dna-cpg-demethylation (l_nmod) modulation_5\NN\7044917|via|activity (l_nmod) activity_8\NN\30358|of|the|small-gtpases (l_nmod) small-gtpases_10\NNS\1740|of
T2_T15 NONE dna-cpg-demethylation_17\NN\1740|by|and|stimulation
T2_T16 NONE dna-cpg-demethylation_17\NN\1740|by|and|stimulation (l_conj) stimulation_19\NN\242808|fas-expression (l_nmod) fas-expression_21\NN\1740|of
T3_T17 NONE farnesyl-transferase-inhibition_11\NN\1740|of
15367040
T3_T6 NONE levetiracetam_4\NN\1740|modulator (l_nmod) modulator_10\NN\1740|as|a|synaptic|vesicle|protein (l_compound) protein_9\NN\14944888|
T1_T4 NONE levetiracetam_0\NN\1740| (r_nsubj) binds_1\VBZ\1290422|levetiracetam|affinity|protein|. (l_nmod) protein_11\NN\14944888|to|a|synaptic|vesicle|known|,|thought
T1_T5 NONE levetiracetam_0\NN\1740| (r_nsubj) binds_1\VBZ\1290422|levetiracetam|affinity|protein|. (l_nmod) protein_11\NN\14944888|to|a|synaptic|vesicle|known|,|thought (l_acl) known_12\VBN\2110220|sv2a (l_nmod) sv2a_14\NN\1740|as
22943130
T1_T7 NONE udp-glucuronosyltransferases_1\NNS\1740|ugts (r_nsubj) group_7\NN\2137|udp-glucuronosyltransferases|are|a|enzymes|. (r_parataxis) _0\_SP\1740|group (r_nsubj) describes_31\VBZ\1001294||report|approach|using|. (l_dobj) approach_33\NN\940842|an|identification (l_nmod) identification_36\NN\151497|for|the|and|quantitation|ugt1a1 (l_nmod) ugt1a1_42\NN\1740|of|human|matrices
T1_T8 NONE udp-glucuronosyltransferases_1\NNS\1740|ugts
T1_T9 NONE udp-glucuronosyltransferases_1\NNS\1740|ugts (l_appos) ugts_3\NNS\1740|(|)
23470776
T3_T8 NONE oxytocin_3\NN\5407119| (r_compound) gene_5\NN\8459252|oxytocin|receptor (l_compound) receptor_4\NN\5225602|
T3_T9 NONE oxytocin_3\NN\5407119| (r_compound) gene_5\NN\8459252|oxytocin|receptor (r_compound) polymorphism_9\NN\11418750|gene|(|oxtr|) (l_compound) oxtr_7\NN\1740|
T1_T5 NONE oxytocin_4\NN\5407119| (r_compound) gene_6\NN\8459252|oxytocin|receptor|oxtr (l_compound) receptor_5\NN\5225602|
T1_T6 NONE oxytocin_4\NN\5407119| (r_compound) gene_6\NN\8459252|oxytocin|receptor|oxtr (l_appos) oxtr_8\NN\1740|(|)
T2_T5 NONE nucleotide_11\NN\14850483| (r_compound) polymorphism_12\NN\11418750|gene|single|nucleotide|snp (l_compound) gene_6\NN\8459252|oxytocin|receptor|oxtr (l_compound) receptor_5\NN\5225602|
T2_T6 NONE nucleotide_11\NN\14850483| (r_compound) polymorphism_12\NN\11418750|gene|single|nucleotide|snp (l_compound) gene_6\NN\8459252|oxytocin|receptor|oxtr (l_appos) oxtr_8\NN\1740|(|)
23386248
T12_T26 NONE 5-fluorouracil/irinotecan-based_16\NN\1740| (r_amod) regimens_17\NNS\5898568|with|5-fluorouracil/irinotecan-based (r_nmod) treated_14\VBN\2376958|regimens (r_acl) patients_13\NNS\9898892|in|metastatic|cancer|treated (r_nmod) toxicity_8\NN\13576101|with|irinotecan-induced|hematological|patients (r_nmod) associated_4\VBN\628491|toxicity (r_acl) haplotype_3\NN\7963711|the|ugt1a|associated (l_compound) ugt1a_2\NN\1740|
T13_T26 NONE 5-fluorouracil/irinotecan-based_16\NN\1740| (r_amod) regimens_17\NNS\5898568|with|5-fluorouracil/irinotecan-based (r_nmod) treated_14\VBN\2376958|regimens (r_acl) patients_13\NNS\9898892|in|metastatic|cancer|treated (r_nmod) toxicity_8\NN\13576101|with|irinotecan-induced|hematological|patients (r_nmod) associated_4\VBN\628491|toxicity (r_acl) haplotype_3\NN\7963711|the|ugt1a|associated (l_compound) ugt1a_2\NN\1740|
T14_T26 NONE irinotecan-induced_6\JJ\1740| (r_amod) toxicity_8\NN\13576101|with|irinotecan-induced|hematological|patients (r_nmod) associated_4\VBN\628491|toxicity (r_acl) haplotype_3\NN\7963711|the|ugt1a|associated (l_compound) ugt1a_2\NN\1740|
T10_T20 NONE irinotecan_12\NN\1740| (r_compound) pharmacogenetics_13\NNS\6075527|in|irinotecan (r_nmod) importance_2\NN\5138488|despite|the|1a1|pharmacogenetics (l_nmod) 1a1_8\NN\1740|of|udp-glucuronosyltransferase|*
T3_T20 NONE udp-glucuronosyltransferase_4\NN\1740|ugt (r_compound) 1a1_8\NN\1740|of|udp-glucuronosyltransferase|*
T1_T18 NONE irinotecan_17\NN\1740| (r_compound) toxicity_18\NN\13576101|irinotecan (r_dobj) influence_16\VB\137313|that|snps|may|toxicity|and|considered (l_nsubj) snps_5\NNS\11493266|specific|ugt1a|,|other|, (l_nmod) ugt1a_7\NN\1740|in
T1_T19 NONE irinotecan_17\NN\1740| (r_compound) toxicity_18\NN\13576101|irinotecan (r_dobj) influence_16\VB\137313|that|snps|may|toxicity|and|considered (l_nsubj) snps_5\NNS\11493266|specific|ugt1a|,|other|, (l_amod) other_9\JJ\1740|* (l_nmod) *_12\$\1740|than|ugt1a1|28 (l_compound) ugt1a1_11\NN\1740|
23403092
T9_T20 CPR:3 deoxynivalenol_3\NN\1740| (r_dep) contaminant_2\NN\14580897|the|food|deoxynivalenol (r_nsubj) activates_4\VBZ\1641914|contaminant|kinases|:|interest|. (l_dobj) kinases_9\NNS\14732946|the|mitogen|activated|protein|intestine
T3_T14 NONE don_22\NN\10127273|of (r_nmod) doses_20\NNS\3740161|of|low|don (r_nmod) ability_17\NN\4723816|the|doses|induce (l_acl) induce_24\VB\1627355|to|changes|intestine|and|activate (l_conj) activate_32\VB\1641914|to|erk (l_dobj) erk_35\NN\1740|the|mapk|1/2|,|p38|and|jnk (l_compound) mapk_34\NN\1740|
T3_T15 NONE don_22\NN\10127273|of (r_nmod) doses_20\NNS\3740161|of|low|don (r_nmod) ability_17\NN\4723816|the|doses|induce (l_acl) induce_24\VB\1627355|to|changes|intestine|and|activate (l_conj) activate_32\VB\1641914|to|erk (l_dobj) erk_35\NN\1740|the|mapk|1/2|,|p38|and|jnk (l_nummod) 1/2_36\CD\1740|
T3_T16 NONE don_22\NN\10127273|of (r_nmod) doses_20\NNS\3740161|of|low|don (r_nmod) ability_17\NN\4723816|the|doses|induce (l_acl) induce_24\VB\1627355|to|changes|intestine|and|activate (l_conj) activate_32\VB\1641914|to|erk (l_dobj) erk_35\NN\1740|the|mapk|1/2|,|p38|and|jnk (l_conj) p38_38\NN\1740|
T3_T17 NONE don_22\NN\10127273|of (r_nmod) doses_20\NNS\3740161|of|low|don (r_nmod) ability_17\NN\4723816|the|doses|induce (l_acl) induce_24\VB\1627355|to|changes|intestine|and|activate (l_conj) activate_32\VB\1641914|to|erk (l_dobj) erk_35\NN\1740|the|mapk|1/2|,|p38|and|jnk (l_conj) jnk_40\NN\1740|
T2_T11 CPR:3 don_16\NN\10127273|to (r_nmod) exposure_11\NN\5042871|in|tissue|don (r_nsubj) lead_17\VBP\1752884|that|exposure|lesions (l_nmod) lesions_21\NNS\14204950|to|similar|intestinal|and|activation (l_conj) activation_23\NN\13561719|mapk (l_nmod) mapk_25\NN\1740|of
22989703
T15_T24 CPR:4 acids_2\NNS\14818238|both|apo-lycopenoic (r_nsubj) decreased_4\VBD\169651|acids|also|production|and|reduced|. (l_conj) reduced_12\VBD\441445|increase (l_dobj) increase_14\NN\13576355|the|expressions (l_nmod) expressions_19\NNS\4679549|in|nox-4|caused (l_compound) nox-4_16\NN\1740|and|cox-2
T15_T25 CPR:4 acids_2\NNS\14818238|both|apo-lycopenoic (r_nsubj) decreased_4\VBD\169651|acids|also|production|and|reduced|. (l_conj) reduced_12\VBD\441445|increase (l_dobj) increase_14\NN\13576355|the|expressions (l_nmod) expressions_19\NNS\4679549|in|nox-4|caused (l_compound) nox-4_16\NN\1740|and|cox-2 (l_conj) cox-2_18\NN\14737847|
T16_T24 NONE 8-ohdg_9\NN\1740| (r_compound) formation_10\NN\7938773|8-ohdg (r_appos) production_7\NN\30358|cse-induced|ros|,|formation (r_dobj) decreased_4\VBD\169651|acids|also|production|and|reduced|. (l_conj) reduced_12\VBD\441445|increase (l_dobj) increase_14\NN\13576355|the|expressions (l_nmod) expressions_19\NNS\4679549|in|nox-4|caused (l_compound) nox-4_16\NN\1740|and|cox-2
T16_T25 NONE 8-ohdg_9\NN\1740| (r_compound) formation_10\NN\7938773|8-ohdg (r_appos) production_7\NN\30358|cse-induced|ros|,|formation (r_dobj) decreased_4\VBD\169651|acids|also|production|and|reduced|. (l_conj) reduced_12\VBD\441445|increase (l_dobj) increase_14\NN\13576355|the|expressions (l_nmod) expressions_19\NNS\4679549|in|nox-4|caused (l_compound) nox-4_16\NN\1740|and|cox-2 (l_conj) cox-2_18\NN\14737847|
22749926
T8_T11 CPR:4 nicotine_14\NN\14712692| (r_compound) group_15\NN\2137|in|the|nicotine (r_nmod) showed_5\VBD\2137132|recordings|activity|group|compared|. (l_dobj) activity_8\NN\30358|reduced|alpha|and|latencies (l_conj) latencies_11\NNS\15269513|p300 (l_compound) p300_10\NN\1740|
T2_T10 CPR:3 nicotine_7\NN\14712692|of (r_nmod) consumption_5\NN\13440063|oral|nicotine (r_nsubj) enhances_8\VBZ\227165|that|consumption|efficacy (l_dobj) efficacy_10\NN\5199286|the|receptors (l_nmod) receptors_14\NNS\5225602|of|nicotinic|acetylcholine
T3_T10 NONE acetylcholine_13\NN\14807558| (r_compound) receptors_14\NNS\5225602|of|nicotinic|acetylcholine
23228696
T16_T40 CPR:4 metformin-mediated_0\JJ\1740| (r_amod) downregulation_1\NN\1740|metformin-mediated|cross-complementing (l_nmod) cross-complementing_9\NN\1740|of|p38|mitogen-activated|protein|kinase-dependent|excision|repair|1 (l_compound) p38_3\NN\1740|
T16_T41 CPR:4 metformin-mediated_0\JJ\1740| (r_amod) downregulation_1\NN\1740|metformin-mediated|cross-complementing (l_nmod) cross-complementing_9\NN\1740|of|p38|mitogen-activated|protein|kinase-dependent|excision|repair|1 (l_amod) kinase-dependent_6\JJ\1740|
T17_T40 NONE paclitaxel_22\NN\1740|to (r_nmod) sensitizes_16\VBZ\126264|cells|paclitaxel (r_conj) decreases_11\VBZ\169651|downregulation|capacity|and|sensitizes|. (l_nsubj) downregulation_1\NN\1740|metformin-mediated|cross-complementing (l_nmod) cross-complementing_9\NN\1740|of|p38|mitogen-activated|protein|kinase-dependent|excision|repair|1 (l_compound) p38_3\NN\1740|
T17_T41 NONE paclitaxel_22\NN\1740|to (r_nmod) sensitizes_16\VBZ\126264|cells|paclitaxel (r_conj) decreases_11\VBZ\169651|downregulation|capacity|and|sensitizes|. (l_nsubj) downregulation_1\NN\1740|metformin-mediated|cross-complementing (l_nmod) cross-complementing_9\NN\1740|of|p38|mitogen-activated|protein|kinase-dependent|excision|repair|1 (l_amod) kinase-dependent_6\JJ\1740|
T12_T28 NONE platinum-containing_31\JJ\1740| (r_amod) chemotherapy_32\NN\661091|with|platinum-containing (r_nmod) treated_29\VBN\2376958|chemotherapy (r_acl) patients_28\NNS\9898892|in|nsclc|treated (r_nmod) capacity_21\NN\5202497|with|the|dna|repair|and|prognosis|patients (r_nmod) associated_16\VBN\628491|levels|have|been|positively|capacity|. (l_nsubjpass) levels_2\NNS\4916342|high|expression|1|cancers (l_nmod) 1_7\CD\13741022|of|cross-complementary|ercc1
T12_T29 NONE platinum-containing_31\JJ\1740| (r_amod) chemotherapy_32\NN\661091|with|platinum-containing (r_nmod) treated_29\VBN\2376958|chemotherapy (r_acl) patients_28\NNS\9898892|in|nsclc|treated (r_nmod) capacity_21\NN\5202497|with|the|dna|repair|and|prognosis|patients (r_nmod) associated_16\VBN\628491|levels|have|been|positively|capacity|. (l_nsubjpass) levels_2\NNS\4916342|high|expression|1|cancers (l_nmod) 1_7\CD\13741022|of|cross-complementary|ercc1 (l_appos) ercc1_9\NN\1740|(|)
T13_T30 CPR:3 paclitaxel_5\NN\1740| (r_nsubjpass) found_7\VBN\2426171|study|,|paclitaxel|was|increase|. (l_xcomp) increase_9\VB\169651|to|phosphorylation (l_dobj) phosphorylation_10\NN\1740|mapk|as|protein|ercc1 (l_nmod) mapk_21\NN\1740|of|mitogen-activated|protein|kinase|(|mapk|)|kinase|(mkk3/6)-p38 (l_compound) kinase_14\NN\14732946|
T13_T31 NONE paclitaxel_5\NN\1740| (r_nsubjpass) found_7\VBN\2426171|study|,|paclitaxel|was|increase|. (l_xcomp) increase_9\VB\169651|to|phosphorylation (l_dobj) phosphorylation_10\NN\1740|mapk|as|protein|ercc1 (l_nmod) mapk_21\NN\1740|of|mitogen-activated|protein|kinase|(|mapk|)|kinase|(mkk3/6)-p38 (l_compound) (mkk3/6)-p38_20\NN\1740|
T13_T32 CPR:3 paclitaxel_5\NN\1740| (r_nsubjpass) found_7\VBN\2426171|study|,|paclitaxel|was|increase|. (l_xcomp) increase_9\VB\169651|to|phosphorylation (l_dobj) phosphorylation_10\NN\1740|mapk|as|protein|ercc1 (l_nmod) mapk_21\NN\1740|of|mitogen-activated|protein|kinase|(|mapk|)|kinase|(mkk3/6)-p38 (l_compound) (mkk3/6)-p38_20\NN\1740|
T13_T33 CPR:3 paclitaxel_5\NN\1740| (r_nsubjpass) found_7\VBN\2426171|study|,|paclitaxel|was|increase|. (l_xcomp) increase_9\VB\169651|to|phosphorylation (l_dobj) phosphorylation_10\NN\1740|mapk|as|protein|ercc1 (l_nmod) mapk_21\NN\1740|of|mitogen-activated|protein|kinase|(|mapk|)|kinase|(mkk3/6)-p38
T13_T34 CPR:3 paclitaxel_5\NN\1740| (r_nsubjpass) found_7\VBN\2426171|study|,|paclitaxel|was|increase|. (l_xcomp) increase_9\VB\169651|to|phosphorylation (l_dobj) phosphorylation_10\NN\1740|mapk|as|protein|ercc1 (l_nmod) ercc1_30\NN\1740|of|cells
T14_T35 CPR:3 paclitaxel-induced_2\JJ\1740| (r_amod) protein_4\NN\14944888|paclitaxel-induced|ercc1|and|mrna (l_compound) ercc1_3\NN\1740|
T14_T36 NONE paclitaxel-induced_2\JJ\1740| (r_amod) protein_4\NN\14944888|paclitaxel-induced|ercc1|and|mrna (r_compound) levels_7\NNS\4916342|protein (r_nsubj) decreased_9\VBD\169651|moreover|,|levels|significantly|downregulation|. (l_nmod) downregulation_12\NN\1740|via|the|activity|sb202190 (l_nmod) activity_15\NN\30358|of|p38 (l_compound) p38_14\NN\1740|
T14_T37 NONE paclitaxel-induced_2\JJ\1740| (r_amod) protein_4\NN\14944888|paclitaxel-induced|ercc1|and|mrna (r_compound) levels_7\NNS\4916342|protein (r_nsubj) decreased_9\VBD\169651|moreover|,|levels|significantly|downregulation|. (l_nmod) downregulation_12\NN\1740|via|the|activity|sb202190 (l_nmod) sb202190_22\NN\1740|by|either|a|p38|mapk|inhibitor|or|knockdown (l_compound) p38_19\NN\1740|
T14_T38 NONE paclitaxel-induced_2\JJ\1740| (r_amod) protein_4\NN\14944888|paclitaxel-induced|ercc1|and|mrna (r_compound) levels_7\NNS\4916342|protein (r_nsubj) decreased_9\VBD\169651|moreover|,|levels|significantly|downregulation|. (l_nmod) downregulation_12\NN\1740|via|the|activity|sb202190 (l_nmod) sb202190_22\NN\1740|by|either|a|p38|mapk|inhibitor|or|knockdown (l_compound) mapk_20\NN\1740|
T14_T39 NONE paclitaxel-induced_2\JJ\1740| (r_amod) protein_4\NN\14944888|paclitaxel-induced|ercc1|and|mrna (r_compound) levels_7\NNS\4916342|protein (r_nsubj) decreased_9\VBD\169651|moreover|,|levels|significantly|downregulation|. (l_nmod) downregulation_12\NN\1740|via|the|activity|sb202190 (l_nmod) sb202190_22\NN\1740|by|either|a|p38|mapk|inhibitor|or|knockdown (l_conj) knockdown_25\NN\1173038|p38|rna (l_compound) p38_24\NN\1740|
T15_T35 NONE sb202190_22\NN\1740|by|either|a|p38|mapk|inhibitor|or|knockdown (r_nmod) downregulation_12\NN\1740|via|the|activity|sb202190 (r_nmod) decreased_9\VBD\169651|moreover|,|levels|significantly|downregulation|. (l_nsubj) levels_7\NNS\4916342|protein (l_compound) protein_4\NN\14944888|paclitaxel-induced|ercc1|and|mrna (l_compound) ercc1_3\NN\1740|
T15_T36 CPR:4 sb202190_22\NN\1740|by|either|a|p38|mapk|inhibitor|or|knockdown (r_nmod) downregulation_12\NN\1740|via|the|activity|sb202190 (l_nmod) activity_15\NN\30358|of|p38 (l_compound) p38_14\NN\1740|
T15_T37 CPR:4 sb202190_22\NN\1740|by|either|a|p38|mapk|inhibitor|or|knockdown (l_compound) p38_19\NN\1740|
T15_T38 CPR:4 sb202190_22\NN\1740|by|either|a|p38|mapk|inhibitor|or|knockdown (l_compound) mapk_20\NN\1740|
T15_T39 NONE sb202190_22\NN\1740|by|either|a|p38|mapk|inhibitor|or|knockdown (l_conj) knockdown_25\NN\1173038|p38|rna (l_compound) p38_24\NN\1740|
T2_T18 NONE paclitaxel-induced_11\JJ\1740| (r_amod) effect_13\NN\34213|the|paclitaxel-induced|cytotoxic|and|inhibition (r_dobj) enhance_9\VB\227165|to|effect (r_xcomp) found_7\VBN\2426171|inhibition|was|enhance|. (l_nsubjpass) inhibition_1\NN\1068773|specific|ercc1|sirna (l_nmod) ercc1_3\NN\1740|of
T3_T19 CPR:4 metformin_2\NN\2719105| (r_nsubj) able_4\JJ\1740|furthermore|,|metformin|was|decrease|. (l_xcomp) decrease_8\VB\169651|to|only|expression|,|but|augment (l_dobj) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_amod) mapk-mediated_12\JJ\1740|p38 (l_nmod:npmod) p38_11\NN\1740|
T3_T20 CPR:4 metformin_2\NN\2719105| (r_nsubj) able_4\JJ\1740|furthermore|,|metformin|was|decrease|. (l_xcomp) decrease_8\VB\169651|to|only|expression|,|but|augment (l_dobj) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_amod) mapk-mediated_12\JJ\1740|p38
T3_T21 CPR:4 metformin_2\NN\2719105| (r_nsubj) able_4\JJ\1740|furthermore|,|metformin|was|decrease|. (l_xcomp) decrease_8\VB\169651|to|only|expression|,|but|augment (l_dobj) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_compound) ercc1_13\NN\1740|
T4_T19 CPR:3 paclitaxel-induced_10\JJ\1740| (r_amod) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_amod) mapk-mediated_12\JJ\1740|p38 (l_nmod:npmod) p38_11\NN\1740|
T4_T20 CPR:3 paclitaxel-induced_10\JJ\1740| (r_amod) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_amod) mapk-mediated_12\JJ\1740|p38
T4_T21 CPR:3 paclitaxel-induced_10\JJ\1740| (r_amod) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_compound) ercc1_13\NN\1740|
T5_T19 NONE paclitaxel_24\NN\1740|by (r_nmod) induced_22\VBN\1627355|paclitaxel (r_acl) effect_21\NN\34213|the|cytotoxic|induced (r_dobj) augment_18\VB\153263|also|effect (r_conj) decrease_8\VB\169651|to|only|expression|,|but|augment (l_dobj) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_amod) mapk-mediated_12\JJ\1740|p38 (l_nmod:npmod) p38_11\NN\1740|
T5_T20 NONE paclitaxel_24\NN\1740|by (r_nmod) induced_22\VBN\1627355|paclitaxel (r_acl) effect_21\NN\34213|the|cytotoxic|induced (r_dobj) augment_18\VB\153263|also|effect (r_conj) decrease_8\VB\169651|to|only|expression|,|but|augment (l_dobj) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_amod) mapk-mediated_12\JJ\1740|p38
T5_T21 NONE paclitaxel_24\NN\1740|by (r_nmod) induced_22\VBN\1627355|paclitaxel (r_acl) effect_21\NN\34213|the|cytotoxic|induced (r_dobj) augment_18\VB\153263|also|effect (r_conj) decrease_8\VB\169651|to|only|expression|,|but|augment (l_dobj) expression_14\NN\4679549|the|paclitaxel-induced|mapk-mediated|ercc1 (l_compound) ercc1_13\NN\1740|
T6_T22 NONE metformin_22\NN\2719105|by|and|paclitaxel (r_nmod) downregulation_20\NN\1740|ercc1|metformin (r_dobj) abrogate_18\VB\2427334|to|downregulation|as|viability (r_xcomp) able_16\JJ\1740|finally|,|expression|was|abrogate|. (l_nsubj) expression_2\NN\4679549|mkk6|cells (l_nmod) mkk6_6\NN\1740|of|constitutive|activate|or|vectors
T6_T23 NONE metformin_22\NN\2719105|by|and|paclitaxel (r_nmod) downregulation_20\NN\1740|ercc1|metformin (r_dobj) abrogate_18\VB\2427334|to|downregulation|as|viability (r_xcomp) able_16\JJ\1740|finally|,|expression|was|abrogate|. (l_nsubj) expression_2\NN\4679549|mkk6|cells (l_nmod) mkk6_6\NN\1740|of|constitutive|activate|or|vectors (l_conj) vectors_10\NNS\5857459|ha-p38|mapk (l_compound) ha-p38_8\NN\1740|
T6_T24 NONE metformin_22\NN\2719105|by|and|paclitaxel (r_nmod) downregulation_20\NN\1740|ercc1|metformin (r_dobj) abrogate_18\VB\2427334|to|downregulation|as|viability (r_xcomp) able_16\JJ\1740|finally|,|expression|was|abrogate|. (l_nsubj) expression_2\NN\4679549|mkk6|cells (l_nmod) mkk6_6\NN\1740|of|constitutive|activate|or|vectors (l_conj) vectors_10\NNS\5857459|ha-p38|mapk (l_compound) mapk_9\NN\1740|
T6_T25 CPR:4 metformin_22\NN\2719105|by|and|paclitaxel (r_nmod) downregulation_20\NN\1740|ercc1|metformin (l_compound) ercc1_19\NN\1740|
T7_T22 NONE paclitaxel_24\NN\1740| (r_conj) metformin_22\NN\2719105|by|and|paclitaxel (r_nmod) downregulation_20\NN\1740|ercc1|metformin (r_dobj) abrogate_18\VB\2427334|to|downregulation|as|viability (r_xcomp) able_16\JJ\1740|finally|,|expression|was|abrogate|. (l_nsubj) expression_2\NN\4679549|mkk6|cells (l_nmod) mkk6_6\NN\1740|of|constitutive|activate|or|vectors
T7_T23 NONE paclitaxel_24\NN\1740| (r_conj) metformin_22\NN\2719105|by|and|paclitaxel (r_nmod) downregulation_20\NN\1740|ercc1|metformin (r_dobj) abrogate_18\VB\2427334|to|downregulation|as|viability (r_xcomp) able_16\JJ\1740|finally|,|expression|was|abrogate|. (l_nsubj) expression_2\NN\4679549|mkk6|cells (l_nmod) mkk6_6\NN\1740|of|constitutive|activate|or|vectors (l_conj) vectors_10\NNS\5857459|ha-p38|mapk (l_compound) ha-p38_8\NN\1740|
T7_T24 NONE paclitaxel_24\NN\1740| (r_conj) metformin_22\NN\2719105|by|and|paclitaxel (r_nmod) downregulation_20\NN\1740|ercc1|metformin (r_dobj) abrogate_18\VB\2427334|to|downregulation|as|viability (r_xcomp) able_16\JJ\1740|finally|,|expression|was|abrogate|. (l_nsubj) expression_2\NN\4679549|mkk6|cells (l_nmod) mkk6_6\NN\1740|of|constitutive|activate|or|vectors (l_conj) vectors_10\NNS\5857459|ha-p38|mapk (l_compound) mapk_9\NN\1740|
T7_T25 CPR:4 paclitaxel_24\NN\1740| (r_conj) metformin_22\NN\2719105|by|and|paclitaxel (r_nmod) downregulation_20\NN\1740|ercc1|metformin (l_compound) ercc1_19\NN\1740|
T8_T26 CPR:4 metformin_13\NN\2719105|by (r_nmod) inhibition_6\NN\1068773|signaling|metformin|coupled (l_nmod) signaling_11\NN\33020|of|the|p38|mapk (l_compound) p38_9\NN\1740|
T8_T27 CPR:4 metformin_13\NN\2719105|by (r_nmod) inhibition_6\NN\1068773|signaling|metformin|coupled (l_nmod) signaling_11\NN\33020|of|the|p38|mapk (l_compound) mapk_10\NN\1740|
T9_T26 NONE paclitaxel_16\NN\1740| (r_compound) therapy_17\NN\657604|with|paclitaxel|cells (r_nmod) coupled_14\VBN\1295275|therapy (r_acl) inhibition_6\NN\1068773|signaling|metformin|coupled (l_nmod) signaling_11\NN\33020|of|the|p38|mapk (l_compound) p38_9\NN\1740|
T9_T27 NONE paclitaxel_16\NN\1740| (r_compound) therapy_17\NN\657604|with|paclitaxel|cells (r_nmod) coupled_14\VBN\1295275|therapy (r_acl) inhibition_6\NN\1068773|signaling|metformin|coupled (l_nmod) signaling_11\NN\33020|of|the|p38|mapk (l_compound) mapk_10\NN\1740|
15192023
T13_T37 NONE prolyl_22\JJ\1740| (r_amod) hydroxylases_23\NNS\1740|of|prolyl
T13_T38 NONE prolyl_22\JJ\1740| (r_amod) hydroxylases_23\NNS\1740|of|prolyl (r_nmod) inhibition_20\NN\1068773|by|hydroxylases (r_nmod) induction_7\NN\7450842|factor-1alpha|inhibition (l_nmod) factor-1alpha_10\NN\1740|of|hypoxia-inducible|,|factor|,|and|angiogenesis
T13_T39 NONE prolyl_22\JJ\1740| (r_amod) hydroxylases_23\NNS\1740|of|prolyl (r_nmod) inhibition_20\NN\1068773|by|hydroxylases (r_nmod) induction_7\NN\7450842|factor-1alpha|inhibition (l_nmod) factor-1alpha_10\NN\1740|of|hypoxia-inducible|,|factor|,|and|angiogenesis (l_conj) factor_15\NN\7326557|vascular|endothelial|growth
T14_T37 CPR:4 hydralazine_5\NN\2721160|for (r_nmod) mechanism_1\NN\13446390|novel|action|hydralazine|:|induction|. (l_dep) induction_7\NN\7450842|factor-1alpha|inhibition (l_nmod) inhibition_20\NN\1068773|by|hydroxylases (l_nmod) hydroxylases_23\NNS\1740|of|prolyl
T14_T38 CPR:3 hydralazine_5\NN\2721160|for (r_nmod) mechanism_1\NN\13446390|novel|action|hydralazine|:|induction|. (l_dep) induction_7\NN\7450842|factor-1alpha|inhibition (l_nmod) factor-1alpha_10\NN\1740|of|hypoxia-inducible|,|factor|,|and|angiogenesis
T14_T39 CPR:3 hydralazine_5\NN\2721160|for (r_nmod) mechanism_1\NN\13446390|novel|action|hydralazine|:|induction|. (l_dep) induction_7\NN\7450842|factor-1alpha|inhibition (l_nmod) factor-1alpha_10\NN\1740|of|hypoxia-inducible|,|factor|,|and|angiogenesis (l_conj) factor_15\NN\7326557|vascular|endothelial|growth
T6_T19 NONE prolyl_1\NN\1740| (r_amod) hydroxylase_2\NN\1740|collagen|prolyl
T7_T19 NONE hydralazine_8\NN\2721160|of (r_nmod) target_6\NN\7258332|hydroxylase|is|a|known|hydralazine|. (l_nsubj) hydroxylase_2\NN\1740|collagen|prolyl
T8_T20 NONE o2-dependent_18\JJ\1740| (r_amod) enzymes_25\NNS\14723628|namely|the|hypoxia-inducible|factor|(hif)-regulating|o2-dependent|domain|(|phd|) (l_compound) factor_16\NN\7326557|
T8_T21 NONE o2-dependent_18\JJ\1740| (r_amod) enzymes_25\NNS\14723628|namely|the|hypoxia-inducible|factor|(hif)-regulating|o2-dependent|domain|(|phd|) (l_punct) (hif)-regulating_17\NN\1740|
T8_T22 NONE o2-dependent_18\JJ\1740| (r_amod) enzymes_25\NNS\14723628|namely|the|hypoxia-inducible|factor|(hif)-regulating|o2-dependent|domain|(|phd|) (l_compound) domain_21\NN\13934596|prolyl|hydroxylase
T8_T23 NONE o2-dependent_18\JJ\1740| (r_amod) enzymes_25\NNS\14723628|namely|the|hypoxia-inducible|factor|(hif)-regulating|o2-dependent|domain|(|phd|) (l_compound) phd_23\NN\6703953|
T9_T20 NONE prolyl_19\JJ\1740| (r_amod) domain_21\NN\13934596|prolyl|hydroxylase (r_compound) enzymes_25\NNS\14723628|namely|the|hypoxia-inducible|factor|(hif)-regulating|o2-dependent|domain|(|phd|) (l_compound) factor_16\NN\7326557|
T9_T21 NONE prolyl_19\JJ\1740| (r_amod) domain_21\NN\13934596|prolyl|hydroxylase (r_compound) enzymes_25\NNS\14723628|namely|the|hypoxia-inducible|factor|(hif)-regulating|o2-dependent|domain|(|phd|) (l_punct) (hif)-regulating_17\NN\1740|
T9_T22 NONE prolyl_19\JJ\1740| (r_amod) domain_21\NN\13934596|prolyl|hydroxylase
T9_T23 NONE prolyl_19\JJ\1740| (r_amod) domain_21\NN\13934596|prolyl|hydroxylase (r_compound) enzymes_25\NNS\14723628|namely|the|hypoxia-inducible|factor|(hif)-regulating|o2-dependent|domain|(|phd|) (l_compound) phd_23\NN\6703953|
T10_T24 CPR:3 hydralazine_0\NN\2721160| (r_nsubj) induced_1\VBD\1627355|hydralazine|expression|cells|and|induced|. (l_dobj) expression_5\NN\4679549|rapid|hif-1alpha (l_nmod) hif-1alpha_7\NN\1740|of|and|targets
T10_T25 CPR:3 hydralazine_0\NN\2721160| (r_nsubj) induced_1\VBD\1627355|hydralazine|expression|cells|and|induced|. (l_dobj) expression_5\NN\4679549|rapid|hif-1alpha (l_nmod) hif-1alpha_7\NN\1740|of|and|targets (l_conj) targets_10\NNS\7258332|downstream|hif (l_nmod) hif_12\NN\1740|of|endothelin-1
T10_T26 CPR:3 hydralazine_0\NN\2721160| (r_nsubj) induced_1\VBD\1627355|hydralazine|expression|cells|and|induced|. (l_dobj) expression_5\NN\4679549|rapid|hif-1alpha (l_nmod) hif-1alpha_7\NN\1740|of|and|targets (l_conj) targets_10\NNS\7258332|downstream|hif (l_nmod) hif_12\NN\1740|of|endothelin-1 (l_dep) endothelin-1_14\NN\1740|(|,|adrenomedullin|,|oxygenase|,|and|factor|)
T10_T27 CPR:3 hydralazine_0\NN\2721160| (r_nsubj) induced_1\VBD\1627355|hydralazine|expression|cells|and|induced|. (l_dobj) expression_5\NN\4679549|rapid|hif-1alpha (l_nmod) hif-1alpha_7\NN\1740|of|and|targets (l_conj) targets_10\NNS\7258332|downstream|hif (l_nmod) hif_12\NN\1740|of|endothelin-1 (l_dep) endothelin-1_14\NN\1740|(|,|adrenomedullin|,|oxygenase|,|and|factor|) (l_conj) adrenomedullin_16\NN\1740|
T10_T28 CPR:3 hydralazine_0\NN\2721160| (r_nsubj) induced_1\VBD\1627355|hydralazine|expression|cells|and|induced|. (l_dobj) expression_5\NN\4679549|rapid|hif-1alpha (l_nmod) hif-1alpha_7\NN\1740|of|and|targets (l_conj) targets_10\NNS\7258332|downstream|hif (l_nmod) hif_12\NN\1740|of|endothelin-1 (l_dep) endothelin-1_14\NN\1740|(|,|adrenomedullin|,|oxygenase|,|and|factor|) (l_conj) oxygenase_19\NN\14971969|haem|1 (l_nummod) 1_20\CD\13741022|
T10_T29 CPR:3 hydralazine_0\NN\2721160| (r_nsubj) induced_1\VBD\1627355|hydralazine|expression|cells|and|induced|. (l_dobj) expression_5\NN\4679549|rapid|hif-1alpha (l_nmod) hif-1alpha_7\NN\1740|of|and|targets (l_conj) targets_10\NNS\7258332|downstream|hif (l_nmod) hif_12\NN\1740|of|endothelin-1 (l_dep) endothelin-1_14\NN\1740|(|,|adrenomedullin|,|oxygenase|,|and|factor|) (l_conj) factor_26\NN\7326557|vascular|endothelial|growth|vegf
T10_T30 CPR:3 hydralazine_0\NN\2721160| (r_nsubj) induced_1\VBD\1627355|hydralazine|expression|cells|and|induced|. (l_dobj) expression_5\NN\4679549|rapid|hif-1alpha (l_nmod) hif-1alpha_7\NN\1740|of|and|targets (l_conj) targets_10\NNS\7258332|downstream|hif (l_nmod) hif_12\NN\1740|of|endothelin-1 (l_dep) endothelin-1_14\NN\1740|(|,|adrenomedullin|,|oxygenase|,|and|factor|) (l_conj) factor_26\NN\7326557|vascular|endothelial|growth|vegf (l_appos) vegf_28\NN\1740|[|]
T11_T31 CPR:4 hydralazine_0\NN\2721160| (r_nsubj) inhibited_2\VBD\2510337|hydralazine|dose-dependently|activity|and|induced|. (l_dobj) activity_4\NN\30358|phd (l_compound) phd_3\NN\6703953|
T11_T32 CPR:3 hydralazine_0\NN\2721160| (r_nsubj) inhibited_2\VBD\2510337|hydralazine|dose-dependently|activity|and|induced|. (l_conj) induced_6\VBD\1627355|hif-1alpha|,|evidence (l_dobj) hif-1alpha_8\NN\1740|nonhydroxylated
T11_T33 NONE hydralazine_0\NN\2721160| (r_nsubj) inhibited_2\VBD\2510337|hydralazine|dose-dependently|activity|and|induced|. (l_conj) induced_6\VBD\1627355|hif-1alpha|,|evidence (l_dobj) evidence_10\NN\5816287|stabilization|inhibition (l_nmod) stabilization_13\NN\1158690|for|hif (l_compound) hif_12\NN\1740|
T11_T34 CPR:4 hydralazine_0\NN\2721160| (r_nsubj) inhibited_2\VBD\2510337|hydralazine|dose-dependently|activity|and|induced|. (l_conj) induced_6\VBD\1627355|hif-1alpha|,|evidence (l_dobj) evidence_10\NN\5816287|stabilization|inhibition (l_nmod) inhibition_16\NN\1068773|by|activity (l_nmod) activity_20\NN\30358|of|phd|enzyme (l_compound) phd_18\NN\6703953|
T12_T15 CPR:3 hydralazine_3\NN\2721160| (r_nsubj) induced_4\VBD\1627355|vivo|,|hydralazine|hif-1alpha|. (l_dobj) hif-1alpha_5\NN\1740|and|protein|extracts|and|levels (l_conj) levels_16\NNS\4916342|elevated|plasma|vegf (l_compound) vegf_15\NN\1740|
T12_T35 CPR:3 hydralazine_3\NN\2721160| (r_nsubj) induced_4\VBD\1627355|vivo|,|hydralazine|hif-1alpha|. (l_dobj) hif-1alpha_5\NN\1740|and|protein|extracts|and|levels
T12_T36 CPR:3 hydralazine_3\NN\2721160| (r_nsubj) induced_4\VBD\1627355|vivo|,|hydralazine|hif-1alpha|. (l_dobj) hif-1alpha_5\NN\1740|and|protein|extracts|and|levels (l_conj) protein_8\NN\14944888|vegf (l_compound) vegf_7\NN\1740|
T2_T16 CPR:3 hydralazine_2\NN\2721160| (r_nsubj) activates_3\VBZ\1641914|thus|,|hydralazine|pathway|inhibition|and|initiates|. (l_dobj) pathway_6\NN\5483677|the|hif (l_compound) hif_5\NN\1740|
T2_T17 CPR:4 hydralazine_2\NN\2721160| (r_nsubj) activates_3\VBZ\1641914|thus|,|hydralazine|pathway|inhibition|and|initiates|. (l_nmod) inhibition_8\NN\1068773|through|activity (l_nmod) activity_11\NN\30358|of|phd (l_compound) phd_10\NN\6703953|
T3_T18 NONE hydralazine_8\NN\2721160|for (r_nmod) mechanism_4\NN\13446390|a|novel|action|hydralazine (r_dobj) represents_1\VBZ\2664769|this|mechanism|and|presents|. (l_conj) presents_10\VBZ\2137132|hif|target (l_dobj) hif_11\NN\1740|
23066089
T18_T50 NONE glutamate_5\NN\15010703| (r_compound) receptors_6\NNS\5225602|of|group|i|metabotropic|glutamate
T18_T51 NONE glutamate_5\NN\15010703| (r_compound) receptors_6\NNS\5225602|of|group|i|metabotropic|glutamate (r_nmod) activation_0\NN\13561719|receptors (r_nsubj) potentiates_7\VBZ\229605|activation|receptors|. (l_dobj) receptors_10\NNS\5225602|heteromeric|kainate
T19_T50 NONE kainate_9\NN\1740| (r_compound) receptors_10\NNS\5225602|heteromeric|kainate (r_dobj) potentiates_7\VBZ\229605|activation|receptors|. (l_nsubj) activation_0\NN\13561719|receptors (l_nmod) receptors_6\NNS\5225602|of|group|i|metabotropic|glutamate
T19_T51 NONE kainate_9\NN\1740| (r_compound) receptors_10\NNS\5225602|heteromeric|kainate
T15_T20 NONE glutamate_10\NN\15010703| (r_compound) receptors_11\NNS\5225602|of|ionotropic|glutamate (r_nmod) family_7\NN\8189659|a|receptors (r_appos) receptors_1\NNS\5225602|kainate|kars|,|family|,
T15_T35 NONE glutamate_10\NN\15010703| (r_compound) receptors_11\NNS\5225602|of|ionotropic|glutamate (r_nmod) family_7\NN\8189659|a|receptors (r_appos) receptors_1\NNS\5225602|kainate|kars|,|family|, (l_appos) kars_3\NNS\1740|(|)
T15_T40 NONE glutamate_10\NN\15010703| (r_compound) receptors_11\NNS\5225602|of|ionotropic|glutamate
T1_T20 NONE kainate_0\NN\1740| (r_compound) receptors_1\NNS\5225602|kainate|kars|,|family|,
T1_T35 NONE kainate_0\NN\1740| (r_compound) receptors_1\NNS\5225602|kainate|kars|,|family|, (l_appos) kars_3\NNS\1740|(|)
T1_T40 NONE kainate_0\NN\1740| (r_compound) receptors_1\NNS\5225602|kainate|kars|,|family|, (l_appos) family_7\NN\8189659|a|receptors (l_nmod) receptors_11\NNS\5225602|of|ionotropic|glutamate
T14_T34 NONE glutamate_6\NN\15010703| (r_compound) receptor_7\NN\5225602|metabotropic|glutamate|mglu (r_compound) signaling_11\NN\33020|by|receptor (r_nmod) influenced_3\VBN\137313|activation|is|signaling|,|but|understood (l_nsubjpass) activation_1\NN\13561719|kar (l_compound) kar_0\NN\1740|
T14_T36 NONE glutamate_6\NN\15010703| (r_compound) receptor_7\NN\5225602|metabotropic|glutamate|mglu
T14_T37 NONE glutamate_6\NN\15010703| (r_compound) receptor_7\NN\5225602|metabotropic|glutamate|mglu (l_appos) mglu_9\NN\1740|(|)
T16_T43 NONE calcium_7\NN\14625458| (r_compound) signal_8\NN\33020|the|calcium|caused (l_acl) caused_9\VBN\1617192|activation (l_nmod) activation_11\NN\13561719|by|kars (l_nmod) kars_14\NNS\1740|of|native
T16_T44 NONE calcium_7\NN\14625458| (r_compound) signal_8\NN\33020|the|calcium|caused (r_nsubjpass) potentiated_16\VBN\229605|cultures|,|signal|was|activation|. (l_nmod) activation_18\NN\13561719|by|receptors (l_nmod) receptors_23\NNS\5225602|of|group|i|mglu
T17_T21 NONE calcium_22\NN\14625458| (r_compound) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) prolonged_34\JJ\1740|acid|,|but|unaffected (l_nmod) acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (l_compound) phosphatase_37\NN\14732946|
T17_T22 NONE calcium_22\NN\14625458| (r_compound) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) prolonged_34\JJ\1740|acid|,|but|unaffected (l_conj) unaffected_43\JJ\1740|a. (l_nmod) a._50\.\1740|inhibitor|lavendustin (l_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (l_compound) kinase_47\NN\14732946|
T17_T47 NONE calcium_22\NN\14625458| (r_compound) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) kars_4\NNS\1740|of|heteromeric
T17_T48 NONE calcium_22\NN\14625458| (r_compound) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) activation_7\NN\13561719|by|mglu1 (l_compound) mglu1_6\NN\1740|
T17_T49 NONE calcium_22\NN\14625458| (r_compound) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (l_nmod) c_19\NN\13714184|of|phospholipase
T2_T21 NONE acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) prolonged_34\JJ\1740|acid|,|but|unaffected (l_nmod) acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (l_compound) phosphatase_37\NN\14732946|
T2_T22 NONE acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) prolonged_34\JJ\1740|acid|,|but|unaffected (l_conj) unaffected_43\JJ\1740|a. (l_nmod) a._50\.\1740|inhibitor|lavendustin (l_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (l_compound) kinase_47\NN\14732946|
T2_T47 CPR:4 acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) kars_4\NNS\1740|of|heteromeric
T2_T48 CPR:4 acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) activation_7\NN\13561719|by|mglu1 (l_compound) mglu1_6\NN\1740|
T2_T49 NONE acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (l_nmod) c_19\NN\13714184|of|phospholipase
T3_T21 NONE bapta_31\NN\1740|(|) (r_appos) acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) prolonged_34\JJ\1740|acid|,|but|unaffected (l_nmod) acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (l_compound) phosphatase_37\NN\14732946|
T3_T22 NONE bapta_31\NN\1740|(|) (r_appos) acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) prolonged_34\JJ\1740|acid|,|but|unaffected (l_conj) unaffected_43\JJ\1740|a. (l_nmod) a._50\.\1740|inhibitor|lavendustin (l_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (l_compound) kinase_47\NN\14732946|
T3_T47 CPR:4 bapta_31\NN\1740|(|) (r_appos) acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) kars_4\NNS\1740|of|heteromeric
T3_T48 CPR:4 bapta_31\NN\1740|(|) (r_appos) acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (r_nmod) blocked_13\VBN\1476483|inhibitor|, (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) activation_7\NN\13561719|by|mglu1 (l_compound) mglu1_6\NN\1740|
T3_T49 NONE bapta_31\NN\1740|(|) (r_appos) acid_29\NN\14818238|1,2-bis(o-aminophenoxy)ethane-n|,|n|,|n',n'-tetraacetic|bapta (r_dep) chelator_23\NN\1740|the|calcium|acid (r_conj) inhibitor_16\NN\20090|by|an|c|or|chelator (l_nmod) c_19\NN\13714184|of|phospholipase
T4_T21 CPR:4 acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (l_compound) phosphatase_37\NN\14732946|
T4_T22 NONE acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (r_nmod) prolonged_34\JJ\1740|acid|,|but|unaffected (l_conj) unaffected_43\JJ\1740|a. (l_nmod) a._50\.\1740|inhibitor|lavendustin (l_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (l_compound) kinase_47\NN\14732946|
T4_T47 CPR:4 acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (r_nmod) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) kars_4\NNS\1740|of|heteromeric
T4_T48 CPR:4 acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (r_nmod) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) activation_7\NN\13561719|by|mglu1 (l_compound) mglu1_6\NN\1740|
T4_T49 NONE acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (r_nmod) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) blocked_13\VBN\1476483|inhibitor|, (l_nmod) inhibitor_16\NN\20090|by|an|c|or|chelator (l_nmod) c_19\NN\13714184|of|phospholipase
T5_T21 NONE tyrosine_46\NN\14601829| (r_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (r_compound) a._50\.\1740|inhibitor|lavendustin (r_nmod) unaffected_43\JJ\1740|a. (r_conj) prolonged_34\JJ\1740|acid|,|but|unaffected (l_nmod) acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (l_compound) phosphatase_37\NN\14732946|
T5_T22 NONE tyrosine_46\NN\14601829| (r_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (l_compound) kinase_47\NN\14732946|
T5_T47 NONE tyrosine_46\NN\14601829| (r_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (r_compound) a._50\.\1740|inhibitor|lavendustin (r_nmod) unaffected_43\JJ\1740|a. (r_conj) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) kars_4\NNS\1740|of|heteromeric
T5_T48 NONE tyrosine_46\NN\14601829| (r_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (r_compound) a._50\.\1740|inhibitor|lavendustin (r_nmod) unaffected_43\JJ\1740|a. (r_conj) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) activation_7\NN\13561719|by|mglu1 (l_compound) mglu1_6\NN\1740|
T5_T49 NONE tyrosine_46\NN\14601829| (r_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (r_compound) a._50\.\1740|inhibitor|lavendustin (r_nmod) unaffected_43\JJ\1740|a. (r_conj) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) blocked_13\VBN\1476483|inhibitor|, (l_nmod) inhibitor_16\NN\20090|by|an|c|or|chelator (l_nmod) c_19\NN\13714184|of|phospholipase
T6_T21 NONE a._50\.\1740|inhibitor|lavendustin (r_nmod) unaffected_43\JJ\1740|a. (r_conj) prolonged_34\JJ\1740|acid|,|but|unaffected (l_nmod) acid_40\NN\14818238|by|the|phosphatase|inhibitor|okadaic (l_compound) phosphatase_37\NN\14732946|
T6_T22 CPR:4 a._50\.\1740|inhibitor|lavendustin (l_compound) inhibitor_48\NN\20090|by|the|tyrosine|kinase (l_compound) kinase_47\NN\14732946|
T6_T47 CPR:4 a._50\.\1740|inhibitor|lavendustin (r_nmod) unaffected_43\JJ\1740|a. (r_conj) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) kars_4\NNS\1740|of|heteromeric
T6_T48 CPR:4 a._50\.\1740|inhibitor|lavendustin (r_nmod) unaffected_43\JJ\1740|a. (r_conj) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_nsubjpass) potentiation_1\NN\13564910|the|kars|activation (l_nmod) activation_7\NN\13561719|by|mglu1 (l_compound) mglu1_6\NN\1740|
T6_T49 NONE a._50\.\1740|inhibitor|lavendustin (r_nmod) unaffected_43\JJ\1740|a. (r_conj) prolonged_34\JJ\1740|acid|,|but|unaffected (r_dep) attenuated_9\VBN\224901|potentiation|was|gdpβs|,|blocked|prolonged (l_dep) blocked_13\VBN\1476483|inhibitor|, (l_nmod) inhibitor_16\NN\20090|by|an|c|or|chelator (l_nmod) c_19\NN\13714184|of|phospholipase
T7_T23 NONE 12-myristate,13-acetate_24\NN\1740|by|phorbol (r_nmod) activation_19\NN\13561719|direct|pkc|12-myristate,13-acetate (r_nsubj) potentiated_25\VBD\229605|conversely|,|activation|gluk2/gluk5|. (r_conj) reduced_7\VBD\441445|inhibition|potentiation|,|and|potentiated (l_nsubj) inhibition_6\NN\1068773|c (l_compound) c_2\NN\13714184|protein|kinase|pkc
T7_T24 NONE 12-myristate,13-acetate_24\NN\1740|by|phorbol (r_nmod) activation_19\NN\13561719|direct|pkc|12-myristate,13-acetate (r_nsubj) potentiated_25\VBD\229605|conversely|,|activation|gluk2/gluk5|. (r_conj) reduced_7\VBD\441445|inhibition|potentiation|,|and|potentiated (l_nsubj) inhibition_6\NN\1068773|c (l_compound) c_2\NN\13714184|protein|kinase|pkc (l_appos) pkc_4\NN\1740|(|)
T7_T25 NONE 12-myristate,13-acetate_24\NN\1740|by|phorbol (r_nmod) activation_19\NN\13561719|direct|pkc|12-myristate,13-acetate (r_nsubj) potentiated_25\VBD\229605|conversely|,|activation|gluk2/gluk5|. (r_conj) reduced_7\VBD\441445|inhibition|potentiation|,|and|potentiated (l_dobj) potentiation_9\NN\13564910|the|mglu1|gluk2/gluk5 (l_nmod) mglu1_11\NN\1740|by
T7_T26 NONE 12-myristate,13-acetate_24\NN\1740|by|phorbol (r_nmod) activation_19\NN\13561719|direct|pkc|12-myristate,13-acetate (r_nsubj) potentiated_25\VBD\229605|conversely|,|activation|gluk2/gluk5|. (r_conj) reduced_7\VBD\441445|inhibition|potentiation|,|and|potentiated (l_dobj) potentiation_9\NN\13564910|the|mglu1|gluk2/gluk5 (l_nmod) gluk2/gluk5_13\NN\1740|of
T7_T27 NONE 12-myristate,13-acetate_24\NN\1740|by|phorbol (r_nmod) activation_19\NN\13561719|direct|pkc|12-myristate,13-acetate (r_nsubj) potentiated_25\VBD\229605|conversely|,|activation|gluk2/gluk5|. (r_conj) reduced_7\VBD\441445|inhibition|potentiation|,|and|potentiated (l_dobj) potentiation_9\NN\13564910|the|mglu1|gluk2/gluk5 (l_nmod) gluk2/gluk5_13\NN\1740|of
T7_T28 CPR:3 12-myristate,13-acetate_24\NN\1740|by|phorbol (r_nmod) activation_19\NN\13561719|direct|pkc|12-myristate,13-acetate (l_nmod) pkc_21\NN\1740|of
T7_T29 CPR:3 12-myristate,13-acetate_24\NN\1740|by|phorbol (r_nmod) activation_19\NN\13561719|direct|pkc|12-myristate,13-acetate (r_nsubj) potentiated_25\VBD\229605|conversely|,|activation|gluk2/gluk5|. (l_dobj) gluk2/gluk5_26\NN\1740|
T7_T30 CPR:3 12-myristate,13-acetate_24\NN\1740|by|phorbol (r_nmod) activation_19\NN\13561719|direct|pkc|12-myristate,13-acetate (r_nsubj) potentiated_25\VBD\229605|conversely|,|activation|gluk2/gluk5|. (l_dobj) gluk2/gluk5_26\NN\1740|
T10_T31 NONE ser836_11\NN\1740| (r_conj) ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_nmod) region_20\NN\27167|within|the|membrane|proximal|domain (l_nmod) domain_25\NN\13934596|of|the|gluk5|c-terminal (l_compound) gluk5_23\NN\1740|
T10_T32 NONE ser836_11\NN\1740| (r_conj) ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_amod) mglu1-mediated_34\JJ\1740|
T10_T33 NONE ser836_11\NN\1740| (r_conj) ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_nmod) kars_37\NNS\1740|of
T11_T31 NONE ser840_14\NN\1740| (r_conj) ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_nmod) region_20\NN\27167|within|the|membrane|proximal|domain (l_nmod) domain_25\NN\13934596|of|the|gluk5|c-terminal (l_compound) gluk5_23\NN\1740|
T11_T32 NONE ser840_14\NN\1740| (r_conj) ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_amod) mglu1-mediated_34\JJ\1740|
T11_T33 NONE ser840_14\NN\1740| (r_conj) ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_nmod) kars_37\NNS\1740|of
T12_T31 NONE c-terminal_24\JJ\1740| (r_amod) domain_25\NN\13934596|of|the|gluk5|c-terminal (l_compound) gluk5_23\NN\1740|
T12_T32 NONE c-terminal_24\JJ\1740| (r_amod) domain_25\NN\13934596|of|the|gluk5|c-terminal (r_nmod) region_20\NN\27167|within|the|membrane|proximal|domain (r_nmod) serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_amod) mglu1-mediated_34\JJ\1740|
T12_T33 NONE c-terminal_24\JJ\1740| (r_amod) domain_25\NN\13934596|of|the|gluk5|c-terminal (r_nmod) region_20\NN\27167|within|the|membrane|proximal|domain (r_nmod) serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_nmod) kars_37\NNS\1740|of
T8_T31 NONE serines_7\NNS\14601829|three|ser833|region|required (l_nmod) region_20\NN\27167|within|the|membrane|proximal|domain (l_nmod) domain_25\NN\13934596|of|the|gluk5|c-terminal (l_compound) gluk5_23\NN\1740|
T8_T32 NONE serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_amod) mglu1-mediated_34\JJ\1740|
T8_T33 NONE serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_nmod) kars_37\NNS\1740|of
T9_T31 NONE ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_nmod) region_20\NN\27167|within|the|membrane|proximal|domain (l_nmod) domain_25\NN\13934596|of|the|gluk5|c-terminal (l_compound) gluk5_23\NN\1740|
T9_T32 NONE ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_amod) mglu1-mediated_34\JJ\1740|
T9_T33 NONE ser833_9\NN\1740|(|,|ser836|,|and|ser840|) (r_dep) serines_7\NNS\14601829|three|ser833|region|required (l_acl:relcl) required_32\VBN\754942|that|,|combination|,|are|potentiation (l_nmod) potentiation_35\NN\13564910|for|mglu1-mediated|kars (l_nmod) kars_37\NNS\1740|of
23218950
T3_T23 NONE 5'-deoxynucleoside-triphosphate_23\NN\1740| (r_amod) precursors_25\NNS\14580897|of|the|available|5'-deoxynucleoside-triphosphate|dna|dntps (r_nmod) quality_16\NN\24264|the|and|concentration(s|precursors (r_conj) accuracy_8\NN\4723816|on|the|polymerase|as|quality (l_nmod) polymerase_11\NN\14732946|of|the
T7_T23 NONE dntps_27\NNS\1740|(|) (r_appos) precursors_25\NNS\14580897|of|the|available|5'-deoxynucleoside-triphosphate|dna|dntps (r_nmod) quality_16\NN\24264|the|and|concentration(s|precursors (r_conj) accuracy_8\NN\4723816|on|the|polymerase|as|quality (l_nmod) polymerase_11\NN\14732946|of|the
T10_T21 NONE diphosphate_9\NN\1740| (r_compound) kinase_10\NN\14732946|nucleoside|diphosphate (r_conj) deaminase_6\NN\1740|in|dctp|and|kinase
T10_T22 NONE diphosphate_9\NN\1740| (r_compound) kinase_10\NN\14732946|nucleoside|diphosphate
T11_T21 NONE dntp_20\NN\1740| (r_compound) pools_21\NNS\3302121|of|dntp (r_nmod) disturbances_18\NNS\407535|by|both|pools|and|phenotype (r_nmod) characterized_15\VBN\609683|strains|are|disturbances|. (l_nsubjpass) strains_1\NNS\7358060|these|,|defective|, (l_amod) defective_3\JJ\1740|deaminase|,|respectively (l_nmod) deaminase_6\NN\1740|in|dctp|and|kinase
T11_T22 NONE dntp_20\NN\1740| (r_compound) pools_21\NNS\3302121|of|dntp (r_nmod) disturbances_18\NNS\407535|by|both|pools|and|phenotype (r_nmod) characterized_15\VBN\609683|strains|are|disturbances|. (l_nsubjpass) strains_1\NNS\7358060|these|,|defective|, (l_amod) defective_3\JJ\1740|deaminase|,|respectively (l_nmod) deaminase_6\NN\1740|in|dctp|and|kinase (l_conj) kinase_10\NN\14732946|nucleoside|diphosphate
T9_T21 NONE dctp_5\NN\1740| (r_compound) deaminase_6\NN\1740|in|dctp|and|kinase
T9_T22 NONE dctp_5\NN\1740| (r_compound) deaminase_6\NN\1740|in|dctp|and|kinase (l_conj) kinase_10\NN\14732946|nucleoside|diphosphate
T12_T14 NONE dctp_11\NN\1740|of (r_nmod) levels_9\NNS\4916342|from|increased|intracellular|dctp|4-fold|and|levels (r_nmod) suffer_5\VBP\2110220|that|strains|levels|,|displaying (l_advcl) displaying_25\VBG\2137132|while|,|measured|,|effect (l_dobj) effect_48\NN\34213|a|strong|mutator|transversions|enhancement (l_nmod) transversions_53\NNS\1740|for|g·c→t·a|a·t→t·a (l_compound) g·c→t·a_50\NN\1740|and
T12_T15 NONE dctp_11\NN\1740|of (r_nmod) levels_9\NNS\4916342|from|increased|intracellular|dctp|4-fold|and|levels (r_nmod) suffer_5\VBP\2110220|that|strains|levels|,|displaying (l_advcl) displaying_25\VBG\2137132|while|,|measured|,|effect (l_dobj) effect_48\NN\34213|a|strong|mutator|transversions|enhancement (l_nmod) transversions_53\NNS\1740|for|g·c→t·a|a·t→t·a (l_compound) a·t→t·a_52\NN\1740|
T12_T25 NONE dctp_11\NN\1740|of (r_nmod) levels_9\NNS\4916342|from|increased|intracellular|dctp|4-fold|and|levels (r_nmod) suffer_5\VBP\2110220|that|strains|levels|,|displaying (l_nsubj) strains_4\NNS\7358060|dcd (l_compound) dcd_3\NN\1740|
T13_T14 NONE dgtp_19\NN\1740|of|2-fold (r_nmod) levels_17\NNS\4916342|reduced|dgtp (r_conj) levels_9\NNS\4916342|from|increased|intracellular|dctp|4-fold|and|levels (r_nmod) suffer_5\VBP\2110220|that|strains|levels|,|displaying (l_advcl) displaying_25\VBG\2137132|while|,|measured|,|effect (l_dobj) effect_48\NN\34213|a|strong|mutator|transversions|enhancement (l_nmod) transversions_53\NNS\1740|for|g·c→t·a|a·t→t·a (l_compound) g·c→t·a_50\NN\1740|and
T13_T15 NONE dgtp_19\NN\1740|of|2-fold (r_nmod) levels_17\NNS\4916342|reduced|dgtp (r_conj) levels_9\NNS\4916342|from|increased|intracellular|dctp|4-fold|and|levels (r_nmod) suffer_5\VBP\2110220|that|strains|levels|,|displaying (l_advcl) displaying_25\VBG\2137132|while|,|measured|,|effect (l_dobj) effect_48\NN\34213|a|strong|mutator|transversions|enhancement (l_nmod) transversions_53\NNS\1740|for|g·c→t·a|a·t→t·a (l_compound) a·t→t·a_52\NN\1740|
T13_T25 NONE dgtp_19\NN\1740|of|2-fold (r_nmod) levels_17\NNS\4916342|reduced|dgtp (r_conj) levels_9\NNS\4916342|from|increased|intracellular|dctp|4-fold|and|levels (r_nmod) suffer_5\VBP\2110220|that|strains|levels|,|displaying (l_nsubj) strains_4\NNS\7358060|dcd (l_compound) dcd_3\NN\1740|
T1_T16 NONE datp_8\NN\1740| (r_compound) level_9\NN\4916342|a|lowered|datp|4-fold (r_dobj) possess_5\VBP\2630189|contrast|,|strains|level|and|level|,|specific|. (l_nsubj) strains_4\NNS\7358060|ndk (l_compound) ndk_3\NN\1740|
T1_T17 NONE datp_8\NN\1740| (r_compound) level_9\NN\4916342|a|lowered|datp|4-fold (r_dobj) possess_5\VBP\2630189|contrast|,|strains|level|and|level|,|specific|. (l_advcl) specific_27\JJ\1740|while|effect|is|transversions (l_nmod) transversions_32\NNS\1740|for|just|the|a·t→t·a (l_compound) a·t→t·a_31\NN\1740|
T2_T16 NONE dctp_16\NN\1740| (r_compound) level_17\NN\4916342|enhanced|dctp|2-fold (r_conj) possess_5\VBP\2630189|contrast|,|strains|level|and|level|,|specific|. (l_nsubj) strains_4\NNS\7358060|ndk (l_compound) ndk_3\NN\1740|
T2_T17 NONE dctp_16\NN\1740| (r_compound) level_17\NN\4916342|enhanced|dctp|2-fold (r_conj) possess_5\VBP\2630189|contrast|,|strains|level|and|level|,|specific|. (l_advcl) specific_27\JJ\1740|while|effect|is|transversions (l_nmod) transversions_32\NNS\1740|for|just|the|a·t→t·a (l_compound) a·t→t·a_31\NN\1740|
T5_T18 NONE dntp_12\NN\1740| (r_compound) alterations_14\NNS\7283608|between|dntp|pool|and|rates (r_nmod) correlation_10\NN\13841213|a|satisfactory|alterations (r_dobj) reveals_4\VBZ\2137132|overall|,|analysis|strains|correlation|,|and|suggests|. (l_conj) suggests_23\VBZ\1010118|also|require (l_ccomp) require_34\VB\754942|that|explanation|does|not|assumptions (l_nsubj) explanation_27\NN\6722453|a|minimal|mutator (l_nmod) mutator_31\NN\1740|for|the|ndk (l_compound) ndk_30\NN\1740|
T6_T18 NONE dntp_42\NN\1740| (r_compound) pools_43\NNS\3302121|of|the|dntp (r_nmod) effect_39\NN\34213|beyond|the|predicted|pools (r_nmod) assumptions_35\NNS\6753299|effect (r_dobj) require_34\VB\754942|that|explanation|does|not|assumptions (l_nsubj) explanation_27\NN\6722453|a|minimal|mutator (l_nmod) mutator_31\NN\1740|for|the|ndk (l_compound) ndk_30\NN\1740|
10933891
T12_T30 CPR:3 bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) activators_7\NNS\19613|alpha|,|bezafibrate|, (l_compound) alpha_3\NN\6828818|peroxisome|proliferator-activated|receptor|pparalpha
T12_T31 CPR:3 bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) activators_7\NNS\19613|alpha|,|bezafibrate|, (r_nsubj) increase_13\VBP\169651|activators|levels|modifying|. (l_dobj) levels_17\NNS\4916342|mrna (l_compound) mrna_16\NN\14832193|uncoupling|protein-3 (l_compound) protein-3_15\NN\1740|
T12_T32 CPR:3 bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) activators_7\NNS\19613|alpha|,|bezafibrate|, (l_compound) alpha_3\NN\6828818|peroxisome|proliferator-activated|receptor|pparalpha (l_appos) pparalpha_5\NN\1740|(|)
T13_T30 CPR:3 wy-14,643_11\CD\1740| (r_conj) bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) activators_7\NNS\19613|alpha|,|bezafibrate|, (l_compound) alpha_3\NN\6828818|peroxisome|proliferator-activated|receptor|pparalpha
T13_T31 CPR:3 wy-14,643_11\CD\1740| (r_conj) bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) activators_7\NNS\19613|alpha|,|bezafibrate|, (r_nsubj) increase_13\VBP\169651|activators|levels|modifying|. (l_dobj) levels_17\NNS\4916342|mrna (l_compound) mrna_16\NN\14832193|uncoupling|protein-3 (l_compound) protein-3_15\NN\1740|
T13_T32 CPR:3 wy-14,643_11\CD\1740| (r_conj) bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) activators_7\NNS\19613|alpha|,|bezafibrate|, (l_compound) alpha_3\NN\6828818|peroxisome|proliferator-activated|receptor|pparalpha (l_appos) pparalpha_5\NN\1740|(|)
T10_T14 CPR:9 )_16\-RRB-\1740| (r_punct) ions_17\NNS\9386422|for|h(+|) (r_nmod) pores_13\NNS\13911429|as|ions (r_nmod) act_11\VBP\1619354|which|pores|,|dissipating (r_acl:relcl) transporters_9\NNS\4490091|proteins|are|inner|mitochondrial|membrane|act|. (l_nsubj) proteins_1\NNS\14944888|uncoupling|ucps
T10_T18 CPR:9 )_16\-RRB-\1740| (r_punct) ions_17\NNS\9386422|for|h(+|) (r_nmod) pores_13\NNS\13911429|as|ions (r_nmod) act_11\VBP\1619354|which|pores|,|dissipating (r_acl:relcl) transporters_9\NNS\4490091|proteins|are|inner|mitochondrial|membrane|act|. (l_nsubj) proteins_1\NNS\14944888|uncoupling|ucps (l_appos) ucps_3\NNS\1740|(|)
T7_T19 NONE bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) fibrates_7\NNS\1740|of|two|,|bezafibrate|, (r_nmod) effects_4\NNS\13245626|the|fibrates|levels|cultures (l_nmod) levels_18\NNS\4916342|on|mrna (l_compound) mrna_17\NN\14832193|ucp-3 (l_compound) ucp-3_14\NN\1740|and|ucp-2
T7_T20 NONE bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) fibrates_7\NNS\1740|of|two|,|bezafibrate|, (r_nmod) effects_4\NNS\13245626|the|fibrates|levels|cultures (l_nmod) levels_18\NNS\4916342|on|mrna (l_compound) mrna_17\NN\14832193|ucp-3 (l_compound) ucp-3_14\NN\1740|and|ucp-2 (l_conj) ucp-2_16\NN\1740|
T8_T19 NONE wy-14,643_11\CD\1740| (r_conj) bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) fibrates_7\NNS\1740|of|two|,|bezafibrate|, (r_nmod) effects_4\NNS\13245626|the|fibrates|levels|cultures (l_nmod) levels_18\NNS\4916342|on|mrna (l_compound) mrna_17\NN\14832193|ucp-3 (l_compound) ucp-3_14\NN\1740|and|ucp-2
T8_T20 NONE wy-14,643_11\CD\1740| (r_conj) bezafibrate_9\NN\1740|and|wy-14,643 (r_appos) fibrates_7\NNS\1740|of|two|,|bezafibrate|, (r_nmod) effects_4\NNS\13245626|the|fibrates|levels|cultures (l_nmod) levels_18\NNS\4916342|on|mrna (l_compound) mrna_17\NN\14832193|ucp-3 (l_compound) ucp-3_14\NN\1740|and|ucp-2 (l_conj) ucp-2_16\NN\1740|
T9_T23 CPR:3 bezafibrate_2\NN\1740| (r_compound) treatment_3\NN\654885|bezafibrate (r_nsubj) resulted_4\VBD\2633881|thus|,|treatment|induction|. (l_nmod) induction_8\NN\7450842|in|an|8-fold|levels|induction (l_nmod) levels_12\NNS\4916342|in|mrna|preadipocytes (l_compound) mrna_11\NN\14832193|ucp-3 (l_compound) ucp-3_10\NN\1740|
T11_T28 NONE bezafibrate_13\NN\1740|by (r_nmod) modified_11\VBN\109660|contrast|,|levels|were|slightly|bezafibrate|adipocytes|. (l_nmod) contrast_1\NN\13854649|in|ucp-3 (l_nmod) ucp-3_3\NN\1740|to
T11_T29 NONE bezafibrate_13\NN\1740|by (r_nmod) modified_11\VBN\109660|contrast|,|levels|were|slightly|bezafibrate|adipocytes|. (l_nsubjpass) levels_7\NNS\4916342|mrna (l_compound) mrna_6\NN\14832193|ucp-2 (l_compound) ucp-2_5\NN\1740|
T1_T15 CPR:3 bezafibrate_20\NN\1740|or|wy-14,643 (r_compound) treatment_23\NN\654885|after|bezafibrate (r_nmod) changes_9\NNS\7283608|by|potential|treatment (r_nmod) accompanied_7\VBN\1835496|induction|was|not|changes|. (l_nsubjpass) induction_1\NN\7450842|the|expression (l_nmod) expression_4\NN\4679549|in|ucp-3 (l_compound) ucp-3_3\NN\1740|
T2_T15 CPR:3 wy-14,643_22\CD\1740| (r_conj) bezafibrate_20\NN\1740|or|wy-14,643 (r_compound) treatment_23\NN\654885|after|bezafibrate (r_nmod) changes_9\NNS\7283608|by|potential|treatment (r_nmod) accompanied_7\VBN\1835496|induction|was|not|changes|. (l_nsubjpass) induction_1\NN\7450842|the|expression (l_nmod) expression_4\NN\4679549|in|ucp-3 (l_compound) ucp-3_3\NN\1740|
T3_T16 NONE bezafibrate_28\NN\1740|and|wy-14|,|643 (r_compound) treatment_33\NN\654885|after|bezafibrate (r_nmod) achieved_26\VBN\2524171|treatment (r_acl) induction_25\NN\7450842|the|ucp-3|achieved (r_nsubj) indicate_35\VB\952524|proposed|,|induction|may|oxidation|,|limiting|. (l_advcl) proposed_4\VBN\1010118|since|it|has|been|involved (l_ccomp) involved_9\VBN\2676054|that|ucp-3|could|be|regulation (l_nsubjpass) ucp-3_6\NN\1740|
T3_T17 CPR:3 bezafibrate_28\NN\1740|and|wy-14|,|643 (r_compound) treatment_33\NN\654885|after|bezafibrate (r_nmod) achieved_26\VBN\2524171|treatment (r_acl) induction_25\NN\7450842|the|ucp-3|achieved (l_compound) ucp-3_24\NN\1740|
T4_T16 NONE 643_32\CD\1740| (r_nummod) bezafibrate_28\NN\1740|and|wy-14|,|643 (r_compound) treatment_33\NN\654885|after|bezafibrate (r_nmod) achieved_26\VBN\2524171|treatment (r_acl) induction_25\NN\7450842|the|ucp-3|achieved (r_nsubj) indicate_35\VB\952524|proposed|,|induction|may|oxidation|,|limiting|. (l_advcl) proposed_4\VBN\1010118|since|it|has|been|involved (l_ccomp) involved_9\VBN\2676054|that|ucp-3|could|be|regulation (l_nsubjpass) ucp-3_6\NN\1740|
T4_T17 CPR:3 643_32\CD\1740| (r_nummod) bezafibrate_28\NN\1740|and|wy-14|,|643 (r_compound) treatment_33\NN\654885|after|bezafibrate (r_nmod) achieved_26\VBN\2524171|treatment (r_acl) induction_25\NN\7450842|the|ucp-3|achieved (l_compound) ucp-3_24\NN\1740|
T5_T16 NONE acids_41\NNS\14818238|of|fatty (r_nmod) oxidation_38\NN\13447361|a|higher|acids (r_dobj) indicate_35\VB\952524|proposed|,|induction|may|oxidation|,|limiting|. (l_advcl) proposed_4\VBN\1010118|since|it|has|been|involved (l_ccomp) involved_9\VBN\2676054|that|ucp-3|could|be|regulation (l_nsubjpass) ucp-3_6\NN\1740|
T5_T17 NONE acids_41\NNS\14818238|of|fatty (r_nmod) oxidation_38\NN\13447361|a|higher|acids (r_dobj) indicate_35\VB\952524|proposed|,|induction|may|oxidation|,|limiting|. (l_nsubj) induction_25\NN\7450842|the|ucp-3|achieved (l_compound) ucp-3_24\NN\1740|
T6_T16 NONE triglycerides_50\NNS\14885088|as (r_nmod) stored_48\VBN\2202384|to|be|triglycerides (r_acl) availability_45\NN\4718563|their|stored (r_dobj) limiting_43\VBG\2510337|availability (r_advcl) indicate_35\VB\952524|proposed|,|induction|may|oxidation|,|limiting|. (l_advcl) proposed_4\VBN\1010118|since|it|has|been|involved (l_ccomp) involved_9\VBN\2676054|that|ucp-3|could|be|regulation (l_nsubjpass) ucp-3_6\NN\1740|
T6_T17 NONE triglycerides_50\NNS\14885088|as (r_nmod) stored_48\VBN\2202384|to|be|triglycerides (r_acl) availability_45\NN\4718563|their|stored (r_dobj) limiting_43\VBG\2510337|availability (r_advcl) indicate_35\VB\952524|proposed|,|induction|may|oxidation|,|limiting|. (l_nsubj) induction_25\NN\7450842|the|ucp-3|achieved (l_compound) ucp-3_24\NN\1740|
16597625
T6_T14 NONE aminoacyl-trna_25\NN\1740| (r_amod) synthetases_26\NNS\1740|aminoacyl-trna|aars|coded|,|and|imported
T6_T15 NONE aminoacyl-trna_25\NN\1740| (r_amod) synthetases_26\NNS\1740|aminoacyl-trna|aars|coded|,|and|imported (l_appos) aars_28\NNS\1740|(|)
T7_T18 NONE mt-aspartate_6\NN\1740| (r_compound) system_7\NN\3575240|the|human|mt-aspartate|recognizes (l_acl:relcl) recognizes_22\VBZ\686447|which|asprs|trna(asp (l_nsubj) asprs_12\NNS\1740|a|prokaryotic-type|,|similar|,
T8_T20 NONE aspartate_13\NN\1740| (r_compound) element_15\NN\5867413|of|a|conserved|major|aspartate|identity|,|g73|,|known (l_appos) g73_17\NN\1740|
T2_T10 NONE gly-269_7\NNP\1740| (r_dobj) placing_6\VBG\1850315|gly-269|position (l_nmod) position_10\NN\8620061|at|a|occupied (l_acl) occupied_11\VBN\2413480|asp-220 (l_nmod) asp-220_13\NN\1740|by|,|residue (l_appos) residue_16\NN\20827|the|contacting|structure (l_acl) contacting_17\VBG\740577|g73 (l_dobj) g73_18\NN\1740|
T2_T11 NONE gly-269_7\NNP\1740| (r_dobj) placing_6\VBG\1850315|gly-269|position (l_nmod) position_10\NN\8620061|at|a|occupied (l_acl) occupied_11\VBN\2413480|asp-220 (l_nmod) asp-220_13\NN\1740|by|,|residue (l_appos) residue_16\NN\20827|the|contacting|structure (l_nmod) structure_22\NN\21939|in|the|crystallographic|complex (l_nmod) complex_28\NN\5869584|of|e.|coli|asprs-trna(asp (l_compound) asprs-trna(asp_26\NN\1740|)
T2_T9 NONE gly-269_7\NNP\1740| (r_dobj) placing_6\VBG\1850315|gly-269|position (r_xcomp) allowed_5\VBD\797697|alignments|placing|. (l_nsubj) alignments_1\NNS\8008335|sequence|asprss (l_nmod) asprss_4\NNS\1740|of|various
T3_T10 NONE asp-220_13\NN\1740|by|,|residue (l_appos) residue_16\NN\20827|the|contacting|structure (l_acl) contacting_17\VBG\740577|g73 (l_dobj) g73_18\NN\1740|
T3_T11 NONE asp-220_13\NN\1740|by|,|residue (l_appos) residue_16\NN\20827|the|contacting|structure (l_nmod) structure_22\NN\21939|in|the|crystallographic|complex (l_nmod) complex_28\NN\5869584|of|e.|coli|asprs-trna(asp (l_compound) asprs-trna(asp_26\NN\1740|)
T3_T9 NONE asp-220_13\NN\1740|by|,|residue (r_nmod) occupied_11\VBN\2413480|asp-220 (r_acl) position_10\NN\8620061|at|a|occupied (r_nmod) placing_6\VBG\1850315|gly-269|position (r_xcomp) allowed_5\VBD\797697|alignments|placing|. (l_nsubj) alignments_1\NNS\8008335|sequence|asprss (l_nmod) asprss_4\NNS\1740|of|various
T4_T12 NONE glycine_2\NN\14601829|this (r_dobj) replacing_0\VBG\1631072|glycine|aspartate (r_csubj) renders_6\VBZ\120316|replacing|discriminative|. (l_ccomp) discriminative_10\JJ\1740|mt-asprs|more|g73 (l_nsubj) mt-asprs_8\NNS\1740|human
T4_T13 NONE glycine_2\NN\14601829|this (r_dobj) replacing_0\VBG\1631072|glycine|aspartate (r_csubj) renders_6\VBZ\120316|replacing|discriminative|. (l_ccomp) discriminative_10\JJ\1740|mt-asprs|more|g73 (l_nmod) g73_12\NN\1740|to
T5_T12 NONE aspartate_5\NN\1740|by|an (r_nmod) replacing_0\VBG\1631072|glycine|aspartate (r_csubj) renders_6\VBZ\120316|replacing|discriminative|. (l_ccomp) discriminative_10\JJ\1740|mt-asprs|more|g73 (l_nsubj) mt-asprs_8\NNS\1740|human
T5_T13 NONE aspartate_5\NN\1740|by|an (r_nmod) replacing_0\VBG\1631072|glycine|aspartate (r_csubj) renders_6\VBZ\120316|replacing|discriminative|. (l_ccomp) discriminative_10\JJ\1740|mt-asprs|more|g73 (l_nmod) g73_12\NN\1740|to
16782282
T18_T35 NONE acid_3\NN\14818238| (r_compound) receptors_4\NNS\5225602|of|retinoic|acid|alpha (l_dep) alpha_5\NN\6828818|,|beta|and|alpha (l_conj) beta_7\NN\6828818|
T18_T36 NONE acid_3\NN\14818238| (r_compound) receptors_4\NNS\5225602|of|retinoic|acid|alpha (l_dep) alpha_5\NN\6828818|,|beta|and|alpha (l_conj) alpha_12\NN\6828818|retinoid|x|receptor
T19_T35 NONE retinoid_9\NN\1740| (r_compound) alpha_12\NN\6828818|retinoid|x|receptor (r_conj) alpha_5\NN\6828818|,|beta|and|alpha (l_conj) beta_7\NN\6828818|
T19_T36 NONE retinoid_9\NN\1740| (r_compound) alpha_12\NN\6828818|retinoid|x|receptor
T6_T25 NONE acid_5\NN\14818238|of|retinoic (r_nmod) effect_2\NN\34213|the|acid (r_nsubjpass) mediated_7\VBN\761713|since|effect|is|receptors (l_nmod) receptors_11\NNS\5225602|via|retinoic|acid|and|receptors
T6_T26 NONE acid_5\NN\14818238|of|retinoic (r_nmod) effect_2\NN\34213|the|acid (r_nsubjpass) mediated_7\VBN\761713|since|effect|is|receptors (l_nmod) receptors_11\NNS\5225602|via|retinoic|acid|and|receptors (l_conj) receptors_15\NNS\5225602|retinoid|x
T7_T25 NONE acid_10\NN\14818238| (r_compound) receptors_11\NNS\5225602|via|retinoic|acid|and|receptors
T7_T26 NONE acid_10\NN\14818238| (r_compound) receptors_11\NNS\5225602|via|retinoic|acid|and|receptors (l_conj) receptors_15\NNS\5225602|retinoid|x
T8_T25 NONE retinoid_13\NN\1740| (r_compound) receptors_15\NNS\5225602|retinoid|x (r_conj) receptors_11\NNS\5225602|via|retinoic|acid|and|receptors
T8_T26 NONE retinoid_13\NN\1740| (r_compound) receptors_15\NNS\5225602|retinoid|x
T10_T27 NONE retinoid_15\NN\1740| (r_compound) alpha_18\NN\6828818|of|retinoid|x|receptor (r_conj) receptors_12\NNS\5225602|of|all|retinoic|acid|and|alpha
T10_T28 NONE retinoid_15\NN\1740| (r_compound) alpha_18\NN\6828818|of|retinoid|x|receptor
T9_T27 NONE acid_11\NN\14818238| (r_compound) receptors_12\NNS\5225602|of|all|retinoic|acid|and|alpha
T9_T28 NONE acid_11\NN\14818238| (r_compound) receptors_12\NNS\5225602|of|all|retinoic|acid|and|alpha (l_conj) alpha_18\NN\6828818|of|retinoid|x|receptor
T12_T29 NONE acid_4\NN\14818238| (r_compound) alpha_6\NN\6828818|of|retinoic|acid|receptor|,|beta|and|alpha
T12_T30 NONE acid_4\NN\14818238| (r_compound) alpha_6\NN\6828818|of|retinoic|acid|receptor|,|beta|and|alpha (l_conj) beta_11\NN\6828818|retinoic|acid|receptor
T12_T31 NONE acid_4\NN\14818238| (r_compound) alpha_6\NN\6828818|of|retinoic|acid|receptor|,|beta|and|alpha (l_conj) alpha_16\NN\6828818|retinoid|x|receptor
T13_T29 NONE acid_9\NN\14818238| (r_compound) beta_11\NN\6828818|retinoic|acid|receptor (r_conj) alpha_6\NN\6828818|of|retinoic|acid|receptor|,|beta|and|alpha
T13_T30 NONE acid_9\NN\14818238| (r_compound) beta_11\NN\6828818|retinoic|acid|receptor
T13_T31 NONE acid_9\NN\14818238| (r_compound) beta_11\NN\6828818|retinoic|acid|receptor (r_conj) alpha_6\NN\6828818|of|retinoic|acid|receptor|,|beta|and|alpha (l_conj) alpha_16\NN\6828818|retinoid|x|receptor
T14_T29 NONE retinoid_13\NN\1740| (r_compound) alpha_16\NN\6828818|retinoid|x|receptor (r_conj) alpha_6\NN\6828818|of|retinoic|acid|receptor|,|beta|and|alpha
T14_T30 NONE retinoid_13\NN\1740| (r_compound) alpha_16\NN\6828818|retinoid|x|receptor (r_conj) alpha_6\NN\6828818|of|retinoic|acid|receptor|,|beta|and|alpha (l_conj) beta_11\NN\6828818|retinoic|acid|receptor
T14_T31 NONE retinoid_13\NN\1740| (r_compound) alpha_16\NN\6828818|retinoid|x|receptor
T15_T32 NONE acid_8\NN\14818238| (r_compound) alpha_10\NN\6828818|of|retinoic|acid|receptor
T15_T33 NONE acid_8\NN\14818238| (r_compound) alpha_10\NN\6828818|of|retinoic|acid|receptor (r_nmod) increase_5\NN\13576355|a|significant|alpha (r_nsubjpass) detected_12\VBN\2163746|nerves|increase|was|days|,|and|beta|. (l_conj) beta_23\NN\6828818|of|retinoic|acid|receptor|days|after|transection
T16_T32 NONE acid_21\NN\14818238| (r_compound) beta_23\NN\6828818|of|retinoic|acid|receptor|days|after|transection (r_conj) detected_12\VBN\2163746|nerves|increase|was|days|,|and|beta|. (l_nsubjpass) increase_5\NN\13576355|a|significant|alpha (l_nmod) alpha_10\NN\6828818|of|retinoic|acid|receptor
T16_T33 NONE acid_21\NN\14818238| (r_compound) beta_23\NN\6828818|of|retinoic|acid|receptor|days|after|transection
T17_T34 NONE retinoid_3\NN\1740| (r_compound) receptors_4\NNS\5225602|of|retinoid
T1_T20 NONE acid_7\NN\14818238| (r_compound) alpha_9\NN\6828818|retinoic|acid|receptor|and|alpha
T1_T21 NONE acid_7\NN\14818238| (r_compound) alpha_9\NN\6828818|retinoic|acid|receptor|and|alpha (l_conj) alpha_14\NN\6828818|retinoid|x|receptor
T1_T22 NONE acid_7\NN\14818238| (r_compound) alpha_9\NN\6828818|retinoic|acid|receptor|and|alpha (r_nsubj) appeared_15\VBD\2604760|that|alpha|nuclei|reaction|,|and|co-localized (l_conj) co-localized_34\JJ\1740|that|alpha-staining|axons (l_nsubj) alpha-staining_33\NN\1740|retinoid|x|receptor
T2_T20 NONE retinoid_11\NN\1740| (r_compound) alpha_14\NN\6828818|retinoid|x|receptor (r_conj) alpha_9\NN\6828818|retinoic|acid|receptor|and|alpha
T2_T21 NONE retinoid_11\NN\1740| (r_compound) alpha_14\NN\6828818|retinoid|x|receptor
T2_T22 NONE retinoid_11\NN\1740| (r_compound) alpha_14\NN\6828818|retinoid|x|receptor (r_conj) alpha_9\NN\6828818|retinoic|acid|receptor|and|alpha (r_nsubj) appeared_15\VBD\2604760|that|alpha|nuclei|reaction|,|and|co-localized (l_conj) co-localized_34\JJ\1740|that|alpha-staining|axons (l_nsubj) alpha-staining_33\NN\1740|retinoid|x|receptor
T3_T20 NONE retinoid_30\NN\1740| (r_compound) alpha-staining_33\NN\1740|retinoid|x|receptor (r_nsubj) co-localized_34\JJ\1740|that|alpha-staining|axons (r_conj) appeared_15\VBD\2604760|that|alpha|nuclei|reaction|,|and|co-localized (l_nsubj) alpha_9\NN\6828818|retinoic|acid|receptor|and|alpha
T3_T21 NONE retinoid_30\NN\1740| (r_compound) alpha-staining_33\NN\1740|retinoid|x|receptor (r_nsubj) co-localized_34\JJ\1740|that|alpha-staining|axons (r_conj) appeared_15\VBD\2604760|that|alpha|nuclei|reaction|,|and|co-localized (l_nsubj) alpha_9\NN\6828818|retinoic|acid|receptor|and|alpha (l_conj) alpha_14\NN\6828818|retinoid|x|receptor
T3_T22 NONE retinoid_30\NN\1740| (r_compound) alpha-staining_33\NN\1740|retinoid|x|receptor
T4_T23 NONE acid_11\NN\14818238|of|retinoic (r_nmod) effect_8\NN\34213|an|acid|expression (l_nmod) expression_14\NN\4679549|on|the|erbb3 (l_nmod) erbb3_19\NN\1740|of|the|neuregulin|receptor (l_compound) receptor_18\NN\5225602|
T4_T24 NONE acid_11\NN\14818238|of|retinoic (r_nmod) effect_8\NN\34213|an|acid|expression (l_nmod) expression_14\NN\4679549|on|the|erbb3 (l_nmod) erbb3_19\NN\1740|of|the|neuregulin|receptor
T5_T23 NONE acid_27\NN\14818238|of|retinoic (r_nmod) function_24\NN\13783581|one|acid (r_nsubj) consists_28\VBZ\2603699|that|function|regulation (r_ccomp) suggesting_21\VBG\1010118|consists (r_advcl) revealed_6\VBD\2137132|experiments|effect|,|suggesting|. (l_dobj) effect_8\NN\34213|an|acid|expression (l_nmod) expression_14\NN\4679549|on|the|erbb3 (l_nmod) erbb3_19\NN\1740|of|the|neuregulin|receptor (l_compound) receptor_18\NN\5225602|
T5_T24 NONE acid_27\NN\14818238|of|retinoic (r_nmod) function_24\NN\13783581|one|acid (r_nsubj) consists_28\VBZ\2603699|that|function|regulation (r_ccomp) suggesting_21\VBG\1010118|consists (r_advcl) revealed_6\VBD\2137132|experiments|effect|,|suggesting|. (l_dobj) effect_8\NN\34213|an|acid|expression (l_nmod) expression_14\NN\4679549|on|the|erbb3 (l_nmod) erbb3_19\NN\1740|of|the|neuregulin|receptor
23567041
23363083
23497878
23403272
T19_T33 CPR:3 paeoniflorin_0\NN\1740| (r_nsubj) protects_1\VBZ\1127795|paeoniflorin|cells|injury|activating|. (l_advcl) activating_12\VBG\1641914|by|pathway (l_dobj) pathway_18\NN\5483677|the|nf-e2-related|factor|2/heme|oxygenase-1 (l_compound) 2/heme_16\NN\1740|
T19_T34 CPR:3 paeoniflorin_0\NN\1740| (r_nsubj) protects_1\VBZ\1127795|paeoniflorin|cells|injury|activating|. (l_advcl) activating_12\VBG\1641914|by|pathway (l_dobj) pathway_18\NN\5483677|the|nf-e2-related|factor|2/heme|oxygenase-1 (l_compound) oxygenase-1_17\NN\1740|
T20_T33 NONE 2/heme_16\NN\1740|
T20_T34 NONE 2/heme_16\NN\1740| (r_compound) pathway_18\NN\5483677|the|nf-e2-related|factor|2/heme|oxygenase-1 (l_compound) oxygenase-1_17\NN\1740|
T10_T29 CPR:4 paeoniflorin_6\NN\1740| (r_nsubj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_dobj) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh
T10_T30 CPR:4 paeoniflorin_6\NN\1740| (r_nsubj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_dobj) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh (l_appos) ldh_31\NN\1740|(|)
T10_T31 CPR:3 paeoniflorin_6\NN\1740| (r_nsubj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod
T10_T32 CPR:3 paeoniflorin_6\NN\1740| (r_nsubj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod (l_appos) sod_51\NN\9335240|(|)
T11_T29 NONE oxygen_14\NN\14622893| (r_compound) species_15\NNS\7992450|of|intracellular|reactive|oxygen|ros (r_nmod) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh
T11_T30 NONE oxygen_14\NN\14622893| (r_compound) species_15\NNS\7992450|of|intracellular|reactive|oxygen|ros (r_nmod) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh (l_appos) ldh_31\NN\1740|(|)
T11_T31 NONE oxygen_14\NN\14622893| (r_compound) species_15\NNS\7992450|of|intracellular|reactive|oxygen|ros (r_nmod) formation_10\NN\7938773|the|species|,|level|, (r_dobj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod
T11_T32 NONE oxygen_14\NN\14622893| (r_compound) species_15\NNS\7992450|of|intracellular|reactive|oxygen|ros (r_nmod) formation_10\NN\7938773|the|species|,|level|, (r_dobj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod (l_appos) sod_51\NN\9335240|(|)
T12_T29 NONE malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh
T12_T30 NONE malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh (l_appos) ldh_31\NN\1740|(|)
T12_T31 NONE malondialdehyde_23\NN\1740|of|mda|and|leakage (r_nmod) level_21\NN\4916342|the|malondialdehyde (r_conj) formation_10\NN\7938773|the|species|,|level|, (r_dobj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod
T12_T32 NONE malondialdehyde_23\NN\1740|of|mda|and|leakage (r_nmod) level_21\NN\4916342|the|malondialdehyde (r_conj) formation_10\NN\7938773|the|species|,|level|, (r_dobj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod (l_appos) sod_51\NN\9335240|(|)
T13_T29 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh
T13_T30 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh (l_appos) ldh_31\NN\1740|(|)
T13_T31 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|of|mda|and|leakage (r_nmod) level_21\NN\4916342|the|malondialdehyde (r_conj) formation_10\NN\7938773|the|species|,|level|, (r_dobj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod
T13_T32 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|of|mda|and|leakage (r_nmod) level_21\NN\4916342|the|malondialdehyde (r_conj) formation_10\NN\7938773|the|species|,|level|, (r_dobj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod (l_appos) sod_51\NN\9335240|(|)
T14_T29 NONE lactate_28\NN\14850483| (r_compound) dehydrogenase_29\NN\1740|lactate|ldh
T14_T30 NONE lactate_28\NN\14850483| (r_compound) dehydrogenase_29\NN\1740|lactate|ldh (l_appos) ldh_31\NN\1740|(|)
T14_T31 NONE lactate_28\NN\14850483| (r_compound) dehydrogenase_29\NN\1740|lactate|ldh (r_compound) leakage_33\NN\7407777|dehydrogenase (r_conj) malondialdehyde_23\NN\1740|of|mda|and|leakage (r_nmod) level_21\NN\4916342|the|malondialdehyde (r_conj) formation_10\NN\7938773|the|species|,|level|, (r_dobj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod
T14_T32 NONE lactate_28\NN\14850483| (r_compound) dehydrogenase_29\NN\1740|lactate|ldh (r_compound) leakage_33\NN\7407777|dehydrogenase (r_conj) malondialdehyde_23\NN\1740|of|mda|and|leakage (r_nmod) level_21\NN\4916342|the|malondialdehyde (r_conj) formation_10\NN\7938773|the|species|,|level|, (r_dobj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_conj) production_37\NN\30358|enhanced|antioxidants (l_nmod) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (l_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod (l_appos) sod_51\NN\9335240|(|)
T15_T29 NONE glutathione_43\NN\1740|gsh|and|dismutase (r_appos) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (r_nmod) production_37\NN\30358|enhanced|antioxidants (r_conj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_dobj) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh
T15_T30 NONE glutathione_43\NN\1740|gsh|and|dismutase (r_appos) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (r_nmod) production_37\NN\30358|enhanced|antioxidants (r_conj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_dobj) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh (l_appos) ldh_31\NN\1740|(|)
T15_T31 NONE glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod
T15_T32 NONE glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod (l_appos) sod_51\NN\9335240|(|)
T16_T29 NONE gsh_45\NN\1740|(|) (r_appos) glutathione_43\NN\1740|gsh|and|dismutase (r_appos) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (r_nmod) production_37\NN\30358|enhanced|antioxidants (r_conj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_dobj) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh
T16_T30 NONE gsh_45\NN\1740|(|) (r_appos) glutathione_43\NN\1740|gsh|and|dismutase (r_appos) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (r_nmod) production_37\NN\30358|enhanced|antioxidants (r_conj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_dobj) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh (l_appos) ldh_31\NN\1740|(|)
T16_T31 NONE gsh_45\NN\1740|(|) (r_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod
T16_T32 NONE gsh_45\NN\1740|(|) (r_appos) glutathione_43\NN\1740|gsh|and|dismutase (l_conj) dismutase_49\NN\1740|superoxide|sod (l_appos) sod_51\NN\9335240|(|)
T17_T29 NONE superoxide_48\NN\14971519| (r_compound) dismutase_49\NN\1740|superoxide|sod (r_conj) glutathione_43\NN\1740|gsh|and|dismutase (r_appos) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (r_nmod) production_37\NN\30358|enhanced|antioxidants (r_conj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_dobj) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh
T17_T30 NONE superoxide_48\NN\14971519| (r_compound) dismutase_49\NN\1740|superoxide|sod (r_conj) glutathione_43\NN\1740|gsh|and|dismutase (r_appos) antioxidants_41\NNS\14724436|of|the|endogenous|,|glutathione|cells (r_nmod) production_37\NN\30358|enhanced|antioxidants (r_conj) reduced_8\VBD\441445|that|paeoniflorin|significantly|formation|and|production (l_dobj) formation_10\NN\7938773|the|species|,|level|, (l_conj) level_21\NN\4916342|the|malondialdehyde (l_nmod) malondialdehyde_23\NN\1740|of|mda|and|leakage (l_conj) leakage_33\NN\7407777|dehydrogenase (l_compound) dehydrogenase_29\NN\1740|lactate|ldh (l_appos) ldh_31\NN\1740|(|)
T17_T31 NONE superoxide_48\NN\14971519| (r_compound) dismutase_49\NN\1740|superoxide|sod
T17_T32 NONE superoxide_48\NN\14971519| (r_compound) dismutase_49\NN\1740|superoxide|sod (l_appos) sod_51\NN\9335240|(|)
T18_T21 CPR:3 paeoniflorin_5\NN\1740|with (r_nmod) treatment_0\NN\654885|cells|paeoniflorin (r_nsubj) induced_7\VBD\1627355|treatment|significantly|expression|. (l_dobj) expression_9\NN\4679549|ho-1 (l_compound) ho-1_8\NN\1740|
T1_T22 NONE paeoniflorin_2\NN\1740| (r_nsubj) promoted_3\VBD\2556126|moreover|,|paeoniflorin|translocation|. (l_dobj) translocation_6\NN\13526110|the|nuclear|factor-2 (l_nmod) factor-2_13\NN\1740|of|nuclear|factor|erythroid|2|related|nrf-2
T1_T23 NONE paeoniflorin_2\NN\1740| (r_nsubj) promoted_3\VBD\2556126|moreover|,|paeoniflorin|translocation|. (l_dobj) translocation_6\NN\13526110|the|nuclear|factor-2 (l_nmod) factor-2_13\NN\1740|of|nuclear|factor|erythroid|2|related|nrf-2 (l_appos) nrf-2_15\NN\1740|(|)
T2_T24 CPR:3 paeoniflorin-induced_1\NN\1740| (r_amod) expression_3\NN\4679549|the|paeoniflorin-induced|ho-1 (l_compound) ho-1_2\NN\1740|
T2_T25 NONE paeoniflorin-induced_1\NN\1740| (r_amod) expression_3\NN\4679549|the|paeoniflorin-induced|ho-1 (r_nsubjpass) abrogated_5\VBN\2427334|expression|was|sirna|. (l_nmod) sirna_8\NN\1740|by|nrf2 (l_compound) nrf2_7\NN\1740|
T3_T26 CPR:4 ix_8\CD\13741022| (r_nummod) protoporphyrin_7\NN\1740|with|zinc|ix|znpp (r_nmod) inhibition_2\NN\1068773|ho-1|protoporphyrin (l_nmod) ho-1_4\NN\1740|of
T4_T26 CPR:4 znpp_10\NN\1740|(|) (r_appos) protoporphyrin_7\NN\1740|with|zinc|ix|znpp (r_nmod) inhibition_2\NN\1068773|ho-1|protoporphyrin (l_nmod) ho-1_4\NN\1740|of
T5_T26 CPR:3 paeoniflorin_18\NN\1740|of (r_nmod) effect_16\NN\34213|the|protective|paeoniflorin|damage (r_dobj) reversed_13\VBD\109660|furthermore|,|inhibition|significantly|effect|. (l_nsubj) inhibition_2\NN\1068773|ho-1|protoporphyrin (l_nmod) ho-1_4\NN\1740|of
T6_T27 CPR:3 paeoniflorin_4\NN\1740| (r_nsubj) protected_5\VBD\1127795|that|paeoniflorin|cells|injury|pathway (l_nmod) pathway_14\NN\5483677|through|the|nrf2/ho-1 (l_compound) nrf2/ho-1_13\NN\1740|
T6_T28 CPR:3 paeoniflorin_4\NN\1740| (r_nsubj) protected_5\VBD\1127795|that|paeoniflorin|cells|injury|pathway (l_nmod) pathway_14\NN\5483677|through|the|nrf2/ho-1 (l_compound) nrf2/ho-1_13\NN\1740|
23500550
T3_T16 NONE n-terminal_14\JJ\1740| (r_amod) peptides_16\NNS\14724264|n-terminal|pthrp (l_compound) pthrp_15\NN\1740|
T1_T17 NONE n-terminal_15\JJ\1740| (r_amod) domain_16\NN\13934596|only|to|its|n-terminal|but|region (r_nmod) ascribed_10\VBN\670261|addition|,|actions|might|be|domain|. (l_nsubjpass) actions_5\NNS\30358|putative|osteogenic|pthrp (l_nmod) pthrp_7\NN\1740|of
T1_T4 NONE n-terminal_15\JJ\1740| (r_amod) domain_16\NN\13934596|only|to|its|n-terminal|but|region (l_conj) region_23\NN\27167|also|to|its|pth-unrelated|c-terminal (l_amod) pth-unrelated_21\JJ\1740|
T2_T17 NONE c-terminal_22\JJ\1740| (r_amod) region_23\NN\27167|also|to|its|pth-unrelated|c-terminal (r_conj) domain_16\NN\13934596|only|to|its|n-terminal|but|region (r_nmod) ascribed_10\VBN\670261|addition|,|actions|might|be|domain|. (l_nsubjpass) actions_5\NNS\30358|putative|osteogenic|pthrp (l_nmod) pthrp_7\NN\1740|of
T2_T4 NONE c-terminal_22\JJ\1740| (r_amod) region_23\NN\27167|also|to|its|pth-unrelated|c-terminal (l_amod) pth-unrelated_21\JJ\1740|
17916059
T4_T13 NONE citalopram_7\NN\1740|than (r_nmod) potent_3\JJ\1740|it|is|more|and|selective|citalopram|inhibiting|,|and|potent|:|potent|. (l_parataxis) potent_43\JJ\1740|particular|,|it|is|less|citalopram|binding (l_nmod) binding_47\VBG\1290422|in|receptors (l_nmod) receptors_54\NNS\5225602|h1 (l_compound) h1_51\NN\1740|to|the|histamine|and|muscarinic
T4_T14 NONE citalopram_7\NN\1740|than (r_nmod) potent_3\JJ\1740|it|is|more|and|selective|citalopram|inhibiting|,|and|potent|:|potent|. (l_parataxis) potent_43\JJ\1740|particular|,|it|is|less|citalopram|binding (l_nmod) binding_47\VBG\1290422|in|receptors (l_nmod) receptors_54\NNS\5225602|h1
T5_T13 NONE serotonin_10\NN\14807737| (r_compound) re-uptake_11\NN\13571580|serotonin|cns (r_dobj) inhibiting_9\VBG\2510337|in|re-uptake (r_advcl) potent_3\JJ\1740|it|is|more|and|selective|citalopram|inhibiting|,|and|potent|:|potent|. (l_parataxis) potent_43\JJ\1740|particular|,|it|is|less|citalopram|binding (l_nmod) binding_47\VBG\1290422|in|receptors (l_nmod) receptors_54\NNS\5225602|h1 (l_compound) h1_51\NN\1740|to|the|histamine|and|muscarinic
T5_T14 NONE serotonin_10\NN\14807737| (r_compound) re-uptake_11\NN\13571580|serotonin|cns (r_dobj) inhibiting_9\VBG\2510337|in|re-uptake (r_advcl) potent_3\JJ\1740|it|is|more|and|selective|citalopram|inhibiting|,|and|potent|:|potent|. (l_parataxis) potent_43\JJ\1740|particular|,|it|is|less|citalopram|binding (l_nmod) binding_47\VBG\1290422|in|receptors (l_nmod) receptors_54\NNS\5225602|h1
T7_T13 NONE serotonin_23\NN\14807737| (r_compound) inhibitors_25\NNS\20090|than|various|other|selective|serotonin|re-uptake (r_nmod) potent_18\JJ\1740|less|inhibitors|relation (r_conj) potent_3\JJ\1740|it|is|more|and|selective|citalopram|inhibiting|,|and|potent|:|potent|. (l_parataxis) potent_43\JJ\1740|particular|,|it|is|less|citalopram|binding (l_nmod) binding_47\VBG\1290422|in|receptors (l_nmod) receptors_54\NNS\5225602|h1 (l_compound) h1_51\NN\1740|to|the|histamine|and|muscarinic
T7_T14 NONE serotonin_23\NN\14807737| (r_compound) inhibitors_25\NNS\20090|than|various|other|selective|serotonin|re-uptake (r_nmod) potent_18\JJ\1740|less|inhibitors|relation (r_conj) potent_3\JJ\1740|it|is|more|and|selective|citalopram|inhibiting|,|and|potent|:|potent|. (l_parataxis) potent_43\JJ\1740|particular|,|it|is|less|citalopram|binding (l_nmod) binding_47\VBG\1290422|in|receptors (l_nmod) receptors_54\NNS\5225602|h1
T8_T13 NONE citalopram_45\NN\1740|than (r_nmod) potent_43\JJ\1740|particular|,|it|is|less|citalopram|binding (l_nmod) binding_47\VBG\1290422|in|receptors (l_nmod) receptors_54\NNS\5225602|h1 (l_compound) h1_51\NN\1740|to|the|histamine|and|muscarinic
T8_T14 NONE citalopram_45\NN\1740|than (r_nmod) potent_43\JJ\1740|particular|,|it|is|less|citalopram|binding (l_nmod) binding_47\VBG\1290422|in|receptors (l_nmod) receptors_54\NNS\5225602|h1
T9_T13 NONE histamine_50\NN\14739004| (r_compound) h1_51\NN\1740|to|the|histamine|and|muscarinic
T9_T14 NONE histamine_50\NN\14739004| (r_compound) h1_51\NN\1740|to|the|histamine|and|muscarinic (r_compound) receptors_54\NNS\5225602|h1
T11_T16 CPR:9 metoprolol_16\NN\2832168|such (r_nmod) drugs_9\NNS\14778436|with|metabolised|,|metoprolol|, (l_acl) metabolised_10\VBN\1740|cyp2d6 (l_nmod) cyp2d6_12\NN\1740|by
17110146
T19_T24 NONE purines_10\NNS\14618253|for|prefer (r_nmod) receptors_8\NNS\5225602|of|cell|surface|purines (r_nmod) class_4\NN\7951464|receptors|are|a|receptors|. (l_nsubj) receptors_1\NNS\5225602|purinergic
T20_T24 NONE atp_13\NN\14964590|or|adp (r_dobj) prefer_12\VBP\1777210|that|atp|adenosine (r_acl:relcl) purines_10\NNS\14618253|for|prefer (r_nmod) receptors_8\NNS\5225602|of|cell|surface|purines (r_nmod) class_4\NN\7951464|receptors|are|a|receptors|. (l_nsubj) receptors_1\NNS\5225602|purinergic
T21_T24 NONE adp_15\NN\14964590| (r_conj) atp_13\NN\14964590|or|adp (r_dobj) prefer_12\VBP\1777210|that|atp|adenosine (r_acl:relcl) purines_10\NNS\14618253|for|prefer (r_nmod) receptors_8\NNS\5225602|of|cell|surface|purines (r_nmod) class_4\NN\7951464|receptors|are|a|receptors|. (l_nsubj) receptors_1\NNS\5225602|purinergic
T23_T24 NONE adenosine_17\NN\14964367|over (r_nmod) prefer_12\VBP\1777210|that|atp|adenosine (r_acl:relcl) purines_10\NNS\14618253|for|prefer (r_nmod) receptors_8\NNS\5225602|of|cell|surface|purines (r_nmod) class_4\NN\7951464|receptors|are|a|receptors|. (l_nsubj) receptors_1\NNS\5225602|purinergic
T9_T35 NONE nucleotides_5\NNS\14850483|for|extracellular (r_nmod) receptors_2\NNS\5225602|the|surface|nucleotides (r_nsubjpass) called_7\VBN\1029852|receptors|are|receptors|. (l_xcomp) receptors_9\NNS\5225602|p2
T13_T36 CPR:3 adp_0\NN\14964590| (r_nsubj) initiates_1\VBZ\1617192|adp|aggregation|activation|. (l_nmod) activation_7\NN\13561719|by|'|simultaneous|receptors (l_nmod) receptors_12\NNS\5225602|of|two|protein-coupled|,|p2y1
T13_T37 CPR:3 adp_0\NN\14964590| (r_nsubj) initiates_1\VBZ\1617192|adp|aggregation|activation|. (l_nmod) activation_7\NN\13561719|by|'|simultaneous|receptors (l_nmod) receptors_12\NNS\5225602|of|two|protein-coupled|,|p2y1 (l_appos) p2y1_14\NN\1740|and|p2y12
T13_T38 CPR:3 adp_0\NN\14964590| (r_nsubj) initiates_1\VBZ\1617192|adp|aggregation|activation|. (l_nmod) activation_7\NN\13561719|by|'|simultaneous|receptors (l_nmod) receptors_12\NNS\5225602|of|two|protein-coupled|,|p2y1 (l_appos) p2y1_14\NN\1740|and|p2y12 (l_conj) p2y12_16\NN\1740|
T14_T39 NONE thienopyridine_10\NN\1740| (r_compound) drugs_11\NNS\14778436|of|the|thienopyridine|,|ticlopidine (r_nmod) target_7\NN\7258332|to|be|the|drugs (r_xcomp) shown_3\VBN\2137132|p2y12|has|been|target|. (l_nsubjpass) p2y12_0\NN\1740|
T15_T39 NONE ticlopidine_13\NN\1740|and|clopidogrel (r_appos) drugs_11\NNS\14778436|of|the|thienopyridine|,|ticlopidine (r_nmod) target_7\NN\7258332|to|be|the|drugs (r_xcomp) shown_3\VBN\2137132|p2y12|has|been|target|. (l_nsubjpass) p2y12_0\NN\1740|
T16_T39 NONE clopidogrel_15\NN\1740| (r_conj) ticlopidine_13\NN\1740|and|clopidogrel (r_appos) drugs_11\NNS\14778436|of|the|thienopyridine|,|ticlopidine (r_nmod) target_7\NN\7258332|to|be|the|drugs (r_xcomp) shown_3\VBN\2137132|p2y12|has|been|target|. (l_nsubjpass) p2y12_0\NN\1740|
T17_T40 NONE atp_8\NN\14964590|for|as|adp (r_nmod) sites_4\NNS\8673395|the|active|p2y12|atp (l_nmod) p2y12_6\NN\1740|of
T18_T40 NONE adp_12\NN\14964590| (r_conj) atp_8\NN\14964590|for|as|adp (r_nmod) sites_4\NNS\8673395|the|active|p2y12|atp (l_nmod) p2y12_6\NN\1740|of
T1_T25 NONE lgtgplrtfv_26\NNP\1740|(|,|87 (r_appos) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (r_appos) areas_19\NNS\8630985|three|distant|:|area (r_dobj) include_16\VBP\690614|which|areas (r_acl:relcl) matrix_13\NN\7939382|the|scoring|,|include (r_dobj) using_10\VBG\1156834|matrix (r_xcomp) predicted_9\VBN\916909|and|sites|were|using|. (l_nsubjpass) sites_5\NNS\8673395|the|probable|active|p2y12 (l_nmod) p2y12_7\NN\1740|of
T1_T26 NONE lgtgplrtfv_26\NNP\1740|(|,|87
T1_T27 NONE lgtgplrtfv_26\NNP\1740|(|,|87 (r_appos) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_conj) area_35\NN\8630985|"|middle|"|vglitnglam|, (l_appos) vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|)
T1_T28 NONE lgtgplrtfv_26\NNP\1740|(|,|87 (r_appos) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_conj) area_35\NN\8630985|"|middle|"|vglitnglam|, (l_appos) vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (l_conj) lgakilsvvi_45\NNP\1740|,|139
T1_T29 NONE lgtgplrtfv_26\NNP\1740|(|,|87 (r_appos) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_conj) area_55\NN\8630985|"|bottom|"|rtrgvgkvpr (l_appos) rtrgvgkvpr_58\NNP\1740|(|,|222|)
T2_T25 NONE vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (r_appos) area_35\NN\8630985|"|middle|"|vglitnglam|, (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (r_appos) areas_19\NNS\8630985|three|distant|:|area (r_dobj) include_16\VBP\690614|which|areas (r_acl:relcl) matrix_13\NN\7939382|the|scoring|,|include (r_dobj) using_10\VBG\1156834|matrix (r_xcomp) predicted_9\VBN\916909|and|sites|were|using|. (l_nsubjpass) sites_5\NNS\8673395|the|probable|active|p2y12 (l_nmod) p2y12_7\NN\1740|of
T2_T26 NONE vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (r_appos) area_35\NN\8630985|"|middle|"|vglitnglam|, (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_appos) lgtgplrtfv_26\NNP\1740|(|,|87
T2_T27 NONE vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|)
T2_T28 NONE vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (l_conj) lgakilsvvi_45\NNP\1740|,|139
T2_T29 NONE vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (r_appos) area_35\NN\8630985|"|middle|"|vglitnglam|, (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_conj) area_55\NN\8630985|"|bottom|"|rtrgvgkvpr (l_appos) rtrgvgkvpr_58\NNP\1740|(|,|222|)
T3_T25 NONE lgakilsvvi_45\NNP\1740|,|139 (r_conj) vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (r_appos) area_35\NN\8630985|"|middle|"|vglitnglam|, (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (r_appos) areas_19\NNS\8630985|three|distant|:|area (r_dobj) include_16\VBP\690614|which|areas (r_acl:relcl) matrix_13\NN\7939382|the|scoring|,|include (r_dobj) using_10\VBG\1156834|matrix (r_xcomp) predicted_9\VBN\916909|and|sites|were|using|. (l_nsubjpass) sites_5\NNS\8673395|the|probable|active|p2y12 (l_nmod) p2y12_7\NN\1740|of
T3_T26 NONE lgakilsvvi_45\NNP\1740|,|139 (r_conj) vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (r_appos) area_35\NN\8630985|"|middle|"|vglitnglam|, (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_appos) lgtgplrtfv_26\NNP\1740|(|,|87
T3_T27 NONE lgakilsvvi_45\NNP\1740|,|139 (r_conj) vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|)
T3_T28 NONE lgakilsvvi_45\NNP\1740|,|139
T3_T29 NONE lgakilsvvi_45\NNP\1740|,|139 (r_conj) vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (r_appos) area_35\NN\8630985|"|middle|"|vglitnglam|, (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_conj) area_55\NN\8630985|"|bottom|"|rtrgvgkvpr (l_appos) rtrgvgkvpr_58\NNP\1740|(|,|222|)
T4_T25 NONE rtrgvgkvpr_58\NNP\1740|(|,|222|) (r_appos) area_55\NN\8630985|"|bottom|"|rtrgvgkvpr (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (r_appos) areas_19\NNS\8630985|three|distant|:|area (r_dobj) include_16\VBP\690614|which|areas (r_acl:relcl) matrix_13\NN\7939382|the|scoring|,|include (r_dobj) using_10\VBG\1156834|matrix (r_xcomp) predicted_9\VBN\916909|and|sites|were|using|. (l_nsubjpass) sites_5\NNS\8673395|the|probable|active|p2y12 (l_nmod) p2y12_7\NN\1740|of
T4_T26 NONE rtrgvgkvpr_58\NNP\1740|(|,|222|) (r_appos) area_55\NN\8630985|"|bottom|"|rtrgvgkvpr (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_appos) lgtgplrtfv_26\NNP\1740|(|,|87
T4_T27 NONE rtrgvgkvpr_58\NNP\1740|(|,|222|) (r_appos) area_55\NN\8630985|"|bottom|"|rtrgvgkvpr (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_conj) area_35\NN\8630985|"|middle|"|vglitnglam|, (l_appos) vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|)
T4_T28 NONE rtrgvgkvpr_58\NNP\1740|(|,|222|) (r_appos) area_55\NN\8630985|"|bottom|"|rtrgvgkvpr (r_conj) area_23\NN\8630985|"|head|"|lgtgplrtfv|)|,|area|and|area (l_conj) area_35\NN\8630985|"|middle|"|vglitnglam|, (l_appos) vglitnglam_38\NNP\1740|(|,|47|,|and|lgakilsvvi|) (l_conj) lgakilsvvi_45\NNP\1740|,|139
T4_T29 NONE rtrgvgkvpr_58\NNP\1740|(|,|222|)
T5_T30 NONE atp/adp_9\NN\1740|with (r_nmod) docked_7\VBN\2016523|subsequently|model|was|atp/adp|comparison|. (l_nsubjpass) model_3\NN\5888929|the|structural|p2y12 (l_nmod) p2y12_5\NN\1740|of
T5_T31 NONE atp/adp_9\NN\1740|with (r_nmod) docked_7\VBN\2016523|subsequently|model|was|atp/adp|comparison|. (l_nmod) comparison_11\NN\635850|in|p2y1 (l_nmod) p2y1_13\NN\1740|with|code
T5_T32 NONE atp/adp_9\NN\1740|with (r_nmod) docked_7\VBN\2016523|subsequently|model|was|atp/adp|comparison|. (l_nmod) comparison_11\NN\635850|in|p2y1 (l_nmod) p2y1_13\NN\1740|with|code (l_appos) code_16\NN\6349220|(|pdb|1ddd|) (l_appos) 1ddd_17\NN\1740|
T6_T30 NONE atp/adp_9\NN\1740|with (r_nmod) docked_7\VBN\2016523|subsequently|model|was|atp/adp|comparison|. (l_nsubjpass) model_3\NN\5888929|the|structural|p2y12 (l_nmod) p2y12_5\NN\1740|of
T6_T31 NONE atp/adp_9\NN\1740|with (r_nmod) docked_7\VBN\2016523|subsequently|model|was|atp/adp|comparison|. (l_nmod) comparison_11\NN\635850|in|p2y1 (l_nmod) p2y1_13\NN\1740|with|code
T6_T32 NONE atp/adp_9\NN\1740|with (r_nmod) docked_7\VBN\2016523|subsequently|model|was|atp/adp|comparison|. (l_nmod) comparison_11\NN\635850|in|p2y1 (l_nmod) p2y1_13\NN\1740|with|code (l_appos) code_16\NN\6349220|(|pdb|1ddd|) (l_appos) 1ddd_17\NN\1740|
T10_T33 CPR:4 adp/atp_12\NN\1740| (r_compound) analogs_13\NNS\4743605|by|adp/atp (r_nmod) inhibited_10\VBN\2510337|to|be|analogs (r_acl) potential_7\NN\14481929|the|inhibited (r_dobj) has_5\VBZ\2108377|that|p2y12|potential (l_nsubj) p2y12_4\NN\1740|
T10_T34 NONE adp/atp_12\NN\1740| (r_compound) analogs_13\NNS\4743605|by|adp/atp (r_nmod) inhibited_10\VBN\2510337|to|be|analogs (r_acl) potential_7\NN\14481929|the|inhibited (r_dobj) has_5\VBZ\2108377|that|p2y12|potential (r_ccomp) imply_2\VBP\943837|results|has|,|and|suggests|. (l_conj) suggests_17\VBZ\1010118|it|acts (l_ccomp) acts_20\VBZ\1619354|that|p2y12|target (l_nsubj) p2y12_19\NN\1740|
T11_T33 CPR:4 adp/atp_12\NN\1740| (r_compound) analogs_13\NNS\4743605|by|adp/atp (r_nmod) inhibited_10\VBN\2510337|to|be|analogs (r_acl) potential_7\NN\14481929|the|inhibited (r_dobj) has_5\VBZ\2108377|that|p2y12|potential (l_nsubj) p2y12_4\NN\1740|
T11_T34 NONE adp/atp_12\NN\1740| (r_compound) analogs_13\NNS\4743605|by|adp/atp (r_nmod) inhibited_10\VBN\2510337|to|be|analogs (r_acl) potential_7\NN\14481929|the|inhibited (r_dobj) has_5\VBZ\2108377|that|p2y12|potential (r_ccomp) imply_2\VBP\943837|results|has|,|and|suggests|. (l_conj) suggests_17\VBZ\1010118|it|acts (l_ccomp) acts_20\VBZ\1619354|that|p2y12|target (l_nsubj) p2y12_19\NN\1740|
11752472
T20_T37 NONE tetrahydrofolate_0\JJ\1740| (r_amod) biosynthesis_1\NN\13565379|tetrahydrofolate|plants|:|characterization|synthetase|. (l_nmod) synthetase_11\NN\1740|of|dihydrofolate|and|isoforms|thaliana (l_conj) isoforms_14\NNS\1740|three|synthetase (l_nmod) synthetase_17\NN\1740|of|folylpolyglutamate
T20_T38 NONE tetrahydrofolate_0\JJ\1740| (r_amod) biosynthesis_1\NN\13565379|tetrahydrofolate|plants|:|characterization|synthetase|. (l_nmod) synthetase_11\NN\1740|of|dihydrofolate|and|isoforms|thaliana
T21_T37 NONE dihydrofolate_10\JJ\1740| (r_amod) synthetase_11\NN\1740|of|dihydrofolate|and|isoforms|thaliana (l_conj) isoforms_14\NNS\1740|three|synthetase (l_nmod) synthetase_17\NN\1740|of|folylpolyglutamate
T21_T38 NONE dihydrofolate_10\JJ\1740| (r_amod) synthetase_11\NN\1740|of|dihydrofolate|and|isoforms|thaliana
T11_T26 NONE folylpolyglutamate_14\NN\1740| (r_compound) synthetase_15\NN\1740|folylpolyglutamate|fpgs (r_conj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase
T11_T27 NONE folylpolyglutamate_14\NN\1740| (r_compound) synthetase_15\NN\1740|folylpolyglutamate|fpgs (r_conj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_appos) dhfs_11\NN\1740|(|)
T11_T28 NONE folylpolyglutamate_14\NN\1740| (r_compound) synthetase_15\NN\1740|folylpolyglutamate|fpgs
T11_T29 NONE folylpolyglutamate_14\NN\1740| (r_compound) synthetase_15\NN\1740|folylpolyglutamate|fpgs (l_appos) fpgs_17\NN\1740|(|)
T12_T26 NONE glutamate_23\NN\15010703| (r_compound) residues_24\NNS\20827|of|glutamate (r_nmod) attachment_21\NN\7544647|the|residues|molecule (r_dobj) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase
T12_T27 NONE glutamate_23\NN\15010703| (r_compound) residues_24\NNS\20827|of|glutamate (r_nmod) attachment_21\NN\7544647|the|residues|molecule (r_dobj) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_appos) dhfs_11\NN\1740|(|)
T12_T28 NONE glutamate_23\NN\15010703| (r_compound) residues_24\NNS\20827|of|glutamate (r_nmod) attachment_21\NN\7544647|the|residues|molecule (r_dobj) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_conj) synthetase_15\NN\1740|folylpolyglutamate|fpgs
T12_T29 NONE glutamate_23\NN\15010703| (r_compound) residues_24\NNS\20827|of|glutamate (r_nmod) attachment_21\NN\7544647|the|residues|molecule (r_dobj) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_conj) synthetase_15\NN\1740|folylpolyglutamate|fpgs (l_appos) fpgs_17\NN\1740|(|)
T13_T26 NONE folate_27\NN\15090742| (r_compound) molecule_28\NN\9465459|to|the|folate (r_nmod) attachment_21\NN\7544647|the|residues|molecule (r_dobj) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase
T13_T27 NONE folate_27\NN\15090742| (r_compound) molecule_28\NN\9465459|to|the|folate (r_nmod) attachment_21\NN\7544647|the|residues|molecule (r_dobj) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_appos) dhfs_11\NN\1740|(|)
T13_T28 NONE folate_27\NN\15090742| (r_compound) molecule_28\NN\9465459|to|the|folate (r_nmod) attachment_21\NN\7544647|the|residues|molecule (r_dobj) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_conj) synthetase_15\NN\1740|folylpolyglutamate|fpgs
T13_T29 NONE folate_27\NN\15090742| (r_compound) molecule_28\NN\9465459|to|the|folate (r_nmod) attachment_21\NN\7544647|the|residues|molecule (r_dobj) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_conj) synthetase_15\NN\1740|folylpolyglutamate|fpgs (l_appos) fpgs_17\NN\1740|(|)
T5_T26 NONE tetrahydrofolate_4\JJ\1740| (r_amod) de_5\FW\1740|tetrahydrofolate|novo (r_dobj) synthesize_3\VBP\193486|that|de (r_acl:relcl) organisms_1\NNS\4258|in|synthesize (r_nmod) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase
T5_T27 NONE tetrahydrofolate_4\JJ\1740| (r_amod) de_5\FW\1740|tetrahydrofolate|novo (r_dobj) synthesize_3\VBP\193486|that|de (r_acl:relcl) organisms_1\NNS\4258|in|synthesize (r_nmod) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_appos) dhfs_11\NN\1740|(|)
T5_T28 NONE tetrahydrofolate_4\JJ\1740| (r_amod) de_5\FW\1740|tetrahydrofolate|novo (r_dobj) synthesize_3\VBP\193486|that|de (r_acl:relcl) organisms_1\NNS\4258|in|synthesize (r_nmod) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_conj) synthetase_15\NN\1740|folylpolyglutamate|fpgs
T5_T29 NONE tetrahydrofolate_4\JJ\1740| (r_amod) de_5\FW\1740|tetrahydrofolate|novo (r_dobj) synthesize_3\VBP\193486|that|de (r_acl:relcl) organisms_1\NNS\4258|in|synthesize (r_nmod) catalyze_19\VBP\146138|organisms|,|synthetase|attachment|. (l_nsubj) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_conj) synthetase_15\NN\1740|folylpolyglutamate|fpgs (l_appos) fpgs_17\NN\1740|(|)
T9_T26 NONE dihydrofolate_8\JJ\1740| (r_amod) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase
T9_T27 NONE dihydrofolate_8\JJ\1740| (r_amod) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_appos) dhfs_11\NN\1740|(|)
T9_T28 NONE dihydrofolate_8\JJ\1740| (r_amod) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_conj) synthetase_15\NN\1740|folylpolyglutamate|fpgs
T9_T29 NONE dihydrofolate_8\JJ\1740| (r_amod) synthetase_9\NN\1740|dihydrofolate|dhfs|and|synthetase (l_conj) synthetase_15\NN\1740|folylpolyglutamate|fpgs (l_appos) fpgs_17\NN\1740|(|)
T16_T32 NONE glutamate_24\NN\15010703| (r_compound) incorporation_25\NN\1237415|in|glutamate|dihydrofolate (r_dobj) measuring_21\VBG\697589|by|incorporation (r_conj) complementation_8\NN\13796779|by|mutants|,|and|measuring (l_nmod) mutants_11\NNS\4475|of|yeast|deficient (l_amod) deficient_12\JJ\1740|dhfs (l_nmod) dhfs_14\NNS\1740|in|or|activity
T16_T33 NONE glutamate_24\NN\15010703| (r_compound) incorporation_25\NN\1237415|in|glutamate|dihydrofolate (r_dobj) measuring_21\VBG\697589|by|incorporation (r_conj) complementation_8\NN\13796779|by|mutants|,|and|measuring (l_nmod) mutants_11\NNS\4475|of|yeast|deficient (l_amod) deficient_12\JJ\1740|dhfs (l_nmod) dhfs_14\NNS\1740|in|or|activity (l_conj) activity_17\NN\30358|fpgs (l_compound) fpgs_16\NNS\1740|
T17_T32 NONE dihydrofolate_27\JJ\1740|into|or|tetrahydrofolate (r_nmod) incorporation_25\NN\1237415|in|glutamate|dihydrofolate (r_dobj) measuring_21\VBG\697589|by|incorporation (r_conj) complementation_8\NN\13796779|by|mutants|,|and|measuring (l_nmod) mutants_11\NNS\4475|of|yeast|deficient (l_amod) deficient_12\JJ\1740|dhfs (l_nmod) dhfs_14\NNS\1740|in|or|activity
T17_T33 NONE dihydrofolate_27\JJ\1740|into|or|tetrahydrofolate (r_nmod) incorporation_25\NN\1237415|in|glutamate|dihydrofolate (r_dobj) measuring_21\VBG\697589|by|incorporation (r_conj) complementation_8\NN\13796779|by|mutants|,|and|measuring (l_nmod) mutants_11\NNS\4475|of|yeast|deficient (l_amod) deficient_12\JJ\1740|dhfs (l_nmod) dhfs_14\NNS\1740|in|or|activity (l_conj) activity_17\NN\30358|fpgs (l_compound) fpgs_16\NNS\1740|
T18_T32 NONE tetrahydrofolate_29\JJ\1740| (r_conj) dihydrofolate_27\JJ\1740|into|or|tetrahydrofolate (r_nmod) incorporation_25\NN\1237415|in|glutamate|dihydrofolate (r_dobj) measuring_21\VBG\697589|by|incorporation (r_conj) complementation_8\NN\13796779|by|mutants|,|and|measuring (l_nmod) mutants_11\NNS\4475|of|yeast|deficient (l_amod) deficient_12\JJ\1740|dhfs (l_nmod) dhfs_14\NNS\1740|in|or|activity
T18_T33 NONE tetrahydrofolate_29\JJ\1740| (r_conj) dihydrofolate_27\JJ\1740|into|or|tetrahydrofolate (r_nmod) incorporation_25\NN\1237415|in|glutamate|dihydrofolate (r_dobj) measuring_21\VBG\697589|by|incorporation (r_conj) complementation_8\NN\13796779|by|mutants|,|and|measuring (l_nmod) mutants_11\NNS\4475|of|yeast|deficient (l_amod) deficient_12\JJ\1740|dhfs (l_nmod) dhfs_14\NNS\1740|in|or|activity (l_conj) activity_17\NN\30358|fpgs (l_compound) fpgs_16\NNS\1740|
T19_T34 CPR:9 dihydrofolate_17\NN\1740|of (r_nmod) synthesis_15\NN\13446390|of|dihydrofolate (r_nmod) site_13\NN\8673395|compartment|the|sole|synthesis|cell (r_ccomp) making_8\VBG\126264|site (r_advcl) present_2\JJ\1740|dhfs|is|mitochondria|,|making|. (l_nsubj) dhfs_0\NN\1740|
T2_T22 NONE tetrahydrofolate_13\JJ\1740| (r_amod) derivatives_14\NNS\5802185|of|gamma-glutamyl-conjugated|tetrahydrofolate (r_nmod) predominance_10\NN\14441825|with|the|derivatives|and|presence (l_conj) presence_17\NN\13954253|the|hydroxymethyltransferase|cytosol (l_nmod) hydroxymethyltransferase_20\NN\1740|of|serine|and|enzymes
T2_T23 NONE tetrahydrofolate_13\JJ\1740| (r_amod) derivatives_14\NNS\5802185|of|gamma-glutamyl-conjugated|tetrahydrofolate (r_nmod) predominance_10\NN\14441825|with|the|derivatives|and|presence (l_conj) presence_17\NN\13954253|the|hydroxymethyltransferase|cytosol (l_nmod) hydroxymethyltransferase_20\NN\1740|of|serine|and|enzymes (l_conj) enzymes_24\NNS\14723628|c1-tetrahydrofolate|interconverting
T2_T36 NONE tetrahydrofolate_13\JJ\1740| (r_amod) derivatives_14\NNS\5802185|of|gamma-glutamyl-conjugated|tetrahydrofolate (r_nmod) predominance_10\NN\14441825|with|the|derivatives|and|presence (r_nmod) agreement_7\NN\6722453|compartmentation|is|in|predominance|. (l_nsubj) compartmentation_1\NN\1740|the|isoforms (l_nmod) isoforms_4\NNS\1740|of|fpgs (l_compound) fpgs_3\NNS\1740|
T3_T22 NONE serine_19\NN\14601829| (r_compound) hydroxymethyltransferase_20\NN\1740|of|serine|and|enzymes
T3_T23 NONE serine_19\NN\14601829| (r_compound) hydroxymethyltransferase_20\NN\1740|of|serine|and|enzymes (l_conj) enzymes_24\NNS\14723628|c1-tetrahydrofolate|interconverting
T3_T36 NONE serine_19\NN\14601829| (r_compound) hydroxymethyltransferase_20\NN\1740|of|serine|and|enzymes (r_nmod) presence_17\NN\13954253|the|hydroxymethyltransferase|cytosol (r_conj) predominance_10\NN\14441825|with|the|derivatives|and|presence (r_nmod) agreement_7\NN\6722453|compartmentation|is|in|predominance|. (l_nsubj) compartmentation_1\NN\1740|the|isoforms (l_nmod) isoforms_4\NNS\1740|of|fpgs (l_compound) fpgs_3\NNS\1740|
T4_T22 NONE c1-tetrahydrofolate_22\JJ\1740| (r_amod) enzymes_24\NNS\14723628|c1-tetrahydrofolate|interconverting (r_conj) hydroxymethyltransferase_20\NN\1740|of|serine|and|enzymes
T4_T23 NONE c1-tetrahydrofolate_22\JJ\1740| (r_amod) enzymes_24\NNS\14723628|c1-tetrahydrofolate|interconverting
T4_T36 NONE c1-tetrahydrofolate_22\JJ\1740| (r_amod) enzymes_24\NNS\14723628|c1-tetrahydrofolate|interconverting (r_conj) hydroxymethyltransferase_20\NN\1740|of|serine|and|enzymes (r_nmod) presence_17\NN\13954253|the|hydroxymethyltransferase|cytosol (r_conj) predominance_10\NN\14441825|with|the|derivatives|and|presence (r_nmod) agreement_7\NN\6722453|compartmentation|is|in|predominance|. (l_nsubj) compartmentation_1\NN\1740|the|isoforms (l_nmod) isoforms_4\NNS\1740|of|fpgs (l_compound) fpgs_3\NNS\1740|
T6_T24 NONE folate-mediated_8\JJ\1740| (r_amod) reactions_9\NNS\13446390|with|these|folate-mediated (r_nmod) combination_3\NN\7951464|the|fpgs|reactions (l_nmod) fpgs_5\NNS\1740|of
T7_T24 NONE folate_17\NN\15090742| (r_compound) coenzymes_18\NNS\14682133|with|the|polyglutamylated|folate|required (r_nmod) supply_11\VB\2199590|thus|,|combination|can|compartment|coenzymes|. (l_nsubj) combination_3\NN\7951464|the|fpgs|reactions (l_nmod) fpgs_5\NNS\1740|of
T8_T24 NONE c1_24\NN\1740| (r_compound) metabolism_25\NN\13526110|of|c1 (r_nmod) reactions_22\NNS\13446390|for|the|metabolism (r_nmod) required_19\VBN\754942|reactions (r_acl) coenzymes_18\NNS\14682133|with|the|polyglutamylated|folate|required (r_nmod) supply_11\VB\2199590|thus|,|combination|can|compartment|coenzymes|. (l_nsubj) combination_3\NN\7951464|the|fpgs|reactions (l_nmod) fpgs_5\NNS\1740|of
T10_T25 NONE folate_16\NN\15090742|of (r_nmod) forms_14\NNS\6286395|the|transported|folate (r_nsubjpass) unconjugated_18\VBN\1740|that|forms|are (r_ccomp) suggests_10\VBZ\1010118|also|,|multicompartmentation|unconjugated|. (l_nsubj) multicompartmentation_3\NN\1740|the|fpgs|cell (l_nmod) fpgs_5\NNS\1740|of
17632548
T17_T39 NONE ltc4_0\NN\1740| (r_compound) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|,
T17_T40 NONE ltc4_0\NN\1740| (r_compound) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (l_appos) ltc4s_3\NN\1740|(|)
T17_T41 NONE ltc4_0\NN\1740| (r_compound) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (r_nsubj) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_acl:relcl) belongs_28\VBZ\2604760|that|superfamily (l_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase
T17_T42 NONE ltc4_0\NN\1740| (r_compound) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (r_nsubj) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_acl:relcl) belongs_28\VBZ\2604760|that|superfamily (l_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts
T17_T43 NONE ltc4_0\NN\1740| (r_compound) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (r_nsubj) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_acl:relcl) belongs_28\VBZ\2604760|that|superfamily (l_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (l_appos) mgsts_49\NNS\1740|(|)
T17_T44 NONE ltc4_0\NN\1740| (r_compound) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (r_nsubj) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_acl:relcl) belongs_28\VBZ\2604760|that|superfamily (l_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (l_nummod) 1_57\CD\13741022|
T18_T39 CPR:9 ltc4_13\NN\1740|of (r_nmod) biosynthesis_11\NN\13565379|for|the|ltc4 (r_nmod) enzyme_8\NN\14723628|the|pivotal|biosynthesis|ref|. (r_appos) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|,
T18_T40 CPR:9 ltc4_13\NN\1740|of (r_nmod) biosynthesis_11\NN\13565379|for|the|ltc4 (r_nmod) enzyme_8\NN\14723628|the|pivotal|biosynthesis|ref|. (r_appos) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (l_appos) ltc4s_3\NN\1740|(|)
T18_T41 NONE ltc4_13\NN\1740|of (r_nmod) biosynthesis_11\NN\13565379|for|the|ltc4 (r_nmod) enzyme_8\NN\14723628|the|pivotal|biosynthesis|ref|. (r_appos) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (r_nsubj) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_acl:relcl) belongs_28\VBZ\2604760|that|superfamily (l_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase
T18_T42 NONE ltc4_13\NN\1740|of (r_nmod) biosynthesis_11\NN\13565379|for|the|ltc4 (r_nmod) enzyme_8\NN\14723628|the|pivotal|biosynthesis|ref|. (r_appos) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (r_nsubj) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_acl:relcl) belongs_28\VBZ\2604760|that|superfamily (l_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts
T18_T43 NONE ltc4_13\NN\1740|of (r_nmod) biosynthesis_11\NN\13565379|for|the|ltc4 (r_nmod) enzyme_8\NN\14723628|the|pivotal|biosynthesis|ref|. (r_appos) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (r_nsubj) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_acl:relcl) belongs_28\VBZ\2604760|that|superfamily (l_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (l_appos) mgsts_49\NNS\1740|(|)
T18_T44 NONE ltc4_13\NN\1740|of (r_nmod) biosynthesis_11\NN\13565379|for|the|ltc4 (r_nmod) enzyme_8\NN\14723628|the|pivotal|biosynthesis|ref|. (r_appos) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (r_nsubj) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_acl:relcl) belongs_28\VBZ\2604760|that|superfamily (l_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (l_nummod) 1_57\CD\13741022|
T21_T39 NONE eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|,
T21_T40 NONE eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (l_appos) ltc4s_3\NN\1740|(|)
T21_T41 NONE eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase
T21_T42 CPR:9 eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts
T21_T43 CPR:9 eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (l_appos) mgsts_49\NNS\1740|(|)
T21_T44 CPR:9 eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (l_nummod) 1_57\CD\13741022|
T22_T39 NONE glutathione_38\NN\1740| (r_conj) eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|,
T22_T40 NONE glutathione_38\NN\1740| (r_conj) eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (l_appos) ltc4s_3\NN\1740|(|)
T22_T41 NONE glutathione_38\NN\1740| (r_conj) eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase
T22_T42 CPR:9 glutathione_38\NN\1740| (r_conj) eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts
T22_T43 CPR:9 glutathione_38\NN\1740| (r_conj) eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (l_appos) mgsts_49\NNS\1740|(|)
T22_T44 CPR:9 glutathione_38\NN\1740| (r_conj) eicosanoid_36\NN\1740|in|and|glutathione (r_compound) metabolism_39\NN\13526110|eicosanoid (r_nmod) proteins_34\NNS\14944888|of|membrane-associated|metabolism (r_nmod) superfamily_31\NN\7992450|to|a|proteins|includes (l_acl:relcl) includes_41\VBZ\690614|that|protein (l_dobj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (l_nummod) 1_57\CD\13741022|
T23_T39 NONE glutathione_46\NN\1740| (r_compound) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (r_dobj) includes_41\VBZ\690614|that|protein (r_acl:relcl) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|,
T23_T40 NONE glutathione_46\NN\1740| (r_compound) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (r_dobj) includes_41\VBZ\690614|that|protein (r_acl:relcl) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (l_appos) ltc4s_3\NN\1740|(|)
T23_T41 NONE glutathione_46\NN\1740| (r_compound) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase
T23_T42 NONE glutathione_46\NN\1740| (r_compound) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts
T23_T43 NONE glutathione_46\NN\1740| (r_compound) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (l_appos) mgsts_49\NNS\1740|(|)
T23_T44 NONE glutathione_46\NN\1740| (r_compound) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (l_nummod) 1_57\CD\13741022|
T24_T39 NONE s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (r_dobj) includes_41\VBZ\690614|that|protein (r_acl:relcl) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|,
T24_T40 NONE s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (r_dobj) includes_41\VBZ\690614|that|protein (r_acl:relcl) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (l_appos) ltc4s_3\NN\1740|(|)
T24_T41 NONE s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase
T24_T42 NONE s-transferases_47\NNS\1740|microsomal|glutathione|mgsts
T24_T43 NONE s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (l_appos) mgsts_49\NNS\1740|(|)
T24_T44 NONE s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (l_nummod) 1_57\CD\13741022|
T25_T39 NONE e_55\NN\14724645| (r_compound) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (r_dobj) includes_41\VBZ\690614|that|protein (r_acl:relcl) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|,
T25_T40 NONE e_55\NN\14724645| (r_compound) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (r_dobj) includes_41\VBZ\690614|that|protein (r_acl:relcl) superfamily_31\NN\7992450|to|a|proteins|includes (r_nmod) belongs_28\VBZ\2604760|that|superfamily (r_acl:relcl) protein_26\NN\14944888|synthase|is|an|18-kda|integral|nuclear|membrane|belongs|. (l_nsubj) synthase_1\NN\1740|ltc4|ltc4s|,|enzyme|, (l_appos) ltc4s_3\NN\1740|(|)
T25_T41 NONE e_55\NN\14724645| (r_compound) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase
T25_T42 NONE e_55\NN\14724645| (r_compound) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts
T25_T43 NONE e_55\NN\14724645| (r_compound) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (r_conj) protein_43\NN\14944888|5-lipoxygenase-activating|,|s-transferases|,|and|synthase (l_conj) s-transferases_47\NNS\1740|microsomal|glutathione|mgsts (l_appos) mgsts_49\NNS\1740|(|)
T25_T44 NONE e_55\NN\14724645| (r_compound) synthase_56\NN\1740|microsomal|prostaglandin|e|1|ref|.|) (l_nummod) 1_57\CD\13741022|
T26_T45 NONE glutathione_2\NN\1740| (r_dobj) conjugates_1\VBZ\394813|ltc4s|glutathione|lta4|. (l_nsubj) ltc4s_0\NN\1740|
T26_T46 NONE glutathione_2\NN\1740| (r_dobj) conjugates_1\VBZ\394813|ltc4s|glutathione|lta4|. (l_nmod) lta4_4\NN\1740|to|,|substrate (l_appos) substrate_8\NN\19613|the|endogenous|derived (l_acl) derived_9\VBN\634472|acid|pathway (l_nmod) pathway_16\NN\5483677|through|the|5-lipoxygenase (l_compound) 5-lipoxygenase_15\NN\1740|
T27_T45 NONE lta4_4\NN\1740|to|,|substrate (r_nmod) conjugates_1\VBZ\394813|ltc4s|glutathione|lta4|. (l_nsubj) ltc4s_0\NN\1740|
T27_T46 NONE lta4_4\NN\1740|to|,|substrate (l_appos) substrate_8\NN\19613|the|endogenous|derived (l_acl) derived_9\VBN\634472|acid|pathway (l_nmod) pathway_16\NN\5483677|through|the|5-lipoxygenase (l_compound) 5-lipoxygenase_15\NN\1740|
T28_T45 NONE acid_12\NN\14818238|from|arachidonic (r_nmod) derived_9\VBN\634472|acid|pathway (r_acl) substrate_8\NN\19613|the|endogenous|derived (r_appos) lta4_4\NN\1740|to|,|substrate (r_nmod) conjugates_1\VBZ\394813|ltc4s|glutathione|lta4|. (l_nsubj) ltc4s_0\NN\1740|
T28_T46 NONE acid_12\NN\14818238|from|arachidonic (r_nmod) derived_9\VBN\634472|acid|pathway (l_nmod) pathway_16\NN\5483677|through|the|5-lipoxygenase (l_compound) 5-lipoxygenase_15\NN\1740|
T31_T47 NONE glutathione_17\NN\1740| (r_dobj) conjugate_16\VB\394813|contrast|,|ltc4s|does|not|glutathione|xenobiotics|. (l_nmod) contrast_1\NN\13854649|in|mgst2 (l_nmod) mgst2_3\NN\1740|with|and|mgst3|refs
T31_T48 NONE glutathione_17\NN\1740| (r_dobj) conjugate_16\VB\394813|contrast|,|ltc4s|does|not|glutathione|xenobiotics|. (l_nmod) contrast_1\NN\13854649|in|mgst2 (l_nmod) mgst2_3\NN\1740|with|and|mgst3|refs (l_conj) mgst3_5\NN\1740|
T31_T49 NONE glutathione_17\NN\1740| (r_dobj) conjugate_16\VB\394813|contrast|,|ltc4s|does|not|glutathione|xenobiotics|. (l_nsubj) ltc4s_13\NN\1740|
T1_T34 NONE glutathione_30\NN\1740|for|and|lta4 (r_nmod) specificity_28\NN\4762633|into|the|high|substrate|glutathione|distinguishes (l_acl:relcl) distinguishes_34\VBZ\618878|that|ltc4s|mgsts (l_dobj) ltc4s_35\NNS\1740|
T1_T35 NONE glutathione_30\NN\1740|for|and|lta4 (r_nmod) specificity_28\NN\4762633|into|the|high|substrate|glutathione|distinguishes (l_acl:relcl) distinguishes_34\VBZ\618878|that|ltc4s|mgsts (l_nmod) mgsts_38\NNS\1740|from|other
T1_T50 NONE glutathione_30\NN\1740|for|and|lta4 (r_nmod) specificity_28\NN\4762633|into|the|high|substrate|glutathione|distinguishes (r_nmod) insights_23\NNS\5710020|specificity (r_dobj) provide_22\VBP\2199590|insights (r_conj) show_2\VBP\2137132|here|we|structure|and|provide|. (l_dobj) structure_5\NN\21939|the|atomic|ltc4s|complex (l_nmod) ltc4s_8\NNS\1740|of|human
T2_T34 NONE lta4_32\NN\1740| (r_conj) glutathione_30\NN\1740|for|and|lta4 (r_nmod) specificity_28\NN\4762633|into|the|high|substrate|glutathione|distinguishes (l_acl:relcl) distinguishes_34\VBZ\618878|that|ltc4s|mgsts (l_dobj) ltc4s_35\NNS\1740|
T2_T35 NONE lta4_32\NN\1740| (r_conj) glutathione_30\NN\1740|for|and|lta4 (r_nmod) specificity_28\NN\4762633|into|the|high|substrate|glutathione|distinguishes (l_acl:relcl) distinguishes_34\VBZ\618878|that|ltc4s|mgsts (l_nmod) mgsts_38\NNS\1740|from|other
T2_T50 NONE lta4_32\NN\1740| (r_conj) glutathione_30\NN\1740|for|and|lta4 (r_nmod) specificity_28\NN\4762633|into|the|high|substrate|glutathione|distinguishes (r_nmod) insights_23\NNS\5710020|specificity (r_dobj) provide_22\VBP\2199590|insights (r_conj) show_2\VBP\2137132|here|we|structure|and|provide|. (l_dobj) structure_5\NN\21939|the|atomic|ltc4s|complex (l_nmod) ltc4s_8\NNS\1740|of|human
T32_T34 NONE glutathione_13\NN\1740|with (r_nmod) complex_11\NN\5869584|in|a|glutathione|resolution|crystallography (r_nmod) structure_5\NN\21939|the|atomic|ltc4s|complex (r_dobj) show_2\VBP\2137132|here|we|structure|and|provide|. (l_conj) provide_22\VBP\2199590|insights (l_dobj) insights_23\NNS\5710020|specificity (l_nmod) specificity_28\NN\4762633|into|the|high|substrate|glutathione|distinguishes (l_acl:relcl) distinguishes_34\VBZ\618878|that|ltc4s|mgsts (l_dobj) ltc4s_35\NNS\1740|
T32_T35 NONE glutathione_13\NN\1740|with (r_nmod) complex_11\NN\5869584|in|a|glutathione|resolution|crystallography (r_nmod) structure_5\NN\21939|the|atomic|ltc4s|complex (r_dobj) show_2\VBP\2137132|here|we|structure|and|provide|. (l_conj) provide_22\VBP\2199590|insights (l_dobj) insights_23\NNS\5710020|specificity (l_nmod) specificity_28\NN\4762633|into|the|high|substrate|glutathione|distinguishes (l_acl:relcl) distinguishes_34\VBZ\618878|that|ltc4s|mgsts (l_nmod) mgsts_38\NNS\1740|from|other
T32_T50 NONE glutathione_13\NN\1740|with (r_nmod) complex_11\NN\5869584|in|a|glutathione|resolution|crystallography (r_nmod) structure_5\NN\21939|the|atomic|ltc4s|complex (l_nmod) ltc4s_8\NNS\1740|of|human
T15_T37 NONE leukotriene_20\NN\1740| (r_compound) ligands_21\NNS\20090|by|three|cysteinyl|leukotriene|different|receptors (r_nmod) mediated_16\VBN\761713|ligands (r_acl) pathway_15\NN\5483677|for|a|proinflammatory|mediated (r_nmod) inhibitors_11\NNS\20090|of|ltc4s|pathway (l_compound) ltc4s_10\NNS\1740|
T15_T38 NONE leukotriene_20\NN\1740| (r_compound) ligands_21\NNS\20090|by|three|cysteinyl|leukotriene|different|receptors (l_conj) receptors_33\NNS\5225602|by|multiple|cysteinyl|leukotriene|non-redundant
T16_T37 NONE leukotriene_32\NN\1740| (r_compound) receptors_33\NNS\5225602|by|multiple|cysteinyl|leukotriene|non-redundant (r_conj) ligands_21\NNS\20090|by|three|cysteinyl|leukotriene|different|receptors (r_nmod) mediated_16\VBN\761713|ligands (r_acl) pathway_15\NN\5483677|for|a|proinflammatory|mediated (r_nmod) inhibitors_11\NNS\20090|of|ltc4s|pathway (l_compound) ltc4s_10\NNS\1740|
T16_T38 NONE leukotriene_32\NN\1740| (r_compound) receptors_33\NNS\5225602|by|multiple|cysteinyl|leukotriene|non-redundant
23567243
T6_T12 CPR:4 dico_5\NN\1740| (r_nsubj) decreased_6\VBD\169651|that|dico|level|and|induced|cause (l_dobj) level_8\NN\4916342|bcl-2 (l_compound) bcl-2_7\NN\1740|
T6_T13 CPR:3 dico_5\NN\1740| (r_nsubj) decreased_6\VBD\169651|that|dico|level|and|induced|cause (l_conj) induced_10\VBD\1627355|translocation (l_dobj) translocation_12\NN\13526110|bax (l_compound) bax_11\NN\1740|
T6_T14 CPR:3 dico_5\NN\1740| (r_nsubj) decreased_6\VBD\169651|that|dico|level|and|induced|cause (l_advcl) cause_14\VB\1617192|to|release (l_dobj) release_17\NN\3748886|cytochrome|c (l_compound) c_16\NN\13714184|
T7_T17 NONE dico_20\NN\1740| (r_compound) treatment_21\NN\654885|to|dico (r_nmod) response_18\NN\11410625|in|treatment (r_nmod) observed_16\VBN\2163746|meanwhile|,|alterations|were|also|response|. (l_nsubjpass) alterations_3\NNS\7283608|the|a (l_nmod) a_6\NN\13649268|of|cyclin|and|b1|,|p-cdk1|levels (l_conj) b1_8\NN\1740|
T7_T18 NONE dico_20\NN\1740| (r_compound) treatment_21\NN\654885|to|dico (r_nmod) response_18\NN\11410625|in|treatment (r_nmod) observed_16\VBN\2163746|meanwhile|,|alterations|were|also|response|. (l_nsubjpass) alterations_3\NNS\7283608|the|a (l_nmod) a_6\NN\13649268|of|cyclin|and|b1|,|p-cdk1|levels (l_conj) p-cdk1_10\NN\1740|and|p-cdc25c
T7_T19 NONE dico_20\NN\1740| (r_compound) treatment_21\NN\654885|to|dico (r_nmod) response_18\NN\11410625|in|treatment (r_nmod) observed_16\VBN\2163746|meanwhile|,|alterations|were|also|response|. (l_nsubjpass) alterations_3\NNS\7283608|the|a (l_nmod) a_6\NN\13649268|of|cyclin|and|b1|,|p-cdk1|levels (l_conj) p-cdk1_10\NN\1740|and|p-cdc25c (l_conj) p-cdc25c_12\NN\1740|
10800083
T1_T4 NONE aminopeptidase-n_39\NN\1740|of|cd13 (r_nmod) expression_37\NN\4679549|increased|aminopeptidase-n (r_conj) loss_23\NN\13252973|differential|receptors|and|expression (l_nmod) receptors_26\NNS\5225602|of|certain|cd16 (l_nmod) cd16_29\NN\1740|(|e.g.|,|cd15|and|cd120b|)
T1_T5 NONE aminopeptidase-n_39\NN\1740|of|cd13 (r_nmod) expression_37\NN\4679549|increased|aminopeptidase-n (r_conj) loss_23\NN\13252973|differential|receptors|and|expression (l_nmod) receptors_26\NNS\5225602|of|certain|cd16 (l_nmod) cd16_29\NN\1740|(|e.g.|,|cd15|and|cd120b|) (l_conj) cd15_31\NN\1740|
T1_T6 NONE aminopeptidase-n_39\NN\1740|of|cd13 (r_nmod) expression_37\NN\4679549|increased|aminopeptidase-n (r_conj) loss_23\NN\13252973|differential|receptors|and|expression (l_nmod) receptors_26\NNS\5225602|of|certain|cd16 (l_nmod) cd16_29\NN\1740|(|e.g.|,|cd15|and|cd120b|) (l_conj) cd120b_33\NN\1740|
T1_T7 NONE aminopeptidase-n_39\NN\1740|of|cd13
T1_T8 NONE aminopeptidase-n_39\NN\1740|of|cd13 (l_appos) cd13_41\NN\1740|(|)
19399743
T1_T3 NONE phosphatidylinositol_19\NN\1740| (r_compound) gene_23\NN\8459252|in|the|phosphatidylinositol|glycan-complementation|class|a (l_det) a_22\DT\13649268|
T1_T4 NONE phosphatidylinositol_19\NN\1740| (r_compound) gene_23\NN\8459252|in|the|phosphatidylinositol|glycan-complementation|class|a (r_nmod) mutations_16\NNS\4475|by|somatic|gene|and|absence (l_conj) absence_27\NN\14449405|the|resulting|protein (l_nmod) protein_33\NN\14944888|of|a|key|complement|regulatory|,|cd59 (l_appos) cd59_35\NN\1740|
22258629
T6_T10 NONE malondialdehyde_8\NN\1740| (r_conj) counts_2\NNS\13582013|blood|complete|,|protein|,|malondialdehyde|and|tests (l_conj) protein_6\NN\14944888|high-sensitive|c-reactive
17347380
T27_T35 NONE creatine_0\NN\14601829| (r_compound) uptake_1\NN\13440063|creatine|brain (l_nmod) brain_3\NN\5462674|in|and|muscle|mice (l_nmod) mice_8\NNS\2329401|of|lacking (l_acl) lacking_9\VBG\1740|methyltransferase (l_dobj) methyltransferase_11\NN\1740|guanidinoacetate
T28_T35 NONE guanidinoacetate_10\NN\1740| (r_compound) methyltransferase_11\NN\1740|guanidinoacetate
T11_T30 NONE cr_28\NN\14625458| (r_compound) supplementation_29\NN\5108947|after|cr|cr|days (r_nmod) studied_26\VBN\630380|levels|were|supplementation|. (l_nsubjpass) levels_4\NNS\4916342|creatine|muscle (l_nmod) muscle_7\NN\5289601|in|skeletal|and|brain|model (l_nmod) model_13\NN\5888929|of|a|mouse|deficiency (l_nmod) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_appos) gamt-/-_23\JJ\1740|(|)
T11_T34 NONE cr_28\NN\14625458| (r_compound) supplementation_29\NN\5108947|after|cr|cr|days (r_nmod) studied_26\VBN\630380|levels|were|supplementation|. (l_nsubjpass) levels_4\NNS\4916342|creatine|muscle (l_nmod) muscle_7\NN\5289601|in|skeletal|and|brain|model (l_nmod) model_13\NN\5888929|of|a|mouse|deficiency (l_nmod) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_compound) methyltransferase_20\NN\1740|guanidinoacetate
T12_T30 NONE cr_35\NN\14625458|with|g.kg|body|wt-1.day-1 (r_nmod) supplementation_29\NN\5108947|after|cr|cr|days (r_nmod) studied_26\VBN\630380|levels|were|supplementation|. (l_nsubjpass) levels_4\NNS\4916342|creatine|muscle (l_nmod) muscle_7\NN\5289601|in|skeletal|and|brain|model (l_nmod) model_13\NN\5888929|of|a|mouse|deficiency (l_nmod) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_appos) gamt-/-_23\JJ\1740|(|)
T12_T34 NONE cr_35\NN\14625458|with|g.kg|body|wt-1.day-1 (r_nmod) supplementation_29\NN\5108947|after|cr|cr|days (r_nmod) studied_26\VBN\630380|levels|were|supplementation|. (l_nsubjpass) levels_4\NNS\4916342|creatine|muscle (l_nmod) muscle_7\NN\5289601|in|skeletal|and|brain|model (l_nmod) model_13\NN\5888929|of|a|mouse|deficiency (l_nmod) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_compound) methyltransferase_20\NN\1740|guanidinoacetate
T1_T30 NONE creatine_0\NN\14601829|cr (r_compound) levels_4\NNS\4916342|creatine|muscle (l_nmod) muscle_7\NN\5289601|in|skeletal|and|brain|model (l_nmod) model_13\NN\5888929|of|a|mouse|deficiency (l_nmod) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_appos) gamt-/-_23\JJ\1740|(|)
T1_T34 NONE creatine_0\NN\14601829|cr (r_compound) levels_4\NNS\4916342|creatine|muscle (l_nmod) muscle_7\NN\5289601|in|skeletal|and|brain|model (l_nmod) model_13\NN\5888929|of|a|mouse|deficiency (l_nmod) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_compound) methyltransferase_20\NN\1740|guanidinoacetate
T21_T30 NONE cr_15\NN\14625458| (r_compound) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_appos) gamt-/-_23\JJ\1740|(|)
T21_T34 NONE cr_15\NN\14625458| (r_compound) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_compound) methyltransferase_20\NN\1740|guanidinoacetate
T25_T30 NONE guanidinoacetate_19\NN\1740| (r_compound) methyltransferase_20\NN\1740|guanidinoacetate (r_compound) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_appos) gamt-/-_23\JJ\1740|(|)
T25_T34 NONE guanidinoacetate_19\NN\1740| (r_compound) methyltransferase_20\NN\1740|guanidinoacetate
T3_T30 NONE cr_2\NN\14625458|(|) (r_appos) creatine_0\NN\14601829|cr (r_compound) levels_4\NNS\4916342|creatine|muscle (l_nmod) muscle_7\NN\5289601|in|skeletal|and|brain|model (l_nmod) model_13\NN\5888929|of|a|mouse|deficiency (l_nmod) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_appos) gamt-/-_23\JJ\1740|(|)
T3_T34 NONE cr_2\NN\14625458|(|) (r_appos) creatine_0\NN\14601829|cr (r_compound) levels_4\NNS\4916342|creatine|muscle (l_nmod) muscle_7\NN\5289601|in|skeletal|and|brain|model (l_nmod) model_13\NN\5888929|of|a|mouse|deficiency (l_nmod) deficiency_16\NN\14449126|of|cr|caused (l_acl) caused_17\VBN\1617192|absence (l_nmod) absence_21\NN\14449405|by|methyltransferase|gamt-/- (l_compound) methyltransferase_20\NN\1740|guanidinoacetate
T13_T32 NONE 1h_1\JJ\1740| (r_amod) spectroscopy_4\NN\646833|localized|1h|magnetic|resonance|mrs (r_nsubjpass) performed_9\VBN\2367363|spectroscopy|was|brain|. (l_nmod) brain_11\NN\5462674|in|cerebellum|and|muscle|supplementation|and|mice (l_conj) muscle_21\NN\5289601|in|hind|leg|mice (l_nmod) mice_24\NNS\2329401|of|gamt-/- (l_amod) gamt-/-_23\NN\1740|
T14_T32 NONE cr_28\NN\14625458| (r_compound) supplementation_29\NN\5108947|before|cr (r_nmod) brain_11\NN\5462674|in|cerebellum|and|muscle|supplementation|and|mice (l_conj) muscle_21\NN\5289601|in|hind|leg|mice (l_nmod) mice_24\NNS\2329401|of|gamt-/- (l_amod) gamt-/-_23\NN\1740|
T15_T33 NONE cr_6\NN\14625458|for (r_nmod) signal_4\NN\33020|a|cr (r_nsubj) detectable_9\JJ\1740|expected|,|signal|was|hardly|spectra|supplementation|. (l_nmod) spectra_12\NNS\7939382|in|mr|mice (l_nmod) mice_15\NNS\2329401|of|gamt-/- (l_amod) gamt-/-_14\JJ\1740|
T16_T33 NONE cr_17\NN\14625458| (r_compound) supplementation_18\NN\5108947|before|cr (r_nmod) detectable_9\JJ\1740|expected|,|signal|was|hardly|spectra|supplementation|. (l_nmod) spectra_12\NNS\7939382|in|mr|mice (l_nmod) mice_15\NNS\2329401|of|gamt-/- (l_amod) gamt-/-_14\JJ\1740|
T4_T29 NONE cr_11\NN\14625458| (r_compound) study_13\NN\635850|in|this|longitudinal|cr|supplementation|mice (l_nmod) mice_16\NNS\2329401|on|gamt-/- (l_amod) gamt-/-_15\JJ\1740|
T5_T29 NONE cr_27\NN\14625458|of (r_nmod) uptake_25\NN\13440063|the|initial|faster|cr|muscle (r_dobj) discover_21\VB\2163746|to|uptake|brain|,|represent (r_xcomp) able_19\JJ\1740|measurements|were|we|discover|. (l_nsubj) measurements_6\NNS\407535|only|because|the|repeated|mrs|performed (l_acl) performed_7\VBN\2367363|study (l_nmod) study_13\NN\635850|in|this|longitudinal|cr|supplementation|mice (l_nmod) mice_16\NNS\2329401|on|gamt-/- (l_amod) gamt-/-_15\JJ\1740|
T6_T29 NONE cr_39\NN\14625458| (r_compound) uptake_40\NN\13440063|muscular|cr|independent (r_dobj) represent_37\VB\2664769|which|may|uptake (r_ccomp) discover_21\VB\2163746|to|uptake|brain|,|represent (r_xcomp) able_19\JJ\1740|measurements|were|we|discover|. (l_nsubj) measurements_6\NNS\407535|only|because|the|repeated|mrs|performed (l_acl) performed_7\VBN\2367363|study (l_nmod) study_13\NN\635850|in|this|longitudinal|cr|supplementation|mice (l_nmod) mice_16\NNS\2329401|on|gamt-/- (l_amod) gamt-/-_15\JJ\1740|
T7_T29 NONE cr_43\NN\14625458| (r_compound) expression_45\NN\4679549|of|cr|transporter (r_nmod) independent_41\JJ\1740|expression (r_amod) uptake_40\NN\13440063|muscular|cr|independent (r_dobj) represent_37\VB\2664769|which|may|uptake (r_ccomp) discover_21\VB\2163746|to|uptake|brain|,|represent (r_xcomp) able_19\JJ\1740|measurements|were|we|discover|. (l_nsubj) measurements_6\NNS\407535|only|because|the|repeated|mrs|performed (l_acl) performed_7\VBN\2367363|study (l_nmod) study_13\NN\635850|in|this|longitudinal|cr|supplementation|mice (l_nmod) mice_16\NNS\2329401|on|gamt-/- (l_amod) gamt-/-_15\JJ\1740|
T10_T31 NONE cr_27\NN\14625458| (r_compound) supplementation_28\NN\5108947|after|cr (r_nmod) patients_25\NNS\9898892|in|supplementation (r_nmod) slow_23\JJ\1740|as|increases|are|patients (r_advcl) optimize_10\VB\473572|to|supplementation|,|slow (l_dobj) supplementation_12\NN\5108947|cr|deficiency (l_nmod) deficiency_15\NN\14449126|in|gamt (l_compound) gamt_14\NN\1740|
T8_T31 NONE cr_11\NN\14625458| (r_compound) supplementation_12\NN\5108947|cr|deficiency (l_nmod) deficiency_15\NN\14449126|in|gamt (l_compound) gamt_14\NN\1740|
T9_T31 NONE cr_21\NN\14625458|in|brain (r_nmod) increases_18\NNS\13576355|cr (r_nsubj) slow_23\JJ\1740|as|increases|are|patients (r_advcl) optimize_10\VB\473572|to|supplementation|,|slow (l_dobj) supplementation_12\NN\5108947|cr|deficiency (l_nmod) deficiency_15\NN\14449126|in|gamt (l_compound) gamt_14\NN\1740|
16322797
T17_T30 NONE acid-induced_6\JJ\1740|nicotinic (r_amod) flushing_7\NN\1740|acid-induced (r_dobj) mediates_4\VBZ\761713|gpr109a|flushing|. (l_nsubj) gpr109a_0\NN\1740|puma-g/hm74a
T17_T31 NONE acid-induced_6\JJ\1740|nicotinic (r_amod) flushing_7\NN\1740|acid-induced (r_dobj) mediates_4\VBZ\761713|gpr109a|flushing|. (l_nsubj) gpr109a_0\NN\1740|puma-g/hm74a (l_appos) puma-g/hm74a_2\NN\1740|(|)
T17_T32 NONE acid-induced_6\JJ\1740|nicotinic (r_amod) flushing_7\NN\1740|acid-induced (r_dobj) mediates_4\VBZ\761713|gpr109a|flushing|. (l_nsubj) gpr109a_0\NN\1740|puma-g/hm74a (l_appos) puma-g/hm74a_2\NN\1740|(|)
T4_T21 NONE hdl-cholesterol_10\NN\1740|
T7_T21 CPR:3 acid_15\NN\14818238|by|nicotinic (r_nmod) induced_12\VBN\1627355|acid (r_acl) levels_11\NNS\4916342|in|hdl-cholesterol|induced (l_compound) hdl-cholesterol_10\NN\1740|
T9_T22 NONE acid-induced_26\JJ\1740|nicotinic (r_amod) effects_28\NNS\13245626|the|acid-induced|antilipolytic|adipocytes (r_dobj) mediate_23\VB\761713|to|effects (r_xcomp) shown_21\VBN\2137132|mediate (r_conj) described_19\VBN\1001294|recently|,|receptor|was|and|shown|. (l_nsubjpass) receptor_4\NN\5225602|a|g-protein-coupled|,|termed|,
T9_T23 NONE acid-induced_26\JJ\1740|nicotinic (r_amod) effects_28\NNS\13245626|the|acid-induced|antilipolytic|adipocytes (r_dobj) mediate_23\VB\761713|to|effects (r_xcomp) shown_21\VBN\2137132|mediate (r_conj) described_19\VBN\1001294|recently|,|receptor|was|and|shown|. (l_nsubjpass) receptor_4\NN\5225602|a|g-protein-coupled|,|termed|, (l_acl) termed_6\VBN\1028748|gpr109a (l_xcomp) gpr109a_7\NN\1740|hm74a
T9_T24 NONE acid-induced_26\JJ\1740|nicotinic (r_amod) effects_28\NNS\13245626|the|acid-induced|antilipolytic|adipocytes (r_dobj) mediate_23\VB\761713|to|effects (r_xcomp) shown_21\VBN\2137132|mediate (r_conj) described_19\VBN\1001294|recently|,|receptor|was|and|shown|. (l_nsubjpass) receptor_4\NN\5225602|a|g-protein-coupled|,|termed|, (l_acl) termed_6\VBN\1028748|gpr109a (l_xcomp) gpr109a_7\NN\1740|hm74a (l_appos) hm74a_9\NN\1740|(|humans|,|puma-g|)
T9_T25 NONE acid-induced_26\JJ\1740|nicotinic (r_amod) effects_28\NNS\13245626|the|acid-induced|antilipolytic|adipocytes (r_dobj) mediate_23\VB\761713|to|effects (r_xcomp) shown_21\VBN\2137132|mediate (r_conj) described_19\VBN\1001294|recently|,|receptor|was|and|shown|. (l_nsubjpass) receptor_4\NN\5225602|a|g-protein-coupled|,|termed|, (l_acl) termed_6\VBN\1028748|gpr109a (l_xcomp) gpr109a_7\NN\1740|hm74a (l_appos) hm74a_9\NN\1740|(|humans|,|puma-g|) (l_appos) puma-g_13\NN\1740|mice
T11_T26 NONE acid-induced_15\JJ\1740|nicotinic (r_amod) flushing_16\NN\1740|acid-induced (r_dobj) show_13\VB\2137132|that|mice|did|not|flushing (l_nsubj) mice_8\NNS\2329401|lacking (l_acl) lacking_9\VBG\1740|puma-g (l_dobj) puma-g_10\NN\1740|
T12_T27 NONE acid_8\NN\14818238|to|nicotinic (r_nmod) response_5\NN\11410625|in|acid (r_nmod) flushing_3\NN\1740|response (r_nsubjpass) abrogated_11\VBN\2427334|addition|,|flushing|was|also|absence|,|and|reduced (l_nmod) absence_14\NN\14449405|in|the|type (l_nmod) type_17\NN\5839024|of|cyclooxygenase|1 (l_nummod) 1_18\CD\13741022|
T12_T28 NONE acid_8\NN\14818238|to|nicotinic (r_nmod) response_5\NN\11410625|in|acid (r_nmod) flushing_3\NN\1740|response (r_nsubjpass) abrogated_11\VBN\2427334|addition|,|flushing|was|also|absence|,|and|reduced (l_conj) reduced_40\VBN\441445|mice|had|responses|. (l_nsubj) mice_21\NNS\2329401|lacking (l_acl) lacking_22\VBG\1740|receptors (l_dobj) receptors_38\NNS\5225602|d(2
T13_T27 NONE )_25\-RRB-\1740|pgd(2 (r_punct) d(2_24\NN\1740|prostaglandin|)|and|e(2 (r_compound) receptors_38\NNS\5225602|d(2 (r_dobj) lacking_22\VBG\1740|receptors (r_acl) mice_21\NNS\2329401|lacking (r_nsubj) reduced_40\VBN\441445|mice|had|responses|. (r_conj) abrogated_11\VBN\2427334|addition|,|flushing|was|also|absence|,|and|reduced (l_nmod) absence_14\NN\14449405|in|the|type (l_nmod) type_17\NN\5839024|of|cyclooxygenase|1 (l_nummod) 1_18\CD\13741022|
T13_T28 NONE )_25\-RRB-\1740|pgd(2 (r_punct) d(2_24\NN\1740|prostaglandin|)|and|e(2 (r_compound) receptors_38\NNS\5225602|d(2
T14_T27 NONE )_28\-RRB-\1740| (r_punct) pgd(2_27\NN\1740|(|)|) (r_appos) )_25\-RRB-\1740|pgd(2 (r_punct) d(2_24\NN\1740|prostaglandin|)|and|e(2 (r_compound) receptors_38\NNS\5225602|d(2 (r_dobj) lacking_22\VBG\1740|receptors (r_acl) mice_21\NNS\2329401|lacking (r_nsubj) reduced_40\VBN\441445|mice|had|responses|. (r_conj) abrogated_11\VBN\2427334|addition|,|flushing|was|also|absence|,|and|reduced (l_nmod) absence_14\NN\14449405|in|the|type (l_nmod) type_17\NN\5839024|of|cyclooxygenase|1 (l_nummod) 1_18\CD\13741022|
T14_T28 NONE )_28\-RRB-\1740| (r_punct) pgd(2_27\NN\1740|(|)|) (r_appos) )_25\-RRB-\1740|pgd(2 (r_punct) d(2_24\NN\1740|prostaglandin|)|and|e(2 (r_compound) receptors_38\NNS\5225602|d(2
T15_T27 NONE )_33\-RRB-\1740|pge(2 (r_punct) e(2_32\NN\1740|prostaglandin|) (r_conj) d(2_24\NN\1740|prostaglandin|)|and|e(2 (r_compound) receptors_38\NNS\5225602|d(2 (r_dobj) lacking_22\VBG\1740|receptors (r_acl) mice_21\NNS\2329401|lacking (r_nsubj) reduced_40\VBN\441445|mice|had|responses|. (r_conj) abrogated_11\VBN\2427334|addition|,|flushing|was|also|absence|,|and|reduced (l_nmod) absence_14\NN\14449405|in|the|type (l_nmod) type_17\NN\5839024|of|cyclooxygenase|1 (l_nummod) 1_18\CD\13741022|
T15_T28 NONE )_33\-RRB-\1740|pge(2 (r_punct) e(2_32\NN\1740|prostaglandin|) (r_conj) d(2_24\NN\1740|prostaglandin|)|and|e(2 (r_compound) receptors_38\NNS\5225602|d(2
T16_T27 NONE )_36\-RRB-\1740|) (r_punct) pge(2_35\NN\1740|(|) (r_appos) )_33\-RRB-\1740|pge(2 (r_punct) e(2_32\NN\1740|prostaglandin|) (r_conj) d(2_24\NN\1740|prostaglandin|)|and|e(2 (r_compound) receptors_38\NNS\5225602|d(2 (r_dobj) lacking_22\VBG\1740|receptors (r_acl) mice_21\NNS\2329401|lacking (r_nsubj) reduced_40\VBN\441445|mice|had|responses|. (r_conj) abrogated_11\VBN\2427334|addition|,|flushing|was|also|absence|,|and|reduced (l_nmod) absence_14\NN\14449405|in|the|type (l_nmod) type_17\NN\5839024|of|cyclooxygenase|1 (l_nummod) 1_18\CD\13741022|
T16_T28 NONE )_36\-RRB-\1740|) (r_punct) pge(2_35\NN\1740|(|) (r_appos) )_33\-RRB-\1740|pge(2 (r_punct) e(2_32\NN\1740|prostaglandin|) (r_conj) d(2_24\NN\1740|prostaglandin|)|and|e(2 (r_compound) receptors_38\NNS\5225602|d(2
T2_T18 NONE acid-induced_31\JJ\1740|nicotinic (r_amod) response_33\NN\11410625|the|acid-induced|flushing (r_dobj) restored_28\VBD\1631072|transplantation|response|. (r_conj) expressed_10\VBN\928630|orthologue|is|highly|macrophages|,|and|restored (l_nsubjpass) orthologue_2\NN\1740|the|mouse|gpr109a|,|puma-g|, (l_appos) puma-g_6\NN\1740|
T2_T19 NONE acid-induced_31\JJ\1740|nicotinic (r_amod) response_33\NN\11410625|the|acid-induced|flushing (r_dobj) restored_28\VBD\1631072|transplantation|response|. (l_nsubj) transplantation_19\NN\671351|marrow|mice (l_nmod) mice_27\NNS\2329401|into|irradiated|puma-g-deficient (l_amod) puma-g-deficient_26\JJ\1740|
T2_T29 NONE acid-induced_31\JJ\1740|nicotinic (r_amod) response_33\NN\11410625|the|acid-induced|flushing (r_dobj) restored_28\VBD\1631072|transplantation|response|. (r_conj) expressed_10\VBN\928630|orthologue|is|highly|macrophages|,|and|restored (l_nsubjpass) orthologue_2\NN\1740|the|mouse|gpr109a|,|puma-g|, (l_nmod) gpr109a_4\NN\1740|of
T3_T20 NONE acid-induced_8\JJ\1740|nicotinic (r_amod) flushing_9\NN\1740|acid-induced (r_dobj) mediates_6\VBZ\761713|that|gpr109a|flushing|and|involves (l_nsubj) gpr109a_5\NN\1740|
T5_T20 NONE )_18\-RRB-\1740| (r_punct) pge(2_17\NN\1740|of|)|and|pgd(2 (r_nmod) release_15\NN\3748886|pge(2|,|cells (r_dobj) involves_14\VBZ\2676054|that|effect|release (r_conj) mediates_6\VBZ\761713|that|gpr109a|flushing|and|involves (l_nsubj) gpr109a_5\NN\1740|
T6_T20 NONE )_21\-RRB-\1740| (r_punct) pgd(2_20\NN\1740|) (r_conj) pge(2_17\NN\1740|of|)|and|pgd(2 (r_nmod) release_15\NN\3748886|pge(2|,|cells (r_dobj) involves_14\VBZ\2676054|that|effect|release (r_conj) mediates_6\VBZ\761713|that|gpr109a|flushing|and|involves (l_nsubj) gpr109a_5\NN\1740|
16488503
T13_T26 NONE gentamicin_2\NN\2716866|of (r_nmod) inhibition_0\NN\1068773|gentamicin|binding|ligands|. (l_nmod) ligands_11\NNS\20090|by|megalin|and|peptides (l_compound) megalin_10\NN\1740|
T4_T15 NONE gentamicin_27\NN\2716866|of (r_nmod) accumulation_25\NN\13497135|renal|gentamicin (r_dobj) inhibits_23\VBZ\2510337|that|coadministration|accumulation (l_nsubj) coadministration_5\NN\1740|c (l_nmod) c_8\NN\13714184|of|cytochrome|and|peptide (l_conj) peptide_13\NN\14724264|a|20-residue|basic|,|n-wasp181 (l_appos) n-wasp181_15\NN\1740|-|200|nishtkekkkgkakkkrltk (l_dep) nishtkekkkgkakkkrltk_19\NN\1740|(|,|pi=10.87|)
T4_T22 NONE gentamicin_27\NN\2716866|of (r_nmod) accumulation_25\NN\13497135|renal|gentamicin (r_dobj) inhibits_23\VBZ\2510337|that|coadministration|accumulation (l_nsubj) coadministration_5\NN\1740|c (l_nmod) c_8\NN\13714184|of|cytochrome|and|peptide
T5_T19 NONE gentamicin_20\NN\2716866|of (r_nmod) uptake_18\NN\13440063|in|renal|gentamicin (r_nmod) involved_15\VBN\2676054|uptake (r_acl) receptor_14\NN\5225602|an|endocytic|involved (r_appos) megalin_10\NN\1740|of|,|receptor|,
T6_T19 NONE gentamicin_34\NN\2716866|on|binding (r_nmod) peptides_24\NNS\14724264|basic|n-wasp180|gentamicin (r_conj) ligands_8\NNS\20090|of|megalin|and|peptides (l_nmod) megalin_10\NN\1740|of|,|receptor|,
T7_T20 NONE gentamicin_0\NN\2716866|binding (r_nsubjpass) inhibited_5\VBN\2510337|gentamicin|was|ligands|manner|. (l_nmod) ligands_8\NNS\20090|by|megalin|,|fragments|,|and|n-wasp181 (l_compound) megalin_7\NN\1740|
T7_T21 NONE gentamicin_0\NN\2716866|binding (r_nsubjpass) inhibited_5\VBN\2510337|gentamicin|was|ligands|manner|. (l_nmod) ligands_8\NNS\20090|by|megalin|,|fragments|,|and|n-wasp181 (l_conj) fragments_12\NNS\9385911|basic|peptide|c (l_nmod) c_15\NN\13714184|of|cytochrome
T10_T23 NONE lysines_4\NNS\14605787|for|n-wasp181 (r_nmod) substituting_1\VBG\126264|by|glycines|lysines (r_advcl) reduced_24\VBN\441445|substituting|,|effect|was|,|related|. (l_ccomp) related_29\JJ\1740|which|may|be|decrease (l_nmod) decrease_32\NN\7296428|to|a|content (l_nmod) content_36\NN\7951464|in|the|alpha-helix|peptide (l_amod) alpha-helix_35\JJ\1740|
T11_T23 NONE gentamicin_19\NN\2716866| (r_compound) binding_20\NN\4688246|on|gentamicin|bbm (r_nmod) effect_17\NN\34213|the|inhibitory|binding (r_nsubjpass) reduced_24\VBN\441445|substituting|,|effect|was|,|related|. (l_ccomp) related_29\JJ\1740|which|may|be|decrease (l_nmod) decrease_32\NN\7296428|to|a|content (l_nmod) content_36\NN\7951464|in|the|alpha-helix|peptide (l_amod) alpha-helix_35\JJ\1740|
T9_T23 NONE glycines_2\NNS\14601829| (r_dobj) substituting_1\VBG\126264|by|glycines|lysines (r_advcl) reduced_24\VBN\441445|substituting|,|effect|was|,|related|. (l_ccomp) related_29\JJ\1740|which|may|be|decrease (l_nmod) decrease_32\NN\7296428|to|a|content (l_nmod) content_36\NN\7951464|in|the|alpha-helix|peptide (l_amod) alpha-helix_35\JJ\1740|
T12_T24 NONE gentamicin_0\NN\2716866|binding|,|disappeared|, (l_acl) binding_1\VBG\1290422|bbm (l_nmod) bbm_3\NNS\1740|to|treated (l_acl) treated_4\VBN\2376958|trypsin (l_nmod) trypsin_6\NN\14732946|with
T12_T25 NONE gentamicin_0\NN\2716866|binding|,|disappeared|, (l_acl:relcl) disappeared_12\VBD\2609764|which|megalin|completely (l_nsubj) megalin_10\NN\1740|
T1_T14 NONE gentamicin_21\NN\2716866| (r_compound) binding_22\NN\4688246|on|gentamicin (r_nmod) effect_15\NN\34213|in|the|inhibitory|n-wasp181|binding (r_nmod) decrease_11\NN\7296428|to|a|effect (r_nmod) led_8\VBD\1752884|addition|,|treatment|decrease|. (l_nsubj) treatment_3\NN\654885|bbm|trypsin (l_nmod) trypsin_7\NN\14732946|with
T2_T16 NONE gentamicin_17\NN\2716866|of (r_nmod) accumulation_15\NN\13497135|renal|gentamicin (r_dobj) decrease_13\VBP\169651|that|ligands|accumulation|inhibiting (l_nsubj) ligands_5\NNS\20090|megalin|and|peptides (l_compound) megalin_4\NN\1740|
T2_T17 NONE gentamicin_17\NN\2716866|of (r_nmod) accumulation_15\NN\13497135|renal|gentamicin (r_dobj) decrease_13\VBP\169651|that|ligands|accumulation|inhibiting (l_advcl) inhibiting_19\VBG\2510337|by|binding|,|interacting (l_advcl) interacting_30\VBG\2367363|partly|megalin (l_nmod) megalin_32\NN\1740|with
T3_T18 NONE gentamicin_23\NN\2716866|of (r_nmod) binding_21\NN\4688246|on|the|gentamicin|bbm (r_nmod) effect_14\NN\34213|in|the|inhibitory|n-wasp181|binding (r_nmod) play_7\VB\1072262|addition|,|conformation|may|role|effect|. (l_nsubj) conformation_5\NN\13897996|the|alpha-helix (l_amod) alpha-helix_4\JJ\1740|
17098734
T5_T17 NONE leci-thin_16\NN\1740|of|a|:|acyltransferase (l_appos) acyltransferase_19\NN\1740|retinol|lratb
T5_T18 NONE leci-thin_16\NN\1740|of|a|:|acyltransferase (l_appos) acyltransferase_19\NN\1740|retinol|lratb (l_appos) lratb_21\NN\1740|(|)
T6_T17 NONE retinol_18\NN\15089803| (r_compound) acyltransferase_19\NN\1740|retinol|lratb
T6_T18 NONE retinol_18\NN\15089803| (r_compound) acyltransferase_19\NN\1740|retinol|lratb (l_appos) lratb_21\NN\1740|(|)
T8_T19 NONE retinal_12\JJ\1740| (r_amod) dehydrogenase_13\NN\1740|to|retinal|2|raldh2|,|enzyme (r_nmod) opposite_10\JJ\1740|dehydrogenase (r_amod) domains_9\NNS\13934596|in|non-overlapping|opposite (r_nmod) expressed_5\VBN\928630|embryogenesis|,|lratb|is|domains|. (l_nsubjpass) lratb_3\NN\1740|
T8_T20 NONE retinal_12\JJ\1740| (r_amod) dehydrogenase_13\NN\1740|to|retinal|2|raldh2|,|enzyme (l_nummod) 2_14\CD\13741022|
T8_T21 NONE retinal_12\JJ\1740| (r_amod) dehydrogenase_13\NN\1740|to|retinal|2|raldh2|,|enzyme (l_appos) raldh2_16\NN\1740|(|)
T9_T19 NONE acid_24\NN\14818238| (r_compound) synthesis_25\NN\13446390|for|retinoic|acid (r_nmod) enzyme_21\NN\14723628|the|key|synthesis (r_appos) dehydrogenase_13\NN\1740|to|retinal|2|raldh2|,|enzyme (r_nmod) opposite_10\JJ\1740|dehydrogenase (r_amod) domains_9\NNS\13934596|in|non-overlapping|opposite (r_nmod) expressed_5\VBN\928630|embryogenesis|,|lratb|is|domains|. (l_nsubjpass) lratb_3\NN\1740|
T9_T20 CPR:9 acid_24\NN\14818238| (r_compound) synthesis_25\NN\13446390|for|retinoic|acid (r_nmod) enzyme_21\NN\14723628|the|key|synthesis (r_appos) dehydrogenase_13\NN\1740|to|retinal|2|raldh2|,|enzyme (l_nummod) 2_14\CD\13741022|
T9_T21 CPR:9 acid_24\NN\14818238| (r_compound) synthesis_25\NN\13446390|for|retinoic|acid (r_nmod) enzyme_21\NN\14723628|the|key|synthesis (r_appos) dehydrogenase_13\NN\1740|to|retinal|2|raldh2|,|enzyme (l_appos) raldh2_16\NN\1740|(|)
T10_T22 CPR:9 ester_2\NN\14727670|retinyl (r_compound) formation_3\NN\7938773|ester (r_dobj) blocking_0\VBG\1476483|formation|down (l_nmod) down_8\NN\1896031|by|a|targeted|knock|lratb (l_nmod) lratb_10\NN\1740|of
T11_T22 NONE acid_16\NN\14818238| (r_compound) levels_17\NNS\4916342|in|increased|retinoic|acid|,|lead (r_nmod) results_11\VBZ\2633881|blocking|levels|. (l_csubj) blocking_0\VBG\1476483|formation|down (l_nmod) down_8\NN\1896031|by|a|targeted|knock|lratb (l_nmod) lratb_10\NN\1740|of
T12_T23 NONE a_16\NN\13649268|for|yolk|vitamin (r_nmod) competition_8\NN\13836841|a|balanced|lratb|a (l_nmod) lratb_10\NN\1740|between|and|raldh2
T12_T24 NONE a_16\NN\13649268|for|yolk|vitamin (r_nmod) competition_8\NN\13836841|a|balanced|lratb|a (l_nmod) lratb_10\NN\1740|between|and|raldh2 (l_conj) raldh2_12\NN\1740|
T13_T23 NONE ester_23\NN\14727670|retinyl|or|acid (r_compound) synthesis_27\NN\13446390|for|ester (r_nmod) defines_17\VBZ\2604760|that|competition|compartments|either|synthesis (l_nsubj) competition_8\NN\13836841|a|balanced|lratb|a (l_nmod) lratb_10\NN\1740|between|and|raldh2
T13_T24 NONE ester_23\NN\14727670|retinyl|or|acid (r_compound) synthesis_27\NN\13446390|for|ester (r_nmod) defines_17\VBZ\2604760|that|competition|compartments|either|synthesis (l_nsubj) competition_8\NN\13836841|a|balanced|lratb|a (l_nmod) lratb_10\NN\1740|between|and|raldh2 (l_conj) raldh2_12\NN\1740|
T14_T23 NONE acid_26\NN\14818238|retinoic (r_conj) ester_23\NN\14727670|retinyl|or|acid (r_compound) synthesis_27\NN\13446390|for|ester (r_nmod) defines_17\VBZ\2604760|that|competition|compartments|either|synthesis (l_nsubj) competition_8\NN\13836841|a|balanced|lratb|a (l_nmod) lratb_10\NN\1740|between|and|raldh2
T14_T24 NONE acid_26\NN\14818238|retinoic (r_conj) ester_23\NN\14727670|retinyl|or|acid (r_compound) synthesis_27\NN\13446390|for|ester (r_nmod) defines_17\VBZ\2604760|that|competition|compartments|either|synthesis (l_nsubj) competition_8\NN\13836841|a|balanced|lratb|a (l_nmod) lratb_10\NN\1740|between|and|raldh2 (l_conj) raldh2_12\NN\1740|
17324065
T10_T20 CPR:3 cocaine_17\NN\3492717| (r_compound) sensitization_18\NN\14531772|during|early|cocaine (r_nmod) activation_1\NN\13561719|differential|protein|subregions|sensitization|. (l_nmod) protein_7\NN\14944888|of|camp|response|element|binding
T11_T20 NONE camp_3\NN\3763727| (r_compound) protein_7\NN\14944888|of|camp|response|element|binding
T1_T15 NONE camp_14\NN\3763727| (r_compound) protein_19\NN\14944888|of|the|cyclic|adenosine|monophosphate|(|camp|)|response|element|binding|creb (l_appos) creb_21\NN\1740|(|)
T1_T18 NONE camp_14\NN\3763727| (r_compound) protein_19\NN\14944888|of|the|cyclic|adenosine|monophosphate|(|camp|)|response|element|binding|creb
T5_T15 CPR:3 cocaine-induced_6\JJ\1740| (r_amod) activation_7\NN\13561719|the|differential|cocaine-induced|protein|zones (l_nmod) protein_19\NN\14944888|of|the|cyclic|adenosine|monophosphate|(|camp|)|response|element|binding|creb (l_appos) creb_21\NN\1740|(|)
T5_T18 CPR:3 cocaine-induced_6\JJ\1740| (r_amod) activation_7\NN\13561719|the|differential|cocaine-induced|protein|zones (l_nmod) protein_19\NN\14944888|of|the|cyclic|adenosine|monophosphate|(|camp|)|response|element|binding|creb
T8_T15 NONE monophosphate_12\NN\1740| (r_compound) protein_19\NN\14944888|of|the|cyclic|adenosine|monophosphate|(|camp|)|response|element|binding|creb (l_appos) creb_21\NN\1740|(|)
T8_T18 NONE monophosphate_12\NN\1740| (r_compound) protein_19\NN\14944888|of|the|cyclic|adenosine|monophosphate|(|camp|)|response|element|binding|creb
T4_T16 NONE cocaine_17\NN\3492717|of (r_nmod) effects_15\NNS\13245626|the|subjective|cocaine (r_conj) changes_9\NNS\7283608|long-lasting|drug-induced|behavior|and|effects (r_dobj) underlie_6\VB\2604760|which|may|changes (r_acl:relcl) transcription_2\NN\6349220|creb-dependent|gene|,|underlie|, (l_amod) creb-dependent_0\JJ\1740|
T6_T17 CPR:3 cocaine_17\NN\3492717|of (r_nmod) days_15\NNS\15140892|after|5|cocaine|,|period|,|and|injection (r_nmod) changes_6\NNS\7283608|phosphorylation|days (l_nmod) phosphorylation_9\NN\1740|in|creb|nac (l_compound) creb_8\NN\1740|
T7_T12 NONE cocaine_1\NN\3492717|repeated (r_nsubj) resulted_2\VBD\2633881|cocaine|phosphorylation|,|but|yielded (l_conj) yielded_36\VBD\2327200|rats|activation|. (l_dobj) activation_40\NN\13561719|a|localized|creb|zones (l_nmod) creb_42\NN\1740|of
T7_T19 CPR:3 cocaine_1\NN\3492717|repeated (r_nsubj) resulted_2\VBD\2633881|cocaine|phosphorylation|,|but|yielded (l_nmod) phosphorylation_5\NN\1740|in|creb|subregions (l_compound) creb_4\NN\1740|
T9_T12 CPR:3 cocaine_27\NN\3492717|of|repeated (r_nmod) cessation_24\NN\7365849|cocaine (r_dep) weeks_22\NNS\15113229|2|after|cessation (r_nmod) subregions_9\NNS\1740|in|all|analyzed|nac|region|weeks (r_nmod) phosphorylation_5\NN\1740|in|creb|subregions (r_nmod) resulted_2\VBD\2633881|cocaine|phosphorylation|,|but|yielded (l_conj) yielded_36\VBD\2327200|rats|activation|. (l_dobj) activation_40\NN\13561719|a|localized|creb|zones (l_nmod) creb_42\NN\1740|of
T9_T19 NONE cocaine_27\NN\3492717|of|repeated (r_nmod) cessation_24\NN\7365849|cocaine (r_dep) weeks_22\NNS\15113229|2|after|cessation (r_nmod) subregions_9\NNS\1740|in|all|analyzed|nac|region|weeks (r_nmod) phosphorylation_5\NN\1740|in|creb|subregions (l_compound) creb_4\NN\1740|
T2_T13 CPR:3 cocaine-induced_6\JJ\1740| (r_amod) activity_8\NN\30358|of|cocaine-induced|creb (l_compound) creb_7\NN\1740|
T2_T14 NONE cocaine-induced_6\JJ\1740| (r_amod) activity_8\NN\30358|of|cocaine-induced|creb (r_nmod) determinants_4\NNS\5686481|the|temporal|activity (r_nsubj) indicate_10\VB\952524|determinants|may|differences|and|suggest|. (l_conj) suggest_18\VB\1010118|involvement (l_dobj) involvement_20\NN\1080366|the|creb|effects (l_nmod) creb_22\NN\1740|of
T3_T13 NONE cocaine_27\NN\3492717| (r_compound) effects_28\NNS\13245626|in|early|cocaine (r_nmod) involvement_20\NN\1080366|the|creb|effects (r_dobj) suggest_18\VB\1010118|involvement (r_conj) indicate_10\VB\952524|determinants|may|differences|and|suggest|. (l_nsubj) determinants_4\NNS\5686481|the|temporal|activity (l_nmod) activity_8\NN\30358|of|cocaine-induced|creb (l_compound) creb_7\NN\1740|
T3_T14 NONE cocaine_27\NN\3492717| (r_compound) effects_28\NNS\13245626|in|early|cocaine (r_nmod) involvement_20\NN\1080366|the|creb|effects (l_nmod) creb_22\NN\1740|of
23295740
T15_T30 CPR:3 tamoxifen_0\NN\2714883| (r_nsubj) represses_1\VBZ\2424652|tamoxifen|micrornas|and|promotes|. (l_conj) promotes_5\VBZ\2556126|transition|up-regulating (l_advcl) up-regulating_9\VBG\1740|by|c-myc|lines (l_dobj) c-myc_10\NN\1740|
T15_T31 CPR:4 tamoxifen_0\NN\2714883| (r_nsubj) represses_1\VBZ\2424652|tamoxifen|micrornas|and|promotes|. (l_dobj) micrornas_3\NNS\1740|mir-200 (l_compound) mir-200_2\NN\1740|
T10_T22 NONE estrogen_8\NN\14745635| (r_compound) modulator_10\NN\1740|a|selective|estrogen|receptor (l_compound) receptor_9\NN\5225602|
T14_T22 NONE tamoxifen_1\NN\2714883|tam|,|modulator|, (l_appos) modulator_10\NN\1740|a|selective|estrogen|receptor (l_compound) receptor_9\NN\5225602|
T5_T22 NONE estrogen-like_25\JJ\1740| (r_amod) effect_26\NN\34213|its|estrogen-like (r_nsubj) increases_27\VBZ\169651|used|,|effect|risk|. (l_advcl) used_15\VBN\1156834|although|tamoxifen|has|been|widely|treatment (l_nsubjpass) tamoxifen_1\NN\2714883|tam|,|modulator|, (l_appos) modulator_10\NN\1740|a|selective|estrogen|receptor (l_compound) receptor_9\NN\5225602|
T7_T22 NONE tam_3\NN\2954340|(|) (r_appos) tamoxifen_1\NN\2714883|tam|,|modulator|, (l_appos) modulator_10\NN\1740|a|selective|estrogen|receptor (l_compound) receptor_9\NN\5225602|
T9_T23 NONE tam-induced_14\JJ\1740| (r_amod) transition_16\NN\199130|in|tam-induced|epithelial-mesenchymal|emt|lines (r_nmod) role_7\NN\719494|the|micrornas|transition (r_dobj) explored_5\VBD\789138|report|,|we|role|and|found|. (l_conj) found_29\VBD\2426171|involved (l_ccomp) involved_32\VBN\2676054|mir-200|is|process|regulation (l_nsubjpass) mir-200_30\NN\1740|
T9_T24 NONE tam-induced_14\JJ\1740| (r_amod) transition_16\NN\199130|in|tam-induced|epithelial-mesenchymal|emt|lines (r_nmod) role_7\NN\719494|the|micrornas|transition (r_dobj) explored_5\VBD\789138|report|,|we|role|and|found|. (l_conj) found_29\VBD\2426171|involved (l_ccomp) involved_32\VBN\2676054|mir-200|is|process|regulation (l_nmod) regulation_38\NN\6652242|via|the|c-myc (l_nmod) c-myc_40\NN\1740|of
T12_T25 CPR:4 tam_22\NN\2954340| (r_compound) treatment_23\NN\654885|to|tam (r_nmod) response_20\NN\11410625|in|treatment (r_nmod) reduced_18\VBN\441445|response (r_xcomp) found_17\VBN\2426171|mir-200|was|reduced|. (l_nsubjpass) mir-200_0\NN\1740|,|family|,
T13_T16 NONE zinc_2\NN\14625458| (r_compound) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (r_nmod) consistent_0\JJ\1740|homeobox (r_advmod) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_parataxis) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (l_nsubj) e-cadherin_38\NN\1740|
T13_T26 NONE zinc_2\NN\14625458| (r_compound) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (l_nummod) 2_7\CD\13741022|
T13_T27 NONE zinc_2\NN\14625458| (r_compound) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (l_acl:relcl) confirmed_11\VBN\1011725|which|was|target (l_nmod) target_15\NN\7258332|as|a|direct|mir-200b|lines (l_nmod) mir-200b_17\NN\1740|of
T13_T28 NONE zinc_2\NN\14625458| (r_compound) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (r_nmod) consistent_0\JJ\1740|homeobox (r_advmod) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_nsubj) factors_27\NNS\7326557|some|other|key|emt|snail (l_nmod) snail_32\NN\1942177|such|and|n-cadherin
T13_T29 NONE zinc_2\NN\14625458| (r_compound) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (r_nmod) consistent_0\JJ\1740|homeobox (r_advmod) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_nsubj) factors_27\NNS\7326557|some|other|key|emt|snail (l_nmod) snail_32\NN\1942177|such|and|n-cadherin (l_conj) n-cadherin_34\NN\1740|
T1_T16 CPR:4 tam-treated_42\JJ\1740| (r_amod) cells_43\NNS\3080309|in|the|tam-treated (r_nmod) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (l_nsubj) e-cadherin_38\NN\1740|
T1_T26 NONE tam-treated_42\JJ\1740| (r_amod) cells_43\NNS\3080309|in|the|tam-treated (r_nmod) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (r_parataxis) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_advmod) consistent_0\JJ\1740|homeobox (l_nmod) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (l_nummod) 2_7\CD\13741022|
T1_T27 NONE tam-treated_42\JJ\1740| (r_amod) cells_43\NNS\3080309|in|the|tam-treated (r_nmod) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (r_parataxis) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_advmod) consistent_0\JJ\1740|homeobox (l_nmod) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (l_acl:relcl) confirmed_11\VBN\1011725|which|was|target (l_nmod) target_15\NN\7258332|as|a|direct|mir-200b|lines (l_nmod) mir-200b_17\NN\1740|of
T1_T28 CPR:3 tam-treated_42\JJ\1740| (r_amod) cells_43\NNS\3080309|in|the|tam-treated (r_nmod) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (r_parataxis) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_nsubj) factors_27\NNS\7326557|some|other|key|emt|snail (l_nmod) snail_32\NN\1942177|such|and|n-cadherin
T1_T29 CPR:3 tam-treated_42\JJ\1740| (r_amod) cells_43\NNS\3080309|in|the|tam-treated (r_nmod) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (r_parataxis) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_nsubj) factors_27\NNS\7326557|some|other|key|emt|snail (l_nmod) snail_32\NN\1942177|such|and|n-cadherin (l_conj) n-cadherin_34\NN\1740|
T2_T16 NONE tam-induced_47\JJ\1740| (r_amod) emt_48\NN\1740|to|tam-induced|cells (r_nmod) contributing_45\VBG\126264|emt (r_xcomp) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (l_nsubj) e-cadherin_38\NN\1740|
T2_T26 NONE tam-induced_47\JJ\1740| (r_amod) emt_48\NN\1740|to|tam-induced|cells (r_nmod) contributing_45\VBG\126264|emt (r_xcomp) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (r_parataxis) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_advmod) consistent_0\JJ\1740|homeobox (l_nmod) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (l_nummod) 2_7\CD\13741022|
T2_T27 NONE tam-induced_47\JJ\1740| (r_amod) emt_48\NN\1740|to|tam-induced|cells (r_nmod) contributing_45\VBG\126264|emt (r_xcomp) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (r_parataxis) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_advmod) consistent_0\JJ\1740|homeobox (l_nmod) homeobox_6\NN\5438642|with|zinc|finger|e-box|binding|2|,|confirmed (l_acl:relcl) confirmed_11\VBN\1011725|which|was|target (l_nmod) target_15\NN\7258332|as|a|direct|mir-200b|lines (l_nmod) mir-200b_17\NN\1740|of
T2_T28 NONE tam-induced_47\JJ\1740| (r_amod) emt_48\NN\1740|to|tam-induced|cells (r_nmod) contributing_45\VBG\126264|emt (r_xcomp) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (r_parataxis) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_nsubj) factors_27\NNS\7326557|some|other|key|emt|snail (l_nmod) snail_32\NN\1942177|such|and|n-cadherin
T2_T29 NONE tam-induced_47\JJ\1740| (r_amod) emt_48\NN\1740|to|tam-induced|cells (r_nmod) contributing_45\VBG\126264|emt (r_xcomp) decreased_39\VBD\169651|e-cadherin|cells|,|contributing (r_parataxis) increased_35\VBD\169651|consistent|,|factors|,|whereas|decreased|. (l_nsubj) factors_27\NNS\7326557|some|other|key|emt|snail (l_nmod) snail_32\NN\1942177|such|and|n-cadherin (l_conj) n-cadherin_34\NN\1740|
T3_T17 NONE tam-treated_22\JJ\1740| (r_amod) cells_25\NNS\3080309|in|tam-treated|endometrial|cancer (r_nmod) up-regulation_20\NN\1740|its|cells (r_nsubj) leads_26\VBZ\1752884|up-regulation|down-regulation (r_conj) binds_8\VBZ\1290422|that|c-myc|directly|to|and|represses|promoter|,|and|leads (l_nsubj) c-myc_6\NN\1740|
T3_T18 NONE tam-treated_22\JJ\1740| (r_amod) cells_25\NNS\3080309|in|tam-treated|endometrial|cancer (r_nmod) up-regulation_20\NN\1740|its|cells (r_nsubj) leads_26\VBZ\1752884|up-regulation|down-regulation (r_conj) binds_8\VBZ\1290422|that|c-myc|directly|to|and|represses|promoter|,|and|leads (l_dobj) promoter_13\NN\9773962|the|mirnas (l_nmod) mirnas_16\NNS\1740|of|mir-200 (l_compound) mir-200_15\NN\1740|
T3_T19 CPR:4 tam-treated_22\JJ\1740| (r_amod) cells_25\NNS\3080309|in|tam-treated|endometrial|cancer (r_nmod) up-regulation_20\NN\1740|its|cells (r_nsubj) leads_26\VBZ\1752884|up-regulation|down-regulation (l_nmod) down-regulation_29\NN\1740|to|the|mir-200|and|emt (l_nmod) mir-200_31\NN\1740|of
T4_T20 CPR:4 tam_6\NN\2954340| (r_nsubj) repress_8\VB\2424652|that|tam|can|family|and|induce (l_dobj) family_11\NN\8189659|the|mir-200 (l_compound) mir-200_10\NN\1740|
T4_T21 CPR:3 tam_6\NN\2954340| (r_nsubj) repress_8\VB\2424652|that|tam|can|family|and|induce (l_conj) induce_13\VB\1627355|emt|up-regulation (l_nmod) up-regulation_17\NN\1740|via|the|c-myc|cells (l_nmod) c-myc_19\NN\1740|of
12901032
T14_T22 NONE warfarin_3\NN\2718259| (r_compound) therapy_4\NN\657604|on|warfarin (r_nmod) stable_1\JJ\1740|therapy|and|taking (l_conj) taking_7\VBG\2367363|concurrently|comparator (l_dobj) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2
T14_T23 NONE warfarin_3\NN\2718259| (r_compound) therapy_4\NN\657604|on|warfarin (r_nmod) stable_1\JJ\1740|therapy|and|taking (l_conj) taking_7\VBG\2367363|concurrently|comparator (l_dobj) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2 (l_appos) cox-2_11\NN\14737847|(|)
T6_T22 CPR:4 salsalate_21\NN\1740| (r_conj) medications_19\NNS\3247620|(|traditional|nonsteroidal|antiinflammatory|,|salsalate|,|or|acetaminophen|) (r_dep) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2
T6_T23 CPR:4 salsalate_21\NN\1740| (r_conj) medications_19\NNS\3247620|(|traditional|nonsteroidal|antiinflammatory|,|salsalate|,|or|acetaminophen|) (r_dep) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2 (l_appos) cox-2_11\NN\14737847|(|)
T7_T22 CPR:4 acetaminophen_24\NN\2707683| (r_conj) medications_19\NNS\3247620|(|traditional|nonsteroidal|antiinflammatory|,|salsalate|,|or|acetaminophen|) (r_dep) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2
T7_T23 CPR:4 acetaminophen_24\NN\2707683| (r_conj) medications_19\NNS\3247620|(|traditional|nonsteroidal|antiinflammatory|,|salsalate|,|or|acetaminophen|) (r_dep) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2 (l_appos) cox-2_11\NN\14737847|(|)
T8_T22 CPR:4 celecoxib_28\NN\3124700| (r_compound) mg/day_30\NN\1740|celecoxib|200|or|mg/day (r_dobj) received_27\VBD\2210855|patients|randomly|mg/day|weeks|. (l_nsubj) patients_0\NNS\9898892|stable (l_amod) stable_1\JJ\1740|therapy|and|taking (l_conj) taking_7\VBG\2367363|concurrently|comparator (l_dobj) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2
T8_T23 CPR:4 celecoxib_28\NN\3124700| (r_compound) mg/day_30\NN\1740|celecoxib|200|or|mg/day (r_dobj) received_27\VBD\2210855|patients|randomly|mg/day|weeks|. (l_nsubj) patients_0\NNS\9898892|stable (l_amod) stable_1\JJ\1740|therapy|and|taking (l_conj) taking_7\VBG\2367363|concurrently|comparator (l_dobj) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2 (l_appos) cox-2_11\NN\14737847|(|)
T9_T22 CPR:4 rofecoxib_32\NN\3124700| (r_compound) mg/day_34\NN\1740|rofecoxib|25 (r_conj) mg/day_30\NN\1740|celecoxib|200|or|mg/day (r_dobj) received_27\VBD\2210855|patients|randomly|mg/day|weeks|. (l_nsubj) patients_0\NNS\9898892|stable (l_amod) stable_1\JJ\1740|therapy|and|taking (l_conj) taking_7\VBG\2367363|concurrently|comparator (l_dobj) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2
T9_T23 CPR:4 rofecoxib_32\NN\3124700| (r_compound) mg/day_34\NN\1740|rofecoxib|25 (r_conj) mg/day_30\NN\1740|celecoxib|200|or|mg/day (r_dobj) received_27\VBD\2210855|patients|randomly|mg/day|weeks|. (l_nsubj) patients_0\NNS\9898892|stable (l_amod) stable_1\JJ\1740|therapy|and|taking (l_conj) taking_7\VBG\2367363|concurrently|comparator (l_dobj) comparator_14\NN\1740|a|cyclooxygenase-2|inhibitor|medications (l_compound) cyclooxygenase-2_9\NN\14737847|cox-2 (l_appos) cox-2_11\NN\14737847|(|)
T1_T21 NONE rofecoxib_22\NN\3124700| (r_compound) group_23\NN\2137|in|the|rofecoxib (r_nmod) higher_19\JJR\1740|rate|was|group|. (r_conj) similar_4\JJ\1740|reactions|were|inhibitor|,|but|higher (l_nmod) inhibitor_8\NN\20090|for|each|cox-2 (l_compound) cox-2_7\NN\14737847|
17869551
T10_T36 NONE oxide_22\NN\14818238| (r_compound) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos
T10_T37 NONE oxide_22\NN\14818238| (r_compound) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos (l_appos) enos_25\NN\1740|(|)
T11_T36 CPR:9 no_3\NN\7204911|(|) (r_appos) oxide_1\NN\14818238|nitric|no (r_nsubj) vasorelaxant_8\NN\1740|oxide|is|an|important|produced|. (l_acl) produced_9\VBN\1617192|along|reaction (l_nmod) reaction_17\NN\13446390|in|a|catalyzed (l_acl) catalyzed_18\VBN\146138|synthase (l_nmod) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos
T11_T37 CPR:9 no_3\NN\7204911|(|) (r_appos) oxide_1\NN\14818238|nitric|no (r_nsubj) vasorelaxant_8\NN\1740|oxide|is|an|important|produced|. (l_acl) produced_9\VBN\1617192|along|reaction (l_nmod) reaction_17\NN\13446390|in|a|catalyzed (l_acl) catalyzed_18\VBN\146138|synthase (l_nmod) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos (l_appos) enos_25\NN\1740|(|)
T1_T36 CPR:9 oxide_1\NN\14818238|nitric|no (r_nsubj) vasorelaxant_8\NN\1740|oxide|is|an|important|produced|. (l_acl) produced_9\VBN\1617192|along|reaction (l_nmod) reaction_17\NN\13446390|in|a|catalyzed (l_acl) catalyzed_18\VBN\146138|synthase (l_nmod) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos
T1_T37 CPR:9 oxide_1\NN\14818238|nitric|no (r_nsubj) vasorelaxant_8\NN\1740|oxide|is|an|important|produced|. (l_acl) produced_9\VBN\1617192|along|reaction (l_nmod) reaction_17\NN\13446390|in|a|catalyzed (l_acl) catalyzed_18\VBN\146138|synthase (l_nmod) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos (l_appos) enos_25\NN\1740|(|)
T23_T36 CPR:9 l-citrulline_12\NN\1740|with (r_nmod) along_10\IN\1740|l-citrulline|l-arginine (r_advmod) produced_9\VBN\1617192|along|reaction (l_nmod) reaction_17\NN\13446390|in|a|catalyzed (l_acl) catalyzed_18\VBN\146138|synthase (l_nmod) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos
T23_T37 CPR:9 l-citrulline_12\NN\1740|with (r_nmod) along_10\IN\1740|l-citrulline|l-arginine (r_advmod) produced_9\VBN\1617192|along|reaction (l_nmod) reaction_17\NN\13446390|in|a|catalyzed (l_acl) catalyzed_18\VBN\146138|synthase (l_nmod) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos (l_appos) enos_25\NN\1740|(|)
T29_T36 CPR:9 l-arginine_14\NN\1740|from (r_nmod) along_10\IN\1740|l-citrulline|l-arginine (r_advmod) produced_9\VBN\1617192|along|reaction (l_nmod) reaction_17\NN\13446390|in|a|catalyzed (l_acl) catalyzed_18\VBN\146138|synthase (l_nmod) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos
T29_T37 CPR:9 l-arginine_14\NN\1740|from (r_nmod) along_10\IN\1740|l-citrulline|l-arginine (r_advmod) produced_9\VBN\1617192|along|reaction (l_nmod) reaction_17\NN\13446390|in|a|catalyzed (l_acl) catalyzed_18\VBN\146138|synthase (l_nmod) synthase_23\NN\1740|by|endothelial|nitric|oxide|enos (l_appos) enos_25\NN\1740|(|)
T2_T34 NONE argininosuccinate_9\NN\1740| (r_compound) synthase_10\NN\1740|of|argininosuccinate|as|,|component
T2_T35 NONE argininosuccinate_9\NN\1740| (r_compound) synthase_10\NN\1740|of|argininosuccinate|as|,|component (l_appos) as_12\NN\14622893|(|)
T31_T34 CPR:4 alpha-methyl-dl-aspartate_4\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|an|synthase (l_nmod) synthase_10\NN\1740|of|argininosuccinate|as|,|component
T31_T35 CPR:4 alpha-methyl-dl-aspartate_4\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|an|synthase (l_nmod) synthase_10\NN\1740|of|argininosuccinate|as|,|component (l_appos) as_12\NN\14622893|(|)
T3_T34 NONE citrulline-no_19\NN\1740| (r_compound) cycle_20\NN\15269513|of|the|citrulline-no (r_nmod) component_16\NN\5867413|a|cycle (r_appos) synthase_10\NN\1740|of|argininosuccinate|as|,|component
T3_T35 NONE citrulline-no_19\NN\1740| (r_compound) cycle_20\NN\15269513|of|the|citrulline-no (r_nmod) component_16\NN\5867413|a|cycle (r_appos) synthase_10\NN\1740|of|argininosuccinate|as|,|component (l_appos) as_12\NN\14622893|(|)
T4_T34 NONE citrulline-no_19\NN\1740| (r_compound) cycle_20\NN\15269513|of|the|citrulline-no (r_nmod) component_16\NN\5867413|a|cycle (r_appos) synthase_10\NN\1740|of|argininosuccinate|as|,|component
T4_T35 NONE citrulline-no_19\NN\1740| (r_compound) cycle_20\NN\15269513|of|the|citrulline-no (r_nmod) component_16\NN\5867413|a|cycle (r_appos) synthase_10\NN\1740|of|argininosuccinate|as|,|component (l_appos) as_12\NN\14622893|(|)
T5_T34 NONE no_23\NN\7204911| (r_compound) production_24\NN\30358|no (r_dobj) inhibited_22\VBD\2510337|support|,|alpha-methyl-dl-aspartate|production|manner|. (l_nsubj) alpha-methyl-dl-aspartate_4\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|an|synthase (l_nmod) synthase_10\NN\1740|of|argininosuccinate|as|,|component
T5_T35 NONE no_23\NN\7204911| (r_compound) production_24\NN\30358|no (r_dobj) inhibited_22\VBD\2510337|support|,|alpha-methyl-dl-aspartate|production|manner|. (l_nsubj) alpha-methyl-dl-aspartate_4\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|an|synthase (l_nmod) synthase_10\NN\1740|of|argininosuccinate|as|,|component (l_appos) as_12\NN\14622893|(|)
9832994
T17_T27 CPR:3 mcpp_21\NN\1740|after|i.v. (r_nmod) increase_12\NN\13576355|a|dose-related|levels|mcpp (l_nmod) levels_18\NNS\4916342|prolactin (l_compound) prolactin_15\NN\5410315|in|plasma|and|acth
T17_T28 CPR:3 mcpp_21\NN\1740|after|i.v. (r_nmod) increase_12\NN\13576355|a|dose-related|levels|mcpp (l_nmod) levels_18\NNS\4916342|prolactin (l_compound) prolactin_15\NN\5410315|in|plasma|and|acth (l_conj) acth_17\NN\5407119|
T18_T27 NONE mcpp-treated_32\JJ\1740| (r_amod) animals_33\NNS\4475|in|these|mcpp-treated (r_nmod) state_27\NN\8491826|to|a|general|arousal|animals (r_nmod) pointing_23\VBG\831651|state (r_advcl) revealed_9\VBD\2137132|experiments|increase|,|pointing|. (l_dobj) increase_12\NN\13576355|a|dose-related|levels|mcpp (l_nmod) levels_18\NNS\4916342|prolactin (l_compound) prolactin_15\NN\5410315|in|plasma|and|acth
T18_T28 NONE mcpp-treated_32\JJ\1740| (r_amod) animals_33\NNS\4475|in|these|mcpp-treated (r_nmod) state_27\NN\8491826|to|a|general|arousal|animals (r_nmod) pointing_23\VBG\831651|state (r_advcl) revealed_9\VBD\2137132|experiments|increase|,|pointing|. (l_dobj) increase_12\NN\13576355|a|dose-related|levels|mcpp (l_nmod) levels_18\NNS\4916342|prolactin (l_compound) prolactin_15\NN\5410315|in|plasma|and|acth (l_conj) acth_17\NN\5407119|
T10_T23 NONE catecholamine_18\NN\5407119| (r_conj) 5-ht_16\NN\1740|mixed|and|catecholamine (r_compound) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T10_T24 NONE catecholamine_18\NN\5407119| (r_conj) 5-ht_16\NN\1740|mixed|and|catecholamine (r_compound) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T10_T25 NONE catecholamine_18\NN\5407119| (r_conj) 5-ht_16\NN\1740|mixed|and|catecholamine (r_compound) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T10_T26 NONE catecholamine_18\NN\5407119| (r_conj) 5-ht_16\NN\1740|mixed|and|catecholamine (r_compound) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T11_T23 NONE mianserin_22\NN\1740|such|and|mirtazapine (r_nmod) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T11_T24 NONE mianserin_22\NN\1740|such|and|mirtazapine (r_nmod) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T11_T25 NONE mianserin_22\NN\1740|such|and|mirtazapine (r_nmod) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T11_T26 NONE mianserin_22\NN\1740|such|and|mirtazapine (r_nmod) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T12_T23 NONE mirtazapine_24\NN\1740| (r_conj) mianserin_22\NN\1740|such|and|mirtazapine (r_nmod) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T12_T24 NONE mirtazapine_24\NN\1740| (r_conj) mianserin_22\NN\1740|such|and|mirtazapine (r_nmod) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T12_T25 NONE mirtazapine_24\NN\1740| (r_conj) mianserin_22\NN\1740|such|and|mirtazapine (r_nmod) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T12_T26 NONE mirtazapine_24\NN\1740| (r_conj) mianserin_22\NN\1740|such|and|mirtazapine (r_nmod) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T13_T23 NONE mcpp-induced_30\JJ\1740| (r_amod) inhibition_32\NN\1068773|of|mcpp-induced|behavioural|rats (r_nmod) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nsubj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T13_T24 NONE mcpp-induced_30\JJ\1740| (r_amod) inhibition_32\NN\1068773|of|mcpp-induced|behavioural|rats (r_nmod) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nsubj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T13_T25 NONE mcpp-induced_30\JJ\1740| (r_amod) inhibition_32\NN\1068773|of|mcpp-induced|behavioural|rats (r_nmod) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T13_T26 NONE mcpp-induced_30\JJ\1740| (r_amod) inhibition_32\NN\1068773|of|mcpp-induced|behavioural|rats (r_nmod) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T14_T23 NONE ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (r_nmod) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nsubj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T14_T24 NONE ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (r_nmod) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nsubj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T14_T25 CPR:6 ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T14_T26 CPR:6 ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T6_T23 CPR:6 pizotifen_10\NN\1740|such|and|methysergide (r_nmod) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T6_T24 CPR:6 pizotifen_10\NN\1740|such|and|methysergide (r_nmod) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T6_T25 NONE pizotifen_10\NN\1740|such|and|methysergide (r_nmod) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T6_T26 NONE pizotifen_10\NN\1740|such|and|methysergide (r_nmod) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T7_T23 CPR:6 methysergide_12\NN\1740| (r_conj) pizotifen_10\NN\1740|such|and|methysergide (r_nmod) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T7_T24 CPR:6 methysergide_12\NN\1740| (r_conj) pizotifen_10\NN\1740|such|and|methysergide (r_nmod) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T7_T25 NONE methysergide_12\NN\1740| (r_conj) pizotifen_10\NN\1740|such|and|methysergide (r_nmod) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T7_T26 NONE methysergide_12\NN\1740| (r_conj) pizotifen_10\NN\1740|such|and|methysergide (r_nmod) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T8_T23 NONE 5-ht_16\NN\1740|mixed|and|catecholamine (r_compound) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T8_T24 NONE 5-ht_16\NN\1740|mixed|and|catecholamine (r_compound) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (l_compound) 5-ht1/5-ht2_5\NN\1740|
T8_T25 NONE 5-ht_16\NN\1740|mixed|and|catecholamine (r_compound) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
T8_T26 NONE 5-ht_16\NN\1740|mixed|and|catecholamine (r_compound) antagonists_19\NNS\7846|5-ht|mianserin (r_conj) antagonists_7\NNS\7846|mixed|5-ht1/5-ht2|receptor|pizotifen|,|and|antagonists (r_nsubj) antagonists_28\NNS\7846|that|antagonists|are|potent|inhibition|ritanserin (l_nmod) ritanserin_41\NN\1740|than|the|selective|5-ht2a/5-ht2c|antagonist (l_compound) 5-ht2a/5-ht2c_39\NN\1740|
2506486
T33_T44 NONE monoamine_2\NN\14739004| (r_compound) oxidase_3\NN\14732946|monoamine
T34_T44 NONE catechols_8\NNS\1740|of|and|acid (r_nmod) levels_6\NNS\4916342|on|catechols|striatum (r_nmod) effects_0\NNS\13245626|inhibitors|levels|. (l_nmod) inhibitors_4\NNS\20090|of|oxidase (l_compound) oxidase_3\NN\14732946|monoamine
T35_T44 NONE acid_11\NN\14818238|homovanillic (r_conj) catechols_8\NNS\1740|of|and|acid (r_nmod) levels_6\NNS\4916342|on|catechols|striatum (r_nmod) effects_0\NNS\13245626|inhibitors|levels|. (l_nmod) inhibitors_4\NNS\20090|of|oxidase (l_compound) oxidase_3\NN\14732946|monoamine
T10_T37 NONE (-)deprenyl_45\NN\1740|by|mg/kg (r_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T10_T38 NONE (-)deprenyl_45\NN\1740|by|mg/kg (r_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T10_T39 CPR:4 (-)deprenyl_45\NN\1740|by|mg/kg (r_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T10_T40 NONE (-)deprenyl_45\NN\1740|by|mg/kg (r_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T10_T41 NONE (-)deprenyl_45\NN\1740|by|mg/kg (r_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T10_T42 NONE (-)deprenyl_45\NN\1740|by|mg/kg (r_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T11_T37 NONE nialamide_57\NN\1740|by|mg/kg (r_nmod) mao-a_53\NN\1740|both|and|mao-b|nialamide (r_appos) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T11_T38 NONE nialamide_57\NN\1740|by|mg/kg (r_nmod) mao-a_53\NN\1740|both|and|mao-b|nialamide (r_appos) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T11_T39 NONE nialamide_57\NN\1740|by|mg/kg (r_nmod) mao-a_53\NN\1740|both|and|mao-b|nialamide (r_appos) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T11_T40 CPR:4 nialamide_57\NN\1740|by|mg/kg (r_nmod) mao-a_53\NN\1740|both|and|mao-b|nialamide
T11_T41 CPR:4 nialamide_57\NN\1740|by|mg/kg (r_nmod) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T11_T42 NONE nialamide_57\NN\1740|by|mg/kg (r_nmod) mao-a_53\NN\1740|both|and|mao-b|nialamide (r_appos) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T12_T37 NONE hva_5\NN\1740|(|) (r_appos) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T12_T38 NONE hva_5\NN\1740|(|) (r_appos) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T12_T39 NONE hva_5\NN\1740|(|) (r_appos) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T12_T40 NONE hva_5\NN\1740|(|) (r_appos) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T12_T41 NONE hva_5\NN\1740|(|) (r_appos) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T12_T42 NONE hva_5\NN\1740|(|) (r_appos) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T13_T37 NONE debrisoquin_68\NN\1740|by|mg/kg (r_nmod) mao_66\NN\14732946|peripheral|neuronal|debrisoquin (r_conj) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T13_T38 NONE debrisoquin_68\NN\1740|by|mg/kg (r_nmod) mao_66\NN\14732946|peripheral|neuronal|debrisoquin (r_conj) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T13_T39 NONE debrisoquin_68\NN\1740|by|mg/kg (r_nmod) mao_66\NN\14732946|peripheral|neuronal|debrisoquin (r_conj) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T13_T40 NONE debrisoquin_68\NN\1740|by|mg/kg (r_nmod) mao_66\NN\14732946|peripheral|neuronal|debrisoquin (r_conj) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T13_T41 NONE debrisoquin_68\NN\1740|by|mg/kg (r_nmod) mao_66\NN\14732946|peripheral|neuronal|debrisoquin (r_conj) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T13_T42 CPR:4 debrisoquin_68\NN\1740|by|mg/kg (r_nmod) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T14_T37 NONE acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T14_T38 NONE acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T14_T39 NONE acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T14_T40 NONE acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T14_T41 NONE acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T14_T42 NONE acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T21_T37 NONE dopac_11\NN\1740|(|) (r_appos) acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T21_T38 NONE dopac_11\NN\1740|(|) (r_appos) acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T21_T39 NONE dopac_11\NN\1740|(|) (r_appos) acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T21_T40 NONE dopac_11\NN\1740|(|) (r_appos) acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T21_T41 NONE dopac_11\NN\1740|(|) (r_appos) acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T21_T42 NONE dopac_11\NN\1740|(|) (r_appos) acid_9\NN\14818238|dihydroxyphenylacetic|dopac (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T27_T37 NONE dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T27_T38 NONE dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T27_T39 NONE dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T27_T40 NONE dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T27_T41 NONE dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T27_T42 NONE dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T2_T37 NONE acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T2_T38 NONE acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T2_T39 NONE acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T2_T40 NONE acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T2_T41 NONE acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T2_T42 NONE acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T32_T37 NONE dhpg_16\NN\1740|(|) (r_appos) dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T32_T38 NONE dhpg_16\NN\1740|(|) (r_appos) dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T32_T39 NONE dhpg_16\NN\1740|(|) (r_appos) dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T32_T40 NONE dhpg_16\NN\1740|(|) (r_appos) dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T32_T41 NONE dhpg_16\NN\1740|(|) (r_appos) dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T32_T42 NONE dhpg_16\NN\1740|(|) (r_appos) dihydroxyphenylglycol_14\NN\1740|dhpg (r_conj) acid_3\NN\14818238|of|homovanillic|hva|,|acid|and|dihydroxyphenylglycol|plasma (r_nmod) levels_0\NNS\4916342|acid (r_nsubjpass) measured_24\VBN\697589|levels|were|inhibition|. (l_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T8_T37 NONE monoamine_28\NN\14739004| (r_compound) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T8_T38 NONE monoamine_28\NN\14739004| (r_compound) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T8_T39 NONE monoamine_28\NN\14739004| (r_compound) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T8_T40 NONE monoamine_28\NN\14739004| (r_compound) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T8_T41 NONE monoamine_28\NN\14739004| (r_compound) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T8_T42 NONE monoamine_28\NN\14739004| (r_compound) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T9_T37 CPR:4 clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a
T9_T38 CPR:4 clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (r_nmod) inhibition_26\NN\1068773|after|a|clorgyline (l_nmod) a_31\NN\13649268|of|monoamine|oxidase|type|mao-a (l_appos) mao-a_33\NN\1740|(|)
T9_T39 NONE clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-b_43\NN\1740|
T9_T40 NONE clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide
T9_T41 NONE clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_appos) mao-a_53\NN\1740|both|and|mao-b|nialamide (l_conj) mao-b_55\NN\1740|
T9_T42 NONE clorgyline_36\NN\1740|by|mg/kg|,|mao-b|(-)deprenyl|,|mao-a|or|mao (l_conj) mao_66\NN\14732946|peripheral|neuronal|debrisoquin
T1_T36 CPR:9 da_15\NN\10484858|of (r_nmod) deamination_13\NN\13446390|from|da|mao-a (l_nmod) mao-a_17\NN\1740|by|neurons
T31_T36 CPR:9 hva_7\NN\1740|of|the|plasma (r_nmod) most_4\JJS\1740|hva (r_nsubjpass) derived_11\VBN\634472|that|most|is|deamination|;|derived (l_nmod) deamination_13\NN\13446390|from|da|mao-a (l_nmod) mao-a_17\NN\1740|by|neurons
T3_T36 NONE dopac_23\NN\1740|plasma (r_nsubjpass) derived_27\VBN\634472|that|dopac|is|cells|;|derived (r_conj) derived_11\VBN\634472|that|most|is|deamination|;|derived (l_nmod) deamination_13\NN\13446390|from|da|mao-a (l_nmod) mao-a_17\NN\1740|by|neurons
T4_T36 NONE dhpg_37\NN\1740|plasma (r_nsubjpass) derived_41\VBN\634472|that|dhpg|is|metabolism|and|provide (r_conj) derived_27\VBN\634472|that|dopac|is|cells|;|derived (r_conj) derived_11\VBN\634472|that|most|is|deamination|;|derived (l_nmod) deamination_13\NN\13446390|from|da|mao-a (l_nmod) mao-a_17\NN\1740|by|neurons
T5_T36 NONE norepinephrine_48\NN\14807929|of|endings (r_nmod) metabolism_46\NN\13526110|exclusively|from|the|norepinephrine (r_nmod) derived_41\VBN\634472|that|dhpg|is|metabolism|and|provide (r_conj) derived_27\VBN\634472|that|dopac|is|cells|;|derived (r_conj) derived_11\VBN\634472|that|most|is|deamination|;|derived (l_nmod) deamination_13\NN\13446390|from|da|mao-a (l_nmod) mao-a_17\NN\1740|by|neurons
T6_T36 NONE hva_58\NN\1740|of (r_nmod) levels_56\NNS\4916342|residual|hva|treatment (r_nsubj) provide_63\VBP\2199590|that|levels|indication (r_conj) derived_41\VBN\634472|that|dhpg|is|metabolism|and|provide (r_conj) derived_27\VBN\634472|that|dopac|is|cells|;|derived (r_conj) derived_11\VBN\634472|that|most|is|deamination|;|derived (l_nmod) deamination_13\NN\13446390|from|da|mao-a (l_nmod) mao-a_17\NN\1740|by|neurons
T7_T36 NONE debrisoquin_62\NN\1740|with (r_nmod) treatment_60\NN\654885|after|debrisoquin (r_nmod) levels_56\NNS\4916342|residual|hva|treatment (r_nsubj) provide_63\VBP\2199590|that|levels|indication (r_conj) derived_41\VBN\634472|that|dhpg|is|metabolism|and|provide (r_conj) derived_27\VBN\634472|that|dopac|is|cells|;|derived (r_conj) derived_11\VBN\634472|that|most|is|deamination|;|derived (l_nmod) deamination_13\NN\13446390|from|da|mao-a (l_nmod) mao-a_17\NN\1740|by|neurons
11393267
T10_T19 NONE organophosphate_5\NN\14919948| (r_compound) poisoning_6\NN\14034177|in|organophosphate (r_nmod) neuroparalysis_0\NN\1740|and|efficacy|poisoning|:|study (l_dep) study_9\NN\635850|a|butyrylcholinesterase|. (l_nmod) butyrylcholinesterase_11\NN\1740|of
T9_T19 NONE oxime_2\NN\14727670| (r_compound) efficacy_3\NN\5199286|oxime (r_conj) neuroparalysis_0\NN\1740|and|efficacy|poisoning|:|study (l_dep) study_9\NN\635850|a|butyrylcholinesterase|. (l_nmod) butyrylcholinesterase_11\NN\1740|of
T2_T14 NONE organophosphate-poisoned_20\JJ\1740| (r_amod) patients_21\NNS\9898892|of|25|organophosphate-poisoned (r_nmod) cohort_17\NN\8184861|in|a|patients (r_nmod) studied_14\VBN\630380|profile|was|cohort|examine|. (l_nsubjpass) profile_2\NN\6999802|the|temporal|butyrylcholinesterase (l_nmod) butyrylcholinesterase_4\NN\1740|of|buche|and|buche
T2_T16 NONE organophosphate-poisoned_20\JJ\1740| (r_amod) patients_21\NNS\9898892|of|25|organophosphate-poisoned (r_nmod) cohort_17\NN\8184861|in|a|patients (r_nmod) studied_14\VBN\630380|profile|was|cohort|examine|. (l_nsubjpass) profile_2\NN\6999802|the|temporal|butyrylcholinesterase (l_nmod) butyrylcholinesterase_4\NN\1740|of|buche|and|buche (l_appos) buche_6\NN\1740|(|)
T2_T18 NONE organophosphate-poisoned_20\JJ\1740| (r_amod) patients_21\NNS\9898892|of|25|organophosphate-poisoned (r_nmod) cohort_17\NN\8184861|in|a|patients (r_nmod) studied_14\VBN\630380|profile|was|cohort|examine|. (l_nsubjpass) profile_2\NN\6999802|the|temporal|butyrylcholinesterase (l_nmod) butyrylcholinesterase_4\NN\1740|of|buche|and|buche (l_conj) buche_12\NN\1740|in|pralidoxime-reactivated
T5_T14 NONE oxime_41\NN\14727670| (r_compound) treatment_42\NN\654885|of|oxime (r_nmod) efficacy_39\NN\5199286|of|treatment (r_nmod) lack_37\NN\14449126|for|efficacy (r_nmod) reasons_35\NNS\9178821|lack (r_dobj) understand_34\VB\588888|to|reasons (r_conj) examine_23\VB\789138|to|relationship|and|understand (r_dep) studied_14\VBN\630380|profile|was|cohort|examine|. (l_nsubjpass) profile_2\NN\6999802|the|temporal|butyrylcholinesterase (l_nmod) butyrylcholinesterase_4\NN\1740|of|buche|and|buche
T5_T16 NONE oxime_41\NN\14727670| (r_compound) treatment_42\NN\654885|of|oxime (r_nmod) efficacy_39\NN\5199286|of|treatment (r_nmod) lack_37\NN\14449126|for|efficacy (r_nmod) reasons_35\NNS\9178821|lack (r_dobj) understand_34\VB\588888|to|reasons (r_conj) examine_23\VB\789138|to|relationship|and|understand (r_dep) studied_14\VBN\630380|profile|was|cohort|examine|. (l_nsubjpass) profile_2\NN\6999802|the|temporal|butyrylcholinesterase (l_nmod) butyrylcholinesterase_4\NN\1740|of|buche|and|buche (l_appos) buche_6\NN\1740|(|)
T5_T18 NONE oxime_41\NN\14727670| (r_compound) treatment_42\NN\654885|of|oxime (r_nmod) efficacy_39\NN\5199286|of|treatment (r_nmod) lack_37\NN\14449126|for|efficacy (r_nmod) reasons_35\NNS\9178821|lack (r_dobj) understand_34\VB\588888|to|reasons (r_conj) examine_23\VB\789138|to|relationship|and|understand (r_dep) studied_14\VBN\630380|profile|was|cohort|examine|. (l_nsubjpass) profile_2\NN\6999802|the|temporal|butyrylcholinesterase (l_nmod) butyrylcholinesterase_4\NN\1740|of|buche|and|buche (l_conj) buche_12\NN\1740|in|pralidoxime-reactivated
T6_T14 NONE pralidoxime-reactivated_11\JJ\1740| (r_amod) buche_12\NN\1740|in|pralidoxime-reactivated (r_conj) butyrylcholinesterase_4\NN\1740|of|buche|and|buche
T6_T16 NONE pralidoxime-reactivated_11\JJ\1740| (r_amod) buche_12\NN\1740|in|pralidoxime-reactivated (r_conj) butyrylcholinesterase_4\NN\1740|of|buche|and|buche (l_appos) buche_6\NN\1740|(|)
T6_T18 CPR:3 pralidoxime-reactivated_11\JJ\1740| (r_amod) buche_12\NN\1740|in|pralidoxime-reactivated
T7_T17 CPR:3 oxime-reactivated_8\JJ\1740|and|-unreactivated (r_amod) activity_12\NN\30358|between|oxime-reactivated|enzyme (r_nmod) difference_6\NN\4723816|(|the|activity|) (r_appos) potentials_1\NNS\14481929|reactivation|buche|difference (l_nmod) buche_3\NN\1740|of
T8_T17 CPR:4 organophosphate_19\NN\14919948| (r_compound) ingestion_20\NN\13440063|after|organophosphate (r_nmod) time_17\NN\7308889|with|ingestion (r_nmod) declined_14\VBD\146138|potentials|significantly|time|. (l_nsubj) potentials_1\NNS\14481929|reactivation|buche|difference (l_nmod) buche_3\NN\1740|of
T1_T11 CPR:4 oxime_3\NN\14727670| (r_dobj) received_2\VBD\2210855|who|oxime|hospitalization (r_acl:relcl) patients_0\NNS\9898892|received (r_nsubj) had_7\VBD\2108377|patients|rate|. (l_dobj) rate_10\NN\13815152|a|higher|syndrome|and|levels|those (l_conj) levels_16\NNS\4916342|lower|buche|admission (l_nmod) buche_18\NN\1740|of
T3_T12 NONE oxime_41\NN\14727670| (r_compound) efficacy_42\NN\5199286|of|oxime (r_nmod) lack_39\NN\14449126|iii|the|efficacy|patients|maybe|severity (r_conj) reflects_8\VBZ\923793|that|i|buche|course|,|confirming|;|associated|and|lack (l_nsubj) buche_7\NN\1740|
T3_T13 NONE oxime_41\NN\14727670| (r_compound) efficacy_42\NN\5199286|of|oxime (r_nmod) lack_39\NN\14449126|iii|the|efficacy|patients|maybe|severity (r_conj) reflects_8\VBZ\923793|that|i|buche|course|,|confirming|;|associated|and|lack (l_conj) associated_26\VBN\628491|ii|syndrome|may|be|inhibition|; (l_nmod) inhibition_30\NN\1068773|with|a|persistent|buche (l_nmod) buche_32\NN\1740|of
T4_T12 NONE oxime_57\NN\14727670| (r_compound) treatment_58\NN\654885|of|oxime (r_nmod) timing_55\NN\5044673|the|treatment (r_conj) severity_50\NN\5036394|due|their|poisoning|and|timing (r_nmod) lack_39\NN\14449126|iii|the|efficacy|patients|maybe|severity (r_conj) reflects_8\VBZ\923793|that|i|buche|course|,|confirming|;|associated|and|lack (l_nsubj) buche_7\NN\1740|
T4_T13 NONE oxime_57\NN\14727670| (r_compound) treatment_58\NN\654885|of|oxime (r_nmod) timing_55\NN\5044673|the|treatment (r_conj) severity_50\NN\5036394|due|their|poisoning|and|timing (r_nmod) lack_39\NN\14449126|iii|the|efficacy|patients|maybe|severity (r_conj) reflects_8\VBZ\923793|that|i|buche|course|,|confirming|;|associated|and|lack (l_conj) associated_26\VBN\628491|ii|syndrome|may|be|inhibition|; (l_nmod) inhibition_30\NN\1068773|with|a|persistent|buche (l_nmod) buche_32\NN\1740|of
10942908
T7_T18 NONE pyridostigmine_10\NN\1740|of|and|exercise (r_nmod) effects_8\NNS\13245626|the|delayed|pyridostigmine|activity (l_nmod) activity_16\NN\30358|on|cholinesterase|,|peroxidation|and|histology|tissues (l_compound) cholinesterase_15\NN\14732946|
T12_T19 CPR:4 pyridostigmine_4\NN\1740|with|alone (r_nmod) treated_2\VBN\2376958|pyridostigmine (r_acl) group_1\NN\2137|the|treated (r_nsubj) showed_6\VBD\2137132|group|activity|%|,|decreased|. (l_dobj) activity_13\NN\30358|decreased|plasma|butyrylcholinesterase (l_compound) butyrylcholinesterase_9\NN\1740|bche
T12_T20 CPR:4 pyridostigmine_4\NN\1740|with|alone (r_nmod) treated_2\VBN\2376958|pyridostigmine (r_acl) group_1\NN\2137|the|treated (r_nsubj) showed_6\VBD\2137132|group|activity|%|,|decreased|. (l_dobj) activity_13\NN\30358|decreased|plasma|butyrylcholinesterase (l_compound) butyrylcholinesterase_9\NN\1740|bche (l_appos) bche_11\NN\1740|(|)
T12_T21 NONE pyridostigmine_4\NN\1740|with|alone (r_nmod) treated_2\VBN\2376958|pyridostigmine (r_acl) group_1\NN\2137|the|treated (r_nsubj) showed_6\VBD\2137132|group|activity|%|,|decreased|. (l_advcl) decreased_26\VBD\169651|whereas|pyridostigmine|significantly|activity|%|,|indicating (l_dobj) activity_29\NN\30358|the|bche (l_compound) bche_28\NN\1740|
T13_T19 NONE pyridostigmine_22\NN\1740|plus|exercise (r_nsubj) decreased_26\VBD\169651|whereas|pyridostigmine|significantly|activity|%|,|indicating (r_advcl) showed_6\VBD\2137132|group|activity|%|,|decreased|. (l_dobj) activity_13\NN\30358|decreased|plasma|butyrylcholinesterase (l_compound) butyrylcholinesterase_9\NN\1740|bche
T13_T20 NONE pyridostigmine_22\NN\1740|plus|exercise (r_nsubj) decreased_26\VBD\169651|whereas|pyridostigmine|significantly|activity|%|,|indicating (r_advcl) showed_6\VBD\2137132|group|activity|%|,|decreased|. (l_dobj) activity_13\NN\30358|decreased|plasma|butyrylcholinesterase (l_compound) butyrylcholinesterase_9\NN\1740|bche (l_appos) bche_11\NN\1740|(|)
T13_T21 CPR:4 pyridostigmine_22\NN\1740|plus|exercise (r_nsubj) decreased_26\VBD\169651|whereas|pyridostigmine|significantly|activity|%|,|indicating (l_dobj) activity_29\NN\30358|the|bche (l_compound) bche_28\NN\1740|
T1_T16 CPR:4 pyridostigmine_20\NN\1740|with|plus|exercise (r_nmod) treated_18\VBN\2376958|pyridostigmine (r_acl) group_17\NN\2137|in|the|treated (r_nmod) decreased_7\VBD\169651|however|,|activity|significantly|%|group|. (l_nsubj) activity_3\NN\30358|ache|muscle (l_compound) ache_2\NN\14322699|
T2_T17 NONE creatine_0\NN\14601829| (r_compound) phosphokinase_1\NN\1740|creatine
T3_T17 CPR:3 pyridostigmine_12\NN\1740|or (r_conj) control_10\NN\5190804|to|,|pyridostigmine|group|) (r_nmod) compared_8\VBN\644583|control (r_advcl) increased_5\VBD\169651|activity|slightly|(|compared|mice|,|indicative|. (l_nsubj) activity_2\NN\30358|phosphokinase|plasma (l_compound) phosphokinase_1\NN\1740|creatine
T4_T17 CPR:3 pyridostigmine_21\NN\1740|with|plus|exercise (r_nmod) treated_19\VBN\2376958|pyridostigmine (r_acl) mice_18\NNS\2329401|in|treated (r_nmod) increased_5\VBD\169651|activity|slightly|(|compared|mice|,|indicative|. (l_nsubj) activity_2\NN\30358|phosphokinase|plasma (l_compound) phosphokinase_1\NN\1740|creatine
12827214
T25_T42 NONE prazosin-binding_7\NN\1740| (r_amod) sites_8\NNS\8673395|unique|prazosin-binding|insensitive (l_acl:relcl) insensitive_11\JJ\1740|that|were|phentolamine|and|unlikely (l_conj) unlikely_17\JJ\1740|were|thus|alpha(1)-adrenoceptors (l_xcomp) alpha(1)-adrenoceptors_20\NNS\1740|to|be
T32_T42 NONE phentolamine_13\NN\4537602|to (r_nmod) insensitive_11\JJ\1740|that|were|phentolamine|and|unlikely (l_conj) unlikely_17\JJ\1740|were|thus|alpha(1)-adrenoceptors (l_xcomp) alpha(1)-adrenoceptors_20\NNS\1740|to|be
T28_T45 NONE [(3)h]prazosin_0\NN\1740| (r_nsubj) bound_1\VBD\1831531|[(3)h]prazosin|sites|monophasically|affinity|pk(d|,|and|that|. (l_conj) that_39\DT\1740|ten|alpha(1)-adrenoceptor (l_nmod) alpha(1)-adrenoceptor_43\NN\1740|of|the|phentolamine-sensitive|pk(d)=9.9+/-0.13|protein|)
T29_T45 NONE phentolamine-insensitive_4\JJ\1740| (r_amod) sites_5\NNS\8673395|to|the|phentolamine-insensitive (r_nmod) bound_1\VBD\1831531|[(3)h]prazosin|sites|monophasically|affinity|pk(d|,|and|that|. (l_conj) that_39\DT\1740|ten|alpha(1)-adrenoceptor (l_nmod) alpha(1)-adrenoceptor_43\NN\1740|of|the|phentolamine-sensitive|pk(d)=9.9+/-0.13|protein|)
T30_T45 NONE phentolamine-sensitive_42\JJ\1740| (r_amod) alpha(1)-adrenoceptor_43\NN\1740|of|the|phentolamine-sensitive|pk(d)=9.9+/-0.13|protein|)
T1_T40 NONE noradrenaline_29\NN\14807929|,|rauwolscine|and|propranolol (r_nsubj) effect_36\NN\34213|noradrenaline|were|without|binding (r_conj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nmod) range_19\NN\5123416|at|a|concentrations (l_nmod) concentrations_21\NNS\4916342|of|exhibit (l_acl:relcl) exhibit_24\VBP\2632167|that|generally|antagonism (l_dobj) antagonism_26\NN\24720|alpha(1)-adrenoceptor (l_compound) alpha(1)-adrenoceptor_25\NN\1740|
T1_T46 NONE noradrenaline_29\NN\14807929|,|rauwolscine|and|propranolol (r_nsubj) effect_36\NN\34213|noradrenaline|were|without|binding (r_conj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nsubj) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (l_compound) alpha(1)-adrenoceptor_3\NN\1740|
T2_T40 NONE rauwolscine_31\NN\1740| (r_conj) noradrenaline_29\NN\14807929|,|rauwolscine|and|propranolol (r_nsubj) effect_36\NN\34213|noradrenaline|were|without|binding (r_conj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nmod) range_19\NN\5123416|at|a|concentrations (l_nmod) concentrations_21\NNS\4916342|of|exhibit (l_acl:relcl) exhibit_24\VBP\2632167|that|generally|antagonism (l_dobj) antagonism_26\NN\24720|alpha(1)-adrenoceptor (l_compound) alpha(1)-adrenoceptor_25\NN\1740|
T2_T46 NONE rauwolscine_31\NN\1740| (r_conj) noradrenaline_29\NN\14807929|,|rauwolscine|and|propranolol (r_nsubj) effect_36\NN\34213|noradrenaline|were|without|binding (r_conj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nsubj) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (l_compound) alpha(1)-adrenoceptor_3\NN\1740|
T36_T40 NONE tamsulosin_6\NN\1740|(|,|wb4101|and|corynanthine|) (r_dep) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (r_nsubj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nmod) range_19\NN\5123416|at|a|concentrations (l_nmod) concentrations_21\NNS\4916342|of|exhibit (l_acl:relcl) exhibit_24\VBP\2632167|that|generally|antagonism (l_dobj) antagonism_26\NN\24720|alpha(1)-adrenoceptor (l_compound) alpha(1)-adrenoceptor_25\NN\1740|
T36_T46 CPR:6 tamsulosin_6\NN\1740|(|,|wb4101|and|corynanthine|) (r_dep) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (l_compound) alpha(1)-adrenoceptor_3\NN\1740|
T37_T40 NONE wb4101_8\NN\1740| (r_conj) tamsulosin_6\NN\1740|(|,|wb4101|and|corynanthine|) (r_dep) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (r_nsubj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nmod) range_19\NN\5123416|at|a|concentrations (l_nmod) concentrations_21\NNS\4916342|of|exhibit (l_acl:relcl) exhibit_24\VBP\2632167|that|generally|antagonism (l_dobj) antagonism_26\NN\24720|alpha(1)-adrenoceptor (l_compound) alpha(1)-adrenoceptor_25\NN\1740|
T37_T46 CPR:6 wb4101_8\NN\1740| (r_conj) tamsulosin_6\NN\1740|(|,|wb4101|and|corynanthine|) (r_dep) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (l_compound) alpha(1)-adrenoceptor_3\NN\1740|
T38_T40 NONE corynanthine_10\NN\1740| (r_conj) tamsulosin_6\NN\1740|(|,|wb4101|and|corynanthine|) (r_dep) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (r_nsubj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nmod) range_19\NN\5123416|at|a|concentrations (l_nmod) concentrations_21\NNS\4916342|of|exhibit (l_acl:relcl) exhibit_24\VBP\2632167|that|generally|antagonism (l_dobj) antagonism_26\NN\24720|alpha(1)-adrenoceptor (l_compound) alpha(1)-adrenoceptor_25\NN\1740|
T38_T46 CPR:6 corynanthine_10\NN\1740| (r_conj) tamsulosin_6\NN\1740|(|,|wb4101|and|corynanthine|) (r_dep) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (l_compound) alpha(1)-adrenoceptor_3\NN\1740|
T3_T40 NONE propranolol_33\NN\1740| (r_conj) noradrenaline_29\NN\14807929|,|rauwolscine|and|propranolol (r_nsubj) effect_36\NN\34213|noradrenaline|were|without|binding (r_conj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nmod) range_19\NN\5123416|at|a|concentrations (l_nmod) concentrations_21\NNS\4916342|of|exhibit (l_acl:relcl) exhibit_24\VBP\2632167|that|generally|antagonism (l_dobj) antagonism_26\NN\24720|alpha(1)-adrenoceptor (l_compound) alpha(1)-adrenoceptor_25\NN\1740|
T3_T46 NONE propranolol_33\NN\1740| (r_conj) noradrenaline_29\NN\14807929|,|rauwolscine|and|propranolol (r_nsubj) effect_36\NN\34213|noradrenaline|were|without|binding (r_conj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nsubj) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (l_compound) alpha(1)-adrenoceptor_3\NN\1740|
T4_T40 NONE [(3)h]prazosin_39\NN\1740| (r_compound) binding_40\NN\4688246|on|the|[(3)h]prazosin (r_nmod) effect_36\NN\34213|noradrenaline|were|without|binding (r_conj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nmod) range_19\NN\5123416|at|a|concentrations (l_nmod) concentrations_21\NNS\4916342|of|exhibit (l_acl:relcl) exhibit_24\VBP\2632167|that|generally|antagonism (l_dobj) antagonism_26\NN\24720|alpha(1)-adrenoceptor (l_compound) alpha(1)-adrenoceptor_25\NN\1740|
T4_T46 NONE [(3)h]prazosin_39\NN\1740| (r_compound) binding_40\NN\4688246|on|the|[(3)h]prazosin (r_nmod) effect_36\NN\34213|noradrenaline|were|without|binding (r_conj) inhibit_14\VB\2510337|however|,|antagonists|did|not|binding|range|,|and|effect|. (l_nsubj) antagonists_4\NNS\7846|other|alpha(1)-adrenoceptor|tamsulosin (l_compound) alpha(1)-adrenoceptor_3\NN\1740|
T10_T41 NONE guanfacine_23\NN\1740| (r_conj) guanabenz_21\NN\2721160|(|,|guanfacine|and|agmatine|) (r_dep) sites_19\NNS\8673395|for|imidazoline|recognition|guanabenz (r_conj) na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T11_T41 NONE agmatine_25\NN\1740| (r_conj) guanabenz_21\NN\2721160|(|,|guanfacine|and|agmatine|) (r_dep) sites_19\NNS\8673395|for|imidazoline|recognition|guanabenz (r_conj) na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T12_T41 NONE [(3)h]prazosin_31\NN\1740|of (r_nmod) binding_29\NN\4688246|the|[(3)h]prazosin|sites (r_dobj) displaced_27\VBD\1850315|hand|,|ligands|binding|concentrations|. (l_nsubj) ligands_5\NNS\20090|na(+)-transporter (l_nmod) na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T13_T41 NONE phentolamine-insensitive_33\JJ\1740| (r_amod) sites_34\NNS\8673395|to|phentolamine-insensitive (r_nmod) binding_29\NN\4688246|the|[(3)h]prazosin|sites (r_dobj) displaced_27\VBD\1850315|hand|,|ligands|binding|concentrations|. (l_nsubj) ligands_5\NNS\20090|na(+)-transporter (l_nmod) na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T5_T41 NONE na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T6_T41 NONE amiloride_11\NN\1740|(|and|triamterene|) (r_dep) na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T7_T41 NONE triamterene_13\NN\1740| (r_conj) amiloride_11\NN\1740|(|and|triamterene|) (r_dep) na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T8_T41 NONE imidazoline_17\NN\1740| (r_compound) sites_19\NNS\8673395|for|imidazoline|recognition|guanabenz (r_conj) na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T9_T41 NONE guanabenz_21\NN\2721160|(|,|guanfacine|and|agmatine|) (r_dep) sites_19\NNS\8673395|for|imidazoline|recognition|guanabenz (r_conj) na(+)-transporter_9\NN\1740|for|the|renal|amiloride|and|sites
T14_T43 NONE [(125)i]iodoarylazidoprazosin_3\NN\1740|with (r_nmod) labeling_1\NN\1740|photoaffinity|[(125)i]iodoarylazidoprazosin (r_nsubj) showed_4\VBD\2137132|labeling|labeling|kda|. (l_nmod) kda_10\NN\1740|at|100|,|size (l_appos) size_14\NN\5090441|a|molecular|larger (l_amod) larger_15\JJR\1740|that (l_nmod) that_17\DT\1740|than|alpha(1a)- (l_nmod) alpha(1a)-_20\NN\1740|of|human|and|alpha(1b)-adrenoceptors|expressed (l_conj) alpha(1b)-adrenoceptors_22\NNS\1740|
T15_T43 NONE phentolamine-insensitive_5\JJ\1740| (r_amod) labeling_6\NN\1740|phentolamine-insensitive (r_dobj) showed_4\VBD\2137132|labeling|labeling|kda|. (l_nmod) kda_10\NN\1740|at|100|,|size (l_appos) size_14\NN\5090441|a|molecular|larger (l_amod) larger_15\JJR\1740|that (l_nmod) that_17\DT\1740|than|alpha(1a)- (l_nmod) alpha(1a)-_20\NN\1740|of|human|and|alpha(1b)-adrenoceptors|expressed (l_conj) alpha(1b)-adrenoceptors_22\NNS\1740|
T17_T44 NONE phentolamine-insensitive_7\JJ\1740| (r_amod) site_9\NN\8673395|no|detectable|phentolamine-insensitive|binding (r_nsubj) was_4\VBD\836236|contrast|,|there|site|but|alpha(1)-adrenoceptors|. (l_conj) alpha(1)-adrenoceptors_13\NNS\1740|were|phentolamine-sensitive|liver|pk(d)=10.0+/-0.06|b(max)=44+/-6|protein|,|n=3|)
T18_T44 NONE phentolamine-sensitive_12\JJ\1740| (r_amod) alpha(1)-adrenoceptors_13\NNS\1740|were|phentolamine-sensitive|liver|pk(d)=10.0+/-0.06|b(max)=44+/-6|protein|,|n=3|)
23201003
T20_T28 NONE d₃_4\NN\1740|of|1α,25-dihydroxyvitamin (r_nmod) effect_1\NN\34213|inhibitory|d₃|excretion|. (l_nmod) excretion_6\NN\13466586|on|jbp485|transporters (l_nmod) transporters_12\NNS\4490091|via|organic|anion|rats
T21_T28 NONE jbp485_8\NN\1740|of (r_nmod) excretion_6\NN\13466586|on|jbp485|transporters (l_nmod) transporters_12\NNS\4490091|via|organic|anion|rats
T13_T25 NONE )_35\-RRB-\1740| (r_punct) 1,25(oh)(2)d(3_34\NN\1740|to|) (r_compound) treatment_36\NN\654885|1,25(oh)(2)d(3 (r_nmod) response_32\NN\11410625|in|treatment (r_nmod) expression_20\NN\4679549|in|the|(oat)1|kidney|response (l_nmod) (oat)1_25\NN\1740|transporter|and|oat3 (l_compound) transporter_24\NN\4490091|of|organic|anion
T13_T26 NONE )_35\-RRB-\1740| (r_punct) 1,25(oh)(2)d(3_34\NN\1740|to|) (r_compound) treatment_36\NN\654885|1,25(oh)(2)d(3 (r_nmod) response_32\NN\11410625|in|treatment (r_nmod) expression_20\NN\4679549|in|the|(oat)1|kidney|response (l_nmod) (oat)1_25\NN\1740|transporter|and|oat3
T13_T27 NONE )_35\-RRB-\1740| (r_punct) 1,25(oh)(2)d(3_34\NN\1740|to|) (r_compound) treatment_36\NN\654885|1,25(oh)(2)d(3 (r_nmod) response_32\NN\11410625|in|treatment (r_nmod) expression_20\NN\4679549|in|the|(oat)1|kidney|response (l_nmod) (oat)1_25\NN\1740|transporter|and|oat3 (l_conj) oat3_27\NN\1740|
T2_T22 CPR:4 )_3\-RRB-\1740| (r_punct) 1,25(oh)(2)d(3_2\NN\1740|) (r_nsubj) decreased_4\VBD\169651|moreover|,|1,25(oh)(2)d(3|expression|. (l_dobj) expression_5\NN\4679549|oat1|kidney (l_nmod) oat1_7\NN\1740|of|and|oat3
T2_T23 CPR:4 )_3\-RRB-\1740| (r_punct) 1,25(oh)(2)d(3_2\NN\1740|) (r_nsubj) decreased_4\VBD\169651|moreover|,|1,25(oh)(2)d(3|expression|. (l_dobj) expression_5\NN\4679549|oat1|kidney (l_nmod) oat1_7\NN\1740|of|and|oat3 (l_conj) oat3_9\NN\1740|
T6_T24 NONE jbp485_5\NN\1740|between|and|1,25(oh)(2)d(3 (r_nmod) interaction_3\NN\37396|of|jbp485 (r_nmod) mechanism_1\NN\13446390|the|interaction (r_nsubjpass) explained_11\VBN\831651|mechanism|could|be|part|effect|. (l_nmod) effect_18\NN\34213|by|inhibitory|1,25(oh)(2)d(3|expression (l_nmod) expression_23\NN\4679549|on|oats|kidney (l_nmod) oats_25\NNS\12141495|of
T7_T24 NONE )_8\-RRB-\1740| (r_punct) 1,25(oh)(2)d(3_7\NN\1740|) (r_conj) jbp485_5\NN\1740|between|and|1,25(oh)(2)d(3 (r_nmod) interaction_3\NN\37396|of|jbp485 (r_nmod) mechanism_1\NN\13446390|the|interaction (r_nsubjpass) explained_11\VBN\831651|mechanism|could|be|part|effect|. (l_nmod) effect_18\NN\34213|by|inhibitory|1,25(oh)(2)d(3|expression (l_nmod) expression_23\NN\4679549|on|oats|kidney (l_nmod) oats_25\NNS\12141495|of
T8_T24 CPR:4 )_21\-RRB-\1740| (r_punct) 1,25(oh)(2)d(3_20\NN\1740|of|) (r_nmod) effect_18\NN\34213|by|inhibitory|1,25(oh)(2)d(3|expression (l_nmod) expression_23\NN\4679549|on|oats|kidney (l_nmod) oats_25\NNS\12141495|of
15299009
T6_T12 NONE retinaldehyde_8\NN\1740| (r_compound) type_10\NN\5839024|in|retinaldehyde|dehydrogenase|ii (l_nummod) ii_11\CD\13741022|
T1_T7 NONE retinaldehyde_0\NN\1740| (r_compound) dehydrogenase_1\NN\1740|retinaldehyde|ii|raldh2 (l_nummod) ii_2\CD\13741022|
T1_T9 NONE retinaldehyde_0\NN\1740| (r_compound) dehydrogenase_1\NN\1740|retinaldehyde|ii|raldh2 (l_appos) raldh2_4\NN\1740|(|)
T2_T10 NONE aldehyde_16\NN\14727670| (r_compound) dehydrogenases_17\NNS\1740|other|aldehyde|superfamily (r_conj) protein_13\NN\14944888|between|this|and|dehydrogenases (r_nmod) difference_10\NN\4723816|an|important|structural|protein (r_dobj) revealed_6\VBD\2137132|structure|difference|;|disordered|. (l_parataxis) disordered_38\VBN\1770501|span|is|,|forms (l_nsubjpass) span_27\NN\15133621|a|20-amino|acid|channel (l_nmod) channel_32\NN\6251781|in|the|substrate|access|dehydrogenase (l_nmod) dehydrogenase_35\NN\1740|in|retinaldehyde|ii (l_nummod) ii_36\CD\13741022|
T2_T11 NONE aldehyde_16\NN\14727670| (r_compound) dehydrogenases_17\NNS\1740|other|aldehyde|superfamily (r_conj) protein_13\NN\14944888|between|this|and|dehydrogenases (r_nmod) difference_10\NN\4723816|an|important|structural|protein (r_dobj) revealed_6\VBD\2137132|structure|difference|;|disordered|. (l_parataxis) disordered_38\VBN\1770501|span|is|,|forms (l_advcl) forms_47\VBZ\1617192|whereas|dehydrogenases|region|wall (l_nmod) dehydrogenases_44\NNS\1740|in|other|aldehyde
T2_T8 NONE aldehyde_16\NN\14727670| (r_compound) dehydrogenases_17\NNS\1740|other|aldehyde|superfamily
T3_T10 NONE acid_26\NN\14818238| (r_compound) span_27\NN\15133621|a|20-amino|acid|channel (l_nmod) channel_32\NN\6251781|in|the|substrate|access|dehydrogenase (l_nmod) dehydrogenase_35\NN\1740|in|retinaldehyde|ii (l_nummod) ii_36\CD\13741022|
T3_T11 NONE acid_26\NN\14818238| (r_compound) span_27\NN\15133621|a|20-amino|acid|channel (r_nsubjpass) disordered_38\VBN\1770501|span|is|,|forms (l_advcl) forms_47\VBZ\1617192|whereas|dehydrogenases|region|wall (l_nmod) dehydrogenases_44\NNS\1740|in|other|aldehyde
T3_T8 NONE acid_26\NN\14818238| (r_compound) span_27\NN\15133621|a|20-amino|acid|channel (r_nsubjpass) disordered_38\VBN\1770501|span|is|,|forms (r_parataxis) revealed_6\VBD\2137132|structure|difference|;|disordered|. (l_dobj) difference_10\NN\4723816|an|important|structural|protein (l_nmod) protein_13\NN\14944888|between|this|and|dehydrogenases (l_conj) dehydrogenases_17\NNS\1740|other|aldehyde|superfamily
T4_T10 NONE retinaldehyde_34\NN\1740| (r_compound) dehydrogenase_35\NN\1740|in|retinaldehyde|ii (l_nummod) ii_36\CD\13741022|
T4_T11 NONE retinaldehyde_34\NN\1740| (r_compound) dehydrogenase_35\NN\1740|in|retinaldehyde|ii (r_nmod) channel_32\NN\6251781|in|the|substrate|access|dehydrogenase (r_nmod) span_27\NN\15133621|a|20-amino|acid|channel (r_nsubjpass) disordered_38\VBN\1770501|span|is|,|forms (l_advcl) forms_47\VBZ\1617192|whereas|dehydrogenases|region|wall (l_nmod) dehydrogenases_44\NNS\1740|in|other|aldehyde
T4_T8 NONE retinaldehyde_34\NN\1740| (r_compound) dehydrogenase_35\NN\1740|in|retinaldehyde|ii (r_nmod) channel_32\NN\6251781|in|the|substrate|access|dehydrogenase (r_nmod) span_27\NN\15133621|a|20-amino|acid|channel (r_nsubjpass) disordered_38\VBN\1770501|span|is|,|forms (r_parataxis) revealed_6\VBD\2137132|structure|difference|;|disordered|. (l_dobj) difference_10\NN\4723816|an|important|structural|protein (l_nmod) protein_13\NN\14944888|between|this|and|dehydrogenases (l_conj) dehydrogenases_17\NNS\1740|other|aldehyde|superfamily
T5_T10 NONE aldehyde_43\NN\14727670| (r_compound) dehydrogenases_44\NNS\1740|in|other|aldehyde (r_nmod) forms_47\VBZ\1617192|whereas|dehydrogenases|region|wall (r_advcl) disordered_38\VBN\1770501|span|is|,|forms (l_nsubjpass) span_27\NN\15133621|a|20-amino|acid|channel (l_nmod) channel_32\NN\6251781|in|the|substrate|access|dehydrogenase (l_nmod) dehydrogenase_35\NN\1740|in|retinaldehyde|ii (l_nummod) ii_36\CD\13741022|
T5_T11 NONE aldehyde_43\NN\14727670| (r_compound) dehydrogenases_44\NNS\1740|in|other|aldehyde
T5_T8 NONE aldehyde_43\NN\14727670| (r_compound) dehydrogenases_44\NNS\1740|in|other|aldehyde (r_nmod) forms_47\VBZ\1617192|whereas|dehydrogenases|region|wall (r_advcl) disordered_38\VBN\1770501|span|is|,|forms (r_parataxis) revealed_6\VBD\2137132|structure|difference|;|disordered|. (l_dobj) difference_10\NN\4723816|an|important|structural|protein (l_nmod) protein_13\NN\14944888|between|this|and|dehydrogenases (l_conj) dehydrogenases_17\NNS\1740|other|aldehyde|superfamily
23639249
T14_T29 CPR:3 3-sulfate_1\NN\1740|indoxyl (r_nsubj) stimulates_2\VBZ\137313|3-sulfate|differentiation|enhancing|worsen|. (l_xcomp) enhancing_5\VBG\227165|phosphorylation (l_dobj) phosphorylation_6\NN\1740|c-src (l_nmod) c-src_8\NN\1740|of|and|stat3
T14_T30 CPR:3 3-sulfate_1\NN\1740|indoxyl (r_nsubj) stimulates_2\VBZ\137313|3-sulfate|differentiation|enhancing|worsen|. (l_xcomp) enhancing_5\VBG\227165|phosphorylation (l_dobj) phosphorylation_6\NN\1740|c-src (l_nmod) c-src_8\NN\1740|of|and|stat3 (l_conj) stat3_10\NN\1740|
T4_T18 CPR:3 3-sulfate_20\NN\1740|by|indoxyl|i3s|,|toxin|, (r_nmod) activation_17\NN\13561719|of|ahr|3-sulfate (l_compound) ahr_16\NN\1740|
T5_T18 CPR:3 i3s_22\NN\1740|(|) (r_appos) 3-sulfate_20\NN\1740|by|indoxyl|i3s|,|toxin|, (r_nmod) activation_17\NN\13561719|of|ahr|3-sulfate (l_compound) ahr_16\NN\1740|
T6_T19 CPR:3 i3s_0\NN\1740| (r_nsubj) increased_1\VBD\169651|i3s|expression|,|and|stimulated|,|manner|2,3,7,8-tetrachlorodibenzo-p-dioxin|. (l_dobj) expression_2\NN\4679549|rorγt (l_nmod) rorγt_4\NN\1740|of|,|factor
T6_T20 NONE i3s_0\NN\1740| (r_nsubj) increased_1\VBD\169651|i3s|expression|,|and|stimulated|,|manner|2,3,7,8-tetrachlorodibenzo-p-dioxin|. (l_nmod) 2,3,7,8-tetrachlorodibenzo-p-dioxin_24\NN\1740|as|tcdd|,|ligand (l_appos) ligand_32\NN\20090|a|prototypical|ahr (l_compound) ahr_31\NN\1740|
T7_T19 NONE 2,3,7,8-tetrachlorodibenzo-p-dioxin_24\NN\1740|as|tcdd|,|ligand (r_nmod) increased_1\VBD\169651|i3s|expression|,|and|stimulated|,|manner|2,3,7,8-tetrachlorodibenzo-p-dioxin|. (l_dobj) expression_2\NN\4679549|rorγt (l_nmod) rorγt_4\NN\1740|of|,|factor
T7_T20 NONE 2,3,7,8-tetrachlorodibenzo-p-dioxin_24\NN\1740|as|tcdd|,|ligand (l_appos) ligand_32\NN\20090|a|prototypical|ahr (l_compound) ahr_31\NN\1740|
T8_T19 NONE tcdd_26\NN\1740|(|) (r_appos) 2,3,7,8-tetrachlorodibenzo-p-dioxin_24\NN\1740|as|tcdd|,|ligand (r_nmod) increased_1\VBD\169651|i3s|expression|,|and|stimulated|,|manner|2,3,7,8-tetrachlorodibenzo-p-dioxin|. (l_dobj) expression_2\NN\4679549|rorγt (l_nmod) rorγt_4\NN\1740|of|,|factor
T8_T20 NONE tcdd_26\NN\1740|(|) (r_appos) 2,3,7,8-tetrachlorodibenzo-p-dioxin_24\NN\1740|as|tcdd|,|ligand (l_appos) ligand_32\NN\20090|a|prototypical|ahr (l_compound) ahr_31\NN\1740|
T10_T21 CPR:3 tcdd_26\NN\1740| (r_conj) i3s_24\NNS\1740|by|and|tcdd (r_nmod) stimulated_22\VBN\137313|activation|was|strongly|i3s|. (l_nsubjpass) activation_0\NN\13561719|stat3 (l_nmod) stat3_2\NN\1740|of|,|phosphorylated
T10_T22 CPR:3 tcdd_26\NN\1740| (r_conj) i3s_24\NNS\1740|by|and|tcdd (r_nmod) stimulated_22\VBN\137313|activation|was|strongly|i3s|. (l_nsubjpass) activation_0\NN\13561719|stat3 (l_nmod) stat3_2\NN\1740|of|,|phosphorylated (l_acl:relcl) phosphorylated_6\VBN\1740|which|is|pathways|and|necessary|, (l_nmod) pathways_11\NNS\5483677|by|the|il-6|signaling (l_compound) il-6_9\NN\1740|
T9_T21 CPR:3 i3s_24\NNS\1740|by|and|tcdd (r_nmod) stimulated_22\VBN\137313|activation|was|strongly|i3s|. (l_nsubjpass) activation_0\NN\13561719|stat3 (l_nmod) stat3_2\NN\1740|of|,|phosphorylated
T9_T22 CPR:3 i3s_24\NNS\1740|by|and|tcdd (r_nmod) stimulated_22\VBN\137313|activation|was|strongly|i3s|. (l_nsubjpass) activation_0\NN\13561719|stat3 (l_nmod) stat3_2\NN\1740|of|,|phosphorylated (l_acl:relcl) phosphorylated_6\VBN\1740|which|is|pathways|and|necessary|, (l_nmod) pathways_11\NNS\5483677|by|the|il-6|signaling (l_compound) il-6_9\NN\1740|
T11_T15 NONE i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_advcl) raising_42\VBG\153263|possibility (l_dobj) possibility_44\NN\5944958|a|exerted (l_ccomp) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_nmod) c-src_62\NN\1740|of
T11_T16 NONE i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_advcl) raising_42\VBG\153263|possibility (l_dobj) possibility_44\NN\5944958|a|exerted (l_ccomp) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_acl:relcl) stimulates_67\VBZ\137313|which|turn|activation (l_dobj) activation_69\NN\13561719|stat3 (l_compound) stat3_68\NN\1740|
T11_T23 CPR:3 i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_nmod) c-src_2\NN\1740|of
T11_T24 NONE i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_acl:relcl) shown_6\VBN\2137132|which|was|activated (l_xcomp) activated_9\VBN\1641914|to|be|ligands (l_nmod) ligands_12\NNS\20090|by|ahr (l_compound) ahr_11\NN\1740|
T11_T25 NONE i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_nsubj) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (l_nmod) activity_26\NN\30358|of|c-src (l_compound) c-src_25\NN\1740|
T11_T27 NONE i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3
T11_T28 NONE i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3 (l_conj) stat3_40\NN\1740|
T12_T15 NONE tcdd_20\NN\1740| (r_conj) i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_advcl) raising_42\VBG\153263|possibility (l_dobj) possibility_44\NN\5944958|a|exerted (l_ccomp) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_nmod) c-src_62\NN\1740|of
T12_T16 NONE tcdd_20\NN\1740| (r_conj) i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_advcl) raising_42\VBG\153263|possibility (l_dobj) possibility_44\NN\5944958|a|exerted (l_ccomp) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_acl:relcl) stimulates_67\VBZ\137313|which|turn|activation (l_dobj) activation_69\NN\13561719|stat3 (l_compound) stat3_68\NN\1740|
T12_T23 CPR:3 tcdd_20\NN\1740| (r_conj) i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_nmod) c-src_2\NN\1740|of
T12_T24 NONE tcdd_20\NN\1740| (r_conj) i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_acl:relcl) shown_6\VBN\2137132|which|was|activated (l_xcomp) activated_9\VBN\1641914|to|be|ligands (l_nmod) ligands_12\NNS\20090|by|ahr (l_compound) ahr_11\NN\1740|
T12_T25 NONE tcdd_20\NN\1740| (r_conj) i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_nsubj) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (l_nmod) activity_26\NN\30358|of|c-src (l_compound) c-src_25\NN\1740|
T12_T27 NONE tcdd_20\NN\1740| (r_conj) i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3
T12_T28 NONE tcdd_20\NN\1740| (r_conj) i3s_18\NN\1740|by|and|tcdd (r_nmod) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_conj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3 (l_conj) stat3_40\NN\1740|
T13_T15 NONE pyrazolo[3,4-d]pyrimidine_30\NN\1740|by|4-amino-5-(4-chlorophenyl)-7-(t-butyl|)|pp2 (r_nmod) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (r_nsubj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_advcl) raising_42\VBG\153263|possibility (l_dobj) possibility_44\NN\5944958|a|exerted (l_ccomp) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_nmod) c-src_62\NN\1740|of
T13_T16 NONE pyrazolo[3,4-d]pyrimidine_30\NN\1740|by|4-amino-5-(4-chlorophenyl)-7-(t-butyl|)|pp2 (r_nmod) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (r_nsubj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_advcl) raising_42\VBG\153263|possibility (l_dobj) possibility_44\NN\5944958|a|exerted (l_ccomp) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_acl:relcl) stimulates_67\VBZ\137313|which|turn|activation (l_dobj) activation_69\NN\13561719|stat3 (l_compound) stat3_68\NN\1740|
T13_T23 NONE pyrazolo[3,4-d]pyrimidine_30\NN\1740|by|4-amino-5-(4-chlorophenyl)-7-(t-butyl|)|pp2 (r_nmod) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (r_nsubj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (r_conj) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_nmod) c-src_2\NN\1740|of
T13_T24 NONE pyrazolo[3,4-d]pyrimidine_30\NN\1740|by|4-amino-5-(4-chlorophenyl)-7-(t-butyl|)|pp2 (r_nmod) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (r_nsubj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (r_conj) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_acl:relcl) shown_6\VBN\2137132|which|was|activated (l_xcomp) activated_9\VBN\1641914|to|be|ligands (l_nmod) ligands_12\NNS\20090|by|ahr (l_compound) ahr_11\NN\1740|
T13_T25 CPR:4 pyrazolo[3,4-d]pyrimidine_30\NN\1740|by|4-amino-5-(4-chlorophenyl)-7-(t-butyl|)|pp2 (r_nmod) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (l_nmod) activity_26\NN\30358|of|c-src (l_compound) c-src_25\NN\1740|
T13_T27 CPR:4 pyrazolo[3,4-d]pyrimidine_30\NN\1740|by|4-amino-5-(4-chlorophenyl)-7-(t-butyl|)|pp2 (r_nmod) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (r_nsubj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3
T13_T28 CPR:4 pyrazolo[3,4-d]pyrimidine_30\NN\1740|by|4-amino-5-(4-chlorophenyl)-7-(t-butyl|)|pp2 (r_nmod) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (r_nsubj) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3 (l_conj) stat3_40\NN\1740|
T1_T15 CPR:3 i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_nmod) c-src_62\NN\1740|of
T1_T16 CPR:3 i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_acl:relcl) stimulates_67\VBZ\137313|which|turn|activation (l_dobj) activation_69\NN\13561719|stat3 (l_compound) stat3_68\NN\1740|
T1_T23 NONE i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (r_conj) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_nmod) c-src_2\NN\1740|of
T1_T24 NONE i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (r_conj) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_acl:relcl) shown_6\VBN\2137132|which|was|activated (l_xcomp) activated_9\VBN\1641914|to|be|ligands (l_nmod) ligands_12\NNS\20090|by|ahr (l_compound) ahr_11\NN\1740|
T1_T25 NONE i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_nsubj) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (l_nmod) activity_26\NN\30358|of|c-src (l_compound) c-src_25\NN\1740|
T1_T27 NONE i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3
T1_T28 NONE i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3 (l_conj) stat3_40\NN\1740|
T2_T15 CPR:3 tcdd_51\NN\1740| (r_conj) i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_nmod) c-src_62\NN\1740|of
T2_T16 CPR:3 tcdd_51\NN\1740| (r_conj) i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (l_nmod) phosphorylation_60\NN\1740|via|increased|c-src|,|stimulates (l_acl:relcl) stimulates_67\VBZ\137313|which|turn|activation (l_dobj) activation_69\NN\13561719|stat3 (l_compound) stat3_68\NN\1740|
T2_T23 NONE tcdd_51\NN\1740| (r_conj) i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (r_conj) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_nmod) c-src_2\NN\1740|of
T2_T24 NONE tcdd_51\NN\1740| (r_conj) i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (r_conj) increased_16\VBN\169651|phosphorylation|was|also|i3s|,|and|inhibited|. (l_nsubjpass) phosphorylation_0\NN\1740|c-src|,|shown|, (l_acl:relcl) shown_6\VBN\2137132|which|was|activated (l_xcomp) activated_9\VBN\1641914|to|be|ligands (l_nmod) ligands_12\NNS\20090|by|ahr (l_compound) ahr_11\NN\1740|
T2_T25 NONE tcdd_51\NN\1740| (r_conj) i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_nsubj) blocking_23\NN\562280|activity|pyrazolo[3,4-d]pyrimidine (l_nmod) activity_26\NN\30358|of|c-src (l_compound) c-src_25\NN\1740|
T2_T27 NONE tcdd_51\NN\1740| (r_conj) i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3
T2_T28 NONE tcdd_51\NN\1740| (r_conj) i3s_49\NNS\1740|of|and|tcdd (r_nmod) activities_47\NNS\30358|stimulatory|i3s|differentiation (r_nsubjpass) exerted_57\VBN\1158872|that|activities|could|be|phosphorylation (r_ccomp) possibility_44\NN\5944958|a|exerted (r_dobj) raising_42\VBG\153263|possibility (r_advcl) inhibited_34\VBD\2510337|blocking|phosphorylation|,|raising (l_dobj) phosphorylation_35\NN\1740|c-src (l_nmod) c-src_38\NN\1740|of|both|and|stat3 (l_conj) stat3_40\NN\1740|
T3_T17 CPR:3 i3s_5\NNS\1740| (r_nsubj) worsened_6\VBD\146138|that|i3s|encephalomyelitis|,|enhancing (l_advcl) enhancing_22\VBG\227165|frequency (l_dobj) frequency_24\NN\15286249|the|cells|nodes (l_nmod) cells_27\NNS\3080309|of|il-17-producing (l_amod) il-17-producing_26\JJ\1740|
11742712
T11_T14 NONE folate-dependent_14\JJ\1740| (r_amod) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase
T11_T15 NONE folate-dependent_14\JJ\1740| (r_amod) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) reductase_21\NN\14732946|dihydrofolate
T11_T16 NONE folate-dependent_14\JJ\1740| (r_amod) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) formyltransferase_26\NN\1740|glycinamide|ribonucleotide
T1_T14 CPR:4 disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antimetabolite_8\NN\2722458|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_10\VBZ\2510337|that|enzymes (l_dobj) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase
T1_T15 CPR:4 disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antimetabolite_8\NN\2722458|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_10\VBZ\2510337|that|enzymes (l_dobj) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) reductase_21\NN\14732946|dihydrofolate
T1_T16 CPR:4 disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antimetabolite_8\NN\2722458|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_10\VBZ\2510337|that|enzymes (l_dobj) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) formyltransferase_26\NN\1740|glycinamide|ribonucleotide
T2_T14 NONE thymidylate_17\NN\1740| (r_compound) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase
T2_T15 NONE thymidylate_17\NN\1740| (r_compound) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) reductase_21\NN\14732946|dihydrofolate
T2_T16 NONE thymidylate_17\NN\1740| (r_compound) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) formyltransferase_26\NN\1740|glycinamide|ribonucleotide
T3_T14 NONE dihydrofolate_20\JJ\1740| (r_amod) reductase_21\NN\14732946|dihydrofolate (r_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase
T3_T15 NONE dihydrofolate_20\JJ\1740| (r_amod) reductase_21\NN\14732946|dihydrofolate
T3_T16 NONE dihydrofolate_20\JJ\1740| (r_amod) reductase_21\NN\14732946|dihydrofolate (r_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) formyltransferase_26\NN\1740|glycinamide|ribonucleotide
T4_T14 NONE ribonucleotide_25\NN\1740| (r_compound) formyltransferase_26\NN\1740|glycinamide|ribonucleotide (r_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase
T4_T15 NONE ribonucleotide_25\NN\1740| (r_compound) formyltransferase_26\NN\1740|glycinamide|ribonucleotide (r_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) reductase_21\NN\14732946|dihydrofolate
T4_T16 NONE ribonucleotide_25\NN\1740| (r_compound) formyltransferase_26\NN\1740|glycinamide|ribonucleotide
T6_T14 CPR:4 alimta_3\NN\1740|(|) (r_appos) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antimetabolite_8\NN\2722458|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_10\VBZ\2510337|that|enzymes (l_dobj) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase
T6_T15 CPR:4 alimta_3\NN\1740|(|) (r_appos) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antimetabolite_8\NN\2722458|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_10\VBZ\2510337|that|enzymes (l_dobj) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) reductase_21\NN\14732946|dihydrofolate
T6_T16 CPR:4 alimta_3\NN\1740|(|) (r_appos) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antimetabolite_8\NN\2722458|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_10\VBZ\2510337|that|enzymes (l_dobj) enzymes_15\NNS\14723628|three|folate-dependent|,|synthase (l_conj) synthase_18\NN\1740|thymidylate|,|reductase|,|and|formyltransferase (l_conj) formyltransferase_26\NN\1740|glycinamide|ribonucleotide
23281812
T6_T20 CPR:4 tetrahydropyrroloquinolinone_0\NN\1740| (r_compound) type_1\NN\5839024|tetrahydropyrroloquinolinone (r_compound) inhibitors_3\NNS\20090|type|dual|synthase|strategy|. (l_nmod) synthase_6\NN\1740|of|aromatase/aldosterone (l_compound) aromatase/aldosterone_5\NN\1740|
T6_T21 CPR:4 tetrahydropyrroloquinolinone_0\NN\1740| (r_compound) type_1\NN\5839024|tetrahydropyrroloquinolinone (r_compound) inhibitors_3\NNS\20090|type|dual|synthase|strategy|. (l_nmod) synthase_6\NN\1740|of|aromatase/aldosterone
T7_T20 NONE aromatase/aldosterone_5\NN\1740|
T7_T21 NONE aromatase/aldosterone_5\NN\1740| (r_compound) synthase_6\NN\1740|of|aromatase/aldosterone
T3_T14 NONE aldosterone_8\NN\14751863| (r_compound) synthase_9\NN\1740|aldosterone|cyp11b2 (r_conj) aromatase_3\NN\1740|of|cyp19|and|synthase
T3_T15 NONE aldosterone_8\NN\14751863| (r_compound) synthase_9\NN\1740|aldosterone|cyp11b2 (r_conj) aromatase_3\NN\1740|of|cyp19|and|synthase (l_appos) cyp19_5\NN\1740|(|)
T3_T16 NONE aldosterone_8\NN\14751863| (r_compound) synthase_9\NN\1740|aldosterone|cyp11b2
T3_T17 NONE aldosterone_8\NN\14751863| (r_compound) synthase_9\NN\1740|aldosterone|cyp11b2 (l_appos) cyp11b2_11\NN\1740|(|)
T4_T18 NONE 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones_20\NN\1740|of|substituted (r_nmod) series_16\NN\8456993|a|1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones (r_nsubjpass) designed_22\VBN\1631534|combining|,|series|were|and|synthesized|. (l_advcl) combining_1\VBG\2630189|by|features|template (l_dobj) features_4\NNS\5849040|decisive|structural|inhibitors (l_nmod) inhibitors_9\NNS\20090|of|cyp11b2 (l_compound) cyp11b2_6\NN\1740|and|cyp19
T4_T19 NONE 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones_20\NN\1740|of|substituted (r_nmod) series_16\NN\8456993|a|1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones (r_nsubjpass) designed_22\VBN\1631534|combining|,|series|were|and|synthesized|. (l_advcl) combining_1\VBG\2630189|by|features|template (l_dobj) features_4\NNS\5849040|decisive|structural|inhibitors (l_nmod) inhibitors_9\NNS\20090|of|cyp11b2 (l_compound) cyp11b2_6\NN\1740|and|cyp19 (l_conj) cyp19_8\NN\1740|
16828882
T11_T30 NONE simvastatin_0\NN\3676175| (r_nsubj) regulates_1\VBZ\296178|simvastatin|activity|pathways|. (l_nmod) pathways_10\NNS\5483677|via|cd11a-mediated (l_amod) cd11a-mediated_9\JJ\1740|
T3_T15 NONE acetylcholine_25\NN\14807558|ach (r_compound) synthesis_29\NN\13446390|in|acetylcholine|and|expression (r_nmod) increases_23\NNS\13576355|by|synthesis (r_nmod) evidenced_21\VBN\1015244|as|increases (r_advcl) stimulates_6\VBZ\137313|that|globulin|system|pathways|,|evidenced (l_nsubj) globulin_5\NN\14736972|antithymocyte
T3_T16 NONE acetylcholine_25\NN\14807558|ach (r_compound) synthesis_29\NN\13446390|in|acetylcholine|and|expression (r_nmod) increases_23\NNS\13576355|by|synthesis (r_nmod) evidenced_21\VBN\1015244|as|increases (r_advcl) stimulates_6\VBZ\137313|that|globulin|system|pathways|,|evidenced (l_nmod) pathways_18\NNS\5483677|via|lfa-1-mediated (l_amod) lfa-1-mediated_17\JJ\1740|
T3_T17 NONE acetylcholine_25\NN\14807558|ach (r_compound) synthesis_29\NN\13446390|in|acetylcholine|and|expression (l_conj) expression_37\NN\4679549|mrna (l_compound) mrna_36\NN\14832193|acetyltransferase (l_compound) acetyltransferase_32\NN\1740|choline|chat
T3_T18 NONE acetylcholine_25\NN\14807558|ach (r_compound) synthesis_29\NN\13446390|in|acetylcholine|and|expression (l_conj) expression_37\NN\4679549|mrna (l_compound) mrna_36\NN\14832193|acetyltransferase (l_compound) acetyltransferase_32\NN\1740|choline|chat (l_appos) chat_34\NN\7133701|(|)
T4_T15 NONE ach_27\NN\1740|(|) (r_appos) acetylcholine_25\NN\14807558|ach (r_compound) synthesis_29\NN\13446390|in|acetylcholine|and|expression (r_nmod) increases_23\NNS\13576355|by|synthesis (r_nmod) evidenced_21\VBN\1015244|as|increases (r_advcl) stimulates_6\VBZ\137313|that|globulin|system|pathways|,|evidenced (l_nsubj) globulin_5\NN\14736972|antithymocyte
T4_T16 NONE ach_27\NN\1740|(|) (r_appos) acetylcholine_25\NN\14807558|ach (r_compound) synthesis_29\NN\13446390|in|acetylcholine|and|expression (r_nmod) increases_23\NNS\13576355|by|synthesis (r_nmod) evidenced_21\VBN\1015244|as|increases (r_advcl) stimulates_6\VBZ\137313|that|globulin|system|pathways|,|evidenced (l_nmod) pathways_18\NNS\5483677|via|lfa-1-mediated (l_amod) lfa-1-mediated_17\JJ\1740|
T4_T17 NONE ach_27\NN\1740|(|) (r_appos) acetylcholine_25\NN\14807558|ach (r_compound) synthesis_29\NN\13446390|in|acetylcholine|and|expression (l_conj) expression_37\NN\4679549|mrna (l_compound) mrna_36\NN\14832193|acetyltransferase (l_compound) acetyltransferase_32\NN\1740|choline|chat
T4_T18 NONE ach_27\NN\1740|(|) (r_appos) acetylcholine_25\NN\14807558|ach (r_compound) synthesis_29\NN\13446390|in|acetylcholine|and|expression (l_conj) expression_37\NN\4679549|mrna (l_compound) mrna_36\NN\14832193|acetyltransferase (l_compound) acetyltransferase_32\NN\1740|choline|chat (l_appos) chat_34\NN\7133701|(|)
T5_T20 NONE cholesterol-lowering_1\JJ\1740| (r_amod) drug_2\NN\14778436|the|cholesterol-lowering|simvastatin (r_nsubj) inhibits_4\VBZ\2510337|drug|signaling|binding|. (l_dobj) signaling_6\NN\33020|lfa-1 (l_compound) lfa-1_5\NN\1740|
T5_T22 NONE cholesterol-lowering_1\JJ\1740| (r_amod) drug_2\NN\14778436|the|cholesterol-lowering|simvastatin (r_nsubj) inhibits_4\VBZ\2510337|drug|signaling|binding|. (l_advcl) binding_8\VBG\1290422|by|site (l_nmod) site_12\NN\8673395|to|an|allosteric|cd11a|,|leads (l_nmod) cd11a_14\NN\1740|on|chain
T5_T23 NONE cholesterol-lowering_1\JJ\1740| (r_amod) drug_2\NN\14778436|the|cholesterol-lowering|simvastatin (r_nsubj) inhibits_4\VBZ\2510337|drug|signaling|binding|. (l_advcl) binding_8\VBG\1290422|by|site (l_nmod) site_12\NN\8673395|to|an|allosteric|cd11a|,|leads (l_nmod) cd11a_14\NN\1740|on|chain (l_appos) chain_18\NN\8457976|(|lfa-1|alpha|)
T6_T20 CPR:4 simvastatin_3\NN\3676175| (r_dep) drug_2\NN\14778436|the|cholesterol-lowering|simvastatin (r_nsubj) inhibits_4\VBZ\2510337|drug|signaling|binding|. (l_dobj) signaling_6\NN\33020|lfa-1 (l_compound) lfa-1_5\NN\1740|
T6_T22 NONE simvastatin_3\NN\3676175| (r_dep) drug_2\NN\14778436|the|cholesterol-lowering|simvastatin (r_nsubj) inhibits_4\VBZ\2510337|drug|signaling|binding|. (l_advcl) binding_8\VBG\1290422|by|site (l_nmod) site_12\NN\8673395|to|an|allosteric|cd11a|,|leads (l_nmod) cd11a_14\NN\1740|on|chain
T6_T23 NONE simvastatin_3\NN\3676175| (r_dep) drug_2\NN\14778436|the|cholesterol-lowering|simvastatin (r_nsubj) inhibits_4\VBZ\2510337|drug|signaling|binding|. (l_advcl) binding_8\VBG\1290422|by|site (l_nmod) site_12\NN\8673395|to|an|allosteric|cd11a|,|leads (l_nmod) cd11a_14\NN\1740|on|chain (l_appos) chain_18\NN\8457976|(|lfa-1|alpha|)
T8_T25 NONE ach_13\NN\1740|synthesis (r_conj) activity_11\NN\30358|chat|,|ach|,|and|expression (r_dobj) increased_9\VBD\169651|that|antibody|activity (l_nsubj) antibody_5\NN\14728724|anti-cd11a|monoclonal|mab (l_amod) anti-cd11a_3\JJ\1740|
T8_T26 NONE ach_13\NN\1740|synthesis (r_conj) activity_11\NN\30358|chat|,|ach|,|and|expression (l_compound) chat_10\NN\7133701|
T8_T27 NONE ach_13\NN\1740|synthesis (r_conj) activity_11\NN\30358|chat|,|ach|,|and|expression (l_conj) expression_19\NN\4679549|chat (l_nmod) chat_21\NN\7133701|of|and|mrna|cells
T8_T28 NONE ach_13\NN\1740|synthesis (r_conj) activity_11\NN\30358|chat|,|ach|,|and|expression (l_conj) expression_19\NN\4679549|chat (l_nmod) chat_21\NN\7133701|of|and|mrna|cells (l_conj) mrna_27\NN\14832193|m5|receptor (l_compound) receptor_26\NN\5225602|muscarinic|ach
T9_T25 NONE ach_25\NN\1740| (r_compound) receptor_26\NN\5225602|muscarinic|ach (r_compound) mrna_27\NN\14832193|m5|receptor (r_conj) chat_21\NN\7133701|of|and|mrna|cells (r_nmod) expression_19\NN\4679549|chat (r_conj) activity_11\NN\30358|chat|,|ach|,|and|expression (r_dobj) increased_9\VBD\169651|that|antibody|activity (l_nsubj) antibody_5\NN\14728724|anti-cd11a|monoclonal|mab (l_amod) anti-cd11a_3\JJ\1740|
T9_T26 NONE ach_25\NN\1740| (r_compound) receptor_26\NN\5225602|muscarinic|ach (r_compound) mrna_27\NN\14832193|m5|receptor (r_conj) chat_21\NN\7133701|of|and|mrna|cells (r_nmod) expression_19\NN\4679549|chat (r_conj) activity_11\NN\30358|chat|,|ach|,|and|expression (l_compound) chat_10\NN\7133701|
T9_T27 NONE ach_25\NN\1740| (r_compound) receptor_26\NN\5225602|muscarinic|ach (r_compound) mrna_27\NN\14832193|m5|receptor (r_conj) chat_21\NN\7133701|of|and|mrna|cells
T9_T28 NONE ach_25\NN\1740| (r_compound) receptor_26\NN\5225602|muscarinic|ach
T10_T29 CPR:4 simvastatin_0\NN\3676175| (r_nsubj) abolished_1\VBD\1740|simvastatin|increases|manner|. (l_dobj) increases_5\NNS\13576355|these|mab-induced|activity (l_amod) mab-induced_4\JJ\1740|anti-cd11a (l_amod) anti-cd11a_3\JJ\1740|
T1_T29 NONE cholesterol-lowering_16\JJ\1740| (r_amod) activity_17\NN\30358|of|its|cholesterol-lowering (r_nmod) independent_13\JJ\1740|activity (r_amod) manner_12\NN\4916342|in|a|independent (r_nmod) abolished_1\VBD\1740|simvastatin|increases|manner|. (l_dobj) increases_5\NNS\13576355|these|mab-induced|activity (l_amod) mab-induced_4\JJ\1740|anti-cd11a (l_amod) anti-cd11a_3\JJ\1740|
T2_T13 NONE simvastatin_20\NN\3676175| (r_nsubj) exerts_21\VBZ\1158872|that|simvastatin|effects|part|modification (r_ccomp) suggest_18\VBP\1010118|exerts (r_conj) indicate_2\VBP\952524|results|contributes|,|and|suggest|. (l_ccomp) contributes_5\VBZ\126264|that|lfa-1|regulation|pathways (l_nsubj) lfa-1_4\NN\1740|
T2_T14 NONE simvastatin_20\NN\3676175| (r_nsubj) exerts_21\VBZ\1158872|that|simvastatin|effects|part|modification (r_ccomp) suggest_18\VBP\1010118|exerts (r_conj) indicate_2\VBP\952524|results|contributes|,|and|suggest|. (l_ccomp) contributes_5\VBZ\126264|that|lfa-1|regulation|pathways (l_nmod) pathways_15\NNS\5483677|via|cd11a-mediated (l_amod) cd11a-mediated_14\JJ\1740|
1359745
T17_T25 CPR:9 leukotrienes_14\NNS\1740|of|lts (r_nmod) production_12\NN\30358|in|the|leukotrienes (r_nmod) role_2\NN\719494|the|unique|enzyme|production (l_nmod) enzyme_5\NN\14723628|of|the|5-lipoxygenase (l_dep) 5-lipoxygenase_6\NN\1740|5-lo
T17_T26 CPR:9 leukotrienes_14\NNS\1740|of|lts (r_nmod) production_12\NN\30358|in|the|leukotrienes (r_nmod) role_2\NN\719494|the|unique|enzyme|production (l_nmod) enzyme_5\NN\14723628|of|the|5-lipoxygenase (l_dep) 5-lipoxygenase_6\NN\1740|5-lo (l_appos) 5-lo_8\NN\1740|(|)
T21_T25 CPR:9 lts_16\NNS\1740|(|) (r_appos) leukotrienes_14\NNS\1740|of|lts (r_nmod) production_12\NN\30358|in|the|leukotrienes (r_nmod) role_2\NN\719494|the|unique|enzyme|production (l_nmod) enzyme_5\NN\14723628|of|the|5-lipoxygenase (l_dep) 5-lipoxygenase_6\NN\1740|5-lo
T21_T26 CPR:9 lts_16\NNS\1740|(|) (r_appos) leukotrienes_14\NNS\1740|of|lts (r_nmod) production_12\NN\30358|in|the|leukotrienes (r_nmod) role_2\NN\719494|the|unique|enzyme|production (l_nmod) enzyme_5\NN\14723628|of|the|5-lipoxygenase (l_dep) 5-lipoxygenase_6\NN\1740|5-lo (l_appos) 5-lo_8\NN\1740|(|)
T11_T24 NONE lts_23\NNS\1740|of (r_nmod) generation_21\NN\7942152|on|the|increased|lts|mucosa|,|metabolite (r_nmod) based_17\VBN\2694933|rationale|is|generation|. (l_nsubjpass) rationale_1\NN\5793000|the|using (l_acl) using_3\VBG\1156834|for|inhibitors|treatment (l_dobj) inhibitors_5\NNS\20090|5-lo (l_compound) 5-lo_4\NN\1740|
T12_T24 NONE ltb4_29\NN\1740| (r_nsubj) metabolite_37\NN\20090|ltb4|being|the|chemotactic|acid (r_appos) generation_21\NN\7942152|on|the|increased|lts|mucosa|,|metabolite (r_nmod) based_17\VBN\2694933|rationale|is|generation|. (l_nsubjpass) rationale_1\NN\5793000|the|using (l_acl) using_3\VBG\1156834|for|inhibitors|treatment (l_dobj) inhibitors_5\NNS\20090|5-lo (l_compound) 5-lo_4\NN\1740|
T13_T24 NONE acid_40\NN\14818238|of|arachidonic (r_nmod) metabolite_37\NN\20090|ltb4|being|the|chemotactic|acid (r_appos) generation_21\NN\7942152|on|the|increased|lts|mucosa|,|metabolite (r_nmod) based_17\VBN\2694933|rationale|is|generation|. (l_nsubjpass) rationale_1\NN\5793000|the|using (l_acl) using_3\VBG\1156834|for|inhibitors|treatment (l_dobj) inhibitors_5\NNS\20090|5-lo (l_compound) 5-lo_4\NN\1740|
T14_T27 NONE sulphasalazine_9\NN\1740| (r_conj) corticosteroids_7\NNS\14745635|such|,|sulphasalazine|,|and|acid (r_nmod) drugs_3\NNS\14778436|conventional|,|corticosteroids|, (r_nsubj) inhibit_15\VBP\2510337|furthermore|,|drugs|production|and|accelerates (l_conj) accelerates_22\VBZ\226566|inhibition|healing|. (l_nsubj) inhibition_21\NN\1068773|specific|5-lo (l_compound) 5-lo_20\NN\1740|
T15_T27 NONE acid_13\NN\14818238|5-aminosalicylic (r_conj) corticosteroids_7\NNS\14745635|such|,|sulphasalazine|,|and|acid (r_nmod) drugs_3\NNS\14778436|conventional|,|corticosteroids|, (r_nsubj) inhibit_15\VBP\2510337|furthermore|,|drugs|production|and|accelerates (l_conj) accelerates_22\VBZ\226566|inhibition|healing|. (l_nsubj) inhibition_21\NN\1068773|specific|5-lo (l_compound) 5-lo_20\NN\1740|
T16_T27 NONE lt_16\NN\1740| (r_compound) production_17\NN\30358|lt (r_dobj) inhibit_15\VBP\2510337|furthermore|,|drugs|production|and|accelerates (l_conj) accelerates_22\VBZ\226566|inhibition|healing|. (l_nsubj) inhibition_21\NN\1068773|specific|5-lo (l_compound) 5-lo_20\NN\1740|
T18_T28 NONE acids_24\NNS\14818238|hydroxamic (r_nsubj) inhibitors_30\NNS\20090|where|acids|are|potent|5-lo (r_acl:relcl) group_18\NN\2137|a|large|miscellaneous|inhibitors|,|inhibitors (r_conj) antioxidants_10\NNS\14724436|into|,|substrate-analogous|,|and|group (r_nmod) divided_8\VBN\140123|compounds|can|be|antioxidants|. (l_nsubjpass) compounds_1\NNS\5869584|the|identified (l_acl) identified_2\VBN\699815|inhibitors (l_nmod) inhibitors_5\NNS\20090|as|5-lo (l_compound) 5-lo_4\NN\1740|
T18_T29 CPR:4 acids_24\NNS\14818238|hydroxamic (r_nsubj) inhibitors_30\NNS\20090|where|acids|are|potent|5-lo (l_nmod) 5-lo_32\NN\1740|of
T19_T30 CPR:4 hydroxyurea_2\NN\1740|the|benzothiophene|,|zileuton|, (r_nsubj) inhibitor_11\NN\20090|hydroxyurea|is|the|first|selective|5-lo|evaluated|. (l_compound) 5-lo_10\NN\1740|
T20_T30 CPR:4 zileuton_4\NN\1740| (r_appos) hydroxyurea_2\NN\1740|the|benzothiophene|,|zileuton|, (r_nsubj) inhibitor_11\NN\20090|hydroxyurea|is|the|first|selective|5-lo|evaluated|. (l_compound) 5-lo_10\NN\1740|
T7_T23 NONE lt_9\NN\1740| (r_compound) production_10\NN\30358|lt (r_dobj) blocking_8\VBG\1476483|that|inhibitor|is|production (l_nsubj) inhibitor_6\NN\20090|any|putative|5-lo (l_compound) 5-lo_5\NN\1740|
23495999
T1_T18 NONE calcium_17\NN\14625458| (r_compound) oscillations_18\NNS\13518963|of|calcium (r_nmod) frequency_13\NN\15286249|the|and|amplitude|oscillations (r_nsubjpass) modified_20\VBN\109660|modulating|,|frequency|is|,|implying|. (l_advcl) modulating_1\VBG\1724459|by|levels (l_dobj) levels_3\NNS\4916342|expression|app|neurons (l_nmod) app_6\NN\1740|of|endogenous
T1_T20 NONE calcium_17\NN\14625458| (r_compound) oscillations_18\NNS\13518963|of|calcium (r_nmod) frequency_13\NN\15286249|the|and|amplitude|oscillations (r_nsubjpass) modified_20\VBN\109660|modulating|,|frequency|is|,|implying|. (l_advcl) implying_22\VBG\943837|role (l_dobj) role_25\NN\719494|a|key|app|maintaining (l_nmod) app_27\NN\1740|for
T2_T18 NONE calcium_31\NN\14625458| (r_compound) homeostasis_32\NN\13934900|neuronal|calcium|essential (r_dobj) maintaining_29\VBG\2202928|in|homeostasis (r_acl) role_25\NN\719494|a|key|app|maintaining (r_dobj) implying_22\VBG\943837|role (r_advcl) modified_20\VBN\109660|modulating|,|frequency|is|,|implying|. (l_advcl) modulating_1\VBG\1724459|by|levels (l_dobj) levels_3\NNS\4916342|expression|app|neurons (l_nmod) app_6\NN\1740|of|endogenous
T2_T20 NONE calcium_31\NN\14625458| (r_compound) homeostasis_32\NN\13934900|neuronal|calcium|essential (r_dobj) maintaining_29\VBG\2202928|in|homeostasis (r_acl) role_25\NN\719494|a|key|app|maintaining (l_nmod) app_27\NN\1740|for
23240892
T15_T17 CPR:4 pkaa_5\NN\1740| (r_nsubj) capable_7\JJ\1740|that|pkaa|is|delivering|and|inhibits (l_conj) inhibits_22\VBZ\2510337|significantly|expression (l_dobj) expression_24\NN\4679549|the|tnf-α (l_nmod) tnf-α_26\NN\1740|of
T15_T21 NONE pkaa_5\NN\1740| (r_nsubj) capable_7\JJ\1740|that|pkaa|is|delivering|and|inhibits (l_advcl) delivering_9\VBG\941990|of|sirna|macrophages (l_dobj) sirna_15\NN\1740|anti-tnf|(|tumor|necrosis|factor)-α (l_amod) anti-tnf_10\JJ\1740|
T15_T22 NONE pkaa_5\NN\1740| (r_nsubj) capable_7\JJ\1740|that|pkaa|is|delivering|and|inhibits (l_advcl) delivering_9\VBG\941990|of|sirna|macrophages (l_dobj) sirna_15\NN\1740|anti-tnf|(|tumor|necrosis|factor)-α (l_compound) factor)-α_14\NN\1740|
T4_T18 NONE pkaa/anti-tnf-α_0\JJ\1740|
T4_T19 CPR:4 pkaa/anti-tnf-α_0\JJ\1740| (r_amod) nanocomplexes_2\NNS\1740|pkaa/anti-tnf-α|sirna (r_nsubj) reduced_4\VBD\441445|nanocomplexes|significantly|alt|. (l_dobj) alt_6\NN\13836371|the|transaminase|and|damages|mice
T4_T20 CPR:4 pkaa/anti-tnf-α_0\JJ\1740| (r_amod) nanocomplexes_2\NNS\1740|pkaa/anti-tnf-α|sirna (r_nsubj) reduced_4\VBD\441445|nanocomplexes|significantly|alt|. (l_dobj) alt_6\NN\13836371|the|transaminase|and|damages|mice (l_appos) transaminase_9\NN\15077571|(|alanine|)
T5_T18 NONE alanine_8\NN\14601829| (r_compound) transaminase_9\NN\15077571|(|alanine|) (r_appos) alt_6\NN\13836371|the|transaminase|and|damages|mice (r_dobj) reduced_4\VBD\441445|nanocomplexes|significantly|alt|. (l_nsubj) nanocomplexes_2\NNS\1740|pkaa/anti-tnf-α|sirna (l_amod) pkaa/anti-tnf-α_0\JJ\1740|
T5_T19 NONE alanine_8\NN\14601829| (r_compound) transaminase_9\NN\15077571|(|alanine|) (r_appos) alt_6\NN\13836371|the|transaminase|and|damages|mice
T5_T20 NONE alanine_8\NN\14601829| (r_compound) transaminase_9\NN\15077571|(|alanine|)
T6_T18 NONE apap-intoxicated_17\JJ\1740| (r_amod) mice_18\NNS\2329401|in|apap-intoxicated (r_nmod) alt_6\NN\13836371|the|transaminase|and|damages|mice (r_dobj) reduced_4\VBD\441445|nanocomplexes|significantly|alt|. (l_nsubj) nanocomplexes_2\NNS\1740|pkaa/anti-tnf-α|sirna (l_amod) pkaa/anti-tnf-α_0\JJ\1740|
T6_T19 NONE apap-intoxicated_17\JJ\1740| (r_amod) mice_18\NNS\2329401|in|apap-intoxicated (r_nmod) alt_6\NN\13836371|the|transaminase|and|damages|mice
T6_T20 NONE apap-intoxicated_17\JJ\1740| (r_amod) mice_18\NNS\2329401|in|apap-intoxicated (r_nmod) alt_6\NN\13836371|the|transaminase|and|damages|mice (l_appos) transaminase_9\NN\15077571|(|alanine|)
21606412
T7_T21 CPR:4 xl184_2\NN\1740|of|cabozantinib|,|inhibitor|, (l_appos) inhibitor_11\NN\20090|an|oral|tyrosine|kinase (l_compound) kinase_10\NN\14732946|
T8_T21 CPR:4 cabozantinib_4\NN\1740|(|) (r_appos) xl184_2\NN\1740|of|cabozantinib|,|inhibitor|, (l_appos) inhibitor_11\NN\20090|an|oral|tyrosine|kinase (l_compound) kinase_10\NN\14732946|
T9_T21 NONE tyrosine_9\NN\14601829| (r_compound) inhibitor_11\NN\20090|an|oral|tyrosine|kinase (l_compound) kinase_10\NN\14732946|
T3_T13 CPR:4 cabozantinib_4\NN\1740|(|) (r_appos) xl184_2\NN\1740|cabozantinib (r_nsubj) inhibitor_9\NN\20090|purpose|:|xl184|is|a|potent|met|,|effects|. (l_nmod) met_11\NN\1740|of|,|receptor (l_conj) receptor_17\NN\5225602|vascular|endothelial|growth|factor|2|vegfr2|,|and|ret (l_appos) vegfr2_20\NN\1740|(|)
T3_T14 CPR:4 cabozantinib_4\NN\1740|(|) (r_appos) xl184_2\NN\1740|cabozantinib (r_nsubj) inhibitor_9\NN\20090|purpose|:|xl184|is|a|potent|met|,|effects|. (l_nmod) met_11\NN\1740|of|,|receptor (l_conj) receptor_17\NN\5225602|vascular|endothelial|growth|factor|2|vegfr2|,|and|ret (l_conj) ret_24\NN\1740|
T3_T18 CPR:4 cabozantinib_4\NN\1740|(|) (r_appos) xl184_2\NN\1740|cabozantinib (r_nsubj) inhibitor_9\NN\20090|purpose|:|xl184|is|a|potent|met|,|effects|. (l_nmod) met_11\NN\1740|of|,|receptor
T3_T19 CPR:4 cabozantinib_4\NN\1740|(|) (r_appos) xl184_2\NN\1740|cabozantinib (r_nsubj) inhibitor_9\NN\20090|purpose|:|xl184|is|a|potent|met|,|effects|. (l_nmod) met_11\NN\1740|of|,|receptor (l_conj) receptor_17\NN\5225602|vascular|endothelial|growth|factor|2|vegfr2|,|and|ret (l_nummod) 2_18\CD\13741022|
T6_T13 CPR:4 xl184_2\NN\1740|cabozantinib (r_nsubj) inhibitor_9\NN\20090|purpose|:|xl184|is|a|potent|met|,|effects|. (l_nmod) met_11\NN\1740|of|,|receptor (l_conj) receptor_17\NN\5225602|vascular|endothelial|growth|factor|2|vegfr2|,|and|ret (l_appos) vegfr2_20\NN\1740|(|)
T6_T14 CPR:4 xl184_2\NN\1740|cabozantinib (r_nsubj) inhibitor_9\NN\20090|purpose|:|xl184|is|a|potent|met|,|effects|. (l_nmod) met_11\NN\1740|of|,|receptor (l_conj) receptor_17\NN\5225602|vascular|endothelial|growth|factor|2|vegfr2|,|and|ret (l_conj) ret_24\NN\1740|
T6_T18 CPR:4 xl184_2\NN\1740|cabozantinib (r_nsubj) inhibitor_9\NN\20090|purpose|:|xl184|is|a|potent|met|,|effects|. (l_nmod) met_11\NN\1740|of|,|receptor
T6_T19 CPR:4 xl184_2\NN\1740|cabozantinib (r_nsubj) inhibitor_9\NN\20090|purpose|:|xl184|is|a|potent|met|,|effects|. (l_nmod) met_11\NN\1740|of|,|receptor (l_conj) receptor_17\NN\5225602|vascular|endothelial|growth|factor|2|vegfr2|,|and|ret (l_nummod) 2_18\CD\13741022|
T2_T15 NONE cabozantinib_0\NN\1740| (r_nsubj) provide_2\VB\2199590|cabozantinib|may|benefit|targeting|. (l_advcl) targeting_7\VBG\1151110|by|simultaneously|pathways (l_dobj) pathways_9\NNS\5483677|multiple|importance|mtc|,|met (l_nmod) met_16\NN\1740|including|,|vegfr2|,|and|ret
T2_T16 NONE cabozantinib_0\NN\1740| (r_nsubj) provide_2\VB\2199590|cabozantinib|may|benefit|targeting|. (l_advcl) targeting_7\VBG\1151110|by|simultaneously|pathways (l_dobj) pathways_9\NNS\5483677|multiple|importance|mtc|,|met (l_nmod) met_16\NN\1740|including|,|vegfr2|,|and|ret (l_conj) vegfr2_18\NN\1740|
T2_T17 NONE cabozantinib_0\NN\1740| (r_nsubj) provide_2\VB\2199590|cabozantinib|may|benefit|targeting|. (l_advcl) targeting_7\VBG\1151110|by|simultaneously|pathways (l_dobj) pathways_9\NNS\5483677|multiple|importance|mtc|,|met (l_nmod) met_16\NN\1740|including|,|vegfr2|,|and|ret (l_conj) ret_21\NN\1740|
23384447
T10_T24 NONE ethanol_24\NN\14708720| (r_compound) exposure_25\NN\5042871|ethanol (r_conj) diet_22\NN\7560652|with|a|fat|and|exposure (r_nmod) combined_15\VBN\2630189|when|diet (r_advcl) treated_28\VBD\2376958|determine|combined|,|we|cells|mixtures|,|and|absence|. (l_nmod) mixtures_39\NNS\19613|with|two|chemicals (l_nmod) chemicals_54\NNS\14580897|organic|detected (l_acl) detected_55\VBN\2163746|blood|2004|presence (l_nmod) presence_66\NN\13954253|in|the|or|absence|lipoprotein (l_nmod) lipoprotein_71\NN\14731135|of|low-density|1.5mg/ml|,|lipoprotein|and|glucose
T10_T25 NONE ethanol_24\NN\14708720| (r_compound) exposure_25\NN\5042871|ethanol (r_conj) diet_22\NN\7560652|with|a|fat|and|exposure (r_nmod) combined_15\VBN\2630189|when|diet (r_advcl) treated_28\VBD\2376958|determine|combined|,|we|cells|mixtures|,|and|absence|. (l_nmod) mixtures_39\NNS\19613|with|two|chemicals (l_nmod) chemicals_54\NNS\14580897|organic|detected (l_acl) detected_55\VBN\2163746|blood|2004|presence (l_nmod) presence_66\NN\13954253|in|the|or|absence|lipoprotein (l_nmod) lipoprotein_71\NN\14731135|of|low-density|1.5mg/ml|,|lipoprotein|and|glucose (l_conj) lipoprotein_77\NN\14731135|very-low-density|1.0mg/ml
T11_T24 NONE glucose_82\NN\14710501|10mmol/l (r_conj) lipoprotein_71\NN\14731135|of|low-density|1.5mg/ml|,|lipoprotein|and|glucose
T11_T25 NONE glucose_82\NN\14710501|10mmol/l (r_conj) lipoprotein_71\NN\14731135|of|low-density|1.5mg/ml|,|lipoprotein|and|glucose (l_conj) lipoprotein_77\NN\14731135|very-low-density|1.0mg/ml
T12_T24 NONE ethanol_99\NN\14708720|of|% (r_nmod) absence_93\NN\14449405|in|the|or|presence|ethanol (r_conj) treated_28\VBD\2376958|determine|combined|,|we|cells|mixtures|,|and|absence|. (l_nmod) mixtures_39\NNS\19613|with|two|chemicals (l_nmod) chemicals_54\NNS\14580897|organic|detected (l_acl) detected_55\VBN\2163746|blood|2004|presence (l_nmod) presence_66\NN\13954253|in|the|or|absence|lipoprotein (l_nmod) lipoprotein_71\NN\14731135|of|low-density|1.5mg/ml|,|lipoprotein|and|glucose
T12_T25 NONE ethanol_99\NN\14708720|of|% (r_nmod) absence_93\NN\14449405|in|the|or|presence|ethanol (r_conj) treated_28\VBD\2376958|determine|combined|,|we|cells|mixtures|,|and|absence|. (l_nmod) mixtures_39\NNS\19613|with|two|chemicals (l_nmod) chemicals_54\NNS\14580897|organic|detected (l_acl) detected_55\VBN\2163746|blood|2004|presence (l_nmod) presence_66\NN\13954253|in|the|or|absence|lipoprotein (l_nmod) lipoprotein_71\NN\14731135|of|low-density|1.5mg/ml|,|lipoprotein|and|glucose (l_conj) lipoprotein_77\NN\14731135|very-low-density|1.0mg/ml
T9_T24 NONE sugar_21\NN\7858595| (r_conj) fat_19\NN\14938907|high|and|sugar (r_compound) diet_22\NN\7560652|with|a|fat|and|exposure (r_nmod) combined_15\VBN\2630189|when|diet (r_advcl) treated_28\VBD\2376958|determine|combined|,|we|cells|mixtures|,|and|absence|. (l_nmod) mixtures_39\NNS\19613|with|two|chemicals (l_nmod) chemicals_54\NNS\14580897|organic|detected (l_acl) detected_55\VBN\2163746|blood|2004|presence (l_nmod) presence_66\NN\13954253|in|the|or|absence|lipoprotein (l_nmod) lipoprotein_71\NN\14731135|of|low-density|1.5mg/ml|,|lipoprotein|and|glucose
T9_T25 NONE sugar_21\NN\7858595| (r_conj) fat_19\NN\14938907|high|and|sugar (r_compound) diet_22\NN\7560652|with|a|fat|and|exposure (r_nmod) combined_15\VBN\2630189|when|diet (r_advcl) treated_28\VBD\2376958|determine|combined|,|we|cells|mixtures|,|and|absence|. (l_nmod) mixtures_39\NNS\19613|with|two|chemicals (l_nmod) chemicals_54\NNS\14580897|organic|detected (l_acl) detected_55\VBN\2163746|blood|2004|presence (l_nmod) presence_66\NN\13954253|in|the|or|absence|lipoprotein (l_nmod) lipoprotein_71\NN\14731135|of|low-density|1.5mg/ml|,|lipoprotein|and|glucose (l_conj) lipoprotein_77\NN\14731135|very-low-density|1.0mg/ml
T1_T15 NONE oxide_49\NN\14818238| (r_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos (r_compound) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor
T1_T16 NONE oxide_49\NN\14818238| (r_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos (r_compound) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_appos) et-1_32\NN\1740|(|)
T1_T17 NONE oxide_49\NN\14818238| (r_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos (r_compound) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_conj) inhibitor_37\NN\20090|plasminogen|activator|pai
T1_T18 NONE oxide_49\NN\14818238| (r_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos (r_compound) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_conj) inhibitor_37\NN\20090|plasminogen|activator|pai (l_appos) pai_39\NN\1740|(|)
T1_T19 NONE oxide_49\NN\14818238| (r_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos
T1_T20 NONE oxide_49\NN\14818238| (r_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos (l_appos) enos_52\NN\1740|(|)
T2_T15 NONE oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor
T2_T16 NONE oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_appos) et-1_32\NN\1740|(|)
T2_T17 NONE oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_conj) inhibitor_37\NN\20090|plasminogen|activator|pai
T2_T18 NONE oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_conj) inhibitor_37\NN\20090|plasminogen|activator|pai (l_appos) pai_39\NN\1740|(|)
T2_T19 NONE oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (l_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos
T2_T20 NONE oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (l_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos (l_appos) enos_52\NN\1740|(|)
T3_T15 NONE no_60\NN\7204911|(|) (r_appos) oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor
T3_T16 NONE no_60\NN\7204911|(|) (r_appos) oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_appos) et-1_32\NN\1740|(|)
T3_T17 NONE no_60\NN\7204911|(|) (r_appos) oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_conj) inhibitor_37\NN\20090|plasminogen|activator|pai
T3_T18 NONE no_60\NN\7204911|(|) (r_appos) oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (r_nmod) changes_45\NNS\7283608|no|expression (r_dobj) causing_43\VBG\1617192|while|changes (r_advcl) affect_4\VB\126264|treatment|did|not|viability|,|but|increased|,|causing|. (l_conj) increased_9\VBD\169651|size|,|disrupted|,|and|decreased (l_conj) decreased_19\VBD\169651|density (l_dobj) density_21\NN\4941325|cell|,|uptake|,|release (l_appos) release_28\NN\3748886|endothelin-1 (l_nmod) endothelin-1_30\NN\1740|of|et-1|and|inhibitor (l_conj) inhibitor_37\NN\20090|plasminogen|activator|pai (l_appos) pai_39\NN\1740|(|)
T3_T19 NONE no_60\NN\7204911|(|) (r_appos) oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (l_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos
T3_T20 NONE no_60\NN\7204911|(|) (r_appos) oxide_58\NN\14818238|nitric|no (r_compound) release_62\NN\3748886|oxide (r_conj) expression_55\NN\4679549|in|synthase|protein|and|release (l_compound) synthase_50\NN\1740|endothelial|nitric|oxide|enos (l_appos) enos_52\NN\1740|(|)
T4_T21 NONE no_22\NN\7204911| (r_compound) release_23\NN\3748886|no (r_conj) viability_6\NN\4916342|cell|,|yield|,|uptake|,|expression|,|and|release (l_conj) expression_19\NN\4679549|enos|protein (l_compound) enos_17\NN\1740|
T4_T22 NONE no_22\NN\7204911| (r_compound) release_23\NN\3748886|no (r_conj) viability_6\NN\4916342|cell|,|yield|,|uptake|,|expression|,|and|release (r_dobj) decreased_4\VBD\169651|contrast|,|ncm2|viability|and|caused|,|but|caused|. (l_conj) caused_30\VBD\1617192|changes (l_dobj) changes_32\NNS\7283608|no|secretion (l_nmod) secretion_35\NN\13526110|in|the|et-1 (l_nmod) et-1_37\NN\1740|of|,|prostacyclin
T4_T23 NONE no_22\NN\7204911| (r_compound) release_23\NN\3748886|no (r_conj) viability_6\NN\4916342|cell|,|yield|,|uptake|,|expression|,|and|release (r_dobj) decreased_4\VBD\169651|contrast|,|ncm2|viability|and|caused|,|but|caused|. (l_conj) caused_30\VBD\1617192|changes (l_dobj) changes_32\NNS\7283608|no|secretion (l_nmod) secretion_35\NN\13526110|in|the|et-1 (l_nmod) et-1_37\NN\1740|of|,|prostacyclin (l_conj) prostacyclin_39\NN\1740|and|pai (l_conj) pai_41\NN\1740|
T5_T21 NONE prostacyclin_39\NN\1740|and|pai (r_conj) et-1_37\NN\1740|of|,|prostacyclin (r_nmod) secretion_35\NN\13526110|in|the|et-1 (r_nmod) changes_32\NNS\7283608|no|secretion (r_dobj) caused_30\VBD\1617192|changes (r_conj) decreased_4\VBD\169651|contrast|,|ncm2|viability|and|caused|,|but|caused|. (l_dobj) viability_6\NN\4916342|cell|,|yield|,|uptake|,|expression|,|and|release (l_conj) expression_19\NN\4679549|enos|protein (l_compound) enos_17\NN\1740|
T5_T22 NONE prostacyclin_39\NN\1740|and|pai (r_conj) et-1_37\NN\1740|of|,|prostacyclin
T5_T23 NONE prostacyclin_39\NN\1740|and|pai (l_conj) pai_41\NN\1740|
10688973
T4_T31 NONE [35s]gtpgammas_19\NN\1740| (r_compound) binding_20\NN\4688246|nociceptin-stimulated|[35s]gtpgammas (r_conj) [3h]nociceptin_16\NN\1740|and|binding (r_dobj) using_15\VBG\1156834|[3h]nociceptin (r_xcomp) determined_14\VBN\1645601|affinity|was|using|. (l_nsubjpass) affinity_1\NN\11426530|the|and|profile|opioids (l_nmod) opioids_6\NNS\1740|of|possessing (l_acl) possessing_7\VBG\2630189|activity|receptor (l_nmod) receptor_12\NN\5225602|at|the|nociceptin
T5_T32 CPR:5 lofentanil_4\NN\1740| (r_appos) agonist_3\NN\9613191|the|receptor-selective|lofentanil (l_amod) receptor-selective_2\JJ\1740|mu-opioid
T6_T33 CPR:5 lofentanil_0\NN\1740| (r_nsubj) exhibited_1\VBD\2632167|lofentanil|agonism|. (l_dobj) agonism_3\NN\1740|full|enhancement (l_nmod) enhancement_5\NN\248977|for|[35s]gtpgammas|ec(50 (l_nmod) [35s]gtpgammas_7\NN\1740|of|binding (l_acl) binding_8\VBG\1290422|receptors (l_nmod) receptors_13\NNS\5225602|to|human|recombinant|orl1 (l_compound) orl1_12\NN\1740|
T7_T33 NONE [35s]gtpgammas_7\NN\1740|of|binding (l_acl) binding_8\VBG\1290422|receptors (l_nmod) receptors_13\NNS\5225602|to|human|recombinant|orl1 (l_compound) orl1_12\NN\1740|
T10_T35 NONE sufentanil_5\NN\1740| (r_conj) ohmefentanyl_3\NN\1740|and|sufentanil (r_dep) piperidines_2\NNS\1740|the|related|ohmefentanyl|and|agonist (l_conj) agonist_11\NN\9613191|the|nonselective|opioid|receptor|etorphine (l_compound) receptor_10\NN\5225602|
T10_T36 CPR:5 sufentanil_5\NN\1740| (r_conj) ohmefentanyl_3\NN\1740|and|sufentanil (r_dep) piperidines_2\NNS\1740|the|related|ohmefentanyl|and|agonist (r_nsubj) agonists_18\NNS\9613191|piperidines|were|potent|nociceptin|receptor|. (l_compound) receptor_17\NN\5225602|
T11_T35 CPR:5 etorphine_12\NN\1740| (r_appos) agonist_11\NN\9613191|the|nonselective|opioid|receptor|etorphine (l_compound) receptor_10\NN\5225602|
T11_T36 CPR:5 etorphine_12\NN\1740| (r_appos) agonist_11\NN\9613191|the|nonselective|opioid|receptor|etorphine (r_conj) piperidines_2\NNS\1740|the|related|ohmefentanyl|and|agonist (r_nsubj) agonists_18\NNS\9613191|piperidines|were|potent|nociceptin|receptor|. (l_compound) receptor_17\NN\5225602|
T8_T35 NONE piperidines_2\NNS\1740|the|related|ohmefentanyl|and|agonist (l_conj) agonist_11\NN\9613191|the|nonselective|opioid|receptor|etorphine (l_compound) receptor_10\NN\5225602|
T8_T36 CPR:5 piperidines_2\NNS\1740|the|related|ohmefentanyl|and|agonist (r_nsubj) agonists_18\NNS\9613191|piperidines|were|potent|nociceptin|receptor|. (l_compound) receptor_17\NN\5225602|
T9_T35 NONE ohmefentanyl_3\NN\1740|and|sufentanil (r_dep) piperidines_2\NNS\1740|the|related|ohmefentanyl|and|agonist (l_conj) agonist_11\NN\9613191|the|nonselective|opioid|receptor|etorphine (l_compound) receptor_10\NN\5225602|
T9_T36 CPR:5 ohmefentanyl_3\NN\1740|and|sufentanil (r_dep) piperidines_2\NNS\1740|the|related|ohmefentanyl|and|agonist (r_nsubj) agonists_18\NNS\9613191|piperidines|were|potent|nociceptin|receptor|. (l_compound) receptor_17\NN\5225602|
T12_T14 CPR:6 benzoylhydrazone_7\NN\1740|the|kappa(1)+kappa(3)-opioid|antagonist|naloxone (r_nsubj) antagonist_11\NN\7846|benzoylhydrazone|was|a|pure|brain|. (l_nmod) brain_15\NN\5462674|at|both|rat|and|receptors (l_conj) receptors_19\NNS\5225602|human|orl1 (l_compound) orl1_18\NN\1740|
T12_T37 CPR:6 benzoylhydrazone_7\NN\1740|the|kappa(1)+kappa(3)-opioid|antagonist|naloxone (l_compound) antagonist_5\NN\7846|receptor|receptor (l_compound) receptor_4\NN\5225602|agonist/mu-opioid
T1_T15 CPR:5 buprenorphine_6\NN\1740|the|nonselective|opioid|agonist|and|(-)-quadazocine (l_compound) agonist_5\NN\9613191|receptor|partial (l_compound) receptor_3\NN\5225602|
T1_T16 NONE buprenorphine_6\NN\1740|the|nonselective|opioid|agonist|and|(-)-quadazocine (l_conj) (-)-quadazocine_13\NN\1740|the|nonselective|antagonist (l_compound) antagonist_12\NN\7846|opioid|receptor (l_compound) receptor_11\NN\5225602|
T1_T19 NONE buprenorphine_6\NN\1740|the|nonselective|opioid|agonist|and|(-)-quadazocine (r_nsubj) exhibited_14\VBD\2632167|buprenorphine|antagonism|receptors|,|but|displayed|. (l_conj) displayed_23\VBD\2137132|agonism|receptors (l_nmod) receptors_29\NNS\5225602|at|human|orl1 (l_compound) orl1_28\NN\1740|
T2_T15 NONE (-)-quadazocine_13\NN\1740|the|nonselective|antagonist (r_conj) buprenorphine_6\NN\1740|the|nonselective|opioid|agonist|and|(-)-quadazocine (l_compound) agonist_5\NN\9613191|receptor|partial (l_compound) receptor_3\NN\5225602|
T2_T16 CPR:6 (-)-quadazocine_13\NN\1740|the|nonselective|antagonist (l_compound) antagonist_12\NN\7846|opioid|receptor (l_compound) receptor_11\NN\5225602|
T2_T19 CPR:5 (-)-quadazocine_13\NN\1740|the|nonselective|antagonist (r_conj) buprenorphine_6\NN\1740|the|nonselective|opioid|agonist|and|(-)-quadazocine (r_nsubj) exhibited_14\VBD\2632167|buprenorphine|antagonism|receptors|,|but|displayed|. (l_conj) displayed_23\VBD\2137132|agonism|receptors (l_nmod) receptors_29\NNS\5225602|at|human|orl1 (l_compound) orl1_28\NN\1740|
T3_T24 NONE (+)-quadazocine_19\NN\1740| (r_nsubj) inactive_21\JJ\1740|since|(+)-quadazocine|is|receptors (r_advcl) appears_9\VBZ\2604760|addition|,|stereospecificity|retained|,|inactive|. (l_nsubj) stereospecificity_4\NN\1740|the|required (l_acl) required_5\VBN\754942|receptors (l_nmod) receptors_8\NNS\5225602|at|opioid
T3_T25 NONE (+)-quadazocine_19\NN\1740| (r_nsubj) inactive_21\JJ\1740|since|(+)-quadazocine|is|receptors (r_advcl) appears_9\VBZ\2604760|addition|,|stereospecificity|retained|,|inactive|. (l_xcomp) retained_12\VBN\2700867|to|be|receptor (l_nmod) receptor_16\NN\5225602|at|the|nociceptin
1687367
T19_T27 NONE labetalol_7\NNP\2721160|of|and|stereoisomers (r_nmod) activities_5\NNS\30358|alpha-|blocking|labetalol|. (l_amod) alpha-_1\NN\1740|the|and|beta-adrenoceptor (l_conj) beta-adrenoceptor_3\NN\5608868|
T17_T25 NONE labetalol_16\NN\2721160|of (r_nmod) potencies_14\NNS\5196375|the|1-adrenoceptor|blocking|labetalol (l_compound) 1-adrenoceptor_12\NN\1740|alpha
T2_T20 NONE labetalol_14\NN\2721160|as (r_nmod) potent_12\JJ\1740|dosing|,|combination|was|twice|labetalol|terms|. (l_nmod) terms_16\NNS\13945919|in|1-|doses (l_nmod) 1-_19\CD\1740|of|alpha|and|1-adrenoceptor|antagonism (l_conj) 1-adrenoceptor_22\NN\1740|beta
T3_T21 NONE labetalol_2\NN\2721160|and|enantiomers (r_nsubj) lacked_6\VBD\1740|4|labetalol|affinity|2-adrenoceptors|prazosin|. (l_nmod) 2-adrenoceptors_10\NNS\1740|at|alpha
T3_T22 NONE labetalol_2\NN\2721160|and|enantiomers (r_nsubj) lacked_6\VBD\1740|4|labetalol|affinity|2-adrenoceptors|prazosin|. (l_advcl) prazosin_20\NN\2698769|while|1-adrenoceptors|order|was|greater (l_nmod) 1-adrenoceptors_14\NNS\1740|at|alpha
T4_T21 NONE prazosin_20\NN\2698769|while|1-adrenoceptors|order|was|greater (r_advcl) lacked_6\VBD\1740|4|labetalol|affinity|2-adrenoceptors|prazosin|. (l_nmod) 2-adrenoceptors_10\NNS\1740|at|alpha
T4_T22 NONE prazosin_20\NN\2698769|while|1-adrenoceptors|order|was|greater (l_nmod) 1-adrenoceptors_14\NNS\1740|at|alpha
T5_T21 NONE labetalol_27\NN\2721160|than (r_nmod) greater_25\JJR\1740|labetalol (r_amod) rr-sr_24\NN\1740|than|greater (r_nmod) greater_22\JJR\1740|much|rr-sr (r_amod) prazosin_20\NN\2698769|while|1-adrenoceptors|order|was|greater (r_advcl) lacked_6\VBD\1740|4|labetalol|affinity|2-adrenoceptors|prazosin|. (l_nmod) 2-adrenoceptors_10\NNS\1740|at|alpha
T5_T22 NONE labetalol_27\NN\2721160|than (r_nmod) greater_25\JJR\1740|labetalol (r_amod) rr-sr_24\NN\1740|than|greater (r_nmod) greater_22\JJR\1740|much|rr-sr (r_amod) prazosin_20\NN\2698769|while|1-adrenoceptors|order|was|greater (l_nmod) 1-adrenoceptors_14\NNS\1740|at|alpha
T6_T23 NONE labetalol.5_16\NN\1740|of (r_nmod) that_14\DT\1740|1-adrenoceptors|,|affinity|was|3|labetalol.5|. (l_nmod) 1-adrenoceptors_2\NNS\1740|at|beta
T7_T24 NONE labetalol_1\NN\2721160| (r_nsubj) mixture_4\NN\19613|as|labetalol|is|a|enantiomers (r_advcl) substitute_41\NN\5695554|mixture|(|terms|,|combination|may|be|a|valuable|labetalol|treatment|. (l_nmod) terms_22\NNS\13945919|in|actions|) (l_nmod) actions_28\NNS\30358|of|alpha|receptor (l_compound) receptor_27\NN\5225602|
T8_T24 NONE labetalol_43\NN\2721160|for (r_nmod) substitute_41\NN\5695554|mixture|(|terms|,|combination|may|be|a|valuable|labetalol|treatment|. (l_nmod) terms_22\NNS\13945919|in|actions|) (l_nmod) actions_28\NNS\30358|of|alpha|receptor (l_compound) receptor_27\NN\5225602|
23002036
T7_T64 NONE glucose-dependent_6\JJ\1740| (r_amod) receptor_9\NN\5225602|adipocyte|glucose-dependent|insulinotropic|polypeptide|gipr (r_compound) expression_13\NN\4679549|impaired|receptor (r_dobj) exhibit_3\VBP\2632167|mice|expression|. (l_nsubj) mice_2\NNS\2329401|resistin|knockout (l_compound) resistin_0\NN\1740|
T7_T65 NONE glucose-dependent_6\JJ\1740| (r_amod) receptor_9\NN\5225602|adipocyte|glucose-dependent|insulinotropic|polypeptide|gipr (l_appos) gipr_11\NN\1740|(|)
T7_T66 NONE glucose-dependent_6\JJ\1740| (r_amod) receptor_9\NN\5225602|adipocyte|glucose-dependent|insulinotropic|polypeptide|gipr
T1_T41 NONE glucose-dependent_0\JJ\1740| (r_amod) polypeptide_2\NN\14743046|glucose-dependent|insulinotropic|gip (l_appos) gip_4\NN\1740|(|)
T1_T45 NONE glucose-dependent_0\JJ\1740| (r_amod) polypeptide_2\NN\14743046|glucose-dependent|insulinotropic|gip (r_nsubj) hormone_9\NN\5404728|polypeptide|is|an|incretin|plays|.
T1_T8 NONE glucose-dependent_0\JJ\1740| (r_amod) polypeptide_2\NN\14743046|glucose-dependent|insulinotropic|gip
T5_T24 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (r_conj) b1_38\NN\1740|of|liver|kinase|lkb1|and|kinase (r_nmod) phosphorylation_34\NN\1740|reduced|b1 (r_conj) activation_24\NN\13561719|involving|b|and|phosphorylation (r_nmod) mediator_11\NN\10351874|to|be|a|key|stimulation|,|activation (r_xcomp) demonstrated_6\VBN\2137132|cells|,|resistin|was|mediator|. (l_nsubjpass) resistin_4\NN\1740|
T5_T31 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (r_conj) b1_38\NN\1740|of|liver|kinase|lkb1|and|kinase (r_nmod) phosphorylation_34\NN\1740|reduced|b1 (r_conj) activation_24\NN\13561719|involving|b|and|phosphorylation (r_nmod) mediator_11\NN\10351874|to|be|a|key|stimulation|,|activation (l_nmod) stimulation_14\NN\242808|of|gip|activity (l_compound) gip_13\NN\1740|
T5_T32 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (r_conj) b1_38\NN\1740|of|liver|kinase|lkb1|and|kinase (r_nmod) phosphorylation_34\NN\1740|reduced|b1 (r_conj) activation_24\NN\13561719|involving|b|and|phosphorylation (r_nmod) mediator_11\NN\10351874|to|be|a|key|stimulation|,|activation (l_nmod) stimulation_14\NN\242808|of|gip|activity (l_nmod) activity_21\NN\30358|of|lipase (l_compound) lipase_17\NN\14732946|lipoprotein|lpl
T5_T33 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (r_conj) b1_38\NN\1740|of|liver|kinase|lkb1|and|kinase (r_nmod) phosphorylation_34\NN\1740|reduced|b1 (r_conj) activation_24\NN\13561719|involving|b|and|phosphorylation (r_nmod) mediator_11\NN\10351874|to|be|a|key|stimulation|,|activation (l_nmod) stimulation_14\NN\242808|of|gip|activity (l_nmod) activity_21\NN\30358|of|lipase (l_compound) lipase_17\NN\14732946|lipoprotein|lpl (l_appos) lpl_19\NN\1740|(|)
T5_T34 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (r_conj) b1_38\NN\1740|of|liver|kinase|lkb1|and|kinase (r_nmod) phosphorylation_34\NN\1740|reduced|b1 (r_conj) activation_24\NN\13561719|involving|b|and|phosphorylation (l_nmod) b_28\NN\1355326|of|protein|kinase|pkb
T5_T35 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (r_conj) b1_38\NN\1740|of|liver|kinase|lkb1|and|kinase (r_nmod) phosphorylation_34\NN\1740|reduced|b1 (r_conj) activation_24\NN\13561719|involving|b|and|phosphorylation (l_nmod) b_28\NN\1355326|of|protein|kinase|pkb (l_appos) pkb_30\NN\1740|(|)
T5_T36 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (r_conj) b1_38\NN\1740|of|liver|kinase|lkb1|and|kinase
T5_T37 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (r_conj) b1_38\NN\1740|of|liver|kinase|lkb1|and|kinase (l_appos) lkb1_40\NN\1740|(|)
T5_T38 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk
T5_T39 NONE amp-activated_43\JJ\1740| (r_amod) kinase_45\NN\14732946|amp-activated|protein|ampk (l_appos) ampk_47\NN\1740|(|)
T6_T43 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (r_ccomp) found_16\VBD\2426171|analysis|stimulated|. (l_nsubj) analysis_0\NN\633864|adipocytes (l_nmod) adipocytes_3\NNS\1740|of|primary|isolated (l_acl) isolated_4\VBN\2512305|mice (l_nmod) mice_15\NNS\2329401|from|retn(-/- (l_amod) retn(-/-_6\JJ\1740|)|,|retn(+/-|)|,|and|retn(+/+
T6_T44 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (r_ccomp) found_16\VBD\2426171|analysis|stimulated|. (l_nsubj) analysis_0\NN\633864|adipocytes (l_nmod) adipocytes_3\NNS\1740|of|primary|isolated (l_acl) isolated_4\VBN\2512305|mice (l_nmod) mice_15\NNS\2329401|from|retn(-/- (l_amod) retn(-/-_6\JJ\1740|)|,|retn(+/-|)|,|and|retn(+/+ (l_conj) retn(+/-_9\JJ\1740|
T6_T46 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (r_ccomp) found_16\VBD\2426171|analysis|stimulated|. (l_nsubj) analysis_0\NN\633864|adipocytes (l_nmod) adipocytes_3\NNS\1740|of|primary|isolated (l_acl) isolated_4\VBN\2512305|mice (l_nmod) mice_15\NNS\2329401|from|retn(-/- (l_amod) retn(-/-_6\JJ\1740|)|,|retn(+/-|)|,|and|retn(+/+ (l_conj) retn(+/+_13\JJ\1740|)
T6_T47 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (l_nsubj) gip_18\NN\1740|
T6_T48 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (l_compound) pkb/lkb1/ampk/lpl_21\NN\1740|
T6_T49 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (l_compound) pkb/lkb1/ampk/lpl_21\NN\1740|
T6_T50 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (l_compound) pkb/lkb1/ampk/lpl_21\NN\1740|
T6_T51 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (l_compound) pkb/lkb1/ampk/lpl_21\NN\1740|
T6_T52 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (l_nmod) adipocytes_31\NNS\1740|only|in|retn(+/+ (l_amod) retn(+/+_29\JJ\1740|)
T6_T53 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (l_advcl) suggesting_33\VBG\1010118|compromised (l_ccomp) compromised_41\VBN\1035530|that|signaling|were|retn(+/- (l_nsubjpass) signaling_36\NN\33020|gip|and/or|responsiveness (l_compound) gip_35\NN\1740|
T6_T54 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (l_advcl) suggesting_33\VBG\1010118|compromised (l_ccomp) compromised_41\VBN\1035530|that|signaling|were|retn(+/- (l_nsubjpass) signaling_36\NN\33020|gip|and/or|responsiveness (l_conj) responsiveness_39\NN\5652926|gip (l_compound) gip_38\NN\1740|
T6_T55 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (l_advcl) suggesting_33\VBG\1010118|compromised (l_ccomp) compromised_41\VBN\1035530|that|signaling|were|retn(+/- (l_nmod) retn(+/-_43\JJ\1740|in|)|and|retn(-/-|adipocytes
T6_T56 NONE acid_25\NN\14818238| (r_compound) uptake_26\NN\13440063|fatty|acid (r_conj) pathway_22\NN\5483677|the|pkb/lkb1/ampk/lpl|and|uptake (r_dobj) stimulated_19\VBD\137313|that|gip|pathway|adipocytes|,|suggesting (l_advcl) suggesting_33\VBG\1010118|compromised (l_ccomp) compromised_41\VBN\1035530|that|signaling|were|retn(+/- (l_nmod) retn(+/-_43\JJ\1740|in|)|and|retn(-/-|adipocytes (l_conj) retn(-/-_46\JJ\1740|)
T2_T10 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (r_dep) proteins_22\NNS\14944888|the|signaling|kinase (r_conj) factor_7\NN\7326557|tumor|necrosis|tnf|,|receptor|,|and|proteins (l_conj) receptor_13\NN\5225602|tnf|2|tnfr2 (l_nummod) 2_14\CD\13741022|
T2_T11 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (r_dep) proteins_22\NNS\14944888|the|signaling|kinase (r_conj) factor_7\NN\7326557|tumor|necrosis|tnf|,|receptor|,|and|proteins (l_conj) receptor_13\NN\5225602|tnf|2|tnfr2 (l_appos) tnfr2_16\NN\1740|(|)
T2_T12 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (l_compound) kinase_25\NN\14732946|protein
T2_T13 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (l_compound) (sapk)/jun_26\NN\1740|
T2_T14 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk
T2_T15 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (l_appos) jnk_30\NN\1740|(|)
T2_T16 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (r_dep) proteins_22\NNS\14944888|the|signaling|kinase (r_conj) factor_7\NN\7326557|tumor|necrosis|tnf|,|receptor|,|and|proteins (r_dobj) encoding_4\VBG\115157|factor (r_acl) genes_3\NNS\8459252|encoding|, (r_nsubjpass) downregulated_34\VBN\1740|addition|,|genes|were|,|and|decreased|. (l_conj) decreased_42\VBN\169651|levels|were|mice (l_nsubjpass) levels_38\NNS\4916342|phosphorylated|sapk/jnk/c-jun (l_nmod) sapk/jnk/c-jun_40\NN\1740|of
T2_T17 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (r_dep) proteins_22\NNS\14944888|the|signaling|kinase (r_conj) factor_7\NN\7326557|tumor|necrosis|tnf|,|receptor|,|and|proteins (r_dobj) encoding_4\VBG\115157|factor (r_acl) genes_3\NNS\8459252|encoding|, (r_nsubjpass) downregulated_34\VBN\1740|addition|,|genes|were|,|and|decreased|. (l_conj) decreased_42\VBN\169651|levels|were|mice (l_nsubjpass) levels_38\NNS\4916342|phosphorylated|sapk/jnk/c-jun (l_nmod) sapk/jnk/c-jun_40\NN\1740|of
T2_T18 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (r_dep) proteins_22\NNS\14944888|the|signaling|kinase (r_conj) factor_7\NN\7326557|tumor|necrosis|tnf|,|receptor|,|and|proteins (r_dobj) encoding_4\VBG\115157|factor (r_acl) genes_3\NNS\8459252|encoding|, (r_nsubjpass) downregulated_34\VBN\1740|addition|,|genes|were|,|and|decreased|. (l_conj) decreased_42\VBN\169651|levels|were|mice (l_nsubjpass) levels_38\NNS\4916342|phosphorylated|sapk/jnk/c-jun (l_nmod) sapk/jnk/c-jun_40\NN\1740|of
T2_T19 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (r_dep) proteins_22\NNS\14944888|the|signaling|kinase (r_conj) factor_7\NN\7326557|tumor|necrosis|tnf|,|receptor|,|and|proteins (r_dobj) encoding_4\VBG\115157|factor (r_acl) genes_3\NNS\8459252|encoding|, (r_nsubjpass) downregulated_34\VBN\1740|addition|,|genes|were|,|and|decreased|. (l_conj) decreased_42\VBN\169651|levels|were|mice (l_nmod) mice_46\NNS\2329401|in|retn(-/- (l_compound) retn(-/-_44\NN\1740|)
T2_T63 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (r_dep) proteins_22\NNS\14944888|the|signaling|kinase (r_conj) factor_7\NN\7326557|tumor|necrosis|tnf|,|receptor|,|and|proteins
T2_T9 NONE nh(2)-terminal_27\JJ\1740| (r_amod) kinase_28\NN\14732946|stress-activated|kinase|(sapk)/jun|nh(2)-terminal|jnk (r_dep) proteins_22\NNS\14944888|the|signaling|kinase (r_conj) factor_7\NN\7326557|tumor|necrosis|tnf|,|receptor|,|and|proteins (l_appos) tnf_9\NN\14828193|(|)
T3_T20 NONE 12-o-tetradecanoylphorbol-13-acetate_8\NN\1740| (r_compound) element_10\NN\5867413|a|12-o-tetradecanoylphorbol-13-acetate|(tpa)-response|tre-iii|responsible
T3_T21 NONE 12-o-tetradecanoylphorbol-13-acetate_8\NN\1740| (r_compound) element_10\NN\5867413|a|12-o-tetradecanoylphorbol-13-acetate|(tpa)-response|tre-iii|responsible (l_appos) tre-iii_12\NN\1740|(|)
T3_T22 NONE 12-o-tetradecanoylphorbol-13-acetate_8\NN\1740| (r_compound) element_10\NN\5867413|a|12-o-tetradecanoylphorbol-13-acetate|(tpa)-response|tre-iii|responsible (l_amod) responsible_14\JJ\1740|activation (l_nmod) activation_18\NN\13561719|for|c-jun-mediated|transcriptional|gipr (l_amod) c-jun-mediated_16\JJ\1740|
T3_T23 NONE 12-o-tetradecanoylphorbol-13-acetate_8\NN\1740| (r_compound) element_10\NN\5867413|a|12-o-tetradecanoylphorbol-13-acetate|(tpa)-response|tre-iii|responsible (l_amod) responsible_14\JJ\1740|activation (l_nmod) activation_18\NN\13561719|for|c-jun-mediated|transcriptional|gipr (l_nmod) gipr_20\NN\1740|of
T4_T20 NONE (tpa)-response_9\NN\1740| (r_punct) element_10\NN\5867413|a|12-o-tetradecanoylphorbol-13-acetate|(tpa)-response|tre-iii|responsible
T4_T21 NONE (tpa)-response_9\NN\1740| (r_punct) element_10\NN\5867413|a|12-o-tetradecanoylphorbol-13-acetate|(tpa)-response|tre-iii|responsible (l_appos) tre-iii_12\NN\1740|(|)
T4_T22 NONE (tpa)-response_9\NN\1740| (r_punct) element_10\NN\5867413|a|12-o-tetradecanoylphorbol-13-acetate|(tpa)-response|tre-iii|responsible (l_amod) responsible_14\JJ\1740|activation (l_nmod) activation_18\NN\13561719|for|c-jun-mediated|transcriptional|gipr (l_amod) c-jun-mediated_16\JJ\1740|
T4_T23 NONE (tpa)-response_9\NN\1740| (r_punct) element_10\NN\5867413|a|12-o-tetradecanoylphorbol-13-acetate|(tpa)-response|tre-iii|responsible (l_amod) responsible_14\JJ\1740|activation (l_nmod) activation_18\NN\13561719|for|c-jun-mediated|transcriptional|gipr (l_nmod) gipr_20\NN\1740|of
17229090
T10_T48 NONE calcium_3\NN\14625458| (r_compound) cyclases_5\NNS\1740|of|the|calcium|modulated
T11_T48 NONE retinal_11\JJ\1740| (r_amod) projections_12\NNS\5775081|of|the|retinal (r_nmod) development_8\NN\248977|in|the|projections (r_nmod) role_0\NN\719494|cyclases|development|. (l_nmod) cyclases_5\NNS\1740|of|the|calcium|modulated
T3_T24 CPR:9 camp_23\NN\3763727| (r_compound) production_24\NN\30358|camp (r_dobj) regulate_22\VB\296178|can|also|production|response (r_conj) integrate_8\VBP\1461328|isoforms|variety|morphogens|and|regulate|. (l_nsubj) isoforms_1\NNS\1740|transmembrane|cyclases (l_nmod) cyclases_4\NNS\1740|of|adenylate|ac
T3_T28 CPR:9 camp_23\NN\3763727| (r_compound) production_24\NN\30358|camp (r_dobj) regulate_22\VB\296178|can|also|production|response (r_conj) integrate_8\VBP\1461328|isoforms|variety|morphogens|and|regulate|. (l_nsubj) isoforms_1\NNS\1740|transmembrane|cyclases (l_nmod) cyclases_4\NNS\1740|of|adenylate|ac (l_appos) ac_6\NNS\14622893|(|)
T4_T24 NONE calcium_28\NN\14625458| (r_compound) entry_29\NN\6502378|to|calcium (r_nmod) response_26\NN\11410625|in|entry (r_nmod) regulate_22\VB\296178|can|also|production|response (r_conj) integrate_8\VBP\1461328|isoforms|variety|morphogens|and|regulate|. (l_nsubj) isoforms_1\NNS\1740|transmembrane|cyclases (l_nmod) cyclases_4\NNS\1740|of|adenylate|ac
T4_T28 NONE calcium_28\NN\14625458| (r_compound) entry_29\NN\6502378|to|calcium (r_nmod) response_26\NN\11410625|in|entry (r_nmod) regulate_22\VB\296178|can|also|production|response (r_conj) integrate_8\VBP\1461328|isoforms|variety|morphogens|and|regulate|. (l_nsubj) isoforms_1\NNS\1740|transmembrane|cyclases (l_nmod) cyclases_4\NNS\1740|of|adenylate|ac (l_appos) ac_6\NNS\14622893|(|)
T5_T24 NONE adenylate_3\NN\1740| (r_compound) cyclases_4\NNS\1740|of|adenylate|ac
T5_T28 NONE adenylate_3\NN\1740| (r_compound) cyclases_4\NNS\1740|of|adenylate|ac (l_appos) ac_6\NNS\14622893|(|)
T6_T23 NONE retinal_22\JJ\1740| (r_amod) inputs_23\NNS\6791372|of|binocular|retinal (r_nmod) segregation_19\NN\13526110|in|the|inputs (r_nmod) involved_16\VBN\2676054|observations|,|gene|was|segregation|. (l_nsubjpass) gene_11\NN\8459252|the|adcy1|ac1 (l_compound) adcy1_10\NN\1740|
T6_T25 NONE retinal_22\JJ\1740| (r_amod) inputs_23\NNS\6791372|of|binocular|retinal (r_nmod) segregation_19\NN\13526110|in|the|inputs (r_nmod) involved_16\VBN\2676054|observations|,|gene|was|segregation|. (l_nsubjpass) gene_11\NN\8459252|the|adcy1|ac1 (l_appos) ac1_13\NN\1740|(|)
T7_T44 NONE calcium_10\NN\14625458| (r_nmod:npmod) modulated_11\JJ\1740|calcium (r_amod) cyclases_12\NNS\1740|of|the|modulated|ac1|fibres
T7_T45 NONE calcium_10\NN\14625458| (r_nmod:npmod) modulated_11\JJ\1740|calcium (r_amod) cyclases_12\NNS\1740|of|the|modulated|ac1|fibres (l_dep) ac1_13\NN\1740|,|ac5|and|ac8
T7_T46 NONE calcium_10\NN\14625458| (r_nmod:npmod) modulated_11\JJ\1740|calcium (r_amod) cyclases_12\NNS\1740|of|the|modulated|ac1|fibres (l_dep) ac1_13\NN\1740|,|ac5|and|ac8 (l_conj) ac5_15\NN\1740|
T7_T47 NONE calcium_10\NN\14625458| (r_nmod:npmod) modulated_11\JJ\1740|calcium (r_amod) cyclases_12\NNS\1740|of|the|modulated|ac1|fibres (l_dep) ac1_13\NN\1740|,|ac5|and|ac8 (l_conj) ac8_17\NN\1740|
T8_T44 NONE retinal_21\JJ\1740| (r_amod) fibres_22\NNS\14580897|for|the|segregation|retinal (r_nmod) cyclases_12\NNS\1740|of|the|modulated|ac1|fibres
T8_T45 NONE retinal_21\JJ\1740| (r_amod) fibres_22\NNS\14580897|for|the|segregation|retinal (r_nmod) cyclases_12\NNS\1740|of|the|modulated|ac1|fibres (l_dep) ac1_13\NN\1740|,|ac5|and|ac8
T8_T46 NONE retinal_21\JJ\1740| (r_amod) fibres_22\NNS\14580897|for|the|segregation|retinal (r_nmod) cyclases_12\NNS\1740|of|the|modulated|ac1|fibres (l_dep) ac1_13\NN\1740|,|ac5|and|ac8 (l_conj) ac5_15\NN\1740|
T8_T47 NONE retinal_21\JJ\1740| (r_amod) fibres_22\NNS\14580897|for|the|segregation|retinal (r_nmod) cyclases_12\NNS\1740|of|the|modulated|ac1|fibres (l_dep) ac1_13\NN\1740|,|ac5|and|ac8 (l_conj) ac8_17\NN\1740|
T1_T12 NONE retinal_13\JJ\1740| (r_amod) projections_14\NNS\5775081|with|overlapping|retinal|eyes (r_nmod) remained_3\VBD\2604760|axons|exuberant|mice|,|projections|. (l_nmod) mice_9\NNS\2329401|in|the|ac1(-/- (l_compound) ac1(-/-_7\NN\1740|)
T9_T12 NONE retinal_1\JJ\1740| (r_amod) axons_2\NNS\5464104|ipsilateral|retinal (r_nsubj) remained_3\VBD\2604760|axons|exuberant|mice|,|projections|. (l_nmod) mice_9\NNS\2329401|in|the|ac1(-/- (l_compound) ac1(-/-_7\NN\1740|)
T2_T18 NONE retinal_11\JJ\1740| (r_amod) terminals_13\NNS\4306080|of|the|retinal|axon (r_nmod) maturation_8\NN\13526110|for|the|terminals (r_nmod) required_5\VBN\754942|thus|,|ac1|is|maturation|needed|. (l_nsubjpass) ac1_3\NN\1740|only
T2_T19 NONE retinal_11\JJ\1740| (r_amod) terminals_13\NNS\4306080|of|the|retinal|axon (r_nmod) maturation_8\NN\13526110|for|the|terminals (r_nmod) required_5\VBN\754942|thus|,|ac1|is|maturation|needed|. (l_advcl) needed_20\VBN\2604760|whereas|ac5|are|not (l_nsubjpass) ac5_15\NN\1740|and|ac8
T2_T20 NONE retinal_11\JJ\1740| (r_amod) terminals_13\NNS\4306080|of|the|retinal|axon (r_nmod) maturation_8\NN\13526110|for|the|terminals (r_nmod) required_5\VBN\754942|thus|,|ac1|is|maturation|needed|. (l_advcl) needed_20\VBN\2604760|whereas|ac5|are|not (l_nsubjpass) ac5_15\NN\1740|and|ac8 (l_conj) ac8_17\NN\1740|
23585333
23254198
T14_T22 CPR:4 bza_45\NN\1740|by (r_nmod) blocked_43\VBN\1476483|increased|,|effects|could|be|completely|bza|. (l_ccomp) increased_6\VBD\169651|ce|synthesis|and|reduced (l_conj) reduced_10\VBD\441445|apoptosis|activation (l_nmod) activation_13\NN\13561719|with|mapk|and|up-regulation (l_nmod) mapk_15\NN\1740|of|,|akt|,|and|p70s6|k
T14_T23 CPR:4 bza_45\NN\1740|by (r_nmod) blocked_43\VBN\1476483|increased|,|effects|could|be|completely|bza|. (l_ccomp) increased_6\VBD\169651|ce|synthesis|and|reduced (l_conj) reduced_10\VBD\441445|apoptosis|activation (l_nmod) activation_13\NN\13561719|with|mapk|and|up-regulation (l_nmod) mapk_15\NN\1740|of|,|akt|,|and|p70s6|k (l_conj) akt_17\NN\1740|
T14_T24 CPR:4 bza_45\NN\1740|by (r_nmod) blocked_43\VBN\1476483|increased|,|effects|could|be|completely|bza|. (l_ccomp) increased_6\VBD\169651|ce|synthesis|and|reduced (l_conj) reduced_10\VBD\441445|apoptosis|activation (l_nmod) activation_13\NN\13561719|with|mapk|and|up-regulation (l_nmod) mapk_15\NN\1740|of|,|akt|,|and|p70s6|k (l_conj) k_21\NN\13608598|
T14_T25 CPR:4 bza_45\NN\1740|by (r_nmod) blocked_43\VBN\1476483|increased|,|effects|could|be|completely|bza|. (l_ccomp) increased_6\VBD\169651|ce|synthesis|and|reduced (l_conj) reduced_10\VBD\441445|apoptosis|activation (l_nmod) activation_13\NN\13561719|with|mapk|and|up-regulation (l_conj) up-regulation_23\NN\1740|factors (l_nmod) factors_26\NNS\7326557|of|antiapoptotic|survivin (l_dep) survivin_27\NN\1740|,|bcl-2|,|and|inhibitor
T14_T26 CPR:4 bza_45\NN\1740|by (r_nmod) blocked_43\VBN\1476483|increased|,|effects|could|be|completely|bza|. (l_ccomp) increased_6\VBD\169651|ce|synthesis|and|reduced (l_conj) reduced_10\VBD\441445|apoptosis|activation (l_nmod) activation_13\NN\13561719|with|mapk|and|up-regulation (l_conj) up-regulation_23\NN\1740|factors (l_nmod) factors_26\NNS\7326557|of|antiapoptotic|survivin (l_dep) survivin_27\NN\1740|,|bcl-2|,|and|inhibitor (l_conj) bcl-2_29\NN\1740|
T14_T27 CPR:4 bza_45\NN\1740|by (r_nmod) blocked_43\VBN\1476483|increased|,|effects|could|be|completely|bza|. (l_ccomp) increased_6\VBD\169651|ce|synthesis|and|reduced (l_conj) reduced_10\VBD\441445|apoptosis|activation (l_nmod) activation_13\NN\13561719|with|mapk|and|up-regulation (l_conj) up-regulation_23\NN\1740|factors (l_nmod) factors_26\NNS\7326557|of|antiapoptotic|survivin (l_dep) survivin_27\NN\1740|,|bcl-2|,|and|inhibitor (l_conj) inhibitor_33\NN\20090|x-linked|protein (l_nmod) protein_36\NN\14944888|of|apoptosis
T1_T17 NONE progesterone_34\NN\14747338| (r_compound) receptor_35\NN\5225602|on|progesterone|and|amphiregulin (r_compound) expression_38\NN\4679549|receptor (r_nmod) effects_30\NNS\13245626|the|stimulatory|ce|expression (r_nsubj) weaker_40\JJR\1740|whereas|effects|were|e(2 (r_advcl) potent_11\JJ\1740|that|ce|were|equally|expression|,|weaker (l_nmod) expression_13\NN\4679549|on|cmyc (l_nmod) cmyc_15\NN\1740|of|,|ps2|,|and|protein
T1_T18 NONE progesterone_34\NN\14747338| (r_compound) receptor_35\NN\5225602|on|progesterone|and|amphiregulin (r_compound) expression_38\NN\4679549|receptor (r_nmod) effects_30\NNS\13245626|the|stimulatory|ce|expression (r_nsubj) weaker_40\JJR\1740|whereas|effects|were|e(2 (r_advcl) potent_11\JJ\1740|that|ce|were|equally|expression|,|weaker (l_nmod) expression_13\NN\4679549|on|cmyc (l_nmod) cmyc_15\NN\1740|of|,|ps2|,|and|protein (l_conj) ps2_17\NN\1740|
T1_T19 NONE progesterone_34\NN\14747338| (r_compound) receptor_35\NN\5225602|on|progesterone|and|amphiregulin (r_compound) expression_38\NN\4679549|receptor (r_nmod) effects_30\NNS\13245626|the|stimulatory|ce|expression (r_nsubj) weaker_40\JJR\1740|whereas|effects|were|e(2 (r_advcl) potent_11\JJ\1740|that|ce|were|equally|expression|,|weaker (l_nmod) expression_13\NN\4679549|on|cmyc (l_nmod) cmyc_15\NN\1740|of|,|ps2|,|and|protein (l_conj) protein_24\NN\14944888|wnt1|inducible|signaling|pathway|2 (l_nummod) 2_25\CD\13741022|
T1_T20 NONE progesterone_34\NN\14747338| (r_compound) receptor_35\NN\5225602|on|progesterone|and|amphiregulin
T1_T21 NONE progesterone_34\NN\14747338| (r_compound) receptor_35\NN\5225602|on|progesterone|and|amphiregulin (l_conj) amphiregulin_37\NN\1740|
23493568
T4_T16 NONE glucose_38\NN\14710501| (r_compound) intolerance_39\NN\4642596|to|glucose (r_nmod) leading_36\VBG\1752884|intolerance (r_acl) secretion_35\NN\13526110|insulin|leading (r_dobj) impair_33\VB\258857|to|secretion (r_xcomp) reported_31\VBN\831651|deficiency|has|been|impair|. (r_conj) factor_10\NN\7326557|protein|is|a|transcription|plays|and|reported (l_nsubj) protein_2\NN\14944888|x-box|binding|1|xbp1 (l_nummod) 1_3\CD\13741022|
T4_T17 NONE glucose_38\NN\14710501| (r_compound) intolerance_39\NN\4642596|to|glucose (r_nmod) leading_36\VBG\1752884|intolerance (r_acl) secretion_35\NN\13526110|insulin|leading (r_dobj) impair_33\VB\258857|to|secretion (r_xcomp) reported_31\VBN\831651|deficiency|has|been|impair|. (r_conj) factor_10\NN\7326557|protein|is|a|transcription|plays|and|reported (l_nsubj) protein_2\NN\14944888|x-box|binding|1|xbp1 (l_appos) xbp1_5\NN\1740|(|)
T4_T18 NONE glucose_38\NN\14710501| (r_compound) intolerance_39\NN\4642596|to|glucose (r_nmod) leading_36\VBG\1752884|intolerance (r_acl) secretion_35\NN\13526110|insulin|leading (l_compound) insulin_34\NN\5407119|
T5_T24 NONE glucose_3\NN\14710501| (r_compound) intolerance_4\NN\4642596|glucose|,|resistance|and|inability (r_dobj) exhibited_2\VBD\2632167|mice|intolerance|. (l_nsubj) mice_1\NNS\2329401|αxbpko (l_compound) αxbpko_0\NN\1740|
T5_T25 NONE glucose_3\NN\14710501| (r_compound) intolerance_4\NN\4642596|glucose|,|resistance|and|inability (l_conj) resistance_8\NN\37396|mild|insulin (l_compound) insulin_7\NN\5407119|
T5_T26 NONE glucose_3\NN\14710501| (r_compound) intolerance_4\NN\4642596|glucose|,|resistance|and|inability (l_conj) inability_11\NN\23271|an|suppress (l_acl) suppress_13\VB\2510337|to|secretion|stimulation (l_dobj) secretion_15\NN\13526110|glucagon (l_compound) glucagon_14\NN\5407119|
T6_T24 NONE glucose_17\NN\14710501| (r_compound) stimulation_18\NN\242808|following|glucose (r_nmod) suppress_13\VB\2510337|to|secretion|stimulation (r_acl) inability_11\NN\23271|an|suppress (r_conj) intolerance_4\NN\4642596|glucose|,|resistance|and|inability (r_dobj) exhibited_2\VBD\2632167|mice|intolerance|. (l_nsubj) mice_1\NNS\2329401|αxbpko (l_compound) αxbpko_0\NN\1740|
T6_T25 NONE glucose_17\NN\14710501| (r_compound) stimulation_18\NN\242808|following|glucose (r_nmod) suppress_13\VB\2510337|to|secretion|stimulation (r_acl) inability_11\NN\23271|an|suppress (r_conj) intolerance_4\NN\4642596|glucose|,|resistance|and|inability (l_conj) resistance_8\NN\37396|mild|insulin (l_compound) insulin_7\NN\5407119|
T6_T26 NONE glucose_17\NN\14710501| (r_compound) stimulation_18\NN\242808|following|glucose (r_nmod) suppress_13\VB\2510337|to|secretion|stimulation (l_dobj) secretion_15\NN\13526110|glucagon (l_compound) glucagon_14\NN\5407119|
T1_T31 NONE tyrosine_8\NN\14601829| (r_compound) phosphorylation_9\NN\1740|tyrosine|irs-1|,|and|phosphorylation (r_dobj) reduced_7\VBD\441445|interestingly|,|treatment|phosphorylation|,|enhancing|. (l_nsubj) treatment_3\NN\654885|insulin|cells (l_compound) insulin_2\NN\5407119|
T1_T32 NONE tyrosine_8\NN\14601829| (r_compound) phosphorylation_9\NN\1740|tyrosine|irs-1|,|and|phosphorylation (r_dobj) reduced_7\VBD\441445|interestingly|,|treatment|phosphorylation|,|enhancing|. (l_nsubj) treatment_3\NN\654885|insulin|cells (l_nmod) cells_6\NNS\3080309|of|αxbpkd (l_compound) αxbpkd_5\NN\1740|
T1_T7 NONE tyrosine_8\NN\14601829| (r_compound) phosphorylation_9\NN\1740|tyrosine|irs-1|,|and|phosphorylation (l_nmod) irs-1_11\NN\1740|of|py(896
T1_T8 NONE tyrosine_8\NN\14601829| (r_compound) phosphorylation_9\NN\1740|tyrosine|irs-1|,|and|phosphorylation (l_conj) phosphorylation_18\NN\1740|akt (l_nmod) akt_20\NN\1740|of
T1_T9 NONE tyrosine_8\NN\14601829| (r_compound) phosphorylation_9\NN\1740|tyrosine|irs-1|,|and|phosphorylation (r_dobj) reduced_7\VBD\441445|interestingly|,|treatment|phosphorylation|,|enhancing|. (l_advcl) enhancing_23\VBG\227165|while|phosphorylation (l_dobj) phosphorylation_25\NN\1740|serine|ps(307|irs-1 (l_nmod) irs-1_31\NN\1740|of
T2_T31 NONE serine_24\NN\14601829| (r_compound) phosphorylation_25\NN\1740|serine|ps(307|irs-1 (r_dobj) enhancing_23\VBG\227165|while|phosphorylation (r_advcl) reduced_7\VBD\441445|interestingly|,|treatment|phosphorylation|,|enhancing|. (l_nsubj) treatment_3\NN\654885|insulin|cells (l_compound) insulin_2\NN\5407119|
T2_T32 NONE serine_24\NN\14601829| (r_compound) phosphorylation_25\NN\1740|serine|ps(307|irs-1 (r_dobj) enhancing_23\VBG\227165|while|phosphorylation (r_advcl) reduced_7\VBD\441445|interestingly|,|treatment|phosphorylation|,|enhancing|. (l_nsubj) treatment_3\NN\654885|insulin|cells (l_nmod) cells_6\NNS\3080309|of|αxbpkd (l_compound) αxbpkd_5\NN\1740|
T2_T7 NONE serine_24\NN\14601829| (r_compound) phosphorylation_25\NN\1740|serine|ps(307|irs-1 (r_dobj) enhancing_23\VBG\227165|while|phosphorylation (r_advcl) reduced_7\VBD\441445|interestingly|,|treatment|phosphorylation|,|enhancing|. (l_dobj) phosphorylation_9\NN\1740|tyrosine|irs-1|,|and|phosphorylation (l_nmod) irs-1_11\NN\1740|of|py(896
T2_T8 NONE serine_24\NN\14601829| (r_compound) phosphorylation_25\NN\1740|serine|ps(307|irs-1 (r_dobj) enhancing_23\VBG\227165|while|phosphorylation (r_advcl) reduced_7\VBD\441445|interestingly|,|treatment|phosphorylation|,|enhancing|. (l_dobj) phosphorylation_9\NN\1740|tyrosine|irs-1|,|and|phosphorylation (l_conj) phosphorylation_18\NN\1740|akt (l_nmod) akt_20\NN\1740|of
T2_T9 NONE serine_24\NN\14601829| (r_compound) phosphorylation_25\NN\1740|serine|ps(307|irs-1 (l_nmod) irs-1_31\NN\1740|of
T3_T10 NONE glucose_18\NN\14710501|of|high (r_nmod) presence_15\NN\13954253|in|the|glucose (r_nmod) exhibited_4\VBD\2632167|consequently|cells|suppression|treatment|presence|. (l_nsubj) cells_3\NNS\3080309|the|αxbpkd (l_compound) αxbpkd_2\NN\1740|
T3_T11 NONE glucose_18\NN\14710501|of|high (r_nmod) presence_15\NN\13954253|in|the|glucose (r_nmod) exhibited_4\VBD\2632167|consequently|cells|suppression|treatment|presence|. (l_dobj) suppression_6\NN\13489037|blunted|secretion (l_nmod) secretion_9\NN\13526110|of|glucagon (l_compound) glucagon_8\NN\5407119|
T3_T12 NONE glucose_18\NN\14710501|of|high (r_nmod) presence_15\NN\13954253|in|the|glucose (r_nmod) exhibited_4\VBD\2632167|consequently|cells|suppression|treatment|presence|. (l_nmod) treatment_12\NN\654885|following|insulin (l_compound) insulin_11\NN\5407119|
3094574
T26_T37 CPR:9 3,4-dihydroxymandelate_7\NN\1740|of (r_nmod) decarboxylation_5\NN\13446390|an|unusual|oxidative|3,4-dihydroxymandelate (r_dobj) catalyzes_1\VBZ\146138|tyrosinase|decarboxylation|. (l_nsubj) tyrosinase_0\NN\1740|
T12_T27 CPR:9 monophenols_6\NNS\1740|of (r_nmod) conversion_4\NN\7359599|the|monophenols|o-diphenols|and|oxidation (r_dobj) catalyzes_2\VBZ\146138|tyrosinase|usually|conversion|. (l_nsubj) tyrosinase_0\NN\1740|
T23_T27 CPR:9 diphenols_12\NNS\1740|of (r_nmod) oxidation_10\NN\13447361|diphenols|quinones (r_conj) conversion_4\NN\7359599|the|monophenols|o-diphenols|and|oxidation (r_dobj) catalyzes_2\VBZ\146138|tyrosinase|usually|conversion|. (l_nsubj) tyrosinase_0\NN\1740|
T13_T29 NONE galactose_11\NN\15062778| (r_compound) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase
T13_T30 NONE galactose_11\NN\15062778| (r_compound) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) ceruloplasmin_14\NN\1740|
T13_T31 NONE galactose_11\NN\15062778| (r_compound) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) dismutase_17\NN\1740|superoxide
T13_T32 NONE galactose_11\NN\15062778| (r_compound) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) oxidase_20\NN\14732946|ascorbate
T13_T33 NONE galactose_11\NN\15062778| (r_compound) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) beta-hydroxylase_23\NN\1740|dopamine
T13_T34 NONE galactose_11\NN\15062778| (r_compound) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) peroxidase_26\NN\14971234|
T14_T29 NONE superoxide_16\NN\14971519| (r_compound) dismutase_17\NN\1740|superoxide (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase
T14_T30 NONE superoxide_16\NN\14971519| (r_compound) dismutase_17\NN\1740|superoxide (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) ceruloplasmin_14\NN\1740|
T14_T31 NONE superoxide_16\NN\14971519| (r_compound) dismutase_17\NN\1740|superoxide
T14_T32 NONE superoxide_16\NN\14971519| (r_compound) dismutase_17\NN\1740|superoxide (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) oxidase_20\NN\14732946|ascorbate
T14_T33 NONE superoxide_16\NN\14971519| (r_compound) dismutase_17\NN\1740|superoxide (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) beta-hydroxylase_23\NN\1740|dopamine
T14_T34 NONE superoxide_16\NN\14971519| (r_compound) dismutase_17\NN\1740|superoxide (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) peroxidase_26\NN\14971234|
T15_T29 NONE ascorbate_19\NN\1740| (r_compound) oxidase_20\NN\14732946|ascorbate (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase
T15_T30 NONE ascorbate_19\NN\1740| (r_compound) oxidase_20\NN\14732946|ascorbate (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) ceruloplasmin_14\NN\1740|
T15_T31 NONE ascorbate_19\NN\1740| (r_compound) oxidase_20\NN\14732946|ascorbate (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) dismutase_17\NN\1740|superoxide
T15_T32 NONE ascorbate_19\NN\1740| (r_compound) oxidase_20\NN\14732946|ascorbate
T15_T33 NONE ascorbate_19\NN\1740| (r_compound) oxidase_20\NN\14732946|ascorbate (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) beta-hydroxylase_23\NN\1740|dopamine
T15_T34 NONE ascorbate_19\NN\1740| (r_compound) oxidase_20\NN\14732946|ascorbate (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) peroxidase_26\NN\14971234|
T16_T29 NONE dopamine_22\NN\14807737| (r_compound) beta-hydroxylase_23\NN\1740|dopamine (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase
T16_T30 NONE dopamine_22\NN\14807737| (r_compound) beta-hydroxylase_23\NN\1740|dopamine (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) ceruloplasmin_14\NN\1740|
T16_T31 NONE dopamine_22\NN\14807737| (r_compound) beta-hydroxylase_23\NN\1740|dopamine (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) dismutase_17\NN\1740|superoxide
T16_T32 NONE dopamine_22\NN\14807737| (r_compound) beta-hydroxylase_23\NN\1740|dopamine (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) oxidase_20\NN\14732946|ascorbate
T16_T33 NONE dopamine_22\NN\14807737| (r_compound) beta-hydroxylase_23\NN\1740|dopamine
T16_T34 NONE dopamine_22\NN\14807737| (r_compound) beta-hydroxylase_23\NN\1740|dopamine (r_conj) oxidase_12\NN\14732946|galactose|,|ceruloplasmin|,|dismutase|,|oxidase|,|beta-hydroxylase|,|and|peroxidase (l_conj) peroxidase_26\NN\14971234|
T17_T35 NONE phenol_0\NN\14727670| (r_compound) inhibitors_2\NNS\20090|phenol|oxidase|phenylthiourea (l_compound) oxidase_1\NN\14732946|
T18_T35 CPR:4 phenylthiourea_5\NN\1740|such|,|cyanide|,|and|azide (r_nmod) inhibitors_2\NNS\20090|phenol|oxidase|phenylthiourea (l_compound) oxidase_1\NN\14732946|
T19_T35 CPR:4 cyanide_8\NN\14727670|potassium (r_conj) phenylthiourea_5\NN\1740|such|,|cyanide|,|and|azide (r_nmod) inhibitors_2\NNS\20090|phenol|oxidase|phenylthiourea (l_compound) oxidase_1\NN\14732946|
T20_T35 CPR:4 azide_12\NN\14818238|sodium (r_conj) phenylthiourea_5\NN\1740|such|,|cyanide|,|and|azide (r_nmod) inhibitors_2\NNS\20090|phenol|oxidase|phenylthiourea (l_compound) oxidase_1\NN\14732946|
T21_T35 NONE copper_25\NN\14821043|of|the|active|site|enzyme (r_nmod) participation_20\NN\1080366|the|copper|catalysis (r_dobj) suggesting_18\VBG\1010118|participation (r_advcl) inhibited_13\VBD\2510337|inhibitors|reaction|drastically|,|suggesting|. (l_nsubj) inhibitors_2\NNS\20090|phenol|oxidase|phenylthiourea (l_compound) oxidase_1\NN\14732946|
T22_T36 CPR:4 mimosine_0\NN\1740|,|inhibitor|, (l_appos) inhibitor_5\NN\20090|a|well-known|competitive|tyrosinase (l_nmod) tyrosinase_7\NN\1740|of
T10_T28 CPR:9 acid_25\NN\14818238|such|3,4-dihydroxymandelic (r_nmod) substrate_21\NN\19613|a|suitable|acid (r_nsubjpass) provided_27\VBN\2199590|if|substrate|is (r_advcl) catalyze_8\VB\146138|that|tyrosinase|will|also|production|copper|provided (l_nsubj) tyrosinase_5\NN\1740|mushroom
T9_T28 CPR:9 methide_10\NN\1740| (r_compound) production_11\NN\30358|quinone|methide (r_dobj) catalyze_8\VB\146138|that|tyrosinase|will|also|production|copper|provided (l_nsubj) tyrosinase_5\NN\1740|mushroom
10226872
T17_T31 NONE cromoglycate_1\NN\1740|disodium (r_nsubj) prevent_4\VB\1740|cromoglycate|does|not|desensitization|. (l_dobj) desensitization_6\NN\13458571|terbutaline-induced|functions (l_nmod) functions_13\NNS\13783581|of|cardiovascular|in|volunteers (l_amod) cardiovascular_10\JJ\1740|2-adrenoceptor-mediated (l_amod) 2-adrenoceptor-mediated_9\JJ\1740|beta
T18_T31 NONE terbutaline-induced_5\JJ\1740| (r_amod) desensitization_6\NN\13458571|terbutaline-induced|functions (l_nmod) functions_13\NNS\13783581|of|cardiovascular|in|volunteers (l_amod) cardiovascular_10\JJ\1740|2-adrenoceptor-mediated (l_amod) 2-adrenoceptor-mediated_9\JJ\1740|beta
T10_T20 NONE ketotifen_32\NN\1740|of|the|antianaphylactic|drug (r_nmod) administration_27\NN\1133281|by|concomitant|ketotifen (r_nmod) blunted_24\VBN\224901|which|can|be|administration (r_acl:relcl) desensitization_14\NN\13458571|to|a|responses|,|blunted (l_nmod) responses_19\NNS\11410625|of|2-adrenoceptor-mediated|cardiovascular (l_amod) 2-adrenoceptor-mediated_17\JJ\1740|beta
T10_T27 NONE ketotifen_32\NN\1740|of|the|antianaphylactic|drug (r_nmod) administration_27\NN\1133281|by|concomitant|ketotifen (r_nmod) blunted_24\VBN\224901|which|can|be|administration (r_acl:relcl) desensitization_14\NN\13458571|to|a|responses|,|blunted (r_nmod) leads_11\VBZ\1752884|humans|,|administration|desensitization|. (l_nsubj) administration_4\NN\1133281|prolonged|agonist (l_nmod) agonist_9\NN\9613191|of|the|beta|2-adrenoceptor|terbutaline (l_compound) 2-adrenoceptor_8\NN\1740|
T15_T20 NONE terbutaline_10\NN\1740| (r_dep) agonist_9\NN\9613191|of|the|beta|2-adrenoceptor|terbutaline (r_nmod) administration_4\NN\1133281|prolonged|agonist (r_nsubj) leads_11\VBZ\1752884|humans|,|administration|desensitization|. (l_nmod) desensitization_14\NN\13458571|to|a|responses|,|blunted (l_nmod) responses_19\NNS\11410625|of|2-adrenoceptor-mediated|cardiovascular (l_amod) 2-adrenoceptor-mediated_17\JJ\1740|beta
T15_T27 CPR:5 terbutaline_10\NN\1740| (r_dep) agonist_9\NN\9613191|of|the|beta|2-adrenoceptor|terbutaline (l_compound) 2-adrenoceptor_8\NN\1740|
T11_T26 NONE cromoglycate_7\NN\1740|of|disodium|,|drug|, (r_nmod) effect_4\NN\34213|the|cromoglycate|desensitization (l_nmod) desensitization_15\NN\13458571|on|terbutaline-induced|responses (l_nmod) responses_21\NNS\11410625|of|cardiovascular (l_amod) cardiovascular_18\JJ\1740|beta-adrenoceptor-mediated|and|noncardiovascular (l_amod) beta-adrenoceptor-mediated_17\JJ\1740|
T12_T26 NONE terbutaline-induced_14\JJ\1740| (r_amod) desensitization_15\NN\13458571|on|terbutaline-induced|responses (l_nmod) responses_21\NNS\11410625|of|cardiovascular (l_amod) cardiovascular_18\JJ\1740|beta-adrenoceptor-mediated|and|noncardiovascular (l_amod) beta-adrenoceptor-mediated_17\JJ\1740|
T16_T28 NONE isoprenaline_29\NN\1740|of|the|unselective|beta-adrenoceptor|agonist (r_nmod) infusion_23\NN\14589223|by|an|incremental|intravenous|isoprenaline (r_nmod) induced_18\VBN\1627355|infusion (r_acl) reduction_13\NN\351485|pressure|induced (r_conj) increase_8\NN\13576355|by|the|rate|and|reduction (r_nmod) assessed_5\VBN\670261|function|was|increase|;|assessed (l_nsubjpass) function_3\NN\13783581|beta|2-adrenoceptor|cardiovascular (l_compound) 2-adrenoceptor_1\NN\1740|
T16_T29 CPR:5 isoprenaline_29\NN\1740|of|the|unselective|beta-adrenoceptor|agonist (l_compound) beta-adrenoceptor_27\NN\5608868|
T16_T30 NONE isoprenaline_29\NN\1740|of|the|unselective|beta-adrenoceptor|agonist (r_nmod) infusion_23\NN\14589223|by|an|incremental|intravenous|isoprenaline (r_nmod) induced_18\VBN\1627355|infusion (r_acl) reduction_13\NN\351485|pressure|induced (r_conj) increase_8\NN\13576355|by|the|rate|and|reduction (r_nmod) assessed_5\VBN\670261|function|was|increase|;|assessed (l_parataxis) assessed_36\VBN\670261|function|was|tachycardia|. (l_nsubjpass) function_34\NN\13783581|beta|1-adrenoceptor|cardiovascular (l_compound) 1-adrenoceptor_32\NN\1740|
T4_T21 NONE cromoglycate_1\NN\1740|disodium (r_nsubj) affected_2\VBD\126264|cromoglycate|shift|administration|. (l_dobj) shift_6\NN\7446404|neither|the|rightward|responses|nor|shift (l_nmod) responses_10\NNS\11410625|of|beta|2-adrenoceptor-mediated (l_amod) 2-adrenoceptor-mediated_9\JJ\1740|
T4_T22 NONE cromoglycate_1\NN\1740|disodium (r_nsubj) affected_2\VBD\126264|cromoglycate|shift|administration|. (l_dobj) shift_6\NN\7446404|neither|the|rightward|responses|nor|shift (l_conj) shift_15\NN\7446404|the|small|rightward|tachycardia (l_nmod) tachycardia_20\NN\14110674|in|beta|1-adrenoceptor-mediated|exercise (l_amod) 1-adrenoceptor-mediated_18\JJ\1740|
T5_T21 NONE terbutaline_27\NN\1740|of (r_nmod) administration_25\NN\1133281|after|weeks|terbutaline (r_nmod) affected_2\VBD\126264|cromoglycate|shift|administration|. (l_dobj) shift_6\NN\7446404|neither|the|rightward|responses|nor|shift (l_nmod) responses_10\NNS\11410625|of|beta|2-adrenoceptor-mediated (l_amod) 2-adrenoceptor-mediated_9\JJ\1740|
T5_T22 NONE terbutaline_27\NN\1740|of (r_nmod) administration_25\NN\1133281|after|weeks|terbutaline (r_nmod) affected_2\VBD\126264|cromoglycate|shift|administration|. (l_dobj) shift_6\NN\7446404|neither|the|rightward|responses|nor|shift (l_conj) shift_15\NN\7446404|the|small|rightward|tachycardia (l_nmod) tachycardia_20\NN\14110674|in|beta|1-adrenoceptor-mediated|exercise (l_amod) 1-adrenoceptor-mediated_18\JJ\1740|
T6_T23 NONE terbutaline_8\NN\1740| (r_compound) administration_9\NN\1133281|of|terbutaline (r_nmod) days_6\NNS\15140892|during|the|first|few|administration (r_nmod) observed_1\VBN\2163746|days (r_acl) tremulousness_0\NN\1740|observed (r_nsubj) disappeared_10\VBD\2609764|tremulousness|days|,|indicating|. (l_advcl) indicating_17\VBG\952524|development (l_dobj) development_18\NN\248977|desensitization (l_nmod) desensitization_20\NN\13458571|of|responses (l_nmod) responses_25\NNS\11410625|of|2-adrenoceptor-mediated|noncardiovascular (l_amod) 2-adrenoceptor-mediated_23\JJ\1740|beta
23397032
T1_T11 CPR:4 dexamethasone_0\NN\2721538| (r_nsubj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_dobj) transcription_4\NN\6349220|il-11|gene|enhanced (l_compound) il-11_2\NN\1740|
T1_T12 NONE dexamethasone_0\NN\2721538| (r_nsubj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_dobj) transcription_4\NN\6349220|il-11|gene|enhanced (l_acl) enhanced_5\VBN\227165|pth(1 (l_nmod) pth(1_7\NN\1740|by|- (l_nummod) -_8\CD\1740|34 (l_nummod) 34_9\CD\1740|) (l_punct) )_10\-RRB-\1740|
T1_T13 NONE dexamethasone_0\NN\2721538| (r_nsubj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_advcl) affecting_12\VBG\126264|without|expression (l_dobj) expression_14\NN\4679549|δfosb|or|phosphorylation (l_compound) δfosb_13\NN\1740|
T1_T14 NONE dexamethasone_0\NN\2721538| (r_nsubj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_conj) bound_24\VBN\1831531|complex|was|jund (l_nsubjpass) complex_22\NN\5869584|dexamethasone-gc|receptor (l_compound) receptor_21\NN\5225602|
T1_T15 NONE dexamethasone_0\NN\2721538| (r_nsubj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_conj) bound_24\VBN\1831531|complex|was|jund (l_nmod) jund_26\NN\1740|to|,|forms
T1_T16 NONE dexamethasone_0\NN\2721538| (r_nsubj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_conj) bound_24\VBN\1831531|complex|was|jund (l_nmod) jund_26\NN\1740|to|,|forms (l_acl:relcl) forms_29\VBZ\1617192|which|heterodimers|δfosb. (l_nmod) δfosb._32\NN\1740|with
T2_T11 NONE dexamethasone-gc_20\NN\1740| (r_compound) complex_22\NN\5869584|dexamethasone-gc|receptor (r_nsubjpass) bound_24\VBN\1831531|complex|was|jund (r_conj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_dobj) transcription_4\NN\6349220|il-11|gene|enhanced (l_compound) il-11_2\NN\1740|
T2_T12 NONE dexamethasone-gc_20\NN\1740| (r_compound) complex_22\NN\5869584|dexamethasone-gc|receptor (r_nsubjpass) bound_24\VBN\1831531|complex|was|jund (r_conj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_dobj) transcription_4\NN\6349220|il-11|gene|enhanced (l_acl) enhanced_5\VBN\227165|pth(1 (l_nmod) pth(1_7\NN\1740|by|- (l_nummod) -_8\CD\1740|34 (l_nummod) 34_9\CD\1740|) (l_punct) )_10\-RRB-\1740|
T2_T13 NONE dexamethasone-gc_20\NN\1740| (r_compound) complex_22\NN\5869584|dexamethasone-gc|receptor (r_nsubjpass) bound_24\VBN\1831531|complex|was|jund (r_conj) suppressed_1\VBD\2510337|dexamethasone|transcription|affecting|,|and|bound (l_advcl) affecting_12\VBG\126264|without|expression (l_dobj) expression_14\NN\4679549|δfosb|or|phosphorylation (l_compound) δfosb_13\NN\1740|
T2_T14 NONE dexamethasone-gc_20\NN\1740| (r_compound) complex_22\NN\5869584|dexamethasone-gc|receptor (l_compound) receptor_21\NN\5225602|
T2_T15 NONE dexamethasone-gc_20\NN\1740| (r_compound) complex_22\NN\5869584|dexamethasone-gc|receptor (r_nsubjpass) bound_24\VBN\1831531|complex|was|jund (l_nmod) jund_26\NN\1740|to|,|forms
T2_T16 NONE dexamethasone-gc_20\NN\1740| (r_compound) complex_22\NN\5869584|dexamethasone-gc|receptor (r_nsubjpass) bound_24\VBN\1831531|complex|was|jund (l_nmod) jund_26\NN\1740|to|,|forms (l_acl:relcl) forms_29\VBZ\1617192|which|heterodimers|δfosb. (l_nmod) δfosb._32\NN\1740|with
T3_T17 NONE dexamethasone_11\NN\2721538|of (r_nmod) effect_9\NN\34213|the|dexamethasone|apoptosis (r_dobj) counteracted_7\VBD\2367363|doses|effect|. (l_nsubj) doses_1\NNS\3740161|high|pth(1 (l_nmod) pth(1_3\NN\1740|of|- (l_nummod) -_4\CD\1740|34 (l_nummod) 34_5\CD\1740|) (l_punct) )_6\-RRB-\1740|
T3_T18 NONE dexamethasone_11\NN\2721538|of (r_nmod) effect_9\NN\34213|the|dexamethasone|apoptosis (l_nmod) apoptosis_13\NN\11486178|on|mpobs|,|blunted (l_acl:relcl) blunted_19\VBN\224901|which|was|neutralizing (l_advcl) neutralizing_21\VBG\126264|by|antibody (l_dobj) antibody_23\NN\14728724|anti-il-11|or|rna (l_amod) anti-il-11_22\JJ\1740|
T3_T19 NONE dexamethasone_11\NN\2721538|of (r_nmod) effect_9\NN\34213|the|dexamethasone|apoptosis (l_nmod) apoptosis_13\NN\11486178|on|mpobs|,|blunted (l_acl:relcl) blunted_19\VBN\224901|which|was|neutralizing (l_advcl) neutralizing_21\VBG\126264|by|antibody (l_dobj) antibody_23\NN\14728724|anti-il-11|or|rna (l_conj) rna_28\NN\14994328|il-11|small|interfering (l_compound) il-11_25\NN\1740|
T4_T20 NONE dexamethasone_30\NN\2721538| (r_conj) -_26\CD\1740|34|and|dexamethasone (r_nummod) pth(1_25\NN\1740|- (r_nsubj) regulate_32\VB\296178|that|pth(1|may|osteoblast|effect (r_ccomp) suggest_23\VBP\1010118|regulate (r_conj) demonstrate_2\VBP\2137132|results|interact|and|suggest|. (l_ccomp) interact_10\VBP\2367363|that|pth(1|regulate (l_nsubj) pth(1_4\NN\1740|- (l_nummod) -_5\CD\1740|34|and|gcs (l_nummod) 34_6\CD\1740|) (l_punct) )_7\-RRB-\1740|
T4_T21 NONE dexamethasone_30\NN\2721538| (r_conj) -_26\CD\1740|34|and|dexamethasone (r_nummod) pth(1_25\NN\1740|- (r_nsubj) regulate_32\VB\296178|that|pth(1|may|osteoblast|effect (r_ccomp) suggest_23\VBP\1010118|regulate (r_conj) demonstrate_2\VBP\2137132|results|interact|and|suggest|. (l_ccomp) interact_10\VBP\2367363|that|pth(1|regulate (l_xcomp) regulate_12\VB\296178|to|expression|parallel (l_dobj) expression_14\NN\4679549|il-11 (l_compound) il-11_13\NN\1740|
T4_T22 NONE dexamethasone_30\NN\2721538| (r_conj) -_26\CD\1740|34|and|dexamethasone (l_nummod) 34_27\CD\1740|) (l_punct) )_28\-RRB-\1740|
T4_T23 NONE dexamethasone_30\NN\2721538| (r_conj) -_26\CD\1740|34|and|dexamethasone (r_nummod) pth(1_25\NN\1740|- (r_nsubj) regulate_32\VB\296178|that|pth(1|may|osteoblast|effect (l_nmod) effect_39\NN\34213|via|their|expression (l_nmod) expression_42\NN\4679549|on|il-11 (l_compound) il-11_41\NN\1740|
17403555
T19_T57 NONE n-methyl-d-aspartate_10\NN\1740| (r_compound) subunits_12\NNS\13604718|nr1/nr2a|n-methyl-d-aspartate|receptor (r_dobj) expressing_6\VBG\928630|subunits (r_acl) cells_5\NNS\3080309|in|hek293|expressing (r_nmod) toxicity_0\NN\13576101|beta-amyloid|cells|. (l_nmod) beta-amyloid_2\NN\1740|of
T19_T58 NONE n-methyl-d-aspartate_10\NN\1740| (r_compound) subunits_12\NNS\13604718|nr1/nr2a|n-methyl-d-aspartate|receptor (l_compound) nr1/nr2a_7\NN\1740|or|nr1/nr2b
T19_T59 NONE n-methyl-d-aspartate_10\NN\1740| (r_compound) subunits_12\NNS\13604718|nr1/nr2a|n-methyl-d-aspartate|receptor (l_compound) nr1/nr2a_7\NN\1740|or|nr1/nr2b
T19_T60 NONE n-methyl-d-aspartate_10\NN\1740| (r_compound) subunits_12\NNS\13604718|nr1/nr2a|n-methyl-d-aspartate|receptor (l_compound) nr1/nr2a_7\NN\1740|or|nr1/nr2b (l_conj) nr1/nr2b_9\NN\1740|
T19_T61 NONE n-methyl-d-aspartate_10\NN\1740| (r_compound) subunits_12\NNS\13604718|nr1/nr2a|n-methyl-d-aspartate|receptor (l_compound) nr1/nr2a_7\NN\1740|or|nr1/nr2b (l_conj) nr1/nr2b_9\NN\1740|
T19_T62 NONE n-methyl-d-aspartate_10\NN\1740| (r_compound) subunits_12\NNS\13604718|nr1/nr2a|n-methyl-d-aspartate|receptor (l_compound) receptor_11\NN\5225602|
T14_T25 NONE glutamate_9\NN\15010703| (r_compound) toxicity_10\NN\13576101|glutamate|,|resulting (l_acl) resulting_12\VBG\2633881|overactivation (l_nmod) overactivation_14\NN\1740|from|receptors|and|elevation (l_nmod) receptors_20\NNS\5225602|of|n-methyl-d-aspartate
T14_T36 NONE glutamate_9\NN\15010703| (r_compound) toxicity_10\NN\13576101|glutamate|,|resulting (r_dobj) involves_8\VBZ\2676054|neurotoxicity|toxicity|. (l_nsubj) neurotoxicity_0\NN\1740|induced (l_acl) induced_1\VBN\1627355|peptide (l_nmod) peptide_4\NN\14724264|by|beta-amyloid|abeta
T14_T45 NONE glutamate_9\NN\15010703| (r_compound) toxicity_10\NN\13576101|glutamate|,|resulting (r_dobj) involves_8\VBZ\2676054|neurotoxicity|toxicity|. (l_nsubj) neurotoxicity_0\NN\1740|induced (l_acl) induced_1\VBN\1627355|peptide (l_nmod) peptide_4\NN\14724264|by|beta-amyloid|abeta (l_appos) abeta_6\NN\1740|(|)
T1_T25 NONE n-methyl-d-aspartate_16\NN\1740|nmda (r_compound) receptors_20\NNS\5225602|of|n-methyl-d-aspartate
T1_T36 NONE n-methyl-d-aspartate_16\NN\1740|nmda (r_compound) receptors_20\NNS\5225602|of|n-methyl-d-aspartate (r_nmod) overactivation_14\NN\1740|from|receptors|and|elevation (r_nmod) resulting_12\VBG\2633881|overactivation (r_acl) toxicity_10\NN\13576101|glutamate|,|resulting (r_dobj) involves_8\VBZ\2676054|neurotoxicity|toxicity|. (l_nsubj) neurotoxicity_0\NN\1740|induced (l_acl) induced_1\VBN\1627355|peptide (l_nmod) peptide_4\NN\14724264|by|beta-amyloid|abeta
T1_T45 NONE n-methyl-d-aspartate_16\NN\1740|nmda (r_compound) receptors_20\NNS\5225602|of|n-methyl-d-aspartate (r_nmod) overactivation_14\NN\1740|from|receptors|and|elevation (r_nmod) resulting_12\VBG\2633881|overactivation (r_acl) toxicity_10\NN\13576101|glutamate|,|resulting (r_dobj) involves_8\VBZ\2676054|neurotoxicity|toxicity|. (l_nsubj) neurotoxicity_0\NN\1740|induced (l_acl) induced_1\VBN\1627355|peptide (l_nmod) peptide_4\NN\14724264|by|beta-amyloid|abeta (l_appos) abeta_6\NN\1740|(|)
T6_T25 NONE nmda_18\NN\1740|(|) (r_appos) n-methyl-d-aspartate_16\NN\1740|nmda (r_compound) receptors_20\NNS\5225602|of|n-methyl-d-aspartate
T6_T36 NONE nmda_18\NN\1740|(|) (r_appos) n-methyl-d-aspartate_16\NN\1740|nmda (r_compound) receptors_20\NNS\5225602|of|n-methyl-d-aspartate (r_nmod) overactivation_14\NN\1740|from|receptors|and|elevation (r_nmod) resulting_12\VBG\2633881|overactivation (r_acl) toxicity_10\NN\13576101|glutamate|,|resulting (r_dobj) involves_8\VBZ\2676054|neurotoxicity|toxicity|. (l_nsubj) neurotoxicity_0\NN\1740|induced (l_acl) induced_1\VBN\1627355|peptide (l_nmod) peptide_4\NN\14724264|by|beta-amyloid|abeta
T6_T45 NONE nmda_18\NN\1740|(|) (r_appos) n-methyl-d-aspartate_16\NN\1740|nmda (r_compound) receptors_20\NNS\5225602|of|n-methyl-d-aspartate (r_nmod) overactivation_14\NN\1740|from|receptors|and|elevation (r_nmod) resulting_12\VBG\2633881|overactivation (r_acl) toxicity_10\NN\13576101|glutamate|,|resulting (r_dobj) involves_8\VBZ\2676054|neurotoxicity|toxicity|. (l_nsubj) neurotoxicity_0\NN\1740|induced (l_acl) induced_1\VBN\1627355|peptide (l_nmod) peptide_4\NN\14724264|by|beta-amyloid|abeta (l_appos) abeta_6\NN\1740|(|)
T9_T25 NONE calcium_25\NN\14625458|of|intracellular (r_nmod) elevation_22\NN\7445480|calcium (r_conj) overactivation_14\NN\1740|from|receptors|and|elevation (l_nmod) receptors_20\NNS\5225602|of|n-methyl-d-aspartate
T9_T36 NONE calcium_25\NN\14625458|of|intracellular (r_nmod) elevation_22\NN\7445480|calcium (r_conj) overactivation_14\NN\1740|from|receptors|and|elevation (r_nmod) resulting_12\VBG\2633881|overactivation (r_acl) toxicity_10\NN\13576101|glutamate|,|resulting (r_dobj) involves_8\VBZ\2676054|neurotoxicity|toxicity|. (l_nsubj) neurotoxicity_0\NN\1740|induced (l_acl) induced_1\VBN\1627355|peptide (l_nmod) peptide_4\NN\14724264|by|beta-amyloid|abeta
T9_T45 NONE calcium_25\NN\14625458|of|intracellular (r_nmod) elevation_22\NN\7445480|calcium (r_conj) overactivation_14\NN\1740|from|receptors|and|elevation (r_nmod) resulting_12\VBG\2633881|overactivation (r_acl) toxicity_10\NN\13576101|glutamate|,|resulting (r_dobj) involves_8\VBZ\2676054|neurotoxicity|toxicity|. (l_nsubj) neurotoxicity_0\NN\1740|induced (l_acl) induced_1\VBN\1627355|peptide (l_nmod) peptide_4\NN\14724264|by|beta-amyloid|abeta (l_appos) abeta_6\NN\1740|(|)
T10_T35 NONE nmda_6\NN\1740| (r_compound) receptors_7\NNS\5225602|of|the|nmda|,|composed
T10_T37 NONE nmda_6\NN\1740| (r_compound) receptors_7\NNS\5225602|of|the|nmda|,|composed (l_acl) composed_10\VBN\2620587|frequently|subunits (l_nmod) subunits_15\NNS\13604718|nr1 (l_compound) nr1_12\NN\1740|of|and|nr2a-d
T10_T38 NONE nmda_6\NN\1740| (r_compound) receptors_7\NNS\5225602|of|the|nmda|,|composed (l_acl) composed_10\VBN\2620587|frequently|subunits (l_nmod) subunits_15\NNS\13604718|nr1 (l_compound) nr1_12\NN\1740|of|and|nr2a-d (l_conj) nr2a-d_14\NN\1740|
T11_T39 NONE nmda_7\NN\1740| (r_compound) subtypes_9\NNS\1740|of|nmda|receptor (l_compound) receptor_8\NN\5225602|
T11_T40 NONE nmda_7\NN\1740| (r_compound) subtypes_9\NNS\1740|of|nmda|receptor (r_nmod) contribution_5\NN\786195|the|subtypes|40|toxicity|cells (l_nmod) 40_13\CD\13745420|on|abeta(1|-|) (l_punct) )_14\-RRB-\1740|
T11_T41 NONE nmda_7\NN\1740| (r_compound) subtypes_9\NNS\1740|of|nmda|receptor (r_nmod) contribution_5\NN\786195|the|subtypes|40|toxicity|cells (l_nmod) cells_18\NNS\3080309|in|hek293|expressing (l_acl) expressing_20\VBG\928630|transiently|subunits (l_dobj) subunits_24\NNS\13604718|nr1/nr2a (l_compound) nr1/nr2a_21\NN\1740|or|nr1/nr2b
T11_T42 NONE nmda_7\NN\1740| (r_compound) subtypes_9\NNS\1740|of|nmda|receptor (r_nmod) contribution_5\NN\786195|the|subtypes|40|toxicity|cells (l_nmod) cells_18\NNS\3080309|in|hek293|expressing (l_acl) expressing_20\VBG\928630|transiently|subunits (l_dobj) subunits_24\NNS\13604718|nr1/nr2a (l_compound) nr1/nr2a_21\NN\1740|or|nr1/nr2b
T11_T43 NONE nmda_7\NN\1740| (r_compound) subtypes_9\NNS\1740|of|nmda|receptor (r_nmod) contribution_5\NN\786195|the|subtypes|40|toxicity|cells (l_nmod) cells_18\NNS\3080309|in|hek293|expressing (l_acl) expressing_20\VBG\928630|transiently|subunits (l_dobj) subunits_24\NNS\13604718|nr1/nr2a (l_compound) nr1/nr2a_21\NN\1740|or|nr1/nr2b (l_conj) nr1/nr2b_23\NN\1740|
T11_T44 NONE nmda_7\NN\1740| (r_compound) subtypes_9\NNS\1740|of|nmda|receptor (r_nmod) contribution_5\NN\786195|the|subtypes|40|toxicity|cells (l_nmod) cells_18\NNS\3080309|in|hek293|expressing (l_acl) expressing_20\VBG\928630|transiently|subunits (l_dobj) subunits_24\NNS\13604718|nr1/nr2a (l_compound) nr1/nr2a_21\NN\1740|or|nr1/nr2b (l_conj) nr1/nr2b_23\NN\1740|
T12_T46 NONE lactate_2\NN\14850483| (r_compound) dehydrogenase_3\NN\1740|lactate|ldh
T12_T47 NONE lactate_2\NN\14850483| (r_compound) dehydrogenase_3\NN\1740|lactate|ldh (l_appos) ldh_5\NN\1740|(|)
T12_T48 NONE lactate_2\NN\14850483| (r_compound) dehydrogenase_3\NN\1740|lactate|ldh (r_compound) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_dobj) increase_14\NN\13576355|an|toxicity|expression (l_nmod) toxicity_20\NN\13576101|in|abeta(1 (l_compound) abeta(1_16\NN\1740|- (l_dep) -_17\CD\1740|40 (l_nummod) 40_18\CD\13745420|) (l_punct) )_19\-RRB-\1740|
T12_T49 NONE lactate_2\NN\14850483| (r_compound) dehydrogenase_3\NN\1740|lactate|ldh (r_compound) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_dobj) increase_14\NN\13576355|an|toxicity|expression (l_nmod) expression_23\NN\4679549|upon|nr1/nr2a (l_compound) nr1/nr2a_22\NN\1740|
T12_T50 NONE lactate_2\NN\14850483| (r_compound) dehydrogenase_3\NN\1740|lactate|ldh (r_compound) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_dobj) increase_14\NN\13576355|an|toxicity|expression (l_nmod) expression_23\NN\4679549|upon|nr1/nr2a (l_compound) nr1/nr2a_22\NN\1740|
T12_T51 NONE lactate_2\NN\14850483| (r_compound) dehydrogenase_3\NN\1740|lactate|ldh (r_compound) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_advcl) compared_25\VBN\644583|nr1/nr2b (l_nmod) nr1/nr2b_27\NN\1740|to
T12_T52 NONE lactate_2\NN\14850483| (r_compound) dehydrogenase_3\NN\1740|lactate|ldh (r_compound) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_advcl) compared_25\VBN\644583|nr1/nr2b (l_nmod) nr1/nr2b_27\NN\1740|to
T13_T46 NONE blue_10\JJ\1740| (r_amod) exclusion_11\NN\13927383|trypan|blue (r_conj) release_7\NN\3748886|of|dehydrogenase|and|exclusion (l_compound) dehydrogenase_3\NN\1740|lactate|ldh
T13_T47 NONE blue_10\JJ\1740| (r_amod) exclusion_11\NN\13927383|trypan|blue (r_conj) release_7\NN\3748886|of|dehydrogenase|and|exclusion (l_compound) dehydrogenase_3\NN\1740|lactate|ldh (l_appos) ldh_5\NN\1740|(|)
T13_T48 NONE blue_10\JJ\1740| (r_amod) exclusion_11\NN\13927383|trypan|blue (r_conj) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_dobj) increase_14\NN\13576355|an|toxicity|expression (l_nmod) toxicity_20\NN\13576101|in|abeta(1 (l_compound) abeta(1_16\NN\1740|- (l_dep) -_17\CD\1740|40 (l_nummod) 40_18\CD\13745420|) (l_punct) )_19\-RRB-\1740|
T13_T49 NONE blue_10\JJ\1740| (r_amod) exclusion_11\NN\13927383|trypan|blue (r_conj) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_dobj) increase_14\NN\13576355|an|toxicity|expression (l_nmod) expression_23\NN\4679549|upon|nr1/nr2a (l_compound) nr1/nr2a_22\NN\1740|
T13_T50 NONE blue_10\JJ\1740| (r_amod) exclusion_11\NN\13927383|trypan|blue (r_conj) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_dobj) increase_14\NN\13576355|an|toxicity|expression (l_nmod) expression_23\NN\4679549|upon|nr1/nr2a (l_compound) nr1/nr2a_22\NN\1740|
T13_T51 NONE blue_10\JJ\1740| (r_amod) exclusion_11\NN\13927383|trypan|blue (r_conj) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_advcl) compared_25\VBN\644583|nr1/nr2b (l_nmod) nr1/nr2b_27\NN\1740|to
T13_T52 NONE blue_10\JJ\1740| (r_amod) exclusion_11\NN\13927383|trypan|blue (r_conj) release_7\NN\3748886|of|dehydrogenase|and|exclusion (r_nmod) analysis_0\NN\633864|release (r_nsubj) revealed_12\VBD\2137132|analysis|increase|,|compared|,|indicating|. (l_advcl) compared_25\VBN\644583|nr1/nr2b (l_nmod) nr1/nr2b_27\NN\1740|to
T15_T53 NONE atp_8\NN\14964590|intracellular (r_dobj) decreased_6\VBD\169651|furthermore|,|abeta(1|atp|cells|. (l_nsubj) abeta(1_2\NN\1740|- (l_nummod) -_3\CD\1740|40 (l_nummod) 40_4\CD\13745420|) (l_punct) )_5\-RRB-\1740|
T15_T54 NONE atp_8\NN\14964590|intracellular (r_dobj) decreased_6\VBD\169651|furthermore|,|abeta(1|atp|cells|. (l_nmod) cells_10\NNS\3080309|in|expressing (l_acl) expressing_11\VBG\928630|nr1/nr2a (l_dobj) nr1/nr2a_12\NN\1740|
T15_T55 NONE atp_8\NN\14964590|intracellular (r_dobj) decreased_6\VBD\169651|furthermore|,|abeta(1|atp|cells|. (l_nmod) cells_10\NNS\3080309|in|expressing (l_acl) expressing_11\VBG\928630|nr1/nr2a (l_dobj) nr1/nr2a_12\NN\1740|
T16_T56 CPR:6 mk-801_0\NN\1740|maleate|,|antagonist|, (l_appos) antagonist_12\NN\7846|a|noncompetitive|nmda|receptor (l_compound) receptor_11\NN\5225602|
T17_T56 CPR:6 maleate_5\NN\2718811|(|(+)-5-methyl-10,11-dihydro-5h-dibenzo[a|,|d]cyclohepten-5,10-imine|) (r_appos) mk-801_0\NN\1740|maleate|,|antagonist|, (l_appos) antagonist_12\NN\7846|a|noncompetitive|nmda|receptor (l_compound) receptor_11\NN\5225602|
T18_T56 NONE nmda_10\NN\1740| (r_compound) antagonist_12\NN\7846|a|noncompetitive|nmda|receptor (l_compound) receptor_11\NN\5225602|
T2_T21 NONE calcium_11\NN\14625458| (r_compound) imaging_12\NN\5765159|by|single-cell|calcium (r_nmod) evidenced_8\VBN\1015244|subtypes|were|further|imaging|. (l_nsubjpass) subtypes_5\NNS\1740|nr1/nr2a|receptor (l_compound) nr1/nr2a_1\NN\1740|functional|and|nr1/nr2b
T2_T22 NONE calcium_11\NN\14625458| (r_compound) imaging_12\NN\5765159|by|single-cell|calcium (r_nmod) evidenced_8\VBN\1015244|subtypes|were|further|imaging|. (l_nsubjpass) subtypes_5\NNS\1740|nr1/nr2a|receptor (l_compound) nr1/nr2a_1\NN\1740|functional|and|nr1/nr2b
T2_T23 NONE calcium_11\NN\14625458| (r_compound) imaging_12\NN\5765159|by|single-cell|calcium (r_nmod) evidenced_8\VBN\1015244|subtypes|were|further|imaging|. (l_nsubjpass) subtypes_5\NNS\1740|nr1/nr2a|receptor (l_compound) nr1/nr2a_1\NN\1740|functional|and|nr1/nr2b (l_conj) nr1/nr2b_3\NN\1740|
T2_T24 NONE calcium_11\NN\14625458| (r_compound) imaging_12\NN\5765159|by|single-cell|calcium (r_nmod) evidenced_8\VBN\1015244|subtypes|were|further|imaging|. (l_nsubjpass) subtypes_5\NNS\1740|nr1/nr2a|receptor (l_compound) nr1/nr2a_1\NN\1740|functional|and|nr1/nr2b (l_conj) nr1/nr2b_3\NN\1740|
T3_T26 NONE nmda/glycine_5\NN\1740|with (r_nmod) stimulation_0\NN\242808|receptors|nmda/glycine (l_nmod) receptors_3\NNS\5225602|of|nr1/nr2a (l_compound) nr1/nr2a_2\NN\1740|
T3_T27 NONE nmda/glycine_5\NN\1740|with (r_nmod) stimulation_0\NN\242808|receptors|nmda/glycine (l_nmod) receptors_3\NNS\5225602|of|nr1/nr2a (l_compound) nr1/nr2a_2\NN\1740|
T3_T28 NONE nmda/glycine_5\NN\1740|with (r_nmod) stimulation_0\NN\242808|receptors|nmda/glycine (r_nsubj) revealed_6\VBD\2137132|stimulation|increase|. (l_dobj) increase_8\NN\13576355|an|calcium|cells (l_nmod) cells_13\NNS\3080309|in|pre-exposed (l_amod) pre-exposed_14\JJ\1740|abeta(1 (l_nmod) abeta(1_16\NN\1740|to|40 (l_prep) 40_18\CD\13745420|-|) (l_punct) )_19\-RRB-\1740|
T4_T26 NONE nmda/glycine_5\NN\1740|with (r_nmod) stimulation_0\NN\242808|receptors|nmda/glycine (l_nmod) receptors_3\NNS\5225602|of|nr1/nr2a (l_compound) nr1/nr2a_2\NN\1740|
T4_T27 NONE nmda/glycine_5\NN\1740|with (r_nmod) stimulation_0\NN\242808|receptors|nmda/glycine (l_nmod) receptors_3\NNS\5225602|of|nr1/nr2a (l_compound) nr1/nr2a_2\NN\1740|
T4_T28 NONE nmda/glycine_5\NN\1740|with (r_nmod) stimulation_0\NN\242808|receptors|nmda/glycine (r_nsubj) revealed_6\VBD\2137132|stimulation|increase|. (l_dobj) increase_8\NN\13576355|an|calcium|cells (l_nmod) cells_13\NNS\3080309|in|pre-exposed (l_amod) pre-exposed_14\JJ\1740|abeta(1 (l_nmod) abeta(1_16\NN\1740|to|40 (l_prep) 40_18\CD\13745420|-|) (l_punct) )_19\-RRB-\1740|
T5_T26 NONE calcium_11\NN\14625458|in|intracellular (r_nmod) increase_8\NN\13576355|an|calcium|cells (r_dobj) revealed_6\VBD\2137132|stimulation|increase|. (l_nsubj) stimulation_0\NN\242808|receptors|nmda/glycine (l_nmod) receptors_3\NNS\5225602|of|nr1/nr2a (l_compound) nr1/nr2a_2\NN\1740|
T5_T27 NONE calcium_11\NN\14625458|in|intracellular (r_nmod) increase_8\NN\13576355|an|calcium|cells (r_dobj) revealed_6\VBD\2137132|stimulation|increase|. (l_nsubj) stimulation_0\NN\242808|receptors|nmda/glycine (l_nmod) receptors_3\NNS\5225602|of|nr1/nr2a (l_compound) nr1/nr2a_2\NN\1740|
T5_T28 NONE calcium_11\NN\14625458|in|intracellular (r_nmod) increase_8\NN\13576355|an|calcium|cells (l_nmod) cells_13\NNS\3080309|in|pre-exposed (l_amod) pre-exposed_14\JJ\1740|abeta(1 (l_nmod) abeta(1_16\NN\1740|to|40 (l_prep) 40_18\CD\13745420|-|) (l_punct) )_19\-RRB-\1740|
T7_T31 NONE nmda_5\NN\1740| (r_compound) receptors_6\NNS\5225602|nr1/nr2a-composed|nmda (l_amod) nr1/nr2a-composed_4\JJ\1740|
T7_T32 NONE nmda_5\NN\1740| (r_compound) receptors_6\NNS\5225602|nr1/nr2a-composed|nmda (l_amod) nr1/nr2a-composed_4\JJ\1740|
T7_T33 NONE nmda_5\NN\1740| (r_compound) receptors_6\NNS\5225602|nr1/nr2a-composed|nmda
T7_T34 NONE nmda_5\NN\1740| (r_compound) receptors_6\NNS\5225602|nr1/nr2a-composed|nmda (r_nsubj) mediate_7\VBP\761713|that|receptors|death (l_dobj) death_10\NN\7296428|necrotic|cell|cells (l_nmod) cells_13\NNS\3080309|in|hek293|exposed (l_acl) exposed_14\VBN\2110927|abeta(1|changes (l_nmod) abeta(1_16\NN\1740|to|- (l_nummod) -_17\CD\1740|40 (l_nummod) 40_18\CD\13745420|) (l_punct) )_19\-RRB-\1740|
T8_T31 NONE calcium_23\NN\14625458| (r_compound) homeostasis_24\NN\13934900|in|calcium (r_nmod) changes_21\NNS\7283608|through|homeostasis (r_nmod) exposed_14\VBN\2110927|abeta(1|changes (r_acl) cells_13\NNS\3080309|in|hek293|exposed (r_nmod) death_10\NN\7296428|necrotic|cell|cells (r_dobj) mediate_7\VBP\761713|that|receptors|death (l_nsubj) receptors_6\NNS\5225602|nr1/nr2a-composed|nmda (l_amod) nr1/nr2a-composed_4\JJ\1740|
T8_T32 NONE calcium_23\NN\14625458| (r_compound) homeostasis_24\NN\13934900|in|calcium (r_nmod) changes_21\NNS\7283608|through|homeostasis (r_nmod) exposed_14\VBN\2110927|abeta(1|changes (r_acl) cells_13\NNS\3080309|in|hek293|exposed (r_nmod) death_10\NN\7296428|necrotic|cell|cells (r_dobj) mediate_7\VBP\761713|that|receptors|death (l_nsubj) receptors_6\NNS\5225602|nr1/nr2a-composed|nmda (l_amod) nr1/nr2a-composed_4\JJ\1740|
T8_T33 NONE calcium_23\NN\14625458| (r_compound) homeostasis_24\NN\13934900|in|calcium (r_nmod) changes_21\NNS\7283608|through|homeostasis (r_nmod) exposed_14\VBN\2110927|abeta(1|changes (r_acl) cells_13\NNS\3080309|in|hek293|exposed (r_nmod) death_10\NN\7296428|necrotic|cell|cells (r_dobj) mediate_7\VBP\761713|that|receptors|death (l_nsubj) receptors_6\NNS\5225602|nr1/nr2a-composed|nmda
T8_T34 NONE calcium_23\NN\14625458| (r_compound) homeostasis_24\NN\13934900|in|calcium (r_nmod) changes_21\NNS\7283608|through|homeostasis (r_nmod) exposed_14\VBN\2110927|abeta(1|changes (l_nmod) abeta(1_16\NN\1740|to|- (l_nummod) -_17\CD\1740|40 (l_nummod) 40_18\CD\13745420|) (l_punct) )_19\-RRB-\1740|
23052195
T10_T43 NONE phenylpropanolamine-treated_15\JJ\1740| (r_amod) rats_16\NNS\2329401|in|phenylpropanolamine-treated (r_nmod) modify_6\VB\109660|knockdown|can|peroxidase|rats|. (l_nsubj) knockdown_4\NN\1173038|neuropeptide|y|y1|receptor (l_compound) receptor_3\NN\5225602|
T10_T44 NONE phenylpropanolamine-treated_15\JJ\1740| (r_amod) rats_16\NNS\2329401|in|phenylpropanolamine-treated (r_nmod) modify_6\VB\109660|knockdown|can|peroxidase|rats|. (l_dobj) peroxidase_8\NN\14971234|glutathione|and|protein
T10_T45 NONE phenylpropanolamine-treated_15\JJ\1740| (r_amod) rats_16\NNS\2329401|in|phenylpropanolamine-treated (r_nmod) modify_6\VB\109660|knockdown|can|peroxidase|rats|. (l_dobj) peroxidase_8\NN\14971234|glutathione|and|protein (l_conj) protein_13\NN\14944888|c-amp|response|element-binding
T11_T43 NONE glutathione_7\NN\1740| (r_compound) peroxidase_8\NN\14971234|glutathione|and|protein (r_dobj) modify_6\VB\109660|knockdown|can|peroxidase|rats|. (l_nsubj) knockdown_4\NN\1173038|neuropeptide|y|y1|receptor (l_compound) receptor_3\NN\5225602|
T11_T44 NONE glutathione_7\NN\1740| (r_compound) peroxidase_8\NN\14971234|glutathione|and|protein
T11_T45 NONE glutathione_7\NN\1740| (r_compound) peroxidase_8\NN\14971234|glutathione|and|protein (l_conj) protein_13\NN\14944888|c-amp|response|element-binding
T12_T43 NONE c-amp_10\NN\1740| (r_compound) protein_13\NN\14944888|c-amp|response|element-binding (r_conj) peroxidase_8\NN\14971234|glutathione|and|protein (r_dobj) modify_6\VB\109660|knockdown|can|peroxidase|rats|. (l_nsubj) knockdown_4\NN\1173038|neuropeptide|y|y1|receptor (l_compound) receptor_3\NN\5225602|
T12_T44 NONE c-amp_10\NN\1740| (r_compound) protein_13\NN\14944888|c-amp|response|element-binding (r_conj) peroxidase_8\NN\14971234|glutathione|and|protein
T12_T45 NONE c-amp_10\NN\1740| (r_compound) protein_13\NN\14944888|c-amp|response|element-binding
T3_T17 NONE phenylpropanolamine_26\NN\2682038| (r_nmod:npmod) (ppa)-mediated_27\JJ\1740|phenylpropanolamine (r_amod) suppression_29\NN\13489037|(ppa)-mediated|appetite (r_dobj) regulating_25\VBG\296178|in|suppression (r_advcl) involved_23\VBN\2676054|that|enzymes|are|regulating (l_nsubjpass) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_conj) protein_18\NN\14944888|c-amp|response|element-binding|creb (l_appos) creb_20\NN\1740|(|)
T3_T28 NONE phenylpropanolamine_26\NN\2682038| (r_nmod:npmod) (ppa)-mediated_27\JJ\1740|phenylpropanolamine (r_amod) suppression_29\NN\13489037|(ppa)-mediated|appetite (r_dobj) regulating_25\VBG\296178|in|suppression (r_advcl) involved_23\VBN\2676054|that|enzymes|are|regulating (l_nsubjpass) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_appos) y_9\NN\14625458|neuropeptide|npy
T3_T30 NONE phenylpropanolamine_26\NN\2682038| (r_nmod:npmod) (ppa)-mediated_27\JJ\1740|phenylpropanolamine (r_amod) suppression_29\NN\13489037|(ppa)-mediated|appetite (r_dobj) regulating_25\VBG\296178|in|suppression (r_advcl) involved_23\VBN\2676054|that|enzymes|are|regulating (l_nsubjpass) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_appos) y_9\NN\14625458|neuropeptide|npy (l_appos) npy_11\NN\1740|(|)
T3_T34 NONE phenylpropanolamine_26\NN\2682038| (r_nmod:npmod) (ppa)-mediated_27\JJ\1740|phenylpropanolamine (r_amod) suppression_29\NN\13489037|(ppa)-mediated|appetite (r_dobj) regulating_25\VBG\296178|in|suppression (r_advcl) involved_23\VBN\2676054|that|enzymes|are|regulating (l_nsubjpass) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_conj) protein_18\NN\14944888|c-amp|response|element-binding|creb
T4_T17 NONE (ppa)-mediated_27\JJ\1740|phenylpropanolamine (r_amod) suppression_29\NN\13489037|(ppa)-mediated|appetite (r_dobj) regulating_25\VBG\296178|in|suppression (r_advcl) involved_23\VBN\2676054|that|enzymes|are|regulating (l_nsubjpass) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_conj) protein_18\NN\14944888|c-amp|response|element-binding|creb (l_appos) creb_20\NN\1740|(|)
T4_T28 NONE (ppa)-mediated_27\JJ\1740|phenylpropanolamine (r_amod) suppression_29\NN\13489037|(ppa)-mediated|appetite (r_dobj) regulating_25\VBG\296178|in|suppression (r_advcl) involved_23\VBN\2676054|that|enzymes|are|regulating (l_nsubjpass) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_appos) y_9\NN\14625458|neuropeptide|npy
T4_T30 NONE (ppa)-mediated_27\JJ\1740|phenylpropanolamine (r_amod) suppression_29\NN\13489037|(ppa)-mediated|appetite (r_dobj) regulating_25\VBG\296178|in|suppression (r_advcl) involved_23\VBN\2676054|that|enzymes|are|regulating (l_nsubjpass) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_appos) y_9\NN\14625458|neuropeptide|npy (l_appos) npy_11\NN\1740|(|)
T4_T34 NONE (ppa)-mediated_27\JJ\1740|phenylpropanolamine (r_amod) suppression_29\NN\13489037|(ppa)-mediated|appetite (r_dobj) regulating_25\VBG\296178|in|suppression (r_advcl) involved_23\VBN\2676054|that|enzymes|are|regulating (l_nsubjpass) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_conj) protein_18\NN\14944888|c-amp|response|element-binding|creb
T8_T17 NONE c-amp_15\NN\1740| (r_compound) protein_18\NN\14944888|c-amp|response|element-binding|creb (l_appos) creb_20\NN\1740|(|)
T8_T28 NONE c-amp_15\NN\1740| (r_compound) protein_18\NN\14944888|c-amp|response|element-binding|creb (r_conj) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_appos) y_9\NN\14625458|neuropeptide|npy
T8_T30 NONE c-amp_15\NN\1740| (r_compound) protein_18\NN\14944888|c-amp|response|element-binding|creb (r_conj) enzymes_6\NNS\14723628|antioxidative|,|y|,|and|protein (l_appos) y_9\NN\14625458|neuropeptide|npy (l_appos) npy_11\NN\1740|(|)
T8_T34 NONE c-amp_15\NN\1740| (r_compound) protein_18\NN\14944888|c-amp|response|element-binding|creb
T6_T20 NONE glutathione_9\NN\1740| (r_compound) peroxidase_10\NN\14971234|glutathione|gp|,|and|creb (r_conj) npy_5\NN\1740|of|,|y1r|,|peroxidase
T6_T21 NONE glutathione_9\NN\1740| (r_compound) peroxidase_10\NN\14971234|glutathione|gp|,|and|creb (r_conj) npy_5\NN\1740|of|,|y1r|,|peroxidase (l_conj) y1r_7\NN\1740|
T6_T22 NONE glutathione_9\NN\1740| (r_compound) peroxidase_10\NN\14971234|glutathione|gp|,|and|creb
T6_T23 NONE glutathione_9\NN\1740| (r_compound) peroxidase_10\NN\14971234|glutathione|gp|,|and|creb (l_appos) gp_12\NN\10020890|(|)
T6_T24 NONE glutathione_9\NN\1740| (r_compound) peroxidase_10\NN\14971234|glutathione|gp|,|and|creb (l_conj) creb_16\NN\1740|
T7_T29 NONE ppa_22\NN\1740| (r_compound) treatment_23\NN\654885|during|ppa (r_nmod) pattern_18\NN\5726345|the|expression|treatment (r_nsubj) opposite_25\JJ\1740|pattern|was|those (r_conj) decreased_4\VBD\169651|contrast|,|npy|reduction||and|opposite|. (l_nsubj) npy_3\NN\1740|
T7_T31 NONE ppa_22\NN\1740| (r_compound) treatment_23\NN\654885|during|ppa (r_nmod) pattern_18\NN\5726345|the|expression|treatment (r_nsubj) opposite_25\JJ\1740|pattern|was|those (l_nmod) those_27\DT\1740|to|y1r (l_nmod) y1r_29\NN\1740|of|,|gp|,|and|creb
T7_T32 NONE ppa_22\NN\1740| (r_compound) treatment_23\NN\654885|during|ppa (r_nmod) pattern_18\NN\5726345|the|expression|treatment (r_nsubj) opposite_25\JJ\1740|pattern|was|those (l_nmod) those_27\DT\1740|to|y1r (l_nmod) y1r_29\NN\1740|of|,|gp|,|and|creb (l_conj) gp_31\NN\10020890|
T7_T33 NONE ppa_22\NN\1740| (r_compound) treatment_23\NN\654885|during|ppa (r_nmod) pattern_18\NN\5726345|the|expression|treatment (r_nsubj) opposite_25\JJ\1740|pattern|was|those (l_nmod) those_27\DT\1740|to|y1r (l_nmod) y1r_29\NN\1740|of|,|gp|,|and|creb (l_conj) creb_34\NN\1740|
T9_T35 NONE ppa_20\NN\1740|of (r_nmod) response_18\NN\11410625|the|anorectic|ppa|and|regulation (r_dobj) modulated_15\VBD\1724459|knockdown|response|,|revealing|. (l_nsubj) knockdown_1\NN\1173038|central|using|or|inhibition (l_conj) inhibition_7\NN\1068773|(|using|expression (l_nmod) expression_14\NN\4679549|of|y1r (l_compound) y1r_13\NN\1740|
T9_T36 NONE ppa_20\NN\1740|of (r_nmod) response_18\NN\11410625|the|anorectic|ppa|and|regulation (l_conj) regulation_24\NN\6652242|the|reciprocal|npy (l_nmod) npy_26\NN\1740|between|and|gp|creb
T9_T37 NONE ppa_20\NN\1740|of (r_nmod) response_18\NN\11410625|the|anorectic|ppa|and|regulation (l_conj) regulation_24\NN\6652242|the|reciprocal|npy (l_nmod) npy_26\NN\1740|between|and|gp|creb (l_conj) gp_28\NN\10020890|
T9_T38 NONE ppa_20\NN\1740|of (r_nmod) response_18\NN\11410625|the|anorectic|ppa|and|regulation (l_conj) regulation_24\NN\6652242|the|reciprocal|npy (l_nmod) npy_26\NN\1740|between|and|gp|creb (l_conj) creb_31\NN\1740|(|or|)
T9_T39 NONE ppa_20\NN\1740|of (r_nmod) response_18\NN\11410625|the|anorectic|ppa|and|regulation (r_dobj) modulated_15\VBD\1724459|knockdown|response|,|revealing|. (l_advcl) revealing_34\VBG\2137132|role (l_dobj) role_37\NN\719494|an|essential|y1r|regulating (l_nmod) y1r_39\NN\1740|of
T9_T40 NONE ppa_20\NN\1740|of (r_nmod) response_18\NN\11410625|the|anorectic|ppa|and|regulation (r_dobj) modulated_15\VBD\1724459|knockdown|response|,|revealing|. (l_advcl) revealing_34\VBG\2137132|role (l_dobj) role_37\NN\719494|an|essential|y1r|regulating (l_acl) regulating_41\VBG\296178|in|npy (l_dobj) npy_42\NN\1740|,|gp|,|and|creb
T9_T41 NONE ppa_20\NN\1740|of (r_nmod) response_18\NN\11410625|the|anorectic|ppa|and|regulation (r_dobj) modulated_15\VBD\1724459|knockdown|response|,|revealing|. (l_advcl) revealing_34\VBG\2137132|role (l_dobj) role_37\NN\719494|an|essential|y1r|regulating (l_acl) regulating_41\VBG\296178|in|npy (l_dobj) npy_42\NN\1740|,|gp|,|and|creb (l_conj) gp_44\NN\10020890|
T9_T42 NONE ppa_20\NN\1740|of (r_nmod) response_18\NN\11410625|the|anorectic|ppa|and|regulation (r_dobj) modulated_15\VBD\1724459|knockdown|response|,|revealing|. (l_advcl) revealing_34\VBG\2137132|role (l_dobj) role_37\NN\719494|an|essential|y1r|regulating (l_acl) regulating_41\VBG\296178|in|npy (l_dobj) npy_42\NN\1740|,|gp|,|and|creb (l_conj) creb_47\NN\1740|
T1_T13 NONE ppa_21\NN\1740| (r_compound) treatment_22\NN\654885|during|ppa|rats (r_nmod) regulation_9\NN\6652242|in|the|reciprocal|npy|treatment (r_nmod) participates_5\VBZ\2367363|that|y1r|regulation (l_nsubj) y1r_4\NN\1740|
T1_T14 NONE ppa_21\NN\1740| (r_compound) treatment_22\NN\654885|during|ppa|rats (r_nmod) regulation_9\NN\6652242|in|the|reciprocal|npy|treatment (l_nmod) npy_11\NN\1740|of|,|gp|,|and|creb|hypothalamus
T1_T15 NONE ppa_21\NN\1740| (r_compound) treatment_22\NN\654885|during|ppa|rats (r_nmod) regulation_9\NN\6652242|in|the|reciprocal|npy|treatment (l_nmod) npy_11\NN\1740|of|,|gp|,|and|creb|hypothalamus (l_conj) gp_13\NN\10020890|
T1_T16 NONE ppa_21\NN\1740| (r_compound) treatment_22\NN\654885|during|ppa|rats (r_nmod) regulation_9\NN\6652242|in|the|reciprocal|npy|treatment (l_nmod) npy_11\NN\1740|of|,|gp|,|and|creb|hypothalamus (l_conj) creb_16\NN\1740|
23229509
T6_T25 NONE adenylyl_2\JJ\1740| (r_amod) cyclase_3\NN\1740|on|adenylyl|vii (l_nummod) vii_4\CD\13741022|
T6_T26 NONE adenylyl_2\JJ\1740| (r_amod) cyclase_3\NN\1740|on|adenylyl|vii (r_nmod) regions_0\NNS\27167|cyclase|required|. (l_acl) required_5\VBN\754942|regulation (l_nmod) regulation_8\NN\6652242|for|selective|pathway (l_nmod) pathway_12\NN\5483677|by|the|g13 (l_compound) g13_11\NN\1740|
T1_T10 NONE adenylyl_3\JJ\1740| (r_amod) cyclases_4\NNS\1740|of|multiple|adenylyl|ac
T1_T13 NONE adenylyl_3\JJ\1740| (r_amod) cyclases_4\NNS\1740|of|multiple|adenylyl|ac (l_appos) ac_6\NNS\14622893|(|)
T5_T10 CPR:9 camp_16\NN\3763727|of|,|messenger (r_nmod) synthesis_14\NN\13446390|the|camp (r_dobj) mediate_12\VB\761713|to|synthesis (r_acl:relcl) inputs_10\NNS\6791372|unique|mediate (r_dobj) provides_8\VBZ\2199590|regulation|inputs|. (l_nsubj) regulation_0\NN\6652242|cyclases (l_nmod) cyclases_4\NNS\1740|of|multiple|adenylyl|ac
T5_T13 CPR:9 camp_16\NN\3763727|of|,|messenger (r_nmod) synthesis_14\NN\13446390|the|camp (r_dobj) mediate_12\VB\761713|to|synthesis (r_acl:relcl) inputs_10\NNS\6791372|unique|mediate (r_dobj) provides_8\VBZ\2199590|regulation|inputs|. (l_nsubj) regulation_0\NN\6652242|cyclases (l_nmod) cyclases_4\NNS\1740|of|multiple|adenylyl|ac (l_appos) ac_6\NNS\14622893|(|)
T2_T8 NONE camp_24\NN\3763727| (r_compound) responses_25\NNS\11410625|of|intracellular|camp|stimuli (r_nmod) control_21\NN\5190804|precise|responses (r_dobj) ensure_19\VB\664483|to|control (r_xcomp) modulated_14\VBN\1724459|stimulation|,|activities|can|be|further|selectively|pathways|ensure|. (l_nmod) stimulation_1\NN\242808|on|g(s (l_nmod) g(s_3\NNS\1740|by|) (l_punct) )_4\-RRB-\1740|
T2_T9 CPR:9 camp_24\NN\3763727| (r_compound) responses_25\NNS\11410625|of|intracellular|camp|stimuli (r_nmod) control_21\NN\5190804|precise|responses (r_dobj) ensure_19\VB\664483|to|control (r_xcomp) modulated_14\VBN\1724459|stimulation|,|activities|can|be|further|selectively|pathways|ensure|. (l_nsubjpass) activities_7\NNS\30358|the|acs (l_nmod) acs_9\NN\14622893|of
T3_T18 NONE camp_8\NN\3763727|of (r_nmod) regulation_6\NN\6652242|camp|gβγ (l_nmod) gβγ_10\NN\1740|by
T3_T19 NONE camp_8\NN\3763727|of (r_nmod) regulation_6\NN\6652242|camp|gβγ (r_dobj) restore_5\VB\1631072|although|enzymes|could|fully|regulation (r_advcl) synergized_19\VBD\1740|restore|,|activation|preferentially|ac7|. (l_nsubj) activation_12\NN\13561719|pathway (l_nmod) pathway_17\NN\5483677|of|the|g(13|) (l_punct) )_16\-RRB-\1740|
T3_T20 NONE camp_8\NN\3763727|of (r_nmod) regulation_6\NN\6652242|camp|gβγ (r_dobj) restore_5\VB\1631072|although|enzymes|could|fully|regulation (r_advcl) synergized_19\VBD\1740|restore|,|activation|preferentially|ac7|. (l_nmod) ac7_21\NN\1740|with
T4_T21 NONE n-terminus_14\NN\1740|the|domain (r_conj) domain_11\NN\13934596|the|c1b|and|n-terminus
T4_T22 NONE n-terminus_14\NN\1740|the|domain (l_nmod) domain_18\NN\13934596|of|the|c1a
T4_T23 NONE n-terminus_14\NN\1740|the|domain (r_conj) domain_11\NN\13934596|the|c1b|and|n-terminus (r_nsubj) important_20\JJ\1740|that|domain|are|directing (l_advcl) directing_22\VBG\746718|for|regulation|pathway (l_dobj) regulation_24\NN\6652242|selective|ac7 (l_nmod) ac7_26\NN\1740|of
T4_T24 NONE n-terminus_14\NN\1740|the|domain (r_conj) domain_11\NN\13934596|the|c1b|and|n-terminus (r_nsubj) important_20\JJ\1740|that|domain|are|directing (l_advcl) directing_22\VBG\746718|for|regulation|pathway (l_nmod) pathway_31\NN\5483677|by|the|g(13|) (l_punct) )_30\-RRB-\1740|
16344985
T25_T36 CPR:4 acid_1\NN\14818238|valproic (r_nsubj) inhibits_3\VBZ\2510337|acid|selectively|conversion|:|relevance|. (l_dobj) conversion_4\NN\7359599|acid|arachidonoyl-coa|synthetases (l_nmod) synthetases_16\NNS\1740|by|brain|microsomal|long-chain|fatty|acyl-coa
T26_T36 NONE acyl-coa_15\NN\1740| (r_compound) synthetases_16\NNS\1740|by|brain|microsomal|long-chain|fatty|acyl-coa
T27_T36 CPR:9 acid_7\NN\14818238|of|arachidonic (r_nmod) conversion_4\NN\7359599|acid|arachidonoyl-coa|synthetases (l_nmod) synthetases_16\NNS\1740|by|brain|microsomal|long-chain|fatty|acyl-coa
T28_T36 CPR:9 arachidonoyl-coa_9\NN\1740|to (r_nmod) conversion_4\NN\7359599|acid|arachidonoyl-coa|synthetases (l_nmod) synthetases_16\NNS\1740|by|brain|microsomal|long-chain|fatty|acyl-coa
T11_T31 NONE acid_31\NN\14818238|docosahexaenoic (r_conj) acid_26\NN\14818238|of|arachidonic|,|not|acid|, (r_nmod) turnover_23\NN\13819207|the|acid (r_dobj) reduce_21\VBP\441445|drugs|,|administered|,|turnover|phospholipids|decreasing (l_advcl) decreasing_37\VBG\169651|by|activity (l_dobj) activity_39\NN\30358|the|a(2 (l_nmod) a(2_45\NN\1740|of|an|arachidonic|acid-selective|phospholipase|) (l_punct) )_46\-RRB-\1740|
T12_T31 NONE acid-selective_43\JJ\1740| (r_amod) a(2_45\NN\1740|of|an|arachidonic|acid-selective|phospholipase|) (l_punct) )_46\-RRB-\1740|
T16_T31 CPR:4 lithium_10\NN\14625458|(|and|carbamazepine|) (r_dep) drugs_3\NNS\14778436|several|used|lithium (r_nsubj) reduce_21\VBP\441445|drugs|,|administered|,|turnover|phospholipids|decreasing (l_advcl) decreasing_37\VBG\169651|by|activity (l_dobj) activity_39\NN\30358|the|a(2 (l_nmod) a(2_45\NN\1740|of|an|arachidonic|acid-selective|phospholipase|) (l_punct) )_46\-RRB-\1740|
T19_T31 CPR:4 carbamazepine_12\NN\1740| (r_conj) lithium_10\NN\14625458|(|and|carbamazepine|) (r_dep) drugs_3\NNS\14778436|several|used|lithium (r_nsubj) reduce_21\VBP\441445|drugs|,|administered|,|turnover|phospholipids|decreasing (l_advcl) decreasing_37\VBG\169651|by|activity (l_dobj) activity_39\NN\30358|the|a(2 (l_nmod) a(2_45\NN\1740|of|an|arachidonic|acid-selective|phospholipase|) (l_punct) )_46\-RRB-\1740|
T7_T31 NONE acid_26\NN\14818238|of|arachidonic|,|not|acid|, (r_nmod) turnover_23\NN\13819207|the|acid (r_dobj) reduce_21\VBP\441445|drugs|,|administered|,|turnover|phospholipids|decreasing (l_advcl) decreasing_37\VBG\169651|by|activity (l_dobj) activity_39\NN\30358|the|a(2 (l_nmod) a(2_45\NN\1740|of|an|arachidonic|acid-selective|phospholipase|) (l_punct) )_46\-RRB-\1740|
T13_T32 NONE acid_3\NN\14818238|chronic|valproic (r_nsubj) produces_4\VBZ\1617192|although|acid|effects|acid (r_advcl) alter_19\VB\126264|produces|,|it|does|not|a(2|activity|,|suggesting|. (l_punct) a(2_21\NN\1740|phospholipase|) (l_punct) )_22\-RRB-\1740|
T14_T32 NONE acid_10\NN\14818238|on|brain|arachidonic|and|acid|turnover (r_nmod) produces_4\VBZ\1617192|although|acid|effects|acid (r_advcl) alter_19\VB\126264|produces|,|it|does|not|a(2|activity|,|suggesting|. (l_punct) a(2_21\NN\1740|phospholipase|) (l_punct) )_22\-RRB-\1740|
T15_T32 NONE acid_13\NN\14818238|docosahexaenoic (r_conj) acid_10\NN\14818238|on|brain|arachidonic|and|acid|turnover (r_nmod) produces_4\VBZ\1617192|although|acid|effects|acid (r_advcl) alter_19\VB\126264|produces|,|it|does|not|a(2|activity|,|suggesting|. (l_punct) a(2_21\NN\1740|phospholipase|) (l_punct) )_22\-RRB-\1740|
T17_T33 NONE acyl-coa_11\NN\1740| (r_compound) synthetases_12\NNS\1740|brain|microsomal|long-chain|fatty|acyl-coa|acsl
T17_T34 NONE acyl-coa_11\NN\1740| (r_compound) synthetases_12\NNS\1740|brain|microsomal|long-chain|fatty|acyl-coa|acsl (l_appos) acsl_14\NNS\1740|(|)
T17_T35 NONE acyl-coa_11\NN\1740| (r_compound) synthetases_12\NNS\1740|brain|microsomal|long-chain|fatty|acyl-coa|acsl (r_dobj) isolating_5\VBG\2512305|by|synthetases (r_advcl) show_18\VBP\2137132|isolating|,|we|vitro|inhibitor (l_ccomp) inhibitor_27\NN\20090|that|acid|is|a|non-competitive|acsl|,|reduces (l_nmod) acsl_29\NN\1740|of
T18_T33 NONE acid_23\NN\14818238|valproic (r_nsubj) inhibitor_27\NN\20090|that|acid|is|a|non-competitive|acsl|,|reduces (r_ccomp) show_18\VBP\2137132|isolating|,|we|vitro|inhibitor (l_advcl) isolating_5\VBG\2512305|by|synthetases (l_dobj) synthetases_12\NNS\1740|brain|microsomal|long-chain|fatty|acyl-coa|acsl
T18_T34 NONE acid_23\NN\14818238|valproic (r_nsubj) inhibitor_27\NN\20090|that|acid|is|a|non-competitive|acsl|,|reduces (r_ccomp) show_18\VBP\2137132|isolating|,|we|vitro|inhibitor (l_advcl) isolating_5\VBG\2512305|by|synthetases (l_dobj) synthetases_12\NNS\1740|brain|microsomal|long-chain|fatty|acyl-coa|acsl (l_appos) acsl_14\NNS\1740|(|)
T18_T35 CPR:4 acid_23\NN\14818238|valproic (r_nsubj) inhibitor_27\NN\20090|that|acid|is|a|non-competitive|acsl|,|reduces (l_nmod) acsl_29\NN\1740|of
T5_T29 NONE valproyl-coa._8\NN\1740| (r_dobj) produce_7\VB\1617192|furthermore|,|acsl|did|not|valproyl-coa. (l_nsubj) acsl_4\NN\1740|brain|microsomal
T6_T30 CPR:4 acid_7\NN\14818238|valproic (r_nsubj) acts_8\VBZ\1619354|that|acid|inhibitor|,|and|substrate-selective (l_nmod) inhibitor_12\NN\20090|as|a|non-competitive|acsl (l_nmod) acsl_16\NN\1740|of|brain|microsomal
23428155
T2_T10 CPR:4 benzoxazinyl-oxazolidinone_22\NN\1740| (r_compound) analogues_23\NNS\4743605|of|benzoxazinyl-oxazolidinone|activity (l_nmod) activity_27\NN\30358|with|high|antibacterial|pathogens|,|that (l_nmod) that_33\DT\1740|including|strains (l_nmod) strains_36\NNS\7358060|against|linezolid-resistant|and|inhibition (l_conj) inhibition_40\NN\1068773|low|herg (l_compound) herg_39\NN\1740|
T3_T10 NONE linezolid-resistant_35\JJ\1740| (r_amod) strains_36\NNS\7358060|against|linezolid-resistant|and|inhibition (l_conj) inhibition_40\NN\1068773|low|herg (l_compound) herg_39\NN\1740|
T5_T10 NONE benzoxazinyl-oxazolidinones_8\NN\1740|of|(|pyridin-3-yl|) (r_nmod) modification_3\NN\191142|the|solubility-driven|structural|benzoxazinyl-oxazolidinones (r_nsubjpass) described_10\VBN\1001294|modification|is|,|resulted|. (l_ccomp) resulted_13\VBD\2633881|which|development (l_nmod) development_16\NN\248977|in|the|series (l_nmod) series_20\NN\8456993|of|a|new|analogues (l_nmod) analogues_23\NNS\4743605|of|benzoxazinyl-oxazolidinone|activity (l_nmod) activity_27\NN\30358|with|high|antibacterial|pathogens|,|that (l_nmod) that_33\DT\1740|including|strains (l_nmod) strains_36\NNS\7358060|against|linezolid-resistant|and|inhibition (l_conj) inhibition_40\NN\1068773|low|herg (l_compound) herg_39\NN\1740|
10839333
T8_T21 NONE dopamine_21\NN\14807737| (r_compound) occupancy_24\NN\1053920|with|high|dopamine|d2|receptor (l_compound) receptor_23\NN\5225602|
T9_T21 NONE quetiapine_6\NN\1740|of|schizophrenia (r_nmod) study_4\NN\635850|a|tomography|quetiapine|:|finding (l_dep) finding_12\NN\43195|a|preliminary|effect|. (l_nmod) effect_16\NN\34213|of|an|antipsychotic|occupancy (l_nmod) occupancy_24\NN\1053920|with|high|dopamine|d2|receptor (l_compound) receptor_23\NN\5225602|
T4_T14 NONE dopamine_15\NN\14807737| (r_compound) type_16\NN\5839024|dopamine|2|d2|and|type (l_nummod) 2_17\CD\13741022|
T4_T16 NONE dopamine_15\NN\14807737| (r_compound) type_16\NN\5839024|dopamine|2|d2|and|type (l_appos) d2_19\NN\1740|(|)
T4_T17 NONE dopamine_15\NN\14807737| (r_compound) type_16\NN\5839024|dopamine|2|d2|and|type (r_compound) systems_29\NNS\3575240|at|the|type|receptor (l_compound) receptor_28\NN\5225602|
T5_T14 NONE serotonin_22\NN\14807737| (r_compound) type_23\NN\5839024|serotonin|2a|5-ht2a (r_conj) type_16\NN\5839024|dopamine|2|d2|and|type (l_nummod) 2_17\CD\13741022|
T5_T16 NONE serotonin_22\NN\14807737| (r_compound) type_23\NN\5839024|serotonin|2a|5-ht2a (r_conj) type_16\NN\5839024|dopamine|2|d2|and|type (l_appos) d2_19\NN\1740|(|)
T5_T17 NONE serotonin_22\NN\14807737| (r_compound) type_23\NN\5839024|serotonin|2a|5-ht2a (r_conj) type_16\NN\5839024|dopamine|2|d2|and|type (r_compound) systems_29\NNS\3575240|at|the|type|receptor (l_compound) receptor_28\NN\5225602|
T7_T20 CPR:3 quetiapine_2\NN\1740| (r_nsubj) antipsychotic_6\NN\4470232|quetiapine|was|an|effective|and|improved (l_conj) improved_8\VBD\126264|symptoms (l_dobj) symptoms_11\NNS\5823932|the|extrapyramidal|and|elevation|noted (l_conj) elevation_15\NN\7445480|prolactin|level (l_compound) prolactin_13\NN\5410315|
T1_T11 NONE quetiapine_7\NN\1740| (r_nsubj) give_9\VB\2327200|that|quetiapine|does|rise|occupancy|hours|dose (l_nmod) occupancy_19\NN\1053920|to|high|d2 (l_compound) d2_18\NN\1740|
T3_T12 NONE quetiapine_2\NN\1740| (r_nsubj) shows_3\VBZ\2137132|quetiapine|occupancy (l_dobj) occupancy_8\NN\1053920|a|high|d2|,|decreases (l_compound) d2_7\NN\1740|
15291969
T2_T23 NONE nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_compound) p2x_27\NN\1740|
T2_T26 NONE nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_conj) receptors_33\NNS\5225602|protein-coupled|p2y
T3_T23 NONE atp_5\NN\14964590|(|,|adp|,|utp|and|udp|) (r_dep) nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_compound) p2x_27\NN\1740|
T3_T26 NONE atp_5\NN\14964590|(|,|adp|,|utp|and|udp|) (r_dep) nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_conj) receptors_33\NNS\5225602|protein-coupled|p2y
T4_T23 NONE adp_7\NN\14964590| (r_conj) atp_5\NN\14964590|(|,|adp|,|utp|and|udp|) (r_dep) nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_compound) p2x_27\NN\1740|
T4_T26 NONE adp_7\NN\14964590| (r_conj) atp_5\NN\14964590|(|,|adp|,|utp|and|udp|) (r_dep) nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_conj) receptors_33\NNS\5225602|protein-coupled|p2y
T5_T23 NONE utp_9\NN\1740| (r_conj) atp_5\NN\14964590|(|,|adp|,|utp|and|udp|) (r_dep) nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_compound) p2x_27\NN\1740|
T5_T26 NONE utp_9\NN\1740| (r_conj) atp_5\NN\14964590|(|,|adp|,|utp|and|udp|) (r_dep) nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_conj) receptors_33\NNS\5225602|protein-coupled|p2y
T6_T23 NONE udp_11\NN\1740| (r_conj) atp_5\NN\14964590|(|,|adp|,|utp|and|udp|) (r_dep) nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_compound) p2x_27\NN\1740|
T6_T26 NONE udp_11\NN\1740| (r_conj) atp_5\NN\14964590|(|,|adp|,|utp|and|udp|) (r_dep) nucleotides_3\NNS\14850483|extracellular|atp (r_nsubj) exert_13\VBP\1158872|nucleotides|range|cells (l_nmod) cells_22\NNS\3080309|in|blood|mediated (l_acl) mediated_23\VBN\761713|receptors (l_nmod) receptors_28\NNS\5225602|by|multiple|ionotropic|p2x|and|receptors (l_conj) receptors_33\NNS\5225602|protein-coupled|p2y
T1_T22 NONE clopidogrel_22\NN\1740|of (r_nmod) effects_20\NNS\13245626|the|anti-inflammatory|clopidogrel|,|receptors|and|expression (r_dobj) explaining_17\VBG\831651|potentially|effects (r_acl) expression_10\NN\4679549|findings|were|the|high|mrna|receptors|explaining (l_nmod) receptors_13\NNS\5225602|of|p2y12|lymphocytes (l_compound) p2y12_12\NN\1740|
T1_T24 NONE clopidogrel_22\NN\1740|of (r_nmod) effects_20\NNS\13245626|the|anti-inflammatory|clopidogrel|,|receptors|and|expression (l_conj) receptors_25\NNS\5225602|p2y13|monocytes (l_compound) p2y13_24\NN\1740|
T1_T25 NONE clopidogrel_22\NN\1740|of (r_nmod) effects_20\NNS\13245626|the|anti-inflammatory|clopidogrel|,|receptors|and|expression (l_conj) expression_32\NN\4679549|a|unrecognised|p2x4|lymphocytes (l_nmod) p2x4_34\NN\1740|of
8697470
T1_T10 NONE acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (r_dobj) received_94\VBD\2210855|finally|,|rabbits|acid (r_parataxis) received_19\VBD\2210855|animals|catheter|;|received|received|;|received (l_parataxis) received_69\VBD\2210855|animals|ridogrel (l_dobj) ridogrel_70\NN\1740|,|inhibitor|bolus|) (l_appos) inhibitor_77\NN\20090|a|dual|thromboxane|a2|synthetase|and|antagonist (l_compound) synthetase_76\NN\1740|
T1_T12 NONE acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (r_dobj) received_94\VBD\2210855|finally|,|rabbits|acid (r_parataxis) received_19\VBD\2210855|animals|catheter|;|received|received|;|received (l_parataxis) received_69\VBD\2210855|animals|ridogrel (l_dobj) ridogrel_70\NN\1740|,|inhibitor|bolus|) (l_appos) inhibitor_77\NN\20090|a|dual|thromboxane|a2|synthetase|and|antagonist (l_conj) antagonist_82\NN\7846|thromboxane|a2|receptor (l_compound) receptor_81\NN\5225602|
T1_T14 CPR:4 acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (l_appos) inhibitor_102\NN\20090|an|interaction|bolus (l_nmod) interaction_109\NN\37396|of|platelet|glycoprotein|ib/von|willebrand|factor (l_compound) ib/von_106\NN\1740|
T1_T15 CPR:4 acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (l_appos) inhibitor_102\NN\20090|an|interaction|bolus (l_nmod) interaction_109\NN\37396|of|platelet|glycoprotein|ib/von|willebrand|factor (l_compound) factor_108\NN\7326557|
T1_T7 NONE acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (r_dobj) received_94\VBD\2210855|finally|,|rabbits|acid (r_parataxis) received_19\VBD\2210855|animals|catheter|;|received|received|;|received (l_nmod) catheter_23\NN\4493505|via|a|small|g|placed|,|infusion (l_appos) infusion_36\NN\14589223|an|intra-arterial|fviiai|mg/kg/min (l_nmod) fviiai_40\NN\1740|of|human|recombinant
T1_T9 NONE acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (r_dobj) received_94\VBD\2210855|finally|,|rabbits|acid (r_parataxis) received_19\VBD\2210855|animals|catheter|;|received|received|;|received (l_parataxis) received_51\VBD\2210855|animals|ap-1|; (l_dobj) ap-1_52\NN\1740|,|antibody|mg/kg (l_appos) antibody_56\NN\14728724|a|monoclonal|tf (l_nmod) tf_59\NN\1740|against|rabbit
T2_T10 NONE ata_98\NN\1740|(|) (r_appos) acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (r_dobj) received_94\VBD\2210855|finally|,|rabbits|acid (r_parataxis) received_19\VBD\2210855|animals|catheter|;|received|received|;|received (l_parataxis) received_69\VBD\2210855|animals|ridogrel (l_dobj) ridogrel_70\NN\1740|,|inhibitor|bolus|) (l_appos) inhibitor_77\NN\20090|a|dual|thromboxane|a2|synthetase|and|antagonist (l_compound) synthetase_76\NN\1740|
T2_T12 NONE ata_98\NN\1740|(|) (r_appos) acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (r_dobj) received_94\VBD\2210855|finally|,|rabbits|acid (r_parataxis) received_19\VBD\2210855|animals|catheter|;|received|received|;|received (l_parataxis) received_69\VBD\2210855|animals|ridogrel (l_dobj) ridogrel_70\NN\1740|,|inhibitor|bolus|) (l_appos) inhibitor_77\NN\20090|a|dual|thromboxane|a2|synthetase|and|antagonist (l_conj) antagonist_82\NN\7846|thromboxane|a2|receptor (l_compound) receptor_81\NN\5225602|
T2_T14 CPR:4 ata_98\NN\1740|(|) (r_appos) acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (l_appos) inhibitor_102\NN\20090|an|interaction|bolus (l_nmod) interaction_109\NN\37396|of|platelet|glycoprotein|ib/von|willebrand|factor (l_compound) ib/von_106\NN\1740|
T2_T15 CPR:4 ata_98\NN\1740|(|) (r_appos) acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (l_appos) inhibitor_102\NN\20090|an|interaction|bolus (l_nmod) interaction_109\NN\37396|of|platelet|glycoprotein|ib/von|willebrand|factor (l_compound) factor_108\NN\7326557|
T2_T7 NONE ata_98\NN\1740|(|) (r_appos) acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (r_dobj) received_94\VBD\2210855|finally|,|rabbits|acid (r_parataxis) received_19\VBD\2210855|animals|catheter|;|received|received|;|received (l_nmod) catheter_23\NN\4493505|via|a|small|g|placed|,|infusion (l_appos) infusion_36\NN\14589223|an|intra-arterial|fviiai|mg/kg/min (l_nmod) fviiai_40\NN\1740|of|human|recombinant
T2_T9 NONE ata_98\NN\1740|(|) (r_appos) acid_96\NN\14818238|aurintrycarboxilic|ata|,|inhibitor (r_dobj) received_94\VBD\2210855|finally|,|rabbits|acid (r_parataxis) received_19\VBD\2210855|animals|catheter|;|received|received|;|received (l_parataxis) received_51\VBD\2210855|animals|ap-1|; (l_dobj) ap-1_52\NN\1740|,|antibody|mg/kg (l_appos) antibody_56\NN\14728724|a|monoclonal|tf (l_nmod) tf_59\NN\1740|against|rabbit
T4_T29 NONE ata_10\NN\1740|ridogrel|e (r_nmod:npmod) treated_11\JJ\1740|ata (r_amod) rabbits_12\NNS\2323902|in|treated|rabbits (r_nmod) restore_5\VB\1631072|to|cfvs|rabbits (r_xcomp) failed_3\VBD\1798936|infusion|restore|,|showing|. (l_nsubj) infusion_0\NN\14589223|fviia (l_nmod) fviia_2\NN\1740|of
T4_T30 NONE ata_10\NN\1740|ridogrel|e (r_nmod:npmod) treated_11\JJ\1740|ata (r_amod) rabbits_12\NNS\2323902|in|treated|rabbits (r_nmod) restore_5\VB\1631072|to|cfvs|rabbits (r_xcomp) failed_3\VBD\1798936|infusion|restore|,|showing|. (l_xcomp) showing_26\VBG\2137132|overcome (l_ccomp) overcome_35\VBN\1101913|that|activation|was|inhibition (l_nsubjpass) activation_28\NN\13561719|coagulation|fviia (l_nmod) fviia_33\NN\1740|by
T5_T32 NONE adp_13\NN\14964590|in|response|to|and|thrombin (l_conj) thrombin_15\NN\14735953|
T5_T33 NONE adp_13\NN\14964590|in|response|to|and|thrombin (r_nmod) aggregation_9\NN\31264|ex|platelet|adp (r_conj) time_3\NN\7308889|activated|partial|thromboplastin|,|and|aggregation|, (r_nsubj) different_19\JJ\1740|time|were|not|infusion|,|prolonged|. (l_nmod) infusion_22\NN\14589223|after|fviiai (l_compound) fviiai_21\NN\1740|
23466488
T38_T58 NONE stretpozotocin-nicotinamide_17\NN\1740| (r_nmod:npmod) induced_18\JJ\1740|stretpozotocin-nicotinamide (r_amod) rats_20\NNS\2329401|in|induced|diabetic (r_nmod) control_15\NN\5190804|glycemic|rats (r_dobj) improves_13\VBZ\126264|control (r_conj) increases_2\VBZ\169651|l-glutamine|secretion|and|improves|. (l_dobj) secretion_11\NN\13526110|active|glp-1|amide (l_compound) glp-1_4\NN\1740|
T39_T58 NONE amide_10\NN\14727670|-|36|) (r_compound) secretion_11\NN\13526110|active|glp-1|amide (l_compound) glp-1_4\NN\1740|
T40_T58 CPR:3 l-glutamine_1\NN\1740|oral (r_nsubj) increases_2\VBZ\169651|l-glutamine|secretion|and|improves|. (l_dobj) secretion_11\NN\13526110|active|glp-1|amide (l_compound) glp-1_4\NN\1740|
T41_T58 NONE stretpozotocin-nicotinamide_17\NN\1740| (r_nmod:npmod) induced_18\JJ\1740|stretpozotocin-nicotinamide (r_amod) rats_20\NNS\2329401|in|induced|diabetic (r_nmod) control_15\NN\5190804|glycemic|rats (r_dobj) improves_13\VBZ\126264|control (r_conj) increases_2\VBZ\169651|l-glutamine|secretion|and|improves|. (l_dobj) secretion_11\NN\13526110|active|glp-1|amide (l_compound) glp-1_4\NN\1740|
T30_T57 NONE sugar_3\NN\7858595|blood|,|secretion (l_appos) secretion_7\NN\13526110|stimulated|insulin (l_compound) insulin_6\NN\5407119|
T18_T54 CPR:3 l-glutamine_9\NN\1740| (r_nsubj) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1
T18_T55 CPR:3 l-glutamine_9\NN\1740| (r_nsubj) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1 (l_appos) glp-1_15\NN\1740|(|)|-
T22_T54 NONE amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1
T22_T55 NONE amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1 (l_appos) glp-1_15\NN\1740|(|)|-
T23_T54 NONE streptozotocin-nicotinamide_25\NN\1740|stz-ntm (r_nmod:npmod) induced_29\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_33\NNS\2329401|in|induced|diabetic|sprague|dawley (r_nmod) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1
T23_T55 NONE streptozotocin-nicotinamide_25\NN\1740|stz-ntm (r_nmod:npmod) induced_29\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_33\NNS\2329401|in|induced|diabetic|sprague|dawley (r_nmod) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1 (l_appos) glp-1_15\NN\1740|(|)|-
T24_T54 NONE streptozotocin-nicotinamide_25\NN\1740|stz-ntm (r_nmod:npmod) induced_29\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_33\NNS\2329401|in|induced|diabetic|sprague|dawley (r_nmod) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1
T24_T55 NONE streptozotocin-nicotinamide_25\NN\1740|stz-ntm (r_nmod:npmod) induced_29\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_33\NNS\2329401|in|induced|diabetic|sprague|dawley (r_nmod) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1 (l_appos) glp-1_15\NN\1740|(|)|-
T25_T54 NONE stz-ntm_27\NN\1740|(|) (r_appos) streptozotocin-nicotinamide_25\NN\1740|stz-ntm (r_nmod:npmod) induced_29\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_33\NNS\2329401|in|induced|diabetic|sprague|dawley (r_nmod) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1
T25_T55 NONE stz-ntm_27\NN\1740|(|) (r_appos) streptozotocin-nicotinamide_25\NN\1740|stz-ntm (r_nmod:npmod) induced_29\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_33\NNS\2329401|in|induced|diabetic|sprague|dawley (r_nmod) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1 (l_appos) glp-1_15\NN\1740|(|)|-
T26_T54 NONE stz-ntm_27\NN\1740|(|) (r_appos) streptozotocin-nicotinamide_25\NN\1740|stz-ntm (r_nmod:npmod) induced_29\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_33\NNS\2329401|in|induced|diabetic|sprague|dawley (r_nmod) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1
T26_T55 NONE stz-ntm_27\NN\1740|(|) (r_appos) streptozotocin-nicotinamide_25\NN\1740|stz-ntm (r_nmod:npmod) induced_29\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_33\NNS\2329401|in|induced|diabetic|sprague|dawley (r_nmod) increases_10\VBZ\169651|l-glutamine|secretion|rats (l_dobj) secretion_23\NN\13526110|amide (l_compound) amide_22\NN\14727670|peptide-1|36|) (l_compound) peptide-1_13\NN\1740|glucagon|like|glp-1 (l_appos) glp-1_15\NN\1740|(|)|-
T2_T42 NONE amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (r_conj) plasma_6\NN\5398023|and|amide (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers
T2_T43 NONE amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (l_compound) glp-1_11\NN\1740|
T2_T44 NONE amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (r_conj) plasma_6\NN\5398023|and|amide (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) expression_21\NN\4679549|mrna|glp-1 (l_nmod) glp-1_24\NN\1740|of|proglucagon
T2_T45 NONE amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (r_conj) plasma_6\NN\5398023|and|amide (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_26\NN\5398023|and|insulin (l_conj) insulin_29\NN\5407119|pancreatic
T2_T46 NONE amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (r_conj) plasma_6\NN\5398023|and|amide (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) biomarkers_35\NNS\1740|stress|dismutase (l_dep) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|)
T2_T47 NONE amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (r_conj) plasma_6\NN\5398023|and|amide (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) biomarkers_35\NNS\1740|stress|dismutase (l_dep) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (l_appos) peroxidase_49\NN\14971234|glutathione
T2_T48 NONE amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (r_conj) plasma_6\NN\5398023|and|amide (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) biomarkers_35\NNS\1740|stress|dismutase (l_dep) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (l_appos) transferase_53\NN\14732946|glutathione|s
T3_T42 NONE glutathione_44\NN\1740|reduced (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers
T3_T43 NONE glutathione_44\NN\1740|reduced (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_6\NN\5398023|and|amide (l_conj) amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (l_compound) glp-1_11\NN\1740|
T3_T44 NONE glutathione_44\NN\1740|reduced (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) expression_21\NN\4679549|mrna|glp-1 (l_nmod) glp-1_24\NN\1740|of|proglucagon
T3_T45 NONE glutathione_44\NN\1740|reduced (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_26\NN\5398023|and|insulin (l_conj) insulin_29\NN\5407119|pancreatic
T3_T46 NONE glutathione_44\NN\1740|reduced (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|)
T3_T47 NONE glutathione_44\NN\1740|reduced (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (l_appos) peroxidase_49\NN\14971234|glutathione
T3_T48 NONE glutathione_44\NN\1740|reduced (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (l_appos) transferase_53\NN\14732946|glutathione|s
T4_T42 NONE malondialdehyde_46\NN\1740| (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers
T4_T43 NONE malondialdehyde_46\NN\1740| (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_6\NN\5398023|and|amide (l_conj) amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (l_compound) glp-1_11\NN\1740|
T4_T44 NONE malondialdehyde_46\NN\1740| (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) expression_21\NN\4679549|mrna|glp-1 (l_nmod) glp-1_24\NN\1740|of|proglucagon
T4_T45 NONE malondialdehyde_46\NN\1740| (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_26\NN\5398023|and|insulin (l_conj) insulin_29\NN\5407119|pancreatic
T4_T46 NONE malondialdehyde_46\NN\1740| (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|)
T4_T47 NONE malondialdehyde_46\NN\1740| (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (l_appos) peroxidase_49\NN\14971234|glutathione
T4_T48 NONE malondialdehyde_46\NN\1740| (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (l_appos) transferase_53\NN\14732946|glutathione|s
T5_T42 NONE glutathione_48\NN\1740| (r_compound) peroxidase_49\NN\14971234|glutathione (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers
T5_T43 NONE glutathione_48\NN\1740| (r_compound) peroxidase_49\NN\14971234|glutathione (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_6\NN\5398023|and|amide (l_conj) amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (l_compound) glp-1_11\NN\1740|
T5_T44 NONE glutathione_48\NN\1740| (r_compound) peroxidase_49\NN\14971234|glutathione (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) expression_21\NN\4679549|mrna|glp-1 (l_nmod) glp-1_24\NN\1740|of|proglucagon
T5_T45 NONE glutathione_48\NN\1740| (r_compound) peroxidase_49\NN\14971234|glutathione (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_26\NN\5398023|and|insulin (l_conj) insulin_29\NN\5407119|pancreatic
T5_T46 NONE glutathione_48\NN\1740| (r_compound) peroxidase_49\NN\14971234|glutathione (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|)
T5_T47 NONE glutathione_48\NN\1740| (r_compound) peroxidase_49\NN\14971234|glutathione
T5_T48 NONE glutathione_48\NN\1740| (r_compound) peroxidase_49\NN\14971234|glutathione (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (l_appos) transferase_53\NN\14732946|glutathione|s
T6_T42 NONE glutathione_51\NN\1740| (r_compound) transferase_53\NN\14732946|glutathione|s (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers
T6_T43 NONE glutathione_51\NN\1740| (r_compound) transferase_53\NN\14732946|glutathione|s (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_6\NN\5398023|and|amide (l_conj) amide_18\NN\14727670|colonic|active|(|glp-1|)|(|7|-|36|) (l_compound) glp-1_11\NN\1740|
T6_T44 NONE glutathione_51\NN\1740| (r_compound) transferase_53\NN\14732946|glutathione|s (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) expression_21\NN\4679549|mrna|glp-1 (l_nmod) glp-1_24\NN\1740|of|proglucagon
T6_T45 NONE glutathione_51\NN\1740| (r_compound) transferase_53\NN\14732946|glutathione|s (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (r_dep) biomarkers_35\NNS\1740|stress|dismutase (r_conj) haemoglobin_1\NN\14888884|glycosylated|,|profile|,|plasma|,|expression|,|plasma|,|histology|and|biomarkers (l_conj) plasma_26\NN\5398023|and|insulin (l_conj) insulin_29\NN\5407119|pancreatic
T6_T46 NONE glutathione_51\NN\1740| (r_compound) transferase_53\NN\14732946|glutathione|s (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|)
T6_T47 NONE glutathione_51\NN\1740| (r_compound) transferase_53\NN\14732946|glutathione|s (r_appos) dismutase_41\NN\1740|(|superoxidase|,|glutathione|,|malondialdehyde|,|peroxidase|,|transferase|) (l_appos) peroxidase_49\NN\14971234|glutathione
T6_T48 NONE glutathione_51\NN\1740| (r_compound) transferase_53\NN\14732946|glutathione|s
T12_T49 NONE glucose_1\NN\14710501|plasma|,|concentration|and|levels (l_conj) concentration_11\NN\4916342|active|glp-1|)|amide (l_compound) glp-1_4\NN\1740|-
T12_T50 NONE glucose_1\NN\14710501|plasma|,|concentration|and|levels (l_conj) levels_14\NNS\4916342|insulin (l_compound) insulin_13\NN\5407119|
T13_T49 NONE amide_10\NN\14727670| (r_compound) concentration_11\NN\4916342|active|glp-1|)|amide (l_compound) glp-1_4\NN\1740|-
T13_T50 NONE amide_10\NN\14727670| (r_compound) concentration_11\NN\4916342|active|glp-1|)|amide (r_conj) glucose_1\NN\14710501|plasma|,|concentration|and|levels (l_conj) levels_14\NNS\4916342|insulin (l_compound) insulin_13\NN\5407119|
T14_T49 NONE glucose_18\NN\14710501| (r_compound) loading_19\NN\4571088|after|glucose (r_nmod) measured_16\VBN\697589|glucose|were|loading|. (l_nsubjpass) glucose_1\NN\14710501|plasma|,|concentration|and|levels (l_conj) concentration_11\NN\4916342|active|glp-1|)|amide (l_compound) glp-1_4\NN\1740|-
T14_T50 NONE glucose_18\NN\14710501| (r_compound) loading_19\NN\4571088|after|glucose (r_nmod) measured_16\VBN\697589|glucose|were|loading|. (l_nsubjpass) glucose_1\NN\14710501|plasma|,|concentration|and|levels (l_conj) levels_14\NNS\4916342|insulin (l_compound) insulin_13\NN\5407119|
T15_T51 NONE l-glutamine_5\NN\1740| (r_nsubj) bind_6\VBP\1290422|that|l-glutamine|receptor (l_nmod) receptor_10\NN\5225602|to|the|glp-1
T16_T52 CPR:3 l-glutamine_0\NN\1740| (r_nsubj) decreased_1\VBD\169651|l-glutamine|glucose|plasma|as|decreased|. (l_dobj) glucose_3\NN\14710501|plasma|,|plasma|, (l_conj) plasma_6\NN\5398023|increased|and|insulin (l_conj) insulin_9\NN\5407119|pancreatic
T16_T53 CPR:3 l-glutamine_0\NN\1740| (r_nsubj) decreased_1\VBD\169651|l-glutamine|glucose|plasma|as|decreased|. (l_dobj) plasma_12\NN\5398023|increased|and|secretion (l_conj) secretion_23\NN\13526110|colonic|active|glp-1|36|)|amide (l_compound) glp-1_16\NN\1740|-
T17_T52 NONE glucose_3\NN\14710501|plasma|,|plasma|, (l_conj) plasma_6\NN\5398023|increased|and|insulin (l_conj) insulin_9\NN\5407119|pancreatic
T17_T53 NONE glucose_3\NN\14710501|plasma|,|plasma|, (r_dobj) decreased_1\VBD\169651|l-glutamine|glucose|plasma|as|decreased|. (l_dobj) plasma_12\NN\5398023|increased|and|secretion (l_conj) secretion_23\NN\13526110|colonic|active|glp-1|36|)|amide (l_compound) glp-1_16\NN\1740|-
T19_T52 NONE amide_22\NN\14727670| (r_compound) secretion_23\NN\13526110|colonic|active|glp-1|36|)|amide (r_conj) plasma_12\NN\5398023|increased|and|secretion (r_dobj) decreased_1\VBD\169651|l-glutamine|glucose|plasma|as|decreased|. (l_dobj) glucose_3\NN\14710501|plasma|,|plasma|, (l_conj) plasma_6\NN\5398023|increased|and|insulin (l_conj) insulin_9\NN\5407119|pancreatic
T19_T53 NONE amide_22\NN\14727670| (r_compound) secretion_23\NN\13526110|colonic|active|glp-1|36|)|amide (l_compound) glp-1_16\NN\1740|-
T20_T52 NONE streptozotocin-nicotinamide_31\NN\1740| (r_nmod:npmod) induced_32\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_34\NNS\2329401|in|induced|diabetic (r_nmod) decreased_27\VBD\169651|stress|rats (r_conj) decreased_1\VBD\169651|l-glutamine|glucose|plasma|as|decreased|. (l_dobj) glucose_3\NN\14710501|plasma|,|plasma|, (l_conj) plasma_6\NN\5398023|increased|and|insulin (l_conj) insulin_9\NN\5407119|pancreatic
T20_T53 NONE streptozotocin-nicotinamide_31\NN\1740| (r_nmod:npmod) induced_32\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_34\NNS\2329401|in|induced|diabetic (r_nmod) decreased_27\VBD\169651|stress|rats (r_conj) decreased_1\VBD\169651|l-glutamine|glucose|plasma|as|decreased|. (l_dobj) plasma_12\NN\5398023|increased|and|secretion (l_conj) secretion_23\NN\13526110|colonic|active|glp-1|36|)|amide (l_compound) glp-1_16\NN\1740|-
T21_T52 NONE streptozotocin-nicotinamide_31\NN\1740| (r_nmod:npmod) induced_32\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_34\NNS\2329401|in|induced|diabetic (r_nmod) decreased_27\VBD\169651|stress|rats (r_conj) decreased_1\VBD\169651|l-glutamine|glucose|plasma|as|decreased|. (l_dobj) glucose_3\NN\14710501|plasma|,|plasma|, (l_conj) plasma_6\NN\5398023|increased|and|insulin (l_conj) insulin_9\NN\5407119|pancreatic
T21_T53 NONE streptozotocin-nicotinamide_31\NN\1740| (r_nmod:npmod) induced_32\JJ\1740|streptozotocin-nicotinamide (r_amod) rats_34\NNS\2329401|in|induced|diabetic (r_nmod) decreased_27\VBD\169651|stress|rats (r_conj) decreased_1\VBD\169651|l-glutamine|glucose|plasma|as|decreased|. (l_dobj) plasma_12\NN\5398023|increased|and|secretion (l_conj) secretion_23\NN\13526110|colonic|active|glp-1|36|)|amide (l_compound) glp-1_16\NN\1740|-
23376217
T5_T22 NONE acyl-coa_8\NN\1740| (r_compound) synthetase_9\NN\1740|acyl-coa (r_compound) gene_11\NN\8459252|of|the|synthetase|4 (l_nummod) 4_10\CD\13741022|
T5_T23 NONE acyl-coa_8\NN\1740| (r_compound) synthetase_9\NN\1740|acyl-coa (r_compound) gene_11\NN\8459252|of|the|synthetase|4 (r_nmod) region_5\NN\27167|of|the|mouse|promoter|gene (r_nmod) characterization_0\NN\6724763|region|:|role (l_dep) role_13\NN\719494|sp1|. (l_nmod) sp1_15\NN\1740|of|and|creb
T5_T24 NONE acyl-coa_8\NN\1740| (r_compound) synthetase_9\NN\1740|acyl-coa (r_compound) gene_11\NN\8459252|of|the|synthetase|4 (r_nmod) region_5\NN\27167|of|the|mouse|promoter|gene (r_nmod) characterization_0\NN\6724763|region|:|role (l_dep) role_13\NN\719494|sp1|. (l_nmod) sp1_15\NN\1740|of|and|creb (l_conj) creb_17\NN\1740|
T1_T6 NONE acyl-coa_0\NN\1740| (r_compound) synthetase_1\NN\1740|acyl-coa|4|acsl4 (l_nummod) 4_2\CD\13741022|
T1_T9 NONE acyl-coa_0\NN\1740| (r_compound) synthetase_1\NN\1740|acyl-coa|4|acsl4 (l_appos) acsl4_4\NN\1740|(|)
T3_T10 NONE camp_4\NN\3763727| (r_compound) regulation_5\NN\6652242|camp|mrna (r_conj) hcg_2\NN\5410315|and|regulation|cells
T3_T11 NONE camp_4\NN\3763727| (r_compound) regulation_5\NN\6652242|camp|mrna (l_nmod) mrna_8\NN\14832193|of|acsl4 (l_compound) acsl4_7\NN\1740|
T2_T18 NONE camp_30\NN\3763727| (r_compound) stimulation_31\NN\242808|in|camp|transcription (r_nmod) involved_28\VBN\2676054|that|site|is|stimulation (r_conj) involved_16\VBN\2676054|that|site|is|activity|and|involved (l_nsubjpass) site_10\NN\8673395|the|specificity|protein/krüppel-like|factor|sp1|binding|promoter (l_amod) protein/krüppel-like_6\JJ\1740|
T2_T19 NONE camp_30\NN\3763727| (r_compound) stimulation_31\NN\242808|in|camp|transcription (r_nmod) involved_28\VBN\2676054|that|site|is|stimulation (r_conj) involved_16\VBN\2676054|that|site|is|activity|and|involved (l_nsubjpass) site_10\NN\8673395|the|specificity|protein/krüppel-like|factor|sp1|binding|promoter (l_compound) factor_7\NN\7326557|
T2_T20 NONE camp_30\NN\3763727| (r_compound) stimulation_31\NN\242808|in|camp|transcription (r_nmod) involved_28\VBN\2676054|that|site|is|stimulation (r_conj) involved_16\VBN\2676054|that|site|is|activity|and|involved (l_nsubjpass) site_10\NN\8673395|the|specificity|protein/krüppel-like|factor|sp1|binding|promoter (l_compound) sp1_8\NN\1740|
T2_T21 NONE camp_30\NN\3763727| (r_compound) stimulation_31\NN\242808|in|camp|transcription (r_nmod) involved_28\VBN\2676054|that|site|is|stimulation (l_nsubjpass) site_26\NN\8673395|the|camp|response|element-binding (l_amod) element-binding_25\JJ\1740|
T2_T7 NONE camp_30\NN\3763727| (r_compound) stimulation_31\NN\242808|in|camp|transcription (l_nmod) transcription_34\NN\6349220|of|acsl4 (l_compound) acsl4_33\NN\1740|
T4_T18 NONE camp_23\NN\3763727| (r_compound) site_26\NN\8673395|the|camp|response|element-binding (r_nsubjpass) involved_28\VBN\2676054|that|site|is|stimulation (r_conj) involved_16\VBN\2676054|that|site|is|activity|and|involved (l_nsubjpass) site_10\NN\8673395|the|specificity|protein/krüppel-like|factor|sp1|binding|promoter (l_amod) protein/krüppel-like_6\JJ\1740|
T4_T19 NONE camp_23\NN\3763727| (r_compound) site_26\NN\8673395|the|camp|response|element-binding (r_nsubjpass) involved_28\VBN\2676054|that|site|is|stimulation (r_conj) involved_16\VBN\2676054|that|site|is|activity|and|involved (l_nsubjpass) site_10\NN\8673395|the|specificity|protein/krüppel-like|factor|sp1|binding|promoter (l_compound) factor_7\NN\7326557|
T4_T20 NONE camp_23\NN\3763727| (r_compound) site_26\NN\8673395|the|camp|response|element-binding (r_nsubjpass) involved_28\VBN\2676054|that|site|is|stimulation (r_conj) involved_16\VBN\2676054|that|site|is|activity|and|involved (l_nsubjpass) site_10\NN\8673395|the|specificity|protein/krüppel-like|factor|sp1|binding|promoter (l_compound) sp1_8\NN\1740|
T4_T21 NONE camp_23\NN\3763727| (r_compound) site_26\NN\8673395|the|camp|response|element-binding (l_amod) element-binding_25\JJ\1740|
T4_T7 NONE camp_23\NN\3763727| (r_compound) site_26\NN\8673395|the|camp|response|element-binding (r_nsubjpass) involved_28\VBN\2676054|that|site|is|stimulation (l_nmod) stimulation_31\NN\242808|in|camp|transcription (l_nmod) transcription_34\NN\6349220|of|acsl4 (l_compound) acsl4_33\NN\1740|
23541670
T3_T10 CPR:4 ethers_7\NNS\14840755|of|novel|5h-pyrrolo[2,3-b]pyrazine-2-phenyl (r_nmod) series_3\NN\8456993|of|a|ethers|,|inhibitors (l_nmod) inhibitors_13\NNS\20090|as|potent|kinase (l_compound) kinase_12\NN\14732946|jak3 (l_compound) jak3_11\NN\1740|
T3_T11 CPR:4 ethers_7\NNS\14840755|of|novel|5h-pyrrolo[2,3-b]pyrazine-2-phenyl (r_nmod) series_3\NN\8456993|of|a|ethers|,|inhibitors (l_nmod) inhibitors_13\NNS\20090|as|potent|kinase (l_compound) kinase_12\NN\14732946|jak3
T1_T8 CPR:4 5h-pyrrolo[2,3-b]pyrazine_20\NN\1740| (r_compound) scaffold_21\NN\3961939|on|the|5h-pyrrolo[2,3-b]pyrazine (r_nmod) based_17\VBN\2694933|scaffold (r_acl) series_7\NN\8456993|of|a|novel|inhibitors|based (l_nmod) inhibitors_16\NNS\20090|of|atp-competitive|kinase (l_compound) kinase_11\NN\14732946|janus|3|jak3 (l_nummod) 3_12\CD\13741022|
T1_T9 CPR:4 5h-pyrrolo[2,3-b]pyrazine_20\NN\1740| (r_compound) scaffold_21\NN\3961939|on|the|5h-pyrrolo[2,3-b]pyrazine (r_nmod) based_17\VBN\2694933|scaffold (r_acl) series_7\NN\8456993|of|a|novel|inhibitors|based (l_nmod) inhibitors_16\NNS\20090|of|atp-competitive|kinase (l_compound) kinase_11\NN\14732946|janus|3|jak3 (l_appos) jak3_14\NN\1740|(|)
T2_T8 NONE atp-competitive_9\JJ\1740| (r_amod) inhibitors_16\NNS\20090|of|atp-competitive|kinase (l_compound) kinase_11\NN\14732946|janus|3|jak3 (l_nummod) 3_12\CD\13741022|
T2_T9 NONE atp-competitive_9\JJ\1740| (r_amod) inhibitors_16\NNS\20090|of|atp-competitive|kinase (l_compound) kinase_11\NN\14732946|janus|3|jak3 (l_appos) jak3_14\NN\1740|(|)
18480678
T14_T30 NONE dopamine_3\NN\14807737| (r_compound) transporter_4\NN\4490091|the|dopamine|and|transporter
T14_T31 NONE dopamine_3\NN\14807737| (r_compound) transporter_4\NN\4490091|the|dopamine|and|transporter (l_conj) transporter_8\NN\4490091|the|norepinephrine
T16_T30 NONE norepinephrine_7\NN\14807929| (r_compound) transporter_8\NN\4490091|the|norepinephrine (r_conj) transporter_4\NN\4490091|the|dopamine|and|transporter
T16_T31 NONE norepinephrine_7\NN\14807929| (r_compound) transporter_8\NN\4490091|the|norepinephrine
T17_T30 CPR:9 monoamines_15\NNS\14739004|of|these (r_nmod) elevations_12\NNS\7445480|in|monoamines|release (r_nmod) resulting_10\VBG\2633881|elevations (r_advcl) inhibits_1\VBZ\2510337|threo-methylphenidate|transporter|,|resulting|. (l_dobj) transporter_4\NN\4490091|the|dopamine|and|transporter
T17_T31 CPR:9 monoamines_15\NNS\14739004|of|these (r_nmod) elevations_12\NNS\7445480|in|monoamines|release (r_nmod) resulting_10\VBG\2633881|elevations (r_advcl) inhibits_1\VBZ\2510337|threo-methylphenidate|transporter|,|resulting|. (l_dobj) transporter_4\NN\4490091|the|dopamine|and|transporter (l_conj) transporter_8\NN\4490091|the|norepinephrine
T8_T30 CPR:4 threo-methylphenidate_0\NN\1740| (r_nsubj) inhibits_1\VBZ\2510337|threo-methylphenidate|transporter|,|resulting|. (l_dobj) transporter_4\NN\4490091|the|dopamine|and|transporter
T8_T31 CPR:4 threo-methylphenidate_0\NN\1740| (r_nsubj) inhibits_1\VBZ\2510337|threo-methylphenidate|transporter|,|resulting|. (l_dobj) transporter_4\NN\4490091|the|dopamine|and|transporter (l_conj) transporter_8\NN\4490091|the|norepinephrine
T24_T32 NONE d-mph_12\NN\1740|of|radiolabeled (r_nmod) binding_9\NN\4688246|the|d-mph|transporter (l_nmod) transporter_15\NN\4490091|to|dopamine
T25_T32 NONE dopamine_14\NN\14807737| (r_compound) transporter_15\NN\4490091|to|dopamine
T26_T32 NONE l-mph_30\NN\1740|of (r_nmod) binding_28\NN\4688246|l-mph (r_nsubj) diffuse_32\JJ\1740|whereas|binding|was|and|nonspecific (r_advcl) selective_20\JJ\1740|to|be|,|saturable|,|and|reversible|,|diffuse (r_xcomp) found_17\VBN\2426171|models|,|binding|was|selective|. (l_nsubjpass) binding_9\NN\4688246|the|d-mph|transporter (l_nmod) transporter_15\NN\4490091|to|dopamine
T10_T29 NONE mph_9\NN\15286249| (r_compound) receptor_10\NN\5225602|mph
T11_T29 NONE d-mph_20\NN\1740| (r_nsubj) binds_21\VBZ\1290422|that|d-mph|specifically|structures|,|nonspecific (r_ccomp) revealing_18\VBG\2137132|binds (r_acl) studies_17\NNS\635850|in|human|imaging|revealing (r_nmod) culminated_13\VBN\2609764|importance|has|studies|. (l_nsubj) importance_1\NN\5138488|the|chirality|targeting (l_nmod) targeting_11\NN\1740|to|system|receptor (l_compound) receptor_10\NN\5225602|mph
T12_T29 NONE l-mph_28\NN\1740| (r_compound) binding_29\NN\4688246|l-mph (r_nsubj) nonspecific_31\JJ\1740|whereas|binding|is (r_advcl) binds_21\VBZ\1290422|that|d-mph|specifically|structures|,|nonspecific (r_ccomp) revealing_18\VBG\2137132|binds (r_acl) studies_17\NNS\635850|in|human|imaging|revealing (r_nmod) culminated_13\VBN\2609764|importance|has|studies|. (l_nsubj) importance_1\NN\5138488|the|chirality|targeting (l_nmod) targeting_11\NN\1740|to|system|receptor (l_compound) receptor_10\NN\5225602|mph
T9_T29 NONE mph_3\NN\15286249| (r_compound) chirality_4\NN\1740|of|mph (r_nmod) importance_1\NN\5138488|the|chirality|targeting (l_nmod) targeting_11\NN\1740|to|system|receptor (l_compound) receptor_10\NN\5225602|mph
23639586
T4_T13 NONE glucose_13\NN\14710501| (r_compound) metabolism_14\NN\13526110|glucose (r_conj) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (l_compound) insulin_9\NN\5407119|
T4_T14 NONE glucose_13\NN\14710501| (r_compound) metabolism_14\NN\13526110|glucose (r_conj) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (r_nmod) associated_7\VBN\628491|pathway (r_acl) functions_6\NNS\13783581|over-represented|associated (r_dobj) identified_4\VBD\699815|analyses|functions|,|consistent|. (l_ccomp) consistent_26\JJ\1740|which|were|results (l_nmod) results_29\NNS\34213|with|the|increase (l_nmod) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activity_35\NN\30358|of|caspase-3 (l_compound) caspase-3_34\NN\1740|
T4_T15 NONE glucose_13\NN\14710501| (r_compound) metabolism_14\NN\13526110|glucose (r_conj) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (r_nmod) associated_7\VBN\628491|pathway (r_acl) functions_6\NNS\13783581|over-represented|associated (r_dobj) identified_4\VBD\699815|analyses|functions|,|consistent|. (l_ccomp) consistent_26\JJ\1740|which|were|results (l_nmod) results_29\NNS\34213|with|the|increase (l_nmod) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activities_49\NNS\30358|glucose-6-phosphatase (l_compound) glucose-6-phosphatase_45\NN\1740|and|carboxykinase
T4_T16 NONE glucose_13\NN\14710501| (r_compound) metabolism_14\NN\13526110|glucose (r_conj) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (r_nmod) associated_7\VBN\628491|pathway (r_acl) functions_6\NNS\13783581|over-represented|associated (r_dobj) identified_4\VBD\699815|analyses|functions|,|consistent|. (l_ccomp) consistent_26\JJ\1740|which|were|results (l_nmod) results_29\NNS\34213|with|the|increase (l_nmod) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activities_49\NNS\30358|glucose-6-phosphatase (l_compound) glucose-6-phosphatase_45\NN\1740|and|carboxykinase (l_conj) carboxykinase_48\NN\1740|phosphoenolpyruvate
T5_T13 NONE glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (r_nmod) results_29\NNS\34213|with|the|increase (r_nmod) consistent_26\JJ\1740|which|were|results (r_ccomp) identified_4\VBD\699815|analyses|functions|,|consistent|. (l_dobj) functions_6\NNS\13783581|over-represented|associated (l_acl) associated_7\VBN\628491|pathway (l_nmod) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (l_compound) insulin_9\NN\5407119|
T5_T14 NONE glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activity_35\NN\30358|of|caspase-3 (l_compound) caspase-3_34\NN\1740|
T5_T15 NONE glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activities_49\NNS\30358|glucose-6-phosphatase (l_compound) glucose-6-phosphatase_45\NN\1740|and|carboxykinase
T5_T16 NONE glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activities_49\NNS\30358|glucose-6-phosphatase (l_compound) glucose-6-phosphatase_45\NN\1740|and|carboxykinase (l_conj) carboxykinase_48\NN\1740|phosphoenolpyruvate
T6_T13 NONE gsh/gssg_42\NN\1740| (r_compound) ratio_43\NN\13815152|gsh/gssg (r_appos) glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (r_nmod) results_29\NNS\34213|with|the|increase (r_nmod) consistent_26\JJ\1740|which|were|results (r_ccomp) identified_4\VBD\699815|analyses|functions|,|consistent|. (l_dobj) functions_6\NNS\13783581|over-represented|associated (l_acl) associated_7\VBN\628491|pathway (l_nmod) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (l_compound) insulin_9\NN\5407119|
T6_T14 NONE gsh/gssg_42\NN\1740| (r_compound) ratio_43\NN\13815152|gsh/gssg (r_appos) glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activity_35\NN\30358|of|caspase-3 (l_compound) caspase-3_34\NN\1740|
T6_T15 NONE gsh/gssg_42\NN\1740| (r_compound) ratio_43\NN\13815152|gsh/gssg (r_appos) glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activities_49\NNS\30358|glucose-6-phosphatase (l_compound) glucose-6-phosphatase_45\NN\1740|and|carboxykinase
T6_T16 NONE gsh/gssg_42\NN\1740| (r_compound) ratio_43\NN\13815152|gsh/gssg (r_appos) glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activities_49\NNS\30358|glucose-6-phosphatase (l_compound) glucose-6-phosphatase_45\NN\1740|and|carboxykinase (l_conj) carboxykinase_48\NN\1740|phosphoenolpyruvate
T7_T13 NONE gsh/gssg_42\NN\1740| (r_compound) ratio_43\NN\13815152|gsh/gssg (r_appos) glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (r_nmod) results_29\NNS\34213|with|the|increase (r_nmod) consistent_26\JJ\1740|which|were|results (r_ccomp) identified_4\VBD\699815|analyses|functions|,|consistent|. (l_dobj) functions_6\NNS\13783581|over-represented|associated (l_acl) associated_7\VBN\628491|pathway (l_nmod) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (l_compound) insulin_9\NN\5407119|
T7_T14 NONE gsh/gssg_42\NN\1740| (r_compound) ratio_43\NN\13815152|gsh/gssg (r_appos) glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activity_35\NN\30358|of|caspase-3 (l_compound) caspase-3_34\NN\1740|
T7_T15 NONE gsh/gssg_42\NN\1740| (r_compound) ratio_43\NN\13815152|gsh/gssg (r_appos) glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activities_49\NNS\30358|glucose-6-phosphatase (l_compound) glucose-6-phosphatase_45\NN\1740|and|carboxykinase
T7_T16 NONE gsh/gssg_42\NN\1740| (r_compound) ratio_43\NN\13815152|gsh/gssg (r_appos) glucose_40\NN\14710501|of|serum|,|ratio|, (r_nmod) reduction_37\NN\351485|glucose (r_conj) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activities_49\NNS\30358|glucose-6-phosphatase (l_compound) glucose-6-phosphatase_45\NN\1740|and|carboxykinase (l_conj) carboxykinase_48\NN\1740|phosphoenolpyruvate
T8_T13 NONE glucose-6-phosphatase_45\NN\1740|and|carboxykinase (r_compound) activities_49\NNS\30358|glucose-6-phosphatase (r_nmod) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (r_nmod) results_29\NNS\34213|with|the|increase (r_nmod) consistent_26\JJ\1740|which|were|results (r_ccomp) identified_4\VBD\699815|analyses|functions|,|consistent|. (l_dobj) functions_6\NNS\13783581|over-represented|associated (l_acl) associated_7\VBN\628491|pathway (l_nmod) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (l_compound) insulin_9\NN\5407119|
T8_T14 NONE glucose-6-phosphatase_45\NN\1740|and|carboxykinase (r_compound) activities_49\NNS\30358|glucose-6-phosphatase (r_nmod) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activity_35\NN\30358|of|caspase-3 (l_compound) caspase-3_34\NN\1740|
T8_T15 NONE glucose-6-phosphatase_45\NN\1740|and|carboxykinase
T8_T16 NONE glucose-6-phosphatase_45\NN\1740|and|carboxykinase (l_conj) carboxykinase_48\NN\1740|phosphoenolpyruvate
T9_T13 NONE phosphoenolpyruvate_47\NN\1740| (r_compound) carboxykinase_48\NN\1740|phosphoenolpyruvate (r_conj) glucose-6-phosphatase_45\NN\1740|and|carboxykinase (r_compound) activities_49\NNS\30358|glucose-6-phosphatase (r_nmod) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (r_nmod) results_29\NNS\34213|with|the|increase (r_nmod) consistent_26\JJ\1740|which|were|results (r_ccomp) identified_4\VBD\699815|analyses|functions|,|consistent|. (l_dobj) functions_6\NNS\13783581|over-represented|associated (l_acl) associated_7\VBN\628491|pathway (l_nmod) pathway_11\NN\5483677|with|insulin|signaling|,|metabolism|,|cycle|,|stress|and|apoptosis (l_compound) insulin_9\NN\5407119|
T9_T14 NONE phosphoenolpyruvate_47\NN\1740| (r_compound) carboxykinase_48\NN\1740|phosphoenolpyruvate (r_conj) glucose-6-phosphatase_45\NN\1740|and|carboxykinase (r_compound) activities_49\NNS\30358|glucose-6-phosphatase (r_nmod) increase_32\NN\13576355|of|significant|activity|and|reduction|activities|,|glycogen (l_nmod) activity_35\NN\30358|of|caspase-3 (l_compound) caspase-3_34\NN\1740|
T9_T15 NONE phosphoenolpyruvate_47\NN\1740| (r_compound) carboxykinase_48\NN\1740|phosphoenolpyruvate (r_conj) glucose-6-phosphatase_45\NN\1740|and|carboxykinase
T9_T16 NONE phosphoenolpyruvate_47\NN\1740| (r_compound) carboxykinase_48\NN\1740|phosphoenolpyruvate
T2_T12 NONE glucose_15\NN\14710501|serum (r_dobj) reduce_13\VB\441445|glucose (r_conj) alter_7\VB\126264|that|treatment|could|status|,|reduce|and|induce|,|consistent (l_advmod) consistent_21\JJ\1740|expression (l_nmod) expression_25\NN\4679549|with|the|differential|genes (l_nmod) genes_27\NNS\8459252|of|involved|,|contribute (l_acl) involved_28\VBN\2676054|pathway (l_nmod) pathway_32\NN\5483677|in|insulin|signaling|,|pathway|and|pathway (l_compound) insulin_30\NN\5407119|
T3_T12 NONE glucose_34\NN\14710501| (r_compound) pathway_36\NN\5483677|glucose|metabolism (r_conj) pathway_32\NN\5483677|in|insulin|signaling|,|pathway|and|pathway (l_compound) insulin_30\NN\5407119|
23530959
T5_T15 NONE peptidyl-dopa_18\NN\1740|through (r_nmod) catalyzed_15\VBD\146138|adhesive|oxidase|curing|peptidyl-dopa|. (l_nsubj) oxidase_14\NN\14732946|catechol
T6_T15 NONE catechol_13\NN\1740| (r_compound) oxidase_14\NN\14732946|catechol
T1_T12 NONE catechol_5\NN\1740| (r_compound) oxidase_6\NN\14732946|catechol|catalyzes
T2_T12 CPR:9 l-dopa_12\NN\14604959|of (r_nmod) cross-linking_10\NN\1740|oxidative|l-dopa (r_dobj) catalyzes_8\VBZ\146138|that|cross-linking (r_acl:relcl) oxidase_6\NN\14732946|catechol|catalyzes
T3_T13 NONE catechol_2\NN\1740| (r_compound) oxidase_3\NN\14732946|of|catechol
T4_T14 NONE catechol_0\NN\1740| (r_compound) oxidase_1\NN\14732946|catechol
17352685
T5_T15 CPR:9 amp_10\NN\13633375| (r_compound) enzyme_12\NN\14723628|phosphodiesterase|is|the|predominant|cyclic|amp|degrading|variety|. (l_nsubj) phosphodiesterase_1\NN\1740|the|pde (l_appos) pde_3\NN\1740|(|)|4 (l_nummod) 4_5\CD\13741022|
T6_T18 CPR:4 cilomilast_5\NNP\1740|including|and|awd (r_nmod) inhibitors_3\NNS\20090|pde4|cilomilast (l_compound) pde4_2\NN\1740|
T7_T18 CPR:4 281_10\CD\1740|- (r_prep) 12_8\CD\13745420|281 (r_nummod) awd_7\NNP\1740|12 (r_conj) cilomilast_5\NNP\1740|including|and|awd (r_nmod) inhibitors_3\NNS\20090|pde4|cilomilast (l_compound) pde4_2\NN\1740|
T8_T19 NONE acid_19\NN\14818238|arachidonic (r_nmod:npmod) induced_20\JJ\1740|acid (r_amod) inflammation_22\NN\14299637|in|the|induced|skin|mice (r_conj) models_8\NNS\5888929|in|dermatitis|,|inflammation (r_nmod) displayed_3\VBD\2137132|inhibitors|action|models|. (l_nsubj) inhibitors_2\NNS\20090|these|pde4 (l_compound) pde4_1\NN\1740|
T8_T20 NONE acid_19\NN\14818238|arachidonic (r_nmod:npmod) induced_20\JJ\1740|acid (r_amod) inflammation_22\NN\14299637|in|the|induced|skin|mice (l_nmod) mice_24\NNS\2329401|in|and|pigs (l_conj) pigs_30\NNS\2395003|in|sensitised|guinea (l_amod) sensitised_28\JJ\1740|ovalbumin (l_nmod:npmod) ovalbumin_27\NN\7809096|
T1_T12 CPR:4 cipamfylline_9\NN\1740|with|both|topically|(|,|cp80,633|)|and|cc-10004 (r_compound) inhibitors_20\NNS\20090|cipamfylline|active|pde4 (l_compound) pde4_19\NN\1740|
T2_T12 CPR:4 cp80,633_11\NN\1740| (r_appos) cipamfylline_9\NN\1740|with|both|topically|(|,|cp80,633|)|and|cc-10004 (r_compound) inhibitors_20\NNS\20090|cipamfylline|active|pde4 (l_compound) pde4_19\NN\1740|
12170059
T20_T37 NONE acetylcholine_1\NN\14807558| (r_compound) receptor_2\NN\5225602|nicotinic|acetylcholine
T21_T37 NONE norepinephrine_6\NN\14807929| (r_compound) release_7\NN\3748886|of|spinal|norepinephrine (r_nmod) regulation_3\NN\6652242|receptor|release|. (l_compound) receptor_2\NN\5225602|nicotinic|acetylcholine
T12_T24 NONE acetylcholine_4\NN\14807558| (r_compound) receptor_5\NN\5225602|neuronal|nicotinic|acetylcholine|nachr
T12_T32 NONE acetylcholine_4\NN\14807558| (r_compound) receptor_5\NN\5225602|neuronal|nicotinic|acetylcholine|nachr (l_appos) nachr_7\NN\1740|(|)
T13_T31 NONE norepinephrine_12\NN\14807929| (r_dep) neurotransmitter_11\NN\14807410|of|the|norepinephrine (r_nmod) release_8\NN\3748886|spinal|neurotransmitter (r_dobj) stimulate_6\VBP\137313|whether|agonists|release|actions|or|stimulating (l_nsubj) agonists_5\NNS\9613191|nachr (l_compound) nachr_4\NN\1740|
T14_T31 NONE norepinephrine_30\NN\14807929| (r_compound) release_31\NN\3748886|norepinephrine (r_dobj) induce_29\VB\1627355|to|release (r_advcl) stimulating_23\VBG\137313|indirectly|by|release|induce (r_conj) stimulate_6\VBP\137313|whether|agonists|release|actions|or|stimulating (l_nsubj) agonists_5\NNS\9613191|nachr (l_compound) nachr_4\NN\1740|
T15_T33 CPR:5 metanicotine_17\NN\1740|the|specific|alpha(4)beta(2|*|)|nachr|agonist (l_compound) nachr_15\NN\1740|
T15_T34 NONE metanicotine_17\NN\1740|the|specific|alpha(4)beta(2|*|)|nachr|agonist (r_conj) nicotine_8\NN\14712692|,|metanicotine|,|or|antagonists (l_conj) antagonists_23\NNS\7846|nicotine|and|norepinephrine (l_compound) nicotine_20\NN\14712692|plus|nachr (l_conj) nachr_22\NN\1740|
T16_T33 CPR:5 nicotine_20\NN\14712692|plus|nachr (r_compound) antagonists_23\NNS\7846|nicotine|and|norepinephrine (r_conj) nicotine_8\NN\14712692|,|metanicotine|,|or|antagonists (l_conj) metanicotine_17\NN\1740|the|specific|alpha(4)beta(2|*|)|nachr|agonist (l_compound) nachr_15\NN\1740|
T16_T34 NONE nicotine_20\NN\14712692|plus|nachr (l_conj) nachr_22\NN\1740|
T17_T33 NONE norepinephrine_25\NN\14807929|measured (r_conj) antagonists_23\NNS\7846|nicotine|and|norepinephrine (r_conj) nicotine_8\NN\14712692|,|metanicotine|,|or|antagonists (l_conj) metanicotine_17\NN\1740|the|specific|alpha(4)beta(2|*|)|nachr|agonist (l_compound) nachr_15\NN\1740|
T17_T34 NONE norepinephrine_25\NN\14807929|measured (r_conj) antagonists_23\NNS\7846|nicotine|and|norepinephrine (l_compound) nicotine_20\NN\14712692|plus|nachr (l_conj) nachr_22\NN\1740|
T18_T35 NONE glutamate_4\NN\15010703| (r_compound) antagonists_6\NNS\7846|of|specific|glutamate|receptor|and|inhibitors (l_compound) receptor_5\NN\5225602|
T18_T36 NONE glutamate_4\NN\15010703| (r_compound) antagonists_6\NNS\7846|of|specific|glutamate|receptor|and|inhibitors (l_conj) inhibitors_11\NNS\20090|synthase (l_compound) synthase_10\NN\1740|nitric|oxide
T19_T35 NONE oxide_9\NN\14818238| (r_compound) synthase_10\NN\1740|nitric|oxide (r_compound) inhibitors_11\NNS\20090|synthase (r_conj) antagonists_6\NNS\7846|of|specific|glutamate|receptor|and|inhibitors (l_compound) receptor_5\NN\5225602|
T19_T36 NONE oxide_9\NN\14818238| (r_compound) synthase_10\NN\1740|nitric|oxide
T1_T25 NONE nicotine_3\NN\14712692|both|and|metanicotine (r_nsubj) induced_6\VBD\1627355|results|nicotine|release|,|effect|. (l_dobj) effect_14\NN\34213|an|reduced (l_acl) reduced_15\VBN\441445|antagonists (l_nmod) antagonists_18\NNS\7846|by|nicotinic|not|antagonists (l_conj) antagonists_22\NNS\7846|glutamate|or|inhibitors (l_conj) inhibitors_27\NNS\20090|nitric|oxide|synthase (l_compound) synthase_26\NN\1740|
T2_T25 NONE metanicotine_5\NN\1740| (r_conj) nicotine_3\NN\14712692|both|and|metanicotine (r_nsubj) induced_6\VBD\1627355|results|nicotine|release|,|effect|. (l_dobj) effect_14\NN\34213|an|reduced (l_acl) reduced_15\VBN\441445|antagonists (l_nmod) antagonists_18\NNS\7846|by|nicotinic|not|antagonists (l_conj) antagonists_22\NNS\7846|glutamate|or|inhibitors (l_conj) inhibitors_27\NNS\20090|nitric|oxide|synthase (l_compound) synthase_26\NN\1740|
T3_T25 NONE norepinephrine_7\NN\14807929| (r_compound) release_8\NN\3748886|norepinephrine|microdialsyates (r_dobj) induced_6\VBD\1627355|results|nicotine|release|,|effect|. (l_dobj) effect_14\NN\34213|an|reduced (l_acl) reduced_15\VBN\441445|antagonists (l_nmod) antagonists_18\NNS\7846|by|nicotinic|not|antagonists (l_conj) antagonists_22\NNS\7846|glutamate|or|inhibitors (l_conj) inhibitors_27\NNS\20090|nitric|oxide|synthase (l_compound) synthase_26\NN\1740|
T4_T25 NONE glutamate_21\NN\15010703| (r_compound) antagonists_22\NNS\7846|glutamate|or|inhibitors (l_conj) inhibitors_27\NNS\20090|nitric|oxide|synthase (l_compound) synthase_26\NN\1740|
T5_T25 NONE oxide_25\NN\14818238| (r_compound) inhibitors_27\NNS\20090|nitric|oxide|synthase (l_compound) synthase_26\NN\1740|
T6_T26 NONE norepinephrine_6\NN\14807929| (r_compound) release_7\NN\3748886|norepinephrine|synaptosomes (r_dobj) stimulated_5\VBD\137313|both|release|,|and|blocked (l_conj) blocked_17\VBN\1476483|effect|was|concentrations|. (l_nmod) concentrations_20\NNS\4916342|at|lower|alpha(4)beta(2*)-|antagonists (l_nmod) alpha(4)beta(2*)-_22\NN\1740|of
T6_T27 NONE norepinephrine_6\NN\14807929| (r_compound) release_7\NN\3748886|norepinephrine|synaptosomes (r_dobj) stimulated_5\VBD\137313|both|release|,|and|blocked (l_conj) blocked_17\VBN\1476483|effect|was|concentrations|. (l_nmod) concentrations_20\NNS\4916342|at|lower|alpha(4)beta(2*)-|antagonists (l_nmod) antagonists_26\NNS\7846|than|alpha(7*)-preferring|nachr (l_amod) alpha(7*)-preferring_24\JJ\1740|
T6_T28 NONE norepinephrine_6\NN\14807929| (r_compound) release_7\NN\3748886|norepinephrine|synaptosomes (r_dobj) stimulated_5\VBD\137313|both|release|,|and|blocked (l_conj) blocked_17\VBN\1476483|effect|was|concentrations|. (l_nmod) concentrations_20\NNS\4916342|at|lower|alpha(4)beta(2*)-|antagonists (l_nmod) antagonists_26\NNS\7846|than|alpha(7*)-preferring|nachr (l_compound) nachr_25\NN\1740|
T7_T26 NONE metanicotine_15\NN\1740|of (r_nmod) effect_13\NN\34213|the|metanicotine (r_nsubjpass) blocked_17\VBN\1476483|effect|was|concentrations|. (l_nmod) concentrations_20\NNS\4916342|at|lower|alpha(4)beta(2*)-|antagonists (l_nmod) alpha(4)beta(2*)-_22\NN\1740|of
T7_T27 NONE metanicotine_15\NN\1740|of (r_nmod) effect_13\NN\34213|the|metanicotine (r_nsubjpass) blocked_17\VBN\1476483|effect|was|concentrations|. (l_nmod) concentrations_20\NNS\4916342|at|lower|alpha(4)beta(2*)-|antagonists (l_nmod) antagonists_26\NNS\7846|than|alpha(7*)-preferring|nachr (l_amod) alpha(7*)-preferring_24\JJ\1740|
T7_T28 NONE metanicotine_15\NN\1740|of (r_nmod) effect_13\NN\34213|the|metanicotine (r_nsubjpass) blocked_17\VBN\1476483|effect|was|concentrations|. (l_nmod) concentrations_20\NNS\4916342|at|lower|alpha(4)beta(2*)-|antagonists (l_nmod) antagonists_26\NNS\7846|than|alpha(7*)-preferring|nachr (l_compound) nachr_25\NN\1740|
T8_T29 NONE norepinephrine_19\NN\14807929| (r_compound) release_20\NN\3748886|spinal|norepinephrine (r_dobj) stimulate_17\VB\137313|is|to|release (l_cop) is_15\VBZ\836236|that|mechanism (l_nsubj) mechanism_7\NN\13446390|one|act (l_acl:relcl) act_12\VBP\1619354|which|agonists|analgesia (l_nsubj) agonists_11\NNS\9613191|nachr (l_compound) nachr_10\NN\1740|
T10_T30 NONE glutamate_31\NN\15010703| (r_compound) release_32\NN\3748886|through|glutamate|or|synthesis (r_nmod) stimulating_27\VBG\137313|by|indirectly|release|release (r_conj) actions_4\NNS\30358|by|nachrs|rather|stimulating (l_nmod) nachrs_9\NNS\1740|on|alpha(4)beta(2|*|)|,|and|subtypes
T11_T30 NONE oxide_35\NN\14818238| (r_compound) synthesis_36\NN\13446390|nitric|oxide (r_conj) release_32\NN\3748886|through|glutamate|or|synthesis (r_nmod) stimulating_27\VBG\137313|by|indirectly|release|release (r_conj) actions_4\NNS\30358|by|nachrs|rather|stimulating (l_nmod) nachrs_9\NNS\1740|on|alpha(4)beta(2|*|)|,|and|subtypes
T9_T30 NONE norepinephrine_28\NN\14807929| (r_compound) release_29\NN\3748886|norepinephrine (r_dobj) stimulating_27\VBG\137313|by|indirectly|release|release (r_conj) actions_4\NNS\30358|by|nachrs|rather|stimulating (l_nmod) nachrs_9\NNS\1740|on|alpha(4)beta(2|*|)|,|and|subtypes
23142699
T3_T19 NONE estrogen_5\NN\14745635| (r_compound) target_7\NN\7258332|pim-1|is|a|novel|estrogen|receptor|associating|. (l_nsubj) pim-1_1\NN\1740|proto-oncogene (l_compound) proto-oncogene_0\NN\5436752|
T3_T20 NONE estrogen_5\NN\14745635| (r_compound) target_7\NN\7258332|pim-1|is|a|novel|estrogen|receptor|associating|. (l_nsubj) pim-1_1\NN\1740|proto-oncogene
T3_T21 NONE estrogen_5\NN\14745635| (r_compound) target_7\NN\7258332|pim-1|is|a|novel|estrogen|receptor|associating|. (l_compound) receptor_6\NN\5225602|
T1_T7 CPR:3 estradiol_12\NN\14749794|to (r_nmod) response_10\NN\11410625|in|estradiol (r_nmod) induced_8\VBN\1627355|that|expression|is|response|cells|and|mediated (l_nsubjpass) expression_4\NN\4679549|the|pim-1 (l_nmod) pim-1_6\NN\1740|of
T1_T8 CPR:3 estradiol_12\NN\14749794|to (r_nmod) response_10\NN\11410625|in|estradiol (r_nmod) induced_8\VBN\1627355|that|expression|is|response|cells|and|mediated (l_conj) mediated_21\VBN\761713|that|induction|is|enhancers (l_nmod) enhancers_24\NNS\5853636|by|erα-regulated|located (l_amod) erα-regulated_23\JJ\1740|
T2_T16 NONE estrogens_18\NNS\14745635| (r_nsubj) contribute_20\VB\126264|which|estrogens|can|proliferation (r_acl:relcl) mechanism_15\NN\13446390|a|potential|contribute (r_dobj) adds_11\VBZ\156601|sum|,|identification|mechanism|. (l_nsubj) identification_3\NN\151497|pim-1|gene (l_nmod) pim-1_5\NN\1740|of
T2_T17 NONE estrogens_18\NNS\14745635| (r_nsubj) contribute_20\VB\126264|which|estrogens|can|proliferation (r_acl:relcl) mechanism_15\NN\13446390|a|potential|contribute (r_dobj) adds_11\VBZ\156601|sum|,|identification|mechanism|. (l_nsubj) identification_3\NN\151497|pim-1|gene (l_nmod) gene_10\NN\8459252|as|an|erα|target (l_compound) erα_8\NN\1740|
1284246
T12_T17 NONE acid_13\NN\14818238| (r_compound) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|) (l_appos) acy-1_16\NN\1740|
T12_T18 NONE acid_13\NN\14818238| (r_compound) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|) (r_dep) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) ec_19\NN\8294696|[|3.5.1.14|] (l_nummod) 3.5.1.14_20\CD\1740|
T12_T21 NONE acid_13\NN\14818238| (r_compound) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|) (r_dep) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) metalloprotein_25\NN\1740|a|dimeric|having
T12_T23 NONE acid_13\NN\14818238| (r_compound) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|) (r_dep) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_nummod) 1_10\CD\13741022|
T12_T25 NONE acid_13\NN\14818238| (r_compound) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|)
T2_T17 NONE +_29\NNS\1740| (r_dobj) having_26\VBG\2108377|zn2|+|molecule (r_acl) metalloprotein_25\NN\1740|a|dimeric|having (r_appos) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_dep) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|) (l_appos) acy-1_16\NN\1740|
T2_T18 NONE +_29\NNS\1740| (r_dobj) having_26\VBG\2108377|zn2|+|molecule (r_acl) metalloprotein_25\NN\1740|a|dimeric|having (r_appos) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) ec_19\NN\8294696|[|3.5.1.14|] (l_nummod) 3.5.1.14_20\CD\1740|
T2_T21 NONE +_29\NNS\1740| (r_dobj) having_26\VBG\2108377|zn2|+|molecule (r_acl) metalloprotein_25\NN\1740|a|dimeric|having
T2_T23 NONE +_29\NNS\1740| (r_dobj) having_26\VBG\2108377|zn2|+|molecule (r_acl) metalloprotein_25\NN\1740|a|dimeric|having (r_appos) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_nummod) 1_10\CD\13741022|
T2_T25 NONE +_29\NNS\1740| (r_dobj) having_26\VBG\2108377|zn2|+|molecule (r_acl) metalloprotein_25\NN\1740|a|dimeric|having (r_appos) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_dep) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|)
T3_T17 CPR:9 acids_41\NNS\14818238|of|n-acylated|l-amino (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_dep) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|) (l_appos) acy-1_16\NN\1740|
T3_T18 CPR:9 acids_41\NNS\14818238|of|n-acylated|l-amino (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) ec_19\NN\8294696|[|3.5.1.14|] (l_nummod) 3.5.1.14_20\CD\1740|
T3_T21 CPR:9 acids_41\NNS\14818238|of|n-acylated|l-amino (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) metalloprotein_25\NN\1740|a|dimeric|having
T3_T23 CPR:9 acids_41\NNS\14818238|of|n-acylated|l-amino (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_nummod) 1_10\CD\13741022|
T3_T25 CPR:9 acids_41\NNS\14818238|of|n-acylated|l-amino (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_dep) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|)
T4_T17 NONE acid_44\NN\14818238|except|l-aspartic (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_dep) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|) (l_appos) acy-1_16\NN\1740|
T4_T18 NONE acid_44\NN\14818238|except|l-aspartic (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) ec_19\NN\8294696|[|3.5.1.14|] (l_nummod) 3.5.1.14_20\CD\1740|
T4_T21 NONE acid_44\NN\14818238|except|l-aspartic (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) metalloprotein_25\NN\1740|a|dimeric|having
T4_T23 NONE acid_44\NN\14818238|except|l-aspartic (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_nummod) 1_10\CD\13741022|
T4_T25 NONE acid_44\NN\14818238|except|l-aspartic (r_nmod) deacylation_37\NN\1740|the|acids|acid (r_dobj) catalyzes_35\VBZ\146138|which|deacylation (r_acl:relcl) cdna_1\NN\14830364|a|encoding|,|catalyzes|, (l_acl) encoding_2\VBG\115157|sequence (l_dobj) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_dep) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|)
T5_T17 NONE acid_6\NN\14818238| (r_compound) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_dep) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|) (l_appos) acy-1_16\NN\1740|
T5_T18 NONE acid_6\NN\14818238| (r_compound) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) ec_19\NN\8294696|[|3.5.1.14|] (l_nummod) 3.5.1.14_20\CD\1740|
T5_T21 NONE acid_6\NN\14818238| (r_compound) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_appos) metalloprotein_25\NN\1740|a|dimeric|having
T5_T23 NONE acid_6\NN\14818238| (r_compound) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_nummod) 1_10\CD\13741022|
T5_T25 NONE acid_6\NN\14818238| (r_compound) sequence_7\NN\8457976|the|complete|amino|acid|aminoacylase (l_nmod) aminoacylase_9\NN\1740|of|1|aminohydrolase|ec|,|metalloprotein (l_dep) aminohydrolase_14\NN\1740|(|n-acylamino|acid|,|acy-1|)
T10_T22 NONE acetylalanine_50\NN\1740|with|n-terminus (r_nmod) chain_44\NN\8457976|of|a|single|acids|acetylalanine (r_nmod) consists_40\VBZ\2603699|each|chain (r_acl:relcl) subunits_30\NNS\13604718|of|two|identical|m(r|,|consists (r_nmod) consists_26\VBZ\2603699|that|acy-1|subunits (l_nsubj) acy-1_25\NN\1740|porcine|kidney
T11_T22 NONE n-terminus_53\NN\1740|at|the (r_nmod) acetylalanine_50\NN\1740|with|n-terminus (r_nmod) chain_44\NN\8457976|of|a|single|acids|acetylalanine (r_nmod) consists_40\VBZ\2603699|each|chain (r_acl:relcl) subunits_30\NNS\13604718|of|two|identical|m(r|,|consists (r_nmod) consists_26\VBZ\2603699|that|acy-1|subunits (l_nsubj) acy-1_25\NN\1740|porcine|kidney
T6_T22 NONE n-_8\JJ\1740|and|c-terminal (r_amod) acid_12\NN\14818238|n-|amino (r_compound) analyses_13\NNS\633864|the|acid|protein (r_conj) analysis_2\NN\633864|from|sequence|cdna|and|analyses (r_nmod) deduced_21\VBN\634472|analysis|,|it|is|consists|. (l_ccomp) consists_26\VBZ\2603699|that|acy-1|subunits (l_nsubj) acy-1_25\NN\1740|porcine|kidney
T7_T22 NONE c-terminal_10\JJ\1740| (r_conj) n-_8\JJ\1740|and|c-terminal (r_amod) acid_12\NN\14818238|n-|amino (r_compound) analyses_13\NNS\633864|the|acid|protein (r_conj) analysis_2\NN\633864|from|sequence|cdna|and|analyses (r_nmod) deduced_21\VBN\634472|analysis|,|it|is|consists|. (l_ccomp) consists_26\VBZ\2603699|that|acy-1|subunits (l_nsubj) acy-1_25\NN\1740|porcine|kidney
T8_T22 NONE acid_12\NN\14818238|n-|amino (r_compound) analyses_13\NNS\633864|the|acid|protein (r_conj) analysis_2\NN\633864|from|sequence|cdna|and|analyses (r_nmod) deduced_21\VBN\634472|analysis|,|it|is|consists|. (l_ccomp) consists_26\VBZ\2603699|that|acy-1|subunits (l_nsubj) acy-1_25\NN\1740|porcine|kidney
T9_T22 NONE acids_48\NNS\14818238|of|406|amino (r_nmod) chain_44\NN\8457976|of|a|single|acids|acetylalanine (r_nmod) consists_40\VBZ\2603699|each|chain (r_acl:relcl) subunits_30\NNS\13604718|of|two|identical|m(r|,|consists (r_nmod) consists_26\VBZ\2603699|that|acy-1|subunits (l_nsubj) acy-1_25\NN\1740|porcine|kidney
T13_T26 NONE acid_2\NN\14818238| (r_compound) sequence_3\NN\8457976|the|amino|acid|deduced (r_nsubj) identical_16\JJ\1740|sequence|was|that|. (l_nmod) that_18\DT\1740|to|deduced (l_acl) deduced_19\VBN\634472|acy-1 (l_nmod) acy-1_23\NN\1740|for|porcine|kidney
T14_T26 NONE nucleotide_7\NN\14850483| (r_compound) sequence_8\NN\8457976|from|the|nucleotide|cdna (r_nmod) deduced_4\VBN\634472|sequence (r_acl) sequence_3\NN\8457976|the|amino|acid|deduced (r_nsubj) identical_16\JJ\1740|sequence|was|that|. (l_nmod) that_18\DT\1740|to|deduced (l_acl) deduced_19\VBN\634472|acy-1 (l_nmod) acy-1_23\NN\1740|for|porcine|kidney
T15_T16 NONE acid_4\NN\14818238| (r_compound) sequence_5\NN\8457976|of|the|amino|acid|acy-1 (r_nmod) comparison_0\NN\635850|sequence|those (l_nmod) those_10\DT\1740|with|metalloenzymes (l_nmod) metalloenzymes_16\NNS\1740|of|other|-binding
T15_T28 NONE acid_4\NN\14818238| (r_compound) sequence_5\NN\8457976|of|the|amino|acid|acy-1 (l_nmod) acy-1_8\NN\1740|of|porcine
T1_T16 NONE +_14\JJ\1740|zn2 (r_nmod:npmod) -binding_15\JJ\1740|+ (r_amod) metalloenzymes_16\NNS\1740|of|other|-binding
T1_T28 NONE +_14\JJ\1740|zn2 (r_nmod:npmod) -binding_15\JJ\1740|+ (r_amod) metalloenzymes_16\NNS\1740|of|other|-binding (r_nmod) those_10\DT\1740|with|metalloenzymes (r_nmod) comparison_0\NN\635850|sequence|those (l_nmod) sequence_5\NN\8457976|of|the|amino|acid|acy-1 (l_nmod) acy-1_8\NN\1740|of|porcine
23220618
T10_T33 CPR:4 img_2\NN\1740|with|and|hyperoside (r_nmod) treatment_0\NN\654885|img (r_nsubj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_nmod) aptt_9\NN\1740|in|prolonged|and|pt|and|inhibition (l_conj) inhibition_13\NN\1068773|activities (l_nmod) activities_16\NNS\30358|of|the|thrombin (l_nmod) thrombin_18\NN\14735953|of|and|fxa
T10_T34 CPR:4 img_2\NN\1740|with|and|hyperoside (r_nmod) treatment_0\NN\654885|img (r_nsubj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_nmod) aptt_9\NN\1740|in|prolonged|and|pt|and|inhibition (l_conj) inhibition_13\NN\1068773|activities (l_nmod) activities_16\NNS\30358|of|the|thrombin (l_nmod) thrombin_18\NN\14735953|of|and|fxa (l_conj) fxa_20\NN\1740|
T10_T35 NONE img_2\NN\1740|with|and|hyperoside (r_nmod) treatment_0\NN\654885|img (r_nsubj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_conj) inhibited_26\VBD\2510337|img|production (l_dobj) production_27\NN\30358|thrombin|huvecs (l_nmod) thrombin_29\NN\14735953|of|and|fxa
T10_T36 NONE img_2\NN\1740|with|and|hyperoside (r_nmod) treatment_0\NN\654885|img (r_nsubj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_conj) inhibited_26\VBD\2510337|img|production (l_dobj) production_27\NN\30358|thrombin|huvecs (l_nmod) thrombin_29\NN\14735953|of|and|fxa (l_conj) fxa_31\NN\1740|
T11_T33 CPR:4 hyperoside_4\NN\1740| (r_conj) img_2\NN\1740|with|and|hyperoside (r_nmod) treatment_0\NN\654885|img (r_nsubj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_nmod) aptt_9\NN\1740|in|prolonged|and|pt|and|inhibition (l_conj) inhibition_13\NN\1068773|activities (l_nmod) activities_16\NNS\30358|of|the|thrombin (l_nmod) thrombin_18\NN\14735953|of|and|fxa
T11_T34 CPR:4 hyperoside_4\NN\1740| (r_conj) img_2\NN\1740|with|and|hyperoside (r_nmod) treatment_0\NN\654885|img (r_nsubj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_nmod) aptt_9\NN\1740|in|prolonged|and|pt|and|inhibition (l_conj) inhibition_13\NN\1068773|activities (l_nmod) activities_16\NNS\30358|of|the|thrombin (l_nmod) thrombin_18\NN\14735953|of|and|fxa (l_conj) fxa_20\NN\1740|
T11_T35 NONE hyperoside_4\NN\1740| (r_conj) img_2\NN\1740|with|and|hyperoside (r_nmod) treatment_0\NN\654885|img (r_nsubj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_conj) inhibited_26\VBD\2510337|img|production (l_dobj) production_27\NN\30358|thrombin|huvecs (l_nmod) thrombin_29\NN\14735953|of|and|fxa
T11_T36 NONE hyperoside_4\NN\1740| (r_conj) img_2\NN\1740|with|and|hyperoside (r_nmod) treatment_0\NN\654885|img (r_nsubj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_conj) inhibited_26\VBD\2510337|img|production (l_dobj) production_27\NN\30358|thrombin|huvecs (l_nmod) thrombin_29\NN\14735953|of|and|fxa (l_conj) fxa_31\NN\1740|
T12_T33 NONE img_23\NN\1740|or|hyperoside (r_nsubj) inhibited_26\VBD\2510337|img|production (r_conj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_nmod) aptt_9\NN\1740|in|prolonged|and|pt|and|inhibition (l_conj) inhibition_13\NN\1068773|activities (l_nmod) activities_16\NNS\30358|of|the|thrombin (l_nmod) thrombin_18\NN\14735953|of|and|fxa
T12_T34 NONE img_23\NN\1740|or|hyperoside (r_nsubj) inhibited_26\VBD\2510337|img|production (r_conj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_nmod) aptt_9\NN\1740|in|prolonged|and|pt|and|inhibition (l_conj) inhibition_13\NN\1068773|activities (l_nmod) activities_16\NNS\30358|of|the|thrombin (l_nmod) thrombin_18\NN\14735953|of|and|fxa (l_conj) fxa_20\NN\1740|
T12_T35 CPR:3 img_23\NN\1740|or|hyperoside (r_nsubj) inhibited_26\VBD\2510337|img|production (l_dobj) production_27\NN\30358|thrombin|huvecs (l_nmod) thrombin_29\NN\14735953|of|and|fxa
T12_T36 CPR:4 img_23\NN\1740|or|hyperoside (r_nsubj) inhibited_26\VBD\2510337|img|production (l_dobj) production_27\NN\30358|thrombin|huvecs (l_nmod) thrombin_29\NN\14735953|of|and|fxa (l_conj) fxa_31\NN\1740|
T13_T33 NONE hyperoside_25\NN\1740| (r_conj) img_23\NN\1740|or|hyperoside (r_nsubj) inhibited_26\VBD\2510337|img|production (r_conj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_nmod) aptt_9\NN\1740|in|prolonged|and|pt|and|inhibition (l_conj) inhibition_13\NN\1068773|activities (l_nmod) activities_16\NNS\30358|of|the|thrombin (l_nmod) thrombin_18\NN\14735953|of|and|fxa
T13_T34 NONE hyperoside_25\NN\1740| (r_conj) img_23\NN\1740|or|hyperoside (r_nsubj) inhibited_26\VBD\2510337|img|production (r_conj) resulted_5\VBD\2633881|treatment|aptt|,|and|inhibited|. (l_nmod) aptt_9\NN\1740|in|prolonged|and|pt|and|inhibition (l_conj) inhibition_13\NN\1068773|activities (l_nmod) activities_16\NNS\30358|of|the|thrombin (l_nmod) thrombin_18\NN\14735953|of|and|fxa (l_conj) fxa_20\NN\1740|
T13_T35 CPR:4 hyperoside_25\NN\1740| (r_conj) img_23\NN\1740|or|hyperoside (r_nsubj) inhibited_26\VBD\2510337|img|production (l_dobj) production_27\NN\30358|thrombin|huvecs (l_nmod) thrombin_29\NN\14735953|of|and|fxa
T13_T36 CPR:4 hyperoside_25\NN\1740| (r_conj) img_23\NN\1740|or|hyperoside (r_nsubj) inhibited_26\VBD\2510337|img|production (l_dobj) production_27\NN\30358|thrombin|huvecs (l_nmod) thrombin_29\NN\14735953|of|and|fxa (l_conj) fxa_31\NN\1740|
T15_T19 CPR:4 img_5\NN\1740|with|and|hyperoside (r_nmod) treatment_3\NN\654885|img (r_nsubj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_nmod) inhibition_10\NN\1068773|in|production (l_nmod) production_13\NN\30358|of|tnf-α-induced|pai-1 (l_amod) tnf-α-induced_12\JJ\1740|
T15_T20 CPR:4 img_5\NN\1740|with|and|hyperoside (r_nmod) treatment_3\NN\654885|img (r_nsubj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_nmod) inhibition_10\NN\1068773|in|production (l_nmod) production_13\NN\30358|of|tnf-α-induced|pai-1 (l_nmod) pai-1_15\NN\1740|of
T15_T21 NONE img_5\NN\1740|with|and|hyperoside (r_nmod) treatment_3\NN\654885|img (r_nsubj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_conj) resulted_21\VBD\2633881|treatment|reduction (l_nmod) reduction_24\NN\351485|in|significant|ratio (l_nmod) ratio_30\NN\13815152|of|the|t-pa (l_compound) t-pa_29\NN\1740|pai-1|to (l_compound) pai-1_27\NN\1740|
T15_T22 NONE img_5\NN\1740|with|and|hyperoside (r_nmod) treatment_3\NN\654885|img (r_nsubj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_conj) resulted_21\VBD\2633881|treatment|reduction (l_nmod) reduction_24\NN\351485|in|significant|ratio (l_nmod) ratio_30\NN\13815152|of|the|t-pa (l_compound) t-pa_29\NN\1740|pai-1|to
T16_T19 CPR:4 hyperoside_7\NN\1740| (r_conj) img_5\NN\1740|with|and|hyperoside (r_nmod) treatment_3\NN\654885|img (r_nsubj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_nmod) inhibition_10\NN\1068773|in|production (l_nmod) production_13\NN\30358|of|tnf-α-induced|pai-1 (l_amod) tnf-α-induced_12\JJ\1740|
T16_T20 CPR:4 hyperoside_7\NN\1740| (r_conj) img_5\NN\1740|with|and|hyperoside (r_nmod) treatment_3\NN\654885|img (r_nsubj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_nmod) inhibition_10\NN\1068773|in|production (l_nmod) production_13\NN\30358|of|tnf-α-induced|pai-1 (l_nmod) pai-1_15\NN\1740|of
T16_T21 NONE hyperoside_7\NN\1740| (r_conj) img_5\NN\1740|with|and|hyperoside (r_nmod) treatment_3\NN\654885|img (r_nsubj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_conj) resulted_21\VBD\2633881|treatment|reduction (l_nmod) reduction_24\NN\351485|in|significant|ratio (l_nmod) ratio_30\NN\13815152|of|the|t-pa (l_compound) t-pa_29\NN\1740|pai-1|to (l_compound) pai-1_27\NN\1740|
T16_T22 NONE hyperoside_7\NN\1740| (r_conj) img_5\NN\1740|with|and|hyperoside (r_nmod) treatment_3\NN\654885|img (r_nsubj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_conj) resulted_21\VBD\2633881|treatment|reduction (l_nmod) reduction_24\NN\351485|in|significant|ratio (l_nmod) ratio_30\NN\13815152|of|the|t-pa (l_compound) t-pa_29\NN\1740|pai-1|to
T2_T19 NONE img_20\NN\1740|with (r_nmod) treatment_18\NN\654885|img (r_nsubj) resulted_21\VBD\2633881|treatment|reduction (r_conj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_nmod) inhibition_10\NN\1068773|in|production (l_nmod) production_13\NN\30358|of|tnf-α-induced|pai-1 (l_amod) tnf-α-induced_12\JJ\1740|
T2_T20 NONE img_20\NN\1740|with (r_nmod) treatment_18\NN\654885|img (r_nsubj) resulted_21\VBD\2633881|treatment|reduction (r_conj) resulted_8\VBD\2633881|addition|,|treatment|inhibition|,|and|resulted|. (l_nmod) inhibition_10\NN\1068773|in|production (l_nmod) production_13\NN\30358|of|tnf-α-induced|pai-1 (l_nmod) pai-1_15\NN\1740|of
T2_T21 CPR:4 img_20\NN\1740|with (r_nmod) treatment_18\NN\654885|img (r_nsubj) resulted_21\VBD\2633881|treatment|reduction (l_nmod) reduction_24\NN\351485|in|significant|ratio (l_nmod) ratio_30\NN\13815152|of|the|t-pa (l_compound) t-pa_29\NN\1740|pai-1|to (l_compound) pai-1_27\NN\1740|
T2_T22 CPR:4 img_20\NN\1740|with (r_nmod) treatment_18\NN\654885|img (r_nsubj) resulted_21\VBD\2633881|treatment|reduction (l_nmod) reduction_24\NN\351485|in|significant|ratio (l_nmod) ratio_30\NN\13815152|of|the|t-pa (l_compound) t-pa_29\NN\1740|pai-1|to
22469981
T2_T6 NONE tetracycline-inducible_1\JJ\1740| (r_amod) model_4\NN\5888929|a|tetracycline-inducible|transgenic|mouse|expressing (l_acl) expressing_5\VBG\928630|β-catenin (l_dobj) β-catenin_7\NN\1740|truncated|δn89β-catenin|exhibited
T2_T7 NONE tetracycline-inducible_1\JJ\1740| (r_amod) model_4\NN\5888929|a|tetracycline-inducible|transgenic|mouse|expressing (l_acl) expressing_5\VBG\928630|β-catenin (l_dobj) β-catenin_7\NN\1740|truncated|δn89β-catenin|exhibited (l_appos) δn89β-catenin_9\NN\1740|(|)
T2_T8 NONE tetracycline-inducible_1\JJ\1740| (r_amod) model_4\NN\5888929|a|tetracycline-inducible|transgenic|mouse|expressing (r_nsubjpass) analyzed_18\VBN\78760|model|was|removal|. (l_nmod) removal_21\NN\383606|during|the|expression|culture (l_nmod) expression_25\NN\4679549|of|oncogenic|β-catenin (l_compound) β-catenin_24\NN\1740|
14722255
T8_T21 NONE monophosphate_23\NN\1740|2-chlorodeoxyadenosine|(cldamp)-substituted (r_compound) sequences_28\NNS\8457976|on|monophosphate|tata|box|consensus (r_nmod) disrupted_20\VBN\362348|that|interactions|were|sequences (l_nsubjpass) interactions_9\NNS\37396|binding|protein (l_nmod) protein_15\NN\14944888|of|the|human|box-binding|tbp
T8_T22 NONE monophosphate_23\NN\1740|2-chlorodeoxyadenosine|(cldamp)-substituted (r_compound) sequences_28\NNS\8457976|on|monophosphate|tata|box|consensus (r_nmod) disrupted_20\VBN\362348|that|interactions|were|sequences (l_nsubjpass) interactions_9\NNS\37396|binding|protein (l_nmod) protein_15\NN\14944888|of|the|human|box-binding|tbp (l_appos) tbp_17\NN\1740|(|)
T8_T23 NONE monophosphate_23\NN\1740|2-chlorodeoxyadenosine|(cldamp)-substituted (r_compound) sequences_28\NNS\8457976|on|monophosphate|tata|box|consensus
T9_T21 NONE (cldamp)-substituted_24\NN\1740| (r_dep) monophosphate_23\NN\1740|2-chlorodeoxyadenosine|(cldamp)-substituted (r_compound) sequences_28\NNS\8457976|on|monophosphate|tata|box|consensus (r_nmod) disrupted_20\VBN\362348|that|interactions|were|sequences (l_nsubjpass) interactions_9\NNS\37396|binding|protein (l_nmod) protein_15\NN\14944888|of|the|human|box-binding|tbp
T9_T22 NONE (cldamp)-substituted_24\NN\1740| (r_dep) monophosphate_23\NN\1740|2-chlorodeoxyadenosine|(cldamp)-substituted (r_compound) sequences_28\NNS\8457976|on|monophosphate|tata|box|consensus (r_nmod) disrupted_20\VBN\362348|that|interactions|were|sequences (l_nsubjpass) interactions_9\NNS\37396|binding|protein (l_nmod) protein_15\NN\14944888|of|the|human|box-binding|tbp (l_appos) tbp_17\NN\1740|(|)
T9_T23 NONE (cldamp)-substituted_24\NN\1740| (r_dep) monophosphate_23\NN\1740|2-chlorodeoxyadenosine|(cldamp)-substituted (r_compound) sequences_28\NNS\8457976|on|monophosphate|tata|box|consensus
T12_T24 NONE triphosphate_19\NN\1740|2-chlorodeoxyadenosine|cldatp (r_compound) incorporation_23\NN\1237415|by|triphosphate|element (r_nmod) affected_16\VBN\126264|that|processes|would|therefore|be|incorporation (l_nsubjpass) processes_12\NNS\407535|human|polymerase|ii|transcriptional (l_nummod) ii_6\CD\13741022|pol
T12_T25 NONE triphosphate_19\NN\1740|2-chlorodeoxyadenosine|cldatp (r_compound) incorporation_23\NN\1237415|by|triphosphate|element (r_nmod) affected_16\VBN\126264|that|processes|would|therefore|be|incorporation (l_nsubjpass) processes_12\NNS\407535|human|polymerase|ii|transcriptional (l_nummod) ii_6\CD\13741022|pol (l_appos) pol_8\NN\9623038|(|ii|) (l_nummod) ii_9\CD\13741022|
T12_T26 NONE triphosphate_19\NN\1740|2-chlorodeoxyadenosine|cldatp (r_compound) incorporation_23\NN\1237415|by|triphosphate|element (l_nmod) element_28\NN\5867413|into|a|promoter|tata
T13_T24 NONE cldatp_21\NN\1740|(|) (r_appos) triphosphate_19\NN\1740|2-chlorodeoxyadenosine|cldatp (r_compound) incorporation_23\NN\1237415|by|triphosphate|element (r_nmod) affected_16\VBN\126264|that|processes|would|therefore|be|incorporation (l_nsubjpass) processes_12\NNS\407535|human|polymerase|ii|transcriptional (l_nummod) ii_6\CD\13741022|pol
T13_T25 NONE cldatp_21\NN\1740|(|) (r_appos) triphosphate_19\NN\1740|2-chlorodeoxyadenosine|cldatp (r_compound) incorporation_23\NN\1237415|by|triphosphate|element (r_nmod) affected_16\VBN\126264|that|processes|would|therefore|be|incorporation (l_nsubjpass) processes_12\NNS\407535|human|polymerase|ii|transcriptional (l_nummod) ii_6\CD\13741022|pol (l_appos) pol_8\NN\9623038|(|ii|) (l_nummod) ii_9\CD\13741022|
T13_T26 NONE cldatp_21\NN\1740|(|) (r_appos) triphosphate_19\NN\1740|2-chlorodeoxyadenosine|cldatp (r_compound) incorporation_23\NN\1237415|by|triphosphate|element (l_nmod) element_28\NN\5867413|into|a|promoter|tata
T15_T17 NONE cldamp_7\NN\1740| (r_compound) substitution_8\NN\7337390|cldamp|damp|box (l_nmod) box_14\NN\3094503|within|the|tata
T15_T18 NONE cldamp_7\NN\1740| (r_compound) substitution_8\NN\7337390|cldamp|damp|box (r_nsubj) decreased_15\VBD\169651|amounts|,|substitution|transcription|%|substrates|. (l_dobj) transcription_20\NN\6349220|in|pol|ii (l_nummod) ii_19\CD\13741022|
T1_T17 NONE damp_10\NN\14534696|for (r_nmod) substitution_8\NN\7337390|cldamp|damp|box (l_nmod) box_14\NN\3094503|within|the|tata
T1_T18 NONE damp_10\NN\14534696|for (r_nmod) substitution_8\NN\7337390|cldamp|damp|box (r_nsubj) decreased_15\VBD\169651|amounts|,|substitution|transcription|%|substrates|. (l_dobj) transcription_20\NN\6349220|in|pol|ii (l_nummod) ii_19\CD\13741022|
T2_T19 NONE cldamp-substituted_5\NN\1740| (r_amod) sequences_7\NNS\8457976|on|cldamp-substituted|tata
T3_T20 NONE cldamp-substituted_2\NN\1740| (r_amod) sequences_4\NNS\8457976|cldamp-substituted|promoter (r_nsubj) trapped_5\VBD\2495038|furthermore|,|sequences|or|sequestered|,|preventing|. (l_advcl) preventing_10\VBG\1740|dissociation|reinitiate (l_dobj) dissociation_12\NN\383606|its|dna|and|binding (l_conj) binding_17\NN\4688246|subsequent|elements (l_nmod) elements_21\NNS\11524662|to|additional|tata
23297412
T7_T25 NONE resveratrol_0\NN\1740| (r_nsubj) improves_1\VBZ\126264|resveratrol|cardiomyopathy|modulation|. (l_nmod) modulation_9\NN\7044917|through|protein-mediated|protein (l_nmod) protein_12\NN\14944888|of|p300 (l_compound) p300_11\NN\1740|
T7_T26 NONE resveratrol_0\NN\1740| (r_nsubj) improves_1\VBZ\126264|resveratrol|cardiomyopathy|modulation|. (l_dobj) cardiomyopathy_2\NN\14103288|mice (l_nmod) mice_5\NNS\2329401|in|dystrophin-deficient (l_amod) dystrophin-deficient_4\JJ\1740|
T7_T27 NONE resveratrol_0\NN\1740| (r_nsubj) improves_1\VBZ\126264|resveratrol|cardiomyopathy|modulation|. (l_nmod) modulation_9\NN\7044917|through|protein-mediated|protein (l_amod) protein-mediated_8\JJ\1740|sirt1 (l_nmod:npmod) sirt1_7\NN\1740|
T1_T10 CPR:3 resveratrol_8\NN\1740|of|,|leads (l_acl:relcl) leads_11\VBZ\1752884|which|activation (l_nmod) activation_13\NN\13561719|to|deacetylase (l_nmod) deacetylase_18\NN\1740|of|an|nad(+)-dependent|protein|sirt1 (l_dep) sirt1_19\NN\1740|
T1_T11 NONE resveratrol_8\NN\1740|of|,|leads (r_nmod) administration_6\NN\1133281|oral|resveratrol|, (r_nsubj) suppresses_21\VBZ\2510337|that|administration|hypertrophy|and|restores (l_conj) restores_27\VBZ\1631072|function (l_dobj) function_30\NN\13783581|cardiac|diastolic|mice (l_nmod) mice_34\NNS\2329401|in|dystrophin-deficient|mdx (l_amod) dystrophin-deficient_32\JJ\1740|
T2_T10 NONE nad(+)-dependent_16\JJ\1740| (r_amod) deacetylase_18\NN\1740|of|an|nad(+)-dependent|protein|sirt1 (l_dep) sirt1_19\NN\1740|
T2_T11 NONE nad(+)-dependent_16\JJ\1740| (r_amod) deacetylase_18\NN\1740|of|an|nad(+)-dependent|protein|sirt1 (r_nmod) activation_13\NN\13561719|to|deacetylase (r_nmod) leads_11\VBZ\1752884|which|activation (r_acl:relcl) resveratrol_8\NN\1740|of|,|leads (r_nmod) administration_6\NN\1133281|oral|resveratrol|, (r_nsubj) suppresses_21\VBZ\2510337|that|administration|hypertrophy|and|restores (l_conj) restores_27\VBZ\1631072|function (l_dobj) function_30\NN\13783581|cardiac|diastolic|mice (l_nmod) mice_34\NNS\2329401|in|dystrophin-deficient|mdx (l_amod) dystrophin-deficient_32\JJ\1740|
T3_T12 NONE resveratrol_17\NN\1740| (r_compound) administration_18\NN\1133281|resveratrol (r_nsubj) down-regulated_19\VBD\1740|administration|level|. (r_conj) up-regulated_10\VBN\1740|protein|was|heart|,|and|down-regulated (l_nsubjpass) protein_4\NN\14944888|the|pro-hypertrophic|co-activator|p300|not|mrna (l_compound) p300_3\NN\1740|
T3_T13 NONE resveratrol_17\NN\1740| (r_compound) administration_18\NN\1133281|resveratrol (r_nsubj) down-regulated_19\VBD\1740|administration|level|. (r_conj) up-regulated_10\VBN\1740|protein|was|heart|,|and|down-regulated (l_nsubjpass) protein_4\NN\14944888|the|pro-hypertrophic|co-activator|p300|not|mrna (l_conj) mrna_8\NN\14832193|p300 (l_compound) p300_7\NN\1740|
T3_T14 CPR:4 resveratrol_17\NN\1740| (r_compound) administration_18\NN\1133281|resveratrol (r_nsubj) down-regulated_19\VBD\1740|administration|level|. (l_dobj) level_23\NN\4916342|the|p300|protein (l_compound) p300_21\NN\1740|
T4_T15 NONE phenylephrine_10\NN\2682038|by|the|α(1)-agonist (r_nmod) induced_6\VBN\1627355|phenylephrine (r_acl) hypertrophy_5\NN\14365950|cardiomyocyte|induced (r_nsubjpass) inhibited_12\VBN\2510337|cardiomyocytes|,|hypertrophy|was|overexpression|. (l_nmod) overexpression_15\NN\1740|by|the|sirt1|down-regulated (l_nmod) sirt1_17\NN\1740|of|as|resveratrol|,
T4_T16 NONE phenylephrine_10\NN\2682038|by|the|α(1)-agonist (r_nmod) induced_6\VBN\1627355|phenylephrine (r_acl) hypertrophy_5\NN\14365950|cardiomyocyte|induced (r_nsubjpass) inhibited_12\VBN\2510337|cardiomyocytes|,|hypertrophy|was|overexpression|. (l_nmod) overexpression_15\NN\1740|by|the|sirt1|down-regulated (l_acl:relcl) down-regulated_26\VBD\1740|both|levels (l_dobj) levels_29\NNS\4916342|protein|not|levels (l_compound) protein_28\NN\14944888|p300 (l_compound) p300_27\NN\1740|
T4_T17 NONE phenylephrine_10\NN\2682038|by|the|α(1)-agonist (r_nmod) induced_6\VBN\1627355|phenylephrine (r_acl) hypertrophy_5\NN\14365950|cardiomyocyte|induced (r_nsubjpass) inhibited_12\VBN\2510337|cardiomyocytes|,|hypertrophy|was|overexpression|. (l_nmod) overexpression_15\NN\1740|by|the|sirt1|down-regulated (l_acl:relcl) down-regulated_26\VBD\1740|both|levels (l_dobj) levels_29\NNS\4916342|protein|not|levels (l_conj) levels_34\NNS\4916342|mrna (l_compound) mrna_33\NN\14832193|p300 (l_compound) p300_32\NN\1740|
T5_T15 NONE resveratrol_21\NN\1740| (r_conj) sirt1_17\NN\1740|of|as|resveratrol|,
T5_T16 CPR:4 resveratrol_21\NN\1740| (r_conj) sirt1_17\NN\1740|of|as|resveratrol|, (r_nmod) overexpression_15\NN\1740|by|the|sirt1|down-regulated (l_acl:relcl) down-regulated_26\VBD\1740|both|levels (l_dobj) levels_29\NNS\4916342|protein|not|levels (l_compound) protein_28\NN\14944888|p300 (l_compound) p300_27\NN\1740|
T5_T17 NONE resveratrol_21\NN\1740| (r_conj) sirt1_17\NN\1740|of|as|resveratrol|, (r_nmod) overexpression_15\NN\1740|by|the|sirt1|down-regulated (l_acl:relcl) down-regulated_26\VBD\1740|both|levels (l_dobj) levels_29\NNS\4916342|protein|not|levels (l_conj) levels_34\NNS\4916342|mrna (l_compound) mrna_33\NN\14832193|p300 (l_compound) p300_32\NN\1740|
T6_T21 NONE lysine_14\NN\14605787| (r_compound) residues_15\NNS\20827|of|lysine (r_nmod) deacetylation_12\NN\1740|by|residues|ubiquitination (r_nmod) induced_4\VBD\1627355|that|sirt1|down-regulation|pathway|deacetylation (l_nsubj) sirt1_3\NN\1740|
T6_T22 NONE lysine_14\NN\14605787| (r_compound) residues_15\NNS\20827|of|lysine (r_nmod) deacetylation_12\NN\1740|by|residues|ubiquitination (r_nmod) induced_4\VBD\1627355|that|sirt1|down-regulation|pathway|deacetylation (l_dobj) down-regulation_6\NN\1740|p300 (l_compound) p300_5\NN\1740|
T6_T23 NONE lysine_14\NN\14605787| (r_compound) residues_15\NNS\20827|of|lysine (r_nmod) deacetylation_12\NN\1740|by|residues|ubiquitination (r_nmod) induced_4\VBD\1627355|that|sirt1|down-regulation|pathway|deacetylation (l_nmod) pathway_10\NN\5483677|via|the|ubiquitin-proteasome (l_amod) ubiquitin-proteasome_9\JJ\1740|
T6_T24 NONE lysine_14\NN\14605787| (r_compound) residues_15\NNS\20827|of|lysine (r_nmod) deacetylation_12\NN\1740|by|residues|ubiquitination (r_nmod) induced_4\VBD\1627355|that|sirt1|down-regulation|pathway|deacetylation (l_nmod) pathway_10\NN\5483677|via|the|ubiquitin-proteasome (l_amod) ubiquitin-proteasome_9\JJ\1740|
23589329
T10_T30 CPR:3 arsenic_0\JJ\1740| (r_nsubj) inhibits_1\VBZ\2510337|arsenic|flux|activating|. (l_xcomp) activating_4\VBG\1641914|pathway|manner (l_dobj) pathway_7\NN\5483677|the|nrf2-keap1 (l_compound) nrf2-keap1_6\NN\1740|
T10_T31 CPR:3 arsenic_0\JJ\1740| (r_nsubj) inhibits_1\VBZ\2510337|arsenic|flux|activating|. (l_xcomp) activating_4\VBG\1641914|pathway|manner (l_dobj) pathway_7\NN\5483677|the|nrf2-keap1 (l_compound) nrf2-keap1_6\NN\1740|
T10_T32 NONE arsenic_0\JJ\1740| (r_nsubj) inhibits_1\VBZ\2510337|arsenic|flux|activating|. (l_xcomp) activating_4\VBG\1641914|pathway|manner (l_nmod) manner_11\NN\4916342|in|a|p62-dependent (l_amod) p62-dependent_10\JJ\1740|
T5_T20 CPR:4 arsenic_0\JJ\1740| (r_nsubj) deregulates_1\VBZ\2564146|arsenic|pathway|blockage|,|resulting|. (l_advcl) resulting_11\VBG\2633881|accumulation (l_nmod) accumulation_13\NN\13497135|in|autophagosomes|and|sequestration (l_conj) sequestration_17\NN\1201021|p62 (l_nmod) p62_19\NN\1740|of|,|keap1|,|and|lc3
T5_T21 CPR:4 arsenic_0\JJ\1740| (r_nsubj) deregulates_1\VBZ\2564146|arsenic|pathway|blockage|,|resulting|. (l_advcl) resulting_11\VBG\2633881|accumulation (l_nmod) accumulation_13\NN\13497135|in|autophagosomes|and|sequestration (l_conj) sequestration_17\NN\1201021|p62 (l_nmod) p62_19\NN\1740|of|,|keap1|,|and|lc3 (l_conj) keap1_21\NN\1740|
T5_T22 CPR:4 arsenic_0\JJ\1740| (r_nsubj) deregulates_1\VBZ\2564146|arsenic|pathway|blockage|,|resulting|. (l_advcl) resulting_11\VBG\2633881|accumulation (l_nmod) accumulation_13\NN\13497135|in|autophagosomes|and|sequestration (l_conj) sequestration_17\NN\1201021|p62 (l_nmod) p62_19\NN\1740|of|,|keap1|,|and|lc3 (l_conj) lc3_24\NN\1740|
T6_T23 CPR:3 arsenic_2\JJ\1740| (r_nsubj) activates_3\VBZ\1641914|thus|,|arsenic|nrf2|mechanism|,|leading|. (l_dobj) nrf2_4\NN\1740|
T6_T24 NONE arsenic_2\JJ\1740| (r_nsubj) activates_3\VBZ\1641914|thus|,|arsenic|nrf2|mechanism|,|leading|. (l_nmod) mechanism_8\NN\13446390|through|a|non-canonical|p62-dependent (l_appos) p62-dependent_10\JJ\1740|(|)
T6_T25 CPR:3 arsenic_2\JJ\1740| (r_nsubj) activates_3\VBZ\1641914|thus|,|arsenic|nrf2|mechanism|,|leading|. (l_advcl) leading_13\VBG\1752884|activation (l_nmod) activation_19\NN\13561719|to|a|chronic|nrf2 (l_nmod) nrf2_21\NN\1740|of
T7_T26 CPR:3 sulforaphane_7\NN\1740|by|and|tert-butylhydroquinone (r_nmod) activation_3\NN\13561719|nrf2|sulforaphane (l_nmod) nrf2_5\NN\1740|of
T7_T27 NONE sulforaphane_7\NN\1740|by|and|tert-butylhydroquinone (r_nmod) activation_3\NN\13561719|nrf2|sulforaphane (r_nsubj) depend_10\VBP\2604760|contrast|,|activation|keap1-c151|. (l_nmod) keap1-c151_12\NN\1740|upon|not|p62
T7_T29 NONE sulforaphane_7\NN\1740|by|and|tert-butylhydroquinone (r_nmod) activation_3\NN\13561719|nrf2|sulforaphane (r_nsubj) depend_10\VBP\2604760|contrast|,|activation|keap1-c151|. (l_nmod) keap1-c151_12\NN\1740|upon|not|p62 (l_conj) p62_15\NN\1740|mechanism
T8_T26 CPR:3 tert-butylhydroquinone_9\NN\1740| (r_conj) sulforaphane_7\NN\1740|by|and|tert-butylhydroquinone (r_nmod) activation_3\NN\13561719|nrf2|sulforaphane (l_nmod) nrf2_5\NN\1740|of
T8_T27 NONE tert-butylhydroquinone_9\NN\1740| (r_conj) sulforaphane_7\NN\1740|by|and|tert-butylhydroquinone (r_nmod) activation_3\NN\13561719|nrf2|sulforaphane (r_nsubj) depend_10\VBP\2604760|contrast|,|activation|keap1-c151|. (l_nmod) keap1-c151_12\NN\1740|upon|not|p62
T8_T29 NONE tert-butylhydroquinone_9\NN\1740| (r_conj) sulforaphane_7\NN\1740|by|and|tert-butylhydroquinone (r_nmod) activation_3\NN\13561719|nrf2|sulforaphane (r_nsubj) depend_10\VBP\2604760|contrast|,|activation|keap1-c151|. (l_nmod) keap1-c151_12\NN\1740|upon|not|p62 (l_conj) p62_15\NN\1740|mechanism
T3_T12 CPR:3 arsenic_7\JJ\1740| (r_nsubj) causes_8\VBZ\1617192|that|arsenic|activation|,|providing (l_dobj) activation_10\NN\13561719|prolonged|nrf2|dysfunction (l_nmod) nrf2_12\NN\1740|of
T3_T13 CPR:3 arsenic_7\JJ\1740| (r_nsubj) causes_8\VBZ\1617192|that|arsenic|activation|,|providing (l_advcl) providing_18\VBG\2199590|possibly|scenario|activation (l_nmod) activation_24\NN\13561719|to|constitutive|nrf2 (l_nmod) nrf2_26\NN\1740|of|found
23161868
T1_T3 CPR:3 corticosterone_46\NN\14752057|by (r_nmod) up-regulated_44\VBN\1740|corticosterone (r_conj) activated_38\VBN\1641914|construct|was|highly|cells|and|up-regulated|. (l_nsubjpass) construct_2\NN\5833840|a|reporter|driven|,|containing|, (l_acl) driven_3\VBN\1224744|kb (l_nmod) kb_6\NN\13601596|by|4|region (l_nmod) region_12\NN\27167|of|the|chicken|ras-dva|5'-flanking (l_compound) ras-dva_10\NN\1740|
T1_T4 CPR:3 corticosterone_46\NN\14752057|by (r_nmod) up-regulated_44\VBN\1740|corticosterone (r_conj) activated_38\VBN\1641914|construct|was|highly|cells|and|up-regulated|. (l_nsubjpass) construct_2\NN\5833840|a|reporter|driven|,|containing|, (l_acl) containing_14\VBG\2632940|sites (l_dobj) sites_24\NNS\8673395|six|putative|factor-1|binding|and|sites
T1_T5 CPR:3 corticosterone_46\NN\14752057|by (r_nmod) up-regulated_44\VBN\1740|corticosterone (r_conj) activated_38\VBN\1641914|construct|was|highly|cells|and|up-regulated|. (l_nsubjpass) construct_2\NN\5833840|a|reporter|driven|,|containing|, (l_acl) containing_14\VBG\2632940|sites (l_dobj) sites_24\NNS\8673395|six|putative|factor-1|binding|and|sites (l_conj) sites_34\NNS\8673395|two|potential|receptor|binding
T2_T10 CPR:3 corticosterone_17\NN\14752057|by (r_nmod) induction_11\NN\7450842|activity|corticosterone (r_dobj) reduce_10\VB\441445|however|,|sites|did|not|substantially|induction|,|suggesting|. (l_nsubj) sites_6\NNS\8673395|mutating|putative|gr|binding
T2_T11 CPR:3 corticosterone_17\NN\14752057|by (r_nmod) induction_11\NN\7450842|activity|corticosterone (l_nmod) activity_15\NN\30358|of|promoter (l_compound) promoter_14\NN\9773962|ras-dva
T2_T12 NONE corticosterone_17\NN\14752057|by (r_nmod) induction_11\NN\7450842|activity|corticosterone (r_dobj) reduce_10\VB\441445|however|,|sites|did|not|substantially|induction|,|suggesting|. (l_advcl) suggesting_19\VBG\1010118|responsible (l_ccomp) responsible_28\JJ\1740|elements|are|regulation (l_nsubj) elements_22\NNS\11524662|additional|dna|region
23638842
T7_T18 NONE -glucoraphanin_6\NN\1740|of|(|rs|)|bioactivated (l_acl) bioactivated_7\VBN\1740|myrosinase|model (l_nmod) myrosinase_9\NN\1740|with
T3_T14 CPR:9 glucosinolates_19\NNS\1740|in|,|release (l_acl:relcl) release_25\VBP\1435380|which|hydrolysis|isothiocyanates (l_nmod) hydrolysis_24\NN\13447361|upon|myrosinase (l_compound) myrosinase_23\NN\1740|
T4_T14 CPR:9 isothiocyanates_28\NNS\15032661|the|corresponding (r_dobj) release_25\VBP\1435380|which|hydrolysis|isothiocyanates (l_nmod) hydrolysis_24\NN\13447361|upon|myrosinase (l_compound) myrosinase_23\NN\1740|
T5_T15 NONE -glucoraphanin_13\NN\1740|of|(|rs|)|kale (l_nmod) kale_17\NNP\13384557|from|tuscan|black|l.|bioactivated (l_acl) bioactivated_27\VBN\1740|myrosinase (l_nmod) myrosinase_29\NN\1740|with|-gra
T6_T15 NONE -gra_33\NN\1740|(|bioactive|rs|) (r_appos) myrosinase_29\NN\1740|with|-gra
T1_T10 CPR:4 -gra_19\NN\1740|with|bioactive|rs (r_nmod) treatment_15\NN\654885|-gra (r_nsubj) decreased_21\VBD\169651|that|treatment|significantly|translocation (l_dobj) translocation_25\NN\13526110|factor|(nf)-kb|,|production|,|and|apoptosis (l_conj) production_29\NN\30358|pro-inflammatory|cytokine|interleukin-1β (l_nmod) interleukin-1β_32\NN\1740|such|il-1β
T1_T11 CPR:4 -gra_19\NN\1740|with|bioactive|rs (r_nmod) treatment_15\NN\654885|-gra (r_nsubj) decreased_21\VBD\169651|that|treatment|significantly|translocation (l_dobj) translocation_25\NN\13526110|factor|(nf)-kb|,|production|,|and|apoptosis (l_conj) production_29\NN\30358|pro-inflammatory|cytokine|interleukin-1β (l_nmod) interleukin-1β_32\NN\1740|such|il-1β (l_appos) il-1β_34\NN\1740|(|)
T1_T12 CPR:4 -gra_19\NN\1740|with|bioactive|rs (r_nmod) treatment_15\NN\654885|-gra (r_nsubj) decreased_21\VBD\169651|that|treatment|significantly|translocation (l_dobj) translocation_25\NN\13526110|factor|(nf)-kb|,|production|,|and|apoptosis (l_conj) apoptosis_38\NN\11486178|bax (l_dep) bax_40\NN\1740|(|and|expression|)
T1_T13 CPR:4 -gra_19\NN\1740|with|bioactive|rs (r_nmod) treatment_15\NN\654885|-gra (r_nsubj) decreased_21\VBD\169651|that|treatment|significantly|translocation (l_dobj) translocation_25\NN\13526110|factor|(nf)-kb|,|production|,|and|apoptosis (l_conj) apoptosis_38\NN\11486178|bax (l_dep) bax_40\NN\1740|(|and|expression|) (l_conj) expression_44\NN\4679549|caspase|3 (l_nummod) 3_43\CD\13741022|
T1_T8 CPR:4 -gra_19\NN\1740|with|bioactive|rs (r_nmod) treatment_15\NN\654885|-gra (r_nsubj) decreased_21\VBD\169651|that|treatment|significantly|translocation (l_dobj) translocation_25\NN\13526110|factor|(nf)-kb|,|production|,|and|apoptosis (l_compound) (nf)-kb_24\NN\1740|
T1_T9 CPR:4 -gra_19\NN\1740|with|bioactive|rs (r_nmod) treatment_15\NN\654885|-gra (r_nsubj) decreased_21\VBD\169651|that|treatment|significantly|translocation (l_dobj) translocation_25\NN\13526110|factor|(nf)-kb|,|production|,|and|apoptosis (l_conj) production_29\NN\30358|pro-inflammatory|cytokine|interleukin-1β (l_compound) cytokine_28\NN\14728724|
23461378
T3_T12 CPR:9 estrone-3-sulfate_2\NN\1740|of (r_nmod) uptake_0\NN\13440063|estrone-3-sulfate| (l_nmod) _5\_SP\1740|(|5|nm|oatp1b1 (l_nmod) oatp1b1_9\NN\1740|by
T1_T13 CPR:9 pitavastatin_35\NN\1740|%|) (r_conj) olmesartan_17\NN\1740|for|%|)|,|valsartan|,|rosuvastatin|,|pitavastatin|and|lopinavir (r_nmod) contribution_9\NN\786195|the|relative|uptake|olmesartan (l_nmod) uptake_12\NN\13440063|of|oatp1b1|hepatocytes (l_compound) oatp1b1_11\NN\1740|
T2_T13 CPR:9 lopinavir_41\NN\1740|%|) (r_conj) olmesartan_17\NN\1740|for|%|)|,|valsartan|,|rosuvastatin|,|pitavastatin|and|lopinavir (r_nmod) contribution_9\NN\786195|the|relative|uptake|olmesartan (l_nmod) uptake_12\NN\13440063|of|oatp1b1|hepatocytes (l_compound) oatp1b1_11\NN\1740|
T4_T13 CPR:9 olmesartan_17\NN\1740|for|%|)|,|valsartan|,|rosuvastatin|,|pitavastatin|and|lopinavir (r_nmod) contribution_9\NN\786195|the|relative|uptake|olmesartan (l_nmod) uptake_12\NN\13440063|of|oatp1b1|hepatocytes (l_compound) oatp1b1_11\NN\1740|
T5_T13 CPR:9 valsartan_23\NN\2712393|%|) (r_conj) olmesartan_17\NN\1740|for|%|)|,|valsartan|,|rosuvastatin|,|pitavastatin|and|lopinavir (r_nmod) contribution_9\NN\786195|the|relative|uptake|olmesartan (l_nmod) uptake_12\NN\13440063|of|oatp1b1|hepatocytes (l_compound) oatp1b1_11\NN\1740|
T6_T13 CPR:9 rosuvastatin_29\NN\1740|%|) (r_conj) olmesartan_17\NN\1740|for|%|)|,|valsartan|,|rosuvastatin|,|pitavastatin|and|lopinavir (r_nmod) contribution_9\NN\786195|the|relative|uptake|olmesartan (l_nmod) uptake_12\NN\13440063|of|oatp1b1|hepatocytes (l_compound) oatp1b1_11\NN\1740|
16262557
T1_T9 NONE ketorolac_3\NN\3828465|,|flurbiprofen|,|ketoprofen|and|indomethacin (r_nsubj) increased_11\VBN\169651|examples|,|ketorolac|have|selectivity|compared|. (l_dobj) selectivity_13\NN\4916342|cox-1 (l_compound) cox-1_12\NN\14737847|
T2_T9 NONE flurbiprofen_5\NN\3828465| (r_conj) ketorolac_3\NN\3828465|,|flurbiprofen|,|ketoprofen|and|indomethacin (r_nsubj) increased_11\VBN\169651|examples|,|ketorolac|have|selectivity|compared|. (l_dobj) selectivity_13\NN\4916342|cox-1 (l_compound) cox-1_12\NN\14737847|
T3_T9 NONE ketoprofen_7\NN\3828465| (r_conj) ketorolac_3\NN\3828465|,|flurbiprofen|,|ketoprofen|and|indomethacin (r_nsubj) increased_11\VBN\169651|examples|,|ketorolac|have|selectivity|compared|. (l_dobj) selectivity_13\NN\4916342|cox-1 (l_compound) cox-1_12\NN\14737847|
T4_T9 NONE indomethacin_9\NN\3828465| (r_conj) ketorolac_3\NN\3828465|,|flurbiprofen|,|ketoprofen|and|indomethacin (r_nsubj) increased_11\VBN\169651|examples|,|ketorolac|have|selectivity|compared|. (l_dobj) selectivity_13\NN\4916342|cox-1 (l_compound) cox-1_12\NN\14737847|
T5_T9 NONE naproxen_17\NN\3828465|with|and|ibuprofen (r_nmod) compared_15\VBN\644583|when|naproxen (r_advcl) increased_11\VBN\169651|examples|,|ketorolac|have|selectivity|compared|. (l_dobj) selectivity_13\NN\4916342|cox-1 (l_compound) cox-1_12\NN\14737847|
T6_T9 NONE ibuprofen_19\NN\3828465| (r_conj) naproxen_17\NN\3828465|with|and|ibuprofen (r_nmod) compared_15\VBN\644583|when|naproxen (r_advcl) increased_11\VBN\169651|examples|,|ketorolac|have|selectivity|compared|. (l_dobj) selectivity_13\NN\4916342|cox-1 (l_compound) cox-1_12\NN\14737847|
17344208
T11_T33 NONE proline_5\NN\14601829| (r_compound) dehydrogenase_6\NN\1740|of|monofunctional|proline|thermophilus
T1_T12 NONE proline_0\NN\14601829| (r_compound) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase
T1_T19 NONE proline_0\NN\14601829| (r_compound) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_appos) prodh_3\NN\1740|(|)
T1_T22 NONE proline_0\NN\14601829| (r_compound) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_conj) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh
T1_T29 NONE proline_0\NN\14601829| (r_compound) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_conj) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh (l_appos) p5cdh_9\NN\1740|(|)
T2_T12 CPR:9 proline_16\NN\14601829|of (r_nmod) oxidation_14\NN\13447361|the|two-step|proline|glutamate (r_dobj) catalyze_11\VBP\146138|dehydrogenase|oxidation|. (l_nsubj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase
T2_T19 CPR:9 proline_16\NN\14601829|of (r_nmod) oxidation_14\NN\13447361|the|two-step|proline|glutamate (r_dobj) catalyze_11\VBP\146138|dehydrogenase|oxidation|. (l_nsubj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_appos) prodh_3\NN\1740|(|)
T2_T22 CPR:9 proline_16\NN\14601829|of (r_nmod) oxidation_14\NN\13447361|the|two-step|proline|glutamate (r_dobj) catalyze_11\VBP\146138|dehydrogenase|oxidation|. (l_nsubj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_conj) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh
T2_T29 CPR:9 proline_16\NN\14601829|of (r_nmod) oxidation_14\NN\13447361|the|two-step|proline|glutamate (r_dobj) catalyze_11\VBP\146138|dehydrogenase|oxidation|. (l_nsubj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_conj) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh (l_appos) p5cdh_9\NN\1740|(|)
T4_T12 CPR:9 glutamate_18\NN\15010703|to (r_nmod) oxidation_14\NN\13447361|the|two-step|proline|glutamate (r_dobj) catalyze_11\VBP\146138|dehydrogenase|oxidation|. (l_nsubj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase
T4_T19 CPR:9 glutamate_18\NN\15010703|to (r_nmod) oxidation_14\NN\13447361|the|two-step|proline|glutamate (r_dobj) catalyze_11\VBP\146138|dehydrogenase|oxidation|. (l_nsubj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_appos) prodh_3\NN\1740|(|)
T4_T22 CPR:9 glutamate_18\NN\15010703|to (r_nmod) oxidation_14\NN\13447361|the|two-step|proline|glutamate (r_dobj) catalyze_11\VBP\146138|dehydrogenase|oxidation|. (l_nsubj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_conj) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh
T4_T29 CPR:9 glutamate_18\NN\15010703|to (r_nmod) oxidation_14\NN\13447361|the|two-step|proline|glutamate (r_dobj) catalyze_11\VBP\146138|dehydrogenase|oxidation|. (l_nsubj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_conj) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh (l_appos) p5cdh_9\NN\1740|(|)
T9_T12 NONE delta(1)-pyrroline-5-carboxylate_6\NN\1740| (r_compound) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh (r_conj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase
T9_T19 NONE delta(1)-pyrroline-5-carboxylate_6\NN\1740| (r_compound) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh (r_conj) dehydrogenase_1\NN\1740|proline|prodh|and|dehydrogenase (l_appos) prodh_3\NN\1740|(|)
T9_T22 NONE delta(1)-pyrroline-5-carboxylate_6\NN\1740| (r_compound) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh
T9_T29 NONE delta(1)-pyrroline-5-carboxylate_6\NN\1740| (r_compound) dehydrogenase_7\NN\1740|delta(1)-pyrroline-5-carboxylate|p5cdh (l_appos) p5cdh_9\NN\1740|(|)
T10_T24 NONE carboxyl-terminal_25\JJ\1740| (r_amod) ends_26\NNS\8568978|above|the|carboxyl-terminal|strands (r_nmod) located_22\JJ\1740|ends (r_amod) domain_16\NN\13934596|a|distorted|(betaalpha)(8|)|barrel|catalytic|core|and|domain|located (r_dobj) reveals_8\VBZ\2137132|structure|domain|. (l_nsubj) structure_3\NN\21939|the|2.0-a|resolution|prodh (l_nmod) prodh_7\NNP\1740|of|thermus|thermophilus
T10_T25 NONE carboxyl-terminal_25\JJ\1740| (r_amod) ends_26\NNS\8568978|above|the|carboxyl-terminal|strands (r_nmod) located_22\JJ\1740|ends (r_amod) domain_16\NN\13934596|a|distorted|(betaalpha)(8|)|barrel|catalytic|core|and|domain|located
T10_T26 NONE carboxyl-terminal_25\JJ\1740| (r_amod) ends_26\NNS\8568978|above|the|carboxyl-terminal|strands (r_nmod) located_22\JJ\1740|ends (r_amod) domain_16\NN\13934596|a|distorted|(betaalpha)(8|)|barrel|catalytic|core|and|domain|located (l_conj) domain_21\NN\13934596|a|hydrophobic|alpha-helical
T6_T15 CPR:9 )_11\-RRB-\1740| (r_punct) o(2_10\NN\1740|with|) (r_nmod) reacts_8\VBZ\2367363|that|prodh|o(2|producing (l_nsubj) prodh_7\NNP\1740|t.|thermophilus
T7_T15 CPR:9 superoxide_13\NN\14971519| (r_dobj) producing_12\VBG\1617192|superoxide (r_xcomp) reacts_8\VBZ\2367363|that|prodh|o(2|producing (l_nsubj) prodh_7\NNP\1740|t.|thermophilus
T8_T16 CPR:9 superoxide_4\NN\14971519| (r_compound) production_5\NN\30358|superoxide (r_nsubj) underlies_6\VBZ\2604760|because|production|role|,|implying (l_dobj) role_8\NN\719494|the|prodh|apoptosis (l_nmod) prodh_11\NN\1740|of|human
T8_T17 NONE superoxide_4\NN\14971519| (r_compound) production_5\NN\30358|superoxide (r_nsubj) underlies_6\VBZ\2604760|because|production|role|,|implying (l_dobj) role_8\NN\719494|the|prodh|apoptosis (l_nmod) apoptosis_14\NN\11486178|in|p53-mediated (l_amod) p53-mediated_13\JJ\1740|
T8_T18 NONE superoxide_4\NN\14971519| (r_compound) production_5\NN\30358|superoxide (r_nsubj) underlies_6\VBZ\2604760|because|production|role|,|implying (l_advcl) implying_16\VBG\943837|commonalities (l_dobj) commonalities_17\NNS\7974025|prodhs (l_nmod) prodhs_23\NNS\1740|between|eukaryotic|monofunctional
3146348
T2_T13 CPR:4 cl-_25\NN\1740|by (r_nmod) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) activator_18\NN\19613|by|human|recombinant|(|rec|)|two-chain|tissue|plasminogen|t-pa (l_appos) t-pa_20\NN\1740|(|)
T2_T15 CPR:4 cl-_25\NN\1740|by (r_nmod) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) [glu1]plasminogen_4\NN\1740|of|human|glu1]pg
T2_T19 CPR:4 cl-_25\NN\1740|by (r_nmod) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) [glu1]plasminogen_4\NN\1740|of|human|glu1]pg (l_appos) glu1]pg_7\NN\1740|[|(|)
T2_T23 CPR:4 cl-_25\NN\1740|by (r_nmod) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) activator_18\NN\19613|by|human|recombinant|(|rec|)|two-chain|tissue|plasminogen|t-pa
T3_T13 CPR:3 acid_35\NN\14818238|by|epsilon-aminocaproic|eaca|,|as|fibrin(ogen (r_nmod) stimulated_32\VBN\137313|acid (r_conj) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) activator_18\NN\19613|by|human|recombinant|(|rec|)|two-chain|tissue|plasminogen|t-pa (l_appos) t-pa_20\NN\1740|(|)
T3_T15 CPR:3 acid_35\NN\14818238|by|epsilon-aminocaproic|eaca|,|as|fibrin(ogen (r_nmod) stimulated_32\VBN\137313|acid (r_conj) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) [glu1]plasminogen_4\NN\1740|of|human|glu1]pg
T3_T19 CPR:3 acid_35\NN\14818238|by|epsilon-aminocaproic|eaca|,|as|fibrin(ogen (r_nmod) stimulated_32\VBN\137313|acid (r_conj) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) [glu1]plasminogen_4\NN\1740|of|human|glu1]pg (l_appos) glu1]pg_7\NN\1740|[|(|)
T3_T23 CPR:3 acid_35\NN\14818238|by|epsilon-aminocaproic|eaca|,|as|fibrin(ogen (r_nmod) stimulated_32\VBN\137313|acid (r_conj) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) activator_18\NN\19613|by|human|recombinant|(|rec|)|two-chain|tissue|plasminogen|t-pa
T4_T13 CPR:3 eaca_37\NN\1740|(|) (r_appos) acid_35\NN\14818238|by|epsilon-aminocaproic|eaca|,|as|fibrin(ogen (r_nmod) stimulated_32\VBN\137313|acid (r_conj) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) activator_18\NN\19613|by|human|recombinant|(|rec|)|two-chain|tissue|plasminogen|t-pa (l_appos) t-pa_20\NN\1740|(|)
T4_T15 CPR:3 eaca_37\NN\1740|(|) (r_appos) acid_35\NN\14818238|by|epsilon-aminocaproic|eaca|,|as|fibrin(ogen (r_nmod) stimulated_32\VBN\137313|acid (r_conj) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) [glu1]plasminogen_4\NN\1740|of|human|glu1]pg
T4_T19 CPR:3 eaca_37\NN\1740|(|) (r_appos) acid_35\NN\14818238|by|epsilon-aminocaproic|eaca|,|as|fibrin(ogen (r_nmod) stimulated_32\VBN\137313|acid (r_conj) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) [glu1]plasminogen_4\NN\1740|of|human|glu1]pg (l_appos) glu1]pg_7\NN\1740|[|(|)
T4_T23 CPR:3 eaca_37\NN\1740|(|) (r_appos) acid_35\NN\14818238|by|epsilon-aminocaproic|eaca|,|as|fibrin(ogen (r_nmod) stimulated_32\VBN\137313|acid (r_conj) inhibited_23\VBN\2510337|activation|is|cl-|,|concentrations|,|and|stimulated|. (l_nsubjpass) activation_1\NN\13561719|the|[glu1]plasminogen|activator (l_nmod) activator_18\NN\19613|by|human|recombinant|(|rec|)|two-chain|tissue|plasminogen|t-pa
T5_T16 NONE chloride_0\NN\14818238| (r_nsubj) functions_1\NNS\13783581|chloride|result|,|rendering|. (l_nmod) result_4\NN\34213|as|a|binding (l_nmod) binding_7\NN\4688246|of|its|[glu1]pg|ki (l_nmod) [glu1]pg_9\NN\1740|to|,
T5_T17 NONE chloride_0\NN\14818238| (r_nsubj) functions_1\NNS\13783581|chloride|result|,|rendering|. (l_advcl) rendering_20\VBG\120316|thereby|substrate (l_ccomp) substrate_25\NN\19613|[glu1]pg|a|effective|rec-t-pa (l_nsubj) [glu1]pg_21\NN\1740|
T5_T18 NONE chloride_0\NN\14818238| (r_nsubj) functions_1\NNS\13783581|chloride|result|,|rendering|. (l_advcl) rendering_20\VBG\120316|thereby|substrate (l_ccomp) substrate_25\NN\19613|[glu1]pg|a|effective|rec-t-pa (l_nmod) rec-t-pa_28\NN\1740|for|two-chain
T9_T20 NONE cl-_31\NN\1740|of (r_nmod) levels_29\NNS\4916342|physiological|cl- (r_dobj) containing_27\VBG\2632940|levels (r_acl) systems_26\NNS\3575240|in|activation|containing (r_nmod) effects_9\NNS\13245626|mainly|through|enzyme|systems (r_nmod) exert_3\VB\1158872|to|properties|effects (r_xcomp) appears_1\VBZ\2604760|fibrinogen|exert|. (l_nsubj) fibrinogen_0\NN\15022776|
T9_T21 NONE cl-_31\NN\1740|of (r_nmod) levels_29\NNS\4916342|physiological|cl- (r_dobj) containing_27\VBG\2632940|levels (r_acl) systems_26\NNS\3575240|in|activation|containing (r_nmod) effects_9\NNS\13245626|mainly|through|enzyme|systems (l_nmod) enzyme_12\NN\14723628|on|the|,|rec-t-pa|,|ka (l_appos) rec-t-pa_15\NN\1740|two-chain
T10_T22 NONE cl-_13\NN\1740|and|fibrinogen (l_conj) fibrinogen_15\NN\15022776|
T10_T24 NONE cl-_13\NN\1740|and|fibrinogen (r_appos) components_11\NNS\5867413|normal|plasma|,|cl-|, (r_nsubj) exert_17\VBP\1158872|that|components|roles|ability (l_nmod) ability_23\NN\4723816|on|the|[glu1]pg|activated (l_nmod) [glu1]pg_25\NN\1740|of
T10_T25 NONE cl-_13\NN\1740|and|fibrinogen (r_appos) components_11\NNS\5867413|normal|plasma|,|cl-|, (r_nsubj) exert_17\VBP\1158872|that|components|roles|ability (l_nmod) ability_23\NN\4723816|on|the|[glu1]pg|activated (l_acl) activated_28\VBN\1641914|to|be|rec-t-pa|,|systems (l_nmod) rec-t-pa_31\NN\1740|by|two-chain
T1_T11 CPR:4 cl-_3\NN\1740|of (r_nmod) presence_1\NN\13954253|the|cl- (r_nsubj) inhibits_4\VBZ\2510337|presence|stimulation|,|result|. (l_dobj) stimulation_6\NN\242808|the|activation|occur (l_nmod) activation_9\NN\13561719|of|[glu1]pg (l_compound) [glu1]pg_8\NN\1740|
T1_T12 NONE cl-_3\NN\1740|of (r_nmod) presence_1\NN\13954253|the|cl- (r_nsubj) inhibits_4\VBZ\2510337|presence|stimulation|,|result|. (l_dobj) stimulation_6\NN\242808|the|activation|occur (l_acl:relcl) occur_13\VB\2623529|that|would|normally|presence (l_nmod) presence_16\NN\13954253|in|the|fibrinogen (l_nmod) fibrinogen_18\NN\15022776|of
T1_T14 NONE cl-_3\NN\1740|of (r_nmod) presence_1\NN\13954253|the|cl- (r_nsubj) inhibits_4\VBZ\2510337|presence|stimulation|,|result|. (l_dobj) result_21\NN\34213|a|importance (l_nmod) importance_24\NN\5138488|of|possible|observation (l_nmod) observation_27\NN\996969|to|the|accompanies (l_ccomp) accompanies_34\VBZ\1835496|that|degree|use (l_dobj) use_36\NN\407535|therapeutic|activator (l_nmod) activator_40\NN\19613|of|tissue|plasminogen
1666997
T5_T23 NONE amoxapine_7\NN\1740|both|and|amitriptyline (r_nsubj) interact_10\VBP\2367363|that|amoxapine|range|receptors (l_nmod) receptors_17\NNS\5225602|with|5-ht2|labelled (l_compound) 5-ht2_16\NN\1740|
T6_T23 NONE amitriptyline_9\NN\4482543| (r_conj) amoxapine_7\NN\1740|both|and|amitriptyline (r_nsubj) interact_10\VBP\2367363|that|amoxapine|range|receptors (l_nmod) receptors_17\NNS\5225602|with|5-ht2|labelled (l_compound) 5-ht2_16\NN\1740|
T7_T23 NONE [3h]ketanserin_20\NN\1740|by|membranes (r_nmod) labelled_18\VBN\1030132|[3h]ketanserin (r_acl) receptors_17\NNS\5225602|with|5-ht2|labelled (l_compound) 5-ht2_16\NN\1740|
T10_T24 NONE amitriptyline_6\NN\4482543| (r_conj) amoxapine_4\NN\1740|neither|nor|amitriptyline (r_nsubjpass) considered_9\VBN\689344|contrast|,|amoxapine|can|be|ligands|because|. (l_nmod) ligands_12\NNS\20090|as|possible|receptors (l_nmod) receptors_17\NNS\5225602|of|5-ht1a (l_compound) 5-ht1a_14\NN\1740|and|5-ht1b
T10_T25 NONE amitriptyline_6\NN\4482543| (r_conj) amoxapine_4\NN\1740|neither|nor|amitriptyline (r_nsubjpass) considered_9\VBN\689344|contrast|,|amoxapine|can|be|ligands|because|. (l_nmod) ligands_12\NNS\20090|as|possible|receptors (l_nmod) receptors_17\NNS\5225602|of|5-ht1a (l_compound) 5-ht1a_14\NN\1740|and|5-ht1b (l_conj) 5-ht1b_16\NN\1740|
T9_T24 NONE amoxapine_4\NN\1740|neither|nor|amitriptyline (r_nsubjpass) considered_9\VBN\689344|contrast|,|amoxapine|can|be|ligands|because|. (l_nmod) ligands_12\NNS\20090|as|possible|receptors (l_nmod) receptors_17\NNS\5225602|of|5-ht1a (l_compound) 5-ht1a_14\NN\1740|and|5-ht1b
T9_T25 NONE amoxapine_4\NN\1740|neither|nor|amitriptyline (r_nsubjpass) considered_9\VBN\689344|contrast|,|amoxapine|can|be|ligands|because|. (l_nmod) ligands_12\NNS\20090|as|possible|receptors (l_nmod) receptors_17\NNS\5225602|of|5-ht1a (l_compound) 5-ht1a_14\NN\1740|and|5-ht1b (l_conj) 5-ht1b_16\NN\1740|
T12_T26 NONE amoxapine_2\NN\1740| (r_nsubj) binds_3\VBZ\1290422|interestingly|,|amoxapine|affinity|=|receptors|. (l_nmod) receptors_16\NNS\5225602|to|5-ht3|labelled (l_compound) 5-ht3_15\NN\1740|
T13_T26 NONE [3h]zacopride_19\NN\1740|by (r_nmod) labelled_17\VBN\1030132|[3h]zacopride|membranes (r_acl) receptors_16\NNS\5225602|to|5-ht3|labelled (l_compound) 5-ht3_15\NN\1740|
T14_T27 NONE amoxapine_9\NN\1740| (r_nsubj) acts_11\VBZ\1619354|that|amoxapine|really|vivo|antagonist|=|,|inactive (r_ccomp) confirmed_7\VBD\1011725|experiments|acts|. (l_nsubj) experiments_1\NNS\641820|complementary|using (l_acl) using_2\VBG\1156834|reflex (l_dobj) reflex_6\NN\859001|the|5-ht3-dependent|bezold-jarisch (l_amod) 5-ht3-dependent_4\JJ\1740|
T14_T28 CPR:6 amoxapine_9\NN\1740| (r_nsubj) acts_11\VBZ\1619354|that|amoxapine|really|vivo|antagonist|=|,|inactive (l_nmod) antagonist_17\NN\7846|as|a|5-ht3 (l_compound) 5-ht3_16\NN\1740|
T14_T29 NONE amoxapine_9\NN\1740| (r_nsubj) acts_11\VBZ\1619354|that|amoxapine|really|vivo|antagonist|=|,|inactive (l_advcl) inactive_30\JJ\1740|whereas|amitriptyline|is|essentially|receptors (l_nmod) receptors_33\NNS\5225602|on|5-ht3 (l_compound) 5-ht3_32\NN\1740|
T15_T27 NONE amitriptyline_27\NN\4482543| (r_nsubj) inactive_30\JJ\1740|whereas|amitriptyline|is|essentially|receptors (r_advcl) acts_11\VBZ\1619354|that|amoxapine|really|vivo|antagonist|=|,|inactive (r_ccomp) confirmed_7\VBD\1011725|experiments|acts|. (l_nsubj) experiments_1\NNS\641820|complementary|using (l_acl) using_2\VBG\1156834|reflex (l_dobj) reflex_6\NN\859001|the|5-ht3-dependent|bezold-jarisch (l_amod) 5-ht3-dependent_4\JJ\1740|
T15_T28 NONE amitriptyline_27\NN\4482543| (r_nsubj) inactive_30\JJ\1740|whereas|amitriptyline|is|essentially|receptors (r_advcl) acts_11\VBZ\1619354|that|amoxapine|really|vivo|antagonist|=|,|inactive (l_nmod) antagonist_17\NN\7846|as|a|5-ht3 (l_compound) 5-ht3_16\NN\1740|
T15_T29 NONE amitriptyline_27\NN\4482543| (r_nsubj) inactive_30\JJ\1740|whereas|amitriptyline|is|essentially|receptors (l_nmod) receptors_33\NNS\5225602|on|5-ht3 (l_compound) 5-ht3_32\NN\1740|
T1_T18 NONE amoxapine_32\NN\1740|with|mg/kg|or|amitriptyline (r_nmod) treatment_30\NN\654885|single|amoxapine (r_nmod) looking_8\VBG\2604760|of|changes|treatment (l_nmod) changes_11\NNS\7283608|for|possible|receptors (l_nmod) receptors_15\NNS\5225602|in|central|5-ht
T2_T18 NONE amitriptyline_41\NN\4482543|mg/kg (r_conj) amoxapine_32\NN\1740|with|mg/kg|or|amitriptyline (r_nmod) treatment_30\NN\654885|single|amoxapine (r_nmod) looking_8\VBG\2604760|of|changes|treatment (l_nmod) changes_11\NNS\7283608|for|possible|receptors (l_nmod) receptors_15\NNS\5225602|in|central|5-ht
T3_T22 NONE amoxapine_9\NN\1740|of|or|amitriptyline (r_nmod) administration_7\NN\1133281|acute|amoxapine (r_nsubj) affected_12\VBD\126264|whether|administration|levels (l_dobj) levels_14\NNS\4916342|the|peptides|regions (l_nmod) peptides_17\NNS\14724264|of|opioid|and|classes (l_conj) classes_23\NNS\7951464|the|mu|receptors (l_nmod) receptors_26\NNS\5225602|of|opioid
T4_T22 NONE amitriptyline_11\NN\4482543| (r_conj) amoxapine_9\NN\1740|of|or|amitriptyline (r_nmod) administration_7\NN\1133281|acute|amoxapine (r_nsubj) affected_12\VBD\126264|whether|administration|levels (l_dobj) levels_14\NNS\4916342|the|peptides|regions (l_nmod) peptides_17\NNS\14724264|of|opioid|and|classes (l_conj) classes_23\NNS\7951464|the|mu|receptors (l_nmod) receptors_26\NNS\5225602|of|opioid
17578749
T1_T10 NONE superoxide_6\NN\14971519| (r_compound) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_appos) sod_9\NN\9335240|(|)
T1_T11 NONE superoxide_6\NN\14971519| (r_compound) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) catalase_12\NN\14732946|cat
T1_T12 NONE superoxide_6\NN\14971519| (r_compound) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) catalase_12\NN\14732946|cat (l_appos) cat_14\NN\2120997|(|)
T1_T13 NONE superoxide_6\NN\14971519| (r_compound) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and
T1_T14 NONE superoxide_6\NN\14971519| (r_compound) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (l_appos) gpx_20\NN\1740|(|)
T1_T9 NONE superoxide_6\NN\14971519| (r_compound) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a.
T2_T10 NONE glutathione_17\NN\1740| (r_compound) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_appos) sod_9\NN\9335240|(|)
T2_T11 NONE glutathione_17\NN\1740| (r_compound) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) catalase_12\NN\14732946|cat
T2_T12 NONE glutathione_17\NN\1740| (r_compound) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) catalase_12\NN\14732946|cat (l_appos) cat_14\NN\2120997|(|)
T2_T13 NONE glutathione_17\NN\1740| (r_compound) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and
T2_T14 NONE glutathione_17\NN\1740| (r_compound) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (l_appos) gpx_20\NN\1740|(|)
T2_T9 NONE glutathione_17\NN\1740| (r_compound) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a.
T3_T10 NONE e_24\NN\14724645|vitamin (r_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_appos) sod_9\NN\9335240|(|)
T3_T11 NONE e_24\NN\14724645|vitamin (r_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) catalase_12\NN\14732946|cat
T3_T12 NONE e_24\NN\14724645|vitamin (r_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) catalase_12\NN\14732946|cat (l_appos) cat_14\NN\2120997|(|)
T3_T13 NONE e_24\NN\14724645|vitamin (r_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and
T3_T14 NONE e_24\NN\14724645|vitamin (r_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (l_appos) gpx_20\NN\1740|(|)
T3_T9 NONE e_24\NN\14724645|vitamin (r_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a.
T4_T10 NONE a._28\.\1740|vitamin (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_appos) sod_9\NN\9335240|(|)
T4_T11 NONE a._28\.\1740|vitamin (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) catalase_12\NN\14732946|cat
T4_T12 NONE a._28\.\1740|vitamin (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) catalase_12\NN\14732946|cat (l_appos) cat_14\NN\2120997|(|)
T4_T13 NONE a._28\.\1740|vitamin (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and
T4_T14 NONE a._28\.\1740|vitamin (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a. (l_conj) peroxidase_18\NN\14971234|glutathione|gpx|,|e|,|and (l_appos) gpx_20\NN\1740|(|)
T4_T9 NONE a._28\.\1740|vitamin (r_conj) dismutase_7\NN\1740|superoxide|sod|,|catalase|,|peroxidase|a.
10460702
T22_T44 CPR:3 5-hydroxytryptamine_0\NN\14807737| (r_nsubj) evokes_1\VBZ\1617192|5-hydroxytryptamine|activation|cultures|. (l_dobj) activation_6\NN\13561719|synthase (l_compound) synthase_5\NN\1740|endothelial|nitric|oxide
T23_T44 NONE oxide_4\NN\14818238| (r_compound) synthase_5\NN\1740|endothelial|nitric|oxide
T19_T32 CPR:9 oxide_15\NN\14818238|of|nitric|no|mediates (r_nmod) production_12\NN\30358|in|the|oxide (r_nmod) results_9\VBZ\2633881|activation|production|. (l_nsubj) activation_0\NN\13561719|synthase (l_nmod) synthase_5\NN\1740|of|endothelial|nitric|oxide|enos
T19_T38 CPR:9 oxide_15\NN\14818238|of|nitric|no|mediates (r_nmod) production_12\NN\30358|in|the|oxide (r_nmod) results_9\VBZ\2633881|activation|production|. (l_nsubj) activation_0\NN\13561719|synthase (l_nmod) synthase_5\NN\1740|of|endothelial|nitric|oxide|enos (l_appos) enos_7\NN\1740|(|)
T20_T32 CPR:9 no_17\NN\7204911|(|) (r_appos) oxide_15\NN\14818238|of|nitric|no|mediates (r_nmod) production_12\NN\30358|in|the|oxide (r_nmod) results_9\VBZ\2633881|activation|production|. (l_nsubj) activation_0\NN\13561719|synthase (l_nmod) synthase_5\NN\1740|of|endothelial|nitric|oxide|enos
T20_T38 CPR:9 no_17\NN\7204911|(|) (r_appos) oxide_15\NN\14818238|of|nitric|no|mediates (r_nmod) production_12\NN\30358|in|the|oxide (r_nmod) results_9\VBZ\2633881|activation|production|. (l_nsubj) activation_0\NN\13561719|synthase (l_nmod) synthase_5\NN\1740|of|endothelial|nitric|oxide|enos (l_appos) enos_7\NN\1740|(|)
T9_T32 NONE oxide_4\NN\14818238| (r_compound) synthase_5\NN\1740|of|endothelial|nitric|oxide|enos
T9_T38 NONE oxide_4\NN\14818238| (r_compound) synthase_5\NN\1740|of|endothelial|nitric|oxide|enos (l_appos) enos_7\NN\1740|(|)
T7_T35 NONE 5-hydroxytryptamine_11\NN\14807737|5-ht (r_nsubj) stimulates_15\VBZ\137313|that|5-hydroxytryptamine|activity (l_dobj) activity_17\NN\30358|enos|cultures (l_compound) enos_16\NN\1740|
T8_T35 NONE 5-ht_13\NN\1740|(|) (r_appos) 5-hydroxytryptamine_11\NN\14807737|5-ht (r_nsubj) stimulates_15\VBZ\137313|that|5-hydroxytryptamine|activity (l_dobj) activity_17\NN\30358|enos|cultures (l_compound) enos_16\NN\1740|
T10_T36 NONE 5-ht_7\NN\1740| (r_compound) receptors_8\NNS\5225602|5-ht
T10_T37 NONE 5-ht_7\NN\1740| (r_compound) receptors_8\NNS\5225602|5-ht (r_nsubj) mediate_9\VBP\761713|that|receptors|activation|measuring (l_dobj) activation_11\NN\13561719|enos (l_compound) enos_10\NN\1740|
T11_T36 NONE [3h]l-citrulline_15\NN\1740|agonist-stimulated|[3h]l-cit (r_compound) formation_19\NN\7938773|[3h]l-citrulline|cultures (r_dobj) measuring_13\VBG\697589|by|formation (r_advcl) mediate_9\VBP\761713|that|receptors|activation|measuring (l_nsubj) receptors_8\NNS\5225602|5-ht
T11_T37 CPR:9 [3h]l-citrulline_15\NN\1740|agonist-stimulated|[3h]l-cit (r_compound) formation_19\NN\7938773|[3h]l-citrulline|cultures (r_dobj) measuring_13\VBG\697589|by|formation (r_advcl) mediate_9\VBP\761713|that|receptors|activation|measuring (l_dobj) activation_11\NN\13561719|enos (l_compound) enos_10\NN\1740|
T12_T36 NONE [3h]l-cit_17\NN\1740|(|) (r_appos) [3h]l-citrulline_15\NN\1740|agonist-stimulated|[3h]l-cit (r_compound) formation_19\NN\7938773|[3h]l-citrulline|cultures (r_dobj) measuring_13\VBG\697589|by|formation (r_advcl) mediate_9\VBP\761713|that|receptors|activation|measuring (l_nsubj) receptors_8\NNS\5225602|5-ht
T12_T37 CPR:9 [3h]l-cit_17\NN\1740|(|) (r_appos) [3h]l-citrulline_15\NN\1740|agonist-stimulated|[3h]l-cit (r_compound) formation_19\NN\7938773|[3h]l-citrulline|cultures (r_dobj) measuring_13\VBG\697589|by|formation (r_advcl) mediate_9\VBP\761713|that|receptors|activation|measuring (l_dobj) activation_11\NN\13561719|enos (l_compound) enos_10\NN\1740|
T13_T39 CPR:3 5-ht_3\NN\1740| (r_nsubj) stimulated_4\VBD\137313|that|5-ht|conversion|,|indicating (l_advcl) indicating_15\VBG\952524|activation (l_dobj) activation_17\NN\13561719|enos (l_compound) enos_16\NN\1740|
T14_T39 CPR:9 [3h]l-arginine_8\NN\1740|of|[3h]l-arg (r_nmod) conversion_6\NN\7359599|the|[3h]l-arginine|[3h]l-cit (r_dobj) stimulated_4\VBD\137313|that|5-ht|conversion|,|indicating (l_advcl) indicating_15\VBG\952524|activation (l_dobj) activation_17\NN\13561719|enos (l_compound) enos_16\NN\1740|
T15_T39 CPR:9 [3h]l-arg_10\NN\1740|(|) (r_appos) [3h]l-arginine_8\NN\1740|of|[3h]l-arg (r_nmod) conversion_6\NN\7359599|the|[3h]l-arginine|[3h]l-cit (r_dobj) stimulated_4\VBD\137313|that|5-ht|conversion|,|indicating (l_advcl) indicating_15\VBG\952524|activation (l_dobj) activation_17\NN\13561719|enos (l_compound) enos_16\NN\1740|
T16_T39 CPR:9 [3h]l-cit_13\NN\1740|to (r_nmod) conversion_6\NN\7359599|the|[3h]l-arginine|[3h]l-cit (r_dobj) stimulated_4\VBD\137313|that|5-ht|conversion|,|indicating (l_advcl) indicating_15\VBG\952524|activation (l_dobj) activation_17\NN\13561719|enos (l_compound) enos_16\NN\1740|
T17_T40 CPR:5 5-nonyloxytryptamine_7\NN\1740| (r_compound) responses_11\NNS\11410625|5-nonyloxytryptamine|(5-not)-stimulated|[3h]l-cit|turnover (r_appos) agonist_5\NN\9613191|the|affinity|5-ht1b|receptor|,|responses|nm|and|time-dependent|. (l_compound) 5-ht1b_3\NN\1740|
T18_T40 NONE [3h]l-cit_9\NN\1740| (r_compound) responses_11\NNS\11410625|5-nonyloxytryptamine|(5-not)-stimulated|[3h]l-cit|turnover (r_appos) agonist_5\NN\9613191|the|affinity|5-ht1b|receptor|,|responses|nm|and|time-dependent|. (l_compound) 5-ht1b_3\NN\1740|
T1_T24 CPR:6 -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (l_compound) enos_22\NN\1740|
T1_T41 NONE -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_compound) 5-ht1b_7\NN\1740|
T1_T42 NONE -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) 5-ht1b/5-ht2_14\NN\1740|
T1_T43 NONE -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) receptor_15\NN\5225602|
T21_T24 NONE methiothepin_18\NN\1740| (r_appos) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (l_compound) enos_22\NN\1740|
T21_T41 NONE methiothepin_18\NN\1740| (r_appos) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_compound) 5-ht1b_7\NN\1740|
T21_T42 CPR:6 methiothepin_18\NN\1740| (r_appos) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) 5-ht1b/5-ht2_14\NN\1740|
T21_T43 CPR:6 methiothepin_18\NN\1740| (r_appos) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) receptor_15\NN\5225602|
T2_T24 CPR:6 l-nmma_34\NN\1740|(|) (r_appos) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (l_compound) enos_22\NN\1740|
T2_T41 NONE l-nmma_34\NN\1740|(|) (r_appos) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_compound) 5-ht1b_7\NN\1740|
T2_T42 NONE l-nmma_34\NN\1740|(|) (r_appos) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) 5-ht1b/5-ht2_14\NN\1740|
T2_T43 NONE l-nmma_34\NN\1740|(|) (r_appos) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) receptor_15\NN\5225602|
T3_T24 CPR:6 omega-iminoethyl-l-ornithine_38\NN\1740|l-n|l-nio (r_conj) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (l_compound) enos_22\NN\1740|
T3_T41 NONE omega-iminoethyl-l-ornithine_38\NN\1740|l-n|l-nio (r_conj) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_compound) 5-ht1b_7\NN\1740|
T3_T42 NONE omega-iminoethyl-l-ornithine_38\NN\1740|l-n|l-nio (r_conj) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) 5-ht1b/5-ht2_14\NN\1740|
T3_T43 NONE omega-iminoethyl-l-ornithine_38\NN\1740|l-n|l-nio (r_conj) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) receptor_15\NN\5225602|
T4_T24 CPR:6 l-nio_40\NN\1740|(|) (r_appos) omega-iminoethyl-l-ornithine_38\NN\1740|l-n|l-nio (r_conj) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (l_compound) enos_22\NN\1740|
T4_T41 NONE l-nio_40\NN\1740|(|) (r_appos) omega-iminoethyl-l-ornithine_38\NN\1740|l-n|l-nio (r_conj) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_compound) 5-ht1b_7\NN\1740|
T4_T42 NONE l-nio_40\NN\1740|(|) (r_appos) omega-iminoethyl-l-ornithine_38\NN\1740|l-n|l-nio (r_conj) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) 5-ht1b/5-ht2_14\NN\1740|
T4_T43 NONE l-nio_40\NN\1740|(|) (r_appos) omega-iminoethyl-l-ornithine_38\NN\1740|l-n|l-nio (r_conj) -monomethyl-l-arginine_32\NN\1740|l-nomega|l-nmma|and|omega-iminoethyl-l-ornithine (r_dep) antagonists_24\NNS\7846|the|enos|selective|microm|-monomethyl-l-arginine (r_conj) antagonist_9\NN\7846|by|the|5-ht1b|receptor|,|isamoltane|,|antagonist|,|methiothepin|,|and|antagonists (l_conj) antagonist_16\NN\7846|the|5-ht1b/5-ht2|receptor (l_compound) receptor_15\NN\5225602|
T5_T29 NONE 5-ht_19\NN\1740|by (r_nmod) activation_15\NN\13561719|for|the|enos|5-ht (r_nmod) accounting_10\VBG\2604760|part|activation (r_advcl) lend_2\VBP\126264|findings|evidence|pathway|,|accounting|. (l_nmod) pathway_8\NN\5483677|of|a|receptor/enos (l_compound) receptor/enos_7\NN\1740|5-ht1b (l_compound) 5-ht1b_6\NN\1740|
T5_T30 NONE 5-ht_19\NN\1740|by (r_nmod) activation_15\NN\13561719|for|the|enos|5-ht (r_nmod) accounting_10\VBG\2604760|part|activation (r_advcl) lend_2\VBP\126264|findings|evidence|pathway|,|accounting|. (l_nmod) pathway_8\NN\5483677|of|a|receptor/enos (l_compound) receptor/enos_7\NN\1740|5-ht1b
T5_T31 CPR:3 5-ht_19\NN\1740|by (r_nmod) activation_15\NN\13561719|for|the|enos|5-ht (l_nmod) enos_17\NN\1740|of
T6_T33 NONE 5-ht_11\NN\1740| (r_compound) receptors_12\NNS\5225602|of|other|vascular|5-ht
T6_T34 NONE 5-ht_11\NN\1740| (r_compound) receptors_12\NNS\5225602|of|other|vascular|5-ht (r_nmod) role_7\NN\719494|the|receptors|stimulation (l_nmod) stimulation_15\NN\242808|in|the|activity (l_nmod) activity_18\NN\30358|of|enos (l_compound) enos_17\NN\1740|
12409268
T11_T30 NONE propionic_9\JJ\1740| (r_amod) acidemia_10\NN\14189204|with|propionic (r_nmod) patients_7\NNS\9898892|in|korean|acidemia (r_nmod) analysis_1\NN\633864|molecular|gene|patients|. (l_nmod) gene_4\NN\8459252|of|pccb (l_compound) pccb_3\NN\1740|
T5_T22 NONE propionyl-coa_7\NN\1740| (r_compound) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme
T5_T23 NONE propionyl-coa_7\NN\1740| (r_compound) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (l_appos) pcc_10\NN\1740|(|,|ec|)
T5_T24 NONE propionyl-coa_7\NN\1740| (r_compound) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (l_appos) pcc_10\NN\1740|(|,|ec|) (l_appos) ec_12\NN\8294696|6.4.1.3 (l_nummod) 6.4.1.3_13\CD\1740|
T5_T25 NONE propionyl-coa_7\NN\1740| (r_compound) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (r_nmod) deficiency_5\NN\14449126|by|a|carboxylase (r_nmod) caused_2\VBN\1617192|it|is|deficiency|enzyme (l_parataxis) enzyme_31\NN\14723628|pcc|is|a|heteropolymeric|composed|. (l_nsubj) pcc_27\NN\1740|
T6_T22 NONE biotin-dependent_17\JJ\1740| (r_amod) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme
T6_T23 NONE biotin-dependent_17\JJ\1740| (r_amod) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (l_appos) pcc_10\NN\1740|(|,|ec|)
T6_T24 NONE biotin-dependent_17\JJ\1740| (r_amod) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (l_appos) pcc_10\NN\1740|(|,|ec|) (l_appos) ec_12\NN\8294696|6.4.1.3 (l_nummod) 6.4.1.3_13\CD\1740|
T6_T25 NONE biotin-dependent_17\JJ\1740| (r_amod) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (r_nmod) deficiency_5\NN\14449126|by|a|carboxylase (r_nmod) caused_2\VBN\1617192|it|is|deficiency|enzyme (l_parataxis) enzyme_31\NN\14723628|pcc|is|a|heteropolymeric|composed|. (l_nsubj) pcc_27\NN\1740|
T7_T22 CPR:9 propionyl-coa_24\NN\1740|of (r_nmod) carboxylation_22\NN\1740|the|propionyl-coa|d-methylmalonyl-coa. (r_dobj) catalyzes_20\VBZ\146138|that|carboxylation (r_acl:relcl) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme
T7_T23 CPR:9 propionyl-coa_24\NN\1740|of (r_nmod) carboxylation_22\NN\1740|the|propionyl-coa|d-methylmalonyl-coa. (r_dobj) catalyzes_20\VBZ\146138|that|carboxylation (r_acl:relcl) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (l_appos) pcc_10\NN\1740|(|,|ec|)
T7_T24 CPR:9 propionyl-coa_24\NN\1740|of (r_nmod) carboxylation_22\NN\1740|the|propionyl-coa|d-methylmalonyl-coa. (r_dobj) catalyzes_20\VBZ\146138|that|carboxylation (r_acl:relcl) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (l_appos) pcc_10\NN\1740|(|,|ec|) (l_appos) ec_12\NN\8294696|6.4.1.3 (l_nummod) 6.4.1.3_13\CD\1740|
T7_T25 NONE propionyl-coa_24\NN\1740|of (r_nmod) carboxylation_22\NN\1740|the|propionyl-coa|d-methylmalonyl-coa. (r_dobj) catalyzes_20\VBZ\146138|that|carboxylation (r_acl:relcl) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (r_nmod) deficiency_5\NN\14449126|by|a|carboxylase (r_nmod) caused_2\VBN\1617192|it|is|deficiency|enzyme (l_parataxis) enzyme_31\NN\14723628|pcc|is|a|heteropolymeric|composed|. (l_nsubj) pcc_27\NN\1740|
T8_T22 CPR:9 d-methylmalonyl-coa._26\NN\1740|to (r_nmod) carboxylation_22\NN\1740|the|propionyl-coa|d-methylmalonyl-coa. (r_dobj) catalyzes_20\VBZ\146138|that|carboxylation (r_acl:relcl) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme
T8_T23 CPR:9 d-methylmalonyl-coa._26\NN\1740|to (r_nmod) carboxylation_22\NN\1740|the|propionyl-coa|d-methylmalonyl-coa. (r_dobj) catalyzes_20\VBZ\146138|that|carboxylation (r_acl:relcl) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (l_appos) pcc_10\NN\1740|(|,|ec|)
T8_T24 CPR:9 d-methylmalonyl-coa._26\NN\1740|to (r_nmod) carboxylation_22\NN\1740|the|propionyl-coa|d-methylmalonyl-coa. (r_dobj) catalyzes_20\VBZ\146138|that|carboxylation (r_acl:relcl) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (l_appos) pcc_10\NN\1740|(|,|ec|) (l_appos) ec_12\NN\8294696|6.4.1.3 (l_nummod) 6.4.1.3_13\CD\1740|
T8_T25 NONE d-methylmalonyl-coa._26\NN\1740|to (r_nmod) carboxylation_22\NN\1740|the|propionyl-coa|d-methylmalonyl-coa. (r_dobj) catalyzes_20\VBZ\146138|that|carboxylation (r_acl:relcl) enzyme_18\NN\14723628|a|biotin-dependent|catalyzes (r_appos) carboxylase_8\NN\1740|of|propionyl-coa|pcc|,|enzyme (r_nmod) deficiency_5\NN\14449126|by|a|carboxylase (r_nmod) caused_2\VBN\1617192|it|is|deficiency|enzyme (l_parataxis) enzyme_31\NN\14723628|pcc|is|a|heteropolymeric|composed|. (l_nsubj) pcc_27\NN\1740|
23452205
T4_T10 NONE glutamate_15\NN\15010703| (r_compound) receptors_16\NNS\5225602|of|metabotropic|glutamate|mglu
T4_T6 NONE glutamate_15\NN\15010703| (r_compound) receptors_16\NNS\5225602|of|metabotropic|glutamate|mglu (r_nmod) subfamily_12\NN\7992450|to|the|group|ii|receptors (r_nmod) belongs_7\VBZ\2604760|which|subfamily (r_acl:relcl) receptor_4\NN\5225602|the|mglu2|,|belongs|receptor|, (l_conj) receptor_24\NN\5225602|along|the|mglu3
T4_T7 NONE glutamate_15\NN\15010703| (r_compound) receptors_16\NNS\5225602|of|metabotropic|glutamate|mglu (r_nmod) subfamily_12\NN\7992450|to|the|group|ii|receptors (r_nmod) belongs_7\VBZ\2604760|which|subfamily (r_acl:relcl) receptor_4\NN\5225602|the|mglu2|,|belongs|receptor|,
T1_T8 NONE glutamate_12\NN\15010703|and|gaba (r_compound) release_15\NN\3748886|glutamate (r_dobj) modulates_11\VBZ\1724459|expressed|,|receptor|negatively|release|and|distributed|. (l_nsubj) receptor_9\NN\5225602|the|mglu2
T2_T8 NONE gaba_14\NN\14601829| (r_conj) glutamate_12\NN\15010703|and|gaba (r_compound) release_15\NN\3748886|glutamate (r_dobj) modulates_11\VBZ\1724459|expressed|,|receptor|negatively|release|and|distributed|. (l_nsubj) receptor_9\NN\5225602|the|mglu2
T3_T9 NONE glutamate_19\NN\15010703| (r_compound) hyperfunction_20\NN\1740|glutamate (r_nsubjpass) implicated_23\VBN\2677097|where|hyperfunction|may|be|disorders (r_acl:relcl) cortex_13\NN\5462674|such|prefrontal|,|hippocampus|amygdala|implicated (r_nmod) areas_9\NNS\8630985|in|brain|cortex (r_nmod) seen_6\VBN\2106506|levels|are|areas|. (l_nsubjpass) levels_1\NNS\4916342|high|receptors (l_nmod) receptors_4\NNS\5225602|of|mglu2
14564902
T1_T5 NONE normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) factor_18\NN\7326557|von|willebrand
T1_T6 NONE normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) anti-thrombin_20\NN\1740|iii (l_nummod) iii_21\CD\13741022|
T1_T7 NONE normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) 1-complex_27\NN\1740|t-plasminogen|activator-plasminogen|activator|inhibitor (l_compound) activator-plasminogen_24\NN\1740|
T1_T8 NONE normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) 1-complex_27\NN\1740|t-plasminogen|activator-plasminogen|activator|inhibitor
T2_T5 NONE normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) factor_18\NN\7326557|von|willebrand
T2_T6 NONE normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) anti-thrombin_20\NN\1740|iii (l_nummod) iii_21\CD\13741022|
T2_T7 NONE normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) 1-complex_27\NN\1740|t-plasminogen|activator-plasminogen|activator|inhibitor (l_compound) activator-plasminogen_24\NN\1740|
T2_T8 NONE normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) 1-complex_27\NN\1740|t-plasminogen|activator-plasminogen|activator|inhibitor
T3_T5 NONE glucose_32\NN\14710501|blood (r_conj) normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) factor_18\NN\7326557|von|willebrand
T3_T6 NONE glucose_32\NN\14710501|blood (r_conj) normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) anti-thrombin_20\NN\1740|iii (l_nummod) iii_21\CD\13741022|
T3_T7 NONE glucose_32\NN\14710501|blood (r_conj) normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) 1-complex_27\NN\1740|t-plasminogen|activator-plasminogen|activator|inhibitor (l_compound) activator-plasminogen_24\NN\1740|
T3_T8 NONE glucose_32\NN\14710501|blood (r_conj) normetanephrine/creatinine_14\NN\1740|for|urine|,|factor|,|anti-thrombin|,|1-complex|,|hematocrit|,|glucose|and|pressure (l_conj) 1-complex_27\NN\1740|t-plasminogen|activator-plasminogen|activator|inhibitor
17354225
T9_T28 NONE argininosuccinate_3\NN\1740| (r_compound) synthetase_4\NN\1740|of|argininosuccinate
T9_T29 NONE argininosuccinate_3\NN\1740| (r_compound) synthetase_4\NN\1740|of|argininosuccinate (r_nmod) regulation_1\NN\6652242|aberrant|synthetase|tnf-alpha|cancer|. (l_nmod) tnf-alpha_6\NN\1740|by
T6_T19 NONE arginine_13\NN\14605787| (r_compound) synthesis_14\NN\13446390|in|arginine|,|synthetase (r_nmod) enzyme_11\NN\14723628|of|arate-limiting|synthesis (r_nmod) expression_8\NN\4679549|enzyme (r_dobj) induces_7\VBZ\1627355|that|tnf-alpha|also|expression|,|linking (l_nsubj) tnf-alpha_5\NN\1740|
T6_T20 NONE arginine_13\NN\14605787| (r_compound) synthesis_14\NN\13446390|in|arginine|,|synthetase (l_appos) synthetase_17\NN\1740|argininosuccinate|as
T6_T21 NONE arginine_13\NN\14605787| (r_compound) synthesis_14\NN\13446390|in|arginine|,|synthetase (l_appos) synthetase_17\NN\1740|argininosuccinate|as (l_appos) as_19\NNP\14622893|(|)
T7_T19 NONE argininosuccinate_16\NN\1740| (r_compound) synthetase_17\NN\1740|argininosuccinate|as (r_appos) synthesis_14\NN\13446390|in|arginine|,|synthetase (r_nmod) enzyme_11\NN\14723628|of|arate-limiting|synthesis (r_nmod) expression_8\NN\4679549|enzyme (r_dobj) induces_7\VBZ\1627355|that|tnf-alpha|also|expression|,|linking (l_nsubj) tnf-alpha_5\NN\1740|
T7_T20 NONE argininosuccinate_16\NN\1740| (r_compound) synthetase_17\NN\1740|argininosuccinate|as
T7_T21 NONE argininosuccinate_16\NN\1740| (r_compound) synthetase_17\NN\1740|argininosuccinate|as (l_appos) as_19\NNP\14622893|(|)
T8_T19 NONE arginine-dependent_27\JJ\1740| (r_amod) pathways_29\NNS\5483677|with|several|arginine-dependent|metabolic|,|implicated (r_nmod) linking_23\VBG\628491|thereby|inflammation|pathways (r_advcl) induces_7\VBZ\1627355|that|tnf-alpha|also|expression|,|linking (l_nsubj) tnf-alpha_5\NN\1740|
T8_T20 NONE arginine-dependent_27\JJ\1740| (r_amod) pathways_29\NNS\5483677|with|several|arginine-dependent|metabolic|,|implicated (r_nmod) linking_23\VBG\628491|thereby|inflammation|pathways (r_advcl) induces_7\VBZ\1627355|that|tnf-alpha|also|expression|,|linking (l_dobj) expression_8\NN\4679549|enzyme (l_nmod) enzyme_11\NN\14723628|of|arate-limiting|synthesis (l_nmod) synthesis_14\NN\13446390|in|arginine|,|synthetase (l_appos) synthetase_17\NN\1740|argininosuccinate|as
T8_T21 NONE arginine-dependent_27\JJ\1740| (r_amod) pathways_29\NNS\5483677|with|several|arginine-dependent|metabolic|,|implicated (r_nmod) linking_23\VBG\628491|thereby|inflammation|pathways (r_advcl) induces_7\VBZ\1627355|that|tnf-alpha|also|expression|,|linking (l_dobj) expression_8\NN\4679549|enzyme (l_nmod) enzyme_11\NN\14723628|of|arate-limiting|synthesis (l_nmod) synthesis_14\NN\13446390|in|arginine|,|synthetase (l_appos) synthetase_17\NN\1740|argininosuccinate|as (l_appos) as_19\NNP\14622893|(|)
T1_T14 NONE arginine-dependent_15\JJ\1740| (r_amod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (l_nmod) expression_7\NN\4679549|of|as (l_compound) as_6\IN\14622893|
T1_T15 NONE arginine-dependent_15\JJ\1740| (r_amod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (r_nsubjpass) regulated_34\VBN\296178|summary|,|levels|is|tnf-alpha|and|provide|. (l_nmod) tnf-alpha_36\NN\1740|by
T2_T14 NONE oxide_25\NN\14818238|of|nitric|,|proline|,|pyrimidines|and|polyamines (r_nmod) production_22\NN\30358|including|the|oxide (r_nmod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (l_nmod) expression_7\NN\4679549|of|as (l_compound) as_6\IN\14622893|
T2_T15 NONE oxide_25\NN\14818238|of|nitric|,|proline|,|pyrimidines|and|polyamines (r_nmod) production_22\NN\30358|including|the|oxide (r_nmod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (r_nsubjpass) regulated_34\VBN\296178|summary|,|levels|is|tnf-alpha|and|provide|. (l_nmod) tnf-alpha_36\NN\1740|by
T3_T14 NONE proline_27\NN\14601829| (r_conj) oxide_25\NN\14818238|of|nitric|,|proline|,|pyrimidines|and|polyamines (r_nmod) production_22\NN\30358|including|the|oxide (r_nmod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (l_nmod) expression_7\NN\4679549|of|as (l_compound) as_6\IN\14622893|
T3_T15 NONE proline_27\NN\14601829| (r_conj) oxide_25\NN\14818238|of|nitric|,|proline|,|pyrimidines|and|polyamines (r_nmod) production_22\NN\30358|including|the|oxide (r_nmod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (r_nsubjpass) regulated_34\VBN\296178|summary|,|levels|is|tnf-alpha|and|provide|. (l_nmod) tnf-alpha_36\NN\1740|by
T4_T14 NONE pyrimidines_29\NNS\14618253| (r_conj) oxide_25\NN\14818238|of|nitric|,|proline|,|pyrimidines|and|polyamines (r_nmod) production_22\NN\30358|including|the|oxide (r_nmod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (l_nmod) expression_7\NN\4679549|of|as (l_compound) as_6\IN\14622893|
T4_T15 NONE pyrimidines_29\NNS\14618253| (r_conj) oxide_25\NN\14818238|of|nitric|,|proline|,|pyrimidines|and|polyamines (r_nmod) production_22\NN\30358|including|the|oxide (r_nmod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (r_nsubjpass) regulated_34\VBN\296178|summary|,|levels|is|tnf-alpha|and|provide|. (l_nmod) tnf-alpha_36\NN\1740|by
T5_T14 NONE polyamines_31\NNS\1740| (r_conj) oxide_25\NN\14818238|of|nitric|,|proline|,|pyrimidines|and|polyamines (r_nmod) production_22\NN\30358|including|the|oxide (r_nmod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (l_nmod) expression_7\NN\4679549|of|as (l_compound) as_6\IN\14622893|
T5_T15 NONE polyamines_31\NNS\1740| (r_conj) oxide_25\NN\14818238|of|nitric|,|proline|,|pyrimidines|and|polyamines (r_nmod) production_22\NN\30358|including|the|oxide (r_nmod) processes_16\NNS\407535|for|several|arginine-dependent|cancer|,|production (r_nmod) required_12\VBN\754942|which|may|be|processes (r_acl:relcl) levels_4\NNS\4916342|high|expression|,|required|, (r_nsubjpass) regulated_34\VBN\296178|summary|,|levels|is|tnf-alpha|and|provide|. (l_nmod) tnf-alpha_36\NN\1740|by
23400747
23265459
T10_T20 NONE glutathione_14\NN\1740| (r_compound) peroxidase_15\NN\14971234|glutathione|gsh-px (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase
T10_T21 NONE glutathione_14\NN\1740| (r_compound) peroxidase_15\NN\14971234|glutathione|gsh-px (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_appos) cat_5\NN\2120997|(|)
T10_T22 NONE glutathione_14\NN\1740| (r_compound) peroxidase_15\NN\14971234|glutathione|gsh-px (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) dismutase_9\NN\1740|superoxide|sod
T10_T23 NONE glutathione_14\NN\1740| (r_compound) peroxidase_15\NN\14971234|glutathione|gsh-px (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) dismutase_9\NN\1740|superoxide|sod (l_appos) sod_11\NN\9335240|(|)
T10_T24 NONE glutathione_14\NN\1740| (r_compound) peroxidase_15\NN\14971234|glutathione|gsh-px
T10_T25 NONE glutathione_14\NN\1740| (r_compound) peroxidase_15\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_17\NN\1740|(|)
T11_T20 NONE gsh-px_17\NN\1740|(|) (r_appos) peroxidase_15\NN\14971234|glutathione|gsh-px (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase
T11_T21 NONE gsh-px_17\NN\1740|(|) (r_appos) peroxidase_15\NN\14971234|glutathione|gsh-px (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_appos) cat_5\NN\2120997|(|)
T11_T22 NONE gsh-px_17\NN\1740|(|) (r_appos) peroxidase_15\NN\14971234|glutathione|gsh-px (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) dismutase_9\NN\1740|superoxide|sod
T11_T23 NONE gsh-px_17\NN\1740|(|) (r_appos) peroxidase_15\NN\14971234|glutathione|gsh-px (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) dismutase_9\NN\1740|superoxide|sod (l_appos) sod_11\NN\9335240|(|)
T11_T24 NONE gsh-px_17\NN\1740|(|) (r_appos) peroxidase_15\NN\14971234|glutathione|gsh-px
T11_T25 NONE gsh-px_17\NN\1740|(|)
T12_T20 NONE malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase
T12_T21 NONE malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_appos) cat_5\NN\2120997|(|)
T12_T22 NONE malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) dismutase_9\NN\1740|superoxide|sod
T12_T23 NONE malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) dismutase_9\NN\1740|superoxide|sod (l_appos) sod_11\NN\9335240|(|)
T12_T24 NONE malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) peroxidase_15\NN\14971234|glutathione|gsh-px
T12_T25 NONE malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) peroxidase_15\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_17\NN\1740|(|)
T13_T20 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase
T13_T21 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_appos) cat_5\NN\2120997|(|)
T13_T22 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) dismutase_9\NN\1740|superoxide|sod
T13_T23 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) dismutase_9\NN\1740|superoxide|sod (l_appos) sod_11\NN\9335240|(|)
T13_T24 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) peroxidase_15\NN\14971234|glutathione|gsh-px
T13_T25 NONE mda_25\NN\1740|(|) (r_appos) malondialdehyde_23\NN\1740|mda (r_compound) levels_27\NNS\4916342|malondialdehyde|serum (r_dobj) decreasing_22\VBG\169651|while|levels (r_advcl) increased_2\VBD\169651|they|also|activity|,|decreasing|. (l_dobj) activity_19\NN\30358|catalase (l_compound) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) peroxidase_15\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_17\NN\1740|(|)
T9_T20 NONE superoxide_8\NN\14971519| (r_compound) dismutase_9\NN\1740|superoxide|sod (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase
T9_T21 NONE superoxide_8\NN\14971519| (r_compound) dismutase_9\NN\1740|superoxide|sod (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_appos) cat_5\NN\2120997|(|)
T9_T22 NONE superoxide_8\NN\14971519| (r_compound) dismutase_9\NN\1740|superoxide|sod
T9_T23 NONE superoxide_8\NN\14971519| (r_compound) dismutase_9\NN\1740|superoxide|sod (l_appos) sod_11\NN\9335240|(|)
T9_T24 NONE superoxide_8\NN\14971519| (r_compound) dismutase_9\NN\1740|superoxide|sod (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) peroxidase_15\NN\14971234|glutathione|gsh-px
T9_T25 NONE superoxide_8\NN\14971519| (r_compound) dismutase_9\NN\1740|superoxide|sod (r_conj) catalase_3\NN\14732946|cat|,|dismutase|and|peroxidase (l_conj) peroxidase_15\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_17\NN\1740|(|)
23558678
22798247
T1_T4 NONE androgen_12\NN\14745635| (r_compound) biosynthesis_13\NN\13565379|androgen (r_dobj) increasing_11\VBG\169651|with|biosynthesis (r_advcl) displayed_6\VBD\2137132|rats|cycles|increasing|. (l_nsubj) rats_0\NNS\2329401|treated (l_acl) treated_1\VBN\2376958|insulin (l_nmod) insulin_3\NN\5407119|with|plus|hcg
T1_T5 NONE androgen_12\NN\14745635| (r_compound) biosynthesis_13\NN\13565379|androgen (r_dobj) increasing_11\VBG\169651|with|biosynthesis (r_advcl) displayed_6\VBD\2137132|rats|cycles|increasing|. (l_nsubj) rats_0\NNS\2329401|treated (l_acl) treated_1\VBN\2376958|insulin (l_nmod) insulin_3\NN\5407119|with|plus|hcg (l_conj) hcg_5\NN\5410315|
23434640
23604720
T4_T12 NONE aldose_36\NN\14954284| (r_compound) reductase_37\NN\14732946|on|aldose|ar|and|formation|lenses
T4_T13 NONE aldose_36\NN\14954284| (r_compound) reductase_37\NN\14732946|on|aldose|ar|and|formation|lenses (l_appos) ar_39\NN\14622893|(|)
T5_T12 NONE galactitol_42\NN\1740| (r_compound) formation_43\NN\7938773|galactitol (r_conj) reductase_37\NN\14732946|on|aldose|ar|and|formation|lenses
T5_T13 NONE galactitol_42\NN\1740| (r_compound) formation_43\NN\7938773|galactitol (r_conj) reductase_37\NN\14732946|on|aldose|ar|and|formation|lenses (l_appos) ar_39\NN\14622893|(|)
T6_T12 NONE glucose_51\NN\14710501|of (r_nmod) levels_49\NNS\4916342|with|high|glucose (r_nmod) lenses_46\NNS\3851341|in|rat|levels (r_nmod) reductase_37\NN\14732946|on|aldose|ar|and|formation|lenses
T6_T13 NONE glucose_51\NN\14710501|of (r_nmod) levels_49\NNS\4916342|with|high|glucose (r_nmod) lenses_46\NNS\3851341|in|rat|levels (r_nmod) reductase_37\NN\14732946|on|aldose|ar|and|formation|lenses (l_appos) ar_39\NN\14622893|(|)
T9_T18 CPR:4 methyl-3,5-di-o-caffeoylquinate_6\NN\1740| (r_nsubj) showed_7\VBD\2137132|compounds|,|methyl-3,5-di-o-caffeoylquinate|inhibition|,|values|. (l_nmod) values_15\NNS\5941423|with|ic50|μm|rar|,|respectively (l_nmod) rar_23\NN\1740|for|and|rhar
T9_T19 CPR:4 methyl-3,5-di-o-caffeoylquinate_6\NN\1740| (r_nsubj) showed_7\VBD\2137132|compounds|,|methyl-3,5-di-o-caffeoylquinate|inhibition|,|values|. (l_nmod) values_15\NNS\5941423|with|ic50|μm|rar|,|respectively (l_nmod) rar_23\NN\1740|for|and|rhar (l_conj) rhar_25\NN\1740|
T10_T11 CPR:4 methyl-3,5-di-o-caffeoylquinate_12\NN\1740| (r_nsubj) showed_13\VBD\2137132|analyses|,|methyl-3,5-di-o-caffeoylquinate|inhibition|. (l_dobj) inhibition_15\NN\1068773|competitive|rhar (l_nmod) rhar_17\NN\1740|of
23261589
T15_T32 NONE salsolinol_0\NN\1740| (r_nsubj) induced_1\VBD\1627355|salsolinol (r_amod) changes_3\NNS\7283608|induced|apoptotic|cells|:|amelioration (l_dep) amelioration_9\NN\248977|support|. (l_nmod) support_12\NN\407535|by|neurotrophin (l_compound) neurotrophin_11\NN\1740|
T14_T31 NONE sal_8\NN\1740|of (r_nmod) toxicity_6\NN\13576101|the|sal|nscs|focusing (l_acl) focusing_11\VBG\628491|apoptosis (l_nmod) apoptosis_13\NN\11486178|on|and|status (l_conj) status_15\NN\24720|signaling (l_nmod) signaling_20\NN\33020|of|pi3|k|survival (l_compound) k_18\NN\13608598|
T5_T19 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_nmod) level_6\NN\4916342|with|reduced|pakt|and|effectors (l_compound) pakt_5\NN\1740|
T5_T20 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_dep) pcreb_12\NN\1740|,|pgsk-3β|,|bcl-2|and|gdnf|suggesting
T5_T21 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_dep) pcreb_12\NN\1740|,|pgsk-3β|,|bcl-2|and|gdnf|suggesting (l_conj) pgsk-3β_14\NN\1740|
T5_T22 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_dep) pcreb_12\NN\1740|,|pgsk-3β|,|bcl-2|and|gdnf|suggesting (l_conj) bcl-2_16\NN\1740|
T5_T23 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_dep) pcreb_12\NN\1740|,|pgsk-3β|,|bcl-2|and|gdnf|suggesting (l_conj) gdnf_19\NN\1740|neurotrophins|,|bdnf (l_compound) neurotrophins_18\NNS\1740|
T5_T24 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_dep) pcreb_12\NN\1740|,|pgsk-3β|,|bcl-2|and|gdnf|suggesting (l_conj) gdnf_19\NN\1740|neurotrophins|,|bdnf
T5_T25 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_dep) pcreb_12\NN\1740|,|pgsk-3β|,|bcl-2|and|gdnf|suggesting (l_conj) gdnf_19\NN\1740|neurotrophins|,|bdnf (l_appos) bdnf_21\NN\1740|
T5_T26 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_dep) pcreb_12\NN\1740|,|pgsk-3β|,|bcl-2|and|gdnf|suggesting (l_acl) suggesting_22\VBG\1010118|signaling (l_dobj) signaling_25\NN\33020|repressed|pi3k/akt (l_compound) pi3k/akt_24\NN\1740|
T5_T27 CPR:4 sal_0\NN\1740| (r_compound) toxicity_1\NN\13576101|sal (r_nsubj) coincided_2\VBD\2604477|toxicity|level|:|pcreb|. (l_dep) pcreb_12\NN\1740|,|pgsk-3β|,|bcl-2|and|gdnf|suggesting (l_acl) suggesting_22\VBG\1010118|signaling (l_dobj) signaling_25\NN\33020|repressed|pi3k/akt (l_compound) pi3k/akt_24\NN\1740|
T7_T28 NONE sal_22\NN\1740|against (r_nmod) protected_19\VBD\1127795|support|potentially|nscs|sal|activating|. (l_advcl) activating_24\VBG\1641914|through|pathway (l_dobj) pathway_26\NN\5483677|pi3k/akt (l_compound) pi3k/akt_25\NN\1740|
T7_T29 NONE sal_22\NN\1740|against (r_nmod) protected_19\VBD\1127795|support|potentially|nscs|sal|activating|. (l_advcl) activating_24\VBG\1641914|through|pathway (l_dobj) pathway_26\NN\5483677|pi3k/akt (l_compound) pi3k/akt_25\NN\1740|
T8_T30 CPR:4 ly294002_5\NN\1740|inhibitor (l_appos) inhibitor_9\NN\20090|the|pi3|k|abolished (l_compound) k_8\NN\13608598|
11056242
T1_T10 NONE danazol_17\NN\1740|such|and|agonist (r_nmod) agents_6\NNS\7347|hormonal|used|,|danazol|, (r_nsubj) exert_22\VBP\1158872|whether|agents|action|expression (l_nmod) expression_33\NN\4679549|on|protein-1|cells (l_compound) protein-1_29\NN\1740|monocyte|chemotactic|mcp-1
T1_T11 NONE danazol_17\NN\1740|such|and|agonist (r_nmod) agents_6\NNS\7347|hormonal|used|,|danazol|, (r_nsubj) exert_22\VBP\1158872|whether|agents|action|expression (l_nmod) expression_33\NN\4679549|on|protein-1|cells (l_compound) protein-1_29\NN\1740|monocyte|chemotactic|mcp-1 (l_appos) mcp-1_31\NN\1740|(|)
T1_T8 NONE danazol_17\NN\1740|such|and|agonist (l_conj) agonist_20\NN\9613191|gnrh (l_compound) gnrh_19\NN\1740|
T5_T12 NONE steroid_19\NN\14727670| (r_compound) analogs_21\NNS\4743605|steroid|hormone (r_conj) cytokines_17\NNS\14728724|of|and|analogs
T2_T15 NONE danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (r_advcl) had_15\VBD\2108377|result(s|acetate|effect|expression|,|whereas|showed|. (l_nsubj) acetate_3\NN\15010703|buserelin|,|agonist|, (l_appos) agonist_7\NN\9613191|a|gnrh|ng/ml (l_compound) gnrh_6\NN\1740|
T2_T7 NONE danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (r_advcl) had_15\VBD\2108377|result(s|acetate|effect|expression|,|whereas|showed|. (l_nmod) expression_21\NN\4679549|on|mcp-1 (l_compound) mcp-1_20\NN\1740|
T2_T9 CPR:4 danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (l_nmod) expression_56\NN\4679549|on|mcp-1 (l_compound) mcp-1_55\NN\1740|
T3_T15 NONE testosterone_32\NN\14747587| (r_compound) analog_33\NN\4743605|a|testosterone (r_conj) danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (r_advcl) had_15\VBD\2108377|result(s|acetate|effect|expression|,|whereas|showed|. (l_nsubj) acetate_3\NN\15010703|buserelin|,|agonist|, (l_appos) agonist_7\NN\9613191|a|gnrh|ng/ml (l_compound) gnrh_6\NN\1740|
T3_T7 NONE testosterone_32\NN\14747587| (r_compound) analog_33\NN\4743605|a|testosterone (r_conj) danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (r_advcl) had_15\VBD\2108377|result(s|acetate|effect|expression|,|whereas|showed|. (l_nmod) expression_21\NN\4679549|on|mcp-1 (l_compound) mcp-1_20\NN\1740|
T3_T9 CPR:4 testosterone_32\NN\14747587| (r_compound) analog_33\NN\4743605|a|testosterone (r_conj) danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (l_nmod) expression_56\NN\4679549|on|mcp-1 (l_compound) mcp-1_55\NN\1740|
T4_T15 NONE dexamethasone_36\NN\2721538|,|hormone (r_conj) danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (r_advcl) had_15\VBD\2108377|result(s|acetate|effect|expression|,|whereas|showed|. (l_nsubj) acetate_3\NN\15010703|buserelin|,|agonist|, (l_appos) agonist_7\NN\9613191|a|gnrh|ng/ml (l_compound) gnrh_6\NN\1740|
T4_T7 NONE dexamethasone_36\NN\2721538|,|hormone (r_conj) danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (r_advcl) had_15\VBD\2108377|result(s|acetate|effect|expression|,|whereas|showed|. (l_nmod) expression_21\NN\4679549|on|mcp-1 (l_compound) mcp-1_20\NN\1740|
T4_T9 CPR:4 dexamethasone_36\NN\2721538|,|hormone (r_conj) danazol_24\NN\1740|m|,|analog|,|and|dexamethasone|, (r_nsubj) showed_46\VBD\2137132|danazol|effect|expression (l_nmod) expression_56\NN\4679549|on|mcp-1 (l_compound) mcp-1_55\NN\1740|
T6_T15 CPR:5 acetate_3\NN\15010703|buserelin|,|agonist|, (l_appos) agonist_7\NN\9613191|a|gnrh|ng/ml (l_compound) gnrh_6\NN\1740|
T6_T7 NONE acetate_3\NN\15010703|buserelin|,|agonist|, (r_nsubj) had_15\VBD\2108377|result(s|acetate|effect|expression|,|whereas|showed|. (l_nmod) expression_21\NN\4679549|on|mcp-1 (l_compound) mcp-1_20\NN\1740|
T6_T9 NONE acetate_3\NN\15010703|buserelin|,|agonist|, (r_nsubj) had_15\VBD\2108377|result(s|acetate|effect|expression|,|whereas|showed|. (l_advcl) showed_46\VBD\2137132|danazol|effect|expression (l_nmod) expression_56\NN\4679549|on|mcp-1 (l_compound) mcp-1_55\NN\1740|
23477419
T17_T21 CPR:5 endomorphin-1_9\NN\1740| (r_compound) analogues_10\NNS\4743605|of|novel|endomorphin-1 (r_nmod) design_0\NN\927261|,|synthesis|,|and|characterization|analogues|agonists|. (l_nmod) agonists_15\NNS\9613191|as|potent|μ-opioid (l_amod) μ-opioid_14\JJ\1740|
T10_T20 NONE dmt(1)-(r)-βpro(2)-trp(3)-(2-furyl)map(4_5\NN\1740|)|analogue (r_nsubj) displayed_11\VBD\2137132|compounds|,|dmt(1)-(r)-βpro(2)-trp(3)-(2-furyl)map(4|affinity|,|range|=|. (l_dobj) affinity_14\NN\11426530|the|highest|mor (l_nmod) mor_16\NN\1740|toward
T11_T20 NONE dmt(1)-(r)-βpro(2)-trp(3)-(2-furyl)map(4_5\NN\1740|)|analogue (r_nsubj) displayed_11\VBD\2137132|compounds|,|dmt(1)-(r)-βpro(2)-trp(3)-(2-furyl)map(4|affinity|,|range|=|. (l_dobj) affinity_14\NN\11426530|the|highest|mor (l_nmod) mor_16\NN\1740|toward
T8_T20 NONE dmt(1)-(r)-βpro(2)-trp(3)-(2-furyl)map(4_5\NN\1740|)|analogue (r_nsubj) displayed_11\VBD\2137132|compounds|,|dmt(1)-(r)-βpro(2)-trp(3)-(2-furyl)map(4|affinity|,|range|=|. (l_dobj) affinity_14\NN\11426530|the|highest|mor (l_nmod) mor_16\NN\1740|toward
T9_T20 NONE dmt(1)-(r)-βpro(2)-trp(3)-(2-furyl)map(4_5\NN\1740|)|analogue (r_nsubj) displayed_11\VBD\2137132|compounds|,|dmt(1)-(r)-βpro(2)-trp(3)-(2-furyl)map(4|affinity|,|range|=|. (l_dobj) affinity_14\NN\11426530|the|highest|mor (l_nmod) mor_16\NN\1740|toward
7756657
T1_T2 CPR:4 dactinomycin_18\NN\1740|as|inhibitor|was|case (l_nsubj) inhibitor_16\NN\20090|the|only|topoisomerase|ii (l_nummod) ii_15\CD\13741022|
T1_T3 NONE dactinomycin_18\NN\1740|as|inhibitor|was|case (r_advcl) vary_5\VBP\2666239|2|histories|leukemia|,|dactinomycin|,|and|,|administered|. (l_conj) administered_34\VBN\2436349|case|,|inhibitor|was (l_nsubjpass) inhibitor_32\NN\20090|no|topoisomerase|ii (l_nummod) ii_31\CD\13741022|
1526623
T31_T43 NONE ketoconazole_0\NN\1740| (r_nsubj) binds_1\VBZ\1290422|ketoconazole|receptor|. (l_nmod) receptor_6\NN\5225602|to|the|human|androgen
T32_T43 NONE androgen_5\NN\14745635| (r_compound) receptor_6\NN\5225602|to|the|human|androgen
T17_T38 NONE ketoconazole_20\NN\1740|of (r_nmod) affinity_18\NN\11426530|ketoconazole|proteins (l_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (l_nmod) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (l_conj) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg
T17_T39 NONE ketoconazole_20\NN\1740|of (r_nmod) affinity_18\NN\11426530|ketoconazole|proteins (l_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (l_nmod) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (l_conj) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg (l_appos) ssbg_37\NN\1740|(|)
T17_T40 NONE ketoconazole_20\NN\1740|of (r_nmod) affinity_18\NN\11426530|ketoconazole|proteins (r_dobj) demonstrating_17\VBG\2137132|affinity (r_acl) work_14\NN\407535|previous|vitro|demonstrating (r_conj) effects_4\NNS\13245626|based|on|these|potent|function|as|work (r_advcl) examined_55\VBN\789138|effects|,|binding|was|also|. (l_nsubjpass) binding_41\NN\4688246|the|ketoconazole|receptors (l_nmod) receptors_47\NNS\5225602|to|human|androgen|ar|vitro
T17_T41 NONE ketoconazole_20\NN\1740|of (r_nmod) affinity_18\NN\11426530|ketoconazole|proteins (r_dobj) demonstrating_17\VBG\2137132|affinity (r_acl) work_14\NN\407535|previous|vitro|demonstrating (r_conj) effects_4\NNS\13245626|based|on|these|potent|function|as|work (r_advcl) examined_55\VBN\789138|effects|,|binding|was|also|. (l_nsubjpass) binding_41\NN\4688246|the|ketoconazole|receptors (l_nmod) receptors_47\NNS\5225602|to|human|androgen|ar|vitro (l_appos) ar_49\NNS\14622893|(|)
T18_T38 NONE d3_29\NN\1740|1,25(oh)2|vitamin (r_conj) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (l_conj) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg
T18_T39 NONE d3_29\NN\1740|1,25(oh)2|vitamin (r_conj) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (l_conj) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg (l_appos) ssbg_37\NN\1740|(|)
T18_T40 NONE d3_29\NN\1740|1,25(oh)2|vitamin (r_conj) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (r_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (r_nmod) affinity_18\NN\11426530|ketoconazole|proteins (r_dobj) demonstrating_17\VBG\2137132|affinity (r_acl) work_14\NN\407535|previous|vitro|demonstrating (r_conj) effects_4\NNS\13245626|based|on|these|potent|function|as|work (r_advcl) examined_55\VBN\789138|effects|,|binding|was|also|. (l_nsubjpass) binding_41\NN\4688246|the|ketoconazole|receptors (l_nmod) receptors_47\NNS\5225602|to|human|androgen|ar|vitro
T18_T41 NONE d3_29\NN\1740|1,25(oh)2|vitamin (r_conj) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (r_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (r_nmod) affinity_18\NN\11426530|ketoconazole|proteins (r_dobj) demonstrating_17\VBG\2137132|affinity (r_acl) work_14\NN\407535|previous|vitro|demonstrating (r_conj) effects_4\NNS\13245626|based|on|these|potent|function|as|work (r_advcl) examined_55\VBN\789138|effects|,|binding|was|also|. (l_nsubjpass) binding_41\NN\4688246|the|ketoconazole|receptors (l_nmod) receptors_47\NNS\5225602|to|human|androgen|ar|vitro (l_appos) ar_49\NNS\14622893|(|)
T19_T38 NONE steroid_33\NN\14727670| (r_compound) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg
T19_T39 NONE steroid_33\NN\14727670| (r_compound) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg (l_appos) ssbg_37\NN\1740|(|)
T19_T40 NONE steroid_33\NN\14727670| (r_compound) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg (r_conj) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (r_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (r_nmod) affinity_18\NN\11426530|ketoconazole|proteins (r_dobj) demonstrating_17\VBG\2137132|affinity (r_acl) work_14\NN\407535|previous|vitro|demonstrating (r_conj) effects_4\NNS\13245626|based|on|these|potent|function|as|work (r_advcl) examined_55\VBN\789138|effects|,|binding|was|also|. (l_nsubjpass) binding_41\NN\4688246|the|ketoconazole|receptors (l_nmod) receptors_47\NNS\5225602|to|human|androgen|ar|vitro
T19_T41 NONE steroid_33\NN\14727670| (r_compound) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg (r_conj) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (r_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (r_nmod) affinity_18\NN\11426530|ketoconazole|proteins (r_dobj) demonstrating_17\VBG\2137132|affinity (r_acl) work_14\NN\407535|previous|vitro|demonstrating (r_conj) effects_4\NNS\13245626|based|on|these|potent|function|as|work (r_advcl) examined_55\VBN\789138|effects|,|binding|was|also|. (l_nsubjpass) binding_41\NN\4688246|the|ketoconazole|receptors (l_nmod) receptors_47\NNS\5225602|to|human|androgen|ar|vitro (l_appos) ar_49\NNS\14622893|(|)
T20_T38 NONE ketoconazole_43\NN\1740|of (r_nmod) binding_41\NN\4688246|the|ketoconazole|receptors (r_nsubjpass) examined_55\VBN\789138|effects|,|binding|was|also|. (l_advcl) effects_4\NNS\13245626|based|on|these|potent|function|as|work (l_conj) work_14\NN\407535|previous|vitro|demonstrating (l_acl) demonstrating_17\VBG\2137132|affinity (l_dobj) affinity_18\NN\11426530|ketoconazole|proteins (l_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (l_nmod) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (l_conj) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg
T20_T39 NONE ketoconazole_43\NN\1740|of (r_nmod) binding_41\NN\4688246|the|ketoconazole|receptors (r_nsubjpass) examined_55\VBN\789138|effects|,|binding|was|also|. (l_advcl) effects_4\NNS\13245626|based|on|these|potent|function|as|work (l_conj) work_14\NN\407535|previous|vitro|demonstrating (l_acl) demonstrating_17\VBG\2137132|affinity (l_dobj) affinity_18\NN\11426530|ketoconazole|proteins (l_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (l_nmod) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (l_conj) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg (l_appos) ssbg_37\NN\1740|(|)
T20_T40 NONE ketoconazole_43\NN\1740|of (r_nmod) binding_41\NN\4688246|the|ketoconazole|receptors (l_nmod) receptors_47\NNS\5225602|to|human|androgen|ar|vitro
T20_T41 NONE ketoconazole_43\NN\1740|of (r_nmod) binding_41\NN\4688246|the|ketoconazole|receptors (l_nmod) receptors_47\NNS\5225602|to|human|androgen|ar|vitro (l_appos) ar_49\NNS\14622893|(|)
T21_T38 NONE androgen_46\NN\14745635| (r_compound) receptors_47\NNS\5225602|to|human|androgen|ar|vitro (r_nmod) binding_41\NN\4688246|the|ketoconazole|receptors (r_nsubjpass) examined_55\VBN\789138|effects|,|binding|was|also|. (l_advcl) effects_4\NNS\13245626|based|on|these|potent|function|as|work (l_conj) work_14\NN\407535|previous|vitro|demonstrating (l_acl) demonstrating_17\VBG\2137132|affinity (l_dobj) affinity_18\NN\11426530|ketoconazole|proteins (l_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (l_nmod) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (l_conj) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg
T21_T39 NONE androgen_46\NN\14745635| (r_compound) receptors_47\NNS\5225602|to|human|androgen|ar|vitro (r_nmod) binding_41\NN\4688246|the|ketoconazole|receptors (r_nsubjpass) examined_55\VBN\789138|effects|,|binding|was|also|. (l_advcl) effects_4\NNS\13245626|based|on|these|potent|function|as|work (l_conj) work_14\NN\407535|previous|vitro|demonstrating (l_acl) demonstrating_17\VBG\2137132|affinity (l_dobj) affinity_18\NN\11426530|ketoconazole|proteins (l_nmod) proteins_23\NNS\14944888|for|receptor|glucocorticoids (l_nmod) glucocorticoids_25\NNS\14751417|for|and|d3|and|globulin (l_conj) globulin_35\NN\14736972|for|sex|steroid|binding|ssbg (l_appos) ssbg_37\NN\1740|(|)
T21_T40 NONE androgen_46\NN\14745635| (r_compound) receptors_47\NNS\5225602|to|human|androgen|ar|vitro
T21_T41 NONE androgen_46\NN\14745635| (r_compound) receptors_47\NNS\5225602|to|human|androgen|ar|vitro (l_appos) ar_49\NNS\14622893|(|)
T27_T42 NONE [3h]r1881_4\NN\1740|of (r_nmod) displacement_2\NN\197772|percent|[3h]r1881|binding (l_acl) binding_5\VBG\1290422|ar (l_nmod) ar_7\NNS\14622893|to
T28_T42 NONE ketoconazole_21\NN\1740|by|m (r_nmod) achieved_9\VBN\2524171|displacement|was|ketoconazole|. (l_nsubjpass) displacement_2\NN\197772|percent|[3h]r1881|binding (l_acl) binding_5\VBG\1290422|ar (l_nmod) ar_7\NNS\14622893|to
T29_T33 NONE ketoconazole_5\NN\1740|with (r_nmod) performed_3\VBN\2367363|ketoconazole|presence (r_acl) studies_2\NNS\635850|additional|binding|performed (r_nsubj) showed_14\VBD\2137132|studies|competitive|. (l_ccomp) competitive_23\JJ\1740|that|interaction|was|analyzed (l_nsubj) interaction_17\NN\37396|the|ketoconazole|ar (l_nmod) ar_21\NNS\14622893|with
T2_T33 NONE ketoconazole_19\NN\1740|of (r_nmod) interaction_17\NN\37396|the|ketoconazole|ar (l_nmod) ar_21\NNS\14622893|with
T30_T33 NONE [3h]r1881_13\NN\1740|of (r_nmod) amounts_11\NNS\13329641|of|increasing|[3h]r1881 (r_nmod) presence_8\NN\13954253|in|the|amounts (r_nmod) performed_3\VBN\2367363|ketoconazole|presence (r_acl) studies_2\NNS\635850|additional|binding|performed (r_nsubj) showed_14\VBD\2137132|studies|competitive|. (l_ccomp) competitive_23\JJ\1740|that|interaction|was|analyzed (l_nsubj) interaction_17\NN\37396|the|ketoconazole|ar (l_nmod) ar_21\NNS\14622893|with
T3_T34 NONE ketoconazole_11\NN\1740|of (r_nmod) dose_9\NN\3740161|the|ketoconazole|required (l_acl) required_12\VBN\754942|occupancy (l_nmod) occupancy_16\NN\1053920|for|%|receptor (l_nmod) receptor_20\NN\5225602|of|the|androgen
T4_T34 NONE androgen_19\NN\14745635| (r_compound) receptor_20\NN\5225602|of|the|androgen
T10_T35 NONE ketoconazole_27\NN\1740|only (r_nsubj) appears_28\VBZ\2604760|that|class|ketoconazole|interact (l_xcomp) interact_30\VB\2367363|to|receptor (l_nmod) receptor_34\NN\5225602|with|the|androgen
T11_T35 NONE androgen_33\NN\14745635| (r_compound) receptor_34\NN\5225602|with|the|androgen
T5_T35 NONE androgen_2\NN\14745635| (r_compound) studies_4\NNS\635850|androgen|binding|performed|, (r_nsubj) revealed_19\VBD\2137132|finally|,|studies|appears|. (l_ccomp) appears_28\VBZ\2604760|that|class|ketoconazole|interact (l_xcomp) interact_30\VB\2367363|to|receptor (l_nmod) receptor_34\NN\5225602|with|the|androgen
T6_T35 NONE imidazoles_8\NNS\14618253|with|other|,|clotrimazole (r_nmod) performed_5\VBN\2367363|imidazoles (r_acl) studies_4\NNS\635850|androgen|binding|performed|, (r_nsubj) revealed_19\VBD\2137132|finally|,|studies|appears|. (l_ccomp) appears_28\VBZ\2604760|that|class|ketoconazole|interact (l_xcomp) interact_30\VB\2367363|to|receptor (l_nmod) receptor_34\NN\5225602|with|the|androgen
T7_T35 NONE clotrimazole_12\NN\1740|such|,|miconazole|,|and|fluconozole (r_nmod) imidazoles_8\NNS\14618253|with|other|,|clotrimazole (r_nmod) performed_5\VBN\2367363|imidazoles (r_acl) studies_4\NNS\635850|androgen|binding|performed|, (r_nsubj) revealed_19\VBD\2137132|finally|,|studies|appears|. (l_ccomp) appears_28\VBZ\2604760|that|class|ketoconazole|interact (l_xcomp) interact_30\VB\2367363|to|receptor (l_nmod) receptor_34\NN\5225602|with|the|androgen
T8_T35 NONE miconazole_14\NN\2720201| (r_conj) clotrimazole_12\NN\1740|such|,|miconazole|,|and|fluconozole (r_nmod) imidazoles_8\NNS\14618253|with|other|,|clotrimazole (r_nmod) performed_5\VBN\2367363|imidazoles (r_acl) studies_4\NNS\635850|androgen|binding|performed|, (r_nsubj) revealed_19\VBD\2137132|finally|,|studies|appears|. (l_ccomp) appears_28\VBZ\2604760|that|class|ketoconazole|interact (l_xcomp) interact_30\VB\2367363|to|receptor (l_nmod) receptor_34\NN\5225602|with|the|androgen
T9_T35 NONE fluconozole_17\NN\1740| (r_conj) clotrimazole_12\NN\1740|such|,|miconazole|,|and|fluconozole (r_nmod) imidazoles_8\NNS\14618253|with|other|,|clotrimazole (r_nmod) performed_5\VBN\2367363|imidazoles (r_acl) studies_4\NNS\635850|androgen|binding|performed|, (r_nsubj) revealed_19\VBD\2137132|finally|,|studies|appears|. (l_ccomp) appears_28\VBZ\2604760|that|class|ketoconazole|interact (l_xcomp) interact_30\VB\2367363|to|receptor (l_nmod) receptor_34\NN\5225602|with|the|androgen
T12_T36 NONE ketoconazole_0\NN\1740| (r_nsubj) appears_1\VBZ\2604760|ketoconazole|example|. (l_xcomp) example_6\NN\5816287|to|be|the|first|compound|,|suggesting (l_nmod) compound_10\NN\5869584|of|a|non-steroidal|binds (l_acl:relcl) binds_12\VBZ\1290422|which|competitively|ssbg (l_nmod) ssbg_16\NN\1740|to|both|and|receptors
T12_T37 NONE ketoconazole_0\NN\1740| (r_nsubj) appears_1\VBZ\2604760|ketoconazole|example|. (l_xcomp) example_6\NN\5816287|to|be|the|first|compound|,|suggesting (l_nmod) compound_10\NN\5869584|of|a|non-steroidal|binds (l_acl:relcl) binds_12\VBZ\1290422|which|competitively|ssbg (l_nmod) ssbg_16\NN\1740|to|both|and|receptors (l_conj) receptors_21\NNS\5225602|multiple|steroid|hormone
T13_T36 NONE non-steroidal_9\JJ\1740| (r_amod) compound_10\NN\5869584|of|a|non-steroidal|binds (l_acl:relcl) binds_12\VBZ\1290422|which|competitively|ssbg (l_nmod) ssbg_16\NN\1740|to|both|and|receptors
T13_T37 NONE non-steroidal_9\JJ\1740| (r_amod) compound_10\NN\5869584|of|a|non-steroidal|binds (l_acl:relcl) binds_12\VBZ\1290422|which|competitively|ssbg (l_nmod) ssbg_16\NN\1740|to|both|and|receptors (l_conj) receptors_21\NNS\5225602|multiple|steroid|hormone
T14_T36 NONE steroid_19\NN\14727670| (r_compound) receptors_21\NNS\5225602|multiple|steroid|hormone (r_conj) ssbg_16\NN\1740|to|both|and|receptors
T14_T37 NONE steroid_19\NN\14727670| (r_compound) receptors_21\NNS\5225602|multiple|steroid|hormone
23178182
T16_T40 NONE 125_2\CD\1740|uccb01|,|inhibitor|, (r_nsubj) reduces_10\VBZ\441445|125|pain|disrupting|:|comparison|. (l_dep) comparison_20\NN\635850|mk-801 (l_nmod) mk-801_26\NN\1740|with|the|nmda|receptor|antagonist (l_compound) receptor_24\NN\5225602|
T17_T40 NONE nmda_23\NN\1740| (r_compound) mk-801_26\NN\1740|with|the|nmda|receptor|antagonist (l_compound) receptor_24\NN\5225602|
T18_T40 CPR:6 mk-801_26\NN\1740|with|the|nmda|receptor|antagonist (l_compound) receptor_24\NN\5225602|
T12_T19 NONE oxide_7\NN\14818238|of|nitric|no (r_nmod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (l_amod) (nmdar)-dependent_3\JJ\1740|receptor (l_nmod:npmod) receptor_2\NN\5225602|n-methyl-d-aspartate
T12_T22 NONE oxide_7\NN\14818238|of|nitric|no (r_nmod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (r_nsubjpass) involved_12\VBN\2676054|production|is|development|,|and|mediated|. (l_conj) mediated_25\VBN\761713|is|protein-95 (l_nmod) protein-95_29\NN\1740|by|postsynaptic|density|psd-95
T12_T23 NONE oxide_7\NN\14818238|of|nitric|no (r_nmod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (r_nsubjpass) involved_12\VBN\2676054|production|is|development|,|and|mediated|. (l_conj) mediated_25\VBN\761713|is|protein-95 (l_nmod) protein-95_29\NN\1740|by|postsynaptic|density|psd-95 (l_appos) psd-95_31\NN\1740|(|)
T12_T30 NONE oxide_7\NN\14818238|of|nitric|no (r_nmod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (l_amod) (nmdar)-dependent_3\JJ\1740|receptor
T15_T19 NONE no_9\NN\7204911|(|) (r_appos) oxide_7\NN\14818238|of|nitric|no (r_nmod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (l_amod) (nmdar)-dependent_3\JJ\1740|receptor (l_nmod:npmod) receptor_2\NN\5225602|n-methyl-d-aspartate
T15_T22 NONE no_9\NN\7204911|(|) (r_appos) oxide_7\NN\14818238|of|nitric|no (r_nmod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (r_nsubjpass) involved_12\VBN\2676054|production|is|development|,|and|mediated|. (l_conj) mediated_25\VBN\761713|is|protein-95 (l_nmod) protein-95_29\NN\1740|by|postsynaptic|density|psd-95
T15_T23 NONE no_9\NN\7204911|(|) (r_appos) oxide_7\NN\14818238|of|nitric|no (r_nmod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (r_nsubjpass) involved_12\VBN\2676054|production|is|development|,|and|mediated|. (l_conj) mediated_25\VBN\761713|is|protein-95 (l_nmod) protein-95_29\NN\1740|by|postsynaptic|density|psd-95 (l_appos) psd-95_31\NN\1740|(|)
T15_T30 NONE no_9\NN\7204911|(|) (r_appos) oxide_7\NN\14818238|of|nitric|no (r_nmod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (l_amod) (nmdar)-dependent_3\JJ\1740|receptor
T2_T19 NONE n-methyl-d-aspartate_1\NN\1740| (r_compound) receptor_2\NN\5225602|n-methyl-d-aspartate
T2_T22 NONE n-methyl-d-aspartate_1\NN\1740| (r_compound) receptor_2\NN\5225602|n-methyl-d-aspartate (r_nmod:npmod) (nmdar)-dependent_3\JJ\1740|receptor (r_amod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (r_nsubjpass) involved_12\VBN\2676054|production|is|development|,|and|mediated|. (l_conj) mediated_25\VBN\761713|is|protein-95 (l_nmod) protein-95_29\NN\1740|by|postsynaptic|density|psd-95
T2_T23 NONE n-methyl-d-aspartate_1\NN\1740| (r_compound) receptor_2\NN\5225602|n-methyl-d-aspartate (r_nmod:npmod) (nmdar)-dependent_3\JJ\1740|receptor (r_amod) production_4\NN\30358|excessive|(nmdar)-dependent|oxide (r_nsubjpass) involved_12\VBN\2676054|production|is|development|,|and|mediated|. (l_conj) mediated_25\VBN\761713|is|protein-95 (l_nmod) protein-95_29\NN\1740|by|postsynaptic|density|psd-95 (l_appos) psd-95_31\NN\1740|(|)
T2_T30 NONE n-methyl-d-aspartate_1\NN\1740| (r_compound) receptor_2\NN\5225602|n-methyl-d-aspartate (r_nmod:npmod) (nmdar)-dependent_3\JJ\1740|receptor
T10_T24 NONE no_23\NN\7204911| (r_compound) production_24\NN\30358|no (r_conj) activation_21\NN\13561719|between|nmdar|and|production (r_nmod) coupling_18\NN\3091374|a|specific|activation (r_dobj) mediates_15\VBZ\761713|binding|,|psd-95|coupling|. (l_nmod) binding_1\VBG\1290422|by|nmdar (l_nmod) nmdar_5\NN\1740|to|both|the|and|synthase
T10_T25 NONE no_23\NN\7204911| (r_compound) production_24\NN\30358|no (r_conj) activation_21\NN\13561719|between|nmdar|and|production (r_nmod) coupling_18\NN\3091374|a|specific|activation (r_dobj) mediates_15\VBZ\761713|binding|,|psd-95|coupling|. (l_nmod) binding_1\VBG\1290422|by|nmdar (l_nmod) nmdar_5\NN\1740|to|both|the|and|synthase (l_conj) synthase_9\NN\1740|neuronal|no|nnos
T10_T26 NONE no_23\NN\7204911| (r_compound) production_24\NN\30358|no (r_conj) activation_21\NN\13561719|between|nmdar|and|production (r_nmod) coupling_18\NN\3091374|a|specific|activation (r_dobj) mediates_15\VBZ\761713|binding|,|psd-95|coupling|. (l_nmod) binding_1\VBG\1290422|by|nmdar (l_nmod) nmdar_5\NN\1740|to|both|the|and|synthase (l_conj) synthase_9\NN\1740|neuronal|no|nnos (l_appos) nnos_11\NN\1740|(|)
T10_T27 NONE no_23\NN\7204911| (r_compound) production_24\NN\30358|no (r_conj) activation_21\NN\13561719|between|nmdar|and|production (r_nmod) coupling_18\NN\3091374|a|specific|activation (r_dobj) mediates_15\VBZ\761713|binding|,|psd-95|coupling|. (l_nsubj) psd-95_14\NN\1740|
T10_T28 NONE no_23\NN\7204911| (r_compound) production_24\NN\30358|no (r_conj) activation_21\NN\13561719|between|nmdar|and|production (l_compound) nmdar_20\NN\1740|
T9_T24 NONE no_8\NN\7204911| (r_compound) synthase_9\NN\1740|neuronal|no|nnos (r_conj) nmdar_5\NN\1740|to|both|the|and|synthase
T9_T25 NONE no_8\NN\7204911| (r_compound) synthase_9\NN\1740|neuronal|no|nnos
T9_T26 NONE no_8\NN\7204911| (r_compound) synthase_9\NN\1740|neuronal|no|nnos (l_appos) nnos_11\NN\1740|(|)
T9_T27 NONE no_8\NN\7204911| (r_compound) synthase_9\NN\1740|neuronal|no|nnos (r_conj) nmdar_5\NN\1740|to|both|the|and|synthase (r_nmod) binding_1\VBG\1290422|by|nmdar (r_nmod) mediates_15\VBZ\761713|binding|,|psd-95|coupling|. (l_nsubj) psd-95_14\NN\1740|
T9_T28 NONE no_8\NN\7204911| (r_compound) synthase_9\NN\1740|neuronal|no|nnos (r_conj) nmdar_5\NN\1740|to|both|the|and|synthase (r_nmod) binding_1\VBG\1290422|by|nmdar (r_nmod) mediates_15\VBZ\761713|binding|,|psd-95|coupling|. (l_dobj) coupling_18\NN\3091374|a|specific|activation (l_nmod) activation_21\NN\13561719|between|nmdar|and|production (l_compound) nmdar_20\NN\1740|
T11_T31 NONE no_20\DT\7204911| (r_compound) production_21\NN\30358|no (r_dobj) decreasing_19\VBG\169651|thereby|production|interfering (r_advcl) perturb_10\VB\1770501|to|complex|targeting|decreasing (r_xcomp) is_8\VBZ\836236|approach|perturb|. (l_nsubj) approach_2\NN\940842|an|alternative|modulate (l_acl) modulate_4\VB\1724459|to|activity (l_dobj) activity_7\NN\30358|the|nmdar-related (l_amod) nmdar-related_6\JJ\1740|
T11_T32 NONE no_20\DT\7204911| (r_compound) production_21\NN\30358|no (r_dobj) decreasing_19\VBG\169651|thereby|production|interfering (r_advcl) perturb_10\VB\1770501|to|complex|targeting|decreasing (l_dobj) complex_13\NN\5869584|the|nmdar/psd-95/nnos (l_compound) nmdar/psd-95/nnos_12\NN\1740|
T11_T33 NONE no_20\DT\7204911| (r_compound) production_21\NN\30358|no (r_dobj) decreasing_19\VBG\169651|thereby|production|interfering (r_advcl) perturb_10\VB\1770501|to|complex|targeting|decreasing (l_dobj) complex_13\NN\5869584|the|nmdar/psd-95/nnos (l_compound) nmdar/psd-95/nnos_12\NN\1740|
T11_T34 NONE no_20\DT\7204911| (r_compound) production_21\NN\30358|no (r_dobj) decreasing_19\VBG\169651|thereby|production|interfering (r_advcl) perturb_10\VB\1770501|to|complex|targeting|decreasing (l_dobj) complex_13\NN\5869584|the|nmdar/psd-95/nnos (l_compound) nmdar/psd-95/nnos_12\NN\1740|
T11_T35 NONE no_20\DT\7204911| (r_compound) production_21\NN\30358|no (r_dobj) decreasing_19\VBG\169651|thereby|production|interfering (r_advcl) perturb_10\VB\1770501|to|complex|targeting|decreasing (l_advcl) targeting_15\VBG\1151110|by|psd-95|, (l_dobj) psd-95_16\NN\1740|
T11_T36 NONE no_20\DT\7204911| (r_compound) production_21\NN\30358|no (r_dobj) decreasing_19\VBG\169651|thereby|production|interfering (l_advcl) interfering_23\VBG\2451370|without|function (l_nmod) function_29\NN\13783581|with|the|channel (l_compound) channel_28\NN\6251781|nmdar|ion (l_compound) nmdar_26\NN\1740|
T11_T37 NONE no_20\DT\7204911| (r_compound) production_21\NN\30358|no (r_dobj) decreasing_19\VBG\169651|thereby|production|interfering (l_advcl) interfering_23\VBG\2451370|without|function (l_nmod) function_29\NN\13783581|with|the|channel (l_compound) channel_28\NN\6251781|nmdar|ion
T13_T38 CPR:4 125_14\CD\1740| (r_nummod) -_13\NN\1740|125 (r_appos) inhibitor_10\NN\20090|of|a|dimeric|psd-95|,|uccb01|-|,|and|antagonist (l_compound) psd-95_9\NN\1740|
T13_T39 NONE 125_14\CD\1740| (r_nummod) -_13\NN\1740|125 (r_appos) inhibitor_10\NN\20090|of|a|dimeric|psd-95|,|uccb01|-|,|and|antagonist (l_conj) antagonist_19\NN\7846|the|nmdar|,|mk-801|, (l_compound) nmdar_18\NN\1740|
T14_T38 NONE mk-801_21\NN\1740| (r_appos) antagonist_19\NN\7846|the|nmdar|,|mk-801|, (r_conj) inhibitor_10\NN\20090|of|a|dimeric|psd-95|,|uccb01|-|,|and|antagonist (l_compound) psd-95_9\NN\1740|
T14_T39 CPR:6 mk-801_21\NN\1740| (r_appos) antagonist_19\NN\7846|the|nmdar|,|mk-801|, (l_compound) nmdar_18\NN\1740|
23376356
T1_T15 CPR:4 ly294002_0\NN\1740|,|inhibitor|, (l_appos) inhibitor_5\NN\20090|a|specific|pi3k/akt (l_compound) pi3k/akt_4\NN\1740|
T1_T16 CPR:4 ly294002_0\NN\1740|,|inhibitor|, (l_appos) inhibitor_5\NN\20090|a|specific|pi3k/akt (l_compound) pi3k/akt_4\NN\1740|
T1_T17 CPR:3 ly294002_0\NN\1740|,|inhibitor|, (r_nsubj) activated_8\VBD\1641914|ly294002|selectively|pathway|and|enhanced|,|but|activate|. (l_dobj) pathway_13\NN\5483677|the|p38|kinase (l_compound) p38_10\NN\1740|
T1_T18 CPR:3 ly294002_0\NN\1740|,|inhibitor|, (r_nsubj) activated_8\VBD\1641914|ly294002|selectively|pathway|and|enhanced|,|but|activate|. (l_dobj) pathway_13\NN\5483677|the|p38|kinase (l_compound) kinase_12\NN\14732946|mapk (l_compound) mapk_11\NN\1740|
T1_T19 CPR:3 ly294002_0\NN\1740|,|inhibitor|, (r_nsubj) activated_8\VBD\1641914|ly294002|selectively|pathway|and|enhanced|,|but|activate|. (l_dobj) pathway_13\NN\5483677|the|p38|kinase (l_compound) kinase_12\NN\14732946|mapk
T1_T20 CPR:3 ly294002_0\NN\1740|,|inhibitor|, (r_nsubj) activated_8\VBD\1641914|ly294002|selectively|pathway|and|enhanced|,|but|activate|. (l_conj) enhanced_15\VBD\227165|phosphorylation (l_dobj) phosphorylation_17\NN\1740|c-jun (l_compound) c-jun_16\NN\1740|
T1_T21 NONE ly294002_0\NN\1740|,|inhibitor|, (r_nsubj) activated_8\VBD\1641914|ly294002|selectively|pathway|and|enhanced|,|but|activate|. (l_conj) activate_22\VB\1641914|did|not|jnk (l_dobj) jnk_23\NN\1740|
T2_T22 CPR:4 sb203580_3\NN\1740|inhibitor|and|sp600125 (l_appos) inhibitor_6\NN\20090|(|p38|) (l_compound) p38_5\NN\1740|
T2_T23 NONE sb203580_3\NN\1740|inhibitor|and|sp600125 (l_conj) sp600125_9\NN\1740|inhibitor (l_appos) inhibitor_13\NN\20090|(|a|jnk|) (l_compound) jnk_12\NN\1740|
T3_T22 NONE sp600125_9\NN\1740|inhibitor (r_conj) sb203580_3\NN\1740|inhibitor|and|sp600125 (l_appos) inhibitor_6\NN\20090|(|p38|) (l_compound) p38_5\NN\1740|
T3_T23 CPR:4 sp600125_9\NN\1740|inhibitor (l_appos) inhibitor_13\NN\20090|(|a|jnk|) (l_compound) jnk_12\NN\1740|
T4_T22 NONE ly294002-induced_22\JJ\1740| (r_amod) apoptosis_23\NN\11486178|from|ly294002-induced (r_nmod) cultures_17\NNS\7966140|primary|cgcs|apoptosis (r_dobj) protected_15\VBD\1127795|inhibitors|cultures|. (l_nsubj) inhibitors_2\NNS\20090|the|pharmacological|sb203580 (l_dep) sb203580_3\NN\1740|inhibitor|and|sp600125 (l_appos) inhibitor_6\NN\20090|(|p38|) (l_compound) p38_5\NN\1740|
T4_T23 NONE ly294002-induced_22\JJ\1740| (r_amod) apoptosis_23\NN\11486178|from|ly294002-induced (r_nmod) cultures_17\NNS\7966140|primary|cgcs|apoptosis (r_dobj) protected_15\VBD\1127795|inhibitors|cultures|. (l_nsubj) inhibitors_2\NNS\20090|the|pharmacological|sb203580 (l_dep) sb203580_3\NN\1740|inhibitor|and|sp600125 (l_conj) sp600125_9\NN\1740|inhibitor (l_appos) inhibitor_13\NN\20090|(|a|jnk|) (l_compound) jnk_12\NN\1740|
11252887
T1_T12 CPR:4 disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) reductase_19\NN\14732946|dihydrofolate
T1_T13 CPR:4 disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) transferase_25\NN\14732946|glycinamide|ribonucleotide|formyl
T1_T14 CPR:4 disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase
T2_T12 NONE dihydrofolate_18\JJ\1740| (r_amod) reductase_19\NN\14732946|dihydrofolate
T2_T13 NONE dihydrofolate_18\JJ\1740| (r_amod) reductase_19\NN\14732946|dihydrofolate (r_conj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) transferase_25\NN\14732946|glycinamide|ribonucleotide|formyl
T2_T14 NONE dihydrofolate_18\JJ\1740| (r_amod) reductase_19\NN\14732946|dihydrofolate (r_conj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase
T3_T12 NONE formyl_24\NN\1740| (r_amod) transferase_25\NN\14732946|glycinamide|ribonucleotide|formyl (r_conj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) reductase_19\NN\14732946|dihydrofolate
T3_T13 NONE formyl_24\NN\1740| (r_amod) transferase_25\NN\14732946|glycinamide|ribonucleotide|formyl
T3_T14 NONE formyl_24\NN\1740| (r_amod) transferase_25\NN\14732946|glycinamide|ribonucleotide|formyl (r_conj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase
T4_T12 CPR:4 alimta_3\NN\1740|(|,|ly231514|) (r_dep) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) reductase_19\NN\14732946|dihydrofolate
T4_T13 CPR:4 alimta_3\NN\1740|(|,|ly231514|) (r_dep) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) transferase_25\NN\14732946|glycinamide|ribonucleotide|formyl
T4_T14 CPR:4 alimta_3\NN\1740|(|,|ly231514|) (r_dep) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase
T6_T12 CPR:4 ly231514_5\CD\1740| (r_appos) alimta_3\NN\1740|(|,|ly231514|) (r_dep) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) reductase_19\NN\14732946|dihydrofolate
T6_T13 CPR:4 ly231514_5\CD\1740| (r_appos) alimta_3\NN\1740|(|,|ly231514|) (r_dep) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) transferase_25\NN\14732946|glycinamide|ribonucleotide|formyl
T6_T14 CPR:4 ly231514_5\CD\1740| (r_appos) alimta_3\NN\1740|(|,|ly231514|) (r_dep) disodium_1\NN\1740|pemetrexed|alimta (r_nsubj) antifolate_12\NN\1740|disodium|is|a|novel|inhibits|. (l_acl:relcl) inhibits_14\VBZ\2510337|that|synthase (l_dobj) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase
T9_T12 NONE thymidylate_15\NN\1740| (r_compound) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) reductase_19\NN\14732946|dihydrofolate
T9_T13 NONE thymidylate_15\NN\1740| (r_compound) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase (l_conj) transferase_25\NN\14732946|glycinamide|ribonucleotide|formyl
T9_T14 NONE thymidylate_15\NN\1740| (r_compound) synthase_16\NN\1740|thymidylate|,|reductase|,|and|transferase
17256745
T11_T42 NONE salt_18\NN\14818238| (r_compound) transport_19\NN\3575240|for|intracellular|bile|salt (r_nmod) implications_14\NNS\5774614|transport (r_dep) enzymes_12\NNS\14723628|n-acyltransferase|are|liver-specific|peroxisomal|:|implications|. (l_nsubj) n-acyltransferase_8\NN\1740|human|bile|acid-coa|:|amino|acid
T12_T42 NONE acid-coa_4\NN\1740| (r_compound) n-acyltransferase_8\NN\1740|human|bile|acid-coa|:|amino|acid
T13_T42 NONE acid-coa_4\NN\1740| (r_compound) n-acyltransferase_8\NN\1740|human|bile|acid-coa|:|amino|acid
T14_T42 NONE acid_7\NN\14818238| (r_compound) n-acyltransferase_8\NN\1740|human|bile|acid-coa|:|amino|acid
T15_T42 NONE n-acyltransferase_8\NN\1740|human|bile|acid-coa|:|amino|acid
T1_T21 NONE acid-coenzyme_3\NN\1740| (r_compound) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat
T1_T32 NONE acid-coenzyme_3\NN\1740| (r_compound) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat (l_appos) baat_10\NN\1740|(|)
T2_T21 CPR:9 acids_24\NNS\14818238|primary|bile (r_nmod) conjugation_18\NN\14418395|for|acids|taurine (r_nmod) responsible_16\JJ\1740|conjugation (r_amod) enzyme_15\NN\14723628|n-acyltransferase|is|the|sole|responsible (l_nsubj) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat
T2_T32 CPR:9 acids_24\NNS\14818238|primary|bile (r_nmod) conjugation_18\NN\14418395|for|acids|taurine (r_nmod) responsible_16\JJ\1740|conjugation (r_amod) enzyme_15\NN\14723628|n-acyltransferase|is|the|sole|responsible (l_nsubj) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat (l_appos) baat_10\NN\1740|(|)
T3_T21 CPR:9 taurine_26\NN\14818238|to|and|glycine (r_nmod) conjugation_18\NN\14418395|for|acids|taurine (r_nmod) responsible_16\JJ\1740|conjugation (r_amod) enzyme_15\NN\14723628|n-acyltransferase|is|the|sole|responsible (l_nsubj) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat
T3_T32 CPR:9 taurine_26\NN\14818238|to|and|glycine (r_nmod) conjugation_18\NN\14418395|for|acids|taurine (r_nmod) responsible_16\JJ\1740|conjugation (r_amod) enzyme_15\NN\14723628|n-acyltransferase|is|the|sole|responsible (l_nsubj) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat (l_appos) baat_10\NN\1740|(|)
T5_T21 CPR:9 glycine_28\NN\14601829| (r_conj) taurine_26\NN\14818238|to|and|glycine (r_nmod) conjugation_18\NN\14418395|for|acids|taurine (r_nmod) responsible_16\JJ\1740|conjugation (r_amod) enzyme_15\NN\14723628|n-acyltransferase|is|the|sole|responsible (l_nsubj) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat
T5_T32 CPR:9 glycine_28\NN\14601829| (r_conj) taurine_26\NN\14818238|to|and|glycine (r_nmod) conjugation_18\NN\14418395|for|acids|taurine (r_nmod) responsible_16\JJ\1740|conjugation (r_amod) enzyme_15\NN\14723628|n-acyltransferase|is|the|sole|responsible (l_nsubj) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat (l_appos) baat_10\NN\1740|(|)
T6_T21 NONE a_4\NN\13649268| (r_compound) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat
T6_T32 NONE a_4\NN\13649268| (r_compound) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat (l_appos) baat_10\NN\1740|(|)
T7_T21 NONE acid_7\NN\14818238| (r_compound) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat
T7_T32 NONE acid_7\NN\14818238| (r_compound) n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat (l_appos) baat_10\NN\1740|(|)
T8_T21 NONE n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat
T8_T32 NONE n-acyltransferase_8\NN\1740|bile|acid-coenzyme|a|:|amino|acid|baat (l_appos) baat_10\NN\1740|(|)
T9_T30 CPR:9 salts_20\NNS\14818238|of|unconjugated/deconjugated|bile (r_nmod) transport_16\NN\3575240|for|the|intracellular|salts (r_nmod) implications_12\NNS\5774614|important|transport (r_dobj) has_10\VBZ\2108377|absence|implications|. (l_nsubj) absence_1\NN\14449405|the|or|presence|pool (l_nmod) pool_7\NN\3302121|of|a|cytosolic|baat (l_nmod) baat_9\NN\1740|of
T10_T31 NONE digitonin_5\NN\1740| (r_compound) assays_7\NNS\5733583|digitonin|permeabilization (r_conj) microscopy_3\NN\636921|immunofluorescence|and|assays (r_dobj) used_1\VBD\1156834|we|microscopy|determine|. (l_advcl) determine_9\VB\1645601|to|location (l_dobj) location_12\NN\2684|the|subcellular|baat (l_nmod) baat_15\NN\1740|of|endogenous|hepatocytes
10698696
T5_T28 NONE ornithine_11\NN\14601829| (r_compound) decarboxylase_12\NN\14732946|ornithine (r_dobj) releases_10\VBZ\1435380|decarboxylase|suppression (r_conj) induced_4\VBN\1627355|inhibitor|is|rapidly|fibroblasts|and|releases|. (l_nsubjpass) inhibitor_1\NN\20090|antizyme
T5_T29 NONE ornithine_11\NN\14601829| (r_compound) decarboxylase_12\NN\14732946|ornithine (r_dobj) releases_10\VBZ\1435380|decarboxylase|suppression (l_nmod) suppression_15\NN\13489037|from|antizyme (l_amod) antizyme_14\JJ\1740|
T5_T30 NONE ornithine_11\NN\14601829| (r_compound) decarboxylase_12\NN\14732946|ornithine
T1_T13 NONE ornithine_0\NN\14601829| (r_compound) decarboxylase_1\NN\14732946|ornithine|odc (l_appos) odc_3\NN\1740|(|)
T1_T6 NONE ornithine_0\NN\14601829| (r_compound) decarboxylase_1\NN\14732946|ornithine|odc
T2_T13 CPR:9 spermidine_17\NN\1740| (r_conj) putrescine_15\NN\14999411|,|spermidine|and|spermine (r_dep) polyamines_14\NNS\1740|of|the|putrescine (r_nmod) synthesis_11\NN\13446390|in|the|polyamines (r_nmod) step_8\NN\168237|the|first|synthesis (r_dobj) catalyses_5\VBZ\146138|decarboxylase|step|. (l_nsubj) decarboxylase_1\NN\14732946|ornithine|odc (l_appos) odc_3\NN\1740|(|)
T2_T6 CPR:9 spermidine_17\NN\1740| (r_conj) putrescine_15\NN\14999411|,|spermidine|and|spermine (r_dep) polyamines_14\NNS\1740|of|the|putrescine (r_nmod) synthesis_11\NN\13446390|in|the|polyamines (r_nmod) step_8\NN\168237|the|first|synthesis (r_dobj) catalyses_5\VBZ\146138|decarboxylase|step|. (l_nsubj) decarboxylase_1\NN\14732946|ornithine|odc
T3_T13 CPR:9 spermine_19\NN\1740| (r_conj) putrescine_15\NN\14999411|,|spermidine|and|spermine (r_dep) polyamines_14\NNS\1740|of|the|putrescine (r_nmod) synthesis_11\NN\13446390|in|the|polyamines (r_nmod) step_8\NN\168237|the|first|synthesis (r_dobj) catalyses_5\VBZ\146138|decarboxylase|step|. (l_nsubj) decarboxylase_1\NN\14732946|ornithine|odc (l_appos) odc_3\NN\1740|(|)
T3_T6 CPR:9 spermine_19\NN\1740| (r_conj) putrescine_15\NN\14999411|,|spermidine|and|spermine (r_dep) polyamines_14\NNS\1740|of|the|putrescine (r_nmod) synthesis_11\NN\13446390|in|the|polyamines (r_nmod) step_8\NN\168237|the|first|synthesis (r_dobj) catalyses_5\VBZ\146138|decarboxylase|step|. (l_nsubj) decarboxylase_1\NN\14732946|ornithine|odc
T4_T13 CPR:9 putrescine_15\NN\14999411|,|spermidine|and|spermine (r_dep) polyamines_14\NNS\1740|of|the|putrescine (r_nmod) synthesis_11\NN\13446390|in|the|polyamines (r_nmod) step_8\NN\168237|the|first|synthesis (r_dobj) catalyses_5\VBZ\146138|decarboxylase|step|. (l_nsubj) decarboxylase_1\NN\14732946|ornithine|odc (l_appos) odc_3\NN\1740|(|)
T4_T6 CPR:9 putrescine_15\NN\14999411|,|spermidine|and|spermine (r_dep) polyamines_14\NNS\1740|of|the|putrescine (r_nmod) synthesis_11\NN\13446390|in|the|polyamines (r_nmod) step_8\NN\168237|the|first|synthesis (r_dobj) catalyses_5\VBZ\146138|decarboxylase|step|. (l_nsubj) decarboxylase_1\NN\14732946|ornithine|odc
23373701
T7_T34 NONE dopamine_0\NN\14807737| (r_compound) receptor_2\NN\5225602|dopamine|d2
T7_T35 NONE dopamine_0\NN\14807737| (r_compound) receptor_2\NN\5225602|dopamine|d2 (r_compound) activation_3\NN\13561719|receptor (r_nsubj) leads_4\VBZ\1752884|activation|up-regulation|. (l_nmod) up-regulation_7\NN\1740|to|an|factor|induction (l_nmod) induction_16\NN\7450842|via|gβγ-erk1/2-dependent|zif268 (l_amod) gβγ-erk1/2-dependent_15\NN\1740|
T7_T36 NONE dopamine_0\NN\14807737| (r_compound) receptor_2\NN\5225602|dopamine|d2 (r_compound) activation_3\NN\13561719|receptor (r_nsubj) leads_4\VBZ\1752884|activation|up-regulation|. (l_nmod) up-regulation_7\NN\1740|to|an|factor|induction (l_nmod) induction_16\NN\7450842|via|gβγ-erk1/2-dependent|zif268 (l_nmod) zif268_18\NN\1740|of
T7_T37 NONE dopamine_0\NN\14807737| (r_compound) receptor_2\NN\5225602|dopamine|d2 (r_compound) activation_3\NN\13561719|receptor (r_nsubj) leads_4\VBZ\1752884|activation|up-regulation|. (l_nmod) up-regulation_7\NN\1740|to|an|factor|induction (l_nmod) factor_13\NN\7326557|of|line-derived|neurotrophic
T1_T23 NONE dopamine_16\NN\14807737| (r_compound) receptor_18\NN\5225602|dopamine|d2|d2r
T1_T25 NONE dopamine_16\NN\14807737| (r_compound) receptor_18\NN\5225602|dopamine|d2|d2r (l_appos) d2r_20\NN\1740|(|)
T1_T26 NONE dopamine_16\NN\14807737| (r_compound) receptor_18\NN\5225602|dopamine|d2|d2r (r_compound) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (r_nmod) treatment_3\NN\654885|cells|agonist (r_nsubj) triggered_26\VBD\1641914|that|treatment|increase (l_dobj) increase_28\NN\13576355|an|expression (l_nmod) expression_31\NN\4679549|in|the|gdnf (l_nmod) gdnf_33\NN\1740|of|preceded
T1_T27 NONE dopamine_16\NN\14807737| (r_compound) receptor_18\NN\5225602|dopamine|d2|d2r (r_compound) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (r_nmod) treatment_3\NN\654885|cells|agonist (r_nsubj) triggered_26\VBD\1641914|that|treatment|increase (l_dobj) increase_28\NN\13576355|an|expression (l_nmod) expression_31\NN\4679549|in|the|gdnf (l_nmod) gdnf_33\NN\1740|of|preceded (l_acl:relcl) preceded_37\VBN\2690708|that|was|temporally|increase (l_nmod) increase_40\NN\13576355|by|an|levels (l_nmod) levels_43\NNS\4916342|in|the|protein (l_nmod) protein_46\NN\14944888|of|zinc-finger|268|,|factor (l_nummod) 268_47\CD\1740|zif268
T1_T28 NONE dopamine_16\NN\14807737| (r_compound) receptor_18\NN\5225602|dopamine|d2|d2r (r_compound) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (r_nmod) treatment_3\NN\654885|cells|agonist (r_nsubj) triggered_26\VBD\1641914|that|treatment|increase (l_dobj) increase_28\NN\13576355|an|expression (l_nmod) expression_31\NN\4679549|in|the|gdnf (l_nmod) gdnf_33\NN\1740|of|preceded (l_acl:relcl) preceded_37\VBN\2690708|that|was|temporally|increase (l_nmod) increase_40\NN\13576355|by|an|levels (l_nmod) levels_43\NNS\4916342|in|the|protein (l_nmod) protein_46\NN\14944888|of|zinc-finger|268|,|factor (l_nummod) 268_47\CD\1740|zif268 (l_appos) zif268_49\NN\1740|(|)
T2_T23 CPR:5 quinpirole_24\NN\1740| (r_appos) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (l_compound) receptor_18\NN\5225602|dopamine|d2|d2r
T2_T25 CPR:5 quinpirole_24\NN\1740| (r_appos) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (l_compound) receptor_18\NN\5225602|dopamine|d2|d2r (l_appos) d2r_20\NN\1740|(|)
T2_T26 CPR:3 quinpirole_24\NN\1740| (r_appos) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (r_nmod) treatment_3\NN\654885|cells|agonist (r_nsubj) triggered_26\VBD\1641914|that|treatment|increase (l_dobj) increase_28\NN\13576355|an|expression (l_nmod) expression_31\NN\4679549|in|the|gdnf (l_nmod) gdnf_33\NN\1740|of|preceded
T2_T27 CPR:3 quinpirole_24\NN\1740| (r_appos) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (r_nmod) treatment_3\NN\654885|cells|agonist (r_nsubj) triggered_26\VBD\1641914|that|treatment|increase (l_dobj) increase_28\NN\13576355|an|expression (l_nmod) expression_31\NN\4679549|in|the|gdnf (l_nmod) gdnf_33\NN\1740|of|preceded (l_acl:relcl) preceded_37\VBN\2690708|that|was|temporally|increase (l_nmod) increase_40\NN\13576355|by|an|levels (l_nmod) levels_43\NNS\4916342|in|the|protein (l_nmod) protein_46\NN\14944888|of|zinc-finger|268|,|factor (l_nummod) 268_47\CD\1740|zif268
T2_T28 CPR:3 quinpirole_24\NN\1740| (r_appos) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (r_nmod) treatment_3\NN\654885|cells|agonist (r_nsubj) triggered_26\VBD\1641914|that|treatment|increase (l_dobj) increase_28\NN\13576355|an|expression (l_nmod) expression_31\NN\4679549|in|the|gdnf (l_nmod) gdnf_33\NN\1740|of|preceded (l_acl:relcl) preceded_37\VBN\2690708|that|was|temporally|increase (l_nmod) increase_40\NN\13576355|by|an|levels (l_nmod) levels_43\NNS\4916342|in|the|protein (l_nmod) protein_46\NN\14944888|of|zinc-finger|268|,|factor (l_nummod) 268_47\CD\1740|zif268 (l_appos) zif268_49\NN\1740|(|)
T3_T23 NONE zinc-finger_45\NN\1740| (r_compound) protein_46\NN\14944888|of|zinc-finger|268|,|factor (r_nmod) levels_43\NNS\4916342|in|the|protein (r_nmod) increase_40\NN\13576355|by|an|levels (r_nmod) preceded_37\VBN\2690708|that|was|temporally|increase (r_acl:relcl) gdnf_33\NN\1740|of|preceded (r_nmod) expression_31\NN\4679549|in|the|gdnf (r_nmod) increase_28\NN\13576355|an|expression (r_dobj) triggered_26\VBD\1641914|that|treatment|increase (l_nsubj) treatment_3\NN\654885|cells|agonist (l_nmod) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (l_compound) receptor_18\NN\5225602|dopamine|d2|d2r
T3_T25 NONE zinc-finger_45\NN\1740| (r_compound) protein_46\NN\14944888|of|zinc-finger|268|,|factor (r_nmod) levels_43\NNS\4916342|in|the|protein (r_nmod) increase_40\NN\13576355|by|an|levels (r_nmod) preceded_37\VBN\2690708|that|was|temporally|increase (r_acl:relcl) gdnf_33\NN\1740|of|preceded (r_nmod) expression_31\NN\4679549|in|the|gdnf (r_nmod) increase_28\NN\13576355|an|expression (r_dobj) triggered_26\VBD\1641914|that|treatment|increase (l_nsubj) treatment_3\NN\654885|cells|agonist (l_nmod) agonist_22\NN\9613191|with|the|receptor|,|quinpirole|, (l_compound) receptor_18\NN\5225602|dopamine|d2|d2r (l_appos) d2r_20\NN\1740|(|)
T3_T26 NONE zinc-finger_45\NN\1740| (r_compound) protein_46\NN\14944888|of|zinc-finger|268|,|factor (r_nmod) levels_43\NNS\4916342|in|the|protein (r_nmod) increase_40\NN\13576355|by|an|levels (r_nmod) preceded_37\VBN\2690708|that|was|temporally|increase (r_acl:relcl) gdnf_33\NN\1740|of|preceded
T3_T27 NONE zinc-finger_45\NN\1740| (r_compound) protein_46\NN\14944888|of|zinc-finger|268|,|factor (l_nummod) 268_47\CD\1740|zif268
T3_T28 NONE zinc-finger_45\NN\1740| (r_compound) protein_46\NN\14944888|of|zinc-finger|268|,|factor (l_nummod) 268_47\CD\1740|zif268 (l_appos) zif268_49\NN\1740|(|)
T4_T29 CPR:4 raclopride_5\NN\1740|the|d2r|inhibitor (l_compound) d2r_3\NN\1740|
T4_T30 CPR:4 raclopride_5\NN\1740|the|d2r|inhibitor (r_nsubj) blocked_6\VBD\1476483|moreover|,|raclopride|increase|. (l_dobj) increase_8\NN\13576355|the|expression|release (l_nmod) expression_14\NN\4679549|of|gdnf (l_compound) gdnf_11\NN\1740|both|and|zif268
T4_T31 CPR:4 raclopride_5\NN\1740|the|d2r|inhibitor (r_nsubj) blocked_6\VBD\1476483|moreover|,|raclopride|increase|. (l_dobj) increase_8\NN\13576355|the|expression|release (l_nmod) expression_14\NN\4679549|of|gdnf (l_compound) gdnf_11\NN\1740|both|and|zif268 (l_conj) zif268_13\NN\1740|
T5_T29 NONE potassium-evoked_16\JJ\1740| (r_amod) release_18\NN\3748886|following|potassium-evoked|dopamine|cells (r_nmod) increase_8\NN\13576355|the|expression|release (r_dobj) blocked_6\VBD\1476483|moreover|,|raclopride|increase|. (l_nsubj) raclopride_5\NN\1740|the|d2r|inhibitor (l_compound) d2r_3\NN\1740|
T5_T30 NONE potassium-evoked_16\JJ\1740| (r_amod) release_18\NN\3748886|following|potassium-evoked|dopamine|cells (r_nmod) increase_8\NN\13576355|the|expression|release (l_nmod) expression_14\NN\4679549|of|gdnf (l_compound) gdnf_11\NN\1740|both|and|zif268
T5_T31 NONE potassium-evoked_16\JJ\1740| (r_amod) release_18\NN\3748886|following|potassium-evoked|dopamine|cells (r_nmod) increase_8\NN\13576355|the|expression|release (l_nmod) expression_14\NN\4679549|of|gdnf (l_compound) gdnf_11\NN\1740|both|and|zif268 (l_conj) zif268_13\NN\1740|
T6_T29 NONE dopamine_17\NN\14807737| (r_compound) release_18\NN\3748886|following|potassium-evoked|dopamine|cells (r_nmod) increase_8\NN\13576355|the|expression|release (r_dobj) blocked_6\VBD\1476483|moreover|,|raclopride|increase|. (l_nsubj) raclopride_5\NN\1740|the|d2r|inhibitor (l_compound) d2r_3\NN\1740|
T6_T30 NONE dopamine_17\NN\14807737| (r_compound) release_18\NN\3748886|following|potassium-evoked|dopamine|cells (r_nmod) increase_8\NN\13576355|the|expression|release (l_nmod) expression_14\NN\4679549|of|gdnf (l_compound) gdnf_11\NN\1740|both|and|zif268
T6_T31 NONE dopamine_17\NN\14807737| (r_compound) release_18\NN\3748886|following|potassium-evoked|dopamine|cells (r_nmod) increase_8\NN\13576355|the|expression|release (l_nmod) expression_14\NN\4679549|of|gdnf (l_compound) gdnf_11\NN\1740|both|and|zif268 (l_conj) zif268_13\NN\1740|
23019137
T11_T34 NONE dopamine_2\NN\14807737| (r_compound) inhibition_5\NN\1068773|of|dopamine|d2|agonist-induced|neurons|neurotransmitters (l_compound) d2_3\NN\1740|
T11_T35 NONE dopamine_2\NN\14807737| (r_compound) inhibition_5\NN\1068773|of|dopamine|d2|agonist-induced|neurons|neurotransmitters (r_nmod) reversal_0\NN\199130|inhibition (r_nsubj) dependent_15\JJ\1740|reversal|is|c|. (l_nmod) c_19\NN\13714184|on|protein|kinase|,|kinase|,|and|dynamin
T11_T36 NONE dopamine_2\NN\14807737| (r_compound) inhibition_5\NN\1068773|of|dopamine|d2|agonist-induced|neurons|neurotransmitters (r_nmod) reversal_0\NN\199130|inhibition (r_nsubj) dependent_15\JJ\1740|reversal|is|c|. (l_nmod) c_19\NN\13714184|on|protein|kinase|,|kinase|,|and|dynamin (l_conj) kinase_24\NN\14732946|g|protein-coupled|receptor
T11_T37 NONE dopamine_2\NN\14807737| (r_compound) inhibition_5\NN\1068773|of|dopamine|d2|agonist-induced|neurons|neurotransmitters (r_nmod) reversal_0\NN\199130|inhibition (r_nsubj) dependent_15\JJ\1740|reversal|is|c|. (l_nmod) c_19\NN\13714184|on|protein|kinase|,|kinase|,|and|dynamin (l_conj) dynamin_27\NN\1740|
T11_T38 NONE dopamine_2\NN\14807737| (r_compound) inhibition_5\NN\1068773|of|dopamine|d2|agonist-induced|neurons|neurotransmitters (l_nmod) neurotransmitters_13\NNS\14807410|by|gq-linked (l_amod) gq-linked_12\JJ\1740|
T6_T19 NONE 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (r_nmod) mediated_2\VBN\761713|dir|is|c|stimulation|. (l_nmod) c_5\NN\13714184|by|phospholipase|and|subtype
T6_T20 NONE 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (r_nmod) mediated_2\VBN\761713|dir|is|c|stimulation|. (l_nmod) c_5\NN\13714184|by|phospholipase|and|subtype (l_conj) subtype_8\NN\1740|conventional|c (l_nmod) c_12\NN\13714184|of|protein|kinase|cpkc
T6_T21 NONE 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (r_nmod) mediated_2\VBN\761713|dir|is|c|stimulation|. (l_nmod) c_5\NN\13714184|by|phospholipase|and|subtype (l_conj) subtype_8\NN\1740|conventional|c (l_nmod) c_12\NN\13714184|of|protein|kinase|cpkc (l_appos) cpkc_14\NN\1740|(|)
T6_T22 NONE 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (l_nmod) receptors_24\NNS\5225602|of|d2|d1-like|da (l_compound) d2_20\NN\1740|and
T6_T23 NONE 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (l_nmod) receptors_24\NNS\5225602|of|d2|d1-like|da
T6_T24 NONE 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (l_compound) d2_28\NN\1740|
T6_T25 NONE 5-ht(2_34\NN\1740|of|)|or|receptors (l_punct) )_35\-RRB-\1740|
T6_T26 NONE 5-ht(2_34\NN\1740|of|)|or|receptors (l_conj) receptors_38\NNS\5225602|neurotensin
T7_T19 NONE neurotensin_37\NN\1740| (r_compound) receptors_38\NNS\5225602|neurotensin (r_conj) 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (r_nmod) mediated_2\VBN\761713|dir|is|c|stimulation|. (l_nmod) c_5\NN\13714184|by|phospholipase|and|subtype
T7_T20 NONE neurotensin_37\NN\1740| (r_compound) receptors_38\NNS\5225602|neurotensin (r_conj) 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (r_nmod) mediated_2\VBN\761713|dir|is|c|stimulation|. (l_nmod) c_5\NN\13714184|by|phospholipase|and|subtype (l_conj) subtype_8\NN\1740|conventional|c (l_nmod) c_12\NN\13714184|of|protein|kinase|cpkc
T7_T21 NONE neurotensin_37\NN\1740| (r_compound) receptors_38\NNS\5225602|neurotensin (r_conj) 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (r_nmod) mediated_2\VBN\761713|dir|is|c|stimulation|. (l_nmod) c_5\NN\13714184|by|phospholipase|and|subtype (l_conj) subtype_8\NN\1740|conventional|c (l_nmod) c_12\NN\13714184|of|protein|kinase|cpkc (l_appos) cpkc_14\NN\1740|(|)
T7_T22 NONE neurotensin_37\NN\1740| (r_compound) receptors_38\NNS\5225602|neurotensin (r_conj) 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (l_nmod) receptors_24\NNS\5225602|of|d2|d1-like|da (l_compound) d2_20\NN\1740|and
T7_T23 NONE neurotensin_37\NN\1740| (r_compound) receptors_38\NNS\5225602|neurotensin (r_conj) 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (r_conj) stimulation_18\NN\242808|through|concurrent|receptors|,|or|stimulation (l_nmod) receptors_24\NNS\5225602|of|d2|d1-like|da
T7_T24 NONE neurotensin_37\NN\1740| (r_compound) receptors_38\NNS\5225602|neurotensin (r_conj) 5-ht(2_34\NN\1740|of|)|or|receptors (r_nmod) activation_32\NN\13561719|with|5-ht(2 (r_nmod) concurrent_30\JJ\1740|activation (r_amod) stimulation_29\NN\242808|by|d2|concurrent (l_compound) d2_28\NN\1740|
T7_T25 NONE neurotensin_37\NN\1740| (r_compound) receptors_38\NNS\5225602|neurotensin (r_conj) 5-ht(2_34\NN\1740|of|)|or|receptors (l_punct) )_35\-RRB-\1740|
T7_T26 NONE neurotensin_37\NN\1740| (r_compound) receptors_38\NNS\5225602|neurotensin
T10_T32 CPR:3 neurotensin_17\NN\1740|by|nm (r_conj) serotonin_10\NN\14807737|by|µm|and|neurotensin (r_nmod) produced_8\VBN\1617192|reversal|was|serotonin|. (l_nsubjpass) reversal_0\NN\199130|inhibition|quinpirole (l_nmod) quinpirole_6\NN\1740|by|d2|agonist (l_compound) d2_4\NN\1740|
T10_T33 NONE neurotensin_17\NN\1740|by|nm
T8_T32 CPR:5 quinpirole_6\NN\1740|by|d2|agonist (l_compound) d2_4\NN\1740|
T8_T33 NONE quinpirole_6\NN\1740|by|d2|agonist (r_nmod) reversal_0\NN\199130|inhibition|quinpirole (r_nsubjpass) produced_8\VBN\1617192|reversal|was|serotonin|. (l_nmod) serotonin_10\NN\14807737|by|µm|and|neurotensin (l_conj) neurotensin_17\NN\1740|by|nm
T9_T32 CPR:3 serotonin_10\NN\14807737|by|µm|and|neurotensin (r_nmod) produced_8\VBN\1617192|reversal|was|serotonin|. (l_nsubjpass) reversal_0\NN\199130|inhibition|quinpirole (l_nmod) quinpirole_6\NN\1740|by|d2|agonist (l_compound) d2_4\NN\1740|
T9_T33 NONE serotonin_10\NN\14807737|by|µm|and|neurotensin (l_conj) neurotensin_17\NN\1740|by|nm
T1_T12 NONE serotonin-induced_0\JJ\1740|or|neurotensin-induced (l_conj) neurotensin-induced_2\JJ\1740|
T1_T13 NONE serotonin-induced_0\JJ\1740|or|neurotensin-induced (r_amod) reversal_3\NN\199130|serotonin-induced (r_nsubjpass) blocked_5\VBN\1476483|reversal|was|inhibitor|. (l_nmod) inhibitor_8\NN\20090|by|β-ark1|,|dynasore|,|or|antagonist (l_conj) antagonist_14\NN\7846|cpkc|5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (l_compound) cpkc_13\NN\1740|
T2_T12 NONE neurotensin-induced_2\JJ\1740|
T2_T13 NONE neurotensin-induced_2\JJ\1740| (r_conj) serotonin-induced_0\JJ\1740|or|neurotensin-induced (r_amod) reversal_3\NN\199130|serotonin-induced (r_nsubjpass) blocked_5\VBN\1476483|reversal|was|inhibitor|. (l_nmod) inhibitor_8\NN\20090|by|β-ark1|,|dynasore|,|or|antagonist (l_conj) antagonist_14\NN\7846|cpkc|5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (l_compound) cpkc_13\NN\1740|
T3_T12 NONE 5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile_15\NN\1740|gö6976 (r_dep) antagonist_14\NN\7846|cpkc|5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (r_conj) inhibitor_8\NN\20090|by|β-ark1|,|dynasore|,|or|antagonist (r_nmod) blocked_5\VBN\1476483|reversal|was|inhibitor|. (l_nsubjpass) reversal_3\NN\199130|serotonin-induced (l_amod) serotonin-induced_0\JJ\1740|or|neurotensin-induced (l_conj) neurotensin-induced_2\JJ\1740|
T3_T13 CPR:6 5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile_15\NN\1740|gö6976 (r_dep) antagonist_14\NN\7846|cpkc|5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (l_compound) cpkc_13\NN\1740|
T4_T12 NONE gö6976_17\NN\1740|(|) (r_appos) 5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile_15\NN\1740|gö6976 (r_dep) antagonist_14\NN\7846|cpkc|5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (r_conj) inhibitor_8\NN\20090|by|β-ark1|,|dynasore|,|or|antagonist (r_nmod) blocked_5\VBN\1476483|reversal|was|inhibitor|. (l_nsubjpass) reversal_3\NN\199130|serotonin-induced (l_amod) serotonin-induced_0\JJ\1740|or|neurotensin-induced (l_conj) neurotensin-induced_2\JJ\1740|
T4_T13 CPR:6 gö6976_17\NN\1740|(|) (r_appos) 5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile_15\NN\1740|gö6976 (r_dep) antagonist_14\NN\7846|cpkc|5,6,7,13-tetrahydro-13-methyl-5-oxo-12h-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (l_compound) cpkc_13\NN\1740|
23220749
T13_T28 NONE apomorphine_0\NN\3786417| (r_nsubj) modulator_4\NN\1740|apomorphine|is|a|bimodal|channels|. (l_nmod) channels_7\NNS\6251781|of|trpa1 (l_compound) trpa1_6\NN\1740|
T7_T18 NONE apomorphine_18\NN\3786417|for (r_nmod) target_16\NN\7258332|whether|channels|are|a|molecular|apomorphine (l_nsubj) channels_12\NNS\6251781|potential
T9_T19 NONE apomorphine_34\NN\3786417| (r_compound) treatment_35\NN\654885|toward|apomorphine (r_nmod) insensitive_32\JJ\1740|that|rtrpv1|are|treatment (l_nsubj) rtrpv1_5\NN\1740|,|rtrpv2|,|rtrpv3|,|and|mtrpv4|,|as|htrpm8|,|expressed|,
T9_T20 NONE apomorphine_34\NN\3786417| (r_compound) treatment_35\NN\654885|toward|apomorphine (r_nmod) insensitive_32\JJ\1740|that|rtrpv1|are|treatment (l_nsubj) rtrpv1_5\NN\1740|,|rtrpv2|,|rtrpv3|,|and|mtrpv4|,|as|htrpm8|,|expressed|, (l_conj) rtrpv2_7\NN\1740|
T9_T21 NONE apomorphine_34\NN\3786417| (r_compound) treatment_35\NN\654885|toward|apomorphine (r_nmod) insensitive_32\JJ\1740|that|rtrpv1|are|treatment (l_nsubj) rtrpv1_5\NN\1740|,|rtrpv2|,|rtrpv3|,|and|mtrpv4|,|as|htrpm8|,|expressed|, (l_conj) rtrpv3_9\NN\1740|
T9_T22 NONE apomorphine_34\NN\3786417| (r_compound) treatment_35\NN\654885|toward|apomorphine (r_nmod) insensitive_32\JJ\1740|that|rtrpv1|are|treatment (l_nsubj) rtrpv1_5\NN\1740|,|rtrpv2|,|rtrpv3|,|and|mtrpv4|,|as|htrpm8|,|expressed|, (l_conj) mtrpv4_12\NN\1740|
T9_T23 NONE apomorphine_34\NN\3786417| (r_compound) treatment_35\NN\654885|toward|apomorphine (r_nmod) insensitive_32\JJ\1740|that|rtrpv1|are|treatment (l_nsubj) rtrpv1_5\NN\1740|,|rtrpv2|,|rtrpv3|,|and|mtrpv4|,|as|htrpm8|,|expressed|, (l_conj) htrpm8_17\NN\1740|,|and|rtrpm3
T9_T24 NONE apomorphine_34\NN\3786417| (r_compound) treatment_35\NN\654885|toward|apomorphine (r_nmod) insensitive_32\JJ\1740|that|rtrpv1|are|treatment (l_nsubj) rtrpv1_5\NN\1740|,|rtrpv2|,|rtrpv3|,|and|mtrpv4|,|as|htrpm8|,|expressed|, (l_conj) htrpm8_17\NN\1740|,|and|rtrpm3 (l_conj) rtrpm3_20\NN\1740|
T11_T26 NONE apomorphine_11\NN\3786417|by (r_nmod) modulated_9\VBN\1724459|contrary|,|trpa1|could|be|concentration-dependently|apomorphine|. (l_nsubjpass) trpa1_5\NN\1740|human
T12_T27 CPR:4 apomorphine_4\NN\3786417|of (r_nmod) addition_2\NN\3081021|the|apomorphine|range (r_nsubj) produced_10\VBD\1617192|whereas|addition|activation (r_advcl) caused_22\VBD\1617192|produced|,|application|inhibition|,|resulting|. (l_dobj) inhibition_26\NN\1068773|a|reversible|voltage-dependent|channels (l_nmod) channels_31\NNS\6251781|of|expressed|trpa1 (l_compound) trpa1_30\NN\1740|
T2_T14 NONE apomorphine_7\NN\3786417| (r_nsubj) acts_9\VBZ\1619354|that|apomorphine|also|trpa1 (l_nmod) trpa1_12\NN\1740|on|endogenous|neurons
T2_T15 CPR:3 apomorphine_7\NN\3786417| (r_nsubj) acts_9\VBZ\1619354|that|apomorphine|also|trpa1 (l_nmod) trpa1_12\NN\1740|on|endogenous|neurons (l_nmod) neurons_18\NNS\5430628|in|cultured|dorsal|root|ganglion|rats|and|qgp-1 (l_conj) qgp-1_28\NN\1740|in|the|enterochromaffin|model|cell|line|,|released (l_acl:relcl) released_34\VBN\1435380|which|serotonin|is|activation (l_nmod) activation_36\NN\13561719|upon|trpa1 (l_nmod) trpa1_38\NN\1740|of
T3_T14 NONE serotonin_32\NN\14807737| (r_nsubjpass) released_34\VBN\1435380|which|serotonin|is|activation (r_acl:relcl) qgp-1_28\NN\1740|in|the|enterochromaffin|model|cell|line|,|released (r_conj) neurons_18\NNS\5430628|in|cultured|dorsal|root|ganglion|rats|and|qgp-1 (r_nmod) trpa1_12\NN\1740|on|endogenous|neurons
T3_T15 NONE serotonin_32\NN\14807737| (r_nsubjpass) released_34\VBN\1435380|which|serotonin|is|activation (l_nmod) activation_36\NN\13561719|upon|trpa1 (l_nmod) trpa1_38\NN\1740|of
T4_T16 NONE apomorphine_10\NN\3786417|for (r_nmod) target_8\NN\7258332|that|trpa1|is|a|apomorphine|,|suggesting (l_nsubj) trpa1_5\NN\1740|human
T4_T17 CPR:3 apomorphine_10\NN\3786417|for (r_nmod) target_8\NN\7258332|that|trpa1|is|a|apomorphine|,|suggesting (l_advcl) suggesting_12\VBG\1010118|contribute (l_ccomp) contribute_19\VB\126264|that|activation|might|effects (l_nsubj) activation_15\NN\13561719|an|trpa1 (l_nmod) trpa1_17\NN\1740|of
T5_T16 NONE apomorphine_37\NN\3786417|with (r_nmod) treatment_35\NN\654885|during|apomorphine (r_nmod) occur_33\VB\2623529|which|can|treatment (r_acl:relcl) nausea_26\NN\14299637|such|and|injections|,|occur (r_nmod) effects_23\NNS\13245626|to|adverse|side|nausea (r_nmod) contribute_19\VB\126264|that|activation|might|effects (r_ccomp) suggesting_12\VBG\1010118|contribute (r_advcl) target_8\NN\7258332|that|trpa1|is|a|apomorphine|,|suggesting (l_nsubj) trpa1_5\NN\1740|human
T5_T17 CPR:3 apomorphine_37\NN\3786417|with (r_nmod) treatment_35\NN\654885|during|apomorphine (r_nmod) occur_33\VB\2623529|which|can|treatment (r_acl:relcl) nausea_26\NN\14299637|such|and|injections|,|occur (r_nmod) effects_23\NNS\13245626|to|adverse|side|nausea (r_nmod) contribute_19\VB\126264|that|activation|might|effects (l_nsubj) activation_15\NN\13561719|an|trpa1 (l_nmod) trpa1_17\NN\1740|of
23229510
T10_T22 NONE acid_27\NN\14818238|amino|metabolism (r_conj) homeostasis_24\NN\13934900|in|redox|and|acid (r_nmod) involved_21\VBN\2676054|homeostasis (r_acl) genes_20\NNS\8459252|involved (r_dobj) regulates_19\VBZ\296178|that|genes (r_acl:relcl) factor_17\NN\7326557|a|transcription|regulates (r_appos) factor_9\NN\7326557|transcription|4|atf4|,|factor (l_nummod) 4_10\CD\13741022|
T10_T23 NONE acid_27\NN\14818238|amino|metabolism (r_conj) homeostasis_24\NN\13934900|in|redox|and|acid (r_nmod) involved_21\VBN\2676054|homeostasis (r_acl) genes_20\NNS\8459252|involved (r_dobj) regulates_19\VBZ\296178|that|genes (r_acl:relcl) factor_17\NN\7326557|a|transcription|regulates (r_appos) factor_9\NN\7326557|transcription|4|atf4|,|factor (l_appos) atf4_12\NN\1740|(|)
T11_T26 CPR:3 e235_5\NN\1740|n-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide (r_appos) compound_3\NN\5869584|one|,|e235|,|activated (l_acl:relcl) activated_11\VBD\1641914|that|isr|and|increased (l_conj) increased_16\VBD\169651|dose-dependently|levels (l_dobj) levels_17\NNS\4916342|atf4|cells (l_nmod) atf4_19\NN\1740|of
T12_T26 CPR:3 )_8\-RRB-\1740| (r_punct) n-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide_7\NN\1740|(|) (r_appos) e235_5\NN\1740|n-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide (r_appos) compound_3\NN\5869584|one|,|e235|,|activated (l_acl:relcl) activated_11\VBD\1641914|that|isr|and|increased (l_conj) increased_16\VBD\169651|dose-dependently|levels (l_dobj) levels_17\NNS\4916342|atf4|cells (l_nmod) atf4_19\NN\1740|of
T1_T27 NONE e235_26\NN\1740|of (r_nmod) effects_24\NNS\13245626|the|antiproliferative|e235 (r_dobj) increased_21\VBD\169651|knockdown|significantly|effects|. (l_nsubj) knockdown_17\NN\1173038|atf4 (l_nmod) atf4_19\NN\1740|of
T3_T13 NONE e235-mediated_0\JJ\1740| (r_amod) induction_1\NN\7450842|e235-mediated|senescence (r_nsubj) dependent_6\JJ\1740|induction|was|not|p21|;|conferred (l_nmod) p21_8\NN\1740|on|or|p53
T3_T14 NONE e235-mediated_0\JJ\1740| (r_amod) induction_1\NN\7450842|e235-mediated|senescence (r_nsubj) dependent_6\JJ\1740|induction|was|not|p21|;|conferred (l_nmod) p21_8\NN\1740|on|or|p53 (l_conj) p53_10\NN\1740|
T3_T15 NONE e235-mediated_0\JJ\1740| (r_amod) induction_1\NN\7450842|e235-mediated|senescence (r_nsubj) dependent_6\JJ\1740|induction|was|not|p21|;|conferred (l_parataxis) conferred_15\VBD\813978|however|,|p21|protection|effects|. (l_nsubj) p21_14\NN\1740|
T4_T13 NONE e235_23\NN\1740|of (r_nmod) effects_21\NNS\13245626|against|the|growth|inhibitory|e235 (r_nmod) conferred_15\VBD\813978|however|,|p21|protection|effects|. (r_parataxis) dependent_6\JJ\1740|induction|was|not|p21|;|conferred (l_nmod) p21_8\NN\1740|on|or|p53
T4_T14 NONE e235_23\NN\1740|of (r_nmod) effects_21\NNS\13245626|against|the|growth|inhibitory|e235 (r_nmod) conferred_15\VBD\813978|however|,|p21|protection|effects|. (r_parataxis) dependent_6\JJ\1740|induction|was|not|p21|;|conferred (l_nmod) p21_8\NN\1740|on|or|p53 (l_conj) p53_10\NN\1740|
T4_T15 NONE e235_23\NN\1740|of (r_nmod) effects_21\NNS\13245626|against|the|growth|inhibitory|e235 (r_nmod) conferred_15\VBD\813978|however|,|p21|protection|effects|. (l_nsubj) p21_14\NN\1740|
T6_T16 CPR:3 e235_0\NN\1740| (r_nsubj) activated_2\VBD\1641914|e235|also|signaling|,|resulting|,|appear|. (l_advcl) resulting_8\VBG\2633881|levels (l_nmod) levels_11\NNS\4916342|in|increased|p53 (l_nmod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase
T6_T17 CPR:3 e235_0\NN\1740| (r_nsubj) activated_2\VBD\1641914|e235|also|signaling|,|resulting|,|appear|. (l_advcl) resulting_8\VBG\2633881|levels (l_nmod) levels_11\NNS\4916342|in|increased|p53 (l_nmod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) γ-h2ax_16\NN\1740|
T6_T18 CPR:3 e235_0\NN\1740| (r_nsubj) activated_2\VBD\1641914|e235|also|signaling|,|resulting|,|appear|. (l_advcl) resulting_8\VBG\2633881|levels (l_nmod) levels_11\NNS\4916342|in|increased|p53 (l_nmod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) kinase_21\NN\14732946|phosphorylated|checkpoint|2|chk2 (l_nummod) 2_22\CD\13741022|
T6_T19 CPR:3 e235_0\NN\1740| (r_nsubj) activated_2\VBD\1641914|e235|also|signaling|,|resulting|,|appear|. (l_advcl) resulting_8\VBG\2633881|levels (l_nmod) levels_11\NNS\4916342|in|increased|p53 (l_nmod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) kinase_21\NN\14732946|phosphorylated|checkpoint|2|chk2 (l_appos) chk2_24\NN\1740|(|)
T7_T16 NONE ser15-phosphorylated_13\JJ\1740| (r_amod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase
T7_T17 NONE ser15-phosphorylated_13\JJ\1740| (r_amod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) γ-h2ax_16\NN\1740|
T7_T18 NONE ser15-phosphorylated_13\JJ\1740| (r_amod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) kinase_21\NN\14732946|phosphorylated|checkpoint|2|chk2 (l_nummod) 2_22\CD\13741022|
T7_T19 NONE ser15-phosphorylated_13\JJ\1740| (r_amod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) kinase_21\NN\14732946|phosphorylated|checkpoint|2|chk2 (l_appos) chk2_24\NN\1740|(|)
T8_T16 NONE e235_28\NN\1740| (r_nsubj) appear_31\VB\2604760|although|e235|does|not|cause (r_advcl) activated_2\VBD\1641914|e235|also|signaling|,|resulting|,|appear|. (l_advcl) resulting_8\VBG\2633881|levels (l_nmod) levels_11\NNS\4916342|in|increased|p53 (l_nmod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase
T8_T17 NONE e235_28\NN\1740| (r_nsubj) appear_31\VB\2604760|although|e235|does|not|cause (r_advcl) activated_2\VBD\1641914|e235|also|signaling|,|resulting|,|appear|. (l_advcl) resulting_8\VBG\2633881|levels (l_nmod) levels_11\NNS\4916342|in|increased|p53 (l_nmod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) γ-h2ax_16\NN\1740|
T8_T18 NONE e235_28\NN\1740| (r_nsubj) appear_31\VB\2604760|although|e235|does|not|cause (r_advcl) activated_2\VBD\1641914|e235|also|signaling|,|resulting|,|appear|. (l_advcl) resulting_8\VBG\2633881|levels (l_nmod) levels_11\NNS\4916342|in|increased|p53 (l_nmod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) kinase_21\NN\14732946|phosphorylated|checkpoint|2|chk2 (l_nummod) 2_22\CD\13741022|
T8_T19 NONE e235_28\NN\1740| (r_nsubj) appear_31\VB\2604760|although|e235|does|not|cause (r_advcl) activated_2\VBD\1641914|e235|also|signaling|,|resulting|,|appear|. (l_advcl) resulting_8\VBG\2633881|levels (l_nmod) levels_11\NNS\4916342|in|increased|p53 (l_nmod) p53_14\NN\1740|of|ser15-phosphorylated|,|γ-h2ax|,|and|kinase (l_conj) kinase_21\NN\14732946|phosphorylated|checkpoint|2|chk2 (l_appos) chk2_24\NN\1740|(|)
17221210
T1_T10 NONE sulphate_21\NN\15010703| (r_compound) 2-sulfotransferase_22\NN\1740|heparan|sulphate
T1_T27 NONE sulphate_21\NN\15010703| (r_compound) 2-sulfotransferase_22\NN\1740|heparan|sulphate (r_conj) glypicans_11\NNS\1740|1|and|2-sulfotransferase (l_dep) 1_12\CD\13741022|,|2|,|3|and|5 (l_conj) 5_18\CD\13741022|
T5_T11 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (l_amod) insulin-positive_0\JJ\1740|
T5_T12 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_nummod) 1_30\CD\13741022|
T5_T13 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_appos) pdx1_32\NN\1740|(|)
T5_T14 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_nummod) 1_39\CD\13741022|
T5_T15 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_appos) pcsk1_41\NN\1740|(|;|known|)
T5_T16 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_appos) pcsk1_41\NN\1740|(|;|known|) (l_acl) known_44\VBN\2110220|previously|convertase (l_nmod) convertase_47\NN\1740|as|pro-hormone|1/3 (l_nummod) 1/3_48\CD\1740|
T5_T17 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_nummod) 2_55\CD\13741022|
T5_T18 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_appos) pcsk2_57\NN\1740|(|;|known|)
T5_T19 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_appos) pcsk2_57\NN\1740|(|;|known|) (l_acl) known_60\VBN\2110220|previously|convertase (l_nmod) convertase_63\NN\1740|as|pro-hormone|2 (l_nummod) 2_64\CD\13741022|
T5_T20 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (l_appos) member_77\NN\9816771|2 (l_nummod) 2_78\CD\13741022|
T5_T21 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (l_appos) slc2a1_80\NN\1740|(|;|known|)
T5_T22 NONE chlorate_8\NN\15010703|of (r_nmod) presence_6\NN\13954253|in|the|chlorate (r_nmod) developed_3\VBD\1753788|that|presence (r_acl:relcl) cells_1\NNS\3080309|insulin-positive|developed (r_nsubj) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_dep) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (l_appos) slc2a1_80\NN\1740|(|;|known|) (l_acl) known_83\VBN\2110220|previously|transporter (l_nmod) transporter_86\NN\4490091|as|glucose|2 (l_nummod) 2_87\CD\13741022|
T6_T11 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (r_dep) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_nsubj) cells_1\NNS\3080309|insulin-positive|developed (l_amod) insulin-positive_0\JJ\1740|
T6_T12 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_nummod) 1_30\CD\13741022|
T6_T13 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_appos) pdx1_32\NN\1740|(|)
T6_T14 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_nummod) 1_39\CD\13741022|
T6_T15 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_appos) pcsk1_41\NN\1740|(|;|known|)
T6_T16 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_appos) pcsk1_41\NN\1740|(|;|known|) (l_acl) known_44\VBN\2110220|previously|convertase (l_nmod) convertase_47\NN\1740|as|pro-hormone|1/3 (l_nummod) 1/3_48\CD\1740|
T6_T17 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_nummod) 2_55\CD\13741022|
T6_T18 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_appos) pcsk2_57\NN\1740|(|;|known|)
T6_T19 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_appos) pcsk2_57\NN\1740|(|;|known|) (l_acl) known_60\VBN\2110220|previously|convertase (l_nmod) convertase_63\NN\1740|as|pro-hormone|2 (l_nummod) 2_64\CD\13741022|
T6_T20 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (l_appos) member_77\NN\9816771|2 (l_nummod) 2_78\CD\13741022|
T6_T21 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (l_appos) slc2a1_80\NN\1740|(|;|known|)
T6_T22 NONE glucose_73\NN\14710501| (r_compound) transporter_74\NN\4490091|(|facilitated|glucose|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (l_appos) slc2a1_80\NN\1740|(|;|known|) (l_acl) known_83\VBN\2110220|previously|transporter (l_nmod) transporter_86\NN\4490091|as|glucose|2 (l_nummod) 2_87\CD\13741022|
T7_T11 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (r_dep) exhibited_9\VBD\2632167|cells|phenotype|regard|:|gene|. (l_nsubj) cells_1\NNS\3080309|insulin-positive|developed (l_amod) insulin-positive_0\JJ\1740|
T7_T12 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_nummod) 1_30\CD\13741022|
T7_T13 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_appos) pdx1_32\NN\1740|(|)
T7_T14 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_nummod) 1_39\CD\13741022|
T7_T15 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_appos) pcsk1_41\NN\1740|(|;|known|)
T7_T16 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_38\NN\5839024|proprotein|convertase|subtilisin/kexin|1|pcsk1 (l_appos) pcsk1_41\NN\1740|(|;|known|) (l_acl) known_44\VBN\2110220|previously|convertase (l_nmod) convertase_47\NN\1740|as|pro-hormone|1/3 (l_nummod) 1/3_48\CD\1740|
T7_T17 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_nummod) 2_55\CD\13741022|
T7_T18 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_appos) pcsk2_57\NN\1740|(|;|known|)
T7_T19 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (r_conj) gene_29\NN\8459252|pancreatic|homeobox|1|pdx1|,|type|,|type|and|family (l_conj) type_54\NN\5839024|proprotein|convertase|subtilisin/kexin|2|pcsk2 (l_appos) pcsk2_57\NN\1740|(|;|known|) (l_acl) known_60\VBN\2110220|previously|convertase (l_nmod) convertase_63\NN\1740|as|pro-hormone|2 (l_nummod) 2_64\CD\13741022|
T7_T20 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|) (r_appos) family_69\NN\8189659|solute|carrier|2|transporter|,|member|slc2a1 (l_appos) member_77\NN\9816771|2 (l_nummod) 2_78\CD\13741022|
T7_T21 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (r_nmod) known_83\VBN\2110220|previously|transporter (r_acl) slc2a1_80\NN\1740|(|;|known|)
T7_T22 NONE glucose_85\NN\14710501| (r_compound) transporter_86\NN\4490091|as|glucose|2 (l_nummod) 2_87\CD\13741022|
T8_T23 CPR:3 chlorate_5\NN\15010703| (r_nsubj) activated_6\VBD\1641914|that|chlorate|development|inducing (l_advcl) inducing_11\VBG\1627355|by|expression (l_dobj) expression_17\NN\4679549|neurogenin|cells (l_compound) neurogenin_12\NN\1740|3|neurog3 (l_nummod) 3_13\CD\13741022|
T8_T24 CPR:3 chlorate_5\NN\15010703| (r_nsubj) activated_6\VBD\1641914|that|chlorate|development|inducing (l_advcl) inducing_11\VBG\1627355|by|expression (l_dobj) expression_17\NN\4679549|neurogenin|cells (l_compound) neurogenin_12\NN\1740|3|neurog3 (l_appos) neurog3_15\NN\1740|(|)
23603382
T10_T15 CPR:4 na2seo3+naaso2_20\NN\1740|combined (r_compound) group_22\NN\2137|in|the|na2seo3+naaso2|treatment (r_nmod) increased_12\VBN\169651|levels|were|significantly|p<0.05|group|. (l_nsubjpass) levels_2\NNS\4916342|the|mrna|sod1 (l_nmod) sod1_4\NN\1740|of|,|cat|,|gpx|and|txnrd1
T10_T16 CPR:4 na2seo3+naaso2_20\NN\1740|combined (r_compound) group_22\NN\2137|in|the|na2seo3+naaso2|treatment (r_nmod) increased_12\VBN\169651|levels|were|significantly|p<0.05|group|. (l_nsubjpass) levels_2\NNS\4916342|the|mrna|sod1 (l_nmod) sod1_4\NN\1740|of|,|cat|,|gpx|and|txnrd1 (l_conj) cat_6\NN\2120997|
T10_T17 CPR:4 na2seo3+naaso2_20\NN\1740|combined (r_compound) group_22\NN\2137|in|the|na2seo3+naaso2|treatment (r_nmod) increased_12\VBN\169651|levels|were|significantly|p<0.05|group|. (l_nsubjpass) levels_2\NNS\4916342|the|mrna|sod1 (l_nmod) sod1_4\NN\1740|of|,|cat|,|gpx|and|txnrd1 (l_conj) gpx_8\NN\1740|
T10_T18 CPR:4 na2seo3+naaso2_20\NN\1740|combined (r_compound) group_22\NN\2137|in|the|na2seo3+naaso2|treatment (r_nmod) increased_12\VBN\169651|levels|were|significantly|p<0.05|group|. (l_nsubjpass) levels_2\NNS\4916342|the|mrna|sod1 (l_nmod) sod1_4\NN\1740|of|,|cat|,|gpx|and|txnrd1 (l_conj) txnrd1_10\NN\1740|
T9_T15 CPR:3 na2seo3+naaso2_20\NN\1740|combined (r_compound) group_22\NN\2137|in|the|na2seo3+naaso2|treatment (r_nmod) increased_12\VBN\169651|levels|were|significantly|p<0.05|group|. (l_nsubjpass) levels_2\NNS\4916342|the|mrna|sod1 (l_nmod) sod1_4\NN\1740|of|,|cat|,|gpx|and|txnrd1
T9_T16 CPR:3 na2seo3+naaso2_20\NN\1740|combined (r_compound) group_22\NN\2137|in|the|na2seo3+naaso2|treatment (r_nmod) increased_12\VBN\169651|levels|were|significantly|p<0.05|group|. (l_nsubjpass) levels_2\NNS\4916342|the|mrna|sod1 (l_nmod) sod1_4\NN\1740|of|,|cat|,|gpx|and|txnrd1 (l_conj) cat_6\NN\2120997|
T9_T17 CPR:3 na2seo3+naaso2_20\NN\1740|combined (r_compound) group_22\NN\2137|in|the|na2seo3+naaso2|treatment (r_nmod) increased_12\VBN\169651|levels|were|significantly|p<0.05|group|. (l_nsubjpass) levels_2\NNS\4916342|the|mrna|sod1 (l_nmod) sod1_4\NN\1740|of|,|cat|,|gpx|and|txnrd1 (l_conj) gpx_8\NN\1740|
T9_T18 CPR:4 na2seo3+naaso2_20\NN\1740|combined (r_compound) group_22\NN\2137|in|the|na2seo3+naaso2|treatment (r_nmod) increased_12\VBN\169651|levels|were|significantly|p<0.05|group|. (l_nsubjpass) levels_2\NNS\4916342|the|mrna|sod1 (l_nmod) sod1_4\NN\1740|of|,|cat|,|gpx|and|txnrd1 (l_conj) txnrd1_10\NN\1740|
T12_T19 CPR:3 naaso2_14\NN\1740| (r_compound) group_15\NN\2137|in|the|naaso2 (r_nmod) increased_11\VBN\169651|expressions|were|group|and|reduced|. (l_nsubjpass) expressions_1\NNS\4679549|the|hsp70 (l_nmod) hsp70_3\NN\1740|of|and|ho-1
T12_T20 CPR:3 naaso2_14\NN\1740| (r_compound) group_15\NN\2137|in|the|naaso2 (r_nmod) increased_11\VBN\169651|expressions|were|group|and|reduced|. (l_nsubjpass) expressions_1\NNS\4679549|the|hsp70 (l_nmod) hsp70_3\NN\1740|of|and|ho-1 (l_conj) ho-1_5\NN\1740|
23474386
T4_T11 CPR:4 5-(benzyloxy)pyridin-2(1h)-one_1\NN\1740| (r_compound) derivatives_2\NNS\5802185|novel|5-(benzyloxy)pyridin-2(1h)-one|inhibitors|. (l_nmod) inhibitors_6\NNS\20090|as|potent|c-met (l_compound) c-met_5\NN\1740|
T3_T5 NONE 5-(benzyloxy)pyridin-2(1h)-ones_4\JJ\1740|of|novel (r_nmod) series_1\NN\8456993|a|5-(benzyloxy)pyridin-2(1h)-ones (r_nsubjpass) designed_6\VBN\1631534|series|were|,|synthesized|and|evaluated|. (l_conj) evaluated_11\VBN\670261|biologically|inhibition (l_nmod) inhibition_14\NN\1068773|for|c-met (l_compound) c-met_13\NN\1740|
23312278
T1_T3 NONE amp_14\NN\13633375| (r_compound) biosynthesis_15\NN\13565379|amp (r_dobj) altering_13\VBG\126264|by|biosynthesis (r_advcl) activate_6\VBP\1641914|stenesen|ampk|both|altering|slow|,|highlighting|. (l_dobj) ampk_7\NN\1740|
T1_T4 NONE amp_14\NN\13633375| (r_compound) biosynthesis_15\NN\13565379|amp (r_dobj) altering_13\VBG\126264|by|biosynthesis (r_advcl) activate_6\VBP\1641914|stenesen|ampk|both|altering|slow|,|highlighting|. (l_advcl) highlighting_22\VBG\514463|ampk|modulator (l_dobj) ampk_23\NN\1740|
23628454
16719540
T11_T20 NONE fluorouracil_18\NN\2722166| (r_compound) exposure_19\NN\5042871|an|optimal|fluorouracil|or|dose (r_dobj) achieving_15\VBG\2524171|exposure (r_conj) predicting_13\VBG\916909|and|achieving (r_conj) defining_11\VBG\2604760|in|,|predicting|index (l_nmod) index_27\NN\13850304|because|a|narrow|therapeutic|,|pharmacokinetics|,|variabilities|,|and|targets (l_conj) targets_41\NNS\7258332|in|synthase (l_nmod) synthase_44\NN\1740|like|thymidylate
T12_T20 NONE thymidylate_43\NN\1740| (r_compound) synthase_44\NN\1740|like|thymidylate
T13_T21 NONE fluorouracil_2\NN\2722166| (r_compound) administration_3\NN\1133281|fluorouracil|dose (r_dobj) individualise_1\VB\650353|to|administration (r_advcl) useful_21\JJ\1740|individualise|,|assessment|may|be|,|controls|. (l_nsubj) assessment_9\NN\5732756|activity (l_nmod) activity_18\NN\30358|of|the|dehydrogenase (l_compound) dehydrogenase_14\NN\1740|individual|dihydropyrimidine|dpd
T13_T22 NONE fluorouracil_2\NN\2722166| (r_compound) administration_3\NN\1133281|fluorouracil|dose (r_dobj) individualise_1\VB\650353|to|administration (r_advcl) useful_21\JJ\1740|individualise|,|assessment|may|be|,|controls|. (l_nsubj) assessment_9\NN\5732756|activity (l_nmod) activity_18\NN\30358|of|the|dehydrogenase (l_compound) dehydrogenase_14\NN\1740|individual|dihydropyrimidine|dpd (l_appos) dpd_16\NN\1740|(|)
T14_T21 NONE dihydropyrimidine_13\NN\1740| (r_compound) dehydrogenase_14\NN\1740|individual|dihydropyrimidine|dpd
T14_T22 NONE dihydropyrimidine_13\NN\1740| (r_compound) dehydrogenase_14\NN\1740|individual|dihydropyrimidine|dpd (l_appos) dpd_16\NN\1740|(|)
T16_T21 NONE fluorouracil_34\NN\2722166| (r_compound) elimination_35\NN\391599|of|fluorouracil (r_nmod) %_32\NN\1740|80|elimination (r_dobj) controls_29\VBZ\2422663|because|enzyme|% (r_advcl) useful_21\JJ\1740|individualise|,|assessment|may|be|,|controls|. (l_nsubj) assessment_9\NN\5732756|activity (l_nmod) activity_18\NN\30358|of|the|dehydrogenase (l_compound) dehydrogenase_14\NN\1740|individual|dihydropyrimidine|dpd
T16_T22 NONE fluorouracil_34\NN\2722166| (r_compound) elimination_35\NN\391599|of|fluorouracil (r_nmod) %_32\NN\1740|80|elimination (r_dobj) controls_29\VBZ\2422663|because|enzyme|% (r_advcl) useful_21\JJ\1740|individualise|,|assessment|may|be|,|controls|. (l_nsubj) assessment_9\NN\5732756|activity (l_nmod) activity_18\NN\30358|of|the|dehydrogenase (l_compound) dehydrogenase_14\NN\1740|individual|dihydropyrimidine|dpd (l_appos) dpd_16\NN\1740|(|)
T17_T23 NONE fluorouracil_23\NN\2722166| (r_compound) exposure_24\NN\5042871|to|increased|fluorouracil|and|toxicity (r_nmod) leads_20\VBZ\1752884|loss|,|respectively|,|exposure|. (l_nsubj) loss_4\NN\13252973|a|complete|activity|% (l_nmod) activity_7\NN\30358|of|dpd (l_compound) dpd_6\NN\1740|
T2_T24 NONE fluorouracil_29\NN\2722166| (r_compound) dose_31\NN\3740161|fluorouracil|test (r_compound) approach_32\NN\940842|the|dose (r_nsubj) as_26\IN\14622893|has|approach (r_advcl) has_23\VBZ\2108377|each|limitations|,|as|. (r_conj) proposed_10\VBN\1010118|methods|have|been|genotyping|,|but|has (l_nsubjpass) methods_1\NNS\5616786|several|assess (l_acl) assess_3\VB\670261|to|activity (l_dobj) activity_5\NN\30358|dpd|patients (l_compound) dpd_4\NN\1740|
T10_T19 NONE fluorouracil_28\NN\2722166| (r_compound) exposure_29\NN\5042871|to|fluorouracil|posteriori (r_nmod) adaptation_24\NN\6362953|the|doses|exposure (r_conj) adaptation_2\NN\6362953|an|dose|results|,|and|adaptation (l_nmod) results_10\NNS\34213|to|the|tests (l_nmod) tests_15\NNS\5798043|of|two|dpd|activity|administration (l_compound) dpd_13\NN\1740|
T8_T19 NONE fluorouracil_5\NN\2722166| (r_compound) dose_7\NN\3740161|of|the|fluorouracil|starting (r_nmod) adaptation_2\NN\6362953|an|dose|results|,|and|adaptation (l_nmod) results_10\NNS\34213|to|the|tests (l_nmod) tests_15\NNS\5798043|of|two|dpd|activity|administration (l_compound) dpd_13\NN\1740|
T9_T19 NONE fluorouracil_17\NN\2722166| (r_compound) administration_18\NN\1133281|before|fluorouracil|priori (r_nmod) tests_15\NNS\5798043|of|two|dpd|activity|administration (l_compound) dpd_13\NN\1740|
12927226
T12_T24 CPR:6 eprosartan_3\NN\1740|by (r_nmod) antagonism_1\NN\24720|at1|eprosartan (l_compound) at1_0\NN\1740|
T7_T19 NONE renin-angiotensin_5\JJ\1740|
T7_T20 NONE renin-angiotensin_5\JJ\1740|
T7_T22 NONE renin-angiotensin_5\JJ\1740| (r_amod) system_6\NN\3575240|of|the|renin-angiotensin|ras (r_nmod) blockade_2\NN\952963|system|inhibitors (l_nmod) inhibitors_12\NNS\20090|by|ace (l_compound) ace_11\NN\13741022|
T8_T21 NONE angiotensin_8\NN\4522421| (r_compound) eprosartan_16\NN\1740|of|the|angiotensin|type|1|at1|)|receptor|blocker (l_compound) receptor_14\NN\5225602|
T9_T21 CPR:4 eprosartan_16\NN\1740|of|the|angiotensin|type|1|at1|)|receptor|blocker (l_compound) receptor_14\NN\5225602|
T11_T13 CPR:3 eprosartan_2\NN\1740| (r_nsubj) tended_3\VBD\2604760|eprosartan|lower|,|increased (l_conj) increased_11\VBD\169651|it|slightly|rate|p<0.05|,|and|increased (l_conj) increased_23\VBD\169651|markedly|levels (l_dobj) levels_26\NNS\4916342|circulating|ang-ii|p<0.01 (l_compound) ang-ii_25\NN\1740|
T1_T13 NONE ang-ii_25\NN\1740|
T3_T14 CPR:6 eprosartan_5\NN\1740|by (r_nmod) antagonism_3\NN\24720|at1|eprosartan (l_compound) at1_2\NN\1740|
T4_T15 NONE ii_14\CD\13741022|
T4_T16 NONE ii_14\CD\13741022| (r_nummod) angiotensin_13\NN\4522421|in|circulating|ii|ang (l_appos) ang_16\NN\8391387|(|ii|) (l_nummod) ii_17\CD\13741022|
T5_T15 NONE ii_17\CD\13741022| (r_nummod) ang_16\NN\8391387|(|ii|) (r_appos) angiotensin_13\NN\4522421|in|circulating|ii|ang (l_nummod) ii_14\CD\13741022|
T5_T16 NONE ii_17\CD\13741022|
T6_T17 NONE angiotensin_7\NN\4522421| (r_compound) type_8\NN\5839024|angiotensin|1|at1 (l_nummod) 1_9\CD\13741022|
T6_T18 NONE angiotensin_7\NN\4522421| (r_compound) type_8\NN\5839024|angiotensin|1|at1 (l_appos) at1_11\NN\1740|(|)
1326878
8032658
T59_T70 NONE 5-hydroxytryptamine_3\NN\14807737| (r_compound) receptors_4\NNS\5225602|of|5-hydroxytryptamine|5-ht2b|muscle
T59_T71 NONE 5-hydroxytryptamine_3\NN\14807737| (r_compound) receptors_4\NNS\5225602|of|5-hydroxytryptamine|5-ht2b|muscle (l_appos) 5-ht2b_7\NNS\1740|(|putative|)
T14_T60 NONE 5-ht_17\NN\1740|(|) (r_appos) 5-hydroxytryptamine_15\NN\14807737|5-ht (r_compound) receptors_19\NNS\5225602|of|5-hydroxytryptamine
T7_T60 NONE 5-hydroxytryptamine_15\NN\14807737|5-ht (r_compound) receptors_19\NNS\5225602|of|5-hydroxytryptamine
T49_T69 NONE monoamine_6\NN\14739004| (r_compound) oxidase_7\NN\14732946|of|monoamine
T50_T69 CPR:4 pargyline_9\NN\1740|with|microm (r_nmod) blockade_4\NN\952963|oxidase|pargyline (l_nmod) oxidase_7\NN\14732946|of|monoamine
T51_T69 NONE 5-methoxytryptamine_26\NN\1740|for|both|5-meo-t|and|tryptamine (r_nmod) displacement_20\NN\197772|a|leftward|curves|5-methoxytryptamine (r_dobj) caused_17\VBD\1617192|conditions|,|blockade|displacement|. (l_nsubj) blockade_4\NN\952963|oxidase|pargyline (l_nmod) oxidase_7\NN\14732946|of|monoamine
T52_T69 NONE 5-meo-t_28\NN\1740|(|) (r_appos) 5-methoxytryptamine_26\NN\1740|for|both|5-meo-t|and|tryptamine (r_nmod) displacement_20\NN\197772|a|leftward|curves|5-methoxytryptamine (r_dobj) caused_17\VBD\1617192|conditions|,|blockade|displacement|. (l_nsubj) blockade_4\NN\952963|oxidase|pargyline (l_nmod) oxidase_7\NN\14732946|of|monoamine
T53_T69 NONE tryptamine_31\NN\1740| (r_conj) 5-methoxytryptamine_26\NN\1740|for|both|5-meo-t|and|tryptamine (r_nmod) displacement_20\NN\197772|a|leftward|curves|5-methoxytryptamine (r_dobj) caused_17\VBD\1617192|conditions|,|blockade|displacement|. (l_nsubj) blockade_4\NN\952963|oxidase|pargyline (l_nmod) oxidase_7\NN\14732946|of|monoamine
T10_T61 CPR:5 24969_22\CD\1740| (r_nummod) ru_21\NN\14625458|24969 (r_conj) 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T10_T62 CPR:5 24969_22\CD\1740| (r_nummod) ru_21\NN\14625458|24969 (r_conj) 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T11_T61 CPR:5 212_25\CD\1740| (r_nummod) mk_24\NN\1740|212 (r_conj) 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T11_T62 CPR:5 212_25\CD\1740| (r_nummod) mk_24\NN\1740|212 (r_conj) 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T12_T61 CPR:5 23390_28\CD\1740| (r_nummod) sch_27\NN\1740|23390 (r_conj) 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T12_T62 CPR:5 23390_28\CD\1740| (r_nummod) sch_27\NN\1740|23390 (r_conj) 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T13_T61 NONE sumatriptan_36\NN\1740|,|renzapride|and|tetralin (r_nsubj) weak_48\JJ\1740|whilst|sumatriptan|were|very|or|inactive (r_advcl) agonists_31\NNS\9613191|addition|ligands|were|also|fundus|weak|. (l_nsubj) ligands_3\NNS\20090|several|known (l_acl) known_4\VBN\2110220|act (l_xcomp) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T13_T62 NONE sumatriptan_36\NN\1740|,|renzapride|and|tetralin (r_nsubj) weak_48\JJ\1740|whilst|sumatriptan|were|very|or|inactive (r_advcl) agonists_31\NNS\9613191|addition|ligands|were|also|fundus|weak|. (l_nsubj) ligands_3\NNS\20090|several|known (l_acl) known_4\VBN\2110220|act (l_xcomp) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T15_T61 NONE renzapride_38\NN\1740| (r_conj) sumatriptan_36\NN\1740|,|renzapride|and|tetralin (r_nsubj) weak_48\JJ\1740|whilst|sumatriptan|were|very|or|inactive (r_advcl) agonists_31\NNS\9613191|addition|ligands|were|also|fundus|weak|. (l_nsubj) ligands_3\NNS\20090|several|known (l_acl) known_4\VBN\2110220|act (l_xcomp) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T15_T62 NONE renzapride_38\NN\1740| (r_conj) sumatriptan_36\NN\1740|,|renzapride|and|tetralin (r_nsubj) weak_48\JJ\1740|whilst|sumatriptan|were|very|or|inactive (r_advcl) agonists_31\NNS\9613191|addition|ligands|were|also|fundus|weak|. (l_nsubj) ligands_3\NNS\20090|several|known (l_acl) known_4\VBN\2110220|act (l_xcomp) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T16_T61 NONE tetralin_42\NN\1740|8-hydroxy-2-(di-n-propylamino|)|8-oh-dpat (r_conj) sumatriptan_36\NN\1740|,|renzapride|and|tetralin (r_nsubj) weak_48\JJ\1740|whilst|sumatriptan|were|very|or|inactive (r_advcl) agonists_31\NNS\9613191|addition|ligands|were|also|fundus|weak|. (l_nsubj) ligands_3\NNS\20090|several|known (l_acl) known_4\VBN\2110220|act (l_xcomp) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T16_T62 NONE tetralin_42\NN\1740|8-hydroxy-2-(di-n-propylamino|)|8-oh-dpat (r_conj) sumatriptan_36\NN\1740|,|renzapride|and|tetralin (r_nsubj) weak_48\JJ\1740|whilst|sumatriptan|were|very|or|inactive (r_advcl) agonists_31\NNS\9613191|addition|ligands|were|also|fundus|weak|. (l_nsubj) ligands_3\NNS\20090|several|known (l_acl) known_4\VBN\2110220|act (l_xcomp) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T17_T61 NONE 8-oh-dpat_44\NN\1740|(|) (r_appos) tetralin_42\NN\1740|8-hydroxy-2-(di-n-propylamino|)|8-oh-dpat (r_conj) sumatriptan_36\NN\1740|,|renzapride|and|tetralin (r_nsubj) weak_48\JJ\1740|whilst|sumatriptan|were|very|or|inactive (r_advcl) agonists_31\NNS\9613191|addition|ligands|were|also|fundus|weak|. (l_nsubj) ligands_3\NNS\20090|several|known (l_acl) known_4\VBN\2110220|act (l_xcomp) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T17_T62 NONE 8-oh-dpat_44\NN\1740|(|) (r_appos) tetralin_42\NN\1740|8-hydroxy-2-(di-n-propylamino|)|8-oh-dpat (r_conj) sumatriptan_36\NN\1740|,|renzapride|and|tetralin (r_nsubj) weak_48\JJ\1740|whilst|sumatriptan|were|very|or|inactive (r_advcl) agonists_31\NNS\9613191|addition|ligands|were|also|fundus|weak|. (l_nsubj) ligands_3\NNS\20090|several|known (l_acl) known_4\VBN\2110220|act (l_xcomp) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T8_T61 CPR:5 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T8_T62 CPR:5 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T9_T61 CPR:5 m-cpp_18\NN\1740|(|) (r_appos) 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2a_11\NN\1740|at|either|or
T9_T62 CPR:5 m-cpp_18\NN\1740|(|) (r_appos) 1-m-chlorophenylpiperazine_16\NN\1740|including|m-cpp|,|ru|,|mk|and|sch (r_nmod) act_6\VB\1619354|to|agonists|1-m-chlorophenylpiperazine (l_nmod) agonists_8\NNS\9613191|as|receptors (l_nmod) receptors_14\NNS\5225602|5-ht2a|5-ht2c (l_compound) 5-ht2c_13\NN\1740|
T44_T64 NONE rauwolscine_13\NN\1740|of|and|yohimbine (r_nmod) selectivity_9\NN\4916342|concerning|the|enantiomeric|and|affinity|rauwolscine (r_nmod) differences_5\NNS\4723816|despite|small|selectivity (r_nmod) maintained_35\VBN\2202928|that|differences|,|identity|is (l_nsubj) identity_20\NN\4617562|the|close|pharmacological|receptors (l_nmod) receptors_23\NNS\5225602|of|5-ht|fundus
T44_T65 NONE rauwolscine_13\NN\1740|of|and|yohimbine (r_nmod) selectivity_9\NN\4916342|concerning|the|enantiomeric|and|affinity|rauwolscine (r_nmod) differences_5\NNS\4723816|despite|small|selectivity (r_nmod) maintained_35\VBN\2202928|that|differences|,|identity|is (l_nsubj) identity_20\NN\4617562|the|close|pharmacological|receptors (l_nmod) receptors_23\NNS\5225602|of|5-ht|fundus (l_nmod) fundus_27\NN\5225602|in|rat|stomach|and|receptor (l_conj) receptor_33\NN\5225602|the|cloned|5-ht2b (l_compound) 5-ht2b_32\NN\1740|
T45_T64 NONE yohimbine_15\NN\1740| (r_conj) rauwolscine_13\NN\1740|of|and|yohimbine (r_nmod) selectivity_9\NN\4916342|concerning|the|enantiomeric|and|affinity|rauwolscine (r_nmod) differences_5\NNS\4723816|despite|small|selectivity (r_nmod) maintained_35\VBN\2202928|that|differences|,|identity|is (l_nsubj) identity_20\NN\4617562|the|close|pharmacological|receptors (l_nmod) receptors_23\NNS\5225602|of|5-ht|fundus
T45_T65 NONE yohimbine_15\NN\1740| (r_conj) rauwolscine_13\NN\1740|of|and|yohimbine (r_nmod) selectivity_9\NN\4916342|concerning|the|enantiomeric|and|affinity|rauwolscine (r_nmod) differences_5\NNS\4723816|despite|small|selectivity (r_nmod) maintained_35\VBN\2202928|that|differences|,|identity|is (l_nsubj) identity_20\NN\4617562|the|close|pharmacological|receptors (l_nmod) receptors_23\NNS\5225602|of|5-ht|fundus (l_nmod) fundus_27\NN\5225602|in|rat|stomach|and|receptor (l_conj) receptor_33\NN\5225602|the|cloned|5-ht2b (l_compound) 5-ht2b_32\NN\1740|
T46_T64 NONE 5-ht_22\NN\1740| (r_compound) receptors_23\NNS\5225602|of|5-ht|fundus
T46_T65 NONE 5-ht_22\NN\1740| (r_compound) receptors_23\NNS\5225602|of|5-ht|fundus (l_nmod) fundus_27\NN\5225602|in|rat|stomach|and|receptor (l_conj) receptor_33\NN\5225602|the|cloned|5-ht2b (l_compound) 5-ht2b_32\NN\1740|
T47_T66 NONE 200646_1\CD\1740| (r_nummod) sb_0\NN\14625458|200646|,|demonstrates|, (l_acl:relcl) demonstrates_4\VBZ\2137132|which|selectivity (l_dobj) selectivity_6\NN\4916342|some|receptors (l_nmod) receptors_9\NNS\5225602|for|5-ht|fundus
T47_T67 NONE 200646_1\CD\1740| (r_nummod) sb_0\NN\14625458|200646|,|demonstrates|, (r_nsubj) provide_16\VB\2199590|sb|should|ligand|confirmation|and|allow|. (l_conj) allow_26\VB\797697|discrimination (l_dobj) discrimination_27\NN\1123598|function|and (l_nmod) function_30\NN\13783581|of|5-ht2b (l_compound) 5-ht2b_29\NN\1740|
T48_T66 NONE 5-ht_8\NN\1740| (r_compound) receptors_9\NNS\5225602|for|5-ht|fundus
T48_T67 NONE 5-ht_8\NN\1740| (r_compound) receptors_9\NNS\5225602|for|5-ht|fundus (r_nmod) selectivity_6\NN\4916342|some|receptors (r_dobj) demonstrates_4\VBZ\2137132|which|selectivity (r_acl:relcl) sb_0\NN\14625458|200646|,|demonstrates|, (r_nsubj) provide_16\VB\2199590|sb|should|ligand|confirmation|and|allow|. (l_conj) allow_26\VB\797697|discrimination (l_dobj) discrimination_27\NN\1123598|function|and (l_nmod) function_30\NN\13783581|of|5-ht2b (l_compound) 5-ht2b_29\NN\1740|
23234313
23208787
15198222
T10_T17 NONE ketoprofen_8\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T10_T18 NONE ketoprofen_8\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T10_T31 NONE ketoprofen_8\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T11_T17 NONE acid_11\NN\14818238|meclofenamic (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T11_T18 NONE acid_11\NN\14818238|meclofenamic (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T11_T31 NONE acid_11\NN\14818238|meclofenamic (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T12_T17 NONE piroxicam_14\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T12_T18 NONE piroxicam_14\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T12_T31 NONE piroxicam_14\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T13_T17 CPR:4 ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T13_T18 CPR:4 ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T13_T31 NONE ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (r_advcl) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T14_T17 CPR:4 carprofen_25\NN\1740| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T14_T18 CPR:4 carprofen_25\NN\1740| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T14_T31 NONE carprofen_25\NN\1740| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (r_advcl) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T15_T17 CPR:4 acid_28\NN\14818238|tolfenamic (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T15_T18 CPR:4 acid_28\NN\14818238|tolfenamic (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T15_T31 NONE acid_28\NN\14818238|tolfenamic (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (r_advcl) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T16_T17 CPR:4 nimesulide_30\NN\1740| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T16_T18 CPR:4 nimesulide_30\NN\1740| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T16_T31 NONE nimesulide_30\NN\1740| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (r_advcl) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T1_T17 CPR:4 etodolac_33\NN\3828465| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T1_T18 CPR:4 etodolac_33\NN\3828465| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T1_T31 NONE etodolac_33\NN\3828465| (r_conj) ns398_23\NN\1740|,|carprofen|,|acid|,|nimesulide|,|and|etodolac (r_nsubj) had_34\VBD\2108377|whereas|ns398|preference (r_advcl) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T7_T17 NONE aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T7_T18 NONE aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T7_T31 NONE aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T8_T17 NONE diclofenac_4\NN\1740| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T8_T18 NONE diclofenac_4\NN\1740| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T8_T31 NONE diclofenac_4\NN\1740| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T9_T17 NONE indomethacin_6\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_acl) inhibiting_42\VBG\2510337|for|cox-2 (l_dobj) cox-2_43\NN\14737847|
T9_T18 NONE indomethacin_6\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_advcl) had_34\VBD\2108377|whereas|ns398|preference (l_dobj) preference_40\NN\7497473|greater|inhibiting|cox-1 (l_nmod) cox-1_45\NN\14737847|than
T9_T31 NONE indomethacin_6\NN\3828465| (r_conj) aspirin_2\NN\2707683|,|diclofenac|,|indomethacin|,|ketoprofen|,|acid|,|and|piroxicam (r_nsubj) had_15\VBD\2108377|results|aspirin|selectivity|,|had|. (l_dobj) selectivity_17\NN\4916342|little|isozymes (l_nmod) isozymes_20\NNS\1740|toward|cox (l_compound) cox_19\NN\14732946|
T2_T22 CPR:4 etodolac_11\NN\3828465|by|,|nimesulide|,|and|ns398 (r_nmod) inhibited_9\VBN\2510337|cox-2|was|selectively|etodolac (l_nsubjpass) cox-2_6\NN\14737847|canine
T2_T23 NONE etodolac_11\NN\3828465|by|,|nimesulide|,|and|ns398 (r_nmod) inhibited_9\VBN\2510337|cox-2|was|selectively|etodolac (r_dep) conclusions_0\NNS\5837957|and|relevance|:|inhibited|;|appeared (l_dep) appeared_23\VBD\2604760|acid|also|inhibitors (l_xcomp) inhibitors_28\NNS\20090|to|be|preferential|cox-2|dogs (l_compound) cox-2_27\NN\14737847|
T3_T22 CPR:4 nimesulide_13\NN\1740| (r_conj) etodolac_11\NN\3828465|by|,|nimesulide|,|and|ns398 (r_nmod) inhibited_9\VBN\2510337|cox-2|was|selectively|etodolac (l_nsubjpass) cox-2_6\NN\14737847|canine
T3_T23 NONE nimesulide_13\NN\1740| (r_conj) etodolac_11\NN\3828465|by|,|nimesulide|,|and|ns398 (r_nmod) inhibited_9\VBN\2510337|cox-2|was|selectively|etodolac (r_dep) conclusions_0\NNS\5837957|and|relevance|:|inhibited|;|appeared (l_dep) appeared_23\VBD\2604760|acid|also|inhibitors (l_xcomp) inhibitors_28\NNS\20090|to|be|preferential|cox-2|dogs (l_compound) cox-2_27\NN\14737847|
T4_T22 CPR:4 ns398_16\NN\1740| (r_conj) etodolac_11\NN\3828465|by|,|nimesulide|,|and|ns398 (r_nmod) inhibited_9\VBN\2510337|cox-2|was|selectively|etodolac (l_nsubjpass) cox-2_6\NN\14737847|canine
T4_T23 NONE ns398_16\NN\1740| (r_conj) etodolac_11\NN\3828465|by|,|nimesulide|,|and|ns398 (r_nmod) inhibited_9\VBN\2510337|cox-2|was|selectively|etodolac (r_dep) conclusions_0\NNS\5837957|and|relevance|:|inhibited|;|appeared (l_dep) appeared_23\VBD\2604760|acid|also|inhibitors (l_xcomp) inhibitors_28\NNS\20090|to|be|preferential|cox-2|dogs (l_compound) cox-2_27\NN\14737847|
T5_T22 NONE acid_19\NN\14818238|tolfenamic|and|carprofen (r_nsubj) appeared_23\VBD\2604760|acid|also|inhibitors (r_dep) conclusions_0\NNS\5837957|and|relevance|:|inhibited|;|appeared (l_dep) inhibited_9\VBN\2510337|cox-2|was|selectively|etodolac (l_nsubjpass) cox-2_6\NN\14737847|canine
T5_T23 CPR:4 acid_19\NN\14818238|tolfenamic|and|carprofen (r_nsubj) appeared_23\VBD\2604760|acid|also|inhibitors (l_xcomp) inhibitors_28\NNS\20090|to|be|preferential|cox-2|dogs (l_compound) cox-2_27\NN\14737847|
T6_T22 NONE carprofen_21\NN\1740| (r_conj) acid_19\NN\14818238|tolfenamic|and|carprofen (r_nsubj) appeared_23\VBD\2604760|acid|also|inhibitors (r_dep) conclusions_0\NNS\5837957|and|relevance|:|inhibited|;|appeared (l_dep) inhibited_9\VBN\2510337|cox-2|was|selectively|etodolac (l_nsubjpass) cox-2_6\NN\14737847|canine
T6_T23 CPR:4 carprofen_21\NN\1740| (r_conj) acid_19\NN\14818238|tolfenamic|and|carprofen (r_nsubj) appeared_23\VBD\2604760|acid|also|inhibitors (l_xcomp) inhibitors_28\NNS\20090|to|be|preferential|cox-2|dogs (l_compound) cox-2_27\NN\14737847|
16973729
T3_T6 NONE glucose_15\NN\14710501| (r_compound) tolerance_16\NN\5032565|impaired|glucose (r_conj) obesity_12\NN\4999401|to|late-onset|and|tolerance (r_nmod) leads_9\VBZ\1752884|which|obesity (r_advcl) consume_4\VBP\1168468|mice|food|,|leads|. (l_nsubj) mice_3\NNS\2329401|5-ht2c|receptor|mutant (l_compound) 5-ht2c_0\NN\1740|
T1_T7 NONE m-chlorophenylpiperazine_2\NN\1740|of|and|fenfluramine|,|induce|, (l_acl:relcl) induce_9\VBP\1627355|both|effects|receptors (l_nmod) receptors_14\NNS\5225602|via|5-ht2c|and/or|receptors (l_compound) 5-ht2c_13\NN\1740|
T1_T8 NONE m-chlorophenylpiperazine_2\NN\1740|of|and|fenfluramine|,|induce|, (l_acl:relcl) induce_9\VBP\1627355|both|effects|receptors (l_nmod) receptors_14\NNS\5225602|via|5-ht2c|and/or|receptors (l_conj) receptors_17\NNS\5225602|5-ht1b (l_compound) 5-ht1b_16\NN\1740|
T2_T7 NONE fenfluramine_4\NN\1740| (r_conj) m-chlorophenylpiperazine_2\NN\1740|of|and|fenfluramine|,|induce|, (l_acl:relcl) induce_9\VBP\1627355|both|effects|receptors (l_nmod) receptors_14\NNS\5225602|via|5-ht2c|and/or|receptors (l_compound) 5-ht2c_13\NN\1740|
T2_T8 NONE fenfluramine_4\NN\1740| (r_conj) m-chlorophenylpiperazine_2\NN\1740|of|and|fenfluramine|,|induce|, (l_acl:relcl) induce_9\VBP\1627355|both|effects|receptors (l_nmod) receptors_14\NNS\5225602|via|5-ht2c|and/or|receptors (l_conj) receptors_17\NNS\5225602|5-ht1b (l_compound) 5-ht1b_16\NN\1740|
23523780
T1_T10 NONE )_20\-RRB-\1740| (r_punct) currents_21\NNS\11449002|presynaptic|ca(2|+|) (r_amod) potentials_25\NNS\14481929|currents|postsynaptic (r_dobj) affect_16\VB\126264|to|potentials (r_xcomp) shown_14\VBN\2137132|has|been|affect (r_conj) blocker_10\NN\10101634|ω-agatoxin-iva|is|a|known|p/q-type|ca(2|+|)|channel|and|shown|. (l_compound) channel_9\NN\6251781|
T1_T5 NONE )_20\-RRB-\1740| (r_punct) currents_21\NNS\11449002|presynaptic|ca(2|+|) (r_amod) potentials_25\NNS\14481929|currents|postsynaptic (r_dobj) affect_16\VB\126264|to|potentials (r_xcomp) shown_14\VBN\2137132|has|been|affect (r_conj) blocker_10\NN\10101634|ω-agatoxin-iva|is|a|known|p/q-type|ca(2|+|)|channel|and|shown|. (l_nsubj) ω-agatoxin-iva_0\NN\1740|
T4_T10 NONE )_8\-RRB-\1740| (r_punct) blocker_10\NN\10101634|ω-agatoxin-iva|is|a|known|p/q-type|ca(2|+|)|channel|and|shown|. (l_compound) channel_9\NN\6251781|
T4_T5 NONE )_8\-RRB-\1740| (r_punct) blocker_10\NN\10101634|ω-agatoxin-iva|is|a|known|p/q-type|ca(2|+|)|channel|and|shown|. (l_nsubj) ω-agatoxin-iva_0\NN\1740|
T3_T9 NONE )_5\-RRB-\1740| (r_punct) channels_6\NNS\6251781|p/q-type|voltage|gated|ca(2|+|)
T2_T6 CPR:4 bicuculline_2\NN\1740|of|,|inhibitor|, (l_appos) inhibitor_6\NN\20090|a|gabaa (l_compound) gabaa_5\NN\1740|
T2_T7 CPR:4 bicuculline_2\NN\1740|of|,|inhibitor|, (r_nmod) administration_0\NN\1133281|bicuculline (r_nsubj) isolated_8\VBD\2512305|administration|response|. (l_dobj) response_11\NN\11410625|a|single|ω-agatoxin|,|characterized (l_nmod) ω-agatoxin_13\NN\1740|to
16018973
T6_T16 NONE niacin_0\NN\15090742| (r_nsubj) mediates_1\VBZ\761713|niacin|lipolysis|tissue|receptor|. (l_nmod) receptor_10\NN\5225602|through|its|g-protein|coupled|hm74a (l_dep) hm74a_11\NN\1740|
T2_T9 NONE niacin_5\NN\15090742|to|acid (r_nmod) receptor_3\NN\5225602|a|g-protein|coupled|niacin
T3_T9 NONE acid_8\NN\14818238|(|nicotinic|) (r_appos) niacin_5\NN\15090742|to|acid (r_nmod) receptor_3\NN\5225602|a|g-protein|coupled|niacin
T1_T10 CPR:3 niacin_14\NN\15090742| (r_dobj) binds_13\VBZ\1290422|that|hm74a|niacin|affinities|and|mediates (l_conj) mediates_20\VBZ\761713|effectively|events (l_dobj) events_23\NNS\23100|gi|signaling|cells (l_compound) gi_21\NN\13634615|
T1_T11 NONE niacin_14\NN\15090742| (r_dobj) binds_13\VBZ\1290422|that|hm74a|niacin|affinities|and|mediates (l_conj) mediates_20\VBZ\761713|effectively|events (l_dobj) events_23\NNS\23100|gi|signaling|cells (l_nmod) cells_29\NNS\3080309|in|human|embryonic|kidney|hek293|as|adipocytes (l_conj) adipocytes_35\NNS\1740|in|3t3l1|expressing (l_acl) expressing_36\VBG\928630|hm74a (l_dobj) hm74a_37\NN\1740|
T1_T7 NONE niacin_14\NN\15090742| (r_dobj) binds_13\VBZ\1290422|that|hm74a|niacin|affinities|and|mediates (l_nsubj) hm74a_7\NN\1740|,|not|hm74|,
T1_T8 NONE niacin_14\NN\15090742| (r_dobj) binds_13\VBZ\1290422|that|hm74a|niacin|affinities|and|mediates (l_nsubj) hm74a_7\NN\1740|,|not|hm74|, (l_conj) hm74_11\NN\1740|
T4_T12 NONE niacin_19\NN\15090742|by (r_nmod) inhibition_15\NN\1068773|lipolysis|niacin (r_dobj) mediated_14\VBD\761713|furthermore|,|hm74a|effectively|inhibition|. (l_nsubj) hm74a_2\NN\1740|,|not|hm74|,|expressed
T4_T13 NONE niacin_19\NN\15090742|by (r_nmod) inhibition_15\NN\1068773|lipolysis|niacin (r_dobj) mediated_14\VBD\761713|furthermore|,|hm74a|effectively|inhibition|. (l_nsubj) hm74a_2\NN\1740|,|not|hm74|,|expressed (l_conj) hm74_6\NN\1740|
T5_T14 NONE niacin_20\NN\15090742|of (r_nmod) effect_18\NN\34213|anti-lipolytic|niacin|tissue (r_dobj) mediate_16\VB\761713|to|effect (r_xcomp) sufficient_14\JJ\1740|that|hm74a|was|mediate (l_nsubj) hm74a_7\NN\1740|,|not|hm74|,
T5_T15 NONE niacin_20\NN\15090742|of (r_nmod) effect_18\NN\34213|anti-lipolytic|niacin|tissue (r_dobj) mediate_16\VB\761713|to|effect (r_xcomp) sufficient_14\JJ\1740|that|hm74a|was|mediate (l_nsubj) hm74a_7\NN\1740|,|not|hm74|, (l_conj) hm74_11\NN\1740|
15325927
T7_T14 NONE carvedilol_2\NN\2832168|of (r_nmod) effects_0\NNS\13245626|carvedilol|concentration|. (l_nmod) concentration_8\NN\4916342|on|plasma|peptide|and|symptoms (l_compound) peptide_7\NN\14724264|b-type|natriuretic
T6_T11 CPR:4 carvedilol_6\NN\2832168| (r_nsubj) improved_8\VBD\126264|months|,|carvedilol|significantly|points|concentration|. (l_dep) concentration_14\NN\4916342|(|plasma|peptide|209|106|pg/ml|,|p|;|class|,|<|;|capacity|,|whereas|did|concentration|capacity (l_nmod) peptide_18\NN\14724264|of|b-type|natriuretic|bnp
T6_T12 CPR:4 carvedilol_6\NN\2832168| (r_nsubj) improved_8\VBD\126264|months|,|carvedilol|significantly|points|concentration|. (l_dep) concentration_14\NN\4916342|(|plasma|peptide|209|106|pg/ml|,|p|;|class|,|<|;|capacity|,|whereas|did|concentration|capacity (l_nmod) peptide_18\NN\14724264|of|b-type|natriuretic|bnp (l_appos) bnp_20\NN\1740|[|]
T6_T13 NONE carvedilol_6\NN\2832168| (r_nsubj) improved_8\VBD\126264|months|,|carvedilol|significantly|points|concentration|. (l_dep) concentration_14\NN\4916342|(|plasma|peptide|209|106|pg/ml|,|p|;|class|,|<|;|capacity|,|whereas|did|concentration|capacity (l_dep) concentration_111\NN\4916342|(|plasma|bnp|186|248|pg/ml|;|class|; (l_compound) bnp_110\NN\1740|
T1_T8 CPR:4 carvedilol_9\NN\2832168|of (r_nmod) use_7\NN\407535|only|the|carvedilol (r_nsubjpass) correlated_11\VBN\2657219|that|use|was|decrease|p (l_nmod) decrease_14\NN\7296428|with|the|concentration (l_nmod) concentration_18\NN\4916342|in|plasma|bnp (l_compound) bnp_17\NN\1740|
T2_T10 NONE carvedilol_39\NN\2832168|of|p|baseline (r_nmod) use_37\NN\407535|carvedilol (r_conj) cause_6\NN\7323922|an|ischemic|failure|p|,|concentration|,|dilation|,|and|use (r_nsubj) predictive_48\JJ\1740|that|cause|were|decrease (l_nmod) decrease_51\NN\7296428|of|a|concentration (l_nmod) concentration_54\NN\4916342|in|plasma|bnp (l_nmod) bnp_56\NN\1740|of
T2_T9 NONE carvedilol_39\NN\2832168|of|p|baseline (r_nmod) use_37\NN\407535|carvedilol (r_conj) cause_6\NN\7323922|an|ischemic|failure|p|,|concentration|,|dilation|,|and|use (l_conj) concentration_18\NN\4916342|high|plasma|bnp|p (l_nmod) bnp_20\NN\1740|of
23274086
T1_T9 NONE glucose_20\NN\14710501| (r_compound) carbon_21\NN\14622893|of|glucose (r_nmod) allocation_18\NN\13285176|increased|carbon|lipids (r_conj) glycolysis_15\NN\13514314|to|aerobic|,|allocation (r_nmod) shift_12\NN\7446404|a|metabolic|glycolysis|,|and|accumulation (r_dobj) promotes_9\VBZ\2556126|inactivation|shift|. (l_nsubj) inactivation_0\NN\13518963|ampkα|cells (l_nmod) ampkα_2\NN\1740|of
T2_T9 NONE carbon_21\NN\14622893|of|glucose (r_nmod) allocation_18\NN\13285176|increased|carbon|lipids (r_conj) glycolysis_15\NN\13514314|to|aerobic|,|allocation (r_nmod) shift_12\NN\7446404|a|metabolic|glycolysis|,|and|accumulation (r_dobj) promotes_9\VBZ\2556126|inactivation|shift|. (l_nsubj) inactivation_0\NN\13518963|ampkα|cells (l_nmod) ampkα_2\NN\1740|of
15694653
T10_T12 NONE dopamine_8\NN\14807737| (r_compound) receptor_10\NN\5225602|with|the|dopamine|d2
T1_T11 NONE haloperidol_20\NN\3713736|and|loxapine (r_dep) antipsychotics_19\NNS\4470232|the|typical|haloperidol|,|and|antipsychotics (r_conj) dopamine_15\NN\14807737|of|,|antipsychotics (r_nmod) interactions_13\NNS\37396|the|receptor|dopamine (r_dobj) study_10\VB\630380|to|interactions (r_xcomp) used_8\VBN\1156834|model|was|study|. (l_nsubjpass) model_1\NN\5888929|a|receptor (l_nmod) receptor_6\NN\5225602|of|the|dopamine|d2
T2_T11 NONE loxapine_22\NN\3713736| (r_conj) haloperidol_20\NN\3713736|and|loxapine (r_dep) antipsychotics_19\NNS\4470232|the|typical|haloperidol|,|and|antipsychotics (r_conj) dopamine_15\NN\14807737|of|,|antipsychotics (r_nmod) interactions_13\NNS\37396|the|receptor|dopamine (r_dobj) study_10\VB\630380|to|interactions (r_xcomp) used_8\VBN\1156834|model|was|study|. (l_nsubjpass) model_1\NN\5888929|a|receptor (l_nmod) receptor_6\NN\5225602|of|the|dopamine|d2
T3_T11 NONE dopamine_4\NN\14807737| (r_compound) receptor_6\NN\5225602|of|the|dopamine|d2
T4_T11 NONE clozapine_28\NN\3713736|and|melperone (r_dep) antipsychotics_27\NNS\4470232|the|atypical|clozapine (r_conj) antipsychotics_19\NNS\4470232|the|typical|haloperidol|,|and|antipsychotics (r_conj) dopamine_15\NN\14807737|of|,|antipsychotics (r_nmod) interactions_13\NNS\37396|the|receptor|dopamine (r_dobj) study_10\VB\630380|to|interactions (r_xcomp) used_8\VBN\1156834|model|was|study|. (l_nsubjpass) model_1\NN\5888929|a|receptor (l_nmod) receptor_6\NN\5225602|of|the|dopamine|d2
T5_T11 NONE melperone_30\NN\1740| (r_conj) clozapine_28\NN\3713736|and|melperone (r_dep) antipsychotics_27\NNS\4470232|the|atypical|clozapine (r_conj) antipsychotics_19\NNS\4470232|the|typical|haloperidol|,|and|antipsychotics (r_conj) dopamine_15\NN\14807737|of|,|antipsychotics (r_nmod) interactions_13\NNS\37396|the|receptor|dopamine (r_dobj) study_10\VB\630380|to|interactions (r_xcomp) used_8\VBN\1156834|model|was|study|. (l_nsubjpass) model_1\NN\5888929|a|receptor (l_nmod) receptor_6\NN\5225602|of|the|dopamine|d2
T9_T11 NONE dopamine_15\NN\14807737|of|,|antipsychotics (r_nmod) interactions_13\NNS\37396|the|receptor|dopamine (r_dobj) study_10\VB\630380|to|interactions (r_xcomp) used_8\VBN\1156834|model|was|study|. (l_nsubjpass) model_1\NN\5888929|a|receptor (l_nmod) receptor_6\NN\5225602|of|the|dopamine|d2
23299080
T1_T12 NONE androstane_4\NN\1740| (r_compound) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_appos) car_7\NN\3791235|(|)
T1_T13 NONE androstane_4\NN\1740| (r_compound) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_conj) receptor_12\NN\5225602|pregnane|x|pxr
T1_T18 NONE androstane_4\NN\1740| (r_compound) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_conj) receptor_12\NN\5225602|pregnane|x|pxr (l_appos) pxr_14\NN\1740|(|)
T1_T19 NONE androstane_4\NN\1740| (r_compound) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_conj) receptor_19\NN\5225602|vitamin|d|vdr
T1_T4 NONE androstane_4\NN\1740| (r_compound) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_conj) receptor_19\NN\5225602|vitamin|d|vdr (l_appos) vdr_21\NN\1740|(|)
T1_T5 NONE androstane_4\NN\1740| (r_compound) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor
T1_T8 NONE androstane_4\NN\1740| (r_compound) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (r_dep) receptors_2\NNS\5225602|the|nuclear|receptor
T2_T12 NONE pregnane_10\NN\1740| (r_compound) receptor_12\NN\5225602|pregnane|x|pxr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_appos) car_7\NN\3791235|(|)
T2_T13 NONE pregnane_10\NN\1740| (r_compound) receptor_12\NN\5225602|pregnane|x|pxr
T2_T18 NONE pregnane_10\NN\1740| (r_compound) receptor_12\NN\5225602|pregnane|x|pxr (l_appos) pxr_14\NN\1740|(|)
T2_T19 NONE pregnane_10\NN\1740| (r_compound) receptor_12\NN\5225602|pregnane|x|pxr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_conj) receptor_19\NN\5225602|vitamin|d|vdr
T2_T4 NONE pregnane_10\NN\1740| (r_compound) receptor_12\NN\5225602|pregnane|x|pxr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_conj) receptor_19\NN\5225602|vitamin|d|vdr (l_appos) vdr_21\NN\1740|(|)
T2_T5 NONE pregnane_10\NN\1740| (r_compound) receptor_12\NN\5225602|pregnane|x|pxr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor
T2_T8 NONE pregnane_10\NN\1740| (r_compound) receptor_12\NN\5225602|pregnane|x|pxr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (r_dep) receptors_2\NNS\5225602|the|nuclear|receptor
T3_T12 NONE d_18\NN\15089472| (r_compound) receptor_19\NN\5225602|vitamin|d|vdr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_appos) car_7\NN\3791235|(|)
T3_T13 NONE d_18\NN\15089472| (r_compound) receptor_19\NN\5225602|vitamin|d|vdr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_conj) receptor_12\NN\5225602|pregnane|x|pxr
T3_T18 NONE d_18\NN\15089472| (r_compound) receptor_19\NN\5225602|vitamin|d|vdr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (l_conj) receptor_12\NN\5225602|pregnane|x|pxr (l_appos) pxr_14\NN\1740|(|)
T3_T19 NONE d_18\NN\15089472| (r_compound) receptor_19\NN\5225602|vitamin|d|vdr
T3_T4 NONE d_18\NN\15089472| (r_compound) receptor_19\NN\5225602|vitamin|d|vdr (l_appos) vdr_21\NN\1740|(|)
T3_T5 NONE d_18\NN\15089472| (r_compound) receptor_19\NN\5225602|vitamin|d|vdr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor
T3_T8 NONE d_18\NN\15089472| (r_compound) receptor_19\NN\5225602|vitamin|d|vdr (r_conj) receptor_5\NN\5225602|constitutive|androstane|car|,|receptor|and|receptor (r_dep) receptors_2\NNS\5225602|the|nuclear|receptor
23042952
T16_T40 NONE nad(+)-dependent_5\JJ\1740| (r_amod) deacetylase_7\NN\1740|nad(+)-dependent|protein (r_compound) sirt1_8\NN\1740|the|deacetylase
T16_T41 NONE nad(+)-dependent_5\JJ\1740| (r_amod) deacetylase_7\NN\1740|nad(+)-dependent|protein (r_compound) sirt1_8\NN\1740|the|deacetylase (r_dobj) activates_3\VBZ\1641914|sirt1 (r_conj) targets_1\VBZ\1151110|rsv|and|activates (r_ccomp) induces_14\VBZ\1627355|targets|;|turn|,|sirt1|mechanism|inducing|. (l_nsubj) sirt1_13\NN\1740|
T16_T42 NONE nad(+)-dependent_5\JJ\1740| (r_amod) deacetylase_7\NN\1740|nad(+)-dependent|protein (r_compound) sirt1_8\NN\1740|the|deacetylase (r_dobj) activates_3\VBZ\1641914|sirt1 (r_conj) targets_1\VBZ\1151110|rsv|and|activates (r_ccomp) induces_14\VBZ\1627355|targets|;|turn|,|sirt1|mechanism|inducing|. (l_advcl) inducing_20\VBG\1627355|by|dismutase (l_dobj) dismutase_23\NN\1740|mitochondrial|superoxide|sod2
T16_T43 NONE nad(+)-dependent_5\JJ\1740| (r_amod) deacetylase_7\NN\1740|nad(+)-dependent|protein (r_compound) sirt1_8\NN\1740|the|deacetylase (r_dobj) activates_3\VBZ\1641914|sirt1 (r_conj) targets_1\VBZ\1151110|rsv|and|activates (r_ccomp) induces_14\VBZ\1627355|targets|;|turn|,|sirt1|mechanism|inducing|. (l_advcl) inducing_20\VBG\1627355|by|dismutase (l_dobj) dismutase_23\NN\1740|mitochondrial|superoxide|sod2 (l_appos) sod2_25\NN\1740|(|)
T19_T40 NONE superoxide_22\NN\14971519| (r_compound) dismutase_23\NN\1740|mitochondrial|superoxide|sod2 (r_dobj) inducing_20\VBG\1627355|by|dismutase (r_advcl) induces_14\VBZ\1627355|targets|;|turn|,|sirt1|mechanism|inducing|. (l_ccomp) targets_1\VBZ\1151110|rsv|and|activates (l_conj) activates_3\VBZ\1641914|sirt1 (l_dobj) sirt1_8\NN\1740|the|deacetylase
T19_T41 NONE superoxide_22\NN\14971519| (r_compound) dismutase_23\NN\1740|mitochondrial|superoxide|sod2 (r_dobj) inducing_20\VBG\1627355|by|dismutase (r_advcl) induces_14\VBZ\1627355|targets|;|turn|,|sirt1|mechanism|inducing|. (l_nsubj) sirt1_13\NN\1740|
T19_T42 NONE superoxide_22\NN\14971519| (r_compound) dismutase_23\NN\1740|mitochondrial|superoxide|sod2
T19_T43 NONE superoxide_22\NN\14971519| (r_compound) dismutase_23\NN\1740|mitochondrial|superoxide|sod2 (l_appos) sod2_25\NN\1740|(|)
T8_T40 CPR:3 rsv_0\NN\1740| (r_nsubj) targets_1\VBZ\1151110|rsv|and|activates (l_conj) activates_3\VBZ\1641914|sirt1 (l_dobj) sirt1_8\NN\1740|the|deacetylase
T8_T41 CPR:3 rsv_0\NN\1740| (r_nsubj) targets_1\VBZ\1151110|rsv|and|activates (r_ccomp) induces_14\VBZ\1627355|targets|;|turn|,|sirt1|mechanism|inducing|. (l_nsubj) sirt1_13\NN\1740|
T8_T42 CPR:3 rsv_0\NN\1740| (r_nsubj) targets_1\VBZ\1151110|rsv|and|activates (r_ccomp) induces_14\VBZ\1627355|targets|;|turn|,|sirt1|mechanism|inducing|. (l_advcl) inducing_20\VBG\1627355|by|dismutase (l_dobj) dismutase_23\NN\1740|mitochondrial|superoxide|sod2
T8_T43 CPR:3 rsv_0\NN\1740| (r_nsubj) targets_1\VBZ\1151110|rsv|and|activates (r_ccomp) induces_14\VBZ\1627355|targets|;|turn|,|sirt1|mechanism|inducing|. (l_advcl) inducing_20\VBG\1627355|by|dismutase (l_dobj) dismutase_23\NN\1740|mitochondrial|superoxide|sod2 (l_appos) sod2_25\NN\1740|(|)
T2_T39 NONE rsv_24\NN\1740|as|with (r_nmod) blunted_28\VBD\224901|rsv|,|knockdown|effects|. (l_nsubj) knockdown_27\NN\1173038|sirt1 (l_compound) sirt1_26\NN\1740|
T2_T45 NONE rsv_24\NN\1740|as|with (r_nmod) blunted_28\VBD\224901|rsv|,|knockdown|effects|. (r_parataxis) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_amod) sirt1-dependent_9\JJ\1740|
T2_T46 NONE rsv_24\NN\1740|as|with (r_nmod) blunted_28\VBD\224901|rsv|,|knockdown|effects|. (r_parataxis) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_compound) h3_11\NN\1740|
T2_T47 NONE rsv_24\NN\1740|as|with (r_nmod) blunted_28\VBD\224901|rsv|,|knockdown|effects|. (r_parataxis) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_conj) expression_15\NN\4679549|sod2 (l_compound) sod2_14\NN\1740|
T35_T39 NONE 4'g-rsv_2\NN\1740|,|not|3g-rsv|, (r_nsubj) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_parataxis) blunted_28\VBD\224901|rsv|,|knockdown|effects|. (l_nsubj) knockdown_27\NN\1173038|sirt1 (l_compound) sirt1_26\NN\1740|
T35_T45 CPR:3 4'g-rsv_2\NN\1740|,|not|3g-rsv|, (r_nsubj) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_amod) sirt1-dependent_9\JJ\1740|
T35_T46 NONE 4'g-rsv_2\NN\1740|,|not|3g-rsv|, (r_nsubj) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_compound) h3_11\NN\1740|
T35_T47 CPR:3 4'g-rsv_2\NN\1740|,|not|3g-rsv|, (r_nsubj) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_conj) expression_15\NN\4679549|sod2 (l_compound) sod2_14\NN\1740|
T36_T39 NONE 3g-rsv_6\NN\1740| (r_conj) 4'g-rsv_2\NN\1740|,|not|3g-rsv|, (r_nsubj) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_parataxis) blunted_28\VBD\224901|rsv|,|knockdown|effects|. (l_nsubj) knockdown_27\NN\1173038|sirt1 (l_compound) sirt1_26\NN\1740|
T36_T45 NONE 3g-rsv_6\NN\1740| (r_conj) 4'g-rsv_2\NN\1740|,|not|3g-rsv|, (r_nsubj) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_amod) sirt1-dependent_9\JJ\1740|
T36_T46 NONE 3g-rsv_6\NN\1740| (r_conj) 4'g-rsv_2\NN\1740|,|not|3g-rsv|, (r_nsubj) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_compound) h3_11\NN\1740|
T36_T47 NONE 3g-rsv_6\NN\1740| (r_conj) 4'g-rsv_2\NN\1740|,|not|3g-rsv|, (r_nsubj) induced_8\VBD\1627355|however|,|4'g-rsv|deacetylation|;|blunted (l_dobj) deacetylation_12\NN\1740|sirt1-dependent|histone|h3|and|expression|myoblasts (l_conj) expression_15\NN\4679549|sod2 (l_compound) sod2_14\NN\1740|
23455312
T21_T37 NONE cholane_7\NN\1740| (r_compound) site_9\NN\8673395|of|the|cholane|steroid-recognition|β1-subunit (l_nmod) β1-subunit_14\NN\1740|in|the|bk|channel
T22_T37 NONE steroid-recognition_8\JJ\1740| (r_amod) site_9\NN\8673395|of|the|cholane|steroid-recognition|β1-subunit (l_nmod) β1-subunit_14\NN\1740|in|the|bk|channel
T10_T34 NONE )_3\-RRB-\1740| (r_punct) subunit_11\NN\13604718|the|ca(2+)/voltage-gated|k(+|)|conductance|(|bk|)|channel|β1 (l_nummod) β1_10\NN\1740|
T14_T34 NONE ca(2+)/voltage-gated_1\JJ\1740| (r_amod) subunit_11\NN\13604718|the|ca(2+)/voltage-gated|k(+|)|conductance|(|bk|)|channel|β1 (l_nummod) β1_10\NN\1740|
T11_T32 NONE acid_4\NN\14818238|the|endogenous|steroid|lithocholic|lca (r_nsubj) dilates_8\VBZ\303465|acid|arteries|activation|. (l_nmod) activation_14\NN\13561719|via|bk|channel|,|requires (l_compound) channel_13\NN\6251781|
T11_T33 NONE acid_4\NN\14818238|the|endogenous|steroid|lithocholic|lca (r_nsubj) dilates_8\VBZ\303465|acid|arteries|activation|. (l_nmod) activation_14\NN\13561719|via|bk|channel|,|requires (l_acl:relcl) requires_17\VBZ\754942|which|recognition (l_dobj) recognition_18\NN\13932421|site (l_nmod) site_23\NN\8673395|by|a|bk|β1|includes (l_compound) β1_22\NN\1740|
T12_T32 NONE lca_6\NN\1740|(|) (r_appos) acid_4\NN\14818238|the|endogenous|steroid|lithocholic|lca (r_nsubj) dilates_8\VBZ\303465|acid|arteries|activation|. (l_nmod) activation_14\NN\13561719|via|bk|channel|,|requires (l_compound) channel_13\NN\6251781|
T12_T33 NONE lca_6\NN\1740|(|) (r_appos) acid_4\NN\14818238|the|endogenous|steroid|lithocholic|lca (r_nsubj) dilates_8\VBZ\303465|acid|arteries|activation|. (l_nmod) activation_14\NN\13561719|via|bk|channel|,|requires (l_acl:relcl) requires_17\VBZ\754942|which|recognition (l_dobj) recognition_18\NN\13932421|site (l_nmod) site_23\NN\8673395|by|a|bk|β1|includes (l_compound) β1_22\NN\1740|
T13_T32 NONE thr169_26\NN\1740| (r_dobj) includes_25\VBZ\690614|that|thr169 (r_acl:relcl) site_23\NN\8673395|by|a|bk|β1|includes (r_nmod) recognition_18\NN\13932421|site (r_dobj) requires_17\VBZ\754942|which|recognition (r_acl:relcl) activation_14\NN\13561719|via|bk|channel|,|requires (l_compound) channel_13\NN\6251781|
T13_T33 NONE thr169_26\NN\1740| (r_dobj) includes_25\VBZ\690614|that|thr169 (r_acl:relcl) site_23\NN\8673395|by|a|bk|β1|includes (l_compound) β1_22\NN\1740|
T9_T32 NONE steroid_2\NN\14727670| (r_compound) acid_4\NN\14818238|the|endogenous|steroid|lithocholic|lca (r_nsubj) dilates_8\VBZ\303465|acid|arteries|activation|. (l_nmod) activation_14\NN\13561719|via|bk|channel|,|requires (l_compound) channel_13\NN\6251781|
T9_T33 NONE steroid_2\NN\14727670| (r_compound) acid_4\NN\14818238|the|endogenous|steroid|lithocholic|lca (r_nsubj) dilates_8\VBZ\303465|acid|arteries|activation|. (l_nmod) activation_14\NN\13561719|via|bk|channel|,|requires (l_acl:relcl) requires_17\VBZ\754942|which|recognition (l_dobj) recognition_18\NN\13932421|site (l_nmod) site_23\NN\8673395|by|a|bk|β1|includes (l_compound) β1_22\NN\1740|
T18_T36 CPR:3 hena_0\NN\1740| (r_nsubj) activated_1\VBD\1641914|hena|channels|potency|. (l_dobj) channels_9\NNS\6251781|the|cbv1|cloned
T19_T36 CPR:3 lca_39\NN\1740|of (r_nmod) that_37\DT\1740|than|lca (r_nmod) greater_35\JJR\1740|significantly|that (r_amod) efficacy_29\NN\5199286|an|potentiation|greater (r_conj) potency_18\NN\5196375|with|a|ec50|and|efficacy (r_nmod) activated_1\VBD\1641914|hena|channels|potency|. (l_dobj) channels_9\NNS\6251781|the|cbv1|cloned
T1_T23 CPR:3 hena_0\NN\1740| (r_nsubj) failed_1\VBD\1798936|hena|activate|,|indicating|. (l_advcl) indicating_19\VBG\952524|targets (l_ccomp) targets_24\VBZ\1151110|that|drug|selectively|channels|site (l_dobj) channels_27\NNS\6251781|β1-containing|bk
T1_T24 NONE hena_0\NN\1740| (r_nsubj) failed_1\VBD\1798936|hena|activate|,|indicating|. (l_advcl) indicating_19\VBG\952524|targets (l_ccomp) targets_24\VBZ\1151110|that|drug|selectively|channels|site (l_nmod) site_33\NN\8673395|via|the|bk|β1|steroid-sensing (l_compound) β1_31\NN\1740|
T2_T23 NONE steroid-sensing_32\JJ\1740| (r_amod) site_33\NN\8673395|via|the|bk|β1|steroid-sensing (r_nmod) targets_24\VBZ\1151110|that|drug|selectively|channels|site (l_dobj) channels_27\NNS\6251781|β1-containing|bk
T2_T24 NONE steroid-sensing_32\JJ\1740| (r_amod) site_33\NN\8673395|via|the|bk|β1|steroid-sensing (l_compound) β1_31\NN\1740|
T5_T25 NONE hena_0\NN\1740| (r_nsubj) failed_1\VBD\1798936|hena|dilate|,|underscoring|. (l_xcomp) dilate_3\VB\303465|to|arteries (l_dobj) arteries_5\NNS\5417975|the|mouse (l_nmod) mouse_10\NN\2329401|from|the|kcnmb1|knockout (l_compound) kcnmb1_8\NN\1740|
T5_T26 NONE hena_0\NN\1740| (r_nsubj) failed_1\VBD\1798936|hena|dilate|,|underscoring|. (l_advcl) underscoring_12\VBG\1013367|role (l_dobj) role_16\NN\719494|β1|action (l_nmod:poss) β1_14\NN\1740|bk|'s
T6_T25 NONE hena_18\NN\1740| (r_compound) action_19\NN\30358|in|hena (r_nmod) role_16\NN\719494|β1|action (r_dobj) underscoring_12\VBG\1013367|role (r_advcl) failed_1\VBD\1798936|hena|dilate|,|underscoring|. (l_xcomp) dilate_3\VB\303465|to|arteries (l_dobj) arteries_5\NNS\5417975|the|mouse (l_nmod) mouse_10\NN\2329401|from|the|kcnmb1|knockout (l_compound) kcnmb1_8\NN\1740|
T6_T26 NONE hena_18\NN\1740| (r_compound) action_19\NN\30358|in|hena (r_nmod) role_16\NN\719494|β1|action (l_nmod:poss) β1_14\NN\1740|bk|'s
T7_T28 NONE hena_5\NN\1740|of|μm (r_nmod) artery-infusion_3\NN\1740|carotid|hena (r_nsubj) dilated_10\VBD\303465|finally|,|artery-infusion|arterioles|targeting|. (l_nmod) targeting_18\NN\1740|via|selective|bk-channel (l_amod) bk-channel_17\NN\1740|
T8_T29 NONE steroid-sensing_22\JJ\1740| (r_amod) site_23\NN\8673395|the|steroid-sensing|β1 (r_dobj) targeting_20\VBG\1151110|by|site|,|rendering (r_advcl) activates_15\VBZ\1641914|that|selectively|channels|targeting (l_dobj) channels_18\NNS\6251781|β1-containing|bk
T8_T31 NONE steroid-sensing_22\JJ\1740| (r_amod) site_23\NN\8673395|the|steroid-sensing|β1 (l_nmod) β1_26\NN\1740|in|bk
23261757
T6_T11 CPR:3 gentamicin_16\NN\2716866| (r_compound) nephrotoxicity_17\NN\1740|to|gentamicin (r_nmod) sensitization_14\NN\14531772|with|chronic|nephrotoxicity|rats (r_nmod) correlates_11\VBZ\2657219|excretion|sensitization|. (l_nsubj) excretion_2\NN\13466586|increased|urinary|albumin (l_nmod) albumin_4\NN\14736972|of|,|hemopexin|,|transferrin|and|vdbp
T6_T12 CPR:3 gentamicin_16\NN\2716866| (r_compound) nephrotoxicity_17\NN\1740|to|gentamicin (r_nmod) sensitization_14\NN\14531772|with|chronic|nephrotoxicity|rats (r_nmod) correlates_11\VBZ\2657219|excretion|sensitization|. (l_nsubj) excretion_2\NN\13466586|increased|urinary|albumin (l_nmod) albumin_4\NN\14736972|of|,|hemopexin|,|transferrin|and|vdbp (l_conj) hemopexin_6\NN\1740|
T6_T13 CPR:3 gentamicin_16\NN\2716866| (r_compound) nephrotoxicity_17\NN\1740|to|gentamicin (r_nmod) sensitization_14\NN\14531772|with|chronic|nephrotoxicity|rats (r_nmod) correlates_11\VBZ\2657219|excretion|sensitization|. (l_nsubj) excretion_2\NN\13466586|increased|urinary|albumin (l_nmod) albumin_4\NN\14736972|of|,|hemopexin|,|transferrin|and|vdbp (l_conj) transferrin_8\NN\15022171|
T6_T14 CPR:3 gentamicin_16\NN\2716866| (r_compound) nephrotoxicity_17\NN\1740|to|gentamicin (r_nmod) sensitization_14\NN\14531772|with|chronic|nephrotoxicity|rats (r_nmod) correlates_11\VBZ\2657219|excretion|sensitization|. (l_nsubj) excretion_2\NN\13466586|increased|urinary|albumin (l_nmod) albumin_4\NN\14736972|of|,|hemopexin|,|transferrin|and|vdbp (l_conj) vdbp_10\NN\1740|
T1_T10 NONE d_11\NN\15089472| (r_compound) protein_13\NN\14944888|vitamin|d|binding
T1_T7 NONE d_11\NN\15089472| (r_compound) protein_13\NN\14944888|vitamin|d|binding (r_conj) albumin_4\NN\14736972|namely|,|hemopexin|,|transferrin|and|protein
T1_T8 NONE d_11\NN\15089472| (r_compound) protein_13\NN\14944888|vitamin|d|binding (r_conj) albumin_4\NN\14736972|namely|,|hemopexin|,|transferrin|and|protein (l_conj) hemopexin_6\NN\1740|
T1_T9 NONE d_11\NN\15089472| (r_compound) protein_13\NN\14944888|vitamin|d|binding (r_conj) albumin_4\NN\14736972|namely|,|hemopexin|,|transferrin|and|protein (l_conj) transferrin_8\NN\15022171|
9631585
T5_T12 CPR:4 etoposide_17\NN\1740|and|mitoxantrone (r_appos) inhibitors_15\NNS\20090|with|dna-topoisomerase|ii|,|etoposide|,|and|agent (l_nummod) ii_14\CD\13741022|
T6_T12 CPR:4 mitoxantrone_19\NN\1740| (r_conj) etoposide_17\NN\1740|and|mitoxantrone (r_appos) inhibitors_15\NNS\20090|with|dna-topoisomerase|ii|,|etoposide|,|and|agent (l_nummod) ii_14\CD\13741022|
T7_T12 NONE cyclophosphamide_26\NN\1740| (r_appos) agent_24\NN\7347|the|alkylating|,|cyclophosphamide (r_conj) inhibitors_15\NNS\20090|with|dna-topoisomerase|ii|,|etoposide|,|and|agent (l_nummod) ii_14\CD\13741022|
T1_T8 CPR:4 etoposide_25\NN\1740|and|mitoxantrone (r_appos) inhibitors_23\NNS\20090|with|dna-topoisomerase|ii|,|etoposide|,|and|agent (l_nummod) ii_22\CD\13741022|
T2_T8 CPR:4 mitoxantrone_27\NN\1740| (r_conj) etoposide_25\NN\1740|and|mitoxantrone (r_appos) inhibitors_23\NNS\20090|with|dna-topoisomerase|ii|,|etoposide|,|and|agent (l_nummod) ii_22\CD\13741022|
T3_T8 NONE cyclophosphamide_34\NN\1740| (r_appos) agent_32\NN\7347|an|alkylating|,|cyclophosphamide (r_conj) inhibitors_23\NNS\20090|with|dna-topoisomerase|ii|,|etoposide|,|and|agent (l_nummod) ii_22\CD\13741022|
23233034
19472276
T4_T11 CPR:9 acetylthiocholine_10\NN\1740|of (r_nmod) hydrolysis_8\NN\13447361|of|the|acetylthiocholine|ph (r_nmod) reaction_5\NN\13446390|of|the|enzymatic|hydrolysis|presence (l_nmod) presence_16\NN\13954253|in|the|ache (l_nmod) ache_18\NN\14322699|of|and|inhibitor
T5_T11 NONE thiocholine_37\NN\1740|tch (r_dep) product_36\NN\3076708|of|the|reaction|thiocholine (r_nmod) area_32\NN\8630985|the|peak|product (r_dobj) measuring_26\VBG\697589|by|nm|area (r_advcl) determined_24\VBN\1645601|progress|is|measuring|. (l_nsubjpass) progress_1\NN\250259|the|reaction (l_nmod) reaction_5\NN\13446390|of|the|enzymatic|hydrolysis|presence (l_nmod) presence_16\NN\13954253|in|the|ache (l_nmod) ache_18\NN\14322699|of|and|inhibitor
T6_T12 NONE borate-phosphate_12\NN\1740| (r_compound) buffer_13\NN\14818238|with|mm|borate-phosphate|ph (r_nmod) filled_8\VBN\126264|method|capillary|was|first|buffer|and|subsequently|injected (l_parataxis) injected_59\VBN\81072|,|plugs|were|hydrodynamically|capillary|,|and|allowed|. (l_nsubjpass) plugs_21\NNS\2853449|water (l_nmod) water_27\NN\14618834|of|i|,|solution|,|solution|,|solution|,|and|water|, (l_conj) solution_33\NN\14586258|ii|ache (l_compound) ache_32\NN\14322699|
T6_T13 NONE borate-phosphate_12\NN\1740| (r_compound) buffer_13\NN\14818238|with|mm|borate-phosphate|ph (r_nmod) filled_8\VBN\126264|method|capillary|was|first|buffer|and|subsequently|injected (l_parataxis) injected_59\VBN\81072|,|plugs|were|hydrodynamically|capillary|,|and|allowed|. (l_nsubjpass) plugs_21\NNS\2853449|water (l_nmod) water_27\NN\14618834|of|i|,|solution|,|solution|,|solution|,|and|water|, (l_conj) solution_49\NN\14586258|iv|ache (l_compound) ache_48\NN\14322699|
T7_T12 NONE borate-phosphate_12\NN\1740| (r_compound) buffer_13\NN\14818238|with|mm|borate-phosphate|ph (r_nmod) filled_8\VBN\126264|method|capillary|was|first|buffer|and|subsequently|injected (l_parataxis) injected_59\VBN\81072|,|plugs|were|hydrodynamically|capillary|,|and|allowed|. (l_nsubjpass) plugs_21\NNS\2853449|water (l_nmod) water_27\NN\14618834|of|i|,|solution|,|solution|,|solution|,|and|water|, (l_conj) solution_33\NN\14586258|ii|ache (l_compound) ache_32\NN\14322699|
T7_T13 NONE borate-phosphate_12\NN\1740| (r_compound) buffer_13\NN\14818238|with|mm|borate-phosphate|ph (r_nmod) filled_8\VBN\126264|method|capillary|was|first|buffer|and|subsequently|injected (l_parataxis) injected_59\VBN\81072|,|plugs|were|hydrodynamically|capillary|,|and|allowed|. (l_nsubjpass) plugs_21\NNS\2853449|water (l_nmod) water_27\NN\14618834|of|i|,|solution|,|solution|,|solution|,|and|water|, (l_conj) solution_49\NN\14586258|iv|ache (l_compound) ache_48\NN\14322699|
1600046
T10_T23 CPR:6 zacopride_17\NN\1740| (r_conj) renzapride_15\NN\1740|tropisetron|and|zacopride (r_conj) ondansetron_10\NN\1740|including|,|granisetron|,|renzapride (r_nmod) developed_8\VBN\1753788|number|have|been|ondansetron|. (l_nsubjpass) number_1\NN\5107765|a|antagonists (l_nmod) antagonists_5\NNS\7846|of|selective|5-ht3 (l_compound) 5-ht3_4\NN\1740|
T6_T23 CPR:6 ondansetron_10\NN\1740|including|,|granisetron|,|renzapride (r_nmod) developed_8\VBN\1753788|number|have|been|ondansetron|. (l_nsubjpass) number_1\NN\5107765|a|antagonists (l_nmod) antagonists_5\NNS\7846|of|selective|5-ht3 (l_compound) 5-ht3_4\NN\1740|
T7_T23 CPR:6 granisetron_12\NN\1740| (r_conj) ondansetron_10\NN\1740|including|,|granisetron|,|renzapride (r_nmod) developed_8\VBN\1753788|number|have|been|ondansetron|. (l_nsubjpass) number_1\NN\5107765|a|antagonists (l_nmod) antagonists_5\NNS\7846|of|selective|5-ht3 (l_compound) 5-ht3_4\NN\1740|
T8_T23 CPR:6 tropisetron_14\NN\1740| (r_compound) renzapride_15\NN\1740|tropisetron|and|zacopride (r_conj) ondansetron_10\NN\1740|including|,|granisetron|,|renzapride (r_nmod) developed_8\VBN\1753788|number|have|been|ondansetron|. (l_nsubjpass) number_1\NN\5107765|a|antagonists (l_nmod) antagonists_5\NNS\7846|of|selective|5-ht3 (l_compound) 5-ht3_4\NN\1740|
T9_T23 CPR:6 renzapride_15\NN\1740|tropisetron|and|zacopride (r_conj) ondansetron_10\NN\1740|including|,|granisetron|,|renzapride (r_nmod) developed_8\VBN\1753788|number|have|been|ondansetron|. (l_nsubjpass) number_1\NN\5107765|a|antagonists (l_nmod) antagonists_5\NNS\7846|of|selective|5-ht3 (l_compound) 5-ht3_4\NN\1740|
T11_T24 CPR:4 benzamide_3\NN\1740| (r_compound) prokinetics_4\NNS\1740|the|substituted|benzamide|metoclopramide (r_nsubj) block_14\VBP\1476483|while|prokinetics|also|receptors|concentrations (l_dobj) receptors_16\NNS\5225602|5-ht3 (l_compound) 5-ht3_15\NN\1740|
T11_T25 CPR:5 benzamide_3\NN\1740| (r_compound) prokinetics_4\NNS\1740|the|substituted|benzamide|metoclopramide (r_nsubj) block_14\VBP\1476483|while|prokinetics|also|receptors|concentrations (r_advcl) believed_25\VBN\686447|block|,|action|is|to|. (l_xcomp) to_26\TO\1740|be|effects (l_nmod) effects_34\NNS\13245626|on|the|basis|of|their|agonist|receptor (l_nmod) receptor_39\NN\5225602|on|the|putative|5-ht4 (l_compound) 5-ht4_38\NN\1740|
T12_T24 CPR:4 metoclopramide_9\NN\1740|(|example|,|,|cisapride|) (r_nmod) prokinetics_4\NNS\1740|the|substituted|benzamide|metoclopramide (r_nsubj) block_14\VBP\1476483|while|prokinetics|also|receptors|concentrations (l_dobj) receptors_16\NNS\5225602|5-ht3 (l_compound) 5-ht3_15\NN\1740|
T12_T25 CPR:5 metoclopramide_9\NN\1740|(|example|,|,|cisapride|) (r_nmod) prokinetics_4\NNS\1740|the|substituted|benzamide|metoclopramide (r_nsubj) block_14\VBP\1476483|while|prokinetics|also|receptors|concentrations (r_advcl) believed_25\VBN\686447|block|,|action|is|to|. (l_xcomp) to_26\TO\1740|be|effects (l_nmod) effects_34\NNS\13245626|on|the|basis|of|their|agonist|receptor (l_nmod) receptor_39\NN\5225602|on|the|putative|5-ht4 (l_compound) 5-ht4_38\NN\1740|
T13_T24 CPR:4 cisapride_11\NN\1740| (r_appos) metoclopramide_9\NN\1740|(|example|,|,|cisapride|) (r_nmod) prokinetics_4\NNS\1740|the|substituted|benzamide|metoclopramide (r_nsubj) block_14\VBP\1476483|while|prokinetics|also|receptors|concentrations (l_dobj) receptors_16\NNS\5225602|5-ht3 (l_compound) 5-ht3_15\NN\1740|
T13_T25 CPR:5 cisapride_11\NN\1740| (r_appos) metoclopramide_9\NN\1740|(|example|,|,|cisapride|) (r_nmod) prokinetics_4\NNS\1740|the|substituted|benzamide|metoclopramide (r_nsubj) block_14\VBP\1476483|while|prokinetics|also|receptors|concentrations (r_advcl) believed_25\VBN\686447|block|,|action|is|to|. (l_xcomp) to_26\TO\1740|be|effects (l_nmod) effects_34\NNS\13245626|on|the|basis|of|their|agonist|receptor (l_nmod) receptor_39\NN\5225602|on|the|putative|5-ht4 (l_compound) 5-ht4_38\NN\1740|
T14_T19 NONE renzapride_11\NN\1740|(|example|,|,|zacopride|) (r_dep) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_conj) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (l_advcl) antagonist_36\NN\7846|while|tropisetron|is|a|5-ht4 (l_compound) 5-ht4_35\NN\1740|
T14_T26 CPR:6 renzapride_11\NN\1740|(|example|,|,|zacopride|) (r_dep) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_nsubj) antagonists_2\NNS\7846|some|5-ht3 (l_compound) 5-ht3_1\NN\1740|
T14_T27 CPR:5 renzapride_11\NN\1740|(|example|,|,|zacopride|) (r_dep) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_dobj) activity_6\NN\30358|5-ht4|agonist (l_compound) 5-ht4_4\NN\1740|
T15_T19 NONE zacopride_13\NN\1740| (r_appos) renzapride_11\NN\1740|(|example|,|,|zacopride|) (r_dep) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_conj) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (l_advcl) antagonist_36\NN\7846|while|tropisetron|is|a|5-ht4 (l_compound) 5-ht4_35\NN\1740|
T15_T26 CPR:6 zacopride_13\NN\1740| (r_appos) renzapride_11\NN\1740|(|example|,|,|zacopride|) (r_dep) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_nsubj) antagonists_2\NNS\7846|some|5-ht3 (l_compound) 5-ht3_1\NN\1740|
T15_T27 CPR:5 zacopride_13\NN\1740| (r_appos) renzapride_11\NN\1740|(|example|,|,|zacopride|) (r_dep) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_dobj) activity_6\NN\30358|5-ht4|agonist (l_compound) 5-ht4_4\NN\1740|
T16_T19 NONE ondansetron_23\NN\1740|(|example|,|,|granisetron|) (r_dep) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (l_advcl) antagonist_36\NN\7846|while|tropisetron|is|a|5-ht4 (l_compound) 5-ht4_35\NN\1740|
T16_T26 NONE ondansetron_23\NN\1740|(|example|,|,|granisetron|) (r_dep) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (r_conj) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_nsubj) antagonists_2\NNS\7846|some|5-ht3 (l_compound) 5-ht3_1\NN\1740|
T16_T27 NONE ondansetron_23\NN\1740|(|example|,|,|granisetron|) (r_dep) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (r_conj) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_dobj) activity_6\NN\30358|5-ht4|agonist (l_compound) 5-ht4_4\NN\1740|
T17_T19 NONE granisetron_25\NN\1740| (r_appos) ondansetron_23\NN\1740|(|example|,|,|granisetron|) (r_dep) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (l_advcl) antagonist_36\NN\7846|while|tropisetron|is|a|5-ht4 (l_compound) 5-ht4_35\NN\1740|
T17_T26 NONE granisetron_25\NN\1740| (r_appos) ondansetron_23\NN\1740|(|example|,|,|granisetron|) (r_dep) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (r_conj) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_nsubj) antagonists_2\NNS\7846|some|5-ht3 (l_compound) 5-ht3_1\NN\1740|
T17_T27 NONE granisetron_25\NN\1740| (r_appos) ondansetron_23\NN\1740|(|example|,|,|granisetron|) (r_dep) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (r_conj) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_dobj) activity_6\NN\30358|5-ht4|agonist (l_compound) 5-ht4_4\NN\1740|
T2_T19 CPR:6 tropisetron_29\NN\1740|concentrations (r_nsubj) antagonist_36\NN\7846|while|tropisetron|is|a|5-ht4 (l_compound) 5-ht4_35\NN\1740|
T2_T26 NONE tropisetron_29\NN\1740|concentrations (r_nsubj) antagonist_36\NN\7846|while|tropisetron|is|a|5-ht4 (r_advcl) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (r_conj) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_nsubj) antagonists_2\NNS\7846|some|5-ht3 (l_compound) 5-ht3_1\NN\1740|
T2_T27 NONE tropisetron_29\NN\1740|concentrations (r_nsubj) antagonist_36\NN\7846|while|tropisetron|is|a|5-ht4 (r_advcl) do_17\VBP\1640855|others|not|ondansetron|,|antagonist (r_conj) have_3\VBP\2108377|antagonists|activity|renzapride|and|do|. (l_dobj) activity_6\NN\30358|5-ht4|agonist (l_compound) 5-ht4_4\NN\1740|
16854582
T3_T23 NONE estrogen_3\NN\14745635| (r_compound) receptors_4\NNS\5225602|estrogen|and|kgfr|,|not|receptor
T3_T25 NONE estrogen_3\NN\14745635| (r_compound) receptors_4\NNS\5225602|estrogen|and|kgfr|,|not|receptor (l_conj) kgfr_6\NN\1740|
T3_T26 NONE estrogen_3\NN\14745635| (r_compound) receptors_4\NNS\5225602|estrogen|and|kgfr|,|not|receptor (l_conj) receptor_11\NN\5225602|androgen
T4_T23 NONE androgen_10\NN\14745635| (r_compound) receptor_11\NN\5225602|androgen (r_conj) receptors_4\NNS\5225602|estrogen|and|kgfr|,|not|receptor
T4_T25 NONE androgen_10\NN\14745635| (r_compound) receptor_11\NN\5225602|androgen (r_conj) receptors_4\NNS\5225602|estrogen|and|kgfr|,|not|receptor (l_conj) kgfr_6\NN\1740|
T4_T26 NONE androgen_10\NN\14745635| (r_compound) receptor_11\NN\5225602|androgen
T1_T10 NONE tamoxifen_5\NN\2714883|or|ici (r_nsubj) reduced_9\VBD\441445|that|tamoxifen|viability|manner|;|prevented (l_parataxis) prevented_20\VBD\1740|however|,|kgf|inhibition|,|demonstrated (l_nsubj) kgf_19\NN\1740|
T1_T11 NONE tamoxifen_5\NN\2714883|or|ici (r_nsubj) reduced_9\VBD\441445|that|tamoxifen|viability|manner|;|prevented (l_parataxis) prevented_20\VBD\1740|however|,|kgf|inhibition|,|demonstrated (l_ccomp) demonstrated_26\VBD\2137132|which|further|triggered (l_ccomp) triggered_28\VBD\1641914|kgf|machinery|activating (l_nsubj) kgf_27\NN\1740|
T1_T12 NONE tamoxifen_5\NN\2714883|or|ici (r_nsubj) reduced_9\VBD\441445|that|tamoxifen|viability|manner|;|prevented (l_parataxis) prevented_20\VBD\1740|however|,|kgf|inhibition|,|demonstrated (l_ccomp) demonstrated_26\VBD\2137132|which|further|triggered (l_ccomp) triggered_28\VBD\1641914|kgf|machinery|activating (l_advcl) activating_32\VBG\1641914|through|expression (l_dobj) expression_36\NN\4679549|bcl-2 (l_compound) bcl-2_33\NN\1740|and|phospho-akt
T1_T13 NONE tamoxifen_5\NN\2714883|or|ici (r_nsubj) reduced_9\VBD\441445|that|tamoxifen|viability|manner|;|prevented (l_parataxis) prevented_20\VBD\1740|however|,|kgf|inhibition|,|demonstrated (l_ccomp) demonstrated_26\VBD\2137132|which|further|triggered (l_ccomp) triggered_28\VBD\1641914|kgf|machinery|activating (l_advcl) activating_32\VBG\1641914|through|expression (l_dobj) expression_36\NN\4679549|bcl-2 (l_compound) bcl-2_33\NN\1740|and|phospho-akt (l_conj) phospho-akt_35\JJ\1740|
T2_T10 NONE 182,780_8\CD\1740| (r_nummod) ici_7\NN\1740|182,780 (r_conj) tamoxifen_5\NN\2714883|or|ici (r_nsubj) reduced_9\VBD\441445|that|tamoxifen|viability|manner|;|prevented (l_parataxis) prevented_20\VBD\1740|however|,|kgf|inhibition|,|demonstrated (l_nsubj) kgf_19\NN\1740|
T2_T11 NONE 182,780_8\CD\1740| (r_nummod) ici_7\NN\1740|182,780 (r_conj) tamoxifen_5\NN\2714883|or|ici (r_nsubj) reduced_9\VBD\441445|that|tamoxifen|viability|manner|;|prevented (l_parataxis) prevented_20\VBD\1740|however|,|kgf|inhibition|,|demonstrated (l_ccomp) demonstrated_26\VBD\2137132|which|further|triggered (l_ccomp) triggered_28\VBD\1641914|kgf|machinery|activating (l_nsubj) kgf_27\NN\1740|
T2_T12 NONE 182,780_8\CD\1740| (r_nummod) ici_7\NN\1740|182,780 (r_conj) tamoxifen_5\NN\2714883|or|ici (r_nsubj) reduced_9\VBD\441445|that|tamoxifen|viability|manner|;|prevented (l_parataxis) prevented_20\VBD\1740|however|,|kgf|inhibition|,|demonstrated (l_ccomp) demonstrated_26\VBD\2137132|which|further|triggered (l_ccomp) triggered_28\VBD\1641914|kgf|machinery|activating (l_advcl) activating_32\VBG\1641914|through|expression (l_dobj) expression_36\NN\4679549|bcl-2 (l_compound) bcl-2_33\NN\1740|and|phospho-akt
T2_T13 NONE 182,780_8\CD\1740| (r_nummod) ici_7\NN\1740|182,780 (r_conj) tamoxifen_5\NN\2714883|or|ici (r_nsubj) reduced_9\VBD\441445|that|tamoxifen|viability|manner|;|prevented (l_parataxis) prevented_20\VBD\1740|however|,|kgf|inhibition|,|demonstrated (l_ccomp) demonstrated_26\VBD\2137132|which|further|triggered (l_ccomp) triggered_28\VBD\1641914|kgf|machinery|activating (l_advcl) activating_32\VBG\1641914|through|expression (l_dobj) expression_36\NN\4679549|bcl-2 (l_compound) bcl-2_33\NN\1740|and|phospho-akt (l_conj) phospho-akt_35\JJ\1740|
23493372
T10_T30 NONE dexamethasone-mediated_0\JJ\1740| (r_amod) changes_1\NNS\7283608|dexamethasone-mediated|metabolism (r_nsubj) exaggerated_7\JJ\1740|changes|are|,|diminished|,|absence|. (l_nmod) absence_14\NN\14449405|in|the|domain (l_nmod) domain_20\NN\13934596|of|a|functional|gr|dimerization
T11_T30 NONE triacylglycerol_4\NN\1740| (r_compound) metabolism_5\NN\13526110|in|adipose|triacylglycerol (r_nmod) changes_1\NNS\7283608|dexamethasone-mediated|metabolism (r_nsubj) exaggerated_7\JJ\1740|changes|are|,|diminished|,|absence|. (l_nmod) absence_14\NN\14449405|in|the|domain (l_nmod) domain_20\NN\13934596|of|a|functional|gr|dimerization
T6_T26 NONE dexamethasone_39\NN\2721538|the|potent|gc|dex (r_dobj) administered_35\VBN\2436349|dexamethasone (r_acl) mice_34\NNS\2329401|in|wild-type|administered (r_nmod) using_22\VBG\1156834|labeling|mice (r_xcomp) measured_13\VBD\697589|understand|,|we|fluxes|using|. (l_advcl) understand_1\VB\588888|to|role (l_dobj) role_3\NN\719494|the|targets|tissues (l_nmod) targets_7\NNS\7258332|of|gr|dimerization-dependent (l_compound) gr_5\NN\1740|
T6_T27 NONE dexamethasone_39\NN\2721538|the|potent|gc|dex (r_dobj) administered_35\VBN\2436349|dexamethasone (r_acl) mice_34\NNS\2329401|in|wild-type|administered (l_amod) wild-type_30\JJ\1740|and|gr(dim/dim (l_conj) gr(dim/dim_32\NN\1740|)
T7_T26 NONE dex_41\NN\1740|(|) (r_appos) dexamethasone_39\NN\2721538|the|potent|gc|dex (r_dobj) administered_35\VBN\2436349|dexamethasone (r_acl) mice_34\NNS\2329401|in|wild-type|administered (r_nmod) using_22\VBG\1156834|labeling|mice (r_xcomp) measured_13\VBD\697589|understand|,|we|fluxes|using|. (l_advcl) understand_1\VB\588888|to|role (l_dobj) role_3\NN\719494|the|targets|tissues (l_nmod) targets_7\NNS\7258332|of|gr|dimerization-dependent (l_compound) gr_5\NN\1740|
T7_T27 NONE dex_41\NN\1740|(|) (r_appos) dexamethasone_39\NN\2721538|the|potent|gc|dex (r_dobj) administered_35\VBN\2436349|dexamethasone (r_acl) mice_34\NNS\2329401|in|wild-type|administered (l_amod) wild-type_30\JJ\1740|and|gr(dim/dim (l_conj) gr(dim/dim_32\NN\1740|)
T8_T28 NONE triglyceride_1\NN\14885088| (r_compound) synthesis_2\NN\13446390|absolute|triglyceride (r_nsubjpass) increased_4\VBN\169651|synthesis|was|mice|dex|depots|. (l_nmod) mice_11\NNS\2329401|in|wild-type (l_amod) wild-type_7\JJ\1740|both|and|gr(dim/dim (l_conj) gr(dim/dim_9\NN\1740|)
T9_T28 NONE dex_13\NN\1740|by (r_nmod) increased_4\VBN\169651|synthesis|was|mice|dex|depots|. (l_nmod) mice_11\NNS\2329401|in|wild-type (l_amod) wild-type_7\JJ\1740|both|and|gr(dim/dim (l_conj) gr(dim/dim_9\NN\1740|)
T1_T29 NONE dex_8\NN\1740|to (r_nmod) response_6\NN\11410625|an|exaggerated|dex (r_dobj) showed_3\VBD\2137132|mice|response|depots|. (l_nsubj) mice_2\NNS\2329401|gr(dim/dim (l_compound) gr(dim/dim_0\NN\1740|)
T2_T12 NONE dex_13\NN\1740|to (r_nmod) response_11\NN\11410625|in|dex (r_nmod) increased_6\VBN\169651|lipogenesis|was|also|greatly|depots|response|gr(dim/dim|. (l_nmod) gr(dim/dim_15\NN\1740|in|)|,|not|mice
T3_T13 NONE dex_7\NN\1740|of (r_nmod) effect_5\NN\34213|the|inhibitory|dex|rates (r_nsubj) greater_16\JJR\1740|contrast|,|effect|was|wild-type|mice|. (l_nmod) mice_23\NNS\2329401|compared|with (l_case) with_20\IN\1740|gr(dim/dim (l_dep) gr(dim/dim_21\NN\1740|)
T4_T14 NONE dex-dependent_6\JJ\1740| (r_amod) decreases_7\NNS\7296428|to|dex-dependent|sensitivity (l_nmod) sensitivity_10\NN\5651971|in|insulin (l_compound) insulin_9\NN\5407119|
T4_T15 NONE dex-dependent_6\JJ\1740| (r_amod) decreases_7\NNS\7296428|to|dex-dependent|sensitivity (r_nmod) sensitive_4\JJ\1740|mice|were|more|decreases|mice|. (l_nmod) mice_14\NNS\2329401|than|gr(dim/dim (l_compound) gr(dim/dim_12\NN\1740|)
T5_T16 NONE dex-dependent_9\JJ\1740| (r_amod) decreases_10\NNS\7296428|to|dex-dependent|synthesis (r_nmod) sensitive_7\JJ\1740|mice|were|equally|decreases|. (l_nsubj) mice_4\NNS\2329401|wild-type (l_amod) wild-type_0\NN\1740|and|gr(dim/dim (l_conj) gr(dim/dim_2\NN\1740|)
23523781
T14_T22 NONE tyrosine_20\NN\14601829| (r_compound) hydroxylase_21\NN\1740|to|tyrosine|nigra
T15_T23 NONE silver_28\NN\14821043| (r_compound) stain_29\NN\4673965|of|silver (r_nmod) uptake_26\NN\13440063|of|stain (r_nmod) absence_24\NN\14449405|by|the|uptake|or|immunolabeling (l_conj) immunolabeling_32\NN\1740|reduced|neurons (l_nmod) neurons_39\NNS\5430628|of|tyrosine-hydroxylase-positive|th(+|)|) (l_amod) tyrosine-hydroxylase-positive_34\JJ\1740|
T15_T24 NONE silver_28\NN\14821043| (r_compound) stain_29\NN\4673965|of|silver (r_nmod) uptake_26\NN\13440063|of|stain (r_nmod) absence_24\NN\14449405|by|the|uptake|or|immunolabeling (l_conj) immunolabeling_32\NN\1740|reduced|neurons (l_nmod) neurons_39\NNS\5430628|of|tyrosine-hydroxylase-positive|th(+|)|) (l_amod) th(+_36\JJ\1740|(
T16_T23 NONE tyrosine-hydroxylase-positive_34\JJ\1740|
T16_T24 NONE tyrosine-hydroxylase-positive_34\JJ\1740| (r_amod) neurons_39\NNS\5430628|of|tyrosine-hydroxylase-positive|th(+|)|) (l_amod) th(+_36\JJ\1740|(
T6_T21 NONE dopamine_35\NN\14807737| (r_compound) levels_36\NNS\4916342|of|dopamine|striatum (r_nmod) modification_33\NN\191142|by|levels (r_conj) death_30\NN\7296428|by|neuronal|cell|or|modification (r_nmod) unaccompanied_26\VBN\1740|that|occurs|,|change|is|death (l_advcl) occurs_16\VBZ\2623529|even|if|reduction|mice (l_nsubj) reduction_8\NN\351485|the|neurons|reported (l_nmod) neurons_12\NNS\5430628|in|th(+|) (l_amod) th(+_10\JJ\1740|
22447684
T9_T11 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|,
T9_T12 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) pon1_14\NN\1740|
T9_T13 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) pparg_16\NN\1740|
T9_T14 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) aldh1b1_18\NN\1740|
T9_T15 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) apoa4_20\NN\1740|
T9_T16 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) abcg5_22\NN\1740|
T9_T17 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) gpam_24\NN\1740|
T9_T18 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) acaca_26\NN\1740|
T9_T19 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) cd36_28\NN\1740|
T9_T20 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) fdft1_30\NN\1740|
T9_T21 NONE quercetin_0\NN\1740| (r_compound) supplementation_1\NN\5108947|quercetin (r_nsubj) altered_2\VBD\126264|supplementation|profiles|relative|. (l_dobj) profiles_4\NNS\6999802|expression|genes (l_nmod) genes_9\NNS\8459252|of|several|metabolism-related|,|fnta (l_nmod) fnta_12\NN\1740|including|,|pon1|,|pparg|,|aldh1b1|,|apoa4|,|abcg5|,|gpam|,|acaca|,|cd36|,|fdft1|,|and|fasn|, (l_conj) fasn_33\NN\1740|
23391443
T1_T10 NONE camp_6\NN\3763727| (r_compound) production_7\NN\30358|camp|cells (l_nmod) cells_13\NNS\3080309|in|human|t47d|breast|cancer|expressing (l_acl) expressing_14\VBG\928630|receptors (l_dobj) receptors_16\NNS\5225602|sct
1329582
T5_T18 CPR:6 2086_7\CD\1740| (r_nummod) web_6\NN\2684|of|2086|,|antagonist|, (l_appos) antagonist_16\NN\7846|a|factor|paf|)|receptor (l_compound) receptor_15\NN\5225602|
23404093
T3_T10 NONE serotonin_7\NN\14807737| (r_compound) antagonist_10\NN\7846|of|a|serotonin|5-ht3|receptor|,|dexamethasone|and|antagonist (l_compound) 5-ht3_8\NN\1740|
T3_T11 NONE serotonin_7\NN\14807737| (r_compound) antagonist_10\NN\7846|of|a|serotonin|5-ht3|receptor|,|dexamethasone|and|antagonist (l_conj) antagonist_21\NN\7846|a|neurokinin|1|nk1|)|receptor (l_compound) receptor_20\NN\5225602|
T4_T10 NONE dexamethasone_12\NN\2721538| (r_conj) antagonist_10\NN\7846|of|a|serotonin|5-ht3|receptor|,|dexamethasone|and|antagonist (l_compound) 5-ht3_8\NN\1740|
T4_T11 NONE dexamethasone_12\NN\2721538| (r_conj) antagonist_10\NN\7846|of|a|serotonin|5-ht3|receptor|,|dexamethasone|and|antagonist (l_conj) antagonist_21\NN\7846|a|neurokinin|1|nk1|)|receptor (l_compound) receptor_20\NN\5225602|
T5_T12 CPR:6 palonosetron_0\NN\1740|,|antagonist (l_appos) antagonist_6\NN\7846|a|second-generation|5-ht3|receptor|half-life (l_compound) 5-ht3_4\NN\1740|
T5_T13 NONE palonosetron_0\NN\1740|,|antagonist (l_appos) antagonist_6\NN\7846|a|second-generation|5-ht3|receptor|half-life (l_nmod) half-life_10\NN\15113229|with|a|different|,|capacity|antagonists (l_nmod) antagonists_27\NNS\7846|than|the|first-generation|receptor (l_compound) receptor_26\NN\5225602|5-ht3 (l_compound) 5-ht3_25\NN\1740|
T6_T14 CPR:6 aprepitant_0\NN\1740|,|agent (l_appos) agent_6\NN\7347|the|first|available (l_amod) available_8\JJ\1740|clinically|class (l_nmod) class_15\NN\7951464|in|the|nk1|receptor|antagonist|drug (l_compound) receptor_12\NN\5225602|
T6_T15 NONE aprepitant_0\NN\1740|,|agent (r_nsubjpass) used_18\VBN\1156834|aprepitant|has|been|effectively|agent|. (l_nmod) agent_23\NN\7347|as|an|additive|antagonists|control (l_nmod) antagonists_28\NNS\7846|to|the|5-ht3|receptor|and|dexamethasone (l_compound) 5-ht3_26\NN\1740|
T7_T14 NONE dexamethasone_30\NN\2721538| (r_conj) antagonists_28\NNS\7846|to|the|5-ht3|receptor|and|dexamethasone (r_nmod) agent_23\NN\7347|as|an|additive|antagonists|control (r_nmod) used_18\VBN\1156834|aprepitant|has|been|effectively|agent|. (l_nsubjpass) aprepitant_0\NN\1740|,|agent (l_appos) agent_6\NN\7347|the|first|available (l_amod) available_8\JJ\1740|clinically|class (l_nmod) class_15\NN\7951464|in|the|nk1|receptor|antagonist|drug (l_compound) receptor_12\NN\5225602|
T7_T15 NONE dexamethasone_30\NN\2721538| (r_conj) antagonists_28\NNS\7846|to|the|5-ht3|receptor|and|dexamethasone (l_compound) 5-ht3_26\NN\1740|
T8_T16 CPR:6 rolapitant_0\NN\1740|and|netupitant (r_nsubj) antagonists_7\NNS\7846|rolapitant|are|other|nk1|receptor|currently|. (l_compound) receptor_6\NN\5225602|
T9_T16 CPR:6 netupitant_2\NN\1740| (r_conj) rolapitant_0\NN\1740|and|netupitant (r_nsubj) antagonists_7\NNS\7846|rolapitant|are|other|nk1|receptor|currently|. (l_compound) receptor_6\NN\5225602|
15737409
T19_T37 NONE sterol_0\NN\14708720| (r_compound) transporters_1\NNS\4490091|sterol|:|targets
T20_T37 NONE sterols_6\NNS\14708720|of|natural|and|drugs (r_nmod) targets_3\NNS\7258332|sterols|. (r_dep) transporters_1\NNS\4490091|sterol|:|targets
T10_T22 NONE atp-binding_6\JJ\1740| (r_amod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (r_nmod) role_4\NN\719494|in|the|transporters|,|discovery|, (r_nmod) insights_1\NNS\5710020|recent|role|as|identification|, (l_conj) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_nummod) 1_38\CD\13741022|
T10_T23 NONE atp-binding_6\JJ\1740| (r_amod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (r_nmod) role_4\NN\719494|in|the|transporters|,|discovery|, (r_nmod) insights_1\NNS\5710020|recent|role|as|identification|, (l_conj) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_compound) npc1l1_40\NN\1740|
T10_T24 NONE atp-binding_6\JJ\1740| (r_amod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5
T10_T32 NONE atp-binding_6\JJ\1740| (r_amod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8
T10_T34 NONE atp-binding_6\JJ\1740| (r_amod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8 (l_conj) abcg8_14\NN\1740|
T2_T22 NONE ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (r_nmod) insights_1\NNS\5710020|recent|role|as|identification|, (l_conj) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_nummod) 1_38\CD\13741022|
T2_T23 NONE ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (r_nmod) insights_1\NNS\5710020|recent|role|as|identification|, (l_conj) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_compound) npc1l1_40\NN\1740|
T2_T24 NONE ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5
T2_T32 NONE ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8
T2_T34 NONE ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8 (l_conj) abcg8_14\NN\1740|
T7_T22 NONE cholesterol_25\NN\15058310| (r_compound) inhibitor_27\NN\20090|the|first|approved|direct|cholesterol|absorption (r_appos) ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (r_nmod) insights_1\NNS\5710020|recent|role|as|identification|, (l_conj) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_nummod) 1_38\CD\13741022|
T7_T23 NONE cholesterol_25\NN\15058310| (r_compound) inhibitor_27\NN\20090|the|first|approved|direct|cholesterol|absorption (r_appos) ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (r_nmod) insights_1\NNS\5710020|recent|role|as|identification|, (l_conj) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_compound) npc1l1_40\NN\1740|
T7_T24 NONE cholesterol_25\NN\15058310| (r_compound) inhibitor_27\NN\20090|the|first|approved|direct|cholesterol|absorption (r_appos) ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5
T7_T32 NONE cholesterol_25\NN\15058310| (r_compound) inhibitor_27\NN\20090|the|first|approved|direct|cholesterol|absorption (r_appos) ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8
T7_T34 NONE cholesterol_25\NN\15058310| (r_compound) inhibitor_27\NN\20090|the|first|approved|direct|cholesterol|absorption (r_appos) ezetimibe_19\NN\1740|of|,|inhibitor (r_nmod) discovery_17\NN\30358|the|ezetimibe (r_conj) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8 (l_conj) abcg8_14\NN\1740|
T8_T22 NONE sterol_44\NN\14708720| (r_compound) transporter_45\NN\4490091|as|sterol|gut (r_nmod) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_nummod) 1_38\CD\13741022|
T8_T23 NONE sterol_44\NN\14708720| (r_compound) transporter_45\NN\4490091|as|sterol|gut (r_nmod) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_compound) npc1l1_40\NN\1740|
T8_T24 NONE sterol_44\NN\14708720| (r_compound) transporter_45\NN\4490091|as|sterol|gut (r_nmod) identification_33\NN\151497|the|protein|transporter (r_conj) insights_1\NNS\5710020|recent|role|as|identification|, (l_nmod) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5
T8_T32 NONE sterol_44\NN\14708720| (r_compound) transporter_45\NN\4490091|as|sterol|gut (r_nmod) identification_33\NN\151497|the|protein|transporter (r_conj) insights_1\NNS\5710020|recent|role|as|identification|, (l_nmod) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8
T8_T34 NONE sterol_44\NN\14708720| (r_compound) transporter_45\NN\4490091|as|sterol|gut (r_nmod) identification_33\NN\151497|the|protein|transporter (r_conj) insights_1\NNS\5710020|recent|role|as|identification|, (l_nmod) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8 (l_conj) abcg8_14\NN\1740|
T9_T22 NONE sterol_53\NN\14708720| (r_compound) processes_55\NNS\407535|on|sterol|transport|intestine (r_nmod) focused_50\VBD\628491|insights|attention|processes|. (l_nsubj) insights_1\NNS\5710020|recent|role|as|identification|, (l_conj) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_nummod) 1_38\CD\13741022|
T9_T23 NONE sterol_53\NN\14708720| (r_compound) processes_55\NNS\407535|on|sterol|transport|intestine (r_nmod) focused_50\VBD\628491|insights|attention|processes|. (l_nsubj) insights_1\NNS\5710020|recent|role|as|identification|, (l_conj) identification_33\NN\151497|the|protein|transporter (l_nmod) protein_42\NN\14944888|of|niemann-pick|c1|like|1|(|npc1l1|) (l_compound) npc1l1_40\NN\1740|
T9_T24 NONE sterol_53\NN\14708720| (r_compound) processes_55\NNS\407535|on|sterol|transport|intestine (r_nmod) focused_50\VBD\628491|insights|attention|processes|. (l_nsubj) insights_1\NNS\5710020|recent|role|as|identification|, (l_nmod) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5
T9_T32 NONE sterol_53\NN\14708720| (r_compound) processes_55\NNS\407535|on|sterol|transport|intestine (r_nmod) focused_50\VBD\628491|insights|attention|processes|. (l_nsubj) insights_1\NNS\5710020|recent|role|as|identification|, (l_nmod) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8
T9_T34 NONE sterol_53\NN\14708720| (r_compound) processes_55\NNS\407535|on|sterol|transport|intestine (r_nmod) focused_50\VBD\628491|insights|attention|processes|. (l_nsubj) insights_1\NNS\5710020|recent|role|as|identification|, (l_nmod) role_4\NN\719494|in|the|transporters|,|discovery|, (l_nmod) transporters_11\NNS\4490091|of|atp-binding|cassette|(|abc|)|abcg5 (l_dep) abcg5_12\NN\1740|and|abcg8 (l_conj) abcg8_14\NN\1740|
T11_T25 NONE sterol_23\NN\14708720| (r_compound) pumps_25\NNS\3736970|as|sterol|efflux|regulating (r_nmod) role_21\NN\719494|their|pumps (r_dobj) elucidated_19\VBD\939277|identification|role|. (l_nsubj) identification_1\NN\151497|the|structures (l_nmod) structures_4\NNS\21939|of|defective|transporters (l_nmod) transporters_10\NNS\4490091|in|the|abcg5|patients (l_compound) abcg5_7\NN\1740|or|abcg8
T11_T26 NONE sterol_23\NN\14708720| (r_compound) pumps_25\NNS\3736970|as|sterol|efflux|regulating (r_nmod) role_21\NN\719494|their|pumps (r_dobj) elucidated_19\VBD\939277|identification|role|. (l_nsubj) identification_1\NN\151497|the|structures (l_nmod) structures_4\NNS\21939|of|defective|transporters (l_nmod) transporters_10\NNS\4490091|in|the|abcg5|patients (l_compound) abcg5_7\NN\1740|or|abcg8 (l_conj) abcg8_9\NN\1740|
T11_T27 NONE sterol_23\NN\14708720| (r_compound) pumps_25\NNS\3736970|as|sterol|efflux|regulating
T12_T25 NONE sterol_33\NN\14708720| (r_compound) absorption_34\NN\13558490|the|intestinal|sterol|and|output (r_dobj) regulating_26\VBG\296178|parts|absorption (r_acl) pumps_25\NNS\3736970|as|sterol|efflux|regulating (r_nmod) role_21\NN\719494|their|pumps (r_dobj) elucidated_19\VBD\939277|identification|role|. (l_nsubj) identification_1\NN\151497|the|structures (l_nmod) structures_4\NNS\21939|of|defective|transporters (l_nmod) transporters_10\NNS\4490091|in|the|abcg5|patients (l_compound) abcg5_7\NN\1740|or|abcg8
T12_T26 NONE sterol_33\NN\14708720| (r_compound) absorption_34\NN\13558490|the|intestinal|sterol|and|output (r_dobj) regulating_26\VBG\296178|parts|absorption (r_acl) pumps_25\NNS\3736970|as|sterol|efflux|regulating (r_nmod) role_21\NN\719494|their|pumps (r_dobj) elucidated_19\VBD\939277|identification|role|. (l_nsubj) identification_1\NN\151497|the|structures (l_nmod) structures_4\NNS\21939|of|defective|transporters (l_nmod) transporters_10\NNS\4490091|in|the|abcg5|patients (l_compound) abcg5_7\NN\1740|or|abcg8 (l_conj) abcg8_9\NN\1740|
T12_T27 NONE sterol_33\NN\14708720| (r_compound) absorption_34\NN\13558490|the|intestinal|sterol|and|output (r_dobj) regulating_26\VBG\296178|parts|absorption (r_acl) pumps_25\NNS\3736970|as|sterol|efflux|regulating
T13_T25 NONE sterol_38\NN\14708720| (r_compound) output_39\NN\4007894|the|hepatic|sterol (r_conj) absorption_34\NN\13558490|the|intestinal|sterol|and|output (r_dobj) regulating_26\VBG\296178|parts|absorption (r_acl) pumps_25\NNS\3736970|as|sterol|efflux|regulating (r_nmod) role_21\NN\719494|their|pumps (r_dobj) elucidated_19\VBD\939277|identification|role|. (l_nsubj) identification_1\NN\151497|the|structures (l_nmod) structures_4\NNS\21939|of|defective|transporters (l_nmod) transporters_10\NNS\4490091|in|the|abcg5|patients (l_compound) abcg5_7\NN\1740|or|abcg8
T13_T26 NONE sterol_38\NN\14708720| (r_compound) output_39\NN\4007894|the|hepatic|sterol (r_conj) absorption_34\NN\13558490|the|intestinal|sterol|and|output (r_dobj) regulating_26\VBG\296178|parts|absorption (r_acl) pumps_25\NNS\3736970|as|sterol|efflux|regulating (r_nmod) role_21\NN\719494|their|pumps (r_dobj) elucidated_19\VBD\939277|identification|role|. (l_nsubj) identification_1\NN\151497|the|structures (l_nmod) structures_4\NNS\21939|of|defective|transporters (l_nmod) transporters_10\NNS\4490091|in|the|abcg5|patients (l_compound) abcg5_7\NN\1740|or|abcg8 (l_conj) abcg8_9\NN\1740|
T13_T27 NONE sterol_38\NN\14708720| (r_compound) output_39\NN\4007894|the|hepatic|sterol (r_conj) absorption_34\NN\13558490|the|intestinal|sterol|and|output (r_dobj) regulating_26\VBG\296178|parts|absorption (r_acl) pumps_25\NNS\3736970|as|sterol|efflux|regulating
T14_T28 NONE cholesterol_7\NN\15058310|by (r_nmod) regulated_5\VBN\296178|abcg5|are|cholesterol|receptors|. (l_nsubjpass) abcg5_0\NN\1740|and|abcg8|themselves
T14_T29 NONE cholesterol_7\NN\15058310|by (r_nmod) regulated_5\VBN\296178|abcg5|are|cholesterol|receptors|. (l_nsubjpass) abcg5_0\NN\1740|and|abcg8|themselves (l_conj) abcg8_2\NN\1740|
T14_T30 NONE cholesterol_7\NN\15058310|by (r_nmod) regulated_5\VBN\296178|abcg5|are|cholesterol|receptors|. (l_nmod) receptors_11\NNS\5225602|via|liver|x|lxrs|,|activated
T14_T31 NONE cholesterol_7\NN\15058310|by (r_nmod) regulated_5\VBN\296178|abcg5|are|cholesterol|receptors|. (l_nmod) receptors_11\NNS\5225602|via|liver|x|lxrs|,|activated (l_appos) lxrs_13\NNS\1740|(|)
T15_T28 NONE sterols_27\NNS\14708720|of|plant (r_nmod) derivatives_24\NNS\5802185|some|sterols (r_conj) oxysterols_21\NNS\1740|by|and|derivatives (r_nmod) activated_19\VBN\1641914|which|are|also|oxysterols (r_acl:relcl) receptors_11\NNS\5225602|via|liver|x|lxrs|,|activated (r_nmod) regulated_5\VBN\296178|abcg5|are|cholesterol|receptors|. (l_nsubjpass) abcg5_0\NN\1740|and|abcg8|themselves
T15_T29 NONE sterols_27\NNS\14708720|of|plant (r_nmod) derivatives_24\NNS\5802185|some|sterols (r_conj) oxysterols_21\NNS\1740|by|and|derivatives (r_nmod) activated_19\VBN\1641914|which|are|also|oxysterols (r_acl:relcl) receptors_11\NNS\5225602|via|liver|x|lxrs|,|activated (r_nmod) regulated_5\VBN\296178|abcg5|are|cholesterol|receptors|. (l_nsubjpass) abcg5_0\NN\1740|and|abcg8|themselves (l_conj) abcg8_2\NN\1740|
T15_T30 NONE sterols_27\NNS\14708720|of|plant (r_nmod) derivatives_24\NNS\5802185|some|sterols (r_conj) oxysterols_21\NNS\1740|by|and|derivatives (r_nmod) activated_19\VBN\1641914|which|are|also|oxysterols (r_acl:relcl) receptors_11\NNS\5225602|via|liver|x|lxrs|,|activated
T15_T31 CPR:3 sterols_27\NNS\14708720|of|plant (r_nmod) derivatives_24\NNS\5802185|some|sterols (r_conj) oxysterols_21\NNS\1740|by|and|derivatives (r_nmod) activated_19\VBN\1641914|which|are|also|oxysterols (r_acl:relcl) receptors_11\NNS\5225602|via|liver|x|lxrs|,|activated (l_appos) lxrs_13\NNS\1740|(|)
T16_T33 NONE sterol_8\NN\14708720| (r_compound) transporter_9\NN\4490091|as|a|major|sterol|uptake (r_nmod) identified_4\VBN\699815|npc1l1|could|recently|be|transporter|. (l_nsubjpass) npc1l1_0\NN\1740|
T16_T35 NONE sterol_8\NN\14708720| (r_compound) transporter_9\NN\4490091|as|a|major|sterol|uptake
T17_T33 CPR:9 cholesterol_15\NN\15058310|of|as|sterols (r_nmod) uptake_13\NN\13440063|for|the|intestinal|cholesterol (r_nmod) transporter_9\NN\4490091|as|a|major|sterol|uptake (r_nmod) identified_4\VBN\699815|npc1l1|could|recently|be|transporter|. (l_nsubjpass) npc1l1_0\NN\1740|
T17_T35 CPR:9 cholesterol_15\NN\15058310|of|as|sterols (r_nmod) uptake_13\NN\13440063|for|the|intestinal|cholesterol (r_nmod) transporter_9\NN\4490091|as|a|major|sterol|uptake
T18_T33 CPR:9 sterols_20\NNS\14708720|plant (r_conj) cholesterol_15\NN\15058310|of|as|sterols (r_nmod) uptake_13\NN\13440063|for|the|intestinal|cholesterol (r_nmod) transporter_9\NN\4490091|as|a|major|sterol|uptake (r_nmod) identified_4\VBN\699815|npc1l1|could|recently|be|transporter|. (l_nsubjpass) npc1l1_0\NN\1740|
T18_T35 CPR:9 sterols_20\NNS\14708720|plant (r_conj) cholesterol_15\NN\15058310|of|as|sterols (r_nmod) uptake_13\NN\13440063|for|the|intestinal|cholesterol (r_nmod) transporter_9\NN\4490091|as|a|major|sterol|uptake
T1_T21 NONE sterols_16\NNS\14708720|of (r_nmod) uptake_14\NN\13440063|for|the|intestinal|sterols (r_nmod) essential_10\JJ\1740|that|transporter|is|uptake|and|involved (l_conj) involved_23\VBN\2676054|that|npc1l1|might|also|be|mechanism (l_nsubjpass) npc1l1_19\NN\1740|
T1_T36 NONE sterols_16\NNS\14708720|of (r_nmod) uptake_14\NN\13440063|for|the|intestinal|sterols (r_nmod) essential_10\JJ\1740|that|transporter|is|uptake|and|involved (r_ccomp) indicate_5\VBP\952524|studies|essential|. (l_nsubj) studies_0\NNS\635850|mice (l_nmod) mice_4\NNS\2329401|in|npc1l1|knockout (l_compound) npc1l1_2\NN\1740|
T3_T21 NONE ezetimibe_30\NN\1740|of (r_nmod) action_28\NN\30358|of|ezetimibe (r_nmod) mechanism_26\NN\13446390|in|the|action (r_nmod) involved_23\VBN\2676054|that|npc1l1|might|also|be|mechanism (l_nsubjpass) npc1l1_19\NN\1740|
T3_T36 NONE ezetimibe_30\NN\1740|of (r_nmod) action_28\NN\30358|of|ezetimibe (r_nmod) mechanism_26\NN\13446390|in|the|action (r_nmod) involved_23\VBN\2676054|that|npc1l1|might|also|be|mechanism (r_conj) essential_10\JJ\1740|that|transporter|is|uptake|and|involved (r_ccomp) indicate_5\VBP\952524|studies|essential|. (l_nsubj) studies_0\NNS\635850|mice (l_nmod) mice_4\NNS\2329401|in|npc1l1|knockout (l_compound) npc1l1_2\NN\1740|
12445705
T50_T64 NONE acetylcholine_15\NN\14807558| (r_conj) dopamine_13\NN\14807737|and|acetylcholine (r_compound) release_16\NN\3748886|dopamine (r_dobj) increase_12\VBP\169651|drugs|preferentially|release|cortex|:|role (l_dep) role_23\NN\719494|agonism (l_nmod) agonism_27\NN\1740|of|5-ht1a|receptor (l_compound) 5-ht1a_25\NN\1740|
T51_T64 NONE quetiapine_4\NN\1740|,|iloperidone|,|and|melperone (r_appos) drugs_2\NNS\14778436|atypical|antipsychotic|,|quetiapine|, (r_nsubj) increase_12\VBP\169651|drugs|preferentially|release|cortex|:|role (l_dep) role_23\NN\719494|agonism (l_nmod) agonism_27\NN\1740|of|5-ht1a|receptor (l_compound) 5-ht1a_25\NN\1740|
T52_T64 NONE iloperidone_6\NN\1740| (r_conj) quetiapine_4\NN\1740|,|iloperidone|,|and|melperone (r_appos) drugs_2\NNS\14778436|atypical|antipsychotic|,|quetiapine|, (r_nsubj) increase_12\VBP\169651|drugs|preferentially|release|cortex|:|role (l_dep) role_23\NN\719494|agonism (l_nmod) agonism_27\NN\1740|of|5-ht1a|receptor (l_compound) 5-ht1a_25\NN\1740|
T53_T64 NONE melperone_9\NN\1740| (r_conj) quetiapine_4\NN\1740|,|iloperidone|,|and|melperone (r_appos) drugs_2\NNS\14778436|atypical|antipsychotic|,|quetiapine|, (r_nsubj) increase_12\VBP\169651|drugs|preferentially|release|cortex|:|role (l_dep) role_23\NN\719494|agonism (l_nmod) agonism_27\NN\1740|of|5-ht1a|receptor (l_compound) 5-ht1a_25\NN\1740|
T54_T64 NONE dopamine_13\NN\14807737|and|acetylcholine (r_compound) release_16\NN\3748886|dopamine (r_dobj) increase_12\VBP\169651|drugs|preferentially|release|cortex|:|role (l_dep) role_23\NN\719494|agonism (l_nmod) agonism_27\NN\1740|of|5-ht1a|receptor (l_compound) 5-ht1a_25\NN\1740|
T27_T57 CPR:5 clozapine_2\NN\3713736|only|and|ziprasidone (r_nsubj) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (l_dobj) agonists_10\NNS\9613191|5-ht(1a|) (l_punct) )_9\-RRB-\1740|
T27_T58 NONE clozapine_2\NN\3713736|only|and|ziprasidone (r_nsubj) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (r_advcl) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_nsubj) way100635_12\NN\1740|,|antagonist|, (l_appos) antagonist_18\NN\7846|a|selective|5-ht(1a|) (l_punct) )_17\-RRB-\1740|
T27_T59 CPR:4 clozapine_2\NN\3713736|only|and|ziprasidone (r_nsubj) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (r_advcl) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_dobj) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (l_acl:relcl) due_33\JJ\1740|that|may|be|blockade (l_nmod) blockade_41\NN\952963|to|5-ht(2a (l_compound) 5-ht(2a_36\NN\1740|combined|)|and|d(2 (l_punct) )_37\-RRB-\1740|
T27_T60 CPR:4 clozapine_2\NN\3713736|only|and|ziprasidone (r_nsubj) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (r_advcl) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_dobj) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (l_acl:relcl) due_33\JJ\1740|that|may|be|blockade (l_nmod) blockade_41\NN\952963|to|5-ht(2a (l_compound) 5-ht(2a_36\NN\1740|combined|)|and|d(2 (l_conj) d(2_39\NN\1740|) (l_punct) )_40\-RRB-\1740|
T28_T57 CPR:5 ziprasidone_4\NN\1740| (r_conj) clozapine_2\NN\3713736|only|and|ziprasidone (r_nsubj) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (l_dobj) agonists_10\NNS\9613191|5-ht(1a|) (l_punct) )_9\-RRB-\1740|
T28_T58 NONE ziprasidone_4\NN\1740| (r_conj) clozapine_2\NN\3713736|only|and|ziprasidone (r_nsubj) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (r_advcl) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_nsubj) way100635_12\NN\1740|,|antagonist|, (l_appos) antagonist_18\NN\7846|a|selective|5-ht(1a|) (l_punct) )_17\-RRB-\1740|
T28_T59 CPR:4 ziprasidone_4\NN\1740| (r_conj) clozapine_2\NN\3713736|only|and|ziprasidone (r_nsubj) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (r_advcl) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_dobj) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (l_acl:relcl) due_33\JJ\1740|that|may|be|blockade (l_nmod) blockade_41\NN\952963|to|5-ht(2a (l_compound) 5-ht(2a_36\NN\1740|combined|)|and|d(2 (l_punct) )_37\-RRB-\1740|
T28_T60 CPR:4 ziprasidone_4\NN\1740| (r_conj) clozapine_2\NN\3713736|only|and|ziprasidone (r_nsubj) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (r_advcl) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_dobj) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (l_acl:relcl) due_33\JJ\1740|that|may|be|blockade (l_nmod) blockade_41\NN\952963|to|5-ht(2a (l_compound) 5-ht(2a_36\NN\1740|combined|)|and|d(2 (l_conj) d(2_39\NN\1740|) (l_punct) )_40\-RRB-\1740|
T29_T57 NONE way100635_12\NN\1740|,|antagonist|, (r_nsubj) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_advcl) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (l_dobj) agonists_10\NNS\9613191|5-ht(1a|) (l_punct) )_9\-RRB-\1740|
T29_T58 CPR:6 way100635_12\NN\1740|,|antagonist|, (l_appos) antagonist_18\NN\7846|a|selective|5-ht(1a|) (l_punct) )_17\-RRB-\1740|
T29_T59 CPR:4 way100635_12\NN\1740|,|antagonist|, (r_nsubj) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_dobj) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (l_acl:relcl) due_33\JJ\1740|that|may|be|blockade (l_nmod) blockade_41\NN\952963|to|5-ht(2a (l_compound) 5-ht(2a_36\NN\1740|combined|)|and|d(2 (l_punct) )_37\-RRB-\1740|
T29_T60 CPR:4 way100635_12\NN\1740|,|antagonist|, (r_nsubj) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_dobj) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (l_acl:relcl) due_33\JJ\1740|that|may|be|blockade (l_nmod) blockade_41\NN\952963|to|5-ht(2a (l_compound) 5-ht(2a_36\NN\1740|combined|)|and|d(2 (l_conj) d(2_39\NN\1740|) (l_punct) )_40\-RRB-\1740|
T31_T57 NONE da_28\NN\10484858| (r_compound) release_29\NN\3748886|in|cortical|da (r_nmod) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (r_dobj) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_advcl) acting_7\VBG\1619354|although|clozapine|are|directly|agonists (l_dobj) agonists_10\NNS\9613191|5-ht(1a|) (l_punct) )_9\-RRB-\1740|
T31_T58 NONE da_28\NN\10484858| (r_compound) release_29\NN\3748886|in|cortical|da (r_nmod) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (r_dobj) attenuates_21\VBZ\224901|acting|,|way100635|partially|increases|. (l_nsubj) way100635_12\NN\1740|,|antagonist|, (l_appos) antagonist_18\NN\7846|a|selective|5-ht(1a|) (l_punct) )_17\-RRB-\1740|
T31_T59 NONE da_28\NN\10484858| (r_compound) release_29\NN\3748886|in|cortical|da (r_nmod) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (l_acl:relcl) due_33\JJ\1740|that|may|be|blockade (l_nmod) blockade_41\NN\952963|to|5-ht(2a (l_compound) 5-ht(2a_36\NN\1740|combined|)|and|d(2 (l_punct) )_37\-RRB-\1740|
T31_T60 NONE da_28\NN\10484858| (r_compound) release_29\NN\3748886|in|cortical|da (r_nmod) increases_25\NNS\13576355|these|atypical|apd-induced|release|due (l_acl:relcl) due_33\JJ\1740|that|may|be|blockade (l_nmod) blockade_41\NN\952963|to|5-ht(2a (l_compound) 5-ht(2a_36\NN\1740|combined|)|and|d(2 (l_conj) d(2_39\NN\1740|) (l_punct) )_40\-RRB-\1740|
T37_T61 NONE quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|)
T37_T62 NONE quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|) (l_punct) )_12\-RRB-\1740|
T37_T63 NONE quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (r_nsubj) antagonist_13\NN\7846|whether|quetiapine|apds (r_advcl) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_conj) related_30\JJ\1740|whether|effects|are|agonism (l_nmod) agonism_34\NN\1740|to|5-ht(1a|) (l_punct) )_33\-RRB-\1740|
T38_T61 NONE iloperidone_7\NN\1740| (r_conj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|)
T38_T62 NONE iloperidone_7\NN\1740| (r_conj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|) (l_punct) )_12\-RRB-\1740|
T38_T63 NONE iloperidone_7\NN\1740| (r_conj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (r_nsubj) antagonist_13\NN\7846|whether|quetiapine|apds (r_advcl) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_conj) related_30\JJ\1740|whether|effects|are|agonism (l_nmod) agonism_34\NN\1740|to|5-ht(1a|) (l_punct) )_33\-RRB-\1740|
T39_T61 NONE melperone_9\NN\1740| (r_conj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|)
T39_T62 NONE melperone_9\NN\1740| (r_conj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|) (l_punct) )_12\-RRB-\1740|
T39_T63 NONE melperone_9\NN\1740| (r_conj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (r_nsubj) antagonist_13\NN\7846|whether|quetiapine|apds (r_advcl) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_conj) related_30\JJ\1740|whether|effects|are|agonism (l_nmod) agonism_34\NN\1740|to|5-ht(1a|) (l_punct) )_33\-RRB-\1740|
T40_T61 NONE da_20\NN\10484858|cortical|and|release (r_dobj) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_advcl) antagonist_13\NN\7846|whether|quetiapine|apds (l_nsubj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|)
T40_T62 NONE da_20\NN\10484858|cortical|and|release (r_dobj) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_advcl) antagonist_13\NN\7846|whether|quetiapine|apds (l_nsubj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|) (l_punct) )_12\-RRB-\1740|
T40_T63 NONE da_20\NN\10484858|cortical|and|release (r_dobj) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_conj) related_30\JJ\1740|whether|effects|are|agonism (l_nmod) agonism_34\NN\1740|to|5-ht(1a|) (l_punct) )_33\-RRB-\1740|
T41_T61 NONE ach_22\NN\1740| (r_compound) release_23\NN\3748886|ach (r_conj) da_20\NN\10484858|cortical|and|release (r_dobj) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_advcl) antagonist_13\NN\7846|whether|quetiapine|apds (l_nsubj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|)
T41_T62 NONE ach_22\NN\1740| (r_compound) release_23\NN\3748886|ach (r_conj) da_20\NN\10484858|cortical|and|release (r_dobj) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_advcl) antagonist_13\NN\7846|whether|quetiapine|apds (l_nsubj) quetiapine_5\NN\1740|,|iloperidone|and|melperone|,|5-ht(2a)/d(2 (l_appos) 5-ht(2a)/d(2_11\NN\1740|) (l_punct) )_12\-RRB-\1740|
T41_T63 NONE ach_22\NN\1740| (r_compound) release_23\NN\3748886|ach (r_conj) da_20\NN\10484858|cortical|and|release (r_dobj) increase_18\VBP\169651|antagonist|,|also|da|,|and|related (l_conj) related_30\JJ\1740|whether|effects|are|agonism (l_nmod) agonism_34\NN\1740|to|5-ht(1a|) (l_punct) )_33\-RRB-\1740|
T16_T55 NONE quetiapine_4\NN\1740|,|iloperidone|and|melperone (r_nsubj) increase_10\VBP\169651|that|quetiapine|preferentially|release|,|nac|mechanism (l_nmod) mechanism_24\NN\13446390|via|a|5-ht(1a)-related (l_amod) 5-ht(1a)-related_23\JJ\1740|
T18_T55 NONE iloperidone_6\NN\1740| (r_conj) quetiapine_4\NN\1740|,|iloperidone|and|melperone (r_nsubj) increase_10\VBP\169651|that|quetiapine|preferentially|release|,|nac|mechanism (l_nmod) mechanism_24\NN\13446390|via|a|5-ht(1a)-related (l_amod) 5-ht(1a)-related_23\JJ\1740|
T19_T55 NONE melperone_8\NN\1740| (r_conj) quetiapine_4\NN\1740|,|iloperidone|and|melperone (r_nsubj) increase_10\VBP\169651|that|quetiapine|preferentially|release|,|nac|mechanism (l_nmod) mechanism_24\NN\13446390|via|a|5-ht(1a)-related (l_amod) 5-ht(1a)-related_23\JJ\1740|
T20_T55 NONE da_11\NN\10484858| (r_compound) release_12\NN\3748886|da|mpfc (r_dobj) increase_10\VBP\169651|that|quetiapine|preferentially|release|,|nac|mechanism (l_nmod) mechanism_24\NN\13446390|via|a|5-ht(1a)-related (l_amod) 5-ht(1a)-related_23\JJ\1740|
T22_T56 CPR:5 quetiapine-induced_10\NN\1740| (r_amod) release_12\NN\3748886|for|quetiapine-induced|ach (r_nmod) important_7\JJ\1740|however|,|agonism|may|be|only|release|. (l_nsubj) agonism_4\NN\1740|5-ht(1a|) (l_punct) )_3\-RRB-\1740|
T23_T56 NONE ach_11\NN\1740| (r_compound) release_12\NN\3748886|for|quetiapine-induced|ach (r_nmod) important_7\JJ\1740|however|,|agonism|may|be|only|release|. (l_nsubj) agonism_4\NN\1740|5-ht(1a|) (l_punct) )_3\-RRB-\1740|
17218486
T32_T54 NONE amphetamine_12\NN\3248958| (r_conj) methamphetamine_10\NN\2704153|of|,|amphetamine|,|and|para-hydroxyamphetamine (r_nmod) isomers_8\NNS\14818238|for|methamphetamine (r_nmod) stereoselectivity_6\NN\1740|species-dependent|isomers (r_dobj) displays_4\VBZ\2137132|receptor|stereoselectivity|. (l_nsubj) receptor_2\NN\5225602|trace|amine-associated|1 (l_nummod) 1_3\CD\13741022|
T33_T54 NONE para-hydroxyamphetamine_15\NN\1740| (r_conj) methamphetamine_10\NN\2704153|of|,|amphetamine|,|and|para-hydroxyamphetamine (r_nmod) isomers_8\NNS\14818238|for|methamphetamine (r_nmod) stereoselectivity_6\NN\1740|species-dependent|isomers (r_dobj) displays_4\VBZ\2137132|receptor|stereoselectivity|. (l_nsubj) receptor_2\NN\5225602|trace|amine-associated|1 (l_nummod) 1_3\CD\13741022|
T34_T54 NONE amine-associated_1\JJ\1740| (r_amod) receptor_2\NN\5225602|trace|amine-associated|1 (l_nummod) 1_3\CD\13741022|
T35_T54 NONE methamphetamine_10\NN\2704153|of|,|amphetamine|,|and|para-hydroxyamphetamine (r_nmod) isomers_8\NNS\14818238|for|methamphetamine (r_nmod) stereoselectivity_6\NN\1740|species-dependent|isomers (r_dobj) displays_4\VBZ\2137132|receptor|stereoselectivity|. (l_nsubj) receptor_2\NN\5225602|trace|amine-associated|1 (l_nummod) 1_3\CD\13741022|
T11_T47 NONE meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T11_T48 NONE meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T12_T47 NONE amph_8\NN\1740| (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T12_T48 NONE amph_8\NN\1740| (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T13_T47 NONE poha_10\NN\1740| (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T13_T48 NONE poha_10\NN\1740| (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T14_T47 NONE para-tyramine_15\NN\1740|tyr|and|beta-phenylethylamine (r_dep) tas_14\NNS\14625458|the|para-tyramine (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T14_T48 NONE para-tyramine_15\NN\1740|tyr|and|beta-phenylethylamine (r_dep) tas_14\NNS\14625458|the|para-tyramine (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T15_T47 NONE tyr_17\NN\1740|(|) (r_appos) para-tyramine_15\NN\1740|tyr|and|beta-phenylethylamine (r_dep) tas_14\NNS\14625458|the|para-tyramine (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T15_T48 NONE tyr_17\NN\1740|(|) (r_appos) para-tyramine_15\NN\1740|tyr|and|beta-phenylethylamine (r_dep) tas_14\NNS\14625458|the|para-tyramine (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T16_T47 NONE beta-phenylethylamine_20\NN\1740|pea (r_conj) para-tyramine_15\NN\1740|tyr|and|beta-phenylethylamine (r_dep) tas_14\NNS\14625458|the|para-tyramine (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T16_T48 NONE beta-phenylethylamine_20\NN\1740|pea (r_conj) para-tyramine_15\NN\1740|tyr|and|beta-phenylethylamine (r_dep) tas_14\NNS\14625458|the|para-tyramine (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T18_T47 NONE pea_22\NN\7708798|(|) (r_appos) beta-phenylethylamine_20\NN\1740|pea (r_conj) para-tyramine_15\NN\1740|tyr|and|beta-phenylethylamine (r_dep) tas_14\NNS\14625458|the|para-tyramine (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T18_T48 NONE pea_22\NN\7708798|(|) (r_appos) beta-phenylethylamine_20\NN\1740|pea (r_conj) para-tyramine_15\NN\1740|tyr|and|beta-phenylethylamine (r_dep) tas_14\NNS\14625458|the|para-tyramine (r_conj) meth_6\NN\2704153|,|amph|,|poha|,|and|tas (r_nsubj) stimulate_24\VBP\137313|that|meth|production (l_dobj) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T19_T47 NONE camp_25\NN\3763727| (r_compound) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T19_T48 NONE camp_25\NN\3763727| (r_compound) production_26\NN\30358|camp|cells (l_nmod) cells_32\NNS\3080309|in|human|embryonic|kidney|(hek)-293|expressing (l_acl) expressing_33\VBG\928630|receptor (l_dobj) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T21_T47 NONE amine-associated_36\JJ\1740| (r_amod) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_nummod) 1_38\CD\13741022|
T21_T48 NONE amine-associated_36\JJ\1740| (r_amod) receptor_37\NN\5225602|rat|trace|amine-associated|1|rtaar1 (l_appos) rtaar1_40\NN\1740|(|)
T22_T49 CPR:3 meth_3\NN\2704153|and|amph (r_nsubj) activate_6\VBP\1641914|that|meth|rtaar1 (l_dobj) rtaar1_8\NN\1740|the
T22_T50 NONE meth_3\NN\2704153|and|amph (r_nsubj) activate_6\VBP\1641914|that|meth|rtaar1 (r_ccomp) discovery_1\NN\30358|the|activate (r_nsubj) motivated_9\VBD\1645601|discovery|us|study|. (l_xcomp) study_12\VB\630380|to|effect (l_dobj) effect_14\NN\34213|the|drugs|taar1 (l_nmod) taar1_21\NN\1740|on|the|mouse|mtaar1|and|chimera
T22_T51 NONE meth_3\NN\2704153|and|amph (r_nsubj) activate_6\VBP\1641914|that|meth|rtaar1 (r_ccomp) discovery_1\NN\30358|the|activate (r_nsubj) motivated_9\VBD\1645601|discovery|us|study|. (l_xcomp) study_12\VB\630380|to|effect (l_dobj) effect_14\NN\34213|the|drugs|taar1 (l_nmod) taar1_21\NN\1740|on|the|mouse|mtaar1|and|chimera (l_appos) mtaar1_23\NN\1740|(|)
T22_T52 NONE meth_3\NN\2704153|and|amph (r_nsubj) activate_6\VBP\1641914|that|meth|rtaar1 (r_ccomp) discovery_1\NN\30358|the|activate (r_nsubj) motivated_9\VBD\1645601|discovery|us|study|. (l_xcomp) study_12\VB\630380|to|effect (l_dobj) effect_14\NN\34213|the|drugs|taar1 (l_nmod) taar1_21\NN\1740|on|the|mouse|mtaar1|and|chimera (l_conj) chimera_28\NN\9492123|a|human-rat|hrchtaar1 (l_appos) hrchtaar1_30\NN\1740|(|)
T23_T49 CPR:3 amph_5\NN\1740| (r_conj) meth_3\NN\2704153|and|amph (r_nsubj) activate_6\VBP\1641914|that|meth|rtaar1 (l_dobj) rtaar1_8\NN\1740|the
T23_T50 NONE amph_5\NN\1740| (r_conj) meth_3\NN\2704153|and|amph (r_nsubj) activate_6\VBP\1641914|that|meth|rtaar1 (r_ccomp) discovery_1\NN\30358|the|activate (r_nsubj) motivated_9\VBD\1645601|discovery|us|study|. (l_xcomp) study_12\VB\630380|to|effect (l_dobj) effect_14\NN\34213|the|drugs|taar1 (l_nmod) taar1_21\NN\1740|on|the|mouse|mtaar1|and|chimera
T23_T51 NONE amph_5\NN\1740| (r_conj) meth_3\NN\2704153|and|amph (r_nsubj) activate_6\VBP\1641914|that|meth|rtaar1 (r_ccomp) discovery_1\NN\30358|the|activate (r_nsubj) motivated_9\VBD\1645601|discovery|us|study|. (l_xcomp) study_12\VB\630380|to|effect (l_dobj) effect_14\NN\34213|the|drugs|taar1 (l_nmod) taar1_21\NN\1740|on|the|mouse|mtaar1|and|chimera (l_appos) mtaar1_23\NN\1740|(|)
T23_T52 NONE amph_5\NN\1740| (r_conj) meth_3\NN\2704153|and|amph (r_nsubj) activate_6\VBP\1641914|that|meth|rtaar1 (r_ccomp) discovery_1\NN\30358|the|activate (r_nsubj) motivated_9\VBD\1645601|discovery|us|study|. (l_xcomp) study_12\VB\630380|to|effect (l_dobj) effect_14\NN\34213|the|drugs|taar1 (l_nmod) taar1_21\NN\1740|on|the|mouse|mtaar1|and|chimera (l_conj) chimera_28\NN\9492123|a|human-rat|hrchtaar1 (l_appos) hrchtaar1_30\NN\1740|(|)
T25_T53 CPR:3 meth_5\NN\2704153|of|and|amph (r_nmod) s-(+)-isomers_3\JJ\1740|meth (r_nsubjpass) reported_9\VBN\831651|because|s-(+)-isomers|are|potent (r_advcl) determined_23\VBD\1645601|furthermore|,|reported|,|we|selectivity|. (l_dobj) selectivity_26\NN\4916342|the|enantiomeric|species (l_nmod) species_30\NNS\7992450|of|all|three|taar1 (l_nmod) taar1_32\NN\1740|of
T26_T53 CPR:3 amph_7\NN\1740| (r_conj) meth_5\NN\2704153|of|and|amph (r_nmod) s-(+)-isomers_3\JJ\1740|meth (r_nsubjpass) reported_9\VBN\831651|because|s-(+)-isomers|are|potent (r_advcl) determined_23\VBD\1645601|furthermore|,|reported|,|we|selectivity|. (l_dobj) selectivity_26\NN\4916342|the|enantiomeric|species (l_nmod) species_30\NNS\7992450|of|all|three|taar1 (l_nmod) taar1_32\NN\1740|of
T28_T36 NONE meth_3\NN\2704153|,|amph|,|or|poha (r_compound) exposure_9\NN\5042871|to|meth (r_nmod) response_1\NN\11410625|in|exposure (r_nmod) concentration-_25\NN\1740|response|,|accumulation|was|and|isomer-dependent|. (l_nsubj) accumulation_12\NN\13497135|the|camp|cells (l_nmod) cells_17\NNS\3080309|by|hek-293|expressing (l_acl) expressing_19\VBG\928630|stably|species (l_dobj) species_21\NNS\7992450|different|taar1 (l_nmod) taar1_23\NN\1740|of
T29_T36 NONE amph_5\NN\1740| (r_conj) meth_3\NN\2704153|,|amph|,|or|poha (r_compound) exposure_9\NN\5042871|to|meth (r_nmod) response_1\NN\11410625|in|exposure (r_nmod) concentration-_25\NN\1740|response|,|accumulation|was|and|isomer-dependent|. (l_nsubj) accumulation_12\NN\13497135|the|camp|cells (l_nmod) cells_17\NNS\3080309|by|hek-293|expressing (l_acl) expressing_19\VBG\928630|stably|species (l_dobj) species_21\NNS\7992450|different|taar1 (l_nmod) taar1_23\NN\1740|of
T30_T36 NONE poha_8\NN\1740| (r_conj) meth_3\NN\2704153|,|amph|,|or|poha (r_compound) exposure_9\NN\5042871|to|meth (r_nmod) response_1\NN\11410625|in|exposure (r_nmod) concentration-_25\NN\1740|response|,|accumulation|was|and|isomer-dependent|. (l_nsubj) accumulation_12\NN\13497135|the|camp|cells (l_nmod) cells_17\NNS\3080309|by|hek-293|expressing (l_acl) expressing_19\VBG\928630|stably|species (l_dobj) species_21\NNS\7992450|different|taar1 (l_nmod) taar1_23\NN\1740|of
T31_T36 NONE camp_14\NN\3763727|of (r_nmod) accumulation_12\NN\13497135|the|camp|cells (l_nmod) cells_17\NNS\3080309|by|hek-293|expressing (l_acl) expressing_19\VBG\928630|stably|species (l_dobj) species_21\NNS\7992450|different|taar1 (l_nmod) taar1_23\NN\1740|of
T1_T37 CPR:3 s-(+)-meth_3\NN\1740|for (r_nmod) values_1\NNS\5941423|ec50|s-(+)-meth (r_nsubj) microm_11\NN\1740|values|were|0.89|rtaar1|,|respectively (l_nmod) rtaar1_13\NNP\1740|for|,|mtaar1|,|and|h-rchtaar1
T1_T38 CPR:3 s-(+)-meth_3\NN\1740|for (r_nmod) values_1\NNS\5941423|ec50|s-(+)-meth (r_nsubj) microm_11\NN\1740|values|were|0.89|rtaar1|,|respectively (l_nmod) rtaar1_13\NNP\1740|for|,|mtaar1|,|and|h-rchtaar1 (l_conj) mtaar1_15\NNP\1740|
T1_T39 CPR:3 s-(+)-meth_3\NN\1740|for (r_nmod) values_1\NNS\5941423|ec50|s-(+)-meth (r_nsubj) microm_11\NN\1740|values|were|0.89|rtaar1|,|respectively (l_nmod) rtaar1_13\NNP\1740|for|,|mtaar1|,|and|h-rchtaar1 (l_conj) h-rchtaar1_18\NNP\1740|
T3_T40 CPR:5 pea_0\NN\7708798| (r_nsubj) agonist_6\NN\9613191|pea|was|a|potent|species|,|agonist|. (l_nmod) species_9\NNS\7992450|at|each|taar1 (l_nmod) taar1_11\NN\1740|of
T3_T41 NONE pea_0\NN\7708798| (r_nsubj) agonist_6\NN\9613191|pea|was|a|potent|species|,|agonist|. (l_parataxis) agonist_18\NN\9613191|whereas|tyr|was|a|full|taar1s|but|agonist (l_nmod) taar1s_22\NNS\1740|for|the|rodent
T3_T42 NONE pea_0\NN\7708798| (r_nsubj) agonist_6\NN\9613191|pea|was|a|potent|species|,|agonist|. (l_parataxis) agonist_18\NN\9613191|whereas|tyr|was|a|full|taar1s|but|agonist (l_conj) agonist_27\NN\9613191|was|a|partial|h-rchtaar1 (l_nmod) h-rchtaar1_29\NN\1740|at
T4_T40 NONE tyr_14\NN\1740| (r_nsubj) agonist_18\NN\9613191|whereas|tyr|was|a|full|taar1s|but|agonist (r_parataxis) agonist_6\NN\9613191|pea|was|a|potent|species|,|agonist|. (l_nmod) species_9\NNS\7992450|at|each|taar1 (l_nmod) taar1_11\NN\1740|of
T4_T41 CPR:5 tyr_14\NN\1740| (r_nsubj) agonist_18\NN\9613191|whereas|tyr|was|a|full|taar1s|but|agonist (l_nmod) taar1s_22\NNS\1740|for|the|rodent
T4_T42 CPR:5 tyr_14\NN\1740| (r_nsubj) agonist_18\NN\9613191|whereas|tyr|was|a|full|taar1s|but|agonist (l_conj) agonist_27\NN\9613191|was|a|partial|h-rchtaar1 (l_nmod) h-rchtaar1_29\NN\1740|at
T5_T43 CPR:5 meth_5\NN\2704153|of (r_nmod) isomers_3\NNS\14818238|both|meth (r_nsubj) agonists_8\NNS\9613191|interestingly|,|isomers|were|full|mtaar1|,|agonists|. (l_nmod) mtaar1_10\NNP\1740|at|and|h-rchtaar1
T5_T44 CPR:5 meth_5\NN\2704153|of (r_nmod) isomers_3\NNS\14818238|both|meth (r_nsubj) agonists_8\NNS\9613191|interestingly|,|isomers|were|full|mtaar1|,|agonists|. (l_nmod) mtaar1_10\NNP\1740|at|and|h-rchtaar1 (l_conj) h-rchtaar1_12\NN\1740|
T5_T45 CPR:5 meth_5\NN\2704153|of (r_nmod) isomers_3\NNS\14818238|both|meth (r_nsubj) agonists_8\NNS\9613191|interestingly|,|isomers|were|full|mtaar1|,|agonists|. (l_advcl) agonists_18\NNS\9613191|whereas|both|were|partial|rtaar1 (l_nmod) rtaar1_20\NNP\1740|at
7902561
T3_T17 NONE dexfenfluramine_7\NN\1740|of (r_nmod) effect_5\NN\34213|the|satiating|dexfenfluramine (r_dobj) mediate_2\VBP\761713|receptors|effect|,|whereas|clear|. (l_nsubj) receptors_1\NNS\5225602|5-ht1b (l_compound) 5-ht1b_0\NN\1740|
T4_T17 NONE 5-ht_14\NN\1740| (r_compound) inhibitors_16\NNS\20090|5-ht|uptake|fluoxetine (r_nsubj) cause_22\VBP\1617192|which|inhibitors|anorexia (r_acl:relcl) mechanism_11\NN\13446390|the|cause (r_nsubj) clear_26\JJ\1740|mechanism|is|not (r_parataxis) mediate_2\VBP\761713|receptors|effect|,|whereas|clear|. (l_nsubj) receptors_1\NNS\5225602|5-ht1b (l_compound) 5-ht1b_0\NN\1740|
T5_T17 NONE fluoxetine_19\NN\4169152|such|and|sertraline (r_nmod) inhibitors_16\NNS\20090|5-ht|uptake|fluoxetine (r_nsubj) cause_22\VBP\1617192|which|inhibitors|anorexia (r_acl:relcl) mechanism_11\NN\13446390|the|cause (r_nsubj) clear_26\JJ\1740|mechanism|is|not (r_parataxis) mediate_2\VBP\761713|receptors|effect|,|whereas|clear|. (l_nsubj) receptors_1\NNS\5225602|5-ht1b (l_compound) 5-ht1b_0\NN\1740|
T6_T17 NONE sertraline_21\NN\4169152| (r_conj) fluoxetine_19\NN\4169152|such|and|sertraline (r_nmod) inhibitors_16\NNS\20090|5-ht|uptake|fluoxetine (r_nsubj) cause_22\VBP\1617192|which|inhibitors|anorexia (r_acl:relcl) mechanism_11\NN\13446390|the|cause (r_nsubj) clear_26\JJ\1740|mechanism|is|not (r_parataxis) mediate_2\VBP\761713|receptors|effect|,|whereas|clear|. (l_nsubj) receptors_1\NNS\5225602|5-ht1b (l_compound) 5-ht1b_0\NN\1740|
T10_T18 NONE phenylpropanolamine_9\NN\2682038| (r_conj) (+)-amphetamine_3\NN\1740|by|,|phentermine|,|diethylpropion|and|phenylpropanolamine (r_nmod) induced_1\VBN\1627355|(+)-amphetamine (r_acl) anorexia_0\NN\14055623|induced (r_nsubj) seems_10\VBZ\2604760|anorexia|result|. (l_xcomp) result_14\NN\34213|to|be|the|ability (l_nmod) ability_17\NN\4723816|of|their|increase (l_acl) increase_19\VB\169651|to|release|and|inhibit|or|,|case|,|stimulate (l_conj) stimulate_42\VB\137313|to|directly|1-adrenoceptors (l_dobj) 1-adrenoceptors_45\NNS\1740|alpha
T11_T18 NONE noradrenaline_23\NN\14807929|of|and/or|dopamine (r_nmod) release_21\NN\3748886|the|noradrenaline|terminals (r_dobj) increase_19\VB\169651|to|release|and|inhibit|or|,|case|,|stimulate (l_conj) stimulate_42\VB\137313|to|directly|1-adrenoceptors (l_dobj) 1-adrenoceptors_45\NNS\1740|alpha
T12_T18 NONE dopamine_25\NN\14807737| (r_conj) noradrenaline_23\NN\14807929|of|and/or|dopamine (r_nmod) release_21\NN\3748886|the|noradrenaline|terminals (r_dobj) increase_19\VB\169651|to|release|and|inhibit|or|,|case|,|stimulate (l_conj) stimulate_42\VB\137313|to|directly|1-adrenoceptors (l_dobj) 1-adrenoceptors_45\NNS\1740|alpha
T14_T18 CPR:3 phenylpropanolamine_39\NN\2682038|of (r_nmod) case_37\NN\7283608|in|the|phenylpropanolamine (r_nmod) increase_19\VB\169651|to|release|and|inhibit|or|,|case|,|stimulate (l_conj) stimulate_42\VB\137313|to|directly|1-adrenoceptors (l_dobj) 1-adrenoceptors_45\NNS\1740|alpha
T7_T18 NONE (+)-amphetamine_3\NN\1740|by|,|phentermine|,|diethylpropion|and|phenylpropanolamine (r_nmod) induced_1\VBN\1627355|(+)-amphetamine (r_acl) anorexia_0\NN\14055623|induced (r_nsubj) seems_10\VBZ\2604760|anorexia|result|. (l_xcomp) result_14\NN\34213|to|be|the|ability (l_nmod) ability_17\NN\4723816|of|their|increase (l_acl) increase_19\VB\169651|to|release|and|inhibit|or|,|case|,|stimulate (l_conj) stimulate_42\VB\137313|to|directly|1-adrenoceptors (l_dobj) 1-adrenoceptors_45\NNS\1740|alpha
T8_T18 NONE phentermine_5\NN\1740| (r_conj) (+)-amphetamine_3\NN\1740|by|,|phentermine|,|diethylpropion|and|phenylpropanolamine (r_nmod) induced_1\VBN\1627355|(+)-amphetamine (r_acl) anorexia_0\NN\14055623|induced (r_nsubj) seems_10\VBZ\2604760|anorexia|result|. (l_xcomp) result_14\NN\34213|to|be|the|ability (l_nmod) ability_17\NN\4723816|of|their|increase (l_acl) increase_19\VB\169651|to|release|and|inhibit|or|,|case|,|stimulate (l_conj) stimulate_42\VB\137313|to|directly|1-adrenoceptors (l_dobj) 1-adrenoceptors_45\NNS\1740|alpha
T9_T18 NONE diethylpropion_7\NN\1740| (r_conj) (+)-amphetamine_3\NN\1740|by|,|phentermine|,|diethylpropion|and|phenylpropanolamine (r_nmod) induced_1\VBN\1627355|(+)-amphetamine (r_acl) anorexia_0\NN\14055623|induced (r_nsubj) seems_10\VBZ\2604760|anorexia|result|. (l_xcomp) result_14\NN\34213|to|be|the|ability (l_nmod) ability_17\NN\4723816|of|their|increase (l_acl) increase_19\VB\169651|to|release|and|inhibit|or|,|case|,|stimulate (l_conj) stimulate_42\VB\137313|to|directly|1-adrenoceptors (l_dobj) 1-adrenoceptors_45\NNS\1740|alpha
T15_T19 NONE dopamine_11\NN\14807737| (r_compound) receptors_12\NNS\5225602|d1|dopamine (r_conj) 1-adrenoceptors_8\NNS\1740|beta-|and|receptors
T15_T20 NONE dopamine_11\NN\14807737| (r_compound) receptors_12\NNS\5225602|d1|dopamine
23436791
T13_T21 NONE atp-competitive_11\JJ\1740| (r_conj) noncompetitive_9\JJ\1740|and|atp-competitive (r_amod) inhibitors_12\NNS\20090|between|noncompetitive (r_nmod) synergism_7\NN\13518963|inhibitors (r_dep) strategy_2\NN\5902545|a|combination|inhibit|:|synergism (l_acl) inhibit_4\VB\2510337|to|pim-1 (l_dobj) pim-1_5\NN\1740|
T3_T14 NONE serine/threonine_3\NN\1740| (r_compound) kinase_4\NN\14732946|pim-1|is|a|serine/threonine|involved|and|considered|. (l_nsubj) pim-1_0\NN\1740|
T3_T15 NONE serine/threonine_3\NN\1740| (r_compound) kinase_4\NN\14732946|pim-1|is|a|serine/threonine|involved|and|considered|.
T5_T14 NONE serine/threonine_3\NN\1740| (r_compound) kinase_4\NN\14732946|pim-1|is|a|serine/threonine|involved|and|considered|. (l_nsubj) pim-1_0\NN\1740|
T5_T15 NONE serine/threonine_3\NN\1740| (r_compound) kinase_4\NN\14732946|pim-1|is|a|serine/threonine|involved|and|considered|.
T6_T19 NONE atp-competitive_13\JJ\1740| (r_amod) scaffold_15\NN\3961939|a|identified|atp-competitive|indolyl-pyrrolone (r_nsubjpass) expanded_17\VBN\230746|effort|,|scaffold|was|derive|. (l_nmod) effort_2\NN\407535|in|an|discover (l_acl) discover_4\VB\2163746|to|inhibitors (l_dobj) inhibitors_8\NNS\20090|new|potent|pim-1 (l_compound) pim-1_7\NN\1740|
T7_T19 NONE indolyl-pyrrolone_14\NN\1740| (r_compound) scaffold_15\NN\3961939|a|identified|atp-competitive|indolyl-pyrrolone (r_nsubjpass) expanded_17\VBN\230746|effort|,|scaffold|was|derive|. (l_nmod) effort_2\NN\407535|in|an|discover (l_acl) discover_4\VB\2163746|to|inhibitors (l_dobj) inhibitors_8\NNS\20090|new|potent|pim-1 (l_compound) pim-1_7\NN\1740|
T1_T16 NONE atp-competitive_10\JJ\1740|and|atp-noncompetitive (r_amod) compounds_13\NNS\5869584|by|atp-competitive (r_nmod) inhibition_5\NN\1068773|in|the|proliferation|compounds (r_nmod) effect_2\NN\34213|a|synergistic|inhibition (r_nsubjpass) observed_16\VBN\2163746|effect|was|also|lines|. (l_nmod) lines_21\NNS\8426461|in|prostate|cancer|cell|pc3|,|showed (l_acl:relcl) showed_32\VBD\2137132|where|inhibitors|synergism (l_nsubj) inhibitors_29\NNS\20090|all|pim-1|tested (l_compound) pim-1_28\NN\1740|
T2_T16 NONE atp-noncompetitive_12\JJ\1740| (r_conj) atp-competitive_10\JJ\1740|and|atp-noncompetitive (r_amod) compounds_13\NNS\5869584|by|atp-competitive (r_nmod) inhibition_5\NN\1068773|in|the|proliferation|compounds (r_nmod) effect_2\NN\34213|a|synergistic|inhibition (r_nsubjpass) observed_16\VBN\2163746|effect|was|also|lines|. (l_nmod) lines_21\NNS\8426461|in|prostate|cancer|cell|pc3|,|showed (l_acl:relcl) showed_32\VBD\2137132|where|inhibitors|synergism (l_nsubj) inhibitors_29\NNS\20090|all|pim-1|tested (l_compound) pim-1_28\NN\1740|
T4_T16 NONE paclitaxel_40\NN\1740| (r_appos) agent_38\NN\7347|with|the|known|anticancer|,|paclitaxel (r_nmod) synergism_33\NN\13518963|agent (r_dobj) showed_32\VBD\2137132|where|inhibitors|synergism (l_nsubj) inhibitors_29\NNS\20090|all|pim-1|tested (l_compound) pim-1_28\NN\1740|
18655903
T34_T75 NONE vasopressin_8\NN\5407119|and|oxytocin
T34_T76 NONE vasopressin_8\NN\5407119|and|oxytocin (l_conj) oxytocin_10\NN\5407119|
T34_T77 NONE vasopressin_8\NN\5407119|and|oxytocin (r_compound) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot
T34_T78 NONE vasopressin_8\NN\5407119|and|oxytocin (r_compound) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (l_conj) v1b_13\NN\1740|
T34_T79 NONE vasopressin_8\NN\5407119|and|oxytocin (r_compound) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (l_conj) v2_15\NN\1740|
T34_T80 NONE vasopressin_8\NN\5407119|and|oxytocin (r_compound) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (r_compound) receptors_18\NNS\5225602|for|the|v1a
T35_T75 NONE oxytocin_10\NN\5407119| (r_conj) vasopressin_8\NN\5407119|and|oxytocin
T35_T76 NONE oxytocin_10\NN\5407119|
T35_T77 NONE oxytocin_10\NN\5407119| (r_conj) vasopressin_8\NN\5407119|and|oxytocin (r_compound) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot
T35_T78 NONE oxytocin_10\NN\5407119| (r_conj) vasopressin_8\NN\5407119|and|oxytocin (r_compound) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (l_conj) v1b_13\NN\1740|
T35_T79 NONE oxytocin_10\NN\5407119| (r_conj) vasopressin_8\NN\5407119|and|oxytocin (r_compound) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (l_conj) v2_15\NN\1740|
T35_T80 NONE oxytocin_10\NN\5407119| (r_conj) vasopressin_8\NN\5407119|and|oxytocin (r_compound) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (r_compound) receptors_18\NNS\5225602|for|the|v1a
T36_T75 NONE ot_17\NN\1740| (r_conj) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (l_compound) vasopressin_8\NN\5407119|and|oxytocin
T36_T76 NONE ot_17\NN\1740| (r_conj) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (l_compound) vasopressin_8\NN\5407119|and|oxytocin (l_conj) oxytocin_10\NN\5407119|
T36_T77 NONE ot_17\NN\1740| (r_conj) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot
T36_T78 NONE ot_17\NN\1740| (r_conj) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (l_conj) v1b_13\NN\1740|
T36_T79 NONE ot_17\NN\1740| (r_conj) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (l_conj) v2_15\NN\1740|
T36_T80 NONE ot_17\NN\1740| (r_conj) v1a_11\NN\1740|vasopressin|,|v1b|,|v2|and|ot (r_compound) receptors_18\NNS\5225602|for|the|v1a
T1_T37 NONE oxytocin_0\NN\5407119|ot|and|vasopressin
T1_T38 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (l_appos) ot_2\NN\1740|(|)
T1_T39 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor
T1_T42 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary
T1_T43 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_dep) v(1a_28\NN\1740|) (l_punct) )_29\-RRB-\1740|
T1_T53 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_appos) v(1b_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T1_T57 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_dep) receptors_45\NNS\5225602|)|renal|) (l_punct) )_41\-RRB-\1740|
T1_T59 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp
T1_T64 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_compound) avp_50\NN\1740|
T1_T67 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_punct) )_52\-RRB-\1740|
T1_T68 NONE oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp (l_appos) avp_7\NN\1740|(|)
T22_T37 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin
T22_T38 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_appos) ot_2\NN\1740|(|)
T22_T39 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor
T22_T42 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary
T22_T43 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_dep) v(1a_28\NN\1740|) (l_punct) )_29\-RRB-\1740|
T22_T53 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_appos) v(1b_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T22_T57 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_dep) receptors_45\NNS\5225602|)|renal|) (l_punct) )_41\-RRB-\1740|
T22_T59 NONE vasopressin_5\NN\5407119|avp
T22_T64 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_compound) avp_50\NN\1740|
T22_T67 NONE vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_punct) )_52\-RRB-\1740|
T22_T68 NONE vasopressin_5\NN\5407119|avp (l_appos) avp_7\NN\1740|(|)
T26_T37 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin
T26_T38 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_appos) ot_2\NN\1740|(|)
T26_T39 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor
T26_T42 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary
T26_T43 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_dep) v(1a_28\NN\1740|) (l_punct) )_29\-RRB-\1740|
T26_T53 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_appos) v(1b_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T26_T57 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_dep) receptors_45\NNS\5225602|)|renal|) (l_punct) )_41\-RRB-\1740|
T26_T59 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp
T26_T64 NONE avp_50\NN\1740|
T26_T67 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_punct) )_52\-RRB-\1740|
T26_T68 NONE avp_50\NN\1740| (r_compound) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp (l_appos) avp_7\NN\1740|(|)
T28_T37 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin
T28_T38 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_appos) ot_2\NN\1740|(|)
T28_T39 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor
T28_T42 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary
T28_T43 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_dep) v(1a_28\NN\1740|) (l_punct) )_29\-RRB-\1740|
T28_T53 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_appos) v(1b_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T28_T57 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_dep) receptors_45\NNS\5225602|)|renal|) (l_punct) )_41\-RRB-\1740|
T28_T59 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp
T28_T64 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_compound) avp_50\NN\1740|
T28_T67 NONE avp_7\NN\1740|(|) (r_appos) vasopressin_5\NN\5407119|avp (r_conj) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_punct) )_52\-RRB-\1740|
T28_T68 NONE avp_7\NN\1740|(|)
T2_T37 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin
T2_T38 NONE ot_2\NN\1740|(|)
T2_T39 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor
T2_T42 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary
T2_T43 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_dep) v(1a_28\NN\1740|) (l_punct) )_29\-RRB-\1740|
T2_T53 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_appos) v(1b_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T2_T57 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_dep) receptors_45\NNS\5225602|)|renal|) (l_punct) )_41\-RRB-\1740|
T2_T59 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp
T2_T64 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_compound) avp_50\NN\1740|
T2_T67 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (r_nsubj) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_advcl) acting_14\VBG\1619354|by|receptors (l_nmod) receptors_18\NNS\5225602|on|four|known|:|ot (l_dep) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_punct) )_52\-RRB-\1740|
T2_T68 NONE ot_2\NN\1740|(|) (r_appos) oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp (l_appos) avp_7\NN\1740|(|)
T3_T37 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin
T3_T38 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_appos) ot_2\NN\1740|(|)
T3_T39 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor
T3_T42 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary
T3_T43 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_dep) v(1a_28\NN\1740|) (l_punct) )_29\-RRB-\1740|
T3_T53 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_appos) v(1b_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T3_T57 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_dep) receptors_45\NNS\5225602|)|renal|) (l_punct) )_41\-RRB-\1740|
T3_T59 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp
T3_T64 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_compound) avp_50\NN\1740|
T3_T67 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_punct) )_52\-RRB-\1740|
T3_T68 NONE ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp (l_appos) avp_7\NN\1740|(|)
T6_T37 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin
T6_T38 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_appos) ot_2\NN\1740|(|)
T6_T39 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor
T6_T42 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary
T6_T43 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_dep) v(1a_28\NN\1740|) (l_punct) )_29\-RRB-\1740|
T6_T53 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (l_appos) v(1b_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T6_T57 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_dep) receptors_45\NNS\5225602|)|renal|) (l_punct) )_41\-RRB-\1740|
T6_T59 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp
T6_T64 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_compound) avp_50\NN\1740|
T6_T67 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (l_conj) receptor_57\NN\5225602|a|fifth|putative|avp|v(1c|)|?|vasodilating|) (l_punct) )_52\-RRB-\1740|
T6_T68 NONE avp_27\NN\1740|the|v(1a|vasopressor|,|v(1b|pituitary (r_conj) ot_21\NN\1740|the|uterine|and|avp|,|v(2|receptors|and|receptor (r_dep) receptors_18\NNS\5225602|on|four|known|:|ot (r_nmod) acting_14\VBG\1619354|by|receptors (r_advcl) mediate_9\VBP\761713|oxytocin|actions|acting|. (l_nsubj) oxytocin_0\NN\5407119|ot|and|vasopressin (l_conj) vasopressin_5\NN\5407119|avp (l_appos) avp_7\NN\1740|(|)
T29_T69 NONE ot_7\NN\1740|
T29_T70 NONE ot_7\NN\1740| (r_compound) antagonists_8\NNS\7846|of|promising|new|selective|ot|and|agonists (l_conj) agonists_12\NNS\9613191|v(1b|) (l_punct) )_11\-RRB-\1740|
T30_T71 NONE ot_5\NNS\1740|of|non-peptide|and|avp|antagonists
T30_T72 NONE ot_5\NNS\1740|of|non-peptide|and|avp|antagonists (l_conj) avp_7\NN\1740|
T31_T71 NONE avp_7\NN\1740| (r_conj) ot_5\NNS\1740|of|non-peptide|and|avp|antagonists
T31_T72 NONE avp_7\NN\1740|
T32_T73 NONE avp_7\NN\1740|and
T32_T74 NONE avp_7\NN\1740|and (r_conj) peptide_4\NN\14724264|of|and|non-peptide|avp|agonists (l_dep) agonists_10\NNS\9613191|ot|and|antagonists (l_compound) ot_9\NN\1740|
T33_T73 NONE ot_9\NN\1740| (r_compound) agonists_10\NNS\9613191|ot|and|antagonists (r_dep) peptide_4\NN\14724264|of|and|non-peptide|avp|agonists (l_conj) avp_7\NN\1740|and
T33_T74 NONE ot_9\NN\1740|
T4_T40 NONE ot_31\NN\1740|of|and|avp
T4_T41 NONE ot_31\NN\1740|of|and|avp (l_conj) avp_33\NN\1740|
T5_T40 NONE avp_33\NN\1740| (r_conj) ot_31\NN\1740|of|and|avp
T5_T41 NONE avp_33\NN\1740|
T10_T44 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T10_T45 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T10_T46 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues
T10_T47 NONE avp_19\NN\1740|
T10_T48 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T10_T49 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T10_T50 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T10_T51 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T10_T52 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T10_T54 NONE avp_19\NN\1740| (r_compound) analogues_20\NNS\4743605|avp (r_conj) ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T11_T44 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T11_T45 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T11_T46 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T11_T47 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T11_T48 CPR:5 carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T11_T49 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T11_T50 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T11_T51 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T11_T52 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T11_T54 NONE carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T12_T44 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T12_T45 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T12_T46 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T12_T47 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T12_T48 NONE ot_26\NN\1740|
T12_T49 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T12_T50 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T12_T51 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T12_T52 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T12_T54 NONE ot_26\NN\1740| (r_compound) agonist_27\NN\9613191|(|ot|) (r_appos) carbetocin_24\NN\1740|such|agonist (r_compound) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T13_T44 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T13_T45 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T13_T46 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T13_T47 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T13_T48 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T13_T49 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T13_T50 CPR:5 desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T13_T51 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T13_T52 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T13_T54 NONE desmopressin_31\NN\1740| (r_compound) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (r_appos) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T14_T44 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T14_T45 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T14_T46 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T14_T47 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T14_T48 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T14_T49 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T14_T50 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T14_T51 CPR:5 terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T14_T52 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T14_T54 NONE terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T15_T44 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T15_T45 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T15_T46 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T15_T47 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T15_T48 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T15_T49 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T15_T50 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T15_T51 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T15_T52 CPR:5 felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T15_T54 NONE felypressin_45\NN\1740|agonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T16_T44 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T16_T45 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T16_T46 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T16_T47 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T16_T48 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T16_T49 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T16_T50 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T16_T51 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T16_T52 NONE atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T16_T54 CPR:6 atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T17_T44 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T17_T45 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T17_T46 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T17_T47 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T17_T48 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T17_T49 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T17_T50 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T17_T51 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T17_T52 NONE tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T17_T54 CPR:6 tractocile_54\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T18_T44 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T18_T45 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T18_T46 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T18_T47 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (r_dep) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T18_T48 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T18_T49 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T18_T50 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (r_conj) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T18_T51 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T18_T52 NONE ot_55\NN\1740| (r_compound) antagonist_56\NN\7846|(|tractocile|ot|) (r_appos) atosiban_52\NN\1740|antagonist (r_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T18_T54 NONE ot_55\NN\1740|
T7_T44 NONE ot_3\NNS\1740|to|and|avp
T7_T45 NONE ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T7_T46 NONE ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T7_T47 NONE ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T7_T48 NONE ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T7_T49 NONE ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T7_T50 NONE ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T7_T51 NONE ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T7_T52 NONE ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T7_T54 NONE ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T8_T44 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp
T8_T45 NONE avp_9\NN\1740|extent|pitressin
T8_T46 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues
T8_T47 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_nmod) ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T8_T48 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T8_T49 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T8_T50 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T8_T51 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T8_T52 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T8_T54 NONE avp_9\NN\1740|extent|pitressin (r_conj) ot_3\NNS\1740|to|and|avp (r_nmod) addition_1\NN\3081021|in|ot (r_nmod) also_59\RB\1740|addition|,|number|are|use (l_nsubj) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T9_T44 NONE ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp
T9_T45 NONE ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (r_nsubj) also_59\RB\1740|addition|,|number|are|use (l_nmod) addition_1\NN\3081021|in|ot (l_nmod) ot_3\NNS\1740|to|and|avp (l_conj) avp_9\NN\1740|extent|pitressin
T9_T46 NONE ot_17\NN\1740|of|and|analogues
T9_T47 NONE ot_17\NN\1740|of|and|analogues (l_conj) analogues_20\NNS\4743605|avp (l_compound) avp_19\NN\1740|
T9_T48 NONE ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_compound) carbetocin_24\NN\1740|such|agonist (l_appos) agonist_27\NN\9613191|(|ot|) (l_compound) ot_26\NN\1740|
T9_T49 NONE ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin
T9_T50 NONE ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_appos) agonist_35\NN\9613191|(|desmopressin|,|v(2|)|) (l_punct) )_34\-RRB-\1740|
T9_T51 NONE ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_appos) agonist_42\NN\9613191|(|v(1a|)|) (l_punct) )_41\-RRB-\1740|
T9_T52 NONE ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) felypressin_45\NN\1740|agonist (l_appos) agonist_49\NN\9613191|(|v(1a|)|) (l_punct) )_48\-RRB-\1740|
T9_T54 NONE ot_17\NN\1740|of|and|analogues (r_nmod) number_15\NN\5107765|a|ot|;|ddavp (l_dep) ddavp_29\NN\1740|carbetocin|agonist|,|terlipressin (l_conj) terlipressin_38\NN\1740|agonist|,|felypressin|and|atosiban (l_conj) atosiban_52\NN\1740|antagonist (l_appos) antagonist_56\NN\7846|(|tractocile|ot|) (l_compound) ot_55\NN\1740|
T19_T58 CPR:6 tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (l_nmod) antagonists_9\NNS\7846|of|active|non-peptide|v(2|)|vaptans (l_punct) )_8\-RRB-\1740|
T19_T60 NONE tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (r_nsubjpass) approved_47\VBN\803325|while|number|;|date|,|v(2)/v(1a|has|been|fda|use|,|treatment|. (l_nsubjpass) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|,
T19_T61 NONE tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (r_nsubjpass) approved_47\VBN\803325|while|number|;|date|,|v(2)/v(1a|has|been|fda|use|,|treatment|. (l_nsubjpass) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|, (l_punct) )_37\-RRB-\1740|
T20_T58 CPR:6 lixivaptan_18\NN\1740| (r_conj) tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (l_nmod) antagonists_9\NNS\7846|of|active|non-peptide|v(2|)|vaptans (l_punct) )_8\-RRB-\1740|
T20_T60 NONE lixivaptan_18\NN\1740| (r_conj) tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (r_nsubjpass) approved_47\VBN\803325|while|number|;|date|,|v(2)/v(1a|has|been|fda|use|,|treatment|. (l_nsubjpass) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|,
T20_T61 NONE lixivaptan_18\NN\1740| (r_conj) tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (r_nsubjpass) approved_47\VBN\803325|while|number|;|date|,|v(2)/v(1a|has|been|fda|use|,|treatment|. (l_nsubjpass) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|, (l_punct) )_37\-RRB-\1740|
T21_T58 CPR:6 satavaptan_20\NN\1740| (r_conj) tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (l_nmod) antagonists_9\NNS\7846|of|active|non-peptide|v(2|)|vaptans (l_punct) )_8\-RRB-\1740|
T21_T60 NONE satavaptan_20\NN\1740| (r_conj) tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (r_nsubjpass) approved_47\VBN\803325|while|number|;|date|,|v(2)/v(1a|has|been|fda|use|,|treatment|. (l_nsubjpass) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|,
T21_T61 NONE satavaptan_20\NN\1740| (r_conj) tolvaptan_16\NN\1740|notably|,|,|lixivaptan|and|satavaptan|,|trials (r_dep) number_2\NN\5107765|a|antagonists|;|tolvaptan (r_nsubjpass) approved_47\VBN\803325|while|number|;|date|,|v(2)/v(1a|has|been|fda|use|,|treatment|. (l_nsubjpass) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|, (l_punct) )_37\-RRB-\1740|
T23_T58 NONE conivaptan_40\NN\1740|antagonist|vaprisol (r_appos) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|, (r_nsubjpass) approved_47\VBN\803325|while|number|;|date|,|v(2)/v(1a|has|been|fda|use|,|treatment|. (l_nsubjpass) number_2\NN\5107765|a|antagonists|;|tolvaptan (l_nmod) antagonists_9\NNS\7846|of|active|non-peptide|v(2|)|vaptans (l_punct) )_8\-RRB-\1740|
T23_T60 CPR:6 conivaptan_40\NN\1740|antagonist|vaprisol (r_appos) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|,
T23_T61 CPR:6 conivaptan_40\NN\1740|antagonist|vaprisol (r_appos) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|, (l_punct) )_37\-RRB-\1740|
T24_T58 NONE vaprisol_42\NN\1740|(|) (r_appos) conivaptan_40\NN\1740|antagonist|vaprisol (r_appos) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|, (r_nsubjpass) approved_47\VBN\803325|while|number|;|date|,|v(2)/v(1a|has|been|fda|use|,|treatment|. (l_nsubjpass) number_2\NN\5107765|a|antagonists|;|tolvaptan (l_nmod) antagonists_9\NNS\7846|of|active|non-peptide|v(2|)|vaptans (l_punct) )_8\-RRB-\1740|
T24_T60 CPR:6 vaprisol_42\NN\1740|(|) (r_appos) conivaptan_40\NN\1740|antagonist|vaprisol (r_appos) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|,
T24_T61 CPR:6 vaprisol_42\NN\1740|(|) (r_appos) conivaptan_40\NN\1740|antagonist|vaprisol (r_appos) v(2)/v(1a_36\NN\1740|only|the|mixed|)|,|conivaptan|, (l_punct) )_37\-RRB-\1740|
T25_T62 NONE ot_6\NN\1740| (r_compound) antagonists_7\NNS\7846|ot|,|as (r_conj) v(1b_3\NN\1740|promising|new|non-peptide|)|and|antagonists|v(2 (l_punct) )_4\-RRB-\1740|
T25_T63 NONE ot_6\NN\1740|
T25_T65 NONE ot_6\NN\1740| (r_compound) antagonists_7\NNS\7846|ot|,|as (r_conj) v(1b_3\NN\1740|promising|new|non-peptide|)|and|antagonists|v(2 (l_conj) v(2_13\NN\1740|non-peptide|)|and|agonists (l_punct) )_14\-RRB-\1740|
T25_T66 NONE ot_6\NN\1740| (r_compound) antagonists_7\NNS\7846|ot|,|as (r_conj) v(1b_3\NN\1740|promising|new|non-peptide|)|and|antagonists|v(2 (l_conj) v(2_13\NN\1740|non-peptide|)|and|agonists (l_conj) agonists_17\NNS\9613191|ot (l_compound) ot_16\NN\1740|
T27_T62 NONE ot_16\NN\1740| (r_compound) agonists_17\NNS\9613191|ot (r_conj) v(2_13\NN\1740|non-peptide|)|and|agonists (r_conj) v(1b_3\NN\1740|promising|new|non-peptide|)|and|antagonists|v(2 (l_punct) )_4\-RRB-\1740|
T27_T63 NONE ot_16\NN\1740| (r_compound) agonists_17\NNS\9613191|ot (r_conj) v(2_13\NN\1740|non-peptide|)|and|agonists (r_conj) v(1b_3\NN\1740|promising|new|non-peptide|)|and|antagonists|v(2 (l_conj) antagonists_7\NNS\7846|ot|,|as (l_compound) ot_6\NN\1740|
T27_T65 NONE ot_16\NN\1740| (r_compound) agonists_17\NNS\9613191|ot (r_conj) v(2_13\NN\1740|non-peptide|)|and|agonists (l_punct) )_14\-RRB-\1740|
T27_T66 NONE ot_16\NN\1740|
23182766
T13_T21 NONE cholesterol_7\NN\15058310| (r_compound) sequence_11\NN\8457976|the|cholesterol|recognition/interaction|amino|acid|protein (l_nmod) protein_15\NN\14944888|of|the|translocator|tspo (l_dep) tspo_16\NN\1740|
T14_T21 NONE acid_10\NN\14818238| (r_compound) sequence_11\NN\8457976|the|cholesterol|recognition/interaction|amino|acid|protein (l_nmod) protein_15\NN\14944888|of|the|translocator|tspo (l_dep) tspo_16\NN\1740|
T9_T18 NONE cholesterol-binding_12\JJ\1740| (r_amod) protein_13\NN\14944888|tspo|is|an|ubiquitous|high|affinity|cholesterol-binding|reported|;|increased|. (l_nsubj) tspo_6\NN\1740|protein
T5_T17 NONE carboxy-terminus_4\NN\1740|in|the|tspo (l_nmod) tspo_6\NN\1740|of
T6_T17 NONE cholesterol_13\NN\15058310| (r_compound) consensus_17\NN\13971065|as|the|cholesterol|recognition/interaction|amino|acid|crac (r_nmod) identified_8\VBN\699815|domain|was|and|characterized|consensus|. (l_nsubjpass) domain_1\NN\13934596|a|carboxy-terminus (l_nmod) carboxy-terminus_4\NN\1740|in|the|tspo (l_nmod) tspo_6\NN\1740|of
T7_T17 NONE acid_16\NN\14818238| (r_compound) consensus_17\NN\13971065|as|the|cholesterol|recognition/interaction|amino|acid|crac (r_nmod) identified_8\VBN\699815|domain|was|and|characterized|consensus|. (l_nsubjpass) domain_1\NN\13934596|a|carboxy-terminus (l_nmod) carboxy-terminus_4\NN\1740|in|the|tspo (l_nmod) tspo_6\NN\1740|of
T10_T19 NONE cholesterol_24\NN\15058310|high (r_compound) diet_25\NN\7560652|with|a|cholesterol|and|mice (l_conj) mice_30\NNS\2329401|apoe|knock-out|b6.129p2-apoetm1unc/j (l_compound) apoe_27\NN\1740|
T11_T20 NONE cholesterol_16\NN\15058310| (r_compound) levels_17\NNS\4916342|in|reduced|circulating|cholesterol|pigs (l_nmod) pigs_20\NNS\2395003|in|guinea|fed|and|mice (l_conj) mice_32\NNS\2329401|apoe|knock-out|b6.129p2-apoetm1unc/j (l_compound) apoe_29\NN\1740|
T12_T20 NONE cholesterol_26\NN\15058310|high (r_compound) diet_27\NN\7560652|with|%|cholesterol (r_nmod) fed_21\VBN\1182709|diet (r_acl) pigs_20\NNS\2395003|in|guinea|fed|and|mice (l_conj) mice_32\NNS\2329401|apoe|knock-out|b6.129p2-apoetm1unc/j (l_compound) apoe_29\NN\1740|
T3_T15 CPR:3 cholesterol_6\NN\15058310| (r_nmod:npmod) diet-induced_7\JJ\1740|high|cholesterol (r_amod) increase_8\NN\13576355|the|diet-induced|kinase (l_nmod) kinase_12\NN\14732946|in|serum|creatine|,|total|,|markers
T4_T15 NONE creatine_11\NN\14601829| (r_compound) kinase_12\NN\14732946|in|serum|creatine|,|total|,|markers
23524567
9710435
T25_T35 CPR:4 ibuprofen_0\NN\3828465| (r_nsubj) inhibits_1\VBZ\2510337|ibuprofen|secretion|. (l_dobj) secretion_8\NN\13526110|regulator-mediated|cl- (l_amod) regulator-mediated_6\JJ\1740|cystic|fibrosis|conductance
T1_T26 NONE ibuprofen_18\NN\3828465|of|and|acid (r_nmod) effects_16\NNS\13245626|the|ibuprofen|channels (r_nsubjpass) evaluated_34\VBN\670261|determine|,|effects|were|. (l_advcl) determine_1\VB\1645601|to|due (l_ccomp) due_8\JJ\1740|whether|inhibition|was|inhibition (l_nmod) inhibition_11\NN\1068773|to|the|cftr (l_nmod) cftr_13\NN\5439413|of
T1_T27 NONE ibuprofen_18\NN\3828465|of|and|acid (r_nmod) effects_16\NNS\13245626|the|ibuprofen|channels (l_nmod) channels_25\NNS\6251781|on|cftr|cl-|patches (l_compound) cftr_23\NN\5439413|
T1_T28 NONE ibuprofen_18\NN\3828465|of|and|acid (r_nmod) effects_16\NNS\13245626|the|ibuprofen|channels (l_nmod) channels_25\NNS\6251781|on|cftr|cl-|patches
T2_T26 NONE acid_21\NN\14818238|salicylic (r_conj) ibuprofen_18\NN\3828465|of|and|acid (r_nmod) effects_16\NNS\13245626|the|ibuprofen|channels (r_nsubjpass) evaluated_34\VBN\670261|determine|,|effects|were|. (l_advcl) determine_1\VB\1645601|to|due (l_ccomp) due_8\JJ\1740|whether|inhibition|was|inhibition (l_nmod) inhibition_11\NN\1068773|to|the|cftr (l_nmod) cftr_13\NN\5439413|of
T2_T27 NONE acid_21\NN\14818238|salicylic (r_conj) ibuprofen_18\NN\3828465|of|and|acid (r_nmod) effects_16\NNS\13245626|the|ibuprofen|channels (l_nmod) channels_25\NNS\6251781|on|cftr|cl-|patches (l_compound) cftr_23\NN\5439413|
T2_T28 NONE acid_21\NN\14818238|salicylic (r_conj) ibuprofen_18\NN\3828465|of|and|acid (r_nmod) effects_16\NNS\13245626|the|ibuprofen|channels (l_nmod) channels_25\NNS\6251781|on|cftr|cl-|patches
T3_T29 CPR:4 ibuprofen_0\NN\3828465|microm (r_nsubj) reduced_5\VBD\441445|ibuprofen|current|%|and|explained|. (l_dobj) current_8\NN\11449002|cftr|cl- (l_compound) cftr_6\NN\5439413|
T4_T30 CPR:4 acid_3\NN\14818238|salicylic|mm (r_nsubj) reduced_8\VBD\441445|similarly|,|acid|current|%|reduction|. (l_dobj) current_11\NN\11449002|cftr|cl- (l_compound) cftr_9\NN\5439413|
T10_T31 NONE k+_37\NN\1740| (r_compound) channels_38\NNS\6251781|basolateral|membrane|k+ (r_conj) channels_31\NNS\6251781|cl-|as|channels (l_compound) cl-_30\NNS\1740|of|cftr (l_compound) cftr_29\NN\5439413|
T10_T32 NONE k+_37\NN\1740| (r_compound) channels_38\NNS\6251781|basolateral|membrane|k+ (r_conj) channels_31\NNS\6251781|cl-|as|channels
T10_T33 NONE k+_37\NN\1740| (r_compound) channels_38\NNS\6251781|basolateral|membrane|k+
T6_T31 CPR:4 ibuprofen_10\NN\3828465|and|acid (r_dep) nsaids_9\NNS\2721538|the|ibuprofen (r_nsubj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels (l_compound) cl-_30\NNS\1740|of|cftr (l_compound) cftr_29\NN\5439413|
T6_T32 CPR:4 ibuprofen_10\NN\3828465|and|acid (r_dep) nsaids_9\NNS\2721538|the|ibuprofen (r_nsubj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels
T6_T33 CPR:4 ibuprofen_10\NN\3828465|and|acid (r_dep) nsaids_9\NNS\2721538|the|ibuprofen (r_nsubj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels (l_conj) channels_38\NNS\6251781|basolateral|membrane|k+
T7_T31 CPR:4 acid_13\NN\14818238|salicylic (r_conj) ibuprofen_10\NN\3828465|and|acid (r_dep) nsaids_9\NNS\2721538|the|ibuprofen (r_nsubj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels (l_compound) cl-_30\NNS\1740|of|cftr (l_compound) cftr_29\NN\5439413|
T7_T32 CPR:4 acid_13\NN\14818238|salicylic (r_conj) ibuprofen_10\NN\3828465|and|acid (r_dep) nsaids_9\NNS\2721538|the|ibuprofen (r_nsubj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels
T7_T33 CPR:4 acid_13\NN\14818238|salicylic (r_conj) ibuprofen_10\NN\3828465|and|acid (r_dep) nsaids_9\NNS\2721538|the|ibuprofen (r_nsubj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels (l_conj) channels_38\NNS\6251781|basolateral|membrane|k+
T8_T31 NONE camp-mediated_15\JJ\1740| (r_amod) secretion_17\NN\13526110|camp-mediated|cl-|epithelia (r_dobj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels (l_compound) cl-_30\NNS\1740|of|cftr (l_compound) cftr_29\NN\5439413|
T8_T32 NONE camp-mediated_15\JJ\1740| (r_amod) secretion_17\NN\13526110|camp-mediated|cl-|epithelia (r_dobj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels
T8_T33 NONE camp-mediated_15\JJ\1740| (r_amod) secretion_17\NN\13526110|camp-mediated|cl-|epithelia (r_dobj) inhibit_14\VBP\2510337|that|nsaids|secretion|inhibition (l_nmod) inhibition_27\NN\1068773|via|a|direct|channels (l_nmod) channels_31\NNS\6251781|cl-|as|channels (l_conj) channels_38\NNS\6251781|basolateral|membrane|k+
23500491
T12_T24 NONE atp-induced_4\JJ\1740| (r_amod) isomerization_5\NN\7415730|for|the|atp-induced|kinesin (l_nmod) kinesin_7\NN\1740|of
T1_T13 NONE atp_19\NN\14964590|of (r_nmod) hydrolysis_17\NN\13447361|from|the|atp (r_nmod) derived_14\VBN\634472|hydrolysis (r_acl) energy_13\NN\11419404|by|the|derived (r_nmod) driven_10\VBN\1224744|energy (r_acl) motors_9\NNS\3699975|proteins|are|microtubule-based|molecular|driven|. (l_nsubj) proteins_2\NNS\14944888|kinesin|superfamily|kifs
T1_T19 NONE atp_19\NN\14964590|of (r_nmod) hydrolysis_17\NN\13447361|from|the|atp (r_nmod) derived_14\VBN\634472|hydrolysis (r_acl) energy_13\NN\11419404|by|the|derived (r_nmod) driven_10\VBN\1224744|energy (r_acl) motors_9\NNS\3699975|proteins|are|microtubule-based|molecular|driven|. (l_nsubj) proteins_2\NNS\14944888|kinesin|superfamily|kifs (l_appos) kifs_4\NNS\1740|(|)
T1_T22 NONE atp_19\NN\14964590|of (r_nmod) hydrolysis_17\NN\13447361|from|the|atp (r_nmod) derived_14\VBN\634472|hydrolysis (r_acl) energy_13\NN\11419404|by|the|derived (r_nmod) driven_10\VBN\1224744|energy (r_acl) motors_9\NNS\3699975|proteins|are|microtubule-based|molecular|driven|.
T2_T18 NONE atp_6\NN\14964590| (r_compound) step_8\NN\168237|the|atp|binding (r_nsubj) crucial_10\JJ\1740|that|step|is|both|and|regulation (l_conj) regulation_23\NN\6652242|for|the|inter-domain|activity|guarantee (l_nmod) activity_26\NN\30358|of|atpase (l_compound) atpase_25\NN\1740|
T2_T20 NONE atp_6\NN\14964590| (r_compound) step_8\NN\168237|the|atp|binding (r_nsubj) crucial_10\JJ\1740|that|step|is|both|and|regulation (l_conj) regulation_23\NN\6652242|for|the|inter-domain|activity|guarantee (l_acl) guarantee_28\VB\884540|to|movement (l_dobj) movement_31\NN\191142|the|processive|kifs (l_nmod) kifs_34\NNS\1740|of|dimeric
T3_T21 NONE atp_14\NN\14964590| (r_compound) analog_15\NN\4743605|with|the|non-hydrolyzable|atp|,|amppnp|,|resolution (r_nmod) complexed_10\VBN\1740|analog (r_acl) kif4_9\NN\1740|of|complexed
T4_T21 NONE amppnp_17\NN\1740|imidodiphosphate (r_appos) analog_15\NN\4743605|with|the|non-hydrolyzable|atp|,|amppnp|,|resolution (r_nmod) complexed_10\VBN\1740|analog (r_acl) kif4_9\NN\1740|of|complexed
T5_T21 NONE imidodiphosphate_20\NN\1740|(|adenylyl|) (r_appos) amppnp_17\NN\1740|imidodiphosphate (r_appos) analog_15\NN\4743605|with|the|non-hydrolyzable|atp|,|amppnp|,|resolution (r_nmod) complexed_10\VBN\1740|analog (r_acl) kif4_9\NN\1740|of|complexed
T6_T23 NONE atp_12\NN\14964590| (r_compound) analogs_13\NNS\4743605|with|two|atp (r_nmod) complexed_9\VBN\1740|analogs (r_acl) structures_8\NNS\21939|with|solved|kif1a|complexed (l_compound) kif1a_7\NN\1740|
T7_T23 NONE atp_18\NN\14964590| (r_compound) binding_19\NN\4688246|during|atp (r_nmod) snapshots_16\NNS\3925226|molecular|binding (r_nsubj) reveal_20\VBP\2137132|combining|,|snapshots|achieved|. (l_advcl) combining_1\VBG\2630189|by|structure|structures (l_nmod) structures_8\NNS\21939|with|solved|kif1a|complexed (l_compound) kif1a_7\NN\1740|
T8_T23 NONE nucleotide-binding_26\JJ\1740| (r_amod) pocket_27\NN\3993180|of|the|nucleotide-binding (r_nmod) closure_23\NN\280853|the|pocket|binding (r_nsubjpass) achieved_32\VBN\2524171|that|closure|is|closure (r_ccomp) reveal_20\VBP\2137132|combining|,|snapshots|achieved|. (l_advcl) combining_1\VBG\2630189|by|structure|structures (l_nmod) structures_8\NNS\21939|with|solved|kif1a|complexed (l_compound) kif1a_7\NN\1740|
T9_T23 NONE atp_29\NN\14964590| (r_compound) binding_30\NN\4688246|during|atp (r_nmod) closure_23\NN\280853|the|pocket|binding (r_nsubjpass) achieved_32\VBN\2524171|that|closure|is|closure (r_ccomp) reveal_20\VBP\2137132|combining|,|snapshots|achieved|. (l_advcl) combining_1\VBG\2630189|by|structure|structures (l_nmod) structures_8\NNS\21939|with|solved|kif1a|complexed (l_compound) kif1a_7\NN\1740|
23598904
T23_T31 NONE cadmium-resistant_9\JJ\1740|and|manganese-resistant (r_amod) cells_13\NNS\3080309|of|cadmium-resistant|rbl-2h3 (r_nmod) feature_7\NN\5849040|suppression|is|a|common|cells|. (l_nsubj) suppression_0\NN\13489037|expression (l_nmod) expression_3\NN\4679549|of|zip8 (l_compound) zip8_2\NN\1740|
T24_T31 NONE manganese-resistant_11\JJ\1740| (r_conj) cadmium-resistant_9\JJ\1740|and|manganese-resistant (r_amod) cells_13\NNS\3080309|of|cadmium-resistant|rbl-2h3 (r_nmod) feature_7\NN\5849040|suppression|is|a|common|cells|. (l_nsubj) suppression_0\NN\13489037|expression (l_nmod) expression_3\NN\4679549|of|zip8 (l_compound) zip8_2\NN\1740|
T10_T27 NONE mncl2_32\NN\1740| (r_conj) cdcl2_30\NN\1740|to|and|mncl2 (r_nmod) exposure_28\NN\5042871|by|continuous|cdcl2 (r_nmod) developed_22\VBN\1753788|clarify|,|cells|were|cells|exposure|,|respectively|. (l_advcl) clarify_1\VB\939277|to|roles (l_dobj) roles_3\NNS\719494|the|transporters|hyperaccumulation (l_nmod) transporters_6\NNS\4490091|of|metal
T5_T27 NONE cadmium_10\NN\14625458|of|and|manganese (r_nmod) hyperaccumulation_8\NN\1740|in|cadmium|cells (r_nmod) roles_3\NNS\719494|the|transporters|hyperaccumulation (l_nmod) transporters_6\NNS\4490091|of|metal
T6_T27 NONE manganese_12\NN\14625458| (r_conj) cadmium_10\NN\14625458|of|and|manganese (r_nmod) hyperaccumulation_8\NN\1740|in|cadmium|cells (r_nmod) roles_3\NNS\719494|the|transporters|hyperaccumulation (l_nmod) transporters_6\NNS\4490091|of|metal
T7_T27 NONE cd-resistant_17\JJ\1740|and|mn-resistant (r_amod) cells_20\NNS\3080309|cd-resistant (r_nsubjpass) developed_22\VBN\1753788|clarify|,|cells|were|cells|exposure|,|respectively|. (l_advcl) clarify_1\VB\939277|to|roles (l_dobj) roles_3\NNS\719494|the|transporters|hyperaccumulation (l_nmod) transporters_6\NNS\4490091|of|metal
T8_T27 NONE mn-resistant_19\JJ\1740| (r_conj) cd-resistant_17\JJ\1740|and|mn-resistant (r_amod) cells_20\NNS\3080309|cd-resistant (r_nsubjpass) developed_22\VBN\1753788|clarify|,|cells|were|cells|exposure|,|respectively|. (l_advcl) clarify_1\VB\939277|to|roles (l_dobj) roles_3\NNS\719494|the|transporters|hyperaccumulation (l_nmod) transporters_6\NNS\4490091|of|metal
T9_T27 NONE cdcl2_30\NN\1740|to|and|mncl2 (r_nmod) exposure_28\NN\5042871|by|continuous|cdcl2 (r_nmod) developed_22\VBN\1753788|clarify|,|cells|were|cells|exposure|,|respectively|. (l_advcl) clarify_1\VB\939277|to|roles (l_dobj) roles_3\NNS\719494|the|transporters|hyperaccumulation (l_nmod) transporters_6\NNS\4490091|of|metal
T18_T28 NONE hgcl2_6\NN\1740|to|and|agno3 (r_nmod) cross-resistance_4\NN\1740|hgcl2 (r_dobj) showed_3\VBD\2137132|cells|also|cross-resistance|expression|. (l_nmod) expression_13\NN\4679549|due|to|enhanced|metallothionein (l_nmod) metallothionein_15\NN\1740|of
T19_T28 NONE agno3_8\NN\1740| (r_conj) hgcl2_6\NN\1740|to|and|agno3 (r_nmod) cross-resistance_4\NN\1740|hgcl2 (r_dobj) showed_3\VBD\2137132|cells|also|cross-resistance|expression|. (l_nmod) expression_13\NN\4679549|due|to|enhanced|metallothionein (l_nmod) metallothionein_15\NN\1740|of
T21_T25 CPR:9 )_11\-RRB-\1740| (r_punct) +_10\JJ\1740|) (r_dep) cd(2_9\NN\1740|of|+|and|mn(2 (r_nmod) uptake_7\NN\13440063|in|the|cd(2 (r_nmod) involved_4\VBN\2676054|uptake (r_acl) transporters_3\NNS\4490091|among|the|possible|involved (r_nmod) showed_32\VBD\2137132|transporters|,|expression|suppression|rbl-cdr|. (l_nsubj) expression_18\NN\4679549|the|zip8 (l_nmod) zip8_20\NN\1740|of|zrt-|,|encoded|, (l_acl) encoded_28\VBN\115157|slc39a8 (l_nmod) slc39a8_30\NN\1740|by
T21_T29 CPR:9 )_11\-RRB-\1740| (r_punct) +_10\JJ\1740|) (r_dep) cd(2_9\NN\1740|of|+|and|mn(2 (r_nmod) uptake_7\NN\13440063|in|the|cd(2 (r_nmod) involved_4\VBN\2676054|uptake (r_acl) transporters_3\NNS\4490091|among|the|possible|involved (r_nmod) showed_32\VBD\2137132|transporters|,|expression|suppression|rbl-cdr|. (l_nsubj) expression_18\NN\4679549|the|zip8 (l_nmod) zip8_20\NN\1740|of|zrt-|,|encoded|,
T21_T30 CPR:9 )_11\-RRB-\1740| (r_punct) +_10\JJ\1740|) (r_dep) cd(2_9\NN\1740|of|+|and|mn(2 (r_nmod) uptake_7\NN\13440063|in|the|cd(2 (r_nmod) involved_4\VBN\2676054|uptake (r_acl) transporters_3\NNS\4490091|among|the|possible|involved (r_nmod) showed_32\VBD\2137132|transporters|,|expression|suppression|rbl-cdr|. (l_nsubj) expression_18\NN\4679549|the|zip8 (l_nmod) zip8_20\NN\1740|of|zrt-|,|encoded|, (l_dep) zrt-_22\NN\1740|(|,|protein|8) (l_punct) 8)_26\-RRB-\1740|
T22_T25 CPR:9 )_15\-RRB-\1740| (r_punct) mn(2_13\NN\1740|+|) (r_conj) cd(2_9\NN\1740|of|+|and|mn(2 (r_nmod) uptake_7\NN\13440063|in|the|cd(2 (r_nmod) involved_4\VBN\2676054|uptake (r_acl) transporters_3\NNS\4490091|among|the|possible|involved (r_nmod) showed_32\VBD\2137132|transporters|,|expression|suppression|rbl-cdr|. (l_nsubj) expression_18\NN\4679549|the|zip8 (l_nmod) zip8_20\NN\1740|of|zrt-|,|encoded|, (l_acl) encoded_28\VBN\115157|slc39a8 (l_nmod) slc39a8_30\NN\1740|by
T22_T29 CPR:9 )_15\-RRB-\1740| (r_punct) mn(2_13\NN\1740|+|) (r_conj) cd(2_9\NN\1740|of|+|and|mn(2 (r_nmod) uptake_7\NN\13440063|in|the|cd(2 (r_nmod) involved_4\VBN\2676054|uptake (r_acl) transporters_3\NNS\4490091|among|the|possible|involved (r_nmod) showed_32\VBD\2137132|transporters|,|expression|suppression|rbl-cdr|. (l_nsubj) expression_18\NN\4679549|the|zip8 (l_nmod) zip8_20\NN\1740|of|zrt-|,|encoded|,
T22_T30 CPR:9 )_15\-RRB-\1740| (r_punct) mn(2_13\NN\1740|+|) (r_conj) cd(2_9\NN\1740|of|+|and|mn(2 (r_nmod) uptake_7\NN\13440063|in|the|cd(2 (r_nmod) involved_4\VBN\2676054|uptake (r_acl) transporters_3\NNS\4490091|among|the|possible|involved (r_nmod) showed_32\VBD\2137132|transporters|,|expression|suppression|rbl-cdr|. (l_nsubj) expression_18\NN\4679549|the|zip8 (l_nmod) zip8_20\NN\1740|of|zrt-|,|encoded|, (l_dep) zrt-_22\NN\1740|(|,|protein|8) (l_punct) 8)_26\-RRB-\1740|
T1_T26 CPR:9 )_17\-RRB-\1740|and|mn(2 (r_punct) +_16\JJR\1740|of|cd(2|) (r_nmod) transport_11\NN\3575240|in|the|and|toxicity|+|cells (r_nmod) plays_5\VBZ\1072262|that|zip8|role|transport (l_nsubj) zip8_4\NN\1740|
T2_T26 CPR:9 )_21\-RRB-\1740| (r_punct) +_20\JJ\1740|) (r_nummod) mn(2_19\NN\1740|+ (r_conj) )_17\-RRB-\1740|and|mn(2 (r_punct) +_16\JJR\1740|of|cd(2|) (r_nmod) transport_11\NN\3575240|in|the|and|toxicity|+|cells (r_nmod) plays_5\VBZ\1072262|that|zip8|role|transport (l_nsubj) zip8_4\NN\1740|
16988497
T6_T20 NONE acids_8\NNS\14818238|of|fatty|fas|diet (r_nmod) composition_5\NN\5075602|the|acids|,|and|expression (l_conj) expression_17\NN\4679549|the|genes|cells (l_nmod) genes_30\NNS\8459252|of|desaturase (l_compound) desaturase_20\NN\1740|delta-6|d6d|and|desaturase (l_appos) d6d_22\NN\1740|(|)
T6_T23 NONE acids_8\NNS\14818238|of|fatty|fas|diet (r_nmod) composition_5\NN\5075602|the|acids|,|and|expression (l_conj) expression_17\NN\4679549|the|genes|cells (l_nmod) genes_30\NNS\8459252|of|desaturase (l_compound) desaturase_20\NN\1740|delta-6|d6d|and|desaturase (l_conj) desaturase_26\NN\1740|delta-5|d5d
T6_T28 NONE acids_8\NNS\14818238|of|fatty|fas|diet (r_nmod) composition_5\NN\5075602|the|acids|,|and|expression (l_conj) expression_17\NN\4679549|the|genes|cells (l_nmod) genes_30\NNS\8459252|of|desaturase (l_compound) desaturase_20\NN\1740|delta-6|d6d|and|desaturase (l_conj) desaturase_26\NN\1740|delta-5|d5d (l_appos) d5d_28\NN\1740|(|)
T6_T33 NONE acids_8\NNS\14818238|of|fatty|fas|diet (r_nmod) composition_5\NN\5075602|the|acids|,|and|expression (l_conj) expression_17\NN\4679549|the|genes|cells (l_nmod) genes_30\NNS\8459252|of|desaturase (l_compound) desaturase_20\NN\1740|delta-6|d6d|and|desaturase
T8_T20 NONE fas_10\NNS\14304060|(|) (r_appos) acids_8\NNS\14818238|of|fatty|fas|diet (r_nmod) composition_5\NN\5075602|the|acids|,|and|expression (l_conj) expression_17\NN\4679549|the|genes|cells (l_nmod) genes_30\NNS\8459252|of|desaturase (l_compound) desaturase_20\NN\1740|delta-6|d6d|and|desaturase (l_appos) d6d_22\NN\1740|(|)
T8_T23 NONE fas_10\NNS\14304060|(|) (r_appos) acids_8\NNS\14818238|of|fatty|fas|diet (r_nmod) composition_5\NN\5075602|the|acids|,|and|expression (l_conj) expression_17\NN\4679549|the|genes|cells (l_nmod) genes_30\NNS\8459252|of|desaturase (l_compound) desaturase_20\NN\1740|delta-6|d6d|and|desaturase (l_conj) desaturase_26\NN\1740|delta-5|d5d
T8_T28 NONE fas_10\NNS\14304060|(|) (r_appos) acids_8\NNS\14818238|of|fatty|fas|diet (r_nmod) composition_5\NN\5075602|the|acids|,|and|expression (l_conj) expression_17\NN\4679549|the|genes|cells (l_nmod) genes_30\NNS\8459252|of|desaturase (l_compound) desaturase_20\NN\1740|delta-6|d6d|and|desaturase (l_conj) desaturase_26\NN\1740|delta-5|d5d (l_appos) d5d_28\NN\1740|(|)
T8_T33 NONE fas_10\NNS\14304060|(|) (r_appos) acids_8\NNS\14818238|of|fatty|fas|diet (r_nmod) composition_5\NN\5075602|the|acids|,|and|expression (l_conj) expression_17\NN\4679549|the|genes|cells (l_nmod) genes_30\NNS\8459252|of|desaturase (l_compound) desaturase_20\NN\1740|delta-6|d6d|and|desaturase
T14_T18 CPR:4 acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (l_conj) expression_46\NN\4679549|the|d6d (l_nmod) d6d_49\NN\1740|of|pbmc|and|d5d|genes
T14_T19 CPR:4 acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (l_conj) expression_46\NN\4679549|the|d6d (l_nmod) d6d_49\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_51\NN\1740|
T14_T34 NONE acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (r_nmod) correlation_28\NN\13841213|a|significant|negative|intake (r_conj) found_5\VBN\2426171|correlation|was|intake|,|but|correlation|. (l_nmod) intake_8\NN\13440063|between|dietary|sfas|and|expression (l_conj) expression_16\NN\4679549|genes (l_nmod) genes_22\NNS\8459252|of|d6d (l_compound) d6d_19\NN\1740|pbmc|and|d5d
T14_T35 NONE acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (r_nmod) correlation_28\NN\13841213|a|significant|negative|intake (r_conj) found_5\VBN\2426171|correlation|was|intake|,|but|correlation|. (l_nmod) intake_8\NN\13440063|between|dietary|sfas|and|expression (l_conj) expression_16\NN\4679549|genes (l_nmod) genes_22\NNS\8459252|of|d6d (l_compound) d6d_19\NN\1740|pbmc|and|d5d (l_conj) d5d_21\NN\1740|
T15_T18 CPR:4 la_36\NN\14625458|(|) (r_appos) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (l_conj) expression_46\NN\4679549|the|d6d (l_nmod) d6d_49\NN\1740|of|pbmc|and|d5d|genes
T15_T19 CPR:4 la_36\NN\14625458|(|) (r_appos) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (l_conj) expression_46\NN\4679549|the|d6d (l_nmod) d6d_49\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_51\NN\1740|
T15_T34 NONE la_36\NN\14625458|(|) (r_appos) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (r_nmod) correlation_28\NN\13841213|a|significant|negative|intake (r_conj) found_5\VBN\2426171|correlation|was|intake|,|but|correlation|. (l_nmod) intake_8\NN\13440063|between|dietary|sfas|and|expression (l_conj) expression_16\NN\4679549|genes (l_nmod) genes_22\NNS\8459252|of|d6d (l_compound) d6d_19\NN\1740|pbmc|and|d5d
T15_T35 NONE la_36\NN\14625458|(|) (r_appos) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (r_nmod) correlation_28\NN\13841213|a|significant|negative|intake (r_conj) found_5\VBN\2426171|correlation|was|intake|,|but|correlation|. (l_nmod) intake_8\NN\13440063|between|dietary|sfas|and|expression (l_conj) expression_16\NN\4679549|genes (l_nmod) genes_22\NNS\8459252|of|d6d (l_compound) d6d_19\NN\1740|pbmc|and|d5d (l_conj) d5d_21\NN\1740|
T16_T18 CPR:4 acid_40\NN\14818238|alpha-linolenic|lna (r_conj) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (l_conj) expression_46\NN\4679549|the|d6d (l_nmod) d6d_49\NN\1740|of|pbmc|and|d5d|genes
T16_T19 CPR:4 acid_40\NN\14818238|alpha-linolenic|lna (r_conj) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (l_conj) expression_46\NN\4679549|the|d6d (l_nmod) d6d_49\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_51\NN\1740|
T16_T34 NONE acid_40\NN\14818238|alpha-linolenic|lna (r_conj) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (r_nmod) correlation_28\NN\13841213|a|significant|negative|intake (r_conj) found_5\VBN\2426171|correlation|was|intake|,|but|correlation|. (l_nmod) intake_8\NN\13440063|between|dietary|sfas|and|expression (l_conj) expression_16\NN\4679549|genes (l_nmod) genes_22\NNS\8459252|of|d6d (l_compound) d6d_19\NN\1740|pbmc|and|d5d
T16_T35 NONE acid_40\NN\14818238|alpha-linolenic|lna (r_conj) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (r_nmod) correlation_28\NN\13841213|a|significant|negative|intake (r_conj) found_5\VBN\2426171|correlation|was|intake|,|but|correlation|. (l_nmod) intake_8\NN\13440063|between|dietary|sfas|and|expression (l_conj) expression_16\NN\4679549|genes (l_nmod) genes_22\NNS\8459252|of|d6d (l_compound) d6d_19\NN\1740|pbmc|and|d5d (l_conj) d5d_21\NN\1740|
T17_T18 CPR:4 lna_42\NN\1740|(|) (r_appos) acid_40\NN\14818238|alpha-linolenic|lna (r_conj) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (l_conj) expression_46\NN\4679549|the|d6d (l_nmod) d6d_49\NN\1740|of|pbmc|and|d5d|genes
T17_T19 CPR:4 lna_42\NN\1740|(|) (r_appos) acid_40\NN\14818238|alpha-linolenic|lna (r_conj) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (l_conj) expression_46\NN\4679549|the|d6d (l_nmod) d6d_49\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_51\NN\1740|
T17_T34 NONE lna_42\NN\1740|(|) (r_appos) acid_40\NN\14818238|alpha-linolenic|lna (r_conj) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (r_nmod) correlation_28\NN\13841213|a|significant|negative|intake (r_conj) found_5\VBN\2426171|correlation|was|intake|,|but|correlation|. (l_nmod) intake_8\NN\13440063|between|dietary|sfas|and|expression (l_conj) expression_16\NN\4679549|genes (l_nmod) genes_22\NNS\8459252|of|d6d (l_compound) d6d_19\NN\1740|pbmc|and|d5d
T17_T35 NONE lna_42\NN\1740|(|) (r_appos) acid_40\NN\14818238|alpha-linolenic|lna (r_conj) acid_34\NN\14818238|of|linoleic|la|and|acid (r_nmod) intake_31\NN\13440063|between|dietary|acid|and|expression (r_nmod) correlation_28\NN\13841213|a|significant|negative|intake (r_conj) found_5\VBN\2426171|correlation|was|intake|,|but|correlation|. (l_nmod) intake_8\NN\13440063|between|dietary|sfas|and|expression (l_conj) expression_16\NN\4679549|genes (l_nmod) genes_22\NNS\8459252|of|d6d (l_compound) d6d_19\NN\1740|pbmc|and|d5d (l_conj) d5d_21\NN\1740|
T1_T21 CPR:3 sfas_5\NNS\1740|of|high|and|mufas (r_nmod) intake_2\NN\13440063|sfas (r_nsubj) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_xcomp) increase_10\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|d6d (l_nmod) d6d_14\NN\1740|of|pbmc|and|d5d|genes
T1_T22 CPR:3 sfas_5\NNS\1740|of|high|and|mufas (r_nmod) intake_2\NN\13440063|sfas (r_nsubj) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_xcomp) increase_10\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|d6d (l_nmod) d6d_14\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_16\NN\1740|
T1_T24 NONE sfas_5\NNS\1740|of|high|and|mufas (r_nmod) intake_2\NN\13440063|sfas (r_nsubj) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_advcl) appears_23\VBZ\2604760|whilst|intake|decrease (l_xcomp) decrease_25\VB\169651|to|expression (l_dobj) expression_26\NN\4679549|d6d (l_nmod) d6d_29\NN\1740|of|pbmc|and|d5d|genes
T1_T25 NONE sfas_5\NNS\1740|of|high|and|mufas (r_nmod) intake_2\NN\13440063|sfas (r_nsubj) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_advcl) appears_23\VBZ\2604760|whilst|intake|decrease (l_xcomp) decrease_25\VB\169651|to|expression (l_dobj) expression_26\NN\4679549|d6d (l_nmod) d6d_29\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_31\NN\1740|
T2_T21 CPR:3 mufas_7\NNS\1740| (r_conj) sfas_5\NNS\1740|of|high|and|mufas (r_nmod) intake_2\NN\13440063|sfas (r_nsubj) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_xcomp) increase_10\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|d6d (l_nmod) d6d_14\NN\1740|of|pbmc|and|d5d|genes
T2_T22 CPR:3 mufas_7\NNS\1740| (r_conj) sfas_5\NNS\1740|of|high|and|mufas (r_nmod) intake_2\NN\13440063|sfas (r_nsubj) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_xcomp) increase_10\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|d6d (l_nmod) d6d_14\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_16\NN\1740|
T2_T24 NONE mufas_7\NNS\1740| (r_conj) sfas_5\NNS\1740|of|high|and|mufas (r_nmod) intake_2\NN\13440063|sfas (r_nsubj) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_advcl) appears_23\VBZ\2604760|whilst|intake|decrease (l_xcomp) decrease_25\VB\169651|to|expression (l_dobj) expression_26\NN\4679549|d6d (l_nmod) d6d_29\NN\1740|of|pbmc|and|d5d|genes
T2_T25 NONE mufas_7\NNS\1740| (r_conj) sfas_5\NNS\1740|of|high|and|mufas (r_nmod) intake_2\NN\13440063|sfas (r_nsubj) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_advcl) appears_23\VBZ\2604760|whilst|intake|decrease (l_xcomp) decrease_25\VB\169651|to|expression (l_dobj) expression_26\NN\4679549|d6d (l_nmod) d6d_29\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_31\NN\1740|
T3_T21 NONE efas_21\NNS\1740| (r_compound) intake_22\NN\13440063|high|efas (r_nsubj) appears_23\VBZ\2604760|whilst|intake|decrease (r_advcl) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_xcomp) increase_10\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|d6d (l_nmod) d6d_14\NN\1740|of|pbmc|and|d5d|genes
T3_T22 NONE efas_21\NNS\1740| (r_compound) intake_22\NN\13440063|high|efas (r_nsubj) appears_23\VBZ\2604760|whilst|intake|decrease (r_advcl) appears_8\VBZ\2604760|conclusion|intake|increase|,|appears|. (l_xcomp) increase_10\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|d6d (l_nmod) d6d_14\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_16\NN\1740|
T3_T24 CPR:4 efas_21\NNS\1740| (r_compound) intake_22\NN\13440063|high|efas (r_nsubj) appears_23\VBZ\2604760|whilst|intake|decrease (l_xcomp) decrease_25\VB\169651|to|expression (l_dobj) expression_26\NN\4679549|d6d (l_nmod) d6d_29\NN\1740|of|pbmc|and|d5d|genes
T3_T25 CPR:4 efas_21\NNS\1740| (r_compound) intake_22\NN\13440063|high|efas (r_nsubj) appears_23\VBZ\2604760|whilst|intake|decrease (l_xcomp) decrease_25\VB\169651|to|expression (l_dobj) expression_26\NN\4679549|d6d (l_nmod) d6d_29\NN\1740|of|pbmc|and|d5d|genes (l_conj) d5d_31\NN\1740|
T4_T26 NONE sfa_20\NN\1740|with|high|and|mufa (r_compound) diets_23\NNS\7560652|sfa (r_nmod) live_14\VBP\2655135|who|countries|diets (r_acl:relcl) chinese_12\NNPS\6929618|in|live (r_nmod) expression_5\NN\4679549|of|the|d6d|chinese (l_nmod) d6d_7\NN\1740|of|and|d5d|genes
T4_T27 NONE sfa_20\NN\1740|with|high|and|mufa (r_compound) diets_23\NNS\7560652|sfa (r_nmod) live_14\VBP\2655135|who|countries|diets (r_acl:relcl) chinese_12\NNPS\6929618|in|live (r_nmod) expression_5\NN\4679549|of|the|d6d|chinese (l_nmod) d6d_7\NN\1740|of|and|d5d|genes (l_conj) d5d_9\NN\1740|
T5_T26 NONE mufa_22\NN\1740| (r_conj) sfa_20\NN\1740|with|high|and|mufa (r_compound) diets_23\NNS\7560652|sfa (r_nmod) live_14\VBP\2655135|who|countries|diets (r_acl:relcl) chinese_12\NNPS\6929618|in|live (r_nmod) expression_5\NN\4679549|of|the|d6d|chinese (l_nmod) d6d_7\NN\1740|of|and|d5d|genes
T5_T27 NONE mufa_22\NN\1740| (r_conj) sfa_20\NN\1740|with|high|and|mufa (r_compound) diets_23\NNS\7560652|sfa (r_nmod) live_14\VBP\2655135|who|countries|diets (r_acl:relcl) chinese_12\NNPS\6929618|in|live (r_nmod) expression_5\NN\4679549|of|the|d6d|chinese (l_nmod) d6d_7\NN\1740|of|and|d5d|genes (l_conj) d5d_9\NN\1740|
23042954
T12_T17 NONE gluk1/ampa_3\NN\1740|
T12_T18 NONE gluk1/ampa_3\NN\1740| (r_compound) antagonist_5\NN\7846|of|the|gluk1/ampa|receptor|ly293558 (l_compound) receptor_4\NN\5225602|
T13_T17 CPR:6 ly293558_6\CD\1740| (r_dep) antagonist_5\NN\7846|of|the|gluk1/ampa|receptor|ly293558 (l_compound) gluk1/ampa_3\NN\1740|
T13_T18 CPR:6 ly293558_6\CD\1740| (r_dep) antagonist_5\NN\7846|of|the|gluk1/ampa|receptor|ly293558 (l_compound) receptor_4\NN\5225602|
T10_T14 CPR:6 acid_34\NN\14818238|of|the|antagonist|(3s,4ar,6r,8ar)-6-[2-(1(2)h-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic|ly293558 (l_compound) antagonist_32\NN\7846|acid|receptor (l_compound) acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (l_compound) gluk1_25\NN\1740|
T10_T15 CPR:6 acid_34\NN\14818238|of|the|antagonist|(3s,4ar,6r,8ar)-6-[2-(1(2)h-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic|ly293558 (l_compound) antagonist_32\NN\7846|acid|receptor (l_compound) acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (l_amod) (glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic_26\NN\1740|
T10_T16 CPR:6 acid_34\NN\14818238|of|the|antagonist|(3s,4ar,6r,8ar)-6-[2-(1(2)h-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic|ly293558 (l_compound) antagonist_32\NN\7846|acid|receptor (l_compound) receptor_31\NN\5225602|
T11_T14 CPR:6 ly293558_36\NN\1740|(|) (r_appos) acid_34\NN\14818238|of|the|antagonist|(3s,4ar,6r,8ar)-6-[2-(1(2)h-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic|ly293558 (l_compound) antagonist_32\NN\7846|acid|receptor (l_compound) acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (l_compound) gluk1_25\NN\1740|
T11_T15 CPR:6 ly293558_36\NN\1740|(|) (r_appos) acid_34\NN\14818238|of|the|antagonist|(3s,4ar,6r,8ar)-6-[2-(1(2)h-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic|ly293558 (l_compound) antagonist_32\NN\7846|acid|receptor (l_compound) acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (l_amod) (glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic_26\NN\1740|
T11_T16 CPR:6 ly293558_36\NN\1740|(|) (r_appos) acid_34\NN\14818238|of|the|antagonist|(3s,4ar,6r,8ar)-6-[2-(1(2)h-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic|ly293558 (l_compound) antagonist_32\NN\7846|acid|receptor (l_compound) receptor_31\NN\5225602|
T8_T14 NONE acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (l_compound) gluk1_25\NN\1740|
T8_T15 NONE acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (l_amod) (glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic_26\NN\1740|
T8_T16 NONE acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (r_compound) antagonist_32\NN\7846|acid|receptor (l_compound) receptor_31\NN\5225602|
T9_T14 NONE ampa_29\NN\1740|(|) (r_appos) acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (l_compound) gluk1_25\NN\1740|
T9_T15 NONE ampa_29\NN\1740|(|) (r_appos) acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (l_amod) (glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic_26\NN\1740|
T9_T16 NONE ampa_29\NN\1740|(|) (r_appos) acid_27\NN\14818238|gluk1|(glur5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic|ampa (r_compound) antagonist_32\NN\7846|acid|receptor (l_compound) receptor_31\NN\5225602|
16325050
T10_T27 NONE catecholamine_5\NN\5407119| (r_compound) effects_6\NNS\13245626|catecholamine|activity (r_conj) polymorphism_3\NN\11418750|the|arg389gly|beta1-adrenoceptor|and|effects|. (l_compound) beta1-adrenoceptor_2\NN\1740|
T10_T28 NONE catecholamine_5\NN\5407119| (r_compound) effects_6\NNS\13245626|catecholamine|activity (r_conj) polymorphism_3\NN\11418750|the|arg389gly|beta1-adrenoceptor|and|effects|. (l_compound) arg389gly_1\NN\1740|
T10_T29 NONE catecholamine_5\NN\5407119| (r_compound) effects_6\NNS\13245626|catecholamine|activity (l_nmod) activity_9\NN\30358|on|plasma-renin (l_amod) plasma-renin_8\JJ\1740|
T6_T14 NONE dobutamine-induced_16\JJ\1740| (r_amod) effects_18\NNS\13245626|dobutamine-induced|hemodynamic|and|increase (l_conj) increase_20\NN\13576355|activity (l_nmod) activity_23\NN\30358|in|plasma-renin|pra (l_amod) plasma-renin_22\JJ\1740|
T6_T17 NONE dobutamine-induced_16\JJ\1740| (r_amod) effects_18\NNS\13245626|dobutamine-induced|hemodynamic|and|increase (r_nsubj) genotype-dependent_33\JJ\1740|whether|,|humans|,|effects|might|be|beta1-adrenoceptor (l_nmod:npmod) beta1-adrenoceptor_29\NN\1740|beta1ar
T6_T18 NONE dobutamine-induced_16\JJ\1740| (r_amod) effects_18\NNS\13245626|dobutamine-induced|hemodynamic|and|increase (r_nsubj) genotype-dependent_33\JJ\1740|whether|,|humans|,|effects|might|be|beta1-adrenoceptor (l_nmod:npmod) beta1-adrenoceptor_29\NN\1740|beta1ar (l_appos) beta1ar_31\NN\1740|(|)
T5_T24 NONE dobutamine_7\NN\1740| (r_nsubj) increased_8\VBD\169651|results|regard|,|dobutamine|pra|potently|subjects|. (l_nmod) subjects_16\NNS\6598915|in|arg389-beta1ar (l_compound) arg389-beta1ar_13\NN\1740|versus|gly389-beta1ar
T5_T25 NONE dobutamine_7\NN\1740| (r_nsubj) increased_8\VBD\169651|results|regard|,|dobutamine|pra|potently|subjects|. (l_nmod) subjects_16\NNS\6598915|in|arg389-beta1ar (l_compound) arg389-beta1ar_13\NN\1740|versus|gly389-beta1ar (l_conj) gly389-beta1ar_15\NN\1740|
T7_T26 NONE bisoprolol_0\NN\1740| (r_nsubj) suppressed_2\VBD\2510337|bisoprolol|markedly|increase|. (l_dobj) increase_6\NN\13576355|the|dobutamine-induced|pra|arg389- (l_nmod) arg389-_8\NN\1740|in|but|subjects (l_conj) subjects_14\NNS\6598915|marginally|gly389-beta1ar (l_amod) gly389-beta1ar_13\NN\1740|in
T8_T26 NONE dobutamine-induced_4\JJ\1740| (r_amod) increase_6\NN\13576355|the|dobutamine-induced|pra|arg389- (l_nmod) arg389-_8\NN\1740|in|but|subjects (l_conj) subjects_14\NNS\6598915|marginally|gly389-beta1ar (l_amod) gly389-beta1ar_13\NN\1740|in
T9_T11 NONE dobutamine_5\NN\1740| (r_nsubj) caused_6\VBD\1617192|regard|,|dobutamine|rate|subjects|. (l_nmod) subjects_22\NNS\6598915|in|arg389- (l_amod) arg389-_19\NN\1740|versus|gly389-beta1ar (l_conj) gly389-beta1ar_21\JJ\1740|
T1_T12 NONE bisoprolol_0\NN\1740| (r_nsubj) reduced_1\VBD\441445|bisoprolol|rate|and|decreases|potently|subjects|. (l_nmod) subjects_19\NNS\6598915|in|arg389- (l_amod) arg389-_16\NN\1740|versus|gly389-beta1ar (l_conj) gly389-beta1ar_18\NN\1740|
T2_T12 NONE dobutamine-induced_2\JJ\1740| (r_amod) rate_4\NN\13815152|dobutamine-induced|heart|and|contractility|increases (r_dobj) reduced_1\VBD\441445|bisoprolol|rate|and|decreases|potently|subjects|. (l_nmod) subjects_19\NNS\6598915|in|arg389- (l_amod) arg389-_16\NN\1740|versus|gly389-beta1ar (l_conj) gly389-beta1ar_18\NN\1740|
23512754
T12_T21 NONE 1-cinnamoyl-3,11-dihydroxymeliacarpin_5\NN\1740|of|the|potent|antiviral (r_nmod) effect_0\NN\34213|1-cinnamoyl-3,11-dihydroxymeliacarpin|production|. (l_nmod) production_8\NN\30358|on|cytokine|macrophages (l_compound) cytokine_7\NN\14728724|
T8_T16 NONE cdm_4\NN\1740|of (r_nmod) action_2\NN\30358|the|antiherpetic|cdm (r_nsubjpass) measured_6\VBN\697589|action|was|assay|,|and|determined (l_conj) determined_17\VBN\1645601|effect|was|measuring|. (l_advcl) measuring_19\VBG\697589|by|production|using (l_dobj) production_22\NN\30358|the|cytokine (l_compound) cytokine_21\NN\14728724|
T11_T17 CPR:3 cdm_17\NN\1740|by|used (r_nmod) increased_15\VBN\169651|macrophages|,|levels|were|cdm|. (l_nsubjpass) levels_3\NNS\4916342|tnf-α (l_nmod) tnf-α_5\NN\1740|of|,|ifn-γ|,|no|,|il-6|and|il-10
T11_T18 CPR:3 cdm_17\NN\1740|by|used (r_nmod) increased_15\VBN\169651|macrophages|,|levels|were|cdm|. (l_nsubjpass) levels_3\NNS\4916342|tnf-α (l_nmod) tnf-α_5\NN\1740|of|,|ifn-γ|,|no|,|il-6|and|il-10 (l_conj) ifn-γ_7\NN\1740|
T11_T19 CPR:3 cdm_17\NN\1740|by|used (r_nmod) increased_15\VBN\169651|macrophages|,|levels|were|cdm|. (l_nsubjpass) levels_3\NNS\4916342|tnf-α (l_nmod) tnf-α_5\NN\1740|of|,|ifn-γ|,|no|,|il-6|and|il-10 (l_conj) il-6_11\NN\1740|
T11_T20 CPR:3 cdm_17\NN\1740|by|used (r_nmod) increased_15\VBN\169651|macrophages|,|levels|were|cdm|. (l_nsubjpass) levels_3\NNS\4916342|tnf-α (l_nmod) tnf-α_5\NN\1740|of|,|ifn-γ|,|no|,|il-6|and|il-10 (l_conj) il-10_13\NN\1740|
T1_T13 CPR:3 cdm_2\NN\1740| (r_nsubj) synergized_5\VBD\1740|besides|,|cdm|only|production|,|but|prolonged|. (l_dobj) production_7\NN\30358|tnf-α|combined (l_compound) tnf-α_6\NN\1740|
T1_T14 CPR:3 cdm_2\NN\1740| (r_nsubj) synergized_5\VBD\1740|besides|,|cdm|only|production|,|but|prolonged|. (l_dobj) production_7\NN\30358|tnf-α|combined (l_acl) combined_8\VBN\2630189|ifn-γ (l_nmod) ifn-γ_10\NN\1740|with
T2_T15 CPR:3 cdm_3\NN\1740| (r_nsubj) inhibits_4\VBZ\2510337|that|cdm|multiplication|and|increases|,|actions (l_conj) increases_12\VBZ\169651|also|production (l_dobj) production_14\NN\30358|cytokine|macrophages (l_compound) cytokine_13\NN\14728724|
12692940
T6_T13 NONE pranlukast_5\NN\1740| (r_nsubj) modify_8\VB\109660|hand|,|pranlukast|did|not|adhesion|. (l_dobj) adhesion_12\NN\14204950|the|eosinophil|spontaneous|cells (l_nmod) cells_22\NNS\3080309|to|the|resting|il-4|pulmonary|endothelial (l_compound) il-4_17\NN\1740|plus|tnf-alpha-stimulated
T6_T14 NONE pranlukast_5\NN\1740| (r_nsubj) modify_8\VB\109660|hand|,|pranlukast|did|not|adhesion|. (l_dobj) adhesion_12\NN\14204950|the|eosinophil|spontaneous|cells (l_nmod) cells_22\NNS\3080309|to|the|resting|il-4|pulmonary|endothelial (l_compound) il-4_17\NN\1740|plus|tnf-alpha-stimulated (l_conj) tnf-alpha-stimulated_19\JJ\1740|
T8_T15 NONE pranlukast_2\NN\1740| (r_nsubj) modulate_5\VB\1724459|similarly|,|pranlukast|did|not|adhesion|. (l_dobj) adhesion_10\NN\14204950|il-5-|eosinophil|cells (l_amod) il-5-_6\NN\1740|or|fmlp-activated
23608239
T16_T23 NONE superoxide_4\NN\14971519| (r_compound) dismutase_5\NN\1740|such|superoxide|,|glutathione|,|catalase|and|peroxidation
T16_T24 NONE superoxide_4\NN\14971519| (r_compound) dismutase_5\NN\1740|such|superoxide|,|glutathione|,|catalase|and|peroxidation (l_conj) catalase_9\NN\14732946|
T17_T23 NONE glutathione_7\NN\1740| (r_conj) dismutase_5\NN\1740|such|superoxide|,|glutathione|,|catalase|and|peroxidation
T17_T24 NONE glutathione_7\NN\1740| (r_conj) dismutase_5\NN\1740|such|superoxide|,|glutathione|,|catalase|and|peroxidation (l_conj) catalase_9\NN\14732946|
T7_T21 NONE gsh_14\NN\1740| (r_conj) sod_10\NN\9335240|such|,|cat|,|gsh|and|lpo|tissues
T7_T22 NONE gsh_14\NN\1740| (r_conj) sod_10\NN\9335240|such|,|cat|,|gsh|and|lpo|tissues (l_conj) cat_12\NN\2120997|
T8_T21 NONE ethanol_24\NN\14708720| (r_compound) group_26\NN\2137|with|ethanol|control (r_nmod) compared_22\VBN\644583|when|group (r_advcl) observed_4\VBN\2163746|changes|were|activities|compared|. (l_nmod) activities_7\NNS\30358|in|enzyme|sod (l_nmod) sod_10\NN\9335240|such|,|cat|,|gsh|and|lpo|tissues
T8_T22 NONE ethanol_24\NN\14708720| (r_compound) group_26\NN\2137|with|ethanol|control (r_nmod) compared_22\VBN\644583|when|group (r_advcl) observed_4\VBN\2163746|changes|were|activities|compared|. (l_nmod) activities_7\NNS\30358|in|enzyme|sod (l_nmod) sod_10\NN\9335240|such|,|cat|,|gsh|and|lpo|tissues (l_conj) cat_12\NN\2120997|
23434829
T10_T24 NONE acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_nsubj) osteopontin_0\NN\1740|opn|,|protein|,
T10_T25 NONE acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_nsubj) osteopontin_0\NN\1740|opn|,|protein|, (l_appos) opn_2\NN\1740|(|)
T10_T26 NONE acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|)
T10_T27 NONE acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_advcl) binding_20\VBG\1290422|for|integrin (l_nmod) integrin_22\NN\1740|to
T8_T24 NONE arginine-glycine-aspartic_13\JJ\1740| (r_amod) acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_nsubj) osteopontin_0\NN\1740|opn|,|protein|,
T8_T25 NONE arginine-glycine-aspartic_13\JJ\1740| (r_amod) acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_nsubj) osteopontin_0\NN\1740|opn|,|protein|, (l_appos) opn_2\NN\1740|(|)
T8_T26 NONE arginine-glycine-aspartic_13\JJ\1740| (r_amod) acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|)
T8_T27 NONE arginine-glycine-aspartic_13\JJ\1740| (r_amod) acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_advcl) binding_20\VBG\1290422|for|integrin (l_nmod) integrin_22\NN\1740|to
T9_T24 NONE arginine-glycine-aspartic_13\JJ\1740| (r_amod) acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_nsubj) osteopontin_0\NN\1740|opn|,|protein|,
T9_T25 NONE arginine-glycine-aspartic_13\JJ\1740| (r_amod) acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_nsubj) osteopontin_0\NN\1740|opn|,|protein|, (l_appos) opn_2\NN\1740|(|)
T9_T26 NONE arginine-glycine-aspartic_13\JJ\1740| (r_amod) acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|)
T9_T27 NONE arginine-glycine-aspartic_13\JJ\1740| (r_amod) acid_14\NN\14818238|arginine-glycine-aspartic (r_compound) domain_18\NN\13934596|a|functional|acid|(|rgd|) (r_dobj) has_10\VBZ\2108377|osteopontin|domain|binding|. (l_advcl) binding_20\VBG\1290422|for|integrin (l_nmod) integrin_22\NN\1740|to
T11_T29 NONE atp-binding_16\JJ\1740| (r_amod) transporter_18\NN\4490091|of|atp-binding|cassette (r_nmod) subfamily_14\NN\7992450|a|transporter (r_appos) p-glycoprotein_8\NN\1740|of|p-gp|,|subfamily (r_nmod) mrna_3\NN\14832193|the|and|expression|p-glycoprotein (r_dobj) increased_1\VBD\169651|opn|mrna|manner|. (l_nsubj) opn_0\NN\1740|
T11_T30 NONE atp-binding_16\JJ\1740| (r_amod) transporter_18\NN\4490091|of|atp-binding|cassette (r_nmod) subfamily_14\NN\7992450|a|transporter (r_appos) p-glycoprotein_8\NN\1740|of|p-gp|,|subfamily
T11_T31 NONE atp-binding_16\JJ\1740| (r_amod) transporter_18\NN\4490091|of|atp-binding|cassette (r_nmod) subfamily_14\NN\7992450|a|transporter (r_appos) p-glycoprotein_8\NN\1740|of|p-gp|,|subfamily (l_appos) p-gp_10\NN\1740|(|)
T11_T32 NONE atp-binding_16\JJ\1740| (r_amod) transporter_18\NN\4490091|of|atp-binding|cassette
T12_T36 NONE daunomycin_0\NN\1740|dun|,|agent|, (r_nsubjpass) used_12\VBN\1156834|daunomycin|was|evaluate|,|and|increased (l_conj) increased_21\VBD\169651|opn|activity|. (l_nsubj) opn_20\NN\1740|
T13_T36 NONE dun_2\NNP\2377703|(|) (r_appos) daunomycin_0\NN\1740|dun|,|agent|, (r_nsubjpass) used_12\VBN\1156834|daunomycin|was|evaluate|,|and|increased (l_conj) increased_21\VBD\169651|opn|activity|. (l_nsubj) opn_20\NN\1740|
T14_T37 NONE dun-induced_2\JJ\1740| (r_amod) death_4\NN\7296428|dun-induced|cell|,|antagonized (r_dobj) inhibited_1\VBD\2510337|opn|death|. (l_nsubj) opn_0\NN\1740|
T14_T38 NONE dun-induced_2\JJ\1740| (r_amod) death_4\NN\7296428|dun-induced|cell|,|antagonized (l_acl:relcl) antagonized_8\VBN\1787955|which|was|antibody (l_nmod) antibody_12\NN\14728724|by|αvβ3|monoclonal (l_compound) αvβ3_10\NN\1740|
T1_T15 NONE dun_3\NNP\2377703|with (r_nmod) treatment_1\NN\654885|long-term|dun (r_nsubj) enhanced_5\VBD\227165|treatment|further|expression|. (l_dobj) expression_7\NN\4679549|the|opn (l_nmod) opn_9\NN\1740|of
T2_T16 NONE dun-induced_6\JJ\1740| (r_amod) apoptosis_7\NN\11486178|the|dun-induced|cells (r_dobj) potentiated_4\VBD\229605|knockdown|apoptosis|. (l_nsubj) knockdown_0\NN\1173038|opn (l_nmod) opn_3\NN\1740|of|endogenous
T3_T17 NONE paclitaxel_14\NN\1740|including|,|doxorubicin|,|actinomycin-d|,|and|rapamycin|,|substrates (r_nmod) drugs_11\NNS\14778436|by|other|,|paclitaxel (r_nmod) caused_8\VBN\1617192|drugs (r_acl) death_7\NN\7296428|cell|caused (r_dobj) enhanced_5\VBD\227165|furthermore|,|knockdown|death|. (l_nsubj) knockdown_2\NN\1173038|opn (l_nmod) opn_4\NN\1740|of
T3_T18 CPR:9 paclitaxel_14\NN\1740|including|,|doxorubicin|,|actinomycin-d|,|and|rapamycin|,|substrates (l_acl:relcl) substrates_27\NNS\19613|which|are|also|p-gp (l_compound) p-gp_26\NN\1740|
T4_T17 NONE doxorubicin_16\NN\2716866| (r_conj) paclitaxel_14\NN\1740|including|,|doxorubicin|,|actinomycin-d|,|and|rapamycin|,|substrates (r_nmod) drugs_11\NNS\14778436|by|other|,|paclitaxel (r_nmod) caused_8\VBN\1617192|drugs (r_acl) death_7\NN\7296428|cell|caused (r_dobj) enhanced_5\VBD\227165|furthermore|,|knockdown|death|. (l_nsubj) knockdown_2\NN\1173038|opn (l_nmod) opn_4\NN\1740|of
T4_T18 CPR:9 doxorubicin_16\NN\2716866| (r_conj) paclitaxel_14\NN\1740|including|,|doxorubicin|,|actinomycin-d|,|and|rapamycin|,|substrates (l_acl:relcl) substrates_27\NNS\19613|which|are|also|p-gp (l_compound) p-gp_26\NN\1740|
T5_T17 NONE actinomycin-d_18\NN\1740| (r_conj) paclitaxel_14\NN\1740|including|,|doxorubicin|,|actinomycin-d|,|and|rapamycin|,|substrates (r_nmod) drugs_11\NNS\14778436|by|other|,|paclitaxel (r_nmod) caused_8\VBN\1617192|drugs (r_acl) death_7\NN\7296428|cell|caused (r_dobj) enhanced_5\VBD\227165|furthermore|,|knockdown|death|. (l_nsubj) knockdown_2\NN\1173038|opn (l_nmod) opn_4\NN\1740|of
T5_T18 CPR:9 actinomycin-d_18\NN\1740| (r_conj) paclitaxel_14\NN\1740|including|,|doxorubicin|,|actinomycin-d|,|and|rapamycin|,|substrates (l_acl:relcl) substrates_27\NNS\19613|which|are|also|p-gp (l_compound) p-gp_26\NN\1740|
T6_T17 NONE rapamycin_21\NN\1740| (r_conj) paclitaxel_14\NN\1740|including|,|doxorubicin|,|actinomycin-d|,|and|rapamycin|,|substrates (r_nmod) drugs_11\NNS\14778436|by|other|,|paclitaxel (r_nmod) caused_8\VBN\1617192|drugs (r_acl) death_7\NN\7296428|cell|caused (r_dobj) enhanced_5\VBD\227165|furthermore|,|knockdown|death|. (l_nsubj) knockdown_2\NN\1173038|opn (l_nmod) opn_4\NN\1740|of
T6_T18 CPR:9 rapamycin_21\NN\1740| (r_conj) paclitaxel_14\NN\1740|including|,|doxorubicin|,|actinomycin-d|,|and|rapamycin|,|substrates (l_acl:relcl) substrates_27\NNS\19613|which|are|also|p-gp (l_compound) p-gp_26\NN\1740|
T7_T19 NONE dun_13\NN\2377703|of (r_nmod) action_11\NN\30358|the|cytotoxic|dun (r_dobj) enhanced_8\VBD\227165|that|knockdown|action (l_nsubj) knockdown_7\NN\1173038|opn (l_compound) opn_6\NN\1740|
23542114
T7_T13 CPR:4 trioxide_1\NN\14971519|arsenic (r_nsubj) depletes_2\VBZ\2267060|trioxide|cells|and|inhibits|. (l_conj) inhibits_7\VBZ\2510337|repopulation|downregulation (l_nmod) downregulation_15\NN\1740|by|pathway (l_nmod) pathway_18\NN\5483677|of|notch (l_compound) notch_17\NN\13908021|
T5_T10 CPR:4 ato_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|ato|phosphorylation|blockade|. (l_dobj) phosphorylation_3\NN\1740|the|and|activation|akt (l_nmod) akt_7\NN\1740|of|and|stat3 (l_conj) stat3_9\NN\1740|
T5_T11 CPR:4 ato_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|ato|phosphorylation|blockade|. (l_nmod) blockade_13\NN\952963|through|notch|signaling (l_compound) notch_11\NN\13908021|
T5_T9 CPR:4 ato_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|ato|phosphorylation|blockade|. (l_dobj) phosphorylation_3\NN\1740|the|and|activation|akt (l_nmod) akt_7\NN\1740|of|and|stat3
T6_T12 CPR:4 ato_5\NN\1740|the (r_nsubj) approach_10\NN\940842|that|ato|is|a|promising|new|decrease (l_acl) decrease_12\VB\169651|to|glioblastoma|downregulation (l_nmod) downregulation_18\NN\1740|by|pathway (l_nmod) pathway_21\NN\5483677|of|notch (l_compound) notch_20\NN\13908021|
23091188
T20_T52 NONE salt_4\NN\14818238| (r_compound) pump_6\NN\3736970|of|the|bile|salt|export|bsep
T20_T54 NONE salt_4\NN\14818238| (r_compound) pump_6\NN\3736970|of|the|bile|salt|export|bsep (l_appos) bsep_8\NN\1740|(|)
T43_T52 NONE acids_16\NNS\14818238|of|bile (r_nmod) accumulation_13\NN\13497135|intracellular|acids (r_dobj) cause_11\VB\1617192|inhibition|can|accumulation|and|factor|. (l_nsubj) inhibition_0\NN\1068773|pump (l_nmod) pump_6\NN\3736970|of|the|bile|salt|export|bsep
T43_T54 NONE acids_16\NNS\14818238|of|bile (r_nmod) accumulation_13\NN\13497135|intracellular|acids (r_dobj) cause_11\VB\1617192|inhibition|can|accumulation|and|factor|. (l_nsubj) inhibition_0\NN\1068773|pump (l_nmod) pump_6\NN\3736970|of|the|bile|salt|export|bsep (l_appos) bsep_8\NN\1740|(|)
T21_T51 CPR:4 lopinavir_3\NN\1740|lpv|and|ritonavir (r_dep) inhibitors_2\NNS\20090|antiretroviral|protease|lopinavir (l_compound) protease_1\NN\14732946|
T21_T53 CPR:4 lopinavir_3\NN\1740|lpv|and|ritonavir (r_dep) inhibitors_2\NNS\20090|antiretroviral|protease|lopinavir (r_nsubj) inhibitors_15\NNS\20090|inhibitors|are|reported|bsep|. (l_compound) bsep_14\NN\1740|
T22_T51 CPR:4 lpv_5\NN\1740|(|) (r_appos) lopinavir_3\NN\1740|lpv|and|ritonavir (r_dep) inhibitors_2\NNS\20090|antiretroviral|protease|lopinavir (l_compound) protease_1\NN\14732946|
T22_T53 CPR:4 lpv_5\NN\1740|(|) (r_appos) lopinavir_3\NN\1740|lpv|and|ritonavir (r_dep) inhibitors_2\NNS\20090|antiretroviral|protease|lopinavir (r_nsubj) inhibitors_15\NNS\20090|inhibitors|are|reported|bsep|. (l_compound) bsep_14\NN\1740|
T23_T51 CPR:4 ritonavir_8\NN\4013993|rtv (r_conj) lopinavir_3\NN\1740|lpv|and|ritonavir (r_dep) inhibitors_2\NNS\20090|antiretroviral|protease|lopinavir (l_compound) protease_1\NN\14732946|
T23_T53 CPR:4 ritonavir_8\NN\4013993|rtv (r_conj) lopinavir_3\NN\1740|lpv|and|ritonavir (r_dep) inhibitors_2\NNS\20090|antiretroviral|protease|lopinavir (r_nsubj) inhibitors_15\NNS\20090|inhibitors|are|reported|bsep|. (l_compound) bsep_14\NN\1740|
T24_T51 CPR:4 rtv_10\NN\1740|(|) (r_appos) ritonavir_8\NN\4013993|rtv (r_conj) lopinavir_3\NN\1740|lpv|and|ritonavir (r_dep) inhibitors_2\NNS\20090|antiretroviral|protease|lopinavir (l_compound) protease_1\NN\14732946|
T24_T53 CPR:4 rtv_10\NN\1740|(|) (r_appos) ritonavir_8\NN\4013993|rtv (r_conj) lopinavir_3\NN\1740|lpv|and|ritonavir (r_dep) inhibitors_2\NNS\20090|antiretroviral|protease|lopinavir (r_nsubj) inhibitors_15\NNS\20090|inhibitors|are|reported|bsep|. (l_compound) bsep_14\NN\1740|
T19_T50 NONE acids_4\NNS\14818238|of|endogenous|bile|scrh (r_nmod) quantification_0\NN\5846355|acids (r_nsubj) reveal_8\VB\2137132|quantification|may|responses|. (l_dobj) responses_11\NNS\11410625|important|adaptive|associated (l_acl) associated_12\VBN\628491|exposure (l_nmod) exposure_14\NN\5042871|with|inhibitors (l_nmod) inhibitors_18\NNS\20090|to|known|bsep (l_compound) bsep_17\NN\1740|
17065601
T14_T23 NONE acid_9\NN\14818238| (r_compound) transporters_10\NNS\4490091|of|cationic|amino|acid
T15_T24 NONE l-arginine_3\NN\1740| (r_compound) kinetics_5\NNS\6100236|the|l-arginine|uptake|,|dependence|,|profiles|,|and|sensitivity (l_conj) sensitivity_27\NN\5651971|stimulation (l_nmod) stimulation_30\NN\242808|to|trans|transporters (l_nmod) transporters_35\NNS\4490091|of|cationic|amino|acid
T16_T24 NONE )_8\-RRB-\1740| (r_punct) na(+_7\JJ\1740|) (r_amod) dependence_9\NN\24720|na(+|transport (r_conj) kinetics_5\NNS\6100236|the|l-arginine|uptake|,|dependence|,|profiles|,|and|sensitivity (l_conj) sensitivity_27\NN\5651971|stimulation (l_nmod) stimulation_30\NN\242808|to|trans|transporters (l_nmod) transporters_35\NNS\4490091|of|cationic|amino|acid
T17_T24 NONE acids_24\NNS\14818238|cationic|amino (r_nmod) inhibition_16\NN\1068773|of|cis|uptake|acids (r_nmod) profiles_13\NNS\6999802|inhibition (r_conj) kinetics_5\NNS\6100236|the|l-arginine|uptake|,|dependence|,|profiles|,|and|sensitivity (l_conj) sensitivity_27\NN\5651971|stimulation (l_nmod) stimulation_30\NN\242808|to|trans|transporters (l_nmod) transporters_35\NNS\4490091|of|cationic|amino|acid
T18_T24 NONE acid_34\NN\14818238| (r_compound) transporters_35\NNS\4490091|of|cationic|amino|acid
T19_T25 CPR:9 l-arginine_4\NN\1740| (r_nsubjpass) taken_6\VBN\2367363|that|l-arginine|is|up|cells|,|y(+)l|,|b(0|making (l_nmod) y(+)l_18\NN\1740|principally|via|system|slc3a2/slc7a6|and|y(+ (l_appos) slc3a2/slc7a6_20\NN\1740|(|)
T19_T26 NONE l-arginine_4\NN\1740| (r_nsubjpass) taken_6\VBN\2367363|that|l-arginine|is|up|cells|,|y(+)l|,|b(0|making (l_nmod) y(+)l_18\NN\1740|principally|via|system|slc3a2/slc7a6|and|y(+ (l_appos) slc3a2/slc7a6_20\NN\1740|(|)
T19_T27 NONE l-arginine_4\NN\1740| (r_nsubjpass) taken_6\VBN\2367363|that|l-arginine|is|up|cells|,|y(+)l|,|b(0|making (l_nmod) y(+)l_18\NN\1740|principally|via|system|slc3a2/slc7a6|and|y(+ (l_conj) y(+_24\NN\1740|system|)|slc7a1 (l_dep) slc7a1_27\NN\1740|(|and|slc7a2|)
T19_T28 NONE l-arginine_4\NN\1740| (r_nsubjpass) taken_6\VBN\2367363|that|l-arginine|is|up|cells|,|y(+)l|,|b(0|making (l_nmod) y(+)l_18\NN\1740|principally|via|system|slc3a2/slc7a6|and|y(+ (l_conj) y(+_24\NN\1740|system|)|slc7a1 (l_dep) slc7a1_27\NN\1740|(|and|slc7a2|) (l_conj) slc7a2_29\NN\1740|
T2_T29 NONE acids_28\NNS\14818238|of|cationic|amino (r_nmod) transport_24\NN\3575240|to|the|acids|spermatocytes (r_nmod) contribution_21\NN\786195|a|major|transport (r_dobj) made_18\VBD\126264|contrast|,|b(0|contribution|. (l_nsubj) b(0_4\NN\1740|system|+|,|associated|, (l_acl) associated_8\VBN\628491|y(+)l (l_nmod) y(+)l_11\NN\1740|with|system|slc3a2/slc7a7 (l_dep) slc3a2/slc7a7_13\NN\1740|(|and|slc7a6|)
T2_T30 NONE acids_28\NNS\14818238|of|cationic|amino (r_nmod) transport_24\NN\3575240|to|the|acids|spermatocytes (r_nmod) contribution_21\NN\786195|a|major|transport (r_dobj) made_18\VBD\126264|contrast|,|b(0|contribution|. (l_nsubj) b(0_4\NN\1740|system|+|,|associated|, (l_acl) associated_8\VBN\628491|y(+)l (l_nmod) y(+)l_11\NN\1740|with|system|slc3a2/slc7a7 (l_dep) slc3a2/slc7a7_13\NN\1740|(|and|slc7a6|)
T2_T31 NONE acids_28\NNS\14818238|of|cationic|amino (r_nmod) transport_24\NN\3575240|to|the|acids|spermatocytes (r_nmod) contribution_21\NN\786195|a|major|transport (r_dobj) made_18\VBD\126264|contrast|,|b(0|contribution|. (l_nsubj) b(0_4\NN\1740|system|+|,|associated|, (l_acl) associated_8\VBN\628491|y(+)l (l_nmod) y(+)l_11\NN\1740|with|system|slc3a2/slc7a7 (l_dep) slc3a2/slc7a7_13\NN\1740|(|and|slc7a6|) (l_conj) slc7a6_15\NN\1740|
T10_T21 NONE no_8\NN\7204911|(|) (r_appos) oxide_6\NN\14818238|nitric|no (r_compound) production_10\NN\30358|oxide (r_dobj) induce_4\VBP\1627355|whereas|cytokines|production|cells (l_nsubj) cytokines_3\NNS\14728724|
T10_T22 NONE no_8\NN\7204911|(|) (r_appos) oxide_6\NN\14818238|nitric|no (r_compound) production_10\NN\30358|oxide (r_dobj) induce_4\VBP\1627355|whereas|cytokines|production|cells (r_advcl) observed_27\VBN\2163746|furthermore|,|induce|,|upregulation|was|cells|. (l_nsubjpass) upregulation_20\NN\1740|little|transport (l_nmod) transport_23\NN\3575240|of|arginine|cytokines (l_nmod) cytokines_25\NNS\14728724|by
T11_T21 NONE arginine_22\NN\14605787| (r_compound) transport_23\NN\3575240|of|arginine|cytokines (r_nmod) upregulation_20\NN\1740|little|transport (r_nsubjpass) observed_27\VBN\2163746|furthermore|,|induce|,|upregulation|was|cells|. (l_advcl) induce_4\VBP\1627355|whereas|cytokines|production|cells (l_nsubj) cytokines_3\NNS\14728724|
T11_T22 NONE arginine_22\NN\14605787| (r_compound) transport_23\NN\3575240|of|arginine|cytokines (l_nmod) cytokines_25\NNS\14728724|by
T9_T21 NONE oxide_6\NN\14818238|nitric|no (r_compound) production_10\NN\30358|oxide (r_dobj) induce_4\VBP\1627355|whereas|cytokines|production|cells (l_nsubj) cytokines_3\NNS\14728724|
T9_T22 NONE oxide_6\NN\14818238|nitric|no (r_compound) production_10\NN\30358|oxide (r_dobj) induce_4\VBP\1627355|whereas|cytokines|production|cells (r_advcl) observed_27\VBN\2163746|furthermore|,|induce|,|upregulation|was|cells|. (l_nsubjpass) upregulation_20\NN\1740|little|transport (l_nmod) transport_23\NN\3575240|of|arginine|cytokines (l_nmod) cytokines_25\NNS\14728724|by
23223177
T6_T11 NONE amp-activated_13\JJ\1740| (r_amod) kinase_15\NN\14732946|of|amp-activated|protein|ampk (l_appos) ampk_17\NN\1740|(|)
T6_T32 NONE amp-activated_13\JJ\1740| (r_amod) kinase_15\NN\14732946|of|amp-activated|protein|ampk
T2_T15 NONE glucose-treated_38\JJ\1740|high (r_amod) cells_42\NNS\3080309|glucose-treated|h9c2|cardiac|myoblast (r_conj) mice_35\NNS\2329401|in|diabetic|and|cells (r_nmod) interaction_20\NN\37396|on|the|beclin1|,|mice (r_nmod) effects_15\NNS\13245626|the|ampk|interaction (r_dobj) examined_13\VBD\789138|effects (r_conj) hypothesized_1\VBD\719734|we|ameliorates|and|examined|. (l_ccomp) ameliorates_5\VBZ\126264|that|autophagy|cardiomyopathy|inhibiting (l_nsubj) autophagy_4\NN\1740|ampk-induced (l_amod) ampk-induced_3\JJ\1740|
T2_T16 NONE glucose-treated_38\JJ\1740|high (r_amod) cells_42\NNS\3080309|glucose-treated|h9c2|cardiac|myoblast (r_conj) mice_35\NNS\2329401|in|diabetic|and|cells (r_nmod) interaction_20\NN\37396|on|the|beclin1|,|mice (r_nmod) effects_15\NNS\13245626|the|ampk|interaction (l_nmod) ampk_17\NN\1740|of
T2_T17 NONE glucose-treated_38\JJ\1740|high (r_amod) cells_42\NNS\3080309|glucose-treated|h9c2|cardiac|myoblast (r_conj) mice_35\NNS\2329401|in|diabetic|and|cells (r_nmod) interaction_20\NN\37396|on|the|beclin1|,|mice (l_nmod) beclin1_22\NN\1740|between|and|bcl-2|,|switch
T2_T18 NONE glucose-treated_38\JJ\1740|high (r_amod) cells_42\NNS\3080309|glucose-treated|h9c2|cardiac|myoblast (r_conj) mice_35\NNS\2329401|in|diabetic|and|cells (r_nmod) interaction_20\NN\37396|on|the|beclin1|,|mice (l_nmod) beclin1_22\NN\1740|between|and|bcl-2|,|switch (l_conj) bcl-2_24\NN\1740|
T3_T19 CPR:4 glucose_6\NN\14710501|to|high (r_nmod) exposure_0\NN\5042871|cells|glucose (r_nsubj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_dobj) activity_9\NN\30358|ampk (l_compound) ampk_8\NN\1740|
T3_T20 CPR:4 glucose_6\NN\14710501|to|high (r_nmod) exposure_0\NN\5042871|cells|glucose (r_nsubj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_conj) inhibited_11\VBD\2510337|signaling (l_dobj) signaling_22\NN\33020|lymphoma (l_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (l_compound) kinase_14\NN\14732946|jun|nh2-terminal|1 (l_nummod) 1_15\CD\13741022|
T3_T21 CPR:4 glucose_6\NN\14710501|to|high (r_nmod) exposure_0\NN\5042871|cells|glucose (r_nsubj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_conj) inhibited_11\VBD\2510337|signaling (l_dobj) signaling_22\NN\33020|lymphoma (l_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (l_compound) (jnk1)-b-cell_16\NN\1740|
T3_T22 CPR:4 glucose_6\NN\14710501|to|high (r_nmod) exposure_0\NN\5042871|cells|glucose (r_nsubj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_conj) inhibited_11\VBD\2510337|signaling (l_dobj) signaling_22\NN\33020|lymphoma (l_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (l_nummod) 2_18\CD\13741022|
T3_T23 CPR:4 glucose_6\NN\14710501|to|high (r_nmod) exposure_0\NN\5042871|cells|glucose (r_nsubj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_conj) inhibited_11\VBD\2510337|signaling (l_dobj) signaling_22\NN\33020|lymphoma (l_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (l_appos) bcl-2_20\NN\1740|(|)
T3_T24 NONE glucose_6\NN\14710501|to|high (r_nmod) exposure_0\NN\5042871|cells|glucose (r_nsubj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_conj) promoted_25\VBD\2556126|beclin1 (l_dobj) beclin1_26\NN\1740|binding
T3_T25 NONE glucose_6\NN\14710501|to|high (r_nmod) exposure_0\NN\5042871|cells|glucose (r_nsubj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_conj) promoted_25\VBD\2556126|beclin1 (l_dobj) beclin1_26\NN\1740|binding (l_amod) binding_27\VBG\1290422|bcl-2 (l_nmod) bcl-2_29\NN\1740|to
T4_T19 NONE nh2-terminal_13\JJ\1740| (r_amod) kinase_14\NN\14732946|jun|nh2-terminal|1 (r_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (r_compound) signaling_22\NN\33020|lymphoma (r_dobj) inhibited_11\VBD\2510337|signaling (r_conj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_dobj) activity_9\NN\30358|ampk (l_compound) ampk_8\NN\1740|
T4_T20 NONE nh2-terminal_13\JJ\1740| (r_amod) kinase_14\NN\14732946|jun|nh2-terminal|1 (l_nummod) 1_15\CD\13741022|
T4_T21 NONE nh2-terminal_13\JJ\1740| (r_amod) kinase_14\NN\14732946|jun|nh2-terminal|1 (r_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (l_compound) (jnk1)-b-cell_16\NN\1740|
T4_T22 NONE nh2-terminal_13\JJ\1740| (r_amod) kinase_14\NN\14732946|jun|nh2-terminal|1 (r_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (l_nummod) 2_18\CD\13741022|
T4_T23 NONE nh2-terminal_13\JJ\1740| (r_amod) kinase_14\NN\14732946|jun|nh2-terminal|1 (r_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (l_appos) bcl-2_20\NN\1740|(|)
T4_T24 NONE nh2-terminal_13\JJ\1740| (r_amod) kinase_14\NN\14732946|jun|nh2-terminal|1 (r_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (r_compound) signaling_22\NN\33020|lymphoma (r_dobj) inhibited_11\VBD\2510337|signaling (r_conj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_conj) promoted_25\VBD\2556126|beclin1 (l_dobj) beclin1_26\NN\1740|binding
T4_T25 NONE nh2-terminal_13\JJ\1740| (r_amod) kinase_14\NN\14732946|jun|nh2-terminal|1 (r_compound) lymphoma_17\NN\14239918|kinase|(jnk1)-b-cell|2|bcl-2 (r_compound) signaling_22\NN\33020|lymphoma (r_dobj) inhibited_11\VBD\2510337|signaling (r_conj) reduced_7\VBD\441445|exposure|activity|,|inhibited|,|and|promoted|. (l_conj) promoted_25\VBD\2556126|beclin1 (l_dobj) beclin1_26\NN\1740|binding (l_amod) binding_27\VBG\1290422|bcl-2 (l_nmod) bcl-2_29\NN\1740|to
T5_T31 NONE glucose-induced_11\JJ\1740|high (r_amod) apoptosis_12\NN\11486178|glucose-induced|cells (r_dobj) attenuated_9\VBD\224901|activation|apoptosis|. (l_nsubj) activation_0\NN\13561719|ampk|,|normalized|, (l_nmod) ampk_2\NN\1740|of
T1_T10 NONE metformin_5\NN\2719105|of (r_nmod) administration_3\NN\1133281|chronic|metformin|mice (r_nsubj) restored_9\VBD\1631072|finally|,|administration|autophagy|activating|. (l_advcl) activating_13\VBG\1641914|by|pathways|and|dissociating (l_conj) dissociating_17\VBG\2431320|beclin1 (l_dobj) beclin1_18\NN\1740|and|bcl-2 (l_conj) bcl-2_20\NN\1740|
T1_T7 CPR:3 metformin_5\NN\2719105|of (r_nmod) administration_3\NN\1133281|chronic|metformin|mice (r_nsubj) restored_9\VBD\1631072|finally|,|administration|autophagy|activating|. (l_advcl) activating_13\VBG\1641914|by|pathways|and|dissociating (l_dobj) pathways_15\NNS\5483677|jnk1-bcl-2 (l_compound) jnk1-bcl-2_14\NN\1740|
T1_T8 CPR:3 metformin_5\NN\2719105|of (r_nmod) administration_3\NN\1133281|chronic|metformin|mice (r_nsubj) restored_9\VBD\1631072|finally|,|administration|autophagy|activating|. (l_advcl) activating_13\VBG\1641914|by|pathways|and|dissociating (l_dobj) pathways_15\NNS\5483677|jnk1-bcl-2 (l_compound) jnk1-bcl-2_14\NN\1740|
T1_T9 NONE metformin_5\NN\2719105|of (r_nmod) administration_3\NN\1133281|chronic|metformin|mice (r_nsubj) restored_9\VBD\1631072|finally|,|administration|autophagy|activating|. (l_advcl) activating_13\VBG\1641914|by|pathways|and|dissociating (l_conj) dissociating_17\VBG\2431320|beclin1 (l_dobj) beclin1_18\NN\1740|and|bcl-2
23546605
T3_T18 NONE estrogen-active_30\JJ\1740| (r_amod) follicles_31\NNS\5517578|in|large|estrogen-active (r_nmod) peaking_21\VBG\2020590|with|insl3|follicles|and|peaking (r_advcl) increased_14\VBD\169651|progressively|maturation|peaking (r_conj) higher_7\JJR\1740|levels|were|much|tic|cell|and|increased|. (l_nsubj) levels_4\NNS\4916342|insl3|mrna (l_compound) insl3_0\NN\1740|and|rxfp2
T3_T19 NONE estrogen-active_30\JJ\1740| (r_amod) follicles_31\NNS\5517578|in|large|estrogen-active (r_nmod) peaking_21\VBG\2020590|with|insl3|follicles|and|peaking (r_advcl) increased_14\VBD\169651|progressively|maturation|peaking (r_conj) higher_7\JJR\1740|levels|were|much|tic|cell|and|increased|. (l_nsubj) levels_4\NNS\4916342|insl3|mrna (l_compound) insl3_0\NN\1740|and|rxfp2 (l_conj) rxfp2_2\NN\1740|
T3_T20 NONE estrogen-active_30\JJ\1740| (r_amod) follicles_31\NNS\5517578|in|large|estrogen-active (r_nmod) peaking_21\VBG\2020590|with|insl3|follicles|and|peaking (l_nsubj) insl3_20\NN\1740|
T3_T21 NONE estrogen-active_30\JJ\1740| (r_amod) follicles_31\NNS\5517578|in|large|estrogen-active (r_nmod) peaking_21\VBG\2020590|with|insl3|follicles|and|peaking (l_conj) peaking_34\VBG\2020590|rxfp2|follicles|declining (l_nsubj) rxfp2_33\NN\1740|
T1_T5 NONE progesterone_31\NN\14747338| (r_compound) secretion_32\NN\13526110|progesterone|and|expression (r_dobj) increasing_30\VBG\169651|while|secretion (r_advcl) attenuated_21\VBD\224901|that|exposure|greatly|expression|increasing (l_nsubj) exposure_11\NN\5042871|in|tic|concentration (l_nmod) concentration_17\NN\4916342|to|a|luteinizing|lh (l_nmod) lh_19\NN\5410315|of
T1_T6 NONE progesterone_31\NN\14747338| (r_compound) secretion_32\NN\13526110|progesterone|and|expression (r_dobj) increasing_30\VBG\169651|while|secretion (r_advcl) attenuated_21\VBD\224901|that|exposure|greatly|expression|increasing (l_dobj) expression_22\NN\4679549|insl3 (l_nmod) insl3_25\NN\1740|of|both|and|receptor
T1_T7 NONE progesterone_31\NN\14747338| (r_compound) secretion_32\NN\13526110|progesterone|and|expression (l_conj) expression_34\NN\4679549|star (l_nmod) star_36\NN\9239740|of|and|cyp11a1
T1_T8 NONE progesterone_31\NN\14747338| (r_compound) secretion_32\NN\13526110|progesterone|and|expression (l_conj) expression_34\NN\4679549|star (l_nmod) star_36\NN\9239740|of|and|cyp11a1 (l_conj) cyp11a1_38\NN\1740|
T2_T10 NONE estradiol-17β_2\NN\1740| (r_conj) insl3_0\NN\1740|and|estradiol-17β
T2_T11 NONE estradiol-17β_2\NN\1740| (r_conj) insl3_0\NN\1740|and|estradiol-17β (r_nsubj) followed_3\VBD\1835496|insl3|pattern|,|increasing|. (l_advcl) increasing_9\VBG\169651|both|luteolysis|,|falling (l_advcl) falling_14\VBG\1835496|before|sharply|surge (l_nmod) surge_19\NN\7405893|after|the|lh (l_compound) lh_18\NN\5410315|
23625910
T4_T30 NONE organophosphate_18\NN\14919948|to (r_nmod) exposed_16\VBN\2110927|organophosphate (r_acl) population_15\NN\7942152|in|turkish|exposed (r_nmod) activities_12\NNS\30358|on|paraoxonase|population (r_nmod) effect_0\NN\34213|polymorphism|activities|. (l_nmod) polymorphism_6\NN\11418750|of|paraoxonase|1|192|q/r (l_nummod) 1_3\CD\13741022|
T4_T31 NONE organophosphate_18\NN\14919948|to (r_nmod) exposed_16\VBN\2110927|organophosphate (r_acl) population_15\NN\7942152|in|turkish|exposed (r_nmod) activities_12\NNS\30358|on|paraoxonase|population (r_nmod) effect_0\NN\34213|polymorphism|activities|. (l_nmod) polymorphism_6\NN\11418750|of|paraoxonase|1|192|q/r (l_compound) q/r_5\NN\1740|
T4_T32 NONE organophosphate_18\NN\14919948|to (r_nmod) exposed_16\VBN\2110927|organophosphate (r_acl) population_15\NN\7942152|in|turkish|exposed (r_nmod) activities_12\NNS\30358|on|paraoxonase|population (l_compound) paraoxonase_8\NN\1740|and|enzyme
T4_T33 NONE organophosphate_18\NN\14919948|to (r_nmod) exposed_16\VBN\2110927|organophosphate (r_acl) population_15\NN\7942152|in|turkish|exposed (r_nmod) activities_12\NNS\30358|on|paraoxonase|population (l_compound) paraoxonase_8\NN\1740|and|enzyme (l_conj) enzyme_11\NN\14723628|acetylcholinesterase (l_compound) acetylcholinesterase_10\NN\1740|
T2_T20 NONE organophosphorus_29\NN\1740| (r_compound) insecticides_30\NNS\14980215|to|organophosphorus (r_nmod) exposed_27\VBN\2110927|who|were|insecticides|reasons (r_acl:relcl) individuals_24\NNS\7347|in|exposed (r_nmod) activities_22\NNS\30358|on|pon|individuals (r_nmod) effects_16\NNS\13245626|its|activities (r_conj) effects_9\NNS\13245626|the|polymorphism|and|effects (l_nmod) polymorphism_13\NN\11418750|of|pon1|gene (l_compound) pon1_11\NN\1740|
T2_T21 NONE organophosphorus_29\NN\1740| (r_compound) insecticides_30\NNS\14980215|to|organophosphorus (r_nmod) exposed_27\VBN\2110927|who|were|insecticides|reasons (r_acl:relcl) individuals_24\NNS\7347|in|exposed (r_nmod) activities_22\NNS\30358|on|pon|individuals (l_compound) pon_18\NN\1740|and|enzyme
T2_T22 NONE organophosphorus_29\NN\1740| (r_compound) insecticides_30\NNS\14980215|to|organophosphorus (r_nmod) exposed_27\VBN\2110927|who|were|insecticides|reasons (r_acl:relcl) individuals_24\NNS\7347|in|exposed (r_nmod) activities_22\NNS\30358|on|pon|individuals (l_compound) pon_18\NN\1740|and|enzyme (l_conj) enzyme_21\NN\14723628|ache (l_compound) ache_20\NN\14322699|
T3_T20 NONE organophosphorus_44\NN\1740| (r_compound) compounds_45\NNS\5869584|to|organophosphorus (r_nmod) susceptibility_42\NN\13920835|of|compounds (r_nmod) probability_40\NN\33615|the|susceptibility (r_dobj) profile_38\VB\1698271|to|probability (r_conj) determine_7\VB\1645601|to|effects|,|and|profile (l_dobj) effects_9\NNS\13245626|the|polymorphism|and|effects (l_nmod) polymorphism_13\NN\11418750|of|pon1|gene (l_compound) pon1_11\NN\1740|
T3_T21 NONE organophosphorus_44\NN\1740| (r_compound) compounds_45\NNS\5869584|to|organophosphorus (r_nmod) susceptibility_42\NN\13920835|of|compounds (r_nmod) probability_40\NN\33615|the|susceptibility (r_dobj) profile_38\VB\1698271|to|probability (r_conj) determine_7\VB\1645601|to|effects|,|and|profile (l_dobj) effects_9\NNS\13245626|the|polymorphism|and|effects (l_conj) effects_16\NNS\13245626|its|activities (l_nmod) activities_22\NNS\30358|on|pon|individuals (l_compound) pon_18\NN\1740|and|enzyme
T3_T22 NONE organophosphorus_44\NN\1740| (r_compound) compounds_45\NNS\5869584|to|organophosphorus (r_nmod) susceptibility_42\NN\13920835|of|compounds (r_nmod) probability_40\NN\33615|the|susceptibility (r_dobj) profile_38\VB\1698271|to|probability (r_conj) determine_7\VB\1645601|to|effects|,|and|profile (l_dobj) effects_9\NNS\13245626|the|polymorphism|and|effects (l_conj) effects_16\NNS\13245626|its|activities (l_nmod) activities_22\NNS\30358|on|pon|individuals (l_compound) pon_18\NN\1740|and|enzyme (l_conj) enzyme_21\NN\14723628|ache (l_compound) ache_20\NN\14322699|
23194511
14506245
T2_T51 NONE nh2-terminal_8\JJ\1740| (r_amod) kinase-1_9\NN\1740|platelet-derived|growth|factor|(|pdgf|)|receptor-alpha-activated|c-jun|nh2-terminal (l_amod) receptor-alpha-activated_6\JJ\1740|
T2_T52 NONE nh2-terminal_8\JJ\1740| (r_amod) kinase-1_9\NN\1740|platelet-derived|growth|factor|(|pdgf|)|receptor-alpha-activated|c-jun|nh2-terminal (r_nsubj) critical_11\JJ\1740|kinase-1|is|activity|. (l_nmod) activity_16\NN\30358|for|pdgf-induced|p21waf1/cip1|promoter|independent (l_amod) pdgf-induced_13\JJ\1740|
T2_T53 NONE nh2-terminal_8\JJ\1740| (r_amod) kinase-1_9\NN\1740|platelet-derived|growth|factor|(|pdgf|)|receptor-alpha-activated|c-jun|nh2-terminal (r_nsubj) critical_11\JJ\1740|kinase-1|is|activity|. (l_nmod) activity_16\NN\30358|for|pdgf-induced|p21waf1/cip1|promoter|independent (l_compound) promoter_15\NN\9773962|
T2_T54 NONE nh2-terminal_8\JJ\1740| (r_amod) kinase-1_9\NN\1740|platelet-derived|growth|factor|(|pdgf|)|receptor-alpha-activated|c-jun|nh2-terminal (r_nsubj) critical_11\JJ\1740|kinase-1|is|activity|. (l_nmod) activity_16\NN\30358|for|pdgf-induced|p21waf1/cip1|promoter|independent (l_amod) independent_17\JJ\1740|p53 (l_nmod) p53_19\NN\1740|of
T2_T55 NONE nh2-terminal_8\JJ\1740| (r_amod) kinase-1_9\NN\1740|platelet-derived|growth|factor|(|pdgf|)|receptor-alpha-activated|c-jun|nh2-terminal
T1_T41 NONE nh2-terminal_14\JJ\1740| (r_amod) kinase-1_15\NN\1740|of|stress-activated|protein|kinase-1/c-jun|nh2-terminal (r_nmod) activation_9\NN\13561719|through|kinase-1 (r_nmod) antagonizes_5\VBZ\1787955|that|alpha-pdgfr|transformation|activation|,|induce (l_nsubj) alpha-pdgfr_4\NN\1740|
T1_T42 NONE nh2-terminal_14\JJ\1740| (r_amod) kinase-1_15\NN\1740|of|stress-activated|protein|kinase-1/c-jun|nh2-terminal (r_nmod) activation_9\NN\13561719|through|kinase-1 (r_nmod) antagonizes_5\VBZ\1787955|that|alpha-pdgfr|transformation|activation|,|induce (l_dobj) transformation_7\NN\7296428|beta-pdgfr-mediated (l_amod) beta-pdgfr-mediated_6\JJ\1740|
T1_T43 NONE nh2-terminal_14\JJ\1740| (r_amod) kinase-1_15\NN\1740|of|stress-activated|protein|kinase-1/c-jun|nh2-terminal (l_compound) kinase-1/c-jun_13\NN\1740|
T1_T44 NONE nh2-terminal_14\JJ\1740| (r_amod) kinase-1_15\NN\1740|of|stress-activated|protein|kinase-1/c-jun|nh2-terminal
T1_T45 NONE nh2-terminal_14\JJ\1740| (r_amod) kinase-1_15\NN\1740|of|stress-activated|protein|kinase-1/c-jun|nh2-terminal (r_nmod) activation_9\NN\13561719|through|kinase-1 (r_nmod) antagonizes_5\VBZ\1787955|that|alpha-pdgfr|transformation|activation|,|induce (l_advcl) induce_22\VBP\1627355|whereas|alpha-pdgfr|signals (l_nsubj) alpha-pdgfr_19\NN\1740|both|and|beta-pdgfr
T1_T47 NONE nh2-terminal_14\JJ\1740| (r_amod) kinase-1_15\NN\1740|of|stress-activated|protein|kinase-1/c-jun|nh2-terminal (r_nmod) activation_9\NN\13561719|through|kinase-1 (r_nmod) antagonizes_5\VBZ\1787955|that|alpha-pdgfr|transformation|activation|,|induce (l_advcl) induce_22\VBP\1627355|whereas|alpha-pdgfr|signals (l_nsubj) alpha-pdgfr_19\NN\1740|both|and|beta-pdgfr (l_conj) beta-pdgfr_21\NN\1740|
10531013
T6_T13 CPR:4 caffeine_0\NN\14712692| (r_nsubj) inhibits_1\VBZ\2510337|caffeine|kinase|. (l_dobj) kinase_4\NN\14732946|the|checkpoint|atm
T6_T14 CPR:4 caffeine_0\NN\14712692| (r_nsubj) inhibits_1\VBZ\2510337|caffeine|kinase|. (l_dobj) kinase_4\NN\14732946|the|checkpoint|atm (l_appos) atm_5\NN\13607985|
T1_T10 NONE caffeine_37\NN\14712692|by (r_nmod) inhibited_35\VBN\2510337|that|activity|is|directly|caffeine|vitro (r_conj) inhibited_23\VBN\2510337|that|activation|is|caffeine|vivo|and|inhibited (l_nsubjpass) activation_5\NN\13561719|the|radiation-induced|kinase|4|(|known (l_nmod) kinase_8\NN\14732946|of|the|cds1
T1_T11 NONE caffeine_37\NN\14712692|by (r_nmod) inhibited_35\VBN\2510337|that|activity|is|directly|caffeine|vitro (r_conj) inhibited_23\VBN\2510337|that|activation|is|caffeine|vivo|and|inhibited (l_nsubjpass) activation_5\NN\13561719|the|radiation-induced|kinase|4|(|known (l_nmod) kinase_8\NN\14732946|of|the|cds1 (l_dep) cds1_9\NN\1740|[
T1_T12 NONE caffeine_37\NN\14712692|by (r_nmod) inhibited_35\VBN\2510337|that|activity|is|directly|caffeine|vitro (r_conj) inhibited_23\VBN\2510337|that|activation|is|caffeine|vivo|and|inhibited (l_nsubjpass) activation_5\NN\13561719|the|radiation-induced|kinase|4|(|known (l_acl) known_15\VBN\2110220|also|chk2|) (l_nmod) chk2_17\NN\1740|as|[|5
T1_T7 CPR:4 caffeine_37\NN\14712692|by (r_nmod) inhibited_35\VBN\2510337|that|activity|is|directly|caffeine|vitro (l_nsubjpass) activity_32\NN\30358|atm|kinase (l_compound) atm_30\NN\13607985|
T1_T8 CPR:4 caffeine_37\NN\14712692|by (r_nmod) inhibited_35\VBN\2510337|that|activity|is|directly|caffeine|vitro (l_nsubjpass) activity_32\NN\30358|atm|kinase (l_compound) kinase_31\NN\14732946|
T5_T10 CPR:4 caffeine_25\NN\14712692|by (r_nmod) inhibited_23\VBN\2510337|that|activation|is|caffeine|vivo|and|inhibited (l_nsubjpass) activation_5\NN\13561719|the|radiation-induced|kinase|4|(|known (l_nmod) kinase_8\NN\14732946|of|the|cds1
T5_T11 CPR:4 caffeine_25\NN\14712692|by (r_nmod) inhibited_23\VBN\2510337|that|activation|is|caffeine|vivo|and|inhibited (l_nsubjpass) activation_5\NN\13561719|the|radiation-induced|kinase|4|(|known (l_nmod) kinase_8\NN\14732946|of|the|cds1 (l_dep) cds1_9\NN\1740|[
T5_T12 CPR:4 caffeine_25\NN\14712692|by (r_nmod) inhibited_23\VBN\2510337|that|activation|is|caffeine|vivo|and|inhibited (l_nsubjpass) activation_5\NN\13561719|the|radiation-induced|kinase|4|(|known (l_acl) known_15\VBN\2110220|also|chk2|) (l_nmod) chk2_17\NN\1740|as|[|5
T5_T7 NONE caffeine_25\NN\14712692|by (r_nmod) inhibited_23\VBN\2510337|that|activation|is|caffeine|vivo|and|inhibited (l_conj) inhibited_35\VBN\2510337|that|activity|is|directly|caffeine|vitro (l_nsubjpass) activity_32\NN\30358|atm|kinase (l_compound) atm_30\NN\13607985|
T5_T8 NONE caffeine_25\NN\14712692|by (r_nmod) inhibited_23\VBN\2510337|that|activation|is|caffeine|vivo|and|inhibited (l_conj) inhibited_35\VBN\2510337|that|activity|is|directly|caffeine|vitro (l_nsubjpass) activity_32\NN\30358|atm|kinase (l_compound) kinase_31\NN\14732946|
T2_T9 CPR:4 caffeine-treated_20\JJ\1740| (r_amod) cells_21\NNS\3080309|of|caffeine-treated (r_nmod) radiosensitivity_18\NN\5652926|for|the|increased|cells|6 (r_conj) attenuation_9\NN\7427337|of|the|responses|and|radiosensitivity (r_nmod) explanation_6\NN\6722453|a|molecular|attenuation (r_dobj) provides_3\VBZ\2199590|inhibition|explanation|. (l_nsubj) inhibition_0\NN\1068773|atm (l_nmod) atm_2\NN\13607985|of
10575283
23611835
T1_T14 CPR:6 sb225002_0\NN\1740|sb (r_nsubj) antagonist_12\NN\7846|sb225002|is|an|b|shown|. (l_compound) b_8\NN\1355326|il-8|receptor|il-8rb
T1_T16 CPR:6 sb225002_0\NN\1740|sb (r_nsubj) antagonist_12\NN\7846|sb225002|is|an|b|shown|. (l_compound) b_8\NN\1355326|il-8|receptor|il-8rb (l_appos) il-8rb_10\NN\1740|(|)
T1_T22 CPR:4 sb225002_0\NN\1740|sb (r_nsubj) antagonist_12\NN\7846|sb225002|is|an|b|shown|. (l_acl:relcl) shown_17\VBN\2137132|that|has|previously|been|inhibit (l_ccomp) inhibit_19\VB\2510337|to|invasion|,|and|possess (l_dobj) invasion_23\NN\975452|il-8-based|cancer|cell (l_amod) il-8-based_20\JJ\1740|
T2_T20 NONE vinblastine-binding_11\JJ\1740| (r_amod) site_12\NN\8673395|towards|vinblastine-binding|subunit (l_nmod) subunit_15\NN\13604718|on|β-tubulin (l_compound) β-tubulin_14\NN\1740|
T3_T21 CPR:6 sb265610_3\NN\1740|analogue (l_acl:relcl) analogue_9\NN\4743605|which|is|a|close|structural|sb225002|activity (l_nmod) activity_17\NN\30358|with|a|potent|il-8rb|antagonistic (l_compound) il-8rb_15\NN\1740|
T4_T21 CPR:6 sb225002_11\NN\1740|of (r_nmod) analogue_9\NN\4743605|which|is|a|close|structural|sb225002|activity (l_nmod) activity_17\NN\30358|with|a|potent|il-8rb|antagonistic (l_compound) il-8rb_15\NN\1740|
23198819
22923473
T3_T7 NONE fructose_7\NN\14927587| (r_compound) infusion_8\NN\14589223|fructose (r_nsubjpass) stopped_10\VBN\2452885|which|infusion|was (r_acl:relcl) period_4\NN\13575869|following|a|2-h|control|stopped (r_nmod) was_13\VBD\836236|period|,|there|period|. (l_attr) period_17\NN\13575869|a|2-h|experimental|measured (l_acl:relcl) measured_42\VBN\697589|which|response|was (l_nsubjpass) response_21\NN\11410625|the|hyperglycemia (l_nmod) hyperglycemia_23\NN\14299637|to|plus|insulin (l_conj) insulin_29\NN\5407119|either|4|×|basal|ins|or|infusion
T3_T8 NONE fructose_7\NN\14927587| (r_compound) infusion_8\NN\14589223|fructose (r_nsubjpass) stopped_10\VBN\2452885|which|infusion|was (r_acl:relcl) period_4\NN\13575869|following|a|2-h|control|stopped (r_nmod) was_13\VBD\836236|period|,|there|period|. (l_attr) period_17\NN\13575869|a|2-h|experimental|measured (l_acl:relcl) measured_42\VBN\697589|which|response|was (l_nsubjpass) response_21\NN\11410625|the|hyperglycemia (l_nmod) hyperglycemia_23\NN\14299637|to|plus|insulin (l_conj) insulin_29\NN\5407119|either|4|×|basal|ins|or|infusion (l_appos) ins_31\NN\8337324|(|)
T4_T7 NONE glucose_36\NN\14710501| (r_compound) infusion_37\NN\14589223|portal|vein|glucose|pog (r_conj) insulin_29\NN\5407119|either|4|×|basal|ins|or|infusion
T4_T8 NONE glucose_36\NN\14710501| (r_compound) infusion_37\NN\14589223|portal|vein|glucose|pog (r_conj) insulin_29\NN\5407119|either|4|×|basal|ins|or|infusion (l_appos) ins_31\NN\8337324|(|)
T5_T10 NONE glucose_7\NN\14710501|of|taken (r_nmod) percent_5\NN\13815742|the|glucose (r_dobj) reduced_3\VBD\441445|glycogen|percent|%|. (l_parataxis) %_26\NN\1740|(|3|53|gly+ins|,|respectively|,|and|%|gly+pog|,|respectively|) (l_nmod) gly+ins_28\NN\1740|in|and|scgly+ins (l_conj) scgly+ins_30\NNP\1740|
T5_T9 NONE glucose_7\NN\14710501|of|taken (r_nmod) percent_5\NN\13815742|the|glucose (r_dobj) reduced_3\VBD\441445|glycogen|percent|%|. (l_parataxis) %_26\NN\1740|(|3|53|gly+ins|,|respectively|,|and|%|gly+pog|,|respectively|) (l_nmod) gly+ins_28\NN\1740|in|and|scgly+ins
23601710
T5_T11 CPR:4 c3-phenyl_19\NN\1740| (r_compound) moiety_20\NN\13736799|of|the|c3-phenyl (r_nmod) relationships_13\NNS\31921|structure-activity|sar|moiety (r_dep) optimization_0\NN\248977|series|:|relationships|. (l_nmod) series_4\NN\8456993|of|a|1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione|inhibitors (l_nmod) inhibitors_9\NNS\20090|of|hiv|capsid|assembly|2 (l_compound) capsid_7\NN\2237424|
T6_T11 CPR:4 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione_3\NN\1740| (r_compound) series_4\NN\8456993|of|a|1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione|inhibitors (l_nmod) inhibitors_9\NNS\20090|of|hiv|capsid|assembly|2 (l_compound) capsid_7\NN\2237424|
T1_T7 CPR:4 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione_19\NN\1740| (r_compound) inhibitors_20\NNS\20090|of|1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione|assembly (l_nmod) assembly_27\NN\3699975|of|capsid (l_compound) capsid_23\NN\2237424|hiv|ca
T1_T8 CPR:4 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione_19\NN\1740| (r_compound) inhibitors_20\NNS\20090|of|1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione|assembly (l_nmod) assembly_27\NN\3699975|of|capsid (l_compound) capsid_23\NN\2237424|hiv|ca (l_appos) ca_25\NN\14625458|(|)
T4_T7 NONE c3-phenyl_5\JJ\1740| (r_compound) moiety_6\NN\13736799|of|the|c3-phenyl (r_nmod) relationships_2\NNS\31921|detailed|structure-activity|moiety|allow (l_acl:relcl) allow_8\VBP\797697|that|optimization (l_nmod) optimization_11\NN\248977|for|the|potency (l_nmod) potency_14\NN\5196375|of|antiviral|series (l_nmod) series_17\NN\8456993|of|a|inhibitors (l_nmod) inhibitors_20\NNS\20090|of|1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione|assembly (l_nmod) assembly_27\NN\3699975|of|capsid (l_compound) capsid_23\NN\2237424|hiv|ca
T4_T8 NONE c3-phenyl_5\JJ\1740| (r_compound) moiety_6\NN\13736799|of|the|c3-phenyl (r_nmod) relationships_2\NNS\31921|detailed|structure-activity|moiety|allow (l_acl:relcl) allow_8\VBP\797697|that|optimization (l_nmod) optimization_11\NN\248977|for|the|potency (l_nmod) potency_14\NN\5196375|of|antiviral|series (l_nmod) series_17\NN\8456993|of|a|inhibitors (l_nmod) inhibitors_20\NNS\20090|of|1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione|assembly (l_nmod) assembly_27\NN\3699975|of|capsid (l_compound) capsid_23\NN\2237424|hiv|ca (l_appos) ca_25\NN\14625458|(|)
12180353
T7_T21 NONE adenosine_7\NN\14964367| (r_compound) uptake_8\NN\13440063|of|adenosine (r_nmod) inhibition_5\NN\1068773|uptake (r_nsubj) is_4\VBZ\836236|addition|,|there|inhibition|,|resulting|. (l_advcl) resulting_11\VBG\2633881|eventually|changes (l_nmod) changes_13\NNS\7283608|in|levels|,|dependent (l_amod) dependent_18\JJ\1740|type (l_nmod) type_21\NN\5839024|on|the|receptors|a1 (l_dep) a1_26\NN\1740|(|or|a2|) (l_punct) )_29\-RRB-\1740|
T8_T21 NONE camp_15\NN\3763727| (r_compound) levels_16\NNS\4916342|in|camp (r_nmod) changes_13\NNS\7283608|in|levels|,|dependent (l_amod) dependent_18\JJ\1740|type (l_nmod) type_21\NN\5839024|on|the|receptors|a1 (l_dep) a1_26\NN\1740|(|or|a2|) (l_punct) )_29\-RRB-\1740|
T9_T21 NONE adenosine_23\NN\14964367| (r_compound) receptors_24\NNS\5225602|of|adenosine (r_nmod) type_21\NN\5839024|on|the|receptors|a1 (l_dep) a1_26\NN\1740|(|or|a2|) (l_punct) )_29\-RRB-\1740|
T15_T22 CPR:3 cilostazol_0\NN\1740| (r_nsubj) decreases_1\VBZ\169651|cilostazol|levels|and|causes|. (l_conj) causes_7\VBZ\1617192|increase (l_dobj) increase_9\NN\13576355|some|levels (l_nmod) levels_12\NNS\4916342|in|hdl-cholesterol (l_compound) hdl-cholesterol_11\NN\1740|
T16_T22 NONE hdl-cholesterol_11\NN\1740|
T3_T18 CPR:9 cilostazol_0\NN\1740| (r_nsubj) undergoes_1\VBZ\109660|cilostazol|metabolism|systems|. (l_nmod) systems_12\NNS\3575240|via|the|cytochrome|p450 (l_compound) p450_11\NN\1740|
23416065
T17_T27 NONE diflunisal_6\JJ\1740| (r_amod) prodrug_7\NN\1740|of|a|diflunisal (r_nmod) design_3\NN\927261|human|serum|albumin-based|prodrug|. (l_amod) albumin-based_2\JJ\1740|
T5_T23 CPR:4 diflunisal_4\NN\3828465| (r_appos) inhibitor_2\NN\20090|the|cyclooxygenase-2|,|diflunisal|, (l_compound) cyclooxygenase-2_1\NN\14737847|
T2_T19 NONE diflunisal_7\NN\3828465|of (r_nmod) dose_5\NN\3740161|of|a|diflunisal (r_nmod) %_2\NN\1740|99|dose (r_nsubj) unavailable_9\JJ\1740|%|is|reaction|,|binds|. (l_advcl) binds_20\VBZ\1290422|because|diflunisal|strongly|albumin (l_nmod) albumin_24\NN\14736972|to|human|serum|hsa
T2_T20 NONE diflunisal_7\NN\3828465|of (r_nmod) dose_5\NN\3740161|of|a|diflunisal (r_nmod) %_2\NN\1740|99|dose (r_nsubj) unavailable_9\JJ\1740|%|is|reaction|,|binds|. (l_advcl) binds_20\VBZ\1290422|because|diflunisal|strongly|albumin (l_nmod) albumin_24\NN\14736972|to|human|serum|hsa (l_appos) hsa_26\NN\1740|(|)
T3_T19 NONE diflunisal_18\NN\3828465| (r_nsubj) binds_20\VBZ\1290422|because|diflunisal|strongly|albumin (l_nmod) albumin_24\NN\14736972|to|human|serum|hsa
T3_T20 NONE diflunisal_18\NN\3828465| (r_nsubj) binds_20\VBZ\1290422|because|diflunisal|strongly|albumin (l_nmod) albumin_24\NN\14736972|to|human|serum|hsa (l_appos) hsa_26\NN\1740|(|)
T4_T21 NONE diflunisal_6\NN\3828465|of (r_nmod) affinity_4\NN\11426530|the|binding|diflunisal|albumin (l_nmod) albumin_8\NN\14736972|to
T6_T21 NONE acetyldiflunisal_16\NN\1740|the|prodrug (r_dobj) designed_11\VBD\1631534|reduce|,|we|and|synthesized|acetyldiflunisal|. (l_advcl) reduce_1\VB\441445|to|affinity (l_dobj) affinity_4\NN\11426530|the|binding|diflunisal|albumin (l_nmod) albumin_8\NN\14736972|to
T10_T22 NONE lysine_26\NN\14605787|199 (r_dobj) acetylates_25\VBZ\109660|that|binding|,|it|lysine (r_conj) binds_14\VBZ\1290422|that|acetyldiflunisal|subdomain|and|acetylates (r_ccomp) revealed_11\VBD\2137132|structure|binds|. (l_nsubj) structure_2\NN\21939|the|crystal|hsa (l_nmod) hsa_4\NN\1740|of|complexed
T10_T24 NONE lysine_26\NN\14605787|199 (r_dobj) acetylates_25\VBZ\109660|that|binding|,|it|lysine (r_conj) binds_14\VBZ\1290422|that|acetyldiflunisal|subdomain|and|acetylates (l_nmod) subdomain_18\NN\1740|to|the|iia
T7_T22 NONE acid_8\NN\14818238|with|fatty|and|acetyldiflunisal (r_nmod) complexed_5\VBN\1740|acid (r_acl) hsa_4\NN\1740|of|complexed
T7_T24 NONE acid_8\NN\14818238|with|fatty|and|acetyldiflunisal (r_nmod) complexed_5\VBN\1740|acid (r_acl) hsa_4\NN\1740|of|complexed (r_nmod) structure_2\NN\21939|the|crystal|hsa (r_nsubj) revealed_11\VBD\2137132|structure|binds|. (l_ccomp) binds_14\VBZ\1290422|that|acetyldiflunisal|subdomain|and|acetylates (l_nmod) subdomain_18\NN\1740|to|the|iia
T8_T22 NONE acetyldiflunisal_10\NN\1740| (r_conj) acid_8\NN\14818238|with|fatty|and|acetyldiflunisal (r_nmod) complexed_5\VBN\1740|acid (r_acl) hsa_4\NN\1740|of|complexed
T8_T24 NONE acetyldiflunisal_10\NN\1740| (r_conj) acid_8\NN\14818238|with|fatty|and|acetyldiflunisal (r_nmod) complexed_5\VBN\1740|acid (r_acl) hsa_4\NN\1740|of|complexed (r_nmod) structure_2\NN\21939|the|crystal|hsa (r_nsubj) revealed_11\VBD\2137132|structure|binds|. (l_ccomp) binds_14\VBZ\1290422|that|acetyldiflunisal|subdomain|and|acetylates (l_nmod) subdomain_18\NN\1740|to|the|iia
T9_T22 NONE acetyldiflunisal_13\NN\1740| (r_nsubj) binds_14\VBZ\1290422|that|acetyldiflunisal|subdomain|and|acetylates (r_ccomp) revealed_11\VBD\2137132|structure|binds|. (l_nsubj) structure_2\NN\21939|the|crystal|hsa (l_nmod) hsa_4\NN\1740|of|complexed
T9_T24 NONE acetyldiflunisal_13\NN\1740| (r_nsubj) binds_14\VBZ\1290422|that|acetyldiflunisal|subdomain|and|acetylates (l_nmod) subdomain_18\NN\1740|to|the|iia
T13_T25 NONE diflunisal_9\NN\3828465|for (r_nmod) affinity_7\NN\11426530|weaker|binding|diflunisal (r_dobj) had_3\VBD\2108377|albumin|affinity|demonstrated|. (l_nsubj) albumin_2\NN\14736972|the|acetylated
T14_T26 NONE diflunisal_5\NN\3828465| (r_nsubjpass) released_9\VBN\1435380|that|diflunisal|is|easily|albumin|circulation (l_nmod) albumin_12\NN\14736972|from|acetylated
T1_T18 NONE diflunisal_26\NN\3828465|of (r_nmod) use_24\NN\407535|toward|effective|diflunisal|clinic (r_nmod) way_20\NN\4916342|the|use (r_dobj) pave_18\VBP\1264283|also|way (r_conj) provide_7\VBP\2199590|taken|,|results|only|template|,|but|pave|. (l_dobj) template_9\NN\5937112|a|design (l_nmod) design_11\NN\927261|for|prodrugs (l_nmod) prodrugs_14\NNS\1740|of|hsa-based (l_amod) hsa-based_13\JJ\1740|
23298577
T3_T23 NONE carbohydrate_22\NN\14944888| (r_compound) receptors_23\NNS\5225602|carbohydrate (r_conj) sialoadhesin_20\NN\1740|towards|and|receptors
T3_T24 NONE carbohydrate_22\NN\14944888| (r_compound) receptors_23\NNS\5225602|carbohydrate
17290783
T7_T16 NONE riboflavin_11\NN\15090742| (r_compound) kinase_12\NN\14732946|riboflavin
T1_T10 NONE riboflavin_23\NN\15090742| (r_compound) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_acl) driven_33\VBN\1224744|promoters (l_nmod) promoters_37\NNS\9773962|by|the|strong|rib1 (l_dep) rib1_41\NN\1740|(|the|regulated|or|promoter|)
T1_T11 NONE riboflavin_23\NN\15090742| (r_compound) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_acl) driven_33\VBN\1224744|promoters (l_nmod) promoters_37\NNS\9773962|by|the|strong|rib1 (l_dep) rib1_41\NN\1740|(|the|regulated|or|promoter|) (l_conj) promoter_45\NN\9773962|tef1
T1_T8 NONE riboflavin_23\NN\15090742| (r_compound) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_compound) fmn1_18\NN\1740|
T1_T9 NONE riboflavin_23\NN\15090742| (r_compound) kinase_24\NN\14732946|the|riboflavin|,|enzyme
T2_T10 NONE riboflavin_29\NN\15090742| (r_dobj) converts_28\VBZ\126264|that|riboflavin|flavinmononucleotide (r_acl:relcl) enzyme_26\NN\14723628|converts (r_appos) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_acl) driven_33\VBN\1224744|promoters (l_nmod) promoters_37\NNS\9773962|by|the|strong|rib1 (l_dep) rib1_41\NN\1740|(|the|regulated|or|promoter|)
T2_T11 NONE riboflavin_29\NN\15090742| (r_dobj) converts_28\VBZ\126264|that|riboflavin|flavinmononucleotide (r_acl:relcl) enzyme_26\NN\14723628|converts (r_appos) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_acl) driven_33\VBN\1224744|promoters (l_nmod) promoters_37\NNS\9773962|by|the|strong|rib1 (l_dep) rib1_41\NN\1740|(|the|regulated|or|promoter|) (l_conj) promoter_45\NN\9773962|tef1
T2_T8 NONE riboflavin_29\NN\15090742| (r_dobj) converts_28\VBZ\126264|that|riboflavin|flavinmononucleotide (r_acl:relcl) enzyme_26\NN\14723628|converts (r_appos) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_compound) fmn1_18\NN\1740|
T2_T9 CPR:9 riboflavin_29\NN\15090742| (r_dobj) converts_28\VBZ\126264|that|riboflavin|flavinmononucleotide (r_acl:relcl) enzyme_26\NN\14723628|converts (r_appos) kinase_24\NN\14732946|the|riboflavin|,|enzyme
T3_T10 NONE flavinmononucleotide_31\NN\1740|to (r_nmod) converts_28\VBZ\126264|that|riboflavin|flavinmononucleotide (r_acl:relcl) enzyme_26\NN\14723628|converts (r_appos) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_acl) driven_33\VBN\1224744|promoters (l_nmod) promoters_37\NNS\9773962|by|the|strong|rib1 (l_dep) rib1_41\NN\1740|(|the|regulated|or|promoter|)
T3_T11 NONE flavinmononucleotide_31\NN\1740|to (r_nmod) converts_28\VBZ\126264|that|riboflavin|flavinmononucleotide (r_acl:relcl) enzyme_26\NN\14723628|converts (r_appos) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_acl) driven_33\VBN\1224744|promoters (l_nmod) promoters_37\NNS\9773962|by|the|strong|rib1 (l_dep) rib1_41\NN\1740|(|the|regulated|or|promoter|) (l_conj) promoter_45\NN\9773962|tef1
T3_T8 NONE flavinmononucleotide_31\NN\1740|to (r_nmod) converts_28\VBZ\126264|that|riboflavin|flavinmononucleotide (r_acl:relcl) enzyme_26\NN\14723628|converts (r_appos) kinase_24\NN\14732946|the|riboflavin|,|enzyme (r_dobj) encoding_21\VBG\115157|kinase|) (r_acl) gene_19\NN\8459252|of|the|fmn1|(|encoding|driven (l_compound) fmn1_18\NN\1740|
T3_T9 CPR:9 flavinmononucleotide_31\NN\1740|to (r_nmod) converts_28\VBZ\126264|that|riboflavin|flavinmononucleotide (r_acl:relcl) enzyme_26\NN\14723628|converts (r_appos) kinase_24\NN\14732946|the|riboflavin|,|enzyme
T4_T12 NONE riboflavin_0\NN\15090742| (r_compound) kinase_1\NN\14732946|riboflavin
T5_T13 NONE riboflavin_7\NN\15090742| (r_compound) kinase_8\NN\14732946|riboflavin
T5_T14 NONE riboflavin_7\NN\15090742| (r_compound) kinase_8\NN\14732946|riboflavin (r_compound) activity_9\NN\30358|of|the|kinase (r_nmod) increase_4\NN\13576355|the|8-fold|activity (r_nsubjpass) shown_11\VBN\2137132|increase|was|strains|. (l_nmod) strains_15\NNS\7358060|in|the|recombinant|containing (l_acl) containing_16\VBG\2632940|gene|promoter (l_dobj) gene_22\NN\8459252|the|integrated|debaryomyces|hansenii|fmn1 (l_compound) fmn1_21\NN\1740|
T5_T15 NONE riboflavin_7\NN\15090742| (r_compound) kinase_8\NN\14732946|riboflavin (r_compound) activity_9\NN\30358|of|the|kinase (r_nmod) increase_4\NN\13576355|the|8-fold|activity (r_nsubjpass) shown_11\VBN\2137132|increase|was|strains|. (l_nmod) strains_15\NNS\7358060|in|the|recombinant|containing (l_acl) containing_16\VBG\2632940|gene|promoter (l_nmod) promoter_28\NN\9773962|under|the|strong|constitutive|tef1
15840827
T12_T27 NONE 5-aminolevulinate_2\NN\1740| (r_compound) synthase_3\NN\1740|of|5-aminolevulinate
T10_T19 NONE (plp)-dependent_15\JJ\1740| (r_dep) 5'-phosphate_14\NN\1740|a|pyridoxal|(plp)-dependent (r_compound) enzyme_16\NN\14723628|5'-phosphate (r_appos) synthase_7\NN\1740|of|dimeric|5-aminolevulinate|alas|,|enzyme|,
T10_T23 NONE (plp)-dependent_15\JJ\1740| (r_dep) 5'-phosphate_14\NN\1740|a|pyridoxal|(plp)-dependent (r_compound) enzyme_16\NN\14723628|5'-phosphate (r_appos) synthase_7\NN\1740|of|dimeric|5-aminolevulinate|alas|,|enzyme|, (l_appos) alas_9\NN\5470189|(|)
T5_T19 NONE acids_29\NNS\14818238|of|essential|amino (r_nmod) contribution_25\NN\786195|with|acids|subunit (r_nmod) located_19\JJ\1740|sites|are|interface|contribution|. (l_nsubj) sites_3\NNS\8673395|the|two|active|synthase (l_nmod) synthase_7\NN\1740|of|dimeric|5-aminolevulinate|alas|,|enzyme|,
T5_T23 NONE acids_29\NNS\14818238|of|essential|amino (r_nmod) contribution_25\NN\786195|with|acids|subunit (r_nmod) located_19\JJ\1740|sites|are|interface|contribution|. (l_nsubj) sites_3\NNS\8673395|the|two|active|synthase (l_nmod) synthase_7\NN\1740|of|dimeric|5-aminolevulinate|alas|,|enzyme|, (l_appos) alas_9\NN\5470189|(|)
T6_T19 NONE 5-aminolevulinate_6\NN\1740| (r_compound) synthase_7\NN\1740|of|dimeric|5-aminolevulinate|alas|,|enzyme|,
T6_T23 NONE 5-aminolevulinate_6\NN\1740| (r_compound) synthase_7\NN\1740|of|dimeric|5-aminolevulinate|alas|,|enzyme|, (l_appos) alas_9\NN\5470189|(|)
T7_T19 NONE 5'-phosphate_14\NN\1740|a|pyridoxal|(plp)-dependent (r_compound) enzyme_16\NN\14723628|5'-phosphate (r_appos) synthase_7\NN\1740|of|dimeric|5-aminolevulinate|alas|,|enzyme|,
T7_T23 NONE 5'-phosphate_14\NN\1740|a|pyridoxal|(plp)-dependent (r_compound) enzyme_16\NN\14723628|5'-phosphate (r_appos) synthase_7\NN\1740|of|dimeric|5-aminolevulinate|alas|,|enzyme|, (l_appos) alas_9\NN\5470189|(|)
T3_T13 NONE quinonoid_10\JJ\1740| (r_amod) intermediate_11\NN\14806838|of|the|quinonoid|eq(2|) (r_nmod) formation_5\NN\7938773|of|the|and|decay|intermediate (r_nmod) analysis_2\NN\633864|transient|kinetic|formation (r_nsubj) indicated_14\VBD\952524|analysis|greater|. (l_ccomp) greater_32\JJR\1740|that|,|similar|,|accumulation|was|reaction (l_advcl) similar_21\JJ\1740|although|rates|were|alas (l_nmod) alas_23\NN\5470189|in|and|2xalas
T3_T14 NONE quinonoid_10\JJ\1740| (r_amod) intermediate_11\NN\14806838|of|the|quinonoid|eq(2|) (r_nmod) formation_5\NN\7938773|of|the|and|decay|intermediate (r_nmod) analysis_2\NN\633864|transient|kinetic|formation (r_nsubj) indicated_14\VBD\952524|analysis|greater|. (l_ccomp) greater_32\JJR\1740|that|,|similar|,|accumulation|was|reaction (l_advcl) similar_21\JJ\1740|although|rates|were|alas (l_nmod) alas_23\NN\5470189|in|and|2xalas (l_conj) 2xalas_25\NN\1740|
T3_T15 NONE quinonoid_10\JJ\1740| (r_amod) intermediate_11\NN\14806838|of|the|quinonoid|eq(2|) (r_nmod) formation_5\NN\7938773|of|the|and|decay|intermediate (r_nmod) analysis_2\NN\633864|transient|kinetic|formation (r_nsubj) indicated_14\VBD\952524|analysis|greater|. (l_ccomp) greater_32\JJR\1740|that|,|similar|,|accumulation|was|reaction (l_nmod) reaction_36\NN\13446390|in|the|2xalas-catalyzed (l_amod) 2xalas-catalyzed_35\JJ\1740|
T4_T16 NONE ketoenamine_6\NN\1740| (r_nsubj) form_10\NN\6286395|that|ketoenamine|is|the|active|coenzyme|and|forms (l_conj) forms_15\VBZ\1617192|structure|2xalas|alas (l_nmod) 2xalas_22\NNP\1740|in
T4_T17 NONE ketoenamine_6\NN\1740| (r_nsubj) form_10\NN\6286395|that|ketoenamine|is|the|active|coenzyme|and|forms (l_conj) forms_15\VBZ\1617192|structure|2xalas|alas (l_nmod) alas_25\NN\5470189|than|in|ph
23454527
T1_T10 NONE n-acetylcysteine_0\NN\1740|nac|and|inhibitor (l_conj) inhibitor_15\NN\20090|the|kinase|sp600125 (l_compound) kinase_11\NN\14732946|c-jun|n-terminal|jnk (l_appos) jnk_13\NN\1740|(|)
T1_T9 NONE n-acetylcysteine_0\NN\1740|nac|and|inhibitor (l_conj) inhibitor_15\NN\20090|the|kinase|sp600125 (l_compound) kinase_11\NN\14732946|c-jun|n-terminal|jnk
T2_T10 NONE nac_2\NN\8310949|(|,|mm|) (r_appos) n-acetylcysteine_0\NN\1740|nac|and|inhibitor (l_conj) inhibitor_15\NN\20090|the|kinase|sp600125 (l_compound) kinase_11\NN\14732946|c-jun|n-terminal|jnk (l_appos) jnk_13\NN\1740|(|)
T2_T9 NONE nac_2\NN\8310949|(|,|mm|) (r_appos) n-acetylcysteine_0\NN\1740|nac|and|inhibitor (l_conj) inhibitor_15\NN\20090|the|kinase|sp600125 (l_compound) kinase_11\NN\14732946|c-jun|n-terminal|jnk
T3_T10 NONE n-terminal_10\JJ\1740| (r_amod) kinase_11\NN\14732946|c-jun|n-terminal|jnk (l_appos) jnk_13\NN\1740|(|)
T3_T9 NONE n-terminal_10\JJ\1740| (r_amod) kinase_11\NN\14732946|c-jun|n-terminal|jnk
T4_T10 CPR:4 sp600125_17\NN\1740|(|,|μm|) (r_dep) inhibitor_15\NN\20090|the|kinase|sp600125 (l_compound) kinase_11\NN\14732946|c-jun|n-terminal|jnk (l_appos) jnk_13\NN\1740|(|)
T4_T9 CPR:4 sp600125_17\NN\1740|(|,|μm|) (r_dep) inhibitor_15\NN\20090|the|kinase|sp600125 (l_compound) kinase_11\NN\14732946|c-jun|n-terminal|jnk
12699389
T1_T10 NONE atp-dependent_1\JJ\1740| (r_amod) pump_4\NN\3736970|atp-dependent|drug|efflux|p-glycoprotein
T1_T13 NONE atp-dependent_1\JJ\1740| (r_amod) pump_4\NN\3736970|atp-dependent|drug|efflux|p-glycoprotein (l_dep) p-glycoprotein_5\NN\1740|p-gp (l_appos) p-gp_7\NN\1740|(|)
T1_T8 NONE atp-dependent_1\JJ\1740| (r_amod) pump_4\NN\3736970|atp-dependent|drug|efflux|p-glycoprotein (l_dep) p-glycoprotein_5\NN\1740|p-gp
T2_T14 NONE silico_4\FW\1740| (r_dep) in_3\FW\13603305|silico (r_amod) predictions_5\NNS\5772356|in|,|assays|(|based|)|,|and|assays (l_conj) assays_23\NNS\5733583|functional|assay (l_dep) assay_27\NN\5733583|(|atpase|activity|and|assay|,|latter|) (l_compound) atpase_25\NN\1740|
T3_T14 NONE rhodamine-123_15\NN\1740|of|or|am (r_nmod) uptake_13\NN\13440063|on|cellular|rhodamine-123 (r_nmod) based_10\VBN\2694933|uptake (r_acl) predictions_5\NNS\5772356|in|,|assays|(|based|)|,|and|assays (l_conj) assays_23\NNS\5733583|functional|assay (l_dep) assay_27\NN\5733583|(|atpase|activity|and|assay|,|latter|) (l_compound) atpase_25\NN\1740|
T4_T14 NONE am_18\NN\14625458|calcein (r_conj) rhodamine-123_15\NN\1740|of|or|am (r_nmod) uptake_13\NN\13440063|on|cellular|rhodamine-123 (r_nmod) based_10\VBN\2694933|uptake (r_acl) predictions_5\NNS\5772356|in|,|assays|(|based|)|,|and|assays (l_conj) assays_23\NNS\5733583|functional|assay (l_dep) assay_27\NN\5733583|(|atpase|activity|and|assay|,|latter|) (l_compound) atpase_25\NN\1740|
16893531
T22_T33 NONE norepinephrine_3\NN\14807929| (r_compound) transporter_4\NN\4490091|norepinephrine
T13_T30 NONE norepinephrine_1\NN\14807929| (r_nsubj) regulator_5\NN\3096960|because|norepinephrine|is|an|important|activity (r_advcl) speculated_12\VBD\719734|regulator|,|we|contributes|. (l_ccomp) contributes_17\VBZ\126264|that|blockade|effects (l_nsubj) blockade_16\NN\952963|norepinephrine|transporter (l_compound) transporter_15\NN\4490091|
T14_T30 NONE norepinephrine_14\NN\14807929| (r_compound) blockade_16\NN\952963|norepinephrine|transporter (l_compound) transporter_15\NN\4490091|
T15_T31 NONE reboxetine_5\NN\2718811|(|,|desipramine|,|imipramine|,|venlafaxine|,|bupropion|) (r_dep) drugs_3\NNS\14778436|antidepressant|reboxetine (r_nsubjpass) administered_16\VBN\2436349|drugs|were|or|mice|,|and|recorded (l_nmod) mice_34\NNS\2329401|to|control (l_amod) control_29\JJ\1740|and|knockout (l_conj) knockout_33\JJ\1740|transporter (l_nmod:npmod) transporter_32\NN\4490091|norepinephrine
T16_T31 NONE desipramine_7\NN\4482543| (r_appos) reboxetine_5\NN\2718811|(|,|desipramine|,|imipramine|,|venlafaxine|,|bupropion|) (r_dep) drugs_3\NNS\14778436|antidepressant|reboxetine (r_nsubjpass) administered_16\VBN\2436349|drugs|were|or|mice|,|and|recorded (l_nmod) mice_34\NNS\2329401|to|control (l_amod) control_29\JJ\1740|and|knockout (l_conj) knockout_33\JJ\1740|transporter (l_nmod:npmod) transporter_32\NN\4490091|norepinephrine
T17_T31 NONE imipramine_9\NN\4482543| (r_appos) reboxetine_5\NN\2718811|(|,|desipramine|,|imipramine|,|venlafaxine|,|bupropion|) (r_dep) drugs_3\NNS\14778436|antidepressant|reboxetine (r_nsubjpass) administered_16\VBN\2436349|drugs|were|or|mice|,|and|recorded (l_nmod) mice_34\NNS\2329401|to|control (l_amod) control_29\JJ\1740|and|knockout (l_conj) knockout_33\JJ\1740|transporter (l_nmod:npmod) transporter_32\NN\4490091|norepinephrine
T18_T31 NONE venlafaxine_11\NN\1740| (r_appos) reboxetine_5\NN\2718811|(|,|desipramine|,|imipramine|,|venlafaxine|,|bupropion|) (r_dep) drugs_3\NNS\14778436|antidepressant|reboxetine (r_nsubjpass) administered_16\VBN\2436349|drugs|were|or|mice|,|and|recorded (l_nmod) mice_34\NNS\2329401|to|control (l_amod) control_29\JJ\1740|and|knockout (l_conj) knockout_33\JJ\1740|transporter (l_nmod:npmod) transporter_32\NN\4490091|norepinephrine
T19_T31 NONE bupropion_13\NN\1740| (r_appos) reboxetine_5\NN\2718811|(|,|desipramine|,|imipramine|,|venlafaxine|,|bupropion|) (r_dep) drugs_3\NNS\14778436|antidepressant|reboxetine (r_nsubjpass) administered_16\VBN\2436349|drugs|were|or|mice|,|and|recorded (l_nmod) mice_34\NNS\2329401|to|control (l_amod) control_29\JJ\1740|and|knockout (l_conj) knockout_33\JJ\1740|transporter (l_nmod:npmod) transporter_32\NN\4490091|norepinephrine
T20_T31 NONE norepinephrine_31\NN\14807929| (r_compound) transporter_32\NN\4490091|norepinephrine
T21_T32 NONE norepinephrine_6\NN\14807929| (r_nmod:npmod) transporter-blocking_7\JJ\1740|norepinephrine
T1_T23 CPR:4 bupropion_3\NN\1740|exception|was|,|blocker|,|tended|. (l_appos) blocker_10\NN\10101634|a|dual|transporter (l_compound) transporter_9\NN\4490091|norepinephrine|transporter/dopamine (l_compound) transporter/dopamine_8\NN\1740|
T1_T24 CPR:4 bupropion_3\NN\1740|exception|was|,|blocker|,|tended|. (l_appos) blocker_10\NN\10101634|a|dual|transporter (l_compound) transporter_9\NN\4490091|norepinephrine|transporter/dopamine
T2_T23 NONE norepinephrine_7\NN\14807929| (r_compound) transporter_9\NN\4490091|norepinephrine|transporter/dopamine (l_compound) transporter/dopamine_8\NN\1740|
T2_T24 NONE norepinephrine_7\NN\14807929| (r_compound) transporter_9\NN\4490091|norepinephrine|transporter/dopamine
T3_T23 NONE transporter/dopamine_8\NN\1740|
T3_T24 NONE transporter/dopamine_8\NN\1740| (r_compound) transporter_9\NN\4490091|norepinephrine|transporter/dopamine
T4_T25 NONE reboxetine_2\NN\2718811|of|and|blocker (l_conj) blocker_7\NN\10101634|the|dopamine|transporter|gbr (l_compound) transporter_6\NN\4490091|
T5_T25 NONE dopamine_5\NN\14807737| (r_compound) blocker_7\NN\10101634|the|dopamine|transporter|gbr (l_compound) transporter_6\NN\4490091|
T6_T25 CPR:4 12909_9\CD\1740| (r_nummod) gbr_8\NN\1740|12909 (r_dep) blocker_7\NN\10101634|the|dopamine|transporter|gbr (l_compound) transporter_6\NN\4490091|
T10_T26 NONE norepinephrine_23\NN\14807929| (r_compound) transporter_24\NN\4490091|norepinephrine (r_compound) mice_26\NNS\2329401|in|transporter|knockout (r_nmod) had_19\VBD\2108377|reboxetine|effect|mice (r_parataxis) had_4\VBD\2108377|mice|activity|,|whereas|had|. (l_nsubj) mice_3\NNS\2329401|transporter|knockout (l_compound) transporter_1\NN\4490091|norepinephrine
T10_T27 NONE norepinephrine_23\NN\14807929| (r_compound) transporter_24\NN\4490091|norepinephrine
T7_T26 NONE norepinephrine_0\NN\14807929| (r_compound) transporter_1\NN\4490091|norepinephrine
T7_T27 NONE norepinephrine_0\NN\14807929| (r_compound) transporter_1\NN\4490091|norepinephrine (r_compound) mice_3\NNS\2329401|transporter|knockout (r_nsubj) had_4\VBD\2108377|mice|activity|,|whereas|had|. (l_parataxis) had_19\VBD\2108377|reboxetine|effect|mice (l_nmod) mice_26\NNS\2329401|in|transporter|knockout (l_compound) transporter_24\NN\4490091|norepinephrine
T8_T26 NONE bupropion_15\NN\1740|by (r_nmod) increased_13\VBN\169651|which|was|bupropion (r_acl:relcl) activity_9\NN\30358|low|basal|spontaneous|locomotor|,|increased (r_dobj) had_4\VBD\2108377|mice|activity|,|whereas|had|. (l_nsubj) mice_3\NNS\2329401|transporter|knockout (l_compound) transporter_1\NN\4490091|norepinephrine
T8_T27 NONE bupropion_15\NN\1740|by (r_nmod) increased_13\VBN\169651|which|was|bupropion (r_acl:relcl) activity_9\NN\30358|low|basal|spontaneous|locomotor|,|increased (r_dobj) had_4\VBD\2108377|mice|activity|,|whereas|had|. (l_parataxis) had_19\VBD\2108377|reboxetine|effect|mice (l_nmod) mice_26\NNS\2329401|in|transporter|knockout (l_compound) transporter_24\NN\4490091|norepinephrine
T9_T26 NONE reboxetine_18\NN\2718811| (r_nsubj) had_19\VBD\2108377|reboxetine|effect|mice (r_parataxis) had_4\VBD\2108377|mice|activity|,|whereas|had|. (l_nsubj) mice_3\NNS\2329401|transporter|knockout (l_compound) transporter_1\NN\4490091|norepinephrine
T9_T27 NONE reboxetine_18\NN\2718811| (r_nsubj) had_19\VBD\2108377|reboxetine|effect|mice (l_nmod) mice_26\NNS\2329401|in|transporter|knockout (l_compound) transporter_24\NN\4490091|norepinephrine
T11_T28 NONE norepinephrine_8\NN\14807929| (r_compound) transporter_9\NN\4490091|of|the|norepinephrine
T11_T29 NONE norepinephrine_8\NN\14807929| (r_compound) transporter_9\NN\4490091|of|the|norepinephrine (r_nmod) inactivation_5\NN\13518963|acute|transporter (r_nsubj) decreases_10\VBZ\169651|inactivation|activity|coupled (l_advcl) coupled_20\VBN\1295275|unless|blockade (l_nmod) blockade_24\NN\952963|with|dopamine|transporter (l_compound) transporter_23\NN\4490091|
T12_T28 NONE dopamine_22\NN\14807737| (r_compound) blockade_24\NN\952963|with|dopamine|transporter (r_nmod) coupled_20\VBN\1295275|unless|blockade (r_advcl) decreases_10\VBZ\169651|inactivation|activity|coupled (l_nsubj) inactivation_5\NN\13518963|acute|transporter (l_nmod) transporter_9\NN\4490091|of|the|norepinephrine
T12_T29 NONE dopamine_22\NN\14807737| (r_compound) blockade_24\NN\952963|with|dopamine|transporter (l_compound) transporter_23\NN\4490091|
23047828
T12_T27 NONE cortisol_11\NN\14751417|adrenocortical|and|aldosterone (r_compound) synthesis_14\NN\13446390|cortisol (r_dobj) accelerates_9\VBZ\226566|lipoprotein|synthesis|. (l_nsubj) lipoprotein_2\NN\14731135|circulating|very-low-density|subjects
T13_T27 NONE aldosterone_13\NN\14751863| (r_conj) cortisol_11\NN\14751417|adrenocortical|and|aldosterone (r_compound) synthesis_14\NN\13446390|cortisol (r_dobj) accelerates_9\VBZ\226566|lipoprotein|synthesis|. (l_nsubj) lipoprotein_2\NN\14731135|circulating|very-low-density|subjects
T14_T27 NONE glucose_7\NN\14710501| (r_compound) tolerance_8\NN\5032565|with|impaired|glucose (r_nmod) subjects_4\NNS\6598915|from|tolerance (r_nmod) lipoprotein_2\NN\14731135|circulating|very-low-density|subjects
T11_T22 NONE cortisol_12\NN\14751417| (r_conj) aldosterone_10\NN\14751863|and|cortisol (r_nsubjpass) implicated_15\VBN\2677097|apart|,|aldosterone|are|also|pathogenesis|. (l_nmod) pathogenesis_18\NN\13533470|in|the|resistance (l_nmod) resistance_21\NN\37396|of|insulin|and|mellitus (l_compound) insulin_20\NN\5407119|
T9_T22 NONE aldosterone_10\NN\14751863|and|cortisol (r_nsubjpass) implicated_15\VBN\2677097|apart|,|aldosterone|are|also|pathogenesis|. (l_nmod) pathogenesis_18\NN\13533470|in|the|resistance (l_nmod) resistance_21\NN\37396|of|insulin|and|mellitus (l_compound) insulin_20\NN\5407119|
T3_T15 NONE aldosterone_8\NN\14751863|on|adrenocortical|and|cortisol|release (r_nmod) induced_1\VBD\1627355|vldl|effect|aldosterone|hdl|. (l_nsubj) vldl_0\NN\14939230|
T3_T16 NONE aldosterone_8\NN\14751863|on|adrenocortical|and|cortisol|release (r_nmod) induced_1\VBD\1627355|vldl|effect|aldosterone|hdl|. (l_advcl) hdl_14\NN\14939230|compared|to|and|ldl
T3_T17 NONE aldosterone_8\NN\14751863|on|adrenocortical|and|cortisol|release (r_nmod) induced_1\VBD\1627355|vldl|effect|aldosterone|hdl|. (l_advcl) hdl_14\NN\14939230|compared|to|and|ldl (l_conj) ldl_16\NN\14939230|
T4_T15 NONE cortisol_10\NN\14751417| (r_conj) aldosterone_8\NN\14751863|on|adrenocortical|and|cortisol|release (r_nmod) induced_1\VBD\1627355|vldl|effect|aldosterone|hdl|. (l_nsubj) vldl_0\NN\14939230|
T4_T16 NONE cortisol_10\NN\14751417| (r_conj) aldosterone_8\NN\14751863|on|adrenocortical|and|cortisol|release (r_nmod) induced_1\VBD\1627355|vldl|effect|aldosterone|hdl|. (l_advcl) hdl_14\NN\14939230|compared|to|and|ldl
T4_T17 NONE cortisol_10\NN\14751417| (r_conj) aldosterone_8\NN\14751863|on|adrenocortical|and|cortisol|release (r_nmod) induced_1\VBD\1627355|vldl|effect|aldosterone|hdl|. (l_advcl) hdl_14\NN\14939230|compared|to|and|ldl (l_conj) ldl_16\NN\14939230|
23341458
T1_T11 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (l_compound) bmp-2_43\NN\1740|
T1_T41 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nsubjpass) pro-bmp-2_4\NN\1740|
T1_T42 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) fsap_8\NN\1740|by
T1_T43 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) site_14\NN\8673395|at|the|canonical|pc|cleavage
T1_T44 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|,
T1_T45 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2
T1_T46 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (l_nmod) bmp-2_37\NN\1740|of|mature
T2_T11 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (l_compound) bmp-2_43\NN\1740|
T2_T41 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nsubjpass) pro-bmp-2_4\NN\1740|
T2_T42 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) fsap_8\NN\1740|by
T2_T43 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) site_14\NN\8673395|at|the|canonical|pc|cleavage
T2_T44 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|,
T2_T45 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2
T2_T46 NONE arg(289)↓lys(290_46\NN\1740|(|) (r_appos) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (r_dobj) generating_39\VBG\1617192|peptide (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (l_nmod) bmp-2_37\NN\1740|of|mature
T6_T11 NONE n-terminal_0\JJ\1740| (r_amod) sequencing_1\NN\1740|n-terminal (r_nsubj) indicated_2\VBD\952524|sequencing|cleaved|. (l_ccomp) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) generating_39\VBG\1617192|peptide (l_dobj) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (l_compound) bmp-2_43\NN\1740|
T6_T41 NONE n-terminal_0\JJ\1740| (r_amod) sequencing_1\NN\1740|n-terminal (r_nsubj) indicated_2\VBD\952524|sequencing|cleaved|. (l_ccomp) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nsubjpass) pro-bmp-2_4\NN\1740|
T6_T42 NONE n-terminal_0\JJ\1740| (r_amod) sequencing_1\NN\1740|n-terminal (r_nsubj) indicated_2\VBD\952524|sequencing|cleaved|. (l_ccomp) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) fsap_8\NN\1740|by
T6_T43 NONE n-terminal_0\JJ\1740| (r_amod) sequencing_1\NN\1740|n-terminal (r_nsubj) indicated_2\VBD\952524|sequencing|cleaved|. (l_ccomp) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) site_14\NN\8673395|at|the|canonical|pc|cleavage
T6_T44 NONE n-terminal_0\JJ\1740| (r_amod) sequencing_1\NN\1740|n-terminal (r_nsubj) indicated_2\VBD\952524|sequencing|cleaved|. (l_ccomp) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|,
T6_T45 NONE n-terminal_0\JJ\1740| (r_amod) sequencing_1\NN\1740|n-terminal (r_nsubj) indicated_2\VBD\952524|sequencing|cleaved|. (l_ccomp) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2
T6_T46 NONE n-terminal_0\JJ\1740| (r_amod) sequencing_1\NN\1740|n-terminal (r_nsubj) indicated_2\VBD\952524|sequencing|cleaved|. (l_ccomp) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) giving_16\VBG\2327200|rise|bmp-2 (l_nmod) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (l_nmod) bmp-2_37\NN\1740|of|mature
T7_T11 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) generating_39\VBG\1617192|peptide (l_dobj) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (l_compound) bmp-2_43\NN\1740|
T7_T41 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nsubjpass) pro-bmp-2_4\NN\1740|
T7_T42 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) fsap_8\NN\1740|by
T7_T43 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) site_14\NN\8673395|at|the|canonical|pc|cleavage
T7_T44 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|,
T7_T45 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2
T7_T46 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (l_nmod) bmp-2_37\NN\1740|of|mature
T8_T11 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) generating_39\VBG\1617192|peptide (l_dobj) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (l_compound) bmp-2_43\NN\1740|
T8_T41 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nsubjpass) pro-bmp-2_4\NN\1740|
T8_T42 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) fsap_8\NN\1740|by
T8_T43 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) site_14\NN\8673395|at|the|canonical|pc|cleavage
T8_T44 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|,
T8_T45 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2
T8_T46 NONE arg(282)↓gln(283_22\NN\1740|(|)|) (r_appos) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (l_conj) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (l_nmod) bmp-2_37\NN\1740|of|mature
T9_T11 NONE n-terminal_31\JJ\1740| (r_amod) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (r_conj) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_advcl) generating_39\VBG\1617192|peptide (l_dobj) peptide_44\NN\14724264|a|truncated|mature|bmp-2|arg(289)↓lys(290|) (l_compound) bmp-2_43\NN\1740|
T9_T41 NONE n-terminal_31\JJ\1740| (r_amod) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (r_conj) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nsubjpass) pro-bmp-2_4\NN\1740|
T9_T42 NONE n-terminal_31\JJ\1740| (r_amod) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (r_conj) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) fsap_8\NN\1740|by
T9_T43 NONE n-terminal_31\JJ\1740| (r_amod) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (r_conj) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|, (r_nmod) giving_16\VBG\2327200|rise|bmp-2 (r_advcl) cleaved_6\VBN\1556346|that|pro-bmp-2|was|fsap|site|,|giving|generating (l_nmod) site_14\NN\8673395|at|the|canonical|pc|cleavage
T9_T44 NONE n-terminal_31\JJ\1740| (r_amod) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (r_conj) bmp-2_20\NN\1740|to|mature|arg(282)↓gln(283|,|as|region|,
T9_T45 NONE n-terminal_31\JJ\1740| (r_amod) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2
T9_T46 NONE n-terminal_31\JJ\1740| (r_amod) region_34\NN\27167|in|the|n-terminal|heparin|binding|bmp-2 (l_nmod) bmp-2_37\NN\1740|of|mature
T3_T12 NONE n-terminal_13\JJ\1740| (r_amod) region_14\NN\27167|within|its|n-terminal (r_nmod) peptide_10\NN\14724264|to|a|truncated|region|arg(289)↓lys(290|) (r_nmod) cleaved_6\VBN\1556346|similarly|,|bmp-2|was|also|peptide|. (l_nsubjpass) bmp-2_3\NN\1740|mature
T4_T12 NONE arg(289)↓lys(290_16\NN\1740|(|) (r_appos) peptide_10\NN\14724264|to|a|truncated|region|arg(289)↓lys(290|) (r_nmod) cleaved_6\VBN\1556346|similarly|,|bmp-2|was|also|peptide|. (l_nsubjpass) bmp-2_3\NN\1740|mature
T5_T12 NONE arg(289)↓lys(290_16\NN\1740|(|) (r_appos) peptide_10\NN\14724264|to|a|truncated|region|arg(289)↓lys(290|) (r_nmod) cleaved_6\VBN\1556346|similarly|,|bmp-2|was|also|peptide|. (l_nsubjpass) bmp-2_3\NN\1740|mature
12137927
T13_T31 NONE norepinephrine_2\NN\14807929| (r_compound) transporter_3\NN\4490091|norepinephrine
T14_T31 NONE catecholamines_6\NNS\5407119|by|and|desipramine (r_nmod) regulation_0\NN\6652242|abundance|catecholamines|vivo|. (l_nmod) abundance_4\NN\5108740|of|transporter (l_compound) transporter_3\NN\4490091|norepinephrine
T15_T31 NONE desipramine_8\NN\4482543| (r_conj) catecholamines_6\NNS\5407119|by|and|desipramine (r_nmod) regulation_0\NN\6652242|abundance|catecholamines|vivo|. (l_nmod) abundance_4\NN\5108740|of|transporter (l_compound) transporter_3\NN\4490091|norepinephrine
T1_T20 NONE norepinephrine_15\NN\14807929|of|synaptic|ne (r_nmod) availability_12\NN\4718563|the|norepinephrine (r_dobj) controlling_10\VBG\2422663|by|availability (r_advcl) regulates_6\VBZ\296178|transporter|signaling|controlling|,|and|target|. (l_nsubj) transporter_2\NN\4490091|the|norepinephrine|net (l_appos) net_4\NN\3085333|(|)
T1_T22 NONE norepinephrine_15\NN\14807929|of|synaptic|ne (r_nmod) availability_12\NN\4718563|the|norepinephrine (r_dobj) controlling_10\VBG\2422663|by|availability (r_advcl) regulates_6\VBZ\296178|transporter|signaling|controlling|,|and|target|. (l_nsubj) transporter_2\NN\4490091|the|norepinephrine|net
T1_T24 NONE norepinephrine_15\NN\14807929|of|synaptic|ne (r_nmod) availability_12\NN\4718563|the|norepinephrine (r_dobj) controlling_10\VBG\2422663|by|availability (r_advcl) regulates_6\VBZ\296178|transporter|signaling|controlling|,|and|target|. (l_dobj) signaling_8\NN\33020|adrenoreceptor (l_compound) adrenoreceptor_7\NN\1740|
T2_T20 NONE ne_17\NN\14622893|(|) (r_appos) norepinephrine_15\NN\14807929|of|synaptic|ne (r_nmod) availability_12\NN\4718563|the|norepinephrine (r_dobj) controlling_10\VBG\2422663|by|availability (r_advcl) regulates_6\VBZ\296178|transporter|signaling|controlling|,|and|target|. (l_nsubj) transporter_2\NN\4490091|the|norepinephrine|net (l_appos) net_4\NN\3085333|(|)
T2_T22 NONE ne_17\NN\14622893|(|) (r_appos) norepinephrine_15\NN\14807929|of|synaptic|ne (r_nmod) availability_12\NN\4718563|the|norepinephrine (r_dobj) controlling_10\VBG\2422663|by|availability (r_advcl) regulates_6\VBZ\296178|transporter|signaling|controlling|,|and|target|. (l_nsubj) transporter_2\NN\4490091|the|norepinephrine|net
T2_T24 NONE ne_17\NN\14622893|(|) (r_appos) norepinephrine_15\NN\14807929|of|synaptic|ne (r_nmod) availability_12\NN\4718563|the|norepinephrine (r_dobj) controlling_10\VBG\2422663|by|availability (r_advcl) regulates_6\VBZ\296178|transporter|signaling|controlling|,|and|target|. (l_dobj) signaling_8\NN\33020|adrenoreceptor (l_compound) adrenoreceptor_7\NN\1740|
T5_T20 NONE norepinephrine_1\NN\14807929| (r_compound) transporter_2\NN\4490091|the|norepinephrine|net (l_appos) net_4\NN\3085333|(|)
T5_T22 NONE norepinephrine_1\NN\14807929| (r_compound) transporter_2\NN\4490091|the|norepinephrine|net
T5_T24 NONE norepinephrine_1\NN\14807929| (r_compound) transporter_2\NN\4490091|the|norepinephrine|net (r_nsubj) regulates_6\VBZ\296178|transporter|signaling|controlling|,|and|target|. (l_dobj) signaling_8\NN\33020|adrenoreceptor (l_compound) adrenoreceptor_7\NN\1740|
T3_T16 NONE ne_15\NN\14622893| (r_dobj) lack_14\VBP\1740|that|ne (r_acl:relcl) mice_12\NNS\2329401|in|knockout|lack (r_nmod) normal_3\JJ\1740|levels|are|mice|,|demonstrating|. (l_nsubj) levels_1\NNS\4916342|net (l_amod) net_0\JJ\1740|
T3_T17 NONE ne_15\NN\14622893| (r_dobj) lack_14\VBP\1740|that|ne (r_acl:relcl) mice_12\NNS\2329401|in|knockout|lack (l_amod) knockout_7\JJ\1740|dopamine|beta-hydroxylase|dbh|-/- (l_compound) beta-hydroxylase_6\NN\1740|
T3_T18 NONE ne_15\NN\14622893| (r_dobj) lack_14\VBP\1740|that|ne (r_acl:relcl) mice_12\NNS\2329401|in|knockout|lack (l_amod) knockout_7\JJ\1740|dopamine|beta-hydroxylase|dbh|-/- (l_dep) dbh_9\JJ\1740|(
T3_T19 NONE ne_15\NN\14622893| (r_dobj) lack_14\VBP\1740|that|ne (r_acl:relcl) mice_12\NNS\2329401|in|knockout|lack (r_nmod) normal_3\JJ\1740|levels|are|mice|,|demonstrating|. (l_xcomp) demonstrating_17\VBG\2137132|require (l_ccomp) require_23\VB\754942|that|net|does|not|ne|regulation (l_nsubj) net_20\JJ\1740|the
T4_T16 NONE ne_25\NNS\14622893|endogenous (r_dobj) require_23\VB\754942|that|net|does|not|ne|regulation (r_ccomp) demonstrating_17\VBG\2137132|require (r_xcomp) normal_3\JJ\1740|levels|are|mice|,|demonstrating|. (l_nsubj) levels_1\NNS\4916342|net (l_amod) net_0\JJ\1740|
T4_T17 NONE ne_25\NNS\14622893|endogenous (r_dobj) require_23\VB\754942|that|net|does|not|ne|regulation (r_ccomp) demonstrating_17\VBG\2137132|require (r_xcomp) normal_3\JJ\1740|levels|are|mice|,|demonstrating|. (l_nmod) mice_12\NNS\2329401|in|knockout|lack (l_amod) knockout_7\JJ\1740|dopamine|beta-hydroxylase|dbh|-/- (l_compound) beta-hydroxylase_6\NN\1740|
T4_T18 NONE ne_25\NNS\14622893|endogenous (r_dobj) require_23\VB\754942|that|net|does|not|ne|regulation (r_ccomp) demonstrating_17\VBG\2137132|require (r_xcomp) normal_3\JJ\1740|levels|are|mice|,|demonstrating|. (l_nmod) mice_12\NNS\2329401|in|knockout|lack (l_amod) knockout_7\JJ\1740|dopamine|beta-hydroxylase|dbh|-/- (l_dep) dbh_9\JJ\1740|(
T4_T19 NONE ne_25\NNS\14622893|endogenous (r_dobj) require_23\VB\754942|that|net|does|not|ne|regulation (l_nsubj) net_20\JJ\1740|the
T10_T21 NONE ne_39\NNS\14622893| (r_conj) catecholamines_36\NNS\5407119|of|not|ne|se (r_nmod) absence_34\NN\14449405|by|a|complete|catecholamines (r_nmod) down-regulated_30\VBN\1740|that|it|is|absence (r_ccomp) suggesting_26\VBG\1010118|down-regulated (r_advcl) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_nsubj) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_compound) hydroxylase_4\NN\1740|
T10_T23 NONE ne_39\NNS\14622893| (r_conj) catecholamines_36\NNS\5407119|of|not|ne|se (r_nmod) absence_34\NN\14449405|by|a|complete|catecholamines (r_nmod) down-regulated_30\VBN\1740|that|it|is|absence (r_ccomp) suggesting_26\VBG\1010118|down-regulated (r_advcl) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_nsubj) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_dep) -/-_8\JJ\1740|(|th|) (l_nmod:npmod) th_7\NN\15163157|
T10_T25 NONE ne_39\NNS\14622893| (r_conj) catecholamines_36\NNS\5407119|of|not|ne|se (r_nmod) absence_34\NN\14449405|by|a|complete|catecholamines (r_nmod) down-regulated_30\VBN\1740|that|it|is|absence (r_ccomp) suggesting_26\VBG\1010118|down-regulated (r_advcl) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_dobj) levels_22\NNS\4916342|reduced|net (l_nmod) net_24\NN\3085333|of
T6_T21 NONE ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_compound) hydroxylase_4\NN\1740|
T6_T23 NONE ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_dep) -/-_8\JJ\1740|(|th|) (l_nmod:npmod) th_7\NN\15163157|
T6_T25 NONE ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (r_nsubj) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_dobj) levels_22\NNS\4916342|reduced|net (l_nmod) net_24\NN\3085333|of
T7_T21 NONE dopamine_16\NN\14807737|da (r_conj) ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_compound) hydroxylase_4\NN\1740|
T7_T23 NONE dopamine_16\NN\14807737|da (r_conj) ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_dep) -/-_8\JJ\1740|(|th|) (l_nmod:npmod) th_7\NN\15163157|
T7_T25 NONE dopamine_16\NN\14807737|da (r_conj) ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (r_nsubj) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_dobj) levels_22\NNS\4916342|reduced|net (l_nmod) net_24\NN\3085333|of
T8_T21 NONE da_18\NN\10484858|(|) (r_appos) dopamine_16\NN\14807737|da (r_conj) ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_compound) hydroxylase_4\NN\1740|
T8_T23 NONE da_18\NN\10484858|(|) (r_appos) dopamine_16\NN\14807737|da (r_conj) ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_dep) -/-_8\JJ\1740|(|th|) (l_nmod:npmod) th_7\NN\15163157|
T8_T25 NONE da_18\NN\10484858|(|) (r_appos) dopamine_16\NN\14807737|da (r_conj) ne_14\NNS\14622893|both|and|dopamine (r_dobj) lack_12\VBP\1740|that|ne (r_acl:relcl) mice_10\NNS\2329401|knockout|lack (r_nsubj) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_dobj) levels_22\NNS\4916342|reduced|net (l_nmod) net_24\NN\3085333|of
T9_T21 NONE catecholamines_36\NNS\5407119|of|not|ne|se (r_nmod) absence_34\NN\14449405|by|a|complete|catecholamines (r_nmod) down-regulated_30\VBN\1740|that|it|is|absence (r_ccomp) suggesting_26\VBG\1010118|down-regulated (r_advcl) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_nsubj) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_compound) hydroxylase_4\NN\1740|
T9_T23 NONE catecholamines_36\NNS\5407119|of|not|ne|se (r_nmod) absence_34\NN\14449405|by|a|complete|catecholamines (r_nmod) down-regulated_30\VBN\1740|that|it|is|absence (r_ccomp) suggesting_26\VBG\1010118|down-regulated (r_advcl) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_nsubj) mice_10\NNS\2329401|knockout|lack (l_amod) knockout_5\NN\10787470|tyrosine|hydroxylase|-/- (l_dep) -/-_8\JJ\1740|(|th|) (l_nmod:npmod) th_7\NN\15163157|
T9_T25 NONE catecholamines_36\NNS\5407119|of|not|ne|se (r_nmod) absence_34\NN\14449405|by|a|complete|catecholamines (r_nmod) down-regulated_30\VBN\1740|that|it|is|absence (r_ccomp) suggesting_26\VBG\1010118|down-regulated (r_advcl) have_20\VBP\2108377|contrast|,|mice|levels|,|suggesting|. (l_dobj) levels_22\NNS\4916342|reduced|net (l_nmod) net_24\NN\3085333|of
T11_T26 CPR:4 desipramine_7\NN\4482543|dmi (r_appos) inhibitor_5\NN\20090|with|the|net|,|desipramine|, (l_amod) net_4\JJ\1740|
T11_T27 CPR:4 desipramine_7\NN\4482543|dmi (r_appos) inhibitor_5\NN\20090|with|the|net|,|desipramine|, (r_nmod) treatment_1\NN\654885|chronic|inhibitor (r_nsubj) reduced_12\VBD\441445|treatment|levels|control|,|demonstrating|. (l_dobj) levels_14\NNS\4916342|net (l_amod) net_13\JJ\1740|
T11_T28 NONE desipramine_7\NN\4482543|dmi (r_appos) inhibitor_5\NN\20090|with|the|net|,|desipramine|, (r_nmod) treatment_1\NN\654885|chronic|inhibitor (r_nsubj) reduced_12\VBD\441445|treatment|levels|control|,|demonstrating|. (l_nmod) control_17\JJ\1740|in|both|and|-/-|mice (l_conj) -/-_20\JJ\1740|dbh (l_amod) dbh_19\JJ\1740|
T11_T29 NONE desipramine_7\NN\4482543|dmi (r_appos) inhibitor_5\NN\20090|with|the|net|,|desipramine|, (r_nmod) treatment_1\NN\654885|chronic|inhibitor (r_nsubj) reduced_12\VBD\441445|treatment|levels|control|,|demonstrating|. (l_advcl) demonstrating_23\VBG\2137132|required (l_ccomp) required_28\VBN\754942|that|ne|is|not|regulation (l_nmod) regulation_31\NN\6652242|for|the|net|drugs (l_nmod) net_33\JJ\1740|of
T12_T26 NONE ne_25\NN\14622893| (r_nsubjpass) required_28\VBN\754942|that|ne|is|not|regulation (r_ccomp) demonstrating_23\VBG\2137132|required (r_advcl) reduced_12\VBD\441445|treatment|levels|control|,|demonstrating|. (l_nsubj) treatment_1\NN\654885|chronic|inhibitor (l_nmod) inhibitor_5\NN\20090|with|the|net|,|desipramine|, (l_amod) net_4\JJ\1740|
T12_T27 NONE ne_25\NN\14622893| (r_nsubjpass) required_28\VBN\754942|that|ne|is|not|regulation (r_ccomp) demonstrating_23\VBG\2137132|required (r_advcl) reduced_12\VBD\441445|treatment|levels|control|,|demonstrating|. (l_dobj) levels_14\NNS\4916342|net (l_amod) net_13\JJ\1740|
T12_T28 NONE ne_25\NN\14622893| (r_nsubjpass) required_28\VBN\754942|that|ne|is|not|regulation (r_ccomp) demonstrating_23\VBG\2137132|required (r_advcl) reduced_12\VBD\441445|treatment|levels|control|,|demonstrating|. (l_nmod) control_17\JJ\1740|in|both|and|-/-|mice (l_conj) -/-_20\JJ\1740|dbh (l_amod) dbh_19\JJ\1740|
T12_T29 NONE ne_25\NN\14622893| (r_nsubjpass) required_28\VBN\754942|that|ne|is|not|regulation (l_nmod) regulation_31\NN\6652242|for|the|net|drugs (l_nmod) net_33\JJ\1740|of
23349489
T1_T2 NONE thymidine_6\NN\14964367| (r_compound) analogs_7\NNS\4743605|of|thymidine|,|cre-lox (l_conj) cre-lox_13\NN\1740|rat|insulin|2|promoter-driven
T1_T3 NONE thymidine_6\NN\14964367| (r_compound) analogs_7\NNS\4743605|of|thymidine|,|cre-lox (l_conj) cre-lox_13\NN\1740|rat|insulin|2|promoter-driven
T1_T4 NONE thymidine_6\NN\14964367| (r_compound) analogs_7\NNS\4743605|of|thymidine|,|cre-lox (r_nmod) administration_4\NN\1133281|sequential|analogs|,|and|cre-lox (l_conj) cre-lox_18\NN\1740|low-frequency|ubiquitous
T1_T5 NONE thymidine_6\NN\14964367| (r_compound) analogs_7\NNS\4743605|of|thymidine|,|cre-lox (r_nmod) administration_4\NN\1133281|sequential|analogs|,|and|cre-lox (l_conj) cre-lox_18\NN\1740|low-frequency|ubiquitous
T1_T7 NONE thymidine_6\NN\14964367| (r_compound) analogs_7\NNS\4743605|of|thymidine|,|cre-lox (l_conj) cre-lox_13\NN\1740|rat|insulin|2|promoter-driven (l_amod) promoter-driven_12\JJ\1740|
23500387
T11_T21 NONE curcumin_0\NN\1740| (r_nsubj) attenuates_1\VBZ\224901|curcumin|inflammation|regulation|. (l_nmod) regulation_6\NN\6652242|by|balance (l_nmod) balance_14\NN\13934900|of|cells|mice (l_nmod) mice_17\NNS\2329401|in|ovalbumin-sensitized (l_amod) ovalbumin-sensitized_16\JJ\1740|
T10_T12 NONE curcumin_14\NN\1740|of (r_nmod) effects_8\NNS\13245626|the|protective|and|mechanisms|curcumin|inflammation (l_nmod) inflammation_19\NN\14299637|on|ovalbumin|(ova)-induced|allergic|model (l_compound) ovalbumin_16\NN\7809096|
T10_T14 NONE curcumin_14\NN\1740|of (r_nmod) effects_8\NNS\13245626|the|protective|and|mechanisms|curcumin|inflammation (l_nmod) inflammation_19\NN\14299637|on|ovalbumin|(ova)-induced|allergic|model (l_punct) (ova)-induced_17\JJ\1740|
T7_T17 NONE hematoxylin_33\NN\1740|and|eosin (r_compound) staining_39\NN\275424|by|hematoxylin (r_nmod) measured_31\VBN\697589|assessment|was|staining (r_parataxis) measured_23\VBN\697589|count|was|staining|,|measured|,|measured (l_parataxis) measured_47\VBN\697589|levels|were|assay|,|evaluated (l_nsubjpass) levels_42\NNS\4916342|balf|cytokines (l_nmod) cytokines_45\NNS\14728724|of|treg/th17
T8_T17 NONE eosin_35\NN\14987695|he (r_conj) hematoxylin_33\NN\1740|and|eosin (r_compound) staining_39\NN\275424|by|hematoxylin (r_nmod) measured_31\VBN\697589|assessment|was|staining (r_parataxis) measured_23\VBN\697589|count|was|staining|,|measured|,|measured (l_parataxis) measured_47\VBN\697589|levels|were|assay|,|evaluated (l_nsubjpass) levels_42\NNS\4916342|balf|cytokines (l_nmod) cytokines_45\NNS\14728724|of|treg/th17
T9_T18 CPR:4 curcumin_4\NN\1740| (r_nsubj) inhibited_5\VBD\2510337|that|curcumin|increases (l_dobj) increases_7\NNS\13576355|ova-induced|count (l_amod) ova-induced_6\JJ\1740|
T9_T19 CPR:4 curcumin_4\NN\1740| (r_nsubj) inhibited_5\VBD\2510337|that|curcumin|increases (r_ccomp) demonstrated_2\VBD\2137132|study|inhibited|;|recovered|. (l_parataxis) recovered_16\VBN\2210855|level|were|fluid|increased (l_nsubjpass) level_14\NN\4916342|interleukin|(il)-17a (l_compound) (il)-17a_13\NN\1740|
T9_T20 CPR:3 curcumin_4\NN\1740| (r_nsubj) inhibited_5\VBD\2510337|that|curcumin|increases (r_ccomp) demonstrated_2\VBD\2137132|study|inhibited|;|recovered|. (l_parataxis) recovered_16\VBN\2210855|level|were|fluid|increased (l_xcomp) increased_21\VBD\169651|level|fluid (l_dobj) level_23\NN\4916342|il-10 (l_compound) il-10_22\NN\1740|
T1_T13 CPR:4 curcumin_4\NN\1740| (r_nsubj) inhibited_6\VBD\2510337|that|curcumin|substantially|eosinophilia (l_dobj) eosinophilia_8\NN\14299637|ova-induced|tissue (l_amod) ova-induced_7\JJ\1740|
T3_T15 CPR:4 curcumin_11\NN\1740| (r_compound) treatments_12\NNS\654885|curcumin (r_nsubj) attenuated_14\VBD\224901|show|;|treatments|markedly|inflammatory|regulating|. (l_ccomp) show_4\VBP\2137132|results|balance (l_dobj) balance_9\NN\13934900|broke|treg/th17 (l_amod) broke_7\VBD\352826|ovalbumin-induced|significantly (l_nsubj) ovalbumin-induced_5\NN\1740|
23411251
23562060
T14_T21 NONE ml326_2\NN\1740|of (r_nmod) discovery_0\NN\30358|ml326|:|pam|. (l_dep) pam_10\NNS\1740|the|first|sub-micromolar|m5 (l_compound) m5_9\NN\1740|
T12_T18 NONE ml129_13\NN\1740|and|ml172 (r_dep) probes_12\NNS\5797597|of|the|m5|pam|mlpcn|ml129 (l_compound) m5_9\NN\1740|
T13_T18 NONE ml172_15\NN\1740| (r_conj) ml129_13\NN\1740|and|ml172 (r_dep) probes_12\NNS\5797597|of|the|m5|pam|mlpcn|ml129 (l_compound) m5_9\NN\1740|
T4_T15 NONE isatin_18\NN\1740| (r_compound) core_19\NN\7996689|with|a|related|isatin|possessed (r_nmod) pams_7\NNS\1740|several|weak|m5|ec50|core (l_compound) m5_6\NN\1740|
T4_T16 NONE isatin_18\NN\1740| (r_compound) core_19\NN\7996689|with|a|related|isatin|possessed (r_nmod) pams_7\NNS\1740|several|weak|m5|ec50|core (l_dep) ec50_10\NN\1740|(|m5|>|) (l_compound) m5_9\NN\1740|
T5_T15 NONE ether_25\NN\14840755| (r_compound) linkage_26\NN\13791389|a|southern|phenethyl|ether (r_dobj) possessed_21\VBD\2630189|that|linkage (r_acl:relcl) core_19\NN\7996689|with|a|related|isatin|possessed (r_nmod) pams_7\NNS\1740|several|weak|m5|ec50|core (l_compound) m5_6\NN\1740|
T5_T16 NONE ether_25\NN\14840755| (r_compound) linkage_26\NN\13791389|a|southern|phenethyl|ether (r_dobj) possessed_21\VBD\2630189|that|linkage (r_acl:relcl) core_19\NN\7996689|with|a|related|isatin|possessed (r_nmod) pams_7\NNS\1740|several|weak|m5|ec50|core (l_dep) ec50_10\NN\1740|(|m5|>|) (l_compound) m5_9\NN\1740|
T10_T17 NONE vu0467903_34\NN\1740|(|) (r_appos) ml326_32\NN\1740|vu0467903 (r_appos) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_compound) m5_29\NN\1740|
T10_T19 NONE vu0467903_34\NN\1740|(|) (r_appos) ml326_32\NN\1740|vu0467903 (r_appos) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_appos) ec50s_42\NNS\1740|(|human|m5|409nm|,|respectively|) (l_compound) m5_41\NN\1740|
T10_T20 NONE vu0467903_34\NN\1740|(|) (r_appos) ml326_32\NN\1740|vu0467903 (r_appos) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (r_nmod) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) selectivity_53\NN\4916342|with|excellent|machr|ec50s|and|shift (l_compound) machr_52\NN\1740|
T11_T17 NONE ach_68\NN\1740| (r_compound) crc_69\NN\1740|of|the|ach (r_nmod) shift_65\NN\7446404|a|robust|20-fold|leftward|crc (r_conj) selectivity_53\NN\4916342|with|excellent|machr|ec50s|and|shift (r_nmod) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_compound) m5_29\NN\1740|
T11_T19 NONE ach_68\NN\1740| (r_compound) crc_69\NN\1740|of|the|ach (r_nmod) shift_65\NN\7446404|a|robust|20-fold|leftward|crc (r_conj) selectivity_53\NN\4916342|with|excellent|machr|ec50s|and|shift (r_nmod) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_appos) ec50s_42\NNS\1740|(|human|m5|409nm|,|respectively|) (l_compound) m5_41\NN\1740|
T11_T20 NONE ach_68\NN\1740| (r_compound) crc_69\NN\1740|of|the|ach (r_nmod) shift_65\NN\7446404|a|robust|20-fold|leftward|crc (r_conj) selectivity_53\NN\4916342|with|excellent|machr|ec50s|and|shift (l_compound) machr_52\NN\1740|
T6_T17 NONE ether_18\NN\14840755| (r_compound) linkage_19\NN\13791389|the|phenethyl|ether (r_dobj) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_compound) m5_29\NN\1740|
T6_T19 NONE ether_18\NN\14840755| (r_compound) linkage_19\NN\13791389|the|phenethyl|ether (r_dobj) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_appos) ec50s_42\NNS\1740|(|human|m5|409nm|,|respectively|) (l_compound) m5_41\NN\1740|
T6_T20 NONE ether_18\NN\14840755| (r_compound) linkage_19\NN\13791389|the|phenethyl|ether (r_dobj) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) selectivity_53\NN\4916342|with|excellent|machr|ec50s|and|shift (l_compound) machr_52\NN\1740|
T7_T17 NONE ml129/ml172_22\NN\1740| (r_compound) cores_23\NNS\7996689|onto|the|ml129/ml172 (r_nmod) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_compound) m5_29\NN\1740|
T7_T19 NONE ml129/ml172_22\NN\1740| (r_compound) cores_23\NNS\7996689|onto|the|ml129/ml172 (r_nmod) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_appos) ec50s_42\NNS\1740|(|human|m5|409nm|,|respectively|) (l_compound) m5_41\NN\1740|
T7_T20 NONE ml129/ml172_22\NN\1740| (r_compound) cores_23\NNS\7996689|onto|the|ml129/ml172 (r_nmod) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) selectivity_53\NN\4916342|with|excellent|machr|ec50s|and|shift (l_compound) machr_52\NN\1740|
T8_T17 NONE ml129/ml172_22\NN\1740| (r_compound) cores_23\NNS\7996689|onto|the|ml129/ml172 (r_nmod) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_compound) m5_29\NN\1740|
T8_T19 NONE ml129/ml172_22\NN\1740| (r_compound) cores_23\NNS\7996689|onto|the|ml129/ml172 (r_nmod) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_appos) ec50s_42\NNS\1740|(|human|m5|409nm|,|respectively|) (l_compound) m5_41\NN\1740|
T8_T20 NONE ml129/ml172_22\NN\1740| (r_compound) cores_23\NNS\7996689|onto|the|ml129/ml172 (r_nmod) grafting_15\VBG\1291069|linkage|cores (r_csubj) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) selectivity_53\NN\4916342|with|excellent|machr|ec50s|and|shift (l_compound) machr_52\NN\1740|
T9_T17 NONE ml326_32\NN\1740|vu0467903 (r_appos) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_compound) m5_29\NN\1740|
T9_T19 NONE ml326_32\NN\1740|vu0467903 (r_appos) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (l_appos) ec50s_42\NNS\1740|(|human|m5|409nm|,|respectively|) (l_compound) m5_41\NN\1740|
T9_T20 NONE ml326_32\NN\1740|vu0467903 (r_appos) pam_30\NN\1740|to|the|first|sub-micromolar|m5|,|ml326|,|ec50s (r_nmod) led_24\VBD\1752884|shallow|,|grafting|pam|selectivity|. (l_nmod) selectivity_53\NN\4916342|with|excellent|machr|ec50s|and|shift (l_compound) machr_52\NN\1740|
23621358
T13_T20 NONE ribavirin_9\NN\2725367|rbv (r_compound) prodrug_13\NN\1740|a|ribavirin (r_dobj) carry_5\VB\1850315|to|hepatocytes|prodrug (r_xcomp) able_3\JJ\1740|potentially|carry (r_amod) micelles_1\NNS\9386422|polymeric|able|,|exploiting (l_acl) exploiting_15\VBG\1158872|presence (l_dobj) presence_17\NN\13954253|the|receptors (l_nmod) receptors_20\NNS\5225602|of|carbohydrate|,|asgpr
T13_T21 NONE ribavirin_9\NN\2725367|rbv (r_compound) prodrug_13\NN\1740|a|ribavirin (r_dobj) carry_5\VB\1850315|to|hepatocytes|prodrug (r_xcomp) able_3\JJ\1740|potentially|carry (r_amod) micelles_1\NNS\9386422|polymeric|able|,|exploiting (l_acl) exploiting_15\VBG\1158872|presence (l_dobj) presence_17\NN\13954253|the|receptors (l_nmod) receptors_20\NNS\5225602|of|carbohydrate|,|asgpr (l_appos) asgpr_24\NN\1740|i.e.|,|,
T15_T20 NONE rbv_11\NN\1740|(|) (r_appos) ribavirin_9\NN\2725367|rbv (r_compound) prodrug_13\NN\1740|a|ribavirin (r_dobj) carry_5\VB\1850315|to|hepatocytes|prodrug (r_xcomp) able_3\JJ\1740|potentially|carry (r_amod) micelles_1\NNS\9386422|polymeric|able|,|exploiting (l_acl) exploiting_15\VBG\1158872|presence (l_dobj) presence_17\NN\13954253|the|receptors (l_nmod) receptors_20\NNS\5225602|of|carbohydrate|,|asgpr
T15_T21 NONE rbv_11\NN\1740|(|) (r_appos) ribavirin_9\NN\2725367|rbv (r_compound) prodrug_13\NN\1740|a|ribavirin (r_dobj) carry_5\VB\1850315|to|hepatocytes|prodrug (r_xcomp) able_3\JJ\1740|potentially|carry (r_amod) micelles_1\NNS\9386422|polymeric|able|,|exploiting (l_acl) exploiting_15\VBG\1158872|presence (l_dobj) presence_17\NN\13954253|the|receptors (l_nmod) receptors_20\NNS\5225602|of|carbohydrate|,|asgpr (l_appos) asgpr_24\NN\1740|i.e.|,|,
T2_T20 NONE carbohydrate_19\NN\14944888| (r_compound) receptors_20\NNS\5225602|of|carbohydrate|,|asgpr
T2_T21 NONE carbohydrate_19\NN\14944888| (r_compound) receptors_20\NNS\5225602|of|carbohydrate|,|asgpr (l_appos) asgpr_24\NN\1740|i.e.|,|,
T3_T20 NONE polylactide-polyaminoacid_32\JJ\1740| (r_amod) conjugate_33\NN\14589223|from|a|galactosylated|polylactide-polyaminoacid (r_nmod) starting_28\VBG\2009433|conjugate (r_advcl) prepared_27\VBN\126264|micelles|were|starting|. (l_nsubjpass) micelles_1\NNS\9386422|polymeric|able|,|exploiting (l_acl) exploiting_15\VBG\1158872|presence (l_dobj) presence_17\NN\13954253|the|receptors (l_nmod) receptors_20\NNS\5225602|of|carbohydrate|,|asgpr
T3_T21 NONE polylactide-polyaminoacid_32\JJ\1740| (r_amod) conjugate_33\NN\14589223|from|a|galactosylated|polylactide-polyaminoacid (r_nmod) starting_28\VBG\2009433|conjugate (r_advcl) prepared_27\VBN\126264|micelles|were|starting|. (l_nsubjpass) micelles_1\NNS\9386422|polymeric|able|,|exploiting (l_acl) exploiting_15\VBG\1158872|presence (l_dobj) presence_17\NN\13954253|the|receptors (l_nmod) receptors_20\NNS\5225602|of|carbohydrate|,|asgpr (l_appos) asgpr_24\NN\1740|i.e.|,|,
2832297
T3_T17 NONE loperamide_0\NN\1740| (r_nsubj) modifies_1\VBZ\109660|loperamide|but|block|. (l_conj) block_5\VB\1476483|does|not|response (l_dobj) response_10\NN\11410625|the|hormone-induced|acth|patients (l_amod) hormone-induced_8\JJ\1740|corticotropin-releasing
T3_T18 NONE loperamide_0\NN\1740| (r_nsubj) modifies_1\VBZ\109660|loperamide|but|block|. (l_conj) block_5\VB\1476483|does|not|response (l_dobj) response_10\NN\11410625|the|hormone-induced|acth|patients (l_compound) acth_9\NN\5407119|
T1_T15 NONE loperamide_3\NN\1740|of|-|agonist|- (r_nmod) effect_1\NN\34213|the|loperamide|response (l_nmod) response_13\NN\11410625|on|plasma|acth|hormone (l_compound) acth_12\NN\5407119|
T1_T16 NONE loperamide_3\NN\1740|of|-|agonist|- (r_nmod) effect_1\NN\34213|the|loperamide|response (l_nmod) response_13\NN\11410625|on|plasma|acth|hormone (l_nmod) hormone_16\NN\5404728|to|corticotropin-releasing|crh
T1_T4 NONE loperamide_3\NN\1740|of|-|agonist|- (r_nmod) effect_1\NN\34213|the|loperamide|response (l_nmod) response_13\NN\11410625|on|plasma|acth|hormone (l_nmod) hormone_16\NN\5404728|to|corticotropin-releasing|crh (l_appos) crh_18\NN\1740|(|)
T2_T10 NONE loperamide_1\NN\1740| (r_compound) administration_2\NN\1133281|after|loperamide (r_nmod) fell_5\VBD\1552519|administration|levels|nadir|,|and|able|;|delayed (l_parataxis) delayed_36\VBN\439958|pattern|was|slightly|. (l_nsubjpass) pattern_28\NN\5726345|the|response (l_nmod) response_31\NN\11410625|of|acth|crh (l_compound) acth_30\NN\5407119|
T2_T11 NONE loperamide_1\NN\1740| (r_compound) administration_2\NN\1133281|after|loperamide (r_nmod) fell_5\VBD\1552519|administration|levels|nadir|,|and|able|;|delayed (l_parataxis) delayed_36\VBN\439958|pattern|was|slightly|. (l_nsubjpass) pattern_28\NN\5726345|the|response (l_nmod) response_31\NN\11410625|of|acth|crh (l_nmod) crh_33\NN\1740|to
T2_T7 CPR:4 loperamide_1\NN\1740| (r_compound) administration_2\NN\1133281|after|loperamide (r_nmod) fell_5\VBD\1552519|administration|levels|nadir|,|and|able|;|delayed (l_nsubj) levels_4\NNS\4916342|acth (l_compound) acth_3\NN\5407119|
T2_T8 NONE loperamide_1\NN\1740| (r_compound) administration_2\NN\1133281|after|loperamide (r_nmod) fell_5\VBD\1552519|administration|levels|nadir|,|and|able|;|delayed (l_conj) able_20\JJ\1740|then|crh|was|still|induce (l_nsubj) crh_17\NN\1740|
T2_T9 CPR:3 loperamide_1\NN\1740| (r_compound) administration_2\NN\1133281|after|loperamide (r_nmod) fell_5\VBD\1552519|administration|levels|nadir|,|and|able|;|delayed (l_conj) able_20\JJ\1740|then|crh|was|still|induce (l_xcomp) induce_22\VB\1627355|to|increase (l_dobj) increase_25\NN\13576355|an|acth (l_compound) acth_24\NN\5407119|
10637238
T10_T16 NONE halotestin_47\NN\1740| (r_compound) markfluoxymesterone_50\NN\1740|halotestin|question (r_conj) tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_nmod:npmod) receptor_15\NN\5225602|estrogen
T10_T17 NONE halotestin_47\NN\1740| (r_compound) markfluoxymesterone_50\NN\1740|halotestin|question (r_conj) tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown
T10_T18 NONE halotestin_47\NN\1740| (r_compound) markfluoxymesterone_50\NN\1740|halotestin|question (r_conj) tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_conj) er-unknown_18\JJ\1740|
T11_T16 NONE markfluoxymesterone_50\NN\1740|halotestin|question (r_conj) tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_nmod:npmod) receptor_15\NN\5225602|estrogen
T11_T17 NONE markfluoxymesterone_50\NN\1740|halotestin|question (r_conj) tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown
T11_T18 NONE markfluoxymesterone_50\NN\1740|halotestin|question (r_conj) tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_conj) er-unknown_18\JJ\1740|
T5_T16 NONE estrogen_14\NN\14745635| (r_compound) receptor_15\NN\5225602|estrogen
T5_T17 NONE estrogen_14\NN\14745635| (r_compound) receptor_15\NN\5225602|estrogen (r_nmod:npmod) (er)-positive_16\JJ\1740|receptor|or|er-unknown
T5_T18 NONE estrogen_14\NN\14745635| (r_compound) receptor_15\NN\5225602|estrogen (r_nmod:npmod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_conj) er-unknown_18\JJ\1740|
T6_T16 NONE cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_nmod:npmod) receptor_15\NN\5225602|estrogen
T6_T17 NONE cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown
T6_T18 NONE cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_conj) er-unknown_18\JJ\1740|
T7_T16 NONE doxorubicin_31\NN\2716866| (r_conj) cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_nmod:npmod) receptor_15\NN\5225602|estrogen
T7_T17 NONE doxorubicin_31\NN\2716866| (r_conj) cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown
T7_T18 NONE doxorubicin_31\NN\2716866| (r_conj) cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_conj) er-unknown_18\JJ\1740|
T8_T16 NONE fluorouracil_34\NN\2722166| (r_compound) markcaf_37\NN\1740|fluorouracil|question (r_conj) cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_nmod:npmod) receptor_15\NN\5225602|estrogen
T8_T17 NONE fluorouracil_34\NN\2722166| (r_compound) markcaf_37\NN\1740|fluorouracil|question (r_conj) cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown
T8_T18 NONE fluorouracil_34\NN\2722166| (r_compound) markcaf_37\NN\1740|fluorouracil|question (r_conj) cyclophosphamide_29\NN\1740|(|,|doxorubicin|,|and|markcaf|) (r_dep) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_conj) er-unknown_18\JJ\1740|
T9_T16 NONE tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_nmod:npmod) receptor_15\NN\5225602|estrogen
T9_T17 NONE tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown
T9_T18 NONE tamoxifen_45\NN\2714883|and|markfluoxymesterone (r_conj) caf_43\NN\1740|(|plus|tamoxifen|;|pharmacia-upjohn|,|kalamazoo|,|mi|markcafth|) (r_dep) therapy_41\NN\657604|chemohormonal|caf (r_conj) chemotherapy_27\NN\661091|either|cyclophosphamide|or|therapy (r_dobj) receive_25\VB\2210855|to|chemotherapy|therapy (r_xcomp) randomized_23\VBN\278117|january|,|patients|were|receive (l_nsubjpass) patients_12\NNS\9898892|231|cancer (l_nmod) cancer_21\NN\14239425|with|(er)-positive|metastatic|breast (l_amod) (er)-positive_16\JJ\1740|receptor|or|er-unknown (l_conj) er-unknown_18\JJ\1740|
23376249
T3_T13 CPR:4 1,3,4-thiadiazole_5\NN\1740| (r_compound) analogues_6\NNS\4743605|of|1,3,4-thiadiazole (r_nmod) evaluation_3\NN\874067|synthesis|analogues|inhibitors|. (l_nmod) inhibitors_12\NNS\20090|as|novel|ache (l_compound) ache_9\NN\14322699|and|buche
T3_T14 CPR:4 1,3,4-thiadiazole_5\NN\1740| (r_compound) analogues_6\NNS\4743605|of|1,3,4-thiadiazole (r_nmod) evaluation_3\NN\874067|synthesis|analogues|inhibitors|. (l_nmod) inhibitors_12\NNS\20090|as|novel|ache (l_compound) ache_9\NN\14322699|and|buche (l_conj) buche_11\NN\1740|
T1_T4 NONE acetyl-_18\JJ\1740|and|butyrylcholinesterase (l_conj) butyrylcholinesterase_20\NN\1740|
T2_T4 CPR:4 1,3,4-thiadiazole_7\NN\1740| (r_compound) derivatives_8\NNS\5802185|of|new|1,3,4-thiadiazole (r_nmod) series_4\NN\8456993|a|derivatives (r_nsubjpass) designed_11\VBN\1631534|paper|series|has|been|,|synthesized|and|evaluated|inhibitors|. (l_nmod) inhibitors_21\NNS\20090|as|the|acetyl- (l_amod) acetyl-_18\JJ\1740|and|butyrylcholinesterase (l_conj) butyrylcholinesterase_20\NN\1740|
17594192
T1_T16 CPR:4 phenserine_0\NN\1740|,|derivative|, (r_nsubjpass) described_9\VBN\1001294|phenserine|was|first|inhibitor|and|shown|. (l_nmod) inhibitor_12\NN\20090|as|an|acetylcholinesterase (l_nmod) acetylcholinesterase_14\NN\1740|of|ache (l_appos) ache_16\NN\14322699|(|)
T1_T27 CPR:4 phenserine_0\NN\1740|,|derivative|, (r_nsubjpass) described_9\VBN\1001294|phenserine|was|first|inhibitor|and|shown|. (l_nmod) inhibitor_12\NN\20090|as|an|acetylcholinesterase (l_nmod) acetylcholinesterase_14\NN\1740|of|ache
T7_T16 CPR:4 physostigmine_5\NN\14712692|of (r_nmod) derivative_3\NN\5802185|a|physostigmine (r_appos) phenserine_0\NN\1740|,|derivative|, (r_nsubjpass) described_9\VBN\1001294|phenserine|was|first|inhibitor|and|shown|. (l_nmod) inhibitor_12\NN\20090|as|an|acetylcholinesterase (l_nmod) acetylcholinesterase_14\NN\1740|of|ache (l_appos) ache_16\NN\14322699|(|)
T7_T27 CPR:4 physostigmine_5\NN\14712692|of (r_nmod) derivative_3\NN\5802185|a|physostigmine (r_appos) phenserine_0\NN\1740|,|derivative|, (r_nsubjpass) described_9\VBN\1001294|phenserine|was|first|inhibitor|and|shown|. (l_nmod) inhibitor_12\NN\20090|as|an|acetylcholinesterase (l_nmod) acetylcholinesterase_14\NN\1740|of|ache
T8_T20 CPR:4 phenserine_0\NN\1740| (r_nsubj) deserves_1\VBZ\2604760|phenserine|attention|quality (r_ccomp) modulates_17\VBZ\1724459|deserves|:|inhibiting|,|it|amount|reducing|. (l_nmod) inhibiting_13\VBG\2510337|in|addition|to|ache (l_dobj) ache_14\NN\14322699|
T8_T21 NONE phenserine_0\NN\1740| (r_nsubj) deserves_1\VBZ\2604760|phenserine|attention|quality (r_ccomp) modulates_17\VBZ\1724459|deserves|:|inhibiting|,|it|amount|reducing|. (l_dobj) amount_19\NN\13329641|the|protein (l_nmod) protein_23\NN\14944888|of|beta-amyloid|precursor|app|culture
T8_T22 NONE phenserine_0\NN\1740| (r_nsubj) deserves_1\VBZ\2604760|phenserine|attention|quality (r_ccomp) modulates_17\VBZ\1724459|deserves|:|inhibiting|,|it|amount|reducing|. (l_dobj) amount_19\NN\13329641|the|protein (l_nmod) protein_23\NN\14944888|of|beta-amyloid|precursor|app|culture (l_appos) app_25\NN\1740|(|)
T8_T23 CPR:4 phenserine_0\NN\1740| (r_nsubj) deserves_1\VBZ\2604760|phenserine|attention|quality (r_ccomp) modulates_17\VBZ\1724459|deserves|:|inhibiting|,|it|amount|reducing|. (l_advcl) reducing_32\VBG\441445|by|translation (l_dobj) translation_34\NN\6502378|app (l_compound) app_33\NN\1740|
T9_T24 NONE phenserine_6\NN\1740|of (r_nmod) interaction_4\NN\37396|phenserine|element (l_nmod) element_10\NN\5867413|with|a|regulatory|region (l_nmod) region_14\NN\27167|in|the|5'-untranslated|gene (l_nmod) gene_18\NN\8459252|of|the|app|controls (l_compound) app_17\NN\1740|
T9_T25 NONE phenserine_6\NN\1740|of (r_nmod) interaction_4\NN\37396|phenserine|element (l_nmod) element_10\NN\5867413|with|a|regulatory|region (l_nmod) region_14\NN\27167|in|the|5'-untranslated|gene (l_nmod) gene_18\NN\8459252|of|the|app|controls (l_acl:relcl) controls_20\VBZ\2422663|that|expression (l_dobj) expression_22\NN\4679549|app (l_compound) app_21\NN\1740|
T10_T26 CPR:4 phenserine_0\NN\1740| (r_nsubj) reduces_2\VBZ\441445|phenserine|apparently|efficiency|protein|,|process|. (l_dobj) efficiency_4\NN\13819207|translational|mrna (l_nmod) mrna_7\NN\14832193|of|app (l_compound) app_6\NN\1740|
T11_T26 NONE iron_19\NN\14625458|with|and/or|element (r_nmod) interaction_17\NN\37396|an|iron (r_dobj) involve_15\VB\2676054|that|may|interaction (r_acl:relcl) process_12\NN\407535|a|involve (r_dobj) reduces_2\VBZ\441445|phenserine|apparently|efficiency|protein|,|process|. (l_dobj) efficiency_4\NN\13819207|translational|mrna (l_nmod) mrna_7\NN\14832193|of|app (l_compound) app_6\NN\1740|
T12_T26 NONE iron-responsive_22\JJ\1740| (r_amod) element_23\NN\5867413|an|iron-responsive (r_conj) iron_19\NN\14625458|with|and/or|element (r_nmod) interaction_17\NN\37396|an|iron (r_dobj) involve_15\VB\2676054|that|may|interaction (r_acl:relcl) process_12\NN\407535|a|involve (r_dobj) reduces_2\VBZ\441445|phenserine|apparently|efficiency|protein|,|process|. (l_dobj) efficiency_4\NN\13819207|translational|mrna (l_nmod) mrna_7\NN\14832193|of|app (l_compound) app_6\NN\1740|
T13_T28 CPR:4 phenserine_4\NN\1740| (r_nsubj) reduces_5\VBZ\441445|consequence|,|phenserine|formation|and|. (l_dobj) formation_11\NN\7938773|peptide (l_compound) peptide_7\NN\14724264|beta-amyloid|abeta (l_compound) beta-amyloid_6\NN\1740|
T13_T29 CPR:4 phenserine_4\NN\1740| (r_nsubj) reduces_5\VBZ\441445|consequence|,|phenserine|formation|and|. (l_dobj) formation_11\NN\7938773|peptide (l_compound) peptide_7\NN\14724264|beta-amyloid|abeta (l_appos) abeta_9\NN\1740|(|)
T14_T17 NONE phenserine_0\NN\1740| (r_nsubj) unique_3\JJ\1740|phenserine|is|also|actions|:|enantiomer|. (l_parataxis) enantiomer_16\NN\14818238|(-)-phenserine|is|the|active|inhibition|,|whereas|has (l_nmod) inhibition_18\NN\1068773|for|ache (l_nmod) ache_20\NN\14322699|of
T14_T18 NONE phenserine_0\NN\1740| (r_nsubj) unique_3\JJ\1740|phenserine|is|also|actions|:|enantiomer|. (l_parataxis) enantiomer_16\NN\14818238|(-)-phenserine|is|the|active|inhibition|,|whereas|has (l_parataxis) has_29\VBZ\2108377|(+)-phenserine|activity|inhibitor|and|dosed (l_nmod) inhibitor_35\NN\20090|as|an|ache (l_compound) ache_34\NN\14322699|
T2_T17 CPR:4 (-)-phenserine_12\NN\1740| (r_nsubj) enantiomer_16\NN\14818238|(-)-phenserine|is|the|active|inhibition|,|whereas|has (l_nmod) inhibition_18\NN\1068773|for|ache (l_nmod) ache_20\NN\14322699|of
T2_T18 NONE (-)-phenserine_12\NN\1740| (r_nsubj) enantiomer_16\NN\14818238|(-)-phenserine|is|the|active|inhibition|,|whereas|has (l_parataxis) has_29\VBZ\2108377|(+)-phenserine|activity|inhibitor|and|dosed (l_nmod) inhibitor_35\NN\20090|as|an|ache (l_compound) ache_34\NN\14322699|
T3_T17 NONE (+)-phenserine_23\NN\1740|posiphen (r_nsubj) has_29\VBZ\2108377|(+)-phenserine|activity|inhibitor|and|dosed (r_parataxis) enantiomer_16\NN\14818238|(-)-phenserine|is|the|active|inhibition|,|whereas|has (l_nmod) inhibition_18\NN\1068773|for|ache (l_nmod) ache_20\NN\14322699|of
T3_T18 CPR:4 (+)-phenserine_23\NN\1740|posiphen (r_nsubj) has_29\VBZ\2108377|(+)-phenserine|activity|inhibitor|and|dosed (l_nmod) inhibitor_35\NN\20090|as|an|ache (l_compound) ache_34\NN\14322699|
T4_T17 NONE posiphen_26\NN\1740|(|'|'|) (r_appos) (+)-phenserine_23\NN\1740|posiphen (r_nsubj) has_29\VBZ\2108377|(+)-phenserine|activity|inhibitor|and|dosed (r_parataxis) enantiomer_16\NN\14818238|(-)-phenserine|is|the|active|inhibition|,|whereas|has (l_nmod) inhibition_18\NN\1068773|for|ache (l_nmod) ache_20\NN\14322699|of
T4_T18 CPR:4 posiphen_26\NN\1740|(|'|'|) (r_appos) (+)-phenserine_23\NN\1740|posiphen (r_nsubj) has_29\VBZ\2108377|(+)-phenserine|activity|inhibitor|and|dosed (l_nmod) inhibitor_35\NN\20090|as|an|ache (l_compound) ache_34\NN\14322699|
23261676
T15_T31 CPR:4 isoproterenol_0\NN\3740161| (r_nmod:npmod) induced_1\JJ\1740|isoproterenol (r_amod) rats_4\NNS\2329401|induced|myocardial|infarcted (r_nsubj) showed_5\VBD\2137132|rats|increase|. (l_dobj) increase_8\NN\13576355|a|significant|levels|and|decrease (l_conj) decrease_27\NN\7296428|a|significant|activities/levels (l_nmod) activities/levels_30\NNS\1740|in|the|peroxidase (l_nmod) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T15_T32 CPR:4 isoproterenol_0\NN\3740161| (r_nmod:npmod) induced_1\JJ\1740|isoproterenol (r_amod) rats_4\NNS\2329401|induced|myocardial|infarcted (r_nsubj) showed_5\VBD\2137132|rats|increase|. (l_dobj) increase_8\NN\13576355|a|significant|levels|and|decrease (l_conj) decrease_27\NN\7296428|a|significant|activities/levels (l_nmod) activities/levels_30\NNS\1740|in|the|peroxidase (l_nmod) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T15_T33 CPR:4 isoproterenol_0\NN\3740161| (r_nmod:npmod) induced_1\JJ\1740|isoproterenol (r_amod) rats_4\NNS\2329401|induced|myocardial|infarcted (r_nsubj) showed_5\VBD\2137132|rats|increase|. (l_dobj) increase_8\NN\13576355|a|significant|levels|and|decrease (l_conj) decrease_27\NN\7296428|a|significant|activities/levels (l_nmod) activities/levels_30\NNS\1740|in|the|peroxidase (l_nmod) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T15_T34 CPR:4 isoproterenol_0\NN\3740161| (r_nmod:npmod) induced_1\JJ\1740|isoproterenol (r_amod) rats_4\NNS\2329401|induced|myocardial|infarcted (r_nsubj) showed_5\VBD\2137132|rats|increase|. (l_dobj) increase_8\NN\13576355|a|significant|levels|and|decrease (l_conj) decrease_27\NN\7296428|a|significant|activities/levels (l_nmod) activities/levels_30\NNS\1740|in|the|peroxidase (l_nmod) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T16_T31 NONE calcium_22\NN\14625458| (r_appos) markers_15\NNS\21939|of|cardiac|diagnostic|,|peroxidation|,|calcium|, (r_nmod) levels_11\NNS\4916342|in|the|markers (r_nmod) increase_8\NN\13576355|a|significant|levels|and|decrease (l_conj) decrease_27\NN\7296428|a|significant|activities/levels (l_nmod) activities/levels_30\NNS\1740|in|the|peroxidase (l_nmod) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T16_T32 NONE calcium_22\NN\14625458| (r_appos) markers_15\NNS\21939|of|cardiac|diagnostic|,|peroxidation|,|calcium|, (r_nmod) levels_11\NNS\4916342|in|the|markers (r_nmod) increase_8\NN\13576355|a|significant|levels|and|decrease (l_conj) decrease_27\NN\7296428|a|significant|activities/levels (l_nmod) activities/levels_30\NNS\1740|in|the|peroxidase (l_nmod) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T16_T33 NONE calcium_22\NN\14625458| (r_appos) markers_15\NNS\21939|of|cardiac|diagnostic|,|peroxidation|,|calcium|, (r_nmod) levels_11\NNS\4916342|in|the|markers (r_nmod) increase_8\NN\13576355|a|significant|levels|and|decrease (l_conj) decrease_27\NN\7296428|a|significant|activities/levels (l_nmod) activities/levels_30\NNS\1740|in|the|peroxidase (l_nmod) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T16_T34 NONE calcium_22\NN\14625458| (r_appos) markers_15\NNS\21939|of|cardiac|diagnostic|,|peroxidation|,|calcium|, (r_nmod) levels_11\NNS\4916342|in|the|markers (r_nmod) increase_8\NN\13576355|a|significant|levels|and|decrease (l_conj) decrease_27\NN\7296428|a|significant|activities/levels (l_nmod) activities/levels_30\NNS\1740|in|the|peroxidase (l_nmod) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T17_T31 NONE glutathione_34\NN\1740| (r_compound) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T17_T32 NONE glutathione_34\NN\1740| (r_compound) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T17_T33 NONE glutathione_34\NN\1740| (r_compound) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T17_T34 NONE glutathione_34\NN\1740| (r_compound) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T18_T31 NONE glutathione_37\NN\1740| (r_compound) reductase_38\NN\14732946|glutathione (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T18_T32 NONE glutathione_37\NN\1740| (r_compound) reductase_38\NN\14732946|glutathione
T18_T33 NONE glutathione_37\NN\1740| (r_compound) reductase_38\NN\14732946|glutathione (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T18_T34 NONE glutathione_37\NN\1740| (r_compound) reductase_38\NN\14732946|glutathione (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T19_T31 NONE glutathione_41\NN\1740|reduced (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T19_T32 NONE glutathione_41\NN\1740|reduced (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T19_T33 NONE glutathione_41\NN\1740|reduced (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T19_T34 NONE glutathione_41\NN\1740|reduced (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T20_T31 NONE isocitrate_43\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T20_T32 NONE isocitrate_43\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T20_T33 NONE isocitrate_43\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T20_T34 NONE isocitrate_43\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T21_T31 NONE succinate_45\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T21_T32 NONE succinate_45\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T21_T33 NONE succinate_45\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T21_T34 NONE succinate_45\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T22_T31 NONE malate_47\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T22_T32 NONE malate_47\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T22_T33 NONE malate_47\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T22_T34 NONE malate_47\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T23_T31 NONE α-ketoglutarate_49\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T23_T32 NONE α-ketoglutarate_49\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T23_T33 NONE α-ketoglutarate_49\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T23_T34 NONE α-ketoglutarate_49\NN\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T24_T31 NONE nadh-dehydrogenases_51\NNS\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T24_T32 NONE nadh-dehydrogenases_51\NNS\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T24_T33 NONE nadh-dehydrogenases_51\NNS\1740|
T24_T34 NONE nadh-dehydrogenases_51\NNS\1740| (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
T25_T31 NONE triphosphate_56\NN\1740|adenosine (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate
T25_T32 NONE triphosphate_56\NN\1740|adenosine (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) reductase_38\NN\14732946|glutathione
T25_T33 NONE triphosphate_56\NN\1740|adenosine (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) nadh-dehydrogenases_51\NNS\1740|
T25_T34 NONE triphosphate_56\NN\1740|adenosine (r_conj) peroxidase_35\NN\14971234|of|heart|mitochondrial|glutathione|,|reductase|,|glutathione|,|isocitrate|,|succinate|,|malate|,|α-ketoglutarate|and|nadh-dehydrogenases|,|cytochrome-c-oxidase|and|triphosphate (l_conj) cytochrome-c-oxidase_53\NN\1740|
17202804
T25_T67 NONE hormone_1\NN\5404728|gonadotropin-releasing
T25_T68 NONE hormone_1\NN\5404728|gonadotropin-releasing (r_nsubj) antagonizes_3\VBZ\1787955|hormone|functionally|activation|complexes|. (l_nmod) complexes_17\NNS\5869584|through|focal|adhesion|involving (l_acl) involving_18\VBG\2676054|hic-5 (l_dobj) hic-5_19\NN\1740|
T25_T69 CPR:6 hormone_1\NN\5404728|gonadotropin-releasing (r_nsubj) antagonizes_3\VBZ\1787955|hormone|functionally|activation|complexes|. (l_dobj) activation_5\NN\13561719|testosterone|receptor (l_nmod) receptor_10\NN\5225602|of|the|human|androgen|cells
T26_T67 NONE testosterone_4\NN\14747587| (r_compound) activation_5\NN\13561719|testosterone|receptor (r_dobj) antagonizes_3\VBZ\1787955|hormone|functionally|activation|complexes|. (l_nsubj) hormone_1\NN\5404728|gonadotropin-releasing
T26_T68 NONE testosterone_4\NN\14747587| (r_compound) activation_5\NN\13561719|testosterone|receptor (r_dobj) antagonizes_3\VBZ\1787955|hormone|functionally|activation|complexes|. (l_nmod) complexes_17\NNS\5869584|through|focal|adhesion|involving (l_acl) involving_18\VBG\2676054|hic-5 (l_dobj) hic-5_19\NN\1740|
T26_T69 CPR:3 testosterone_4\NN\14747587| (r_compound) activation_5\NN\13561719|testosterone|receptor (l_nmod) receptor_10\NN\5225602|of|the|human|androgen|cells
T17_T27 NONE gnrh_3\NN\1740|(|) (r_appos) hormone_1\NN\5404728|gonadotropin-releasing|gnrh
T17_T54 NONE gnrh_3\NN\1740|(|)
T1_T27 NONE hormone_1\NN\5404728|gonadotropin-releasing|gnrh
T1_T54 NONE hormone_1\NN\5404728|gonadotropin-releasing|gnrh (l_appos) gnrh_3\NN\1740|(|)
T16_T53 NONE gnrh_2\NN\1740|
T18_T55 NONE gnrh_2\NN\1740| (r_compound) receptor_3\NN\5225602|the|gnrh
T18_T56 NONE gnrh_2\NN\1740| (r_compound) receptor_3\NN\5225602|the|gnrh (r_nsubjpass) shown_6\VBN\2137132|since|receptor|has|been|affect (l_xcomp) affect_8\VB\126264|to|function (l_dobj) function_13\NN\13783581|receptor (l_compound) receptor_12\NN\5225602|sex|steroid|hormone
T18_T57 NONE gnrh_2\NN\1740| (r_compound) receptor_3\NN\5225602|the|gnrh (r_nsubjpass) shown_6\VBN\2137132|since|receptor|has|been|affect (r_advcl) considered_16\VBD\689344|shown|,|we|mediated|. (l_ccomp) mediated_28\VBN\761713|that|part|may|be|modulation (l_nsubjpass) part_18\NN\31921|actions (l_nmod) actions_22\NNS\30358|of|gnrh|analog|cells (l_compound) gnrh_20\NN\1740|
T18_T58 NONE gnrh_2\NN\1740| (r_compound) receptor_3\NN\5225602|the|gnrh (r_nsubjpass) shown_6\VBN\2137132|since|receptor|has|been|affect (r_advcl) considered_16\VBD\689344|shown|,|we|mediated|. (l_ccomp) mediated_28\VBN\761713|that|part|may|be|modulation (l_nmod) modulation_30\NN\7044917|through|receptor (l_nmod) receptor_35\NN\5225602|of|the|human|androgen
T19_T55 NONE gnrh_20\NN\1740| (r_compound) actions_22\NNS\30358|of|gnrh|analog|cells (r_nmod) part_18\NN\31921|actions (r_nsubjpass) mediated_28\VBN\761713|that|part|may|be|modulation (r_ccomp) considered_16\VBD\689344|shown|,|we|mediated|. (l_advcl) shown_6\VBN\2137132|since|receptor|has|been|affect (l_nsubjpass) receptor_3\NN\5225602|the|gnrh
T19_T56 NONE gnrh_20\NN\1740| (r_compound) actions_22\NNS\30358|of|gnrh|analog|cells (r_nmod) part_18\NN\31921|actions (r_nsubjpass) mediated_28\VBN\761713|that|part|may|be|modulation (r_ccomp) considered_16\VBD\689344|shown|,|we|mediated|. (l_advcl) shown_6\VBN\2137132|since|receptor|has|been|affect (l_xcomp) affect_8\VB\126264|to|function (l_dobj) function_13\NN\13783581|receptor (l_compound) receptor_12\NN\5225602|sex|steroid|hormone
T19_T57 NONE gnrh_20\NN\1740|
T19_T58 NONE gnrh_20\NN\1740| (r_compound) actions_22\NNS\30358|of|gnrh|analog|cells (r_nmod) part_18\NN\31921|actions (r_nsubjpass) mediated_28\VBN\761713|that|part|may|be|modulation (l_nmod) modulation_30\NN\7044917|through|receptor (l_nmod) receptor_35\NN\5225602|of|the|human|androgen
T20_T59 NONE gnrh_8\NN\1740| (r_compound) receptor_9\NN\5225602|the|gnrh
T20_T60 NONE gnrh_8\NN\1740| (r_compound) receptor_9\NN\5225602|the|gnrh (r_dobj) expressing_6\VBG\928630|receptor (r_acl) line_5\NN\8426461|a|model|hek293|cell|expressing (r_dobj) using_0\VBG\1156834|line|,|demonstrated (l_parataxis) demonstrated_12\VBD\2137132|we|pathway|. (l_dobj) pathway_16\NN\5483677|a|novel|signalling|receptor (l_nmod) receptor_20\NN\5225602|of|the|gnrh|induces
T20_T61 NONE gnrh_8\NN\1740| (r_compound) receptor_9\NN\5225602|the|gnrh (r_dobj) expressing_6\VBG\928630|receptor (r_acl) line_5\NN\8426461|a|model|hek293|cell|expressing (r_dobj) using_0\VBG\1156834|line|,|demonstrated (l_parataxis) demonstrated_12\VBD\2137132|we|pathway|. (l_dobj) pathway_16\NN\5483677|a|novel|signalling|receptor (l_nmod) receptor_20\NN\5225602|of|the|gnrh|induces (l_acl:relcl) induces_22\VBZ\1627355|that|translocation (l_dobj) translocation_24\NN\13526110|nuclear|receptor|renders (l_nmod) receptor_28\NN\5225602|of|the|androgen
T21_T59 NONE gnrh_19\NN\1740| (r_compound) receptor_20\NN\5225602|of|the|gnrh|induces (r_nmod) pathway_16\NN\5483677|a|novel|signalling|receptor (r_dobj) demonstrated_12\VBD\2137132|we|pathway|. (r_parataxis) using_0\VBG\1156834|line|,|demonstrated (l_dobj) line_5\NN\8426461|a|model|hek293|cell|expressing (l_acl) expressing_6\VBG\928630|receptor (l_dobj) receptor_9\NN\5225602|the|gnrh
T21_T60 NONE gnrh_19\NN\1740| (r_compound) receptor_20\NN\5225602|of|the|gnrh|induces
T21_T61 NONE gnrh_19\NN\1740| (r_compound) receptor_20\NN\5225602|of|the|gnrh|induces (l_acl:relcl) induces_22\VBZ\1627355|that|translocation (l_dobj) translocation_24\NN\13526110|nuclear|receptor|renders (l_nmod) receptor_28\NN\5225602|of|the|androgen
T22_T28 NONE calcium-dependent_4\JJ\1740| (r_amod) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5
T22_T29 NONE calcium-dependent_4\JJ\1740| (r_amod) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5 (l_appos) hic-5_22\NN\1740|
T22_T62 NONE calcium-dependent_4\JJ\1740| (r_amod) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_compound) kinase_6\NN\14732946|
T22_T63 NONE calcium-dependent_4\JJ\1740| (r_amod) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor
T22_T64 NONE calcium-dependent_4\JJ\1740| (r_amod) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase (l_compound) kinase_12\NN\14732946|
T22_T65 NONE calcium-dependent_4\JJ\1740| (r_amod) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase
T22_T66 NONE calcium-dependent_4\JJ\1740| (r_amod) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5 (l_compound) protein/steroid_18\NN\1740|
T23_T28 NONE tyrosine_5\NN\14601829| (r_compound) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5
T23_T29 NONE tyrosine_5\NN\14601829| (r_compound) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5 (l_appos) hic-5_22\NN\1740|
T23_T62 NONE tyrosine_5\NN\14601829| (r_compound) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_compound) kinase_6\NN\14732946|
T23_T63 NONE tyrosine_5\NN\14601829| (r_compound) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor
T23_T64 NONE tyrosine_5\NN\14601829| (r_compound) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase (l_compound) kinase_12\NN\14732946|
T23_T65 NONE tyrosine_5\NN\14601829| (r_compound) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase
T23_T66 NONE tyrosine_5\NN\14601829| (r_compound) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5 (l_compound) protein/steroid_18\NN\1740|
T24_T28 NONE tyrosine_11\NN\14601829| (r_compound) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase (r_conj) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5
T24_T29 NONE tyrosine_11\NN\14601829| (r_compound) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase (r_conj) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5 (l_appos) hic-5_22\NN\1740|
T24_T62 NONE tyrosine_11\NN\14601829| (r_compound) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase (r_conj) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_compound) kinase_6\NN\14732946|
T24_T63 NONE tyrosine_11\NN\14601829| (r_compound) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase (r_conj) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor
T24_T64 NONE tyrosine_11\NN\14601829| (r_compound) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase (l_compound) kinase_12\NN\14732946|
T24_T65 NONE tyrosine_11\NN\14601829| (r_compound) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase
T24_T66 NONE tyrosine_11\NN\14601829| (r_compound) c-src_13\NN\1740|the|non-receptor|tyrosine|kinase (r_conj) pyk2_7\NN\1740|the|calcium-dependent|tyrosine|kinase|,|c-src|and|co-factor (l_conj) co-factor_20\NN\1740|the|focal|adhesion|protein/steroid|receptor|,|hic-5 (l_compound) protein/steroid_18\NN\1740|
T2_T30 NONE gnrh-induced_6\JJ\1740|
T2_T31 NONE gnrh-induced_6\JJ\1740| (r_amod) association_7\NN\8008335|a|gnrh-induced|and|translocation|receptor|hic-5 (l_nmod) receptor_14\NN\5225602|of|the|androgen
T2_T32 NONE gnrh-induced_6\JJ\1740| (r_amod) association_7\NN\8008335|a|gnrh-induced|and|translocation|receptor|hic-5 (l_nmod) hic-5_16\NN\1740|with
T3_T33 NONE gnrh-induced_0\JJ\1740|
T3_T34 CPR:3 gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|pyk2 (l_compound) pyk2_1\NN\1740|
T3_T35 CPR:4 gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|pyk2 (r_nsubj) opposed_3\VBD\773432|activation|association|enhanced|. (l_dobj) association_5\NN\8008335|the|hic-5|receptor (l_nmod) hic-5_7\NN\1740|of
T3_T36 CPR:4 gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|pyk2 (r_nsubj) opposed_3\VBD\773432|activation|association|enhanced|. (l_dobj) association_5\NN\8008335|the|hic-5|receptor (l_nmod) receptor_10\NN\5225602|with|androgen
T3_T37 NONE gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|pyk2 (r_nsubj) opposed_3\VBD\773432|activation|association|enhanced|. (l_parataxis) enhanced_18\VBD\227165|overexpression|translocation (l_nsubj) overexpression_12\NN\1740|as|pyk2 (l_nmod) pyk2_17\NN\1740|of|a|dominant|negative
T3_T38 NONE gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|pyk2 (r_nsubj) opposed_3\VBD\773432|activation|association|enhanced|. (l_parataxis) enhanced_18\VBD\227165|overexpression|translocation (l_dobj) translocation_22\NN\13526110|the|gnrh-induced|nuclear|receptor (l_amod) gnrh-induced_20\JJ\1740|
T3_T39 NONE gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|pyk2 (r_nsubj) opposed_3\VBD\773432|activation|association|enhanced|. (l_parataxis) enhanced_18\VBD\227165|overexpression|translocation (l_dobj) translocation_22\NN\13526110|the|gnrh-induced|nuclear|receptor (l_nmod) receptor_30\NN\5225602|of|a|green|fluorescent|protein-tagged|human|androgen
T4_T33 NONE gnrh-induced_20\JJ\1740| (r_amod) translocation_22\NN\13526110|the|gnrh-induced|nuclear|receptor (r_dobj) enhanced_18\VBD\227165|overexpression|translocation (r_parataxis) opposed_3\VBD\773432|activation|association|enhanced|. (l_nsubj) activation_2\NN\13561719|gnrh-induced|pyk2 (l_amod) gnrh-induced_0\JJ\1740|
T4_T34 NONE gnrh-induced_20\JJ\1740| (r_amod) translocation_22\NN\13526110|the|gnrh-induced|nuclear|receptor (r_dobj) enhanced_18\VBD\227165|overexpression|translocation (r_parataxis) opposed_3\VBD\773432|activation|association|enhanced|. (l_nsubj) activation_2\NN\13561719|gnrh-induced|pyk2 (l_compound) pyk2_1\NN\1740|
T4_T35 NONE gnrh-induced_20\JJ\1740| (r_amod) translocation_22\NN\13526110|the|gnrh-induced|nuclear|receptor (r_dobj) enhanced_18\VBD\227165|overexpression|translocation (r_parataxis) opposed_3\VBD\773432|activation|association|enhanced|. (l_dobj) association_5\NN\8008335|the|hic-5|receptor (l_nmod) hic-5_7\NN\1740|of
T4_T36 NONE gnrh-induced_20\JJ\1740| (r_amod) translocation_22\NN\13526110|the|gnrh-induced|nuclear|receptor (r_dobj) enhanced_18\VBD\227165|overexpression|translocation (r_parataxis) opposed_3\VBD\773432|activation|association|enhanced|. (l_dobj) association_5\NN\8008335|the|hic-5|receptor (l_nmod) receptor_10\NN\5225602|with|androgen
T4_T37 NONE gnrh-induced_20\JJ\1740| (r_amod) translocation_22\NN\13526110|the|gnrh-induced|nuclear|receptor (r_dobj) enhanced_18\VBD\227165|overexpression|translocation (l_nsubj) overexpression_12\NN\1740|as|pyk2 (l_nmod) pyk2_17\NN\1740|of|a|dominant|negative
T4_T38 NONE gnrh-induced_20\JJ\1740|
T4_T39 NONE gnrh-induced_20\JJ\1740| (r_amod) translocation_22\NN\13526110|the|gnrh-induced|nuclear|receptor (l_nmod) receptor_30\NN\5225602|of|a|green|fluorescent|protein-tagged|human|androgen
T5_T40 NONE gnrh-induced_0\JJ\1740|
T5_T41 CPR:3 gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|c-src (l_compound) c-src_1\NN\1740|
T5_T42 NONE gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|c-src (r_nsubj) resulted_3\VBD\2633881|activation|phosphorylation|and|promoted|. (l_nmod) phosphorylation_6\NN\1740|in|the|hic-5 (l_nmod) hic-5_9\NN\1740|of|expressed
T5_T43 NONE gnrh-induced_0\JJ\1740| (r_amod) activation_2\NN\13561719|gnrh-induced|c-src (r_nsubj) resulted_3\VBD\2633881|activation|phosphorylation|and|promoted|. (l_conj) promoted_11\VBD\2556126|association (l_dobj) association_13\NN\8008335|its|receptor (l_nmod) receptor_18\NN\5225602|with|the|human|androgen
T6_T44 NONE testosterone_3\NN\14747587|to (r_nmod) contrast_1\NN\13854649|in|testosterone (r_nmod) activate_11\VB\1641914|contrast|,|translocation|did|not|transcriptionally|receptor|. (l_nsubj) translocation_7\NN\13526110|gnrh-induced|nuclear (l_amod) gnrh-induced_5\JJ\1740|
T6_T45 CPR:3 testosterone_3\NN\14747587|to (r_nmod) contrast_1\NN\13854649|in|testosterone (r_nmod) activate_11\VB\1641914|contrast|,|translocation|did|not|transcriptionally|receptor|. (l_dobj) receptor_14\NN\5225602|the|androgen
T7_T44 NONE gnrh-induced_5\JJ\1740|
T7_T45 NONE gnrh-induced_5\JJ\1740| (r_amod) translocation_7\NN\13526110|gnrh-induced|nuclear (r_nsubj) activate_11\VB\1641914|contrast|,|translocation|did|not|transcriptionally|receptor|. (l_dobj) receptor_14\NN\5225602|the|androgen
T8_T46 NONE gnrh_4\NN\1740|
T8_T47 NONE gnrh_4\NN\1740| (r_nsubj) stimulate_7\VB\137313|that|gnrh|can|also|mobilization|pc3|mechanism (l_dobj) mobilization_10\NN\1123598|androgen|receptor (l_compound) receptor_9\NN\5225602|
T10_T48 NONE gnrh_17\NN\1740|of (r_nmod) effect_15\NN\34213|the|gnrh|cultures (r_dobj) examined_13\VBD\789138|determine|,|we|effect|and|demonstrated|. (l_advcl) determine_1\VB\1645601|to|antagonize (l_advcl) antagonize_5\VB\1787955|if|gnrh|could|effects (l_nsubj) gnrh_3\NN\1740|
T10_T49 NONE gnrh_17\NN\1740|of
T10_T50 NONE gnrh_17\NN\1740|of (r_nmod) effect_15\NN\34213|the|gnrh|cultures (r_dobj) examined_13\VBD\789138|determine|,|we|effect|and|demonstrated|. (l_conj) demonstrated_25\VBD\2137132|antagonize (l_ccomp) antagonize_30\VB\1787955|that|gnrh|can|functionally|actions (l_nsubj) gnrh_27\NN\1740|
T11_T48 NONE gnrh_27\NN\1740| (r_nsubj) antagonize_30\VB\1787955|that|gnrh|can|functionally|actions (r_ccomp) demonstrated_25\VBD\2137132|antagonize (r_conj) examined_13\VBD\789138|determine|,|we|effect|and|demonstrated|. (l_advcl) determine_1\VB\1645601|to|antagonize (l_advcl) antagonize_5\VB\1787955|if|gnrh|could|effects (l_nsubj) gnrh_3\NN\1740|
T11_T49 NONE gnrh_27\NN\1740| (r_nsubj) antagonize_30\VB\1787955|that|gnrh|can|functionally|actions (r_ccomp) demonstrated_25\VBD\2137132|antagonize (r_conj) examined_13\VBD\789138|determine|,|we|effect|and|demonstrated|. (l_dobj) effect_15\NN\34213|the|gnrh|cultures (l_nmod) gnrh_17\NN\1740|of
T11_T50 NONE gnrh_27\NN\1740|
T12_T48 NONE testosterone_34\NN\14747587|of (r_nmod) actions_32\NNS\30358|the|testosterone|proliferation (r_dobj) antagonize_30\VB\1787955|that|gnrh|can|functionally|actions (r_ccomp) demonstrated_25\VBD\2137132|antagonize (r_conj) examined_13\VBD\789138|determine|,|we|effect|and|demonstrated|. (l_advcl) determine_1\VB\1645601|to|antagonize (l_advcl) antagonize_5\VB\1787955|if|gnrh|could|effects (l_nsubj) gnrh_3\NN\1740|
T12_T49 NONE testosterone_34\NN\14747587|of (r_nmod) actions_32\NNS\30358|the|testosterone|proliferation (r_dobj) antagonize_30\VB\1787955|that|gnrh|can|functionally|actions (r_ccomp) demonstrated_25\VBD\2137132|antagonize (r_conj) examined_13\VBD\789138|determine|,|we|effect|and|demonstrated|. (l_dobj) effect_15\NN\34213|the|gnrh|cultures (l_nmod) gnrh_17\NN\1740|of
T12_T50 NONE testosterone_34\NN\14747587|of (r_nmod) actions_32\NNS\30358|the|testosterone|proliferation (r_dobj) antagonize_30\VB\1787955|that|gnrh|can|functionally|actions (l_nsubj) gnrh_27\NN\1740|
T9_T48 NONE gnrh_3\NN\1740|
T9_T49 NONE gnrh_3\NN\1740| (r_nsubj) antagonize_5\VB\1787955|if|gnrh|could|effects (r_advcl) determine_1\VB\1645601|to|antagonize (r_advcl) examined_13\VBD\789138|determine|,|we|effect|and|demonstrated|. (l_dobj) effect_15\NN\34213|the|gnrh|cultures (l_nmod) gnrh_17\NN\1740|of
T9_T50 NONE gnrh_3\NN\1740| (r_nsubj) antagonize_5\VB\1787955|if|gnrh|could|effects (r_advcl) determine_1\VB\1645601|to|antagonize (r_advcl) examined_13\VBD\789138|determine|,|we|effect|and|demonstrated|. (l_conj) demonstrated_25\VBD\2137132|antagonize (l_ccomp) antagonize_30\VB\1787955|that|gnrh|can|functionally|actions (l_nsubj) gnrh_27\NN\1740|
T13_T51 NONE testosterone_3\NN\14747587| (r_compound) action_4\NN\30358|of|testosterone (r_nmod) antagonism_1\NN\24720|this|action|gnrh (l_nmod) gnrh_6\NN\1740|by
T13_T52 NONE testosterone_3\NN\14747587| (r_compound) action_4\NN\30358|of|testosterone (r_nmod) antagonism_1\NN\24720|this|action|gnrh (r_nsubj) underlie_8\VB\2604760|antagonism|may|part|capacity|. (l_dobj) capacity_12\NN\5202497|the|activation|inhibit (l_nmod) activation_16\NN\13561719|of|gnrh|receptor (l_compound) receptor_15\NN\5225602|
T14_T51 NONE gnrh_6\NN\1740|by
T14_T52 NONE gnrh_6\NN\1740|by (r_nmod) antagonism_1\NN\24720|this|action|gnrh (r_nsubj) underlie_8\VB\2604760|antagonism|may|part|capacity|. (l_dobj) capacity_12\NN\5202497|the|activation|inhibit (l_nmod) activation_16\NN\13561719|of|gnrh|receptor (l_compound) receptor_15\NN\5225602|
T15_T51 NONE gnrh_14\NN\1740| (r_compound) activation_16\NN\13561719|of|gnrh|receptor (r_nmod) capacity_12\NN\5202497|the|activation|inhibit (r_dobj) underlie_8\VB\2604760|antagonism|may|part|capacity|. (l_nsubj) antagonism_1\NN\24720|this|action|gnrh (l_nmod) gnrh_6\NN\1740|by
T15_T52 NONE gnrh_14\NN\1740| (r_compound) activation_16\NN\13561719|of|gnrh|receptor (l_compound) receptor_15\NN\5225602|
22709946
T3_T14 NONE dhpg-stimulated_11\JJ\1740| (r_amod) hydrolysis_13\NN\13447361|of|dhpg-stimulated|polyphosphoinositides (r_nmod) measurement_9\NN\407535|by|in|hydrolysis (r_nmod) examined_2\VBD\789138|we|also|signaling|measurement|. (l_dobj) signaling_5\NN\33020|mglu1/5|receptor (l_compound) mglu1/5_3\NN\1740|
T4_T14 NONE polyphosphoinositides_12\NNS\1740| (r_compound) hydrolysis_13\NN\13447361|of|dhpg-stimulated|polyphosphoinositides (r_nmod) measurement_9\NN\407535|by|in|hydrolysis (r_nmod) examined_2\VBD\789138|we|also|signaling|measurement|. (l_dobj) signaling_5\NN\33020|mglu1/5|receptor (l_compound) mglu1/5_3\NN\1740|
T1_T9 CPR:3 mpep_8\NN\1740|with (r_nmod) treatment_3\NN\654885|chronic|rats|mpep (r_nsubj) reverse_11\VB\109660|however|,|treatment|did|not|helplessness|,|indicating|. (l_advcl) indicating_15\VBG\952524|player (l_ccomp) player_26\NN\9613191|that|function|is|not|the|only|phenotype (l_nsubj) function_21\NN\13783581|the|enhanced|mglu5|receptor (l_compound) receptor_20\NN\5225602|
T2_T10 NONE glutamate_11\NN\15010703| (r_compound) receptors_12\NNS\5225602|'|metabotropic|glutamate|'
15474503
T16_T41 NONE pitavastatin_2\NN\1740|of (r_nmod) effect_0\NN\34213|pitavastatin|production|. (l_nmod) production_6\NN\30358|on|a-i|cell (l_compound) a-i_5\NN\1740|apolipoprotein
T10_T30 NONE hmg-coa_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|of|hmg-coa|reductase|statins (r_nmod) action_9\NN\30358|of|hdl-elevating|inhibitors (l_amod) hdl-elevating_8\JJ\1740|
T10_T35 NONE hmg-coa_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|of|hmg-coa|reductase|statins (l_compound) reductase_12\NN\14732946|
T3_T28 NONE pitavastatin_19\NN\1740|microm)>simvastatin|microm)>atorvastatin (r_dep) induction_18\NN\7450842|of|the|apoa-i|pitavastatin (r_nmod) order_14\NN\7168131|the|rank|induction|. (r_parataxis) induced_2\VBD\1627355|statin|expression|dose-dependently|:|order (l_dobj) expression_4\NN\4679549|apoa-i|mrna (l_compound) apoa-i_3\NN\1740|
T3_T29 CPR:3 pitavastatin_19\NN\1740|microm)>simvastatin|microm)>atorvastatin (r_dep) induction_18\NN\7450842|of|the|apoa-i|pitavastatin (l_compound) apoa-i_17\NN\1740|
T4_T28 NONE microm)>simvastatin_22\NN\1740|(|3 (r_dep) pitavastatin_19\NN\1740|microm)>simvastatin|microm)>atorvastatin (r_dep) induction_18\NN\7450842|of|the|apoa-i|pitavastatin (r_nmod) order_14\NN\7168131|the|rank|induction|. (r_parataxis) induced_2\VBD\1627355|statin|expression|dose-dependently|:|order (l_dobj) expression_4\NN\4679549|apoa-i|mrna (l_compound) apoa-i_3\NN\1740|
T4_T29 CPR:3 microm)>simvastatin_22\NN\1740|(|3 (r_dep) pitavastatin_19\NN\1740|microm)>simvastatin|microm)>atorvastatin (r_dep) induction_18\NN\7450842|of|the|apoa-i|pitavastatin (l_compound) apoa-i_17\NN\1740|
T5_T28 NONE microm)>atorvastatin_25\NN\1740|(|10|microm (r_appos) pitavastatin_19\NN\1740|microm)>simvastatin|microm)>atorvastatin (r_dep) induction_18\NN\7450842|of|the|apoa-i|pitavastatin (r_nmod) order_14\NN\7168131|the|rank|induction|. (r_parataxis) induced_2\VBD\1627355|statin|expression|dose-dependently|:|order (l_dobj) expression_4\NN\4679549|apoa-i|mrna (l_compound) apoa-i_3\NN\1740|
T5_T29 CPR:3 microm)>atorvastatin_25\NN\1740|(|10|microm (r_appos) pitavastatin_19\NN\1740|microm)>simvastatin|microm)>atorvastatin (r_dep) induction_18\NN\7450842|of|the|apoa-i|pitavastatin (l_compound) apoa-i_17\NN\1740|
T6_T31 CPR:4 mevalonate_10\NN\1740|of (r_nmod) addition_8\NN\3081021|with|mevalonate (r_nmod) disappeared_6\VBD\2609764|induction|addition|,|indicates|. (l_nsubj) induction_1\NN\7450842|the|apoa-i|statins (l_nmod) apoa-i_3\NN\1740|of
T6_T32 NONE mevalonate_10\NN\1740|of (r_nmod) addition_8\NN\3081021|with|mevalonate (r_nmod) disappeared_6\VBD\2609764|induction|addition|,|indicates|. (l_ccomp) indicates_13\VBZ\952524|which|inhibition-dependent (l_ccomp) inhibition-dependent_20\JJ\1740|that|effect|is|reductase (l_nmod:npmod) reductase_19\NN\14732946|hmg-coa
T7_T31 NONE hmg-coa_18\NN\1740| (r_compound) reductase_19\NN\14732946|hmg-coa (r_nmod:npmod) inhibition-dependent_20\JJ\1740|that|effect|is|reductase (r_ccomp) indicates_13\VBZ\952524|which|inhibition-dependent (r_ccomp) disappeared_6\VBD\2609764|induction|addition|,|indicates|. (l_nsubj) induction_1\NN\7450842|the|apoa-i|statins (l_nmod) apoa-i_3\NN\1740|of
T7_T32 NONE hmg-coa_18\NN\1740| (r_compound) reductase_19\NN\14732946|hmg-coa
T11_T33 NONE simvastatin_11\NN\3676175|than|and|atorvastatin (r_nmod) efficiently_9\RB\1740|more|simvastatin (r_advmod) inhibition_4\NN\1068773|on|reductase|apoa-i|efficiently (l_compound) reductase_3\NN\14732946|hmg-coa
T11_T34 CPR:3 simvastatin_11\NN\3676175|than|and|atorvastatin (r_nmod) efficiently_9\RB\1740|more|simvastatin (r_advmod) inhibition_4\NN\1068773|on|reductase|apoa-i|efficiently (l_appos) apoa-i_7\NN\1740|,|pitavastatin-induced
T12_T33 NONE atorvastatin_13\NN\3676175| (r_conj) simvastatin_11\NN\3676175|than|and|atorvastatin (r_nmod) efficiently_9\RB\1740|more|simvastatin (r_advmod) inhibition_4\NN\1068773|on|reductase|apoa-i|efficiently (l_compound) reductase_3\NN\14732946|hmg-coa
T12_T34 CPR:3 atorvastatin_13\NN\3676175| (r_conj) simvastatin_11\NN\3676175|than|and|atorvastatin (r_nmod) efficiently_9\RB\1740|more|simvastatin (r_advmod) inhibition_4\NN\1068773|on|reductase|apoa-i|efficiently (l_appos) apoa-i_7\NN\1740|,|pitavastatin-induced
T8_T33 NONE hmg-coa_2\NN\1740| (r_compound) reductase_3\NN\14732946|hmg-coa
T8_T34 NONE hmg-coa_2\NN\1740| (r_compound) reductase_3\NN\14732946|hmg-coa (r_compound) inhibition_4\NN\1068773|on|reductase|apoa-i|efficiently (l_appos) apoa-i_7\NN\1740|,|pitavastatin-induced
T9_T33 NONE pitavastatin-induced_6\NN\1740| (r_amod) apoa-i_7\NN\1740|,|pitavastatin-induced (r_appos) inhibition_4\NN\1068773|on|reductase|apoa-i|efficiently (l_compound) reductase_3\NN\14732946|hmg-coa
T9_T34 CPR:3 pitavastatin-induced_6\NN\1740| (r_amod) apoa-i_7\NN\1740|,|pitavastatin-induced
T13_T36 CPR:3 pitavastatin_4\NN\1740| (r_nsubj) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_dobj) mrna_7\NN\14832193|abca1 (l_compound) abca1_6\NN\1740|
T13_T37 NONE pitavastatin_4\NN\1740| (r_nsubj) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_nmod) manner_11\NN\4916342|in|hmg-coa|reductase-dependent (l_amod) reductase-dependent_10\JJ\1740|
T13_T38 NONE pitavastatin_4\NN\1740| (r_nsubj) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_conj) increased_25\VBD\169651|that|rho|production|cells (l_nsubj) rho_14\NN\6828818|and|inhibitor|c3
T13_T39 NONE pitavastatin_4\NN\1740| (r_nsubj) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_conj) increased_25\VBD\169651|that|rho|production|cells (l_nsubj) rho_14\NN\6828818|and|inhibitor|c3 (l_conj) inhibitor_18\NN\20090|rho|kinase (l_compound) kinase_17\NN\14732946|
T13_T40 NONE pitavastatin_4\NN\1740| (r_nsubj) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_conj) increased_25\VBD\169651|that|rho|production|cells (l_dobj) production_27\NN\30358|apoa-i (l_compound) apoa-i_26\NN\1740|
T14_T36 NONE hmg-coa_9\NN\1740| (r_compound) manner_11\NN\4916342|in|hmg-coa|reductase-dependent (r_nmod) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_dobj) mrna_7\NN\14832193|abca1 (l_compound) abca1_6\NN\1740|
T14_T37 NONE hmg-coa_9\NN\1740| (r_compound) manner_11\NN\4916342|in|hmg-coa|reductase-dependent (l_amod) reductase-dependent_10\JJ\1740|
T14_T38 NONE hmg-coa_9\NN\1740| (r_compound) manner_11\NN\4916342|in|hmg-coa|reductase-dependent (r_nmod) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_conj) increased_25\VBD\169651|that|rho|production|cells (l_nsubj) rho_14\NN\6828818|and|inhibitor|c3
T14_T39 NONE hmg-coa_9\NN\1740| (r_compound) manner_11\NN\4916342|in|hmg-coa|reductase-dependent (r_nmod) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_conj) increased_25\VBD\169651|that|rho|production|cells (l_nsubj) rho_14\NN\6828818|and|inhibitor|c3 (l_conj) inhibitor_18\NN\20090|rho|kinase (l_compound) kinase_17\NN\14732946|
T14_T40 NONE hmg-coa_9\NN\1740| (r_compound) manner_11\NN\4916342|in|hmg-coa|reductase-dependent (r_nmod) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_conj) increased_25\VBD\169651|that|rho|production|cells (l_dobj) production_27\NN\30358|apoa-i (l_compound) apoa-i_26\NN\1740|
T15_T36 NONE y27632_23\NN\1740| (r_conj) t_21\NN\14999913|and|y27632 (r_dep) c3_20\NN\1740|(|t|) (r_dep) rho_14\NN\6828818|and|inhibitor|c3 (r_nsubj) increased_25\VBD\169651|that|rho|production|cells (r_conj) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_dobj) mrna_7\NN\14832193|abca1 (l_compound) abca1_6\NN\1740|
T15_T37 NONE y27632_23\NN\1740| (r_conj) t_21\NN\14999913|and|y27632 (r_dep) c3_20\NN\1740|(|t|) (r_dep) rho_14\NN\6828818|and|inhibitor|c3 (r_nsubj) increased_25\VBD\169651|that|rho|production|cells (r_conj) increased_5\VBD\169651|that|pitavastatin|mrna|manner|and|increased (l_nmod) manner_11\NN\4916342|in|hmg-coa|reductase-dependent (l_amod) reductase-dependent_10\JJ\1740|
T15_T38 CPR:4 y27632_23\NN\1740| (r_conj) t_21\NN\14999913|and|y27632 (r_dep) c3_20\NN\1740|(|t|) (r_dep) rho_14\NN\6828818|and|inhibitor|c3
T15_T39 CPR:4 y27632_23\NN\1740| (r_conj) t_21\NN\14999913|and|y27632 (r_dep) c3_20\NN\1740|(|t|) (r_dep) rho_14\NN\6828818|and|inhibitor|c3 (l_conj) inhibitor_18\NN\20090|rho|kinase (l_compound) kinase_17\NN\14732946|
T15_T40 CPR:3 y27632_23\NN\1740| (r_conj) t_21\NN\14999913|and|y27632 (r_dep) c3_20\NN\1740|(|t|) (r_dep) rho_14\NN\6828818|and|inhibitor|c3 (r_nsubj) increased_25\VBD\169651|that|rho|production|cells (l_dobj) production_27\NN\30358|apoa-i (l_compound) apoa-i_26\NN\1740|
T1_T17 CPR:3 pitavastatin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|pitavastatin|efficiently|apoa-i|promoting (l_dobj) apoa-i_7\NN\1740|medium
T1_T18 CPR:3 pitavastatin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|pitavastatin|efficiently|apoa-i|promoting (l_advcl) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_dobj) production_18\NN\30358|apoa-i (l_compound) apoa-i_17\NN\1740|
T1_T19 CPR:4 pitavastatin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|pitavastatin|efficiently|apoa-i|promoting (l_advcl) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_nmod) inhibition_20\NN\1068773|through|reductase|and|suppression (l_nmod) reductase_23\NN\14732946|of|hmg-coa
T1_T20 CPR:4 pitavastatin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|pitavastatin|efficiently|apoa-i|promoting (l_advcl) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_nmod) inhibition_20\NN\1068773|through|reductase|and|suppression (l_conj) suppression_25\NN\13489037|activity (l_nmod) activity_28\NN\30358|of|rho (l_compound) rho_27\NN\6828818|
T1_T21 NONE pitavastatin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|pitavastatin|efficiently|apoa-i|promoting (l_advcl) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_conj) protecting_31\VBG\1127795|by|apoa-i|catabolism|induction (l_dobj) apoa-i_32\NN\1740|
T1_T22 CPR:3 pitavastatin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|pitavastatin|efficiently|apoa-i|promoting (l_advcl) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_conj) protecting_31\VBG\1127795|by|apoa-i|catabolism|induction (l_nmod) induction_37\NN\7450842|through|abca1|and|lipidation (l_compound) abca1_36\NN\1740|
T1_T23 CPR:3 pitavastatin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|pitavastatin|efficiently|apoa-i|promoting (l_advcl) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_conj) protecting_31\VBG\1127795|by|apoa-i|catabolism|induction (l_nmod) induction_37\NN\7450842|through|abca1|and|lipidation (l_conj) lipidation_39\NN\1740|apoa-i. (l_nmod) apoa-i._41\NN\1740|of
T2_T17 NONE hmg-coa_22\NN\1740| (r_compound) reductase_23\NN\14732946|of|hmg-coa (r_nmod) inhibition_20\NN\1068773|through|reductase|and|suppression (r_nmod) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (r_advcl) increases_6\VBZ\169651|that|pitavastatin|efficiently|apoa-i|promoting (l_dobj) apoa-i_7\NN\1740|medium
T2_T18 NONE hmg-coa_22\NN\1740| (r_compound) reductase_23\NN\14732946|of|hmg-coa (r_nmod) inhibition_20\NN\1068773|through|reductase|and|suppression (r_nmod) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_dobj) production_18\NN\30358|apoa-i (l_compound) apoa-i_17\NN\1740|
T2_T19 NONE hmg-coa_22\NN\1740| (r_compound) reductase_23\NN\14732946|of|hmg-coa
T2_T20 NONE hmg-coa_22\NN\1740| (r_compound) reductase_23\NN\14732946|of|hmg-coa (r_nmod) inhibition_20\NN\1068773|through|reductase|and|suppression (l_conj) suppression_25\NN\13489037|activity (l_nmod) activity_28\NN\30358|of|rho (l_compound) rho_27\NN\6828818|
T2_T21 NONE hmg-coa_22\NN\1740| (r_compound) reductase_23\NN\14732946|of|hmg-coa (r_nmod) inhibition_20\NN\1068773|through|reductase|and|suppression (r_nmod) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_conj) protecting_31\VBG\1127795|by|apoa-i|catabolism|induction (l_dobj) apoa-i_32\NN\1740|
T2_T22 NONE hmg-coa_22\NN\1740| (r_compound) reductase_23\NN\14732946|of|hmg-coa (r_nmod) inhibition_20\NN\1068773|through|reductase|and|suppression (r_nmod) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_conj) protecting_31\VBG\1127795|by|apoa-i|catabolism|induction (l_nmod) induction_37\NN\7450842|through|abca1|and|lipidation (l_compound) abca1_36\NN\1740|
T2_T23 NONE hmg-coa_22\NN\1740| (r_compound) reductase_23\NN\14732946|of|hmg-coa (r_nmod) inhibition_20\NN\1068773|through|reductase|and|suppression (r_nmod) promoting_16\VBG\2556126|by|production|inhibition|and|protecting (l_conj) protecting_31\VBG\1127795|by|apoa-i|catabolism|induction (l_nmod) induction_37\NN\7450842|through|abca1|and|lipidation (l_conj) lipidation_39\NN\1740|apoa-i. (l_nmod) apoa-i._41\NN\1740|of
15811959
T4_T19 NONE bexarotene_14\NN\1740| (r_appos) retinoid_12\NN\1740|the|receptor|,|bexarotene|,|concentrations|, (l_compound) receptor_8\NN\5225602|retinoid|x|rxr
T4_T20 NONE bexarotene_14\NN\1740| (r_appos) retinoid_12\NN\1740|the|receptor|,|bexarotene|,|concentrations|, (l_compound) receptor_8\NN\5225602|retinoid|x|rxr (l_appos) rxr_10\NN\1740|(|)
T4_T21 CPR:3 bexarotene_14\NN\1740| (r_appos) retinoid_12\NN\1740|the|receptor|,|bexarotene|,|concentrations|, (r_nsubj) upregulated_29\VBD\1740|that|retinoid|subunits|and|enhanced (l_dobj) subunits_35\NNS\13604718|both|the|p55|il-2r (l_compound) p55_32\NN\1740|and|p75
T4_T22 CPR:3 bexarotene_14\NN\1740| (r_appos) retinoid_12\NN\1740|the|receptor|,|bexarotene|,|concentrations|, (r_nsubj) upregulated_29\VBD\1740|that|retinoid|subunits|and|enhanced (l_dobj) subunits_35\NNS\13604718|both|the|p55|il-2r (l_compound) p55_32\NN\1740|and|p75 (l_conj) p75_34\NN\1740|
T4_T23 CPR:3 bexarotene_14\NN\1740| (r_appos) retinoid_12\NN\1740|the|receptor|,|bexarotene|,|concentrations|, (r_nsubj) upregulated_29\VBD\1740|that|retinoid|subunits|and|enhanced (l_dobj) subunits_35\NNS\13604718|both|the|p55|il-2r (l_nmod) il-2r_38\NN\1740|of|the
T1_T7 NONE bexarotene_10\NN\1740| (r_compound) dose_11\NN\3740161|at|a|bexarotene|mg/day (r_nmod) observed_5\VBN\2163746|modulation|was|dose|. (l_nsubjpass) modulation_0\NN\7044917|expression (l_nmod) expression_3\NN\4679549|of|il-2r (l_compound) il-2r_2\NN\1740|
T2_T8 NONE bexarotene_10\NN\1740| (r_conj) diftitox_8\NN\1740|of|denileukin|and|bexarotene (r_nmod) combination_5\NN\7951464|the|diftitox (r_nsubjpass) tolerated_13\VBN\802318|that|combination|is|well|and|capable (l_conj) capable_26\JJ\1740|that|doses|are|upregulation (l_nmod) upregulation_30\NN\1740|of|in|expression (l_nmod) expression_33\NN\4679549|of|cd25|cells (l_compound) cd25_32\NN\1740|
T3_T8 CPR:3 bexarotene_24\NN\1740|of (r_nmod) doses_18\NNS\3740161|even|low|mg/day|bexarotene (r_nsubj) capable_26\JJ\1740|that|doses|are|upregulation (l_nmod) upregulation_30\NN\1740|of|in|expression (l_nmod) expression_33\NN\4679549|of|cd25|cells (l_compound) cd25_32\NN\1740|
17496727
T11_T26 NONE 5'-monophosphate_7\NN\1740| (r_compound) dehydrogenase_8\NN\1740|in|human|inosine|5'-monophosphate|2 (r_nmod) l263f_3\NN\1740|a|novel|variant|dehydrogenase
T11_T27 NONE 5'-monophosphate_7\NN\1740| (r_compound) dehydrogenase_8\NN\1740|in|human|inosine|5'-monophosphate|2 (l_nummod) 2_9\CD\13741022|
T7_T21 NONE 5'-monophosphate_5\NN\1740| (r_compound) dehydrogenase_6\NN\1740|inosine|5'-monophosphate|2 (l_nummod) 2_7\CD\13741022|
T8_T16 NONE acid_27\NN\14818238|mycophenolic (r_dobj) receiving_25\VBG\2210855|acid (r_acl) recipients_24\NNS\9764201|in|transplant|receiving (r_nmod) variability_11\NN\4733640|for|the|large|inter-individual|activity|recipients (r_nmod) account_6\VB\2604760|variants|may|variability|. (l_nsubj) variants_0\NNS\7366289|gene (l_nmod) gene_4\NN\8459252|in|the|impdh2 (l_compound) impdh2_3\NN\1740|
T9_T24 NONE 5'-monophosphate_12\NN\1740| (r_compound) strain_14\NN\7358060|to|an|inosine|5'-monophosphate|dehydrogenase-deficient|h712 (l_amod) dehydrogenase-deficient_13\JJ\1740|
T1_T12 NONE 5'-monophosphate_16\NN\1740| (r_compound) activity_18\NN\30358|the|inosine|5'-monophosphate|dehydrogenase|variant (r_nsubjpass) decreased_23\VBN\169651|that|activity|was|% (r_ccomp) demonstrated_12\VBD\2137132|assay|decreased|. (r_conj) identified_6\VBN\699815|l263f|was|,|and|demonstrated (l_nsubjpass) l263f_4\NN\1740|a|variant
T1_T13 NONE 5'-monophosphate_16\NN\1740| (r_compound) activity_18\NN\30358|the|inosine|5'-monophosphate|dehydrogenase|variant (l_compound) dehydrogenase_17\NN\1740|
T1_T14 NONE 5'-monophosphate_16\NN\1740| (r_compound) activity_18\NN\30358|the|inosine|5'-monophosphate|dehydrogenase|variant (l_nmod) variant_21\NN\7366289|of|l263f (l_compound) l263f_20\NN\1740|
T2_T15 CPR:4 acid_4\NN\14818238| (r_compound) inhibition_5\NN\1068773|for|mycophenolic|acid|variant (l_nmod) variant_9\NN\7366289|of|the|l263f (l_compound) l263f_8\NN\1740|
T3_T15 NONE 5'-monophosphate_22\NN\1740|for|inosine|and|dinucleotide (r_nmod) km_19\NN\13649268|the|variant|5'-monophosphate (r_nsubj) change_29\VB\46534|km|did|not|significantly|. (r_conj) comparable_11\JJ\1740|ki|was|wild-type|,|and|change (l_nsubj) ki_1\NN\14050143|the|inhibition (l_nmod) inhibition_5\NN\1068773|for|mycophenolic|acid|variant (l_nmod) variant_9\NN\7366289|of|the|l263f (l_compound) l263f_8\NN\1740|
T4_T15 NONE dinucleotide_26\NN\1740|nicotinamide|adenine (r_conj) 5'-monophosphate_22\NN\1740|for|inosine|and|dinucleotide (r_nmod) km_19\NN\13649268|the|variant|5'-monophosphate (r_nsubj) change_29\VB\46534|km|did|not|significantly|. (r_conj) comparable_11\JJ\1740|ki|was|wild-type|,|and|change (l_nsubj) ki_1\NN\14050143|the|inhibition (l_nmod) inhibition_5\NN\1068773|for|mycophenolic|acid|variant (l_nmod) variant_9\NN\7366289|of|the|l263f (l_compound) l263f_8\NN\1740|
T5_T17 NONE 5'-monophosphate_19\NN\1740| (r_compound) activity_21\NN\30358|on|inosine|5'-monophosphate|dehydrogenase (r_nmod) has_13\VBZ\2108377|l263f|impact|activity (r_conj) has_3\VBZ\2108377|impdh2|diversity|,|but|has|. (l_nsubj) impdh2_2\NN\1740|
T5_T18 NONE 5'-monophosphate_19\NN\1740| (r_compound) activity_21\NN\30358|on|inosine|5'-monophosphate|dehydrogenase (r_nmod) has_13\VBZ\2108377|l263f|impact|activity (l_nsubj) l263f_12\NN\1740|the|nonsynonymous|variant
T5_T19 NONE 5'-monophosphate_19\NN\1740| (r_compound) activity_21\NN\30358|on|inosine|5'-monophosphate|dehydrogenase (l_compound) dehydrogenase_20\NN\1740|
T6_T20 NONE 5'-monophosphate_18\NN\1740| (r_compound) activity_20\NN\30358|of|baseline|inosine|5'-monophosphate|dehydrogenase (l_compound) dehydrogenase_19\NN\1740|
23267840
T15_T28 NONE nmda_0\NN\1740|and|receptor (l_conj) receptor_3\NN\5225602|ampa
T16_T28 NONE curcumin_18\NN\1740|of (r_nmod) effects_16\NNS\13245626|ameliorating|curcumin|. (r_dep) excitotoxicity_5\NN\1740|mediated|cortex|:|effects (l_amod) mediated_4\JJ\1740|nmda (l_nmod:npmod) nmda_0\NN\1740|and|receptor (l_conj) receptor_3\NN\5225602|ampa
T17_T28 NONE streptozotocin_10\NN\1740| (r_nmod:npmod) induced_11\JJ\1740|streptozotocin (r_amod) rat_13\NN\2329401|of|induced|diabetic (r_nmod) cortex_8\NN\5462674|in|cerebral|rat (r_nmod) excitotoxicity_5\NN\1740|mediated|cortex|:|effects (l_amod) mediated_4\JJ\1740|nmda (l_nmod:npmod) nmda_0\NN\1740|and|receptor (l_conj) receptor_3\NN\5225602|ampa
T18_T28 NONE ampa_2\NN\1740| (r_compound) receptor_3\NN\5225602|ampa
T6_T21 NONE glutamate_11\NN\15010703| (r_compound) mrna_13\NN\14832193|of|glutamate|decarboxylase (l_compound) decarboxylase_12\NN\14732946|
T7_T21 NONE glutamate_18\NN\15010703|of (r_nmod) accumulation_16\NN\13497135|to|glutamate (r_nmod) leading_14\VBG\1752884|accumulation (r_acl) regulation_9\NN\6652242|a|down|mrna|leading (l_nmod) mrna_13\NN\14832193|of|glutamate|decarboxylase (l_compound) decarboxylase_12\NN\14732946|
T8_T22 NONE propionate_9\NN\1740|α-amino-3-hydroxy-5-methyl-4-isoxazole|and|n-methyl-d-aspartate (r_compound) receptors_12\NNS\5225602|propionate
T9_T22 NONE n-methyl-d-aspartate_11\NN\1740| (r_conj) propionate_9\NN\1740|α-amino-3-hydroxy-5-methyl-4-isoxazole|and|n-methyl-d-aspartate (r_compound) receptors_12\NNS\5225602|propionate
T10_T23 NONE glutathione_1\NN\1740| (r_compound) peroxidases_2\NNS\14971234|glutathione
T11_T24 NONE glutamate_6\NN\15010703| (r_compound) transporter_8\NN\4490091|of|glutamate|aspartate|,|reduces
T12_T24 NONE aspartate_7\NN\1740| (r_compound) transporter_8\NN\4490091|of|glutamate|aspartate|,|reduces
T13_T24 CPR:9 glutamate_14\NN\15010703| (r_compound) transport_15\NN\3575240|glutamate (r_dobj) reduces_13\VBZ\441445|which|turn|transport (r_acl:relcl) transporter_8\NN\4490091|of|glutamate|aspartate|,|reduces
T14_T19 NONE curcumin_0\NN\1740|and|insulin (l_conj) insulin_2\NN\5407119|
16985933
T1_T5 NONE testosterone_19\NN\14747587|in|serum (r_nmod) surge_16\NN\7405893|a|testosterone|precipitate (r_dobj) causing_14\VBG\1617192|surge (r_advcl) stimulate_8\VBP\137313|started|,|agonists|initially|release|,|causing|. (l_nsubj) agonists_6\NNS\9613191|lhrh (l_compound) lhrh_5\NN\1740|
T1_T6 NONE testosterone_19\NN\14747587|in|serum (r_nmod) surge_16\NN\7405893|a|testosterone|precipitate (r_dobj) causing_14\VBG\1617192|surge (r_advcl) stimulate_8\VBP\137313|started|,|agonists|initially|release|,|causing|. (l_dobj) release_10\NN\3748886|the|lh (l_nmod) lh_12\NN\5410315|of
T2_T11 NONE testosterone_22\NN\14747587| (r_compound) surge_23\NN\7405893|testosterone (r_dobj) causing_21\VBG\1617192|quickly|and|without|surge (r_advcl) produces_14\VBZ\1617192|that|abarelix|castration|causing|,|compared (l_advcl) compared_26\VBN\644583|as|agonists (l_nmod) agonists_29\NNS\9613191|with|lhrh|antagonist (l_compound) lhrh_28\NN\1740|
23044709
T1_T3 NONE tartrate-resistant_0\JJ\1740| (r_amod) phosphatase_2\NN\14732946|tartrate-resistant|acid|trap
T1_T4 NONE tartrate-resistant_0\JJ\1740| (r_amod) phosphatase_2\NN\14732946|tartrate-resistant|acid|trap (l_appos) trap_4\NN\3183080|(|)
T1_T5 NONE tartrate-resistant_0\JJ\1740| (r_amod) phosphatase_2\NN\14732946|tartrate-resistant|acid|trap (r_compound) staining_6\NN\275424|phosphatase (r_nsubj) revealed_7\VBD\2137132|staining|numbers|. (l_dobj) numbers_10\NNS\508091|increased|osteoclast|tibias|,|and|numbers (l_nmod) tibias_12\NNS\5594037|in|mice (l_nmod) mice_16\NNS\2329401|of|2-month-old|col1a1-cnn1 (l_compound) col1a1-cnn1_15\NN\1740|
T1_T6 NONE tartrate-resistant_0\JJ\1740| (r_amod) phosphatase_2\NN\14732946|tartrate-resistant|acid|trap (r_compound) staining_6\NN\275424|phosphatase (r_nsubj) revealed_7\VBD\2137132|staining|numbers|. (l_dobj) numbers_10\NNS\508091|increased|osteoclast|tibias|,|and|numbers (l_nmod) tibias_12\NNS\5594037|in|mice (l_nmod) mice_16\NNS\2329401|of|2-month-old|col1a1-cnn1 (l_compound) col1a1-cnn1_15\NN\1740|
T1_T7 NONE tartrate-resistant_0\JJ\1740| (r_amod) phosphatase_2\NN\14732946|tartrate-resistant|acid|trap (r_compound) staining_6\NN\275424|phosphatase (r_nsubj) revealed_7\VBD\2137132|staining|numbers|. (l_dobj) numbers_10\NNS\508091|increased|osteoclast|tibias|,|and|numbers (l_conj) numbers_20\NNS\508091|increased|osteoclasts (l_nmod) osteoclasts_22\NNS\5447599|of|co-cultured (l_acl) co-cultured_23\VBN\1740|osteoblasts (l_nmod) osteoblasts_26\NNS\5447757|with|col1a1-cnn1 (l_compound) col1a1-cnn1_25\NN\1740|
T1_T8 NONE tartrate-resistant_0\JJ\1740| (r_amod) phosphatase_2\NN\14732946|tartrate-resistant|acid|trap (r_compound) staining_6\NN\275424|phosphatase (r_nsubj) revealed_7\VBD\2137132|staining|numbers|. (l_dobj) numbers_10\NNS\508091|increased|osteoclast|tibias|,|and|numbers (l_conj) numbers_20\NNS\508091|increased|osteoclasts (l_nmod) osteoclasts_22\NNS\5447599|of|co-cultured (l_acl) co-cultured_23\VBN\1740|osteoblasts (l_nmod) osteoblasts_26\NNS\5447757|with|col1a1-cnn1 (l_compound) col1a1-cnn1_25\NN\1740|
7825862
T12_T14 NONE prostaglandin_5\NN\5414534| (r_compound) synthase_10\NN\1740|of|prostaglandin|endoperoxide|(|pgh|)|cyclooxygenase (r_nmod) isozymes_3\NNS\1740|two|synthase|called (l_acl) called_14\VBN\1029852|synthase-1 (l_xcomp) synthase-1_16\NN\1740|pgh|and|-2|or|cox (l_conj) cox_20\NN\14732946|i (l_dep) i_21\CD\14622893|and|ii (l_conj) ii_23\CD\13741022|
T12_T25 NONE prostaglandin_5\NN\5414534| (r_compound) synthase_10\NN\1740|of|prostaglandin|endoperoxide|(|pgh|)|cyclooxygenase
T12_T32 NONE prostaglandin_5\NN\5414534| (r_compound) synthase_10\NN\1740|of|prostaglandin|endoperoxide|(|pgh|)|cyclooxygenase (l_appos) cyclooxygenase_12\NN\14732946|(|)
T12_T35 NONE prostaglandin_5\NN\5414534| (r_compound) synthase_10\NN\1740|of|prostaglandin|endoperoxide|(|pgh|)|cyclooxygenase (r_nmod) isozymes_3\NNS\1740|two|synthase|called (l_acl) called_14\VBN\1029852|synthase-1 (l_xcomp) synthase-1_16\NN\1740|pgh|and|-2|or|cox (l_conj) -2_18\CD\1740|
T1_T13 CPR:4 indomethacin_0\NN\3828465|,|piroxicam|,|and|sulfide (r_nsubjpass) found_8\VBN\2426171|indomethacin|were|inhibit|. (l_xcomp) inhibit_11\VB\2510337|to|preferentially|pghs-1 (l_dobj) pghs-1_12\NN\1740|
T2_T13 CPR:4 piroxicam_2\NN\3828465| (r_conj) indomethacin_0\NN\3828465|,|piroxicam|,|and|sulfide (r_nsubjpass) found_8\VBN\2426171|indomethacin|were|inhibit|. (l_xcomp) inhibit_11\VB\2510337|to|preferentially|pghs-1 (l_dobj) pghs-1_12\NN\1740|
T3_T13 CPR:4 sulfide_6\NN\14818238|sulindac (r_conj) indomethacin_0\NN\3828465|,|piroxicam|,|and|sulfide (r_nsubjpass) found_8\VBN\2426171|indomethacin|were|inhibit|. (l_xcomp) inhibit_11\VB\2510337|to|preferentially|pghs-1 (l_dobj) pghs-1_12\NN\1740|
T5_T15 CPR:4 acid_1\NN\14818238|6-methoxy-2-naphthylacetic|,|metabolite|, (r_nsubj) inhibits_9\VBZ\2510337|acid|pghs-2|preferentially|. (l_dobj) pghs-2_11\NN\1740|murine
T6_T15 CPR:4 relafen_7\NN\3828465|of (r_nmod) metabolite_5\NN\20090|the|active|relafen (r_appos) acid_1\NN\14818238|6-methoxy-2-naphthylacetic|,|metabolite|, (r_nsubj) inhibits_9\VBZ\2510337|acid|pghs-2|preferentially|. (l_dobj) pghs-2_11\NN\1740|murine
T10_T16 NONE 15-hete_32\NN\1740|(|) (r_appos) acid_30\NN\14818238|15-hydroxy-5c,8c,11c,13t-eicosatetraenoic|15-hete|of|pgh2 (r_dobj) form_28\VB\1617192|to|acid (r_xcomp) causes_24\VBZ\1617192|contrast|,|treatment|enzyme|form|. (r_parataxis) inhibits_2\VBZ\2510337|aspirin|irreversibly|pghs-1|,|preventing|;|causes (l_dobj) pghs-1_3\NN\1740|
T10_T17 CPR:9 15-hete_32\NN\1740|(|) (r_appos) acid_30\NN\14818238|15-hydroxy-5c,8c,11c,13t-eicosatetraenoic|15-hete|of|pgh2 (r_dobj) form_28\VB\1617192|to|acid (r_xcomp) causes_24\VBZ\1617192|contrast|,|treatment|enzyme|form|. (l_nsubj) treatment_21\NN\654885|aspirin|pghs-2 (l_nmod) pghs-2_23\NN\1740|of
T7_T16 CPR:4 aspirin_0\NN\2707683| (r_nsubj) inhibits_2\VBZ\2510337|aspirin|irreversibly|pghs-1|,|preventing|;|causes (l_dobj) pghs-1_3\NN\1740|
T7_T17 NONE aspirin_0\NN\2707683| (r_nsubj) inhibits_2\VBZ\2510337|aspirin|irreversibly|pghs-1|,|preventing|;|causes (l_parataxis) causes_24\VBZ\1617192|contrast|,|treatment|enzyme|form|. (l_nsubj) treatment_21\NN\654885|aspirin|pghs-2 (l_nmod) pghs-2_23\NN\1740|of
T8_T16 NONE aspirin_20\NN\2707683| (r_compound) treatment_21\NN\654885|aspirin|pghs-2 (r_nsubj) causes_24\VBZ\1617192|contrast|,|treatment|enzyme|form|. (r_parataxis) inhibits_2\VBZ\2510337|aspirin|irreversibly|pghs-1|,|preventing|;|causes (l_dobj) pghs-1_3\NN\1740|
T8_T17 NONE aspirin_20\NN\2707683| (r_compound) treatment_21\NN\654885|aspirin|pghs-2 (l_nmod) pghs-2_23\NN\1740|of
T9_T16 NONE acid_30\NN\14818238|15-hydroxy-5c,8c,11c,13t-eicosatetraenoic|15-hete|of|pgh2 (r_dobj) form_28\VB\1617192|to|acid (r_xcomp) causes_24\VBZ\1617192|contrast|,|treatment|enzyme|form|. (r_parataxis) inhibits_2\VBZ\2510337|aspirin|irreversibly|pghs-1|,|preventing|;|causes (l_dobj) pghs-1_3\NN\1740|
T9_T17 CPR:9 acid_30\NN\14818238|15-hydroxy-5c,8c,11c,13t-eicosatetraenoic|15-hete|of|pgh2 (r_dobj) form_28\VB\1617192|to|acid (r_xcomp) causes_24\VBZ\1617192|contrast|,|treatment|enzyme|form|. (l_nsubj) treatment_21\NN\654885|aspirin|pghs-2 (l_nmod) pghs-2_23\NN\1740|of
12783542
T4_T25 NONE 5tfi_0\NN\1740| (r_nsubjpass) incorporated_2\VBN\1461328|5tfi|was|protein|. (l_nmod) protein_7\NN\14944888|into|a|model|target|,|reductase|,|strain (l_appos) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr
T4_T26 NONE 5tfi_0\NN\1740| (r_nsubjpass) incorporated_2\VBN\1461328|5tfi|was|protein|. (l_nmod) protein_7\NN\14944888|into|a|model|target|,|reductase|,|strain (l_appos) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr (l_appos) mdhfr_13\NN\1740|(|)
T5_T25 NONE dihydrofolate_10\JJ\1740| (r_amod) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr
T5_T26 NONE dihydrofolate_10\JJ\1740| (r_amod) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr (l_appos) mdhfr_13\NN\1740|(|)
T6_T25 NONE isoleucine_18\NN\14605787| (r_compound) strain_23\NN\7358060|in|an|isoleucine|auxotrophic|escherichia|coli|host|suspended (r_nmod) protein_7\NN\14944888|into|a|model|target|,|reductase|,|strain (l_appos) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr
T6_T26 NONE isoleucine_18\NN\14605787| (r_compound) strain_23\NN\7358060|in|an|isoleucine|auxotrophic|escherichia|coli|host|suspended (r_nmod) protein_7\NN\14944888|into|a|model|target|,|reductase|,|strain (l_appos) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr (l_appos) mdhfr_13\NN\1740|(|)
T8_T25 NONE 5tfi-supplemented_26\NN\1740| (r_amod) medium_28\NN\3575240|in|5tfi-supplemented|minimal|depleted (r_nmod) suspended_24\VBN\1481360|medium (r_acl) strain_23\NN\7358060|in|an|isoleucine|auxotrophic|escherichia|coli|host|suspended (r_nmod) protein_7\NN\14944888|into|a|model|target|,|reductase|,|strain (l_appos) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr
T8_T26 NONE 5tfi-supplemented_26\NN\1740| (r_amod) medium_28\NN\3575240|in|5tfi-supplemented|minimal|depleted (r_nmod) suspended_24\VBN\1481360|medium (r_acl) strain_23\NN\7358060|in|an|isoleucine|auxotrophic|escherichia|coli|host|suspended (r_nmod) protein_7\NN\14944888|into|a|model|target|,|reductase|,|strain (l_appos) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr (l_appos) mdhfr_13\NN\1740|(|)
T9_T25 NONE isoleucine_31\NN\14605787|of (r_nmod) depleted_29\VBN\2267060|isoleucine (r_acl) medium_28\NN\3575240|in|5tfi-supplemented|minimal|depleted (r_nmod) suspended_24\VBN\1481360|medium (r_acl) strain_23\NN\7358060|in|an|isoleucine|auxotrophic|escherichia|coli|host|suspended (r_nmod) protein_7\NN\14944888|into|a|model|target|,|reductase|,|strain (l_appos) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr
T9_T26 NONE isoleucine_31\NN\14605787|of (r_nmod) depleted_29\VBN\2267060|isoleucine (r_acl) medium_28\NN\3575240|in|5tfi-supplemented|minimal|depleted (r_nmod) suspended_24\VBN\1481360|medium (r_acl) strain_23\NN\7358060|in|an|isoleucine|auxotrophic|escherichia|coli|host|suspended (r_nmod) protein_7\NN\14944888|into|a|model|target|,|reductase|,|strain (l_appos) reductase_11\NN\14732946|murine|dihydrofolate|mdhfr (l_appos) mdhfr_13\NN\1740|(|)
T15_T27 NONE 5tfi_7\NN\1740|of (r_nmod) activation_5\NN\13561719|of|5tfi (r_nmod) rate_3\NN\13815152|of|the|activation (r_nmod) measurement_0\NN\407535|rate|synthetase (l_nmod) synthetase_13\NN\1740|by|the|e.|coli|isoleucyl-trna|ilers
T15_T28 NONE 5tfi_7\NN\1740|of (r_nmod) activation_5\NN\13561719|of|5tfi (r_nmod) rate_3\NN\13815152|of|the|activation (r_nmod) measurement_0\NN\407535|rate|synthetase (l_nmod) synthetase_13\NN\1740|by|the|e.|coli|isoleucyl-trna|ilers (l_appos) ilers_15\NN\1740|(|)
T16_T27 NONE isoleucyl-trna_12\NN\1740| (r_compound) synthetase_13\NN\1740|by|the|e.|coli|isoleucyl-trna|ilers
T16_T28 NONE isoleucyl-trna_12\NN\1740| (r_compound) synthetase_13\NN\1740|by|the|e.|coli|isoleucyl-trna|ilers (l_appos) ilers_15\NN\1740|(|)
T17_T27 NONE isoleucine_30\NN\14605787|for (r_nmod) that_28\DT\1740|than|isoleucine (r_nmod) lower_26\JJR\1740|134-fold|that (r_amod) constant_20\NN\5855125|a|specificity|k(cat)/k(m|lower (r_dobj) yielded_17\VBD\2327200|measurement|constant|. (l_nsubj) measurement_0\NN\407535|rate|synthetase (l_nmod) synthetase_13\NN\1740|by|the|e.|coli|isoleucyl-trna|ilers
T17_T28 NONE isoleucine_30\NN\14605787|for (r_nmod) that_28\DT\1740|than|isoleucine (r_nmod) lower_26\JJR\1740|134-fold|that (r_amod) constant_20\NN\5855125|a|specificity|k(cat)/k(m|lower (r_dobj) yielded_17\VBD\2327200|measurement|constant|. (l_nsubj) measurement_0\NN\407535|rate|synthetase (l_nmod) synthetase_13\NN\1740|by|the|e.|coli|isoleucyl-trna|ilers (l_appos) ilers_15\NN\1740|(|)
T18_T29 NONE 5tfi_0\NN\1740| (r_nsubjpass) introduced_3\VBN\831651|5tfi|was|successfully|cytokine|positions|. (l_nmod) cytokine_6\NN\14728724|into|the|interleukin-2
T18_T30 NONE 5tfi_0\NN\1740| (r_nsubjpass) introduced_3\VBN\831651|5tfi|was|successfully|cytokine|positions|. (l_nmod) cytokine_6\NN\14728724|into|the|interleukin-2 (l_dep) interleukin-2_8\NN\1740|murine|mil-2
T18_T31 NONE 5tfi_0\NN\1740| (r_nsubjpass) introduced_3\VBN\831651|5tfi|was|successfully|cytokine|positions|. (l_nmod) cytokine_6\NN\14728724|into|the|interleukin-2 (l_dep) interleukin-2_8\NN\1740|murine|mil-2 (l_appos) mil-2_10\NN\1740|(|)
T20_T29 NONE isoleucine_15\NN\14605787| (r_compound) positions_16\NNS\8620061|at|the|encoded|isoleucine (r_nmod) introduced_3\VBN\831651|5tfi|was|successfully|cytokine|positions|. (l_nmod) cytokine_6\NN\14728724|into|the|interleukin-2
T20_T30 NONE isoleucine_15\NN\14605787| (r_compound) positions_16\NNS\8620061|at|the|encoded|isoleucine (r_nmod) introduced_3\VBN\831651|5tfi|was|successfully|cytokine|positions|. (l_nmod) cytokine_6\NN\14728724|into|the|interleukin-2 (l_dep) interleukin-2_8\NN\1740|murine|mil-2
T20_T31 NONE isoleucine_15\NN\14605787| (r_compound) positions_16\NNS\8620061|at|the|encoded|isoleucine (r_nmod) introduced_3\VBN\831651|5tfi|was|successfully|cytokine|positions|. (l_nmod) cytokine_6\NN\14728724|into|the|interleukin-2 (l_dep) interleukin-2_8\NN\1740|murine|mil-2 (l_appos) mil-2_10\NN\1740|(|)
T2_T24 NONE 3tfi_0\NN\1740| (r_nsubj) yielded_1\VBD\2327200|3tfi|evidence|. (l_dobj) evidence_3\NN\5816287|no|incorporation|,|and|evidence (l_conj) evidence_14\NN\5816287|no|activation (l_nmod) activation_16\NN\13561719|for|ilers|vitro (l_nmod) ilers_18\NNS\1740|by
23327668
1881457
T1_T26 NONE n2-acetylphenelzine_0\NN\1740| (r_nsubj) inhibitor_5\NN\20090|n2-acetylphenelzine|is|a|potent|oxidase-a|and|causes|. (l_nmod) oxidase-a_8\NN\1740|of|monoamine|and|-b (l_conj) -b_10\NN\1740|
T2_T26 NONE monoamine_7\NN\14739004| (r_compound) oxidase-a_8\NN\1740|of|monoamine|and|-b (l_conj) -b_10\NN\1740|
T3_T26 NONE noradrenaline_18\NN\14807929|of|and|5-hydroxytryptamine (r_nmod) levels_16\NNS\4916342|in|whole-brain|noradrenaline (r_nmod) increases_13\NNS\13576355|levels|,|and|decreases (r_dobj) causes_12\VBZ\1617192|increases|administration (r_conj) inhibitor_5\NN\20090|n2-acetylphenelzine|is|a|potent|oxidase-a|and|causes|. (l_nmod) oxidase-a_8\NN\1740|of|monoamine|and|-b (l_conj) -b_10\NN\1740|
T4_T26 NONE 5-hydroxytryptamine_20\NN\14807737| (r_conj) noradrenaline_18\NN\14807929|of|and|5-hydroxytryptamine (r_nmod) levels_16\NNS\4916342|in|whole-brain|noradrenaline (r_nmod) increases_13\NNS\13576355|levels|,|and|decreases (r_dobj) causes_12\VBZ\1617192|increases|administration (r_conj) inhibitor_5\NN\20090|n2-acetylphenelzine|is|a|potent|oxidase-a|and|causes|. (l_nmod) oxidase-a_8\NN\1740|of|monoamine|and|-b (l_conj) -b_10\NN\1740|
T5_T26 NONE acid_26\NN\14818238|in|homovanillic|,|acid|,|and|acetic (r_nmod) decreases_23\NNS\7296428|acid (r_conj) increases_13\NNS\13576355|levels|,|and|decreases (r_dobj) causes_12\VBZ\1617192|increases|administration (r_conj) inhibitor_5\NN\20090|n2-acetylphenelzine|is|a|potent|oxidase-a|and|causes|. (l_nmod) oxidase-a_8\NN\1740|of|monoamine|and|-b (l_conj) -b_10\NN\1740|
T6_T26 NONE acid_29\NN\14818238|5-hydroxyindole-3-acetic (r_conj) acid_26\NN\14818238|in|homovanillic|,|acid|,|and|acetic (r_nmod) decreases_23\NNS\7296428|acid (r_conj) increases_13\NNS\13576355|levels|,|and|decreases (r_dobj) causes_12\VBZ\1617192|increases|administration (r_conj) inhibitor_5\NN\20090|n2-acetylphenelzine|is|a|potent|oxidase-a|and|causes|. (l_nmod) oxidase-a_8\NN\1740|of|monoamine|and|-b (l_conj) -b_10\NN\1740|
T8_T26 NONE acetic_33\NN\1740|3,4-dihydroxyphenylacetic (r_conj) acid_26\NN\14818238|in|homovanillic|,|acid|,|and|acetic (r_nmod) decreases_23\NNS\7296428|acid (r_conj) increases_13\NNS\13576355|levels|,|and|decreases (r_dobj) causes_12\VBZ\1617192|increases|administration (r_conj) inhibitor_5\NN\20090|n2-acetylphenelzine|is|a|potent|oxidase-a|and|causes|. (l_nmod) oxidase-a_8\NN\1740|of|monoamine|and|-b (l_conj) -b_10\NN\1740|
T10_T27 NONE monoamine_5\NN\14739004| (r_compound) oxidase_6\NN\14732946|monoamine
T9_T27 CPR:4 phenelzine_0\NN\3783017| (r_nsubj) inhibitor_7\NN\20090|phenelzine|is|a|potent|oxidase (l_compound) oxidase_6\NN\14732946|monoamine
T17_T28 CPR:4 phenelzine_2\NN\3783017|of (r_nmod) acetylation_0\NN\13426948|phenelzine|position (r_nsubj) interferes_8\VBZ\2451370|acetylation|presumably|inhibition|. (l_nmod) inhibition_11\NN\1068773|with|the|enzymes|acid (l_nmod) enzymes_15\NNS\14723628|of|the|transaminase (l_compound) transaminase_14\NN\15077571|
T18_T28 CPR:4 n2_5\NN\1740| (r_compound) position_6\NN\8620061|at|the|n2 (r_nmod) acetylation_0\NN\13426948|phenelzine|position (r_nsubj) interferes_8\VBZ\2451370|acetylation|presumably|inhibition|. (l_nmod) inhibition_11\NN\1068773|with|the|enzymes|acid (l_nmod) enzymes_15\NNS\14723628|of|the|transaminase (l_compound) transaminase_14\NN\15077571|
T20_T28 CPR:4 acid_18\NN\14818238|for|gamma-aminobutyric|and|alanine (r_nmod) inhibition_11\NN\1068773|with|the|enzymes|acid (l_nmod) enzymes_15\NNS\14723628|of|the|transaminase (l_compound) transaminase_14\NN\15077571|
T21_T28 CPR:4 alanine_20\NN\14601829| (r_conj) acid_18\NN\14818238|for|gamma-aminobutyric|and|alanine (r_nmod) inhibition_11\NN\1068773|with|the|enzymes|acid (l_nmod) enzymes_15\NNS\14723628|of|the|transaminase (l_compound) transaminase_14\NN\15077571|
17379925
T11_T26 NONE acid_9\NN\14818238| (r_compound) activity_16\NN\30358|of|bile|acid|coenzyme|n-acyltransferase|liver (l_compound) n-acyltransferase_15\NN\1740|a|:|amino|acid
T12_T26 NONE a_11\NN\13649268| (r_compound) n-acyltransferase_15\NN\1740|a|:|amino|acid
T13_T26 NONE acid_14\NN\14818238| (r_compound) n-acyltransferase_15\NN\1740|a|:|amino|acid
T10_T14 CPR:9 acids_18\NNS\14818238|of|bile (r_nmod) amidation_15\NN\1740|for|the|acids|acids (r_nmod) responsible_12\JJ\1740|n-acyltransferase|is|amidation|. (l_nsubj) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat
T10_T20 CPR:9 acids_18\NNS\14818238|of|bile (r_nmod) amidation_15\NN\1740|for|the|acids|acids (r_nmod) responsible_12\JJ\1740|n-acyltransferase|is|amidation|. (l_nsubj) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat (l_appos) bat_9\NN\1886756|(|)
T1_T14 NONE acid_1\NN\14818238| (r_compound) a_3\NN\13649268|bile|acid|coenzyme (r_compound) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat
T1_T20 NONE acid_1\NN\14818238| (r_compound) a_3\NN\13649268|bile|acid|coenzyme (r_compound) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat (l_appos) bat_9\NN\1886756|(|)
T2_T14 NONE a_3\NN\13649268|bile|acid|coenzyme (r_compound) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat
T2_T20 NONE a_3\NN\13649268|bile|acid|coenzyme (r_compound) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat (l_appos) bat_9\NN\1886756|(|)
T4_T14 NONE acids_22\NNS\14818238|with|the|amino|glycine (r_nmod) amidation_15\NN\1740|for|the|acids|acids (r_nmod) responsible_12\JJ\1740|n-acyltransferase|is|amidation|. (l_nsubj) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat
T4_T20 NONE acids_22\NNS\14818238|with|the|amino|glycine (r_nmod) amidation_15\NN\1740|for|the|acids|acids (r_nmod) responsible_12\JJ\1740|n-acyltransferase|is|amidation|. (l_nsubj) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat (l_appos) bat_9\NN\1886756|(|)
T5_T14 NONE glycine_23\NN\14601829|and|taurine (r_dep) acids_22\NNS\14818238|with|the|amino|glycine (r_nmod) amidation_15\NN\1740|for|the|acids|acids (r_nmod) responsible_12\JJ\1740|n-acyltransferase|is|amidation|. (l_nsubj) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat
T5_T20 NONE glycine_23\NN\14601829|and|taurine (r_dep) acids_22\NNS\14818238|with|the|amino|glycine (r_nmod) amidation_15\NN\1740|for|the|acids|acids (r_nmod) responsible_12\JJ\1740|n-acyltransferase|is|amidation|. (l_nsubj) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat (l_appos) bat_9\NN\1886756|(|)
T6_T14 NONE taurine_25\NN\14818238| (r_conj) glycine_23\NN\14601829|and|taurine (r_dep) acids_22\NNS\14818238|with|the|amino|glycine (r_nmod) amidation_15\NN\1740|for|the|acids|acids (r_nmod) responsible_12\JJ\1740|n-acyltransferase|is|amidation|. (l_nsubj) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat
T6_T20 NONE taurine_25\NN\14818238| (r_conj) glycine_23\NN\14601829|and|taurine (r_dep) acids_22\NNS\14818238|with|the|amino|glycine (r_nmod) amidation_15\NN\1740|for|the|acids|acids (r_nmod) responsible_12\JJ\1740|n-acyltransferase|is|amidation|. (l_nsubj) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat (l_appos) bat_9\NN\1886756|(|)
T7_T14 NONE acid_6\NN\14818238| (r_compound) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat
T7_T20 NONE acid_6\NN\14818238| (r_compound) n-acyltransferase_7\NN\1740|a|:|amino|acid|bat (l_appos) bat_9\NN\1886756|(|)
T8_T24 NONE rosiglitazone_2\NN\1740|with|or|cholestyramine (r_nmod) treatment_0\NN\654885|rosiglitazone (r_nsubj) had_5\VBD\2108377|treatment|effect|activity|. (l_nmod) activity_10\NN\30358|on|bat|compartment (l_compound) bat_9\NN\1886756|
T9_T24 NONE cholestyramine_4\NN\1740| (r_conj) rosiglitazone_2\NN\1740|with|or|cholestyramine (r_nmod) treatment_0\NN\654885|rosiglitazone (r_nsubj) had_5\VBD\2108377|treatment|effect|activity|. (l_nmod) activity_10\NN\30358|on|bat|compartment (l_compound) bat_9\NN\1886756|
T3_T16 NONE clofibrate_7\NN\3740161| (r_compound) treatment_8\NN\654885|clofibrate (r_nsubj) regulate_12\VB\296178|that|treatment|does|not|directly|activity|but|alter (l_dobj) activity_14\NN\30358|bat (l_compound) bat_13\NN\1886756|
T3_T17 NONE clofibrate_7\NN\3740161| (r_compound) treatment_8\NN\654885|clofibrate (r_nsubj) regulate_12\VB\296178|that|treatment|does|not|directly|activity|but|alter (l_conj) alter_17\VB\126264|does|localization (l_dobj) localization_20\NN\151497|the|subcellular|bat (l_nmod) bat_22\NN\1886756|of
11481271
T23_T39 NONE brimonidine_4\NN\1740|by (r_nmod) vasoconstriction_2\NN\1149911|potent|alpha(2a)-adrenoceptor-mediated|brimonidine|arteries|. (l_amod) alpha(2a)-adrenoceptor-mediated_1\JJ\1740|
T16_T29 CPR:5 brimonidine_8\NN\1740|,|apraclonidine|,|and|oxymetazoline (r_dep) agonists_7\NNS\9613191|with|the|alpha(2)-adrenoceptor|brimonidine (l_compound) alpha(2)-adrenoceptor_6\NN\1740|
T17_T29 CPR:5 apraclonidine_10\NN\1740| (r_conj) brimonidine_8\NN\1740|,|apraclonidine|,|and|oxymetazoline (r_dep) agonists_7\NNS\9613191|with|the|alpha(2)-adrenoceptor|brimonidine (l_compound) alpha(2)-adrenoceptor_6\NN\1740|
T18_T29 CPR:5 oxymetazoline_13\NN\1740| (r_conj) brimonidine_8\NN\1740|,|apraclonidine|,|and|oxymetazoline (r_dep) agonists_7\NNS\9613191|with|the|alpha(2)-adrenoceptor|brimonidine (l_compound) alpha(2)-adrenoceptor_6\NN\1740|
T19_T30 NONE brimonidine_27\NN\1740|for (r_nmod) curves_25\NNS\13863771|concentration-response|brimonidine (r_nsubjpass) obtained_29\VBN\2210855|before|curves|were (r_advcl) added_18\VBN\156601|determine|,|antagonists|were|bath|obtained|. (l_advcl) determine_1\VB\1645601|to|mediate (l_ccomp) mediate_7\VBP\761713|subtypes|contraction (l_nsubj) subtypes_3\NNS\1740|which|alpha(2)-adrenoceptor (l_nmod) alpha(2)-adrenoceptor_6\NN\1740|of|the
T19_T31 NONE brimonidine_27\NN\1740|for (r_nmod) curves_25\NNS\13863771|concentration-response|brimonidine (r_nsubjpass) obtained_29\VBN\2210855|before|curves|were (r_advcl) added_18\VBN\156601|determine|,|antagonists|were|bath|obtained|. (l_nsubjpass) antagonists_11\NNS\7846|subselective (l_amod) subselective_12\JJ\1740|alpha(2)-adrenoceptors (l_nmod) alpha(2)-adrenoceptors_16\NNS\1740|for|the|different
T20_T32 NONE brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (r_dobj) applied_5\VBN\2676054|antagonists|were|:|brl44408|. (l_nsubjpass) antagonists_3\NNS\7846|the|following|alpha(2)-adrenoceptor (l_compound) alpha(2)-adrenoceptor_2\NN\1740|
T20_T33 CPR:6 brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_appos) alpha(2a)-selective_9\NN\1740|(|)
T20_T34 NONE brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_conj) arc239_12\NN\1740|alpha(2b)- (l_dep) alpha(2b)-_14\NN\1740|(|and|alpha(2c)-selective|)
T20_T35 NONE brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_conj) arc239_12\NN\1740|alpha(2b)- (l_dep) alpha(2b)-_14\NN\1740|(|and|alpha(2c)-selective|) (l_conj) alpha(2c)-selective_16\JJ\1740|
T20_T36 NONE brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_conj) prazosin_20\NN\2698769|alpha(2b)- (l_dep) alpha(2b)-_22\NN\1740|(|and|alpha(2c)-selective|)
T20_T37 NONE brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_conj) prazosin_20\NN\2698769|alpha(2b)- (l_dep) alpha(2b)-_22\NN\1740|(|and|alpha(2c)-selective|) (l_conj) alpha(2c)-selective_24\JJ\1740|
T21_T32 NONE arc239_12\NN\1740|alpha(2b)- (r_conj) brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (r_dobj) applied_5\VBN\2676054|antagonists|were|:|brl44408|. (l_nsubjpass) antagonists_3\NNS\7846|the|following|alpha(2)-adrenoceptor (l_compound) alpha(2)-adrenoceptor_2\NN\1740|
T21_T33 NONE arc239_12\NN\1740|alpha(2b)- (r_conj) brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_appos) alpha(2a)-selective_9\NN\1740|(|)
T21_T34 CPR:6 arc239_12\NN\1740|alpha(2b)- (l_dep) alpha(2b)-_14\NN\1740|(|and|alpha(2c)-selective|)
T21_T35 CPR:6 arc239_12\NN\1740|alpha(2b)- (l_dep) alpha(2b)-_14\NN\1740|(|and|alpha(2c)-selective|) (l_conj) alpha(2c)-selective_16\JJ\1740|
T21_T36 NONE arc239_12\NN\1740|alpha(2b)- (r_conj) brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_conj) prazosin_20\NN\2698769|alpha(2b)- (l_dep) alpha(2b)-_22\NN\1740|(|and|alpha(2c)-selective|)
T21_T37 NONE arc239_12\NN\1740|alpha(2b)- (r_conj) brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_conj) prazosin_20\NN\2698769|alpha(2b)- (l_dep) alpha(2b)-_22\NN\1740|(|and|alpha(2c)-selective|) (l_conj) alpha(2c)-selective_24\JJ\1740|
T22_T32 NONE prazosin_20\NN\2698769|alpha(2b)- (r_conj) brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (r_dobj) applied_5\VBN\2676054|antagonists|were|:|brl44408|. (l_nsubjpass) antagonists_3\NNS\7846|the|following|alpha(2)-adrenoceptor (l_compound) alpha(2)-adrenoceptor_2\NN\1740|
T22_T33 NONE prazosin_20\NN\2698769|alpha(2b)- (r_conj) brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_appos) alpha(2a)-selective_9\NN\1740|(|)
T22_T34 NONE prazosin_20\NN\2698769|alpha(2b)- (r_conj) brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_conj) arc239_12\NN\1740|alpha(2b)- (l_dep) alpha(2b)-_14\NN\1740|(|and|alpha(2c)-selective|)
T22_T35 NONE prazosin_20\NN\2698769|alpha(2b)- (r_conj) brl44408_7\NN\1740|alpha(2a)-selective|,|arc239|,|and|prazosin (l_conj) arc239_12\NN\1740|alpha(2b)- (l_dep) alpha(2b)-_14\NN\1740|(|and|alpha(2c)-selective|) (l_conj) alpha(2c)-selective_16\JJ\1740|
T22_T36 CPR:6 prazosin_20\NN\2698769|alpha(2b)- (l_dep) alpha(2b)-_22\NN\1740|(|and|alpha(2c)-selective|)
T22_T37 CPR:6 prazosin_20\NN\2698769|alpha(2b)- (l_dep) alpha(2b)-_22\NN\1740|(|and|alpha(2c)-selective|) (l_conj) alpha(2c)-selective_24\JJ\1740|
T1_T38 CPR:5 brimonidine_25\NN\1740|2.11|,|oxymetazoline|,|and|apraclonidine (r_dep) induced_5\VBD\1627355|results|agonists|vasoconstriction|artery|order|:|brimonidine|. (l_nsubj) agonists_4\NNS\9613191|the|alpha(2)-adrenoceptor (l_compound) alpha(2)-adrenoceptor_3\NN\1740|
T2_T38 CPR:5 oxymetazoline_28\NN\1740|5.26 (r_conj) brimonidine_25\NN\1740|2.11|,|oxymetazoline|,|and|apraclonidine (r_dep) induced_5\VBD\1627355|results|agonists|vasoconstriction|artery|order|:|brimonidine|. (l_nsubj) agonists_4\NNS\9613191|the|alpha(2)-adrenoceptor (l_compound) alpha(2)-adrenoceptor_3\NN\1740|
T3_T38 CPR:5 apraclonidine_32\NN\1740|13.0 (r_conj) brimonidine_25\NN\1740|2.11|,|oxymetazoline|,|and|apraclonidine (r_dep) induced_5\VBD\1627355|results|agonists|vasoconstriction|artery|order|:|brimonidine|. (l_nsubj) agonists_4\NNS\9613191|the|alpha(2)-adrenoceptor (l_compound) alpha(2)-adrenoceptor_3\NN\1740|
T10_T24 CPR:6 brl44408_23\NN\1740|for|(|7.8|,|arc|and|prazosin (r_nmod) potencies_17\NNS\5196375|functional|antagonist|pk(b|brl44408 (r_conj) slopes_11\NNS\9287968|with|unity|and|potencies (r_nmod) lines_9\NNS\8426461|regression|slopes (r_dobj) yielded_7\VBD\2327200|analyses|lines|suggesting|. (l_advcl) suggesting_39\VBG\1010118|presence (l_dobj) presence_41\NN\13954253|the|alpha(2a)-adrenoceptors (l_nmod) alpha(2a)-adrenoceptors_44\NNS\1740|of|functional
T11_T24 CPR:6 239_29\CD\1740| (r_nummod) arc_28\NN\11512650|239|(|5.8 (r_appos) brl44408_23\NN\1740|for|(|7.8|,|arc|and|prazosin (r_nmod) potencies_17\NNS\5196375|functional|antagonist|pk(b|brl44408 (r_conj) slopes_11\NNS\9287968|with|unity|and|potencies (r_nmod) lines_9\NNS\8426461|regression|slopes (r_dobj) yielded_7\VBD\2327200|analyses|lines|suggesting|. (l_advcl) suggesting_39\VBG\1010118|presence (l_dobj) presence_41\NN\13954253|the|alpha(2a)-adrenoceptors (l_nmod) alpha(2a)-adrenoceptors_44\NNS\1740|of|functional
T12_T24 CPR:6 prazosin_35\NN\2698769|for|6.0 (r_conj) brl44408_23\NN\1740|for|(|7.8|,|arc|and|prazosin (r_nmod) potencies_17\NNS\5196375|functional|antagonist|pk(b|brl44408 (r_conj) slopes_11\NNS\9287968|with|unity|and|potencies (r_nmod) lines_9\NNS\8426461|regression|slopes (r_dobj) yielded_7\VBD\2327200|analyses|lines|suggesting|. (l_advcl) suggesting_39\VBG\1010118|presence (l_dobj) presence_41\NN\13954253|the|alpha(2a)-adrenoceptors (l_nmod) alpha(2a)-adrenoceptors_44\NNS\1740|of|functional
T9_T24 NONE brimonidine_6\NN\1740|against (r_nmod) antagonists_4\NNS\7846|for|the|brimonidine (r_nmod) analyses_1\NNS\633864|schild|antagonists (r_nsubj) yielded_7\VBD\2327200|analyses|lines|suggesting|. (l_advcl) suggesting_39\VBG\1010118|presence (l_dobj) presence_41\NN\13954253|the|alpha(2a)-adrenoceptors (l_nmod) alpha(2a)-adrenoceptors_44\NNS\1740|of|functional
T13_T26 CPR:5 brimonidine_5\NN\1740|,|apraclonidine|,|and|oxymetazoline (r_dep) agonists_4\NNS\9613191|the|alpha(2)-adrenoceptor|brimonidine (l_amod) alpha(2)-adrenoceptor_3\NN\1740|
T14_T26 CPR:5 apraclonidine_7\NN\1740| (r_conj) brimonidine_5\NN\1740|,|apraclonidine|,|and|oxymetazoline (r_dep) agonists_4\NNS\9613191|the|alpha(2)-adrenoceptor|brimonidine (l_amod) alpha(2)-adrenoceptor_3\NN\1740|
T15_T26 CPR:5 oxymetazoline_10\NN\1740| (r_conj) brimonidine_5\NN\1740|,|apraclonidine|,|and|oxymetazoline (r_dep) agonists_4\NNS\9613191|the|alpha(2)-adrenoceptor|brimonidine (l_amod) alpha(2)-adrenoceptor_3\NN\1740|
12588370
T3_T12 CPR:4 celecoxib_17\NN\3124700| (r_appos) inhibitor_15\NN\20090|of|the|selective|cox-2|,|celecoxib (l_compound) cox-2_14\NN\14737847|
T3_T13 NONE celecoxib_17\NN\3124700| (r_appos) inhibitor_15\NN\20090|of|the|selective|cox-2|,|celecoxib (r_nmod) use_10\NN\407535|the|widespread|inhibitor (r_conj) effects_6\NNS\13245626|because|these|physiological|and|use (r_nmod) wanted_20\VBD\2604760|effects|,|we|determine|. (l_xcomp) determine_22\VB\1645601|to|affect (l_ccomp) affect_28\VB\126264|if|inhibition|would|healing (l_nsubj) inhibition_24\NN\1068773|cox-2 (l_nmod) cox-2_26\NN\14737847|of
T4_T15 NONE diclofenac_38\NN\1740| (r_appos) inhibitor_36\NN\20090|of|a|nonselective|cox|,|diclofenac|, (r_nmod) effects_31\NNS\13245626|the|inhibitor (r_dobj) comparing_29\VBG\644583|by|effects|inhibitor (r_advcl) evaluated_18\VBD\670261|methods|using|,|we|role|comparing|. (l_dobj) role_20\NN\719494|the|cox-2|process (l_nmod) cox-2_22\NN\14737847|of
T4_T16 CPR:4 diclofenac_38\NN\1740| (r_appos) inhibitor_36\NN\20090|of|a|nonselective|cox|,|diclofenac|, (l_compound) cox_35\NN\14732946|
T4_T17 NONE diclofenac_38\NN\1740| (r_appos) inhibitor_36\NN\20090|of|a|nonselective|cox|,|diclofenac|, (r_nmod) effects_31\NNS\13245626|the|inhibitor (r_dobj) comparing_29\VBG\644583|by|effects|inhibitor (l_nmod) inhibitor_44\NN\20090|with|a|selective|cox-2|,|sc-791 (l_compound) cox-2_43\NN\14737847|
T1_T6 NONE dexamethasone_23\NN\2721538| (r_compound) treatment_24\NN\654885|dexamethasone (r_nsubj) resulted_25\VBD\2633881|whereas|treatment|atrophy (r_advcl) had_8\VBD\2108377|cox-2|effect|morphology|,|resulted|. (l_nsubj) cox-2_2\NN\14737847|neither|selective|,|nor|inhibition
T1_T7 NONE dexamethasone_23\NN\2721538| (r_compound) treatment_24\NN\654885|dexamethasone (r_nsubj) resulted_25\VBD\2633881|whereas|treatment|atrophy (r_advcl) had_8\VBD\2108377|cox-2|effect|morphology|,|resulted|. (l_nsubj) cox-2_2\NN\14737847|neither|selective|,|nor|inhibition (l_conj) inhibition_7\NN\1068773|nonselective|cox (l_compound) cox_6\NN\14732946|
T2_T8 NONE dexamethasone_28\NN\2721538| (r_nsubj) reduced_29\VBD\441445|whereas|dexamethasone|strength|%|period (r_advcl) altered_11\VBD\126264|addition|,|cox-2|keratinocyte|,|reduced|. (l_nsubj) cox-2_5\NN\14737847|neither|selective|,|nor|inhibition
T2_T9 NONE dexamethasone_28\NN\2721538| (r_nsubj) reduced_29\VBD\441445|whereas|dexamethasone|strength|%|period (r_advcl) altered_11\VBD\126264|addition|,|cox-2|keratinocyte|,|reduced|. (l_nsubj) cox-2_5\NN\14737847|neither|selective|,|nor|inhibition (l_conj) inhibition_10\NN\1068773|nonselective|cox (l_compound) cox_9\NN\14732946|
23102509
T10_T26 NONE glucose_10\NN\14710501|plasma|,|hemoglobin (l_conj) hemoglobin_13\NN\14888884|glycosylated
T10_T27 NONE glucose_10\NN\14710501|plasma|,|hemoglobin (r_nmod) increased_7\VBN\169651|significant|glucose|and|decreased (l_conj) decreased_19\VBD\169651|significant|insulin (l_nmod) insulin_22\NN\5407119|in|circulating|and|hemoglobin
T10_T28 NONE glucose_10\NN\14710501|plasma|,|hemoglobin (r_nmod) increased_7\VBN\169651|significant|glucose|and|decreased (l_conj) decreased_19\VBD\169651|significant|insulin (l_nmod) insulin_22\NN\5407119|in|circulating|and|hemoglobin (l_conj) hemoglobin_24\NN\14888884|
T11_T21 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_appos) ast_49\NN\1740|(|)
T11_T22 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt
T11_T23 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt (l_appos) alt_55\NN\13836371|(|)
T11_T24 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp
T11_T25 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp (l_appos) alp_61\NN\9359803|(|)
T11_T29 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism
T11_T30 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (l_conj) fructose-1,6-bisphosphatase_10\NN\1740|
T11_T31 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content
T11_T32 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) kinase_23\NN\14732946|pyruvate
T11_T33 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) dehydrogenase_26\NN\1740|glucose-6-phosphate
T11_T34 NONE glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase
T12_T21 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_appos) ast_49\NN\1740|(|)
T12_T22 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt
T12_T23 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt (l_appos) alt_55\NN\13836371|(|)
T12_T24 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp
T12_T25 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp (l_appos) alp_61\NN\9359803|(|)
T12_T29 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism
T12_T30 NONE fructose-1,6-bisphosphatase_10\NN\1740|
T12_T31 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content
T12_T32 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) kinase_23\NN\14732946|pyruvate
T12_T33 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) dehydrogenase_26\NN\1740|glucose-6-phosphate
T12_T34 NONE fructose-1,6-bisphosphatase_10\NN\1740| (r_conj) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase
T13_T21 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_appos) ast_49\NN\1740|(|)
T13_T22 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt
T13_T23 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt (l_appos) alt_55\NN\13836371|(|)
T13_T24 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp
T13_T25 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp (l_appos) alp_61\NN\9359803|(|)
T13_T29 CPR:9 carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism
T13_T30 CPR:9 carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (l_conj) fructose-1,6-bisphosphatase_10\NN\1740|
T13_T31 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content
T13_T32 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) kinase_23\NN\14732946|pyruvate
T13_T33 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) dehydrogenase_26\NN\1740|glucose-6-phosphate
T13_T34 NONE carbohydrate_12\NN\14944888| (r_compound) metabolism_13\NN\13526110|of|carbohydrate (r_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (r_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (r_nmod) activities_2\NNS\30358|the|altered|enzymes (r_nsubj) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase
T14_T21 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_appos) ast_49\NN\1740|(|)
T14_T22 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt
T14_T23 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt (l_appos) alt_55\NN\13836371|(|)
T14_T24 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp
T14_T25 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp (l_appos) alp_61\NN\9359803|(|)
T14_T29 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nsubj) activities_2\NNS\30358|the|altered|enzymes (l_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (l_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism
T14_T30 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nsubj) activities_2\NNS\30358|the|altered|enzymes (l_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (l_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (l_conj) fructose-1,6-bisphosphatase_10\NN\1740|
T14_T31 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content
T14_T32 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate
T14_T33 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) dehydrogenase_26\NN\1740|glucose-6-phosphate
T14_T34 NONE pyruvate_22\NN\1740| (r_compound) kinase_23\NN\14732946|pyruvate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase
T15_T21 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_appos) ast_49\NN\1740|(|)
T15_T22 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt
T15_T23 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt (l_appos) alt_55\NN\13836371|(|)
T15_T24 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp
T15_T25 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp (l_appos) alp_61\NN\9359803|(|)
T15_T29 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nsubj) activities_2\NNS\30358|the|altered|enzymes (l_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (l_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism
T15_T30 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nsubj) activities_2\NNS\30358|the|altered|enzymes (l_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (l_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (l_conj) fructose-1,6-bisphosphatase_10\NN\1740|
T15_T31 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content
T15_T32 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) kinase_23\NN\14732946|pyruvate
T15_T33 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate
T15_T34 NONE glucose-6-phosphate_25\NN\1740| (r_compound) dehydrogenase_26\NN\1740|glucose-6-phosphate (r_conj) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (r_nmod) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_dep) decreased_34\VBD\169651|significantly|liver|and|increased (l_conj) increased_43\VBD\169651|also|activities (l_dobj) activities_44\NNS\30358|transaminase (l_nmod) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase
T16_T21 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_appos) ast_49\NN\1740|(|)
T16_T22 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt
T16_T23 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) transaminase_53\NN\15077571|alanine|alt (l_appos) alt_55\NN\13836371|(|)
T16_T24 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp
T16_T25 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp (l_appos) alp_61\NN\9359803|(|)
T16_T29 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nsubj) activities_2\NNS\30358|the|altered|enzymes (l_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (l_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism
T16_T30 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nsubj) activities_2\NNS\30358|the|altered|enzymes (l_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (l_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (l_conj) fructose-1,6-bisphosphatase_10\NN\1740|
T16_T31 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content
T16_T32 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) kinase_23\NN\14732946|pyruvate
T16_T33 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) dehydrogenase_26\NN\1740|glucose-6-phosphate
T16_T34 NONE aspartate_46\NN\1740| (r_compound) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase
T2_T21 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_appos) ast_49\NN\1740|(|)
T2_T22 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt
T2_T23 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (l_appos) alt_55\NN\13836371|(|)
T2_T24 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp
T2_T25 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (l_conj) phosphatase_59\NN\14732946|alkaline|alp (l_appos) alp_61\NN\9359803|(|)
T2_T29 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nsubj) activities_2\NNS\30358|the|altered|enzymes (l_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (l_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism
T2_T30 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nsubj) activities_2\NNS\30358|the|altered|enzymes (l_nmod) enzymes_5\NNS\14723628|of|key|glucose-6-phosphatase (l_nmod) glucose-6-phosphatase_8\NN\1740|such|and|fructose-1,6-bisphosphatase|metabolism (l_conj) fructose-1,6-bisphosphatase_10\NN\1740|
T2_T31 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content
T2_T32 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) kinase_23\NN\14732946|pyruvate
T2_T33 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase (r_nmod) activities_44\NNS\30358|transaminase (r_dobj) increased_43\VBD\169651|also|activities (r_conj) decreased_34\VBD\169651|significantly|liver|and|increased (r_dep) increased_18\VBD\169651|activities|significantly|whereas|hexokinase|decreased|. (l_nmod) hexokinase_20\NN\1740|,|kinase|,|dehydrogenase|and|content (l_conj) dehydrogenase_26\NN\1740|glucose-6-phosphate
T2_T34 NONE alanine_52\NN\14601829| (r_compound) transaminase_53\NN\15077571|alanine|alt (r_conj) transaminase_47\NN\15077571|of|aspartate|ast|,|transaminase|and|phosphatase
23085436
T3_T13 NONE ldl-cholesterol_34\NN\1740| (r_conj) insulin_32\NN\5407119|circulating|and|ldl-cholesterol|< (r_conj) intake_16\NN\13440063|energy|p|weight|<|insulin (r_dobj) reduced_14\VBD\441445|injection|intake|and|improved|. (l_nsubj) injection_2\NN\320852|daily|(pglu-gln)-cck-8|mice (l_nmod) (pglu-gln)-cck-8_4\NN\1740|of
T3_T14 NONE ldl-cholesterol_34\NN\1740| (r_conj) insulin_32\NN\5407119|circulating|and|ldl-cholesterol|<
T3_T15 NONE ldl-cholesterol_34\NN\1740|
T3_T16 NONE ldl-cholesterol_34\NN\1740| (r_conj) insulin_32\NN\5407119|circulating|and|ldl-cholesterol|< (r_conj) intake_16\NN\13440063|energy|p|weight|<|insulin (r_dobj) reduced_14\VBD\441445|injection|intake|and|improved|. (l_conj) improved_41\VBD\126264|sensitivity (l_dobj) sensitivity_43\NN\5651971|insulin|<|as|tolerance (l_compound) insulin_42\NN\5407119|
T4_T13 NONE glucose_60\NN\14710501| (r_compound) tolerance_61\NN\5032565|oral|glucose (r_conj) sensitivity_43\NN\5651971|insulin|<|as|tolerance (r_dobj) improved_41\VBD\126264|sensitivity (r_conj) reduced_14\VBD\441445|injection|intake|and|improved|. (l_nsubj) injection_2\NN\320852|daily|(pglu-gln)-cck-8|mice (l_nmod) (pglu-gln)-cck-8_4\NN\1740|of
T4_T14 NONE glucose_60\NN\14710501| (r_compound) tolerance_61\NN\5032565|oral|glucose (r_conj) sensitivity_43\NN\5651971|insulin|<|as|tolerance (r_dobj) improved_41\VBD\126264|sensitivity (r_conj) reduced_14\VBD\441445|injection|intake|and|improved|. (l_dobj) intake_16\NN\13440063|energy|p|weight|<|insulin (l_conj) insulin_32\NN\5407119|circulating|and|ldl-cholesterol|<
T4_T15 NONE glucose_60\NN\14710501| (r_compound) tolerance_61\NN\5032565|oral|glucose (r_conj) sensitivity_43\NN\5651971|insulin|<|as|tolerance (r_dobj) improved_41\VBD\126264|sensitivity (r_conj) reduced_14\VBD\441445|injection|intake|and|improved|. (l_dobj) intake_16\NN\13440063|energy|p|weight|<|insulin (l_conj) insulin_32\NN\5407119|circulating|and|ldl-cholesterol|< (l_conj) ldl-cholesterol_34\NN\1740|
T4_T16 NONE glucose_60\NN\14710501| (r_compound) tolerance_61\NN\5032565|oral|glucose (r_conj) sensitivity_43\NN\5651971|insulin|<|as|tolerance (l_compound) insulin_42\NN\5407119|
T5_T18 NONE glucose_9\NN\14710501| (r_compound) tolerance_10\NN\5032565|glucose (r_conj) intake_1\NN\13440063|energy|,|weight|,|insulin|and|tolerance|mice (l_conj) insulin_7\NN\5407119|circulating
T5_T19 NONE glucose_9\NN\14710501| (r_compound) tolerance_10\NN\5032565|glucose (r_conj) intake_1\NN\13440063|energy|,|weight|,|insulin|and|tolerance|mice (l_nmod) mice_13\NNS\2329401|of|(pglu-gln)-cck-8 (l_compound) (pglu-gln)-cck-8_12\NN\1740|
T6_T20 NONE triacylglycerol_12\NN\1740| (r_compound) accumulation_13\NN\13497135|on|triacylglycerol|liver (r_nmod) effect_6\NN\34213|the|feeding|accumulation (r_dobj) prevented_4\VBD\1740|addition|,|(pglu-gln)-cck-8|effect|. (l_nsubj) (pglu-gln)-cck-8_3\NN\1740|
T1_T10 NONE glucose_42\NN\14710501|<|circulating|p|and|insulin (l_conj) insulin_53\NN\5407119|p
T1_T11 NONE glucose_42\NN\14710501|<|circulating|p|and|insulin (r_conj) intake_22\NN\13440063|including|reduced|energy|p|,|weight|glucose|and|tolerance (l_conj) tolerance_66\NN\5032565|improved|glucose|p|and|sensitivity (l_conj) sensitivity_74\NN\5651971|insulin|< (l_compound) insulin_73\NN\5407119|
T1_T9 NONE glucose_42\NN\14710501|<|circulating|p|and|insulin (r_conj) intake_22\NN\13440063|including|reduced|energy|p|,|weight|glucose|and|tolerance (r_nmod) observed_4\VBN\2163746|effects|were|similarly|mice|,|intake|. (l_nmod) mice_8\NNS\2329401|in|ob/ob|treated (l_acl) treated_9\VBN\2376958|daily|(pglu-gln)-cck-8|days (l_nmod) (pglu-gln)-cck-8_13\NN\1740|with
T2_T10 NONE glucose_65\NN\14710501| (r_compound) tolerance_66\NN\5032565|improved|glucose|p|and|sensitivity (r_conj) intake_22\NN\13440063|including|reduced|energy|p|,|weight|glucose|and|tolerance (l_conj) glucose_42\NN\14710501|<|circulating|p|and|insulin (l_conj) insulin_53\NN\5407119|p
T2_T11 NONE glucose_65\NN\14710501| (r_compound) tolerance_66\NN\5032565|improved|glucose|p|and|sensitivity (l_conj) sensitivity_74\NN\5651971|insulin|< (l_compound) insulin_73\NN\5407119|
T2_T9 NONE glucose_65\NN\14710501| (r_compound) tolerance_66\NN\5032565|improved|glucose|p|and|sensitivity (r_conj) intake_22\NN\13440063|including|reduced|energy|p|,|weight|glucose|and|tolerance (r_nmod) observed_4\VBN\2163746|effects|were|similarly|mice|,|intake|. (l_nmod) mice_8\NNS\2329401|in|ob/ob|treated (l_acl) treated_9\VBN\2376958|daily|(pglu-gln)-cck-8|days (l_nmod) (pglu-gln)-cck-8_13\NN\1740|with
23556445
T2_T13 NONE hydroxyurea_13\NN\1740| (r_compound) efficacy_15\NN\5199286|hydroxyurea|treatment (r_conj) severity_11\NN\5036394|with|β-thalassemia|disease|and|efficacy (r_nmod) associated_7\VBN\628491|variation|is|severity|. (l_nsubjpass) variation_1\NN\7296428|genomic|gene (l_nmod) gene_5\NN\8459252|in|the|map3k5 (l_compound) map3k5_4\NN\1740|
T1_T10 NONE hydroxyurea_41\NN\1740|hu (r_compound) treatment_45\NN\654885|to|hydroxyurea (r_nmod) response_39\NN\11410625|with|treatment (r_nmod) association_34\NN\8008335|the|variants|response (r_conj) association_8\NN\8008335|the|variations|,|as|association (l_nmod) variations_11\NNS\7296428|between|genetic|map3k5|,|residing|,|and|severity (l_nmod) map3k5_13\NN\1740|in|and|genes (l_conj) genes_16\NNS\8459252|pde7b (l_compound) pde7b_15\NN\1740|
T1_T9 NONE hydroxyurea_41\NN\1740|hu (r_compound) treatment_45\NN\654885|to|hydroxyurea (r_nmod) response_39\NN\11410625|with|treatment (r_nmod) association_34\NN\8008335|the|variants|response (r_conj) association_8\NN\8008335|the|variations|,|as|association (l_nmod) variations_11\NNS\7296428|between|genetic|map3k5|,|residing|,|and|severity (l_nmod) map3k5_13\NN\1740|in|and|genes
20496522
T5_T7 NONE etomidate_7\NN\1740|of (r_nmod) profile_5\NN\6999802|mediated|hemodynamic|etomidate|. (l_amod) mediated_3\JJ\1740|receptor (l_nmod:npmod) receptor_2\NN\5225602|alpha-2b|adrenergic
23403537
23382379
T6_T16 NONE n-terminal_8\JJ\1740| (r_amod) domain_10\NN\13934596|an|n-terminal|pdz (r_dobj) has_6\VBZ\2108377|isoform|,|additionally|,|domain|. (l_nsubj) isoform_2\NN\1740|the|myosin-18aα (l_compound) myosin-18aα_1\NN\1740|
T6_T17 NONE n-terminal_8\JJ\1740| (r_amod) domain_10\NN\13934596|an|n-terminal|pdz
T1_T21 NONE nucleotide_7\NN\14850483|of (r_nmod) presence_5\NN\13954253|by|nucleotide (r_nmod) unchanged_3\JJ\1740|binding|was|presence|. (l_nsubj) binding_1\NN\4688246|actin (l_compound) actin_0\NN\14736972|
T2_T7 NONE n-methylanthraniloyl-nucleotides_4\NNS\1740| (r_dobj) bound_3\VBD\1831531|isoforms|n-methylanthraniloyl-nucleotides|,|but|slow (l_nsubj) isoforms_2\NNS\1740|both|myosin-18a (l_compound) myosin-18a_1\NN\1740|
T2_T8 NONE n-methylanthraniloyl-nucleotides_4\NNS\1740| (r_dobj) bound_3\VBD\1831531|isoforms|n-methylanthraniloyl-nucleotides|,|but|slow (l_conj) slow_14\JJ\1740|rate|was|very|s(-1|)|and|enhanced|. (l_conj) enhanced_24\VBN\227165|not|significantly|actin (l_nmod) actin_26\NN\14736972|by
T3_T7 NONE atp_10\NN\14964590| (r_compound) hydrolysis_11\NN\13447361|of|atp (r_nmod) rate_8\NN\13815152|the|hydrolysis (r_nsubj) slow_14\JJ\1740|rate|was|very|s(-1|)|and|enhanced|. (r_conj) bound_3\VBD\1831531|isoforms|n-methylanthraniloyl-nucleotides|,|but|slow (l_nsubj) isoforms_2\NNS\1740|both|myosin-18a (l_compound) myosin-18a_1\NN\1740|
T3_T8 NONE atp_10\NN\14964590| (r_compound) hydrolysis_11\NN\13447361|of|atp (r_nmod) rate_8\NN\13815152|the|hydrolysis (r_nsubj) slow_14\JJ\1740|rate|was|very|s(-1|)|and|enhanced|. (l_conj) enhanced_24\VBN\227165|not|significantly|actin (l_nmod) actin_26\NN\14736972|by
T4_T9 NONE atp_10\NN\14964590| (r_compound) hydrolysis_11\NN\13447361|on|atp (r_nmod) had_6\VBD\2108377|phosphorylation|effect|hydrolysis|,|and|did (l_conj) did_15\VBD\1640855|neither|addition|. (l_nsubj) addition_17\NN\3081021|the|tropomyosin (l_nmod) tropomyosin_19\NN\1740|of|or|golph3 (l_conj) golph3_22\NN\1740|of|,|partner (l_appos) partner_27\NN\10024362|a|myosin-18a|binding (l_compound) myosin-18a_25\NN\1740|
T5_T10 NONE atp_32\NN\14964590|of (r_nmod) presence_30\NN\13954253|of|the|atp (r_nmod) regardless_27\RB\1740|presence (r_advmod) conformation_26\NN\13897996|a|pre-power|stroke|regardless (r_dobj) suggesting_22\VBG\1010118|conformation (r_advcl) angled_10\VBN\1835496|that|lever|is|strongly|respect|,|suggesting (r_ccomp) showed_4\VBD\2137132|microscopy|angled|. (l_nsubj) microscopy_1\NN\636921|electron|myosin-18a-s1 (l_nmod) myosin-18a-s1_3\NN\1740|of
11392054
T24_T25 CPR:9 co2_16\NN\14836127|of (r_nmod) reaction_14\NN\13446390|the|reversible|hydration|co2 (r_dobj) catalyses_10\VBZ\146138|that|reaction|and|plays (r_acl:relcl) enzyme_8\NN\14723628|anhydrase|is|a|zinc|catalyses|. (l_nsubj) anhydrase_1\NN\1740|carbonic|ca
T24_T31 CPR:9 co2_16\NN\14836127|of (r_nmod) reaction_14\NN\13446390|the|reversible|hydration|co2 (r_dobj) catalyses_10\VBZ\146138|that|reaction|and|plays (r_acl:relcl) enzyme_8\NN\14723628|anhydrase|is|a|zinc|catalyses|. (l_nsubj) anhydrase_1\NN\1740|carbonic|ca (l_appos) ca_3\NN\14625458|(|)
T6_T25 NONE zinc_7\NN\14625458| (r_compound) enzyme_8\NN\14723628|anhydrase|is|a|zinc|catalyses|. (l_nsubj) anhydrase_1\NN\1740|carbonic|ca
T6_T31 NONE zinc_7\NN\14625458| (r_compound) enzyme_8\NN\14723628|anhydrase|is|a|zinc|catalyses|. (l_nsubj) anhydrase_1\NN\1740|carbonic|ca (l_appos) ca_3\NN\14625458|(|)
T10_T35 NONE b4_17\NN\1740|leukotriene (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T10_T36 NONE b4_17\NN\1740|leukotriene (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T10_T37 NONE b4_17\NN\1740|leukotriene (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T10_T38 NONE b4_17\NN\1740|leukotriene (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T11_T35 NONE ii_20\CD\13741022|
T11_T36 NONE ii_20\CD\13741022| (r_nummod) angiotensin_19\NN\4522421|ii (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T11_T37 NONE ii_20\CD\13741022| (r_nummod) angiotensin_19\NN\4522421|ii (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T11_T38 NONE ii_20\CD\13741022| (r_nummod) angiotensin_19\NN\4522421|ii (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T12_T35 NONE vasopressin_22\NN\5407119| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T12_T36 NONE vasopressin_22\NN\5407119|
T12_T37 NONE vasopressin_22\NN\5407119| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T12_T38 NONE vasopressin_22\NN\5407119| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T13_T35 NONE indomethacin_24\NN\3828465| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T13_T36 NONE indomethacin_24\NN\3828465| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T13_T37 NONE indomethacin_24\NN\3828465| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T13_T38 NONE indomethacin_24\NN\3828465| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T14_T35 NONE prazosin_26\NN\2698769| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T14_T36 NONE prazosin_26\NN\2698769| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T14_T37 NONE prazosin_26\NN\2698769| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T14_T38 NONE prazosin_26\NN\2698769| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T15_T35 NONE hydralazine_28\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T15_T36 NONE hydralazine_28\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T15_T37 NONE hydralazine_28\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T15_T38 NONE hydralazine_28\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T16_T35 NONE clonidine_30\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T16_T36 NONE clonidine_30\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T16_T37 NONE clonidine_30\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T16_T38 NONE clonidine_30\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T17_T35 NONE reserpine_32\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T17_T36 NONE reserpine_32\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T17_T37 NONE reserpine_32\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T17_T38 NONE reserpine_32\NN\2721160| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T18_T35 NONE i2_35\NN\1740|prostaglandin (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T18_T36 NONE i2_35\NN\1740|prostaglandin (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T18_T37 NONE i2_35\NN\1740|prostaglandin (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T18_T38 NONE i2_35\NN\1740|prostaglandin (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T19_T35 NONE indapamide_37\NN\3214670| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T19_T36 NONE indapamide_37\NN\3214670| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T19_T37 NONE indapamide_37\NN\3214670| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T19_T38 NONE indapamide_37\NN\3214670| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T20_T35 NONE furosemide_39\NN\3214670| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T20_T36 NONE furosemide_39\NN\3214670| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T20_T37 NONE furosemide_39\NN\3214670| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T20_T38 NONE furosemide_39\NN\3214670| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T21_T35 NONE amlodipine_41\NN\1740| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T21_T36 NONE amlodipine_41\NN\1740| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T21_T37 NONE amlodipine_41\NN\1740| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T21_T38 NONE amlodipine_41\NN\1740| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T22_T35 NONE verapamil_43\NN\2938514| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T22_T36 NONE verapamil_43\NN\2938514| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T22_T37 NONE verapamil_43\NN\2938514| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T22_T38 NONE verapamil_43\NN\2938514| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T23_T35 NONE irbesartan_45\NN\1740| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T23_T36 NONE irbesartan_45\NN\1740| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T23_T37 NONE irbesartan_45\NN\1740| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T23_T38 NONE irbesartan_45\NN\1740| (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T7_T35 NONE noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T7_T36 NONE noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T7_T37 NONE noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T7_T38 NONE noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T8_T35 NONE alpha_11\NN\6828818|prostaglandin|f2 (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T8_T36 NONE alpha_11\NN\6828818|prostaglandin|f2 (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T8_T37 NONE alpha_11\NN\6828818|prostaglandin|f2 (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T8_T38 NONE alpha_11\NN\6828818|prostaglandin|f2 (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
T9_T35 NONE a2_14\NN\1740|thromboxane (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) angiotensin_19\NN\4522421|ii (l_nummod) ii_20\CD\13741022|
T9_T36 NONE a2_14\NN\1740|thromboxane (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (l_conj) vasopressin_22\NN\5407119|
T9_T37 NONE a2_14\NN\1740|thromboxane (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca
T9_T38 NONE a2_14\NN\1740|thromboxane (r_conj) noradrenaline_7\NN\14807929|of|,|alpha|,|a2|,|b4|,|angiotensin|,|vasopressin|,|indomethacin|,|prazosin|,|hydralazine|,|clonidine|,|reserpine|,|i2|,|indapamide|,|furosemide|,|amlodipine|,|verapamil|and|irbesartan (r_nmod) effects_5\NNS\13245626|the|in|noradrenaline|i (l_nmod) i_53\NN\14622893|on|purified|ca|and|ca (l_conj) ca_58\NN\14625458|vascular|smooth|muscle|i|isolated (l_nummod) i_59\NN\14622893|
23220614
T23_T49 NONE isoorientin_8\NN\1740|by (r_nmod) induced_6\VBN\1627355|isoorientin|cells (r_acl) apoptosis_5\NN\11486178|mitochondrial-mediated|induced (r_dobj) regulate_3\VBP\296178|pathways|apoptosis|. (l_nsubj) pathways_2\NNS\5483677|mapk|signaling (l_compound) mapk_0\NN\1740|
T13_T35 CPR:4 iso_0\NN\1740| (r_nsubj) able_2\JJ\1740|iso|is|induce|,|however|remain|. (l_xcomp) induce_4\VB\1627355|to|apoptosis|dysfunction (l_nmod) dysfunction_8\NN\14204950|through|mitochondrial|and|inhibition|cells (l_conj) inhibition_10\NN\1068773|pathway (l_nmod) pathway_14\NN\5483677|of|pi3k/akt|signaling (l_compound) pi3k/akt_12\NN\1740|
T13_T36 CPR:4 iso_0\NN\1740| (r_nsubj) able_2\JJ\1740|iso|is|induce|,|however|remain|. (l_xcomp) induce_4\VB\1627355|to|apoptosis|dysfunction (l_nmod) dysfunction_8\NN\14204950|through|mitochondrial|and|inhibition|cells (l_conj) inhibition_10\NN\1068773|pathway (l_nmod) pathway_14\NN\5483677|of|pi3k/akt|signaling (l_compound) pi3k/akt_12\NN\1740|
T13_T37 NONE iso_0\NN\1740| (r_nsubj) able_2\JJ\1740|iso|is|induce|,|however|remain|. (l_parataxis) remain_29\VBP\2604760|,|effects|unknown (l_nsubj) effects_22\NNS\13245626|the|iso|pathways (l_nmod) pathways_28\NNS\5483677|on|mapk|signaling (l_compound) mapk_26\NN\1740|
T15_T35 NONE iso_24\NN\1740|of (r_nmod) effects_22\NNS\13245626|the|iso|pathways (r_nsubj) remain_29\VBP\2604760|,|effects|unknown (r_parataxis) able_2\JJ\1740|iso|is|induce|,|however|remain|. (l_xcomp) induce_4\VB\1627355|to|apoptosis|dysfunction (l_nmod) dysfunction_8\NN\14204950|through|mitochondrial|and|inhibition|cells (l_conj) inhibition_10\NN\1068773|pathway (l_nmod) pathway_14\NN\5483677|of|pi3k/akt|signaling (l_compound) pi3k/akt_12\NN\1740|
T15_T36 NONE iso_24\NN\1740|of (r_nmod) effects_22\NNS\13245626|the|iso|pathways (r_nsubj) remain_29\VBP\2604760|,|effects|unknown (r_parataxis) able_2\JJ\1740|iso|is|induce|,|however|remain|. (l_xcomp) induce_4\VB\1627355|to|apoptosis|dysfunction (l_nmod) dysfunction_8\NN\14204950|through|mitochondrial|and|inhibition|cells (l_conj) inhibition_10\NN\1068773|pathway (l_nmod) pathway_14\NN\5483677|of|pi3k/akt|signaling (l_compound) pi3k/akt_12\NN\1740|
T15_T37 NONE iso_24\NN\1740|of (r_nmod) effects_22\NNS\13245626|the|iso|pathways (l_nmod) pathways_28\NNS\5483677|on|mapk|signaling (l_compound) mapk_26\NN\1740|
T16_T38 NONE iso_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|the|iso|pathway|,|and|roles (l_conj) roles_14\NNS\719494|the|kinases|apoptosis (l_nmod) kinases_17\NNS\14732946|of|mapk (l_compound) mapk_16\NN\1740|
T16_T39 NONE iso_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|the|iso|pathway|,|and|roles (l_conj) roles_14\NNS\719494|the|kinases|apoptosis (l_nmod) kinases_17\NNS\14732946|of|mapk
T20_T40 NONE iso_0\NN\1740| (r_nsubj) inhibited_2\VBD\2510337|iso|significantly|levels|and|increased|. (l_dobj) levels_4\NNS\4916342|the|kinase (l_nmod) kinase_7\NN\14732946|of|erk1/2 (l_compound) erk1/2_6\NN\1740|
T20_T41 CPR:3 iso_0\NN\1740| (r_nsubj) inhibited_2\VBD\2510337|iso|significantly|levels|and|increased|. (l_conj) increased_9\VBD\169651|expression (l_dobj) expression_11\NN\4679549|the|jnk (l_nmod) jnk_13\NN\1740|of|and|kinases
T20_T42 CPR:3 iso_0\NN\1740| (r_nsubj) inhibited_2\VBD\2510337|iso|significantly|levels|and|increased|. (l_conj) increased_9\VBD\169651|expression (l_dobj) expression_11\NN\4679549|the|jnk (l_nmod) jnk_13\NN\1740|of|and|kinases (l_conj) kinases_16\NNS\14732946|p38 (l_compound) p38_15\NN\1740|
T20_T43 CPR:3 iso_0\NN\1740| (r_nsubj) inhibited_2\VBD\2510337|iso|significantly|levels|and|increased|. (l_conj) increased_9\VBD\169651|expression (l_dobj) expression_11\NN\4679549|the|jnk (l_nmod) jnk_13\NN\1740|of|and|kinases (l_conj) kinases_16\NNS\14732946|p38
T21_T44 NONE u0126_2\NN\1740|inhibitor (l_appos) inhibitor_6\NN\20090|(|an|erk1/2|) (l_compound) erk1/2_5\NN\1740|
T21_T45 CPR:3 u0126_2\NN\1740|inhibitor (r_nsubj) enhanced_9\VBD\227165|furthermore|,|u0126|significantly|ratio|. (l_dobj) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (l_compound) bax/bcl-2_13\NN\1740|
T21_T46 CPR:3 u0126_2\NN\1740|inhibitor (r_nsubj) enhanced_9\VBD\227165|furthermore|,|u0126|significantly|ratio|. (l_dobj) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (l_compound) bax/bcl-2_13\NN\1740|
T21_T47 NONE u0126_2\NN\1740|inhibitor (r_nsubj) enhanced_9\VBD\227165|furthermore|,|u0126|significantly|ratio|. (l_dobj) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (l_conj) release_17\NN\3748886|the|c|fraction (l_nmod) c_20\NN\13714184|of|cytochrome
T21_T48 NONE u0126_2\NN\1740|inhibitor (r_nsubj) enhanced_9\VBD\227165|furthermore|,|u0126|significantly|ratio|. (l_dobj) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (l_conj) levels_28\NNS\4916342|the|caspase-3 (l_nmod) caspase-3_31\NN\1740|of|cleaved
T22_T44 NONE iso-induced_11\JJ\1740|the (r_amod) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (r_dobj) enhanced_9\VBD\227165|furthermore|,|u0126|significantly|ratio|. (l_nsubj) u0126_2\NN\1740|inhibitor (l_appos) inhibitor_6\NN\20090|(|an|erk1/2|) (l_compound) erk1/2_5\NN\1740|
T22_T45 CPR:3 iso-induced_11\JJ\1740|the (r_amod) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (l_compound) bax/bcl-2_13\NN\1740|
T22_T46 CPR:3 iso-induced_11\JJ\1740|the (r_amod) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (l_compound) bax/bcl-2_13\NN\1740|
T22_T47 NONE iso-induced_11\JJ\1740|the (r_amod) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (l_conj) release_17\NN\3748886|the|c|fraction (l_nmod) c_20\NN\13714184|of|cytochrome
T22_T48 NONE iso-induced_11\JJ\1740|the (r_amod) ratio_14\NN\13815152|iso-induced|the|bax/bcl-2|,|release|,|and|levels (l_conj) levels_28\NNS\4916342|the|caspase-3 (l_nmod) caspase-3_31\NN\1740|of|cleaved
T2_T24 CPR:4 sp600125_1\NN\1740|inhibitor|and|sb203580 (l_appos) inhibitor_5\NN\20090|(|a|jnk|) (l_compound) jnk_4\NN\1740|
T2_T25 NONE sp600125_1\NN\1740|inhibitor|and|sb203580 (l_conj) sb203580_8\NN\1740|inhibitor (l_appos) inhibitor_12\NN\20090|(|a|p38|) (l_compound) p38_11\NN\1740|
T3_T24 NONE sb203580_8\NN\1740|inhibitor (r_conj) sp600125_1\NN\1740|inhibitor|and|sb203580 (l_appos) inhibitor_5\NN\20090|(|a|jnk|) (l_compound) jnk_4\NN\1740|
T3_T25 CPR:4 sb203580_8\NN\1740|inhibitor (l_appos) inhibitor_12\NN\20090|(|a|p38|) (l_compound) p38_11\NN\1740|
T4_T24 CPR:3 iso_23\NN\1740|by (r_nmod) induced_21\VBN\1627355|iso (r_acl) expression_17\NN\4679549|the|proteins|induced (r_dobj) prevented_15\VBD\1740|while|sp600125|markedly|expression|. (l_nsubj) sp600125_1\NN\1740|inhibitor|and|sb203580 (l_appos) inhibitor_5\NN\20090|(|a|jnk|) (l_compound) jnk_4\NN\1740|
T4_T25 CPR:3 iso_23\NN\1740|by (r_nmod) induced_21\VBN\1627355|iso (r_acl) expression_17\NN\4679549|the|proteins|induced (r_dobj) prevented_15\VBD\1740|while|sp600125|markedly|expression|. (l_nsubj) sp600125_1\NN\1740|inhibitor|and|sb203580 (l_conj) sb203580_8\NN\1740|inhibitor (l_appos) inhibitor_12\NN\20090|(|a|p38|) (l_compound) p38_11\NN\1740|
T5_T26 NONE nac_6\NN\8310949|(|) (r_appos) inhibitor_4\NN\20090|the|ros|nac (r_nsubj) promoted_9\VBD\2556126|furthermore|,|inhibitor|notably|effect|. (l_dobj) effect_12\NN\34213|the|inhibited|iso|kinase (l_nmod) kinase_18\NN\14732946|on|the|erk1/2 (l_compound) erk1/2_17\NN\1740|
T6_T26 NONE iso_14\NN\1740|of (r_nmod) effect_12\NN\34213|the|inhibited|iso|kinase (l_nmod) kinase_18\NN\14732946|on|the|erk1/2 (l_compound) erk1/2_17\NN\1740|
T7_T27 CPR:4 nac_0\NN\8310949| (r_nsubj) suppressed_2\VBD\2510337|nac|also|p-jnk|,|but|failed|. (l_dobj) p-jnk_4\NN\1740|the|and|p-p38
T7_T28 CPR:4 nac_0\NN\8310949| (r_nsubj) suppressed_2\VBD\2510337|nac|also|p-jnk|,|but|failed|. (l_dobj) p-jnk_4\NN\1740|the|and|p-p38 (l_conj) p-p38_6\NN\1740|
T8_T27 NONE iso_15\NN\1740|of (r_nmod) effects_13\NNS\13245626|the|iso (r_dobj) reverse_11\VB\109660|to|effects (r_xcomp) failed_9\VBD\1798936|reverse (r_conj) suppressed_2\VBD\2510337|nac|also|p-jnk|,|but|failed|. (l_dobj) p-jnk_4\NN\1740|the|and|p-p38
T8_T28 NONE iso_15\NN\1740|of (r_nmod) effects_13\NNS\13245626|the|iso (r_dobj) reverse_11\VB\109660|to|effects (r_xcomp) failed_9\VBD\1798936|reverse (r_conj) suppressed_2\VBD\2510337|nac|also|p-jnk|,|but|failed|. (l_dobj) p-jnk_4\NN\1740|the|and|p-p38 (l_conj) p-p38_6\NN\1740|
T10_T29 NONE iso_8\NN\1740| (r_nsubj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_advcl) inactivating_15\VBG\1097743|through|kinase|and|activating (l_dobj) kinase_17\NN\14732946|erk1/2 (l_compound) erk1/2_16\NN\1740|
T10_T30 CPR:3 iso_8\NN\1740| (r_nsubj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_advcl) inactivating_15\VBG\1097743|through|kinase|and|activating (l_conj) activating_19\VBG\1641914|jnk (l_dobj) jnk_20\NN\1740|and|kinases
T10_T31 CPR:3 iso_8\NN\1740| (r_nsubj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_advcl) inactivating_15\VBG\1097743|through|kinase|and|activating (l_conj) activating_19\VBG\1641914|jnk (l_dobj) jnk_20\NN\1740|and|kinases (l_conj) kinases_23\NNS\14732946|p38 (l_compound) p38_22\NN\1740|
T10_T32 CPR:3 iso_8\NN\1740| (r_nsubj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_advcl) inactivating_15\VBG\1097743|through|kinase|and|activating (l_conj) activating_19\VBG\1641914|jnk (l_dobj) jnk_20\NN\1740|and|kinases (l_conj) kinases_23\NNS\14732946|p38
T10_T33 NONE iso_8\NN\1740| (r_nsubj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_conj) able_31\JJ\1740|ros|is|activate (l_xcomp) activate_33\VB\1641914|to|pathway|molecules (l_dobj) pathway_37\NN\5483677|the|mapk|singaling (l_compound) mapk_35\NN\1740|
T11_T29 NONE iso_29\NN\1740|by (r_nmod) stimulated_27\VBN\137313|iso (r_acl) ros_26\NN\6894544|stimulated (r_nsubj) able_31\JJ\1740|ros|is|activate (r_conj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_advcl) inactivating_15\VBG\1097743|through|kinase|and|activating (l_dobj) kinase_17\NN\14732946|erk1/2 (l_compound) erk1/2_16\NN\1740|
T11_T30 NONE iso_29\NN\1740|by (r_nmod) stimulated_27\VBN\137313|iso (r_acl) ros_26\NN\6894544|stimulated (r_nsubj) able_31\JJ\1740|ros|is|activate (r_conj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_advcl) inactivating_15\VBG\1097743|through|kinase|and|activating (l_conj) activating_19\VBG\1641914|jnk (l_dobj) jnk_20\NN\1740|and|kinases
T11_T31 NONE iso_29\NN\1740|by (r_nmod) stimulated_27\VBN\137313|iso (r_acl) ros_26\NN\6894544|stimulated (r_nsubj) able_31\JJ\1740|ros|is|activate (r_conj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_advcl) inactivating_15\VBG\1097743|through|kinase|and|activating (l_conj) activating_19\VBG\1641914|jnk (l_dobj) jnk_20\NN\1740|and|kinases (l_conj) kinases_23\NNS\14732946|p38 (l_compound) p38_22\NN\1740|
T11_T32 NONE iso_29\NN\1740|by (r_nmod) stimulated_27\VBN\137313|iso (r_acl) ros_26\NN\6894544|stimulated (r_nsubj) able_31\JJ\1740|ros|is|activate (r_conj) induces_9\VBZ\1627355|that|iso|apoptosis|cells|inactivating|,|and|able (l_advcl) inactivating_15\VBG\1097743|through|kinase|and|activating (l_conj) activating_19\VBG\1641914|jnk (l_dobj) jnk_20\NN\1740|and|kinases (l_conj) kinases_23\NNS\14732946|p38
T11_T33 CPR:3 iso_29\NN\1740|by (r_nmod) stimulated_27\VBN\137313|iso (r_acl) ros_26\NN\6894544|stimulated (r_nsubj) able_31\JJ\1740|ros|is|activate (l_xcomp) activate_33\VB\1641914|to|pathway|molecules (l_dobj) pathway_37\NN\5483677|the|mapk|singaling (l_compound) mapk_35\NN\1740|
T12_T34 NONE iso_8\NN\1740|by (r_nmod) induced_6\VBN\1627355|iso (r_acl) apoptosis_5\NN\11486178|of|the|mitochondrial-mediated|induced (r_nmod) event_1\NN\23100|initiating|apoptosis (r_nsubj) signals_11\NNS\33020|event|is|mapk|. (l_compound) mapk_10\NN\1740|
23644200
22370636
T1_T12 NONE phosphoinositide-3-kinase_8\NN\1740|pi3 (r_compound) k_11\NN\13608598|the|phosphoinositide-3-kinase|) (r_compound) p110α_15\NN\1740|k|catalytic|subunit
T1_T4 NONE phosphoinositide-3-kinase_8\NN\1740|pi3 (r_compound) k_11\NN\13608598|the|phosphoinositide-3-kinase|) (r_compound) p110α_15\NN\1740|k|catalytic|subunit (r_dobj) encodes_6\VBZ\115157|which|p110α (r_acl:relcl) pik3ca_3\NN\1740|in|,|encodes
T2_T13 NONE trp53_12\NN\1740| (r_compound) mutations_13\NNS\4475|including|trp53|appeared (r_nmod) mutations_9\NNS\4475|multiple|,|mutations (r_dobj) identified_7\VBD\699815|analysis|mutations|. (l_nsubj) analysis_1\NN\633864|whole-exome|tumors (l_nmod) tumors_6\NNS\14234074|of|the|pik3ca(h1047r)-driven|mammary (l_amod) pik3ca(h1047r)-driven_4\NN\1740|
T2_T14 NONE trp53_12\NN\1740| (r_compound) mutations_13\NNS\4475|including|trp53|appeared (r_nmod) mutations_9\NNS\4475|multiple|,|mutations (r_dobj) identified_7\VBD\699815|analysis|mutations|. (l_nsubj) analysis_1\NN\633864|whole-exome|tumors (l_nmod) tumors_6\NNS\14234074|of|the|pik3ca(h1047r)-driven|mammary (l_amod) pik3ca(h1047r)-driven_4\NN\1740|
T2_T15 NONE trp53_12\NN\1740|
T3_T16 CPR:4 gdc-0941_11\NN\1740|of|,|inhibitor|, (l_appos) inhibitor_16\NN\20090|a|pi3|k (l_compound) k_15\NN\13608598|
T3_T17 CPR:4 gdc-0941_11\NN\1740|of|,|inhibitor|, (r_nmod) efficacy_9\NN\5199286|the|gdc-0941|development (r_dobj) test_7\VB\670261|to|efficacy (r_advcl) used_3\VBD\1156834|further|,|we|model|test|,|and|showed|. (l_conj) showed_23\VBD\2137132|respond (l_ccomp) respond_27\VBP\2367363|that|tumors|inhibition (l_nmod) inhibition_31\NN\1068773|to|pi3|k (l_compound) k_30\NN\13608598|
17090056
T27_T33 NONE 5'-methylthioadenosine_4\NN\1740| (r_compound) phosphorylase_5\NN\1740|of|human|5'-methylthioadenosine
T9_T28 NONE 5'-methylthioadenosine_22\NN\1740| (r_compound) phosphorylase_23\NN\1740|of|human|5'-methylthioadenosine|mtap
T9_T30 NONE 5'-methylthioadenosine_22\NN\1740| (r_compound) phosphorylase_23\NN\1740|of|human|5'-methylthioadenosine|mtap (l_appos) mtap_25\NN\1740|(|)
T17_T31 CPR:9 5'-methylthioadenosine_7\NN\1740|of|mta|catalyzed (l_acl) catalyzed_11\VBN\146138|mtap (l_nmod) mtap_13\NN\1740|by
T18_T31 CPR:9 mta_9\NN\1740|(|) (r_appos) 5'-methylthioadenosine_7\NN\1740|of|mta|catalyzed (l_acl) catalyzed_11\VBN\146138|mtap (l_nmod) mtap_13\NN\1740|by
T20_T32 NONE 1'-(14)c_5\CD\1740|and|9-(15)n|) (r_intj) (_4\-LRB-\1740|1'-(14)c (r_punct) suggest_9\VBP\1010118|kies|(|has|. (l_ccomp) has_12\VBZ\2108377|that|mtap|state (l_nsubj) mtap_11\NNP\1740|
T21_T32 NONE 9-(15)n_7\CD\1740| (r_conj) 1'-(14)c_5\CD\1740|and|9-(15)n|) (r_intj) (_4\-LRB-\1740|1'-(14)c (r_punct) suggest_9\VBP\1010118|kies|(|has|. (l_ccomp) has_12\VBZ\2108377|that|mtap|state (l_nsubj) mtap_11\NNP\1740|
T22_T32 NONE carbon_25\NN\14622893|at|the|anomeric (r_nmod) center_21\NN\8497294|with|its|cationic|carbon|and|order (r_nmod) state_17\NN\8491826|a|dissociative|s(n)1|transition|center (r_dobj) has_12\VBZ\2108377|that|mtap|state (l_nsubj) mtap_11\NNP\1740|
T16_T29 NONE phosphate_15\NN\15010703| (r_compound) nucleophile_16\NN\1740|of|the|phosphate (r_nmod) participation_12\NN\1080366|with|significant|nucleophile (r_nmod) state_9\NN\8491826|by|a|late|s(n)1|transition|participation (r_nmod) characterized_3\VBN\609683|mtap|is|state|. (l_nsubjpass) mtap_1\NN\1740|human
23517558
T6_T8 CPR:4 221_10\CD\1740| (r_nummod) amg_9\NN\1740|221 (r_dep) inhibitor_8\NN\20090|of|the|11β-hsd1|amg (l_compound) 11β-hsd1_7\NN\1740|
T2_T7 CPR:4 221_22\CD\1740| (r_nummod) amg_21\NNP\1740|221 (r_appos) inhibitor_19\NN\20090|for|an|11β-hsd1|,|amg (l_compound) 11β-hsd1_18\NN\1740|
23228697
T13_T35 NONE orlistat_10\NN\1740| (r_dep) agent_9\NN\7347|of|the|antiobesity|orlistat (r_nmod) target_5\NN\7258332|carboxylesterase-2|is|a|sensitive|agent|implications|. (l_nsubj) carboxylesterase-2_0\NN\1740|
T1_T17 CPR:4 orlistat_0\NN\1740| (r_nsubj) drug_7\NN\14778436|orlistat|has|been|the|used|anti-obesity|and|reduce (l_conj) reduce_16\VB\441445|mechanism|is|to|absorption|inhibiting|. (l_advcl) inhibiting_20\VBG\2510337|by|lipases (l_dobj) lipases_22\NNS\14732946|gastrointestinal
T6_T25 CPR:4 orlistat_9\NN\1740| (r_nsubj) inhibits_10\VBZ\2510337|that|orlistat|cess|potency (l_dobj) cess_11\NN\14625458|
T6_T26 CPR:4 orlistat_9\NN\1740| (r_nsubj) inhibits_10\VBZ\2510337|that|orlistat|cess|potency (l_nmod) potency_14\NN\5196375|with|higher|ces1 (l_nmod) ces1_16\NN\1740|toward|ces2
T6_T27 CPR:4 orlistat_9\NN\1740| (r_nsubj) inhibits_10\VBZ\2510337|that|orlistat|cess|potency (l_nmod) potency_14\NN\5196375|with|higher|ces1 (l_nmod) ces1_16\NN\1740|toward|ces2 (l_nmod) ces2_18\NN\1740|than|,|carboxylesterase
T6_T28 CPR:4 orlistat_9\NN\1740| (r_nsubj) inhibits_10\VBZ\2510337|that|orlistat|cess|potency (l_nmod) potency_14\NN\5196375|with|higher|ces1 (l_nmod) ces1_16\NN\1740|toward|ces2 (l_nmod) ces2_18\NN\1740|than|,|carboxylesterase (l_appos) carboxylesterase_21\NN\1740|a|activity
T6_T29 CPR:4 orlistat_9\NN\1740| (r_nsubj) inhibits_10\VBZ\2510337|that|orlistat|cess|potency (l_nmod) potency_14\NN\5196375|with|higher|ces1 (l_nmod) ces1_16\NN\1740|toward|ces2 (l_nmod) ces2_18\NN\1740|than|,|carboxylesterase (l_appos) carboxylesterase_21\NN\1740|a|activity (l_nmod) activity_25\NN\30358|with|little|lipase (l_compound) lipase_24\NN\14732946|
T10_T30 NONE ppd_28\NN\1740|(|) (r_appos) doxazolidine_26\NN\1740|of|ppd|and|irinotecan (r_nmod) carbamate_24\NN\15010703|of|p-aminobenzyl|doxazolidine (r_nmod) carbamate_21\NN\15010703|pentyl|carbamate (r_dep) prodrugs_19\NNS\1740|the|anticancer|carbamate (r_conj) substrates_15\NNS\19613|of|standard|and|prodrugs (r_nmod) hydrolysis_12\NN\13447361|of|the|substrates (r_nmod) inhibition_9\NN\1068773|for|the|hydrolysis (r_nmod) tested_6\VBN\670261|microsomes|were|inhibition|. (l_nsubjpass) microsomes_1\NNS\9291513|liver|and|cess (l_conj) cess_4\NN\14625458|recombinant
T11_T30 NONE irinotecan_31\NN\1740| (r_conj) doxazolidine_26\NN\1740|of|ppd|and|irinotecan (r_nmod) carbamate_24\NN\15010703|of|p-aminobenzyl|doxazolidine (r_nmod) carbamate_21\NN\15010703|pentyl|carbamate (r_dep) prodrugs_19\NNS\1740|the|anticancer|carbamate (r_conj) substrates_15\NNS\19613|of|standard|and|prodrugs (r_nmod) hydrolysis_12\NN\13447361|of|the|substrates (r_nmod) inhibition_9\NN\1068773|for|the|hydrolysis (r_nmod) tested_6\VBN\670261|microsomes|were|inhibition|. (l_nsubjpass) microsomes_1\NNS\9291513|liver|and|cess (l_conj) cess_4\NN\14625458|recombinant
T7_T30 NONE carbamate_21\NN\15010703|pentyl|carbamate (r_dep) prodrugs_19\NNS\1740|the|anticancer|carbamate (r_conj) substrates_15\NNS\19613|of|standard|and|prodrugs (r_nmod) hydrolysis_12\NN\13447361|of|the|substrates (r_nmod) inhibition_9\NN\1068773|for|the|hydrolysis (r_nmod) tested_6\VBN\670261|microsomes|were|inhibition|. (l_nsubjpass) microsomes_1\NNS\9291513|liver|and|cess (l_conj) cess_4\NN\14625458|recombinant
T8_T30 NONE carbamate_24\NN\15010703|of|p-aminobenzyl|doxazolidine (r_nmod) carbamate_21\NN\15010703|pentyl|carbamate (r_dep) prodrugs_19\NNS\1740|the|anticancer|carbamate (r_conj) substrates_15\NNS\19613|of|standard|and|prodrugs (r_nmod) hydrolysis_12\NN\13447361|of|the|substrates (r_nmod) inhibition_9\NN\1068773|for|the|hydrolysis (r_nmod) tested_6\VBN\670261|microsomes|were|inhibition|. (l_nsubjpass) microsomes_1\NNS\9291513|liver|and|cess (l_conj) cess_4\NN\14625458|recombinant
T9_T30 NONE doxazolidine_26\NN\1740|of|ppd|and|irinotecan (r_nmod) carbamate_24\NN\15010703|of|p-aminobenzyl|doxazolidine (r_nmod) carbamate_21\NN\15010703|pentyl|carbamate (r_dep) prodrugs_19\NNS\1740|the|anticancer|carbamate (r_conj) substrates_15\NNS\19613|of|standard|and|prodrugs (r_nmod) hydrolysis_12\NN\13447361|of|the|substrates (r_nmod) inhibition_9\NN\1068773|for|the|hydrolysis (r_nmod) tested_6\VBN\670261|microsomes|were|inhibition|. (l_nsubjpass) microsomes_1\NNS\9291513|liver|and|cess (l_conj) cess_4\NN\14625458|recombinant
T12_T31 CPR:4 orlistat_30\NN\1740|of (r_nmod) targets_28\NNS\7258332|of|the|sensitive|orlistat (r_nmod) one_23\CD\13741022|targets (r_xcomp) placing_21\VBG\1850315|ces2|one (r_advcl) inhibited_9\VBD\2510337|contrary|,|orlistat|activity|%|but|inhibition|,|placing|. (l_dobj) activity_11\NN\30358|ces2 (l_compound) ces2_10\NN\1740|
T12_T32 NONE orlistat_30\NN\1740|of (r_nmod) targets_28\NNS\7258332|of|the|sensitive|orlistat (r_nmod) one_23\CD\13741022|targets (r_xcomp) placing_21\VBG\1850315|ces2|one (r_advcl) inhibited_9\VBD\2510337|contrary|,|orlistat|activity|%|but|inhibition|,|placing|. (l_conj) inhibition_17\NN\1068773|no|ces1 (l_nmod) ces1_19\NN\1740|on
T12_T33 CPR:4 orlistat_30\NN\1740|of (r_nmod) targets_28\NNS\7258332|of|the|sensitive|orlistat (r_nmod) one_23\CD\13741022|targets (r_xcomp) placing_21\VBG\1850315|ces2|one (l_dobj) ces2_22\NN\1740|
T4_T16 CPR:4 orlistat_19\NN\1740|with (r_nmod) co-administered_17\VBN\1740|if|orlistat (r_advcl) presents_5\VBZ\2137132|inhibition|probably|source|co-administered|. (l_nsubj) inhibition_0\NN\1068773|carboxylesterase (l_nmod) carboxylesterase_3\NN\1740|of|this
16819260
T1_T12 NONE retinoid_0\NN\1740| (r_nsubj) term_4\NN\6286395|retinoid|is|a|collective|compounds|. (l_nmod) compounds_6\NNS\5869584|for|bind (l_acl:relcl) bind_8\VBP\1290422|which|to|and|activate|receptors (l_dobj) receptors_14\NNS\5225602|retinoic|acid|raralpha (l_dep) raralpha_16\NN\1740|(|,|beta|,|gamma|and|beta|,|gamma|)|,|members (l_appos) gamma_26\NN\6828818|
T1_T13 CPR:3 retinoid_0\NN\1740| (r_nsubj) term_4\NN\6286395|retinoid|is|a|collective|compounds|. (l_nmod) compounds_6\NNS\5869584|for|bind (l_acl:relcl) bind_8\VBP\1290422|which|to|and|activate|receptors (l_dobj) receptors_14\NNS\5225602|retinoic|acid|raralpha (l_dep) raralpha_16\NN\1740|(|,|beta|,|gamma|and|beta|,|gamma|)|,|members (l_appos) members_29\NNS\9816771|superfamily (l_nmod) superfamily_34\NN\7992450|of|nuclear|hormone|receptor (l_compound) receptor_33\NN\5225602|
T1_T19 CPR:3 retinoid_0\NN\1740| (r_nsubj) term_4\NN\6286395|retinoid|is|a|collective|compounds|. (l_nmod) compounds_6\NNS\5869584|for|bind (l_acl:relcl) bind_8\VBP\1290422|which|to|and|activate|receptors (l_dobj) receptors_14\NNS\5225602|retinoic|acid|raralpha
T1_T20 NONE retinoid_0\NN\1740| (r_nsubj) term_4\NN\6286395|retinoid|is|a|collective|compounds|. (l_nmod) compounds_6\NNS\5869584|for|bind (l_acl:relcl) bind_8\VBP\1290422|which|to|and|activate|receptors (l_dobj) receptors_14\NNS\5225602|retinoic|acid|raralpha (l_dep) raralpha_16\NN\1740|(|,|beta|,|gamma|and|beta|,|gamma|)|,|members (l_appos) gamma_20\NN\6828818|
T3_T14 NONE retinoid_4\NN\1740|the|important|endogeneous (r_nsubj) acid_7\NN\14818238|retinoid|is|all-trans-retinoic|atra|ligand|. (l_acl:relcl) ligand_19\NN\20090|which|is|an|raralpha (l_compound) raralpha_14\NN\1740|,|beta (l_conj) beta_16\NN\6828818|and|gamma (l_conj) gamma_18\NN\6828818|
T4_T14 NONE acid_7\NN\14818238|retinoid|is|all-trans-retinoic|atra|ligand|. (l_acl:relcl) ligand_19\NN\20090|which|is|an|raralpha (l_compound) raralpha_14\NN\1740|,|beta (l_conj) beta_16\NN\6828818|and|gamma (l_conj) gamma_18\NN\6828818|
T5_T14 NONE atra_9\NN\1740|(|) (r_appos) acid_7\NN\14818238|retinoid|is|all-trans-retinoic|atra|ligand|. (l_acl:relcl) ligand_19\NN\20090|which|is|an|raralpha (l_compound) raralpha_14\NN\1740|,|beta (l_conj) beta_16\NN\6828818|and|gamma (l_conj) gamma_18\NN\6828818|
T7_T15 NONE tamibarotene_3\NN\1740|am80 (r_nsubj) retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma-
T7_T16 NONE tamibarotene_3\NN\1740|am80 (r_nsubj) retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rarbeta-specific_11\JJ\1740|
T7_T17 NONE tamibarotene_3\NN\1740|am80 (r_nsubj) retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rargamma-_14\NN\1740|but|and|rxrs-nonbinding
T7_T18 NONE tamibarotene_3\NN\1740|am80 (r_nsubj) retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rargamma-_14\NN\1740|but|and|rxrs-nonbinding (l_conj) rxrs-nonbinding_16\JJ\1740|
T8_T15 NONE am80_5\NN\1740|(|) (r_appos) tamibarotene_3\NN\1740|am80 (r_nsubj) retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma-
T8_T16 NONE am80_5\NN\1740|(|) (r_appos) tamibarotene_3\NN\1740|am80 (r_nsubj) retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rarbeta-specific_11\JJ\1740|
T8_T17 NONE am80_5\NN\1740|(|) (r_appos) tamibarotene_3\NN\1740|am80 (r_nsubj) retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rargamma-_14\NN\1740|but|and|rxrs-nonbinding
T8_T18 NONE am80_5\NN\1740|(|) (r_appos) tamibarotene_3\NN\1740|am80 (r_nsubj) retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rargamma-_14\NN\1740|but|and|rxrs-nonbinding (l_conj) rxrs-nonbinding_16\JJ\1740|
T9_T15 NONE retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma-
T9_T16 NONE retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rarbeta-specific_11\JJ\1740|
T9_T17 NONE retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rargamma-_14\NN\1740|but|and|rxrs-nonbinding
T9_T18 NONE retinoid_19\NN\1740|them|,|tamibarotene|is|an|raralpha-|)|synthetic|effective|. (l_amod) raralpha-_9\NN\1740|and|rarbeta-specific|(|rargamma- (l_conj) rargamma-_14\NN\1740|but|and|rxrs-nonbinding (l_conj) rxrs-nonbinding_16\JJ\1740|
17380207
T3_T11 NONE asparagine_25\NN\14601829| (r_compound) depletion_26\NN\351638|to|asparagine (r_nmod) sensitive_23\JJ\1740|expression|,|cells|are|exquisitely|depletion|. (l_nmod) expression_9\NN\4679549|because|of|synthetase|and|biosynthesis (l_compound) synthetase_5\NN\1740|their|low|asparagine|asns (l_appos) asns_7\NN\1740|(|)
T3_T9 NONE asparagine_25\NN\14601829| (r_compound) depletion_26\NN\351638|to|asparagine (r_nmod) sensitive_23\JJ\1740|expression|,|cells|are|exquisitely|depletion|. (l_nmod) expression_9\NN\4679549|because|of|synthetase|and|biosynthesis (l_compound) synthetase_5\NN\1740|their|low|asparagine|asns
T4_T11 NONE asparagine_4\NN\14601829| (r_compound) synthetase_5\NN\1740|their|low|asparagine|asns (l_appos) asns_7\NN\1740|(|)
T4_T9 NONE asparagine_4\NN\14601829| (r_compound) synthetase_5\NN\1740|their|low|asparagine|asns
T5_T11 CPR:9 asparagine_11\NN\14601829| (r_compound) biosynthesis_12\NN\13565379|asparagine (r_conj) expression_9\NN\4679549|because|of|synthetase|and|biosynthesis (l_compound) synthetase_5\NN\1740|their|low|asparagine|asns (l_appos) asns_7\NN\1740|(|)
T5_T9 CPR:9 asparagine_11\NN\14601829| (r_compound) biosynthesis_12\NN\13565379|asparagine (r_conj) expression_9\NN\4679549|because|of|synthetase|and|biosynthesis (l_compound) synthetase_5\NN\1740|their|low|asparagine|asns
T1_T6 CPR:9 asparagine_0\NN\14601829| (r_compound) secretion_1\NN\13526110|asparagine|mscs (r_nsubj) related_6\JJ\1740|secretion|was|directly|levels|,|suggesting|. (l_nmod) levels_11\NNS\4916342|to|their|asns|expression (l_compound) asns_9\NNS\1740|
T2_T6 NONE asparagine_20\NN\14601829|of (r_nmod) concentrations_18\NNS\4916342|a|mechanism|-|increased|asparagine|microenvironment|effects (r_dobj) suggesting_13\VBG\1010118|concentrations (r_advcl) related_6\JJ\1740|secretion|was|directly|levels|,|suggesting|. (l_nmod) levels_11\NNS\4916342|to|their|asns|expression (l_compound) asns_9\NNS\1740|
23628605
T4_T24 CPR:9 cholesterol_16\NN\15058310| (r_compound) enzyme_19\NN\14723628|the|cholesterol|side-chain|cleavage|,|p450scc|,|and|partners (l_appos) p450scc_21\NN\1740|
T4_T25 NONE cholesterol_16\NN\15058310| (r_compound) enzyme_19\NN\14723628|the|cholesterol|side-chain|cleavage|,|p450scc|,|and|partners (l_conj) partners_27\NNS\10024362|its|two|electron-transfer|,|reductase (l_appos) reductase_30\NN\14732946|ferredoxin|and|ferredoxin
T4_T26 NONE cholesterol_16\NN\15058310| (r_compound) enzyme_19\NN\14723628|the|cholesterol|side-chain|cleavage|,|p450scc|,|and|partners (l_conj) partners_27\NNS\10024362|its|two|electron-transfer|,|reductase (l_appos) reductase_30\NN\14732946|ferredoxin|and|ferredoxin (l_conj) ferredoxin_32\NN\1740|
T8_T27 NONE 3β-hydroxysteroid_6\NN\1740| (r_compound) dehydrogenase_7\NN\1740|including|3β-hydroxysteroid|,|11β-hydroxylase|and|synthase
T8_T28 NONE 3β-hydroxysteroid_6\NN\1740| (r_compound) dehydrogenase_7\NN\1740|including|3β-hydroxysteroid|,|11β-hydroxylase|and|synthase (l_conj) 11β-hydroxylase_9\NN\1740|
T8_T29 NONE 3β-hydroxysteroid_6\NN\1740| (r_compound) dehydrogenase_7\NN\1740|including|3β-hydroxysteroid|,|11β-hydroxylase|and|synthase (l_conj) synthase_12\NN\1740|aldosterone
T9_T27 NONE aldosterone_11\NN\14751863| (r_compound) synthase_12\NN\1740|aldosterone (r_conj) dehydrogenase_7\NN\1740|including|3β-hydroxysteroid|,|11β-hydroxylase|and|synthase
T9_T28 NONE aldosterone_11\NN\14751863| (r_compound) synthase_12\NN\1740|aldosterone (r_conj) dehydrogenase_7\NN\1740|including|3β-hydroxysteroid|,|11β-hydroxylase|and|synthase (l_conj) 11β-hydroxylase_9\NN\1740|
T9_T29 NONE aldosterone_11\NN\14751863| (r_compound) synthase_12\NN\1740|aldosterone
T11_T30 NONE cholesterol_3\NN\15058310|of (r_nmod) access_1\NN\5174653|the|cholesterol|mitochondria (r_nsubjpass) regulated_8\VBN\296178|access|is|protein|. (l_nmod) protein_14\NN\14944888|by|the|steroidogenic|acute|regulatory|,|star|,|serving
T11_T31 NONE cholesterol_3\NN\15058310|of (r_nmod) access_1\NN\5174653|the|cholesterol|mitochondria (r_nsubjpass) regulated_8\VBN\296178|access|is|protein|. (l_nmod) protein_14\NN\14944888|by|the|steroidogenic|acute|regulatory|,|star|,|serving (l_appos) star_16\NN\9239740|
T1_T22 CPR:9 cholesterol_10\NN\15058310| (r_dobj) move_9\VBP\2367363|cholesterol|omm|p450scc (l_nmod) p450scc_15\NN\1740|to
T2_T22 NONE cholesterol_22\NN\15058310| (r_nsubjpass) loaded_24\VBN\452512|which|cholesterol|is|omm (r_acl:relcl) means_19\NNS\44150|the|loaded (r_conj) fashion_2\NN\4916342|the|precise|interact|,|and|means|, (l_acl:relcl) interact_7\VBP\2367363|which|proteins|and|move (l_conj) move_9\VBP\2367363|cholesterol|omm|p450scc (l_nmod) p450scc_15\NN\1740|to
T3_T23 NONE cholesterol_29\NN\15058310| (r_compound) machine_31\NN\3183080|of|the|cholesterol|import (r_nmod) components_26\NNS\5867413|for|the|machine (r_conj) proteins_22\NNS\14944888|not|for|the|electron|transfer|or|components (r_conj) enzymes_14\NNS\14723628|for|all|the|mitochondrial|steroidogenic|,|but|proteins (r_conj) star_7\NN\9239740|for|and|enzymes
16957773
T4_T17 NONE glutamate_6\NN\15010703| (r_compound) transporter_7\NN\4490091|vesicular|glutamate|1|vglut1|,|essential (l_nummod) 1_8\CD\13741022|
T4_T18 NONE glutamate_6\NN\15010703| (r_compound) transporter_7\NN\4490091|vesicular|glutamate|1|vglut1|,|essential (l_appos) vglut1_10\NN\1740|(|)
T5_T17 CPR:9 glutamate_23\NN\15010703|of (r_nmod) exocytosis_21\NN\1740|subsequent|glutamate (r_conj) storage_18\NN\810598|for|vesicular|and|exocytosis|neurons (r_nmod) essential_15\JJ\1740|which|is|storage (r_acl:relcl) transporter_7\NN\4490091|vesicular|glutamate|1|vglut1|,|essential (l_nummod) 1_8\CD\13741022|
T5_T18 CPR:9 glutamate_23\NN\15010703|of (r_nmod) exocytosis_21\NN\1740|subsequent|glutamate (r_conj) storage_18\NN\810598|for|vesicular|and|exocytosis|neurons (r_nmod) essential_15\JJ\1740|which|is|storage (r_acl:relcl) transporter_7\NN\4490091|vesicular|glutamate|1|vglut1|,|essential (l_appos) vglut1_10\NN\1740|(|)
T6_T19 CPR:9 l-glutamate_8\NN\1740| (r_dobj) accumulates_7\VBZ\2281093|l-glutamate (r_conj) localized_2\JJ\1740|vglut1|is|vesicles|and|accumulates|. (l_nsubj) vglut1_0\NN\1740|
T11_T20 NONE kcl-_0\NN\1740|and|atp-dependent (r_amod) secretion_3\NN\13526110|kcl-|l-glutamate (r_nsubj) absent_7\JJ\1740|secretion|was|osteoclasts|. (l_nmod) osteoclasts_9\NNS\5447599|in|prepared (l_acl) prepared_10\VBN\126264|mice (l_nmod) mice_14\NNS\2329401|from|vglut1-/-|knockout (l_amod) vglut1-/-_12\JJ\1740|
T12_T20 NONE atp-dependent_2\JJ\1740| (r_conj) kcl-_0\NN\1740|and|atp-dependent (r_amod) secretion_3\NN\13526110|kcl-|l-glutamate (r_nsubj) absent_7\JJ\1740|secretion|was|osteoclasts|. (l_nmod) osteoclasts_9\NNS\5447599|in|prepared (l_acl) prepared_10\VBN\126264|mice (l_nmod) mice_14\NNS\2329401|from|vglut1-/-|knockout (l_amod) vglut1-/-_12\JJ\1740|
T13_T20 NONE l-glutamate_5\NN\1740|of (r_nmod) secretion_3\NN\13526110|kcl-|l-glutamate (r_nsubj) absent_7\JJ\1740|secretion|was|osteoclasts|. (l_nmod) osteoclasts_9\NNS\5447599|in|prepared (l_acl) prepared_10\VBN\126264|mice (l_nmod) mice_14\NNS\2329401|from|vglut1-/-|knockout (l_amod) vglut1-/-_12\JJ\1740|
T14_T21 NONE glutamate_8\NN\15010703| (r_compound) receptor_9\NN\5225602|a|class|iii|metabotropic|glutamate (r_appos) mglur8_2\NN\1740|,|receptor
T14_T22 NONE glutamate_8\NN\15010703| (r_compound) receptor_9\NN\5225602|a|class|iii|metabotropic|glutamate
23597507
T17_T23 NONE capsaicin-induced_3\JJ\1740| (r_amod) behavior_5\NN\407535|capsaicin-induced|nociceptive|and|hypersensitivity (r_dobj) prevents_2\VBZ\1740|toxin|behavior|acting|. (l_advcl) acting_10\VBG\1619354|without|channels (l_nmod) channels_13\NNS\6251781|on|trpv1 (l_compound) trpv1_12\NN\1740|
T10_T20 NONE )_10\-RRB-\1740| (r_punct) transients_11\NNS\9629752|on|ca(2|+|)|neurons (l_nmod) neurons_20\NNS\5430628|in|cultured|ganglia|and|cells|expressing (l_acl) expressing_24\VBG\928630|receptor (l_dobj) receptor_27\NN\5225602|the|trpv1 (l_compound) trpv1_26\NN\1740|
T11_T21 NONE capsaicin_14\NN\15032661|by (r_nmod) induced_12\VBN\1627355|capsaicin (r_acl) behavior_8\NN\407535|both|nocifensive|and|hypersensitivity|induced (r_dobj) reduced_5\VBD\441445|phα1β|behavior|that|. (l_nmod) that_17\DT\1740|similarly|to|observed (l_acl) observed_18\VBN\2163746|sb366791 (l_nmod) sb366791_20\NN\1740|with|,|antagonist (l_appos) antagonist_25\NN\7846|a|specific|trpv1 (l_compound) trpv1_24\NN\1740|
T12_T21 CPR:6 sb366791_20\NN\1740|with|,|antagonist (l_appos) antagonist_25\NN\7846|a|specific|trpv1 (l_compound) trpv1_24\NN\1740|
T16_T22 NONE )_11\-RRB-\1740| (r_punct) blocker_13\NN\10101634|(|a|selective|n-type|ca(2|+|)|channel (l_compound) channel_12\NN\6251781|
T7_T18 NONE capsaicin-activated_6\JJ\1740| (r_amod) currents_7\NNS\11449002|capsaicin-activated|recordings (l_nmod) recordings_10\NNS\6791372|in|patch-clamp|cells (l_nmod) cells_13\NNS\3080309|of|hek293|expressed (l_acl:relcl) expressed_15\VBD\928630|that|receptors (l_dobj) receptors_17\NNS\5225602|trpv1 (l_compound) trpv1_16\NN\1740|
17413769
T10_T30 NONE warfarin_4\NN\2718259|of (r_nmod) ratio_2\NN\13815152|plasma|s/r|warfarin (r_nsubj) co-varies_5\VBZ\2662297|ratio|haplotype|. (l_nmod) haplotype_8\NN\7963711|with|vkorc1 (l_compound) vkorc1_7\NN\1740|
T9_T17 NONE warfarin_16\NN\2718259| (r_compound) requirement_18\NN\1129920|for|warfarin|dose (r_nmod) determinant_14\NN\5686481|that|haplotype|is|an|important|genetic|requirement|and|associated (l_conj) associated_21\VBN\628491|is|difficulties (l_nmod) difficulties_23\NNS\621627|with|attain (l_acl) attain_25\VB\2524171|to|time (l_dobj) time_29\NN\7308889|stable|therapeutic|prothrombin|--|ratio|patients (l_compound) prothrombin_28\NN\15022776|
T9_T19 NONE warfarin_16\NN\2718259| (r_compound) requirement_18\NN\1129920|for|warfarin|dose (r_nmod) determinant_14\NN\5686481|that|haplotype|is|an|important|genetic|requirement|and|associated (l_nsubj) haplotype_9\NN\7963711|the|low-dose|vkorc1|*|2 (l_compound) vkorc1_6\NN\1740|
T5_T18 NONE s/r_30\NN\1740| (r_compound) ratios_31\NNS\13815152|different|warfarin|s/r (r_dobj) had_27\VBD\2108377|whether|patients|ratios|plasma|,|and|related (l_nsubj) patients_9\NNS\9898892|vkorc1|patients (l_nmod) vkorc1_11\NN\1740|with|*
T5_T20 NONE s/r_30\NN\1740| (r_compound) ratios_31\NNS\13815152|different|warfarin|s/r (r_dobj) had_27\VBD\2108377|whether|patients|ratios|plasma|,|and|related (l_nsubj) patients_9\NNS\9898892|vkorc1|patients (l_nmod) patients_16\NNS\9898892|compared|with|carrying (l_acl) carrying_17\VBG\1850315|haplotypes (l_dobj) haplotypes_19\NNS\7963711|high-dose|* (l_dep) *_21\NN\1740|vkorc1|3|or|vkorc1 (l_compound) vkorc1_20\NN\1740|
T5_T21 NONE s/r_30\NN\1740| (r_compound) ratios_31\NNS\13815152|different|warfarin|s/r (r_dobj) had_27\VBD\2108377|whether|patients|ratios|plasma|,|and|related (l_nsubj) patients_9\NNS\9898892|vkorc1|patients (l_nmod) patients_16\NNS\9898892|compared|with|carrying (l_acl) carrying_17\VBG\1850315|haplotypes (l_dobj) haplotypes_19\NNS\7963711|high-dose|* (l_dep) *_21\NN\1740|vkorc1|3|or|vkorc1 (l_conj) vkorc1_24\NN\1740|*
T5_T22 NONE s/r_30\NN\1740| (r_compound) ratios_31\NNS\13815152|different|warfarin|s/r (r_dobj) had_27\VBD\2108377|whether|patients|ratios|plasma|,|and|related (l_conj) related_40\JJ\1740|whether|that|was|variants (l_nmod) variants_43\NNS\7366289|to|cyp2c9|*|or|factors (l_compound) cyp2c9_42\NN\1740|
T5_T23 NONE s/r_30\NN\1740| (r_compound) ratios_31\NNS\13815152|different|warfarin|s/r (r_dobj) had_27\VBD\2108377|whether|patients|ratios|plasma|,|and|related (l_conj) related_40\JJ\1740|whether|that|was|variants (l_nmod) variants_43\NNS\7366289|to|cyp2c9|*|or|factors (l_dep) *_45\NN\1740|cyp2c9|2|and|* (l_compound) cyp2c9_44\NN\1740|
T5_T24 NONE s/r_30\NN\1740| (r_compound) ratios_31\NNS\13815152|different|warfarin|s/r (r_dobj) had_27\VBD\2108377|whether|patients|ratios|plasma|,|and|related (l_conj) related_40\JJ\1740|whether|that|was|variants (l_nmod) variants_43\NNS\7366289|to|cyp2c9|*|or|factors (l_dep) *_45\NN\1740|cyp2c9|2|and|* (l_conj) *_49\NN\1740|cyp2c9|3 (l_compound) cyp2c9_48\NN\1740|
T6_T25 NONE warfarin_11\NN\2718259| (r_compound) concentration_12\NN\4916342|for|plasma|warfarin (r_nmod) measured_8\VBN\697589|concentration (r_conj) haplotyped_4\VBN\1740|previously|vkorc1|and|measured (l_nmod) vkorc1_6\NN\1740|for
T6_T26 NONE warfarin_11\NN\2718259| (r_compound) concentration_12\NN\4916342|for|plasma|warfarin (r_nmod) measured_8\VBN\697589|concentration (r_conj) haplotyped_4\VBN\1740|previously|vkorc1|and|measured (r_dep) patients_2\NNS\9898892|from|haplotyped (r_nmod) samples_0\NNS\5820620|patients (r_nsubjpass) genotyped_14\VBN\1740|samples|were|variants|. (l_nmod) variants_18\NNS\7366289|for|the|cyp2c9|* (l_compound) cyp2c9_17\NN\1740|
T6_T27 NONE warfarin_11\NN\2718259| (r_compound) concentration_12\NN\4916342|for|plasma|warfarin (r_nmod) measured_8\VBN\697589|concentration (r_conj) haplotyped_4\VBN\1740|previously|vkorc1|and|measured (r_dep) patients_2\NNS\9898892|from|haplotyped (r_nmod) samples_0\NNS\5820620|patients (r_nsubjpass) genotyped_14\VBN\1740|samples|were|variants|. (l_nmod) variants_18\NNS\7366289|for|the|cyp2c9|* (l_dep) *_20\NN\1740|cyp2c9|2|and|* (l_compound) cyp2c9_19\NN\1740|
T6_T28 NONE warfarin_11\NN\2718259| (r_compound) concentration_12\NN\4916342|for|plasma|warfarin (r_nmod) measured_8\VBN\697589|concentration (r_conj) haplotyped_4\VBN\1740|previously|vkorc1|and|measured (r_dep) patients_2\NNS\9898892|from|haplotyped (r_nmod) samples_0\NNS\5820620|patients (r_nsubjpass) genotyped_14\VBN\1740|samples|were|variants|. (l_nmod) variants_18\NNS\7366289|for|the|cyp2c9|* (l_dep) *_20\NN\1740|cyp2c9|2|and|* (l_conj) *_24\NN\1740|cyp2c9|3 (l_compound) cyp2c9_23\NN\1740|
T8_T11 NONE s/r_14\NN\1740| (r_compound) ratios_15\NNS\13815152|in|warfarin|s/r (r_nmod) difference_8\NN\4723816|a|significant|p<0.01|ratios|patients (l_nmod) patients_28\NNS\9898892|between|vkorc1 (l_compound) vkorc1_17\NNP\1740|*|2|and|vkorc1 (l_conj) vkorc1_21\NNP\1740|*|3|or|vkorc1
T8_T12 NONE s/r_14\NN\1740| (r_compound) ratios_15\NNS\13815152|in|warfarin|s/r (r_nmod) difference_8\NN\4723816|a|significant|p<0.01|ratios|patients (l_nmod) patients_28\NNS\9898892|between|vkorc1 (l_compound) vkorc1_17\NNP\1740|*|2|and|vkorc1 (l_conj) vkorc1_21\NNP\1740|*|3|or|vkorc1 (l_conj) vkorc1_25\NNP\1740|*|4
T8_T29 NONE s/r_14\NN\1740| (r_compound) ratios_15\NNS\13815152|in|warfarin|s/r (r_nmod) difference_8\NN\4723816|a|significant|p<0.01|ratios|patients (l_nmod) patients_28\NNS\9898892|between|vkorc1 (l_compound) vkorc1_17\NNP\1740|*|2|and|vkorc1
T1_T16 NONE warfarin_18\NN\2718259| (r_compound) enantiomers_19\NNS\14818238|of|warfarin (r_nmod) clearance_16\NN\5089947|in|the|metabolic|enantiomers (r_nmod) involved_12\VBN\2676054|clearance (r_acl) factors_11\NNS\7326557|to|some|unidentified|involved (r_nmod) linked_7\VBN\628491|that|haplotypes|possibly|are|factors (l_nsubjpass) haplotypes_4\NNS\7963711|vkorc1 (l_compound) vkorc1_3\NN\1740|
8150771
T5_T20 NONE ceftazidime_15\NN\2996840|to|both|and|cefepime (r_nmod) resistant_12\JJ\1740|strains|may|be|ceftazidime|. (l_nsubj) strains_1\NNS\7358060|only|aeruginosa|producing (l_acl) producing_5\VBG\1617192|amounts (l_dobj) amounts_7\NNS\13329641|large|beta-lactamase (l_nmod) beta-lactamase_9\NN\14732946|of
T6_T20 NONE cefepime_17\NN\1740| (r_conj) ceftazidime_15\NN\2996840|to|both|and|cefepime (r_nmod) resistant_12\JJ\1740|strains|may|be|ceftazidime|. (l_nsubj) strains_1\NNS\7358060|only|aeruginosa|producing (l_acl) producing_5\VBG\1617192|amounts (l_dobj) amounts_7\NNS\13329641|large|beta-lactamase (l_nmod) beta-lactamase_9\NN\14732946|of
23282066
T12_T16 NONE midazolam_25\NN\2830852|of|and|triazolam (r_nmod) oxidation_23\NN\13447361|via|in|midazolam (r_nmod) metabolized_13\VBN\1740|to|be|enzymes|oxidation (l_nmod) enzymes_16\NNS\14723628|by|cyp3a (l_compound) cyp3a_15\NN\1740|
T13_T16 NONE triazolam_27\NN\2830852| (r_conj) midazolam_25\NN\2830852|of|and|triazolam (r_nmod) oxidation_23\NN\13447361|via|in|midazolam (r_nmod) metabolized_13\VBN\1740|to|be|enzymes|oxidation (l_nmod) enzymes_16\NNS\14723628|by|cyp3a (l_compound) cyp3a_15\NN\1740|
T1_T14 CPR:4 mdz_2\NN\1740| (r_nsubj) caused_3\VBD\1617192|furthermore|,|mdz|inactivation|potencies|. (l_dobj) inactivation_5\NN\13518963|mechanism-based|1'-hydroxylation|microsomes (l_nmod) 1'-hydroxylation_11\NN\1740|of|cytochrome|p450|3a-dependent|trz (l_amod) 3a-dependent_9\JJ\1740|
T2_T14 CPR:9 trz_10\NN\1740| (r_compound) 1'-hydroxylation_11\NN\1740|of|cytochrome|p450|3a-dependent|trz (l_amod) 3a-dependent_9\JJ\1740|
23257735
23425605
T2_T27 NONE tyrosine_1\NN\14601829| (r_compound) α-methyltyrosine_4\NN\1740|the|tyrosine|hydroxylase|inhibitor|300µm (l_compound) hydroxylase_2\NN\1740|
T3_T27 CPR:4 α-methyltyrosine_4\NN\1740|the|tyrosine|hydroxylase|inhibitor|300µm (l_compound) hydroxylase_2\NN\1740|
T4_T27 NONE mehg-induced_12\JJ\1740| (r_amod) release_14\NN\3748886|mehg-induced|da (r_dobj) abolished_11\VBD\1740|α-methyltyrosine|completely|release|. (l_nsubj) α-methyltyrosine_4\NN\1740|the|tyrosine|hydroxylase|inhibitor|300µm (l_compound) hydroxylase_2\NN\1740|
T5_T28 NONE mehg_0\NN\1740| (r_nsubj) increased_2\VBD\169651|mehg|significantly|accumulation|,|revealing|. (l_advcl) revealing_15\VBG\2137132|increases (l_ccomp) increases_18\VBZ\169651|that|mehg|activity (l_dobj) activity_21\NN\30358|tyrosine|hydroxylase (l_compound) hydroxylase_20\NN\1740|
T6_T28 NONE 3-hydroxybenzylhydrazine_10\NN\1740|with|10µm (r_nmod) treated_8\VBN\2376958|3-hydroxybenzylhydrazine (r_acl) cells_7\NNS\3080309|in|treated (r_nmod) accumulation_5\NN\13497135|da|precursor|cells (r_dobj) increased_2\VBD\169651|mehg|significantly|accumulation|,|revealing|. (l_advcl) revealing_15\VBG\2137132|increases (l_ccomp) increases_18\VBZ\169651|that|mehg|activity (l_dobj) activity_21\NN\30358|tyrosine|hydroxylase (l_compound) hydroxylase_20\NN\1740|
T7_T28 CPR:3 mehg_17\NN\1740| (r_nsubj) increases_18\VBZ\169651|that|mehg|activity (l_dobj) activity_21\NN\30358|tyrosine|hydroxylase (l_compound) hydroxylase_20\NN\1740|
T8_T28 NONE tyrosine_19\NN\14601829| (r_compound) activity_21\NN\30358|tyrosine|hydroxylase (l_compound) hydroxylase_20\NN\1740|
23215039
T1_T2 NONE cysteine_4\NN\14601829| (r_compound) protease_5\NN\14732946|legumain|is|a|lysosomal|cysteine|remains|. (l_nsubj) legumain_0\NN\1740|
T1_T3 NONE cysteine_4\NN\14601829| (r_compound) protease_5\NN\14732946|legumain|is|a|lysosomal|cysteine|remains|.
12080538
T12_T22 NONE estrogen_8\NN\14745635| (r_nmod:npmod) receptor-positive_9\JJ\1740|estrogen|or|receptor-positive
T12_T25 NONE estrogen_8\NN\14745635| (r_nmod:npmod) receptor-positive_9\JJ\1740|estrogen|or|receptor-positive (l_conj) receptor-positive_12\JJ\1740|progesterone
T17_T22 NONE progesterone_11\NN\14747338| (r_nmod:npmod) receptor-positive_12\JJ\1740|progesterone (r_conj) receptor-positive_9\JJ\1740|estrogen|or|receptor-positive
T17_T25 NONE progesterone_11\NN\14747338| (r_nmod:npmod) receptor-positive_12\JJ\1740|progesterone
T6_T20 NONE tamoxifen_5\NN\2714883|therapies|are|,|acetate|,|and|inhibitors|. (l_conj) inhibitors_12\NNS\20090|aromatase (l_compound) aromatase_11\NN\1740|
T7_T20 NONE acetate_8\NN\15010703|megestrol (r_conj) tamoxifen_5\NN\2714883|therapies|are|,|acetate|,|and|inhibitors|. (l_conj) inhibitors_12\NNS\20090|aromatase (l_compound) aromatase_11\NN\1740|
T13_T21 NONE tamoxifen_10\NN\2714883| (r_compound) failure_11\NN\66216|after|tamoxifen (r_nmod) used_5\VBN\1156834|inhibitors|are|currently|therapy|failure|. (l_nsubjpass) inhibitors_2\NNS\20090|the|aromatase (l_compound) aromatase_1\NN\1740|
T14_T23 CPR:4 anastrozole_5\NN\1740|,|inhibitor|, (l_appos) inhibitor_9\NN\20090|an|aromatase (l_compound) aromatase_8\NN\1740|
T15_T23 NONE tamoxifen_18\NN\2714883|to (r_nmod) superior_16\JJ\1740|even|tamoxifen (r_conj) effective_13\JJ\1740|that|anastrozole|is|as|or|superior|used (l_nsubj) anastrozole_5\NN\1740|,|inhibitor|, (l_appos) inhibitor_9\NN\20090|an|aromatase (l_compound) aromatase_8\NN\1740|
T16_T24 NONE estrogen_7\NN\14745635| (r_compound) receptor_8\NN\5225602|estrogen
T18_T19 CPR:4 fulvestrant_0\NN\1740|,|agent|, (r_nsubj) induces_12\VBZ\1627355|fulvestrant|only|degradation|but|antagonist|;|provides|. (l_dobj) degradation_14\NN\199130|the|receptor (l_nmod) receptor_18\NN\5225602|of|the|estrogen
T1_T19 NONE estrogen_17\NN\14745635| (r_compound) receptor_18\NN\5225602|of|the|estrogen
T2_T19 NONE estrogen_23\NN\14745635| (r_compound) antagonist_24\NN\7846|also|is|an|estrogen (r_conj) induces_12\VBZ\1627355|fulvestrant|only|degradation|but|antagonist|;|provides|. (l_dobj) degradation_14\NN\199130|the|receptor (l_nmod) receptor_18\NN\5225602|of|the|estrogen
23267011
T22_T32 NONE 8-oxoguanine_11\NN\1740| (r_compound) lesion_12\NN\14204950|of|a|templating|8-oxoguanine (r_nmod) bypass_7\NN\3519981|mutagenic|lesion (r_dobj) modulate_5\VBP\1724459|interactions|bypass|. (l_nsubj) interactions_4\NNS\37396|dna|groove (l_compound) groove_3\NN\13896369|polymerase|minor
T14_T27 NONE 8-oxog._20\NN\1740|filling|opposite (r_nmod) confronted_15\VBN\1079480|repair|,|β|is|8-oxog. (l_nsubjpass) β_13\NN\1740|polymerase
T16_T28 NONE syn-8-oxog_9\JJ\1740| (r_conj) anti-_7\JJ\1740|between|and|syn-8-oxog (r_nmod) discriminates_5\VBZ\650353|how|β|anti- (l_nsubj) β_4\NN\1740|pol
T16_T29 NONE syn-8-oxog_9\JJ\1740| (r_conj) anti-_7\JJ\1740|between|and|syn-8-oxog (r_nmod) discriminates_5\VBZ\650353|how|β|anti- (r_ccomp) determine_1\VB\1645601|to|discriminates (r_advcl) introduced_12\VBD\831651|determine|,|we|mutation|alter|. (l_dobj) mutation_15\NN\4475|a|point|r283|k (l_appos) k_18\NN\13608598|)
T17_T30 NONE 8-oxog._12\NN\1740| (r_nmod) results_6\VBZ\2633881|that|substitution|fidelity|8-oxog. (r_ccomp) demonstrate_2\VBP\2137132|studies|results|show (l_parataxis) show_20\VBP\2137132|studies|has|. (l_nsubj) studies_14\NNS\635850|structural|β (l_nmod) β_19\NN\1740|with|r283|k|pol (l_compound) k_17\NN\13608598|
T17_T31 NONE 8-oxog._12\NN\1740| (r_nmod) results_6\VBZ\2633881|that|substitution|fidelity|8-oxog. (r_ccomp) demonstrate_2\VBP\2137132|studies|results|show (l_parataxis) show_20\VBP\2137132|studies|has|. (l_nsubj) studies_14\NNS\635850|structural|β (l_nmod) β_19\NN\1740|with|r283|k|pol
T18_T30 NONE 8-oxog_27\NN\1740| (r_dobj) has_26\VBZ\2108377|that|complex|8-oxog|equilibrium (r_ccomp) show_20\VBP\2137132|studies|has|. (l_nsubj) studies_14\NNS\635850|structural|β (l_nmod) β_19\NN\1740|with|r283|k|pol (l_compound) k_17\NN\13608598|
T18_T31 NONE 8-oxog_27\NN\1740| (r_dobj) has_26\VBZ\2108377|that|complex|8-oxog|equilibrium (r_ccomp) show_20\VBP\2137132|studies|has|. (l_nsubj) studies_14\NNS\635850|structural|β (l_nmod) β_19\NN\1740|with|r283|k|pol
T2_T23 NONE datp-analogue_18\NN\1740|with|an|incoming|and|8-oxog (r_nmod) complex_9\NN\5869584|the|ternary|mutant|datp-analogue (r_nsubj) resembles_22\VBZ\2657219|contrast|,|complex|structure|adopting|. (l_nmod) contrast_1\NN\13854649|in|β (l_nmod) β_5\NN\1740|to|wild-type|pol
T2_T24 NONE datp-analogue_18\NN\1740|with|an|incoming|and|8-oxog (r_nmod) complex_9\NN\5869584|the|ternary|mutant|datp-analogue (l_nmod) mutant_14\NN\4475|of|the|r283|k (l_compound) k_13\NN\13608598|
T3_T23 NONE 8-oxog_21\NN\1740|templating (r_conj) datp-analogue_18\NN\1740|with|an|incoming|and|8-oxog (r_nmod) complex_9\NN\5869584|the|ternary|mutant|datp-analogue (r_nsubj) resembles_22\VBZ\2657219|contrast|,|complex|structure|adopting|. (l_nmod) contrast_1\NN\13854649|in|β (l_nmod) β_5\NN\1740|to|wild-type|pol
T3_T24 NONE 8-oxog_21\NN\1740|templating (r_conj) datp-analogue_18\NN\1740|with|an|incoming|and|8-oxog (r_nmod) complex_9\NN\5869584|the|ternary|mutant|datp-analogue (l_nmod) mutant_14\NN\4475|of|the|r283|k (l_compound) k_13\NN\13608598|
T4_T23 NONE 8-oxog_28\NN\1740| (r_nsubj) adopting_29\VBG\674607|with|8-oxog|anti-conformation (r_advcl) resembles_22\VBZ\2657219|contrast|,|complex|structure|adopting|. (l_nmod) contrast_1\NN\13854649|in|β (l_nmod) β_5\NN\1740|to|wild-type|pol
T4_T24 NONE 8-oxog_28\NN\1740| (r_nsubj) adopting_29\VBG\674607|with|8-oxog|anti-conformation (r_advcl) resembles_22\VBZ\2657219|contrast|,|complex|structure|adopting|. (l_nsubj) complex_9\NN\5869584|the|ternary|mutant|datp-analogue (l_nmod) mutant_14\NN\4475|of|the|r283|k (l_compound) k_13\NN\13608598|
T5_T25 NONE nucleotide_6\NN\14850483|the|incoming (r_nsubj) unable_8\JJ\1740|that|nucleotide|is|induce (l_xcomp) induce_10\VB\1627355|to|conformation|interactions (l_nmod) interactions_19\NNS\37396|without|minor|groove|dna|polymerase|influence (l_compound) groove_16\NN\13896369|
T5_T26 NONE nucleotide_6\NN\14850483|the|incoming (r_nsubj) unable_8\JJ\1740|that|nucleotide|is|induce (l_xcomp) induce_10\VB\1627355|to|conformation|interactions (l_nmod) interactions_19\NNS\37396|without|minor|groove|dna|polymerase|influence (l_compound) polymerase_18\NN\14732946|
T6_T25 NONE syn-8-oxog_12\NN\1740| (r_amod) conformation_13\NN\13897996|a|syn-8-oxog (r_dobj) induce_10\VB\1627355|to|conformation|interactions (l_nmod) interactions_19\NNS\37396|without|minor|groove|dna|polymerase|influence (l_compound) groove_16\NN\13896369|
T6_T26 NONE syn-8-oxog_12\NN\1740| (r_amod) conformation_13\NN\13897996|a|syn-8-oxog (r_dobj) induce_10\VB\1627355|to|conformation|interactions (l_nmod) interactions_19\NNS\37396|without|minor|groove|dna|polymerase|influence (l_compound) polymerase_18\NN\14732946|
T7_T25 NONE 8-oxog_27\NN\1740|of (r_nmod) templating_22\NN\1740|anti-/syn-equilibrium|8-oxog (r_dobj) influence_21\VBP\137313|that|templating|modulating (r_acl:relcl) interactions_19\NNS\37396|without|minor|groove|dna|polymerase|influence (l_compound) groove_16\NN\13896369|
T7_T26 NONE 8-oxog_27\NN\1740|of (r_nmod) templating_22\NN\1740|anti-/syn-equilibrium|8-oxog (r_dobj) influence_21\VBP\137313|that|templating|modulating (r_acl:relcl) interactions_19\NNS\37396|without|minor|groove|dna|polymerase|influence (l_compound) polymerase_18\NN\14732946|
17315258
T16_T41 NONE dihydrolipoamide_5\NN\1740| (r_compound) activity_8\NN\30358|of|dihydrolipoamide|dehydrogenase|diaphorase (l_compound) dehydrogenase_6\NN\1740|
T16_T42 NONE dihydrolipoamide_5\NN\1740| (r_compound) activity_8\NN\30358|of|dihydrolipoamide|dehydrogenase|diaphorase (l_compound) diaphorase_7\NN\1740|
T10_T17 NONE dihydrolipoamide_2\NN\1740| (r_compound) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh
T10_T26 NONE dihydrolipoamide_2\NN\1740| (r_compound) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (r_nsubj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_conj) act_20\VB\1619354|can|also|diaphorase (l_nmod) diaphorase_23\NN\1740|as|a|catalyzing
T10_T34 NONE dihydrolipoamide_2\NN\1740| (r_compound) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|)
T10_T35 NONE dihydrolipoamide_2\NN\1740| (r_compound) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|) (l_appos) ec_7\NN\8294696|1.8.1.4 (l_nummod) 1.8.1.4_8\CD\1740|
T11_T17 NONE tetrazolium_44\NN\1740|nitroblue|nbt (r_conj) ubiquinone_41\NN\14800277|such|and|tetrazolium (r_nmod) molecules_38\NNS\9465459|of|electron-accepting|ubiquinone (r_nmod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh
T11_T26 NONE tetrazolium_44\NN\1740|nitroblue|nbt (r_conj) ubiquinone_41\NN\14800277|such|and|tetrazolium (r_nmod) molecules_38\NNS\9465459|of|electron-accepting|ubiquinone (r_nmod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing
T11_T34 NONE tetrazolium_44\NN\1740|nitroblue|nbt (r_conj) ubiquinone_41\NN\14800277|such|and|tetrazolium (r_nmod) molecules_38\NNS\9465459|of|electron-accepting|ubiquinone (r_nmod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|)
T11_T35 NONE tetrazolium_44\NN\1740|nitroblue|nbt (r_conj) ubiquinone_41\NN\14800277|such|and|tetrazolium (r_nmod) molecules_38\NNS\9465459|of|electron-accepting|ubiquinone (r_nmod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|) (l_appos) ec_7\NN\8294696|1.8.1.4 (l_nummod) 1.8.1.4_8\CD\1740|
T12_T17 NONE nbt_46\NN\1740|(|) (r_appos) tetrazolium_44\NN\1740|nitroblue|nbt (r_conj) ubiquinone_41\NN\14800277|such|and|tetrazolium (r_nmod) molecules_38\NNS\9465459|of|electron-accepting|ubiquinone (r_nmod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh
T12_T26 NONE nbt_46\NN\1740|(|) (r_appos) tetrazolium_44\NN\1740|nitroblue|nbt (r_conj) ubiquinone_41\NN\14800277|such|and|tetrazolium (r_nmod) molecules_38\NNS\9465459|of|electron-accepting|ubiquinone (r_nmod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing
T12_T34 NONE nbt_46\NN\1740|(|) (r_appos) tetrazolium_44\NN\1740|nitroblue|nbt (r_conj) ubiquinone_41\NN\14800277|such|and|tetrazolium (r_nmod) molecules_38\NNS\9465459|of|electron-accepting|ubiquinone (r_nmod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|)
T12_T35 NONE nbt_46\NN\1740|(|) (r_appos) tetrazolium_44\NN\1740|nitroblue|nbt (r_conj) ubiquinone_41\NN\14800277|such|and|tetrazolium (r_nmod) molecules_38\NNS\9465459|of|electron-accepting|ubiquinone (r_nmod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|) (l_appos) ec_7\NN\8294696|1.8.1.4 (l_nummod) 1.8.1.4_8\CD\1740|
T15_T17 NONE nad(+)-dependent_11\JJ\1740| (r_amod) oxidation_12\NN\13447361|nad(+)-dependent|dihydrolipoamide (r_dobj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh
T15_T26 NONE nad(+)-dependent_11\JJ\1740| (r_amod) oxidation_12\NN\13447361|nad(+)-dependent|dihydrolipoamide (r_dobj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_conj) act_20\VB\1619354|can|also|diaphorase (l_nmod) diaphorase_23\NN\1740|as|a|catalyzing
T15_T34 NONE nad(+)-dependent_11\JJ\1740| (r_amod) oxidation_12\NN\13447361|nad(+)-dependent|dihydrolipoamide (r_dobj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|)
T15_T35 NONE nad(+)-dependent_11\JJ\1740| (r_amod) oxidation_12\NN\13447361|nad(+)-dependent|dihydrolipoamide (r_dobj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|) (l_appos) ec_7\NN\8294696|1.8.1.4 (l_nummod) 1.8.1.4_8\CD\1740|
T2_T17 NONE dihydrolipoamide_14\NN\1740|of (r_nmod) oxidation_12\NN\13447361|nad(+)-dependent|dihydrolipoamide (r_dobj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh
T2_T26 NONE dihydrolipoamide_14\NN\1740|of (r_nmod) oxidation_12\NN\13447361|nad(+)-dependent|dihydrolipoamide (r_dobj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_conj) act_20\VB\1619354|can|also|diaphorase (l_nmod) diaphorase_23\NN\1740|as|a|catalyzing
T2_T34 NONE dihydrolipoamide_14\NN\1740|of (r_nmod) oxidation_12\NN\13447361|nad(+)-dependent|dihydrolipoamide (r_dobj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|)
T2_T35 NONE dihydrolipoamide_14\NN\1740|of (r_nmod) oxidation_12\NN\13447361|nad(+)-dependent|dihydrolipoamide (r_dobj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|) (l_appos) ec_7\NN\8294696|1.8.1.4 (l_nummod) 1.8.1.4_8\CD\1740|
T8_T17 NONE )_33\-RRB-\1740| (r_punct) form_32\NN\6286395|(|reduced|) (r_appos) dinucleotide_29\NN\1740|form (r_compound) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh
T8_T26 NONE )_33\-RRB-\1740| (r_punct) form_32\NN\6286395|(|reduced|) (r_appos) dinucleotide_29\NN\1740|form (r_compound) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing
T8_T34 NONE )_33\-RRB-\1740| (r_punct) form_32\NN\6286395|(|reduced|) (r_appos) dinucleotide_29\NN\1740|form (r_compound) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|)
T8_T35 NONE )_33\-RRB-\1740| (r_punct) form_32\NN\6286395|(|reduced|) (r_appos) dinucleotide_29\NN\1740|form (r_compound) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|) (l_appos) ec_7\NN\8294696|1.8.1.4 (l_nummod) 1.8.1.4_8\CD\1740|
T9_T17 NONE (nadh)-dependent_34\JJ\1740| (r_amod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh
T9_T26 NONE (nadh)-dependent_34\JJ\1740| (r_amod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing
T9_T34 NONE (nadh)-dependent_34\JJ\1740| (r_amod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|)
T9_T35 NONE (nadh)-dependent_34\JJ\1740| (r_amod) reduction_35\NN\351485|in|vitro|nicotinamide|adenine|dinucleotide|(nadh)-dependent|molecules (r_dobj) catalyzing_24\VBG\146138|reduction (r_acl) diaphorase_23\NN\1740|as|a|catalyzing (r_nmod) act_20\VB\1619354|can|also|diaphorase (r_conj) catalyzes_10\VBZ\146138|dehydrogenase|oxidation|vivo|and|act|. (l_nsubj) dehydrogenase_3\NN\1740|mammalian|mitochondrial|dihydrolipoamide|dldh (l_appos) dldh_5\NN\1740|(|,|ec|) (l_appos) ec_7\NN\8294696|1.8.1.4 (l_nummod) 1.8.1.4_8\CD\1740|
T13_T33 NONE nadh_30\NN\1740| (r_dobj) using_29\VBG\1156834|nadh|donor (r_acl) staining_28\NN\275424|by|diaphorase|activity|using (r_nmod) followed_24\VBN\1835496|which|was|staining (r_acl:relcl) bn-page_16\NN\1740|by|nongradient|%|,|followed (r_nmod) resolved_13\VBN\352826|extracts|were|bn-page|. (l_nsubjpass) extracts_3\NNS\14589223|brain|mitochondrial|,|used|, (l_acl) used_5\VBN\1156834|source (l_nmod) source_8\NN\8620061|as|the|dldh (l_nmod) dldh_10\NN\1740|of
T13_T36 NONE nadh_30\NN\1740| (r_dobj) using_29\VBG\1156834|nadh|donor (r_acl) staining_28\NN\275424|by|diaphorase|activity|using (l_compound) diaphorase_26\NN\1740|
T14_T33 NONE nbt_36\NN\1740| (r_conj) donor_34\NN\9608709|as|the|electron|and|nbt|acceptor (r_nmod) using_29\VBG\1156834|nadh|donor (r_acl) staining_28\NN\275424|by|diaphorase|activity|using (r_nmod) followed_24\VBN\1835496|which|was|staining (r_acl:relcl) bn-page_16\NN\1740|by|nongradient|%|,|followed (r_nmod) resolved_13\VBN\352826|extracts|were|bn-page|. (l_nsubjpass) extracts_3\NNS\14589223|brain|mitochondrial|,|used|, (l_acl) used_5\VBN\1156834|source (l_nmod) source_8\NN\8620061|as|the|dldh (l_nmod) dldh_10\NN\1740|of
T14_T36 NONE nbt_36\NN\1740| (r_conj) donor_34\NN\9608709|as|the|electron|and|nbt|acceptor (r_nmod) using_29\VBG\1156834|nadh|donor (r_acl) staining_28\NN\275424|by|diaphorase|activity|using (l_compound) diaphorase_26\NN\1740|
T1_T39 NONE dihydrolipoamide_24\NN\1740| (r_dobj) using_23\VBG\1156834|dihydrolipoamide|substrate (r_advcl) measures_19\VBZ\697589|that|activity|using (l_dobj) activity_22\NN\30358|dldh|dehydrogenase (l_compound) dldh_20\NN\1740|
T1_T40 NONE dihydrolipoamide_24\NN\1740| (r_dobj) using_23\VBG\1156834|dihydrolipoamide|substrate (r_advcl) measures_19\VBZ\697589|that|activity|using (l_dobj) activity_22\NN\30358|dldh|dehydrogenase (l_compound) dehydrogenase_21\NN\1740|
T3_T22 NONE thiol-reactive_5\JJ\1740| (r_amod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) dldh_18\NN\1740|
T3_T23 NONE thiol-reactive_5\JJ\1740| (r_amod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) diaphorase_19\NN\1740|
T3_T24 NONE thiol-reactive_5\JJ\1740| (r_amod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) dldh_31\NN\1740|
T3_T25 NONE thiol-reactive_5\JJ\1740| (r_amod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) diaphorase_32\NN\1740|
T3_T27 NONE thiol-reactive_5\JJ\1740| (r_amod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_advcl) having_38\VBG\2108377|without|remove (l_xcomp) remove_40\VB\2012344|to|reagents (l_dobj) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dldh_52\NN\1740|
T3_T28 NONE thiol-reactive_5\JJ\1740| (r_amod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_advcl) having_38\VBG\2108377|without|remove (l_xcomp) remove_40\VB\2012344|to|reagents (l_dobj) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dehydrogenase_53\NN\1740|
T4_T22 NONE n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) dldh_18\NN\1740|
T4_T23 NONE n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) diaphorase_19\NN\1740|
T4_T24 NONE n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) dldh_31\NN\1740|
T4_T25 NONE n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) diaphorase_32\NN\1740|
T4_T27 NONE n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_advcl) having_38\VBG\2108377|without|remove (l_xcomp) remove_40\VB\2012344|to|reagents (l_dobj) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dldh_52\NN\1740|
T4_T28 NONE n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_advcl) having_38\VBG\2108377|without|remove (l_xcomp) remove_40\VB\2012344|to|reagents (l_dobj) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dehydrogenase_53\NN\1740|
T5_T22 NONE nem_11\NN\1740|(|) (r_appos) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) dldh_18\NN\1740|
T5_T23 NONE nem_11\NN\1740|(|) (r_appos) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) diaphorase_19\NN\1740|
T5_T24 NONE nem_11\NN\1740|(|) (r_appos) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) dldh_31\NN\1740|
T5_T25 NONE nem_11\NN\1740|(|) (r_appos) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) diaphorase_32\NN\1740|
T5_T27 NONE nem_11\NN\1740|(|) (r_appos) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_advcl) having_38\VBG\2108377|without|remove (l_xcomp) remove_40\VB\2012344|to|reagents (l_dobj) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dldh_52\NN\1740|
T5_T28 NONE nem_11\NN\1740|(|) (r_appos) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_advcl) having_38\VBG\2108377|without|remove (l_xcomp) remove_40\VB\2012344|to|reagents (l_dobj) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dehydrogenase_53\NN\1740|
T6_T22 NONE oxide_15\NN\14818238| (r_compound) donors_16\NNS\9608709|nitric|oxide (r_conj) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) dldh_18\NN\1740|
T6_T23 NONE oxide_15\NN\14818238| (r_compound) donors_16\NNS\9608709|nitric|oxide (r_conj) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) diaphorase_19\NN\1740|
T6_T24 NONE oxide_15\NN\14818238| (r_compound) donors_16\NNS\9608709|nitric|oxide (r_conj) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) dldh_31\NN\1740|
T6_T25 NONE oxide_15\NN\14818238| (r_compound) donors_16\NNS\9608709|nitric|oxide (r_conj) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) diaphorase_32\NN\1740|
T6_T27 NONE oxide_15\NN\14818238| (r_compound) donors_16\NNS\9608709|nitric|oxide (r_conj) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_advcl) having_38\VBG\2108377|without|remove (l_xcomp) remove_40\VB\2012344|to|reagents (l_dobj) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dldh_52\NN\1740|
T6_T28 NONE oxide_15\NN\14818238| (r_compound) donors_16\NNS\9608709|nitric|oxide (r_conj) n-ethylmaleimide_9\NN\1740|such|nem|and|donors (r_nmod) reagents_6\NNS\14779550|of|thiol-reactive|n-ethylmaleimide (r_nmod) effects_3\NNS\13245626|the|reagents|activity (r_nsubjpass) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_advcl) demonstrating_24\VBG\2137132|determined (l_ccomp) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_advcl) having_38\VBG\2108377|without|remove (l_xcomp) remove_40\VB\2012344|to|reagents (l_dobj) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dehydrogenase_53\NN\1740|
T7_T22 NONE thiol-reactive_42\JJ\1740| (r_amod) reagents_43\NNS\14779550|these|thiol-reactive|interfere (r_dobj) remove_40\VB\2012344|to|reagents (r_xcomp) having_38\VBG\2108377|without|remove (r_advcl) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (r_ccomp) demonstrating_24\VBG\2137132|determined (r_advcl) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_nsubjpass) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) dldh_18\NN\1740|
T7_T23 NONE thiol-reactive_42\JJ\1740| (r_amod) reagents_43\NNS\14779550|these|thiol-reactive|interfere (r_dobj) remove_40\VB\2012344|to|reagents (r_xcomp) having_38\VBG\2108377|without|remove (r_advcl) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (r_ccomp) demonstrating_24\VBG\2137132|determined (r_advcl) evaluated_22\VBN\670261|finally|,|effects|were|,|demonstrating|. (l_nsubjpass) effects_3\NNS\13245626|the|reagents|activity (l_nmod) activity_20\NN\30358|on|dldh|diaphorase (l_compound) diaphorase_19\NN\1740|
T7_T24 NONE thiol-reactive_42\JJ\1740| (r_amod) reagents_43\NNS\14779550|these|thiol-reactive|interfere (r_dobj) remove_40\VB\2012344|to|reagents (r_xcomp) having_38\VBG\2108377|without|remove (r_advcl) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) dldh_31\NN\1740|
T7_T25 NONE thiol-reactive_42\JJ\1740| (r_amod) reagents_43\NNS\14779550|these|thiol-reactive|interfere (r_dobj) remove_40\VB\2012344|to|reagents (r_xcomp) having_38\VBG\2108377|without|remove (r_advcl) determined_36\VBN\1645601|that|,|method|,|activity|can|be|having (l_nsubjpass) activity_33\NN\30358|dldh|diaphorase (l_compound) diaphorase_32\NN\1740|
T7_T27 NONE thiol-reactive_42\JJ\1740| (r_amod) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dldh_52\NN\1740|
T7_T28 NONE thiol-reactive_42\JJ\1740| (r_amod) reagents_43\NNS\14779550|these|thiol-reactive|interfere (l_acl:relcl) interfere_47\VB\2451370|that|may|otherwise|measurement (l_nmod) measurement_50\NN\407535|with|spectrophotometric|activity (l_nmod) activity_54\NN\30358|of|dldh|dehydrogenase (l_compound) dehydrogenase_53\NN\1740|
23604819
23416002
T7_T17 CPR:4 acid_1\NN\14818238|amino (r_nmod:npmod) derived_2\VBD\634472|acid (r_amod) quinazolines_3\NNS\1740|derived|inhibitors|. (l_nmod) inhibitors_6\NNS\20090|as|rock/pka (l_compound) rock/pka_5\NN\1740|
T7_T18 CPR:4 acid_1\NN\14818238|amino (r_nmod:npmod) derived_2\VBD\634472|acid (r_amod) quinazolines_3\NNS\1740|derived|inhibitors|. (l_nmod) inhibitors_6\NNS\20090|as|rock/pka (l_compound) rock/pka_5\NN\1740|
T8_T17 CPR:4 quinazolines_3\NNS\1740|derived|inhibitors|. (l_nmod) inhibitors_6\NNS\20090|as|rock/pka (l_compound) rock/pka_5\NN\1740|
T8_T18 CPR:4 quinazolines_3\NNS\1740|derived|inhibitors|. (l_nmod) inhibitors_6\NNS\20090|as|rock/pka (l_compound) rock/pka_5\NN\1740|
T5_T13 CPR:4 acid-derived_11\JJ\1740|amino (r_amod) quinazolines_12\NNS\1740|on|acid-derived (r_nmod) based_8\VBN\2694933|quinazolines (r_prep) studies_4\NNS\635850|sar|inhibitors|based (l_nmod) inhibitors_7\NNS\20090|for|rock (l_compound) rock_6\NN\19128|
T6_T13 CPR:4 quinazolines_12\NNS\1740|on|acid-derived (r_nmod) based_8\VBN\2694933|quinazolines (r_prep) studies_4\NNS\635850|sar|inhibitors|based (l_nmod) inhibitors_7\NNS\20090|for|rock (l_compound) rock_6\NN\19128|
T1_T9 NONE acid_5\NN\14818238|amino (r_nmod:npmod) derived_6\VBN\634472|acid (r_amod) quinazolinones_7\NNS\1740|these|derived (r_nsubj) inhibitors_16\NNS\20090|that|quinazolinones|were|mainly|pan-rock (l_compound) pan-rock_10\NN\1740|i (l_dep) i_12\CD\14622893|(|&|ii|) (l_punct) )_15\-RRB-\1740|
T2_T9 NONE quinazolinones_7\NNS\1740|these|derived (r_nsubj) inhibitors_16\NNS\20090|that|quinazolinones|were|mainly|pan-rock (l_compound) pan-rock_10\NN\1740|i (l_dep) i_12\CD\14622893|(|&|ii|) (l_punct) )_15\-RRB-\1740|
T3_T12 CPR:4 acid_9\NN\14818238|non-amino (r_nmod:npmod) derived_10\VBN\634472|acid (r_amod) quinazolinones_11\NNS\1740|based|on|derived|,|selectivity (r_nmod) inhibitors_5\NNS\20090|from|rock|quinazolinones (l_compound) rock_4\NN\19128|
T3_T14 CPR:4 acid_9\NN\14818238|non-amino (r_nmod:npmod) derived_10\VBN\634472|acid (r_amod) quinazolinones_11\NNS\1740|based|on|derived|,|selectivity (l_acl:relcl) selectivity_15\NN\4916342|where|high|pka (l_nmod) pka_17\NN\1740|against
T3_T15 NONE acid_9\NN\14818238|non-amino (r_nmod:npmod) derived_10\VBN\634472|acid (r_amod) quinazolinones_11\NNS\1740|based|on|derived|,|selectivity (r_nmod) inhibitors_5\NNS\20090|from|rock|quinazolinones (r_nmod) distinct_2\JJ\1740|this|is|inhibitors|obtained.(22|possessed (l_dep) possessed_29\VBD\2630189|inhibitors|inhibition|. (l_dobj) inhibition_31\NN\1068773|sub-nanomolar|rock|,|potency|,|inhibition|,|and|stability (l_nmod) rock_33\NN\19128|of
T3_T16 NONE acid_9\NN\14818238|non-amino (r_nmod:npmod) derived_10\VBN\634472|acid (r_amod) quinazolinones_11\NNS\1740|based|on|derived|,|selectivity (r_nmod) inhibitors_5\NNS\20090|from|rock|quinazolinones (r_nmod) distinct_2\JJ\1740|this|is|inhibitors|obtained.(22|possessed (l_dep) possessed_29\VBD\2630189|inhibitors|inhibition|. (l_dobj) inhibition_31\NN\1068773|sub-nanomolar|rock|,|potency|,|inhibition|,|and|stability (l_conj) inhibition_48\NN\1068773|low|cytochrome|p-450 (l_compound) p-450_47\NN\1740|
T4_T12 CPR:4 quinazolinones_11\NNS\1740|based|on|derived|,|selectivity (r_nmod) inhibitors_5\NNS\20090|from|rock|quinazolinones (l_compound) rock_4\NN\19128|
T4_T14 CPR:4 quinazolinones_11\NNS\1740|based|on|derived|,|selectivity (l_acl:relcl) selectivity_15\NN\4916342|where|high|pka (l_nmod) pka_17\NN\1740|against
T4_T15 NONE quinazolinones_11\NNS\1740|based|on|derived|,|selectivity (r_nmod) inhibitors_5\NNS\20090|from|rock|quinazolinones (r_nmod) distinct_2\JJ\1740|this|is|inhibitors|obtained.(22|possessed (l_dep) possessed_29\VBD\2630189|inhibitors|inhibition|. (l_dobj) inhibition_31\NN\1068773|sub-nanomolar|rock|,|potency|,|inhibition|,|and|stability (l_nmod) rock_33\NN\19128|of
T4_T16 NONE quinazolinones_11\NNS\1740|based|on|derived|,|selectivity (r_nmod) inhibitors_5\NNS\20090|from|rock|quinazolinones (r_nmod) distinct_2\JJ\1740|this|is|inhibitors|obtained.(22|possessed (l_dep) possessed_29\VBD\2630189|inhibitors|inhibition|. (l_dobj) inhibition_31\NN\1068773|sub-nanomolar|rock|,|potency|,|inhibition|,|and|stability (l_conj) inhibition_48\NN\1068773|low|cytochrome|p-450 (l_compound) p-450_47\NN\1740|
23424207
T21_T41 CPR:4 cd_5\NN\14625458| (r_nsubj) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) dehydrogenase_19\NN\1740|lactate
T21_T42 CPR:4 cd_5\NN\14625458| (r_nsubj) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_22\NN\14732946|acid
T21_T43 CPR:4 cd_5\NN\14625458| (r_nsubj) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_25\NN\14732946|alkaline
T21_T44 CPR:4 cd_5\NN\14625458| (r_nsubj) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) enzymes_29\NNS\14723628|testicular|steroidogenic
T21_T45 CPR:4 cd_5\NN\14625458| (r_nsubj) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|,
T21_T46 CPR:4 cd_5\NN\14625458| (r_nsubj) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) hsd_34\NN\1740|(|)
T21_T47 CPR:4 cd_5\NN\14625458| (r_nsubj) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) activities_38\NNS\30358|17β-hsd (l_compound) 17β-hsd_37\NN\1740|
T22_T41 NONE testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) dehydrogenase_19\NN\1740|lactate
T22_T42 NONE testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_22\NN\14732946|acid
T22_T43 NONE testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_25\NN\14732946|alkaline
T22_T44 NONE testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) enzymes_29\NNS\14723628|testicular|steroidogenic
T22_T45 NONE testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (r_dobj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|,
T22_T46 NONE testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (r_dobj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) hsd_34\NN\1740|(|)
T22_T47 NONE testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (r_dobj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) activities_38\NNS\30358|17β-hsd (l_compound) 17β-hsd_37\NN\1740|
T23_T41 NONE lactate_18\NN\14850483| (r_compound) dehydrogenase_19\NN\1740|lactate
T23_T42 NONE lactate_18\NN\14850483| (r_compound) dehydrogenase_19\NN\1740|lactate (r_conj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_22\NN\14732946|acid
T23_T43 NONE lactate_18\NN\14850483| (r_compound) dehydrogenase_19\NN\1740|lactate (r_conj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_25\NN\14732946|alkaline
T23_T44 NONE lactate_18\NN\14850483| (r_compound) dehydrogenase_19\NN\1740|lactate (r_conj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) enzymes_29\NNS\14723628|testicular|steroidogenic
T23_T45 NONE lactate_18\NN\14850483| (r_compound) dehydrogenase_19\NN\1740|lactate (r_conj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (r_dobj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|,
T23_T46 NONE lactate_18\NN\14850483| (r_compound) dehydrogenase_19\NN\1740|lactate (r_conj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (r_dobj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) hsd_34\NN\1740|(|)
T23_T47 NONE lactate_18\NN\14850483| (r_compound) dehydrogenase_19\NN\1740|lactate (r_conj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (r_dobj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) activities_38\NNS\30358|17β-hsd (l_compound) 17β-hsd_37\NN\1740|
T24_T41 NONE 3β-hydroxysteroid_31\NN\1740| (r_compound) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (r_dep) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) dehydrogenase_19\NN\1740|lactate
T24_T42 NONE 3β-hydroxysteroid_31\NN\1740| (r_compound) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (r_dep) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_22\NN\14732946|acid
T24_T43 NONE 3β-hydroxysteroid_31\NN\1740| (r_compound) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (r_dep) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_25\NN\14732946|alkaline
T24_T44 NONE 3β-hydroxysteroid_31\NN\1740| (r_compound) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (r_dep) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) enzymes_29\NNS\14723628|testicular|steroidogenic
T24_T45 NONE 3β-hydroxysteroid_31\NN\1740| (r_compound) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|,
T24_T46 NONE 3β-hydroxysteroid_31\NN\1740| (r_compound) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) hsd_34\NN\1740|(|)
T24_T47 NONE 3β-hydroxysteroid_31\NN\1740| (r_compound) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) activities_38\NNS\30358|17β-hsd (l_compound) 17β-hsd_37\NN\1740|
T25_T41 NONE rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) dehydrogenase_19\NN\1740|lactate
T25_T42 NONE rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_22\NN\14732946|acid
T25_T43 NONE rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_25\NN\14732946|alkaline
T25_T44 NONE rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) enzymes_29\NNS\14723628|testicular|steroidogenic
T25_T45 NONE rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|,
T25_T46 NONE rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) hsd_34\NN\1740|(|)
T25_T47 NONE rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) activities_38\NNS\30358|17β-hsd (l_compound) 17β-hsd_37\NN\1740|
T26_T41 NONE se_51\NN\14724645| (r_conj) rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) dehydrogenase_19\NN\1740|lactate
T26_T42 NONE se_51\NN\14724645| (r_conj) rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_22\NN\14732946|acid
T26_T43 NONE se_51\NN\14724645| (r_conj) rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) phosphatase_25\NN\14732946|alkaline
T26_T44 NONE se_51\NN\14724645| (r_conj) rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dobj) testosterone_16\NN\14747587|plasma|,|dehydrogenase|,|phosphatase|,|phosphatase|and|enzymes (l_conj) enzymes_29\NNS\14723628|testicular|steroidogenic
T26_T45 NONE se_51\NN\14724645| (r_conj) rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|,
T26_T46 NONE se_51\NN\14724645| (r_conj) rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) hsd_34\NN\1740|(|)
T26_T47 NONE se_51\NN\14724645| (r_conj) rut_49\NN\13893786|and|se (r_compound) treatment_52\NN\654885|rut (r_nsubj) reversed_53\VBD\109660|while|treatment|change|values (r_advcl) increased_6\VBD\169651|that|cd|peroxidation|and|decreased|reversed (l_conj) decreased_14\VBD\169651|testosterone|:|dehydrogenase (l_dep) dehydrogenase_32\NN\1740|3β-hydroxysteroid|hsd|,|activities|as|sperm|, (l_appos) activities_38\NNS\30358|17β-hsd (l_compound) 17β-hsd_37\NN\1740|
T27_T40 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T27_T48 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T27_T49 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T27_T50 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T27_T51 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T27_T52 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px
T27_T53 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_31\NN\1740|(|)
T27_T54 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr
T27_T55 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T27_T56 CPR:4 cd_3\NN\14625458|with (r_nmod) intoxication_1\NN\14034177|acute|cd (r_nsubjpass) followed_6\VBN\1835496|intoxication|was|also|activity|. (l_nmod) activity_10\NN\30358|by|decreased|system (l_nmod) system_15\NN\3575240|of|the|antioxidant|defence|dismutase (l_dep) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst
T28_T40 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T28_T48 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T28_T49 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T28_T50 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T28_T51 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T28_T52 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px
T28_T53 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_31\NN\1740|(|)
T28_T54 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr
T28_T55 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T28_T56 NONE superoxide_17\NN\14971519| (r_compound) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst
T29_T40 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T29_T48 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T29_T49 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T29_T50 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T29_T51 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T29_T52 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px
T29_T53 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_31\NN\1740|(|)
T29_T54 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr
T29_T55 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T29_T56 NONE glutathione_28\NN\1740| (r_compound) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst
T31_T40 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T31_T48 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T31_T49 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T31_T50 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T31_T51 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T31_T52 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px
T31_T53 NONE gsh-px_31\NN\1740|(|)
T31_T54 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr
T31_T55 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T31_T56 NONE gsh-px_31\NN\1740|(|) (r_appos) peroxidase_29\NN\14971234|glutathione|gsh-px (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst
T32_T40 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T32_T48 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T32_T49 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T32_T50 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T32_T51 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T32_T52 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px
T32_T53 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_31\NN\1740|(|)
T32_T54 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr
T32_T55 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T32_T56 NONE glutathione_34\NN\1740| (r_compound) reductase_35\NN\14732946|glutathione|gr (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst
T33_T40 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T33_T48 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T33_T49 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T33_T50 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T33_T51 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T33_T52 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px
T33_T53 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_31\NN\1740|(|)
T33_T54 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr
T33_T55 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T33_T56 NONE glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst
T34_T40 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T34_T48 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T34_T49 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T34_T50 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T34_T51 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T34_T52 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px
T34_T53 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_31\NN\1740|(|)
T34_T54 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr
T34_T55 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T34_T56 NONE gsh_42\NN\1740|(|) (r_appos) glutathione_40\NN\1740|gsh (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) glutathione-s-transferase_46\NN\1740|gst
T35_T40 NONE glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T35_T48 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T35_T49 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T35_T50 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T35_T51 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T35_T52 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px
T35_T53 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_31\NN\1740|(|)
T35_T54 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr
T35_T55 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T35_T56 NONE glutathione-s-transferase_46\NN\1740|gst
T36_T40 NONE glutathione-s-transferase_46\NN\1740|gst (l_appos) gst_48\NN\1740|(|)
T36_T48 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|)
T36_T49 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_appos) sod_20\NN\9335240|(|)
T36_T50 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat
T36_T51 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) catalase_23\NN\14732946|cat (l_appos) cat_25\NN\2120997|(|)
T36_T52 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px
T36_T53 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) peroxidase_29\NN\14971234|glutathione|gsh-px (l_appos) gsh-px_31\NN\1740|(|)
T36_T54 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr
T36_T55 NONE glutathione-s-transferase_46\NN\1740|gst (r_conj) dismutase_18\NN\1740|(|superoxide|sod|,|catalase|,|peroxidase|,|reductase|,|glutathione|,|and|glutathione-s-transferase|) (l_conj) reductase_35\NN\14732946|glutathione|gr (l_appos) gr_37\NN\1740|(|)
T36_T56 NONE glutathione-s-transferase_46\NN\1740|gst
10439935
T15_T26 NONE catechol-o-methyltransferase_9\NN\1740|comt
T15_T28 NONE catechol-o-methyltransferase_9\NN\1740|comt (l_appos) comt_11\NN\1740|(|)
T17_T26 NONE catechol-o-methyltransferase_9\NN\1740|comt
T17_T28 NONE catechol-o-methyltransferase_9\NN\1740|comt (l_appos) comt_11\NN\1740|(|)
T5_T26 CPR:4 entacapone_2\NN\1740| (r_nsubj) inhibitor_13\NN\20090|entacapone|is|a|potent|peripheral|catechol-o-methyltransferase (l_compound) catechol-o-methyltransferase_9\NN\1740|comt
T5_T28 CPR:4 entacapone_2\NN\1740| (r_nsubj) inhibitor_13\NN\20090|entacapone|is|a|potent|peripheral|catechol-o-methyltransferase (l_compound) catechol-o-methyltransferase_9\NN\1740|comt (l_appos) comt_11\NN\1740|(|)
T12_T24 NONE levodopa_36\NN\14604959|to (r_nmod) response_34\NN\11410625|in|the|levodopa (r_nmod) deterioration_31\NN\14560612|end-of-dose|response|phenomenon (r_conj) patients_24\NNS\9898892|to|disease|and|deterioration (r_nmod) given_22\VBN\2327200|when|patients (r_advcl) improve_5\VB\126264|to|benefits|given (l_dobj) benefits_8\NNS\13278375|the|clinical|levodopa (l_nmod) levodopa_10\NN\14604959|of|plus|inhibitor (l_conj) inhibitor_17\NN\20090|an|aromatic|l-amino|acid|decarboxylase|aadc (l_compound) decarboxylase_16\NN\14732946|
T12_T25 NONE levodopa_36\NN\14604959|to (r_nmod) response_34\NN\11410625|in|the|levodopa (r_nmod) deterioration_31\NN\14560612|end-of-dose|response|phenomenon (r_conj) patients_24\NNS\9898892|to|disease|and|deterioration (r_nmod) given_22\VBN\2327200|when|patients (r_advcl) improve_5\VB\126264|to|benefits|given (l_dobj) benefits_8\NNS\13278375|the|clinical|levodopa (l_nmod) levodopa_10\NN\14604959|of|plus|inhibitor (l_conj) inhibitor_17\NN\20090|an|aromatic|l-amino|acid|decarboxylase|aadc (l_appos) aadc_19\NN\1740|(|)
T7_T24 NONE levodopa_10\NN\14604959|of|plus|inhibitor (l_conj) inhibitor_17\NN\20090|an|aromatic|l-amino|acid|decarboxylase|aadc (l_compound) decarboxylase_16\NN\14732946|
T7_T25 NONE levodopa_10\NN\14604959|of|plus|inhibitor (l_conj) inhibitor_17\NN\20090|an|aromatic|l-amino|acid|decarboxylase|aadc (l_appos) aadc_19\NN\1740|(|)
T9_T24 NONE acid_15\NN\14818238| (r_compound) inhibitor_17\NN\20090|an|aromatic|l-amino|acid|decarboxylase|aadc (l_compound) decarboxylase_16\NN\14732946|
T9_T25 NONE acid_15\NN\14818238| (r_compound) inhibitor_17\NN\20090|an|aromatic|l-amino|acid|decarboxylase|aadc (l_appos) aadc_19\NN\1740|(|)
T14_T27 NONE entacapone_18\NN\1740|with|mg (l_dep) mg_21\NN\13717155|(|200|dose|) (l_nmod) dose_24\NN\3740161|with|each|inhibitor (l_nmod) inhibitor_27\NN\20090|of|levodopa/aadc (l_compound) levodopa/aadc_26\NN\1740|
T16_T27 NONE levodopa/aadc_26\NN\1740|
T19_T21 NONE entacapone_0\NN\1740| (r_nsubj) provided_2\VBD\2199590|entacapone|also|benefits|given|. (l_advcl) given_5\VBN\2327200|when|inhibitor|trials (l_nmod) inhibitor_11\NN\20090|with|release|levodopa/|aadc|or|inhibitor (l_compound) aadc_10\NN\1740|
T19_T22 NONE entacapone_0\NN\1740| (r_nsubj) provided_2\VBD\2199590|entacapone|also|benefits|given|. (l_advcl) given_5\VBN\2327200|when|inhibitor|trials (l_nmod) inhibitor_11\NN\20090|with|release|levodopa/|aadc|or|inhibitor (l_conj) inhibitor_16\NN\20090|with|standard|levodopa/aadc|and|selegiline (l_compound) levodopa/aadc_15\NN\1740|
T1_T21 NONE levodopa/_9\NN\1740| (r_compound) inhibitor_11\NN\20090|with|release|levodopa/|aadc|or|inhibitor (l_compound) aadc_10\NN\1740|
T1_T22 NONE levodopa/_9\NN\1740| (r_compound) inhibitor_11\NN\20090|with|release|levodopa/|aadc|or|inhibitor (l_conj) inhibitor_16\NN\20090|with|standard|levodopa/aadc|and|selegiline (l_compound) levodopa/aadc_15\NN\1740|
T2_T21 NONE levodopa/aadc_15\NN\1740| (r_compound) inhibitor_16\NN\20090|with|standard|levodopa/aadc|and|selegiline (r_conj) inhibitor_11\NN\20090|with|release|levodopa/|aadc|or|inhibitor (l_compound) aadc_10\NN\1740|
T2_T22 NONE levodopa/aadc_15\NN\1740|
T3_T21 NONE selegiline_18\NN\1740| (r_conj) inhibitor_16\NN\20090|with|standard|levodopa/aadc|and|selegiline (r_conj) inhibitor_11\NN\20090|with|release|levodopa/|aadc|or|inhibitor (l_compound) aadc_10\NN\1740|
T3_T22 NONE selegiline_18\NN\1740| (r_conj) inhibitor_16\NN\20090|with|standard|levodopa/aadc|and|selegiline (l_compound) levodopa/aadc_15\NN\1740|
T8_T23 NONE levodopa/aadc_10\NN\1740|
16675639
T14_T36 NONE serotonin_12\NN\14807737| (r_compound) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter
T14_T37 NONE serotonin_12\NN\14807737| (r_compound) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_appos) hsert_18\NN\1740|(|)
T14_T38 NONE serotonin_12\NN\14807737| (r_compound) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_conj) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet
T14_T39 NONE serotonin_12\NN\14807737| (r_compound) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_conj) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (l_appos) hnet_27\NN\1740|(|)
T15_T36 NONE 5-ht_14\NN\1740|( (r_compound) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter
T15_T37 NONE 5-ht_14\NN\1740|( (r_compound) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_appos) hsert_18\NN\1740|(|)
T15_T38 NONE 5-ht_14\NN\1740|( (r_compound) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_conj) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet
T15_T39 NONE 5-ht_14\NN\1740|( (r_compound) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_conj) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (l_appos) hnet_27\NN\1740|(|)
T16_T36 NONE norepinephrine_21\NN\14807929| (r_compound) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (r_conj) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter
T16_T37 NONE norepinephrine_21\NN\14807929| (r_compound) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (r_conj) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_appos) hsert_18\NN\1740|(|)
T16_T38 NONE norepinephrine_21\NN\14807929| (r_compound) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet
T16_T39 NONE norepinephrine_21\NN\14807929| (r_compound) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (l_appos) hnet_27\NN\1740|(|)
T17_T36 NONE ne_23\NN\14622893| (r_compound) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (r_conj) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter
T17_T37 NONE ne_23\NN\14622893| (r_compound) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (r_conj) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_appos) hsert_18\NN\1740|(|)
T17_T38 NONE ne_23\NN\14622893| (r_compound) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet
T17_T39 NONE ne_23\NN\14622893| (r_compound) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (l_appos) hnet_27\NN\1740|(|)
T18_T36 CPR:4 dvs_34\NNS\1740|for|nm (r_nmod) values_32\NNS\5941423|with|k(i|dvs (r_nmod) using_6\VBG\1156834|cells|values|respectively (l_dobj) cells_7\NNS\3080309|expressing (l_acl) expressing_8\VBG\928630|transporter (l_dobj) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter
T18_T37 CPR:4 dvs_34\NNS\1740|for|nm (r_nmod) values_32\NNS\5941423|with|k(i|dvs (r_nmod) using_6\VBG\1156834|cells|values|respectively (l_dobj) cells_7\NNS\3080309|expressing (l_acl) expressing_8\VBG\928630|transporter (l_dobj) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_appos) hsert_18\NN\1740|(|)
T18_T38 CPR:4 dvs_34\NNS\1740|for|nm (r_nmod) values_32\NNS\5941423|with|k(i|dvs (r_nmod) using_6\VBG\1156834|cells|values|respectively (l_dobj) cells_7\NNS\3080309|expressing (l_acl) expressing_8\VBG\928630|transporter (l_dobj) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_conj) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet
T18_T39 CPR:4 dvs_34\NNS\1740|for|nm (r_nmod) values_32\NNS\5941423|with|k(i|dvs (r_nmod) using_6\VBG\1156834|cells|values|respectively (l_dobj) cells_7\NNS\3080309|expressing (l_acl) expressing_8\VBG\928630|transporter (l_dobj) transporter_16\NN\4490091|either|the|human|serotonin|5-ht|)|hsert|or|transporter (l_conj) transporter_25\NN\4490091|norepinephrine|(|ne|)|hnet (l_appos) hnet_27\NN\1740|(|)
T19_T40 NONE dvs_0\NNS\1740| (r_nsubj) showed_1\VBD\2137132|dvs|affinity|transporter|. (l_nmod) transporter_20\NN\4490091|at|the|human|dopamine
T20_T40 NONE dopamine_16\NN\14807737|da (r_compound) transporter_20\NN\4490091|at|the|human|dopamine
T21_T40 NONE da_18\NN\10484858|(|) (r_appos) dopamine_16\NN\14807737|da (r_compound) transporter_20\NN\4490091|at|the|human|dopamine
T22_T41 CPR:9 [3h]5-ht_2\NN\1740|or|[3h]ne (r_compound) uptake_5\NN\13440063|of|[3h]5-ht (r_nmod) inhibition_0\NN\1068773|uptake|dvs (l_nmod) dvs_7\NN\1740|by|hsert (l_nmod) hsert_10\NN\1740|for|the|or|hnet
T22_T42 NONE [3h]5-ht_2\NN\1740|or|[3h]ne (r_compound) uptake_5\NN\13440063|of|[3h]5-ht (r_nmod) inhibition_0\NN\1068773|uptake|dvs (l_nmod) dvs_7\NN\1740|by|hsert (l_nmod) hsert_10\NN\1740|for|the|or|hnet (l_conj) hnet_12\NN\1740|
T23_T41 NONE [3h]ne_4\NN\1740| (r_conj) [3h]5-ht_2\NN\1740|or|[3h]ne (r_compound) uptake_5\NN\13440063|of|[3h]5-ht (r_nmod) inhibition_0\NN\1068773|uptake|dvs (l_nmod) dvs_7\NN\1740|by|hsert (l_nmod) hsert_10\NN\1740|for|the|or|hnet
T23_T42 CPR:9 [3h]ne_4\NN\1740| (r_conj) [3h]5-ht_2\NN\1740|or|[3h]ne (r_compound) uptake_5\NN\13440063|of|[3h]5-ht (r_nmod) inhibition_0\NN\1068773|uptake|dvs (l_nmod) dvs_7\NN\1740|by|hsert (l_nmod) hsert_10\NN\1740|for|the|or|hnet (l_conj) hnet_12\NN\1740|
T24_T41 NONE dvs_7\NN\1740|by|hsert (l_nmod) hsert_10\NN\1740|for|the|or|hnet
T24_T42 NONE dvs_7\NN\1740|by|hsert (l_nmod) hsert_10\NN\1740|for|the|or|hnet (l_conj) hnet_12\NN\1740|
T3_T34 NONE serotonin_4\NN\14807737| (r_compound) treatment_7\NN\654885|chronic|selective|serotonin|inhibitor (r_dobj) mimic_1\VB\1742886|to|treatment|and|block|,|antagonist|, (l_conj) block_10\VB\1476483|to|autoreceptors (l_dobj) autoreceptors_15\NNS\1740|the|inhibitory|5-ht(1a|) (l_punct) )_14\-RRB-\1740|
T3_T35 NONE serotonin_4\NN\14807737| (r_compound) treatment_7\NN\654885|chronic|selective|serotonin|inhibitor (r_dobj) mimic_1\VB\1742886|to|treatment|and|block|,|antagonist|, (l_dobj) antagonist_20\NN\7846|a|5-ht(1a|,|salt (l_compound) 5-ht(1a_18\NN\1740|) (l_punct) )_19\-RRB-\1740|
T4_T34 NONE salt_25\NN\14818238|n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-2-pyridinylcyclo|hexanecarboxamide|maleate|way-100635|s.c. (r_appos) antagonist_20\NN\7846|a|5-ht(1a|,|salt (r_dobj) mimic_1\VB\1742886|to|treatment|and|block|,|antagonist|, (l_conj) block_10\VB\1476483|to|autoreceptors (l_dobj) autoreceptors_15\NNS\1740|the|inhibitory|5-ht(1a|) (l_punct) )_14\-RRB-\1740|
T4_T35 CPR:6 salt_25\NN\14818238|n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-2-pyridinylcyclo|hexanecarboxamide|maleate|way-100635|s.c. (r_appos) antagonist_20\NN\7846|a|5-ht(1a|,|salt (l_compound) 5-ht(1a_18\NN\1740|) (l_punct) )_19\-RRB-\1740|
T5_T34 NONE way-100635_27\CD\1740|(|) (r_appos) salt_25\NN\14818238|n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-2-pyridinylcyclo|hexanecarboxamide|maleate|way-100635|s.c. (r_appos) antagonist_20\NN\7846|a|5-ht(1a|,|salt (r_dobj) mimic_1\VB\1742886|to|treatment|and|block|,|antagonist|, (l_conj) block_10\VB\1476483|to|autoreceptors (l_dobj) autoreceptors_15\NNS\1740|the|inhibitory|5-ht(1a|) (l_punct) )_14\-RRB-\1740|
T5_T35 CPR:6 way-100635_27\CD\1740|(|) (r_appos) salt_25\NN\14818238|n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-2-pyridinylcyclo|hexanecarboxamide|maleate|way-100635|s.c. (r_appos) antagonist_20\NN\7846|a|5-ht(1a|,|salt (l_compound) 5-ht(1a_18\NN\1740|) (l_punct) )_19\-RRB-\1740|
T6_T34 NONE dvs_38\NN\1740|with|mg/kg (r_nmod) administered_36\VBN\2436349|mimic|was|dvs|. (l_advcl) mimic_1\VB\1742886|to|treatment|and|block|,|antagonist|, (l_conj) block_10\VB\1476483|to|autoreceptors (l_dobj) autoreceptors_15\NNS\1740|the|inhibitory|5-ht(1a|) (l_punct) )_14\-RRB-\1740|
T6_T35 NONE dvs_38\NN\1740|with|mg/kg (r_nmod) administered_36\VBN\2436349|mimic|was|dvs|. (l_advcl) mimic_1\VB\1742886|to|treatment|and|block|,|antagonist|, (l_dobj) antagonist_20\NN\7846|a|5-ht(1a|,|salt (l_compound) 5-ht(1a_18\NN\1740|) (l_punct) )_19\-RRB-\1740|
15563928
T10_T17 NONE non-steroidal_9\JJ\1740| (r_amod) drugs_11\NNS\14778436|of|non-steroidal|anti-inflammatory|nsaids|,|inhibit (l_acl:relcl) inhibit_17\VBP\2510337|which|isoforms (l_dobj) isoforms_19\NNS\1740|cyclooxygenase|cox-1 (l_compound) cyclooxygenase_18\NN\14732946|
T10_T18 NONE non-steroidal_9\JJ\1740| (r_amod) drugs_11\NNS\14778436|of|non-steroidal|anti-inflammatory|nsaids|,|inhibit (l_acl:relcl) inhibit_17\VBP\2510337|which|isoforms (l_dobj) isoforms_19\NNS\1740|cyclooxygenase|cox-1 (l_dep) cox-1_21\NN\14737847|(|and|cox-2|)
T10_T19 NONE non-steroidal_9\JJ\1740| (r_amod) drugs_11\NNS\14778436|of|non-steroidal|anti-inflammatory|nsaids|,|inhibit (l_acl:relcl) inhibit_17\VBP\2510337|which|isoforms (l_dobj) isoforms_19\NNS\1740|cyclooxygenase|cox-1 (l_dep) cox-1_21\NN\14737847|(|and|cox-2|) (l_conj) cox-2_23\NN\14737847|
T9_T24 NONE phenylbutazone_23\NN\2721538|with|the|non-selective|cox|inhibitor|horses (r_nmod) compare_8\VB\644583|to|effects|phenylbutazone (l_dobj) effects_11\NNS\13245626|the|anti-inflammatory|etodolac (l_nmod) etodolac_17\NN\3828465|of|the|preferential|cox-2|inhibitor (l_compound) cox-2_15\NN\14737847|
T9_T25 CPR:4 phenylbutazone_23\NN\2721538|with|the|non-selective|cox|inhibitor|horses (l_compound) cox_21\NN\14732946|
T2_T16 NONE pge2_7\NN\1740| (r_compound) levels_8\NNS\4916342|pge2|p<0.05 (r_dobj) reduced_6\VBD\441445|addition|,|drugs|significantly|levels|injection|,|reduced|. (l_parataxis) reduced_25\VBN\441445|whereas|txb2|was|significantly|phenylbutazone (l_nsubjpass) txb2_22\NN\1740|the|probable|cox-1|prostanoid (l_compound) cox-1_20\NN\14737847|
T3_T16 NONE prostanoid_21\NN\1740| (r_compound) txb2_22\NN\1740|the|probable|cox-1|prostanoid (l_compound) cox-1_20\NN\14737847|
T4_T16 NONE txb2_22\NN\1740|the|probable|cox-1|prostanoid (l_compound) cox-1_20\NN\14737847|
T5_T16 CPR:4 phenylbutazone_27\NN\2721538|by|p<0.05|,|not|etodolac (r_nmod) reduced_25\VBN\441445|whereas|txb2|was|significantly|phenylbutazone (l_nsubjpass) txb2_22\NN\1740|the|probable|cox-1|prostanoid (l_compound) cox-1_20\NN\14737847|
T6_T16 NONE etodolac_34\NN\3828465| (r_conj) phenylbutazone_27\NN\2721538|by|p<0.05|,|not|etodolac (r_nmod) reduced_25\VBN\441445|whereas|txb2|was|significantly|phenylbutazone (l_nsubjpass) txb2_22\NN\1740|the|probable|cox-1|prostanoid (l_compound) cox-1_20\NN\14737847|
23334403
T19_T27 NONE almorexant_0\JJ\1740| (r_amod) effects_1\NNS\13245626|almorexant|activity|studied|. (l_nmod) activity_4\NN\30358|on|cyp3a4 (l_compound) cyp3a4_3\NN\1740|
T20_T27 NONE simvastatin_13\NN\3676175|with|and|atorvastatin (r_nmod) administration_11\NN\1133281|by|its|simultaneous|simvastatin (r_nmod) studied_5\VBN\630380|administration (r_acl) effects_1\NNS\13245626|almorexant|activity|studied|. (l_nmod) activity_4\NN\30358|on|cyp3a4 (l_compound) cyp3a4_3\NN\1740|
T21_T27 NONE atorvastatin_15\NN\3676175| (r_conj) simvastatin_13\NN\3676175|with|and|atorvastatin (r_nmod) administration_11\NN\1133281|by|its|simultaneous|simvastatin (r_nmod) studied_5\VBN\630380|administration (r_acl) effects_1\NNS\13245626|almorexant|activity|studied|. (l_nmod) activity_4\NN\30358|on|cyp3a4 (l_compound) cyp3a4_3\NN\1740|
T5_T22 CPR:6 almorexant_21\NN\1740|of|the|dual|receptor|antagonist (l_compound) receptor_19\NN\5225602|orexin
T5_T25 NONE almorexant_21\NN\1740|of|the|dual|receptor|antagonist (r_nmod) interaction_14\NN\37396|the|observed|3a4|almorexant (l_compound) 3a4_10\NN\1740|cytochrome|p450|cyp3a4
T5_T26 NONE almorexant_21\NN\1740|of|the|dual|receptor|antagonist (r_nmod) interaction_14\NN\37396|the|observed|3a4|almorexant (l_compound) 3a4_10\NN\1740|cytochrome|p450|cyp3a4 (l_appos) cyp3a4_12\NN\1740|(|)
T10_T23 NONE simvastatin_9\NN\3676175|with (r_nmod) interaction_5\NN\37396|the|observed|almorexant|simvastatin (r_nsubjpass) caused_12\VBN\1617192|that|interaction|is|mainly|inhibition|,|due (l_nmod) inhibition_16\NN\1068773|by|intestinal|cyp3a4 (l_compound) cyp3a4_15\NN\1740|
T10_T24 NONE simvastatin_9\NN\3676175|with (r_nmod) interaction_5\NN\37396|the|observed|almorexant|simvastatin (r_nsubjpass) caused_12\VBN\1617192|that|interaction|is|mainly|inhibition|,|due (l_advcl) due_25\JJ\1740|whereas|interaction|is|more|inhibition (l_nmod) inhibition_29\NN\1068773|to|hepatic|cyp3a4 (l_compound) cyp3a4_28\NN\1740|
T11_T23 NONE atorvastatin_22\NN\3676175|with (r_nmod) interaction_20\NN\37396|the|atorvastatin (r_nsubj) due_25\JJ\1740|whereas|interaction|is|more|inhibition (r_advcl) caused_12\VBN\1617192|that|interaction|is|mainly|inhibition|,|due (l_nmod) inhibition_16\NN\1068773|by|intestinal|cyp3a4 (l_compound) cyp3a4_15\NN\1740|
T11_T24 NONE atorvastatin_22\NN\3676175|with (r_nmod) interaction_20\NN\37396|the|atorvastatin (r_nsubj) due_25\JJ\1740|whereas|interaction|is|more|inhibition (l_nmod) inhibition_29\NN\1068773|to|hepatic|cyp3a4 (l_compound) cyp3a4_28\NN\1740|
T9_T23 NONE almorexant_7\NN\1740|of (r_nmod) interaction_5\NN\37396|the|observed|almorexant|simvastatin (r_nsubjpass) caused_12\VBN\1617192|that|interaction|is|mainly|inhibition|,|due (l_nmod) inhibition_16\NN\1068773|by|intestinal|cyp3a4 (l_compound) cyp3a4_15\NN\1740|
T9_T24 NONE almorexant_7\NN\1740|of (r_nmod) interaction_5\NN\37396|the|observed|almorexant|simvastatin (r_nsubjpass) caused_12\VBN\1617192|that|interaction|is|mainly|inhibition|,|due (l_advcl) due_25\JJ\1740|whereas|interaction|is|more|inhibition (l_nmod) inhibition_29\NN\1068773|to|hepatic|cyp3a4 (l_compound) cyp3a4_28\NN\1740|
10917903
T21_T32 CPR:4 acid_13\NN\14818238|of|eicosapentaenoic|epa (r_nmod) addition_10\NN\3081021|acid (r_nsubj) blocked_17\VBD\1476483|that|addition|activity (l_dobj) activity_19\NN\30358|delta-5-desaturase|,|step (l_compound) delta-5-desaturase_18\NN\1740|
T22_T32 CPR:4 epa_15\NN\8338847|(|) (r_appos) acid_13\NN\14818238|of|eicosapentaenoic|epa (r_nmod) addition_10\NN\3081021|acid (r_nsubj) blocked_17\VBD\1476483|that|addition|activity (l_dobj) activity_19\NN\30358|delta-5-desaturase|,|step (l_compound) delta-5-desaturase_18\NN\1740|
T23_T32 NONE aa_26\NN\14930989| (r_compound) synthesis_27\NN\13446390|in|aa (r_nmod) step_24\NN\168237|the|terminal|enzymatic|synthesis (r_appos) activity_19\NN\30358|delta-5-desaturase|,|step (l_compound) delta-5-desaturase_18\NN\1740|
11318430
T1_T10 CPR:4 acid_1\NN\14818238|nordihydroguaiaretic|ndga (r_nsubjpass) shown_7\VBN\2137132|acid|has|been|inhibit|and|active|. (l_xcomp) inhibit_9\VB\2510337|to|5-lipoxygenase (l_dobj) 5-lipoxygenase_11\NN\1740|both|and|decarboxylase (l_conj) decarboxylase_14\NN\14732946|ornithine
T1_T9 CPR:4 acid_1\NN\14818238|nordihydroguaiaretic|ndga (r_nsubjpass) shown_7\VBN\2137132|acid|has|been|inhibit|and|active|. (l_xcomp) inhibit_9\VB\2510337|to|5-lipoxygenase (l_dobj) 5-lipoxygenase_11\NN\1740|both|and|decarboxylase
T3_T10 CPR:4 ndga_3\NN\1740|(|) (r_appos) acid_1\NN\14818238|nordihydroguaiaretic|ndga (r_nsubjpass) shown_7\VBN\2137132|acid|has|been|inhibit|and|active|. (l_xcomp) inhibit_9\VB\2510337|to|5-lipoxygenase (l_dobj) 5-lipoxygenase_11\NN\1740|both|and|decarboxylase (l_conj) decarboxylase_14\NN\14732946|ornithine
T3_T9 CPR:4 ndga_3\NN\1740|(|) (r_appos) acid_1\NN\14818238|nordihydroguaiaretic|ndga (r_nsubjpass) shown_7\VBN\2137132|acid|has|been|inhibit|and|active|. (l_xcomp) inhibit_9\VB\2510337|to|5-lipoxygenase (l_dobj) 5-lipoxygenase_11\NN\1740|both|and|decarboxylase
T7_T10 NONE ornithine_13\NN\14601829| (r_compound) decarboxylase_14\NN\14732946|ornithine
T7_T9 NONE ornithine_13\NN\14601829| (r_compound) decarboxylase_14\NN\14732946|ornithine (r_conj) 5-lipoxygenase_11\NN\1740|both|and|decarboxylase
23430109
T18_T38 NONE ponatinib_2\NN\1740|of (r_nmod) activity_0\NN\30358|ponatinib|mutants|. (l_nmod) mutants_8\NNS\4475|against|clinically-relevant|ac220-resistant|kinase|domain|flt3-itd (l_compound) domain_7\NN\13934596|
T18_T39 NONE ponatinib_2\NN\1740|of (r_nmod) activity_0\NN\30358|ponatinib|mutants|. (l_nmod) mutants_8\NNS\4475|against|clinically-relevant|ac220-resistant|kinase|domain|flt3-itd (l_nmod) flt3-itd_10\NN\1740|of
T19_T38 NONE ac220-resistant_5\JJ\1740| (r_amod) mutants_8\NNS\4475|against|clinically-relevant|ac220-resistant|kinase|domain|flt3-itd (l_compound) domain_7\NN\13934596|
T19_T39 NONE ac220-resistant_5\JJ\1740| (r_amod) mutants_8\NNS\4475|against|clinically-relevant|ac220-resistant|kinase|domain|flt3-itd (l_nmod) flt3-itd_10\NN\1740|of
T10_T24 NONE tyrosine_6\NN\14601829| (r_compound) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd (r_nmod) mutations_2\NNS\4475|secondary|point|domain (r_nsubj) causes_20\NNS\7323922|mutations|are|common|resistance|. (l_nmod) resistance_24\NN\37396|of|acquired|clinical|inhibitors (l_nmod) inhibitors_28\NNS\20090|to|the|flt3|ac220 (l_compound) flt3_27\NN\1740|
T10_T27 NONE tyrosine_6\NN\14601829| (r_compound) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd
T10_T35 NONE tyrosine_6\NN\14601829| (r_compound) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd (l_appos) kd_16\NN\1740|(|)
T12_T24 NONE tyrosine_12\NN\14601829| (r_compound) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd (r_nmod) mutations_2\NNS\4475|secondary|point|domain (r_nsubj) causes_20\NNS\7323922|mutations|are|common|resistance|. (l_nmod) resistance_24\NN\37396|of|acquired|clinical|inhibitors (l_nmod) inhibitors_28\NNS\20090|to|the|flt3|ac220 (l_compound) flt3_27\NN\1740|
T12_T27 NONE tyrosine_12\NN\14601829| (r_compound) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd
T12_T35 NONE tyrosine_12\NN\14601829| (r_compound) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd (l_appos) kd_16\NN\1740|(|)
T3_T24 CPR:4 ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (l_compound) flt3_27\NN\1740|
T3_T27 NONE ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (r_nmod) resistance_24\NN\37396|of|acquired|clinical|inhibitors (r_nmod) causes_20\NNS\7323922|mutations|are|common|resistance|. (l_nsubj) mutations_2\NNS\4475|secondary|point|domain (l_nmod) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd
T3_T35 NONE ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (r_nmod) resistance_24\NN\37396|of|acquired|clinical|inhibitors (r_nmod) causes_20\NNS\7323922|mutations|are|common|resistance|. (l_nsubj) mutations_2\NNS\4475|secondary|point|domain (l_nmod) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd (l_appos) kd_16\NN\1740|(|)
T4_T24 CPR:4 quizartinib_31\NN\1740|(|) (r_appos) ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (l_compound) flt3_27\NN\1740|
T4_T27 NONE quizartinib_31\NN\1740|(|) (r_appos) ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (r_nmod) resistance_24\NN\37396|of|acquired|clinical|inhibitors (r_nmod) causes_20\NNS\7323922|mutations|are|common|resistance|. (l_nsubj) mutations_2\NNS\4475|secondary|point|domain (l_nmod) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd
T4_T35 NONE quizartinib_31\NN\1740|(|) (r_appos) ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (r_nmod) resistance_24\NN\37396|of|acquired|clinical|inhibitors (r_nmod) causes_20\NNS\7323922|mutations|are|common|resistance|. (l_nsubj) mutations_2\NNS\4475|secondary|point|domain (l_nmod) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd (l_appos) kd_16\NN\1740|(|)
T5_T24 CPR:4 sorafenib_34\NN\1740| (r_conj) ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (l_compound) flt3_27\NN\1740|
T5_T27 NONE sorafenib_34\NN\1740| (r_conj) ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (r_nmod) resistance_24\NN\37396|of|acquired|clinical|inhibitors (r_nmod) causes_20\NNS\7323922|mutations|are|common|resistance|. (l_nsubj) mutations_2\NNS\4475|secondary|point|domain (l_nmod) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd
T5_T35 NONE sorafenib_34\NN\1740| (r_conj) ac220_29\NN\1740|quizartinib|and|sorafenib (r_dep) inhibitors_28\NNS\20090|to|the|flt3|ac220 (r_nmod) resistance_24\NN\37396|of|acquired|clinical|inhibitors (r_nmod) causes_20\NNS\7323922|mutations|are|common|resistance|. (l_nsubj) mutations_2\NNS\4475|secondary|point|domain (l_nmod) domain_14\NN\13934596|in|the|fms-like|tyrosine|kinase|tyrosine|kinase|kd (l_appos) kd_16\NN\1740|(|)
T6_T25 CPR:4 ponatinib_0\NN\1740|ap24534 (r_nsubj) inhibitor_7\NN\20090|ponatinib|is|a|multikinase|activity|. (l_compound) multikinase_6\NN\1740|
T6_T26 NONE ponatinib_0\NN\1740|ap24534 (r_nsubj) inhibitor_7\NN\20090|ponatinib|is|a|multikinase|activity|. (l_nmod) activity_13\NN\30358|with|in|leukemia (l_nmod) leukemia_21\NN\14239918|in|inhibitor|chronic|myeloid|,|irrespective (l_compound) inhibitor_17\NN\20090|tyrosine|kinase|(tki)-resistant (l_compound) kinase_16\NN\14732946|
T6_T28 NONE ponatinib_0\NN\1740|ap24534 (r_nsubj) inhibitor_7\NN\20090|ponatinib|is|a|multikinase|activity|. (l_nmod) activity_13\NN\30358|with|in|leukemia (l_nmod) leukemia_21\NN\14239918|in|inhibitor|chronic|myeloid|,|irrespective (l_advmod) irrespective_23\RB\1740|mutation (l_nmod) mutation_27\NN\4475|of|bcr-abl|kd (l_compound) kd_26\NN\1740|
T7_T25 CPR:4 ap24534_2\NN\1740|(|) (r_appos) ponatinib_0\NN\1740|ap24534 (r_nsubj) inhibitor_7\NN\20090|ponatinib|is|a|multikinase|activity|. (l_compound) multikinase_6\NN\1740|
T7_T26 NONE ap24534_2\NN\1740|(|) (r_appos) ponatinib_0\NN\1740|ap24534 (r_nsubj) inhibitor_7\NN\20090|ponatinib|is|a|multikinase|activity|. (l_nmod) activity_13\NN\30358|with|in|leukemia (l_nmod) leukemia_21\NN\14239918|in|inhibitor|chronic|myeloid|,|irrespective (l_compound) inhibitor_17\NN\20090|tyrosine|kinase|(tki)-resistant (l_compound) kinase_16\NN\14732946|
T7_T28 NONE ap24534_2\NN\1740|(|) (r_appos) ponatinib_0\NN\1740|ap24534 (r_nsubj) inhibitor_7\NN\20090|ponatinib|is|a|multikinase|activity|. (l_nmod) activity_13\NN\30358|with|in|leukemia (l_nmod) leukemia_21\NN\14239918|in|inhibitor|chronic|myeloid|,|irrespective (l_advmod) irrespective_23\RB\1740|mutation (l_nmod) mutation_27\NN\4475|of|bcr-abl|kd (l_compound) kd_26\NN\1740|
T8_T25 NONE tyrosine_15\NN\14601829| (r_compound) inhibitor_17\NN\20090|tyrosine|kinase|(tki)-resistant (r_compound) leukemia_21\NN\14239918|in|inhibitor|chronic|myeloid|,|irrespective (r_nmod) activity_13\NN\30358|with|in|leukemia (r_nmod) inhibitor_7\NN\20090|ponatinib|is|a|multikinase|activity|. (l_compound) multikinase_6\NN\1740|
T8_T26 NONE tyrosine_15\NN\14601829| (r_compound) inhibitor_17\NN\20090|tyrosine|kinase|(tki)-resistant (l_compound) kinase_16\NN\14732946|
T8_T28 NONE tyrosine_15\NN\14601829| (r_compound) inhibitor_17\NN\20090|tyrosine|kinase|(tki)-resistant (r_compound) leukemia_21\NN\14239918|in|inhibitor|chronic|myeloid|,|irrespective (l_advmod) irrespective_23\RB\1740|mutation (l_nmod) mutation_27\NN\4475|of|bcr-abl|kd (l_compound) kd_26\NN\1740|
T9_T29 NONE ponatinib_0\NN\1740| (r_nsubj) demonstrated_2\VBN\2137132|ponatinib|has|efficacy|patients|. (l_nmod) patients_14\NNS\9898892|in|leukemia|mutations (l_nmod) mutations_22\NNS\4475|with|duplication|flt3 (l_nmod) flt3_24\NN\1740|in
T11_T30 NONE ponatinib_7\NN\1740|of (r_nmod) activity_5\NN\30358|the|in|ponatinib|isoforms (l_nmod) isoforms_13\NNS\1740|against|relevant|flt3-itd|mutant|confer (l_compound) flt3-itd_11\NN\1740|
T13_T30 NONE ac220_18\NN\1740|to|or|sorafenib (r_nmod) resistance_16\NN\37396|ac220 (r_dobj) confer_15\VBP\813978|that|resistance (r_acl:relcl) isoforms_13\NNS\1740|against|relevant|flt3-itd|mutant|confer (l_compound) flt3-itd_11\NN\1740|
T14_T30 NONE sorafenib_20\NN\1740| (r_conj) ac220_18\NN\1740|to|or|sorafenib (r_nmod) resistance_16\NN\37396|ac220 (r_dobj) confer_15\VBP\813978|that|resistance (r_acl:relcl) isoforms_13\NNS\1740|against|relevant|flt3-itd|mutant|confer (l_compound) flt3-itd_11\NN\1740|
T15_T31 NONE phenylalanine_7\NN\14605787|of|the|flt3|"|gatekeeper|" (l_compound) flt3_3\NN\1740|
T15_T32 NONE phenylalanine_7\NN\14605787|of|the|flt3|"|gatekeeper|" (r_nmod) substitution_0\NN\7337390|phenylalanine|leucine (l_nmod) leucine_9\NN\14605787|with|f691l (l_appos) f691l_11\NN\1740|(|)
T15_T33 NONE phenylalanine_7\NN\14605787|of|the|flt3|"|gatekeeper|" (r_nmod) substitution_0\NN\7337390|phenylalanine|leucine (r_nsubj) conferred_13\VBD\813978|substitution|resistance|,|but|conferred (l_conj) conferred_31\VBD\813978|substitutions|degree|. (l_nsubj) substitutions_20\NNS\7337390|d835 (l_nmod) d835_30\NN\1740|at|the|loop|(|al|)|residue (l_compound) loop_25\NN\3323703|flt3|activation
T15_T34 NONE phenylalanine_7\NN\14605787|of|the|flt3|"|gatekeeper|" (r_nmod) substitution_0\NN\7337390|phenylalanine|leucine (r_nsubj) conferred_13\VBD\813978|substitution|resistance|,|but|conferred (l_conj) conferred_31\VBD\813978|substitutions|degree|. (l_nsubj) substitutions_20\NNS\7337390|d835 (l_nmod) d835_30\NN\1740|at|the|loop|(|al|)|residue (l_compound) al_27\NN\14625458|
T16_T31 NONE leucine_9\NN\14605787|with|f691l (r_nmod) substitution_0\NN\7337390|phenylalanine|leucine (l_nmod) phenylalanine_7\NN\14605787|of|the|flt3|"|gatekeeper|" (l_compound) flt3_3\NN\1740|
T16_T32 NONE leucine_9\NN\14605787|with|f691l (l_appos) f691l_11\NN\1740|(|)
T16_T33 NONE leucine_9\NN\14605787|with|f691l (r_nmod) substitution_0\NN\7337390|phenylalanine|leucine (r_nsubj) conferred_13\VBD\813978|substitution|resistance|,|but|conferred (l_conj) conferred_31\VBD\813978|substitutions|degree|. (l_nsubj) substitutions_20\NNS\7337390|d835 (l_nmod) d835_30\NN\1740|at|the|loop|(|al|)|residue (l_compound) loop_25\NN\3323703|flt3|activation
T16_T34 NONE leucine_9\NN\14605787|with|f691l (r_nmod) substitution_0\NN\7337390|phenylalanine|leucine (r_nsubj) conferred_13\VBD\813978|substitution|resistance|,|but|conferred (l_conj) conferred_31\VBD\813978|substitutions|degree|. (l_nsubj) substitutions_20\NNS\7337390|d835 (l_nmod) d835_30\NN\1740|at|the|loop|(|al|)|residue (l_compound) al_27\NN\14625458|
T17_T31 NONE ponatinib_17\NN\1740|to (r_nmod) resistance_15\NN\37396|mild|ponatinib (r_dobj) conferred_13\VBD\813978|substitution|resistance|,|but|conferred (l_nsubj) substitution_0\NN\7337390|phenylalanine|leucine (l_nmod) phenylalanine_7\NN\14605787|of|the|flt3|"|gatekeeper|" (l_compound) flt3_3\NN\1740|
T17_T32 NONE ponatinib_17\NN\1740|to (r_nmod) resistance_15\NN\37396|mild|ponatinib (r_dobj) conferred_13\VBD\813978|substitution|resistance|,|but|conferred (l_nsubj) substitution_0\NN\7337390|phenylalanine|leucine (l_nmod) leucine_9\NN\14605787|with|f691l (l_appos) f691l_11\NN\1740|(|)
T17_T33 NONE ponatinib_17\NN\1740|to (r_nmod) resistance_15\NN\37396|mild|ponatinib (r_dobj) conferred_13\VBD\813978|substitution|resistance|,|but|conferred (l_conj) conferred_31\VBD\813978|substitutions|degree|. (l_nsubj) substitutions_20\NNS\7337390|d835 (l_nmod) d835_30\NN\1740|at|the|loop|(|al|)|residue (l_compound) loop_25\NN\3323703|flt3|activation
T17_T34 NONE ponatinib_17\NN\1740|to (r_nmod) resistance_15\NN\37396|mild|ponatinib (r_dobj) conferred_13\VBD\813978|substitution|resistance|,|but|conferred (l_conj) conferred_31\VBD\813978|substitutions|degree|. (l_nsubj) substitutions_20\NNS\7337390|d835 (l_nmod) d835_30\NN\1740|at|the|loop|(|al|)|residue (l_compound) al_27\NN\14625458|
T1_T20 NONE dcc-2036_4\NN\1740| (r_dep) inhibitor_3\NN\20090|the|control|dcc-2036 (r_nsubj) inactive_7\JJ\1740|inhibitor|was|similarly|mutations|. (l_nmod) mutations_11\NNS\4475|against|flt3|al (l_compound) flt3_9\NN\1740|
T2_T21 NONE ponatinib_18\NN\1740|of (r_nmod) evaluation_16\NN\874067|further|clinical|ponatinib|tki-naive (r_nsubjpass) warranted_28\VBN\1012073|basis|,|evaluation|is|. (l_nmod) basis_2\NN\13790712|on|the|activity (l_nmod) activity_7\NN\30358|of|its|in|substitutions (l_nmod) substitutions_12\NNS\7337390|against|tki-resistant|f691 (l_amod) tki-resistant_10\JJ\1740|flt3 (l_nmod:npmod) flt3_9\NN\1740|
T2_T22 NONE ponatinib_18\NN\1740|of (r_nmod) evaluation_16\NN\874067|further|clinical|ponatinib|tki-naive (l_nmod) tki-naive_20\JJ\1740|in|and|patients (l_conj) patients_26\NNS\9898892|select|tki-resistant|flt3-itd+|aml (l_amod) flt3-itd+_24\JJ\1740|
10373224
T14_T31 NONE ii_7\CD\13741022| (r_nummod) blockers_11\NNS\10101634|of|the|angiotensin|ii|type|1|receptor|arb|candesartan (l_compound) receptor_10\NN\5225602|
T1_T31 CPR:4 irbesartan_17\NN\1740| (r_conj) candesartan_15\NN\1740|;|irbesartan|;|and|losartan (r_dep) blockers_11\NNS\10101634|of|the|angiotensin|ii|type|1|receptor|arb|candesartan (l_compound) receptor_10\NN\5225602|
T24_T31 CPR:4 candesartan_15\NN\1740|;|irbesartan|;|and|losartan (r_dep) blockers_11\NNS\10101634|of|the|angiotensin|ii|type|1|receptor|arb|candesartan (l_compound) receptor_10\NN\5225602|
T3_T31 CPR:4 losartan_20\NN\1740|and|exp (r_conj) candesartan_15\NN\1740|;|irbesartan|;|and|losartan (r_dep) blockers_11\NNS\10101634|of|the|angiotensin|ii|type|1|receptor|arb|candesartan (l_compound) receptor_10\NN\5225602|
T8_T31 CPR:4 3174_26\CD\1740| (r_nummod) exp_25\NN\1740|its|active|metabolite|3174|exp (r_conj) losartan_20\NN\1740|and|exp (r_conj) candesartan_15\NN\1740|;|irbesartan|;|and|losartan (r_dep) blockers_11\NNS\10101634|of|the|angiotensin|ii|type|1|receptor|arb|candesartan (l_compound) receptor_10\NN\5225602|
T9_T31 CPR:4 exp_28\NN\1740|(|) (r_appos) exp_25\NN\1740|its|active|metabolite|3174|exp (r_conj) losartan_20\NN\1740|and|exp (r_conj) candesartan_15\NN\1740|;|irbesartan|;|and|losartan (r_dep) blockers_11\NNS\10101634|of|the|angiotensin|ii|type|1|receptor|arb|candesartan (l_compound) receptor_10\NN\5225602|
T15_T32 CPR:4 candesartan_5\NNP\1740| (r_nsubj) caused_6\VBD\1617192|preparations|,|candesartan|decrease|. (l_dobj) decrease_9\NN\7296428|a|marked|response (l_nmod) response_14\NN\11410625|in|the|maximal|contractile|curve (l_nmod) curve_24\NN\13863771|of|the|angiotensin|ii|concentration-response (l_nummod) ii_18\CD\13741022|ang
T15_T33 CPR:4 candesartan_5\NNP\1740| (r_nsubj) caused_6\VBD\1617192|preparations|,|candesartan|decrease|. (l_dobj) decrease_9\NN\7296428|a|marked|response (l_nmod) response_14\NN\11410625|in|the|maximal|contractile|curve (l_nmod) curve_24\NN\13863771|of|the|angiotensin|ii|concentration-response (l_nummod) ii_18\CD\13741022|ang (l_appos) ang_20\NN\8391387|(|ii|) (l_nummod) ii_21\CD\13741022|
T16_T32 NONE ii_18\CD\13741022|ang
T16_T33 NONE ii_18\CD\13741022|ang (l_appos) ang_20\NN\8391387|(|ii|) (l_nummod) ii_21\CD\13741022|
T17_T32 NONE ii_21\CD\13741022| (r_nummod) ang_20\NN\8391387|(|ii|) (r_appos) ii_18\CD\13741022|ang
T17_T33 NONE ii_21\CD\13741022|
T21_T34 NONE ii_15\CD\13741022|
T2_T27 NONE candesartan_14\NN\1740|of (r_nmod) administration_12\NN\1133281|before|candesartan (r_nmod) cooling_0\NN\13566212|preparations|c|administration (r_nsubj) prevented_15\VBD\1740|cooling|inhibition|independent|. (l_dobj) inhibition_18\NN\1068773|the|persistent|response|seen (l_nmod) response_22\NN\11410625|of|ang|ii (l_nummod) ii_21\CD\13741022|
T2_T28 NONE candesartan_14\NN\1740|of (r_nmod) administration_12\NN\1133281|before|candesartan (r_nmod) cooling_0\NN\13566212|preparations|c|administration (r_nsubj) prevented_15\VBD\1740|cooling|inhibition|independent|. (l_parataxis) independent_49\JJ\1740|arbs|,|magnitude|were|temperature (l_nsubj) magnitude_35\NN\4916342|the|inhibition|and|speed (l_conj) speed_40\NN\15286249|the|recovery (l_nmod) recovery_42\NN\7357388|of|response (l_nmod) response_47\NN\11410625|of|the|ang|ii (l_nummod) ii_46\CD\13741022|
T4_T27 NONE ii_21\CD\13741022|
T4_T28 NONE ii_21\CD\13741022| (r_nummod) response_22\NN\11410625|of|ang|ii (r_nmod) inhibition_18\NN\1068773|the|persistent|response|seen (r_dobj) prevented_15\VBD\1740|cooling|inhibition|independent|. (l_parataxis) independent_49\JJ\1740|arbs|,|magnitude|were|temperature (l_nsubj) magnitude_35\NN\4916342|the|inhibition|and|speed (l_conj) speed_40\NN\15286249|the|recovery (l_nmod) recovery_42\NN\7357388|of|response (l_nmod) response_47\NN\11410625|of|the|ang|ii (l_nummod) ii_46\CD\13741022|
T5_T27 NONE ii_46\CD\13741022| (r_nummod) response_47\NN\11410625|of|the|ang|ii (r_nmod) recovery_42\NN\7357388|of|response (r_nmod) speed_40\NN\15286249|the|recovery (r_conj) magnitude_35\NN\4916342|the|inhibition|and|speed (r_nsubj) independent_49\JJ\1740|arbs|,|magnitude|were|temperature (r_parataxis) prevented_15\VBD\1740|cooling|inhibition|independent|. (l_dobj) inhibition_18\NN\1068773|the|persistent|response|seen (l_nmod) response_22\NN\11410625|of|ang|ii (l_nummod) ii_21\CD\13741022|
T5_T28 NONE ii_46\CD\13741022|
T10_T29 NONE candesartan_30\NN\1740|of (r_nmod) concentrations_28\NNS\4916342|despite|nondetectable|plasma|candesartan|hours (r_nmod) persisted_20\VBD\118523|addition|,|given|,|effect|period|concentrations|. (l_nsubj) effect_13\NN\34213|the|inhibitory|responses (l_nmod) responses_19\NNS\11410625|on|ii-induced|blood|pressure (l_amod) ii-induced_16\JJ\1740|ang
T6_T29 CPR:4 candesartan_4\NN\1740| (r_nsubjpass) given_6\VBN\2327200|when|candesartan|was|rats (r_advcl) persisted_20\VBD\118523|addition|,|given|,|effect|period|concentrations|. (l_nsubj) effect_13\NN\34213|the|inhibitory|responses (l_nmod) responses_19\NNS\11410625|on|ii-induced|blood|pressure (l_amod) ii-induced_16\JJ\1740|ang
T7_T29 NONE ii-induced_16\JJ\1740|ang
T12_T30 CPR:4 candesartan_5\NN\1740| (r_nsubj) antagonist_11\NN\7846|concentrations|,|candesartan|is|an|insurmountable|responses|. (l_nmod) responses_16\NNS\11410625|of|the|vascular|contractile|ang (l_nmod) ang_18\NN\8391387|to|ii (l_nummod) ii_19\CD\13741022|
T13_T30 NONE ii_19\CD\13741022|
15787205
T6_T12 NONE dopamine_3\NN\14807737| (r_compound) activity_5\NN\30358|of|dopamine|transporter|dat (l_compound) transporter_4\NN\4490091|
T6_T13 NONE dopamine_3\NN\14807737| (r_compound) activity_5\NN\30358|of|dopamine|transporter|dat (l_appos) dat_7\NN\2757810|(|)
T7_T12 NONE bupropion_13\NN\1740|of (r_nmod) action_11\NN\30358|during|the|bupropion|depression (r_nmod) change_1\NN\7283608|[|activity|action|]|. (l_nmod) activity_5\NN\30358|of|dopamine|transporter|dat (l_compound) transporter_4\NN\4490091|
T7_T13 NONE bupropion_13\NN\1740|of (r_nmod) action_11\NN\30358|during|the|bupropion|depression (r_nmod) change_1\NN\7283608|[|activity|action|]|. (l_nmod) activity_5\NN\30358|of|dopamine|transporter|dat (l_appos) dat_7\NN\2757810|(|)
T1_T11 CPR:4 bupropion_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|bupropion|effect|blocking|. (l_advcl) blocking_6\VBG\1476483|through|transporter (l_dobj) transporter_9\NN\4490091|the|dopamine
T5_T11 NONE dopamine_8\NN\14807737| (r_compound) transporter_9\NN\4490091|the|dopamine
T2_T9 NONE bupropion_4\NN\1740| (r_compound) treatment_5\NN\654885|after|weeks|bupropion (r_nmod) studied_7\VBD\630380|treatment|we|change|. (l_dobj) change_9\NN\7283608|the|activity|,|corresponds (l_nmod) activity_12\NN\30358|in|dat (l_compound) dat_11\NN\2757810|
T3_T9 NONE bupropion_20\NN\1740|of (r_nmod) occupancy_18\NN\1053920|to|the|bupropion (r_nmod) corresponds_15\VBZ\2664769|which|occupancy (r_acl:relcl) change_9\NN\7283608|the|activity|,|corresponds (l_nmod) activity_12\NN\30358|in|dat (l_compound) dat_11\NN\2757810|
T4_T10 NONE bupropion_4\NN\1740|of (r_nmod) occupancy_2\NN\1053920|the|average|bupropion|dat (l_nmod) dat_6\NN\2757810|on
23633618
T6_T11 NONE paroxetine_10\NN\1740|with (r_nmod) complex_8\NN\5869584|in|paroxetine (r_nmod) p450_5\NN\1740|of|cytochrome|2b4|complex (l_nummod) 2b4_6\NN\1740|
T5_T8 NONE paroxetine_13\NN\1740| (r_dep) drug_12\NN\14778436|with|the|paroxetine (r_nmod) complex_9\NN\5869584|in|drug (r_nmod) structure_3\NN\21939|an|x-ray|crystal|p450|complex (l_nmod) p450_6\NN\1740|of|cytochrome|2b4 (l_nummod) 2b4_7\CD\1740|
T3_T10 NONE 2b4-paroxetine_1\NN\1740|
15646028
T10_T19 NONE acid_19\NN\14818238| (r_compound) substance_21\NN\20827|thiobarbituric|acid|reactive|tbars (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T10_T20 NONE acid_19\NN\14818238| (r_compound) substance_21\NN\20827|thiobarbituric|acid|reactive|tbars (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T10_T21 NONE acid_19\NN\14818238| (r_compound) substance_21\NN\20827|thiobarbituric|acid|reactive|tbars (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T10_T22 NONE acid_19\NN\14818238| (r_compound) substance_21\NN\20827|thiobarbituric|acid|reactive|tbars (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T10_T23 NONE acid_19\NN\14818238| (r_compound) substance_21\NN\20827|thiobarbituric|acid|reactive|tbars (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T10_T24 NONE acid_19\NN\14818238| (r_compound) substance_21\NN\20827|thiobarbituric|acid|reactive|tbars (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T11_T19 NONE atp_32\NN\14964590| (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T11_T20 NONE atp_32\NN\14964590| (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T11_T21 NONE atp_32\NN\14964590| (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T11_T22 NONE atp_32\NN\14964590| (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T11_T23 NONE atp_32\NN\14964590| (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T11_T24 NONE atp_32\NN\14964590| (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T12_T19 NONE nadh-ubiquinone_34\NN\1740| (r_compound) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T12_T20 NONE nadh-ubiquinone_34\NN\1740| (r_compound) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T12_T21 NONE nadh-ubiquinone_34\NN\1740| (r_compound) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T12_T22 NONE nadh-ubiquinone_34\NN\1740| (r_compound) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T12_T23 NONE nadh-ubiquinone_34\NN\1740| (r_compound) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T12_T24 NONE nadh-ubiquinone_34\NN\1740| (r_compound) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T13_T19 NONE nadh-cytochrome_40\NN\1740| (r_compound) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T13_T20 NONE nadh-cytochrome_40\NN\1740| (r_compound) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T13_T21 NONE nadh-cytochrome_40\NN\1740| (r_compound) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T13_T22 NONE nadh-cytochrome_40\NN\1740| (r_compound) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T13_T23 NONE nadh-cytochrome_40\NN\1740| (r_compound) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T13_T24 NONE nadh-cytochrome_40\NN\1740| (r_compound) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T14_T19 NONE succinate-cytochrome_48\JJ\1740| (r_amod) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T14_T20 NONE succinate-cytochrome_48\JJ\1740| (r_amod) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T14_T21 NONE succinate-cytochrome_48\JJ\1740| (r_amod) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T14_T22 NONE succinate-cytochrome_48\JJ\1740| (r_amod) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (r_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T14_T23 NONE succinate-cytochrome_48\JJ\1740| (r_amod) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T14_T24 NONE succinate-cytochrome_48\JJ\1740| (r_amod) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T5_T19 NONE superoxide_2\NN\14971519| (r_compound) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T5_T20 NONE superoxide_2\NN\14971519| (r_compound) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T5_T21 NONE superoxide_2\NN\14971519| (r_compound) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T5_T22 NONE superoxide_2\NN\14971519| (r_compound) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T5_T23 NONE superoxide_2\NN\14971519| (r_compound) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T5_T24 NONE superoxide_2\NN\14971519| (r_compound) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T6_T19 NONE o2-_5\NN\1740|(|) (r_appos) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T6_T20 NONE o2-_5\NN\1740|(|) (r_appos) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T6_T21 NONE o2-_5\NN\1740|(|) (r_appos) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T6_T22 NONE o2-_5\NN\1740|(|) (r_appos) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T6_T23 NONE o2-_5\NN\1740|(|) (r_appos) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T6_T24 NONE o2-_5\NN\1740|(|) (r_appos) anion_3\NN\9315159|of|superoxide|o2-|,|glutathione|and|potential (l_conj) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T7_T19 NONE glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T7_T20 NONE glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T7_T21 NONE glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T7_T22 NONE glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T7_T23 NONE glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T7_T24 NONE glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T8_T19 NONE gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T8_T20 NONE gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T8_T21 NONE gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T8_T22 NONE gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T8_T23 NONE gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T8_T24 NONE gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T9_T19 NONE gssg_15\NN\1740| (r_conj) gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i
T9_T20 NONE gssg_15\NN\1740| (r_conj) gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_35\NN\14732946|nadh-ubiquinone|complex-i (l_appos) complex-i_37\NN\1740|(|)
T9_T21 NONE gssg_15\NN\1740| (r_conj) gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex
T9_T22 NONE gssg_15\NN\1740| (r_conj) gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_42\NN\14732946|nadh-cytochrome|c|complex (l_appos) complex_44\NN\5869584|(|i/ii|) (l_nummod) i/ii_45\CD\1740|
T9_T23 NONE gssg_15\NN\1740| (r_conj) gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex
T9_T24 NONE gssg_15\NN\1740| (r_conj) gsh_13\NN\1740|(|or|gssg|) (r_dep) glutathione_11\NN\1740|reduced|gsh|,|substance|,|carbonyl|,|atp|,|oxidoreductase|,|oxidoreductase|,|oxidoreductase (l_conj) oxidoreductase_50\NN\14732946|succinate-cytochrome|c|complex (l_appos) complex_52\NN\5869584|(|ii/iii|) (l_nummod) ii/iii_53\CD\1740|
T3_T16 CPR:3 gsh_7\NN\1740|of (r_nmod) levels_5\NNS\4916342|gsh (r_dobj) enhanced_4\VBD\227165|administration|levels|increase|and|inhibited|. (l_dobj) increase_9\NN\13576355|induced|activity (l_nmod) activity_27\NN\30358|i|complex|ii/iii|h (l_compound) i_12\CD\14622893|in|complex|h|,|i/iii
T3_T17 CPR:3 gsh_7\NN\1740|of (r_nmod) levels_5\NNS\4916342|gsh (r_dobj) enhanced_4\VBD\227165|administration|levels|increase|and|inhibited|. (l_dobj) increase_9\NN\13576355|induced|activity (l_nmod) activity_27\NN\30358|i|complex|ii/iii|h (l_compound) i_12\CD\14622893|in|complex|h|,|i/iii (l_appos) i/iii_20\CD\1740|complex
T3_T18 CPR:3 gsh_7\NN\1740|of (r_nmod) levels_5\NNS\4916342|gsh (r_dobj) enhanced_4\VBD\227165|administration|levels|increase|and|inhibited|. (l_dobj) increase_9\NN\13576355|induced|activity (l_nmod) activity_27\NN\30358|i|complex|ii/iii|h (l_nummod) ii/iii_26\CD\1740|
23307549
16782438
T13_T27 NONE imatinib_3\NN\1740|of (r_nmod) effects_1\NNS\13245626|cellular|imatinib|cells|. (l_nmod) cells_8\NNS\3080309|on|medullary|thyroid|cancer|harboring (l_acl) harboring_9\VBG\1771535|mutations (l_dobj) mutations_19\NNS\4475|type|associated|ret (l_compound) ret_18\NN\1740|
T8_T20 NONE tyrosine_12\NN\14601829| (r_compound) receptor_14\NN\5225602|a|tyrosine|kinase (r_dobj) encodes_10\VBZ\115157|which|receptor (r_acl:relcl) gene_7\NN\8459252|in|the|ret|,|encodes (l_compound) ret_6\NN\1740|
T8_T24 NONE tyrosine_12\NN\14601829| (r_compound) receptor_14\NN\5225602|a|tyrosine|kinase
T6_T19 CPR:4 imatinib_2\NN\1740|,|inhibitor (l_appos) inhibitor_7\NN\20090|a|tyrosine|kinase|used (l_compound) kinase_6\NN\14732946|
T6_T21 NONE imatinib_2\NN\1740|,|inhibitor (r_dobj) evaluated_1\VBD\670261|we|imatinib|,|drug|. (l_nmod) drug_23\NN\14778436|as|a|potential|treatment|,|lines (l_nmod) lines_34\NNS\8426461|in|2|mtc-derived|cell|expressing (l_acl) expressing_35\VBG\928630|receptors (l_dobj) receptors_41\NNS\5225602|multiple|neoplasia-associated|mutant|ret
T7_T19 NONE tyrosine_5\NN\14601829| (r_compound) inhibitor_7\NN\20090|a|tyrosine|kinase|used (l_compound) kinase_6\NN\14732946|
T7_T21 NONE tyrosine_5\NN\14601829| (r_compound) inhibitor_7\NN\20090|a|tyrosine|kinase|used (r_appos) imatinib_2\NN\1740|,|inhibitor (r_dobj) evaluated_1\VBD\670261|we|imatinib|,|drug|. (l_nmod) drug_23\NN\14778436|as|a|potential|treatment|,|lines (l_nmod) lines_34\NNS\8426461|in|2|mtc-derived|cell|expressing (l_acl) expressing_35\VBG\928630|receptors (l_dobj) receptors_41\NNS\5225602|multiple|neoplasia-associated|mutant|ret
T12_T25 CPR:4 imatinib_2\NN\1740| (r_nsubj) inhibited_3\VBD\2510337|imatinib|phosphorylation|manner|hours (l_dobj) phosphorylation_6\NN\1740|y1062 (l_compound) y1062_5\NN\1740|ret (l_compound) ret_4\NN\1740|
T12_T26 CPR:4 imatinib_2\NN\1740| (r_nsubj) inhibited_3\VBD\2510337|imatinib|phosphorylation|manner|hours (l_dobj) phosphorylation_6\NN\1740|y1062 (l_compound) y1062_5\NN\1740|ret
T3_T16 CPR:4 imatinib_2\NN\1740| (r_nsubj) inhibits_3\VBZ\2510337|imatinib|growth|affecting|manner (l_dobj) growth_7\NN\13526110|ret-mediated|mtc|cell (l_amod) ret-mediated_4\JJ\1740|
T3_T17 CPR:4 imatinib_2\NN\1740| (r_nsubj) inhibits_3\VBZ\2510337|imatinib|growth|affecting|manner (l_advcl) affecting_8\VBG\126264|levels|vitro (l_dobj) levels_11\NNS\4916342|protein (l_compound) protein_10\NN\14944888|ret (l_compound) ret_9\NN\1740|
T4_T18 CPR:4 imatinib_3\NN\1740|of (r_nmod) concentration_1\NN\4916342|the|imatinib|necessary (l_amod) necessary_4\JJ\1740|inhibit (l_xcomp) inhibit_6\VB\2510337|to|ret|vitro (l_dobj) ret_7\NN\1740|
T5_T18 NONE imatinib_19\NN\1740| (r_compound) monotherapy_20\NN\1740|imatinib (r_nsubj) option_25\NN\6480506|that|monotherapy|will|be|a|good|therapy (r_ccomp) conclude_17\VB\628491|to|option (r_xcomp) impossible_15\JJ\1740|it|conclude (r_ccomp) makes_13\VBZ\126264|concentration|,|however|,|impossible|. (l_nsubj) concentration_1\NN\4916342|the|imatinib|necessary (l_amod) necessary_4\JJ\1740|inhibit (l_xcomp) inhibit_6\VB\2510337|to|ret|vitro (l_dobj) ret_7\NN\1740|
23614643
T4_T19 NONE tris-xylosides_11\NNS\1740| (r_conj) bis-_9\JJ\1740|of|and|tris-xylosides|produce (r_nmod) library_7\NN\4105893|a|bis- (r_dobj) utilized_5\VBD\161225|report|,|we|library|,|mimicking|examine|. (l_advcl) examine_31\VB\789138|to|importance (l_dobj) importance_33\NN\5138488|the|valency|regulating (l_acl) regulating_41\VBG\296178|in|interactions|vivo|zebrafish (l_dobj) interactions_43\NNS\37396|fgf/fgfr (l_compound) fgf/fgfr_42\NN\1740|
T4_T20 NONE tris-xylosides_11\NNS\1740| (r_conj) bis-_9\JJ\1740|of|and|tris-xylosides|produce (r_nmod) library_7\NN\4105893|a|bis- (r_dobj) utilized_5\VBD\161225|report|,|we|library|,|mimicking|examine|. (l_advcl) examine_31\VB\789138|to|importance (l_dobj) importance_33\NN\5138488|the|valency|regulating (l_acl) regulating_41\VBG\296178|in|interactions|vivo|zebrafish (l_dobj) interactions_43\NNS\37396|fgf/fgfr (l_compound) fgf/fgfr_42\NN\1740|
T1_T10 NONE su5402_15\NN\1740|by|the|inhibitor|,|mrna|,|or|morpholino (l_conj) mrna_17\NN\14832193|sprouty4 (l_nmod) sprouty4_22\NN\1740|for|the|fgfr|antagonist (l_compound) fgfr_20\NN\1740|
T1_T11 NONE su5402_15\NN\1740|by|the|inhibitor|,|mrna|,|or|morpholino (l_conj) mrna_17\NN\14832193|sprouty4 (l_nmod) sprouty4_22\NN\1740|for|the|fgfr|antagonist
T1_T12 NONE su5402_15\NN\1740|by|the|inhibitor|,|mrna|,|or|morpholino (l_conj) morpholino_26\NN\1740|fgf8 (l_compound) fgf8_25\NN\1740|
T1_T9 CPR:4 su5402_15\NN\1740|by|the|inhibitor|,|mrna|,|or|morpholino (l_compound) inhibitor_14\NN\20090|tyrosine|kinase (l_compound) kinase_13\NN\14732946|
T3_T13 NONE xylosides_22\NNS\1740|with|the|bivalent (r_nmod) observed_18\VBN\2163746|xylosides (r_acl) phenotype_17\NN\4933544|the|elongation|observed (r_dobj) recapitulates_14\VBZ\1007924|furthermore|,|expression|phenotype|. (l_nsubj) expression_2\NN\4679549|multivalent (l_nmod) multivalent_5\JJ\1740|of|a|not|monovalent|gag (l_dep) gag_10\NN\6776138|containing (l_acl) containing_11\VBG\2632940|proteoglycan (l_dobj) proteoglycan_13\NN\1740|syndecan-1 (l_compound) syndecan-1_12\NN\1740|
18604229
T21_T29 NONE amiodarone_8\NN\2715941|and|amiodarone (r_compound) analogues_11\NNS\4743605|of|amiodarone (r_nmod) cytotoxicity_6\NN\13583478|analogues (r_conj) interaction_0\NN\37396|channel|and|cytotoxicity|. (l_nmod) channel_4\NN\6251781|with|the|herg (l_compound) herg_3\NN\1740|
T22_T29 NONE amiodarone_10\NN\2715941| (r_conj) amiodarone_8\NN\2715941|and|amiodarone (r_compound) analogues_11\NNS\4743605|of|amiodarone (r_nmod) cytotoxicity_6\NN\13583478|analogues (r_conj) interaction_0\NN\37396|channel|and|cytotoxicity|. (l_nmod) channel_4\NN\6251781|with|the|herg (l_compound) herg_3\NN\1740|
T12_T27 CPR:4 amiodarone_9\NN\2715941| (r_compound) analogues_10\NNS\4743605|amiodarone|retained (l_acl:relcl) retained_12\VBD\2700867|that|inhibition|but|cytotoxicity (l_dobj) inhibition_20\NN\1068773|protein|channel (l_compound) channel_19\NN\6251781|
T6_T23 NONE nitrogen_21\NN\14622893|a|basic (r_dobj) carrying_18\VBG\1850315|nitrogen|chain (r_acl) compounds_17\NNS\5869584|carrying (r_nsubj) display_26\VBP\2137132|that|compounds|affinity (r_ccomp) revealed_15\VBD\2137132|investigations|display|. (l_nsubj) investigations_4\NNS\5797597|pharmacological|interactions (l_nmod) interactions_7\NNS\37396|concerning|the|compounds|channel (l_nmod) channel_14\NN\6251781|with|the|herg (l_compound) herg_13\NN\1740|
T7_T24 NONE b2-o-ch(2)-ch(2)-n-piperidine_2\NN\1740|and|b2-o-ch(2)-ch(2)-n-pyrrolidine (r_nsubj) revealed_5\VBD\2137132|specifically|,|b2-o-ch(2)-ch(2)-n-piperidine|affinity|. (l_dobj) affinity_8\NN\11426530|a|higher|channels|amiodarone (l_nmod) channels_11\NNS\6251781|towards|herg (l_compound) herg_10\NN\1740|
T8_T24 NONE b2-o-ch(2)-ch(2)-n-pyrrolidine_4\NN\1740| (r_conj) b2-o-ch(2)-ch(2)-n-piperidine_2\NN\1740|and|b2-o-ch(2)-ch(2)-n-pyrrolidine (r_nsubj) revealed_5\VBD\2137132|specifically|,|b2-o-ch(2)-ch(2)-n-piperidine|affinity|. (l_dobj) affinity_8\NN\11426530|a|higher|channels|amiodarone (l_nmod) channels_11\NNS\6251781|towards|herg (l_compound) herg_10\NN\1740|
T9_T24 NONE amiodarone_13\NN\2715941|than (r_nmod) affinity_8\NN\11426530|a|higher|channels|amiodarone (l_nmod) channels_11\NNS\6251781|towards|herg (l_compound) herg_10\NN\1740|
T10_T25 CPR:4 amiodarone_4\NN\2715941| (r_compound) analogues_5\NNS\4743605|amiodarone|inhibition (l_nmod) inhibition_10\NN\1068773|with|better|herg|channel|and|profiles|compound (l_compound) herg_8\NN\1740|
T10_T26 NONE amiodarone_4\NN\2715941| (r_compound) analogues_5\NNS\4743605|amiodarone|inhibition (r_nsubjpass) identified_20\VBN\699815|analogues|have|been|,|demonstrating (l_advcl) demonstrating_22\VBG\2137132|properties (l_ccomp) properties_34\NNS\32613|distinct|compounds (l_amod) distinct_31\JJ\1740|that|cytotoxicity|are|mechanistically|and|separable (l_nsubj) cytotoxicity_24\NN\13583478|and|interaction (l_conj) interaction_28\NN\37396|herg|channel (l_compound) herg_26\NN\1740|
23220644
T6_T17 CPR:4 5-hydroxytryptamines_2\NNS\14807737|of (r_nmod) optimization_0\NN\248977|5-hydroxytryptamines|inhibitors|. (l_nmod) inhibitors_6\NNS\20090|as|dual|function|targeting (l_acl) targeting_7\VBG\1151110|a2 (l_dobj) a2_9\NN\1740|phospholipase|and|hydrolase
T6_T18 CPR:4 5-hydroxytryptamines_2\NNS\14807737|of (r_nmod) optimization_0\NN\248977|5-hydroxytryptamines|inhibitors|. (l_nmod) inhibitors_6\NNS\20090|as|dual|function|targeting (l_acl) targeting_7\VBG\1151110|a2 (l_dobj) a2_9\NN\1740|phospholipase|and|hydrolase (l_conj) hydrolase_13\NN\1740|leukotriene|a4
T1_T12 CPR:9 acid_23\NN\14818238|arachidonic|aa (r_compound) network_28\NN\8435388|the|acid|metabolic (r_dobj) balance_20\VB\456740|inhibitors|may|network|and|used|. (l_nsubj) inhibitors_2\NNS\20090|function|targeting (l_acl) targeting_3\VBG\1151110|a(2 (l_dobj) a(2_5\NN\1740|phospholipase|)|pla(2|and|hydrolase (l_appos) pla(2_8\NN\1740|(|)|) (l_punct) )_9\-RRB-\1740|
T1_T13 CPR:9 acid_23\NN\14818238|arachidonic|aa (r_compound) network_28\NN\8435388|the|acid|metabolic (r_dobj) balance_20\VB\456740|inhibitors|may|network|and|used|. (l_nsubj) inhibitors_2\NNS\20090|function|targeting (l_acl) targeting_3\VBG\1151110|a(2 (l_dobj) a(2_5\NN\1740|phospholipase|)|pla(2|and|hydrolase (l_conj) hydrolase_15\NN\1740|leukotriene|a(4|)|lta(4)h
T1_T16 CPR:9 acid_23\NN\14818238|arachidonic|aa (r_compound) network_28\NN\8435388|the|acid|metabolic (r_dobj) balance_20\VB\456740|inhibitors|may|network|and|used|. (l_nsubj) inhibitors_2\NNS\20090|function|targeting (l_acl) targeting_3\VBG\1151110|a(2 (l_dobj) a(2_5\NN\1740|phospholipase|)|pla(2|and|hydrolase (l_conj) hydrolase_15\NN\1740|leukotriene|a(4|)|lta(4)h (l_appos) lta(4)h_17\NN\1740|(|)
T1_T8 CPR:9 acid_23\NN\14818238|arachidonic|aa (r_compound) network_28\NN\8435388|the|acid|metabolic (r_dobj) balance_20\VB\456740|inhibitors|may|network|and|used|. (l_nsubj) inhibitors_2\NNS\20090|function|targeting (l_acl) targeting_3\VBG\1151110|a(2 (l_dobj) a(2_5\NN\1740|phospholipase|)|pla(2|and|hydrolase (l_punct) )_6\-RRB-\1740|
T2_T10 CPR:4 4_22\CD\13741022| (r_nummod) jmc08_20\NN\1740|(|-|4|) (r_appos) inhibitor_18\NN\20090|a|dual-target|jmc08|a(2 (l_nmod) a(2_29\NN\1740|for|human|nonpancreatic|secretory|phospholipase|)|hnps-pla(2|and|hydrolase (l_conj) hydrolase_40\NN\1740|human|leukotriene|a(4|)|lta(4)h-h
T2_T11 CPR:4 4_22\CD\13741022| (r_nummod) jmc08_20\NN\1740|(|-|4|) (r_appos) inhibitor_18\NN\20090|a|dual-target|jmc08|a(2 (l_nmod) a(2_29\NN\1740|for|human|nonpancreatic|secretory|phospholipase|)|hnps-pla(2|and|hydrolase (l_conj) hydrolase_40\NN\1740|human|leukotriene|a(4|)|lta(4)h-h (l_appos) lta(4)h-h_42\NN\1740|(|)
T2_T7 CPR:4 4_22\CD\13741022| (r_nummod) jmc08_20\NN\1740|(|-|4|) (r_appos) inhibitor_18\NN\20090|a|dual-target|jmc08|a(2 (l_nmod) a(2_29\NN\1740|for|human|nonpancreatic|secretory|phospholipase|)|hnps-pla(2|and|hydrolase (l_punct) )_30\-RRB-\1740|
T2_T9 CPR:4 4_22\CD\13741022| (r_nummod) jmc08_20\NN\1740|(|-|4|) (r_appos) inhibitor_18\NN\20090|a|dual-target|jmc08|a(2 (l_nmod) a(2_29\NN\1740|for|human|nonpancreatic|secretory|phospholipase|)|hnps-pla(2|and|hydrolase (l_appos) hnps-pla(2_32\NN\1740|(|)|) (l_punct) )_33\-RRB-\1740|
23386417
T13_T26 NONE androgen_0\NN\14745635| (r_compound) mrna_2\NN\14832193|androgen|receptor|measured (l_compound) receptor_1\NN\5225602|
T1_T22 NONE androgen_0\NN\14745635| (r_compound) action_1\NN\30358|androgen (r_nsubjpass) exerted_3\VBN\1158872|action|is|receptor|. (l_nmod) receptor_7\NN\5225602|through|the|androgen
T9_T22 NONE androgen_6\NN\14745635| (r_compound) receptor_7\NN\5225602|through|the|androgen
T3_T15 NONE androgen_7\NN\14745635| (r_compound) expression_10\NN\4679549|on|androgen|receptor|gene|,|specific (l_compound) receptor_8\NN\5225602|
T3_T21 NONE androgen_7\NN\14745635| (r_compound) expression_10\NN\4679549|on|androgen|receptor|gene|,|specific (r_nmod) depends_5\VBZ\2604760|virilization|expression|,|and|requires|. (l_conj) requires_18\VBZ\754942|levels (l_dobj) levels_23\NNS\4916342|normal|mrna|tissues (l_compound) mrna_22\NN\14832193|androgen|receptor (l_compound) receptor_21\NN\5225602|
T6_T15 NONE androgen_20\NN\14745635| (r_compound) mrna_22\NN\14832193|androgen|receptor (r_compound) levels_23\NNS\4916342|normal|mrna|tissues (r_dobj) requires_18\VBZ\754942|levels (r_conj) depends_5\VBZ\2604760|virilization|expression|,|and|requires|. (l_nmod) expression_10\NN\4679549|on|androgen|receptor|gene|,|specific (l_compound) receptor_8\NN\5225602|
T6_T21 NONE androgen_20\NN\14745635| (r_compound) mrna_22\NN\14832193|androgen|receptor (l_compound) receptor_21\NN\5225602|
T7_T15 NONE androgen_25\NN\14745635| (r_compound) tissues_27\NNS\5220461|in|androgen|sensitive (r_nmod) levels_23\NNS\4916342|normal|mrna|tissues (r_dobj) requires_18\VBZ\754942|levels (r_conj) depends_5\VBZ\2604760|virilization|expression|,|and|requires|. (l_nmod) expression_10\NN\4679549|on|androgen|receptor|gene|,|specific (l_compound) receptor_8\NN\5225602|
T7_T21 NONE androgen_25\NN\14745635| (r_compound) tissues_27\NNS\5220461|in|androgen|sensitive (r_nmod) levels_23\NNS\4916342|normal|mrna|tissues (l_compound) mrna_22\NN\14832193|androgen|receptor (l_compound) receptor_21\NN\5225602|
T10_T23 NONE androgen_18\NN\14745635| (r_compound) mrna_20\NN\14832193|of|androgen|receptor (l_compound) receptor_19\NN\5225602|
T10_T24 NONE androgen_18\NN\14745635| (r_compound) mrna_20\NN\14832193|of|androgen|receptor (r_nmod) amount_16\NN\13329641|the|mrna|cells (r_dobj) compare_7\VB\644583|to|,|pcr|,|amount|levels (l_nmod) levels_39\NNS\4916342|with|the|mrna|observed (l_compound) mrna_38\NN\14832193|androgen|receptor (l_compound) receptor_37\NN\5225602|
T11_T23 NONE androgen_36\NN\14745635| (r_compound) mrna_38\NN\14832193|androgen|receptor (r_compound) levels_39\NNS\4916342|with|the|mrna|observed (r_nmod) compare_7\VB\644583|to|,|pcr|,|amount|levels (l_dobj) amount_16\NN\13329641|the|mrna|cells (l_nmod) mrna_20\NN\14832193|of|androgen|receptor (l_compound) receptor_19\NN\5225602|
T11_T24 NONE androgen_36\NN\14745635| (r_compound) mrna_38\NN\14832193|androgen|receptor (l_compound) receptor_37\NN\5225602|
T12_T25 NONE androgen_4\NN\14745635| (r_compound) mrna_6\NN\14832193|less|androgen|receptor (l_compound) receptor_5\NN\5225602|
T2_T14 NONE androgen_6\NN\14745635| (r_compound) expression_9\NN\4679549|of|androgen|receptor|mrna (l_compound) receptor_7\NN\5225602|
T4_T16 NONE androgen_13\NN\14745635| (r_compound) gene_15\NN\8459252|of|the|androgen|receptor (r_nmod) exon_9\NN\14830364|in|1|gene (r_nmod) repeats_7\NNS\7296190|of|cag|exon
T4_T17 NONE androgen_13\NN\14745635| (r_compound) gene_15\NN\8459252|of|the|androgen|receptor (l_compound) receptor_14\NN\5225602|
T5_T20 NONE androgen_9\NN\14745635| (r_compound) receptor_10\NN\5225602|androgen
23466460
3812589
T12_T16 NONE methionine_0\NN\14605787| (r_compound) synthase_1\NN\1740|methionine
23380477
T5_T21 NONE )_14\-RRB-\1740| (r_punct) cocl(2_13\NN\1740|to|mimetic|) (r_nmod) response_9\NN\11410625|in|cocl(2 (r_nmod) takes_1\VBZ\2367363|autophagy|place|cells|response|. (l_nmod) cells_7\NNS\3080309|in|mutated|p53|neuroblastoma (l_compound) p53_5\NN\1740|
T1_T15 CPR:3 chloride_5\NN\14818238|cobalt|,|mimetic (l_appos) mimetic_9\NN\1740|a|hypoxia|inhibits (l_acl:relcl) inhibits_11\VBZ\2510337|that|degradation|and|generates (l_dobj) degradation_14\NN\199130|proteasomal|hif-1 (l_compound) hif-1_13\NN\1740|
T2_T15 NONE oxygen_18\NN\14622893| (r_compound) species_19\NNS\7992450|reactive|oxygen|ros (r_dobj) generates_16\VBZ\1617192|species (r_conj) inhibits_11\VBZ\2510337|that|degradation|and|generates (l_dobj) degradation_14\NN\199130|proteasomal|hif-1 (l_compound) hif-1_13\NN\1740|
T3_T16 NONE cocl2-induced_3\JJ\1740| (r_amod) death_5\NN\7296428|on|cocl2-induced|cell|line (l_nmod) line_13\NN\8426461|in|a|dna-binding|mutated|p53|neuroblastoma|cell|sknbe(2c (l_compound) p53_10\NN\1740|
T4_T17 NONE cocl2_26\NN\1740| (r_compound) exposure_28\NN\5042871|with|cocl2|time (r_nmod) decreased_24\VBD\169651|whereas|presence|exposure (r_advcl) evidenced_4\VBN\1015244|signaling|was|increase|decreased|. (l_nmod) increase_7\NN\13576355|by|an|beclin-1 (l_nmod) beclin-1_9\NN\1740|of|,|-|,|and|lc3-ii|expression
T4_T18 NONE cocl2_26\NN\1740| (r_compound) exposure_28\NN\5042871|with|cocl2|time (r_nmod) decreased_24\VBD\169651|whereas|presence|exposure (r_advcl) evidenced_4\VBN\1015244|signaling|was|increase|decreased|. (l_nmod) increase_7\NN\13576355|by|an|beclin-1 (l_nmod) beclin-1_9\NN\1740|of|,|-|,|and|lc3-ii|expression (l_conj) -_13\NN\1740|atg|12 (l_nummod) 12_14\CD\13745420|
T4_T19 NONE cocl2_26\NN\1740| (r_compound) exposure_28\NN\5042871|with|cocl2|time (r_nmod) decreased_24\VBD\169651|whereas|presence|exposure (r_advcl) evidenced_4\VBN\1015244|signaling|was|increase|decreased|. (l_nmod) increase_7\NN\13576355|by|an|beclin-1 (l_nmod) beclin-1_9\NN\1740|of|,|-|,|and|lc3-ii|expression (l_conj) lc3-ii_17\NN\1740|
T4_T20 CPR:4 cocl2_26\NN\1740| (r_compound) exposure_28\NN\5042871|with|cocl2|time (r_nmod) decreased_24\VBD\169651|whereas|presence|exposure (l_nsubj) presence_23\NN\13954253|the|p53(mut (l_compound) p53(mut_21\NN\1740|)
23187687
2125244
T6_T15 NONE phosphate_3\NN\15010703|estramustine (r_compound) binding_4\NN\4688246|of|phosphate|map2 (r_nmod) stoichiometry_0\NN\13819207|binding|measured|. (l_acl) measured_7\VBN\697589|disassembly (l_nmod) disassembly_10\NN\407535|by|the|microtubules (l_nmod) microtubules_15\NNS\5246796|of|brain|map2:tubulin (l_compound) map2:tubulin_14\NN\1740|
T6_T16 NONE phosphate_3\NN\15010703|estramustine (r_compound) binding_4\NN\4688246|of|phosphate|map2 (l_nmod) map2_6\NN\1740|to
T6_T17 NONE phosphate_3\NN\15010703|estramustine (r_compound) binding_4\NN\4688246|of|phosphate|map2 (r_nmod) stoichiometry_0\NN\13819207|binding|measured|. (l_acl) measured_7\VBN\697589|disassembly (l_nmod) disassembly_10\NN\407535|by|the|microtubules (l_nmod) microtubules_15\NNS\5246796|of|brain|map2:tubulin (l_compound) map2:tubulin_14\NN\1740|
T1_T7 CPR:3 phosphate_4\NN\15010703|of|estramustine (r_nmod) concentration_1\NN\4916342|the|phosphate|required (l_acl) required_5\VBN\754942|inhibit (l_ccomp) inhibit_7\VB\2510337|to|assembly|or|induce (l_conj) induce_12\VB\1627355|to|disassembly (l_dobj) disassembly_14\NN\407535|the|microtubules (l_nmod) microtubules_19\NNS\5246796|of|chick|brain|map2:tubulin (l_compound) map2:tubulin_18\NN\1740|
T1_T8 CPR:3 phosphate_4\NN\15010703|of|estramustine (r_nmod) concentration_1\NN\4916342|the|phosphate|required (l_acl) required_5\VBN\754942|inhibit (l_ccomp) inhibit_7\VB\2510337|to|assembly|or|induce (l_conj) induce_12\VB\1627355|to|disassembly (l_dobj) disassembly_14\NN\407535|the|microtubules (l_nmod) microtubules_19\NNS\5246796|of|chick|brain|map2:tubulin (l_compound) map2:tubulin_18\NN\1740|
T2_T10 NONE phosphate_7\NN\15010703|estramustine|and|tubulin (r_nsubj) compete_10\VBP\1740|that|phosphate|sites|,|bind (l_nmod) sites_14\NNS\8673395|for|common|map2 (l_compound) map2_13\NN\1740|
T2_T11 NONE phosphate_7\NN\15010703|estramustine|and|tubulin (r_nsubj) compete_10\VBP\1740|that|phosphate|sites|,|bind (l_conj) bind_19\VB\1290422|that|map2|can|phosphate|,|and|congruent (l_nsubj) map2_17\NN\1740|
T2_T9 NONE phosphate_7\NN\15010703|estramustine|and|tubulin (l_conj) tubulin_9\NN\1740|
T3_T10 NONE phosphate_25\NN\15010703|6|moles.mole-1|estramustine (r_dobj) bind_19\VB\1290422|that|map2|can|phosphate|,|and|congruent (r_conj) compete_10\VBP\1740|that|phosphate|sites|,|bind (l_nmod) sites_14\NNS\8673395|for|common|map2 (l_compound) map2_13\NN\1740|
T3_T11 NONE phosphate_25\NN\15010703|6|moles.mole-1|estramustine (r_dobj) bind_19\VB\1290422|that|map2|can|phosphate|,|and|congruent (l_nsubj) map2_17\NN\1740|
T3_T9 NONE phosphate_25\NN\15010703|6|moles.mole-1|estramustine (r_dobj) bind_19\VB\1290422|that|map2|can|phosphate|,|and|congruent (r_conj) compete_10\VBP\1740|that|phosphate|sites|,|bind (l_nsubj) phosphate_7\NN\15010703|estramustine|and|tubulin (l_conj) tubulin_9\NN\1740|
T4_T10 NONE phosphate_40\NN\15010703|to|microm|estramustine (r_nmod) congruent_35\JJ\1740|that|kd|is|phosphate (r_conj) bind_19\VB\1290422|that|map2|can|phosphate|,|and|congruent (r_conj) compete_10\VBP\1740|that|phosphate|sites|,|bind (l_nmod) sites_14\NNS\8673395|for|common|map2 (l_compound) map2_13\NN\1740|
T4_T11 NONE phosphate_40\NN\15010703|to|microm|estramustine (r_nmod) congruent_35\JJ\1740|that|kd|is|phosphate (r_conj) bind_19\VB\1290422|that|map2|can|phosphate|,|and|congruent (l_nsubj) map2_17\NN\1740|
T4_T9 NONE phosphate_40\NN\15010703|to|microm|estramustine (r_nmod) congruent_35\JJ\1740|that|kd|is|phosphate (r_conj) bind_19\VB\1290422|that|map2|can|phosphate|,|and|congruent (r_conj) compete_10\VBP\1740|that|phosphate|sites|,|bind (l_nsubj) phosphate_7\NN\15010703|estramustine|and|tubulin (l_conj) tubulin_9\NN\1740|
T5_T12 NONE phosphate_8\NN\15010703|of|estramustine (r_nmod) molecules_5\NNS\9465459|two|phosphate (r_nsubj) interact_9\VBP\2367363|that|molecules|each|and|inhibit (l_nmod) each_11\DT\1740|with|sites (l_nmod) sites_16\NNS\8673395|of|the|three|tubulin-binding|map2 (l_nmod) map2_18\NN\1740|of
T5_T13 CPR:4 phosphate_8\NN\15010703|of|estramustine (r_nmod) molecules_5\NNS\9465459|two|phosphate (r_nsubj) interact_9\VBP\2367363|that|molecules|each|and|inhibit (l_conj) inhibit_20\VBP\2510337|interaction|neutralising (l_dobj) interaction_23\NN\37396|the|map2:tubulin (l_compound) map2:tubulin_22\NN\1740|
T5_T14 CPR:4 phosphate_8\NN\15010703|of|estramustine (r_nmod) molecules_5\NNS\9465459|two|phosphate (r_nsubj) interact_9\VBP\2367363|that|molecules|each|and|inhibit (l_conj) inhibit_20\VBP\2510337|interaction|neutralising (l_dobj) interaction_23\NN\37396|the|map2:tubulin (l_compound) map2:tubulin_22\NN\1740|
17409318
T11_T26 CPR:9 dha_45\NN\1740|of|ala (r_nmod) synthesis_41\NN\13446390|in|the|and|accumulation|dha (r_nmod) play_34\VB\1072262|that|enzyme|may|role|synthesis (r_ccomp) suggests_29\VBZ\1010118|use|play|. (l_nsubj) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d
T11_T28 CPR:9 dha_45\NN\1740|of|ala (r_nmod) synthesis_41\NN\13446390|in|the|and|accumulation|dha (r_nmod) play_34\VB\1072262|that|enzyme|may|role|synthesis (r_ccomp) suggests_29\VBZ\1010118|use|play|. (l_nsubj) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d (l_appos) d6d_7\NN\1740|(|)
T12_T26 CPR:9 ala_47\NN\5470189|from (r_nmod) dha_45\NN\1740|of|ala (r_nmod) synthesis_41\NN\13446390|in|the|and|accumulation|dha (r_nmod) play_34\VB\1072262|that|enzyme|may|role|synthesis (r_ccomp) suggests_29\VBZ\1010118|use|play|. (l_nsubj) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d
T12_T28 CPR:9 ala_47\NN\5470189|from (r_nmod) dha_45\NN\1740|of|ala (r_nmod) synthesis_41\NN\13446390|in|the|and|accumulation|dha (r_nmod) play_34\VB\1072262|that|enzyme|may|role|synthesis (r_ccomp) suggests_29\VBZ\1010118|use|play|. (l_nsubj) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d (l_appos) d6d_7\NN\1740|(|)
T19_T26 CPR:9 acid_15\NN\14818238|of|alpha-linolenic|ala (r_nmod) conversion_12\NN\7359599|in|the|acid|acid (r_nmod) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d
T19_T28 CPR:9 acid_15\NN\14818238|of|alpha-linolenic|ala (r_nmod) conversion_12\NN\7359599|in|the|acid|acid (r_nmod) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d (l_appos) d6d_7\NN\1740|(|)
T23_T26 CPR:9 ala_17\NN\5470189|(|;|18:3n-3|) (r_appos) acid_15\NN\14818238|of|alpha-linolenic|ala (r_nmod) conversion_12\NN\7359599|in|the|acid|acid (r_nmod) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d
T23_T28 CPR:9 ala_17\NN\5470189|(|;|18:3n-3|) (r_appos) acid_15\NN\14818238|of|alpha-linolenic|ala (r_nmod) conversion_12\NN\7359599|in|the|acid|acid (r_nmod) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d (l_appos) d6d_7\NN\1740|(|)
T2_T26 CPR:9 acid_23\NN\14818238|to|docosahexaenoic|dha (r_nmod) conversion_12\NN\7359599|in|the|acid|acid (r_nmod) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d
T2_T28 CPR:9 acid_23\NN\14818238|to|docosahexaenoic|dha (r_nmod) conversion_12\NN\7359599|in|the|acid|acid (r_nmod) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d (l_appos) d6d_7\NN\1740|(|)
T8_T26 CPR:9 dha_25\NN\1740|(|;|22:6n-3|) (r_appos) acid_23\NN\14818238|to|docosahexaenoic|dha (r_nmod) conversion_12\NN\7359599|in|the|acid|acid (r_nmod) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d
T8_T28 CPR:9 dha_25\NN\1740|(|;|22:6n-3|) (r_appos) acid_23\NN\14818238|to|docosahexaenoic|dha (r_nmod) conversion_12\NN\7359599|in|the|acid|acid (r_nmod) use_1\NN\407535|the|desaturase|twice|conversion (l_nmod) desaturase_5\NN\1740|of|delta|6|d6d (l_appos) d6d_7\NN\1740|(|)
T20_T29 CPR:9 dha_11\NN\1740| (r_conj) 24:6n-3_9\NN\1740|and|dha (r_conj) 22:5n-3_7\NN\1740|of|,|24:6n-3|, (r_nmod) products_5\NNS\3076708|of|the|post-d6d|22:5n-3 (l_amod) post-d6d_4\JJ\1740|
T21_T29 NONE ala_24\NN\5470189|of|microm (r_nmod) concentrations_19\NNS\4916342|at|ala (r_nmod) saturated_17\VBN\126264|accumulation|was|concentrations|. (l_nsubjpass) accumulation_1\NN\13497135|the|products|phospholipids (l_nmod) products_5\NNS\3076708|of|the|post-d6d|22:5n-3 (l_amod) post-d6d_4\JJ\1740|
T10_T27 CPR:9 dha_33\NN\1740|of (r_nmod) accumulation_31\NN\13497135|to|the|limited|dha|membranes (r_nmod) contribute_27\VB\126264|that|competition|may|accumulation (l_nsubj) competition_19\NN\13836841|the|24:5n-3|d6d (l_nmod) d6d_25\NN\1740|for
T6_T27 NONE dha_8\NN\1740| (r_conj) 24:6n-3_6\NN\1740|of|and|dha (r_nmod) accumulation_4\NN\13497135|of|24:6n-3|response (r_nmod) pattern_2\NN\5726345|the|parallel|accumulation (r_nsubj) suggests_16\VBZ\1010118|pattern|contribute|. (l_ccomp) contribute_27\VB\126264|that|competition|may|accumulation (l_nsubj) competition_19\NN\13836841|the|24:5n-3|d6d (l_nmod) d6d_25\NN\1740|for
T7_T27 NONE ala_15\NN\5470189|of (r_nmod) concentrations_13\NNS\4916342|to|increasing|ala (r_nmod) response_10\NN\11410625|in|concentrations (r_nmod) accumulation_4\NN\13497135|of|24:6n-3|response (r_nmod) pattern_2\NN\5726345|the|parallel|accumulation (r_nsubj) suggests_16\VBZ\1010118|pattern|contribute|. (l_ccomp) contribute_27\VB\126264|that|competition|may|accumulation (l_nsubj) competition_19\NN\13836841|the|24:5n-3|d6d (l_nmod) d6d_25\NN\1740|for
T9_T27 CPR:9 ala_23\NN\5470189| (r_conj) 24:5n-3_21\NN\1740|between|and|ala (r_nmod) competition_19\NN\13836841|the|24:5n-3|d6d (l_nmod) d6d_25\NN\1740|for
23456038
T2_T15 NONE phospho-ww_7\NN\1740|of|the
T3_T15 NONE phosphate_19\NN\15010703| (r_compound) moiety_20\NN\13736799|the|phosphate|phospho-s16 (r_nsubj) compete_24\VB\1740|that|moiety|could|phospho-substrate (r_ccomp) suggests_16\VBZ\1010118|additionally|,|model|compete|. (l_nsubj) model_4\NN\5888929|a|structural|phospho-ww|obtained (l_nmod) phospho-ww_7\NN\1740|of|the
T4_T15 NONE phospho-s16_22\NN\1740|of (r_nmod) moiety_20\NN\13736799|the|phosphate|phospho-s16 (r_nsubj) compete_24\VB\1740|that|moiety|could|phospho-substrate (r_ccomp) suggests_16\VBZ\1010118|additionally|,|model|compete|. (l_nsubj) model_4\NN\5888929|a|structural|phospho-ww|obtained (l_nmod) phospho-ww_7\NN\1740|of|the
T5_T15 NONE phospho-substrate_27\NN\1740|with|the (r_nmod) compete_24\VB\1740|that|moiety|could|phospho-substrate (r_ccomp) suggests_16\VBZ\1010118|additionally|,|model|compete|. (l_nsubj) model_4\NN\5888929|a|structural|phospho-ww|obtained (l_nmod) phospho-ww_7\NN\1740|of|the
19651196
T17_T27 CPR:4 op_3\NN\1740| (r_compound) poisoning_4\NN\14034177|of|op (r_nmod) mechanism_1\NN\13446390|the|poisoning (r_nsubj) involves_5\VBZ\2676054|mechanism|inhibition|. (l_dobj) inhibition_6\NN\1068773|acetylcholinesterase|leading (l_nmod) acetylcholinesterase_8\NN\1740|of|ache
T17_T28 CPR:4 op_3\NN\1740| (r_compound) poisoning_4\NN\14034177|of|op (r_nmod) mechanism_1\NN\13446390|the|poisoning (r_nsubj) involves_5\VBZ\2676054|mechanism|inhibition|. (l_dobj) inhibition_6\NN\1068773|acetylcholinesterase|leading (l_nmod) acetylcholinesterase_8\NN\1740|of|ache (l_appos) ache_10\NN\14322699|(|)
T18_T29 NONE acetylcholine_7\NN\14807558|of (r_nmod) accumulation_5\NN\13497135|in|the|acetylcholine|sites (r_nmod) results_2\VBZ\2633881|inhibition|accumulation|,|producing|. (l_nsubj) inhibition_1\NN\1068773|ache (l_compound) ache_0\NN\14322699|
T21_T30 CPR:4 op_8\NN\1740|by (r_nmod) inhibited_6\VBN\2510337|op (r_acl) ache_5\NN\14322699|of|inhibited
T10_T26 CPR:3 trimedoxime_25\NN\1740| (r_conj) pralidoxime_23\NN\1740|(|,|trimedoxime|,|obidoxime|and|hi-6|)|and|diazepam (r_dep) oximes_21\NNS\14727670|of|the|recommended|pyridinium|pralidoxime (r_nmod) one_16\CD\13741022|such|oximes (r_nmod) atropine_10\NN\14712692|e.g.|,|reactivator|one (l_appos) reactivator_13\NN\1740|ache (l_compound) ache_12\NN\14322699|
T11_T26 CPR:3 obidoxime_27\NN\1740| (r_conj) pralidoxime_23\NN\1740|(|,|trimedoxime|,|obidoxime|and|hi-6|)|and|diazepam (r_dep) oximes_21\NNS\14727670|of|the|recommended|pyridinium|pralidoxime (r_nmod) one_16\CD\13741022|such|oximes (r_nmod) atropine_10\NN\14712692|e.g.|,|reactivator|one (l_appos) reactivator_13\NN\1740|ache (l_compound) ache_12\NN\14322699|
T12_T26 CPR:3 hi-6_29\NN\1740| (r_conj) pralidoxime_23\NN\1740|(|,|trimedoxime|,|obidoxime|and|hi-6|)|and|diazepam (r_dep) oximes_21\NNS\14727670|of|the|recommended|pyridinium|pralidoxime (r_nmod) one_16\CD\13741022|such|oximes (r_nmod) atropine_10\NN\14712692|e.g.|,|reactivator|one (l_appos) reactivator_13\NN\1740|ache (l_compound) ache_12\NN\14322699|
T13_T26 CPR:3 diazepam_32\NN\2830852| (r_conj) pralidoxime_23\NN\1740|(|,|trimedoxime|,|obidoxime|and|hi-6|)|and|diazepam (r_dep) oximes_21\NNS\14727670|of|the|recommended|pyridinium|pralidoxime (r_nmod) one_16\CD\13741022|such|oximes (r_nmod) atropine_10\NN\14712692|e.g.|,|reactivator|one (l_appos) reactivator_13\NN\1740|ache (l_compound) ache_12\NN\14322699|
T14_T26 CPR:4 op_39\NN\1740| (r_compound) poisoning_40\NN\14034177|of|op|humans (r_nmod) treatment_37\NN\654885|for|the|poisoning (r_nmod) used_34\VBN\1156834|presently|,|combination|are|treatment|. (l_nsubjpass) combination_3\NN\7951464|a|agent (l_nmod) agent_7\NN\7347|of|an|antimuscarinic|,|atropine (l_appos) atropine_10\NN\14712692|e.g.|,|reactivator|one (l_appos) reactivator_13\NN\1740|ache (l_compound) ache_12\NN\14322699|
T7_T26 CPR:3 atropine_10\NN\14712692|e.g.|,|reactivator|one (l_appos) reactivator_13\NN\1740|ache (l_compound) ache_12\NN\14322699|
T8_T26 CPR:3 oximes_21\NNS\14727670|of|the|recommended|pyridinium|pralidoxime (r_nmod) one_16\CD\13741022|such|oximes (r_nmod) atropine_10\NN\14712692|e.g.|,|reactivator|one (l_appos) reactivator_13\NN\1740|ache (l_compound) ache_12\NN\14322699|
T9_T26 CPR:3 pralidoxime_23\NN\1740|(|,|trimedoxime|,|obidoxime|and|hi-6|)|and|diazepam (r_dep) oximes_21\NNS\14727670|of|the|recommended|pyridinium|pralidoxime (r_nmod) one_16\CD\13741022|such|oximes (r_nmod) atropine_10\NN\14712692|e.g.|,|reactivator|one (l_appos) reactivator_13\NN\1740|ache (l_compound) ache_12\NN\14322699|
23485402
T2_T14 NONE tetrodotoxin-sensitive_0\JJ\1740| (r_amod) neurotransmission_3\NN\1740|tetrodotoxin-sensitive|spontaneous|cholinergic (r_nsubjpass) blocked_5\VBN\1476483|neurotransmission|was|%||cleaving|. (l_nmod) _11\_SP\1740|by|1|pm (l_dep) pm_12\NN\635850|bont/a (l_dep) bont/a_13\NN\1740|
T2_T15 NONE tetrodotoxin-sensitive_0\JJ\1740| (r_amod) neurotransmission_3\NN\1740|tetrodotoxin-sensitive|spontaneous|cholinergic (r_nsubjpass) blocked_5\VBN\1476483|neurotransmission|was|%||cleaving|. (l_advcl) cleaving_15\VBG\1556346|despite|% (l_dobj) %_18\NN\1740|20|snap-25 (l_nmod) snap-25_21\NN\1740|of|the
T1_T10 NONE n-terminus_17\NN\1740|to|the|bont/a. (l_nmod) bont/a._19\NN\1740|of
T1_T7 NONE n-terminus_17\NN\1740|to|the|bont/a. (r_nmod) fused_14\VBN\140123|when|n-terminus (r_advcl) conferred_7\VBN\813978|moreover|,|cleavage|was|protease|fused (l_nsubjpass) cleavage_3\NN\24720|limited|snap-25 (l_nmod) snap-25_5\NN\1740|of
T1_T8 NONE n-terminus_17\NN\1740|to|the|bont/a. (r_nmod) fused_14\VBN\140123|when|n-terminus (r_advcl) conferred_7\VBN\813978|moreover|,|cleavage|was|protease|fused (l_nmod) protease_10\NN\14732946|onto|the|bont/e
T1_T9 NONE n-terminus_17\NN\1740|to|the|bont/a. (r_nmod) fused_14\VBN\140123|when|n-terminus (r_advcl) conferred_7\VBN\813978|moreover|,|cleavage|was|protease|fused (l_nmod) protease_10\NN\14732946|onto|the|bont/e (l_nmod) bont/e_12\NN\1740|from
23510370
T1_T11 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1
T1_T12 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) thyroperoxidase_23\NN\1740|
T1_T13 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) factor-1_27\NN\1740|thyroid|transcription|ttf-1/titf-1/nkx2.1
T1_T14 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) factor-1_27\NN\1740|thyroid|transcription|ttf-1/titf-1/nkx2.1 (l_appos) ttf-1/titf-1/nkx2.1_29\NN\1740|(|)
T1_T15 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) factor-1_27\NN\1740|thyroid|transcription|ttf-1/titf-1/nkx2.1 (l_appos) ttf-1/titf-1/nkx2.1_29\NN\1740|(|)
T1_T16 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) factor-1_27\NN\1740|thyroid|transcription|ttf-1/titf-1/nkx2.1 (l_appos) ttf-1/titf-1/nkx2.1_29\NN\1740|(|)
T1_T17 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) ae1/ae3_36\NN\1740|cytokeratin (l_compound) cytokeratin_32\NN\1740|ck
T1_T18 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) ae1/ae3_36\NN\1740|cytokeratin (l_compound) cytokeratin_32\NN\1740|ck (l_appos) ck_34\NN\1740|(|)
T1_T19 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_appos) ck_38\NN\1740|7 (l_nummod) 7_39\CD\13741022|
T1_T20 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) pendrin_41\NN\1740|
T1_T21 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis
T1_T22 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (l_appos) hnis_48\NN\1740|(|)
T1_T23 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) gene_53\NN\8459252|paired|box|8|pax8 (l_nummod) 8_54\CD\13741022|
T1_T24 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) gene_53\NN\8459252|paired|box|8|pax8 (l_appos) pax8_56\NN\1740|(|)
T1_T25 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) foxe1_59\NN\1740|ttf-2
T1_T26 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (l_conj) foxe1_59\NN\1740|ttf-2 (l_appos) ttf-2_61\NN\1740|(|)
T1_T2 NONE iodide_45\NN\14904359| (r_compound) symporter_46\NN\1740|human|sodium|iodide|hnis (r_conj) thyroglobulin_21\NN\14734761|for|,|thyroperoxidase|,|factor-1|,|ae1/ae3|,|ck|,|pendrin|,|symporter|,|gene|and|foxe1 (r_nmod) positivity_19\NN\13856574|by|immunohistochemical|thyroglobulin|,|as|positivity (l_conj) positivity_67\NN\13856574|rna|analysis (l_nmod) rna_71\NN\14994328|for|the|messenger|gene (l_nmod) gene_75\NN\8459252|of|the|thyroglobulin (l_compound) thyroglobulin_74\NN\14734761|
16449956
T1_T11 NONE citrulline_10\NN\14601829| (r_compound) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (l_conj) inhibitor_27\NN\20090|serum|pancreatic|secretory|trypsin|psti|ng/ml (l_appos) psti_29\NN\1740|(|)
T1_T12 NONE citrulline_10\NN\14601829| (r_compound) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (r_nmod) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_conj) decrease_42\NN\7296428|activity|% (l_nmod) activity_47\NN\30358|in|hepatic|argininosuccinate|synthetase (l_compound) synthetase_46\NN\1740|
T1_T13 NONE citrulline_10\NN\14601829| (r_compound) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (r_nmod) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_conj) lack_55\NN\14449126|expression (l_nmod) expression_60\NN\4679549|of|hepatic|citrin|protein (l_compound) citrin_58\NN\15089645|
T1_T14 NONE citrulline_10\NN\14601829| (r_compound) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (r_nmod) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_conj) mutations_62\NNS\4475|gene (l_nmod) gene_65\NN\8459252|in|slc25a13 (l_compound) slc25a13_64\NN\1740|
T1_T16 NONE citrulline_10\NN\14601829| (r_compound) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (r_nmod) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_dep) heterozygote_68\NN\5431926|(|compound|s225x|) (l_nmod) s225x_70\NN\1740|with|and|a
T1_T17 NONE citrulline_10\NN\14601829| (r_compound) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (r_nmod) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_dep) heterozygote_68\NN\5431926|(|compound|s225x|) (l_nmod) s225x_70\NN\1740|with|and|a (l_conj) a_76\NN\13649268|ex1|-|1g|>
T1_T9 NONE citrulline_10\NN\14601829| (r_compound) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (l_conj) inhibitor_27\NN\20090|serum|pancreatic|secretory|trypsin|psti|ng/ml
T2_T11 NONE argininosuccinate_45\NN\1740| (r_compound) activity_47\NN\30358|in|hepatic|argininosuccinate|synthetase (r_nmod) decrease_42\NN\7296428|activity|% (r_conj) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_nmod) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (l_conj) inhibitor_27\NN\20090|serum|pancreatic|secretory|trypsin|psti|ng/ml (l_appos) psti_29\NN\1740|(|)
T2_T12 NONE argininosuccinate_45\NN\1740| (r_compound) activity_47\NN\30358|in|hepatic|argininosuccinate|synthetase (l_compound) synthetase_46\NN\1740|
T2_T13 NONE argininosuccinate_45\NN\1740| (r_compound) activity_47\NN\30358|in|hepatic|argininosuccinate|synthetase (r_nmod) decrease_42\NN\7296428|activity|% (r_conj) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_conj) lack_55\NN\14449126|expression (l_nmod) expression_60\NN\4679549|of|hepatic|citrin|protein (l_compound) citrin_58\NN\15089645|
T2_T14 NONE argininosuccinate_45\NN\1740| (r_compound) activity_47\NN\30358|in|hepatic|argininosuccinate|synthetase (r_nmod) decrease_42\NN\7296428|activity|% (r_conj) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_conj) mutations_62\NNS\4475|gene (l_nmod) gene_65\NN\8459252|in|slc25a13 (l_compound) slc25a13_64\NN\1740|
T2_T16 NONE argininosuccinate_45\NN\1740| (r_compound) activity_47\NN\30358|in|hepatic|argininosuccinate|synthetase (r_nmod) decrease_42\NN\7296428|activity|% (r_conj) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_dep) heterozygote_68\NN\5431926|(|compound|s225x|) (l_nmod) s225x_70\NN\1740|with|and|a
T2_T17 NONE argininosuccinate_45\NN\1740| (r_compound) activity_47\NN\30358|in|hepatic|argininosuccinate|synthetase (r_nmod) decrease_42\NN\7296428|activity|% (r_conj) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_dep) heterozygote_68\NN\5431926|(|compound|s225x|) (l_nmod) s225x_70\NN\1740|with|and|a (l_conj) a_76\NN\13649268|ex1|-|1g|>
T2_T9 NONE argininosuccinate_45\NN\1740| (r_compound) activity_47\NN\30358|in|hepatic|argininosuccinate|synthetase (r_nmod) decrease_42\NN\7296428|activity|% (r_conj) elevations_7\NNS\7445480|by|level|,|decrease|,|lack|and|mutations|heterozygote (l_nmod) level_11\NN\4916342|of|plasma|citrulline|nmol/ml|and|inhibitor (l_conj) inhibitor_27\NN\20090|serum|pancreatic|secretory|trypsin|psti|ng/ml
22966070
T4_T27 NONE glucose_37\NN\14710501| (r_compound) metabolism_38\NN\13526110|hepatic|glucose (r_conj) balance_30\NN\13934900|on|energy|,|expression|,|and|metabolism (r_nmod) consequences_27\NNS\34213|possible|balance (r_dobj) investigated_25\VBD\644583|we|consequences (r_conj) investigated_6\VBD\644583|study|,|we|modulate|,|and|investigated|. (l_ccomp) modulate_15\VB\1724459|whether|insulin|can|tub|vivo|nuclei (l_nsubj) insulin_8\NN\5407119|,|leptin|,|and|obesity
T4_T28 NONE glucose_37\NN\14710501| (r_compound) metabolism_38\NN\13526110|hepatic|glucose (r_conj) balance_30\NN\13934900|on|energy|,|expression|,|and|metabolism (r_nmod) consequences_27\NNS\34213|possible|balance (r_dobj) investigated_25\VBD\644583|we|consequences (r_conj) investigated_6\VBD\644583|study|,|we|modulate|,|and|investigated|. (l_ccomp) modulate_15\VB\1724459|whether|insulin|can|tub|vivo|nuclei (l_nsubj) insulin_8\NN\5407119|,|leptin|,|and|obesity (l_conj) leptin_10\NN\1740|
T4_T29 NONE glucose_37\NN\14710501| (r_compound) metabolism_38\NN\13526110|hepatic|glucose (r_conj) balance_30\NN\13934900|on|energy|,|expression|,|and|metabolism (r_nmod) consequences_27\NNS\34213|possible|balance (r_dobj) investigated_25\VBD\644583|we|consequences (r_conj) investigated_6\VBD\644583|study|,|we|modulate|,|and|investigated|. (l_ccomp) modulate_15\VB\1724459|whether|insulin|can|tub|vivo|nuclei (l_dobj) tub_16\NN\4531098|
T5_T33 NONE tyrosine_1\NN\14601829| (r_compound) phosphorylation_2\NN\1740|tub|tyrosine|tub-p-tyr (l_compound) tub_0\NN\4531098|
T6_T33 NONE tub-p-tyr_4\NN\1740|(|) (r_appos) phosphorylation_2\NN\1740|tub|tyrosine|tub-p-tyr (l_compound) tub_0\NN\4531098|
T7_T35 NONE tyrosine_7\NN\14601829| (r_compound) kinase_8\NN\14732946|of|insulin|receptor|tyrosine|irtk|and|kinase|nuclei (r_nmod) substrate_3\NN\19613|tub|is|a|kinase|. (l_nsubj) tub_0\NN\4531098|
T7_T36 NONE tyrosine_7\NN\14601829| (r_compound) kinase_8\NN\14732946|of|insulin|receptor|tyrosine|irtk|and|kinase|nuclei
T7_T37 NONE tyrosine_7\NN\14601829| (r_compound) kinase_8\NN\14732946|of|insulin|receptor|tyrosine|irtk|and|kinase|nuclei (l_appos) irtk_10\NN\1740|(|)
T7_T38 NONE tyrosine_7\NN\14601829| (r_compound) kinase_8\NN\14732946|of|insulin|receptor|tyrosine|irtk|and|kinase|nuclei (l_conj) kinase_16\NN\14732946|receptor|(lepr)-janus|2|jak2 (l_compound) receptor_14\NN\5225602|leptin
T7_T39 NONE tyrosine_7\NN\14601829| (r_compound) kinase_8\NN\14732946|of|insulin|receptor|tyrosine|irtk|and|kinase|nuclei (l_conj) kinase_16\NN\14732946|receptor|(lepr)-janus|2|jak2 (l_compound) (lepr)-janus_15\NN\1740|
T7_T40 NONE tyrosine_7\NN\14601829| (r_compound) kinase_8\NN\14732946|of|insulin|receptor|tyrosine|irtk|and|kinase|nuclei (l_conj) kinase_16\NN\14732946|receptor|(lepr)-janus|2|jak2 (l_nummod) 2_17\CD\13741022|
T7_T41 NONE tyrosine_7\NN\14601829| (r_compound) kinase_8\NN\14732946|of|insulin|receptor|tyrosine|irtk|and|kinase|nuclei (l_conj) kinase_16\NN\14732946|receptor|(lepr)-janus|2|jak2 (l_appos) jak2_19\NN\1740|(|)
T1_T10 NONE )_23\-RRB-\1740| (r_punct) consumption_24\NN\13440063|o(2|) (r_dobj) decreased_21\VBD\169651|consumption (r_conj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) insulin_31\NN\5407119|of|or|leptin
T1_T11 NONE )_23\-RRB-\1740| (r_punct) consumption_24\NN\13440063|o(2|) (r_dobj) decreased_21\VBD\169651|consumption (r_conj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) insulin_31\NN\5407119|of|or|leptin (l_conj) leptin_33\NN\1740|
T1_T12 NONE )_23\-RRB-\1740| (r_punct) consumption_24\NN\13440063|o(2|) (r_dobj) decreased_21\VBD\169651|consumption (r_conj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression
T1_T13 NONE )_23\-RRB-\1740| (r_punct) consumption_24\NN\13440063|o(2|) (r_dobj) decreased_21\VBD\169651|consumption (r_conj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) hormone_38\NN\5404728|thyroid-releasing
T1_T14 NONE )_23\-RRB-\1740| (r_punct) consumption_24\NN\13440063|o(2|) (r_dobj) decreased_21\VBD\169651|consumption (r_conj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) hormone_41\NN\5404728|melanin-concentrating
T1_T15 NONE )_23\-RRB-\1740| (r_punct) consumption_24\NN\13440063|o(2|) (r_dobj) decreased_21\VBD\169651|consumption (r_conj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) expression_45\NN\4679549|orexin (l_compound) orexin_44\NN\1740|
T1_T45 NONE )_23\-RRB-\1740| (r_punct) consumption_24\NN\13440063|o(2|) (r_dobj) decreased_21\VBD\169651|consumption (r_conj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_nsubj) inhibition_0\NN\1068773|expression|aso (l_nmod) expression_3\NN\4679549|of|tub|hypothalamus (l_compound) tub_2\NN\4531098|
T8_T10 NONE glucose_14\NN\14710501|fasting|blood (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) insulin_31\NN\5407119|of|or|leptin
T8_T11 NONE glucose_14\NN\14710501|fasting|blood (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) insulin_31\NN\5407119|of|or|leptin (l_conj) leptin_33\NN\1740|
T8_T12 NONE glucose_14\NN\14710501|fasting|blood (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression
T8_T13 NONE glucose_14\NN\14710501|fasting|blood (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) hormone_38\NN\5404728|thyroid-releasing
T8_T14 NONE glucose_14\NN\14710501|fasting|blood (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) hormone_41\NN\5404728|melanin-concentrating
T8_T15 NONE glucose_14\NN\14710501|fasting|blood (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) expression_45\NN\4679549|orexin (l_compound) orexin_44\NN\1740|
T8_T45 NONE glucose_14\NN\14710501|fasting|blood (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_nsubj) inhibition_0\NN\1068773|expression|aso (l_nmod) expression_3\NN\4679549|of|tub|hypothalamus (l_compound) tub_2\NN\4531098|
T9_T10 NONE glucose_18\NN\14710501| (r_compound) output_19\NN\4007894|hepatic|glucose (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) insulin_31\NN\5407119|of|or|leptin
T9_T11 NONE glucose_18\NN\14710501| (r_compound) output_19\NN\4007894|hepatic|glucose (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) insulin_31\NN\5407119|of|or|leptin (l_conj) leptin_33\NN\1740|
T9_T12 NONE glucose_18\NN\14710501| (r_compound) output_19\NN\4007894|hepatic|glucose (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression
T9_T13 NONE glucose_18\NN\14710501| (r_compound) output_19\NN\4007894|hepatic|glucose (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) hormone_38\NN\5404728|thyroid-releasing
T9_T14 NONE glucose_18\NN\14710501| (r_compound) output_19\NN\4007894|hepatic|glucose (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) hormone_41\NN\5404728|melanin-concentrating
T9_T15 NONE glucose_18\NN\14710501| (r_compound) output_19\NN\4007894|hepatic|glucose (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_conj) blunted_27\VBD\224901|effect (l_dobj) effect_29\NN\34213|the|insulin|proopiomelanocortin (l_nmod) proopiomelanocortin_35\NN\1740|on|,|hormone|,|hormone|,|and|expression (l_conj) expression_45\NN\4679549|orexin (l_compound) orexin_44\NN\1740|
T9_T45 NONE glucose_18\NN\14710501| (r_compound) output_19\NN\4007894|hepatic|glucose (r_conj) intake_10\NN\13440063|food|,|glucose|,|and|output (r_dobj) increased_8\VBD\169651|inhibition|intake|,|decreased|,|and|blunted|. (l_nsubj) inhibition_0\NN\1068773|expression|aso (l_nmod) expression_3\NN\4679549|of|tub|hypothalamus (l_compound) tub_2\NN\4531098|
T2_T17 NONE tub-p-tyr_17\NN\1740|in|leptin|and|translocation (l_compound) leptin_14\NN\1740|and|insulin-induced
T2_T18 NONE tub-p-tyr_17\NN\1740|in|leptin|and|translocation (l_compound) leptin_14\NN\1740|and|insulin-induced (l_conj) insulin-induced_16\JJ\1740|
T2_T19 NONE tub-p-tyr_17\NN\1740|in|leptin|and|translocation
T2_T20 NONE tub-p-tyr_17\NN\1740|in|leptin|and|translocation (r_nmod) reduction_12\NN\351485|a|tub-p-tyr|,|reversed (l_acl:relcl) reversed_24\VBN\109660|which|is|reducing (l_advcl) reducing_26\VBG\441445|by|expression (l_dobj) expression_31\NN\4679549|protein|tyrosine|phosphatase|1b (l_compound) 1b_30\NN\1740|
T3_T17 NONE tyrosine_28\NN\14601829| (r_compound) expression_31\NN\4679549|protein|tyrosine|phosphatase|1b (r_dobj) reducing_26\VBG\441445|by|expression (r_advcl) reversed_24\VBN\109660|which|is|reducing (r_acl:relcl) reduction_12\NN\351485|a|tub-p-tyr|,|reversed (l_nmod) tub-p-tyr_17\NN\1740|in|leptin|and|translocation (l_compound) leptin_14\NN\1740|and|insulin-induced
T3_T18 NONE tyrosine_28\NN\14601829| (r_compound) expression_31\NN\4679549|protein|tyrosine|phosphatase|1b (r_dobj) reducing_26\VBG\441445|by|expression (r_advcl) reversed_24\VBN\109660|which|is|reducing (r_acl:relcl) reduction_12\NN\351485|a|tub-p-tyr|,|reversed (l_nmod) tub-p-tyr_17\NN\1740|in|leptin|and|translocation (l_compound) leptin_14\NN\1740|and|insulin-induced (l_conj) insulin-induced_16\JJ\1740|
T3_T19 NONE tyrosine_28\NN\14601829| (r_compound) expression_31\NN\4679549|protein|tyrosine|phosphatase|1b (r_dobj) reducing_26\VBG\441445|by|expression (r_advcl) reversed_24\VBN\109660|which|is|reducing (r_acl:relcl) reduction_12\NN\351485|a|tub-p-tyr|,|reversed (l_nmod) tub-p-tyr_17\NN\1740|in|leptin|and|translocation
T3_T20 NONE tyrosine_28\NN\14601829| (r_compound) expression_31\NN\4679549|protein|tyrosine|phosphatase|1b (l_compound) 1b_30\NN\1740|
18593822
T1_T62 NONE n-terminal_2\JJ\1740| (r_amod) residues_6\NNS\20827|of|n-terminal|receptor|activity-modifying|protein|important (l_amod) important_7\JJ\1740|peptide (l_nmod) peptide_11\NN\14724264|for|gene-related|,|adrenomedullin|,|and|function (l_conj) adrenomedullin_13\NN\1740|
T1_T63 NONE n-terminal_2\JJ\1740| (r_amod) residues_6\NNS\20827|of|n-terminal|receptor|activity-modifying|protein|important (l_amod) important_7\JJ\1740|peptide (l_nmod) peptide_11\NN\14724264|for|gene-related|,|adrenomedullin|,|and|function (l_conj) function_18\NN\13783581|receptor (l_compound) receptor_17\NN\5225602|amylin
T1_T64 NONE n-terminal_2\JJ\1740| (r_amod) residues_6\NNS\20827|of|n-terminal|receptor|activity-modifying|protein|important (l_amod) important_7\JJ\1740|peptide (l_nmod) peptide_11\NN\14724264|for|gene-related|,|adrenomedullin|,|and|function
17475961
T1_T16 NONE somatostatin_12\NN\1740| (r_compound) receptors_13\NNS\5225602|such|somatostatin
T1_T3 NONE somatostatin_12\NN\1740| (r_compound) receptors_13\NNS\5225602|such|somatostatin (r_nmod) receptors_4\NNS\5225602|peptide|hormone|overexpressed|,|receptors|,
23231492
T1_T10 NONE acid_36\NN\14818238| (r_compound) sequence_37\NN\8457976|to|the|amino|acid|h1 (r_nmod) effect_29\NN\34213|the|mutations|sequence (r_dobj) studying_27\VBG\630380|by|effect (r_advcl) tilt_4\VB\2035919|to|"|"|stability|conformation|conformation|studying (l_dobj) stability_7\NN\4777852|the|structure (l_nmod) structure_12\NN\21939|of|the|h1|loop (l_compound) loop_11\NN\3323703|
T1_T11 NONE acid_36\NN\14818238| (r_compound) sequence_37\NN\8457976|to|the|amino|acid|h1 (l_nmod) h1_40\NN\1740|of|the|,|h2|,|and|residues
T1_T12 NONE acid_36\NN\14818238| (r_compound) sequence_37\NN\8457976|to|the|amino|acid|h1 (l_nmod) h1_40\NN\1740|of|the|,|h2|,|and|residues (l_conj) h2_42\NN\1740|
23395804
T7_T40 NONE na+/cl-_7\NN\1740| (r_compound) cotransporter_8\NN\1740|ion|uptake|na+/cl-|ncc (r_compound) gene_12\NN\8459252|of|the|cotransporter|gill (r_nmod) transcription_2\NN\6349220|gene (r_dobj) regulates_1\VBZ\296178|prolactin|transcription|. (l_nsubj) prolactin_0\NN\5410315|
T7_T41 NONE na+/cl-_7\NN\1740| (r_compound) cotransporter_8\NN\1740|ion|uptake|na+/cl-|ncc
T7_T42 NONE na+/cl-_7\NN\1740| (r_compound) cotransporter_8\NN\1740|ion|uptake|na+/cl-|ncc (l_appos) ncc_10\NN\1740|(|)
T8_T40 NONE na+/cl-_7\NN\1740| (r_compound) cotransporter_8\NN\1740|ion|uptake|na+/cl-|ncc (r_compound) gene_12\NN\8459252|of|the|cotransporter|gill (r_nmod) transcription_2\NN\6349220|gene (r_dobj) regulates_1\VBZ\296178|prolactin|transcription|. (l_nsubj) prolactin_0\NN\5410315|
T8_T41 NONE na+/cl-_7\NN\1740| (r_compound) cotransporter_8\NN\1740|ion|uptake|na+/cl-|ncc
T8_T42 NONE na+/cl-_7\NN\1740| (r_compound) cotransporter_8\NN\1740|ion|uptake|na+/cl-|ncc (l_appos) ncc_10\NN\1740|(|)
T2_T15 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts
T2_T16 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_appos) prlra_12\NN\1740|(|)
T2_T17 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|)
T2_T18 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) ncc_19\NN\1740|(|;
T2_T19 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) slc12a10.2_21\NN\1740|
T2_T20 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|)
T2_T21 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) nhe3b_28\NN\1740|(|;
T2_T22 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) slc9a3.2_30\NN\1740|
T2_T23 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac
T2_T24 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|)
T2_T25 NONE na(+)/cl(-_15\JJ\1740| (r_amod) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|) (l_dep) trpv6_42\NN\1740|
T3_T15 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts
T3_T16 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_appos) prlra_12\NN\1740|(|)
T3_T17 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|)
T3_T18 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) ncc_19\NN\1740|(|;
T3_T19 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) slc12a10.2_21\NN\1740|
T3_T20 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|)
T3_T21 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) nhe3b_28\NN\1740|(|;
T3_T22 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) slc9a3.2_30\NN\1740|
T3_T23 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac
T3_T24 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|)
T3_T25 NONE )_16\-RRB-\1740| (r_compound) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|) (l_dep) trpv6_42\NN\1740|
T4_T15 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts
T4_T16 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_appos) prlra_12\NN\1740|(|)
T4_T17 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|)
T4_T18 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) ncc_19\NN\1740|(|;
T4_T19 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) slc12a10.2_21\NN\1740|
T4_T20 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|)
T4_T21 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) nhe3b_28\NN\1740|(|;
T4_T22 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) slc9a3.2_30\NN\1740|
T4_T23 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac
T4_T24 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|)
T4_T25 NONE na(+)/h(+_24\NN\1740| (r_compound) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|) (l_dep) trpv6_42\NN\1740|
T5_T15 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts
T5_T16 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_appos) prlra_12\NN\1740|(|)
T5_T17 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|)
T5_T18 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) ncc_19\NN\1740|(|;
T5_T19 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) slc12a10.2_21\NN\1740|
T5_T20 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|)
T5_T21 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) nhe3b_28\NN\1740|(|;
T5_T22 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) slc9a3.2_30\NN\1740|
T5_T23 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac
T5_T24 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|)
T5_T25 NONE )_25\-RRB-\1740| (r_punct) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) transcripts_44\NNS\6362953|channel (l_compound) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|) (l_dep) trpv6_42\NN\1740|
T6_T15 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (r_compound) transcripts_44\NNS\6362953|channel (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts
T6_T16 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (r_compound) transcripts_44\NNS\6362953|channel (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_appos) prlra_12\NN\1740|(|)
T6_T17 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (r_compound) transcripts_44\NNS\6362953|channel (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|)
T6_T18 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (r_compound) transcripts_44\NNS\6362953|channel (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) ncc_19\NN\1740|(|;
T6_T19 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (r_compound) transcripts_44\NNS\6362953|channel (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) cotransporter_17\NN\1740|na(+)/cl(-|)|ncc|slc12a10.2|) (l_appos) slc12a10.2_21\NN\1740|
T6_T20 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (r_compound) transcripts_44\NNS\6362953|channel (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|)
T6_T21 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (r_compound) transcripts_44\NNS\6362953|channel (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) nhe3b_28\NN\1740|(|;
T6_T22 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (r_compound) transcripts_44\NNS\6362953|channel (r_conj) receptor_10\NN\5225602|of|prl|prlra|,|cotransporter|,|exchanger|,|and|transcripts (l_conj) exchanger_26\NN\9624980|na(+)/h(+|)|nhe3b|slc9a3.2|) (l_appos) slc9a3.2_30\NN\1740|
T6_T23 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac
T6_T24 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|)
T6_T25 NONE )_37\-RRB-\1740| (r_punct) channel_38\NN\6251781|epithelial|ca(2|+|)|ecac (l_appos) ecac_40\NN\1740|(|;|trpv6|) (l_dep) trpv6_42\NN\1740|
T1_T10 NONE )_28\-RRB-\1740| (r_punct) uptake_29\NN\13440063|of|cl(-|)|zebrafish (r_nmod) effector_25\NN\7846|with|an|uptake (r_nmod) linking_19\VBG\628491|thereby|hormone|effector|time (r_advcl) regulates_12\VBZ\296178|that|signaling|expression|,|linking (l_dobj) expression_14\NN\4679549|the|ncc (l_nmod) ncc_16\NN\1740|of
T1_T11 NONE )_28\-RRB-\1740| (r_punct) uptake_29\NN\13440063|of|cl(-|)|zebrafish (r_nmod) effector_25\NN\7846|with|an|uptake (r_nmod) linking_19\VBG\628491|thereby|hormone|effector|time (l_dobj) hormone_22\NN\5404728|this|pituitary
T1_T38 NONE )_28\-RRB-\1740| (r_punct) uptake_29\NN\13440063|of|cl(-|)|zebrafish (r_nmod) effector_25\NN\7846|with|an|uptake (r_nmod) linking_19\VBG\628491|thereby|hormone|effector|time (r_advcl) regulates_12\VBZ\296178|that|signaling|expression|,|linking (l_nsubj) signaling_5\NN\33020|prl|receptors (l_compound) prl_4\NN\1740|
T1_T39 NONE )_28\-RRB-\1740| (r_punct) uptake_29\NN\13440063|of|cl(-|)|zebrafish (r_nmod) effector_25\NN\7846|with|an|uptake (r_nmod) linking_19\VBG\628491|thereby|hormone|effector|time (r_advcl) regulates_12\VBZ\296178|that|signaling|expression|,|linking (l_nsubj) signaling_5\NN\33020|prl|receptors (l_nmod) receptors_8\NNS\5225602|through|prl|gill
12217700
T13_T27 CPR:9 glucose-1-phosphate_27\NN\1740|as|glc1p (r_nmod) removing_18\VBG\2012344|residues|glucose-1-phosphate (r_advcl) catalyses_8\VBZ\146138|enzyme|phosphorolysis|,|removing|. (l_nsubj) enzyme_2\NN\14723628|the|bacterial|phosphorylase (l_dep) phosphorylase_4\NN\1740|maltodextrin|malp
T13_T33 CPR:9 glucose-1-phosphate_27\NN\1740|as|glc1p (r_nmod) removing_18\VBG\2012344|residues|glucose-1-phosphate (r_advcl) catalyses_8\VBZ\146138|enzyme|phosphorolysis|,|removing|. (l_nsubj) enzyme_2\NN\14723628|the|bacterial|phosphorylase (l_dep) phosphorylase_4\NN\1740|maltodextrin|malp (l_appos) malp_6\NN\1740|(|)
T14_T27 CPR:9 glc1p_29\NN\1740|(|) (r_appos) glucose-1-phosphate_27\NN\1740|as|glc1p (r_nmod) removing_18\VBG\2012344|residues|glucose-1-phosphate (r_advcl) catalyses_8\VBZ\146138|enzyme|phosphorolysis|,|removing|. (l_nsubj) enzyme_2\NN\14723628|the|bacterial|phosphorylase (l_dep) phosphorylase_4\NN\1740|maltodextrin|malp
T14_T33 CPR:9 glc1p_29\NN\1740|(|) (r_appos) glucose-1-phosphate_27\NN\1740|as|glc1p (r_nmod) removing_18\VBG\2012344|residues|glucose-1-phosphate (r_advcl) catalyses_8\VBZ\146138|enzyme|phosphorolysis|,|removing|. (l_nsubj) enzyme_2\NN\14723628|the|bacterial|phosphorylase (l_dep) phosphorylase_4\NN\1740|maltodextrin|malp (l_appos) malp_6\NN\1740|(|)
T5_T27 NONE glucosyl_21\NN\1740| (r_compound) residues_22\NNS\20827|the|non-reducing|glucosyl|oligosaccharides (r_dobj) removing_18\VBG\2012344|residues|glucose-1-phosphate (r_advcl) catalyses_8\VBZ\146138|enzyme|phosphorolysis|,|removing|. (l_nsubj) enzyme_2\NN\14723628|the|bacterial|phosphorylase (l_dep) phosphorylase_4\NN\1740|maltodextrin|malp
T5_T33 NONE glucosyl_21\NN\1740| (r_compound) residues_22\NNS\20827|the|non-reducing|glucosyl|oligosaccharides (r_dobj) removing_18\VBG\2012344|residues|glucose-1-phosphate (r_advcl) catalyses_8\VBZ\146138|enzyme|phosphorolysis|,|removing|. (l_nsubj) enzyme_2\NN\14723628|the|bacterial|phosphorylase (l_dep) phosphorylase_4\NN\1740|maltodextrin|malp (l_appos) malp_6\NN\1740|(|)
T16_T34 NONE malp/glc1p_6\NN\1740|
T16_T35 NONE malp/glc1p_6\NN\1740| (r_compound) complex_8\NN\5869584|of|the|malp/glc1p|binary (r_nmod) structure_3\NN\21939|the|2.0a|crystal|complex (r_nsubj) shows_9\VBZ\2137132|structure|adopts|. (l_ccomp) adopts_14\VBZ\674607|that|substrate|conformation|,|group (l_dobj) conformation_16\NN\13897996|a|seen (l_acl) seen_17\VBN\2106506|previously|forms (l_nmod) forms_24\NNS\6286395|with|inactive|gp (l_nmod) gp_27\NN\10020890|of|mammalian
T17_T34 NONE glc1p_12\NN\1740| (r_compound) substrate_13\NN\19613|the|glc1p (r_nsubj) adopts_14\VBZ\674607|that|substrate|conformation|,|group (r_ccomp) shows_9\VBZ\2137132|structure|adopts|. (l_nsubj) structure_3\NN\21939|the|2.0a|crystal|complex (l_nmod) complex_8\NN\5869584|of|the|malp/glc1p|binary (l_compound) malp/glc1p_6\NN\1740|
T17_T35 NONE glc1p_12\NN\1740| (r_compound) substrate_13\NN\19613|the|glc1p (r_nsubj) adopts_14\VBZ\674607|that|substrate|conformation|,|group (l_dobj) conformation_16\NN\13897996|a|seen (l_acl) seen_17\VBN\2106506|previously|forms (l_nmod) forms_24\NNS\6286395|with|inactive|gp (l_nmod) gp_27\NN\10020890|of|mammalian
T18_T34 NONE phosphate_31\NN\15010703| (r_compound) group_32\NN\2137|with|the|phosphate|contact (r_nmod) adopts_14\VBZ\674607|that|substrate|conformation|,|group (r_ccomp) shows_9\VBZ\2137132|structure|adopts|. (l_nsubj) structure_3\NN\21939|the|2.0a|crystal|complex (l_nmod) complex_8\NN\5869584|of|the|malp/glc1p|binary (l_compound) malp/glc1p_6\NN\1740|
T18_T35 NONE phosphate_31\NN\15010703| (r_compound) group_32\NN\2137|with|the|phosphate|contact (r_nmod) adopts_14\VBZ\674607|that|substrate|conformation|,|group (l_dobj) conformation_16\NN\13897996|a|seen (l_acl) seen_17\VBN\2106506|previously|forms (l_nmod) forms_24\NNS\6286395|with|inactive|gp (l_nmod) gp_27\NN\10020890|of|mammalian
T19_T34 NONE 5'-phosphate_39\JJ\1740| (r_amod) group_40\NN\2137|with|the|5'-phosphate|cofactor (r_nmod) contact_36\NN\39021|not|in|close|group (r_nmod) group_32\NN\2137|with|the|phosphate|contact (r_nmod) adopts_14\VBZ\674607|that|substrate|conformation|,|group (r_ccomp) shows_9\VBZ\2137132|structure|adopts|. (l_nsubj) structure_3\NN\21939|the|2.0a|crystal|complex (l_nmod) complex_8\NN\5869584|of|the|malp/glc1p|binary (l_compound) malp/glc1p_6\NN\1740|
T19_T35 NONE 5'-phosphate_39\JJ\1740| (r_amod) group_40\NN\2137|with|the|5'-phosphate|cofactor (r_nmod) contact_36\NN\39021|not|in|close|group (r_nmod) group_32\NN\2137|with|the|phosphate|contact (r_nmod) adopts_14\VBZ\674607|that|substrate|conformation|,|group (l_dobj) conformation_16\NN\13897996|a|seen (l_acl) seen_17\VBN\2106506|previously|forms (l_nmod) forms_24\NNS\6286395|with|inactive|gp (l_nmod) gp_27\NN\10020890|of|mammalian
T20_T34 NONE phosphate_45\NN\15010703|pyridoxal|plp (r_compound) cofactor_49\NN\14818238|of|the|essential|phosphate (r_nmod) group_40\NN\2137|with|the|5'-phosphate|cofactor (r_nmod) contact_36\NN\39021|not|in|close|group (r_nmod) group_32\NN\2137|with|the|phosphate|contact (r_nmod) adopts_14\VBZ\674607|that|substrate|conformation|,|group (r_ccomp) shows_9\VBZ\2137132|structure|adopts|. (l_nsubj) structure_3\NN\21939|the|2.0a|crystal|complex (l_nmod) complex_8\NN\5869584|of|the|malp/glc1p|binary (l_compound) malp/glc1p_6\NN\1740|
T20_T35 NONE phosphate_45\NN\15010703|pyridoxal|plp (r_compound) cofactor_49\NN\14818238|of|the|essential|phosphate (r_nmod) group_40\NN\2137|with|the|5'-phosphate|cofactor (r_nmod) contact_36\NN\39021|not|in|close|group (r_nmod) group_32\NN\2137|with|the|phosphate|contact (r_nmod) adopts_14\VBZ\674607|that|substrate|conformation|,|group (l_dobj) conformation_16\NN\13897996|a|seen (l_acl) seen_17\VBN\2106506|previously|forms (l_nmod) forms_24\NNS\6286395|with|inactive|gp (l_nmod) gp_27\NN\10020890|of|mammalian
T21_T34 NONE plp_47\NN\1740|(|) (r_appos) phosphate_45\NN\15010703|pyridoxal|plp (r_compound) cofactor_49\NN\14818238|of|the|essential|phosphate (r_nmod) group_40\NN\2137|with|the|5'-phosphate|cofactor (r_nmod) contact_36\NN\39021|not|in|close|group (r_nmod) group_32\NN\2137|with|the|phosphate|contact (r_nmod) adopts_14\VBZ\674607|that|substrate|conformation|,|group (r_ccomp) shows_9\VBZ\2137132|structure|adopts|. (l_nsubj) structure_3\NN\21939|the|2.0a|crystal|complex (l_nmod) complex_8\NN\5869584|of|the|malp/glc1p|binary (l_compound) malp/glc1p_6\NN\1740|
T21_T35 NONE plp_47\NN\1740|(|) (r_appos) phosphate_45\NN\15010703|pyridoxal|plp (r_compound) cofactor_49\NN\14818238|of|the|essential|phosphate (r_nmod) group_40\NN\2137|with|the|5'-phosphate|cofactor (r_nmod) contact_36\NN\39021|not|in|close|group (r_nmod) group_32\NN\2137|with|the|phosphate|contact (r_nmod) adopts_14\VBZ\674607|that|substrate|conformation|,|group (l_dobj) conformation_16\NN\13897996|a|seen (l_acl) seen_17\VBN\2106506|previously|forms (l_nmod) forms_24\NNS\6286395|with|inactive|gp (l_nmod) gp_27\NN\10020890|of|mammalian
T22_T36 NONE glc1p_12\NN\1740|the|negative-charged (r_dobj) stabilizes_9\VBZ\126264|enzyme|,|residue|glc1p|,|held|. (l_nmod) enzyme_4\NN\14723628|in|the|active|malp (l_compound) malp_3\NN\1740|
T22_T37 NONE glc1p_12\NN\1740|the|negative-charged (r_dobj) stabilizes_9\VBZ\126264|enzyme|,|residue|glc1p|,|held|. (l_advcl) held_25\VBN\2439501|whereas|form|residue|is|away|280s|and|required (l_nmod) form_18\NN\6286395|in|the|inactive|gp (l_nmod) gp_20\NN\10020890|of
T1_T23 NONE 6-hydroxyl_15\NN\1740| (r_compound) group_16\NN\2137|with|the|6-hydroxyl|substrate (r_nmod) bond_12\NN\11426530|through|a|hydrogen|group (r_nmod) triggers_21\VBZ\1641914|that|his377|,|bond|,|change (r_ccomp) shows_5\VBZ\2137132|comparison|triggers|. (l_nsubj) comparison_1\NN\635850|the|structures (l_nmod) structures_4\NNS\21939|between|malp (l_compound) malp_3\NN\1740|
T2_T23 NONE glc1p_18\NN\1740| (r_compound) substrate_19\NN\19613|of|glc1p (r_nmod) group_16\NN\2137|with|the|6-hydroxyl|substrate (r_nmod) bond_12\NN\11426530|through|a|hydrogen|group (r_nmod) triggers_21\VBZ\1641914|that|his377|,|bond|,|change (r_ccomp) shows_5\VBZ\2137132|comparison|triggers|. (l_nsubj) comparison_1\NN\635850|the|structures (l_nmod) structures_4\NNS\21939|between|malp (l_compound) malp_3\NN\1740|
T3_T25 NONE maltotetraose_10\NN\1740|(|either|,|g4|or|maltopentaose|,|g5|) (r_dep) oligosaccharides_7\NNS\14792703|of|maltotetraose (r_nmod) diffusion_5\NN\13518963|after|the|oligosaccharides|crystals (l_nmod) crystals_20\NNS\15046900|into|malp/glc1p (l_compound) malp/glc1p_19\NN\1740|
T4_T25 NONE maltopentaose_14\NN\1740| (r_conj) maltotetraose_10\NN\1740|(|either|,|g4|or|maltopentaose|,|g5|) (r_dep) oligosaccharides_7\NNS\14792703|of|maltotetraose (r_nmod) diffusion_5\NN\13518963|after|the|oligosaccharides|crystals (l_nmod) crystals_20\NNS\15046900|into|malp/glc1p (l_compound) malp/glc1p_19\NN\1740|
T6_T25 NONE malp/glc1p_19\NN\1740|
T7_T25 NONE phosphate_25\NN\15010703|of (r_nmod) formation_23\NN\7938773|the|phosphate|and|elongation (r_dobj) show_21\VBP\2137132|structures|formation|. (l_nsubj) structures_1\NNS\21939|the|solved (l_acl) solved_2\VBN\588888|diffusion (l_nmod) diffusion_5\NN\13518963|after|the|oligosaccharides|crystals (l_nmod) crystals_20\NNS\15046900|into|malp/glc1p (l_compound) malp/glc1p_19\NN\1740|
T12_T26 NONE malp/glc1p_10\NN\1740|
7601910
T2_T15 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_appos) nachr_17\NN\1740|(|)
T2_T16 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) beta_23\NN\6828818|transforming|growth|factor|2|beta (l_nummod) 2_24\CD\13741022|
T2_T17 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) beta_23\NN\6828818|transforming|growth|factor|2|beta (l_appos) beta_27\NN\6828818|(|tgf|2|) (l_nummod) 2_28\CD\13741022|
T2_T18 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1
T2_T19 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (l_appos) crbp-1_38\NN\1740|(|)
T2_T20 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) gamma_44\NN\6828818|retinoic|acid|receptor|gamma
T2_T21 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (l_appos) gamma_47\NN\6828818|(|rar|)
T2_T22 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_55\NN\14944888|camp|response|element|binding|creb
T2_T23 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_55\NN\14944888|camp|response|element|binding|creb (l_appos) creb_57\NN\1740|(|)
T2_T24 NONE acetylcholine_12\NN\14807558| (r_compound) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein
T3_T15 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_appos) nachr_17\NN\1740|(|)
T3_T16 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) beta_23\NN\6828818|transforming|growth|factor|2|beta (l_nummod) 2_24\CD\13741022|
T3_T17 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) beta_23\NN\6828818|transforming|growth|factor|2|beta (l_appos) beta_27\NN\6828818|(|tgf|2|) (l_nummod) 2_28\CD\13741022|
T3_T18 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1
T3_T19 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (l_appos) crbp-1_38\NN\1740|(|)
T3_T20 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) gamma_44\NN\6828818|retinoic|acid|receptor|gamma
T3_T21 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (l_appos) gamma_47\NN\6828818|(|rar|)
T3_T22 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_55\NN\14944888|camp|response|element|binding|creb
T3_T23 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_55\NN\14944888|camp|response|element|binding|creb (l_appos) creb_57\NN\1740|(|)
T3_T24 NONE retinoid_34\NN\1740| (r_compound) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein
T4_T15 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_appos) nachr_17\NN\1740|(|)
T4_T16 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) beta_23\NN\6828818|transforming|growth|factor|2|beta (l_nummod) 2_24\CD\13741022|
T4_T17 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) beta_23\NN\6828818|transforming|growth|factor|2|beta (l_appos) beta_27\NN\6828818|(|tgf|2|) (l_nummod) 2_28\CD\13741022|
T4_T18 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1
T4_T19 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (l_appos) crbp-1_38\NN\1740|(|)
T4_T20 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma
T4_T21 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (l_appos) gamma_47\NN\6828818|(|rar|)
T4_T22 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_55\NN\14944888|camp|response|element|binding|creb
T4_T23 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_55\NN\14944888|camp|response|element|binding|creb (l_appos) creb_57\NN\1740|(|)
T4_T24 NONE acid_42\NN\14818238| (r_compound) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein
T5_T15 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_appos) nachr_17\NN\1740|(|)
T5_T16 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) beta_23\NN\6828818|transforming|growth|factor|2|beta (l_nummod) 2_24\CD\13741022|
T5_T17 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) beta_23\NN\6828818|transforming|growth|factor|2|beta (l_appos) beta_27\NN\6828818|(|tgf|2|) (l_nummod) 2_28\CD\13741022|
T5_T18 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1
T5_T19 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) protein_36\NN\14944888|type|1|cellular|retinoid|binding|crbp-1 (l_appos) crbp-1_38\NN\1740|(|)
T5_T20 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) gamma_44\NN\6828818|retinoic|acid|receptor|gamma
T5_T21 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein (l_conj) gamma_44\NN\6828818|retinoic|acid|receptor|gamma (l_appos) gamma_47\NN\6828818|(|rar|)
T5_T22 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb
T5_T23 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (l_appos) creb_57\NN\1740|(|)
T5_T24 NONE camp_51\NN\3763727| (r_compound) protein_55\NN\14944888|camp|response|element|binding|creb (r_conj) alpha_15\NN\6828818|of|the|nicotinic|acetylcholine|receptor|subunit|nachr|,|beta|,|protein|,|gamma|,|and|protein
23389043
2857786
T1_T18 CPR:6 ambenonium_0\NN\1740| (r_nsubjpass) known_2\VBN\2110220|ambenonium|is|inhibitor|,|and|shown (l_conj) shown_14\VBN\2137132|data|have|drug|antagonize|. (l_xcomp) antagonize_18\VB\1787955|to|receptors|well (l_dobj) receptors_20\NNS\5225602|muscarinic
T1_T20 CPR:4 ambenonium_0\NN\1740| (r_nsubjpass) known_2\VBN\2110220|ambenonium|is|inhibitor|,|and|shown (l_xcomp) inhibitor_6\NN\20090|to|be|an|acetylcholinesterase (l_nmod) acetylcholinesterase_8\NN\1740|of
T11_T21 NONE ambenonium_0\NN\1740| (r_nsubj) antagonist_5\NN\7846|ambenonium|was|a|potent|responses|,|and|eliminated (l_conj) eliminated_29\VBN\1619929|underestimation|could|be|treatment|. (l_nmod) treatment_32\NN\654885|by|prior|tissues|neostigmine (l_nmod) neostigmine_39\NN\2718084|with|the|acetylcholinesterase|inhibitor (l_compound) acetylcholinesterase_37\NN\1740|
T12_T21 NONE acetylcholine_10\NN\14807558|to (r_nmod) responses_8\NNS\11410625|of|tissue|acetylcholine (r_nmod) antagonist_5\NN\7846|ambenonium|was|a|potent|responses|,|and|eliminated (l_conj) eliminated_29\VBN\1619929|underestimation|could|be|treatment|. (l_nmod) treatment_32\NN\654885|by|prior|tissues|neostigmine (l_nmod) neostigmine_39\NN\2718084|with|the|acetylcholinesterase|inhibitor (l_compound) acetylcholinesterase_37\NN\1740|
T13_T21 NONE bethanechol_25\NN\1740|with (r_nmod) obtained_23\VBN\2210855|bethanechol (r_acl) that_22\DT\1740|to|obtained (r_nmod) compared_20\VBN\644583|(|as|that|) (r_dep) underestimation_14\NN\5803379|the|pkb|compared (r_nsubjpass) eliminated_29\VBN\1619929|underestimation|could|be|treatment|. (l_nmod) treatment_32\NN\654885|by|prior|tissues|neostigmine (l_nmod) neostigmine_39\NN\2718084|with|the|acetylcholinesterase|inhibitor (l_compound) acetylcholinesterase_37\NN\1740|
T14_T21 CPR:4 neostigmine_39\NN\2718084|with|the|acetylcholinesterase|inhibitor (l_compound) acetylcholinesterase_37\NN\1740|
T15_T17 CPR:4 ambenonium_4\NN\1740| (r_nsubj) had_5\VBD\2108377|that|ambenonium|effect (l_dobj) effect_8\NN\34213|a|dual|responses|and|antagonism (l_nmod) responses_11\NNS\11410625|on|tissue|potentiation (l_nmod) potentiation_14\NN\13564910|to|acetylcholine-producing|blockade (l_nmod) blockade_16\NN\952963|by|acetylcholinesterase (l_nmod) acetylcholinesterase_18\NN\1740|of
T15_T19 CPR:4 ambenonium_4\NN\1740| (r_nsubj) had_5\VBD\2108377|that|ambenonium|effect (l_dobj) effect_8\NN\34213|a|dual|responses|and|antagonism (l_conj) antagonism_21\NN\24720|concomitant|blockade (l_nmod) blockade_23\NN\952963|by|receptors (l_nmod) receptors_26\NNS\5225602|of|muscarinic
T2_T17 CPR:5 acetylcholine-producing_13\JJ\1740| (r_amod) potentiation_14\NN\13564910|to|acetylcholine-producing|blockade (l_nmod) blockade_16\NN\952963|by|acetylcholinesterase (l_nmod) acetylcholinesterase_18\NN\1740|of
T2_T19 NONE acetylcholine-producing_13\JJ\1740| (r_amod) potentiation_14\NN\13564910|to|acetylcholine-producing|blockade (r_nmod) responses_11\NNS\11410625|on|tissue|potentiation (r_nmod) effect_8\NN\34213|a|dual|responses|and|antagonism (l_conj) antagonism_21\NN\24720|concomitant|blockade (l_nmod) blockade_23\NN\952963|by|receptors (l_nmod) receptors_26\NNS\5225602|of|muscarinic
2994716
T5_T10 NONE nucleotide_0\NN\14850483| (r_compound) sequence_1\NN\8457976|nucleotide|gene|. (l_nmod) gene_4\NN\8459252|of|the|factor (l_nmod) factor_7\NN\7326557|for|human|ix (l_nummod) ix_8\CD\13741022|b
T5_T11 NONE nucleotide_0\NN\14850483| (r_compound) sequence_1\NN\8457976|nucleotide|gene|. (l_nmod) gene_4\NN\8459252|of|the|factor (l_nmod) factor_7\NN\7326557|for|human|ix (l_nummod) ix_8\CD\13741022|b (l_appos) b_12\NN\1355326|(|antihemophilic|factor|)
23075005
T9_T19 CPR:4 [(14)c]anagliptin_4\NN\1740|of|,|inhibitor|, (l_appos) inhibitor_10\NN\20090|a|novel|dipeptidyl|peptidase-4 (l_compound) peptidase-4_9\NN\1740|
T3_T18 NONE [(14)c]anagliptin_27\NN\1740|of|mbq (r_nmod) dose_22\NN\3740161|after|a|single|oral|[(14)c]anagliptin (r_nmod) investigated_17\VBN\644583||disposition|was|dose|men|. (l_nsubjpass) disposition_2\NN\4623113|the|anagliptin (l_nmod) anagliptin_4\NN\1740|of|,|inhibitor|, (l_appos) inhibitor_14\NN\20090|an|active|selective|dipeptidyl|peptidase-4 (l_compound) peptidase-4_13\NN\1740|
T4_T18 CPR:4 anagliptin_4\NN\1740|of|,|inhibitor|, (l_appos) inhibitor_14\NN\20090|an|active|selective|dipeptidyl|peptidase-4 (l_compound) peptidase-4_13\NN\1740|
T1_T10 NONE anagliptin_4\NN\1740|of|unbound|and|m1 (r_nmod) clearance_1\NN\5089947|renal|anagliptin (r_nsubj) exceeded_9\VBD\2673965|clearance|far|rate|,|indicating|:|reflect|. (l_parataxis) reflect_21\VB\923793|that|might|fact (l_dobj) fact_23\NN\5816287|the|substrate (l_ccomp) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_nmod) oat1_31\NN\1740|of|,|oat3|,|mdr1|and|mrp2
T1_T11 NONE anagliptin_4\NN\1740|of|unbound|and|m1 (r_nmod) clearance_1\NN\5089947|renal|anagliptin (r_nsubj) exceeded_9\VBD\2673965|clearance|far|rate|,|indicating|:|reflect|. (l_parataxis) reflect_21\VB\923793|that|might|fact (l_dobj) fact_23\NN\5816287|the|substrate (l_ccomp) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_nmod) oat1_31\NN\1740|of|,|oat3|,|mdr1|and|mrp2 (l_conj) oat3_33\NN\1740|
T1_T12 NONE anagliptin_4\NN\1740|of|unbound|and|m1 (r_nmod) clearance_1\NN\5089947|renal|anagliptin (r_nsubj) exceeded_9\VBD\2673965|clearance|far|rate|,|indicating|:|reflect|. (l_parataxis) reflect_21\VB\923793|that|might|fact (l_dobj) fact_23\NN\5816287|the|substrate (l_ccomp) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_nmod) oat1_31\NN\1740|of|,|oat3|,|mdr1|and|mrp2 (l_conj) mdr1_35\NN\1740|
T1_T13 NONE anagliptin_4\NN\1740|of|unbound|and|m1 (r_nmod) clearance_1\NN\5089947|renal|anagliptin (r_nsubj) exceeded_9\VBD\2673965|clearance|far|rate|,|indicating|:|reflect|. (l_parataxis) reflect_21\VB\923793|that|might|fact (l_dobj) fact_23\NN\5816287|the|substrate (l_ccomp) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_nmod) oat1_31\NN\1740|of|,|oat3|,|mdr1|and|mrp2 (l_conj) mrp2_37\NN\1740|
T1_T14 NONE anagliptin_4\NN\1740|of|unbound|and|m1 (r_nmod) clearance_1\NN\5089947|renal|anagliptin (r_nsubj) exceeded_9\VBD\2673965|clearance|far|rate|,|indicating|:|reflect|. (l_parataxis) reflect_21\VB\923793|that|might|fact (l_dobj) fact_23\NN\5816287|the|substrate (l_ccomp) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_conj) m1_40\NN\13357178|substrate (l_appos) substrate_42\NN\19613|a|oat3 (l_nmod) oat3_44\NN\1740|of|,|bcrp|,|mrp2|and|mrp4
T1_T15 NONE anagliptin_4\NN\1740|of|unbound|and|m1 (r_nmod) clearance_1\NN\5089947|renal|anagliptin (r_nsubj) exceeded_9\VBD\2673965|clearance|far|rate|,|indicating|:|reflect|. (l_parataxis) reflect_21\VB\923793|that|might|fact (l_dobj) fact_23\NN\5816287|the|substrate (l_ccomp) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_conj) m1_40\NN\13357178|substrate (l_appos) substrate_42\NN\19613|a|oat3 (l_nmod) oat3_44\NN\1740|of|,|bcrp|,|mrp2|and|mrp4 (l_conj) bcrp_46\NN\1740|
T1_T16 NONE anagliptin_4\NN\1740|of|unbound|and|m1 (r_nmod) clearance_1\NN\5089947|renal|anagliptin (r_nsubj) exceeded_9\VBD\2673965|clearance|far|rate|,|indicating|:|reflect|. (l_parataxis) reflect_21\VB\923793|that|might|fact (l_dobj) fact_23\NN\5816287|the|substrate (l_ccomp) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_conj) m1_40\NN\13357178|substrate (l_appos) substrate_42\NN\19613|a|oat3 (l_nmod) oat3_44\NN\1740|of|,|bcrp|,|mrp2|and|mrp4 (l_conj) mrp2_48\NN\1740|
T1_T17 NONE anagliptin_4\NN\1740|of|unbound|and|m1 (r_nmod) clearance_1\NN\5089947|renal|anagliptin (r_nsubj) exceeded_9\VBD\2673965|clearance|far|rate|,|indicating|:|reflect|. (l_parataxis) reflect_21\VB\923793|that|might|fact (l_dobj) fact_23\NN\5816287|the|substrate (l_ccomp) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_conj) m1_40\NN\13357178|substrate (l_appos) substrate_42\NN\19613|a|oat3 (l_nmod) oat3_44\NN\1740|of|,|bcrp|,|mrp2|and|mrp4 (l_conj) mrp4_50\NN\1740|
T2_T10 CPR:9 anagliptin_25\NN\1740| (r_nsubj) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_nmod) oat1_31\NN\1740|of|,|oat3|,|mdr1|and|mrp2
T2_T11 CPR:9 anagliptin_25\NN\1740| (r_nsubj) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_nmod) oat1_31\NN\1740|of|,|oat3|,|mdr1|and|mrp2 (l_conj) oat3_33\NN\1740|
T2_T12 CPR:9 anagliptin_25\NN\1740| (r_nsubj) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_nmod) oat1_31\NN\1740|of|,|oat3|,|mdr1|and|mrp2 (l_conj) mdr1_35\NN\1740|
T2_T13 CPR:9 anagliptin_25\NN\1740| (r_nsubj) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_nmod) oat1_31\NN\1740|of|,|oat3|,|mdr1|and|mrp2 (l_conj) mrp2_37\NN\1740|
T2_T14 NONE anagliptin_25\NN\1740| (r_nsubj) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_conj) m1_40\NN\13357178|substrate (l_appos) substrate_42\NN\19613|a|oat3 (l_nmod) oat3_44\NN\1740|of|,|bcrp|,|mrp2|and|mrp4
T2_T15 NONE anagliptin_25\NN\1740| (r_nsubj) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_conj) m1_40\NN\13357178|substrate (l_appos) substrate_42\NN\19613|a|oat3 (l_nmod) oat3_44\NN\1740|of|,|bcrp|,|mrp2|and|mrp4 (l_conj) bcrp_46\NN\1740|
T2_T16 NONE anagliptin_25\NN\1740| (r_nsubj) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_conj) m1_40\NN\13357178|substrate (l_appos) substrate_42\NN\19613|a|oat3 (l_nmod) oat3_44\NN\1740|of|,|bcrp|,|mrp2|and|mrp4 (l_conj) mrp2_48\NN\1740|
T2_T17 NONE anagliptin_25\NN\1740| (r_nsubj) substrate_29\NN\19613|that|anagliptin|may|be|a|oat1|,|and|m1 (l_conj) m1_40\NN\13357178|substrate (l_appos) substrate_42\NN\19613|a|oat3 (l_nmod) oat3_44\NN\1740|of|,|bcrp|,|mrp2|and|mrp4 (l_conj) mrp4_50\NN\1740|
19002123
T10_T22 NONE tamsulosin_65\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T10_T23 NONE tamsulosin_65\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T11_T22 NONE terazosin_67\NN\2698769| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T11_T23 NONE terazosin_67\NN\2698769| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T12_T22 NONE dutasteride_69\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T12_T23 NONE dutasteride_69\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T13_T22 NONE finasteride_71\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T13_T23 NONE finasteride_71\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T14_T22 NONE tolterodine_73\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T14_T23 NONE tolterodine_73\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T15_T22 NONE flavoxate_75\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T15_T23 NONE flavoxate_75\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T16_T22 NONE propiverine_77\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T16_T23 NONE propiverine_77\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T17_T22 NONE oxybutynin_79\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T17_T23 NONE oxybutynin_79\NN\1740| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T18_T22 NONE sildenafil_84\NN\4537602| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T18_T23 NONE sildenafil_84\NN\4537602| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T19_T22 NONE vardenafil_86\NN\4537602|and (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T19_T23 NONE vardenafil_86\NN\4537602|and (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T20_T22 NONE tadalafil_88\NN\4537602| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T20_T23 NONE tadalafil_88\NN\4537602| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T8_T22 NONE alfuzosin_61\NN\1740| (r_appos) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T8_T23 NONE alfuzosin_61\NN\1740| (r_appos) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
T9_T22 NONE doxazosin_63\NN\2721160| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) antagonists_49\NNS\7846|alpha(1)-adrenergic|receptor (l_compound) receptor_48\NN\5225602|
T9_T23 NONE doxazosin_63\NN\2721160| (r_conj) hyperplasia_40\NN\14365950|benign|prostatic|,|symptoms|,|antagonists|,|inhibitors|,|anti-muscarinics|,|anticholinergics|,|therapy|,|alfuzosin|,|doxazosin|,|tamsulosin|,|terazosin|,|dutasteride|,|finasteride|,|tolterodine|,|flavoxate|,|propiverine|,|oxybutynin|,|dysfunction|,|sildenafil|,|vardenafil|tadalafil (l_conj) inhibitors_52\NNS\20090|5alpha-reductase (l_compound) 5alpha-reductase_51\NN\1740|
14619588
T10_T19 NONE phenylpropionate_5\NN\1740|of|nandrolone (r_nmod) effects_2\NNS\13245626|[|the|phenylpropionate|receptor|]|. (l_nmod) receptor_8\NN\5225602|on|androgen|liver
T3_T16 NONE phenylpropionate_8\NN\1740|of|nandrolone|np (r_nmod) effects_5\NNS\13245626|the|phenylpropionate|receptor (l_nmod) receptor_14\NN\5225602|on|androgen|ar|liver
T3_T18 NONE phenylpropionate_8\NN\1740|of|nandrolone|np (r_nmod) effects_5\NNS\13245626|the|phenylpropionate|receptor (l_nmod) receptor_14\NN\5225602|on|androgen|ar|liver (l_appos) ar_16\NN\14622893|(|)
T6_T16 NONE np_10\NN\14625458|(|) (r_appos) phenylpropionate_8\NN\1740|of|nandrolone|np (r_nmod) effects_5\NNS\13245626|the|phenylpropionate|receptor (l_nmod) receptor_14\NN\5225602|on|androgen|ar|liver
T6_T18 NONE np_10\NN\14625458|(|) (r_appos) phenylpropionate_8\NN\1740|of|nandrolone|np (r_nmod) effects_5\NNS\13245626|the|phenylpropionate|receptor (l_nmod) receptor_14\NN\5225602|on|androgen|ar|liver (l_appos) ar_16\NN\14622893|(|)
T7_T15 CPR:3 np_10\NNP\14625458| (r_compound) group_11\NN\2137|in|np (r_nmod) tissue_8\NN\5220461|in|liver|group (r_nmod) ar_5\NNS\14622893|of|tissue
T8_T17 NONE np_14\NNP\14625458| (r_compound) group_15\NN\2137|between|np|and|group (r_nmod) difference_12\NN\4723816|no|significant|group (r_dobj) showed_9\VBD\2137132|density|difference|time-point|>|. (l_nsubj) density_1\NN\4941325|the|ar (l_nmod) ar_3\NNS\14622893|of|testis
T1_T11 CPR:3 phenylpropionate_3\NN\1740|nandrolone (r_nsubj) up-regulated_4\VBD\1740|conclusion|:|phenylpropionate|density|,|whereas|had|. (l_dobj) density_6\NN\4941325|the|ar (l_nmod) ar_8\NNS\14622893|of|tissue
T1_T12 NONE phenylpropionate_3\NN\1740|nandrolone (r_nsubj) up-regulated_4\VBD\1740|conclusion|:|phenylpropionate|density|,|whereas|had|. (l_advcl) had_15\VBD\2108377|it|effects|density (l_nmod) density_21\NN\4941325|on|the|ar (l_nmod) ar_23\NNS\14622893|of|tissues
23547843
17468175
T14_T26 NONE dopamine_0\NN\14807737| (r_compound) agonist_3\NN\9613191|dopamine|receptor|and|antagonist (l_compound) receptor_2\NN\5225602|d1
T14_T27 NONE dopamine_0\NN\14807737| (r_compound) agonist_3\NN\9613191|dopamine|receptor|and|antagonist (l_conj) antagonist_7\NN\7846|d2|receptor (l_compound) receptor_6\NN\5225602|
T15_T26 CPR:5 (-)-stepholidine_13\NN\1740|of|the|product|: (r_nmod) effects_8\NNS\13245626|agonist|(-)-stepholidine|modeling (l_compound) agonist_3\NN\9613191|dopamine|receptor|and|antagonist (l_compound) receptor_2\NN\5225602|d1
T15_T27 CPR:6 (-)-stepholidine_13\NN\1740|of|the|product|: (r_nmod) effects_8\NNS\13245626|agonist|(-)-stepholidine|modeling (l_compound) agonist_3\NN\9613191|dopamine|receptor|and|antagonist (l_conj) antagonist_7\NN\7846|d2|receptor (l_compound) receptor_6\NN\5225602|
T1_T18 CPR:5 (-)-stepholidine_0\NN\1740|spd|,|ingredient|, (r_nsubj) compound_17\NN\5869584|(-)-stepholidine|is|the|first|found|. (l_acl) found_18\VBN\2426171|have (l_xcomp) have_20\VB\2108377|to|function|agonist (l_nmod) agonist_28\NN\9613191|as|a|dopamine|receptor|d1|and|antagonist (l_compound) d1_27\NN\1740|
T1_T19 CPR:6 (-)-stepholidine_0\NN\1740|spd|,|ingredient|, (r_nsubj) compound_17\NN\5869584|(-)-stepholidine|is|the|first|found|. (l_acl) found_18\VBN\2426171|have (l_xcomp) have_20\VB\2108377|to|function|agonist (l_nmod) agonist_28\NN\9613191|as|a|dopamine|receptor|d1|and|antagonist (l_conj) antagonist_31\NN\7846|d2 (l_compound) d2_30\NN\1740|
T4_T18 NONE dopamine_25\NN\14807737| (r_compound) agonist_28\NN\9613191|as|a|dopamine|receptor|d1|and|antagonist (l_compound) d1_27\NN\1740|
T4_T19 NONE dopamine_25\NN\14807737| (r_compound) agonist_28\NN\9613191|as|a|dopamine|receptor|d1|and|antagonist (l_conj) antagonist_31\NN\7846|d2 (l_compound) d2_30\NN\1740|
T8_T18 CPR:5 spd_2\NN\1740|(|) (r_appos) (-)-stepholidine_0\NN\1740|spd|,|ingredient|, (r_nsubj) compound_17\NN\5869584|(-)-stepholidine|is|the|first|found|. (l_acl) found_18\VBN\2426171|have (l_xcomp) have_20\VB\2108377|to|function|agonist (l_nmod) agonist_28\NN\9613191|as|a|dopamine|receptor|d1|and|antagonist (l_compound) d1_27\NN\1740|
T8_T19 CPR:6 spd_2\NN\1740|(|) (r_appos) (-)-stepholidine_0\NN\1740|spd|,|ingredient|, (r_nsubj) compound_17\NN\5869584|(-)-stepholidine|is|the|first|found|. (l_acl) found_18\VBN\2426171|have (l_xcomp) have_20\VB\2108377|to|function|agonist (l_nmod) agonist_28\NN\9613191|as|a|dopamine|receptor|d1|and|antagonist (l_conj) antagonist_31\NN\7846|d2 (l_compound) d2_30\NN\1740|
T10_T20 NONE dopamine_25\NN\14807737| (r_compound) receptors_26\NNS\5225602|of|dopamine (r_nmod) characteristics_23\NNS\5849040|the|structural|receptors (r_dobj) understanding_18\VBG\588888|in|characteristics (r_advcl) crucial_16\JJ\1740|insights|are|understanding|. (l_nsubj) insights_0\NNS\5710020|behaviors (l_nmod) behaviors_3\NNS\407535|into|dynamical|receptors|and|modes (l_nmod) receptors_8\NNS\5225602|of|d1
T10_T21 NONE dopamine_25\NN\14807737| (r_compound) receptors_26\NNS\5225602|of|dopamine
T9_T20 NONE spd_14\NN\1740|with (r_nmod) modes_12\NNS\4916342|their|interaction|spd (r_conj) behaviors_3\NNS\407535|into|dynamical|receptors|and|modes (l_nmod) receptors_8\NNS\5225602|of|d1
T9_T21 NONE spd_14\NN\1740|with (r_nmod) modes_12\NNS\4916342|their|interaction|spd (r_conj) behaviors_3\NNS\407535|into|dynamical|receptors|and|modes (r_nmod) insights_0\NNS\5710020|behaviors (r_nsubj) crucial_16\JJ\1740|insights|are|understanding|. (l_advcl) understanding_18\VBG\588888|in|characteristics (l_dobj) characteristics_23\NNS\5849040|the|structural|receptors (l_nmod) receptors_26\NNS\5225602|of|dopamine
T11_T22 NONE spd_29\NN\1740|of|receptors (l_nmod) receptors_35\NNS\5225602|on|the|d1
T12_T23 NONE dopamine_24\NN\14807737| (r_compound) receptors_25\NNS\5225602|of|two|dopamine
T13_T16 NONE d1-spd_13\NN\1740|and|d2-spd (l_conj) d2-spd_15\JJ\1740|
T13_T24 NONE d1-spd_13\NN\1740|and|d2-spd (r_amod) complexes_16\NNS\5869584|the|d1-spd (r_nsubjpass) generated_18\VBN\1617192|complexes|were|,|agreement|. (r_conj) obtained_9\VBN\2210855|conformations|were|,|and|generated (l_nsubjpass) conformations_2\NNS\13897996|potential|binding|receptors (l_nmod) receptors_7\NNS\5225602|of|d1
T13_T25 NONE d1-spd_13\NN\1740|and|d2-spd
T2_T16 NONE d2-spd_15\JJ\1740|
T2_T24 NONE d2-spd_15\JJ\1740| (r_conj) d1-spd_13\NN\1740|and|d2-spd (r_amod) complexes_16\NNS\5869584|the|d1-spd (r_nsubjpass) generated_18\VBN\1617192|complexes|were|,|agreement|. (r_conj) obtained_9\VBN\2210855|conformations|were|,|and|generated (l_nsubjpass) conformations_2\NNS\13897996|potential|binding|receptors (l_nmod) receptors_7\NNS\5225602|of|d1
T2_T25 NONE d2-spd_15\JJ\1740| (r_conj) d1-spd_13\NN\1740|and|d2-spd
T3_T17 NONE d1-spd_1\NN\1740|
T5_T17 NONE spd_39\NN\1740|of (r_nmod) binding_37\NN\4688246|the|spd (r_conj) change_30\NN\7283608|for|both|the|conformational|domain|and|binding (r_nmod) plays_22\VBZ\1072262|that|bridge|role|change (r_ccomp) shows_3\VBZ\2137132|structure|plays|. (l_nsubj) structure_2\NN\21939|the|d1-spd (l_compound) d1-spd_1\NN\1740|
12824918
T2_T10 CPR:4 etodolac_17\NN\3828465| (r_appos) inhibitor_15\NN\20090|a|selective|cox-2|,|etodolac|, (l_compound) cox-2_14\NN\14737847|
T2_T11 NONE etodolac_17\NN\3828465| (r_appos) inhibitor_15\NN\20090|a|selective|cox-2|,|etodolac|, (r_nsubjpass) tested_20\VBN\670261|investigate|,|inhibitor|was|variants|,|increases (l_nmod) increases_39\NNS\13576355|with|graded|potential (l_nmod) potential_45\NN\14481929|of|in|matrigel|invasive|and|levels (l_conj) levels_49\NNS\4916342|expression (l_compound) expression_48\NN\4679549|cox-2 (l_compound) cox-2_47\NN\14737847|
16926278
T21_T59 NONE sildenafil_14\NN\4537602|over|and|tadalafil (r_nmod) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_conj) involved_19\VBN\2676054|is|dimerization (l_nmod) dimerization_22\NN\1740|in|phosphodiesterase-5 (l_compound) phosphodiesterase-5_21\NN\1740|
T21_T60 NONE sildenafil_14\NN\4537602|over|and|tadalafil (r_nmod) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_nsubj) segment_3\NN\3892891|a|46-amino|acid|domain (l_nmod) domain_7\NN\13934596|in|phosphodiesterase-5|gaf-b (l_compound) phosphodiesterase-5_5\NN\1740|
T21_T61 NONE sildenafil_14\NN\4537602|over|and|tadalafil (r_nmod) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_nsubj) segment_3\NN\3892891|a|46-amino|acid|domain (l_nmod) domain_7\NN\13934596|in|phosphodiesterase-5|gaf-b
T22_T59 NONE tadalafil_16\NN\4537602| (r_conj) sildenafil_14\NN\4537602|over|and|tadalafil (r_nmod) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_conj) involved_19\VBN\2676054|is|dimerization (l_nmod) dimerization_22\NN\1740|in|phosphodiesterase-5 (l_compound) phosphodiesterase-5_21\NN\1740|
T22_T60 NONE tadalafil_16\NN\4537602| (r_conj) sildenafil_14\NN\4537602|over|and|tadalafil (r_nmod) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_nsubj) segment_3\NN\3892891|a|46-amino|acid|domain (l_nmod) domain_7\NN\13934596|in|phosphodiesterase-5|gaf-b (l_compound) phosphodiesterase-5_5\NN\1740|
T22_T61 NONE tadalafil_16\NN\4537602| (r_conj) sildenafil_14\NN\4537602|over|and|tadalafil (r_nmod) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_nsubj) segment_3\NN\3892891|a|46-amino|acid|domain (l_nmod) domain_7\NN\13934596|in|phosphodiesterase-5|gaf-b
T23_T59 NONE acid_2\NN\14818238| (r_compound) segment_3\NN\3892891|a|46-amino|acid|domain (r_nsubj) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_conj) involved_19\VBN\2676054|is|dimerization (l_nmod) dimerization_22\NN\1740|in|phosphodiesterase-5 (l_compound) phosphodiesterase-5_21\NN\1740|
T23_T60 NONE acid_2\NN\14818238| (r_compound) segment_3\NN\3892891|a|46-amino|acid|domain (l_nmod) domain_7\NN\13934596|in|phosphodiesterase-5|gaf-b (l_compound) phosphodiesterase-5_5\NN\1740|
T23_T61 NONE acid_2\NN\14818238| (r_compound) segment_3\NN\3892891|a|46-amino|acid|domain (l_nmod) domain_7\NN\13934596|in|phosphodiesterase-5|gaf-b
T24_T59 NONE vardenafil_11\NN\4537602| (r_compound) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_conj) involved_19\VBN\2676054|is|dimerization (l_nmod) dimerization_22\NN\1740|in|phosphodiesterase-5 (l_compound) phosphodiesterase-5_21\NN\1740|
T24_T60 NONE vardenafil_11\NN\4537602| (r_compound) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_nsubj) segment_3\NN\3892891|a|46-amino|acid|domain (l_nmod) domain_7\NN\13934596|in|phosphodiesterase-5|gaf-b (l_compound) phosphodiesterase-5_5\NN\1740|
T24_T61 NONE vardenafil_11\NN\4537602| (r_compound) potency_12\NN\5196375|for|high|vardenafil|sildenafil (r_nmod) provides_8\VBZ\2199590|segment|potency|and|involved|. (l_nsubj) segment_3\NN\3892891|a|46-amino|acid|domain (l_nmod) domain_7\NN\13934596|in|phosphodiesterase-5|gaf-b
T13_T25 NONE adenylyl_31\JJ\1740| (r_amod) cyclases_32\NNS\1740|anabaena|adenylyl (r_appos) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (r_dobj) contains_24\VBZ\2632940|that|phosphodiesterase (r_acl:relcl) domain_18\NN\13934596|a|regulatory|domain|contains (r_conj) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (r_dobj) contains_4\VBZ\2632940|phosphodiesterase-5|domain|. (l_nsubj) phosphodiesterase-5_0\NN\1740|pde5
T13_T32 NONE adenylyl_31\JJ\1740| (r_amod) cyclases_32\NNS\1740|anabaena|adenylyl (r_appos) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site
T13_T38 NONE adenylyl_31\JJ\1740| (r_amod) cyclases_32\NNS\1740|anabaena|adenylyl
T13_T39 NONE adenylyl_31\JJ\1740| (r_amod) cyclases_32\NNS\1740|anabaena|adenylyl (r_appos) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) fhlas_36\NNS\1740|escherichia|coli|gafs|a
T13_T40 NONE adenylyl_31\JJ\1740| (r_amod) cyclases_32\NNS\1740|anabaena|adenylyl (r_appos) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (r_dobj) contains_24\VBZ\2632940|that|phosphodiesterase (r_acl:relcl) domain_18\NN\13934596|a|regulatory|domain|contains (r_conj) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (r_dobj) contains_4\VBZ\2632940|phosphodiesterase-5|domain|. (l_nsubj) phosphodiesterase-5_0\NN\1740|pde5 (l_appos) pde5_2\NN\1740|(|)
T13_T41 NONE adenylyl_31\JJ\1740| (r_amod) cyclases_32\NNS\1740|anabaena|adenylyl (r_appos) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) fhlas_36\NNS\1740|escherichia|coli|gafs|a (l_dep) a_41\NN\13649268|(|and|b|) (l_punct) )_44\-RRB-\1740|
T13_T42 NONE adenylyl_31\JJ\1740| (r_amod) cyclases_32\NNS\1740|anabaena|adenylyl (r_appos) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_conj) site_48\NN\8673395|a|phosphorylation|kinases (l_nmod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks
T13_T43 NONE adenylyl_31\JJ\1740| (r_amod) cyclases_32\NNS\1740|anabaena|adenylyl (r_appos) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_conj) site_48\NN\8673395|a|phosphorylation|kinases (l_nmod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (l_appos) cnpks_55\NNS\1740|(|)
T14_T25 NONE nucleotide-dependent_51\JJ\1740|cyclic (r_amod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (r_nmod) site_48\NN\8673395|a|phosphorylation|kinases (r_conj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (r_dobj) contains_24\VBZ\2632940|that|phosphodiesterase (r_acl:relcl) domain_18\NN\13934596|a|regulatory|domain|contains (r_conj) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (r_dobj) contains_4\VBZ\2632940|phosphodiesterase-5|domain|. (l_nsubj) phosphodiesterase-5_0\NN\1740|pde5
T14_T32 NONE nucleotide-dependent_51\JJ\1740|cyclic (r_amod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (r_nmod) site_48\NN\8673395|a|phosphorylation|kinases (r_conj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site
T14_T38 NONE nucleotide-dependent_51\JJ\1740|cyclic (r_amod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (r_nmod) site_48\NN\8673395|a|phosphorylation|kinases (r_conj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) cyclases_32\NNS\1740|anabaena|adenylyl
T14_T39 NONE nucleotide-dependent_51\JJ\1740|cyclic (r_amod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (r_nmod) site_48\NN\8673395|a|phosphorylation|kinases (r_conj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) fhlas_36\NNS\1740|escherichia|coli|gafs|a
T14_T40 NONE nucleotide-dependent_51\JJ\1740|cyclic (r_amod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (r_nmod) site_48\NN\8673395|a|phosphorylation|kinases (r_conj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (r_dobj) contains_24\VBZ\2632940|that|phosphodiesterase (r_acl:relcl) domain_18\NN\13934596|a|regulatory|domain|contains (r_conj) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (r_dobj) contains_4\VBZ\2632940|phosphodiesterase-5|domain|. (l_nsubj) phosphodiesterase-5_0\NN\1740|pde5 (l_appos) pde5_2\NN\1740|(|)
T14_T41 NONE nucleotide-dependent_51\JJ\1740|cyclic (r_amod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (r_nmod) site_48\NN\8673395|a|phosphorylation|kinases (r_conj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) fhlas_36\NNS\1740|escherichia|coli|gafs|a (l_dep) a_41\NN\13649268|(|and|b|) (l_punct) )_44\-RRB-\1740|
T14_T42 NONE nucleotide-dependent_51\JJ\1740|cyclic (r_amod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks
T14_T43 NONE nucleotide-dependent_51\JJ\1740|cyclic (r_amod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (l_appos) cnpks_55\NNS\1740|(|)
T19_T25 CPR:9 cgmp_14\NN\1740| (r_dobj) hydrolyzes_13\VBZ\109660|that|cgmp (r_acl:relcl) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (r_dobj) contains_4\VBZ\2632940|phosphodiesterase-5|domain|. (l_nsubj) phosphodiesterase-5_0\NN\1740|pde5
T19_T32 NONE cgmp_14\NN\1740| (r_dobj) hydrolyzes_13\VBZ\109660|that|cgmp (r_acl:relcl) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (l_conj) domain_18\NN\13934596|a|regulatory|domain|contains (l_acl:relcl) contains_24\VBZ\2632940|that|phosphodiesterase (l_dobj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site
T19_T38 NONE cgmp_14\NN\1740| (r_dobj) hydrolyzes_13\VBZ\109660|that|cgmp (r_acl:relcl) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (l_conj) domain_18\NN\13934596|a|regulatory|domain|contains (l_acl:relcl) contains_24\VBZ\2632940|that|phosphodiesterase (l_dobj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) cyclases_32\NNS\1740|anabaena|adenylyl
T19_T39 NONE cgmp_14\NN\1740| (r_dobj) hydrolyzes_13\VBZ\109660|that|cgmp (r_acl:relcl) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (l_conj) domain_18\NN\13934596|a|regulatory|domain|contains (l_acl:relcl) contains_24\VBZ\2632940|that|phosphodiesterase (l_dobj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) fhlas_36\NNS\1740|escherichia|coli|gafs|a
T19_T40 CPR:9 cgmp_14\NN\1740| (r_dobj) hydrolyzes_13\VBZ\109660|that|cgmp (r_acl:relcl) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (r_dobj) contains_4\VBZ\2632940|phosphodiesterase-5|domain|. (l_nsubj) phosphodiesterase-5_0\NN\1740|pde5 (l_appos) pde5_2\NN\1740|(|)
T19_T41 NONE cgmp_14\NN\1740| (r_dobj) hydrolyzes_13\VBZ\109660|that|cgmp (r_acl:relcl) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (l_conj) domain_18\NN\13934596|a|regulatory|domain|contains (l_acl:relcl) contains_24\VBZ\2632940|that|phosphodiesterase (l_dobj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) fhlas_36\NNS\1740|escherichia|coli|gafs|a (l_dep) a_41\NN\13649268|(|and|b|) (l_punct) )_44\-RRB-\1740|
T19_T42 NONE cgmp_14\NN\1740| (r_dobj) hydrolyzes_13\VBZ\109660|that|cgmp (r_acl:relcl) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (l_conj) domain_18\NN\13934596|a|regulatory|domain|contains (l_acl:relcl) contains_24\VBZ\2632940|that|phosphodiesterase (l_dobj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_conj) site_48\NN\8673395|a|phosphorylation|kinases (l_nmod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks
T19_T43 NONE cgmp_14\NN\1740| (r_dobj) hydrolyzes_13\VBZ\109660|that|cgmp (r_acl:relcl) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (l_conj) domain_18\NN\13934596|a|regulatory|domain|contains (l_acl:relcl) contains_24\VBZ\2632940|that|phosphodiesterase (l_dobj) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_conj) site_48\NN\8673395|a|phosphorylation|kinases (l_nmod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (l_appos) cnpks_55\NNS\1740|(|)
T9_T25 NONE cgmp-binding_27\JJ\1740| (r_amod) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (r_dobj) contains_24\VBZ\2632940|that|phosphodiesterase (r_acl:relcl) domain_18\NN\13934596|a|regulatory|domain|contains (r_conj) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (r_dobj) contains_4\VBZ\2632940|phosphodiesterase-5|domain|. (l_nsubj) phosphodiesterase-5_0\NN\1740|pde5
T9_T32 NONE cgmp-binding_27\JJ\1740| (r_amod) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site
T9_T38 NONE cgmp-binding_27\JJ\1740| (r_amod) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) cyclases_32\NNS\1740|anabaena|adenylyl
T9_T39 NONE cgmp-binding_27\JJ\1740| (r_amod) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) fhlas_36\NNS\1740|escherichia|coli|gafs|a
T9_T40 NONE cgmp-binding_27\JJ\1740| (r_amod) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (r_dobj) contains_24\VBZ\2632940|that|phosphodiesterase (r_acl:relcl) domain_18\NN\13934596|a|regulatory|domain|contains (r_conj) domain_7\NN\13934596|a|catalytic|domain|hydrolyzes|and|domain (r_dobj) contains_4\VBZ\2632940|phosphodiesterase-5|domain|. (l_nsubj) phosphodiesterase-5_0\NN\1740|pde5 (l_appos) pde5_2\NN\1740|(|)
T9_T41 NONE cgmp-binding_27\JJ\1740| (r_amod) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_appos) fhlas_36\NNS\1740|escherichia|coli|gafs|a (l_dep) a_41\NN\13649268|(|and|b|) (l_punct) )_44\-RRB-\1740|
T9_T42 NONE cgmp-binding_27\JJ\1740| (r_amod) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_conj) site_48\NN\8673395|a|phosphorylation|kinases (l_nmod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks
T9_T43 NONE cgmp-binding_27\JJ\1740| (r_amod) phosphodiesterase_28\NN\1740|two|mammalian|cgmp-binding|,|cyclases|,|fhlas|and|site (l_conj) site_48\NN\8673395|a|phosphorylation|kinases (l_nmod) kinases_53\NNS\14732946|for|nucleotide-dependent|protein|cnpks (l_appos) cnpks_55\NNS\1740|(|)
T15_T44 NONE cgmp_2\NN\1740|of (r_nmod) binding_0\NN\4688246|cgmp|gaf-a (l_nmod) gaf-a_4\NN\1740|to
T15_T45 CPR:3 cgmp_2\NN\1740|of (r_nmod) binding_0\NN\4688246|cgmp|gaf-a (r_nsubj) increases_5\VBZ\169651|binding|phosphorylation|and|improves|. (l_dobj) phosphorylation_7\NN\1740|cnpk|pde5 (l_compound) cnpk_6\NN\1740|
T15_T46 CPR:3 cgmp_2\NN\1740|of (r_nmod) binding_0\NN\4688246|cgmp|gaf-a (r_nsubj) increases_5\VBZ\169651|binding|phosphorylation|and|improves|. (l_dobj) phosphorylation_7\NN\1740|cnpk|pde5 (l_nmod) pde5_9\NN\1740|of
T16_T44 NONE cgmp_16\NN\1740|for|or|inhibitors (r_nmod) affinity_14\NN\11426530|catalytic|site|cgmp (r_dobj) improves_11\VBZ\126264|affinity (r_conj) increases_5\VBZ\169651|binding|phosphorylation|and|improves|. (l_nsubj) binding_0\NN\4688246|cgmp|gaf-a (l_nmod) gaf-a_4\NN\1740|to
T16_T45 NONE cgmp_16\NN\1740|for|or|inhibitors (r_nmod) affinity_14\NN\11426530|catalytic|site|cgmp (r_dobj) improves_11\VBZ\126264|affinity (r_conj) increases_5\VBZ\169651|binding|phosphorylation|and|improves|. (l_dobj) phosphorylation_7\NN\1740|cnpk|pde5 (l_compound) cnpk_6\NN\1740|
T16_T46 NONE cgmp_16\NN\1740|for|or|inhibitors (r_nmod) affinity_14\NN\11426530|catalytic|site|cgmp (r_dobj) improves_11\VBZ\126264|affinity (r_conj) increases_5\VBZ\169651|binding|phosphorylation|and|improves|. (l_dobj) phosphorylation_7\NN\1740|cnpk|pde5 (l_nmod) pde5_9\NN\1740|of
T17_T47 NONE cgmp_9\NN\1740| (r_compound) binding_10\NN\4688246|of|cgmp|gaf-a (r_nmod) inhibition_7\NN\1068773|binding (r_conj) dimerization_3\NN\1740|to|pde5|,|inhibition|,|and|sequestration (r_nmod) contributes_1\VBZ\126264|gaf-b|dimerization|. (l_nsubj) gaf-b_0\NN\1740|
T17_T48 NONE cgmp_9\NN\1740| (r_compound) binding_10\NN\4688246|of|cgmp|gaf-a (r_nmod) inhibition_7\NN\1068773|binding (r_conj) dimerization_3\NN\1740|to|pde5|,|inhibition|,|and|sequestration (l_nmod) pde5_5\NN\1740|of
T17_T49 NONE cgmp_9\NN\1740| (r_compound) binding_10\NN\4688246|of|cgmp|gaf-a (l_nmod) gaf-a_12\NN\1740|to
T18_T50 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_advcl) probe_1\VB\789138|to|effects (l_dobj) effects_6\NNS\13245626|potential|domain|affinity (l_compound) domain_5\NN\13934596|pde5|r
T18_T51 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_parataxis) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_nsubj) pde5delta1_22\NN\1740|-|321 (l_nummod) 321_24\CD\1740|
T18_T52 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_parataxis) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_dobj) domain_27\NN\13934596|gaf-b|,|domain|,|and|sequence
T18_T53 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_parataxis) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_dobj) domain_27\NN\13934596|gaf-b|,|domain|,|and|sequence (l_conj) sequence_34\NN\8457976|the|gaf-a (l_nmod) gaf-a_36\NN\1740|between|and|-b (l_conj) -b_38\NN\1740|
T18_T54 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_parataxis) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (l_nsubj) pde5delta1_40\NN\1740|-|419 (l_nummod) 419_42\CD\1740|
T18_T55 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_parataxis) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (l_dobj) gaf-b_44\NN\1740|and|domain (l_conj) domain_47\NN\13934596|c
T18_T56 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_parataxis) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (l_conj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (l_nsubj) pde5delta1_49\NN\1740|-|465 (l_nummod) 465_51\CD\1740|
T18_T57 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_parataxis) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (l_conj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (l_dobj) domain_55\NN\13934596|the|c|and|portion (l_conj) portion_59\NN\31921|the|c-terminal|gaf-b (l_nmod) gaf-b_61\NN\1740|of
T18_T58 NONE n-terminal_16\JJ\1740| (r_amod) mutants_18\NNS\4475|four|n-terminal|truncation (r_nsubjpass) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_parataxis) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (l_conj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (l_conj) contained_67\VBD\2632940|pde5delta1|domain (l_nsubj) pde5delta1_64\NN\1740|-|534 (l_nummod) 534_66\CD\1740|
T20_T50 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (r_conj) domain_55\NN\13934596|the|c|and|portion (r_dobj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (r_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (r_conj) contained_25\VBD\2632940|pde5delta1|domain|;|contained (r_parataxis) generated_20\VBN\1617192|probe|,|mutants|were|:|contained (l_advcl) probe_1\VB\789138|to|effects (l_dobj) effects_6\NNS\13245626|potential|domain|affinity (l_compound) domain_5\NN\13934596|pde5|r
T20_T51 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (r_conj) domain_55\NN\13934596|the|c|and|portion (r_dobj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (r_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (r_conj) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_nsubj) pde5delta1_22\NN\1740|-|321 (l_nummod) 321_24\CD\1740|
T20_T52 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (r_conj) domain_55\NN\13934596|the|c|and|portion (r_dobj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (r_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (r_conj) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_dobj) domain_27\NN\13934596|gaf-b|,|domain|,|and|sequence
T20_T53 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (r_conj) domain_55\NN\13934596|the|c|and|portion (r_dobj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (r_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (r_conj) contained_25\VBD\2632940|pde5delta1|domain|;|contained (l_dobj) domain_27\NN\13934596|gaf-b|,|domain|,|and|sequence (l_conj) sequence_34\NN\8457976|the|gaf-a (l_nmod) gaf-a_36\NN\1740|between|and|-b (l_conj) -b_38\NN\1740|
T20_T54 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (r_conj) domain_55\NN\13934596|the|c|and|portion (r_dobj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (r_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (l_nsubj) pde5delta1_40\NN\1740|-|419 (l_nummod) 419_42\CD\1740|
T20_T55 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (r_conj) domain_55\NN\13934596|the|c|and|portion (r_dobj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (r_conj) contained_43\VBD\2632940|pde5delta1|gaf-b|;|contained (l_dobj) gaf-b_44\NN\1740|and|domain (l_conj) domain_47\NN\13934596|c
T20_T56 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (r_conj) domain_55\NN\13934596|the|c|and|portion (r_dobj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (l_nsubj) pde5delta1_49\NN\1740|-|465 (l_nummod) 465_51\CD\1740|
T20_T57 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (l_nmod) gaf-b_61\NN\1740|of
T20_T58 NONE c-terminal_58\JJ\1740| (r_amod) portion_59\NN\31921|the|c-terminal|gaf-b (r_conj) domain_55\NN\13934596|the|c|and|portion (r_dobj) contained_52\VBD\2632940|pde5delta1|domain|;|and|contained (l_conj) contained_67\VBD\2632940|pde5delta1|domain (l_nsubj) pde5delta1_64\NN\1740|-|534 (l_nummod) 534_66\CD\1740|
T1_T26 NONE n-terminal_13\JJ\1740| (r_amod) acids_16\NNS\14818238|the|n-terminal|46|amino|gaf-b (r_dobj) lacking_11\VBG\1740|acids (r_acl) those_10\DT\1740|lacking (r_nsubj) monomers_20\NNS\14818238|those|were|,|indicating (r_conj) dimers_7\NNS\14818238|proteins|were|,|but|monomers|. (l_nsubj) proteins_1\NNS\14944888|truncated|gaf-b (l_nmod) gaf-b_5\NN\1740|with|a|complete
T1_T27 NONE n-terminal_13\JJ\1740| (r_amod) acids_16\NNS\14818238|the|n-terminal|46|amino|gaf-b (l_nmod) gaf-b_18\NN\1740|of
T1_T28 NONE n-terminal_13\JJ\1740| (r_amod) acids_16\NNS\14818238|the|n-terminal|46|amino|gaf-b (r_dobj) lacking_11\VBG\1740|acids (r_acl) those_10\DT\1740|lacking (r_nsubj) monomers_20\NNS\14818238|those|were|,|indicating (l_advcl) indicating_22\VBG\952524|vital (l_ccomp) vital_27\JJ\1740|that|residues|are|dimerization (l_nmod) dimerization_31\NN\1740|for|gaf-b-mediated|pde5 (l_amod) gaf-b-mediated_29\JJ\1740|
T1_T29 NONE n-terminal_13\JJ\1740| (r_amod) acids_16\NNS\14818238|the|n-terminal|46|amino|gaf-b (r_dobj) lacking_11\VBG\1740|acids (r_acl) those_10\DT\1740|lacking (r_nsubj) monomers_20\NNS\14818238|those|were|,|indicating (l_advcl) indicating_22\VBG\952524|vital (l_ccomp) vital_27\JJ\1740|that|residues|are|dimerization (l_nmod) dimerization_31\NN\1740|for|gaf-b-mediated|pde5 (l_compound) pde5_30\NN\1740|
T2_T26 NONE acids_16\NNS\14818238|the|n-terminal|46|amino|gaf-b (r_dobj) lacking_11\VBG\1740|acids (r_acl) those_10\DT\1740|lacking (r_nsubj) monomers_20\NNS\14818238|those|were|,|indicating (r_conj) dimers_7\NNS\14818238|proteins|were|,|but|monomers|. (l_nsubj) proteins_1\NNS\14944888|truncated|gaf-b (l_nmod) gaf-b_5\NN\1740|with|a|complete
T2_T27 NONE acids_16\NNS\14818238|the|n-terminal|46|amino|gaf-b (l_nmod) gaf-b_18\NN\1740|of
T2_T28 NONE acids_16\NNS\14818238|the|n-terminal|46|amino|gaf-b (r_dobj) lacking_11\VBG\1740|acids (r_acl) those_10\DT\1740|lacking (r_nsubj) monomers_20\NNS\14818238|those|were|,|indicating (l_advcl) indicating_22\VBG\952524|vital (l_ccomp) vital_27\JJ\1740|that|residues|are|dimerization (l_nmod) dimerization_31\NN\1740|for|gaf-b-mediated|pde5 (l_amod) gaf-b-mediated_29\JJ\1740|
T2_T29 NONE acids_16\NNS\14818238|the|n-terminal|46|amino|gaf-b (r_dobj) lacking_11\VBG\1740|acids (r_acl) those_10\DT\1740|lacking (r_nsubj) monomers_20\NNS\14818238|those|were|,|indicating (l_advcl) indicating_22\VBG\952524|vital (l_ccomp) vital_27\JJ\1740|that|residues|are|dimerization (l_nmod) dimerization_31\NN\1740|for|gaf-b-mediated|pde5 (l_compound) pde5_30\NN\1740|
T3_T30 CPR:9 cgmp_7\NN\1740|for (r_nmod) values_2\NNS\5941423|k(m|mutants|cgmp (r_nsubj) similar_9\JJ\1740|values|were|that|. (l_nmod) that_11\DT\1740|to|pde5 (l_nmod) pde5_14\NN\1740|of|full-length
T4_T31 NONE 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_nsubj) constructs_2\NNS\5833840|all|pde5 (l_compound) pde5_1\NN\1740|
T4_T33 NONE 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_conj) had_22\VBD\2108377|mutants|affinity|those (l_nsubj) mutants_17\NNS\4475|containing (l_acl) containing_18\VBG\2632940|gaf-b (l_dobj) gaf-b_21\NN\1740|a|complete
T4_T34 NONE 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_conj) had_22\VBD\2108377|mutants|affinity|those (l_advcl) those_33\DT\1740|compared|with|lacking (l_acl) lacking_34\VBG\1740|gaf-b. (l_dobj) gaf-b._37\NN\1740|a|complete
T5_T31 NONE sildenafil_9\NN\4537602| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_nsubj) constructs_2\NNS\5833840|all|pde5 (l_compound) pde5_1\NN\1740|
T5_T33 NONE sildenafil_9\NN\4537602| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_conj) had_22\VBD\2108377|mutants|affinity|those (l_nsubj) mutants_17\NNS\4475|containing (l_acl) containing_18\VBG\2632940|gaf-b (l_dobj) gaf-b_21\NN\1740|a|complete
T5_T34 NONE sildenafil_9\NN\4537602| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_conj) had_22\VBD\2108377|mutants|affinity|those (l_advcl) those_33\DT\1740|compared|with|lacking (l_acl) lacking_34\VBG\1740|gaf-b. (l_dobj) gaf-b._37\NN\1740|a|complete
T6_T31 NONE tadalafil_11\NN\4537602| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_nsubj) constructs_2\NNS\5833840|all|pde5 (l_compound) pde5_1\NN\1740|
T6_T33 NONE tadalafil_11\NN\4537602| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_conj) had_22\VBD\2108377|mutants|affinity|those (l_nsubj) mutants_17\NNS\4475|containing (l_acl) containing_18\VBG\2632940|gaf-b (l_dobj) gaf-b_21\NN\1740|a|complete
T6_T34 NONE tadalafil_11\NN\4537602| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_conj) had_22\VBD\2108377|mutants|affinity|those (l_advcl) those_33\DT\1740|compared|with|lacking (l_acl) lacking_34\VBG\1740|gaf-b. (l_dobj) gaf-b._37\NN\1740|a|complete
T7_T31 NONE uk-122764_14\NNP\1740| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_nsubj) constructs_2\NNS\5833840|all|pde5 (l_compound) pde5_1\NN\1740|
T7_T33 NONE uk-122764_14\NNP\1740| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_conj) had_22\VBD\2108377|mutants|affinity|those (l_nsubj) mutants_17\NNS\4475|containing (l_acl) containing_18\VBG\2632940|gaf-b (l_dobj) gaf-b_21\NN\1740|a|complete
T7_T34 NONE uk-122764_14\NNP\1740| (r_conj) 3-isobutyl-1-methylxanthine_7\NN\1740|for|,|sildenafil|,|tadalafil|,|and|uk-122764 (r_nmod) affinities_5\NNS\11426530|similar|3-isobutyl-1-methylxanthine (r_dobj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_conj) had_22\VBD\2108377|mutants|affinity|those (l_advcl) those_33\DT\1740|compared|with|lacking (l_acl) lacking_34\VBG\1740|gaf-b. (l_dobj) gaf-b._37\NN\1740|a|complete
T8_T31 NONE vardenafil-based_29\JJ\1740| (r_amod) compounds_30\NNS\5869584|for|vardenafil-based (r_nmod) affinity_27\NN\11426530|higher|compounds (r_dobj) had_22\VBD\2108377|mutants|affinity|those (r_conj) had_3\VBD\2108377|constructs|affinities|,|but|had (l_nsubj) constructs_2\NNS\5833840|all|pde5 (l_compound) pde5_1\NN\1740|
T8_T33 NONE vardenafil-based_29\JJ\1740| (r_amod) compounds_30\NNS\5869584|for|vardenafil-based (r_nmod) affinity_27\NN\11426530|higher|compounds (r_dobj) had_22\VBD\2108377|mutants|affinity|those (l_nsubj) mutants_17\NNS\4475|containing (l_acl) containing_18\VBG\2632940|gaf-b (l_dobj) gaf-b_21\NN\1740|a|complete
T8_T34 NONE vardenafil-based_29\JJ\1740| (r_amod) compounds_30\NNS\5869584|for|vardenafil-based (r_nmod) affinity_27\NN\11426530|higher|compounds (r_dobj) had_22\VBD\2108377|mutants|affinity|those (l_advcl) those_33\DT\1740|compared|with|lacking (l_acl) lacking_34\VBG\1740|gaf-b. (l_dobj) gaf-b._37\NN\1740|a|complete
T10_T35 NONE n-terminal_4\JJ\1740| (r_amod) acids_7\NNS\14818238|the|n-terminal|46|amino|gaf-b (l_nmod) gaf-b_9\NN\1740|in
T11_T35 NONE acids_7\NNS\14818238|the|n-terminal|46|amino|gaf-b (l_nmod) gaf-b_9\NN\1740|in
T12_T35 NONE vardenafil_14\NN\4537602| (r_compound) potency_15\NN\5196375|for|high|vardenafil (r_nmod) required_11\VBN\754942|that|acids|are|potency (l_nsubjpass) acids_7\NNS\14818238|the|n-terminal|46|amino|gaf-b (l_nmod) gaf-b_9\NN\1740|in
23454148
T12_T26 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T12_T27 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) n_13\NN\14622893|aminopeptidase
T12_T28 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T12_T29 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T12_T30 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T12_T31 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T12_T32 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T12_T33 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T12_T34 NONE glutathione_9\NN\1740| (r_compound) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (l_conj) oxidase_47\NN\14732946|depleted|xanthine
T13_T26 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T13_T27 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) n_13\NN\14622893|aminopeptidase
T13_T28 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T13_T29 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T13_T30 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T13_T31 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T13_T32 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T13_T33 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T13_T34 NONE s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (l_conj) oxidase_47\NN\14732946|depleted|xanthine
T14_T26 NONE n_13\NN\14622893|aminopeptidase (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T14_T27 NONE n_13\NN\14622893|aminopeptidase
T14_T28 NONE n_13\NN\14622893|aminopeptidase (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T14_T29 NONE n_13\NN\14622893|aminopeptidase (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T14_T30 NONE n_13\NN\14622893|aminopeptidase (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T14_T31 NONE n_13\NN\14622893|aminopeptidase (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T14_T32 NONE n_13\NN\14622893|aminopeptidase (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T14_T33 NONE n_13\NN\14622893|aminopeptidase (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T14_T34 NONE n_13\NN\14622893|aminopeptidase (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (l_conj) oxidase_47\NN\14732946|depleted|xanthine
T15_T26 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T15_T27 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) n_13\NN\14622893|aminopeptidase
T15_T28 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T15_T29 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T15_T30 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T15_T31 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T15_T32 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T15_T33 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T15_T34 NONE cysteine_15\NN\14601829| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (l_conj) oxidase_47\NN\14732946|depleted|xanthine
T16_T26 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T16_T27 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) n_13\NN\14622893|aminopeptidase
T16_T28 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T16_T29 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T16_T30 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T16_T31 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T16_T32 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T16_T33 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T16_T34 NONE s-conjugate_16\NN\1740| (r_compound) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (r_conj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (r_dobj) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (r_ccomp) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (l_conj) oxidase_47\NN\14732946|depleted|xanthine
T17_T26 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (r_compound) activities_36\NNS\30358|dehydrogenase (r_dobj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T17_T27 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (r_compound) activities_36\NNS\30358|dehydrogenase (r_dobj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) n_13\NN\14622893|aminopeptidase
T17_T28 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (r_compound) activities_36\NNS\30358|dehydrogenase (r_dobj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T17_T29 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (r_compound) activities_36\NNS\30358|dehydrogenase (r_dobj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T17_T30 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (r_compound) activities_36\NNS\30358|dehydrogenase (r_dobj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T17_T31 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T17_T32 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T17_T33 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (r_compound) activities_36\NNS\30358|dehydrogenase (r_dobj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T17_T34 NONE dihydropyrimidine_30\NN\1740| (r_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (r_compound) activities_36\NNS\30358|dehydrogenase (r_dobj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_conj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (l_conj) oxidase_47\NN\14732946|depleted|xanthine
T19_T26 NONE pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T19_T27 NONE pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) n_13\NN\14622893|aminopeptidase
T19_T28 NONE pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T19_T29 NONE pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T19_T30 NONE pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T19_T31 NONE pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T19_T32 NONE pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T19_T33 CPR:3 pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T19_T34 CPR:4 pm-mmc_38\NN\1740| (r_compound) rats_39\NNS\2329401|pm-mmc (r_nsubj) showed_40\VBD\2137132|rats|reductase (l_dobj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (l_conj) oxidase_47\NN\14732946|depleted|xanthine
T20_T26 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T20_T27 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) n_13\NN\14622893|aminopeptidase
T20_T28 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T20_T29 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T20_T30 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T20_T31 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T20_T32 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T20_T33 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T20_T34 NONE quinone_42\NN\14818238| (r_compound) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (l_conj) oxidase_47\NN\14732946|depleted|xanthine
T21_T26 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine (r_conj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities
T21_T27 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine (r_conj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) n_13\NN\14622893|aminopeptidase
T21_T28 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine (r_conj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl
T21_T29 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine (r_conj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) beta-lyase_17\NN\1740|cysteine|s-conjugate|ccbl (l_appos) ccbl_19\NN\1740|(|)
T21_T30 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine (r_conj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_ccomp) exhibited_7\VBD\2632167|counterparts|,|rats|s-transferase (l_dobj) s-transferase_10\NN\1740|higher|glutathione|,|n|and|beta-lyase|and|activities (l_conj) activities_24\NNS\30358|lower|gamma-glutamyltransferase (l_compound) gamma-glutamyltransferase_23\NN\1740|
T21_T31 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine (r_conj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2
T21_T32 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine (r_conj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities (r_dobj) showed_40\VBD\2137132|rats|reductase (r_conj) exhibited_28\VBD\2632167|exhibited|,|rats|activities|and|showed|. (l_dobj) activities_36\NNS\30358|dehydrogenase (l_compound) dehydrogenase_31\NN\1740|decreased|dihydropyrimidine|and|p450|1a1/2 (l_conj) 1a1/2_35\CD\1740|
T21_T33 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine (r_conj) reductase_43\NN\14732946|higher|quinone|and|oxidase|activities
T21_T34 NONE xanthine_46\NN\14727670| (r_compound) oxidase_47\NN\14732946|depleted|xanthine
T5_T25 CPR:9 mmc_9\NN\1740| (r_conj) fu_7\NN\1740|and|mmc (r_conj) cp_5\NN\1740|,|fu (r_compound) metabolism_10\NN\13526110|cp|stomach (r_dobj) alters_4\VBZ\126264|conclusively|,|malnutrition|metabolism|enhancing|potentiating|. (l_advcl) enhancing_15\VBG\227165|by|pathway|,|delaying (l_dobj) pathway_17\NN\5483677|ccbl|activation (l_compound) ccbl_16\NN\1740|
T7_T25 NONE mmc_30\NN\1740|of (r_nmod) reduction_28\NN\351485|two-electron|mmc (r_dobj) activating_26\VBG\1641914|reduction (r_conj) delaying_22\VBG\439958|elimination|and|activating|, (r_conj) enhancing_15\VBG\227165|by|pathway|,|delaying (l_dobj) pathway_17\NN\5483677|ccbl|activation (l_compound) ccbl_16\NN\1740|
22578098
T4_T16 NONE ca(2+)atpase_5\NN\1740|between|cardiac|sarcoplasmic|and|phospholamban
T4_T19 NONE ca(2+)atpase_5\NN\1740|between|cardiac|sarcoplasmic|and|phospholamban (l_conj) phospholamban_7\NN\1740|
T3_T14 NONE ca(2+)atpase_10\NN\1740|of|sarcoplasmic
T3_T15 NONE ca(2+)atpase_10\NN\1740|of|sarcoplasmic (r_nmod) inhibition_7\NN\1068773|in|the|ca(2+)atpase|phospholamban (l_nmod) phospholamban_12\NN\1740|by
T5_T17 NONE ca(2+)atpase_20\NN\1740|on|sarcoplasmic (r_nmod) activity_15\NN\30358|with|the|inhibitory|phospholamban|ca(2+)atpase (l_nmod) phospholamban_17\NN\1740|of
T5_T18 NONE ca(2+)atpase_20\NN\1740|on|sarcoplasmic
T1_T8 NONE acid_16\NN\14818238|which|amino (r_nsubj) important_18\JJ\1740|acid|was|inhibition (r_ccomp) identified_13\VBD\699815|synthesizing|,|we|important|. (l_advcl) synthesizing_1\VBG\193486|by|and|testing|series (l_dobj) series_5\NN\8456993|a|peptides (l_nmod) peptides_10\NNS\14724264|of|point-mutated|cyclic
T1_T9 NONE acid_16\NN\14818238|which|amino (r_nsubj) important_18\JJ\1740|acid|was|inhibition (l_nmod) inhibition_21\NN\1068773|for|the|function (l_nmod) function_25\NN\13783581|of|the|phospholamban (l_compound) phospholamban_24\NN\1740|
T7_T8 NONE alanine_7\NN\14601829| (r_nmod:npmod) point-mutated_8\JJ\1740|alanine (r_amod) peptides_10\NNS\14724264|of|point-mutated|cyclic
T7_T9 NONE alanine_7\NN\14601829| (r_nmod:npmod) point-mutated_8\JJ\1740|alanine (r_amod) peptides_10\NNS\14724264|of|point-mutated|cyclic (r_nmod) series_5\NN\8456993|a|peptides (r_dobj) synthesizing_1\VBG\193486|by|and|testing|series (r_advcl) identified_13\VBD\699815|synthesizing|,|we|important|. (l_ccomp) important_18\JJ\1740|acid|was|inhibition (l_nmod) inhibition_21\NN\1068773|for|the|function (l_nmod) function_25\NN\13783581|of|the|phospholamban (l_compound) phospholamban_24\NN\1740|
T2_T10 NONE alanine-mutated_6\JJ\1740| (r_amod) peptides_8\NNS\14724264|of|active|alanine-mutated|cyclic|,|and|phospholamban
T2_T11 NONE alanine-mutated_6\JJ\1740| (r_amod) peptides_8\NNS\14724264|of|active|alanine-mutated|cyclic|,|and|phospholamban (l_conj) phospholamban_12\NN\1740|of|1|, (l_appos) 1_14\CD\13741022|(|36|) (l_punct) )_17\-RRB-\1740|
23432582
T11_T21 NONE bisacylimidoselenocarbamates_0\NNS\1740| (r_nsubj) cause_1\VBP\1617192|bisacylimidoselenocarbamates|arrest|. (l_dobj) arrest_3\NN\88481|g2/m|associated (l_acl) associated_4\VBN\628491|modulation (l_nmod) modulation_7\NN\7044917|with|the|cdk1 (l_nmod) cdk1_9\NN\1740|of|and|chk2|cells
T11_T22 NONE bisacylimidoselenocarbamates_0\NNS\1740| (r_nsubj) cause_1\VBP\1617192|bisacylimidoselenocarbamates|arrest|. (l_dobj) arrest_3\NN\88481|g2/m|associated (l_acl) associated_4\VBN\628491|modulation (l_nmod) modulation_7\NN\7044917|with|the|cdk1 (l_nmod) cdk1_9\NN\1740|of|and|chk2|cells (l_conj) chk2_11\NN\1740|
T10_T17 NONE z-vad-fmk_37\NN\1740|with|the|pancaspase|inhibitor (r_nmod) pretreatment_32\NN\1740|by|z-vad-fmk (r_nmod) prevented_30\VBN\1740|since|death|could|not|be|pretreatment (r_advcl) discarded_23\VBN\2224055|however|,|involvement|is|prevented|. (l_nsubjpass) involvement_3\NN\1080366|the|pathway|process (l_nmod) pathway_7\NN\5483677|of|the|caspase-dependent (l_amod) caspase-dependent_6\JJ\1740|
T10_T18 CPR:4 z-vad-fmk_37\NN\1740|with|the|pancaspase|inhibitor (l_compound) pancaspase_35\NN\1740|
T9_T17 NONE bsc_17\NN\1740| (r_compound) 3_18\NN\13741022|by|either|bsc|g (r_nmod) induced_14\VBN\1627355|3 (r_acl) process_10\NN\407535|in|the|death|induced (r_nmod) involvement_3\NN\1080366|the|pathway|process (l_nmod) pathway_7\NN\5483677|of|the|caspase-dependent (l_amod) caspase-dependent_6\JJ\1740|
T9_T18 NONE bsc_17\NN\1740| (r_compound) 3_18\NN\13741022|by|either|bsc|g (r_nmod) induced_14\VBN\1627355|3 (r_acl) process_10\NN\407535|in|the|death|induced (r_nmod) involvement_3\NN\1080366|the|pathway|process (r_nsubjpass) discarded_23\VBN\2224055|however|,|involvement|is|prevented|. (l_advcl) prevented_30\VBN\1740|since|death|could|not|be|pretreatment (l_nmod) pretreatment_32\NN\1740|by|z-vad-fmk (l_nmod) z-vad-fmk_37\NN\1740|with|the|pancaspase|inhibitor (l_compound) pancaspase_35\NN\1740|
T2_T12 NONE bsc_23\NN\1740| (r_compound) 3_24\CD\13741022|bsc (r_compound) g_25\NN\13717155|after|3|or|3n (r_compound) treatment_28\NN\654885|g (r_nmod) detected_18\VBN\2163746|since|levels|could|be|cells|treatment (l_nsubjpass) levels_4\NNS\4916342|reduced|proteins|but|change (l_conj) change_12\NN\7283608|no|levels (l_nmod) levels_15\NNS\4916342|in|p53 (l_compound) p53_14\NN\1740|
T2_T19 CPR:4 bsc_23\NN\1740| (r_compound) 3_24\CD\13741022|bsc (r_compound) g_25\NN\13717155|after|3|or|3n (r_compound) treatment_28\NN\654885|g (r_nmod) detected_18\VBN\2163746|since|levels|could|be|cells|treatment (l_nsubjpass) levels_4\NNS\4916342|reduced|proteins|but|change (l_nmod) proteins_9\NNS\14944888|of|p21cip1 (l_compound) p21cip1_6\NN\1740|and|chk2
T2_T20 CPR:4 bsc_23\NN\1740| (r_compound) 3_24\CD\13741022|bsc (r_compound) g_25\NN\13717155|after|3|or|3n (r_compound) treatment_28\NN\654885|g (r_nmod) detected_18\VBN\2163746|since|levels|could|be|cells|treatment (l_nsubjpass) levels_4\NNS\4916342|reduced|proteins|but|change (l_nmod) proteins_9\NNS\14944888|of|p21cip1 (l_compound) p21cip1_6\NN\1740|and|chk2 (l_conj) chk2_8\NN\1740|
T3_T12 NONE bsc_33\NN\1740| (r_compound) cells_35\NNS\3080309|bsc|treated (r_nsubj) die_36\VBP\146138|that|cells|mitosis (r_ccomp) suggest_31\VBP\1010118|moreover|,|detected|results|die|. (l_advcl) detected_18\VBN\2163746|since|levels|could|be|cells|treatment (l_nsubjpass) levels_4\NNS\4916342|reduced|proteins|but|change (l_conj) change_12\NN\7283608|no|levels (l_nmod) levels_15\NNS\4916342|in|p53 (l_compound) p53_14\NN\1740|
T3_T19 NONE bsc_33\NN\1740| (r_compound) cells_35\NNS\3080309|bsc|treated (r_nsubj) die_36\VBP\146138|that|cells|mitosis (r_ccomp) suggest_31\VBP\1010118|moreover|,|detected|results|die|. (l_advcl) detected_18\VBN\2163746|since|levels|could|be|cells|treatment (l_nsubjpass) levels_4\NNS\4916342|reduced|proteins|but|change (l_nmod) proteins_9\NNS\14944888|of|p21cip1 (l_compound) p21cip1_6\NN\1740|and|chk2
T3_T20 NONE bsc_33\NN\1740| (r_compound) cells_35\NNS\3080309|bsc|treated (r_nsubj) die_36\VBP\146138|that|cells|mitosis (r_ccomp) suggest_31\VBP\1010118|moreover|,|detected|results|die|. (l_advcl) detected_18\VBN\2163746|since|levels|could|be|cells|treatment (l_nsubjpass) levels_4\NNS\4916342|reduced|proteins|but|change (l_nmod) proteins_9\NNS\14944888|of|p21cip1 (l_compound) p21cip1_6\NN\1740|and|chk2 (l_conj) chk2_8\NN\1740|
15992586
T27_T39 NONE benzoimidazole_1\NN\1740|2-[4-(3,4-dimethylphenyl)piperazin-1-ylmethyl]-1h|a-381393|,|antagonist|. (l_appos) antagonist_11\NN\7846|a|selective|receptor (l_compound) receptor_10\NN\5225602|dopamine|d4
T28_T39 NONE a-381393_3\CD\1740|(|) (r_appos) benzoimidazole_1\NN\1740|2-[4-(3,4-dimethylphenyl)piperazin-1-ylmethyl]-1h|a-381393|,|antagonist|. (l_appos) antagonist_11\NN\7846|a|selective|receptor (l_compound) receptor_10\NN\5225602|dopamine|d4
T29_T39 NONE dopamine_8\NN\14807737| (r_compound) receptor_10\NN\5225602|dopamine|d4
T1_T30 NONE benzoimidazole_1\NN\1740|2-[4-(3,4-dimethylphenlyl)piperazin-1-ylmethyl]-1h|a-381393 (r_nsubjpass) identified_6\VBN\699815|benzoimidazole|was|antagonist|. (l_nmod) antagonist_13\NN\7846|as|a|potent|dopamine|d4|receptor|selectivity (l_compound) receptor_12\NN\5225602|
T21_T30 NONE a-381393_3\CD\1740|(|) (r_appos) benzoimidazole_1\NN\1740|2-[4-(3,4-dimethylphenlyl)piperazin-1-ylmethyl]-1h|a-381393 (r_nsubjpass) identified_6\VBN\699815|benzoimidazole|was|antagonist|. (l_nmod) antagonist_13\NN\7846|as|a|potent|dopamine|d4|receptor|selectivity (l_compound) receptor_12\NN\5225602|
T3_T30 NONE dopamine_10\NN\14807737| (r_compound) antagonist_13\NN\7846|as|a|potent|dopamine|d4|receptor|selectivity (l_compound) receptor_12\NN\5225602|
T11_T33 NONE [3h]-spiperone_0\NN\1740| (r_compound) assays_3\NNS\5733583|[3h]-spiperone|competition|binding (r_nsubj) showed_4\VBD\2137132|assays|bound|. (l_ccomp) bound_8\VBD\1831531|that|a-381393|potently|membrane (l_nmod) membrane_10\NN\4188643|to|cells (l_nmod) cells_12\NNS\3080309|from|expressing (l_acl) expressing_13\VBG\928630|receptor (l_dobj) receptor_18\NN\5225602|recombinant|human|dopamine|d4.4|nm|,|higher
T12_T33 NONE a-381393_6\CD\1740| (r_nsubj) bound_8\VBD\1831531|that|a-381393|potently|membrane (l_nmod) membrane_10\NN\4188643|to|cells (l_nmod) cells_12\NNS\3080309|from|expressing (l_acl) expressing_13\VBG\928630|receptor (l_dobj) receptor_18\NN\5225602|recombinant|human|dopamine|d4.4|nm|,|higher
T13_T33 NONE dopamine_16\NN\14807737| (r_compound) receptor_18\NN\5225602|recombinant|human|dopamine|d4.4|nm|,|higher
T14_T33 NONE clozapine_31\NN\3713736|of|nm (r_nmod) that_29\DT\1740|than|clozapine (r_nmod) higher_27\JJR\1740|which|was|20-fold|that (r_acl:relcl) receptor_18\NN\5225602|recombinant|human|dopamine|d4.4|nm|,|higher
T15_T34 NONE a-381393_0\CD\1740| (r_nsubj) exhibited_1\VBD\2632167|a-381393|binding|compared|. (l_dobj) binding_4\NN\4688246|selective|receptor (l_nmod) receptor_9\NN\5225602|for|the|dopamine|d4.4|2700-fold
T15_T35 NONE a-381393_0\CD\1740| (r_nsubj) exhibited_1\VBD\2632167|a-381393|binding|compared|. (l_advcl) compared_15\VBN\644583|when|receptors (l_nmod) receptors_25\NNS\5225602|d1|dopamine
T16_T34 NONE dopamine_7\NN\14807737| (r_compound) receptor_9\NN\5225602|for|the|dopamine|d4.4|2700-fold
T16_T35 NONE dopamine_7\NN\14807737| (r_compound) receptor_9\NN\5225602|for|the|dopamine|d4.4|2700-fold (r_nmod) binding_4\NN\4688246|selective|receptor (r_dobj) exhibited_1\VBD\2632167|a-381393|binding|compared|. (l_advcl) compared_15\VBN\644583|when|receptors (l_nmod) receptors_25\NNS\5225602|d1|dopamine
T17_T34 NONE dopamine_24\NN\14807737| (r_compound) receptors_25\NNS\5225602|d1|dopamine (r_nmod) compared_15\VBN\644583|when|receptors (r_advcl) exhibited_1\VBD\2632167|a-381393|binding|compared|. (l_dobj) binding_4\NN\4688246|selective|receptor (l_nmod) receptor_9\NN\5225602|for|the|dopamine|d4.4|2700-fold
T17_T35 NONE dopamine_24\NN\14807737| (r_compound) receptors_25\NNS\5225602|d1|dopamine
T18_T36 NONE clozapine_5\NN\3713736|to|and|l-745870 (r_nmod) comparison_3\NN\635850|in|clozapine (r_nmod) exhibits_10\VBZ\2632167|furthermore|,|comparison|,|a-381393|selectivity|,|showing|. (l_advcl) showing_15\VBG\2137132|affinity|microm|panel|,|exception (l_nmod) exception_35\NN\5706954|with|the|affinity (l_nmod) affinity_38\NN\11426530|of|moderate|5-ht2a (l_nmod) 5-ht2a_40\NN\1740|for|nm
T19_T36 NONE l-745870_7\NN\1740| (r_conj) clozapine_5\NN\3713736|to|and|l-745870 (r_nmod) comparison_3\NN\635850|in|clozapine (r_nmod) exhibits_10\VBZ\2632167|furthermore|,|comparison|,|a-381393|selectivity|,|showing|. (l_advcl) showing_15\VBG\2137132|affinity|microm|panel|,|exception (l_nmod) exception_35\NN\5706954|with|the|affinity (l_nmod) affinity_38\NN\11426530|of|moderate|5-ht2a (l_nmod) 5-ht2a_40\NN\1740|for|nm
T20_T36 NONE a-381393_9\NNP\1740| (r_nsubj) exhibits_10\VBZ\2632167|furthermore|,|comparison|,|a-381393|selectivity|,|showing|. (l_advcl) showing_15\VBG\2137132|affinity|microm|panel|,|exception (l_nmod) exception_35\NN\5706954|with|the|affinity (l_nmod) affinity_38\NN\11426530|of|moderate|5-ht2a (l_nmod) 5-ht2a_40\NN\1740|for|nm
T22_T37 NONE a-381393_0\NN\1740| (r_nsubj) inhibited_2\VBD\2510337|a-381393|potently|activity|. (l_dobj) activity_5\NN\30358|the|functional|assay|cells (l_nmod) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_compound) receptor_22\NN\5225602|
T22_T38 NONE a-381393_0\NN\1740| (r_nsubj) inhibited_2\VBD\2510337|a-381393|potently|activity|. (l_dobj) activity_5\NN\30358|the|functional|assay|cells (l_nmod) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_conj) d2l_31\NN\1740|not|in|human|dopamine|or|cells (l_conj) cells_35\NNS\3080309|d3|receptor (l_compound) receptor_34\NN\5225602|
T23_T37 NONE gtp-gamma-s_8\NN\1740| (r_compound) assay_10\NN\5733583|of|agonist-induced|gtp-gamma-s|binding|and|flux (r_nmod) activity_5\NN\30358|the|functional|assay|cells (l_nmod) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_compound) receptor_22\NN\5225602|
T23_T38 NONE gtp-gamma-s_8\NN\1740| (r_compound) assay_10\NN\5733583|of|agonist-induced|gtp-gamma-s|binding|and|flux (r_nmod) activity_5\NN\30358|the|functional|assay|cells (l_nmod) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_conj) d2l_31\NN\1740|not|in|human|dopamine|or|cells (l_conj) cells_35\NNS\3080309|d3|receptor (l_compound) receptor_34\NN\5225602|
T24_T37 NONE dopamine_14\NN\14807737| (r_nmod:npmod) induced-ca2_15\NN\1740|dopamine (r_amod) flux_17\NN\15286249|microm|induced-ca2|+ (r_conj) assay_10\NN\5733583|of|agonist-induced|gtp-gamma-s|binding|and|flux (r_nmod) activity_5\NN\30358|the|functional|assay|cells (l_nmod) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_compound) receptor_22\NN\5225602|
T24_T38 NONE dopamine_14\NN\14807737| (r_nmod:npmod) induced-ca2_15\NN\1740|dopamine (r_amod) flux_17\NN\15286249|microm|induced-ca2|+ (r_conj) assay_10\NN\5733583|of|agonist-induced|gtp-gamma-s|binding|and|flux (r_nmod) activity_5\NN\30358|the|functional|assay|cells (l_nmod) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_conj) d2l_31\NN\1740|not|in|human|dopamine|or|cells (l_conj) cells_35\NNS\3080309|d3|receptor (l_compound) receptor_34\NN\5225602|
T25_T37 NONE +_16\NN\1740| (r_compound) flux_17\NN\15286249|microm|induced-ca2|+ (r_conj) assay_10\NN\5733583|of|agonist-induced|gtp-gamma-s|binding|and|flux (r_nmod) activity_5\NN\30358|the|functional|assay|cells (l_nmod) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_compound) receptor_22\NN\5225602|
T25_T38 NONE +_16\NN\1740| (r_compound) flux_17\NN\15286249|microm|induced-ca2|+ (r_conj) assay_10\NN\5733583|of|agonist-induced|gtp-gamma-s|binding|and|flux (r_nmod) activity_5\NN\30358|the|functional|assay|cells (l_nmod) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_conj) d2l_31\NN\1740|not|in|human|dopamine|or|cells (l_conj) cells_35\NNS\3080309|d3|receptor (l_compound) receptor_34\NN\5225602|
T26_T37 NONE dopamine_20\NN\14807737| (r_compound) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_compound) receptor_22\NN\5225602|
T26_T38 NONE dopamine_20\NN\14807737| (r_compound) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_conj) d2l_31\NN\1740|not|in|human|dopamine|or|cells (l_conj) cells_35\NNS\3080309|d3|receptor (l_compound) receptor_34\NN\5225602|
T2_T37 NONE dopamine_30\NN\14807737| (r_compound) d2l_31\NN\1740|not|in|human|dopamine|or|cells (r_conj) cells_24\NNS\3080309|in|human|dopamine|d4.4|receptor|expressing|,|but|d2l (l_compound) receptor_22\NN\5225602|
T2_T38 NONE dopamine_30\NN\14807737| (r_compound) d2l_31\NN\1740|not|in|human|dopamine|or|cells (l_conj) cells_35\NNS\3080309|d3|receptor (l_compound) receptor_34\NN\5225602|
T4_T31 NONE l-745870_3\NNP\1740|to (r_nmod) contrast_1\NN\13854649|in|l-745870 (r_nmod) exhibit_8\VB\2632167|contrast|,|a-381393|did|not|activity|receptor|. (l_nmod) receptor_16\NN\5225602|in|a|d4.4
T5_T31 NONE a-381393_5\NNP\1740| (r_nsubj) exhibit_8\VB\2632167|contrast|,|a-381393|did|not|activity|receptor|. (l_nmod) receptor_16\NN\5225602|in|a|d4.4
T10_T32 NONE dopamine_16\NN\14807737| (r_compound) receptors_18\NNS\5225602|dopamine|d4
T9_T32 NONE a-381393_2\NN\1740| (r_nsubj) antagonist_8\NN\7846|thus|,|a-381393|is|a|novel|selective|d4|enhance|. (l_acl:relcl) enhance_11\VB\227165|that|will|ability (l_dobj) ability_13\NN\4723816|the|study (l_acl) study_15\VB\630380|to|receptors|and (l_dobj) receptors_18\NNS\5225602|dopamine|d4
16371234
T16_T48 CPR:9 e2_12\NN\1740| (r_compound) production_13\NN\30358|in|liposome-induced|prostaglandin|e2|microglia (r_nmod) involvement_0\NN\1080366|cox-1|production|. (l_nmod) cox-1_2\NN\14737847|of|and|synthases
T16_T49 CPR:9 e2_12\NN\1740| (r_compound) production_13\NN\30358|in|liposome-induced|prostaglandin|e2|microglia (r_nmod) involvement_0\NN\1080366|cox-1|production|. (l_nmod) cox-1_2\NN\14737847|of|and|synthases (l_conj) synthases_7\NNS\1740|up-regulated|prostaglandin|e
T17_T48 NONE e_6\NN\14724645| (r_compound) synthases_7\NNS\1740|up-regulated|prostaglandin|e (r_conj) cox-1_2\NN\14737847|of|and|synthases
T17_T49 NONE e_6\NN\14724645| (r_compound) synthases_7\NNS\1740|up-regulated|prostaglandin|e
T18_T48 NONE phosphatidylserine_9\NN\1740| (r_nmod:npmod) liposome-induced_10\JJ\1740|phosphatidylserine (r_amod) production_13\NN\30358|in|liposome-induced|prostaglandin|e2|microglia (r_nmod) involvement_0\NN\1080366|cox-1|production|. (l_nmod) cox-1_2\NN\14737847|of|and|synthases
T18_T49 NONE phosphatidylserine_9\NN\1740| (r_nmod:npmod) liposome-induced_10\JJ\1740|phosphatidylserine (r_amod) production_13\NN\30358|in|liposome-induced|prostaglandin|e2|microglia (r_nmod) involvement_0\NN\1080366|cox-1|production|. (l_nmod) cox-1_2\NN\14737847|of|and|synthases (l_conj) synthases_7\NNS\1740|up-regulated|prostaglandin|e
T14_T42 NONE pge2_20\NN\1740| (r_compound) production_21\NN\30358|ps|liposome-induced|pge2 (r_dobj) suppressed_17\VBD\2510337|ligand|significantly|production|. (l_nsubj) ligand_2\NN\20090|the|specific|receptor|,|lipoprotein|, (l_nmod) receptor_7\NN\5225602|for|class|b|scavenger|sr-b
T14_T43 NONE pge2_20\NN\1740| (r_compound) production_21\NN\30358|ps|liposome-induced|pge2 (r_dobj) suppressed_17\VBD\2510337|ligand|significantly|production|. (l_nsubj) ligand_2\NN\20090|the|specific|receptor|,|lipoprotein|, (l_nmod) receptor_7\NN\5225602|for|class|b|scavenger|sr-b (l_appos) sr-b_9\NN\1740|(|)
T14_T44 NONE pge2_20\NN\1740| (r_compound) production_21\NN\30358|ps|liposome-induced|pge2 (r_dobj) suppressed_17\VBD\2510337|ligand|significantly|production|. (l_nsubj) ligand_2\NN\20090|the|specific|receptor|,|lipoprotein|, (l_appos) lipoprotein_14\NN\14731135|high|density
T15_T19 NONE e_5\NN\14724645| (r_compound) synthase-1_6\NN\1740|membrane-bound|prostaglandin|e|mpges-1 (l_appos) mpges-1_8\NN\1740|(|)
T15_T45 NONE e_5\NN\14724645| (r_compound) synthase-1_6\NN\1740|membrane-bound|prostaglandin|e|mpges-1 (r_conj) cyclooxygenase_0\NN\14732946|(cox)-2|and|synthase-1
T15_T46 NONE e_5\NN\14724645| (r_compound) synthase-1_6\NN\1740|membrane-bound|prostaglandin|e|mpges-1 (r_conj) cyclooxygenase_0\NN\14732946|(cox)-2|and|synthase-1 (l_punct) (cox)-2_1\NN\1740|
T15_T47 NONE e_5\NN\14724645| (r_compound) synthase-1_6\NN\1740|membrane-bound|prostaglandin|e|mpges-1
T3_T24 NONE pge2_4\NN\1740| (r_compound) production_5\NN\30358|liposome-induced|pge2 (r_nsubjpass) suppressed_8\VBN\2510337|furthermore|,|production|was|significantly|indomethacin|. (l_nmod) indomethacin_10\NN\3828465|by|,|inhibitor|,|but|ns-398 (l_appos) inhibitor_15\NN\20090|a|preferential|cox-1 (l_compound) cox-1_14\NN\14737847|
T3_T25 NONE pge2_4\NN\1740| (r_compound) production_5\NN\30358|liposome-induced|pge2 (r_nsubjpass) suppressed_8\VBN\2510337|furthermore|,|production|was|significantly|indomethacin|. (l_nmod) indomethacin_10\NN\3828465|by|,|inhibitor|,|but|ns-398 (l_conj) ns-398_20\NN\1740|not|by|,|inhibitor (l_appos) inhibitor_25\NN\20090|a|selective|cox-2 (l_compound) cox-2_24\NN\14737847|
T4_T24 CPR:4 indomethacin_10\NN\3828465|by|,|inhibitor|,|but|ns-398 (l_appos) inhibitor_15\NN\20090|a|preferential|cox-1 (l_compound) cox-1_14\NN\14737847|
T4_T25 NONE indomethacin_10\NN\3828465|by|,|inhibitor|,|but|ns-398 (l_conj) ns-398_20\NN\1740|not|by|,|inhibitor (l_appos) inhibitor_25\NN\20090|a|selective|cox-2 (l_compound) cox-2_24\NN\14737847|
T5_T24 NONE ns-398_20\NN\1740|not|by|,|inhibitor (r_conj) indomethacin_10\NN\3828465|by|,|inhibitor|,|but|ns-398 (l_appos) inhibitor_15\NN\20090|a|preferential|cox-1 (l_compound) cox-1_14\NN\14737847|
T5_T25 CPR:4 ns-398_20\NN\1740|not|by|,|inhibitor (l_appos) inhibitor_25\NN\20090|a|selective|cox-2 (l_compound) cox-2_24\NN\14737847|
T6_T33 CPR:9 pge2_27\NN\1740| (r_compound) production_28\NN\30358|in|liposome-induced|pge2|microglia (r_nmod) plays_20\VBZ\1072262|that|up-regulation|role|production (l_nsubj) up-regulation_6\NN\1740|the|pgess (l_nmod) pgess_9\NNS\1740|of|terminal|coupled|,
T6_T34 CPR:9 pge2_27\NN\1740| (r_compound) production_28\NN\30358|in|liposome-induced|pge2|microglia (r_nmod) plays_20\VBZ\1072262|that|up-regulation|role|production (l_nsubj) up-regulation_6\NN\1740|the|pgess (l_nmod) pgess_9\NNS\1740|of|terminal|coupled|, (l_acl:relcl) coupled_13\VBN\1295275|that|are|preferentially|cox-1 (l_nmod) cox-1_15\NN\14737847|with|,|mpges-2
T6_T35 CPR:9 pge2_27\NN\1740| (r_compound) production_28\NN\30358|in|liposome-induced|pge2|microglia (r_nmod) plays_20\VBZ\1072262|that|up-regulation|role|production (l_nsubj) up-regulation_6\NN\1740|the|pgess (l_nmod) pgess_9\NNS\1740|of|terminal|coupled|, (l_acl:relcl) coupled_13\VBN\1295275|that|are|preferentially|cox-1 (l_nmod) cox-1_15\NN\14737847|with|,|mpges-2 (l_appos) mpges-2_18\NN\1740|especially
T7_T36 NONE pge2_9\NN\1740| (r_compound) production_10\NN\30358|in|liposome-induced|pge2 (r_nmod) plays_2\VBZ\1072262|although|sr-bi|role|production (l_nsubj) sr-bi_1\NN\1740|
T7_T37 NONE pge2_9\NN\1740| (r_compound) production_10\NN\30358|in|liposome-induced|pge2 (r_nmod) plays_2\VBZ\1072262|although|sr-bi|role|production (r_advcl) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_nsubj) receptors_14\NNS\5225602|other|ps-recognizing|,|receptor|,
T7_T38 NONE pge2_9\NN\1740| (r_compound) production_10\NN\30358|in|liposome-induced|pge2 (r_nmod) plays_2\VBZ\1072262|although|sr-bi|role|production (r_advcl) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_nsubj) receptors_14\NNS\5225602|other|ps-recognizing|,|receptor|, (l_appos) receptor_18\NN\5225602|possibly|ps-specific
T7_T39 NONE pge2_9\NN\1740| (r_compound) production_10\NN\30358|in|liposome-induced|pge2 (r_nmod) plays_2\VBZ\1072262|although|sr-bi|role|production (r_advcl) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_advcl) transducing_26\VBG\381013|by|signals|treatment (l_dobj) signals_28\NNS\33020|intracellular|erk (l_nmod) erk_31\NN\1740|including|p44/p42 (l_compound) p44/p42_30\NN\1740|
T7_T40 NONE pge2_9\NN\1740| (r_compound) production_10\NN\30358|in|liposome-induced|pge2 (r_nmod) plays_2\VBZ\1072262|although|sr-bi|role|production (r_advcl) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_advcl) transducing_26\VBG\381013|by|signals|treatment (l_dobj) signals_28\NNS\33020|intracellular|erk (l_nmod) erk_31\NN\1740|including|p44/p42 (l_compound) p44/p42_30\NN\1740|
T7_T41 NONE pge2_9\NN\1740| (r_compound) production_10\NN\30358|in|liposome-induced|pge2 (r_nmod) plays_2\VBZ\1072262|although|sr-bi|role|production (r_advcl) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_advcl) transducing_26\VBG\381013|by|signals|treatment (l_dobj) signals_28\NNS\33020|intracellular|erk (l_nmod) erk_31\NN\1740|including|p44/p42
T8_T36 NONE pge2_23\NN\1740| (r_compound) production_24\NN\30358|pge2 (r_dobj) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_advcl) plays_2\VBZ\1072262|although|sr-bi|role|production (l_nsubj) sr-bi_1\NN\1740|
T8_T37 NONE pge2_23\NN\1740| (r_compound) production_24\NN\30358|pge2 (r_dobj) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_nsubj) receptors_14\NNS\5225602|other|ps-recognizing|,|receptor|,
T8_T38 NONE pge2_23\NN\1740| (r_compound) production_24\NN\30358|pge2 (r_dobj) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_nsubj) receptors_14\NNS\5225602|other|ps-recognizing|,|receptor|, (l_appos) receptor_18\NN\5225602|possibly|ps-specific
T8_T39 NONE pge2_23\NN\1740| (r_compound) production_24\NN\30358|pge2 (r_dobj) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_advcl) transducing_26\VBG\381013|by|signals|treatment (l_dobj) signals_28\NNS\33020|intracellular|erk (l_nmod) erk_31\NN\1740|including|p44/p42 (l_compound) p44/p42_30\NN\1740|
T8_T40 NONE pge2_23\NN\1740| (r_compound) production_24\NN\30358|pge2 (r_dobj) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_advcl) transducing_26\VBG\381013|by|signals|treatment (l_dobj) signals_28\NNS\33020|intracellular|erk (l_nmod) erk_31\NN\1740|including|p44/p42 (l_compound) p44/p42_30\NN\1740|
T8_T41 NONE pge2_23\NN\1740| (r_compound) production_24\NN\30358|pge2 (r_dobj) promote_22\VB\2556126|plays|,|receptors|could|also|production|transducing|. (l_advcl) transducing_26\VBG\381013|by|signals|treatment (l_dobj) signals_28\NNS\33020|intracellular|erk (l_nmod) erk_31\NN\1740|including|p44/p42
10579749
T33_T45 NONE ii_4\CD\13741022| (r_nummod) antagonists_6\NNS\7846|of|angiotensin|ii|receptor (l_compound) receptor_5\NN\5225602|
T16_T37 NONE renin-angiotensin-aldosterone_34\JJ\1740|
T16_T38 NONE renin-angiotensin-aldosterone_34\JJ\1740|
T16_T39 NONE renin-angiotensin-aldosterone_34\JJ\1740| (r_amod) system_35\NN\3575240|the|renin-angiotensin-aldosterone (r_dobj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_nmod) level_38\NN\4916342|at|the|receptor (l_nmod) receptor_42\NN\5225602|of|the|at1|mediates (l_compound) at1_41\NN\1740|
T16_T40 NONE renin-angiotensin-aldosterone_34\JJ\1740| (r_amod) system_35\NN\3575240|the|renin-angiotensin-aldosterone (r_dobj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_nmod) level_38\NN\4916342|at|the|receptor (l_nmod) receptor_42\NN\5225602|of|the|at1|mediates (l_acl:relcl) mediates_44\VBZ\761713|that|most|, (l_dobj) most_45\JJS\1740|not|all|,|actions (l_nmod) actions_54\NNS\30358|of|the|important|angiotensin (l_nmod) angiotensin_56\NN\4522421|of|ii (l_nummod) ii_57\CD\13741022|
T16_T41 NONE renin-angiotensin-aldosterone_34\JJ\1740| (r_amod) system_35\NN\3575240|the|renin-angiotensin-aldosterone (r_dobj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_conj) avoid_60\VB\2452885|nonspecificity (l_dobj) nonspecificity_62\NN\1740|the|inhibitors (l_nmod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (l_compound) enzyme_68\NN\14723628|
T16_T43 NONE renin-angiotensin-aldosterone_34\JJ\1740| (r_amod) system_35\NN\3575240|the|renin-angiotensin-aldosterone (r_dobj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (r_acl) benefits_29\NNS\13278375|the|blocking (r_dobj) obtain_27\VB\2210855|to|benefits (r_acl) opportunity_25\NN\14481929|the|obtain (r_dobj) provided_23\VBN\2199590|availability|has|opportunity|. (l_nsubj) availability_1\NN\4718563|the|antagonists (l_nmod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (l_compound) receptor_20\NN\5225602|
T17_T37 NONE renin-angiotensin-aldosterone_34\JJ\1740|
T17_T38 NONE renin-angiotensin-aldosterone_34\JJ\1740|
T17_T39 NONE renin-angiotensin-aldosterone_34\JJ\1740| (r_amod) system_35\NN\3575240|the|renin-angiotensin-aldosterone (r_dobj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_nmod) level_38\NN\4916342|at|the|receptor (l_nmod) receptor_42\NN\5225602|of|the|at1|mediates (l_compound) at1_41\NN\1740|
T17_T40 NONE renin-angiotensin-aldosterone_34\JJ\1740| (r_amod) system_35\NN\3575240|the|renin-angiotensin-aldosterone (r_dobj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_nmod) level_38\NN\4916342|at|the|receptor (l_nmod) receptor_42\NN\5225602|of|the|at1|mediates (l_acl:relcl) mediates_44\VBZ\761713|that|most|, (l_dobj) most_45\JJS\1740|not|all|,|actions (l_nmod) actions_54\NNS\30358|of|the|important|angiotensin (l_nmod) angiotensin_56\NN\4522421|of|ii (l_nummod) ii_57\CD\13741022|
T17_T41 NONE renin-angiotensin-aldosterone_34\JJ\1740| (r_amod) system_35\NN\3575240|the|renin-angiotensin-aldosterone (r_dobj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_conj) avoid_60\VB\2452885|nonspecificity (l_dobj) nonspecificity_62\NN\1740|the|inhibitors (l_nmod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (l_compound) enzyme_68\NN\14723628|
T17_T43 NONE renin-angiotensin-aldosterone_34\JJ\1740| (r_amod) system_35\NN\3575240|the|renin-angiotensin-aldosterone (r_dobj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (r_acl) benefits_29\NNS\13278375|the|blocking (r_dobj) obtain_27\VB\2210855|to|benefits (r_acl) opportunity_25\NN\14481929|the|obtain (r_dobj) provided_23\VBN\2199590|availability|has|opportunity|. (l_nsubj) availability_1\NN\4718563|the|antagonists (l_nmod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (l_compound) receptor_20\NN\5225602|
T18_T37 NONE ii_57\CD\13741022| (r_nummod) angiotensin_56\NN\4522421|of|ii (r_nmod) actions_54\NNS\30358|of|the|important|angiotensin (r_nmod) most_45\JJS\1740|not|all|,|actions (r_dobj) mediates_44\VBZ\761713|that|most|, (r_acl:relcl) receptor_42\NN\5225602|of|the|at1|mediates (r_nmod) level_38\NN\4916342|at|the|receptor (r_nmod) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_dobj) system_35\NN\3575240|the|renin-angiotensin-aldosterone (l_amod) renin-angiotensin-aldosterone_34\JJ\1740|
T18_T38 NONE ii_57\CD\13741022| (r_nummod) angiotensin_56\NN\4522421|of|ii (r_nmod) actions_54\NNS\30358|of|the|important|angiotensin (r_nmod) most_45\JJS\1740|not|all|,|actions (r_dobj) mediates_44\VBZ\761713|that|most|, (r_acl:relcl) receptor_42\NN\5225602|of|the|at1|mediates (r_nmod) level_38\NN\4916342|at|the|receptor (r_nmod) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_dobj) system_35\NN\3575240|the|renin-angiotensin-aldosterone (l_amod) renin-angiotensin-aldosterone_34\JJ\1740|
T18_T39 NONE ii_57\CD\13741022| (r_nummod) angiotensin_56\NN\4522421|of|ii (r_nmod) actions_54\NNS\30358|of|the|important|angiotensin (r_nmod) most_45\JJS\1740|not|all|,|actions (r_dobj) mediates_44\VBZ\761713|that|most|, (r_acl:relcl) receptor_42\NN\5225602|of|the|at1|mediates (l_compound) at1_41\NN\1740|
T18_T40 NONE ii_57\CD\13741022|
T18_T41 NONE ii_57\CD\13741022| (r_nummod) angiotensin_56\NN\4522421|of|ii (r_nmod) actions_54\NNS\30358|of|the|important|angiotensin (r_nmod) most_45\JJS\1740|not|all|,|actions (r_dobj) mediates_44\VBZ\761713|that|most|, (r_acl:relcl) receptor_42\NN\5225602|of|the|at1|mediates (r_nmod) level_38\NN\4916342|at|the|receptor (r_nmod) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_conj) avoid_60\VB\2452885|nonspecificity (l_dobj) nonspecificity_62\NN\1740|the|inhibitors (l_nmod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (l_compound) enzyme_68\NN\14723628|
T18_T43 NONE ii_57\CD\13741022| (r_nummod) angiotensin_56\NN\4522421|of|ii (r_nmod) actions_54\NNS\30358|of|the|important|angiotensin (r_nmod) most_45\JJS\1740|not|all|,|actions (r_dobj) mediates_44\VBZ\761713|that|most|, (r_acl:relcl) receptor_42\NN\5225602|of|the|at1|mediates (r_nmod) level_38\NN\4916342|at|the|receptor (r_nmod) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (r_acl) benefits_29\NNS\13278375|the|blocking (r_dobj) obtain_27\VB\2210855|to|benefits (r_acl) opportunity_25\NN\14481929|the|obtain (r_dobj) provided_23\VBN\2199590|availability|has|opportunity|. (l_nsubj) availability_1\NN\4718563|the|antagonists (l_nmod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (l_compound) receptor_20\NN\5225602|
T19_T37 NONE i_66\CD\14622893| (r_nummod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (r_nmod) nonspecificity_62\NN\1740|the|inhibitors (r_dobj) avoid_60\VB\2452885|nonspecificity (r_conj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_dobj) system_35\NN\3575240|the|renin-angiotensin-aldosterone (l_amod) renin-angiotensin-aldosterone_34\JJ\1740|
T19_T38 NONE i_66\CD\14622893| (r_nummod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (r_nmod) nonspecificity_62\NN\1740|the|inhibitors (r_dobj) avoid_60\VB\2452885|nonspecificity (r_conj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_dobj) system_35\NN\3575240|the|renin-angiotensin-aldosterone (l_amod) renin-angiotensin-aldosterone_34\JJ\1740|
T19_T39 NONE i_66\CD\14622893| (r_nummod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (r_nmod) nonspecificity_62\NN\1740|the|inhibitors (r_dobj) avoid_60\VB\2452885|nonspecificity (r_conj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_nmod) level_38\NN\4916342|at|the|receptor (l_nmod) receptor_42\NN\5225602|of|the|at1|mediates (l_compound) at1_41\NN\1740|
T19_T40 NONE i_66\CD\14622893| (r_nummod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (r_nmod) nonspecificity_62\NN\1740|the|inhibitors (r_dobj) avoid_60\VB\2452885|nonspecificity (r_conj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_nmod) level_38\NN\4916342|at|the|receptor (l_nmod) receptor_42\NN\5225602|of|the|at1|mediates (l_acl:relcl) mediates_44\VBZ\761713|that|most|, (l_dobj) most_45\JJS\1740|not|all|,|actions (l_nmod) actions_54\NNS\30358|of|the|important|angiotensin (l_nmod) angiotensin_56\NN\4522421|of|ii (l_nummod) ii_57\CD\13741022|
T19_T41 NONE i_66\CD\14622893| (r_nummod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (l_compound) enzyme_68\NN\14723628|
T19_T43 NONE i_66\CD\14622893| (r_nummod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (r_nmod) nonspecificity_62\NN\1740|the|inhibitors (r_dobj) avoid_60\VB\2452885|nonspecificity (r_conj) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (r_acl) benefits_29\NNS\13278375|the|blocking (r_dobj) obtain_27\VB\2210855|to|benefits (r_acl) opportunity_25\NN\14481929|the|obtain (r_dobj) provided_23\VBN\2199590|availability|has|opportunity|. (l_nsubj) availability_1\NN\4718563|the|antagonists (l_nmod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (l_compound) receptor_20\NN\5225602|
T29_T37 NONE ii_14\CD\13741022| (r_nummod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (r_nmod) availability_1\NN\4718563|the|antagonists (r_nsubj) provided_23\VBN\2199590|availability|has|opportunity|. (l_dobj) opportunity_25\NN\14481929|the|obtain (l_acl) obtain_27\VB\2210855|to|benefits (l_dobj) benefits_29\NNS\13278375|the|blocking (l_acl) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_dobj) system_35\NN\3575240|the|renin-angiotensin-aldosterone (l_amod) renin-angiotensin-aldosterone_34\JJ\1740|
T29_T38 NONE ii_14\CD\13741022| (r_nummod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (r_nmod) availability_1\NN\4718563|the|antagonists (r_nsubj) provided_23\VBN\2199590|availability|has|opportunity|. (l_dobj) opportunity_25\NN\14481929|the|obtain (l_acl) obtain_27\VB\2210855|to|benefits (l_dobj) benefits_29\NNS\13278375|the|blocking (l_acl) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_dobj) system_35\NN\3575240|the|renin-angiotensin-aldosterone (l_amod) renin-angiotensin-aldosterone_34\JJ\1740|
T29_T39 NONE ii_14\CD\13741022| (r_nummod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (r_nmod) availability_1\NN\4718563|the|antagonists (r_nsubj) provided_23\VBN\2199590|availability|has|opportunity|. (l_dobj) opportunity_25\NN\14481929|the|obtain (l_acl) obtain_27\VB\2210855|to|benefits (l_dobj) benefits_29\NNS\13278375|the|blocking (l_acl) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_nmod) level_38\NN\4916342|at|the|receptor (l_nmod) receptor_42\NN\5225602|of|the|at1|mediates (l_compound) at1_41\NN\1740|
T29_T40 NONE ii_14\CD\13741022| (r_nummod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (r_nmod) availability_1\NN\4718563|the|antagonists (r_nsubj) provided_23\VBN\2199590|availability|has|opportunity|. (l_dobj) opportunity_25\NN\14481929|the|obtain (l_acl) obtain_27\VB\2210855|to|benefits (l_dobj) benefits_29\NNS\13278375|the|blocking (l_acl) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_nmod) level_38\NN\4916342|at|the|receptor (l_nmod) receptor_42\NN\5225602|of|the|at1|mediates (l_acl:relcl) mediates_44\VBZ\761713|that|most|, (l_dobj) most_45\JJS\1740|not|all|,|actions (l_nmod) actions_54\NNS\30358|of|the|important|angiotensin (l_nmod) angiotensin_56\NN\4522421|of|ii (l_nummod) ii_57\CD\13741022|
T29_T41 NONE ii_14\CD\13741022| (r_nummod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (r_nmod) availability_1\NN\4718563|the|antagonists (r_nsubj) provided_23\VBN\2199590|availability|has|opportunity|. (l_dobj) opportunity_25\NN\14481929|the|obtain (l_acl) obtain_27\VB\2210855|to|benefits (l_dobj) benefits_29\NNS\13278375|the|blocking (l_acl) blocking_32\VBG\1476483|of|selectively|system|level|and|avoid (l_conj) avoid_60\VB\2452885|nonspecificity (l_dobj) nonspecificity_62\NN\1740|the|inhibitors (l_nmod) inhibitors_69\NNS\20090|of|the|angiotensin|i|converting|enzyme (l_compound) enzyme_68\NN\14723628|
T29_T43 NONE ii_14\CD\13741022| (r_nummod) antagonists_21\NNS\7846|of|acting|nonpeptide|angiotensin|ii|type|1|(|at1|)|receptor (l_compound) receptor_20\NN\5225602|
T1_T44 CPR:6 losartan_35\NN\1740|of (r_nmod) metabolite_33\NN\20090|(|the|active|losartan|) (r_appos) e3174_29\NN\1740|metabolite|10 (r_conj) candesartan_23\NN\1740|antagonists|,|order|is|:|1|,|telmisartan|,|e3174|,|tasosartan|,|losartan|,|eprosartan|and|cilexetil|. (l_nmod) antagonists_5\NNS\7846|among|the|current|at1|receptor (l_compound) at1_3\NN\1740|
T2_T44 CPR:6 tasosartan_39\NN\1740|20 (r_conj) candesartan_23\NN\1740|antagonists|,|order|is|:|1|,|telmisartan|,|e3174|,|tasosartan|,|losartan|,|eprosartan|and|cilexetil|. (l_nmod) antagonists_5\NNS\7846|among|the|current|at1|receptor (l_compound) at1_3\NN\1740|
T30_T44 CPR:6 candesartan_23\NN\1740|antagonists|,|order|is|:|1|,|telmisartan|,|e3174|,|tasosartan|,|losartan|,|eprosartan|and|cilexetil|. (l_nmod) antagonists_5\NNS\7846|among|the|current|at1|receptor (l_compound) at1_3\NN\1740|
T31_T44 CPR:6 telmisartan_26\NN\1740|10 (r_conj) candesartan_23\NN\1740|antagonists|,|order|is|:|1|,|telmisartan|,|e3174|,|tasosartan|,|losartan|,|eprosartan|and|cilexetil|. (l_nmod) antagonists_5\NNS\7846|among|the|current|at1|receptor (l_compound) at1_3\NN\1740|
T32_T44 CPR:6 e3174_29\NN\1740|metabolite|10 (r_conj) candesartan_23\NN\1740|antagonists|,|order|is|:|1|,|telmisartan|,|e3174|,|tasosartan|,|losartan|,|eprosartan|and|cilexetil|. (l_nmod) antagonists_5\NNS\7846|among|the|current|at1|receptor (l_compound) at1_3\NN\1740|
T3_T44 CPR:6 losartan_42\NN\1740|50 (r_conj) candesartan_23\NN\1740|antagonists|,|order|is|:|1|,|telmisartan|,|e3174|,|tasosartan|,|losartan|,|eprosartan|and|cilexetil|. (l_nmod) antagonists_5\NNS\7846|among|the|current|at1|receptor (l_compound) at1_3\NN\1740|
T4_T44 CPR:6 eprosartan_45\NN\1740|100 (r_conj) candesartan_23\NN\1740|antagonists|,|order|is|:|1|,|telmisartan|,|e3174|,|tasosartan|,|losartan|,|eprosartan|and|cilexetil|. (l_nmod) antagonists_5\NNS\7846|among|the|current|at1|receptor (l_compound) at1_3\NN\1740|
T5_T44 CPR:6 cilexetil_51\NN\1740|the|prodrug|candesartan|280 (r_conj) candesartan_23\NN\1740|antagonists|,|order|is|:|1|,|telmisartan|,|e3174|,|tasosartan|,|losartan|,|eprosartan|and|cilexetil|. (l_nmod) antagonists_5\NNS\7846|among|the|current|at1|receptor (l_compound) at1_3\NN\1740|
T10_T34 CPR:6 saprisartan_26\NN\1740| (r_appos) candesartan_24\NN\1740|(|,|saprisartan|,|zolasartan|,|irbesartan|,|valsartan|,|telmisartan|,|e3174|) (r_dep) insurmountable/noncompetitive_22\JJ\1740|candesartan (r_conj) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T11_T34 CPR:6 zolasartan_28\NN\1740| (r_appos) candesartan_24\NN\1740|(|,|saprisartan|,|zolasartan|,|irbesartan|,|valsartan|,|telmisartan|,|e3174|) (r_dep) insurmountable/noncompetitive_22\JJ\1740|candesartan (r_conj) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T12_T34 CPR:6 irbesartan_30\NN\1740| (r_appos) candesartan_24\NN\1740|(|,|saprisartan|,|zolasartan|,|irbesartan|,|valsartan|,|telmisartan|,|e3174|) (r_dep) insurmountable/noncompetitive_22\JJ\1740|candesartan (r_conj) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T13_T34 CPR:6 valsartan_32\NN\2712393| (r_appos) candesartan_24\NN\1740|(|,|saprisartan|,|zolasartan|,|irbesartan|,|valsartan|,|telmisartan|,|e3174|) (r_dep) insurmountable/noncompetitive_22\JJ\1740|candesartan (r_conj) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T14_T34 CPR:6 telmisartan_34\NN\1740| (r_appos) candesartan_24\NN\1740|(|,|saprisartan|,|zolasartan|,|irbesartan|,|valsartan|,|telmisartan|,|e3174|) (r_dep) insurmountable/noncompetitive_22\JJ\1740|candesartan (r_conj) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T15_T34 CPR:6 e3174_36\NN\1740| (r_appos) candesartan_24\NN\1740|(|,|saprisartan|,|zolasartan|,|irbesartan|,|valsartan|,|telmisartan|,|e3174|) (r_dep) insurmountable/noncompetitive_22\JJ\1740|candesartan (r_conj) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T6_T34 CPR:6 losartan_15\NN\1740|(|,|tasosartan|,|eprosartan|) (r_dep) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T7_T34 CPR:6 tasosartan_17\NN\1740| (r_appos) losartan_15\NN\1740|(|,|tasosartan|,|eprosartan|) (r_dep) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T8_T34 CPR:6 eprosartan_19\NN\1740| (r_appos) losartan_15\NN\1740|(|,|tasosartan|,|eprosartan|) (r_dep) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
T9_T34 CPR:6 candesartan_24\NN\1740|(|,|saprisartan|,|zolasartan|,|irbesartan|,|valsartan|,|telmisartan|,|e3174|) (r_dep) insurmountable/noncompetitive_22\JJ\1740|candesartan (r_conj) surmountable/noncompetitive_13\JJ\1740|as|losartan|or|insurmountable/noncompetitive (r_nmod) characterized_11\VBN\609683|mode|has|been|surmountable/noncompetitive|. (l_nsubjpass) mode_1\NN\4916342|the|antagonism (l_nmod) antagonism_8\NN\24720|of|functional|)|at1|receptor (l_compound) at1_6\NN\1740|
23376546
T20_T34 NONE bup-related_19\JJ\1740| (r_amod) toxicity_21\NN\13576101|to|bup-related|respiratory (r_nmod) contributes_16\VBZ\126264|that|modulation|highly|toxicity|,|limiting (l_nsubj) modulation_8\NN\7044917|p-glycoprotein|barrier (l_compound) p-glycoprotein_4\NN\1740|p-gp
T20_T35 NONE bup-related_19\JJ\1740| (r_amod) toxicity_21\NN\13576101|to|bup-related|respiratory (r_nmod) contributes_16\VBZ\126264|that|modulation|highly|toxicity|,|limiting (l_nsubj) modulation_8\NN\7044917|p-glycoprotein|barrier (l_compound) p-glycoprotein_4\NN\1740|p-gp (l_appos) p-gp_6\NN\1740|(|)
T21_T34 NONE nbup_25\NN\1740| (r_compound) entrance_26\NN\2671062|nbup|brain (r_dobj) limiting_24\VBG\2510337|by|entrance (r_advcl) contributes_16\VBZ\126264|that|modulation|highly|toxicity|,|limiting (l_nsubj) modulation_8\NN\7044917|p-glycoprotein|barrier (l_compound) p-glycoprotein_4\NN\1740|p-gp
T21_T35 NONE nbup_25\NN\1740| (r_compound) entrance_26\NN\2671062|nbup|brain (r_dobj) limiting_24\VBG\2510337|by|entrance (r_advcl) contributes_16\VBZ\126264|that|modulation|highly|toxicity|,|limiting (l_nsubj) modulation_8\NN\7044917|p-glycoprotein|barrier (l_compound) p-glycoprotein_4\NN\1740|p-gp (l_appos) p-gp_6\NN\1740|(|)
T23_T36 NONE bup_22\NN\1740|of|and|effects (r_nmod) gender_17\NN\6309383|in|and|variability|bup|mice (r_nmod) role_9\NN\719494|the|transport|gender (l_nmod) transport_12\NN\3575240|of|p-gp-mediated|bbb (l_amod) p-gp-mediated_11\JJ\1740|
T24_T36 NONE nbup-induced_24\JJ\1740| (r_amod) effects_26\NNS\13245626|nbup-induced|respiratory (r_conj) bup_22\NN\1740|of|and|effects (r_nmod) gender_17\NN\6309383|in|and|variability|bup|mice (r_nmod) role_9\NN\719494|the|transport|gender (l_nmod) transport_12\NN\3575240|of|p-gp-mediated|bbb (l_amod) p-gp-mediated_11\JJ\1740|
T12_T32 NONE bup_6\NN\1740|and|nbup (r_compound) transport_9\NN\3575240|bup|bbb (r_conj) expression_4\NN\4679549|in|p-gp|or|transport (l_compound) p-gp_3\NN\1740|
T13_T32 NONE nbup_8\NN\1740| (r_conj) bup_6\NN\1740|and|nbup (r_compound) transport_9\NN\3575240|bup|bbb (r_conj) expression_4\NN\4679549|in|p-gp|or|transport (l_compound) p-gp_3\NN\1740|
T15_T33 NONE bup_20\NN\1740|in|and|toxicity|mice (r_nmod) variability_18\NN\4733640|in|gender|bup (r_nmod) play_11\VB\1072262|that|transport|does|not|key-role|variability (l_nsubj) transport_5\NN\3575240|p-gp-mediated|bbb (l_amod) p-gp-mediated_4\JJ\1740|
T16_T33 NONE nbup-induced_22\JJ\1740| (r_amod) toxicity_24\NN\13576101|nbup-induced|respiratory (r_conj) bup_20\NN\1740|in|and|toxicity|mice (r_nmod) variability_18\NN\4733640|in|gender|bup (r_nmod) play_11\VB\1072262|that|transport|does|not|key-role|variability (l_nsubj) transport_5\NN\3575240|p-gp-mediated|bbb (l_amod) p-gp-mediated_4\JJ\1740|
22614014
T1_T2 NONE cysteine_12\NN\14601829| (r_compound) k_15\NN\13608598|including|cysteine|protease|cathepsin|ctsk (r_nmod) factors_7\NNS\7326557|of|inflammatory|and|proteases|k (l_conj) proteases_9\NNS\14732946|,
T1_T3 NONE cysteine_12\NN\14601829| (r_compound) k_15\NN\13608598|including|cysteine|protease|cathepsin|ctsk (l_compound) protease_13\NN\14732946|
T1_T4 NONE cysteine_12\NN\14601829| (r_compound) k_15\NN\13608598|including|cysteine|protease|cathepsin|ctsk
T1_T5 NONE cysteine_12\NN\14601829| (r_compound) k_15\NN\13608598|including|cysteine|protease|cathepsin|ctsk (l_appos) ctsk_17\NN\1740|(|)
15854045
T1_T4 NONE )_16\-RRB-\1740| (r_punct) +_15\NN\1740|ca(2|) (r_compound) manner_18\NN\4916342|in|a|+|ion-dependent (r_nmod) convert_5\VBP\126264|deiminases|residues|residues|manner|. (l_nsubj) deiminases_1\NNS\1740|peptidylarginine|pad
T1_T8 NONE )_16\-RRB-\1740| (r_punct) +_15\NN\1740|ca(2|) (r_compound) manner_18\NN\4916342|in|a|+|ion-dependent (r_nmod) convert_5\VBP\126264|deiminases|residues|residues|manner|. (l_nsubj) deiminases_1\NNS\1740|peptidylarginine|pad (l_appos) pad_3\NN\14974264|(|)
T2_T4 NONE arginine_7\NN\14605787| (r_compound) residues_8\NNS\20827|protein-bound|arginine (r_dobj) convert_5\VBP\126264|deiminases|residues|residues|manner|. (l_nsubj) deiminases_1\NNS\1740|peptidylarginine|pad
T2_T8 NONE arginine_7\NN\14605787| (r_compound) residues_8\NNS\20827|protein-bound|arginine (r_dobj) convert_5\VBP\126264|deiminases|residues|residues|manner|. (l_nsubj) deiminases_1\NNS\1740|peptidylarginine|pad (l_appos) pad_3\NN\14974264|(|)
T3_T4 NONE citrulline_10\NN\14601829| (r_compound) residues_11\NNS\20827|into|citrulline (r_nmod) convert_5\VBP\126264|deiminases|residues|residues|manner|. (l_nsubj) deiminases_1\NNS\1740|peptidylarginine|pad
T3_T8 NONE citrulline_10\NN\14601829| (r_compound) residues_11\NNS\20827|into|citrulline (r_nmod) convert_5\VBP\126264|deiminases|residues|residues|manner|. (l_nsubj) deiminases_1\NNS\1740|peptidylarginine|pad (l_appos) pad_3\NN\14974264|(|)
6725552
T10_T27 NONE polyacrylamide_14\NN\1740| (r_compound) electrophoresis_16\NN\13518963|by|sulfate|polyacrylamide|gel|sds-page (r_nmod) analyzed_2\VBD\78760|we|also|formation|electrophoresis|. (l_dobj) formation_4\NN\7938773|the|complexes (l_nmod) complexes_9\NNS\5869584|of|125i-factor|xiif|-inhibitor (l_compound) xiif_7\NN\1740|
T8_T27 NONE 125i-factor_6\NN\1740| (r_amod) complexes_9\NNS\5869584|of|125i-factor|xiif|-inhibitor (l_compound) xiif_7\NN\1740|
T9_T27 NONE sulfate_13\NN\15010703|sodium|dodecyl (r_compound) electrophoresis_16\NN\13518963|by|sulfate|polyacrylamide|gel|sds-page (r_nmod) analyzed_2\VBD\78760|we|also|formation|electrophoresis|. (l_dobj) formation_4\NN\7938773|the|complexes (l_nmod) complexes_9\NNS\5869584|of|125i-factor|xiif|-inhibitor (l_compound) xiif_7\NN\1740|
T11_T28 NONE c-1-inhibitor_15\NN\1740|with|,|2-antiplasmin|,|and|antithrombin (r_nmod) reactions_10\NNS\13446390|for|the|xiif|c-1-inhibitor (l_nmod) xiif_13\NN\1740|of|factor
T11_T29 NONE c-1-inhibitor_15\NN\1740|with|,|2-antiplasmin|,|and|antithrombin
T11_T30 NONE c-1-inhibitor_15\NN\1740|with|,|2-antiplasmin|,|and|antithrombin (l_conj) 2-antiplasmin_18\NN\1740|alpha
T11_T31 NONE c-1-inhibitor_15\NN\1740|with|,|2-antiplasmin|,|and|antithrombin (l_conj) antithrombin_21\NN\1740|iii (l_nummod) iii_22\CD\13741022|
T12_T32 NONE 125i-factor_12\NN\1740| (r_compound) xiif_13\NN\1740|between|125i-factor|and|each
T1_T14 NONE c-1-inhibitor_29\NN\1740|of (r_nmod) less_23\JJR\1740|%|c-1-inhibitor (r_dep) immunodepleted_21\VBN\1740|that|had|been|(|less (r_acl:relcl) plasma_17\NN\5398023|by|prekallikrein-deficient|immunodepleted (r_nmod) inactivated_14\VBN\1097743|when|xiif|was|plasma (l_nsubjpass) xiif_12\NN\1740|factor
T1_T15 NONE c-1-inhibitor_29\NN\1740|of (r_nmod) less_23\JJR\1740|%|c-1-inhibitor (r_dep) immunodepleted_21\VBN\1740|that|had|been|(|less (r_acl:relcl) plasma_17\NN\5398023|by|prekallikrein-deficient|immunodepleted (l_amod) prekallikrein-deficient_16\JJ\1740|
T1_T16 NONE c-1-inhibitor_29\NN\1740|of
T2_T17 NONE 125i-factor_14\NN\1740| (r_compound) xiif_15\NN\1740|of|the|active|125i-factor
T2_T18 NONE 125i-factor_14\NN\1740| (r_compound) xiif_15\NN\1740|of|the|active|125i-factor (r_nmod) %_10\NN\1740|74|xiif (r_nsubjpass) found_17\VBN\2426171|addition|,|inactivation|,|%|was|form|,|whereas|formed|. (l_xcomp) form_19\VB\1617192|to|complex|c-1-inhibitor (l_nmod) c-1-inhibitor_23\NN\1740|with
T2_T19 NONE 125i-factor_14\NN\1740| (r_compound) xiif_15\NN\1740|of|the|active|125i-factor (r_nmod) %_10\NN\1740|74|xiif (r_nsubjpass) found_17\VBN\2426171|addition|,|inactivation|,|%|was|form|,|whereas|formed|. (l_parataxis) formed_31\VBD\1617192|%|complexes|2-antiplasmin (l_nmod) 2-antiplasmin_35\NN\1740|with|alpha|and|antithrombin
T2_T20 NONE 125i-factor_14\NN\1740| (r_compound) xiif_15\NN\1740|of|the|active|125i-factor (r_nmod) %_10\NN\1740|74|xiif (r_nsubjpass) found_17\VBN\2426171|addition|,|inactivation|,|%|was|form|,|whereas|formed|. (l_parataxis) formed_31\VBD\1617192|%|complexes|2-antiplasmin (l_nmod) 2-antiplasmin_35\NN\1740|with|alpha|and|antithrombin (l_conj) antithrombin_37\NN\1740|iii (l_nummod) iii_38\CD\13741022|
T3_T17 NONE c-1-inhibitor_23\NN\1740|with (r_nmod) form_19\VB\1617192|to|complex|c-1-inhibitor (r_xcomp) found_17\VBN\2426171|addition|,|inactivation|,|%|was|form|,|whereas|formed|. (l_nsubjpass) %_10\NN\1740|74|xiif (l_nmod) xiif_15\NN\1740|of|the|active|125i-factor
T3_T18 NONE c-1-inhibitor_23\NN\1740|with
T3_T19 NONE c-1-inhibitor_23\NN\1740|with (r_nmod) form_19\VB\1617192|to|complex|c-1-inhibitor (r_xcomp) found_17\VBN\2426171|addition|,|inactivation|,|%|was|form|,|whereas|formed|. (l_parataxis) formed_31\VBD\1617192|%|complexes|2-antiplasmin (l_nmod) 2-antiplasmin_35\NN\1740|with|alpha|and|antithrombin
T3_T20 NONE c-1-inhibitor_23\NN\1740|with (r_nmod) form_19\VB\1617192|to|complex|c-1-inhibitor (r_xcomp) found_17\VBN\2426171|addition|,|inactivation|,|%|was|form|,|whereas|formed|. (l_parataxis) formed_31\VBD\1617192|%|complexes|2-antiplasmin (l_nmod) 2-antiplasmin_35\NN\1740|with|alpha|and|antithrombin (l_conj) antithrombin_37\NN\1740|iii (l_nummod) iii_38\CD\13741022|
T4_T21 NONE c-1-inhibitor_12\NN\1740|with
T4_T22 NONE c-1-inhibitor_12\NN\1740|with (r_nmod) complexed_10\VBN\1740|furthermore|,|%|was|still|c-1-inhibitor|inactivated|. (l_advcl) inactivated_17\VBN\1097743|when|xii|was|plasma (l_nsubjpass) xii_15\NN\13745420|125i-factor
T4_T23 NONE c-1-inhibitor_12\NN\1740|with (r_nmod) complexed_10\VBN\1740|furthermore|,|%|was|still|c-1-inhibitor|inactivated|. (l_advcl) inactivated_17\VBN\1097743|when|xii|was|plasma (l_nmod) plasma_21\NN\5398023|in|hereditary|angioedema|contained (l_acl:relcl) contained_23\VBD\2632940|that|% (l_dobj) %_25\NN\1740|32|c-1-inhibitor (l_nmod) c-1-inhibitor_28\NN\1740|of|functional
T5_T21 NONE 125i-factor_14\NN\1740| (r_compound) xii_15\NN\13745420|125i-factor (r_nsubjpass) inactivated_17\VBN\1097743|when|xii|was|plasma (r_advcl) complexed_10\VBN\1740|furthermore|,|%|was|still|c-1-inhibitor|inactivated|. (l_nmod) c-1-inhibitor_12\NN\1740|with
T5_T22 NONE 125i-factor_14\NN\1740| (r_compound) xii_15\NN\13745420|125i-factor
T5_T23 NONE 125i-factor_14\NN\1740| (r_compound) xii_15\NN\13745420|125i-factor (r_nsubjpass) inactivated_17\VBN\1097743|when|xii|was|plasma (l_nmod) plasma_21\NN\5398023|in|hereditary|angioedema|contained (l_acl:relcl) contained_23\VBD\2632940|that|% (l_dobj) %_25\NN\1740|32|c-1-inhibitor (l_nmod) c-1-inhibitor_28\NN\1740|of|functional
T6_T21 NONE c-1-inhibitor_28\NN\1740|of|functional (r_nmod) %_25\NN\1740|32|c-1-inhibitor (r_dobj) contained_23\VBD\2632940|that|% (r_acl:relcl) plasma_21\NN\5398023|in|hereditary|angioedema|contained (r_nmod) inactivated_17\VBN\1097743|when|xii|was|plasma (r_advcl) complexed_10\VBN\1740|furthermore|,|%|was|still|c-1-inhibitor|inactivated|. (l_nmod) c-1-inhibitor_12\NN\1740|with
T6_T22 NONE c-1-inhibitor_28\NN\1740|of|functional (r_nmod) %_25\NN\1740|32|c-1-inhibitor (r_dobj) contained_23\VBD\2632940|that|% (r_acl:relcl) plasma_21\NN\5398023|in|hereditary|angioedema|contained (r_nmod) inactivated_17\VBN\1097743|when|xii|was|plasma (l_nsubjpass) xii_15\NN\13745420|125i-factor
T6_T23 NONE c-1-inhibitor_28\NN\1740|of|functional
T7_T25 NONE c-1-inhibitor_8\NN\1740|of
T7_T26 NONE c-1-inhibitor_8\NN\1740|of (r_nmod) role_6\NN\719494|the|dominant|c-1-inhibitor|inactivation (l_nmod) inactivation_11\NN\13518963|in|the|xiif|milieu (l_nmod) xiif_14\NN\1740|of|factor
20151846
T5_T14 NONE tamoxifen_11\NN\2714883|including|and|inhibitors|, (l_conj) inhibitors_15\NNS\20090|the|aromatase (l_compound) aromatase_14\NN\1740|
T6_T14 NONE estrogen-sensitive_25\JJ\1740| (r_amod) cancer_27\NN\14239425|of|estrogen-sensitive|breast (r_nmod) mortality_23\NN\5054863|to|the|reduced|cancer (r_nmod) contributed_18\VBN\126264|advances|have|significantly|mortality|. (l_nsubj) advances_1\NNS\7311115|pharmacologic|field|decades|,|tamoxifen (l_nmod) tamoxifen_11\NN\2714883|including|and|inhibitors|, (l_conj) inhibitors_15\NNS\20090|the|aromatase (l_compound) aromatase_14\NN\1740|
T8_T15 CPR:4 fulvestrant_0\NN\1740|,|downregulator|, (l_appos) downregulator_6\NN\1740|a|pure|estrogen|receptor (l_compound) receptor_5\NN\5225602|
T9_T15 NONE estrogen_4\NN\14745635| (r_compound) downregulator_6\NN\1740|a|pure|estrogen|receptor (l_compound) receptor_5\NN\5225602|
10931813
T15_T25 NONE )_4\-RRB-\1740| (r_punct) opener_6\NN\7325190|of|a|k(+|)|channel|reduce (l_compound) channel_5\NN\6251781|
T7_T21 CPR:3 nicorandil_8\NN\1740|of|,|opener|, (l_appos) opener_14\NN\7325190|a|k(+|)|channel (l_compound) channel_13\NN\6251781|
T9_T21 NONE )_12\-RRB-\1740| (r_punct) opener_14\NN\7325190|a|k(+|)|channel (l_compound) channel_13\NN\6251781|
T10_T22 CPR:4 d-sotalol_17\NN\1740|micromol/l|block (l_dep) block_23\VB\1476483|to|i(kr|,|and|atx-ii (l_dobj) i(kr_24\NN\1740|)|model (l_punct) )_25\-RRB-\1740|
T10_T23 CPR:4 d-sotalol_17\NN\1740|micromol/l|block (l_dep) block_23\VB\1476483|to|i(kr|,|and|atx-ii (l_conj) atx-ii_32\NN\1740|nmol/l
T11_T22 NONE i(na_40\NN\1740|late|)|model (r_dobj) augment_38\VB\153263|to|i(na (r_advcl) mimic_10\VB\1742886|to|increase|,|d-sotalol|augment (l_conj) d-sotalol_17\NN\1740|micromol/l|block (l_dep) block_23\VB\1476483|to|i(kr|,|and|atx-ii (l_dobj) i(kr_24\NN\1740|)|model (l_punct) )_25\-RRB-\1740|
T11_T23 NONE i(na_40\NN\1740|late|)|model (r_dobj) augment_38\VB\153263|to|i(na (r_advcl) mimic_10\VB\1742886|to|increase|,|d-sotalol|augment (l_conj) d-sotalol_17\NN\1740|micromol/l|block (l_dep) block_23\VB\1476483|to|i(kr|,|and|atx-ii (l_conj) atx-ii_32\NN\1740|nmol/l
T8_T22 CPR:4 isoproterenol_0\NN\3740161|nmol/l (r_nsubjpass) used_8\VBN\1156834|isoproterenol|was|mimic|. (l_xcomp) mimic_10\VB\1742886|to|increase|,|d-sotalol|augment (l_conj) d-sotalol_17\NN\1740|micromol/l|block (l_dep) block_23\VB\1476483|to|i(kr|,|and|atx-ii (l_dobj) i(kr_24\NN\1740|)|model (l_punct) )_25\-RRB-\1740|
T8_T23 CPR:4 isoproterenol_0\NN\3740161|nmol/l (r_nsubjpass) used_8\VBN\1156834|isoproterenol|was|mimic|. (l_xcomp) mimic_10\VB\1742886|to|increase|,|d-sotalol|augment (l_conj) d-sotalol_17\NN\1740|micromol/l|block (l_dep) block_23\VB\1476483|to|i(kr|,|and|atx-ii (l_conj) atx-ii_32\NN\1740|nmol/l
T12_T24 NONE isoproterenol+chromanol_0\NN\1740|293b|,|d-sotalol|,|and|atx-ii (l_conj) atx-ii_6\NN\1740|
T13_T24 NONE 293b_1\CD\1740| (r_dep) isoproterenol+chromanol_0\NN\1740|293b|,|d-sotalol|,|and|atx-ii (l_conj) atx-ii_6\NN\1740|
T14_T24 NONE d-sotalol_3\NN\1740| (r_conj) isoproterenol+chromanol_0\NN\1740|293b|,|d-sotalol|,|and|atx-ii (l_conj) atx-ii_6\NN\1740|
T4_T16 NONE nicorandil_0\NN\1740|micromol/l (r_nsubj) reversed_3\VBD\109660|nicorandil|%|and|failed|. (l_dobj) %_6\NN\1740|only|50|effect (l_nmod) effect_9\NN\34213|of|the|atx-ii (l_nmod) atx-ii_11\NN\1740|of
T5_T17 NONE )_7\-RRB-\1740| (r_punct) openers_9\NNS\7325190|k(+|)|channel (l_compound) channel_8\NN\6251781|
T5_T18 NONE )_7\-RRB-\1740| (r_punct) openers_9\NNS\7325190|k(+|)|channel (r_nsubj) capable_12\JJ\1740|that|openers|may|be|abbreviating (l_advcl) abbreviating_14\VBG\441445|of|interval|,|reducing|,|and|preventing (l_conj) preventing_24\VBG\1740|tdp|secondary (l_advcl) secondary_35\JJ\1740|when|lqts|is|i(kr|but|i(na (l_nmod) i(kr_38\NN\1740|to|reduced|)|or|i(ks (l_punct) )_39\-RRB-\1740|
T5_T19 NONE )_7\-RRB-\1740| (r_punct) openers_9\NNS\7325190|k(+|)|channel (r_nsubj) capable_12\JJ\1740|that|openers|may|be|abbreviating (l_advcl) abbreviating_14\VBG\441445|of|interval|,|reducing|,|and|preventing (l_conj) preventing_24\VBG\1740|tdp|secondary (l_advcl) secondary_35\JJ\1740|when|lqts|is|i(kr|but|i(na (l_nmod) i(kr_38\NN\1740|to|reduced|)|or|i(ks (l_conj) i(ks_41\NN\1740|) (l_punct) )_42\-RRB-\1740|
T6_T17 NONE i(na_53\NN\1740|so|when|due|to|augmented|late|) (r_conj) secondary_35\JJ\1740|when|lqts|is|i(kr|but|i(na (r_advcl) preventing_24\VBG\1740|tdp|secondary (r_conj) abbreviating_14\VBG\441445|of|interval|,|reducing|,|and|preventing (r_advcl) capable_12\JJ\1740|that|openers|may|be|abbreviating (l_nsubj) openers_9\NNS\7325190|k(+|)|channel (l_compound) channel_8\NN\6251781|
T6_T18 NONE i(na_53\NN\1740|so|when|due|to|augmented|late|) (r_conj) secondary_35\JJ\1740|when|lqts|is|i(kr|but|i(na (l_nmod) i(kr_38\NN\1740|to|reduced|)|or|i(ks (l_punct) )_39\-RRB-\1740|
T6_T19 NONE i(na_53\NN\1740|so|when|due|to|augmented|late|) (r_conj) secondary_35\JJ\1740|when|lqts|is|i(kr|but|i(na (l_nmod) i(kr_38\NN\1740|to|reduced|)|or|i(ks (l_conj) i(ks_41\NN\1740|) (l_punct) )_42\-RRB-\1740|
1322429
T1_T20 CPR:4 loperamide_0\NN\1740|,|agonist|, (r_nsubjpass) reported_13\VBN\831651|loperamide|was|recently|suppress|. (l_xcomp) suppress_15\VB\2510337|to|levels|subjects (l_dobj) levels_19\NNS\4916342|acth (l_compound) acth_16\NN\5407119|and|cortisol
T1_T32 NONE loperamide_0\NN\1740|,|agonist|, (r_nsubjpass) reported_13\VBN\831651|loperamide|was|recently|suppress|. (l_xcomp) suppress_15\VB\2510337|to|levels|subjects (l_nmod) subjects_22\NNS\6598915|in|normal|,|but|patients (l_conj) patients_27\NNS\9898892|not|in|disease (l_nmod) disease_33\NN\14061805|with|proven|acth-dependent|cushing (l_amod) acth-dependent_30\JJ\1740|
T2_T20 NONE cortisol_18\NN\14751417| (r_conj) acth_16\NN\5407119|and|cortisol
T2_T32 NONE cortisol_18\NN\14751417| (r_conj) acth_16\NN\5407119|and|cortisol (r_compound) levels_19\NNS\4916342|acth (r_dobj) suppress_15\VB\2510337|to|levels|subjects (l_nmod) subjects_22\NNS\6598915|in|normal|,|but|patients (l_conj) patients_27\NNS\9898892|not|in|disease (l_nmod) disease_33\NN\14061805|with|proven|acth-dependent|cushing (l_amod) acth-dependent_30\JJ\1740|
T14_T33 CPR:4 loperamide_15\NN\1740| (r_compound) administration_16\NN\1133281|loperamide (r_dep) h_13\NN\14622893|3|after|administration|mg (r_nmod) suppressed_11\VBN\2510337|subjects|,|levels|were|significantly|h|pmol/l|p|. (l_nsubjpass) levels_8\NNS\4916342|basal|acth|plasma (l_compound) acth_6\NN\5407119|
T15_T34 NONE gnrh_14\NN\1740|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|)
T15_T35 NONE gnrh_14\NN\1740|micrograms
T15_T36 NONE gnrh_14\NN\1740|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) hormone_19\NN\5404728|micrograms|gh-releasing
T15_T37 NONE gnrh_14\NN\1740|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) trh_24\NN\5407119|micrograms
T15_T38 NONE gnrh_14\NN\1740|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (r_dep) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_nsubjpass) peak_29\NN\13758296|the|acth|increase (l_compound) acth_28\NN\5407119|
T15_T39 NONE gnrh_14\NN\1740|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (r_dep) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_conj) reduced_71\VBN\441445|area|was|35|h|0.05|. (l_nsubjpass) area_59\NN\8630985|the|curve (l_nmod) curve_62\NN\13863771|under|the|acth (l_nmod) acth_64\NN\5407119|of|min
T16_T34 NONE hormone_19\NN\5404728|micrograms|gh-releasing (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|)
T16_T35 NONE hormone_19\NN\5404728|micrograms|gh-releasing (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) gnrh_14\NN\1740|micrograms
T16_T36 NONE hormone_19\NN\5404728|micrograms|gh-releasing
T16_T37 NONE hormone_19\NN\5404728|micrograms|gh-releasing (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) trh_24\NN\5407119|micrograms
T16_T38 NONE hormone_19\NN\5404728|micrograms|gh-releasing (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (r_dep) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_nsubjpass) peak_29\NN\13758296|the|acth|increase (l_compound) acth_28\NN\5407119|
T16_T39 NONE hormone_19\NN\5404728|micrograms|gh-releasing (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (r_dep) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_conj) reduced_71\VBN\441445|area|was|35|h|0.05|. (l_nsubjpass) area_59\NN\8630985|the|curve (l_nmod) curve_62\NN\13863771|under|the|acth (l_nmod) acth_64\NN\5407119|of|min
T17_T34 NONE trh_24\NN\5407119|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|)
T17_T35 NONE trh_24\NN\5407119|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) gnrh_14\NN\1740|micrograms
T17_T36 NONE trh_24\NN\5407119|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) hormone_19\NN\5404728|micrograms|gh-releasing
T17_T37 NONE trh_24\NN\5407119|micrograms
T17_T38 NONE trh_24\NN\5407119|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (r_dep) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_nsubjpass) peak_29\NN\13758296|the|acth|increase (l_compound) acth_28\NN\5407119|
T17_T39 NONE trh_24\NN\5407119|micrograms (r_conj) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (r_dep) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_conj) reduced_71\VBN\441445|area|was|35|h|0.05|. (l_nsubjpass) area_59\NN\8630985|the|curve (l_nmod) curve_62\NN\13863771|under|the|acth (l_nmod) acth_64\NN\5407119|of|min
T18_T34 CPR:4 loperamide_41\NN\1740|by (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_nmod) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (l_dep) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|)
T18_T35 CPR:4 loperamide_41\NN\1740|by (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_nmod) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (l_dep) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) gnrh_14\NN\1740|micrograms
T18_T36 CPR:4 loperamide_41\NN\1740|by (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_nmod) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (l_dep) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) hormone_19\NN\5404728|micrograms|gh-releasing
T18_T37 CPR:4 loperamide_41\NN\1740|by (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_nmod) test_5\NN\5798043|after|the|combined|pituitary|stimulation|crh (l_dep) crh_10\NN\1740|(|micrograms|human|,|gnrh|,|hormone|,|and|trh|) (l_conj) trh_24\NN\5407119|micrograms
T18_T38 CPR:4 loperamide_41\NN\1740|by (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_nsubjpass) peak_29\NN\13758296|the|acth|increase (l_compound) acth_28\NN\5407119|
T18_T39 CPR:4 loperamide_41\NN\1740|by (r_nmod) blunted_39\VBN\224901|test|,|peak|was|significantly|loperamide|pmol/l|and|reduced (l_conj) reduced_71\VBN\441445|area|was|35|h|0.05|. (l_nsubjpass) area_59\NN\8630985|the|curve (l_nmod) curve_62\NN\13863771|under|the|acth (l_nmod) acth_64\NN\5407119|of|min
T3_T21 NONE loperamide_25\NN\1740|by (r_nmod) affected_23\VBN\126264|test|,|peak|was|loperamide|. (l_nmod) test_3\NN\5798043|in|the|insulin-hypoglycemia|bw (l_amod) insulin-hypoglycemia_2\NN\1740|
T3_T22 NONE loperamide_25\NN\1740|by (r_nmod) affected_23\VBN\126264|test|,|peak|was|loperamide|. (l_nsubjpass) peak_13\NN\13758296|neither|the|acth|nor|area (l_compound) acth_12\NN\5407119|
T3_T23 NONE loperamide_25\NN\1740|by (r_nmod) affected_23\VBN\126264|test|,|peak|was|loperamide|. (l_nsubjpass) peak_13\NN\13758296|neither|the|acth|nor|area (l_conj) area_16\NN\8630985|the|curve (l_nmod) curve_19\NN\13863771|under|the|acth (l_nmod) acth_21\NN\5407119|of
T4_T24 NONE cortisol_23\NN\14751417| (r_conj) acth_21\NN\5407119|neither|basal|and|cortisol
T4_T25 NONE cortisol_23\NN\14751417| (r_conj) acth_21\NN\5407119|neither|basal|and|cortisol (r_compound) levels_24\NNS\4916342|acth|nor|levels (l_conj) levels_27\NNS\4916342|crh-stimulated (l_amod) crh-stimulated_26\JJ\1740|
T5_T24 NONE loperamide_31\NN\1740|by (r_nmod) influenced_29\VBN\137313|patients|,|levels|were|loperamide|. (l_nsubjpass) levels_24\NNS\4916342|acth|nor|levels (l_compound) acth_21\NN\5407119|neither|basal|and|cortisol
T5_T25 NONE loperamide_31\NN\1740|by (r_nmod) influenced_29\VBN\137313|patients|,|levels|were|loperamide|. (l_nsubjpass) levels_24\NNS\4916342|acth|nor|levels (l_conj) levels_27\NNS\4916342|crh-stimulated (l_amod) crh-stimulated_26\JJ\1740|
T6_T26 NONE loperamide_7\NN\1740| (r_nsubj) able_10\JJ\1740|adenomas|,|loperamide|was|not|reduce|. (l_xcomp) reduce_12\VB\441445|to|secretion (l_dobj) secretion_17\NN\13526110|basal|acth (l_amod) basal_13\JJ\1740|and|crh-induced (l_conj) crh-induced_15\JJ\1740|
T6_T27 NONE loperamide_7\NN\1740| (r_nsubj) able_10\JJ\1740|adenomas|,|loperamide|was|not|reduce|. (l_xcomp) reduce_12\VB\441445|to|secretion (l_dobj) secretion_17\NN\13526110|basal|acth (l_compound) acth_16\NN\5407119|
T7_T28 CPR:4 loperamide_3\NN\1740| (r_nsubj) able_5\JJ\1740|summary|,|loperamide|is|reduce|. (l_xcomp) reduce_7\VB\441445|to|levels|subjects (l_dobj) levels_14\NNS\4916342|basal|acth (l_amod) basal_8\JJ\1740|and|crh-induced (l_conj) crh-induced_10\JJ\1740|
T7_T29 CPR:4 loperamide_3\NN\1740| (r_nsubj) able_5\JJ\1740|summary|,|loperamide|is|reduce|. (l_xcomp) reduce_7\VB\441445|to|levels|subjects (l_dobj) levels_14\NNS\4916342|basal|acth (l_compound) acth_11\NN\5407119|and|cortisol
T8_T28 NONE cortisol_13\NN\14751417| (r_conj) acth_11\NN\5407119|and|cortisol (r_compound) levels_14\NNS\4916342|basal|acth (l_amod) basal_8\JJ\1740|and|crh-induced (l_conj) crh-induced_10\JJ\1740|
T8_T29 NONE cortisol_13\NN\14751417| (r_conj) acth_11\NN\5407119|and|cortisol
T10_T30 NONE cortisol_9\NN\14751417| (r_conj) acth_7\NN\5407119|insulin-hypoglycemia-induced|and|cortisol (l_amod) insulin-hypoglycemia-induced_6\JJ\1740|
T10_T31 NONE cortisol_9\NN\14751417| (r_conj) acth_7\NN\5407119|insulin-hypoglycemia-induced|and|cortisol
T9_T30 NONE loperamide_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|loperamide|effect|. (l_dobj) effect_4\NN\34213|no|significant|levels|and|,|therefore|,|effect (l_nmod) levels_10\NNS\4916342|on|acth (l_compound) acth_7\NN\5407119|insulin-hypoglycemia-induced|and|cortisol (l_amod) insulin-hypoglycemia-induced_6\JJ\1740|
T9_T31 NONE loperamide_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|loperamide|effect|. (l_dobj) effect_4\NN\34213|no|significant|levels|and|,|therefore|,|effect (l_nmod) levels_10\NNS\4916342|on|acth (l_compound) acth_7\NN\5407119|insulin-hypoglycemia-induced|and|cortisol
14583450
T6_T52 NONE ribonucleotide_2\NN\1740| (r_compound) hrrm2_5\NN\1740|the|human|ribonucleotide|reductase|subunit (r_nsubj) complements_6\VBZ\2673134|hrrm2|p53r2|response|. (l_nmod) response_9\NN\11410625|in|repair (l_nmod) repair_13\NN\248977|to|uv-induced|dna|cells (l_nmod) cells_15\NNS\3080309|in|p53 (l_nmod) p53_18\NN\1740|with|mutant
T6_T53 NONE ribonucleotide_2\NN\1740| (r_compound) hrrm2_5\NN\1740|the|human|ribonucleotide|reductase|subunit
T6_T54 NONE ribonucleotide_2\NN\1740| (r_compound) hrrm2_5\NN\1740|the|human|ribonucleotide|reductase|subunit (r_nsubj) complements_6\VBZ\2673134|hrrm2|p53r2|response|. (l_dobj) p53r2_7\NNP\1740|
T1_T40 NONE ribonucleotide_0\NN\1740| (r_compound) reductase_1\NN\14732946|ribonucleotide|rr (l_appos) rr_3\NN\1740|(|)
T1_T7 NONE ribonucleotide_0\NN\1740| (r_compound) reductase_1\NN\14732946|ribonucleotide|rr
T2_T40 CPR:9 diphosphates_18\NNS\1740|to|deoxyribonucleoside|,|essential (r_nmod) conversion_11\NN\7359599|for|the|de|diphosphates|diphosphates (r_nmod) responsible_6\JJ\1740|reductase|is|conversion|. (l_nsubj) reductase_1\NN\14732946|ribonucleotide|rr (l_appos) rr_3\NN\1740|(|)
T2_T7 CPR:9 diphosphates_18\NNS\1740|to|deoxyribonucleoside|,|essential (r_nmod) conversion_11\NN\7359599|for|the|de|diphosphates|diphosphates (r_nmod) responsible_6\JJ\1740|reductase|is|conversion|. (l_nsubj) reductase_1\NN\14732946|ribonucleotide|rr
T5_T40 CPR:9 diphosphates_15\NNS\1740|of|the|ribonucleoside (r_nmod) conversion_11\NN\7359599|for|the|de|diphosphates|diphosphates (r_nmod) responsible_6\JJ\1740|reductase|is|conversion|. (l_nsubj) reductase_1\NN\14732946|ribonucleotide|rr (l_appos) rr_3\NN\1740|(|)
T5_T7 CPR:9 diphosphates_15\NNS\1740|of|the|ribonucleoside (r_nmod) conversion_11\NN\7359599|for|the|de|diphosphates|diphosphates (r_nmod) responsible_6\JJ\1740|reductase|is|conversion|. (l_nsubj) reductase_1\NN\14732946|ribonucleotide|rr
T4_T44 NONE cooh-terminal_31\NN\1740|with|a|truncated (r_nmod) p53_27\NN\1740|mutant|cooh-terminal (r_dobj) possess_25\VBP\2630189|which|p53 (r_acl:relcl) cells_22\NNS\3080309|in|human|prostate|cancer|pc3|,|possess|,|and|cells (r_nmod) investigated_5\VBD\644583|study|,|we|expression|cells|. (l_dobj) expression_7\NN\4679549|the|and|function|p53r2|treatment (l_nmod) p53r2_11\NN\1740|of|and|hrrm2
T4_T45 NONE cooh-terminal_31\NN\1740|with|a|truncated (r_nmod) p53_27\NN\1740|mutant|cooh-terminal (r_dobj) possess_25\VBP\2630189|which|p53 (r_acl:relcl) cells_22\NNS\3080309|in|human|prostate|cancer|pc3|,|possess|,|and|cells (r_nmod) investigated_5\VBD\644583|study|,|we|expression|cells|. (l_dobj) expression_7\NN\4679549|the|and|function|p53r2|treatment (l_nmod) p53r2_11\NN\1740|of|and|hrrm2 (l_conj) hrrm2_13\NN\1740|
T4_T46 NONE cooh-terminal_31\NN\1740|with|a|truncated (r_nmod) p53_27\NN\1740|mutant|cooh-terminal
T4_T47 NONE cooh-terminal_31\NN\1740|with|a|truncated (r_nmod) p53_27\NN\1740|mutant|cooh-terminal (r_dobj) possess_25\VBP\2630189|which|p53 (r_acl:relcl) cells_22\NNS\3080309|in|human|prostate|cancer|pc3|,|possess|,|and|cells (l_conj) cells_39\NNS\3080309|in|human|oropharyngeal|cancer|kb|,|possess (l_acl:relcl) possess_42\VBP\2630189|which|p53 (l_dobj) p53_44\NN\1740|wild-type
T3_T26 CPR:4 hydroxyurea_4\NN\1740| (r_nsubj) inhibited_5\VBD\2510337|cells|,|hydroxyurea|hrrm2|and|resulted|. (l_dobj) hrrm2_6\NN\1740|
14588118
T3_T14 CPR:4 minocycline_3\NN\4416530| (r_compound) treatment_4\NN\654885|minocycline (r_nsubj) reduced_6\VBD\441445|addition|,|treatment|significantly|activity|compared|. (l_dobj) activity_10\NN\30358|the|specific|caspase-3|sci (l_compound) caspase-3_9\NN\1740|
T4_T15 CPR:3 minocycline_6\NN\4416530| (r_compound) treatment_7\NN\654885|minocycline (r_nsubj) increased_8\VBD\169651|that|treatment|expression|but|decreased (l_dobj) expression_9\NN\4679549|mrna (l_nmod) mrna_12\NN\14832193|of|interleukin-10 (l_compound) interleukin-10_11\NN\1740|
T4_T16 CPR:4 minocycline_6\NN\4416530| (r_compound) treatment_7\NN\654885|minocycline (r_nsubj) increased_8\VBD\169651|that|treatment|expression|but|decreased (l_conj) decreased_14\VBD\169651|expression (l_dobj) expression_18\NN\4679549|tumor|necrosis|factor-alpha (l_compound) factor-alpha_17\NN\1740|
T5_T17 NONE minocycline_8\NN\4416530| (r_compound) treatment_9\NN\654885|minocycline (r_nsubj) modulated_10\VBD\1724459|that|,|sci|,|treatment|expression|,|attenuated|and|improved (l_dobj) expression_11\NN\4679549|cytokines (l_nmod) cytokines_13\NNS\14728724|of
16741658
T9_T34 NONE paclitaxel_10\NN\1740|to (r_nmod) resistance_8\NN\37396|with|paclitaxel|tumors (r_nmod) correlates_6\VBZ\2657219|expression|resistance|. (l_nsubj) expression_0\NN\4679549|factor (l_nmod) factor_5\NN\7326557|of|basic|fibroblast|growth
T6_T19 NONE paclitaxel_8\NN\1740| (r_compound) activity_9\NN\30358|paclitaxel (r_conj) expression_6\NN\4679549|between|fgf|and|activity|tumors (l_compound) fgf_5\NN\1740|
T8_T22 NONE paclitaxel_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|antiproliferative|paclitaxel (r_nsubjpass) quantified_7\VBN\947077|effects|were|and|correlated|. (l_conj) correlated_9\VBN\2657219|expression (l_nmod) expression_11\NN\4679549|with|afgf (l_nmod) afgf_13\NN\1740|of|,|bfgf|,|p-glycoprotein|,|p53|,|and|bcl-2
T8_T23 NONE paclitaxel_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|antiproliferative|paclitaxel (r_nsubjpass) quantified_7\VBN\947077|effects|were|and|correlated|. (l_conj) correlated_9\VBN\2657219|expression (l_nmod) expression_11\NN\4679549|with|afgf (l_nmod) afgf_13\NN\1740|of|,|bfgf|,|p-glycoprotein|,|p53|,|and|bcl-2 (l_conj) bfgf_15\NN\1740|
T8_T24 NONE paclitaxel_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|antiproliferative|paclitaxel (r_nsubjpass) quantified_7\VBN\947077|effects|were|and|correlated|. (l_conj) correlated_9\VBN\2657219|expression (l_nmod) expression_11\NN\4679549|with|afgf (l_nmod) afgf_13\NN\1740|of|,|bfgf|,|p-glycoprotein|,|p53|,|and|bcl-2 (l_conj) p-glycoprotein_17\NN\1740|pgp
T8_T25 NONE paclitaxel_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|antiproliferative|paclitaxel (r_nsubjpass) quantified_7\VBN\947077|effects|were|and|correlated|. (l_conj) correlated_9\VBN\2657219|expression (l_nmod) expression_11\NN\4679549|with|afgf (l_nmod) afgf_13\NN\1740|of|,|bfgf|,|p-glycoprotein|,|p53|,|and|bcl-2 (l_conj) p-glycoprotein_17\NN\1740|pgp (l_appos) pgp_19\NN\1740|(|)
T8_T26 NONE paclitaxel_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|antiproliferative|paclitaxel (r_nsubjpass) quantified_7\VBN\947077|effects|were|and|correlated|. (l_conj) correlated_9\VBN\2657219|expression (l_nmod) expression_11\NN\4679549|with|afgf (l_nmod) afgf_13\NN\1740|of|,|bfgf|,|p-glycoprotein|,|p53|,|and|bcl-2 (l_conj) p53_22\NN\1740|
T8_T27 NONE paclitaxel_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|antiproliferative|paclitaxel (r_nsubjpass) quantified_7\VBN\947077|effects|were|and|correlated|. (l_conj) correlated_9\VBN\2657219|expression (l_nmod) expression_11\NN\4679549|with|afgf (l_nmod) afgf_13\NN\1740|of|,|bfgf|,|p-glycoprotein|,|p53|,|and|bcl-2 (l_conj) bcl-2_25\NN\1740|
T3_T11 NONE paclitaxel_9\NN\1740|to (r_nmod) sensitivity_7\NN\5651971|with|tumor|paclitaxel (r_nmod) correlate_4\VB\2657219|expression|did|not|sensitivity|,|showed|. (l_nsubj) expression_1\NN\4679549|afgf (l_compound) afgf_0\NN\1740|
T3_T12 NONE paclitaxel_9\NN\1740|to (r_nmod) sensitivity_7\NN\5651971|with|tumor|paclitaxel (r_nmod) correlate_4\VB\2657219|expression|did|not|sensitivity|,|showed|. (l_parataxis) showed_14\VBD\2137132|whereas|expression|correlation|p (l_nsubj) expression_13\NN\4679549|bfgf (l_compound) bfgf_12\NN\1740|
T4_T13 NONE paclitaxel_7\NN\1740| (r_compound) resistance_8\NN\37396|of|paclitaxel (r_nmod) predictor_5\NN\10756433|expression|was|a|stronger|resistance|pgp|. (l_nsubj) expression_1\NN\4679549|bfgf (l_compound) bfgf_0\NN\1740|
T4_T14 NONE paclitaxel_7\NN\1740| (r_compound) resistance_8\NN\37396|of|paclitaxel (r_nmod) predictor_5\NN\10756433|expression|was|a|stronger|resistance|pgp|. (l_nmod) pgp_11\NN\1740|compared|to|,|p53|,|or|bcl-2
T4_T15 NONE paclitaxel_7\NN\1740| (r_compound) resistance_8\NN\37396|of|paclitaxel (r_nmod) predictor_5\NN\10756433|expression|was|a|stronger|resistance|pgp|. (l_nmod) pgp_11\NN\1740|compared|to|,|p53|,|or|bcl-2 (l_conj) p53_13\NN\1740|
T4_T16 NONE paclitaxel_7\NN\1740| (r_compound) resistance_8\NN\37396|of|paclitaxel (r_nmod) predictor_5\NN\10756433|expression|was|a|stronger|resistance|pgp|. (l_nmod) pgp_11\NN\1740|compared|to|,|p53|,|or|bcl-2 (l_conj) bcl-2_16\NN\1740|
T5_T17 NONE paclitaxel_10\NN\1740| (r_compound) resistance_11\NN\37396|in|paclitaxel|tumors (r_nmod) role_6\NN\719494|a|bfgf|resistance (l_nmod) bfgf_8\NN\1740|of
23305921
T23_T28 CPR:4 phenylalanyl/prolyl_7\NN\1740| (r_compound) derivatives_10\NNS\5802185|of|hydroxycinnamoyl|phenylalanyl/prolyl|hydroxamic|acid (r_nmod) synthesis_0\NN\13446390|and|effects|derivatives|inhibitor|. (l_nmod) inhibitor_13\NN\20090|as|tyrosinase|and|antioxidant (l_compound) tyrosinase_12\NN\1740|
T24_T28 CPR:4 acid_9\NN\14818238| (r_compound) derivatives_10\NNS\5802185|of|hydroxycinnamoyl|phenylalanyl/prolyl|hydroxamic|acid (r_nmod) synthesis_0\NN\13446390|and|effects|derivatives|inhibitor|. (l_nmod) inhibitor_13\NN\20090|as|tyrosinase|and|antioxidant (l_compound) tyrosinase_12\NN\1740|
T15_T25 CPR:4 ca-xaa-nhoh_8\NN\1740|(|) (r_appos) acid_6\NN\14818238|caffeoyl-amino|acidyl-hydroxamic|ca-xaa-nhoh (r_nsubj) acted_10\VBD\1619354|that|acid|antioxidant|,|conjugated (l_nmod) antioxidant_15\NN\14724436|as|both|a|good|and|inhibitor (l_conj) inhibitor_18\NN\20090|tyrosinase (l_compound) tyrosinase_17\NN\1740|
T1_T25 NONE acid_24\NN\14818238|caffeic (r_nsubjpass) conjugated_26\VBN\394813|particular|when|acid|was|proline (r_advcl) acted_10\VBD\1619354|that|acid|antioxidant|,|conjugated (l_nmod) antioxidant_15\NN\14724436|as|both|a|good|and|inhibitor (l_conj) inhibitor_18\NN\20090|tyrosinase (l_compound) tyrosinase_17\NN\1740|
T2_T25 NONE proline_28\NN\14601829|with|or|acids (r_nmod) conjugated_26\VBN\394813|particular|when|acid|was|proline (r_advcl) acted_10\VBD\1619354|that|acid|antioxidant|,|conjugated (l_nmod) antioxidant_15\NN\14724436|as|both|a|good|and|inhibitor (l_conj) inhibitor_18\NN\20090|tyrosinase (l_compound) tyrosinase_17\NN\1740|
T3_T25 NONE acids_31\NNS\14818238|amino|having (r_conj) proline_28\NN\14601829|with|or|acids (r_nmod) conjugated_26\VBN\394813|particular|when|acid|was|proline (r_advcl) acted_10\VBD\1619354|that|acid|antioxidant|,|conjugated (l_nmod) antioxidant_15\NN\14724436|as|both|a|good|and|inhibitor (l_conj) inhibitor_18\NN\20090|tyrosinase (l_compound) tyrosinase_17\NN\1740|
T4_T25 NONE phenylalanine_36\NN\14605787|like (r_nmod) ring_34\NN\4981139|aromatic|phenylalanine (r_dobj) having_32\VBG\2108377|ring (r_acl) acids_31\NNS\14818238|amino|having (r_conj) proline_28\NN\14601829|with|or|acids (r_nmod) conjugated_26\VBN\394813|particular|when|acid|was|proline (r_advcl) acted_10\VBD\1619354|that|acid|antioxidant|,|conjugated (l_nmod) antioxidant_15\NN\14724436|as|both|a|good|and|inhibitor (l_conj) inhibitor_18\NN\20090|tyrosinase (l_compound) tyrosinase_17\NN\1740|
T6_T25 CPR:4 acid_6\NN\14818238|caffeoyl-amino|acidyl-hydroxamic|ca-xaa-nhoh (r_nsubj) acted_10\VBD\1619354|that|acid|antioxidant|,|conjugated (l_nmod) antioxidant_15\NN\14724436|as|both|a|good|and|inhibitor (l_conj) inhibitor_18\NN\20090|tyrosinase (l_compound) tyrosinase_17\NN\1740|
T10_T26 NONE hca-phe-nhoh_21\NN\1740|(|and|hca-pro-nhoh|) (r_dep) acid_15\NN\14818238|with|phenylalanyl|hydroxamic|and|acid|hca-phe-nhoh (r_nmod) conjugated_11\VBN\394813|here|,|derivatives|were|further|acid|study|. (l_xcomp) study_26\VB\630380|to|relationship|antioxidants (l_nmod) antioxidants_34\NNS\14724436|as|both|and|inhibitors (l_conj) inhibitors_37\NNS\20090|tyrosinase (l_compound) tyrosinase_36\NN\1740|
T11_T26 NONE hca-pro-nhoh_23\NN\1740| (r_conj) hca-phe-nhoh_21\NN\1740|(|and|hca-pro-nhoh|) (r_dep) acid_15\NN\14818238|with|phenylalanyl|hydroxamic|and|acid|hca-phe-nhoh (r_nmod) conjugated_11\VBN\394813|here|,|derivatives|were|further|acid|study|. (l_xcomp) study_26\VB\630380|to|relationship|antioxidants (l_nmod) antioxidants_34\NNS\14724436|as|both|and|inhibitors (l_conj) inhibitors_37\NNS\20090|tyrosinase (l_compound) tyrosinase_36\NN\1740|
T5_T26 NONE acid_4\NN\14818238|various|hydroxycinnamic|hca (r_compound) derivatives_8\NNS\5802185|acid (r_nsubjpass) conjugated_11\VBN\394813|here|,|derivatives|were|further|acid|study|. (l_xcomp) study_26\VB\630380|to|relationship|antioxidants (l_nmod) antioxidants_34\NNS\14724436|as|both|and|inhibitors (l_conj) inhibitors_37\NNS\20090|tyrosinase (l_compound) tyrosinase_36\NN\1740|
T7_T26 NONE hca_6\NN\1740|(|) (r_appos) acid_4\NN\14818238|various|hydroxycinnamic|hca (r_compound) derivatives_8\NNS\5802185|acid (r_nsubjpass) conjugated_11\VBN\394813|here|,|derivatives|were|further|acid|study|. (l_xcomp) study_26\VB\630380|to|relationship|antioxidants (l_nmod) antioxidants_34\NNS\14724436|as|both|and|inhibitors (l_conj) inhibitors_37\NNS\20090|tyrosinase (l_compound) tyrosinase_36\NN\1740|
T8_T26 NONE acid_15\NN\14818238|with|phenylalanyl|hydroxamic|and|acid|hca-phe-nhoh (r_nmod) conjugated_11\VBN\394813|here|,|derivatives|were|further|acid|study|. (l_xcomp) study_26\VB\630380|to|relationship|antioxidants (l_nmod) antioxidants_34\NNS\14724436|as|both|and|inhibitors (l_conj) inhibitors_37\NNS\20090|tyrosinase (l_compound) tyrosinase_36\NN\1740|
T9_T26 NONE acid_19\NN\14818238|prolyl|hydroxamic (r_conj) acid_15\NN\14818238|with|phenylalanyl|hydroxamic|and|acid|hca-phe-nhoh (r_nmod) conjugated_11\VBN\394813|here|,|derivatives|were|further|acid|study|. (l_xcomp) study_26\VB\630380|to|relationship|antioxidants (l_nmod) antioxidants_34\NNS\14724436|as|both|and|inhibitors (l_conj) inhibitors_37\NNS\20090|tyrosinase (l_compound) tyrosinase_36\NN\1740|
T21_T27 CPR:4 acid_6\NN\14818238|of|caffeic|and|acid (r_nmod) derivatives_3\NNS\5802185|acid (r_nsubj) inhibited_11\VBD\2510337|addition|,|derivatives|efficiently|activity|and|reduced|. (l_dobj) activity_13\NN\30358|tyrosinase (l_compound) tyrosinase_12\NN\1740|
T22_T27 CPR:4 acid_9\NN\14818238|sinapic (r_conj) acid_6\NN\14818238|of|caffeic|and|acid (r_nmod) derivatives_3\NNS\5802185|acid (r_nsubj) inhibited_11\VBD\2510337|addition|,|derivatives|efficiently|activity|and|reduced|. (l_dobj) activity_13\NN\30358|tyrosinase (l_compound) tyrosinase_12\NN\1740|
16268464
T12_T31 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_compound) mtrra66_2\NN\1740|
T12_T32 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_compound) g_3\NN\13717155|
T12_T33 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_dep) t_11\NN\14999913|c677|and|a1298c|,|g|,|c776|g|) (l_compound) c677_10\NN\1740|(|but|not|of|mthfr (l_compound) mthfr_9\NN\1740|
T12_T34 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_dep) t_11\NN\14999913|c677|and|a1298c|,|g|,|c776|g|)
T12_T35 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_dep) t_11\NN\14999913|c677|and|a1298c|,|g|,|c776|g|) (l_conj) a1298c_13\NN\1740|
T12_T36 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_dep) t_11\NN\14999913|c677|and|a1298c|,|g|,|c776|g|) (l_appos) g_16\NN\13717155|mtra2756 (l_compound) mtra2756_15\NN\1740|
T12_T37 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_dep) t_11\NN\14999913|c677|and|a1298c|,|g|,|c776|g|) (l_appos) g_16\NN\13717155|mtra2756
T12_T38 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_dep) t_11\NN\14999913|c677|and|a1298c|,|g|,|c776|g|) (l_appos) c776_19\NN\1740|tcn (l_compound) tcn_18\NN\1740|
T12_T39 NONE homocysteine_23\NN\1740|with|and|disease (r_nmod) association_0\NN\8008335|polymorphism|homocysteine|. (l_nmod) polymorphism_4\NN\11418750|of|mtrra66|g|t (l_dep) t_11\NN\14999913|c677|and|a1298c|,|g|,|c776|g|) (l_appos) g_20\NN\13717155|
T1_T13 NONE methylenetetrahydrofolate_0\JJ\1740| (r_amod) polymorphism_2\NN\11418750|methylenetetrahydrofolate|reductase|t (l_compound) reductase_1\NN\14732946|
T1_T27 NONE methylenetetrahydrofolate_0\JJ\1740| (r_amod) polymorphism_2\NN\11418750|methylenetetrahydrofolate|reductase|t (l_appos) t_6\NN\14999913|(|mthfr|c677|) (l_compound) mthfr_4\NN\1740|
T1_T28 NONE methylenetetrahydrofolate_0\JJ\1740| (r_amod) polymorphism_2\NN\11418750|methylenetetrahydrofolate|reductase|t (l_appos) t_6\NN\14999913|(|mthfr|c677|)
T4_T18 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66 (r_nmod) g_9\NN\13717155|a2756|synthase|g|and|g
T4_T19 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66
T4_T20 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66 (l_appos) mtr_14\NN\1740|(|)
T4_T21 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66 (r_nmod) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_18\NN\13717155|reductase
T4_T22 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66 (r_nmod) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_18\NN\13717155|reductase (l_nmod) reductase_22\NN\14732946|of|methionine|synthase|mtrr
T4_T23 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66 (r_nmod) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_18\NN\13717155|reductase (l_nmod) reductase_22\NN\14732946|of|methionine|synthase|mtrr (l_appos) mtrr_24\NN\1740|(|)
T4_T24 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66 (r_nmod) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin
T4_T25 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66 (r_nmod) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin (l_nmod) transcobalamin_30\NN\1740|of|tcn
T4_T26 NONE methionine_11\NN\14605787| (r_compound) synthase_12\NN\1740|of|methionine|mtr|,|a66 (r_nmod) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin (l_nmod) transcobalamin_30\NN\1740|of|tcn (l_appos) tcn_32\NN\1740|(|)
T5_T18 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr (r_nmod) g_18\NN\13717155|reductase (r_conj) g_9\NN\13717155|a2756|synthase|g|and|g
T5_T19 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr (r_nmod) g_18\NN\13717155|reductase (r_conj) g_9\NN\13717155|a2756|synthase|g|and|g (l_nmod) synthase_12\NN\1740|of|methionine|mtr|,|a66
T5_T20 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr (r_nmod) g_18\NN\13717155|reductase (r_conj) g_9\NN\13717155|a2756|synthase|g|and|g (l_nmod) synthase_12\NN\1740|of|methionine|mtr|,|a66 (l_appos) mtr_14\NN\1740|(|)
T5_T21 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr (r_nmod) g_18\NN\13717155|reductase
T5_T22 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr
T5_T23 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr (l_appos) mtrr_24\NN\1740|(|)
T5_T24 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr (r_nmod) g_18\NN\13717155|reductase (r_conj) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin
T5_T25 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr (r_nmod) g_18\NN\13717155|reductase (r_conj) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin (l_nmod) transcobalamin_30\NN\1740|of|tcn
T5_T26 NONE methionine_20\NN\14605787| (r_compound) reductase_22\NN\14732946|of|methionine|synthase|mtrr (r_nmod) g_18\NN\13717155|reductase (r_conj) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin (l_nmod) transcobalamin_30\NN\1740|of|tcn (l_appos) tcn_32\NN\1740|(|)
T6_T18 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g
T6_T19 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g (l_nmod) synthase_12\NN\1740|of|methionine|mtr|,|a66
T6_T20 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g (l_nmod) synthase_12\NN\1740|of|methionine|mtr|,|a66 (l_appos) mtr_14\NN\1740|(|)
T6_T21 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_18\NN\13717155|reductase
T6_T22 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_18\NN\13717155|reductase (l_nmod) reductase_22\NN\14732946|of|methionine|synthase|mtrr
T6_T23 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_18\NN\13717155|reductase (l_nmod) reductase_22\NN\14732946|of|methionine|synthase|mtrr (l_appos) mtrr_24\NN\1740|(|)
T6_T24 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin
T6_T25 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin (l_nmod) transcobalamin_30\NN\1740|of|tcn
T6_T26 NONE t-hcys_36\NNS\1740|to|both|and|cad (r_nmod) association_4\NN\8008335|the|substitutions|t-hcys (l_nmod) substitutions_7\NNS\7337390|of|the|g (l_dep) g_9\NN\13717155|a2756|synthase|g|and|g (l_conj) g_28\NN\13717155|c776|transcobalamin (l_nmod) transcobalamin_30\NN\1740|of|tcn (l_appos) tcn_32\NN\1740|(|)
T10_T29 NONE t-hcys_0\NNS\1740| (r_nsubj) higher_2\JJR\1740|t-hcys|was|group|controls|those|. (l_nmod) controls_9\NNS\5190804|than|in|microm|and|carriers (l_conj) carriers_22\NNS\9629752|in|mtrraa (l_nmod) mtrraa_24\NN\1740|of|and|677tt
T10_T30 NONE t-hcys_0\NNS\1740| (r_nsubj) higher_2\JJR\1740|t-hcys|was|group|controls|those|. (l_nmod) controls_9\NNS\5190804|than|in|microm|and|carriers (l_conj) carriers_22\NNS\9629752|in|mtrraa (l_nmod) mtrraa_24\NN\1740|of|and|677tt (l_conj) 677tt_27\NN\1740|mthfr (l_compound) mthfr_26\NN\1740|
T2_T16 NONE t-hcys_4\NNS\1740|> (r_compound) median_6\NN\6021761|t-hcys|and|genotype (l_conj) genotype_9\NN\7941170|mtrraa (l_compound) mtrraa_8\NN\1740|
15671155
T10_T26 CPR:9 l-cysteine_10\NN\1740| (r_dobj) utilize_9\VBP\161225|cystathionine-gamma-lyase|l-cysteine|substrate|form|. (l_nsubj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_appos) cse_2\NN\8342039|(|)
T10_T29 CPR:9 l-cysteine_10\NN\1740| (r_dobj) utilize_9\VBP\161225|cystathionine-gamma-lyase|l-cysteine|substrate|form|. (l_nsubj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_conj) cystathionine-beta-synthase_5\NN\1740|cbs
T10_T30 CPR:9 l-cysteine_10\NN\1740| (r_dobj) utilize_9\VBP\161225|cystathionine-gamma-lyase|l-cysteine|substrate|form|. (l_nsubj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_conj) cystathionine-beta-synthase_5\NN\1740|cbs (l_appos) cbs_7\NN\1740|(|)
T10_T36 CPR:9 l-cysteine_10\NN\1740| (r_dobj) utilize_9\VBP\161225|cystathionine-gamma-lyase|l-cysteine|substrate|form|. (l_nsubj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase
T16_T26 CPR:9 h2s_15\NN\1740| (r_dobj) form_14\VB\1617192|to|h2s (r_xcomp) utilize_9\VBP\161225|cystathionine-gamma-lyase|l-cysteine|substrate|form|. (l_nsubj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_appos) cse_2\NN\8342039|(|)
T16_T29 CPR:9 h2s_15\NN\1740| (r_dobj) form_14\VB\1617192|to|h2s (r_xcomp) utilize_9\VBP\161225|cystathionine-gamma-lyase|l-cysteine|substrate|form|. (l_nsubj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_conj) cystathionine-beta-synthase_5\NN\1740|cbs
T16_T30 CPR:9 h2s_15\NN\1740| (r_dobj) form_14\VB\1617192|to|h2s (r_xcomp) utilize_9\VBP\161225|cystathionine-gamma-lyase|l-cysteine|substrate|form|. (l_nsubj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_conj) cystathionine-beta-synthase_5\NN\1740|cbs (l_appos) cbs_7\NN\1740|(|)
T16_T36 CPR:9 h2s_15\NN\1740| (r_dobj) form_14\VB\1617192|to|h2s (r_xcomp) utilize_9\VBP\161225|cystathionine-gamma-lyase|l-cysteine|substrate|form|. (l_nsubj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase
T24_T26 NONE cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_appos) cse_2\NN\8342039|(|)
T24_T29 NONE cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_conj) cystathionine-beta-synthase_5\NN\1740|cbs
T24_T30 NONE cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_conj) cystathionine-beta-synthase_5\NN\1740|cbs (l_appos) cbs_7\NN\1740|(|)
T24_T36 NONE cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase
T5_T26 NONE cystathionine-beta-synthase_5\NN\1740|cbs (r_conj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase (l_appos) cse_2\NN\8342039|(|)
T5_T29 NONE cystathionine-beta-synthase_5\NN\1740|cbs
T5_T30 NONE cystathionine-beta-synthase_5\NN\1740|cbs (l_appos) cbs_7\NN\1740|(|)
T5_T36 NONE cystathionine-beta-synthase_5\NN\1740|cbs (r_conj) cystathionine-gamma-lyase_0\NN\1740|cse|and|cystathionine-beta-synthase
T17_T32 NONE cystathionine-gamma-lyase_5\NN\1740|cse
T17_T33 NONE cystathionine-gamma-lyase_5\NN\1740|cse (l_appos) cse_7\NN\8342039|(|)
T18_T32 CPR:9 h2s_18\NNS\1740| (r_dobj) forms_17\VBZ\1617192|that|h2s|system (r_acl:relcl) enzyme_15\NN\14723628|to|be|the|key|forms (r_xcomp) believed_10\VBN\686447|enzymes|,|cystathionine-gamma-lyase|is|enzyme|. (l_nsubjpass) cystathionine-gamma-lyase_5\NN\1740|cse
T18_T33 CPR:9 h2s_18\NNS\1740| (r_dobj) forms_17\VBZ\1617192|that|h2s|system (r_acl:relcl) enzyme_15\NN\14723628|to|be|the|key|forms (r_xcomp) believed_10\VBN\686447|enzymes|,|cystathionine-gamma-lyase|is|enzyme|. (l_nsubjpass) cystathionine-gamma-lyase_5\NN\1740|cse (l_appos) cse_7\NN\8342039|(|)
T20_T34 NONE h2s_9\NNS\1740|of|synthesizing|(|determined (l_acl) synthesizing_10\VBG\193486|activity (l_dobj) activity_12\NN\30358|enzyme|and|cse (l_conj) cse_14\NN\8342039|
T11_T27 NONE pag_180\NN\1740|,|1.41+/-0.97 (r_appos) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T11_T28 NONE pag_180\NN\1740|,|1.41+/-0.97 (r_appos) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T11_T35 NONE pag_180\NN\1740|,|1.41+/-0.97 (r_appos) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T11_T37 NONE pag_180\NN\1740|,|1.41+/-0.97 (r_appos) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T12_T27 NONE pag_185\NN\1740| (r_compound) animals_191\NNS\4475|p<0.05|pag|c.f|n=24|group (r_dep) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T12_T28 NONE pag_185\NN\1740| (r_compound) animals_191\NNS\4475|p<0.05|pag|c.f|n=24|group (r_dep) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T12_T35 NONE pag_185\NN\1740| (r_compound) animals_191\NNS\4475|p<0.05|pag|c.f|n=24|group (r_dep) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T12_T37 NONE pag_185\NN\1740| (r_compound) animals_191\NNS\4475|p<0.05|pag|c.f|n=24|group (r_dep) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T21_T27 NONE dl-propargylglycine_15\NN\1740|pag (r_appos) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (r_nmod) treatment_9\NN\654885|prophylactic|inhibitor (r_nsubj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T21_T28 NONE dl-propargylglycine_15\NN\1740|pag (r_appos) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (r_nmod) treatment_9\NN\654885|prophylactic|inhibitor (r_nsubj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T21_T35 CPR:4 dl-propargylglycine_15\NN\1740|pag (r_appos) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T21_T37 NONE dl-propargylglycine_15\NN\1740|pag (r_appos) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (r_nmod) treatment_9\NN\654885|prophylactic|inhibitor (r_nsubj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T22_T27 NONE pag_17\NN\1740|(|) (r_appos) dl-propargylglycine_15\NN\1740|pag (r_appos) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (r_nmod) treatment_9\NN\654885|prophylactic|inhibitor (r_nsubj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T22_T28 NONE pag_17\NN\1740|(|) (r_appos) dl-propargylglycine_15\NN\1740|pag (r_appos) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (r_nmod) treatment_9\NN\654885|prophylactic|inhibitor (r_nsubj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T22_T35 CPR:4 pag_17\NN\1740|(|) (r_appos) dl-propargylglycine_15\NN\1740|pag (r_appos) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T22_T37 NONE pag_17\NN\1740|(|) (r_appos) dl-propargylglycine_15\NN\1740|pag (r_appos) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (r_nmod) treatment_9\NN\654885|prophylactic|inhibitor (r_nsubj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T23_T27 NONE caerulein-induced_25\JJ\1740| (r_amod) pancreatitis_26\NN\14336539|of|caerulein-induced|and|injury (r_nmod) severity_23\NN\5036394|the|pancreatitis (r_dobj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T23_T28 NONE caerulein-induced_25\JJ\1740| (r_amod) pancreatitis_26\NN\14336539|of|caerulein-induced|and|injury (r_nmod) severity_23\NN\5036394|the|pancreatitis (r_dobj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T23_T35 NONE caerulein-induced_25\JJ\1740| (r_amod) pancreatitis_26\NN\14336539|of|caerulein-induced|and|injury (r_nmod) severity_23\NN\5036394|the|pancreatitis (r_dobj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T23_T37 NONE caerulein-induced_25\JJ\1740| (r_amod) pancreatitis_26\NN\14336539|of|caerulein-induced|and|injury (r_nmod) severity_23\NN\5036394|the|pancreatitis (r_dobj) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_advcl) determined_33\VBN\1645601|as|hyperamylasemia (l_nmod) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T2_T27 NONE pag_57\NN\1740|,|7904+/-495 (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T2_T28 NONE pag_57\NN\1740|,|7904+/-495 (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T2_T35 NONE pag_57\NN\1740|,|7904+/-495 (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T2_T37 NONE pag_57\NN\1740|,|7904+/-495 (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T3_T27 NONE pag_68\NN\1740|,|7811+/-428 (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T3_T28 NONE pag_68\NN\1740|,|7811+/-428 (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T3_T35 NONE pag_68\NN\1740|,|7811+/-428 (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T3_T37 NONE pag_68\NN\1740|,|7811+/-428 (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T4_T27 NONE pag_73\NN\1740| (r_compound) animals_79\NNS\4475|p<0.05|pag|c.f|n=24|group (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T4_T28 NONE pag_73\NN\1740| (r_compound) animals_79\NNS\4475|p<0.05|pag|c.f|n=24|group (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T4_T35 NONE pag_73\NN\1740| (r_compound) animals_79\NNS\4475|p<0.05|pag|c.f|n=24|group (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|] (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T4_T37 NONE pag_73\NN\1740| (r_compound) animals_79\NNS\4475|p<0.05|pag|c.f|n=24|group (r_appos) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T6_T27 CPR:3 pag_114\NN\1740|,|2.97+/-0.39 (r_conj) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T6_T28 CPR:3 pag_114\NN\1740|,|2.97+/-0.39 (r_conj) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T6_T35 NONE pag_114\NN\1740|,|2.97+/-0.39 (r_conj) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (r_dep) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (r_appos) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T6_T37 NONE pag_114\NN\1740|,|2.97+/-0.39 (r_conj) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (r_dep) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (r_appos) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T7_T27 NONE pag_125\NN\1740|,|3.03+/-0.47 (r_dep) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T7_T28 NONE pag_125\NN\1740|,|3.03+/-0.47 (r_dep) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T7_T35 NONE pag_125\NN\1740|,|3.03+/-0.47 (r_dep) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (r_dep) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (r_appos) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T7_T37 NONE pag_125\NN\1740|,|3.03+/-0.47 (r_dep) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (r_dep) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (r_appos) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T8_T27 NONE pag_130\NN\1740| (r_compound) c.f_131\NN\1740|pag|.|placebo|;|animals|) (r_dep) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T8_T28 NONE pag_130\NN\1740| (r_compound) c.f_131\NN\1740|pag|.|placebo|;|animals|) (r_dep) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T8_T35 NONE pag_130\NN\1740| (r_compound) c.f_131\NN\1740|pag|.|placebo|;|animals|) (r_dep) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (r_dep) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (r_appos) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T8_T37 NONE pag_130\NN\1740| (r_compound) c.f_131\NN\1740|pag|.|placebo|;|animals|) (r_dep) treatment_108\NN\654885|(|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|p<0.05|c.f|] (r_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (r_dep) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (r_appos) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T9_T27 NONE pag_169\NN\1740|,|1.34+/-0.14 (r_dep) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo
T9_T28 NONE pag_169\NN\1740|,|1.34+/-0.14 (r_dep) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_appos) sequestration_88\NN\1201021|2|neutrophil|pancreas|activity (l_dep) activity_99\NN\30358|[|oxidase|increase|treatment|;|injury/necrosis|; (l_compound) oxidase_95\NN\14732946|pancreatic|myeloperoxidase|mpo (l_appos) mpo_97\NN\1740|(|)
T9_T35 NONE pag_169\NN\1740|,|1.34+/-0.14 (r_dep) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (r_nmod) determined_33\VBN\1645601|as|hyperamylasemia (r_advcl) reduced_21\VBD\441445|also|,|treatment|significantly|severity|,|determined|. (l_nsubj) treatment_9\NN\654885|prophylactic|inhibitor (l_nmod) inhibitor_13\NN\20090|with|the|cse|,|dl-propargylglycine|, (l_compound) cse_12\NN\8342039|
T9_T37 NONE pag_169\NN\1740|,|1.34+/-0.14 (r_dep) treatment_163\NN\654885|[|prophylactic|:|placebo|;|pag|;|treatment|;|pag|;|animals|] (r_dep) activity_154\NN\30358|4|lung|mpo|increase|treatment (r_dep) hyperamylasemia_37\NN\1740|by|1|amylase|;|sequestration|activity|;|and|evidence (l_dep) amylase_40\NN\14732946|[|plasma|u/l|control|;|treatment|pag|;|treatment|pag|;|animals|]
T14_T31 NONE h2s_11\NNS\1740|of (r_nmod) role_9\NN\719494|an|important|proinflammatory|h2s|regulating (r_dobj) suggest_5\VBP\1010118|effects|role|and|raise|. (l_nsubj) effects_1\NNS\13245626|these|blockade (l_nmod) blockade_4\NN\952963|of|cse (l_compound) cse_3\NN\8342039|
T15_T31 NONE h2s_27\NNS\1740| (r_nsubj) exert_29\VB\1158872|that|h2s|may|activity|forms (r_ccomp) possibility_25\NN\5944958|the|exert (r_dobj) raise_23\VBP\153263|possibility (r_conj) suggest_5\VBP\1010118|effects|role|and|raise|. (l_nsubj) effects_1\NNS\13245626|these|blockade (l_nmod) blockade_4\NN\952963|of|cse (l_compound) cse_3\NN\8342039|
16316409
T8_T37 NONE acid_18\NN\14818238| (r_compound) microarray_19\NN\1740|a|complementary|deoxyribonucleic|acid|composed (r_dobj) utilized_14\VBD\161225|understand|,|we|microarray|determine|. (l_advcl) understand_2\VB\588888|to|better|mechanism (l_dobj) mechanism_5\NN\13446390|the|molecular|p75(ntr|suppression (l_nmod) p75(ntr_7\NN\1740|of|) (l_punct) )_8\-RRB-\1740|
T8_T39 NONE acid_18\NN\14818238| (r_compound) microarray_19\NN\1740|a|complementary|deoxyribonucleic|acid|composed (r_dobj) utilized_14\VBD\161225|understand|,|we|microarray|determine|. (l_advcl) determine_28\VB\1645601|to|pattern (l_dobj) pattern_32\NN\5726345|the|gene|expression|altered (l_acl) altered_33\VBN\126264|re-introduction (l_nmod) re-introduction_35\NN\7162194|by|p75ntr|cells (l_nmod) p75ntr_37\NN\1740|of
T1_T10 NONE acid-binding_7\JJ\1740| (r_amod) protein_8\NN\14944888|cellular|retinoic|acid-binding|i|crabpi|and|protein (l_appos) crabpi_11\NN\1740|(|)
T1_T11 NONE acid-binding_7\JJ\1740| (r_amod) protein_8\NN\14944888|cellular|retinoic|acid-binding|i|crabpi|and|protein (l_conj) protein_15\NN\14944888|igfbp5 (l_compound) igfbp5_14\NN\1740|
T1_T12 NONE acid-binding_7\JJ\1740| (r_amod) protein_8\NN\14944888|cellular|retinoic|acid-binding|i|crabpi|and|protein (r_compound) levels_16\NNS\4916342|increased|protein (r_dobj) confirmed_3\VBD\1011725|analysis|further|levels|and|level|. (l_conj) level_19\NN\4916342|decreased|protein|expression (l_nmod) protein_22\NN\14944888|of|plaur (l_compound) plaur_21\NN\1740|
T1_T13 NONE acid-binding_7\JJ\1740| (r_amod) protein_8\NN\14944888|cellular|retinoic|acid-binding|i|crabpi|and|protein (r_compound) levels_16\NNS\4916342|increased|protein (r_dobj) confirmed_3\VBD\1011725|analysis|further|levels|and|level|. (l_conj) level_19\NN\4916342|decreased|protein|expression (l_nmod) expression_27\NN\4679549|with|increasing|p75ntr|protein (l_compound) p75ntr_25\NN\1740|
T1_T9 NONE acid-binding_7\JJ\1740| (r_amod) protein_8\NN\14944888|cellular|retinoic|acid-binding|i|crabpi|and|protein (l_nummod) i_9\CD\14622893|
T2_T14 NONE retinoids_15\NNS\1740|the|,|acid|,|bind|, (r_nsubj) promoted_29\VBD\2556126|that|retinoids|differentiation (r_ccomp) observed_12\VBD\2163746|elevated|,|we|promoted|. (l_advcl) elevated_3\VBN\2391803|as|crabpi|was|more (l_nsubj) crabpi_1\NN\1740|
T2_T15 NONE retinoids_15\NNS\1740|the|,|acid|,|bind|, (l_acl:relcl) bind_26\VBP\1290422|that|crabpi (l_dobj) crabpi_27\NN\1740|
T2_T16 NONE retinoids_15\NNS\1740|the|,|acid|,|bind|, (r_nsubj) promoted_29\VBD\2556126|that|retinoids|differentiation (l_dobj) differentiation_34\NN\5748054|nitroblue|tetrazolium-associated|functional|cell|cells (l_nmod) cells_38\NNS\3080309|in|p75ntr|pc-3|,|but|cells (l_compound) p75ntr_36\NN\1740|
T3_T14 NONE acid_19\NN\14818238|all-trans|retinoic|and|acid (r_appos) retinoids_15\NNS\1740|the|,|acid|,|bind|, (r_nsubj) promoted_29\VBD\2556126|that|retinoids|differentiation (r_ccomp) observed_12\VBD\2163746|elevated|,|we|promoted|. (l_advcl) elevated_3\VBN\2391803|as|crabpi|was|more (l_nsubj) crabpi_1\NN\1740|
T3_T15 NONE acid_19\NN\14818238|all-trans|retinoic|and|acid (r_appos) retinoids_15\NNS\1740|the|,|acid|,|bind|, (l_acl:relcl) bind_26\VBP\1290422|that|crabpi (l_dobj) crabpi_27\NN\1740|
T3_T16 NONE acid_19\NN\14818238|all-trans|retinoic|and|acid (r_appos) retinoids_15\NNS\1740|the|,|acid|,|bind|, (r_nsubj) promoted_29\VBD\2556126|that|retinoids|differentiation (l_dobj) differentiation_34\NN\5748054|nitroblue|tetrazolium-associated|functional|cell|cells (l_nmod) cells_38\NNS\3080309|in|p75ntr|pc-3|,|but|cells (l_compound) p75ntr_36\NN\1740|
T4_T14 NONE acid_23\NN\14818238|9-cis|retinoic (r_conj) acid_19\NN\14818238|all-trans|retinoic|and|acid (r_appos) retinoids_15\NNS\1740|the|,|acid|,|bind|, (r_nsubj) promoted_29\VBD\2556126|that|retinoids|differentiation (r_ccomp) observed_12\VBD\2163746|elevated|,|we|promoted|. (l_advcl) elevated_3\VBN\2391803|as|crabpi|was|more (l_nsubj) crabpi_1\NN\1740|
T4_T15 NONE acid_23\NN\14818238|9-cis|retinoic (r_conj) acid_19\NN\14818238|all-trans|retinoic|and|acid (r_appos) retinoids_15\NNS\1740|the|,|acid|,|bind|, (l_acl:relcl) bind_26\VBP\1290422|that|crabpi (l_dobj) crabpi_27\NN\1740|
T4_T16 NONE acid_23\NN\14818238|9-cis|retinoic (r_conj) acid_19\NN\14818238|all-trans|retinoic|and|acid (r_appos) retinoids_15\NNS\1740|the|,|acid|,|bind|, (r_nsubj) promoted_29\VBD\2556126|that|retinoids|differentiation (l_dobj) differentiation_34\NN\5748054|nitroblue|tetrazolium-associated|functional|cell|cells (l_nmod) cells_38\NNS\3080309|in|p75ntr|pc-3|,|but|cells (l_compound) p75ntr_36\NN\1740|
T5_T14 NONE tetrazolium-associated_31\JJ\1740| (r_amod) differentiation_34\NN\5748054|nitroblue|tetrazolium-associated|functional|cell|cells (r_dobj) promoted_29\VBD\2556126|that|retinoids|differentiation (r_ccomp) observed_12\VBD\2163746|elevated|,|we|promoted|. (l_advcl) elevated_3\VBN\2391803|as|crabpi|was|more (l_nsubj) crabpi_1\NN\1740|
T5_T15 NONE tetrazolium-associated_31\JJ\1740| (r_amod) differentiation_34\NN\5748054|nitroblue|tetrazolium-associated|functional|cell|cells (r_dobj) promoted_29\VBD\2556126|that|retinoids|differentiation (l_nsubj) retinoids_15\NNS\1740|the|,|acid|,|bind|, (l_acl:relcl) bind_26\VBP\1290422|that|crabpi (l_dobj) crabpi_27\NN\1740|
T5_T16 NONE tetrazolium-associated_31\JJ\1740| (r_amod) differentiation_34\NN\5748054|nitroblue|tetrazolium-associated|functional|cell|cells (l_nmod) cells_38\NNS\3080309|in|p75ntr|pc-3|,|but|cells (l_compound) p75ntr_36\NN\1740|
T6_T17 NONE acid_5\NN\14818238| (r_compound) receptors_6\NNS\5225602|retinoic|acid|rars
T6_T18 NONE acid_5\NN\14818238| (r_compound) receptors_6\NNS\5225602|retinoic|acid|rars (l_appos) rars_8\NNS\1740|(|)
T6_T19 NONE acid_5\NN\14818238| (r_compound) receptors_6\NNS\5225602|retinoic|acid|rars (r_compound) expression_10\NN\4679549|receptors (r_compound) levels_11\NNS\4916342|of|the|expression (r_nmod) examination_1\NN\633864|subsequent|levels (r_nsubj) demonstrated_12\VBD\2137132|examination|absence|. (l_dobj) absence_14\NN\14449405|an|rar-beta|cells|and|re-expression|,|consistent (l_nmod) rar-beta_16\NN\1740|of
T6_T20 NONE acid_5\NN\14818238| (r_compound) receptors_6\NNS\5225602|retinoic|acid|rars (r_compound) expression_10\NN\4679549|receptors (r_compound) levels_11\NNS\4916342|of|the|expression (r_nmod) examination_1\NN\633864|subsequent|levels (r_nsubj) demonstrated_12\VBD\2137132|examination|absence|. (l_dobj) absence_14\NN\14449405|an|rar-beta|cells|and|re-expression|,|consistent (l_conj) re-expression_23\NN\1740|cells (l_nmod) cells_28\NNS\3080309|in|the|expressing (l_amod) expressing_27\NN\1740|p75ntr (l_nmod:npmod) p75ntr_26\NN\1740|
T6_T21 NONE acid_5\NN\14818238| (r_compound) receptors_6\NNS\5225602|retinoic|acid|rars (r_compound) expression_10\NN\4679549|receptors (r_compound) levels_11\NNS\4916342|of|the|expression (r_nmod) examination_1\NN\633864|subsequent|levels (r_nsubj) demonstrated_12\VBD\2137132|examination|absence|. (l_dobj) absence_14\NN\14449405|an|rar-beta|cells|and|re-expression|,|consistent (l_amod) consistent_30\JJ\1740|findings (l_nmod) findings_33\NNS\7951464|with|previous|believed (l_acl:relcl) believed_37\VBN\686447|where|rar-beta|is|play (l_nsubjpass) rar-beta_35\NN\1740|
T7_T32 NONE retinoids_25\NNS\1740|of|available (r_nmod) sequestration_23\NN\1201021|for|localized|retinoids (r_nmod) up-regulating_16\VBG\1740|by|expression|sequestration (r_advcl) reverse_9\VB\109660|to|partially|de-differentiation|up-regulating (r_xcomp) appears_6\VBZ\2604760|hence|,|re-expression|reverse|. (l_nsubj) re-expression_2\NN\1740|p75ntr (l_nmod) p75ntr_5\NN\1740|of|the
T7_T33 CPR:3 retinoids_25\NNS\1740|of|available (r_nmod) sequestration_23\NN\1201021|for|localized|retinoids (r_nmod) up-regulating_16\VBG\1740|by|expression|sequestration (l_dobj) expression_18\NN\4679549|the|crabpi (l_nmod) crabpi_20\NN\1740|of
T7_T34 NONE retinoids_25\NNS\1740|of|available (l_acl:relcl) available_28\JJ\1740|that|are|rar-beta (l_nmod) rar-beta_32\NN\1740|to|up-regulated|,|rxr-alpha|,|and|rxr-beta
T7_T35 NONE retinoids_25\NNS\1740|of|available (l_acl:relcl) available_28\JJ\1740|that|are|rar-beta (l_nmod) rar-beta_32\NN\1740|to|up-regulated|,|rxr-alpha|,|and|rxr-beta (l_conj) rxr-alpha_34\NN\1740|
T7_T36 NONE retinoids_25\NNS\1740|of|available (l_acl:relcl) available_28\JJ\1740|that|are|rar-beta (l_nmod) rar-beta_32\NN\1740|to|up-regulated|,|rxr-alpha|,|and|rxr-beta (l_conj) rxr-beta_37\NN\1740|
8566141
T17_T31 CPR:3 amantadine_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|amantadine|c-fos|striatum|:|reversal|. (l_dobj) c-fos_2\NN\1740|
T17_T32 NONE amantadine_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|amantadine|c-fos|striatum|:|reversal|. (l_dep) reversal_7\VBG\1740|antagonists (l_nmod) antagonists_14\NNS\7846|d1 (l_compound) d1_10\NN\1740|with|dopamine|and|receptor
T17_T33 NONE amantadine_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|amantadine|c-fos|striatum|:|reversal|. (l_dep) reversal_7\VBG\1740|antagonists (l_nmod) antagonists_14\NNS\7846|d1 (l_compound) d1_10\NN\1740|with|dopamine|and|receptor (l_conj) receptor_13\NN\5225602|nmda
T18_T31 NONE dopamine_9\NN\14807737| (r_compound) d1_10\NN\1740|with|dopamine|and|receptor (r_compound) antagonists_14\NNS\7846|d1 (r_nmod) reversal_7\VBG\1740|antagonists (r_dep) induces_1\VBZ\1627355|amantadine|c-fos|striatum|:|reversal|. (l_dobj) c-fos_2\NN\1740|
T18_T32 NONE dopamine_9\NN\14807737| (r_compound) d1_10\NN\1740|with|dopamine|and|receptor
T18_T33 NONE dopamine_9\NN\14807737| (r_compound) d1_10\NN\1740|with|dopamine|and|receptor (l_conj) receptor_13\NN\5225602|nmda
T19_T31 NONE nmda_12\NN\1740| (r_compound) receptor_13\NN\5225602|nmda (r_conj) d1_10\NN\1740|with|dopamine|and|receptor (r_compound) antagonists_14\NNS\7846|d1 (r_nmod) reversal_7\VBG\1740|antagonists (r_dep) induces_1\VBZ\1627355|amantadine|c-fos|striatum|:|reversal|. (l_dobj) c-fos_2\NN\1740|
T19_T32 NONE nmda_12\NN\1740| (r_compound) receptor_13\NN\5225602|nmda (r_conj) d1_10\NN\1740|with|dopamine|and|receptor
T19_T33 NONE nmda_12\NN\1740| (r_compound) receptor_13\NN\5225602|nmda
T1_T24 CPR:3 amantadine_0\NN\1740|1-aminoadamantane (r_nsubj) induced_4\VBD\1627355|amantadine|expression|part|. (l_dobj) expression_6\NN\4679549|fos (l_compound) fos_5\NN\9943239|
T2_T24 CPR:3 1-aminoadamantane_2\NN\1740|(|) (r_appos) amantadine_0\NN\1740|1-aminoadamantane (r_nsubj) induced_4\VBD\1627355|amantadine|expression|part|. (l_dobj) expression_6\NN\4679549|fos (l_compound) fos_5\NN\9943239|
T3_T20 CPR:3 amantadine_7\NN\1740|by (r_nmod) induced_5\VBN\1627355|amantadine (r_acl) fos_4\NN\9943239|of|induced
T3_T21 NONE amantadine_7\NN\1740|by (r_nmod) induced_5\VBN\1627355|amantadine (r_acl) fos_4\NN\9943239|of|induced (r_nmod) pattern_2\NN\5726345|the|distribution|fos (r_nsubj) similar_10\JJ\1740|pattern|was|more|those|. (l_nmod) those_12\DT\1740|to|seen (l_acl) seen_13\VBN\2106506|dopaminomimetics|antagonists (l_nmod) antagonists_23\NNS\7846|than|with|n-methyl-d-aspartate|receptor (l_compound) receptor_22\NN\5225602|
T4_T20 NONE n-methyl-d-aspartate_18\NN\1740|nmda (r_compound) antagonists_23\NNS\7846|than|with|n-methyl-d-aspartate|receptor (r_nmod) seen_13\VBN\2106506|dopaminomimetics|antagonists (r_acl) those_12\DT\1740|to|seen (r_nmod) similar_10\JJ\1740|pattern|was|more|those|. (l_nsubj) pattern_2\NN\5726345|the|distribution|fos (l_nmod) fos_4\NN\9943239|of|induced
T4_T21 NONE n-methyl-d-aspartate_18\NN\1740|nmda (r_compound) antagonists_23\NNS\7846|than|with|n-methyl-d-aspartate|receptor (l_compound) receptor_22\NN\5225602|
T5_T20 NONE nmda_20\NN\1740|(|) (r_appos) n-methyl-d-aspartate_18\NN\1740|nmda (r_compound) antagonists_23\NNS\7846|than|with|n-methyl-d-aspartate|receptor (r_nmod) seen_13\VBN\2106506|dopaminomimetics|antagonists (r_acl) those_12\DT\1740|to|seen (r_nmod) similar_10\JJ\1740|pattern|was|more|those|. (l_nsubj) pattern_2\NN\5726345|the|distribution|fos (l_nmod) fos_4\NN\9943239|of|induced
T5_T21 NONE nmda_20\NN\1740|(|) (r_appos) n-methyl-d-aspartate_18\NN\1740|nmda (r_compound) antagonists_23\NNS\7846|than|with|n-methyl-d-aspartate|receptor (l_compound) receptor_22\NN\5225602|
T10_T22 NONE amantadine_19\NN\1740| (r_compound) induction_20\NN\7450842|amantadine|fos|striatum (r_dobj) blocked_18\VBD\1476483|pretreatment|induction|. (l_nsubj) pretreatment_0\NN\1740|antagonist (l_nmod) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (l_compound) receptor_5\NN\5225602|
T10_T23 NONE amantadine_19\NN\1740| (r_compound) induction_20\NN\7450842|amantadine|fos|striatum (r_dobj) blocked_18\VBD\1476483|pretreatment|induction|. (l_nsubj) pretreatment_0\NN\1740|antagonist (l_nmod) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (l_conj) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (l_compound) receptor_13\NN\5225602|
T10_T25 CPR:3 amantadine_19\NN\1740| (r_compound) induction_20\NN\7450842|amantadine|fos|striatum (l_nmod) fos_22\NN\9943239|of
T6_T22 NONE dopamine_3\NN\14807737| (r_compound) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (l_compound) receptor_5\NN\5225602|
T6_T23 NONE dopamine_3\NN\14807737| (r_compound) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (l_conj) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (l_compound) receptor_13\NN\5225602|
T6_T25 NONE dopamine_3\NN\14807737| (r_compound) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (r_nmod) pretreatment_0\NN\1740|antagonist (r_nsubj) blocked_18\VBD\1476483|pretreatment|induction|. (l_dobj) induction_20\NN\7450842|amantadine|fos|striatum (l_nmod) fos_22\NN\9943239|of
T7_T22 CPR:6 sch23390_8\NN\1740| (r_appos) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (l_compound) receptor_5\NN\5225602|
T7_T23 NONE sch23390_8\NN\1740| (r_appos) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (l_conj) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (l_compound) receptor_13\NN\5225602|
T7_T25 CPR:4 sch23390_8\NN\1740| (r_appos) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (r_nmod) pretreatment_0\NN\1740|antagonist (r_nsubj) blocked_18\VBD\1476483|pretreatment|induction|. (l_dobj) induction_20\NN\7450842|amantadine|fos|striatum (l_nmod) fos_22\NN\9943239|of
T8_T22 NONE nmda_12\NN\1740| (r_compound) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (r_conj) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (l_compound) receptor_5\NN\5225602|
T8_T23 NONE nmda_12\NN\1740| (r_compound) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (l_compound) receptor_13\NN\5225602|
T8_T25 NONE nmda_12\NN\1740| (r_compound) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (r_conj) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (r_nmod) pretreatment_0\NN\1740|antagonist (r_nsubj) blocked_18\VBD\1476483|pretreatment|induction|. (l_dobj) induction_20\NN\7450842|amantadine|fos|striatum (l_nmod) fos_22\NN\9943239|of
T9_T22 NONE mk-801_16\NN\1740| (r_appos) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (r_conj) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (l_compound) receptor_5\NN\5225602|
T9_T23 CPR:6 mk-801_16\NN\1740| (r_appos) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (l_compound) receptor_13\NN\5225602|
T9_T25 CPR:4 mk-801_16\NN\1740| (r_appos) antagonist_14\NN\7846|the|nmda|receptor|,|mk-801|, (r_conj) antagonist_6\NN\7846|with|the|dopamine|d1|receptor|,|sch23390|,|and|antagonist (r_nmod) pretreatment_0\NN\1740|antagonist (r_nsubj) blocked_18\VBD\1476483|pretreatment|induction|. (l_dobj) induction_20\NN\7450842|amantadine|fos|striatum (l_nmod) fos_22\NN\9943239|of
T11_T26 CPR:3 amantadine_2\NN\1740| (r_compound) induction_3\NN\7450842|amantadine|fos|striatum (l_nmod) fos_5\NN\9943239|of
T11_T27 NONE amantadine_2\NN\1740| (r_compound) induction_3\NN\7450842|amantadine|fos|striatum (r_nsubj) unaffected_10\JJ\1740|however|,|induction|was|antagonist|. (l_nmod) antagonist_16\NN\7846|by|the|dopamine|d2|receptor|,|sulpiride (l_compound) receptor_15\NN\5225602|
T12_T26 NONE dopamine_13\NN\14807737| (r_compound) antagonist_16\NN\7846|by|the|dopamine|d2|receptor|,|sulpiride (r_nmod) unaffected_10\JJ\1740|however|,|induction|was|antagonist|. (l_nsubj) induction_3\NN\7450842|amantadine|fos|striatum (l_nmod) fos_5\NN\9943239|of
T12_T27 NONE dopamine_13\NN\14807737| (r_compound) antagonist_16\NN\7846|by|the|dopamine|d2|receptor|,|sulpiride (l_compound) receptor_15\NN\5225602|
T13_T26 NONE sulpiride_18\NN\1740| (r_appos) antagonist_16\NN\7846|by|the|dopamine|d2|receptor|,|sulpiride (r_nmod) unaffected_10\JJ\1740|however|,|induction|was|antagonist|. (l_nsubj) induction_3\NN\7450842|amantadine|fos|striatum (l_nmod) fos_5\NN\9943239|of
T13_T27 CPR:6 sulpiride_18\NN\1740| (r_appos) antagonist_16\NN\7846|by|the|dopamine|d2|receptor|,|sulpiride (l_compound) receptor_15\NN\5225602|
T14_T28 CPR:3 amantadine_4\NN\1740| (r_compound) induction_5\NN\7450842|amantadine|fos|striatum (l_nmod) fos_7\NN\9943239|of
T14_T29 NONE amantadine_4\NN\1740| (r_compound) induction_5\NN\7450842|amantadine|fos|striatum (r_nsubj) related_13\JJ\1740|that|induction|is|receptors (l_nmod) receptors_19\NNS\5225602|d1 (l_compound) d1_16\NN\1740|to|dopamine|and|nmda
T14_T30 NONE amantadine_4\NN\1740| (r_compound) induction_5\NN\7450842|amantadine|fos|striatum (r_nsubj) related_13\JJ\1740|that|induction|is|receptors (l_nmod) receptors_19\NNS\5225602|d1
T15_T28 NONE dopamine_15\NN\14807737| (r_compound) d1_16\NN\1740|to|dopamine|and|nmda (r_compound) receptors_19\NNS\5225602|d1 (r_nmod) related_13\JJ\1740|that|induction|is|receptors (l_nsubj) induction_5\NN\7450842|amantadine|fos|striatum (l_nmod) fos_7\NN\9943239|of
T15_T29 NONE dopamine_15\NN\14807737| (r_compound) d1_16\NN\1740|to|dopamine|and|nmda
T15_T30 NONE dopamine_15\NN\14807737| (r_compound) d1_16\NN\1740|to|dopamine|and|nmda (r_compound) receptors_19\NNS\5225602|d1
T16_T28 NONE nmda_18\NN\1740| (r_conj) d1_16\NN\1740|to|dopamine|and|nmda (r_compound) receptors_19\NNS\5225602|d1 (r_nmod) related_13\JJ\1740|that|induction|is|receptors (l_nsubj) induction_5\NN\7450842|amantadine|fos|striatum (l_nmod) fos_7\NN\9943239|of
T16_T29 NONE nmda_18\NN\1740| (r_conj) d1_16\NN\1740|to|dopamine|and|nmda
T16_T30 NONE nmda_18\NN\1740| (r_conj) d1_16\NN\1740|to|dopamine|and|nmda (r_compound) receptors_19\NNS\5225602|d1
23265505
17327402
T7_T20 NONE gamma-glutamyl_5\JJ\1740| (r_amod) carboxylase_6\NN\1740|gamma-glutamyl
T1_T16 NONE gamma-glutamyl_16\JJ\1740| (r_amod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase
T1_T9 NONE gamma-glutamyl_16\JJ\1740| (r_amod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase (l_appos) gamma-carboxylase_19\NN\1740|(|)
T2_T16 CPR:9 acid_4\NN\14818238| (r_compound) residues_5\NNS\20827|of|glutamic|acid (r_nmod) carboxylation_1\NN\1740|the|residues|acid|carboxylase (l_nmod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase
T2_T9 CPR:9 acid_4\NN\14818238| (r_compound) residues_5\NNS\20827|of|glutamic|acid (r_nmod) carboxylation_1\NN\1740|the|residues|acid|carboxylase (l_nmod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase (l_appos) gamma-carboxylase_19\NN\1740|(|)
T3_T16 CPR:9 acid_8\NN\14818238|to|gamma-carboxyglutamic|gla (r_nmod) carboxylation_1\NN\1740|the|residues|acid|carboxylase (l_nmod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase
T3_T9 CPR:9 acid_8\NN\14818238|to|gamma-carboxyglutamic|gla (r_nmod) carboxylation_1\NN\1740|the|residues|acid|carboxylase (l_nmod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase (l_appos) gamma-carboxylase_19\NN\1740|(|)
T5_T16 CPR:9 gla_10\NN\1740|(|) (r_appos) acid_8\NN\14818238|to|gamma-carboxyglutamic|gla (r_nmod) carboxylation_1\NN\1740|the|residues|acid|carboxylase (l_nmod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase
T5_T9 CPR:9 gla_10\NN\1740|(|) (r_appos) acid_8\NN\14818238|to|gamma-carboxyglutamic|gla (r_nmod) carboxylation_1\NN\1740|the|residues|acid|carboxylase (l_nmod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase (l_appos) gamma-carboxylase_19\NN\1740|(|)
T6_T16 NONE k-dependent_15\JJ\1740|vitamin (r_amod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase
T6_T9 NONE k-dependent_15\JJ\1740|vitamin (r_amod) carboxylase_17\NN\1740|by|the|k-dependent|gamma-glutamyl|gamma-carboxylase (l_appos) gamma-carboxylase_19\NN\1740|(|)
T4_T10 NONE k-dependent_30\JJ\1740| (r_amod) factors_32\NNS\7326557|of|the|vitamin|k-dependent|clotting|ix (r_nmod) activity_26\NN\30358|normal|functional|factors (r_conj) evidence_20\NN\5816287|with|no|hemorrhage|and|activity (r_nmod) development_15\NN\248977|normal|and|survival|evidence (r_dobj) exhibit_13\VBP\2632167|mice|development|. (l_nsubj) mice_1\NNS\2329401|heterozygous|carrying (l_acl) carrying_2\VBG\1850315|mutation|gene (l_nmod) gene_12\NN\8459252|at|the|gamma-carboxylase|(|ggcx|) (l_compound) gamma-carboxylase_8\NN\1740|
T4_T11 NONE k-dependent_30\JJ\1740| (r_amod) factors_32\NNS\7326557|of|the|vitamin|k-dependent|clotting|ix (r_nmod) activity_26\NN\30358|normal|functional|factors (r_conj) evidence_20\NN\5816287|with|no|hemorrhage|and|activity (r_nmod) development_15\NN\248977|normal|and|survival|evidence (r_dobj) exhibit_13\VBP\2632167|mice|development|. (l_nsubj) mice_1\NNS\2329401|heterozygous|carrying (l_acl) carrying_2\VBG\1850315|mutation|gene (l_nmod) gene_12\NN\8459252|at|the|gamma-carboxylase|(|ggcx|) (l_compound) ggcx_10\NN\1740|
T4_T12 NONE k-dependent_30\JJ\1740| (r_amod) factors_32\NNS\7326557|of|the|vitamin|k-dependent|clotting|ix (l_dep) ix_33\CD\13741022|,|x|,|and|prothrombin (l_conj) x_35\NN\13745420|
T4_T13 NONE k-dependent_30\JJ\1740| (r_amod) factors_32\NNS\7326557|of|the|vitamin|k-dependent|clotting|ix (l_dep) ix_33\CD\13741022|,|x|,|and|prothrombin (l_conj) prothrombin_38\NN\15022776|
19852528
T15_T23 NONE serotonin_4\NN\14807737| (r_compound) receptor_6\NN\5225602|serotonin|5-ht3 (r_compound) antagonist_7\NN\7846|palonosetron|is|a|second-generation|receptor|,|profile|. (l_nmod) profile_13\NN\6999802|with|a|distinct|pharmacological|differs (l_acl:relcl) differs_15\VBZ\1740|that|antagonists (l_nmod) antagonists_20\NNS\7846|from|first-generation|5-ht3|receptor (l_compound) receptor_19\NN\5225602|
T15_T25 NONE serotonin_4\NN\14807737| (r_compound) receptor_6\NN\5225602|serotonin|5-ht3
T1_T23 CPR:6 palonosetron_0\NNP\1740| (r_nsubj) antagonist_7\NN\7846|palonosetron|is|a|second-generation|receptor|,|profile|. (l_nmod) profile_13\NN\6999802|with|a|distinct|pharmacological|differs (l_acl:relcl) differs_15\VBZ\1740|that|antagonists (l_nmod) antagonists_20\NNS\7846|from|first-generation|5-ht3|receptor (l_compound) receptor_19\NN\5225602|
T1_T25 CPR:6 palonosetron_0\NNP\1740| (r_nsubj) antagonist_7\NN\7846|palonosetron|is|a|second-generation|receptor|,|profile|. (l_compound) receptor_6\NN\5225602|serotonin|5-ht3
T12_T24 CPR:6 palonosetron_1\NN\1740|oral (r_nsubj) likely_3\JJ\1740|palonosetron|is|addition|. (l_xcomp) addition_8\NN\3081021|to|be|a|useful|formulations|preventing (l_nmod) formulations_11\NNS\14818238|to|oral|antagonists (l_nmod) antagonists_16\NNS\7846|of|other|receptor (l_compound) receptor_15\NN\5225602|5-ht3
23603059
T11_T29 CPR:3 arsenic_0\JJ\1740| (r_nsubj) upregulates_1\VBZ\1740|arsenic|expression|. (l_dobj) expression_3\NN\4679549|the|receptor|cells (l_nmod) receptor_9\NN\5225602|of|angiotensin|ii|type|i
T6_T21 CPR:3 arsenite_21\NN\1740|sodium|sa (r_compound) treatment_25\NN\654885|following|arsenite (r_nmod) increases_6\NNS\13576355|significant|levels|treatment (l_nmod) levels_10\NNS\4916342|in|the|mrna|subtypes (l_nmod) subtypes_14\NNS\1740|of|2|at1r|,|at1ar (l_compound) at1r_13\NN\1740|
T6_T22 CPR:3 arsenite_21\NN\1740|sodium|sa (r_compound) treatment_25\NN\654885|following|arsenite (r_nmod) increases_6\NNS\13576355|significant|levels|treatment (l_nmod) levels_10\NNS\4916342|in|the|mrna|subtypes (l_nmod) subtypes_14\NNS\1740|of|2|at1r|,|at1ar (l_appos) at1ar_16\NN\1740|and|at1br
T6_T23 CPR:3 arsenite_21\NN\1740|sodium|sa (r_compound) treatment_25\NN\654885|following|arsenite (r_nmod) increases_6\NNS\13576355|significant|levels|treatment (l_nmod) levels_10\NNS\4916342|in|the|mrna|subtypes (l_nmod) subtypes_14\NNS\1740|of|2|at1r|,|at1ar (l_appos) at1ar_16\NN\1740|and|at1br (l_conj) at1br_18\NN\1740|
T8_T24 NONE n-terminal_14\JJ\1740| (r_amod) kinases_15\NNS\14732946|of|c-jun|n-terminal|jnk|and|protein
T8_T25 NONE n-terminal_14\JJ\1740| (r_amod) kinases_15\NNS\14732946|of|c-jun|n-terminal|jnk|and|protein (l_appos) jnk_17\NNS\1740|(|)
T8_T26 NONE n-terminal_14\JJ\1740| (r_amod) kinases_15\NNS\14732946|of|c-jun|n-terminal|jnk|and|protein (l_conj) protein_21\NN\14944888|activated|1|ap-1 (l_nummod) 1_22\CD\13741022|
T8_T27 NONE n-terminal_14\JJ\1740| (r_amod) kinases_15\NNS\14732946|of|c-jun|n-terminal|jnk|and|protein (l_conj) protein_21\NN\14944888|activated|1|ap-1 (l_appos) ap-1_24\NN\1740|(|)
T1_T12 CPR:4 sp6001325_18\NN\1740| (r_appos) inhibitor_16\NN\20090|specific|jnk|,|sp6001325 (l_compound) jnk_15\NN\1740|
T1_T13 NONE sp6001325_18\NN\1740| (r_appos) inhibitor_16\NN\20090|specific|jnk|,|sp6001325 (r_conj) nac_12\NN\8310949|by|and|inhibitor (r_nmod) prevented_9\VBN\1740|to|be|both|nac|, (r_xcomp) found_6\VBN\2426171|finally|,|expression|was|prevented|indicating|. (l_xcomp) indicating_21\VBG\952524|strongly|result (l_ccomp) result_27\NN\34213|that|upregulation|is|a|activation (l_nsubj) upregulation_24\NN\1740|at1r (l_compound) at1r_23\NN\1740|
T1_T14 NONE sp6001325_18\NN\1740| (r_appos) inhibitor_16\NN\20090|specific|jnk|,|sp6001325 (r_conj) nac_12\NN\8310949|by|and|inhibitor (r_nmod) prevented_9\VBN\1740|to|be|both|nac|, (r_xcomp) found_6\VBN\2426171|finally|,|expression|was|prevented|indicating|. (l_xcomp) indicating_21\VBG\952524|strongly|result (l_ccomp) result_27\NN\34213|that|upregulation|is|a|activation (l_nmod) activation_31\NN\13561719|of|the|ros-mediated|pathway (l_nmod) pathway_36\NN\5483677|of|the|jnk|signaling (l_compound) jnk_34\NN\1740|
T1_T28 CPR:4 sp6001325_18\NN\1740| (r_appos) inhibitor_16\NN\20090|specific|jnk|,|sp6001325 (r_conj) nac_12\NN\8310949|by|and|inhibitor (r_nmod) prevented_9\VBN\1740|to|be|both|nac|, (r_xcomp) found_6\VBN\2426171|finally|,|expression|was|prevented|indicating|. (l_nsubjpass) expression_4\NN\4679549|sa-induced|at1r (l_compound) at1r_3\NN\1740|
T2_T15 CPR:3 arsenic_7\JJ\1740| (r_nsubj) upregulates_9\VBZ\1740|that|arsenic|indeed|expression|,|highlighting (l_dobj) expression_12\NN\4679549|the|at1r (l_compound) at1r_11\NN\1740|
T2_T16 NONE arsenic_7\JJ\1740| (r_nsubj) upregulates_9\VBZ\1740|that|arsenic|indeed|expression|,|highlighting (l_advcl) highlighting_15\VBG\514463|thus|role (l_dobj) role_17\NN\719494|a|signaling|pathogenesis (l_nmod) signaling_22\NN\33020|of|arsenic-induced|aberrant|at1r (l_compound) at1r_21\NN\1740|
T3_T15 NONE arsenic-induced_19\JJ\1740| (r_amod) signaling_22\NN\33020|of|arsenic-induced|aberrant|at1r (r_nmod) role_17\NN\719494|a|signaling|pathogenesis (r_dobj) highlighting_15\VBG\514463|thus|role (r_advcl) upregulates_9\VBZ\1740|that|arsenic|indeed|expression|,|highlighting (l_dobj) expression_12\NN\4679549|the|at1r (l_compound) at1r_11\NN\1740|
T3_T16 CPR:3 arsenic-induced_19\JJ\1740| (r_amod) signaling_22\NN\33020|of|arsenic-induced|aberrant|at1r (l_compound) at1r_21\NN\1740|
16938288
T11_T37 CPR:4 telmisartan_0\NN\1740| (r_nsubj) downregulates_1\VBZ\1740|telmisartan|receptor|activation|. (l_dobj) receptor_6\NN\5225602|angiotensin|ii|type|1
T11_T38 CPR:3 telmisartan_0\NN\1740| (r_nsubj) downregulates_1\VBZ\1740|telmisartan|receptor|activation|. (l_nmod) activation_8\NN\13561719|through|gamma (l_nmod) gamma_13\NN\6828818|of|peroxisome|proliferator-activated|receptor
T3_T19 CPR:5 telmisartan_2\NN\1740|,|antagonist|, (r_appos) objective_0\NN\5980875|:|telmisartan (r_nsubjpass) found_16\VBN\2426171|objective|was|have|:|agonist|. (l_parataxis) agonist_27\NN\9613191|it|is|a|partial|gamma (l_nmod) gamma_32\NN\6828818|of|peroxisome|proliferator-activated|receptor|ppargamma
T3_T26 CPR:5 telmisartan_2\NN\1740|,|antagonist|, (r_appos) objective_0\NN\5980875|:|telmisartan (r_nsubjpass) found_16\VBN\2426171|objective|was|have|:|agonist|. (l_parataxis) agonist_27\NN\9613191|it|is|a|partial|gamma (l_nmod) gamma_32\NN\6828818|of|peroxisome|proliferator-activated|receptor|ppargamma (l_appos) ppargamma_34\NN\1740|(|)
T3_T28 CPR:6 telmisartan_2\NN\1740|,|antagonist|, (l_appos) antagonist_13\NN\7846|an|receptor (l_compound) receptor_9\NN\5225602|angiotensin|ii|type|1|at1r
T3_T32 CPR:6 telmisartan_2\NN\1740|,|antagonist|, (l_appos) antagonist_13\NN\7846|an|receptor (l_compound) receptor_9\NN\5225602|angiotensin|ii|type|1|at1r (l_appos) at1r_11\NN\1740|(|)
T8_T27 NONE telmisartan_15\NN\1740| (r_nsubj) affects_16\VBZ\126264|whether|telmisartan|expression (r_ccomp) examined_13\VBD\789138|demonstrated|,|we|affects|. (l_advcl) demonstrated_4\VBN\2137132|since|studies|have|suppressed (l_ccomp) suppressed_8\VBD\2510337|that|activators|expression (l_nsubj) activators_7\NNS\19613|ppargamma (l_compound) ppargamma_6\NN\1740|
T8_T29 NONE telmisartan_15\NN\1740| (r_nsubj) affects_16\VBZ\126264|whether|telmisartan|expression (r_ccomp) examined_13\VBD\789138|demonstrated|,|we|affects|. (l_advcl) demonstrated_4\VBN\2137132|since|studies|have|suppressed (l_ccomp) suppressed_8\VBD\2510337|that|activators|expression (l_dobj) expression_10\NN\4679549|at1r (l_compound) at1r_9\NN\1740|
T8_T30 NONE telmisartan_15\NN\1740| (r_nsubj) affects_16\VBZ\126264|whether|telmisartan|expression (l_dobj) expression_18\NN\4679549|at1r|cells (l_compound) at1r_17\NN\1740|
T9_T34 CPR:4 telmisartan_2\NN\1740| (r_appos) results_0\NNS\34213|:|telmisartan (r_nsubj) decreased_3\VBD\169651|results|expression|levels|manner|. (l_dobj) expression_5\NN\4679549|the|at1r (l_nmod) at1r_7\NN\1740|of
T10_T35 NONE telmisartan_10\NN\1740| (r_nsubj) suppressed_11\VBD\2510337|that|telmisartan|expression|level (r_ccomp) suggested_8\VBD\1010118|activity|suppressed|. (l_nsubj) activity_3\NN\30358|decreased|at1r|promoter|stability (l_compound) promoter_2\NN\9773962|
T10_T36 CPR:4 telmisartan_10\NN\1740| (r_nsubj) suppressed_11\VBD\2510337|that|telmisartan|expression|level (l_dobj) expression_14\NN\4679549|at1r|gene (l_compound) at1r_12\NN\1740|
T1_T12 NONE candesartan_15\NN\1740|such|or|olmesartan (r_nmod) antagonists_12\NNS\7846|by|other|at1r|candesartan (r_nmod) suppressed_8\VBN\2510337|however|,|expression|was|not|antagonists|. (l_nsubjpass) expression_3\NN\4679549|the|at1r (l_nmod) at1r_5\NN\1740|of
T1_T13 CPR:6 candesartan_15\NN\1740|such|or|olmesartan (r_nmod) antagonists_12\NNS\7846|by|other|at1r|candesartan (l_compound) at1r_11\NN\1740|
T2_T12 NONE olmesartan_17\NN\1740| (r_conj) candesartan_15\NN\1740|such|or|olmesartan (r_nmod) antagonists_12\NNS\7846|by|other|at1r|candesartan (r_nmod) suppressed_8\VBN\2510337|however|,|expression|was|not|antagonists|. (l_nsubjpass) expression_3\NN\4679549|the|at1r (l_nmod) at1r_5\NN\1740|of
T2_T13 CPR:6 olmesartan_17\NN\1740| (r_conj) candesartan_15\NN\1740|such|or|olmesartan (r_nmod) antagonists_12\NNS\7846|by|other|at1r|candesartan (l_compound) at1r_11\NN\1740|
T4_T14 CPR:3 gw9662_11\NN\1740|with (r_nmod) pretreatment_9\NN\1740|by|gw9662 (r_nmod) prevented_7\VBN\1740|since|suppression|was|pretreatment (l_nsubjpass) suppression_2\NN\13489037|the|expression (l_nmod) expression_5\NN\4679549|of|at1r (l_compound) at1r_4\NN\1740|
T4_T15 CPR:6 gw9662_11\NN\1740|with (r_nmod) pretreatment_9\NN\1740|by|gw9662 (r_nmod) prevented_7\VBN\1740|since|suppression|was|pretreatment (r_advcl) participated_20\VBN\2367363|prevented|,|antagonist|should|have|process|. (l_nsubj) antagonist_15\NN\7846|a|ppargamma|,|ppargamma (l_compound) ppargamma_14\NN\1740|
T4_T16 NONE gw9662_11\NN\1740|with (r_nmod) pretreatment_9\NN\1740|by|gw9662 (r_nmod) prevented_7\VBN\1740|since|suppression|was|pretreatment (r_advcl) participated_20\VBN\2367363|prevented|,|antagonist|should|have|process|. (l_nsubj) antagonist_15\NN\7846|a|ppargamma|,|ppargamma (l_appos) ppargamma_17\NN\1740|
T5_T17 CPR:4 telmisartan-induced_25\JJ\1740| (r_amod) downregulation_26\NN\1740|for|the|telmisartan-induced (r_nmod) responsible_22\JJ\1740|that|box|is|downregulation (r_ccomp) indicated_10\VBD\952524|deletion|responsible|. (l_nsubj) deletion_1\NN\13508333|the|and|mutation|analysis|promoter (l_nmod) promoter_9\NN\9773962|of|the|at1r|gene (l_compound) at1r_7\NN\1740|
T5_T18 CPR:4 telmisartan-induced_25\JJ\1740| (r_amod) downregulation_26\NN\1740|for|the|telmisartan-induced (r_nmod) responsible_22\JJ\1740|that|box|is|downregulation (l_nsubj) box_14\NN\3094503|a|gc|located
T7_T20 CPR:4 telmisartan_0\NN\1740| (r_nsubj) inhibits_1\VBZ\2510337|telmisartan|expression|activation|. (l_dobj) expression_4\NN\4679549|at1r|gene (l_compound) at1r_2\NN\1740|
T7_T21 CPR:3 telmisartan_0\NN\1740| (r_nsubj) inhibits_1\VBZ\2510337|telmisartan|expression|activation|. (l_nmod) activation_7\NN\13561719|through|ppargamma (l_compound) ppargamma_6\NN\1740|
23434223
T7_T11 CPR:4 dihydrobenzo[b]thiophenes_9\NNS\1740|of|functionalized (r_nmod) synthesis_3\NN\13446390|a|one-pot|domino|and|discovery|dihydrobenzo[b]thiophenes|inhibitors|. (l_nmod) inhibitors_12\NNS\20090|as|ache (l_compound) ache_11\NN\14322699|
T6_T10 CPR:4 5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile_13\NN\1740| (r_nsubjpass) found_15\VBN\2426171|5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile|was|potent (l_xcomp) potent_20\JJ\1740|to|be|the|most|ache|ic50 (l_nmod) ache_22\NN\14322699|against
T6_T8 NONE 5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile_13\NN\1740| (r_nsubjpass) found_15\VBN\2426171|5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile|was|potent (r_conj) evaluated_3\VBN\670261|compounds|were|activity|and|found (l_nmod) activity_11\NN\30358|for|their|acetylcholinesterase|inhibitory (l_compound) acetylcholinesterase_6\NN\1740|ache
T6_T9 NONE 5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile_13\NN\1740| (r_nsubjpass) found_15\VBN\2426171|5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile|was|potent (r_conj) evaluated_3\VBN\670261|compounds|were|activity|and|found (l_nmod) activity_11\NN\30358|for|their|acetylcholinesterase|inhibitory (l_compound) acetylcholinesterase_6\NN\1740|ache (l_appos) ache_8\NN\14322699|(|)
15557593
T4_T17 NONE tyrosine_18\NN\14601829| (r_compound) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (l_compound) kinase_19\NN\14732946|
T4_T18 NONE tyrosine_18\NN\14601829| (r_compound) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (r_nsubjpass) used_27\VBN\1156834|materials|improve|,|inhibitors|were|disrupt|. (l_xcomp) disrupt_29\VB\362348|to|support|concert (l_dobj) support_32\NN\407535|pdgfr-mediated|pericyte|cells (l_amod) pdgfr-mediated_30\JJ\1740|
T4_T19 NONE tyrosine_18\NN\14601829| (r_compound) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (r_nsubjpass) used_27\VBN\1156834|materials|improve|,|inhibitors|were|disrupt|. (l_xcomp) disrupt_29\VB\362348|to|support|concert (l_nmod) concert_38\NN\6891493|in|dose (l_nmod) dose_41\NN\3740161|with|maximum-tolerated|mtd|or|chemotherapy (l_conj) chemotherapy_47\NN\661091|metronomic|and/or|inhibition (l_conj) inhibition_50\NN\1068773|vegfr (l_compound) vegfr_49\NN\1740|
T5_T17 CPR:4 imatinib_22\NN\1740|and|su11248 (r_appos) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (l_compound) kinase_19\NN\14732946|
T5_T18 CPR:4 imatinib_22\NN\1740|and|su11248 (r_appos) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (r_nsubjpass) used_27\VBN\1156834|materials|improve|,|inhibitors|were|disrupt|. (l_xcomp) disrupt_29\VB\362348|to|support|concert (l_dobj) support_32\NN\407535|pdgfr-mediated|pericyte|cells (l_amod) pdgfr-mediated_30\JJ\1740|
T5_T19 CPR:4 imatinib_22\NN\1740|and|su11248 (r_appos) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (r_nsubjpass) used_27\VBN\1156834|materials|improve|,|inhibitors|were|disrupt|. (l_xcomp) disrupt_29\VB\362348|to|support|concert (l_nmod) concert_38\NN\6891493|in|dose (l_nmod) dose_41\NN\3740161|with|maximum-tolerated|mtd|or|chemotherapy (l_conj) chemotherapy_47\NN\661091|metronomic|and/or|inhibition (l_conj) inhibition_50\NN\1068773|vegfr (l_compound) vegfr_49\NN\1740|
T6_T17 CPR:4 su11248_24\NN\1740| (r_conj) imatinib_22\NN\1740|and|su11248 (r_appos) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (l_compound) kinase_19\NN\14732946|
T6_T18 CPR:4 su11248_24\NN\1740| (r_conj) imatinib_22\NN\1740|and|su11248 (r_appos) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (r_nsubjpass) used_27\VBN\1156834|materials|improve|,|inhibitors|were|disrupt|. (l_xcomp) disrupt_29\VB\362348|to|support|concert (l_dobj) support_32\NN\407535|pdgfr-mediated|pericyte|cells (l_amod) pdgfr-mediated_30\JJ\1740|
T6_T19 CPR:4 su11248_24\NN\1740| (r_conj) imatinib_22\NN\1740|and|su11248 (r_appos) inhibitors_20\NNS\20090|two|receptor|tyrosine|kinase|,|imatinib|, (r_nsubjpass) used_27\VBN\1156834|materials|improve|,|inhibitors|were|disrupt|. (l_xcomp) disrupt_29\VB\362348|to|support|concert (l_nmod) concert_38\NN\6891493|in|dose (l_nmod) dose_41\NN\3740161|with|maximum-tolerated|mtd|or|chemotherapy (l_conj) chemotherapy_47\NN\661091|metronomic|and/or|inhibition (l_conj) inhibition_50\NN\1068773|vegfr (l_compound) vegfr_49\NN\1740|
T7_T8 CPR:4 imatinib_2\NN\1740| (r_nsubj) reduced_10\VBD\441445|imatinib|,|efficacy|coverage|and|enhanced|. (l_conj) enhanced_17\VBD\227165|efficacy (l_dobj) efficacy_18\NN\5199286|combination (l_nmod) combination_20\NN\7951464|in|chemotherapy (l_nmod) chemotherapy_23\NN\661091|with|metronomic|or|inhibition (l_conj) inhibition_26\NN\1068773|vegfr (l_compound) vegfr_25\NN\1740|
17768678
T34_T44 CPR:4 phenelzine_0\NN\3783017| (r_nsubj) causes_1\VBZ\1617192|phenelzine|increase|. (l_dobj) increase_3\NN\13576355|an|ornithine|prevented (l_acl:relcl) prevented_9\VBN\1740|that|is|inhibition (l_nmod) inhibition_14\NN\1068773|by|prior|oxidase (l_compound) oxidase_13\NN\14732946|monoamine
T35_T44 NONE monoamine_12\NN\14739004| (r_compound) oxidase_13\NN\14732946|monoamine
T14_T36 NONE gaba_26\NN\14601829| (r_compound) levels_27\NNS\4916342|brain|gaba (r_dobj) increasing_24\VBG\169651|markedly|levels (r_advcl) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_dobj) gaba-transaminase_18\NN\1740|gaba-t (l_appos) gaba-t_20\NN\1740|(|)
T14_T39 NONE gaba_26\NN\14601829| (r_compound) levels_27\NNS\4916342|brain|gaba (r_dobj) increasing_24\VBG\169651|markedly|levels (r_advcl) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_nsubj) phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao
T14_T40 NONE gaba_26\NN\14601829| (r_compound) levels_27\NNS\4916342|brain|gaba (r_dobj) increasing_24\VBG\169651|markedly|levels (r_advcl) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_nsubj) phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao (l_appos) mao_13\NN\14732946|(|)
T14_T43 NONE gaba_26\NN\14601829| (r_compound) levels_27\NNS\4916342|brain|gaba (r_dobj) increasing_24\VBG\169651|markedly|levels (r_advcl) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_dobj) gaba-transaminase_18\NN\1740|gaba-t
T1_T36 CPR:4 phenelzine_0\NN\3783017|plz|,|inhibitor|, (r_nsubj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_dobj) gaba-transaminase_18\NN\1740|gaba-t (l_appos) gaba-t_20\NN\1740|(|)
T1_T39 CPR:4 phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao
T1_T40 CPR:4 phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao (l_appos) mao_13\NN\14732946|(|)
T1_T43 CPR:4 phenelzine_0\NN\3783017|plz|,|inhibitor|, (r_nsubj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_dobj) gaba-transaminase_18\NN\1740|gaba-t
T27_T36 NONE monoamine_10\NN\14739004| (r_compound) oxidase_11\NN\14732946|of|monoamine|mao (r_nmod) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (r_appos) phenelzine_0\NN\3783017|plz|,|inhibitor|, (r_nsubj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_dobj) gaba-transaminase_18\NN\1740|gaba-t (l_appos) gaba-t_20\NN\1740|(|)
T27_T39 NONE monoamine_10\NN\14739004| (r_compound) oxidase_11\NN\14732946|of|monoamine|mao
T27_T40 NONE monoamine_10\NN\14739004| (r_compound) oxidase_11\NN\14732946|of|monoamine|mao (l_appos) mao_13\NN\14732946|(|)
T27_T43 NONE monoamine_10\NN\14739004| (r_compound) oxidase_11\NN\14732946|of|monoamine|mao (r_nmod) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (r_appos) phenelzine_0\NN\3783017|plz|,|inhibitor|, (r_nsubj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_dobj) gaba-transaminase_18\NN\1740|gaba-t
T33_T36 NONE gaba-transaminase_18\NN\1740|gaba-t (l_appos) gaba-t_20\NN\1740|(|)
T33_T39 NONE gaba-transaminase_18\NN\1740|gaba-t (r_dobj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_nsubj) phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao
T33_T40 NONE gaba-transaminase_18\NN\1740|gaba-t (r_dobj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_nsubj) phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao (l_appos) mao_13\NN\14732946|(|)
T33_T43 NONE gaba-transaminase_18\NN\1740|gaba-t
T5_T36 NONE gaba-t_20\NN\1740|(|)
T5_T39 NONE gaba-t_20\NN\1740|(|) (r_appos) gaba-transaminase_18\NN\1740|gaba-t (r_dobj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_nsubj) phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao
T5_T40 NONE gaba-t_20\NN\1740|(|) (r_appos) gaba-transaminase_18\NN\1740|gaba-t (r_dobj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_nsubj) phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao (l_appos) mao_13\NN\14732946|(|)
T5_T43 NONE gaba-t_20\NN\1740|(|) (r_appos) gaba-transaminase_18\NN\1740|gaba-t
T6_T36 CPR:4 plz_2\NN\1740|(|) (r_appos) phenelzine_0\NN\3783017|plz|,|inhibitor|, (r_nsubj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_dobj) gaba-transaminase_18\NN\1740|gaba-t (l_appos) gaba-t_20\NN\1740|(|)
T6_T39 CPR:4 plz_2\NN\1740|(|) (r_appos) phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao
T6_T40 CPR:4 plz_2\NN\1740|(|) (r_appos) phenelzine_0\NN\3783017|plz|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_11\NN\14732946|of|monoamine|mao (l_appos) mao_13\NN\14732946|(|)
T6_T43 CPR:4 plz_2\NN\1740|(|) (r_appos) phenelzine_0\NN\3783017|plz|,|inhibitor|, (r_nsubj) inhibits_17\VBZ\2510337|phenelzine|also|gaba-transaminase|,|increasing|. (l_dobj) gaba-transaminase_18\NN\1740|gaba-t
T16_T38 CPR:9 plz_0\NN\1740| (r_nsubj) substrate_4\NN\19613|plz|is|also|a|mao|,|and|suggest|. (l_nmod) mao_6\NN\14732946|for
T17_T38 NONE plz_22\NN\1740|on (r_nmod) action_17\NN\30358|by|the|enzyme|plz (r_nmod) formed_14\VBN\1617192|action (r_acl) metabolite_13\NN\20090|a|formed (r_nsubj) responsible_25\JJ\1740|that|metabolite|may|be|increase (r_ccomp) suggest_10\VBP\1010118|studies|responsible (r_conj) substrate_4\NN\19613|plz|is|also|a|mao|,|and|suggest|. (l_nmod) mao_6\NN\14732946|for
T18_T38 NONE gaba_30\NN\14601829|in|observed (r_nmod) increase_28\NN\13576355|for|the|gaba (r_nmod) responsible_25\JJ\1740|that|metabolite|may|be|increase (r_ccomp) suggest_10\VBP\1010118|studies|responsible (r_conj) substrate_4\NN\19613|plz|is|also|a|mao|,|and|suggest|. (l_nmod) mao_6\NN\14732946|for
T29_T41 NONE plz_12\NN\1740|on (r_nmod) action_8\NN\30358|by|the|mao|plz (l_nmod) mao_10\NN\14732946|of
T29_T42 NONE plz_12\NN\1740|on (r_nmod) action_8\NN\30358|by|the|mao|plz (r_nmod) formed_5\VBN\1617192|action (r_acl) metabolite_4\NN\20090|a|formed (r_nsubj) responsible_15\JJ\1740|whether|metabolite|may|be|elevation (r_ccomp) determine_1\VB\1645601|to|responsible|, (r_advcl) pretreated_26\VBN\1740|determine|animals|were|vehicle|vehicle|,|and|brains|. (l_nmod) vehicle_28\NN\3100490|with|or|tranylcypromine (l_conj) tranylcypromine_33\NN\3783017|the|mao|inhibitor|tcp (l_compound) mao_31\NN\14732946|
T2_T41 NONE plz_40\NN\1740|mg/kg (r_conj) vehicle_38\NN\3100490|before|or|plz (r_nmod) pretreated_26\VBN\1740|determine|animals|were|vehicle|vehicle|,|and|brains|. (l_advcl) determine_1\VB\1645601|to|responsible|, (l_ccomp) responsible_15\JJ\1740|whether|metabolite|may|be|elevation (l_nsubj) metabolite_4\NN\20090|a|formed (l_acl) formed_5\VBN\1617192|action (l_nmod) action_8\NN\30358|by|the|mao|plz (l_nmod) mao_10\NN\14732946|of
T2_T42 NONE plz_40\NN\1740|mg/kg (r_conj) vehicle_38\NN\3100490|before|or|plz (r_nmod) pretreated_26\VBN\1740|determine|animals|were|vehicle|vehicle|,|and|brains|. (l_nmod) vehicle_28\NN\3100490|with|or|tranylcypromine (l_conj) tranylcypromine_33\NN\3783017|the|mao|inhibitor|tcp (l_compound) mao_31\NN\14732946|
T30_T41 NONE orn_21\NN\1740|in|brain (r_nmod) elevation_18\NN\7445480|for|the|orn|observed (r_nmod) responsible_15\JJ\1740|whether|metabolite|may|be|elevation (l_nsubj) metabolite_4\NN\20090|a|formed (l_acl) formed_5\VBN\1617192|action (l_nmod) action_8\NN\30358|by|the|mao|plz (l_nmod) mao_10\NN\14732946|of
T30_T42 NONE orn_21\NN\1740|in|brain (r_nmod) elevation_18\NN\7445480|for|the|orn|observed (r_nmod) responsible_15\JJ\1740|whether|metabolite|may|be|elevation (r_ccomp) determine_1\VB\1645601|to|responsible|, (r_advcl) pretreated_26\VBN\1740|determine|animals|were|vehicle|vehicle|,|and|brains|. (l_nmod) vehicle_28\NN\3100490|with|or|tranylcypromine (l_conj) tranylcypromine_33\NN\3783017|the|mao|inhibitor|tcp (l_compound) mao_31\NN\14732946|
T31_T41 NONE tranylcypromine_33\NN\3783017|the|mao|inhibitor|tcp (r_conj) vehicle_28\NN\3100490|with|or|tranylcypromine (r_nmod) pretreated_26\VBN\1740|determine|animals|were|vehicle|vehicle|,|and|brains|. (l_advcl) determine_1\VB\1645601|to|responsible|, (l_ccomp) responsible_15\JJ\1740|whether|metabolite|may|be|elevation (l_nsubj) metabolite_4\NN\20090|a|formed (l_acl) formed_5\VBN\1617192|action (l_nmod) action_8\NN\30358|by|the|mao|plz (l_nmod) mao_10\NN\14732946|of
T31_T42 CPR:4 tranylcypromine_33\NN\3783017|the|mao|inhibitor|tcp (l_compound) mao_31\NN\14732946|
T32_T41 NONE tcp_35\NN\6665108|(|) (r_appos) tranylcypromine_33\NN\3783017|the|mao|inhibitor|tcp (r_conj) vehicle_28\NN\3100490|with|or|tranylcypromine (r_nmod) pretreated_26\VBN\1740|determine|animals|were|vehicle|vehicle|,|and|brains|. (l_advcl) determine_1\VB\1645601|to|responsible|, (l_ccomp) responsible_15\JJ\1740|whether|metabolite|may|be|elevation (l_nsubj) metabolite_4\NN\20090|a|formed (l_acl) formed_5\VBN\1617192|action (l_nmod) action_8\NN\30358|by|the|mao|plz (l_nmod) mao_10\NN\14732946|of
T32_T42 CPR:4 tcp_35\NN\6665108|(|) (r_appos) tranylcypromine_33\NN\3783017|the|mao|inhibitor|tcp (l_compound) mao_31\NN\14732946|
T10_T37 NONE gaba_16\NN\14601829|as|with (r_nmod) suggesting_12\VBG\1010118|,|gaba|,|responsible (l_ccomp) responsible_30\JJ\1740|that|metabolite|is|elevation (l_nsubj) metabolite_20\NN\20090|a|plz|formed (l_acl) formed_23\VBN\1617192|action (l_nmod) action_26\NN\30358|by|the|mao (l_nmod) mao_28\NN\14732946|of
T11_T37 CPR:9 plz_22\NN\1740|of (r_nmod) metabolite_20\NN\20090|a|plz|formed (l_acl) formed_23\VBN\1617192|action (l_nmod) action_26\NN\30358|by|the|mao (l_nmod) mao_28\NN\14732946|of
T12_T37 NONE orn_36\NN\1740|of|brain (r_nmod) elevation_33\NN\7445480|for|the|orn|observed (r_nmod) responsible_30\JJ\1740|that|metabolite|is|elevation (l_nsubj) metabolite_20\NN\20090|a|plz|formed (l_acl) formed_23\VBN\1617192|action (l_nmod) action_26\NN\30358|by|the|mao (l_nmod) mao_28\NN\14732946|of
T7_T37 NONE tcp_2\NN\6665108|with (r_nmod) pretreatment_0\NN\1740|tcp (r_nsubj) abolished_4\VBD\1740|pretreatment|completely|increase|,|suggesting|. (l_advcl) suggesting_12\VBG\1010118|,|gaba|,|responsible (l_ccomp) responsible_30\JJ\1740|that|metabolite|is|elevation (l_nsubj) metabolite_20\NN\20090|a|plz|formed (l_acl) formed_23\VBN\1617192|action (l_nmod) action_26\NN\30358|by|the|mao (l_nmod) mao_28\NN\14732946|of
T8_T37 NONE plz-induced_6\JJ\1740| (r_amod) increase_7\NN\13576355|the|plz-induced|orn (r_dobj) abolished_4\VBD\1740|pretreatment|completely|increase|,|suggesting|. (l_advcl) suggesting_12\VBG\1010118|,|gaba|,|responsible (l_ccomp) responsible_30\JJ\1740|that|metabolite|is|elevation (l_nsubj) metabolite_20\NN\20090|a|plz|formed (l_acl) formed_23\VBN\1617192|action (l_nmod) action_26\NN\30358|by|the|mao (l_nmod) mao_28\NN\14732946|of
T9_T37 NONE orn_10\NN\1740|in|brain (r_nmod) increase_7\NN\13576355|the|plz-induced|orn (r_dobj) abolished_4\VBD\1740|pretreatment|completely|increase|,|suggesting|. (l_advcl) suggesting_12\VBG\1010118|,|gaba|,|responsible (l_ccomp) responsible_30\JJ\1740|that|metabolite|is|elevation (l_nsubj) metabolite_20\NN\20090|a|plz|formed (l_acl) formed_23\VBN\1617192|action (l_nmod) action_26\NN\30358|by|the|mao (l_nmod) mao_28\NN\14732946|of
9521275
T3_T10 NONE testosterone_5\NN\14747587|of|and|testolactone (l_conj) testolactone_10\NN\1740|the|aromatase|inhibitor (l_compound) aromatase_8\NN\1740|
T4_T10 CPR:4 testolactone_10\NN\1740|the|aromatase|inhibitor (l_compound) aromatase_8\NN\1740|
T5_T10 NONE testosterone_24\NN\14747587|than|alone (r_nmod) effects_15\NNS\13245626|better|function|frequency|testosterone (r_dobj) have_12\VB\2108377|treatment|may|effects|. (l_nsubj) treatment_0\NN\654885|using (l_acl) using_1\VBG\1156834|combination (l_dobj) combination_3\NN\7951464|a|testosterone (l_nmod) testosterone_5\NN\14747587|of|and|testolactone (l_conj) testolactone_10\NN\1740|the|aromatase|inhibitor (l_compound) aromatase_8\NN\1740|
23494802
T6_T15 NONE curcuminoids_0\NNS\1740| (r_nsubj) modulate_1\VBP\1724459|curcuminoids|balance|. (l_dobj) balance_3\NN\13934900|pro-oxidant-antioxidant|not|response (l_conj) response_8\NN\11410625|the|immune|protein (l_nmod) protein_12\NN\14944888|to|heat|shock|27|and|ldl|individuals (l_conj) ldl_16\NN\14939230|oxidized
T6_T16 NONE curcuminoids_0\NNS\1740| (r_nsubj) modulate_1\VBP\1724459|curcuminoids|balance|. (l_dobj) balance_3\NN\13934900|pro-oxidant-antioxidant|not|response (l_conj) response_8\NN\11410625|the|immune|protein (l_nmod) protein_12\NN\14944888|to|heat|shock|27|and|ldl|individuals (l_nummod) 27_13\CD\13745420|
T3_T10 NONE curcuminoid_12\NN\1740| (r_compound) supplement_13\NN\6365467|of|a|curcuminoid (r_nmod) effects_9\NNS\13245626|the|supplement|balance (l_nmod) balance_17\NN\13934900|on|serum|pro-oxidant-antioxidant|pab|and|titres (l_conj) titres_23\NNS\5038593|antibody|hsp27 (l_nmod) hsp27_25\NN\1740|to|anti-hsp27|and|oxldl (l_conj) oxldl_30\NN\1740|anti-oxldl (l_appos) anti-oxldl_32\NN\1740|(|)
T3_T7 NONE curcuminoid_12\NN\1740| (r_compound) supplement_13\NN\6365467|of|a|curcuminoid (r_nmod) effects_9\NNS\13245626|the|supplement|balance (l_nmod) balance_17\NN\13934900|on|serum|pro-oxidant-antioxidant|pab|and|titres (l_conj) titres_23\NNS\5038593|antibody|hsp27 (l_nmod) hsp27_25\NN\1740|to|anti-hsp27|and|oxldl
T3_T8 NONE curcuminoid_12\NN\1740| (r_compound) supplement_13\NN\6365467|of|a|curcuminoid (r_nmod) effects_9\NNS\13245626|the|supplement|balance (l_nmod) balance_17\NN\13934900|on|serum|pro-oxidant-antioxidant|pab|and|titres (l_conj) titres_23\NNS\5038593|antibody|hsp27 (l_nmod) hsp27_25\NN\1740|to|anti-hsp27|and|oxldl (l_appos) anti-hsp27_27\NN\1740|(|)
T3_T9 NONE curcuminoid_12\NN\1740| (r_compound) supplement_13\NN\6365467|of|a|curcuminoid (r_nmod) effects_9\NNS\13245626|the|supplement|balance (l_nmod) balance_17\NN\13934900|on|serum|pro-oxidant-antioxidant|pab|and|titres (l_conj) titres_23\NNS\5038593|antibody|hsp27 (l_nmod) hsp27_25\NN\1740|to|anti-hsp27|and|oxldl (l_conj) oxldl_30\NN\1740|anti-oxldl
10193665
T24_T30 NONE neuroleptics_3\NNS\4470232|of (r_nmod) profile_1\NN\6999802|pharmacological|neuroleptics|transporters|. (l_nmod) transporters_7\NNS\4490091|at|human|monoamine
T25_T30 NONE monoamine_6\NN\14739004| (r_compound) transporters_7\NNS\4490091|at|human|monoamine
T1_T26 NONE neuroleptics_17\NNS\4470232|for|37|and|metabolite (l_conj) metabolite_20\NN\20090|one|neuroleptic|transporters (l_nmod) transporters_37\NNS\4490091|for|the|serotonin
T2_T26 NONE haloperidol_25\NN\3713736| (r_compound) metabolite_26\NN\20090|(|haloperidol|) (r_appos) neuroleptic_23\NN\4470232|of|a|metabolite (r_nmod) metabolite_20\NN\20090|one|neuroleptic|transporters (l_nmod) transporters_37\NNS\4490091|for|the|serotonin
T3_T26 NONE serotonin_31\NN\14807737|human|,|norepinephrine|,|and|dopamine (r_compound) transporters_37\NNS\4490091|for|the|serotonin
T4_T26 NONE norepinephrine_33\NN\14807929| (r_conj) serotonin_31\NN\14807737|human|,|norepinephrine|,|and|dopamine (r_compound) transporters_37\NNS\4490091|for|the|serotonin
T5_T26 NONE dopamine_36\NN\14807737| (r_conj) serotonin_31\NN\14807737|human|,|norepinephrine|,|and|dopamine (r_compound) transporters_37\NNS\4490091|for|the|serotonin
T6_T26 NONE [3h]imipramine_39\NN\1740|with|,|[3h]nisoxetine|,|and|[3h]win35428|, (r_nmod) determined_6\VBD\1645601|using|,|we|constants|[3h]imipramine|respectively|. (l_dobj) constants_10\NNS\5855125|the|equilibrium|dissociation|k(d|neuroleptics (l_nmod) neuroleptics_17\NNS\4470232|for|37|and|metabolite (l_conj) metabolite_20\NN\20090|one|neuroleptic|transporters (l_nmod) transporters_37\NNS\4490091|for|the|serotonin
T7_T26 NONE [3h]nisoxetine_41\NN\1740| (r_conj) [3h]imipramine_39\NN\1740|with|,|[3h]nisoxetine|,|and|[3h]win35428|, (r_nmod) determined_6\VBD\1645601|using|,|we|constants|[3h]imipramine|respectively|. (l_dobj) constants_10\NNS\5855125|the|equilibrium|dissociation|k(d|neuroleptics (l_nmod) neuroleptics_17\NNS\4470232|for|37|and|metabolite (l_conj) metabolite_20\NN\20090|one|neuroleptic|transporters (l_nmod) transporters_37\NNS\4490091|for|the|serotonin
T8_T26 NONE [3h]win35428_44\NN\1740| (r_conj) [3h]imipramine_39\NN\1740|with|,|[3h]nisoxetine|,|and|[3h]win35428|, (r_nmod) determined_6\VBD\1645601|using|,|we|constants|[3h]imipramine|respectively|. (l_dobj) constants_10\NNS\5855125|the|equilibrium|dissociation|k(d|neuroleptics (l_nmod) neuroleptics_17\NNS\4470232|for|37|and|metabolite (l_conj) metabolite_20\NN\20090|one|neuroleptic|transporters (l_nmod) transporters_37\NNS\4490091|for|the|serotonin
T10_T27 NONE serotonin_11\NN\14807737| (r_compound) transporter_12\NN\4490091|at|the|human|serotonin
T10_T28 NONE serotonin_11\NN\14807737| (r_compound) transporter_12\NN\4490091|at|the|human|serotonin (r_nmod) compounds_7\NNS\5869584|the|four|potent|transporter (r_nsubj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_conj) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T11_T27 NONE triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T11_T28 NONE triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_conj) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T12_T27 NONE fluperlapine_16\NN\1740| (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T12_T28 NONE fluperlapine_16\NN\1740| (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_conj) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T13_T27 NONE chlorpromazine_18\NN\3713736| (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T13_T28 NONE chlorpromazine_18\NN\3713736| (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_conj) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T14_T27 NONE ziprasidone_21\NN\1740| (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T14_T28 NONE ziprasidone_21\NN\1740| (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_conj) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T15_T27 NONE norepinephrine_34\NN\14807929| (r_compound) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T15_T28 NONE norepinephrine_34\NN\14807929| (r_compound) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T16_T27 NONE chlorpromazine_37\NN\3713736|,|zotepine|,|chlorprothixene|,|and|promazine (r_appos) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T16_T28 NONE chlorpromazine_37\NN\3713736|,|zotepine|,|chlorprothixene|,|and|promazine (r_appos) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T17_T27 NONE zotepine_39\NN\1740| (r_conj) chlorpromazine_37\NN\3713736|,|zotepine|,|chlorprothixene|,|and|promazine (r_appos) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T17_T28 NONE zotepine_39\NN\1740| (r_conj) chlorpromazine_37\NN\3713736|,|zotepine|,|chlorprothixene|,|and|promazine (r_appos) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T18_T27 NONE chlorprothixene_41\NN\1740| (r_conj) chlorpromazine_37\NN\3713736|,|zotepine|,|chlorprothixene|,|and|promazine (r_appos) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T18_T28 NONE chlorprothixene_41\NN\1740| (r_conj) chlorpromazine_37\NN\3713736|,|zotepine|,|chlorprothixene|,|and|promazine (r_appos) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T19_T27 NONE promazine_44\NN\1740| (r_conj) chlorpromazine_37\NN\3713736|,|zotepine|,|chlorprothixene|,|and|promazine (r_appos) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d (r_conj) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T19_T28 NONE promazine_44\NN\1740| (r_conj) chlorpromazine_37\NN\3713736|,|zotepine|,|chlorprothixene|,|and|promazine (r_appos) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T9_T27 NONE neuroleptics_1\NNS\4470232|among (r_nmod) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_nsubj) compounds_7\NNS\5869584|the|four|potent|transporter (l_nmod) transporter_12\NN\4490091|at|the|human|serotonin
T9_T28 NONE neuroleptics_1\NNS\4470232|among (r_nmod) triflupromazine_14\NN\1740|neuroleptics|,|compounds|were|,|fluperlapine|,|chlorpromazine|,|and|ziprasidone|k(d|;|and|transporter|. (l_conj) transporter_35\NN\4490091|at|the|norepinephrine|,|chlorpromazine|k(d
T20_T29 NONE dopamine_3\NN\14807737| (r_compound) transporter_4\NN\4490091|at|the|human|dopamine
T21_T29 NONE pimozide_7\NN\3203641|only (r_nsubj) =_11\JJ\1740|pimozide|(|k(d|69+/-3|)|ziprasidone|= (r_intj) ,_5\,\1740|= (r_punct) had_21\VBD\2108377|transporter|,|potency|. (l_nmod) transporter_4\NN\4490091|at|the|human|dopamine
T22_T29 NONE ziprasidone_14\NN\1740| (r_nmod:npmod) =_11\JJ\1740|pimozide|(|k(d|69+/-3|)|ziprasidone|= (r_intj) ,_5\,\1740|= (r_punct) had_21\VBD\2108377|transporter|,|potency|. (l_nmod) transporter_4\NN\4490091|at|the|human|dopamine
23591044
T30_T53 NONE melatonin_0\NN\5407119|and|intake (r_nsubj) exert_4\VBP\1158872|melatonin|effects|estradiol|and|regulate|. (l_conj) regulate_14\VBP\296178|differentially|receptors (l_dobj) receptors_17\NNS\5225602|sex|steroid|ovaries
T31_T53 NONE steroid_16\NN\14727670| (r_compound) receptors_17\NNS\5225602|sex|steroid|ovaries
T32_T53 NONE ethanol_2\NN\14708720| (r_compound) intake_3\NN\13440063|ethanol (r_conj) melatonin_0\NN\5407119|and|intake (r_nsubj) exert_4\VBP\1158872|melatonin|effects|estradiol|and|regulate|. (l_conj) regulate_14\VBP\296178|differentially|receptors (l_dobj) receptors_17\NNS\5225602|sex|steroid|ovaries
T33_T53 NONE estradiol_9\NN\14749794|on|circulating|and|progesterone (r_nmod) exert_4\VBP\1158872|melatonin|effects|estradiol|and|regulate|. (l_conj) regulate_14\VBP\296178|differentially|receptors (l_dobj) receptors_17\NNS\5225602|sex|steroid|ovaries
T34_T53 NONE progesterone_11\NN\14747338| (r_conj) estradiol_9\NN\14749794|on|circulating|and|progesterone (r_nmod) exert_4\VBP\1158872|melatonin|effects|estradiol|and|regulate|. (l_conj) regulate_14\VBP\296178|differentially|receptors (l_dobj) receptors_17\NNS\5225602|sex|steroid|ovaries
T10_T38 NONE melatonin_8\NN\5407119| (r_compound) treatment_9\NN\654885|melatonin (r_conj) intake_6\NN\13440063|of|ethanol|and|treatment|(|doses|) (r_nmod) effects_3\NNS\13245626|the|intake|hormones (l_nmod) hormones_18\NNS\5404728|on|sex|and|receptors|ovaries (l_conj) receptors_21\NNS\5225602|steroid
T11_T38 NONE steroid_20\NN\14727670| (r_compound) receptors_21\NNS\5225602|steroid
T12_T38 NONE ethanol-preferring_30\JJ\1740| (r_amod) rats_31\NNS\2329401|of|ethanol-preferring (r_nmod) ovaries_24\NNS\11675842|in|the|,|oviducts|and|uteri|rats (r_nmod) hormones_18\NNS\5404728|on|sex|and|receptors|ovaries (l_conj) receptors_21\NNS\5225602|steroid
T9_T38 NONE ethanol_5\NN\14708720| (r_compound) intake_6\NN\13440063|of|ethanol|and|treatment|(|doses|) (r_nmod) effects_3\NNS\13245626|the|intake|hormones (l_nmod) hormones_18\NNS\5404728|on|sex|and|receptors|ovaries (l_conj) receptors_21\NNS\5225602|steroid
T13_T39 NONE androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_compound) receptor_24\NN\5225602|
T13_T40 NONE androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|)
T13_T41 NONE androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) er-α_29\NN\1740|
T13_T42 NONE androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) er-β_31\NN\1740|
T13_T43 NONE androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_appos) pra_33\NN\1740|
T13_T44 NONE androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) prb_35\NN\1740|
T13_T45 NONE androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) mt1r_37\NN\1740|
T14_T39 NONE estrogen_19\NN\14745635| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_compound) receptor_24\NN\5225602|
T14_T40 NONE estrogen_19\NN\14745635| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|)
T14_T41 NONE estrogen_19\NN\14745635| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) er-α_29\NN\1740|
T14_T42 NONE estrogen_19\NN\14745635| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) er-β_31\NN\1740|
T14_T43 NONE estrogen_19\NN\14745635| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_appos) pra_33\NN\1740|
T14_T44 NONE estrogen_19\NN\14745635| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) prb_35\NN\1740|
T14_T45 NONE estrogen_19\NN\14745635| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) mt1r_37\NN\1740|
T15_T39 NONE progesterone_21\NN\14747338| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_compound) receptor_24\NN\5225602|
T15_T40 NONE progesterone_21\NN\14747338| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|)
T15_T41 NONE progesterone_21\NN\14747338| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) er-α_29\NN\1740|
T15_T42 NONE progesterone_21\NN\14747338| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) er-β_31\NN\1740|
T15_T43 NONE progesterone_21\NN\14747338| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_appos) pra_33\NN\1740|
T15_T44 NONE progesterone_21\NN\14747338| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) prb_35\NN\1740|
T15_T45 NONE progesterone_21\NN\14747338| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) mt1r_37\NN\1740|
T16_T39 NONE melatonin_23\NN\5407119| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_compound) receptor_24\NN\5225602|
T16_T40 NONE melatonin_23\NN\5407119| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|)
T16_T41 NONE melatonin_23\NN\5407119| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) er-α_29\NN\1740|
T16_T42 NONE melatonin_23\NN\5407119| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) er-β_31\NN\1740|
T16_T43 NONE melatonin_23\NN\5407119| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_appos) pra_33\NN\1740|
T16_T44 NONE melatonin_23\NN\5407119| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) prb_35\NN\1740|
T16_T45 NONE melatonin_23\NN\5407119| (r_conj) androgen_17\NN\14745635|,|estrogen|,|progesterone|and|melatonin (r_compound) subunits_25\NNS\13604718|androgen|receptor|ar (l_dep) ar_27\NNS\14622893|(|,|er-α|and|er-β|,|pra|,|prb|and|mt1r|,|respectively|) (l_conj) mt1r_37\NN\1740|
T25_T46 NONE ethanol-melatonin_15\NN\1740| (r_compound) combination_16\NN\7951464|after|ethanol-melatonin (r_nmod) reduced_13\VBN\441445|ar|was|combination|. (r_conj) influenced_4\VBN\137313|ar|was|not|treatment|,|and|reduced (l_nsubjpass) ar_1\NNS\14622893|ovarian
T25_T47 CPR:4 ethanol-melatonin_15\NN\1740| (r_compound) combination_16\NN\7951464|after|ethanol-melatonin (r_nmod) reduced_13\VBN\441445|ar|was|combination|. (l_nsubjpass) ar_11\NN\14622893|oviduct
T26_T46 NONE ethanol-melatonin_15\NN\1740| (r_compound) combination_16\NN\7951464|after|ethanol-melatonin (r_nmod) reduced_13\VBN\441445|ar|was|combination|. (r_conj) influenced_4\VBN\137313|ar|was|not|treatment|,|and|reduced (l_nsubjpass) ar_1\NNS\14622893|ovarian
T26_T47 CPR:4 ethanol-melatonin_15\NN\1740| (r_compound) combination_16\NN\7951464|after|ethanol-melatonin (r_nmod) reduced_13\VBN\441445|ar|was|combination|. (l_nsubjpass) ar_11\NN\14622893|oviduct
T27_T48 CPR:4 ethanol_11\NN\14708720|by|either|or|melatonin (r_nmod) down-regulated_8\VBN\1740|er-α|were|ethanol|. (l_nsubjpass) er-α_1\NN\1740|oviduct|,|er-β|and|er-β
T27_T49 CPR:4 ethanol_11\NN\14708720|by|either|or|melatonin (r_nmod) down-regulated_8\VBN\1740|er-α|were|ethanol|. (l_nsubjpass) er-α_1\NN\1740|oviduct|,|er-β|and|er-β (l_conj) er-β_3\NN\1740|
T27_T50 CPR:4 ethanol_11\NN\14708720|by|either|or|melatonin (r_nmod) down-regulated_8\VBN\1740|er-α|were|ethanol|. (l_nsubjpass) er-α_1\NN\1740|oviduct|,|er-β|and|er-β (l_conj) er-β_6\NN\1740|uterine
T28_T48 CPR:4 melatonin_13\NN\5407119| (r_conj) ethanol_11\NN\14708720|by|either|or|melatonin (r_nmod) down-regulated_8\VBN\1740|er-α|were|ethanol|. (l_nsubjpass) er-α_1\NN\1740|oviduct|,|er-β|and|er-β
T28_T49 CPR:4 melatonin_13\NN\5407119| (r_conj) ethanol_11\NN\14708720|by|either|or|melatonin (r_nmod) down-regulated_8\VBN\1740|er-α|were|ethanol|. (l_nsubjpass) er-α_1\NN\1740|oviduct|,|er-β|and|er-β (l_conj) er-β_3\NN\1740|
T28_T50 CPR:4 melatonin_13\NN\5407119| (r_conj) ethanol_11\NN\14708720|by|either|or|melatonin (r_nmod) down-regulated_8\VBN\1740|er-α|were|ethanol|. (l_nsubjpass) er-α_1\NN\1740|oviduct|,|er-β|and|er-β (l_conj) er-β_6\NN\1740|uterine
T1_T35 NONE ethanol_10\NN\14708720|and (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_parataxis) down-regulated_18\VBN\1740|pra|was|uterus|consumption (l_nsubjpass) pra_16\NN\1740|
T1_T51 NONE ethanol_10\NN\14708720|and (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_nsubjpass) pra_3\NN\1740|ovarian|and|prb
T1_T52 NONE ethanol_10\NN\14708720|and (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_nsubjpass) pra_3\NN\1740|ovarian|and|prb (l_conj) prb_5\NN\1740|
T2_T35 NONE ethanol-melatonin_12\NN\1740| (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_parataxis) down-regulated_18\VBN\1740|pra|was|uterus|consumption (l_nsubjpass) pra_16\NN\1740|
T2_T51 NONE ethanol-melatonin_12\NN\1740| (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_nsubjpass) pra_3\NN\1740|ovarian|and|prb
T2_T52 NONE ethanol-melatonin_12\NN\1740| (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_nsubjpass) pra_3\NN\1740|ovarian|and|prb (l_conj) prb_5\NN\1740|
T3_T35 NONE ethanol-melatonin_12\NN\1740| (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_parataxis) down-regulated_18\VBN\1740|pra|was|uterus|consumption (l_nsubjpass) pra_16\NN\1740|
T3_T51 NONE ethanol-melatonin_12\NN\1740| (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_nsubjpass) pra_3\NN\1740|ovarian|and|prb
T3_T52 NONE ethanol-melatonin_12\NN\1740| (r_compound) combination_13\NN\7951464|by|ethanol|ethanol-melatonin (r_nmod) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_nsubjpass) pra_3\NN\1740|ovarian|and|prb (l_conj) prb_5\NN\1740|
T4_T35 CPR:4 ethanol_25\NN\14708720| (r_compound) consumption_26\NN\13440063|after|ethanol (r_nmod) down-regulated_18\VBN\1740|pra|was|uterus|consumption (l_nsubjpass) pra_16\NN\1740|
T4_T51 NONE ethanol_25\NN\14708720| (r_compound) consumption_26\NN\13440063|after|ethanol (r_nmod) down-regulated_18\VBN\1740|pra|was|uterus|consumption (r_parataxis) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_nsubjpass) pra_3\NN\1740|ovarian|and|prb
T4_T52 NONE ethanol_25\NN\14708720| (r_compound) consumption_26\NN\13440063|after|ethanol (r_nmod) down-regulated_18\VBN\1740|pra|was|uterus|consumption (r_parataxis) regulated_8\VBN\296178|conversely|,|pra|were|positively|combination|,|whereas|down-regulated|. (l_nsubjpass) pra_3\NN\1740|ovarian|and|prb (l_conj) prb_5\NN\1740|
T5_T36 CPR:3 melatonin-treated_8\JJ\1740| (r_amod) rats_9\NNS\2329401|of|melatonin-treated (r_nmod) ovaries_4\NNS\11675842|in|and|uteri|rats (r_nmod) increased_2\VBN\169651|mt1r|was|ovaries|. (l_nsubjpass) mt1r_0\NN\1740|
T6_T37 NONE ethanol_0\NN\14708720|and|melatonin (r_nsubj) exert_3\VBP\1158872|ethanol|effects|e2|,|and|regulate|. (l_conj) regulate_14\VBP\296178|they|differentially|expression (l_dobj) expression_16\NN\4679549|the|receptors|tissues (l_nmod) receptors_20\NNS\5225602|of|sex|steroid
T7_T37 NONE melatonin_2\NN\5407119| (r_conj) ethanol_0\NN\14708720|and|melatonin (r_nsubj) exert_3\VBP\1158872|ethanol|effects|e2|,|and|regulate|. (l_conj) regulate_14\VBP\296178|they|differentially|expression (l_dobj) expression_16\NN\4679549|the|receptors|tissues (l_nmod) receptors_20\NNS\5225602|of|sex|steroid
T8_T37 NONE steroid_19\NN\14727670| (r_compound) receptors_20\NNS\5225602|of|sex|steroid
15837926
T1_T10 NONE glutamate_4\NN\15010703| (r_compound) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates (r_nmod) acts_1\VBZ\1619354|psma|carboxypeptidase|. (l_nsubj) psma_0\NN\1740|
T1_T11 NONE glutamate_4\NN\15010703| (r_compound) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates
T1_T12 NONE glutamate_4\NN\15010703| (r_compound) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates (l_appos) gcpii_7\NN\1740|(|)
T2_T10 CPR:9 folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates (r_nmod) acts_1\VBZ\1619354|psma|carboxypeptidase|. (l_nsubj) psma_0\NN\1740|
T2_T11 CPR:9 folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates
T2_T12 CPR:9 folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates (l_appos) gcpii_7\NN\1740|(|)
T3_T10 CPR:9 methotrexate_20\NN\2722166|the|anticancer|drug (r_conj) folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates (r_nmod) acts_1\VBZ\1619354|psma|carboxypeptidase|. (l_nsubj) psma_0\NN\1740|
T3_T11 CPR:9 methotrexate_20\NN\2722166|the|anticancer|drug (r_conj) folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates
T3_T12 CPR:9 methotrexate_20\NN\2722166|the|anticancer|drug (r_conj) folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates (l_appos) gcpii_7\NN\1740|(|)
T4_T10 CPR:9 n-acetyl-l-aspartyl-l-glutamate_25\NN\1740|the|neuropeptide (r_conj) folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates (r_nmod) acts_1\VBZ\1619354|psma|carboxypeptidase|. (l_nsubj) psma_0\NN\1740|
T4_T11 CPR:9 n-acetyl-l-aspartyl-l-glutamate_25\NN\1740|the|neuropeptide (r_conj) folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates
T4_T12 NONE n-acetyl-l-aspartyl-l-glutamate_25\NN\1740|the|neuropeptide (r_conj) folate_15\NN\15090742|including|,|methotrexate|,|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) substrates_12\NNS\19613|on|molecule|,|folate (r_nmod) carboxypeptidase_5\NN\1740|as|a|glutamate|gcpii|substrates (l_appos) gcpii_7\NN\1740|(|)
T5_T14 NONE iron-loaded_26\JJ\1740| (r_amod) transferrin_27\NN\15022171|for|iron-loaded (r_nmod) receptor_24\NN\5225602|a|transferrin|lacks (r_appos) receptor_21\NN\5225602|to|transferrin|,|receptor (r_nmod) similarity_18\NN\4742535|with|structural|receptor (r_nmod) homodimer_15\NN\1740|a|similarity (r_dobj) reveals_13\VBZ\2137132|which|homodimer (r_acl:relcl) structure_6\NN\21939|the|3.5-a|crystal|ectodomain|,|reveals (l_nmod) ectodomain_10\NN\1740|of|the|psma
T5_T15 NONE iron-loaded_26\JJ\1740| (r_amod) transferrin_27\NN\15022171|for|iron-loaded (r_nmod) receptor_24\NN\5225602|a|transferrin|lacks (r_appos) receptor_21\NN\5225602|to|transferrin|,|receptor
T5_T16 NONE iron-loaded_26\JJ\1740| (r_amod) transferrin_27\NN\15022171|for|iron-loaded
T5_T17 NONE iron-loaded_26\JJ\1740| (r_amod) transferrin_27\NN\15022171|for|iron-loaded (r_nmod) receptor_24\NN\5225602|a|transferrin|lacks (l_acl:relcl) lacks_29\VBZ\1740|that|activity (l_dobj) activity_31\NN\30358|protease (l_compound) protease_30\NN\14732946|
T6_T18 NONE zinc_12\NN\14625458| (r_compound) site_13\NN\8673395|a|binuclear|zinc|,|residues|,|and|patch (r_dobj) contains_9\VBZ\2632940|receptor|,|domain|site|. (l_nmod) receptor_2\NN\5225602|unlike|transferrin
T6_T19 NONE zinc_12\NN\14625458| (r_compound) site_13\NN\8673395|a|binuclear|zinc|,|residues|,|and|patch (r_dobj) contains_9\VBZ\2632940|receptor|,|domain|site|. (l_nsubj) domain_6\NN\13934596|the|protease|psma
T6_T20 NONE zinc_12\NN\14625458| (r_compound) site_13\NN\8673395|a|binuclear|zinc|,|residues|,|and|patch (r_dobj) contains_9\VBZ\2632940|receptor|,|domain|site|. (l_nsubj) domain_6\NN\13934596|the|protease|psma (l_nmod) psma_8\NN\1740|of
T7_T18 NONE arginine_22\NN\14605787| (r_compound) patch_23\NN\4680285|a|proposed|substrate-binding|arginine (r_conj) site_13\NN\8673395|a|binuclear|zinc|,|residues|,|and|patch (r_dobj) contains_9\VBZ\2632940|receptor|,|domain|site|. (l_nmod) receptor_2\NN\5225602|unlike|transferrin
T7_T19 NONE arginine_22\NN\14605787| (r_compound) patch_23\NN\4680285|a|proposed|substrate-binding|arginine (r_conj) site_13\NN\8673395|a|binuclear|zinc|,|residues|,|and|patch (r_dobj) contains_9\VBZ\2632940|receptor|,|domain|site|. (l_nsubj) domain_6\NN\13934596|the|protease|psma
T7_T20 NONE arginine_22\NN\14605787| (r_compound) patch_23\NN\4680285|a|proposed|substrate-binding|arginine (r_conj) site_13\NN\8673395|a|binuclear|zinc|,|residues|,|and|patch (r_dobj) contains_9\VBZ\2632940|receptor|,|domain|site|. (l_nsubj) domain_6\NN\13934596|the|protease|psma (l_nmod) psma_8\NN\1740|of
T8_T21 CPR:9 n-acetyl-l-aspartyl-l-glutamate_25\NN\1740|the|natural|substrate (r_conj) inhibitors_20\NNS\20090|of|and|n-acetyl-l-aspartyl-l-glutamate (r_nmod) recognition_18\NN\13932421|into|the|inhibitors (r_nmod) insight_15\NN\5710020|recognition (r_dobj) provides_14\VBZ\2199590|elucidation|insight|. (l_nsubj) elucidation_0\NN\7232421|structure|combined (l_nmod) structure_4\NN\21939|of|the|psma (l_compound) psma_3\NN\1740|
23585555
17311416
T24_T46 NONE acid_5\NN\14818238| (r_compound) transporters_6\NNS\4490091|in|neutral|amino|acid
T25_T46 NONE alanine_14\NN\14601829| (r_compound) derivative_15\NN\5802185|of|a|new|caged|alanine (r_nmod) photolysis_9\NN\1740|by|derivative (r_nmod) induced_7\VBN\1627355|photolysis (r_acl) currents_1\NNS\11449002|pre-steady-state|transporters|induced|. (l_nmod) transporters_6\NNS\4490091|in|neutral|amino|acid
T10_T28 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (r_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T10_T30 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T10_T31 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T10_T32 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T10_T33 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T10_T34 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T10_T35 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T10_T36 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T10_T37 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T10_T38 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T10_T39 NONE serine_36\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T11_T28 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (r_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T11_T30 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T11_T31 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T11_T32 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T11_T33 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T11_T34 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T11_T35 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T11_T36 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T11_T37 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T11_T38 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T11_T39 NONE cysteine_37\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T12_T28 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (r_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T12_T30 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T12_T31 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T12_T32 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T12_T33 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T12_T34 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T12_T35 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T12_T36 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T12_T37 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T12_T38 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T12_T39 NONE sodium-coupled_51\JJ\1740| (r_amod) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T13_T28 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (r_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T13_T30 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T13_T31 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T13_T32 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T13_T33 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T13_T34 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T13_T35 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T13_T36 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T13_T37 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T13_T38 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T13_T39 NONE acid_54\NN\14818238| (r_compound) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T18_T28 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T18_T30 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T18_T31 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T18_T32 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T18_T33 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T18_T34 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T18_T35 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T18_T36 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T18_T37 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T18_T38 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T18_T39 CPR:9 acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T1_T28 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T1_T30 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T1_T31 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T1_T32 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T1_T33 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T1_T34 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T1_T35 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T1_T36 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T1_T37 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T1_T38 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T1_T39 NONE na+-dependent_0\JJ\1740| (r_amod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T21_T28 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T21_T30 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T21_T31 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T21_T32 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T21_T33 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T21_T34 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T21_T35 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T21_T36 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T21_T37 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T21_T38 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T21_T39 CPR:9 glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T23_T28 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T23_T30 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T23_T31 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T23_T32 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T23_T33 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T23_T34 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T23_T35 NONE alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T23_T36 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T23_T37 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T23_T38 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T23_T39 CPR:9 alanine_13\NN\14601829| (r_conj) glutamine_11\NN\14601829|such|and|alanine (r_nmod) acids_7\NNS\14818238|of|small|neutral|amino|,|glutamine (r_nmod) transport_2\NN\3575240|na+-dependent|transmembrane|acids|, (r_nsubjpass) mediated_16\VBN\761713|transport|is|,|others|,|transporters|. (l_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T5_T28 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T5_T30 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T5_T31 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T5_T32 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T5_T33 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T5_T34 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T5_T35 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T5_T36 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T5_T37 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T5_T38 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T5_T39 NONE acid_25\NN\14818238| (r_compound) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier (l_nmod) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T9_T28 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (r_nmod) transporters_26\NNS\4490091|by|the|neutral|amino|acid|carrier
T9_T30 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_nummod) 1_31\CD\13741022|
T9_T31 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|]
T9_T32 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (l_nummod) 1_39\CD\13741022|
T9_T33 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_appos) asct1_41\NN\1740|
T9_T34 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (l_conj) asct2_45\NN\1740|
T9_T35 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_conj) families_49\NNS\8189659|slc38 (l_compound) slc38_48\NN\1740|
T9_T36 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_nummod) 1_56\CD\13741022|
T9_T37 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat1_58\NN\1740|(|)
T9_T38 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_appos) snat2_61\NN\1740|
T9_T39 NONE alanine_35\NN\14601829| (r_compound) transporter_38\NN\4490091|alanine|serine|cysteine|1 (r_appos) slc1_33\NN\1740|[|,|transporter|(|asct1|)|,|and|asct2|] (r_dep) carrier_30\NN\9629752|of|the|solute|1|slc1|and|families|transporter (l_dep) transporter_55\NN\4490091|[|sodium-coupled|neutral|amino|acid|1|snat1|,|snat2|,|and|snat4|] (l_conj) snat4_64\NN\1740|
T15_T40 CPR:9 alanine_7\NN\14601829| (r_compound) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2
T15_T41 CPR:9 alanine_7\NN\14601829| (r_compound) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2 (l_conj) snat1_36\NNP\1740|
T15_T42 CPR:9 alanine_7\NN\14601829| (r_compound) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2 (l_conj) snat2_39\NNP\1740|
T16_T40 CPR:9 alanine_13\NN\14601829|of (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2
T16_T41 CPR:9 alanine_13\NN\14601829|of (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2 (l_conj) snat1_36\NNP\1740|
T16_T42 CPR:9 alanine_13\NN\14601829|of (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2 (l_conj) snat2_39\NNP\1740|
T17_T40 CPR:9 4-methoxy-7-nitroindolinyl_16\NN\1740|mni (r_compound) group_21\NN\2137|with|the|4-methoxy-7-nitroindolinyl|caging (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2
T17_T41 CPR:9 4-methoxy-7-nitroindolinyl_16\NN\1740|mni (r_compound) group_21\NN\2137|with|the|4-methoxy-7-nitroindolinyl|caging (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2 (l_conj) snat1_36\NNP\1740|
T17_T42 CPR:9 4-methoxy-7-nitroindolinyl_16\NN\1740|mni (r_compound) group_21\NN\2137|with|the|4-methoxy-7-nitroindolinyl|caging (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2 (l_conj) snat2_39\NNP\1740|
T19_T40 CPR:9 mni_18\NN\1740|(|) (r_appos) 4-methoxy-7-nitroindolinyl_16\NN\1740|mni (r_compound) group_21\NN\2137|with|the|4-methoxy-7-nitroindolinyl|caging (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2
T19_T41 CPR:9 mni_18\NN\1740|(|) (r_appos) 4-methoxy-7-nitroindolinyl_16\NN\1740|mni (r_compound) group_21\NN\2137|with|the|4-methoxy-7-nitroindolinyl|caging (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2 (l_conj) snat1_36\NNP\1740|
T19_T42 CPR:9 mni_18\NN\1740|(|) (r_appos) 4-methoxy-7-nitroindolinyl_16\NN\1740|mni (r_compound) group_21\NN\2137|with|the|4-methoxy-7-nitroindolinyl|caging (r_nmod) protection_11\NN\407535|on|alanine|group (r_nmod) based_9\VBN\2694933|protection (r_acl) derivative_8\NN\5802185|a|new|photolabile|alanine|based (r_dobj) describe_3\VBP\1001294|here|,|we|derivative|,|use|. (l_acl:relcl) use_25\VBP\1156834|which|we|analysis (l_nmod) analysis_29\NN\633864|for|pre-steady-state|kinetic|transport (l_nmod) transport_32\NN\3575240|of|alanine|asct2 (l_nmod) asct2_34\NNP\1740|by|,|snat1|,|and|snat2 (l_conj) snat2_39\NNP\1740|
T22_T43 NONE alanine_4\NN\14601829|of|free (r_nmod) release_1\NN\3748886|photolytic|alanine (r_nsubj) results_5\VBZ\2633881|release|generation|. (l_nmod) generation_8\NN\7942152|in|the|components|cells (l_nmod) cells_16\NNS\3080309|in|hek293|expressing (l_acl) expressing_17\VBG\928630|proteins (l_dobj) proteins_25\NNS\14944888|the|asct2 (l_compound) asct2_19\NN\1740|,|snat1|,|and|snat2
T22_T44 NONE alanine_4\NN\14601829|of|free (r_nmod) release_1\NN\3748886|photolytic|alanine (r_nsubj) results_5\VBZ\2633881|release|generation|. (l_nmod) generation_8\NN\7942152|in|the|components|cells (l_nmod) cells_16\NNS\3080309|in|hek293|expressing (l_acl) expressing_17\VBG\928630|proteins (l_dobj) proteins_25\NNS\14944888|the|asct2 (l_compound) asct2_19\NN\1740|,|snat1|,|and|snat2 (l_conj) snat1_21\NN\1740|
T22_T45 NONE alanine_4\NN\14601829|of|free (r_nmod) release_1\NN\3748886|photolytic|alanine (r_nsubj) results_5\VBZ\2633881|release|generation|. (l_nmod) generation_8\NN\7942152|in|the|components|cells (l_nmod) cells_16\NNS\3080309|in|hek293|expressing (l_acl) expressing_17\VBG\928630|proteins (l_dobj) proteins_25\NNS\14944888|the|asct2 (l_compound) asct2_19\NN\1740|,|snat1|,|and|snat2 (l_conj) snat2_24\NN\1740|
23402270
23294326
T2_T10 NONE ganglioside-enriched_5\JJ\1740| (r_amod) microdomains_6\NNS\1740|the|ganglioside-enriched|clusters|membranes (r_nsubj) play_15\VBP\1072262|that|microdomains|role|initiation (l_nmod) initiation_21\NN\7450842|in|the|process (l_nmod) process_26\NN\407535|of|the|aβ|assembly (l_compound) aβ_24\NN\1740|
T3_T10 NONE ganglioside_8\NN\1740| (r_compound) clusters_9\NNS\7959269|(|ganglioside|) (r_appos) microdomains_6\NNS\1740|the|ganglioside-enriched|clusters|membranes (r_nsubj) play_15\VBP\1072262|that|microdomains|role|initiation (l_nmod) initiation_21\NN\7450842|in|the|process (l_nmod) process_26\NN\407535|of|the|aβ|assembly (l_compound) aβ_24\NN\1740|
T4_T11 NONE ganglioside_4\NN\1740| (r_compound) clusters_5\NNS\7959269|all|ganglioside (r_nsubj) accelerate_6\VBP\226566|however|,|clusters|assembly|. (l_dobj) assembly_8\NN\3699975|aβ (l_compound) aβ_7\NN\1740|
T5_T14 NONE ganglioside_17\NN\1740| (r_compound) nanocluster_18\NN\1740|as|the|aβ-sensitive|ganglioside|asign (r_nmod) characterized_13\VBN\609683|which|was|nanocluster (r_acl:relcl) domain_9\NN\13934596|on|a|distinctive|gm1|,|characterized (r_nmod) generated_4\VBN\1617192|assembly|was|domain|. (l_nsubjpass) assembly_2\NN\3699975|the|aβ (l_compound) aβ_1\NN\1740|
T5_T15 NONE ganglioside_17\NN\1740| (r_compound) nanocluster_18\NN\1740|as|the|aβ-sensitive|ganglioside|asign (r_nmod) characterized_13\VBN\609683|which|was|nanocluster (r_acl:relcl) domain_9\NN\13934596|on|a|distinctive|gm1|,|characterized
T5_T16 NONE ganglioside_17\NN\1740| (r_compound) nanocluster_18\NN\1740|as|the|aβ-sensitive|ganglioside|asign (l_amod) aβ-sensitive_16\JJ\1740|
T1_T6 NONE ganglioside-bound_4\JJ\1740| (r_amod) aβ_5\NN\1740|ganglioside-bound|gaβ|,|acts|,
T1_T7 NONE ganglioside-bound_4\JJ\1740| (r_amod) aβ_5\NN\1740|ganglioside-bound|gaβ|,|acts|, (l_appos) gaβ_7\NN\1740|(|)
T1_T8 NONE ganglioside-bound_4\JJ\1740| (r_amod) aβ_5\NN\1740|ganglioside-bound|gaβ|,|acts|, (l_acl:relcl) acts_11\VBZ\1619354|which|seed (l_nmod) seed_15\NN\13134947|as|an|endogenous|formation (l_nmod) formation_19\NN\7938773|for|aβ|fibril|brains (l_compound) aβ_17\NN\1740|
7516184
T5_T13 NONE n-terminal_1\JJ\1740| (r_amod) portion_2\NN\31921|the|n-terminal|tsg-6 (r_nsubj) shows_5\VBZ\2137132|portion|homology|. (l_dobj) homology_7\NN\4743605|sequence|members (l_nmod) members_9\NNS\9816771|to|family (l_nmod) family_15\NN\8189659|of|the|cartilage|link|protein|proteins (l_nmod) proteins_19\NNS\14944888|of|hyaluronan|binding
T5_T28 NONE n-terminal_1\JJ\1740| (r_amod) portion_2\NN\31921|the|n-terminal|tsg-6 (l_nmod) tsg-6_4\NN\1740|of
T3_T15 NONE c-terminal_1\JJ\1740| (r_amod) half_2\NN\13732295|the|c-terminal|tsg-6 (l_nmod) tsg-6_4\NN\1740|of
T3_T16 NONE c-terminal_1\JJ\1740| (r_amod) half_2\NN\13732295|the|c-terminal|tsg-6 (r_nsubj) contains_5\VBZ\2632940|half|domain|. (l_dobj) domain_9\NN\13934596|a|so-called|cub|,|characteristic
T6_T21 NONE n-terminal_20\JJ\1740| (r_amod) microsequencing_21\NN\1740|by|n-terminal (r_nmod) identified_11\VBN\699815|inter-alpha-inhibitor|microsequencing (r_conj) purified_6\VBN\205885|protein|was|serum|and|identified|. (l_nsubjpass) protein_1\NN\14944888|the|binds (l_acl:relcl) binds_3\VBZ\1290422|that|tsg-6 (l_dobj) tsg-6_4\NN\1740|
T6_T22 NONE n-terminal_20\JJ\1740| (r_amod) microsequencing_21\NN\1740|by|n-terminal (r_nmod) identified_11\VBN\699815|inter-alpha-inhibitor|microsequencing (l_nmod) inter-alpha-inhibitor_13\NN\1740|as|alpha
T6_T23 NONE n-terminal_20\JJ\1740| (r_amod) microsequencing_21\NN\1740|by|n-terminal (r_nmod) identified_11\VBN\699815|inter-alpha-inhibitor|microsequencing (l_nmod) inter-alpha-inhibitor_13\NN\1740|as|alpha (l_appos) alpha_16\NN\6828818|(|i|i|) (l_nummod) i_17\NN\14622893|
T1_T10 NONE sulfate_9\NN\15010703| (r_compound) lyase_11\NN\1740|by|chondroitin|sulfate|abc (r_nmod) cleaved_6\VBN\1556346|complex|was|lyase|,|suggesting|. (l_nsubjpass) complex_4\NN\5869584|the|tsg-6/i|alpha|i (l_compound) tsg-6/i_1\NN\1740|
T1_T11 NONE sulfate_9\NN\15010703| (r_compound) lyase_11\NN\1740|by|chondroitin|sulfate|abc (r_nmod) cleaved_6\VBN\1556346|complex|was|lyase|,|suggesting|. (l_nsubjpass) complex_4\NN\5869584|the|tsg-6/i|alpha|i (l_nummod) i_3\CD\14622893|
T1_T12 NONE sulfate_9\NN\15010703| (r_compound) lyase_11\NN\1740|by|chondroitin|sulfate|abc
T2_T10 NONE sulfate_18\NN\15010703|by|chondroitin (r_nmod) cross-linking_15\NN\1740|sulfate (r_nsubjpass) required_20\VBN\754942|that|cross-linking|is|stability (r_ccomp) suggesting_13\VBG\1010118|required (r_advcl) cleaved_6\VBN\1556346|complex|was|lyase|,|suggesting|. (l_nsubjpass) complex_4\NN\5869584|the|tsg-6/i|alpha|i (l_compound) tsg-6/i_1\NN\1740|
T2_T11 NONE sulfate_18\NN\15010703|by|chondroitin (r_nmod) cross-linking_15\NN\1740|sulfate (r_nsubjpass) required_20\VBN\754942|that|cross-linking|is|stability (r_ccomp) suggesting_13\VBG\1010118|required (r_advcl) cleaved_6\VBN\1556346|complex|was|lyase|,|suggesting|. (l_nsubjpass) complex_4\NN\5869584|the|tsg-6/i|alpha|i (l_nummod) i_3\CD\14622893|
T2_T12 NONE sulfate_18\NN\15010703|by|chondroitin (r_nmod) cross-linking_15\NN\1740|sulfate (r_nsubjpass) required_20\VBN\754942|that|cross-linking|is|stability (r_ccomp) suggesting_13\VBG\1010118|required (r_advcl) cleaved_6\VBN\1556346|complex|was|lyase|,|suggesting|. (l_nmod) lyase_11\NN\1740|by|chondroitin|sulfate|abc
15058382
T4_T17 NONE acid_9\NN\14818238| (r_compound) genes_11\NNS\8459252|of|amino|acid|transporter (l_compound) transporter_10\NN\4490091|
T1_T5 NONE acid_10\NN\14818238| (r_compound) transporter_11\NN\4490091|the|lysosomal|amino|acid|lyaat1/pat1 (r_dobj) encodes_6\VBZ\115157|which|transporter (r_acl:relcl) gene_3\NN\8459252|the|human|slc36a1|,|encodes|, (l_compound) slc36a1_2\NN\1740|
T1_T6 NONE acid_10\NN\14818238| (r_compound) transporter_11\NN\4490091|the|lysosomal|amino|acid|lyaat1/pat1 (l_dep) lyaat1/pat1_12\NN\1740|
T1_T7 NONE acid_10\NN\14818238| (r_compound) transporter_11\NN\4490091|the|lysosomal|amino|acid|lyaat1/pat1 (l_dep) lyaat1/pat1_12\NN\1740|
T3_T10 NONE glycine_15\NN\14601829| (r_compound) transporter_16\NN\4490091|the|glycine
T3_T11 NONE glycine_15\NN\14601829| (r_compound) transporter_16\NN\4490091|the|glycine (r_compound) tramdorinl/pat2_17\NN\1740|transporter
T3_T12 NONE glycine_15\NN\14601829| (r_compound) transporter_16\NN\4490091|the|glycine (r_compound) tramdorinl/pat2_17\NN\1740|transporter
T3_T8 NONE glycine_15\NN\14601829| (r_compound) transporter_16\NN\4490091|the|glycine (r_compound) tramdorinl/pat2_17\NN\1740|transporter (r_dobj) encodes_13\VBZ\115157|which|tramdorinl/pat2 (r_acl:relcl) slc36a2_10\NN\1740|of|,|encodes (r_nmod) expression_8\NN\4679549|slc36a2|, (r_nsubj) abundant_21\JJ\1740|whereas|expression|is|most|kidney (r_advcl) expressed_2\VBN\928630|slc36a1|is|tissues|,|abundant|. (l_nsubjpass) slc36a1_0\NN\1740|
T3_T9 NONE glycine_15\NN\14601829| (r_compound) transporter_16\NN\4490091|the|glycine (r_compound) tramdorinl/pat2_17\NN\1740|transporter (r_dobj) encodes_13\VBZ\115157|which|tramdorinl/pat2 (r_acl:relcl) slc36a2_10\NN\1740|of|,|encodes
23511711
T12_T20 CPR:9 midazolam_8\NN\2830852|of|the|cyp3a|probe|substrate (l_compound) cyp3a_5\NN\1740|
T3_T18 NONE midazolam_27\NN\2830852|of (r_nmod) doses_25\NNS\3740161|inert|nanogram|midazolam (r_dobj) using_21\VBG\1156834|doses (r_advcl) establish_7\VB\2426171|to|method|using (l_dobj) method_11\NN\5616786|an|in|assessing (l_acl) assessing_13\VBG\670261|for|activity (l_dobj) activity_20\NN\30358|3a (l_compound) 3a_16\NN\1740|p450|cyp3a
T3_T19 NONE midazolam_27\NN\2830852|of (r_nmod) doses_25\NNS\3740161|inert|nanogram|midazolam (r_dobj) using_21\VBG\1156834|doses (r_advcl) establish_7\VB\2426171|to|method|using (l_dobj) method_11\NN\5616786|an|in|assessing (l_acl) assessing_13\VBG\670261|for|activity (l_dobj) activity_20\NN\30358|3a (l_compound) 3a_16\NN\1740|p450|cyp3a (l_appos) cyp3a_18\NN\1740|(|)
T4_T15 NONE midazolam_8\NN\2830852|of|oral|3 (r_nmod) doses_5\NNS\3740161|four|escalating|single|midazolam (r_dobj) administered_1\VBD\2436349|we|doses||participants|,|stratified|,|assess|. (l_advcl) stratified_21\VBN\650353|status (l_nmod) status_26\NN\24720|according|cyp3a5|carrier (l_compound) cyp3a5_24\NN\1740|
T5_T16 CPR:4 ketoconazole_9\NN\1740|with|the|cyp3a|inhibitor (l_compound) cyp3a_7\NN\1740|
T6_T16 NONE midazolam_23\NN\2830852|of (r_nmod) doses_21\NNS\3740161|regular|midazolam (r_conj) nanogram_18\NN\13717155|after|and|doses (r_nmod) evaluated_2\VBD\670261|we|then|interactions||nanogram|. (l_dobj) interactions_4\NNS\37396|the|ketoconazole (l_nmod) ketoconazole_9\NN\1740|with|the|cyp3a|inhibitor (l_compound) cyp3a_7\NN\1740|
T10_T17 CPR:4 ketoconazole_14\NN\1740|by (r_nmod) inhibition_12\NN\1068773|its|ketoconazole (r_conj) clearance_9\NN\5089947|on|midazolam|oral|or|inhibition (r_nmod) influence_5\NN\5190804|no|clearance (r_dobj) had_3\VBD\2108377|status|influence|. (l_nsubj) status_2\NN\24720|carrier (l_compound) carrier_1\NN\9629752|cyp3a5 (l_compound) cyp3a5_0\NN\1740|
T9_T17 CPR:9 midazolam_7\NN\2830852| (r_compound) clearance_9\NN\5089947|on|midazolam|oral|or|inhibition (r_nmod) influence_5\NN\5190804|no|clearance (r_dobj) had_3\VBD\2108377|status|influence|. (l_nsubj) status_2\NN\24720|carrier (l_compound) carrier_1\NN\9629752|cyp3a5 (l_compound) cyp3a5_0\NN\1740|
T11_T13 NONE midazolam_7\NN\2830852| (r_compound) pharmacokinetics_8\NNS\6054892|midazolam (r_nsubj) linear_10\JJ\1740|that|pharmacokinetics|is|range|,|and|therefore|predict (l_ccomp) predict_28\VB\916909|that|doses|can|reliably|pharmacokinetics|doses|and|used (l_conj) used_39\VBN\1156834|can|be|assess (l_xcomp) assess_41\VB\670261|to|activity|inhibitors (l_dobj) activity_43\NN\30358|cyp3a (l_compound) cyp3a_42\NN\1740|
T11_T14 NONE midazolam_7\NN\2830852| (r_compound) pharmacokinetics_8\NNS\6054892|midazolam (r_nsubj) linear_10\JJ\1740|that|pharmacokinetics|is|range|,|and|therefore|predict (l_ccomp) predict_28\VB\916909|that|doses|can|reliably|pharmacokinetics|doses|and|used (l_conj) used_39\VBN\1156834|can|be|assess (l_xcomp) assess_41\VB\670261|to|activity|inhibitors (l_nmod) inhibitors_51\NNS\20090|even|in|the|presence|of|strong|cyp3a (l_compound) cyp3a_50\NN\1740|
T1_T13 NONE midazolam_25\NN\2830852|of (r_nmod) doses_23\NNS\3740161|nano-|midazolam (r_nsubj) predict_28\VB\916909|that|doses|can|reliably|pharmacokinetics|doses|and|used (l_conj) used_39\VBN\1156834|can|be|assess (l_xcomp) assess_41\VB\670261|to|activity|inhibitors (l_dobj) activity_43\NN\30358|cyp3a (l_compound) cyp3a_42\NN\1740|
T1_T14 NONE midazolam_25\NN\2830852|of (r_nmod) doses_23\NNS\3740161|nano-|midazolam (r_nsubj) predict_28\VB\916909|that|doses|can|reliably|pharmacokinetics|doses|and|used (l_conj) used_39\VBN\1156834|can|be|assess (l_xcomp) assess_41\VB\670261|to|activity|inhibitors (l_nmod) inhibitors_51\NNS\20090|even|in|the|presence|of|strong|cyp3a (l_compound) cyp3a_50\NN\1740|
T2_T13 NONE midazolam_32\NN\2830852|of (r_nmod) pharmacokinetics_30\NNS\6054892|the|midazolam (r_dobj) predict_28\VB\916909|that|doses|can|reliably|pharmacokinetics|doses|and|used (l_conj) used_39\VBN\1156834|can|be|assess (l_xcomp) assess_41\VB\670261|to|activity|inhibitors (l_dobj) activity_43\NN\30358|cyp3a (l_compound) cyp3a_42\NN\1740|
T2_T14 NONE midazolam_32\NN\2830852|of (r_nmod) pharmacokinetics_30\NNS\6054892|the|midazolam (r_dobj) predict_28\VB\916909|that|doses|can|reliably|pharmacokinetics|doses|and|used (l_conj) used_39\VBN\1156834|can|be|assess (l_xcomp) assess_41\VB\670261|to|activity|inhibitors (l_nmod) inhibitors_51\NNS\20090|even|in|the|presence|of|strong|cyp3a (l_compound) cyp3a_50\NN\1740|
19837759
T9_T22 NONE 18f-av-45_3\NN\1740|of|:|agent (l_appos) agent_7\NN\7347|a|pet|plaques (l_nmod) plaques_10\NNS\4682462|for|abeta|brain (l_compound) abeta_9\NN\1740|
T5_T17 NONE (18)f-av-45_6\NN\1740|of (r_nmod) binding_4\NN\4688246|in|(18)f-av-45|plaques (l_nmod) plaques_9\NNS\4682462|to|abeta|tissue (l_compound) abeta_8\NN\1740|
T6_T18 NONE (18)f-av-45_4\NN\1740|of (r_nmod) biodistribution_2\NN\1740|in|(18)f-av-45|mice|and|autoradiography (l_conj) autoradiography_10\NN\13545382|ex|mice (l_nmod) mice_14\NNS\2329401|of|ad|transgenic|appswe/psen1|aggregates (l_appos) appswe/psen1_16\NN\1740|(|)
T6_T19 NONE (18)f-av-45_4\NN\1740|of (r_nmod) biodistribution_2\NN\1740|in|(18)f-av-45|mice|and|autoradiography (l_conj) autoradiography_10\NN\13545382|ex|mice (l_nmod) mice_14\NNS\2329401|of|ad|transgenic|appswe/psen1|aggregates (l_appos) appswe/psen1_16\NN\1740|(|)
T6_T20 NONE (18)f-av-45_4\NN\1740|of (r_nmod) biodistribution_2\NN\1740|in|(18)f-av-45|mice|and|autoradiography (l_conj) autoradiography_10\NN\13545382|ex|mice (l_nmod) mice_14\NNS\2329401|of|ad|transgenic|appswe/psen1|aggregates (l_nmod) aggregates_20\NNS\3553|with|abeta|brain (l_compound) abeta_19\NN\1740|
T8_T10 NONE (18)f-av-45_2\NN\1740| (r_nsubj) displayed_3\VBD\2137132|(18)f-av-45|affinity|plaques (l_nmod) plaques_12\NNS\4682462|to|abeta (l_compound) abeta_11\NN\1740|
T1_T12 NONE (18)f-av-45_0\NN\1740| (r_nsubj) displayed_1\VBD\2137132|(18)f-av-45|affinity|autoradiography|. (l_dobj) affinity_4\NN\11426530|excellent|binding|plaques (l_nmod) plaques_7\NNS\4682462|to|abeta|brain (l_compound) abeta_6\NN\1740|
T2_T13 NONE (18)f-av-45_5\NN\1740| (r_nsubj) agent_11\NN\7347|that|(18)f-av-45|may|be|a|useful|pet|detecting (l_acl) detecting_13\VBG\2163746|for|plaques|brain (l_dobj) plaques_15\NNS\4682462|abeta (l_compound) abeta_14\NN\1740|
9486667
T16_T40 CPR:4 dofetilide_3\NN\1740| (r_compound) block_4\NN\21939|of|dofetilide|channels (l_nmod) channels_8\NNS\6251781|of|herg|k+ (l_compound) herg_6\NN\1740|
T16_T41 CPR:4 dofetilide_3\NN\1740| (r_compound) block_4\NN\21939|of|dofetilide|channels (l_nmod) channels_8\NNS\6251781|of|herg|k+
T17_T40 NONE k+_7\NN\1740| (r_compound) channels_8\NNS\6251781|of|herg|k+ (l_compound) herg_6\NN\1740|
T17_T41 NONE k+_7\NN\1740| (r_compound) channels_8\NNS\6251781|of|herg|k+
T13_T19 NONE k+_9\NN\1740| (r_compound) channel_10\NN\6251781|a|k+|properties (l_nmod) properties_13\NNS\32613|with|biophysical|identical (l_amod) identical_15\JJ\1740|nearly|component (l_nmod) component_19\NN\5867413|to|the|rapid|current (l_nmod) current_26\NN\11449002|of|the|cardiac|delayed|rectifier|k+|ikr
T13_T25 NONE k+_9\NN\1740| (r_compound) channel_10\NN\6251781|a|k+|properties (l_nmod) properties_13\NNS\32613|with|biophysical|identical (l_amod) identical_15\JJ\1740|nearly|component (l_nmod) component_19\NN\5867413|to|the|rapid|current (l_nmod) current_26\NN\11449002|of|the|cardiac|delayed|rectifier|k+|ikr (l_appos) ikr_28\NN\1740|(|)
T13_T29 NONE k+_9\NN\1740| (r_compound) channel_10\NN\6251781|a|k+|properties (r_dobj) encodes_7\VBZ\115157|gene|channel|. (l_nsubj) gene_3\NN\8459252|the|human|ether-a-go-go-related|herg (l_appos) herg_5\NN\1740|(|)
T13_T30 NONE k+_9\NN\1740| (r_compound) channel_10\NN\6251781|a|k+|properties (r_dobj) encodes_7\VBZ\115157|gene|channel|. (l_nsubj) gene_3\NN\8459252|the|human|ether-a-go-go-related|herg
T13_T33 NONE k+_9\NN\1740| (r_compound) channel_10\NN\6251781|a|k+|properties
T3_T19 NONE k+_25\NN\1740| (r_compound) current_26\NN\11449002|of|the|cardiac|delayed|rectifier|k+|ikr
T3_T25 NONE k+_25\NN\1740| (r_compound) current_26\NN\11449002|of|the|cardiac|delayed|rectifier|k+|ikr (l_appos) ikr_28\NN\1740|(|)
T3_T29 NONE k+_25\NN\1740| (r_compound) current_26\NN\11449002|of|the|cardiac|delayed|rectifier|k+|ikr (r_nmod) component_19\NN\5867413|to|the|rapid|current (r_nmod) identical_15\JJ\1740|nearly|component (r_amod) properties_13\NNS\32613|with|biophysical|identical (r_nmod) channel_10\NN\6251781|a|k+|properties (r_dobj) encodes_7\VBZ\115157|gene|channel|. (l_nsubj) gene_3\NN\8459252|the|human|ether-a-go-go-related|herg (l_appos) herg_5\NN\1740|(|)
T3_T30 NONE k+_25\NN\1740| (r_compound) current_26\NN\11449002|of|the|cardiac|delayed|rectifier|k+|ikr (r_nmod) component_19\NN\5867413|to|the|rapid|current (r_nmod) identical_15\JJ\1740|nearly|component (r_amod) properties_13\NNS\32613|with|biophysical|identical (r_nmod) channel_10\NN\6251781|a|k+|properties (r_dobj) encodes_7\VBZ\115157|gene|channel|. (l_nsubj) gene_3\NN\8459252|the|human|ether-a-go-go-related|herg
T3_T33 NONE k+_25\NN\1740| (r_compound) current_26\NN\11449002|of|the|cardiac|delayed|rectifier|k+|ikr (r_nmod) component_19\NN\5867413|to|the|rapid|current (r_nmod) identical_15\JJ\1740|nearly|component (r_amod) properties_13\NNS\32613|with|biophysical|identical (r_nmod) channel_10\NN\6251781|a|k+|properties
T10_T26 CPR:4 e4031_27\NN\1740| (r_conj) dofetilide_25\NN\1740|such|,|e4031|,|and|mk-499 (r_nmod) drugs_21\NNS\14778436|by|class|iii|antiarrhythmic|methanesulfonanilide|,|dofetilide|, (r_nmod) blocked_15\VBN\1476483|are|selectively|drugs|concentrations (r_conj) target_5\NN\7258332|channels|are|a|prime|management|and|blocked|. (l_nsubj) channels_1\NNS\6251781|herg/ikr (l_compound) herg/ikr_0\NN\1740|
T10_T28 CPR:4 e4031_27\NN\1740| (r_conj) dofetilide_25\NN\1740|such|,|e4031|,|and|mk-499 (r_nmod) drugs_21\NNS\14778436|by|class|iii|antiarrhythmic|methanesulfonanilide|,|dofetilide|, (r_nmod) blocked_15\VBN\1476483|are|selectively|drugs|concentrations (r_conj) target_5\NN\7258332|channels|are|a|prime|management|and|blocked|. (l_nsubj) channels_1\NNS\6251781|herg/ikr (l_compound) herg/ikr_0\NN\1740|
T11_T26 CPR:4 mk-499_30\NN\1740| (r_conj) dofetilide_25\NN\1740|such|,|e4031|,|and|mk-499 (r_nmod) drugs_21\NNS\14778436|by|class|iii|antiarrhythmic|methanesulfonanilide|,|dofetilide|, (r_nmod) blocked_15\VBN\1476483|are|selectively|drugs|concentrations (r_conj) target_5\NN\7258332|channels|are|a|prime|management|and|blocked|. (l_nsubj) channels_1\NNS\6251781|herg/ikr (l_compound) herg/ikr_0\NN\1740|
T11_T28 CPR:4 mk-499_30\NN\1740| (r_conj) dofetilide_25\NN\1740|such|,|e4031|,|and|mk-499 (r_nmod) drugs_21\NNS\14778436|by|class|iii|antiarrhythmic|methanesulfonanilide|,|dofetilide|, (r_nmod) blocked_15\VBN\1476483|are|selectively|drugs|concentrations (r_conj) target_5\NN\7258332|channels|are|a|prime|management|and|blocked|. (l_nsubj) channels_1\NNS\6251781|herg/ikr (l_compound) herg/ikr_0\NN\1740|
T8_T26 CPR:4 methanesulfonanilide_20\NN\1740| (r_compound) drugs_21\NNS\14778436|by|class|iii|antiarrhythmic|methanesulfonanilide|,|dofetilide|, (r_nmod) blocked_15\VBN\1476483|are|selectively|drugs|concentrations (r_conj) target_5\NN\7258332|channels|are|a|prime|management|and|blocked|. (l_nsubj) channels_1\NNS\6251781|herg/ikr (l_compound) herg/ikr_0\NN\1740|
T8_T28 CPR:4 methanesulfonanilide_20\NN\1740| (r_compound) drugs_21\NNS\14778436|by|class|iii|antiarrhythmic|methanesulfonanilide|,|dofetilide|, (r_nmod) blocked_15\VBN\1476483|are|selectively|drugs|concentrations (r_conj) target_5\NN\7258332|channels|are|a|prime|management|and|blocked|. (l_nsubj) channels_1\NNS\6251781|herg/ikr (l_compound) herg/ikr_0\NN\1740|
T9_T26 CPR:4 dofetilide_25\NN\1740|such|,|e4031|,|and|mk-499 (r_nmod) drugs_21\NNS\14778436|by|class|iii|antiarrhythmic|methanesulfonanilide|,|dofetilide|, (r_nmod) blocked_15\VBN\1476483|are|selectively|drugs|concentrations (r_conj) target_5\NN\7258332|channels|are|a|prime|management|and|blocked|. (l_nsubj) channels_1\NNS\6251781|herg/ikr (l_compound) herg/ikr_0\NN\1740|
T9_T28 CPR:4 dofetilide_25\NN\1740|such|,|e4031|,|and|mk-499 (r_nmod) drugs_21\NNS\14778436|by|class|iii|antiarrhythmic|methanesulfonanilide|,|dofetilide|, (r_nmod) blocked_15\VBN\1476483|are|selectively|drugs|concentrations (r_conj) target_5\NN\7258332|channels|are|a|prime|management|and|blocked|. (l_nsubj) channels_1\NNS\6251781|herg/ikr (l_compound) herg/ikr_0\NN\1740|
T12_T31 NONE dofetilide_17\NN\1740|to (r_nmod) sensitive_15\JJ\1740|contrast|,|channel|is|less|dofetilide|. (l_nsubj) channel_8\NN\6251781|the|related|bovine|ether-a-go-go|beag
T12_T32 NONE dofetilide_17\NN\1740|to (r_nmod) sensitive_15\JJ\1740|contrast|,|channel|is|less|dofetilide|. (l_nsubj) channel_8\NN\6251781|the|related|bovine|ether-a-go-go|beag (l_appos) beag_10\NNP\1740|(|)
T14_T34 NONE dofetilide_6\NN\1740| (r_compound) block_7\NN\21939|for|dofetilide (r_nmod) determinants_4\NNS\5686481|the|molecular|block (r_dobj) identify_1\VB\699815|to|determinants (r_advcl) engineered_11\VBD\1639714|identify|,|we|first|chimeras|and|used|. (l_dobj) chimeras_12\NNS\9492123|herg (l_nmod) herg_14\NN\1740|between|and|beag
T14_T35 NONE dofetilide_6\NN\1740| (r_compound) block_7\NN\21939|for|dofetilide (r_nmod) determinants_4\NNS\5686481|the|molecular|block (r_dobj) identify_1\VB\699815|to|determinants (r_advcl) engineered_11\VBD\1639714|identify|,|we|first|chimeras|and|used|. (l_dobj) chimeras_12\NNS\9492123|herg (l_nmod) herg_14\NN\1740|between|and|beag (l_conj) beag_16\NN\1740|
T15_T34 NONE acid_26\NN\14818238| (r_compound) residues_27\NNS\20827|single|amino|acid|responsible (r_dobj) localize_23\VB\2694933|to|residues (r_xcomp) used_19\VBD\1156834|then|mutagenesis|localize (r_conj) engineered_11\VBD\1639714|identify|,|we|first|chimeras|and|used|. (l_dobj) chimeras_12\NNS\9492123|herg (l_nmod) herg_14\NN\1740|between|and|beag
T15_T35 NONE acid_26\NN\14818238| (r_compound) residues_27\NNS\20827|single|amino|acid|responsible (r_dobj) localize_23\VB\2694933|to|residues (r_xcomp) used_19\VBD\1156834|then|mutagenesis|localize (r_conj) engineered_11\VBD\1639714|identify|,|we|first|chimeras|and|used|. (l_dobj) chimeras_12\NNS\9492123|herg (l_nmod) herg_14\NN\1740|between|and|beag (l_conj) beag_16\NN\1740|
T1_T18 NONE dofetilide_9\NN\1740| (r_compound) binding_10\NN\4688246|of|dofetilide (r_nmod) determinants_7\NNS\5686481|important|binding (r_nsubj) localized_12\JJ\1740|that|determinants|are|region (l_nmod) region_16\NN\27167|to|the|pore|herg (l_nmod) herg_18\NN\1740|of
T4_T21 NONE k+_12\NN\1740| (r_compound) channels_13\NNS\6251781|of|beag|k+|dofetilide (r_nmod) affinity_9\NN\11426530|the|channels (r_dobj) increased_7\VBD\169651|moreover|,|t432s|affinity|,|recovered|. (l_nsubj) t432s_6\NNS\1740|the|reverse|mutation|beag (l_compound) beag_5\NN\1740|
T4_T22 NONE k+_12\NN\1740| (r_compound) channels_13\NNS\6251781|of|beag|k+|dofetilide (r_nmod) affinity_9\NN\11426530|the|channels (r_dobj) increased_7\VBD\169651|moreover|,|t432s|affinity|,|recovered|. (l_nsubj) t432s_6\NNS\1740|the|reverse|mutation|beag
T4_T23 NONE k+_12\NN\1740| (r_compound) channels_13\NNS\6251781|of|beag|k+|dofetilide (l_compound) beag_11\NN\1740|
T4_T24 NONE k+_12\NN\1740| (r_compound) channels_13\NNS\6251781|of|beag|k+|dofetilide
T5_T21 NONE dofetilide_15\NN\1740|for (r_nmod) channels_13\NNS\6251781|of|beag|k+|dofetilide (r_nmod) affinity_9\NN\11426530|the|channels (r_dobj) increased_7\VBD\169651|moreover|,|t432s|affinity|,|recovered|. (l_nsubj) t432s_6\NNS\1740|the|reverse|mutation|beag (l_compound) beag_5\NN\1740|
T5_T22 NONE dofetilide_15\NN\1740|for (r_nmod) channels_13\NNS\6251781|of|beag|k+|dofetilide (r_nmod) affinity_9\NN\11426530|the|channels (r_dobj) increased_7\VBD\169651|moreover|,|t432s|affinity|,|recovered|. (l_nsubj) t432s_6\NNS\1740|the|reverse|mutation|beag
T5_T23 NONE dofetilide_15\NN\1740|for (r_nmod) channels_13\NNS\6251781|of|beag|k+|dofetilide (l_compound) beag_11\NN\1740|
T5_T24 NONE dofetilide_15\NN\1740|for (r_nmod) channels_13\NNS\6251781|of|beag|k+|dofetilide
T6_T27 NONE serine_3\NN\14601829|the|position (l_nmod) position_5\NN\8620061|in|herg (l_dep) herg_6\NN\1740|620
T7_T27 NONE dofetilide_12\NN\1740| (r_compound) binding_13\NN\4688246|in|dofetilide (r_nmod) participate_9\VB\2367363|thus|,|serine|may|directly|binding|;|seems (l_nsubj) serine_3\NN\14601829|the|position (l_nmod) position_5\NN\8620061|in|herg (l_dep) herg_6\NN\1740|620
2891463
T2_T28 CPR:4 betaxolol_2\NN\1740| (r_nsubj) produces_3\VBZ\1617192|however|,|betaxolol|2-|timolol|. (l_dobj) 2-_7\CD\1740|systemic|beta|and|1-adrenergic|blockade (l_dep) blockade_13\NN\952963|receptor (l_compound) receptor_12\NN\5225602|
T3_T28 CPR:4 timolol_16\NN\2832168|than|either|or|levobunolol (r_nmod) produces_3\VBZ\1617192|however|,|betaxolol|2-|timolol|. (l_dobj) 2-_7\CD\1740|systemic|beta|and|1-adrenergic|blockade (l_dep) blockade_13\NN\952963|receptor (l_compound) receptor_12\NN\5225602|
T4_T28 CPR:4 levobunolol_18\NN\1740| (r_conj) timolol_16\NN\2832168|than|either|or|levobunolol (r_nmod) produces_3\VBZ\1617192|however|,|betaxolol|2-|timolol|. (l_dobj) 2-_7\CD\1740|systemic|beta|and|1-adrenergic|blockade (l_dep) blockade_13\NN\952963|receptor (l_compound) receptor_12\NN\5225602|
16425993
T3_T21 CPR:4 sorafenib_25\NN\1740|,|sunitinib (r_dep) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_amod) multiple-kinase_20\JJ\1740|
T3_T23 CPR:4 sorafenib_25\NN\1740|,|sunitinib (r_dep) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_acl:relcl) target_33\VBP\1151110|which|vegfrs (l_dobj) vegfrs_35\NNS\1740|multiple|as|pdgfr-beta
T3_T24 CPR:4 sorafenib_25\NN\1740|,|sunitinib (r_dep) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_acl:relcl) target_33\VBP\1151110|which|vegfrs (l_dobj) vegfrs_35\NNS\1740|multiple|as|pdgfr-beta (l_conj) pdgfr-beta_39\NN\1740|
T4_T21 CPR:4 sunitinib_27\NN\1740| (r_conj) sorafenib_25\NN\1740|,|sunitinib (r_dep) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_amod) multiple-kinase_20\JJ\1740|
T4_T23 CPR:4 sunitinib_27\NN\1740| (r_conj) sorafenib_25\NN\1740|,|sunitinib (r_dep) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_acl:relcl) target_33\VBP\1151110|which|vegfrs (l_dobj) vegfrs_35\NNS\1740|multiple|as|pdgfr-beta
T4_T24 CPR:4 sunitinib_27\NN\1740| (r_conj) sorafenib_25\NN\1740|,|sunitinib (r_dep) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_acl:relcl) target_33\VBP\1151110|which|vegfrs (l_dobj) vegfrs_35\NNS\1740|multiple|as|pdgfr-beta (l_conj) pdgfr-beta_39\NN\1740|
T5_T21 CPR:4 ag013736_30\NN\1740| (r_conj) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_amod) multiple-kinase_20\JJ\1740|
T5_T23 CPR:4 ag013736_30\NN\1740| (r_conj) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_acl:relcl) target_33\VBP\1151110|which|vegfrs (l_dobj) vegfrs_35\NNS\1740|multiple|as|pdgfr-beta
T5_T24 CPR:4 ag013736_30\NN\1740| (r_conj) inhibitors_21\NNS\20090|including|the|multiple-kinase|mkis|sorafenib|,|and|ag013736|,|target (l_acl:relcl) target_33\VBP\1151110|which|vegfrs (l_dobj) vegfrs_35\NNS\1740|multiple|as|pdgfr-beta (l_conj) pdgfr-beta_39\NN\1740|
T6_T25 CPR:4 sorafenib_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|sorafenib|advantage|,|enables|. (l_dobj) advantage_4\NN\5154517|the|added|inhibiting (l_acl) inhibiting_6\VBG\2510337|of|isoforms (l_dobj) isoforms_10\NNS\1740|multiple|different|raf (l_compound) raf_9\NN\8196024|
T6_T26 CPR:4 sorafenib_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|sorafenib|advantage|,|enables|. (l_advcl) enables_13\VBZ\126264|which|it|target|and|enhance (l_xcomp) target_16\VB\1151110|to|signaling (l_dobj) signaling_18\NN\33020|tgf-alpha/egfr (l_compound) tgf-alpha/egfr_17\NN\1740|
T6_T27 CPR:4 sorafenib_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|sorafenib|advantage|,|enables|. (l_advcl) enables_13\VBZ\126264|which|it|target|and|enhance (l_xcomp) target_16\VB\1151110|to|signaling (l_dobj) signaling_18\NN\33020|tgf-alpha/egfr (l_compound) tgf-alpha/egfr_17\NN\1740|
T6_T28 CPR:4 sorafenib_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|sorafenib|advantage|,|enables|. (l_advcl) enables_13\VBZ\126264|which|it|target|and|enhance (l_conj) enhance_22\VB\227165|may|also|inhibition (l_dobj) inhibition_24\NN\1068773|its|vegfr (l_nmod) vegfr_26\NN\1740|of|and|pdgfr-beta
T6_T29 CPR:4 sorafenib_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|sorafenib|advantage|,|enables|. (l_advcl) enables_13\VBZ\126264|which|it|target|and|enhance (l_conj) enhance_22\VB\227165|may|also|inhibition (l_dobj) inhibition_24\NN\1068773|its|vegfr (l_nmod) vegfr_26\NN\1740|of|and|pdgfr-beta (l_conj) pdgfr-beta_28\NN\1740|
12046682
T1_T4 CPR:4 thalidomide_0\NN\4166841|--|removed (r_nsubj) has_14\VBZ\2108377|thalidomide|effects|. (l_dobj) effects_18\NNS\13245626|anti-angiogenic|,|inhibition (l_nmod) inhibition_22\NN\1068773|including|the|alpha (l_nmod) alpha_25\NN\6828818|of|tnf
23000451
T7_T16 NONE cocaine_10\NN\3492717| (r_compound) activity_12\NN\30358|for|enhanced|cocaine|hydrolase (r_nmod) designed_7\VBN\1631534|activity (r_acl) variants_6\NNS\7366289|of|butyrylcholinesterase|designed (l_compound) butyrylcholinesterase_5\NN\1740|
T7_T17 NONE cocaine_10\NN\3492717| (r_compound) activity_12\NN\30358|for|enhanced|cocaine|hydrolase (l_compound) hydrolase_11\NN\1740|
T3_T10 CPR:9 (-)-cocaine_32\NN\1740|occurring (r_nmod) breaking_28\VBG\352826|of|down|(-)-cocaine|influence (r_advcl) capable_26\JJ\1740|which|is|breaking (r_acl:relcl) butyrylcholinesterase_19\NN\1740|of|the|serum|enzyme|bche|,|capable
T3_T11 CPR:9 (-)-cocaine_32\NN\1740|occurring (r_nmod) breaking_28\VBG\352826|of|down|(-)-cocaine|influence (r_advcl) capable_26\JJ\1740|which|is|breaking (r_acl:relcl) butyrylcholinesterase_19\NN\1740|of|the|serum|enzyme|bche|,|capable (l_appos) bche_21\NN\1740|(|)
T4_T13 CPR:9 (-)-cocaine_15\NN\1740|against (r_nmod) activity_13\NN\30358|improved|catalytic|(-)-cocaine (r_dobj) exhibit_9\VBP\2632167|which|activity (r_acl:relcl) variants_5\NNS\7366289|of|bche|exhibit (l_nmod) bche_7\NNP\1740|of
T5_T14 NONE cocaine_11\NN\3492717| (r_compound) variants_13\NNS\7366289|of|these|cocaine|hydrolase|bche (l_compound) hydrolase_12\NN\1740|
T5_T15 NONE cocaine_11\NN\3492717| (r_compound) variants_13\NNS\7366289|of|these|cocaine|hydrolase|bche (l_nmod) bche_15\NN\1740|of
T2_T8 CPR:9 cocaine-hydrolyzing_4\JJ\1740| (r_amod) mutants_5\NNS\4475|cocaine-hydrolyzing|bche (l_nmod) bche_7\NN\1740|of
T2_T9 NONE cocaine-hydrolyzing_4\JJ\1740| (r_amod) mutants_5\NNS\4475|cocaine-hydrolyzing|bche (r_dobj) expressing_3\VBG\928630|in|mutants|benthamiana|using|,|and|reporting (r_advcl) provide_28\VBP\2199590|here|,|expressing|,|we|proof-of-principle|express|. (l_ccomp) express_33\VB\928630|that|plants|can|proteins|properties (l_dobj) proteins_36\NNS\14944888|engineered|bche (l_compound) bche_35\NN\1740|
23608535
T2_T19 NONE ca(2+)-atpase_33\NN\1740|serca (r_compound) gene_38\NN\8459252|the|fiber-specific|sarco/endoplasmic|reticulum|ca(2+)-atpase|2 (r_conj) iid/x_26\NN\1740|of|the|fast|fiber-specific|myosin|chain|and|gene (r_nmod) promoters_18\NNS\9773962|the|iid/x (r_dobj) regulated_16\VBD\296178|that|activity|directly|promoters (l_nsubj) activity_14\NN\30358|mk2|catalytic (l_compound) mk2_12\NN\1740|
T2_T21 NONE ca(2+)-atpase_33\NN\1740|serca (r_compound) gene_38\NN\8459252|the|fiber-specific|sarco/endoplasmic|reticulum|ca(2+)-atpase|2 (r_conj) iid/x_26\NN\1740|of|the|fast|fiber-specific|myosin|chain|and|gene
T2_T22 NONE ca(2+)-atpase_33\NN\1740|serca (r_compound) gene_38\NN\8459252|the|fiber-specific|sarco/endoplasmic|reticulum|ca(2+)-atpase|2 (l_nummod) 2_37\CD\13741022|
T1_T3 NONE calcium_8\NN\14625458| (r_compound) dynamics_9\NNS\6100236|of|calcium (r_nmod) regulation_6\NN\6652242|to|the|dynamics (r_nmod) link_2\VBP\628491|results|mk2/3|regulation|and|identify|. (l_dobj) mk2/3_3\NN\1740|
T1_T5 NONE calcium_8\NN\14625458| (r_compound) dynamics_9\NNS\6100236|of|calcium (r_nmod) regulation_6\NN\6652242|to|the|dynamics (r_nmod) link_2\VBP\628491|results|mk2/3|regulation|and|identify|. (l_conj) identify_11\VBP\699815|activity|factor (l_dobj) activity_13\NN\30358|enzymatic|mk2/3 (l_nmod) mk2/3_15\NN\1740|of
T1_T7 NONE calcium_8\NN\14625458| (r_compound) dynamics_9\NNS\6100236|of|calcium (r_nmod) regulation_6\NN\6652242|to|the|dynamics (r_nmod) link_2\VBP\628491|results|mk2/3|regulation|and|identify|. (l_conj) identify_11\VBP\699815|activity|factor (l_nmod) factor_19\NN\7326557|as|a|critical|modulating (l_acl) modulating_21\VBG\1724459|for|function|generating (l_advcl) generating_26\VBG\1617192|by|phenotype (l_dobj) phenotype_30\NN\4933544|a|unique|muscle|exhibiting (l_acl) exhibiting_31\VBG\2632167|both (l_dobj) both_32\DT\1740|,|fatigability (l_conj) fatigability_35\NN\5040275|reduced|and|force|mice (l_nmod) mice_42\NNS\2329401|in|mk2/3(-/- (l_compound) mk2/3(-/-_40\NN\1740|)
3004987
T5_T8 NONE polyacrylamide_2\NN\1740| (r_compound) gels_3\NNS\14588219|of|polyacrylamide|receptor (l_nmod) receptor_7\NN\5225602|of|cross-linked|calcitonin
16855093
T16_T27 CPR:9 glutamate_5\NN\15010703| (r_compound) uptake_6\NN\13440063|glutamate (r_dobj) mediates_4\VBZ\761713|transporter|uptake|synapses|. (l_nsubj) transporter_2\NN\4490091|the|glutamate-aspartate|glast (l_dep) glast_3\NN\1740|
T16_T28 CPR:9 glutamate_5\NN\15010703| (r_compound) uptake_6\NN\13440063|glutamate (r_dobj) mediates_4\VBZ\761713|transporter|uptake|synapses|. (l_nsubj) transporter_2\NN\4490091|the|glutamate-aspartate|glast
T8_T20 NONE d-aspartate_6\NN\1740|of|the|transporter|substrate (r_nmod) application_1\NN\947128|focal|d-aspartate (r_nsubj) elicited_7\VBD\1617192|application|currents|. (l_dobj) currents_9\NNS\11449002|inward|ipcs|,|larger (l_acl:relcl) larger_15\JJR\1740|which|were|anions (l_nmod) anions_20\NNS\9315159|in|presence|of|permeate (l_acl:relcl) permeate_22\VBP\1227675|that|channel|and|blocked (l_dobj) channel_26\NN\6251781|the|transporter-associated|anion
T9_T20 CPR:6 l-threo-beta-benzyloxyaspartate_35\NN\1740|by|the|transporter|antagonist|d|, (r_nmod) blocked_28\VBN\1476483|l-threo-beta-benzyloxyaspartate (r_conj) permeate_22\VBP\1227675|that|channel|and|blocked (l_dobj) channel_26\NN\6251781|the|transporter-associated|anion
T10_T21 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter
T10_T22 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) glast_8\NN\1740|(|)
T10_T23 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (l_nummod) 1_15\CD\13741022|
T10_T24 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_nmod) dihydrokainate_23\NN\1740|by|,|antagonist (l_appos) antagonist_26\NN\7846|an|transporter-1 (l_nmod) transporter-1_29\NN\1740|of|glutamate|transporter
T10_T25 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_nmod) dihydrokainate_23\NN\1740|by|,|antagonist (l_appos) antagonist_26\NN\7846|an|transporter-1 (l_nmod) transporter-1_29\NN\1740|of|glutamate|transporter (l_appos) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (l_nummod) 2_35\CD\13741022|
T10_T26 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_conj) absent_39\JJ\1740|were|ipcs (l_nmod) ipcs_41\NNS\1740|from|cochleas (l_nmod) cochleas_44\NNS\5246511|in|glast-/- (l_amod) glast-/-_43\JJ\1740|
T11_T21 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter
T11_T22 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) glast_8\NN\1740|(|)
T11_T23 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (l_nummod) 1_15\CD\13741022|
T11_T24 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_nmod) dihydrokainate_23\NN\1740|by|,|antagonist (l_appos) antagonist_26\NN\7846|an|transporter-1 (l_nmod) transporter-1_29\NN\1740|of|glutamate|transporter
T11_T25 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_nmod) dihydrokainate_23\NN\1740|by|,|antagonist (l_appos) antagonist_26\NN\7846|an|transporter-1 (l_nmod) transporter-1_29\NN\1740|of|glutamate|transporter (l_appos) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (l_nummod) 2_35\CD\13741022|
T11_T26 NONE glutamate-aspartate_5\NN\1740| (r_compound) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_conj) absent_39\JJ\1740|were|ipcs (l_nmod) ipcs_41\NNS\1740|from|cochleas (l_nmod) cochleas_44\NNS\5246511|in|glast-/- (l_amod) glast-/-_43\JJ\1740|
T12_T21 NONE acid_13\NN\14818238| (r_compound) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (r_appos) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter
T12_T22 NONE acid_13\NN\14818238| (r_compound) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (r_appos) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) glast_8\NN\1740|(|)
T12_T23 NONE acid_13\NN\14818238| (r_compound) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (l_nummod) 1_15\CD\13741022|
T12_T24 NONE acid_13\NN\14818238| (r_compound) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (r_appos) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_nmod) dihydrokainate_23\NN\1740|by|,|antagonist (l_appos) antagonist_26\NN\7846|an|transporter-1 (l_nmod) transporter-1_29\NN\1740|of|glutamate|transporter
T12_T25 NONE acid_13\NN\14818238| (r_compound) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (r_appos) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_nmod) dihydrokainate_23\NN\1740|by|,|antagonist (l_appos) antagonist_26\NN\7846|an|transporter-1 (l_nmod) transporter-1_29\NN\1740|of|glutamate|transporter (l_appos) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (l_nummod) 2_35\CD\13741022|
T12_T26 NONE acid_13\NN\14818238| (r_compound) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (r_appos) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (r_nmod) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_advcl) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_conj) absent_39\JJ\1740|were|ipcs (l_nmod) ipcs_41\NNS\1740|from|cochleas (l_nmod) cochleas_44\NNS\5246511|in|glast-/- (l_amod) glast-/-_43\JJ\1740|
T13_T21 CPR:4 dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter
T13_T22 CPR:4 dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) glast_8\NN\1740|(|)
T13_T23 CPR:4 dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (l_nummod) 1_15\CD\13741022|
T13_T24 CPR:6 dihydrokainate_23\NN\1740|by|,|antagonist (l_appos) antagonist_26\NN\7846|an|transporter-1 (l_nmod) transporter-1_29\NN\1740|of|glutamate|transporter
T13_T25 CPR:6 dihydrokainate_23\NN\1740|by|,|antagonist (l_appos) antagonist_26\NN\7846|an|transporter-1 (l_nmod) transporter-1_29\NN\1740|of|glutamate|transporter (l_appos) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (l_nummod) 2_35\CD\13741022|
T13_T26 NONE dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_conj) absent_39\JJ\1740|were|ipcs (l_nmod) ipcs_41\NNS\1740|from|cochleas (l_nmod) cochleas_44\NNS\5246511|in|glast-/- (l_amod) glast-/-_43\JJ\1740|
T14_T21 NONE glutamate_28\NN\15010703| (r_compound) transporter-1_29\NN\1740|of|glutamate|transporter (r_nmod) antagonist_26\NN\7846|an|transporter-1 (r_appos) dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter
T14_T22 NONE glutamate_28\NN\15010703| (r_compound) transporter-1_29\NN\1740|of|glutamate|transporter (r_nmod) antagonist_26\NN\7846|an|transporter-1 (r_appos) dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) glast_8\NN\1740|(|)
T14_T23 NONE glutamate_28\NN\15010703| (r_compound) transporter-1_29\NN\1740|of|glutamate|transporter (r_nmod) antagonist_26\NN\7846|an|transporter-1 (r_appos) dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (l_nummod) 1_15\CD\13741022|
T14_T24 NONE glutamate_28\NN\15010703| (r_compound) transporter-1_29\NN\1740|of|glutamate|transporter
T14_T25 NONE glutamate_28\NN\15010703| (r_compound) transporter-1_29\NN\1740|of|glutamate|transporter (l_appos) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (l_nummod) 2_35\CD\13741022|
T14_T26 NONE glutamate_28\NN\15010703| (r_compound) transporter-1_29\NN\1740|of|glutamate|transporter (r_nmod) antagonist_26\NN\7846|an|transporter-1 (r_appos) dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_conj) absent_39\JJ\1740|were|ipcs (l_nmod) ipcs_41\NNS\1740|from|cochleas (l_nmod) cochleas_44\NNS\5246511|in|glast-/- (l_amod) glast-/-_43\JJ\1740|
T15_T21 NONE acid_33\NN\14818238| (r_compound) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (r_appos) transporter-1_29\NN\1740|of|glutamate|transporter (r_nmod) antagonist_26\NN\7846|an|transporter-1 (r_appos) dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter
T15_T22 NONE acid_33\NN\14818238| (r_compound) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (r_appos) transporter-1_29\NN\1740|of|glutamate|transporter (r_nmod) antagonist_26\NN\7846|an|transporter-1 (r_appos) dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) glast_8\NN\1740|(|)
T15_T23 NONE acid_33\NN\14818238| (r_compound) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (r_appos) transporter-1_29\NN\1740|of|glutamate|transporter (r_nmod) antagonist_26\NN\7846|an|transporter-1 (r_appos) dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (r_advcl) produced_3\VBN\1617192|currents|were|transporters|inhibited|. (l_nmod) transporters_6\NNS\4490091|by|glutamate-aspartate|glast|transporter (l_appos) transporter_14\NN\4490091|(|excitatory|amino|acid|1|) (l_nummod) 1_15\CD\13741022|
T15_T24 NONE acid_33\NN\14818238| (r_compound) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (r_appos) transporter-1_29\NN\1740|of|glutamate|transporter
T15_T25 NONE acid_33\NN\14818238| (r_compound) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (l_nummod) 2_35\CD\13741022|
T15_T26 NONE acid_33\NN\14818238| (r_compound) transporter_34\NN\4490091|(|excitatory|amino|acid|2|) (r_appos) transporter-1_29\NN\1740|of|glutamate|transporter (r_nmod) antagonist_26\NN\7846|an|transporter-1 (r_appos) dihydrokainate_23\NN\1740|by|,|antagonist (r_nmod) inhibited_21\VBN\2510337|because|they|were|weakly|dihydrokainate|and|absent (l_conj) absent_39\JJ\1740|were|ipcs (l_nmod) ipcs_41\NNS\1740|from|cochleas (l_nmod) cochleas_44\NNS\5246511|in|glast-/- (l_amod) glast-/-_43\JJ\1740|
T1_T17 NONE d-aspartate-induced_2\JJ\1740| (r_amod) currents_3\NNS\11449002|d-aspartate-induced|patches (r_nsubj) exhibited_9\VBD\2632167|furthermore|,|currents|currents|,|and|revealed (l_dobj) currents_12\NNS\11449002|larger|steady-state|responses (l_nmod) responses_14\NNS\11410625|than|elicited (l_acl) elicited_15\VBN\1617192|l-glutamate (l_nmod) l-glutamate_17\NN\1740|by|,|feature (l_appos) feature_21\NN\5849040|a|prominent|glast (l_nmod) glast_23\NN\1740|of
T1_T18 NONE d-aspartate-induced_2\JJ\1740| (r_amod) currents_3\NNS\11449002|d-aspartate-induced|patches (r_nsubj) exhibited_9\VBD\2632167|furthermore|,|currents|currents|,|and|revealed (l_conj) revealed_38\VBD\2137132|examination|restricted (l_nsubj) examination_26\NN\633864|cochlea (l_nmod) cochlea_28\NN\5246511|of|mice (l_nmod) mice_37\NNS\2329401|from|red|promoter|reporter (l_compound) red_31\NN\4959672|glast-discosoma|dsred (l_compound) glast-discosoma_30\NN\1740|
T2_T17 CPR:9 l-glutamate_17\NN\1740|by|,|feature (l_appos) feature_21\NN\5849040|a|prominent|glast (l_nmod) glast_23\NN\1740|of
T2_T18 NONE l-glutamate_17\NN\1740|by|,|feature (r_nmod) elicited_15\VBN\1617192|l-glutamate (r_acl) responses_14\NNS\11410625|than|elicited (r_nmod) currents_12\NNS\11449002|larger|steady-state|responses (r_dobj) exhibited_9\VBD\2632167|furthermore|,|currents|currents|,|and|revealed (l_conj) revealed_38\VBD\2137132|examination|restricted (l_nsubj) examination_26\NN\633864|cochlea (l_nmod) cochlea_28\NN\5246511|of|mice (l_nmod) mice_37\NNS\2329401|from|red|promoter|reporter (l_compound) red_31\NN\4959672|glast-discosoma|dsred (l_compound) glast-discosoma_30\NN\1740|
23572520
T13_T21 NONE s-nitrosation_0\NN\1740|p1 (l_nmod) p1_4\NN\1740|of|glutathione|transferase|-|1 (l_nummod) 1_6\CD\13741022|
T14_T21 NONE glutathione_2\NN\1740| (r_compound) p1_4\NN\1740|of|glutathione|transferase|-|1 (l_nummod) 1_6\CD\13741022|
T8_T17 NONE glutathione_16\NN\1740| (r_compound) transferase_17\NN\14732946|human|glutathione (r_compound) p1_21\NN\1740|of|transferase|gst|)|- (l_punct) -_22\HYPH\1740|1 (l_nummod) 1_23\CD\13741022|,|enzyme
T9_T18 NONE s-nitrosated_6\VBN\1740|c47|is|steps|,|limited|. (l_nsubjpass) c47_0\NN\1740|gstp1|- (l_punct) -_3\NN\1740|1 (l_nummod) 1_4\CD\13741022|
T12_T15 NONE cysno_26\NN\1740| (r_dobj) using_25\VBG\1156834|cysno (r_acl) experiments_24\NNS\641820|nitrosation|using (r_conj) calorimetry_19\NN\996969|isothermal|titration|as|experiments (r_nsubj) demonstrate_27\VBP\2137132|presence|,|calorimetry|precede|. (l_ccomp) precede_33\VB\2690708|that|binding|does|not|s-nitrosation (l_dobj) s-nitrosation_34\NN\1740|gstp1|1 (l_nummod) 1_38\CD\13741022|
T12_T19 NONE cysno_26\NN\1740| (r_dobj) using_25\VBG\1156834|cysno (r_acl) experiments_24\NNS\641820|nitrosation|using (r_conj) calorimetry_19\NN\996969|isothermal|titration|as|experiments (r_nsubj) demonstrate_27\VBP\2137132|presence|,|calorimetry|precede|. (l_nmod) presence_2\NN\13954253|despite|the|site|site|1 (l_nmod) site_7\NN\8673395|of|a|gsno|binding
T12_T20 NONE cysno_26\NN\1740| (r_dobj) using_25\VBG\1156834|cysno (r_acl) experiments_24\NNS\641820|nitrosation|using (r_conj) calorimetry_19\NN\996969|isothermal|titration|as|experiments (r_nsubj) demonstrate_27\VBP\2137132|presence|,|calorimetry|precede|. (l_nmod) presence_2\NN\13954253|despite|the|site|site|1 (l_nmod) 1_15\NN\13741022|
T2_T15 NONE s-nitrosation_34\NN\1740|gstp1|1 (l_nummod) 1_38\CD\13741022|
T2_T19 NONE s-nitrosation_34\NN\1740|gstp1|1 (r_dobj) precede_33\VB\2690708|that|binding|does|not|s-nitrosation (r_ccomp) demonstrate_27\VBP\2137132|presence|,|calorimetry|precede|. (l_nmod) presence_2\NN\13954253|despite|the|site|site|1 (l_nmod) site_7\NN\8673395|of|a|gsno|binding
T2_T20 NONE s-nitrosation_34\NN\1740|gstp1|1 (r_dobj) precede_33\VB\2690708|that|binding|does|not|s-nitrosation (r_ccomp) demonstrate_27\VBP\2137132|presence|,|calorimetry|precede|. (l_nmod) presence_2\NN\13954253|despite|the|site|site|1 (l_nmod) 1_15\NN\13741022|
23364612
23131177
T12_T28 CPR:5 phenylpropylamides_3\NNS\1740|of|substituted (r_nmod) characterization_0\NN\6724763|phenylpropylamides|agonists|. (l_nmod) agonists_7\NNS\9613191|as|selective|receptor (l_nmod) receptor_12\NN\5225602|at|the|melatonin|mt2
T13_T28 NONE melatonin_10\NN\5407119| (r_compound) receptor_12\NN\5225602|at|the|melatonin|mt2
T5_T22 NONE melatonin_17\NN\5407119|of (r_nmod) actions_15\NNS\30358|the|melatonin (r_dobj) mediating_13\VBG\761713|for|actions (r_advcl) responsible_11\JJ\1740|subtypes|are|primarily|mediating|. (l_nsubj) subtypes_2\NNS\1740|the|two|receptors (l_nmod) receptors_8\NNS\5225602|of|mammalian|protein-coupled|melatonin
T6_T23 NONE melatonin_2\NN\5407119|
T7_T24 NONE amides_10\NNS\14727670|of|substituted|n-[3-(3-methoxyphenyl)propyl|] (r_nmod) series_5\NN\8456993|of|a|amides (r_nmod) potencies_2\NNS\5196375|the|pharmacological|series|receptors (l_nmod) receptors_19\NNS\5225602|towards|mt(1 (l_compound) mt(1_14\NN\1740|human|melatonin|)|and|mt(2 (l_punct) )_15\-RRB-\1740|
T7_T25 NONE amides_10\NNS\14727670|of|substituted|n-[3-(3-methoxyphenyl)propyl|] (r_nmod) series_5\NN\8456993|of|a|amides (r_nmod) potencies_2\NNS\5196375|the|pharmacological|series|receptors (l_nmod) receptors_19\NNS\5225602|towards|mt(1
T7_T26 NONE amides_10\NNS\14727670|of|substituted|n-[3-(3-methoxyphenyl)propyl|] (r_nmod) series_5\NN\8456993|of|a|amides (r_nmod) potencies_2\NNS\5196375|the|pharmacological|series|receptors (r_nsubjpass) evaluated_21\VBN\670261|potencies|were|assay|,|verified|. (l_advcl) verified_34\VBN\665886|whilst|subtype-selectivity|was|subsequently|phosphorylation (l_nmod) phosphorylation_37\NN\1740|with|erk|and|assays (l_compound) erk_36\NN\1740|
T8_T24 NONE melatonin_13\NN\5407119| (r_compound) mt(1_14\NN\1740|human|melatonin|)|and|mt(2 (l_punct) )_15\-RRB-\1740|
T8_T25 NONE melatonin_13\NN\5407119| (r_compound) mt(1_14\NN\1740|human|melatonin|)|and|mt(2 (r_compound) receptors_19\NNS\5225602|towards|mt(1
T8_T26 NONE melatonin_13\NN\5407119| (r_compound) mt(1_14\NN\1740|human|melatonin|)|and|mt(2 (r_compound) receptors_19\NNS\5225602|towards|mt(1 (r_nmod) potencies_2\NNS\5196375|the|pharmacological|series|receptors (r_nsubjpass) evaluated_21\VBN\670261|potencies|were|assay|,|verified|. (l_advcl) verified_34\VBN\665886|whilst|subtype-selectivity|was|subsequently|phosphorylation (l_nmod) phosphorylation_37\NN\1740|with|erk|and|assays (l_compound) erk_36\NN\1740|
T9_T24 NONE camp_39\NN\3763727| (r_compound) assays_40\NNS\5733583|camp (r_conj) phosphorylation_37\NN\1740|with|erk|and|assays (r_nmod) verified_34\VBN\665886|whilst|subtype-selectivity|was|subsequently|phosphorylation (r_advcl) evaluated_21\VBN\670261|potencies|were|assay|,|verified|. (l_nsubjpass) potencies_2\NNS\5196375|the|pharmacological|series|receptors (l_nmod) receptors_19\NNS\5225602|towards|mt(1 (l_compound) mt(1_14\NN\1740|human|melatonin|)|and|mt(2 (l_punct) )_15\-RRB-\1740|
T9_T25 NONE camp_39\NN\3763727| (r_compound) assays_40\NNS\5733583|camp (r_conj) phosphorylation_37\NN\1740|with|erk|and|assays (r_nmod) verified_34\VBN\665886|whilst|subtype-selectivity|was|subsequently|phosphorylation (r_advcl) evaluated_21\VBN\670261|potencies|were|assay|,|verified|. (l_nsubjpass) potencies_2\NNS\5196375|the|pharmacological|series|receptors (l_nmod) receptors_19\NNS\5225602|towards|mt(1
T9_T26 NONE camp_39\NN\3763727| (r_compound) assays_40\NNS\5733583|camp (r_conj) phosphorylation_37\NN\1740|with|erk|and|assays (l_compound) erk_36\NN\1740|
T10_T14 NONE benzyloxyl_21\NN\1740| (r_compound) substituent_22\NN\1740|a|benzyloxyl|incorporated (r_nsubj) enhanced_32\VBD\227165|that|substituent|dramatically|potency|and|decreased (l_dobj) potency_36\NN\5196375|the|mt(2 (l_compound) mt(2_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T10_T15 NONE benzyloxyl_21\NN\1740| (r_compound) substituent_22\NN\1740|a|benzyloxyl|incorporated (r_nsubj) enhanced_32\VBD\227165|that|substituent|dramatically|potency|and|decreased (l_conj) decreased_42\VBD\169651|time|potency (l_dobj) potency_45\NN\5196375|mt(1|) (l_punct) )_44\-RRB-\1740|
T10_T27 NONE benzyloxyl_21\NN\1740| (r_compound) substituent_22\NN\1740|a|benzyloxyl|incorporated (r_nsubj) enhanced_32\VBD\227165|that|substituent|dramatically|potency|and|decreased (r_ccomp) revealed_18\VBD\2137132|analysis|enhanced|. (l_nsubj) analysis_2\NN\633864|structure-activity|relationship|ligands|mt(2 (l_dep) mt(2_9\NN\1740|(|)|ec(50|pm|) (l_punct) )_10\-RRB-\1740|
T11_T14 NONE 3-methoxyphenyl_29\NN\1740| (r_compound) ring_30\NN\4981139|of|the|3-methoxyphenyl (r_nmod) position_26\NN\8620061|at|c6|ring (r_nmod) incorporated_23\VBN\1461328|position (r_acl) substituent_22\NN\1740|a|benzyloxyl|incorporated (r_nsubj) enhanced_32\VBD\227165|that|substituent|dramatically|potency|and|decreased (l_dobj) potency_36\NN\5196375|the|mt(2 (l_compound) mt(2_34\NN\1740|) (l_punct) )_35\-RRB-\1740|
T11_T15 NONE 3-methoxyphenyl_29\NN\1740| (r_compound) ring_30\NN\4981139|of|the|3-methoxyphenyl (r_nmod) position_26\NN\8620061|at|c6|ring (r_nmod) incorporated_23\VBN\1461328|position (r_acl) substituent_22\NN\1740|a|benzyloxyl|incorporated (r_nsubj) enhanced_32\VBD\227165|that|substituent|dramatically|potency|and|decreased (l_conj) decreased_42\VBD\169651|time|potency (l_dobj) potency_45\NN\5196375|mt(1|) (l_punct) )_44\-RRB-\1740|
T11_T27 NONE 3-methoxyphenyl_29\NN\1740| (r_compound) ring_30\NN\4981139|of|the|3-methoxyphenyl (r_nmod) position_26\NN\8620061|at|c6|ring (r_nmod) incorporated_23\VBN\1461328|position (r_acl) substituent_22\NN\1740|a|benzyloxyl|incorporated (r_nsubj) enhanced_32\VBD\227165|that|substituent|dramatically|potency|and|decreased (r_ccomp) revealed_18\VBD\2137132|analysis|enhanced|. (l_nsubj) analysis_2\NN\633864|structure-activity|relationship|ligands|mt(2 (l_dep) mt(2_9\NN\1740|(|)|ec(50|pm|) (l_punct) )_10\-RRB-\1740|
T2_T17 NONE melatonin_17\NN\5407119|than (r_nmod) potency_11\NN\5196375|a|higher|receptor|melatonin (l_nmod) receptor_15\NN\5225602|for|mt(2|)
T3_T17 NONE [ca(2+)]i_21\NN\1740|of (r_nmod) elevation_19\NN\7445480|for|[ca(2+)]i|and|inhibition (r_nmod) had_7\VBD\2108377|ligand|potency|elevation|. (l_dobj) potency_11\NN\5196375|a|higher|receptor|melatonin (l_nmod) receptor_15\NN\5225602|for|mt(2|)
T4_T21 NONE melatonin_12\NN\5407119| (r_compound) subtypes_14\NNS\1740|of|distinct|melatonin|receptor (l_compound) receptor_13\NN\5225602|
23473037
T1_T8 NONE leucine-to-proline_20\JJ\1740| (r_amod) mutation_21\NN\4475|to|a|leucine-to-proline|residue (r_nmod) corresponding_17\VBG\2664769|mutation (r_acl) exchange_10\NN\11409059|of|a|t-to-c|exon|,|corresponding (l_nmod) exon_12\NN\14830364|in|1|sirt1 (l_nmod) sirt1_15\NN\1740|of
T1_T9 NONE leucine-to-proline_20\JJ\1740| (r_amod) mutation_21\NN\4475|to|a|leucine-to-proline|residue (l_nmod) residue_23\NN\20827|at|107 (l_nummod) 107_24\CD\1740|
T2_T8 NONE leucine-to-proline_20\JJ\1740| (r_amod) mutation_21\NN\4475|to|a|leucine-to-proline|residue (r_nmod) corresponding_17\VBG\2664769|mutation (r_acl) exchange_10\NN\11409059|of|a|t-to-c|exon|,|corresponding (l_nmod) exon_12\NN\14830364|in|1|sirt1 (l_nmod) sirt1_15\NN\1740|of
T2_T9 NONE leucine-to-proline_20\JJ\1740| (r_amod) mutation_21\NN\4475|to|a|leucine-to-proline|residue (l_nmod) residue_23\NN\20827|at|107 (l_nummod) 107_24\CD\1740|
T3_T10 NONE oxide_11\NN\14818238|of|nitric|,|cytokines|,|and|chemokines (r_nmod) overproduction_8\NN\913705|in|oxide (r_nmod) resulted_6\VBD\2633881|expression|overproduction|. (l_nsubj) expression_0\NN\4679549|sirt1-l107p|cells (l_nmod) sirt1-l107p_2\NN\1740|of
T3_T11 NONE oxide_11\NN\14818238|of|nitric|,|cytokines|,|and|chemokines (r_nmod) overproduction_8\NN\913705|in|oxide (r_nmod) resulted_6\VBD\2633881|expression|overproduction|. (l_nsubj) expression_0\NN\4679549|sirt1-l107p|cells (l_nmod) sirt1-l107p_2\NN\1740|of
T3_T12 NONE oxide_11\NN\14818238|of|nitric|,|cytokines|,|and|chemokines (r_nmod) overproduction_8\NN\913705|in|oxide (r_nmod) resulted_6\VBD\2633881|expression|overproduction|. (l_nsubj) expression_0\NN\4679549|sirt1-l107p|cells (l_nmod) cells_5\NNS\3080309|in|insulin-producing (l_amod) insulin-producing_4\JJ\1740|
T3_T14 NONE oxide_11\NN\14818238|of|nitric|,|cytokines|,|and|chemokines (l_conj) cytokines_13\NNS\14728724|
T3_T15 NONE oxide_11\NN\14818238|of|nitric|,|cytokines|,|and|chemokines (l_conj) chemokines_16\NNS\1740|
16775509
T7_T14 CPR:6 medoxomil_8\NN\1740|antagonist (l_compound) antagonist_6\NN\7846|of|at1|olmesartan (l_compound) at1_5\NN\1740|
T3_T12 NONE ii_21\CD\13741022| (r_nummod) receptor_24\NN\5225602|angiotensin|ii|type|1|at1 (l_appos) at1_26\NN\1740|(|)
T3_T9 NONE ii_21\CD\13741022| (r_nummod) receptor_24\NN\5225602|angiotensin|ii|type|1|at1
T4_T10 NONE phosphate_14\NN\15010703| (r_compound) levels_15\NNS\4916342|myocardial|high-energy|phosphate (r_conj) expression_10\NN\4679549|in|both|mitochondrial|f0f1-atpase|and|levels (l_compound) f0f1-atpase_9\NN\1740|
T5_T11 CPR:6 medoxomil_18\NN\1740| (r_dobj) prevented_12\VBN\1740|thus|,|dysfunction|were|olmesartan|medoxomil|. (l_nmod) olmesartan_17\NN\1740|by|the|antagonist (l_compound) antagonist_16\NN\7846|at1 (l_compound) at1_15\NN\1740|
9876137
T8_T23 CPR:4 cocaine_1\NN\3492717| (r_compound) block_2\NN\21939|state-dependent|cocaine|isoforms|. (l_nmod) isoforms_6\NNS\1740|of|sodium|channel|,|chimeras|,|and|channels (l_compound) channel_5\NN\6251781|
T9_T23 NONE sodium_4\NN\14625458| (r_compound) isoforms_6\NNS\1740|of|sodium|channel|,|chimeras|,|and|channels (l_compound) channel_5\NN\6251781|
T1_T10 CPR:4 cocaine_0\NN\3492717| (r_compound) block_1\NN\21939|cocaine|cardiac (l_nmod) cardiac_4\JJ\1740|of|human|hh1|and|channels (l_appos) hh1_6\NN\1740|(|) (l_punct) )_7\-RRB-\1740|
T1_T15 CPR:4 cocaine_0\NN\3492717| (r_compound) block_1\NN\21939|cocaine|cardiac (l_nmod) cardiac_4\JJ\1740|of|human|hh1|and|channels (l_conj) channels_16\NNS\6251781|muscle|sodium
T7_T10 NONE sodium_15\NN\14625458| (r_compound) channels_16\NNS\6251781|muscle|sodium (r_conj) cardiac_4\JJ\1740|of|human|hh1|and|channels (l_appos) hh1_6\NN\1740|(|) (l_punct) )_7\-RRB-\1740|
T7_T15 NONE sodium_15\NN\14625458| (r_compound) channels_16\NNS\6251781|muscle|sodium
T5_T13 CPR:4 cocaine_0\NN\3492717| (r_compound) block_1\NN\21939|cocaine|channels (l_nmod) channels_4\NNS\6251781|of|hh1
T5_T14 CPR:4 cocaine_0\NN\3492717| (r_compound) block_1\NN\21939|cocaine|channels (r_nsubj) greater_6\JJR\1740|block|was|block|,|suggesting|. (l_nmod) block_8\NN\21939|than|channels|voltages (l_nmod) channels_11\NNS\6251781|of|mu1
T5_T16 CPR:4 cocaine_0\NN\3492717| (r_compound) block_1\NN\21939|cocaine|channels (r_nsubj) greater_6\JJR\1740|block|was|block|,|suggesting|. (l_advcl) suggesting_21\VBG\1010118|makes (l_ccomp) makes_33\VBZ\126264|that|inactivation|susceptible (l_nsubj) inactivation_25\NN\13518963|greater|steady-state|channels|range (l_nmod) channels_28\NNS\6251781|of|hh1
T6_T13 NONE cocaine_38\NN\3492717| (r_compound) block_39\NN\21939|to|cocaine (r_nmod) susceptible_36\JJ\1740|them|more|block (r_ccomp) makes_33\VBZ\126264|that|inactivation|susceptible (r_ccomp) suggesting_21\VBG\1010118|makes (r_advcl) greater_6\JJR\1740|block|was|block|,|suggesting|. (l_nsubj) block_1\NN\21939|cocaine|channels (l_nmod) channels_4\NNS\6251781|of|hh1
T6_T14 NONE cocaine_38\NN\3492717| (r_compound) block_39\NN\21939|to|cocaine (r_nmod) susceptible_36\JJ\1740|them|more|block (r_ccomp) makes_33\VBZ\126264|that|inactivation|susceptible (r_ccomp) suggesting_21\VBG\1010118|makes (r_advcl) greater_6\JJR\1740|block|was|block|,|suggesting|. (l_nmod) block_8\NN\21939|than|channels|voltages (l_nmod) channels_11\NNS\6251781|of|mu1
T6_T16 CPR:4 cocaine_38\NN\3492717| (r_compound) block_39\NN\21939|to|cocaine (r_nmod) susceptible_36\JJ\1740|them|more|block (r_ccomp) makes_33\VBZ\126264|that|inactivation|susceptible (l_nsubj) inactivation_25\NN\13518963|greater|steady-state|channels|range (l_nmod) channels_28\NNS\6251781|of|hh1
2554783
T1_T2 NONE glutathione_18\NN\1740| (r_compound) hydrolase_19\NN\1740|s-formyl|glutathione (r_xcomp) called_16\VBN\1029852|also|hydrolase (r_acl) catalase_10\NN\14732946|for|and|d|,|called|,|enzymes
T1_T3 NONE glutathione_18\NN\1740| (r_compound) hydrolase_19\NN\1740|s-formyl|glutathione (r_xcomp) called_16\VBN\1029852|also|hydrolase (r_acl) catalase_10\NN\14732946|for|and|d|,|called|,|enzymes (l_conj) d_13\NN\15089472|esterase
T1_T4 NONE glutathione_18\NN\1740| (r_compound) hydrolase_19\NN\1740|s-formyl|glutathione
23639191
T24_T45 NONE calycopterin_15\NN\1740|by|the|flavonoid|isolated (r_nmod) mediated_11\VBN\761713|calycopterin (r_acl) neuroprotection_10\NN\1740|in|mediated (r_nmod) involvement_0\NN\1080366|p-creb|neuroprotection|. (l_nmod) p-creb_2\NN\1740|of|and|enzyme|system
T24_T46 NONE calycopterin_15\NN\1740|by|the|flavonoid|isolated (r_nmod) mediated_11\VBN\761713|calycopterin (r_acl) neuroprotection_10\NN\1740|in|mediated (r_nmod) involvement_0\NN\1080366|p-creb|neuroprotection|. (l_nmod) p-creb_2\NN\1740|of|and|enzyme|system (l_conj) enzyme_7\NN\14723628|phase|ii|detoxifying
T16_T33 NONE calycopterin_12\NN\1740| (r_appos) flavonoid_10\NN\14983143|of|a|natural|neuroprotective|,|calycopterin|, (r_nmod) effect_5\NN\34213|the|flavonoid|disruption (l_nmod) disruption_16\NN\1066163|on|h2o2-induced|system|and|phosphorylation (l_nmod) system_22\NN\3575240|of|enzyme (l_compound) enzyme_21\NN\14723628|phase|ii|detoxifying
T16_T34 NONE calycopterin_12\NN\1740| (r_appos) flavonoid_10\NN\14983143|of|a|natural|neuroprotective|,|calycopterin|, (r_nmod) effect_5\NN\34213|the|flavonoid|disruption (l_nmod) disruption_16\NN\1066163|on|h2o2-induced|system|and|phosphorylation (l_conj) phosphorylation_32\NN\1740|protein (l_compound) protein_28\NN\14944888|camp|response|element|binding|creb
T16_T35 NONE calycopterin_12\NN\1740| (r_appos) flavonoid_10\NN\14983143|of|a|natural|neuroprotective|,|calycopterin|, (r_nmod) effect_5\NN\34213|the|flavonoid|disruption (l_nmod) disruption_16\NN\1066163|on|h2o2-induced|system|and|phosphorylation (l_conj) phosphorylation_32\NN\1740|protein (l_compound) protein_28\NN\14944888|camp|response|element|binding|creb (l_appos) creb_30\NN\1740|(|)
T17_T33 CPR:4 h2o2-induced_15\JJ\1740| (r_amod) disruption_16\NN\1066163|on|h2o2-induced|system|and|phosphorylation (l_nmod) system_22\NN\3575240|of|enzyme (l_compound) enzyme_21\NN\14723628|phase|ii|detoxifying
T17_T34 CPR:4 h2o2-induced_15\JJ\1740| (r_amod) disruption_16\NN\1066163|on|h2o2-induced|system|and|phosphorylation (l_conj) phosphorylation_32\NN\1740|protein (l_compound) protein_28\NN\14944888|camp|response|element|binding|creb
T17_T35 CPR:4 h2o2-induced_15\JJ\1740| (r_amod) disruption_16\NN\1066163|on|h2o2-induced|system|and|phosphorylation (l_conj) phosphorylation_32\NN\1740|protein (l_compound) protein_28\NN\14944888|camp|response|element|binding|creb (l_appos) creb_30\NN\1740|(|)
T18_T33 NONE camp_24\NN\3763727| (r_compound) protein_28\NN\14944888|camp|response|element|binding|creb (r_compound) phosphorylation_32\NN\1740|protein (r_conj) disruption_16\NN\1066163|on|h2o2-induced|system|and|phosphorylation (l_nmod) system_22\NN\3575240|of|enzyme (l_compound) enzyme_21\NN\14723628|phase|ii|detoxifying
T18_T34 NONE camp_24\NN\3763727| (r_compound) protein_28\NN\14944888|camp|response|element|binding|creb
T18_T35 NONE camp_24\NN\3763727| (r_compound) protein_28\NN\14944888|camp|response|element|binding|creb (l_appos) creb_30\NN\1740|(|)
T21_T36 NONE glutamylcysteine_16\NN\1740| (r_compound) synthetase_17\NN\1740|glutamylcysteine|γ-gcs (r_conj) creb_4\NN\1740|of|phosphorylated|,|factor|,|synthetase|and|oxygenase
T21_T37 NONE glutamylcysteine_16\NN\1740| (r_compound) synthetase_17\NN\1740|glutamylcysteine|γ-gcs (r_conj) creb_4\NN\1740|of|phosphorylated|,|factor|,|synthetase|and|oxygenase (l_conj) factor_10\NN\7326557|nuclear|factor|erythroid|2-related|2|nrf2 (l_nummod) 2_11\CD\13741022|
T21_T38 NONE glutamylcysteine_16\NN\1740| (r_compound) synthetase_17\NN\1740|glutamylcysteine|γ-gcs (r_conj) creb_4\NN\1740|of|phosphorylated|,|factor|,|synthetase|and|oxygenase (l_conj) factor_10\NN\7326557|nuclear|factor|erythroid|2-related|2|nrf2 (l_appos) nrf2_13\NN\1740|(|)
T21_T39 NONE glutamylcysteine_16\NN\1740| (r_compound) synthetase_17\NN\1740|glutamylcysteine|γ-gcs
T21_T40 NONE glutamylcysteine_16\NN\1740| (r_compound) synthetase_17\NN\1740|glutamylcysteine|γ-gcs (l_appos) γ-gcs_19\NNS\1740|(|)
T21_T41 NONE glutamylcysteine_16\NN\1740| (r_compound) synthetase_17\NN\1740|glutamylcysteine|γ-gcs (r_conj) creb_4\NN\1740|of|phosphorylated|,|factor|,|synthetase|and|oxygenase (l_conj) oxygenase_23\NN\14971969|heme|1|ho-1 (l_nummod) 1_24\CD\13741022|
T21_T42 NONE glutamylcysteine_16\NN\1740| (r_compound) synthetase_17\NN\1740|glutamylcysteine|γ-gcs (r_conj) creb_4\NN\1740|of|phosphorylated|,|factor|,|synthetase|and|oxygenase (l_conj) oxygenase_23\NN\14971969|heme|1|ho-1 (l_appos) ho-1_26\NN\1740|(|)
T6_T25 NONE h2o2-treated_1\JJ\1740| (r_amod) cells_2\NNS\3080309|in|h2o2-treated (r_nmod) suppressed_6\VBD\2510337|cells|,|calycopterin|also|release|. (l_dobj) release_9\NN\3748886|c|cytosol|necessary (l_compound) c_8\NN\13714184|cytochrome
T7_T25 CPR:4 calycopterin_4\NN\1740| (r_nsubj) suppressed_6\VBD\2510337|cells|,|calycopterin|also|release|. (l_dobj) release_9\NN\3748886|c|cytosol|necessary (l_compound) c_8\NN\13714184|cytochrome
T8_T26 CPR:3 calycopterin_2\NN\1740| (r_nsubj) inhibited_8\VBD\2510337|moreover|,|calycopterin|,|presence|decrease|. (l_dobj) decrease_10\NN\7296428|the|caused (l_acl) caused_11\VBN\1617192|stress|factors (l_nmod) factors_18\NNS\7326557|in|stress-sensing|transcription|,|creb|,|play (l_appos) creb_20\NN\1740|and|nrf2
T8_T27 CPR:3 calycopterin_2\NN\1740| (r_nsubj) inhibited_8\VBD\2510337|moreover|,|calycopterin|,|presence|decrease|. (l_dobj) decrease_10\NN\7296428|the|caused (l_acl) caused_11\VBN\1617192|stress|factors (l_nmod) factors_18\NNS\7326557|in|stress-sensing|transcription|,|creb|,|play (l_appos) creb_20\NN\1740|and|nrf2 (l_conj) nrf2_22\NN\1740|
T9_T26 NONE h2o2_7\NN\1740|of (r_nmod) presence_5\NN\13954253|in|h2o2 (r_nmod) inhibited_8\VBD\2510337|moreover|,|calycopterin|,|presence|decrease|. (l_dobj) decrease_10\NN\7296428|the|caused (l_acl) caused_11\VBN\1617192|stress|factors (l_nmod) factors_18\NNS\7326557|in|stress-sensing|transcription|,|creb|,|play (l_appos) creb_20\NN\1740|and|nrf2
T9_T27 NONE h2o2_7\NN\1740|of (r_nmod) presence_5\NN\13954253|in|h2o2 (r_nmod) inhibited_8\VBD\2510337|moreover|,|calycopterin|,|presence|decrease|. (l_dobj) decrease_10\NN\7296428|the|caused (l_acl) caused_11\VBN\1617192|stress|factors (l_nmod) factors_18\NNS\7326557|in|stress-sensing|transcription|,|creb|,|play (l_appos) creb_20\NN\1740|and|nrf2 (l_conj) nrf2_22\NN\1740|
T10_T28 CPR:3 calycopterin_11\NN\1740| (r_nmod:npmod) pretreated_12\JJ\1740|calycopterin (r_amod) cells_13\NNS\3080309|in|pretreated (r_nmod) increase_4\NN\13576355|an|levels|cells (l_nmod) levels_9\NNS\4916342|γ-gcs (l_compound) γ-gcs_6\NNS\1740|in|and|ho-1
T10_T29 CPR:3 calycopterin_11\NN\1740| (r_nmod:npmod) pretreated_12\JJ\1740|calycopterin (r_amod) cells_13\NNS\3080309|in|pretreated (r_nmod) increase_4\NN\13576355|an|levels|cells (l_nmod) levels_9\NNS\4916342|γ-gcs (l_compound) γ-gcs_6\NNS\1740|in|and|ho-1 (l_conj) ho-1_8\NN\1740|
T11_T30 NONE h2o2_4\NN\1740|of (r_nmod) presence_2\NN\13954253|in|the|h2o2 (r_nmod) inhibited_7\VBD\2510337|presence|,|calycopterin|decrease|. (l_dobj) decrease_8\NN\7296428|level|and|activity (l_conj) activity_14\NN\30358|sod (l_compound) sod_13\NN\9335240|
T12_T30 CPR:3 calycopterin_6\NN\1740| (r_nsubj) inhibited_7\VBD\2510337|presence|,|calycopterin|decrease|. (l_dobj) decrease_8\NN\7296428|level|and|activity (l_conj) activity_14\NN\30358|sod (l_compound) sod_13\NN\9335240|
T13_T30 NONE gsh_10\NN\1740| (r_compound) level_11\NN\4916342|in|gsh (r_nmod) decrease_8\NN\7296428|level|and|activity (l_conj) activity_14\NN\30358|sod (l_compound) sod_13\NN\9335240|
T14_T31 NONE calycopterin_13\NN\1740| (r_appos) flavone_11\NN\14818238|of|a|natural|,|calycopterin|, (r_nmod) effect_7\NN\34213|of|neuroprotective|flavone|stress (r_nmod) documentation_4\NN\6650070|effect (r_dobj) provided_3\VBD\2199590|we|documentation|modulating (l_advcl) modulating_24\VBG\1724459|by|level (l_dobj) level_26\NN\4916342|the|phosphorylation (l_nmod) phosphorylation_29\NN\1740|of|creb|and|pathway (l_compound) creb_28\NN\1740|
T14_T32 NONE calycopterin_13\NN\1740| (r_appos) flavone_11\NN\14818238|of|a|natural|,|calycopterin|, (r_nmod) effect_7\NN\34213|of|neuroprotective|flavone|stress (r_nmod) documentation_4\NN\6650070|effect (r_dobj) provided_3\VBD\2199590|we|documentation|modulating (l_advcl) modulating_24\VBG\1724459|by|level (l_dobj) level_26\NN\4916342|the|phosphorylation (l_nmod) phosphorylation_29\NN\1740|of|creb|and|pathway (l_conj) pathway_32\NN\5483677|nrf2 (l_compound) nrf2_31\NN\1740|
T15_T31 NONE h2o2-induced_16\JJ\1740| (r_amod) stress_18\NN\7083732|against|h2o2-induced|oxidative|cells (r_nmod) effect_7\NN\34213|of|neuroprotective|flavone|stress (r_nmod) documentation_4\NN\6650070|effect (r_dobj) provided_3\VBD\2199590|we|documentation|modulating (l_advcl) modulating_24\VBG\1724459|by|level (l_dobj) level_26\NN\4916342|the|phosphorylation (l_nmod) phosphorylation_29\NN\1740|of|creb|and|pathway (l_compound) creb_28\NN\1740|
T15_T32 NONE h2o2-induced_16\JJ\1740| (r_amod) stress_18\NN\7083732|against|h2o2-induced|oxidative|cells (r_nmod) effect_7\NN\34213|of|neuroprotective|flavone|stress (r_nmod) documentation_4\NN\6650070|effect (r_dobj) provided_3\VBD\2199590|we|documentation|modulating (l_advcl) modulating_24\VBG\1724459|by|level (l_dobj) level_26\NN\4916342|the|phosphorylation (l_nmod) phosphorylation_29\NN\1740|of|creb|and|pathway (l_conj) pathway_32\NN\5483677|nrf2 (l_compound) nrf2_31\NN\1740|
15612980
T2_T23 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_compound) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr
T2_T24 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_compound) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (l_appos) mthfr_16\NN\1740|(|)
T2_T25 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c
T2_T26 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c (l_conj) a1298c_21\NN\1740|
T2_T27 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms
T2_T28 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms (l_appos) ms_26\NN\14187378|(|)
T2_T29 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g
T2_T30 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66 (l_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr
T2_T31 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66 (l_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr (l_appos) mtrr_35\NN\1740|(|)
T2_T32 NONE hcy-regulating_10\NN\1740| (r_compound) genes_11\NNS\8459252|in|hcy-regulating (r_nmod) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66
T4_T23 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr
T4_T24 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (l_appos) mthfr_16\NN\1740|(|)
T4_T25 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (r_compound) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c
T4_T26 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (r_compound) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c (l_conj) a1298c_21\NN\1740|
T4_T27 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (r_compound) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms
T4_T28 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (r_compound) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms (l_appos) ms_26\NN\14187378|(|)
T4_T29 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (r_compound) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g
T4_T30 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (r_compound) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66 (l_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr
T4_T31 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (r_compound) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66 (l_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr (l_appos) mtrr_35\NN\1740|(|)
T4_T32 NONE methylenetetrahydrofolate_13\NN\1740| (r_amod) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (r_compound) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66
T6_T23 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (r_compound) g_29\NN\13717155|a2756|;|g (r_conj) c677_18\NN\1740|[|reductase|t|;|g|] (l_compound) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr
T6_T24 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (r_compound) g_29\NN\13717155|a2756|;|g (r_conj) c677_18\NN\1740|[|reductase|t|;|g|] (l_compound) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (l_appos) mthfr_16\NN\1740|(|)
T6_T25 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (r_compound) g_29\NN\13717155|a2756|;|g (r_conj) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c
T6_T26 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (r_compound) g_29\NN\13717155|a2756|;|g (r_conj) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c (l_conj) a1298c_21\NN\1740|
T6_T27 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms
T6_T28 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms (l_appos) ms_26\NN\14187378|(|)
T6_T29 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (r_compound) g_29\NN\13717155|a2756|;|g
T6_T30 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (r_compound) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66 (l_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr
T6_T31 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (r_compound) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66 (l_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr (l_appos) mtrr_35\NN\1740|(|)
T6_T32 NONE methionine_23\NN\14605787| (r_compound) a2756_28\NN\1740|methionine|synthase (r_compound) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66
T7_T23 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (r_compound) g_38\NN\13717155|a66 (r_conj) g_29\NN\13717155|a2756|;|g (r_conj) c677_18\NN\1740|[|reductase|t|;|g|] (l_compound) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr
T7_T24 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (r_compound) g_38\NN\13717155|a66 (r_conj) g_29\NN\13717155|a2756|;|g (r_conj) c677_18\NN\1740|[|reductase|t|;|g|] (l_compound) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (l_appos) mthfr_16\NN\1740|(|)
T7_T25 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (r_compound) g_38\NN\13717155|a66 (r_conj) g_29\NN\13717155|a2756|;|g (r_conj) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c
T7_T26 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (r_compound) g_38\NN\13717155|a66 (r_conj) g_29\NN\13717155|a2756|;|g (r_conj) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c (l_conj) a1298c_21\NN\1740|
T7_T27 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (r_compound) g_38\NN\13717155|a66 (r_conj) g_29\NN\13717155|a2756|;|g (l_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms
T7_T28 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (r_compound) g_38\NN\13717155|a66 (r_conj) g_29\NN\13717155|a2756|;|g (l_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms (l_appos) ms_26\NN\14187378|(|)
T7_T29 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (r_compound) g_38\NN\13717155|a66 (r_conj) g_29\NN\13717155|a2756|;|g
T7_T30 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr
T7_T31 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr (l_appos) mtrr_35\NN\1740|(|)
T7_T32 NONE methionine_31\NN\14605787| (r_compound) a66_37\NN\1740|methionine|synthase|reductase (r_compound) g_38\NN\13717155|a66
T9_T23 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_compound) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr
T9_T24 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_compound) reductase_14\NN\14732946|methylenetetrahydrofolate|mthfr (l_appos) mthfr_16\NN\1740|(|)
T9_T25 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c
T9_T26 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_dep) t_19\NN\14999913|and|a1298c (l_conj) a1298c_21\NN\1740|
T9_T27 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms
T9_T28 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_compound) a2756_28\NN\1740|methionine|synthase (l_compound) synthase_24\NN\1740|ms (l_appos) ms_26\NN\14187378|(|)
T9_T29 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g
T9_T30 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66 (l_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr
T9_T31 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66 (l_compound) a66_37\NN\1740|methionine|synthase|reductase (l_compound) reductase_33\NN\14732946|mtrr (l_appos) mtrr_35\NN\1740|(|)
T9_T32 NONE hcy_45\NN\1740| (r_compound) levels_46\NNS\4916342|to|total|plasma|hcy|,|disease|and|episodes|patients (r_nmod) relation_41\NN\2137|in|levels (r_nmod) studied_1\VBD\630380|we|polymorphisms|relation|,|and|compared|. (l_dobj) polymorphisms_5\NNS\11418750|several|single|nucleotide|snp|genes|c677 (l_dep) c677_18\NN\1740|[|reductase|t|;|g|] (l_conj) g_29\NN\13717155|a2756|;|g (l_conj) g_38\NN\13717155|a66
T12_T13 NONE cobalamin_9\NN\15090742| (r_compound) levels_10\NNS\4916342|with|cobalamin (r_nmod) associated_7\VBN\628491|however|,|g|was|significantly|levels|genotype|,|was|. (l_advcl) was_36\VBD\836236|as|a66 (l_nsubj) a66_38\NN\1740|mtrr|g|ag|and|gg|) (l_compound) mtrr_37\NN\1740|
T12_T14 NONE cobalamin_9\NN\15090742| (r_compound) levels_10\NNS\4916342|with|cobalamin (r_nmod) associated_7\VBN\628491|however|,|g|was|significantly|levels|genotype|,|was|. (l_advcl) was_36\VBD\836236|as|a66 (l_nsubj) a66_38\NN\1740|mtrr|g|ag|and|gg|) (l_dep) g_39\NN\13717155|pmol/l
T12_T35 NONE cobalamin_9\NN\15090742| (r_compound) levels_10\NNS\4916342|with|cobalamin (r_nmod) associated_7\VBN\628491|however|,|g|was|significantly|levels|genotype|,|was|. (l_nsubjpass) g_4\NN\13717155|a2756 (l_compound) a2756_3\NN\1740|ms (l_compound) ms_2\NN\14187378|
T12_T36 NONE cobalamin_9\NN\15090742| (r_compound) levels_10\NNS\4916342|with|cobalamin (r_nmod) associated_7\VBN\628491|however|,|g|was|significantly|levels|genotype|,|was|. (l_nsubjpass) g_4\NN\13717155|a2756
T1_T19 NONE cobalamin_2\NN\15090742|and|folate (r_compound) levels_5\NNS\4916342|in|cobalamin (r_nmod) differences_0\NNS\4723816|levels|polymorphisms (l_nmod) polymorphisms_15\NNS\11418750|with|the|g (l_compound) g_10\NN\13717155|a66|and|g (l_compound) a66_9\NN\1740|mtrr (l_compound) mtrr_8\NN\1740|
T1_T20 NONE cobalamin_2\NN\15090742|and|folate (r_compound) levels_5\NNS\4916342|in|cobalamin (r_nmod) differences_0\NNS\4723816|levels|polymorphisms (l_nmod) polymorphisms_15\NNS\11418750|with|the|g (l_compound) g_10\NN\13717155|a66|and|g
T1_T21 NONE cobalamin_2\NN\15090742|and|folate (r_compound) levels_5\NNS\4916342|in|cobalamin (r_nmod) differences_0\NNS\4723816|levels|polymorphisms (l_nmod) polymorphisms_15\NNS\11418750|with|the|g (l_compound) g_10\NN\13717155|a66|and|g (l_conj) g_14\NN\13717155|ms|a2756 (l_compound) ms_12\NN\14187378|
T1_T22 NONE cobalamin_2\NN\15090742|and|folate (r_compound) levels_5\NNS\4916342|in|cobalamin (r_nmod) differences_0\NNS\4723816|levels|polymorphisms (l_nmod) polymorphisms_15\NNS\11418750|with|the|g (l_compound) g_10\NN\13717155|a66|and|g (l_conj) g_14\NN\13717155|ms|a2756
23265905
T2_T9 CPR:4 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7h)-one_5\NN\1740| (r_compound) derivatives_6\NNS\5802185|of|novel|2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7h)-one (r_nmod) design_0\NN\927261|and|synthesis|derivatives|inhibitors|. (l_nmod) inhibitors_9\NNS\20090|as|telomerase (l_compound) telomerase_8\NN\14732946|
23519149
T9_T24 NONE elisidepsin_0\NN\1740| (r_nsubjpass) shown_2\VBN\2137132|elisidepsin|was|induce|. (l_xcomp) induce_4\VB\1627355|to|oncosis|cells (l_nmod) cells_9\NNS\3080309|in|erbb3-expressing (l_amod) erbb3-expressing_8\JJ\1740|
T14_T25 NONE elisidepsin_4\NN\1740| (r_nsubj) active_7\JJ\1740|that|elisidepsin|is|more|cells (l_nmod) cells_9\NNS\3080309|in|harboring (l_acl) harboring_10\VBG\1771535|phenotype|e-cadherin (l_nmod) e-cadherin_15\NN\1740|with|high|and|expression
T14_T26 NONE elisidepsin_4\NN\1740| (r_nsubj) active_7\JJ\1740|that|elisidepsin|is|more|cells (l_nmod) cells_9\NNS\3080309|in|harboring (l_acl) harboring_10\VBG\1771535|phenotype|e-cadherin (l_nmod) e-cadherin_15\NN\1740|with|high|and|expression (l_conj) expression_19\NN\4679549|low|vimentin (l_compound) vimentin_18\NN\1740|
T16_T27 NONE elisidepsin_13\NN\1740|to (r_nmod) sensitivity_11\NN\5651971|with|elisidepsin (r_nmod) correlated_9\VBN\2657219|addition|,|erbb3|was|sensitivity|,|associated|. (l_nsubjpass) erbb3_4\NN\1740|high|and|muc1|expression
T16_T28 NONE elisidepsin_13\NN\1740|to (r_nmod) sensitivity_11\NN\5651971|with|elisidepsin (r_nmod) correlated_9\VBN\2657219|addition|,|erbb3|was|sensitivity|,|associated|. (l_nsubjpass) erbb3_4\NN\1740|high|and|muc1|expression (l_conj) muc1_6\NN\1740|
T16_T29 NONE elisidepsin_13\NN\1740|to (r_nmod) sensitivity_11\NN\5651971|with|elisidepsin (r_nmod) correlated_9\VBN\2657219|addition|,|erbb3|was|sensitivity|,|associated|. (l_advcl) associated_23\VBN\628491|whereas|presence|was|resistance (l_nsubjpass) presence_17\NN\13954253|the|mutations (l_nmod) mutations_21\NNS\4475|of|kras|activating (l_compound) kras_19\NN\1740|
T2_T19 CPR:4 elisidepsin_7\NN\1740|to (r_nmod) resistance_5\NN\37396|with|acquired|elisidepsin (r_nmod) cells_2\NNS\3080309|in|du-pm|resistance (r_nmod) decreased_12\VBN\169651|cells|,|expression|was|,|increased|. (l_nsubjpass) expression_10\NN\4679549|erbb3 (l_compound) erbb3_9\NN\1740|
T2_T20 CPR:3 elisidepsin_7\NN\1740|to (r_nmod) resistance_5\NN\37396|with|acquired|elisidepsin (r_nmod) cells_2\NNS\3080309|in|du-pm|resistance (r_nmod) decreased_12\VBN\169651|cells|,|expression|was|,|increased|. (l_advcl) increased_17\VBN\169651|while|bcl2|was (l_nsubjpass) bcl2_15\NN\1740|
22889582
23602986
T10_T24 NONE nic_9\NN\1740|(|) (r_appos) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T10_T25 NONE nic_9\NN\1740|(|) (r_appos) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T11_T24 NONE cotinine_12\NN\1740|cot (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T11_T25 NONE cotinine_12\NN\1740|cot (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T15_T24 NONE cot_14\NN\4187061|(|) (r_appos) cotinine_12\NN\1740|cot (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T15_T25 NONE cot_14\NN\4187061|(|) (r_appos) cotinine_12\NN\1740|cot (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T16_T24 NONE mecamylamine_17\NN\1740|mec (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T16_T25 NONE mecamylamine_17\NN\1740|mec (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T19_T24 NONE mec_19\NN\1740|(|) (r_appos) mecamylamine_17\NN\1740|mec (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T19_T25 NONE mec_19\NN\1740|(|) (r_appos) mecamylamine_17\NN\1740|mec (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T20_T24 NONE methyllycaconitine_22\NN\1740|mla (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T20_T25 NONE methyllycaconitine_22\NN\1740|mla (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T2_T24 NONE mla_24\NN\1740|(|) (r_appos) methyllycaconitine_22\NN\1740|mla (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T2_T25 NONE mla_24\NN\1740|(|) (r_appos) methyllycaconitine_22\NN\1740|mla (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T4_T24 NONE dihydro-beta-eritroidine_27\NN\1740|dhβe (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T4_T25 NONE dihydro-beta-eritroidine_27\NN\1740|dhβe (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T8_T24 NONE dhβe_29\NN\1740|(|) (r_appos) dihydro-beta-eritroidine_27\NN\1740|dhβe (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T8_T25 NONE dhβe_29\NN\1740|(|) (r_appos) dihydro-beta-eritroidine_27\NN\1740|dhβe (r_conj) nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T9_T24 NONE nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk
T9_T25 NONE nicotine_7\NN\14712692|of|nic|,|cotinine|,|mecamylamine|,|methyllycaconitine|and|dihydro-beta-eritroidine (r_nmod) effects_5\NNS\13245626|the|nicotine|extinction|:|peroxidation (l_dep) peroxidation_44\NN\1740|lipid|lpo|,|capacity|and|phosphorylation (l_conj) phosphorylation_56\NN\1740|the|kinase (l_nmod) kinase_59\NN\14732946|of|extracellular-signal-regulated|erk (l_appos) erk_61\NN\1740|(|1/2|) (l_nummod) 1/2_62\CD\1740|
T1_T23 NONE nicotine_13\NN\14712692|as (r_nmod) fashion_11\NN\4916342|in|a|similar|nicotine (r_nmod) increased_2\VBD\169651|cotinine|also|phosphorylation|fashion|. (l_dobj) phosphorylation_4\NN\1740|the|erk (l_nmod) erk_6\NN\1740|of|1/2 (l_nummod) 1/2_7\CD\1740|
T21_T23 NONE cotinine_0\NN\1740| (r_nsubj) increased_2\VBD\169651|cotinine|also|phosphorylation|fashion|. (l_dobj) phosphorylation_4\NN\1740|the|erk (l_nmod) erk_6\NN\1740|of|1/2 (l_nummod) 1/2_7\CD\1740|
2268554
T18_T28 CPR:4 progestins_4\NNS\14745635|of|synthetic|,|4-ma (r_nmod) effect_1\NN\34213|inhibitory|progestins|activity|. (l_nmod) activity_17\NN\30358|on|human|placental|dehydrogenase/5|-|---4-ene-isomerase (l_compound) ---4-ene-isomerase_16\NN\1740|
T19_T28 CPR:4 4-ma_6\NN\1740|and|cyanoketone (r_appos) progestins_4\NNS\14745635|of|synthetic|,|4-ma (r_nmod) effect_1\NN\34213|inhibitory|progestins|activity|. (l_nmod) activity_17\NN\30358|on|human|placental|dehydrogenase/5|-|---4-ene-isomerase (l_compound) ---4-ene-isomerase_16\NN\1740|
T20_T28 CPR:4 cyanoketone_8\NN\1740| (r_conj) 4-ma_6\NN\1740|and|cyanoketone (r_appos) progestins_4\NNS\14745635|of|synthetic|,|4-ma (r_nmod) effect_1\NN\34213|inhibitory|progestins|activity|. (l_nmod) activity_17\NN\30358|on|human|placental|dehydrogenase/5|-|---4-ene-isomerase (l_compound) ---4-ene-isomerase_16\NN\1740|
T21_T28 NONE beta-hydroxysteroid_13\NN\1740| (r_compound) dehydrogenase/5_14\NN\1740|3|beta-hydroxysteroid (r_compound) activity_17\NN\30358|on|human|placental|dehydrogenase/5|-|---4-ene-isomerase (l_compound) ---4-ene-isomerase_16\NN\1740|
T1_T22 CPR:9 pregnenolone_19\NN\1740|(|and|pregnenolone|) (r_dep) c-21_17\NN\1740|pregnenolone|as|steroids (r_dobj) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified
T1_T26 CPR:9 pregnenolone_19\NN\1740|(|and|pregnenolone|) (r_dep) c-21_17\NN\1740|pregnenolone|as|steroids (r_dobj) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified (l_appos) beta-hsd_10\NN\1740|(|3|)
T2_T22 CPR:9 pregnenolone_23\NN\1740|17|alpha-hydroxy (r_conj) pregnenolone_19\NN\1740|(|and|pregnenolone|) (r_dep) c-21_17\NN\1740|pregnenolone|as|steroids (r_dobj) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified
T2_T26 CPR:9 pregnenolone_23\NN\1740|17|alpha-hydroxy (r_conj) pregnenolone_19\NN\1740|(|and|pregnenolone|) (r_dep) c-21_17\NN\1740|pregnenolone|as|steroids (r_dobj) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified (l_appos) beta-hsd_10\NN\1740|(|3|)
T3_T22 NONE beta-hydroxysteroid_3\NN\1740| (r_compound) dehydrogenase/5_4\NN\1740|beta-hydroxysteroid (r_compound) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified
T3_T26 NONE beta-hydroxysteroid_3\NN\1740| (r_compound) dehydrogenase/5_4\NN\1740|beta-hydroxysteroid (r_compound) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified (l_appos) beta-hsd_10\NN\1740|(|3|)
T4_T22 CPR:9 dehydroepiandrosterone_30\NN\1740|(|and|beta-diol (r_compound) steroids_38\NNS\14727670|c-19|dehydroepiandrosterone (r_conj) c-21_17\NN\1740|pregnenolone|as|steroids (r_dobj) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified
T4_T26 CPR:9 dehydroepiandrosterone_30\NN\1740|(|and|beta-diol (r_compound) steroids_38\NNS\14727670|c-19|dehydroepiandrosterone (r_conj) c-21_17\NN\1740|pregnenolone|as|steroids (r_dobj) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified (l_appos) beta-hsd_10\NN\1740|(|3|)
T5_T22 CPR:9 beta-diol_36\NN\1740|androst-5-ene-3|beta|,|17|) (r_conj) dehydroepiandrosterone_30\NN\1740|(|and|beta-diol (r_compound) steroids_38\NNS\14727670|c-19|dehydroepiandrosterone (r_conj) c-21_17\NN\1740|pregnenolone|as|steroids (r_dobj) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified
T5_T26 CPR:9 beta-diol_36\NN\1740|androst-5-ene-3|beta|,|17|) (r_conj) dehydroepiandrosterone_30\NN\1740|(|and|beta-diol (r_compound) steroids_38\NNS\14727670|c-19|dehydroepiandrosterone (r_conj) c-21_17\NN\1740|pregnenolone|as|steroids (r_dobj) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified (l_appos) beta-hsd_10\NN\1740|(|3|)
T6_T22 CPR:9 3-keto-4-ene-steroids_42\NNS\1740|into|the|corresponding (r_nmod) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified
T6_T26 CPR:9 3-keto-4-ene-steroids_42\NNS\1740|into|the|corresponding (r_nmod) transforms_16\VBZ\126264|isomerase|c-21|3-keto-4-ene-steroids|and|involved|. (l_nsubj) isomerase_7\NN\14732946|human|placental|3|dehydrogenase/5|-|---4-ene|beta-hsd|purified (l_appos) beta-hsd_10\NN\1740|(|3|)
T7_T23 CPR:4 trilostane_0\NN\1740|,|epostane|and|cyanoketone (r_nsubj) inhibitors_7\NNS\20090|trilostane|are|potent|beta-hsd|values (l_nmod) beta-hsd_10\NN\1740|of|3
T8_T23 CPR:4 epostane_2\NN\1740| (r_conj) trilostane_0\NN\1740|,|epostane|and|cyanoketone (r_nsubj) inhibitors_7\NNS\20090|trilostane|are|potent|beta-hsd|values (l_nmod) beta-hsd_10\NN\1740|of|3
T9_T23 CPR:4 cyanoketone_4\NN\1740| (r_conj) trilostane_0\NN\1740|,|epostane|and|cyanoketone (r_nsubj) inhibitors_7\NNS\20090|trilostane|are|potent|beta-hsd|values (l_nmod) beta-hsd_10\NN\1740|of|3
T10_T24 CPR:4 4-ma_0\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|a|known|alpha-reductase (l_compound) alpha-reductase_6\NN\1740|5
T10_T25 CPR:4 4-ma_0\NN\1740|,|inhibitor|, (r_nsubj) inhibitor_13\NN\20090|4-ma|is|also|a|potent|beta-hsd|value (l_nmod) beta-hsd_16\NN\1740|of|3
T14_T27 CPR:4 acetate_1\NN\15010703|cyproterone|,|progestin|as|norgestrel (r_nsubj) inhibit_30\VBP\2510337|acetate|also|activity|values|,|respectively|. (l_dobj) activity_33\NN\30358|3|beta-hsd (l_compound) beta-hsd_32\NN\1740|
T15_T27 CPR:4 progestin_4\NN\14745635|a|used (r_appos) acetate_1\NN\15010703|cyproterone|,|progestin|as|norgestrel (r_nsubj) inhibit_30\VBP\2510337|acetate|also|activity|values|,|respectively|. (l_dobj) activity_33\NN\30358|3|beta-hsd (l_compound) beta-hsd_32\NN\1740|
T16_T27 CPR:4 norgestrel_19\NN\14747338|and|norethindrone|used (r_conj) acetate_1\NN\15010703|cyproterone|,|progestin|as|norgestrel (r_nsubj) inhibit_30\VBP\2510337|acetate|also|activity|values|,|respectively|. (l_dobj) activity_33\NN\30358|3|beta-hsd (l_compound) beta-hsd_32\NN\1740|
T17_T27 CPR:4 norethindrone_21\NN\14747338| (r_conj) norgestrel_19\NN\14747338|and|norethindrone|used (r_conj) acetate_1\NN\15010703|cyproterone|,|progestin|as|norgestrel (r_nsubj) inhibit_30\VBP\2510337|acetate|also|activity|values|,|respectively|. (l_dobj) activity_33\NN\30358|3|beta-hsd (l_compound) beta-hsd_32\NN\1740|
16971132
T4_T12 CPR:4 4(3h)-quinazolinone_16\NN\1740| (r_compound) analogs_17\NNS\4743605|of|some|new|4(3h)-quinazolinone (r_nmod) study_12\NN\635850|molecular|modeling|analogs (r_conj) synthesis_0\NN\13446390|,|inhibition|,|testing|,|and|study|. (l_conj) inhibition_4\NN\1068773|dihydrofolate|reductase (l_compound) reductase_3\NN\14732946|
T5_T12 NONE dihydrofolate_2\JJ\1740| (r_amod) inhibition_4\NN\1068773|dihydrofolate|reductase (l_compound) reductase_3\NN\14732946|
T1_T7 CPR:4 methotrexate_21\NN\2722166|mtx (r_compound) features_28\NNS\5849040|methotrexate|structure (r_dobj) resemble_20\VB\2657219|to|features (r_xcomp) designed_18\VBN\1631534|produce|,|series|was|resemble|and|fitted|. (l_conj) fitted_30\VBN\2667900|groups (l_nmod) groups_33\NNS\2137|with|functional|believed (l_acl) believed_34\VBN\686447|enhance (l_xcomp) enhance_36\VB\227165|to|inhibition (l_dobj) inhibition_37\NN\1068773|activity (l_nmod) activity_41\NN\30358|of|mammalian|dhfr (l_compound) dhfr_40\NN\1740|
T2_T7 CPR:4 mtx_23\NN\1740|(|,|1|) (r_appos) methotrexate_21\NN\2722166|mtx (r_compound) features_28\NNS\5849040|methotrexate|structure (r_dobj) resemble_20\VB\2657219|to|features (r_xcomp) designed_18\VBN\1631534|produce|,|series|was|resemble|and|fitted|. (l_conj) fitted_30\VBN\2667900|groups (l_nmod) groups_33\NNS\2137|with|functional|believed (l_acl) believed_34\VBN\686447|enhance (l_xcomp) enhance_36\VB\227165|to|inhibition (l_dobj) inhibition_37\NN\1068773|activity (l_nmod) activity_41\NN\30358|of|mammalian|dhfr (l_compound) dhfr_40\NN\1740|
T3_T7 CPR:4 quinazoline_15\NN\1740| (r_compound) analogs_16\NNS\4743605|of|quinazoline (r_nmod) series_13\NN\8456993|a|new|analogs (r_nsubjpass) designed_18\VBN\1631534|produce|,|series|was|resemble|and|fitted|. (l_conj) fitted_30\VBN\2667900|groups (l_nmod) groups_33\NNS\2137|with|functional|believed (l_acl) believed_34\VBN\686447|enhance (l_xcomp) enhance_36\VB\227165|to|inhibition (l_dobj) inhibition_37\NN\1068773|activity (l_nmod) activity_41\NN\30358|of|mammalian|dhfr (l_compound) dhfr_40\NN\1740|
12818701
T14_T27 NONE phentolamine_18\NN\4537602|mg/kg|and|phenoxybenzamine (r_appos) antagonists_16\NNS\7846|of|nonselective|alpha-adrenoceptor|,|phentolamine|, (r_nmod) administration_12\NN\1133281|by|systemic|antagonists|as|antagonist (r_nmod) inhibited_9\VBN\2510337|as|responses|were|administration (r_advcl) established_4\VBN\2426171|involvement|was|inhibited|. (l_nsubjpass) involvement_0\NN\1080366|alpha(1)-adrenoceptors (l_nmod) alpha(1)-adrenoceptors_2\NNS\1740|of
T14_T28 CPR:6 phentolamine_18\NN\4537602|mg/kg|and|phenoxybenzamine (r_appos) antagonists_16\NNS\7846|of|nonselective|alpha-adrenoceptor|,|phentolamine|, (l_compound) alpha-adrenoceptor_15\NN\5608868|
T14_T30 NONE phentolamine_18\NN\4537602|mg/kg|and|phenoxybenzamine (r_appos) antagonists_16\NNS\7846|of|nonselective|alpha-adrenoceptor|,|phentolamine|, (r_nmod) administration_12\NN\1133281|by|systemic|antagonists|as|antagonist (l_conj) antagonist_41\NN\7846|by|the|selective|alpha(1)-adrenoceptor|,|prazosin (l_compound) alpha(1)-adrenoceptor_40\NN\1740|
T15_T27 NONE phenoxybenzamine_26\NN\1740|mg/kg (r_conj) phentolamine_18\NN\4537602|mg/kg|and|phenoxybenzamine (r_appos) antagonists_16\NNS\7846|of|nonselective|alpha-adrenoceptor|,|phentolamine|, (r_nmod) administration_12\NN\1133281|by|systemic|antagonists|as|antagonist (r_nmod) inhibited_9\VBN\2510337|as|responses|were|administration (r_advcl) established_4\VBN\2426171|involvement|was|inhibited|. (l_nsubjpass) involvement_0\NN\1080366|alpha(1)-adrenoceptors (l_nmod) alpha(1)-adrenoceptors_2\NNS\1740|of
T15_T28 CPR:6 phenoxybenzamine_26\NN\1740|mg/kg (r_conj) phentolamine_18\NN\4537602|mg/kg|and|phenoxybenzamine (r_appos) antagonists_16\NNS\7846|of|nonselective|alpha-adrenoceptor|,|phentolamine|, (l_compound) alpha-adrenoceptor_15\NN\5608868|
T15_T30 NONE phenoxybenzamine_26\NN\1740|mg/kg (r_conj) phentolamine_18\NN\4537602|mg/kg|and|phenoxybenzamine (r_appos) antagonists_16\NNS\7846|of|nonselective|alpha-adrenoceptor|,|phentolamine|, (r_nmod) administration_12\NN\1133281|by|systemic|antagonists|as|antagonist (l_conj) antagonist_41\NN\7846|by|the|selective|alpha(1)-adrenoceptor|,|prazosin (l_compound) alpha(1)-adrenoceptor_40\NN\1740|
T16_T27 NONE prazosin_43\NN\2698769|mg/kg (r_appos) antagonist_41\NN\7846|by|the|selective|alpha(1)-adrenoceptor|,|prazosin (r_conj) administration_12\NN\1133281|by|systemic|antagonists|as|antagonist (r_nmod) inhibited_9\VBN\2510337|as|responses|were|administration (r_advcl) established_4\VBN\2426171|involvement|was|inhibited|. (l_nsubjpass) involvement_0\NN\1080366|alpha(1)-adrenoceptors (l_nmod) alpha(1)-adrenoceptors_2\NNS\1740|of
T16_T28 NONE prazosin_43\NN\2698769|mg/kg (r_appos) antagonist_41\NN\7846|by|the|selective|alpha(1)-adrenoceptor|,|prazosin (r_conj) administration_12\NN\1133281|by|systemic|antagonists|as|antagonist (l_nmod) antagonists_16\NNS\7846|of|nonselective|alpha-adrenoceptor|,|phentolamine|, (l_compound) alpha-adrenoceptor_15\NN\5608868|
T16_T30 CPR:6 prazosin_43\NN\2698769|mg/kg (r_appos) antagonist_41\NN\7846|by|the|selective|alpha(1)-adrenoceptor|,|prazosin (l_compound) alpha(1)-adrenoceptor_40\NN\1740|
T17_T31 CPR:6 rauwolscine_4\NN\1740|mg/kg (r_appos) antagonist_2\NN\7846|the|alpha(2)-adrenoceptor|,|rauwolscine|, (l_compound) alpha(2)-adrenoceptor_1\NN\1740|
T18_T20 NONE 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_compound) alpha(1b)-adrenoceptor_23\NN\1740|
T18_T21 NONE 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_conj) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (l_compound) alpha(1d)-adrenoceptor_43\NN\1740|the
T18_T22 NONE 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (r_nsubjpass) used_56\VBN\1156834|antagonists|were|delineate|. (l_xcomp) delineate_58\VB\2137132|to|subtypes (l_dobj) subtypes_61\NNS\1740|the|adrenoceptor|involved (l_compound) adrenoceptor_60\NN\1740|
T18_T32 CPR:6 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_compound) alpha(1a)-adrenoceptor_0\NN\1740|
T19_T20 NONE wb-4101_6\NN\1740|(|;|mg/kg|) (r_appos) 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_compound) alpha(1b)-adrenoceptor_23\NN\1740|
T19_T21 NONE wb-4101_6\NN\1740|(|;|mg/kg|) (r_appos) 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_conj) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (l_compound) alpha(1d)-adrenoceptor_43\NN\1740|the
T19_T22 NONE wb-4101_6\NN\1740|(|;|mg/kg|) (r_appos) 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (r_nsubjpass) used_56\VBN\1156834|antagonists|were|delineate|. (l_xcomp) delineate_58\VB\2137132|to|subtypes (l_dobj) subtypes_61\NNS\1740|the|adrenoceptor|involved (l_compound) adrenoceptor_60\NN\1740|
T19_T32 CPR:6 wb-4101_6\NN\1740|(|;|mg/kg|) (r_appos) 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_compound) alpha(1a)-adrenoceptor_0\NN\1740|
T1_T20 NONE 5-methylurapidil_14\NN\1740|mg/kg (r_conj) 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_compound) alpha(1b)-adrenoceptor_23\NN\1740|
T1_T21 NONE 5-methylurapidil_14\NN\1740|mg/kg (r_conj) 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_conj) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (l_compound) alpha(1d)-adrenoceptor_43\NN\1740|the
T1_T22 NONE 5-methylurapidil_14\NN\1740|mg/kg (r_conj) 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (r_nsubjpass) used_56\VBN\1156834|antagonists|were|delineate|. (l_xcomp) delineate_58\VB\2137132|to|subtypes (l_dobj) subtypes_61\NNS\1740|the|adrenoceptor|involved (l_compound) adrenoceptor_60\NN\1740|
T1_T32 CPR:6 5-methylurapidil_14\NN\1740|mg/kg (r_conj) 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane_4\NN\1740|wb-4101|and|5-methylurapidil (r_appos) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_compound) alpha(1a)-adrenoceptor_0\NN\1740|
T2_T20 CPR:6 [(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline_29\NN\1740|4-amino-2-[4-[1-(benzyloxycarbonyl)-2(s)-|[|l-765314 (r_appos) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_compound) alpha(1b)-adrenoceptor_23\NN\1740|
T2_T21 NONE [(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline_29\NN\1740|4-amino-2-[4-[1-(benzyloxycarbonyl)-2(s)-|[|l-765314 (r_appos) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_conj) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (l_compound) alpha(1d)-adrenoceptor_43\NN\1740|the
T2_T22 NONE [(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline_29\NN\1740|4-amino-2-[4-[1-(benzyloxycarbonyl)-2(s)-|[|l-765314 (r_appos) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (r_conj) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (r_nsubjpass) used_56\VBN\1156834|antagonists|were|delineate|. (l_xcomp) delineate_58\VB\2137132|to|subtypes (l_dobj) subtypes_61\NNS\1740|the|adrenoceptor|involved (l_compound) adrenoceptor_60\NN\1740|
T2_T32 NONE [(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline_29\NN\1740|4-amino-2-[4-[1-(benzyloxycarbonyl)-2(s)-|[|l-765314 (r_appos) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (r_conj) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_compound) alpha(1a)-adrenoceptor_0\NN\1740|
T3_T20 CPR:6 l-765314_31\NN\1740|(|;|mg/kg|) (r_appos) [(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline_29\NN\1740|4-amino-2-[4-[1-(benzyloxycarbonyl)-2(s)-|[|l-765314 (r_appos) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_compound) alpha(1b)-adrenoceptor_23\NN\1740|
T3_T21 NONE l-765314_31\NN\1740|(|;|mg/kg|) (r_appos) [(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline_29\NN\1740|4-amino-2-[4-[1-(benzyloxycarbonyl)-2(s)-|[|l-765314 (r_appos) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_conj) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (l_compound) alpha(1d)-adrenoceptor_43\NN\1740|the
T3_T22 NONE l-765314_31\NN\1740|(|;|mg/kg|) (r_appos) [(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline_29\NN\1740|4-amino-2-[4-[1-(benzyloxycarbonyl)-2(s)-|[|l-765314 (r_appos) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (r_conj) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (r_nsubjpass) used_56\VBN\1156834|antagonists|were|delineate|. (l_xcomp) delineate_58\VB\2137132|to|subtypes (l_dobj) subtypes_61\NNS\1740|the|adrenoceptor|involved (l_compound) adrenoceptor_60\NN\1740|
T3_T32 NONE l-765314_31\NN\1740|(|;|mg/kg|) (r_appos) [(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline_29\NN\1740|4-amino-2-[4-[1-(benzyloxycarbonyl)-2(s)-|[|l-765314 (r_appos) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (r_conj) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_compound) alpha(1a)-adrenoceptor_0\NN\1740|
T4_T20 NONE 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione_47\NN\1740|bmy-7378 (r_appos) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (r_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_compound) alpha(1b)-adrenoceptor_23\NN\1740|
T4_T21 CPR:6 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione_47\NN\1740|bmy-7378 (r_appos) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (l_compound) alpha(1d)-adrenoceptor_43\NN\1740|the
T4_T22 NONE 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione_47\NN\1740|bmy-7378 (r_appos) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (r_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (r_conj) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (r_nsubjpass) used_56\VBN\1156834|antagonists|were|delineate|. (l_xcomp) delineate_58\VB\2137132|to|subtypes (l_dobj) subtypes_61\NNS\1740|the|adrenoceptor|involved (l_compound) adrenoceptor_60\NN\1740|
T4_T32 NONE 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione_47\NN\1740|bmy-7378 (r_appos) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (r_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (r_conj) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_compound) alpha(1a)-adrenoceptor_0\NN\1740|
T5_T20 NONE bmy-7378_49\NN\1740|(|mg/kg (r_appos) 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione_47\NN\1740|bmy-7378 (r_appos) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (r_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (l_compound) alpha(1b)-adrenoceptor_23\NN\1740|
T5_T21 CPR:6 bmy-7378_49\NN\1740|(|mg/kg (r_appos) 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione_47\NN\1740|bmy-7378 (r_appos) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (l_compound) alpha(1d)-adrenoceptor_43\NN\1740|the
T5_T22 NONE bmy-7378_49\NN\1740|(|mg/kg (r_appos) 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione_47\NN\1740|bmy-7378 (r_appos) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (r_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (r_conj) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (r_nsubjpass) used_56\VBN\1156834|antagonists|were|delineate|. (l_xcomp) delineate_58\VB\2137132|to|subtypes (l_dobj) subtypes_61\NNS\1740|the|adrenoceptor|involved (l_compound) adrenoceptor_60\NN\1740|
T5_T32 NONE bmy-7378_49\NN\1740|(|mg/kg (r_appos) 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione_47\NN\1740|bmy-7378 (r_appos) antagonist_45\NN\7846|alpha(1d)-adrenoceptor|selective|,|8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (r_conj) antagonist_25\NN\7846|the|alpha(1b)-adrenoceptor|selective|,|[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline|,|as|antagonist|, (r_conj) antagonists_2\NNS\7846|alpha(1a)-adrenoceptor|selective|,|2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane|,|antagonist (l_compound) alpha(1a)-adrenoceptor_0\NN\1740|
10381787
T11_T21 CPR:4 meloxicam_9\NN\1740|by (r_nmod) inhibition_1\NN\1068773|dose-dependent|cyclooxygenase-1|meloxicam|subjects|. (l_nmod) cyclooxygenase-1_4\NN\14737847|of|platelet|and|cyclooxygenase-2
T11_T22 CPR:4 meloxicam_9\NN\1740|by (r_nmod) inhibition_1\NN\1068773|dose-dependent|cyclooxygenase-1|meloxicam|subjects|. (l_nmod) cyclooxygenase-1_4\NN\14737847|of|platelet|and|cyclooxygenase-2 (l_conj) cyclooxygenase-2_7\NN\14737847|monocyte
T7_T12 NONE meloxicam_7\NN\1740|of (r_nmod) levels_5\NNS\4916342|therapeutic|blood|meloxicam (r_nsubjpass) associated_9\VBN\628491|whether|levels|are|inhibition (l_nmod) inhibition_12\NN\1068773|with|selective|monocyte (l_nmod) monocyte_14\NN\5449959|of|(cox)-2|and (l_dep) (cox)-2_16\NN\1740|cyclooxygenase
T5_T17 CPR:4 meloxicam_19\NN\1740|of (r_nmod) incubation_17\NN\654885|after|the|meloxicam|samples (r_nmod) obtained_12\VBN\2210855|curves|were|vitro|incubation|. (l_nsubjpass) curves_1\NNS\13863771|concentration-response|inhibition (l_nmod) inhibition_4\NN\1068773|for|the|cox-2 (l_nmod) cox-2_7\NN\14737847|of|monocyte|and|cox-1
T5_T18 CPR:4 meloxicam_19\NN\1740|of (r_nmod) incubation_17\NN\654885|after|the|meloxicam|samples (r_nmod) obtained_12\VBN\2210855|curves|were|vitro|incubation|. (l_nsubjpass) curves_1\NNS\13863771|concentration-response|inhibition (l_nmod) inhibition_4\NN\1068773|for|the|cox-2 (l_nmod) cox-2_7\NN\14737847|of|monocyte|and|cox-1 (l_conj) cox-1_10\NN\14737847|platelet
T8_T19 CPR:9 e2_35\NN\1740|prostaglandin (r_nsubjpass) measured_37\VBN\697589|e2|was|plasma|index|. (l_nmod) index_42\NN\13850304|as|an|activity (l_nmod) activity_46\NN\30358|of|monocyte|cox-2 (l_compound) cox-2_45\NN\14737847|
T9_T20 CPR:9 b2_4\NN\1740|of|thromboxane (r_nmod) production_1\NN\30358|the|b2|blood|allowed (r_nsubjpass) assessed_19\VBN\670261|production|was|index|. (l_nmod) index_22\NN\13850304|as|an|activity (l_nmod) activity_26\NN\30358|of|platelet|cox-1 (l_compound) cox-1_25\NN\14737847|
T2_T13 CPR:4 meloxicam_11\NN\1740|of (r_nmod) mg_9\NN\13717155|of|7.5|meloxicam (r_nmod) administration_4\NN\1133281|the|mg (r_nsubj) caused_12\VBD\1617192|contrast|,|administration|reductions|. (l_dobj) reductions_14\NNS\351485|dose-dependent|activity (l_nmod) activity_18\NN\30358|in|monocyte|cox-2|%|,|respectively|,|and|activity|,|respectively (l_compound) cox-2_17\NN\14737847|
T2_T14 CPR:4 meloxicam_11\NN\1740|of (r_nmod) mg_9\NN\13717155|of|7.5|meloxicam (r_nmod) administration_4\NN\1133281|the|mg (r_nsubj) caused_12\VBD\1617192|contrast|,|administration|reductions|. (l_dobj) reductions_14\NNS\351485|dose-dependent|activity (l_nmod) activity_18\NN\30358|in|monocyte|cox-2|%|,|respectively|,|and|activity|,|respectively (l_conj) activity_32\NN\30358|in|platelet|cox-1|% (l_compound) cox-1_31\NN\14737847|
T3_T15 CPR:4 meloxicam_5\NN\1740|of (r_nmod) value_3\NN\5856066|the|ic50|meloxicam|inhibition (l_nmod) inhibition_7\NN\1068773|for|cox-1 (l_nmod) cox-1_9\NN\14737847|of
T3_T16 CPR:4 meloxicam_5\NN\1740|of (r_nmod) value_3\NN\5856066|the|ic50|meloxicam|inhibition (r_nsubj) higher_12\JJR\1740|although|value|was|10-fold|value|vitro (l_nmod) value_16\NN\5856066|than|the|ic50|cox-2 (l_nmod) cox-2_18\NN\14737847|of
T4_T15 NONE meloxicam_33\NN\1740|of (r_nmod) effects_31\NNS\13245626|the|meloxicam|isozymes|dosing (r_dobj) separate_29\VB\1850315|to|clearly|effects|function (r_xcomp) inadequate_26\JJ\1740|higher|,|selectivity|was|separate|. (l_advcl) higher_12\JJR\1740|although|value|was|10-fold|value|vitro (l_nsubj) value_3\NN\5856066|the|ic50|meloxicam|inhibition (l_nmod) inhibition_7\NN\1068773|for|cox-1 (l_nmod) cox-1_9\NN\14737847|of
T4_T16 NONE meloxicam_33\NN\1740|of (r_nmod) effects_31\NNS\13245626|the|meloxicam|isozymes|dosing (r_dobj) separate_29\VB\1850315|to|clearly|effects|function (r_xcomp) inadequate_26\JJ\1740|higher|,|selectivity|was|separate|. (l_advcl) higher_12\JJR\1740|although|value|was|10-fold|value|vitro (l_nmod) value_16\NN\5856066|than|the|ic50|cox-2 (l_nmod) cox-2_18\NN\14737847|of
12383039
T2_T7 NONE sodium_3\NN\14625458|fondaparinux (r_nsubj) first_6\JJ\1740|:|sodium|is|the|class (l_nmod) class_10\NN\7951464|in|a|new|inhibitors|binds (l_acl:relcl) binds_17\VBZ\1290422|that|reversibly|affinity|antithrombin (l_nmod) antithrombin_23\NN\1740|to|iii (l_nummod) iii_24\CD\13741022|
T2_T8 CPR:4 sodium_3\NN\14625458|fondaparinux (r_nsubj) first_6\JJ\1740|:|sodium|is|the|class (l_nmod) class_10\NN\7951464|in|a|new|inhibitors|binds (l_nmod) inhibitors_15\NNS\20090|of|synthetic|factor|xa (l_compound) xa_14\NN\1740|
22722028
T7_T16 NONE d-cycloserine_9\NN\1740|with|agonist|or|ms-275|,|applied (l_conj) ms-275_16\NN\1740|inhibitor (l_appos) inhibitor_23\NN\20090|(|deacetylase|hdac|)|) (l_compound) deacetylase_19\NN\1740|histone
T7_T17 NONE d-cycloserine_9\NN\1740|with|agonist|or|ms-275|,|applied (l_conj) ms-275_16\NN\1740|inhibitor (l_appos) inhibitor_23\NN\20090|(|deacetylase|hdac|)|) (l_compound) hdac_21\NN\1740|(
T8_T16 NONE n-methly-d-aspartate_11\NN\1740| (r_compound) agonist_13\NN\9613191|(|n-methly-d-aspartate|partial|) (r_appos) d-cycloserine_9\NN\1740|with|agonist|or|ms-275|,|applied (l_conj) ms-275_16\NN\1740|inhibitor (l_appos) inhibitor_23\NN\20090|(|deacetylase|hdac|)|) (l_compound) deacetylase_19\NN\1740|histone
T8_T17 NONE n-methly-d-aspartate_11\NN\1740| (r_compound) agonist_13\NN\9613191|(|n-methly-d-aspartate|partial|) (r_appos) d-cycloserine_9\NN\1740|with|agonist|or|ms-275|,|applied (l_conj) ms-275_16\NN\1740|inhibitor (l_appos) inhibitor_23\NN\20090|(|deacetylase|hdac|)|) (l_compound) hdac_21\NN\1740|(
T9_T16 CPR:4 ms-275_16\NN\1740|inhibitor (l_appos) inhibitor_23\NN\20090|(|deacetylase|hdac|)|) (l_compound) deacetylase_19\NN\1740|histone
T9_T17 CPR:4 ms-275_16\NN\1740|inhibitor (l_appos) inhibitor_23\NN\20090|(|deacetylase|hdac|)|) (l_compound) hdac_21\NN\1740|(
T1_T10 CPR:4 acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_dep) enhancer_23\NN\5853636|(|a|gabaergic|and|inhibitor|) (l_conj) inhibitor_26\NN\20090|hdac (l_compound) hdac_25\NN\1740|
T1_T11 NONE acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_conj) amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|) (l_nummod) 7_34\CD\13741022|
T1_T12 NONE acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_conj) amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|)
T1_T13 NONE acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (r_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (r_nmod) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_advcl) failed_50\VBD\1798936|while|ms-275|affect (l_nsubj) ms-275_42\NN\1740|or|pepa (l_conj) pepa_44\NN\1740|potentiator (l_appos) potentiator_48\NN\1740|(|ampa|receptor|) (l_compound) receptor_47\NN\5225602|
T2_T10 NONE amn082_29\NN\1740|agonist (r_conj) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_dep) enhancer_23\NN\5853636|(|a|gabaergic|and|inhibitor|) (l_conj) inhibitor_26\NN\20090|hdac (l_compound) hdac_25\NN\1740|
T2_T11 CPR:5 amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|) (l_nummod) 7_34\CD\13741022|
T2_T12 CPR:5 amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|)
T2_T13 NONE amn082_29\NN\1740|agonist (r_conj) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (r_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (r_nmod) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_advcl) failed_50\VBD\1798936|while|ms-275|affect (l_nsubj) ms-275_42\NN\1740|or|pepa (l_conj) pepa_44\NN\1740|potentiator (l_appos) potentiator_48\NN\1740|(|ampa|receptor|) (l_compound) receptor_47\NN\5225602|
T3_T10 NONE glutamate_32\NN\15010703| (r_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (r_compound) agonist_38\NN\9613191|[|receptor|] (r_appos) amn082_29\NN\1740|agonist (r_conj) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_dep) enhancer_23\NN\5853636|(|a|gabaergic|and|inhibitor|) (l_conj) inhibitor_26\NN\20090|hdac (l_compound) hdac_25\NN\1740|
T3_T11 NONE glutamate_32\NN\15010703| (r_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|) (l_nummod) 7_34\CD\13741022|
T3_T12 NONE glutamate_32\NN\15010703| (r_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|)
T3_T13 NONE glutamate_32\NN\15010703| (r_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (r_compound) agonist_38\NN\9613191|[|receptor|] (r_appos) amn082_29\NN\1740|agonist (r_conj) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (r_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (r_nmod) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_advcl) failed_50\VBD\1798936|while|ms-275|affect (l_nsubj) ms-275_42\NN\1740|or|pepa (l_conj) pepa_44\NN\1740|potentiator (l_appos) potentiator_48\NN\1740|(|ampa|receptor|) (l_compound) receptor_47\NN\5225602|
T4_T10 NONE ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_dep) enhancer_23\NN\5853636|(|a|gabaergic|and|inhibitor|) (l_conj) inhibitor_26\NN\20090|hdac (l_compound) hdac_25\NN\1740|
T4_T11 NONE ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_conj) amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|) (l_nummod) 7_34\CD\13741022|
T4_T12 NONE ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_conj) amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|)
T4_T13 CPR:3 ms-275_42\NN\1740|or|pepa (l_conj) pepa_44\NN\1740|potentiator (l_appos) potentiator_48\NN\1740|(|ampa|receptor|) (l_compound) receptor_47\NN\5225602|
T5_T10 NONE pepa_44\NN\1740|potentiator (r_conj) ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_dep) enhancer_23\NN\5853636|(|a|gabaergic|and|inhibitor|) (l_conj) inhibitor_26\NN\20090|hdac (l_compound) hdac_25\NN\1740|
T5_T11 NONE pepa_44\NN\1740|potentiator (r_conj) ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_conj) amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|) (l_nummod) 7_34\CD\13741022|
T5_T12 NONE pepa_44\NN\1740|potentiator (r_conj) ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_conj) amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|)
T5_T13 CPR:3 pepa_44\NN\1740|potentiator (l_appos) potentiator_48\NN\1740|(|ampa|receptor|) (l_compound) receptor_47\NN\5225602|
T6_T10 NONE ampa_46\NN\1740| (r_compound) potentiator_48\NN\1740|(|ampa|receptor|) (r_appos) pepa_44\NN\1740|potentiator (r_conj) ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_dep) enhancer_23\NN\5853636|(|a|gabaergic|and|inhibitor|) (l_conj) inhibitor_26\NN\20090|hdac (l_compound) hdac_25\NN\1740|
T6_T11 NONE ampa_46\NN\1740| (r_compound) potentiator_48\NN\1740|(|ampa|receptor|) (r_appos) pepa_44\NN\1740|potentiator (r_conj) ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_conj) amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|) (l_nummod) 7_34\CD\13741022|
T6_T12 NONE ampa_46\NN\1740| (r_compound) potentiator_48\NN\1740|(|ampa|receptor|) (r_appos) pepa_44\NN\1740|potentiator (r_conj) ms-275_42\NN\1740|or|pepa (r_nsubj) failed_50\VBD\1798936|while|ms-275|affect (r_advcl) achieved_11\VBN\2524171|rescue|was|administration|,|failed|. (l_nmod) administration_16\NN\1133281|with|prior|extinction|training|acid (l_nmod) acid_19\NN\14818238|of|valproic|enhancer|or|amn082 (l_conj) amn082_29\NN\1740|agonist (l_appos) agonist_38\NN\9613191|[|receptor|] (l_compound) receptor_33\NN\5225602|metabotropic|glutamate|mglu7 (l_appos) mglu7_36\NN\1740|7|(|)
T6_T13 NONE ampa_46\NN\1740| (r_compound) potentiator_48\NN\1740|(|ampa|receptor|) (l_compound) receptor_47\NN\5225602|
10082498
T21_T33 NONE ii_1\CD\13741022| (r_nummod) blockade_3\NN\952963|angiotensin|ii|receptor|subjects|:|comparison|. (l_compound) receptor_2\NN\5225602|
T21_T34 NONE ii_1\CD\13741022| (r_nummod) blockade_3\NN\952963|angiotensin|ii|receptor|subjects|:|comparison|. (l_dep) comparison_10\NN\635850|a|direct|antagonists (l_nmod) antagonists_15\NNS\7846|of|three|at1|receptor (l_compound) receptor_14\NN\5225602|
T14_T28 NONE angiotensin_2\NN\4522421| (r_compound) antagonists_9\NNS\7846|of|angiotensin|(|ang|)|ii|at1|receptor (l_compound) receptor_8\NN\5225602|
T8_T28 NONE ang_4\NN\8391387| (r_compound) antagonists_9\NNS\7846|of|angiotensin|(|ang|)|ii|at1|receptor (l_compound) receptor_8\NN\5225602|
T9_T25 NONE ii_6\CD\13741022| (r_nummod) blockade_8\NN\952963|the|ang|ii|receptor|induced (l_compound) receptor_7\NN\5225602|
T13_T26 NONE renin-angiotensin_3\JJ\1740|
T13_T27 NONE renin-angiotensin_3\JJ\1740|
T13_T29 NONE renin-angiotensin_3\JJ\1740| (r_amod) system_4\NN\3575240|of|the|renin-angiotensin (r_nmod) blockade_0\NN\952963|system (r_nsubjpass) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nmod) methods_22\NNS\5616786|by|3|independent|:|inhibition (l_appos) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_nmod) response_29\NN\11410625|of|the|blood|pressure|ang (l_nmod) ang_32\NN\8391387|to|exogenous|ii (l_nummod) ii_33\CD\13741022|
T13_T30 NONE renin-angiotensin_3\JJ\1740| (r_amod) system_4\NN\3575240|of|the|renin-angiotensin (r_nmod) blockade_0\NN\952963|system (r_nsubjpass) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nmod) methods_22\NNS\5616786|by|3|independent|:|inhibition (l_appos) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_conj) assay_40\NN\5733583|in|ang|ii|receptor (l_compound) receptor_39\NN\5225602|
T13_T31 NONE renin-angiotensin_3\JJ\1740| (r_amod) system_4\NN\3575240|of|the|renin-angiotensin (r_nmod) blockade_0\NN\952963|system (r_nsubjpass) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nmod) methods_22\NNS\5616786|by|3|independent|:|inhibition (l_appos) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_conj) changes_44\NNS\7283608|reactive|levels (l_nmod) levels_49\NNS\4916342|in|plasma|ang|ii (l_nummod) ii_48\CD\13741022|
T15_T26 NONE ii_33\CD\13741022| (r_nummod) ang_32\NN\8391387|to|exogenous|ii (r_nmod) response_29\NN\11410625|of|the|blood|pressure|ang (r_nmod) inhibition_24\NN\1068773|response|,|assay|,|and|changes (r_appos) methods_22\NNS\5616786|by|3|independent|:|inhibition (r_nmod) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nsubjpass) blockade_0\NN\952963|system (l_nmod) system_4\NN\3575240|of|the|renin-angiotensin (l_amod) renin-angiotensin_3\JJ\1740|
T15_T27 NONE ii_33\CD\13741022| (r_nummod) ang_32\NN\8391387|to|exogenous|ii (r_nmod) response_29\NN\11410625|of|the|blood|pressure|ang (r_nmod) inhibition_24\NN\1068773|response|,|assay|,|and|changes (r_appos) methods_22\NNS\5616786|by|3|independent|:|inhibition (r_nmod) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nsubjpass) blockade_0\NN\952963|system (l_nmod) system_4\NN\3575240|of|the|renin-angiotensin (l_amod) renin-angiotensin_3\JJ\1740|
T15_T29 NONE ii_33\CD\13741022|
T15_T30 NONE ii_33\CD\13741022| (r_nummod) ang_32\NN\8391387|to|exogenous|ii (r_nmod) response_29\NN\11410625|of|the|blood|pressure|ang (r_nmod) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_conj) assay_40\NN\5733583|in|ang|ii|receptor (l_compound) receptor_39\NN\5225602|
T15_T31 NONE ii_33\CD\13741022| (r_nummod) ang_32\NN\8391387|to|exogenous|ii (r_nmod) response_29\NN\11410625|of|the|blood|pressure|ang (r_nmod) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_conj) changes_44\NNS\7283608|reactive|levels (l_nmod) levels_49\NNS\4916342|in|plasma|ang|ii (l_nummod) ii_48\CD\13741022|
T16_T26 NONE ii_38\CD\13741022| (r_nummod) assay_40\NN\5733583|in|ang|ii|receptor (r_conj) inhibition_24\NN\1068773|response|,|assay|,|and|changes (r_appos) methods_22\NNS\5616786|by|3|independent|:|inhibition (r_nmod) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nsubjpass) blockade_0\NN\952963|system (l_nmod) system_4\NN\3575240|of|the|renin-angiotensin (l_amod) renin-angiotensin_3\JJ\1740|
T16_T27 NONE ii_38\CD\13741022| (r_nummod) assay_40\NN\5733583|in|ang|ii|receptor (r_conj) inhibition_24\NN\1068773|response|,|assay|,|and|changes (r_appos) methods_22\NNS\5616786|by|3|independent|:|inhibition (r_nmod) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nsubjpass) blockade_0\NN\952963|system (l_nmod) system_4\NN\3575240|of|the|renin-angiotensin (l_amod) renin-angiotensin_3\JJ\1740|
T16_T29 NONE ii_38\CD\13741022| (r_nummod) assay_40\NN\5733583|in|ang|ii|receptor (r_conj) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_nmod) response_29\NN\11410625|of|the|blood|pressure|ang (l_nmod) ang_32\NN\8391387|to|exogenous|ii (l_nummod) ii_33\CD\13741022|
T16_T30 NONE ii_38\CD\13741022| (r_nummod) assay_40\NN\5733583|in|ang|ii|receptor (l_compound) receptor_39\NN\5225602|
T16_T31 NONE ii_38\CD\13741022| (r_nummod) assay_40\NN\5733583|in|ang|ii|receptor (r_conj) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_conj) changes_44\NNS\7283608|reactive|levels (l_nmod) levels_49\NNS\4916342|in|plasma|ang|ii (l_nummod) ii_48\CD\13741022|
T17_T26 NONE ii_48\CD\13741022| (r_nummod) levels_49\NNS\4916342|in|plasma|ang|ii (r_nmod) changes_44\NNS\7283608|reactive|levels (r_conj) inhibition_24\NN\1068773|response|,|assay|,|and|changes (r_appos) methods_22\NNS\5616786|by|3|independent|:|inhibition (r_nmod) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nsubjpass) blockade_0\NN\952963|system (l_nmod) system_4\NN\3575240|of|the|renin-angiotensin (l_amod) renin-angiotensin_3\JJ\1740|
T17_T27 NONE ii_48\CD\13741022| (r_nummod) levels_49\NNS\4916342|in|plasma|ang|ii (r_nmod) changes_44\NNS\7283608|reactive|levels (r_conj) inhibition_24\NN\1068773|response|,|assay|,|and|changes (r_appos) methods_22\NNS\5616786|by|3|independent|:|inhibition (r_nmod) assessed_6\VBN\670261|blockade|was|intake|methods|. (l_nsubjpass) blockade_0\NN\952963|system (l_nmod) system_4\NN\3575240|of|the|renin-angiotensin (l_amod) renin-angiotensin_3\JJ\1740|
T17_T29 NONE ii_48\CD\13741022| (r_nummod) levels_49\NNS\4916342|in|plasma|ang|ii (r_nmod) changes_44\NNS\7283608|reactive|levels (r_conj) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_nmod) response_29\NN\11410625|of|the|blood|pressure|ang (l_nmod) ang_32\NN\8391387|to|exogenous|ii (l_nummod) ii_33\CD\13741022|
T17_T30 NONE ii_48\CD\13741022| (r_nummod) levels_49\NNS\4916342|in|plasma|ang|ii (r_nmod) changes_44\NNS\7283608|reactive|levels (r_conj) inhibition_24\NN\1068773|response|,|assay|,|and|changes (l_conj) assay_40\NN\5733583|in|ang|ii|receptor (l_compound) receptor_39\NN\5225602|
T17_T31 NONE ii_48\CD\13741022|
T18_T32 NONE ii-induced_6\JJ\1740|ang
T19_T32 CPR:4 valsartan_12\NN\2712393|,|%|;|and|irbesartan|p<0.01 (r_conj) blocked_0\VBD\1476483|%|;|valsartan|. (l_dobj) %_2\NN\1740|43|increase (l_nmod) increase_10\NN\13576355|of|the|ii-induced|systolic|blood|pressure (l_amod) ii-induced_6\JJ\1740|ang
T20_T32 CPR:4 irbesartan_18\NNP\1740|,|% (r_conj) valsartan_12\NN\2712393|,|%|;|and|irbesartan|p<0.01 (r_conj) blocked_0\VBD\1476483|%|;|valsartan|. (l_dobj) %_2\NN\1740|43|increase (l_nmod) increase_10\NN\13576355|of|the|ii-induced|systolic|blood|pressure (l_amod) ii-induced_6\JJ\1740|ang
T2_T22 NONE ii_6\CD\13741022| (r_nummod) blockade_8\NN\952963|ang|ii|receptor (l_compound) receptor_7\NN\5225602|
T2_T23 NONE ii_6\CD\13741022| (r_nummod) blockade_8\NN\952963|ang|ii|receptor (r_nsubjpass) assessed_10\VBN\670261|when|blockade|was|assay (l_nmod) assay_16\NN\5733583|with|an|in|vitro|receptor|and|rise (l_conj) rise_21\NN\7324673|by|the|reactive|levels (l_nmod) levels_26\NNS\4916342|in|plasma|ang|ii (l_nummod) ii_25\CD\13741022|
T3_T22 NONE ii_25\CD\13741022| (r_nummod) levels_26\NNS\4916342|in|plasma|ang|ii (r_nmod) rise_21\NN\7324673|by|the|reactive|levels (r_conj) assay_16\NN\5733583|with|an|in|vitro|receptor|and|rise (r_nmod) assessed_10\VBN\670261|when|blockade|was|assay (l_nsubjpass) blockade_8\NN\952963|ang|ii|receptor (l_compound) receptor_7\NN\5225602|
T3_T23 NONE ii_25\CD\13741022|
T4_T24 CPR:4 irbesartan_14\NN\1740|of (r_nmod) dose_12\NN\3740161|of|the|recommended|starting|irbesartan (r_nmod) administration_7\NN\1133281|the|first|dose (r_nsubj) induces_15\VBZ\1627355|that|administration|blockade (l_dobj) blockade_24\NN\952963|a|greater|ang|ii|receptor|that (l_compound) receptor_23\NN\5225602|
T5_T24 NONE ii_22\CD\13741022| (r_nummod) blockade_24\NN\952963|a|greater|ang|ii|receptor|that (l_compound) receptor_23\NN\5225602|
T6_T24 CPR:4 valsartan_28\NN\2712393|of|and|losartan (r_nmod) that_26\DT\1740|than|valsartan|subjects (r_nmod) blockade_24\NN\952963|a|greater|ang|ii|receptor|that (l_compound) receptor_23\NN\5225602|
T7_T24 CPR:4 losartan_30\.\1740| (r_conj) valsartan_28\NN\2712393|of|and|losartan (r_nmod) that_26\DT\1740|than|valsartan|subjects (r_nmod) blockade_24\NN\952963|a|greater|ang|ii|receptor|that (l_compound) receptor_23\NN\5225602|
11309392
T9_T30 NONE diacylglycerol_1\NN\1740| (r_compound) kinase-theta_2\NN\1740|nuclear|diacylglycerol (r_nsubjpass) activated_4\VBN\1641914|kinase-theta|is|response|. (l_nmod) response_6\NN\11410625|in|alpha-thrombin (l_nmod) alpha-thrombin_8\NN\1740|to
T9_T31 NONE diacylglycerol_1\NN\1740| (r_compound) kinase-theta_2\NN\1740|nuclear|diacylglycerol
T3_T25 NONE diacylglycerol_30\NN\1740| (r_compound) mass_31\NN\13575869|in|nuclear|diacylglycerol (r_nmod) increase_27\NN\13576355|an|mass|and|activation (r_dep) leads_13\VBZ\1752884|that|stimulation|production|:|increase (l_nsubj) stimulation_7\NN\242808|fibroblasts|alpha-thrombin (l_nmod) alpha-thrombin_12\NN\1740|with
T4_T25 NONE phosphatidylcholine_44\NN\1740|of (r_nmod) hydrolysis_42\NN\13447361|the|phosphatidylcholine (r_dobj) catalyzes_40\VBZ\146138|which|hydrolysis|generate (r_acl:relcl) d_37\NN\15089472|of|phospholipase|,|catalyzes (r_nmod) activation_34\NN\13561719|an|d (r_conj) increase_27\NN\13576355|an|mass|and|activation (r_dep) leads_13\VBZ\1752884|that|stimulation|production|:|increase (l_nsubj) stimulation_7\NN\242808|fibroblasts|alpha-thrombin (l_nmod) alpha-thrombin_12\NN\1740|with
T5_T25 NONE acid_48\NN\14818238|phosphatidic (r_dobj) generate_46\VB\1617192|to|acid (r_xcomp) catalyzes_40\VBZ\146138|which|hydrolysis|generate (r_acl:relcl) d_37\NN\15089472|of|phospholipase|,|catalyzes (r_nmod) activation_34\NN\13561719|an|d (r_conj) increase_27\NN\13576355|an|mass|and|activation (r_dep) leads_13\VBZ\1752884|that|stimulation|production|:|increase (l_nsubj) stimulation_7\NN\242808|fibroblasts|alpha-thrombin (l_nmod) alpha-thrombin_12\NN\1740|with
T6_T26 NONE diacylglycerol_0\NN\1740| (r_compound) kinase_1\NN\14732946|diacylglycerol|dgk
T6_T27 NONE diacylglycerol_0\NN\1740| (r_compound) kinase_1\NN\14732946|diacylglycerol|dgk (l_appos) dgk_3\NN\1740|(|)
T7_T26 CPR:9 diacylglycerol_9\NN\1740|of (r_nmod) conversion_7\NN\7359599|the|diacylglycerol|acid (r_dobj) catalyzes_5\VBZ\146138|kinase|conversion|,|making|. (l_nsubj) kinase_1\NN\14732946|diacylglycerol|dgk
T7_T27 CPR:9 diacylglycerol_9\NN\1740|of (r_nmod) conversion_7\NN\7359599|the|diacylglycerol|acid (r_dobj) catalyzes_5\VBZ\146138|kinase|conversion|,|making|. (l_nsubj) kinase_1\NN\14732946|diacylglycerol|dgk (l_appos) dgk_3\NN\1740|(|)
T8_T26 CPR:9 acid_12\NN\14818238|to|phosphatidic (r_nmod) conversion_7\NN\7359599|the|diacylglycerol|acid (r_dobj) catalyzes_5\VBZ\146138|kinase|conversion|,|making|. (l_nsubj) kinase_1\NN\14732946|diacylglycerol|dgk
T8_T27 CPR:9 acid_12\NN\14818238|to|phosphatidic (r_nmod) conversion_7\NN\7359599|the|diacylglycerol|acid (r_dobj) catalyzes_5\VBZ\146138|kinase|conversion|,|making|. (l_nsubj) kinase_1\NN\14732946|diacylglycerol|dgk (l_appos) dgk_3\NN\1740|(|)
T1_T12 CPR:4 phosphatidylserine_8\NN\1740| (r_nsubj) inhibits_9\VBZ\2510337|that|phosphatidylserine|dgk-delta|reviewed|and|inhibits (l_dobj) dgk-delta_10\NN\1740|
T1_T13 NONE phosphatidylserine_8\NN\1740| (r_nsubj) inhibits_9\VBZ\2510337|that|phosphatidylserine|dgk-delta|reviewed|and|inhibits (l_conj) inhibits_53\VBZ\2510337|rhoa|dgk-theta|reviewed (l_nsubj) rhoa_52\NN\1740|active
T1_T14 NONE phosphatidylserine_8\NN\1740| (r_nsubj) inhibits_9\VBZ\2510337|that|phosphatidylserine|dgk-delta|reviewed|and|inhibits (l_conj) inhibits_53\VBZ\2510337|rhoa|dgk-theta|reviewed (l_dobj) dgk-theta_54\NN\1740|
T1_T15 NONE phosphatidylserine_8\NN\1740| (r_nsubj) inhibits_9\VBZ\2510337|that|phosphatidylserine|dgk-delta|reviewed|and|inhibits (r_ccomp) observations_6\NNS\996969|of|the|previous|inhibits (r_nmod) advantage_2\NN\5154517|observations (r_dobj) took_1\VBD\2367363|we|advantage|identify|. (l_advcl) identify_97\VB\699815|to|activity (l_dobj) activity_99\NN\30358|the|induced (l_acl) induced_100\VBN\1627355|alpha-thrombin (l_nmod) alpha-thrombin_102\NN\1740|by
T2_T16 NONE phosphatidylserine_10\NN\1740| (r_nsubj) have_13\VB\2108377|phosphatidylserine|did|not|effect (r_parataxis) inhibited_3\VBD\2510337|rhoa|activity|,|whereas|have|. (l_nsubj) rhoa_2\NN\1740|active
11893059
T1_T7 CPR:4 physostigmine_8\NN\14712692|namely|,|and|tacrine (r_appos) inhibitors_4\NNS\20090|the|earliest|known|ache|,|physostigmine|, (l_compound) ache_3\NN\14322699|
T2_T7 CPR:4 tacrine_10\NN\1740| (r_conj) physostigmine_8\NN\14712692|namely|,|and|tacrine (r_appos) inhibitors_4\NNS\20090|the|earliest|known|ache|,|physostigmine|, (l_compound) ache_3\NN\14322699|
T3_T8 CPR:4 hydrochloride_1\NN\14817592|donepezil (r_nsubj) inaugurates_2\VBZ\1650610|hydrochloride|class|action|. (l_dobj) class_5\NN\7951464|a|new|inhibitors (l_nmod) inhibitors_8\NNS\20090|of|ache (l_compound) ache_7\NN\14322699|
23411279
T8_T10 CPR:4 ethanol_1\NN\14708720|aqueous|% (r_compound) extract_6\NN\14589223|ethanol|hulls (r_nsubj) exhibited_10\VBD\2632167|extract|activities|inhibiting|,|whereas|exerted|. (l_advcl) inhibiting_17\VBG\2510337|preferentially|15-lox|,|effects (l_dobj) 15-lox_18\NN\1740|ic(50
T8_T11 CPR:4 ethanol_1\NN\14708720|aqueous|% (r_compound) extract_6\NN\14589223|ethanol|hulls (r_nsubj) exhibited_10\VBD\2632167|extract|activities|inhibiting|,|whereas|exerted|. (l_advcl) inhibiting_17\VBG\2510337|preferentially|15-lox|,|effects (l_nmod) effects_47\NNS\13245626|with|cox-1|inhibitory|pathway (l_compound) cox-1_29\NN\14737847|moderate|ic(50|and|cox-2
T8_T12 CPR:4 ethanol_1\NN\14708720|aqueous|% (r_compound) extract_6\NN\14589223|ethanol|hulls (r_nsubj) exhibited_10\VBD\2632167|extract|activities|inhibiting|,|whereas|exerted|. (l_advcl) inhibiting_17\VBG\2510337|preferentially|15-lox|,|effects (l_nmod) effects_47\NNS\13245626|with|cox-1|inhibitory|pathway (l_compound) cox-1_29\NN\14737847|moderate|ic(50|and|cox-2 (l_conj) cox-2_38\NN\14737847|ic(50
T8_T13 CPR:4 ethanol_1\NN\14708720|aqueous|% (r_compound) extract_6\NN\14589223|ethanol|hulls (r_nsubj) exhibited_10\VBD\2632167|extract|activities|inhibiting|,|whereas|exerted|. (l_advcl) inhibiting_17\VBG\2510337|preferentially|15-lox|,|effects (l_nmod) effects_47\NNS\13245626|with|cox-1|inhibitory|pathway (l_nmod) pathway_51\NN\5483677|on|the|cox (l_compound) cox_50\NN\14732946|
T8_T14 CPR:4 ethanol_1\NN\14708720|aqueous|% (r_compound) extract_6\NN\14589223|ethanol|hulls (r_nsubj) exhibited_10\VBD\2632167|extract|activities|inhibiting|,|whereas|exerted|. (l_parataxis) exerted_58\VBD\1158872|extracts|activity (l_dobj) activity_63\NN\30358|mild|lox|inhibitory (l_compound) lox_61\NN\14648100|
23474014
23588308
T1_T7 NONE simvastatin_1\NN\3676175| (r_compound) auc_2\NN\1740|elevated|simvastatin|patients|,|pg/ml (l_nmod) pg/ml_11\NN\1740|following|100|il-6 (l_nmod) il-6_13\NN\1740|of
T2_T9 NONE cyclosporine_18\NN\1740| (r_compound) auc_19\NN\1740|in|cyclosporine (r_nmod) increase_16\NN\13576355|in|auc|agreement (r_nmod) resulted_14\VBD\2633881|patients|,|pg/ml|increase|. (l_nsubj) pg/ml_11\NN\1740|500|il-6 (l_nmod) il-6_13\NN\1740|of
T3_T11 NONE cyclosporine_9\NN\1740|with (r_nmod) treated_7\VBN\2376958|cyclosporine (r_acl) patients_6\NNS\9898892|of|bmt|treated (r_nmod) group_3\NN\2137|in|a|different|patients (r_nmod) predicted_19\VBN\916909|group|,|magnitude|was|under|~3-fold|. (l_nsubj) magnitude_12\NN\4916342|the|interaction (l_nmod) interaction_14\NN\37396|of|il-6 (l_nmod) il-6_16\NN\1740|with
16642960
T6_T13 NONE monophosphate-activated_4\JJ\1740| (r_amod) kinase_6\NN\14732946|adenosine|monophosphate-activated|protein|and|a.
T7_T13 NONE a._10\.\1740|malonyl|coenzyme (r_conj) kinase_6\NN\14732946|adenosine|monophosphate-activated|protein|and|a.
T1_T8 NONE monophosphate-activated_24\JJ\1740| (r_amod) kinase_26\NN\14732946|adenosine|monophosphate-activated|protein
T1_T9 NONE monophosphate-activated_24\JJ\1740| (r_amod) kinase_26\NN\14732946|adenosine|monophosphate-activated|protein (r_compound) a_29\NN\13649268|kinase|(ampk)/malonyl|coenzyme|coa (l_compound) (ampk)/malonyl_27\NN\1740|
T2_T8 NONE a_29\NN\13649268|kinase|(ampk)/malonyl|coenzyme|coa (l_compound) kinase_26\NN\14732946|adenosine|monophosphate-activated|protein
T2_T9 NONE a_29\NN\13649268|kinase|(ampk)/malonyl|coenzyme|coa (l_compound) (ampk)/malonyl_27\NN\1740|
T3_T10 NONE coa_10\NN\1740|in|malonyl (r_nmod) increases_7\NNS\13576355|by|isolated|coa|or|changes (l_conj) changes_14\NNS\7283608|by|concurrent|coa|,|alter (l_nmod) coa_17\NN\1740|in|malonyl|and|ampk (l_conj) ampk_19\NN\1740|
T4_T10 NONE coa_17\NN\1740|in|malonyl|and|ampk (l_conj) ampk_19\NN\1740|
T5_T11 NONE coa_17\NN\1740|malonyl (r_dobj) decrease_15\VBP\169651|coa (r_conj) activate_12\VBP\1641914|that|ampk|and/or|decrease (l_dobj) ampk_13\NN\1740|
23611809
T10_T40 NONE udp-glucuronosyltransferase_5\NN\1740|human|ugt|2b10 (l_nummod) 2b10_9\CD\1740|
T3_T40 CPR:9 amine-containing_13\JJ\1740| (r_amod) compounds_14\NNS\5869584|of|amine-containing (r_nmod) n-glucuronidation_11\NN\1740|compounds (r_dobj) catalyzes_10\VBZ\146138|that|udp-glucuronosyltransferase|n-glucuronidation (l_nsubj) udp-glucuronosyltransferase_5\NN\1740|human|ugt|2b10 (l_nummod) 2b10_9\CD\1740|
T11_T41 CPR:9 amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T12_T41 CPR:9 imipramine_14\NN\4482543| (r_conj) amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T13_T41 CPR:9 ketotifen_16\NN\1740| (r_conj) amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T14_T41 CPR:9 pizotifen_18\NN\1740| (r_conj) amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T15_T41 CPR:9 olanzapine_20\NN\1740| (r_conj) amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T16_T41 CPR:9 diphenhydramine_22\NN\2720725| (r_conj) amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T17_T41 CPR:9 tamoxifen_24\NN\2714883| (r_conj) amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T18_T41 CPR:9 ketoconazole_26\NN\1740| (r_conj) amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T19_T41 CPR:9 midazolam_28\NN\2830852| (r_conj) amitriptyline_12\NN\4482543|of|,|imipramine|,|ketotifen|,|pizotifen|,|olanzapine|,|diphenhydramine|,|tamoxifen|,|ketoconazole|and|midazolam (r_nmod) n-glucuronidation_10\NN\1740|the|amitriptyline (r_dobj) catalyzes_8\VBZ\146138|that|it|n-glucuronidation (r_ccomp) found_5\VBD\2426171|using|,|we|catalyzes|. (l_advcl) using_0\VBG\1156834|ugt2b10 (l_dobj) ugt2b10_2\NN\1740|recombinant
T20_T42 NONE amines_23\NNS\14951377|either|tertiary|aliphatic|,|amines|,|or|group (r_dobj) contain_16\VBP\2632940|that|structure|amines (r_conj) reported_6\VBN\831651|that|were|previously|substrates|and|contain (l_xcomp) substrates_9\NNS\19613|to|be|ugt1a4 (l_nmod) ugt1a4_11\NN\1740|for|or|ugt1a3
T20_T43 NONE amines_23\NNS\14951377|either|tertiary|aliphatic|,|amines|,|or|group (r_dobj) contain_16\VBP\2632940|that|structure|amines (r_conj) reported_6\VBN\831651|that|were|previously|substrates|and|contain (l_xcomp) substrates_9\NNS\19613|to|be|ugt1a4 (l_nmod) ugt1a4_11\NN\1740|for|or|ugt1a3 (l_conj) ugt1a3_13\NN\1740|
T21_T42 NONE amines_26\NNS\14951377|cyclic (r_conj) amines_23\NNS\14951377|either|tertiary|aliphatic|,|amines|,|or|group (r_dobj) contain_16\VBP\2632940|that|structure|amines (r_conj) reported_6\VBN\831651|that|were|previously|substrates|and|contain (l_xcomp) substrates_9\NNS\19613|to|be|ugt1a4 (l_nmod) ugt1a4_11\NN\1740|for|or|ugt1a3
T21_T43 NONE amines_26\NNS\14951377|cyclic (r_conj) amines_23\NNS\14951377|either|tertiary|aliphatic|,|amines|,|or|group (r_dobj) contain_16\VBP\2632940|that|structure|amines (r_conj) reported_6\VBN\831651|that|were|previously|substrates|and|contain (l_xcomp) substrates_9\NNS\19613|to|be|ugt1a4 (l_nmod) ugt1a4_11\NN\1740|for|or|ugt1a3 (l_conj) ugt1a3_13\NN\1740|
T22_T42 NONE imidazole_30\NN\14618253| (r_amod) group_31\NN\2137|an|imidazole (r_conj) amines_23\NNS\14951377|either|tertiary|aliphatic|,|amines|,|or|group (r_dobj) contain_16\VBP\2632940|that|structure|amines (r_conj) reported_6\VBN\831651|that|were|previously|substrates|and|contain (l_xcomp) substrates_9\NNS\19613|to|be|ugt1a4 (l_nmod) ugt1a4_11\NN\1740|for|or|ugt1a3
T22_T43 NONE imidazole_30\NN\14618253| (r_amod) group_31\NN\2137|an|imidazole (r_conj) amines_23\NNS\14951377|either|tertiary|aliphatic|,|amines|,|or|group (r_dobj) contain_16\VBP\2632940|that|structure|amines (r_conj) reported_6\VBN\831651|that|were|previously|substrates|and|contain (l_xcomp) substrates_9\NNS\19613|to|be|ugt1a4 (l_nmod) ugt1a4_11\NN\1740|for|or|ugt1a3 (l_conj) ugt1a3_13\NN\1740|
T23_T44 NONE desipramine_7\NN\4482543|of|,|nortriptyline|,|carbamazepine|and|afloqualone (r_nmod) glucuronidation_5\NN\1740|in|the|desipramine (r_nmod) inactive_2\JJ\1740|ugt2b10|was|glucuronidation|. (l_nsubj) ugt2b10_0\NN\1740|
T24_T44 NONE nortriptyline_9\NN\4482543| (r_conj) desipramine_7\NN\4482543|of|,|nortriptyline|,|carbamazepine|and|afloqualone (r_nmod) glucuronidation_5\NN\1740|in|the|desipramine (r_nmod) inactive_2\JJ\1740|ugt2b10|was|glucuronidation|. (l_nsubj) ugt2b10_0\NN\1740|
T25_T44 NONE carbamazepine_11\NN\1740| (r_conj) desipramine_7\NN\4482543|of|,|nortriptyline|,|carbamazepine|and|afloqualone (r_nmod) glucuronidation_5\NN\1740|in|the|desipramine (r_nmod) inactive_2\JJ\1740|ugt2b10|was|glucuronidation|. (l_nsubj) ugt2b10_0\NN\1740|
T26_T44 NONE afloqualone_13\NN\1740| (r_conj) desipramine_7\NN\4482543|of|,|nortriptyline|,|carbamazepine|and|afloqualone (r_nmod) glucuronidation_5\NN\1740|in|the|desipramine (r_nmod) inactive_2\JJ\1740|ugt2b10|was|glucuronidation|. (l_nsubj) ugt2b10_0\NN\1740|
T27_T45 NONE amines_8\NNS\14951377|secondary (r_dobj) contains_4\VBZ\2632940|group|amines|,|and|suggest (l_conj) suggest_13\VBP\1010118|results|conjugates|. (l_ccomp) conjugates_17\VBZ\394813|that|ugt2b10|preferably|amines (l_nsubj) ugt2b10_15\NN\1740|
T28_T45 CPR:9 amines_19\NNS\14951377|tertiary (r_dobj) conjugates_17\VBZ\394813|that|ugt2b10|preferably|amines (l_nsubj) ugt2b10_15\NN\1740|
T1_T29 NONE amine_12\NN\14951377|the|tertiary|cyclic (r_dobj) conjugate_8\VB\394813|because|ugt2b10|did|not|amine|trifluoperazine (l_nsubj) ugt2b10_5\NN\1740|
T2_T29 NONE trifluoperazine_14\NN\1740|in (r_nmod) conjugate_8\VB\394813|because|ugt2b10|did|not|amine|trifluoperazine (l_nsubj) ugt2b10_5\NN\1740|
T4_T30 CPR:9 amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (l_nmod) ugt2b10_9\NN\1740|of
T4_T31 CPR:9 amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_nmod) values_23\NNS\5941423|than|the|corresponding|ugt1a4 (l_nmod) ugt1a4_25\NN\1740|of|and|ugt1a3
T4_T32 NONE amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_nmod) values_23\NNS\5941423|than|the|corresponding|ugt1a4 (l_nmod) ugt1a4_25\NN\1740|of|and|ugt1a3 (l_conj) ugt1a3_27\NN\1740|
T4_T33 CPR:9 amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_advcl) higher_40\JJR\1740|although|values|are|considerably (l_nsubj) values_32\NNS\5941423|the|vmax|ugt1a4|drugs (l_nmod) ugt1a4_34\NN\1740|of
T5_T30 CPR:9 imipramine_13\NN\4482543| (r_conj) amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (l_nmod) ugt2b10_9\NN\1740|of
T5_T31 CPR:9 imipramine_13\NN\4482543| (r_conj) amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_nmod) values_23\NNS\5941423|than|the|corresponding|ugt1a4 (l_nmod) ugt1a4_25\NN\1740|of|and|ugt1a3
T5_T32 CPR:9 imipramine_13\NN\4482543| (r_conj) amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_nmod) values_23\NNS\5941423|than|the|corresponding|ugt1a4 (l_nmod) ugt1a4_25\NN\1740|of|and|ugt1a3 (l_conj) ugt1a3_27\NN\1740|
T5_T33 CPR:9 imipramine_13\NN\4482543| (r_conj) amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_advcl) higher_40\JJR\1740|although|values|are|considerably (l_nsubj) values_32\NNS\5941423|the|vmax|ugt1a4|drugs (l_nmod) ugt1a4_34\NN\1740|of
T6_T30 CPR:9 diphenhydramine_16\NN\2720725| (r_conj) amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (l_nmod) ugt2b10_9\NN\1740|of
T6_T31 CPR:9 diphenhydramine_16\NN\2720725| (r_conj) amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_nmod) values_23\NNS\5941423|than|the|corresponding|ugt1a4 (l_nmod) ugt1a4_25\NN\1740|of|and|ugt1a3
T6_T32 CPR:9 diphenhydramine_16\NN\2720725| (r_conj) amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_nmod) values_23\NNS\5941423|than|the|corresponding|ugt1a4 (l_nmod) ugt1a4_25\NN\1740|of|and|ugt1a3 (l_conj) ugt1a3_27\NN\1740|
T6_T33 CPR:9 diphenhydramine_16\NN\2720725| (r_conj) amitriptyline_11\NN\4482543|for|,|imipramine|,|and|diphenhydramine (r_nmod) affinity_5\NN\11426530|the|and|clearance|ugt2b10|amitriptyline (r_nsubj) higher_19\JJR\1740|that|affinity|are|significantly|values|,|higher (l_advcl) higher_40\JJR\1740|although|values|are|considerably (l_nsubj) values_32\NNS\5941423|the|vmax|ugt1a4|drugs (l_nmod) ugt1a4_34\NN\1740|of
T9_T35 CPR:9 amines_20\NNS\14951377|for|tertiary|affinities (r_nmod) preference_17\NN\7497473|its|amines (r_dobj) highlighting_15\VBG\514463|preference (r_advcl) expands_5\VBZ\230746|conclusion|,|study|understanding|,|highlighting|. (l_dobj) understanding_7\NN\5804793|the|specificity (l_nmod) specificity_11\NN\4762633|of|the|substrate|ugt2b10 (l_nmod) ugt2b10_13\NN\1740|of
T9_T36 CPR:9 amines_20\NNS\14951377|for|tertiary|affinities (l_nmod) affinities_23\NNS\11426530|with|higher|and|values|those (l_nmod) those_28\DT\1740|than|ugt1a4 (l_nmod) ugt1a4_30\NN\1740|of|and|ugt1a3
T9_T37 CPR:9 amines_20\NNS\14951377|for|tertiary|affinities (l_nmod) affinities_23\NNS\11426530|with|higher|and|values|those (l_nmod) those_28\DT\1740|than|ugt1a4 (l_nmod) ugt1a4_30\NN\1740|of|and|ugt1a3 (l_conj) ugt1a3_32\NN\1740|
17234158
T9_T25 CPR:4 pirfenidone_0\NN\1740| (r_nsubj) inhibits_1\VBZ\2510337|pirfenidone|expression|. (l_dobj) expression_3\NN\4679549|tgf-beta|cells (l_compound) tgf-beta_2\NN\1740|
T1_T11 CPR:4 5-methyl-1-phenyl-2-(1h)-pyridone_8\NN\1740|pirfenidone (r_dep) drug_7\NN\14778436|the|antifibrotic|5-methyl-1-phenyl-2-(1h)-pyridone (r_nsubj) elicits_14\VBZ\1617192|that|drug|effects|and|reduces (l_conj) reduces_18\VBZ\441445|levels (l_dobj) levels_21\NNS\4916342|protein|lines (l_compound) protein_20\NN\14944888|tgf-beta2 (l_compound) tgf-beta2_19\NN\1740|
T2_T11 CPR:4 pirfenidone_10\NN\1740|(|,|pfd|) (r_dep) 5-methyl-1-phenyl-2-(1h)-pyridone_8\NN\1740|pirfenidone (r_dep) drug_7\NN\14778436|the|antifibrotic|5-methyl-1-phenyl-2-(1h)-pyridone (r_nsubj) elicits_14\VBZ\1617192|that|drug|effects|and|reduces (l_conj) reduces_18\VBZ\441445|levels (l_dobj) levels_21\NNS\4916342|protein|lines (l_compound) protein_20\NN\14944888|tgf-beta2 (l_compound) tgf-beta2_19\NN\1740|
T3_T11 CPR:4 pfd_12\NN\1740| (r_appos) pirfenidone_10\NN\1740|(|,|pfd|) (r_dep) 5-methyl-1-phenyl-2-(1h)-pyridone_8\NN\1740|pirfenidone (r_dep) drug_7\NN\14778436|the|antifibrotic|5-methyl-1-phenyl-2-(1h)-pyridone (r_nsubj) elicits_14\VBZ\1617192|that|drug|effects|and|reduces (l_conj) reduces_18\VBZ\441445|levels (l_dobj) levels_21\NNS\4916342|protein|lines (l_compound) protein_20\NN\14944888|tgf-beta2 (l_compound) tgf-beta2_19\NN\1740|
T4_T12 CPR:4 pfd_8\NN\1740| (r_compound) treatment_9\NN\654885|pfd (r_nsubj) reduces_10\VBZ\441445|since|treatment|inhibition (r_advcl) relevant_6\JJ\1740|reduction|is|biologically|reduces|. (l_nsubj) reduction_1\NN\351485|this|tgf-beta2 (l_nmod) tgf-beta2_3\NN\1740|in
T4_T14 CPR:4 pfd_8\NN\1740| (r_compound) treatment_9\NN\654885|pfd (r_nsubj) reduces_10\VBZ\441445|since|treatment|inhibition (l_dobj) inhibition_13\NN\1068773|the|growth|cells (l_nmod) cells_17\NNS\3080309|of|tgf-beta-sensitive|ccl-64|mediated (l_amod) tgf-beta-sensitive_15\JJ\1740|
T5_T17 CPR:4 pfd_0\NN\1740| (r_nsubj) leads_1\VBZ\1752884|pfd|reduction|. (l_nmod) reduction_4\NN\351485|to|a|levels|expression (l_nmod) levels_8\NNS\4916342|of|mrna|and|protein (l_compound) mrna_7\NN\14832193|tgf-beta2 (l_compound) tgf-beta2_6\NN\1740|
T5_T18 CPR:4 pfd_0\NN\1740| (r_nsubj) leads_1\VBZ\1752884|pfd|reduction|. (l_nmod) reduction_4\NN\351485|to|a|levels|expression (l_nmod) levels_8\NNS\4916342|of|mrna|and|protein (l_conj) protein_14\NN\14944888|of|the|mature|tgf-beta2 (l_compound) tgf-beta2_13\NN\1740|
T5_T19 CPR:4 pfd_0\NN\1740| (r_nsubj) leads_1\VBZ\1752884|pfd|reduction|. (l_nmod) reduction_4\NN\351485|to|a|levels|expression (l_nmod) expression_18\NN\4679549|due|to|decreased|and|inhibition|furin (l_nmod) furin_27\NN\1740|of|the|tgf-beta|pro-protein|convertase (l_compound) tgf-beta_24\NN\1740|
T5_T20 CPR:4 pfd_0\NN\1740| (r_nsubj) leads_1\VBZ\1752884|pfd|reduction|. (l_nmod) reduction_4\NN\351485|to|a|levels|expression (l_nmod) expression_18\NN\4679549|due|to|decreased|and|inhibition|furin (l_nmod) furin_27\NN\1740|of|the|tgf-beta|pro-protein|convertase (l_compound) convertase_26\NN\1740|
T5_T21 CPR:4 pfd_0\NN\1740| (r_nsubj) leads_1\VBZ\1752884|pfd|reduction|. (l_nmod) reduction_4\NN\351485|to|a|levels|expression (l_nmod) expression_18\NN\4679549|due|to|decreased|and|inhibition|furin (l_nmod) furin_27\NN\1740|of|the|tgf-beta|pro-protein|convertase
T6_T22 CPR:4 pfd_3\NN\1740| (r_nsubj) reduces_4\VBZ\441445|addition|,|pfd|levels|. (l_dobj) levels_7\NNS\4916342|the|protein|metalloproteinase (l_nmod) metalloproteinase_11\NN\1740|of|the|matrix|(mmp)-11|,|gene (l_nummod) (mmp)-11_12\NN\1740|
T6_T23 CPR:4 pfd_3\NN\1740| (r_nsubj) reduces_4\VBZ\441445|addition|,|pfd|levels|. (l_dobj) levels_7\NNS\4916342|the|protein|metalloproteinase (l_nmod) metalloproteinase_11\NN\1740|of|the|matrix|(mmp)-11|,|gene (l_appos) gene_17\NN\8459252|a|tgf-beta|target|and|substrate|involved (l_compound) tgf-beta_15\NN\1740|
T6_T24 NONE pfd_3\NN\1740| (r_nsubj) reduces_4\VBZ\441445|addition|,|pfd|levels|. (l_dobj) levels_7\NNS\4916342|the|protein|metalloproteinase (l_nmod) metalloproteinase_11\NN\1740|of|the|matrix|(mmp)-11|,|gene (l_appos) gene_17\NN\8459252|a|tgf-beta|target|and|substrate|involved (l_conj) substrate_20\NN\19613|furin (l_compound) furin_19\NN\1740|
T7_T10 NONE pfd_3\NN\1740|or|agents (r_dobj) define_2\VBP\2604760|data|pfd|agents|. (l_nmod) agents_9\NNS\7347|as|promising|cancers (l_nmod) cancers_12\NNS\14239425|for|human|associated (l_acl) associated_13\VBN\628491|activity (l_nmod) activity_17\NN\30358|with|enhanced|tgf-beta (l_compound) tgf-beta_16\NN\1740|
T8_T10 NONE pfd-related_5\JJ\1740| (r_amod) agents_6\NNS\7347|pfd-related (r_conj) pfd_3\NN\1740|or|agents (r_dobj) define_2\VBP\2604760|data|pfd|agents|. (l_nmod) agents_9\NNS\7347|as|promising|cancers (l_nmod) cancers_12\NNS\14239425|for|human|associated (l_acl) associated_13\VBN\628491|activity (l_nmod) activity_17\NN\30358|with|enhanced|tgf-beta (l_compound) tgf-beta_16\NN\1740|
8740147
T32_T57 CPR:9 amezinium_0\NN\1740|and|debrisoquine (r_nsubj) substrates_4\NNS\19613|amezinium|are|uptake1|and|inhibitors|lungs|. (l_nmod) uptake1_6\NN\1740|of
T32_T58 CPR:4 amezinium_0\NN\1740|and|debrisoquine (r_nsubj) substrates_4\NNS\19613|amezinium|are|uptake1|and|inhibitors|lungs|. (l_conj) inhibitors_9\NNS\20090|potent|oxidase (l_nmod) oxidase_12\NN\14732946|of|monoamine
T33_T57 CPR:9 debrisoquine_2\NN\1740| (r_conj) amezinium_0\NN\1740|and|debrisoquine (r_nsubj) substrates_4\NNS\19613|amezinium|are|uptake1|and|inhibitors|lungs|. (l_nmod) uptake1_6\NN\1740|of
T33_T58 CPR:4 debrisoquine_2\NN\1740| (r_conj) amezinium_0\NN\1740|and|debrisoquine (r_nsubj) substrates_4\NNS\19613|amezinium|are|uptake1|and|inhibitors|lungs|. (l_conj) inhibitors_9\NNS\20090|potent|oxidase (l_nmod) oxidase_12\NN\14732946|of|monoamine
T34_T57 NONE monoamine_11\NN\14739004| (r_compound) oxidase_12\NN\14732946|of|monoamine (r_nmod) inhibitors_9\NNS\20090|potent|oxidase (r_conj) substrates_4\NNS\19613|amezinium|are|uptake1|and|inhibitors|lungs|. (l_nmod) uptake1_6\NN\1740|of
T34_T58 NONE monoamine_11\NN\14739004| (r_compound) oxidase_12\NN\14732946|of|monoamine
T1_T35 NONE monoamine_15\NN\14739004| (r_compound) oxidase_16\NN\14732946|of|neuronal|monoamine|mao
T1_T36 NONE monoamine_15\NN\14739004| (r_compound) oxidase_16\NN\14732946|of|neuronal|monoamine|mao (l_appos) mao_18\NN\14732946|(|)
T1_T40 NONE monoamine_15\NN\14739004| (r_compound) oxidase_16\NN\14732946|of|neuronal|monoamine|mao (r_nmod) inhibitor_12\NN\20090|as|a|selective|oxidase (r_nmod) classification_6\NN\1012360|in|the|amezinium|inhibitor (r_nmod) resulted_3\VBN\2633881|studies|have|classification|,|inhibitor|. (l_advcl) inhibitor_29\NN\20090|because|it|is|a|potent|mao|tissues (l_compound) mao_28\NN\14732946|
T22_T35 CPR:4 amezinium_8\NN\1740|of (r_nmod) classification_6\NN\1012360|in|the|amezinium|inhibitor (l_nmod) inhibitor_12\NN\20090|as|a|selective|oxidase (l_nmod) oxidase_16\NN\14732946|of|neuronal|monoamine|mao
T22_T36 CPR:4 amezinium_8\NN\1740|of (r_nmod) classification_6\NN\1012360|in|the|amezinium|inhibitor (l_nmod) inhibitor_12\NN\20090|as|a|selective|oxidase (l_nmod) oxidase_16\NN\14732946|of|neuronal|monoamine|mao (l_appos) mao_18\NN\14732946|(|)
T22_T40 CPR:4 amezinium_8\NN\1740|of (r_nmod) classification_6\NN\1012360|in|the|amezinium|inhibitor (r_nmod) resulted_3\VBN\2633881|studies|have|classification|,|inhibitor|. (l_advcl) inhibitor_29\NN\20090|because|it|is|a|potent|mao|tissues (l_compound) mao_28\NN\14732946|
T19_T50 NONE amezinium_8\NN\1740|of (r_nmod) effects_6\NNS\13245626|the|amezinium|deamination (r_nsubjpass) investigated_15\VBN\644583|study|,|effects|were|lungs|,|site|. (l_advcl) site_29\NN\8673395|since|cells|are|a|uptake1 (l_acl:relcl) uptake1_36\NN\1740|where|transporter|is|non-neuronal
T20_T50 NONE noradrenaline_13\NN\14807929|of (r_nmod) deamination_11\NN\13446390|on|the|noradrenaline (r_nmod) effects_6\NNS\13245626|the|amezinium|deamination (r_nsubjpass) investigated_15\VBN\644583|study|,|effects|were|lungs|,|site|. (l_advcl) site_29\NN\8673395|since|cells|are|a|uptake1 (l_acl:relcl) uptake1_36\NN\1740|where|transporter|is|non-neuronal
T21_T50 NONE catecholamine_32\NN\5407119| (r_compound) transporter_33\NN\4490091|the|catecholamine (r_nsubj) uptake1_36\NN\1740|where|transporter|is|non-neuronal
T23_T51 CPR:9 debrisoquine_17\NN\1740| (r_appos) inhibitor_15\NN\20090|a|mao|,|debrisoquine|, (r_conj) substrate_9\NN\19613|that|is|both|a|uptake1|and|inhibitor (l_nmod) uptake1_11\NN\1740|of
T23_T52 CPR:4 debrisoquine_17\NN\1740| (r_appos) inhibitor_15\NN\20090|a|mao|,|debrisoquine|, (l_compound) mao_14\NN\14732946|
T24_T53 NONE amezinium_10\NNP\1740|and|debrisoquine (r_nsubj) substrates_14\NNS\19613|whether|amezinium|are|uptake1|lungs (l_nmod) uptake1_16\NN\1740|of
T25_T53 NONE debrisoquine_12\NN\1740| (r_conj) amezinium_10\NNP\1740|and|debrisoquine (r_nsubj) substrates_14\NNS\19613|whether|amezinium|are|uptake1|lungs (l_nmod) uptake1_16\NN\1740|of
T26_T54 NONE 3h-noradrenaline_7\NN\1740|with|inhibited (l_dep) inhibited_15\JJ\1740|mao|) (l_nsubj) mao_9\NN\14732946|(|and|catechol-o-methyltransferase
T26_T55 NONE 3h-noradrenaline_7\NN\1740|with|inhibited (l_dep) inhibited_15\JJ\1740|mao|) (l_nsubj) mao_9\NN\14732946|(|and|catechol-o-methyltransferase (l_conj) catechol-o-methyltransferase_11\NN\1740|comt
T26_T56 NONE 3h-noradrenaline_7\NN\1740|with|inhibited (l_dep) inhibited_15\JJ\1740|mao|) (l_nsubj) mao_9\NN\14732946|(|and|catechol-o-methyltransferase (l_conj) catechol-o-methyltransferase_11\NN\1740|comt (l_appos) comt_13\NN\1740|(|)
T27_T54 NONE catechol-o-methyltransferase_11\NN\1740|comt (r_conj) mao_9\NN\14732946|(|and|catechol-o-methyltransferase
T27_T55 NONE catechol-o-methyltransferase_11\NN\1740|comt
T27_T56 NONE catechol-o-methyltransferase_11\NN\1740|comt (l_appos) comt_13\NN\1740|(|)
T28_T54 NONE catechol-o-methyltransferase_11\NN\1740|comt (r_conj) mao_9\NN\14732946|(|and|catechol-o-methyltransferase
T28_T55 NONE catechol-o-methyltransferase_11\NN\1740|comt
T28_T56 NONE catechol-o-methyltransferase_11\NN\1740|comt (l_appos) comt_13\NN\1740|(|)
T29_T54 NONE 3h-noradrenaline_21\NN\1740|of (r_nmod) efflux_19\NN\13482330|the|3h-noradrenaline (r_nsubjpass) measured_23\VBN\697589|loading|,|efflux|was|min|. (l_nmod) loading_1\NN\4571088|after|lungs|3h-noradrenaline (l_nmod) 3h-noradrenaline_7\NN\1740|with|inhibited (l_dep) inhibited_15\JJ\1740|mao|) (l_nsubj) mao_9\NN\14732946|(|and|catechol-o-methyltransferase
T29_T55 NONE 3h-noradrenaline_21\NN\1740|of (r_nmod) efflux_19\NN\13482330|the|3h-noradrenaline (r_nsubjpass) measured_23\VBN\697589|loading|,|efflux|was|min|. (l_nmod) loading_1\NN\4571088|after|lungs|3h-noradrenaline (l_nmod) 3h-noradrenaline_7\NN\1740|with|inhibited (l_dep) inhibited_15\JJ\1740|mao|) (l_nsubj) mao_9\NN\14732946|(|and|catechol-o-methyltransferase (l_conj) catechol-o-methyltransferase_11\NN\1740|comt
T29_T56 NONE 3h-noradrenaline_21\NN\1740|of (r_nmod) efflux_19\NN\13482330|the|3h-noradrenaline (r_nsubjpass) measured_23\VBN\697589|loading|,|efflux|was|min|. (l_nmod) loading_1\NN\4571088|after|lungs|3h-noradrenaline (l_nmod) 3h-noradrenaline_7\NN\1740|with|inhibited (l_dep) inhibited_15\JJ\1740|mao|) (l_nsubj) mao_9\NN\14732946|(|and|catechol-o-methyltransferase (l_conj) catechol-o-methyltransferase_11\NN\1740|comt (l_appos) comt_13\NN\1740|(|)
T4_T38 NONE 3h-noradrenaline_6\NN\1740|with|nmol/l|inhibited (l_appos) inhibited_9\JJ\1740|(|comt|) (l_nsubj) comt_8\NN\1740|
T5_T38 NONE amezinium_18\NN\1740|nmol/l (r_nsubj) caused_19\VBD\1617192|lungs|,|amezinium|%|respectively|,|and|caused|. (l_nmod) lungs_1\NNS\5528060|in|perfused (l_acl) perfused_2\VBN\454868|3h-noradrenaline (l_nmod) 3h-noradrenaline_6\NN\1740|with|nmol/l|inhibited (l_appos) inhibited_9\JJ\1740|(|comt|) (l_nsubj) comt_8\NN\1740|
T6_T38 NONE noradrenaline_30\NN\14807929| (r_compound) deamination_31\NN\13446390|of|noradrenaline (r_nmod) %_21\NN\1740|58|,|%|and|%|inhibition|deamination|, (r_dobj) caused_19\VBD\1617192|lungs|,|amezinium|%|respectively|,|and|caused|. (l_nmod) lungs_1\NNS\5528060|in|perfused (l_acl) perfused_2\VBN\454868|3h-noradrenaline (l_nmod) 3h-noradrenaline_6\NN\1740|with|nmol/l|inhibited (l_appos) inhibited_9\JJ\1740|(|comt|) (l_nsubj) comt_8\NN\1740|
T7_T38 NONE debrisoquine_42\NN\1740|nmol/l (r_nsubj) caused_43\VBD\1617192|debrisoquine|%|respectively (r_conj) caused_19\VBD\1617192|lungs|,|amezinium|%|respectively|,|and|caused|. (l_nmod) lungs_1\NNS\5528060|in|perfused (l_acl) perfused_2\VBN\454868|3h-noradrenaline (l_nmod) 3h-noradrenaline_6\NN\1740|with|nmol/l|inhibited (l_appos) inhibited_9\JJ\1740|(|comt|) (l_nsubj) comt_8\NN\1740|
T8_T38 NONE noradrenaline_54\NN\14807929| (r_compound) deamination_55\NN\13446390|of|noradrenaline (r_nmod) %_45\NN\1740|56|,|%|and|%|inhibition|deamination|, (r_dobj) caused_43\VBD\1617192|debrisoquine|%|respectively (r_conj) caused_19\VBD\1617192|lungs|,|amezinium|%|respectively|,|and|caused|. (l_nmod) lungs_1\NNS\5528060|in|perfused (l_acl) perfused_2\VBN\454868|3h-noradrenaline (l_nmod) 3h-noradrenaline_6\NN\1740|with|nmol/l|inhibited (l_appos) inhibited_9\JJ\1740|(|comt|) (l_nsubj) comt_8\NN\1740|
T10_T39 NONE noradrenaline_17\NN\14807929|of (r_nmod) deamination_15\NN\13446390|of|the|noradrenaline|mao-a|lungs (r_nmod) inhibition_12\NN\1068773|%|deamination (r_dobj) caused_9\VBD\1617192|inhibited|,|amezinium|inhibition|. (l_advcl) inhibited_4\VBN\2510337|when|mao-b|was|also (l_nsubjpass) mao-b_1\NN\1740|
T10_T41 NONE noradrenaline_17\NN\14807929|of (r_nmod) deamination_15\NN\13446390|of|the|noradrenaline|mao-a|lungs (l_nmod) mao-a_19\NN\1740|by
T9_T39 NONE amezinium_8\NN\1740|nmol/l (r_nsubj) caused_9\VBD\1617192|inhibited|,|amezinium|inhibition|. (l_advcl) inhibited_4\VBN\2510337|when|mao-b|was|also (l_nsubjpass) mao-b_1\NN\1740|
T9_T41 CPR:4 amezinium_8\NN\1740|nmol/l (r_nsubj) caused_9\VBD\1617192|inhibited|,|amezinium|inhibition|. (l_dobj) inhibition_12\NN\1068773|%|deamination (l_nmod) deamination_15\NN\13446390|of|the|noradrenaline|mao-a|lungs (l_nmod) mao-a_19\NN\1740|by
T11_T42 NONE 3h-noradrenaline_9\NN\1740|with|nmol/l (r_nmod) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited
T11_T43 NONE 3h-noradrenaline_9\NN\1740|with|nmol/l (r_nmod) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited (l_parataxis) inhibited_26\VBD\2510337|comt|) (l_nsubj) comt_20\NN\1740|(|,|uptake1|and|transport
T11_T44 NONE 3h-noradrenaline_9\NN\1740|with|nmol/l (r_nmod) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited (l_parataxis) inhibited_26\VBD\2510337|comt|) (l_nsubj) comt_20\NN\1740|(|,|uptake1|and|transport (l_appos) uptake1_22\NN\1740|
T12_T42 NONE amezinium_31\NN\1740|nmol/l (r_nsubj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited
T12_T43 NONE amezinium_31\NN\1740|nmol/l (r_nsubj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited (l_parataxis) inhibited_26\VBD\2510337|comt|) (l_nsubj) comt_20\NN\1740|(|,|uptake1|and|transport
T12_T44 NONE amezinium_31\NN\1740|nmol/l (r_nsubj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited (l_parataxis) inhibited_26\VBD\2510337|comt|) (l_nsubj) comt_20\NN\1740|(|,|uptake1|and|transport (l_appos) uptake1_22\NN\1740|
T13_T42 NONE amezinium_38\NN\1740|nmol/l (r_nsubj) caused_39\VBD\1617192|amezinium|inhibition (r_conj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited
T13_T43 NONE amezinium_38\NN\1740|nmol/l (r_nsubj) caused_39\VBD\1617192|amezinium|inhibition (r_conj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited (l_parataxis) inhibited_26\VBD\2510337|comt|) (l_nsubj) comt_20\NN\1740|(|,|uptake1|and|transport
T13_T44 NONE amezinium_38\NN\1740|nmol/l (r_nsubj) caused_39\VBD\1617192|amezinium|inhibition (r_conj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited (l_parataxis) inhibited_26\VBD\2510337|comt|) (l_nsubj) comt_20\NN\1740|(|,|uptake1|and|transport (l_appos) uptake1_22\NN\1740|
T14_T42 NONE noradrenaline_47\NN\14807929|of (r_nmod) deamination_45\NN\13446390|of|noradrenaline (r_nmod) inhibition_43\NN\1068773|%|deamination (r_dobj) caused_39\VBD\1617192|amezinium|inhibition (r_conj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited
T14_T43 NONE noradrenaline_47\NN\14807929|of (r_nmod) deamination_45\NN\13446390|of|noradrenaline (r_nmod) inhibition_43\NN\1068773|%|deamination (r_dobj) caused_39\VBD\1617192|amezinium|inhibition (r_conj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited (l_parataxis) inhibited_26\VBD\2510337|comt|) (l_nsubj) comt_20\NN\1740|(|,|uptake1|and|transport
T14_T44 NONE noradrenaline_47\NN\14807929|of (r_nmod) deamination_45\NN\13446390|of|noradrenaline (r_nmod) inhibition_43\NN\1068773|%|deamination (r_dobj) caused_39\VBD\1617192|amezinium|inhibition (r_conj) had_32\VBD\2108377|contrast|,|hearts|,|amezinium|effect|and|caused|. (l_nmod) hearts_4\NNS\496167|in|perfused (l_acl) perfused_5\VBN\454868|3h-noradrenaline|conditions (l_nmod) conditions_11\NNS\14512817|under|accumulated (l_acl:relcl) accumulated_16\VBN\2281093|where|amine|was|uptake2 (l_nmod) uptake2_18\NN\1740|by|inhibited (l_parataxis) inhibited_26\VBD\2510337|comt|) (l_nsubj) comt_20\NN\1740|(|,|uptake1|and|transport (l_appos) uptake1_22\NN\1740|
T15_T45 CPR:4 amezinium_12\NN\1740| (r_nsubj) potent_18\JJ\1740|that|amezinium|is|times|more|and|potent (l_conj) potent_26\JJ\1740|debrisoquine|is|times|more|inhibition|homogenates (l_nmod) inhibition_29\NN\1068773|for|mao|lungs (l_compound) mao_28\NN\14732946|
T15_T46 CPR:9 amezinium_12\NN\1740| (r_nsubj) potent_18\JJ\1740|that|amezinium|is|times|more|and|potent (r_ccomp) show_10\VBP\2137132|potent (r_advcl) considered_3\VBN\689344|results|when|reports|show|,|and|transport|. (l_conj) transport_50\NN\3575240|reason|is|and|accumulation|drugs|cells|uptake1 (l_nmod) uptake1_62\NN\1740|by
T16_T45 CPR:4 debrisoquine_20\NN\1740| (r_nsubj) potent_26\JJ\1740|debrisoquine|is|times|more|inhibition|homogenates (l_nmod) inhibition_29\NN\1068773|for|mao|lungs (l_compound) mao_28\NN\14732946|
T16_T46 CPR:9 debrisoquine_20\NN\1740| (r_nsubj) potent_26\JJ\1740|debrisoquine|is|times|more|inhibition|homogenates (r_conj) potent_18\JJ\1740|that|amezinium|is|times|more|and|potent (r_ccomp) show_10\VBP\2137132|potent (r_advcl) considered_3\VBN\689344|results|when|reports|show|,|and|transport|. (l_conj) transport_50\NN\3575240|reason|is|and|accumulation|drugs|cells|uptake1 (l_nmod) uptake1_62\NN\1740|by
T17_T47 CPR:4 amezinium_0\NN\1740| (r_nsubj) potent_4\JJ\1740|amezinium|is|less|inhibitor|cells|. (l_nmod) inhibitor_8\NN\20090|as|a|mao (l_compound) mao_7\NN\14732946|
T17_T48 CPR:9 amezinium_0\NN\1740| (r_nsubj) potent_4\JJ\1740|amezinium|is|less|inhibitor|cells|. (l_nmod) cells_10\NNS\3080309|in|transporter|,|cells (l_nmod) transporter_14\NN\4490091|with|the|uptake2
T18_T49 CPR:4 amezinium_7\NN\1740| (r_nsubj) selective_10\JJ\1740|that|amezinium|is|highly|mao-a. (l_nmod) mao-a._12\NN\1740|for
11246504
T11_T17 NONE nicotinamide_7\NN\1740| (r_compound) cofactors_8\NNS\14818238|nicotinamide (r_conj) 4a_2\NN\1740|,|enzymes|and|cofactors
T2_T14 NONE acid_8\NN\14818238| (r_compound) activity_10\NN\30358|of|microsomal|lauric|acid|hydroxylase|and|activity (l_compound) hydroxylase_9\NN\1740|
T10_T15 NONE acid_45\NN\14818238| (r_compound) identity_47\NN\4617562|amino|acid|sequence|cyp4a11 (r_dobj) deduced_43\VBD\634472|identity (r_conj) led_23\VBD\1752884|transcription|cloning|and|deduced|. (l_nsubj) transcription_1\NN\6349220|reverse|mrna|,|followed (l_acl) followed_7\VBN\1835496|reaction (l_nmod) reaction_11\NN\13446390|by|polymerase|chain|using (l_acl) using_12\VBG\1156834|primers (l_dobj) primers_13\NNS\6414372|areas (l_nmod) areas_18\NNS\8630985|based|on|conserved|family (l_nmod) family_22\NN\8189659|in|the|cyp4a (l_compound) cyp4a_21\NN\1740|
T10_T16 NONE acid_45\NN\14818238| (r_compound) identity_47\NN\4617562|amino|acid|sequence|cyp4a11 (l_nmod) cyp4a11_50\NN\1740|to|human
T9_T15 NONE nucleotide_41\NN\14850483|with|% (r_nmod) clone_36\NN\10027246|of|a|partial|,|cdna|nucleotide (r_nmod) cloning_26\NN\638080|to|the|clone (r_nmod) led_23\VBD\1752884|transcription|cloning|and|deduced|. (l_nsubj) transcription_1\NN\6349220|reverse|mrna|,|followed (l_acl) followed_7\VBN\1835496|reaction (l_nmod) reaction_11\NN\13446390|by|polymerase|chain|using (l_acl) using_12\VBG\1156834|primers (l_dobj) primers_13\NNS\6414372|areas (l_nmod) areas_18\NNS\8630985|based|on|conserved|family (l_nmod) family_22\NN\8189659|in|the|cyp4a (l_compound) cyp4a_21\NN\1740|
T9_T16 NONE nucleotide_41\NN\14850483|with|% (r_nmod) clone_36\NN\10027246|of|a|partial|,|cdna|nucleotide (r_nmod) cloning_26\NN\638080|to|the|clone (r_nmod) led_23\VBD\1752884|transcription|cloning|and|deduced|. (l_conj) deduced_43\VBD\634472|identity (l_dobj) identity_47\NN\4617562|amino|acid|sequence|cyp4a11 (l_nmod) cyp4a11_50\NN\1740|to|human
18045203
T7_T15 NONE oxybutynin_8\NN\1740|and|n-desethyloxybutynin (r_compound) enantiomers_11\NNS\14818238|of|oxybutynin (r_nmod) preparation_1\NN\407535|the|and|profiling|enantiomers|. (l_conj) profiling_6\NN\6885083|human|receptor (l_compound) receptor_5\NN\5225602|muscarinic
T8_T15 NONE n-desethyloxybutynin_10\NN\1740| (r_conj) oxybutynin_8\NN\1740|and|n-desethyloxybutynin (r_compound) enantiomers_11\NNS\14818238|of|oxybutynin (r_nmod) preparation_1\NN\407535|the|and|profiling|enantiomers|. (l_conj) profiling_6\NN\6885083|human|receptor (l_compound) receptor_5\NN\5225602|muscarinic
T1_T10 CPR:6 oxybutynin_0\NN\1740|1 (r_nsubj) antagonist_9\NN\7846|oxybutynin|is|a|non-selective|muscarinic|receptor|used|. (l_compound) receptor_8\NN\5225602|
T4_T9 NONE chloride_16\NN\14818238|n-ct(3)-scopolamine|(3)h-nms (r_compound) binding_20\NN\4688246|chloride|receptors (l_nmod) receptors_28\NNS\5225602|on|human|cloned|muscarinic|m1|-|5
T5_T9 NONE (3)h-nms_18\NN\1740|(|) (r_appos) chloride_16\NN\14818238|n-ct(3)-scopolamine|(3)h-nms (r_compound) binding_20\NN\4688246|chloride|receptors (l_nmod) receptors_28\NNS\5225602|on|human|cloned|muscarinic|m1|-|5
T6_T11 NONE (3)h-nms_6\NN\1740| (r_compound) binding_7\NN\4688246|(3)h-nms (r_dobj) displaced_5\VBD\1850315|compounds|potently|binding|receptors|,|but|potent|. (l_nmod) receptors_14\NNS\5225602|at|m1
T6_T12 NONE (3)h-nms_6\NN\1740| (r_compound) binding_7\NN\4688246|(3)h-nms (r_dobj) displaced_5\VBD\1850315|compounds|potently|binding|receptors|,|but|potent|. (l_conj) potent_19\JJ\1740|were|less|subtypes (l_nmod) subtypes_25\NNS\1740|at|the|m2 (l_compound) m2_22\NN\13357178|and|m5
T6_T13 NONE (3)h-nms_6\NN\1740| (r_compound) binding_7\NN\4688246|(3)h-nms (r_dobj) displaced_5\VBD\1850315|compounds|potently|binding|receptors|,|but|potent|. (l_conj) potent_19\JJ\1740|were|less|subtypes (l_nmod) subtypes_25\NNS\1740|at|the|m2 (l_compound) m2_22\NN\13357178|and|m5 (l_conj) m5_24\NN\1740|
23631440
T9_T21 CPR:4 3-mercaptopyrrolidine_6\NN\1740| (r_compound) core_7\NN\7996689|on|the|3-mercaptopyrrolidine (r_nmod) based_3\VBN\2694933|core (r_prep) inhibitors_2\NNS\20090|matrix|metalloproteinase|based|. (l_compound) metalloproteinase_1\NN\1740|
T1_T11 CPR:4 mercaptosulfide_4\NN\1740|of|pyrrolidine|,|arylsulfonamide|,|and|inhibitors (l_conj) inhibitors_14\NNS\20090|pyrrolidine|matrix|metalloproteinase|mmpis (l_compound) metalloproteinase_13\NN\1740|
T3_T11 CPR:4 arylsulfonamide_7\NN\1740|2-mercaptocyclopentane (r_conj) mercaptosulfide_4\NN\1740|of|pyrrolidine|,|arylsulfonamide|,|and|inhibitors (l_conj) inhibitors_14\NNS\20090|pyrrolidine|matrix|metalloproteinase|mmpis (l_compound) metalloproteinase_13\NN\1740|
T7_T11 CPR:4 pyrrolidine_11\NN\1740|3-mercapto-4-arylsulfonamido (r_compound) inhibitors_14\NNS\20090|pyrrolidine|matrix|metalloproteinase|mmpis (l_compound) metalloproteinase_13\NN\1740|
T2_T12 CPR:4 hydroxamates_9\NNS\1740|(|e.g.|,|) (r_appos) mmpis_5\NNS\6474603|over|other|hydroxamates (r_nmod) properties_2\NNS\32613|unique|mmpis (r_dobj) exhibiting_0\VBG\2632167|properties (r_advcl) capable_17\JJ\1740|exhibiting|,|compounds|are|modulating|. (l_advcl) modulating_19\VBG\1724459|of|activities (l_dobj) activities_20\NNS\30358|mmps|,|mmp-2 (l_nmod) mmps_23\NNS\1740|of|several|range
T2_T13 CPR:4 hydroxamates_9\NNS\1740|(|e.g.|,|) (r_appos) mmpis_5\NNS\6474603|over|other|hydroxamates (r_nmod) properties_2\NNS\32613|unique|mmpis (r_dobj) exhibiting_0\VBG\2632167|properties (r_advcl) capable_17\JJ\1740|exhibiting|,|compounds|are|modulating|. (l_advcl) modulating_19\VBG\1724459|of|activities (l_dobj) activities_20\NNS\30358|mmps|,|mmp-2 (l_nmod) mmp-2_31\NN\1740|including|(|nm|)|,|mmp-13|,|and|mmp-14
T2_T14 CPR:4 hydroxamates_9\NNS\1740|(|e.g.|,|) (r_appos) mmpis_5\NNS\6474603|over|other|hydroxamates (r_nmod) properties_2\NNS\32613|unique|mmpis (r_dobj) exhibiting_0\VBG\2632167|properties (r_advcl) capable_17\JJ\1740|exhibiting|,|compounds|are|modulating|. (l_advcl) modulating_19\VBG\1724459|of|activities (l_dobj) activities_20\NNS\30358|mmps|,|mmp-2 (l_nmod) mmp-2_31\NN\1740|including|(|nm|)|,|mmp-13|,|and|mmp-14 (l_conj) mmp-13_39\NN\1740|nm
T2_T15 CPR:4 hydroxamates_9\NNS\1740|(|e.g.|,|) (r_appos) mmpis_5\NNS\6474603|over|other|hydroxamates (r_nmod) properties_2\NNS\32613|unique|mmpis (r_dobj) exhibiting_0\VBG\2632167|properties (r_advcl) capable_17\JJ\1740|exhibiting|,|compounds|are|modulating|. (l_advcl) modulating_19\VBG\1724459|of|activities (l_dobj) activities_20\NNS\30358|mmps|,|mmp-2 (l_nmod) mmp-2_31\NN\1740|including|(|nm|)|,|mmp-13|,|and|mmp-14 (l_conj) mmp-14_48\NN\1740|nm
T4_T20 NONE mercaptosulfide_5\NN\1740| (r_compound) functionality_6\NN\5151088|with|the|mercaptosulfide|attached (r_nmod) work_2\NN\407535|our|previous|functionality (r_nsubj) demonstrated_14\VBD\2137132|work|optimal|. (l_ccomp) optimal_20\JJ\1740|that|stereochemistry|was|all (l_nmod) all_22\DT\1740|for|mmps (l_nmod) mmps_25\NNS\1740|of|the|tested
T5_T20 NONE cyclopentane_10\NN\1740|both|and|pyrrolidine (r_compound) frameworks_13\NNS\5888929|to|cyclopentane (r_nmod) attached_7\VBN\1354673|frameworks (r_acl) functionality_6\NN\5151088|with|the|mercaptosulfide|attached (r_nmod) work_2\NN\407535|our|previous|functionality (r_nsubj) demonstrated_14\VBD\2137132|work|optimal|. (l_ccomp) optimal_20\JJ\1740|that|stereochemistry|was|all (l_nmod) all_22\DT\1740|for|mmps (l_nmod) mmps_25\NNS\1740|of|the|tested
T6_T20 NONE pyrrolidine_12\NN\1740| (r_conj) cyclopentane_10\NN\1740|both|and|pyrrolidine (r_compound) frameworks_13\NNS\5888929|to|cyclopentane (r_nmod) attached_7\VBN\1354673|frameworks (r_acl) functionality_6\NN\5151088|with|the|mercaptosulfide|attached (r_nmod) work_2\NN\407535|our|previous|functionality (r_nsubj) demonstrated_14\VBD\2137132|work|optimal|. (l_ccomp) optimal_20\JJ\1740|that|stereochemistry|was|all (l_nmod) all_22\DT\1740|for|mmps (l_nmod) mmps_25\NNS\1740|of|the|tested
23164615
T8_T15 NONE glutamate_13\NN\15010703| (r_compound) compounds_16\NNS\5869584|by|orthosteric|allosteric|metabotropic|glutamate|receptor|8 (l_nummod) 8_15\CD\13741022|
T1_T10 NONE az12216052_27\NN\1740|az|and (r_appos) modulator_23\NN\1740|a|identified|positive|allosteric|mglur8|,|az12216052|(s)-3,4-dicarboxyphenylglycine (l_nmod) mglur8_25\NN\1740|of
T1_T11 NONE az12216052_27\NN\1740|az|and (r_appos) modulator_23\NN\1740|a|identified|positive|allosteric|mglur8|,|az12216052|(s)-3,4-dicarboxyphenylglycine (l_conj) (s)-3,4-dicarboxyphenylglycine_36\NN\1740|the|mglur8-specific|agonist|dcpg (l_amod) mglur8-specific_33\JJ\1740|
T1_T12 NONE az12216052_27\NN\1740|az|and (r_appos) modulator_23\NN\1740|a|identified|positive|allosteric|mglur8|,|az12216052|(s)-3,4-dicarboxyphenylglycine (r_dobj) used_17\VBD\1156834|investigate|we|modulator (l_advcl) investigate_1\VB\644583|to|role|, (l_dobj) role_3\NN\719494|the|mglur8|modulating (l_nmod) mglur8_5\NN\1740|of
T2_T10 NONE (s)-3,4-dicarboxyphenylglycine_36\NN\1740|the|mglur8-specific|agonist|dcpg (r_conj) modulator_23\NN\1740|a|identified|positive|allosteric|mglur8|,|az12216052|(s)-3,4-dicarboxyphenylglycine (l_nmod) mglur8_25\NN\1740|of
T2_T11 CPR:5 (s)-3,4-dicarboxyphenylglycine_36\NN\1740|the|mglur8-specific|agonist|dcpg (l_amod) mglur8-specific_33\JJ\1740|
T2_T12 NONE (s)-3,4-dicarboxyphenylglycine_36\NN\1740|the|mglur8-specific|agonist|dcpg (r_conj) modulator_23\NN\1740|a|identified|positive|allosteric|mglur8|,|az12216052|(s)-3,4-dicarboxyphenylglycine (r_dobj) used_17\VBD\1156834|investigate|we|modulator (l_advcl) investigate_1\VB\644583|to|role|, (l_dobj) role_3\NN\719494|the|mglur8|modulating (l_nmod) mglur8_5\NN\1740|of
T3_T10 NONE dcpg_38\NN\1740|(|) (r_appos) (s)-3,4-dicarboxyphenylglycine_36\NN\1740|the|mglur8-specific|agonist|dcpg (r_conj) modulator_23\NN\1740|a|identified|positive|allosteric|mglur8|,|az12216052|(s)-3,4-dicarboxyphenylglycine (l_nmod) mglur8_25\NN\1740|of
T3_T11 CPR:5 dcpg_38\NN\1740|(|) (r_appos) (s)-3,4-dicarboxyphenylglycine_36\NN\1740|the|mglur8-specific|agonist|dcpg (l_amod) mglur8-specific_33\JJ\1740|
T3_T12 NONE dcpg_38\NN\1740|(|) (r_appos) (s)-3,4-dicarboxyphenylglycine_36\NN\1740|the|mglur8-specific|agonist|dcpg (r_conj) modulator_23\NN\1740|a|identified|positive|allosteric|mglur8|,|az12216052|(s)-3,4-dicarboxyphenylglycine (r_dobj) used_17\VBD\1156834|investigate|we|modulator (l_advcl) investigate_1\VB\644583|to|role|, (l_dobj) role_3\NN\719494|the|mglur8|modulating (l_nmod) mglur8_5\NN\1740|of
T5_T13 NONE glutamate_22\NN\15010703|by|endogenous (r_nmod) stimulation_19\NN\242808|receptor|glutamate (r_nsubj) stronger_24\JJR\1740|with|stimulation|being|stimulation|and|localized (l_conj) localized_35\JJ\1740|receptors|mainly|being|away|,|immuno-labeled (l_nsubj) receptors_32\NNS\5225602|with|mglur8 (l_compound) mglur8_31\NN\1740|
T5_T14 NONE glutamate_22\NN\15010703|by|endogenous (r_nmod) stimulation_19\NN\242808|receptor|glutamate (r_nsubj) stronger_24\JJR\1740|with|stimulation|being|stimulation|and|localized (l_conj) localized_35\JJ\1740|receptors|mainly|being|away|,|immuno-labeled (l_advmod) immuno-labeled_42\JJ\1740|vglut1 (l_nmod) vglut1_44\NN\1740|with
T6_T13 NONE glutamate_38\NN\15010703| (r_compound) sites_40\NNS\8673395|from|glutamate|release (r_nmod) away_36\RB\1740|sites (r_advmod) localized_35\JJ\1740|receptors|mainly|being|away|,|immuno-labeled (l_nsubj) receptors_32\NNS\5225602|with|mglur8 (l_compound) mglur8_31\NN\1740|
T6_T14 NONE glutamate_38\NN\15010703| (r_compound) sites_40\NNS\8673395|from|glutamate|release (r_nmod) away_36\RB\1740|sites (r_advmod) localized_35\JJ\1740|receptors|mainly|being|away|,|immuno-labeled (l_advmod) immuno-labeled_42\JJ\1740|vglut1 (l_nmod) vglut1_44\NN\1740|with
T7_T9 NONE dcpg_9\NN\1740|to|and|az (r_nmod) sensitivity_2\NN\5651971|the|differential|responses|dcpg (r_nsubj) supports_12\VBZ\2199590|sensitivity|sites|. (l_dobj) sites_14\NNS\8673395|multiple|modulates (l_acl:relcl) modulates_17\VBZ\1724459|where|mglur8|responses (l_nsubj) mglur8_16\NN\1740|
12545144
T13_T15 NONE potassium_12\NN\14625458| (r_compound) channel_13\NN\6251781|potassium (r_compound) opener_14\NN\7325190|background|:|drug|is|the|first|selective|m-current|channel|channels|. (l_nmod) channels_19\NNS\6251781|for|kcnq2/3 (l_compound) kcnq2/3_16\NN\1740|and|kcnq3/5
T13_T16 NONE potassium_12\NN\14625458| (r_compound) channel_13\NN\6251781|potassium (r_compound) opener_14\NN\7325190|background|:|drug|is|the|first|selective|m-current|channel|channels|. (l_nmod) channels_19\NNS\6251781|for|kcnq2/3 (l_compound) kcnq2/3_16\NN\1740|and|kcnq3/5 (l_conj) kcnq3/5_18\NN\1740|
T13_T17 NONE potassium_12\NN\14625458| (r_compound) channel_13\NN\6251781|potassium
T8_T15 CPR:3 retigabine_6\NN\1740| (r_dep) drug_5\NN\14778436|the|novel|antiepileptic|retigabine (r_nsubj) opener_14\NN\7325190|background|:|drug|is|the|first|selective|m-current|channel|channels|. (l_nmod) channels_19\NNS\6251781|for|kcnq2/3 (l_compound) kcnq2/3_16\NN\1740|and|kcnq3/5
T8_T16 CPR:3 retigabine_6\NN\1740| (r_dep) drug_5\NN\14778436|the|novel|antiepileptic|retigabine (r_nsubj) opener_14\NN\7325190|background|:|drug|is|the|first|selective|m-current|channel|channels|. (l_nmod) channels_19\NNS\6251781|for|kcnq2/3 (l_compound) kcnq2/3_16\NN\1740|and|kcnq3/5 (l_conj) kcnq3/5_18\NN\1740|
T8_T17 CPR:3 retigabine_6\NN\1740| (r_dep) drug_5\NN\14778436|the|novel|antiepileptic|retigabine (r_nsubj) opener_14\NN\7325190|background|:|drug|is|the|first|selective|m-current|channel|channels|. (l_compound) channel_13\NN\6251781|potassium
10796070
T10_T18 CPR:3 dexamethasone_5\NN\2721538|by (r_nmod) activated_3\VBN\1641914|receptors|were|dexamethasone|assessed|. (l_nsubjpass) receptors_1\NNS\5225602|glucocorticoid
T2_T11 CPR:6 ru-486_4\NN\1740|the|receptor|antagonist|mifepristone (l_compound) receptor_2\NN\5225602|glucocorticoid
T2_T12 NONE ru-486_4\NN\1740|the|receptor|antagonist|mifepristone (r_nsubj) counteracted_9\VBD\2367363|ru-486|significantly|effect|,|indicating|. (l_dobj) effect_11\NN\34213|the|dexamethasone|activation (l_nmod) activation_17\NN\13561719|on|receptor (l_compound) receptor_16\NN\5225602|glucocorticoid
T2_T13 NONE ru-486_4\NN\1740|the|receptor|antagonist|mifepristone (r_nsubj) counteracted_9\VBD\2367363|ru-486|significantly|effect|,|indicating|. (l_advcl) indicating_19\VBG\952524|specific (l_ccomp) specific_25\JJ\1740|that|effect|is|and|mediated (l_conj) mediated_28\VBN\761713|is|receptor (l_nmod) receptor_32\NN\5225602|through|the|glucocorticoid
T3_T11 CPR:6 mifepristone_6\NN\2667906|(|) (r_appos) ru-486_4\NN\1740|the|receptor|antagonist|mifepristone (l_compound) receptor_2\NN\5225602|glucocorticoid
T3_T12 NONE mifepristone_6\NN\2667906|(|) (r_appos) ru-486_4\NN\1740|the|receptor|antagonist|mifepristone (r_nsubj) counteracted_9\VBD\2367363|ru-486|significantly|effect|,|indicating|. (l_dobj) effect_11\NN\34213|the|dexamethasone|activation (l_nmod) activation_17\NN\13561719|on|receptor (l_compound) receptor_16\NN\5225602|glucocorticoid
T3_T13 NONE mifepristone_6\NN\2667906|(|) (r_appos) ru-486_4\NN\1740|the|receptor|antagonist|mifepristone (r_nsubj) counteracted_9\VBD\2367363|ru-486|significantly|effect|,|indicating|. (l_advcl) indicating_19\VBG\952524|specific (l_ccomp) specific_25\JJ\1740|that|effect|is|and|mediated (l_conj) mediated_28\VBN\761713|is|receptor (l_nmod) receptor_32\NN\5225602|through|the|glucocorticoid
T4_T11 NONE dexamethasone_13\NN\2721538|of (r_nmod) effect_11\NN\34213|the|dexamethasone|activation (r_dobj) counteracted_9\VBD\2367363|ru-486|significantly|effect|,|indicating|. (l_nsubj) ru-486_4\NN\1740|the|receptor|antagonist|mifepristone (l_compound) receptor_2\NN\5225602|glucocorticoid
T4_T12 NONE dexamethasone_13\NN\2721538|of (r_nmod) effect_11\NN\34213|the|dexamethasone|activation (l_nmod) activation_17\NN\13561719|on|receptor (l_compound) receptor_16\NN\5225602|glucocorticoid
T4_T13 NONE dexamethasone_13\NN\2721538|of (r_nmod) effect_11\NN\34213|the|dexamethasone|activation (r_dobj) counteracted_9\VBD\2367363|ru-486|significantly|effect|,|indicating|. (l_advcl) indicating_19\VBG\952524|specific (l_ccomp) specific_25\JJ\1740|that|effect|is|and|mediated (l_conj) mediated_28\VBN\761713|is|receptor (l_nmod) receptor_32\NN\5225602|through|the|glucocorticoid
T5_T11 NONE dexamethasone_22\NN\2721538| (r_compound) effect_23\NN\34213|the|dexamethasone (r_nsubj) specific_25\JJ\1740|that|effect|is|and|mediated (r_ccomp) indicating_19\VBG\952524|specific (r_advcl) counteracted_9\VBD\2367363|ru-486|significantly|effect|,|indicating|. (l_nsubj) ru-486_4\NN\1740|the|receptor|antagonist|mifepristone (l_compound) receptor_2\NN\5225602|glucocorticoid
T5_T12 NONE dexamethasone_22\NN\2721538| (r_compound) effect_23\NN\34213|the|dexamethasone (r_nsubj) specific_25\JJ\1740|that|effect|is|and|mediated (r_ccomp) indicating_19\VBG\952524|specific (r_advcl) counteracted_9\VBD\2367363|ru-486|significantly|effect|,|indicating|. (l_dobj) effect_11\NN\34213|the|dexamethasone|activation (l_nmod) activation_17\NN\13561719|on|receptor (l_compound) receptor_16\NN\5225602|glucocorticoid
T5_T13 NONE dexamethasone_22\NN\2721538| (r_compound) effect_23\NN\34213|the|dexamethasone (r_nsubj) specific_25\JJ\1740|that|effect|is|and|mediated (l_conj) mediated_28\VBN\761713|is|receptor (l_nmod) receptor_32\NN\5225602|through|the|glucocorticoid
T7_T15 NONE steroids_26\NNS\14727670|of|inhaled (r_nmod) effects_23\NNS\13245626|for|the|anti-inflammatory|steroids (r_nmod) target_19\NN\7258332|that|epithelium|may|be|a|effects (r_ccomp) indicates_11\VBZ\952524|target (r_conj) confers_5\VBZ\813978|presence|responsiveness|and|indicates|. (l_nsubj) presence_1\NN\13954253|the|receptors (l_nmod) receptors_4\NNS\5225602|of|glucocorticoid
22982218
T7_T22 NONE pj34_3\NN\1740|the|parp|inhibitor (r_nsubj) modifies_4\VBZ\109660|pj34|proliferation|lines|. (l_dobj) proliferation_5\NN\13489037|,|expression|and|marks (l_conj) expression_8\NN\4679549|nis (l_compound) nis_7\NNS\14625458|
T7_T23 CPR:4 pj34_3\NN\1740|the|parp|inhibitor (l_compound) parp_1\NN\1740|
T1_T13 NONE pj34_29\NN\1740|of|the|parp|inhibitor (r_nmod) effect_24\NN\34213|the|pj34|properties (r_nsubjpass) investigated_39\VBN\644583|supposed|,|study|effect|was|. (l_advcl) supposed_3\VBN\927049|since|parp-1|is|part (l_nsubjpass) parp-1_1\NN\1740|
T1_T15 NONE pj34_29\NN\1740|of|the|parp|inhibitor (r_nmod) effect_24\NN\34213|the|pj34|properties (r_nsubjpass) investigated_39\VBN\644583|supposed|,|study|effect|was|. (l_advcl) supposed_3\VBN\927049|since|parp-1|is|part (l_xcomp) part_6\NN\31921|to|be|repressor (l_nmod) repressor_10\NN\9190918|of|a|multimeric|expression (l_nmod) expression_18\NN\4679549|of|symporter (l_compound) symporter_14\NN\1740|sodium|iodide|nis
T1_T19 NONE pj34_29\NN\1740|of|the|parp|inhibitor (r_nmod) effect_24\NN\34213|the|pj34|properties (r_nsubjpass) investigated_39\VBN\644583|supposed|,|study|effect|was|. (l_advcl) supposed_3\VBN\927049|since|parp-1|is|part (l_xcomp) part_6\NN\31921|to|be|repressor (l_nmod) repressor_10\NN\9190918|of|a|multimeric|expression (l_nmod) expression_18\NN\4679549|of|symporter (l_compound) symporter_14\NN\1740|sodium|iodide|nis (l_appos) nis_16\NN\14625458|(|)
T1_T9 CPR:4 pj34_29\NN\1740|of|the|parp|inhibitor (l_compound) parp_27\NN\1740|
T6_T13 NONE iodide_13\NN\14904359| (r_compound) symporter_14\NN\1740|sodium|iodide|nis (r_compound) expression_18\NN\4679549|of|symporter (r_nmod) repressor_10\NN\9190918|of|a|multimeric|expression (r_nmod) part_6\NN\31921|to|be|repressor (r_xcomp) supposed_3\VBN\927049|since|parp-1|is|part (l_nsubjpass) parp-1_1\NN\1740|
T6_T15 NONE iodide_13\NN\14904359| (r_compound) symporter_14\NN\1740|sodium|iodide|nis
T6_T19 NONE iodide_13\NN\14904359| (r_compound) symporter_14\NN\1740|sodium|iodide|nis (l_appos) nis_16\NN\14625458|(|)
T6_T9 NONE iodide_13\NN\14904359| (r_compound) symporter_14\NN\1740|sodium|iodide|nis (r_compound) expression_18\NN\4679549|of|symporter (r_nmod) repressor_10\NN\9190918|of|a|multimeric|expression (r_nmod) part_6\NN\31921|to|be|repressor (r_xcomp) supposed_3\VBN\927049|since|parp-1|is|part (r_advcl) investigated_39\VBN\644583|supposed|,|study|effect|was|. (l_nsubjpass) effect_24\NN\34213|the|pj34|properties (l_nmod) pj34_29\NN\1740|of|the|parp|inhibitor (l_compound) parp_27\NN\1740|
T2_T10 CPR:3 pj34_10\NN\1740| (r_appos) tpc1_1\NNP\1740|in|,|bcpap|,|fro|,|lines|pj34 (r_nmod) induced_11\VBD\1627355|tpc1|increase|. (l_dobj) increase_14\NN\13576355|a|strong|levels (l_nmod) levels_18\NNS\4916342|in|mrna (l_compound) mrna_17\NN\14832193|nis (l_compound) nis_16\NN\14625458|
T4_T11 CPR:3 pj34_12\NN\1740|with (r_nmod) treatment_10\NN\654885|pj34 (r_nsubj) increased_13\VBD\169651|accordingly|,|experiments|,|treatment|activity|affecting|. (l_dobj) activity_16\NN\30358|nis|promoter (l_compound) promoter_15\NN\9773962|
T4_T12 NONE pj34_12\NN\1740|with (r_nmod) treatment_10\NN\654885|pj34 (r_nsubj) increased_13\VBD\169651|accordingly|,|experiments|,|treatment|activity|affecting|. (l_advcl) affecting_18\VBG\126264|without|binding (l_dobj) binding_20\NN\4688246|parp-1|sequence (l_compound) parp-1_19\NN\1740|
T5_T14 NONE pj34_10\NN\1740| (r_compound) treatment_11\NN\654885|after|pj34|line (r_nmod) status_5\NN\24720|the|epigenetic|promoter|treatment (l_nmod) promoter_8\NN\9773962|of|nis
T5_T16 CPR:3 pj34_10\NN\1740| (r_compound) treatment_11\NN\654885|after|pj34|line (r_nmod) status_5\NN\24720|the|epigenetic|promoter|treatment (r_dobj) investigated_2\VBD\644583|we|also|status|:|observed (l_parataxis) observed_35\VBD\2163746|addition|,|surprisingly|we|also|increase|. (l_nmod) addition_18\NN\3081021|in|increase (l_nmod) increase_21\NN\13576355|to|an|marks (l_nmod) marks_26\NNS\5736149|of|histone|modification|activation|h3k9k14ac
T5_T17 CPR:3 pj34_10\NN\1740| (r_compound) treatment_11\NN\654885|after|pj34|line (r_nmod) status_5\NN\24720|the|epigenetic|promoter|treatment (r_dobj) investigated_2\VBD\644583|we|also|status|:|observed (l_parataxis) observed_35\VBD\2163746|addition|,|surprisingly|we|also|increase|. (l_nmod) addition_18\NN\3081021|in|increase (l_nmod) increase_21\NN\13576355|to|an|marks (l_nmod) marks_26\NNS\5736149|of|histone|modification|activation|h3k9k14ac (l_dep) h3k9k14ac_28\NN\1740|(|,|h3k4me3|)
T5_T18 CPR:3 pj34_10\NN\1740| (r_compound) treatment_11\NN\654885|after|pj34|line (r_nmod) status_5\NN\24720|the|epigenetic|promoter|treatment (r_dobj) investigated_2\VBD\644583|we|also|status|:|observed (l_parataxis) observed_35\VBD\2163746|addition|,|surprisingly|we|also|increase|. (l_nmod) addition_18\NN\3081021|in|increase (l_nmod) increase_21\NN\13576355|to|an|marks (l_nmod) marks_26\NNS\5736149|of|histone|modification|activation|h3k9k14ac (l_dep) h3k9k14ac_28\NN\1740|(|,|h3k4me3|) (l_appos) h3k4me3_30\NN\1740|
23541399
T1_T5 NONE androgen_2\NN\14745635| (r_compound) deprivation_3\NN\14493145|the|androgen|pre-puberty|up (r_nsubj) alter_11\VB\126264|although|deprivation|did|not|organization|puberty (r_advcl) impaired_29\VBD\258857|alter|,|treatment|expression|. (l_dobj) expression_31\NN\4679549|the|proteins|tissue (l_nmod) tissue_37\NN\5220461|in|epididymal|puberty (l_nmod) puberty_39\NN\15144371|at|and|adulthood|receptor (l_dep) receptor_44\NN\5225602|(|androgen|,|calmodulin|,|rab11a|)
T1_T6 NONE androgen_2\NN\14745635| (r_compound) deprivation_3\NN\14493145|the|androgen|pre-puberty|up (r_nsubj) alter_11\VB\126264|although|deprivation|did|not|organization|puberty (r_advcl) impaired_29\VBD\258857|alter|,|treatment|expression|. (l_dobj) expression_31\NN\4679549|the|proteins|tissue (l_nmod) tissue_37\NN\5220461|in|epididymal|puberty (l_nmod) puberty_39\NN\15144371|at|and|adulthood|receptor (l_dep) receptor_44\NN\5225602|(|androgen|,|calmodulin|,|rab11a|) (l_appos) calmodulin_46\NN\1740|
T1_T7 NONE androgen_2\NN\14745635| (r_compound) deprivation_3\NN\14493145|the|androgen|pre-puberty|up (r_nsubj) alter_11\VB\126264|although|deprivation|did|not|organization|puberty (r_advcl) impaired_29\VBD\258857|alter|,|treatment|expression|. (l_dobj) expression_31\NN\4679549|the|proteins|tissue (l_nmod) tissue_37\NN\5220461|in|epididymal|puberty (l_nmod) puberty_39\NN\15144371|at|and|adulthood|receptor (l_dep) receptor_44\NN\5225602|(|androgen|,|calmodulin|,|rab11a|) (l_appos) rab11a_48\NN\1740|
T3_T5 NONE androgen_43\NN\14745635| (r_compound) receptor_44\NN\5225602|(|androgen|,|calmodulin|,|rab11a|)
T3_T6 NONE androgen_43\NN\14745635| (r_compound) receptor_44\NN\5225602|(|androgen|,|calmodulin|,|rab11a|) (l_appos) calmodulin_46\NN\1740|
T3_T7 NONE androgen_43\NN\14745635| (r_compound) receptor_44\NN\5225602|(|androgen|,|calmodulin|,|rab11a|) (l_appos) rab11a_48\NN\1740|
23504356
T1_T3 NONE fenfluramine_3\NN\1740|of|,|secretin|,|opiates (l_conj) secretin_5\NN\5408684|
T2_T4 NONE oxytocin_11\NN\5407119|
23181488
17980251
T27_T30 CPR:6 clopidogrel_16\NN\1740|with|patients (r_nmod) compared_14\VBN\644583|inhibition|clopidogrel|. (l_nsubj) inhibition_0\NN\1068773|aggregation|azd6140|, (l_nmod) azd6140_5\NN\1740|by|,|antagonist (l_appos) antagonist_12\NN\7846|a|reversible|oral|receptor (l_compound) receptor_11\NN\5225602|p2y12 (l_compound) p2y12_10\NN\1740|
T28_T30 CPR:6 azd6140_5\NN\1740|by|,|antagonist (l_appos) antagonist_12\NN\7846|a|reversible|oral|receptor (l_compound) receptor_11\NN\5225602|p2y12 (l_compound) p2y12_10\NN\1740|
T20_T29 CPR:6 azd6140_0\NN\1740| (r_nsubj) antagonist_8\NN\7846|azd6140|is|a|reversible|oral|p2y(12|)|receptor|studied|. (l_punct) )_6\-RRB-\1740|
T21_T29 CPR:6 clopidogrel_19\NN\1740|with (r_nmod) comparison_17\NN\635850|in|clopidogrel (r_nmod) studied_12\VBN\630380|that|has|been|patients|comparison|study (r_acl:relcl) antagonist_8\NN\7846|azd6140|is|a|reversible|oral|p2y(12|)|receptor|studied|. (l_punct) )_6\-RRB-\1740|
23319419
T18_T39 CPR:3 ica-105574_0\CD\1740| (r_nsubj) interacts_1\VBZ\2367363|ica-105574|site|elicit|. (l_xcomp) elicit_8\VB\1617192|to|effects|gating (l_nmod) gating_13\NN\1740|on|inactivation|channels (l_nmod) channels_19\NNS\6251781|eag|potassium (l_compound) eag_15\NN\1740|of|and|erg
T18_T40 CPR:3 ica-105574_0\CD\1740| (r_nsubj) interacts_1\VBZ\2367363|ica-105574|site|elicit|. (l_xcomp) elicit_8\VB\1617192|to|effects|gating (l_nmod) gating_13\NN\1740|on|inactivation|channels (l_nmod) channels_19\NNS\6251781|eag|potassium (l_compound) eag_15\NN\1740|of|and|erg (l_conj) erg_17\NN\13609507|
T18_T41 CPR:3 ica-105574_0\CD\1740| (r_nsubj) interacts_1\VBZ\2367363|ica-105574|site|elicit|. (l_xcomp) elicit_8\VB\1617192|to|effects|gating (l_nmod) gating_13\NN\1740|on|inactivation|channels (l_nmod) channels_19\NNS\6251781|eag|potassium
T19_T39 NONE potassium_18\NN\14625458| (r_compound) channels_19\NNS\6251781|eag|potassium (l_compound) eag_15\NN\1740|of|and|erg
T19_T40 NONE potassium_18\NN\14625458| (r_compound) channels_19\NNS\6251781|eag|potassium (l_compound) eag_15\NN\1740|of|and|erg (l_conj) erg_17\NN\13609507|
T19_T41 NONE potassium_18\NN\14625458| (r_compound) channels_19\NNS\6251781|eag|potassium
T15_T23 NONE ether-a-go-go-related_9\JJ\1740| (r_amod) channels_16\NNS\6251781|in|ether-a-go-go-related|gene|k(+|) (l_compound) gene_10\NN\8459252|erg (l_appos) erg_12\NN\13609507|(|)
T15_T24 NONE ether-a-go-go-related_9\JJ\1740| (r_amod) channels_16\NNS\6251781|in|ether-a-go-go-related|gene|k(+|)
T15_T38 NONE ether-a-go-go-related_9\JJ\1740| (r_amod) channels_16\NNS\6251781|in|ether-a-go-go-related|gene|k(+|) (l_compound) gene_10\NN\8459252|erg
T1_T23 NONE )_15\-RRB-\1740| (r_punct) channels_16\NNS\6251781|in|ether-a-go-go-related|gene|k(+|) (l_compound) gene_10\NN\8459252|erg (l_appos) erg_12\NN\13609507|(|)
T1_T24 NONE )_15\-RRB-\1740| (r_punct) channels_16\NNS\6251781|in|ether-a-go-go-related|gene|k(+|)
T1_T38 NONE )_15\-RRB-\1740| (r_punct) channels_16\NNS\6251781|in|ether-a-go-go-related|gene|k(+|) (l_compound) gene_10\NN\8459252|erg
T7_T31 NONE ether-a-go-go_6\NN\1740|
T7_T32 NONE ether-a-go-go_6\NN\1740| (r_compound) channels_12\NNS\6251781|of|related|ether-a-go-go|eag|)|k(+|) (l_compound) eag_8\NN\1740|(
T7_T33 NONE ether-a-go-go_6\NN\1740| (r_compound) channels_12\NNS\6251781|of|related|ether-a-go-go|eag|)|k(+|)
T8_T31 NONE )_11\-RRB-\1740| (r_punct) channels_12\NNS\6251781|of|related|ether-a-go-go|eag|)|k(+|) (l_compound) ether-a-go-go_6\NN\1740|
T8_T32 NONE )_11\-RRB-\1740| (r_punct) channels_12\NNS\6251781|of|related|ether-a-go-go|eag|)|k(+|) (l_compound) eag_8\NN\1740|(
T8_T33 NONE )_11\-RRB-\1740| (r_punct) channels_12\NNS\6251781|of|related|ether-a-go-go|eag|)|k(+|)
T12_T34 CPR:3 ica_1\NNP\1740| (r_nsubj) attenuates_3\VBZ\224901|although|ica|greatly|inactivation|shifting (l_dobj) inactivation_5\NN\13518963|erg (l_compound) erg_4\NN\13609507|
T12_T35 CPR:4 ica_1\NNP\1740| (r_nsubj) attenuates_3\VBZ\224901|although|ica|greatly|inactivation|shifting (r_advcl) enhances_17\VBZ\227165|attenuates|,|it|rate|altering|. (l_dobj) rate_19\NN\13815152|the|and|extent|inactivation (l_nmod) inactivation_24\NN\13518963|of|eag (l_compound) eag_23\NN\1740|
T13_T36 NONE ica_10\NN\1740|to (r_nmod) response_8\NN\11410625|the|inverse|functional|ica|channels (l_nmod) channels_15\NNS\6251781|in|eag (l_compound) eag_12\NN\1740|and|erg
T13_T37 NONE ica_10\NN\1740|to (r_nmod) response_8\NN\11410625|the|inverse|functional|ica|channels (l_nmod) channels_15\NNS\6251781|in|eag (l_compound) eag_12\NN\1740|and|erg (l_conj) erg_14\NN\13609507|
T14_T36 NONE ica_21\NN\1740| (r_compound) site_23\NN\8673395|in|ica|binding (r_nmod) differences_19\NNS\4723816|to|site|or|mechanisms (r_nmod) related_17\JJ\1740|whether|response|is|differences (l_nsubj) response_8\NN\11410625|the|inverse|functional|ica|channels (l_nmod) channels_15\NNS\6251781|in|eag (l_compound) eag_12\NN\1740|and|erg
T14_T37 NONE ica_21\NN\1740| (r_compound) site_23\NN\8673395|in|ica|binding (r_nmod) differences_19\NNS\4723816|to|site|or|mechanisms (r_nmod) related_17\JJ\1740|whether|response|is|differences (l_nsubj) response_8\NN\11410625|the|inverse|functional|ica|channels (l_nmod) channels_15\NNS\6251781|in|eag (l_compound) eag_12\NN\1740|and|erg (l_conj) erg_14\NN\13609507|
T17_T20 CPR:5 ica_0\NN\1740| (r_nsubj) agonist_4\NN\9613191|ica|is|a|mixed|channels|. (l_nmod) channels_11\NNS\6251781|eag|inactivate (l_compound) eag_7\NN\1740|of|mutant|and|chimera
T17_T21 CPR:5 ica_0\NN\1740| (r_nsubj) agonist_4\NN\9613191|ica|is|a|mixed|channels|. (l_nmod) channels_11\NNS\6251781|eag|inactivate (l_compound) eag_7\NN\1740|of|mutant|and|chimera (l_conj) chimera_10\NN\9492123|eag/erg (l_compound) eag/erg_9\NN\1740|
T17_T22 CPR:5 ica_0\NN\1740| (r_nsubj) agonist_4\NN\9613191|ica|is|a|mixed|channels|. (l_nmod) channels_11\NNS\6251781|eag|inactivate (l_compound) eag_7\NN\1740|of|mutant|and|chimera (l_conj) chimera_10\NN\9492123|eag/erg (l_compound) eag/erg_9\NN\1740|
T2_T25 NONE acids_10\NNS\14818238|the|specific|amino|form (l_acl:relcl) form_12\VBP\1617192|that|pocket (l_dobj) pocket_16\NN\3993180|the|putative|binding|ica (l_nmod) ica_18\NN\1740|for|erg (l_nmod) erg_20\NN\13609507|in
T2_T26 NONE acids_10\NNS\14818238|the|specific|amino|form (r_nsubjpass) conserved_22\VBN\2681795|exception|,|acids|are|eag|. (l_nmod) eag_24\NN\1740|in
T3_T25 NONE ica_18\NN\1740|for|erg (l_nmod) erg_20\NN\13609507|in
T3_T26 NONE ica_18\NN\1740|for|erg (r_nmod) pocket_16\NN\3993180|the|putative|binding|ica (r_dobj) form_12\VBP\1617192|that|pocket (r_acl:relcl) acids_10\NNS\14818238|the|specific|amino|form (r_nsubjpass) conserved_22\VBN\2681795|exception|,|acids|are|eag|. (l_nmod) eag_24\NN\1740|in
T4_T27 NONE ica_7\NN\1740| (r_compound) site_9\NN\8673395|the|ica|binding|erg (r_dobj) replicate_5\VB\2035919|to|site (r_xcomp) introduced_1\VBN\831651|eag|replicate (l_nmod) eag_3\NN\1740|into
T4_T28 NONE ica_7\NN\1740| (r_compound) site_9\NN\8673395|the|ica|binding|erg (l_nmod) erg_11\NN\13609507|in
T5_T27 NONE ica_19\NN\1740|to (r_nmod) response_17\NN\11410625|the|functional|ica (r_dobj) alter_14\VB\126264|mutations|did|not|response|. (l_nsubj) mutations_0\NNS\4475|introduced (l_acl) introduced_1\VBN\831651|eag|replicate (l_nmod) eag_3\NN\1740|into
T5_T28 NONE ica_19\NN\1740|to (r_nmod) response_17\NN\11410625|the|functional|ica (r_dobj) alter_14\VB\126264|mutations|did|not|response|. (l_nsubj) mutations_0\NNS\4475|introduced (l_acl) introduced_1\VBN\831651|eag|replicate (l_xcomp) replicate_5\VB\2035919|to|site (l_dobj) site_9\NN\8673395|the|ica|binding|erg (l_nmod) erg_11\NN\13609507|in
T6_T29 NONE ica_5\NN\1740| (r_nsubj) binds_6\VBZ\1290422|that|ica|site|elicit (l_nmod) site_10\NN\8673395|to|the|same|channels (l_nmod) channels_15\NNS\6251781|in|eag (l_compound) eag_12\NN\1740|and|erg
T6_T30 NONE ica_5\NN\1740| (r_nsubj) binds_6\VBZ\1290422|that|ica|site|elicit (l_nmod) site_10\NN\8673395|to|the|same|channels (l_nmod) channels_15\NNS\6251781|in|eag (l_compound) eag_12\NN\1740|and|erg (l_conj) erg_14\NN\13609507|
23512537
T9_T23 CPR:9 dipropionate_3\NN\1740|of|beclomethasone (r_nmod) metabolism_0\NN\13526110|dipropionate|enzymes|. (l_nmod) enzymes_8\NNS\14723628|by|cytochrome|p450|3a (l_compound) 3a_7\NN\1740|
T4_T14 CPR:9 bdp_12\NN\1740|of (r_nmod) metabolism_10\NN\13526110|in|cytochrome|p450|3a|enzyme-mediated|bdp (l_compound) 3a_8\NN\1740|
T5_T15 NONE bdp_22\NN\1740|of (r_nmod) metabolism_20\NN\13526110|in|the|bdp (r_nmod) contributions_7\NNS\786195|the|cyp3a4|metabolism|vitro (l_nmod) cyp3a4_9\NN\1740|of|,|3a5|,|3a7|,|and|enzymes (l_conj) 3a7_13\NN\1740|
T5_T16 CPR:9 bdp_22\NN\1740|of (r_nmod) metabolism_20\NN\13526110|in|the|bdp (r_nmod) contributions_7\NNS\786195|the|cyp3a4|metabolism|vitro (l_nmod) cyp3a4_9\NN\1740|of|,|3a5|,|3a7|,|and|enzymes (l_conj) enzymes_17\NNS\14723628|esterase (l_compound) esterase_16\NN\1740|
T5_T17 NONE bdp_22\NN\1740|of (r_nmod) metabolism_20\NN\13526110|in|the|bdp (r_nmod) contributions_7\NNS\786195|the|cyp3a4|metabolism|vitro (r_dobj) evaluating_5\VBG\670261|by|contributions|and|relating (l_conj) relating_26\VBG\628491|metabolism|changes (l_nmod) changes_29\NNS\7283608|to|expression|receptor (l_nmod) expression_34\NN\4679549|in|cyp3a|enzyme|mrna (l_compound) cyp3a_31\NN\1740|
T5_T18 NONE bdp_22\NN\1740|of (r_nmod) metabolism_20\NN\13526110|in|the|bdp (r_nmod) contributions_7\NNS\786195|the|cyp3a4|metabolism|vitro (r_dobj) evaluating_5\VBG\670261|by|contributions|and|relating (l_conj) relating_26\VBG\628491|metabolism|changes (l_nmod) changes_29\NNS\7283608|to|expression|receptor (l_nmod) receptor_38\NN\5225602|via|the|glucocorticoid|lung
T7_T19 CPR:9 bdp_4\NN\1740| (r_dobj) metabolized_3\VBD\1740|cyp3a4|bdp|hydroxylation|rates|;|metabolize (l_nsubj) cyp3a4_0\NN\1740|and|cyp3a5
T7_T20 CPR:9 bdp_4\NN\1740| (r_dobj) metabolized_3\VBD\1740|cyp3a4|bdp|hydroxylation|rates|;|metabolize (l_nsubj) cyp3a4_0\NN\1740|and|cyp3a5 (l_conj) cyp3a5_2\NN\1740|
T7_T21 NONE bdp_4\NN\1740| (r_dobj) metabolized_3\VBD\1740|cyp3a4|bdp|hydroxylation|rates|;|metabolize (l_parataxis) metabolize_30\VB\1740|cyp3a7|did|not|bdp|. (l_nsubj) cyp3a7_27\NN\1740|
T8_T19 NONE bdp_31\NN\1740| (r_dobj) metabolize_30\VB\1740|cyp3a7|did|not|bdp|. (r_parataxis) metabolized_3\VBD\1740|cyp3a4|bdp|hydroxylation|rates|;|metabolize (l_nsubj) cyp3a4_0\NN\1740|and|cyp3a5
T8_T20 NONE bdp_31\NN\1740| (r_dobj) metabolize_30\VB\1740|cyp3a7|did|not|bdp|. (r_parataxis) metabolized_3\VBD\1740|cyp3a4|bdp|hydroxylation|rates|;|metabolize (l_nsubj) cyp3a4_0\NN\1740|and|cyp3a5 (l_conj) cyp3a5_2\NN\1740|
T8_T21 NONE bdp_31\NN\1740| (r_dobj) metabolize_30\VB\1740|cyp3a7|did|not|bdp|. (l_nsubj) cyp3a7_27\NN\1740|
T1_T11 CPR:9 bdp_8\NN\1740| (r_dobj) metabolize_7\VBP\1740|that|cyp3a4|bdp|metabolites (l_nsubj) cyp3a4_4\NN\1740|and|cyp3a5
T1_T12 CPR:9 bdp_8\NN\1740| (r_dobj) metabolize_7\VBP\1740|that|cyp3a4|bdp|metabolites (l_nsubj) cyp3a4_4\NN\1740|and|cyp3a5 (l_conj) cyp3a5_6\NN\1740|
T2_T11 NONE bdp_31\NN\1740| (r_compound) disposition_32\NN\4623113|bdp|humans (r_dobj) influence_30\VB\137313|that|differences|could|disposition (r_ccomp) suggest_13\VBP\1010118|influence (r_conj) show_2\VBP\2137132|studies|metabolize|and|suggest|. (l_ccomp) metabolize_7\VBP\1740|that|cyp3a4|bdp|metabolites (l_nsubj) cyp3a4_4\NN\1740|and|cyp3a5
T2_T12 NONE bdp_31\NN\1740| (r_compound) disposition_32\NN\4623113|bdp|humans (r_dobj) influence_30\VB\137313|that|differences|could|disposition (r_ccomp) suggest_13\VBP\1010118|influence (r_conj) show_2\VBP\2137132|studies|metabolize|and|suggest|. (l_ccomp) metabolize_7\VBP\1740|that|cyp3a4|bdp|metabolites (l_nsubj) cyp3a4_4\NN\1740|and|cyp3a5 (l_conj) cyp3a5_6\NN\1740|
17320868
T21_T36 NONE estrogen_2\NN\14745635|by (r_nmod) neuroprotection_0\NN\1740|estrogen|death (r_nsubjpass) mediated_9\VBN\761713|neuroprotection|is|eralpha|cultures|. (l_nmod) eralpha_11\NN\1740|by
T22_T36 NONE mpp+-induced_4\JJ\1740| (r_amod) death_7\NN\7296428|against|mpp+-induced|dopamine|neuron (r_nmod) neuroprotection_0\NN\1740|estrogen|death (r_nsubjpass) mediated_9\VBN\761713|neuroprotection|is|eralpha|cultures|. (l_nmod) eralpha_11\NN\1740|by
T23_T36 NONE dopamine_5\NN\14807737| (r_compound) death_7\NN\7296428|against|mpp+-induced|dopamine|neuron (r_nmod) neuroprotection_0\NN\1740|estrogen|death (r_nsubjpass) mediated_9\VBN\761713|neuroprotection|is|eralpha|cultures|. (l_nmod) eralpha_11\NN\1740|by
T11_T26 NONE estrogen_10\NN\14745635| (r_compound) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta
T11_T27 NONE estrogen_10\NN\14745635| (r_compound) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (l_appos) eralpha_14\NN\1740|(|)
T11_T28 NONE estrogen_10\NN\14745635| (r_compound) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (l_conj) beta_19\NN\6828818|estrogen|receptor|erbeta
T11_T29 NONE estrogen_10\NN\14745635| (r_compound) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (l_conj) beta_19\NN\6828818|estrogen|receptor|erbeta (l_appos) erbeta_21\NN\1740|(|)
T11_T30 NONE estrogen_10\NN\14745635| (r_compound) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (r_nmod) expression_7\NN\4679549|alpha|predominance (l_nmod) predominance_25\NN\14441825|with|a|eralpha|neurons (l_nmod) eralpha_27\NN\1740|of
T12_T26 NONE estrogen_17\NN\14745635| (r_compound) beta_19\NN\6828818|estrogen|receptor|erbeta (r_conj) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta
T12_T27 NONE estrogen_17\NN\14745635| (r_compound) beta_19\NN\6828818|estrogen|receptor|erbeta (r_conj) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (l_appos) eralpha_14\NN\1740|(|)
T12_T28 NONE estrogen_17\NN\14745635| (r_compound) beta_19\NN\6828818|estrogen|receptor|erbeta
T12_T29 NONE estrogen_17\NN\14745635| (r_compound) beta_19\NN\6828818|estrogen|receptor|erbeta (l_appos) erbeta_21\NN\1740|(|)
T12_T30 NONE estrogen_17\NN\14745635| (r_compound) beta_19\NN\6828818|estrogen|receptor|erbeta (r_conj) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (r_nmod) expression_7\NN\4679549|alpha|predominance (l_nmod) predominance_25\NN\14441825|with|a|eralpha|neurons (l_nmod) eralpha_27\NN\1740|of
T13_T26 NONE dopamine_30\NN\14807737| (r_compound) neurons_31\NNS\5430628|on|both|dopamine|and|astrocytes (r_nmod) predominance_25\NN\14441825|with|a|eralpha|neurons (r_nmod) expression_7\NN\4679549|alpha|predominance (l_nmod) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta
T13_T27 NONE dopamine_30\NN\14807737| (r_compound) neurons_31\NNS\5430628|on|both|dopamine|and|astrocytes (r_nmod) predominance_25\NN\14441825|with|a|eralpha|neurons (r_nmod) expression_7\NN\4679549|alpha|predominance (l_nmod) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (l_appos) eralpha_14\NN\1740|(|)
T13_T28 NONE dopamine_30\NN\14807737| (r_compound) neurons_31\NNS\5430628|on|both|dopamine|and|astrocytes (r_nmod) predominance_25\NN\14441825|with|a|eralpha|neurons (r_nmod) expression_7\NN\4679549|alpha|predominance (l_nmod) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (l_conj) beta_19\NN\6828818|estrogen|receptor|erbeta
T13_T29 NONE dopamine_30\NN\14807737| (r_compound) neurons_31\NNS\5430628|on|both|dopamine|and|astrocytes (r_nmod) predominance_25\NN\14441825|with|a|eralpha|neurons (r_nmod) expression_7\NN\4679549|alpha|predominance (l_nmod) alpha_12\NN\6828818|of|both|estrogen|receptor|eralpha|and|beta (l_conj) beta_19\NN\6828818|estrogen|receptor|erbeta (l_appos) erbeta_21\NN\1740|(|)
T13_T30 NONE dopamine_30\NN\14807737| (r_compound) neurons_31\NNS\5430628|on|both|dopamine|and|astrocytes (r_nmod) predominance_25\NN\14441825|with|a|eralpha|neurons (l_nmod) eralpha_27\NN\1740|of
T14_T31 NONE 17beta-estradiol_4\NN\1740| (r_nsubj) protects_5\VBZ\1127795|that|17beta-estradiol|neurons|injury|manner (l_nmod) manner_28\NN\4916342|in|a|time- (l_amod) time-_25\NN\1740|and|er-dependent (l_conj) er-dependent_27\JJ\1740|
T15_T31 NONE dopamine_6\NN\14807737| (r_compound) neurons_7\NNS\5430628|dopamine (r_dobj) protects_5\VBZ\1127795|that|17beta-estradiol|neurons|injury|manner (l_nmod) manner_28\NN\4916342|in|a|time- (l_amod) time-_25\NN\1740|and|er-dependent (l_conj) er-dependent_27\JJ\1740|
T16_T31 NONE pyridinium_18\NN\1740|1-methyl-4-phenyl|mpp(+|) (r_appos) inhibitor_15\NN\20090|by|the|complex|i|,|pyridinium (r_nmod) induced_10\VBN\1627355|inhibitor (r_acl) injury_9\NN\14052046|from|induced (r_nmod) protects_5\VBZ\1127795|that|17beta-estradiol|neurons|injury|manner (l_nmod) manner_28\NN\4916342|in|a|time- (l_amod) time-_25\NN\1740|and|er-dependent (l_conj) er-dependent_27\JJ\1740|
T17_T31 NONE )_21\-RRB-\1740| (r_punct) mpp(+_20\NN\1740|(|) (r_appos) pyridinium_18\NN\1740|1-methyl-4-phenyl|mpp(+|) (r_appos) inhibitor_15\NN\20090|by|the|complex|i|,|pyridinium (r_nmod) induced_10\VBN\1627355|inhibitor (r_acl) injury_9\NN\14052046|from|induced (r_nmod) protects_5\VBZ\1127795|that|17beta-estradiol|neurons|injury|manner (l_nmod) manner_28\NN\4916342|in|a|time- (l_amod) time-_25\NN\1740|and|er-dependent (l_conj) er-dependent_27\JJ\1740|
T18_T32 NONE estrogen_5\NN\14745635| (r_compound) pre-treatment_6\NN\1740|of|estrogen (r_nmod) h_3\NN\14622893|4|pre-treatment (r_nsubjpass) required_8\VBN\754942|h|was|elicit|. (l_xcomp) elicit_10\VB\1617192|to|protection|,|effect (l_dobj) effect_14\NN\34213|an|blocked (l_acl:relcl) blocked_17\VBN\1476483|that|was|antagonist (l_nmod) antagonist_21\NN\7846|by|the|er|,|ici (l_compound) er_20\NN\14625458|
T19_T32 CPR:6 182,780_24\CD\1740| (r_nummod) ici_23\NN\1740|182,780 (r_appos) antagonist_21\NN\7846|by|the|er|,|ici (l_compound) er_20\NN\14625458|
T20_T33 NONE estrogen_8\NN\14745635|by (r_nmod) afforded_6\VBN\2267060|estrogen (r_acl) protection_5\NN\407535|the|afforded (r_dobj) mediated_3\VBD\761713|moreover|,|eralpha|protection|protected|. (l_nsubj) eralpha_2\NN\1740|
T20_T34 NONE estrogen_8\NN\14745635|by (r_nmod) afforded_6\VBN\2267060|estrogen (r_acl) protection_5\NN\407535|the|afforded (r_dobj) mediated_3\VBD\761713|moreover|,|eralpha|protection|protected|. (l_advcl) protected_25\VBD\1127795|since|agonist|loss (l_nsubj) agonist_13\NN\9613191|only|the|eralpha|,|hpte|,|not|agonist (l_compound) eralpha_12\NN\1740|
T20_T35 NONE estrogen_8\NN\14745635|by (r_nmod) afforded_6\VBN\2267060|estrogen (r_acl) protection_5\NN\407535|the|afforded (r_dobj) mediated_3\VBD\761713|moreover|,|eralpha|protection|protected|. (l_advcl) protected_25\VBD\1127795|since|agonist|loss (l_nsubj) agonist_13\NN\9613191|only|the|eralpha|,|hpte|,|not|agonist (l_conj) agonist_21\NN\9613191|the|erbeta|,|dpn|, (l_compound) erbeta_20\NN\1740|
T2_T33 NONE dpn_23\NN\1740| (r_appos) agonist_21\NN\9613191|the|erbeta|,|dpn|, (r_conj) agonist_13\NN\9613191|only|the|eralpha|,|hpte|,|not|agonist (r_nsubj) protected_25\VBD\1127795|since|agonist|loss (r_advcl) mediated_3\VBD\761713|moreover|,|eralpha|protection|protected|. (l_nsubj) eralpha_2\NN\1740|
T2_T34 NONE dpn_23\NN\1740| (r_appos) agonist_21\NN\9613191|the|erbeta|,|dpn|, (r_conj) agonist_13\NN\9613191|only|the|eralpha|,|hpte|,|not|agonist (l_compound) eralpha_12\NN\1740|
T2_T35 CPR:5 dpn_23\NN\1740| (r_appos) agonist_21\NN\9613191|the|erbeta|,|dpn|, (l_compound) erbeta_20\NN\1740|
T3_T33 NONE dopamine_27\NN\14807737| (r_compound) loss_29\NN\13252973|against|dopamine|cell (r_nmod) protected_25\VBD\1127795|since|agonist|loss (r_advcl) mediated_3\VBD\761713|moreover|,|eralpha|protection|protected|. (l_nsubj) eralpha_2\NN\1740|
T3_T34 NONE dopamine_27\NN\14807737| (r_compound) loss_29\NN\13252973|against|dopamine|cell (r_nmod) protected_25\VBD\1127795|since|agonist|loss (l_nsubj) agonist_13\NN\9613191|only|the|eralpha|,|hpte|,|not|agonist (l_compound) eralpha_12\NN\1740|
T3_T35 NONE dopamine_27\NN\14807737| (r_compound) loss_29\NN\13252973|against|dopamine|cell (r_nmod) protected_25\VBD\1127795|since|agonist|loss (l_nsubj) agonist_13\NN\9613191|only|the|eralpha|,|hpte|,|not|agonist (l_conj) agonist_21\NN\9613191|the|erbeta|,|dpn|, (l_compound) erbeta_20\NN\1740|
T4_T24 NONE estrogen-mediated_19\JJ\1740| (r_amod) neuroprotection_20\NN\1740|of|estrogen-mediated|interaction (r_nmod) mechanism_17\NN\13446390|a|possible|indirect|neuroprotection (r_dobj) investigated_13\VBD\644583|shown|,|we|mechanism|. (l_advcl) shown_4\VBN\2137132|since|cells|were|express (l_xcomp) express_6\VB\928630|to|levels (l_dobj) levels_8\NNS\4916342|significant|eralpha (l_nmod) eralpha_10\NN\1740|of
T8_T25 NONE estrogen_7\NN\14745635|by (r_nmod) provided_5\VBN\2199590|estrogen|toxicity (r_acl) neuroprotection_4\NN\1740|provided (r_nsubjpass) mediated_13\VBN\761713|that|neuroprotection|is|eralpha|and|involves (l_nmod) eralpha_15\NN\1740|by
T9_T25 NONE )_10\-RRB-\1740| (r_punct) mpp(+_9\NN\1740|) (r_compound) toxicity_11\NN\13576101|against|mpp(+ (r_nmod) provided_5\VBN\2199590|estrogen|toxicity (r_acl) neuroprotection_4\NN\1740|provided (r_nsubjpass) mediated_13\VBN\761713|that|neuroprotection|is|eralpha|and|involves (l_nmod) eralpha_15\NN\1740|by
23123298
T6_T17 CPR:3 helenalin_3\NN\1740| (r_nsubj) induced_5\VBD\1627355|that|helenalin|markedly|genes (l_dobj) genes_12\NNS\8459252|reticulum|stress-related|,|regulated (l_nmod) regulated_16\VBN\296178|such|development|,|activating (l_nmod) development_18\NN\248977|in|and|responses (l_conj) responses_22\NNS\11410625|dna|damage|redd (l_appos) redd_24\NN\1740|(|)|1 (l_nummod) 1_26\CD\13741022|
T6_T18 CPR:3 helenalin_3\NN\1740| (r_nsubj) induced_5\VBD\1627355|that|helenalin|markedly|genes (l_dobj) genes_12\NNS\8459252|reticulum|stress-related|,|regulated (l_nmod) regulated_16\VBN\296178|such|development|,|activating (l_advcl) activating_28\VBG\1641914|factor-4 (l_dobj) factor-4_30\NN\1740|transcription|atf4|and/or|protein
T6_T19 CPR:3 helenalin_3\NN\1740| (r_nsubj) induced_5\VBD\1627355|that|helenalin|markedly|genes (l_dobj) genes_12\NNS\8459252|reticulum|stress-related|,|regulated (l_nmod) regulated_16\VBN\296178|such|development|,|activating (l_advcl) activating_28\VBG\1641914|factor-4 (l_dobj) factor-4_30\NN\1740|transcription|atf4|and/or|protein (l_appos) atf4_32\NN\1740|(|)
T6_T20 CPR:3 helenalin_3\NN\1740| (r_nsubj) induced_5\VBD\1627355|that|helenalin|markedly|genes (l_dobj) genes_12\NNS\8459252|reticulum|stress-related|,|regulated (l_nmod) regulated_16\VBN\296178|such|development|,|activating (l_advcl) activating_28\VBG\1641914|factor-4 (l_dobj) factor-4_30\NN\1740|transcription|atf4|and/or|protein (l_conj) protein_39\NN\14944888|the|ccaat|enhancer-binding|protein-homologous|chop
T6_T21 CPR:3 helenalin_3\NN\1740| (r_nsubj) induced_5\VBD\1627355|that|helenalin|markedly|genes (l_dobj) genes_12\NNS\8459252|reticulum|stress-related|,|regulated (l_nmod) regulated_16\VBN\296178|such|development|,|activating (l_advcl) activating_28\VBG\1641914|factor-4 (l_dobj) factor-4_30\NN\1740|transcription|atf4|and/or|protein (l_conj) protein_39\NN\14944888|the|ccaat|enhancer-binding|protein-homologous|chop (l_appos) chop_41\NN\11419404|(|)
T7_T22 NONE helenalin-induced_14\JJ\1740| (r_amod) apoptosis_15\NN\11486178|on|helenalin-induced|cells (r_nmod) had_10\VBD\2108377|however|,|down-regulation|effect|apoptosis|. (l_nsubj) down-regulation_2\NN\1740|atf4|sirna (l_nmod) atf4_4\NN\1740|of|and/or|chop|expression
T7_T23 NONE helenalin-induced_14\JJ\1740| (r_amod) apoptosis_15\NN\11486178|on|helenalin-induced|cells (r_nmod) had_10\VBD\2108377|however|,|down-regulation|effect|apoptosis|. (l_nsubj) down-regulation_2\NN\1740|atf4|sirna (l_nmod) atf4_4\NN\1740|of|and/or|chop|expression (l_conj) chop_6\NN\11419404|
23455597
T15_T21 CPR:6 abt-288_6\NN\1740|of|,|antagonist (l_appos) antagonist_13\NN\7846|a|novel|receptor (l_compound) receptor_12\NN\5225602|histamine|h3
T16_T21 NONE histamine_10\NN\14739004| (r_compound) receptor_12\NN\5225602|histamine|h3
T10_T17 CPR:6 abt-288_9\NN\1740|such (r_nmod) antagonists_5\NNS\7846|histamine|h3|receptor|,|abt-288|, (l_compound) receptor_4\NN\5225602|
T2_T17 NONE histamine_2\NN\14739004| (r_compound) antagonists_5\NNS\7846|histamine|h3|receptor|,|abt-288|, (l_compound) receptor_4\NN\5225602|
T7_T18 NONE abt-288_21\NN\1740| (r_nsubj) unlikely_23\JJ\1740|that|abt-288|is|possess (r_ccomp) indicates_19\VBZ\952524|sum|unlikely|and|suggests|. (l_nsubj) sum_3\NN\13329641|the|data|, (l_nmod) data_7\NNS\7951464|of|these|preclinical|,|first (l_appos) first_10\JJ\1740|the|kind|applied (l_acl) applied_14\VBN\2676054|antagonists (l_nmod) antagonists_17\NNS\7846|to|h3 (l_compound) h3_16\NN\1740|
T7_T19 CPR:6 abt-288_21\NN\1740| (r_nsubj) unlikely_23\JJ\1740|that|abt-288|is|possess (r_ccomp) indicates_19\VBZ\952524|sum|unlikely|and|suggests|. (l_conj) suggests_36\VBZ\1010118|similar (l_ccomp) similar_46\JJ\1740|that|antagonists|,|class|,|are|regard (l_nsubj) antagonists_39\NNS\7846|h3 (l_compound) h3_38\NN\1740|
23353901
T24_T48 NONE 2,5-dimethoxy-4-iodoamphetamine_19\NN\1740| (r_compound) model_23\NN\5888929|the|2,5-dimethoxy-4-iodoamphetamine|elicited|head-twitch|response (r_conj) ligands_16\NNS\20090|diverse|5-ht2c|receptor|and|model (l_compound) 5-ht2c_14\NN\1740|
T24_T49 NONE 2,5-dimethoxy-4-iodoamphetamine_19\NN\1740| (r_compound) model_23\NN\5888929|the|2,5-dimethoxy-4-iodoamphetamine|elicited|head-twitch|response (r_conj) ligands_16\NNS\20090|diverse|5-ht2c|receptor|and|model (r_dobj) utilizing_9\VBG\161225|vivo|ligands (r_acl) support_0\NN\407535|selectivity||utilizing|. (l_nmod) selectivity_5\NN\4916342|for|receptor|functional (l_compound) receptor_3\NN\5225602|5-ht2c (l_compound) 5-ht2c_2\NN\1740|
T10_T32 NONE doi_35\NN\8123167|(|) (r_appos) 2,5-dimethoxy-4-iodoamphetamine_33\NN\1740|doi (r_dep) agonist_32\NN\9613191|by|the|hallucinogenic|5-ht2a/2b/2c|receptor|2,5-dimethoxy-4-iodoamphetamine (l_compound) receptor_31\NN\5225602|
T10_T46 NONE doi_35\NN\8123167|(|) (r_appos) 2,5-dimethoxy-4-iodoamphetamine_33\NN\1740|doi (r_dep) agonist_32\NN\9613191|by|the|hallucinogenic|5-ht2a/2b/2c|receptor|2,5-dimethoxy-4-iodoamphetamine (r_nmod) elicited_26\VBN\1617192|agonist (r_acl) response_22\NN\11410625|in|the|mouse|head-twitch|htr|elicited (r_nmod) role_10\NN\719494|regarding|the|receptors|response (l_nmod) receptors_17\NNS\5225602|of|serotonin|(|5-ht|)|5-ht2c (l_compound) 5-ht2c_16\NN\1740|
T17_T32 NONE serotonin_12\NN\14807737| (r_compound) receptors_17\NNS\5225602|of|serotonin|(|5-ht|)|5-ht2c (r_nmod) role_10\NN\719494|regarding|the|receptors|response (l_nmod) response_22\NN\11410625|in|the|mouse|head-twitch|htr|elicited (l_acl) elicited_26\VBN\1617192|agonist (l_nmod) agonist_32\NN\9613191|by|the|hallucinogenic|5-ht2a/2b/2c|receptor|2,5-dimethoxy-4-iodoamphetamine (l_compound) receptor_31\NN\5225602|
T17_T46 NONE serotonin_12\NN\14807737| (r_compound) receptors_17\NNS\5225602|of|serotonin|(|5-ht|)|5-ht2c (l_compound) 5-ht2c_16\NN\1740|
T20_T32 NONE 5-ht_14\NN\1740| (r_compound) receptors_17\NNS\5225602|of|serotonin|(|5-ht|)|5-ht2c (r_nmod) role_10\NN\719494|regarding|the|receptors|response (l_nmod) response_22\NN\11410625|in|the|mouse|head-twitch|htr|elicited (l_acl) elicited_26\VBN\1617192|agonist (l_nmod) agonist_32\NN\9613191|by|the|hallucinogenic|5-ht2a/2b/2c|receptor|2,5-dimethoxy-4-iodoamphetamine (l_compound) receptor_31\NN\5225602|
T20_T46 NONE 5-ht_14\NN\1740| (r_compound) receptors_17\NNS\5225602|of|serotonin|(|5-ht|)|5-ht2c (l_compound) 5-ht2c_16\NN\1740|
T9_T32 NONE 2,5-dimethoxy-4-iodoamphetamine_33\NN\1740|doi (r_dep) agonist_32\NN\9613191|by|the|hallucinogenic|5-ht2a/2b/2c|receptor|2,5-dimethoxy-4-iodoamphetamine (l_compound) receptor_31\NN\5225602|
T9_T46 NONE 2,5-dimethoxy-4-iodoamphetamine_33\NN\1740|doi (r_dep) agonist_32\NN\9613191|by|the|hallucinogenic|5-ht2a/2b/2c|receptor|2,5-dimethoxy-4-iodoamphetamine (r_nmod) elicited_26\VBN\1617192|agonist (r_acl) response_22\NN\11410625|in|the|mouse|head-twitch|htr|elicited (r_nmod) role_10\NN\719494|regarding|the|receptors|response (l_nmod) receptors_17\NNS\5225602|of|serotonin|(|5-ht|)|5-ht2c (l_compound) 5-ht2c_16\NN\1740|
T11_T40 NONE doi-elicited-htr_16\NN\1740|the|strain (r_dobj) attenuate_14\VB\224901|that|classes|could|doi-elicited-htr (l_nsubj) classes_8\NNS\7951464|both|compounds (l_nmod) compounds_12\NNS\5869584|of|5-ht2c|receptor (l_compound) 5-ht2c_10\NN\1740|
T12_T41 CPR:5 809101_5\CD\1740| (r_nummod) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T12_T42 NONE 809101_5\CD\1740| (r_nummod) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T12_T43 NONE 809101_5\CD\1740| (r_nummod) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T12_T44 NONE 809101_5\CD\1740| (r_nummod) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T12_T45 NONE 809101_5\CD\1740| (r_nummod) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T12_T47 NONE 809101_5\CD\1740| (r_nummod) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T13_T41 CPR:5 0175_10\CD\1740| (r_nummod) ro_7\NN\6894544|60|-|0175 (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T13_T42 NONE 0175_10\CD\1740| (r_nummod) ro_7\NN\6894544|60|-|0175 (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T13_T43 NONE 0175_10\CD\1740| (r_nummod) ro_7\NN\6894544|60|-|0175 (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T13_T44 NONE 0175_10\CD\1740| (r_nummod) ro_7\NN\6894544|60|-|0175 (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T13_T45 NONE 0175_10\CD\1740| (r_nummod) ro_7\NN\6894544|60|-|0175 (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T13_T47 NONE 0175_10\CD\1740| (r_nummod) ro_7\NN\6894544|60|-|0175 (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T14_T41 CPR:5 161503_13\CD\1740| (r_nummod) way_12\NN\4916342|161503 (r_appos) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T14_T42 NONE 161503_13\CD\1740| (r_nummod) way_12\NN\4916342|161503 (r_appos) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T14_T43 NONE 161503_13\CD\1740| (r_nummod) way_12\NN\4916342|161503 (r_appos) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T14_T44 NONE 161503_13\CD\1740| (r_nummod) way_12\NN\4916342|161503 (r_appos) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T14_T45 NONE 161503_13\CD\1740| (r_nummod) way_12\NN\4916342|161503 (r_appos) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T14_T47 NONE 161503_13\CD\1740| (r_nummod) way_12\NN\4916342|161503 (r_appos) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T15_T41 CPR:5 mcpp_15\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T15_T42 NONE mcpp_15\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T15_T43 NONE mcpp_15\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T15_T44 NONE mcpp_15\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T15_T45 NONE mcpp_15\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T15_T47 NONE mcpp_15\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T16_T41 CPR:5 1-methylpsilocin_18\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T16_T42 NONE 1-methylpsilocin_18\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T16_T43 NONE 1-methylpsilocin_18\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T16_T44 NONE 1-methylpsilocin_18\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T16_T45 NONE 1-methylpsilocin_18\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T16_T47 NONE 1-methylpsilocin_18\NN\1740| (r_conj) cp_4\NN\1740|(|809101|,|ro|,|way|,|mcpp|,|and|1-methylpsilocin|) (r_dep) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T18_T41 NONE n-dimethyl-aminotetralin_25\JJ\1740| (r_amod) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T18_T42 CPR:5 n-dimethyl-aminotetralin_25\JJ\1740| (r_amod) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T18_T43 NONE n-dimethyl-aminotetralin_25\JJ\1740| (r_amod) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T18_T44 NONE n-dimethyl-aminotetralin_25\JJ\1740| (r_amod) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T18_T45 NONE n-dimethyl-aminotetralin_25\JJ\1740| (r_amod) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T18_T47 NONE n-dimethyl-aminotetralin_25\JJ\1740| (r_amod) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T19_T41 NONE (pat)-type_26\NN\1740| (r_punct) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T19_T42 CPR:5 (pat)-type_26\NN\1740| (r_punct) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T19_T43 NONE (pat)-type_26\NN\1740| (r_punct) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T19_T44 NONE (pat)-type_26\NN\1740| (r_punct) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T19_T45 NONE (pat)-type_26\NN\1740| (r_punct) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T19_T47 NONE (pat)-type_26\NN\1740| (r_punct) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T1_T41 NONE doi-elicited-htr_58\NN\1740|the (r_dobj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T1_T42 NONE doi-elicited-htr_58\NN\1740|the (r_dobj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T1_T43 NONE doi-elicited-htr_58\NN\1740|the (r_dobj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T1_T44 NONE doi-elicited-htr_58\NN\1740|the (r_dobj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T1_T45 NONE doi-elicited-htr_58\NN\1740|the (r_dobj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T1_T47 NONE doi-elicited-htr_58\NN\1740|the (r_dobj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_conj) antagonists_37\NNS\7846|selective (l_amod) selective_38\JJ\1740|receptors (l_nmod) receptors_55\NNS\5225602|5-ht2a (l_compound) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T21_T41 NONE m100907_42\NN\1740|(|) (r_appos) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T21_T42 NONE m100907_42\NN\1740|(|) (r_appos) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T21_T43 NONE m100907_42\NN\1740|(|) (r_appos) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T21_T44 CPR:6 m100907_42\NN\1740|(|) (r_appos) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T21_T45 NONE m100907_42\NN\1740|(|) (r_appos) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T21_T47 NONE m100907_42\NN\1740|(|) (r_appos) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T22_T41 NONE sb-242084_47\NN\1740|(|) (r_appos) 5-ht2c_45\NN\1740|sb-242084 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T22_T42 NONE sb-242084_47\NN\1740|(|) (r_appos) 5-ht2c_45\NN\1740|sb-242084 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T22_T43 NONE sb-242084_47\NN\1740|(|) (r_appos) 5-ht2c_45\NN\1740|sb-242084 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T22_T44 NONE sb-242084_47\NN\1740|(|) (r_appos) 5-ht2c_45\NN\1740|sb-242084 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T22_T45 CPR:6 sb-242084_47\NN\1740|(|) (r_appos) 5-ht2c_45\NN\1740|sb-242084
T22_T47 NONE sb-242084_47\NN\1740|(|) (r_appos) 5-ht2c_45\NN\1740|sb-242084 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2b/2c_51\NN\1740|sb-206553
T23_T41 NONE sb-206553_53\CD\1740|(|) (r_appos) 5-ht2b/2c_51\NN\1740|sb-206553 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (r_nsubj) attenuated_56\VBD\224901|agonists|agonists|doi-elicited-htr|. (l_nsubj) agonists_2\NNS\9613191|commercially-available|5-ht2c|cp|,| (l_compound) 5-ht2c_1\NN\1740|
T23_T42 NONE sb-206553_53\CD\1740|(|) (r_appos) 5-ht2b/2c_51\NN\1740|sb-206553 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_compound) 5-ht2c_27\NN\1740|
T23_T43 NONE sb-206553_53\CD\1740|(|) (r_appos) 5-ht2b/2c_51\NN\1740|sb-206553 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (r_compound) receptors_55\NNS\5225602|5-ht2a (r_nmod) selective_38\JJ\1740|receptors (r_amod) antagonists_37\NNS\7846|selective (r_conj) agonists_28\NNS\9613191|4-phenyl-2-n|,|n-dimethyl-aminotetralin|(pat)-type|5-ht2c|activity|,|and|antagonists (l_nmod) activity_33\NN\30358|(|with|5-ht2a/2b|antagonist|) (l_compound) 5-ht2a/2b_31\NN\1740|
T23_T44 NONE sb-206553_53\CD\1740|(|) (r_appos) 5-ht2b/2c_51\NN\1740|sb-206553 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c
T23_T45 NONE sb-206553_53\CD\1740|(|) (r_appos) 5-ht2b/2c_51\NN\1740|sb-206553 (r_conj) 5-ht2a_40\NN\1740|for|m100907|,|5-ht2c|,|and|5-ht2b/2c (l_conj) 5-ht2c_45\NN\1740|sb-242084
T23_T47 NONE sb-206553_53\CD\1740|(|) (r_appos) 5-ht2b/2c_51\NN\1740|sb-206553
T2_T25 NONE m100907_4\NN\1740| (r_conj) agonists_2\NNS\9613191|the|5-ht2c|and|m100907 (l_compound) 5-ht2c_1\NN\1740|
T3_T25 NONE sb-242084_8\NN\1740| (r_nsubj) increased_9\VBD\169651|sb-242084|locomotion|,|resulted (r_conj) decreased_5\VBD\169651|agonists|locomotion|,|increased|. (l_nsubj) agonists_2\NNS\9613191|the|5-ht2c|and|m100907 (l_compound) 5-ht2c_1\NN\1740|
T4_T25 NONE sb-206553_12\NN\1740| (r_nsubj) resulted_13\VBD\2633881|sb-206553|effects|,|and|alter (r_conj) increased_9\VBD\169651|sb-242084|locomotion|,|resulted (r_conj) decreased_5\VBD\169651|agonists|locomotion|,|increased|. (l_nsubj) agonists_2\NNS\9613191|the|5-ht2c|and|m100907 (l_compound) 5-ht2c_1\NN\1740|
T5_T26 NONE doi-elicited-htr_13\NN\1740|the (r_dobj) attenuating_11\VBG\224901|for|doi-elicited-htr (r_advcl) potent_9\JJ\1740|attenuating (r_amod) agonists_8\NNS\9613191|5-ht2c|potent (l_compound) 5-ht2c_7\NN\1740|
T5_T27 NONE doi-elicited-htr_13\NN\1740|the (r_dobj) attenuating_11\VBG\224901|for|doi-elicited-htr (r_advcl) potent_9\JJ\1740|attenuating (r_amod) agonists_8\NNS\9613191|5-ht2c|potent (r_nsubj) reduced_15\VBD\441445|that|agonists|also|efficacy (l_dobj) efficacy_17\NN\5199286|the|doi|activate (l_acl) activate_21\VB\1641914|to|signaling (l_dobj) signaling_26\NN\33020|mouse|receptor-mediated|plc|cells (l_amod) receptor-mediated_24\JJ\1740|5-ht2c (l_nmod:npmod) 5-ht2c_23\NN\1740|
T5_T28 NONE doi-elicited-htr_13\NN\1740|the (r_dobj) attenuating_11\VBG\224901|for|doi-elicited-htr (r_advcl) potent_9\JJ\1740|attenuating (r_amod) agonists_8\NNS\9613191|5-ht2c|potent (r_nsubj) reduced_15\VBD\441445|that|agonists|also|efficacy (l_dobj) efficacy_17\NN\5199286|the|doi|activate (l_acl) activate_21\VB\1641914|to|signaling (l_dobj) signaling_26\NN\33020|mouse|receptor-mediated|plc|cells (l_compound) plc_25\NN\1740|
T6_T26 NONE doi_19\NN\8123167|of (r_nmod) efficacy_17\NN\5199286|the|doi|activate (r_dobj) reduced_15\VBD\441445|that|agonists|also|efficacy (l_nsubj) agonists_8\NNS\9613191|5-ht2c|potent (l_compound) 5-ht2c_7\NN\1740|
T6_T27 CPR:3 doi_19\NN\8123167|of (r_nmod) efficacy_17\NN\5199286|the|doi|activate (l_acl) activate_21\VB\1641914|to|signaling (l_dobj) signaling_26\NN\33020|mouse|receptor-mediated|plc|cells (l_amod) receptor-mediated_24\JJ\1740|5-ht2c (l_nmod:npmod) 5-ht2c_23\NN\1740|
T6_T28 NONE doi_19\NN\8123167|of (r_nmod) efficacy_17\NN\5199286|the|doi|activate (l_acl) activate_21\VB\1641914|to|signaling (l_dobj) signaling_26\NN\33020|mouse|receptor-mediated|plc|cells (l_compound) plc_25\NN\1740|
T7_T31 NONE doi-elicited-htr_10\NN\1740|the|mice (r_dobj) attenuate_8\VBP\224901|that|receptor|doi-elicited-htr (l_nsubj) receptor_4\NN\5225602|5-ht2c|agonists (l_compound) 5-ht2c_3\NN\1740|
T7_T33 NONE doi-elicited-htr_10\NN\1740|the|mice (r_dobj) attenuate_8\VBP\224901|that|receptor|doi-elicited-htr (r_ccomp) indicate_1\VBP\952524|results|attenuate|,|and|suggest|. (l_conj) suggest_16\VBP\1010118|result (l_ccomp) result_22\VBP\2633881|that|ligands|outcomes|doi (l_nsubj) ligands_21\NNS\20090|diverse|5-ht2c (l_compound) 5-ht2c_20\NN\1740|
T7_T34 NONE doi-elicited-htr_10\NN\1740|the|mice (r_dobj) attenuate_8\VBP\224901|that|receptor|doi-elicited-htr (r_ccomp) indicate_1\VBP\952524|results|attenuate|,|and|suggest|. (l_conj) suggest_16\VBP\1010118|result (l_ccomp) result_22\VBP\2633881|that|ligands|outcomes|doi (l_nmod) outcomes_28\NNS\7291312|in|different|receptor|signaling (l_compound) receptor_26\NN\5225602|5-ht2c (l_compound) 5-ht2c_25\NN\1740|
T8_T31 NONE doi_31\NN\8123167|compared|to (r_nmod) result_22\VBP\2633881|that|ligands|outcomes|doi (r_ccomp) suggest_16\VBP\1010118|result (r_conj) indicate_1\VBP\952524|results|attenuate|,|and|suggest|. (l_ccomp) attenuate_8\VBP\224901|that|receptor|doi-elicited-htr (l_nsubj) receptor_4\NN\5225602|5-ht2c|agonists (l_compound) 5-ht2c_3\NN\1740|
T8_T33 NONE doi_31\NN\8123167|compared|to (r_nmod) result_22\VBP\2633881|that|ligands|outcomes|doi (l_nsubj) ligands_21\NNS\20090|diverse|5-ht2c (l_compound) 5-ht2c_20\NN\1740|
T8_T34 NONE doi_31\NN\8123167|compared|to (r_nmod) result_22\VBP\2633881|that|ligands|outcomes|doi (l_nmod) outcomes_28\NNS\7291312|in|different|receptor|signaling (l_compound) receptor_26\NN\5225602|5-ht2c (l_compound) 5-ht2c_25\NN\1740|
17590520
T3_T8 NONE nicotine_0\NN\14712692| (r_compound) chrna4_3\NN\1740|nicotine|receptor|gene
T1_T4 NONE thymine-to-cytosine_3\JJ\1740| (r_amod) polymorphism_4\NN\11418750|the|same|sense|thymine-to-cytosine|ser543ser (l_appos) ser543ser_8\NN\1740|(|c.1629t-c|;|) (l_compound) c.1629t-c_6\NN\1740|
T1_T5 NONE thymine-to-cytosine_3\JJ\1740| (r_amod) polymorphism_4\NN\11418750|the|same|sense|thymine-to-cytosine|ser543ser (l_appos) ser543ser_8\NN\1740|(|c.1629t-c|;|)
T2_T4 NONE thymine-to-cytosine_3\JJ\1740| (r_amod) polymorphism_4\NN\11418750|the|same|sense|thymine-to-cytosine|ser543ser (l_appos) ser543ser_8\NN\1740|(|c.1629t-c|;|) (l_compound) c.1629t-c_6\NN\1740|
T2_T5 NONE thymine-to-cytosine_3\JJ\1740| (r_amod) polymorphism_4\NN\11418750|the|same|sense|thymine-to-cytosine|ser543ser (l_appos) ser543ser_8\NN\1740|(|c.1629t-c|;|)
12181427
T12_T32 NONE cilostazol_13\NN\1740| (r_conj) milrinone_11\NN\1740|with|and|cilostazol (r_nmod) sites_3\NNS\8673395|of|interaction|type|milrinone (l_nmod) type_8\NN\5839024|of|cyclic|nucleotide|phosphodiesterase|3a (l_nummod) 3a_9\CD\1740|
T13_T32 NONE nucleotide_6\NN\14850483| (r_compound) type_8\NN\5839024|of|cyclic|nucleotide|phosphodiesterase|3a (l_nummod) 3a_9\CD\1740|
T14_T32 NONE milrinone_11\NN\1740|with|and|cilostazol (r_nmod) sites_3\NNS\8673395|of|interaction|type|milrinone (l_nmod) type_8\NN\5839024|of|cyclic|nucleotide|phosphodiesterase|3a (l_nummod) 3a_9\CD\1740|
T3_T20 NONE acid_3\NN\14818238| (r_compound) residues_4\NNS\20827|amino|acid|involved (r_dobj) identify_1\VB\699815|to|residues|,|selected|using|. (l_parataxis) selected_12\VBD\697589|we|residues|pocket (l_nmod) pocket_20\NN\3993180|in|the|substrate-binding|pde3a (l_nmod) pde3a_22\NN\1740|of
T3_T21 NONE acid_3\NN\14818238| (r_compound) residues_4\NNS\20827|amino|acid|involved (r_dobj) identify_1\VB\699815|to|residues|,|selected|using|. (l_advcl) using_23\VBG\1156834|model (l_dobj) model_25\NN\5888929|a|created (l_acl) created_26\VBN\2367363|homology (l_nmod) homology_30\NN\4743605|on|basis|of|structure (l_nmod) structure_35\NN\21939|to|the|pde4b|crystal (l_compound) pde4b_33\NN\1740|
T3_T22 NONE acid_3\NN\14818238| (r_compound) residues_4\NNS\20827|amino|acid|involved (l_acl) involved_5\VBN\2676054|binding (l_nmod) binding_9\NN\4688246|in|pde3-selective|inhibitor (l_amod) pde3-selective_7\JJ\1740|
T5_T23 NONE alanine_5\NN\14601829|to (r_nmod) changed_1\VBD\46534|we|residues|alanine|using|expressed|. (l_dep) expressed_11\VBD\928630|mutants|system|,|and|analyzed (l_conj) analyzed_21\VBD\78760|characteristics (l_dobj) characteristics_24\NNS\5849040|the|kinetic|inhibition (l_nmod) inhibition_26\NN\1068773|of|enzymes|milrinone (l_nmod) milrinone_32\NN\1740|by|and|cilostazol|,|inhibitors (l_appos) inhibitors_37\NNS\20090|specific|pde3 (l_nmod) pde3_39\NN\1740|of
T6_T23 CPR:4 milrinone_32\NN\1740|by|and|cilostazol|,|inhibitors (l_appos) inhibitors_37\NNS\20090|specific|pde3 (l_nmod) pde3_39\NN\1740|of
T7_T23 CPR:4 cilostazol_34\NN\1740| (r_conj) milrinone_32\NN\1740|by|and|cilostazol|,|inhibitors (l_appos) inhibitors_37\NNS\20090|specific|pde3 (l_nmod) pde3_39\NN\1740|of
T8_T24 CPR:4 milrinone_11\NN\1740|to (r_nmod) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (r_dobj) had_7\VBD\2108377|mutants|sensitivity|higher|. (l_nsubj) mutants_0\NNS\4475|y751a (l_dep) y751a_1\NN\1740|,|d950a|,|and|f1004a
T8_T25 CPR:4 milrinone_11\NN\1740|to (r_nmod) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (r_dobj) had_7\VBD\2108377|mutants|sensitivity|higher|. (l_nsubj) mutants_0\NNS\4475|y751a (l_dep) y751a_1\NN\1740|,|d950a|,|and|f1004a (l_conj) d950a_3\NN\1740|
T8_T26 CPR:4 milrinone_11\NN\1740|to (r_nmod) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (r_dobj) had_7\VBD\2108377|mutants|sensitivity|higher|. (l_nsubj) mutants_0\NNS\4475|y751a (l_dep) y751a_1\NN\1740|,|d950a|,|and|f1004a (l_conj) f1004a_6\NN\1740|
T8_T27 CPR:4 milrinone_11\NN\1740|to (r_nmod) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (l_dep) changed_15\VBN\46534|(|k(i|microm|microm|) (l_nmod) microm_18\NNS\1740|from|0.66|pde3a (l_nmod) pde3a_22\NN\1740|for|the|recombinant
T8_T28 NONE milrinone_11\NN\1740|to (r_nmod) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (r_dobj) had_7\VBD\2108377|mutants|sensitivity|higher|. (l_parataxis) higher_48\JJR\1740|(|k(i|were|371-fold|that|) (l_nmod) that_50\DT\1740|than|pde3a (l_nmod) pde3a_54\NN\1740|of|the|recombinant
T9_T24 NONE cilostazol_37\NN\1740|to (r_nmod) sensitivity_35\NN\5651971|diminished|cilostazol (r_conj) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (r_dobj) had_7\VBD\2108377|mutants|sensitivity|higher|. (l_nsubj) mutants_0\NNS\4475|y751a (l_dep) y751a_1\NN\1740|,|d950a|,|and|f1004a
T9_T25 NONE cilostazol_37\NN\1740|to (r_nmod) sensitivity_35\NN\5651971|diminished|cilostazol (r_conj) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (r_dobj) had_7\VBD\2108377|mutants|sensitivity|higher|. (l_nsubj) mutants_0\NNS\4475|y751a (l_dep) y751a_1\NN\1740|,|d950a|,|and|f1004a (l_conj) d950a_3\NN\1740|
T9_T26 NONE cilostazol_37\NN\1740|to (r_nmod) sensitivity_35\NN\5651971|diminished|cilostazol (r_conj) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (r_dobj) had_7\VBD\2108377|mutants|sensitivity|higher|. (l_nsubj) mutants_0\NNS\4475|y751a (l_dep) y751a_1\NN\1740|,|d950a|,|and|f1004a (l_conj) f1004a_6\NN\1740|
T9_T27 NONE cilostazol_37\NN\1740|to (r_nmod) sensitivity_35\NN\5651971|diminished|cilostazol (r_conj) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (l_dep) changed_15\VBN\46534|(|k(i|microm|microm|) (l_nmod) microm_18\NNS\1740|from|0.66|pde3a (l_nmod) pde3a_22\NN\1740|for|the|recombinant
T9_T28 CPR:4 cilostazol_37\NN\1740|to (r_nmod) sensitivity_35\NN\5651971|diminished|cilostazol (r_conj) sensitivity_9\NN\5651971|reduced|milrinone|changed|,|and|sensitivity (r_dobj) had_7\VBD\2108377|mutants|sensitivity|higher|. (l_parataxis) higher_48\JJR\1740|(|k(i|were|371-fold|that|) (l_nmod) that_50\DT\1740|than|pde3a (l_nmod) pde3a_54\NN\1740|of|the|recombinant
T10_T15 CPR:4 cilostazol_15\NN\1740|for (r_nmod) k(i_12\NN\1740|increased|)|cilostazol (r_dobj) showed_10\VBD\2137132|contrast|,|mutants|k(i|but|difference|. (l_conj) difference_18\NN\4723816|no|milrinone|pde3a (l_nmod) pde3a_24\NN\1740|from|the|recombinant
T10_T29 CPR:4 cilostazol_15\NN\1740|for (r_nmod) k(i_12\NN\1740|increased|)|cilostazol (r_dobj) showed_10\VBD\2137132|contrast|,|mutants|k(i|but|difference|. (l_nsubj) mutants_4\NNS\4475|the|t844a (l_dep) t844a_5\NN\1740|,|f972a|and|q975a
T10_T30 CPR:4 cilostazol_15\NN\1740|for (r_nmod) k(i_12\NN\1740|increased|)|cilostazol (r_dobj) showed_10\VBD\2137132|contrast|,|mutants|k(i|but|difference|. (l_nsubj) mutants_4\NNS\4475|the|t844a (l_dep) t844a_5\NN\1740|,|f972a|and|q975a (l_conj) f972a_7\NN\1740|
T10_T31 CPR:4 cilostazol_15\NN\1740|for (r_nmod) k(i_12\NN\1740|increased|)|cilostazol (r_dobj) showed_10\VBD\2137132|contrast|,|mutants|k(i|but|difference|. (l_nsubj) mutants_4\NNS\4475|the|t844a (l_dep) t844a_5\NN\1740|,|f972a|and|q975a (l_conj) q975a_9\NN\1740|
T11_T15 CPR:4 milrinone_20\NN\1740|for (r_nmod) difference_18\NN\4723816|no|milrinone|pde3a (l_nmod) pde3a_24\NN\1740|from|the|recombinant
T11_T29 CPR:4 milrinone_20\NN\1740|for (r_nmod) difference_18\NN\4723816|no|milrinone|pde3a (r_conj) showed_10\VBD\2137132|contrast|,|mutants|k(i|but|difference|. (l_nsubj) mutants_4\NNS\4475|the|t844a (l_dep) t844a_5\NN\1740|,|f972a|and|q975a
T11_T30 CPR:4 milrinone_20\NN\1740|for (r_nmod) difference_18\NN\4723816|no|milrinone|pde3a (r_conj) showed_10\VBD\2137132|contrast|,|mutants|k(i|but|difference|. (l_nsubj) mutants_4\NNS\4475|the|t844a (l_dep) t844a_5\NN\1740|,|f972a|and|q975a (l_conj) f972a_7\NN\1740|
T11_T31 CPR:4 milrinone_20\NN\1740|for (r_nmod) difference_18\NN\4723816|no|milrinone|pde3a (r_conj) showed_10\VBD\2137132|contrast|,|mutants|k(i|but|difference|. (l_nsubj) mutants_4\NNS\4475|the|t844a (l_dep) t844a_5\NN\1740|,|f972a|and|q975a (l_conj) q975a_9\NN\1740|
T1_T16 CPR:4 cilostazol_7\NN\1740|and|milrinone (r_dep) inhibitors_6\NNS\20090|the|pde3|cilostazol (l_compound) pde3_5\NN\1740|
T1_T17 NONE cilostazol_7\NN\1740|and|milrinone (r_dep) inhibitors_6\NNS\20090|the|pde3|cilostazol (r_nsubj) share_10\VBP\2660631|that|inhibitors|some|but|interact|,|suggesting (l_advcl) suggesting_25\VBG\1010118|designed (l_ccomp) designed_31\VBN\1631534|that|inhibitors|can|be|size|site (l_nmod) site_38\NN\8673395|against|pde3|active (l_compound) pde3_36\NN\1740|
T2_T16 CPR:4 milrinone_9\NN\1740| (r_conj) cilostazol_7\NN\1740|and|milrinone (r_dep) inhibitors_6\NNS\20090|the|pde3|cilostazol (l_compound) pde3_5\NN\1740|
T2_T17 NONE milrinone_9\NN\1740| (r_conj) cilostazol_7\NN\1740|and|milrinone (r_dep) inhibitors_6\NNS\20090|the|pde3|cilostazol (r_nsubj) share_10\VBP\2660631|that|inhibitors|some|but|interact|,|suggesting (l_advcl) suggesting_25\VBG\1010118|designed (l_ccomp) designed_31\VBN\1631534|that|inhibitors|can|be|size|site (l_nmod) site_38\NN\8673395|against|pde3|active (l_compound) pde3_36\NN\1740|
T4_T18 CPR:4 cilostazol_35\NN\1740| (r_compound) selectivity_36\NN\4916342|for|the|cilostazol|pde3a (r_nmod) responsible_32\JJ\1740|t844|may|be|selectivity (r_conj) residues_18\NNS\20827|that|residuals|are|key|binding|,|and|responsible (l_nsubj) residuals_6\NNS\13809207|conserved|y751|families (l_nmod) families_15\NNS\8189659|in|the|pde (l_compound) pde_14\NN\1740|
T4_T19 CPR:4 cilostazol_35\NN\1740| (r_compound) selectivity_36\NN\4916342|for|the|cilostazol|pde3a (l_nmod) pde3a_38\NN\1740|of
14757145
T11_T20 NONE isoprenaline-induced_10\JJ\1740| (r_amod) fibrosis_12\NN\14204950|isoprenaline-induced|cardiac (r_dobj) reduce_9\VBP\441445|blockade|fibrosis|. (l_nsubj) blockade_0\NN\952963|beta|and|desensitization (l_nmod) beta_2\NN\6828818|of|1- (l_nummod) 1-_3\CD\1740|
T11_T21 NONE isoprenaline-induced_10\JJ\1740| (r_amod) fibrosis_12\NN\14204950|isoprenaline-induced|cardiac (r_dobj) reduce_9\VBP\441445|blockade|fibrosis|. (l_nsubj) blockade_0\NN\952963|beta|and|desensitization (l_conj) desensitization_5\NN\13458571|2-adrenoceptors (l_nmod) 2-adrenoceptors_8\NNS\1740|of|beta
T10_T17 NONE catecholamine-induced_17\JJ\1740| (r_amod) remodeling_19\NN\1740|in|the|catecholamine-induced|myocardial|,|fibrosis (r_nmod) role_10\NN\719494|the|beta(1)-|remodeling (l_nmod) beta(1)-_12\NN\1740|of|and|beta(2)-adrenoceptors (l_conj) beta(2)-adrenoceptors_14\NNS\1740|
T3_T14 CPR:6 bisoprolol_11\NN\1740|p.o. (r_appos) antagonist_9\NN\7846|with|the|selective|beta(1)-adrenoceptor|,|bisoprolol (l_compound) beta(1)-adrenoceptor_8\NN\1740|
T3_T15 NONE bisoprolol_11\NN\1740|p.o. (r_appos) antagonist_9\NN\7846|with|the|selective|beta(1)-adrenoceptor|,|bisoprolol (r_nmod) treatment_4\NN\654885|a|concomitant|antagonist (r_dobj) received_1\VBD\2210855|rats|treatment|or|pretreated|. (l_conj) pretreated_20\VBN\1740|were|chronically|agonist|week|induce (l_nmod) agonist_25\NN\9613191|with|the|selective|beta(2)-adrenoceptor|salbutamol (l_compound) beta(2)-adrenoceptor_24\NN\1740|
T3_T16 NONE bisoprolol_11\NN\1740|p.o. (r_appos) antagonist_9\NN\7846|with|the|selective|beta(1)-adrenoceptor|,|bisoprolol (r_nmod) treatment_4\NN\654885|a|concomitant|antagonist (r_dobj) received_1\VBD\2210855|rats|treatment|or|pretreated|. (l_conj) pretreated_20\VBN\1740|were|chronically|agonist|week|induce (l_xcomp) induce_35\VB\1627355|to|desensitization (l_dobj) desensitization_37\NN\13458571|beta(2)-adrenoceptor (l_compound) beta(2)-adrenoceptor_36\NN\1740|
T4_T14 NONE salbutamol_26\NN\1740|microg/kg/h (r_dep) agonist_25\NN\9613191|with|the|selective|beta(2)-adrenoceptor|salbutamol (r_nmod) pretreated_20\VBN\1740|were|chronically|agonist|week|induce (r_conj) received_1\VBD\2210855|rats|treatment|or|pretreated|. (l_dobj) treatment_4\NN\654885|a|concomitant|antagonist (l_nmod) antagonist_9\NN\7846|with|the|selective|beta(1)-adrenoceptor|,|bisoprolol (l_compound) beta(1)-adrenoceptor_8\NN\1740|
T4_T15 CPR:5 salbutamol_26\NN\1740|microg/kg/h (r_dep) agonist_25\NN\9613191|with|the|selective|beta(2)-adrenoceptor|salbutamol (l_compound) beta(2)-adrenoceptor_24\NN\1740|
T4_T16 NONE salbutamol_26\NN\1740|microg/kg/h (r_dep) agonist_25\NN\9613191|with|the|selective|beta(2)-adrenoceptor|salbutamol (r_nmod) pretreated_20\VBN\1740|were|chronically|agonist|week|induce (l_xcomp) induce_35\VB\1627355|to|desensitization (l_dobj) desensitization_37\NN\13458571|beta(2)-adrenoceptor (l_compound) beta(2)-adrenoceptor_36\NN\1740|
T5_T18 CPR:4 salbutamol_3\NN\1740|with (r_nmod) pretreatment_1\NN\1740|the|salbutamol (r_nsubj) induced_4\VBD\1627355|pretreatment|down-regulation|. (l_dobj) down-regulation_8\NN\1740|a|%|beta(2)-adrenoceptors|control (l_nmod) beta(2)-adrenoceptors_12\NNS\1740|of|ventricular
T1_T12 NONE isoprenaline-induced_9\JJ\1740| (r_amod) fibrosis_12\NN\14204950|against|isoprenaline-induced|cardiac|interstitial (r_nmod) protection_7\NN\407535|similar|fibrosis (r_dobj) provided_5\VBD\2199590|blockade|protection|suggesting|. (l_nsubj) blockade_1\NN\952963|beta(1)-adrenoceptor|and|down-regulation (l_conj) down-regulation_4\NN\1740|beta(2)-adrenoceptors (l_compound) beta(2)-adrenoceptors_3\NNS\1740|
T1_T13 NONE isoprenaline-induced_9\JJ\1740| (r_amod) fibrosis_12\NN\14204950|against|isoprenaline-induced|cardiac|interstitial (r_nmod) protection_7\NN\407535|similar|fibrosis (r_dobj) provided_5\VBD\2199590|blockade|protection|suggesting|. (l_advcl) suggesting_13\VBG\1010118|involved (l_ccomp) involved_18\VBN\2676054|that|beta-adrenoceptors|are|process (l_nsubjpass) beta-adrenoceptors_16\NNS\5608868|both
T1_T19 NONE isoprenaline-induced_9\JJ\1740| (r_amod) fibrosis_12\NN\14204950|against|isoprenaline-induced|cardiac|interstitial (r_nmod) protection_7\NN\407535|similar|fibrosis (r_dobj) provided_5\VBD\2199590|blockade|protection|suggesting|. (l_nsubj) blockade_1\NN\952963|beta(1)-adrenoceptor|and|down-regulation (l_compound) beta(1)-adrenoceptor_0\NN\1740|
23583258
T11_T23 CPR:3 oxysterols_27\NNS\1740|of (r_compound) representative_28\NN\10351874|oxysterols|diet (r_nmod) mixture_25\NN\19613|by|a|representative (r_nmod) caused_22\VBN\1617192|mixture (r_acl) interleukins_16\NNS\14943950|of|two|key|inflammatory|,|il-6|,|caused
T11_T24 CPR:3 oxysterols_27\NNS\1740|of (r_compound) representative_28\NN\10351874|oxysterols|diet (r_nmod) mixture_25\NN\19613|by|a|representative (r_nmod) caused_22\VBN\1617192|mixture (r_acl) interleukins_16\NNS\14943950|of|two|key|inflammatory|,|il-6|,|caused (l_appos) il-6_18\NN\1740|and|il-8
T11_T25 CPR:3 oxysterols_27\NNS\1740|of (r_compound) representative_28\NN\10351874|oxysterols|diet (r_nmod) mixture_25\NN\19613|by|a|representative (r_nmod) caused_22\VBN\1617192|mixture (r_acl) interleukins_16\NNS\14943950|of|two|key|inflammatory|,|il-6|,|caused (l_appos) il-6_18\NN\1740|and|il-8 (l_conj) il-8_20\NN\1740|
T12_T23 CPR:3 cholesterol_32\NN\15058310| (r_compound) diet_33\NN\7560652|of|a|high|cholesterol (r_nmod) representative_28\NN\10351874|oxysterols|diet (r_nmod) mixture_25\NN\19613|by|a|representative (r_nmod) caused_22\VBN\1617192|mixture (r_acl) interleukins_16\NNS\14943950|of|two|key|inflammatory|,|il-6|,|caused
T12_T24 CPR:3 cholesterol_32\NN\15058310| (r_compound) diet_33\NN\7560652|of|a|high|cholesterol (r_nmod) representative_28\NN\10351874|oxysterols|diet (r_nmod) mixture_25\NN\19613|by|a|representative (r_nmod) caused_22\VBN\1617192|mixture (r_acl) interleukins_16\NNS\14943950|of|two|key|inflammatory|,|il-6|,|caused (l_appos) il-6_18\NN\1740|and|il-8
T12_T25 CPR:3 cholesterol_32\NN\15058310| (r_compound) diet_33\NN\7560652|of|a|high|cholesterol (r_nmod) representative_28\NN\10351874|oxysterols|diet (r_nmod) mixture_25\NN\19613|by|a|representative (r_nmod) caused_22\VBN\1617192|mixture (r_acl) interleukins_16\NNS\14943950|of|two|key|inflammatory|,|il-6|,|caused (l_appos) il-6_18\NN\1740|and|il-8 (l_conj) il-8_20\NN\1740|
T14_T26 NONE oxygen_23\NN\14622893| (r_compound) species_24\NNS\7992450|of|reactive|oxygen (r_nmod) levels_20\NNS\4916342|of|excessive|species (r_nmod) production_17\NN\30358|with|the|levels|activation (l_nmod) activation_30\NN\13561719|through|the|colonic|nadph-oxidase|nox1 (l_compound) nadph-oxidase_28\NN\1740|
T14_T27 NONE oxygen_23\NN\14622893| (r_compound) species_24\NNS\7992450|of|reactive|oxygen (r_nmod) levels_20\NNS\4916342|of|excessive|species (r_nmod) production_17\NN\30358|with|the|levels|activation (l_nmod) activation_30\NN\13561719|through|the|colonic|nadph-oxidase|nox1 (l_compound) nox1_29\NN\1740|
T15_T26 NONE nadph-oxidase_28\NN\1740|
T15_T27 NONE nadph-oxidase_28\NN\1740| (r_compound) activation_30\NN\13561719|through|the|colonic|nadph-oxidase|nox1 (l_compound) nox1_29\NN\1740|
T17_T29 CPR:3 oxysterol-dependent_0\JJ\1740| (r_amod) activation_2\NN\13561719|oxysterol-dependent|nox1|,|as|synthesis|, (l_compound) nox1_1\NN\1740|
T17_T30 CPR:3 oxysterol-dependent_0\JJ\1740| (r_amod) activation_2\NN\13561719|oxysterol-dependent|nox1|,|as|synthesis|, (l_conj) synthesis_8\NN\13446390|interleukin (l_compound) interleukin_7\NN\14943950|
T2_T29 CPR:4 acids_28\NNS\14818238|particular|phenolic|and|flavonoids (r_nmod) contains_19\VBZ\2632940|that|fraction|,|acids (r_acl:relcl) extract_17\NN\14589223|by|cannonau|wine|contains (r_nmod) prevented_12\VBN\1740|activation|were|completely|extract|. (l_nsubjpass) activation_2\NN\13561719|oxysterol-dependent|nox1|,|as|synthesis|, (l_compound) nox1_1\NN\1740|
T2_T30 CPR:4 acids_28\NNS\14818238|particular|phenolic|and|flavonoids (r_nmod) contains_19\VBZ\2632940|that|fraction|,|acids (r_acl:relcl) extract_17\NN\14589223|by|cannonau|wine|contains (r_nmod) prevented_12\VBN\1740|activation|were|completely|extract|. (l_nsubjpass) activation_2\NN\13561719|oxysterol-dependent|nox1|,|as|synthesis|, (l_conj) synthesis_8\NN\13446390|interleukin (l_compound) interleukin_7\NN\14943950|
T3_T29 CPR:4 flavonoids_30\NNS\14983143| (r_conj) acids_28\NNS\14818238|particular|phenolic|and|flavonoids (r_nmod) contains_19\VBZ\2632940|that|fraction|,|acids (r_acl:relcl) extract_17\NN\14589223|by|cannonau|wine|contains (r_nmod) prevented_12\VBN\1740|activation|were|completely|extract|. (l_nsubjpass) activation_2\NN\13561719|oxysterol-dependent|nox1|,|as|synthesis|, (l_compound) nox1_1\NN\1740|
T3_T30 CPR:4 flavonoids_30\NNS\14983143| (r_conj) acids_28\NNS\14818238|particular|phenolic|and|flavonoids (r_nmod) contains_19\VBZ\2632940|that|fraction|,|acids (r_acl:relcl) extract_17\NN\14589223|by|cannonau|wine|contains (r_nmod) prevented_12\VBN\1740|activation|were|completely|extract|. (l_nsubjpass) activation_2\NN\13561719|oxysterol-dependent|nox1|,|as|synthesis|, (l_conj) synthesis_8\NN\13446390|interleukin (l_compound) interleukin_7\NN\14943950|
T4_T20 CPR:3 oxysterols_28\NNS\1740|by|dietary (r_nmod) induced_25\VBN\1627355|oxysterols (r_acl) synthesis_24\NN\13446390|in|interleukin|induced (r_nmod) ineffective_21\JJ\1740|was|synthesis (r_conj) showed_13\VBD\2137132|conversely|,|pre-treatment|down-regulation|and|ineffective|. (l_dobj) down-regulation_18\NN\1740|only|a|partial|nox1 (l_compound) nox1_17\NN\1740|
T4_T21 CPR:3 oxysterols_28\NNS\1740|by|dietary (r_nmod) induced_25\VBN\1627355|oxysterols (r_acl) synthesis_24\NN\13446390|in|interleukin|induced (l_compound) interleukin_23\NN\14943950|
T10_T22 NONE oxysterols_38\NNS\1740|by|dietary (r_nmod) triggered_35\VBN\1641914|oxysterols (r_acl) events_34\NNS\23100|the|pro-oxidant|triggered (r_dobj) preventing_29\VBG\1740|thus|totally|events (r_advcl) exert_16\VB\1158872|activity|,|excess|,|may|action|blocking|,|preventing|. (l_advcl) blocking_22\VBG\1476483|by|induction (l_dobj) induction_25\NN\7450842|oxysterol-related|nox1 (l_compound) nox1_24\NN\1740|
T8_T22 CPR:4 phenolic_8\JJ\1740| (r_amod) compounds_9\NNS\5869584|of|phenolic|detectable (r_nmod) excess_6\NN\5119367|an|compounds (r_nsubj) exert_16\VB\1158872|activity|,|excess|,|may|action|blocking|,|preventing|. (l_advcl) blocking_22\VBG\1476483|by|induction (l_dobj) induction_25\NN\7450842|oxysterol-related|nox1 (l_compound) nox1_24\NN\1740|
T9_T22 CPR:3 oxysterol-related_23\JJ\1740| (r_amod) induction_25\NN\7450842|oxysterol-related|nox1 (l_compound) nox1_24\NN\1740|
15446566
T11_T19 NONE thalidomide_0\NN\4166841| (r_nsubj) decreased_1\VBD\169651|thalidomide|stability|. (l_dobj) stability_3\NN\4777852|the|tnf-mrna (l_nmod) tnf-mrna_5\NN\1740|of|and|mrna
T11_T20 NONE thalidomide_0\NN\4166841| (r_nsubj) decreased_1\VBD\169651|thalidomide|stability|. (l_dobj) stability_3\NN\4777852|the|tnf-mrna (l_nmod) tnf-mrna_5\NN\1740|of|and|mrna (l_conj) mrna_8\NN\14832193|cox-2 (l_compound) cox-2_7\NN\14737847|
T12_T24 NONE celecoxib_1\NN\3124700| (r_nsubj) inhibits_2\VBZ\2510337|although|celecoxib|biosynthesis (r_advcl) affect_9\VB\126264|inhibits|,|most|do|not|activity|. (l_dobj) activity_12\NN\30358|the|peroxidase|cox|,|generate (l_compound) peroxidase_11\NN\14971234|
T12_T25 NONE celecoxib_1\NN\3124700| (r_nsubj) inhibits_2\VBZ\2510337|although|celecoxib|biosynthesis (r_advcl) affect_9\VB\126264|inhibits|,|most|do|not|activity|. (l_dobj) activity_12\NN\30358|the|peroxidase|cox|,|generate (l_nmod) cox_14\NN\14732946|of
T13_T26 NONE thalidomide_1\NN\4166841| (r_nsubj) inhibit_5\VB\2510337|because|thalidomide|does|not|completely|expression (l_dobj) expression_7\NN\4679549|cox-2|or|biosynthesis (l_compound) cox-2_6\NN\14737847|
T14_T26 NONE celecoxib_16\NN\3124700| (r_dobj) combining_15\VBG\2630189|celecoxib|thalidomide (r_acl) strategy_14\NN\5902545|a|therapeutic|combining (r_nsubj) effective_22\JJ\1740|inhibit|,|strategy|might|be|more|using|. (l_advcl) inhibit_5\VB\2510337|because|thalidomide|does|not|completely|expression (l_dobj) expression_7\NN\4679549|cox-2|or|biosynthesis (l_compound) cox-2_6\NN\14737847|
T15_T26 NONE thalidomide_18\NN\4166841|with (r_nmod) combining_15\VBG\2630189|celecoxib|thalidomide (r_acl) strategy_14\NN\5902545|a|therapeutic|combining (r_nsubj) effective_22\JJ\1740|inhibit|,|strategy|might|be|more|using|. (l_advcl) inhibit_5\VB\2510337|because|thalidomide|does|not|completely|expression (l_dobj) expression_7\NN\4679549|cox-2|or|biosynthesis (l_compound) cox-2_6\NN\14737847|
19057128
T14_T29 NONE captopril_0\NN\2673637| (r_nsubj) attenuates_1\VBZ\224901|captopril|metalloproteinase-2|hypertrophy|. (l_dobj) metalloproteinase-2_3\NN\1740|matrix|and|-9 (l_conj) -9_5\CD\1740|
T15_T29 NONE monocrotaline-induced_7\JJ\1740| (r_amod) hypertrophy_10\NN\14365950|in|monocrotaline-induced|ventricular|rats (r_nmod) attenuates_1\VBZ\224901|captopril|metalloproteinase-2|hypertrophy|. (l_dobj) metalloproteinase-2_3\NN\1740|matrix|and|-9 (l_conj) -9_5\CD\1740|
T10_T16 NONE angiotensin_7\NN\4522421| (r_compound) enzyme_9\NN\14723628|angiotensin|converting|ace (r_compound) inhibitors_13\NNS\20090|of|enzyme (r_nmod) influence_5\NN\5190804|about|the|inhibitors|metalloproteinase (l_nmod) metalloproteinase_16\NN\1740|on|matrix|mmp|remodeling (l_appos) mmp_18\NN\1740|(|)
T10_T24 NONE angiotensin_7\NN\4522421| (r_compound) enzyme_9\NN\14723628|angiotensin|converting|ace
T10_T27 NONE angiotensin_7\NN\4522421| (r_compound) enzyme_9\NN\14723628|angiotensin|converting|ace (l_appos) ace_11\NN\13741022|(|)
T10_T28 NONE angiotensin_7\NN\4522421| (r_compound) enzyme_9\NN\14723628|angiotensin|converting|ace (r_compound) inhibitors_13\NNS\20090|of|enzyme (r_nmod) influence_5\NN\5190804|about|the|inhibitors|metalloproteinase (l_nmod) metalloproteinase_16\NN\1740|on|matrix|mmp|remodeling
T7_T21 CPR:4 captopril_5\NN\2673637|of|,|inhibitor|, (l_appos) inhibitor_9\NN\20090|an|ace (l_compound) ace_8\NN\13741022|
T7_T22 NONE captopril_5\NN\2673637|of|,|inhibitor|, (r_nmod) effect_3\NN\34213|the|captopril|mmp-2 (l_nmod) mmp-2_12\NN\1740|on|and|mmp-9|hypertrophy
T7_T23 NONE captopril_5\NN\2673637|of|,|inhibitor|, (r_nmod) effect_3\NN\34213|the|captopril|mmp-2 (l_nmod) mmp-2_12\NN\1740|on|and|mmp-9|hypertrophy (l_conj) mmp-9_14\NN\1740|
T8_T21 NONE monocrotaline-induced_16\JJ\1740| (r_amod) hypertrophy_19\NN\14365950|in|monocrotaline-induced|ventricular (r_nmod) mmp-2_12\NN\1740|on|and|mmp-9|hypertrophy (r_nmod) effect_3\NN\34213|the|captopril|mmp-2 (l_nmod) captopril_5\NN\2673637|of|,|inhibitor|, (l_appos) inhibitor_9\NN\20090|an|ace (l_compound) ace_8\NN\13741022|
T8_T22 NONE monocrotaline-induced_16\JJ\1740| (r_amod) hypertrophy_19\NN\14365950|in|monocrotaline-induced|ventricular (r_nmod) mmp-2_12\NN\1740|on|and|mmp-9|hypertrophy
T8_T23 NONE monocrotaline-induced_16\JJ\1740| (r_amod) hypertrophy_19\NN\14365950|in|monocrotaline-induced|ventricular (r_nmod) mmp-2_12\NN\1740|on|and|mmp-9|hypertrophy (l_conj) mmp-9_14\NN\1740|
T3_T17 CPR:3 monocrotaline-injected_12\JJ\1740| (r_amod) rats_13\NNS\2329401|in|monocrotaline-injected (r_nmod) increased_9\VBD\169651|mmp-2|significantly|rats|and|inhibited|. (l_nsubj) mmp-2_0\NN\1740|and|mmp-9|expressions|ventricles
T3_T18 CPR:3 monocrotaline-injected_12\JJ\1740| (r_amod) rats_13\NNS\2329401|in|monocrotaline-injected (r_nmod) increased_9\VBD\169651|mmp-2|significantly|rats|and|inhibited|. (l_nsubj) mmp-2_0\NN\1740|and|mmp-9|expressions|ventricles (l_conj) mmp-9_2\NN\1740|
T4_T17 CPR:4 captopril_15\NN\2673637| (r_nsubj) inhibited_16\VBD\2510337|captopril|them (r_conj) increased_9\VBD\169651|mmp-2|significantly|rats|and|inhibited|. (l_nsubj) mmp-2_0\NN\1740|and|mmp-9|expressions|ventricles
T4_T18 CPR:4 captopril_15\NN\2673637| (r_nsubj) inhibited_16\VBD\2510337|captopril|them (r_conj) increased_9\VBD\169651|mmp-2|significantly|rats|and|inhibited|. (l_nsubj) mmp-2_0\NN\1740|and|mmp-9|expressions|ventricles (l_conj) mmp-9_2\NN\1740|
T5_T19 CPR:4 captopril_4\NN\2673637| (r_nsubj) attenuates_5\VBZ\224901|that|captopril|development|association (l_nmod) association_14\NN\8008335|in|inhibition (l_nmod) inhibition_16\NN\1068773|with|mmp-2 (l_nmod) mmp-2_18\NN\1740|of|and|mmp-9|rats
T5_T20 CPR:4 captopril_4\NN\2673637| (r_nsubj) attenuates_5\VBZ\224901|that|captopril|development|association (l_nmod) association_14\NN\8008335|in|inhibition (l_nmod) inhibition_16\NN\1068773|with|mmp-2 (l_nmod) mmp-2_18\NN\1740|of|and|mmp-9|rats (l_conj) mmp-9_20\NN\1740|
T6_T19 CPR:3 monocrotaline-induced_9\JJ\1740| (r_amod) hypertrophy_12\NN\14365950|of|monocrotaline-induced|right|ventricular (r_nmod) development_7\NN\248977|the|hypertrophy (r_dobj) attenuates_5\VBZ\224901|that|captopril|development|association (l_nmod) association_14\NN\8008335|in|inhibition (l_nmod) inhibition_16\NN\1068773|with|mmp-2 (l_nmod) mmp-2_18\NN\1740|of|and|mmp-9|rats
T6_T20 CPR:3 monocrotaline-induced_9\JJ\1740| (r_amod) hypertrophy_12\NN\14365950|of|monocrotaline-induced|right|ventricular (r_nmod) development_7\NN\248977|the|hypertrophy (r_dobj) attenuates_5\VBZ\224901|that|captopril|development|association (l_nmod) association_14\NN\8008335|in|inhibition (l_nmod) inhibition_16\NN\1068773|with|mmp-2 (l_nmod) mmp-2_18\NN\1740|of|and|mmp-9|rats (l_conj) mmp-9_20\NN\1740|
1543672
T18_T25 CPR:4 terbinafine_0\NN\2720201|:|mode (l_dep) mode_2\NN\4916342|action|and|properties|. (l_conj) properties_6\NNS\32613|inhibition (l_nmod) inhibition_11\NN\1068773|of|the|squalene|epoxidase (l_compound) epoxidase_10\NN\1740|
T19_T25 NONE squalene_9\NN\1740| (r_compound) inhibition_11\NN\1068773|of|the|squalene|epoxidase (l_compound) epoxidase_10\NN\1740|
T1_T20 CPR:4 terbinafine_0\NN\2720201|lamisil (r_nsubj) has_4\VBZ\2108377|terbinafine|action|fungi|result|. (l_nmod) result_13\NN\34213|as|a|mechanism (l_nmod) mechanism_17\NN\13446390|of|its|specific|inhibition (l_nmod) inhibition_21\NN\1068773|of|squalene|epoxidase (l_compound) epoxidase_20\NN\1740|
T5_T20 NONE squalene_19\NN\1740| (r_compound) inhibition_21\NN\1068773|of|squalene|epoxidase (l_compound) epoxidase_20\NN\1740|
T7_T20 CPR:4 lamisil_2\NN\2720201|(|) (r_appos) terbinafine_0\NN\2720201|lamisil (r_nsubj) has_4\VBZ\2108377|terbinafine|action|fungi|result|. (l_nmod) result_13\NN\34213|as|a|mechanism (l_nmod) mechanism_17\NN\13446390|of|its|specific|inhibition (l_nmod) inhibition_21\NN\1068773|of|squalene|epoxidase (l_compound) epoxidase_20\NN\1740|
T15_T23 CPR:4 terbinafine_0\NN\2720201| (r_nsubj) inhibitor_5\NN\20090|terbinafine|is|a|potent|non-competitive|epoxidase|=|. (l_nmod) epoxidase_8\NN\1740|of|squalene|candida
T16_T23 NONE squalene_7\NN\1740| (r_compound) epoxidase_8\NN\1740|of|squalene|candida
T17_T24 NONE squalene_7\NN\1740| (r_compound) epoxidase_8\NN\1740|of|rat|liver|squalene
T2_T24 CPR:4 squalene_26\NN\1740|with (r_nmod) competitive_24\JJ\1740|is|squalene (r_conj) occurs_10\VBZ\2623529|contrast|,|inhibition|only|concentrations|ki|,|and|competitive|. (l_nsubj) inhibition_3\NN\1068773|epoxidase (l_nmod) epoxidase_8\NN\1740|of|rat|liver|squalene
T6_T21 NONE squalene_0\NN\1740| (r_compound) epoxidase_1\NN\1740|squalene
T6_T22 NONE squalene_0\NN\1740| (r_compound) epoxidase_1\NN\1740|squalene (r_nsubj) enzyme_5\NN\14723628|epoxidase|is|not|an|type|,|avoiding|. (l_nmod) type_10\NN\5839024|of|the|cytochrome|p-450 (l_compound) p-450_9\NN\1740|
17604186
T20_T30 CPR:4 nimesulide_3\NN\1740|of|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|preferential|cox-2 (l_compound) cox-2_7\NN\14737847|
T21_T30 NONE pentylenetetrazol_11\NN\3740161| (r_nmod:npmod) (ptz)-induced_12\JJ\1740|pentylenetetrazol (r_amod) kindling_14\NN\15101361|against|(ptz)-induced|chemical|and|parameters (r_nmod) effect_1\NN\34213|neuroprotective|nimesulide|kindling|. (l_nmod) nimesulide_3\NN\1740|of|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|preferential|cox-2 (l_compound) cox-2_7\NN\14737847|
T22_T30 NONE (ptz)-induced_12\JJ\1740|pentylenetetrazol (r_amod) kindling_14\NN\15101361|against|(ptz)-induced|chemical|and|parameters (r_nmod) effect_1\NN\34213|neuroprotective|nimesulide|kindling|. (l_nmod) nimesulide_3\NN\1740|of|,|inhibitor|, (l_appos) inhibitor_8\NN\20090|a|preferential|cox-2 (l_compound) cox-2_7\NN\14737847|
T15_T25 CPR:9 prostaglandin_10\NN\5414534| (r_compound) synthesis_11\NN\13446390|in|prostaglandin (r_nmod) enzyme_8\NN\14723628|the|rate-limiting|synthesis (r_appos) cyclooxygenases_1\NNS\14732946|brain|cox|,|enzyme|, (l_appos) cox_3\NN\14732946|(|)
T15_T29 CPR:9 prostaglandin_10\NN\5414534| (r_compound) synthesis_11\NN\13446390|in|prostaglandin (r_nmod) enzyme_8\NN\14723628|the|rate-limiting|synthesis (r_appos) cyclooxygenases_1\NNS\14732946|brain|cox|,|enzyme|,
T10_T26 NONE rofecoxib_14\NN\3124700|inhibitor (r_conj) naproxen_8\NN\3828465|of|cox-inhibitor|or|rofecoxib (l_appos) cox-inhibitor_11\NN\1740|(|non-selective|)
T10_T27 CPR:4 rofecoxib_14\NN\3124700|inhibitor (l_appos) inhibitor_18\NN\20090|(|selective|cox-2|) (l_compound) cox-2_17\NN\14737847|
T9_T26 CPR:4 naproxen_8\NN\3828465|of|cox-inhibitor|or|rofecoxib (l_appos) cox-inhibitor_11\NN\1740|(|non-selective|)
T9_T27 NONE naproxen_8\NN\3828465|of|cox-inhibitor|or|rofecoxib (l_conj) rofecoxib_14\NN\3124700|inhibitor (l_appos) inhibitor_18\NN\20090|(|selective|cox-2|) (l_compound) cox-2_17\NN\14737847|
T11_T28 CPR:4 nimesulide_15\NN\1740|of|inhibitor (l_appos) inhibitor_20\NN\20090|(|a|preferential|cox-2|) (l_compound) cox-2_19\NN\14737847|
T12_T28 NONE pentylenetetrazol_23\NN\3740161| (r_nmod:npmod) (ptz)-induced_24\NN\1740|pentylenetetrazol (r_amod) epilepsy_26\NN\14085708|against|(ptz)-induced|kindling|mice (r_nmod) effect_13\NN\34213|the|possible|nimesulide|epilepsy (l_nmod) nimesulide_15\NN\1740|of|inhibitor (l_appos) inhibitor_20\NN\20090|(|a|preferential|cox-2|) (l_compound) cox-2_19\NN\14737847|
T13_T28 NONE (ptz)-induced_24\NN\1740|pentylenetetrazol (r_amod) epilepsy_26\NN\14085708|against|(ptz)-induced|kindling|mice (r_nmod) effect_13\NN\34213|the|possible|nimesulide|epilepsy (l_nmod) nimesulide_15\NN\1740|of|inhibitor (l_appos) inhibitor_20\NN\20090|(|a|preferential|cox-2|) (l_compound) cox-2_19\NN\14737847|
T1_T23 CPR:3 ptz-kindled_6\JJ\1740| (r_amod) mice_7\NNS\2329401|ptz-kindled (r_nsubj) had_8\VBD\2108377|group|,|mice|levels|but|had|. (l_dobj) levels_11\NNS\4916342|higher|malondialdehyde (l_nmod) malondialdehyde_13\NN\1740|of|,|nitrite|,|myeloperoxidase (l_appos) myeloperoxidase_17\NN\1740|
T2_T23 NONE malondialdehyde_13\NN\1740|of|,|nitrite|,|myeloperoxidase (l_appos) myeloperoxidase_17\NN\1740|
T3_T23 NONE nitrite_15\NN\14621446| (r_appos) malondialdehyde_13\NN\1740|of|,|nitrite|,|myeloperoxidase (l_appos) myeloperoxidase_17\NN\1740|
T4_T23 NONE glutathione_24\NN\1740|of|reduced (r_nmod) levels_21\NNS\4916342|lower|glutathione (r_dobj) had_19\VBD\2108377|levels|homogenate (r_conj) had_8\VBD\2108377|group|,|mice|levels|but|had|. (l_dobj) levels_11\NNS\4916342|higher|malondialdehyde (l_nmod) malondialdehyde_13\NN\1740|of|,|nitrite|,|myeloperoxidase (l_appos) myeloperoxidase_17\NN\1740|
T7_T24 CPR:4 nimesulide_4\NN\1740|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|preferential|cox-2 (l_compound) cox-2_8\NN\14737847|
T8_T24 NONE ptz-induced_13\JJ\1740| (r_amod) kindling_14\NN\15101361|against|ptz-induced|mice (r_nmod) neuroprotection_11\NN\1740|kindling (r_dobj) offered_10\VBD\2327200|that|nimesulide|neuroprotection (l_nsubj) nimesulide_4\NN\1740|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|preferential|cox-2 (l_compound) cox-2_8\NN\14737847|
23561166
T6_T13 CPR:4 fisetin_30\NN\1740|with (r_nmod) supplementation_28\NN\5108947|by|fisetin (r_nmod) reversed_26\VBN\109660|which|was|subsequently|supplementation (r_advcl) increased_5\VBD\169651|diet|significantly|expressions|comparison|,|reversed|. (l_dobj) expressions_8\NNS\4679549|hepatic|mrna|pparγ (l_nmod) pparγ_10\NN\1740|of|,|srebp1c|and|scd-1|genes
T6_T14 CPR:4 fisetin_30\NN\1740|with (r_nmod) supplementation_28\NN\5108947|by|fisetin (r_nmod) reversed_26\VBN\109660|which|was|subsequently|supplementation (r_advcl) increased_5\VBD\169651|diet|significantly|expressions|comparison|,|reversed|. (l_dobj) expressions_8\NNS\4679549|hepatic|mrna|pparγ (l_nmod) pparγ_10\NN\1740|of|,|srebp1c|and|scd-1|genes (l_conj) srebp1c_12\NN\1740|
T6_T15 CPR:4 fisetin_30\NN\1740|with (r_nmod) supplementation_28\NN\5108947|by|fisetin (r_nmod) reversed_26\VBN\109660|which|was|subsequently|supplementation (r_advcl) increased_5\VBD\169651|diet|significantly|expressions|comparison|,|reversed|. (l_dobj) expressions_8\NNS\4679549|hepatic|mrna|pparγ (l_nmod) pparγ_10\NN\1740|of|,|srebp1c|and|scd-1|genes (l_conj) scd-1_14\NN\1740|
T7_T16 CPR:4 fisetin_3\NN\1740| (r_compound) supplementation_4\NN\5108947|fisetin (r_nsubj) reduced_6\VBD\441445|addition|,|supplementation|significantly|abundance|group|. (l_dobj) abundance_9\NN\5108740|hepatic|mrna|fas (l_nmod) fas_11\NN\14304060|of|,|atpcl|and|g6pase
T7_T17 CPR:4 fisetin_3\NN\1740| (r_compound) supplementation_4\NN\5108947|fisetin (r_nsubj) reduced_6\VBD\441445|addition|,|supplementation|significantly|abundance|group|. (l_dobj) abundance_9\NN\5108740|hepatic|mrna|fas (l_nmod) fas_11\NN\14304060|of|,|atpcl|and|g6pase (l_conj) atpcl_13\NN\1740|
T7_T18 CPR:4 fisetin_3\NN\1740| (r_compound) supplementation_4\NN\5108947|fisetin (r_nsubj) reduced_6\VBD\441445|addition|,|supplementation|significantly|abundance|group|. (l_dobj) abundance_9\NN\5108740|hepatic|mrna|fas (l_nmod) fas_11\NN\14304060|of|,|atpcl|and|g6pase (l_conj) g6pase_15\NN\1740|
T8_T19 CPR:3 fisetin_11\NN\1740| (r_compound) supplementation_12\NN\5108947|by|fisetin (r_nmod) increased_9\VBN\169651|finally|,|abundance|was|significantly|supplementation|,|levels|. (l_nsubjpass) abundance_4\NN\5108740|epididymal|mrna|glut4 (l_nmod) glut4_6\NN\1740|of
T9_T20 CPR:3 fisetin_5\NN\1740|by (r_nmod) enhancement_0\NN\248977|expression|fisetin (l_nmod) expression_3\NN\4679549|of|glut4 (l_compound) glut4_2\NN\1740|
16596248
T6_T13 NONE thymidylate_0\NN\1740| (r_compound) synthase_1\NN\1740|thymidylate
T7_T13 NONE 5-fluorouracil_23\NN\1740|with (r_nmod) treated_21\VBN\2376958|5-fluorouracil (r_acl) patients_17\NNS\9898892|in|cancer|treated (r_nmod) survival_15\NN\13961642|for|disease-free|patients (r_nmod) predictors_12\NNS\10756433|pattern|are|survival|. (l_nsubj) pattern_3\NN\5726345|synthase|expression|,|level|and|polymorphism (l_compound) synthase_1\NN\1740|thymidylate
T8_T13 NONE nucleotide_9\NN\14850483| (r_compound) polymorphism_10\NN\11418750|single|nucleotide (r_conj) pattern_3\NN\5726345|synthase|expression|,|level|and|polymorphism (l_compound) synthase_1\NN\1740|thymidylate
T1_T10 NONE 5fu_16\NN\1740|(|) (r_appos) 5-fluorouracil_14\NN\1740|of|5fu (r_nmod) target_12\NN\7258332|the|biological|5-fluorouracil (r_appos) synthase_5\NN\1740|to|thymidylate|ts|,|target
T1_T11 NONE 5fu_16\NN\1740|(|) (r_appos) 5-fluorouracil_14\NN\1740|of|5fu (r_nmod) target_12\NN\7258332|the|biological|5-fluorouracil (r_appos) synthase_5\NN\1740|to|thymidylate|ts|,|target (l_appos) ts_7\NN\14999913|(|)
T3_T10 NONE thymidylate_4\NN\1740| (r_compound) synthase_5\NN\1740|to|thymidylate|ts|,|target
T3_T11 NONE thymidylate_4\NN\1740| (r_compound) synthase_5\NN\1740|to|thymidylate|ts|,|target (l_appos) ts_7\NN\14999913|(|)
T5_T10 NONE 5-fluorouracil_14\NN\1740|of|5fu (r_nmod) target_12\NN\7258332|the|biological|5-fluorouracil (r_appos) synthase_5\NN\1740|to|thymidylate|ts|,|target
T5_T11 NONE 5-fluorouracil_14\NN\1740|of|5fu (r_nmod) target_12\NN\7258332|the|biological|5-fluorouracil (r_appos) synthase_5\NN\1740|to|thymidylate|ts|,|target (l_appos) ts_7\NN\14999913|(|)
T2_T9 CPR:4 5fu_26\NN\1740|with (r_nmod) treated_24\VBN\2376958|5fu (r_acl) patients_23\NNS\9898892|in|treated (r_nmod) survival_18\NN\13961642|to|longer|progression-free|pfs|patients (r_nmod) associated_14\VBN\628491|survival (r_acl) variables_13\NNS\2452|as|associated (r_nmod) arose_11\VBD\2623529|levels|variables|. (l_nsubj) levels_3\NNS\4916342|low|ts|expression|,|pattern|and|snp (l_compound) ts_1\NN\14999913|
23570998
T15_T24 CPR:3 quercetin_0\NN\1740|and|rutin (r_nsubj) increased_4\VBD\169651|quercetin|also|activity|%|and|demonstrated|. (l_dobj) activity_7\NN\30358|alkaline|phosphatase (l_compound) phosphatase_6\NN\14732946|
T16_T24 CPR:3 rutin_2\NN\1740| (r_conj) quercetin_0\NN\1740|and|rutin (r_nsubj) increased_4\VBD\169651|quercetin|also|activity|%|and|demonstrated|. (l_dobj) activity_7\NN\30358|alkaline|phosphatase (l_compound) phosphatase_6\NN\14732946|
T17_T19 CPR:3 flavonoids_4\NNS\14983143|both|the (r_nsubjpass) found_7\VBN\2426171|further|,|flavonoids|were|also|increase|. (l_xcomp) increase_9\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|the|some (l_nmod) some_13\DT\1740|of|markers (l_nmod) markers_17\NNS\21939|of|the|prominent|differentiation (l_nmod) differentiation_19\NN\5748054|for|osteoblast|osteopontin (l_nmod) osteopontin_23\NN\1740|like|,|osterix|,|runx2|,|osteoprotegerin|and|osteocalcin
T17_T20 CPR:3 flavonoids_4\NNS\14983143|both|the (r_nsubjpass) found_7\VBN\2426171|further|,|flavonoids|were|also|increase|. (l_xcomp) increase_9\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|the|some (l_nmod) some_13\DT\1740|of|markers (l_nmod) markers_17\NNS\21939|of|the|prominent|differentiation (l_nmod) differentiation_19\NN\5748054|for|osteoblast|osteopontin (l_nmod) osteopontin_23\NN\1740|like|,|osterix|,|runx2|,|osteoprotegerin|and|osteocalcin (l_conj) osterix_25\NN\1740|
T17_T21 CPR:3 flavonoids_4\NNS\14983143|both|the (r_nsubjpass) found_7\VBN\2426171|further|,|flavonoids|were|also|increase|. (l_xcomp) increase_9\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|the|some (l_nmod) some_13\DT\1740|of|markers (l_nmod) markers_17\NNS\21939|of|the|prominent|differentiation (l_nmod) differentiation_19\NN\5748054|for|osteoblast|osteopontin (l_nmod) osteopontin_23\NN\1740|like|,|osterix|,|runx2|,|osteoprotegerin|and|osteocalcin (l_conj) runx2_27\NN\1740|
T17_T22 CPR:3 flavonoids_4\NNS\14983143|both|the (r_nsubjpass) found_7\VBN\2426171|further|,|flavonoids|were|also|increase|. (l_xcomp) increase_9\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|the|some (l_nmod) some_13\DT\1740|of|markers (l_nmod) markers_17\NNS\21939|of|the|prominent|differentiation (l_nmod) differentiation_19\NN\5748054|for|osteoblast|osteopontin (l_nmod) osteopontin_23\NN\1740|like|,|osterix|,|runx2|,|osteoprotegerin|and|osteocalcin (l_conj) osteoprotegerin_29\NN\1740|
T17_T23 CPR:3 flavonoids_4\NNS\14983143|both|the (r_nsubjpass) found_7\VBN\2426171|further|,|flavonoids|were|also|increase|. (l_xcomp) increase_9\VB\169651|to|expression (l_dobj) expression_11\NN\4679549|the|some (l_nmod) some_13\DT\1740|of|markers (l_nmod) markers_17\NNS\21939|of|the|prominent|differentiation (l_nmod) differentiation_19\NN\5748054|for|osteoblast|osteopontin (l_nmod) osteopontin_23\NN\1740|like|,|osterix|,|runx2|,|osteoprotegerin|and|osteocalcin (l_conj) osteocalcin_31\NN\1740|
23194548
23266270
T2_T19 CPR:4 dpep_0\NN\1740| (r_nsubj) induced_1\VBD\1627355|dpep|reduction|. (l_dobj) reduction_3\NN\351485|dose-dependent|levels (l_nmod) levels_7\NNS\4916342|of|the|protein|synthase (l_nmod) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction
T2_T20 CPR:4 dpep_0\NN\1740| (r_nsubj) induced_1\VBD\1627355|dpep|reduction|. (l_dobj) reduction_3\NN\351485|dose-dependent|levels (l_nmod) levels_7\NNS\4916342|of|the|protein|synthase (l_nmod) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_appos) inos_14\NN\1740|(|)
T2_T21 CPR:4 dpep_0\NN\1740| (r_nsubj) induced_1\VBD\1627355|dpep|reduction|. (l_dobj) reduction_3\NN\351485|dose-dependent|levels (l_nmod) levels_7\NNS\4916342|of|the|protein|synthase (l_nmod) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2
T2_T22 CPR:4 dpep_0\NN\1740| (r_nsubj) induced_1\VBD\1627355|dpep|reduction|. (l_dobj) reduction_3\NN\351485|dose-dependent|levels (l_nmod) levels_7\NNS\4916342|of|the|protein|synthase (l_nmod) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2 (l_appos) cox-2_19\NN\14737847|(|)
T3_T19 NONE oxide_11\NN\14818238| (r_compound) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction
T3_T20 NONE oxide_11\NN\14818238| (r_compound) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_appos) inos_14\NN\1740|(|)
T3_T21 NONE oxide_11\NN\14818238| (r_compound) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2
T3_T22 NONE oxide_11\NN\14818238| (r_compound) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2 (l_appos) cox-2_19\NN\14737847|(|)
T4_T19 NONE no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction
T4_T20 NONE no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_appos) inos_14\NN\1740|(|)
T4_T21 NONE no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2
T4_T22 NONE no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2 (l_appos) cox-2_19\NN\14737847|(|)
T5_T19 NONE )_32\-RRB-\1740| (r_punct) e(2_31\NN\1740|prostaglandin|)|pge(2 (r_conj) no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction
T5_T20 NONE )_32\-RRB-\1740| (r_punct) e(2_31\NN\1740|prostaglandin|)|pge(2 (r_conj) no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_appos) inos_14\NN\1740|(|)
T5_T21 NONE )_32\-RRB-\1740| (r_punct) e(2_31\NN\1740|prostaglandin|)|pge(2 (r_conj) no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2
T5_T22 NONE )_32\-RRB-\1740| (r_punct) e(2_31\NN\1740|prostaglandin|)|pge(2 (r_conj) no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2 (l_appos) cox-2_19\NN\14737847|(|)
T6_T19 NONE )_35\-RRB-\1740| (r_punct) pge(2_34\NN\1740|(|)|) (r_appos) e(2_31\NN\1740|prostaglandin|)|pge(2 (r_conj) no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction
T6_T20 NONE )_35\-RRB-\1740| (r_punct) pge(2_34\NN\1740|(|)|) (r_appos) e(2_31\NN\1740|prostaglandin|)|pge(2 (r_conj) no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_appos) inos_14\NN\1740|(|)
T6_T21 NONE )_35\-RRB-\1740| (r_punct) pge(2_34\NN\1740|(|)|) (r_appos) e(2_31\NN\1740|prostaglandin|)|pge(2 (r_conj) no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2
T6_T22 NONE )_35\-RRB-\1740| (r_punct) pge(2_34\NN\1740|(|)|) (r_appos) e(2_31\NN\1740|prostaglandin|)|pge(2 (r_conj) no_28\NN\7204911|of|and|e(2 (r_nmod) production_26\NN\30358|in|the|no (r_nmod) reduction_23\NN\351485|concomitant|production (r_conj) synthase_12\NN\1740|of|inducible|nitric|oxide|inos|and|cyclooxygenase-2|and|reduction (l_conj) cyclooxygenase-2_17\NN\14737847|cox-2 (l_appos) cox-2_19\NN\14737847|(|)
T7_T23 CPR:4 dpep_2\NN\1740| (r_nsubj) suppressed_3\VBD\2510337|additionally|,|dpep|production|. (l_dobj) production_5\NN\30358|the|cytokines (l_nmod) cytokines_8\NNS\14728724|of|inflammatory|,|factor-α
T7_T24 CPR:4 dpep_2\NN\1740| (r_nsubj) suppressed_3\VBD\2510337|additionally|,|dpep|production|. (l_dobj) production_5\NN\30358|the|cytokines (l_nmod) cytokines_8\NNS\14728724|of|inflammatory|,|factor-α (l_nmod) factor-α_13\NN\1740|including|tumor|necrosis|tnf-α|,|(il)-1β|,|and|il-6
T7_T25 CPR:4 dpep_2\NN\1740| (r_nsubj) suppressed_3\VBD\2510337|additionally|,|dpep|production|. (l_dobj) production_5\NN\30358|the|cytokines (l_nmod) cytokines_8\NNS\14728724|of|inflammatory|,|factor-α (l_nmod) factor-α_13\NN\1740|including|tumor|necrosis|tnf-α|,|(il)-1β|,|and|il-6 (l_appos) tnf-α_15\NN\1740|(|)
T7_T26 CPR:4 dpep_2\NN\1740| (r_nsubj) suppressed_3\VBD\2510337|additionally|,|dpep|production|. (l_dobj) production_5\NN\30358|the|cytokines (l_nmod) cytokines_8\NNS\14728724|of|inflammatory|,|factor-α (l_nmod) factor-α_13\NN\1740|including|tumor|necrosis|tnf-α|,|(il)-1β|,|and|il-6 (l_conj) (il)-1β_19\NN\1740|interleukin
T7_T27 CPR:4 dpep_2\NN\1740| (r_nsubj) suppressed_3\VBD\2510337|additionally|,|dpep|production|. (l_dobj) production_5\NN\30358|the|cytokines (l_nmod) cytokines_8\NNS\14728724|of|inflammatory|,|factor-α (l_nmod) factor-α_13\NN\1740|including|tumor|necrosis|tnf-α|,|(il)-1β|,|and|il-6 (l_conj) il-6_22\NN\1740|
T10_T28 NONE no_8\NN\7204911|and|pge(2 (r_dobj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_compound) factor-κb_18\NN\1740|nuclear|nf-κb
T10_T29 NONE no_8\NN\7204911|and|pge(2 (r_dobj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_compound) factor-κb_18\NN\1740|nuclear|nf-κb (l_appos) nf-κb_20\NN\1740|(|)
T10_T30 NONE no_8\NN\7204911|and|pge(2 (r_dobj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_nmod) pathway_31\NN\5483677|within|the|kinase|,|pathway (l_compound) kinase_27\NN\14732946|mitogen-activated|protein|mapk
T10_T31 NONE no_8\NN\7204911|and|pge(2 (r_dobj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_nmod) pathway_31\NN\5483677|within|the|kinase|,|pathway (l_compound) kinase_27\NN\14732946|mitogen-activated|protein|mapk (l_appos) mapk_29\NN\1740|(|)
T11_T28 NONE )_11\-RRB-\1740| (r_punct) pge(2_10\NN\1740|) (r_conj) no_8\NN\7204911|and|pge(2 (r_dobj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_compound) factor-κb_18\NN\1740|nuclear|nf-κb
T11_T29 NONE )_11\-RRB-\1740| (r_punct) pge(2_10\NN\1740|) (r_conj) no_8\NN\7204911|and|pge(2 (r_dobj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_compound) factor-κb_18\NN\1740|nuclear|nf-κb (l_appos) nf-κb_20\NN\1740|(|)
T11_T30 NONE )_11\-RRB-\1740| (r_punct) pge(2_10\NN\1740|) (r_conj) no_8\NN\7204911|and|pge(2 (r_dobj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_nmod) pathway_31\NN\5483677|within|the|kinase|,|pathway (l_compound) kinase_27\NN\14732946|mitogen-activated|protein|mapk
T11_T31 NONE )_11\-RRB-\1740| (r_punct) pge(2_10\NN\1740|) (r_conj) no_8\NN\7204911|and|pge(2 (r_dobj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_nmod) pathway_31\NN\5483677|within|the|kinase|,|pathway (l_compound) kinase_27\NN\14732946|mitogen-activated|protein|mapk (l_appos) mapk_29\NN\1740|(|)
T9_T28 NONE dpep_6\NN\1740| (r_nsubj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_compound) factor-κb_18\NN\1740|nuclear|nf-κb
T9_T29 NONE dpep_6\NN\1740| (r_nsubj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_compound) factor-κb_18\NN\1740|nuclear|nf-κb (l_appos) nf-κb_20\NN\1740|(|)
T9_T30 NONE dpep_6\NN\1740| (r_nsubj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_nmod) pathway_31\NN\5483677|within|the|kinase|,|pathway (l_compound) kinase_27\NN\14732946|mitogen-activated|protein|mapk
T9_T31 NONE dpep_6\NN\1740| (r_nsubj) inhibits_7\VBZ\2510337|which|dpep|no|examining (l_advcl) examining_13\VBG\789138|by|level (l_dobj) level_15\NN\4916342|the|activation (l_nmod) activation_22\NN\13561719|of|factor-κb|pathway (l_nmod) pathway_31\NN\5483677|within|the|kinase|,|pathway (l_compound) kinase_27\NN\14732946|mitogen-activated|protein|mapk (l_appos) mapk_29\NN\1740|(|)
T12_T32 CPR:4 dpep_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|dpep|phosphorylation|. (l_dobj) phosphorylation_3\NN\1740|lps-induced|erk (l_nmod) erk_5\NN\1740|of|,|jnk|,|and|p38
T12_T33 CPR:4 dpep_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|dpep|phosphorylation|. (l_dobj) phosphorylation_3\NN\1740|lps-induced|erk (l_nmod) erk_5\NN\1740|of|,|jnk|,|and|p38 (l_conj) jnk_7\NN\1740|
T12_T34 CPR:4 dpep_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|dpep|phosphorylation|. (l_dobj) phosphorylation_3\NN\1740|lps-induced|erk (l_nmod) erk_5\NN\1740|of|,|jnk|,|and|p38 (l_conj) p38_10\NN\1740|
T13_T16 CPR:4 dpep_2\NN\1740| (r_nsubj) inhibited_3\VBD\2510337|furthermore|,|dpep|phosphorylation|. (l_dobj) phosphorylation_6\NN\1740|the|lps-induced|(iκb)-α (l_nmod) (iκb)-α_10\NN\1740|of|inhibitor|κb|and|p50 (l_conj) p50_13\NN\1740|nf-κb
T13_T35 CPR:4 dpep_2\NN\1740| (r_nsubj) inhibited_3\VBD\2510337|furthermore|,|dpep|phosphorylation|. (l_dobj) phosphorylation_6\NN\1740|the|lps-induced|(iκb)-α (l_nmod) (iκb)-α_10\NN\1740|of|inhibitor|κb|and|p50
T13_T36 CPR:4 dpep_2\NN\1740| (r_nsubj) inhibited_3\VBD\2510337|furthermore|,|dpep|phosphorylation|. (l_dobj) phosphorylation_6\NN\1740|the|lps-induced|(iκb)-α (l_nmod) (iκb)-α_10\NN\1740|of|inhibitor|κb|and|p50 (l_conj) p50_13\NN\1740|nf-κb (l_compound) nf-κb_12\NN\1740|
T1_T17 CPR:4 dpep_10\NN\1740| (r_nsubj) inhibits_11\VBZ\2510337|that|dpep|inflammation|blocking (l_advcl) blocking_15\VBG\1476483|by|pathways (l_dobj) pathways_20\NNS\5483677|the|nf-κb|macrophages (l_compound) nf-κb_17\NN\1740|and|mapk
T1_T18 CPR:4 dpep_10\NN\1740| (r_nsubj) inhibits_11\VBZ\2510337|that|dpep|inflammation|blocking (l_advcl) blocking_15\VBG\1476483|by|pathways (l_dobj) pathways_20\NNS\5483677|the|nf-κb|macrophages (l_compound) nf-κb_17\NN\1740|and|mapk (l_conj) mapk_19\NN\1740|
23473679
T8_T11 NONE lu-177-labeled_5\JJ\1740| (r_amod) peptide_9\NN\14724264|of|a|lu-177-labeled|lactam|bridge-cyclized|alpha-msh (l_compound) alpha-msh_8\NN\1740|
T9_T11 NONE lactam_6\NN\1740| (r_compound) peptide_9\NN\14724264|of|a|lu-177-labeled|lactam|bridge-cyclized|alpha-msh (l_compound) alpha-msh_8\NN\1740|
T6_T10 NONE (177)lu-dota-ggnle-cycmshhex_13\NN\1740|of
23117151
T13_T32 NONE androgen_0\NN\14745635| (r_compound) length_4\NN\5093581|androgen|receptor|cag|repeat (l_compound) receptor_1\NN\5225602|
T13_T33 NONE androgen_0\NN\14745635| (r_compound) length_4\NN\5093581|androgen|receptor|cag|repeat (l_compound) repeat_3\NN\7296190|
T14_T32 NONE 2,3,7,8-tetrachlorodibenzo-p-dioxin_9\NN\1740|of (r_nmod) effect_7\NN\34213|the|2,3,7,8-tetrachlorodibenzo-p-dioxin|activity (r_dobj) modifies_5\VBZ\109660|length|effect|. (l_nsubj) length_4\NN\5093581|androgen|receptor|cag|repeat (l_compound) receptor_1\NN\5225602|
T14_T33 NONE 2,3,7,8-tetrachlorodibenzo-p-dioxin_9\NN\1740|of (r_nmod) effect_7\NN\34213|the|2,3,7,8-tetrachlorodibenzo-p-dioxin|activity (r_dobj) modifies_5\VBZ\109660|length|effect|. (l_nsubj) length_4\NN\5093581|androgen|receptor|cag|repeat (l_compound) repeat_3\NN\7296190|
T2_T15 NONE tcdd_0\NN\1740| (r_nsubj) acts_1\VBZ\1619354|tcdd|receptor|. (l_nmod) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts
T2_T16 NONE tcdd_0\NN\1740| (r_nsubj) acts_1\VBZ\1619354|tcdd|receptor|. (l_nmod) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts (l_appos) ahr_8\NN\1740|(|)
T2_T17 NONE tcdd_0\NN\1740| (r_nsubj) acts_1\VBZ\1619354|tcdd|receptor|. (l_nmod) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts (l_acl:relcl) interacts_12\VBZ\2367363|which|receptor (l_nmod) receptor_16\NN\5225602|with|the|androgen|ar
T2_T18 NONE tcdd_0\NN\1740| (r_nsubj) acts_1\VBZ\1619354|tcdd|receptor|. (l_nmod) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts (l_acl:relcl) interacts_12\VBZ\2367363|which|receptor (l_nmod) receptor_16\NN\5225602|with|the|androgen|ar (l_appos) ar_18\NN\14622893|(|)
T3_T15 NONE hydrocarbon_5\NN\14727670| (r_compound) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts
T3_T16 NONE hydrocarbon_5\NN\14727670| (r_compound) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts (l_appos) ahr_8\NN\1740|(|)
T3_T17 NONE hydrocarbon_5\NN\14727670| (r_compound) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts (l_acl:relcl) interacts_12\VBZ\2367363|which|receptor (l_nmod) receptor_16\NN\5225602|with|the|androgen|ar
T3_T18 NONE hydrocarbon_5\NN\14727670| (r_compound) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts (l_acl:relcl) interacts_12\VBZ\2367363|which|receptor (l_nmod) receptor_16\NN\5225602|with|the|androgen|ar (l_appos) ar_18\NN\14622893|(|)
T4_T15 NONE androgen_15\NN\14745635| (r_compound) receptor_16\NN\5225602|with|the|androgen|ar (r_nmod) interacts_12\VBZ\2367363|which|receptor (r_acl:relcl) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts
T4_T16 NONE androgen_15\NN\14745635| (r_compound) receptor_16\NN\5225602|with|the|androgen|ar (r_nmod) interacts_12\VBZ\2367363|which|receptor (r_acl:relcl) receptor_6\NN\5225602|through|the|aryl|hydrocarbon|ahr|,|interacts (l_appos) ahr_8\NN\1740|(|)
T4_T17 NONE androgen_15\NN\14745635| (r_compound) receptor_16\NN\5225602|with|the|androgen|ar
T4_T18 NONE androgen_15\NN\14745635| (r_compound) receptor_16\NN\5225602|with|the|androgen|ar (l_appos) ar_18\NN\14622893|(|)
T5_T21 NONE tcdd_5\NN\1740|of (r_nmod) influence_3\NN\5190804|the|tcdd|cells (l_nmod) cells_9\NNS\3080309|on|prostate|cancer|pc-3|and|cells|ars (l_nmod) ars_22\NNS\14622893|on|5α-dihydrotestosterone-activated|containing
T5_T22 NONE tcdd_5\NN\1740|of (r_nmod) influence_3\NN\5190804|the|tcdd|cells (l_nmod) cells_9\NNS\3080309|on|prostate|cancer|pc-3|and|cells|ars (l_nmod) ars_22\NNS\14622893|on|5α-dihydrotestosterone-activated|containing (l_acl) containing_23\VBG\2632940|repeats (l_dobj) repeats_25\NNS\7296190|cag|range
T6_T21 NONE 5α-dihydrotestosterone-activated_21\JJ\1740| (r_amod) ars_22\NNS\14622893|on|5α-dihydrotestosterone-activated|containing
T6_T22 NONE 5α-dihydrotestosterone-activated_21\JJ\1740| (r_amod) ars_22\NNS\14622893|on|5α-dihydrotestosterone-activated|containing (l_acl) containing_23\VBG\2632940|repeats (l_dobj) repeats_25\NNS\7296190|cag|range
T7_T23 NONE tcdd_10\NN\1740|by (r_nmod) induced_8\VBN\1627355|expression|was|tcdd|,|but|affected|. (l_nsubjpass) expression_6\NN\4679549|the|ahr|target|gene|cyp1a1|mrna (l_compound) ahr_1\NN\1740|
T7_T24 CPR:3 tcdd_10\NN\1740|by (r_nmod) induced_8\VBN\1627355|expression|was|tcdd|,|but|affected|. (l_nsubjpass) expression_6\NN\4679549|the|ahr|target|gene|cyp1a1|mrna (l_compound) cyp1a1_4\NN\1740|
T7_T25 NONE tcdd_10\NN\1740|by (r_nmod) induced_8\VBN\1627355|expression|was|tcdd|,|but|affected|. (l_conj) affected_15\VBN\126264|was|not|length (l_nmod) length_20\NN\5093581|by|the|ar|cag (l_compound) ar_18\NN\14622893|
T7_T26 NONE tcdd_10\NN\1740|by (r_nmod) induced_8\VBN\1627355|expression|was|tcdd|,|but|affected|. (l_conj) affected_15\VBN\126264|was|not|length (l_nmod) length_20\NN\5093581|by|the|ar|cag (l_compound) cag_19\NN\1740|
T8_T27 NONE tcdd_0\NN\1740| (r_nsubj) had_1\VBD\2108377|tcdd|effect|activity|,|induced|. (l_nmod) activity_6\NN\30358|on|ar|cells (l_compound) ar_5\NN\14622893|
T8_T28 NONE tcdd_0\NN\1740| (r_nsubj) had_1\VBD\2108377|tcdd|effect|activity|,|induced|. (l_advcl) induced_17\VBN\1627355|whereas|variant|was|tcdd|cells (l_nsubjpass) variant_15\NN\7366289|the|shortest|ar (l_compound) ar_14\NN\14622893|
T9_T27 NONE tcdd_19\NN\1740|by (r_nmod) induced_17\VBN\1627355|whereas|variant|was|tcdd|cells (r_advcl) had_1\VBD\2108377|tcdd|effect|activity|,|induced|. (l_nmod) activity_6\NN\30358|on|ar|cells (l_compound) ar_5\NN\14622893|
T9_T28 CPR:3 tcdd_19\NN\1740|by (r_nmod) induced_17\VBN\1627355|whereas|variant|was|tcdd|cells (l_nsubjpass) variant_15\NN\7366289|the|shortest|ar (l_compound) ar_14\NN\14622893|
T11_T29 NONE tcdd_9\NN\1740|of (r_nmod) effect_7\NN\34213|the|dependent|tcdd|activity|, (l_amod) dependent_6\JJ\1740|cag|length (l_nmod:npmod) cag_4\NN\1740|
T11_T30 NONE tcdd_9\NN\1740|of (r_nmod) effect_7\NN\34213|the|dependent|tcdd|activity|, (l_nmod) activity_12\NN\30358|on|ar|pnt1a (l_compound) ar_11\NN\14622893|
T11_T31 NONE tcdd_9\NN\1740|of (r_nmod) effect_7\NN\34213|the|dependent|tcdd|activity|, (r_nsubj) indicates_22\VBZ\952524|conclusion|,|effect|effect|. (l_nmod) effect_26\NN\34213|as|a|cell-specific|tcdd|activity (l_nmod) activity_31\NN\30358|on|ar (l_compound) ar_30\NN\14622893|
T12_T29 NONE tcdd_28\NN\1740|of (r_nmod) effect_26\NN\34213|as|a|cell-specific|tcdd|activity (r_nmod) indicates_22\VBZ\952524|conclusion|,|effect|effect|. (l_nsubj) effect_7\NN\34213|the|dependent|tcdd|activity|, (l_amod) dependent_6\JJ\1740|cag|length (l_nmod:npmod) cag_4\NN\1740|
T12_T30 NONE tcdd_28\NN\1740|of (r_nmod) effect_26\NN\34213|as|a|cell-specific|tcdd|activity (r_nmod) indicates_22\VBZ\952524|conclusion|,|effect|effect|. (l_nsubj) effect_7\NN\34213|the|dependent|tcdd|activity|, (l_nmod) activity_12\NN\30358|on|ar|pnt1a (l_compound) ar_11\NN\14622893|
T12_T31 NONE tcdd_28\NN\1740|of (r_nmod) effect_26\NN\34213|as|a|cell-specific|tcdd|activity (l_nmod) activity_31\NN\30358|on|ar (l_compound) ar_30\NN\14622893|
23331067
T4_T17 NONE calcium-binding_35\JJ\1740| (r_amod) protein_36\NN\14944888|a|calcium-binding|associated (r_appos) calbindin-d28k_32\NN\1740|,|protein
T4_T18 NONE calcium-binding_35\JJ\1740| (r_amod) protein_36\NN\14944888|a|calcium-binding|associated (r_appos) calbindin-d28k_32\NN\1740|,|protein
T4_T19 NONE calcium-binding_35\JJ\1740| (r_amod) protein_36\NN\14944888|a|calcium-binding|associated
T5_T20 NONE mptp_21\NN\1740|to|and|neurotoxins (r_nmod) susceptible_19\JJ\1740|particularly|mptp (r_amod) region_17\NN\27167|a|susceptible (r_appos) sn_14\NN\14625458|in|the|ventral|,|region (r_nmod) expressed_10\VBN\928630|that|pitx3|is|primarily|sn (l_nsubjpass) pitx3_7\NN\1740|
T1_T21 NONE mptp_9\NN\1740| (r_compound) treatment_10\NN\654885|following|mptp (r_nmod) lost_7\VBN\1794668|furthermore|,|cells|are|preferentially|treatment|. (l_nsubjpass) cells_4\NNS\3080309|pitx3-expressing|sn (l_amod) pitx3-expressing_2\JJ\1740|
T2_T6 NONE mptp_15\NN\1740|to (r_nmod) exposed_13\VBN\2110927|when|mptp (r_advcl) show_9\VBP\2137132|finally|,|neurons|sensitivity|exposed|. (l_nsubj) neurons_4\NNS\5430628|sn|mda|mice (l_nmod) mice_8\NNS\2329401|in|pitx3|hemizygous (l_compound) pitx3_6\NN\1740|
T3_T10 NONE mptp-resistant_14\JJ\1740| (r_amod) pitx3-autonomous_15\JJ\1740|including|mptp-resistant|,|neurons|,|and|cells|display (l_conj) cells_23\NNS\3080309|calbindin-negative|pitx-3-dependent (l_amod) calbindin-negative_21\JJ\1740|
T3_T11 NONE mptp-resistant_14\JJ\1740| (r_amod) pitx3-autonomous_15\JJ\1740|including|mptp-resistant|,|neurons|,|and|cells|display (l_conj) cells_23\NNS\3080309|calbindin-negative|pitx-3-dependent (l_amod) pitx-3-dependent_22\JJ\1740|
T3_T8 NONE mptp-resistant_14\JJ\1740| (r_amod) pitx3-autonomous_15\JJ\1740|including|mptp-resistant|,|neurons|,|and|cells|display
T3_T9 NONE mptp-resistant_14\JJ\1740| (r_amod) pitx3-autonomous_15\JJ\1740|including|mptp-resistant|,|neurons|,|and|cells|display (l_conj) neurons_18\NNS\5430628|calbindin-positive (l_amod) calbindin-positive_17\JJ\1740|
17319904
T11_T27 NONE aspirin_12\NN\2707683|of (r_nmod) effects_10\NNS\13245626|the|antiplatelet|aspirin (r_dobj) decrease_7\VBP\169651|platelets|effects|. (l_nsubj) platelets_1\NNS\5432736|reticulated|and|cox-1 (l_conj) cox-1_4\NN\14737847|uninhibited|and|cox-2
T11_T28 NONE aspirin_12\NN\2707683|of (r_nmod) effects_10\NNS\13245626|the|antiplatelet|aspirin (r_dobj) decrease_7\VBP\169651|platelets|effects|. (l_nsubj) platelets_1\NNS\5432736|reticulated|and|cox-1 (l_conj) cox-1_4\NN\14737847|uninhibited|and|cox-2 (l_conj) cox-2_6\NN\14737847|
T2_T19 NONE aspirin_11\NN\2707683|of (r_nmod) effects_9\NNS\13245626|the|antiplatelet|aspirin (r_dobj) modulate_6\VB\1724459|platelets|may|effects|(cox)-1|. (l_nmod) (cox)-1_15\NN\1740|through|uninhibited|cyclooxygenase|and|cox-2 (l_compound) cyclooxygenase_14\NN\14732946|
T2_T20 NONE aspirin_11\NN\2707683|of (r_nmod) effects_9\NNS\13245626|the|antiplatelet|aspirin (r_dobj) modulate_6\VB\1724459|platelets|may|effects|(cox)-1|. (l_nmod) (cox)-1_15\NN\1740|through|uninhibited|cyclooxygenase|and|cox-2
T2_T21 NONE aspirin_11\NN\2707683|of (r_nmod) effects_9\NNS\13245626|the|antiplatelet|aspirin (r_dobj) modulate_6\VB\1724459|platelets|may|effects|(cox)-1|. (l_nmod) (cox)-1_15\NN\1740|through|uninhibited|cyclooxygenase|and|cox-2 (l_conj) cox-2_17\NN\14737847|
T7_T22 NONE )_18\-RRB-\1740|txb(2 (r_punct) b(2_17\NN\1740|serum|thromboxane|) (r_compound) levels_23\NNS\4916342|b(2 (r_conj) aggregometry_5\NN\1740|light|transmission|;|expression|and|levels (l_conj) expression_12\NN\4679549|p-selectin|, (l_compound) p-selectin_7\NN\1740|and|alpha(iib)beta(3
T7_T23 NONE )_18\-RRB-\1740|txb(2 (r_punct) b(2_17\NN\1740|serum|thromboxane|) (r_compound) levels_23\NNS\4916342|b(2 (r_conj) aggregometry_5\NN\1740|light|transmission|;|expression|and|levels (l_conj) expression_12\NN\4679549|p-selectin|, (l_compound) p-selectin_7\NN\1740|and|alpha(iib)beta(3 (l_conj) alpha(iib)beta(3_10\NN\1740|integrin|) (l_punct) )_11\-RRB-\1740|
T8_T22 NONE )_21\-RRB-\1740| (r_punct) txb(2_20\NN\1740|(|)|) (r_appos) )_18\-RRB-\1740|txb(2 (r_punct) b(2_17\NN\1740|serum|thromboxane|) (r_compound) levels_23\NNS\4916342|b(2 (r_conj) aggregometry_5\NN\1740|light|transmission|;|expression|and|levels (l_conj) expression_12\NN\4679549|p-selectin|, (l_compound) p-selectin_7\NN\1740|and|alpha(iib)beta(3
T8_T23 NONE )_21\-RRB-\1740| (r_punct) txb(2_20\NN\1740|(|)|) (r_appos) )_18\-RRB-\1740|txb(2 (r_punct) b(2_17\NN\1740|serum|thromboxane|) (r_compound) levels_23\NNS\4916342|b(2 (r_conj) aggregometry_5\NN\1740|light|transmission|;|expression|and|levels (l_conj) expression_12\NN\4679549|p-selectin|, (l_compound) p-selectin_7\NN\1740|and|alpha(iib)beta(3 (l_conj) alpha(iib)beta(3_10\NN\1740|integrin|) (l_punct) )_11\-RRB-\1740|
T10_T25 NONE adp_19\NN\14964590|and|collagen (r_dep) microm_15\NN\1740|to|5|and|microm|adp (r_nmod) aggregations_12\NNS\31264|postaspirin|microm (r_conj) aggregation_2\NN\31264|baseline|platelet|collagen|,|and|aggregations|, (l_nmod) collagen_8\NN\15026716|to|1|microg|ml(-1|)
T10_T26 NONE adp_19\NN\14964590|and|collagen (l_conj) collagen_21\NN\15026716|
T1_T12 CPR:3 aspirin_18\NN\2707683|both|before (r_nmod) higher_9\JJR\1740|p-selectin|were|also|tertile|aspirin|. (l_nsubj) p-selectin_1\NN\1740|stimulated|and|expression
T1_T13 CPR:3 aspirin_18\NN\2707683|both|before (r_nmod) higher_9\JJR\1740|p-selectin|were|also|tertile|aspirin|. (l_nsubj) p-selectin_1\NN\1740|stimulated|and|expression (l_conj) expression_6\NN\4679549|alpha(iib)beta(3 (l_compound) alpha(iib)beta(3_4\NN\1740|integrin|) (l_punct) )_5\-RRB-\1740|
T3_T17 NONE aspirin_11\NN\2707683|of (r_nmod) effects_9\NNS\13245626|with|diminished|antiplatelet|aspirin|and|resistance (r_nmod) associated_5\VBN\628491|platelets|are|effects|,|reactivity (l_nmod) reactivity_21\NN\5652926|possibly|because|increased|,|and|activity (l_conj) activity_28\NN\30358|uninhibited|cox-1 (l_compound) cox-1_25\NN\14737847|and|cox-2
T3_T18 NONE aspirin_11\NN\2707683|of (r_nmod) effects_9\NNS\13245626|with|diminished|antiplatelet|aspirin|and|resistance (r_nmod) associated_5\VBN\628491|platelets|are|effects|,|reactivity (l_nmod) reactivity_21\NN\5652926|possibly|because|increased|,|and|activity (l_conj) activity_28\NN\30358|uninhibited|cox-1 (l_compound) cox-1_25\NN\14737847|and|cox-2 (l_conj) cox-2_27\NN\14737847|
T4_T17 NONE aspirin_14\NN\2707683| (r_compound) resistance_15\NN\37396|increased|aspirin (r_conj) effects_9\NNS\13245626|with|diminished|antiplatelet|aspirin|and|resistance (r_nmod) associated_5\VBN\628491|platelets|are|effects|,|reactivity (l_nmod) reactivity_21\NN\5652926|possibly|because|increased|,|and|activity (l_conj) activity_28\NN\30358|uninhibited|cox-1 (l_compound) cox-1_25\NN\14737847|and|cox-2
T4_T18 NONE aspirin_14\NN\2707683| (r_compound) resistance_15\NN\37396|increased|aspirin (r_conj) effects_9\NNS\13245626|with|diminished|antiplatelet|aspirin|and|resistance (r_nmod) associated_5\VBN\628491|platelets|are|effects|,|reactivity (l_nmod) reactivity_21\NN\5652926|possibly|because|increased|,|and|activity (l_conj) activity_28\NN\30358|uninhibited|cox-1 (l_compound) cox-1_25\NN\14737847|and|cox-2 (l_conj) cox-2_27\NN\14737847|
23598363
T20_T52 NONE platinum-damaged_2\JJ\1740| (r_amod) oocytes_3\NNS\5458412|of|platinum-damaged (r_nmod) rescue_0\NN\45907|oocytes|death|inactivation|. (l_nmod) inactivation_9\NN\13518963|through|network (l_nmod) network_15\NN\8435388|of|the|family|signaling (l_compound) family_13\NN\8189659|p53 (l_compound) p53_12\NN\1740|
T11_T46 CPR:4 mesylate_7\NN\1740|imatinib|imatinib (r_dep) inhibitor_5\NN\20090|the|c-abl|kinase|mesylate (l_amod) c-abl_3\JJ\1740|
T11_T47 CPR:4 mesylate_7\NN\1740|imatinib|imatinib (r_dep) inhibitor_5\NN\20090|the|c-abl|kinase|mesylate (l_compound) kinase_4\NN\14732946|
T12_T46 CPR:4 imatinib_9\NN\1740|(|) (r_appos) mesylate_7\NN\1740|imatinib|imatinib (r_dep) inhibitor_5\NN\20090|the|c-abl|kinase|mesylate (l_amod) c-abl_3\JJ\1740|
T12_T47 CPR:4 imatinib_9\NN\1740|(|) (r_appos) mesylate_7\NN\1740|imatinib|imatinib (r_dep) inhibitor_5\NN\20090|the|c-abl|kinase|mesylate (l_compound) kinase_4\NN\14732946|
T13_T46 NONE cisplatin_22\NN\1740|against (r_nmod) drug_20\NN\14778436|as|a|fertoprotective|cisplatin (r_nmod) become_12\VBN\146138|recently|,|inhibitor|has|focus|drug|. (l_nsubj) inhibitor_5\NN\20090|the|c-abl|kinase|mesylate (l_amod) c-abl_3\JJ\1740|
T13_T47 NONE cisplatin_22\NN\1740|against (r_nmod) drug_20\NN\14778436|as|a|fertoprotective|cisplatin (r_nmod) become_12\VBN\146138|recently|,|inhibitor|has|focus|drug|. (l_nsubj) inhibitor_5\NN\20090|the|c-abl|kinase|mesylate (l_compound) kinase_4\NN\14732946|
T17_T48 CPR:3 cisplatin_7\NN\1740| (r_nsubj) induces_8\VBZ\1627355|that|,|apoptosis|,|cisplatin|expression (l_dobj) expression_12\NN\4679549|c-abl|oocyte (l_amod) c-abl_9\JJ\1740|and|tap73
T17_T49 CPR:3 cisplatin_7\NN\1740| (r_nsubj) induces_8\VBZ\1627355|that|,|apoptosis|,|cisplatin|expression (l_dobj) expression_12\NN\4679549|c-abl|oocyte (l_amod) c-abl_9\JJ\1740|and|tap73 (l_conj) tap73_11\JJ\1740|
T18_T21 NONE imatinib_1\NN\1740| (r_nsubj) unable_3\JJ\1740|while|imatinib|was|block (l_xcomp) block_5\VB\1476483|to|damage (l_dobj) damage_8\NN\7296428|cisplatin-induced|dna|and|response|,|upregulation (l_nmod) upregulation_16\NN\1740|such|the|p53 (l_nmod) p53_18\NN\1740|of
T18_T22 NONE imatinib_1\NN\1740| (r_nsubj) unable_3\JJ\1740|while|imatinib|was|block (r_advcl) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_nmod) c-abl/tap73_27\JJ\1740|of
T18_T23 NONE imatinib_1\NN\1740| (r_nsubj) unable_3\JJ\1740|while|imatinib|was|block (r_advcl) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_nmod) c-abl/tap73_27\JJ\1740|of
T18_T24 NONE imatinib_1\NN\1740| (r_nsubj) unable_3\JJ\1740|while|imatinib|was|block (r_advcl) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_conj) downregulation_31\NN\1740|the|subsequent|tap63|and|upregulation (l_nmod) tap63_33\NN\1740|of
T18_T25 NONE imatinib_1\NN\1740| (r_nsubj) unable_3\JJ\1740|while|imatinib|was|block (r_advcl) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_conj) downregulation_31\NN\1740|the|subsequent|tap63|and|upregulation (l_conj) upregulation_35\NN\1740|bax (l_nmod) bax_37\NN\1740|of
T19_T21 CPR:3 cisplatin-induced_6\JJ\1740| (r_amod) damage_8\NN\7296428|cisplatin-induced|dna|and|response|,|upregulation (l_nmod) upregulation_16\NN\1740|such|the|p53 (l_nmod) p53_18\NN\1740|of
T19_T22 NONE cisplatin-induced_6\JJ\1740| (r_amod) damage_8\NN\7296428|cisplatin-induced|dna|and|response|,|upregulation (r_dobj) block_5\VB\1476483|to|damage (r_xcomp) unable_3\JJ\1740|while|imatinib|was|block (r_advcl) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_nmod) c-abl/tap73_27\JJ\1740|of
T19_T23 NONE cisplatin-induced_6\JJ\1740| (r_amod) damage_8\NN\7296428|cisplatin-induced|dna|and|response|,|upregulation (r_dobj) block_5\VB\1476483|to|damage (r_xcomp) unable_3\JJ\1740|while|imatinib|was|block (r_advcl) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_nmod) c-abl/tap73_27\JJ\1740|of
T19_T24 NONE cisplatin-induced_6\JJ\1740| (r_amod) damage_8\NN\7296428|cisplatin-induced|dna|and|response|,|upregulation (r_dobj) block_5\VB\1476483|to|damage (r_xcomp) unable_3\JJ\1740|while|imatinib|was|block (r_advcl) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_conj) downregulation_31\NN\1740|the|subsequent|tap63|and|upregulation (l_nmod) tap63_33\NN\1740|of
T19_T25 NONE cisplatin-induced_6\JJ\1740| (r_amod) damage_8\NN\7296428|cisplatin-induced|dna|and|response|,|upregulation (r_dobj) block_5\VB\1476483|to|damage (r_xcomp) unable_3\JJ\1740|while|imatinib|was|block (r_advcl) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_conj) downregulation_31\NN\1740|the|subsequent|tap63|and|upregulation (l_conj) upregulation_35\NN\1740|bax (l_nmod) bax_37\NN\1740|of
T1_T21 NONE imatinib_20\NN\1740| (r_nsubj) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_advcl) unable_3\JJ\1740|while|imatinib|was|block (l_xcomp) block_5\VB\1476483|to|damage (l_dobj) damage_8\NN\7296428|cisplatin-induced|dna|and|response|,|upregulation (l_nmod) upregulation_16\NN\1740|such|the|p53 (l_nmod) p53_18\NN\1740|of
T1_T22 CPR:4 imatinib_20\NN\1740| (r_nsubj) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_nmod) c-abl/tap73_27\JJ\1740|of
T1_T23 CPR:4 imatinib_20\NN\1740| (r_nsubj) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_nmod) c-abl/tap73_27\JJ\1740|of
T1_T24 CPR:3 imatinib_20\NN\1740| (r_nsubj) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_conj) downregulation_31\NN\1740|the|subsequent|tap63|and|upregulation (l_nmod) tap63_33\NN\1740|of
T1_T25 CPR:4 imatinib_20\NN\1740| (r_nsubj) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_dobj) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_conj) downregulation_31\NN\1740|the|subsequent|tap63|and|upregulation (l_conj) upregulation_35\NN\1740|bax (l_nmod) bax_37\NN\1740|of
T2_T21 NONE cisplatin-induced_23\JJ\1740| (r_amod) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (r_dobj) inhibited_21\VBD\2510337|unable|,|imatinib|accumulation|,|abrogating|. (l_advcl) unable_3\JJ\1740|while|imatinib|was|block (l_xcomp) block_5\VB\1476483|to|damage (l_dobj) damage_8\NN\7296428|cisplatin-induced|dna|and|response|,|upregulation (l_nmod) upregulation_16\NN\1740|such|the|p53 (l_nmod) p53_18\NN\1740|of
T2_T22 CPR:3 cisplatin-induced_23\JJ\1740| (r_amod) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_nmod) c-abl/tap73_27\JJ\1740|of
T2_T23 CPR:3 cisplatin-induced_23\JJ\1740| (r_amod) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_nmod) c-abl/tap73_27\JJ\1740|of
T2_T24 CPR:4 cisplatin-induced_23\JJ\1740| (r_amod) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_conj) downregulation_31\NN\1740|the|subsequent|tap63|and|upregulation (l_nmod) tap63_33\NN\1740|of
T2_T25 CPR:3 cisplatin-induced_23\JJ\1740| (r_amod) accumulation_25\NN\13497135|the|cisplatin-induced|nuclear|c-abl/tap73|and|downregulation (l_conj) downregulation_31\NN\1740|the|subsequent|tap63|and|upregulation (l_conj) upregulation_35\NN\1740|bax (l_nmod) bax_37\NN\1740|of
T3_T26 NONE trp63_6\NN\1740|of|,|not|δnp63|,
T3_T27 NONE trp63_6\NN\1740|of|,|not|δnp63|, (l_conj) δnp63_10\NN\1740|
T3_T28 NONE trp63_6\NN\1740|of|,|not|δnp63|, (r_nmod) deletion_4\NN\13508333|the|conditional|trp63|oocytes (r_nsubj) inhibited_14\VBD\2510337|surprisingly|,|deletion|apoptosis|. (l_dobj) apoptosis_15\NN\11486178|,|as|accumulation (l_conj) accumulation_21\NN\13497135|the|c-abl (l_nmod) c-abl_23\JJ\1740|of|and|tap73|caused
T3_T29 NONE trp63_6\NN\1740|of|,|not|δnp63|, (r_nmod) deletion_4\NN\13508333|the|conditional|trp63|oocytes (r_nsubj) inhibited_14\VBD\2510337|surprisingly|,|deletion|apoptosis|. (l_dobj) apoptosis_15\NN\11486178|,|as|accumulation (l_conj) accumulation_21\NN\13497135|the|c-abl (l_nmod) c-abl_23\JJ\1740|of|and|tap73|caused (l_conj) tap73_25\NN\1740|
T4_T26 NONE cisplatin_28\NN\1740|by (r_nmod) caused_26\VBN\1617192|cisplatin (r_acl) c-abl_23\JJ\1740|of|and|tap73|caused (r_nmod) accumulation_21\NN\13497135|the|c-abl (r_conj) apoptosis_15\NN\11486178|,|as|accumulation (r_dobj) inhibited_14\VBD\2510337|surprisingly|,|deletion|apoptosis|. (l_nsubj) deletion_4\NN\13508333|the|conditional|trp63|oocytes (l_nmod) trp63_6\NN\1740|of|,|not|δnp63|,
T4_T27 NONE cisplatin_28\NN\1740|by (r_nmod) caused_26\VBN\1617192|cisplatin (r_acl) c-abl_23\JJ\1740|of|and|tap73|caused (r_nmod) accumulation_21\NN\13497135|the|c-abl (r_conj) apoptosis_15\NN\11486178|,|as|accumulation (r_dobj) inhibited_14\VBD\2510337|surprisingly|,|deletion|apoptosis|. (l_nsubj) deletion_4\NN\13508333|the|conditional|trp63|oocytes (l_nmod) trp63_6\NN\1740|of|,|not|δnp63|, (l_conj) δnp63_10\NN\1740|
T4_T28 CPR:3 cisplatin_28\NN\1740|by (r_nmod) caused_26\VBN\1617192|cisplatin (r_acl) c-abl_23\JJ\1740|of|and|tap73|caused
T4_T29 CPR:3 cisplatin_28\NN\1740|by (r_nmod) caused_26\VBN\1617192|cisplatin (r_acl) c-abl_23\JJ\1740|of|and|tap73|caused (l_conj) tap73_25\NN\1740|
T5_T30 NONE cisplatin-induced_10\JJ\1740| (r_amod) death_12\NN\7296428|of|cisplatin-induced|oocyte (r_nmod) regulator_8\NN\3096960|that|tap63|is|the|master|death (l_nsubj) tap63_4\NN\1740|
T6_T31 NONE cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (r_ccomp) suggest_9\VBP\1010118|kinetics|activates|. (l_nsubj) kinetics_2\NNS\6100236|the|expression|tap63 (l_nmod) tap63_4\NN\1740|of|,|c-abl|and|tap73
T6_T32 NONE cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (r_ccomp) suggest_9\VBP\1010118|kinetics|activates|. (l_nsubj) kinetics_2\NNS\6100236|the|expression|tap63 (l_nmod) tap63_4\NN\1740|of|,|c-abl|and|tap73 (l_conj) c-abl_6\JJ\1740|
T6_T33 NONE cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (r_ccomp) suggest_9\VBP\1010118|kinetics|activates|. (l_nsubj) kinetics_2\NNS\6100236|the|expression|tap63 (l_nmod) tap63_4\NN\1740|of|,|c-abl|and|tap73 (l_conj) tap73_8\NN\1740|
T6_T34 CPR:3 cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (l_dobj) expression_14\NN\4679549|tap63-dependent|c-abl (l_amod) tap63-dependent_13\JJ\1740|
T6_T35 CPR:3 cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (l_dobj) expression_14\NN\4679549|tap63-dependent|c-abl (l_nmod) c-abl_16\JJ\1740|of|and|tap73
T6_T36 CPR:3 cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (l_dobj) expression_14\NN\4679549|tap63-dependent|c-abl (l_nmod) c-abl_16\JJ\1740|of|and|tap73 (l_conj) tap73_18\NN\1740|
T6_T37 CPR:3 cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (l_conj) activation_25\NN\13561719|the|tap73|expression (l_nmod) tap73_27\NN\1740|of
T6_T38 CPR:3 cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (l_conj) activation_25\NN\13561719|the|tap73|expression (l_nmod) expression_31\NN\4679549|by|c-abl-induced|bax (l_amod) c-abl-induced_29\JJ\1740|
T6_T39 CPR:3 cisplatin_11\NN\1740| (r_nsubj) activates_12\VBZ\1641914|that|cisplatin|expression|and|,|turn|,|activation (l_conj) activation_25\NN\13561719|the|tap73|expression (l_nmod) expression_31\NN\4679549|by|c-abl-induced|bax (l_compound) bax_30\NN\1740|
T7_T40 CPR:4 imatinib_4\NN\1740| (r_nsubj) protects_5\VBZ\1127795|that|imatinib|oocytes|death|inhibiting (l_advcl) inhibiting_12\VBG\2510337|by|kinase (l_dobj) kinase_14\NN\14732946|c-abl|,|activate (l_amod) c-abl_13\JJ\1740|
T7_T41 CPR:3 imatinib_4\NN\1740| (r_nsubj) protects_5\VBZ\1127795|that|imatinib|oocytes|death|inhibiting (l_advcl) inhibiting_12\VBG\2510337|by|kinase (l_dobj) kinase_14\NN\14732946|c-abl|,|activate
T7_T42 CPR:4 imatinib_4\NN\1740| (r_nsubj) protects_5\VBZ\1127795|that|imatinib|oocytes|death|inhibiting (l_advcl) inhibiting_12\VBG\2510337|by|kinase (l_dobj) kinase_14\NN\14732946|c-abl|,|activate (l_acl:relcl) activate_19\VB\1641914|which|would|otherwise|apoptosis (l_dobj) apoptosis_21\NN\11486178|tap73-bax-mediated (l_amod) tap73-bax-mediated_20\JJ\1740|
T7_T43 CPR:4 imatinib_4\NN\1740| (r_nsubj) protects_5\VBZ\1127795|that|imatinib|oocytes|death|inhibiting (l_advcl) inhibiting_12\VBG\2510337|by|kinase (l_dobj) kinase_14\NN\14732946|c-abl|,|activate (l_acl:relcl) activate_19\VB\1641914|which|would|otherwise|apoptosis (l_dobj) apoptosis_21\NN\11486178|tap73-bax-mediated (l_amod) tap73-bax-mediated_20\JJ\1740|
T8_T40 CPR:3 cisplatin-induced_8\JJ\1740| (r_amod) death_10\NN\7296428|from|cisplatin-induced|cell (r_nmod) protects_5\VBZ\1127795|that|imatinib|oocytes|death|inhibiting (l_advcl) inhibiting_12\VBG\2510337|by|kinase (l_dobj) kinase_14\NN\14732946|c-abl|,|activate (l_amod) c-abl_13\JJ\1740|
T8_T41 CPR:3 cisplatin-induced_8\JJ\1740| (r_amod) death_10\NN\7296428|from|cisplatin-induced|cell (r_nmod) protects_5\VBZ\1127795|that|imatinib|oocytes|death|inhibiting (l_advcl) inhibiting_12\VBG\2510337|by|kinase (l_dobj) kinase_14\NN\14732946|c-abl|,|activate
T8_T42 CPR:3 cisplatin-induced_8\JJ\1740| (r_amod) death_10\NN\7296428|from|cisplatin-induced|cell (r_nmod) protects_5\VBZ\1127795|that|imatinib|oocytes|death|inhibiting (l_advcl) inhibiting_12\VBG\2510337|by|kinase (l_dobj) kinase_14\NN\14732946|c-abl|,|activate (l_acl:relcl) activate_19\VB\1641914|which|would|otherwise|apoptosis (l_dobj) apoptosis_21\NN\11486178|tap73-bax-mediated (l_amod) tap73-bax-mediated_20\JJ\1740|
T8_T43 CPR:3 cisplatin-induced_8\JJ\1740| (r_amod) death_10\NN\7296428|from|cisplatin-induced|cell (r_nmod) protects_5\VBZ\1127795|that|imatinib|oocytes|death|inhibiting (l_advcl) inhibiting_12\VBG\2510337|by|kinase (l_dobj) kinase_14\NN\14732946|c-abl|,|activate (l_acl:relcl) activate_19\VB\1641914|which|would|otherwise|apoptosis (l_dobj) apoptosis_21\NN\11486178|tap73-bax-mediated (l_amod) tap73-bax-mediated_20\JJ\1740|
T10_T44 NONE cisplatin-induced_15\JJ\1740| (r_amod) death_17\NN\7296428|cisplatin-induced|oocyte|follicles (r_dobj) halt_14\VB\1859221|to|death|and|conserve (r_acl:relcl) way_12\NN\4916342|an|intriguing|new|halt (r_dobj) provide_8\VBP\2199590|thus|,|imatinib|way|. (l_nsubj) imatinib_2\NN\1740|and|inhibitors (l_conj) inhibitors_7\NNS\20090|other|c-abl|kinase (l_amod) c-abl_5\JJ\1740|
T10_T45 NONE cisplatin-induced_15\JJ\1740| (r_amod) death_17\NN\7296428|cisplatin-induced|oocyte|follicles (r_dobj) halt_14\VB\1859221|to|death|and|conserve (r_acl:relcl) way_12\NN\4916342|an|intriguing|new|halt (r_dobj) provide_8\VBP\2199590|thus|,|imatinib|way|. (l_nsubj) imatinib_2\NN\1740|and|inhibitors (l_conj) inhibitors_7\NNS\20090|other|c-abl|kinase (l_compound) kinase_6\NN\14732946|
T9_T44 CPR:4 imatinib_2\NN\1740|and|inhibitors (l_conj) inhibitors_7\NNS\20090|other|c-abl|kinase (l_amod) c-abl_5\JJ\1740|
T9_T45 CPR:4 imatinib_2\NN\1740|and|inhibitors (l_conj) inhibitors_7\NNS\20090|other|c-abl|kinase (l_compound) kinase_6\NN\14732946|
23073075
T1_T27 CPR:3 fingolimod_0\NN\1740|fty720|,|drug|, (r_nsubj) activates_17\VBZ\1641914|fingolimod|subtypes|. (l_dobj) subtypes_24\NNS\1740|different|receptor (l_compound) receptor_20\NN\5225602|sphingosine-1-phosphate|s1pr
T1_T28 CPR:3 fingolimod_0\NN\1740|fty720|,|drug|, (r_nsubj) activates_17\VBZ\1641914|fingolimod|subtypes|. (l_dobj) subtypes_24\NNS\1740|different|receptor (l_compound) receptor_20\NN\5225602|sphingosine-1-phosphate|s1pr (l_appos) s1pr_22\NN\1740|(|)
T6_T27 CPR:3 fty720_2\NN\1740|(|) (r_appos) fingolimod_0\NN\1740|fty720|,|drug|, (r_nsubj) activates_17\VBZ\1641914|fingolimod|subtypes|. (l_dobj) subtypes_24\NNS\1740|different|receptor (l_compound) receptor_20\NN\5225602|sphingosine-1-phosphate|s1pr
T6_T28 CPR:3 fty720_2\NN\1740|(|) (r_appos) fingolimod_0\NN\1740|fty720|,|drug|, (r_nsubj) activates_17\VBZ\1641914|fingolimod|subtypes|. (l_dobj) subtypes_24\NNS\1740|different|receptor (l_compound) receptor_20\NN\5225602|sphingosine-1-phosphate|s1pr (l_appos) s1pr_22\NN\1740|(|)
T7_T27 NONE sphingosine-1-phosphate_19\NN\1740| (r_compound) receptor_20\NN\5225602|sphingosine-1-phosphate|s1pr
T7_T28 NONE sphingosine-1-phosphate_19\NN\1740| (r_compound) receptor_20\NN\5225602|sphingosine-1-phosphate|s1pr (l_appos) s1pr_22\NN\1740|(|)
T9_T29 NONE fty720_9\NN\1740|of (r_nmod) action_7\NN\30358|the|fty720 (r_nsubj) involves_10\VBZ\2676054|that|action|s1prs (l_dobj) s1prs_11\NN\1740|expressed
T2_T21 CPR:6 w146_19\NN\1740| (r_appos) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (l_compound) s1pr_13\NN\1740|s1p1r
T2_T22 CPR:6 w146_19\NN\1740| (r_appos) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (l_compound) s1pr_13\NN\1740|s1p1r (l_appos) s1p1r_15\NN\1740|(|)
T2_T23 NONE w146_19\NN\1740| (r_appos) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (l_conj) inhibitors_23\NNS\20090|by|kinase (l_nmod) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways
T2_T24 NONE w146_19\NN\1740| (r_appos) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (l_conj) inhibitors_23\NNS\20090|by|kinase (l_nmod) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways (l_appos) mapk_31\NN\1740|(|)
T2_T25 NONE w146_19\NN\1740| (r_appos) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (l_conj) inhibitors_23\NNS\20090|by|kinase (l_nmod) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways (l_conj) pathways_39\NNS\5483677|phosphatidylinositol-3-kinase (l_compound) phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k
T2_T26 NONE w146_19\NN\1740| (r_appos) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (l_conj) inhibitors_23\NNS\20090|by|kinase (l_nmod) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways (l_conj) pathways_39\NNS\5483677|phosphatidylinositol-3-kinase (l_compound) phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k (l_appos) ptdins-3-k_37\NN\1740|(|)
T2_T30 NONE w146_19\NN\1740| (r_appos) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (r_nmod) inhibited_8\VBN\2510337|antagonist (r_conj) attenuated_2\VBN\224901|neuroprotection|was|toxin|,|and|inhibited|. (l_nmod) toxin_5\NN\15032376|by|pertussis
T3_T21 NONE phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k (r_compound) pathways_39\NNS\5483677|phosphatidylinositol-3-kinase (r_conj) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways (r_nmod) inhibitors_23\NNS\20090|by|kinase (r_conj) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (l_compound) s1pr_13\NN\1740|s1p1r
T3_T22 NONE phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k (r_compound) pathways_39\NNS\5483677|phosphatidylinositol-3-kinase (r_conj) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways (r_nmod) inhibitors_23\NNS\20090|by|kinase (r_conj) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (l_compound) s1pr_13\NN\1740|s1p1r (l_appos) s1p1r_15\NN\1740|(|)
T3_T23 NONE phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k (r_compound) pathways_39\NNS\5483677|phosphatidylinositol-3-kinase (r_conj) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways
T3_T24 NONE phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k (r_compound) pathways_39\NNS\5483677|phosphatidylinositol-3-kinase (r_conj) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways (l_appos) mapk_31\NN\1740|(|)
T3_T25 NONE phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k
T3_T26 NONE phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k (l_appos) ptdins-3-k_37\NN\1740|(|)
T3_T30 NONE phosphatidylinositol-3-kinase_35\NN\1740|the|ptdins-3-k (r_compound) pathways_39\NNS\5483677|phosphatidylinositol-3-kinase (r_conj) kinase_29\NN\14732946|of|the|mitogen|associated|protein|mapk|and|pathways (r_nmod) inhibitors_23\NNS\20090|by|kinase (r_conj) antagonist_17\NN\7846|by|the|selective|type-1|s1pr|,|w146|,|and|inhibitors (r_nmod) inhibited_8\VBN\2510337|antagonist (r_conj) attenuated_2\VBN\224901|neuroprotection|was|toxin|,|and|inhibited|. (l_nmod) toxin_5\NN\15032376|by|pertussis
23200732
T8_T22 NONE estrogen_15\NN\14745635| (r_compound) alpha_17\NN\6828818|of|the|estrogen|receptor (r_nmod) functions_7\NNS\13783581|of|the|activation|af-1|alpha
T8_T23 NONE estrogen_15\NN\14745635| (r_compound) alpha_17\NN\6828818|of|the|estrogen|receptor (r_nmod) functions_7\NNS\13783581|of|the|activation|af-1|alpha (l_dep) af-1_9\NN\1740|(|and|af-2|)
T8_T24 NONE estrogen_15\NN\14745635| (r_compound) alpha_17\NN\6828818|of|the|estrogen|receptor (r_nmod) functions_7\NNS\13783581|of|the|activation|af-1|alpha (l_dep) af-1_9\NN\1740|(|and|af-2|) (l_conj) af-2_11\NN\1740|
T8_T25 NONE estrogen_15\NN\14745635| (r_compound) alpha_17\NN\6828818|of|the|estrogen|receptor
T6_T14 NONE estrogen_8\NN\14745635| (r_compound) receptors_9\NNS\5225602|estrogen|er (r_compound) alpha_13\NN\6828818|of|receptors|erα|and|beta (l_conj) beta_18\NN\6828818|erβ
T6_T15 NONE estrogen_8\NN\14745635| (r_compound) receptors_9\NNS\5225602|estrogen|er (r_compound) alpha_13\NN\6828818|of|receptors|erα|and|beta (l_conj) beta_18\NN\6828818|erβ (l_appos) erβ_20\NN\1740|(|)
T6_T16 NONE estrogen_8\NN\14745635| (r_compound) receptors_9\NNS\5225602|estrogen|er (r_compound) alpha_13\NN\6828818|of|receptors|erα|and|beta (r_nmod) activation_6\NN\13561719|by|the|alpha|,|regulate (l_acl:relcl) regulate_24\VBP\296178|which|transcription|functions|,|but|elicit (l_nmod) functions_36\NNS\13783581|through|two|independent|activation|(af)-1
T6_T17 NONE estrogen_8\NN\14745635| (r_compound) receptors_9\NNS\5225602|estrogen|er (r_compound) alpha_13\NN\6828818|of|receptors|erα|and|beta (r_nmod) activation_6\NN\13561719|by|the|alpha|,|regulate (l_acl:relcl) regulate_24\VBP\296178|which|transcription|functions|,|but|elicit (l_nmod) functions_36\NNS\13783581|through|two|independent|activation|(af)-1 (l_dep) (af)-1_37\NN\1740|and|af-2
T6_T18 NONE estrogen_8\NN\14745635| (r_compound) receptors_9\NNS\5225602|estrogen|er (r_compound) alpha_13\NN\6828818|of|receptors|erα|and|beta (r_nmod) activation_6\NN\13561719|by|the|alpha|,|regulate (l_acl:relcl) regulate_24\VBP\296178|which|transcription|functions|,|but|elicit (l_nmod) functions_36\NNS\13783581|through|two|independent|activation|(af)-1 (l_dep) (af)-1_37\NN\1740|and|af-2 (l_conj) af-2_39\NN\1740|
T7_T14 NONE steroid_48\NN\14727670| (r_compound) signals_49\NNS\33020|rapid|initiated|steroid|miss (r_dobj) elicit_44\VB\1617192|can|also|signals (r_conj) regulate_24\VBP\296178|which|transcription|functions|,|but|elicit (r_acl:relcl) activation_6\NN\13561719|by|the|alpha|,|regulate (l_nmod) alpha_13\NN\6828818|of|receptors|erα|and|beta (l_conj) beta_18\NN\6828818|erβ
T7_T15 NONE steroid_48\NN\14727670| (r_compound) signals_49\NNS\33020|rapid|initiated|steroid|miss (r_dobj) elicit_44\VB\1617192|can|also|signals (r_conj) regulate_24\VBP\296178|which|transcription|functions|,|but|elicit (r_acl:relcl) activation_6\NN\13561719|by|the|alpha|,|regulate (l_nmod) alpha_13\NN\6828818|of|receptors|erα|and|beta (l_conj) beta_18\NN\6828818|erβ (l_appos) erβ_20\NN\1740|(|)
T7_T16 NONE steroid_48\NN\14727670| (r_compound) signals_49\NNS\33020|rapid|initiated|steroid|miss (r_dobj) elicit_44\VB\1617192|can|also|signals (r_conj) regulate_24\VBP\296178|which|transcription|functions|,|but|elicit (l_nmod) functions_36\NNS\13783581|through|two|independent|activation|(af)-1
T7_T17 NONE steroid_48\NN\14727670| (r_compound) signals_49\NNS\33020|rapid|initiated|steroid|miss (r_dobj) elicit_44\VB\1617192|can|also|signals (r_conj) regulate_24\VBP\296178|which|transcription|functions|,|but|elicit (l_nmod) functions_36\NNS\13783581|through|two|independent|activation|(af)-1 (l_dep) (af)-1_37\NN\1740|and|af-2
T7_T18 NONE steroid_48\NN\14727670| (r_compound) signals_49\NNS\33020|rapid|initiated|steroid|miss (r_dobj) elicit_44\VB\1617192|can|also|signals (r_conj) regulate_24\VBP\296178|which|transcription|functions|,|but|elicit (l_nmod) functions_36\NNS\13783581|through|two|independent|activation|(af)-1 (l_dep) (af)-1_37\NN\1740|and|af-2 (l_conj) af-2_39\NN\1740|
T2_T11 NONE estrogens_6\NNS\14745635|of|these|or|modulators (l_conj) modulators_11\NNS\1740|selective|estrogen|receptors|serms (l_compound) receptors_10\NNS\5225602|
T3_T11 NONE estrogen_9\NN\14745635| (r_compound) modulators_11\NNS\1740|selective|estrogen|receptors|serms (l_compound) receptors_10\NNS\5225602|
23588312
T3_T7 NONE 5-fu_3\NN\1740|to (r_nmod) responses_1\NNS\11410625|the|5-fu|, (r_nsubj) vary_13\VBP\2666239|responses|respect|,|groups|,|variability|. (l_nmod) variability_21\NN\4733640|potentially|because|levels (l_nmod) levels_25\NNS\4916342|in|the|activity|enzyme (l_nmod) enzyme_28\NN\14723628|of|the|dehydrogenase (l_dep) dehydrogenase_30\NN\1740|dihydropyrimidine|dpd
T3_T8 NONE 5-fu_3\NN\1740|to (r_nmod) responses_1\NNS\11410625|the|5-fu|, (r_nsubj) vary_13\VBP\2666239|responses|respect|,|groups|,|variability|. (l_nmod) variability_21\NN\4733640|potentially|because|levels (l_nmod) levels_25\NNS\4916342|in|the|activity|enzyme (l_nmod) enzyme_28\NN\14723628|of|the|dehydrogenase (l_dep) dehydrogenase_30\NN\1740|dihydropyrimidine|dpd (l_appos) dpd_32\NN\1740|(|,|encoded|)
T3_T9 NONE 5-fu_3\NN\1740|to (r_nmod) responses_1\NNS\11410625|the|5-fu|, (r_nsubj) vary_13\VBP\2666239|responses|respect|,|groups|,|variability|. (l_nmod) variability_21\NN\4733640|potentially|because|levels (l_nmod) levels_25\NNS\4916342|in|the|activity|enzyme (l_nmod) enzyme_28\NN\14723628|of|the|dehydrogenase (l_dep) dehydrogenase_30\NN\1740|dihydropyrimidine|dpd (l_appos) dpd_32\NN\1740|(|,|encoded|) (l_acl) encoded_34\VBN\115157|gene (l_nmod) gene_38\NN\8459252|by|the|dpyd (l_compound) dpyd_37\NN\1740|
T5_T7 NONE dihydropyrimidine_29\NN\1740| (r_compound) dehydrogenase_30\NN\1740|dihydropyrimidine|dpd
T5_T8 NONE dihydropyrimidine_29\NN\1740| (r_compound) dehydrogenase_30\NN\1740|dihydropyrimidine|dpd (l_appos) dpd_32\NN\1740|(|,|encoded|)
T5_T9 NONE dihydropyrimidine_29\NN\1740| (r_compound) dehydrogenase_30\NN\1740|dihydropyrimidine|dpd (l_appos) dpd_32\NN\1740|(|,|encoded|) (l_acl) encoded_34\VBN\115157|gene (l_nmod) gene_38\NN\8459252|by|the|dpyd (l_compound) dpyd_37\NN\1740|
T2_T17 NONE 5-fu_37\NN\1740| (r_compound) mg(-1_40\NN\1740|152|pmol|5-fu|min(-1|)|)|,|respectively|;|= (r_dobj) _34\_SP\1740|152|±|mg(-1 (r_nmod) _28\_SP\1740|±| (r_nmod) compared_21\VBN\644583|as|noncarriers|| (r_advcl) showed_14\VBD\2137132|cohort|,|excluding|,|carriers|activity|compared (l_advcl) excluding_6\VBG\471711|after|carriers (l_dobj) carriers_8\NNS\9629752|y186c (l_compound) y186c_7\NN\1740|
T2_T18 NONE 5-fu_37\NN\1740| (r_compound) mg(-1_40\NN\1740|152|pmol|5-fu|min(-1|)|)|,|respectively|;|= (r_dobj) _34\_SP\1740|152|±|mg(-1 (r_nmod) _28\_SP\1740|±| (r_nmod) compared_21\VBN\644583|as|noncarriers|| (r_advcl) showed_14\VBD\2137132|cohort|,|excluding|,|carriers|activity|compared (l_nsubj) carriers_11\NNS\9629752|homozygous|c29r (l_nmod) c29r_13\NN\1740|of
T2_T19 NONE 5-fu_37\NN\1740| (r_compound) mg(-1_40\NN\1740|152|pmol|5-fu|min(-1|)|)|,|respectively|;|= (r_dobj) _34\_SP\1740|152|±|mg(-1 (r_nmod) _28\_SP\1740|±| (r_nmod) compared_21\VBN\644583|as|noncarriers|| (r_advcl) showed_14\VBD\2137132|cohort|,|excluding|,|carriers|activity|compared (l_dobj) activity_19\NN\30358|higher|dpd (l_compound) dpd_18\NN\1740|
23537702
17013809
T9_T15 NONE progesterone_3\NN\14747338| (r_compound) ligands_5\NNS\20090|of|progesterone|receptor (l_compound) receptor_4\NN\5225602|
T1_T12 NONE progesterone_0\NN\14747338| (r_nsubj) one_2\CD\13741022|progesterone|is|hormones|. (l_nmod) hormones_8\NNS\5404728|of|the|first|nuclear|receptor|described (l_compound) receptor_7\NN\5225602|
T2_T10 NONE progesterone_1\NN\14747338|1 (r_nsubj) affects_5\VBZ\126264|because|progesterone|menstruation|receptor (l_nmod) receptor_13\NN\5225602|via|the|progesterone|pr
T2_T11 NONE progesterone_1\NN\14747338|1 (r_nsubj) affects_5\VBZ\126264|because|progesterone|menstruation|receptor (l_nmod) receptor_13\NN\5225602|via|the|progesterone|pr (l_appos) pr_15\NN\14625458|(|)
T3_T10 NONE progesterone_12\NN\14747338| (r_compound) receptor_13\NN\5225602|via|the|progesterone|pr
T3_T11 NONE progesterone_12\NN\14747338| (r_compound) receptor_13\NN\5225602|via|the|progesterone|pr (l_appos) pr_15\NN\14625458|(|)
T4_T13 NONE steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (r_appos) periods_19\NNS\13575869|into|three|:|steroids (r_nmod) divided_16\VBN\140123|evolution|can|be|crudely|periods (r_conj) developed_6\VBN\1753788|however|,|ligands|were|drugs|,|and|divided|. (l_nsubjpass) ligands_2\NNS\20090|pr (l_nmod) pr_4\NN\14625458|for
T4_T14 NONE steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (l_conj) ligands_55\NNS\20090|3|non-steroidal|pr|selectivity (l_compound) pr_54\NN\14625458|
T5_T13 NONE progesterone_32\NN\14747338|of (r_nmod) properties_30\NNS\32613|the|gestational|progesterone (r_dobj) mimic_27\VBP\1742886|that|properties (r_acl:relcl) steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (r_appos) periods_19\NNS\13575869|into|three|:|steroids (r_nmod) divided_16\VBN\140123|evolution|can|be|crudely|periods (r_conj) developed_6\VBN\1753788|however|,|ligands|were|drugs|,|and|divided|. (l_nsubjpass) ligands_2\NNS\20090|pr (l_nmod) pr_4\NN\14625458|for
T5_T14 NONE progesterone_32\NN\14747338|of (r_nmod) properties_30\NNS\32613|the|gestational|progesterone (r_dobj) mimic_27\VBP\1742886|that|properties (r_acl:relcl) steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (l_conj) ligands_55\NNS\20090|3|non-steroidal|pr|selectivity (l_compound) pr_54\NN\14625458|
T6_T13 NONE steroids_38\NNS\14727670|2|drug-like|properties|applications (r_conj) steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (r_appos) periods_19\NNS\13575869|into|three|:|steroids (r_nmod) divided_16\VBN\140123|evolution|can|be|crudely|periods (r_conj) developed_6\VBN\1753788|however|,|ligands|were|drugs|,|and|divided|. (l_nsubjpass) ligands_2\NNS\20090|pr (l_nmod) pr_4\NN\14625458|for
T6_T14 NONE steroids_38\NNS\14727670|2|drug-like|properties|applications (r_conj) steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (l_conj) ligands_55\NNS\20090|3|non-steroidal|pr|selectivity (l_compound) pr_54\NN\14625458|
T7_T13 NONE progesterone_43\NN\14747338|from (r_nmod) properties_41\NNS\32613|with|different|progesterone|and (r_nmod) steroids_38\NNS\14727670|2|drug-like|properties|applications (r_conj) steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (r_appos) periods_19\NNS\13575869|into|three|:|steroids (r_nmod) divided_16\VBN\140123|evolution|can|be|crudely|periods (r_conj) developed_6\VBN\1753788|however|,|ligands|were|drugs|,|and|divided|. (l_nsubjpass) ligands_2\NNS\20090|pr (l_nmod) pr_4\NN\14625458|for
T7_T14 NONE progesterone_43\NN\14747338|from (r_nmod) properties_41\NNS\32613|with|different|progesterone|and (r_nmod) steroids_38\NNS\14727670|2|drug-like|properties|applications (r_conj) steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (l_conj) ligands_55\NNS\20090|3|non-steroidal|pr|selectivity (l_compound) pr_54\NN\14625458|
T8_T13 NONE non-steroidal_53\JJ\1740| (r_amod) ligands_55\NNS\20090|3|non-steroidal|pr|selectivity (r_conj) steroids_25\NNS\14727670|1|drug-like|mimic|;|steroids|;|and|ligands (r_appos) periods_19\NNS\13575869|into|three|:|steroids (r_nmod) divided_16\VBN\140123|evolution|can|be|crudely|periods (r_conj) developed_6\VBN\1753788|however|,|ligands|were|drugs|,|and|divided|. (l_nsubjpass) ligands_2\NNS\20090|pr (l_nmod) pr_4\NN\14625458|for
T8_T14 NONE non-steroidal_53\JJ\1740| (r_amod) ligands_55\NNS\20090|3|non-steroidal|pr|selectivity (l_compound) pr_54\NN\14625458|
9596079
T13_T28 NONE thiazide-sensitive_16\JJ\1740| (r_amod) cotransport_18\NN\1740|for|abnormal|thiazide-sensitive|nacl (r_nmod) evidence_13\NN\5816287|cotransport (r_dep) express_4\VBP\928630|cells|mrna|syndrome|:|evidence|. (l_dobj) mrna_7\NN\14832193|mutated|ncct (l_compound) ncct_6\NN\1740|
T14_T28 NONE nacl_17\NN\1740| (r_compound) cotransport_18\NN\1740|for|abnormal|thiazide-sensitive|nacl (r_nmod) evidence_13\NN\5816287|cotransport (r_dep) express_4\VBP\928630|cells|mrna|syndrome|:|evidence|. (l_dobj) mrna_7\NN\14832193|mutated|ncct (l_compound) ncct_6\NN\1740|
T10_T17 NONE thiazide-sensitive_9\JJ\1740| (r_amod) gene_13\NN\8459252|between|the|human|thiazide-sensitive|sodium|chloride|cotransporter|ncct|and|syndrome (l_dep) ncct_15\NN\1740|(|or|tsc|)
T10_T18 NONE thiazide-sensitive_9\JJ\1740| (r_amod) gene_13\NN\8459252|between|the|human|thiazide-sensitive|sodium|chloride|cotransporter|ncct|and|syndrome (l_dep) ncct_15\NN\1740|(|or|tsc|) (l_conj) tsc_17\NN\1740|
T10_T25 NONE thiazide-sensitive_9\JJ\1740| (r_amod) gene_13\NN\8459252|between|the|human|thiazide-sensitive|sodium|chloride|cotransporter|ncct|and|syndrome (l_compound) cotransporter_12\NN\1740|
T12_T17 NONE chloride_11\NN\14818238| (r_compound) gene_13\NN\8459252|between|the|human|thiazide-sensitive|sodium|chloride|cotransporter|ncct|and|syndrome (l_dep) ncct_15\NN\1740|(|or|tsc|)
T12_T18 NONE chloride_11\NN\14818238| (r_compound) gene_13\NN\8459252|between|the|human|thiazide-sensitive|sodium|chloride|cotransporter|ncct|and|syndrome (l_dep) ncct_15\NN\1740|(|or|tsc|) (l_conj) tsc_17\NN\1740|
T12_T25 NONE chloride_11\NN\14818238| (r_compound) gene_13\NN\8459252|between|the|human|thiazide-sensitive|sodium|chloride|cotransporter|ncct|and|syndrome (l_compound) cotransporter_12\NN\1740|
T9_T22 NONE nacl_21\NN\1740| (r_compound) cotransport_22\NN\1740|defective|pbmc|nacl (r_nsubjpass) demonstrated_25\VBN\2137132|whether|cotransport|could|be|gs (r_conj) express_14\VBP\928630|whether|cells|mrna|and|demonstrated (l_dobj) mrna_16\NN\14832193|ncct (l_compound) ncct_15\NN\1740|
T8_T21 NONE nacl_15\NN\1740| (r_compound) cotransport_16\NN\1740|that|cause|is|defective|ncct|nacl (l_compound) ncct_14\NN\1740|
17333241
T11_T15 NONE nucleotide_4\NN\14850483| (r_amod) polymorphisms_5\NNS\11418750|of|the|single|nucleotide|gclc-129|and|deletions (l_conj) deletions_22\NNS\13508333|gstm1 (l_nmod) gstm1_24\NN\1740|of|and|gstt1
T11_T16 NONE nucleotide_4\NN\14850483| (r_amod) polymorphisms_5\NNS\11418750|of|the|single|nucleotide|gclc-129|and|deletions (l_conj) deletions_22\NNS\13508333|gstm1 (l_nmod) gstm1_24\NN\1740|of|and|gstt1 (l_conj) gstt1_26\NN\1740|
T11_T21 NONE nucleotide_4\NN\14850483| (r_amod) polymorphisms_5\NNS\11418750|of|the|single|nucleotide|gclc-129|and|deletions (l_dep) gclc-129_6\NN\1740|,|gclm-588|,|gsta1|,|gstp1|-|105|and|gstp1
T11_T22 NONE nucleotide_4\NN\14850483| (r_amod) polymorphisms_5\NNS\11418750|of|the|single|nucleotide|gclc-129|and|deletions (l_dep) gclc-129_6\NN\1740|,|gclm-588|,|gsta1|,|gstp1|-|105|and|gstp1 (l_conj) gclm-588_8\NN\1740|
T11_T23 NONE nucleotide_4\NN\14850483| (r_amod) polymorphisms_5\NNS\11418750|of|the|single|nucleotide|gclc-129|and|deletions (l_dep) gclc-129_6\NN\1740|,|gclm-588|,|gsta1|,|gstp1|-|105|and|gstp1 (l_conj) gsta1_10\NN\1740|-|52
T11_T24 NONE nucleotide_4\NN\14850483| (r_amod) polymorphisms_5\NNS\11418750|of|the|single|nucleotide|gclc-129|and|deletions (l_dep) gclc-129_6\NN\1740|,|gclm-588|,|gsta1|,|gstp1|-|105|and|gstp1 (l_conj) gstp1_14\NN\1740|
T11_T25 NONE nucleotide_4\NN\14850483| (r_amod) polymorphisms_5\NNS\11418750|of|the|single|nucleotide|gclc-129|and|deletions (l_dep) gclc-129_6\NN\1740|,|gclm-588|,|gsta1|,|gstp1|-|105|and|gstp1 (l_conj) gstp1_18\NN\1740|-|114
T2_T17 NONE ttca-levels_14\NNS\1740|in (r_nmod) differences_12\NNS\4723816|significant|ttca-levels|genotypes (r_attr) were_9\VBD\836236|furthermore|,|respect|there|differences|. (l_nmod) respect_3\NN\5817845|with|gstm1 (l_nmod) gstm1_5\NN\1740|to|and|gstt1
T2_T18 NONE ttca-levels_14\NNS\1740|in (r_nmod) differences_12\NNS\4723816|significant|ttca-levels|genotypes (r_attr) were_9\VBD\836236|furthermore|,|respect|there|differences|. (l_nmod) respect_3\NN\5817845|with|gstm1 (l_nmod) gstm1_5\NN\1740|to|and|gstt1 (l_conj) gstt1_7\NN\1740|
2751392
T9_T17 NONE lactate_3\NN\14850483| (r_compound) dehydrogenase-x_4\NN\1740|lactate
T1_T10 NONE lactate_35\NN\14850483| (r_compound) dehydrogenase-x_36\NN\1740|lactate|ldh-x
T1_T11 NONE lactate_35\NN\14850483| (r_compound) dehydrogenase-x_36\NN\1740|lactate|ldh-x (l_appos) ldh-x_38\NN\1740|(|)
T2_T10 NONE testosterone_43\NN\14747587| (r_compound) levels_44\NNS\4916342|serum|testosterone (r_conj) activity_27\NN\30358|by|the|testis|,|and|levels (l_nmod) testis_30\NN\5524430|of|a|and|enzyme (l_conj) enzyme_33\NN\14723628|sperm-specific|,|dehydrogenase-x (l_appos) dehydrogenase-x_36\NN\1740|lactate|ldh-x
T2_T11 NONE testosterone_43\NN\14747587| (r_compound) levels_44\NNS\4916342|serum|testosterone (r_conj) activity_27\NN\30358|by|the|testis|,|and|levels (l_nmod) testis_30\NN\5524430|of|a|and|enzyme (l_conj) enzyme_33\NN\14723628|sperm-specific|,|dehydrogenase-x (l_appos) dehydrogenase-x_36\NN\1740|lactate|ldh-x (l_appos) ldh-x_38\NN\1740|(|)
T3_T12 NONE dinucleotide_12\NN\1740|of|reduced|nicotinamide|adenine|nadh (r_nmod) oxidation_7\NN\13447361|by|dinucleotide (r_nmod) determined_5\VBN\1645601|activity|was|oxidation|. (l_nsubjpass) activity_3\NN\30358|testicular|cytosolic|ldh-x (l_compound) ldh-x_2\NN\1740|
T4_T12 NONE nadh_14\NN\1740|(|) (r_appos) dinucleotide_12\NN\1740|of|reduced|nicotinamide|adenine|nadh (r_nmod) oxidation_7\NN\13447361|by|dinucleotide (r_nmod) determined_5\VBN\1645601|activity|was|oxidation|. (l_nsubjpass) activity_3\NN\30358|testicular|cytosolic|ldh-x (l_compound) ldh-x_2\NN\1740|
T7_T15 NONE testosterone_4\NN\14747587| (r_compound) levels_5\NNS\4916342|serum|testosterone (r_conj) activity_1\NN\30358|ldh-x|and|levels (l_compound) ldh-x_0\NN\1740|
T8_T16 NONE testosterone_19\NN\14747587| (r_compound) levels_20\NNS\4916342|serum|testosterone (r_conj) activity_16\NN\30358|to|be|due|lower|ldh-x|and|levels (l_compound) ldh-x_15\NN\1740|
23466526
T2_T17 NONE zinc-finger_1\NN\1740| (r_amod) mutations_3\NNS\4475|zeb2|zinc-finger|missense (l_compound) zeb2_0\NN\1740|
T2_T18 NONE zinc-finger_1\NN\1740|
T1_T12 NONE c-zinc-finger_31\NN\1740| (r_compound) domain_35\NN\13934596|in|the|conserved|c-zinc-finger|(|c-zf|)|zeb2 (r_nmod) identified_26\VBN\699815|domain (r_acl) mutations_15\NNS\4475|of|three|novel|missense|,|tyr1055cys|,|identified (l_appos) tyr1055cys_18\NN\1740|p.|,|ser1071pro|and|his1045arg
T1_T13 NONE c-zinc-finger_31\NN\1740| (r_compound) domain_35\NN\13934596|in|the|conserved|c-zinc-finger|(|c-zf|)|zeb2 (r_nmod) identified_26\VBN\699815|domain (r_acl) mutations_15\NNS\4475|of|three|novel|missense|,|tyr1055cys|,|identified (l_appos) tyr1055cys_18\NN\1740|p.|,|ser1071pro|and|his1045arg (l_conj) ser1071pro_21\NN\1740|p.
T1_T14 NONE c-zinc-finger_31\NN\1740| (r_compound) domain_35\NN\13934596|in|the|conserved|c-zinc-finger|(|c-zf|)|zeb2 (r_nmod) identified_26\VBN\699815|domain (r_acl) mutations_15\NNS\4475|of|three|novel|missense|,|tyr1055cys|,|identified (l_appos) tyr1055cys_18\NN\1740|p.|,|ser1071pro|and|his1045arg (l_conj) his1045arg_24\NN\1740|p.
T1_T15 NONE c-zinc-finger_31\NN\1740| (r_compound) domain_35\NN\13934596|in|the|conserved|c-zinc-finger|(|c-zf|)|zeb2
T1_T16 NONE c-zinc-finger_31\NN\1740| (r_compound) domain_35\NN\13934596|in|the|conserved|c-zinc-finger|(|c-zf|)|zeb2 (l_nmod) zeb2_37\NN\1740|of
11772142
T7_T33 CPR:4 rabeprazole_2\NN\1740| (r_nsubj) inhibitor_5\NN\20090|unlabelled|:|rabeprazole|is|an|pump|. (l_nmod) pump_10\NN\3736970|of|the|gastric|proton
T18_T31 CPR:4 rabeprazole_2\NN\1740| (r_nsubj) inhibitor_9\NN\20090|rabeprazole|is|a|tolerated|pump (l_compound) pump_8\NN\3736970|proton
10362188
T13_T23 NONE novastan_26\NN\1740|with|and|study (r_nmod) infarction_24\NN\14204950|myocardial|novastan (r_appos) study_4\NN\635850|a|multicenter|argatroban|adjunct|infarction (l_nmod) adjunct_10\NN\9312645|as|activator|: (l_nmod) activator_14\NN\19613|to|tissue|plasminogen|tpa|infarction (l_appos) tpa_16\NN\1740|(|)
T13_T24 NONE novastan_26\NN\1740|with|and|study (l_conj) study_32\NN\635850|tpa (l_compound) tpa_28\NN\1740|mint
T13_T25 NONE novastan_26\NN\1740|with|and|study (r_nmod) infarction_24\NN\14204950|myocardial|novastan (r_appos) study_4\NN\635850|a|multicenter|argatroban|adjunct|infarction (l_nmod) adjunct_10\NN\9312645|as|activator|: (l_nmod) activator_14\NN\19613|to|tissue|plasminogen|tpa|infarction
T14_T23 NONE argatroban_6\NN\1740|of|versus|heparin (r_nmod) study_4\NN\635850|a|multicenter|argatroban|adjunct|infarction (l_nmod) adjunct_10\NN\9312645|as|activator|: (l_nmod) activator_14\NN\19613|to|tissue|plasminogen|tpa|infarction (l_appos) tpa_16\NN\1740|(|)
T14_T24 NONE argatroban_6\NN\1740|of|versus|heparin (r_nmod) study_4\NN\635850|a|multicenter|argatroban|adjunct|infarction (l_appos) infarction_24\NN\14204950|myocardial|novastan (l_nmod) novastan_26\NN\1740|with|and|study (l_conj) study_32\NN\635850|tpa (l_compound) tpa_28\NN\1740|mint
T14_T25 NONE argatroban_6\NN\1740|of|versus|heparin (r_nmod) study_4\NN\635850|a|multicenter|argatroban|adjunct|infarction (l_nmod) adjunct_10\NN\9312645|as|activator|: (l_nmod) activator_14\NN\19613|to|tissue|plasminogen|tpa|infarction
T12_T15 NONE argatroban_15\NN\1740| (r_appos) inhibitor_13\NN\20090|of|a|small-molecule|,|direct|thrombin|,|argatroban|, (r_nmod) effect_6\NN\34213|the|inhibitor|reperfusion (l_nmod) reperfusion_18\NN\1740|on|induced (l_acl) induced_19\VBN\1627355|activator (l_nmod) activator_23\NN\19613|by|tissue|plasminogen|tpa|patients
T12_T17 NONE argatroban_15\NN\1740| (r_appos) inhibitor_13\NN\20090|of|a|small-molecule|,|direct|thrombin|,|argatroban|, (r_nmod) effect_6\NN\34213|the|inhibitor|reperfusion (l_nmod) reperfusion_18\NN\1740|on|induced (l_acl) induced_19\VBN\1627355|activator (l_nmod) activator_23\NN\19613|by|tissue|plasminogen|tpa|patients (l_appos) tpa_25\NN\1740|(|)
T12_T22 CPR:4 argatroban_15\NN\1740| (r_appos) inhibitor_13\NN\20090|of|a|small-molecule|,|direct|thrombin|,|argatroban|, (l_compound) thrombin_12\NN\14735953|
T7_T19 CPR:4 argatroban_9\NNP\1740| (r_nsubj) has_10\VBZ\2108377|that|argatroban|advantages|inhibition (l_nmod) inhibition_16\NN\1068773|for|the|thrombin|and|enhancement (l_nmod) thrombin_19\NN\14735953|of|clot-bound
T7_T20 NONE argatroban_9\NNP\1740| (r_nsubj) has_10\VBZ\2108377|that|argatroban|advantages|inhibition (l_nmod) inhibition_16\NN\1068773|for|the|thrombin|and|enhancement (l_conj) enhancement_23\NN\248977|for|the|thrombolysis (l_nmod) thrombolysis_25\NN\13509528|of|tpa (l_nmod) tpa_27\NN\1740|with
T8_T21 NONE argatroban_18\NN\1740|low-dose|or|argatroban (r_conj) heparin_15\NN\2718259|to|,|argatroban|addition (l_nmod) addition_23\NN\3081021|in|tpa (l_nmod) tpa_25\NN\1740|to
T9_T21 NONE argatroban_21\NN\1740|high-dose (r_conj) argatroban_18\NN\1740|low-dose|or|argatroban (r_conj) heparin_15\NN\2718259|to|,|argatroban|addition (l_nmod) addition_23\NN\3081021|in|tpa (l_nmod) tpa_25\NN\1740|to
T5_T16 NONE argatroban_2\NN\1740|, (r_nsubj) appears_9\VBZ\2604760|argatroban|compared|,|enhance (l_xcomp) enhance_11\VB\227165|to|reperfusion (l_dobj) reperfusion_12\NN\1740|tpa|patients (l_nmod) tpa_14\NN\1740|with
19888521
T1_T6 NONE glucosamine_9\NN\14617597|individual|and|acid (r_compound) residues_13\NNS\20827|glucosamine (r_conj) groups_6\NNS\2137|of|terminal|and|residues|substituents (r_nmod) content_3\NN\7951464|the|groups (r_dobj) providing_1\VBG\2199590|besides|content (r_advcl) permitted_22\VBD\797697|providing|,|spectra|us|evaluate (l_xcomp) evaluate_25\VB\670261|to|and|correlate|content|quantification (l_dobj) content_29\NN\7951464|the|pentasaccharide (l_nmod) pentasaccharide_32\NN\1740|of|the|a-g-a*-i-a (l_dep) a-g-a*-i-a_36\NN\1740|,|at-binding|sequence|at-bs
T2_T6 NONE acid_12\NN\14818238|uronic (r_conj) glucosamine_9\NN\14617597|individual|and|acid (r_compound) residues_13\NNS\20827|glucosamine (r_conj) groups_6\NNS\2137|of|terminal|and|residues|substituents (r_nmod) content_3\NN\7951464|the|groups (r_dobj) providing_1\VBG\2199590|besides|content (r_advcl) permitted_22\VBD\797697|providing|,|spectra|us|evaluate (l_xcomp) evaluate_25\VB\670261|to|and|correlate|content|quantification (l_dobj) content_29\NN\7951464|the|pentasaccharide (l_nmod) pentasaccharide_32\NN\1740|of|the|a-g-a*-i-a (l_dep) a-g-a*-i-a_36\NN\1740|,|at-binding|sequence|at-bs
T3_T6 NONE sulfate_16\NN\15010703| (r_compound) substituents_17\NNS\1740|with|different|sulfate (r_nmod) groups_6\NNS\2137|of|terminal|and|residues|substituents (r_nmod) content_3\NN\7951464|the|groups (r_dobj) providing_1\VBG\2199590|besides|content (r_advcl) permitted_22\VBD\797697|providing|,|spectra|us|evaluate (l_xcomp) evaluate_25\VB\670261|to|and|correlate|content|quantification (l_dobj) content_29\NN\7951464|the|pentasaccharide (l_nmod) pentasaccharide_32\NN\1740|of|the|a-g-a*-i-a (l_dep) a-g-a*-i-a_36\NN\1740|,|at-binding|sequence|at-bs
T4_T6 NONE pentasaccharide_32\NN\1740|of|the|a-g-a*-i-a (l_dep) a-g-a*-i-a_36\NN\1740|,|at-binding|sequence|at-bs
T5_T6 NONE disaccharide_46\NN\14969044| (r_compound) g-a*._48\NN\1740|of|the|disaccharide|sequence (r_nmod) signals_43\NNS\33020|of|g-a*. (r_nmod) quantification_41\NN\5846355|through|signals (r_nmod) evaluate_25\VB\670261|to|and|correlate|content|quantification (l_dobj) content_29\NN\7951464|the|pentasaccharide (l_nmod) pentasaccharide_32\NN\1740|of|the|a-g-a*-i-a (l_dep) a-g-a*-i-a_36\NN\1740|,|at-binding|sequence|at-bs
23517733
T14_T18 NONE 6-dialkylaminoalkyl_9\NN\1740|,|6-acylaminoalkyl (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) response_28\NN\11410625|on|phytohemagglutin|a|(pha)-induced|proliferative|cells|and (l_compound) a_25\NN\13649268|
T14_T19 NONE 6-dialkylaminoalkyl_9\NN\1740|,|6-acylaminoalkyl (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) response_28\NN\11410625|on|phytohemagglutin|a|(pha)-induced|proliferative|cells|and (l_amod) (pha)-induced_26\JJ\1740|
T14_T20 NONE 6-dialkylaminoalkyl_9\NN\1740|,|6-acylaminoalkyl (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) production_48\NN\30358|(lps)-induced|alpha|cells (l_compound) alpha_44\NN\6828818|tumor|necrosis|factor|tnf-α
T14_T21 NONE 6-dialkylaminoalkyl_9\NN\1740|,|6-acylaminoalkyl (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) production_48\NN\30358|(lps)-induced|alpha|cells (l_compound) alpha_44\NN\6828818|tumor|necrosis|factor|tnf-α (l_appos) tnf-α_46\NN\1740|(|)
T15_T18 NONE 6-acylaminoalkyl_11\NN\1740| (r_conj) 6-dialkylaminoalkyl_9\NN\1740|,|6-acylaminoalkyl (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) response_28\NN\11410625|on|phytohemagglutin|a|(pha)-induced|proliferative|cells|and (l_compound) a_25\NN\13649268|
T15_T19 NONE 6-acylaminoalkyl_11\NN\1740| (r_conj) 6-dialkylaminoalkyl_9\NN\1740|,|6-acylaminoalkyl (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) response_28\NN\11410625|on|phytohemagglutin|a|(pha)-induced|proliferative|cells|and (l_amod) (pha)-induced_26\JJ\1740|
T15_T20 NONE 6-acylaminoalkyl_11\NN\1740| (r_conj) 6-dialkylaminoalkyl_9\NN\1740|,|6-acylaminoalkyl (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) production_48\NN\30358|(lps)-induced|alpha|cells (l_compound) alpha_44\NN\6828818|tumor|necrosis|factor|tnf-α
T15_T21 NONE 6-acylaminoalkyl_11\NN\1740| (r_conj) 6-dialkylaminoalkyl_9\NN\1740|,|6-acylaminoalkyl (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) production_48\NN\30358|(lps)-induced|alpha|cells (l_compound) alpha_44\NN\6828818|tumor|necrosis|factor|tnf-α (l_appos) tnf-α_46\NN\1740|(|)
T16_T18 NONE sulfonylaminoalkyl_13\NN\1740| (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) response_28\NN\11410625|on|phytohemagglutin|a|(pha)-induced|proliferative|cells|and (l_compound) a_25\NN\13649268|
T16_T19 NONE sulfonylaminoalkyl_13\NN\1740| (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) response_28\NN\11410625|on|phytohemagglutin|a|(pha)-induced|proliferative|cells|and (l_amod) (pha)-induced_26\JJ\1740|
T16_T20 NONE sulfonylaminoalkyl_13\NN\1740| (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) production_48\NN\30358|(lps)-induced|alpha|cells (l_compound) alpha_44\NN\6828818|tumor|necrosis|factor|tnf-α
T16_T21 NONE sulfonylaminoalkyl_13\NN\1740| (r_conj) 6h_7\NN\1740|,|6-dialkylaminoalkyl|and|sulfonylaminoalkyl (r_compound) derivatives_14\NNS\5802185|as|the|6h (r_nmod) grouped_4\VBN\654625|derivatives (r_acl) compounds_2\NNS\5869584|one|,|grouped|, (r_nsubjpass) tested_17\VBN\670261|compounds|were|cytotoxicity|. (l_nmod) cytotoxicity_19\NN\13583478|for|,|effects (l_conj) effects_22\NNS\13245626|their|response|production (l_nmod) production_48\NN\30358|(lps)-induced|alpha|cells (l_compound) alpha_44\NN\6828818|tumor|necrosis|factor|tnf-α (l_appos) tnf-α_46\NN\1740|(|)
22287617
T7_T24 NONE superoxide_3\NN\14971519| (r_compound) dismutase_4\NN\1740|of|superoxide|,|catalase|and|peroxidase
T7_T25 NONE superoxide_3\NN\14971519| (r_compound) dismutase_4\NN\1740|of|superoxide|,|catalase|and|peroxidase (l_conj) catalase_6\NN\14732946|
T7_T26 NONE superoxide_3\NN\14971519| (r_compound) dismutase_4\NN\1740|of|superoxide|,|catalase|and|peroxidase (l_conj) peroxidase_9\NN\14971234|glutathione
T8_T24 NONE glutathione_8\NN\1740| (r_compound) peroxidase_9\NN\14971234|glutathione (r_conj) dismutase_4\NN\1740|of|superoxide|,|catalase|and|peroxidase
T8_T25 NONE glutathione_8\NN\1740| (r_compound) peroxidase_9\NN\14971234|glutathione (r_conj) dismutase_4\NN\1740|of|superoxide|,|catalase|and|peroxidase (l_conj) catalase_6\NN\14732946|
T8_T26 NONE glutathione_8\NN\1740| (r_compound) peroxidase_9\NN\14971234|glutathione
8836617
T18_T25 NONE bradykinin_4\NN\1740| (r_conj) tachykinin_2\NN\1740|and|bradykinin (r_compound) receptors_5\NNS\5225602|of|tachykinin|and|cells
T19_T25 NONE formaldehyde-induced_11\JJ\1740| (r_amod) leakage_14\NN\7407777|in|gaseous|formaldehyde-induced|airway|microvascular|rats (r_nmod) role_0\NN\719494|receptors|leakage|. (l_nmod) receptors_5\NNS\5225602|of|tachykinin|and|cells
T10_T20 NONE histamine_39\NN\14739004| (r_compound) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (r_appos) ketotifen_30\NN\1740|fumarate|,|antagonist|, (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T10_T23 NONE histamine_39\NN\14739004| (r_compound) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (r_appos) ketotifen_30\NN\1740|fumarate|,|antagonist|, (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_conj) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T10_T24 NONE histamine_39\NN\14739004| (r_compound) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T11_T20 CPR:6 cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T11_T23 NONE cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_conj) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T11_T24 NONE cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) ketotifen_30\NN\1740|fumarate|,|antagonist|, (l_appos) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T12_T20 CPR:6 ]_9\-RRB-\1740| (r_punct) (+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine_8\NN\1740|[|] (r_appos) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T12_T23 NONE ]_9\-RRB-\1740| (r_punct) (+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine_8\NN\1740|[|] (r_appos) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_conj) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T12_T24 NONE ]_9\-RRB-\1740| (r_punct) (+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine_8\NN\1740|[|] (r_appos) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) ketotifen_30\NN\1740|fumarate|,|antagonist|, (l_appos) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T13_T20 NONE formaldehyde_54\NN\14584765|by|gaseous (r_nmod) induced_51\VBN\1627355|formaldehyde (r_acl) leakage_50\NN\7407777|on|microvascular|induced (r_nmod) effects_4\NNS\13245626|the|cp-99,994|leakage (l_nmod) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T13_T23 NONE formaldehyde_54\NN\14584765|by|gaseous (r_nmod) induced_51\VBN\1627355|formaldehyde (r_acl) leakage_50\NN\7407777|on|microvascular|induced (r_nmod) effects_4\NNS\13245626|the|cp-99,994|leakage (l_nmod) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_conj) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T13_T24 NONE formaldehyde_54\NN\14584765|by|gaseous (r_nmod) induced_51\VBN\1627355|formaldehyde (r_acl) leakage_50\NN\7407777|on|microvascular|induced (r_nmod) effects_4\NNS\13245626|the|cp-99,994|leakage (l_nmod) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) ketotifen_30\NN\1740|fumarate|,|antagonist|, (l_appos) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T5_T20 NONE 140_18\CD\1740| (r_nummod) hoe_17\NN\4451818|140|d-arg[hyp3,thi5,d-tic7,oic8]bradykinin (r_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T5_T23 CPR:6 140_18\CD\1740| (r_nummod) hoe_17\NN\4451818|140|d-arg[hyp3,thi5,d-tic7,oic8]bradykinin (r_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_conj) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T5_T24 NONE 140_18\CD\1740| (r_nummod) hoe_17\NN\4451818|140|d-arg[hyp3,thi5,d-tic7,oic8]bradykinin (r_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) ketotifen_30\NN\1740|fumarate|,|antagonist|, (l_appos) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T6_T20 NONE )_21\-RRB-\1740| (r_punct) d-arg[hyp3,thi5,d-tic7,oic8]bradykinin_20\NN\1740|(|) (r_appos) hoe_17\NN\4451818|140|d-arg[hyp3,thi5,d-tic7,oic8]bradykinin (r_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T6_T23 CPR:6 )_21\-RRB-\1740| (r_punct) d-arg[hyp3,thi5,d-tic7,oic8]bradykinin_20\NN\1740|(|) (r_appos) hoe_17\NN\4451818|140|d-arg[hyp3,thi5,d-tic7,oic8]bradykinin (r_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_conj) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T6_T24 NONE )_21\-RRB-\1740| (r_punct) d-arg[hyp3,thi5,d-tic7,oic8]bradykinin_20\NN\1740|(|) (r_appos) hoe_17\NN\4451818|140|d-arg[hyp3,thi5,d-tic7,oic8]bradykinin (r_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) ketotifen_30\NN\1740|fumarate|,|antagonist|, (l_appos) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T7_T20 NONE bradykinin_24\NN\1740| (r_compound) antagonist_27\NN\7846|a|bradykinin|b2|receptor (r_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T7_T23 NONE bradykinin_24\NN\1740| (r_compound) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T7_T24 NONE bradykinin_24\NN\1740| (r_compound) antagonist_27\NN\7846|a|bradykinin|b2|receptor (r_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) ketotifen_30\NN\1740|fumarate|,|antagonist|, (l_appos) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T8_T20 NONE ketotifen_30\NN\1740|fumarate|,|antagonist|, (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T8_T23 NONE ketotifen_30\NN\1740|fumarate|,|antagonist|, (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_conj) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T8_T24 CPR:6 ketotifen_30\NN\1740|fumarate|,|antagonist|, (l_appos) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T9_T20 NONE )_36\-RRB-\1740| (r_punct) fumarate_35\NN\1740|(|4-(1-methyl-4-piperidylidene)4|h-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9h)-one|hydrogen|) (r_appos) ketotifen_30\NN\1740|fumarate|,|antagonist|, (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_compound) receptor_14\NN\5225602|
T9_T23 NONE )_36\-RRB-\1740| (r_punct) fumarate_35\NN\1740|(|4-(1-methyl-4-piperidylidene)4|h-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9h)-one|hydrogen|) (r_appos) ketotifen_30\NN\1740|fumarate|,|antagonist|, (r_conj) cp-99,994_6\NN\1740|of|(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine|,|antagonist|,|and|ketotifen (l_conj) antagonist_15\NN\7846|a|tachykinin|nk1|receptor|,|hoe|,|antagonist (l_conj) antagonist_27\NN\7846|a|bradykinin|b2|receptor (l_compound) receptor_26\NN\5225602|
T9_T24 CPR:6 )_36\-RRB-\1740| (r_punct) fumarate_35\NN\1740|(|4-(1-methyl-4-piperidylidene)4|h-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9h)-one|hydrogen|) (r_appos) ketotifen_30\NN\1740|fumarate|,|antagonist|, (l_appos) antagonist_42\NN\7846|a|histamine|h1|receptor|properties (l_compound) receptor_41\NN\5225602|
T3_T21 NONE formaldehyde_7\NN\14584765|by (r_nmod) induced_5\VBN\1627355|formaldehyde|airway (r_acl) increase_1\NN\13576355|the|permeability|induced (r_nsubjpass) mediated_13\VBN\761713|increase|was|predominantly|stimulation|. (l_nmod) stimulation_18\NN\242808|by|nk1|receptor (l_compound) receptor_17\NN\5225602|
T4_T22 NONE bradykinin_2\NN\1740| (r_compound) receptors_3\NNS\5225602|of|bradykinin|and|cells
10064839
T49_T56 NONE dextromethorphan_17\NN\1740|with|and|dextrorphan (r_nmod) compared_15\VBN\644583|binding|dextromethorphan|. (l_nsubj) binding_0\NN\4688246|dimemorfan|receptor|and|effects|, (l_nmod) receptor_5\NN\5225602|to|sigma-1
T50_T56 NONE dimemorfan_2\NN\1740|of (r_nmod) binding_0\NN\4688246|dimemorfan|receptor|and|effects|, (l_nmod) receptor_5\NN\5225602|to|sigma-1
T51_T56 NONE dextrorphan_19\NN\1740| (r_conj) dextromethorphan_17\NN\1740|with|and|dextrorphan (r_nmod) compared_15\VBN\644583|binding|dextromethorphan|. (l_nsubj) binding_0\NN\4688246|dimemorfan|receptor|and|effects|, (l_nmod) receptor_5\NN\5225602|to|sigma-1
T40_T54 NONE df_7\NN\1740|of (r_nmod) binding_5\NN\4688246|the|df|receptors (l_nmod) receptors_11\NNS\5225602|to|the|sigma|and|sites
T41_T54 NONE nmda-linked_13\JJ\1740| (r_amod) sites_15\NNS\8673395|nmda-linked|pcp (r_conj) receptors_11\NNS\5225602|to|the|sigma|and|sites
T42_T54 NONE pcp_14\NN\10480253| (r_compound) sites_15\NNS\8673395|nmda-linked|pcp (r_conj) receptors_11\NNS\5225602|to|the|sigma|and|sites
T43_T54 NONE df_26\NN\1740|of (r_nmod) anticonvulsant_19\JJ\1740|the|as|locomotor|effects|df|mice (r_dobj) examined_17\VBD\789138|anticonvulsant|comparison (r_conj) characterized_3\VBD\609683|study|therefore|binding|and|examined|. (l_dobj) binding_5\NN\4688246|the|df|receptors (l_nmod) receptors_11\NNS\5225602|to|the|sigma|and|sites
T44_T54 NONE dm_34\NN\14117805|of|and|dr (r_nmod) those_32\DT\1740|with|dm (r_nmod) comparison_30\NN\635850|in|those (r_nmod) examined_17\VBD\789138|anticonvulsant|comparison (r_conj) characterized_3\VBD\609683|study|therefore|binding|and|examined|. (l_dobj) binding_5\NN\4688246|the|df|receptors (l_nmod) receptors_11\NNS\5225602|to|the|sigma|and|sites
T45_T54 NONE dr_36\NN\1740| (r_conj) dm_34\NN\14117805|of|and|dr (r_nmod) those_32\DT\1740|with|dm (r_nmod) comparison_30\NN\635850|in|those (r_nmod) examined_17\VBD\789138|anticonvulsant|comparison (r_conj) characterized_3\VBD\609683|study|therefore|binding|and|examined|. (l_dobj) binding_5\NN\4688246|the|df|receptors (l_nmod) receptors_11\NNS\5225602|to|the|sigma|and|sites
T46_T52 NONE df_3\NN\1740|,|dm|,|and|dr (r_nsubj) ligands_12\NNS\20090|that|df|were|relative|high-affinity|receptors|nm|respectively|) (r_ccomp) found_1\VBD\2426171|we|ligands|while|. (l_advcl) while_26\IN\15122231|all|were|affinity (l_nmod) affinity_33\NN\11426530|with|low|receptors (l_nmod) receptors_36\NNS\5225602|at|sigma-2|microm
T46_T55 NONE df_3\NN\1740|,|dm|,|and|dr (r_nsubj) ligands_12\NNS\20090|that|df|were|relative|high-affinity|receptors|nm|respectively|) (l_nmod) receptors_15\NNS\5225602|at|sigma-1
T47_T52 NONE dm_5\NN\14117805| (r_conj) df_3\NN\1740|,|dm|,|and|dr (r_nsubj) ligands_12\NNS\20090|that|df|were|relative|high-affinity|receptors|nm|respectively|) (r_ccomp) found_1\VBD\2426171|we|ligands|while|. (l_advcl) while_26\IN\15122231|all|were|affinity (l_nmod) affinity_33\NN\11426530|with|low|receptors (l_nmod) receptors_36\NNS\5225602|at|sigma-2|microm
T47_T55 NONE dm_5\NN\14117805| (r_conj) df_3\NN\1740|,|dm|,|and|dr (r_nsubj) ligands_12\NNS\20090|that|df|were|relative|high-affinity|receptors|nm|respectively|) (l_nmod) receptors_15\NNS\5225602|at|sigma-1
T48_T52 NONE dr_8\NN\1740| (r_conj) df_3\NN\1740|,|dm|,|and|dr (r_nsubj) ligands_12\NNS\20090|that|df|were|relative|high-affinity|receptors|nm|respectively|) (r_ccomp) found_1\VBD\2426171|we|ligands|while|. (l_advcl) while_26\IN\15122231|all|were|affinity (l_nmod) affinity_33\NN\11426530|with|low|receptors (l_nmod) receptors_36\NNS\5225602|at|sigma-2|microm
T48_T55 NONE dr_8\NN\1740| (r_conj) df_3\NN\1740|,|dm|,|and|dr (r_nsubj) ligands_12\NNS\20090|that|df|were|relative|high-affinity|receptors|nm|respectively|) (l_nmod) receptors_15\NNS\5225602|at|sigma-1
T18_T53 NONE df_21\NN\1740|of (r_nmod) affinity_19\NN\11426530|the|low|df|sites (r_nsubj) suggest_26\VB\1010118|furthermore|,|have|,|affinity|may|requisite|. (l_advcl) have_4\VBP\2108377|since|they|effects (l_dobj) effects_7\NNS\13245626|equipotent|anticonvulsant|and|affinities (l_conj) affinities_11\NNS\11426530|similar|binding|receptors (l_nmod) receptors_14\NNS\5225602|to|sigma-1
T19_T53 NONE pcp_23\NN\10480253| (r_compound) sites_24\NNS\8673395|at|pcp (r_nmod) affinity_19\NN\11426530|the|low|df|sites (r_nsubj) suggest_26\VB\1010118|furthermore|,|have|,|affinity|may|requisite|. (l_advcl) have_4\VBP\2108377|since|they|effects (l_dobj) effects_7\NNS\13245626|equipotent|anticonvulsant|and|affinities (l_conj) affinities_11\NNS\11426530|similar|binding|receptors (l_nmod) receptors_14\NNS\5225602|to|sigma-1
T20_T53 NONE pcp_31\NN\10480253| (r_compound) sites_32\NNS\8673395|on|the|pcp (r_nmod) acting_28\VBG\1619354|sites (r_nsubj) requisite_37\NN\2452|that|acting|may|not|be|the|mediating (r_ccomp) suggest_26\VB\1010118|furthermore|,|have|,|affinity|may|requisite|. (l_advcl) have_4\VBP\2108377|since|they|effects (l_dobj) effects_7\NNS\13245626|equipotent|anticonvulsant|and|affinities (l_conj) affinities_11\NNS\11426530|similar|binding|receptors (l_nmod) receptors_14\NNS\5225602|to|sigma-1
T21_T53 NONE dm_45\NN\14117805| (r_compound) analogs_46\NNS\4743605|of|these|dm (r_nmod) activity_42\NN\30358|the|anticonvulsant|analogs (r_dobj) mediating_39\VBG\761713|for|activity (r_advcl) requisite_37\NN\2452|that|acting|may|not|be|the|mediating (r_ccomp) suggest_26\VB\1010118|furthermore|,|have|,|affinity|may|requisite|. (l_advcl) have_4\VBP\2108377|since|they|effects (l_dobj) effects_7\NNS\13245626|equipotent|anticonvulsant|and|affinities (l_conj) affinities_11\NNS\11426530|similar|binding|receptors (l_nmod) receptors_14\NNS\5225602|to|sigma-1
23047022
T1_T24 CPR:9 acetylcholine_14\NN\14807558| (r_dep) neurotransmitter_13\NN\14807410|the|acetylcholine (r_dobj) metabolising_11\VBG\1740|neurotransmitter|synapses (r_advcl) enzyme_9\NN\14723628|although|acetylcholinesterase|is|primarily|a|hydrolytic|,|metabolising (l_nsubj) acetylcholinesterase_1\NN\1740|ache (l_appos) ache_3\NN\14322699|(|)
T1_T36 CPR:9 acetylcholine_14\NN\14807558| (r_dep) neurotransmitter_13\NN\14807410|the|acetylcholine (r_dobj) metabolising_11\VBG\1740|neurotransmitter|synapses (r_advcl) enzyme_9\NN\14723628|although|acetylcholinesterase|is|primarily|a|hydrolytic|,|metabolising (l_nsubj) acetylcholinesterase_1\NN\1740|ache
T11_T27 NONE proline_18\NN\14601829| (r_compound) anchor_21\NN\3532672|via|the|proline|rich|membrane|prima|,|protein (r_nmod) established_15\VBN\2426171|possess|,|anchorage|is|anchor|. (l_advcl) possess_4\VB\2630189|since|ache|does|not|domain (l_nsubj) ache_1\NN\14322699|
T11_T28 NONE proline_18\NN\14601829| (r_compound) anchor_21\NN\3532672|via|the|proline|rich|membrane|prima|,|protein (r_nmod) established_15\VBN\2426171|possess|,|anchorage|is|anchor|. (l_advcl) possess_4\VB\2630189|since|ache|does|not|domain (l_dobj) domain_7\NN\13934596|a|transmembrane
T11_T29 NONE proline_18\NN\14601829| (r_compound) anchor_21\NN\3532672|via|the|proline|rich|membrane|prima|,|protein
T11_T30 NONE proline_18\NN\14601829| (r_compound) anchor_21\NN\3532672|via|the|proline|rich|membrane|prima|,|protein (l_appos) prima_23\NN\7739506|(|)
T2_T12 NONE edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta- (r_nmod) mediated_26\VBN\761713|to|be|part|metalloprotease|,|involvement (r_xcomp) likely_23\JJ\1740|that|it|is|mediated (r_ccomp) showed_19\VBD\2137132|which|likely (r_acl:relcl) treatments_16\NNS\654885|several|pharmacological|,|showed (r_dobj) used_13\VBN\1156834|effort|,|we|have|treatments|. (l_nmod) effort_2\NN\407535|in|an|understand (l_acl) understand_4\VB\588888|to|process (l_dobj) process_7\NN\407535|the|shedding|ache (l_nmod) ache_9\NN\14322699|of
T2_T13 NONE edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta-
T2_T14 NONE edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta- (r_nmod) mediated_26\VBN\761713|to|be|part|metalloprotease|,|involvement (l_nmod) involvement_43\NN\1080366|with|the|possible|additional|isomerase (l_nmod) isomerase_47\NN\14732946|of|a|thiol
T3_T12 NONE batimastat-sensitive_33\JJ\1740| (r_conj) edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta- (r_nmod) mediated_26\VBN\761713|to|be|part|metalloprotease|,|involvement (r_xcomp) likely_23\JJ\1740|that|it|is|mediated (r_ccomp) showed_19\VBD\2137132|which|likely (r_acl:relcl) treatments_16\NNS\654885|several|pharmacological|,|showed (r_dobj) used_13\VBN\1156834|effort|,|we|have|treatments|. (l_nmod) effort_2\NN\407535|in|an|understand (l_acl) understand_4\VB\588888|to|process (l_dobj) process_7\NN\407535|the|shedding|ache (l_nmod) ache_9\NN\14322699|of
T3_T13 NONE batimastat-sensitive_33\JJ\1740| (r_conj) edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta-
T3_T14 NONE batimastat-sensitive_33\JJ\1740| (r_conj) edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta- (r_nmod) mediated_26\VBN\761713|to|be|part|metalloprotease|,|involvement (l_nmod) involvement_43\NN\1080366|with|the|possible|additional|isomerase (l_nmod) isomerase_47\NN\14732946|of|a|thiol
T4_T12 NONE gm6001-insensitive_36\JJ\1740| (r_conj) edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta- (r_nmod) mediated_26\VBN\761713|to|be|part|metalloprotease|,|involvement (r_xcomp) likely_23\JJ\1740|that|it|is|mediated (r_ccomp) showed_19\VBD\2137132|which|likely (r_acl:relcl) treatments_16\NNS\654885|several|pharmacological|,|showed (r_dobj) used_13\VBN\1156834|effort|,|we|have|treatments|. (l_nmod) effort_2\NN\407535|in|an|understand (l_acl) understand_4\VB\588888|to|process (l_dobj) process_7\NN\407535|the|shedding|ache (l_nmod) ache_9\NN\14322699|of
T4_T13 NONE gm6001-insensitive_36\JJ\1740| (r_conj) edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta-
T4_T14 NONE gm6001-insensitive_36\JJ\1740| (r_conj) edta-_31\NN\1740|and|batimastat-sensitive|,|but|gm6001-insensitive (r_amod) metalloprotease_37\NN\1740|by|an|edta- (r_nmod) mediated_26\VBN\761713|to|be|part|metalloprotease|,|involvement (l_nmod) involvement_43\NN\1080366|with|the|possible|additional|isomerase (l_nmod) isomerase_47\NN\14732946|of|a|thiol
T5_T12 NONE thiol_46\NN\1740| (r_compound) isomerase_47\NN\14732946|of|a|thiol (r_nmod) involvement_43\NN\1080366|with|the|possible|additional|isomerase (r_nmod) mediated_26\VBN\761713|to|be|part|metalloprotease|,|involvement (r_xcomp) likely_23\JJ\1740|that|it|is|mediated (r_ccomp) showed_19\VBD\2137132|which|likely (r_acl:relcl) treatments_16\NNS\654885|several|pharmacological|,|showed (r_dobj) used_13\VBN\1156834|effort|,|we|have|treatments|. (l_nmod) effort_2\NN\407535|in|an|understand (l_acl) understand_4\VB\588888|to|process (l_dobj) process_7\NN\407535|the|shedding|ache (l_nmod) ache_9\NN\14322699|of
T5_T13 NONE thiol_46\NN\1740| (r_compound) isomerase_47\NN\14732946|of|a|thiol (r_nmod) involvement_43\NN\1080366|with|the|possible|additional|isomerase (r_nmod) mediated_26\VBN\761713|to|be|part|metalloprotease|,|involvement (l_nmod) metalloprotease_37\NN\1740|by|an|edta-
T5_T14 NONE thiol_46\NN\1740| (r_compound) isomerase_47\NN\14732946|of|a|thiol
T10_T15 CPR:4 atropine_32\NN\14712692| (r_dep) antagonist_31\NN\7846|by|the|machr|atropine (r_nmod) blocked_27\VBN\1476483|with|effect|antagonist (r_advcl) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nsubjpass) release_1\NN\3748886|cellular|ache|sh-sy5y (l_nmod) ache_3\NN\14322699|of
T10_T16 NONE atropine_32\NN\14712692| (r_dep) antagonist_31\NN\7846|by|the|machr|atropine (r_nmod) blocked_27\VBN\1476483|with|effect|antagonist (r_advcl) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nmod) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (l_compound) receptor_13\NN\5225602|acetylcholine|machr
T10_T17 NONE atropine_32\NN\14712692| (r_dep) antagonist_31\NN\7846|by|the|machr|atropine (r_nmod) blocked_27\VBN\1476483|with|effect|antagonist (r_advcl) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nmod) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (l_compound) receptor_13\NN\5225602|acetylcholine|machr (l_appos) machr_15\NN\1740|(|)
T10_T18 CPR:6 atropine_32\NN\14712692| (r_dep) antagonist_31\NN\7846|by|the|machr|atropine (l_compound) machr_30\NN\1740|
T6_T15 NONE acetylcholine_12\NN\14807558| (r_compound) receptor_13\NN\5225602|acetylcholine|machr (r_compound) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (r_nmod) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nsubjpass) release_1\NN\3748886|cellular|ache|sh-sy5y (l_nmod) ache_3\NN\14322699|of
T6_T16 NONE acetylcholine_12\NN\14807558| (r_compound) receptor_13\NN\5225602|acetylcholine|machr
T6_T17 NONE acetylcholine_12\NN\14807558| (r_compound) receptor_13\NN\5225602|acetylcholine|machr (l_appos) machr_15\NN\1740|(|)
T6_T18 NONE acetylcholine_12\NN\14807558| (r_compound) receptor_13\NN\5225602|acetylcholine|machr (r_compound) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (r_nmod) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_advcl) blocked_27\VBN\1476483|with|effect|antagonist (l_nmod) antagonist_31\NN\7846|by|the|machr|atropine (l_compound) machr_30\NN\1740|
T7_T15 CPR:3 carbachol_18\NN\1740|or|muscarine (r_dep) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (r_nmod) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nsubjpass) release_1\NN\3748886|cellular|ache|sh-sy5y (l_nmod) ache_3\NN\14322699|of
T7_T16 CPR:5 carbachol_18\NN\1740|or|muscarine (r_dep) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (l_compound) receptor_13\NN\5225602|acetylcholine|machr
T7_T17 CPR:5 carbachol_18\NN\1740|or|muscarine (r_dep) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (l_compound) receptor_13\NN\5225602|acetylcholine|machr (l_appos) machr_15\NN\1740|(|)
T7_T18 NONE carbachol_18\NN\1740|or|muscarine (r_dep) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (r_nmod) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_advcl) blocked_27\VBN\1476483|with|effect|antagonist (l_nmod) antagonist_31\NN\7846|by|the|machr|atropine (l_compound) machr_30\NN\1740|
T8_T15 CPR:3 muscarine_20\NN\1740| (r_conj) carbachol_18\NN\1740|or|muscarine (r_dep) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (r_nmod) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nsubjpass) release_1\NN\3748886|cellular|ache|sh-sy5y (l_nmod) ache_3\NN\14322699|of
T8_T16 CPR:5 muscarine_20\NN\1740| (r_conj) carbachol_18\NN\1740|or|muscarine (r_dep) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (l_compound) receptor_13\NN\5225602|acetylcholine|machr
T8_T17 CPR:5 muscarine_20\NN\1740| (r_conj) carbachol_18\NN\1740|or|muscarine (r_dep) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (l_compound) receptor_13\NN\5225602|acetylcholine|machr (l_appos) machr_15\NN\1740|(|)
T8_T18 NONE muscarine_20\NN\1740| (r_conj) carbachol_18\NN\1740|or|muscarine (r_dep) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (r_nmod) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_advcl) blocked_27\VBN\1476483|with|effect|antagonist (l_nmod) antagonist_31\NN\7846|by|the|machr|atropine (l_compound) machr_30\NN\1740|
T9_T15 CPR:3 carbachol_26\NN\1740|of (r_nmod) effect_24\NN\34213|the|carbachol (r_nsubj) blocked_27\VBN\1476483|with|effect|antagonist (r_advcl) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nsubjpass) release_1\NN\3748886|cellular|ache|sh-sy5y (l_nmod) ache_3\NN\14322699|of
T9_T16 NONE carbachol_26\NN\1740|of (r_nmod) effect_24\NN\34213|the|carbachol (r_nsubj) blocked_27\VBN\1476483|with|effect|antagonist (r_advcl) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nmod) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (l_compound) receptor_13\NN\5225602|acetylcholine|machr
T9_T17 NONE carbachol_26\NN\1740|of (r_nmod) effect_24\NN\34213|the|carbachol (r_nsubj) blocked_27\VBN\1476483|with|effect|antagonist (r_advcl) enhanced_8\VBN\227165|release|is|significantly|agonists|,|blocked|. (l_nmod) agonists_17\NNS\9613191|by|the|muscarinic|receptor|carbachol (l_compound) receptor_13\NN\5225602|acetylcholine|machr (l_appos) machr_15\NN\1740|(|)
T9_T18 NONE carbachol_26\NN\1740|of (r_nmod) effect_24\NN\34213|the|carbachol (r_nsubj) blocked_27\VBN\1476483|with|effect|antagonist (l_nmod) antagonist_31\NN\7846|by|the|machr|atropine (l_compound) machr_30\NN\1740|
23221600
T7_T33 NONE hormone_20\NN\5404728| (r_compound) receptor_21\NN\5225602|of|thyroid|hormone (r_nmod) binding_17\NN\4688246|without|direct|receptor|promoter (r_nmod) regulated_11\VBN\296178|expression|is|negatively|hormone|binding|. (l_nsubjpass) expression_8\NN\4679549|human|desaturase|gene (l_compound) desaturase_2\NN\1740|stearoyl-coa|1|scd-1 (l_nummod) 1_3\CD\13741022|
T7_T34 NONE hormone_20\NN\5404728| (r_compound) receptor_21\NN\5225602|of|thyroid|hormone
T7_T35 NONE hormone_20\NN\5404728| (r_compound) receptor_21\NN\5225602|of|thyroid|hormone (r_nmod) binding_17\NN\4688246|without|direct|receptor|promoter (r_nmod) regulated_11\VBN\296178|expression|is|negatively|hormone|binding|. (l_nsubjpass) expression_8\NN\4679549|human|desaturase|gene (l_compound) desaturase_2\NN\1740|stearoyl-coa|1|scd-1 (l_appos) scd-1_5\NN\1740|(|)
T8_T33 NONE stearoyl-coa_1\NN\1740| (r_compound) desaturase_2\NN\1740|stearoyl-coa|1|scd-1 (l_nummod) 1_3\CD\13741022|
T8_T34 NONE stearoyl-coa_1\NN\1740| (r_compound) desaturase_2\NN\1740|stearoyl-coa|1|scd-1 (r_compound) expression_8\NN\4679549|human|desaturase|gene (r_nsubjpass) regulated_11\VBN\296178|expression|is|negatively|hormone|binding|. (l_nmod) binding_17\NN\4688246|without|direct|receptor|promoter (l_nmod) receptor_21\NN\5225602|of|thyroid|hormone
T8_T35 NONE stearoyl-coa_1\NN\1740| (r_compound) desaturase_2\NN\1740|stearoyl-coa|1|scd-1 (l_appos) scd-1_5\NN\1740|(|)
T9_T33 CPR:4 hormone_14\NN\5404728|by|thyroid (r_nmod) regulated_11\VBN\296178|expression|is|negatively|hormone|binding|. (l_nsubjpass) expression_8\NN\4679549|human|desaturase|gene (l_compound) desaturase_2\NN\1740|stearoyl-coa|1|scd-1 (l_nummod) 1_3\CD\13741022|
T9_T34 NONE hormone_14\NN\5404728|by|thyroid (r_nmod) regulated_11\VBN\296178|expression|is|negatively|hormone|binding|. (l_nmod) binding_17\NN\4688246|without|direct|receptor|promoter (l_nmod) receptor_21\NN\5225602|of|thyroid|hormone
T9_T35 CPR:4 hormone_14\NN\5404728|by|thyroid (r_nmod) regulated_11\VBN\296178|expression|is|negatively|hormone|binding|. (l_nsubjpass) expression_8\NN\4679549|human|desaturase|gene (l_compound) desaturase_2\NN\1740|stearoyl-coa|1|scd-1 (l_appos) scd-1_5\NN\1740|(|)
T1_T10 NONE stearoyl-coa_0\NN\1740| (r_compound) desaturase-1_1\NN\1740|stearoyl-coa|scd-1
T1_T22 NONE stearoyl-coa_0\NN\1740| (r_compound) desaturase-1_1\NN\1740|stearoyl-coa|scd-1 (l_appos) scd-1_3\NN\1740|(|)
T2_T10 NONE carbohydrate_19\NN\14944888| (r_compound) intake_20\NN\13440063|of|dietary|carbohydrate (r_nmod) excess_16\NN\5119367|by|an|intake (r_nmod) increase_11\NN\13576355|in|an|triglyceride|excess (r_nmod) plays_5\VBZ\1072262|desaturase-1|role|increase|. (l_nsubj) desaturase-1_1\NN\1740|stearoyl-coa|scd-1
T2_T22 NONE carbohydrate_19\NN\14944888| (r_compound) intake_20\NN\13440063|of|dietary|carbohydrate (r_nmod) excess_16\NN\5119367|by|an|intake (r_nmod) increase_11\NN\13576355|in|an|triglyceride|excess (r_nmod) plays_5\VBZ\1072262|desaturase-1|role|increase|. (l_nsubj) desaturase-1_1\NN\1740|stearoyl-coa|scd-1 (l_appos) scd-1_3\NN\1740|(|)
T6_T10 NONE triglyceride_13\NN\14885088|of (r_nmod) increase_11\NN\13576355|in|an|triglyceride|excess (r_nmod) plays_5\VBZ\1072262|desaturase-1|role|increase|. (l_nsubj) desaturase-1_1\NN\1740|stearoyl-coa|scd-1
T6_T22 NONE triglyceride_13\NN\14885088|of (r_nmod) increase_11\NN\13576355|in|an|triglyceride|excess (r_nmod) plays_5\VBZ\1072262|desaturase-1|role|increase|. (l_nsubj) desaturase-1_1\NN\1740|stearoyl-coa|scd-1 (l_appos) scd-1_3\NN\1740|(|)
T3_T19 CPR:3 carbohydrates_1\NNS\14944888|dietary (r_nsubj) increase_2\VBP\169651|carbohydrates|expression|pathways|. (l_dobj) expression_5\NN\4679549|scd-1|gene|liver (l_compound) scd-1_3\NN\1740|
T3_T20 NONE carbohydrates_1\NNS\14944888|dietary (r_nsubj) increase_2\VBP\169651|carbohydrates|expression|pathways|. (l_nmod) pathways_18\NNS\5483677|by|(srebp)-1c-dependent (l_amod) (srebp)-1c-dependent_14\JJ\1740|protein|and|-independent
T3_T21 NONE carbohydrates_1\NNS\14944888|dietary (r_nsubj) increase_2\VBP\169651|carbohydrates|expression|pathways|. (l_nmod) pathways_18\NNS\5483677|by|(srebp)-1c-dependent (l_amod) (srebp)-1c-dependent_14\JJ\1740|protein|and|-independent (l_conj) -independent_17\JJ\1740|srebp-1c (l_nmod:npmod) srebp-1c_16\JJ\1740|
T4_T19 NONE sterol_9\NN\14708720| (r_compound) protein_13\NN\14944888|sterol|response|element|binding (r_nmod:npmod) (srebp)-1c-dependent_14\JJ\1740|protein|and|-independent (r_amod) pathways_18\NNS\5483677|by|(srebp)-1c-dependent (r_nmod) increase_2\VBP\169651|carbohydrates|expression|pathways|. (l_dobj) expression_5\NN\4679549|scd-1|gene|liver (l_compound) scd-1_3\NN\1740|
T4_T20 NONE sterol_9\NN\14708720| (r_compound) protein_13\NN\14944888|sterol|response|element|binding (r_nmod:npmod) (srebp)-1c-dependent_14\JJ\1740|protein|and|-independent
T4_T21 NONE sterol_9\NN\14708720| (r_compound) protein_13\NN\14944888|sterol|response|element|binding (r_nmod:npmod) (srebp)-1c-dependent_14\JJ\1740|protein|and|-independent (l_conj) -independent_17\JJ\1740|srebp-1c (l_nmod:npmod) srebp-1c_16\JJ\1740|
T5_T23 CPR:4 hormone_5\NN\5404728|thyroid|th (r_nsubj) regulates_10\VBZ\296178|that|hormone|negatively|promoter|revealed (l_dobj) promoter_14\NN\9773962|mouse|scd-1|gene
T5_T24 NONE hormone_5\NN\5404728|thyroid|th (r_nsubj) regulates_10\VBZ\296178|that|hormone|negatively|promoter|revealed (l_advcl) revealed_18\VBN\2137132|before|srebp-1c|was (l_nsubjpass) srebp-1c_16\NN\1740|
23261524
T2_T21 CPR:4 nutlin-3_2\NN\1740|,|disruptor|, (l_appos) disruptor_6\NN\1740|a|well-known|interaction (l_nmod) interaction_9\NN\37396|of|p53-mdm2 (l_compound) p53-mdm2_8\NN\1740|
T2_T22 CPR:4 nutlin-3_2\NN\1740|,|disruptor|, (l_appos) disruptor_6\NN\1740|a|well-known|interaction (l_nmod) interaction_9\NN\37396|of|p53-mdm2 (l_compound) p53-mdm2_8\NN\1740|
T1_T4 CPR:3 nutlin-3_7\NN\1740|by (r_nmod) mediated_5\VBN\761713|nutlin-3 (r_acl) signal_4\NN\33020|of|bifc|mediated (r_nmod) reduction_1\NN\351485|the|signal (r_nsubjpass) correlated_9\VBN\2657219|reduction|was|increase|. (l_nmod) increase_12\NN\13576355|with|an|transactivation (l_nmod) transactivation_15\NN\1740|in|puma|,|cleavage|,|and|death (l_compound) puma_14\NN\2124623|
T1_T5 CPR:3 nutlin-3_7\NN\1740|by (r_nmod) mediated_5\VBN\761713|nutlin-3 (r_acl) signal_4\NN\33020|of|bifc|mediated (r_nmod) reduction_1\NN\351485|the|signal (r_nsubjpass) correlated_9\VBN\2657219|reduction|was|increase|. (l_nmod) increase_12\NN\13576355|with|an|transactivation (l_nmod) transactivation_15\NN\1740|in|puma|,|cleavage|,|and|death (l_conj) cleavage_18\NN\24720|parp (l_compound) parp_17\NN\1740|
17550897
T10_T40 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|to|receptor-induced|calcium|lymphocytes (r_nmod) prerequisite_11\NN\1129920|is|release (r_conj) associates_6\VBZ\628491|domain|calmodulin|and|prerequisite|. (l_nsubj) domain_3\NN\13934596|the|calponin|homology|vav1 (l_nmod) vav1_5\NN\1740|of
T10_T41 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|to|receptor-induced|calcium|lymphocytes (r_nmod) prerequisite_11\NN\1129920|is|release (r_conj) associates_6\VBZ\628491|domain|calmodulin|and|prerequisite|. (l_nsubj) domain_3\NN\13934596|the|calponin|homology|vav1
T10_T42 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|to|receptor-induced|calcium|lymphocytes (r_nmod) prerequisite_11\NN\1129920|is|release (r_conj) associates_6\VBZ\628491|domain|calmodulin|and|prerequisite|. (l_nmod) calmodulin_8\NN\1740|with
T10_T43 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|to|receptor-induced|calcium|lymphocytes (l_amod) receptor-induced_16\JJ\1740|t|cell|antigen
T1_T11 NONE nucleotide_4\NN\14850483| (r_compound) factor_6\NN\7326557|vav1|is|a|guanine|nucleotide|exchange|expressed|. (l_nsubj) vav1_0\NN\1740|
T1_T14 NONE nucleotide_4\NN\14850483| (r_compound) factor_6\NN\7326557|vav1|is|a|guanine|nucleotide|exchange|expressed|.
T5_T22 NONE nucleotide_13\NN\14850483| (r_compound) activity_15\NN\30358|both|its|guanine|nucleotide|exchange|and|function (r_dobj) facilitate_9\VB\2547586|so|as|to|activity|engagement (r_advcl) consists_1\VBZ\2603699|vav1|domains|facilitate|. (l_nsubj) vav1_0\NN\1740|
T5_T23 NONE nucleotide_13\NN\14850483| (r_compound) activity_15\NN\30358|both|its|guanine|nucleotide|exchange|and|function (r_dobj) facilitate_9\VB\2547586|so|as|to|activity|engagement (l_nmod) engagement_27\NN\952963|following|receptor (l_compound) receptor_23\NN\5225602|t|cell|antigen|tcr
T5_T24 NONE nucleotide_13\NN\14850483| (r_compound) activity_15\NN\30358|both|its|guanine|nucleotide|exchange|and|function (r_dobj) facilitate_9\VB\2547586|so|as|to|activity|engagement (l_nmod) engagement_27\NN\952963|following|receptor (l_compound) receptor_23\NN\5225602|t|cell|antigen|tcr (l_appos) tcr_25\NN\1740|(|)
T6_T25 NONE calcium_17\NN\14625458| (r_compound) mobilization_18\NN\1123598|for|tcr-stimulated|calcium|and|activation (r_nmod) required_14\VBN\754942|that|domain|is|mobilization (l_nsubjpass) domain_10\NN\13934596|the|calponin|homology|(|ch|)|vav1
T6_T26 NONE calcium_17\NN\14625458| (r_compound) mobilization_18\NN\1123598|for|tcr-stimulated|calcium|and|activation (r_nmod) required_14\VBN\754942|that|domain|is|mobilization (l_nsubjpass) domain_10\NN\13934596|the|calponin|homology|(|ch|)|vav1 (l_nmod) vav1_12\NN\1740|of
T6_T27 NONE calcium_17\NN\14625458| (r_compound) mobilization_18\NN\1123598|for|tcr-stimulated|calcium|and|activation (l_amod) tcr-stimulated_16\JJ\1740|
T6_T28 NONE calcium_17\NN\14625458| (r_compound) mobilization_18\NN\1123598|for|tcr-stimulated|calcium|and|activation (l_conj) activation_22\NN\13561719|thus|downstream|cells (l_nmod) cells_29\NNS\3080309|of|nuclear|factor|of|activated|t
T7_T29 NONE calcium_10\NN\14625458| (r_compound) flux_11\NN\15286249|calcium (r_dobj) regulating_9\VBG\296178|in|flux (r_advcl) functions_7\VBZ\2669789|how|vav1|regulating (l_nsubj) vav1_6\NNP\1740|
T8_T30 NONE calcium-dependent_19\JJ\1740|and|activation-independent (r_amod) manner_23\NN\4916342|in|a|calcium-dependent (r_nmod) bound_14\VBD\1831531|that|calmodulin|vav1|manner (r_ccomp) found_11\VBD\2426171|effort|,|we|bound|. (l_nmod) effort_2\NN\407535|in|an|explore (l_acl) explore_4\VB\789138|to|molecules (l_dobj) molecules_5\NNS\9465459|interacting (l_acl) interacting_6\VBG\2367363|vav1 (l_nmod) vav1_8\NN\1740|with
T8_T31 NONE calcium-dependent_19\JJ\1740|and|activation-independent (r_amod) manner_23\NN\4916342|in|a|calcium-dependent (r_nmod) bound_14\VBD\1831531|that|calmodulin|vav1|manner (l_nsubj) calmodulin_13\NN\1740|
T8_T32 NONE calcium-dependent_19\JJ\1740|and|activation-independent (r_amod) manner_23\NN\4916342|in|a|calcium-dependent (r_nmod) bound_14\VBD\1831531|that|calmodulin|vav1|manner (l_nmod) vav1_16\NN\1740|to
T8_T33 NONE calcium-dependent_19\JJ\1740|and|activation-independent (l_conj) activation-independent_22\JJ\1740|tcr (l_nmod:npmod) tcr_21\NN\1740|
T9_T12 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|in|calcium (r_nmod) exhibited_12\VBD\2632167|reconstitution|deficiency|release|extent|. (l_nmod) extent_22\NN\13939892|to|the|same|that (l_nmod) that_24\DT\1740|as|cells (l_nmod) cells_27\NNS\3080309|of|jurkat|treated (l_acl) treated_28\VBN\2376958|inhibitor (l_nmod) inhibitor_32\NN\20090|with|the|calmodulin|or|cells (l_compound) calmodulin_31\NN\1740|
T9_T13 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|in|calcium (r_nmod) exhibited_12\VBD\2632167|reconstitution|deficiency|release|extent|. (l_nmod) extent_22\NN\13939892|to|the|same|that (l_nmod) that_24\DT\1740|as|cells (l_nmod) cells_27\NNS\3080309|of|jurkat|treated (l_acl) treated_28\VBN\2376958|inhibitor (l_nmod) inhibitor_32\NN\20090|with|the|calmodulin|or|cells (l_conj) cells_35\NNS\3080309|j.vav1 (l_compound) j.vav1_34\NN\1740|
T9_T36 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|in|calcium (r_nmod) exhibited_12\VBD\2632167|reconstitution|deficiency|release|extent|. (l_nsubj) reconstitution_0\NN\1740|cells|vav1 (l_nmod) cells_5\NNS\3080309|of|vav1-null|jurkat|t|j.vav1 (l_amod) vav1-null_2\JJ\1740|
T9_T37 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|in|calcium (r_nmod) exhibited_12\VBD\2632167|reconstitution|deficiency|release|extent|. (l_nsubj) reconstitution_0\NN\1740|cells|vav1 (l_nmod) cells_5\NNS\3080309|of|vav1-null|jurkat|t|j.vav1 (l_appos) j.vav1_7\NNP\1740|(|)
T9_T38 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|in|calcium (r_nmod) exhibited_12\VBD\2632167|reconstitution|deficiency|release|extent|. (l_nsubj) reconstitution_0\NN\1740|cells|vav1 (l_nmod) vav1_11\NN\1740|with|ch-deleted (l_amod) ch-deleted_10\JJ\1740|
T9_T39 NONE calcium_17\NN\14625458| (r_compound) release_18\NN\3748886|in|calcium (r_nmod) exhibited_12\VBD\2632167|reconstitution|deficiency|release|extent|. (l_nsubj) reconstitution_0\NN\1740|cells|vav1 (l_nmod) vav1_11\NN\1740|with|ch-deleted
T2_T15 NONE calcium_19\NN\14625458| (r_compound) signaling_20\NN\33020|in|calcium (r_nmod) role_13\NN\719494|a|prerequisite|domain|signaling (r_dobj) indicating_10\VBG\952524|role (r_advcl) persisted_2\VBD\118523|defect|activated|,|indicating|. (l_advcl) activated_8\VBN\1641914|even|when|phospholipase-cgamma1|was|fully (l_nsubjpass) phospholipase-cgamma1_5\NN\1740|
T2_T16 NONE calcium_19\NN\14625458| (r_compound) signaling_20\NN\33020|in|calcium (r_nmod) role_13\NN\719494|a|prerequisite|domain|signaling (l_nmod) domain_17\NN\13934596|of|vav1|ch
T3_T17 NONE calcium_12\NN\14625458| (r_compound) release_13\NN\3748886|tcr-induced|calcium (r_dobj) potentiate_10\VB\229605|to|release (r_xcomp) function_7\VBP\2669789|that|vav1|cooperatively|potentiate (l_nsubj) vav1_4\NN\1740|and|calmodulin
T3_T18 NONE calcium_12\NN\14625458| (r_compound) release_13\NN\3748886|tcr-induced|calcium (r_dobj) potentiate_10\VB\229605|to|release (r_xcomp) function_7\VBP\2669789|that|vav1|cooperatively|potentiate (l_nsubj) vav1_4\NN\1740|and|calmodulin (l_conj) calmodulin_6\NN\1740|
T3_T19 NONE calcium_12\NN\14625458| (r_compound) release_13\NN\3748886|tcr-induced|calcium (l_amod) tcr-induced_11\JJ\1740|
T4_T20 NONE calcium_14\NN\14625458| (r_compound) signaling_15\NN\33020|in|calcium (r_nmod) involved_12\VBN\2676054|which|domain|is|signaling (l_nsubjpass) domain_10\NN\13934596|the|vav1|ch
T4_T21 NONE calcium_14\NN\14625458| (r_compound) signaling_15\NN\33020|in|calcium (r_nmod) involved_12\VBN\2676054|which|domain|is|signaling (r_acl:relcl) mechanism_4\NN\13446390|a|involved (r_dobj) unveiled_2\VBD\1339505|study|mechanism|and|provides|. (l_conj) provides_17\VBZ\2199590|insight (l_dobj) insight_18\NN\5710020|understanding (l_nmod) understanding_21\NN\5804793|into|our|role (l_nmod) role_24\NN\719494|of|the|vav1|activation (l_nmod) vav1_26\NN\1740|of
23205763
9525919
T16_T26 NONE bepridil_5\NN\1740|for|and|trifluoperazine (r_nmod) sites_3\NNS\8673395|of|binding|bepridil (r_nmod) identification_0\NN\151497|sites|c. (l_nmod) c._11\.\1740|on|cardiac|troponin
T17_T26 NONE trifluoperazine_7\NN\1740| (r_conj) bepridil_5\NN\1740|for|and|trifluoperazine (r_nmod) sites_3\NNS\8673395|of|binding|bepridil (r_nmod) identification_0\NN\151497|sites|c. (l_nmod) c._11\.\1740|on|cardiac|troponin
T5_T20 NONE n-terminal_13\JJ\1740| (r_amod) domain_14\NN\13934596|of|the|regulatory|n-terminal|c (l_nmod) c_21\NN\13714184|in|+|-bound|cardiac|troponin|ctnc
T5_T21 NONE n-terminal_13\JJ\1740| (r_amod) domain_14\NN\13934596|of|the|regulatory|n-terminal|c (l_nmod) c_21\NN\13714184|in|+|-bound|cardiac|troponin|ctnc (l_appos) ctnc_23\NN\1740|(|)
T6_T20 NONE +_17\JJ\1740|ca2 (r_amod) c_21\NN\13714184|in|+|-bound|cardiac|troponin|ctnc
T6_T21 NONE +_17\JJ\1740|ca2 (r_amod) c_21\NN\13714184|in|+|-bound|cardiac|troponin|ctnc (l_appos) ctnc_23\NN\1740|(|)
T7_T20 NONE +_33\JJ\1740| (r_amod) compounds_35\NNS\5869584|for|ca2|+|-sensitizing (r_nmod) surface_30\NN\21939|a|different|binding|compounds|thought (r_dobj) presents_25\VBZ\2137132|that|conformation|surface (l_nsubj) conformation_9\NN\13897996|the|closed|domain (l_nmod) domain_14\NN\13934596|of|the|regulatory|n-terminal|c (l_nmod) c_21\NN\13714184|in|+|-bound|cardiac|troponin|ctnc
T7_T21 NONE +_33\JJ\1740| (r_amod) compounds_35\NNS\5869584|for|ca2|+|-sensitizing (r_nmod) surface_30\NN\21939|a|different|binding|compounds|thought (r_dobj) presents_25\VBZ\2137132|that|conformation|surface (l_nsubj) conformation_9\NN\13897996|the|closed|domain (l_nmod) domain_14\NN\13934596|of|the|regulatory|n-terminal|c (l_nmod) c_21\NN\13714184|in|+|-bound|cardiac|troponin|ctnc (l_appos) ctnc_23\NN\1740|(|)
T10_T23 NONE [methyl-13c]met-labeled_35\JJ\1740| (r_amod) ctnc_36\NN\1740|of|[methyl-13c]met-labeled (r_nmod) spectra_33\NNS\7939382|in|the|nmr|heteronuclear|single-quantum|coherence|ctnc (r_nmod) changes_26\NNS\7283608|dependent|spectra (r_nsubj) indicate_37\VBP\952524|changes|bind|. (r_parataxis) report_1\VBP\831651|we|here|use|indicate (l_dobj) use_4\NN\407535|the|groups|markers|identify (l_acl) identify_14\VB\699815|to|sites|ctnc. (l_nmod) ctnc._23\NN\1740|on
T10_T24 NONE [methyl-13c]met-labeled_35\JJ\1740| (r_amod) ctnc_36\NN\1740|of|[methyl-13c]met-labeled
T11_T23 NONE bepridil_39\NN\1740|and|trifluoperazine (r_nsubj) bind_42\VBP\1290422|that|bepridil|sites|but|presence|+ (r_ccomp) indicate_37\VBP\952524|changes|bind|. (r_parataxis) report_1\VBP\831651|we|here|use|indicate (l_dobj) use_4\NN\407535|the|groups|markers|identify (l_acl) identify_14\VB\699815|to|sites|ctnc. (l_nmod) ctnc._23\NN\1740|on
T11_T24 NONE bepridil_39\NN\1740|and|trifluoperazine (r_nsubj) bind_42\VBP\1290422|that|bepridil|sites|but|presence|+ (r_ccomp) indicate_37\VBP\952524|changes|bind|. (l_nsubj) changes_26\NNS\7283608|dependent|spectra (l_nmod) spectra_33\NNS\7939382|in|the|nmr|heteronuclear|single-quantum|coherence|ctnc (l_nmod) ctnc_36\NN\1740|of|[methyl-13c]met-labeled
T12_T23 NONE trifluoperazine_41\NN\1740| (r_conj) bepridil_39\NN\1740|and|trifluoperazine (r_nsubj) bind_42\VBP\1290422|that|bepridil|sites|but|presence|+ (r_ccomp) indicate_37\VBP\952524|changes|bind|. (r_parataxis) report_1\VBP\831651|we|here|use|indicate (l_dobj) use_4\NN\407535|the|groups|markers|identify (l_acl) identify_14\VB\699815|to|sites|ctnc. (l_nmod) ctnc._23\NN\1740|on
T12_T24 NONE trifluoperazine_41\NN\1740| (r_conj) bepridil_39\NN\1740|and|trifluoperazine (r_nsubj) bind_42\VBP\1290422|that|bepridil|sites|but|presence|+ (r_ccomp) indicate_37\VBP\952524|changes|bind|. (l_nsubj) changes_26\NNS\7283608|dependent|spectra (l_nmod) spectra_33\NNS\7939382|in|the|nmr|heteronuclear|single-quantum|coherence|ctnc (l_nmod) ctnc_36\NN\1740|of|[methyl-13c]met-labeled
T13_T23 NONE +_53\NN\1740|ca2 (r_nmod) bind_42\VBP\1290422|that|bepridil|sites|but|presence|+ (r_ccomp) indicate_37\VBP\952524|changes|bind|. (r_parataxis) report_1\VBP\831651|we|here|use|indicate (l_dobj) use_4\NN\407535|the|groups|markers|identify (l_acl) identify_14\VB\699815|to|sites|ctnc. (l_nmod) ctnc._23\NN\1740|on
T13_T24 NONE +_53\NN\1740|ca2 (r_nmod) bind_42\VBP\1290422|that|bepridil|sites|but|presence|+ (r_ccomp) indicate_37\VBP\952524|changes|bind|. (l_nsubj) changes_26\NNS\7283608|dependent|spectra (l_nmod) spectra_33\NNS\7939382|in|the|nmr|heteronuclear|single-quantum|coherence|ctnc (l_nmod) ctnc_36\NN\1740|of|[methyl-13c]met-labeled
T8_T23 NONE trifluoperazine_19\NN\1740|for|and|bepridil (r_nmod) sites_17\NNS\8673395|drug|binding|trifluoperazine (r_dobj) identify_14\VB\699815|to|sites|ctnc. (l_nmod) ctnc._23\NN\1740|on
T8_T24 NONE trifluoperazine_19\NN\1740|for|and|bepridil (r_nmod) sites_17\NNS\8673395|drug|binding|trifluoperazine (r_dobj) identify_14\VB\699815|to|sites|ctnc. (r_acl) use_4\NN\407535|the|groups|markers|identify (r_dobj) report_1\VBP\831651|we|here|use|indicate (l_parataxis) indicate_37\VBP\952524|changes|bind|. (l_nsubj) changes_26\NNS\7283608|dependent|spectra (l_nmod) spectra_33\NNS\7939382|in|the|nmr|heteronuclear|single-quantum|coherence|ctnc (l_nmod) ctnc_36\NN\1740|of|[methyl-13c]met-labeled
T9_T23 NONE bepridil_21\NN\1740| (r_conj) trifluoperazine_19\NN\1740|for|and|bepridil (r_nmod) sites_17\NNS\8673395|drug|binding|trifluoperazine (r_dobj) identify_14\VB\699815|to|sites|ctnc. (l_nmod) ctnc._23\NN\1740|on
T9_T24 NONE bepridil_21\NN\1740| (r_conj) trifluoperazine_19\NN\1740|for|and|bepridil (r_nmod) sites_17\NNS\8673395|drug|binding|trifluoperazine (r_dobj) identify_14\VB\699815|to|sites|ctnc. (r_acl) use_4\NN\407535|the|groups|markers|identify (r_dobj) report_1\VBP\831651|we|here|use|indicate (l_parataxis) indicate_37\VBP\952524|changes|bind|. (l_nsubj) changes_26\NNS\7283608|dependent|spectra (l_nmod) spectra_33\NNS\7939382|in|the|nmr|heteronuclear|single-quantum|coherence|ctnc (l_nmod) ctnc_36\NN\1740|of|[methyl-13c]met-labeled
T14_T25 NONE n-_10\JJ\1740|and|c-terminal (r_amod) domains_13\NNS\13934596|in|the|n-|ctnc (l_nmod) ctnc_16\NN\1740|of|intact
T15_T25 NONE c-terminal_12\JJ\1740| (r_conj) n-_10\JJ\1740|and|c-terminal (r_amod) domains_13\NNS\13934596|in|the|n-|ctnc (l_nmod) ctnc_16\NN\1740|of|intact
T4_T18 NONE +_16\JJ\1740| (r_amod) compounds_18\NNS\5869584|new|ca2|+|-sensitizing (r_dobj) design_11\VB\1631534|which|to|compounds (r_acl:relcl) target_7\NN\7258332|a|likely|design (r_dobj) makes_4\VBZ\126264|subregion|target|. (l_nsubj) subregion_1\NN\1740|this|ctnc (l_nmod) ctnc_3\NNP\1740|in
10742288
T2_T22 CPR:5 a-54741_11\NN\1740|cells|order|was|pec(50)=8.96)>dexmedetomidine|(8.88)>uk-14304|(8.42)>b-ht|(7.05)>noradrenaline|. (l_nmod) cells_3\NNS\3080309|in|alpha(2a)-adrenoceptor|transfected (l_compound) alpha(2a)-adrenoceptor_1\NN\1740|
T3_T22 CPR:5 pec(50)=8.96)>dexmedetomidine_14\NN\1740|(|mean (r_dep) a-54741_11\NN\1740|cells|order|was|pec(50)=8.96)>dexmedetomidine|(8.88)>uk-14304|(8.42)>b-ht|(7.05)>noradrenaline|. (l_nmod) cells_3\NNS\3080309|in|alpha(2a)-adrenoceptor|transfected (l_compound) alpha(2a)-adrenoceptor_1\NN\1740|
T4_T22 CPR:5 (8.88)>uk-14304_15\CD\1740| (r_punct) a-54741_11\NN\1740|cells|order|was|pec(50)=8.96)>dexmedetomidine|(8.88)>uk-14304|(8.42)>b-ht|(7.05)>noradrenaline|. (l_nmod) cells_3\NNS\3080309|in|alpha(2a)-adrenoceptor|transfected (l_compound) alpha(2a)-adrenoceptor_1\NN\1740|
T5_T22 CPR:5 920_17\CD\1740| (r_nummod) (8.42)>b-ht_16\NN\1740|920 (r_punct) a-54741_11\NN\1740|cells|order|was|pec(50)=8.96)>dexmedetomidine|(8.88)>uk-14304|(8.42)>b-ht|(7.05)>noradrenaline|. (l_nmod) cells_3\NNS\3080309|in|alpha(2a)-adrenoceptor|transfected (l_compound) alpha(2a)-adrenoceptor_1\NN\1740|
T6_T22 CPR:5 (7.05)>noradrenaline_18\NN\1740|6.92 (r_punct) a-54741_11\NN\1740|cells|order|was|pec(50)=8.96)>dexmedetomidine|(8.88)>uk-14304|(8.42)>b-ht|(7.05)>noradrenaline|. (l_nmod) cells_3\NNS\3080309|in|alpha(2a)-adrenoceptor|transfected (l_compound) alpha(2a)-adrenoceptor_1\NN\1740|
T12_T23 NONE rauwolscine_4\NN\1740| (r_dep) ligand_3\NN\20090|the|selective|alpha(2)-adrenoceptor|rauwolscine (l_compound) alpha(2)-adrenoceptor_2\NN\1740|
T13_T23 NONE noradrenaline_26\NN\14807929|against (r_nmod) affinity_19\NN\11426530|the|pk(b|noradrenaline (r_nsubj) 8.43_28\CD\1740|affinity|was|. (r_parataxis) antagonized_5\VBD\1787955|ligand|changes|affinity|;|8.43 (l_nsubj) ligand_3\NN\20090|the|selective|alpha(2)-adrenoceptor|rauwolscine (l_compound) alpha(2)-adrenoceptor_2\NN\1740|
T14_T24 NONE prazosin_4\NN\2698769|and|doxazosin (r_dep) ligands_3\NNS\20090|the|selective|alpha(1)-adrenoceptor|prazosin|microm (l_compound) alpha(1)-adrenoceptor_2\NN\1740|
T15_T24 NONE doxazosin_6\NN\2721160| (r_conj) prazosin_4\NN\2698769|and|doxazosin (r_dep) ligands_3\NNS\20090|the|selective|alpha(1)-adrenoceptor|prazosin|microm (l_compound) alpha(1)-adrenoceptor_2\NN\1740|
T16_T24 NONE noradrenaline_16\NN\14807929| (r_compound) responses_17\NNS\11410625|on|noradrenaline (r_nmod) had_12\VBD\2108377|ligands|effect|responses|. (l_nsubj) ligands_3\NNS\20090|the|selective|alpha(1)-adrenoceptor|prazosin|microm (l_compound) alpha(1)-adrenoceptor_2\NN\1740|
1730582
T29_T44 NONE ornithine_7\NN\14601829| (r_compound) decarboxylase_8\NN\14732946|of|mouse|ornithine
T30_T44 CPR:4 alpha-difluoromethylornithine_10\NN\1740|by (r_nmod) inactivation_4\NN\13518963|of|the|irreversible|decarboxylase|alpha-difluoromethylornithine (l_nmod) decarboxylase_8\NN\14732946|of|mouse|ornithine
T16_T31 CPR:4 alpha-difluoromethylornithine_43\NN\1740|dfmo (r_appos) inhibitor_41\NN\20090|by|the|enzyme-activated|irreversible|,|alpha-difluoromethylornithine (r_nmod) inactivation_33\NN\13518963|in|the|enzyme|inhibitor (r_nmod) modified_30\VBN\109660|inactivation (r_acl) residues_29\NNS\20827|of|the|modified (r_conj) site_22\NN\8673395|of|the|binding|5'-phosphate|and|residues (r_nmod) determination_18\NN\43195|for|site (r_nmod) used_16\VBN\1156834|determination (r_acl) enzyme_15\NN\14723628|the|purified|recombinant|used (r_conj) expressed_7\VBN\928630|decarboxylase|was|coli|and|enzyme|. (l_nsubjpass) decarboxylase_2\NN\14732946|mouse|ornithine|odc
T16_T36 CPR:4 alpha-difluoromethylornithine_43\NN\1740|dfmo (r_appos) inhibitor_41\NN\20090|by|the|enzyme-activated|irreversible|,|alpha-difluoromethylornithine (r_nmod) inactivation_33\NN\13518963|in|the|enzyme|inhibitor (r_nmod) modified_30\VBN\109660|inactivation (r_acl) residues_29\NNS\20827|of|the|modified (r_conj) site_22\NN\8673395|of|the|binding|5'-phosphate|and|residues (r_nmod) determination_18\NN\43195|for|site (r_nmod) used_16\VBN\1156834|determination (r_acl) enzyme_15\NN\14723628|the|purified|recombinant|used (r_conj) expressed_7\VBN\928630|decarboxylase|was|coli|and|enzyme|. (l_nsubjpass) decarboxylase_2\NN\14732946|mouse|ornithine|odc (l_appos) odc_4\NN\1740|(|)
T17_T31 CPR:4 dfmo_45\NN\1740|(|) (r_appos) alpha-difluoromethylornithine_43\NN\1740|dfmo (r_appos) inhibitor_41\NN\20090|by|the|enzyme-activated|irreversible|,|alpha-difluoromethylornithine (r_nmod) inactivation_33\NN\13518963|in|the|enzyme|inhibitor (r_nmod) modified_30\VBN\109660|inactivation (r_acl) residues_29\NNS\20827|of|the|modified (r_conj) site_22\NN\8673395|of|the|binding|5'-phosphate|and|residues (r_nmod) determination_18\NN\43195|for|site (r_nmod) used_16\VBN\1156834|determination (r_acl) enzyme_15\NN\14723628|the|purified|recombinant|used (r_conj) expressed_7\VBN\928630|decarboxylase|was|coli|and|enzyme|. (l_nsubjpass) decarboxylase_2\NN\14732946|mouse|ornithine|odc
T17_T36 CPR:4 dfmo_45\NN\1740|(|) (r_appos) alpha-difluoromethylornithine_43\NN\1740|dfmo (r_appos) inhibitor_41\NN\20090|by|the|enzyme-activated|irreversible|,|alpha-difluoromethylornithine (r_nmod) inactivation_33\NN\13518963|in|the|enzyme|inhibitor (r_nmod) modified_30\VBN\109660|inactivation (r_acl) residues_29\NNS\20827|of|the|modified (r_conj) site_22\NN\8673395|of|the|binding|5'-phosphate|and|residues (r_nmod) determination_18\NN\43195|for|site (r_nmod) used_16\VBN\1156834|determination (r_acl) enzyme_15\NN\14723628|the|purified|recombinant|used (r_conj) expressed_7\VBN\928630|decarboxylase|was|coli|and|enzyme|. (l_nsubjpass) decarboxylase_2\NN\14732946|mouse|ornithine|odc (l_appos) odc_4\NN\1740|(|)
T23_T31 NONE ornithine_1\NN\14601829| (r_compound) decarboxylase_2\NN\14732946|mouse|ornithine|odc
T23_T36 NONE ornithine_1\NN\14601829| (r_compound) decarboxylase_2\NN\14732946|mouse|ornithine|odc (l_appos) odc_4\NN\1740|(|)
T6_T31 NONE 5'-phosphate_25\NN\1740|for|pyridoxal (r_nmod) site_22\NN\8673395|of|the|binding|5'-phosphate|and|residues (r_nmod) determination_18\NN\43195|for|site (r_nmod) used_16\VBN\1156834|determination (r_acl) enzyme_15\NN\14723628|the|purified|recombinant|used (r_conj) expressed_7\VBN\928630|decarboxylase|was|coli|and|enzyme|. (l_nsubjpass) decarboxylase_2\NN\14732946|mouse|ornithine|odc
T6_T36 NONE 5'-phosphate_25\NN\1740|for|pyridoxal (r_nmod) site_22\NN\8673395|of|the|binding|5'-phosphate|and|residues (r_nmod) determination_18\NN\43195|for|site (r_nmod) used_16\VBN\1156834|determination (r_acl) enzyme_15\NN\14723628|the|purified|recombinant|used (r_conj) expressed_7\VBN\928630|decarboxylase|was|coli|and|enzyme|. (l_nsubjpass) decarboxylase_2\NN\14732946|mouse|ornithine|odc (l_appos) odc_4\NN\1740|(|)
T18_T37 NONE 5'-phosphate_2\NN\1740| (r_compound) lysine_4\NN\14605787|the|pyridoxal|5'-phosphate|binding|odc (l_nmod) odc_7\NN\1740|in|mouse
T18_T38 NONE 5'-phosphate_2\NN\1740| (r_compound) lysine_4\NN\14605787|the|pyridoxal|5'-phosphate|binding|odc (r_nsubjpass) identified_9\VBN\699815|lysine|was|lysine|reduction|. (l_nmod) reduction_18\NN\351485|by|form|nab[3h]4|followed (l_acl) followed_26\VBN\1835496|digestion (l_nmod) digestion_28\NN\13446390|by|protein|lys-c|using (l_nmod) lys-c_35\NN\1740|with|endoproteinase|,|mapping
T19_T37 NONE lysine_4\NN\14605787|the|pyridoxal|5'-phosphate|binding|odc (l_nmod) odc_7\NN\1740|in|mouse
T19_T38 NONE lysine_4\NN\14605787|the|pyridoxal|5'-phosphate|binding|odc (r_nsubjpass) identified_9\VBN\699815|lysine|was|lysine|reduction|. (l_nmod) reduction_18\NN\351485|by|form|nab[3h]4|followed (l_acl) followed_26\VBN\1835496|digestion (l_nmod) digestion_28\NN\13446390|by|protein|lys-c|using (l_nmod) lys-c_35\NN\1740|with|endoproteinase|,|mapping
T20_T37 NONE lysine_11\NN\14605787|as|69|sequence (r_nmod) identified_9\VBN\699815|lysine|was|lysine|reduction|. (l_nsubjpass) lysine_4\NN\14605787|the|pyridoxal|5'-phosphate|binding|odc (l_nmod) odc_7\NN\1740|in|mouse
T20_T38 NONE lysine_11\NN\14605787|as|69|sequence (r_nmod) identified_9\VBN\699815|lysine|was|lysine|reduction|. (l_nmod) reduction_18\NN\351485|by|form|nab[3h]4|followed (l_acl) followed_26\VBN\1835496|digestion (l_nmod) digestion_28\NN\13446390|by|protein|lys-c|using (l_nmod) lys-c_35\NN\1740|with|endoproteinase|,|mapping
T21_T37 NONE nab[3h]4_25\NN\1740|with (r_nmod) reduction_18\NN\351485|by|form|nab[3h]4|followed (r_nmod) identified_9\VBN\699815|lysine|was|lysine|reduction|. (l_nsubjpass) lysine_4\NN\14605787|the|pyridoxal|5'-phosphate|binding|odc (l_nmod) odc_7\NN\1740|in|mouse
T21_T38 NONE nab[3h]4_25\NN\1740|with (r_nmod) reduction_18\NN\351485|by|form|nab[3h]4|followed (l_acl) followed_26\VBN\1835496|digestion (l_nmod) digestion_28\NN\13446390|by|protein|lys-c|using (l_nmod) lys-c_35\NN\1740|with|endoproteinase|,|mapping
T22_T37 NONE lys-c_35\NN\1740|with|endoproteinase|,|mapping (r_nmod) digestion_28\NN\13446390|by|protein|lys-c|using (r_nmod) followed_26\VBN\1835496|digestion (r_acl) reduction_18\NN\351485|by|form|nab[3h]4|followed (r_nmod) identified_9\VBN\699815|lysine|was|lysine|reduction|. (l_nsubjpass) lysine_4\NN\14605787|the|pyridoxal|5'-phosphate|binding|odc (l_nmod) odc_7\NN\1740|in|mouse
T22_T38 NONE lys-c_35\NN\1740|with|endoproteinase|,|mapping
T24_T39 NONE lysine_1\NN\14605787|this (r_nsubjpass) contained_3\VBN\2632940|lysine|is|sequence|. (l_nmod) sequence_6\NN\8457976|in|the|pfyavkc|,|found (l_dep) pfyavkc_7\NN\1740|
T24_T40 NONE lysine_1\NN\14605787|this (r_nsubjpass) contained_3\VBN\2632940|lysine|is|sequence|. (l_nmod) sequence_6\NN\8457976|in|the|pfyavkc|,|found (l_acl:relcl) found_11\VBN\2426171|which|is|odcs (l_nmod) odcs_15\NNS\1740|in|all|known|eukaryotes
T25_T39 NONE pfyavkc_7\NN\1740|
T25_T40 NONE pfyavkc_7\NN\1740| (r_dep) sequence_6\NN\8457976|in|the|pfyavkc|,|found (l_acl:relcl) found_11\VBN\2426171|which|is|odcs (l_nmod) odcs_15\NNS\1740|in|all|known|eukaryotes
T26_T41 NONE acids_3\NNS\14818238|the|preceding|amino (r_nsubj) conform_6\VB\109660|acids|do|not|sequence|. (l_nmod) sequence_10\NN\8457976|to|the|consensus|sxhk (l_nmod) sxhk_12\NN\1740|of|,|contains
T26_T42 NONE acids_3\NNS\14818238|the|preceding|amino (r_nsubj) conform_6\VB\109660|acids|do|not|sequence|. (l_nmod) sequence_10\NN\8457976|to|the|consensus|sxhk (l_nmod) sxhk_12\NN\1740|of|,|contains (l_acl:relcl) contains_15\VBZ\2632940|which|lysine|number (l_nmod) number_23\NN\5107765|in|a|decarboxylases (l_nmod) decarboxylases_26\NNS\14732946|of|other|odcs
T26_T43 NONE acids_3\NNS\14818238|the|preceding|amino (r_nsubj) conform_6\VB\109660|acids|do|not|sequence|. (l_nmod) sequence_10\NN\8457976|to|the|consensus|sxhk (l_nmod) sxhk_12\NN\1740|of|,|contains (l_acl:relcl) contains_15\VBZ\2632940|which|lysine|number (l_nmod) number_23\NN\5107765|in|a|decarboxylases (l_nmod) decarboxylases_26\NNS\14732946|of|other|odcs (l_nmod) odcs_28\NNS\1740|including|coli
T27_T41 NONE 5'-phosphate_18\NN\1740| (r_compound) lysine_20\NN\14605787|the|pyridoxal|5'-phosphate|binding (r_dobj) contains_15\VBZ\2632940|which|lysine|number (r_acl:relcl) sxhk_12\NN\1740|of|,|contains
T27_T42 NONE 5'-phosphate_18\NN\1740| (r_compound) lysine_20\NN\14605787|the|pyridoxal|5'-phosphate|binding (r_dobj) contains_15\VBZ\2632940|which|lysine|number (l_nmod) number_23\NN\5107765|in|a|decarboxylases (l_nmod) decarboxylases_26\NNS\14732946|of|other|odcs
T27_T43 NONE 5'-phosphate_18\NN\1740| (r_compound) lysine_20\NN\14605787|the|pyridoxal|5'-phosphate|binding (r_dobj) contains_15\VBZ\2632940|which|lysine|number (l_nmod) number_23\NN\5107765|in|a|decarboxylases (l_nmod) decarboxylases_26\NNS\14732946|of|other|odcs (l_nmod) odcs_28\NNS\1740|including|coli
T28_T41 NONE lysine_20\NN\14605787|the|pyridoxal|5'-phosphate|binding (r_dobj) contains_15\VBZ\2632940|which|lysine|number (r_acl:relcl) sxhk_12\NN\1740|of|,|contains
T28_T42 NONE lysine_20\NN\14605787|the|pyridoxal|5'-phosphate|binding (r_dobj) contains_15\VBZ\2632940|which|lysine|number (l_nmod) number_23\NN\5107765|in|a|decarboxylases (l_nmod) decarboxylases_26\NNS\14732946|of|other|odcs
T28_T43 NONE lysine_20\NN\14605787|the|pyridoxal|5'-phosphate|binding (r_dobj) contains_15\VBZ\2632940|which|lysine|number (l_nmod) number_23\NN\5107765|in|a|decarboxylases (l_nmod) decarboxylases_26\NNS\14732946|of|other|odcs (l_nmod) odcs_28\NNS\1740|including|coli
T1_T32 NONE 14c]dfmo_13\NN\1740|with|[5|- (r_nmod) reaction_9\NN\13446390|by|14c]dfmo (r_nmod) labeled_7\VBN\1030132|reaction (r_acl) odc_6\NN\1740|labeled
T2_T32 NONE lysine_19\NN\14605787|69|and|cysteine (r_nsubj) formed_24\VBD\1617192|that|lysine|adducts (r_ccomp) found_17\VBN\2426171|using|it|was|formed|. (l_advcl) using_0\VBG\1156834|procedure|analyze|, (l_advcl) analyze_5\VB\78760|to|odc (l_dobj) odc_6\NN\1740|labeled
T3_T32 NONE cysteine_22\NN\14601829|360 (r_conj) lysine_19\NN\14605787|69|and|cysteine (r_nsubj) formed_24\VBD\1617192|that|lysine|adducts (r_ccomp) found_17\VBN\2426171|using|it|was|formed|. (l_advcl) using_0\VBG\1156834|procedure|analyze|, (l_advcl) analyze_5\VB\78760|to|odc (l_dobj) odc_6\NN\1740|labeled
T4_T33 NONE cysteine_0\NN\14601829|360|,|adduct|, (r_nsubjpass) contained_19\VBN\2632940|cysteine|is|-wgptcdgl(i)d-|. (l_nmod) -wgptcdgl(i)d-_23\NN\1740|within|the|sequence|,|present
T4_T34 NONE cysteine_0\NN\14601829|360|,|adduct|, (r_nsubjpass) contained_19\VBN\2632940|cysteine|is|-wgptcdgl(i)d-|. (l_nmod) -wgptcdgl(i)d-_23\NN\1740|within|the|sequence|,|present (l_acl:relcl) present_27\JJ\1740|which|is|odcs (l_nmod) odcs_32\NNS\1740|in|all|known|eukaryote
T5_T33 NONE -wgptcdgl(i)d-_23\NN\1740|within|the|sequence|,|present
T5_T34 NONE -wgptcdgl(i)d-_23\NN\1740|within|the|sequence|,|present (l_acl:relcl) present_27\JJ\1740|which|is|odcs (l_nmod) odcs_32\NNS\1740|in|all|known|eukaryote
23382381
T2_T28 CPR:4 etoposide_7\NN\1740|by|or|doxorubicin (r_nmod) induced_5\VBN\1627355|etoposide (r_acl) damage_4\NN\7296428|to|dna|induced (r_nmod) responses_1\NNS\11410625|cellular|damage (r_nsubj) include_10\VBP\690614|responses|down-regulation|. (l_dobj) down-regulation_11\NN\1740|supervillin|coincident (l_nmod) supervillin_14\NN\1740|of|endogenous
T2_T29 CPR:3 etoposide_7\NN\1740|by|or|doxorubicin (r_nmod) induced_5\VBN\1627355|etoposide (r_acl) damage_4\NN\7296428|to|dna|induced (r_nmod) responses_1\NNS\11410625|cellular|damage (r_nsubj) include_10\VBP\690614|responses|down-regulation|. (l_dobj) down-regulation_11\NN\1740|supervillin|coincident (l_amod) coincident_15\JJ\1740|increases (l_nmod) increases_17\NNS\13576355|with|p53 (l_nmod) p53_19\NN\1740|in
T3_T28 CPR:4 doxorubicin_9\NN\2716866| (r_conj) etoposide_7\NN\1740|by|or|doxorubicin (r_nmod) induced_5\VBN\1627355|etoposide (r_acl) damage_4\NN\7296428|to|dna|induced (r_nmod) responses_1\NNS\11410625|cellular|damage (r_nsubj) include_10\VBP\690614|responses|down-regulation|. (l_dobj) down-regulation_11\NN\1740|supervillin|coincident (l_nmod) supervillin_14\NN\1740|of|endogenous
T3_T29 CPR:3 doxorubicin_9\NN\2716866| (r_conj) etoposide_7\NN\1740|by|or|doxorubicin (r_nmod) induced_5\VBN\1627355|etoposide (r_acl) damage_4\NN\7296428|to|dna|induced (r_nmod) responses_1\NNS\11410625|cellular|damage (r_nsubj) include_10\VBP\690614|responses|down-regulation|. (l_dobj) down-regulation_11\NN\1740|supervillin|coincident (l_amod) coincident_15\JJ\1740|increases (l_nmod) increases_17\NNS\13576355|with|p53 (l_nmod) p53_19\NN\1740|in
T1_T12 NONE n_6\NN\14622893| (r_compound) terminus_7\NN\8566028|to|the|supervillin|n (r_nmod) binds_1\VBZ\1290422|usp7|directly|terminus|and|deubiquitinate|. (l_nsubj) usp7_0\NN\1740|
T1_T13 NONE n_6\NN\14622893| (r_compound) terminus_7\NN\8566028|to|the|supervillin|n (l_compound) supervillin_5\NN\1740|
T1_T14 NONE n_6\NN\14622893| (r_compound) terminus_7\NN\8566028|to|the|supervillin|n (r_nmod) binds_1\VBZ\1290422|usp7|directly|terminus|and|deubiquitinate|. (l_conj) deubiquitinate_10\VB\1740|can|and|stabilize|supervillin (l_dobj) supervillin_13\NN\1740|
23461841
T5_T20 NONE glucose_1\NN\14710501| (r_compound) test_3\NN\5798043|a|glucose|tolerance|load (r_nsubjpass) performed_11\VBN\2367363|test|was|treatment|,|collecting|. (l_advcl) collecting_17\VBG\2281093|blood|0|h|insulin (l_nmod) insulin_28\NN\5407119|for|,|glucose|,|ffa|and|aldosterone
T6_T20 NONE glucose_8\NN\14710501| (r_compound) load_9\NN\4571088|with||g|glucose (r_nmod) test_3\NN\5798043|a|glucose|tolerance|load (r_nsubjpass) performed_11\VBN\2367363|test|was|treatment|,|collecting|. (l_advcl) collecting_17\VBG\2281093|blood|0|h|insulin (l_nmod) insulin_28\NN\5407119|for|,|glucose|,|ffa|and|aldosterone
T8_T20 NONE glucose_30\NN\14710501| (r_conj) insulin_28\NN\5407119|for|,|glucose|,|ffa|and|aldosterone
T9_T20 NONE aldosterone_34\NN\14751863| (r_conj) insulin_28\NN\5407119|for|,|glucose|,|ffa|and|aldosterone
T2_T18 NONE spironolactone_18\NN\2721160| (r_nsubj) useful_21\JJ\1740|that|spironolactone|may|be|lowering (r_ccomp) suggest_16\VBP\1010118|known|,|results|useful|. (l_advcl) known_3\VBN\2110220|since|ffas|are|involved (l_xcomp) involved_6\VBN\2676054|to|be|development (l_nmod) development_9\NN\248977|in|the|resistance (l_nmod) resistance_12\NN\37396|of|insulin (l_compound) insulin_11\NN\5407119|
T2_T19 NONE spironolactone_18\NN\2721160| (r_nsubj) useful_21\JJ\1740|that|spironolactone|may|be|lowering (l_advcl) lowering_23\VBG\1850315|for|resistance (l_dobj) resistance_25\NN\37396|insulin|patients (l_compound) insulin_24\NN\5407119|
23494944
T9_T18 CPR:4 alcl3_0\NN\1740| (r_nsubj) reduced_2\VBD\441445|alcl3|markedly|performance|. (l_dobj) performance_4\NN\6619065|aa|and|activities (l_conj) activities_6\NNS\30358|oxidase (l_nmod) oxidase_10\NN\14732946|of|cytochrome|c|cox|and|acetylcholinesterase|regions
T9_T19 CPR:4 alcl3_0\NN\1740| (r_nsubj) reduced_2\VBD\441445|alcl3|markedly|performance|. (l_dobj) performance_4\NN\6619065|aa|and|activities (l_conj) activities_6\NNS\30358|oxidase (l_nmod) oxidase_10\NN\14732946|of|cytochrome|c|cox|and|acetylcholinesterase|regions (l_appos) cox_12\NN\14732946|(|)
T9_T20 CPR:4 alcl3_0\NN\1740| (r_nsubj) reduced_2\VBD\441445|alcl3|markedly|performance|. (l_dobj) performance_4\NN\6619065|aa|and|activities (l_conj) activities_6\NNS\30358|oxidase (l_nmod) oxidase_10\NN\14732946|of|cytochrome|c|cox|and|acetylcholinesterase|regions (l_conj) acetylcholinesterase_15\NN\1740|ache
T9_T21 CPR:4 alcl3_0\NN\1740| (r_nsubj) reduced_2\VBD\441445|alcl3|markedly|performance|. (l_dobj) performance_4\NN\6619065|aa|and|activities (l_conj) activities_6\NNS\30358|oxidase (l_nmod) oxidase_10\NN\14732946|of|cytochrome|c|cox|and|acetylcholinesterase|regions (l_conj) acetylcholinesterase_15\NN\1740|ache (l_appos) ache_17\NN\14322699|(|)
T11_T13 CPR:4 alcl3_8\NN\1740|of (r_nmod) effects_6\NNS\13245626|the|damaging|alcl3|activity (l_nmod) activity_14\NN\30358|on|aa (l_compound) aa_10\NN\14930989|and|dismutase (l_conj) dismutase_13\NN\1740|superoxide
T11_T14 CPR:4 alcl3_8\NN\1740|of (r_nmod) effects_6\NNS\13245626|the|damaging|alcl3|activity (r_dobj) reversed_3\VBD\109660|pretreatment|completely|effects|,|corrected|improved|. (l_conj) corrected_17\VBD\138508|markedly|activities|,|and (l_dobj) activities_21\NNS\30358|cox (l_compound) cox_18\NN\14732946|and|ache
T11_T15 CPR:4 alcl3_8\NN\1740|of (r_nmod) effects_6\NNS\13245626|the|damaging|alcl3|activity (r_dobj) reversed_3\VBD\109660|pretreatment|completely|effects|,|corrected|improved|. (l_conj) corrected_17\VBD\138508|markedly|activities|,|and (l_dobj) activities_21\NNS\30358|cox (l_compound) cox_18\NN\14732946|and|ache (l_conj) ache_20\NN\14322699|
T2_T13 NONE superoxide_12\NN\14971519| (r_compound) dismutase_13\NN\1740|superoxide
T2_T14 NONE superoxide_12\NN\14971519| (r_compound) dismutase_13\NN\1740|superoxide (r_conj) aa_10\NN\14930989|and|dismutase (r_compound) activity_14\NN\30358|on|aa (r_nmod) effects_6\NNS\13245626|the|damaging|alcl3|activity (r_dobj) reversed_3\VBD\109660|pretreatment|completely|effects|,|corrected|improved|. (l_conj) corrected_17\VBD\138508|markedly|activities|,|and (l_dobj) activities_21\NNS\30358|cox (l_compound) cox_18\NN\14732946|and|ache
T2_T15 NONE superoxide_12\NN\14971519| (r_compound) dismutase_13\NN\1740|superoxide (r_conj) aa_10\NN\14930989|and|dismutase (r_compound) activity_14\NN\30358|on|aa (r_nmod) effects_6\NNS\13245626|the|damaging|alcl3|activity (r_dobj) reversed_3\VBD\109660|pretreatment|completely|effects|,|corrected|improved|. (l_conj) corrected_17\VBD\138508|markedly|activities|,|and (l_dobj) activities_21\NNS\30358|cox (l_compound) cox_18\NN\14732946|and|ache (l_conj) ache_20\NN\14322699|
23443628
T9_T14 NONE memantine_5\NN\1740| (r_conj) inhibitors_3\NNS\20090|cholinesterase|and|memantine (l_compound) cholinesterase_2\NN\14732946|
23499825
T4_T6 NONE glycoside_4\NN\14727670|the|(22r)-spirosolanol|(|11|) (r_nsubj) induced_9\VBD\1627355|furthermore|,|glycoside|selectively|apoptosis|cells|affecting|. (l_advcl) affecting_15\VBG\126264|without|level (l_dobj) level_19\NN\4916342|the|caspase-3|activity (l_compound) caspase-3_17\NN\1740|
23525167
23423972
23618921
T20_T39 NONE flavonoid_17\NN\14983143| (r_compound) fisetin_18\NN\1740|by|the|flavonoid (r_nmod) enhancement_11\NN\248977|the|levels|fisetin (r_dobj) mediates_9\VBZ\761713|regulation|enhancement|. (l_nsubj) regulation_1\NN\6652242|concurrent|factors (l_nmod) factors_5\NNS\7326557|of|the|transcription|nrf2 (l_dep) nrf2_6\NN\1740|and|atf4
T20_T40 NONE flavonoid_17\NN\14983143| (r_compound) fisetin_18\NN\1740|by|the|flavonoid (r_nmod) enhancement_11\NN\248977|the|levels|fisetin (r_dobj) mediates_9\VBZ\761713|regulation|enhancement|. (l_nsubj) regulation_1\NN\6652242|concurrent|factors (l_nmod) factors_5\NNS\7326557|of|the|transcription|nrf2 (l_dep) nrf2_6\NN\1740|and|atf4 (l_conj) atf4_8\NN\1740|
T21_T39 NONE fisetin_18\NN\1740|by|the|flavonoid (r_nmod) enhancement_11\NN\248977|the|levels|fisetin (r_dobj) mediates_9\VBZ\761713|regulation|enhancement|. (l_nsubj) regulation_1\NN\6652242|concurrent|factors (l_nmod) factors_5\NNS\7326557|of|the|transcription|nrf2 (l_dep) nrf2_6\NN\1740|and|atf4
T21_T40 NONE fisetin_18\NN\1740|by|the|flavonoid (r_nmod) enhancement_11\NN\248977|the|levels|fisetin (r_dobj) mediates_9\VBZ\761713|regulation|enhancement|. (l_nsubj) regulation_1\NN\6652242|concurrent|factors (l_nmod) factors_5\NNS\7326557|of|the|transcription|nrf2 (l_dep) nrf2_6\NN\1740|and|atf4 (l_conj) atf4_8\NN\1740|
T22_T39 NONE glutathione_13\NN\1740| (r_compound) levels_14\NNS\4916342|of|glutathione (r_nmod) enhancement_11\NN\248977|the|levels|fisetin (r_dobj) mediates_9\VBZ\761713|regulation|enhancement|. (l_nsubj) regulation_1\NN\6652242|concurrent|factors (l_nmod) factors_5\NNS\7326557|of|the|transcription|nrf2 (l_dep) nrf2_6\NN\1740|and|atf4
T22_T40 NONE glutathione_13\NN\1740| (r_compound) levels_14\NNS\4916342|of|glutathione (r_nmod) enhancement_11\NN\248977|the|levels|fisetin (r_dobj) mediates_9\VBZ\761713|regulation|enhancement|. (l_nsubj) regulation_1\NN\6652242|concurrent|factors (l_nmod) factors_5\NNS\7326557|of|the|transcription|nrf2 (l_dep) nrf2_6\NN\1740|and|atf4 (l_conj) atf4_8\NN\1740|
T13_T31 NONE gsh_9\NN\1740| (r_compound) metabolism_10\NN\13526110|in|gsh (r_nmod) play_5\VBP\1072262|that|roles|metabolism (r_acl:relcl) factors_3\NNS\7326557|among|the|transcription|play|factor|. (l_dep) factor_13\NN\7326557|are|nf-e2-related|2|nrf2|and|factor (l_nummod) 2_14\CD\13741022|
T13_T32 NONE gsh_9\NN\1740| (r_compound) metabolism_10\NN\13526110|in|gsh (r_nmod) play_5\VBP\1072262|that|roles|metabolism (r_acl:relcl) factors_3\NNS\7326557|among|the|transcription|play|factor|. (l_dep) factor_13\NN\7326557|are|nf-e2-related|2|nrf2|and|factor (l_appos) nrf2_16\NN\1740|(|)
T13_T33 NONE gsh_9\NN\1740| (r_compound) metabolism_10\NN\13526110|in|gsh (r_nmod) play_5\VBP\1072262|that|roles|metabolism (r_acl:relcl) factors_3\NNS\7326557|among|the|transcription|play|factor|. (l_dep) factor_13\NN\7326557|are|nf-e2-related|2|nrf2|and|factor (l_conj) factor_21\NN\7326557|activating|transcription|4|atf4 (l_nummod) 4_22\CD\13741022|
T13_T34 NONE gsh_9\NN\1740| (r_compound) metabolism_10\NN\13526110|in|gsh (r_nmod) play_5\VBP\1072262|that|roles|metabolism (r_acl:relcl) factors_3\NNS\7326557|among|the|transcription|play|factor|. (l_dep) factor_13\NN\7326557|are|nf-e2-related|2|nrf2|and|factor (l_conj) factor_21\NN\7326557|activating|transcription|4|atf4 (l_appos) atf4_24\NN\1740|(|)
T19_T35 CPR:3 fisetin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|fisetin|rapidly|levels|mechanisms (l_dobj) levels_8\NNS\4916342|the|nrf2 (l_nmod) nrf2_11\NN\1740|of|both|and|atf4|as|transcription
T19_T36 CPR:3 fisetin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|fisetin|rapidly|levels|mechanisms (l_dobj) levels_8\NNS\4916342|the|nrf2 (l_nmod) nrf2_11\NN\1740|of|both|and|atf4|as|transcription (l_conj) atf4_13\NN\1740|
T19_T37 CPR:3 fisetin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|fisetin|rapidly|levels|mechanisms (l_dobj) levels_8\NNS\4916342|the|nrf2 (l_nmod) nrf2_11\NN\1740|of|both|and|atf4|as|transcription (l_conj) transcription_21\NN\6349220|nrf2-|gene (l_amod) nrf2-_17\NN\1740|and|atf4-dependent
T19_T38 CPR:3 fisetin_4\NN\1740| (r_nsubj) increases_6\VBZ\169651|that|fisetin|rapidly|levels|mechanisms (l_dobj) levels_8\NNS\4916342|the|nrf2 (l_nmod) nrf2_11\NN\1740|of|both|and|atf4|as|transcription (l_conj) transcription_21\NN\6349220|nrf2-|gene (l_amod) nrf2-_17\NN\1740|and|atf4-dependent (l_conj) atf4-dependent_19\JJ\1740|
T2_T23 CPR:3 fisetin_1\NN\1740| (r_nsubj) increases_3\VBZ\169651|although|fisetin|greatly|stability (l_dobj) stability_5\NN\4777852|the|nrf2 (l_nmod) nrf2_8\NN\1740|of|both|and|atf4
T2_T24 CPR:3 fisetin_1\NN\1740| (r_nsubj) increases_3\VBZ\169651|although|fisetin|greatly|stability (l_dobj) stability_5\NN\4777852|the|nrf2 (l_nmod) nrf2_8\NN\1740|of|both|and|atf4 (l_conj) atf4_10\NN\1740|
T2_T25 NONE fisetin_1\NN\1740| (r_nsubj) increases_3\VBZ\169651|although|fisetin|greatly|stability (r_advcl) dependent_18\JJ\1740|increases|,|effect|is|activity|. (l_nsubj) effect_14\NN\34213|only|the|atf4 (l_nmod) atf4_16\NN\1740|on
T2_T26 NONE fisetin_1\NN\1740| (r_nsubj) increases_3\VBZ\169651|although|fisetin|greatly|stability (r_advcl) dependent_18\JJ\1740|increases|,|effect|is|activity|. (l_nmod) activity_22\NN\30358|on|protein|kinase (l_compound) kinase_21\NN\14732946|
T3_T27 NONE fisetin_14\NN\1740|'s (r_nmod:poss) ability_16\NN\4723816|for|fisetin|increase (r_nmod) important_12\JJ\1740|that|atf4|is|ability|appear (l_nsubj) atf4_5\NN\1740|,|not|nrf2|,
T3_T28 NONE fisetin_14\NN\1740|'s (r_nmod:poss) ability_16\NN\4723816|for|fisetin|increase (r_nmod) important_12\JJ\1740|that|atf4|is|ability|appear (l_nsubj) atf4_5\NN\1740|,|not|nrf2|, (l_conj) nrf2_9\NN\1740|
T3_T29 NONE fisetin_14\NN\1740|'s (r_nmod:poss) ability_16\NN\4723816|for|fisetin|increase (r_nmod) important_12\JJ\1740|that|atf4|is|ability|appear (l_advcl) appear_29\VBP\2604760|whereas|atf4|cooperate (l_nsubj) atf4_26\NN\1740|both|and|nrf2
T3_T30 NONE fisetin_14\NN\1740|'s (r_nmod:poss) ability_16\NN\4723816|for|fisetin|increase (r_nmod) important_12\JJ\1740|that|atf4|is|ability|appear (l_advcl) appear_29\VBP\2604760|whereas|atf4|cooperate (l_nsubj) atf4_26\NN\1740|both|and|nrf2 (l_conj) nrf2_28\NN\1740|
T4_T27 NONE gsh_19\NN\1740| (r_compound) levels_20\NNS\4916342|gsh (r_dobj) increase_18\VB\169651|to|levels|conditions (r_acl) ability_16\NN\4723816|for|fisetin|increase (r_nmod) important_12\JJ\1740|that|atf4|is|ability|appear (l_nsubj) atf4_5\NN\1740|,|not|nrf2|,
T4_T28 NONE gsh_19\NN\1740| (r_compound) levels_20\NNS\4916342|gsh (r_dobj) increase_18\VB\169651|to|levels|conditions (r_acl) ability_16\NN\4723816|for|fisetin|increase (r_nmod) important_12\JJ\1740|that|atf4|is|ability|appear (l_nsubj) atf4_5\NN\1740|,|not|nrf2|, (l_conj) nrf2_9\NN\1740|
T4_T29 NONE gsh_19\NN\1740| (r_compound) levels_20\NNS\4916342|gsh (r_dobj) increase_18\VB\169651|to|levels|conditions (r_acl) ability_16\NN\4723816|for|fisetin|increase (r_nmod) important_12\JJ\1740|that|atf4|is|ability|appear (l_advcl) appear_29\VBP\2604760|whereas|atf4|cooperate (l_nsubj) atf4_26\NN\1740|both|and|nrf2
T4_T30 NONE gsh_19\NN\1740| (r_compound) levels_20\NNS\4916342|gsh (r_dobj) increase_18\VB\169651|to|levels|conditions (r_acl) ability_16\NN\4723816|for|fisetin|increase (r_nmod) important_12\JJ\1740|that|atf4|is|ability|appear (l_advcl) appear_29\VBP\2604760|whereas|atf4|cooperate (l_nsubj) atf4_26\NN\1740|both|and|nrf2 (l_conj) nrf2_28\NN\1740|
T6_T27 NONE gsh_34\NN\1740| (r_compound) levels_35\NNS\4916342|gsh (r_dobj) increase_33\VB\169651|to|levels|conditions (r_xcomp) cooperate_31\VB\2413480|to|increase (r_xcomp) appear_29\VBP\2604760|whereas|atf4|cooperate (r_advcl) important_12\JJ\1740|that|atf4|is|ability|appear (l_nsubj) atf4_5\NN\1740|,|not|nrf2|,
T6_T28 NONE gsh_34\NN\1740| (r_compound) levels_35\NNS\4916342|gsh (r_dobj) increase_33\VB\169651|to|levels|conditions (r_xcomp) cooperate_31\VB\2413480|to|increase (r_xcomp) appear_29\VBP\2604760|whereas|atf4|cooperate (r_advcl) important_12\JJ\1740|that|atf4|is|ability|appear (l_nsubj) atf4_5\NN\1740|,|not|nrf2|, (l_conj) nrf2_9\NN\1740|
T6_T29 NONE gsh_34\NN\1740| (r_compound) levels_35\NNS\4916342|gsh (r_dobj) increase_33\VB\169651|to|levels|conditions (r_xcomp) cooperate_31\VB\2413480|to|increase (r_xcomp) appear_29\VBP\2604760|whereas|atf4|cooperate (l_nsubj) atf4_26\NN\1740|both|and|nrf2
T6_T30 NONE gsh_34\NN\1740| (r_compound) levels_35\NNS\4916342|gsh (r_dobj) increase_33\VB\169651|to|levels|conditions (r_xcomp) cooperate_31\VB\2413480|to|increase (r_xcomp) appear_29\VBP\2604760|whereas|atf4|cooperate (l_nsubj) atf4_26\NN\1740|both|and|nrf2 (l_conj) nrf2_28\NN\1740|
16874462
T10_T26 NONE proline_2\NN\14601829| (r_compound) oxidase_3\NN\14732946|of|proline
T11_T26 CPR:9 proline-dependent_5\JJ\1740|and|mitochondria-mediated (r_amod) apoptosis_8\NN\11486178|proline-dependent (r_dobj) induces_4\VBZ\1627355|overexpression|apoptosis|. (l_nsubj) overexpression_0\NN\1740|oxidase (l_nmod) oxidase_3\NN\14732946|of|proline
T1_T12 NONE proline_0\NN\14601829| (r_compound) oxidase_1\NN\14732946|proline|pox|,|protein|,
T1_T14 NONE proline_0\NN\14601829| (r_compound) oxidase_1\NN\14732946|proline|pox|,|protein|, (l_appos) pox_3\NN\14133159|(|)
T3_T12 CPR:9 proline_16\NN\14601829|of (r_nmod) oxidation_14\NN\13447361|the|rate-limiting|proline|5-carboxylate (r_dobj) catalyzes_11\VBZ\146138|oxidase|oxidation|. (l_nsubj) oxidase_1\NN\14732946|proline|pox|,|protein|,
T3_T14 CPR:9 proline_16\NN\14601829|of (r_nmod) oxidation_14\NN\13447361|the|rate-limiting|proline|5-carboxylate (r_dobj) catalyzes_11\VBZ\146138|oxidase|oxidation|. (l_nsubj) oxidase_1\NN\14732946|proline|pox|,|protein|, (l_appos) pox_3\NN\14133159|(|)
T4_T12 CPR:9 5-carboxylate_19\NN\1740|to|pyrroline-|p5c (r_nmod) oxidation_14\NN\13447361|the|rate-limiting|proline|5-carboxylate (r_dobj) catalyzes_11\VBZ\146138|oxidase|oxidation|. (l_nsubj) oxidase_1\NN\14732946|proline|pox|,|protein|,
T4_T14 CPR:9 5-carboxylate_19\NN\1740|to|pyrroline-|p5c (r_nmod) oxidation_14\NN\13447361|the|rate-limiting|proline|5-carboxylate (r_dobj) catalyzes_11\VBZ\146138|oxidase|oxidation|. (l_nsubj) oxidase_1\NN\14732946|proline|pox|,|protein|, (l_appos) pox_3\NN\14133159|(|)
T5_T12 CPR:9 p5c_21\NN\1740|(|) (r_appos) 5-carboxylate_19\NN\1740|to|pyrroline-|p5c (r_nmod) oxidation_14\NN\13447361|the|rate-limiting|proline|5-carboxylate (r_dobj) catalyzes_11\VBZ\146138|oxidase|oxidation|. (l_nsubj) oxidase_1\NN\14732946|proline|pox|,|protein|,
T5_T14 CPR:9 p5c_21\NN\1740|(|) (r_appos) 5-carboxylate_19\NN\1740|to|pyrroline-|p5c (r_nmod) oxidation_14\NN\13447361|the|rate-limiting|proline|5-carboxylate (r_dobj) catalyzes_11\VBZ\146138|oxidase|oxidation|. (l_nsubj) oxidase_1\NN\14732946|proline|pox|,|protein|, (l_appos) pox_3\NN\14133159|(|)
T6_T15 NONE oxygen_13\NN\14622893| (r_compound) species_14\NNS\7992450|of|reactive|oxygen|ros (r_nmod) generation_10\NN\7942152|with|species|and|apoptosis (r_nmod) associated_8\VBN\628491|that|overexpression|is|generation (l_nsubjpass) overexpression_4\NN\1740|pox (l_nmod) pox_6\NN\14133159|of
T6_T16 NONE oxygen_13\NN\14622893| (r_compound) species_14\NNS\7992450|of|reactive|oxygen|ros (r_nmod) generation_10\NN\7942152|with|species|and|apoptosis (l_conj) apoptosis_19\NN\11486178|cells (l_nmod) cells_24\NNS\3080309|in|pox-inducible|colorectal|cancer|,|dld-1.pox (l_amod) pox-inducible_21\JJ\1740|
T6_T17 NONE oxygen_13\NN\14622893| (r_compound) species_14\NNS\7992450|of|reactive|oxygen|ros (r_nmod) generation_10\NN\7942152|with|species|and|apoptosis (l_conj) apoptosis_19\NN\11486178|cells (l_nmod) cells_24\NNS\3080309|in|pox-inducible|colorectal|cancer|,|dld-1.pox (l_appos) dld-1.pox_26\NN\1740|
T7_T20 NONE l-proline-dependent_23\JJ\1740| (r_amod) response_25\NN\11410625|an|l-proline-dependent|apoptotic (r_dobj) exhibit_21\VBP\2632167|that|cells|response (r_ccomp) show_16\VB\2137132|to|exhibit (r_advcl) utilized_11\VBD\161225|investigate|,|we|cells|show|. (l_advcl) investigate_2\VB\644583|to|further|basis (l_dobj) basis_5\NN\13790712|the|molecular|apoptosis (l_nmod) apoptosis_8\NN\11486178|of|pox-induced (l_amod) pox-induced_7\JJ\1740|
T7_T21 NONE l-proline-dependent_23\JJ\1740| (r_amod) response_25\NN\11410625|an|l-proline-dependent|apoptotic (r_dobj) exhibit_21\VBP\2632167|that|cells|response (r_ccomp) show_16\VB\2137132|to|exhibit (r_advcl) utilized_11\VBD\161225|investigate|,|we|cells|show|. (l_dobj) cells_14\NNS\3080309|the|dld-1.pox (l_compound) dld-1.pox_13\NN\1740|
T7_T22 CPR:9 l-proline-dependent_23\JJ\1740| (r_amod) response_25\NN\11410625|an|l-proline-dependent|apoptotic (r_dobj) exhibit_21\VBP\2632167|that|cells|response (l_nsubj) cells_18\NNS\3080309|overproducing (l_acl) overproducing_19\VBG\1739814|pox (l_dobj) pox_20\NN\14133159|
T8_T23 NONE l-proline_6\NN\1740|for (r_nmod) specific_4\JJ\1740|effect|is|l-proline|,|detectable|,|and|occurs|. (l_conj) occurs_19\VBZ\2623529|h (l_nmod) h_24\NN\14622893|during|72|addition (l_nmod) addition_27\NN\3081021|following|the|l-proline|cells (l_nmod) cells_31\NNS\3080309|to|pox (l_nmod) pox_35\NN\14133159|with|induced
T9_T23 CPR:9 l-proline_29\NN\1740|of (r_nmod) addition_27\NN\3081021|following|the|l-proline|cells (l_nmod) cells_31\NNS\3080309|to|pox (l_nmod) pox_35\NN\14133159|with|induced
T2_T13 CPR:9 proline_7\NN\14601829|of (r_nmod) presence_5\NN\13954253|in|the|proline (r_nmod) sufficient_13\JJ\1740|that|presence|,|activity|is|induce (l_nsubj) activity_11\NN\30358|high|pox (l_compound) pox_10\NN\14133159|
23265539
11970990
T1_T22 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (r_dobj) have_7\VB\2108377|to|substitutions (r_xcomp) engineered_5\VBN\1639714|have (r_acl) isoforms_2\NNS\1740|alefacept|engineered (l_nmod) alefacept_4\NN\1740|of
T1_T23 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (l_nmod) domain_15\NN\13934596|in|the|igg1|c(h)2
T1_T24 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (l_acl:relcl) impact_17\VBP\1527271|that|binding (l_dobj) binding_21\NN\4688246|r (l_compound) r_20\NN\13635336|fc|gamma
T1_T25 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (r_dobj) have_7\VB\2108377|to|substitutions (r_xcomp) engineered_5\VBN\1639714|have (r_acl) isoforms_2\NNS\1740|alefacept|engineered (r_dobj) using_1\VBG\1156834|isoforms (r_acl) experimentation_0\NN\5797597|using (r_nsubj) indicate_22\VBP\952524|experimentation|mediates (l_ccomp) mediates_25\VBZ\761713|that|alefacept|interactions|activate (l_nsubj) alefacept_24\NN\1740|
T1_T26 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (r_dobj) have_7\VB\2108377|to|substitutions (r_xcomp) engineered_5\VBN\1639714|have (r_acl) isoforms_2\NNS\1740|alefacept|engineered (r_dobj) using_1\VBG\1156834|isoforms (r_acl) experimentation_0\NN\5797597|using (r_nsubj) indicate_22\VBP\952524|experimentation|mediates (l_ccomp) mediates_25\VBZ\761713|that|alefacept|interactions|activate (l_dobj) interactions_27\NNS\37396|cognate|cells (l_nmod) cells_29\NNS\3080309|between|expressing (l_acl) expressing_30\VBG\928630|cd2 (l_dobj) cd2_32\NN\1740|human|and|cd16
T1_T27 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (r_dobj) have_7\VB\2108377|to|substitutions (r_xcomp) engineered_5\VBN\1639714|have (r_acl) isoforms_2\NNS\1740|alefacept|engineered (r_dobj) using_1\VBG\1156834|isoforms (r_acl) experimentation_0\NN\5797597|using (r_nsubj) indicate_22\VBP\952524|experimentation|mediates (l_ccomp) mediates_25\VBZ\761713|that|alefacept|interactions|activate (l_dobj) interactions_27\NNS\37396|cognate|cells (l_nmod) cells_29\NNS\3080309|between|expressing (l_acl) expressing_30\VBG\928630|cd2 (l_dobj) cd2_32\NN\1740|human|and|cd16 (l_conj) cd16_34\NN\1740|
T1_T3 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (r_dobj) have_7\VB\2108377|to|substitutions (r_xcomp) engineered_5\VBN\1639714|have (r_acl) isoforms_2\NNS\1740|alefacept|engineered (r_dobj) using_1\VBG\1156834|isoforms (r_acl) experimentation_0\NN\5797597|using (r_nsubj) indicate_22\VBP\952524|experimentation|mediates (l_ccomp) mediates_25\VBZ\761713|that|alefacept|interactions|activate (l_xcomp) activate_36\VB\1641914|to|cells|,|e.g.|,|increase (l_dep) increase_41\VBP\169651|phosphorylation|,|up-regulate|,|and|induce (l_dobj) phosphorylation_45\NN\1740|extracellular|signal-regulated|kinase (l_compound) kinase_44\NN\14732946|
T1_T5 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (r_dobj) have_7\VB\2108377|to|substitutions (r_xcomp) engineered_5\VBN\1639714|have (r_acl) isoforms_2\NNS\1740|alefacept|engineered (r_dobj) using_1\VBG\1156834|isoforms (r_acl) experimentation_0\NN\5797597|using (r_nsubj) indicate_22\VBP\952524|experimentation|mediates (l_ccomp) mediates_25\VBZ\761713|that|alefacept|interactions|activate (l_xcomp) activate_36\VB\1641914|to|cells|,|e.g.|,|increase (l_dep) increase_41\VBP\169651|phosphorylation|,|up-regulate|,|and|induce (l_conj) up-regulate_47\VBP\1740|expression (l_dobj) expression_50\NN\4679549|cell|surface|cd25 (l_nmod) cd25_55\NN\1740|of|the|activation|marker
T1_T6 NONE acid_9\NN\14818238| (r_compound) substitutions_10\NNS\7337390|amino|acid|domain|impact (r_dobj) have_7\VB\2108377|to|substitutions (r_xcomp) engineered_5\VBN\1639714|have (r_acl) isoforms_2\NNS\1740|alefacept|engineered (r_dobj) using_1\VBG\1156834|isoforms (r_acl) experimentation_0\NN\5797597|using (r_nsubj) indicate_22\VBP\952524|experimentation|mediates (l_ccomp) mediates_25\VBZ\761713|that|alefacept|interactions|activate (l_xcomp) activate_36\VB\1641914|to|cells|,|e.g.|,|increase (l_dep) increase_41\VBP\169651|phosphorylation|,|up-regulate|,|and|induce (l_conj) induce_58\VB\1627355|release (l_dobj) release_59\NN\3748886|b. (l_nmod) b._62\NN\1740|of|granzyme
23511125
T12_T25 NONE glutamate_7\NN\15010703| (r_compound) inputs_8\NNS\6791372|of|glutamate|interneurons (r_nmod) modulation_5\NN\7044917|endogenous|nicotinic|inputs (r_dobj) reveals_2\VBZ\2137132|inhibition|modulation|. (l_nsubj) inhibition_1\NN\1068773|acetylcholinesterase (l_compound) acetylcholinesterase_0\NN\1740|
T8_T13 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|of|brain|nicotinic|acetylcholine|nachrs (r_nmod) involvement_1\NN\1080366|the|receptors|effects (l_nmod) effects_13\NNS\13245626|in|the|neurotoxicological|soman (l_nmod) soman_15\NN\14970136|of|,|inhibitor|, (l_appos) inhibitor_23\NN\20090|a|potent|acetylcholinesterase|and|agent (l_compound) acetylcholinesterase_19\NN\1740|ache
T8_T14 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|of|brain|nicotinic|acetylcholine|nachrs (r_nmod) involvement_1\NN\1080366|the|receptors|effects (l_nmod) effects_13\NNS\13245626|in|the|neurotoxicological|soman (l_nmod) soman_15\NN\14970136|of|,|inhibitor|, (l_appos) inhibitor_23\NN\20090|a|potent|acetylcholinesterase|and|agent (l_compound) acetylcholinesterase_19\NN\1740|ache (l_appos) ache_21\NN\14322699|(|)
T8_T17 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|of|brain|nicotinic|acetylcholine|nachrs
T8_T22 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|of|brain|nicotinic|acetylcholine|nachrs (l_appos) nachrs_8\NNS\1740|(|)
T10_T20 NONE glutamate_19\NN\15010703| (r_compound) transmission_20\NN\121166|nachr-dependent|glutamate (r_dobj) facilitates_17\VBZ\2547586|transmission (r_conj) builds_7\VBZ\1617192|that|inhibition|acetylcholine|brain|and|facilitates (l_nsubj) inhibition_6\NN\1068773|ache (l_compound) ache_5\NN\14322699|
T10_T21 NONE glutamate_19\NN\15010703| (r_compound) transmission_20\NN\121166|nachr-dependent|glutamate (l_amod) nachr-dependent_18\JJ\1740|
T11_T20 NONE glutamate_30\NN\15010703| (r_compound) currents_33\NNS\11449002|spontaneous|glutamate|excitatory|postsynaptic|epscs|interneurons (r_dobj) record_28\VB\2225492|to|currents (r_advcl) used_23\VBD\1156834|test|,|we|technique|record|. (l_advcl) test_1\VB\670261|to|hypothesis (l_dobj) hypothesis_3\NN\7162194|the|builds (l_ccomp) builds_7\VBZ\1617192|that|inhibition|acetylcholine|brain|and|facilitates (l_nsubj) inhibition_6\NN\1068773|ache (l_compound) ache_5\NN\14322699|
T11_T21 NONE glutamate_30\NN\15010703| (r_compound) currents_33\NNS\11449002|spontaneous|glutamate|excitatory|postsynaptic|epscs|interneurons (r_dobj) record_28\VB\2225492|to|currents (r_advcl) used_23\VBD\1156834|test|,|we|technique|record|. (l_advcl) test_1\VB\670261|to|hypothesis (l_dobj) hypothesis_3\NN\7162194|the|builds (l_ccomp) builds_7\VBZ\1617192|that|inhibition|acetylcholine|brain|and|facilitates (l_conj) facilitates_17\VBZ\2547586|transmission (l_dobj) transmission_20\NN\121166|nachr-dependent|glutamate (l_amod) nachr-dependent_18\JJ\1740|
T9_T20 NONE acetylcholine_9\NN\14807558|sufficient|ach (r_dobj) builds_7\VBZ\1617192|that|inhibition|acetylcholine|brain|and|facilitates (l_nsubj) inhibition_6\NN\1068773|ache (l_compound) ache_5\NN\14322699|
T9_T21 NONE acetylcholine_9\NN\14807558|sufficient|ach (r_dobj) builds_7\VBZ\1617192|that|inhibition|acetylcholine|brain|and|facilitates (l_conj) facilitates_17\VBZ\2547586|transmission (l_dobj) transmission_20\NN\121166|nachr-dependent|glutamate (l_amod) nachr-dependent_18\JJ\1740|
T1_T24 CPR:4 donepezil_19\NN\1740|100nm (r_dep) inhibitor_18\NN\20090|with|the|reversible|ache|donepezil (l_compound) ache_17\NN\14322699|
T7_T15 NONE glutamate_13\NN\15010703| (r_compound) transmission_14\NN\121166|nachr-dependent|glutamate|hippocampus (r_dobj) recruit_11\VB\2471690|to|transmission (r_xcomp) able_9\JJ\1740|that|inhibition|is|recruit (l_nsubj) inhibition_7\NN\1068773|ache (l_compound) ache_6\NN\14322699|
T7_T16 NONE glutamate_13\NN\15010703| (r_compound) transmission_14\NN\121166|nachr-dependent|glutamate|hippocampus (l_amod) nachr-dependent_12\JJ\1740|
18973551
T22_T37 NONE dopamine_0\NN\14807737| (r_compound) agonists_3\NNS\9613191|dopamine|d3|receptor-preferring (l_amod) receptor-preferring_2\JJ\1740|
T22_T38 NONE dopamine_0\NN\14807737| (r_compound) agonists_3\NNS\9613191|dopamine|d3|receptor-preferring (r_nsubj) increase_4\VBP\169651|agonists|arborization|phosphorylation|. (l_nmod) phosphorylation_15\NN\1740|via|extracellular|signal-regulated|kinase (l_compound) kinase_14\NN\14732946|
T16_T34 NONE dopamine_8\NN\14807737| (r_compound) agonists_11\NNS\9613191|by|dopamine|d3|receptor-preferring (l_amod) receptor-preferring_10\JJ\1740|
T12_T32 NONE dopamine_6\NN\14807737| (r_compound) agonists_7\NNS\9613191|dopamine (r_nsubj) produce_8\VBP\1617192|whether|agonists|effects|acting|,|release (l_nmod) release_32\NN\3748886|via|factors (l_nmod) factors_35\NNS\7326557|of|neurotrophic
T13_T33 NONE dopamine_10\NN\14807737| (r_compound) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (l_amod) receptor-preferring_12\JJ\1740|d3
T13_T35 NONE dopamine_10\NN\14807737| (r_compound) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_compound) hydroxylase_38\NN\1740|
T13_T36 NONE dopamine_10\NN\14807737| (r_compound) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_appos) th-ir_41\NN\1740|(|)
T14_T33 NONE quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (l_amod) receptor-preferring_12\JJ\1740|d3
T14_T35 NONE quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_compound) hydroxylase_38\NN\1740|
T14_T36 NONE quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_appos) th-ir_41\NN\1740|(|)
T15_T33 NONE n-di-propyl-2-aminotetralin_18\NN\1740|7-hydroxy-n|,|7-oh-dpat (r_conj) quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (l_amod) receptor-preferring_12\JJ\1740|d3
T15_T35 NONE n-di-propyl-2-aminotetralin_18\NN\1740|7-hydroxy-n|,|7-oh-dpat (r_conj) quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_compound) hydroxylase_38\NN\1740|
T15_T36 NONE n-di-propyl-2-aminotetralin_18\NN\1740|7-hydroxy-n|,|7-oh-dpat (r_conj) quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_appos) th-ir_41\NN\1740|(|)
T17_T33 NONE 7-oh-dpat_20\NN\1740|(|) (r_appos) n-di-propyl-2-aminotetralin_18\NN\1740|7-hydroxy-n|,|7-oh-dpat (r_conj) quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (l_amod) receptor-preferring_12\JJ\1740|d3
T17_T35 NONE 7-oh-dpat_20\NN\1740|(|) (r_appos) n-di-propyl-2-aminotetralin_18\NN\1740|7-hydroxy-n|,|7-oh-dpat (r_conj) quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_compound) hydroxylase_38\NN\1740|
T17_T36 NONE 7-oh-dpat_20\NN\1740|(|) (r_appos) n-di-propyl-2-aminotetralin_18\NN\1740|7-hydroxy-n|,|7-oh-dpat (r_conj) quinpirole_14\NN\1740|and|n-di-propyl-2-aminotetralin (r_dep) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_appos) th-ir_41\NN\1740|(|)
T18_T33 NONE amphetamine_30\NN\3248958|of|the|indirect|agonist|, (r_conj) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (l_amod) receptor-preferring_12\JJ\1740|d3
T18_T35 NONE amphetamine_30\NN\3248958|of|the|indirect|agonist|, (r_conj) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_compound) hydroxylase_38\NN\1740|
T18_T36 NONE amphetamine_30\NN\3248958|of|the|indirect|agonist|, (r_conj) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) neurons_34\NNS\5430628|on|dopaminergic|identified (l_acl) identified_35\VBN\699815|immunoreactivity (l_nmod) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_appos) th-ir_41\NN\1740|(|)
T19_T33 NONE tyrosine_37\NN\14601829| (r_compound) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (r_nmod) identified_35\VBN\699815|immunoreactivity (r_acl) neurons_34\NNS\5430628|on|dopaminergic|identified (r_nmod) effects_7\NNS\13245626|the|agonists|neurons (l_nmod) agonists_13\NNS\9613191|of|the|dopamine|receptor-preferring|quinpirole|,|as|amphetamine (l_amod) receptor-preferring_12\JJ\1740|d3
T19_T35 NONE tyrosine_37\NN\14601829| (r_compound) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_compound) hydroxylase_38\NN\1740|
T19_T36 NONE tyrosine_37\NN\14601829| (r_compound) immunoreactivity_39\NN\1740|by|tyrosine|hydroxylase|th-ir (l_appos) th-ir_41\NN\1740|(|)
T1_T23 NONE [3h]dopamine_44\NN\1740| (r_compound) uptake_45\NN\13440063|[3h]dopamine|< (l_dep) <_48\JJR\1740|(|p|0.01|neurons (l_nmod) neurons_54\NNS\5430628|of|th-ir-positive|mesencephalic (l_amod) th-ir-positive_52\JJ\1740|
T20_T23 NONE quinpirole_7\NN\1740|both|microm|and|7-oh-dpat (r_nsubj) increased_23\VBD\169651|days|,|quinpirole|dose-dependently|length|. (l_dobj) length_27\NN\5093581|the|maximal|dendrite|<|number|<|and|uptake (l_conj) uptake_45\NN\13440063|[3h]dopamine|< (l_dep) <_48\JJR\1740|(|p|0.01|neurons (l_nmod) neurons_54\NNS\5430628|of|th-ir-positive|mesencephalic (l_amod) th-ir-positive_52\JJ\1740|
T21_T23 NONE 7-oh-dpat_15\NN\1740|nm (r_conj) quinpirole_7\NN\1740|both|microm|and|7-oh-dpat (r_nsubj) increased_23\VBD\169651|days|,|quinpirole|dose-dependently|length|. (l_dobj) length_27\NN\5093581|the|maximal|dendrite|<|number|<|and|uptake (l_conj) uptake_45\NN\13440063|[3h]dopamine|< (l_dep) <_48\JJR\1740|(|p|0.01|neurons (l_nmod) neurons_54\NNS\5430628|of|th-ir-positive|mesencephalic (l_amod) th-ir-positive_52\JJ\1740|
T3_T24 NONE sulpiride_11\NN\1740|by|the|unselective|d2/d3|receptor|antagonist|microm|and|antagonist (l_compound) receptor_9\NN\5225602|
T3_T25 NONE sulpiride_11\NN\1740|by|the|unselective|d2/d3|receptor|antagonist|microm|and|antagonist (l_conj) antagonist_22\NN\7846|by|the|selective|d3|receptor|sb-277011-a|dose (l_compound) receptor_21\NN\5225602|
T4_T24 NONE sb-277011-a_23\NN\1740| (r_dep) antagonist_22\NN\7846|by|the|selective|d3|receptor|sb-277011-a|dose (r_conj) sulpiride_11\NN\1740|by|the|unselective|d2/d3|receptor|antagonist|microm|and|antagonist (l_compound) receptor_9\NN\5225602|
T4_T25 CPR:6 sb-277011-a_23\NN\1740| (r_dep) antagonist_22\NN\7846|by|the|selective|d3|receptor|sb-277011-a|dose (l_compound) receptor_21\NN\5225602|
T10_T26 NONE ly294002_40\NN\1740| (r_conj) pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (r_parataxis) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk
T10_T27 NONE ly294002_40\NN\1740| (r_conj) pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (r_parataxis) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk (l_appos) erk_12\NN\1740|(|)
T10_T28 NONE ly294002_40\NN\1740| (r_conj) pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) pathway_30\NN\5483677|of|the|d2/d3|receptor|signalling (l_compound) receptor_28\NN\5225602|
T10_T29 NONE ly294002_40\NN\1740| (r_conj) pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) erk_32\NN\1740|to
T5_T26 CPR:3 quinpirole_0\NN\1740|and|7-oh-dpat (r_nsubj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk
T5_T27 CPR:3 quinpirole_0\NN\1740|and|7-oh-dpat (r_nsubj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk (l_appos) erk_12\NN\1740|(|)
T5_T28 NONE quinpirole_0\NN\1740|and|7-oh-dpat (r_nsubj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_parataxis) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) pathway_30\NN\5483677|of|the|d2/d3|receptor|signalling (l_compound) receptor_28\NN\5225602|
T5_T29 NONE quinpirole_0\NN\1740|and|7-oh-dpat (r_nsubj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_parataxis) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) erk_32\NN\1740|to
T6_T26 CPR:3 7-oh-dpat_2\NN\1740| (r_conj) quinpirole_0\NN\1740|and|7-oh-dpat (r_nsubj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk
T6_T27 CPR:3 7-oh-dpat_2\NN\1740| (r_conj) quinpirole_0\NN\1740|and|7-oh-dpat (r_nsubj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk (l_appos) erk_12\NN\1740|(|)
T6_T28 NONE 7-oh-dpat_2\NN\1740| (r_conj) quinpirole_0\NN\1740|and|7-oh-dpat (r_nsubj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_parataxis) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) pathway_30\NN\5483677|of|the|d2/d3|receptor|signalling (l_compound) receptor_28\NN\5225602|
T6_T29 NONE 7-oh-dpat_2\NN\1740| (r_conj) quinpirole_0\NN\1740|and|7-oh-dpat (r_nsubj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_parataxis) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) erk_32\NN\1740|to
T7_T26 CPR:4 sb-277011-a._23\NN\1740|with (r_nmod) pretreatment_21\NN\1740|by|sb-277011-a. (r_nmod) blocked_19\VBN\1476483|pretreatment (r_acl) effect_18\NN\34213|an|blocked (r_dobj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk
T7_T27 CPR:4 sb-277011-a._23\NN\1740|with (r_nmod) pretreatment_21\NN\1740|by|sb-277011-a. (r_nmod) blocked_19\VBN\1476483|pretreatment (r_acl) effect_18\NN\34213|an|blocked (r_dobj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk (l_appos) erk_12\NN\1740|(|)
T7_T28 NONE sb-277011-a._23\NN\1740|with (r_nmod) pretreatment_21\NN\1740|by|sb-277011-a. (r_nmod) blocked_19\VBN\1476483|pretreatment (r_acl) effect_18\NN\34213|an|blocked (r_dobj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_parataxis) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) pathway_30\NN\5483677|of|the|d2/d3|receptor|signalling (l_compound) receptor_28\NN\5225602|
T7_T29 NONE sb-277011-a._23\NN\1740|with (r_nmod) pretreatment_21\NN\1740|by|sb-277011-a. (r_nmod) blocked_19\VBN\1476483|pretreatment (r_acl) effect_18\NN\34213|an|blocked (r_dobj) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_parataxis) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) erk_32\NN\1740|to
T8_T26 NONE pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (r_parataxis) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk
T8_T27 NONE pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (r_parataxis) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk (l_appos) erk_12\NN\1740|(|)
T8_T28 NONE pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) pathway_30\NN\5483677|of|the|d2/d3|receptor|signalling (l_compound) receptor_28\NN\5225602|
T8_T29 NONE pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) erk_32\NN\1740|to
T9_T26 NONE gf109203_38\NN\1740| (r_conj) pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (r_parataxis) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk
T9_T27 NONE gf109203_38\NN\1740| (r_conj) pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (r_parataxis) increased_4\VBD\169651|quinpirole|also|phosphorylation|minutes|,|effect|obtained (l_dobj) phosphorylation_6\NN\1740|the|kinase (l_nmod) kinase_10\NN\14732946|of|extracellular|signal-regulated|erk (l_appos) erk_12\NN\1740|(|)
T9_T28 NONE gf109203_38\NN\1740| (r_conj) pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) pathway_30\NN\5483677|of|the|d2/d3|receptor|signalling (l_compound) receptor_28\NN\5225602|
T9_T29 NONE gf109203_38\NN\1740| (r_conj) pd98059_36\NN\1740|with|,|gf109203|or|ly294002 (r_nmod) obtained_34\VBN\2210855|inhibition|was|pd98059|,|resulting|. (l_nsubjpass) inhibition_24\NN\1068773|pathway|erk (l_nmod) erk_32\NN\1740|to
T11_T30 NONE dopamine_4\NN\14807737| (r_compound) agonists_5\NNS\9613191|dopamine (r_nsubj) increase_6\VBP\169651|that|agonists|arborizations|effect (l_nmod) effect_16\NN\34213|via|a|direct|receptors|,|involving (l_nmod) receptors_19\NNS\5225602|on|d2/d3
23537661
T1_T16 CPR:5 pc-dibenzofurans_21\NNS\1740| (r_conj) pc-dibenzodioxins_19\NNS\1740|and|pc-dibenzofurans (r_conj) pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (l_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr
T1_T17 NONE pc-dibenzofurans_21\NNS\1740| (r_conj) pc-dibenzodioxins_19\NNS\1740|and|pc-dibenzofurans (r_conj) pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (l_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr (l_appos) ahr_12\NN\1740|(|)
T1_T9 NONE pc-dibenzofurans_21\NNS\1740| (r_conj) pc-dibenzodioxins_19\NNS\1740|and|pc-dibenzofurans (r_conj) pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (r_nmod) mixture_6\NN\19613|of|a|agonists|m (l_nmod) m_27\NN\13649268|without|or|with|0.5|0.5mahr (l_appos) 0.5mahr_29\CD\1740|(|)
T6_T16 NONE hydrocarbon_9\NN\14727670| (r_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr
T6_T17 NONE hydrocarbon_9\NN\14727670| (r_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr (l_appos) ahr_12\NN\1740|(|)
T6_T9 NONE hydrocarbon_9\NN\14727670| (r_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr (r_compound) agonists_14\NNS\9613191|of|receptor|pcbs (r_nmod) mixture_6\NN\19613|of|a|agonists|m (l_nmod) m_27\NN\13649268|without|or|with|0.5|0.5mahr (l_appos) 0.5mahr_29\CD\1740|(|)
T7_T16 CPR:5 pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (l_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr
T7_T17 NONE pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (l_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr (l_appos) ahr_12\NN\1740|(|)
T7_T9 NONE pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (r_nmod) mixture_6\NN\19613|of|a|agonists|m (l_nmod) m_27\NN\13649268|without|or|with|0.5|0.5mahr (l_appos) 0.5mahr_29\CD\1740|(|)
T8_T16 CPR:5 pc-dibenzodioxins_19\NNS\1740|and|pc-dibenzofurans (r_conj) pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (l_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr
T8_T17 NONE pc-dibenzodioxins_19\NNS\1740|and|pc-dibenzofurans (r_conj) pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (l_compound) receptor_10\NN\5225602|aryl|hydrocarbon|ahr (l_appos) ahr_12\NN\1740|(|)
T8_T9 NONE pc-dibenzodioxins_19\NNS\1740|and|pc-dibenzofurans (r_conj) pcbs_17\NNS\1740|(|non-ortho|,|pc-dibenzodioxins|) (r_dep) agonists_14\NNS\9613191|of|receptor|pcbs (r_nmod) mixture_6\NN\19613|of|a|agonists|m (l_nmod) m_27\NN\13649268|without|or|with|0.5|0.5mahr (l_appos) 0.5mahr_29\CD\1740|(|)
23123662
T28_T43 CPR:9 copper_10\NN\14821043|and|platinum (r_compound) drugs_14\NNS\14778436|of|copper|anticancer (r_nmod) uptake_6\NN\13440063|to|the|and|toxicity|drugs|neurons (r_nmod) contributions_0\NNS\786195|ctr1|uptake|. (l_nmod) ctr1_3\NN\1740|of|rat
T29_T43 CPR:9 platinum_12\NN\14627081| (r_conj) copper_10\NN\14821043|and|platinum (r_compound) drugs_14\NNS\14778436|of|copper|anticancer (r_nmod) uptake_6\NN\13440063|to|the|and|toxicity|drugs|neurons (r_nmod) contributions_0\NNS\786195|ctr1|uptake|. (l_nmod) ctr1_3\NN\1740|of|rat
T14_T35 NONE copper_8\NN\14821043| (r_compound) transporter_9\NN\4490091|of|copper|1|ctr1 (l_nummod) 1_10\CD\13741022|
T14_T36 NONE copper_8\NN\14821043| (r_compound) transporter_9\NN\4490091|of|copper|1|ctr1 (l_appos) ctr1_12\NN\1740|(|)
T14_T37 NONE copper_8\NN\14821043| (r_compound) transporter_9\NN\4490091|of|copper|1|ctr1 (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_conj) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1
T14_T38 NONE copper_8\NN\14821043| (r_compound) transporter_9\NN\4490091|of|copper|1|ctr1 (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_conj) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1 (l_appos) rctr1_38\NN\1740|(|)
T15_T35 NONE copper_20\NN\14821043|and|platinum (r_compound) drugs_23\NNS\14778436|of|copper (r_nmod) uptake_16\NN\13440063|in|the|and|toxicity|drugs|neurons (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_nmod) transporter_9\NN\4490091|of|copper|1|ctr1 (l_nummod) 1_10\CD\13741022|
T15_T36 NONE copper_20\NN\14821043|and|platinum (r_compound) drugs_23\NNS\14778436|of|copper (r_nmod) uptake_16\NN\13440063|in|the|and|toxicity|drugs|neurons (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_nmod) transporter_9\NN\4490091|of|copper|1|ctr1 (l_appos) ctr1_12\NN\1740|(|)
T15_T37 NONE copper_20\NN\14821043|and|platinum (r_compound) drugs_23\NNS\14778436|of|copper (r_nmod) uptake_16\NN\13440063|in|the|and|toxicity|drugs|neurons (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_conj) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1
T15_T38 NONE copper_20\NN\14821043|and|platinum (r_compound) drugs_23\NNS\14778436|of|copper (r_nmod) uptake_16\NN\13440063|in|the|and|toxicity|drugs|neurons (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_conj) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1 (l_appos) rctr1_38\NN\1740|(|)
T16_T35 NONE platinum_22\NN\14627081| (r_conj) copper_20\NN\14821043|and|platinum (r_compound) drugs_23\NNS\14778436|of|copper (r_nmod) uptake_16\NN\13440063|in|the|and|toxicity|drugs|neurons (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_nmod) transporter_9\NN\4490091|of|copper|1|ctr1 (l_nummod) 1_10\CD\13741022|
T16_T36 NONE platinum_22\NN\14627081| (r_conj) copper_20\NN\14821043|and|platinum (r_compound) drugs_23\NNS\14778436|of|copper (r_nmod) uptake_16\NN\13440063|in|the|and|toxicity|drugs|neurons (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_nmod) transporter_9\NN\4490091|of|copper|1|ctr1 (l_appos) ctr1_12\NN\1740|(|)
T16_T37 NONE platinum_22\NN\14627081| (r_conj) copper_20\NN\14821043|and|platinum (r_compound) drugs_23\NNS\14778436|of|copper (r_nmod) uptake_16\NN\13440063|in|the|and|toxicity|drugs|neurons (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_conj) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1
T16_T38 NONE platinum_22\NN\14627081| (r_conj) copper_20\NN\14821043|and|platinum (r_compound) drugs_23\NNS\14778436|of|copper (r_nmod) uptake_16\NN\13440063|in|the|and|toxicity|drugs|neurons (r_nmod) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_conj) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1 (l_appos) rctr1_38\NN\1740|(|)
T17_T35 NONE copper_45\NN\14821043|of|and|drugs (r_nmod) transporter_43\NN\4490091|as|a|membrane|copper (r_nmod) activities_33\NNS\30358|the|functional|ctr1|transporter (r_conj) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_nmod) transporter_9\NN\4490091|of|copper|1|ctr1 (l_nummod) 1_10\CD\13741022|
T17_T36 NONE copper_45\NN\14821043|of|and|drugs (r_nmod) transporter_43\NN\4490091|as|a|membrane|copper (r_nmod) activities_33\NNS\30358|the|functional|ctr1|transporter (r_conj) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_nmod) transporter_9\NN\4490091|of|copper|1|ctr1 (l_appos) ctr1_12\NN\1740|(|)
T17_T37 NONE copper_45\NN\14821043|of|and|drugs (r_nmod) transporter_43\NN\4490091|as|a|membrane|copper (r_nmod) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1
T17_T38 NONE copper_45\NN\14821043|of|and|drugs (r_nmod) transporter_43\NN\4490091|as|a|membrane|copper (r_nmod) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1 (l_appos) rctr1_38\NN\1740|(|)
T18_T35 NONE platinum_47\NN\14627081| (r_compound) drugs_48\NNS\14778436|platinum (r_conj) copper_45\NN\14821043|of|and|drugs (r_nmod) transporter_43\NN\4490091|as|a|membrane|copper (r_nmod) activities_33\NNS\30358|the|functional|ctr1|transporter (r_conj) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_nmod) transporter_9\NN\4490091|of|copper|1|ctr1 (l_nummod) 1_10\CD\13741022|
T18_T36 NONE platinum_47\NN\14627081| (r_compound) drugs_48\NNS\14778436|platinum (r_conj) copper_45\NN\14821043|of|and|drugs (r_nmod) transporter_43\NN\4490091|as|a|membrane|copper (r_nmod) activities_33\NNS\30358|the|functional|ctr1|transporter (r_conj) role_6\NN\719494|the|transporter|uptake|,|and|activities (l_nmod) transporter_9\NN\4490091|of|copper|1|ctr1 (l_appos) ctr1_12\NN\1740|(|)
T18_T37 NONE platinum_47\NN\14627081| (r_compound) drugs_48\NNS\14778436|platinum (r_conj) copper_45\NN\14821043|of|and|drugs (r_nmod) transporter_43\NN\4490091|as|a|membrane|copper (r_nmod) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1
T18_T38 NONE platinum_47\NN\14627081| (r_compound) drugs_48\NNS\14778436|platinum (r_conj) copper_45\NN\14821043|of|and|drugs (r_nmod) transporter_43\NN\4490091|as|a|membrane|copper (r_nmod) activities_33\NNS\30358|the|functional|ctr1|transporter (l_nmod) ctr1_36\NN\1740|of|rat|rctr1 (l_appos) rctr1_38\NN\1740|(|)
T20_T39 CPR:9 copper_17\NN\14821043|of|,|oxaliplatin|,|cisplatin|and|carboplatin (r_nmod) uptake_13\NN\13440063|the|and|cytotoxicity|copper (r_dobj) increased_11\VBD\169651|expression|uptake|,|comparison|. (l_nsubj) expression_1\NN\4679549|heterologous|rctr1|cells (l_nmod) rctr1_3\NN\1740|of
T20_T40 CPR:9 copper_17\NN\14821043|of|,|oxaliplatin|,|cisplatin|and|carboplatin (r_nmod) uptake_13\NN\13440063|the|and|cytotoxicity|copper (r_dobj) increased_11\VBD\169651|expression|uptake|,|comparison|. (l_nsubj) expression_1\NN\4679549|heterologous|rctr1|cells (l_nmod) cells_6\NNS\3080309|in|hek293|cells (l_appos) cells_9\NNS\3080309|(|hek/rctr1|) (l_compound) hek/rctr1_8\NN\1740|
T21_T39 CPR:9 oxaliplatin_19\NN\1740| (r_conj) copper_17\NN\14821043|of|,|oxaliplatin|,|cisplatin|and|carboplatin (r_nmod) uptake_13\NN\13440063|the|and|cytotoxicity|copper (r_dobj) increased_11\VBD\169651|expression|uptake|,|comparison|. (l_nsubj) expression_1\NN\4679549|heterologous|rctr1|cells (l_nmod) rctr1_3\NN\1740|of
T21_T40 CPR:9 oxaliplatin_19\NN\1740| (r_conj) copper_17\NN\14821043|of|,|oxaliplatin|,|cisplatin|and|carboplatin (r_nmod) uptake_13\NN\13440063|the|and|cytotoxicity|copper (r_dobj) increased_11\VBD\169651|expression|uptake|,|comparison|. (l_nsubj) expression_1\NN\4679549|heterologous|rctr1|cells (l_nmod) cells_6\NNS\3080309|in|hek293|cells (l_appos) cells_9\NNS\3080309|(|hek/rctr1|) (l_compound) hek/rctr1_8\NN\1740|
T22_T39 CPR:9 cisplatin_21\NN\1740| (r_conj) copper_17\NN\14821043|of|,|oxaliplatin|,|cisplatin|and|carboplatin (r_nmod) uptake_13\NN\13440063|the|and|cytotoxicity|copper (r_dobj) increased_11\VBD\169651|expression|uptake|,|comparison|. (l_nsubj) expression_1\NN\4679549|heterologous|rctr1|cells (l_nmod) rctr1_3\NN\1740|of
T22_T40 CPR:9 cisplatin_21\NN\1740| (r_conj) copper_17\NN\14821043|of|,|oxaliplatin|,|cisplatin|and|carboplatin (r_nmod) uptake_13\NN\13440063|the|and|cytotoxicity|copper (r_dobj) increased_11\VBD\169651|expression|uptake|,|comparison|. (l_nsubj) expression_1\NN\4679549|heterologous|rctr1|cells (l_nmod) cells_6\NNS\3080309|in|hek293|cells (l_appos) cells_9\NNS\3080309|(|hek/rctr1|) (l_compound) hek/rctr1_8\NN\1740|
T23_T39 CPR:9 carboplatin_23\NN\1740| (r_conj) copper_17\NN\14821043|of|,|oxaliplatin|,|cisplatin|and|carboplatin (r_nmod) uptake_13\NN\13440063|the|and|cytotoxicity|copper (r_dobj) increased_11\VBD\169651|expression|uptake|,|comparison|. (l_nsubj) expression_1\NN\4679549|heterologous|rctr1|cells (l_nmod) rctr1_3\NN\1740|of
T23_T40 CPR:9 carboplatin_23\NN\1740| (r_conj) copper_17\NN\14821043|of|,|oxaliplatin|,|cisplatin|and|carboplatin (r_nmod) uptake_13\NN\13440063|the|and|cytotoxicity|copper (r_dobj) increased_11\VBD\169651|expression|uptake|,|comparison|. (l_nsubj) expression_1\NN\4679549|heterologous|rctr1|cells (l_nmod) cells_6\NNS\3080309|in|hek293|cells (l_appos) cells_9\NNS\3080309|(|hek/rctr1|) (l_compound) hek/rctr1_8\NN\1740|
T24_T41 CPR:9 copper_25\NN\14821043| (r_dobj) taking_23\VBG\2367363|for|up|copper (r_acl) capacity_21\NN\5202497|substantial|taking (r_dobj) displayed_19\VBD\2137132|capacity|,|but|resistant (r_conj) expressed_5\VBD\928630|neurons|endogenously|protein|membranes|,|and|displayed|. (l_dobj) protein_7\NN\14944888|rctr1 (l_compound) rctr1_6\NN\1740|
T25_T41 NONE copper_31\NN\14821043| (r_compound) toxicity_32\NN\13576101|to|copper (r_nmod) resistant_29\JJ\1740|were|toxicity (r_conj) displayed_19\VBD\2137132|capacity|,|but|resistant (r_conj) expressed_5\VBD\928630|neurons|endogenously|protein|membranes|,|and|displayed|. (l_dobj) protein_7\NN\14944888|rctr1 (l_compound) rctr1_6\NN\1740|
T1_T30 NONE zinc_23\NN\14625458| (r_conj) temperature_19\NN\13575869|by|cold|,|silver|and|zinc|, (r_nmod) inhibited_16\VBN\2510337|temperature (r_conj) saturable_14\JJ\1740|uptake|was|and|inhibited|consistent|. (l_advmod) consistent_25\JJ\1740|mediated (l_advcl) mediated_29\VBN\761713|with|it|being|rctr1 (l_nmod) rctr1_31\NN\1740|by
T1_T42 NONE zinc_23\NN\14625458| (r_conj) temperature_19\NN\13575869|by|cold|,|silver|and|zinc|, (r_nmod) inhibited_16\VBN\2510337|temperature (r_conj) saturable_14\JJ\1740|uptake|was|and|inhibited|consistent|. (l_nsubj) uptake_1\NN\13440063|the|copper|neurons (l_nmod) neurons_9\NNS\5430628|by|both|cultured|rat|drg|and|cells (l_conj) cells_12\NNS\3080309|hek/rctr1 (l_compound) hek/rctr1_11\NN\1740|
T26_T30 NONE copper_3\NN\14821043|of (r_nmod) uptake_1\NN\13440063|the|copper|neurons (r_nsubj) saturable_14\JJ\1740|uptake|was|and|inhibited|consistent|. (l_advmod) consistent_25\JJ\1740|mediated (l_advcl) mediated_29\VBN\761713|with|it|being|rctr1 (l_nmod) rctr1_31\NN\1740|by
T26_T42 CPR:9 copper_3\NN\14821043|of (r_nmod) uptake_1\NN\13440063|the|copper|neurons (l_nmod) neurons_9\NNS\5430628|by|both|cultured|rat|drg|and|cells (l_conj) cells_12\NNS\3080309|hek/rctr1 (l_compound) hek/rctr1_11\NN\1740|
T27_T30 NONE silver_21\NN\14821043| (r_conj) temperature_19\NN\13575869|by|cold|,|silver|and|zinc|, (r_nmod) inhibited_16\VBN\2510337|temperature (r_conj) saturable_14\JJ\1740|uptake|was|and|inhibited|consistent|. (l_advmod) consistent_25\JJ\1740|mediated (l_advcl) mediated_29\VBN\761713|with|it|being|rctr1 (l_nmod) rctr1_31\NN\1740|by
T27_T42 NONE silver_21\NN\14821043| (r_conj) temperature_19\NN\13575869|by|cold|,|silver|and|zinc|, (r_nmod) inhibited_16\VBN\2510337|temperature (r_conj) saturable_14\JJ\1740|uptake|was|and|inhibited|consistent|. (l_nsubj) uptake_1\NN\13440063|the|copper|neurons (l_nmod) neurons_9\NNS\5430628|by|both|cultured|rat|drg|and|cells (l_conj) cells_12\NNS\3080309|hek/rctr1 (l_compound) hek/rctr1_11\NN\1740|
T5_T31 NONE platinum_3\NN\14627081|of (r_nmod) accumulation_1\NN\13497135|the|platinum|neurons (l_nmod) neurons_9\NNS\5430628|by|both|cultured|rat|drg|and|cells (l_conj) cells_12\NNS\3080309|hek/rctr1 (l_compound) hek/rctr1_11\NN\1740|
T5_T32 NONE platinum_3\NN\14627081|of (r_nmod) accumulation_1\NN\13497135|the|platinum|neurons (r_nsubj) saturable_19\JJ\1740|accumulation|,|exposure|,|was|and|dependent|,|but|inhibited|. (l_conj) inhibited_26\VBN\2510337|was|copper|cells (l_nmod) cells_32\NNS\3080309|only|in|hek/rctr1 (l_compound) hek/rctr1_31\NN\1740|
T6_T31 NONE oxaliplatin_15\NN\1740| (r_compound) exposure_16\NN\5042871|during|oxaliplatin (r_nmod) saturable_19\JJ\1740|accumulation|,|exposure|,|was|and|dependent|,|but|inhibited|. (l_nsubj) accumulation_1\NN\13497135|the|platinum|neurons (l_nmod) neurons_9\NNS\5430628|by|both|cultured|rat|drg|and|cells (l_conj) cells_12\NNS\3080309|hek/rctr1 (l_compound) hek/rctr1_11\NN\1740|
T6_T32 NONE oxaliplatin_15\NN\1740| (r_compound) exposure_16\NN\5042871|during|oxaliplatin (r_nmod) saturable_19\JJ\1740|accumulation|,|exposure|,|was|and|dependent|,|but|inhibited|. (l_conj) inhibited_26\VBN\2510337|was|copper|cells (l_nmod) cells_32\NNS\3080309|only|in|hek/rctr1 (l_compound) hek/rctr1_31\NN\1740|
T7_T31 NONE copper_28\NN\14821043|by (r_nmod) inhibited_26\VBN\2510337|was|copper|cells (r_conj) saturable_19\JJ\1740|accumulation|,|exposure|,|was|and|dependent|,|but|inhibited|. (l_nsubj) accumulation_1\NN\13497135|the|platinum|neurons (l_nmod) neurons_9\NNS\5430628|by|both|cultured|rat|drg|and|cells (l_conj) cells_12\NNS\3080309|hek/rctr1 (l_compound) hek/rctr1_11\NN\1740|
T7_T32 NONE copper_28\NN\14821043|by (r_nmod) inhibited_26\VBN\2510337|was|copper|cells (l_nmod) cells_32\NNS\3080309|only|in|hek/rctr1 (l_compound) hek/rctr1_31\NN\1740|
T10_T33 CPR:9 platinum_8\NN\14627081| (r_compound) drugs_9\NNS\14778436|platinum (r_conj) copper_6\NN\14821043|and|drugs (r_dobj) transport_5\VB\1850315|conclusion|,|rctr1|can|copper|,|and|sensitizes|. (l_nsubj) rctr1_3\NNP\1740|
T9_T33 CPR:9 copper_6\NN\14821043|and|drugs (r_dobj) transport_5\VB\1850315|conclusion|,|rctr1|can|copper|,|and|sensitizes|. (l_nsubj) rctr1_3\NNP\1740|
T11_T34 CPR:9 copper_7\NN\14821043| (r_dobj) accumulating_6\VBG\2281093|for|copper|process (l_nmod) process_11\NN\407535|via|a|transport|mediated (l_acl) mediated_12\VBN\761713|rctr1 (l_nmod) rctr1_14\NN\1740|by
T12_T34 NONE copper_21\NN\14821043| (r_compound) toxicity_22\NN\13576101|copper (r_dobj) resist_20\VB\2723232|to|toxicity|and|use (r_xcomp) able_18\JJ\1740|resist (r_xcomp) appear_17\VBP\2604760|able (r_conj) display_2\VBP\2137132|neurons|capacity|,|but|appear|. (l_dobj) capacity_4\NN\5202497|substantial|accumulating (l_acl) accumulating_6\VBG\2281093|for|copper|process (l_nmod) process_11\NN\407535|via|a|transport|mediated (l_acl) mediated_12\VBN\761713|rctr1 (l_nmod) rctr1_14\NN\1740|by
T13_T34 CPR:9 oxaliplatin_30\NN\1740| (r_dobj) take_28\VB\2367363|to|up|oxaliplatin (r_xcomp) use_24\VB\1156834|mechanisms|take (r_conj) resist_20\VB\2723232|to|toxicity|and|use (r_xcomp) able_18\JJ\1740|resist (r_xcomp) appear_17\VBP\2604760|able (r_conj) display_2\VBP\2137132|neurons|capacity|,|but|appear|. (l_dobj) capacity_4\NN\5202497|substantial|accumulating (l_acl) accumulating_6\VBG\2281093|for|copper|process (l_nmod) process_11\NN\407535|via|a|transport|mediated (l_acl) mediated_12\VBN\761713|rctr1 (l_nmod) rctr1_14\NN\1740|by
17367165
T19_T37 NONE +_16\NN\1740| (r_compound) affinity_17\NN\11426530|ca2|+ (r_dobj) enhance_14\VBP\227165|pools|affinity|. (r_dep) mechanism_0\NN\13446390|targeting|:|enhance (l_nmod) targeting_4\NN\1740|of|specific|membrane|domains (l_nmod) domains_7\NNS\13934596|by|c2
T8_T23 CPR:3 +_13\NN\1740| (r_compound) binding_14\NN\4688246|by|ca2|+ (r_nmod) activated_10\VBN\1641914|exists|,|domains|are|binding|and|dock|. (l_nsubjpass) domains_8\NNS\13934596|most|c2
T11_T27 NONE +_33\NN\1740| (r_compound) signal_34\NN\33020|during|an|intracellular|ca2|+ (r_nmod) dock_24\VB\2016523|to|surfaces|signal (r_xcomp) known_22\VBN\2110220|domains|,|example|,|are|dock|. (l_nsubjpass) domains_2\NNS\13934596|the|c2|calpha
T11_T28 NONE +_33\NN\1740| (r_compound) signal_34\NN\33020|during|an|intracellular|ca2|+ (r_nmod) dock_24\VB\2016523|to|surfaces|signal (r_xcomp) known_22\VBN\2110220|domains|,|example|,|are|dock|. (l_nsubjpass) domains_2\NNS\13934596|the|c2|calpha (l_nmod) calpha_6\NN\1740|of|protein|kinase|pkcalpha|and|a2alpha
T11_T29 NONE +_33\NN\1740| (r_compound) signal_34\NN\33020|during|an|intracellular|ca2|+ (r_nmod) dock_24\VB\2016523|to|surfaces|signal (r_xcomp) known_22\VBN\2110220|domains|,|example|,|are|dock|. (l_nsubjpass) domains_2\NNS\13934596|the|c2|calpha (l_nmod) calpha_6\NN\1740|of|protein|kinase|pkcalpha|and|a2alpha (l_appos) pkcalpha_8\NN\1740|(|)
T11_T30 NONE +_33\NN\1740| (r_compound) signal_34\NN\33020|during|an|intracellular|ca2|+ (r_nmod) dock_24\VB\2016523|to|surfaces|signal (r_xcomp) known_22\VBN\2110220|domains|,|example|,|are|dock|. (l_nsubjpass) domains_2\NNS\13934596|the|c2|calpha (l_nmod) calpha_6\NN\1740|of|protein|kinase|pkcalpha|and|a2alpha (l_conj) a2alpha_13\NN\1740|cytosolic|phospholipase|cpla2alpha
T11_T31 NONE +_33\NN\1740| (r_compound) signal_34\NN\33020|during|an|intracellular|ca2|+ (r_nmod) dock_24\VB\2016523|to|surfaces|signal (r_xcomp) known_22\VBN\2110220|domains|,|example|,|are|dock|. (l_nsubjpass) domains_2\NNS\13934596|the|c2|calpha (l_nmod) calpha_6\NN\1740|of|protein|kinase|pkcalpha|and|a2alpha (l_conj) a2alpha_13\NN\1740|cytosolic|phospholipase|cpla2alpha (l_appos) cpla2alpha_15\NN\1740|(|)
T12_T34 NONE +_1\NN\1740| (r_compound) activation_2\NN\13561719|ca2|+ (r_nsubj) targets_3\VBZ\1151110|activation|domain|membrane|and|domain|membranes|,|overlap|. (l_dobj) domain_7\NN\13934596|the|pkcalpha|c2
T12_T35 NONE +_1\NN\1740| (r_compound) activation_2\NN\13561719|ca2|+ (r_nsubj) targets_3\VBZ\1151110|activation|domain|membrane|and|domain|membranes|,|overlap|. (l_conj) domain_16\NN\13934596|the|cpla2alpha|c2
T14_T20 NONE +_12\NN\1740| (r_compound) levels_13\NNS\4916342|in|the|presence|of|physiological|ca2|+ (r_nmod) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_xcomp) recruit_31\VB\2471690|to|domain|mixture (l_dobj) domain_35\NN\13934596|the|pkcalpha|c2
T14_T36 NONE +_12\NN\1740| (r_compound) levels_13\NNS\4916342|in|the|presence|of|physiological|ca2|+ (r_nmod) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_nmod) domain_5\NN\13934596|for|the|isolated|pkcalpha|c2
T15_T20 NONE phosphatidylserine_18\NN\1740|ps|and|phosphatidylinositol-4,5-bisphosphate (r_dep) lipids_17\NNS\14944888|the|target|phosphatidylserine (r_nsubj) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_xcomp) recruit_31\VB\2471690|to|domain|mixture (l_dobj) domain_35\NN\13934596|the|pkcalpha|c2
T15_T36 NONE phosphatidylserine_18\NN\1740|ps|and|phosphatidylinositol-4,5-bisphosphate (r_dep) lipids_17\NNS\14944888|the|target|phosphatidylserine (r_nsubj) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_nmod) domain_5\NN\13934596|for|the|isolated|pkcalpha|c2
T16_T20 NONE ps_20\NN\6763273|(|) (r_appos) phosphatidylserine_18\NN\1740|ps|and|phosphatidylinositol-4,5-bisphosphate (r_dep) lipids_17\NNS\14944888|the|target|phosphatidylserine (r_nsubj) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_xcomp) recruit_31\VB\2471690|to|domain|mixture (l_dobj) domain_35\NN\13934596|the|pkcalpha|c2
T16_T36 NONE ps_20\NN\6763273|(|) (r_appos) phosphatidylserine_18\NN\1740|ps|and|phosphatidylinositol-4,5-bisphosphate (r_dep) lipids_17\NNS\14944888|the|target|phosphatidylserine (r_nsubj) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_nmod) domain_5\NN\13934596|for|the|isolated|pkcalpha|c2
T17_T20 NONE phosphatidylinositol-4,5-bisphosphate_23\NN\1740|pip2 (r_conj) phosphatidylserine_18\NN\1740|ps|and|phosphatidylinositol-4,5-bisphosphate (r_dep) lipids_17\NNS\14944888|the|target|phosphatidylserine (r_nsubj) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_xcomp) recruit_31\VB\2471690|to|domain|mixture (l_dobj) domain_35\NN\13934596|the|pkcalpha|c2
T17_T36 NONE phosphatidylinositol-4,5-bisphosphate_23\NN\1740|pip2 (r_conj) phosphatidylserine_18\NN\1740|ps|and|phosphatidylinositol-4,5-bisphosphate (r_dep) lipids_17\NNS\14944888|the|target|phosphatidylserine (r_nsubj) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_nmod) domain_5\NN\13934596|for|the|isolated|pkcalpha|c2
T18_T20 NONE pip2_25\NN\1740|(|) (r_appos) phosphatidylinositol-4,5-bisphosphate_23\NN\1740|pip2 (r_conj) phosphatidylserine_18\NN\1740|ps|and|phosphatidylinositol-4,5-bisphosphate (r_dep) lipids_17\NNS\14944888|the|target|phosphatidylserine (r_nsubj) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_xcomp) recruit_31\VB\2471690|to|domain|mixture (l_dobj) domain_35\NN\13934596|the|pkcalpha|c2
T18_T36 NONE pip2_25\NN\1740|(|) (r_appos) phosphatidylinositol-4,5-bisphosphate_23\NN\1740|pip2 (r_conj) phosphatidylserine_18\NN\1740|ps|and|phosphatidylinositol-4,5-bisphosphate (r_dep) lipids_17\NNS\14944888|the|target|phosphatidylserine (r_nsubj) sufficient_29\JJ\1740|domain|levels|,|lipids|are|together|recruit|. (l_nmod) domain_5\NN\13934596|for|the|isolated|pkcalpha|c2
T1_T21 NONE phosphatidylcholine_9\NN\1740|the|target|lipid|pc (r_nsubj) appears_13\VBZ\2604760|domain|,|phosphatidylcholine|sufficient|,|rule|. (l_nmod) domain_4\NN\13934596|for|the|cpla2alpha|c2
T2_T21 NONE pc_11\NN\3196324|(|) (r_appos) phosphatidylcholine_9\NN\1740|the|target|lipid|pc (r_nsubj) appears_13\VBZ\2604760|domain|,|phosphatidylcholine|sufficient|,|rule|. (l_nmod) domain_4\NN\13934596|for|the|cpla2alpha|c2
T3_T21 NONE +_29\NN\1740| (r_compound) levels_30\NNS\4916342|at|physiological|ca2|+ (r_nmod) drive_18\VB\1224744|to|targeting|mimic|levels (r_xcomp) sufficient_16\JJ\1740|to|be|drive (r_xcomp) appears_13\VBZ\2604760|domain|,|phosphatidylcholine|sufficient|,|rule|. (l_nmod) domain_4\NN\13934596|for|the|cpla2alpha|c2
T5_T22 NONE +_17\NN\1740|and|lipids (r_punct) ca2_16\NN\1740|(|+|) (r_dep) signals_14\NNS\33020|of|multiple|ca2 (r_nmod) detection_11\NN\5708432|coincidence|signals (r_dobj) requires_9\VBZ\754942|which|detection (r_acl:relcl) targeting_6\NN\1740|domain-directed|intracellular|,|requires|, (l_amod) domain-directed_4\JJ\1740|c2
T6_T24 NONE +_17\NN\1740| (r_compound) affinity_18\NN\11426530|the|domain|ca2|+ (r_nsubj) low_21\JJ\1740|which|affinity|is|too|activated (r_acl:relcl) mechanism_9\NN\13446390|the|tama|,|low (r_dobj) utilize_6\VBP\161225|domains|mechanism|. (l_nsubj) domains_2\NNS\13934596|the|c2|studied|both
T6_T25 NONE +_17\NN\1740| (r_compound) affinity_18\NN\11426530|the|domain|ca2|+ (l_compound) domain_15\NN\13934596|c2
T7_T24 NONE +_28\NN\1740| (r_compound) signals_29\NNS\33020|by|physiological|ca2|+|regions (r_nmod) activated_24\VBN\1641914|to|be|signals (r_xcomp) low_21\JJ\1740|which|affinity|is|too|activated (r_acl:relcl) mechanism_9\NN\13446390|the|tama|,|low (r_dobj) utilize_6\VBP\161225|domains|mechanism|. (l_nsubj) domains_2\NNS\13934596|the|c2|studied|both
T7_T25 NONE +_28\NN\1740| (r_compound) signals_29\NNS\33020|by|physiological|ca2|+|regions (r_nmod) activated_24\VBN\1641914|to|be|signals (r_xcomp) low_21\JJ\1740|which|affinity|is|too|activated (l_nsubj) affinity_18\NN\11426530|the|domain|ca2|+ (l_compound) domain_15\NN\13934596|c2
T10_T26 NONE +_39\NN\1740| (r_compound) activation_40\NN\13561719|substantial|ca2|+|and|docking (r_dobj) enables_36\VBZ\126264|that|activation (r_acl:relcl) level_34\NN\4916342|to|a|enables (r_nmod) increased_26\VBN\169651|equilibrium|level (r_acl) affinity_25\NN\11426530|the|effective|ca2|+|increased (r_nsubj) only_0\RB\1740|nears|is|affinity (l_advcl) nears_5\VBZ\1849221|when|domain|membrane|, (l_nsubj) domain_4\NN\13934596|the|c2
T9_T26 NONE +_24\NN\1740| (r_compound) affinity_25\NN\11426530|the|effective|ca2|+|increased (r_nsubj) only_0\RB\1740|nears|is|affinity (l_advcl) nears_5\VBZ\1849221|when|domain|membrane|, (l_nsubj) domain_4\NN\13934596|the|c2
1665782
T17_T27 NONE [d-pen2,d-pen5]enkephalin_3\NN\1740|of (r_nmod) effect_1\NN\34213|chronic|[d-pen2,d-pen5]enkephalin|receptors|. (l_nmod) receptors_8\NNS\5225602|on|brain|opioid
T10_T20 NONE etorphine_9\NN\1740|chronic|or|[d-ala2,d-leu5]enkephalin (r_compound) treatment_15\NN\654885|etorphine|rats (r_nsubj) results_18\VBZ\2633881|that|treatment|reduction|develops (l_nmod) reduction_21\NN\351485|in|the|activities (l_nmod) activities_28\NNS\30358|mu-|receptor|binding (l_compound) receptor_26\NN\5225602|
T13_T20 NONE [d-ala2,d-leu5]enkephalin_11\NN\1740|dadle (r_conj) etorphine_9\NN\1740|chronic|or|[d-ala2,d-leu5]enkephalin (r_compound) treatment_15\NN\654885|etorphine|rats (r_nsubj) results_18\VBZ\2633881|that|treatment|reduction|develops (l_nmod) reduction_21\NN\351485|in|the|activities (l_nmod) activities_28\NNS\30358|mu-|receptor|binding (l_compound) receptor_26\NN\5225602|
T16_T20 NONE dadle_13\NN\1740|(|) (r_appos) [d-ala2,d-leu5]enkephalin_11\NN\1740|dadle (r_conj) etorphine_9\NN\1740|chronic|or|[d-ala2,d-leu5]enkephalin (r_compound) treatment_15\NN\654885|etorphine|rats (r_nsubj) results_18\VBZ\2633881|that|treatment|reduction|develops (l_nmod) reduction_21\NN\351485|in|the|activities (l_nmod) activities_28\NNS\30358|mu-|receptor|binding (l_compound) receptor_26\NN\5225602|
T7_T24 NONE etorphine_2\NN\1740|both|and|dadle (r_nsubj) ligands_9\NNS\20090|as|etorphine|are|non-specific|opioid|,|interacting (l_advcl) interacting_11\VBG\2367363|mu- (l_nmod) mu-_14\NN\1740|with|both|and|delta-receptors (l_conj) delta-receptors_16\NNS\1740|
T8_T24 NONE dadle_4\NN\1740| (r_conj) etorphine_2\NN\1740|both|and|dadle (r_nsubj) ligands_9\NNS\20090|as|etorphine|are|non-specific|opioid|,|interacting (l_advcl) interacting_11\VBG\2367363|mu- (l_nmod) mu-_14\NN\1740|with|both|and|delta-receptors (l_conj) delta-receptors_16\NNS\1740|
T11_T25 CPR:5 dpdpe_18\NN\1740|(|) (r_appos) [d-pen2,d-pen5]enkephalin_16\NN\1740|dpdpe (r_dep) agonist_15\NN\9613191|to|the|receptor-selective|[d-pen2,d-pen5]enkephalin (l_amod) receptor-selective_14\JJ\1740|delta-opioid
T9_T25 CPR:5 [d-pen2,d-pen5]enkephalin_16\NN\1740|dpdpe (r_dep) agonist_15\NN\9613191|to|the|receptor-selective|[d-pen2,d-pen5]enkephalin (l_amod) receptor-selective_14\JJ\1740|delta-opioid
T15_T26 NONE [3h]dpdpe_7\NN\1740| (r_dobj) using_6\VBG\1156834|by|[3h]dpdpe (r_advcl) determined_4\VBN\1645601|when|binding|was|using (l_nsubjpass) binding_2\NN\4688246|delta-receptor (l_amod) delta-receptor_1\NN\1740|
T1_T26 NONE dpdpe_42\NN\1740| (r_compound) treatment_43\NN\654885|of|dpdpe (r_nmod) days_40\NNS\15140892|after|3|treatment (r_nmod) observed_35\VBN\2163746|determined|,|decrease|were|days|. (l_advcl) determined_4\VBN\1645601|when|binding|was|using (l_nsubjpass) binding_2\NN\4688246|delta-receptor (l_amod) delta-receptor_1\NN\1740|
T3_T18 NONE [3h]tyr-d-ala-gly-mephe-gly-ol_11\NN\1740|damgo (r_dobj) using_10\VBG\1156834|by|[3h]tyr-d-ala-gly-mephe-gly-ol (r_advcl) determined_8\VBN\1645601|when|binding|was|using (l_nsubjpass) binding_6\NN\4688246|mu-receptor (l_compound) mu-receptor_5\NN\1740|
T4_T18 NONE damgo_13\NN\1740|(|) (r_appos) [3h]tyr-d-ala-gly-mephe-gly-ol_11\NN\1740|damgo (r_dobj) using_10\VBG\1156834|by|[3h]tyr-d-ala-gly-mephe-gly-ol (r_advcl) determined_8\VBN\1645601|when|binding|was|using (l_nsubjpass) binding_6\NN\4688246|mu-receptor (l_compound) mu-receptor_5\NN\1740|
T5_T18 NONE dpdpe_36\NN\1740| (r_compound) treatment_37\NN\654885|of|dpdpe (r_nmod) days_34\NNS\15140892|after|4|treatment (r_nmod) observed_26\VBN\2163746|surprise|,|determined|,|decrease|was|also|midbrain|days|. (l_advcl) determined_8\VBN\1645601|when|binding|was|using (l_nsubjpass) binding_6\NN\4688246|mu-receptor (l_compound) mu-receptor_5\NN\1740|
T6_T19 CPR:4 dpdpe_5\NN\1740| (r_compound) treatment_6\NN\654885|chronic|dpdpe (r_nsubj) reduces_8\VBZ\441445|that|treatment|preferentially|activity (l_dobj) activity_12\NN\30358|receptor|binding (l_compound) receptor_10\NN\5225602|delta-opioid
12623106
T15_T23 NONE norepinephrine_15\NN\14807929| (r_compound) transporter_16\NN\4490091|of|the|norepinephrine
T10_T18 NONE norepinephrine_15\NN\14807929| (r_compound) transporter_16\NN\4490091|for|the|norepinephrine|net
T10_T19 NONE norepinephrine_15\NN\14807929| (r_compound) transporter_16\NN\4490091|for|the|norepinephrine|net (l_appos) net_18\NN\3085333|(|)
T9_T18 NONE reboxetine_6\NN\2718811|of|,|ligand (l_appos) ligand_12\NN\20090|a|potent|transporter (l_nmod) transporter_16\NN\4490091|for|the|norepinephrine|net
T9_T19 NONE reboxetine_6\NN\2718811|of|,|ligand (l_appos) ligand_12\NN\20090|a|potent|transporter (l_nmod) transporter_16\NN\4490091|for|the|norepinephrine|net (l_appos) net_18\NN\3085333|(|)
T7_T16 NONE s)-[(11)c]-mener_12\NN\1740| (r_dep) (s_10\-LRB-\1740|with|,|s)-[(11)c]-mener (r_nmod) studies_3\NNS\635850|in|autoradiography|slices|(s (r_nsubj) produced_13\VBD\1617192|studies|pattern|. (l_dobj) pattern_17\NN\5726345|a|regional|distribution|consistent (l_acl:relcl) consistent_20\JJ\1740|that|was|distribution (l_nmod) distribution_24\NN\5726596|with|the|reported|net (l_nmod) net_26\NN\3085333|of
T8_T17 NONE s)-[(11)c]-mener_2\NN\1740|(s|, (r_nsubj) has_3\VBZ\2108377|s)-[(11)c]-mener|potential|. (l_dobj) potential_5\NN\14481929|the|be (l_acl) be_7\VB\836236|to|ligand (l_attr) ligand_12\NN\20090|the|first|successful|pet|net (l_nmod) net_15\NN\3085333|image
23385325
T6_T11 NONE acids_14\NNS\14818238|of|buried|aspartic|bacteriorhodopsin (l_nmod) bacteriorhodopsin_16\NN\1740|in|and|channelrhodopsin-2
T6_T12 NONE acids_14\NNS\14818238|of|buried|aspartic|bacteriorhodopsin (l_nmod) bacteriorhodopsin_16\NN\1740|in|and|channelrhodopsin-2 (l_conj) channelrhodopsin-2_18\NNP\1740|
8384716
T22_T45 NONE 5-hydroxytryptamine_10\NN\14807737| (r_compound) genes_12\NNS\8459252|of|5-ht1e-like|rat|5-hydroxytryptamine|receptor (l_amod) 5-ht1e-like_6\JJ\1740|
T22_T46 NONE 5-hydroxytryptamine_10\NN\14807737| (r_compound) genes_12\NNS\8459252|of|5-ht1e-like|rat|5-hydroxytryptamine|receptor (l_compound) receptor_11\NN\5225602|
T1_T24 NONE nucleotide-binding_15\JJ\1740|guanine (r_amod) receptor_18\NN\5225602|a|nucleotide-binding|protein|(g-protein)-coupled|cdna
T14_T35 NONE oligonucleotides_1\NNS\1740|degenerate|corresponding (l_acl) corresponding_2\VBG\2664769|acids (l_nmod) acids_6\NNS\14818238|to|conserved|amino|domains (l_nmod) domains_9\NNS\13934596|from|transmembrane|iii|receptors (l_nmod) receptors_18\NNS\5225602|of|known|5-ht1a (l_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|]
T14_T36 NONE oligonucleotides_1\NNS\1740|degenerate|corresponding (l_acl) corresponding_2\VBG\2664769|acids (l_nmod) acids_6\NNS\14818238|to|conserved|amino|domains (l_nmod) domains_9\NNS\13934596|from|transmembrane|iii|receptors (l_nmod) receptors_18\NNS\5225602|of|known|5-ht1a (l_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht1c_22\NN\1740|
T14_T37 NONE oligonucleotides_1\NNS\1740|degenerate|corresponding (l_acl) corresponding_2\VBG\2664769|acids (l_nmod) acids_6\NNS\14818238|to|conserved|amino|domains (l_nmod) domains_9\NNS\13934596|from|transmembrane|iii|receptors (l_nmod) receptors_18\NNS\5225602|of|known|5-ht1a (l_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht2_25\NN\1740|
T15_T35 NONE acids_6\NNS\14818238|to|conserved|amino|domains (l_nmod) domains_9\NNS\13934596|from|transmembrane|iii|receptors (l_nmod) receptors_18\NNS\5225602|of|known|5-ht1a (l_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|]
T15_T36 NONE acids_6\NNS\14818238|to|conserved|amino|domains (l_nmod) domains_9\NNS\13934596|from|transmembrane|iii|receptors (l_nmod) receptors_18\NNS\5225602|of|known|5-ht1a (l_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht1c_22\NN\1740|
T15_T37 NONE acids_6\NNS\14818238|to|conserved|amino|domains (l_nmod) domains_9\NNS\13934596|from|transmembrane|iii|receptors (l_nmod) receptors_18\NNS\5225602|of|known|5-ht1a (l_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht2_25\NN\1740|
T16_T35 NONE 5-ht_27\NN\1740| (r_nsubj) serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|]
T16_T36 NONE 5-ht_27\NN\1740| (r_nsubj) serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht1c_22\NN\1740|
T16_T37 NONE 5-ht_27\NN\1740| (r_nsubj) serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht2_25\NN\1740|
T17_T35 NONE serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|]
T17_T36 NONE serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht1c_22\NN\1740|
T17_T37 NONE serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht2_25\NN\1740|
T18_T35 NONE 5-hydroxytryptamine_31\NN\14807737|(|) (r_appos) serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|]
T18_T36 NONE 5-hydroxytryptamine_31\NN\14807737|(|) (r_appos) serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht1c_22\NN\1740|
T18_T37 NONE 5-hydroxytryptamine_31\NN\14807737|(|) (r_appos) serotonin_29\NN\14807737|5-ht|is|5-hydroxytryptamine (r_dep) 5-ht1a_20\NN\1740|[|,|5-ht1c|,|and|5-ht2|;|serotonin|] (l_conj) 5-ht2_25\NN\1740|
T19_T38 NONE acid_30\NN\14818238| (r_compound) protein_33\NN\14944888|a|366-amino|acid|seven-transmembrane|domain (r_dobj) encoding_27\VBG\115157|protein (r_acl) frame_26\NN\3391770|an|intronless|open|reading|encoding (r_dobj) containing_21\VBG\2632940|frame (r_acl) clone_17\NN\10027246|a|full-length|mr77|containing (l_appos) mr77_19\NN\1740|(|)
T19_T39 NONE acid_30\NN\14818238| (r_compound) protein_33\NN\14944888|a|366-amino|acid|seven-transmembrane|domain (r_dobj) encoding_27\VBG\115157|protein (r_acl) frame_26\NN\3391770|an|intronless|open|reading|encoding
T19_T40 NONE acid_30\NN\14818238| (r_compound) protein_33\NN\14944888|a|366-amino|acid|seven-transmembrane|domain
T21_T41 NONE acid_23\NN\14818238| (r_compound) identity_24\NN\4617562|amino|acid (r_conj) %_11\NN\1740|52|,|%|,|%|,|and|%|identity (r_dobj) exhibit_8\VBP\2632167|domains|,|sequences|%|5-ht1a|respectively|. (l_nmod) 5-ht1a_29\NN\1740|with|the|known|rat|,|5-ht1b|,|5-ht1d|,|and|receptors|,
T21_T42 NONE acid_23\NN\14818238| (r_compound) identity_24\NN\4617562|amino|acid (r_conj) %_11\NN\1740|52|,|%|,|%|,|and|%|identity (r_dobj) exhibit_8\VBP\2632167|domains|,|sequences|%|5-ht1a|respectively|. (l_nmod) 5-ht1a_29\NN\1740|with|the|known|rat|,|5-ht1b|,|5-ht1d|,|and|receptors|, (l_conj) 5-ht1b_32\NN\1740|rat
T21_T43 NONE acid_23\NN\14818238| (r_compound) identity_24\NN\4617562|amino|acid (r_conj) %_11\NN\1740|52|,|%|,|%|,|and|%|identity (r_dobj) exhibit_8\VBP\2632167|domains|,|sequences|%|5-ht1a|respectively|. (l_nmod) 5-ht1a_29\NN\1740|with|the|known|rat|,|5-ht1b|,|5-ht1d|,|and|receptors|, (l_conj) 5-ht1d_35\NN\1740|rat
T21_T44 NONE acid_23\NN\14818238| (r_compound) identity_24\NN\4617562|amino|acid (r_conj) %_11\NN\1740|52|,|%|,|%|,|and|%|identity (r_dobj) exhibit_8\VBP\2632167|domains|,|sequences|%|5-ht1a|respectively|. (l_nmod) 5-ht1a_29\NN\1740|with|the|known|rat|,|5-ht1b|,|5-ht1d|,|and|receptors|, (l_conj) receptors_40\NNS\5225602|5-ht1e (l_compound) 5-ht1e_39\NN\1740|human
T6_T25 CPR:5 sumatriptan_10\NN\1740| (r_appos) agonist_9\NN\9613191|by|the|selective|5-ht1d|sumatriptan|agonist (l_compound) 5-ht1d_8\NN\1740|
T6_T26 NONE sumatriptan_10\NN\1740| (r_appos) agonist_9\NN\9613191|by|the|selective|5-ht1d|sumatriptan|agonist (l_dep) agonist_17\NN\9613191|not|by|the|mixed|5-ht1a/1d|5-carboxyamidotryptamine (l_compound) 5-ht1a/1d_16\NN\1740|
T7_T25 NONE 5-carboxyamidotryptamine_18\NN\1740| (r_dep) agonist_17\NN\9613191|not|by|the|mixed|5-ht1a/1d|5-carboxyamidotryptamine (r_dep) agonist_9\NN\9613191|by|the|selective|5-ht1d|sumatriptan|agonist (l_compound) 5-ht1d_8\NN\1740|
T7_T26 NONE 5-carboxyamidotryptamine_18\NN\1740| (r_dep) agonist_17\NN\9613191|not|by|the|mixed|5-ht1a/1d|5-carboxyamidotryptamine (l_compound) 5-ht1a/1d_16\NN\1740|
T11_T27 NONE adenylate_10\NN\1740| (r_compound) cyclase_11\NN\1740|of|adenylate (r_nmod) inhibition_8\NN\1068773|cyclase (r_dobj) exhibited_7\VBD\2632167|cells|inhibition|response|. (l_nsubj) cells_1\NNS\3080309|hela|transfected (l_acl) transfected_2\VBN\1740|gene (l_nmod) gene_6\NN\8459252|with|the|mr77 (l_compound) mr77_5\NN\1740|
T11_T28 NONE adenylate_10\NN\1740| (r_compound) cyclase_11\NN\1740|of|adenylate
T12_T27 NONE serotonin_15\NN\14807737|to (r_nmod) response_13\NN\11410625|in|serotonin (r_nmod) exhibited_7\VBD\2632167|cells|inhibition|response|. (l_nsubj) cells_1\NNS\3080309|hela|transfected (l_acl) transfected_2\VBN\1740|gene (l_nmod) gene_6\NN\8459252|with|the|mr77 (l_compound) mr77_5\NN\1740|
T12_T28 CPR:4 serotonin_15\NN\14807737|to (r_nmod) response_13\NN\11410625|in|serotonin (r_nmod) exhibited_7\VBD\2632167|cells|inhibition|response|. (l_dobj) inhibition_8\NN\1068773|cyclase (l_nmod) cyclase_11\NN\1740|of|adenylate
T13_T30 NONE 5-ht_4\NN\1740| (r_compound) receptor_5\NN\5225602|a|5-ht|class (r_dobj) represents_2\VBZ\2664769|mr77|thus|receptor|,|and|propose|. (l_nsubj) mr77_0\NN\1740|
T13_T31 NONE 5-ht_4\NN\1740| (r_compound) receptor_5\NN\5225602|a|5-ht|class
T13_T32 NONE 5-ht_4\NN\1740| (r_compound) receptor_5\NN\5225602|a|5-ht|class (l_nmod) class_9\NN\7951464|of|the|5-ht1 (l_compound) 5-ht1_8\NN\1740|
T13_T33 NONE 5-ht_4\NN\1740| (r_compound) receptor_5\NN\5225602|a|5-ht|class (r_dobj) represents_2\VBZ\2664769|mr77|thus|receptor|,|and|propose|. (l_conj) propose_13\VBP\1010118|we|represents (l_ccomp) represents_23\VBZ\2664769|that|,|characterization|,|mr77|receptor (l_nsubj) mr77_22\NN\1740|
T13_T34 NONE 5-ht_4\NN\1740| (r_compound) receptor_5\NN\5225602|a|5-ht|class (r_dobj) represents_2\VBZ\2664769|mr77|thus|receptor|,|and|propose|. (l_conj) propose_13\VBP\1010118|we|represents (l_ccomp) represents_23\VBZ\2664769|that|,|characterization|,|mr77|receptor (l_dobj) receptor_27\NN\5225602|an|additional|5-ht1e-like (l_amod) 5-ht1e-like_26\JJ\1740|
16763553
T4_T22 NONE ra_2\NN\14625458| (r_compound) level_3\NN\4916342|the|tissue|ra (r_nsubjpass) maintained_5\VBN\2202928|level|is|cascade|. (l_nmod) cascade_8\NN\9475292|through|a|reactions (l_nmod) reactions_11\NNS\13446390|of|metabolic|catalyze (l_acl:relcl) catalyze_18\VBP\146138|where|dehydrogenases|reaction (l_nsubj) dehydrogenases_14\NNS\1740|retinal|raldhs
T4_T23 NONE ra_2\NN\14625458| (r_compound) level_3\NN\4916342|the|tissue|ra (r_nsubjpass) maintained_5\VBN\2202928|level|is|cascade|. (l_nmod) cascade_8\NN\9475292|through|a|reactions (l_nmod) reactions_11\NNS\13446390|of|metabolic|catalyze (l_acl:relcl) catalyze_18\VBP\146138|where|dehydrogenases|reaction (l_nsubj) dehydrogenases_14\NNS\1740|retinal|raldhs (l_appos) raldhs_16\NNS\1740|(|)
T6_T22 NONE retinal_13\NN\14989820| (r_compound) dehydrogenases_14\NNS\1740|retinal|raldhs
T6_T23 NONE retinal_13\NN\14989820| (r_compound) dehydrogenases_14\NNS\1740|retinal|raldhs (l_appos) raldhs_16\NNS\1740|(|)
T7_T22 CPR:9 ra_23\NN\14625458| (r_compound) biosynthesis_24\NN\13565379|of|ra|retinal (r_nmod) reaction_21\NN\13446390|the|terminal|biosynthesis|,|step (r_dobj) catalyze_18\VBP\146138|where|dehydrogenases|reaction (l_nsubj) dehydrogenases_14\NNS\1740|retinal|raldhs
T7_T23 CPR:9 ra_23\NN\14625458| (r_compound) biosynthesis_24\NN\13565379|of|ra|retinal (r_nmod) reaction_21\NN\13446390|the|terminal|biosynthesis|,|step (r_dobj) catalyze_18\VBP\146138|where|dehydrogenases|reaction (l_nsubj) dehydrogenases_14\NNS\1740|retinal|raldhs (l_appos) raldhs_16\NNS\1740|(|)
T8_T22 CPR:9 retinal_26\NN\14989820|from (r_nmod) biosynthesis_24\NN\13565379|of|ra|retinal (r_nmod) reaction_21\NN\13446390|the|terminal|biosynthesis|,|step (r_dobj) catalyze_18\VBP\146138|where|dehydrogenases|reaction (l_nsubj) dehydrogenases_14\NNS\1740|retinal|raldhs
T8_T23 CPR:9 retinal_26\NN\14989820|from (r_nmod) biosynthesis_24\NN\13565379|of|ra|retinal (r_nmod) reaction_21\NN\13446390|the|terminal|biosynthesis|,|step (r_dobj) catalyze_18\VBP\146138|where|dehydrogenases|reaction (l_nsubj) dehydrogenases_14\NNS\1740|retinal|raldhs (l_appos) raldhs_16\NNS\1740|(|)
T10_T24 NONE ra_18\NN\14625458| (r_compound) content_19\NN\7951464|the|cellular|ra (r_conj) expression_9\NN\4679549|the|raldh1|and|genes|and|content|organs (l_conj) genes_14\NNS\8459252|2 (l_nummod) 2_13\CD\13741022|
T9_T24 NONE cholesterol_6\NN\15058310|of (r_nmod) supplement_4\NN\6365467|dietary|cholesterol (r_nsubj) enhanced_7\VBD\227165|that|supplement|expression (l_dobj) expression_9\NN\4679549|the|raldh1|and|genes|and|content|organs (l_conj) genes_14\NNS\8459252|2 (l_nummod) 2_13\CD\13741022|
T11_T25 NONE cholesterol-lowering_3\JJ\1740| (r_amod) agent_4\NN\7347|the|cholesterol-lowering|sodium (r_nsubj) downregulated_9\VBD\1740|consistently|,|agent|expression|. (l_dobj) expression_11\NN\4679549|the|raldh1|organs (l_nmod) raldh1_13\NN\1740|of|and|genes (l_conj) genes_16\NNS\8459252|2 (l_nummod) 2_15\CD\13741022|
T12_T25 NONE sodium_7\NN\14625458|(|pravastatin|) (r_appos) agent_4\NN\7347|the|cholesterol-lowering|sodium (r_nsubj) downregulated_9\VBD\1740|consistently|,|agent|expression|. (l_dobj) expression_11\NN\4679549|the|raldh1|organs (l_nmod) raldh1_13\NN\1740|of|and|genes (l_conj) genes_16\NNS\8459252|2 (l_nummod) 2_15\CD\13741022|
T14_T26 NONE cholesterol_2\NN\15058310| (r_compound) metabolites_3\NNS\20090|cholesterol|,|oxysterols|, (l_appos) oxysterols_7\NNS\1740|predominantly|the|,|ligands (l_appos) ligands_11\NNS\20090|the|natural|receptor (l_nmod) receptor_15\NN\5225602|for|liver|x|lxr
T14_T27 NONE cholesterol_2\NN\15058310| (r_compound) metabolites_3\NNS\20090|cholesterol|,|oxysterols|, (l_appos) oxysterols_7\NNS\1740|predominantly|the|,|ligands (l_appos) ligands_11\NNS\20090|the|natural|receptor (l_nmod) receptor_15\NN\5225602|for|liver|x|lxr (l_appos) lxr_17\NN\1740|(|)
T14_T28 CPR:3 cholesterol_2\NN\15058310| (r_compound) metabolites_3\NNS\20090|cholesterol|,|oxysterols|, (r_nsubj) induced_20\VBD\1627355|further|,|metabolites|genes|upregulation|. (l_nmod) upregulation_24\NN\1740|via|protein-1c (l_nmod) protein-1c_30\NN\1740|of|sterol|regulatory|element|binding|srebp-1c|bound
T14_T29 CPR:3 cholesterol_2\NN\15058310| (r_compound) metabolites_3\NNS\20090|cholesterol|,|oxysterols|, (r_nsubj) induced_20\VBD\1627355|further|,|metabolites|genes|upregulation|. (l_nmod) upregulation_24\NN\1740|via|protein-1c (l_nmod) protein-1c_30\NN\1740|of|sterol|regulatory|element|binding|srebp-1c|bound (l_appos) srebp-1c_32\NN\1740|(|)
T15_T26 NONE oxysterols_7\NNS\1740|predominantly|the|,|ligands (l_appos) ligands_11\NNS\20090|the|natural|receptor (l_nmod) receptor_15\NN\5225602|for|liver|x|lxr
T15_T27 NONE oxysterols_7\NNS\1740|predominantly|the|,|ligands (l_appos) ligands_11\NNS\20090|the|natural|receptor (l_nmod) receptor_15\NN\5225602|for|liver|x|lxr (l_appos) lxr_17\NN\1740|(|)
T15_T28 CPR:3 oxysterols_7\NNS\1740|predominantly|the|,|ligands (r_appos) metabolites_3\NNS\20090|cholesterol|,|oxysterols|, (r_nsubj) induced_20\VBD\1627355|further|,|metabolites|genes|upregulation|. (l_nmod) upregulation_24\NN\1740|via|protein-1c (l_nmod) protein-1c_30\NN\1740|of|sterol|regulatory|element|binding|srebp-1c|bound
T15_T29 CPR:3 oxysterols_7\NNS\1740|predominantly|the|,|ligands (r_appos) metabolites_3\NNS\20090|cholesterol|,|oxysterols|, (r_nsubj) induced_20\VBD\1627355|further|,|metabolites|genes|upregulation|. (l_nmod) upregulation_24\NN\1740|via|protein-1c (l_nmod) protein-1c_30\NN\1740|of|sterol|regulatory|element|binding|srebp-1c|bound (l_appos) srebp-1c_32\NN\1740|(|)
T16_T26 NONE sterol_26\NN\14708720| (r_compound) protein-1c_30\NN\1740|of|sterol|regulatory|element|binding|srebp-1c|bound (r_nmod) upregulation_24\NN\1740|via|protein-1c (r_nmod) induced_20\VBD\1627355|further|,|metabolites|genes|upregulation|. (l_nsubj) metabolites_3\NNS\20090|cholesterol|,|oxysterols|, (l_appos) oxysterols_7\NNS\1740|predominantly|the|,|ligands (l_appos) ligands_11\NNS\20090|the|natural|receptor (l_nmod) receptor_15\NN\5225602|for|liver|x|lxr
T16_T27 NONE sterol_26\NN\14708720| (r_compound) protein-1c_30\NN\1740|of|sterol|regulatory|element|binding|srebp-1c|bound (r_nmod) upregulation_24\NN\1740|via|protein-1c (r_nmod) induced_20\VBD\1627355|further|,|metabolites|genes|upregulation|. (l_nsubj) metabolites_3\NNS\20090|cholesterol|,|oxysterols|, (l_appos) oxysterols_7\NNS\1740|predominantly|the|,|ligands (l_appos) ligands_11\NNS\20090|the|natural|receptor (l_nmod) receptor_15\NN\5225602|for|liver|x|lxr (l_appos) lxr_17\NN\1740|(|)
T16_T28 NONE sterol_26\NN\14708720| (r_compound) protein-1c_30\NN\1740|of|sterol|regulatory|element|binding|srebp-1c|bound
T16_T29 NONE sterol_26\NN\14708720| (r_compound) protein-1c_30\NN\1740|of|sterol|regulatory|element|binding|srebp-1c|bound (l_appos) srebp-1c_32\NN\1740|(|)
7500004
T24_T38 NONE sodium-dependent_0\JJ\1740| (r_amod) currents_2\NNS\11449002|sodium-dependent|norepinephrine-induced|cells (l_nmod) cells_6\NNS\3080309|in|norepinephrine-transporter-transfected|hek-293 (l_amod) norepinephrine-transporter-transfected_4\JJ\1740|
T25_T38 CPR:4 cocaine_9\NN\3492717|by|and|antidepressants (r_nmod) blocked_7\VBN\1476483|currents|cocaine|. (l_nsubj) currents_2\NNS\11449002|sodium-dependent|norepinephrine-induced|cells (l_nmod) cells_6\NNS\3080309|in|norepinephrine-transporter-transfected|hek-293 (l_amod) norepinephrine-transporter-transfected_4\JJ\1740|
T26_T38 CPR:3 norepinephrine-induced_1\JJ\1740| (r_amod) currents_2\NNS\11449002|sodium-dependent|norepinephrine-induced|cells (l_nmod) cells_6\NNS\3080309|in|norepinephrine-transporter-transfected|hek-293 (l_amod) norepinephrine-transporter-transfected_4\JJ\1740|
T27_T38 NONE norepinephrine-transporter-transfected_4\JJ\1740|
T13_T32 NONE catecholamine_5\NN\5407119| (r_compound) transport_6\NN\3575240|between|catecholamine|and|permeation|transporter (l_nmod) transporter_13\NN\4490091|through|the|ne
T13_T33 NONE catecholamine_5\NN\5407119| (r_compound) transport_6\NN\3575240|between|catecholamine|and|permeation|transporter (r_nmod) relationship_3\NN\31921|the|transport (r_dobj) explore_1\VB\789138|to|relationship|,|established (l_parataxis) established_16\VBD\2426171|we|line (l_dobj) line_25\NN\8426461|a|transporter|cell|suitable (l_compound) transporter_20\NN\4490091|human|norepinephrine|hnet
T13_T34 NONE catecholamine_5\NN\5407119| (r_compound) transport_6\NN\3575240|between|catecholamine|and|permeation|transporter (r_nmod) relationship_3\NN\31921|the|transport (r_dobj) explore_1\VB\789138|to|relationship|,|established (l_parataxis) established_16\VBD\2426171|we|line (l_dobj) line_25\NN\8426461|a|transporter|cell|suitable (l_compound) transporter_20\NN\4490091|human|norepinephrine|hnet (l_appos) hnet_22\NN\1740|(|)
T15_T32 NONE ne_12\NN\14622893| (r_compound) transporter_13\NN\4490091|through|the|ne
T15_T33 NONE ne_12\NN\14622893| (r_compound) transporter_13\NN\4490091|through|the|ne (r_nmod) transport_6\NN\3575240|between|catecholamine|and|permeation|transporter (r_nmod) relationship_3\NN\31921|the|transport (r_dobj) explore_1\VB\789138|to|relationship|,|established (l_parataxis) established_16\VBD\2426171|we|line (l_dobj) line_25\NN\8426461|a|transporter|cell|suitable (l_compound) transporter_20\NN\4490091|human|norepinephrine|hnet
T15_T34 NONE ne_12\NN\14622893| (r_compound) transporter_13\NN\4490091|through|the|ne (r_nmod) transport_6\NN\3575240|between|catecholamine|and|permeation|transporter (r_nmod) relationship_3\NN\31921|the|transport (r_dobj) explore_1\VB\789138|to|relationship|,|established (l_parataxis) established_16\VBD\2426171|we|line (l_dobj) line_25\NN\8426461|a|transporter|cell|suitable (l_compound) transporter_20\NN\4490091|human|norepinephrine|hnet (l_appos) hnet_22\NN\1740|(|)
T16_T32 NONE norepinephrine_19\NN\14807929| (r_compound) transporter_20\NN\4490091|human|norepinephrine|hnet (r_compound) line_25\NN\8426461|a|transporter|cell|suitable (r_dobj) established_16\VBD\2426171|we|line (r_parataxis) explore_1\VB\789138|to|relationship|,|established (l_dobj) relationship_3\NN\31921|the|transport (l_nmod) transport_6\NN\3575240|between|catecholamine|and|permeation|transporter (l_nmod) transporter_13\NN\4490091|through|the|ne
T16_T33 NONE norepinephrine_19\NN\14807929| (r_compound) transporter_20\NN\4490091|human|norepinephrine|hnet
T16_T34 NONE norepinephrine_19\NN\14807929| (r_compound) transporter_20\NN\4490091|human|norepinephrine|hnet (l_appos) hnet_22\NN\1740|(|)
T18_T35 NONE na(+)-dependent_47\JJ\1740| (r_amod) transport_48\NN\3575240|2|high-affinity|na(+)-dependent|ne (r_conj) binding_37\NN\4688246|by|radioligand|and|antibodies|,|transport (r_nmod) detected_34\VBN\2163746|as|binding|,|and|sensitivities (r_advcl) exhibiting_16\VBG\2632167|number|,|detected (r_acl) lines_15\NNS\8426461|in|exhibiting (r_nmod) results_13\VBZ\2633881|transfection|lines|. (l_nsubj) transfection_1\NN\1740|stable|cdna|cells (l_nmod) cdna_4\NN\14830364|of|hnet (l_compound) hnet_3\NN\1740|
T18_T36 NONE na(+)-dependent_47\JJ\1740| (r_amod) transport_48\NN\3575240|2|high-affinity|na(+)-dependent|ne (r_conj) binding_37\NN\4688246|by|radioligand|and|antibodies|,|transport (l_conj) antibodies_40\NNS\14728724|hnet-specific (l_amod) hnet-specific_39\JJ\1740|
T19_T35 NONE ne_50\NNS\14622893|of (r_nmod) transport_48\NN\3575240|2|high-affinity|na(+)-dependent|ne (r_conj) binding_37\NN\4688246|by|radioligand|and|antibodies|,|transport (r_nmod) detected_34\VBN\2163746|as|binding|,|and|sensitivities (r_advcl) exhibiting_16\VBG\2632167|number|,|detected (r_acl) lines_15\NNS\8426461|in|exhibiting (r_nmod) results_13\VBZ\2633881|transfection|lines|. (l_nsubj) transfection_1\NN\1740|stable|cdna|cells (l_nmod) cdna_4\NN\14830364|of|hnet (l_compound) hnet_3\NN\1740|
T19_T36 NONE ne_50\NNS\14622893|of (r_nmod) transport_48\NN\3575240|2|high-affinity|na(+)-dependent|ne (r_conj) binding_37\NN\4688246|by|radioligand|and|antibodies|,|transport (l_conj) antibodies_40\NNS\14728724|hnet-specific (l_amod) hnet-specific_39\JJ\1740|
T20_T37 CPR:3 ne-induced_6\JJ\1740| (r_amod) currents_9\NNS\11449002|ne-induced|,|na(+)-dependent|blocked|absent (r_dobj) reveals_5\VBZ\2137132|voltage-clamp|currents|. (l_nsubj) voltage-clamp_1\NN\1740|whole-cell|cells (l_nmod) cells_4\NNS\3080309|of|hnet-293 (l_compound) hnet-293_3\NN\1740|
T21_T37 NONE na(+)-dependent_8\JJ\1740| (r_amod) currents_9\NNS\11449002|ne-induced|,|na(+)-dependent|blocked|absent (r_dobj) reveals_5\VBZ\2137132|voltage-clamp|currents|. (l_nsubj) voltage-clamp_1\NN\1740|whole-cell|cells (l_nmod) cells_4\NNS\3080309|of|hnet-293 (l_compound) hnet-293_3\NN\1740|
T22_T37 CPR:4 cocaine_14\NN\3492717| (r_conj) antidepressants_12\NNS\3740161|by|and|cocaine (r_nmod) blocked_10\VBN\1476483|antidepressants (r_acl) currents_9\NNS\11449002|ne-induced|,|na(+)-dependent|blocked|absent (r_dobj) reveals_5\VBZ\2137132|voltage-clamp|currents|. (l_nsubj) voltage-clamp_1\NN\1740|whole-cell|cells (l_nmod) cells_4\NNS\3080309|of|hnet-293 (l_compound) hnet-293_3\NN\1740|
T1_T28 NONE ne-independent_10\JJ\1740| (r_amod) mode_11\NN\4916342|an|ne-independent|movement (l_nmod) movement_14\NN\191142|of|charge|mediated (l_acl) mediated_15\VBN\761713|hnet (l_nmod) hnet_17\NN\1740|by
T23_T28 NONE ne-dependent_3\JJ\1740| (r_amod) currents_4\NNS\11449002|to|ne-dependent (r_nmod) addition_1\NN\3081021|in|currents (r_nmod) posses_8\VBP\1740|addition|,|cells|mode|. (l_dobj) mode_11\NN\4916342|an|ne-independent|movement (l_nmod) movement_14\NN\191142|of|charge|mediated (l_acl) mediated_15\VBN\761713|hnet (l_nmod) hnet_17\NN\1740|by
T2_T29 NONE ne-dependent_9\JJ\1740|both|and|ne-independent (r_amod) modes_12\NNS\4916342|ne-dependent|movement (r_dobj) abolish_7\VBP\1740|antagonists|modes|. (l_nsubj) antagonists_1\NNS\7846|hnet|effect (l_compound) hnet_0\NN\1740|
T3_T29 NONE ne-independent_11\JJ\1740| (r_conj) ne-dependent_9\JJ\1740|both|and|ne-independent (r_amod) modes_12\NNS\4916342|ne-dependent|movement (r_dobj) abolish_7\VBP\1740|antagonists|modes|. (l_nsubj) antagonists_1\NNS\7846|hnet|effect (l_compound) hnet_0\NN\1740|
T6_T30 CPR:9 ne_22\NN\14622893| (r_compound) transport_23\NN\3575240|to|ne (r_nmod) relating_18\VBG\628491|flux|transport (r_acl) stoichiometry_17\NN\13819207|with|an|indefinite|relating (r_nmod) channels_13\NNS\6251781|as|ion-gated|ligand|stoichiometry (r_nmod) function_9\VBP\2669789|that|hnets|channels (l_nsubj) hnets_8\NNS\1740|
T6_T31 NONE ne_22\NN\14622893| (r_compound) transport_23\NN\3575240|to|ne (r_nmod) relating_18\VBG\628491|flux|transport (r_acl) stoichiometry_17\NN\13819207|with|an|indefinite|relating (r_nmod) channels_13\NNS\6251781|as|ion-gated|ligand|stoichiometry
17100196
17303537
T5_T10 NONE glutathione_2\NN\1740| (r_compound) activity_4\NN\30358|the|increased|glutathione|peroxidase|rats (r_nsubjpass) associated_11\VBN\628491|activity|was|fall|. (l_nmod) fall_14\NN\15236475|with|a|glutathione|and|increase (l_conj) increase_25\NN\13576355|a|marked|activity (l_nmod) activity_30\NN\30358|in|the|glutathione|reductase (l_compound) reductase_29\NN\14732946|
T5_T9 NONE glutathione_2\NN\1740| (r_compound) activity_4\NN\30358|the|increased|glutathione|peroxidase|rats (l_compound) peroxidase_3\NN\14971234|
T6_T10 NONE glutathione_18\NN\1740|of|the|reduced|homogenate (r_nmod) fall_14\NN\15236475|with|a|glutathione|and|increase (l_conj) increase_25\NN\13576355|a|marked|activity (l_nmod) activity_30\NN\30358|in|the|glutathione|reductase (l_compound) reductase_29\NN\14732946|
T6_T9 NONE glutathione_18\NN\1740|of|the|reduced|homogenate (r_nmod) fall_14\NN\15236475|with|a|glutathione|and|increase (r_nmod) associated_11\VBN\628491|activity|was|fall|. (l_nsubjpass) activity_4\NN\30358|the|increased|glutathione|peroxidase|rats (l_compound) peroxidase_3\NN\14971234|
T7_T10 NONE glutathione_28\NN\1740| (r_compound) activity_30\NN\30358|in|the|glutathione|reductase (l_compound) reductase_29\NN\14732946|
T7_T9 NONE glutathione_28\NN\1740| (r_compound) activity_30\NN\30358|in|the|glutathione|reductase (r_nmod) increase_25\NN\13576355|a|marked|activity (r_conj) fall_14\NN\15236475|with|a|glutathione|and|increase (r_nmod) associated_11\VBN\628491|activity|was|fall|. (l_nsubjpass) activity_4\NN\30358|the|increased|glutathione|peroxidase|rats (l_compound) peroxidase_3\NN\14971234|
12837768
T13_T26 NONE desipramine_4\NN\4482543|and|cocaine (r_compound) sites_8\NNS\8673395|desipramine|binding|transporter
T13_T27 NONE desipramine_4\NN\4482543|and|cocaine (r_compound) sites_8\NNS\8673395|desipramine|binding|transporter (l_nmod) transporter_13\NN\4490091|on|the|human|norepinephrine
T14_T26 NONE cocaine_6\NN\3492717| (r_conj) desipramine_4\NN\4482543|and|cocaine (r_compound) sites_8\NNS\8673395|desipramine|binding|transporter
T14_T27 NONE cocaine_6\NN\3492717| (r_conj) desipramine_4\NN\4482543|and|cocaine (r_compound) sites_8\NNS\8673395|desipramine|binding|transporter (l_nmod) transporter_13\NN\4490091|on|the|human|norepinephrine
T15_T26 NONE norepinephrine_12\NN\14807929| (r_compound) transporter_13\NN\4490091|on|the|human|norepinephrine (r_nmod) sites_8\NNS\8673395|desipramine|binding|transporter
T15_T27 NONE norepinephrine_12\NN\14807929| (r_compound) transporter_13\NN\4490091|on|the|human|norepinephrine
T10_T18 NONE norepinephrine_8\NN\14807929| (r_compound) transporter_9\NN\4490091|with|the|human|norepinephrine|hnet (r_nmod) interactions_1\NNS\37396|the|mria|transporter (r_nsubjpass) investigated_14\VBN\644583|interactions|were|determining|. (l_advcl) determining_16\VBG\1645601|by|effects (l_dobj) effects_18\NNS\13245626|the|mutations|potency (l_nmod) mutations_22\NNS\4475|of|hnet|point (l_compound) hnet_20\NN\1740|
T10_T22 NONE norepinephrine_8\NN\14807929| (r_compound) transporter_9\NN\4490091|with|the|human|norepinephrine|hnet
T10_T25 NONE norepinephrine_8\NN\14807929| (r_compound) transporter_9\NN\4490091|with|the|human|norepinephrine|hnet (l_appos) hnet_11\NN\1740|(|)
T5_T19 CPR:9 [3h]norepinephrine_13\NN\1740|of|ki (r_nmod) inhibition_7\NN\1068773|for|uptake|hnet|[3h]norepinephrine|[3h]dopamine (l_nmod) hnet_11\NN\1740|by
T5_T20 NONE [3h]norepinephrine_13\NN\1740|of|ki (r_nmod) inhibition_7\NN\1068773|for|uptake|hnet|[3h]norepinephrine|[3h]dopamine (r_nmod) greater_5\JJR\1740|potency|was|inhibition|,|and|inhibited (l_conj) inhibited_37\VBN\2510337|transporter|were|not|mria|. (l_nsubjpass) transporter_31\NN\4490091|the|human|dopamine|and|transporter
T5_T21 NONE [3h]norepinephrine_13\NN\1740|of|ki (r_nmod) inhibition_7\NN\1068773|for|uptake|hnet|[3h]norepinephrine|[3h]dopamine (r_nmod) greater_5\JJR\1740|potency|was|inhibition|,|and|inhibited (l_conj) inhibited_37\VBN\2510337|transporter|were|not|mria|. (l_nsubjpass) transporter_31\NN\4490091|the|human|dopamine|and|transporter (l_conj) transporter_34\NN\4490091|serotonin
T6_T19 CPR:9 [3h]dopamine_20\NN\1740|than|ki (r_nmod) inhibition_7\NN\1068773|for|uptake|hnet|[3h]norepinephrine|[3h]dopamine (l_nmod) hnet_11\NN\1740|by
T6_T20 NONE [3h]dopamine_20\NN\1740|than|ki (r_nmod) inhibition_7\NN\1068773|for|uptake|hnet|[3h]norepinephrine|[3h]dopamine (r_nmod) greater_5\JJR\1740|potency|was|inhibition|,|and|inhibited (l_conj) inhibited_37\VBN\2510337|transporter|were|not|mria|. (l_nsubjpass) transporter_31\NN\4490091|the|human|dopamine|and|transporter
T6_T21 NONE [3h]dopamine_20\NN\1740|than|ki (r_nmod) inhibition_7\NN\1068773|for|uptake|hnet|[3h]norepinephrine|[3h]dopamine (r_nmod) greater_5\JJR\1740|potency|was|inhibition|,|and|inhibited (l_conj) inhibited_37\VBN\2510337|transporter|were|not|mria|. (l_nsubjpass) transporter_31\NN\4490091|the|human|dopamine|and|transporter (l_conj) transporter_34\NN\4490091|serotonin
T7_T19 NONE dopamine_30\NN\14807737| (r_compound) transporter_31\NN\4490091|the|human|dopamine|and|transporter (r_nsubjpass) inhibited_37\VBN\2510337|transporter|were|not|mria|. (r_conj) greater_5\JJR\1740|potency|was|inhibition|,|and|inhibited (l_nmod) inhibition_7\NN\1068773|for|uptake|hnet|[3h]norepinephrine|[3h]dopamine (l_nmod) hnet_11\NN\1740|by
T7_T20 NONE dopamine_30\NN\14807737| (r_compound) transporter_31\NN\4490091|the|human|dopamine|and|transporter
T7_T21 NONE dopamine_30\NN\14807737| (r_compound) transporter_31\NN\4490091|the|human|dopamine|and|transporter (l_conj) transporter_34\NN\4490091|serotonin
T8_T19 NONE serotonin_33\NN\14807737| (r_compound) transporter_34\NN\4490091|serotonin (r_conj) transporter_31\NN\4490091|the|human|dopamine|and|transporter (r_nsubjpass) inhibited_37\VBN\2510337|transporter|were|not|mria|. (r_conj) greater_5\JJR\1740|potency|was|inhibition|,|and|inhibited (l_nmod) inhibition_7\NN\1068773|for|uptake|hnet|[3h]norepinephrine|[3h]dopamine (l_nmod) hnet_11\NN\1740|by
T8_T20 NONE serotonin_33\NN\14807737| (r_compound) transporter_34\NN\4490091|serotonin (r_conj) transporter_31\NN\4490091|the|human|dopamine|and|transporter
T8_T21 NONE serotonin_33\NN\14807737| (r_compound) transporter_34\NN\4490091|serotonin
T11_T23 NONE dopamine_15\NN\14807737| (r_compound) transporter_16\NN\4490091|of|the|human|dopamine (r_nmod) those_11\DT\1740|with|transporter (r_nmod) exchanged_9\VBN\2220461|where|residues|were|those (l_nsubjpass) residues_7\NNS\20827|hnet|amino|acid (l_compound) hnet_4\NN\1740|
T11_T24 NONE dopamine_15\NN\14807737| (r_compound) transporter_16\NN\4490091|of|the|human|dopamine
T12_T23 NONE [3h]norepinephrine_25\NN\1740| (r_compound) uptake_26\NN\13440063|of|[3h]norepinephrine (r_nmod) inhibition_23\NN\1068773|for|uptake|mutations (r_nmod) potency_21\NN\5196375|inhibition (r_dobj) increased_20\VBN\169651|mutations|,|mria|had|potency|and|decreased|. (l_nmod) mutations_2\NNS\4475|of|18|exchanged (l_acl:relcl) exchanged_9\VBN\2220461|where|residues|were|those (l_nsubjpass) residues_7\NNS\20827|hnet|amino|acid (l_compound) hnet_4\NN\1740|
T12_T24 NONE [3h]norepinephrine_25\NN\1740| (r_compound) uptake_26\NN\13440063|of|[3h]norepinephrine (r_nmod) inhibition_23\NN\1068773|for|uptake|mutations (r_nmod) potency_21\NN\5196375|inhibition (r_dobj) increased_20\VBN\169651|mutations|,|mria|had|potency|and|decreased|. (l_nmod) mutations_2\NNS\4475|of|18|exchanged (l_acl:relcl) exchanged_9\VBN\2220461|where|residues|were|those (l_nmod) those_11\DT\1740|with|transporter (l_nmod) transporter_16\NN\4490091|of|the|human|dopamine
T9_T23 NONE acid_6\NN\14818238| (r_compound) residues_7\NNS\20827|hnet|amino|acid (l_compound) hnet_4\NN\1740|
T9_T24 NONE acid_6\NN\14818238| (r_compound) residues_7\NNS\20827|hnet|amino|acid (r_nsubjpass) exchanged_9\VBN\2220461|where|residues|were|those (l_nmod) those_11\DT\1740|with|transporter (l_nmod) transporter_16\NN\4490091|of|the|human|dopamine
T1_T16 NONE desipramine_9\NN\4482543|and|cocaine (r_compound) inhibition_12\NN\1068773|for|desipramine|uptake|hnets (l_nmod) hnets_19\NNS\1740|by|the|mutant
T1_T17 NONE desipramine_9\NN\4482543|and|cocaine (r_compound) inhibition_12\NN\1068773|for|desipramine|uptake|hnets (r_nmod) data_7\NNS\7951464|with|previous|inhibition (r_nmod) comparison_1\NN\635850|a|results|data (r_nsubj) reveals_20\VBZ\2137132|comparison|occurs|. (l_ccomp) occurs_26\VBZ\2623529|that|binding|site (l_nsubj) binding_23\NN\4688246|mria|hnet (l_nmod) hnet_25\NN\1740|to
T2_T16 CPR:9 norepinephrine_14\NN\14807929| (r_compound) uptake_15\NN\13440063|of|norepinephrine (r_nmod) inhibition_12\NN\1068773|for|desipramine|uptake|hnets (l_nmod) hnets_19\NNS\1740|by|the|mutant
T2_T17 NONE norepinephrine_14\NN\14807929| (r_compound) uptake_15\NN\13440063|of|norepinephrine (r_nmod) inhibition_12\NN\1068773|for|desipramine|uptake|hnets (r_nmod) data_7\NNS\7951464|with|previous|inhibition (r_nmod) comparison_1\NN\635850|a|results|data (r_nsubj) reveals_20\VBZ\2137132|comparison|occurs|. (l_ccomp) occurs_26\VBZ\2623529|that|binding|site (l_nsubj) binding_23\NN\4688246|mria|hnet (l_nmod) hnet_25\NN\1740|to
T3_T16 NONE tricyclic_41\NNS\2718811| (r_amod) antidepressants_42\NNS\3740161|for|tricyclic|and|cocaine (r_nmod) sites_39\NNS\8673395|with|the|binding|antidepressants (r_nmod) overlaps_35\VBZ\2660442|sites (r_conj) distinct_32\JJ\1740|that|is|from|but|overlaps (r_acl:relcl) site_29\NN\8673395|at|a|distinct (r_nmod) occurs_26\VBZ\2623529|that|binding|site (r_ccomp) reveals_20\VBZ\2137132|comparison|occurs|. (l_nsubj) comparison_1\NN\635850|a|results|data (l_nmod) data_7\NNS\7951464|with|previous|inhibition (l_nmod) inhibition_12\NN\1068773|for|desipramine|uptake|hnets (l_nmod) hnets_19\NNS\1740|by|the|mutant
T3_T17 NONE tricyclic_41\NNS\2718811| (r_amod) antidepressants_42\NNS\3740161|for|tricyclic|and|cocaine (r_nmod) sites_39\NNS\8673395|with|the|binding|antidepressants (r_nmod) overlaps_35\VBZ\2660442|sites (r_conj) distinct_32\JJ\1740|that|is|from|but|overlaps (r_acl:relcl) site_29\NN\8673395|at|a|distinct (r_nmod) occurs_26\VBZ\2623529|that|binding|site (l_nsubj) binding_23\NN\4688246|mria|hnet (l_nmod) hnet_25\NN\1740|to
T4_T16 NONE cocaine_44\NN\3492717| (r_conj) antidepressants_42\NNS\3740161|for|tricyclic|and|cocaine (r_nmod) sites_39\NNS\8673395|with|the|binding|antidepressants (r_nmod) overlaps_35\VBZ\2660442|sites (r_conj) distinct_32\JJ\1740|that|is|from|but|overlaps (r_acl:relcl) site_29\NN\8673395|at|a|distinct (r_nmod) occurs_26\VBZ\2623529|that|binding|site (r_ccomp) reveals_20\VBZ\2137132|comparison|occurs|. (l_nsubj) comparison_1\NN\635850|a|results|data (l_nmod) data_7\NNS\7951464|with|previous|inhibition (l_nmod) inhibition_12\NN\1068773|for|desipramine|uptake|hnets (l_nmod) hnets_19\NNS\1740|by|the|mutant
T4_T17 NONE cocaine_44\NN\3492717| (r_conj) antidepressants_42\NNS\3740161|for|tricyclic|and|cocaine (r_nmod) sites_39\NNS\8673395|with|the|binding|antidepressants (r_nmod) overlaps_35\VBZ\2660442|sites (r_conj) distinct_32\JJ\1740|that|is|from|but|overlaps (r_acl:relcl) site_29\NN\8673395|at|a|distinct (r_nmod) occurs_26\VBZ\2623529|that|binding|site (l_nsubj) binding_23\NN\4688246|mria|hnet (l_nmod) hnet_25\NN\1740|to
11157886
T8_T21 CPR:4 halothane_3\NN\3570838| (r_compound) anesthesia_4\NN\14034177|of|halothane (r_nmod) effect_1\NN\34213|protective|anesthesia|damage|:|inhibition|. (l_dep) inhibition_10\NN\1068773|regeneration (l_nmod) regeneration_14\NN\13526110|of|metabolic|rhodopsin (l_compound) rhodopsin_13\NN\15089104|
T5_T20 NONE halothane_8\NN\3570838|the|volatile|anesthetic (r_nsubj) protects_9\VBZ\1127795|whether|halothane|degeneration (l_nmod) degeneration_13\NN\29677|against|light-induced|photoreceptor|retina (l_compound) photoreceptor_12\NN\1740|
T6_T17 CPR:4 halothane_2\NN\3570838| (r_compound) anesthesia_3\NN\14034177|halothane (r_nsubj) inhibited_5\VBD\2510337|results|:|anesthesia|reversibly|regeneration|and|prevented|. (l_dobj) regeneration_8\NN\13526110|metabolic|rhodopsin (l_compound) rhodopsin_7\NN\15089104|
T6_T18 CPR:4 halothane_2\NN\3570838| (r_compound) anesthesia_3\NN\14034177|halothane (r_nsubj) inhibited_5\VBD\2510337|results|:|anesthesia|reversibly|regeneration|and|prevented|. (l_conj) prevented_11\VBD\1740|thus|rhodopsin|absorbing (l_dobj) rhodopsin_12\NN\15089104|
T7_T19 NONE halothane_9\NN\3570838|with (r_nmod) anesthetized_7\VBN\84738|halothane (r_acl) mice_4\NNS\2329401|of|and|rats|anesthetized (r_nmod) photoreceptors_2\NNS\1740|mice
T2_T10 CPR:4 halothane_7\NN\3570838| (r_nsubj) impeded_8\VBD\2450505|conclusions|:|bleach|,|halothane|absorption|inhibiting|. (l_advcl) inhibiting_14\VBG\2510337|by|regeneration (l_dobj) regeneration_17\NN\13526110|metabolic|rhodopsin (l_compound) rhodopsin_16\NN\15089104|
T2_T9 NONE halothane_7\NN\3570838| (r_nsubj) impeded_8\VBD\2450505|conclusions|:|bleach|,|halothane|absorption|inhibiting|. (l_dobj) absorption_10\NN\13558490|photon|rhodopsin (l_nmod) rhodopsin_12\NN\15089104|by
23122072
23128353
T8_T19 CPR:4 glucosamine_16\NN\14617597|by (r_nmod) effect_14\NN\34213|an|inhibitory|glucosamine|20 (r_dobj) found_11\VBD\2426171|examination|,|we|effect||mm. (l_advcl) examination_0\NN\633864|phosphorylation (l_nmod) phosphorylation_2\NN\1740|of|protein (l_nmod) protein_8\NN\14944888|in|retinoblastoma|(|rb|)
T10_T20 NONE heme_18\NN\14989820| (r_compound) oxygenase-1_19\NN\1740|heme|ho-1 (r_conj) p53_16\NN\1740|of|and|oxygenase-1
T10_T21 NONE heme_18\NN\14989820| (r_compound) oxygenase-1_19\NN\1740|heme|ho-1
T10_T22 NONE heme_18\NN\14989820| (r_compound) oxygenase-1_19\NN\1740|heme|ho-1 (l_appos) ho-1_21\NN\1740|(|)
T10_T23 NONE heme_18\NN\14989820| (r_compound) oxygenase-1_19\NN\1740|heme|ho-1 (r_conj) p53_16\NN\1740|of|and|oxygenase-1 (r_nmod) mrna_11\NN\14832193|both|the|and|protein|expression|p53 (r_dobj) elevate_8\VB\2391803|to|mrna|,|but|caused (l_conj) caused_26\VBD\1617192|also|reduction (l_dobj) reduction_28\NN\351485|a|expression (l_nmod) expression_32\NN\4679549|in|p21|protein (l_compound) p21_30\NN\1740|
T9_T20 CPR:3 glucosamine_0\NN\14617597| (r_nsubjpass) demonstrated_6\VBN\2137132|glucosamine|was|elevate|. (l_xcomp) elevate_8\VB\2391803|to|mrna|,|but|caused (l_dobj) mrna_11\NN\14832193|both|the|and|protein|expression|p53 (l_nmod) p53_16\NN\1740|of|and|oxygenase-1
T9_T21 CPR:3 glucosamine_0\NN\14617597| (r_nsubjpass) demonstrated_6\VBN\2137132|glucosamine|was|elevate|. (l_xcomp) elevate_8\VB\2391803|to|mrna|,|but|caused (l_dobj) mrna_11\NN\14832193|both|the|and|protein|expression|p53 (l_nmod) p53_16\NN\1740|of|and|oxygenase-1 (l_conj) oxygenase-1_19\NN\1740|heme|ho-1
T9_T22 NONE glucosamine_0\NN\14617597| (r_nsubjpass) demonstrated_6\VBN\2137132|glucosamine|was|elevate|. (l_xcomp) elevate_8\VB\2391803|to|mrna|,|but|caused (l_dobj) mrna_11\NN\14832193|both|the|and|protein|expression|p53 (l_nmod) p53_16\NN\1740|of|and|oxygenase-1 (l_conj) oxygenase-1_19\NN\1740|heme|ho-1 (l_appos) ho-1_21\NN\1740|(|)
T9_T23 CPR:4 glucosamine_0\NN\14617597| (r_nsubjpass) demonstrated_6\VBN\2137132|glucosamine|was|elevate|. (l_xcomp) elevate_8\VB\2391803|to|mrna|,|but|caused (l_conj) caused_26\VBD\1617192|also|reduction (l_dobj) reduction_28\NN\351485|a|expression (l_nmod) expression_32\NN\4679549|in|p21|protein (l_compound) p21_30\NN\1740|
T1_T12 CPR:4 glucosamine_3\NN\14617597| (r_nsubj) attenuated_4\VBD\224901|addition|,|glucosamine|stability|pathway|,|inducing|. (l_dobj) stability_7\NN\4777852|p21|protein (l_compound) p21_5\NN\1740|
T1_T13 CPR:3 glucosamine_3\NN\14617597| (r_nsubj) attenuated_4\VBD\224901|addition|,|glucosamine|stability|pathway|,|inducing|. (l_advcl) inducing_17\VBG\1627355|as|accumulation (l_dobj) accumulation_20\NN\13497135|p21|nuclear (l_compound) p21_18\NN\1740|
T2_T14 CPR:4 glucosamine_10\NN\14617597|of (r_nmod) dose_8\NN\3740161|a|high|glucosamine (r_nsubj) inhibit_12\VB\2510337|that|dose|may|proliferation|apoptosis|and|disturb|,|and|occurs (l_conj) occurs_33\VBZ\2623529|that|this|,|part|,|reduction (l_nmod) reduction_42\NN\351485|by|a|phosphorylation|modulation (l_nmod) phosphorylation_45\NN\1740|in|rb (l_compound) rb_44\NN\14625458|
T2_T15 NONE glucosamine_10\NN\14617597|of (r_nmod) dose_8\NN\3740161|a|high|glucosamine (r_nsubj) inhibit_12\VB\2510337|that|dose|may|proliferation|apoptosis|and|disturb|,|and|occurs (l_conj) occurs_33\VBZ\2623529|that|this|,|part|,|reduction (l_nmod) reduction_42\NN\351485|by|a|phosphorylation|modulation (l_nmod) modulation_48\NN\7044917|together|with|expression (l_nmod) expression_55\NN\4679549|of|p21|,|and|accumulation (l_compound) p21_50\NN\1740|,|p53
T2_T16 NONE glucosamine_10\NN\14617597|of (r_nmod) dose_8\NN\3740161|a|high|glucosamine (r_nsubj) inhibit_12\VB\2510337|that|dose|may|proliferation|apoptosis|and|disturb|,|and|occurs (l_conj) occurs_33\VBZ\2623529|that|this|,|part|,|reduction (l_nmod) reduction_42\NN\351485|by|a|phosphorylation|modulation (l_nmod) modulation_48\NN\7044917|together|with|expression (l_nmod) expression_55\NN\4679549|of|p21|,|and|accumulation (l_compound) p21_50\NN\1740|,|p53 (l_conj) p53_52\NN\1740|and|ho-1
T2_T17 NONE glucosamine_10\NN\14617597|of (r_nmod) dose_8\NN\3740161|a|high|glucosamine (r_nsubj) inhibit_12\VB\2510337|that|dose|may|proliferation|apoptosis|and|disturb|,|and|occurs (l_conj) occurs_33\VBZ\2623529|that|this|,|part|,|reduction (l_nmod) reduction_42\NN\351485|by|a|phosphorylation|modulation (l_nmod) modulation_48\NN\7044917|together|with|expression (l_nmod) expression_55\NN\4679549|of|p21|,|and|accumulation (l_compound) p21_50\NN\1740|,|p53 (l_conj) p53_52\NN\1740|and|ho-1 (l_conj) ho-1_54\NN\1740|
T2_T18 CPR:3 glucosamine_10\NN\14617597|of (r_nmod) dose_8\NN\3740161|a|high|glucosamine (r_nsubj) inhibit_12\VB\2510337|that|dose|may|proliferation|apoptosis|and|disturb|,|and|occurs (l_conj) occurs_33\VBZ\2623529|that|this|,|part|,|reduction (l_nmod) reduction_42\NN\351485|by|a|phosphorylation|modulation (l_nmod) modulation_48\NN\7044917|together|with|expression (l_nmod) expression_55\NN\4679549|of|p21|,|and|accumulation (l_conj) accumulation_60\NN\13497135|nuclear|p21 (l_compound) p21_59\NN\1740|
17603545
T1_T6 NONE noradrenaline_9\NN\14807929|to (r_nmod) response_7\NN\11410625|in|noradrenaline (r_nmod) decreased_12\VBN\169651|tension|response|was|markedly|mice|,|and|abolished (l_nmod) mice_16\NNS\2329401|in|alpha(1a)-adrenoceptor|ko (l_compound) alpha(1a)-adrenoceptor_14\NN\1740|
T1_T7 NONE noradrenaline_9\NN\14807929|to (r_nmod) response_7\NN\11410625|in|noradrenaline (r_nmod) decreased_12\VBN\169651|tension|response|was|markedly|mice|,|and|abolished (l_conj) abolished_23\VBN\1740|contraction|was|completely|mice|. (l_nmod) mice_27\NNS\2329401|in|alpha(1)-adrenoceptor|triple-ko (l_compound) alpha(1)-adrenoceptor_25\NN\1740|
23384387
T11_T21 CPR:3 acylethanolamide_1\NN\1740| (r_compound) derivatives_2\NNS\5802185|novel|acylethanolamide|modulate|. (l_acl:relcl) modulate_4\VBP\1724459|that|weight|enhancement (l_nmod) enhancement_8\NN\248977|through|pro-opiomelanocortin (l_nmod) pro-opiomelanocortin_11\NN\1740|of|hypothalamic|pomc|and/or|y (l_appos) pomc_13\NN\1740|(|)
T11_T22 CPR:4 acylethanolamide_1\NN\1740| (r_compound) derivatives_2\NNS\5802185|novel|acylethanolamide|modulate|. (l_acl:relcl) modulate_4\VBP\1724459|that|weight|enhancement (l_nmod) enhancement_8\NN\248977|through|pro-opiomelanocortin (l_nmod) pro-opiomelanocortin_11\NN\1740|of|hypothalamic|pomc|and/or|y (l_conj) y_18\NN\14625458|decreased|neuropeptide|npy
T11_T23 CPR:4 acylethanolamide_1\NN\1740| (r_compound) derivatives_2\NNS\5802185|novel|acylethanolamide|modulate|. (l_acl:relcl) modulate_4\VBP\1724459|that|weight|enhancement (l_nmod) enhancement_8\NN\248977|through|pro-opiomelanocortin (l_nmod) pro-opiomelanocortin_11\NN\1740|of|hypothalamic|pomc|and/or|y (l_conj) y_18\NN\14625458|decreased|neuropeptide|npy (l_appos) npy_20\NN\1740|(|)
T11_T24 CPR:3 acylethanolamide_1\NN\1740| (r_compound) derivatives_2\NNS\5802185|novel|acylethanolamide|modulate|. (l_acl:relcl) modulate_4\VBP\1724459|that|weight|enhancement (l_nmod) enhancement_8\NN\248977|through|pro-opiomelanocortin (l_nmod) pro-opiomelanocortin_11\NN\1740|of|hypothalamic|pomc|and/or|y
17554001
T6_T19 CPR:9 glycine_22\NN\14601829|and|gaba (r_appos) transmitters_20\NNS\9610660|the|two|main|inhibitory|,|glycine|, (r_nsubj) share_26\VBP\2660631|because|transmitters|transporter|and|present (l_dobj) transporter_33\NN\4490091|the|same|vesicular|inhibitory|amino|acid|viaat
T6_T20 CPR:9 glycine_22\NN\14601829|and|gaba (r_appos) transmitters_20\NNS\9610660|the|two|main|inhibitory|,|glycine|, (r_nsubj) share_26\VBP\2660631|because|transmitters|transporter|and|present (l_dobj) transporter_33\NN\4490091|the|same|vesicular|inhibitory|amino|acid|viaat (l_appos) viaat_35\NN\1740|(|)
T7_T19 CPR:9 gaba_24\NN\14601829| (r_conj) glycine_22\NN\14601829|and|gaba (r_appos) transmitters_20\NNS\9610660|the|two|main|inhibitory|,|glycine|, (r_nsubj) share_26\VBP\2660631|because|transmitters|transporter|and|present (l_dobj) transporter_33\NN\4490091|the|same|vesicular|inhibitory|amino|acid|viaat
T7_T20 CPR:9 gaba_24\NN\14601829| (r_conj) glycine_22\NN\14601829|and|gaba (r_appos) transmitters_20\NNS\9610660|the|two|main|inhibitory|,|glycine|, (r_nsubj) share_26\VBP\2660631|because|transmitters|transporter|and|present (l_dobj) transporter_33\NN\4490091|the|same|vesicular|inhibitory|amino|acid|viaat (l_appos) viaat_35\NN\1740|(|)
T8_T19 NONE acid_32\NN\14818238| (r_compound) transporter_33\NN\4490091|the|same|vesicular|inhibitory|amino|acid|viaat
T8_T20 NONE acid_32\NN\14818238| (r_compound) transporter_33\NN\4490091|the|same|vesicular|inhibitory|amino|acid|viaat (l_appos) viaat_35\NN\1740|(|)
T10_T21 CPR:9 gaba_11\NN\14601829| (r_conj) glycine_9\NN\14601829|for|and|gaba (r_nmod) viaat_3\NN\1740|and|transporters|glycine
T10_T22 CPR:9 gaba_11\NN\14601829| (r_conj) glycine_9\NN\14601829|for|and|gaba (r_nmod) viaat_3\NN\1740|and|transporters|glycine (l_conj) transporters_7\NNS\4490091|the|plasmalemmal
T11_T21 NONE glycine_23\NN\14601829|of|and|gaba (r_nmod) release_21\NN\3748886|the|quantal|glycine (r_dobj) measured_18\VBD\697589|release|using (r_conj) expressed_2\VBN\928630|we|have|viaat|line|and|measured|. (l_dobj) viaat_3\NN\1740|and|transporters|glycine
T11_T22 NONE glycine_23\NN\14601829|of|and|gaba (r_nmod) release_21\NN\3748886|the|quantal|glycine (r_dobj) measured_18\VBD\697589|release|using (r_conj) expressed_2\VBN\928630|we|have|viaat|line|and|measured|. (l_dobj) viaat_3\NN\1740|and|transporters|glycine (l_conj) transporters_7\NNS\4490091|the|plasmalemmal
T12_T21 NONE gaba_25\NN\14601829| (r_conj) glycine_23\NN\14601829|of|and|gaba (r_nmod) release_21\NN\3748886|the|quantal|glycine (r_dobj) measured_18\VBD\697589|release|using (r_conj) expressed_2\VBN\928630|we|have|viaat|line|and|measured|. (l_dobj) viaat_3\NN\1740|and|transporters|glycine
T12_T22 NONE gaba_25\NN\14601829| (r_conj) glycine_23\NN\14601829|of|and|gaba (r_nmod) release_21\NN\3748886|the|quantal|glycine (r_dobj) measured_18\VBD\697589|release|using (r_conj) expressed_2\VBN\928630|we|have|viaat|line|and|measured|. (l_dobj) viaat_3\NN\1740|and|transporters|glycine (l_conj) transporters_7\NNS\4490091|the|plasmalemmal
T9_T21 CPR:9 glycine_9\NN\14601829|for|and|gaba (r_nmod) viaat_3\NN\1740|and|transporters|glycine
T9_T22 CPR:9 glycine_9\NN\14601829|for|and|gaba (r_nmod) viaat_3\NN\1740|and|transporters|glycine (l_conj) transporters_7\NNS\4490091|the|plasmalemmal
T13_T23 CPR:9 glycine_3\NN\14601829| (r_nsubjpass) released_5\VBN\1435380|that|glycine|is|vesicles|coexpressed (l_advcl) coexpressed_11\VBN\1740|when|viaat|is|glyt2 (l_nsubjpass) viaat_9\NN\1740|
T13_T24 NONE glycine_3\NN\14601829| (r_nsubjpass) released_5\VBN\1435380|that|glycine|is|vesicles|coexpressed (l_advcl) coexpressed_11\VBN\1740|when|viaat|is|glyt2 (l_nmod) glyt2_17\NN\1740|transporter|or|transporter (l_compound) transporter_16\NN\4490091|with|either|the|neuronal
T13_T25 NONE glycine_3\NN\14601829| (r_nsubjpass) released_5\VBN\1435380|that|glycine|is|vesicles|coexpressed (l_advcl) coexpressed_11\VBN\1740|when|viaat|is|glyt2 (l_nmod) glyt2_17\NN\1740|transporter|or|transporter
T13_T26 NONE glycine_3\NN\14601829| (r_nsubjpass) released_5\VBN\1435380|that|glycine|is|vesicles|coexpressed (l_advcl) coexpressed_11\VBN\1740|when|viaat|is|glyt2 (l_nmod) glyt2_17\NN\1740|transporter|or|transporter (l_conj) transporter_21\NN\4490091|the|glial|glyt1
T13_T27 NONE glycine_3\NN\14601829| (r_nsubjpass) released_5\VBN\1435380|that|glycine|is|vesicles|coexpressed (l_advcl) coexpressed_11\VBN\1740|when|viaat|is|glyt2 (l_nmod) glyt2_17\NN\1740|transporter|or|transporter (l_conj) transporter_21\NN\4490091|the|glial|glyt1 (l_dep) glyt1_22\NN\1740|
T14_T28 NONE glycine_31\NN\14601829| (r_compound) concentration_32\NN\4916342|the|high|cytosolic|glycine|required (r_dobj) maintaining_27\VBG\2202928|in|concentration (r_advcl) gives_22\VBZ\2327200|which|it|advantage|maintaining (r_ccomp) unable_13\JJ\1740|probably|because|glyt2|is|operate|,|gives (r_advcl) effective_5\JJ\1740|however|,|glyt2|was|more|glyt1|,|unable|. (l_nsubj) glyt2_2\NN\1740|
T14_T29 NONE glycine_31\NN\14601829| (r_compound) concentration_32\NN\4916342|the|high|cytosolic|glycine|required (r_dobj) maintaining_27\VBG\2202928|in|concentration (r_advcl) gives_22\VBZ\2327200|which|it|advantage|maintaining (r_ccomp) unable_13\JJ\1740|probably|because|glyt2|is|operate|,|gives (r_advcl) effective_5\JJ\1740|however|,|glyt2|was|more|glyt1|,|unable|. (l_nmod) glyt1_7\NN\1740|than
T14_T30 NONE glycine_31\NN\14601829| (r_compound) concentration_32\NN\4916342|the|high|cytosolic|glycine|required (r_dobj) maintaining_27\VBG\2202928|in|concentration (r_advcl) gives_22\VBZ\2327200|which|it|advantage|maintaining (r_ccomp) unable_13\JJ\1740|probably|because|glyt2|is|operate|,|gives (l_nsubj) glyt2_11\NN\1740|
T14_T31 CPR:9 glycine_31\NN\14601829| (r_compound) concentration_32\NN\4916342|the|high|cytosolic|glycine|required (l_acl) required_33\VBN\754942|loading (l_nmod) loading_37\NN\4571088|for|efficient|vesicular|viaat (l_nmod) viaat_39\NN\1740|by
T1_T15 CPR:9 gaba_15\NN\14601829| (r_nsubjpass) introduced_17\VBN\831651|when|gaba|is|cell|and|competes (l_conj) competes_23\VBZ\1740|uptake (l_nmod) uptake_25\NN\13440063|for|viaat (l_nmod) viaat_27\NN\1740|by
T2_T16 NONE glycine_15\NN\14601829| (r_compound) transmission_16\NN\121166|glycine (r_dobj) lacking_14\VBG\1740|transmission (r_acl) species_13\NN\7992450|a|lacking (r_appos) elegans_7\FW\1740|from|caenorhabditis|unc-47|)|,|species|, (r_nmod) ortholog_4\NN\1740|the|viaat|elegans (l_compound) viaat_3\NN\1740|
T2_T17 NONE glycine_15\NN\14601829| (r_compound) transmission_16\NN\121166|glycine (r_dobj) lacking_14\VBG\1740|transmission (r_acl) species_13\NN\7992450|a|lacking (r_appos) elegans_7\FW\1740|from|caenorhabditis|unc-47|)|,|species|, (r_nmod) ortholog_4\NN\1740|the|viaat|elegans (r_nsubj) supports_19\VBZ\2199590|interestingly|,|ortholog|also|exocytosis|presence|,|and|confers (l_nmod) presence_24\NN\13954253|in|the|glyt2 (l_nmod) glyt2_26\NN\1740|of
T3_T16 NONE glycine_20\NN\14601829| (r_compound) exocytosis_21\NN\1740|glycine (r_dobj) supports_19\VBZ\2199590|interestingly|,|ortholog|also|exocytosis|presence|,|and|confers (l_nsubj) ortholog_4\NN\1740|the|viaat|elegans (l_compound) viaat_3\NN\1740|
T3_T17 CPR:9 glycine_20\NN\14601829| (r_compound) exocytosis_21\NN\1740|glycine (r_dobj) supports_19\VBZ\2199590|interestingly|,|ortholog|also|exocytosis|presence|,|and|confers (l_nmod) presence_24\NN\13954253|in|the|glyt2 (l_nmod) glyt2_26\NN\1740|of
T4_T16 NONE gaba_36\NN\14601829| (r_compound) transmission_37\NN\121166|gaba|worm (r_dobj) abolishes_35\VBZ\1740|that|transmission (r_acl:relcl) mutation_31\NN\4475|a|point|unc-47|abolishes (r_nsubj) confers_41\VBZ\813978|mutation|specificity|. (r_conj) supports_19\VBZ\2199590|interestingly|,|ortholog|also|exocytosis|presence|,|and|confers (l_nsubj) ortholog_4\NN\1740|the|viaat|elegans (l_compound) viaat_3\NN\1740|
T4_T17 NONE gaba_36\NN\14601829| (r_compound) transmission_37\NN\121166|gaba|worm (r_dobj) abolishes_35\VBZ\1740|that|transmission (r_acl:relcl) mutation_31\NN\4475|a|point|unc-47|abolishes (r_nsubj) confers_41\VBZ\813978|mutation|specificity|. (r_conj) supports_19\VBZ\2199590|interestingly|,|ortholog|also|exocytosis|presence|,|and|confers (l_nmod) presence_24\NN\13954253|in|the|glyt2 (l_nmod) glyt2_26\NN\1740|of
T5_T18 CPR:9 glycine_11\NN\14601829|of (r_nmod) availability_9\NN\4718563|an|increased|cytosolic|glycine|terminals (l_nmod) terminals_14\NNS\4306080|in|viaat-containing (l_amod) viaat-containing_13\JJ\1740|
19293728
T7_T23 NONE norepinephrine_9\NN\14807929|of (r_nmod) effect_7\NN\34213|the|stimulatory|norepinephrine|proliferation (r_nsubjpass) inhibited_14\VBN\2510337|that|effect|is|receptors (l_nmod) receptors_17\NNS\5225602|by|d1-like|and|receptor
T7_T24 NONE norepinephrine_9\NN\14807929|of (r_nmod) effect_7\NN\34213|the|stimulatory|norepinephrine|proliferation (r_nsubjpass) inhibited_14\VBN\2510337|that|effect|is|receptors (l_nmod) receptors_17\NNS\5225602|by|d1-like|and|receptor (l_conj) receptor_22\NN\5225602|the|d3|dopamine|,|member
T7_T25 NONE norepinephrine_9\NN\14807929|of (r_nmod) effect_7\NN\34213|the|stimulatory|norepinephrine|proliferation (r_nsubjpass) inhibited_14\VBN\2510337|that|effect|is|receptors (l_nmod) receptors_17\NNS\5225602|by|d1-like|and|receptor (l_conj) receptor_22\NN\5225602|the|d3|dopamine|,|member (l_appos) member_25\NN\9816771|a|family (l_nmod) family_30\NN\8189659|of|the|d2-like|receptor (l_compound) receptor_29\NN\5225602|
T8_T23 NONE dopamine_21\NN\14807737| (r_compound) receptor_22\NN\5225602|the|d3|dopamine|,|member (r_conj) receptors_17\NNS\5225602|by|d1-like|and|receptor
T8_T24 NONE dopamine_21\NN\14807737| (r_compound) receptor_22\NN\5225602|the|d3|dopamine|,|member
T8_T25 NONE dopamine_21\NN\14807737| (r_compound) receptor_22\NN\5225602|the|d3|dopamine|,|member (l_appos) member_25\NN\9816771|a|family (l_nmod) family_30\NN\8189659|of|the|d2-like|receptor (l_compound) receptor_29\NN\5225602|
T9_T33 NONE [h]-thymidine_7\NN\1740| (r_compound) incorporation_8\NN\1237415|by|[h]-thymidine (r_nmod) determined_5\VBN\1645601|methods|:|proliferation|was|incorporation|;|determined (l_parataxis) determined_17\VBN\1645601|mrna|were|rt-pcr|. (l_nsubjpass) mrna_12\NN\14832193|insulin|receptor|and|expressions (l_compound) receptor_11\NN\5225602|
T1_T34 NONE [h]-thymidine_14\NN\1740| (r_compound) incorporation_15\NN\1237415|by|[h]-thymidine (r_nmod) determined_12\VBN\1645601|incorporation (r_advcl) increased_3\VBD\169651|results|insulin|proliferation|,|determined|. (l_nsubj) insulin_2\NN\5407119|
T2_T10 NONE fenoldopam_17\NN\1740|with|,|agonist|, (r_nmod) stimulation_15\NN\242808|fenoldopam (r_nsubj) inhibited_24\VBD\2510337|had|,|stimulation|effect|. (l_advcl) had_8\VBD\2108377|although|receptor|,|itself|,|effect|proliferation (l_nsubj) receptor_3\NN\5225602|the|d1-like
T2_T11 CPR:5 fenoldopam_17\NN\1740|with|,|agonist|, (l_appos) agonist_22\NN\9613191|a|d1-like|receptor (l_compound) receptor_21\NN\5225602|
T2_T12 CPR:4 fenoldopam_17\NN\1740|with|,|agonist|, (r_nmod) stimulation_15\NN\242808|fenoldopam (r_nsubj) inhibited_24\VBD\2510337|had|,|stimulation|effect|. (l_dobj) effect_27\NN\34213|the|stimulatory|insulin (l_nmod) insulin_29\NN\5407119|of
T3_T13 CPR:4 fenoldopam_4\NN\1740|of (r_nmod) effect_2\NN\34213|the|inhibitory|fenoldopam|proliferation (l_nmod) proliferation_8\NN\13489037|on|insulin-mediated|vsmc (l_amod) insulin-mediated_6\JJ\1740|
T3_T14 NONE fenoldopam_4\NN\1740|of (r_nmod) effect_2\NN\34213|the|inhibitory|fenoldopam|proliferation (r_nsubj) specific_11\JJ\1740|effect|was|receptor|,|blocked|. (l_advcl) blocked_18\VBN\1476483|because|effect|could|be|sch23390 (l_nmod) sch23390_20\NN\1740|by|,|antagonist (l_appos) antagonist_25\NN\7846|a|d1-like|receptor (l_compound) receptor_24\NN\5225602|
T4_T13 NONE sch23390_20\NN\1740|by|,|antagonist (r_nmod) blocked_18\VBN\1476483|because|effect|could|be|sch23390 (r_advcl) specific_11\JJ\1740|effect|was|receptor|,|blocked|. (l_nsubj) effect_2\NN\34213|the|inhibitory|fenoldopam|proliferation (l_nmod) proliferation_8\NN\13489037|on|insulin-mediated|vsmc (l_amod) insulin-mediated_6\JJ\1740|
T4_T14 CPR:6 sch23390_20\NN\1740|by|,|antagonist (l_appos) antagonist_25\NN\7846|a|d1-like|receptor (l_compound) receptor_24\NN\5225602|
T5_T15 CPR:4 fenoldopam_0\NN\1740| (r_nsubj) inhibited_2\VBD\2510337|fenoldopam|also|mrna|. (l_dobj) mrna_5\NN\14832193|insulin|receptor|and|expression|,|dependent (l_compound) receptor_4\NN\5225602|
T6_T16 NONE fenoldopam_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|inhibitory|fenoldopam|expression (r_dobj) blocked_6\VBD\1476483|pkc|effect|,|indicating|. (l_nsubj) pkc_1\NN\1740|a|or|inhibitor
T6_T17 NONE fenoldopam_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|inhibitory|fenoldopam|expression (r_dobj) blocked_6\VBD\1476483|pkc|effect|,|indicating|. (l_nsubj) pkc_1\NN\1740|a|or|inhibitor (l_conj) inhibitor_5\NN\20090|map|kinase (l_compound) kinase_4\NN\14732946|
T6_T18 CPR:4 fenoldopam_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|inhibitory|fenoldopam|expression (l_nmod) expression_15\NN\4679549|on|receptor (l_compound) receptor_14\NN\5225602|insulin
T6_T19 NONE fenoldopam_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|inhibitory|fenoldopam|expression (r_dobj) blocked_6\VBD\1476483|pkc|effect|,|indicating|. (l_advcl) indicating_17\VBG\952524|involved (l_ccomp) involved_24\VBN\2676054|that|pkc|were|pathway (l_nsubjpass) pkc_19\NN\1740|and|kinase
T6_T20 NONE fenoldopam_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|inhibitory|fenoldopam|expression (r_dobj) blocked_6\VBD\1476483|pkc|effect|,|indicating|. (l_advcl) indicating_17\VBG\952524|involved (l_ccomp) involved_24\VBN\2676054|that|pkc|were|pathway (l_nsubjpass) pkc_19\NN\1740|and|kinase (l_conj) kinase_22\NN\14732946|map
23623750
T11_T50 NONE flavin-containing_5\JJ\1740| (r_amod) monooxygenases_6\NNS\1740|of|flavin-containing|macaque
T1_T12 NONE flavin-containing_0\JJ\1740| (r_amod) monooxygenases_1\NNS\1740|flavin-containing|fmos|,|enzymes|,
T1_T28 NONE flavin-containing_0\JJ\1740| (r_amod) monooxygenases_1\NNS\1740|flavin-containing|fmos|,|enzymes|, (r_nsubjpass) characterized_21\VBN\609683|monooxygenases|have|been|human|(|fmo1|,|but|remain|. (l_nmod) fmo1_26\NN\1740|including|-|) (l_nummod) -_27\NN\1740|5 (l_nummod) 5_28\CD\13741022|and|fmo6p
T1_T29 NONE flavin-containing_0\JJ\1740| (r_amod) monooxygenases_1\NNS\1740|flavin-containing|fmos|,|enzymes|, (r_nsubjpass) characterized_21\VBN\609683|monooxygenases|have|been|human|(|fmo1|,|but|remain|. (l_nmod) fmo1_26\NN\1740|including|-|) (l_nummod) -_27\NN\1740|5 (l_nummod) 5_28\CD\13741022|and|fmo6p (l_conj) fmo6p_30\NN\1740|
T1_T32 NONE flavin-containing_0\JJ\1740| (r_amod) monooxygenases_1\NNS\1740|flavin-containing|fmos|,|enzymes|, (l_appos) fmos_3\NNS\1740|(|)
T9_T33 NONE acid_1\NN\14818238| (r_compound) sequences_2\NNS\8457976|amino|acid|cynomolgus|,|respectively (l_nmod) cynomolgus_4\NN\1740|of|fmo1 (l_dep) fmo1_5\NN\1740|-|5 (l_nummod) 5_7\CD\13741022|
T9_T34 NONE acid_1\NN\14818238| (r_compound) sequences_2\NNS\8457976|amino|acid|cynomolgus|,|respectively (r_nsubj) shared_11\VBD\2660631|sequences|,|identities|and|clustered|. (l_conj) clustered_24\VBN\2428924|were|closely|tree (l_nmod) tree_28\NN\13103136|in|a|phylogenetic|,|fmo1 (l_nmod) fmo1_32\NN\1740|with|human|-|5 (l_nummod) 5_34\CD\13741022|
T10_T13 NONE benzydamine_10\NN\1740| (r_dobj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_conj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3
T10_T14 NONE benzydamine_10\NN\1740| (r_dobj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_conj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3
T10_T15 NONE benzydamine_10\NN\1740| (r_dobj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_conj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3 (l_conj) fmo3_15\NN\1740|
T10_T46 CPR:9 benzydamine_10\NN\1740| (r_dobj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5
T10_T47 CPR:9 benzydamine_10\NN\1740| (r_dobj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo2_3\NN\1740|
T10_T48 CPR:9 benzydamine_10\NN\1740| (r_dobj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo3_5\NN\1740|
T10_T49 CPR:9 benzydamine_10\NN\1740| (r_dobj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo5_8\NN\1740|
T2_T13 CPR:9 methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3
T2_T14 CPR:9 methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3
T2_T15 CPR:9 methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3 (l_conj) fmo3_15\NN\1740|
T2_T46 NONE methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (r_conj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5
T2_T47 NONE methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (r_conj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo2_3\NN\1740|
T2_T48 NONE methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (r_conj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo3_5\NN\1740|
T2_T49 NONE methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (r_conj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo5_8\NN\1740|
T3_T13 CPR:9 trimethylamine_20\NN\1740| (r_conj) methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3
T3_T14 CPR:9 trimethylamine_20\NN\1740| (r_conj) methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3
T3_T15 CPR:9 trimethylamine_20\NN\1740| (r_conj) methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (l_nsubj) fmo1/fmo3_13\NN\1740|and|fmo3 (l_conj) fmo3_15\NN\1740|
T3_T46 NONE trimethylamine_20\NN\1740| (r_conj) methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (r_conj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5
T3_T47 NONE trimethylamine_20\NN\1740| (r_conj) methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (r_conj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo2_3\NN\1740|
T3_T48 NONE trimethylamine_20\NN\1740| (r_conj) methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (r_conj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo3_5\NN\1740|
T3_T49 NONE trimethylamine_20\NN\1740| (r_conj) methimazole_18\NN\1740|and|trimethylamine (r_dobj) metabolized_17\VBD\1740|fmo1/fmo3|also|methimazole|,|respectively|. (r_conj) metabolized_9\VBD\1740|fmo1|benzydamine|,|and|metabolized (l_nsubj) fmo1_1\NN\1740|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5 (l_conj) fmo5_8\NN\1740|
T4_T16 CPR:9 benzydamine_2\NN\1740| (r_compound) n-oxygenation_3\NN\1740|of|benzydamine (r_nmod) rates_0\NNS\13308999|n-oxygenation|catalyzed (l_acl) catalyzed_5\VBN\146138|(|fmo3|) (l_nmod) fmo3_7\NN\1740|by
T4_T17 NONE benzydamine_2\NN\1740| (r_compound) n-oxygenation_3\NN\1740|of|benzydamine (r_nmod) rates_0\NNS\13308999|n-oxygenation|catalyzed (r_nsubj) varied_9\VBD\2666239|rates|20-fold|livers|and|correlated|,|indicating|. (l_conj) correlated_22\VBN\2657219|were|significantly|expression (l_nmod) expression_26\NN\4679549|with|fmo3|protein (l_compound) fmo3_24\NN\1740|
T4_T18 NONE benzydamine_2\NN\1740| (r_compound) n-oxygenation_3\NN\1740|of|benzydamine (r_nmod) rates_0\NNS\13308999|n-oxygenation|catalyzed (r_nsubj) varied_9\VBD\2666239|rates|20-fold|livers|and|correlated|,|indicating|. (l_xcomp) indicating_28\VBG\952524|accounted (l_ccomp) accounted_39\VBN\2604760|that|variations|might|be|partly|for|expression (l_nmod) expression_45\NN\4679549|by|the|variable|fmo3 (l_compound) fmo3_44\NN\1740|
T5_T16 CPR:9 n-oxygenation_3\NN\1740|of|benzydamine (r_nmod) rates_0\NNS\13308999|n-oxygenation|catalyzed (l_acl) catalyzed_5\VBN\146138|(|fmo3|) (l_nmod) fmo3_7\NN\1740|by
T5_T17 NONE n-oxygenation_3\NN\1740|of|benzydamine (r_nmod) rates_0\NNS\13308999|n-oxygenation|catalyzed (r_nsubj) varied_9\VBD\2666239|rates|20-fold|livers|and|correlated|,|indicating|. (l_conj) correlated_22\VBN\2657219|were|significantly|expression (l_nmod) expression_26\NN\4679549|with|fmo3|protein (l_compound) fmo3_24\NN\1740|
T5_T18 NONE n-oxygenation_3\NN\1740|of|benzydamine (r_nmod) rates_0\NNS\13308999|n-oxygenation|catalyzed (r_nsubj) varied_9\VBD\2666239|rates|20-fold|livers|and|correlated|,|indicating|. (l_xcomp) indicating_28\VBG\952524|accounted (l_ccomp) accounted_39\VBN\2604760|that|variations|might|be|partly|for|expression (l_nmod) expression_45\NN\4679549|by|the|variable|fmo3 (l_compound) fmo3_44\NN\1740|
T6_T16 NONE benzydamine_34\NN\1740| (r_compound) n-oxygenation_35\NN\1740|in|benzydamine (r_nmod) variations_32\NNS\7296428|the|inter-animal|n-oxygenation (r_nsubjpass) accounted_39\VBN\2604760|that|variations|might|be|partly|for|expression (r_ccomp) indicating_28\VBG\952524|accounted (r_xcomp) varied_9\VBD\2666239|rates|20-fold|livers|and|correlated|,|indicating|. (l_nsubj) rates_0\NNS\13308999|n-oxygenation|catalyzed (l_acl) catalyzed_5\VBN\146138|(|fmo3|) (l_nmod) fmo3_7\NN\1740|by
T6_T17 NONE benzydamine_34\NN\1740| (r_compound) n-oxygenation_35\NN\1740|in|benzydamine (r_nmod) variations_32\NNS\7296428|the|inter-animal|n-oxygenation (r_nsubjpass) accounted_39\VBN\2604760|that|variations|might|be|partly|for|expression (r_ccomp) indicating_28\VBG\952524|accounted (r_xcomp) varied_9\VBD\2666239|rates|20-fold|livers|and|correlated|,|indicating|. (l_conj) correlated_22\VBN\2657219|were|significantly|expression (l_nmod) expression_26\NN\4679549|with|fmo3|protein (l_compound) fmo3_24\NN\1740|
T6_T18 CPR:9 benzydamine_34\NN\1740| (r_compound) n-oxygenation_35\NN\1740|in|benzydamine (r_nmod) variations_32\NNS\7296428|the|inter-animal|n-oxygenation (r_nsubjpass) accounted_39\VBN\2604760|that|variations|might|be|partly|for|expression (l_nmod) expression_45\NN\4679549|by|the|variable|fmo3 (l_compound) fmo3_44\NN\1740|
T7_T16 NONE n-oxygenation_35\NN\1740|in|benzydamine (r_nmod) variations_32\NNS\7296428|the|inter-animal|n-oxygenation (r_nsubjpass) accounted_39\VBN\2604760|that|variations|might|be|partly|for|expression (r_ccomp) indicating_28\VBG\952524|accounted (r_xcomp) varied_9\VBD\2666239|rates|20-fold|livers|and|correlated|,|indicating|. (l_nsubj) rates_0\NNS\13308999|n-oxygenation|catalyzed (l_acl) catalyzed_5\VBN\146138|(|fmo3|) (l_nmod) fmo3_7\NN\1740|by
T7_T17 NONE n-oxygenation_35\NN\1740|in|benzydamine (r_nmod) variations_32\NNS\7296428|the|inter-animal|n-oxygenation (r_nsubjpass) accounted_39\VBN\2604760|that|variations|might|be|partly|for|expression (r_ccomp) indicating_28\VBG\952524|accounted (r_xcomp) varied_9\VBD\2666239|rates|20-fold|livers|and|correlated|,|indicating|. (l_conj) correlated_22\VBN\2657219|were|significantly|expression (l_nmod) expression_26\NN\4679549|with|fmo3|protein (l_compound) fmo3_24\NN\1740|
T7_T18 CPR:9 n-oxygenation_35\NN\1740|in|benzydamine (r_nmod) variations_32\NNS\7296428|the|inter-animal|n-oxygenation (r_nsubjpass) accounted_39\VBN\2604760|that|variations|might|be|partly|for|expression (l_nmod) expression_45\NN\4679549|by|the|variable|fmo3 (l_compound) fmo3_44\NN\1740|
T8_T19 CPR:9 benzydamine_3\NN\1740| (r_dobj) metabolized_2\VBD\1740|fmo6|benzydamine|slightly|,|but|precludes (l_nsubj) fmo6_1\NN\1740|cynomolgus
T8_T20 NONE benzydamine_3\NN\1740| (r_dobj) metabolized_2\VBD\1740|fmo6|benzydamine|slightly|,|but|precludes (l_conj) precludes_15\VBZ\2629256|expression|importance|,|fmo1|. (l_nsubj) expression_9\NN\4679549|minimal|fmo6|tissue (l_nmod) fmo6_11\NN\1740|of
T8_T21 NONE benzydamine_3\NN\1740| (r_dobj) metabolized_2\VBD\1740|fmo6|benzydamine|slightly|,|but|precludes (l_conj) precludes_15\VBZ\2629256|expression|importance|,|fmo1|. (l_dobj) importance_17\NN\5138488|the|fmo6|metabolism (l_nmod) fmo6_19\NN\1740|of
T8_T22 CPR:9 benzydamine_3\NN\1740| (r_dobj) metabolized_2\VBD\1740|fmo6|benzydamine|slightly|,|but|precludes (l_conj) precludes_15\VBZ\2629256|expression|importance|,|fmo1|. (l_nmod) fmo1_26\NN\1740|unlike|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5|functional
T8_T23 CPR:9 benzydamine_3\NN\1740| (r_dobj) metabolized_2\VBD\1740|fmo6|benzydamine|slightly|,|but|precludes (l_conj) precludes_15\VBZ\2629256|expression|importance|,|fmo1|. (l_nmod) fmo1_26\NN\1740|unlike|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5|functional (l_conj) fmo2_28\NN\1740|
T8_T24 CPR:9 benzydamine_3\NN\1740| (r_dobj) metabolized_2\VBD\1740|fmo6|benzydamine|slightly|,|but|precludes (l_conj) precludes_15\VBZ\2629256|expression|importance|,|fmo1|. (l_nmod) fmo1_26\NN\1740|unlike|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5|functional (l_conj) fmo3_30\NN\1740|
T8_T25 CPR:9 benzydamine_3\NN\1740| (r_dobj) metabolized_2\VBD\1740|fmo6|benzydamine|slightly|,|but|precludes (l_conj) precludes_15\VBZ\2629256|expression|importance|,|fmo1|. (l_nmod) fmo1_26\NN\1740|unlike|cynomolgus|,|fmo2|,|fmo3|,|and|fmo5|functional (l_conj) fmo5_33\NN\1740|
7714410
T22_T25 CPR:6 emedastine_3\NN\1740|of|,|antagonist (l_appos) antagonist_11\NN\7846|a|potent|,|selective|h1|use (l_compound) h1_10\NN\1740|histamine
T23_T25 NONE histamine_9\NN\14739004| (r_compound) h1_10\NN\1740|histamine
T21_T24 NONE emedastine_0\NN\1740|% (r_nsubj) failed_5\VBD\1798936|emedastine|attenuate|indicating|. (l_xcomp) indicating_17\VBG\952524|selectivity (l_dobj) selectivity_19\NN\4916342|high|receptor (l_nmod) receptor_24\NN\5225602|for|the|histamine|h1
T2_T24 NONE histamine_22\NN\14739004| (r_compound) receptor_24\NN\5225602|for|the|histamine|h1
23266271
23473801
T12_T26 CPR:4 hinokitiol_5\NN\1740|(|1 (r_nsubj) inhibited_11\VBD\2510337|study|,|hinokitiol|aggregation|,|but|inhibit|. (l_dobj) aggregation_14\NN\31264|the|collagen-induced|platelets (l_amod) collagen-induced_13\JJ\1740|
T12_T27 NONE hinokitiol_5\NN\1740|(|1 (r_nsubj) inhibited_11\VBD\2510337|study|,|hinokitiol|aggregation|,|but|inhibit|. (l_conj) inhibit_22\VB\2510337|did|not|activation (l_dobj) activation_24\NN\13561719|the|platelets|agonists (l_nmod) agonists_29\NNS\9613191|by|other|,|thrombin (l_nmod) thrombin_32\NN\14735953|including|,|acid|,|and|adp
T13_T26 NONE acid_35\NN\14818238|arachidonic (r_conj) thrombin_32\NN\14735953|including|,|acid|,|and|adp (r_nmod) agonists_29\NNS\9613191|by|other|,|thrombin (r_nmod) activation_24\NN\13561719|the|platelets|agonists (r_dobj) inhibit_22\VB\2510337|did|not|activation (r_conj) inhibited_11\VBD\2510337|study|,|hinokitiol|aggregation|,|but|inhibit|. (l_dobj) aggregation_14\NN\31264|the|collagen-induced|platelets (l_amod) collagen-induced_13\JJ\1740|
T13_T27 NONE acid_35\NN\14818238|arachidonic (r_conj) thrombin_32\NN\14735953|including|,|acid|,|and|adp
T14_T26 NONE adp_38\NN\14964590| (r_conj) thrombin_32\NN\14735953|including|,|acid|,|and|adp (r_nmod) agonists_29\NNS\9613191|by|other|,|thrombin (r_nmod) activation_24\NN\13561719|the|platelets|agonists (r_dobj) inhibit_22\VB\2510337|did|not|activation (r_conj) inhibited_11\VBD\2510337|study|,|hinokitiol|aggregation|,|but|inhibit|. (l_dobj) aggregation_14\NN\31264|the|collagen-induced|platelets (l_amod) collagen-induced_13\JJ\1740|
T14_T27 NONE adp_38\NN\14964590| (r_conj) thrombin_32\NN\14735953|including|,|acid|,|and|adp
T15_T28 CPR:4 hinokitiol_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases
T15_T29 CPR:4 hinokitiol_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) c_11\NN\13714184|protein|kinase|pkc
T15_T30 CPR:4 hinokitiol_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) c_11\NN\13714184|protein|kinase|pkc (l_appos) pkc_13\NN\1740|(|)
T15_T31 CPR:4 hinokitiol_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) kinases_18\NNS\14732946|mitogen-activated|protein|mapks
T15_T32 CPR:4 hinokitiol_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) kinases_18\NNS\14732946|mitogen-activated|protein|mapks (l_appos) mapks_20\NNS\1740|(|)
T15_T33 CPR:4 hinokitiol_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_conj) akt_24\NN\1740|
T15_T34 CPR:4 hinokitiol_0\NN\1740| (r_nsubj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) platelets_28\NNS\5432736|in|collagen-activated|human (l_amod) collagen-activated_26\JJ\1740|
T16_T28 NONE calcium_34\NN\14625458| (r_compound) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases
T16_T29 NONE calcium_34\NN\14625458| (r_compound) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) c_11\NN\13714184|protein|kinase|pkc
T16_T30 NONE calcium_34\NN\14625458| (r_compound) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) c_11\NN\13714184|protein|kinase|pkc (l_appos) pkc_13\NN\1740|(|)
T16_T31 NONE calcium_34\NN\14625458| (r_compound) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) kinases_18\NNS\14732946|mitogen-activated|protein|mapks
T16_T32 NONE calcium_34\NN\14625458| (r_compound) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) kinases_18\NNS\14732946|mitogen-activated|protein|mapks (l_appos) mapks_20\NNS\1740|(|)
T16_T33 NONE calcium_34\NN\14625458| (r_compound) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_conj) akt_24\NN\1740|
T16_T34 NONE calcium_34\NN\14625458| (r_compound) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) platelets_28\NNS\5432736|in|collagen-activated|human (l_amod) collagen-activated_26\JJ\1740|
T17_T28 NONE hydroxyl_37\NN\14621446| (r_compound) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases
T17_T29 NONE hydroxyl_37\NN\14621446| (r_compound) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) c_11\NN\13714184|protein|kinase|pkc
T17_T30 NONE hydroxyl_37\NN\14621446| (r_compound) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) c_11\NN\13714184|protein|kinase|pkc (l_appos) pkc_13\NN\1740|(|)
T17_T31 NONE hydroxyl_37\NN\14621446| (r_compound) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) kinases_18\NNS\14732946|mitogen-activated|protein|mapks
T17_T32 NONE hydroxyl_37\NN\14621446| (r_compound) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) kinases_18\NNS\14732946|mitogen-activated|protein|mapks (l_appos) mapks_20\NNS\1740|(|)
T17_T33 NONE hydroxyl_37\NN\14621446| (r_compound) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_conj) akt_24\NN\1740|
T17_T34 NONE hydroxyl_37\NN\14621446| (r_compound) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) platelets_28\NNS\5432736|in|collagen-activated|human (l_amod) collagen-activated_26\JJ\1740|
T18_T28 NONE oh_40\NN\1740|(|) (r_appos) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases
T18_T29 NONE oh_40\NN\1740|(|) (r_appos) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) c_11\NN\13714184|protein|kinase|pkc
T18_T30 NONE oh_40\NN\1740|(|) (r_appos) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) c_11\NN\13714184|protein|kinase|pkc (l_appos) pkc_13\NN\1740|(|)
T18_T31 NONE oh_40\NN\1740|(|) (r_appos) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) kinases_18\NNS\14732946|mitogen-activated|protein|mapks
T18_T32 NONE oh_40\NN\1740|(|) (r_appos) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) (plc)γ2_7\NN\1740|of|c|,|c|,|kinases (l_conj) kinases_18\NNS\14732946|mitogen-activated|protein|mapks (l_appos) mapks_20\NNS\1740|(|)
T18_T33 NONE oh_40\NN\1740|(|) (r_appos) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_conj) akt_24\NN\1740|
T18_T34 NONE oh_40\NN\1740|(|) (r_appos) radical_38\NN\9465459|hydroxyl|oh (r_compound) formation_42\NN\7938773|radical (r_conj) mobilization_35\NN\1123598|intracellular|calcium|and|formation (r_dobj) reduced_32\VBD\441445|significantly|mobilization (r_conj) inhibited_1\VBD\2510337|hinokitiol|phosphorylation|,|and|reduced|. (l_dobj) phosphorylation_3\NN\1740|the|(plc)γ2|,|and|akt|platelets (l_nmod) platelets_28\NNS\5432736|in|collagen-activated|human (l_amod) collagen-activated_26\JJ\1740|
T19_T35 CPR:4 hinokitiol_0\NN\1740| (r_nsubj) reduced_2\VBD\441445|hinokitiol|also|activation|. (l_dobj) activation_5\NN\13561719|the|pkc|and|aggregation (l_compound) pkc_4\NN\1740|
T3_T21 NONE hinokitiol_0\NN\1740| (r_nsubj) influence_3\VB\137313|hinokitiol|did|not|binding|,|and|reversed|. (l_dobj) binding_5\NN\4688246|the|probe|integrin (l_nmod) integrin_14\NN\1740|to|the|αiibβ3|membrane
T4_T21 NONE odq_21\NN\1740|neither|nor|sq22536 (r_nsubj) reversed_25\VBD\109660|odq|significantly|inhibition (r_conj) influence_3\VB\137313|hinokitiol|did|not|binding|,|and|reversed|. (l_dobj) binding_5\NN\4688246|the|probe|integrin (l_nmod) integrin_14\NN\1740|to|the|αiibβ3|membrane
T5_T21 NONE sq22536_23\NN\1740| (r_conj) odq_21\NN\1740|neither|nor|sq22536 (r_nsubj) reversed_25\VBD\109660|odq|significantly|inhibition (r_conj) influence_3\VB\137313|hinokitiol|did|not|binding|,|and|reversed|. (l_dobj) binding_5\NN\4688246|the|probe|integrin (l_nmod) integrin_14\NN\1740|to|the|αiibβ3|membrane
T6_T21 NONE hinokitiol-mediated_27\JJ\1740| (r_amod) inhibition_28\NN\1068773|the|hinokitiol-mediated|aggregation (r_dobj) reversed_25\VBD\109660|odq|significantly|inhibition (r_conj) influence_3\VB\137313|hinokitiol|did|not|binding|,|and|reversed|. (l_dobj) binding_5\NN\4688246|the|probe|integrin (l_nmod) integrin_14\NN\1740|to|the|αiibβ3|membrane
T7_T22 CPR:4 hinokitiol_3\NN\1740| (r_nsubj) inhibit_5\VB\2510337|conclusion|,|hinokitiol|may|activation|inhibiting|followed|. (l_advcl) inhibiting_9\VBG\2510337|by|cascade|, (l_dobj) cascade_12\NN\9475292|the|plcγ2-pkc|and|formation (l_compound) plcγ2-pkc_11\NN\1740|
T7_T23 CPR:4 hinokitiol_3\NN\1740| (r_nsubj) inhibit_5\VB\2510337|conclusion|,|hinokitiol|may|activation|inhibiting|followed|. (l_advcl) inhibiting_9\VBG\2510337|by|cascade|, (l_dobj) cascade_12\NN\9475292|the|plcγ2-pkc|and|formation (l_compound) plcγ2-pkc_11\NN\1740|
T7_T24 CPR:4 hinokitiol_3\NN\1740| (r_nsubj) inhibit_5\VB\2510337|conclusion|,|hinokitiol|may|activation|inhibiting|followed|. (l_advcl) followed_18\VBN\1835496|suppressing (l_advcl) suppressing_20\VBG\2510337|by|activation (l_dobj) activation_22\NN\13561719|the|mapks (l_nmod) mapks_24\NNS\1740|of|and|akt
T7_T25 CPR:4 hinokitiol_3\NN\1740| (r_nsubj) inhibit_5\VB\2510337|conclusion|,|hinokitiol|may|activation|inhibiting|followed|. (l_advcl) followed_18\VBN\1835496|suppressing (l_advcl) suppressing_20\VBG\2510337|by|activation (l_dobj) activation_22\NN\13561719|the|mapks (l_nmod) mapks_24\NNS\1740|of|and|akt (l_conj) akt_26\NN\1740|
T8_T22 NONE hydroxyl_14\NN\14621446| (r_compound) formation_16\NN\7938773|hydroxyl|radical (r_conj) cascade_12\NN\9475292|the|plcγ2-pkc|and|formation (l_compound) plcγ2-pkc_11\NN\1740|
T8_T23 NONE hydroxyl_14\NN\14621446| (r_compound) formation_16\NN\7938773|hydroxyl|radical (r_conj) cascade_12\NN\9475292|the|plcγ2-pkc|and|formation (l_compound) plcγ2-pkc_11\NN\1740|
T8_T24 NONE hydroxyl_14\NN\14621446| (r_compound) formation_16\NN\7938773|hydroxyl|radical (r_conj) cascade_12\NN\9475292|the|plcγ2-pkc|and|formation (r_dobj) inhibiting_9\VBG\2510337|by|cascade|, (r_advcl) inhibit_5\VB\2510337|conclusion|,|hinokitiol|may|activation|inhibiting|followed|. (l_advcl) followed_18\VBN\1835496|suppressing (l_advcl) suppressing_20\VBG\2510337|by|activation (l_dobj) activation_22\NN\13561719|the|mapks (l_nmod) mapks_24\NNS\1740|of|and|akt
T8_T25 NONE hydroxyl_14\NN\14621446| (r_compound) formation_16\NN\7938773|hydroxyl|radical (r_conj) cascade_12\NN\9475292|the|plcγ2-pkc|and|formation (r_dobj) inhibiting_9\VBG\2510337|by|cascade|, (r_advcl) inhibit_5\VB\2510337|conclusion|,|hinokitiol|may|activation|inhibiting|followed|. (l_advcl) followed_18\VBN\1835496|suppressing (l_advcl) suppressing_20\VBG\2510337|by|activation (l_dobj) activation_22\NN\13561719|the|mapks (l_nmod) mapks_24\NNS\1740|of|and|akt (l_conj) akt_26\NN\1740|
23535337
T11_T29 NONE proline_14\NN\14601829| (r_compound) content_15\NN\7951464|proline|and|activities|catalase (l_nmod) catalase_19\NN\14732946|of|and|peroxidase
T11_T30 NONE proline_14\NN\14601829| (r_compound) content_15\NN\7951464|proline|and|activities|catalase (r_dobj) modulating_13\VBG\1724459|via|content (r_advcl) enhances_3\VBZ\227165|disruption|tolerance|modulating|. (l_nsubj) disruption_0\NN\1066163|atwnk8 (l_nmod) atwnk8_2\NN\1740|of
T11_T31 NONE proline_14\NN\14601829| (r_compound) content_15\NN\7951464|proline|and|activities|catalase (l_nmod) catalase_19\NN\14732946|of|and|peroxidase (l_conj) peroxidase_21\NN\14971234|
T10_T12 NONE lysine_2\NN\14605787| (r_compound) kinases_3\NNS\14732946|lysine|wnks
T10_T18 NONE lysine_2\NN\14605787| (r_compound) kinases_3\NNS\14732946|lysine|wnks (l_appos) wnks_5\NNS\1740|(|)
T2_T17 NONE nacl_22\NN\1740|and|sorbitol (r_compound) treatment_25\NN\654885|by|nacl (r_nmod) induced_20\VBN\1627355|is|treatment (r_conj) expressed_8\VBN\928630|that|atwnk8|is|mainly|root|and|induced (l_nsubjpass) atwnk8_5\NN\1740|
T3_T17 NONE sorbitol_24\NN\1740| (r_conj) nacl_22\NN\1740|and|sorbitol (r_compound) treatment_25\NN\654885|by|nacl (r_nmod) induced_20\VBN\1627355|is|treatment (r_conj) expressed_8\VBN\928630|that|atwnk8|is|mainly|root|and|induced (l_nsubjpass) atwnk8_5\NN\1740|
T4_T19 NONE nacl_33\NN\1740|and|sorbitol (r_compound) treatment_36\NN\654885|in|the|nacl (r_nmod) %_24\NN\1740|by|27|and|%|more|weight|treatment|, (r_nmod) indicated_21\VBN\952524|as|%|respectively (r_advcl) tolerant_12\JJ\1740|compared|,|mutant|was|more|stresses|,|indicated|. (l_nsubj) mutant_9\NN\4475|the|t-dna|knock-out|wnk8 (l_compound) wnk8_8\NN\1740|
T5_T19 NONE sorbitol_35\NN\1740| (r_conj) nacl_33\NN\1740|and|sorbitol (r_compound) treatment_36\NN\654885|in|the|nacl (r_nmod) %_24\NN\1740|by|27|and|%|more|weight|treatment|, (r_nmod) indicated_21\VBN\952524|as|%|respectively (r_advcl) tolerant_12\JJ\1740|compared|,|mutant|was|more|stresses|,|indicated|. (l_nsubj) mutant_9\NN\4475|the|t-dna|knock-out|wnk8 (l_compound) wnk8_8\NN\1740|
T6_T20 NONE proline_7\NN\14601829|more (r_dobj) accumulated_4\VBD\2281093|mutant|also|proline|wild-type|treatment|. (l_nsubj) mutant_2\NN\4475|the|wnk8 (l_compound) wnk8_1\NN\1740|
T7_T20 NONE sorbitol_13\NN\1740| (r_compound) treatment_14\NN\654885|in|the|sorbitol (r_nmod) accumulated_4\VBD\2281093|mutant|also|proline|wild-type|treatment|. (l_nsubj) mutant_2\NN\4475|the|wnk8 (l_compound) wnk8_1\NN\1740|
T8_T21 CPR:3 nacl_1\NN\1740|and|sorbitol (r_compound) stresses_4\NNS\7083732|under|nacl (r_nmod) 1.92-_15\CD\1740|stresses|,|activity|was|and|3.7-times|that|,|respectively|. (l_nsubj) activity_10\NN\30358|catalase|mutant (l_compound) catalase_6\NN\14732946|cat
T8_T22 CPR:3 nacl_1\NN\1740|and|sorbitol (r_compound) stresses_4\NNS\7083732|under|nacl (r_nmod) 1.92-_15\CD\1740|stresses|,|activity|was|and|3.7-times|that|,|respectively|. (l_nsubj) activity_10\NN\30358|catalase|mutant (l_compound) catalase_6\NN\14732946|cat (l_appos) cat_8\NN\2120997|(|)
T8_T23 NONE nacl_1\NN\1740|and|sorbitol (r_compound) stresses_4\NNS\7083732|under|nacl (r_nmod) 1.92-_15\CD\1740|stresses|,|activity|was|and|3.7-times|that|,|respectively|. (l_nsubj) activity_10\NN\30358|catalase|mutant (l_nmod) mutant_13\NN\4475|in|wnk8 (l_compound) wnk8_12\NN\1740|
T9_T21 CPR:3 sorbitol_3\NN\1740| (r_conj) nacl_1\NN\1740|and|sorbitol (r_compound) stresses_4\NNS\7083732|under|nacl (r_nmod) 1.92-_15\CD\1740|stresses|,|activity|was|and|3.7-times|that|,|respectively|. (l_nsubj) activity_10\NN\30358|catalase|mutant (l_compound) catalase_6\NN\14732946|cat
T9_T22 CPR:3 sorbitol_3\NN\1740| (r_conj) nacl_1\NN\1740|and|sorbitol (r_compound) stresses_4\NNS\7083732|under|nacl (r_nmod) 1.92-_15\CD\1740|stresses|,|activity|was|and|3.7-times|that|,|respectively|. (l_nsubj) activity_10\NN\30358|catalase|mutant (l_compound) catalase_6\NN\14732946|cat (l_appos) cat_8\NN\2120997|(|)
T9_T23 NONE sorbitol_3\NN\1740| (r_conj) nacl_1\NN\1740|and|sorbitol (r_compound) stresses_4\NNS\7083732|under|nacl (r_nmod) 1.92-_15\CD\1740|stresses|,|activity|was|and|3.7-times|that|,|respectively|. (l_nsubj) activity_10\NN\30358|catalase|mutant (l_nmod) mutant_13\NN\4475|in|wnk8 (l_compound) wnk8_12\NN\1740|
T1_T13 NONE proline_33\NN\14601829|more|and|activities (r_dobj) accumulating_31\VBG\2281093|proline (r_csubj) result_42\VB\2633881|accumulating|might|tolerance (r_conj) enhances_23\VBZ\227165|that|disruption|tolerance|,|and|result (l_nsubj) disruption_20\NN\1066163|the|atwnk8 (l_nmod) atwnk8_22\NN\1740|of
T1_T14 NONE proline_33\NN\14601829|more|and|activities (l_conj) activities_36\NNS\30358|higher|cat (l_nmod) cat_38\NN\2120997|of|and|pod
T1_T15 NONE proline_33\NN\14601829|more|and|activities (l_conj) activities_36\NNS\30358|higher|cat (l_nmod) cat_38\NN\2120997|of|and|pod (l_conj) pod_40\NN\13139647|
T1_T16 NONE proline_33\NN\14601829|more|and|activities (r_dobj) accumulating_31\VBG\2281093|proline (r_csubj) result_42\VB\2633881|accumulating|might|tolerance (l_nmod) tolerance_46\NN\5032565|in|the|higher|wnk8|stress (l_nmod) wnk8_48\NN\1740|of
T1_T27 NONE proline_33\NN\14601829|more|and|activities (r_dobj) accumulating_31\VBG\2281093|proline (r_csubj) result_42\VB\2633881|accumulating|might|tolerance (r_conj) enhances_23\VBZ\227165|that|disruption|tolerance|,|and|result (r_acl:relcl) reasons_17\NNS\9178821|of|the|enhances (r_nmod) one_14\CD\13741022|that|maintaining|might|be|reasons (l_csubj) maintaining_6\VBG\2202928|activities (l_nmod) activities_11\NNS\30358|cat (l_compound) cat_8\NN\2120997|higher|and|pod
T1_T28 NONE proline_33\NN\14601829|more|and|activities (r_dobj) accumulating_31\VBG\2281093|proline (r_csubj) result_42\VB\2633881|accumulating|might|tolerance (r_conj) enhances_23\VBZ\227165|that|disruption|tolerance|,|and|result (r_acl:relcl) reasons_17\NNS\9178821|of|the|enhances (r_nmod) one_14\CD\13741022|that|maintaining|might|be|reasons (l_csubj) maintaining_6\VBG\2202928|activities (l_nmod) activities_11\NNS\30358|cat (l_compound) cat_8\NN\2120997|higher|and|pod (l_conj) pod_10\NN\13139647|
23261591
1351412
1318989
T17_T28 NONE naloxone_0\NN\3808977| (r_nsubj) prevent_3\VB\1740|naloxone|did|not|or|reverse|activity|;|change|. (l_parataxis) change_19\VB\46534|moreover|,|pretreatment|did|not|value (l_dobj) value_22\NN\5856066|the|pa2|displayed (l_acl) displayed_23\VBN\2137132|antagonist (l_nmod) antagonist_26\NN\7846|by|the|receptor (l_nmod) receptor_30\NN\5225602|at|the|mu
T18_T29 CPR:5 clonidine_8\NN\2721160| (r_dep) agonist_7\NN\9613191|of|the|2-adrenoceptor|clonidine (l_compound) 2-adrenoceptor_6\NN\1740|alpha
T19_T29 NONE n-acetyl_17\JJ\1740| (r_amod) beta-endorphin-(1_18\NN\1740|with|alpha|n-acetyl|31 (r_nmod) treated_14\VBN\2376958|beta-endorphin-(1 (r_acl) mice_13\NNS\2329401|in|treated (r_nmod) increased_11\VBN\169651|activity|was|also|mice|. (l_nsubjpass) activity_2\NN\30358|the|antinociceptive|agonist (l_nmod) agonist_7\NN\9613191|of|the|2-adrenoceptor|clonidine (l_compound) 2-adrenoceptor_6\NN\1740|alpha
T1_T22 NONE morphine-_11\NN\1740|and|beta-endorphin-induced (r_amod) analgesia_14\NN\14034177|upon|morphine- (r_nmod) activity_2\NN\30358|the|reducing|beta-endorphin-(1|analgesia (r_nsubjpass) exhibited_17\VBN\2632167|activity|was|not|mice|. (l_nmod) mice_19\NNS\2329401|in|undergoing (l_acl) undergoing_20\VBG\109660|treatment (l_dobj) treatment_21\NN\654885|toxin (l_nmod) toxin_24\NN\15032376|with|pertussis|or|n-ethylmaleimide|,|agents (l_appos) agents_28\NNS\7347|known (l_acl) known_29\VBN\2110220|impair (l_xcomp) impair_31\VB\258857|to|function (l_dobj) function_33\NN\13783581|the|proteins (l_nmod) proteins_37\NNS\14944888|of|gi/go|transducer (l_compound) gi/go_35\NN\1740|
T1_T23 NONE morphine-_11\NN\1740|and|beta-endorphin-induced (r_amod) analgesia_14\NN\14034177|upon|morphine- (r_nmod) activity_2\NN\30358|the|reducing|beta-endorphin-(1|analgesia (r_nsubjpass) exhibited_17\VBN\2632167|activity|was|not|mice|. (l_nmod) mice_19\NNS\2329401|in|undergoing (l_acl) undergoing_20\VBG\109660|treatment (l_dobj) treatment_21\NN\654885|toxin (l_nmod) toxin_24\NN\15032376|with|pertussis|or|n-ethylmaleimide|,|agents (l_appos) agents_28\NNS\7347|known (l_acl) known_29\VBN\2110220|impair (l_xcomp) impair_31\VB\258857|to|function (l_dobj) function_33\NN\13783581|the|proteins (l_nmod) proteins_37\NNS\14944888|of|gi/go|transducer (l_compound) gi/go_35\NN\1740|
T20_T22 NONE n-acetyl_5\JJ\1740| (r_amod) beta-endorphin-(1_6\NN\1740|of|alpha|n-acetyl|-|31 (r_nmod) activity_2\NN\30358|the|reducing|beta-endorphin-(1|analgesia (r_nsubjpass) exhibited_17\VBN\2632167|activity|was|not|mice|. (l_nmod) mice_19\NNS\2329401|in|undergoing (l_acl) undergoing_20\VBG\109660|treatment (l_dobj) treatment_21\NN\654885|toxin (l_nmod) toxin_24\NN\15032376|with|pertussis|or|n-ethylmaleimide|,|agents (l_appos) agents_28\NNS\7347|known (l_acl) known_29\VBN\2110220|impair (l_xcomp) impair_31\VB\258857|to|function (l_dobj) function_33\NN\13783581|the|proteins (l_nmod) proteins_37\NNS\14944888|of|gi/go|transducer (l_compound) gi/go_35\NN\1740|
T20_T23 NONE n-acetyl_5\JJ\1740| (r_amod) beta-endorphin-(1_6\NN\1740|of|alpha|n-acetyl|-|31 (r_nmod) activity_2\NN\30358|the|reducing|beta-endorphin-(1|analgesia (r_nsubjpass) exhibited_17\VBN\2632167|activity|was|not|mice|. (l_nmod) mice_19\NNS\2329401|in|undergoing (l_acl) undergoing_20\VBG\109660|treatment (l_dobj) treatment_21\NN\654885|toxin (l_nmod) toxin_24\NN\15032376|with|pertussis|or|n-ethylmaleimide|,|agents (l_appos) agents_28\NNS\7347|known (l_acl) known_29\VBN\2110220|impair (l_xcomp) impair_31\VB\258857|to|function (l_dobj) function_33\NN\13783581|the|proteins (l_nmod) proteins_37\NNS\14944888|of|gi/go|transducer (l_compound) gi/go_35\NN\1740|
T2_T22 NONE n-ethylmaleimide_26\NN\1740| (r_conj) toxin_24\NN\15032376|with|pertussis|or|n-ethylmaleimide|,|agents (l_appos) agents_28\NNS\7347|known (l_acl) known_29\VBN\2110220|impair (l_xcomp) impair_31\VB\258857|to|function (l_dobj) function_33\NN\13783581|the|proteins (l_nmod) proteins_37\NNS\14944888|of|gi/go|transducer (l_compound) gi/go_35\NN\1740|
T2_T23 NONE n-ethylmaleimide_26\NN\1740| (r_conj) toxin_24\NN\15032376|with|pertussis|or|n-ethylmaleimide|,|agents (l_appos) agents_28\NNS\7347|known (l_acl) known_29\VBN\2110220|impair (l_xcomp) impair_31\VB\258857|to|function (l_dobj) function_33\NN\13783581|the|proteins (l_nmod) proteins_37\NNS\14944888|of|gi/go|transducer (l_compound) gi/go_35\NN\1740|
T6_T24 NONE n-acetyl_9\JJ\1740| (r_amod) beta-endorphin-(1_10\NN\1740|of|alpha|n-acetyl|-|31|acting (l_acl) acting_14\VBG\1619354|regulator (l_nmod) regulator_18\NN\3096960|as|a|non-competitive|antinociception (l_nmod) antinociception_26\NN\1740|of|opioid-|supraspinal (l_amod) opioid-_21\NN\1740|mu|and|2-adrenoceptor-mediated
T6_T25 NONE n-acetyl_9\JJ\1740| (r_amod) beta-endorphin-(1_10\NN\1740|of|alpha|n-acetyl|-|31|acting (l_acl) acting_14\VBG\1619354|regulator (l_nmod) regulator_18\NN\3096960|as|a|non-competitive|antinociception (l_nmod) antinociception_26\NN\1740|of|opioid-|supraspinal (l_amod) opioid-_21\NN\1740|mu|and|2-adrenoceptor-mediated (l_conj) 2-adrenoceptor-mediated_24\JJ\1740|alpha
23202250
16292755
T23_T38 NONE e_1\NN\14724645| (r_compound) supplementation_2\NN\5108947|vitamin|e (r_nsubj) alters_3\VBZ\126264|supplementation|concentration|:|comparison|. (l_dobj) concentration_5\NN\4916342|hdl-cholesterol|and|activity|rabbits (l_compound) hdl-cholesterol_4\NN\1740|
T23_T39 NONE e_1\NN\14724645| (r_compound) supplementation_2\NN\5108947|vitamin|e (r_nsubj) alters_3\VBZ\126264|supplementation|concentration|:|comparison|. (l_dobj) concentration_5\NN\4916342|hdl-cholesterol|and|activity|rabbits (l_conj) activity_8\NN\30358|paraoxonase (l_compound) paraoxonase_7\NN\1740|
T24_T38 NONE high-cholesterol_12\JJ\1740| (r_amod) diet_13\NN\7560652|high-cholesterol (r_dobj) fed_11\VBG\1182709|diet (r_acl) rabbits_10\NNS\2323902|in|fed (r_nmod) concentration_5\NN\4916342|hdl-cholesterol|and|activity|rabbits (l_compound) hdl-cholesterol_4\NN\1740|
T24_T39 NONE high-cholesterol_12\JJ\1740| (r_amod) diet_13\NN\7560652|high-cholesterol (r_dobj) fed_11\VBG\1182709|diet (r_acl) rabbits_10\NNS\2323902|in|fed (r_nmod) concentration_5\NN\4916342|hdl-cholesterol|and|activity|rabbits (l_conj) activity_8\NN\30358|paraoxonase (l_compound) paraoxonase_7\NN\1740|
T25_T38 NONE probucol_17\NN\1740|with (r_nmod) comparison_15\NN\635850|probucol (r_dep) alters_3\VBZ\126264|supplementation|concentration|:|comparison|. (l_dobj) concentration_5\NN\4916342|hdl-cholesterol|and|activity|rabbits (l_compound) hdl-cholesterol_4\NN\1740|
T25_T39 NONE probucol_17\NN\1740|with (r_nmod) comparison_15\NN\635850|probucol (r_dep) alters_3\VBZ\126264|supplementation|concentration|:|comparison|. (l_dobj) concentration_5\NN\4916342|hdl-cholesterol|and|activity|rabbits (l_conj) activity_8\NN\30358|paraoxonase (l_compound) paraoxonase_7\NN\1740|
T26_T38 NONE hdl-cholesterol_4\NN\1740|
T26_T39 NONE hdl-cholesterol_4\NN\1740| (r_compound) concentration_5\NN\4916342|hdl-cholesterol|and|activity|rabbits (l_conj) activity_8\NN\30358|paraoxonase (l_compound) paraoxonase_7\NN\1740|
T10_T31 CPR:4 e_1\NN\14724645|vitamin|and|probucol (r_nsubj) suppressed_5\VBD\2510337|e|significantly|increase|. (l_dobj) increase_7\NN\13576355|an|plasma|group (l_nmod) plasma_9\NN\5398023|in|total-cholesterol (l_dep) total-cholesterol_10\NN\1740|total-c|and|cholesterol (l_conj) cholesterol_17\NN\15058310|low-density|lipoprotein (l_compound) lipoprotein_16\NN\14731135|
T11_T31 CPR:4 probucol_3\NN\1740| (r_conj) e_1\NN\14724645|vitamin|and|probucol (r_nsubj) suppressed_5\VBD\2510337|e|significantly|increase|. (l_dobj) increase_7\NN\13576355|an|plasma|group (l_nmod) plasma_9\NN\5398023|in|total-cholesterol (l_dep) total-cholesterol_10\NN\1740|total-c|and|cholesterol (l_conj) cholesterol_17\NN\15058310|low-density|lipoprotein (l_compound) lipoprotein_16\NN\14731135|
T12_T31 NONE total-cholesterol_10\NN\1740|total-c|and|cholesterol (l_conj) cholesterol_17\NN\15058310|low-density|lipoprotein (l_compound) lipoprotein_16\NN\14731135|
T13_T31 NONE cholesterol_17\NN\15058310|low-density|lipoprotein (l_compound) lipoprotein_16\NN\14731135|
T14_T32 NONE lipoprotein-cholesterol_4\NN\1740|plasma|high-density|hdl-c|and|ratio
T14_T33 NONE lipoprotein-cholesterol_4\NN\1740|plasma|high-density|hdl-c|and|ratio (l_appos) hdl-c_6\NN\1740|(|)
T14_T34 NONE lipoprotein-cholesterol_4\NN\1740|plasma|high-density|hdl-c|and|ratio (l_conj) ratio_10\NN\13815152|hdl-c/total-c (l_compound) hdl-c/total-c_9\NN\1740|
T14_T35 NONE lipoprotein-cholesterol_4\NN\1740|plasma|high-density|hdl-c|and|ratio (r_compound) levels_11\NNS\4916342|lipoprotein-cholesterol|and|activity (l_conj) activity_15\NN\30358|plasma|paraoxonase (l_compound) paraoxonase_14\NN\1740|
T15_T32 CPR:3 e_22\NN\14724645| (r_compound) group_23\NN\2137|in|vitamin|e (r_nmod) higher_19\JJR\1740|however|,|levels|were|significantly|group|weeks|. (l_nsubj) levels_11\NNS\4916342|lipoprotein-cholesterol|and|activity (l_compound) lipoprotein-cholesterol_4\NN\1740|plasma|high-density|hdl-c|and|ratio
T15_T33 CPR:3 e_22\NN\14724645| (r_compound) group_23\NN\2137|in|vitamin|e (r_nmod) higher_19\JJR\1740|however|,|levels|were|significantly|group|weeks|. (l_nsubj) levels_11\NNS\4916342|lipoprotein-cholesterol|and|activity (l_compound) lipoprotein-cholesterol_4\NN\1740|plasma|high-density|hdl-c|and|ratio (l_appos) hdl-c_6\NN\1740|(|)
T15_T34 CPR:3 e_22\NN\14724645| (r_compound) group_23\NN\2137|in|vitamin|e (r_nmod) higher_19\JJR\1740|however|,|levels|were|significantly|group|weeks|. (l_nsubj) levels_11\NNS\4916342|lipoprotein-cholesterol|and|activity (l_compound) lipoprotein-cholesterol_4\NN\1740|plasma|high-density|hdl-c|and|ratio (l_conj) ratio_10\NN\13815152|hdl-c/total-c (l_compound) hdl-c/total-c_9\NN\1740|
T15_T35 CPR:3 e_22\NN\14724645| (r_compound) group_23\NN\2137|in|vitamin|e (r_nmod) higher_19\JJR\1740|however|,|levels|were|significantly|group|weeks|. (l_nsubj) levels_11\NNS\4916342|lipoprotein-cholesterol|and|activity (l_conj) activity_15\NN\30358|plasma|paraoxonase (l_compound) paraoxonase_14\NN\1740|
T16_T36 CPR:4 e_9\NN\14724645|in|both|vitamin|and|probucol (r_compound) groups_12\NNS\2137|e (r_nmod) lower_5\JJR\1740|activity|was|significantly|groups|group|,|highest|. (l_nsubj) activity_2\NN\30358|hepatic|acat (l_compound) acat_1\NN\1740|
T16_T37 NONE e_9\NN\14724645|in|both|vitamin|and|probucol (r_compound) groups_12\NNS\2137|e (r_nmod) lower_5\JJR\1740|activity|was|significantly|groups|group|,|highest|. (l_advcl) highest_24\JJS\1740|while|activity|was|the|group (l_nsubj) activity_21\NN\30358|hmg-coa|reductase (l_compound) reductase_20\NN\14732946|
T17_T36 CPR:4 probucol_11\NN\1740| (r_conj) e_9\NN\14724645|in|both|vitamin|and|probucol (r_compound) groups_12\NNS\2137|e (r_nmod) lower_5\JJR\1740|activity|was|significantly|groups|group|,|highest|. (l_nsubj) activity_2\NN\30358|hepatic|acat (l_compound) acat_1\NN\1740|
T17_T37 NONE probucol_11\NN\1740| (r_conj) e_9\NN\14724645|in|both|vitamin|and|probucol (r_compound) groups_12\NNS\2137|e (r_nmod) lower_5\JJR\1740|activity|was|significantly|groups|group|,|highest|. (l_advcl) highest_24\JJS\1740|while|activity|was|the|group (l_nsubj) activity_21\NN\30358|hmg-coa|reductase (l_compound) reductase_20\NN\14732946|
T18_T36 NONE hmg-coa_19\NN\1740| (r_compound) activity_21\NN\30358|hmg-coa|reductase (r_nsubj) highest_24\JJS\1740|while|activity|was|the|group (r_advcl) lower_5\JJR\1740|activity|was|significantly|groups|group|,|highest|. (l_nsubj) activity_2\NN\30358|hepatic|acat (l_compound) acat_1\NN\1740|
T18_T37 NONE hmg-coa_19\NN\1740| (r_compound) activity_21\NN\30358|hmg-coa|reductase (l_compound) reductase_20\NN\14732946|
T19_T36 NONE probucol_28\NN\1740| (r_compound) group_29\NN\2137|only|in|the|probucol (r_nmod) highest_24\JJS\1740|while|activity|was|the|group (r_advcl) lower_5\JJR\1740|activity|was|significantly|groups|group|,|highest|. (l_nsubj) activity_2\NN\30358|hepatic|acat (l_compound) acat_1\NN\1740|
T19_T37 CPR:3 probucol_28\NN\1740| (r_compound) group_29\NN\2137|only|in|the|probucol (r_nmod) highest_24\JJS\1740|while|activity|was|the|group (l_nsubj) activity_21\NN\30358|hmg-coa|reductase (l_compound) reductase_20\NN\14732946|
T2_T27 CPR:4 probucol_13\NN\1740| (r_compound) group_14\NN\2137|in|probucol (r_nmod) lower_11\JJR\1740|expressions|were|significantly|group|groups|. (l_nsubj) expressions_2\NNS\4679549|hepatic|mrna|b-100 (l_nmod) b-100_5\NN\1740|of|apo|and|c-iii
T2_T28 CPR:4 probucol_13\NN\1740| (r_compound) group_14\NN\2137|in|probucol (r_nmod) lower_11\JJR\1740|expressions|were|significantly|group|groups|. (l_nsubj) expressions_2\NNS\4679549|hepatic|mrna|b-100 (l_nmod) b-100_5\NN\1740|of|apo|and|c-iii (l_conj) c-iii_8\NN\1740|apo
T3_T29 NONE e_1\NN\14724645| (r_compound) supplementation_2\NN\5108947|vitamin|e (r_nsubjpass) found_4\VBN\2426171|supplementation|was|alter|;|effective (l_xcomp) alter_6\VB\126264|to|factors (l_dobj) factors_10\NNS\7326557|the|plasma|hdl-c-related (l_amod) hdl-c-related_9\JJ\1740|
T3_T30 NONE e_1\NN\14724645| (r_compound) supplementation_2\NN\5108947|vitamin|e (r_nsubjpass) found_4\VBN\2426171|supplementation|was|alter|;|effective (l_parataxis) effective_18\JJ\1740|meanwhile|,|supplementation|was|very|enhancing|,|effect|. (l_nmod) effect_28\NN\34213|except|for|a|negative|reduced (l_acl:relcl) reduced_30\VBD\441445|that|concentration (l_dobj) concentration_33\NN\4916342|plasma|hdl-c (l_compound) hdl-c_32\NN\1740|
T4_T29 NONE probucol_14\NN\1740| (r_compound) supplementation_15\NN\5108947|probucol (r_nsubj) effective_18\JJ\1740|meanwhile|,|supplementation|was|very|enhancing|,|effect|. (r_parataxis) found_4\VBN\2426171|supplementation|was|alter|;|effective (l_xcomp) alter_6\VB\126264|to|factors (l_dobj) factors_10\NNS\7326557|the|plasma|hdl-c-related (l_amod) hdl-c-related_9\JJ\1740|
T4_T30 CPR:4 probucol_14\NN\1740| (r_compound) supplementation_15\NN\5108947|probucol (r_nsubj) effective_18\JJ\1740|meanwhile|,|supplementation|was|very|enhancing|,|effect|. (l_nmod) effect_28\NN\34213|except|for|a|negative|reduced (l_acl:relcl) reduced_30\VBD\441445|that|concentration (l_dobj) concentration_33\NN\4916342|plasma|hdl-c (l_compound) hdl-c_32\NN\1740|
T5_T29 NONE cholesterol_21\NN\15058310| (r_compound) metabolism_22\NN\13526110|cholesterol (r_dobj) enhancing_20\VBG\227165|in|metabolism (r_advcl) effective_18\JJ\1740|meanwhile|,|supplementation|was|very|enhancing|,|effect|. (r_parataxis) found_4\VBN\2426171|supplementation|was|alter|;|effective (l_xcomp) alter_6\VB\126264|to|factors (l_dobj) factors_10\NNS\7326557|the|plasma|hdl-c-related (l_amod) hdl-c-related_9\JJ\1740|
T5_T30 NONE cholesterol_21\NN\15058310| (r_compound) metabolism_22\NN\13526110|cholesterol (r_dobj) enhancing_20\VBG\227165|in|metabolism (r_advcl) effective_18\JJ\1740|meanwhile|,|supplementation|was|very|enhancing|,|effect|. (l_nmod) effect_28\NN\34213|except|for|a|negative|reduced (l_acl:relcl) reduced_30\VBD\441445|that|concentration (l_dobj) concentration_33\NN\4916342|plasma|hdl-c (l_compound) hdl-c_32\NN\1740|
10683249
T17_T36 NONE nad(p)h_6\NN\1740| (r_compound) oxidoreductases_9\NNS\14732946|of|microsomal|nad(p)h|quinone
T18_T36 NONE quinone_8\NN\14818238|: (r_compound) oxidoreductases_9\NNS\14732946|of|microsomal|nad(p)h|quinone
T1_T19 NONE quinone_0\NN\14818238| (r_compound) oxidoreductases_1\NNS\14732946|quinone
T2_T19 CPR:9 quinones_11\NNS\14818238|of (r_nmod) reduction_7\NN\351485|two-electron|and|detoxification|quinones (r_dobj) catalyze_5\VBP\146138|that|reduction (r_acl:relcl) flavoproteins_3\NNS\1740|oxidoreductases|are|catalyze|. (l_nsubj) oxidoreductases_1\NNS\14732946|quinone
T10_T24 NONE quinone_18\NN\14818238| (r_compound) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (r_conj) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (r_dep) forms_2\NNS\6286395|two|cytosolic|oxidoreductases|oxidoreductase (l_nmod) oxidoreductases_5\NNS\14732946|of|quinone
T10_T25 NONE quinone_18\NN\14818238| (r_compound) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (r_conj) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_nummod) 1_11\CD\13741022|
T10_T26 NONE quinone_18\NN\14818238| (r_compound) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (r_conj) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_appos) nqo1_13\NN\1740|(|)
T10_T27 NONE quinone_18\NN\14818238| (r_compound) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (l_nummod) 2_20\CD\13741022|
T10_T28 NONE quinone_18\NN\14818238| (r_compound) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (l_appos) nqo2_22\NN\1740|(|)
T7_T24 NONE quinone_4\NN\14818238| (r_compound) oxidoreductases_5\NNS\14732946|of|quinone
T7_T25 NONE quinone_4\NN\14818238| (r_compound) oxidoreductases_5\NNS\14732946|of|quinone (r_nmod) forms_2\NNS\6286395|two|cytosolic|oxidoreductases|oxidoreductase (l_dep) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_nummod) 1_11\CD\13741022|
T7_T26 NONE quinone_4\NN\14818238| (r_compound) oxidoreductases_5\NNS\14732946|of|quinone (r_nmod) forms_2\NNS\6286395|two|cytosolic|oxidoreductases|oxidoreductase (l_dep) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_appos) nqo1_13\NN\1740|(|)
T7_T27 NONE quinone_4\NN\14818238| (r_compound) oxidoreductases_5\NNS\14732946|of|quinone (r_nmod) forms_2\NNS\6286395|two|cytosolic|oxidoreductases|oxidoreductase (l_dep) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_conj) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (l_nummod) 2_20\CD\13741022|
T7_T28 NONE quinone_4\NN\14818238| (r_compound) oxidoreductases_5\NNS\14732946|of|quinone (r_nmod) forms_2\NNS\6286395|two|cytosolic|oxidoreductases|oxidoreductase (l_dep) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_conj) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (l_appos) nqo2_22\NN\1740|(|)
T8_T24 NONE nad(p)h_7\NN\1740| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (r_dep) forms_2\NNS\6286395|two|cytosolic|oxidoreductases|oxidoreductase (l_nmod) oxidoreductases_5\NNS\14732946|of|quinone
T8_T25 NONE nad(p)h_7\NN\1740| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_nummod) 1_11\CD\13741022|
T8_T26 NONE nad(p)h_7\NN\1740| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_appos) nqo1_13\NN\1740|(|)
T8_T27 NONE nad(p)h_7\NN\1740| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_conj) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (l_nummod) 2_20\CD\13741022|
T8_T28 NONE nad(p)h_7\NN\1740| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_conj) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (l_appos) nqo2_22\NN\1740|(|)
T9_T24 NONE quinone_9\NN\14818238| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (r_dep) forms_2\NNS\6286395|two|cytosolic|oxidoreductases|oxidoreductase (l_nmod) oxidoreductases_5\NNS\14732946|of|quinone
T9_T25 NONE quinone_9\NN\14818238| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_nummod) 1_11\CD\13741022|
T9_T26 NONE quinone_9\NN\14818238| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_appos) nqo1_13\NN\1740|(|)
T9_T27 NONE quinone_9\NN\14818238| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_conj) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (l_nummod) 2_20\CD\13741022|
T9_T28 NONE quinone_9\NN\14818238| (r_compound) oxidoreductase_10\NN\14732946|[|nad(p)h|:|quinone|1|nqo1|and|oxidoreductase|] (l_conj) oxidoreductase_19\NN\14732946|nrh|:|quinone|2|nqo2 (l_appos) nqo2_22\NN\1740|(|)
T11_T29 CPR:9 quinones_18\NNS\14818238|of (r_nmod) mutagenicity_16\NN\1740|quinones (r_conj) stress_11\NN\7083732|from|oxidative|,|cytotoxicity|,|and|mutagenicity (r_nmod) protection_6\NN\407535|in|cells|stress (r_nmod) role_1\NN\719494|a|nqo1|protection (l_nmod) nqo1_4\NN\1740|of|cytosolic
T12_T33 NONE nadh_8\NN\1740|for (r_nmod) affinity_6\NN\11426530|higher|nadh|nadph|donors (r_dobj) showed_3\VBD\2137132|activity|affinity|and|catalyzed|. (l_nsubj) activity_2\NN\30358|the|mnqo (l_compound) mnqo_1\NN\1740|
T13_T33 NONE nadph_10\NN\1740|than (r_nmod) affinity_6\NN\11426530|higher|nadh|nadph|donors (r_dobj) showed_3\VBD\2137132|activity|affinity|and|catalyzed|. (l_nsubj) activity_2\NN\30358|the|mnqo (l_compound) mnqo_1\NN\1740|
T14_T33 CPR:9 2,6-dichlorophenolindophenol_18\NN\1740|of|and|menadione (r_nmod) reduction_16\NN\351485|2,6-dichlorophenolindophenol (r_dobj) catalyzed_15\VBD\146138|reduction (r_conj) showed_3\VBD\2137132|activity|affinity|and|catalyzed|. (l_nsubj) activity_2\NN\30358|the|mnqo (l_compound) mnqo_1\NN\1740|
T15_T33 CPR:9 menadione_20\NN\15092751| (r_conj) 2,6-dichlorophenolindophenol_18\NN\1740|of|and|menadione (r_nmod) reduction_16\NN\351485|2,6-dichlorophenolindophenol (r_dobj) catalyzed_15\VBD\146138|reduction (r_conj) showed_3\VBD\2137132|activity|affinity|and|catalyzed|. (l_nsubj) activity_2\NN\30358|the|mnqo (l_compound) mnqo_1\NN\1740|
T16_T34 NONE dicoumarol_6\NN\2718259|to|,|inhibitor (r_nmod) insensitive_4\JJ\1740|activity|was|dicoumarol|. (l_nsubj) activity_2\NN\30358|the|mnqo (l_compound) mnqo_1\NN\1740|
T16_T35 CPR:4 dicoumarol_6\NN\2718259|to|,|inhibitor (l_appos) inhibitor_10\NN\20090|a|potent|nqo1 (l_nmod) nqo1_13\NN\1740|of|cytosolic
T3_T21 NONE sulfate_15\NN\15010703| (r_compound) fractionation_16\NN\13497928|ammonium|sulfate (r_conj) chaps_12\NN\9624168|with|detergent|,|fractionation|,|and|chromatography (r_nmod) solubilization_7\NN\1740|by|microsomes|chaps (r_nmod) purified_5\VBN\205885|activity|was|partially|solubilization|. (l_nsubjpass) activity_2\NN\30358|the|mnqo (l_compound) mnqo_1\NN\1740|
T4_T21 NONE deae-sephacel_19\NN\1740| (r_compound) chromatography_21\NN\13518963|deae-sephacel|column (r_conj) chaps_12\NN\9624168|with|detergent|,|fractionation|,|and|chromatography (r_nmod) solubilization_7\NN\1740|by|microsomes|chaps (r_nmod) purified_5\VBN\205885|activity|was|partially|solubilization|. (l_nsubjpass) activity_2\NN\30358|the|mnqo (l_compound) mnqo_1\NN\1740|
T5_T22 NONE quinone_14\NN\14818238| (r_compound) toxicity_15\NN\13576101|against|quinone|and|mutagenicity (r_nmod) protection_9\NN\407535|additional|nqos|toxicity (r_dobj) provide_7\VB\2199590|to|protection (r_xcomp) expected_5\VBN\670261|proteins|are|provide|. (l_nsubjpass) proteins_3\NNS\14944888|the|microsomal|mnqo (l_compound) mnqo_2\NN\1740|
T5_T23 NONE quinone_14\NN\14818238| (r_compound) toxicity_15\NN\13576101|against|quinone|and|mutagenicity (r_nmod) protection_9\NN\407535|additional|nqos|toxicity (l_nmod) nqos_12\NN\1740|after|cytosolic
23319591
T1_T17 NONE lysine_5\NN\14605787|on|4 (r_nmod) methylation_0\NN\1740|h3|lysine|protein (l_nmod) h3_3\NN\1740|of|histone
T1_T18 NONE lysine_5\NN\14605787|on|4 (r_nmod) methylation_0\NN\1740|h3|lysine|protein (l_nmod) protein_12\NN\14944888|by|the|lysine|methyltransferase|set1 (l_compound) methyltransferase_10\NN\1740|
T1_T19 NONE lysine_5\NN\14605787|on|4 (r_nmod) methylation_0\NN\1740|h3|lysine|protein (l_nmod) protein_12\NN\14944888|by|the|lysine|methyltransferase|set1 (l_compound) set1_11\NN\1740|
T2_T17 NONE lysine_9\NN\14605787| (r_compound) protein_12\NN\14944888|by|the|lysine|methyltransferase|set1 (r_nmod) methylation_0\NN\1740|h3|lysine|protein (l_nmod) h3_3\NN\1740|of|histone
T2_T18 NONE lysine_9\NN\14605787| (r_compound) protein_12\NN\14944888|by|the|lysine|methyltransferase|set1 (l_compound) methyltransferase_10\NN\1740|
T2_T19 NONE lysine_9\NN\14605787| (r_compound) protein_12\NN\14944888|by|the|lysine|methyltransferase|set1 (l_compound) set1_11\NN\1740|
11808879
T3_T11 NONE diazoxide_17\NN\4522904|to (r_nmod) resistant_15\JJ\1740|patients|were|diazoxide|. (l_nsubj) patients_2\NNS\9898892|all|mutations (l_nmod) mutations_13\NNS\4475|sur1 (l_compound) sur1_4\NN\1740|with|38/41|or|kir6.2
T3_T12 NONE diazoxide_17\NN\4522904|to (r_nmod) resistant_15\JJ\1740|patients|were|diazoxide|. (l_nsubj) patients_2\NNS\9898892|all|mutations (l_nmod) mutations_13\NNS\4475|sur1 (l_compound) sur1_4\NN\1740|with|38/41|or|kir6.2 (l_conj) kir6.2_9\NN\1740|5/7
T4_T13 NONE glutamate_10\NN\15010703| (r_compound) gene_12\NN\8459252|in|the|glutamate|dehydrogenase (l_compound) dehydrogenase_11\NN\1740|
23318833
T10_T26 NONE s-transferase_8\NN\1740| (r_compound) form_10\NN\6286395|glutathione|s-transferase|placental|(gst-p)(+
T10_T27 NONE s-transferase_8\NN\1740| (r_compound) form_10\NN\6286395|glutathione|s-transferase|placental|(gst-p)(+ (l_dep) (gst-p)(+_11\JJ\1740|)
T8_T26 CPR:3 taa_0\NN\1740| (r_nsubj) increased_1\VBD\169651|taa|number|. (l_dobj) number_3\NN\5107765|the|and|area|foci|and|numbers (l_nmod) foci_15\NNS\5704266|of|form|liver|cell (l_compound) form_10\NN\6286395|glutathione|s-transferase|placental|(gst-p)(+
T8_T27 CPR:3 taa_0\NN\1740| (r_nsubj) increased_1\VBD\169651|taa|number|. (l_dobj) number_3\NN\5107765|the|and|area|foci|and|numbers (l_nmod) foci_15\NNS\5704266|of|form|liver|cell (l_compound) form_10\NN\6286395|glutathione|s-transferase|placental|(gst-p)(+ (l_dep) (gst-p)(+_11\JJ\1740|)
T9_T26 NONE glutathione_7\NN\1740| (r_compound) form_10\NN\6286395|glutathione|s-transferase|placental|(gst-p)(+
T9_T27 NONE glutathione_7\NN\1740| (r_compound) form_10\NN\6286395|glutathione|s-transferase|placental|(gst-p)(+ (l_dep) (gst-p)(+_11\JJ\1740|)
T12_T28 CPR:4 taa_0\NN\1740| (r_nsubj) increased_2\VBD\169651|taa|also|numbers|. (l_dobj) numbers_4\NNS\508091|the|ed2(+|,|as|number (l_nmod) ed2(+_6\JJ\1740|of|)|,|cyclooxygenase-2(+|,|and|oxygenase-1(+|cells (l_conj) cyclooxygenase-2(+_9\NN\1740|)
T12_T29 CPR:4 taa_0\NN\1740| (r_nsubj) increased_2\VBD\169651|taa|also|numbers|. (l_dobj) numbers_4\NNS\508091|the|ed2(+|,|as|number (l_nmod) ed2(+_6\JJ\1740|of|)|,|cyclooxygenase-2(+|,|and|oxygenase-1(+|cells (l_conj) oxygenase-1(+_14\NN\1740|heme|)
T12_T30 CPR:4 taa_0\NN\1740| (r_nsubj) increased_2\VBD\169651|taa|also|numbers|. (l_dobj) numbers_4\NNS\508091|the|ed2(+|,|as|number (l_conj) number_23\NN\5107765|the|lymphocytes (l_nmod) lymphocytes_27\NNS\5449959|of|cd3(+|) (l_amod) cd3(+_25\JJ\1740|
T13_T28 NONE heme_13\NN\14989820| (r_compound) oxygenase-1(+_14\NN\1740|heme|) (r_conj) ed2(+_6\JJ\1740|of|)|,|cyclooxygenase-2(+|,|and|oxygenase-1(+|cells (l_conj) cyclooxygenase-2(+_9\NN\1740|)
T13_T29 NONE heme_13\NN\14989820| (r_compound) oxygenase-1(+_14\NN\1740|heme|)
T13_T30 NONE heme_13\NN\14989820| (r_compound) oxygenase-1(+_14\NN\1740|heme|) (r_conj) ed2(+_6\JJ\1740|of|)|,|cyclooxygenase-2(+|,|and|oxygenase-1(+|cells (r_nmod) numbers_4\NNS\508091|the|ed2(+|,|as|number (l_conj) number_23\NN\5107765|the|lymphocytes (l_nmod) lymphocytes_27\NNS\5449959|of|cd3(+|) (l_amod) cd3(+_25\JJ\1740|
T14_T17 NONE acid-reactive_6\JJ\1740| (r_amod) substance_7\NN\20827|of|thiobarbituric|acid-reactive|and|8-hydroxydeoxyguanosine (r_nmod) levels_3\NNS\4916342|liver|substance (r_dobj) increased_1\VBD\169651|emiq|levels|,|and|cells|foci|. (l_conj) cells_15\NNS\3080309|tunel(+|)|apoptotic|,|cells|and|cells (l_conj) cells_22\NNS\3080309|death|receptor|5|(dr5)(+|) (l_nummod) 5_19\CD\13741022|
T14_T18 NONE acid-reactive_6\JJ\1740| (r_amod) substance_7\NN\20827|of|thiobarbituric|acid-reactive|and|8-hydroxydeoxyguanosine (r_nmod) levels_3\NNS\4916342|liver|substance (r_dobj) increased_1\VBD\169651|emiq|levels|,|and|cells|foci|. (l_conj) cells_15\NNS\3080309|tunel(+|)|apoptotic|,|cells|and|cells (l_conj) cells_22\NNS\3080309|death|receptor|5|(dr5)(+|) (l_amod) (dr5)(+_20\JJ\1740|
T14_T19 NONE acid-reactive_6\JJ\1740| (r_amod) substance_7\NN\20827|of|thiobarbituric|acid-reactive|and|8-hydroxydeoxyguanosine (r_nmod) levels_3\NNS\4916342|liver|substance (r_dobj) increased_1\VBD\169651|emiq|levels|,|and|cells|foci|. (l_nmod) foci_30\NNS\5704266|within|gst-p(+|) (l_amod) gst-p(+_28\JJ\1740|
T1_T17 NONE 8-hydroxydeoxyguanosine_9\NN\1740| (r_conj) substance_7\NN\20827|of|thiobarbituric|acid-reactive|and|8-hydroxydeoxyguanosine (r_nmod) levels_3\NNS\4916342|liver|substance (r_dobj) increased_1\VBD\169651|emiq|levels|,|and|cells|foci|. (l_conj) cells_15\NNS\3080309|tunel(+|)|apoptotic|,|cells|and|cells (l_conj) cells_22\NNS\3080309|death|receptor|5|(dr5)(+|) (l_nummod) 5_19\CD\13741022|
T1_T18 NONE 8-hydroxydeoxyguanosine_9\NN\1740| (r_conj) substance_7\NN\20827|of|thiobarbituric|acid-reactive|and|8-hydroxydeoxyguanosine (r_nmod) levels_3\NNS\4916342|liver|substance (r_dobj) increased_1\VBD\169651|emiq|levels|,|and|cells|foci|. (l_conj) cells_15\NNS\3080309|tunel(+|)|apoptotic|,|cells|and|cells (l_conj) cells_22\NNS\3080309|death|receptor|5|(dr5)(+|) (l_amod) (dr5)(+_20\JJ\1740|
T1_T19 NONE 8-hydroxydeoxyguanosine_9\NN\1740| (r_conj) substance_7\NN\20827|of|thiobarbituric|acid-reactive|and|8-hydroxydeoxyguanosine (r_nmod) levels_3\NNS\4916342|liver|substance (r_dobj) increased_1\VBD\169651|emiq|levels|,|and|cells|foci|. (l_nmod) foci_30\NNS\5704266|within|gst-p(+|) (l_amod) gst-p(+_28\JJ\1740|
T2_T17 NONE 4-hydroxy-2-nonenal(+_24\NN\1740| (r_amod) cells_26\NNS\3080309|4-hydroxy-2-nonenal(+|) (r_conj) cells_15\NNS\3080309|tunel(+|)|apoptotic|,|cells|and|cells (l_conj) cells_22\NNS\3080309|death|receptor|5|(dr5)(+|) (l_nummod) 5_19\CD\13741022|
T2_T18 NONE 4-hydroxy-2-nonenal(+_24\NN\1740| (r_amod) cells_26\NNS\3080309|4-hydroxy-2-nonenal(+|) (r_conj) cells_15\NNS\3080309|tunel(+|)|apoptotic|,|cells|and|cells (l_conj) cells_22\NNS\3080309|death|receptor|5|(dr5)(+|) (l_amod) (dr5)(+_20\JJ\1740|
T2_T19 NONE 4-hydroxy-2-nonenal(+_24\NN\1740| (r_amod) cells_26\NNS\3080309|4-hydroxy-2-nonenal(+|) (r_conj) cells_15\NNS\3080309|tunel(+|)|apoptotic|,|cells|and|cells (r_conj) increased_1\VBD\169651|emiq|levels|,|and|cells|foci|. (l_nmod) foci_30\NNS\5704266|within|gst-p(+|) (l_amod) gst-p(+_28\JJ\1740|
23159479
T6_T12 NONE oxytocin_3\NN\5407119|
T2_T8 NONE oxytocin_10\NN\5407119|
T1_T7 NONE oxytocin_17\NN\5407119|of|intranasal
T3_T9 NONE oxytocin_18\NN\5407119|after
T4_T10 NONE oxytocin_3\NN\5407119|
T5_T11 NONE oxytocin_0\NN\5407119|
16741870
T10_T28 NONE hormone_1\NN\5404728| (r_compound) receptor_2\NN\5225602|thyroid|hormone
T1_T17 NONE hormone_12\NN\5404728| (r_compound) receptors_13\NNS\5225602|to|thyroid|hormone|trs
T1_T18 NONE hormone_12\NN\5404728| (r_compound) receptors_13\NNS\5225602|to|thyroid|hormone|trs (l_appos) trs_15\NNS\1740|(|)
T3_T19 NONE hormone_13\NN\5404728|to|thyroid (r_nmod) response_7\NN\11410625|of|tissues|hormone (r_nmod) acquisition_5\NN\41899|on|the|response (r_nmod) depends_2\VBZ\2604760|since|metamorphosis|acquisition (r_advcl) aimed_16\VBD\1987160|depends|,|we|determine|. (l_xcomp) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (l_compound) tr_19\NN\1740|
T3_T20 NONE hormone_13\NN\5404728|to|thyroid (r_nmod) response_7\NN\11410625|of|tissues|hormone (r_nmod) acquisition_5\NN\41899|on|the|response (r_nmod) depends_2\VBZ\2604760|since|metamorphosis|acquisition (r_advcl) aimed_16\VBD\1987160|depends|,|we|determine|. (l_xcomp) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) protein_39\NN\14944888|
T3_T21 NONE hormone_13\NN\5404728|to|thyroid (r_nmod) response_7\NN\11410625|of|tissues|hormone (r_nmod) acquisition_5\NN\41899|on|the|response (r_nmod) depends_2\VBZ\2604760|since|metamorphosis|acquisition (r_advcl) aimed_16\VBD\1987160|depends|,|we|determine|. (l_xcomp) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) (cthbp)-m2-pyruvate_40\NN\1740|
T3_T22 NONE hormone_13\NN\5404728|to|thyroid (r_nmod) response_7\NN\11410625|of|tissues|hormone (r_nmod) acquisition_5\NN\41899|on|the|response (r_nmod) depends_2\VBZ\2604760|since|metamorphosis|acquisition (r_advcl) aimed_16\VBD\1987160|depends|,|we|determine|. (l_xcomp) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene
T3_T23 NONE hormone_13\NN\5404728|to|thyroid (r_nmod) response_7\NN\11410625|of|tissues|hormone (r_nmod) acquisition_5\NN\41899|on|the|response (r_nmod) depends_2\VBZ\2604760|since|metamorphosis|acquisition (r_advcl) aimed_16\VBD\1987160|depends|,|we|determine|. (l_xcomp) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_appos) gene_44\NN\8459252|a|encoding (l_acl) encoding_45\VBG\115157|protein (l_dobj) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin
T3_T24 NONE hormone_13\NN\5404728|to|thyroid (r_nmod) response_7\NN\11410625|of|tissues|hormone (r_nmod) acquisition_5\NN\41899|on|the|response (r_nmod) depends_2\VBZ\2604760|since|metamorphosis|acquisition (r_advcl) aimed_16\VBD\1987160|depends|,|we|determine|. (l_xcomp) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_appos) gene_44\NN\8459252|a|encoding (l_acl) encoding_45\VBG\115157|protein (l_dobj) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (l_conj) stromelysin_52\NN\1740|3|,|gene (l_nummod) 3_53\CD\13741022|
T5_T19 NONE th-related_33\JJ\1740| (r_amod) genes_34\NNS\8459252|of|two|th-related (r_nmod) expression_30\NN\4679549|the|genes (r_conj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (l_compound) tr_19\NN\1740|
T5_T20 NONE th-related_33\JJ\1740| (r_amod) genes_34\NNS\8459252|of|two|th-related (r_nmod) expression_30\NN\4679549|the|genes (r_conj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (r_dobj) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) protein_39\NN\14944888|
T5_T21 NONE th-related_33\JJ\1740| (r_amod) genes_34\NNS\8459252|of|two|th-related (r_nmod) expression_30\NN\4679549|the|genes (r_conj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (r_dobj) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) (cthbp)-m2-pyruvate_40\NN\1740|
T5_T22 NONE th-related_33\JJ\1740| (r_amod) genes_34\NNS\8459252|of|two|th-related (r_nmod) expression_30\NN\4679549|the|genes (r_conj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (r_dobj) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene
T5_T23 NONE th-related_33\JJ\1740| (r_amod) genes_34\NNS\8459252|of|two|th-related (r_nmod) expression_30\NN\4679549|the|genes (r_conj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (r_dobj) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_appos) gene_44\NN\8459252|a|encoding (l_acl) encoding_45\VBG\115157|protein (l_dobj) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin
T5_T24 NONE th-related_33\JJ\1740| (r_amod) genes_34\NNS\8459252|of|two|th-related (r_nmod) expression_30\NN\4679549|the|genes (r_conj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (r_dobj) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_appos) gene_44\NN\8459252|a|encoding (l_acl) encoding_45\VBG\115157|protein (l_dobj) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (l_conj) stromelysin_52\NN\1740|3|,|gene (l_nummod) 3_53\CD\13741022|
T6_T19 NONE hormone-binding_38\JJ\1740| (r_amod) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (r_dobj) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (l_compound) tr_19\NN\1740|
T6_T20 NONE hormone-binding_38\JJ\1740| (r_amod) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) protein_39\NN\14944888|
T6_T21 NONE hormone-binding_38\JJ\1740| (r_amod) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) (cthbp)-m2-pyruvate_40\NN\1740|
T6_T22 NONE hormone-binding_38\JJ\1740| (r_amod) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene
T6_T23 NONE hormone-binding_38\JJ\1740| (r_amod) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_appos) gene_44\NN\8459252|a|encoding (l_acl) encoding_45\VBG\115157|protein (l_dobj) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin
T6_T24 NONE hormone-binding_38\JJ\1740| (r_amod) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_appos) gene_44\NN\8459252|a|encoding (l_acl) encoding_45\VBG\115157|protein (l_dobj) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (l_conj) stromelysin_52\NN\1740|3|,|gene (l_nummod) 3_53\CD\13741022|
T7_T19 NONE (cthbp)-m2-pyruvate_40\NN\1740| (r_compound) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (r_dobj) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (l_compound) tr_19\NN\1740|
T7_T20 NONE (cthbp)-m2-pyruvate_40\NN\1740| (r_compound) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) protein_39\NN\14944888|
T7_T21 NONE (cthbp)-m2-pyruvate_40\NN\1740|
T7_T22 NONE (cthbp)-m2-pyruvate_40\NN\1740| (r_compound) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene
T7_T23 NONE (cthbp)-m2-pyruvate_40\NN\1740| (r_compound) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_appos) gene_44\NN\8459252|a|encoding (l_acl) encoding_45\VBG\115157|protein (l_dobj) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin
T7_T24 NONE (cthbp)-m2-pyruvate_40\NN\1740| (r_compound) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_appos) gene_44\NN\8459252|a|encoding (l_acl) encoding_45\VBG\115157|protein (l_dobj) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (l_conj) stromelysin_52\NN\1740|3|,|gene (l_nummod) 3_53\CD\13741022|
T8_T19 NONE th_48\NN\15163157| (r_compound) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (r_dobj) encoding_45\VBG\115157|protein (r_acl) gene_44\NN\8459252|a|encoding (r_appos) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (r_dobj) determine_18\VB\1645601|to|patterns|:|kinase (l_dobj) patterns_22\NNS\5726345|tr|gene|expression|maculosus|as|expression (l_compound) tr_19\NN\1740|
T8_T20 NONE th_48\NN\15163157| (r_compound) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (r_dobj) encoding_45\VBG\115157|protein (r_acl) gene_44\NN\8459252|a|encoding (r_appos) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) protein_39\NN\14944888|
T8_T21 NONE th_48\NN\15163157| (r_compound) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (r_dobj) encoding_45\VBG\115157|protein (r_acl) gene_44\NN\8459252|a|encoding (r_appos) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene (l_compound) (cthbp)-m2-pyruvate_40\NN\1740|
T8_T22 NONE th_48\NN\15163157| (r_compound) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (r_dobj) encoding_45\VBG\115157|protein (r_acl) gene_44\NN\8459252|a|encoding (r_appos) kinase_41\NN\14732946|cytosolic|thyroid|hormone-binding|protein|(cthbp)-m2-pyruvate|,|gene
T8_T23 NONE th_48\NN\15163157| (r_compound) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin
T8_T24 NONE th_48\NN\15163157| (r_compound) protein_50\NN\14944888|a|cytosolic|th|binding|and|stromelysin (l_conj) stromelysin_52\NN\1740|3|,|gene (l_nummod) 3_53\CD\13741022|
16359899
T5_T13 NONE biotin_38\NN\15090742|of|the|vitamin (r_nmod) aspects_34\NNS\5849789|with|different|biotin (r_nmod) deal_31\VBP\964911|aspects|,|starting (l_advcl) starting_40\VBG\2009433|patient (l_nmod) patient_43\NN\9898892|with|a|deficiency (l_nmod) deficiency_47\NN\14449126|with|multiple|carboxylase|mcd (l_compound) carboxylase_46\NN\1740|
T1_T10 CPR:3 biotin_23\NN\15090742| (r_compound) injection_24\NN\320852|upon|biotin (r_nmod) increased_21\VBD\169651|injection (r_conj) low_14\JJ\1740|hand|,|levels|were|markedly|animals|,|and|increased|. (l_nsubj) levels_11\NNS\4916342|synthetase|mrna (l_compound) synthetase_6\NN\1740|holocarboxylase|hcs (l_appos) hcs_8\NNS\1740|(|)
T1_T9 CPR:3 biotin_23\NN\15090742| (r_compound) injection_24\NN\320852|upon|biotin (r_nmod) increased_21\VBD\169651|injection (r_conj) low_14\JJ\1740|hand|,|levels|were|markedly|animals|,|and|increased|. (l_nsubj) levels_11\NNS\4916342|synthetase|mrna (l_compound) synthetase_6\NN\1740|holocarboxylase|hcs
T3_T11 NONE biotin_34\NN\15090742| (r_compound) effects_35\NNS\13245626|for|biotin|genes (l_nmod) genes_38\NNS\8459252|on|specific|and|proteins|,|hcs|,|and|proteomes (l_nmod) hcs_44\NNS\1740|such|and|hexokinases
T3_T12 NONE biotin_34\NN\15090742| (r_compound) effects_35\NNS\13245626|for|biotin|genes (l_nmod) genes_38\NNS\8459252|on|specific|and|proteins|,|hcs|,|and|proteomes (l_nmod) hcs_44\NNS\1740|such|and|hexokinases (l_conj) hexokinases_46\NNS\1740|
T4_T11 NONE hcs_44\NNS\1740|such|and|hexokinases
T4_T12 NONE hcs_44\NNS\1740|such|and|hexokinases (l_conj) hexokinases_46\NNS\1740|
11243491
T15_T27 NONE serotonin_8\NN\14807737| (r_compound) inhibitors_10\NNS\20090|selective|serotonin|reuptake (r_nsubj) inactive_12\JJ\1740|that|inhibitors|were|mice|test|,|alteration (l_nmod) alteration_27\NN\7283608|possibly|because|receptors (l_nmod) receptors_30\NNS\5225602|of|5-ht1 (l_compound) 5-ht1_29\NN\1740|
T14_T32 NONE imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T14_T33 NONE imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T14_T34 NONE imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T14_T35 NONE imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T16_T32 NONE tricyclic_9\NN\2718811|(|) (r_appos) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T16_T33 NONE tricyclic_9\NN\2718811|(|) (r_appos) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T16_T34 NONE tricyclic_9\NN\2718811|(|) (r_appos) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T16_T35 NONE tricyclic_9\NN\2718811|(|) (r_appos) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T17_T32 NONE maprotiline_12\NN\1740|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T17_T33 NONE maprotiline_12\NN\1740|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T17_T34 NONE maprotiline_12\NN\1740|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T17_T35 NONE maprotiline_12\NN\1740|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T18_T32 NONE noradrenline_14\NN\1740| (r_compound) inhibitor_16\NN\20090|(|noradrenline|reuptake|) (r_appos) maprotiline_12\NN\1740|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T18_T33 NONE noradrenline_14\NN\1740| (r_compound) inhibitor_16\NN\20090|(|noradrenline|reuptake|) (r_appos) maprotiline_12\NN\1740|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T18_T34 NONE noradrenline_14\NN\1740| (r_compound) inhibitor_16\NN\20090|(|noradrenline|reuptake|) (r_appos) maprotiline_12\NN\1740|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T18_T35 NONE noradrenline_14\NN\1740| (r_compound) inhibitor_16\NN\20090|(|noradrenline|reuptake|) (r_appos) maprotiline_12\NN\1740|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T19_T32 NONE venlafaxine_19\NN\1740| (r_compound) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T19_T33 NONE venlafaxine_19\NN\1740| (r_compound) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T19_T34 NONE venlafaxine_19\NN\1740| (r_compound) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T19_T35 NONE venlafaxine_19\NN\1740| (r_compound) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T20_T32 NONE serotonin_22\NN\14807737|(|mixed|and|noradrenaline (r_amod) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T20_T33 NONE serotonin_22\NN\14807737|(|mixed|and|noradrenaline (r_amod) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T20_T34 NONE serotonin_22\NN\14807737|(|mixed|and|noradrenaline (r_amod) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T20_T35 NONE serotonin_22\NN\14807737|(|mixed|and|noradrenaline (r_amod) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T21_T32 NONE noradrenaline_24\NN\14807929| (r_conj) serotonin_22\NN\14807737|(|mixed|and|noradrenaline (r_amod) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T21_T33 NONE noradrenaline_24\NN\14807929| (r_conj) serotonin_22\NN\14807737|(|mixed|and|noradrenaline (r_amod) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T21_T34 NONE noradrenaline_24\NN\14807929| (r_conj) serotonin_22\NN\14807737|(|mixed|and|noradrenaline (r_amod) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T21_T35 NONE noradrenaline_24\NN\14807929| (r_conj) serotonin_22\NN\14807737|(|mixed|and|noradrenaline (r_amod) inhibitors_26\NNS\20090|venlafaxine|serotonin|reuptake (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T22_T32 NONE fluvoxamine_29\NN\1740| (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T22_T33 NONE fluvoxamine_29\NN\1740| (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T22_T34 NONE fluvoxamine_29\NN\1740| (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T22_T35 NONE fluvoxamine_29\NN\1740| (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T23_T32 NONE sertraline_31\NN\4169152|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T23_T33 NONE sertraline_31\NN\4169152|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T23_T34 NONE sertraline_31\NN\4169152|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T23_T35 NONE sertraline_31\NN\4169152|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T24_T32 NONE serotonin_34\NN\14807737| (r_compound) inhibitor_36\NN\20090|(|selective|serotonin|reuptake|) (r_appos) sertraline_31\NN\4169152|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T24_T33 NONE serotonin_34\NN\14807737| (r_compound) inhibitor_36\NN\20090|(|selective|serotonin|reuptake|) (r_appos) sertraline_31\NN\4169152|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T24_T34 NONE serotonin_34\NN\14807737| (r_compound) inhibitor_36\NN\20090|(|selective|serotonin|reuptake|) (r_appos) sertraline_31\NN\4169152|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T24_T35 NONE serotonin_34\NN\14807737| (r_compound) inhibitor_36\NN\20090|(|selective|serotonin|reuptake|) (r_appos) sertraline_31\NN\4169152|inhibitor (r_conj) imipramine_7\NN\4482543|[|tricyclic|,|maprotiline|,|inhibitors|)|,|fluvoxamine|and|sertraline|] (r_dep) antidepressants_5\NNS\3740161|of|imipramine (r_nmod) classes_3\NNS\7951464|different|antidepressants (r_nsubjpass) tested_40\VBN\670261|classes|were|session|,|and|test|. (l_advmod) and_49\CC\1740|alone|combination (l_conj) combination_51\NN\7951464|in|agonists (l_nmod) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_dep) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T25_T32 NONE buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (r_dep) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T25_T33 NONE buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (r_dep) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T25_T34 CPR:5 buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T25_T35 NONE buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
T26_T32 NONE anpirtoline_66\NN\1740|agonist (r_appos) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (r_dep) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b
T26_T33 NONE anpirtoline_66\NN\1740|agonist (r_appos) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (r_dep) agonists_57\NNS\9613191|with|5-ht1a|receptor|buspirone (l_compound) 5-ht1a_53\NN\1740|and|5-ht1b (l_conj) 5-ht1b_55\NN\1740|
T26_T34 NONE anpirtoline_66\NN\1740|agonist (r_appos) buspirone_59\NN\3771443|[|agonist|,|anpirtoline|] (l_appos) agonist_63\NN\9613191|(|partial|5-ht1a|) (l_compound) 5-ht1a_62\NN\1740|
T26_T35 CPR:5 anpirtoline_66\NN\1740|agonist (l_appos) agonist_69\NN\9613191|(|5-ht1b|) (l_compound) 5-ht1b_68\NN\1740|
12657913
T23_T31 NONE histamine_0\NN\14739004| (r_compound) antagonists_2\NNS\7846|histamine|h1-receptor|,|promethazine|, (l_compound) h1-receptor_1\NN\1740|
T24_T31 NONE haloperidol_14\NN\3713736|of (r_nmod) concentrations_12\NNS\4916342|the|steady-state|plasma|haloperidol (r_dobj) increase_8\VBP\169651|antagonists|concentrations|and|reduced|. (l_nsubj) antagonists_2\NNS\7846|histamine|h1-receptor|,|promethazine|, (l_compound) h1-receptor_1\NN\1740|
T25_T31 NONE haloperidol_17\NN\3713736| (r_dobj) reduced_16\VBD\441445|haloperidol (r_conj) increase_8\VBP\169651|antagonists|concentrations|and|reduced|. (l_nsubj) antagonists_2\NNS\7846|histamine|h1-receptor|,|promethazine|, (l_compound) h1-receptor_1\NN\1740|
T26_T31 CPR:6 promethazine_4\NN\2719750|and|homochlorcyclizine (r_appos) antagonists_2\NNS\7846|histamine|h1-receptor|,|promethazine|, (l_compound) h1-receptor_1\NN\1740|
T27_T31 CPR:6 homochlorcyclizine_6\NN\1740| (r_conj) promethazine_4\NN\2719750|and|homochlorcyclizine (r_appos) antagonists_2\NNS\7846|histamine|h1-receptor|,|promethazine|, (l_compound) h1-receptor_1\NN\1740|
T11_T28 NONE haloperidol_28\NN\3713736|of|and|haloperidol (r_nmod) concentrations_23\NNS\4916342|on|the|steady-state|plasma|css|haloperidol (r_nmod) effects_1\NNS\13245626|the|antagonists|concentrations (l_nmod) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_acl:relcl) inhibitors_15\NNS\20090|both|are|cyp2d6 (l_nmod) cyp2d6_17\NN\1740|of
T11_T29 NONE haloperidol_28\NN\3713736|of|and|haloperidol (r_nmod) concentrations_23\NNS\4916342|on|the|steady-state|plasma|css|haloperidol (r_nmod) effects_1\NNS\13245626|the|antagonists|concentrations (l_nmod) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_compound) h1-receptor_4\NN\1740|
T12_T28 NONE haloperidol_31\NN\3713736|reduced (r_conj) haloperidol_28\NN\3713736|of|and|haloperidol (r_nmod) concentrations_23\NNS\4916342|on|the|steady-state|plasma|css|haloperidol (r_nmod) effects_1\NNS\13245626|the|antagonists|concentrations (l_nmod) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_acl:relcl) inhibitors_15\NNS\20090|both|are|cyp2d6 (l_nmod) cyp2d6_17\NN\1740|of
T12_T29 NONE haloperidol_31\NN\3713736|reduced (r_conj) haloperidol_28\NN\3713736|of|and|haloperidol (r_nmod) concentrations_23\NNS\4916342|on|the|steady-state|plasma|css|haloperidol (r_nmod) effects_1\NNS\13245626|the|antagonists|concentrations (l_nmod) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_compound) h1-receptor_4\NN\1740|
T13_T28 NONE haloperidol_39\NN\3713736|,|mg/d (r_dobj) receiving_38\VBG\2210855|haloperidol|,|weeks (r_acl) inpatients_37\NNS\10405694|in|23|schizophrenic|receiving (r_nmod) studied_33\VBN\630380|effects|were|inpatients|. (l_nsubjpass) effects_1\NNS\13245626|the|antagonists|concentrations (l_nmod) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_acl:relcl) inhibitors_15\NNS\20090|both|are|cyp2d6 (l_nmod) cyp2d6_17\NN\1740|of
T13_T29 NONE haloperidol_39\NN\3713736|,|mg/d (r_dobj) receiving_38\VBG\2210855|haloperidol|,|weeks (r_acl) inpatients_37\NNS\10405694|in|23|schizophrenic|receiving (r_nmod) studied_33\VBN\630380|effects|were|inpatients|. (l_nsubjpass) effects_1\NNS\13245626|the|antagonists|concentrations (l_nmod) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_compound) h1-receptor_4\NN\1740|
T16_T28 CPR:4 promethazine_7\NN\2719750|and|homochlorcyclizine (r_appos) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_acl:relcl) inhibitors_15\NNS\20090|both|are|cyp2d6 (l_nmod) cyp2d6_17\NN\1740|of
T16_T29 CPR:6 promethazine_7\NN\2719750|and|homochlorcyclizine (r_appos) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_compound) h1-receptor_4\NN\1740|
T19_T28 CPR:4 homochlorcyclizine_9\NN\1740| (r_conj) promethazine_7\NN\2719750|and|homochlorcyclizine (r_appos) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_acl:relcl) inhibitors_15\NNS\20090|both|are|cyp2d6 (l_nmod) cyp2d6_17\NN\1740|of
T19_T29 CPR:6 homochlorcyclizine_9\NN\1740| (r_conj) promethazine_7\NN\2719750|and|homochlorcyclizine (r_appos) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_compound) h1-receptor_4\NN\1740|
T4_T28 NONE histamine_3\NN\14739004| (r_compound) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_acl:relcl) inhibitors_15\NNS\20090|both|are|cyp2d6 (l_nmod) cyp2d6_17\NN\1740|of
T4_T29 NONE histamine_3\NN\14739004| (r_compound) antagonists_5\NNS\7846|of|histamine|h1-receptor|,|promethazine|,|inhibitors|, (l_compound) h1-receptor_4\NN\1740|
T10_T30 CPR:9 haloperidol_35\NN\3713736|reduced (r_conj) haloperidol_32\NN\3713736|of|and|haloperidol (r_nmod) metabolism_30\NN\13526110|on|the|cyp2d6-catalyzed|haloperidol (l_amod) cyp2d6-catalyzed_29\JJ\1740|
T5_T30 CPR:4 promethazine_12\NN\2719750|of|and|homochlorcyclizine (r_nmod) doses_10\NNS\3740161|of|clinical|promethazine (r_nmod) coadministration_7\NN\1740|doses (r_nsubj) increases_15\VBZ\169651|that|coadministration|css|and|reduced|effects (l_nmod) effects_26\NNS\13245626|via|the|inhibitory|metabolism (l_nmod) metabolism_30\NN\13526110|on|the|cyp2d6-catalyzed|haloperidol (l_amod) cyp2d6-catalyzed_29\JJ\1740|
T6_T30 CPR:4 homochlorcyclizine_14\NN\1740| (r_conj) promethazine_12\NN\2719750|of|and|homochlorcyclizine (r_nmod) doses_10\NNS\3740161|of|clinical|promethazine (r_nmod) coadministration_7\NN\1740|doses (r_nsubj) increases_15\VBZ\169651|that|coadministration|css|and|reduced|effects (l_nmod) effects_26\NNS\13245626|via|the|inhibitory|metabolism (l_nmod) metabolism_30\NN\13526110|on|the|cyp2d6-catalyzed|haloperidol (l_amod) cyp2d6-catalyzed_29\JJ\1740|
T7_T30 NONE haloperidol_19\NN\3713736|of (r_nmod) css_17\NN\14625458|the|haloperidol (r_dobj) increases_15\VBZ\169651|that|coadministration|css|and|reduced|effects (l_nmod) effects_26\NNS\13245626|via|the|inhibitory|metabolism (l_nmod) metabolism_30\NN\13526110|on|the|cyp2d6-catalyzed|haloperidol (l_amod) cyp2d6-catalyzed_29\JJ\1740|
T8_T30 NONE haloperidol_22\NN\3713736| (r_dobj) reduced_21\VBD\441445|haloperidol (r_conj) increases_15\VBZ\169651|that|coadministration|css|and|reduced|effects (l_nmod) effects_26\NNS\13245626|via|the|inhibitory|metabolism (l_nmod) metabolism_30\NN\13526110|on|the|cyp2d6-catalyzed|haloperidol (l_amod) cyp2d6-catalyzed_29\JJ\1740|
T9_T30 CPR:9 haloperidol_32\NN\3713736|of|and|haloperidol (r_nmod) metabolism_30\NN\13526110|on|the|cyp2d6-catalyzed|haloperidol (l_amod) cyp2d6-catalyzed_29\JJ\1740|
23402856
T15_T28 NONE glutathione_8\NN\1740| (r_compound) form_11\NN\6286395|for|glutathione|s-transferase|placental|gst-p
T15_T29 NONE glutathione_8\NN\1740| (r_compound) form_11\NN\6286395|for|glutathione|s-transferase|placental|gst-p (l_appos) gst-p_13\NN\1740|(|)
T16_T28 NONE s-transferase_9\NN\1740| (r_compound) form_11\NN\6286395|for|glutathione|s-transferase|placental|gst-p
T16_T29 NONE s-transferase_9\NN\1740| (r_compound) form_11\NN\6286395|for|glutathione|s-transferase|placental|gst-p (l_appos) gst-p_13\NN\1740|(|)
T18_T28 CPR:3 hep_32\NN\1740|with|or|hcb|alone (r_nmod) treated_30\VBN\2376958|hep (r_acl) groups_29\NNS\2137|in|the|treated (r_nmod) values_26\NNS\5941423|of|individual|groups (r_nmod) sum_23\NN\13329641|than|the|values (r_nmod) higher_17\JJR\1740|number|were|consistently|groups|sum|. (l_nsubj) number_0\NN\5107765|and|area|foci (l_nmod) foci_5\NNS\5704266|of|preneoplastic|positive (l_amod) positive_6\JJ\1740|form (l_nmod) form_11\NN\6286395|for|glutathione|s-transferase|placental|gst-p
T18_T29 CPR:3 hep_32\NN\1740|with|or|hcb|alone (r_nmod) treated_30\VBN\2376958|hep (r_acl) groups_29\NNS\2137|in|the|treated (r_nmod) values_26\NNS\5941423|of|individual|groups (r_nmod) sum_23\NN\13329641|than|the|values (r_nmod) higher_17\JJR\1740|number|were|consistently|groups|sum|. (l_nsubj) number_0\NN\5107765|and|area|foci (l_nmod) foci_5\NNS\5704266|of|preneoplastic|positive (l_amod) positive_6\JJ\1740|form (l_nmod) form_11\NN\6286395|for|glutathione|s-transferase|placental|gst-p (l_appos) gst-p_13\NN\1740|(|)
T19_T28 CPR:3 hcb_34\NN\1740| (r_conj) hep_32\NN\1740|with|or|hcb|alone (r_nmod) treated_30\VBN\2376958|hep (r_acl) groups_29\NNS\2137|in|the|treated (r_nmod) values_26\NNS\5941423|of|individual|groups (r_nmod) sum_23\NN\13329641|than|the|values (r_nmod) higher_17\JJR\1740|number|were|consistently|groups|sum|. (l_nsubj) number_0\NN\5107765|and|area|foci (l_nmod) foci_5\NNS\5704266|of|preneoplastic|positive (l_amod) positive_6\JJ\1740|form (l_nmod) form_11\NN\6286395|for|glutathione|s-transferase|placental|gst-p
T19_T29 CPR:3 hcb_34\NN\1740| (r_conj) hep_32\NN\1740|with|or|hcb|alone (r_nmod) treated_30\VBN\2376958|hep (r_acl) groups_29\NNS\2137|in|the|treated (r_nmod) values_26\NNS\5941423|of|individual|groups (r_nmod) sum_23\NN\13329641|than|the|values (r_nmod) higher_17\JJR\1740|number|were|consistently|groups|sum|. (l_nsubj) number_0\NN\5107765|and|area|foci (l_nmod) foci_5\NNS\5704266|of|preneoplastic|positive (l_amod) positive_6\JJ\1740|form (l_nmod) form_11\NN\6286395|for|glutathione|s-transferase|placental|gst-p (l_appos) gst-p_13\NN\1740|(|)
T1_T30 NONE hep_41\NNS\1740|of|and|hcb (r_nmod) activation_39\NN\13561719|to|efficient|metabolic|hep (r_nmod) lead_34\VB\1752884|which|may|activation (r_acl:relcl) induction_16\NN\7450842|on|cell|proliferation|foci|and|induction|,|lead (l_conj) induction_30\NN\7450842|2b1 (l_compound) 2b1_27\NN\1740|p450|and|3a1 (l_conj) 3a1_29\NN\1740|
T20_T30 NONE hep_5\NN\1740|and|hcb (r_nsubj) had_8\VBD\2108377|consistent|,|hep|effects|induction|. (l_nmod) induction_16\NN\7450842|on|cell|proliferation|foci|and|induction|,|lead (l_conj) induction_30\NN\7450842|2b1 (l_compound) 2b1_27\NN\1740|p450|and|3a1 (l_conj) 3a1_29\NN\1740|
T22_T30 NONE hcb_7\NN\1740| (r_conj) hep_5\NN\1740|and|hcb (r_nsubj) had_8\VBD\2108377|consistent|,|hep|effects|induction|. (l_nmod) induction_16\NN\7450842|on|cell|proliferation|foci|and|induction|,|lead (l_conj) induction_30\NN\7450842|2b1 (l_compound) 2b1_27\NN\1740|p450|and|3a1 (l_conj) 3a1_29\NN\1740|
T2_T30 NONE hcb_43\NN\1740| (r_conj) hep_41\NNS\1740|of|and|hcb (r_nmod) activation_39\NN\13561719|to|efficient|metabolic|hep (r_nmod) lead_34\VB\1752884|which|may|activation (r_acl:relcl) induction_16\NN\7450842|on|cell|proliferation|foci|and|induction|,|lead (l_conj) induction_30\NN\7450842|2b1 (l_compound) 2b1_27\NN\1740|p450|and|3a1 (l_conj) 3a1_29\NN\1740|
T3_T27 CPR:3 hep_10\NN\1740|and|hcb (r_nsubj) have_13\VBP\2108377|that|hep|effects|development|and|associated (l_nmod) development_20\NN\248977|on|the|foci (l_nmod) foci_23\NNS\5704266|of|gst-p-positive (l_amod) gst-p-positive_22\JJ\1740|
T5_T27 CPR:3 hcb_12\NN\1740| (r_conj) hep_10\NN\1740|and|hcb (r_nsubj) have_13\VBP\2108377|that|hep|effects|development|and|associated (l_nmod) development_20\NN\248977|on|the|foci (l_nmod) foci_23\NNS\5704266|of|gst-p-positive (l_amod) gst-p-positive_22\JJ\1740|
T6_T27 NONE organochlorine_35\NN\1740| (r_amod) pesticides_36\NNS\14806838|of|residual|organochlorine|foods (r_nmod) combination_32\NN\7951464|with|a|pesticides|pesticides (r_nmod) associated_29\VBN\628491|that|risks|are|combination (r_conj) have_13\VBP\2108377|that|hep|effects|development|and|associated (l_nmod) development_20\NN\248977|on|the|foci (l_nmod) foci_23\NNS\5704266|of|gst-p-positive (l_amod) gst-p-positive_22\JJ\1740|
T7_T27 NONE organochlorine_43\NN\1740| (r_compound) pesticides_44\NNS\14806838|than|with|individual|residual|organochlorine (r_nmod) combination_32\NN\7951464|with|a|pesticides|pesticides (r_nmod) associated_29\VBN\628491|that|risks|are|combination (r_conj) have_13\VBP\2108377|that|hep|effects|development|and|associated (l_nmod) development_20\NN\248977|on|the|foci (l_nmod) foci_23\NNS\5704266|of|gst-p-positive (l_amod) gst-p-positive_22\JJ\1740|
14757700
T39_T60 NONE cold-menthol_4\NN\1740| (r_compound) receptor_5\NN\5225602|mouse|cold-menthol
T39_T61 NONE cold-menthol_4\NN\1740| (r_compound) receptor_5\NN\5225602|mouse|cold-menthol (r_compound) trpm8_6\NN\1740|of|the|receptor|and|vr1
T39_T62 NONE cold-menthol_4\NN\1740| (r_compound) receptor_5\NN\5225602|mouse|cold-menthol (r_compound) trpm8_6\NN\1740|of|the|receptor|and|vr1 (l_conj) vr1_11\NN\1740|vanilloid|receptor|type-1 (l_amod) type-1_10\JJ\1740|
T39_T63 NONE cold-menthol_4\NN\1740| (r_compound) receptor_5\NN\5225602|mouse|cold-menthol (r_compound) trpm8_6\NN\1740|of|the|receptor|and|vr1 (l_conj) vr1_11\NN\1740|vanilloid|receptor|type-1
T19_T40 NONE ca(2+)-permeable_6\JJ\1740| (r_amod) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|. (l_nsubj) trpm8_0\NN\1740|cmr1 (l_appos) cmr1_2\NN\1740|(|)
T19_T51 NONE ca(2+)-permeable_6\JJ\1740| (r_amod) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|.
T19_T55 NONE ca(2+)-permeable_6\JJ\1740| (r_amod) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|. (l_nsubj) trpm8_0\NN\1740|cmr1
T1_T40 CPR:3 eucalyptol_19\NN\1740| (r_conj) menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|. (l_nsubj) trpm8_0\NN\1740|cmr1 (l_appos) cmr1_2\NN\1740|(|)
T1_T51 CPR:3 eucalyptol_19\NN\1740| (r_conj) menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|.
T1_T55 CPR:3 eucalyptol_19\NN\1740| (r_conj) menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|. (l_nsubj) trpm8_0\NN\1740|cmr1
T35_T40 CPR:3 menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|. (l_nsubj) trpm8_0\NN\1740|cmr1 (l_appos) cmr1_2\NN\1740|(|)
T35_T51 CPR:3 menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|.
T35_T55 CPR:3 menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|. (l_nsubj) trpm8_0\NN\1740|cmr1
T7_T40 CPR:3 icilin_21\NN\1740| (r_conj) menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|. (l_nsubj) trpm8_0\NN\1740|cmr1 (l_appos) cmr1_2\NN\1740|(|)
T7_T51 CPR:3 icilin_21\NN\1740| (r_conj) menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|.
T7_T55 CPR:3 icilin_21\NN\1740| (r_conj) menthol_17\NN\14818238|,|eucalyptol|and|icilin (r_appos) temperatures_15\NNS\13575869|by|low|,|menthol (r_nmod) activated_12\VBN\1641914|which|can|be|temperatures (r_acl:relcl) channel_7\NN\6251781|trpm8|is|a|ca(2+)-permeable|,|activated|. (l_nsubj) trpm8_0\NN\1740|cmr1
T20_T54 NONE menthol_9\NN\14818238|to (r_nmod) related_7\JJ\1740|which|are|structurally|menthol|,|or|produce (r_acl:relcl) substances_3\NNS\20827|related (r_nsubj) activate_19\VB\1641914|whether|substances|could|trpm8 (l_dobj) trpm8_20\NNP\1740|
T20_T56 NONE menthol_9\NN\14818238|to (r_nmod) related_7\JJ\1740|which|are|structurally|menthol|,|or|produce (r_acl:relcl) substances_3\NNS\20827|related (r_nsubj) activate_19\VB\1641914|whether|substances|could|trpm8 (r_ccomp) tested_1\VBD\670261|we|activate|,|and|compared|. (l_conj) compared_23\VBD\644583|responses (l_dobj) responses_25\NNS\11410625|the|trpm8|ligands (l_nmod) trpm8_27\NN\1740|of|and|vr1
T20_T57 NONE menthol_9\NN\14818238|to (r_nmod) related_7\JJ\1740|which|are|structurally|menthol|,|or|produce (r_acl:relcl) substances_3\NNS\20827|related (r_nsubj) activate_19\VB\1641914|whether|substances|could|trpm8 (r_ccomp) tested_1\VBD\670261|we|activate|,|and|compared|. (l_conj) compared_23\VBD\644583|responses (l_dobj) responses_25\NNS\11410625|the|trpm8|ligands (l_nmod) trpm8_27\NN\1740|of|and|vr1 (l_conj) vr1_29\NNP\1740|
T21_T58 NONE menthol-related_8\JJ\1740| (r_amod) substances_9\NNS\20827|menthol-related (r_conj) odorants_6\NNS\1740|of|70|and|substances (r_nmod) effects_3\NNS\13245626|the|odorants|trpm8|, (l_nmod) trpm8_13\NN\1740|on|recombinant|mouse|mtrpm8|,|expressed
T21_T59 NONE menthol-related_8\JJ\1740| (r_amod) substances_9\NNS\20827|menthol-related (r_conj) odorants_6\NNS\1740|of|70|and|substances (r_nmod) effects_3\NNS\13245626|the|odorants|trpm8|, (l_nmod) trpm8_13\NN\1740|on|recombinant|mouse|mtrpm8|,|expressed (l_appos) mtrpm8_15\NN\1740|(|)
T11_T41 CPR:6 bctc_6\NN\1740|(|,|thio-bctc|and|capsazepine|) (r_dep) antagonists_4\NNS\7846|known|vr1|bctc (l_compound) vr1_3\NN\1740|
T11_T42 CPR:4 bctc_6\NN\1740|(|,|thio-bctc|and|capsazepine|) (r_dep) antagonists_4\NNS\7846|known|vr1|bctc (r_nsubj) able_14\JJ\1740|4|antagonists|were|also|block|. (l_xcomp) block_16\VB\1476483|to|response|ic(50|respectively|) (l_dobj) response_18\NN\11410625|the|trpm8|menthol (l_nmod) trpm8_20\NN\1740|of
T12_T41 CPR:6 thio-bctc_8\NN\1740| (r_conj) bctc_6\NN\1740|(|,|thio-bctc|and|capsazepine|) (r_dep) antagonists_4\NNS\7846|known|vr1|bctc (l_compound) vr1_3\NN\1740|
T12_T42 CPR:4 thio-bctc_8\NN\1740| (r_conj) bctc_6\NN\1740|(|,|thio-bctc|and|capsazepine|) (r_dep) antagonists_4\NNS\7846|known|vr1|bctc (r_nsubj) able_14\JJ\1740|4|antagonists|were|also|block|. (l_xcomp) block_16\VB\1476483|to|response|ic(50|respectively|) (l_dobj) response_18\NN\11410625|the|trpm8|menthol (l_nmod) trpm8_20\NN\1740|of
T13_T41 CPR:6 capsazepine_10\NN\1740| (r_conj) bctc_6\NN\1740|(|,|thio-bctc|and|capsazepine|) (r_dep) antagonists_4\NNS\7846|known|vr1|bctc (l_compound) vr1_3\NN\1740|
T13_T42 CPR:4 capsazepine_10\NN\1740| (r_conj) bctc_6\NN\1740|(|,|thio-bctc|and|capsazepine|) (r_dep) antagonists_4\NNS\7846|known|vr1|bctc (r_nsubj) able_14\JJ\1740|4|antagonists|were|also|block|. (l_xcomp) block_16\VB\1476483|to|response|ic(50|respectively|) (l_dobj) response_18\NN\11410625|the|trpm8|menthol (l_nmod) trpm8_20\NN\1740|of
T14_T41 NONE menthol_22\NN\14818238|to (r_nmod) response_18\NN\11410625|the|trpm8|menthol (r_dobj) block_16\VB\1476483|to|response|ic(50|respectively|) (r_xcomp) able_14\JJ\1740|4|antagonists|were|also|block|. (l_nsubj) antagonists_4\NNS\7846|known|vr1|bctc (l_compound) vr1_3\NN\1740|
T14_T42 CPR:3 menthol_22\NN\14818238|to (r_nmod) response_18\NN\11410625|the|trpm8|menthol (l_nmod) trpm8_20\NN\1740|of
T15_T44 NONE )_3\-RRB-\1740| (r_punct) +_2\NN\1740|) (r_dep) ca(2_1\NN\1740|+ (r_compound) response_4\NN\11410625|the|ca(2|cells|n-arachidonoyl-dopamine (l_nmod) cells_8\NNS\3080309|of|hvr1-transfected|hek293 (l_amod) hvr1-transfected_6\JJ\1740|
T15_T45 NONE )_3\-RRB-\1740| (r_punct) +_2\NN\1740|) (r_dep) ca(2_1\NN\1740|+ (r_compound) response_4\NN\11410625|the|ca(2|cells|n-arachidonoyl-dopamine (l_nmod) n-arachidonoyl-dopamine_14\NN\1740|to|the|endogenous|agonist (l_compound) agonist_13\NN\9613191|vr1 (l_compound) vr1_12\NN\1740|
T16_T44 CPR:3 n-arachidonoyl-dopamine_14\NN\1740|to|the|endogenous|agonist (r_nmod) response_4\NN\11410625|the|ca(2|cells|n-arachidonoyl-dopamine (l_nmod) cells_8\NNS\3080309|of|hvr1-transfected|hek293 (l_amod) hvr1-transfected_6\JJ\1740|
T16_T45 CPR:5 n-arachidonoyl-dopamine_14\NN\1740|to|the|endogenous|agonist (l_compound) agonist_13\NN\9613191|vr1 (l_compound) vr1_12\NN\1740|
T17_T46 CPR:3 menthol-_3\NN\1740|and|icilin-activated (r_amod) currents_7\NNS\11449002|menthol-|trpm8 (l_compound) trpm8_6\NN\1740|
T18_T46 CPR:3 icilin-activated_5\JJ\1740| (r_conj) menthol-_3\NN\1740|and|icilin-activated (r_amod) currents_7\NNS\11449002|menthol-|trpm8 (l_compound) trpm8_6\NN\1740|
23500058
T1_T17 NONE sulphate_8\NN\15010703|to|dextran|sodium|dss (r_nmod) exposed_4\VBN\2110927|mice|were|sulphate|and|treated|. (l_conj) treated_13\VBN\2376958|administration (l_nmod) administration_16\NN\1133281|by|intrarectal|tnf-α (l_nmod) tnf-α_20\NN\1740|with|either|cd.sirna|or|solution
23424204
T15_T32 NONE bisphenol-a_2\NN\1740|of (r_nmod) effect_0\NN\34213|bisphenol-a|transduction|. (l_nmod) transduction_6\NN\13526110|on|insulin|signal|and|oxidation|muscle (l_compound) insulin_4\NN\5407119|
T16_T32 NONE glucose_8\NN\14710501| (r_compound) oxidation_9\NN\13447361|glucose (r_conj) transduction_6\NN\13526110|on|insulin|signal|and|oxidation|muscle (l_compound) insulin_4\NN\5407119|
T10_T24 NONE bpa_11\NN\1740|of (r_nmod) effects_9\NNS\13245626|the|possible|bpa|molecules (l_nmod) molecules_14\NNS\9465459|on|insulin-signaling|and|oxidation|muscle (l_amod) insulin-signaling_13\JJ\1740|
T11_T24 NONE glucose_16\NN\14710501| (r_compound) oxidation_17\NN\13447361|glucose (r_conj) molecules_14\NNS\9465459|on|insulin-signaling|and|oxidation|muscle (l_amod) insulin-signaling_13\JJ\1740|
T13_T17 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (r_conj) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (r_nmod) levels_7\NNS\4916342|in|the|receptor (r_nmod) was_2\VBD\836236|although|there|change|levels (r_advcl) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_dobj) ir_34\NN\14625458|the|,|akt|and|protein|levels|membrane|muscle (l_conj) akt_36\NN\1740|
T13_T18 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (r_conj) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (r_nmod) levels_7\NNS\4916342|in|the|receptor (r_nmod) was_2\VBD\836236|although|there|change|levels (r_advcl) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_dobj) ir_34\NN\14625458|the|,|akt|and|protein|levels|membrane|muscle (l_conj) protein_39\NN\14944888|glut4 (l_compound) glut4_38\NN\1740|
T13_T25 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (r_conj) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna
T13_T26 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (r_conj) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (l_appos) ir_12\NN\14625458|(|)
T13_T27 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (r_conj) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (l_conj) akt_15\NN\1740|b
T13_T28 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (r_conj) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (l_conj) akt_15\NN\1740|b (l_appos) b_19\NN\1355326|(|protein|kinase|)
T13_T29 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (l_compound) transporter-4_23\NN\1740|
T13_T30 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (l_compound) glut4_25\NN\1740|
T13_T31 NONE glucose_22\NN\14710501| (r_compound) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (r_conj) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (r_nmod) levels_7\NNS\4916342|in|the|receptor (r_nmod) was_2\VBD\836236|although|there|change|levels (r_advcl) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_dobj) ir_34\NN\14625458|the|,|akt|and|protein|levels|membrane|muscle
T14_T17 CPR:4 bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_dobj) ir_34\NN\14625458|the|,|akt|and|protein|levels|membrane|muscle (l_conj) akt_36\NN\1740|
T14_T18 CPR:4 bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_dobj) ir_34\NN\14625458|the|,|akt|and|protein|levels|membrane|muscle (l_conj) protein_39\NN\14944888|glut4 (l_compound) glut4_38\NN\1740|
T14_T25 NONE bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_advcl) was_2\VBD\836236|although|there|change|levels (l_nmod) levels_7\NNS\4916342|in|the|receptor (l_nmod) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna
T14_T26 NONE bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_advcl) was_2\VBD\836236|although|there|change|levels (l_nmod) levels_7\NNS\4916342|in|the|receptor (l_nmod) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (l_appos) ir_12\NN\14625458|(|)
T14_T27 NONE bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_advcl) was_2\VBD\836236|although|there|change|levels (l_nmod) levels_7\NNS\4916342|in|the|receptor (l_nmod) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (l_conj) akt_15\NN\1740|b
T14_T28 NONE bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_advcl) was_2\VBD\836236|although|there|change|levels (l_nmod) levels_7\NNS\4916342|in|the|receptor (l_nmod) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (l_conj) akt_15\NN\1740|b (l_appos) b_19\NN\1355326|(|protein|kinase|)
T14_T29 NONE bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_advcl) was_2\VBD\836236|although|there|change|levels (l_nmod) levels_7\NNS\4916342|in|the|receptor (l_nmod) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (l_conj) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (l_compound) transporter-4_23\NN\1740|
T14_T30 NONE bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_advcl) was_2\VBD\836236|although|there|change|levels (l_nmod) levels_7\NNS\4916342|in|the|receptor (l_nmod) receptor_10\NN\5225602|of|insulin|ir|,|akt|and|rna (l_conj) rna_28\NN\14994328|glucose|transporter-4|(|glut4|)|messenger (l_compound) glut4_25\NN\1740|
T14_T31 CPR:4 bpa_30\NN\1740| (r_nsubj) decreased_32\VBD\169651|was|,|bpa|significantly|ir|. (l_dobj) ir_34\NN\14625458|the|,|akt|and|protein|levels|membrane|muscle
T2_T19 NONE testosterone_11\NN\14747587|serum (r_compound) levels_12\NNS\4916342|in|testosterone (r_nmod) decrease_8\NN\7296428|levels (r_conj) increase_3\NN\13576355|an|insulin|and|decrease (l_nmod) insulin_6\NN\5407119|in|serum
T3_T19 NONE glucose_16\NN\14710501| (r_compound) level_17\NN\4916342|fasting|blood|glucose (r_nsubj) remained_18\VBD\2604760|level|unaltered|. (r_conj) was_1\VBD\836236|there|increase|but|remained (l_nsubj) increase_3\NN\13576355|an|insulin|and|decrease (l_nmod) insulin_6\NN\5407119|in|serum
T4_T20 CPR:4 bpa_3\NN\1740| (r_nsubj) has_4\VBZ\2108377|conclusion|,|bpa|effects|phosphorylation|. (l_nmod) phosphorylation_8\NN\1740|on|akt|,|translocation|and|oxidation (l_nmod) akt_10\NN\1740|of
T4_T21 CPR:4 bpa_3\NN\1740| (r_nsubj) has_4\VBZ\2108377|conclusion|,|bpa|effects|phosphorylation|. (l_nmod) phosphorylation_8\NN\1740|on|akt|,|translocation|and|oxidation (l_conj) translocation_13\NN\13526110|glut4 (l_compound) glut4_12\NN\1740|
T5_T20 NONE (14)c-glucose_15\NN\1740| (r_compound) oxidation_16\NN\13447361|(14)c-glucose (r_conj) phosphorylation_8\NN\1740|on|akt|,|translocation|and|oxidation (l_nmod) akt_10\NN\1740|of
T5_T21 NONE (14)c-glucose_15\NN\1740| (r_compound) oxidation_16\NN\13447361|(14)c-glucose (r_conj) phosphorylation_8\NN\1740|on|akt|,|translocation|and|oxidation (l_conj) translocation_13\NN\13526110|glut4 (l_compound) glut4_12\NN\1740|
18803986
T30_T52 CPR:4 lapatinib_0\NN\1740|:|inhibitor|. (l_appos) inhibitor_4\NN\20090|a|dual|kinases (l_nmod) kinases_12\NNS\14732946|of|human|epidermal|growth|factor|receptor|tyrosine (l_compound) receptor_10\NN\5225602|
T30_T53 CPR:4 lapatinib_0\NN\1740|:|inhibitor|. (l_appos) inhibitor_4\NN\20090|a|dual|kinases (l_nmod) kinases_12\NNS\14732946|of|human|epidermal|growth|factor|receptor|tyrosine
T31_T52 NONE tyrosine_11\NN\14601829| (r_compound) kinases_12\NNS\14732946|of|human|epidermal|growth|factor|receptor|tyrosine (l_compound) receptor_10\NN\5225602|
T31_T53 NONE tyrosine_11\NN\14601829| (r_compound) kinases_12\NNS\14732946|of|human|epidermal|growth|factor|receptor|tyrosine
T5_T35 CPR:4 lapatinib_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|the|first|dual|receptor (l_nmod) receptor_12\NN\5225602|of|epidermal|growth|factor|egfr|and|kinases (l_conj) kinases_27\NNS\14732946|human|epidermal|growth|factor|receptor|tyrosine (l_compound) receptor_21\NN\5225602|2|her2 (l_appos) her2_24\NN\1740|(|)
T5_T37 CPR:4 lapatinib_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|the|first|dual|receptor (l_nmod) receptor_12\NN\5225602|of|epidermal|growth|factor|egfr|and|kinases (l_conj) kinases_27\NNS\14732946|human|epidermal|growth|factor|receptor|tyrosine
T5_T49 CPR:4 lapatinib_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|the|first|dual|receptor (l_nmod) receptor_12\NN\5225602|of|epidermal|growth|factor|egfr|and|kinases
T5_T50 CPR:4 lapatinib_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|the|first|dual|receptor (l_nmod) receptor_12\NN\5225602|of|epidermal|growth|factor|egfr|and|kinases (l_appos) egfr_14\NN\1740|(|)
T5_T51 CPR:4 lapatinib_2\NN\1740|,|inhibitor|, (l_appos) inhibitor_7\NN\20090|the|first|dual|receptor (l_nmod) receptor_12\NN\5225602|of|epidermal|growth|factor|egfr|and|kinases (l_conj) kinases_27\NNS\14732946|human|epidermal|growth|factor|receptor|tyrosine (l_compound) receptor_21\NN\5225602|2|her2 (l_nummod) 2_22\CD\13741022|
T7_T35 NONE tyrosine_26\NN\14601829| (r_compound) kinases_27\NNS\14732946|human|epidermal|growth|factor|receptor|tyrosine (l_compound) receptor_21\NN\5225602|2|her2 (l_appos) her2_24\NN\1740|(|)
T7_T37 NONE tyrosine_26\NN\14601829| (r_compound) kinases_27\NNS\14732946|human|epidermal|growth|factor|receptor|tyrosine
T7_T49 NONE tyrosine_26\NN\14601829| (r_compound) kinases_27\NNS\14732946|human|epidermal|growth|factor|receptor|tyrosine (r_conj) receptor_12\NN\5225602|of|epidermal|growth|factor|egfr|and|kinases
T7_T50 NONE tyrosine_26\NN\14601829| (r_compound) kinases_27\NNS\14732946|human|epidermal|growth|factor|receptor|tyrosine (r_conj) receptor_12\NN\5225602|of|epidermal|growth|factor|egfr|and|kinases (l_appos) egfr_14\NN\1740|(|)
T7_T51 NONE tyrosine_26\NN\14601829| (r_compound) kinases_27\NNS\14732946|human|epidermal|growth|factor|receptor|tyrosine (l_compound) receptor_21\NN\5225602|2|her2 (l_nummod) 2_22\CD\13741022|
T22_T47 NONE capecitabine_8\NN\1740|with (r_nmod) combination_6\NN\7951464|in|capecitabine (r_nmod) use_4\NN\407535|for|combination (r_nmod) indicated_2\VBN\952524|it|is|use|treatment|. (l_nmod) treatment_11\NN\654885|for|the|patients (l_nmod) patients_13\NNS\9898892|of|cancer (l_nmod) cancer_17\NN\14239425|with|advanced|breast|or|cancer|overexpress (l_acl:relcl) overexpress_27\VBP\1740|tumors|her2|and|received (l_dobj) her2_28\NN\1740|erbb2
T22_T48 NONE capecitabine_8\NN\1740|with (r_nmod) combination_6\NN\7951464|in|capecitabine (r_nmod) use_4\NN\407535|for|combination (r_nmod) indicated_2\VBN\952524|it|is|use|treatment|. (l_nmod) treatment_11\NN\654885|for|the|patients (l_nmod) patients_13\NNS\9898892|of|cancer (l_nmod) cancer_17\NN\14239425|with|advanced|breast|or|cancer|overexpress (l_acl:relcl) overexpress_27\VBP\1740|tumors|her2|and|received (l_dobj) her2_28\NN\1740|erbb2 (l_appos) erbb2_30\NN\1740|(|)
T27_T47 NONE anthracycline_41\NN\1740|an|,|taxane|,|and|trastuzumab (r_dobj) included_39\VBD\690614|that|anthracycline (r_acl:relcl) treatment_37\NN\654885|previous|included (r_dobj) received_35\VBN\2210855|who|have|treatment (r_conj) overexpress_27\VBP\1740|tumors|her2|and|received (l_dobj) her2_28\NN\1740|erbb2
T27_T48 NONE anthracycline_41\NN\1740|an|,|taxane|,|and|trastuzumab (r_dobj) included_39\VBD\690614|that|anthracycline (r_acl:relcl) treatment_37\NN\654885|previous|included (r_dobj) received_35\VBN\2210855|who|have|treatment (r_conj) overexpress_27\VBP\1740|tumors|her2|and|received (l_dobj) her2_28\NN\1740|erbb2 (l_appos) erbb2_30\NN\1740|(|)
T28_T47 NONE taxane_44\NN\1740|a (r_conj) anthracycline_41\NN\1740|an|,|taxane|,|and|trastuzumab (r_dobj) included_39\VBD\690614|that|anthracycline (r_acl:relcl) treatment_37\NN\654885|previous|included (r_dobj) received_35\VBN\2210855|who|have|treatment (r_conj) overexpress_27\VBP\1740|tumors|her2|and|received (l_dobj) her2_28\NN\1740|erbb2
T28_T48 NONE taxane_44\NN\1740|a (r_conj) anthracycline_41\NN\1740|an|,|taxane|,|and|trastuzumab (r_dobj) included_39\VBD\690614|that|anthracycline (r_acl:relcl) treatment_37\NN\654885|previous|included (r_dobj) received_35\VBN\2210855|who|have|treatment (r_conj) overexpress_27\VBP\1740|tumors|her2|and|received (l_dobj) her2_28\NN\1740|erbb2 (l_appos) erbb2_30\NN\1740|(|)
T1_T32 NONE lapatinib_3\NN\1740|,|gw572016|,|her2|,|egfr|,|kinase|,|blockade|,|events|,|and|trials (l_conj) her2_7\NN\1740|
T1_T33 NONE lapatinib_3\NN\1740|,|gw572016|,|her2|,|egfr|,|kinase|,|blockade|,|events|,|and|trials (l_conj) egfr_9\NN\1740|
T1_T34 NONE lapatinib_3\NN\1740|,|gw572016|,|her2|,|egfr|,|kinase|,|blockade|,|events|,|and|trials (l_conj) kinase_13\NN\14732946|receptor|tyrosine
T2_T32 NONE gw572016_5\NN\1740| (r_conj) lapatinib_3\NN\1740|,|gw572016|,|her2|,|egfr|,|kinase|,|blockade|,|events|,|and|trials (l_conj) her2_7\NN\1740|
T2_T33 NONE gw572016_5\NN\1740| (r_conj) lapatinib_3\NN\1740|,|gw572016|,|her2|,|egfr|,|kinase|,|blockade|,|events|,|and|trials (l_conj) egfr_9\NN\1740|
T2_T34 NONE gw572016_5\NN\1740| (r_conj) lapatinib_3\NN\1740|,|gw572016|,|her2|,|egfr|,|kinase|,|blockade|,|events|,|and|trials (l_conj) kinase_13\NN\14732946|receptor|tyrosine
T3_T32 NONE tyrosine_12\NN\14601829| (r_compound) kinase_13\NN\14732946|receptor|tyrosine (r_conj) lapatinib_3\NN\1740|,|gw572016|,|her2|,|egfr|,|kinase|,|blockade|,|events|,|and|trials (l_conj) her2_7\NN\1740|
T3_T33 NONE tyrosine_12\NN\14601829| (r_compound) kinase_13\NN\14732946|receptor|tyrosine (r_conj) lapatinib_3\NN\1740|,|gw572016|,|her2|,|egfr|,|kinase|,|blockade|,|events|,|and|trials (l_conj) egfr_9\NN\1740|
T3_T34 NONE tyrosine_12\NN\14601829| (r_compound) kinase_13\NN\14732946|receptor|tyrosine
T6_T36 CPR:9 lapatinib_0\NN\1740| (r_nsubjpass) metabolized_2\VBN\1740|lapatinib|is|isozyme|,|remaining|. (l_nmod) isozyme_9\NN\1740|by|the|cytochrome|p450|3a4 (l_compound) 3a4_8\NN\1740|
T6_T38 NONE lapatinib_0\NN\1740| (r_nsubjpass) metabolized_2\VBN\1740|lapatinib|is|isozyme|,|remaining|. (l_advcl) remaining_14\VBG\2604760|with|metabolite|active (l_xcomp) active_15\JJ\1740|egfr (l_nmod) egfr_17\NN\1740|against|not|her2
T6_T39 NONE lapatinib_0\NN\1740| (r_nsubjpass) metabolized_2\VBN\1740|lapatinib|is|isozyme|,|remaining|. (l_advcl) remaining_14\VBG\2604760|with|metabolite|active (l_xcomp) active_15\JJ\1740|egfr (l_nmod) egfr_17\NN\1740|against|not|her2 (l_conj) her2_20\NN\1740|
T10_T40 NONE capecitabine_8\NN\1740| (r_conj) lapatinib_6\NN\1740|and|capecitabine|capecitabine (r_dobj) comparing_5\VBG\644583|lapatinib|women (l_nmod) women_13\NNS\9605289|in|cancer (l_nmod) cancer_20\NN\14239425|with|her2-positive|,|advanced|breast|or|mbc|progressed (l_amod) her2-positive_15\JJ\1740|
T11_T40 NONE capecitabine_10\NN\1740|with|alone (r_nmod) lapatinib_6\NN\1740|and|capecitabine|capecitabine (r_dobj) comparing_5\VBG\644583|lapatinib|women (l_nmod) women_13\NNS\9605289|in|cancer (l_nmod) cancer_20\NN\14239425|with|her2-positive|,|advanced|breast|or|mbc|progressed (l_amod) her2-positive_15\JJ\1740|
T12_T40 NONE anthracycline_30\NN\1740|with|an|,|taxane|,|and|trastuzumab (r_nmod) treatment_27\NN\654885|after|anthracycline (r_nmod) progressed_25\VBN\252019|that|had|treatment (r_acl:relcl) cancer_20\NN\14239425|with|her2-positive|,|advanced|breast|or|mbc|progressed (l_amod) her2-positive_15\JJ\1740|
T13_T40 NONE taxane_33\NN\1740|a (r_conj) anthracycline_30\NN\1740|with|an|,|taxane|,|and|trastuzumab (r_nmod) treatment_27\NN\654885|after|anthracycline (r_nmod) progressed_25\VBN\252019|that|had|treatment (r_acl:relcl) cancer_20\NN\14239425|with|her2-positive|,|advanced|breast|or|mbc|progressed (l_amod) her2-positive_15\JJ\1740|
T14_T40 NONE lapatinib_41\NN\1740|of|and|capecitabine (r_nmod) combination_39\NN\7951464|the|lapatinib (r_nsubjpass) associated_45\VBN\628491|trial|,|combination|was|improvement|. (l_nmod) trial_4\NN\786195|in|a|phase|iii|comparing (l_acl) comparing_5\VBG\644583|lapatinib|women (l_nmod) women_13\NNS\9605289|in|cancer (l_nmod) cancer_20\NN\14239425|with|her2-positive|,|advanced|breast|or|mbc|progressed (l_amod) her2-positive_15\JJ\1740|
T15_T40 NONE capecitabine_43\NN\1740| (r_conj) lapatinib_41\NN\1740|of|and|capecitabine (r_nmod) combination_39\NN\7951464|the|lapatinib (r_nsubjpass) associated_45\VBN\628491|trial|,|combination|was|improvement|. (l_nmod) trial_4\NN\786195|in|a|phase|iii|comparing (l_acl) comparing_5\VBG\644583|lapatinib|women (l_nmod) women_13\NNS\9605289|in|cancer (l_nmod) cancer_20\NN\14239425|with|her2-positive|,|advanced|breast|or|mbc|progressed (l_amod) her2-positive_15\JJ\1740|
T16_T40 NONE capecitabine_55\NN\1740|compared|with|alone (r_nmod) improvement_49\NN\7359599|with|a|numeric|rate|capecitabine|%|and|increase (r_nmod) associated_45\VBN\628491|trial|,|combination|was|improvement|. (l_nmod) trial_4\NN\786195|in|a|phase|iii|comparing (l_acl) comparing_5\VBG\644583|lapatinib|women (l_nmod) women_13\NNS\9605289|in|cancer (l_nmod) cancer_20\NN\14239425|with|her2-positive|,|advanced|breast|or|mbc|progressed (l_amod) her2-positive_15\JJ\1740|
T9_T40 NONE lapatinib_6\NN\1740|and|capecitabine|capecitabine (r_dobj) comparing_5\VBG\644583|lapatinib|women (l_nmod) women_13\NNS\9605289|in|cancer (l_nmod) cancer_20\NN\14239425|with|her2-positive|,|advanced|breast|or|mbc|progressed (l_amod) her2-positive_15\JJ\1740|
T24_T41 CPR:4 lapatinib_2\NN\1740| (r_nsubj) inhibitor_6\NN\20090|lapatinib|is|a|dual|egfr (l_nmod) egfr_9\NN\1740|of|the|and|kinases
T24_T42 CPR:4 lapatinib_2\NN\1740| (r_nsubj) inhibitor_6\NN\20090|lapatinib|is|a|dual|egfr (l_nmod) egfr_9\NN\1740|of|the|and|kinases (l_conj) kinases_13\NNS\14732946|her2|tyrosine (l_compound) her2_11\NN\1740|
T24_T43 CPR:4 lapatinib_2\NN\1740| (r_nsubj) inhibitor_6\NN\20090|lapatinib|is|a|dual|egfr (l_nmod) egfr_9\NN\1740|of|the|and|kinases (l_conj) kinases_13\NNS\14732946|her2|tyrosine
T25_T41 NONE tyrosine_12\NN\14601829| (r_compound) kinases_13\NNS\14732946|her2|tyrosine (r_conj) egfr_9\NN\1740|of|the|and|kinases
T25_T42 NONE tyrosine_12\NN\14601829| (r_compound) kinases_13\NNS\14732946|her2|tyrosine (l_compound) her2_11\NN\1740|
T25_T43 NONE tyrosine_12\NN\14601829| (r_compound) kinases_13\NNS\14732946|her2|tyrosine
T26_T44 NONE capecitabine_11\NN\1740|with (r_nmod) combination_9\NN\7951464|in|capecitabine (r_nmod) use_7\NN\407535|for|combination|treatment (l_nmod) treatment_14\NN\654885|for|the|mbc (l_nmod) mbc_17\NN\1740|of|her2-positive|progressed (l_amod) her2-positive_16\JJ\1740|
8294418
T20_T37 CPR:4 norepinephrine_3\NN\14807929| (r_conj) esters_1\NNS\14727670|phorbol|and|norepinephrine (r_nsubj) destabilize_4\VBP\109660|esters|mrna|cells|. (l_dobj) mrna_8\NN\14832193|alpha|1b-adrenergic|receptor (l_compound) receptor_7\NN\5225602|
T3_T29 CPR:4 norepinephrine_4\NN\14807929|ne (r_nsubj) down-regulates_8\VBZ\1740|which|norepinephrine|mrna (l_dobj) mrna_15\NN\14832193|receptor (l_compound) receptor_11\NN\5225602|alpha|1b-adrenergic|alpha-ar
T3_T35 CPR:4 norepinephrine_4\NN\14807929|ne (r_nsubj) down-regulates_8\VBZ\1740|which|norepinephrine|mrna (l_dobj) mrna_15\NN\14832193|receptor (l_compound) receptor_11\NN\5225602|alpha|1b-adrenergic|alpha-ar (l_appos) alpha-ar_13\NN\1740|(|)
T8_T29 CPR:4 ne_6\NN\14622893|(|) (r_appos) norepinephrine_4\NN\14807929|ne (r_nsubj) down-regulates_8\VBZ\1740|which|norepinephrine|mrna (l_dobj) mrna_15\NN\14832193|receptor (l_compound) receptor_11\NN\5225602|alpha|1b-adrenergic|alpha-ar
T8_T35 CPR:4 ne_6\NN\14622893|(|) (r_appos) norepinephrine_4\NN\14807929|ne (r_nsubj) down-regulates_8\VBZ\1740|which|norepinephrine|mrna (l_dobj) mrna_15\NN\14832193|receptor (l_compound) receptor_11\NN\5225602|alpha|1b-adrenergic|alpha-ar (l_appos) alpha-ar_13\NN\1740|(|)
T1_T24 NONE ne_0\NNS\14622893|,|esters|,|and|bradykinin|each (l_conj) bradykinin_6\NN\1740|
T1_T25 CPR:4 ne_0\NNS\14622893|,|esters|,|and|bradykinin|each (r_nsubj) decreased_8\VBD\169651|ne|levels|%|. (l_dobj) levels_11\NNS\4916342|mrna (l_compound) mrna_10\NN\14832193|alpha-ar (l_compound) alpha-ar_9\NN\1740|
T2_T24 NONE esters_3\NNS\14727670|phorbol (r_conj) ne_0\NNS\14622893|,|esters|,|and|bradykinin|each (l_conj) bradykinin_6\NN\1740|
T2_T25 CPR:4 esters_3\NNS\14727670|phorbol (r_conj) ne_0\NNS\14622893|,|esters|,|and|bradykinin|each (r_nsubj) decreased_8\VBD\169651|ne|levels|%|. (l_dobj) levels_11\NNS\4916342|mrna (l_compound) mrna_10\NN\14832193|alpha-ar (l_compound) alpha-ar_9\NN\1740|
T4_T26 CPR:4 dihydrochloride_6\NN\1740|the|inhibitor|(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine|h-7 (l_compound) inhibitor_4\NN\20090|protein|kinase|c (l_compound) c_3\NN\13714184|
T5_T26 CPR:4 h-7_8\NN\1740|(|) (r_appos) dihydrochloride_6\NN\1740|the|inhibitor|(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine|h-7 (l_compound) inhibitor_4\NN\20090|protein|kinase|c (l_compound) c_3\NN\13714184|
T6_T26 NONE esters_15\NNS\14727670|of|phorbol|and|ne (r_nmod) effects_12\NNS\13245626|the|esters (r_dobj) abolished_10\VBD\1740|dihydrochloride|effects|and|decreased|. (l_nsubj) dihydrochloride_6\NN\1740|the|inhibitor|(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine|h-7 (l_compound) inhibitor_4\NN\20090|protein|kinase|c (l_compound) c_3\NN\13714184|
T7_T26 NONE ne_17\NNS\14622893| (r_conj) esters_15\NNS\14727670|of|phorbol|and|ne (r_nmod) effects_12\NNS\13245626|the|esters (r_dobj) abolished_10\VBD\1740|dihydrochloride|effects|and|decreased|. (l_nsubj) dihydrochloride_6\NN\1740|the|inhibitor|(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine|h-7 (l_compound) inhibitor_4\NN\20090|protein|kinase|c (l_compound) c_3\NN\13714184|
T10_T27 CPR:3 egta_3\NN\1740| (r_conj) ryanodine_1\NN\1740|neither|nor|egta (r_nsubj) inhibited_4\VBD\2510337|ryanodine|down-regulation|. (l_dobj) down-regulation_5\NN\1740|mrna|ne (l_nmod) mrna_8\NN\14832193|of|alpha-ar (l_compound) alpha-ar_7\NN\1740|
T11_T27 CPR:4 ne_10\NNS\14622893|by (r_nmod) down-regulation_5\NN\1740|mrna|ne (l_nmod) mrna_8\NN\14832193|of|alpha-ar (l_compound) alpha-ar_7\NN\1740|
T9_T27 CPR:3 ryanodine_1\NN\1740|neither|nor|egta (r_nsubj) inhibited_4\VBD\2510337|ryanodine|down-regulation|. (l_dobj) down-regulation_5\NN\1740|mrna|ne (l_nmod) mrna_8\NN\14832193|of|alpha-ar (l_compound) alpha-ar_7\NN\1740|
T12_T28 CPR:4 d_1\NN\15089472|actinomycin (r_nsubj) caused_2\VBD\1617192|d|level|decrease|and|blocked|. (l_dobj) level_5\NN\4916342|mrna (l_compound) mrna_4\NN\14832193|alpha-ar (l_compound) alpha-ar_3\NN\1740|
T12_T30 CPR:4 d_1\NN\15089472|actinomycin (r_nsubj) caused_2\VBD\1617192|d|level|decrease|and|blocked|. (l_conj) blocked_17\VBD\1476483|effect (l_dobj) effect_19\NN\34213|the|h-7|decrease (l_acl) decrease_23\VB\169651|to|level (l_dobj) level_27\NN\4916342|basal|alpha-ar|mrna (l_compound) alpha-ar_25\NN\1740|
T13_T28 NONE h-7_21\NN\1740|of (r_nmod) effect_19\NN\34213|the|h-7|decrease (r_dobj) blocked_17\VBD\1476483|effect (r_conj) caused_2\VBD\1617192|d|level|decrease|and|blocked|. (l_dobj) level_5\NN\4916342|mrna (l_compound) mrna_4\NN\14832193|alpha-ar (l_compound) alpha-ar_3\NN\1740|
T13_T30 NONE h-7_21\NN\1740|of (r_nmod) effect_19\NN\34213|the|h-7|decrease (l_acl) decrease_23\VB\169651|to|level (l_dobj) level_27\NN\4916342|basal|alpha-ar|mrna (l_compound) alpha-ar_25\NN\1740|
T14_T31 CPR:4 ne_1\NNS\14622893|both|and|esters (r_nsubj) increased_5\VBD\169651|ne|rate|. (l_dobj) rate_7\NN\13815152|the|degradation (l_nmod) degradation_11\NN\199130|of|alpha-ar|mrna (l_compound) alpha-ar_9\NN\1740|
T15_T31 CPR:4 esters_4\NNS\14727670|phorbol (r_conj) ne_1\NNS\14622893|both|and|esters (r_nsubj) increased_5\VBD\169651|ne|rate|. (l_dobj) rate_7\NN\13815152|the|degradation (l_nmod) degradation_11\NN\199130|of|alpha-ar|mrna (l_compound) alpha-ar_9\NN\1740|
T16_T32 NONE ne-desensitized_1\JJ\1740| (r_amod) cells_2\NNS\3080309|in|ne-desensitized (r_nmod) caused_9\VBD\1617192|cells|,|esters|down-regulation|. (l_nsubj) esters_5\NNS\14727670|phorbol|and|bradykinin|each (l_conj) bradykinin_7\NN\1740|
T16_T33 CPR:4 ne-desensitized_1\JJ\1740| (r_amod) cells_2\NNS\3080309|in|ne-desensitized (r_nmod) caused_9\VBD\1617192|cells|,|esters|down-regulation|. (l_dobj) down-regulation_12\NN\1740|the|expected|mrna (l_nmod) mrna_15\NN\14832193|of|alpha-ar (l_compound) alpha-ar_14\NN\1740|
T17_T32 NONE esters_5\NNS\14727670|phorbol|and|bradykinin|each (l_conj) bradykinin_7\NN\1740|
T17_T33 CPR:4 esters_5\NNS\14727670|phorbol|and|bradykinin|each (r_nsubj) caused_9\VBD\1617192|cells|,|esters|down-regulation|. (l_dobj) down-regulation_12\NN\1740|the|expected|mrna (l_nmod) mrna_15\NN\14832193|of|alpha-ar (l_compound) alpha-ar_14\NN\1740|
T18_T34 CPR:4 acid_5\NN\14818238|the|protein|phosphatase|inhibitor|okadaic (l_compound) phosphatase_2\NN\14732946|
T19_T34 NONE ne_12\NNS\14622893|of (r_nmod) effect_10\NN\34213|the|transient|ne (r_dobj) prolonged_6\VBD\317700|acid|effect|h. (l_nsubj) acid_5\NN\14818238|the|protein|phosphatase|inhibitor|okadaic (l_compound) phosphatase_2\NN\14732946|
15109613
T6_T12 NONE hormone_11\NN\5404728| (r_compound) modulator_13\NN\1740|of|a|selective|thyroid|hormone|receptor|,|gc-1 (l_compound) receptor_12\NN\5225602|
T1_T9 NONE hormone_10\NN\5404728| (r_compound) receptor_11\NN\5225602|of|the|thyroid|hormone
T2_T10 NONE cholesterol_11\NN\15058310| (r_dobj) lowers_10\VBZ\1850315|that|gc-1|cholesterol|potency (l_nmod) potency_17\NN\5196375|with|more|and|efficacy (l_conj) efficacy_24\NN\5199286|approximately|two-|atorvastatin (l_nmod) atorvastatin_26\NN\3676175|than|,|compound (l_appos) compound_29\NN\5869584|a|blocks (l_acl:relcl) blocks_31\VBZ\1476483|that|reductase (l_dobj) reductase_33\NN\14732946|hmg-coa
T3_T10 CPR:4 atorvastatin_26\NN\3676175|than|,|compound (l_appos) compound_29\NN\5869584|a|blocks (l_acl:relcl) blocks_31\VBZ\1476483|that|reductase (l_dobj) reductase_33\NN\14732946|hmg-coa
T4_T10 NONE hmg-coa_32\NN\1740| (r_compound) reductase_33\NN\14732946|hmg-coa
T5_T11 NONE triglyceride_6\NN\14885088|of|and|a (l_conj) a_10\NN\13649268|lipoprotein|(|) (l_punct) )_11\-RRB-\1740|
15629255
T10_T23 CPR:6 bosentan_2\NN\1740|of|antagonist (l_appos) antagonist_6\NN\7846|(|eta/etb|receptor|) (l_compound) eta/etb_4\NN\1740|
T10_T24 CPR:6 bosentan_2\NN\1740|of|antagonist (l_appos) antagonist_6\NN\7846|(|eta/etb|receptor|) (l_compound) eta/etb_4\NN\1740|
T4_T17 CPR:6 bosentan_15\NN\1740|kg(-1 (r_appos) antagonist_13\NN\7846|of|the|endothelin|receptor|,|bosentan|) (l_compound) receptor_12\NN\5225602|
T4_T18 NONE bosentan_15\NN\1740|kg(-1 (r_appos) antagonist_13\NN\7846|of|the|endothelin|receptor|,|bosentan|) (r_nmod) effect_8\NN\34213|the|possible|antagonist|levels (l_nmod) levels_29\NNS\4916342|on|glucose|as|contents (l_compound) glucose_26\NN\14710501|serum|and|insulin (l_conj) insulin_28\NN\5407119|
T5_T17 NONE glucose_26\NN\14710501|serum|and|insulin (r_compound) levels_29\NNS\4916342|on|glucose|as|contents (r_nmod) effect_8\NN\34213|the|possible|antagonist|levels (l_nmod) antagonist_13\NN\7846|of|the|endothelin|receptor|,|bosentan|) (l_compound) receptor_12\NN\5225602|
T5_T18 NONE glucose_26\NN\14710501|serum|and|insulin (l_conj) insulin_28\NN\5407119|
T6_T19 NONE bosentan_6\NN\1740|of (r_nmod) effect_4\NN\34213|the|bosentan|levels|and|effect (l_nmod) levels_12\NNS\4916342|on|glucose|rats (l_compound) glucose_9\NN\14710501|serum|and|insulin (l_conj) insulin_11\NN\5407119|
T6_T20 NONE bosentan_6\NN\1740|of (r_nmod) effect_4\NN\34213|the|bosentan|levels|and|effect (l_conj) effect_22\NN\34213|its|hypoglycemia (l_nmod) hypoglycemia_25\NN\14299637|on|insulin-induced (l_amod) insulin-induced_24\JJ\1740|
T7_T19 NONE glucose_9\NN\14710501|serum|and|insulin (l_conj) insulin_11\NN\5407119|
T7_T20 NONE glucose_9\NN\14710501|serum|and|insulin (r_compound) levels_12\NNS\4916342|on|glucose|rats (r_nmod) effect_4\NN\34213|the|bosentan|levels|and|effect (l_conj) effect_22\NN\34213|its|hypoglycemia (l_nmod) hypoglycemia_25\NN\14299637|on|insulin-induced (l_amod) insulin-induced_24\JJ\1740|
T1_T11 NONE bosentan_0\NN\1740| (r_nsubj) prevented_2\VBD\1740|bosentan|partially|hyperglycemia|blocked|. (l_advcl) blocked_14\VBD\1476483|while|it|completely|decrease (l_dobj) decrease_17\NN\7296428|the|stress-induced|level (l_nmod) level_20\NN\4916342|in|insulin|rats (l_compound) insulin_19\NN\5407119|
T2_T13 NONE bosentan_0\NN\1740| (r_nsubj) decreased_2\VBD\169651|bosentan|also|level|effect|and|potentiated|. (l_nmod) effect_8\NN\34213|without|any|secretion (l_nmod) secretion_11\NN\13526110|on|insulin|rats (l_compound) insulin_10\NN\5407119|
T2_T14 NONE bosentan_0\NN\1740| (r_nsubj) decreased_2\VBD\169651|bosentan|also|level|effect|and|potentiated|. (l_conj) potentiated_17\VBD\229605|action (l_dobj) action_20\NN\30358|the|hypoglycemic|insulin (l_nmod) insulin_22\NN\5407119|of
T3_T13 NONE glucose_4\NN\14710501| (r_compound) level_5\NN\4916342|serum|glucose (r_dobj) decreased_2\VBD\169651|bosentan|also|level|effect|and|potentiated|. (l_nmod) effect_8\NN\34213|without|any|secretion (l_nmod) secretion_11\NN\13526110|on|insulin|rats (l_compound) insulin_10\NN\5407119|
T3_T14 NONE glucose_4\NN\14710501| (r_compound) level_5\NN\4916342|serum|glucose (r_dobj) decreased_2\VBD\169651|bosentan|also|level|effect|and|potentiated|. (l_conj) potentiated_17\VBD\229605|action (l_dobj) action_20\NN\30358|the|hypoglycemic|insulin (l_nmod) insulin_22\NN\5407119|of
23194076
T8_T24 CPR:3 orlistat_5\NN\1740| (r_compound) administration_6\NN\1133281|orlistat (r_conj) exercise_3\NN\621627|physical|and|administration (r_conj) diet_0\NN\7560652|,|exercise (r_nsubj) increase_7\VBP\169651|diet|levels|. (l_dobj) levels_14\NNS\4916342|hormone|women (l_compound) hormone_10\NN\5404728|serum|anti-müllerian|amh
T8_T25 CPR:3 orlistat_5\NN\1740| (r_compound) administration_6\NN\1133281|orlistat (r_conj) exercise_3\NN\621627|physical|and|administration (r_conj) diet_0\NN\7560652|,|exercise (r_nsubj) increase_7\VBP\169651|diet|levels|. (l_dobj) levels_14\NNS\4916342|hormone|women (l_compound) hormone_10\NN\5404728|serum|anti-müllerian|amh (l_appos) amh_12\NN\1740|(|)
T6_T12 NONE orlistat_13\NN\1740| (r_conj) exercise_11\NN\621627|physical|and|orlistat (r_conj) diet_8\NN\7560652|of|,|exercise|weeks (r_nmod) effect_6\NN\34213|the|combined|diet|,|levels (l_nmod) levels_25\NNS\4916342|on|hormone|women (l_compound) hormone_21\NN\5404728|serum|anti-müllerian|amh (l_appos) amh_23\NN\1740|(|)
T6_T9 NONE orlistat_13\NN\1740| (r_conj) exercise_11\NN\621627|physical|and|orlistat (r_conj) diet_8\NN\7560652|of|,|exercise|weeks (r_nmod) effect_6\NN\34213|the|combined|diet|,|levels (l_nmod) levels_25\NNS\4916342|on|hormone|women (l_compound) hormone_21\NN\5404728|serum|anti-müllerian|amh
T2_T13 NONE androgens_20\NNS\14745635| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin
T2_T14 NONE androgens_20\NNS\14745635| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) fsh_14\NN\5410315|
T2_T15 NONE androgens_20\NNS\14745635| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) lh_16\NN\5410315|
T2_T16 NONE androgens_20\NNS\14745635| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) prl_18\NN\1740|
T2_T17 NONE androgens_20\NNS\14745635| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) globulin_24\NN\14736972|sex|hormone-binding|shbg
T2_T18 NONE androgens_20\NNS\14745635| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) globulin_24\NN\14736972|sex|hormone-binding|shbg (l_appos) shbg_26\NN\1740|(|)
T2_T19 NONE androgens_20\NNS\14745635| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) insulin_32\NN\5407119|
T2_T20 NONE androgens_20\NNS\14745635| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (r_nmod) levels_10\NNS\4916342|serum|amh (r_nsubjpass) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_conj) calculated_50\VBN\632627|indices|were (l_nsubjpass) indices_48\NNS\13850304|index|resistance (l_compound) resistance_44\NN\37396|insulin|ir (l_compound) insulin_43\NN\5407119|
T3_T13 NONE glucose_29\NN\14710501| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin
T3_T14 NONE glucose_29\NN\14710501| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) fsh_14\NN\5410315|
T3_T15 NONE glucose_29\NN\14710501| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) lh_16\NN\5410315|
T3_T16 NONE glucose_29\NN\14710501| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) prl_18\NN\1740|
T3_T17 NONE glucose_29\NN\14710501| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) globulin_24\NN\14736972|sex|hormone-binding|shbg
T3_T18 NONE glucose_29\NN\14710501| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) globulin_24\NN\14736972|sex|hormone-binding|shbg (l_appos) shbg_26\NN\1740|(|)
T3_T19 NONE glucose_29\NN\14710501| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) insulin_32\NN\5407119|
T3_T20 NONE glucose_29\NN\14710501| (r_conj) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (r_nmod) levels_10\NNS\4916342|serum|amh (r_nsubjpass) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_conj) calculated_50\VBN\632627|indices|were (l_nsubjpass) indices_48\NNS\13850304|index|resistance (l_compound) resistance_44\NN\37396|insulin|ir (l_compound) insulin_43\NN\5407119|
T4_T13 NONE androgen_37\NN\14745635| (r_compound) index_38\NN\13850304|free|androgen|fai|and (r_compound) indices_48\NNS\13850304|index|resistance (r_nsubjpass) calculated_50\VBN\632627|indices|were (r_conj) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_nsubjpass) levels_10\NNS\4916342|serum|amh (l_nmod) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin
T4_T14 NONE androgen_37\NN\14745635| (r_compound) index_38\NN\13850304|free|androgen|fai|and (r_compound) indices_48\NNS\13850304|index|resistance (r_nsubjpass) calculated_50\VBN\632627|indices|were (r_conj) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_nsubjpass) levels_10\NNS\4916342|serum|amh (l_nmod) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) fsh_14\NN\5410315|
T4_T15 NONE androgen_37\NN\14745635| (r_compound) index_38\NN\13850304|free|androgen|fai|and (r_compound) indices_48\NNS\13850304|index|resistance (r_nsubjpass) calculated_50\VBN\632627|indices|were (r_conj) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_nsubjpass) levels_10\NNS\4916342|serum|amh (l_nmod) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) lh_16\NN\5410315|
T4_T16 NONE androgen_37\NN\14745635| (r_compound) index_38\NN\13850304|free|androgen|fai|and (r_compound) indices_48\NNS\13850304|index|resistance (r_nsubjpass) calculated_50\VBN\632627|indices|were (r_conj) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_nsubjpass) levels_10\NNS\4916342|serum|amh (l_nmod) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) prl_18\NN\1740|
T4_T17 NONE androgen_37\NN\14745635| (r_compound) index_38\NN\13850304|free|androgen|fai|and (r_compound) indices_48\NNS\13850304|index|resistance (r_nsubjpass) calculated_50\VBN\632627|indices|were (r_conj) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_nsubjpass) levels_10\NNS\4916342|serum|amh (l_nmod) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) globulin_24\NN\14736972|sex|hormone-binding|shbg
T4_T18 NONE androgen_37\NN\14745635| (r_compound) index_38\NN\13850304|free|androgen|fai|and (r_compound) indices_48\NNS\13850304|index|resistance (r_nsubjpass) calculated_50\VBN\632627|indices|were (r_conj) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_nsubjpass) levels_10\NNS\4916342|serum|amh (l_nmod) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) globulin_24\NN\14736972|sex|hormone-binding|shbg (l_appos) shbg_26\NN\1740|(|)
T4_T19 NONE androgen_37\NN\14745635| (r_compound) index_38\NN\13850304|free|androgen|fai|and (r_compound) indices_48\NNS\13850304|index|resistance (r_nsubjpass) calculated_50\VBN\632627|indices|were (r_conj) measured_34\VBN\697589|baseline|,|levels|were|and|calculated|. (l_nsubjpass) levels_10\NNS\4916342|serum|amh (l_nmod) amh_12\NN\1740|of|,|fsh|,|lh|,|prl|,|androgens|,|globulin|,|glucose|,|and|insulin (l_conj) insulin_32\NN\5407119|
T4_T20 NONE androgen_37\NN\14745635| (r_compound) index_38\NN\13850304|free|androgen|fai|and (r_compound) indices_48\NNS\13850304|index|resistance (l_compound) resistance_44\NN\37396|insulin|ir (l_compound) insulin_43\NN\5407119|
T5_T22 NONE testosterone_10\NN\14747587| (r_nsubj) decreased_11\VBD\169651|while|testosterone (r_advcl) increased_7\VBN\169651|weeks|lh|were|,|decreased|. (l_nsubjpass) lh_3\NN\5410315|and|shbg
T5_T23 NONE testosterone_10\NN\14747587| (r_nsubj) decreased_11\VBD\169651|while|testosterone (r_advcl) increased_7\VBN\169651|weeks|lh|were|,|decreased|. (l_nsubjpass) lh_3\NN\5410315|and|shbg (l_conj) shbg_5\NN\1740|
T7_T10 NONE orlistat_10\NN\1740| (r_compound) administration_11\NN\1133281|orlistat|,|combined|,|weeks (r_nsubj) resulted_24\VBD\2633881|that|women|administration|,|loss (l_nmod) loss_28\NN\13252973|in|significant|weight|,|improvement|,|and|levels (l_conj) improvement_30\NN\7359599|hyperandrogenism (l_nmod) hyperandrogenism_32\NN\1740|of|and|sensitivity (l_conj) sensitivity_35\NN\5651971|insulin (l_compound) insulin_34\NN\5407119|
T7_T11 CPR:3 orlistat_10\NN\1740| (r_compound) administration_11\NN\1133281|orlistat|,|combined|,|weeks (r_nsubj) resulted_24\VBD\2633881|that|women|administration|,|loss (l_nmod) loss_28\NN\13252973|in|significant|weight|,|improvement|,|and|levels (l_conj) levels_41\NNS\4916342|increased|serum|amh (l_compound) amh_40\NNS\1740|
23321689
T5_T21 NONE acetylcholine_3\NN\14807558| (r_compound) receptor_4\NN\5225602|the|α7|nicotinic|acetylcholine|nachr (l_appos) nachr_6\NN\1740|(|)
T5_T22 NONE acetylcholine_3\NN\14807558| (r_compound) receptor_4\NN\5225602|the|α7|nicotinic|acetylcholine|nachr
T6_T20 NONE nicotine_1\NN\14712692|,|activates|, (l_acl:relcl) activates_4\VBZ\1641914|which|subtypes (l_dobj) subtypes_9\NNS\1740|α7|nachrs (l_nmod) nachrs_11\NNS\1740|of
T1_T15 NONE pnu-282987_0\NN\1740| (r_nsubj) displayed_5\VBD\2137132|pnu-282987|hand|increase|dose|. (l_nmod) dose_14\NN\3740161|at|a|higher| (l_appos) _17\_SP\1740|(|10|mg/kg (l_appos) mg/kg_18\NN\1740|)|reduced (l_acl:relcl) reduced_23\VBN\441445|that|was|significantly|way-100135 (l_nmod) way-100135_30\NN\1740|by|the|receptor|antagonist (l_compound) receptor_28\NN\5225602|serotonin|5-ht1a
T2_T15 CPR:6 way-100135_30\NN\1740|by|the|receptor|antagonist (l_compound) receptor_28\NN\5225602|serotonin|5-ht1a
T3_T16 CPR:6 methyllycaconitine_5\NN\1740|the|α7|receptor|antagonist (l_compound) receptor_3\NN\5225602|
T4_T16 NONE pnu-282987_15\NN\1740|with (r_nmod) seen_13\VBN\2106506|pnu-282987 (r_acl) effects_12\NNS\13245626|these|anxiety-like|seen (r_dobj) reverse_9\VB\109660|to|effects (r_xcomp) unable_7\JJ\1740|however|methyllycaconitine|was|reverse|. (l_nsubj) methyllycaconitine_5\NN\1740|the|α7|receptor|antagonist (l_compound) receptor_3\NN\5225602|
23512501
T13_T19 NONE nad(p)h_0\NN\1740| (r_compound) activity_6\NN\30358|nad(p)h|oxidoreductase|1|inducer|plants|. (l_nummod) 1_4\CD\13741022|
T14_T19 NONE quinone_2\NN\14818238| (r_compound) oxidoreductase_3\NN\14732946|:|quinone (r_compound) activity_6\NN\30358|nad(p)h|oxidoreductase|1|inducer|plants|. (l_nummod) 1_4\CD\13741022|
T7_T16 NONE nad(p)h_6\NN\1740| (r_compound) oxidoreductase_9\NN\14732946|enzyme|is|nad(p)h|:|quinone|.
T8_T16 NONE quinone_8\NN\14818238| (r_compound) oxidoreductase_9\NN\14732946|enzyme|is|nad(p)h|:|quinone|.
T10_T17 NONE quinone_28\NN\14818238|: (r_compound) oxidoreductase_29\NN\14732946|nad(p)h|quinone
T9_T17 NONE nad(p)h_26\NN\1740| (r_compound) oxidoreductase_29\NN\14732946|nad(p)h|quinone
T11_T18 NONE nad(p)h_10\NN\1740| (r_compound) activity_15\NN\30358|of|nad(p)h|quinone|oxidoreductase|inducer
T12_T18 NONE quinone_12\NN\14818238|: (r_compound) activity_15\NN\30358|of|nad(p)h|quinone|oxidoreductase|inducer
T5_T15 NONE nad(p)h_3\NN\1740| (r_compound) activity_8\NN\30358|the|nad(p)h|quinone|oxidoreductase|inducer|extracts (l_compound) oxidoreductase_6\NN\14732946|
T6_T15 NONE quinone_5\NN\14818238|: (r_compound) activity_8\NN\30358|the|nad(p)h|quinone|oxidoreductase|inducer|extracts (l_compound) oxidoreductase_6\NN\14732946|
23339682
T1_T10 NONE caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2c9_20\NN\1740|
T1_T11 NONE caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2e1_22\NN\1740|
T1_T12 NONE caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2d6_24\NN\1740|
T1_T13 NONE caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp3a4_26\NN\1740|
T1_T9 NONE caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|,
T2_T10 NONE chlorzoxazone_45\NN\1740| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2c9_20\NN\1740|
T2_T11 NONE chlorzoxazone_45\NN\1740| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2e1_22\NN\1740|
T2_T12 NONE chlorzoxazone_45\NN\1740| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2d6_24\NN\1740|
T2_T13 NONE chlorzoxazone_45\NN\1740| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp3a4_26\NN\1740|
T2_T9 NONE chlorzoxazone_45\NN\1740| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|,
T3_T10 NONE tolbutamide_47\NN\14914301| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2c9_20\NN\1740|
T3_T11 NONE tolbutamide_47\NN\14914301| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2e1_22\NN\1740|
T3_T12 NONE tolbutamide_47\NN\14914301| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2d6_24\NN\1740|
T3_T13 NONE tolbutamide_47\NN\14914301| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp3a4_26\NN\1740|
T3_T9 NONE tolbutamide_47\NN\14914301| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|,
T4_T10 NONE metoprolol_49\NN\2832168| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2c9_20\NN\1740|
T4_T11 NONE metoprolol_49\NN\2832168| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2e1_22\NN\1740|
T4_T12 NONE metoprolol_49\NN\2832168| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2d6_24\NN\1740|
T4_T13 NONE metoprolol_49\NN\2832168| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp3a4_26\NN\1740|
T4_T9 NONE metoprolol_49\NN\2832168| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|,
T5_T10 NONE midazolam_51\NN\2830852| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2c9_20\NN\1740|
T5_T11 NONE midazolam_51\NN\2830852| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2e1_22\NN\1740|
T5_T12 NONE midazolam_51\NN\2830852| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp2d6_24\NN\1740|
T5_T13 NONE midazolam_51\NN\2830852| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|, (l_conj) cyp3a4_26\NN\1740|
T5_T9 NONE midazolam_51\NN\2830852| (r_conj) caffeine_43\NN\14712692|,|chlorzoxazone|,|tolbutamide|,|metoprolol|and|midazolam (r_dep) drugs_41\NNS\14778436|of|five|specific|probe|:|caffeine (r_nmod) parameters_36\NNS\5858936|of|pharmacokinetic|drugs (r_nmod) changes_33\NNS\7283608|by|the|parameters (r_nmod) reflected_30\VBN\923793|which|were|changes (r_acl:relcl) cyp1a2_18\NN\1740|of|,|cyp2c9|,|cyp2e1|,|cyp2d6|and|cyp3a4|,|reflected|,
10546982
T8_T20 NONE serotonin_0\NN\14807737| (r_compound) transporter_1\NN\4490091|serotonin
T9_T20 NONE rti-76_9\NNP\1740|with (r_nmod) studies_7\NNS\635850|rti-76 (r_dep) production_2\NN\30358|transporter|and|rates|:|studies|. (l_compound) transporter_1\NN\4490091|serotonin
T6_T15 NONE serotonin_12\NN\14807737| (r_compound) transporter_13\NN\4490091|of|the|serotonin|sert
T6_T18 NONE serotonin_12\NN\14807737| (r_compound) transporter_13\NN\4490091|of|the|serotonin|sert (l_appos) sert_15\NN\1740|(|)
T2_T12 CPR:4 rti-76_16\NN\1740|of|,|inhibitor (r_nmod) administration_14\NN\1133281|after|rti-76 (r_nmod) recovery_10\NN\7357388|of|binding|administration (r_nmod) rate_8\NN\13815152|from|the|recovery (r_nmod) determined_5\VBN\1645601|turnover|was|rate|. (l_nsubjpass) turnover_1\NN\13819207|the|sert (l_nmod) sert_3\NN\1740|of
T3_T13 CPR:4 rti-76_12\NN\1740|with (r_nmod) incubation_6\NN\654885|in|cortex|rti-76 (r_nsubj) produced_13\VBD\1617192|studies|,|incubation|inhibition|. (l_dobj) inhibition_19\NN\1068773|a|resistant|densities (l_nmod) densities_23\NNS\4941325|of|sert|binding|bmax (l_compound) sert_21\NN\1740|
T4_T14 NONE citalopram_0\NN\1740| (r_nsubj) protected_1\VBD\1127795|citalopram|inhibition|. (l_nmod) inhibition_5\NN\1068773|against|the|rti-76-induced|binding (l_nmod) binding_8\NN\4688246|of|sert (l_compound) sert_7\NN\1740|
T5_T14 CPR:4 rti-76-induced_4\JJ\1740| (r_amod) inhibition_5\NN\1068773|against|the|rti-76-induced|binding (l_nmod) binding_8\NN\4688246|of|sert (l_compound) sert_7\NN\1740|
T7_T16 NONE rti-76_12\NN\1740|of (r_nmod) nmol_10\NN\1740|of|100|rti-76 (r_nmod) injections_7\NNS\320852|of|in|intracerebroventricular|nmol (r_nmod) h_2\NN\14622893|following|6|injections (r_nmod) was_15\VBD\836236|h|,|there|reduction|,|change|. (l_nsubj) reduction_20\NN\351485|a|dose-|%|binding (l_nmod) binding_28\NN\4688246|of|sert|hippocampus (l_compound) sert_27\NN\1740|
T1_T11 CPR:9 [3h]-5-ht_5\NN\1740| (r_compound) uptake_6\NN\13440063|of|[3h]-5-ht (r_nmod) decrease_1\NN\7296428|the|and|recovery|uptake (r_nsubj) correlated_7\VBD\2657219|decrease|highly|=|recovery|. (l_nmod) recovery_16\NN\7357388|with|the|binding (l_nmod) binding_19\NN\4688246|of|sert (l_compound) sert_18\NN\1740|
10432475
T41_T61 NONE (-)-pindolol_22\NN\1740|by|and (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_punct) ,_38\,\1740|
T41_T62 NONE (-)-pindolol_22\NN\1740|by|and (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_conj) 5-ht1b_40\NN\1740|
T42_T61 NONE 5-ht_28\NN\1740| (r_compound) inhibitors_30\NNS\20090|with|5-ht|reuptake (r_nmod) association_26\NN\8008335|in|inhibitors (r_conj) and_24\CC\1740|alone|association (r_advmod) (-)-pindolol_22\NN\1740|by|and (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_punct) ,_38\,\1740|
T42_T62 NONE 5-ht_28\NN\1740| (r_compound) inhibitors_30\NNS\20090|with|5-ht|reuptake (r_nmod) association_26\NN\8008335|in|inhibitors (r_conj) and_24\CC\1740|alone|association (r_advmod) (-)-pindolol_22\NN\1740|by|and (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_conj) 5-ht1b_40\NN\1740|
T43_T61 NONE dopamine_5\NN\14807737|of|,|noradrenaline|,|and|serotonin|cortex (r_nmod) levels_3\NNS\4916342|of|dialysate|dopamine (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_punct) ,_38\,\1740|
T43_T62 NONE dopamine_5\NN\14807737|of|,|noradrenaline|,|and|serotonin|cortex (r_nmod) levels_3\NNS\4916342|of|dialysate|dopamine (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_conj) 5-ht1b_40\NN\1740|
T44_T61 NONE noradrenaline_7\NN\14807929| (r_conj) dopamine_5\NN\14807737|of|,|noradrenaline|,|and|serotonin|cortex (r_nmod) levels_3\NNS\4916342|of|dialysate|dopamine (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_punct) ,_38\,\1740|
T44_T62 NONE noradrenaline_7\NN\14807929| (r_conj) dopamine_5\NN\14807737|of|,|noradrenaline|,|and|serotonin|cortex (r_nmod) levels_3\NNS\4916342|of|dialysate|dopamine (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_conj) 5-ht1b_40\NN\1740|
T45_T61 NONE serotonin_10\NN\14807737|5-ht (r_conj) dopamine_5\NN\14807737|of|,|noradrenaline|,|and|serotonin|cortex (r_nmod) levels_3\NNS\4916342|of|dialysate|dopamine (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_punct) ,_38\,\1740|
T45_T62 NONE serotonin_10\NN\14807737|5-ht (r_conj) dopamine_5\NN\14807737|of|,|noradrenaline|,|and|serotonin|cortex (r_nmod) levels_3\NNS\4916342|of|dialysate|dopamine (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_conj) 5-ht1b_40\NN\1740|
T46_T61 NONE 5-ht_12\NN\1740|(|) (r_appos) serotonin_10\NN\14807737|5-ht (r_conj) dopamine_5\NN\14807737|of|,|noradrenaline|,|and|serotonin|cortex (r_nmod) levels_3\NNS\4916342|of|dialysate|dopamine (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_punct) ,_38\,\1740|
T46_T62 NONE 5-ht_12\NN\1740|(|) (r_appos) serotonin_10\NN\14807737|5-ht (r_conj) dopamine_5\NN\14807737|of|,|noradrenaline|,|and|serotonin|cortex (r_nmod) levels_3\NNS\4916342|of|dialysate|dopamine (r_nmod) modulation_0\NN\7044917|levels|(-)-pindolol|:|roles (l_dep) roles_33\NNS\719494|comparative|receptors|. (l_nmod) receptors_41\NNS\5225602|of|beta-adrenergic (l_amod) beta-adrenergic_35\JJ\1740|,|5-ht1a|,|and|5-ht1b (l_conj) 5-ht1b_40\NN\1740|
T1_T48 NONE (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors
T1_T54 NONE (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s
T1_T56 NONE (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) 5-ht1b_9\NN\1740|
T1_T58 NONE (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors (l_compound) receptors_14\NNS\5225602|1/2-adrenergic
T21_T48 NONE dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors
T21_T54 NONE dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s
T21_T56 NONE dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) 5-ht1b_9\NN\1740|
T21_T58 NONE dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors (l_compound) receptors_14\NNS\5225602|1/2-adrenergic
T22_T48 NONE da_24\NN\10484858|(|) (r_appos) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors
T22_T54 NONE da_24\NN\10484858|(|) (r_appos) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s
T22_T56 NONE da_24\NN\10484858|(|) (r_appos) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) 5-ht1b_9\NN\1740|
T22_T58 NONE da_24\NN\10484858|(|) (r_appos) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors (l_compound) receptors_14\NNS\5225602|1/2-adrenergic
T24_T48 NONE noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors
T24_T54 NONE noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s
T24_T56 NONE noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) 5-ht1b_9\NN\1740|
T24_T58 NONE noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors (l_compound) receptors_14\NNS\5225602|1/2-adrenergic
T25_T48 NONE nad_29\NN\14800277|(|) (r_appos) noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors
T25_T54 NONE nad_29\NN\14800277|(|) (r_appos) noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s
T25_T56 NONE nad_29\NN\14800277|(|) (r_appos) noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) 5-ht1b_9\NN\1740|
T25_T58 NONE nad_29\NN\14800277|(|) (r_appos) noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors (l_compound) receptors_14\NNS\5225602|1/2-adrenergic
T26_T48 NONE 5-ht_32\NN\1740| (r_conj) noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors
T26_T54 NONE 5-ht_32\NN\1740| (r_conj) noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s
T26_T56 NONE 5-ht_32\NN\1740| (r_conj) noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) 5-ht1b_9\NN\1740|
T26_T58 NONE 5-ht_32\NN\1740| (r_conj) noradrenaline_27\NN\14807929|nad|versus|5-ht (r_conj) dopamine_22\NN\14807737|of|da|and|noradrenaline (r_nmod) levels_20\NNS\4916342|extracellular|dopamine (r_dobj) increased_18\VBD\169651|(-)-pindolol|dose-dependently|levels|,|dialysates|. (l_nsubj) (-)-pindolol_0\NN\1740|,|possesses|, (l_acl:relcl) possesses_3\VBZ\2630189|which|affinity (l_dobj) affinity_5\NN\11426530|significant|5-ht1a (l_nmod) 5-ht1a_7\NN\1740|for|,|5-ht1b|,|and|(ar)s (l_conj) (ar)s_15\NNS\1740|receptors (l_compound) receptors_14\NNS\5225602|1/2-adrenergic
T27_T52 CPR:6 betaxolol_9\NN\1740| (r_appos) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_compound) 1-ar_6\NN\1740|
T27_T53 NONE betaxolol_9\NN\1740| (r_appos) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_conj) antagonist_16\NN\7846|the|preferential|beta|2-ar|,|ici118,551|, (l_compound) 2-ar_15\NN\1740|
T28_T52 NONE ici118,551_18\CD\1740| (r_appos) antagonist_16\NN\7846|the|preferential|beta|2-ar|,|ici118,551|, (r_conj) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_compound) 1-ar_6\NN\1740|
T28_T53 CPR:6 ici118,551_18\CD\1740| (r_appos) antagonist_16\NN\7846|the|preferential|beta|2-ar|,|ici118,551|, (l_compound) 2-ar_15\NN\1740|
T29_T52 NONE da_26\NN\10484858|of|,|nad|,|or|5-ht (r_nmod) levels_24\NNS\4916342|basal|da (r_dobj) increase_22\VB\169651|distinction|,|antagonist|did|not|levels|. (l_nsubj) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_compound) 1-ar_6\NN\1740|
T29_T53 NONE da_26\NN\10484858|of|,|nad|,|or|5-ht (r_nmod) levels_24\NNS\4916342|basal|da (r_dobj) increase_22\VB\169651|distinction|,|antagonist|did|not|levels|. (l_nsubj) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_conj) antagonist_16\NN\7846|the|preferential|beta|2-ar|,|ici118,551|, (l_compound) 2-ar_15\NN\1740|
T30_T52 NONE nad_28\NN\14800277| (r_conj) da_26\NN\10484858|of|,|nad|,|or|5-ht (r_nmod) levels_24\NNS\4916342|basal|da (r_dobj) increase_22\VB\169651|distinction|,|antagonist|did|not|levels|. (l_nsubj) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_compound) 1-ar_6\NN\1740|
T30_T53 NONE nad_28\NN\14800277| (r_conj) da_26\NN\10484858|of|,|nad|,|or|5-ht (r_nmod) levels_24\NNS\4916342|basal|da (r_dobj) increase_22\VB\169651|distinction|,|antagonist|did|not|levels|. (l_nsubj) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_conj) antagonist_16\NN\7846|the|preferential|beta|2-ar|,|ici118,551|, (l_compound) 2-ar_15\NN\1740|
T31_T52 NONE 5-ht_31\NN\1740| (r_conj) da_26\NN\10484858|of|,|nad|,|or|5-ht (r_nmod) levels_24\NNS\4916342|basal|da (r_dobj) increase_22\VB\169651|distinction|,|antagonist|did|not|levels|. (l_nsubj) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_compound) 1-ar_6\NN\1740|
T31_T53 NONE 5-ht_31\NN\1740| (r_conj) da_26\NN\10484858|of|,|nad|,|or|5-ht (r_nmod) levels_24\NNS\4916342|basal|da (r_dobj) increase_22\VB\169651|distinction|,|antagonist|did|not|levels|. (l_nsubj) antagonist_7\NN\7846|the|preferential|beta|1-ar|,|betaxolol|,|and|antagonist (l_conj) antagonist_16\NN\7846|the|preferential|beta|2-ar|,|ici118,551|, (l_compound) 2-ar_15\NN\1740|
T35_T55 CPR:6 way100,635_6\CD\1740| (r_appos) antagonist_4\NN\7846|the|selective|5-ht1a|receptor|,|way100,635|, (l_compound) 5-ht1a_2\NN\1740|
T35_T57 NONE way100,635_6\CD\1740| (r_appos) antagonist_4\NN\7846|the|selective|5-ht1a|receptor|,|way100,635|, (r_nsubj) attenuated_9\VBD\224901|antagonist|slightly|increase|,|ineffective|. (l_advcl) ineffective_28\JJ\1740|while|antagonist|was (l_nsubj) antagonist_23\NN\7846|the|selective|5-ht1b|,|sb224,289|, (l_compound) 5-ht1b_22\NN\1740|
T36_T55 NONE (-)-pindolol-induced_11\JJ\1740| (r_amod) increase_12\NN\13576355|the|(-)-pindolol-induced|levels (r_dobj) attenuated_9\VBD\224901|antagonist|slightly|increase|,|ineffective|. (l_nsubj) antagonist_4\NN\7846|the|selective|5-ht1a|receptor|,|way100,635|, (l_compound) 5-ht1a_2\NN\1740|
T36_T57 NONE (-)-pindolol-induced_11\JJ\1740| (r_amod) increase_12\NN\13576355|the|(-)-pindolol-induced|levels (r_dobj) attenuated_9\VBD\224901|antagonist|slightly|increase|,|ineffective|. (l_advcl) ineffective_28\JJ\1740|while|antagonist|was (l_nsubj) antagonist_23\NN\7846|the|selective|5-ht1b|,|sb224,289|, (l_compound) 5-ht1b_22\NN\1740|
T37_T55 NONE da_14\NN\10484858|and|nad (r_compound) levels_17\NNS\4916342|in|da (r_nmod) increase_12\NN\13576355|the|(-)-pindolol-induced|levels (r_dobj) attenuated_9\VBD\224901|antagonist|slightly|increase|,|ineffective|. (l_nsubj) antagonist_4\NN\7846|the|selective|5-ht1a|receptor|,|way100,635|, (l_compound) 5-ht1a_2\NN\1740|
T37_T57 NONE da_14\NN\10484858|and|nad (r_compound) levels_17\NNS\4916342|in|da (r_nmod) increase_12\NN\13576355|the|(-)-pindolol-induced|levels (r_dobj) attenuated_9\VBD\224901|antagonist|slightly|increase|,|ineffective|. (l_advcl) ineffective_28\JJ\1740|while|antagonist|was (l_nsubj) antagonist_23\NN\7846|the|selective|5-ht1b|,|sb224,289|, (l_compound) 5-ht1b_22\NN\1740|
T38_T55 NONE nad_16\NN\14800277| (r_conj) da_14\NN\10484858|and|nad (r_compound) levels_17\NNS\4916342|in|da (r_nmod) increase_12\NN\13576355|the|(-)-pindolol-induced|levels (r_dobj) attenuated_9\VBD\224901|antagonist|slightly|increase|,|ineffective|. (l_nsubj) antagonist_4\NN\7846|the|selective|5-ht1a|receptor|,|way100,635|, (l_compound) 5-ht1a_2\NN\1740|
T38_T57 NONE nad_16\NN\14800277| (r_conj) da_14\NN\10484858|and|nad (r_compound) levels_17\NNS\4916342|in|da (r_nmod) increase_12\NN\13576355|the|(-)-pindolol-induced|levels (r_dobj) attenuated_9\VBD\224901|antagonist|slightly|increase|,|ineffective|. (l_advcl) ineffective_28\JJ\1740|while|antagonist|was (l_nsubj) antagonist_23\NN\7846|the|selective|5-ht1b|,|sb224,289|, (l_compound) 5-ht1b_22\NN\1740|
T39_T55 NONE sb224,289_25\NN\1740| (r_appos) antagonist_23\NN\7846|the|selective|5-ht1b|,|sb224,289|, (r_nsubj) ineffective_28\JJ\1740|while|antagonist|was (r_advcl) attenuated_9\VBD\224901|antagonist|slightly|increase|,|ineffective|. (l_nsubj) antagonist_4\NN\7846|the|selective|5-ht1a|receptor|,|way100,635|, (l_compound) 5-ht1a_2\NN\1740|
T39_T57 CPR:6 sb224,289_25\NN\1740| (r_appos) antagonist_23\NN\7846|the|selective|5-ht1b|,|sb224,289|, (l_compound) 5-ht1b_22\NN\1740|
T40_T47 NONE (-)-pindolol_4\NN\1740| (r_nsubj) facilitates_5\VBZ\2547586|that|(-)-pindolol|transmission|activation|,|involved (l_advcl) involved_37\VBN\2676054|whereas|receptors|are|not (l_nsubjpass) receptors_34\NNS\5225602|5-ht1b (l_compound) 5-ht1b_33\NN\1740|
T40_T59 NONE (-)-pindolol_4\NN\1740| (r_nsubj) facilitates_5\VBZ\2547586|that|(-)-pindolol|transmission|activation|,|involved (l_nmod) activation_15\NN\13561719|primarily|by|1/2-ars|and|degree|,|stimulation (l_nmod) 1/2-ars_18\NNS\1740|of|beta
T40_T60 NONE (-)-pindolol_4\NN\1740| (r_nsubj) facilitates_5\VBZ\2547586|that|(-)-pindolol|transmission|activation|,|involved (l_nmod) activation_15\NN\13561719|primarily|by|1/2-ars|and|degree|,|stimulation (l_conj) stimulation_27\NN\242808|by|receptors (l_nmod) receptors_30\NNS\5225602|of|5-ht1a (l_compound) 5-ht1a_29\NN\1740|
T19_T49 NONE (-)-pindolol_3\NN\1740| (r_nsubj) modulates_4\VBZ\1724459|conclusion|,|(-)-pindolol|,|and|inhibitors|,|transmission|pattern|. (l_nmod) pattern_28\NN\5726345|via|a|complex|actions (l_nmod) actions_30\NNS\30358|of|1/2-ars (l_nmod) 1/2-ars_33\NNS\1740|at|beta|,|5-ht1a|,|and|5-ht1b|receptors
T19_T50 NONE (-)-pindolol_3\NN\1740| (r_nsubj) modulates_4\VBZ\1724459|conclusion|,|(-)-pindolol|,|and|inhibitors|,|transmission|pattern|. (l_nmod) pattern_28\NN\5726345|via|a|complex|actions (l_nmod) actions_30\NNS\30358|of|1/2-ars (l_nmod) 1/2-ars_33\NNS\1740|at|beta|,|5-ht1a|,|and|5-ht1b|receptors (l_conj) 5-ht1a_35\NN\1740|
T19_T51 NONE (-)-pindolol_3\NN\1740| (r_nsubj) modulates_4\VBZ\1724459|conclusion|,|(-)-pindolol|,|and|inhibitors|,|transmission|pattern|. (l_nmod) pattern_28\NN\5726345|via|a|complex|actions (l_nmod) actions_30\NNS\30358|of|1/2-ars (l_nmod) 1/2-ars_33\NNS\1740|at|beta|,|5-ht1a|,|and|5-ht1b|receptors (l_conj) 5-ht1b_38\NN\1740|
T20_T49 NONE 5-ht_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|with|5-ht|reuptake (r_nmod) modulates_4\VBZ\1724459|conclusion|,|(-)-pindolol|,|and|inhibitors|,|transmission|pattern|. (l_nmod) pattern_28\NN\5726345|via|a|complex|actions (l_nmod) actions_30\NNS\30358|of|1/2-ars (l_nmod) 1/2-ars_33\NNS\1740|at|beta|,|5-ht1a|,|and|5-ht1b|receptors
T20_T50 NONE 5-ht_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|with|5-ht|reuptake (r_nmod) modulates_4\VBZ\1724459|conclusion|,|(-)-pindolol|,|and|inhibitors|,|transmission|pattern|. (l_nmod) pattern_28\NN\5726345|via|a|complex|actions (l_nmod) actions_30\NNS\30358|of|1/2-ars (l_nmod) 1/2-ars_33\NNS\1740|at|beta|,|5-ht1a|,|and|5-ht1b|receptors (l_conj) 5-ht1a_35\NN\1740|
T20_T51 NONE 5-ht_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|with|5-ht|reuptake (r_nmod) modulates_4\VBZ\1724459|conclusion|,|(-)-pindolol|,|and|inhibitors|,|transmission|pattern|. (l_nmod) pattern_28\NN\5726345|via|a|complex|actions (l_nmod) actions_30\NNS\30358|of|1/2-ars (l_nmod) 1/2-ars_33\NNS\1740|at|beta|,|5-ht1a|,|and|5-ht1b|receptors (l_conj) 5-ht1b_38\NN\1740|
17617661
T5_T20 NONE glutathione_0\NN\1740| (r_compound) polymorphisms_2\NNS\11418750|glutathione|s-transferase|,|intake|study|. (l_compound) s-transferase_1\NN\1740|
T6_T20 NONE s-transferase_1\NN\1740|
T1_T10 NONE isothiocyanates_0\NNS\15032661|,|thought|, (r_nsubjpass) conjugated_16\VBN\394813|isothiocyanates|are|glutathione|s-transferases|excretion|. (l_nmod) s-transferases_21\NNS\1740|by|glutathione|gsts
T1_T11 NONE isothiocyanates_0\NNS\15032661|,|thought|, (r_nsubjpass) conjugated_16\VBN\394813|isothiocyanates|are|glutathione|s-transferases|excretion|. (l_nmod) s-transferases_21\NNS\1740|by|glutathione|gsts (l_appos) gsts_23\NNS\1740|(|)
T2_T10 NONE glutathione_18\NN\1740|to (r_nmod) conjugated_16\VBN\394813|isothiocyanates|are|glutathione|s-transferases|excretion|. (l_nmod) s-transferases_21\NNS\1740|by|glutathione|gsts
T2_T11 NONE glutathione_18\NN\1740|to (r_nmod) conjugated_16\VBN\394813|isothiocyanates|are|glutathione|s-transferases|excretion|. (l_nmod) s-transferases_21\NNS\1740|by|glutathione|gsts (l_appos) gsts_23\NNS\1740|(|)
T3_T10 NONE glutathione_20\NN\1740| (r_compound) s-transferases_21\NNS\1740|by|glutathione|gsts
T3_T11 NONE glutathione_20\NN\1740| (r_compound) s-transferases_21\NNS\1740|by|glutathione|gsts (l_appos) gsts_23\NNS\1740|(|)
T4_T10 NONE s-transferases_21\NNS\1740|by|glutathione|gsts
T4_T11 NONE s-transferases_21\NNS\1740|by|glutathione|gsts (l_appos) gsts_23\NNS\1740|(|)
23296100
12063741
T1_T11 CPR:4 leflunomide_3\NN\2724966|as|a|prodrug (r_nsubjpass) converted_6\VBN\126264|leflunomide|is|completely|a|. (l_nmod) a_11\NN\13649268|to|its|active|metabolite|1726|blocks (l_acl:relcl) blocks_18\VBZ\1476483|which|dehydrogenase (l_dobj) dehydrogenase_21\NN\1740|the|dihydroorotate|,|enzyme
T2_T11 CPR:4 1726_13\CD\1740|77|m1 (r_nummod) a_11\NN\13649268|to|its|active|metabolite|1726|blocks (l_acl:relcl) blocks_18\VBZ\1476483|which|dehydrogenase (l_dobj) dehydrogenase_21\NN\1740|the|dihydroorotate|,|enzyme
T3_T11 NONE dihydroorotate_20\NN\1740| (r_compound) dehydrogenase_21\NN\1740|the|dihydroorotate|,|enzyme
T5_T11 NONE pyrimidine_28\NN\14618253| (r_compound) synthesis_31\NN\13446390|of|the|pyrimidine|de (r_nmod) enzyme_25\NN\14723628|a|key|synthesis (r_appos) dehydrogenase_21\NN\1740|the|dihydroorotate|,|enzyme
11146120
T14_T33 NONE d_13\NN\15089472| (r_compound) receptor_14\NN\5225602|of|vitamin|d|and (r_compound) agonists_17\NNS\9613191|receptor|beta(2)-adrenoceptor (l_compound) beta(2)-adrenoceptor_16\NN\1740|
T14_T34 NONE d_13\NN\15089472| (r_compound) receptor_14\NN\5225602|of|vitamin|d|and (r_compound) agonists_17\NNS\9613191|receptor|beta(2)-adrenoceptor (r_nmod) comparison_10\NN\635850|a|mechanistic|agonists (r_dep) modulation_1\NN\7044917|pharmacological|synthesis|:|comparison (l_nmod) synthesis_6\NN\13446390|of|nerve|growth|factor (l_compound) factor_5\NN\7326557|
T14_T35 NONE d_13\NN\15089472| (r_compound) receptor_14\NN\5225602|of|vitamin|d|and
T5_T24 NONE )_13\-RRB-\1740| (r_punct) analogue_14\NN\4743605|a|vitamin|d(3|)|cb1093|effects (r_appos) compounds_8\NNS\5869584|two|,|analogue|,|and|clenbuterol (l_conj) clenbuterol_24\NN\1740|,|agonist|,|induce (l_appos) agonist_29\NN\9613191|a|long-acting|beta(2)-adrenoceptor (l_compound) beta(2)-adrenoceptor_28\NN\1740|
T5_T26 CPR:4 )_13\-RRB-\1740| (r_punct) analogue_14\NN\4743605|a|vitamin|d(3|)|cb1093|effects (r_appos) compounds_8\NNS\5869584|two|,|analogue|,|and|clenbuterol (l_conj) clenbuterol_24\NN\1740|,|agonist|,|induce (l_acl:relcl) induce_34\VBP\1627355|both|synthesis|vivo (l_dobj) synthesis_36\NN\13446390|ngf (l_compound) ngf_35\NN\14734348|
T6_T24 NONE cb1093_16\NN\1740|(|) (r_appos) analogue_14\NN\4743605|a|vitamin|d(3|)|cb1093|effects (r_appos) compounds_8\NNS\5869584|two|,|analogue|,|and|clenbuterol (l_conj) clenbuterol_24\NN\1740|,|agonist|,|induce (l_appos) agonist_29\NN\9613191|a|long-acting|beta(2)-adrenoceptor (l_compound) beta(2)-adrenoceptor_28\NN\1740|
T6_T26 CPR:3 cb1093_16\NN\1740|(|) (r_appos) analogue_14\NN\4743605|a|vitamin|d(3|)|cb1093|effects (r_appos) compounds_8\NNS\5869584|two|,|analogue|,|and|clenbuterol (l_conj) clenbuterol_24\NN\1740|,|agonist|,|induce (l_acl:relcl) induce_34\VBP\1627355|both|synthesis|vivo (l_dobj) synthesis_36\NN\13446390|ngf (l_compound) ngf_35\NN\14734348|
T7_T24 CPR:5 clenbuterol_24\NN\1740|,|agonist|,|induce (l_appos) agonist_29\NN\9613191|a|long-acting|beta(2)-adrenoceptor (l_compound) beta(2)-adrenoceptor_28\NN\1740|
T7_T26 CPR:3 clenbuterol_24\NN\1740|,|agonist|,|induce (l_acl:relcl) induce_34\VBP\1627355|both|synthesis|vivo (l_dobj) synthesis_36\NN\13446390|ngf (l_compound) ngf_35\NN\14734348|
T8_T27 CPR:3 clenbuterol_0\NN\1740| (r_nsubj) caused_1\VBD\1617192|clenbuterol|increases|;|maxima|. (l_dobj) increases_3\NNS\13576355|significant|ngf|cells (l_nmod) ngf_6\NN\14734348|in|both|mrna
T10_T28 NONE propranolol_9\NN\1740|by (r_nmod) antagonized_7\VBN\1787955|effects|were|propranolol|. (l_nsubjpass) effects_0\NNS\13245626|clenbuterol|mrna (l_nmod) mrna_5\NN\14832193|on|ngf (l_compound) ngf_4\NN\14734348|
T9_T28 NONE clenbuterol_2\NN\1740|of (r_nmod) effects_0\NNS\13245626|clenbuterol|mrna (l_nmod) mrna_5\NN\14832193|on|ngf (l_compound) ngf_4\NN\14734348|
T11_T29 NONE clenbuterol_9\NN\1740| (r_nsubj) increased_10\VBD\169651|that|clenbuterol|binding|increasing (l_dobj) binding_12\NN\4688246|ap1|cells (l_compound) ap1_11\NN\1740|
T11_T30 CPR:3 clenbuterol_9\NN\1740| (r_nsubj) increased_10\VBD\169651|that|clenbuterol|binding|increasing (l_advcl) increasing_18\VBG\169651|prior|to|synthesis (l_dobj) synthesis_20\NN\13446390|ngf (l_compound) ngf_19\NN\14734348|
T12_T31 NONE clenbuterol_0\NN\1740| (r_nsubj) effect_3\NN\34213|clenbuterol|was|without|levels|,|caused (l_nmod) levels_7\NNS\4916342|on|ngf|mrna|cells (l_compound) ngf_5\NN\14734348|
T12_T32 NONE clenbuterol_0\NN\1740| (r_nsubj) effect_3\NN\34213|clenbuterol|was|without|levels|,|caused (l_parataxis) caused_14\VBD\1617192|whereas|cb1093|increases (l_dobj) increases_16\NNS\13576355|significant|mrna (l_nmod) mrna_20\NN\14832193|in|both|ngf|and|levels|3t3 (l_compound) ngf_19\NN\14734348|
T13_T31 NONE cb1093_13\NN\1740| (r_nsubj) caused_14\VBD\1617192|whereas|cb1093|increases (r_parataxis) effect_3\NN\34213|clenbuterol|was|without|levels|,|caused (l_nmod) levels_7\NNS\4916342|on|ngf|mrna|cells (l_compound) ngf_5\NN\14734348|
T13_T32 CPR:3 cb1093_13\NN\1740| (r_nsubj) caused_14\VBD\1617192|whereas|cb1093|increases (l_dobj) increases_16\NNS\13576355|significant|mrna (l_nmod) mrna_20\NN\14832193|in|both|ngf|and|levels|3t3 (l_compound) ngf_19\NN\14734348|
T1_T15 NONE d_4\NN\15089472| (r_compound) receptor_6\NN\5225602|to|the|vitamin|d|nuclear|vdr|,|acts|,
T1_T16 NONE d_4\NN\15089472| (r_compound) receptor_6\NN\5225602|to|the|vitamin|d|nuclear|vdr|,|acts|, (l_appos) vdr_8\NN\1740|(|)
T2_T15 NONE cb1093_30\NNP\1740|of (r_nmod) exposure_27\NN\5042871|to|cb1093 (r_dep) min_25\NN\15154774|30|after|exposure (r_nmod) increased_20\VBN\169651|binding|was|min|and|maintained (l_nsubjpass) binding_0\NN\4688246|receptor (l_nmod) receptor_6\NN\5225602|to|the|vitamin|d|nuclear|vdr|,|acts|,
T2_T16 NONE cb1093_30\NNP\1740|of (r_nmod) exposure_27\NN\5042871|to|cb1093 (r_dep) min_25\NN\15154774|30|after|exposure (r_nmod) increased_20\VBN\169651|binding|was|min|and|maintained (l_nsubjpass) binding_0\NN\4688246|receptor (l_nmod) receptor_6\NN\5225602|to|the|vitamin|d|nuclear|vdr|,|acts|, (l_appos) vdr_8\NN\1740|(|)
T3_T21 CPR:3 cb1093_4\NN\1740|and|clenbuterol (r_nsubj) stimulate_7\VBP\137313|that|cb1093|levels|vitro|and|commonality (l_dobj) levels_9\NNS\4916342|ngf (l_compound) ngf_8\NN\14734348|
T3_T22 NONE cb1093_4\NN\1740|and|clenbuterol (r_nsubj) stimulate_7\VBP\137313|that|cb1093|levels|vitro|and|commonality (l_conj) commonality_19\NN\7974025|that|binding|could|be|a|mechanism (l_nsubj) binding_15\NN\4688246|ap-1 (l_compound) ap-1_14\NN\1740|
T3_T23 CPR:3 cb1093_4\NN\1740|and|clenbuterol (r_nsubj) stimulate_7\VBP\137313|that|cb1093|levels|vitro|and|commonality (l_conj) commonality_19\NN\7974025|that|binding|could|be|a|mechanism (l_nmod) mechanism_22\NN\13446390|between|the|induction (l_nmod) induction_25\NN\7450842|of|ngf|compounds (l_compound) ngf_24\NN\14734348|
T4_T21 CPR:3 clenbuterol_6\NN\1740| (r_conj) cb1093_4\NN\1740|and|clenbuterol (r_nsubj) stimulate_7\VBP\137313|that|cb1093|levels|vitro|and|commonality (l_dobj) levels_9\NNS\4916342|ngf (l_compound) ngf_8\NN\14734348|
T4_T22 NONE clenbuterol_6\NN\1740| (r_conj) cb1093_4\NN\1740|and|clenbuterol (r_nsubj) stimulate_7\VBP\137313|that|cb1093|levels|vitro|and|commonality (l_conj) commonality_19\NN\7974025|that|binding|could|be|a|mechanism (l_nsubj) binding_15\NN\4688246|ap-1 (l_compound) ap-1_14\NN\1740|
T4_T23 CPR:3 clenbuterol_6\NN\1740| (r_conj) cb1093_4\NN\1740|and|clenbuterol (r_nsubj) stimulate_7\VBP\137313|that|cb1093|levels|vitro|and|commonality (l_conj) commonality_19\NN\7974025|that|binding|could|be|a|mechanism (l_nmod) mechanism_22\NN\13446390|between|the|induction (l_nmod) induction_25\NN\7450842|of|ngf|compounds (l_compound) ngf_24\NN\14734348|
1868500
T5_T17 NONE acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (l_appos) inhibitors_13\NNS\20090|hmg-coa|reductase (l_compound) reductase_12\NN\14732946|
T5_T18 CPR:4 acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins
T5_T19 CPR:4 acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_appos) vldl_20\NNS\14939230|(|)
T5_T20 CPR:4 acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_conj) lipoproteins_24\NNS\14731135|low-density|ldl
T5_T21 CPR:4 acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_conj) lipoproteins_24\NNS\14731135|low-density|ldl (l_appos) ldl_26\NNS\14939230|(|)
T6_T17 NONE acid_7\NN\14818238|nicotinic (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (l_appos) inhibitors_13\NNS\20090|hmg-coa|reductase (l_compound) reductase_12\NN\14732946|
T6_T18 CPR:4 acid_7\NN\14818238|nicotinic (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins
T6_T19 CPR:4 acid_7\NN\14818238|nicotinic (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_appos) vldl_20\NNS\14939230|(|)
T6_T20 CPR:4 acid_7\NN\14818238|nicotinic (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_conj) lipoproteins_24\NNS\14731135|low-density|ldl
T6_T21 CPR:4 acid_7\NN\14818238|nicotinic (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_conj) lipoproteins_24\NNS\14731135|low-density|ldl (l_appos) ldl_26\NNS\14939230|(|)
T7_T17 NONE probucol_9\NN\1740| (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (l_appos) inhibitors_13\NNS\20090|hmg-coa|reductase (l_compound) reductase_12\NN\14732946|
T7_T18 CPR:4 probucol_9\NN\1740| (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins
T7_T19 CPR:4 probucol_9\NN\1740| (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_appos) vldl_20\NNS\14939230|(|)
T7_T20 CPR:4 probucol_9\NN\1740| (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_conj) lipoproteins_24\NNS\14731135|low-density|ldl
T7_T21 CPR:4 probucol_9\NN\1740| (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_conj) lipoproteins_24\NNS\14731135|low-density|ldl (l_appos) ldl_26\NNS\14939230|(|)
T8_T17 NONE hmg-coa_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|hmg-coa|reductase (l_compound) reductase_12\NN\14732946|
T8_T18 NONE hmg-coa_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|hmg-coa|reductase (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins
T8_T19 NONE hmg-coa_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|hmg-coa|reductase (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_appos) vldl_20\NNS\14939230|(|)
T8_T20 NONE hmg-coa_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|hmg-coa|reductase (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_conj) lipoproteins_24\NNS\14731135|low-density|ldl
T8_T21 NONE hmg-coa_11\NN\1740| (r_compound) inhibitors_13\NNS\20090|hmg-coa|reductase (r_appos) acids_4\NNS\14818238|(|fibric|,|acid|,|probucol|,|inhibitors|) (r_dep) drugs_1\NNS\14778436|absorbable|acids (r_nsubj) reduce_15\VBP\441445|drugs|lipoproteins|variety|. (l_dobj) lipoproteins_18\NNS\14731135|plasma|very-low-density|vldl|and/or|lipoproteins (l_conj) lipoproteins_24\NNS\14731135|low-density|ldl (l_appos) ldl_26\NNS\14939230|(|)
T9_T22 CPR:4 acids_1\NNS\14818238|fibric (r_nsubj) act_6\VBP\1619354|acids|,|particular|,|stimulating|favoring|. (l_advcl) stimulating_8\VBG\137313|by|catabolism|and|also|,|consequence|,|improving (l_dobj) catabolism_10\NN\13526110|the|vldl (l_nmod) vldl_12\NN\14939230|of
T9_T23 NONE acids_1\NNS\14818238|fibric (r_nsubj) act_6\VBP\1619354|acids|,|particular|,|stimulating|favoring|. (l_advcl) stimulating_8\VBG\137313|by|catabolism|and|also|,|consequence|,|improving (l_conj) improving_20\VBG\126264|delipidation|, (l_dobj) delipidation_22\NN\1740|ldl (l_compound) ldl_21\NN\14939230|
T10_T24 NONE acid_1\NN\14818238|nicotinic|and|acipimox (r_nsubj) interfere_4\VBP\2451370|acid|biosynthesis|and|improve|. (l_nmod) biosynthesis_7\NN\13565379|with|the|ldl (l_nmod) ldl_9\NN\14939230|of
T10_T25 NONE acid_1\NN\14818238|nicotinic|and|acipimox (r_nsubj) interfere_4\VBP\2451370|acid|biosynthesis|and|improve|. (l_conj) improve_13\VB\126264|can|also|clearance (l_dobj) clearance_15\NN\5089947|the|vldl/ldl (l_nmod) vldl/ldl_17\NN\1740|of
T10_T26 NONE acid_1\NN\14818238|nicotinic|and|acipimox (r_nsubj) interfere_4\VBP\2451370|acid|biosynthesis|and|improve|. (l_conj) improve_13\VB\126264|can|also|clearance (l_dobj) clearance_15\NN\5089947|the|vldl/ldl (l_nmod) vldl/ldl_17\NN\1740|of
T11_T27 NONE probucol_0\NN\1740| (r_nsubj) acts_1\VBZ\1619354|probucol|mechanism|accelerating|. (l_advcl) accelerating_9\VBG\226566|i.e.|transport (l_dobj) transport_11\NN\3575240|reverse|esters|lipoproteins|lipoproteins (l_nmod) lipoproteins_17\NNS\14731135|from|high-density
T11_T28 NONE probucol_0\NN\1740| (r_nsubj) acts_1\VBZ\1619354|probucol|mechanism|accelerating|. (l_advcl) accelerating_9\VBG\226566|i.e.|transport (l_dobj) transport_11\NN\3575240|reverse|esters|lipoproteins|lipoproteins (l_nmod) lipoproteins_20\NNS\14731135|to|lower-density
T12_T27 CPR:9 esters_14\NNS\14727670|of|cholesteryl (r_nmod) transport_11\NN\3575240|reverse|esters|lipoproteins|lipoproteins (l_nmod) lipoproteins_17\NNS\14731135|from|high-density
T12_T28 CPR:9 esters_14\NNS\14727670|of|cholesteryl (r_nmod) transport_11\NN\3575240|reverse|esters|lipoproteins|lipoproteins (l_nmod) lipoproteins_20\NNS\14731135|to|lower-density
T13_T15 NONE hmg-coa_2\NN\1740| (r_compound) inhibitors_4\NNS\20090|hmg-coa|reductase|,|interfering|, (r_nsubj) induce_14\VB\1627355|finally|,|inhibitors|can|expression|. (l_dobj) expression_17\NN\4679549|an|increased|receptors (l_nmod) receptors_22\NNS\5225602|of|liver|high-affinity|lipoprotein
T13_T29 NONE hmg-coa_2\NN\1740| (r_compound) inhibitors_4\NNS\20090|hmg-coa|reductase|,|interfering|, (l_compound) reductase_3\NN\14732946|
T14_T15 NONE cholesterol_11\NN\15058310|of (r_nmod) biosynthesis_9\NN\13565379|with|the|cholesterol (r_nmod) interfering_6\VBG\2451370|biosynthesis (r_acl) inhibitors_4\NNS\20090|hmg-coa|reductase|,|interfering|, (r_nsubj) induce_14\VB\1627355|finally|,|inhibitors|can|expression|. (l_dobj) expression_17\NN\4679549|an|increased|receptors (l_nmod) receptors_22\NNS\5225602|of|liver|high-affinity|lipoprotein
T14_T29 NONE cholesterol_11\NN\15058310|of (r_nmod) biosynthesis_9\NN\13565379|with|the|cholesterol (r_nmod) interfering_6\VBG\2451370|biosynthesis (r_acl) inhibitors_4\NNS\20090|hmg-coa|reductase|,|interfering|, (l_compound) reductase_3\NN\14732946|
7703721
T3_T11 NONE estramustine_0\NN\1740| (r_compound) protein_2\NN\14944888|estramustine|binding|tumours|.
T1_T4 NONE estrogen_21\NN\14745635| (r_compound) receptor_22\NN\5225602|from|the|estrogen
T1_T5 NONE estrogen_21\NN\14745635| (r_compound) receptor_22\NN\5225602|from|the|estrogen (r_nmod) distinct_18\JJ\1740|which|is|receptor (r_acl:relcl) protein_5\NN\14944888|of|estramustine|binding|embp|,|glycoprotein|,|distinct|,
T1_T8 NONE estrogen_21\NN\14745635| (r_compound) receptor_22\NN\5225602|from|the|estrogen (r_nmod) distinct_18\JJ\1740|which|is|receptor (r_acl:relcl) protein_5\NN\14944888|of|estramustine|binding|embp|,|glycoprotein|,|distinct|, (l_appos) embp_7\NN\1740|(|)
T2_T4 NONE estramustine_3\NN\1740| (r_compound) protein_5\NN\14944888|of|estramustine|binding|embp|,|glycoprotein|,|distinct|, (l_acl:relcl) distinct_18\JJ\1740|which|is|receptor (l_nmod) receptor_22\NN\5225602|from|the|estrogen
T2_T5 NONE estramustine_3\NN\1740| (r_compound) protein_5\NN\14944888|of|estramustine|binding|embp|,|glycoprotein|,|distinct|,
T2_T8 NONE estramustine_3\NN\1740| (r_compound) protein_5\NN\14944888|of|estramustine|binding|embp|,|glycoprotein|,|distinct|, (l_appos) embp_7\NN\1740|(|)
17334413
T28_T60 NONE histamine_1\NN\14739004| (r_compound) agonist_3\NN\9613191|h3|histamine|receptor (l_compound) receptor_2\NN\5225602|
T28_T61 NONE histamine_1\NN\14739004| (r_compound) agonist_3\NN\9613191|h3|histamine|receptor (r_nsubj) inhibits_4\VBZ\2510337|agonist|growth|downregulation|. (l_nmod) downregulation_11\NN\1740|by|pathway (l_nmod) pathway_16\NN\5483677|of|the|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_15\NN\1740|
T28_T62 NONE histamine_1\NN\14739004| (r_compound) agonist_3\NN\9613191|h3|histamine|receptor (r_nsubj) inhibits_4\VBZ\2510337|agonist|growth|downregulation|. (l_nmod) downregulation_11\NN\1740|by|pathway (l_nmod) pathway_16\NN\5483677|of|the|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_15\NN\1740|
T28_T63 NONE histamine_1\NN\14739004| (r_compound) agonist_3\NN\9613191|h3|histamine|receptor (r_nsubj) inhibits_4\VBZ\2510337|agonist|growth|downregulation|. (l_nmod) downregulation_11\NN\1740|by|pathway (l_nmod) pathway_16\NN\5483677|of|the|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_15\NN\1740|
T29_T60 NONE camp-dependent_14\JJ\1740| (r_amod) pathway_16\NN\5483677|of|the|camp-dependent|pka/erk1/2/elk-1 (r_nmod) downregulation_11\NN\1740|by|pathway (r_nmod) inhibits_4\VBZ\2510337|agonist|growth|downregulation|. (l_nsubj) agonist_3\NN\9613191|h3|histamine|receptor (l_compound) receptor_2\NN\5225602|
T29_T61 NONE camp-dependent_14\JJ\1740| (r_amod) pathway_16\NN\5483677|of|the|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_15\NN\1740|
T29_T62 NONE camp-dependent_14\JJ\1740| (r_amod) pathway_16\NN\5483677|of|the|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_15\NN\1740|
T29_T63 NONE camp-dependent_14\JJ\1740| (r_amod) pathway_16\NN\5483677|of|the|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_15\NN\1740|
T1_T30 NONE histamine_0\NN\14739004| (r_nsubj) regulates_1\VBZ\296178|histamine|functions|binding|. (l_advcl) binding_5\VBG\1290422|by|proteins (l_nmod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r (l_dep) h1r_13\NN\1740|(|,|h2r|,|h3r|and|h4r|) (l_conj) h3r_17\NN\1740|
T1_T31 NONE histamine_0\NN\14739004| (r_nsubj) regulates_1\VBZ\296178|histamine|functions|binding|. (l_advcl) binding_5\VBG\1290422|by|proteins (l_nmod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r (l_dep) h1r_13\NN\1740|(|,|h2r|,|h3r|and|h4r|) (l_conj) h4r_19\NN\1740|
T1_T49 NONE histamine_0\NN\14739004| (r_nsubj) regulates_1\VBZ\296178|histamine|functions|binding|. (l_advcl) binding_5\VBG\1290422|by|proteins (l_nmod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r
T1_T57 NONE histamine_0\NN\14739004| (r_nsubj) regulates_1\VBZ\296178|histamine|functions|binding|. (l_advcl) binding_5\VBG\1290422|by|proteins (l_nmod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r (l_dep) h1r_13\NN\1740|(|,|h2r|,|h3r|and|h4r|)
T1_T59 NONE histamine_0\NN\14739004| (r_nsubj) regulates_1\VBZ\296178|histamine|functions|binding|. (l_advcl) binding_5\VBG\1290422|by|proteins (l_nmod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r (l_dep) h1r_13\NN\1740|(|,|h2r|,|h3r|and|h4r|) (l_conj) h2r_15\NN\1740|
T23_T30 NONE histamine_8\NN\14739004| (r_nmod:npmod) g-coupled_9\JJ\1740|histamine (r_amod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r (l_dep) h1r_13\NN\1740|(|,|h2r|,|h3r|and|h4r|) (l_conj) h3r_17\NN\1740|
T23_T31 NONE histamine_8\NN\14739004| (r_nmod:npmod) g-coupled_9\JJ\1740|histamine (r_amod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r (l_dep) h1r_13\NN\1740|(|,|h2r|,|h3r|and|h4r|) (l_conj) h4r_19\NN\1740|
T23_T49 NONE histamine_8\NN\14739004| (r_nmod:npmod) g-coupled_9\JJ\1740|histamine (r_amod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r
T23_T57 NONE histamine_8\NN\14739004| (r_nmod:npmod) g-coupled_9\JJ\1740|histamine (r_amod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r (l_dep) h1r_13\NN\1740|(|,|h2r|,|h3r|and|h4r|)
T23_T59 NONE histamine_8\NN\14739004| (r_nmod:npmod) g-coupled_9\JJ\1740|histamine (r_amod) proteins_11\NNS\14944888|to|four|g-coupled|receptor|h1r (l_dep) h1r_13\NN\1740|(|,|h2r|,|h3r|and|h4r|) (l_conj) h2r_15\NN\1740|
T14_T32 NONE 5'-monophosphate_16\NN\1740|adenosine|3|'|,|camp (r_compound) levels_20\NNS\4916342|5'-monophosphate|player (r_dobj) reducing_11\VBG\441445|levels (r_acl) proteins_10\NNS\14944888|to|galpha(i/o|)|reducing (r_nmod) coupling_6\NN\3091374|by|proteins (r_nmod) exerts_2\VBZ\1158872|as|h3r|effects|coupling (l_nsubj) h3r_1\NN\1740|
T14_T38 NONE 5'-monophosphate_16\NN\1740|adenosine|3|'|,|camp (r_compound) levels_20\NNS\4916342|5'-monophosphate|player (r_dobj) reducing_11\VBG\441445|levels (r_acl) proteins_10\NNS\14944888|to|galpha(i/o|)|reducing (l_punct) )_9\-RRB-\1740|
T14_T46 NONE 5'-monophosphate_16\NN\1740|adenosine|3|'|,|camp (r_compound) levels_20\NNS\4916342|5'-monophosphate|player (r_dobj) reducing_11\VBG\441445|levels (r_acl) proteins_10\NNS\14944888|to|galpha(i/o|)|reducing (r_nmod) coupling_6\NN\3091374|by|proteins (r_nmod) exerts_2\VBZ\1158872|as|h3r|effects|coupling (r_advcl) evaluated_34\VBD\670261|exerts|,|we|role|. (l_dobj) role_36\NN\719494|the|h3r|regulation (l_nmod) h3r_38\NN\1740|of
T19_T32 NONE camp_18\NN\3763727|(|) (r_appos) 5'-monophosphate_16\NN\1740|adenosine|3|'|,|camp (r_compound) levels_20\NNS\4916342|5'-monophosphate|player (r_dobj) reducing_11\VBG\441445|levels (r_acl) proteins_10\NNS\14944888|to|galpha(i/o|)|reducing (r_nmod) coupling_6\NN\3091374|by|proteins (r_nmod) exerts_2\VBZ\1158872|as|h3r|effects|coupling (l_nsubj) h3r_1\NN\1740|
T19_T38 NONE camp_18\NN\3763727|(|) (r_appos) 5'-monophosphate_16\NN\1740|adenosine|3|'|,|camp (r_compound) levels_20\NNS\4916342|5'-monophosphate|player (r_dobj) reducing_11\VBG\441445|levels (r_acl) proteins_10\NNS\14944888|to|galpha(i/o|)|reducing (l_punct) )_9\-RRB-\1740|
T19_T46 NONE camp_18\NN\3763727|(|) (r_appos) 5'-monophosphate_16\NN\1740|adenosine|3|'|,|camp (r_compound) levels_20\NNS\4916342|5'-monophosphate|player (r_dobj) reducing_11\VBG\441445|levels (r_acl) proteins_10\NNS\14944888|to|galpha(i/o|)|reducing (r_nmod) coupling_6\NN\3091374|by|proteins (r_nmod) exerts_2\VBZ\1158872|as|h3r|effects|coupling (r_advcl) evaluated_34\VBD\670261|exerts|,|we|role|. (l_dobj) role_36\NN\719494|the|h3r|regulation (l_nmod) h3r_38\NN\1740|of
T20_T48 CPR:5 dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_appos) agonist_15\NN\9613191|(|h3r|) (l_compound) h3r_14\NN\1740|
T20_T50 NONE dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_conj) maleate_19\NN\2718811|thioperamide|antagonist (l_appos) antagonist_22\NN\7846|(|h3r|) (l_compound) h3r_21\NN\1740|
T21_T48 CPR:5 ramh_11\NN\1740|(|) (r_appos) dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_appos) agonist_15\NN\9613191|(|h3r|) (l_compound) h3r_14\NN\1740|
T21_T50 NONE ramh_11\NN\1740|(|) (r_appos) dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_conj) maleate_19\NN\2718811|thioperamide|antagonist (l_appos) antagonist_22\NN\7846|(|h3r|) (l_compound) h3r_21\NN\1740|
T22_T48 NONE maleate_19\NN\2718811|thioperamide|antagonist (r_conj) dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_appos) agonist_15\NN\9613191|(|h3r|) (l_compound) h3r_14\NN\1740|
T22_T50 CPR:6 maleate_19\NN\2718811|thioperamide|antagonist (l_appos) antagonist_22\NN\7846|(|h3r|) (l_compound) h3r_21\NN\1740|
T24_T48 NONE histamine_25\NN\14739004| (r_conj) dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_appos) agonist_15\NN\9613191|(|h3r|) (l_compound) h3r_14\NN\1740|
T24_T50 NONE histamine_25\NN\14739004| (r_conj) dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_conj) maleate_19\NN\2718811|thioperamide|antagonist (l_appos) antagonist_22\NN\7846|(|h3r|) (l_compound) h3r_21\NN\1740|
T25_T48 NONE maleate_32\NN\2718811|of|thioperamide (r_nmod) absence/presence_29\NN\1740|in|the|maleate (r_nmod) administration_6\NN\1133281|in|dihydrobromide|,|absence/presence|,|rats (l_nmod) dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_appos) agonist_15\NN\9613191|(|h3r|) (l_compound) h3r_14\NN\1740|
T25_T50 NONE maleate_32\NN\2718811|of|thioperamide (r_nmod) absence/presence_29\NN\1740|in|the|maleate (r_nmod) administration_6\NN\1133281|in|dihydrobromide|,|absence/presence|,|rats (l_nmod) dihydrobromide_9\NN\1740|of|(r)-(alpha)-(-)-methylhistamine|ramh|agonist|,|maleate|or|histamine (l_conj) maleate_19\NN\2718811|thioperamide|antagonist (l_appos) antagonist_22\NN\7846|(|h3r|) (l_compound) h3r_21\NN\1740|
T26_T51 NONE ramh_5\NN\1740| (r_nsubj) inhibit_6\VB\2510337|and|3|does|ramh|proliferation|downregulation|? (l_nmod) downregulation_10\NN\1740|by|phosphorylation (l_nmod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_compound) kinase_20\NN\14732946|a|signal-regulated|1/2|(erk1/2)/ets-like (l_compound) a_17\NN\13649268|protein|kinase|(pka)/extracellular
T26_T52 NONE ramh_5\NN\1740| (r_nsubj) inhibit_6\VB\2510337|and|3|does|ramh|proliferation|downregulation|? (l_nmod) downregulation_10\NN\1740|by|phosphorylation (l_nmod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_compound) kinase_20\NN\14732946|a|signal-regulated|1/2|(erk1/2)/ets-like (l_compound) a_17\NN\13649268|protein|kinase|(pka)/extracellular (l_punct) (pka)/extracellular_18\NN\1740|
T26_T53 NONE ramh_5\NN\1740| (r_nsubj) inhibit_6\VB\2510337|and|3|does|ramh|proliferation|downregulation|? (l_nmod) downregulation_10\NN\1740|by|phosphorylation (l_nmod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_compound) kinase_20\NN\14732946|a|signal-regulated|1/2|(erk1/2)/ets-like (l_nummod) 1/2_21\CD\1740|
T26_T54 NONE ramh_5\NN\1740| (r_nsubj) inhibit_6\VB\2510337|and|3|does|ramh|proliferation|downregulation|? (l_nmod) downregulation_10\NN\1740|by|phosphorylation (l_nmod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_compound) kinase_20\NN\14732946|a|signal-regulated|1/2|(erk1/2)/ets-like (l_dep) (erk1/2)/ets-like_22\JJ\1740|
T26_T55 NONE ramh_5\NN\1740| (r_nsubj) inhibit_6\VB\2510337|and|3|does|ramh|proliferation|downregulation|? (l_nmod) downregulation_10\NN\1740|by|phosphorylation (l_nmod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1
T26_T56 NONE ramh_5\NN\1740| (r_nsubj) inhibit_6\VB\2510337|and|3|does|ramh|proliferation|downregulation|? (l_nmod) downregulation_10\NN\1740|by|phosphorylation (l_nmod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_appos) elk-1_25\NN\1740|(|)
T27_T51 NONE camp-dependent_12\JJ\1740| (r_amod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_compound) kinase_20\NN\14732946|a|signal-regulated|1/2|(erk1/2)/ets-like (l_compound) a_17\NN\13649268|protein|kinase|(pka)/extracellular
T27_T52 NONE camp-dependent_12\JJ\1740| (r_amod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_compound) kinase_20\NN\14732946|a|signal-regulated|1/2|(erk1/2)/ets-like (l_compound) a_17\NN\13649268|protein|kinase|(pka)/extracellular (l_punct) (pka)/extracellular_18\NN\1740|
T27_T53 NONE camp-dependent_12\JJ\1740| (r_amod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_compound) kinase_20\NN\14732946|a|signal-regulated|1/2|(erk1/2)/ets-like (l_nummod) 1/2_21\CD\1740|
T27_T54 NONE camp-dependent_12\JJ\1740| (r_amod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_compound) kinase_20\NN\14732946|a|signal-regulated|1/2|(erk1/2)/ets-like (l_dep) (erk1/2)/ets-like_22\JJ\1740|
T27_T55 NONE camp-dependent_12\JJ\1740| (r_amod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1
T27_T56 NONE camp-dependent_12\JJ\1740| (r_amod) phosphorylation_13\NN\1740|of|camp-dependent|gene-1 (l_nmod) gene-1_23\NN\1740|of|kinase|elk-1 (l_appos) elk-1_25\NN\1740|(|)
T6_T33 NONE ramh_8\NN\1740|with (r_nmod) treatment_3\NN\654885|following|in|rats|ramh|week|,|and|stimulation (r_nmod) evaluated_24\VBD\670261|treatment|,|we|proliferation|. (l_dobj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation
T6_T34 NONE ramh_8\NN\1740|with (r_nmod) treatment_3\NN\654885|following|in|rats|ramh|week|,|and|stimulation (r_nmod) evaluated_24\VBD\670261|treatment|,|we|proliferation|. (l_dobj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation (l_appos) erk1/2_33\NN\1740|and
T6_T35 NONE ramh_8\NN\1740|with (r_nmod) treatment_3\NN\654885|following|in|rats|ramh|week|,|and|stimulation (r_nmod) evaluated_24\VBD\670261|treatment|,|we|proliferation|. (l_dobj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation (l_dep) phosphorylation_36\NN\1740|elk-1 (l_compound) elk-1_35\NN\1740|
T7_T33 NONE ramh_21\NN\1740|with (r_nmod) stimulation_16\NN\242808|in|cholangiocytes|ramh (r_conj) treatment_3\NN\654885|following|in|rats|ramh|week|,|and|stimulation (r_nmod) evaluated_24\VBD\670261|treatment|,|we|proliferation|. (l_dobj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation
T7_T34 NONE ramh_21\NN\1740|with (r_nmod) stimulation_16\NN\242808|in|cholangiocytes|ramh (r_conj) treatment_3\NN\654885|following|in|rats|ramh|week|,|and|stimulation (r_nmod) evaluated_24\VBD\670261|treatment|,|we|proliferation|. (l_dobj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation (l_appos) erk1/2_33\NN\1740|and
T7_T35 NONE ramh_21\NN\1740|with (r_nmod) stimulation_16\NN\242808|in|cholangiocytes|ramh (r_conj) treatment_3\NN\654885|following|in|rats|ramh|week|,|and|stimulation (r_nmod) evaluated_24\VBD\670261|treatment|,|we|proliferation|. (l_dobj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation (l_dep) phosphorylation_36\NN\1740|elk-1 (l_compound) elk-1_35\NN\1740|
T8_T33 NONE camp_28\NN\3763727| (r_compound) levels_29\NNS\4916342|camp (r_conj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation
T8_T34 NONE camp_28\NN\3763727| (r_compound) levels_29\NNS\4916342|camp (r_conj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation (l_appos) erk1/2_33\NN\1740|and
T8_T35 NONE camp_28\NN\3763727| (r_compound) levels_29\NNS\4916342|camp (r_conj) proliferation_26\NN\13489037|cholangiocyte|,|levels|and|pka (l_conj) pka_31\NN\1740|,|erk1/2|phosphorylation (l_dep) phosphorylation_36\NN\1740|elk-1 (l_compound) elk-1_35\NN\1740|
T16_T39 CPR:4 ramh_0\NN\1740| (r_compound) inhibition_1\NN\1068773|ramh|growth (r_nsubjpass) associated_6\VBN\628491|inhibition|was|levels|. (l_nmod) levels_10\NNS\4916342|with|decreased|camp|and|phosphorylation (l_conj) phosphorylation_13\NN\1740|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_12\NN\1740|
T16_T40 CPR:4 ramh_0\NN\1740| (r_compound) inhibition_1\NN\1068773|ramh|growth (r_nsubjpass) associated_6\VBN\628491|inhibition|was|levels|. (l_nmod) levels_10\NNS\4916342|with|decreased|camp|and|phosphorylation (l_conj) phosphorylation_13\NN\1740|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_12\NN\1740|
T16_T41 CPR:4 ramh_0\NN\1740| (r_compound) inhibition_1\NN\1068773|ramh|growth (r_nsubjpass) associated_6\VBN\628491|inhibition|was|levels|. (l_nmod) levels_10\NNS\4916342|with|decreased|camp|and|phosphorylation (l_conj) phosphorylation_13\NN\1740|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_12\NN\1740|
T17_T39 NONE camp_9\NN\3763727| (r_compound) levels_10\NNS\4916342|with|decreased|camp|and|phosphorylation (l_conj) phosphorylation_13\NN\1740|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_12\NN\1740|
T17_T40 NONE camp_9\NN\3763727| (r_compound) levels_10\NNS\4916342|with|decreased|camp|and|phosphorylation (l_conj) phosphorylation_13\NN\1740|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_12\NN\1740|
T17_T41 NONE camp_9\NN\3763727| (r_compound) levels_10\NNS\4916342|with|decreased|camp|and|phosphorylation (l_conj) phosphorylation_13\NN\1740|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_12\NN\1740|
T18_T42 NONE camp-dependent_2\JJ\1740| (r_amod) phosphorylation_4\NN\1740|of|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_3\NN\1740|
T18_T43 NONE camp-dependent_2\JJ\1740| (r_amod) phosphorylation_4\NN\1740|of|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_3\NN\1740|
T18_T44 NONE camp-dependent_2\JJ\1740| (r_amod) phosphorylation_4\NN\1740|of|camp-dependent|pka/erk1/2/elk-1 (l_compound) pka/erk1/2/elk-1_3\NN\1740|
T18_T45 NONE camp-dependent_2\JJ\1740| (r_amod) phosphorylation_4\NN\1740|of|camp-dependent|pka/erk1/2/elk-1 (r_nmod) downregulation_0\NN\1740|phosphorylation|activation (l_nmod) activation_7\NN\13561719|(|by|h3r|) (l_nmod) h3r_9\NN\1740|of
17053736
9673855
T1_T40 CPR:4 selegiline_0\NN\1740|deprenyl|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|selective|b (l_nmod) b_14\NN\1355326|type|mao-b
T1_T41 CPR:4 selegiline_0\NN\1740|deprenyl|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|selective|b (l_nmod) b_14\NN\1355326|type|mao-b (l_appos) mao-b_16\NN\1740|(|)
T28_T40 NONE monoamine_11\NN\14739004| (r_compound) type_13\NN\5839024|of|monoamine|oxidase (r_compound) b_14\NN\1355326|type|mao-b
T28_T41 NONE monoamine_11\NN\14739004| (r_compound) type_13\NN\5839024|of|monoamine|oxidase (r_compound) b_14\NN\1355326|type|mao-b (l_appos) mao-b_16\NN\1740|(|)
T2_T40 CPR:4 deprenyl_2\NN\1740|(|) (r_appos) selegiline_0\NN\1740|deprenyl|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|selective|b (l_nmod) b_14\NN\1355326|type|mao-b
T2_T41 CPR:4 deprenyl_2\NN\1740|(|) (r_appos) selegiline_0\NN\1740|deprenyl|,|inhibitor (l_appos) inhibitor_9\NN\20090|a|selective|b (l_nmod) b_14\NN\1355326|type|mao-b (l_appos) mao-b_16\NN\1740|(|)
T25_T39 CPR:4 selegiline_6\NN\1740| (r_nsubj) potentiate_10\VB\229605|inhibitors|,|selegiline|does|not|significantly|hypertension|dosages|. (l_nmod) inhibitors_4\NNS\20090|unlike|the|nonselective|mao (l_compound) mao_3\NN\14732946|
T26_T39 NONE tyramine-induced_11\JJ\1740| (r_amod) hypertension_12\NN\14057371|tyramine-induced|effect (r_dobj) potentiate_10\VB\229605|inhibitors|,|selegiline|does|not|significantly|hypertension|dosages|. (l_nmod) inhibitors_4\NNS\20090|unlike|the|nonselective|mao (l_compound) mao_3\NN\14732946|
T11_T36 NONE tyramine_2\NN\14601829| (r_compound) diet_3\NN\7560652|a|low|tyramine (r_nsubjpass) recommended_5\VBN\875394|diet|is|used|. (l_advcl) used_9\VBN\1156834|if|selegiline|is|inhibitors (l_nmod) inhibitors_14\NNS\20090|with|nonselective|mao|or|inhibitor (l_compound) mao_13\NN\14732946|
T11_T37 NONE tyramine_2\NN\14601829| (r_compound) diet_3\NN\7560652|a|low|tyramine (r_nsubjpass) recommended_5\VBN\875394|diet|is|used|. (l_advcl) used_9\VBN\1156834|if|selegiline|is|inhibitors (l_nmod) inhibitors_14\NNS\20090|with|nonselective|mao|or|inhibitor (l_conj) inhibitor_21\NN\20090|the|selective|mao-a|,|moclobemide (l_compound) mao-a_20\NN\1740|
T12_T36 CPR:4 selegiline_7\NN\1740| (r_nsubjpass) used_9\VBN\1156834|if|selegiline|is|inhibitors (l_nmod) inhibitors_14\NNS\20090|with|nonselective|mao|or|inhibitor (l_compound) mao_13\NN\14732946|
T12_T37 NONE selegiline_7\NN\1740| (r_nsubjpass) used_9\VBN\1156834|if|selegiline|is|inhibitors (l_nmod) inhibitors_14\NNS\20090|with|nonselective|mao|or|inhibitor (l_conj) inhibitor_21\NN\20090|the|selective|mao-a|,|moclobemide (l_compound) mao-a_20\NN\1740|
T13_T36 NONE moclobemide_23\NN\1740| (r_appos) inhibitor_21\NN\20090|the|selective|mao-a|,|moclobemide (r_conj) inhibitors_14\NNS\20090|with|nonselective|mao|or|inhibitor (l_compound) mao_13\NN\14732946|
T13_T37 CPR:4 moclobemide_23\NN\1740| (r_appos) inhibitor_21\NN\20090|the|selective|mao-a|,|moclobemide (l_compound) mao-a_20\NN\1740|
8425287
T26_T40 NONE adenosine_5\NN\14964367|of|exogenous|and|valsalva (r_nmod) effects_2\NNS\13245626|the|antiarrhythmic|adenosine|form (r_nsubj) due_15\JJ\1740|effects|may|be|modulate (l_ccomp) modulate_33\VB\1724459|inhibition|,|adenosine|may|vt|alterations|activation|,|and|shown|. (l_nmod) inhibition_18\NN\1068773|to|receptor-mediated|cyclase|or|effects (l_nmod) cyclase_21\NN\1740|of|adenylate
T26_T41 NONE adenosine_5\NN\14964367|of|exogenous|and|valsalva (r_nmod) effects_2\NNS\13245626|the|antiarrhythmic|adenosine|form (r_nsubj) due_15\JJ\1740|effects|may|be|modulate (l_ccomp) modulate_33\VB\1724459|inhibition|,|adenosine|may|vt|alterations|activation|,|and|shown|. (l_nmod) activation_41\NN\13561719|by|chemoreceptors (l_nmod) chemoreceptors_44\NNS\5299178|of|arterial
T27_T40 NONE adenylate_20\NN\1740| (r_compound) cyclase_21\NN\1740|of|adenylate
T27_T41 NONE adenylate_20\NN\1740| (r_compound) cyclase_21\NN\1740|of|adenylate (r_nmod) inhibition_18\NN\1068773|to|receptor-mediated|cyclase|or|effects (r_nmod) modulate_33\VB\1724459|inhibition|,|adenosine|may|vt|alterations|activation|,|and|shown|. (l_nmod) activation_41\NN\13561719|by|chemoreceptors (l_nmod) chemoreceptors_44\NNS\5299178|of|arterial
T28_T40 NONE adenosine_31\NN\14964367|exogenous (r_nsubj) modulate_33\VB\1724459|inhibition|,|adenosine|may|vt|alterations|activation|,|and|shown|. (l_nmod) inhibition_18\NN\1068773|to|receptor-mediated|cyclase|or|effects (l_nmod) cyclase_21\NN\1740|of|adenylate
T28_T41 CPR:3 adenosine_31\NN\14964367|exogenous (r_nsubj) modulate_33\VB\1724459|inhibition|,|adenosine|may|vt|alterations|activation|,|and|shown|. (l_nmod) activation_41\NN\13561719|by|chemoreceptors (l_nmod) chemoreceptors_44\NNS\5299178|of|arterial
T42_T34 NONE competitive_9\JJ\1740| (r_amod) antagonist_12\NN\7846|a|competitive|adenosine|a1-receptor (l_amod) a1-receptor_11\JJ\1740|
T8_T34 CPR:6 aminophylline_6\NN\2905612|of|,|antagonist (l_appos) antagonist_12\NN\7846|a|competitive|adenosine|a1-receptor (l_amod) a1-receptor_11\JJ\1740|
T9_T34 NONE adenosine_10\NN\14964367| (r_compound) antagonist_12\NN\7846|a|competitive|adenosine|a1-receptor (l_amod) a1-receptor_11\JJ\1740|
T10_T35 CPR:4 edrophonium_0\NN\1740|mg|,|inhibitor|, (l_appos) inhibitor_9\NN\20090|a|cholinesterase|potentiates (l_compound) cholinesterase_8\NN\14732946|
T10_T36 NONE edrophonium_0\NN\1740|mg|,|inhibitor|, (l_appos) inhibitor_9\NN\20090|a|cholinesterase|potentiates (l_acl:relcl) potentiates_11\VBZ\229605|that|effects (l_dobj) effects_13\NNS\13245626|the|acetylcholine|receptor (l_nmod) receptor_20\NN\5225602|at|the|muscarinic|cholinergic
T11_T35 NONE acetylcholine_15\NN\14807558|of (r_nmod) effects_13\NNS\13245626|the|acetylcholine|receptor (r_dobj) potentiates_11\VBZ\229605|that|effects (r_acl:relcl) inhibitor_9\NN\20090|a|cholinesterase|potentiates (l_compound) cholinesterase_8\NN\14732946|
T11_T36 NONE acetylcholine_15\NN\14807558|of (r_nmod) effects_13\NNS\13245626|the|acetylcholine|receptor (l_nmod) receptor_20\NN\5225602|at|the|muscarinic|cholinergic
T13_T35 NONE atropine_36\NN\14712692|by (r_nmod) reversed_34\VBN\109660|that|was|atropine (r_acl:relcl) effect_31\NN\34213|an|reversed (r_dobj) terminated_22\VBD\126264|edrophonium|vt|four|,|effect|. (l_nsubj) edrophonium_0\NN\1740|mg|,|inhibitor|, (l_appos) inhibitor_9\NN\20090|a|cholinesterase|potentiates (l_compound) cholinesterase_8\NN\14732946|
T13_T36 CPR:4 atropine_36\NN\14712692|by (r_nmod) reversed_34\VBN\109660|that|was|atropine (r_acl:relcl) effect_31\NN\34213|an|reversed (r_dobj) terminated_22\VBD\126264|edrophonium|vt|four|,|effect|. (l_nsubj) edrophonium_0\NN\1740|mg|,|inhibitor|, (l_appos) inhibitor_9\NN\20090|a|cholinesterase|potentiates (l_acl:relcl) potentiates_11\VBZ\229605|that|effects (l_dobj) effects_13\NNS\13245626|the|acetylcholine|receptor (l_nmod) receptor_20\NN\5225602|at|the|muscarinic|cholinergic
T19_T37 NONE adenosine_15\NN\14964367| (r_compound) a1_16\NN\1740|of|the|adenosine|or|receptor
T19_T38 NONE adenosine_15\NN\14964367| (r_compound) a1_16\NN\1740|of|the|adenosine|or|receptor (l_conj) receptor_20\NN\5225602|muscarinic|cholinergic
T19_T39 NONE adenosine_15\NN\14964367| (r_compound) a1_16\NN\1740|of|the|adenosine|or|receptor (r_nmod) activation_12\NN\13561719|to|a1|,|results (l_acl:relcl) results_23\VBZ\2633881|which|inhibition (l_nmod) inhibition_25\NN\1068773|in|cyclase (l_nmod) cyclase_28\NN\1740|of|adenylate
T20_T37 NONE adenylate_27\NN\1740| (r_compound) cyclase_28\NN\1740|of|adenylate (r_nmod) inhibition_25\NN\1068773|in|cyclase (r_nmod) results_23\VBZ\2633881|which|inhibition (r_acl:relcl) activation_12\NN\13561719|to|a1|,|results (l_nmod) a1_16\NN\1740|of|the|adenosine|or|receptor
T20_T38 NONE adenylate_27\NN\1740| (r_compound) cyclase_28\NN\1740|of|adenylate (r_nmod) inhibition_25\NN\1068773|in|cyclase (r_nmod) results_23\VBZ\2633881|which|inhibition (r_acl:relcl) activation_12\NN\13561719|to|a1|,|results (l_nmod) a1_16\NN\1740|of|the|adenosine|or|receptor (l_conj) receptor_20\NN\5225602|muscarinic|cholinergic
T20_T39 NONE adenylate_27\NN\1740| (r_compound) cyclase_28\NN\1740|of|adenylate
18620538
T8_T14 NONE acids_6\NNS\14818238|with|fatty (r_nmod) interaction_0\NN\37396|alpha-lactalbumin|acids|:|determination (l_nmod) alpha-lactalbumin_3\NN\1740|of|human
T7_T11 NONE acids_11\NNS\14818238|with|fatty (r_nmod) interaction_1\NN\37396|the|holo-|acids (l_nmod) holo-_3\NNS\1740|of|and|apo-forms|alpha-lactalbumin (l_nmod) alpha-lactalbumin_8\NN\1740|of|human
T1_T9 NONE edta_6\NN\14682133|with (r_nmod) treatment_4\NN\654885|by|edta (r_nmod) obtained_2\VBN\2210855|treatment (r_acl) apo-alpha-lactalbumin_0\NN\1740|,|obtained|,
T2_T9 NONE acids_14\NNS\14818238|for|fatty (r_nmod) site_11\NN\8673395|one|binding|acids (r_dobj) displays_8\VBZ\2137132|apo-alpha-lactalbumin|site|,|m(-1|,|respectively|. (l_nsubj) apo-alpha-lactalbumin_0\NN\1740|,|obtained|,
T3_T9 NONE acids_23\NNS\14818238|oleic (r_nmod) constants_18\NNS\5855125|the|association|acids (r_nsubj) m(-1_30\NN\1740|constants|being|1.9.10(6|) (r_parataxis) displays_8\VBZ\2137132|apo-alpha-lactalbumin|site|,|m(-1|,|respectively|. (l_nsubj) apo-alpha-lactalbumin_0\NN\1740|,|obtained|,
T4_T10 NONE acids_8\NNS\14818238|fatty (r_dobj) bind_6\VB\1290422|to|acids (r_xcomp) unable_4\JJ\1740|however|,|holo-alpha-lactalbumin|was|bind|measured|. (l_nsubj) holo-alpha-lactalbumin_2\NN\1740|
T5_T12 NONE acids_4\NNS\14818238|no|fatty|bound|, (l_acl) bound_5\VBN\1831531|holo-alpha-lactalbumin (l_nmod) holo-alpha-lactalbumin_7\NN\1740|to|,|isolated
T6_T13 NONE calcium_14\NN\14625458|of (r_nmod) removal_12\NN\383606|by|the|calcium (r_nmod) induced_7\VBN\1627355|alpha-lactalbumin|removal (l_nmod) alpha-lactalbumin_9\JJ\1740|in
19119014
T1_T24 CPR:4 thiazide_0\NN\3214670|and|diuretics (r_nsubjpass) shown_7\VBN\2137132|thiazide|were|recently|inhibit|. (l_xcomp) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_appos) ca_17\NN\14625458|(|,|ec|)
T1_T26 CPR:4 thiazide_0\NN\3214670|and|diuretics (r_nsubjpass) shown_7\VBN\2137132|thiazide|were|recently|inhibit|. (l_xcomp) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_appos) ca_17\NN\14625458|(|,|ec|) (l_appos) ec_19\NN\8294696|4.2.1.1 (l_nummod) 4.2.1.1_20\CD\1740|
T1_T36 CPR:4 thiazide_0\NN\3214670|and|diuretics (r_nsubjpass) shown_7\VBN\2137132|thiazide|were|recently|inhibit|. (l_xcomp) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_nmod) anhydrase_15\NN\1740|of|carbonic
T7_T24 CPR:4 acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_appos) ca_17\NN\14625458|(|,|ec|)
T7_T26 CPR:4 acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_appos) ca_17\NN\14625458|(|,|ec|) (l_appos) ec_19\NN\8294696|4.2.1.1 (l_nummod) 4.2.1.1_20\CD\1740|
T7_T36 CPR:4 acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_nmod) anhydrase_15\NN\1740|of|carbonic
T8_T24 CPR:4 methazolamide_37\NN\1740| (r_conj) acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_appos) ca_17\NN\14625458|(|,|ec|)
T8_T26 CPR:4 methazolamide_37\NN\1740| (r_conj) acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_appos) ca_17\NN\14625458|(|,|ec|) (l_appos) ec_19\NN\8294696|4.2.1.1 (l_nummod) 4.2.1.1_20\CD\1740|
T8_T36 CPR:4 methazolamide_37\NN\1740| (r_conj) acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_nmod) anhydrase_15\NN\1740|of|carbonic
T9_T24 CPR:4 ethoxzolamide_40\NN\1740| (r_conj) acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_appos) ca_17\NN\14625458|(|,|ec|)
T9_T26 CPR:4 ethoxzolamide_40\NN\1740| (r_conj) acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_appos) ca_17\NN\14625458|(|,|ec|) (l_appos) ec_19\NN\8294696|4.2.1.1 (l_nummod) 4.2.1.1_20\CD\1740|
T9_T36 CPR:4 ethoxzolamide_40\NN\1740| (r_conj) acetazolamide_35\NN\1740|such|,|methazolamide|,|and|ethoxzolamide (r_nmod) inhibitors_31\NNS\20090|to|classical|,|acetazolamide (r_nmod) compared_28\VBN\644583|as|inhibitors (r_advcl) inhibit_9\VB\2510337|to|isoforms|profile|compared (l_dobj) isoforms_12\NNS\1740|all|mammalian|anhydrase|ca (l_nmod) anhydrase_15\NN\1740|of|carbonic
T10_T29 NONE chlorthalidone_19\NN\3214670|with|,|trichloromethiazide|,|and|furosemide (r_nsubj) inhibitors_27\NNS\20090|chlorthalidone|being|efficient|ca|k(i)s (r_nmod) have_6\VBP\2108377|some|behavior|isozyme|,|inhibitors|,|one|. (l_nmod) isozyme_14\NN\1740|against|the|widespread|ca (l_dep) ca_15\NN\14625458|ii (l_nummod) ii_16\CD\13741022|
T10_T30 CPR:4 chlorthalidone_19\NN\3214670|with|,|trichloromethiazide|,|and|furosemide (r_nsubj) inhibitors_27\NNS\20090|chlorthalidone|being|efficient|ca|k(i)s (l_nmod) ca_29\NN\14625458|against|ii (l_nummod) ii_30\CD\13741022|
T11_T29 NONE trichloromethiazide_21\NN\1740| (r_conj) chlorthalidone_19\NN\3214670|with|,|trichloromethiazide|,|and|furosemide (r_nsubj) inhibitors_27\NNS\20090|chlorthalidone|being|efficient|ca|k(i)s (r_nmod) have_6\VBP\2108377|some|behavior|isozyme|,|inhibitors|,|one|. (l_nmod) isozyme_14\NN\1740|against|the|widespread|ca (l_dep) ca_15\NN\14625458|ii (l_nummod) ii_16\CD\13741022|
T11_T30 CPR:4 trichloromethiazide_21\NN\1740| (r_conj) chlorthalidone_19\NN\3214670|with|,|trichloromethiazide|,|and|furosemide (r_nsubj) inhibitors_27\NNS\20090|chlorthalidone|being|efficient|ca|k(i)s (l_nmod) ca_29\NN\14625458|against|ii (l_nummod) ii_30\CD\13741022|
T12_T29 NONE furosemide_24\NN\3214670| (r_conj) chlorthalidone_19\NN\3214670|with|,|trichloromethiazide|,|and|furosemide (r_nsubj) inhibitors_27\NNS\20090|chlorthalidone|being|efficient|ca|k(i)s (r_nmod) have_6\VBP\2108377|some|behavior|isozyme|,|inhibitors|,|one|. (l_nmod) isozyme_14\NN\1740|against|the|widespread|ca (l_dep) ca_15\NN\14625458|ii (l_nummod) ii_16\CD\13741022|
T12_T30 CPR:4 furosemide_24\NN\3214670| (r_conj) chlorthalidone_19\NN\3214670|with|,|trichloromethiazide|,|and|furosemide (r_nsubj) inhibitors_27\NNS\20090|chlorthalidone|being|efficient|ca|k(i)s (l_nmod) ca_29\NN\14625458|against|ii (l_nummod) ii_30\CD\13741022|
T13_T29 NONE indapamide_41\NN\3214670| (r_nsubj) one_46\NN\13741022|whereas|indapamide|is|a|weaker|k(i (r_advcl) have_6\VBP\2108377|some|behavior|isozyme|,|inhibitors|,|one|. (l_nmod) isozyme_14\NN\1740|against|the|widespread|ca (l_dep) ca_15\NN\14625458|ii (l_nummod) ii_16\CD\13741022|
T13_T30 CPR:4 indapamide_41\NN\3214670| (r_nsubj) one_46\NN\13741022|whereas|indapamide|is|a|weaker|k(i (r_advcl) have_6\VBP\2108377|some|behavior|isozyme|,|inhibitors|,|one|. (l_nmod) inhibitors_27\NNS\20090|chlorthalidone|being|efficient|ca|k(i)s (l_nmod) ca_29\NN\14625458|against|ii (l_nummod) ii_30\CD\13741022|
T14_T31 NONE chlorthalidone_21\NN\3214670|example|,|hca|;|indapamide (l_nmod) hca_23\NN\1740|against|vb|vii|,|ix|,|and|xiii (l_conj) xiii_31\CD\13745420|
T14_T32 NONE chlorthalidone_21\NN\3214670|example|,|hca|;|indapamide (l_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_dep) vii_36\CD\13741022|,|ix|,|xii|,|and|xiii (l_conj) xiii_43\CD\13745420|
T14_T33 NONE chlorthalidone_21\NN\3214670|example|,|hca|;|indapamide (l_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_conj) trichloromethiazide_45\NN\1740|ca (l_nmod) ca_47\NN\14625458|against|vii (l_dep) vii_48\CD\13741022|and|ix (l_conj) ix_50\CD\13741022|
T14_T34 NONE chlorthalidone_21\NN\3214670|example|,|hca|;|indapamide (l_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_conj) furosemide_53\NN\3214670|ca (l_nmod) ca_55\NNP\14625458|against|i (l_nummod) i_56\CD\14622893|and|xiv (l_conj) xiv_58\CD\13745420|
T15_T31 NONE indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (r_conj) chlorthalidone_21\NN\3214670|example|,|hca|;|indapamide (l_nmod) hca_23\NN\1740|against|vb|vii|,|ix|,|and|xiii (l_conj) xiii_31\CD\13745420|
T15_T32 NONE indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_dep) vii_36\CD\13741022|,|ix|,|xii|,|and|xiii (l_conj) xiii_43\CD\13745420|
T15_T33 NONE indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_conj) trichloromethiazide_45\NN\1740|ca (l_nmod) ca_47\NN\14625458|against|vii (l_dep) vii_48\CD\13741022|and|ix (l_conj) ix_50\CD\13741022|
T15_T34 NONE indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_conj) furosemide_53\NN\3214670|ca (l_nmod) ca_55\NNP\14625458|against|i (l_nummod) i_56\CD\14622893|and|xiv (l_conj) xiv_58\CD\13745420|
T16_T31 NONE trichloromethiazide_45\NN\1740|ca (r_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (r_conj) chlorthalidone_21\NN\3214670|example|,|hca|;|indapamide (l_nmod) hca_23\NN\1740|against|vb|vii|,|ix|,|and|xiii (l_conj) xiii_31\CD\13745420|
T16_T32 NONE trichloromethiazide_45\NN\1740|ca (r_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_dep) vii_36\CD\13741022|,|ix|,|xii|,|and|xiii (l_conj) xiii_43\CD\13745420|
T16_T33 NONE trichloromethiazide_45\NN\1740|ca (l_nmod) ca_47\NN\14625458|against|vii (l_dep) vii_48\CD\13741022|and|ix (l_conj) ix_50\CD\13741022|
T16_T34 NONE trichloromethiazide_45\NN\1740|ca (r_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_conj) furosemide_53\NN\3214670|ca (l_nmod) ca_55\NNP\14625458|against|i (l_nummod) i_56\CD\14622893|and|xiv (l_conj) xiv_58\CD\13745420|
T17_T31 NONE furosemide_53\NN\3214670|ca (r_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (r_conj) chlorthalidone_21\NN\3214670|example|,|hca|;|indapamide (l_nmod) hca_23\NN\1740|against|vb|vii|,|ix|,|and|xiii (l_conj) xiii_31\CD\13745420|
T17_T32 NONE furosemide_53\NN\3214670|ca (r_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_dep) vii_36\CD\13741022|,|ix|,|xii|,|and|xiii (l_conj) xiii_43\CD\13745420|
T17_T33 NONE furosemide_53\NN\3214670|ca (r_conj) indapamide_33\NN\3214670|ca|vii|,|trichloromethiazide|,|and|furosemide (l_conj) trichloromethiazide_45\NN\1740|ca (l_nmod) ca_47\NN\14625458|against|vii (l_dep) vii_48\CD\13741022|and|ix (l_conj) ix_50\CD\13741022|
T17_T34 NONE furosemide_53\NN\3214670|ca (l_nmod) ca_55\NNP\14625458|against|i (l_nummod) i_56\CD\14622893|and|xiv (l_conj) xiv_58\CD\13745420|
T18_T35 NONE chlorthalidone_27\NN\3214670|,|trichloromethiazide|,|and|furosemide (r_compound) scaffolds_33\NNS\3961939|with|the|chlorthalidone|responsible (r_nmod) interacting_24\VBG\2367363|scaffolds (r_acl) molecules_23\NNS\9465459|several|3|site|water|interacting (r_dobj) observed_13\VBD\2163746|examining|,|we|molecules|. (l_advcl) examining_0\VBG\789138|structures (l_dobj) structures_5\NNS\21939|the|four|x-ray|crystal|adducts (l_nmod) adducts_10\NNS\14818238|of|their|ii (l_nummod) ii_9\CD\13741022|ca
T19_T35 NONE trichloromethiazide_29\NN\1740| (r_conj) chlorthalidone_27\NN\3214670|,|trichloromethiazide|,|and|furosemide (r_compound) scaffolds_33\NNS\3961939|with|the|chlorthalidone|responsible (r_nmod) interacting_24\VBG\2367363|scaffolds (r_acl) molecules_23\NNS\9465459|several|3|site|water|interacting (r_dobj) observed_13\VBD\2163746|examining|,|we|molecules|. (l_advcl) examining_0\VBG\789138|structures (l_dobj) structures_5\NNS\21939|the|four|x-ray|crystal|adducts (l_nmod) adducts_10\NNS\14818238|of|their|ii (l_nummod) ii_9\CD\13741022|ca
T2_T35 NONE furosemide_32\NN\3214670| (r_conj) chlorthalidone_27\NN\3214670|,|trichloromethiazide|,|and|furosemide (r_compound) scaffolds_33\NNS\3961939|with|the|chlorthalidone|responsible (r_nmod) interacting_24\VBG\2367363|scaffolds (r_acl) molecules_23\NNS\9465459|several|3|site|water|interacting (r_dobj) observed_13\VBD\2163746|examining|,|we|molecules|. (l_advcl) examining_0\VBG\789138|structures (l_dobj) structures_5\NNS\21939|the|four|x-ray|crystal|adducts (l_nmod) adducts_10\NNS\14818238|of|their|ii (l_nummod) ii_9\CD\13741022|ca
T3_T25 NONE indapamide_2\NN\3214670|bound (l_acl) bound_3\VBN\1831531|ca (l_nmod) ca_5\NN\14625458|to|ii (l_nummod) ii_6\CD\13741022|
T4_T27 NONE chlorthalidone_0\NN\3214670|bound (l_acl) bound_1\VBN\1831531|site (l_nmod) site_7\NN\8673395|within|the|ca|ii|active (l_nummod) ii_5\CD\13741022|
T5_T27 NONE oh_21\NN\1740|the|enolic (r_nsubj) participating_23\VBG\2367363|with|oh|also|bonds (r_advcl) form_16\NN\6286395|chlorthalidone|is|in|an|tautomeric|,|participating (l_nsubj) chlorthalidone_0\NN\3214670|bound (l_acl) bound_1\VBN\1831531|site (l_nmod) site_7\NN\8673395|within|the|ca|ii|active (l_nummod) ii_5\CD\13741022|
T6_T27 NONE hydrogen_27\NN\14622893| (r_compound) bonds_28\NNS\11426530|in|two|strong|hydrogen|asn67 (r_nmod) participating_23\VBG\2367363|with|oh|also|bonds (r_advcl) form_16\NN\6286395|chlorthalidone|is|in|an|tautomeric|,|participating (l_nsubj) chlorthalidone_0\NN\3214670|bound (l_acl) bound_1\VBN\1831531|site (l_nmod) site_7\NN\8673395|within|the|ca|ii|active (l_nummod) ii_5\CD\13741022|
16784786
T22_T47 NONE mo_8\NN\15122231| (r_nsubj) constituent_11\NN\3892891|where|mo|is|a|femo-cofactor (r_acl:relcl) nitrogenase_5\NN\14732946|of|bacterial|,|constituent
T23_T47 NONE femo-cofactor_14\NN\1740|of|the (r_nmod) constituent_11\NN\3892891|where|mo|is|a|femo-cofactor (r_acl:relcl) nitrogenase_5\NN\14732946|of|bacterial|,|constituent
T24_T47 NONE mo_16\NN\15122231| (r_nsubjpass) bound_18\VBN\1831531|exception|,|mo|is|pterin|,|forming|. (l_nmod) exception_2\NN\5706954|with|the|nitrogenase (l_nmod) nitrogenase_5\NN\14732946|of|bacterial|,|constituent
T25_T47 NONE pterin_21\NN\1740|to|a (r_nmod) bound_18\VBN\1831531|exception|,|mo|is|pterin|,|forming|. (l_nmod) exception_2\NN\5706954|with|the|nitrogenase (l_nmod) nitrogenase_5\NN\14732946|of|bacterial|,|constituent
T26_T47 NONE molybdenum_26\NN\14625458| (r_compound) cofactor_27\NN\14818238|the|molybdenum|moco|compound (r_dobj) forming_24\VBG\1617192|thus|cofactor (r_advcl) bound_18\VBN\1831531|exception|,|mo|is|pterin|,|forming|. (l_nmod) exception_2\NN\5706954|with|the|nitrogenase (l_nmod) nitrogenase_5\NN\14732946|of|bacterial|,|constituent
T27_T47 NONE mo-enzymes_43\NNS\1740|of|all|other (r_nmod) site_39\NN\8673395|at|the|catalytic|mo-enzymes (r_nmod) compound_35\NN\5869584|which|is|the|active|site (r_acl:relcl) cofactor_27\NN\14818238|the|molybdenum|moco|compound (r_dobj) forming_24\VBG\1617192|thus|cofactor (r_advcl) bound_18\VBN\1831531|exception|,|mo|is|pterin|,|forming|. (l_nmod) exception_2\NN\5706954|with|the|nitrogenase (l_nmod) nitrogenase_5\NN\14732946|of|bacterial|,|constituent
T1_T39 NONE nitrate_83\NN\14818238| (r_compound) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T1_T48 NONE nitrate_83\NN\14818238| (r_compound) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T1_T49 NONE nitrate_83\NN\14818238| (r_compound) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T1_T50 NONE nitrate_83\NN\14818238| (r_compound) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T28_T39 NONE mo-enzymes_6\NNS\1740|the|prominent (r_nsubj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T28_T48 NONE mo-enzymes_6\NNS\1740|the|prominent (r_nsubj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T28_T49 NONE mo-enzymes_6\NNS\1740|the|prominent (r_nsubj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T28_T50 NONE mo-enzymes_6\NNS\1740|the|prominent (r_nsubj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T29_T39 NONE sulfur-containing_23\JJ\1740| (r_amod) acids_25\NNS\14818238|of|sulfur-containing|amino (r_nmod) degradation_21\NN\199130|in|the|acids (r_nmod) step_18\NN\168237|the|final|degradation (r_dobj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T29_T48 CPR:9 sulfur-containing_23\JJ\1740| (r_amod) acids_25\NNS\14818238|of|sulfur-containing|amino (r_nmod) degradation_21\NN\199130|in|the|acids (r_nmod) step_18\NN\168237|the|final|degradation (r_dobj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T29_T49 NONE sulfur-containing_23\JJ\1740| (r_amod) acids_25\NNS\14818238|of|sulfur-containing|amino (r_nmod) degradation_21\NN\199130|in|the|acids (r_nmod) step_18\NN\168237|the|final|degradation (r_dobj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T29_T50 NONE sulfur-containing_23\JJ\1740| (r_amod) acids_25\NNS\14818238|of|sulfur-containing|amino (r_nmod) degradation_21\NN\199130|in|the|acids (r_nmod) step_18\NN\168237|the|final|degradation (r_dobj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T2_T39 NONE nitrogen_93\NN\14622893| (r_compound) assimilation_94\NN\13928668|in|inorganic|nitrogen (r_nmod) step_90\NN\168237|the|key|assimilation (r_dobj) catalyzes_87\VBZ\146138|which|step (r_acl:relcl) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T2_T48 NONE nitrogen_93\NN\14622893| (r_compound) assimilation_94\NN\13928668|in|inorganic|nitrogen (r_nmod) step_90\NN\168237|the|key|assimilation (r_dobj) catalyzes_87\VBZ\146138|which|step (r_acl:relcl) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T2_T49 NONE nitrogen_93\NN\14622893| (r_compound) assimilation_94\NN\13928668|in|inorganic|nitrogen (r_nmod) step_90\NN\168237|the|key|assimilation (r_dobj) catalyzes_87\VBZ\146138|which|step (r_acl:relcl) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T2_T50 NONE nitrogen_93\NN\14622893| (r_compound) assimilation_94\NN\13928668|in|inorganic|nitrogen (r_nmod) step_90\NN\168237|the|key|assimilation (r_dobj) catalyzes_87\VBZ\146138|which|step (r_acl:relcl) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T30_T39 NONE acids_25\NNS\14818238|of|sulfur-containing|amino (r_nmod) degradation_21\NN\199130|in|the|acids (r_nmod) step_18\NN\168237|the|final|degradation (r_dobj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T30_T48 NONE acids_25\NNS\14818238|of|sulfur-containing|amino (r_nmod) degradation_21\NN\199130|in|the|acids (r_nmod) step_18\NN\168237|the|final|degradation (r_dobj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T30_T49 NONE acids_25\NNS\14818238|of|sulfur-containing|amino (r_nmod) degradation_21\NN\199130|in|the|acids (r_nmod) step_18\NN\168237|the|final|degradation (r_dobj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T30_T50 NONE acids_25\NNS\14818238|of|sulfur-containing|amino (r_nmod) degradation_21\NN\199130|in|the|acids (r_nmod) step_18\NN\168237|the|final|degradation (r_dobj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T31_T39 NONE sulfite_32\NN\1740|excess (r_dobj) detoxifying_30\VBG\173338|in|sulfite (r_advcl) involved_28\VBN\2676054|is|detoxifying (r_conj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T31_T48 NONE sulfite_32\NN\1740|excess (r_dobj) detoxifying_30\VBG\173338|in|sulfite (r_advcl) involved_28\VBN\2676054|is|detoxifying (r_conj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T31_T49 NONE sulfite_32\NN\1740|excess (r_dobj) detoxifying_30\VBG\173338|in|sulfite (r_advcl) involved_28\VBN\2676054|is|detoxifying (r_conj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T31_T50 NONE sulfite_32\NN\1740|excess (r_dobj) detoxifying_30\VBG\173338|in|sulfite (r_advcl) involved_28\VBN\2676054|is|detoxifying (r_conj) catalyzes_15\VBZ\146138|which|step|and|involved (r_acl:relcl) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T32_T39 NONE xanthine_37\NN\14727670| (r_compound) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T32_T48 NONE xanthine_37\NN\14727670| (r_compound) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T32_T49 NONE xanthine_37\NN\14727670| (r_compound) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T32_T50 NONE xanthine_37\NN\14727670| (r_compound) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T33_T39 NONE purine_44\NN\14618253| (r_compound) catabolism_45\NN\13526110|in|purine|and|production (r_nmod) involved_42\VBN\2676054|which|is|catabolism (r_acl:relcl) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T33_T48 NONE purine_44\NN\14618253| (r_compound) catabolism_45\NN\13526110|in|purine|and|production (r_nmod) involved_42\VBN\2676054|which|is|catabolism (r_acl:relcl) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T33_T49 NONE purine_44\NN\14618253| (r_compound) catabolism_45\NN\13526110|in|purine|and|production (r_nmod) involved_42\VBN\2676054|which|is|catabolism (r_acl:relcl) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T33_T50 NONE purine_44\NN\14618253| (r_compound) catabolism_45\NN\13526110|in|purine|and|production (r_nmod) involved_42\VBN\2676054|which|is|catabolism (r_acl:relcl) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T34_T39 NONE oxygen_48\NN\14622893| (r_compound) production_49\NN\30358|reactive|oxygen (r_conj) catabolism_45\NN\13526110|in|purine|and|production (r_nmod) involved_42\VBN\2676054|which|is|catabolism (r_acl:relcl) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T34_T48 NONE oxygen_48\NN\14622893| (r_compound) production_49\NN\30358|reactive|oxygen (r_conj) catabolism_45\NN\13526110|in|purine|and|production (r_nmod) involved_42\VBN\2676054|which|is|catabolism (r_acl:relcl) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T34_T49 NONE oxygen_48\NN\14622893| (r_compound) production_49\NN\30358|reactive|oxygen (r_conj) catabolism_45\NN\13526110|in|purine|and|production (r_nmod) involved_42\VBN\2676054|which|is|catabolism (r_acl:relcl) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T34_T50 NONE oxygen_48\NN\14622893| (r_compound) production_49\NN\30358|reactive|oxygen (r_conj) catabolism_45\NN\13526110|in|purine|and|production (r_nmod) involved_42\VBN\2676054|which|is|catabolism (r_acl:relcl) dehydrogenase_38\NN\1740|2|xanthine|,|involved|, (r_appos) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_conj) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T35_T39 NONE aldehyde_54\NN\14727670| (r_compound) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T35_T48 NONE aldehyde_54\NN\14727670| (r_compound) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T35_T49 NONE aldehyde_54\NN\14727670| (r_compound) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T35_T50 NONE aldehyde_54\NN\14727670| (r_compound) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T36_T39 NONE aldehydes_62\NNS\14727670|of (r_nmod) variety_60\NN\7951464|a|aldehydes (r_dobj) oxidizes_58\VBZ\109660|which|variety|and|essential (r_acl:relcl) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T36_T48 NONE aldehydes_62\NNS\14727670|of (r_nmod) variety_60\NN\7951464|a|aldehydes (r_dobj) oxidizes_58\VBZ\109660|which|variety|and|essential (r_acl:relcl) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T36_T49 NONE aldehydes_62\NNS\14727670|of (r_nmod) variety_60\NN\7951464|a|aldehydes (r_dobj) oxidizes_58\VBZ\109660|which|variety|and|essential (r_acl:relcl) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T36_T50 NONE aldehydes_62\NNS\14727670|of (r_nmod) variety_60\NN\7951464|a|aldehydes (r_dobj) oxidizes_58\VBZ\109660|which|variety|and|essential (r_acl:relcl) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T37_T39 NONE acid_73\NN\14818238|of|the|phytohormone|abscisic (r_nmod) biosynthesis_68\NN\13565379|for|the|acid (r_nmod) essential_65\JJ\1740|is|biosynthesis (r_conj) oxidizes_58\VBZ\109660|which|variety|and|essential (r_acl:relcl) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) reductase_84\NN\14732946|also|4|nitrate|,|catalyzes
T37_T48 NONE acid_73\NN\14818238|of|the|phytohormone|abscisic (r_nmod) biosynthesis_68\NN\13565379|for|the|acid (r_nmod) essential_65\JJ\1740|is|biosynthesis (r_conj) oxidizes_58\VBZ\109660|which|variety|and|essential (r_acl:relcl) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|.
T37_T49 NONE acid_73\NN\14818238|of|the|phytohormone|abscisic (r_nmod) biosynthesis_68\NN\13565379|for|the|acid (r_nmod) essential_65\JJ\1740|is|biosynthesis (r_conj) oxidizes_58\VBZ\109660|which|variety|and|essential (r_acl:relcl) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes (r_conj) oxidase_12\NN\14732946|eukaryotes|,|mo-enzymes|are|1|sulfite|,|catalyzes|,|dehydrogenase|oxidase|,|and|organisms|reductase|. (l_appos) dehydrogenase_38\NN\1740|2|xanthine|,|involved|,
T37_T50 NONE acid_73\NN\14818238|of|the|phytohormone|abscisic (r_nmod) biosynthesis_68\NN\13565379|for|the|acid (r_nmod) essential_65\JJ\1740|is|biosynthesis (r_conj) oxidizes_58\VBZ\109660|which|variety|and|essential (r_acl:relcl) oxidase_55\NN\14732946|3|aldehyde|,|oxidizes
T3_T40 NONE mo-enzymes_1\NNS\1740|all|,|oxidase|, (l_nmod) oxidase_6\NN\14732946|except|plant|sulfite
T4_T40 NONE sulfite_5\NN\1740| (r_compound) oxidase_6\NN\14732946|except|plant|sulfite
T5_T40 NONE iron_21\NN\14625458|transfer (r_dobj) involving_20\VBG\2676054|iron (r_acl) many_17\DT\1740|them|involving (r_dobj) need_8\VBP\2604760|mo-enzymes|center|many|. (l_nsubj) mo-enzymes_1\NNS\1740|all|,|oxidase|, (l_nmod) oxidase_6\NN\14732946|except|plant|sulfite
T10_T41 NONE sulfite_8\NN\1740| (r_compound) oxidase_9\NN\14732946|sulfite|and|reductase (r_conj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|,
T10_T42 NONE sulfite_8\NN\1740| (r_compound) oxidase_9\NN\14732946|sulfite|and|reductase (r_conj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_4\NN\14732946|aldehyde
T10_T43 NONE sulfite_8\NN\1740| (r_compound) oxidase_9\NN\14732946|sulfite|and|reductase
T10_T44 NONE sulfite_8\NN\1740| (r_compound) oxidase_9\NN\14732946|sulfite|and|reductase (l_conj) reductase_12\NN\14732946|nitrate
T11_T41 NONE nitrate_11\NN\14818238| (r_compound) reductase_12\NN\14732946|nitrate (r_conj) oxidase_9\NN\14732946|sulfite|and|reductase (r_conj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|,
T11_T42 NONE nitrate_11\NN\14818238| (r_compound) reductase_12\NN\14732946|nitrate (r_conj) oxidase_9\NN\14732946|sulfite|and|reductase (r_conj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_4\NN\14732946|aldehyde
T11_T43 NONE nitrate_11\NN\14818238| (r_compound) reductase_12\NN\14732946|nitrate (r_conj) oxidase_9\NN\14732946|sulfite|and|reductase
T11_T44 NONE nitrate_11\NN\14818238| (r_compound) reductase_12\NN\14732946|nitrate
T12_T41 NONE mo-site_20\NN\1740|of|their (r_nmod) sulfuration_17\NN\1740|the|post-translational|mo-site (r_dobj) require_14\VBP\754942|dehydrogenase|sulfuration|becoming|. (l_nsubj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|,
T12_T42 NONE mo-site_20\NN\1740|of|their (r_nmod) sulfuration_17\NN\1740|the|post-translational|mo-site (r_dobj) require_14\VBP\754942|dehydrogenase|sulfuration|becoming|. (l_nsubj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_4\NN\14732946|aldehyde
T12_T43 NONE mo-site_20\NN\1740|of|their (r_nmod) sulfuration_17\NN\1740|the|post-translational|mo-site (r_dobj) require_14\VBP\754942|dehydrogenase|sulfuration|becoming|. (l_nsubj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_9\NN\14732946|sulfite|and|reductase
T12_T44 NONE mo-site_20\NN\1740|of|their (r_nmod) sulfuration_17\NN\1740|the|post-translational|mo-site (r_dobj) require_14\VBP\754942|dehydrogenase|sulfuration|becoming|. (l_nsubj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_9\NN\14732946|sulfite|and|reductase (l_conj) reductase_12\NN\14732946|nitrate
T8_T41 NONE xanthine_0\NN\14727670| (r_compound) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|,
T8_T42 NONE xanthine_0\NN\14727670| (r_compound) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_4\NN\14732946|aldehyde
T8_T43 NONE xanthine_0\NN\14727670| (r_compound) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_9\NN\14732946|sulfite|and|reductase
T8_T44 NONE xanthine_0\NN\14727670| (r_compound) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_9\NN\14732946|sulfite|and|reductase (l_conj) reductase_12\NN\14732946|nitrate
T9_T41 NONE aldehyde_3\NN\14727670| (r_compound) oxidase_4\NN\14732946|aldehyde (r_conj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|,
T9_T42 NONE aldehyde_3\NN\14727670| (r_compound) oxidase_4\NN\14732946|aldehyde
T9_T43 NONE aldehyde_3\NN\14727670| (r_compound) oxidase_4\NN\14732946|aldehyde (r_conj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_9\NN\14732946|sulfite|and|reductase
T9_T44 NONE aldehyde_3\NN\14727670| (r_compound) oxidase_4\NN\14732946|aldehyde (r_conj) dehydrogenase_1\NN\1740|xanthine|and|oxidase|,|not|oxidase|, (l_conj) oxidase_9\NN\14732946|sulfite|and|reductase (l_conj) reductase_12\NN\14732946|nitrate
T14_T45 NONE sulfur_13\NN\14622893| (r_dobj) mobilizes_12\VBZ\1380638|which|sulfur|l-cysteine|manner|as (r_acl:relcl) enzyme_9\NN\14723628|by|a|moco-sulfurase|,|mobilizes (l_compound) moco-sulfurase_8\NN\1740|
T14_T46 NONE sulfur_13\NN\14622893| (r_dobj) mobilizes_12\VBZ\1380638|which|sulfur|l-cysteine|manner|as (l_prep) as_21\IN\14622893|typical (l_amod) typical_22\JJ\1740|desulfurases (l_nmod) desulfurases_25\NNS\1740|for|cysteine
T15_T45 NONE l-cysteine_15\NN\1740|from (r_nmod) mobilizes_12\VBZ\1380638|which|sulfur|l-cysteine|manner|as (r_acl:relcl) enzyme_9\NN\14723628|by|a|moco-sulfurase|,|mobilizes (l_compound) moco-sulfurase_8\NN\1740|
T15_T46 NONE l-cysteine_15\NN\1740|from (r_nmod) mobilizes_12\VBZ\1380638|which|sulfur|l-cysteine|manner|as (l_prep) as_21\IN\14622893|typical (l_amod) typical_22\JJ\1740|desulfurases (l_nmod) desulfurases_25\NNS\1740|for|cysteine
T16_T45 NONE phosphate-dependent_19\JJ\1740| (r_amod) manner_20\NN\4916342|in|a|pyridoxal|phosphate-dependent (r_nmod) mobilizes_12\VBZ\1380638|which|sulfur|l-cysteine|manner|as (r_acl:relcl) enzyme_9\NN\14723628|by|a|moco-sulfurase|,|mobilizes (l_compound) moco-sulfurase_8\NN\1740|
T16_T46 NONE phosphate-dependent_19\JJ\1740| (r_amod) manner_20\NN\4916342|in|a|pyridoxal|phosphate-dependent (r_nmod) mobilizes_12\VBZ\1380638|which|sulfur|l-cysteine|manner|as (l_prep) as_21\IN\14622893|typical (l_amod) typical_22\JJ\1740|desulfurases (l_nmod) desulfurases_25\NNS\1740|for|cysteine
T18_T45 NONE cysteine_24\NN\14601829| (r_compound) desulfurases_25\NNS\1740|for|cysteine (r_nmod) typical_22\JJ\1740|desulfurases (r_amod) as_21\IN\14622893|typical (r_prep) mobilizes_12\VBZ\1380638|which|sulfur|l-cysteine|manner|as (r_acl:relcl) enzyme_9\NN\14723628|by|a|moco-sulfurase|,|mobilizes (l_compound) moco-sulfurase_8\NN\1740|
T18_T46 NONE cysteine_24\NN\14601829| (r_compound) desulfurases_25\NNS\1740|for|cysteine
23478260
T2_T5 NONE ala34_39\NN\1740|for|and|gly36 (r_nmod) codons_37\NNS\8459252|common|ala34 (r_dobj) convert_35\VBP\126264|that|codons|codons (r_acl:relcl) exon_30\NN\14830364|within|1|htra1|convert (r_nmod) harbor_26\VBP\1771535|that|variants|snps|exon (l_nsubj) variants_5\NNS\7366289|two|common|a1|increase (l_nmod) a1_9\NN\1740|of|high-temperature|requirement|htra1
T2_T6 NONE ala34_39\NN\1740|for|and|gly36 (r_nmod) codons_37\NNS\8459252|common|ala34 (r_dobj) convert_35\VBP\126264|that|codons|codons (r_acl:relcl) exon_30\NN\14830364|within|1|htra1|convert (r_nmod) harbor_26\VBP\1771535|that|variants|snps|exon (l_nsubj) variants_5\NNS\7366289|two|common|a1|increase (l_nmod) a1_9\NN\1740|of|high-temperature|requirement|htra1 (l_appos) htra1_11\NN\1740|(|)
T2_T7 NONE ala34_39\NN\1740|for|and|gly36 (r_nmod) codons_37\NNS\8459252|common|ala34 (r_dobj) convert_35\VBP\126264|that|codons|codons (r_acl:relcl) exon_30\NN\14830364|within|1|htra1|convert (l_nmod) htra1_33\NN\1740|of
T3_T5 NONE gly36_41\NN\1740| (r_conj) ala34_39\NN\1740|for|and|gly36 (r_nmod) codons_37\NNS\8459252|common|ala34 (r_dobj) convert_35\VBP\126264|that|codons|codons (r_acl:relcl) exon_30\NN\14830364|within|1|htra1|convert (r_nmod) harbor_26\VBP\1771535|that|variants|snps|exon (l_nsubj) variants_5\NNS\7366289|two|common|a1|increase (l_nmod) a1_9\NN\1740|of|high-temperature|requirement|htra1
T3_T6 NONE gly36_41\NN\1740| (r_conj) ala34_39\NN\1740|for|and|gly36 (r_nmod) codons_37\NNS\8459252|common|ala34 (r_dobj) convert_35\VBP\126264|that|codons|codons (r_acl:relcl) exon_30\NN\14830364|within|1|htra1|convert (r_nmod) harbor_26\VBP\1771535|that|variants|snps|exon (l_nsubj) variants_5\NNS\7366289|two|common|a1|increase (l_nmod) a1_9\NN\1740|of|high-temperature|requirement|htra1 (l_appos) htra1_11\NN\1740|(|)
T3_T7 NONE gly36_41\NN\1740| (r_conj) ala34_39\NN\1740|for|and|gly36 (r_nmod) codons_37\NNS\8459252|common|ala34 (r_dobj) convert_35\VBP\126264|that|codons|codons (r_acl:relcl) exon_30\NN\14830364|within|1|htra1|convert (l_nmod) htra1_33\NN\1740|of
23322164
T22_T46 NONE carnitine_0\NN\1740| (r_compound) palmitoyltransferase_1\NN\1740|carnitine|2|and|translocase (l_nummod) 2_2\CD\13741022|
T22_T47 NONE carnitine_0\NN\1740| (r_compound) palmitoyltransferase_1\NN\1740|carnitine|2|and|translocase (l_conj) translocase_5\NN\1740|carnitine/acylcarnitine
T23_T46 CPR:9 acylcarnitines_15\NNS\1740|of (r_nmod) synthesis_11\NN\13446390|in|the|mitochondrial|and|export|acylcarnitines (r_nmod) involved_7\VBN\2676054|palmitoyltransferase|are|synthesis|. (l_nsubjpass) palmitoyltransferase_1\NN\1740|carnitine|2|and|translocase (l_nummod) 2_2\CD\13741022|
T23_T47 CPR:9 acylcarnitines_15\NNS\1740|of (r_nmod) synthesis_11\NN\13446390|in|the|mitochondrial|and|export|acylcarnitines (r_nmod) involved_7\VBN\2676054|palmitoyltransferase|are|synthesis|. (l_nsubjpass) palmitoyltransferase_1\NN\1740|carnitine|2|and|translocase (l_conj) translocase_5\NN\1740|carnitine/acylcarnitine
T24_T46 NONE carnitine/acylcarnitine_4\NN\1740| (r_compound) translocase_5\NN\1740|carnitine/acylcarnitine (r_conj) palmitoyltransferase_1\NN\1740|carnitine|2|and|translocase (l_nummod) 2_2\CD\13741022|
T24_T47 NONE carnitine/acylcarnitine_4\NN\1740| (r_compound) translocase_5\NN\1740|carnitine/acylcarnitine
T25_T46 NONE carnitine/acylcarnitine_4\NN\1740| (r_compound) translocase_5\NN\1740|carnitine/acylcarnitine (r_conj) palmitoyltransferase_1\NN\1740|carnitine|2|and|translocase (l_nummod) 2_2\CD\13741022|
T25_T47 NONE carnitine/acylcarnitine_4\NN\1740| (r_compound) translocase_5\NN\1740|carnitine/acylcarnitine
T12_T36 NONE acyl-coa_11\NN\1740| (r_compound) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control
T12_T37 NONE acyl-coa_11\NN\1740| (r_compound) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_appos) mcad_14\NN\1740|(|)
T12_T38 NONE acyl-coa_11\NN\1740| (r_compound) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_nmod) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (l_nummod) 2_21\CD\13741022|
T12_T39 NONE acyl-coa_11\NN\1740| (r_compound) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_nmod) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)-
T12_T40 NONE acyl-coa_11\NN\1740| (r_compound) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_nmod) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_conj) translocase_25\NN\1740|carnitine/acylcarnitine
T12_T41 NONE acyl-coa_11\NN\1740| (r_compound) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_nmod) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_punct) (cact)-_26\NN\1740|
T12_T42 NONE acyl-coa_11\NN\1740| (r_compound) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_nmod) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) fibroblasts_34\NNS\5447757|transporter|human (l_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient
T12_T43 NONE acyl-coa_11\NN\1740| (r_compound) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_nmod) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) fibroblasts_34\NNS\5447757|transporter|human (l_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (l_punct) (octn2)-deficient_32\NN\1740|
T13_T36 NONE carnitine_19\NN\1740| (r_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (r_compound) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (r_nmod) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control
T13_T37 NONE carnitine_19\NN\1740| (r_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (r_compound) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (r_nmod) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_appos) mcad_14\NN\1740|(|)
T13_T38 NONE carnitine_19\NN\1740| (r_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (l_nummod) 2_21\CD\13741022|
T13_T39 NONE carnitine_19\NN\1740| (r_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (r_compound) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)-
T13_T40 NONE carnitine_19\NN\1740| (r_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (r_compound) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_conj) translocase_25\NN\1740|carnitine/acylcarnitine
T13_T41 NONE carnitine_19\NN\1740| (r_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (r_compound) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_punct) (cact)-_26\NN\1740|
T13_T42 NONE carnitine_19\NN\1740| (r_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (r_compound) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) fibroblasts_34\NNS\5447757|transporter|human (l_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient
T13_T43 NONE carnitine_19\NN\1740| (r_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (r_compound) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) fibroblasts_34\NNS\5447757|transporter|human (l_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (l_punct) (octn2)-deficient_32\NN\1740|
T14_T36 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (r_nmod) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control
T14_T37 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (r_nmod) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_appos) mcad_14\NN\1740|(|)
T14_T38 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (l_nummod) 2_21\CD\13741022|
T14_T39 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)-
T14_T40 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine
T14_T41 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_punct) (cact)-_26\NN\1740|
T14_T42 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) fibroblasts_34\NNS\5447757|transporter|human (l_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient
T14_T43 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) fibroblasts_34\NNS\5447757|transporter|human (l_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (l_punct) (octn2)-deficient_32\NN\1740|
T15_T36 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (r_nmod) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control
T15_T37 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (r_nmod) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_appos) mcad_14\NN\1740|(|)
T15_T38 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (l_nummod) 2_21\CD\13741022|
T15_T39 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)-
T15_T40 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine
T15_T41 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_punct) (cact)-_26\NN\1740|
T15_T42 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) fibroblasts_34\NNS\5447757|transporter|human (l_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient
T15_T43 NONE carnitine/acylcarnitine_24\NN\1740| (r_compound) translocase_25\NN\1740|carnitine/acylcarnitine (r_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) fibroblasts_34\NNS\5447757|transporter|human (l_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (l_punct) (octn2)-deficient_32\NN\1740|
T16_T36 NONE carnitine_30\NN\1740| (r_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (r_compound) fibroblasts_34\NNS\5447757|transporter|human (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (r_nmod) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control
T16_T37 NONE carnitine_30\NN\1740| (r_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (r_compound) fibroblasts_34\NNS\5447757|transporter|human (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (r_nmod) dehydrogenase_12\NN\1740|of|medium-chain|acyl-coa|mcad|control (l_appos) mcad_14\NN\1740|(|)
T16_T38 NONE carnitine_30\NN\1740| (r_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (r_compound) fibroblasts_34\NNS\5447757|transporter|human (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_compound) palmitoyltransferase_20\NN\1740|carnitine|2 (l_nummod) 2_21\CD\13741022|
T16_T39 NONE carnitine_30\NN\1740| (r_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (r_compound) fibroblasts_34\NNS\5447757|transporter|human (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)-
T16_T40 NONE carnitine_30\NN\1740| (r_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (r_compound) fibroblasts_34\NNS\5447757|transporter|human (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_conj) translocase_25\NN\1740|carnitine/acylcarnitine
T16_T41 NONE carnitine_30\NN\1740| (r_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (r_compound) fibroblasts_34\NNS\5447757|transporter|human (r_conj) control_17\NN\5190804|in|and|(cpt2)-|,|and|fibroblasts (l_conj) (cpt2)-_22\NN\1740|palmitoyltransferase|,|translocase|(cact)- (l_punct) (cact)-_26\NN\1740|
T16_T42 NONE carnitine_30\NN\1740| (r_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient
T16_T43 NONE carnitine_30\NN\1740| (r_compound) transporter_31\NN\4490091|plasmalemmal|carnitine|(octn2)-deficient (l_punct) (octn2)-deficient_32\NN\1740|
T21_T44 NONE octanoylcarnitine_11\NN\1740|of (r_nmod) production_9\NN\30358|the|octanoylcarnitine (r_dobj) increased_7\VBD\169651|fibroblasts|,|knockdown|markedly|production|3-fold|. (l_nsubj) knockdown_5\NN\1173038|mcad (l_compound) mcad_4\NN\1740|
T2_T26 NONE octanoylcarnitine_8\NN\1740|of (r_nmod) accumulation_6\NN\13497135|extracellular|octanoylcarnitine (r_dobj) showed_4\VBD\2137132|lines|also|accumulation|2.8-fold|,|suggesting|. (l_advcl) suggesting_15\VBG\1010118|depend (l_ccomp) depend_24\VB\2604760|that|export|does|not|octn2 (l_nmod) octn2_26\NN\1740|on
T2_T45 NONE octanoylcarnitine_8\NN\1740|of (r_nmod) accumulation_6\NN\13497135|extracellular|octanoylcarnitine (r_dobj) showed_4\VBD\2137132|lines|also|accumulation|2.8-fold|,|suggesting|. (l_nsubj) lines_2\NNS\8426461|octn2-deficient|cell (l_amod) octn2-deficient_0\JJ\1740|
T3_T26 NONE acylcarnitines_21\NNS\1740|of (r_nmod) export_19\NN\3076708|the|cellular|acylcarnitines (r_nsubj) depend_24\VB\2604760|that|export|does|not|octn2 (l_nmod) octn2_26\NN\1740|on
T3_T45 NONE acylcarnitines_21\NNS\1740|of (r_nmod) export_19\NN\3076708|the|cellular|acylcarnitines (r_nsubj) depend_24\VB\2604760|that|export|does|not|octn2 (r_ccomp) suggesting_15\VBG\1010118|depend (r_advcl) showed_4\VBD\2137132|lines|also|accumulation|2.8-fold|,|suggesting|. (l_nsubj) lines_2\NNS\8426461|octn2-deficient|cell (l_amod) octn2-deficient_0\JJ\1740|
T4_T27 NONE octanoylcarnitine_12\NN\1740|of (r_nmod) accumulation_10\NN\13497135|the|octanoylcarnitine|medium (r_nsubj) increase_19\VB\169651|contrast|,|cells|,|accumulation|did|not|significantly|knockdown|. (l_nmod) cells_7\NNS\3080309|in|cpt2- (l_amod) cpt2-_4\NN\1740|and|cact-deficient
T4_T28 NONE octanoylcarnitine_12\NN\1740|of (r_nmod) accumulation_10\NN\13497135|the|octanoylcarnitine|medium (r_nsubj) increase_19\VB\169651|contrast|,|cells|,|accumulation|did|not|significantly|knockdown|. (l_nmod) cells_7\NNS\3080309|in|cpt2- (l_amod) cpt2-_4\NN\1740|and|cact-deficient (l_conj) cact-deficient_6\JJ\1740|
T4_T29 NONE octanoylcarnitine_12\NN\1740|of (r_nmod) accumulation_10\NN\13497135|the|octanoylcarnitine|medium (r_nsubj) increase_19\VB\169651|contrast|,|cells|,|accumulation|did|not|significantly|knockdown|. (l_nmod) knockdown_23\NN\1173038|in|the|mcad (l_compound) mcad_22\NN\1740|
T10_T32 NONE acylcarnitines_68\NNS\1740|of (r_nmod) synthesis_64\NN\13446390|in|the|mitochondrial|and|export|acylcarnitines (r_nmod) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (r_ccomp) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact
T10_T33 NONE acylcarnitines_68\NNS\1740|of (r_nmod) synthesis_64\NN\13446390|in|the|mitochondrial|and|export|acylcarnitines (r_nmod) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (r_ccomp) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact (l_conj) cact_5\NN\1740|
T10_T34 CPR:9 acylcarnitines_68\NNS\1740|of (r_nmod) synthesis_64\NN\13446390|in|the|mitochondrial|and|export|acylcarnitines (r_nmod) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (l_nsubjpass) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (l_nummod) 2_55\CD\13741022|
T10_T35 CPR:9 acylcarnitines_68\NNS\1740|of (r_nmod) synthesis_64\NN\13446390|in|the|mitochondrial|and|export|acylcarnitines (r_nmod) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (l_nsubjpass) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (l_conj) translocase_58\NN\1740|carnitine/acylcarnitine
T5_T32 CPR:9 acylcarnitine_10\NN\1740|for|mitochondrial|formation|s. (r_nmod) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact
T5_T33 CPR:9 acylcarnitine_10\NN\1740|for|mitochondrial|formation|s. (r_nmod) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact (l_conj) cact_5\NN\1740|
T5_T34 NONE acylcarnitine_10\NN\1740|for|mitochondrial|formation|s. (r_nmod) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_ccomp) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (l_nsubjpass) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (l_nummod) 2_55\CD\13741022|
T5_T35 NONE acylcarnitine_10\NN\1740|for|mitochondrial|formation|s. (r_nmod) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_ccomp) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (l_nsubjpass) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (l_conj) translocase_58\NN\1740|carnitine/acylcarnitine
T7_T32 NONE carnitine_53\NN\1740| (r_compound) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (r_nsubjpass) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (r_ccomp) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact
T7_T33 NONE carnitine_53\NN\1740| (r_compound) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (r_nsubjpass) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (r_ccomp) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact (l_conj) cact_5\NN\1740|
T7_T34 NONE carnitine_53\NN\1740| (r_compound) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (l_nummod) 2_55\CD\13741022|
T7_T35 NONE carnitine_53\NN\1740| (r_compound) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (l_conj) translocase_58\NN\1740|carnitine/acylcarnitine
T8_T32 NONE carnitine/acylcarnitine_57\NN\1740| (r_compound) translocase_58\NN\1740|carnitine/acylcarnitine (r_conj) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (r_nsubjpass) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (r_ccomp) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact
T8_T33 NONE carnitine/acylcarnitine_57\NN\1740| (r_compound) translocase_58\NN\1740|carnitine/acylcarnitine (r_conj) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (r_nsubjpass) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (r_ccomp) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact (l_conj) cact_5\NN\1740|
T8_T34 NONE carnitine/acylcarnitine_57\NN\1740| (r_compound) translocase_58\NN\1740|carnitine/acylcarnitine (r_conj) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (l_nummod) 2_55\CD\13741022|
T8_T35 NONE carnitine/acylcarnitine_57\NN\1740| (r_compound) translocase_58\NN\1740|carnitine/acylcarnitine
T9_T32 NONE carnitine/acylcarnitine_57\NN\1740| (r_compound) translocase_58\NN\1740|carnitine/acylcarnitine (r_conj) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (r_nsubjpass) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (r_ccomp) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact
T9_T33 NONE carnitine/acylcarnitine_57\NN\1740| (r_compound) translocase_58\NN\1740|carnitine/acylcarnitine (r_conj) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (r_nsubjpass) involved_60\VBN\2676054|palmitoyltransferase|are|synthesis (r_ccomp) crucial_7\JJ\1740|that|cpt2|are|acylcarnitine|involved (l_nsubj) cpt2_3\NN\1740|and|cact (l_conj) cact_5\NN\1740|
T9_T34 NONE carnitine/acylcarnitine_57\NN\1740| (r_compound) translocase_58\NN\1740|carnitine/acylcarnitine (r_conj) palmitoyltransferase_54\NN\1740|carnitine|2|and|translocase (l_nummod) 2_55\CD\13741022|
T9_T35 NONE carnitine/acylcarnitine_57\NN\1740| (r_compound) translocase_58\NN\1740|carnitine/acylcarnitine
17512091
T21_T40 NONE glutathione_5\NN\1740| (r_compound) loss_6\NN\13252973|glutathione (r_conj) glutaredoxin_2\NN\1740|of|not|loss
T11_T37 NONE thiol_11\NN\1740|by|the|antioxidant|,|glutathione (l_conj) glutathione_13\NN\1740|and|enzyme (l_conj) enzyme_16\NN\14723628|related|,|glutaredoxin (l_appos) glutaredoxin_18\NN\1740|
T12_T37 NONE glutathione_13\NN\1740|and|enzyme (l_conj) enzyme_16\NN\14723628|related|,|glutaredoxin (l_appos) glutaredoxin_18\NN\1740|
T13_T37 NONE amino-l-alanine_28\NN\1740|by|beta-n-oxalyl|l-boaa|,|factor (r_nmod) caused_25\VBN\1617192|amino-l-alanine (r_acl) excitotoxicity_24\NN\1740|during|caused (r_nmod) maintaining_20\VBG\2202928|in|function|excitotoxicity (r_advcl) played_5\VBN\1072262|thiol|maintaining (l_nmod) thiol_11\NN\1740|by|the|antioxidant|,|glutathione (l_conj) glutathione_13\NN\1740|and|enzyme (l_conj) enzyme_16\NN\14723628|related|,|glutaredoxin (l_appos) glutaredoxin_18\NN\1740|
T14_T37 NONE l-boaa_30\NN\1740|(|) (r_appos) amino-l-alanine_28\NN\1740|by|beta-n-oxalyl|l-boaa|,|factor (r_nmod) caused_25\VBN\1617192|amino-l-alanine (r_acl) excitotoxicity_24\NN\1740|during|caused (r_nmod) maintaining_20\VBG\2202928|in|function|excitotoxicity (r_advcl) played_5\VBN\1072262|thiol|maintaining (l_nmod) thiol_11\NN\1740|by|the|antioxidant|,|glutathione (l_conj) glutathione_13\NN\1740|and|enzyme (l_conj) enzyme_16\NN\14723628|related|,|glutaredoxin (l_appos) glutaredoxin_18\NN\1740|
T15_T38 CPR:4 l-boaa_0\NN\1740| (r_nsubj) causes_1\VBZ\1617192|l-boaa|loss|cord|oxidation|,|resistant|. (l_dobj) loss_2\NN\13252973|gsh|and|inhibition (l_conj) inhibition_6\NN\1068773|complex (l_nmod) complex_9\NN\5869584|of|mitochondrial|i (l_nummod) i_10\CD\14622893|
T16_T38 NONE gsh_4\NN\1740|of (r_nmod) loss_2\NN\13252973|gsh|and|inhibition (l_conj) inhibition_6\NN\1068773|complex (l_nmod) complex_9\NN\5869584|of|mitochondrial|i (l_nummod) i_10\CD\14622893|
T17_T38 NONE thiol_20\NN\1740| (r_compound) groups_21\NNS\2137|of|thiol (r_nmod) oxidation_18\NN\13447361|through|groups (r_nmod) causes_1\VBZ\1617192|l-boaa|loss|cord|oxidation|,|resistant|. (l_dobj) loss_2\NN\13252973|gsh|and|inhibition (l_conj) inhibition_6\NN\1068773|complex (l_nmod) complex_9\NN\5869584|of|mitochondrial|i (l_nummod) i_10\CD\14622893|
T18_T39 NONE gsh_1\NN\1740| (r_compound) levels_2\NNS\4916342|gsh|cns (r_dobj) reducing_0\VBG\441445|levels|pretreatment (r_csubj) result_17\VB\2633881|reducing|did|not|inhibition|,|mice|. (l_nmod) inhibition_19\NN\1068773|in|activity (l_nmod) activity_23\NN\30358|of|complex|i (l_nummod) i_22\CD\14622893|
T19_T39 NONE maleate_11\NN\2718811|with|diethyl|or|glycine (r_nmod) pretreatment_8\NN\1740|by|maleate (r_nmod) reducing_0\VBG\441445|levels|pretreatment (r_csubj) result_17\VB\2633881|reducing|did|not|inhibition|,|mice|. (l_nmod) inhibition_19\NN\1068773|in|activity (l_nmod) activity_23\NN\30358|of|complex|i (l_nummod) i_22\CD\14622893|
T20_T39 NONE glycine_14\NN\14601829|l-propargyl (r_conj) maleate_11\NN\2718811|with|diethyl|or|glycine (r_nmod) pretreatment_8\NN\1740|by|maleate (r_nmod) reducing_0\VBG\441445|levels|pretreatment (r_csubj) result_17\VB\2633881|reducing|did|not|inhibition|,|mice|. (l_nmod) inhibition_19\NN\1068773|in|activity (l_nmod) activity_23\NN\30358|of|complex|i (l_nummod) i_22\CD\14622893|
T1_T22 NONE gsh_8\NN\1740|of (r_nmod) depleted_6\VBN\2267060|gsh (r_acl) mice_5\NNS\2329401|of|female|depleted (r_nmod) treatment_2\NN\654885|mice|l-boaa (r_nsubj) induce_13\VB\1627355|further|,|treatment|did|not|inhibition|indicating|. (l_dobj) inhibition_14\NN\1068773|i (l_nmod) i_17\CD\14622893|of|complex
T1_T23 NONE gsh_8\NN\1740|of (r_nmod) depleted_6\VBN\2267060|gsh (r_acl) mice_5\NNS\2329401|of|female|depleted (r_nmod) treatment_2\NN\654885|mice|l-boaa (r_nsubj) induce_13\VB\1627355|further|,|treatment|did|not|inhibition|indicating|. (l_advcl) indicating_18\VBG\952524|critical (l_ccomp) critical_24\JJ\1740|that|levels|were|not|maintaining (l_advcl) maintaining_26\VBG\2202928|for|activity|mice|counterpart (l_dobj) activity_29\NN\30358|complex|i (l_nummod) i_28\CD\14622893|
T2_T22 NONE l-boaa_10\NN\1740|with (r_nmod) treatment_2\NN\654885|mice|l-boaa (r_nsubj) induce_13\VB\1627355|further|,|treatment|did|not|inhibition|indicating|. (l_dobj) inhibition_14\NN\1068773|i (l_nmod) i_17\CD\14622893|of|complex
T2_T23 NONE l-boaa_10\NN\1740|with (r_nmod) treatment_2\NN\654885|mice|l-boaa (r_nsubj) induce_13\VB\1627355|further|,|treatment|did|not|inhibition|indicating|. (l_advcl) indicating_18\VBG\952524|critical (l_ccomp) critical_24\JJ\1740|that|levels|were|not|maintaining (l_advcl) maintaining_26\VBG\2202928|for|activity|mice|counterpart (l_dobj) activity_29\NN\30358|complex|i (l_nummod) i_28\CD\14622893|
T3_T22 NONE gsh_20\NN\1740| (r_compound) levels_21\NNS\4916342|gsh (r_nsubj) critical_24\JJ\1740|that|levels|were|not|maintaining (r_ccomp) indicating_18\VBG\952524|critical (r_advcl) induce_13\VB\1627355|further|,|treatment|did|not|inhibition|indicating|. (l_dobj) inhibition_14\NN\1068773|i (l_nmod) i_17\CD\14622893|of|complex
T3_T23 NONE gsh_20\NN\1740| (r_compound) levels_21\NNS\4916342|gsh (r_nsubj) critical_24\JJ\1740|that|levels|were|not|maintaining (l_advcl) maintaining_26\VBG\2202928|for|activity|mice|counterpart (l_dobj) activity_29\NN\30358|complex|i (l_nummod) i_28\CD\14622893|
T4_T24 NONE disulfide_4\NN\1740| (r_compound) oxidoreductase_5\NN\14732946|a|thiol|disulfide (r_appos) glutaredoxin_0\NN\1740|,|oxidoreductase
T4_T25 NONE disulfide_4\NN\1740| (r_compound) oxidoreductase_5\NN\14732946|a|thiol|disulfide
T4_T26 NONE disulfide_4\NN\1740| (r_compound) oxidoreductase_5\NN\14732946|a|thiol|disulfide (r_appos) glutaredoxin_0\NN\1740|,|oxidoreductase (r_nsubj) helps_6\VBZ\2556126|glutaredoxin|maintain|and|results|. (l_conj) results_16\VBZ\2633881|downregulation|loss (l_nsubj) downregulation_13\NN\1740|glutaredoxin (l_nmod) glutaredoxin_15\NN\1740|of
T4_T27 NONE disulfide_4\NN\1740| (r_compound) oxidoreductase_5\NN\14732946|a|thiol|disulfide (r_appos) glutaredoxin_0\NN\1740|,|oxidoreductase (r_nsubj) helps_6\VBZ\2556126|glutaredoxin|maintain|and|results|. (l_conj) results_16\VBZ\2633881|downregulation|loss (l_nmod) loss_18\NN\13252973|in|activity (l_nmod) activity_23\NN\30358|of|mitochondrial|complex|i (l_nummod) i_22\CD\14622893|
T6_T28 NONE l-boaa_21\NN\1740| (r_compound) toxicity_22\NN\13576101|to|l-boaa|seen (r_nmod) sensitizes_18\VBZ\126264|downregulation|them|toxicity (r_conj) levels_4\NNS\4916342|higher|glutaredoxin|regions|and|sensitizes (l_nmod) glutaredoxin_6\NN\1740|of
T6_T29 NONE l-boaa_21\NN\1740| (r_compound) toxicity_22\NN\13576101|to|l-boaa|seen (r_nmod) sensitizes_18\VBZ\126264|downregulation|them|toxicity (l_nsubj) downregulation_12\NN\1740|glutaredoxin|using (l_nmod) glutaredoxin_14\NN\1740|of
T6_T30 CPR:4 l-boaa_21\NN\1740| (r_compound) toxicity_22\NN\13576101|to|l-boaa|seen (l_acl) seen_23\VBN\2106506|loss (l_nmod) loss_28\NN\13252973|as|mitochondrial|complex|i (l_nummod) i_27\CD\14622893|
T7_T31 NONE l-boaa_9\NN\1740| (r_compound) toxicity_10\NN\13576101|to|l-boaa (r_nmod) vulnerable_7\JJ\1740|mice|toxicity|evidenced (r_ccomp) renders_4\VBZ\120316|vulnerable (r_conj) downregulates_1\VBZ\1740|ovariectomy|glutaredoxin|and|renders|. (l_dobj) glutaredoxin_2\NN\1740|
T7_T32 CPR:3 l-boaa_9\NN\1740| (r_compound) toxicity_10\NN\13576101|to|l-boaa (r_nmod) vulnerable_7\JJ\1740|mice|toxicity|evidenced (l_advcl) evidenced_12\VBN\1015244|as|activation (l_nmod) activation_14\NN\13561719|by|ap1|,|loss|indicating (l_nmod) ap1_16\NN\1740|of
T7_T33 CPR:3 l-boaa_9\NN\1740| (r_compound) toxicity_10\NN\13576101|to|l-boaa (r_nmod) vulnerable_7\JJ\1740|mice|toxicity|evidenced (l_advcl) evidenced_12\VBN\1015244|as|activation (l_nmod) activation_14\NN\13561719|by|ap1|,|loss|indicating (l_conj) loss_18\NN\13252973|gsh|and|activity (l_conj) activity_24\NN\30358|i (l_compound) i_23\CD\14622893|complex
T7_T34 NONE l-boaa_9\NN\1740| (r_compound) toxicity_10\NN\13576101|to|l-boaa (r_nmod) vulnerable_7\JJ\1740|mice|toxicity|evidenced (l_advcl) evidenced_12\VBN\1015244|as|activation (l_nmod) activation_14\NN\13561719|by|ap1|,|loss|indicating (l_acl) indicating_25\VBG\952524|role (l_dobj) role_28\NN\719494|the|important|glutaredoxin|neuroprotection (l_nmod) glutaredoxin_30\NN\1740|of
T8_T31 NONE gsh_20\NN\1740|of (r_nmod) loss_18\NN\13252973|gsh|and|activity (r_conj) activation_14\NN\13561719|by|ap1|,|loss|indicating (r_nmod) evidenced_12\VBN\1015244|as|activation (r_advcl) vulnerable_7\JJ\1740|mice|toxicity|evidenced (r_ccomp) renders_4\VBZ\120316|vulnerable (r_conj) downregulates_1\VBZ\1740|ovariectomy|glutaredoxin|and|renders|. (l_dobj) glutaredoxin_2\NN\1740|
T8_T32 NONE gsh_20\NN\1740|of (r_nmod) loss_18\NN\13252973|gsh|and|activity (r_conj) activation_14\NN\13561719|by|ap1|,|loss|indicating (l_nmod) ap1_16\NN\1740|of
T8_T33 NONE gsh_20\NN\1740|of (r_nmod) loss_18\NN\13252973|gsh|and|activity (l_conj) activity_24\NN\30358|i (l_compound) i_23\CD\14622893|complex
T8_T34 NONE gsh_20\NN\1740|of (r_nmod) loss_18\NN\13252973|gsh|and|activity (r_conj) activation_14\NN\13561719|by|ap1|,|loss|indicating (l_acl) indicating_25\VBG\952524|role (l_dobj) role_28\NN\719494|the|important|glutaredoxin|neuroprotection (l_nmod) glutaredoxin_30\NN\1740|of
T9_T35 CPR:3 estrogen_0\NN\14745635| (r_nsubj) protects_1\VBZ\1127795|estrogen|dysfunction|maintaining|. (l_advcl) maintaining_9\VBG\2202928|by|status|expression (l_nmod) expression_16\NN\4679549|through|higher|constitutive|glutaredoxin|cns (l_nmod) glutaredoxin_18\NN\1740|of
15049511
T7_T22 NONE monoamine_4\NN\14739004| (r_compound) tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (r_nmod) effects_1\NNS\13245626|inhibitory|tranylcypromine|enzymes|. (l_nmod) enzymes_12\NNS\14723628|on|the|cytochrome|p450|cyp2c19 (l_dep) cyp2c19_13\NN\1740|,|cyp2c9|,|and|cyp2d6
T7_T23 NONE monoamine_4\NN\14739004| (r_compound) tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (r_nmod) effects_1\NNS\13245626|inhibitory|tranylcypromine|enzymes|. (l_nmod) enzymes_12\NNS\14723628|on|the|cytochrome|p450|cyp2c19 (l_dep) cyp2c19_13\NN\1740|,|cyp2c9|,|and|cyp2d6 (l_conj) cyp2c9_15\NN\1740|
T7_T24 NONE monoamine_4\NN\14739004| (r_compound) tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (r_nmod) effects_1\NNS\13245626|inhibitory|tranylcypromine|enzymes|. (l_nmod) enzymes_12\NNS\14723628|on|the|cytochrome|p450|cyp2c19 (l_dep) cyp2c19_13\NN\1740|,|cyp2c9|,|and|cyp2d6 (l_conj) cyp2d6_18\NN\1740|
T7_T25 NONE monoamine_4\NN\14739004| (r_compound) tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (l_compound) oxidase_5\NN\14732946|
T7_T26 NONE monoamine_4\NN\14739004| (r_compound) tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (r_nmod) effects_1\NNS\13245626|inhibitory|tranylcypromine|enzymes|. (l_nmod) enzymes_12\NNS\14723628|on|the|cytochrome|p450|cyp2c19 (l_compound) p450_11\NN\1740|
T8_T22 NONE tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (r_nmod) effects_1\NNS\13245626|inhibitory|tranylcypromine|enzymes|. (l_nmod) enzymes_12\NNS\14723628|on|the|cytochrome|p450|cyp2c19 (l_dep) cyp2c19_13\NN\1740|,|cyp2c9|,|and|cyp2d6
T8_T23 NONE tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (r_nmod) effects_1\NNS\13245626|inhibitory|tranylcypromine|enzymes|. (l_nmod) enzymes_12\NNS\14723628|on|the|cytochrome|p450|cyp2c19 (l_dep) cyp2c19_13\NN\1740|,|cyp2c9|,|and|cyp2d6 (l_conj) cyp2c9_15\NN\1740|
T8_T24 NONE tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (r_nmod) effects_1\NNS\13245626|inhibitory|tranylcypromine|enzymes|. (l_nmod) enzymes_12\NNS\14723628|on|the|cytochrome|p450|cyp2c19 (l_dep) cyp2c19_13\NN\1740|,|cyp2c9|,|and|cyp2d6 (l_conj) cyp2d6_18\NN\1740|
T8_T25 CPR:4 tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (l_compound) oxidase_5\NN\14732946|
T8_T26 NONE tranylcypromine_7\NN\3783017|of|the|monoamine|oxidase|inhibitor (r_nmod) effects_1\NNS\13245626|inhibitory|tranylcypromine|enzymes|. (l_nmod) enzymes_12\NNS\14723628|on|the|cytochrome|p450|cyp2c19 (l_compound) p450_11\NN\1740|
T2_T10 NONE tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_compound) p450_22\NN\1740|cyp
T2_T11 NONE tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_compound) p450_22\NN\1740|cyp (l_appos) cyp_24\NN\1740|(
T2_T12 NONE tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_appos) cyp2c9_29\NN\1740|namely|,|cyp2c19|,|and|cyp2d6
T2_T13 NONE tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_appos) cyp2c9_29\NN\1740|namely|,|cyp2c19|,|and|cyp2d6 (l_conj) cyp2c19_31\NN\1740|
T2_T14 NONE tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_appos) cyp2c9_29\NN\1740|namely|,|cyp2c19|,|and|cyp2d6 (l_conj) cyp2d6_34\NN\1740|
T2_T20 CPR:4 tranylcypromine_6\NN\3783017|of|,|inhibitor|, (l_appos) inhibitor_11\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_14\NN\14732946|of|monoamine|mao
T2_T9 CPR:4 tranylcypromine_6\NN\3783017|of|,|inhibitor|, (l_appos) inhibitor_11\NN\20090|a|nonselective|irreversible|oxidase (l_nmod) oxidase_14\NN\14732946|of|monoamine|mao (l_appos) mao_16\NN\14732946|(|)
T5_T10 NONE monoamine_13\NN\14739004| (r_compound) oxidase_14\NN\14732946|of|monoamine|mao (r_nmod) inhibitor_11\NN\20090|a|nonselective|irreversible|oxidase (r_appos) tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_compound) p450_22\NN\1740|cyp
T5_T11 NONE monoamine_13\NN\14739004| (r_compound) oxidase_14\NN\14732946|of|monoamine|mao (r_nmod) inhibitor_11\NN\20090|a|nonselective|irreversible|oxidase (r_appos) tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_compound) p450_22\NN\1740|cyp (l_appos) cyp_24\NN\1740|(
T5_T12 NONE monoamine_13\NN\14739004| (r_compound) oxidase_14\NN\14732946|of|monoamine|mao (r_nmod) inhibitor_11\NN\20090|a|nonselective|irreversible|oxidase (r_appos) tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_appos) cyp2c9_29\NN\1740|namely|,|cyp2c19|,|and|cyp2d6
T5_T13 NONE monoamine_13\NN\14739004| (r_compound) oxidase_14\NN\14732946|of|monoamine|mao (r_nmod) inhibitor_11\NN\20090|a|nonselective|irreversible|oxidase (r_appos) tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_appos) cyp2c9_29\NN\1740|namely|,|cyp2c19|,|and|cyp2d6 (l_conj) cyp2c19_31\NN\1740|
T5_T14 NONE monoamine_13\NN\14739004| (r_compound) oxidase_14\NN\14732946|of|monoamine|mao (r_nmod) inhibitor_11\NN\20090|a|nonselective|irreversible|oxidase (r_appos) tranylcypromine_6\NN\3783017|of|,|inhibitor|, (r_nmod) effects_4\NNS\13245626|the|inhibitory|tranylcypromine|enzymes (l_nmod) enzymes_26\NNS\14723628|on|three|cytochrome|p450|)|,|cyp2c9|, (l_appos) cyp2c9_29\NN\1740|namely|,|cyp2c19|,|and|cyp2d6 (l_conj) cyp2d6_34\NN\1740|
T5_T20 NONE monoamine_13\NN\14739004| (r_compound) oxidase_14\NN\14732946|of|monoamine|mao
T5_T9 NONE monoamine_13\NN\14739004| (r_compound) oxidase_14\NN\14732946|of|monoamine|mao (l_appos) mao_16\NN\14732946|(|)
T3_T16 NONE tranylcypromine_13\NN\3783017| (r_compound) concentrations_14\NNS\4916342|of|tranylcypromine (r_nmod) range_11\NN\5123416|with|a|concentrations (r_nmod) coincubated_8\VBN\1740|3|range|was|range|presence|c|period|. (l_nmod) presence_17\NN\13954253|in|the|each (l_nmod) each_19\DT\1740|of|enzymes (l_nmod) enzymes_23\NNS\14723628|of|the|cyp (l_compound) cyp_22\NN\1740|
T4_T17 CPR:4 tranylcypromine_6\NN\3783017| (r_nsubj) inhibitor_10\NN\20090|that|tranylcypromine|is|a|competitive|cyp2c19|and|inhibitor (l_nmod) cyp2c19_12\NN\1740|of|=|and|cyp2d6
T4_T18 CPR:4 tranylcypromine_6\NN\3783017| (r_nsubj) inhibitor_10\NN\20090|that|tranylcypromine|is|a|competitive|cyp2c19|and|inhibitor (l_nmod) cyp2c19_12\NN\1740|of|=|and|cyp2d6 (l_conj) cyp2d6_20\NN\1740|=
T4_T19 CPR:4 tranylcypromine_6\NN\3783017| (r_nsubj) inhibitor_10\NN\20090|that|tranylcypromine|is|a|competitive|cyp2c19|and|inhibitor (l_conj) inhibitor_30\NN\20090|a|noncompetitive|cyp2c9|= (l_nmod) cyp2c9_32\NN\1740|of
T1_T21 NONE tranylcypromine_28\NN\3783017| (r_nsubjpass) coadministered_30\VBN\1740|particularly|when|tranylcypromine|is|drugs (r_advcl) occur_24\VB\2623529|however|,|situations|,|interactions|might|,|coadministered|. (l_nmod) situations_4\NNS\24720|in|certain|therapy (l_nmod) therapy_10\NN\657604|such|dose|tranylcypromine|,|or|metabolizers (l_conj) metabolizers_15\NNS\1740|in|poor|substrates (l_nmod) substrates_18\NNS\19613|of|cyp2c19 (l_compound) cyp2c19_17\NN\1740|
T6_T21 NONE tranylcypromine_9\NN\3783017| (r_compound) therapy_10\NN\657604|such|dose|tranylcypromine|,|or|metabolizers (l_conj) metabolizers_15\NNS\1740|in|poor|substrates (l_nmod) substrates_18\NNS\19613|of|cyp2c19 (l_compound) cyp2c19_17\NN\1740|
23625813
23536314
T7_T10 CPR:4 cilostazol_7\NN\1740| (r_compound) treatment_8\NN\654885|cilostazol (r_nsubj) reduced_9\VBD\441445|that|treatment|expression|retinas (l_dobj) expression_13\NN\4679549|gfap (l_compound) gfap_10\NN\1740|and|vegf (l_conj) vegf_12\NN\1740|
T7_T9 CPR:4 cilostazol_7\NN\1740| (r_compound) treatment_8\NN\654885|cilostazol (r_nsubj) reduced_9\VBD\441445|that|treatment|expression|retinas (l_dobj) expression_13\NN\4679549|gfap (l_compound) gfap_10\NN\1740|and|vegf
23192339
T1_T13 CPR:3 glucose-stimulated_2\JJ\1740| (r_amod) secretion_4\NN\13526110|glucose-stimulated|insulin (l_compound) insulin_3\NN\5407119|
T1_T9 NONE glucose-stimulated_2\JJ\1740| (r_amod) secretion_4\NN\13526110|glucose-stimulated|insulin (r_dobj) potentiates_1\VBZ\229605|gip|secretion|and|induces|. (l_nsubj) gip_0\NN\1740|
17627474
T19_T32 NONE prolyl-4-hydroxylase_4\NN\1740| (r_compound) domain_5\NN\13934596|prolyl-4-hydroxylase|phd (r_compound) proteins_11\NNS\14944888|of|the|domain|oxygen|sensor
T20_T32 NONE oxygen_9\NN\14622893| (r_compound) proteins_11\NNS\14944888|of|the|domain|oxygen|sensor
T12_T24 NONE prolyl-4-hydroxylase_5\NN\1740| (r_compound) domain_6\NN\13934596|prolyl-4-hydroxylase|phd (r_compound) proteins_10\NNS\14944888|by|domain|hydroxylate
T12_T29 NONE prolyl-4-hydroxylase_5\NN\1740| (r_compound) domain_6\NN\13934596|prolyl-4-hydroxylase|phd (r_compound) proteins_10\NNS\14944888|by|domain|hydroxylate (l_acl:relcl) hydroxylate_12\VBP\1740|that|subunits (l_dobj) subunits_19\NNS\13604718|hypoxia-inducible|factor|(|hif|)|alpha (l_compound) alpha_18\NN\6828818|
T14_T24 NONE hydroxylate_12\VBP\1740|that|subunits (r_acl:relcl) proteins_10\NNS\14944888|by|domain|hydroxylate
T14_T29 NONE hydroxylate_12\VBP\1740|that|subunits (l_dobj) subunits_19\NNS\13604718|hypoxia-inducible|factor|(|hif|)|alpha (l_compound) alpha_18\NN\6828818|
T17_T24 NONE oxygen_1\NN\14622893|cellular (r_nsubjpass) sensed_3\VBN\2106506|oxygen|is|proteins|. (l_nmod) proteins_10\NNS\14944888|by|domain|hydroxylate
T17_T29 NONE oxygen_1\NN\14622893|cellular (r_nsubjpass) sensed_3\VBN\2106506|oxygen|is|proteins|. (l_nmod) proteins_10\NNS\14944888|by|domain|hydroxylate (l_acl:relcl) hydroxylate_12\VBP\1740|that|subunits (l_dobj) subunits_19\NNS\13604718|hypoxia-inducible|factor|(|hif|)|alpha (l_compound) alpha_18\NN\6828818|
T13_T28 NONE oxygen_4\NN\14622893| (r_compound) sensors_5\NNS\3183080|the|phd|oxygen|themselves (l_compound) phd_3\NN\6703953|
T15_T30 NONE iron_19\NN\14625458|of|ferrous|,|intermediates|,|metals|,|and|c (r_nmod) influence_16\NN\5190804|the|iron|activity (l_nmod) activity_36\NN\30358|on|the|phd1 (l_nmod) phd1_39\NN\1740|of|purified|to|3 (l_dep) 3_41\CD\13741022|
T16_T30 NONE c_30\NN\13714184|vitamin|and|antioxidants (r_conj) iron_19\NN\14625458|of|ferrous|,|intermediates|,|metals|,|and|c (r_nmod) influence_16\NN\5190804|the|iron|activity (l_nmod) activity_36\NN\30358|on|the|phd1 (l_nmod) phd1_39\NN\1740|of|purified|to|3 (l_dep) 3_41\CD\13741022|
T18_T31 NONE oxygen_6\NN\14622893| (r_compound) availability_7\NN\4718563|on|oxygen (r_nmod) depends_2\VBZ\2604760|activity|only|availability|but|regulated|,|suggesting|. (l_nsubj) activity_1\NN\30358|phd (l_compound) phd_0\NN\6703953|
T1_T31 NONE iron_13\NN\14625458|by|,|c|,|and|intermediates (r_nmod) regulated_11\VBN\296178|is|also|iron (r_conj) depends_2\VBZ\2604760|activity|only|availability|but|regulated|,|suggesting|. (l_nsubj) activity_1\NN\30358|phd (l_compound) phd_0\NN\6703953|
T2_T31 NONE c_16\NN\13714184|vitamin (r_conj) iron_13\NN\14625458|by|,|c|,|and|intermediates (r_nmod) regulated_11\VBN\296178|is|also|iron (r_conj) depends_2\VBZ\2604760|activity|only|availability|but|regulated|,|suggesting|. (l_nsubj) activity_1\NN\30358|phd (l_compound) phd_0\NN\6703953|
T10_T21 NONE acid_18\NN\14818238|gallic|or|gallate (r_nsubj) inhibited_23\VBD\2510337|acid|efficiently|activity|,|demonstrating (r_conj) had_12\VBD\2108377|essential|,|n-acetyl-l-cysteine|effect|,|and|inhibited|. (l_advcl) essential_4\JJ\1740|while|c|is|activity|vitro (l_nmod) activity_7\NN\30358|for|phd (l_compound) phd_6\NN\6703953|
T10_T22 CPR:4 acid_18\NN\14818238|gallic|or|gallate (r_nsubj) inhibited_23\VBD\2510337|acid|efficiently|activity|,|demonstrating (l_dobj) activity_25\NN\30358|the|phds (l_nmod) phds_29\NNS\6703953|of|all|three
T11_T21 NONE gallate_21\NN\1740|n-propyl (r_conj) acid_18\NN\14818238|gallic|or|gallate (r_nsubj) inhibited_23\VBD\2510337|acid|efficiently|activity|,|demonstrating (r_conj) had_12\VBD\2108377|essential|,|n-acetyl-l-cysteine|effect|,|and|inhibited|. (l_advcl) essential_4\JJ\1740|while|c|is|activity|vitro (l_nmod) activity_7\NN\30358|for|phd (l_compound) phd_6\NN\6703953|
T11_T22 CPR:4 gallate_21\NN\1740|n-propyl (r_conj) acid_18\NN\14818238|gallic|or|gallate (r_nsubj) inhibited_23\VBD\2510337|acid|efficiently|activity|,|demonstrating (l_dobj) activity_25\NN\30358|the|phds (l_nmod) phds_29\NNS\6703953|of|all|three
T8_T21 NONE c_2\NN\13714184|vitamin (r_nsubj) essential_4\JJ\1740|while|c|is|activity|vitro (l_nmod) activity_7\NN\30358|for|phd (l_compound) phd_6\NN\6703953|
T8_T22 NONE c_2\NN\13714184|vitamin (r_nsubj) essential_4\JJ\1740|while|c|is|activity|vitro (r_advcl) had_12\VBD\2108377|essential|,|n-acetyl-l-cysteine|effect|,|and|inhibited|. (l_conj) inhibited_23\VBD\2510337|acid|efficiently|activity|,|demonstrating (l_dobj) activity_25\NN\30358|the|phds (l_nmod) phds_29\NNS\6703953|of|all|three
T9_T21 NONE n-acetyl-l-cysteine_11\NN\1740| (r_nsubj) had_12\VBD\2108377|essential|,|n-acetyl-l-cysteine|effect|,|and|inhibited|. (l_advcl) essential_4\JJ\1740|while|c|is|activity|vitro (l_nmod) activity_7\NN\30358|for|phd (l_compound) phd_6\NN\6703953|
T9_T22 NONE n-acetyl-l-cysteine_11\NN\1740| (r_nsubj) had_12\VBD\2108377|essential|,|n-acetyl-l-cysteine|effect|,|and|inhibited|. (l_conj) inhibited_23\VBD\2510337|acid|efficiently|activity|,|demonstrating (l_dobj) activity_25\NN\30358|the|phds (l_nmod) phds_29\NNS\6703953|of|all|three
23047912
T16_T21 CPR:3 l-bmaa_0\NN\1740| (r_nsubj) induced_1\VBD\1627355|l-bmaa|stress|and|enhanced|. (l_conj) enhanced_5\VBD\227165|cleavage|cells|concentrations (l_dobj) cleavage_8\NN\24720|caspase|12 (l_nummod) 12_7\CD\13745420|
T15_T17 CPR:3 l-bmaa_3\NN\1740| (r_compound) concentrations_4\NNS\4916342|low|l-bmaa|h|) (r_nsubj) increased_12\VBD\169651|nevertheless|,|concentrations|ubiquitination|and|phosphorylation|. (l_dobj) ubiquitination_14\NN\1740|protein|,|proteasomal|,|expression|, (l_conj) proteasomal_17\JJ\1740|20s|and|caspase|activity
T15_T18 CPR:3 l-bmaa_3\NN\1740| (r_compound) concentrations_4\NNS\4916342|low|l-bmaa|h|) (r_nsubj) increased_12\VBD\169651|nevertheless|,|concentrations|ubiquitination|and|phosphorylation|. (l_dobj) ubiquitination_14\NN\1740|protein|,|proteasomal|,|expression|, (l_conj) proteasomal_17\JJ\1740|20s|and|caspase|activity (l_dep) activity_21\NN\30358|12 (l_nummod) 12_20\CD\13745420|
T15_T19 CPR:3 l-bmaa_3\NN\1740| (r_compound) concentrations_4\NNS\4916342|low|l-bmaa|h|) (r_nsubj) increased_12\VBD\169651|nevertheless|,|concentrations|ubiquitination|and|phosphorylation|. (l_dobj) ubiquitination_14\NN\1740|protein|,|proteasomal|,|expression|, (l_appos) expression_23\NN\4679549|chop (l_nmod) chop_33\NN\11419404|of|the|reticulum|er|stress|marker
T15_T20 CPR:3 l-bmaa_3\NN\1740| (r_compound) concentrations_4\NNS\4916342|low|l-bmaa|h|) (r_nsubj) increased_12\VBD\169651|nevertheless|,|concentrations|ubiquitination|and|phosphorylation|. (l_conj) phosphorylation_37\NN\1740|enhanced|elf2α|cells (l_nmod) elf2α_39\NN\1740|of
23042953
T10_T15 NONE acids_2\NNS\14818238|hydrophobic|amino|region (r_nsubj) essential_14\JJ\1740|acids|are|promoting|. (l_advcl) promoting_16\VBG\2556126|for|efflux (l_dobj) efflux_18\NN\13482330|cholesterol|transporter (l_nmod) transporter_22\NN\4490091|by|the|abca1 (l_compound) abca1_21\NN\1740|
T10_T16 NONE acids_2\NNS\14818238|hydrophobic|amino|region (l_nmod) region_6\NN\27167|in|the|hinge|peptide (l_nmod) peptide_12\NN\14724264|of|the|5a|apolipoprotein|mimetic (l_compound) apolipoprotein_10\NN\1740|
T9_T15 CPR:9 cholesterol_17\NN\15058310| (r_compound) efflux_18\NN\13482330|cholesterol|transporter (l_nmod) transporter_22\NN\4490091|by|the|abca1 (l_compound) abca1_21\NN\1740|
T9_T16 NONE cholesterol_17\NN\15058310| (r_compound) efflux_18\NN\13482330|cholesterol|transporter (r_dobj) promoting_16\VBG\2556126|for|efflux (r_advcl) essential_14\JJ\1740|acids|are|promoting|. (l_nsubj) acids_2\NNS\14818238|hydrophobic|amino|region (l_nmod) region_6\NN\27167|in|the|hinge|peptide (l_nmod) peptide_12\NN\14724264|of|the|5a|apolipoprotein|mimetic (l_compound) apolipoprotein_10\NN\1740|
T5_T12 CPR:9 cholesterol_7\NN\15058310| (r_dobj) effluxes_6\VBZ\1740|5a|cholesterol|cells|and|reduces|. (l_nsubj) 5a_5\NN\1740|peptide
T7_T14 CPR:9 cholesterol_26\NN\15058310| (r_dobj) effluxing_25\VBG\1740|in|cholesterol|transporter (l_nmod) transporter_30\NN\4490091|by|the|abca1 (l_compound) abca1_29\NN\1740|
T3_T11 NONE cholesterol_38\NN\15058310| (r_compound) process_40\NN\407535|during|the|cholesterol|efflux (r_nmod) created_31\VBN\2367363|transporter|process (r_acl) microdomain_30\NN\1740|in|the|lipid|created (r_nmod) phospholipids_26\NNS\14938907|with|microdomain (r_nmod) interaction_19\NN\37396|into|the|residues|apolipoproteins|phospholipids (r_nmod) insights_16\NNS\5710020|new|interaction (r_dobj) provide_14\VBP\2199590|insights (r_conj) provide_2\VBP\2199590|results|rationale|and|provide|. (l_dobj) rationale_4\NN\5793000|a|design (l_nmod) design_7\NN\927261|for|future|peptides (l_nmod) peptides_12\NNS\14724264|of|therapeutic|apolipoprotein|mimetic (l_compound) apolipoprotein_10\NN\1740|
T3_T13 CPR:9 cholesterol_38\NN\15058310| (r_compound) process_40\NN\407535|during|the|cholesterol|efflux (r_nmod) created_31\VBN\2367363|transporter|process (l_nmod) transporter_35\NN\4490091|by|the|abca1 (l_compound) abca1_34\NN\1740|
23411280
T11_T18 NONE histidine_9\NN\14605787| (r_compound) decarboxylase_10\NN\14732946|on|recombinant|human|histidine
T10_T12 CPR:9 amine_13\NN\14951377|a|bioactive (r_appos) histamine_9\NN\14739004|of|,|amine (r_nmod) formation_7\NN\7938773|the|histamine (r_dobj) catalyses_5\VBZ\146138|decarboxylase|formation|. (l_nsubj) decarboxylase_1\NN\14732946|histidine|hdc
T10_T15 CPR:9 amine_13\NN\14951377|a|bioactive (r_appos) histamine_9\NN\14739004|of|,|amine (r_nmod) formation_7\NN\7938773|the|histamine (r_dobj) catalyses_5\VBZ\146138|decarboxylase|formation|. (l_nsubj) decarboxylase_1\NN\14732946|histidine|hdc (l_appos) hdc_3\NN\1740|(|)
T1_T12 NONE histidine_0\NN\14605787| (r_compound) decarboxylase_1\NN\14732946|histidine|hdc
T1_T15 NONE histidine_0\NN\14605787| (r_compound) decarboxylase_1\NN\14732946|histidine|hdc (l_appos) hdc_3\NN\1740|(|)
T8_T12 CPR:9 histamine_9\NN\14739004|of|,|amine (r_nmod) formation_7\NN\7938773|the|histamine (r_dobj) catalyses_5\VBZ\146138|decarboxylase|formation|. (l_nsubj) decarboxylase_1\NN\14732946|histidine|hdc
T8_T15 CPR:9 histamine_9\NN\14739004|of|,|amine (r_nmod) formation_7\NN\7938773|the|histamine (r_dobj) catalyses_5\VBZ\146138|decarboxylase|formation|. (l_nsubj) decarboxylase_1\NN\14732946|histidine|hdc (l_appos) hdc_3\NN\1740|(|)
T2_T13 NONE histamine-mediated_9\JJ\1740| (r_amod) symptoms_10\NNS\5823932|histamine-mediated|,|allergies (r_dobj) treating_8\VBG\2376958|for|symptoms (r_advcl) beneficial_6\JJ\1740|agents|are|treating|. (l_nsubj) agents_0\NNS\7347|control (l_acl:relcl) control_2\VBP\2422663|that|activity (l_dobj) activity_4\NN\30358|hdc (l_compound) hdc_3\NN\1740|
T3_T14 CPR:4 acetate_9\NN\15010703| (r_compound) extract_10\NN\14589223|from|the|ethyl|acetate|petal|,|called (r_nmod) inhibitors_3\NNS\20090|for|hdc|extract (l_nmod) hdc_5\NN\1740|of
16769115
T2_T6 NONE acid_16\NN\14818238| (r_compound) carboxylase_18\NN\1740|in|glutamic|acid|de|67|gad67|,|arbors|cortex (l_nummod) 67_19\CD\1740|
T2_T7 NONE acid_16\NN\14818238| (r_compound) carboxylase_18\NN\1740|in|glutamic|acid|de|67|gad67|,|arbors|cortex (l_appos) gad67_21\NN\1740|(|)
T1_T11 CPR:3 methionine_13\NN\14605787|with (r_nmod) treating_10\VBG\2376958|by|mice|methionine (r_advcl) induced_8\VBN\1627355|hypermethlyation|can|be|treating|,|and|display (l_nsubjpass) hypermethlyation_0\NN\1740|promoters (l_nmod) promoters_5\NNS\9773962|reln
23615471
T18_T39 CPR:4 ester_3\NN\14727670|caffeic|acid|phenethyl (r_nsubj) suppresses_4\VBZ\2510337|ester|proliferation|inhibition|. (l_nmod) inhibition_15\NN\1068773|via|signaling (l_nmod) signaling_18\NN\33020|of|akt (l_compound) akt_17\NN\1740|
T10_T19 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T10_T20 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T10_T21 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T10_T22 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T10_T23 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser473_16\NN\1740|phospho-akt (l_compound) phospho-akt_15\NN\1740|
T10_T24 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr_19\NN\1740|phospho-akt|308 (l_compound) phospho-akt_18\NN\1740|
T10_T25 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T10_T26 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T10_T27 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T10_T28 NONE phospho-foxo1_28\NN\1740|
T10_T29 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) thr32_32\NN\1740|phospho-foxo3a (l_compound) phospho-foxo3a_31\NN\1740|
T10_T30 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T10_T31 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) ser536_37\NN\1740|phospho-nf-κb (l_compound) phospho-nf-κb_36\NN\1740|
T10_T32 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T10_T33 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser807/811_42\NN\1740|phospho-rb (l_compound) phospho-rb_41\NN\1740|
T10_T34 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T10_T35 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T10_T36 NONE phospho-foxo1_28\NN\1740| (r_compound) thr24_29\NN\1740|phospho-foxo1 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (r_nmod) abundance_5\NN\5108740|protein|akt (r_dobj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T11_T19 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T11_T20 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T11_T21 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T11_T22 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T11_T23 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser473_16\NN\1740|phospho-akt (l_compound) phospho-akt_15\NN\1740|
T11_T24 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr_19\NN\1740|phospho-akt|308 (l_compound) phospho-akt_18\NN\1740|
T11_T25 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T11_T26 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T11_T27 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T11_T28 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr24_29\NN\1740|phospho-foxo1 (l_compound) phospho-foxo1_28\NN\1740|
T11_T29 NONE phospho-foxo3a_31\NN\1740|
T11_T30 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T11_T31 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) ser536_37\NN\1740|phospho-nf-κb (l_compound) phospho-nf-κb_36\NN\1740|
T11_T32 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T11_T33 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser807/811_42\NN\1740|phospho-rb (l_compound) phospho-rb_41\NN\1740|
T11_T34 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T11_T35 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T11_T36 NONE phospho-foxo3a_31\NN\1740| (r_compound) thr32_32\NN\1740|phospho-foxo3a (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (r_nmod) abundance_5\NN\5108740|protein|akt (r_dobj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T12_T19 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T12_T20 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T12_T21 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T12_T22 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T12_T23 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser473_16\NN\1740|phospho-akt (l_compound) phospho-akt_15\NN\1740|
T12_T24 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr_19\NN\1740|phospho-akt|308 (l_compound) phospho-akt_18\NN\1740|
T12_T25 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T12_T26 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T12_T27 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T12_T28 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr24_29\NN\1740|phospho-foxo1 (l_compound) phospho-foxo1_28\NN\1740|
T12_T29 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) thr32_32\NN\1740|phospho-foxo3a (l_compound) phospho-foxo3a_31\NN\1740|
T12_T30 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T12_T31 NONE phospho-nf-κb_36\NN\1740|
T12_T32 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T12_T33 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser807/811_42\NN\1740|phospho-rb (l_compound) phospho-rb_41\NN\1740|
T12_T34 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T12_T35 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T12_T36 NONE phospho-nf-κb_36\NN\1740| (r_compound) ser536_37\NN\1740|phospho-nf-κb (r_conj) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (r_nmod) abundance_5\NN\5108740|protein|akt (r_dobj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T13_T19 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T13_T20 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T13_T21 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T13_T22 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T13_T23 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser473_16\NN\1740|phospho-akt (l_compound) phospho-akt_15\NN\1740|
T13_T24 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr_19\NN\1740|phospho-akt|308 (l_compound) phospho-akt_18\NN\1740|
T13_T25 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T13_T26 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T13_T27 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T13_T28 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr24_29\NN\1740|phospho-foxo1 (l_compound) phospho-foxo1_28\NN\1740|
T13_T29 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) thr32_32\NN\1740|phospho-foxo3a (l_compound) phospho-foxo3a_31\NN\1740|
T13_T30 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T13_T31 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) ser536_37\NN\1740|phospho-nf-κb (l_compound) phospho-nf-κb_36\NN\1740|
T13_T32 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T13_T33 NONE phospho-rb_41\NN\1740|
T13_T34 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T13_T35 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T13_T36 NONE phospho-rb_41\NN\1740| (r_compound) ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (r_nmod) abundance_5\NN\5108740|protein|akt (r_dobj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T14_T19 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T14_T20 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T14_T21 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T14_T22 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T14_T23 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser473_16\NN\1740|phospho-akt (l_compound) phospho-akt_15\NN\1740|
T14_T24 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr_19\NN\1740|phospho-akt|308 (l_compound) phospho-akt_18\NN\1740|
T14_T25 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T14_T26 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T14_T27 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T14_T28 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr24_29\NN\1740|phospho-foxo1 (l_compound) phospho-foxo1_28\NN\1740|
T14_T29 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) thr32_32\NN\1740|phospho-foxo3a (l_compound) phospho-foxo3a_31\NN\1740|
T14_T30 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T14_T31 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) ser536_37\NN\1740|phospho-nf-κb (l_compound) phospho-nf-κb_36\NN\1740|
T14_T32 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T14_T33 NONE ser807/811_42\NN\1740|phospho-rb (l_compound) phospho-rb_41\NN\1740|
T14_T34 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T14_T35 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T14_T36 NONE ser807/811_42\NN\1740|phospho-rb (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (r_nmod) abundance_5\NN\5108740|protein|akt (r_dobj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T6_T19 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T6_T20 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T6_T21 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T6_T22 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T6_T23 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser473_16\NN\1740|phospho-akt (l_compound) phospho-akt_15\NN\1740|
T6_T24 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr_19\NN\1740|phospho-akt|308 (l_compound) phospho-akt_18\NN\1740|
T6_T25 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T6_T26 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T6_T27 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T6_T28 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr24_29\NN\1740|phospho-foxo1 (l_compound) phospho-foxo1_28\NN\1740|
T6_T29 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) thr32_32\NN\1740|phospho-foxo3a (l_compound) phospho-foxo3a_31\NN\1740|
T6_T30 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T6_T31 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) ser536_37\NN\1740|phospho-nf-κb (l_compound) phospho-nf-κb_36\NN\1740|
T6_T32 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T6_T33 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser807/811_42\NN\1740|phospho-rb (l_compound) phospho-rb_41\NN\1740|
T6_T34 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T6_T35 CPR:4 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_dobj) abundance_5\NN\5108740|protein|akt (l_nmod) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T6_T36 CPR:3 cape_2\NN\9334396|with (r_nmod) treatment_0\NN\654885|cape (r_nsubj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T7_T19 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T7_T20 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T7_T21 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T7_T22 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T7_T23 NONE phospho-akt_15\NN\1740|
T7_T24 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr_19\NN\1740|phospho-akt|308 (l_compound) phospho-akt_18\NN\1740|
T7_T25 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T7_T26 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T7_T27 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T7_T28 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr24_29\NN\1740|phospho-foxo1 (l_compound) phospho-foxo1_28\NN\1740|
T7_T29 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) thr32_32\NN\1740|phospho-foxo3a (l_compound) phospho-foxo3a_31\NN\1740|
T7_T30 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T7_T31 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) ser536_37\NN\1740|phospho-nf-κb (l_compound) phospho-nf-κb_36\NN\1740|
T7_T32 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T7_T33 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser807/811_42\NN\1740|phospho-rb (l_compound) phospho-rb_41\NN\1740|
T7_T34 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T7_T35 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T7_T36 NONE phospho-akt_15\NN\1740| (r_compound) ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (r_nmod) abundance_5\NN\5108740|protein|akt (r_dobj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T8_T19 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T8_T20 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T8_T21 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T8_T22 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T8_T23 NONE ser473_16\NN\1740|phospho-akt (l_compound) phospho-akt_15\NN\1740|
T8_T24 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr_19\NN\1740|phospho-akt|308 (l_compound) phospho-akt_18\NN\1740|
T8_T25 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T8_T26 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T8_T27 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T8_T28 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr24_29\NN\1740|phospho-foxo1 (l_compound) phospho-foxo1_28\NN\1740|
T8_T29 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) thr32_32\NN\1740|phospho-foxo3a (l_compound) phospho-foxo3a_31\NN\1740|
T8_T30 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T8_T31 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) ser536_37\NN\1740|phospho-nf-κb (l_compound) phospho-nf-κb_36\NN\1740|
T8_T32 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T8_T33 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser807/811_42\NN\1740|phospho-rb (l_compound) phospho-rb_41\NN\1740|
T8_T34 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T8_T35 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T8_T36 NONE ser473_16\NN\1740|phospho-akt (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (r_nmod) abundance_5\NN\5108740|protein|akt (r_dobj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T9_T19 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1
T9_T20 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt1_9\NN\1740|
T9_T21 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt2_11\NN\1740|
T9_T22 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) akt3_13\NN\1740|
T9_T23 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser473_16\NN\1740|phospho-akt (l_compound) phospho-akt_15\NN\1740|
T9_T24 NONE phospho-akt_18\NN\1740|
T9_T25 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) gsk3β_22\NN\1740|
T9_T26 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo1_24\NN\1740|
T9_T27 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) foxo3a_26\NN\1740|
T9_T28 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) thr24_29\NN\1740|phospho-foxo1 (l_compound) phospho-foxo1_28\NN\1740|
T9_T29 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) thr32_32\NN\1740|phospho-foxo3a (l_compound) phospho-foxo3a_31\NN\1740|
T9_T30 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) nf-κb_34\NN\1740|
T9_T31 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) ser536_37\NN\1740|phospho-nf-κb (l_compound) phospho-nf-κb_36\NN\1740|
T9_T32 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) rb_39\NN\14625458|
T9_T33 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) ser807/811_42\NN\1740|phospho-rb (l_compound) phospho-rb_41\NN\1740|
T9_T34 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_appos) skp2_44\NN\1740|
T9_T35 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (l_conj) d1_48\NN\1740|cyclin
T9_T36 NONE phospho-akt_18\NN\1740| (r_compound) thr_19\NN\1740|phospho-akt|308 (r_appos) akt_7\NN\1740|of|,|akt1|,|akt2|,|akt3|,|ser473|,|thr|,|gsk3β|,|foxo1|,|foxo3a|,|thr24|,|thr32|,|nf-κb|,|ser536|,|rb|,|ser807/811|,|skp2|,|and|d1 (r_nmod) abundance_5\NN\5108740|protein|akt (r_dobj) decreased_3\VBD\169651|treatment|abundance|,|but|increased|. (l_conj) increased_51\VBD\169651|p27kip (l_dobj) p27kip_55\NN\1740|cell|cycle|inhibitor
T15_T37 NONE cape_13\NN\9334396| (r_compound) treatment_14\NN\654885|by|cape (r_nmod) caused_11\VBN\1617192|treatment (r_acl) inhibition_10\NN\1068773|growth|caused (r_dobj) rescued_8\VBD\2551832|overexpression|inhibition|. (l_nsubj) overexpression_0\NN\1740|akt1|cells (l_nmod) akt1_2\NN\1740|of|or|akt2
T15_T38 NONE cape_13\NN\9334396| (r_compound) treatment_14\NN\654885|by|cape (r_nmod) caused_11\VBN\1617192|treatment (r_acl) inhibition_10\NN\1068773|growth|caused (r_dobj) rescued_8\VBD\2551832|overexpression|inhibition|. (l_nsubj) overexpression_0\NN\1740|akt1|cells (l_nmod) akt1_2\NN\1740|of|or|akt2 (l_conj) akt2_4\NN\1740|
14602594
T9_T17 NONE salinomycin_3\NN\1740|of (r_nmod) productivity_1\NN\5147381|increased|salinomycin|mutant (l_nmod) mutant_8\NN\4475|in|the|str(r|)|(|containing|) (l_acl) containing_10\VBG\2632940|mutation (l_dobj) mutation_13\NN\4475|the|k88r|protein (l_compound) k88r_12\NN\1740|
T9_T18 NONE salinomycin_3\NN\1740|of (r_nmod) productivity_1\NN\5147381|increased|salinomycin|mutant (l_nmod) mutant_8\NN\4475|in|the|str(r|)|(|containing|) (l_acl) containing_10\VBG\2632940|mutation (l_dobj) mutation_13\NN\4475|the|k88r|protein (l_nmod) protein_17\NN\14944888|in|the|s12 (l_compound) s12_16\NN\1740|
T2_T10 NONE )_15\-RRB-\1740| (r_punct) +_14\NN\1740|low|mg(2|) (r_compound) concentrations_16\NNS\4916342|in|+ (r_nmod) stability_10\NN\4777852|by|increased|70s|complex|concentrations (r_nmod) characterized_5\VBN\609683|ribosome|was|stability|. (l_nsubjpass) ribosome_3\NN\5445668|the|k88r|mutant (l_compound) k88r_1\NN\1740|
T2_T11 NONE )_15\-RRB-\1740| (r_punct) +_14\NN\1740|low|mg(2|) (r_compound) concentrations_16\NNS\4916342|in|+ (r_nmod) stability_10\NN\4777852|by|increased|70s|complex|concentrations (l_compound) complex_9\NN\5869584|
T3_T12 NONE salinomycin_31\NN\1740| (r_compound) enhancement_33\NN\248977|for|the|remarkable|salinomycin|production|obtained (r_nmod) responsible_27\JJ\1740|that|ability|is|enhancement (l_nsubj) ability_7\NN\4723816|this|aberrant|protein|synthesis|mutant|,|result|, (l_acl:relcl) result_17\NN\34213|which|is|a|stability (l_nmod) stability_20\NN\4777852|of|increased|complex (l_nmod) complex_24\NN\5869584|of|the|70s
14659797
T8_T14 NONE serotonin_0\NN\14807737| (r_compound) mutation_7\NN\4475|serotonin|5-ht(2b|)|receptor|loss|patient|. (l_compound) receptor_3\NN\5225602|
T9_T14 NONE fenfluramine-associated_12\NN\1740| (r_amod) hypertension_15\NN\14057371|with|fenfluramine-associated|primary|pulmonary (r_nmod) patient_10\NN\9898892|in|a|hypertension (r_nmod) mutation_7\NN\4475|serotonin|5-ht(2b|)|receptor|loss|patient|. (l_compound) receptor_3\NN\5225602|
T3_T11 NONE serotonin_5\NN\14807737| (r_compound) receptor_8\NN\5225602|the|serotonin|5-ht(2b|)
T4_T11 NONE oxide_27\NN\14818238| (r_compound) production_28\NN\30358|via|nitric|oxide (r_nmod) mediate_21\VB\761713|to|relaxation|production (r_xcomp) shown_19\VBN\2137132|where|receptor|has|been|mediate (r_acl:relcl) models_13\NNS\5888929|with|other|shown (r_nmod) contrasts_10\VBZ\650353|models (r_conj) incriminates_3\VBZ\930368|model|receptor|but|contrasts|. (l_dobj) receptor_8\NN\5225602|the|serotonin|5-ht(2b|)
T1_T10 NONE serotonin_4\NN\14807737| (r_compound) function_8\NN\13783581|of|serotonin|5-ht(2b|)|receptor (l_compound) receptor_7\NN\5225602|
T2_T10 NONE fenfluramine-associated_12\NN\1740| (r_amod) pph_13\NN\1740|to|fenfluramine-associated|man (r_nmod) predispose_10\VB\680841|loss|may|pph (l_nsubj) loss_2\NN\13252973|function (l_nmod) function_8\NN\13783581|of|serotonin|5-ht(2b|)|receptor (l_compound) receptor_7\NN\5225602|
10697523
T1_T20 NONE thymidylate_0\NN\1740| (r_compound) synthase_1\NN\1740|thymidylate|and|kinase
T1_T22 NONE thymidylate_0\NN\1740| (r_compound) synthase_1\NN\1740|thymidylate|and|kinase (l_conj) kinase_4\NN\14732946|thymidine
T2_T20 CPR:9 nucleotide_18\NN\14850483|pyrimidine (r_compound) synthesis_19\NN\13446390|for|nucleotide (r_nmod) pathways_15\NNS\5483677|in|the|novo|synthesis (r_nmod) involved_8\VBN\2676054|pathways|,|respectively (r_acl) enzymes_7\NNS\14723628|synthase|are|key|involved|. (l_nsubj) synthase_1\NN\1740|thymidylate|and|kinase
T2_T22 CPR:9 nucleotide_18\NN\14850483|pyrimidine (r_compound) synthesis_19\NN\13446390|for|nucleotide (r_nmod) pathways_15\NNS\5483677|in|the|novo|synthesis (r_nmod) involved_8\VBN\2676054|pathways|,|respectively (r_acl) enzymes_7\NNS\14723628|synthase|are|key|involved|. (l_nsubj) synthase_1\NN\1740|thymidylate|and|kinase (l_conj) kinase_4\NN\14732946|thymidine
T5_T20 NONE thymidine_3\NN\14964367| (r_compound) kinase_4\NN\14732946|thymidine (r_conj) synthase_1\NN\1740|thymidylate|and|kinase
T5_T22 NONE thymidine_3\NN\14964367| (r_compound) kinase_4\NN\14732946|thymidine
T3_T21 NONE thymidylate_0\NN\1740| (r_compound) synthase_1\NN\1740|thymidylate
T4_T21 CPR:4 monophosphate_6\NN\1740|by|5-fluorodeoxyuridine (r_nmod) inhibited_3\VBN\2510337|synthase|is|monophosphate|,|forming|. (l_nsubjpass) synthase_1\NN\1740|thymidylate
T6_T21 NONE folate_15\NN\15090742|with|intracellular (r_nmod) forming_8\VBG\1617192|complex|folate (r_advcl) inhibited_3\VBN\2510337|synthase|is|monophosphate|,|forming|. (l_nsubjpass) synthase_1\NN\1740|thymidylate
T12_T23 CPR:4 uft_3\NN\1740|of (r_nmod) administration_1\NN\1133281|thirty-week|uft|leucovorin (r_nsubj) suppressed_9\VBD\2510337|administration|markedly|carcinogenesis|,|resulted|. (l_dep) resulted_17\VBD\2633881|increase (l_nmod) increase_20\NN\13576355|in|the|inhibition|and|decrease (l_nmod) inhibition_24\NN\1068773|of|synthase (l_compound) synthase_23\NN\1740|thymidylate
T12_T24 CPR:4 uft_3\NN\1740|of (r_nmod) administration_1\NN\1133281|thirty-week|uft|leucovorin (r_nsubj) suppressed_9\VBD\2510337|administration|markedly|carcinogenesis|,|resulted|. (l_dep) resulted_17\VBD\2633881|increase (l_nmod) increase_20\NN\13576355|in|the|inhibition|and|decrease (l_conj) decrease_27\NN\7296428|the|activity (l_nmod) activity_31\NN\30358|of|thymidine|kinase|cells (l_compound) kinase_30\NN\14732946|
T13_T23 CPR:4 leucovorin_7\NN\1740|with|or|without (r_nmod) administration_1\NN\1133281|thirty-week|uft|leucovorin (r_nsubj) suppressed_9\VBD\2510337|administration|markedly|carcinogenesis|,|resulted|. (l_dep) resulted_17\VBD\2633881|increase (l_nmod) increase_20\NN\13576355|in|the|inhibition|and|decrease (l_nmod) inhibition_24\NN\1068773|of|synthase (l_compound) synthase_23\NN\1740|thymidylate
T13_T24 CPR:4 leucovorin_7\NN\1740|with|or|without (r_nmod) administration_1\NN\1133281|thirty-week|uft|leucovorin (r_nsubj) suppressed_9\VBD\2510337|administration|markedly|carcinogenesis|,|resulted|. (l_dep) resulted_17\VBD\2633881|increase (l_nmod) increase_20\NN\13576355|in|the|inhibition|and|decrease (l_conj) decrease_27\NN\7296428|the|activity (l_nmod) activity_31\NN\30358|of|thymidine|kinase|cells (l_compound) kinase_30\NN\14732946|
T14_T23 NONE thymidylate_22\NN\1740| (r_compound) synthase_23\NN\1740|thymidylate
T14_T24 NONE thymidylate_22\NN\1740| (r_compound) synthase_23\NN\1740|thymidylate (r_compound) inhibition_24\NN\1068773|of|synthase (r_nmod) increase_20\NN\13576355|in|the|inhibition|and|decrease (l_conj) decrease_27\NN\7296428|the|activity (l_nmod) activity_31\NN\30358|of|thymidine|kinase|cells (l_compound) kinase_30\NN\14732946|
T15_T23 NONE thymidine_29\NN\14964367| (r_compound) activity_31\NN\30358|of|thymidine|kinase|cells (r_nmod) decrease_27\NN\7296428|the|activity (r_conj) increase_20\NN\13576355|in|the|inhibition|and|decrease (l_nmod) inhibition_24\NN\1068773|of|synthase (l_compound) synthase_23\NN\1740|thymidylate
T15_T24 NONE thymidine_29\NN\14964367| (r_compound) activity_31\NN\30358|of|thymidine|kinase|cells (l_compound) kinase_30\NN\14732946|
11799102
T27_T47 NONE ii_1\CD\13741022|
T27_T48 NONE ii_1\CD\13741022| (r_nummod) suppression_2\NN\13489037|angiotensin|ii|humans|aliskiren (l_nmod) aliskiren_11\NN\1740|by|the|inhibitor|spp100 (l_compound) inhibitor_10\NN\20090|active|renin (l_compound) renin_9\NN\14999106|
T28_T47 NONE enalapril_17\NN\2673637|with (r_nmod) comparison_15\NN\635850|suppression|enalapril|. (l_nsubj) suppression_2\NN\13489037|angiotensin|ii|humans|aliskiren (l_nummod) ii_1\CD\13741022|
T28_T48 NONE enalapril_17\NN\2673637|with (r_nmod) comparison_15\NN\635850|suppression|enalapril|. (l_nsubj) suppression_2\NN\13489037|angiotensin|ii|humans|aliskiren (l_nmod) aliskiren_11\NN\1740|by|the|inhibitor|spp100 (l_compound) inhibitor_10\NN\20090|active|renin (l_compound) renin_9\NN\14999106|
T29_T47 CPR:4 aliskiren_11\NN\1740|by|the|inhibitor|spp100 (r_nmod) suppression_2\NN\13489037|angiotensin|ii|humans|aliskiren (l_nummod) ii_1\CD\13741022|
T29_T48 CPR:4 aliskiren_11\NN\1740|by|the|inhibitor|spp100 (l_compound) inhibitor_10\NN\20090|active|renin (l_compound) renin_9\NN\14999106|
T30_T47 CPR:4 spp100_13\NN\1740|(|): (r_appos) aliskiren_11\NN\1740|by|the|inhibitor|spp100 (r_nmod) suppression_2\NN\13489037|angiotensin|ii|humans|aliskiren (l_nummod) ii_1\CD\13741022|
T30_T48 CPR:4 spp100_13\NN\1740|(|): (r_appos) aliskiren_11\NN\1740|by|the|inhibitor|spp100 (l_compound) inhibitor_10\NN\20090|active|renin (l_compound) renin_9\NN\14999106|
T19_T31 NONE ii_10\CD\13741022| (r_nummod) levels_11\NNS\4916342|of|angiotensin|ii (r_nmod) determinant_4\NN\5686481|renin|is|the|main|levels|. (l_nsubj) renin_0\NN\14999106|
T19_T43 NONE ii_10\CD\13741022|
T2_T33 NONE ii_10\CD\13741022|
T2_T35 NONE ii_10\CD\13741022| (r_nummod) levels_11\NNS\4916342|ang|ii (r_dobj) reduce_8\VB\441445|to|levels|inhibition (l_nmod) inhibition_14\NN\1068773|by|direct|renin (l_nmod) renin_16\NN\14999106|of
T16_T42 CPR:4 spp100_9\NN\1740|the|new|active|nonpeptidic|renin|inhibitor (l_compound) renin_7\NN\14999106|
T17_T42 CPR:4 aliskiren_11\NN\1740|(|,|octanamide|) (r_dep) tested_1\VBD\670261|we|spp100|aliskiren|volunteers|diet|using|. (l_dobj) spp100_9\NN\1740|the|new|active|nonpeptidic|renin|inhibitor (l_compound) renin_7\NN\14999106|
T18_T42 CPR:4 octanamide_14\NN\1740|an|concentration|range (r_appos) aliskiren_11\NN\1740|(|,|octanamide|) (r_dep) tested_1\VBD\670261|we|spp100|aliskiren|volunteers|diet|using|. (l_dobj) spp100_9\NN\1740|the|new|active|nonpeptidic|renin|inhibitor (l_compound) renin_7\NN\14999106|
T20_T42 NONE sodium_39\NN\14625458| (r_compound) diet_40\NN\7560652|on|a|constant|mmol/d|sodium (r_nmod) tested_1\VBD\670261|we|spp100|aliskiren|volunteers|diet|using|. (l_dobj) spp100_9\NN\1740|the|new|active|nonpeptidic|renin|inhibitor (l_compound) renin_7\NN\14999106|
T1_T32 NONE ii_39\CD\13741022|
T1_T44 NONE ii_39\CD\13741022| (r_nummod) levels_40\NNS\4916342|in|ang|ii (r_nmod) decreases_36\NNS\7296428|with|maximal|levels|%|days|,|respectively (r_nmod) dosing_33\NN\1740|after|repeated|decreases (r_nmod) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (r_parataxis) was_1\VBD\836236|there|decrease|marked (l_nsubj) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_compound) renin_7\NN\14999106|
T1_T45 NONE ii_39\CD\13741022| (r_nummod) levels_40\NNS\4916342|in|ang|ii (r_nmod) decreases_36\NNS\7296428|with|maximal|levels|%|days|,|respectively (r_nmod) dosing_33\NN\1740|after|repeated|decreases (r_nmod) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (r_parataxis) was_1\VBD\836236|there|decrease|marked (l_nsubj) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_appos) ang_10\NN\8391387|i (l_nummod) i_11\CD\14622893|
T1_T46 NONE ii_39\CD\13741022| (r_nummod) levels_40\NNS\4916342|in|ang|ii (r_nmod) decreases_36\NNS\7296428|with|maximal|levels|%|days|,|respectively (r_nmod) dosing_33\NN\1740|after|repeated|decreases (r_nmod) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (r_parataxis) was_1\VBD\836236|there|decrease|marked (l_nsubj) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_conj) ang_14\NN\8391387|ii (l_nummod) ii_15\CD\13741022|
T24_T32 NONE i_11\CD\14622893| (r_nummod) ang_10\NN\8391387|i (r_appos) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (r_nmod) decrease_4\NN\7296428|a|dose-dependent|activity|doses (r_nsubj) was_1\VBD\836236|there|decrease|marked (l_parataxis) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (l_nmod) dosing_33\NN\1740|after|repeated|decreases (l_nmod) decreases_36\NNS\7296428|with|maximal|levels|%|days|,|respectively (l_nmod) levels_40\NNS\4916342|in|ang|ii (l_nummod) ii_39\CD\13741022|
T24_T44 NONE i_11\CD\14622893| (r_nummod) ang_10\NN\8391387|i (r_appos) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_compound) renin_7\NN\14999106|
T24_T45 NONE i_11\CD\14622893|
T24_T46 NONE i_11\CD\14622893| (r_nummod) ang_10\NN\8391387|i (r_appos) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_conj) ang_14\NN\8391387|ii (l_nummod) ii_15\CD\13741022|
T25_T32 NONE ii_15\CD\13741022| (r_nummod) ang_14\NN\8391387|ii (r_conj) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (r_nmod) decrease_4\NN\7296428|a|dose-dependent|activity|doses (r_nsubj) was_1\VBD\836236|there|decrease|marked (l_parataxis) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (l_nmod) dosing_33\NN\1740|after|repeated|decreases (l_nmod) decreases_36\NNS\7296428|with|maximal|levels|%|days|,|respectively (l_nmod) levels_40\NNS\4916342|in|ang|ii (l_nummod) ii_39\CD\13741022|
T25_T44 NONE ii_15\CD\13741022| (r_nummod) ang_14\NN\8391387|ii (r_conj) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_compound) renin_7\NN\14999106|
T25_T45 NONE ii_15\CD\13741022| (r_nummod) ang_14\NN\8391387|ii (r_conj) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_appos) ang_10\NN\8391387|i (l_nummod) i_11\CD\14622893|
T25_T46 NONE ii_15\CD\13741022|
T26_T32 NONE aliskiren_20\NN\1740|of (r_nmod) doses_18\NNS\3740161|following|single|aliskiren|starting (r_nmod) decrease_4\NN\7296428|a|dose-dependent|activity|doses (r_nsubj) was_1\VBD\836236|there|decrease|marked (l_parataxis) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (l_nmod) dosing_33\NN\1740|after|repeated|decreases (l_nmod) decreases_36\NNS\7296428|with|maximal|levels|%|days|,|respectively (l_nmod) levels_40\NNS\4916342|in|ang|ii (l_nummod) ii_39\CD\13741022|
T26_T44 CPR:4 aliskiren_20\NN\1740|of (r_nmod) doses_18\NNS\3740161|following|single|aliskiren|starting (r_nmod) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_compound) renin_7\NN\14999106|
T26_T45 CPR:4 aliskiren_20\NN\1740|of (r_nmod) doses_18\NNS\3740161|following|single|aliskiren|starting (r_nmod) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_appos) ang_10\NN\8391387|i (l_nummod) i_11\CD\14622893|
T26_T46 CPR:4 aliskiren_20\NN\1740|of (r_nmod) doses_18\NNS\3740161|following|single|aliskiren|starting (r_nmod) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_conj) ang_14\NN\8391387|ii (l_nummod) ii_15\CD\13741022|
T3_T32 CPR:4 aliskiren_60\NN\1740|of (r_nmod) dose_58\NN\3740161|the|highest|aliskiren (r_nsubjpass) compared_62\VBN\644583|when|dose|was|placebo (r_advcl) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (l_nmod) dosing_33\NN\1740|after|repeated|decreases (l_nmod) decreases_36\NNS\7296428|with|maximal|levels|%|days|,|respectively (l_nmod) levels_40\NNS\4916342|in|ang|ii (l_nummod) ii_39\CD\13741022|
T3_T44 NONE aliskiren_60\NN\1740|of (r_nmod) dose_58\NN\3740161|the|highest|aliskiren (r_nsubjpass) compared_62\VBN\644583|when|dose|was|placebo (r_advcl) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (r_parataxis) was_1\VBD\836236|there|decrease|marked (l_nsubj) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_compound) renin_7\NN\14999106|
T3_T45 NONE aliskiren_60\NN\1740|of (r_nmod) dose_58\NN\3740161|the|highest|aliskiren (r_nsubjpass) compared_62\VBN\644583|when|dose|was|placebo (r_advcl) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (r_parataxis) was_1\VBD\836236|there|decrease|marked (l_nsubj) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_appos) ang_10\NN\8391387|i (l_nummod) i_11\CD\14622893|
T3_T46 NONE aliskiren_60\NN\1740|of (r_nmod) dose_58\NN\3740161|the|highest|aliskiren (r_nsubjpass) compared_62\VBN\644583|when|dose|was|placebo (r_advcl) marked_28\JJ\1740|inhibition|was|still|and|significant|dosing|,|compared|. (r_parataxis) was_1\VBD\836236|there|decrease|marked (l_nsubj) decrease_4\NN\7296428|a|dose-dependent|activity|doses (l_nmod) activity_8\NN\30358|in|plasma|renin|,|ang|,|and|ang (l_conj) ang_14\NN\8391387|ii (l_nummod) ii_15\CD\13741022|
T4_T34 CPR:3 aliskiren_19\NN\1740|of (r_nmod) dose_17\NN\3740161|at|the|highest|aliskiren (r_nmod) increased_10\VBN\169651|time|,|renin|was|16-|dose|. (l_nsubjpass) renin_8\NN\14999106|mean|plasma|active
T11_T37 CPR:4 aliskiren_6\NN\1740|the|renin|inhibitor (l_compound) renin_4\NN\14999106|
T11_T38 CPR:4 aliskiren_6\NN\1740|the|renin|inhibitor (r_nsubj) decreases_8\VBZ\169651|conclusion|,|aliskiren|dose-dependently|levels|administration|. (l_dobj) levels_11\NNS\4916342|ang|ii|humans (l_nummod) ii_10\CD\13741022|
T12_T37 NONE ii_10\CD\13741022| (r_nummod) levels_11\NNS\4916342|ang|ii|humans (r_dobj) decreases_8\VBZ\169651|conclusion|,|aliskiren|dose-dependently|levels|administration|. (l_nsubj) aliskiren_6\NN\1740|the|renin|inhibitor (l_compound) renin_4\NN\14999106|
T12_T38 NONE ii_10\CD\13741022|
T14_T39 CPR:4 aliskiren_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|aliskiren|potential|. (l_dobj) potential_3\NN\14481929|the|become (l_acl) become_5\VB\146138|to|inhibitor (l_attr) inhibitor_11\NN\20090|the|first|active|renin|provides (l_compound) renin_10\NN\14999106|
T14_T40 CPR:4 aliskiren_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|aliskiren|potential|. (l_dobj) potential_3\NN\14481929|the|become (l_acl) become_5\VB\146138|to|inhibitor (l_attr) inhibitor_11\NN\20090|the|first|active|renin|provides (l_acl:relcl) provides_13\VBZ\2199590|that|alternative (l_dobj) alternative_16\NN\5788149|a|true|ace-inhibitors|therapy (l_nmod) ace-inhibitors_18\NNS\1740|to|and|antagonists
T14_T41 CPR:6 aliskiren_0\NN\1740| (r_nsubj) has_1\VBZ\2108377|aliskiren|potential|. (l_dobj) potential_3\NN\14481929|the|become (l_acl) become_5\VB\146138|to|inhibitor (l_attr) inhibitor_11\NN\20090|the|first|active|renin|provides (l_acl:relcl) provides_13\VBZ\2199590|that|alternative (l_dobj) alternative_16\NN\5788149|a|true|ace-inhibitors|therapy (l_nmod) ace-inhibitors_18\NNS\1740|to|and|antagonists (l_conj) antagonists_23\NNS\7846|ang|ii|receptor (l_compound) receptor_22\NN\5225602|
T15_T39 NONE ii_21\CD\13741022| (r_nummod) antagonists_23\NNS\7846|ang|ii|receptor (r_conj) ace-inhibitors_18\NNS\1740|to|and|antagonists (r_nmod) alternative_16\NN\5788149|a|true|ace-inhibitors|therapy (r_dobj) provides_13\VBZ\2199590|that|alternative (r_acl:relcl) inhibitor_11\NN\20090|the|first|active|renin|provides (l_compound) renin_10\NN\14999106|
T15_T40 NONE ii_21\CD\13741022| (r_nummod) antagonists_23\NNS\7846|ang|ii|receptor (r_conj) ace-inhibitors_18\NNS\1740|to|and|antagonists
T15_T41 NONE ii_21\CD\13741022| (r_nummod) antagonists_23\NNS\7846|ang|ii|receptor (l_compound) receptor_22\NN\5225602|
1612232
17228881
T24_T40 CPR:4 sulfonamide_19\NN\2716205|and|sulfamate (r_compound) inhibitors_22\NNS\20090|for|sulfonamide (r_nmod) target_17\NN\7258332|a|new|inhibitors (r_appos) isoform_12\NN\1740|of|the|human|secretory|vi|,|target (l_nummod) vi_13\CD\13741022|
T25_T40 CPR:4 sulfamate_21\NN\1740| (r_conj) sulfonamide_19\NN\2716205|and|sulfamate (r_compound) inhibitors_22\NNS\20090|for|sulfonamide (r_nmod) target_17\NN\7258332|a|new|inhibitors (r_appos) isoform_12\NN\1740|of|the|human|secretory|vi|,|target (l_nummod) vi_13\CD\13741022|
T13_T30 CPR:9 co2_5\NN\14836127| (r_compound) reaction_7\NN\13446390|for|the|co2|hydration (r_nmod) parameters_2\NNS\5858936|the|kinetic|reaction (r_nsubj) proved_8\VBD\2604760|parameters|vi|possess|. (l_dobj) vi_10\CD\13741022|hca
T16_T37 NONE benzenesulfonamides_1\NNS\1740|simple (r_nsubj) inhibitors_7\NNS\20090|benzenesulfonamides|were|ineffective|vi|,|constants|detected (l_compound) vi_6\NN\13741022|hca
T17_T37 NONE 4-amino-_30\NN\1740|,|4-aminomethyl- (r_conj) 2-_28\CD\1740|or|4-amino- (r_compound) moieties_36\NNS\13736799|2- (r_dobj) bearing_27\VBG\2630189|moieties (r_acl) derivatives_26\NNS\5802185|among|such|bearing|or|sulfanilamides (r_nmod) detected_23\VBN\2163746|inhibitors|were|derivatives|. (r_parataxis) inhibitors_7\NNS\20090|benzenesulfonamides|were|ineffective|vi|,|constants|detected (l_compound) vi_6\NN\13741022|hca
T18_T37 NONE 4-aminomethyl-_32\NN\1740|,|or|4-hydroxymethyl (r_conj) 4-amino-_30\NN\1740|,|4-aminomethyl- (r_conj) 2-_28\CD\1740|or|4-amino- (r_compound) moieties_36\NNS\13736799|2- (r_dobj) bearing_27\VBG\2630189|moieties (r_acl) derivatives_26\NNS\5802185|among|such|bearing|or|sulfanilamides (r_nmod) detected_23\VBN\2163746|inhibitors|were|derivatives|. (r_parataxis) inhibitors_7\NNS\20090|benzenesulfonamides|were|ineffective|vi|,|constants|detected (l_compound) vi_6\NN\13741022|hca
T19_T37 NONE 4-hydroxymethyl_35\NN\1740| (r_conj) 4-aminomethyl-_32\NN\1740|,|or|4-hydroxymethyl (r_conj) 4-amino-_30\NN\1740|,|4-aminomethyl- (r_conj) 2-_28\CD\1740|or|4-amino- (r_compound) moieties_36\NNS\13736799|2- (r_dobj) bearing_27\VBG\2630189|moieties (r_acl) derivatives_26\NNS\5802185|among|such|bearing|or|sulfanilamides (r_nmod) detected_23\VBN\2163746|inhibitors|were|derivatives|. (r_parataxis) inhibitors_7\NNS\20090|benzenesulfonamides|were|ineffective|vi|,|constants|detected (l_compound) vi_6\NN\13741022|hca
T20_T37 NONE sulfanilamides_40\NNS\4352070|among|halogenated|values (r_conj) derivatives_26\NNS\5802185|among|such|bearing|or|sulfanilamides (r_nmod) detected_23\VBN\2163746|inhibitors|were|derivatives|. (r_parataxis) inhibitors_7\NNS\20090|benzenesulfonamides|were|ineffective|vi|,|constants|detected (l_compound) vi_6\NN\13741022|hca
T1_T26 CPR:4 dichlorophenamide_13\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T1_T27 NONE dichlorophenamide_13\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T21_T26 CPR:4 acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T21_T27 NONE acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T22_T26 CPR:4 methazolamide_9\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T22_T27 NONE methazolamide_9\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T23_T26 CPR:4 ethoxzolamide_11\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T23_T27 NONE ethoxzolamide_11\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T2_T26 CPR:4 dorzolamide_15\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T2_T27 NONE dorzolamide_15\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T3_T26 CPR:4 brinzolamide_17\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T3_T27 NONE brinzolamide_17\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T4_T26 CPR:4 topiramate_19\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T4_T27 NONE topiramate_19\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T5_T26 CPR:4 sulpiride_21\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T5_T27 NONE sulpiride_21\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T6_T26 CPR:4 indisulam_24\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T6_T27 NONE indisulam_24\NN\1740| (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T7_T26 CPR:4 benzolamide_30\NN\1740|the|orphan|drug (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T7_T27 NONE benzolamide_30\NN\1740|the|orphan|drug (r_conj) acetazolamide_7\NN\1740|such|,|methazolamide|,|ethoxzolamide|,|dichlorophenamide|,|dorzolamide|,|brinzolamide|,|topiramate|,|sulpiride|,|and|indisulam|,|or|benzolamide (r_nmod) compounds_3\NNS\5869584|some|used|,|acetazolamide|, (r_nsubj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T8_T26 NONE brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (r_dobj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T8_T27 CPR:4 brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T9_T26 NONE sulpiride_53\NN\1740| (r_conj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (r_dobj) showed_32\VBD\2137132|compounds|activity|,|constants|nm.|brinzolamide|. (l_dobj) activity_37\NN\30358|effective|vi|inhibitory (l_compound) vi_35\CD\13741022|hca
T9_T27 CPR:4 sulpiride_53\NN\1740| (r_conj) brinzolamide_51\NN\1740|inhibitors|were|and|sulpiride|values|,|inhibitor (l_acl:relcl) inhibitor_72\NN\20090|compound|being|also|a|vi-selective (l_amod) vi-selective_71\JJ\1740|ca
T10_T28 CPR:4 sulfonamides_13\NNS\2716205|with|systemic (r_nmod) treatment_10\NN\654885|after|the|sulfonamides (r_nmod) reported_3\VBN\831651|effect|treatment (r_acl) taste_2\NN\5712076|the|metallic|reported (r_nsubj) due_16\JJ\1740|taste|may|be|inhibition|. (l_nmod) inhibition_19\NN\1068773|to|the|vi (l_nmod) vi_24\NN\13741022|of|the|salivary|ca
T11_T29 CPR:9 co2_23\NN\14836127| (r_compound) activity_25\NN\30358|by|the|relevant|co2|hydrase|vi|,|leads (l_nmod) vi_29\CD\13741022|of|enamel|ca
T12_T29 CPR:9 bicarbonate_39\NN\14798450| (r_conj) protons_37\NNS\9374886|of|and|bicarbonate (r_nmod) formation_35\NN\7938773|to|the|protons (r_nmod) leads_32\VBZ\1752884|which|formation|and|have (r_acl:relcl) activity_25\NN\30358|by|the|relevant|co2|hydrase|vi|,|leads (l_nmod) vi_29\CD\13741022|of|enamel|ca
17023173
T2_T9 CPR:4 decitabine_0\NN\1740| (r_nsubj) inhibits_1\VBZ\2510337|decitabine|methyltransferase|and|shown|. (l_dobj) methyltransferase_3\NN\1740|dna
23159329
T11_T24 CPR:3 methamphetamine_3\NN\2704153|of (r_nmod) roles_1\NNS\719494|distinct|methamphetamine|modulating|. (l_acl) modulating_5\VBG\1724459|in|consolidation (l_dobj) consolidation_8\NN\7373803|memory|,|retrieval|,|reconsolidation|and|changes (l_conj) changes_16\NNS\7283608|the|accompanying|activation (l_nmod) activation_21\NN\13561719|of|erk|hippocampus (l_compound) erk_18\NN\1740|and|creb
T11_T25 CPR:3 methamphetamine_3\NN\2704153|of (r_nmod) roles_1\NNS\719494|distinct|methamphetamine|modulating|. (l_acl) modulating_5\VBG\1724459|in|consolidation (l_dobj) consolidation_8\NN\7373803|memory|,|retrieval|,|reconsolidation|and|changes (l_conj) changes_16\NNS\7283608|the|accompanying|activation (l_nmod) activation_21\NN\13561719|of|erk|hippocampus (l_compound) erk_18\NN\1740|and|creb (l_conj) creb_20\NN\1740|
T5_T12 NONE camp_11\NN\3763727| (r_compound) protein_14\NN\14944888|the|transcription|factor|camp|response|element-binding|creb (r_conj) kinase_3\NN\14732946|the|extracellular|signal-regulated|erk|and|protein
T5_T17 NONE camp_11\NN\3763727| (r_compound) protein_14\NN\14944888|the|transcription|factor|camp|response|element-binding|creb (r_conj) kinase_3\NN\14732946|the|extracellular|signal-regulated|erk|and|protein (l_appos) erk_5\NN\1740|(|)
T5_T18 NONE camp_11\NN\3763727| (r_compound) protein_14\NN\14944888|the|transcription|factor|camp|response|element-binding|creb
T5_T19 NONE camp_11\NN\3763727| (r_compound) protein_14\NN\14944888|the|transcription|factor|camp|response|element-binding|creb (l_appos) creb_16\NN\1740|(|)
T1_T22 NONE meth-treated_21\JJ\1740| (r_amod) groups_23\NNS\2137|in|meth-treated|mouse (r_nmod) retrieval_17\NN\13450862|not|after|or|reconsolidation|groups (r_conj) consolidation_13\NN\7373803|following|memory|retrieval (r_nmod) found_10\VBN\2426171|activation|was|consolidation|. (l_nsubjpass) activation_0\NN\13561719|erk|hippocampus (l_nmod) erk_3\NN\1740|of|both|and|creb
T1_T23 NONE meth-treated_21\JJ\1740| (r_amod) groups_23\NNS\2137|in|meth-treated|mouse (r_nmod) retrieval_17\NN\13450862|not|after|or|reconsolidation|groups (r_conj) consolidation_13\NN\7373803|following|memory|retrieval (r_nmod) found_10\VBN\2426171|activation|was|consolidation|. (l_nsubjpass) activation_0\NN\13561719|erk|hippocampus (l_nmod) erk_3\NN\1740|of|both|and|creb (l_conj) creb_5\NN\1740|
T2_T13 CPR:3 meth-treated_22\JJ\1740| (r_amod) groups_24\NNS\2137|in|meth-treated|mouse (r_nmod) retrieval_16\NN\13450862|following|memory|not|processes|groups (r_nmod) found_13\VBN\2426171|contrast|,|activation|was|retrieval|. (l_nsubjpass) activation_3\NN\13561719|erk|pfc (l_nmod) erk_6\NN\1740|of|both|and|creb
T2_T14 CPR:3 meth-treated_22\JJ\1740| (r_amod) groups_24\NNS\2137|in|meth-treated|mouse (r_nmod) retrieval_16\NN\13450862|following|memory|not|processes|groups (r_nmod) found_13\VBN\2426171|contrast|,|activation|was|retrieval|. (l_nsubjpass) activation_3\NN\13561719|erk|pfc (l_nmod) erk_6\NN\1740|of|both|and|creb (l_conj) creb_8\NN\1740|
T4_T15 CPR:3 meth-induced_17\JJ\1740| (r_amod) changes_20\NNS\7283608|in|meth-induced|spatial|memory (r_nmod) involved_15\VBN\2676054|moreover|,|activation|might|be|changes|. (l_nsubjpass) activation_2\NN\13561719|pathway|hippocampus (l_nmod) pathway_9\NN\5483677|of|the|erk|signaling (l_compound) erk_5\NN\1740|and|creb
T4_T16 CPR:3 meth-induced_17\JJ\1740| (r_amod) changes_20\NNS\7283608|in|meth-induced|spatial|memory (r_nmod) involved_15\VBN\2676054|moreover|,|activation|might|be|changes|. (l_nsubjpass) activation_2\NN\13561719|pathway|hippocampus (l_nmod) pathway_9\NN\5483677|of|the|erk|signaling (l_compound) erk_5\NN\1740|and|creb (l_conj) creb_7\NN\1740|
23601700
T3_T19 NONE sds-stable_10\JJ\1740| (r_conj) sensitive_8\JJ\1740|reduction|and|sds-stable (r_amod) heteromers_11\NNS\1740|sensitive (r_nsubjpass) reconstituted_14\VBN\404222|that|heteromers|can|be|vitro|mixing (l_advcl) mixing_18\VBG\140123|by|prommp-9|serglycin (l_dobj) prommp-9_19\NN\1740|
T3_T20 NONE sds-stable_10\JJ\1740| (r_conj) sensitive_8\JJ\1740|reduction|and|sds-stable (r_amod) heteromers_11\NNS\1740|sensitive (r_nsubjpass) reconstituted_14\VBN\404222|that|heteromers|can|be|vitro|mixing (l_advcl) mixing_18\VBG\140123|by|prommp-9|serglycin (l_nmod) serglycin_22\NN\1740|with|either|,|versican|or|cspgs|isolated (l_conj) cspgs_26\NN\1740|
T4_T21 NONE sds-soluble_6\JJ\1740| (r_conj) strong_4\JJ\1740|but|sds-soluble (r_amod) heteromer_8\NN\1740|a|strong|prommp-9·cspg (l_compound) prommp-9·cspg_7\NN\1740|
T4_T22 NONE sds-soluble_6\JJ\1740| (r_conj) strong_4\JJ\1740|but|sds-soluble (r_amod) heteromer_8\NN\1740|a|strong|prommp-9·cspg (l_compound) prommp-9·cspg_7\NN\1740|
T7_T24 NONE sds-stable_13\JJ\1740|reconstituted|and|sds-soluble (r_amod) heteromers_16\NNS\1740|the|sds-stable (r_nsubj) had_17\VBD\2108377|heteromer|,|heteromers|binding|. (l_dobj) binding_20\NN\4688246|a|weaker|gelatin|monomer (l_nmod) monomer_26\NN\14818238|than|the|prommp-9 (l_compound) prommp-9_25\NN\1740|
T8_T24 NONE sds-soluble_15\JJ\1740| (r_conj) sds-stable_13\JJ\1740|reconstituted|and|sds-soluble (r_amod) heteromers_16\NNS\1740|the|sds-stable (r_nsubj) had_17\VBD\2108377|heteromer|,|heteromers|binding|. (l_dobj) binding_20\NN\4688246|a|weaker|gelatin|monomer (l_nmod) monomer_26\NN\14818238|than|the|prommp-9 (l_compound) prommp-9_25\NN\1740|
T1_T13 NONE sds-soluble_11\JJ\1740| (r_amod) heteromer_12\NN\1740|of|the|sds-soluble|,|not|heteromer (r_nmod) formation_8\NN\7938773|the|heteromer (r_dobj) inhibited_6\VBD\2510337|however|,|presence|formation|. (l_nsubj) presence_3\NN\13954253|the|timp-1 (l_nmod) timp-1_5\NN\1740|of
T2_T13 NONE sds-stable_17\JJ\1740| (r_amod) heteromer_20\NN\1740|the|sds-stable|sensitive (r_conj) heteromer_12\NN\1740|of|the|sds-soluble|,|not|heteromer (r_nmod) formation_8\NN\7938773|the|heteromer (r_dobj) inhibited_6\VBD\2510337|however|,|presence|formation|. (l_nsubj) presence_3\NN\13954253|the|timp-1 (l_nmod) timp-1_5\NN\1740|of
23411235
T11_T14 NONE phenolates_14\NNS\1740|of|phytosteryl (r_nmod) properties_11\NNS\32613|of|the|physiochemical|phenolates|,|synthesized (r_nmod) study_5\NN\635850|of|a|comprehensive|properties (r_nmod) part_1\NN\31921|as|study (r_nmod) evaluated_27\VBN\670261|part|,|activity|was|using|. (l_xcomp) using_28\VBG\1156834|systems (l_dobj) systems_34\NNS\3575240|three|different|in|model|,|system (l_appos) system_40\NN\3575240|namely|oil|model|,|system|and|assay (l_conj) assay_53\NN\5733583|cholesterol|oxidation (l_compound) cholesterol_48\NN\15058310|low-density|lipoprotein|ldl-c (l_compound) lipoprotein_47\NN\14731135|
T11_T15 NONE phenolates_14\NNS\1740|of|phytosteryl (r_nmod) properties_11\NNS\32613|of|the|physiochemical|phenolates|,|synthesized (r_nmod) study_5\NN\635850|of|a|comprehensive|properties (r_nmod) part_1\NN\31921|as|study (r_nmod) evaluated_27\VBN\670261|part|,|activity|was|using|. (l_xcomp) using_28\VBG\1156834|systems (l_dobj) systems_34\NNS\3575240|three|different|in|model|,|system (l_appos) system_40\NN\3575240|namely|oil|model|,|system|and|assay (l_conj) assay_53\NN\5733583|cholesterol|oxidation (l_compound) cholesterol_48\NN\15058310|low-density|lipoprotein|ldl-c (l_appos) ldl-c_50\NN\1740|(|)
T1_T14 NONE β-carotene-linoleate_42\NN\1740| (r_compound) system_44\NN\3575240|β-carotene-linoleate|model (r_conj) system_40\NN\3575240|namely|oil|model|,|system|and|assay (l_conj) assay_53\NN\5733583|cholesterol|oxidation (l_compound) cholesterol_48\NN\15058310|low-density|lipoprotein|ldl-c (l_compound) lipoprotein_47\NN\14731135|
T1_T15 NONE β-carotene-linoleate_42\NN\1740| (r_compound) system_44\NN\3575240|β-carotene-linoleate|model (r_conj) system_40\NN\3575240|namely|oil|model|,|system|and|assay (l_conj) assay_53\NN\5733583|cholesterol|oxidation (l_compound) cholesterol_48\NN\15058310|low-density|lipoprotein|ldl-c (l_appos) ldl-c_50\NN\1740|(|)
T2_T14 NONE β-carotene-linoleate_42\NN\1740| (r_compound) system_44\NN\3575240|β-carotene-linoleate|model (r_conj) system_40\NN\3575240|namely|oil|model|,|system|and|assay (l_conj) assay_53\NN\5733583|cholesterol|oxidation (l_compound) cholesterol_48\NN\15058310|low-density|lipoprotein|ldl-c (l_compound) lipoprotein_47\NN\14731135|
T2_T15 NONE β-carotene-linoleate_42\NN\1740| (r_compound) system_44\NN\3575240|β-carotene-linoleate|model (r_conj) system_40\NN\3575240|namely|oil|model|,|system|and|assay (l_conj) assay_53\NN\5733583|cholesterol|oxidation (l_compound) cholesterol_48\NN\15058310|low-density|lipoprotein|ldl-c (l_appos) ldl-c_50\NN\1740|(|)
T3_T14 NONE cholesterol_48\NN\15058310|low-density|lipoprotein|ldl-c (l_compound) lipoprotein_47\NN\14731135|
T3_T15 NONE cholesterol_48\NN\15058310|low-density|lipoprotein|ldl-c (l_appos) ldl-c_50\NN\1740|(|)
T10_T16 CPR:4 phenolates_8\NNS\1740|by|phytosteryl (r_nmod) oxidation_5\NN\13447361|of|ldl-c|phenolates (l_compound) ldl-c_4\NN\1740|
18974361
T18_T27 NONE +_7\NN\1740| (r_compound) channels_8\NNS\6251781|of|human|cav3.2|t-type|ca2|+ (l_compound) cav3.2_4\NN\1740|
T18_T28 NONE +_7\NN\1740| (r_compound) channels_8\NNS\6251781|of|human|cav3.2|t-type|ca2|+
T4_T19 NONE )_27\-RRB-\1740| (r_punct) channels_28\NNS\6251781|of|l-type|ca(2|+|)|muscle
T4_T22 NONE )_27\-RRB-\1740| (r_punct) channels_28\NNS\6251781|of|l-type|ca(2|+|)|muscle (r_nmod) role_22\NN\719494|the|physiological|channels (r_dobj) establish_19\VB\2426171|to|role (r_xcomp) used_17\VBN\1156834|drugs|have|been|establish|. (l_nsubjpass) drugs_1\NNS\14778436|antihypertensive|class (l_nmod) class_14\NN\7951464|blocker (l_compound) blocker_7\NN\10101634|of|the|"|calcium|channel|"|or|antagonist (l_compound) channel_6\NN\6251781|
T6_T19 NONE calcium_5\NN\14625458| (r_compound) blocker_7\NN\10101634|of|the|"|calcium|channel|"|or|antagonist (r_compound) class_14\NN\7951464|blocker (r_nmod) drugs_1\NNS\14778436|antihypertensive|class (r_nsubjpass) used_17\VBN\1156834|drugs|have|been|establish|. (l_xcomp) establish_19\VB\2426171|to|role (l_dobj) role_22\NN\719494|the|physiological|channels (l_nmod) channels_28\NNS\6251781|of|l-type|ca(2|+|)|muscle
T6_T22 NONE calcium_5\NN\14625458| (r_compound) blocker_7\NN\10101634|of|the|"|calcium|channel|"|or|antagonist (l_compound) channel_6\NN\6251781|
T8_T19 NONE calcium_11\NN\14625458| (r_compound) antagonist_12\NN\7846|"|calcium|" (r_conj) blocker_7\NN\10101634|of|the|"|calcium|channel|"|or|antagonist (r_compound) class_14\NN\7951464|blocker (r_nmod) drugs_1\NNS\14778436|antihypertensive|class (r_nsubjpass) used_17\VBN\1156834|drugs|have|been|establish|. (l_xcomp) establish_19\VB\2426171|to|role (l_dobj) role_22\NN\719494|the|physiological|channels (l_nmod) channels_28\NNS\6251781|of|l-type|ca(2|+|)|muscle
T8_T22 NONE calcium_11\NN\14625458| (r_compound) antagonist_12\NN\7846|"|calcium|" (r_conj) blocker_7\NN\10101634|of|the|"|calcium|channel|"|or|antagonist (l_compound) channel_6\NN\6251781|
T5_T20 NONE )_14\-RRB-\1740| (r_punct) channels_15\NNS\6251781|on|the|pharmacology|t-type|ca(2|+|)
T7_T21 NONE aldosterone_9\NN\14751863| (r_compound) secretion_10\NN\13526110|aldosterone (r_conj) pacemaking_7\NN\1740|in|cardiac|,|secretion|,|and|hemodynamics (r_nmod) play_2\VBP\1072262|channels|role|pacemaking|,|leading|. (l_nsubj) channels_1\NNS\6251781|t-type
T10_T23 NONE mibefradil_30\NN\1740|e.g.|, (r_appos) phenylalkylamines_26\NNS\1740|(|mibefradil|)|and|dihydropyridines (r_appos) classes_22\NNS\7951464|on|two|compounds|:|phenylalkylamines (r_nmod) focusing_19\VBG\628491|classes (r_advcl) identify_7\VB\699815|to|compounds|,|focusing (l_dobj) compounds_8\NNS\5869584|block (l_acl:relcl) block_10\VBP\1476483|that|channel|affinity (l_dobj) channel_14\NN\6251781|the|ca(v)3.2|t-type (l_compound) ca(v)3.2_12\NN\1740|
T10_T24 NONE mibefradil_30\NN\1740|e.g.|, (r_appos) phenylalkylamines_26\NNS\1740|(|mibefradil|)|and|dihydropyridines (r_appos) classes_22\NNS\7951464|on|two|compounds|:|phenylalkylamines (r_nmod) focusing_19\VBG\628491|classes (r_advcl) identify_7\VB\699815|to|compounds|,|focusing (l_dobj) compounds_8\NNS\5869584|block (l_acl:relcl) block_10\VBP\1476483|that|channel|affinity (l_dobj) channel_14\NN\6251781|the|ca(v)3.2|t-type
T11_T23 NONE dihydropyridines_33\NNS\1740|efonidipine (r_conj) phenylalkylamines_26\NNS\1740|(|mibefradil|)|and|dihydropyridines (r_appos) classes_22\NNS\7951464|on|two|compounds|:|phenylalkylamines (r_nmod) focusing_19\VBG\628491|classes (r_advcl) identify_7\VB\699815|to|compounds|,|focusing (l_dobj) compounds_8\NNS\5869584|block (l_acl:relcl) block_10\VBP\1476483|that|channel|affinity (l_dobj) channel_14\NN\6251781|the|ca(v)3.2|t-type (l_compound) ca(v)3.2_12\NN\1740|
T11_T24 NONE dihydropyridines_33\NNS\1740|efonidipine (r_conj) phenylalkylamines_26\NNS\1740|(|mibefradil|)|and|dihydropyridines (r_appos) classes_22\NNS\7951464|on|two|compounds|:|phenylalkylamines (r_nmod) focusing_19\VBG\628491|classes (r_advcl) identify_7\VB\699815|to|compounds|,|focusing (l_dobj) compounds_8\NNS\5869584|block (l_acl:relcl) block_10\VBP\1476483|that|channel|affinity (l_dobj) channel_14\NN\6251781|the|ca(v)3.2|t-type
T12_T23 NONE efonidipine_37\NN\1740|(|e.g.|,|) (r_appos) dihydropyridines_33\NNS\1740|efonidipine (r_conj) phenylalkylamines_26\NNS\1740|(|mibefradil|)|and|dihydropyridines (r_appos) classes_22\NNS\7951464|on|two|compounds|:|phenylalkylamines (r_nmod) focusing_19\VBG\628491|classes (r_advcl) identify_7\VB\699815|to|compounds|,|focusing (l_dobj) compounds_8\NNS\5869584|block (l_acl:relcl) block_10\VBP\1476483|that|channel|affinity (l_dobj) channel_14\NN\6251781|the|ca(v)3.2|t-type (l_compound) ca(v)3.2_12\NN\1740|
T12_T24 NONE efonidipine_37\NN\1740|(|e.g.|,|) (r_appos) dihydropyridines_33\NNS\1740|efonidipine (r_conj) phenylalkylamines_26\NNS\1740|(|mibefradil|)|and|dihydropyridines (r_appos) classes_22\NNS\7951464|on|two|compounds|:|phenylalkylamines (r_nmod) focusing_19\VBG\628491|classes (r_advcl) identify_7\VB\699815|to|compounds|,|focusing (l_dobj) compounds_8\NNS\5869584|block (l_acl:relcl) block_10\VBP\1476483|that|channel|affinity (l_dobj) channel_14\NN\6251781|the|ca(v)3.2|t-type
T9_T23 NONE phenylalkylamines_26\NNS\1740|(|mibefradil|)|and|dihydropyridines (r_appos) classes_22\NNS\7951464|on|two|compounds|:|phenylalkylamines (r_nmod) focusing_19\VBG\628491|classes (r_advcl) identify_7\VB\699815|to|compounds|,|focusing (l_dobj) compounds_8\NNS\5869584|block (l_acl:relcl) block_10\VBP\1476483|that|channel|affinity (l_dobj) channel_14\NN\6251781|the|ca(v)3.2|t-type (l_compound) ca(v)3.2_12\NN\1740|
T9_T24 NONE phenylalkylamines_26\NNS\1740|(|mibefradil|)|and|dihydropyridines (r_appos) classes_22\NNS\7951464|on|two|compounds|:|phenylalkylamines (r_nmod) focusing_19\VBG\628491|classes (r_advcl) identify_7\VB\699815|to|compounds|,|focusing (l_dobj) compounds_8\NNS\5869584|block (l_acl:relcl) block_10\VBP\1476483|that|channel|affinity (l_dobj) channel_14\NN\6251781|the|ca(v)3.2|t-type
T13_T25 NONE )_8\-RRB-\1740| (r_punct) assay_10\NN\5733583|a|validated|ca(2|+|)|influx (r_dobj) using_3\VBG\1156834|assay|line (l_nmod) line_14\NN\8426461|into|a|cell|expressing (l_acl) expressing_15\VBG\928630|channels (l_dobj) channels_18\NNS\6251781|recombinant|ca(v)3.2 (l_compound) ca(v)3.2_17\NN\1740|
T14_T26 CPR:4 efonidipine_9\NN\1740|(|,|felodipine|,|isradipine|,|and|nitrendipine|) (r_dep) drugs_7\NNS\14778436|four|approved|antihypertensive|efonidipine (r_dobj) identified_2\VBD\699815|study|drugs|blockers|. (l_nmod) blockers_21\NNS\10101634|as|potent|t-channel|ic(50 (l_amod) t-channel_20\NN\1740|
T15_T26 CPR:4 felodipine_11\NN\1740| (r_conj) efonidipine_9\NN\1740|(|,|felodipine|,|isradipine|,|and|nitrendipine|) (r_dep) drugs_7\NNS\14778436|four|approved|antihypertensive|efonidipine (r_dobj) identified_2\VBD\699815|study|drugs|blockers|. (l_nmod) blockers_21\NNS\10101634|as|potent|t-channel|ic(50 (l_amod) t-channel_20\NN\1740|
T16_T26 CPR:4 isradipine_13\NN\1740| (r_conj) efonidipine_9\NN\1740|(|,|felodipine|,|isradipine|,|and|nitrendipine|) (r_dep) drugs_7\NNS\14778436|four|approved|antihypertensive|efonidipine (r_dobj) identified_2\VBD\699815|study|drugs|blockers|. (l_nmod) blockers_21\NNS\10101634|as|potent|t-channel|ic(50 (l_amod) t-channel_20\NN\1740|
T17_T26 CPR:4 nitrendipine_16\NN\1740| (r_conj) efonidipine_9\NN\1740|(|,|felodipine|,|isradipine|,|and|nitrendipine|) (r_dep) drugs_7\NNS\14778436|four|approved|antihypertensive|efonidipine (r_dobj) identified_2\VBD\699815|study|drugs|blockers|. (l_nmod) blockers_21\NNS\10101634|as|potent|t-channel|ic(50 (l_amod) t-channel_20\NN\1740|
23212306
T10_T22 NONE n-methyl-d-aspartate_23\NN\1740| (r_compound) receptor_27\NN\5225602|of|the|n-methyl-d-aspartate|(|nmda|)|and|genes
T11_T22 NONE nmda_25\NN\1740| (r_compound) receptor_27\NN\5225602|of|the|n-methyl-d-aspartate|(|nmda|)|and|genes
T9_T22 NONE diazinon_10\NN\1740|to (r_nmod) exposure_8\NN\5042871|of|neonatal|diazinon (r_nmod) effect_5\NN\34213|the|exposure|performance (l_nmod) performance_17\NN\6619065|on|hippocampus-dependent|novel|object|recognition|test|and|expression (l_conj) expression_20\NN\4679549|the|receptor|hippocampi (l_nmod) receptor_27\NN\5225602|of|the|n-methyl-d-aspartate|(|nmda|)|and|genes
T13_T23 NONE nmda_28\NN\1740| (r_compound) receptor_29\NN\5225602|the|nmda (r_conj) neurotrophins_25\NNS\1740|of|and|receptor|and|genes
T13_T24 NONE nmda_28\NN\1740| (r_compound) receptor_29\NN\5225602|the|nmda
T2_T16 NONE nmda_1\NN\1740| (r_compound) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_dep) nr1_4\NN\1740|and|nr2b (l_conj) nr2b_6\NN\1740|
T2_T17 NONE nmda_1\NN\1740| (r_compound) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_conj) (camk)-iv_15\NN\1740|the|kinase (l_compound) kinase_14\NN\14732946|related|protein|kinase|calcium/calmodulin-dependent|protein (l_compound) kinase_11\NN\14732946|
T2_T18 NONE nmda_1\NN\1740| (r_compound) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_conj) (camk)-iv_15\NN\1740|the|kinase
T2_T19 NONE nmda_1\NN\1740| (r_compound) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_conj) levels_28\NNS\4916342|mrna (l_compound) mrna_27\NN\14832193|the|transcription|factor|protein|(creb)-1 (l_compound) (creb)-1_26\NN\1740|
T3_T16 NONE calcium/calmodulin-dependent_12\JJ\1740| (r_amod) kinase_14\NN\14732946|related|protein|kinase|calcium/calmodulin-dependent|protein (r_compound) (camk)-iv_15\NN\1740|the|kinase (r_conj) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_dep) nr1_4\NN\1740|and|nr2b (l_conj) nr2b_6\NN\1740|
T3_T17 NONE calcium/calmodulin-dependent_12\JJ\1740| (r_amod) kinase_14\NN\14732946|related|protein|kinase|calcium/calmodulin-dependent|protein (l_compound) kinase_11\NN\14732946|
T3_T18 NONE calcium/calmodulin-dependent_12\JJ\1740| (r_amod) kinase_14\NN\14732946|related|protein|kinase|calcium/calmodulin-dependent|protein (r_compound) (camk)-iv_15\NN\1740|the|kinase
T3_T19 NONE calcium/calmodulin-dependent_12\JJ\1740| (r_amod) kinase_14\NN\14732946|related|protein|kinase|calcium/calmodulin-dependent|protein (r_compound) (camk)-iv_15\NN\1740|the|kinase (r_conj) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_conj) levels_28\NNS\4916342|mrna (l_compound) mrna_27\NN\14832193|the|transcription|factor|protein|(creb)-1 (l_compound) (creb)-1_26\NN\1740|
T4_T16 NONE amp_21\NN\13633375| (r_compound) protein_25\NN\14944888|cyclic|amp|responsive|element|binding (r_compound) mrna_27\NN\14832193|the|transcription|factor|protein|(creb)-1 (r_compound) levels_28\NNS\4916342|mrna (r_conj) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_dep) nr1_4\NN\1740|and|nr2b (l_conj) nr2b_6\NN\1740|
T4_T17 NONE amp_21\NN\13633375| (r_compound) protein_25\NN\14944888|cyclic|amp|responsive|element|binding (r_compound) mrna_27\NN\14832193|the|transcription|factor|protein|(creb)-1 (r_compound) levels_28\NNS\4916342|mrna (r_conj) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_conj) (camk)-iv_15\NN\1740|the|kinase (l_compound) kinase_14\NN\14732946|related|protein|kinase|calcium/calmodulin-dependent|protein (l_compound) kinase_11\NN\14732946|
T4_T18 NONE amp_21\NN\13633375| (r_compound) protein_25\NN\14944888|cyclic|amp|responsive|element|binding (r_compound) mrna_27\NN\14832193|the|transcription|factor|protein|(creb)-1 (r_compound) levels_28\NNS\4916342|mrna (r_conj) subunits_3\NNS\13604718|the|nmda|receptor|nr1|and|(camk)-iv|and|levels (l_conj) (camk)-iv_15\NN\1740|the|kinase
T4_T19 NONE amp_21\NN\13633375| (r_compound) protein_25\NN\14944888|cyclic|amp|responsive|element|binding (r_compound) mrna_27\NN\14832193|the|transcription|factor|protein|(creb)-1 (l_compound) (creb)-1_26\NN\1740|
T7_T21 NONE diazinon_5\NN\1740| (r_compound) exposure_6\NN\5042871|neonatal|diazinon (r_nsubj) impaired_7\VBD\258857|that|exposure|ability|,|accompanied (l_advcl) accompanied_15\VBN\1835496|modulation (l_nmod) modulation_18\NN\7044917|by|a|expressions (l_nmod) expressions_21\NNS\4679549|in|the|receptor (l_nmod) receptor_25\NN\5225602|of|the|nmda|and|neurotrophin|mice
T8_T21 NONE nmda_24\NN\1740| (r_compound) receptor_25\NN\5225602|of|the|nmda|and|neurotrophin|mice
12082550
T14_T28 NONE a_5\NN\13649268|3-hydroxy-3-methylglutaryl|coenzyme (r_compound) reductase_9\NN\14732946|a|hmg-coa|)|,|enzyme
T18_T28 NONE hmg-coa_7\NN\1740|( (r_compound) reductase_9\NN\14732946|a|hmg-coa|)|,|enzyme
T16_T29 CPR:4 lovastatin_0\NN\3676175|,|inhibitor|, (l_appos) inhibitor_4\NN\20090|a|specific|reductase (l_nmod) reductase_7\NN\14732946|of|hmg-coa
T17_T29 NONE hmg-coa_6\NN\1740| (r_compound) reductase_7\NN\14732946|of|hmg-coa
T2_T22 NONE diazepam-binding_2\JJ\1740| (r_amod) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_amod) inhibitor/acyl-coa-binding_3\JJ\1740|
T2_T23 NONE diazepam-binding_2\JJ\1740| (r_amod) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_punct) ,_5\,\1740|
T2_T24 NONE diazepam-binding_2\JJ\1740| (r_amod) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_conj) factor_9\NN\7326557|the|activated|transcription|4 (l_nummod) 4_10\CD\13741022|
T2_T25 NONE diazepam-binding_2\JJ\1740| (r_amod) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_conj) rhoa._12\NN\1740|
T3_T22 NONE inhibitor/acyl-coa-binding_3\JJ\1740|
T3_T23 NONE inhibitor/acyl-coa-binding_3\JJ\1740| (r_amod) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_punct) ,_5\,\1740|
T3_T24 NONE inhibitor/acyl-coa-binding_3\JJ\1740| (r_amod) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_conj) factor_9\NN\7326557|the|activated|transcription|4 (l_nummod) 4_10\CD\13741022|
T3_T25 NONE inhibitor/acyl-coa-binding_3\JJ\1740| (r_amod) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_conj) rhoa._12\NN\1740|
T4_T22 NONE mevalonate_17\NN\1740|of (r_nmod) biosynthesis_15\NN\13565379|the|mevalonate (r_nsubj) leads_18\VBZ\1752884|because|biosynthesis|incorporation (r_advcl) evaluated_39\VBN\670261|leads|,|role|was|also|. (r_ccomp) included_1\VBD\690614|these|protein|evaluated (l_dobj) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_amod) inhibitor/acyl-coa-binding_3\JJ\1740|
T4_T23 NONE mevalonate_17\NN\1740|of (r_nmod) biosynthesis_15\NN\13565379|the|mevalonate (r_nsubj) leads_18\VBZ\1752884|because|biosynthesis|incorporation (r_advcl) evaluated_39\VBN\670261|leads|,|role|was|also|. (r_ccomp) included_1\VBD\690614|these|protein|evaluated (l_dobj) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_punct) ,_5\,\1740|
T4_T24 NONE mevalonate_17\NN\1740|of (r_nmod) biosynthesis_15\NN\13565379|the|mevalonate (r_nsubj) leads_18\VBZ\1752884|because|biosynthesis|incorporation (r_advcl) evaluated_39\VBN\670261|leads|,|role|was|also|. (r_ccomp) included_1\VBD\690614|these|protein|evaluated (l_dobj) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_conj) factor_9\NN\7326557|the|activated|transcription|4 (l_nummod) 4_10\CD\13741022|
T4_T25 NONE mevalonate_17\NN\1740|of (r_nmod) biosynthesis_15\NN\13565379|the|mevalonate (r_nsubj) leads_18\VBZ\1752884|because|biosynthesis|incorporation (r_advcl) evaluated_39\VBN\670261|leads|,|role|was|also|. (r_ccomp) included_1\VBD\690614|these|protein|evaluated (l_dobj) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_conj) rhoa._12\NN\1740|
T5_T22 NONE lovastatin-induced_35\JJ\1740| (r_amod) apoptosis_36\NN\11486178|in|lovastatin-induced (r_nmod) role_33\NN\719494|their|apoptosis (r_nsubjpass) evaluated_39\VBN\670261|leads|,|role|was|also|. (r_ccomp) included_1\VBD\690614|these|protein|evaluated (l_dobj) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_amod) inhibitor/acyl-coa-binding_3\JJ\1740|
T5_T23 NONE lovastatin-induced_35\JJ\1740| (r_amod) apoptosis_36\NN\11486178|in|lovastatin-induced (r_nmod) role_33\NN\719494|their|apoptosis (r_nsubjpass) evaluated_39\VBN\670261|leads|,|role|was|also|. (r_ccomp) included_1\VBD\690614|these|protein|evaluated (l_dobj) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_punct) ,_5\,\1740|
T5_T24 NONE lovastatin-induced_35\JJ\1740| (r_amod) apoptosis_36\NN\11486178|in|lovastatin-induced (r_nmod) role_33\NN\719494|their|apoptosis (r_nsubjpass) evaluated_39\VBN\670261|leads|,|role|was|also|. (r_ccomp) included_1\VBD\690614|these|protein|evaluated (l_dobj) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_conj) factor_9\NN\7326557|the|activated|transcription|4 (l_nummod) 4_10\CD\13741022|
T5_T25 NONE lovastatin-induced_35\JJ\1740| (r_amod) apoptosis_36\NN\11486178|in|lovastatin-induced (r_nmod) role_33\NN\719494|their|apoptosis (r_nsubjpass) evaluated_39\VBN\670261|leads|,|role|was|also|. (r_ccomp) included_1\VBD\690614|these|protein|evaluated (l_dobj) protein_4\NN\14944888|diazepam-binding|inhibitor/acyl-coa-binding|,|factor|and|rhoa. (l_conj) rhoa._12\NN\1740|
T10_T26 NONE ggpp_3\NN\1740| (r_dobj) requires_2\VBZ\754942|because|rhoa|ggpp|function (l_nsubj) rhoa_1\NN\1740|
T10_T27 NONE ggpp_3\NN\1740| (r_dobj) requires_2\VBZ\754942|because|rhoa|ggpp|function (r_advcl) links_9\VBZ\628491|requires|,|this|data|and|identifies|. (l_conj) identifies_16\VBZ\699815|rhoa|mediator (l_dobj) rhoa_17\NN\1740|
T11_T26 NONE lovastatin_27\NN\3676175|of (r_nmod) properties_25\NNS\32613|of|the|anticancer|lovastatin (r_nmod) mediator_21\NN\10351874|as|a|potential|properties (r_nmod) identifies_16\VBZ\699815|rhoa|mediator (r_conj) links_9\VBZ\628491|requires|,|this|data|and|identifies|. (l_advcl) requires_2\VBZ\754942|because|rhoa|ggpp|function (l_nsubj) rhoa_1\NN\1740|
T11_T27 NONE lovastatin_27\NN\3676175|of (r_nmod) properties_25\NNS\32613|of|the|anticancer|lovastatin (r_nmod) mediator_21\NN\10351874|as|a|potential|properties (r_nmod) identifies_16\VBZ\699815|rhoa|mediator (l_dobj) rhoa_17\NN\1740|
23349488
T1_T6 NONE glucose_14\NN\14710501| (r_compound) stimulation_15\NN\242808|in|response|to|oral|glucose|humans (r_nmod) secretion_9\NN\13526110|with|decreased|insulin|stimulation (r_nmod) associated_5\VBN\628491|locus|is|secretion|. (l_nsubjpass) locus_3\NN\8645963|the|hhex/ide|t2d (l_compound) hhex/ide_1\NN\1740|
T1_T7 NONE glucose_14\NN\14710501| (r_compound) stimulation_15\NN\242808|in|response|to|oral|glucose|humans (r_nmod) secretion_9\NN\13526110|with|decreased|insulin|stimulation (r_nmod) associated_5\VBN\628491|locus|is|secretion|. (l_nsubjpass) locus_3\NN\8645963|the|hhex/ide|t2d (l_compound) hhex/ide_1\NN\1740|
T1_T8 NONE glucose_14\NN\14710501| (r_compound) stimulation_15\NN\242808|in|response|to|oral|glucose|humans (r_nmod) secretion_9\NN\13526110|with|decreased|insulin|stimulation (l_compound) insulin_8\NN\5407119|
T2_T10 NONE glucose_3\NN\14710501| (r_nmod:npmod) stimulated_4\JJ\1740|glucose (r_amod) secretion_6\NN\13526110|stimulated|insulin|gsis (l_compound) insulin_5\NN\5407119|
T2_T11 NONE glucose_3\NN\14710501| (r_nmod:npmod) stimulated_4\JJ\1740|glucose (r_amod) secretion_6\NN\13526110|stimulated|insulin|gsis (r_nsubjpass) decreased_11\VBN\169651|that|secretion|is|mice|replenishment|and|haploinsufficient (l_nmod) mice_15\NNS\2329401|in|ide|ko (l_compound) ide_13\NN\1740|
T2_T12 NONE glucose_3\NN\14710501| (r_nmod:npmod) stimulated_4\JJ\1740|glucose (r_amod) secretion_6\NN\13526110|stimulated|insulin|gsis (r_nsubjpass) decreased_11\VBN\169651|that|secretion|is|mice|replenishment|and|haploinsufficient (l_conj) haploinsufficient_32\JJ\1740|that|gene|is (l_nsubj) gene_30\NN\8459252|the|ide (l_compound) ide_29\NN\1740|
23406025
23361846
T21_T33 NONE methadone_5\NN\3808564| (r_compound) metabolism_6\NN\13526110|in|methadone|and|clearance (r_nmod) role_0\NN\719494|p4502b6|metabolism|. (l_nmod) p4502b6_3\NN\1740|of|cytochrome
T1_T24 CPR:9 methadone_0\NN\3808564| (r_compound) n-demethylation_1\NN\1740|methadone (r_nsubjpass) catalyzed_5\VBN\146138|n-demethylation|vitro|is|p4502b6|,|but|attributed (l_conj) attributed_21\VBN\670261|disposition|is|often|cyp3a4|. (l_nmod) cyp3a4_23\NN\1740|to
T1_T30 CPR:9 methadone_0\NN\3808564| (r_compound) n-demethylation_1\NN\1740|methadone (r_nsubjpass) catalyzed_5\VBN\146138|n-demethylation|vitro|is|p4502b6|,|but|attributed (l_nmod) p4502b6_9\NN\1740|by|hepatic|cytochrome|cyp2b6|and|cyp3a4
T1_T31 CPR:9 methadone_0\NN\3808564| (r_compound) n-demethylation_1\NN\1740|methadone (r_nsubjpass) catalyzed_5\VBN\146138|n-demethylation|vitro|is|p4502b6|,|but|attributed (l_nmod) p4502b6_9\NN\1740|by|hepatic|cytochrome|cyp2b6|and|cyp3a4 (l_appos) cyp2b6_11\NN\1740|(|)
T1_T32 CPR:9 methadone_0\NN\3808564| (r_compound) n-demethylation_1\NN\1740|methadone (r_nsubjpass) catalyzed_5\VBN\146138|n-demethylation|vitro|is|p4502b6|,|but|attributed (l_nmod) p4502b6_9\NN\1740|by|hepatic|cytochrome|cyp2b6|and|cyp3a4 (l_conj) cyp3a4_14\NN\1740|
T2_T24 CPR:9 n-demethylation_1\NN\1740|methadone (r_nsubjpass) catalyzed_5\VBN\146138|n-demethylation|vitro|is|p4502b6|,|but|attributed (l_conj) attributed_21\VBN\670261|disposition|is|often|cyp3a4|. (l_nmod) cyp3a4_23\NN\1740|to
T2_T30 CPR:9 n-demethylation_1\NN\1740|methadone (r_nsubjpass) catalyzed_5\VBN\146138|n-demethylation|vitro|is|p4502b6|,|but|attributed (l_nmod) p4502b6_9\NN\1740|by|hepatic|cytochrome|cyp2b6|and|cyp3a4
T2_T31 CPR:9 n-demethylation_1\NN\1740|methadone (r_nsubjpass) catalyzed_5\VBN\146138|n-demethylation|vitro|is|p4502b6|,|but|attributed (l_nmod) p4502b6_9\NN\1740|by|hepatic|cytochrome|cyp2b6|and|cyp3a4 (l_appos) cyp2b6_11\NN\1740|(|)
T2_T32 CPR:9 n-demethylation_1\NN\1740|methadone (r_nsubjpass) catalyzed_5\VBN\146138|n-demethylation|vitro|is|p4502b6|,|but|attributed (l_nmod) p4502b6_9\NN\1740|by|hepatic|cytochrome|cyp2b6|and|cyp3a4 (l_conj) cyp3a4_14\NN\1740|
T7_T25 CPR:9 methadone_15\NN\3808564| (r_compound) n-demethylation_16\NN\1740|for|clinical|methadone|and|clearance (r_nmod) responsible_12\JJ\1740|n-demethylation (r_amod) isoform_11\NN\1740|that|cyp2b6|is|a|prominent|cyp|responsible (l_nsubj) cyp2b6_6\NN\1740|
T7_T26 CPR:9 methadone_15\NN\3808564| (r_compound) n-demethylation_16\NN\1740|for|clinical|methadone|and|clearance (r_nmod) responsible_12\JJ\1740|n-demethylation (r_amod) isoform_11\NN\1740|that|cyp2b6|is|a|prominent|cyp|responsible (l_compound) cyp_10\NN\1740|
T7_T27 NONE methadone_15\NN\3808564| (r_compound) n-demethylation_16\NN\1740|for|clinical|methadone|and|clearance (r_nmod) responsible_12\JJ\1740|n-demethylation (r_amod) isoform_11\NN\1740|that|cyp2b6|is|a|prominent|cyp|responsible (r_ccomp) hypothesis_4\NN\7162194|the|isoform (r_dobj) tested_2\VBD\670261|investigation|hypothesis|,|using|. (l_advcl) using_20\VBG\1156834|ticlopidine (l_dobj) ticlopidine_27\NN\1740|the|inhibitor|,|given (l_compound) inhibitor_26\NN\20090|in|mechanism-based|cyp2b6 (l_compound) cyp2b6_25\NN\1740|
T8_T25 CPR:9 n-demethylation_16\NN\1740|for|clinical|methadone|and|clearance (r_nmod) responsible_12\JJ\1740|n-demethylation (r_amod) isoform_11\NN\1740|that|cyp2b6|is|a|prominent|cyp|responsible (l_nsubj) cyp2b6_6\NN\1740|
T8_T26 CPR:9 n-demethylation_16\NN\1740|for|clinical|methadone|and|clearance (r_nmod) responsible_12\JJ\1740|n-demethylation (r_amod) isoform_11\NN\1740|that|cyp2b6|is|a|prominent|cyp|responsible (l_compound) cyp_10\NN\1740|
T8_T27 NONE n-demethylation_16\NN\1740|for|clinical|methadone|and|clearance (r_nmod) responsible_12\JJ\1740|n-demethylation (r_amod) isoform_11\NN\1740|that|cyp2b6|is|a|prominent|cyp|responsible (r_ccomp) hypothesis_4\NN\7162194|the|isoform (r_dobj) tested_2\VBD\670261|investigation|hypothesis|,|using|. (l_advcl) using_20\VBG\1156834|ticlopidine (l_dobj) ticlopidine_27\NN\1740|the|inhibitor|,|given (l_compound) inhibitor_26\NN\20090|in|mechanism-based|cyp2b6 (l_compound) cyp2b6_25\NN\1740|
T9_T25 NONE ticlopidine_27\NN\1740|the|inhibitor|,|given (r_dobj) using_20\VBG\1156834|ticlopidine (r_advcl) tested_2\VBD\670261|investigation|hypothesis|,|using|. (l_dobj) hypothesis_4\NN\7162194|the|isoform (l_ccomp) isoform_11\NN\1740|that|cyp2b6|is|a|prominent|cyp|responsible (l_nsubj) cyp2b6_6\NN\1740|
T9_T26 NONE ticlopidine_27\NN\1740|the|inhibitor|,|given (r_dobj) using_20\VBG\1156834|ticlopidine (r_advcl) tested_2\VBD\670261|investigation|hypothesis|,|using|. (l_dobj) hypothesis_4\NN\7162194|the|isoform (l_ccomp) isoform_11\NN\1740|that|cyp2b6|is|a|prominent|cyp|responsible (l_compound) cyp_10\NN\1740|
T9_T27 CPR:4 ticlopidine_27\NN\1740|the|inhibitor|,|given (l_compound) inhibitor_26\NN\20090|in|mechanism-based|cyp2b6 (l_compound) cyp2b6_25\NN\1740|
T10_T28 NONE alfentanil_9\NN\1740|with|the|probe (l_compound) probe_8\NN\5797597|cyp3a4/5|substrate (l_compound) cyp3a4/5_6\NN\1740|
T10_T29 NONE alfentanil_9\NN\1740|with|the|probe (r_nmod) investigation_3\NN\5797597|a|preliminary|clinical|alfentanil (r_nsubj) established_10\VBD\2426171|investigation|inhibit|. (l_ccomp) inhibit_15\VB\2510337|that|ticlopidine|did|not|cyp3a4/5 (l_dobj) cyp3a4/5_19\NN\1740|intestinal
T11_T28 NONE ticlopidine_12\NN\1740| (r_nsubj) inhibit_15\VB\2510337|that|ticlopidine|did|not|cyp3a4/5 (r_ccomp) established_10\VBD\2426171|investigation|inhibit|. (l_nsubj) investigation_3\NN\5797597|a|preliminary|clinical|alfentanil (l_nmod) alfentanil_9\NN\1740|with|the|probe (l_compound) probe_8\NN\5797597|cyp3a4/5|substrate (l_compound) cyp3a4/5_6\NN\1740|
T11_T29 NONE ticlopidine_12\NN\1740| (r_nsubj) inhibit_15\VB\2510337|that|ticlopidine|did|not|cyp3a4/5 (l_dobj) cyp3a4/5_19\NN\1740|intestinal
T3_T22 NONE methadone_3\NN\3808564| (r_compound) n-demethylation_4\NN\1740|methadone|and|clearance (r_dobj) reduces_2\VBZ\441445|inhibition|n-demethylation|,|and|alters|,|demonstrating|. (l_nsubj) inhibition_1\NN\1068773|cyp2b6 (l_compound) cyp2b6_0\NN\1740|
T3_T23 NONE methadone_3\NN\3808564| (r_compound) n-demethylation_4\NN\1740|methadone|and|clearance (r_dobj) reduces_2\VBZ\441445|inhibition|n-demethylation|,|and|alters|,|demonstrating|. (l_advcl) demonstrating_13\VBG\2137132|role (l_dobj) role_16\NN\719494|an|important|cyp2b6|disposition (l_nmod) cyp2b6_18\NN\1740|for
T4_T22 NONE n-demethylation_4\NN\1740|methadone|and|clearance (r_dobj) reduces_2\VBZ\441445|inhibition|n-demethylation|,|and|alters|,|demonstrating|. (l_nsubj) inhibition_1\NN\1068773|cyp2b6 (l_compound) cyp2b6_0\NN\1740|
T4_T23 NONE n-demethylation_4\NN\1740|methadone|and|clearance (r_dobj) reduces_2\VBZ\441445|inhibition|n-demethylation|,|and|alters|,|demonstrating|. (l_advcl) demonstrating_13\VBG\2137132|role (l_dobj) role_16\NN\719494|an|important|cyp2b6|disposition (l_nmod) cyp2b6_18\NN\1740|for
T5_T22 NONE methadone_10\NN\3808564| (r_compound) concentrations_11\NNS\4916342|methadone (r_dobj) alters_9\VBZ\126264|concentrations (r_conj) reduces_2\VBZ\441445|inhibition|n-demethylation|,|and|alters|,|demonstrating|. (l_nsubj) inhibition_1\NN\1068773|cyp2b6 (l_compound) cyp2b6_0\NN\1740|
T5_T23 NONE methadone_10\NN\3808564| (r_compound) concentrations_11\NNS\4916342|methadone (r_dobj) alters_9\VBZ\126264|concentrations (r_conj) reduces_2\VBZ\441445|inhibition|n-demethylation|,|and|alters|,|demonstrating|. (l_advcl) demonstrating_13\VBG\2137132|role (l_dobj) role_16\NN\719494|an|important|cyp2b6|disposition (l_nmod) cyp2b6_18\NN\1740|for
T6_T22 NONE methadone_21\NN\3808564| (r_compound) disposition_22\NN\4623113|in|clinical|methadone (r_nmod) role_16\NN\719494|an|important|cyp2b6|disposition (r_dobj) demonstrating_13\VBG\2137132|role (r_advcl) reduces_2\VBZ\441445|inhibition|n-demethylation|,|and|alters|,|demonstrating|. (l_nsubj) inhibition_1\NN\1068773|cyp2b6 (l_compound) cyp2b6_0\NN\1740|
T6_T23 CPR:9 methadone_21\NN\3808564| (r_compound) disposition_22\NN\4623113|in|clinical|methadone (r_nmod) role_16\NN\719494|an|important|cyp2b6|disposition (l_nmod) cyp2b6_18\NN\1740|for
10866053
T2_T20 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (r_nmod) compared_5\VBD\644583|study|,|we|properties|aspart|. (l_dobj) properties_12\NNS\32613|the|receptor|binding|and|potencies (l_compound) receptor_10\NN\5225602|insulin (l_compound) insulin_7\NN\5407119|and|igf-i
T2_T21 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (r_nmod) compared_5\VBD\644583|study|,|we|properties|aspart|. (l_dobj) properties_12\NNS\32613|the|receptor|binding|and|potencies (l_compound) receptor_10\NN\5225602|insulin
T2_T22 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (l_compound) insulin_19\NN\5407119|
T2_T23 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (l_appos) insulin_24\NN\5407119|(|b28asp|human|)
T2_T24 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (l_conj) lispro_28\NN\1740|insulin|b28lys (l_compound) insulin_27\NN\5407119|
T2_T25 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (l_conj) lispro_28\NN\1740|insulin|b28lys (l_dep) b28lys_30\NN\1740|(|,|insulin|) (l_appos) insulin_34\NN\5407119|b29pro|human
T2_T26 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (l_conj) glargine_38\NN\1740|insulin|a21gly (l_compound) insulin_37\NN\5407119|
T2_T27 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (l_conj) glargine_38\NN\1740|insulin|a21gly (l_dep) a21gly_40\NN\1740|(|,|b31arg|,|b32arg|insulin|) (l_appos) insulin_46\NN\5407119|human
T2_T28 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (l_compound) insulin_49\NN\5407119|
T2_T29 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (l_appos) insulin_60\NN\5407119|desb30|human
T2_T30 NONE b29lys(epsilon-tetradecanoyl_55\NN\1740|[|) (r_appos) detemir_50\NN\1740|insulin|nn304|b29lys(epsilon-tetradecanoyl|,|insulin|] (r_conj) aspart_20\NN\1740|of|insulin|insulin|,|lispro|,|glargine|,|detemir|,|and|analogs (l_conj) analogs_66\NNS\4743605|reference|insulin (l_compound) insulin_65\NN\5407119|
T1_T14 NONE acid_5\NN\14818238| (r_compound) chain_6\NN\8457976|of|a|fatty|acid (r_nmod) attachment_1\NN\7544647|the|chain|lysb29 (r_nsubj) provided_9\VBD\2199590|attachment|detemir|affinities|but|change|. (l_dobj) detemir_11\NN\1740|insulin (l_compound) insulin_10\NN\5407119|
23511016
T6_T11 CPR:4 dota_3\NN\1740| (r_compound) gd(3+))-conjugate_5\NN\1740|of|a|dota|(|pantoprazole (l_nmod) pantoprazole_9\NN\1740|of|inhibitor (l_compound) inhibitor_8\NN\20090|proton-pump (l_amod) proton-pump_7\JJ\1740|
T7_T11 CPR:4 gd(3+))-conjugate_5\NN\1740|of|a|dota|(|pantoprazole (l_nmod) pantoprazole_9\NN\1740|of|inhibitor (l_compound) inhibitor_8\NN\20090|proton-pump (l_amod) proton-pump_7\JJ\1740|
T8_T11 CPR:4 pantoprazole_9\NN\1740|of|inhibitor (l_compound) inhibitor_8\NN\20090|proton-pump (l_amod) proton-pump_7\JJ\1740|
T1_T10 NONE gd-based_15\JJ\1740| (r_amod) agent_18\NN\7347|a|gd-based|mri|contrast|,|encaged (l_acl) encaged_20\VBN\1740|agent (l_nmod) agent_24\NN\7347|with|a|chelating|dota|,|pantoprazole (l_nmod) pantoprazole_30\NN\1740|with|,|inhibitor (l_acl:relcl) inhibitor_39\NN\20090|which|is|a|used|proton|pump|binds (l_acl:relcl) binds_41\VBZ\1290422|that|pumps (l_nmod) pumps_44\NNS\3736970|to|proton|stomach
T1_T9 CPR:4 gd-based_15\JJ\1740| (r_amod) agent_18\NN\7347|a|gd-based|mri|contrast|,|encaged (l_acl) encaged_20\VBN\1740|agent (l_nmod) agent_24\NN\7347|with|a|chelating|dota|,|pantoprazole (l_nmod) pantoprazole_30\NN\1740|with|,|inhibitor (l_acl:relcl) inhibitor_39\NN\20090|which|is|a|used|proton|pump|binds (l_compound) pump_38\NN\3736970|
T2_T10 NONE dota_26\NN\1740|(|) (r_appos) agent_24\NN\7347|with|a|chelating|dota|,|pantoprazole (l_nmod) pantoprazole_30\NN\1740|with|,|inhibitor (l_acl:relcl) inhibitor_39\NN\20090|which|is|a|used|proton|pump|binds (l_acl:relcl) binds_41\VBZ\1290422|that|pumps (l_nmod) pumps_44\NNS\3736970|to|proton|stomach
T2_T9 CPR:4 dota_26\NN\1740|(|) (r_appos) agent_24\NN\7347|with|a|chelating|dota|,|pantoprazole (l_nmod) pantoprazole_30\NN\1740|with|,|inhibitor (l_acl:relcl) inhibitor_39\NN\20090|which|is|a|used|proton|pump|binds (l_compound) pump_38\NN\3736970|
T3_T10 NONE pantoprazole_30\NN\1740|with|,|inhibitor (l_acl:relcl) inhibitor_39\NN\20090|which|is|a|used|proton|pump|binds (l_acl:relcl) binds_41\VBZ\1290422|that|pumps (l_nmod) pumps_44\NNS\3736970|to|proton|stomach
T3_T9 CPR:4 pantoprazole_30\NN\1740|with|,|inhibitor (l_acl:relcl) inhibitor_39\NN\20090|which|is|a|used|proton|pump|binds (l_compound) pump_38\NN\3736970|
23528299
T6_T10 CPR:4 lb-4b_7\NN\1740| (r_dep) inhibitor_6\NN\20090|of|a|synthetic|n|lb-4b (l_compound) n_5\NN\14622893|aminopeptidase
T5_T8 CPR:4 lb-4b_0\NN\1740| (r_nsubj) inhibitor_6\NN\20090|lb-4b|is|the|first|synthetic|apn|evaluated|. (l_compound) apn_5\NN\1740|
T1_T9 CPR:4 bestatin_10\NN\1740|versus|8.1μm|) (r_conj) ic50=850nm_7\NN\1740|(|,|bestatin (r_dep) inhibitor_5\NN\20090|as|a|potent|synthetic|apn|ic50=850nm (l_compound) apn_4\NN\1740|
T2_T9 CPR:4 lb-4b_15\NN\1740| (r_nsubjpass) determined_17\VBN\1645601|inhibitor|,|lb-4b|was|have|. (l_nmod) inhibitor_5\NN\20090|as|a|potent|synthetic|apn|ic50=850nm (l_compound) apn_4\NN\1740|
T3_T9 CPR:4 bestatin_31\NN\1740|than (r_nmod) cell_26\NN\3080309|to|cancer|invasion|bestatin (r_nmod) effects_23\NNS\13245626|significant|block|cell (r_dobj) have_19\VB\2108377|to|effects (r_xcomp) determined_17\VBN\1645601|inhibitor|,|lb-4b|was|have|. (l_nmod) inhibitor_5\NN\20090|as|a|potent|synthetic|apn|ic50=850nm (l_compound) apn_4\NN\1740|
17125913
T13_T43 NONE cadmium_0\NN\14625458| (r_nsubj) induces_1\VBZ\1627355|cadmium|signaling|cell|mechanism|. (l_nmod) mechanism_11\NN\13446390|by|an|eralpha-dependent (l_amod) eralpha-dependent_10\JJ\1740|
T6_T18 NONE estradiol_0\NN\14749794|e2 (r_nsubj) stimulates_4\VBZ\137313|estradiol|proliferation|binding|. (l_advcl) binding_9\VBG\1290422|by|receptor (l_dobj) receptor_12\NN\5225602|the|estrogen|er
T6_T23 NONE estradiol_0\NN\14749794|e2 (r_nsubj) stimulates_4\VBZ\137313|estradiol|proliferation|binding|. (l_advcl) binding_9\VBG\1290422|by|receptor (l_dobj) receptor_12\NN\5225602|the|estrogen|er (l_appos) er_14\NN\14625458|(|)
T8_T18 NONE e2_2\NN\1740|(|) (r_appos) estradiol_0\NN\14749794|e2 (r_nsubj) stimulates_4\VBZ\137313|estradiol|proliferation|binding|. (l_advcl) binding_9\VBG\1290422|by|receptor (l_dobj) receptor_12\NN\5225602|the|estrogen|er
T8_T23 NONE e2_2\NN\1740|(|) (r_appos) estradiol_0\NN\14749794|e2 (r_nsubj) stimulates_4\VBZ\137313|estradiol|proliferation|binding|. (l_advcl) binding_9\VBG\1290422|by|receptor (l_dobj) receptor_12\NN\5225602|the|estrogen|er (l_appos) er_14\NN\14625458|(|)
T4_T24 NONE cd_8\NN\14625458| (r_nsubj) regulates_9\VBZ\296178|whether|cd|proliferation|activating (l_advcl) activating_14\VBG\1641914|by|erk1/2 (l_dobj) erk1/2_15\NN\1740|,|akt|and|kinases
T4_T25 NONE cd_8\NN\14625458| (r_nsubj) regulates_9\VBZ\296178|whether|cd|proliferation|activating (l_advcl) activating_14\VBG\1641914|by|erk1/2 (l_dobj) erk1/2_15\NN\1740|,|akt|and|kinases (l_conj) akt_17\NN\1740|
T4_T26 NONE cd_8\NN\14625458| (r_nsubj) regulates_9\VBZ\296178|whether|cd|proliferation|activating (l_advcl) activating_14\VBG\1641914|by|erk1/2 (l_dobj) erk1/2_15\NN\1740|,|akt|and|kinases (l_conj) kinases_20\NNS\14732946|pdgfralpha (l_compound) pdgfralpha_19\NN\1740|
T4_T27 NONE cd_8\NN\14625458| (r_nsubj) regulates_9\VBZ\296178|whether|cd|proliferation|activating (l_advcl) activating_14\VBG\1641914|by|erk1/2 (l_dobj) erk1/2_15\NN\1740|,|akt|and|kinases (l_conj) kinases_20\NNS\14732946|pdgfralpha
T5_T28 NONE cd_0\NN\14625458| (r_nsubj) increased_1\VBD\169651|cd|proliferation|and|blunted (l_conj) blunted_9\VBD\224901|ici|it|. (l_nsubj) ici_7\NN\1740|the|er-antagonist|182,780 (l_amod) er-antagonist_6\JJ\1740|
T7_T31 CPR:4 cd_0\NN\14625458| (r_nsubj) decreased_1\VBD\169651|cd|expression|. (l_dobj) expression_3\NN\4679549|eralpha|,|not|erbeta (l_compound) eralpha_2\NN\1740|
T7_T32 NONE cd_0\NN\14625458| (r_nsubj) decreased_1\VBD\169651|cd|expression|. (l_dobj) expression_3\NN\4679549|eralpha|,|not|erbeta (l_conj) erbeta_7\NN\1740|
T9_T33 NONE cd_0\NN\14625458| (r_nsubj) increased_2\VBD\169651|cd|also|phosphorylation|blocked|. (l_dobj) phosphorylation_8\NN\1740|erk1/2 (l_compound) erk1/2_3\NN\1740|,|akt|and|pdgfralpha
T9_T34 CPR:3 cd_0\NN\14625458| (r_nsubj) increased_2\VBD\169651|cd|also|phosphorylation|blocked|. (l_dobj) phosphorylation_8\NN\1740|erk1/2 (l_compound) erk1/2_3\NN\1740|,|akt|and|pdgfralpha (l_conj) akt_5\NN\1740|
T9_T35 CPR:3 cd_0\NN\14625458| (r_nsubj) increased_2\VBD\169651|cd|also|phosphorylation|blocked|. (l_dobj) phosphorylation_8\NN\1740|erk1/2 (l_compound) erk1/2_3\NN\1740|,|akt|and|pdgfralpha (l_conj) pdgfralpha_7\NN\1740|
T10_T39 CPR:3 cd_0\NN\14625458| (r_nsubj) increased_2\VBD\169651|cd|rapidly|expression|. (l_dobj) expression_8\NN\4679549|c-jun (l_compound) c-jun_3\NN\1740|,|c-fos|and|pdgfa
T10_T40 CPR:3 cd_0\NN\14625458| (r_nsubj) increased_2\VBD\169651|cd|rapidly|expression|. (l_dobj) expression_8\NN\4679549|c-jun (l_compound) c-jun_3\NN\1740|,|c-fos|and|pdgfa (l_conj) c-fos_5\NN\1740|
T10_T41 CPR:3 cd_0\NN\14625458| (r_nsubj) increased_2\VBD\169651|cd|rapidly|expression|. (l_dobj) expression_8\NN\4679549|c-jun (l_compound) c-jun_3\NN\1740|,|c-fos|and|pdgfa (l_conj) pdgfa_7\NN\1740|
T11_T42 NONE cd_6\NN\14625458|with|the|and|inhibitors|,|blocked (l_conj) inhibitors_10\NNS\20090|kinases (l_compound) kinases_9\NNS\14732946|specific
T12_T42 NONE cd-stimulated_15\JJ\1740| (r_amod) proliferation_16\NN\13489037|the|cd-stimulated (r_dobj) blocked_13\VBD\1476483|which|proliferation (r_acl:relcl) cd_6\NN\14625458|with|the|and|inhibitors|,|blocked (l_conj) inhibitors_10\NNS\20090|kinases (l_compound) kinases_9\NNS\14732946|specific
T1_T14 CPR:3 cd_7\NN\14625458| (r_nsubj) increases_8\VBZ\169651|that|cd|proliferation|vitro|stimulating (l_advcl) stimulating_15\VBG\137313|by|activity|activating (l_dobj) activity_22\NN\30358|akt (l_compound) akt_16\NN\1740|,|erk1/2|and|kinases
T1_T15 NONE cd_7\NN\14625458| (r_nsubj) increases_8\VBZ\169651|that|cd|proliferation|vitro|stimulating (l_advcl) stimulating_15\VBG\137313|by|activity|activating (l_dobj) activity_22\NN\30358|akt (l_compound) akt_16\NN\1740|,|erk1/2|and|kinases (l_conj) erk1/2_18\NN\1740|
T1_T16 CPR:3 cd_7\NN\14625458| (r_nsubj) increases_8\VBZ\169651|that|cd|proliferation|vitro|stimulating (l_advcl) stimulating_15\VBG\137313|by|activity|activating (l_dobj) activity_22\NN\30358|akt (l_compound) akt_16\NN\1740|,|erk1/2|and|kinases (l_conj) kinases_21\NNS\14732946|pdgfralpha (l_compound) pdgfralpha_20\NN\1740|
T1_T17 CPR:3 cd_7\NN\14625458| (r_nsubj) increases_8\VBZ\169651|that|cd|proliferation|vitro|stimulating (l_advcl) stimulating_15\VBG\137313|by|activity|activating (l_dobj) activity_22\NN\30358|akt (l_compound) akt_16\NN\1740|,|erk1/2|and|kinases (l_conj) kinases_21\NNS\14732946|pdgfralpha
T1_T19 CPR:3 cd_7\NN\14625458| (r_nsubj) increases_8\VBZ\169651|that|cd|proliferation|vitro|stimulating (l_advcl) stimulating_15\VBG\137313|by|activity|activating (l_advcl) activating_25\VBG\1641914|likely|by|c-fos|mechanism (l_dobj) c-fos_26\NN\1740|,|c-jun|and|pdgfa
T1_T20 CPR:3 cd_7\NN\14625458| (r_nsubj) increases_8\VBZ\169651|that|cd|proliferation|vitro|stimulating (l_advcl) stimulating_15\VBG\137313|by|activity|activating (l_advcl) activating_25\VBG\1641914|likely|by|c-fos|mechanism (l_dobj) c-fos_26\NN\1740|,|c-jun|and|pdgfa (l_conj) c-jun_28\NN\1740|
T1_T21 CPR:3 cd_7\NN\14625458| (r_nsubj) increases_8\VBZ\169651|that|cd|proliferation|vitro|stimulating (l_advcl) stimulating_15\VBG\137313|by|activity|activating (l_advcl) activating_25\VBG\1641914|likely|by|c-fos|mechanism (l_dobj) c-fos_26\NN\1740|,|c-jun|and|pdgfa (l_conj) pdgfa_30\NN\1740|
T1_T22 NONE cd_7\NN\14625458| (r_nsubj) increases_8\VBZ\169651|that|cd|proliferation|vitro|stimulating (l_advcl) stimulating_15\VBG\137313|by|activity|activating (l_advcl) activating_25\VBG\1641914|likely|by|c-fos|mechanism (l_nmod) mechanism_34\NN\13446390|by|an|eralpha-dependent (l_amod) eralpha-dependent_33\JJ\1740|
15937104
T6_T26 NONE heroin-seeking_17\NN\1740| (r_compound) behavior_18\NN\407535|of|heroin-seeking (r_nmod) relapse_15\NN\66636|behavior (r_conj) activation_8\NN\13561719|opiate|signaling|and|relapse (r_dobj) regulates_6\VBZ\296178|activator|activation|. (l_nsubj) activator_0\NN\19613|signaling (l_nmod) signaling_4\NN\33020|of|g|protein|3 (l_nummod) 3_5\CD\13741022|
T6_T27 NONE heroin-seeking_17\NN\1740| (r_compound) behavior_18\NN\407535|of|heroin-seeking (r_nmod) relapse_15\NN\66636|behavior (r_conj) activation_8\NN\13561719|opiate|signaling|and|relapse (l_nmod) signaling_13\NN\33020|of|a (l_compound) a_12\NN\13649268|protein|kinase
T1_T10 NONE camp_3\NN\3763727| (r_compound) production_4\NN\30358|camp (r_dobj) inhibits_2\VBZ\2510337|galpha(i|production|,|but|regulates|. (l_conj) regulates_8\VBZ\296178|betagamma|pathways (l_dobj) pathways_11\NNS\5483677|several|molecular|,|a (l_nmod) a_16\NN\13649268|including|protein|kinase|pka (l_appos) pka_18\NN\1740|(|)
T1_T8 NONE camp_3\NN\3763727| (r_compound) production_4\NN\30358|camp (r_dobj) inhibits_2\VBZ\2510337|galpha(i|production|,|but|regulates|. (l_nsubj) galpha(i_0\NN\1740|) (l_punct) )_1\-RRB-\1740|
T1_T9 NONE camp_3\NN\3763727| (r_compound) production_4\NN\30358|camp (r_dobj) inhibits_2\VBZ\2510337|galpha(i|production|,|but|regulates|. (l_conj) regulates_8\VBZ\296178|betagamma|pathways (l_dobj) pathways_11\NNS\5483677|several|molecular|,|a (l_nmod) a_16\NN\13649268|including|protein|kinase|pka
T3_T20 NONE heroin_3\NN\3492717| (r_dobj) self-administering_2\VBG\1740|heroin (r_acl) rats_1\NNS\2329401|in|self-administering (r_nmod) eliminates_16\VBZ\1619929|rats|,|ags3|reinstatement|. (l_nsubj) ags3_5\NN\1740|antisense
T4_T20 NONE heroin-seeking_19\NN\1740| (r_compound) behavior_20\NN\407535|of|heroin-seeking|,|model (r_nmod) reinstatement_17\NN\13920835|behavior (r_dobj) eliminates_16\VBZ\1619929|rats|,|ags3|reinstatement|. (l_nsubj) ags3_5\NN\1740|antisense
T5_T22 NONE heroin-seeking_16\NN\1740| (r_compound) behavior_17\NN\407535|heroin-seeking (r_conj) activation_9\NN\13561719|mu|opiate|receptor|signaling|as|behavior (r_dobj) mediate_5\VB\761713|to|activation (r_xcomp) appears_3\VBZ\2604760|thus|,|galpha(i3)/betagamma/ags3|mediate|. (l_nsubj) galpha(i3)/betagamma/ags3_2\NN\1740|
T5_T23 NONE heroin-seeking_16\NN\1740| (r_compound) behavior_17\NN\407535|heroin-seeking (r_conj) activation_9\NN\13561719|mu|opiate|receptor|signaling|as|behavior (r_dobj) mediate_5\VB\761713|to|activation (r_xcomp) appears_3\VBZ\2604760|thus|,|galpha(i3)/betagamma/ags3|mediate|. (l_nsubj) galpha(i3)/betagamma/ags3_2\NN\1740|
T5_T24 NONE heroin-seeking_16\NN\1740| (r_compound) behavior_17\NN\407535|heroin-seeking (r_conj) activation_9\NN\13561719|mu|opiate|receptor|signaling|as|behavior (l_compound) receptor_8\NN\5225602|
T5_T25 NONE heroin-seeking_16\NN\1740| (r_compound) behavior_17\NN\407535|heroin-seeking (r_conj) activation_9\NN\13561719|mu|opiate|receptor|signaling|as|behavior (l_nmod) signaling_12\NN\33020|of|pka (l_compound) pka_11\NN\1740|
16597468
T2_T10 NONE adenine_13\NN\14706749| (r_compound) phosphoribosyltransferase_14\NN\1740|adenine|aprt
T2_T11 NONE adenine_13\NN\14706749| (r_compound) phosphoribosyltransferase_14\NN\1740|adenine|aprt (l_appos) aprt_16\NN\1740|(|)
T2_T12 NONE adenine_13\NN\14706749| (r_compound) phosphoribosyltransferase_14\NN\1740|adenine|aprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_21\NN\1740|xanthine|xprt
T2_T13 NONE adenine_13\NN\14706749| (r_compound) phosphoribosyltransferase_14\NN\1740|adenine|aprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (l_appos) xprt_23\NN\1740|(|)
T2_T14 NONE adenine_13\NN\14706749| (r_compound) phosphoribosyltransferase_14\NN\1740|adenine|aprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (r_appos) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_compound) phosphoribosyltransferase_4\NN\1740|
T2_T15 NONE adenine_13\NN\14706749| (r_compound) phosphoribosyltransferase_14\NN\1740|adenine|aprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase
T2_T9 NONE adenine_13\NN\14706749| (r_compound) phosphoribosyltransferase_14\NN\1740|adenine|aprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_appos) hgprt_10\NN\1740|(|)
T3_T10 NONE xanthine_20\NN\14727670| (r_compound) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_14\NN\1740|adenine|aprt
T3_T11 NONE xanthine_20\NN\14727670| (r_compound) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_14\NN\1740|adenine|aprt (l_appos) aprt_16\NN\1740|(|)
T3_T12 NONE xanthine_20\NN\14727670| (r_compound) phosphoribosyltransferase_21\NN\1740|xanthine|xprt
T3_T13 NONE xanthine_20\NN\14727670| (r_compound) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (l_appos) xprt_23\NN\1740|(|)
T3_T14 NONE xanthine_20\NN\14727670| (r_compound) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (r_appos) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_compound) phosphoribosyltransferase_4\NN\1740|
T3_T15 NONE xanthine_20\NN\14727670| (r_compound) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase
T3_T9 NONE xanthine_20\NN\14727670| (r_compound) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (r_conj) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_appos) hgprt_10\NN\1740|(|)
T4_T10 NONE purine_32\NN\14618253| (r_compound) nutrients_33\NNS\20090|purine (r_dobj) acquire_31\VB\109660|to|nutrients|hosts (r_xcomp) enable_27\VBP\126264|which|genus|acquire (r_acl:relcl) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_appos) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_14\NN\1740|adenine|aprt
T4_T11 NONE purine_32\NN\14618253| (r_compound) nutrients_33\NNS\20090|purine (r_dobj) acquire_31\VB\109660|to|nutrients|hosts (r_xcomp) enable_27\VBP\126264|which|genus|acquire (r_acl:relcl) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_appos) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_14\NN\1740|adenine|aprt (l_appos) aprt_16\NN\1740|(|)
T4_T12 NONE purine_32\NN\14618253| (r_compound) nutrients_33\NNS\20090|purine (r_dobj) acquire_31\VB\109660|to|nutrients|hosts (r_xcomp) enable_27\VBP\126264|which|genus|acquire (r_acl:relcl) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_appos) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_21\NN\1740|xanthine|xprt
T4_T13 NONE purine_32\NN\14618253| (r_compound) nutrients_33\NNS\20090|purine (r_dobj) acquire_31\VB\109660|to|nutrients|hosts (r_xcomp) enable_27\VBP\126264|which|genus|acquire (r_acl:relcl) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_appos) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (l_appos) xprt_23\NN\1740|(|)
T4_T14 NONE purine_32\NN\14618253| (r_compound) nutrients_33\NNS\20090|purine (r_dobj) acquire_31\VB\109660|to|nutrients|hosts (r_xcomp) enable_27\VBP\126264|which|genus|acquire (r_acl:relcl) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_compound) phosphoribosyltransferase_4\NN\1740|
T4_T15 NONE purine_32\NN\14618253| (r_compound) nutrients_33\NNS\20090|purine (r_dobj) acquire_31\VB\109660|to|nutrients|hosts (r_xcomp) enable_27\VBP\126264|which|genus|acquire (r_acl:relcl) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_appos) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase
T4_T9 NONE purine_32\NN\14618253| (r_compound) nutrients_33\NNS\20090|purine (r_dobj) acquire_31\VB\109660|to|nutrients|hosts (r_xcomp) enable_27\VBP\126264|which|genus|acquire (r_acl:relcl) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_appos) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_appos) hgprt_10\NN\1740|(|)
T5_T10 NONE hypoxanthine-guanine_7\NN\1740| (r_compound) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_14\NN\1740|adenine|aprt
T5_T11 NONE hypoxanthine-guanine_7\NN\1740| (r_compound) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_14\NN\1740|adenine|aprt (l_appos) aprt_16\NN\1740|(|)
T5_T12 NONE hypoxanthine-guanine_7\NN\1740| (r_compound) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_21\NN\1740|xanthine|xprt
T5_T13 NONE hypoxanthine-guanine_7\NN\1740| (r_compound) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_conj) phosphoribosyltransferase_21\NN\1740|xanthine|xprt (l_appos) xprt_23\NN\1740|(|)
T5_T14 NONE hypoxanthine-guanine_7\NN\1740| (r_compound) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (r_appos) enzymes_5\NNS\14723628|three|phosphoribosyltransferase|,|phosphoribosyltransferase|,|enable (l_compound) phosphoribosyltransferase_4\NN\1740|
T5_T15 NONE hypoxanthine-guanine_7\NN\1740| (r_compound) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase
T5_T9 NONE hypoxanthine-guanine_7\NN\1740| (r_compound) phosphoribosyltransferase_8\NN\1740|hypoxanthine-guanine|hgprt|,|phosphoribosyltransferase|,|and|phosphoribosyltransferase (l_appos) hgprt_10\NN\1740|(|)
T6_T16 NONE purine_14\NN\14618253| (r_compound) salvage_15\NN\3076708|for|purine|or|viability|itself (r_nmod) essential_12\JJ\1740|that|none|is|salvage|and|occurs (l_nsubj) none_6\NN\15228378|phosphoribosyltransferases (l_nmod) phosphoribosyltransferases_10\NNS\1740|of|the|three
T7_T16 NONE purine_22\NN\14618253| (r_compound) salvage_23\NN\3076708|purine (r_nsubj) occurs_24\VBZ\2623529|that|salvage|routes|stages (r_conj) essential_12\JJ\1740|that|none|is|salvage|and|occurs (l_nsubj) none_6\NN\15228378|phosphoribosyltransferases (l_nmod) phosphoribosyltransferases_10\NNS\1740|of|the|three
T1_T8 NONE adenine_9\NN\14706749| (r_compound) enzyme_11\NN\14723628|of|an|adenine|aminohydrolase (l_compound) aminohydrolase_10\NN\1740|
23545458
23050902
T17_T47 CPR:3 ribavirin-induced_0\JJ\1740| (r_amod) depletion_3\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) activates_4\VBZ\1641914|depletion|elongation|. (l_dobj) elongation_6\NN\5133287|transcription|expression (l_nmod) expression_12\NN\4679549|in|coagulation|factor|vii|gene (l_nummod) vii_10\CD\13741022|
T18_T47 NONE gtp_2\NN\1740| (r_compound) depletion_3\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) activates_4\VBZ\1641914|depletion|elongation|. (l_dobj) elongation_6\NN\5133287|transcription|expression (l_nmod) expression_12\NN\4679549|in|coagulation|factor|vii|gene (l_nummod) vii_10\CD\13741022|
T7_T19 NONE k-dependent_9\JJ\1740|vitamin (r_amod) glycoprotein_10\NN\14731135|fvii|is|a|k-dependent|synthesized|. (l_nsubj) fvii_1\NN\1740|coagulation|vii
T7_T36 NONE k-dependent_9\JJ\1740|vitamin (r_amod) glycoprotein_10\NN\14731135|fvii|is|a|k-dependent|synthesized|. (l_nsubj) fvii_1\NN\1740|coagulation|vii (l_appos) vii_4\NN\13741022|(|factor|)
T6_T28 CPR:3 ribavirin_14\NN\2725367| (r_compound) treatment_15\NN\654885|by|ribavirin (r_nmod) up-regulated_12\VBN\1740|that|expression|was|treatment|patients (l_nsubjpass) expression_10\NN\4679549|gene (l_compound) gene_6\NN\8459252|fvii|f7 (l_compound) fvii_5\NN\1740|
T6_T34 CPR:3 ribavirin_14\NN\2725367| (r_compound) treatment_15\NN\654885|by|ribavirin (r_nmod) up-regulated_12\VBN\1740|that|expression|was|treatment|patients (l_nsubjpass) expression_10\NN\4679549|gene (l_compound) gene_6\NN\8459252|fvii|f7 (l_appos) f7_8\NN\1740|(|)
T8_T37 CPR:3 ribavirin-induced_11\JJ\1740| (r_amod) up-regulation_12\NN\1740|of|ribavirin-induced|expression (l_nmod) expression_15\NN\4679549|of|f7|hepg2 (l_compound) f7_14\NN\1740|
T10_T38 NONE ribavirin_7\NN\2725367|by (r_nmod) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (l_conj) inhibitors_17\NNS\20090|other|impdh|,|acid|, (l_compound) impdh_12\NN\1740|dehydrogenase
T10_T39 NONE ribavirin_7\NN\2725367|by (r_nmod) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (l_conj) inhibitors_17\NNS\20090|other|impdh|,|acid|, (l_compound) impdh_12\NN\1740|dehydrogenase (l_appos) dehydrogenase_15\NN\1740|(|inosine-5'-monophosphate|)
T10_T40 NONE ribavirin_7\NN\2725367|by (r_nmod) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (r_nsubj) up-regulated_26\VBD\1740|that|depletion|expression (l_dobj) expression_28\NN\4679549|f7 (l_compound) f7_27\NN\1740|
T11_T38 NONE inosine-5'-monophosphate_14\NN\1740| (r_compound) dehydrogenase_15\NN\1740|(|inosine-5'-monophosphate|) (r_appos) impdh_12\NN\1740|dehydrogenase
T11_T39 NONE inosine-5'-monophosphate_14\NN\1740| (r_compound) dehydrogenase_15\NN\1740|(|inosine-5'-monophosphate|)
T11_T40 NONE inosine-5'-monophosphate_14\NN\1740| (r_compound) dehydrogenase_15\NN\1740|(|inosine-5'-monophosphate|) (r_appos) impdh_12\NN\1740|dehydrogenase (r_compound) inhibitors_17\NNS\20090|other|impdh|,|acid|, (r_conj) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (r_nsubj) up-regulated_26\VBD\1740|that|depletion|expression (l_dobj) expression_28\NN\4679549|f7 (l_compound) f7_27\NN\1740|
T12_T38 NONE acid_22\NN\14818238|such|mycophenolic|and|6-mercaptopurine (r_nmod) inhibitors_17\NNS\20090|other|impdh|,|acid|, (l_compound) impdh_12\NN\1740|dehydrogenase
T12_T39 NONE acid_22\NN\14818238|such|mycophenolic|and|6-mercaptopurine (r_nmod) inhibitors_17\NNS\20090|other|impdh|,|acid|, (l_compound) impdh_12\NN\1740|dehydrogenase (l_appos) dehydrogenase_15\NN\1740|(|inosine-5'-monophosphate|)
T12_T40 CPR:3 acid_22\NN\14818238|such|mycophenolic|and|6-mercaptopurine (r_nmod) inhibitors_17\NNS\20090|other|impdh|,|acid|, (r_conj) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (r_nsubj) up-regulated_26\VBD\1740|that|depletion|expression (l_dobj) expression_28\NN\4679549|f7 (l_compound) f7_27\NN\1740|
T13_T38 NONE 6-mercaptopurine_24\NN\1740| (r_conj) acid_22\NN\14818238|such|mycophenolic|and|6-mercaptopurine (r_nmod) inhibitors_17\NNS\20090|other|impdh|,|acid|, (l_compound) impdh_12\NN\1740|dehydrogenase
T13_T39 NONE 6-mercaptopurine_24\NN\1740| (r_conj) acid_22\NN\14818238|such|mycophenolic|and|6-mercaptopurine (r_nmod) inhibitors_17\NNS\20090|other|impdh|,|acid|, (l_compound) impdh_12\NN\1740|dehydrogenase (l_appos) dehydrogenase_15\NN\1740|(|inosine-5'-monophosphate|)
T13_T40 CPR:3 6-mercaptopurine_24\NN\1740| (r_conj) acid_22\NN\14818238|such|mycophenolic|and|6-mercaptopurine (r_nmod) inhibitors_17\NNS\20090|other|impdh|,|acid|, (r_conj) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (r_nsubj) up-regulated_26\VBD\1740|that|depletion|expression (l_dobj) expression_28\NN\4679549|f7 (l_compound) f7_27\NN\1740|
T9_T38 NONE gtp_4\NN\1740| (r_compound) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (l_conj) inhibitors_17\NNS\20090|other|impdh|,|acid|, (l_compound) impdh_12\NN\1740|dehydrogenase
T9_T39 NONE gtp_4\NN\1740| (r_compound) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (l_conj) inhibitors_17\NNS\20090|other|impdh|,|acid|, (l_compound) impdh_12\NN\1740|dehydrogenase (l_appos) dehydrogenase_15\NN\1740|(|inosine-5'-monophosphate|)
T9_T40 NONE gtp_4\NN\1740| (r_compound) depletion_5\NN\351638|intracellular|gtp|ribavirin|as|inhibitors (r_nsubj) up-regulated_26\VBD\1740|that|depletion|expression (l_dobj) expression_28\NN\4679549|f7 (l_compound) f7_27\NN\1740|
T14_T44 CPR:3 ribavirin_0\NN\2725367| (r_nmod:npmod) unregulated_1\JJ\1740|ribavirin (r_amod) ell_2\NN\2713594|unregulated|leukaemia|expression|up-regulation|.
T14_T45 CPR:3 ribavirin_0\NN\2725367| (r_nmod:npmod) unregulated_1\JJ\1740|ribavirin (r_amod) ell_2\NN\2713594|unregulated|leukaemia|expression|up-regulation|. (l_appos) expression_10\NN\4679549|3|mrna (l_nummod) 3_8\CD\13741022|
T14_T46 CPR:3 ribavirin_0\NN\2725367| (r_nmod:npmod) unregulated_1\JJ\1740|ribavirin (r_amod) ell_2\NN\2713594|unregulated|leukaemia|expression|up-regulation|. (l_nmod) up-regulation_13\NN\1740|before|f7 (l_compound) f7_12\NN\1740|
T15_T44 NONE lysine-rich_5\JJ\1740| (r_amod) leukaemia_6\NN\14239918|(|eleven-nineteen|lysine-rich|) (r_appos) ell_2\NN\2713594|unregulated|leukaemia|expression|up-regulation|.
T15_T45 NONE lysine-rich_5\JJ\1740| (r_amod) leukaemia_6\NN\14239918|(|eleven-nineteen|lysine-rich|) (r_appos) ell_2\NN\2713594|unregulated|leukaemia|expression|up-regulation|. (l_appos) expression_10\NN\4679549|3|mrna (l_nummod) 3_8\CD\13741022|
T15_T46 NONE lysine-rich_5\JJ\1740| (r_amod) leukaemia_6\NN\14239918|(|eleven-nineteen|lysine-rich|) (r_appos) ell_2\NN\2713594|unregulated|leukaemia|expression|up-regulation|. (l_nmod) up-regulation_13\NN\1740|before|f7 (l_compound) f7_12\NN\1740|
T16_T20 CPR:3 ribavirin_3\NN\2725367| (r_nsubj) enhanced_4\VBD\227165|that|ribavirin|recruitment|,|diminished (l_dobj) recruitment_6\NN\35189|ell3|f7 (l_compound) ell3_5\NN\1740|
T16_T21 CPR:3 ribavirin_3\NN\2725367| (r_nsubj) enhanced_4\VBD\227165|that|ribavirin|recruitment|,|diminished (l_dobj) recruitment_6\NN\35189|ell3|f7 (l_nmod) f7_8\NN\1740|to
T16_T22 NONE ribavirin_3\NN\2725367| (r_nsubj) enhanced_4\VBD\227165|that|ribavirin|recruitment|,|diminished (l_advcl) diminished_14\VBD\169651|whereas|knockdown|up-regulation (l_nsubj) knockdown_11\NN\1173038|ell3 (l_nmod) ell3_13\NN\1740|of
T16_T23 NONE ribavirin_3\NN\2725367| (r_nsubj) enhanced_4\VBD\227165|that|ribavirin|recruitment|,|diminished (l_advcl) diminished_14\VBD\169651|whereas|knockdown|up-regulation (l_dobj) up-regulation_18\NN\1740|ribavirin-induced|fvii|mrna (l_compound) fvii_16\NN\1740|
T1_T20 NONE ribavirin-induced_15\JJ\1740| (r_amod) up-regulation_18\NN\1740|ribavirin-induced|fvii|mrna (r_dobj) diminished_14\VBD\169651|whereas|knockdown|up-regulation (r_advcl) enhanced_4\VBD\227165|that|ribavirin|recruitment|,|diminished (l_dobj) recruitment_6\NN\35189|ell3|f7 (l_compound) ell3_5\NN\1740|
T1_T21 NONE ribavirin-induced_15\JJ\1740| (r_amod) up-regulation_18\NN\1740|ribavirin-induced|fvii|mrna (r_dobj) diminished_14\VBD\169651|whereas|knockdown|up-regulation (r_advcl) enhanced_4\VBD\227165|that|ribavirin|recruitment|,|diminished (l_dobj) recruitment_6\NN\35189|ell3|f7 (l_nmod) f7_8\NN\1740|to
T1_T22 NONE ribavirin-induced_15\JJ\1740| (r_amod) up-regulation_18\NN\1740|ribavirin-induced|fvii|mrna (r_dobj) diminished_14\VBD\169651|whereas|knockdown|up-regulation (l_nsubj) knockdown_11\NN\1173038|ell3 (l_nmod) ell3_13\NN\1740|of
T1_T23 CPR:3 ribavirin-induced_15\JJ\1740| (r_amod) up-regulation_18\NN\1740|ribavirin-induced|fvii|mrna (l_compound) fvii_16\NN\1740|
T2_T24 CPR:3 ribavirin_0\NN\2725367| (r_nsubj) enhanced_2\VBD\227165|ribavirin|also|recruitment|. (l_dobj) recruitment_3\NN\35189|cdk9|f7 (l_nmod) cdk9_5\NN\1740|of|kinase|and|aff4
T2_T25 CPR:3 ribavirin_0\NN\2725367| (r_nsubj) enhanced_2\VBD\227165|ribavirin|also|recruitment|. (l_dobj) recruitment_3\NN\35189|cdk9|f7 (l_nmod) cdk9_5\NN\1740|of|kinase|and|aff4 (l_appos) kinase_8\NN\14732946|(|cyclin-dependent|9|) (l_nummod) 9_9\CD\13741022|
T2_T26 CPR:3 ribavirin_0\NN\2725367| (r_nsubj) enhanced_2\VBD\227165|ribavirin|also|recruitment|. (l_dobj) recruitment_3\NN\35189|cdk9|f7 (l_nmod) cdk9_5\NN\1740|of|kinase|and|aff4 (l_conj) aff4_12\NN\1740|
T2_T27 CPR:3 ribavirin_0\NN\2725367| (r_nsubj) enhanced_2\VBD\227165|ribavirin|also|recruitment|. (l_dobj) recruitment_3\NN\35189|cdk9|f7 (l_nmod) f7_14\NN\1740|to
T3_T29 CPR:3 ribavirin-induced_4\JJ\1740| (r_amod) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_dobj) complex_12\NN\5869584|a|super|elongation|containing (l_acl) containing_13\VBG\2632940|p-tefb (l_dobj) p-tefb_14\NN\1740|,|aff4|and|ell3|,
T3_T30 CPR:3 ribavirin-induced_4\JJ\1740| (r_amod) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_dobj) complex_12\NN\5869584|a|super|elongation|containing (l_acl) containing_13\VBG\2632940|p-tefb (l_dobj) p-tefb_14\NN\1740|,|aff4|and|ell3|, (l_conj) aff4_16\NN\1740|
T3_T31 CPR:3 ribavirin-induced_4\JJ\1740| (r_amod) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_dobj) complex_12\NN\5869584|a|super|elongation|containing (l_acl) containing_13\VBG\2632940|p-tefb (l_dobj) p-tefb_14\NN\1740|,|aff4|and|ell3|, (l_conj) ell3_18\NN\1740|
T3_T32 CPR:3 ribavirin-induced_4\JJ\1740| (r_amod) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_nmod) f7_21\NN\1740|to
T3_T33 NONE ribavirin-induced_4\JJ\1740| (r_amod) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_conj) modulates_24\VBZ\1724459|elongation (l_dobj) elongation_28\NN\5133287|fvii|mrna|transcription (l_compound) fvii_25\NN\1740|
T4_T29 NONE gtp_6\NN\1740| (r_compound) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_dobj) complex_12\NN\5869584|a|super|elongation|containing (l_acl) containing_13\VBG\2632940|p-tefb (l_dobj) p-tefb_14\NN\1740|,|aff4|and|ell3|,
T4_T30 NONE gtp_6\NN\1740| (r_compound) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_dobj) complex_12\NN\5869584|a|super|elongation|containing (l_acl) containing_13\VBG\2632940|p-tefb (l_dobj) p-tefb_14\NN\1740|,|aff4|and|ell3|, (l_conj) aff4_16\NN\1740|
T4_T31 NONE gtp_6\NN\1740| (r_compound) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_dobj) complex_12\NN\5869584|a|super|elongation|containing (l_acl) containing_13\VBG\2632940|p-tefb (l_dobj) p-tefb_14\NN\1740|,|aff4|and|ell3|, (l_conj) ell3_18\NN\1740|
T4_T32 NONE gtp_6\NN\1740| (r_compound) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_nmod) f7_21\NN\1740|to
T4_T33 NONE gtp_6\NN\1740| (r_compound) depletion_7\NN\351638|ribavirin-induced|intracellular|gtp (r_nsubj) recruits_8\VBZ\2471690|that|depletion|complex|f7|,|and|modulates (l_conj) modulates_24\VBZ\1724459|elongation (l_dobj) elongation_28\NN\5133287|fvii|mrna|transcription (l_compound) fvii_25\NN\1740|
T5_T35 CPR:3 ribavirin-induced_9\JJ\1740| (r_amod) up-regulation_12\NN\1740|for|ribavirin-induced|mrna|acceleration (l_compound) mrna_11\NN\14832193|fvii (l_compound) fvii_10\NN\1740|
8710929
T13_T21 NONE norepinephrine_0\NN\14807929| (r_compound) transporters_1\NNS\4490091|norepinephrine
T1_T16 NONE acid_4\NN\14818238| (r_compound) family_7\NN\8189659|of|the|gamma-aminobutyric|acid|transporter|gene (l_compound) transporter_5\NN\4490091|
T2_T17 NONE norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_appos) ne_21\NNS\14622893|human|hnet (l_appos) hnet_23\NN\1740|(|)
T2_T18 NONE norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_nmod) family_31\NN\8189659|in|the|gamma-aminobutyric|acid|transporter|gene (l_compound) transporter_29\NN\4490091|
T3_T17 NONE (ne)+_12\NN\1740| (r_dep) norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_appos) ne_21\NNS\14622893|human|hnet (l_appos) hnet_23\NN\1740|(|)
T3_T18 NONE (ne)+_12\NN\1740| (r_dep) norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_nmod) family_31\NN\8189659|in|the|gamma-aminobutyric|acid|transporter|gene (l_compound) transporter_29\NN\4490091|
T4_T17 NONE na+_14\NN\1740| (r_conj) norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_appos) ne_21\NNS\14622893|human|hnet (l_appos) hnet_23\NN\1740|(|)
T4_T18 NONE na+_14\NN\1740| (r_conj) norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_nmod) family_31\NN\8189659|in|the|gamma-aminobutyric|acid|transporter|gene (l_compound) transporter_29\NN\4490091|
T5_T17 NONE cl-_17\NN\1740| (r_conj) norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_appos) ne_21\NNS\14622893|human|hnet (l_appos) hnet_23\NN\1740|(|)
T5_T18 NONE cl-_17\NN\1740| (r_conj) norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_nmod) family_31\NN\8189659|in|the|gamma-aminobutyric|acid|transporter|gene (l_compound) transporter_29\NN\4490091|
T6_T17 NONE ne_21\NNS\14622893|human|hnet (l_appos) hnet_23\NN\1740|(|)
T6_T18 NONE ne_21\NNS\14622893|human|hnet (r_appos) norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_nmod) family_31\NN\8189659|in|the|gamma-aminobutyric|acid|transporter|gene (l_compound) transporter_29\NN\4490091|
T7_T17 NONE acid_28\NN\14818238| (r_compound) family_31\NN\8189659|in|the|gamma-aminobutyric|acid|transporter|gene (r_nmod) norepinephrine_11\NN\14807929|[|(ne)+|,|na+|,|and|cl-|]|,|ne|family (l_appos) ne_21\NNS\14622893|human|hnet (l_appos) hnet_23\NN\1740|(|)
T7_T18 NONE acid_28\NN\14818238| (r_compound) family_31\NN\8189659|in|the|gamma-aminobutyric|acid|transporter|gene (l_compound) transporter_29\NN\4490091|
T10_T19 CPR:4 cocaine_19\NN\3492717|by|and|desipramine (r_nmod) blocked_17\VBN\1476483|they|are|cocaine|. (r_conj) stimulated_3\VBN\137313|events|are|ne|,|and|blocked (l_nmod) ne_5\NN\14622893|by|and|guanethidine (l_conj) guanethidine_8\NN\1740|by|,|substrate (l_appos) substrate_12\NN\19613|an|hnet (l_compound) hnet_11\NN\1740|
T11_T19 CPR:4 desipramine_23\NN\4482543|the|antidepressant (r_conj) cocaine_19\NN\3492717|by|and|desipramine (r_nmod) blocked_17\VBN\1476483|they|are|cocaine|. (r_conj) stimulated_3\VBN\137313|events|are|ne|,|and|blocked (l_nmod) ne_5\NN\14622893|by|and|guanethidine (l_conj) guanethidine_8\NN\1740|by|,|substrate (l_appos) substrate_12\NN\19613|an|hnet (l_compound) hnet_11\NN\1740|
T8_T19 CPR:9 ne_5\NN\14622893|by|and|guanethidine (l_conj) guanethidine_8\NN\1740|by|,|substrate (l_appos) substrate_12\NN\19613|an|hnet (l_compound) hnet_11\NN\1740|
T9_T19 CPR:9 guanethidine_8\NN\1740|by|,|substrate (l_appos) substrate_12\NN\19613|an|hnet (l_compound) hnet_11\NN\1740|
T12_T20 CPR:9 ne_4\NN\14622893| (r_compound) data_6\NNS\7951464|with|ne|uptake|cells (r_nmod) combined_2\VBN\2630189|data (r_acl) data_1\NNS\7951464|voltage-clamp|combined (r_nsubj) indicate_11\VBP\952524|data|have|. (l_ccomp) have_14\VBP\2108377|that|hnets|modes (l_nsubj) hnets_13\NNS\1740|
23099431
T8_T11 NONE 6_6\CD\13741022| (r_nummod) peptide_5\NN\14724264|of|growth|hormone-releasing|6|ghrp-6|volunteers (l_amod) hormone-releasing_4\JJ\1740|
T9_T11 NONE ghrp-6_8\NN\1740|(|) (r_appos) peptide_5\NN\14724264|of|growth|hormone-releasing|6|ghrp-6|volunteers (l_amod) hormone-releasing_4\JJ\1740|
T1_T10 CPR:3 ghrp-6_0\NN\1740| (r_nsubj) secretagogue_5\NN\1740|ghrp-6|is|a|growth|hormone|enhances|. (l_compound) hormone_4\NN\5404728|
